FN Clarivate Analytics Web of Science
VR 1.0
PT J
AU Mitsuyama, H
   Matsuyama, W
   Watanabe, M
   Shirahama, Y
   Higashimoto, I
   Wada, T
   Osame, M
   Arimura, K
AF Mitsuyama, Hideo
   Matsuyama, Wataru
   Watanabe, Masaki
   Shirahama, Yuko
   Higashimoto, Ikkou
   Wada, Takashi
   Osame, Mitsuhiro
   Arimura, Kimiyoshi
TI RETRACTED: Increased expression of TRAIL receptor 3 on eosinophils in
   Churg-Strauss syndrome (Retracted article. See vol 58, pg. 2924, 2008)
SO ARTHRITIS AND RHEUMATISM
LA English
DT Article; Retracted Publication
ID APOPTOSIS-INDUCING LIGAND; TERM-FOLLOW-UP; ENDOTHELIAL GROWTH-FACTOR;
   TRAIL-INDUCED APOPTOSIS; MAJOR BASIC-PROTEIN; INTRACELLULAR REGULATION;
   RECEPTOR FAMILY; DEATH DOMAIN; T-CELLS; INVOLVEMENT
AB Objective. Prolonged survival of eosinophils plays an important role in the pathogenesis of Churg-Strauss syndrome (CSS); however, its detailed molecular mechanism is still unclear. TRAIL and its receptors are expressed on a variety of cells, including eosinophils. In this study, we examined the expression of TRAIL receptors on eosinophils from patients with CSS.
   Methods. TRAIL receptor expression was assessed on eosinophils from healthy volunteers, patients with CSS, patients with asthma, and patients with hypereosinophilia due to parasitic infection. TRAIL-induced apoptosis of eosinophils was compared between the patients with CSS and patients with asthma. RNA interference was used to assess the effects of suppression of TRAIL receptor 3.
   Results. Expression of TRAIL receptor 3, a decoy receptor that acts as an antiapoptotic receptor, on eosinophils from patients with CSS was significantly higher than that in the other subjects. Moreover, in CSS, serum TRAIL receptor 3 levels showed a significant positive correlation with peripheral eosinophil counts, tissue-infiltrating eosinophils stained positive for this receptor, and peripheral T cells expressed TRAIL on their surface. Compared with asthma patients, eosinophils from CSS patients showed a significantly lower percentage of recombinant TRAIL, less autologous T cell-induced apoptosis, and decreased level of active caspase 3. Suppression of TRAIL receptor 3 through RNA interference significantly increased the recombinant TRAIL-induced apoptosis of eosinophils from CSS patients.
   Conclusion. Increased expression of TRAIL receptor 3 on cosinophils from patients with CSS was observed. These alterations in TRAIL receptor 3 expression might be involved in the molecular pathogenesis of CSS eosinophilia.
C1 Kagoshima Univ Hosp, Div Resp Med, Resp & Stress Care Ctr, Kagoshima 8908520, Japan.
   Kanazawa Univ, Kanazawa, Ishikawa 920, Japan.
RP Matsuyama, W (reprint author), Kagoshima Univ Hosp, Div Resp Med, Resp & Stress Care Ctr, Sakuragaoka 8-35-1, Kagoshima 8908520, Japan.
EM vega@xa2.so-net.ne.jp
CR Bloom JW, 2004, APOPTOSIS, V9, P97, DOI 10.1023/B:APPT.0000012126.06126.c4
   Conron M, 2000, THORAX, V55, P870, DOI 10.1136/thorax.55.10.870
   CORRIGAN CJ, 1992, IMMUNOL TODAY, V13, P501, DOI 10.1016/0167-5699(92)90026-4
   Daigle I, 2001, SWISS MED WKLY, V131, P231
   DegliEsposti MA, 1997, J EXP MED, V186, P1165, DOI 10.1084/jem.186.7.1165
   Drage LA, 2002, J AM ACAD DERMATOL, V47, P209, DOI 10.1067/mjd.2002.124600
   Gayraud M, 2001, ARTHRITIS RHEUM, V44, P666, DOI 10.1002/1529-0131(200103)44:3<666::AID-ANR116>3.3.CO;2-1
   GLEICH GJ, 1979, J IMMUNOL, V123, P2925
   Griffith TS, 1998, J IMMUNOL, V161, P2833
   Gross WL, 2002, CURR OPIN RHEUMATOL, V14, P11, DOI 10.1097/00002281-200201000-00003
   Guillevin L, 1999, MEDICINE, V78, P26, DOI 10.1097/00005792-199901000-00003
   Hao CH, 2001, CANCER RES, V61, P1162
   Haslett C, 1999, AM J RESP CRIT CARE, V160, pS5, DOI 10.1164/ajrccm.160.supplement_1.4
   Hellmich B, 2003, CLIN EXP RHEUMATOL, V21, pS69
   KITA H, 1995, J IMMUNOL, V154, P4749
   LANHAM JG, 1984, MEDICINE, V63, P65, DOI 10.1097/00005792-198403000-00001
   Lee SH, 2005, J IMMUNOL, V175, P8226, DOI 10.4049/jimmunol.175.12.8226
   Leverkus M, 2000, CANCER RES, V60, P553
   Marsters SA, 1997, CURR BIOL, V7, P1003, DOI 10.1016/S0960-9822(06)00422-2
   MASI AT, 1990, ARTHRITIS RHEUM, V33, P1094, DOI 10.1002/art.1780330806
   Matsuyama W, 2005, AM J RESP CELL MOL, V33, P565, DOI 10.1165/rcmb.2005-0236OC
   Matsuyama W, 2005, J IMMUNOL, V174, P6490, DOI 10.4049/jimmunol.174.10.6490
   Matsuyama W, 2004, BLOOD, V104, P184, DOI 10.1182/blood-2003-12-4274
   Matsuyama W, 2000, AM J RESP CRIT CARE, V162, P1120, DOI 10.1164/ajrccm.162.3.9911010
   Meagher LC, 1996, J IMMUNOL, V156, P4422
   Mitsuyama H, 2006, CHEST, V129, P407, DOI 10.1378/chest.129.2.407
   Muschen M, 1999, AM J PATHOL, V155, P915, DOI 10.1016/S0002-9440(10)65191-7
   Noth I, 2003, LANCET, V361, P587, DOI 10.1016/S0140-6736(03)12518-4
   Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815
   Pan GH, 1998, FEBS LETT, V424, P41, DOI 10.1016/S0014-5793(98)00135-5
   Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111
   Robertson NM, 2002, J IMMUNOL, V169, P5986, DOI 10.4049/jimmunol.169.10.5986
   Robertson NM, 2004, VITAM HORM, V67, P149
   Rus V, 2005, CLIN IMMUNOL, V117, P48, DOI 10.1016/j.clim.2005.05.001
   Sable-Fourtassou G, 2005, ANN INTERN MED, V143, P632, DOI 10.7326/0003-4819-143-9-200511010-00006
   Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818
   Sinico RA, 2005, ARTHRITIS RHEUM, V52, P2926, DOI 10.1002/art.21250
   Sinicrope FA, 2004, CLIN CANCER RES, V10, P8284, DOI 10.1158/1078-0432.CCR-04-1289
   Solans R, 2001, RHEUMATOLOGY, V40, P763, DOI 10.1093/rheumatology/40.7.763
   Tatsis E, 1998, ANN INTERN MED, V129, P370, DOI 10.7326/0003-4819-129-5-199809010-00004
   Vassina E, 2005, J INVEST DERMATOL, V125, P746, DOI 10.1111/j.0022-202X.2005.23878.x
   Walsh GM, 2003, J ENDOCRINOL, V178, P37, DOI 10.1677/joe.0.1780037
   Weller Peter F., 2001, Journal of Allergy and Clinical Immunology, V108, P175, DOI 10.1067/mai.2001.117176
   Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8
NR 44
TC 7
Z9 7
U1 2
U2 9
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0004-3591
EI 1529-0131
J9 ARTHRITIS RHEUM-US
JI Arthritis Rheum.
PD FEB
PY 2007
VL 56
IS 2
BP 662
EP 673
DI 10.1002/art.22387
PG 16
WC Rheumatology
SC Rheumatology
GA 135HS
UT WOS:000244145300031
PM 17265502
DA 2018-12-27
ER

PT J
AU Soboleva, GM
   Sukhikh, GT
AF Soboleva, G. M.
   Sukhikh, G. T.
TI RETRACTED: Genetic aberrations in tissue inhibitor of
   metalloproteinases-3 lead to manifestations of the myofibroblast
   phenotype in mouse fibroblasts and fibroblasts of patients with Sorsby
   fundus dystrophy (Retracted article. See vol. 147, pg. 669, 2009)
SO BULLETIN OF EXPERIMENTAL BIOLOGY AND MEDICINE
LA English
DT Article; Retracted Publication
DE Sorsby fundus dystrophy; tissue inhibitor of metalloproteinases-3
ID MESSENGER-RNA EXPRESSION; APOPTOSIS; INVASION; CELLS; TIMP3
AB Mutations in the C-terminal domain of tissue inhibitor of metalloproteinases-3 (TIMP-3) lead to autosomal dominant hereditary disease of the retina (Sorsby fundus dystrophy). Mouse knock-out and heterozygous knock-in fibroblasts and fibroblasts from patients with Sorsby fundus dystrophy exhibit some characteristics of myofibroblasts. Genetic changes in the timp-3 gene (TIMP-3) lead to a shift towards the myofibroblast phenotype in the fibroblast culture. It is hypothesized that Timp-3 (TIMP-3) plays a role of antitransformation agent preventing myofibroblast transformation in vivo and that the pathogenesis of Sorsby fundus dystrophy is associated with the loss of the antitransformation function by the mutant protein.
C1 Russian Acad Med Sci, Res Ctr Obstet Gynecol & Perinatol, Moscow 109801, Russia.
RP Soboleva, GM (reprint author), Russian Acad Med Sci, Res Ctr Obstet Gynecol & Perinatol, Moscow 109801, Russia.
EM soboleva_galina@hotmail.com
RI Sukhikh, Gennady/J-1496-2012
CR Ahonen M, 1998, CANCER RES, V58, P2310
   AnandApte B, 1997, INVEST OPHTH VIS SCI, V38, P817
   Baker AH, 1998, J CLIN INVEST, V101, P1478, DOI 10.1172/JCI1584
   Karan D, 2003, INT J ONCOL, V23, P1365
   Kotzsch M, 2005, EUR J CANCER, V41, P2760, DOI 10.1016/j.ejca.2005.09.002
   Mattila L, 1998, J INVEST DERMATOL, V110, P416, DOI 10.1046/j.1523-1747.1998.00138.x
   Nakamura M, 2005, LAB INVEST, V85, P165, DOI 10.1038/labinvest.3700223
   Powell DW, 1999, AM J PHYSIOL-CELL PH, V277, pC1
   Selman M, 2000, AM J PHYSIOL-LUNG C, V279, pL562
   Soboleva G, 2003, J CELL PHYSIOL, V197, P149, DOI 10.1002/jcp.10361
   SUKHIKH GT, 2007, B EKSP BIOL MED, V143, P70
   Tomasek JJ, 2002, NAT REV MOL CELL BIO, V3, P349, DOI 10.1038/nrm809
   WEBER BHF, 1994, NAT GENET, V7, P158, DOI 10.1038/ng0694-158
   Weber BHF, 2002, INVEST OPHTH VIS SCI, V43, P2732
   WEBER BHF, 1994, NAT GENET, V8, P352, DOI 10.1038/ng1294-352
NR 15
TC 1
Z9 1
U1 4
U2 9
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0007-4888
J9 B EXP BIOL MED+
JI Bull. Exp. Biol. Med.
PD FEB
PY 2007
VL 143
IS 2
BP 231
EP 235
DI 10.1007/s10517-007-0058-2
PG 5
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA 195NH
UT WOS:000248418400019
PM 17970209
DA 2018-12-27
ER

PT J
AU Pulukuri, SMK
   Estes, N
   Patel, J
   Rao, JS
AF Pulukuri, Sai Murali Krishna
   Estes, Norman
   Patel, Jitendra
   Rao, Jasti S.
TI RETRACTED: Demethylation-linked activation of urokinase plasminogen
   activator is involved in progression of prostate cancer (Retracted
   article. See vol. 78, pg. 3397, 2018)
SO CANCER RESEARCH
LA English
DT Article; Retracted Publication
ID CELL-LINES; IN-VIVO; PROMOTER HYPOMETHYLATION; DNA METHYLATION;
   BREAST-CANCER; UPA PROMOTER; TUMOR-GROWTH; EXPRESSION; METASTASIS;
   INVASION
AB Increased expression of urokinase plasminogen activator (uPA) has been reported in various malignancies including prostate cancer. However, the mechanism by which uPA is abnormally expressed in prostate cancer remains elusive. Here, we show that uPA is aberrantly expressed in a high percentage of human prostate cancer tissues but rarely expressed either in tumor-matched nonneoplastic adjacent tissues or benign prostatic hyperplasia samples. This aberrant expression is associated with cancer-linked demethylation of the uPA promoter. Furthermore, treatment with demethylation inhibitor S-adenosylmethionine or stable expression of uPA short hairpin RNA significantly inhibits uPA expression and tumor cell invasion in vitro and tumor growth and incidence of lung metastasis in vivo. Collectively, these findings strongly suggest that DNA demethylation is a common mechanism underlying the abnormal expression of uPA and is a critical contributing factor to the malignant progression of human prostate tumors.
C1 Univ Illinois, Coll Med, Dept Canc Biol & Pharmacol, Peoria, IL 61656 USA.
   Univ Illinois, Coll Med, Dept Surg, Peoria, IL 61656 USA.
   Univ Illinois, Coll Med, Dept Pathol, Peoria, IL 61656 USA.
   Univ Illinois, Coll Med, Dept Neurosurg, Peoria, IL 61656 USA.
RP Rao, JS (reprint author), Univ Illinois, Coll Med, Dept Canc Biol & Pharmacol, Box 1649, Peoria, IL 61656 USA.
EM jsrao@uic.edu
FU NCI NIH HHS [R01 CA095058, CA 92393, CA 95058, R01 CA116708, CA 75557,
   CA 116708, R01 CA075557, R01 CA092393]; NINDS NIH HHS [R01 NS047699, NS
   47699, NS 57529]
CR Aguirre-Ghiso JA, 2003, CANCER RES, V63, P1684
   Baylin SB, 1998, ADV CANCER RES, V72, P141
   Blasi F, 2002, NAT REV MOL CELL BIO, V3, P932, DOI 10.1038/nrm977
   Bubendorf L, 2000, HUM PATHOL, V31, P578, DOI 10.1053/hp.2000.6698
   Detich N, 2003, J BIOL CHEM, V278, P20812, DOI 10.1074/jbc.M211813200
   FIDLER IJ, 1990, CANCER RES, V50, P6130
   GARCIA AGP, 1989, PLACENTA, V10, P1
   GAYLIS FD, 1989, J UROLOGY, V142, P193, DOI 10.1016/S0022-5347(17)38709-8
   Gondi CS, 2003, ONCOGENE, V22, P5967, DOI 10.1038/sj.onc.1206535
   Halabi S, 2003, J CLIN ONCOL, V21, P1232, DOI 10.1200/JCO.2003.06.100
   Hegeman Robert B, 2004, Clin Prostate Cancer, V3, P150, DOI 10.3816/CGC.2004.n.025
   HIENERT G, 1988, J UROLOGY, V140, P1466, DOI 10.1016/S0022-5347(17)42074-X
   HOOSEIN NM, 1991, CANCER COMMUN, V3, P255
   HSU DW, 1995, AM J PATHOL, V147, P114
   Hull GW, 2002, J UROLOGY, V167, P528, DOI 10.1016/S0022-5347(01)69079-7
   Jemal A, 2003, CA-CANCER J CLIN, V53, P5, DOI 10.3322/canjclin.53.1.5
   Jemal A, 2004, CA-CANCER J CLIN, V54, P8, DOI 10.3322/canjclin.54.1.8
   KEER HN, 1991, PROSTATE, V18, P201, DOI 10.1002/pros.2990180303
   KUHN W, 1994, GYNECOL ONCOL, V55, P401, DOI 10.1006/gyno.1994.1313
   Lakka SS, 2005, BRAIN PATHOL, V15, P327
   Lakka SS, 2001, INT J ONCOL, V18, P71
   Legrand C, 2001, EXP CELL RES, V264, P326, DOI 10.1006/excr.2000.5125
   LIOTTA LA, 1993, PRINCIPLES MOL CELL, P134
   Liu HY, 2005, CANCER RES, V65, P7635, DOI 10.1158/0008-5472.CAN-05-1089
   Lodygin D, 2005, CANCER RES, V65, P4218, DOI 10.1158/0008-5472.CAN-04-4407
   Look MP, 1999, APMIS, V107, P150, DOI 10.1111/j.1699-0463.1999.tb01538.x
   Miyake H, 1999, INT J ONCOL, V14, P535
   Nishigaki M, 2005, CANCER RES, V65, P2115, DOI 10.1158/0008-5472.CAN-04-3340
   Ogishima T, 2005, CLIN CANCER RES, V11, P1028
   Pakneshan P, 2004, J BIOL CHEM, V279, P31735, DOI 10.1074/jbc.M401669200
   Pakneshan P, 2004, CLIN CANCER RES, V10, P3035, DOI 10.1158/1078-0432.CCR-03-0545
   Pakneshan P, 2003, FASEB J, V17, P1081, DOI 10.1096/fj.02-0973com
   Paredes J, 2005, CLIN CANCER RES, V11, P5869, DOI 10.1158/1078-0432.CCR-05-0059
   Pollack A, 2000, INT J RADIAT ONCOL, V48, P507, DOI 10.1016/S0360-3016(00)00620-9
   Pulukuri SM, 2006, ONCOGENE, V25, P4559, DOI 10.1038/sj.onc.1209462
   Pulukuri SM, 2005, J BIOL CHEM, V280, P36529, DOI 10.1074/jbc.M503111200
   PYKE C, 1991, AM J PATHOL, V138, P1059
   Rao JS, 2003, NAT REV CANCER, V3, P489, DOI 10.1038/nrc1121
   Salvi A, 2004, MOL CANCER THER, V3, P671
   Schweinitz A, 2004, J BIOL CHEM, V279, P33613, DOI 10.1074/jbc.M314151200
   Siddique K, 2003, INT J ONCOL, V22, P289
   Singh S, 2004, CLIN CANCER RES, V10, P8743, DOI 10.1158/1078-0432.CCR-04-0266
   SKRIVER L, 1984, J CELL BIOL, V99, P753, DOI 10.1083/jcb.99.2.753
   Stewart Delisha A, 2004, Reprod Biol Endocrinol, V2, P2, DOI 10.1186/1477-7827-2-2
   Szyf M, 2005, BIOCHEMISTRY-MOSCOW+, V70, P533, DOI 10.1007/s10541-005-0147-7
   Tokizane T, 2005, CLIN CANCER RES, V11, P5793, DOI 10.1158/1078-0432.CCR-04-2545
   VanVeldhuizen PJ, 1996, AM J MED SCI, V312, P8, DOI 10.1097/00000441-199607000-00002
   YAMAMOTO M, 1994, CANCER RES, V54, P3656
   Yang JL, 2000, INT J CANCER, V89, P431, DOI 10.1002/1097-0215(20000920)89:5<431::AID-IJC6>3.0.CO;2-V
   Yoshida BA, 2000, JNCI-J NATL CANCER I, V92, P1717, DOI 10.1093/jnci/92.21.1717
NR 50
TC 54
Z9 57
U1 1
U2 1
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD FEB 1
PY 2007
VL 67
IS 3
BP 930
EP 939
DI 10.1158/0008-5472.CAN-06-2892
PG 10
WC Oncology
SC Oncology
GA 135EQ
UT WOS:000244137300014
PM 17283123
OA Green Accepted, Bronze
DA 2018-12-27
ER

PT J
AU Abou-Elela, A
   Reyad, I
   Morsy, A
   Elgammal, M
   Bedair, AS
   Abdelkader, M
AF Abou-Elela, A.
   Reyad, I.
   Morsy, A.
   Elgammal, M.
   Bedair, A. S.
   Abdelkader, M.
TI RETRACTED: Continence after radical prostatectomy with bladder neck
   preservation (Retracted article. See vol. 35, pg. 447, 2009)
SO EJSO
LA English
DT Article; Retracted Publication
DE radical prostatectomy; urinary incontinence; prostatic neoplasms
ID RETROPUBIC PROSTATECTOMY; URINARY CONTINENCE; ANASTOMOTIC STRICTURES;
   IMPACT; PATHOPHYSIOLOGY; RECONSTRUCTION; INCONTINENCE; MANAGEMENT
AB Purpose: Bladder neck preservation during radical prostatectomy has been advocated for improving urinary continence. We evaluate bladder neck preservation looking at continence rates, surgical cancer control and bladder neck contracture.
   Materials and methods: A total of 40 patients underwent retropubic radical prostatectomy for clinically localized carcinoma of the prostate. The prostatic urethra was dissected in continuity with the bladder away from the lumen of the prostate, which allows for a true urethra-to-urethra anastomosis.
   Results: Continence was noted immediately in 26 patients, within 2 weeks in 9 and within 6 weeks in 3. Only 2 patients required pads 3 months postoperatively. Microscopic positive surgical margins were noted in 2 of 40 patients. In 1 patient the 1 urethral margins were not involved with carcinoma. In the other patient the urethra was not the sole positive margin and microscopic positive margins were noted elsewhere. Early results of cancer control were good.
   Conclusions: Early follow-up of this technique of radical retropubic prostatectomy suggest that preservation of the continence mechanism at the level of the bladder neck and prostatic urethra results in significantly improved postoperative urinary continence without adversely affecting cancer control. (C) 2006 Elsevier Ltd. All rights reserved.
C1 Cairo Univ, Dept Urol, Cairo 35290, Egypt.
RP Abou-Elela, A (reprint author), Cairo Univ, Dept Urol, 1 Obour Bldg,Salah Salem St, Cairo 35290, Egypt.
EM ashrafaboelela@yahoo.co.uk
CR CATALONA WJ, 1993, J UROLOGY, V150, P905, DOI 10.1016/S0022-5347(17)35645-8
   FOOTE J, 1991, UROL CLIN N AM, V18, P229
   Gaker DL, 1996, J UROLOGY, V156, P445, DOI 10.1016/S0022-5347(01)65875-0
   Gaker Douglas L, 2004, J Urol, V172, P2549, DOI 10.1097/01.ju.0000144071.24113.1c
   LEANDRI P, 1992, J UROLOGY, V147, P883, DOI 10.1016/S0022-5347(17)37412-8
   LEVY JB, 1994, UROLOGY, V44, P888, DOI 10.1016/S0090-4295(94)80176-2
   LICHT MR, 1994, UROLOGY, V44, P883, DOI 10.1016/S0090-4295(94)80175-4
   Lowe BA, 1996, UROLOGY, V48, P889, DOI 10.1016/S0090-4295(96)00324-X
   Poon M, 2000, J UROLOGY, V163, P194, DOI 10.1016/S0022-5347(05)68003-2
   PRESTI JC, 1990, J UROLOGY, V143, P975, DOI 10.1016/S0022-5347(17)40155-8
   Seaman EK, 1996, UROLOGY, V47, P532, DOI 10.1016/S0090-4295(99)80490-7
   Shelfo SW, 1998, UROLOGY, V51, P73, DOI 10.1016/S0090-4295(97)00463-9
   Srougi M, 2001, J UROLOGY, V165, P815, DOI 10.1016/S0022-5347(05)66534-2
   STEINER MS, 1991, J UROLOGY, V145, P512, DOI 10.1016/S0022-5347(17)38382-9
   SURYA BV, 1990, J UROLOGY, V143, P755, DOI 10.1016/S0022-5347(17)40082-6
NR 15
TC 4
Z9 4
U1 3
U2 10
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0748-7983
EI 1532-2157
J9 EJSO-EUR J SURG ONC
JI EJSO
PD FEB
PY 2007
VL 33
IS 1
BP 96
EP 101
DI 10.1016/j.ejso.2006.10.006
PG 6
WC Oncology; Surgery
SC Oncology; Surgery
GA 145CI
UT WOS:000244842500018
PM 17123772
DA 2018-12-27
ER

PT J
AU Roman-Gomez, J
   Jimenez-Velasco, A
   Agirre, X
   Castillejo, JA
   Navarro, G
   San Jose-Eneriz, E
   Garate, L
   Cordeu, L
   Cervantes, F
   Prosper, F
   Heiniger, A
   Torres, A
AF Roman-Gomez, Jose
   Jimenez-Velasco, Antonio
   Agirre, Xabier
   Castillejo, Juan A.
   Navarro, German
   San Jose-Eneriz, Edurne
   Garate, Leire
   Cordeu, Lucia
   Cervantes, Francisco
   Prosper, Felipe
   Heiniger, Anabel
   Torres, Antonio
TI RETRACTED: Epigenetic regulation of human cancer/testis antigen gene,
   HAGE, in chronic myeloid leukemia (Retracted article. See vol. 97, pg.
   1452, 2012)
SO HAEMATOLOGICA-THE HEMATOLOGY JOURNAL
LA English
DT Article; Retracted Publication
DE cancer testis antigens; HAGE; hypomethylation; CML
ID CHRONIC MYELOGENOUS LEUKEMIA; GLOBAL DNA HYPOMETHYLATION; HUMAN
   CUTANEOUS MELANOMA; BCR-ABL; PROMOTER HYPOMETHYLATION; GENOMIC
   HYPOMETHYLATION; RESIDUAL DISEASE; RNA HELICASE; CPG ISLANDS; EXPRESSION
AB Background and Objectives Cancer testis antigens (CTA) provide attractive targets for cancer-specific immunotherapy. Although CTA genes are expressed in some normal tissues, such as the testis, this immunologically protected site lacks MHC I expression and as such, does not present self antigens to T cells. To date, CTA genes have been shown to be expressed in a range of solid tumors via demethylation of their promoter CpG islands, but rarely in chronic myeloid leukemia (CIVIL) or other hematologic malignancies.
   Design and Methods In this study, the methylation status of the HAGE CTA gene promoter was analyzed by quantitative methylation-specific polymerase chain reaction (MSP) and sequencing in four Philadelphia-positive cell lines (TCC-S, K562, KU812 and KYO-1) and in CIVIL samples taken from patients in chronic phase (CP n=215) or blast crisis (BC n=47). HAGE expression was assessed by quantitative reverse transcriptase-polymerase chain reaction.
   Results
   The TCC-S cell line showed demethylation of HAGE that was associated with overexpression of this gene. HAGE hypomethylation was significantly more frequent in BC (46%) than in CP (22%) (p=0.01) and was correlated with high expression levels of HAGE transcripts (p < 0.0001). Of note, in CP-CML, extensive HAGE hypomethylation was associated with poorer prognosis in terms of cytogenetic response to interferon (p=0.01) or imatinib (p=0.01), molecular response to imatinib (p=0.003) and progression-free survival (p=0.05).
   Interpretations and Conclusion The methylation status of the HAGE promoter directly correlates with its expression in both CIVIL cell lines and patients and is associated with advanced disease and poor outcome.
C1 Reina Sofia Hosp, Hematol Dept, Cordoba 14004, Spain.
   Carlos Haya Hosp, Hematol Dept, Malaga, Spain.
   Univ Navarra, Fdn Appl Med Res, Sch Med, Cellular Therapy Area,Hematol Dept, E-31080 Pamplona, Spain.
   Univ Barcelona, Hosp Clin, IDIBAPS, Hematol Dept, Barcelona, Spain.
RP Roman-Gomez, J (reprint author), Reina Sofia Hosp, Hematol Dept, Avda Menendez Pidal S-N, Cordoba 14004, Spain.
EM peperosa@teleline.es
RI Prosper, Felipe/H-6859-2017; Torres, Antoni/H-6128-2017
OI Prosper, Felipe/0000-0001-6115-8790; Torres, Antoni/0000-0002-8643-2167
CR Adams SP, 2002, LEUKEMIA, V16, P2238, DOI 10.1038/sj.leu.2402732
   Bocchia M, 2005, LANCET, V365, P657
   Bocchia M, 1996, BLOOD, V87, P3587
   Calabretta B, 2004, BLOOD, V103, P4010, DOI 10.1182/blood-2003-12-4111
   Chen QY, 2004, P NATL ACAD SCI USA, V101, P9363, DOI 10.1073/pnas.0403271101
   CHU B, 2003, BIOCHEM BIOPH RES CO, V18, P307
   Deininger M, 2005, BLOOD, V105, P2640, DOI 10.1182/blood-2004-08-3097
   DESMET C, 1995, IMMUNOGENETICS, V42, P282, DOI 10.1007/BF00176446
   Gabert J, 2003, LEUKEMIA, V17, P2318, DOI 10.1038/sj.leu.2403135
   Gaudet F, 2003, SCIENCE, V300, P489, DOI 10.1126/science.1083558
   Grunebach F, 2006, CANCER RES, V66, P5892, DOI 10.1158/0008-5472.CAN-05-2868
   Grunau C, 2005, GENE CHROMOSOME CANC, V43, P11, DOI 10.1002/gcc.20155
   Hasford J, 1998, J NATL CANCER I, V90, P850, DOI 10.1093/jnci/90.11.850
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Honda T, 2004, BRIT J CANCER, V90, P838, DOI 10.1038/sj.bjc.6601600
   Huntly BJP, 2003, BLOOD, V102, P1160, DOI 10.1182/blood-2003-01-0123
   IGGO R, 1990, NUCLEIC ACIDS RES, V18, P5413, DOI 10.1093/nar/18.18.5413
   Issa JPJ, 2004, BLOOD, V103, P1635, DOI 10.1182/blood-2003-03-0687
   Kaneda A, 2004, CANCER SCI, V95, P58, DOI 10.1111/j.1349-7006.2004.tb03171.x
   KIM YI, 1994, CANCER, V74, P893, DOI 10.1002/1097-0142(19940801)74:3<893::AID-CNCR2820740316>3.0.CO;2-B
   Kurashige T, 2001, CANCER RES, V61, P4671
   Lim JH, 2005, INT J CANCER, V116, P200, DOI 10.1002/ijc.21007
   Lim SH, 1999, BRIT J CANCER, V81, P1162, DOI 10.1038/sj.bjc.6690824
   Lurquin C, 2005, J EXP MED, V201, P249, DOI 10.1084/jem.20041378
   Martelange V, 2000, CANCER RES, V60, P3848
   O'Brien SG, 2003, NEW ENGL J MED, V348, P994, DOI 10.1056/NEJMoa022457
   Otte M, 2001, CANCER RES, V61, P6682
   Piyathilake CJ, 2001, HUM PATHOL, V32, P856, DOI 10.1053/hupa.2001.26471
   Qu GZ, 1999, MUTAT RES-FUND MOL M, V423, P91, DOI 10.1016/S0027-5107(98)00229-2
   Ren R, 2005, NAT REV CANCER, V5, P172, DOI 10.1038/nrc1567
   Rizwana R, 1999, J CELL SCI, V112, P4513
   Roman-Gomez J, 2005, ONCOGENE, V24, P7213, DOI 10.1038/sj.onc.1208866
   Salesse S, 2004, LEUKEMIA, V18, P727, DOI 10.1038/sj.leu.2403310
   Sigalotti L, 2004, CANCER RES, V64, P9167, DOI 10.1158/0008-5472.CAN-04-1442
   Sigalotti L, 2002, J IMMUNOTHER, V25, P16, DOI 10.1097/00002371-200201000-00002
   Simpson AJG, 2005, NAT REV CANCER, V5, P615, DOI 10.1038/nrc1669
   Soares J, 1999, CANCER, V85, P112, DOI 10.1002/(SICI)1097-0142(19990101)85:1<112::AID-CNCR16>3.0.CO;2-T
   SOKAL JE, 1984, BLOOD, V63, P789
   Wang ZQ, 2006, INT J CANCER, V118, P1436, DOI 10.1002/ijc.21499
   Yakirevich E, 2003, CLIN CANCER RES, V9, P6453
   Yang LQ, 2005, MOL CANCER RES, V3, P355, DOI 10.1158/1541-7786.MCR-05-0022
   Yasukawa M, 2001, BLOOD, V98, P1498, DOI 10.1182/blood.V98.5.1498
NR 42
TC 38
Z9 41
U1 2
U2 12
PU FERRATA STORTI FOUNDATION
PI PAVIA
PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY
SN 0390-6078
EI 1592-8721
J9 HAEMATOL-HEMATOL J
JI Haematol-Hematol. J.
PD FEB
PY 2007
VL 92
IS 2
BP 153
EP 162
DI 10.3324/haematol.10782
PG 10
WC Hematology
SC Hematology
GA 136OI
UT WOS:000244233600003
PM 17296563
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Azadani, PN
   Jafarimehr, E
   Shokatbakhsh, A
   Pourhoseingholi, MA
   Ghougeghi, A
AF Azadani, Peyman Nejatbakhsh
   Jafarimehr, Elnaz
   Shokatbakhsh, Abdorahman
   Pourhoseingholi, Mohamad Amin
   Ghougeghi, Aman
TI RETRACTED: The effect of dental overbite on eustachian tube dysfunction
   in Iranian children (Retracted Article. See vol 71, pg 1815, 2007)
SO INTERNATIONAL JOURNAL OF PEDIATRIC OTORHINOLARYNGOLOGY
LA English
DT Article; Retracted Publication
DE otitis media; eustachian tube dysfunction; overbite; dental occlusion
ID ACUTE OTITIS-MEDIA; CIGARETTE-SMOKE EXPOSURE; RISK-FACTORS; EFFUSION;
   LIFE; CARE
AB Objective: To investigate the association between deep dental overbite and eustachian tube dysfunction.
   Methods: It was designed as a case-control study. Among hospitalized patients in otolaryngology department at Taleghani Hospital in Tehran, Iran, from January to December 2005, 132 patients between the ages of 2 and 6 years were recruited. Dental overbite, overjet, and occlusal relationships were measured by one observer. Eustachian tube dysfunction was defined as having ventilation tubes with an abnormal tympanometry. In addition, demographic information, medical and social histories were prospectively recorded. Univariate and multivariate logistic regression model were used.
   Results: In a multivariate model, children with deep bites were 10.6 times more likely to have eustachian tube dysfunction than those without deep bites (P < 0.05). Other independent risk factors for eustachian tube dysfunction identified in this model were family history of otitis media, daycare exposure, and non-breast-feeding.
   Conclusions: Children with deep dental overbites are at a significantly increased risk for developing eustachian tube dysfunction. (C) 2006 Elsevier Ireland Ltd. All rights reserved.
C1 Shahid Beheshti Univ Med Sci, Dept Orthodont, Tehran 1951935313, Iran.
   Shahid Beheshti Univ Med Sci, Dept Biostat, Tehran 1951935313, Iran.
   Shahid Beheshti Univ Med Sci, Taleghani Hosp, Dept Otorhinolaryngol, Tehran 1951935313, Iran.
RP Azadani, PN (reprint author), Shahid Beheshti Univ Med Sci, Dept Orthodont, 4 Kahkeshan Alley,N Dibaji St,Farmanieh St, Tehran 1951935313, Iran.
EM drpeyman103@hotmail.com; ejfmehr@yahoo.com; clinic@ghoujeghi.com
CR Acuin J, 2004, BURDEN ILLNESS MANAG
   ASPIN MM, 1994, J PEDIATR-US, V125, P136, DOI 10.1016/S0022-3476(94)70140-7
   Betzenberger D, 1999, ANGLE ORTHOD, V69, P27
   Branam S R, 1998, J Clin Pediatr Dent, V22, P203
   BYLANDER A, 1984, RECENT ADV OTITIS ME, P56
   COSTEN JB, 1934, ANN OTO RHINOL LARYN, V43, P1, DOI [10.1177/000348943404300101, DOI 10.1177/000348943404300101]
   DUNCAN B, 1993, PEDIATRICS, V91, P867
   INGLIS AF, 2005, CUMMINGS OTOLARYNGOL, P4445
   Jackson Jonathan M., 1999, Pediatric Dentistry, V21, P255
   KENNA MA, 1998, HEAD NECK SURG OTOLA, P1297
   KERO P, 1987, ACTA PAEDIATR SCAND, V76, P618, DOI 10.1111/j.1651-2227.1987.tb10531.x
   KITAJIRI M, 1985, ANN OTO RHINOL LARYN, V94, P44
   KLEIN LO, 1998, TXB PEDIAT INFECT DI, P195
   KRAEMER MJ, 1983, JAMA-J AM MED ASSOC, V249, P1022, DOI 10.1001/jama.249.8.1022
   Loudon M E, 1990, Funct Orthod, V7, P10
   MANN W, 1979, ACTA OTO-LARYNGOL, V87, P451, DOI 10.3109/00016487909126450
   MARASA FK, 1988, CRANIO, V6, P256, DOI 10.1080/08869634.1988.11678247
   McDonnell JP, 2001, LARYNGOSCOPE, V111, P310, DOI 10.1097/00005537-200102000-00023
   MEW JRC, 1992, J LARYNGOL OTOL, V106, P7, DOI 10.1017/S0022215100118468
   Monsell EM, 1996, OTOLARYNG CLIN N AM, V29, P437
   Myrhaug H, 1970, Quintessenz, V21, P107
   NIEMELA M, 1995, PEDIATRICS, V96, P884
   NIEMELA M, 1994, J LARYNGOL OTOL, V108, P299
   OWEN MJ, 1993, J PEDIATR-US, V123, P702, DOI 10.1016/S0022-3476(05)80843-1
   PROFFIT W, 1993, CONT ORTHODONTICS, P206
   SAARINEN UM, 1982, ACTA PAEDIATR SCAND, V71, P567, DOI 10.1111/j.1651-2227.1982.tb09476.x
   Sassen ML, 1997, AM J OTOLARYNG, V18, P324, DOI 10.1016/S0196-0709(97)90027-2
   Scarano E, 2003, ACTA OTO-LARYNGOL, V123, P288, DOI 10.1080/00016480310001141
   SCHAPPERT SM, 1992, VITAL HLTH STATISTIC, V214, P1
   Schendel S A, 1976, Am J Orthod, V70, P398
   SELDIN HM, 1955, NY STATE DENT J, V21, P313
   SICHER H, 1948, J AM DENT ASSOC, V36, P131, DOI 10.14219/jada.archive.1948.0021
   Stack B C, 1977, J Pedod, V1, P240
   STAHLBERG MR, 1986, PEDIATR INFECT DIS J, V5, P30, DOI 10.1097/00006454-198601000-00006
   TEELE DW, 1989, J INFECT DIS, V160, P83, DOI 10.1093/infdis/160.1.83
   Watase Scot, 1998, Pediatric Dentistry, V20, P327
   YOUNG MW, 1952, ANAT REC, V112, P438
NR 37
TC 4
Z9 4
U1 3
U2 10
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0165-5876
EI 1872-8464
J9 INT J PEDIATR OTORHI
JI Int. J. Pediatr. Otorhinolaryngol.
PD FEB
PY 2007
VL 71
IS 2
BP 325
EP 331
DI 10.1016/j.ijporl.2006.10.023
PG 7
WC Otorhinolaryngology; Pediatrics
SC Otorhinolaryngology; Pediatrics
GA 133MZ
UT WOS:000244018300019
PM 17141333
DA 2018-12-27
ER

PT J
AU Qiao, CH
   Zhang, KL
   Xia, JH
AF Qiao Chenhui
   Zhang Kailun
   Xia Jiahong
TI RETRACTED: Influence of oxidized low density lipoprotein on the
   proliferation of human artery smooth muscle cells in vitro (Retracted
   Article. See vol 28, pg 234, 2008)
SO JOURNAL OF HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY-MEDICAL
   SCIENCES
LA English
DT Article; Retracted Publication
DE oxidized low density lipoprotein; smooth muscle cell; proliferation;
   atherosclerosis
ID OXIDATIVE MODIFICATION; LDL OXIDATION; APOPTOSIS; ATHEROSCLEROSIS;
   ATHEROGENESIS; CHOLESTEROL
AB The effects of oxidized low density lipoprotein (ox-LDL) on the proliferation of cultured human vascular smooth muscle cells (vSMC) were investigated in vitro. By using NaBr density gradient centrifugation, LDL was isolated and purified from human plasma. Ox-LDL was produced from LDL by being incubated with CUSO4. ox-LDL was then added to the culture medium at different concentrations (35, 60, 85, 110, 135 and 160 mu g/mL) for 7 days. The influence of, ox-LDL on vSMC proliferation was observed in growth curve, mitosis index, and in situ determination of apoptosis. The data were analyzed with SPSS 10.0 software. The results showed that the ox-LDL produced in vitro had a good purity and optimal oxidative degree, which was similar to the intrinsic ox-LDL in atherosclerotic plaque. ox-LDL at a concentration of 35 mu g/mL demonstrated the strongest proliferation inducement, and at a concentration of 135 mu g/mL, ox-LDL could inhibit the growth of vSMC. ox-LDL at concentrations of 35 and 50 mu g/mL presented powerful mitotic trigger, and with the increase of ox-LDL concentration, the mitotic index of vSMC was decreased gradually. ox-LDL at higher concentrations promoted more apoptotic vSMCs. ox-LDL at lower concentrations triggered proliferation of vSMCs, and at higher concentrations induced apoptosis in vSMCs. ox-LDL played a promotional role in the pathogenesis and development of atherosclerosis by affecting vSMC proliferation and apoptosis.
C1 [Qiao Chenhui; Zhang Kailun; Xia Jiahong] Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Dept Cardiovasc Surg, Wuhan 430022, Peoples R China.
   [Qiao Chenhui] Zhengzhou Univ, Affiliated Hosp 1, Dept Cardiovasc Thorac Surg, Zhengzhou 450052, Peoples R China.
RP Zhang, KL (reprint author), Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Dept Cardiovasc Surg, Wuhan 430022, Peoples R China.
EM qchenhui@hotmail.com
CR Alexander JJ, 2002, J SURG RES, V103, P41, DOI 10.1006/jsre.2001.6345
   Argmann CA, 2004, ARTERIOSCL THROM VAS, V24, P1290, DOI 10.1161/01.ATV.0000131260.80316.37
   Bachem MG, 1999, CLIN CHEM LAB MED, V37, P319, DOI 10.1515/CCLM.1999.054
   Carpenter KLH, 2003, FEBS LETT, V553, P145, DOI 10.1016/S0014-5793(03)01007-X
   Kohno M, 1997, CIRC RES, V81, P585, DOI 10.1161/01.RES.81.4.585
   Li HH, 2000, CHINESE MED J-PEKING, V113, P657
   Mata P, 1997, ARTERIOSCL THROM VAS, V17, P2088, DOI 10.1161/01.ATV.17.10.2088
   Mayr M, 2001, EXP GERONTOL, V36, P969, DOI 10.1016/S0531-5565(01)00090-0
   Napoli C, 2000, FASEB J, V14, P1996, DOI 10.1096/fj.99-0986com
   NATARAJAN V, 1995, J LIPID RES, V36, P2005
   NIGRIS F, 2000, CIRCULATION, V102, P2111
   Norata GD, 2002, NUTR METAB CARDIOVAS, V12, P297
   Shen CM, 2001, LIFE SCI, V70, P443, DOI 10.1016/S0024-3205(01)01428-X
   STEINBERG D, 1989, NEW ENGL J MED, V320, P915
   STEINBRECHER UP, 1990, FREE RADICAL BIO MED, V9, P155, DOI 10.1016/0891-5849(90)90119-4
   Taguchi S, 2000, J Atheroscler Thromb, V7, P132
   Tepe G, 2001, ATHEROSCLEROSIS, V157, P383, DOI 10.1016/S0021-9150(00)00753-X
   Thorne SA, 1996, HEART, V75, P11, DOI 10.1136/hrt.75.1.11
   Verhamme P, 2002, CARDIOVASC RES, V56, P135, DOI 10.1016/S0008-6363(02)00515-1
   VRIES CJ, 2000, J BIOL CHEM, V275, P23939
   Wells KE, 1997, J SURG RES, V67, P126, DOI 10.1006/jsre.1996.4991
   Zhao GF, 2003, CHINESE MED J-PEKING, V116, P166
   Zhou YF, 1996, J CLIN INVEST, V98, P2129, DOI 10.1172/JCI119019
NR 23
TC 5
Z9 7
U1 3
U2 15
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1672-0733
EI 1993-1352
J9 J HUAZHONG U SCI-MED
JI J. Huazhong Univ. Sci. Tech.-Med.
PD FEB
PY 2007
VL 27
IS 1
BP 20
EP 23
DI 10.1007/s11596-007-0106-1
PG 4
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 284RD
UT WOS:000254722600006
PM 17393100
DA 2018-12-27
ER

PT J
AU Radhakrishnan, S
   Nguyen, LT
   Ciric, B
   Van Keulen, VP
   Pease, LR
AF Radhakrishnan, Suresh
   Nguyen, Loc T.
   Ciric, Bogoljub
   Van Keulen, Virginia P.
   Pease, Larry R.
TI RETRACTED: B7-DC/PD-L2 cross-linking induces NF-kappa B-dependent
   protection of dendritic cells from cell death (Retracted article. See
   vol. 184, pg. 6554, 2010)
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article; Retracted Publication
ID TUMOR-NECROSIS-FACTOR; INDUCED APOPTOSIS; SELECTIVE-INHIBITION;
   SIGNALING PATHWAYS; T-CELLS; ACTIVATION; B7-DC; KINASE; SURVIVAL;
   IMMUNITY
AB Cross-linking cell surface molecules with IgM Abs is a specific approach for activating cells in vitro or in vivo. Dendritic cells (DC) activated with a human B7-DC (PD-L2)-specific IgM Ab can induce strong antitumor responses and block inflammatory airway disease in experimental models, yet the Ab-mediated molecular events promoting these responses remain unclear. Analysis of human or mouse DC treated with the B7-DC cross-linking Ab revealed PI3K-dependent phosphorylation of AKT accompanied by mobilization of NF-kappa B. Ab-activated DC up-regulated expression of cytokine and chemokine genes in an NF-kappa B-dependent manner. Importantly, PI3K -> AKT -> NF-kappa B activation was found to be indispensable for B7-DC cross-linking Ab-mediated protection of DC from cell death caused by cytokine withdrawal. Although other DC activators similarly protect DC from cell death, a synergy between cross-linking B7-DC and ligating RANK was observed. The parallel signaling events induced in human and mouse DC demonstrate that activation of cells using IgM Ab results in a response governed by a common mechanism and support the hypothesis that B7-DC cross-linking using this Ab may provide beneficial therapeutic immune modulation in human patients similar to those seen in animal models.
C1 Mayo Clin & Mayo Fdn, Coll Med, Dept Immunol, Rochester, MN 55905 USA.
RP Pease, LR (reprint author), Mayo Clin & Mayo Fdn, Coll Med, Dept Immunol, 200 1st St SW, Rochester, MN 55905 USA.
EM pease.larry@mayo.edu
FU NCI NIH HHS [R01 CA104996]
CR AHMED SA, 1994, J IMMUNOL METHODS, V170, P211
   Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560
   Banchereau J, 2000, ANNU REV IMMUNOL, V18, P767, DOI 10.1146/annurev.immunol.18.1.767
   Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588
   BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0
   CAUX C, 1994, J EXP MED, V180, P1263, DOI 10.1084/jem.180.4.1263
   Croft M, 2003, NAT REV IMMUNOL, V3, P609, DOI 10.1038/nri1148
   Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661
   Geissmann F, 2003, J EXP MED, V198, P623, DOI 10.1084/jem.20030390
   Ghosh-Choudhury N, 2002, J BIOL CHEM, V277, P33361, DOI 10.1074/jbc.M205053200
   Greenwald RJ, 2005, ANNU REV IMMUNOL, V23, P515, DOI 10.1146/annurev.immunol.23.021704.115611
   Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704
   Huxford T, 1998, CELL, V95, P759, DOI 10.1016/S0092-8674(00)81699-2
   Iwasaki A, 2004, NAT IMMUNOL, V5, P987, DOI 10.1038/ni1112
   Jankovic D, 2002, IMMUNITY, V16, P429, DOI 10.1016/S1074-7613(02)00278-9
   Kane LP, 2002, MOL CELL BIOL, V22, P5962, DOI 10.1128/MCB.22.16.5962-5974.2002
   Karin M, 2005, NAT REV IMMUNOL, V5, P749, DOI 10.1038/nri1703
   KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0
   Kawai T, 1999, IMMUNITY, V11, P115, DOI 10.1016/S1074-7613(00)80086-2
   Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701
   Latchman Y, 2001, NAT IMMUNOL, V2, P261, DOI 10.1038/85330
   Luo JL, 2005, J CLIN INVEST, V115, P2625, DOI 10.1172/JCI126322
   May MJ, 2000, SCIENCE, V289, P1550, DOI 10.1126/science.289.5484.1550
   McLellan A, 2000, EUR J IMMUNOL, V30, P2612, DOI 10.1002/1521-4141(200009)30:9<2612::AID-IMMU2612>3.0.CO;2-G
   Medzhitov R, 1998, MOL CELL, V2, P253, DOI 10.1016/S1097-2765(00)80136-7
   Mellman I, 2001, CELL, V106, P255, DOI 10.1016/S0092-8674(01)00449-4
   Natoli G, 2005, NAT IMMUNOL, V6, P439, DOI 10.1038/ni1196
   Nguyen LT, 2002, J EXP MED, V196, P1393, DOI 10.1084/jem.20021466
   Ozes ON, 1999, NATURE, V401, P82
   Penna G, 2000, J IMMUNOL, V164, P2405, DOI 10.4049/jimmunol.164.5.2405
   Pennington KN, 2001, MOL CELL BIOL, V21, P1930, DOI 10.1128/MCB.21.6.1930-1941.2001
   Quezada SA, 2004, ANNU REV IMMUNOL, V22, P307, DOI 10.1146/annurev.immunol.22.012703.104533
   Radhakrishnan S, 2005, J ALLERGY CLIN IMMUN, V116, P668, DOI 10.1016/j.jaci.2005.04.038
   Radhakrishnan S, 2005, P NATL ACAD SCI USA, V102, P11438, DOI 10.1073/pnas.0501420102
   Radhakrishnan S, 2004, J IMMUNOL, V173, P1360, DOI 10.4049/jimmunol.173.2.1360
   Radhakrishnan S, 2004, CANCER RES, V64, P4965, DOI 10.1158/0008-5472.CAN-03-3025
   Radhakrishnan S, 2003, J IMMUNOL, V170, P1830, DOI 10.4049/jimmunol.170.4.1830
   Romashkova JA, 1999, NATURE, V401, P86
   Schnare M, 2001, NAT IMMUNOL, V2, P947, DOI 10.1038/ni712
   Shin T, 2005, J EXP MED, V201, P1531, DOI 10.1084/jem.20050072
   Takeda K, 2004, SEMIN IMMUNOL, V16, P3, DOI 10.1016/j.smim.2003.10.003
   Tas SW, 2005, EUR J IMMUNOL, V35, P1164, DOI 10.1002/eji.200425956
   Tseng SY, 2001, J EXP MED, V193, P839, DOI 10.1084/jem.193.7.839
   Wang SD, 2003, J EXP MED, V197, P1083, DOI 10.1084/jem.20021752
   Wong BR, 1997, J EXP MED, V186, P2075, DOI 10.1084/jem.186.12.2075
   Xie J, 2005, EXP HEMATOL, V33, P564, DOI 10.1016/j.exphem.2005.03.001
   YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324
   Yuan JY, 2000, NATURE, V407, P802, DOI 10.1038/35037739
   Zong WX, 1999, GENE DEV, V13, P382, DOI 10.1101/gad.13.4.382
NR 49
TC 24
Z9 25
U1 4
U2 12
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD FEB 1
PY 2007
VL 178
IS 3
BP 1426
EP 1432
DI 10.4049/jimmunol.178.3.1426
PG 7
WC Immunology
SC Immunology
GA 130TC
UT WOS:000243820900025
PM 17237390
OA Bronze
DA 2018-12-27
ER

PT J
AU Goodwill, MH
   Lawrence, DA
   Seegal, RF
AF Goodwill, Meleik Hebert
   Lawrence, David A.
   Seegal, Richard F.
TI RETRACTED: Polychlorinated biphenyls induce proinflammatory cytokine
   release and dopaminergic dysfunction: Protection in interleukin-6
   knockout mice (Retracted Article. See vol 197, pg 87, 2008)
SO JOURNAL OF NEUROIMMUNOLOGY
LA English
DT Article; Retracted Publication
DE polychlorinated biphenyl; environmental contaminant; dopamine;
   neurodegeneration; cytokines; IL-6
ID VENTRICULAR CEREBROSPINAL-FLUID; GROWTH-FACTOR-ALPHA;
   PARKINSONS-DISEASE; INFLAMMATORY RESPONSE; MICROGLIAL ACTIVATION;
   DEFICIENT MICE; BRAIN-INJURY; IN-VITRO; IMMUNE; MODEL
AB Proinflammatory cytokines are not only important mediators of brain development, but also pose an increased risk for neurodegeneration following exposure to neurotoxicants or trauma. We have used the ubiquitous environmental and occupational neurotoxicant polychlorinated biphenyls (PCBs) to investigate the putative role of inflammatory agents in mediating processes involved in basal ganglia dysfunctions. PCBs induced inflammatory responses in C57BL/6 adult male mice, significantly elevating serum levels of IL-6 (31%), IL-1 beta (71%) and TNF-alpha (22%) and significantly reducing striatal dopamine (DA, 21%), tyrosine hydroxylase (TH, 26%), dopamine transporter (DAT, 39%), and synaptophysin (29%) concentrations. We also exposed mice deficient in the proinflammatory cytokine interleukin-6 (IL-6(-/-)) to PCBs, to explore the role of this specific cytokine in mediating PCB-induced DA neurodegeneration. Not only did the PCB-treated IL-6-/- mice exhibit a decrease in serum levels of IL-1 and TNF-alpha, but they were also protected from PCB-induced striatal dopaminergic dysfunction, displaying no signs of toxicant-induced reductions in DA levels, or TH, DAT or synaptophysin expression. Taken together, these results suggest that: (1) PC13 exposure results in a peripheral inflammatory response associated with striatal terminal degeneration; and (2) the absence of IL-6 prevents PCB-induced dopaminergic losses in the striatum. (c) 2006 Elsevier B.V. All rights reserved.
C1 New York State Dept Hlth, Wadsworth Ctr, Albany, NY 12201 USA.
RP Goodwill, MH (reprint author), New York State Dept Hlth, Wadsworth Ctr, Empire State Plaza,POB 509, Albany, NY 12201 USA.
EM goodwill@wadsworth.org
FU NIEHS NIH HHS [5R21ES01326902]
CR Anisman H, 2002, BRAIN BEHAV IMMUN, V16, P544, DOI 10.1016/S0889-1591(02)00011-9
   Bemis JC, 2004, TOXICOL SCI, V80, P288, DOI 10.1093/toxsci/kfh153
   BlumDegen D, 1995, NEUROSCI LETT, V202, P17, DOI 10.1016/0304-3940(95)12192-7
   CHISHTI MA, 1992, TOXICOLOGIST, V12, P320
   Darvill T, 2000, NEUROTOXICOLOGY, V21, P1029
   Diao H, 2005, INFECT IMMUN, V73, P3745, DOI 10.1128/IAI.73.6.3745-3748.2005
   Dunn AJ, 2000, ANN NY ACAD SCI, V917, P608, DOI 10.1111/j.1749-6632.2000.tb05426.x
   Dunn AJ, 1995, NEUROIMMUNOMODULAT, V2, P319, DOI 10.1159/000097211
   ERICKSON MD, 1977, ANAL CHEM PCBS
   FATTORI E, 1994, J EXP MED, V180, P1243, DOI 10.1084/jem.180.4.1243
   Filipov NM, 2002, J NEUROIMMUNOL, V132, P129, DOI 10.1016/S0165-5728(02)00321-1
   Gadient RA, 1997, PROG NEUROBIOL, V52, P379, DOI 10.1016/S0301-0082(97)00021-X
   Godbout JP, 2005, FASEB J, V19, P1329, DOI 10.1096/fj.05-3776fje
   Hartmann A, 2003, EXP NEUROL, V184, P561, DOI 10.1016/j.expneurol.2003.08.004
   Hebert G, 2003, NEUROSCI LETT, V349, P191, DOI 10.1016/S034-3940(03)00832-2
   Hennig B, 2002, TOXICOL APPL PHARM, V181, P174, DOI 10.1006/taap.2002.9408
   Judd AM, 1998, HORM METAB RES, V30, P404, DOI 10.1055/s-2007-978905
   Kinoshita K, 2006, NEUROGASTROENT MOTIL, V18, P578, DOI 10.1111/j.1365-2982.2006.00784.x
   Kohutnicka M, 1998, IMMUNOPHARMACOLOGY, V39, P167, DOI 10.1016/S0162-3109(98)00022-8
   KOPF M, 1994, NATURE, V368, P339, DOI 10.1038/368339a0
   Lawrence DA, 2000, TOXICOLOGY, V142, P189, DOI 10.1016/S0300-483X(99)00144-4
   Le WD, 2001, J NEUROSCI, V21, P8447
   Liu B, 2003, ENVIRON HEALTH PERSP, V111, P1065, DOI 10.1289/ehp.6361
   Liu X, 2005, J NEUROSCI RES, V81, P653, DOI 10.1002/jnr.20583
   MALKIEWICZ K, 2005, TOXICOL LETT, V161, P152
   Marchetti B, 2005, TRENDS PHARMACOL SCI, V26, P517, DOI 10.1016/j.tips.2005.08.007
   McCluskey LP, 2000, J NEUROPATH EXP NEUR, V59, P177, DOI 10.1093/jnen/59.3.177
   McGeer PL, 2004, PARKINSONISM RELAT D, V10, pS3, DOI 10.1016/j.parkreldis.2004.01.005
   MCGEER PL, 1988, NEUROLOGY, V38, P1285, DOI 10.1212/WNL.38.8.1285
   Mogi M, 1996, NEUROSCI LETT, V211, P13, DOI 10.1016/0304-3940(96)12706-3
   MOGI M, 1994, NEUROSCI LETT, V180, P147, DOI 10.1016/0304-3940(94)90508-8
   MOGI M, 1995, J NEURAL TRANSM-PARK, V9, P87, DOI 10.1007/BF02252965
   Muller T, 1998, ACTA NEUROL SCAND, V98, P142
   Nagatsu T, 2000, J NEURAL TRANSM-SUPP, P143
   Paludan SR, 2000, J LEUKOCYTE BIOL, V67, P18
   Penkowa M, 2000, GLIA, V32, P271, DOI 10.1002/1098-1136(200012)32:3<271::AID-GLIA70>3.0.CO;2-5
   Penkowa M, 1999, GLIA, V25, P343
   SCHECTER A, 1994, ENVIRON HEALTH PERSP, V102, P149, DOI 10.1289/ehp.94102s1149
   SEEGAL RF, 1986, TOXICOL LETT, V30, P197, DOI 10.1016/0378-4274(86)90103-7
   Seegal RF, 2002, ENVIRON TOXICOL PHAR, V12, P63, DOI 10.1016/S1382-6689(02)00023-6
   Selikhova MV, 2002, B EXP BIOL MED+, V133, P81, DOI 10.1023/A:1015120930920
   SHINTANI F, 1995, J NEUROSCI, V15, P1961
   Steenland K, 2006, EPIDEMIOLOGY, V17, P8, DOI 10.1097/01.ede.0000190707.51536.2b
   Stewart P, 2005, NEUROTOXICOL TERATOL, V27, P771, DOI 10.1016/j.ntt.2005.07.003
   Suzuki Y, 1997, INFECT IMMUN, V65, P2339
   Teismann P, 2003, MOVEMENT DISORD, V18, P121, DOI 10.1002/mds.10332
   Turrin NP, 2000, BRAIN RES BULL, V51, P3, DOI 10.1016/S0361-9230(99)00203-8
   Um SJ, 2000, INT J CANCER, V85, P416, DOI 10.1002/(SICI)1097-0215(20000201)85:3<416::AID-IJC19>3.3.CO;2-V
   vanderPoll T, 1997, J INFECT DIS, V176, P439, DOI 10.1086/514062
   Vawter MP, 1996, EXP NEUROL, V142, P313, DOI 10.1006/exnr.1996.0200
   Wu DC, 2002, J NEUROSCI, V22, P1763, DOI 10.1523/JNEUROSCI.22-05-01763.2002
   Yimin, 2006, J IMMUNOL, V177, P642
   Zhang JJ, 2001, NEUROCHEM INT, V38, P303, DOI 10.1016/S0197-0186(00)00099-1
NR 53
TC 11
Z9 11
U1 3
U2 10
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0165-5728
J9 J NEUROIMMUNOL
JI J. Neuroimmunol.
PD FEB
PY 2007
VL 183
IS 1-2
BP 125
EP 132
DI 10.1016/j.jneuroim.2006.11.030
PG 8
WC Immunology; Neurosciences
SC Immunology; Neurosciences & Neurology
GA 144CN
UT WOS:000244773000016
PM 17229471
DA 2018-12-27
ER

PT J
AU Pogrel, MA
AF Pogrel, M. Anthony
TI RETRACTED: Decompression and marsupialization as definitive treatment
   for keratocysts - A partial retraction (Retracted Article)
SO JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY
LA English
DT Correction; Retracted Publication
CR Pogrel MA, 2005, J ORAL MAXIL SURG, V63, P1667, DOI 10.1016/j.joms.2005.08.008
   Pogrel MA, 2004, J ORAL MAXIL SURG, V62, P651, DOI 10.1016/j.joms.2003.08.029
NR 2
TC 15
Z9 16
U1 5
U2 22
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0278-2391
J9 J ORAL MAXIL SURG
JI J. Oral Maxillofac. Surg.
PD FEB
PY 2007
VL 65
IS 2
BP 362
EP 363
DI 10.1016/j.joms.2006.09.032
PG 2
WC Dentistry, Oral Surgery & Medicine
SC Dentistry, Oral Surgery & Medicine
GA 133LH
UT WOS:000244013900042
PM 17236955
DA 2018-12-27
ER

PT J
AU Hagiwara, S
   Iwasaka, H
   Matsumoto, S
   Noguchi, T
   Yoshioka, H
AF Hagiwara, Satoshi
   Iwasaka, Hideo
   Matsumoto, Shigekiyo
   Noguchi, Takayuki
   Yoshioka, Hidekatsu
TI RETRACTED: Coexpression of HSP47 gene and type I and type III collagen
   genes in LPS-induced pulmonary fibrosis in rats (Retracted article. See
   vol. 193, pg. 617, 2015)
SO LUNG
LA English
DT Article; Retracted Publication
DE acute respiratory distress syndrome (ARDS); collagen; heat shock protein
   47; lipopolysaccharide; pulmonary fibrosis
ID STRESS-PROTEIN HSP47; BINDING PROTEIN; EXPRESSION; PROCOLLAGEN;
   CHAPERONE; DISEASES
AB Diffuse alveolar damage is the histopathologic hallmark of acute respiratory distress syndrome (ARDS). A significant proportion of ARDS survivors have residual pulmonary fibrosis and compromised pulmonary function. On the other hand, heat shock protein 47 (HSP47) is a collagen-binding stress protein that is assumed to act as a collagen-specific molecular chaperone during the biosynthesis and secretion of procollagen in living cells. The synthesis of HSP47 has been reported to correlate with that of collagen in several cell lines. We examined the expression of HSP47 mRNA and protein during the progression of lipopolysaccharide (LPS)-induced ARDS in rat lung. Male Wistar rats were randomly divided into two groups: a control group with instillation of 0.9% NaCl solution alone, and a LPS group with instillation of LPS dissolved in 0.9% NaCl solution (10 mg/kg). Histologic changes thereafter appeared in the LPS-treated rats. Northern blot analysis revealed the expression of HSP47 mRNA to be markedly induced during the progression of lung damage in parallel with type I and type III collagen mRNA. These results suggest that the upregulation of HSP47 and collagen may play an important role in the fibrotic process of LPS-induced ARDS lung.
C1 Oita Univ, Fac Med, Dept Brain & Nerve Sci, Yufu, Oita 8795593, Japan.
   Oita Univ, Fac Med, Dept Anat Biol & Med, Yufu, Oita 8795593, Japan.
RP Hagiwara, S (reprint author), Oita Univ, Fac Med, Dept Brain & Nerve Sci, 1-1 Idaigaoka Hasamamachi, Yufu, Oita 8795593, Japan.
EM saku@med.oita-u.ac.jp
CR ASHCROFT T, 1988, J CLIN PATHOL, V41, P467, DOI 10.1136/jcp.41.4.467
   Brown KE, 2005, LAB INVEST, V85, P789, DOI 10.1038/labinvest.3700271
   COLLINS JF, 1984, CHEST, V85, P641, DOI 10.1378/chest.85.5.641
   Hickey AJ, 2002, CRIT REV BIOCHEM MOL, V37, P537, DOI 10.1080/10409230290771555
   HOSOKAWA N, 1993, GENE, V126, P187
   KAZUHIRO N, 1988, MATRIX BIOL, V16, P379
   LAMY M, 1976, AM REV RESPIR DIS, V114, P267
   NAGATA K, 1986, J BIOL CHEM, V261, P7531
   Nagata K, 2003, SEMIN CELL DEV BIOL, V14, P275, DOI 10.1016/j.semcdb.2003.09.020
   NAKAI A, 1989, BIOCHEM BIOPH RES CO, V164, P259, DOI 10.1016/0006-291X(89)91711-7
   NAKAI A, 1992, J CELL BIOL, V117, P903, DOI 10.1083/jcb.117.4.903
   NAKAMURA K, 1989, EUR J PHARMACOL, V169, P259, DOI 10.1016/0014-2999(89)90023-X
   NATSUME T, 1994, J BIOL CHEM, V269, P31224
   RAGHU G, 1985, AM REV RESPIR DIS, V131, P281
   Razzaque MS, 1999, HISTOL HISTOPATHOL, V14, P1199, DOI 10.14670/HH-14.1199
   Razzaque MS, 2005, CONTRIB NEPHROL, V148, P57
   Razzaque MS, 1998, MODERN PATHOL, V11, P1183
   SAGA S, 1987, J CELL BIOL, V105, P517, DOI 10.1083/jcb.105.1.517
   Satoh M, 1996, J CELL BIOL, V133, P469, DOI 10.1083/jcb.133.2.469
   Steltzer H, 1999, INTENS CARE MED, V25, P887, DOI 10.1007/s001340050975
   TAKECHI H, 1992, EUR J BIOCHEM, V206, P323, DOI 10.1111/j.1432-1033.1992.tb16930.x
NR 21
TC 18
Z9 20
U1 4
U2 6
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0341-2040
EI 1432-1750
J9 LUNG
JI Lung
PD FEB
PY 2007
VL 185
IS 1
BP 31
EP 37
DI 10.1007/s00408-006-0085-1
PG 7
WC Respiratory System
SC Respiratory System
GA 138BQ
UT WOS:000244338000006
PM 17310300
DA 2018-12-27
ER

PT J
AU Hamdoun, B
   Charara, J
   Zaiour, A
AF Hamdoun, B.
   Charara, J.
   Zaiour, A.
TI RETRACTED: Hydrodynamic kinetics of two-dimensional domains in thin
   smectic-A films (Retracted article. See vol. 19, pg. 499, 2012)
SO MECHANICS OF ADVANCED MATERIALS AND STRUCTURES
LA English
DT Article; Retracted Publication
DE thin film structure and morphology; smectics; copolymers; ferrofiuids;
   defects in liquid crystals; growth
ID DIBLOCK COPOLYMER FILMS; ATOMIC-FORCE MICROSCOPY; FREE-SURFACE; EDGE
   DISLOCATIONS; LAMELLAR; GROWTH; ISLANDS; HOLES
AB Thin films of smectic materials based on symmetric diblock copolymers deposited on flat solid substrates form lamellae parallel to the substrate. The uppermost layer of the film may be incomplete and made of circular relief domains with a thickness equal to the lamellar period L. The domain edge is associated to a dislocation in the lamellar order. We investigated theoretically these domains and proposed the equations governing the time evolution of the domain size distribution. We hypothesized that interlayer frictions dominate the evolution process of the domain. The growth kinetics of a single hole in a finite film was solved explicitly. The flow involved in the domain growth was confined into a bilayer that was disrupted at the dislocations lines. Its radius was found to decay as a 1/3 power law of its life time.
C1 Islam Univ Lebanon, Fac Engn, Beirut, Lebanon.
   Lebanese Univ, Fac Sci 1, Dept Phys & Elect, Hadeth, Lebanon.
RP Hamdoun, B (reprint author), Islam Univ Lebanon, Fac Engn, POB 30014, Beirut, Lebanon.
EM bassamhamdoun@hotmail.com
CR Ambrozic M, 2002, EUR PHYS J E, V8, P413, DOI 10.1140/epje/i2002-10024-2
   AUSSERRE D, 1990, J PHYS-PARIS, V51, P2571, DOI 10.1051/jphys:0199000510220257100
   BATES FS, 1990, ANNU REV PHYS CHEM, V41, P525, DOI 10.1146/annurev.pc.41.100190.002521
   BINDER K, 1984, PHYS REV A, V29, P341, DOI 10.1103/PhysRevA.29.341
   Bohbot-Raviv Y, 2000, PHYS REV LETT, V85, P3428, DOI 10.1103/PhysRevLett.85.3428
   BOURDIEU L, 1992, ANN CHIM-SCI MAT, V17, P229
   BROTONS G, 2000, THESIS GRENOBLE U FR
   COLIN B, 1991, THESIS PARIS 6 U FRA
   COLLIN B, 1992, MACROMOLECULES, V25, P1621, DOI 10.1021/ma00031a042
   COULON G, 1993, J PHYS II, V3, P697
   COULON G, 1990, J PHYS-PARIS, V51, P777, DOI 10.1051/jphys:01990005108077700
   COULON G, 1990, J PHYS-PARIS, V51, P2801, DOI 10.1051/jphys:0199000510240280100
   COULON G, 1993, MACROMOLECULES, V26, P1582, DOI 10.1021/ma00059a015
   Gunton J. D., 1983, PHASE TRANSITIONS CR, V8, P267
   Hamdoun B, 1996, J PHYS II, V6, P493, DOI 10.1051/jp2:1996106
   Hamdoun B, 2004, MECH ADV MATER STRUC, V11, P277, DOI 10.1080/15376490490427234
   HAMDOUN B, 2004, INORGANIC MAT, V40, P1
   HAMDOUN B, 1995, THESIS MAINE U FRANC
   HAMLEY IW, 1999, PHYS BLOCK COPOLYMER
   HOLYST R, 1994, PHYS REV LETT, V72, P4097, DOI 10.1103/PhysRevLett.72.4097
   Holyst R, 2001, MACROMOL THEOR SIMUL, V10, P1, DOI 10.1002/1521-3919(20010101)10:1<1::AID-MATS1>3.0.CO;2-D
   JOLY S, 1997, THESIS MAINE U FRANC
   Lauter-Pasyuk V, 1998, PHYSICA B, V248, P243, DOI 10.1016/S0921-4526(98)00241-5
   LEFEBURE S, 1998, PROG COLLOID POLYM S, V110, P94
   MAALOUM M, 1992, PHYS REV LETT, V68, P1575, DOI 10.1103/PhysRevLett.68.1575
   MAALOUM M, 1993, PHYS REV LETT, V70, P2577, DOI 10.1103/PhysRevLett.70.2577
   Matsen MW, 1996, MACROMOLECULES, V29, P1091, DOI 10.1021/ma951138i
   Matsen MW, 2002, J PHYS-CONDENS MAT, V14, pR21, DOI 10.1088/0953-8984/14/2/201
   STEPHEN L, 2002, J CHEM PHYS, V116, P2289
   TURNER MS, 1994, J PHYS II, V4, P689, DOI 10.1051/jp2:1994156
   VOORHEES PW, 1985, J STAT PHYS, V38, P231, DOI 10.1007/BF01017860
NR 31
TC 1
Z9 1
U1 3
U2 8
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1537-6494
EI 1537-6532
J9 MECH ADV MATER STRUC
JI Mech. Adv. Mater. Struct.
PD FEB
PY 2007
VL 14
IS 2
BP 131
EP 138
DI 10.1080/15376490600691981
PG 8
WC Materials Science, Multidisciplinary; Mechanics; Materials Science,
   Characterization & Testing; Materials Science, Composites
SC Materials Science; Mechanics
GA 138FG
UT WOS:000244347900005
DA 2018-12-27
ER

PT J
AU Han, CS
AF Han, Chang Suk
TI RETRACTED: Dislocation-particle interaction in precipitation
   strengthened L1(2)-ordered Ni3Al (Retracted article. See vol. 21, pg.
   608, 2015)
SO METALS AND MATERIALS INTERNATIONAL
LA English
DT Article; Retracted Publication
DE L1(2)-ordered Ni3Al; superdislocation; attractive interaction; repulsive
   interaction
ID ALUMINUM; ALLOYS; PHASE; GAMMA
AB Transmission electron microscope investigation has been performed on the particle-dislocation interactions in Ni3Al-based intermetallics containing various types of fine precipitates. In an L1(2)-ordered Ni3Al alloy with 4 mol.% of chromium and 0.2-0.5 mol.% of carbon, fine octahedral precipitates Of M23C6 type carbide, which has a cube-cube orientation relationship with the matrix, appear during aging. Typical Orowan loops are formed in Ni3Al containing fine dispersions Of M23C6 Particles. In the alloys with appropriate titanium content, fine precipitates of coherent disordered gamma are formed during aging. The gamma precipitates are initially spherical or rounded cubic in shape and grow into platelets as aging proceeds. Loss of coherency is initiated by the introduction of dislocations at the gamma/gamma' interface and results in step formation at the dislocations. The gamma precipitates become globular after the loss of coherency. In the gamma' phase hardened by the precipitation of the disordered 7 phase, dislocations are attracted into the disordered 7 phase and cut through the particles during deformation at any stage of aging. In Ni3Al containing a fine dispersion of disordered gamma, superdislocations are strongly attracted to the disordered particles and dissociate on the (111) plane in the 7 particles, while they dissociate on the (010) plane in the matrix. It is shown by comparison that the strengthening due to attractive interaction is more effective than that due to repulsive interaction. The roles of the variation of the interaction modes and of the dissociation of superdislocations in the matrix and particles are discussed in connection with the optimum microstructures of L1(2)-ordered interinetallics as high temperature structural materials.
C1 Hosei Univ, Dept Def Sci & Technol, Chungnam, South Korea.
RP Han, CS (reprint author), Hosei Univ, Dept Def Sci & Technol, 165 Sechulri, Chungnam, South Korea.
EM hancs@office.hoseo.ac.kr
CR AOKI K, 1979, J JAPAN I METALS, V43, P170
   ARDELL AJ, 1985, METALL TRANS A, V16, P2131, DOI 10.1007/BF02670416
   CORNWELL LR, 1974, METALL TRANS, V5, P780, DOI 10.1007/BF02644679
   FUJITA A, 1989, MATER RES SOC S P, V123, P573
   GOLDSCHMIDT HJ, 1967, INTERSTITIAL ALLOYS, P187
   GUO JT, 1984, METALL TRANS A, V15, P1331
   HUETTER LJ, 1958, ACTA METALL MATER, V6, P367, DOI 10.1016/0001-6160(58)90074-9
   NOGUCHI O, 1981, METALL TRANS A, V12, P1647, DOI 10.1007/BF02643570
   OBLAK JM, 1974, METALL TRANS, V5, P1252, DOI 10.1007/BF02644342
   SCHNEIBEL JH, 1992, NATO ADV SCI I E-APP, V213, P565
   Song SH, 2004, MET MATER-INT, V10, P307, DOI 10.1007/BF03185978
   STATONBEVAN AE, 1975, PHYS STATUS SOLIDI A, V29, P613, DOI 10.1002/pssa.2210290232
   YANG R, 1992, MAT SCI ENG A-STRUCT, V152, P227, DOI 10.1016/0921-5093(92)90071-8
NR 13
TC 12
Z9 12
U1 4
U2 22
PU KOREAN INST METALS MATERIALS
PI SEOUL
PA KIM BLDG 6TH FLOOR, SEOCHO-DAERO 56 GIL 38, SEOCHO-GU, SEOUL 137-881,
   SOUTH KOREA
SN 1598-9623
EI 2005-4149
J9 MET MATER INT
JI Met. Mater.-Int.
PD FEB
PY 2007
VL 13
IS 1
BP 31
EP 37
DI 10.1007/BF03027820
PG 7
WC Materials Science, Multidisciplinary; Metallurgy & Metallurgical
   Engineering
SC Materials Science; Metallurgy & Metallurgical Engineering
GA 137OX
UT WOS:000244303000005
DA 2018-12-27
ER

PT J
AU Kim, MS
   Fujiki, R
   Kitagawa, H
   Kato, S
AF Kim, Mi-Sun
   Fujiki, Ryoji
   Kitagawa, Hirochika
   Kato, Shigeaki
TI RETRACTED: 1 alpha,25(OH)(2)D-3-induced DNA methylation suppresses the
   human CYP27B1 gene (Retracted article. See vol. 424, pg. 128, 2016)
SO MOLECULAR AND CELLULAR ENDOCRINOLOGY
LA English
DT Article; Proceedings Paper; Retracted Publication
CT Joint Meeting of the 6th Conference on the Adrenal Cortex/Molecular
   Steroidogenesis Workshop
CY JUN 20-23, 2006
CL Boston, MA
DE CYP27B1; transrepression; VDIR; VDR; WSTF
ID D-3 1-ALPHA-HYDROXYLASE GENE; NUCLEAR RECEPTORS; COMPLEX;
   TRANSREPRESSION; TRANSCRIPTION; SUPERFAMILY; PROMOTER; VDR
AB CYP27B1 is a critical enzyme of Vitamin D biosynthesis that hydroxylates 25(OH)D-3 at the final step of the biosynthetic pathway. The CYP27B1 gene is expressed primarily in kidney and negatively controlled by Vitamin D receptor. We have characterized the negative vitamin D response element and its binding protein, a bHLH transcription factor. This factor directly binds to the 1 alpha nVDRE and activates transcription, but its transcriptional activity is suppressed by the ligand-activated Vitamin D receptor through recruitment of histone deacetylase. We have shown that histone deacetylation is a critical step for chromatin structure remodeling in suppression of the CYP27B1 gene. We have further demonstrated that, in addition to histone acetylation, this transrepression by VDR requires DNA methylation in the CYP27B1 gene promoter. Thus, transcriptional regulation of the CYP27B1 gene appears to be mediated by dual epigenetic modifications. (c) 2006 Elsevier Ireland Ltd. All rights reserved.
C1 Univ Tokyo, Inst Mol & Cellular Biol, Bunkyo Ku, Tokyo 1130032, Japan.
   Japan Sci & Technol Agcy, ERATO, Kawaguchi, Saitama 3320012, Japan.
RP Kato, S (reprint author), Univ Tokyo, Inst Mol & Cellular Biol, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 1130032, Japan.
EM uskato@mail.ecc.u-tokyo.ac.jp
CR Emerson BM, 2002, CELL, V109, P267, DOI 10.1016/S0092-8674(02)00740-7
   Fujiki R, 2005, EMBO J, V24, P3881, DOI 10.1038/sj.emboj.7600853
   Glass CK, 2000, GENE DEV, V14, P121
   Gu W, 1999, MOL CELL, V3, P97, DOI 10.1016/S1097-2765(00)80178-1
   Hassan AH, 2002, CELL, V111, P369, DOI 10.1016/S0092-8674(02)01005-X
   Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0
   Ito T, 1997, CELL, V90, P145, DOI 10.1016/S0092-8674(00)80321-9
   Jones MH, 2000, GENOMICS, V63, P40, DOI 10.1006/geno.1999.6071
   Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6
   Kato S, 2003, J BONE MINER METAB, V21, P323, DOI 10.1007/s00774-003-0453-3
   Kato S, 1998, CURR OPIN NEPHROL HY, V7, P377, DOI 10.1097/00041552-199807000-00005
   KIM MS, 2006, IN PRESS MOL EN 1109
   Kitagawa H, 2003, CELL, V113, P905, DOI 10.1016/S0092-8674(03)00436-7
   MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X
   Margueron R, 2005, CURR OPIN GENET DEV, V15, P163, DOI 10.1016/j.gde.2005.01.005
   Martin C, 2005, NAT REV MOL CELL BIO, V6, P838, DOI 10.1038/nrm1761
   McKenna NJ, 2002, CELL, V108, P465, DOI 10.1016/S0092-8674(02)00641-4
   Murayama A, 2004, EMBO J, V23, P1598, DOI 10.1038/sj.emboj.7600157
   Murayama A, 1998, BIOCHEM BIOPH RES CO, V249, P11, DOI 10.1006/bbrc.1998.9098
   Narlikar GJ, 2002, CELL, V108, P475, DOI 10.1016/S0092-8674(02)00654-2
   ONATE SA, 1995, SCIENCE, V270, P1354
   Pascual G, 2005, NATURE, V437, P759, DOI 10.1038/nature03988
   Rachez C, 1998, GENE DEV, V12, P1787, DOI 10.1101/gad.12.12.1787
   Takeyama K, 1997, SCIENCE, V277, P1827, DOI 10.1126/science.277.5333.1827
   Yanagisawa J, 2002, MOL CELL, V9, P553, DOI 10.1016/S1097-2765(02)00478-1
NR 25
TC 60
Z9 61
U1 3
U2 25
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0303-7207
J9 MOL CELL ENDOCRINOL
JI Mol. Cell. Endocrinol.
PD FEB
PY 2007
VL 265
BP 168
EP 173
DI 10.1016/j.mce.2006.12.014
PG 6
WC Cell Biology; Endocrinology & Metabolism
SC Cell Biology; Endocrinology & Metabolism
GA 148AH
UT WOS:000245046400029
PM 17250953
DA 2018-12-27
ER

PT J
AU Hussain, HM
   Hotopf, M
   Oyebode, F
AF Hussain, Hadi Meeran
   Hotopf, Matthew
   Oyebode, Femi
TI RETRACTED: Atypical antipsychotic drugs and Alzheimer's disease
   (Retracted Article. See vol 356, pg 1481, 2007)
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Letter; Retracted Publication
C1 Mil Hosp, Rawalpindi 46000, Pakistan.
   Kings Coll London, London WCR2 2LS, England.
   Queen Elizabeth Psychiat Hosp, Birmingham B15 2QZ, W Midlands, England.
RP Hussain, HM (reprint author), Mil Hosp, Rawalpindi 46000, Pakistan.
RI Hotopf, Matthew/E-4971-2010
OI Hotopf, Matthew/0000-0002-3980-4466
CR Karlawish J, 2006, NEW ENGL J MED, V355, P1604, DOI 10.1056/NEJMe068163
   Schneider LS, 2006, NEW ENGL J MED, V355, P1525, DOI 10.1056/NEJMoa061240
NR 2
TC 2
Z9 2
U1 3
U2 10
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
EI 1533-4406
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD JAN 25
PY 2007
VL 356
IS 4
BP 416
EP 416
PG 1
WC Medicine, General & Internal
SC General & Internal Medicine
GA 128FT
UT WOS:000243644300016
PM 17251541
DA 2018-12-27
ER

PT J
AU Mandal, PK
   Williams, JP
   Mandal, R
AF Mandal, Pravat K.
   Williams, John P.
   Mandal, Ratna
TI RETRACTED: Molecular understanding of Alpha beta peptide interaction
   with isoflurane, propofol, and thiopental: NMR spectroscopic study
   (Retracted Article. See vol 46, pg 12887, 2007)
SO BIOCHEMISTRY
LA English
DT Article; Retracted Publication
ID VOLATILE GENERAL-ANESTHETICS; MEMBRANE MIMIC ENVIRONMENT; ARTERY
   BYPASS-SURGERY; ALZHEIMERS-DISEASE; A-BETA(1-40) PEPTIDE; INHALED
   ANESTHETICS; PROTEIN; PATHOGENESIS; HALOTHANE; EXPOSURE
AB A beta peptide is the major component of senile plaques (SP), which accumulate in the brain of a patient with Alzheimer's disease (AD). A recent report indicated that isoflurane enhanced A beta oligomerization (micro-aggregation) and subsequent cytotoxicity of the A beta peptide. A separate study showed that a clinically relevant concentration of isoflurane induces apoptosis and increases A beta production in a human neuroglioma cell line. In vitro studies have indicated that halothane interacts specifically with A beta peptide to induce oligomerization and that A beta 42 oligomerizes faster than A beta 40. The specific interactions of isoflurane, propofol, and thiopental with uniformly N-15 labeled A beta 40 and A beta 42 peptide were investigated using multidimensional nuclear magnetic resonance (NMR) experiments. We found that isoflurane and propofol (at higher concentration) interact with A beta 40 peptides and induce A, oligomerization. Thiopental does not interact with specific residues (G29, A30, and I31) of A beta 40; hence, the peptide remains in the monomeric form. On the basis of our NMR study, thiopental does not oligomerize A beta 40 even at higher concentrations.
C1 Univ Pittsburgh, Sch Med, Dept Psychiat, Western Psychiat Inst & Clin, Pittsburgh, PA 15213 USA.
   Univ Pittsburgh, Sch Med, Dept Anesthesiol, Pittsburgh, PA 15261 USA.
RP Mandal, PK (reprint author), Univ Pittsburgh, Sch Med, Dept Psychiat, Western Psychiat Inst & Clin, Pittsburgh, PA 15213 USA.
EM mandalp@upmc.edu
CR Balasubramanian SV, 2002, CHEM PHYS LIPIDS, V114, P35, DOI 10.1016/S0009-3084(01)00199-2
   BEDFORD PD, 1955, LANCET, V2, P259
   BOHNEN N, 1994, INT J NEUROSCI, V77, P181, DOI 10.3109/00207459408986029
   BOHNEN NILJ, 1994, J AM GERIATR SOC, V42, P198, DOI 10.1111/j.1532-5415.1994.tb04952.x
   Bone I, 2000, ANAESTHESIA, V55, P592, DOI 10.1046/j.1365-2044.2000.01479-5.x
   CARNINI A, 2006, IN PRESS CURR ALZHEI
   Coates KM, 2001, ANESTH ANALG, V92, P930, DOI 10.1097/00000539-200104000-00026
   Coles M, 1998, BIOCHEMISTRY-US, V37, P11064, DOI 10.1021/bi972979f
   DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809
   Duda JE, 2000, J NEUROSCI RES, V61, P121, DOI 10.1002/1097-4547(20000715)61:2<121::AID-JNR1>3.0.CO;2-4
   Eckenhoff RG, 1999, ANESTHESIOLOGY, V91, P856, DOI 10.1097/00000542-199909000-00039
   Eckenhoff RG, 2004, ANESTHESIOLOGY, V101, P703, DOI 10.1097/00000542-200409000-00019
   Eckenhoff RG, 1997, PHARMACOL REV, V49, P343
   EGER EI, 1992, ANESTH ANALG, V75, pS3
   EGER EI, 1965, ANESTHESIOLOGY, V26, P756, DOI 10.1097/00000542-196511000-00010
   EGER EI, 1992, ANESTH ANALG, V75, pS8
   FRANKS NP, 1993, BRIT J ANAESTH, V71, P65, DOI 10.1093/bja/71.1.65
   GARRETT DS, 1991, J MAGN RESON, V95, P214, DOI 10.1016/0022-2364(91)90341-P
   GODDARD TD, 1994, SPARKY 3
   Hardy J, 1997, P NATL ACAD SCI USA, V94, P2095, DOI 10.1073/pnas.94.6.2095
   JARRETT JT, 1993, BIOCHEMISTRY-US, V32, P4693, DOI 10.1021/bi00069a001
   Jerschow A, 1998, MACROMOLECULES, V31, P6573, DOI 10.1021/ma9801772
   Johansson JS, 1999, ANESTHESIOLOGY, V90, P235, DOI 10.1097/00000542-199901000-00030
   KNOPES KD, 2002, GERIATRIC ANESTHESIO, P29
   KOKMEN E, 1991, NEUROLOGY, V41, P1393, DOI 10.1212/WNL.41.9.1393
   LERMAN J, 1984, ANESTHESIOLOGY, V61, P139, DOI 10.1097/00000542-198408000-00005
   Mandal PK, 2004, NEUROCHEM RES, V29, P2267, DOI 10.1007/s11064-004-7035-1
   Mandal PK, 2004, CONCEPT MAGN RESON A, V20A, P1, DOI 10.1002/cmr.a.10095
   Mandal PK, 2004, NEUROCHEM RES, V29, P447, DOI 10.1023/B:NERE.0000013750.80925.25
   Mandal PK, 2006, NEUROCHEM RES, V31, P883, DOI 10.1007/s11064-006-9092-0
   Mazoit JX, 1999, BRIT J CLIN PHARMACO, V47, P35, DOI 10.1046/j.1365-2125.1999.00860.x
   MCKEONOMALLEY C, 2001, FUNCTIONAL NEUROLOGY, P333
   Moller JT, 1998, LANCET, V351, P857, DOI 10.1016/S0140-6736(97)07382-0
   Newman MF, 2001, NEW ENGL J MED, V344, P395, DOI 10.1056/NEJM200102083440601
   Pidikiti R, 2005, BIOCHEMISTRY-US, V44, P12128, DOI 10.1021/bi050896q
   Pidikiti R, 2005, BIOMACROMOLECULES, V6, P1516, DOI 10.1021/bm049226a
   Pohorille A, 1996, CHEM PHYS, V204, P337, DOI 10.1016/0301-0104(95)00292-8
   RITCHIE K, 1992, REV GERIAT, V17, P251
   Selnes OA, 2002, CURR OPIN PSYCHIATR, V15, P285, DOI 10.1097/00001504-200205000-00010
   STEVENS WC, 1975, ANESTHESIOLOGY, V42, P197, DOI 10.1097/00000542-197502000-00014
   Teplow DB, 1998, AMYLOID, V5, P121, DOI 10.3109/13506129808995290
   Xie ZC, 2006, ANESTHESIOLOGY, V104, P988, DOI 10.1097/00000542-200605000-00015
   YOKONO S, 1989, BIOCHIM BIOPHYS ACTA, V982, P300, DOI 10.1016/0005-2736(89)90068-0
NR 43
TC 12
Z9 13
U1 3
U2 12
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0006-2960
J9 BIOCHEMISTRY-US
JI Biochemistry
PD JAN 23
PY 2007
VL 46
IS 3
BP 762
EP 771
DI 10.1021/bi062184l
PG 10
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 125ZX
UT WOS:000243483100014
PM 17223697
DA 2018-12-27
ER

PT J
AU Rao, JS
   Bazinet, RP
   Rapoport, SI
   Lee, HJ
AF Rao, Jagadeesh S.
   Bazinet, Richard P.
   Rapoport, Stanley I.
   Lee, Ho-Joo
TI RETRACTED: Chronic administration of carbamazepine down-regulates AP-2
   DNA-binding activity and AP-2 alpha protein expression in rat frontal
   cortex(Retracted article. See vol.81,pg.971,2017)
SO BIOLOGICAL PSYCHIATRY
LA English
DT Article; Retracted Publication
DE AP-2; AP-2 alpha; arachidonic acid; bipolar disorder; brain;
   carbamazepine; NF-kappa B; PKA; PKC; phospholipase A(2); transcription
   factors
ID BIPOLAR AFFECTIVE-DISORDER; ARACHIDONIC-ACID; BRAIN PHOSPHOLIPIDS;
   CHRONIC LITHIUM; KINASE-A; DOCOSAHEXAENOIC ACID; SIGNAL-TRANSDUCTION;
   TREATMENT DECREASES; UNANESTHETIZED RAT; MOOD STABILIZERS
AB Background: Despite being approved for treating bipolar disorder, carbamazepine's (CBZ) mechanism of action is not fully understood. Carbamazepine and lithium, when administered chronically to rats, decrease brain messenger ribonucleic acid (mRNA), lprotein, and activity levels of the arachidonic acid-selective cytosolic phospholipase A(2) (cPLA(2)). The ability of lithium to decrease cPLA(2) mRNA was ascribed to its ability to down-regulate the cPLA(2) transcription factor, AP-2. The present study was Undertaken to see whether chronic CBZ treatment also would down-regulate the AP-2 transcription factor.
   Methods. Male CDF-344 rats received (intraperitonally for 30 days) 25 mg/kg per day or vehicle. Transcription factors regulating cPLA(2) were measured by gelshift assay in the frontal cortex.
   Results: Chronic CBZ decreased AP-2 transciption/factors binding activity, cyclic adenosine monopbosphate (cAMP)-dependent protein kinase A (PKA) activity, nuclear phospho AP-2 alpha and the protein but not mRNA level of AP-2 alpha in rat frontal cortex. There was no significant change in activator protein (AP) 1, nuclear factor kappa B (NF-kappa B), glucocorticoid response element, or polyoma enhancer activator 3 (PEA3).
   Conclusions. These results support the hypothesis that, like lithium, CBZs down-regulation of AP-2 transcription factor activity may be responsible for down-regulating cPLA2 gene transcription. Chronically administered CBZ appears to decrease AP-2 DNA-binding activity by decreasing cAMP-dependent PKA activity, phospborylation of AP-2 protein, and the protein level of its AP-2 alpha subunit in rat frontal cortex.
C1 NIA, Brain Physiol & Metab Sect, NIH, Bethesda, MD 20892 USA.
RP Rao, JS (reprint author), NIA, Brain Physiol & Metab Sect, NIH, 9000 Rockville Pike,Bldg 9,1S-128, Bethesda, MD 20892 USA.
EM jrao@mail.nih.gov
RI Rao, Jagadeesh/C-1250-2009
FU Intramural NIH HHS
CR ADAMS SR, 1991, NATURE, V349, P694, DOI 10.1038/349694a0
   Arnold CN, 2005, HORIZ CANC RES, V4, P1
   AXELROD J, 1990, BIOCHEM SOC T, V18, P503, DOI 10.1042/bst0180503
   BAF MHM, 1994, NEUROCHEM INT, V24, P67
   Bazinet RP, 2006, BIOL PSYCHIAT, V59, P401, DOI 10.1016/j.biopsych.2005.07.024
   Bazinet RP, 2006, PSYCHOPHARMACOLOGY, V184, P122, DOI 10.1007/s00213-005-0272-4
   Bialer M, 1998, THER DRUG MONIT, V20, P56, DOI 10.1097/00007691-199802000-00010
   Bosetti F, 2003, J NEUROCHEM, V85, P690, DOI 10.1046/j.1471-4159.2003.01701.x
   Bosetti F, 2002, MOL PSYCHIATR, V7, P845, DOI 10.1038/sj.mp.4001111
   Bown CD, 2003, NEUROSCIENCE, V117, P949, DOI 10.1016/S0306-4522(02)00743-1
   Chang A, 2003, MOL BRAIN RES, V116, P27, DOI 10.1016/S0169-328X(03)00211-0
   Chang A, 2003, J NEUROCHEM, V84, P781, DOI 10.1046/j.0022-3042.2003.01605.x
   Chang MCJ, 1996, NEUROSCI LETT, V220, P171, DOI 10.1016/S0304-3940(96)13264-X
   Chang MCJ, 1998, NEUROCHEM RES, V23, P887, DOI 10.1023/A:1022415113421
   Chang MCJ, 2001, J NEUROCHEM, V77, P796, DOI 10.1046/j.1471-4159.2001.00311.x
   Chen G, 1996, J NEUROCHEM, V67, P2079
   Damberg M, 2001, NEUROSCI LETT, V313, P102, DOI 10.1016/S0304-3940(01)02243-1
   Garcia MA, 1999, FEBS LETT, V444, P27, DOI 10.1016/S0014-5793(99)00021-6
   Ghelardoni S, 2005, PSYCHOPHARMACOLOGY, V180, P523, DOI 10.1007/s00213-005-2189-3
   Ghelardoni S, 2004, BIOL PSYCHIAT, V56, P248, DOI 10.1016/j.biophysc.2004.05.012
   HAROOTUNIAN AT, 1993, MOL BIOL CELL, V4, P993
   Hasegawa H, 2003, BRAIN RES, V994, P19, DOI 10.1016/j.brainres.2003.09.027
   IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8
   Jakobsen SN, 1998, BRAIN RES, V780, P46, DOI 10.1016/S0006-8993(97)01181-5
   Jensen JB, 1997, EUR NEUROPSYCHOPHARM, V7, P173
   Karege F, 2004, J AFFECT DISORDERS, V79, P187, DOI 10.1016/S0165-0327(02)00463-9
   KOIDE H, 1992, P NATL ACAD SCI USA, V89, P1149, DOI 10.1073/pnas.89.4.1149
   Lee HJ, 2005, NEUROCHEM RES, V30, P677, DOI 10.1007/s11064-005-2756-3
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   MORII H, 1994, BIOCHEM BIOPH RES CO, V205, P6, DOI 10.1006/bbrc.1994.2621
   Moser M, 1997, DEV DYNAM, V208, P115, DOI 10.1002/(SICI)1097-0177(199701)208:1<115::AID-AJA11>3.0.CO;2-5
   Perez J, 2002, MOL PSYCHIATR, V7, P208, DOI 10.1038/sj.mp.4000969
   Post RM, 1998, NEUROPSYCHOPHARMACOL, V19, P206, DOI 10.1016/S0893-133X(98)00020-7
   Rao JS, 2005, NEUROPSYCHOPHARMACOL, V30, P2006, DOI 10.1038/sj.npp.1300740
   RAO JS, IN PRESS BIPOLAR DIS
   Rintala J, 1999, NEUROREPORT, V10, P3887, DOI 10.1097/00001756-199912160-00030
   SACHS GS, 2004, AM PSYCH ASS ANN M N
   Sun GY, 2004, J LIPID RES, V45, P205, DOI 10.1194/jlr.R300016-JLR200
   Tardito D, 2003, J AFFECT DISORDERS, V76, P249, DOI 10.1016/S0165-0327(02)00065-4
NR 39
TC 30
Z9 30
U1 2
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0006-3223
EI 1873-2402
J9 BIOL PSYCHIAT
JI Biol. Psychiatry
PD JAN 15
PY 2007
VL 61
IS 2
BP 154
EP 161
DI 10.1016/j.biopsych.2006.03.029
PG 8
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 125PS
UT WOS:000243454900005
PM 16806101
DA 2018-12-27
ER

PT J
AU McDermott, DF
AF McDermott, David F.
TI RETRACTED: Update on the application of interleukin-2 in the treatment
   of renal cell carcinoma (Retracted article. See vol. 24, pg. 3783, 2018)
SO CLINICAL CANCER RESEARCH
LA English
DT Article; Proceedings Paper; Retracted Publication
CT 2nd International Conference on the Innovations and Challenges in Renal
   Cancer
CY MAR 24-25, 2006
CL Cambridge, MA
ID RECOMBINANT HUMAN INTERLEUKIN-2; CARBONIC-ANHYDRASE-IX; SUBCUTANEOUS
   INTERLEUKIN-2; INTERFERON ALPHA-2A; DOSE INTERLEUKIN-2; HOME-THERAPY;
   CANCER; SURVIVAL; TRIAL; PROGNOSIS
AB High-dose bolus interleukin 2 (IL-2) was granted Food and Drug Administration approval based on its ability to produce durable complete responses in a small number of patients with metastatic renal cell carcinoma. Results from randomized phase 3 trials suggest that regimens involving lower doses of IL-2, either alone or in combination with IFN, produce fewer tumor regressions of less overall quality. Given the toxicity, expense, and limited efficacy of this treatment, recent studies have focused on identifying predictors of response (or resistance) to IL-2 therapy. This year, investigators launched a clinical trial designed to prospectively determine if patients who are more likely to respond to high-dose IL-2 can be identified before starting therapy. As the list of effective therapies for metastatic renal cell carcinoma grows, improvements in patient selection will be necessary to ensure that patients who might attain a durable remission with IL-2 will not miss this opportunity.
C1 Beth Israel Deaconess Med Ctr, Kirstein Room 153,330 Brookline Ave, Boston, MA 02215 USA.
   Dana Farber Harvard Canc Ctr, Renal Canc Program, Boston, MA USA.
RP McDermott, DF (reprint author), Beth Israel Deaconess Med Ctr, Kirstein Room 153,330 Brookline Ave, Boston, MA 02215 USA.
EM dmcdermo@bidmc.harvard.edu
FU NCI NIH HHS [P50 CA 101942-01]
CR Atkins M, 2005, CLIN CANCER RES, V11, P3714, DOI 10.1158/1078-0432.CCR-04-2019
   ATZPODIEN J, 1995, J CLIN ONCOL, V13, P497, DOI 10.1200/JCO.1995.13.2.497
   ATZPODIEN J, 1993, EJC SUPPL, V29, P6
   BELLDEGRUN A, 1989, J UROLOGY, V141, P499, DOI 10.1016/S0022-5347(17)40872-X
   Bui MHT, 2003, CLIN CANCER RES, V9, P802
   Cangiano T, 1999, J CLIN ONCOL, V17, P523, DOI 10.1200/JCO.1999.17.2.523
   Cohen HT, 2005, NEW ENGL J MED, V353, P2477, DOI 10.1056/NEJMra043172
   Dutcher J, 2002, ONCOLOGY-NY, V16, P4
   FIGLIN RA, 1992, J CLIN ONCOL, V10, P414, DOI 10.1200/JCO.1992.10.3.414
   Fisher RI, 2000, CANCER J SCI AM, V6, pS55
   FYFE G, 1995, J CLIN ONCOL, V13, P688, DOI 10.1200/JCO.1995.13.3.688
   Hanninen EL, 1996, J UROLOGY, V155, P19, DOI 10.1016/S0022-5347(01)66527-3
   LINEHAN WM, 2005, CANC PRINCIPLES PRAC
   MARGOLIN KA, 1989, J CLIN ONCOL, V7, P486, DOI 10.1200/JCO.1989.7.4.486
   McDermott R, 2002, POLIT PSYCHOL, V23, P133, DOI 10.1111/0162-895X.00274
   Motzer RJ, 1999, J CLIN ONCOL, V17, P2530, DOI 10.1200/JCO.1999.17.8.2530
   Motzer RJ, 2002, J CLIN ONCOL, V20, P2376, DOI 10.1200/JCO.2002.11.123
   Motzer RJ, 2006, J CLIN ONCOL, V24, P16, DOI 10.1200/JCO.2005.022574
   Negrier S, 1998, NEW ENGL J MED, V338, P1272, DOI 10.1056/NEJM199804303381805
   NEGRIER S, 2005, P AN M AM SOC CLIN, V4, P511
   Pantuck AJ, 2005, P AN M AM SOC CLIN, V4, P535
   Rosenberg SA, 1998, ANN SURG, V228, P307, DOI 10.1097/00000658-199809000-00004
   SLEIJFER DT, 1992, J CLIN ONCOL, V10, P1119, DOI 10.1200/JCO.1992.10.7.1119
   Upton MP, 2005, J IMMUNOTHER, V28, P488, DOI 10.1097/01.cji.0000170357.14962.9b
   VOGELZANG NJ, 1993, J CLIN ONCOL, V11, P1809, DOI 10.1200/JCO.1993.11.9.1809
   YANG JC, 1994, J CLIN ONCOL, V12, P1572, DOI 10.1200/JCO.1994.12.8.1572
   Yang JC, 2003, NEW ENGL J MED, V349, P427, DOI 10.1056/NEJMoa021491
   Yang JC, 2003, J CLIN ONCOL, V21, P3127, DOI 10.1200/JCO.2003.02.122
NR 28
TC 42
Z9 43
U1 0
U2 2
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
EI 1557-3265
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD JAN 15
PY 2007
VL 13
IS 2
SU S
BP 716S
EP 720S
DI 10.1158/1078-0432.CCR-06-1872
PN 2
PG 5
WC Oncology
SC Oncology
GA 133WC
UT WOS:000244043600009
PM 17255299
OA Bronze
DA 2018-12-27
ER

PT J
AU Malicdan, MCV
   Noguchi, S
   Nonaka, I
   Hayashi, YK
   Nishino, I
AF Malicdan, May Christine V.
   Noguchi, Satoru
   Nonaka, Ikuya
   Hayashi, Yukiko K.
   Nishino, Ichizo
TI RETRACTED: A Gne knockout mouse expressing human V572L mutation develops
   features similar to distal myopathy with rimmed vacuoles or hereditary
   inclusion body myopathy (Retracted Article. See vol 16, pg 2647, 2007)
SO HUMAN MOLECULAR GENETICS
LA English
DT Article; Retracted Publication
ID AMYLOID PRECURSOR PROTEIN; SIALIC-ACID; ENDOPLASMIC-RETICULUM;
   MUSCLE-FIBERS; SIALYLATION; GENE; KINASE; GLYCOSYLATION; MYOSITIS; CELLS
AB Distal myopathy with rimmed vacuoles (DMRV) or hereditary inclusion myopathy (h-IBM) is an early adult-onset distal myopathy caused by mutations in the UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase (GNE) gene which encodes for a bifunctional enzyme involved in sialic acid biosynthesis. It is pathologically characterized by the presence of rimmed vacuoles especially in atrophic fibers, which also occasionally contain congophilic materials that are immunoreactive to beta-amyloid, lysosomal proteins, ubiquitin and tau proteins. To elucidate the pathomechanism of this myopathy and to explore the treatment options, we generated a mouse model of DMRV/h-IBM. We knocked out the Gne gene in the mouse, but this resulted in embryonic lethality. We therefore generated a transgenic mouse that expressed the human GNEV572L mutation, which is the most prevalent among Japanese DMRV patients, and crossed this with Gne((+/-)) mouse to obtain Gne((-/-))hGNEV572L-Tg. Interestingly, these mice exhibit marked hyposialylation in serum, muscle and other organs. Reduction in motor performance in these mice can only be seen from 30 weeks of age. A compelling finding is the development of beta-amyloid deposition in myofibers by 32 weeks, which clearly precedes rimmed vacuole formation at 42 weeks. These results show that the Gne((-/-)) hGNEV572L-Tg mouse mimics the clinical, histopathological and biochemical features of DMRV/h-IBM, making it useful for understanding the pathomechanism of this myopathy and for employing different strategies for therapy. Our findings underscore the notion that hyposialylation plays an important role in the pathomechanism of DMRV/h-IBM.
C1 Natl Ctr Neurol & Psychiat, Natl Inst Neurosci, Dept Neuromuscular Res, Kodaira, Tokyo 1878502, Japan.
RP Noguchi, S (reprint author), Natl Ctr Neurol & Psychiat, Natl Inst Neurosci, Dept Neuromuscular Res, 4-1-1 Ogawahigashi Cho, Kodaira, Tokyo 1878502, Japan.
EM noguchi@ncnp.go.jp
RI Malicdan, May Christine/F-2806-2013
OI Nishino, Ichizo/0000-0001-9452-112X
CR AKANAS V, 2006, NEUROLOGY S1, V66, pS39
   Amouri R, 2005, NEUROMUSCULAR DISORD, V15, P361, DOI 10.1016/j.nmd.2005.01.012
   Argov Z, 2003, NEUROLOGY, V60, P1519, DOI 10.1212/01.WNL.0000061617.71839.42
   ARGOV Z, 1984, J NEUROL SCI, V64, P33, DOI 10.1016/0022-510X(84)90053-4
   ASKANAS V, 1993, NEUROLOGY, V43, P1265, DOI 10.1212/WNL.43.6.1265-a
   Askanas V, 2003, CURR OPIN RHEUMATOL, V15, P737, DOI 10.1097/00002281-200311000-00009
   ASKANAS V, 1993, ANN NEUROL, V34, P551, DOI 10.1002/ana.410340408
   ASKANAS V, 2003, MOL GENETIC BASIS NE, P501
   Askanas Valerie, 1995, Current Opinion in Rheumatology, V7, P486, DOI 10.1097/00002281-199511000-00005
   Bennett E, 1997, J GEN PHYSIOL, V109, P327, DOI 10.1085/jgp.109.3.327
   Broccolini A, 2004, HUM MUTAT, V23, DOI 10.1002/humu.9252
   BROOKS SA, 2002, FUNCTIONAL MOL GYCOB
   Eisenberg I, 2001, NAT GENET, V29, P83, DOI 10.1038/ng718
   Eisenberg Iris, 2003, Hum Mutat, V21, P99, DOI 10.1002/humu.9100
   Ellis RJ, 2002, NATURE, V416, P483, DOI 10.1038/416483a
   GEORGOPOULOU N, 2001, BIOCH SOC S, V67, P23
   Gregori L, 1997, J BIOL CHEM, V272, P58
   HARA S, 1986, J CHROMATOGR, V377, P111, DOI 10.1016/S0378-4347(00)80766-5
   Helenius A, 2004, ANNU REV BIOCHEM, V73, P1019, DOI 10.1146/annurev.biochem.73.011303.073752
   Hinderlich S, 2004, FEBS LETT, V566, P105, DOI 10.1016/j.febslet.2004.04.013
   Horstkorte R, 1999, EUR J BIOCHEM, V260, P923, DOI 10.1046/j.1432-1327.1999.00253.x
   Ikeuchi T, 1997, ANN NEUROL, V41, P432, DOI 10.1002/ana.410410405
   Ishii A, 1999, MUSCLE NERVE, V22, P592, DOI 10.1002/(SICI)1097-4598(199905)22:5<592::AID-MUS7>3.0.CO;2-2
   Keppler OT, 1999, SCIENCE, V284, P1372, DOI 10.1126/science.284.5418.1372
   Kim BJ, 2006, J HUM GENET, V51, P137, DOI 10.1007/s10038-005-0338-5
   Kimpara T, 1993, Rinsho Shinkeigaku, V33, P886
   Kumamoto T, 1998, INTERNAL MED, V37, P746, DOI 10.2169/internalmedicine.37.746
   LIEWLUCK T, MUSCLE NERVE
   Marengo FD, 1998, J MOL CELL CARDIOL, V30, P127, DOI 10.1006/jmcc.1997.0579
   McFarlane I, 1999, NEUROSCIENCE, V90, P15, DOI 10.1016/S0306-4522(98)00361-3
   Mirabella M, 1996, J NEUROPATH EXP NEUR, V55, P774, DOI 10.1097/00005072-199607000-00003
   MitraniRosenbaum S, 1996, HUM MOL GENET, V5, P159, DOI 10.1093/hmg/5.1.159
   Nakagawa K, 2006, J NEUROCHEM, V96, P924, DOI 10.1111/j.1471-4159.2005.03595.x
   Nishida H, 2005, GENES GENET SYST, V80, P83, DOI 10.1266/ggs.80.83
   Nishino I, 2002, NEUROLOGY, V59, P1689, DOI 10.1212/01.WNL.0000041631.28557.C6
   Nishino Ichizo, 2003, Curr Neurol Neurosci Rep, V3, P64, DOI 10.1007/s11910-003-0040-y
   NIWA H, 1991, GENE, V108, P193
   Noguchi S, 2004, J BIOL CHEM, V279, P11402, DOI 10.1074/jbc.M313171200
   NONAKA I, 1981, J NEUROL SCI, V51, P141, DOI 10.1016/0022-510X(81)90067-8
   Nonaka Ikuya, 2005, Curr Neurol Neurosci Rep, V5, P61, DOI 10.1007/s11910-005-0025-0
   Pahlsson P, 1996, ARCH BIOCHEM BIOPHYS, V331, P177, DOI 10.1006/abbi.1996.0296
   POST JA, 1992, AM J PHYSIOL, V263, pH147
   Ro LS, 2005, J NEUROL NEUROSUR PS, V76, P752, DOI 10.1136/jnnp.2004.048876
   Salama I, 2005, BIOCHEM BIOPH RES CO, V328, P221, DOI 10.1016/j.bbrc.2004.12.157
   Schwarzkopf M, 2002, P NATL ACAD SCI USA, V99, P5267, DOI 10.1073/pnas.072066199
   SOEIRO MNC, 1994, J SUBMICR CYTOL PATH, V26, P121
   Sugarman MC, 2006, NEUROBIOL AGING, V27, P423, DOI 10.1016/j.neurobiolaging.2005.02.011
   Tomimitsu H, 2004, NEUROLOGY, V62, P1607, DOI 10.1212/01.WNL.0000123115.23652.6C
   Tsai B, 2002, NAT REV MOL CELL BIO, V3, P246, DOI 10.1038/nrm780
   Ufret-Vincenty CA, 2001, AM J PHYSIOL-CELL PH, V281, pC464
   WANG YP, 2006, J NEURAL TRANSM
   WOODS WT, 1982, CIRC RES, V50, P228, DOI 10.1161/01.RES.50.2.228
   Yazaki M, 1996, NEUROSCI LETT, V221, P57, DOI 10.1016/S0304-3940(96)13285-7
NR 53
TC 17
Z9 17
U1 3
U2 8
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0964-6906
EI 1460-2083
J9 HUM MOL GENET
JI Hum. Mol. Genet.
PD JAN 15
PY 2007
VL 16
IS 2
BP 115
EP 128
DI 10.1093/hmg/ddl446
PG 14
WC Biochemistry & Molecular Biology; Genetics & Heredity
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 130NP
UT WOS:000243806600001
PM 17164266
OA Bronze
DA 2018-12-27
ER

PT J
AU Sakthivel, K
   Balachandran, K
   Lavanya, R
AF Sakthivel, K.
   Balachandran, K.
   Lavanya, R.
TI RETRACTED: Exact controllability of partial integrodifferential
   equations with mixed boundary conditions (Retracted article. See vol.
   368, pg. 391, 2010)
SO JOURNAL OF MATHEMATICAL ANALYSIS AND APPLICATIONS
LA English
DT Article; Retracted Publication
DE controllability; observability; Carleman estimates; integrodifferential
   equations
AB In this work the exact controllability of linear parabolic integrodifferential equations with mixed boundary conditions are studied. Carleman estimate for the linearized problem providing the observability results is fundamental to the analysis and by duality it provides exact global controllability. (c) 2006 Elsevier Inc. All rights reserved.
C1 Bharathiar Univ, Dept Math, Coimbatore 641046, Tamil Nadu, India.
RP Balachandran, K (reprint author), Bharathiar Univ, Dept Math, Coimbatore 641046, Tamil Nadu, India.
EM balachandran_k@lycos.com
CR Adams RA, 2003, SOBOLEV SPACES
   Barbu V, 2003, COMMUN PUR APPL MATH, V56, P732, DOI 10.1002/cpa.10072
   BARBU V., 2002, SCI MATH JPN, V56, P143
   Chae D., 1996, J DYN CONTROL SYST, V2, P449
   Fursikov A. V., 1996, LECT NOTES SERIES, V34
   Fursikov AV, 1999, RUSS MATH SURV+, V54, P565, DOI 10.1070/RM1999v054n03ABEH000153
   HORMANDER L, 1985, LINEAR PARTIAL DIFFE
   Imanuvilov OY, 2003, PUBL RES I MATH SCI, V39, P227, DOI 10.2977/prims/1145476103
   IMANUVILOV OY, 1995, SB MATH, V186, P879, DOI DOI 10.1070/SM1995V186N06ABEH000047
   Ladyzenskaya OA, 1969, MATH THEORY VISCOUS
   SAKTHIVAL K, IN PRESS COMPUT MATH
   Tataru D., 1997, CONT MATH, V209, P267
   TEMAM R, 1983, NAVIER STOKES EQUATI
NR 13
TC 8
Z9 8
U1 2
U2 9
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0022-247X
EI 1096-0813
J9 J MATH ANAL APPL
JI J. Math. Anal. Appl.
PD JAN 15
PY 2007
VL 325
IS 2
BP 1257
EP 1279
DI 10.1016/j.jmaa.2006.02.034
PG 23
WC Mathematics, Applied; Mathematics
SC Mathematics
GA 115JM
UT WOS:000242730600034
OA Bronze
DA 2018-12-27
ER

PT J
AU Gong, ZY
   Chai, CL
   Tu, CY
   Lin, JF
   Gao, Y
   Qiu, YW
AF Gong, Zhenyu
   Chai, Chenliang
   Tu, Chunyu
   Lin, Jinfen
   Gao, Yi
   Qiu, Yinwei
TI RETRACTED: Injuries after a typhoon in China (Retracted article. see vol
   359, pg 657, 2008)
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Letter; Retracted Publication
C1 Zhejiang Ctr Dis Control & Prevent, Hangzhou 310009, Peoples R China.
RP Gong, ZY (reprint author), Zhejiang Ctr Dis Control & Prevent, Hangzhou 310009, Peoples R China.
EM 87235011@163.com
CR *ICECI COORD DEV G, 2003, INT CLASS EXT CAUS I, V1
NR 1
TC 4
Z9 4
U1 4
U2 16
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
EI 1533-4406
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD JAN 11
PY 2007
VL 356
IS 2
BP 196
EP 197
DI 10.1056/NEJMc062898
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA 124NE
UT WOS:000243373700032
PM 17215543
DA 2018-12-27
ER

PT J
AU Guo, HY
AF Guo, Hangyuan
TI RETRACTED: Complication of central venous catheterization (Retracted
   Article. See vol 356, pg 1075, 2007)
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Editorial Material; Retracted Publication
C1 Shaoxing Peoples Hosp, Shaoxing 31200, Zhejiang, Peoples R China.
RP Guo, HY (reprint author), Shaoxing Peoples Hosp, Shaoxing 31200, Zhejiang, Peoples R China.
EM ghangyuan@hotmail.com
NR 0
TC 3
Z9 3
U1 5
U2 16
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
EI 1533-4406
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD JAN 11
PY 2007
VL 356
IS 2
BP E2
EP E2
DI 10.1056/NEJMicm053415
PG 1
WC Medicine, General & Internal
SC General & Internal Medicine
GA 124NE
UT WOS:000243373700011
PM 17215525
DA 2018-12-27
ER

PT J
AU Sathyanarayana, UG
   Moore, AY
   Li, L
   Padar, A
   Majmudar, K
   Stastny, V
   Makarla, P
   Suzuki, M
   Minna, JD
   Feng, ZD
   Gazdar, AF
AF Sathyanarayana, Ubaradka G.
   Moore, Angela Yen
   Li, Lin
   Padar, Asha
   Majmudar, Kuntal
   Stastny, Victor
   Makarla, Prakash
   Suzuki, Makoto
   Minna, John D.
   Feng, Ziding
   Gazdar, Adi F.
TI RETRACTED: Sun exposure related methylation in malignant and
   non-malignant skin lesions (Retracted article. See vol. 432, pg. 272,
   2018)
SO CANCER LETTERS
LA English
DT Article; Retracted Publication
DE MSP; methylation; skin cancer; laminin-5; cadherins
ID ABERRANT PROMOTER METHYLATION; CPG ISLAND HYPERMETHYLATION;
   SQUAMOUS-CELL CARCINOMA; TUMOR-SUPPRESSOR GENES; EPIGENETIC
   INACTIVATION; PROSTATE CANCERS; LUNG CARCINOMAS; DOWN-REGULATION; BREAST
   CANCERS; CADHERIN GENE
AB We investigated the aberrant promoter methylation status of 12 genes in skin lesions, both malignant (basal cell carcinomas (BCCs), n = 68 and squamous cell carcinomas (SCCs), n = 35) and non-malignant (tags, n = 5 8) skin lesions and compared the results of lesions from sun exposed (SE) and sun protected (SP) regions. Methylation was studied using a methylation specific PCR (MSP) and methylation of CDHI was also measured using a semi-quantitative fluorescence based real-time MSP method. The methylation index (MI) was calculated as the methylated fraction of the genes examined. In this report, we found high frequencies of methylation of several known or suspected tumor suppressor genes in tags and skin cancers. Among the 12 genes, for the cadherin genes CDHI and CDH3 and for two of the laminin 5 encoding genes LAMA3 and LAMC2 methylation frequencies greater than 30% were noted in one or more specimen types. We investigated whether methylation was tumor related. Surprisingly, the differences in the methylation profile of genes among the three specimen types were modest, and the MI, indicators of overall methylation frequencies, was nearly identical. However, significant differences were noted in the frequencies of methylation among the three specimen types for the genes RASSFIA (P=0.002), CDHI (P=0.007) and one or more of three CAD genes (P = 0.02). Methylation was highly significantly related to sun exposure, and sun protected specimens had little or no methylation. As methylation of CDHI was completely SE specific we analyzed all the skin samples using a semi-quantitative real-time PCR assay for the CDHI gene. The concordance between standard MSP and real-time MSP for all the samples (n= 161) was 75% (P < 0.0001). While weak signals were detected in the SP samples by real time PCR, the differences between SE and SP specimens were 148 fold for tags and 390 fold for BCCs. These differences were highly significant (P < 0.0001). These findings suggest that methylation commences in UV exposed skin at a relatively early age and occurs in skin prior to the onset of recognizable preneoplastic changes. (c) 2006 Elsevier Ireland Ltd. All rights reserved.
C1 Univ Texas, SW Med Ctr Dallas, Hamon Ctr Therapeut Oncol Res, Dallas, TX 75390 USA.
   Univ Texas, SW Med Ctr Dallas, Dept Pathol, Dallas, TX 75390 USA.
   Baylor Univ, Med Ctr, Dept Dermatol, Dallas, TX 75246 USA.
   Arlington Ctr Dermatol, Arlington, TX 76011 USA.
   Univ Texas Branch, Dept Dermatol, Galveston, TX 77550 USA.
   Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Seattle, WA 98109 USA.
RP Gazdar, AF (reprint author), Univ Texas, SW Med Ctr Dallas, Hamon Ctr Therapeut Oncol Res, 6000 Harry Hines Blvd, Dallas, TX 75390 USA.
EM adi.gazdar@utsouthwestern.edu
CR *AJCC, 2002, CANC STAG MAN, P203
   Backvall H, 2004, BRIT J DERMATOL, V150, P259, DOI 10.1111/j.1365-2133.2004.05683.x
   Baker SE, 1996, J CELL SCI, V109, P2509
   Baylin SB, 1998, ADV CANCER RES, V72, P141
   Brown VL, 2004, J INVEST DERMATOL, V122, P1284, DOI 10.1111/j.0022-202X.2004.22501.x
   Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691
   Chiles MC, 2003, MODERN PATHOL, V16, P1014, DOI 10.1097/01.MP.0000089779.35435.9D
   Costello JF, 2000, NAT GENET, V24, P132, DOI 10.1038/72785
   Eads CA, 1999, CANCER RES, V59, P2302
   Esteller M, 2002, ONCOGENE, V21, P5427, DOI 10.1038/sj.onc.1205600
   Evron E, 2001, CANCER RES, V61, P2782
   Ferguson JW, 2003, MECH DEVELOP, V120, P851, DOI 10.1016/S0925-4773(03)00165-5
   Giannelli G, 2001, CLIN EXP METASTAS, V18, P439
   Green CL, 2004, SEMIN CANCER BIOL, V14, P63, DOI 10.1016/j.semcancer.2003.11.007
   Henning K, 1999, HISTOPATHOLOGY, V34, P305
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   HERRMANN BG, 1987, METHOD ENZYMOL, V152, P180
   Issa JP, 2003, CLIN IMMUNOL, V109, P103, DOI 10.1016/S1521-6616(03)00203-1
   Jemal A, 2005, CA-CANCER J CLIN, V55, P10, DOI 10.3322/canjclin.55.1.10
   Jeronimo C, 2001, J NATL CANCER I, V93, P1747, DOI 10.1093/jnci/93.22.1747
   Jonason AS, 1996, P NATL ACAD SCI USA, V93, P14025, DOI 10.1073/pnas.93.24.14025
   Kanai Y, 1997, INT J CANCER, V71, P355
   Kominsky SL, 2003, ONCOGENE, V22, P2021, DOI 10.1038/sj.onc.1206199
   KRICKER A, 1991, INT J CANCER, V48, P650, DOI 10.1002/ijc.2910480504
   Manda R, 2000, BIOCHEM BIOPH RES CO, V275, P440, DOI 10.1006/bbrc.2000.3331
   MARKS R, 1990, MED J AUSTRALIA, V152, P62
   Martin KJ, 1998, MOL MED, V4, P602, DOI 10.1007/BF03401760
   Maruyama R, 2002, CLIN CANCER RES, V8, P514
   Matsumura Y, 2004, TOXICOL APPL PHARM, V195, P298, DOI 10.1016/j.taap.2003.08.019
   Matter K, 2003, NAT REV MOL CELL BIO, V4, P225, DOI 10.1038/nrm1055
   Melnikova VO, 2005, MUTAT RES-FUND MOL M, V571, P91, DOI 10.1016/j.mrfmmm.2004.11.015
   Padar A, 2003, CLIN CANCER RES, V9, P4730
   SAFAI B, 1977, CANC PRINCIPLES PRAC, P1883
   Sathyanarayana UG, 2003, CLIN CANCER RES, V9, P2665
   Sato N, 2003, CANCER RES, V63, P3735
   SHAPIRO GI, 1995, CANCER RES, V55, P6200
   Tommasi S, 1997, CANCER RES, V57, P4727
   Toyooka KO, 2002, AM J PATHOL, V161, P629, DOI 10.1016/S0002-9440(10)64218-6
   Toyooka KO, 2001, CANCER RES, V61, P4556
   Zhao YL, 2002, ONCOGENE, V21, P7471, DOI 10.1038/sj.onc.1205891
NR 40
TC 23
Z9 26
U1 2
U2 5
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0304-3835
EI 1872-7980
J9 CANCER LETT
JI Cancer Lett.
PD JAN 8
PY 2007
VL 245
IS 1-2
BP 112
EP 120
DI 10.1016/j.canlet.2005.12.042
PG 9
WC Oncology
SC Oncology
GA 135IA
UT WOS:000244146100014
PM 16494996
DA 2018-12-27
ER

PT J
AU Hwang, ES
   Kim, GH
AF Hwang, Eun-Sun
   Kim, Gun-Hee
TI RETRACTED: Biomarkers for oxidative stress status of DNA, lipids, and
   proteins in vitro and in vivo cancer research (Retracted article. See
   vol 241, pg 98, 2007)
SO TOXICOLOGY
LA English
DT Review; Retracted Publication
DE biomarker; oxidative stress; DNA damage; lipid peroxidation; protein
   damage; cancer
ID BASE EXCISION-REPAIR; TOTAL HYDROXYOCTADECADIENOIC ACID; COLI
   ENDONUCLEASE III; THYMINE GLYCOL; BIOLOGICAL SIGNIFICANCE;
   HUMAN-DISEASE; DAMAGE; PEROXIDATION; CELLS; MECHANISMS
AB Oxidation and the production of free radicals are an integral part of human metabolism, and oxidative stress is related to many diseases, including cancer and heart disease. The use of biomarkers for oxidative stress may provide further evidence of a causal relationship between oxidative damage to macromolecules (DNA, lipids, and proteins) and cancer. A wide variety of functional assays, both in vivo and ex vivo, include various measures of DNA oxidation (oxidized DNA bases such as 8-OHdG, autoantibodies to oxidized DNA, modified comet assay), lipid oxidation (thiobarbituric acid-reactive substances, exhaled pentane/ethane, low-density lipoprotein resistance to oxidation, isoprostanes), and protein oxidation (protein carbonyls). The objective of this review is to discuss characteristics and methodologic issues for studies involving biomarkers of exposure to antioxidant nutrients and of oxidative stress status. This paper provides an overview on the current knowledge of oxidative DNA, lipid, and protein damage and cancer incidence. (c) 2006 Elsevier Ireland Ltd. All rights reserved.
C1 Seoul Natl Univ, Coll Agr & Life Sci, Ctr Agr Biomat, Seoul 151921, South Korea.
   Duksung Womens Univ, Dept Food & Nutr, Seoul 132714, South Korea.
   Duksung Womens Univ, Plant Resources Res Inst, Seoul 132714, South Korea.
RP Hwang, ES (reprint author), Seoul Natl Univ, Coll Agr & Life Sci, Ctr Agr Biomat, San 56-1,Shillim Dong, Seoul 151921, South Korea.
EM ehwang5@snu.ac.kr
CR Asagoshi K, 2000, BIOCHEMISTRY-US, V39, P11389, DOI 10.1021/bi000422l
   Aukrust P, 2005, BLOOD, V105, P4730, DOI 10.1182/blood-2004-11-4272
   Baird WM, 2004, MUTAT RES-FUND MOL M, V547, P1, DOI 10.1016/j.mrfmmm.2003.10.008
   Bartsch H, 2004, CANCER DETECT PREV, V28, P385, DOI 10.1016/j.cdp.2004.07.004
   Berlett BS, 1997, J BIOL CHEM, V272, P20313, DOI 10.1074/jbc.272.33.20313
   Bessho T, 1999, NUCLEIC ACIDS RES, V27, P979, DOI 10.1093/nar/27.4.979
   Biri H, 1999, CANCER INVEST, V17, P314, DOI 10.3109/07357909909032872
   BOWEN PE, 1995, AM J CLIN NUTR, V62, P1403
   BOYD NF, 1995, CANCER EPIDEM BIOMAR, V4, P727
   CATALONA WJ, 1995, JAMA-J AM MED ASSOC, V274, P1214
   Dalle-Donne I, 2003, CLIN CHIM ACTA, V329, P23, DOI 10.1016/S0009-8981(03)00003-2
   Dianov GL, 2000, J BIOL CHEM, V275, P11809, DOI 10.1074/jbc.275.16.11809
   Duthie SJ, 1996, CANCER RES, V56, P1291
   Faure V, 2005, BIOCHEM BIOPH RES CO, V328, P1188, DOI 10.1016/j.bbrc.2005.01.082
   Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687
   Fujikawa K, 2001, NUCLEIC ACIDS RES, V29, P449, DOI 10.1093/nar/29.2.449
   Giovannini C, 2004, ANTICANCER RES, V24, P3955
   GROOTVELD M, 1986, BIOCHEM J, V237, P499, DOI 10.1042/bj2370499
   HALLIWELL B, 1994, LANCET, V344, P721, DOI 10.1016/S0140-6736(94)92211-X
   HALLIWELL B, 1993, AM J CLIN NUTR, V57, P715
   HIETANEN E, 1994, EUR J CLIN NUTR, V48, P575
   Hoelzl C, 2005, J Physiol Pharmacol, V56 Suppl 2, P49
   Huang DJ, 2005, J AGR FOOD CHEM, V53, P1841, DOI 10.1021/jf030723c
   Hwang ES, 2004, FOOD SCI BIOTECHNOL, V13, P297
   Hwang ES, 2004, FOOD SCI BIOTECHNOL, V13, P253
   Ikeda S, 1998, J BIOL CHEM, V273, P21585, DOI 10.1074/jbc.273.34.21585
   Jungst C, 2004, HEPATOLOGY, V39, P1663, DOI 10.1002/hep.20241
   Kadiiska MB, 2005, FREE RADICAL BIO MED, V38, P711, DOI 10.1016/freeradbiomed.2004.10.024
   Kanabrocki E L, 2006, Clin Ter, V157, P117
   Kasai H, 2006, ANTIOXID REDOX SIGN, V8, P981, DOI 10.1089/ars.2006.8.981
   Klungland A, 1999, MOL CELL, V3, P33, DOI 10.1016/S1097-2765(00)80172-0
   Korchazhkina O, 2003, J CHROMATOGR B, V794, P353, DOI 10.1016/S1570-0232(03)00495-1
   Kung HC, 1997, J BIOL CHEM, V272, P9227
   Kweon MH, 2006, FREE RADICAL BIO MED, V40, P1349, DOI 10.1016/j.freeradbiomed.2005.12.002
   Liu X, 2002, J MOL BIOL, V321, P265, DOI 10.1016/S0022-2836(02)00623-X
   Makropoulos W, 2000, RENAL FAILURE, V22, P499, DOI 10.1081/JDI-100100891
   Marangon K, 1999, FREE RADICAL BIO MED, V27, P1114, DOI 10.1016/S0891-5849(99)00155-0
   Morimura K, 2004, ONCOL REP, V11, P881
   MUINDI JF, 1994, CANCER RES, V54, P2125
   Nakabeppu Y, 2004, ANN NY ACAD SCI, V1011, P101, DOI 10.1196/annals.1293.011
   Niki E, 2005, BIOCHEM BIOPH RES CO, V338, P668, DOI 10.1016/j.bbrc.2005.08.072
   Ocampo-Hafalla MT, 2006, DNA REPAIR, V5, P444, DOI 10.1016/j.dnarep.2005.12.004
   Orimo H, 2006, CANCER SCI, V97, P99, DOI 10.1111/j.1349-7006.2006.00151.x
   Palozza P, 2004, CARCINOGENESIS, V25, P1315, DOI 10.1093/carcin/bgh142
   PoolZobel BL, 1997, CARCINOGENESIS, V18, P1847, DOI 10.1093/carcin/18.9.1847
   Reardon JT, 1997, P NATL ACAD SCI USA, V94, P9463, DOI 10.1073/pnas.94.17.9463
   Reilly M, 1996, CIRCULATION, V94, P19, DOI 10.1161/01.CIR.94.1.19
   REZNICK AZ, 1992, BIOCHEM J, V286, P607, DOI 10.1042/bj2860607
   Romero FJ, 1998, ENVIRON HEALTH PERSP, V106, P1229, DOI 10.2307/3433990
   Seitz HK, 2006, BIOL CHEM, V387, P349, DOI 10.1515/BC.2006.047
   Seljeskog E, 2006, CLIN BIOCHEM, V39, P947, DOI 10.1016/j.clinbiochem.2006.03.012
   Shinall H, 2005, BIOCHEMISTRY-US, V44, P15345, DOI 10.1021/bi050650l
   Simmons RA, 2005, J BIOL CHEM, V280, P28785, DOI 10.1074/jbc.M505695200
   Sodergren E, 2000, J NUTR, V130, P10
   STILLWELL WG, 1989, CHEM RES TOXICOL, V2, P94, DOI 10.1021/tx00008a004
   Stojic L, 2004, DNA REPAIR, V3, P1091, DOI 10.1016/j.dnarep.2004.06.006
   Svoboda P, 2006, ANTIOXID REDOX SIGN, V8, P985, DOI 10.1089/ars.2006.8.985
   Tanito M, 2006, NEUROSCI LETT, V398, P63, DOI 10.1016/j.neulet.2005.12.070
   Tavridou A, 2006, EUR J CLIN PHARMACOL, V62, P485, DOI 10.1007/s00228-006-0097-z
   Thier R, 1999, ARCH TOXICOL, V73, P479, DOI 10.1007/s002040050638
   Thompson HJ, 2005, J AGR FOOD CHEM, V53, P6126, DOI 10.1021/jf050493x
   Thomson CA, 2005, NUTR CANCER, V51, P146, DOI 10.1207/s15327914nc5102_4
   Tsai KV, 2000, FREE RADICAL BIO MED, V28, P926, DOI 10.1016/S0891-5849(00)00180-5
   Weisburger JH, 2001, MUTAT RES-FUND MOL M, V480, P23, DOI 10.1016/S0027-5107(01)00166-X
   Winterbourn CC, 1999, METHOD ENZYMOL, V300, P106
   Wong YT, 2006, FREE RADICAL RES, V40, P393, DOI 10.1080/10715760600556074
   Xu Y, 2001, J PHARMACOL EXP THER, V296, P825
   Yang N, 2004, DNA REPAIR, V3, P1323, DOI 10.1016/j.dnarep.2004.04.014
   Yeh CT, 2005, J AGR FOOD CHEM, V53, P1740, DOI 10.1021/jf048955e
   Yoshida Y, 2004, FREE RADICAL RES, V38, P787, DOI 10.1080/10715760410001700460
   Zhang QM, 2005, DNA REPAIR, V4, P71, DOI 10.1016/j.dnarep.2004.08.002
NR 71
TC 100
Z9 109
U1 2
U2 27
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0300-483X
J9 TOXICOLOGY
JI Toxicology
PD JAN 5
PY 2007
VL 229
IS 1-2
BP 1
EP 10
DI 10.1016/j.tox.2006.10.013
PG 10
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA 125TZ
UT WOS:000243467000001
PM 17118505
DA 2018-12-27
ER

PT J
AU Zhong, H
   Zeng, XR
   Luo, QY
AF Zhong, H.
   Zeng, X. -R.
   Luo, Q. -Y.
TI RETRACTED: Aquachlorobis(1,10-phenanthroline)cobalt(II) chloride
   thioacetamide solvate (Retracted article. See vol. 66, pg. E11, 2010)
SO ACTA CRYSTALLOGRAPHICA SECTION E-STRUCTURE REPORTS ONLINE
LA English
DT Article; Retracted Publication
AB The Co atom in the cation of the title complex, [CoCl(C(12)H(8)N(2)) 2(H(2)O)]Cl(.)H(2)NC(CH(3))S, exists within a distorted octahedral coordination geometry defined by a Cl atom, the O atom of a water molecule, and four N atoms from two 1,10-phenanthroline ligands. Molecules are linked into a three-dimensional framework primarily by O - H (...) Cl hydrogen bonds and pi-pi stacking interactions.
C1 Jinggangshan Univ, Prov Key Lab Coordinat Chem, Coll Chem & Chem Engn, Jian 343009, Peoples R China.
RP Zhong, H (reprint author), Jinggangshan Univ, Prov Key Lab Coordinat Chem, Coll Chem & Chem Engn, Jian 343009, Peoples R China.
EM huazhong06@126.com
CR DEISENHOFER J, 1989, EMBO J, V8, P2149, DOI 10.1002/j.1460-2075.1989.tb08338.x
   Li H, 2005, ACTA CRYSTALLOGR C, V61, pM19, DOI 10.1107/S0108270104029580
   Pan TT, 2004, ACTA CRYSTALLOGR E, V60, pM56, DOI 10.1107/S1600536803028149
   Sheldrick G. M., 1997, SHELXS97 SHELXL97
   SHELDRICK GM, 1996, SABABS
   *SIEM, 1996, SMART SAINT SHELXTL
   Wu ZY, 2003, ACTA CRYSTALLOGR E, V59, pM809, DOI 10.1107/S1600536803018762
NR 7
TC 4
Z9 4
U1 3
U2 8
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1600-5368
J9 ACTA CRYSTALLOGR E
JI Acta Crystallogr. Sect. E.-Struct Rep. Online
PD JAN
PY 2007
VL 63
BP M221
EP M223
DI 10.1107/S1600536806053530
PN 1
PG 3
WC Crystallography
SC Crystallography
GA 121XT
UT WOS:000243191000090
DA 2018-12-27
ER

PT J
AU Zhong, H
   Zeng, XR
   Liu, YQ
   Luo, QY
AF Zhong, H.
   Zeng, X. -R.
   Liu, Y. -Q.
   Luo, Q. -Y.
TI RETRACTED: (8-quinolinol-kappa N-2,O)bis(8-quinolinolato-kappa
   N-2,O)-nickel(II) glyoxal hemisolvate monohydrate (Retracted article.
   See vol. 66, pg. E11, 2010)
SO ACTA CRYSTALLOGRAPHICA SECTION E-STRUCTURE REPORTS ONLINE
LA English
DT Article; Retracted Publication
AB The Ni-II atom in the title complex, [Ni(C9H6NO)(2)(C9H7NO)]center dot 0.5C(2)H(2)O(2) , has an octahedral coordination geometry defined by three O and three N atoms from one 8-hydoxyquinoline and two 8-oxoquinaoline ligands. The glyoxal molecule lies on an inversion centre. In the crystal structure, molecules are linked into a three-dimensional framework by O - H center dot center dot center dot O hydrogen bonds and pi - pi stacking interactions.
C1 Jinggangshan Univ, Coll Chem & Chem Engn, Provincial Key Lab Coordinat Chem, Jian 343009, Peoples R China.
RP Zhong, H (reprint author), Jinggangshan Univ, Coll Chem & Chem Engn, Provincial Key Lab Coordinat Chem, Jian 343009, Peoples R China.
EM huazhong06@126.com
CR BARTON JK, 1986, SCIENCE, V233, P727, DOI 10.1126/science.3016894
   DEISENHOFER J, 1989, EMBO J, V8, P2149, DOI 10.1002/j.1460-2075.1989.tb08338.x
   Li H, 2005, ACTA CRYSTALLOGR C, V61, pM19, DOI 10.1107/S0108270104029580
   Liu BX, 2004, ACTA CRYSTALLOGR C, V60, pM183, DOI 10.1107/S0108270104005529
   NAING K, 1995, INORG CHEM, V34, P350, DOI 10.1021/ic00105a054
   Pan TT, 2004, ACTA CRYSTALLOGR E, V60, pM56, DOI 10.1107/S1600536803028149
   Pope M. T., 1983, HETEROPOLY ISOPOLY O
   Pope M. T., 2001, POLYOXOMETALATE CHEM
   Sheldrick G. M., 1997, SHELXS97 SHELXL97
   Sheldrick G.M, 1996, SADABS
   *SIEM AN XRAY INST, 1996, SMART SAINT SHELXTL
   Wall M, 1999, J AM CHEM SOC, V121, P4710, DOI 10.1021/ja981227l
   Wu ZY, 2003, ACTA CRYSTALLOGR E, V59, pM809, DOI 10.1107/S1600536803018762
NR 13
TC 1
Z9 1
U1 5
U2 10
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1600-5368
J9 ACTA CRYSTALLOGR E
JI Acta Crystallogr. Sect. E.-Struct Rep. Online
PD JAN
PY 2007
VL 63
BP M187
EP M189
DI 10.1107/S1600536806053232
PN 1
PG 3
WC Crystallography
SC Crystallography
GA 121XT
UT WOS:000243191000078
DA 2018-12-27
ER

PT J
AU Pauw, BR
   Lohmeijer, BGG
   Holder, E
   Marin, V
   Schubert, US
AF Pauw, Brian R.
   Lohmeijer, Bas G. G.
   Holder, Elisabeth
   Marin, Veronica
   Schubert, Ulrich S.
TI RETRACTED: Capillary zone electrophoresis of iridium(III) and
   ruthenium(II) polypyridyl complexes in non-aqueous solvents (Retracted
   article. See vol. 40, pg. 3473, 2007)
SO ANALYTICAL LETTERS
LA English
DT Article; Retracted Publication
DE capillary zone electrophoresis; separation; mobility; polypyridyl
   complexes; metal-containing polymers
ID BIOLOGICAL LABELING REAGENTS; ANALYTICAL ULTRACENTRIFUGATION;
   TERPYRIDINE COMPLEXES; POLY(ETHYLENE OXIDE); OXYGEN SENSOR; SEPARATION;
   POLYMERS; MOIETIES; SYSTEMS; LIGAND
AB A method of non-aqueous capillary zone electrophoresis has been optimised for the characterisation of five functionalised mixed-ligand iridium( III) polypyridyl complexes and four functionalised ruthenium( II) bis-terpyridine complexes. Their mobilities, the relation to their molar mass and the capillary lifetime ( measured in number of injections) have been determined.
C1 Eindhoven Univ Technol, Lab Macromol Chem & Nanosci, NL-5600 MB Eindhoven, Netherlands.
   Dutch Polymer Inst, Eindhoven, Netherlands.
RP Schubert, US (reprint author), Eindhoven Univ Technol, Lab Macromol Chem & Nanosci, POB 513, NL-5600 MB Eindhoven, Netherlands.
EM u.s.schubert@tue.nl
RI Pauw, Brian/C-8392-2013; Holder, Elisabeth/C-9741-2011; Schubert,
   Ulrich/B-5777-2009
OI Pauw, Brian/0000-0002-8605-838X; Holder, Elisabeth/0000-0002-0478-4119;
   Schubert, Ulrich/0000-0003-4978-4670
CR Baranoff E, 2004, CHEM SOC REV, V33, P147, DOI 10.1039/b308983e
   BECKERS JL, 2000, ELEKTROFORESE
   DeRosa MC, 2004, J AM CHEM SOC, V126, P7619, DOI 10.1021/ja049872h
   DeRosa MC, 2003, INORG CHEM, V42, P4864, DOI 10.1021/ic026230r
   Dixon IM, 2000, CHEM SOC REV, V29, P385, DOI 10.1039/b000704h
   Holder E, 2005, ADV MATER, V17, P1109, DOI 10.1002/adma.200400284
   Holder E, 2005, MACROMOL CHEM PHYSIC, V206, P989, DOI 10.1002/macp.200400544
   Holder E, 2004, CHIRALITY, V16, P363, DOI 10.1002/chir.20042
   Holder E, 2002, TETRAHEDRON-ASYMMETR, V13, P2673, DOI 10.1016/S0957-4166(02)00753-X
   Holder E, 2001, TETRAHEDRON-ASYMMETR, V12, P2289, DOI 10.1016/S0957-4166(01)00407-4
   Huynh L, 2005, CHEM MATER, V17, P4765, DOI 10.1021/cm047794r
   Lepeltier M, 2005, EUR J INORG CHEM, P110, DOI 10.1002/ejic.200400418
   Lo KKW, 2005, COORDIN CHEM REV, V249, P1434, DOI 10.1016/j.ccr.2004.10.004
   Lo KKW, 2005, ORGANOMETALLICS, V24, P4594, DOI 10.1021/om050327e
   Lo KKW, 2004, ORGANOMETALLICS, V23, P3108, DOI 10.1021/om0499355
   Lo KKW, 2002, NEW J CHEM, V26, P81
   Lohmeijer BGG, 2003, MACROMOL CHEM PHYSIC, V204, P1072, DOI 10.1002/macp.200390078
   Marin V, 2006, DALTON T, P1636, DOI 10.1039/b513957k
   Meier MAR, 2003, MACROMOL RAPID COMM, V24, P852, DOI 10.1002/marc.200350031
   Meier MAR, 2003, J MASS SPECTROM, V38, P510, DOI 10.1002/jms.463
   Neve F, 1999, INORG CHEM, V38, P2250, DOI 10.1021/ic981308i
   Oudhoff K., 2004, THESIS U AMSTERDAM
   Oudhoff KA, 2004, CHROMATOGRAPHIA, V60, P475, DOI 10.1365/s10337-004-0390-x
   Rasa M, 2006, PROG COLL POL SCI S, V131, P165
   Schubert D, 1999, CHEM-EUR J, V5, P1377, DOI 10.1002/(SICI)1521-3765(19990503)5:5<1377::AID-CHEM1377>3.0.CO;2-H
NR 25
TC 2
Z9 2
U1 3
U2 17
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA
SN 0003-2719
J9 ANAL LETT
JI Anal. Lett.
PY 2007
VL 40
IS 9
BP 1791
EP 1799
DI 10.1080/00032710701380814
PG 9
WC Chemistry, Analytical
SC Chemistry
GA 186EM
UT WOS:000247761900010
DA 2018-12-27
ER

PT J
AU Radenovic, L
   Selakovic, V
   Janac, B
   Todorovic, D
AF Radenovic, Lidija
   Selakovic, Vesna
   Janac, Branka
   Todorovic, Dajana
TI RETRACTED: Effect of glutamate antagonists on nitric oxide production in
   rat brain following intrahippocampal injection (Retracted article. See
   vol. 67, pg. 745, 2015)
SO ARCHIVES OF BIOLOGICAL SCIENCES
LA English
DT Article; Retracted Publication
DE APV; CNQX; excitotoxicity; kainate; neuroprotection; oxidative stress;
   nitrite; NO
ID RECEPTOR-MEDIATED NEUROTOXICITY; AFFINITY KAINATE RECEPTORS;
   CA2+-PERMEABLE AMPA/KAINATE; SUPEROXIDE-PRODUCTION; SUBUNIT EXPRESSION;
   STRIATAL NEURONS; MOTOR-NEURONS; MOUSE-BRAIN; KAINIC ACID; IN-VITRO
AB Stimulation of glutamate receptors induces neuronal nitric oxide (NO) release, which in turn modulates glutamate transmission. The involvement of ionotropic glutamate NMDA and AMPA/kainate receptors in induction of NO production in the rat brain was examined after injection of kainate, a non-NMDA receptor agonist; kainate plus 6-cyano7-nitroquinoxaline-2,3-dione (CNQX), a selective AMPA/kainate receptor antagonist; or kainate plus 2-amino-5-phosphonopentanoic acid (APV), a selective NMDA receptor antagonist. Competitive glutamate receptor antagonists were injected with kainate unilaterally into the CA3 region of the rat hippocampus. The accumulation of nitrite, the stable metabolite of NO, was measured by the Griess reaction at different times (5 min, 15 min, 2 h, 48 h, and 7 days) in hippocampus, forebrain cortex, striatum, and cerebellum homogenates. The used glutamate antagonists APV and CNQX both provided sufficient neuroprotection in the sense of reducing nitrite concentrations, but with different mechanisms and time dynamics. Our findings suggest that NMDA and AMPA/kainate receptors are differentially-involved in nitric oxide production.
C1 [Radenovic, Lidija] Univ Belgrade, Fac Biol, Dept Physiol & Biochem, Belgrade 11000, Serbia.
   [Selakovic, Vesna] Mil Med Acad, Inst Med Res, Belgrade 11000, Serbia.
   [Janac, Branka; Todorovic, Dajana] Sinisa Stankovic Inst Biol Res, Belgrade 11060, Serbia.
RP Radenovic, L (reprint author), Univ Belgrade, Fac Biol, Dept Physiol & Biochem, Belgrade 11000, Serbia.
CR Alabadi JA, 1999, BRAIN RES, V839, P305, DOI 10.1016/S0006-8993(99)01749-7
   Bailey A, 2001, EUR J PHARMACOL, V431, P305, DOI 10.1016/S0014-2999(01)01463-7
   Becker AJ, 1999, MOL BRAIN RES, V67, P172, DOI 10.1016/S0169-328X(99)00060-1
   Bidmon HJ, 1999, ANN ANAT, V181, P345, DOI 10.1016/S0940-9602(99)80125-3
   Brorson JR, 1999, J NEUROSCI, V19, P147
   Brown GC, 1999, BBA-BIOENERGETICS, V1411, P351, DOI 10.1016/S0005-2728(99)00025-0
   Candelario-Jalil E, 2001, J APPL TOXICOL, V21, P403, DOI 10.1002/jat.768
   Carriedo SG, 1996, J NEUROSCI, V16, P4069
   Carriedo SG, 2000, J NEUROSCI, V20, P240, DOI 10.1523/JNEUROSCI.20-01-00240.2000
   Carriedo SG, 1998, J NEUROSCI, V18, P7727
   Carroll FY, 1998, NEUROSCI LETT, V255, P71, DOI 10.1016/S0304-3940(98)00720-4
   Ciriolo MR, 2001, J NEUROCHEM, V77, P1433, DOI 10.1046/j.1471-4159.2001.00383.x
   Gratacos E, 2001, J NEUROCHEM, V78, P1287, DOI 10.1046/j.1471-4159.2001.00538.x
   GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X
   Guevara I, 1998, CLIN CHIM ACTA, V274, P177, DOI 10.1016/S0009-8981(98)00060-6
   GUNASEKAR PG, 1995, J NEUROCHEM, V65, P2016
   Halasz AS, 2004, NEUROCHEM INT, V44, P641, DOI 10.1016/j.neuint.2003.09.003
   Heales SJR, 1999, BBA-BIOENERGETICS, V1410, P215, DOI 10.1016/S0005-2728(98)00168-6
   Hyrc K, 1997, J NEUROSCI, V17, P6669
   Janssens N, 2001, J NEUROCHEM, V77, P1457, DOI 10.1046/j.1471-4159.2001.00369.x
   Kaczmarek L, 1997, PHYSIOL REV, V77, P217
   Kashihara K, 1998, NEUROSCI RES, V32, P189, DOI 10.1016/S0168-0102(98)00086-8
   Kashihara K, 2000, NEUROL RES, V22, P409, DOI 10.1080/01616412.2000.11758606
   KOH JY, 1990, J NEUROSCI, V10, P693
   Lei BP, 1999, STROKE, V30, P669, DOI 10.1161/01.STR.30.3.669
   Lere C, 2002, BRAIN RES PROTOC, V9, P49, DOI 10.1016/S1385-299X(01)00136-2
   LOWRY OH, 1951, J BIOL CHEM, V193, P265
   Lu YM, 1996, J NEUROSCI, V16, P5457
   MULSCH A, 1994, NEUROREPORT, V5, P2325
   Nakaki T, 2000, NEUROSCI LETT, V290, P209, DOI 10.1016/S0304-3940(00)01363-X
   Nicholls DG, 2000, PHYSIOL REV, V80, P315
   Patel M, 2003, NEUROSCIENCE, V118, P431, DOI 10.1016/S0306-4522(02)00979-X
   Peng TI, 1998, EXP NEUROL, V149, P1, DOI 10.1006/exnr.1997.6599
   Radenovic L, 2004, BRAIN RES BULL, V64, P85, DOI 10.1016/j.brainresbull.2004.06.001
   Radenovic L, 2003, COMP BIOCHEM PHYS C, V135, P443, DOI 10.1016/S1532-0456(03)00150-9
   Sengpiel B, 1998, EUR J NEUROSCI, V10, P1903, DOI 10.1046/j.1460-9568.1998.00202.x
   Tseng WP, 2003, NEUROCHEM INT, V42, P333, DOI 10.1016/S0197-0186(02)00118-3
   Varju P, 2001, J NEUROCHEM, V77, P1444, DOI 10.1046/j.1471-4159.2001.00352.x
   WEISS JH, 1994, NEUROSCIENCE, V60, P659, DOI 10.1016/0306-4522(94)90494-4
   Yasuda H, 2001, EPILEPSIA, V42, P13, DOI 10.1046/j.1528-1157.2001.083032.x
NR 40
TC 1
Z9 1
U1 4
U2 9
PU INST BIOLOSKA ISTRAZIVANJA SINISA STANKOVIC
PI BEOGRAD
PA 29 NOVEMBRA 142, BEOGRAD, 11060, SERBIA
SN 0354-4664
EI 1821-4339
J9 ARCH BIOL SCI
JI Arch. Biol. Sci.
PY 2007
VL 59
IS 1
BP 29
EP 36
DI 10.2298/ABS0701029R
PG 8
WC Biology
SC Life Sciences & Biomedicine - Other Topics
GA 284SM
UT WOS:000254726100004
OA DOAJ Gold
DA 2018-12-27
ER

PT J
AU Matsuyama, W
   Mitsuyama, H
   Ono, M
   Shirahama, Y
   Higashimoto, I
   Osame, M
   Arimura, K
AF Matsuyama, Wataru
   Mitsuyama, Hideo
   Ono, Mikiko
   Shirahama, Yuko
   Higashimoto, Ikkou
   Osame, Mituhiro
   Arimura, Kimiyoshi
TI RETRACTED: Discoidin domain receptor 1 contributes to eosinophil
   survival in an NF-kappa B-dependent manner in Churg-Strauss syndrome
   (Retracted Article. See vol 111, pg 2537, 2008)
SO BLOOD
LA English
DT Article; Retracted Publication
ID ACTIVATED PROTEIN-KINASE; COLONY-STIMULATING FACTOR; TERM-FOLLOW-UP;
   ENDOTHELIAL GROWTH-FACTOR; TYROSINE KINASE; EXTRACELLULAR-MATRIX;
   CHEMOKINE PRODUCTION; SYSTEMIC VASCULITIS; ISOFORM-B; IN-VITRO
AB Churg-Strauss syndrome (CSS) is a systemic disease that shows marked eosinophilia along with eosinophil infiltration in the tissue. Prolonged eosinophil survival plays an important role in the pathogenesis of CSS; however, its detailed molecular mechanism remains unclear. Discoidin domain receptor 1 (DDR1) is a receptor tyrosine kinase, and its ligand is collagen. DDR1 was expressed in human leukocytes and fibroblasts, and it plays an important role in leukocyte cytokine production and fibroblast survival in an NF-kappa B-dependent manner. In this study, we examined in vitro and in vivo eosinophil DDR1 expression and its function in CSS patients. The expression level of DDR1 was significantly higher in the eosinophils of CSS patients, and the predominant isoform was DDR1b. Immunohistochemical findings revealed that the tissue-infiltrating eosinophils expressed endogenous DDR1. In CSS patients, DDR1 activation inhibited Fas agonistic antibody-induced apoptosis and up-regulated Fas agonistic antibody-induced cytokine production of eosinophils in an NF-kappa B-dependent manner. Suppression of DDR1 expression in the eosinophils by using RNA interference and addition of the DDR1-blocking protein abolished these effects. We propose that DDR1 contributes to the eosinophil survival in the tissue microenvironment of CSS and that it might be involved in the development of CSS.
C1 Kagoshima Univ Hosp, Div Resp Med, Resp & Stress Care Ctr, Kagoshima 8908520, Japan.
RP Matsuyama, W (reprint author), Kagoshima Univ Hosp, Div Resp Med, Resp & Stress Care Ctr, Kagoshima 8908520, Japan.
EM vega@xa2.so-net.ne.jp
CR ANWAR ARF, 1993, J EXP MED, V177, P839, DOI 10.1084/jem.177.3.839
   Blagosklonny MV, 2001, LEUKEMIA, V15, P869, DOI 10.1038/sj.leu.2402134
   Chihara J, 2000, J ALLERGY CLIN IMMUN, V106, pS99, DOI 10.1067/mai.2000.106884
   Conron M, 2000, THORAX, V55, P870, DOI 10.1136/thorax.55.10.870
   Coward WR, 2004, CLIN EXP ALLERGY, V34, P1071, DOI 10.1111/j.1365-2222.2004.02003.x
   Curat CA, 2002, J AM SOC NEPHROL, V13, P2648, DOI 10.1097/01.ASN.0000032419.13208.0C
   Deng XM, 2001, J BIOL CHEM, V276, P23681, DOI 10.1074/jbc.M100279200
   Eustace JA, 1999, J AM SOC NEPHROL, V10, P2048
   Fujioka Akira, 1998, Journal of Dermatology (Tokyo), V25, P171
   Gayraud M, 2001, ARTHRITIS RHEUM, V44, P666, DOI 10.1002/1529-0131(200103)44:3<666::AID-ANR116>3.3.CO;2-1
   Gross WL, 2002, CURR OPIN RHEUMATOL, V14, P11, DOI 10.1097/00002281-200201000-00003
   Guillevin L, 1999, MEDICINE, V78, P26, DOI 10.1097/00005792-199901000-00003
   Hellmich B, 2005, ANN NY ACAD SCI, V1051, P121, DOI 10.1196/annals.1361.053
   Hellmich B, 2003, CLIN EXP RHEUMATOL, V21, pS69
   Higashimoto I, 1996, INT ARCH ALLERGY IMM, V111, P66, DOI 10.1159/000237420
   Hoontrakoon R, 2002, AM J RESP CELL MOL, V26, P404, DOI 10.1165/ajrcmb.26.4.4517
   Hou GP, 2002, CIRC RES, V90, P1147, DOI 10.1161/01.RES.0000022166.74073.F8
   Hou GP, 2001, J CLIN INVEST, V107, P727, DOI 10.1172/JCI10720
   Kamohara H, 2001, FASEB J, V15, P2724, DOI 10.1096/fj.01-0359fje
   Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221
   Koo DHH, 2006, FEBS LETT, V580, P15, DOI 10.1016/j.febslet.2005.11.035
   LANHAM JG, 1984, MEDICINE, V63, P65, DOI 10.1097/00005792-198403000-00001
   Maehnss K, 2002, J AUTOIMMUN, V18, P239, DOI 10.1006/jaut.2002.0582
   Marra F, 1997, FEBS LETT, V414, P221, DOI 10.1016/S0014-5793(97)01004-1
   MASI AT, 1990, ARTHRITIS RHEUM, V33, P1094, DOI 10.1002/art.1780330806
   Matsuyama W, 2003, J IMMUNOL, V171, P3520, DOI 10.4049/jimmunol.171.7.3520
   Matsuyama W, 2006, AM J PATHOL, V168, P866, DOI 10.2353/ajpath.2006.050801
   Matsuyama W, 2005, AM J RESP CELL MOL, V33, P565, DOI 10.1165/rcmb.2005-0236OC
   Matsuyama W, 2005, J IMMUNOL, V174, P6490, DOI 10.4049/jimmunol.174.10.6490
   Matsuyama W, 2004, J IMMUNOL, V172, P2332, DOI 10.4049/jimmunol.172.4.2332
   Matsuyama W, 2003, FASEB J, V17, P1286, DOI 10.1096/fj.02-0320fje
   Matsuyama W, 2001, J NEUROL SCI, V186, P75, DOI 10.1016/S0022-510X(01)00515-9
   Matsuyama W, 2004, BLOOD, V104, P184, DOI 10.1182/blood-2003-12-4274
   Matsuyama W, 2000, AM J RESP CRIT CARE, V162, P1120, DOI 10.1164/ajrccm.162.3.9911010
   Meerschaert J, 1999, J IMMUNOL, V163, P6217
   Motegi Y, 1998, J IMMUNOL, V161, P4340
   Murphy KM, 2000, J BIOL CHEM, V275, P17225, DOI 10.1074/jbc.C900590199
   Muschen M, 1999, AM J PATHOL, V155, P915, DOI 10.1016/S0002-9440(10)65191-7
   *NIH, 2002, 2 NAT ASTHM ED PREV
   Noth I, 2003, LANCET, V361, P587, DOI 10.1016/S0140-6736(03)12518-4
   Okada S, 1997, AM J RESP CELL MOL, V16, P455, DOI 10.1165/ajrcmb.16.4.9115757
   RAGHU G, 1985, AM REV RESPIR DIS, V131, P281
   Rothenberg ME, 1998, NEW ENGL J MED, V338, P1592, DOI 10.1056/NEJM199805283382206
   Schmitt WH, 1998, ARTHRITIS RHEUM, V41, P445, DOI 10.1002/1529-0131(199803)41:3<445::AID-ART10>3.3.CO;2-V
   Shrivastava A, 1997, MOL CELL, V1, P25, DOI 10.1016/S1097-2765(00)80004-0
   Solans R, 2001, RHEUMATOLOGY, V40, P763, DOI 10.1093/rheumatology/40.7.763
   Tatsis E, 1998, ANN INTERN MED, V129, P370, DOI 10.7326/0003-4819-129-5-199809010-00004
   TOURKIN A, 1993, CELL ADHES COMMUN, V1, P161, DOI 10.3109/15419069309095692
   Vogel W, 1997, MOL CELL, V1, P13, DOI 10.1016/S1097-2765(00)80003-9
   Vogel W, 1999, FASEB J, V13, pS77
   Vogel WF, 2001, MOL CELL BIOL, V21, P2906, DOI 10.1128/MCB.21.8.2906-2917.2001
   Vogel WF, 2006, CELL SIGNAL, V18, P1108, DOI 10.1016/j.cellsig.2006.02.012
   Walsh GM, 1997, J ALLERGY CLIN IMMUN, V100, P208, DOI 10.1016/S0091-6749(97)70226-4
   Wang CB, 2005, ALLERGY, V60, P1378, DOI 10.1111/j.1398-9995.2005.00884.x
   Wong CK, 2005, AM J RESP CELL MOL, V33, P186, DOI 10.1165/rcmb.2005-0034OC
   Yoshikawa M, 2002, INT ARCH ALLERGY IMM, V128, P3, DOI 10.1159/000059412
NR 56
TC 8
Z9 9
U1 2
U2 8
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD JAN 1
PY 2007
VL 109
IS 1
BP 22
EP 30
DI 10.1182/blood-2006-04-015206
PG 9
WC Hematology
SC Hematology
GA 121JM
UT WOS:000243153900014
PM 16968898
OA Bronze
DA 2018-12-27
ER

PT J
AU Sukhikh, GT
   Soboleva, GM
AF Sukhikh, G. T.
   Soboleva, G. M.
TI RETRACTED: Sorsby fundus dystrophy-related mutation in tissue inhibitor
   of metalloproteinases-3 impairs regulation of its expression in mouse
   fibroblasts (Retracted article. See vol. 147, pg. 668, 2009)
SO BULLETIN OF EXPERIMENTAL BIOLOGY AND MEDICINE
LA English
DT Article; Retracted Publication
DE sorsby fundus dystrophy; tissue inhibitor of metalloproteinases-3
ID MACULAR DEGENERATION; PROTEIN; TIMP-3; PHENOTYPE; CELLS
AB Mutations in the C-terminal domain of tissue inhibitor of metalloproteinases-3 (TIMP-3) are linked with Sorsby fundus dystrophy (autosomal dominant retinal dystrophy). Experiments on timp-3 gene knock-out and knock-in mice, carriers of dystrophy-linked Timp-3(S156C) mutation, showed that expression of mutant Timp-3(S156C), in contrast to the normal one, is not regulated by phorbol-myristate-12-acetate and is retained at a high level in a medium without FCS. The mutant protein is not transported into the nucleus, while fibroblasts expressing it survive without FCS and other growth factors. It is hypothesized that normal Timp-3 is involved in the regulation of expression of its own timp-3 gene and, probably, other genes associated with growth and proliferation. The absence of this characteristic in mutant Timp-3(S156C) is presumably responsible for its accumulation in the extracellular matrix.
C1 Russian Acad Med Sci, Res Ctr Obstet Gynecol & Perinatol, Moscow, Russia.
RP Soboleva, GM (reprint author), Russian Acad Med Sci, Res Ctr Obstet Gynecol & Perinatol, Moscow, Russia.
EM soboleva_galina@hotmail.com
RI Sukhikh, Gennady/J-1496-2012
CR Brew K, 2000, BBA-PROTEIN STRUCT M, V1477, P267, DOI 10.1016/S0167-4838(99)00279-4
   BUNGNO M, 1999, FEBS LETT, V448, P9
   Chong NHV, 2000, INVEST OPHTH VIS SCI, V41, P898
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   HAYAKAWA T, 1992, FEBS LETT, V298, P29, DOI 10.1016/0014-5793(92)80015-9
   Langton KP, 2000, J BIOL CHEM, V275, P27027
   LECO KJ, 1994, J BIOL CHEM, V269, P9352
   NEMETH JA, 1993, EXP CELL RES, V207, P376, DOI 10.1006/excr.1993.1204
   Soboleva G, 2003, J CELL PHYSIOL, V197, P149, DOI 10.1002/jcp.10361
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Weber BHF, 2002, INVEST OPHTH VIS SCI, V43, P2732
   WICK M, 1994, J BIOL CHEM, V269, P18953
   Woessner JF, 2002, MOL BIOTECHNOL, V22, P33, DOI 10.1385/MB:22:1:033
   YANG TT, 1992, P NATL ACAD SCI USA, V89, P10676, DOI 10.1073/pnas.89.22.10676
NR 14
TC 2
Z9 2
U1 4
U2 11
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0007-4888
EI 1573-8221
J9 B EXP BIOL MED+
JI Bull. Exp. Biol. Med.
PD JAN
PY 2007
VL 143
IS 1
BP 64
EP 67
DI 10.1007/s10517-007-0018-x
PG 4
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA 185SX
UT WOS:000247731800018
PM 18019015
DA 2018-12-27
ER

PT J
AU Manna, SK
   Manna, P
   Sarkar, A
AF Manna, S. K.
   Manna, P.
   Sarkar, A.
TI RETRACTED: Inhibition of RelA phosphorylation sensitizes apoptosis in
   constitutive NF-kappaB-expressing and chemoresistant cells (Retracted
   article. See vol. 20, pg. 784, 2013)
SO CELL DEATH AND DIFFERENTIATION
LA English
DT Article; Retracted Publication
DE 1,2,4-thiadiazolidine; NF-kappa B; cell signaling; apoptosis
ID B P65 SUBUNIT; PROINFLAMMATORY CYTOKINE EXPRESSION; CASEIN KINASE-II;
   TRANSCRIPTION FACTOR; POTENTIATES APOPTOSIS; CANCER-CELLS; IN-VIVO;
   ACTIVATION; ALPHA; CARCINOMA
AB The compound 5-(4-methoxyarylimino)-2-N-(3,4-dichlorophenyl)-3-oxo-1,2,4-thiadiazolidine (P-3-25) is known to possess antibacterial, anti-fungal, anti-tubercular, and local anesthetic activities. We studied the anti-tumorigenic activity of P-3-25 and the role of nuclear transcription factor kappaB (NF-KB) in this process. In constitutive NF-KB-expressing cells, treatment with P-3-25 inhibited the expression of NF-KB-dependent reporter gene, adhesion molecules, and cyclooxygenase. It downregulated phosphorylation of p65 by inhibiting upstream kinases, such as protein kinase A and casein kinase II, but did not alter NF-KB DNA-binding activity. Alone, P-3-25 induced apoptosis in NF-KB- expressing and doxorubicin-resistant breast cancer cells, and in the presence of other chemotherapeutic agents, it potentiated apoptosis. Overall, our results suggest that P-3-25 exerts antitumorigenic activity by inhibiting phosphorylation of p65, the transcriptionally active subunit of NF-KB by inhibiting its upstream kinases, and potentiates apoptosis mediated by chemotherapeutic agents. These results suggest novel approaches for designing of anticancer drugs for combination chemotherapy.
C1 Ctr DNA Fingerprinting & Diagnost, Immunol Lab, Hyderabad 500076, Andhra Pradesh, India.
   Banaras Hindu Univ, Inst Technol, Dept Appl Chem, Varanasi 221005, Uttar Pradesh, India.
RP Manna, SK (reprint author), Ctr DNA Fingerprinting & Diagnost, Immunol Lab, ECIL Rd, Hyderabad 500076, Andhra Pradesh, India.
EM manna@cdfd.org.in
CR ABDELHALIM AM, 1994, INDIAN J HETEROCY CH, V4, P45
   Baeuerle PA, 1997, ADV IMMUNOL, V65, P111, DOI 10.1016/S0065-2776(08)60742-7
   Barkett M, 1999, ONCOGENE, V18, P6910, DOI 10.1038/sj.onc.1203238
   BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0
   Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782
   Bhat-Nakshatri P, 2002, ONCOGENE, V21, P2066, DOI 10.1038/sj/onc/1205243
   Broemer M, 2004, ONCOGENE, V23, P5378, DOI 10.1038/sj.onc.1207705
   Chantome A, 2004, J BIOL CHEM, V279, P23953, DOI 10.1074/jbc.M313731200
   Choubey AK, 1998, INDIAN J CHEM B, V37, P145
   Dai Y, 2005, MOL CELL BIOL, V25, P5429, DOI 10.1128/MCB.25.13.5429-5444.2005
   Delghandi MP, 2005, CELL SIGNAL, V17, P1343, DOI 10.1016/j.cellsig.2005.02.003
   Devarajan E, 2002, INT J ONCOL, V20, P913
   Djavaheri-Mergny M, 2004, FEBS LETT, V578, P111, DOI 10.1016/j.febslet.2004.10.082
   Dong G, 1999, CANCER RES, V59, P3495
   Duffey DC, 1999, CANCER RES, V59, P3468
   Esaki M, 2005, HUM PATHOL, V36, P66, DOI 10.1016/j.humpath.2004.10.014
   Gasparian AV, 2002, J CELL SCI, V115, P141
   GEARD C, 2003, J MED CHEM, V46, P427
   Hammar EB, 2005, J BIOL CHEM, V280, P30630, DOI 10.1074/jbc.M502493200
   Heyninck K, 2005, TRENDS BIOCHEM SCI, V30, P1, DOI 10.1016/j.tiba.2004.11.001
   Hubinger G, 2004, EXP HEMATOL, V32, P382, DOI 10.1016/j.exphem.2004.01.003
   Izeradjene K, 2004, CLIN CANCER RES, V10, P6650, DOI 10.1158/1078-0432.CCR-04-0576
   Karin M, 2005, NAT REV IMMUNOL, V5, P749, DOI 10.1038/nri1703
   Krappmann D, 1999, ONCOGENE, V18, P943, DOI 10.1038/sj.onc.1202351
   Lee JY, 2005, J CELL PHYSIOL, V203, P493, DOI 10.1002/jcp.20257
   Li YW, 2005, CANCER RES, V65, P6934, DOI 10.1158/0008-5472.CAN-04-4604
   Manna P, 2005, INT J CANCER, V113, P549, DOI 10.1002/ijc.20590
   Manna P, 2004, INDIAN J HETEROCY CH, V13, P249
   Manna SK, 1998, J BIOL CHEM, V273, P13245, DOI 10.1074/jbc.273.21.13245
   Manna SK, 2005, J BIOL CHEM, V280, P7010, DOI 10.1074/jbc.M410994200
   Manna SK, 1999, J IMMUNOL, V162, P1510
   Porter CM, 2000, J BIOL CHEM, V275, P3543, DOI 10.1074/jbc.275.5.3543
   Rayet B, 1999, ONCOGENE, V18, P6938, DOI 10.1038/sj.onc.1203221
   Ruegg C, 2003, CELL MOL LIFE SCI, V60, P1135, DOI 10.1007/s00018-003-2297-3
   Sakurai H, 1999, J BIOL CHEM, V274, P30353, DOI 10.1074/jbc.274.43.30353
   Sarkar A, 2004, J BIOL CHEM, V279, P33768, DOI 10.1074/jbc.M403424200
   Scholzen TE, 2003, ENDOCRINOLOGY, V144, P360, DOI 10.1210/en.2002-220651
   Sors A, 2006, BLOOD, V107, P2354, DOI 10.1182/blood-2005-06-2536
   Sreenivasan Y, 2003, ONCOGENE, V22, P4356, DOI 10.1038/sj.onc.1206486
   VAN AD, 1996, SCIENCE, V274, P787
   Vermeulen L, 2003, EMBO J, V22, P1313, DOI 10.1093/emboj/cdg139
   von Knethen A, 1999, J IMMUNOL, V163, P2858
   Wang CY, 1999, NAT MED, V5, P412
   Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784
   Wang D, 2000, J BIOL CHEM, V275, P32592, DOI 10.1074/jbc.M001358200
   Wu AW, 2004, WORLD J GASTROENTERO, V10, P2323
   Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0
NR 47
TC 24
Z9 24
U1 2
U2 10
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1350-9047
EI 1476-5403
J9 CELL DEATH DIFFER
JI Cell Death Differ.
PD JAN
PY 2007
VL 14
IS 1
BP 158
EP 170
DI 10.1038/sj.cdd.4401929
PG 13
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 117CP
UT WOS:000242850600017
PM 16645640
OA Bronze, Green Published
DA 2018-12-27
ER

PT J
AU Gravel, E
   Poupon, E
   Hocquemiller, R
AF Gravel, Edmond
   Poupon, Erwan
   Hocquemiller, Reynald
TI RETRACTED: Biogenetic hypothesis and first steps towards a biomimetic
   synthesis of haouamines (Retracted article. See issue 2, pg 262, 2008)
SO CHEMICAL COMMUNICATIONS
LA English
DT Article; Retracted Publication
ID SPHEROPLAST FORMING ACTIVITY; MUREIDOMYCINS-A-D; PSEUDOMONAS-AERUGINOSA
   ACTIVITY; PEPTIDYLNUCLEOSIDE ANTIBIOTICS; PHENYLALANINE; BIOSYNTHESIS;
   PACIDAMYCINS; FERMENTATION; ALDEHYDES; TRIFLATE
AB A detailed hypothesis for the biogenesis of haouamines is reported herein, supported by experiments headed towards biomimetic synthesis of these compounds.
C1 Univ Paris 11, CNRS, Lab Pharmacognosie, UMR 8076,BioCIS,Ctr Etud Pharmaceut, F-92290 Chatenay Malabry, France.
RP Poupon, E (reprint author), Univ Paris 11, CNRS, Lab Pharmacognosie, UMR 8076,BioCIS,Ctr Etud Pharmaceut, 5 Rue Jean Baptiste Clement, F-92290 Chatenay Malabry, France.
EM erwan.poupon@cep.u-psud.fr
OI Poupon, Erwan/0000-0002-1178-6083
CR Baran PS, 2006, J AM CHEM SOC, V128, P8678, DOI 10.1021/ja061660s
   Baran PS, 2006, J AM CHEM SOC, V128, P3908, DOI 10.1021/ja0602997
   CHEN RH, 1989, J ANTIBIOT, V42, P512, DOI 10.7164/antibiotics.42.512
   FERNANDES PB, 1989, J ANTIBIOT, V42, P521, DOI 10.7164/antibiotics.42.521
   FRANK RL, 1949, J AM CHEM SOC, V71, P2629, DOI 10.1021/ja01176a008
   FUKAMI MH, 1990, BIOCHEM J, V268, P525, DOI 10.1042/bj2680525
   Garrido L, 2003, J ORG CHEM, V68, P293, DOI 10.1021/jo020487p
   GE CH, 2006, EUR J ORG CHEM, V18, P4106
   Gravel E, 2005, ORG LETT, V7, P2497, DOI 10.1021/ol050849q
   Grundl MA, 2006, ORG LETT, V8, P23, DOI 10.1021/ol052262h
   INUKAI M, 1989, J ANTIBIOT, V42, P662, DOI 10.7164/antibiotics.42.662
   ISONO F, 1989, J ANTIBIOT, V42, P674, DOI 10.7164/antibiotics.42.674
   ISONO F, 1989, J ANTIBIOT, V42, P667, DOI 10.7164/antibiotics.42.667
   ISONO F, 1993, J ANTIBIOT, V46, P1203, DOI 10.7164/antibiotics.46.1203
   ISONO K, 1988, J ANTIBIOT, V41, P1711, DOI 10.7164/antibiotics.41.1711
   Jakubowicz K, 2005, J ORG CHEM, V70, P7780, DOI 10.1021/jo050937o
   Jeong JH, 2006, ORG LETT, V8, P2309, DOI 10.1021/ol060556c
   KARWOWSKI JP, 1989, J ANTIBIOT, V42, P506, DOI 10.7164/antibiotics.42.506
   KAUR H, 1988, ANAL BIOCHEM, V172, P360, DOI 10.1016/0003-2697(88)90456-3
   Keseru GM, 1998, STUD NAT PROD CHEM, V20, P263
   Luo SZ, 2005, MINI-REV ORG CHEM, V2, P177, DOI 10.2174/1570193053544472
   Manabe K, 2005, BIOORGAN MED CHEM, V13, P5154, DOI 10.1016/j.bmc.2005.05.018
   Sakai N, 2006, TETRAHEDRON LETT, V47, P1261, DOI 10.1016/j.tetlet.2005.12.080
   Smith ND, 2005, ORG LETT, V7, P4309, DOI 10.1021/ol0512740
   Snider BB, 2005, ORG LETT, V7, P2715, DOI 10.1021/ol050931l
   Sperry J, 2006, CHEM COMMUN, P2397, DOI 10.1039/b604294e
   TONG JH, 1971, BIOCHEM BIOPH RES CO, V44, P229, DOI 10.1016/S0006-291X(71)80183-3
   Wang LM, 2006, J FLUORINE CHEM, V127, P1570, DOI 10.1016/j.jfluchem.2006.08.005
   Wipf P, 2006, ORG LETT, V8, P1901, DOI 10.1021/ol060455e
   Yu LB, 1997, J ORG CHEM, V62, P208, DOI 10.1021/jo961175n
NR 30
TC 11
Z9 11
U1 3
U2 12
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 1359-7345
EI 1364-548X
J9 CHEM COMMUN
JI Chem. Commun.
PY 2007
IS 7
BP 719
EP 721
DI 10.1039/b613737g
PG 3
WC Chemistry, Multidisciplinary
SC Chemistry
GA 134YD
UT WOS:000244119500012
PM 17392961
DA 2018-12-27
ER

PT J
AU Kesherwani, V
   Sodhi, A
AF Kesherwani, Varun
   Sodhi, Ajit
TI RETRACTED: Quantitative role of p42/44 and p38 in the production and
   regulation of cytokines TNF-alpha, IL-1 beta and IL-12 by murine
   peritoneal macrophages in vitro by Concanavalin A (Retracted article.
   See vol 54, pg 338, 2011)
SO CYTOKINE
LA English
DT Article; Retracted Publication
DE macrophages; cytokines; chemokines; Concanavalin A; signal transduction
ID SIGNAL-TRANSDUCTION PATHWAY; RAT ALVEOLAR MACROPHAGES;
   PROTEIN-CARBOHYDRATE INTERACTION; METHIONYL-LEUCYL-PHENYLALANINE;
   INFLAMMATORY-BOWEL-DISEASE; NITRIC-OXIDE SYNTHASE; PHOSPHATIDYLINOSITOL
   TURNOVER; PROINFLAMMATORY CYTOKINES; SUPEROXIDE PRODUCTION; MOLECULAR
   MECHANISMS
AB In the present study the quantitative role of p42/44 and p38 in the production of TNF-alpha, IL-1 beta and IL-12 by murine peritoneal macrophages, in vitro, on treatment with Concanavalin A (ConA) has been investigated. Maximum expression/production of cytokines TNF-alpha, IL-1 beta and IL-12 was observed after 16 h by RT-PCR and 24 h by ELISA, on in vitro treatment with ConA. To investigate the role of MAP kinases in the production of cytokines, pharmacological inhibitors of MAP kinases-PD98059, SB202190 and SP600125, were used. The expression of TNF-alpha, IL-1 beta and IL-12 was down regulated in the presence of PD98059 and SB202190 in a dose dependent manner, suggesting the involvement of p42/44 and p38 in ConA induced production of TNF-alpha, IL-1 beta and IL-12 by macrophages. It was observed that SP600125 did not have any effect on the expression of TNF-alpha, IL-1 beta and IL-12. Using different combinations of MAPK inhibitors, it was found that 45% signal is conveyed via p42/44 and 25% via p38 in the production of these cytokines, by ConA treated macrophages while 30% signal passes through unidentified pathways. (c) 2007 Elsevier Ltd. All rights reserved.
C1 Banaras Hindu Univ, Fac Sci, Sch Biotechnol, Varanasi 221005, Uttar Pradesh, India.
RP Kesherwani, V (reprint author), Banaras Hindu Univ, Fac Sci, Sch Biotechnol, Varanasi 221005, Uttar Pradesh, India.
EM varun.kesherwani@gmail.com
CR ADAMS DO, 1983, IMMUNOL TODAY, V4, P166, DOI 10.1016/0167-5699(83)90005-1
   ADAMS DO, 1984, ANNU REV IMMUNOL, V2, P238
   AGRAWAL BBL, 1968, CAN J BIOCHEM CELL B, V46, P1147, DOI 10.1139/o68-170
   AMIN ARM, 2003, CANCER RES, V63, P334
   BACON KB, 1999, CHEMOKINE INDUCED SI
   Biswas SK, 2002, J INTERF CYTOK RES, V22, P527, DOI 10.1089/10799900252982007
   BOLDT DH, 1975, J IMMUNOL, V114, P1532
   BRUMMER E, 1983, INFECT IMMUN, V39, P817
   CAMERON AR, 1983, P NATL ACAD SCI-BIOL, V80, P3726, DOI 10.1073/pnas.80.12.3726
   CHOWDHURY TK, 1975, P INT S CONC A
   CILDA A, 1986, J IMMUNOL, V137, P2373
   DORIO RJ, 1988, ANN CLIN LAB SCI, V18, P190
   DRYSDALE BE, 1987, J IMMUNOL, V138, P951
   Eason S, 1995, ARCH INT PHARMACOD T, V330, P225
   FERNANDIS AZ, 1998, MOL IMMUNOL, V35, P14
   FORMAN HJ, 1983, J APPL PHYSIOL, V54, P1249
   HAMILTON TA, 1987, IMMUNOL TODAY, V8, P151, DOI 10.1016/0167-5699(87)90145-9
   Hoffmann JC, 2002, PATHOBIOLOGY, V70, P121, DOI 10.1159/000068143
   Hommes DW, 2003, GUT, V52, P144, DOI 10.1136/gut.52.1.144
   KESHERWANI V, IN PRESS J INTERFERO
   Kesherwani V, 2007, NITRIC OXIDE-BIOL CH, V16, P294, DOI 10.1016/j.niox.2006.11.001
   KEY ME, 1982, ADV EXP MED BIOL, V146, P265
   KHOLODENKO BN, 1988, FEBS LETT, V232, P383, DOI 10.1016/0014-5793(88)80775-0
   Kholodenko BN, 1997, FEBS LETT, V414, P430, DOI 10.1016/S0014-5793(97)01018-1
   KLOSTERGAARD J, 1991, J IMMUNOL, V147, P2802
   Korzeniewski B, 1998, BIOPHYS CHEM, V75, P73, DOI 10.1016/S0301-4622(98)00193-8
   KUMAR R, 1994, J CLIN BIOCHEM NUTR, V17, P53
   LIANG SL, 1990, J CELL PHYSIOL, V145, P295, DOI 10.1002/jcp.1041450214
   MALDONADO G, 1994, IMMUNOL INVEST, V23, P429, DOI 10.3109/08820139409066837
   MATSUBARA T, 1983, RHEUMATOL INT, V3, P29, DOI 10.1007/BF00541229
   MATSUBARA T, 1983, EXP CELL BIOL, V51, P77
   MIZEL SB, 1982, IMMUNOL REV, V63, P51, DOI 10.1111/j.1600-065X.1982.tb00411.x
   NAKANE M, 1991, BIOCHEM BIOPH RES CO, V180, P1396, DOI 10.1016/S0006-291X(05)81351-8
   OHTA S, 1992, EUR J BIOCHEM, V206, P895, DOI 10.1111/j.1432-1033.1992.tb16998.x
   Rodrigues MR, 2002, BIOCHEM BIOPH RES CO, V292, P869, DOI 10.1006/bbrc.2002.6724
   RUGTVEIT J, 1994, GUT, V35, P669, DOI 10.1136/gut.35.5.669
   Sein TT, 2000, ONCOGENE, V19, P5539, DOI 10.1038/sj.onc.1203932
   Sethi G, 2004, MOL IMMUNOL, V40, P1315, DOI 10.1016/j.molimm.2004.01.001
   SHARON N, 1972, SCIENCE, V177, P949, DOI 10.1126/science.177.4053.949
   Singh RAK, 1998, IMMUNOL LETT, V62, P159, DOI 10.1016/S0165-2478(98)00040-6
   SMITH EE, 1967, ARCH BIOCHEM BIOPHYS, V121, P88, DOI 10.1016/0003-9861(67)90012-4
   Sodhi A, 2003, IMMUNOL LETT, V90, P123, DOI 10.1016/j.imlet.2003.08.008
   SODHI A, 1992, CLIN EXP IMMUNOL, V888, P350
   Stoika R, 2001, Med Sci Monit, V7, P652
   WEINSTEIN SL, 1991, P NATL ACAD SCI USA, V88, P4148, DOI 10.1073/pnas.88.10.4148
NR 45
TC 11
Z9 11
U1 3
U2 12
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 1043-4666
J9 CYTOKINE
JI Cytokine
PD JAN
PY 2007
VL 37
IS 1
BP 62
EP 70
DI 10.1016/j.cyto.2007.02.018
PG 9
WC Biochemistry & Molecular Biology; Cell Biology; Immunology
SC Biochemistry & Molecular Biology; Cell Biology; Immunology
GA 167QN
UT WOS:000246466300010
PM 17395477
DA 2018-12-27
ER

PT J
AU Souglakos, J
   Vardakis, N
   Androulakis, N
   Kakolyris, S
   Kourousis, C
   Mavroudis, D
   Pallis, A
   Agelaki, S
   Kalbakis, K
   Georgoulias, V
AF Souglakos, J.
   Vardakis, N.
   Androulakis, N.
   Kakolyris, S.
   Kourousis, C.
   Mavroudis, D.
   Pallis, A.
   Agelaki, S.
   Kalbakis, K.
   Georgoulias, V.
TI RETRACTED: Irinotecan plus weekly 5-fluorouracil and leucovorin as
   salvage treatment for patients with metastatic colorectal cancer: A
   phase II trial (Retracted Article. See vol 26, pg 188, 2008)
SO DIGESTIVE DISEASES
LA English
DT Article; Retracted Publication
DE irinotecan; 5-fluorouracil; leucovorin; CPT-11/5-FU/LV(AIO schedule);
   metastatic colorectal cancer; metastatic colorectal cancer, salvage
   treatment; oxaliplatin
ID MULTICENTER RANDOMIZED-TRIAL; 1ST-LINE TREATMENT; FLUOROURACIL FAILURE;
   OXALIPLATIN; CHEMOTHERAPY; INFUSION
AB Background: A phase II study was conducted to evaluate the toxicity and efficacy of irinotecan/5-fluorouracil/leucovorin (CPT-11/5-FU/LV (AIO schedule)) as salvage treatment in patients with metastatic colorectal cancer. Patients and Methods: 33 patients relapsing after oxaliplatin (L-OHP)based first-line chemotherapy were enrolled. Their median age was 69 years, 20 (61%) patients were male, and performance status (WHO) was 0, 1, and 2 in 15, 16 and 2 patients respectively; prior surgery 20 (61%) patients; adjuvant chemotherapy 11 (33%) patients, and adjuvant radiotherapy 6 (18%) patients. The number of metastatic sites was 1, 2, and >= 3 in 11, 11, and 11 patients, respectively. CPT-11 was administered on day 1 at the dose of 80 mg/m(2) in 30-90 min infusion and LV (500 mg/m(2)) on the same day as a 2-hour infusion followed by 5-FU (2,600 mg/m(2)/day) as a 22-hour infusion on day 1 for 6 subsequent weeks. The regimen was repeated every 7 weeks. Results: All patients were evaluable for toxicity and for response. Complete response was achieved in 2 patients (6%) and partial response in 4 patients (12%) (RR 18%, CI 5.95-35.43%); 13 patients (40%) had stable disease, and 14 (42%) progressive disease. After a median follow-up period of 9 months, the median duration of response was 5 months, the median time to progression 7.5 months, and OS 14 months. Grade 3-4 neutropenia occurred in 13 patients (39%), febrile neutropenia in 3 (9%), grade 2 anemia in 11 (33%), grade 4 thrombocytopenia in 1 (3%). Grade 3-4 diarrhea occurred in 12 patients (36%), grade 3-4 neurotoxicity in 3 (9%), and grade 3 asthenia in 4 (12%). No treatment-related deaths occurred. The median dose intensity was 85% for CPT-11, and 88% for 5-FU and LV. Conclusions: The combination of weekly CPT-11 and infusional 5FU/LV is an active and relatively well-tolerated regimen as salvage treatment in MCC. Copyright (c) 2007 S. Karger AG, Basel
C1 Univ Gen Hosp, Dept Med Oncol, GR-71110 Iraklion, Greece.
RP Georgoulias, V (reprint author), Univ Gen Hosp, Dept Med Oncol, POB 1352, GR-71110 Iraklion, Greece.
EM georsec@med.uch.gr
CR *ACS, 2000, CANC FACTS FIG 2000
   *ADV COL CANC MET, 1992, J CLIN ONCOL, V10, P896
   Black RJ, 1997, EUR J CANCER, V33, P1075, DOI 10.1016/S0959-8049(96)00492-3
   BLEIBERG H, 1998, BR J CANC S4, V77, pS1
   Cox DR, 1970, ANAL BINARY DATA
   Cunningham D, 1998, LANCET, V352, P1413, DOI 10.1016/S0140-6736(98)02309-5
   de Gramont A, 2000, J CLIN ONCOL, V18, P2938, DOI 10.1200/JCO.2000.18.16.2938
   deGramont A, 1997, J CLIN ONCOL, V15, P808, DOI 10.1200/JCO.1997.15.2.808
   Douillard JY, 2000, LANCET, V355, P1041, DOI 10.1016/S0140-6736(00)02034-1
   Fischel J. L., 1999, Proceedings of the American Association for Cancer Research Annual Meeting, V40, P589
   Giacchetti S, 2000, J CLIN ONCOL, V18, P136, DOI 10.1200/JCO.2000.18.1.136
   KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868
   Kohne CH, 1998, J CLIN ONCOL, V16, P418
   Machover D, 1996, ANN ONCOL, V7, P95
   Rougier P, 1998, LANCET, V352, P1407, DOI 10.1016/S0140-6736(98)03085-2
   SALTZ LB, 2000, P ASCO, V19, P242
   TOURNIGAND C, 2001, P AN M AM SOC CLIN, V20, P124
   Ulrich-Pur H, 2001, ANN ONCOL, V12, P1269, DOI 10.1023/A:1012240201462
   Vanhoefer U, 1999, J CLIN ONCOL, V17, P907, DOI 10.1200/JCO.1999.17.3.907
NR 19
TC 3
Z9 3
U1 3
U2 9
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0257-2753
EI 1421-9875
J9 DIGEST DIS
JI Dig. Dis.
PY 2007
VL 25
IS 1
BP 100
EP 105
DI 10.1159/000099177
PG 6
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 152US
UT WOS:000245388100013
PM 17384515
OA Bronze
DA 2018-12-27
ER

PT J
AU Zhang, JX
   Da, QL
   Wang, YH
AF Zhang, Jixiang
   Da, Qingli
   Wang, Yanhua
TI RETRACTED: Analysis of nonlinear duopoly game with heterogeneous players
   (Retracted article. See vol. 41, pg. 435, 2014)
SO ECONOMIC MODELLING
LA English
DT Article; Retracted Publication
DE discrete dynamical system; Cournot duopoly games; heterogenous
   expectations; complex dynamics
ID BOUNDED RATIONALITY; DYNAMICS; MODEL; STABILITY
AB The paper considers a nonlinear duopoly game with heterogeneous players, boundely rational and naive expectations. A duopoly game is modelled by two nonlinear difference equations. The existence and stability of the equilibria of this system are studied. The complex dynamics, bifurcations and chaos are displayed by computing numerically the largest Lyapunov exponents, sensitive dependence on initial conditions and fractal dimension of the chaotic attractor. (c) 2006 Elsevier B.V. All rights reserved.
C1 Southeast Univ, Sch Econ & Management, Nanjing 210096, Jiangsu, Peoples R China.
   Shanghai Jiao Tong Univ, Sch Environm Sci & Engn, Shanghai 200240, Peoples R China.
RP Zhang, JX (reprint author), Southeast Univ, Sch Econ & Management, Nanjing 210096, Jiangsu, Peoples R China.
EM zhang_jixiang@126.com
RI Wang, Yanhua/A-3808-2014
CR Agiza HN, 1999, CHAOS SOLITON FRACT, V10, P1909, DOI 10.1016/S0960-0779(98)00210-0
   Agiza HN, 2004, APPL MATH COMPUT, V149, P843, DOI 10.1016/S0096-3003(03)00190-5
   Agiza HN, 1998, CHAOS SOLITON FRACT, V9, P1955, DOI 10.1016/S0960-0779(98)00006-X
   Agiza HN, 2003, PHYSICA A, V320, P512, DOI 10.1016/S0378-4371(02)01648-5
   Agiza HN, 2002, MATH COMPUT SIMULAT, V58, P133, DOI 10.1016/S0378-4754(01)00347-0
   Agiza HN, 2001, CHAOS SOLITON FRACT, V12, P1705, DOI 10.1016/S0960-0779(00)00021-7
   Bischi G. I., 1999, ADV DYNAMIC GAMES AP, V5
   Cournot A., 1838, RECHERCHES PRINCIPES
   Den Haan WJ, 2001, J ECON DYN CONTROL, V25, P721, DOI 10.1016/S0165-1889(00)00038-5
   DIXIT A, 1986, INT ECON REV, V27, P107, DOI 10.2307/2526609
   HENON M, 1976, COMMUN MATH PHYS, V50, P69, DOI 10.1007/BF01608556
   KAPLAN JL, 1979, COMMUN MATH PHYS, V67, P93, DOI 10.1007/BF01221359
   Kopel M, 1996, CHAOS SOLITON FRACT, V7, P2031, DOI 10.1016/S0960-0779(96)00070-7
   Leonard D, 1999, ANN OPER RES, V89, P165, DOI 10.1023/A:1018919522127
   ONAZAKI T, IN PRESS J EC DYNAMI
   Puu T, 1991, CHAOS SOLITON FRACT, V1, P573, DOI 10.1016/0960-0779(91)90045-B
   PUU T, 1998, J ECON BEHAV ORGAN, V37, P385
   Puu T., 2000, ATTRACTORS BIFURCATI
   vonBremen HF, 1997, PHYSICA D, V101, P1, DOI 10.1016/S0167-2789(96)00216-3
NR 19
TC 63
Z9 66
U1 3
U2 14
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0264-9993
EI 1873-6122
J9 ECON MODEL
JI Econ. Model.
PD JAN
PY 2007
VL 24
IS 1
BP 138
EP 148
DI 10.1016/j.econmod.2006.06.007
PG 11
WC Economics
SC Business & Economics
GA 128GP
UT WOS:000243646500009
DA 2018-12-27
ER

PT J
AU Sebastianelli, A
   Bruce, IJ
AF Sebastianelli, Antonio
   Bruce, Ian J.
TI RETRACTED: Tn5530 from Burkholderia cepacia strain 2a encodes a chloride
   channel protein essential for the catabolism of
   2,4-dichlorophenoxyacetic acid (Retracted Article. See vol 10, pg 2190,
   2008)
SO ENVIRONMENTAL MICROBIOLOGY
LA English
DT Article; Retracted Publication
ID ESCHERICHIA-COLI; SELECTIVITY; BACTERIA; BIOREMEDIATION; DEGRADATION;
   SEQUENCE; SYSTEM; PH
AB Chloride channel proteins (ClC) are found in living systems where they transport chloride ions across cell membranes. Recently, the structure/function of two prokaryotic ClC has been determined but little is known about the role of these proteins in the microbial metabolism of chlorinated compounds. Here we show that transposon Tn5530 from Burkholderia cepacia strain 2a encodes a ClC protein (BcClC) which is responsible for expelling Cl(-) ions generated during the catabolism of 2,4-dichlorophenoxyacetic acid (a chlorinated herbicide). We found that BcClC has the ability to transport Cl(-) ions across reconstituted proteoliposome membranes. We created two mutants in which the intrachannel glutamate residue of the protein, known to be responsible for opening and closing the channel (i.e. gating), was changed in order to create constitutively open and closed forms. We observed that cells carrying the closed-channel protein accumulated Cl(-) ions intracellularly leading to a decrease in intracellular pH, cell stasis and death. Further, we established that BcClC has the same gating mechanism as that reported for the ClC protein from Salmonella typhimurium. Our results show that the physiological role of ClC is to maintain cellular homeostasis which can be impaired by the catabolism of chlorinated compounds.
C1 Univ Kent, Dept Biosci, Canterbury CT2 7NJ, Kent, England.
RP Bruce, IJ (reprint author), Univ Kent, Dept Biosci, Giles Lane, Canterbury CT2 7NJ, Kent, England.
EM i.j.bruce@kent.ac.uk
CR Abe M, 1996, GENE, V174, P191, DOI 10.1016/0378-1119(96)00038-8
   Accardi A, 2004, NATURE, V427, P803, DOI 10.1038/nature02314
   Aso Y, 2006, NAT BIOTECHNOL, V24, P188, DOI 10.1038/nbt1181
   BEADLE CA, 1982, EUR J BIOCHEM, V123, P323, DOI 10.1111/j.1432-1033.1982.tb19771.x
   BOOTH IR, 1985, MICROBIOL REV, V49, P359
   BULLOCK WO, 1987, BIOTECHNIQUES, V5, P376
   CHOTHIA C, 1984, ANNU REV BIOCHEM, V53, P537
   CHOTHIA C, 1986, EMBO J, V5, P823, DOI 10.1002/j.1460-2075.1986.tb04288.x
   Dutzler R, 2002, NATURE, V415, P287, DOI 10.1038/415287a
   Dutzler R, 2003, SCIENCE, V300, P108, DOI 10.1126/science.1082708
   Edwards JC, 1998, J MEMBRANE BIOL, V163, P119
   Fahlke C, 2001, AM J PHYSIOL-RENAL, V280, pF748
   Hooft RWW, 1996, NATURE, V381, P272, DOI 10.1038/381272a0
   Jentsch TJ, 2002, PHYSIOL REV, V82, P503, DOI 10.1152/physrev.00029.2001
   Ke SH, 1997, NUCLEIC ACIDS RES, V25, P3371, DOI 10.1093/nar/25.16.3371
   Lund O, 2002, CASP5 C, pA102
   Maduke M, 2000, ANNU REV BIOPH BIOM, V29, P411, DOI 10.1146/annurev.biophys.29.1.411
   NEIDHARDT C, 1990, PHYSL BACTERIAL CELL
   Pieper DH, 2000, CURR OPIN BIOTECH, V11, P262, DOI 10.1016/S0958-1669(00)00094-X
   Poh R, 2001, MICROBIOS, V105, P43
   Poh RPC, 2002, PLASMID, V48, P1, DOI 10.1016/S0147-619X(02)00018-5
   PRESTON CL, 1992, AM J PHYSIOL, V263, pC879
   REINEKE W, 1988, ANNU REV MICROBIOL, V42, P263, DOI 10.1146/annurev.mi.42.100188.001403
   Riondet C, 1997, BIOTECHNOL TECH, V11, P735, DOI 10.1023/A:1018492217623
   Roe AJ, 1998, J BACTERIOL, V180, P767
   Sambrook J., 2001, MOL CLONING LAB MANU
   SCHWEIZER HP, 1995, GENE, V158, P15, DOI 10.1016/0378-1119(95)00055-B
   THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673
   Traverso S, 2003, J GEN PHYSIOL, V122, P295, DOI 10.1085/jgp.200308784
   vanderMeer JR, 1997, ANTON LEEUW INT J G, V71, P159, DOI 10.1023/A:1000166400935
   VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V
NR 31
TC 2
Z9 2
U1 4
U2 13
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1462-2912
J9 ENVIRON MICROBIOL
JI Environ. Microbiol.
PD JAN
PY 2007
VL 9
IS 1
BP 256
EP 265
DI 10.1111/j.1462-2920.2006.01136.x
PG 10
WC Microbiology
SC Microbiology
GA 123KN
UT WOS:000243294900033
PM 17227430
DA 2018-12-27
ER

PT J
AU Crawford, RM
   Treharne, KJ
   Arnaud-Dabernat, S
   Daniel, JY
   Foretz, M
   Viollet, B
   Mehta, A
AF Crawford, Russell M.
   Treharne, Kate J.
   Arnaud-Dabernat, Sandrine
   Daniel, Jean-Yves
   Foretz, Marc
   Viollet, Benoit
   Mehta, Anil
TI RETRACTED: Protein kinase CK2 acts as a signal molecule switching
   between the NDPK-A/AMPK alpha 1 complex and NDPK-B (Retracted Article.
   See vol 21, pg 3398, 2007)
SO FASEB JOURNAL
LA English
DT Article; Retracted Publication
DE substrate channeling; substrate steal; translocation; pleiotropic
ID NUCLEOSIDE-DIPHOSPHATE KINASE; BREAST-CARCINOMA CELLS; PHOSDUCIN-LIKE
   PROTEIN; IN-VITRO; BINDING; SITE; PHOSPHORYLATION; METASTASIS;
   EXPRESSION; NM23-H1
AB Previously we elucidated the molecular interaction between the nucleoside diphosphate kinase A ( NDPK-A)/AMP-activated protein kinase ( AMPK) alpha 1 complex, discovering a process we termed "substrate channeling." Here, we investigate the protein-protein interaction of the substrate channeling complex with the pleiotropic protein kinase, CK2 ( formerly casein kinase 2). We show that CK2 is part of the NDPK-A/AMPK alpha 1 complex under basal ( background AMPK activity) conditions, binding directly to each of the complex components independently. We report that when S122 on NDPK-A is phosphorylated by AMPK alpha 1 in vivo, ( i.e., stimulation of AMPK using either metformin or phenformin) initiating the substrate channeling mechanism, the catalytic subunit of CK2 ( CK2 alpha) is expelled from the complex and translocates to bind NDPK-B, a closely related but independent isoform of NDPK. Thus, we find that the AMPK-dependent phosphostatus of S122 on NDPK-A determines whether CK2 alpha swaps partners between NDPK-A and NDPK-B. This is the first reported linkage between NDPK-A and NDPK-B via a phosphorylation pathway and could explain the complex biology of NDPK. This study also offers an explanation as to how CK2 alpha exclusion mutations ( S120A or S122D of NDPK-A) on NDPK-A might have implications in cancer biology and general cellular energy metabolism.
C1 Univ Dundee, Div Maternal & Child Hlth Sci, Ninewells Hosp & Med Sch, Dundee DD1 9SY, Scotland.
   Univ Victor Segalen Bordeaux 2, Lab Biol Differenciat & Dev, Bordeaux, France.
   Inst Cochin, INSERM, CNRS, U567,URM8104,Dept GDPM, Paris, France.
RP Mehta, A (reprint author), Univ Dundee, Div Maternal & Child Hlth Sci, Dundee DD1 9SY, Scotland.
EM a.mehta@dundee.ac.uk
RI FORETZ, Marc/O-7334-2017
OI FORETZ, Marc/0000-0001-7017-9032
FU Wellcome Trust [075237/Z/04/Z]
CR Ahmad KA, 2005, ANTI-CANCER DRUG, V16, P1037, DOI 10.1097/00001813-200511000-00001
   Almgren MAE, 2004, MOL CANCER RES, V2, P387
   Arnaud-Dabernat S, 2003, J BIOENERG BIOMEMBR, V35, P19, DOI 10.1023/A:1023561821551
   Biondi RM, 1996, FEBS LETT, V399, P183, DOI 10.1016/S0014-5793(96)01299-9
   Bosnar MH, 2004, EXP CELL RES, V298, P275, DOI 10.1016/j.yexcr.2004.04.018
   Cervoni L, 2006, J CELL BIOCHEM, V98, P421, DOI 10.1002/jcb.20808
   Crawford RM, 2005, BIOCHEM J, V392, P201, DOI 10.1042/BJ20050269
   Crawford RM, 2001, FASEB J, V15, P102, DOI 10.1096/fj.01-0446fje
   Crawford RM, 2006, MOL CELL BIOL, V26, P5921, DOI 10.1128/MCB.00315-06
   Russell M, 2006, CELL SIGNAL, V18, P1595, DOI 10.1016/j.cellsig.2006.01.001
   Daval M, 2006, J PHYSIOL-LONDON, V574, P55, DOI 10.1113/jphysiol.2006.111484
   ENGEL M, 1995, EUR J BIOCHEM, V234, P200, DOI 10.1111/j.1432-1033.1995.200_c.x
   Freije JMP, 1997, J BIOL CHEM, V272, P5525, DOI 10.1074/jbc.272.9.5525
   Hardie DG, 2001, BIOESSAYS, V23, P1112, DOI 10.1002/bies.10009
   Hardie DG, 1997, EUR J BIOCHEM, V246, P259, DOI 10.1111/j.1432-1033.1997.00259.x
   HEIDBUCHEL H, 1992, CIRC RES, V71, P808, DOI 10.1161/01.RES.71.4.808
   Leroy D, 1997, BIOCHEMISTRY-US, V36, P1242, DOI 10.1021/bi961949u
   Litchfield DW, 2001, MOL CELL BIOCHEM, V227, P21, DOI 10.1023/A:1013188101465
   Lukov GL, 2006, J BIOL CHEM, V281, P22261, DOI 10.1074/jbc.M601590200
   Lukov GL, 2004, BIOCHEMISTRY-US, V43, P5651, DOI 10.1021/bi035903u
   MacDonald NJ, 1996, J BIOL CHEM, V271, P25107, DOI 10.1074/jbc.271.41.25107
   MARIN O, 1994, BIOCHEM BIOPH RES CO, V198, P898, DOI 10.1006/bbrc.1994.1128
   McKendrick L, 1999, MOL CELL BIOCHEM, V191, P187, DOI 10.1023/A:1006854109926
   Meggio F, 2003, FASEB J, V17, P349, DOI 10.1096/fj.02-0473rev
   MEGGIO F, 1994, CELL MOL BIOL RES, V40, P401
   Muimo R, 2000, J BIOL CHEM, V275, P36632, DOI 10.1074/jbc.M000829200
   Nielsen JN, 2003, J APPL PHYSIOL, V94, P631, DOI 10.1152/japplphysiol.00642.2002
   Olsten MEK, 2005, MOL CELL BIOCHEM, V274, P115, DOI 10.1007/s11010-005-3072-6
   Pinna LA, 2003, ACCOUNTS CHEM RES, V36, P378, DOI 10.1021/ar020164f
   Postel EH, 2000, J BIOENERG BIOMEMBR, V32, P277, DOI 10.1023/A:1005541114029
   Ranki HJ, 2002, MECH AGEING DEV, V123, P695, DOI 10.1016/S0047-6374(01)00415-8
   Roymans D, 2002, CLIN EXP METASTAS, V19, P465, DOI 10.1023/A:1020396722860
   Salerno M, 2005, MOL CELL BIOL, V25, P1379, DOI 10.1128/MCB.25.4.1379-1388.2005
   Stapleton D, 1996, J BIOL CHEM, V271, P611, DOI 10.1074/jbc.271.2.611
   SULLIVAN JE, 1994, BIOCHEM BIOPH RES CO, V200, P1551, DOI 10.1006/bbrc.1994.1627
   Viollet B, 2003, J CLIN INVEST, V111, P91, DOI 10.1172/JCI200316567
   Yang Zhan, 2003, Hua Xi Kou Qiang Yi Xue Za Zhi, V21, P263
NR 37
TC 4
Z9 5
U1 2
U2 10
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
EI 1530-6860
J9 FASEB J
JI Faseb J.
PD JAN
PY 2007
VL 21
IS 1
BP 88
EP 98
DI 10.1096/fj.06-6804com
PG 11
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
   Topics; Cell Biology
GA 121AX
UT WOS:000243130200011
PM 17135357
DA 2018-12-27
ER

PT J
AU Zemkova, M
   Jebavy, L
   Kotlarova, J
   Vlcek, J
   Meyboom, RHB
AF Zemkova, M.
   Jebavy, L.
   Kotlarova, J.
   Vlcek, J.
   Meyboom, R. H. B.
TI RETRACTED: The spectrum and types of adverse side effects to biological
   immune modulators: A proposal for new classification (Retracted article.
   See vol. 53, pg. 222, 2008)
SO FOLIA BIOLOGICA
LA English
DT Review; Retracted Publication
DE anti-inflammatory therapy; adverse side effects; biological immune
   modulators; fusion proteins; monoclonal antibodies; tumour therapy
ID INTERFERON-ALPHA THERAPY; CHRONIC HEPATITIS-C; RHEUMATOID-ARTHRITIS;
   AUTOIMMUNE-DISEASE; CROHNS-DISEASE; MONOCLONAL-ANTIBODY; DRUG-REACTIONS;
   INFLIXIMAB; TNF; ASSOCIATION
AB In recent years, a growing number of biological agents such as cytokines, monoclonal antibodies and fusion proteins have become available for the treatment of various autoimmune, neoplastic, cardiovascular, infectious, allergic, and other conditions. Their introduction has resulted in marked clinical improvements for many patients. Nevertheless, a variety of adverse side effects have been observed with these agents. Based on the special features of biological agents a new classification of these side effects of biological agents is proposed - related but clearly distinct from the classification of side effects observed with chemicals and drugs. This classification differentiates five distinct types, namely clinical reactions due to high cytokine levels (type alpha), hypersensitivity due to an immune reaction against the biological agents (type beta), immune or cytokine imbalance syndromes (type gamma), symptoms due to cross-reactivity (type delta), and symptoms not directly affecting the immune system (type epsilon). This classification could help to better deal with the clinical features of these side effects, to identify possible individual and general risk factors and to direct research in this novel area of medicine.
C1 WHO, Collaborating Ctr Int Drug Monitoring, Uppsala Monitoring Ctr, Uppsala, Sweden.
   Sch Pharm, Dept Social & Clin Pharm, Hradec Kralove 50005, Czech Republic.
   Charles Univ Prague, Univ Hosp & Med Fac, Dept Clin Haematol, Hradec Kralove, Czech Republic.
   Charles Univ Prague, Univ Hosp & Med Fac, Internal Clin, Hradec Kralove, Czech Republic.
   Univ Def Hradec Kralove, Fac Mil Hlth Sci, Dept Field Internal Med, Hradec Kralove, Czech Republic.
   Utrecht Inst Pharmaceut Sci, Dept Pharmacoepidemiol & Pharmacotherapy, Utrecht, Netherlands.
RP Zemkova, M (reprint author), Sch Pharm, Dept Social & Clin Pharm, Acad Heyrovsky St 1203, Hradec Kralove 50005, Czech Republic.
EM Marcela.Zemkova@faf.cuni.cz
RI Vlcek, Jiri/U-4417-2017
OI Vlcek, Jiri/0000-0002-8431-8897
CR Abbas AK, 1996, NATURE, V383, P787, DOI 10.1038/383787a0
   ABBAS AK, 2005, CELLUAR MOL IMMUNOLO
   ABRAMOWICZ D, 1992, NEW ENGL J MED, V327, P736
   Arimura K, 2004, ACTA HAEMATOL-BASEL, V112, P217, DOI 10.1159/000081276
   Baert F, 2003, NEW ENGL J MED, V348, P601, DOI 10.1056/NEJMoa020888
   Bagheri H, 2004, PHARMACOTHERAPY, V24, P1546, DOI 10.1592/phco.24.16.1546.50947
   Banchereau J, 2004, IMMUNITY, V20, P539, DOI 10.1016/S1074-7613(04)00108-6
   Boven K, 2005, NEPHROL DIAL TRANSPL, V20, pIII33, DOI 10.1093/ndt/gfh1072
   Boz C, 2004, J CLIN NEUROSCI, V11, P523, DOI 10.1016/j.jocn.2003.04.009
   Chamberlain AJ, 2004, INTERN MED J, V34, P519, DOI 10.1111/j.1445-5994.2004.00660.x
   Chan Joanna L, 2004, J Drugs Dermatol, V3, P315
   CHATENOUD L, 1993, CLIN TRANSPLANT, V7, P422
   Danese S, 2005, CRIT REV IMMUNOL, V25, P103
   Day R, 2002, LANCET, V359, P540, DOI 10.1016/S0140-6736(02)07718-8
   Debandt M, 2003, CLIN RHEUMATOL, V22, P56, DOI 10.1007/s10067-002-0654-5
   Devos SA, 2003, DERMATOLOGY, V206, P388, DOI 10.1159/000069965
   Doi F, 2005, LIVER INT, V25, P242, DOI 10.1111/j.1478-3231.2005.01089.x
   Gomez-Reino JJ, 2003, ARTHRITIS RHEUM, V48, P2122, DOI 10.1002/art.11137
   Han PD, 2004, DRUGS, V64, P1767, DOI 10.2165/00003495-200464160-00004
   Hershberger RE, 2005, NEW ENGL J MED, V352, P2705, DOI 10.1056/NEJMoa032953
   HOIGNE R, 1993, MONOGR ALLERGY, V31, P147
   Kasahara A, 2004, J GASTROENTEROL, V39, P1106, DOI 10.1007/s00535-004-1452-4
   Kassiotis G, 2001, J CLIN INVEST, V107, P1507, DOI 10.1172/JCI13362
   Kwon HJ, 2003, ANN INTERN MED, V138, P807, DOI 10.7326/0003-4819-138-10-200305200-00008
   Lee SJ, 2005, J ALLERGY CLIN IMMUN, V116, P900, DOI 10.1016/j.jaci.2005.03.028
   Lipsky PE, 2000, NEW ENGL J MED, V343, P1594, DOI 10.1056/NEJM200011303432202
   Menon Y, 2004, AM J MED SCI, V328, P173, DOI 10.1097/00000441-200409000-00008
   Naisbitt DJ, 2000, DRUG SAFETY, V23, P483, DOI 10.2165/00002018-200023060-00002
   Niewold TB, 2005, CLIN RHEUMATOL, V24, P178, DOI 10.1007/s10067-004-1024-2
   Panwar P, 2005, CANCER BIOL THER, V4, P854, DOI 10.4161/cbt.4.8.1893
   Perez-Soler R, 2005, J CLIN ONCOL, V23, P5235, DOI 10.1200/JCO.2005.00.6916
   Phan GQ, 2003, P NATL ACAD SCI USA, V100, P8372, DOI 10.1073/pnas.1533209100
   Pichler WJ, 2003, ANN INTERN MED, V139, P683, DOI 10.7326/0003-4819-139-8-200310210-00012
   Rifkin IR, 2005, IMMUNOL REV, V204, P27, DOI 10.1111/j.0105-2896.2005.00239.x
   Seckin D, 2004, PEDIATR DERMATOL, V21, P577, DOI 10.1111/j.0736-8046.2004.21512.x
   Solans R, 2004, CLIN EXP RHEUMATOL, V22, P625
   Taylor A, 2004, INT ARCH ALLERGY IMM, V135, P73, DOI 10.1159/000080523
   VASQUEZ EM, 1995, TRANSPLANT P, V27, P873
   Vermeire S, 2003, GASTROENTEROLOGY, V125, P32, DOI 10.1016/S0016-5085(03)00701-7
   WALKER C, 1989, J AUTOIMMUN, V2, P643, DOI 10.1016/S0896-8411(89)80003-4
   Waugh J, 2005, BIODRUGS, V19, P189, DOI 10.2165/00063030-200519030-00005
   Weber Richard W, 2004, Curr Opin Allergy Clin Immunol, V4, P277, DOI 10.1097/01.all.0000136757.58818.10
   Wellington K, 2005, AM J CLIN DERMATOL, V6, P113, DOI 10.2165/00128071-200506020-00006
   Werth VP, 2001, ARCH DERMATOL, V137, P953
NR 44
TC 3
Z9 3
U1 3
U2 13
PU CHARLES UNIV PRAGUE, FIRST FACULTY MEDICINE
PI PRAGUE 6
PA FLEMINGOVO NAM. 2, PRAGUE 6 166 37, CZECH REPUBLIC
SN 0015-5500
J9 FOLIA BIOL-PRAGUE
JI Folia Biol.-Prague
PY 2007
VL 53
IS 4
BP 146
EP 155
PG 10
WC Biochemistry & Molecular Biology; Biology; Oncology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
   Topics; Oncology; Cell Biology
GA 187DJ
UT WOS:000247827200006
PM 17706021
DA 2018-12-27
ER

PT J
AU Taechowisan, T
   Tuntiwachwuttikul, P
   Lu, C
   Shen, Y
   Lumyong, S
   Taylor, WC
AF Taechowisan, Thongchai
   Tuntiwachwuttikul, Pittaya
   Lu, Chunhua
   Shen, Yuemao
   Lumyong, Saisamorn
   Taylor, Walter C.
TI RETRACTED: Anti-inflammatory activity of 4-arylcoumarins from endophytic
   Streptomyces aureofaciens CMUAc130 in murine macrophage RAW 264.7 cells
   (Retracted article. See vol. 38, pg. 869, 2009)
SO IMMUNOLOGICAL INVESTIGATIONS
LA English
DT Article; Retracted Publication
DE 4-arylcoumarins; anti-inflammatory activity; endophytic Streptomyces;
   murine macrophage RAW 264.7 cells
ID NITRIC-OXIDE GENERATION; ANTIFUNGAL ACTIVITY; LIPOPOLYSACCHARIDE;
   COUMARINS; INFLAMMATION; ROOTS
AB This research was undertaken to test the in vitro anti-inflammatory action of 5,7,4'-trimethoxy-4-phenylcoumarin and 5,7-dimethoxy-4-phenylcoumarin produced by Streptomyces aureofaciens CMUAc130. The effects of the two coumarins were investigated on the formation of NO, PGE(2), and TNF-alpha and also on inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) in lipopolysaccharide (LPS)-induced murine macrophage RAW 264.7 cells. The data obtained were consistent with the modulation of iNOS enzyme expression. A similar effect was also observed when LPS-induced PGE(2) release and COX-2 expression were tested. The inhibitory effects were shown in concentration-dependent manners. The 5,7,4'-Trimethoxy-4-phenylcoumarin and 5,7-dimethoxy-4-phenylcoumarin also mildly but significantly reduced the formation of TNF-alpha.
C1 Silpakorn Univ, Dept Microbiol, Fac Sci, Pathom 73000, Thailand.
   Silpakorn Univ, Dept Chem, Fac Sci, Pathom 73000, Thailand.
   Xiamen Univ, Sch Life Sci, Xiamen, Peoples R China.
   Chinese Acad Sci, Kunming Inst Bot, Kunming, Peoples R China.
   Chiang Mai Univ, Fac Sci, Dept Biol, Chiang Mai 50000, Thailand.
   Univ Sydney, Sch Chem, Sydney, NSW 2006, Australia.
RP Taechowisan, T (reprint author), Silpakorn Univ, Dept Microbiol, Fac Sci, Pathom 73000, Thailand.
EM tthongch@su.ac.th
CR Feldmann M, 1996, ANNU REV IMMUNOL, V14, P397, DOI 10.1146/annurev.immunol.14.1.397
   Fylaktakidou KC, 2004, CURR PHARM DESIGN, V10, P3813, DOI 10.2174/1381612043382710
   GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X
   HARADA A, 1994, J LEUKOCYTE BIOL, V56, P559
   Hoult JRS, 1996, GEN PHARMACOL-VASC S, V27, P713, DOI 10.1016/0306-3623(95)02112-4
   Khaleel A. E., 2001, AL AZHAR J PHARM SCI, V28, P285
   KIMURA Y, 1985, BIOCHIM BIOPHYS ACTA, V834, P224
   LEE SH, 1992, J BIOL CHEM, V267, P25934
   Murakami A, 1999, J AGR FOOD CHEM, V47, P333, DOI 10.1021/jf980523e
   Murakami A, 2000, BIOORG MED CHEM LETT, V10, P59, DOI 10.1016/S0960-894X(99)00578-8
   Murray R. D. H., 1991, PROGR CHEM ORGANIC N, V58, P84
   OHSHIMA H, 1994, MUTAT RES, V305, P253, DOI 10.1016/0027-5107(94)90245-3
   SAXENA RC, 1982, PLANTA MED, V44, P246, DOI 10.1055/s-2007-971459
   SEIBERT K, 1994, P NATL ACAD SCI USA, V91, P12013, DOI 10.1073/pnas.91.25.12013
   Taechowisan T, 2005, MICROBIOL-SGM, V151, P1691, DOI 10.1099/mic.0.27758-0
   Taechowisan T, 2003, ANN MICROBIOL, V53, P291
   Taechowisan T, 2003, WORLD J MICROB BIOT, V19, P381, DOI 10.1023/A:1023901107182
   Yoshikawa M, 2006, BIOORGAN MED CHEM, V14, P456, DOI 10.1016/j.bmc.2005.08.038
NR 18
TC 11
Z9 12
U1 5
U2 19
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA
SN 0882-0139
J9 IMMUNOL INVEST
JI Immunol. Invest.
PY 2007
VL 36
IS 2
BP 203
EP 211
DI 10.1080/08820130600992115
PG 9
WC Immunology
SC Immunology
GA 150UI
UT WOS:000245244700007
PM 17365020
DA 2018-12-27
ER

PT J
AU Matsuyama, W
   Mitsuyama, H
   Koreeda, Y
   Higashimoto, I
   Osame, M
   Arimura, K
AF Matsuyama, Wataru
   Mitsuyama, Hideo
   Koreeda, Yoshimizu
   Higashimoto, Ikkou
   Osame, Mitsuhiro
   Arimura, Kimiyoshi
TI RETRACTED: Use of tiotropium bromide for pre-operative treatment in
   chronic obstructive pulmonary disease patients: Comparison with
   oxitropium bromide (Retracted Article. See vol 47, pg 1371, 2008)
SO INTERNAL MEDICINE
LA English
DT Article; Retracted Publication
DE surgery; COPD; pulmonary complications
ID COPD PATIENTS; LUNG-CANCER; RISK-FACTORS; CLINICAL-TRIAL; HEALTH-STATUS;
   COMPLICATIONS; SURGERY; EPIDEMIOLOGY; COMBINATION; ASTHMA
AB Objective Chronic obstructive pulmonary disease (COPD), which ranks fifth in terms of the global burden of diseases, is one of the major risk factors of post-operative pulmonary complications. Tiotropium bromide is a new inhaled bronchodilator for COPD patients with a sustained duration of action; it has superior efficacy compared to other bronchodilators. However, little is known regarding its clinical value as a preoperative treatment for COPD patients. In this study, we compared the incidence of post-operative complications between COPD patients who received with tiotropium bromide and those who did not.
   Methods Retrospective study. Patients For 1 month before surgery we examined 84 and 82 patients treated with tiotropium bromide (tiotropium group) and oxitropium bromide (oxitropium group), respectively, in combination with other medications. We performed a statistical comparison of clinical features, pulmonary functions, and postoperative complications between the 2 groups.
   Results The improvements in clinical symptoms and forced expiratory volume in 1 second were better in the tiotropium group than in the oxitropium group. The incidence of post-operative pulmonary complications (refractory bronchospasm, pulmonary infection, and acute respiratory failure) was significantly lower in the tiotropium group than in the oxitropium group. Three patients in the tiotropium group complained of dry mouth; however, the symptoms could be controlled. The incidence of post-operative non-pulmonary complications was not significantly different between the 2 groups.
   Conclusion We propose that tiotropium bromide might be a safe and useful drug for pre-operative treatment of COPD patients.
C1 [Matsuyama, Wataru; Mitsuyama, Hideo; Koreeda, Yoshimizu; Higashimoto, Ikkou; Osame, Mitsuhiro; Arimura, Kimiyoshi] Kagoshima Univ Hosp, Div Resp Med, Resp & Stress Care Ctr, Kagoshima, Japan.
RP Matsuyama, W (reprint author), Kagoshima Univ Hosp, Div Resp Med, Resp & Stress Care Ctr, Kagoshima, Japan.
EM vega@xa2.so-net.ne.jp
CR Adams SG, 2006, RESP MED, V100, P1495, DOI 10.1016/j.rmed.2006.03.034
   Bellia V, 2002, RESP MED, V96, P881, DOI 10.1053/rmed.2002.1380
   Bonde P, 2002, EUR J CARDIO-THORAC, V22, P18, DOI 10.1016/S1010-7940(02)00205-1
   Bousquet J, 2000, AM J RESP CRIT CARE, V161, P1720, DOI 10.1164/ajrccm.161.5.9903102
   Bush RL, 2003, CARDIOVASC SURG, V11, P179, DOI 10.1016/S0967-2109(03)00013-9
   Casaburi R, 2005, CHEST, V127, P809, DOI 10.1378/chest.127.3.809
   Casaburi R, 2002, EUR RESPIR J, V19, P217, DOI 10.1183/09031936.02.00269802
   Celli BR, 2004, EUR RESPIR J, V23, P932, DOI 10.1183/09031936.04.00014304
   Crapo RO, 2002, AM J RESP CRIT CARE, V166, P111, DOI 10.1164/rccm.166/1/111
   Disse B, 1999, LIFE SCI, V64, P457, DOI 10.1016/S0024-3205(98)00588-8
   Donohue JF, 2002, CHEST, V122, P47, DOI 10.1378/chest.122.1.47
   Engel LS, 2003, J NATL CANCER I, V95, P1404, DOI 10.1093/jnci/djg047
   Ezzati M, 2005, CIRCULATION, V112, P489, DOI 10.1161/CIRCULATIONAHA.104.521708
   Feldmann E, 2005, STROKE, V36, P1881, DOI 10.1161/01.STR.0000177480.62341.6b
   Fukuchi Y, 2004, RESPIROLOGY, V9, P458, DOI 10.1111/j.1440-1843.2004.00637.x
   Goffi L, 1999, EUR J SURG, V165, P730
   Gross NJ, 2004, CHEST, V126, P1946, DOI 10.1378/chest.126.6.1946
   GROSS NJ, 1989, CHEST, V96, P984, DOI 10.1378/chest.96.5.984
   GROVER FL, 1990, ANN THORAC SURG, V50, P12, DOI 10.1016/0003-4975(90)90073-F
   HALL JC, 1991, CHEST, V99, P923, DOI 10.1378/chest.99.4.923
   INCORVAIA C, 2006, RESP MED
   JONES PW, 1992, AM REV RESPIR DIS, V145, P1321, DOI 10.1164/ajrccm/145.6.1321
   Kesten S, 2006, CHEST, V130, P1695, DOI 10.1378/chest.130.6.1695
   KROENKE K, 1992, ARCH INTERN MED, V152, P967, DOI 10.1001/archinte.152.5.967
   Layke JC, 2006, AM FAM PHYSICIAN, V73, P2187
   Littner MR, 2000, AM J RESP CRIT CARE, V161, P1136, DOI 10.1164/ajrccm.161.4.9903044
   Mannisto S, 2004, CANCER EPIDEM BIOMAR, V13, P40, DOI 10.1158/1055-9965.EPI-038-3
   Mathew J T, 1999, J Assoc Physicians India, V47, P1086
   Matsuyama W, 2005, CHEST, V128, P3817, DOI 10.1378/chest.128.6.3817
   MILLEDGE JS, 1975, BRIT MED J, V3, P670, DOI 10.1136/bmj.3.5985.670
   Naunheim KS, 2006, J THORAC CARDIOV SUR, V131, P43, DOI 10.1016/j.jtcvs.2005.09.006
   Niewoehner DE, 2005, ANN INTERN MED, V143, P317, DOI 10.7326/0003-4819-143-5-200509060-00007
   NISAR M, 1992, AM REV RESPIR DIS, V146, P555, DOI 10.1164/ajrccm/146.3.555
   Ozdilekcan Cigdem, 2004, Tuberk Toraks, V52, P248
   Pauwels Romain A., 2001, American Journal of Respiratory and Critical Care Medicine, V163, P1256
   Perng DW, 2006, RESPIROLOGY, V11, P598, DOI 10.1111/j.1400-1843.2006.00889.x
   PIEN LC, 1988, J ALLERGY CLIN IMMUN, V82, P696, DOI 10.1016/0091-6749(88)90985-2
   Ramsey Scott D, 2006, Proc Am Thorac Soc, V3, P635, DOI 10.1513/pats.200603-094SS
   RAO MK, 1992, LARYNGOSCOPE, V102, P45
   Ross RK, 1996, SEMIN ONCOL, V23, P536
   Salpeter SR, 2004, CHEST, V125, P2309, DOI 10.1378/chest.125.6.2309
   Sansores R, 2003, ARCH MED RES, V34, P292, DOI 10.1016/S0188-4409(03)00047-X
   Sekine Y, 2002, LUNG CANCER-J IASLC, V37, P95, DOI 10.1016/S0169-5002(02)00014-4
   Sekine Y, 2001, CHEST, V120, P1783, DOI 10.1378/chest.120.6.1783
   Sekine Y, 2005, GEN THORAC CARDIOVAS, V53, P237, DOI 10.1007/s11748-005-0032-8
   Vaezi MF, 2006, AM J MED, V119, P768, DOI 10.1016/j.amjmed.2006.01.019
   Viegi G, 2006, RESPIROLOGY, V11, P523, DOI 10.1111/j.1400-1843.2006.00886.x
   Wasswa-Kintu S, 2005, THORAX, V60, P570, DOI 10.1136/thx.2004.037135
   WONG DH, 1995, ANESTH ANALG, V80, P276, DOI 10.1097/00000539-199502000-00013
   1987, AM REV RESP DIS, V136, P225
NR 50
TC 4
Z9 4
U1 4
U2 10
PU JAPAN SOC INTERNAL MEDICINE
PI TOKYO
PA 34-3 3-CHOME HONGO BUNKYO-KU, TOKYO, 113, JAPAN
SN 0918-2918
EI 1349-7235
J9 INTERNAL MED
JI Intern. Med.
PY 2007
VL 46
IS 17
BP 1373
EP 1379
DI 10.2169/internalmedicine.46.0072
PG 7
WC Medicine, General & Internal
SC General & Internal Medicine
GA 343HV
UT WOS:000258845000009
PM 17827835
OA Bronze
DA 2018-12-27
ER

PT J
AU Hagiwara, S
   Iwasaka, H
   Noguchi, T
AF Hagiwara, Satoshi
   Iwasaka, Hideo
   Noguchi, Takayuki
TI RETRACTED: Nafamostat mesilate inhibits the expression of HMGB1 in
   lipopolysaccharide-induced acute lung injury (Retracted article. See
   vol. 29, pg. 484, 2015)
SO JOURNAL OF ANESTHESIA
LA English
DT Article; Retracted Publication
DE LPS; lung injury; sepsis; acute respiratory distress syndrome;
   anticoagulant
ID RESPIRATORY-DISTRESS-SYNDROME; PULMONARY VASCULAR INJURY;
   TUMOR-NECROSIS-FACTOR; INTRAVASCULAR COAGULATION; PROTEASE INHIBITOR;
   HUMAN MONOCYTES; LATE MEDIATOR; INFLAMMATION; RATS; ACTIVATION
AB Purpose. High mobility group box 1 (HMGB1) protein has recently been shown to be an important late mediator of acute lung injury and a promising therapeutic target. Nafamostat mesilate (NM) is a broad-range synthetic protease inhibitor with some anti-inflammatory action. The purpose of this study was to evaluate the effect of NM on HMGB1 in lipopolysaccharide (LPS)-induced lung injury in rats.
   Methods. Male Wistar rats were given either saline (LPS group) or NM (NM+LPS group) 30 min before the intravenous injection of a bolus of LPS (5 mg.kg(-1)). After the administration of LPS, injury to the lung and the expression of HMGB1, tumor necrosis factor-alpha (TNF-alpha), and plasminogen activator inhibitor-1 (PAI-1) were examined.
   Results. Histological examination revealed that interstitial edema, leukocytic infiltration, and HMGB1 protein expression were markedly reduced in the NM+LPS group compared to the LPS group. Furthermore, the LPS-induced increases in PAI-1 activity and in plasma TNF-alpha concentrations were also lower in the rats given both NM and LPS than in the rats given LPS alone.
   Conclusions. The anticoagulatory activity of NM may have inhibited PAI-1, while its anti-inflammatory activity blockaded TNF-alpha thereby indirectly inhibiting HMGB1 and reducing tissue damage in the lung. These findings indicate that NM can inhibit the lung injury induced by LPS in rats. NM is an excellent candidate for use in new therapeutic strategies to prevent or minimize lung injury.
C1 [Hagiwara, Satoshi; Iwasaka, Hideo; Noguchi, Takayuki] Oita Univ, Fac Med, Dept Brain & Nerve Sci, Oita 8795593, Japan.
RP Hagiwara, S (reprint author), Oita Univ, Fac Med, Dept Brain & Nerve Sci, 1-1 Idaigaoka,Hasama Machi, Oita 8795593, Japan.
CR Abraham E, 2000, J IMMUNOL, V165, P2950, DOI 10.4049/jimmunol.165.6.2950
   Andersson U, 2000, J EXP MED, V192, P565, DOI 10.1084/jem.192.4.565
   AOYAMA T, 1984, JPN J PHARMACOL, V35, P203, DOI 10.1254/jjp.35.203
   Bustin M, 1999, MOL CELL BIOL, V19, P5237
   Dixon B, 2004, ANAESTH INTENS CARE, V32, P619
   Fiuza C, 2003, BLOOD, V101, P2652, DOI 10.1182/blood-2002-05-1300
   HASEGAWA N, 1994, CHEST, V105, P268, DOI 10.1378/chest.105.1.268
   Hoyert D L, 2001, Natl Vital Stat Rep, V49, P1
   Idell S, 2003, CRIT CARE MED, V31, pS213, DOI 10.1097/01.CCM.0000057846.21303.AB
   KAPLAN JE, 1987, SEMIN THROMB HEMOST, V13, P398, DOI 10.1055/s-2007-1003517
   Keck T, 2005, PANCREATOLOGY, V5, P241, DOI 10.1159/000085278
   Kirschfink M, 2001, IMMUNOL REV, V180, P177, DOI 10.1034/j.1600-065X.2001.1800116.x
   Kokkola R, 2005, SCAND J IMMUNOL, V61, P1, DOI 10.1111/j.0300-9475.2005.01534.x
   Martin GS, 2003, NEW ENGL J MED, V348, P1546, DOI 10.1056/NEJMoa022139
   Mellgren K, 1998, THROMB HAEMOSTASIS, V79, P342
   Noguchi S, 2003, INT IMMUNOPHARMACOL, V3, P1335, DOI 10.1016/S1567-5769(03)00146-2
   Okajima K, 2003, J THROMB HAEMOST, V1, P1316, DOI 10.1046/j.1538-7836.2003.t01-2-00326.x
   PAQUES EP, 1991, THROMB RES, V64, P11, DOI 10.1016/0049-3848(91)90201-7
   Park JS, 2004, J BIOL CHEM, V279, P7370, DOI 10.1074/jbc.M306793200
   Riedemann NC, 2003, J CLIN INVEST, V112, P460, DOI 10.1172/JCI200319523
   Sugita H, 1999, RES COMMUN MOL PATH, V103, P57
   UCHIBA M, 1995, THROMB RES, V78, P117, DOI 10.1016/0049-3848(95)00040-2
   Uchiba M, 1997, AM J RESP CRIT CARE, V155, P711, DOI 10.1164/ajrccm.155.2.9032217
   Ueno H, 2004, AM J RESP CRIT CARE, V170, P1310, DOI 10.1164/rccm.200402-1880C
   Wang H, 2004, J INTERN MED, V255, P320, DOI 10.1111/j.1365-2796.2003.01302.x
   Wang HC, 1999, SCIENCE, V285, P248, DOI 10.1126/science.285.5425.248
   Wang HC, 1999, SURGERY, V126, P389, DOI 10.1067/msy.1999.99167
   Wang HH, 2001, AM J RESP CRIT CARE, V164, P1768, DOI 10.1164/ajrccm.164.10.2106117
   Ware LB, 2000, NEW ENGL J MED, V342, P1334, DOI 10.1056/NEJM200005043421806
   Wyncoll DLA, 1999, LANCET, V354, P497, DOI 10.1016/S0140-6736(98)08129-X
   YOSHIKAWA T, 1983, HAEMOSTASIS, V13, P374
NR 31
TC 12
Z9 13
U1 3
U2 8
PU SPRINGER JAPAN KK
PI TOKYO
PA CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065,
   JAPAN
SN 0913-8668
EI 1438-8359
J9 J ANESTH
JI J. Anesth.
PY 2007
VL 21
IS 2
BP 164
EP 170
DI 10.1007/s00540-006-0468-8
PG 7
WC Anesthesiology
SC Anesthesiology
GA 281PB
UT WOS:000254509300008
PM 17458645
DA 2018-12-27
ER

PT J
AU Rani, PU
   Kumari, SI
   Sriramakrishna, T
   Sudhakar, TR
AF Rani, P. Usha
   Kumari, S. Indu
   Sriramakrishna, T.
   Sudhakar, T. Ratna
TI RETRACTED: Kairomones extracted from rice yellow stem borer and their
   influence on egg parasitization by Trichogramma japonicum ashmead
   (Retracted Article. See vol 33, pg 1297, 2007)
SO JOURNAL OF CHEMICAL ECOLOGY
LA English
DT Article; Retracted Publication
DE rice yellow stem borer; Scripophaga incertulas Walker; oviposition;
   parasitoid; cuticular extracts
ID INSECT PARASITOIDS; HOST EGGS; HYMENOPTERA; FIELD; LEPIDOPTERA;
   MANAGEMENT; RESPONSES; CHILONIS; PLANTS
AB Host location and acceptance by egg parasitoids can be mediated by close-range host stimuli. In this study, we tested the response of Trichogramma japonicum Ashmead to cuticular extracts of adult and larval rice yellow stem borer (YSB), Scripophaga incertulas Walker. We also studied the wasps' response to extracts from YSB larval frass. Laboratory bioassays revealed that hexane extracts of the adult host body stimulate ovipositor probing of T. japonicum. Extracts of larval frass also stimulated parasitization. In contrast, host larval cuticular extracts had no effect on parasitization rates. Fractionation of the crude extracts of adult YSB cuticular extracts was performed using silica gel chromatography, followed by bioassays of the individual fractions to test their effects on wasp behavior. Analyses of the most active fractions by gas chromatography-mass spectrometry revealed that the extract contained saturated long chain alkanes and alkenes, with carbon numbers ranging from C-20 to C-32. Hydrocarbons were applied onto host eggs to test their effects on parasitization rates. Treatments of eggs with docosane, tetracosane, pentacosane, and eicosane enhanced host egg parasitization, while pentadecane, hexadecane, and nonadecane deterred oviposition.
C1 Indian Inst Chem Technol, Div Biol & Biotechnol, Hyderabad 500007, Andhra Pradesh, India.
   Acharya NG Ranga ANGR Univ, Rice Res Stn, Hyderabad, Andhra Pradesh, India.
RP Rani, PU (reprint author), Indian Inst Chem Technol, Div Biol & Biotechnol, Hyderabad 500007, Andhra Pradesh, India.
EM usharani65@gmail.com
CR ANANTHAKRISHNAN TN, 1991, J BIOSCIENCE, V16, P111, DOI 10.1007/BF02703363
   Boo KS, 2000, J CHEM ECOL, V26, P359, DOI 10.1023/A:1005453220792
   DETHIER VG, 1960, J ECON ENTOMOL, V53, P134, DOI 10.1093/jee/53.1.134
   DICKE M, 1990, J CHEM ECOL, V16, P3091, DOI 10.1007/BF00979614
   DORN S, 1999, AGR ECOSYST ENVIRON, V1422, P1
   Dutton A, 2002, J CHEM ECOL, V28, P103, DOI 10.1023/A:1013514903036
   ELZEN GW, 1984, J CHEM ECOL, V10, P1251, DOI 10.1007/BF00988552
   Faucher C, 2006, J EXP BIOL, V209, P2739, DOI 10.1242/jeb.02297
   GROSS HR, 1984, ENVIRON ENTOMOL, V13, P981, DOI 10.1093/ee/13.4.981
   Hilker M, 2006, J CHEM ECOL, V32, P1379, DOI 10.1007/s10886-006-9057-4
   JONES RL, 1973, ENVIRON ENTOMOL, P2593
   KNUTSON A, 1998, TRICHOGRAMMA MANUAL, P35
   Lewis WJ, 1975, J CHEM ECOL, V1, P349, DOI 10.1007/BF00988837
   Lewis WJ, 1975, J CHEM ECOL, V1, P343, DOI 10.1007/BF00988836
   LEWIS WJ, 1972, ANN ENTOMOL SOC AM, V65, P1087, DOI 10.1093/aesa/65.5.1087
   LEWIS WJ, 1971, ANN ENTOMOL SOC AM, V64, P298
   Meiners T, 2000, J CHEM ECOL, V26, P221, DOI 10.1023/A:1005453830961
   Mumm R, 2005, CHEM SENSES, V30, P337, DOI 10.1093/chemse/bji028
   Nelson D, 1995, WAXES CHEM MOL BIOL, P1
   NORDLUND DA, 1984, AGR ECOSYST ENVIRON, V2, P127
   PATHAK M, 1994, INSECT PESTS RICE
   PEREZ ML, 1986, PHITPP ENTOMOL, V65, P463
   Rutledge CE, 1996, CHEMOECOLOGY, V7, P121, DOI 10.1007/BF01245964
   STRAND MR, 1982, ENTOMOL EXP APPL, V31, P308, DOI 10.1111/j.1570-7458.1982.tb03150.x
   Strong DR, 1984, INSECTS PLANTS COMMU
   TURLINGS TCJ, 1995, P NATL ACAD SCI USA, V92, P4169, DOI 10.1073/pnas.92.10.4169
   VANVREDEN G, 1986, PESTS RICE THEIR NAT
   VET LEM, 1990, J CHEM ECOL, V16, P3119, DOI 10.1007/BF00979615
   VINSON SB, 1976, ANNU REV ENTOMOL, V21, P109, DOI 10.1146/annurev.en.21.010176.000545
   WAAGE JK, 1978, PHYSIOL ENTOMOL, V3, P135, DOI 10.1111/j.1365-3032.1978.tb00143.x
   WACKERS FL, 1994, BIOL CONTROL, V4, P105, DOI 10.1006/bcon.1994.1018
   WESELOH RM, 1980, ENVIRON ENTOMOL, V9, P345, DOI 10.1093/ee/9.3.345
NR 32
TC 10
Z9 13
U1 2
U2 20
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0098-0331
EI 1573-1561
J9 J CHEM ECOL
JI J. Chem. Ecol.
PD JAN
PY 2007
VL 33
IS 1
BP 59
EP 73
DI 10.1007/s10886-006-9203-z
PG 15
WC Biochemistry & Molecular Biology; Ecology
SC Biochemistry & Molecular Biology; Environmental Sciences & Ecology
GA 119GZ
UT WOS:000243002100006
PM 17146721
DA 2018-12-27
ER

PT J
AU Trampe, D
   Stapel, DA
   Siero, FW
AF Trampe, Debra
   Stapel, Diederik A.
   Siero, Frans W.
TI RETRACTED: On models and vases: Body dissatisfaction and proneness to
   social comparison effects (Retracted article. See vol. 103, pg. 398,
   2012)
SO JOURNAL OF PERSONALITY AND SOCIAL PSYCHOLOGY
LA English
DT Article; Retracted Publication
DE social comparison; comparison relevance; mass media; self-evaluation;
   body dissatisfaction
ID THIN MEDIA IMAGES; EATING-DISORDERS; ACCURACY MOTIVATION;
   SELF-EVALUATIONS; ACTIVATION; EXPOSURE; WOMEN; ATTRACTIVENESS; IMPACT;
   DISTURBANCE
AB When and why do media-portrayed physically attractive women affect perceivers' self-evaluations? In 6 studies, the authors showed that whether such images affect self-evaluations depends jointly on target features and perceiver features. In Study 1, exposure to a physically attractive target, compared with exposure to an equally attractive model, lowered women's self-evaluations. Study 2 showed that body-dissatisfied women, to a greater extent than body-satisfied women, report that they compare their bodies with other women's bodies. In Study 3, body-dissatisfied women, but not body-satisfied women, were affected by both attractive models and nonmodels. Furthermore, in Study 4, it was body-dissatisfied women, rather than body-satisfied women, who evaluated themselves negatively after exposure to a thin (versus a fat) vase. The authors replicated this result in Study 5 by manipulating, instead of measuring, body dissatisfaction. Finally, Study 6 results suggested that body dissatisfaction increases proneness to social comparison effects because body dissatisfaction increases self-activation.
C1 Univ Groningen, Dept Social & Org Psychol, Groningen, Netherlands.
   Tilburg Univ, Tilburg Inst Behav Econ Res, NL-5000 LE Tilburg, Netherlands.
RP Trampe, D (reprint author), Dept Marketing, Dierenriemstr 100, NL-9742 AK Groningen, Netherlands.
EM d.trampe@rug.nl
CR Bargh J. A, 2000, HDB RES METHODS SOCI, P253
   BROWN JD, 1992, J PERS SOC PSYCHOL, V62, P717, DOI 10.1037//0022-3514.62.5.717
   CASH TF, 1983, PERS SOC PSYCHOL B, V9, P351, DOI 10.1177/0146167283093004
   Dijksterhuis A, 2000, SOC COGNITION, V18, P55, DOI 10.1521/soco.2000.18.1.55
   DITTMAR H, 2005, J SOCIAL CLIN PSYCHO, V24
   Durkin SJ, 2002, J PSYCHOSOM RES, V53, P995, DOI 10.1016/S0022-3999(02)00489-0
   Festinger L, 1954, HUM RELAT, V7, P117, DOI 10.1177/001872675400700202
   GARNER DM, 1983, INT J EAT DISORDER, V2, P15, DOI 10.1002/1098-108X(198321)2:2<15::AID-EAT2260020203>3.0.CO;2-6
   GILBERT DT, 1995, J PERS SOC PSYCHOL, V69, P227, DOI 10.1037/0022-3514.69.2.227
   Goethals G. R., 1977, SOCIAL COMP PROCESSE, P259
   Groesz LM, 2002, INT J EAT DISORDER, V31, P1, DOI 10.1002/eat.10005
   Halliwell Emma, 2005, Body Image, V2, P249, DOI 10.1016/j.bodyim.2005.05.001
   Hargreaves D, 2002, J SOC CLIN PSYCHOL, V21, P287, DOI 10.1521/jscp.21.3.287.22532
   Hausenblas HA, 2004, J SOC CLIN PSYCHOL, V23, P45, DOI 10.1521/jscp.23.1.45.26985
   Heatherton TF., 1993, PSYCHOL ADDICT BEHAV, V7, P225
   HEINBERG LJ, 1992, J SOC BEHAV PERS, V7, P335
   Heinberg LJ, 1995, J SOC CLIN PSYCHOL, V14, P325, DOI 10.1521/jscp.1995.14.4.325
   IRVING LM, 1990, J SOC CLIN PSYCHOL, V9, P230, DOI 10.1521/jscp.1990.9.2.230
   Irving LM, 2001, J SOC CLIN PSYCHOL, V20, P259, DOI 10.1521/jscp.20.3.259.22305
   Jansen A, 2005, BEHAV RES THER, V43, P183, DOI 10.1016/j.brat.2004.01.003
   Lockwood P, 1997, J PERS SOC PSYCHOL, V73, P91, DOI 10.1037//0022-3514.73.1.91
   Martin M., 1994, GENDER ISSUES CONSUM, P104
   MARTIN MC, 1993, PSYCHOL MARKET, V10, P513, DOI DOI 10.1002/MAR.4220100605
   Mills JS, 2002, PERS SOC PSYCHOL B, V28, P1687, DOI 10.1177/014616702237650
   Mussweiler T, 2004, J EXP SOC PSYCHOL, V40, P689, DOI 10.1016/j.jesp.2004.01.004
   Patrick H, 2004, PERS SOC PSYCHOL B, V30, P501, DOI 10.1177/0146167203261891
   Polivy J, 2002, ANNU REV PSYCHOL, V53, P187, DOI 10.1146/annurev.psych.53.100901.135103
   Polivy J, 2004, J SOC CLIN PSYCHOL, V23, P1, DOI 10.1521/jscp.23.1.1.26986
   Posavac HD, 1998, SEX ROLES, V38, P187, DOI 10.1023/A:1018729015490
   Schwinghammer SA, 2006, PERS SOC PSYCHOL B, V32, P27, DOI 10.1177/0146167205277096
   Stapel DA, 1998, J PERS SOC PSYCHOL, V74, P878, DOI 10.1037//0022-3514.74.4.878
   Stapel DA, 2000, J PERS SOC PSYCHOL, V78, P19, DOI 10.1037//0022-3514.78.1.19
   Stapel DA, 2004, J PERS SOC PSYCHOL, V87, P860, DOI 10.1037/0022-3514.87.6.860
   Stapel DA, 2004, J PERS SOC PSYCHOL, V87, P468, DOI 10.1037/0022-3514.87.4.468
   Stapel DA, 2004, SOC COGNITION, V22, P147, DOI 10.1521/soco.22.1.147.30989
   Stapel DA, 2001, J PERS SOC PSYCHOL, V80, P766, DOI 10.1037//0022-3514.80.5.766
   Stapel DA, 2001, J PERS SOC PSYCHOL, V81, P742, DOI 10.1037//0022-3514.81.4.742
   STICE E, 1994, J ABNORM PSYCHOL, V103, P836, DOI 10.1037/0021-843X.103.4.836
   STICE E, 1994, J SOC CLIN PSYCHOL, V13, P288, DOI 10.1521/jscp.1994.13.3.288
   STRIEGELMOORE R, 1986, INT J EAT DISORDER, V5, P935, DOI 10.1002/1098-108X(198607)5:5<935::AID-EAT2260050514>3.0.CO;2-0
   THOMPSON EP, 1994, J PERS SOC PSYCHOL, V66, P474, DOI 10.1037//0022-3514.66.3.474
   THOMPSON JK, 1993, INT J EAT DISORDER, V14, P59, DOI 10.1002/1098-108X(199307)14:1<59::AID-EAT2260140108>3.0.CO;2-T
   Thompson JK, 2001, CURR DIR PSYCHOL SCI, V10, P181, DOI 10.1111/1467-8721.00144
   Tiggemann M, 2004, J SOC CLIN PSYCHOL, V23, P23, DOI 10.1521/jscp.23.1.23.26991
   West S. G, 1991, MULTIPLE REGRESSION
   Wilcox K, 2000, J RES PERS, V34, P278, DOI 10.1006/jrpe.1999.2281
   WOOD JV, 1989, PSYCHOL BULL, V106, P231, DOI 10.1037//0033-2909.106.2.231
   Wood JV, 1996, PERS SOC PSYCHOL B, V22, P520, DOI 10.1177/0146167296225009
NR 48
TC 65
Z9 66
U1 3
U2 45
PU AMER PSYCHOLOGICAL ASSOC
PI WASHINGTON
PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA
SN 0022-3514
EI 1939-1315
J9 J PERS SOC PSYCHOL
JI J. Pers. Soc. Psychol.
PD JAN
PY 2007
VL 92
IS 1
BP 106
EP 118
DI 10.1037/0022-3514.92.1.106
PG 13
WC Psychology, Social
SC Psychology
GA 122TH
UT WOS:000243249300009
PM 17201546
DA 2018-12-27
ER

PT J
AU Jie, H
   He, DH
   Xue, XK
   Gao, L
   Wu, WJ
   Han, XY
   Cai, Z
AF Hu Jie
   He Donghua
   Xue Xingkui
   Gao Liang
   Wu Wenjun
   Han Xiaoyan
   Cai Zhen
TI RETRACTED: Homoharringtonine-induced apoptosis of MDS cell line MUTZ-1
   cells is mediated by the endoplasmic reticulum stress pathway (Retracted
   article. See vol. 57, pg. 1241, 2016)
SO LEUKEMIA & LYMPHOMA
LA English
DT Article; Retracted Publication
DE homoharringtonine; apoptosis; ER stress; mitochondrial membrane
   potential; Bid
EM caizhen1@yahoo.com
RI HU, JIE/A-4460-2012
NR 0
TC 17
Z9 17
U1 4
U2 7
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1042-8194
EI 1029-2403
J9 LEUKEMIA LYMPHOMA
JI Leuk. Lymphoma
PY 2007
VL 48
IS 5
BP 964
EP 977
DI 10.1080/10428190701216360
PG 14
WC Oncology; Hematology
SC Oncology; Hematology
GA 171FH
UT WOS:000246719800020
PM 17487741
DA 2018-12-27
ER

PT J
AU Al-Sweiti, YM
   Soffker, D
AF Al-Sweiti, Yousef M.
   Soeffker, Dirk
TI RETRACTED: Cargo pendulation suppression of ship cranes with elastic
   booms (Retracted article. See vol. 20, pg. 1920, 2014)
SO MATHEMATICAL AND COMPUTER MODELLING OF DYNAMICAL SYSTEMS
LA English
DT Article; Retracted Publication
DE elastic cranes; multi-model problem; variable-gain controller;
   variable-gain; PI-observer; disturbance estimation; disturbance
   compensation
AB This article concerns modelling and controller design for elastic ship-mounted cranes with the Maryland Rigging. Three inputs are employed to control the vibrations in the plane of the boom; the luff angle is utilized to ensure the controllability of the elastic boom, and the total length of the upper cable in conjunction with the position of its lower suspension point are used to guarantee the controllability of the payload. The dynamic behaviour of the crane is described by a multi-model approach depending on the current values of the cable length and boom luff angle. Consequently, a variable-gain observer and a variable-gain controller are designed to control the vibrations of the crane; the numerical values of the gains are updated according to the current operating region, which is determined by a region finder. Simulation and experimental results show that the expressed control strategy performs well and has a significant effect in controlling the vibrations of the crane for different operating conditions and payload masses.
C1 Univ Duisburg Essen, Chair Dynam & Control, Fac Engn, D-47057 Duisburg, Germany.
RP Al-Sweiti, YM (reprint author), Univ Duisburg Essen, Chair Dynam & Control, Fac Engn, D-47057 Duisburg, Germany.
EM yousef.alsweiti@uni-due.de
CR Abdel-Rahman EM, 2003, J VIB CONTROL, V9, P1327, DOI 10.1177/107754603031164
   ALSWEITI Y, 2005, 2005 ASME 20 BIENN C
   DADONE P, 1999, INTELLIGENT ENG SYST, V9, P751
   INMAN DJ, 1989, VIBRATION CONTROL ME, P141
   Kimiaghalam B., 1999, Proceedings of the 1999 American Control Conference (Cat. No. 99CH36251), P586, DOI 10.1109/ACC.1999.782895
   Kimiaghalam B., 2000, P AM CONTR C CHIC IL, V2, P1047
   KRAJCIN I, 2005, DETC 2005 ASME 20 BI
   MICROVITCH L, 1986, ELEMENTS VIBRATION A, V9, P1327
   MULLER PC, 1998, P IEE INT C CONTR, V88, P734
   SOFFKER D, 1993, INT J SYST SCI, V26, P1571
   SOFFKER D, 1993, ASME J DYNAMIC SYSTE, V3, P518
   YADEGARI S, 2003, P 6 INT C DIT AUD EF
   YUAN GH, 1997, DETC 97 P ASME DES E
NR 13
TC 5
Z9 5
U1 3
U2 7
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1387-3954
EI 1744-5051
J9 MATH COMP MODEL DYN
JI Math. Comput. Model. Dyn. Syst.
PY 2007
VL 13
IS 6
BP 503
EP 529
DI 10.1080/13873950701214424
PG 27
WC Computer Science, Interdisciplinary Applications; Mathematics, Applied
SC Computer Science; Mathematics
GA 224KH
UT WOS:000250445400001
DA 2018-12-27
ER

PT J
AU Rao, JS
   Ertley, RN
   Lee, HJ
   Demar, JC
   Arnold, JT
   Rapoport, SI
   Bazinet, RP
AF Rao, J. S.
   Ertley, R. N.
   Lee, H-J
   DeMar, J. C., Jr.
   Arnold, J. T.
   Rapoport, S. I.
   Bazinet, R. P.
TI RETRACTED: n-3 oolyunsaturated fatty acid deprivation in rats decreases
   frontal cortex BDNF via a p38 MAPK-dependent mechanism (Retracted
   article. See vol. 23, 2018)
SO MOLECULAR PSYCHIATRY
LA English
DT Article; Retracted Publication
DE docosahexaenoic acid; BDNF; MAPK; PKA; brain; rat; bipolar disorder
ID ACTIVATED PROTEIN-KINASE; GENE CONFERS SUSCEPTIBILITY; SIGNAL-REGULATED
   KINASE; DOCOSAHEXAENOIC ACID; BIPOLAR DISORDER; NEUROTROPHIC FACTOR;
   POSTMORTEM BRAIN; RESPONSE ELEMENT; DOUBLE-BLIND; EXPRESSION
AB Decreased docosahexaenoic acid (DHA) and brain-derived neurotrophic factor ( BDNF) have been implicated in bipolar disorder. It also has been reported that dietary deprivation of n-3 polyunsaturated fatty acids (PUFAs) for 15 weeks in rats, increased their depression and aggression scores. Here, we show that n-3 PUFA deprivation for 15 weeks decreased the frontal cortex DHA level and reduced frontal cortex BDNF expression, cAMP response element binding protein ( CREB) transcription factor activity and p38 mitogen-activated protein kinase ( MAPK) activity. Activities of other CREB activating protein kinases were not significantly changed. The addition of DHA to rat primary cortical astrocytes in vitro, induced BDNF protein expression and this was blocked by a p38 MAPK inhibitor. DHA's ability to regulate BDNF via a p38 MAPK-dependent mechanism may contribute to its therapeutic efficacy in brain diseases having disordered cell survival and neuroplasticity.
C1 NIA, Brain Physiol & Metab Sect, NIH, Bethesda, MD 20892 USA.
   NIH, Endocrine Sect, Clin Invest Lab, Div Intramural Res,Natl Ctr Complementary & Alter, Bethesda, MD 20892 USA.
RP Rao, JS (reprint author), NIA, Brain Physiol & Metab Sect, NIH, 9000 Rockville Pike,Bldg 9,1S-126, Bethesda, MD 20892 USA.
EM jrao@mail.nih.gov
RI Rao, Jagadeesh/C-1250-2009
FU Intramural NIH HHS
CR Akbar M, 2005, P NATL ACAD SCI USA, V102, P10858, DOI 10.1073/pnas.0502903102
   Bazinet RP, 2005, PSYCHOPHARMACOLOGY, V182, P180, DOI 10.1007/s00213-005-0059-7
   Berton O, 2006, SCIENCE, V311, P864, DOI 10.1126/science.1120972
   Blendy JA, 2006, BIOL PSYCHIAT, V59, P1144, DOI 10.1016/j.biopsych.2005.11.003
   Blois JT, 2004, J BIOL CHEM, V279, P30123, DOI 10.1074/jbc.M402793200
   Calderon F, 2004, J NEUROCHEM, V90, P979, DOI 10.1111/j.1471-4159.2004.02520.x
   Calon F, 2004, NEURON, V43, P633, DOI 10.1016/j.neuron.2004.08.013
   Carlezon WA, 2005, BIOL PSYCHIAT, V57, P343, DOI 10.1016/j.biopsych.2004.11.038
   Chang A, 2003, MOL BRAIN RES, V116, P27, DOI 10.1016/S0169-328X(03)00211-0
   Chang A, 2003, J NEUROCHEM, V84, P781, DOI 10.1046/j.0022-3042.2003.01605.x
   Chen C, 2005, PROSTAG OTH LIPID M, V77, P65, DOI 10.1016/j.prostaglandins.2005.07.001
   Chiu CC, 2003, EUR NEUROPSYCHOPHARM, V13, P99, DOI 10.1016/S0924-977X(02)00130-X
   Chuang De-Maw, 2004, Critical Reviews in Neurobiology, V16, P83, DOI 10.1615/CritRevNeurobiol.v16.i12.90
   Cunha ABM, 2006, NEUROSCI LETT, V398, P215, DOI 10.1016/j.neulet.2005.12.085
   D'Sa C, 2002, BIPOLAR DISORD, V4, P183, DOI 10.1034/j.1399-5618.2002.01203.x
   Darios F, 2006, NATURE, V440, P813, DOI 10.1038/nature04598
   DAVIS RJ, 1993, J BIOL CHEM, V268, P14553
   Deak M, 1998, EMBO J, V17, P4426, DOI 10.1093/emboj/17.15.4426
   DeMar JC, 2006, J LIPID RES, V47, P172, DOI 10.1194/jlr.M500362-JLR200
   DeMar JC, 2005, J NEUROCHEM, V94, P1063, DOI 10.1111/j.1471-4159.2005.03258.x
   DeMar JC, 2004, J NEUROCHEM, V91, P1125, DOI 10.1111/j.1471-4159.2004.02789.x
   Diau GY, 2005, BMC MED, V3, DOI 10.1186/1741-7015-3-11
   Duman RS, 2002, EUR PSYCHIAT, V17, p306S
   Dwivedi Y, 2006, MOL PSYCHIATR, V11, P86, DOI 10.1038/sj.mp.4001744
   Dwivedi Y, 2001, J NEUROCHEM, V77, P916, DOI 10.1046/j.1471-4159.2001.00300.x
   Einat H, 2003, DRUG NEWS PERSPECT, V16, P453, DOI 10.1358/dnp.2003.16.7.829357
   Einat H, 2003, J NEUROSCI, V23, P7311
   Finkbeiner S, 1997, NEURON, V19, P1031, DOI 10.1016/S0896-6273(00)80395-5
   FOLCH J, 1957, J BIOL CHEM, V226, P497
   Frangou S, 2006, BRIT J PSYCHIAT, V188, P46, DOI 10.1192/bjp.188.1.46
   Frey BN, 2006, LIFE SCI, V79, P281, DOI 10.1016/j.lfs.2006.01.002
   Ghelardoni S, 2004, BIOL PSYCHIAT, V56, P248, DOI 10.1016/j.biophysc.2004.05.012
   GHOSH A, 1994, SCIENCE, V263, P1618, DOI 10.1126/science.7907431
   GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5
   Hashimoto K, 2004, BRAIN RES REV, V45, P104, DOI 10.1016/j.brainresrev.2004.02.003
   Innis SM, 2003, J PEDIATR-US, V143, pS1, DOI 10.1067/S0022-3476(03)00396-2
   Karege F, 2004, J AFFECT DISORDERS, V79, P187, DOI 10.1016/S0165-0327(02)00463-9
   Knable MB, 2004, MOL PSYCHIATR, V9, P609, DOI 10.1038/sj.mp.4001471
   Kodas E, 2004, J NEUROCHEM, V89, P695, DOI 10.1111/j.1471-4159.2004.02401.x
   Kuperstein F, 2005, J NEUROCHEM, V95, P1550, DOI 10.1111/j.1471-4159.2005.03513.x
   Lahiri DK, 1998, MOL BRAIN RES, V58, P112, DOI 10.1016/S0169-328X(98)00115-6
   Laifenfeld D, 2005, BIOL PSYCHIAT, V57, P716, DOI 10.1016/j.biopsych.2004.12.016
   Lin ZC, 2003, J BIOL CHEM, V278, P20162, DOI 10.1074/jbc.M209584200
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lohoff FW, 2005, AM J MED GENET B, V139B, P51, DOI 10.1002/ajmg.b.30215
   Lopez-Larson MP, 2002, BIOL PSYCHIAT, V52, P93, DOI 10.1016/S0006-3223(02)01350-1
   Lukiw WJ, 2005, J CLIN INVEST, V115, P2774, DOI 10.1172/JCI25420
   Lyoo IK, 2004, BIOL PSYCHIAT, V55, P648, DOI 10.1016/j.biopsych.2003.10.017
   Maitre M, 1996, ANN BIOL CLIN-PARIS, V54, P49
   MAKRIDES M, 1994, AM J CLIN NUTR, V60, P189
   Manji HK, 2000, MOL PSYCHIATR, V5, P578, DOI 10.1038/sj.mp.4000811
   Marcheselli VL, 2003, J BIOL CHEM, V278, P43807, DOI 10.1074/jbc.M305841200
   McNamara RK, 2006, BIOL PSYCHIAT, V59, p30S
   Mercier G, 2004, J MOL NEUROSCI, V24, P207, DOI 10.1385/JMN:24:2:207
   Mirnikjoo B, 2001, J BIOL CHEM, V276, P10888, DOI 10.1074/jbc.M008150200
   MONTEGGIA LM, 2006, BIOL PSYCHIAT   0511
   MONTMINY MR, 1987, NATURE, V328, P175, DOI 10.1038/328175a0
   Moriguchi T, 2001, J LIPID RES, V42, P419
   Moron JA, 2003, J NEUROSCI, V23, P8480
   Naliwaiko K, 2004, NUTR NEUROSCI, V7, P91, DOI 10.1080/10284150410001704525
   Neves-Pereira M, 2002, AM J HUM GENET, V71, P651, DOI 10.1086/342288
   Nibuya M, 1996, J NEUROSCI, V16, P2365
   Noaghiul S, 2003, AM J PSYCHIAT, V160, P2222, DOI 10.1176/appi.ajp.160.12.2222
   Noetzel M, 2001, J MOL NEUROSCI, V16, P317
   Okada T, 2006, MOL PSYCHIATR, V11, P695, DOI 10.1038/sj.mp.4001822
   Padma M, 1999, PROSTAG LEUKOTR ESS, V60, P55, DOI 10.1054/plef.1998.0008
   Perez J, 2002, MOL PSYCHIATR, V7, P208, DOI 10.1038/sj.mp.4000969
   Rajkowska G, 2002, BIPOLAR DISORD, V4, P105, DOI 10.1034/j.1399-5618.2002.01149.x
   Ranjekar PK, 2003, PSYCHIAT RES, V121, P109, DOI 10.1016/S0165-1781(03)00220-8
   RAO BPC, 2002, J NONDESTRUCTIVE TES, V2, P23
   Rao JS, 2005, NEUROPSYCHOPHARMACOL, V30, P2006, DOI 10.1038/sj.npp.1300740
   Salem N, 2001, LIPIDS, V36, P945, DOI 10.1007/s11745-001-0805-6
   Salem N, 2001, J MOL NEUROSCI, V16, P299, DOI 10.1385/JMN:16:2-3:299
   Samuvel DJ, 2005, J NEUROSCI, V25, P29, DOI 10.1523/JNEUROSCI.3754-04.2005
   SASTRY PS, 1985, PROG LIPID RES, V24, P69, DOI 10.1016/0163-7827(85)90011-6
   SEGER R, 1995, FASEB J, V9, P726
   Sklar P, 2002, MOL PSYCHIATR, V7, P579, DOI 10.1038/sj.mp.4001058
   Soares JC, 2005, NEUROREPORT, V16, P541, DOI 10.1097/00001756-200504250-00004
   Sprecher H, 2000, BBA-MOL CELL BIOL L, V1486, P219, DOI 10.1016/S1388-1981(00)00077-9
   Stoll AL, 1999, ARCH GEN PSYCHIAT, V56, P407, DOI 10.1001/archpsyc.56.5.407
   Takenaka M, 2005, BIOL PHARM BULL, V28, P1291, DOI 10.1248/bpb.28.1291
   Tardito D, 2003, J AFFECT DISORDERS, V76, P249, DOI 10.1016/S0165-0327(02)00065-4
   Tiraboschi E, 2004, NEUROPSYCHOPHARMACOL, V29, P1831, DOI 10.1038/sj.npp.1300488
   VAIDYANATHAN VV, 1994, NEUROSCI LETT, V179, P171, DOI 10.1016/0304-3940(94)90961-X
   Wang HY, 1996, BIOL PSYCHIAT, V40, P568, DOI 10.1016/0006-3223(95)00611-7
   Watanabe S, 2004, PHYSIOL BEHAV, V81, P605, DOI 10.1016/j.physbeh.2004.02.021
   Wu A, 2004, J NEUROTRAUM, V21, P1457, DOI 10.1089/neu.2004.21.1457
   Xing J, 1998, MOL CELL BIOL, V18, P1946, DOI 10.1128/MCB.18.4.1946
   YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0
   Yatham LN, 2005, BIPOLAR DISORD, V7, P13, DOI 10.1111/j.1399-5618.2005.00211.x
   Zarate CA, 2006, BIOL PSYCHIAT, V59, P1006, DOI 10.1016/j.biopsych.2005.10.021
NR 91
TC 200
Z9 207
U1 3
U2 9
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1359-4184
EI 1476-5578
J9 MOL PSYCHIATR
JI Mol. Psychiatr.
PD JAN
PY 2007
VL 12
IS 1
BP 36
EP 46
DI 10.1038/sj.mp.4001888
PG 11
WC Biochemistry & Molecular Biology; Neurosciences; Psychiatry
SC Biochemistry & Molecular Biology; Neurosciences & Neurology; Psychiatry
GA 119EF
UT WOS:000242994300003
PM 16983391
OA Bronze
DA 2018-12-27
ER

PT J
AU Yang, J
   Yang, Y
   Chen, JM
   Wang, G
   Xu, HT
   Liu, WY
   Lin, BC
AF Yang, Jun
   Yang, Yu
   Chen, Jian-Min
   Wang, Gen
   Xu, Hong-Tao
   Liu, Wen-Yan
   Lin, Bao-Cheng
TI RETRACTED: Periaqueductal gray knockdown of V2, not V1a and V1b receptor
   influences nociception in the rat (Retracted article. see vol. 65, pg.
   214, 2009)
SO NEUROSCIENCE RESEARCH
LA English
DT Article; Retracted Publication
DE gene knockdown; vasopressin receptor; periaqueductal gray; nociception;
   rat
ID MEDIATED GENETIC INTERFERENCE; ENDOGENOUS OPIATE PEPTIDES;
   ARGININE-VASOPRESSIN; PARAVENTRICULAR NUCLEUS; ACUPUNCTURE ANALGESIA;
   RNA INTERFERENCE; BETA-ENDORPHIN; OXYTOCIN; BRAIN; LOCALIZATION
AB Our pervious study has proved that arginine vasopressin (AVP) in periaqueductal gray (PAG) plays a role in antinociception. After establishing a model of local special gene knockdown, the nociceptive effect of vasopressin receptor subunit in PAG was investigated in the rat. Microinjection of short-interfering RNA (siRNA) into PAG, which targeted vasopressin receptor subtypes (V-1a, V-1b and V-2) locally weakened the associated mRNA expression and depressed the related receptor synthesis in a dose-dependent manner, in which the significant inhibitive effect occurred on from 7th day to 14th day following 1 mu g or 2 mu g siRNA administration. PAG knockdown of V-2 receptor gene markedly decreased pain threshold in from 6th day to 13th day after siRNA administration, whereas local knockdown of either V-1a or V-1b receptor gene could not influence pain threshold. The data suggest that V-2 rather than V-1a and V-1b receptor in PAG involves in nociception. (c) 2006 Elsevier Ireland Ltd and the Japan Neuroscience Society. All rights reserved.
C1 Guangdong Bangmin Pharmaceut Co Ltd, Inst Pharmaceut & Med Sci, Jiangmen 529000, Guangdong, Peoples R China.
   McGill Univ, Jewish Gen Hosp, Lady Davis Inst Med Res, Montreal, PQ H3T 1E2, Canada.
   Natl Res Council Canada, Inst Nutrisci & Hlth, Charlottetown, PE C1A 5T1, Canada.
   Jining Med Coll, Dept Physiol, Shandong 272113, Peoples R China.
   Second Mil Med Univ, Dept Neurobiol, Shanghai 200433, Peoples R China.
RP Yang, J (reprint author), Guangdong Bangmin Pharmaceut Co Ltd, Inst Pharmaceut & Med Sci, 10-6655 Fielding Ave, Montreal, PQ H4V 1N4, Canada.
EM yj6676@yahoo.com
CR ANTUNES JL, 1978, J COMP NEUROL, V181, P539
   BODNAR RJ, 1984, INT J NEUROSCI, V24, P149, DOI 10.3109/00207458409089803
   de Vries GJ, 1998, PROG BRAIN RES, V119, P3
   DEVRIES GJ, 1983, BRAIN RES, V273, P307, DOI 10.1016/0006-8993(83)90855-7
   Elbashir SM, 2001, GENE DEV, V15, P188, DOI 10.1101/gad.862301
   Hernando F, 2001, ENDOCRINOLOGY, V142, P1659, DOI 10.1210/en.142.4.1659
   HUGHES J, 1975, NATURE, V258, P577, DOI 10.1038/258577a0
   JOHNSON AE, 1993, BRAIN RES, V622, P9, DOI 10.1016/0006-8993(93)90795-O
   JUN Y, 1992, ACUPUNCTURE ELECTRO, V17, P209, DOI 10.3727/036012992816357639
   Kennerdell JR, 1998, CELL, V95, P1017, DOI 10.1016/S0092-8674(00)81725-0
   KORDOWER JH, 1984, PEPTIDES, V5, P747, DOI 10.1016/0196-9781(84)90017-2
   LOWRY OH, 1951, J BIOL CHEM, V193, P265
   MADRAZO I, 1987, APPL NEUROPHYSIOL, V50, P427
   MARTIN R, 1981, NATURE, V289, P502, DOI 10.1038/289502a0
   MARTIN R, 1983, NEUROSCIENCE, V8, P213, DOI 10.1016/0306-4522(83)90061-1
   MCEWEN BB, 2004, ROLES VASOPRESSIN OX, V50
   Miyagishi M, 2002, NAT BIOTECHNOL, V20, P497, DOI 10.1038/nbt0502-497
   Montgomery MK, 1998, P NATL ACAD SCI USA, V95, P15502, DOI 10.1073/pnas.95.26.15502
   SAWCHENKO PE, 1990, J COMP NEUROL, V291, P269, DOI 10.1002/cne.902910209
   Shiraishi T., 1995, Neurobiology (Budapest), V3, P393
   Svoboda P, 2000, DEVELOPMENT, V127, P4147
   Tan PH, 2005, GENE THER, V12, P59, DOI 10.1038/sj.gt.3302376
   WATSON SJ, 1982, SCIENCE, V216, P85, DOI 10.1126/science.6121376
   WEITZMAN RE, 1977, ENDOCRINOLOGY, V101, P1643, DOI 10.1210/endo-101-5-1643
   WENG NQ, 1987, PAIN ANALGESIA
   WU W, 2003, GENE BIOTECHNOLOGY
   Yang J, 2006, BRAIN RES BULL, V68, P453, DOI 10.1016/j.brainresbull.2005.10.002
   Yang J, 2006, NEUROSCI RES, V54, P49, DOI 10.1016/j.neures.2005.10.006
   YANG J, 1992, ACAD J SEC MIL MED U, V13, P120
   YANG J, 1992, ACUPUNCTURE RES, V17, P677
   YANG J, 1992, ACTA ACUPUNCT SINA, V5, P31
   Yang J, 2006, REGUL PEPTIDES, V137, P156, DOI 10.1016/j.regpep.2006.07.004
   ZIMMERMANN M, 1983, PAIN, V16, P109, DOI 10.1016/0304-3959(83)90201-4
NR 34
TC 19
Z9 19
U1 3
U2 16
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0168-0102
EI 1872-8111
J9 NEUROSCI RES
JI Neurosci. Res.
PD JAN
PY 2007
VL 57
IS 1
BP 104
EP 111
DI 10.1016/j.neures.2006.09.011
PG 8
WC Neurosciences
SC Neurosciences & Neurology
GA 133ZN
UT WOS:000244052500010
PM 17056144
DA 2018-12-27
ER

PT J
AU Moore, JL
   Roche, RAP
AF Moore, Jennifer L.
   Roche, Richard A. P.
TI RETRACTED: Reconsolidation revisited: A review and commentary on the
   phenomenon (Retracted article. See vol. 26, pg. 119, 2015)
SO REVIEWS IN THE NEUROSCIENCES
LA English
DT Review; Retracted Publication
DE memory; consolidation; reconsolidation; hippocarnpus; encoding;
   retrieval
ID LONG-TERM-MEMORY; REQUIRES PROTEIN-SYNTHESIS; COCAINE-SEEKING BEHAVIOR;
   MEDIAL TEMPORAL-LOBE; CONDITIONED PLACE PREFERENCE; GRADED
   RETROGRADE-AMNESIA; TIME-LIMITED ROLE; ELECTROCONVULSIVE SHOCK;
   NUCLEUS-ACCUMBENS; TASTE-AVERSION
AB Consolidation and reconsolidation constitute a large proportion of current research into memory formation. The evidence in favour of the Consolidation Theory is widespread, on both the cellular and systems level. Research has indicated that consolidation and reconsolidation employ similar mechanisms; both consolidation and reconsolidation of memory require protein synthesis and glutaminergic input, and both seem to be associated with the hippocampal formation. Despite this, other data seem to argue that the two concepts are entirely separate processes. The great interest in this topic is shown in the proliferation of studies. The current literature has been subject to extensive and continual review. The current manuscript attempts to address the inconsistency in the consolidation-reconsolidation literature by providing a selective review of some of the most pertinent experimental work in both areas. The core question underpinning this review paper is whether reconsolidation is an entity distinct from consolidation, or merely an extension of the consolidation process. It is concluded that consolidation and reconsolidation may be distinct, albeit similar, processes, and that only a subset of the brain areas involved in consolidation are implicated in reconsolidation. In addition, with advances in our understanding of, and approach to these processes (i.e., incorporation of boundary conditions of reconsolidation into the design of contemporary studies and the increased awareness of the need to temper the interpretation of data emerging from studies employing divergent methodologies), it is suggested that future reconsolidation research may yield significant progress into the vast potential underpinning the reconsolidation phenomenon.
C1 Natl Univ Ireland Maynooth, Co Kildare, Dept Psychol, Maynooth, Kildare, Ireland.
   Univ Dublin, Trinity Coll, Inst Neurosci, Dept Psychol, Dublin, Ireland.
RP Moore, JL (reprint author), Natl Univ Ireland Maynooth, Co Kildare, Dept Psychol, Maynooth, Kildare, Ireland.
EM moorejl@eircom.net
CR Alberini CM, 2006, CELL MOL LIFE SCI, V63, P999, DOI 10.1007/s00018-006-6025-7
   Alberini CM, 2005, TRENDS NEUROSCI, V28, P51, DOI 10.1016/j.tins.2004.11.001
   Anokhin KV, 2002, EUR J NEUROSCI, V15, P1759, DOI 10.1046/j.1460-9568.2002.02023.x
   Bahar A, 2004, EUR J NEUROSCI, V19, P1115, DOI 10.1111/j.1460-9568.2004.03215.x
   Bayley PJ, 2003, NEURON, V38, P135, DOI 10.1016/S0896-6273(03)00156-9
   Bayley PJ, 2002, J NEUROSCI, V22, P5741
   Beckner VE, 2006, BEHAV NEUROSCI, V120, P518, DOI 10.1037/0735-7044.120.3.518
   Berman DE, 2001, SCIENCE, V291, P2417, DOI 10.1126/science.1058165
   Berman DE, 2003, LEARN MEMORY, V10, P16, DOI 10.1101/lm.53703
   Bernardi RE, 2006, NEUROREPORT, V17, P1443, DOI 10.1097/01.wnr.0000233098.20655.26
   Biedenkapp JC, 2004, BEHAV NEUROSCI, V118, P956, DOI 10.1037/0735-7044.118.5.956
   Blaiss CA, 2006, BEHAV BRAIN RES, V171, P329, DOI 10.1016/j.bbr.2006.04.018
   Blum S, 2006, BMC NEUROSCI, V7, DOI 10.1186/1471-2202-7-67
   Bontempi B, 1999, NATURE, V400, P671, DOI 10.1038/23270
   Bourtchouladze R, 1998, LEARN MEMORY, V5, P365
   Bozon B, 2003, NEURON, V40, P695, DOI 10.1016/S0896-6273(03)00674-3
   BROOKS DN, 1976, NEUROPSYCHOLOGIA, V14, P111, DOI 10.1016/0028-3932(76)90012-9
   Burnham WH, 1903, AM J PSYCHOL, V14, P382
   Cahill L, 1997, ANN NY ACAD SCI, V821, P238, DOI 10.1111/j.1749-6632.1997.tb48283.x
   Cammarota M, 2004, LEARN MEMORY, V11, P572, DOI 10.1101/lm.76804
   CHEVALIER JA, 1965, J COMP PHYSIOL PSYCH, V59, P125, DOI 10.1037/h0021605
   Child FM, 2003, BIOL BULL-US, V205, P218, DOI 10.2307/1543261
   Childress A. R., 1999, Society for Neuroscience Abstracts, V25, P815
   CHO YH, 1993, J NEUROSCI, V13, P1759
   Clark RE, 2002, J NEUROSCI, V22, P4663, DOI 10.1523/JNEUROSCI.22-11-04663.2002
   Cohen NJ., 1984, NEUROPSYCHOLOGY MEMO, P83
   Conklin CA, 2002, ADDICTION, V97, P155, DOI 10.1046/j.1360-0443.2002.00014.x
   Corkin S, 2002, NAT REV NEUROSCI, V3, P153, DOI 10.1038/nrn726
   DAVIS HP, 1984, PSYCHOL BULL, V96, P518, DOI 10.1037//0033-2909.96.3.518
   DAWSON RG, 1969, SCIENCE, V166, P525, DOI 10.1126/science.166.3904.525
   Debiec J, 2002, NEURON, V36, P527, DOI 10.1016/S0896-6273(02)01001-2
   Debiec J, 2004, NEUROSCIENCE, V129, P267, DOI 10.1016/j.neuroscience.2004.08.018
   DEWIT H, 1981, PSYCHOPHARMACOLOGY, V75, P134, DOI 10.1007/BF00432175
   Di Ciano P, 2004, J NEUROSCI, V24, P7167, DOI 10.1523/JNEUROSCI.1581-04.2004
   Dudai Y, 2006, CURR OPIN NEUROBIOL, V16, P174, DOI 10.1016/j.conb.2006.03.010
   Dudai Y, 2004, NEURON, V44, P93, DOI 10.1016/j.neuron.2004.09.003
   Dudai Y, 2004, ANNU REV PSYCHOL, V55, P51, DOI 10.1146/annurev.psych.55.090902.142050
   EHRMAN RN, 1992, PSYCHOPHARMACOLOGY, V107, P523, DOI 10.1007/BF02245266
   Eisenberg M, 2004, EUR J NEUROSCI, V20, P3397, DOI 10.1111/j.1460-9568.2004.03818.x
   Eisenberg M, 2003, SCIENCE, V301, P1102, DOI 10.1126/science.1086881
   Frankland PW, 2001, NATURE, V411, P309, DOI 10.1038/35077089
   Frenkel L, 2005, EUR J NEUROSCI, V22, P1757, DOI 10.1111/j.1460-9568.2005.04373.x
   Fuchs RA, 1998, PSYCHOPHARMACOLOGY, V135, P151, DOI 10.1007/s002130050496
   Gainutdinova TH, 2005, LEARN MEMORY, V12, P620, DOI 10.1101/lm.25705
   GAWIN FH, 1991, SCIENCE, V251, P1580, DOI 10.1126/science.2011738
   GOELET P, 1986, NATURE, V322, P419, DOI 10.1038/322419a0
   GORDON WC, 1981, INFORM PROCESSING AN
   Gruest N, 2004, J NEUROSCI, V24, P10488, DOI 10.1523/JNEUROSCI.2984-04.2004
   Gruest N, 2004, DEV PSYCHOBIOL, V44, P189, DOI 10.1002/dev.20004
   Haist F, 2001, NAT NEUROSCI, V4, P1139, DOI 10.1038/nn739
   Hernandez PJ, 2002, NAT NEUROSCI, V5, P1327, DOI 10.1038/nn973
   Inda MC, 2005, J NEUROSCI, V25, P2070, DOI 10.1523/JNEUROSCI.4163-04.2005
   Izquierdo I, 2004, SCIENCE, V304, P829, DOI 10.1126/science.1098139
   Izquierdo I, 1997, EUR J NEUROSCI, V9, P786, DOI 10.1111/j.1460-9568.1997.tb01427.x
   JUDGE ME, 1982, PHYSIOL BEHAV, V28, P585, DOI 10.1016/0031-9384(82)90034-8
   Kelly A, 2003, J NEUROSCI, V23, P5354
   Kida S, 2002, NAT NEUROSCI, V5, P348, DOI 10.1038/nn819
   KIM JJ, 1995, BEHAV NEUROSCI, V109, P195, DOI 10.1037/0735-7044.109.2.195
   KIM JJ, 1992, SCIENCE, V256, P675, DOI 10.1126/science.1585183
   Knowlton BJ, 1996, SCIENCE, V273, P1399, DOI 10.1126/science.273.5280.1399
   Koh MT, 2003, NEUROREPORT, V14, P405, DOI 10.1097/01.wnr.0000058519.74643.df
   Kubie JL, 1999, PSYCHOBIOLOGY, V27, P313
   Lattal KM, 2004, P NATL ACAD SCI USA, V101, P4667, DOI 10.1073/pnas.0306546101
   Lee JLC, 2005, NEURON, V47, P795, DOI 10.1016/j.neuron.2005.08.007
   Lee JLC, 2004, SCIENCE, V304, P839, DOI 10.1126/science.1095760
   LEWIS DJ, 1972, J COMP PHYSIOL PSYCH, V81, P243, DOI 10.1037/h0033524
   LEWIS DJ, 1965, PSYCHOL REV, V72, P225, DOI 10.1037/h0021810
   LEWIS DJ, 1979, PSYCHOL BULL, V86, P1054, DOI 10.1037//0033-2909.86.5.1054
   LEWIS DJ, 1969, PSYCHOL REV, V76, P461, DOI 10.1037/h0028177
   LEWIS DJ, 1968, J COMP PHYSIOL PSYCH, V66, P48, DOI 10.1037/h0025963
   Litvin O O, 2000, Neurosci Behav Physiol, V30, P671, DOI 10.1023/A:1026698700139
   Lu L, 2006, TRENDS NEUROSCI, V29, P695, DOI 10.1016/j.tins.2006.10.005
   Luft AR, 2004, J NEUROSCI, V24, P6515, DOI 10.1523/JNEUROSCI.1034-04.2004
   Lupien SJ, 2006, BEHAV NEUROSCI, V120, P735, DOI 10.1037/0735-7044.120.3.735
   LUTTGES MW, 1967, SCIENCE, V156, P408, DOI 10.1126/science.156.3773.408
   MACTUTUS CF, 1979, SCIENCE, V204, P1319, DOI 10.1126/science.572083
   McGaugh JL, 2000, SCIENCE, V287, P248, DOI 10.1126/science.287.5451.248
   McGaugh JL, 2004, ANNU REV NEUROSCI, V27, P1, DOI 10.1146/annurev.neuro.27.070203.144157
   Meil WM, 1996, BEHAV PHARMACOL, V7, P754
   MEYER DR, 1972, AM PSYCHOL, V27, P124, DOI 10.1037/h0032688
   Milekic MH, 2002, NEURON, V36, P521, DOI 10.1016/S0896-6273(02)00976-5
   Miller CA, 2005, NEURON, V47, P873, DOI 10.1016/j.neuron.2005.08.006
   MILLER MM, 2004, SOC NEUR ABSTR
   Millin PM, 2001, NAT REV NEUROSCI, V2, P68, DOI 10.1038/35049075
   MILNER B, 1968, NEUROPSYCHOLOGIA, V6, P215, DOI 10.1016/0028-3932(68)90021-3
   MISANIN JR, 1968, SCIENCE, V160, P554, DOI 10.1126/science.160.3827.554
   Morris RGM, 2006, NEURON, V50, P479, DOI 10.1016/j.neuron.2006.04.012
   Myers KM, 2002, NEURON, V36, P340, DOI 10.1016/S0896-6273(02)01017-6
   Nader K, 2005, TRENDS NEUROSCI, V28, P346, DOI 10.1016/j.tins.2005.04.011
   Nader K, 2003, TRENDS NEUROSCI, V26, P65, DOI 10.1016/S0166-2236(02)00042-5
   Nader K, 2000, NATURE, V406, P722, DOI 10.1038/35021052
   Niki K, 2002, J COGNITIVE NEUROSCI, V14, P500, DOI 10.1162/089892902317362010
   Nyberg L, 1996, PSYCHON B REV, V3, P135, DOI 10.3758/BF03212412
   O'Brien CP, 1998, J PSYCHOPHARMACOL, V12, P15, DOI 10.1177/026988119801200103
   Pedreira ME, 2004, LEARN MEMORY, V11, P579, DOI 10.1016/lm.76904
   Pedreira ME, 2003, NEURON, V38, P863, DOI 10.1016/S0896-6273(03)00352-0
   Pedreira ME, 2002, J NEUROSCI, V22, P8305
   Pitman RK, 2005, CNS SPECTRUMS, V10, P99, DOI 10.1017/S109285290001943X
   Pitman RK, 2002, BIOL PSYCHIAT, V51, P189, DOI 10.1016/S0006-3223(01)01279-3
   Power AE, 2006, LEARN MEMORY, V13, P27, DOI 10.1101/lm.91206
   Prado-Alcala RA, 2006, NEUROBIOL LEARN MEM, V86, P144, DOI 10.1016/j.nlm.2006.01.006
   Przybyslawski J, 1997, BEHAV BRAIN RES, V84, P241, DOI 10.1016/S0166-4328(96)00153-2
   Przybyslawski J, 1999, J NEUROSCI, V19, P6623
   RIBOT TA, 1982, DIS MEMORY
   Riccio DC, 2006, LEARN MEMORY, V13, P536, DOI 10.1101/lm.290706
   Riccio DC, 2003, CURR DIR PSYCHOL SCI, V12, P41, DOI 10.1111/1467-8721.01222
   Riccio DC, 2002, INTEGR PHYS BEH SCI, V37, P245, DOI 10.1007/BF02734247
   RICHARDSON R, 1982, PHYSIOL BEHAV, V29, P1117, DOI 10.1016/0031-9384(82)90307-9
   Riedel G, 1999, NAT NEUROSCI, V2, P898
   Rodriguez-Ortiz CJ, 2005, LEARN MEMORY, V12, P533, DOI 10.1101/lm.94505
   Roozendaal B, 2002, NEUROBIOL LEARN MEM, V78, P578, DOI 10.1006/nlme.2002.4080
   Roullet P, 1998, NEURAL PLAST, V6, P63, DOI 10.1155/NP.1998.63
   RUSSELL WR, 1946, BRAIN, V69, P280, DOI 10.1093/brain/69.4.280
   Salinska E, 2004, EUR J NEUROSCI, V19, P3042, DOI 10.1111/j.1460-9568.2004.03407.x
   Sangha S, 2003, J NEUROSCI, V23, P8034
   Santini E, 2004, J NEUROSCI, V24, P5704, DOI 10.1523/JNEUROSCI.0786-04.2004
   Sara SJ, 2000, LEARN MEMORY, V7, P73, DOI 10.1101/lm.7.2.73
   Sara SJ, 2006, LEARN MEMORY, V13, P515, DOI 10.1101/lm.338406
   SCHNEIDER AM, 1968, SCIENCE, V159, P219, DOI 10.1126/science.159.3811.219
   SCOVILLE WB, 1957, J NEUROL NEUROSUR PS, V20, P11, DOI 10.1136/jnnp.20.1.11
   SPEAR NE, MEMORY PHENOMENA PRI
   SQUIRE LR, 1995, CURR OPIN NEUROBIOL, V5, P169, DOI 10.1016/0959-4388(95)80023-9
   Squire LR, 2001, HIPPOCAMPUS, V11, P50, DOI 10.1002/1098-1063(2001)11:1<50::AID-HIPO1019>3.0.CO;2-G
   Stickgold R, 2005, TRENDS NEUROSCI, V28, P408, DOI 10.1016/j.tins.2005.06.004
   Stollhoff N, 2005, J NEUROSCI, V25, P4485, DOI 10.1523/JNEUROSCI.0117-05.2005
   Suzuki A, 2004, J NEUROSCI, V24, P4787, DOI 10.1523/JNEUROSCI.5491-03.2004
   Taubenfeld SM, 2001, NAT NEUROSCI, V4, P813, DOI 10.1038/90520
   Torras-Garcia M, 2005, LEARN MEMORY, V12, P18, DOI 10.1101/lm.80905
   Tronel S, 2002, LEARN MEMORY, V9, P105, DOI 10.1101/lm.47802
   Tronson NC, 2006, NAT NEUROSCI, V9, P167, DOI 10.1038/nn1628
   Vianna MR, 2004, CURR NEUROVASC RES, V1, P55, DOI 10.2174/1567202043480170
   Vianna MRM, 2001, P NATL ACAD SCI USA, V98, P12251, DOI 10.1073/pnas.211433298
   Walker MP, 2006, ANNU REV PSYCHOL, V57, P139, DOI 10.1146/annurev.psych.56.091103.070307
   Walker MP, 2002, NEURON, V35, P205, DOI 10.1016/S0896-6273(02)00746-8
   Walker MP, 2003, NATURE, V425, P616, DOI 10.1038/nature01930
   Wang SH, 2005, J NEUROSCI, V25, P830, DOI 10.1523/JNEUROSCI.4716-04.2005
   Weiss F, 2000, P NATL ACAD SCI USA, V97, P4321, DOI 10.1073/pnas.97.8.4321
   WINOCUR G, 1990, BEHAV BRAIN RES, V38, P145, DOI 10.1016/0166-4328(90)90012-4
   Wolf OT, 2004, ANN NY ACAD SCI, V1032, P195, DOI 10.1196/annals.1314.019
   ZOLAMORGAN SM, 1990, SCIENCE, V250, P288, DOI 10.1126/science.2218534
NR 140
TC 5
Z9 5
U1 3
U2 12
PU WALTER DE GRUYTER GMBH
PI BERLIN
PA GENTHINER STRASSE 13, D-10785 BERLIN, GERMANY
SN 0334-1763
EI 1607-8470
J9 REV NEUROSCIENCE
JI Rev. Neurosci.
PY 2007
VL 18
IS 5
BP 365
EP 382
PG 18
WC Neurosciences
SC Neurosciences & Neurology
GA 238EC
UT WOS:000251429100003
PM 19544623
DA 2018-12-27
ER

PT J
AU Soultanis, KC
   Payatakes, AH
   Chouliaras, VT
   Mandellos, GC
   Pyrovolou, NE
   Pliarchopoulou, FM
   Soucacos, PN
AF Soultanis, Konstantinos C.
   Payatakes, Alexandros H.
   Chouliaras, Vasilios T.
   Mandellos, Georgios C.
   Pyrovolou, Nikolaos E.
   Pliarchopoulou, Fani M.
   Soucacos, Panayotis N.
TI RETRACTED: Rare causes of scoliosis and spine deformity: experience and
   particular features (Retracted article. See vol. 13, art no 9, 2018)
SO SCOLIOSIS AND SPINAL DISORDERS
LA English
DT Article; Retracted Publication
AB Background: Spine deformity can be idiopathic (more than 80% of cases), neuromuscular, congenital or neurofibromatosis-related. However, there are many disorders that may also be involved. We present our experience treating patients with scoliosis or other spine deformities related to rare clinical entities.
   Methods: A retrospective study of the records of a school-screening study in North-West Greece was performed, covering a 10-year period (1992-2002). The records were searched for patients with deformities related to rare disorders. These patients were reviewed as regards to characteristics of underlying disorder and spine deformity, treatment and results, complications, intraoperative and anaesthesiologic difficulties particular to each case.
   Results: In 13 cases, the spine deformity presented in relation to rare disorders. The underlying disorder was rare neurological disease in 2 cases (Rett syndrome, progressive hemidystonia), muscular disorders (facioscapulohumeral muscular dystrophy, arthrogryposis) in 2 patients, osteogenesis imperfecta in 2 cases, Marfan syndrome, osteopetrosis tarda, spondyloepiphyseal dysplasia congenita, cleidocranial dysplasia and Noonan syndrome in 1 case each. In 2 cases scoliosis was related to other congenital anomalies (phocomelia, blindness). Nine of these patients were surgically treated. Surgery was avoided in 3 patients.
   Conclusion: This study illustrates the fact that different disorders are related with curves with different characteristics, different accompanying problems and possible complications. Investigation and understanding of the underlying pathology is an essential part of the clinical evaluation and preoperative work-up, as clinical experience at any specific center is limited.
C1 [Soultanis, Konstantinos C.; Pyrovolou, Nikolaos E.; Soucacos, Panayotis N.] Univ Athens, Attikon Hosp, Sch Med, Dept Orthopaed Surg 1, Rimini 1 Haidari, Athens 12462, Greece.
   [Payatakes, Alexandros H.; Chouliaras, Vasilios T.; Mandellos, Georgios C.] Univ Ioannina, Sch Med, Dept Orthopaed Surg, Ioannina 45110, Greece.
   [Payatakes, Alexandros H.] Duke Univ, Med Ctr, Dept Surg, Div Orthopaed Surg, Durham, NC 27710 USA.
   [Pliarchopoulou, Fani M.] Univ Athens, Attikon Hosp, Sch Med, Dept Internal Med 4, Athens 12462, Greece.
RP Soultanis, KC (reprint author), Univ Athens, Attikon Hosp, Sch Med, Dept Orthopaed Surg 1, Rimini 1 Haidari, Athens 12462, Greece.
EM ksoultanis@otenet.gr; apayatakes@hotmail.com; vhoulio@yahoo.gr;
   gmandellos@yahoo.co.uk; nikpyr@otenet.gr; kpliarc@otenet.gr;
   soukakos@panafone.grt
CR AULISA L, 1986, Italian Journal of Orthopaedics and Traumatology, V12, P85
   Banta J V, 1999, Instr Course Lect, V48, P551
   Benichou OD, 2000, BONE, V26, P87, DOI 10.1016/S8756-3282(99)00244-6
   BENSON DR, 1981, CLIN ORTHOP RELAT R, P147
   Codsi M J, 2000, Am J Orthop (Belle Mead NJ), V29, P383
   Cooper SC, 2001, AM J MED GENET, V104, P1, DOI 10.1002/ajmg.10024
   CRISTOFARO RL, 1979, CLIN ORTHOP RELAT R, P40
   Dearlove OR, 1996, PAEDIATR ANAESTH, V6, P155, DOI 10.1111/j.1460-9592.1996.tb00381.x
   DORE DD, 1987, CLIN ORTHOP RELAT R, P229
   Furukawa Y, 2000, NEUROLOGY, V54, P2187, DOI 10.1212/WNL.54.11.2187
   Hauser FM, 1999, ANASTH INTENSIV NOTF, V34, P582
   Huang T J, 1994, Orthop Rev, V23, P931
   Karbowski A, 1999, Z ORTHOP GRENZGEB, V137, P219, DOI 10.1055/s-2008-1037397
   KILMER DD, 1995, AM J PHYS MED REHAB, V74, pS131, DOI 10.1097/00002060-199509001-00007
   Lee CK, 2001, J BONE JOINT SURG AM, V83A, P1495, DOI 10.2106/00004623-200110000-00006
   LESTER DK, 1986, CLIN ORTHOP RELAT R, P205
   Lipton GE, 2002, J PEDIATR ORTHOPED, V22, P302, DOI 10.1097/00004694-200205000-00006
   MICHELI F, 1991, CLIN NEUROPHARMACOL, V14, P367, DOI 10.1097/00002826-199108000-00009
   NEL G, 1983, S AFR MED J, V63, P893
   Parisini P, 1996, Chir Organi Mov, V81, P129
   POWERS TA, 1983, J PEDIATR ORTHOPED, V3, P471, DOI 10.1097/01241398-198309000-00010
   Roberts W, 1995, AANA J, V63, P332
   ROBINS PR, 1975, J BONE JOINT SURG AM, VA 57, P358, DOI 10.2106/00004623-197557030-00014
   SCRANTON PE, 1978, J BONE JOINT SURG AM, V60, P363, DOI 10.2106/00004623-197860030-00017
   Soucacos PN, 1997, J BONE JOINT SURG AM, V79A, P1498, DOI 10.2106/00004623-199710000-00006
   Soultanis K, 2000, ACTA ORTHOP TRAUMATO, V51, P407
   Sponseller PD, 2000, SPINE, V25, P2797, DOI 10.1097/00007632-200011010-00012
   SPONSELLER PD, 1995, J BONE JOINT SURG AM, V77A, P867, DOI 10.2106/00004623-199506000-00007
   Sponseller PD, 2000, SPINE, V25, P2350, DOI 10.1097/00007632-200009150-00013
   Stein I, 1955, LIVING BONE HLTH DIS, P1532
   Taglialavoro G, 1983, Ital J Orthop Traumatol, V9, P507
   Tolo V T, 1990, Instr Course Lect, V39, P399
   TREVATHAN E, 1988, ANN NEUROL, V23, P425
   Watanabe N, 2000, Masui, V49, P62
   Westerlund LE, 2000, SPINE, V25, P265, DOI 10.1097/00007632-200001150-00020
   Widmann RF, 1999, SPINE, V24, P1673, DOI 10.1097/00007632-199908150-00008
   WINTER S, 1994, ORTHOP CLIN N AM, V25, P239
NR 37
TC 9
Z9 12
U1 0
U2 1
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1748-7161
J9 SCOLIOSIS SPINAL DIS
JI Scoliosis Spinal Disord.
PY 2007
VL 2
AR 15
DI 10.1186/1748-7161-2-15
PG 10
WC Orthopedics
SC Orthopedics
GA V10NH
UT WOS:000214216800015
PM 17956633
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Hosseinkhani, H
   Hosseinkhani, M
   Tian, FR
   Kobayashi, H
   Tabata, Y
AF Hosseinkhani, Hossein
   Hosseinkhani, Mohsen
   Tian, Furong
   Kobayashi, Hisatoshi
   Tabata, Yasuhiko
TI RETRACTED: Bone regeneration on a collagen sponge self-assembled
   peptide-amphiphile nanofiber hybrid scaffold (Retracted article. See
   vol. 21, pg. 2777, 2015)
SO TISSUE ENGINEERING
LA English
DT Article; Retracted Publication
ID FIBROBLAST-GROWTH-FACTOR; MESENCHYMAL STEM-CELLS; CONTROLLED-RELEASE;
   IN-VIVO; PERFUSION CULTURE; FACTOR BFGF; HYDROGELS; REPAIR;
   DIFFERENTIATION; GRAFTS
AB The objective of this study was to create a novel approach to promote bone induction through sustained release of growth factor from a 3-dimensional (3D) hybrid scaffold. Peptide-amphiphile (PA) was synthesized by standard solid-phase chemistry that ends with the alkylation of the NH2 terminus of the peptide. Collagen sponge was reinforced by incorporation of poly(glycolic acid) (PGA) fiber. A 3D network of nanofibers was formed by mixing basic fibroblast growth factor (bFGF) suspensions with dilute aqueous solutions of PA. A hybrid scaffold was fabricated by combination of self-assembled PA nanofibers and collagen sponge reinforced with incorporation of PGA fibers. The in vitro release profile of bFGF from hybrid scaffold was investigated, and ectopic bone formation induced by the released bFGF was assessed after subcutaneous implantation of hybrid scaffold into the backs of rats. Homogeneous bone formation was histologically observed throughout the hybrid scaffolds, in marked contrast to collagen sponge-incorporated bFGF. The level of alkaline phosphatase activity and osteocalcin content at the implanted sites of hybrid scaffolds were significantly high compared with collagen sponge incorporated with bFGF. The combination of bFGF incorporated in a collagen sponge self-assembled PA nanofiber hybrid scaffold is a promising procedure to improve bone regeneration.
C1 Natl Inst Mat Sci, Int Ctr Young Scientists, Ibaraki, Japan.
   Kyoto Univ Hosp, Grad Sch Med, Dept Cardiovasc Med, Kyoto 606, Japan.
   Natl Inst Mat Sci, Ctr Biomat, Ibaraki, Japan.
   Tokyo Med & Dent Univ, Inst Biomat & Bioengn, Tokyo, Japan.
   Kyoto Univ, Inst Frontier Med Sci, Dept Biomat Field Tissue Engn, Kyoto, Japan.
RP Hosseinkhani, H (reprint author), Natl Inst Mat Sci, Int Ctr Young Scientists, Ibaraki, Japan.
EM hossein.hosseinkhani@nims.go.jp
RI kobayashi, hisatoshi/H-2720-2011
OI kobayashi, hisatoshi/0000-0001-9487-0725; Tian,
   Furong/0000-0002-4953-1131
CR Andreopoulos FM, 2006, BIOMATERIALS, V27, P2468, DOI 10.1016/j.biomaterials.2005.11.019
   Cai SS, 2005, BIOMATERIALS, V26, P6054, DOI 10.1016/j.biomaterials.2005.03.012
   Christodoulou AG, 2006, CLIN ORTHOP RELAT R, P60, DOI 10.1097/01.blo.0000201175.87635.28
   Dogan AK, 2005, J BIOMED MATER RES B, V74B, P504
   DOWNS EC, 1992, J CELL PHYSIOL, V152, P422, DOI 10.1002/jcp.1041520225
   EDELMAN ER, 1991, BIOMATERIALS, V12, P619, DOI 10.1016/0142-9612(91)90107-L
   FIELDS GB, 1990, INT J PEPT PROT RES, V35, P161, DOI 10.1111/j.1399-3011.1990.tb00939.x
   Hartgerink JD, 2001, SCIENCE, V294, P1684, DOI 10.1126/science.1063187
   Hendrich C, 2006, J BONE JOINT SURG AM, V88A, P387, DOI 10.2106/JBJS.D.02373
   Hosseinkhani H, 2006, BIOMATERIALS, V27, P1387, DOI 10.1016/j.biomaterials.2005.08.017
   Hosseinkhani H, 2005, TISSUE ENG, V11, P1476, DOI 10.1089/ten.2005.11.1476
   IWAKURA A, 2001, CIRCULATION, V104, P1325
   KAWAGUCHI H, 1994, ENDOCRINOLOGY, V135, P774, DOI 10.1210/en.135.2.774
   Kawai K, 2001, J BIOMED MATER RES, V57, P346, DOI 10.1002/1097-4636(20011205)57:3<346::AID-JBM1177>3.0.CO;2-8
   Kawamura K, 2006, PLAST RECONSTR SURG, V117, P1471, DOI 10.1097/01.prs.0000197883.17428.22
   Keizer SB, 2006, J BONE JOINT SURG BR, V88B, P460, DOI 10.1302/0301-620x.88b4.16950
   LADOKHIN AS, 2000, ENCY ANAL CHEM, P5762
   Lieberman JR, 2002, J BONE JOINT SURG AM, V84A, P1032, DOI 10.2106/00004623-200206000-00022
   Ma ZW, 2005, TISSUE ENG, V11, P101, DOI 10.1089/ten.2005.11.101
   MONT MA, 1998, CLIN ORTHOP S, V355, P314
   Movassaghi K, 2006, PLAST RECONSTR SURG, V117, P202, DOI 10.1097/01.prs.0000187152.48402.17
   NAGAI H, 1995, BONE, V16, P367, DOI 10.1016/8756-3282(94)00049-2
   Ozeki M, 2002, TISSUE ENG, V8, P359, DOI 10.1089/107632702760184637
   RODAN SB, 1989, CONNECT TISSUE RES, V20, P283, DOI 10.3109/03008208909023898
   SHIN H, 2003, BIOMATERIALS, V24, P353
   Silva GA, 2004, SCIENCE, V303, P1352, DOI 10.1126/science.1093783
   Smith LA, 2004, COLLOID SURFACE B, V39, P125, DOI 10.1016/j.colsurfb.2003.l2.004
   Tabata Y, 1998, BIOMATERIALS, V19, P807, DOI 10.1016/S0142-9612(98)00233-6
   Tabata Y, 1999, BIOMATERIALS, V20, P2169, DOI 10.1016/S0142-9612(99)00121-0
   TAYLOR JM, 1972, J BIOL CHEM, V247, P5928
   Tsuda H, 2003, MOL THER, V7, P354, DOI 10.1016/S1525-0016(02)00062-X
   Ueda H, 2002, BIOMATERIALS, V23, P1003, DOI 10.1016/S0142-9612(01)00211-3
   Woo KM, 2003, J BIOMED MATER RES A, V67A, P531, DOI 10.1002/jbm.a.10098
   Yamagiwa H, 2001, J BONE MINER METAB, V19, P20, DOI 10.1007/s007740170056
NR 34
TC 72
Z9 74
U1 2
U2 30
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 2152-4947
J9 TISSUE ENG
JI Tissue Eng.
PD JAN
PY 2007
VL 13
IS 1
BP 11
EP 19
DI 10.1089/ten.2006.0120
PG 9
WC Cell & Tissue Engineering
SC Cell Biology
GA 130PU
UT WOS:000243812300003
PM 17518577
DA 2018-12-27
ER

PT J
AU Khatami, M
AF Khatami, Mahmoud
TI RETRACTED: On the illuminationist approach to imaginal power: outline of
   a perspective (Retracted article. See vol. 34, pg. 307, 2015)
SO TOPOI-AN INTERNATIONAL REVIEW OF PHILOSOPHY
LA English
DT Article; Retracted Publication
DE illuminationism; imaginal power; imagination; knowledge by presence;
   Mulla Sadra; Ontetic; Sohravardi
AB Imagination has always been a mysterious issue for modem philosophy and psychology. In this paper, however, I will not deal with modem theories of imagination; instead, I will suggest an alternative notion of imaginal power by stepping back toward Persian illuminative thought within which we may glimpse a hint of a transcendent concept of imagination as the source of human subjectivity and its power to create the object and the world. My objective here is to extend some noetic aspects of this concept and extract further conclusions theoretically. To this end, I will first introduce a brief account of the noetic characteristic of the Illuminationist perspective of the imagination, then I outline aspects of its efficiency which may shed some light on the modem debate on the subject and its relation to the object.
C1 Univ Tehran, Tehran, Iran.
RP Khatami, M (reprint author), Univ Tehran, 16 Azar St,Enghelab Ave, Tehran, Iran.
EM mahmoud.khatami@gmail.com
CR ALDIN SS, 1976, MAJMUAH MUSANNAFAT S
   ALSAFA I, 1957, RASAIL
   Chittick W, 1989, SUFI PATH KNOWLEDGE
   CHITTICK WC, 1995, IMAGINAL WORLDS IBNA
   Corbin H., 1971, EN ISLAM IRANIEN ASP, V2
   Corbin H., 1960, TERRE CELESTE CORPS
   CORBIN H, 1976, IMAGINATION MUNDUS I
   Corbin Henry, 1981, CREATIVE IMAGINATION
   DAMAD M, 1983, QABASAT
   FARABI, 1983, FUSUS ALHIKAM
   KHATAMI M, 2004, SADRAEAN POINT VIEW
   NASR SH, 1963, HIST MUSLIM PHILOS, V1
   SADRA M, 1981, ASFAR
   SADRA M, 1983, TAFSIR QURAN KARIM
   SHAYEGAN D, 1990, H CORBIN
   SINA I, ALSHIFA
   Ziai H., 1996, HIST ISLAMIC PHILOS, P434
   Ziai Hossein, 1990, KNOWLEDGE ILLUMINATI
NR 18
TC 2
Z9 2
U1 1
U2 4
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0167-7411
EI 1572-8749
J9 TOPOI-INT REV PHILOS
JI Topoi-Int. Rev. Philos.
PY 2007
VL 26
IS 2
BP 221
EP 229
DI 10.1007/s11245-007-9015-y
PG 9
WC Philosophy
SC Philosophy
GA 210PQ
UT WOS:000249468500006
DA 2018-12-27
ER

PT J
AU Yoo, HS
   Eah, JY
   Kim, JS
   Kim, YJ
   Min, MS
   Paek, WK
   Lee, H
   Kim, CB
AF Yoo, Hye Sook
   Eah, Jae-Yong
   Kim, Jong Soo
   Kim, Young-Jun
   Min, Mi-Sook
   Paek, Woon Kee
   Lee, Hang
   Kim, Chang-Bae
TI RETRACTED: DNA barcoding Korean birds (Retracted article. See vol. 35,
   pg. 357, 2013)
SO MOLECULES AND CELLS
LA English
DT Article; Retracted Publication
DE bird; DNA barcode; Korea; mitochondrial cytochrome C oxidase I;
   phylogeny
ID GENE; SEQUENCES; TREES
AB DNA barcoding, an inventory of DNA sequences from a standardized genomic region, provides a bio-barcode for identifying and discovering species. Several recent studies suggest that the sequence diversity in a 648 by region of the mitochondrial gene for cytochrome c oxidase I (COI) might serve as a DNA barcode for identifying animal species such as North American birds, insects and fishes. The present study tested the effectiveness of a COI barcode in discriminating Korean bird species. We determined the 5' terminus of the COI barcode for 92 species of Korean birds and found that species identification was unambiguous; the genetic differences between closely related species were, on average, 25 times higher than the differences within species. We identified only one misidentified species out of 239 specimens in a genetic resource bank, so confirming the accuracy of species identification in the banking system. We also identified two potential composite species, calling for further investigation using more samples. The finding of large COI sequence differences between species confirms the effectiveness of COI barcodes for identifying Korean bird species. To bring greater reliability to the identification of species, increased intra- and interspecies sampling, as well as supplementation of the mitochondrial barcodes with nuclear ones, is needed.
C1 Korea Res Inst Biosci & Biotechnol, Korea Bioinformat Ctr, Biol Resource Ctr, Taejon 305333, South Korea.
   Natl Sci Museum, Nat Hist Team, Taejon 305705, South Korea.
   Seoul Natl Univ, Coll Vet Med, CGRB, Conservat Genome Resource Bank Korean Wildlife, Seoul 151742, South Korea.
   Seoul Natl Univ, Program Vet Sci BK21, Seoul 151742, South Korea.
   Hankuk Acad Foreign Studies, Yongin 449854, South Korea.
RP Kim, CB (reprint author), Korea Res Inst Biosci & Biotechnol, Korea Bioinformat Ctr, Biol Resource Ctr, Taejon 305333, South Korea.
EM changbae@kribb.re.kr
CR Hajibabaei M, 2006, P NATL ACAD SCI USA, V103, P968, DOI 10.1073/pnas.0510466103
   Hebert PDN, 2004, P NATL ACAD SCI USA, V101, P14812, DOI 10.1073/pnas.0406166101
   Hebert PDN, 2003, P ROY SOC B-BIOL SCI, V270, P313, DOI 10.1098/rspb.2002.2218
   Hebert PDN, 2004, PLOS BIOL, V2, P1657, DOI 10.1371/journal.pbio.0020312
   HOWARD R, 1998, COMPLETE CHECKLIST B
   Johns GC, 1998, MOL BIOL EVOL, V15, P1481, DOI 10.1093/oxfordjournals.molbev.a025875
   KIMURA M, 1980, J MOL EVOL, V16, P111, DOI 10.1007/BF01731581
   Klicka J, 1997, SCIENCE, V277, P1666, DOI 10.1126/science.277.5332.1666
   Kumar S, 2004, BRIEF BIOINFORM, V5, P150, DOI 10.1093/bib/5.2.150
   Lee W, 2000, FIELD GUIDE BIRDS KO
   MOORE WS, 1995, EVOLUTION, V49, P718, DOI 10.1111/j.1558-5646.1995.tb02308.x
   SAITOU N, 1987, MOL BIOL EVOL, V4, P406
   Smith MA, 2006, P NATL ACAD SCI USA, V103, P3657, DOI 10.1073/pnas.0511318103
   Ward RD, 2005, PHILOS T R SOC B, V360, P1847, DOI 10.1098/rstb.2005.1716
   Weibel AC, 2002, MOL PHYLOGENET EVOL, V22, P65, DOI 10.1006/mpev.2001.1010
NR 15
TC 77
Z9 108
U1 3
U2 27
PU KOREAN SOC MOLECULAR & CELLULAR  BIOLOGY
PI SEOUL
PA 635-4, YUCKSAM-DONG, GANGNAM-GU, SEOUL 135-703, SOUTH KOREA
SN 1016-8478
EI 0219-1032
J9 MOL CELLS
JI Mol. Cells
PD DEC 31
PY 2006
VL 22
IS 3
BP 323
EP 327
PG 5
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 124LY
UT WOS:000243370500011
PM 17202861
DA 2018-12-27
ER

PT J
AU Moissiard, G
   Voinnet, O
AF Moissiard, Guillaume
   Voinnet, Olivier
TI RETRACTED: RNA silencing of host transcripts by cauliflower mosaic virus
   requires coordinated action of the four Arabidopsis Dicer-like proteins
   (Retracted article. See vol. 112, pg. E4818, 2015)
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article; Retracted Publication
ID PLANT; GENE; BIOGENESIS; SUPPRESSION; THALIANA; PATHWAYS; SIRNAS;
   INTERFERENCE; DICER-LIKE-4; EXPRESSION
AB RNA silencing is an ancient mechanism of gene regulation with important antiviral roles in plants and insects. Although induction of RNA silencing by RNA viruses has been well documented in plants, the interactions between DNA viruses and the host silencing machinery remain poorly understood. We investigate this question with cauliflower mosaic virus (CaMV), a dsDNA virus that expresses its genome through the polycistronic 355 RNA, which carries an unusually extensive secondary structure known as translational leader. We show that CaMV-derived siRNAs accumulate in turnip- and Arabidopsis-infected plants and that the leader is a major, albeit not exclusive, source for those molecules. Biogenesis of leader-derived siRNA requires the coordinated and hierarchical action of the four Arabidopsis Dicer-like (DCL) proteins. Our study also uncovers a "facilitating" role exerted by the microRNA bio-synthetic enzyme DCL1 on accumulation of DCL2-, DCL3-, and DCL4-dependent siRNAs derived from the 355 leader. This feature of DCL1 defines a small RNA biosynthetic pathway that might have relevance for endogenous gene regulation. Several leader-derived siRNAs were found to bear near-perfect sequence complementalrity to Arabidopsis transcripts, and, using a sensor transgene, we provide direct evidence that at least one of those molecules acts as a bona fide siRNIA in infected turnip. Extensive bioinformatics searches identified > 100 transcripts potentially targeted by CaMV-derived siRNAs, several of which are effectively down-regulated during infection. The implications of virus-directed silencing of host gene expression are discussed.
C1 CNRS, Inst Biol Mol Plantes, Unite Propre Rech 2357, F-67084 Strasbourg, France.
RP Voinnet, O (reprint author), CNRS, Inst Biol Mol Plantes, Unite Propre Rech 2357, 12 Rue Gen Zimmer, F-67084 Strasbourg, France.
EM olivier.voinnet@ibmp-ulp.u-strasbg.fr
CR Akbergenov R, 2006, NUCLEIC ACIDS RES, V34, P462, DOI 10.1093/nar/gkj447
   Al-Kaff NS, 1998, SCIENCE, V279, P2113, DOI 10.1126/science.279.5359.2113
   Al-Kaff NS, 2000, NAT BIOTECHNOL, V18, P995, DOI 10.1038/79501
   Allen E, 2005, CELL, V121, P207, DOI 10.1016/j.cell.2005.04.004
   Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5
   Baulcombe D, 2004, NATURE, V431, P356, DOI 10.1038/nature02874
   Borsani O, 2005, CELL, V123, P1279, DOI 10.1016/j.cell.2005.11.035
   Bouche N, 2006, EMBO J, V25, P3347, DOI 10.1038/sj.emboj.7601217
   Brodersen P, 2006, TRENDS GENET, V22, P268, DOI 10.1016/j.tig.2006.03.003
   Chellappan P, 2004, J VIROL, V78, P7465, DOI 10.1128/JVI.78.14.7465-7477.2004
   Cullen BR, 2006, NAT GENET, V38, pS25, DOI 10.1038/ng1793
   Deleris A, 2006, SCIENCE, V313, P68, DOI 10.1126/science.1128214
   Dominguez DI, 1998, J BIOL CHEM, V273, P3669, DOI 10.1074/jbc.273.6.3669
   Dunoyer P, 2005, NAT GENET, V37, P1356, DOI 10.1038/ng1675
   Dunoyer P, 2005, CURR OPIN PLANT BIOL, V8, P415, DOI 10.1016/j.pbi.2005.05.012
   Gasciolli V, 2005, CURR BIOL, V15, P1494, DOI 10.1016/j.cub.2005.07.024
   Golden TA, 2002, PLANT PHYSIOL, V130, P808, DOI 10.1104/pp.003491
   Gupta A, 2006, NATURE, V442, P82, DOI 10.1038/nature04836
   Jacobsen SE, 1999, DEVELOPMENT, V126, P5231
   Kurihara Y, 2004, P NATL ACAD SCI USA, V101, P12753, DOI 10.1073/pnas.0403115101
   Lee Y, 2003, NATURE, V425, P415, DOI 10.1038/nature01957
   LEISNER SM, 1993, PLANT CELL, V5, P191
   Park W, 2002, CURR BIOL, V12, P1484, DOI 10.1016/S0960-9822(02)01017-5
   Pooggin MM, 2000, J BIOL CHEM, V275, P17288, DOI 10.1074/jbc.M001143200
   Ryabova LA, 2000, GENE DEV, V14, P817
   Silhavy D, 2004, TRENDS PLANT SCI, V9, P76, DOI 10.1016/j.tplants.2003.12.010
   Szittya G, 2002, PLANT CELL, V14, P359, DOI 10.1105/tpc.010366
   Vaucheret H, 2006, GENE DEV, V20, P759, DOI 10.1101/gad.1410506
   Voinnet O, 2005, NAT REV GENET, V6, P206, DOI 10.1038/nrg1555
   Voinnet O, 2003, PLANT J, V33, P949, DOI 10.1046/j.1365-313X.2003.01676.x
   Wang MB, 2004, P NATL ACAD SCI USA, V101, P3275, DOI 10.1073/pnas.0400104101
   Wang XH, 2006, SCIENCE, V312, P452, DOI 10.1126/science.1125694
   Whitham SA, 2003, PLANT J, V33, P271, DOI 10.1046/j.1365-313X.2003.01625.x
   Xie ZX, 2005, P NATL ACAD SCI USA, V102, P12984, DOI 10.1073/pnas.0506426102
   Xie ZX, 2004, PLOS BIOL, V2, P642, DOI 10.1371/journal.pbio.0020104
   Yu B, 2005, SCIENCE, V307, P932, DOI 10.1126/science.1107130
   Yu WC, 2003, MOL PLANT MICROBE IN, V16, P35, DOI 10.1094/MPMI.2003.16.1.35
   Zhang YJ, 2005, NUCLEIC ACIDS RES, V33, pW701, DOI 10.1093/nar/gki383
NR 38
TC 167
Z9 176
U1 41
U2 68
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD DEC 19
PY 2006
VL 103
IS 51
BP 19593
EP 19598
DI 10.1073/pnas.0604627103
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 121OJ
UT WOS:000243166600067
PM 17164336
OA Green Published, Bronze
DA 2018-12-27
ER

PT J
AU Sahoo, NK
   Tokas, RB
   Thakur, S
AF Sahoo, N. K.
   Tokas, R. B.
   Thakur, S.
TI RETRACTED: Analysis of codeposited Gd2O3/SiO2 composite thin films by
   phase modulated spectroscopic ellipsometric technique (Retracted
   article. See vol. 427, pg. 1280, 2018)
SO APPLIED SURFACE SCIENCE
LA English
DT Article; Retracted Publication
DE optical coatings; codeposition; electron beam evaporation; thin film
   multilayers; ellipsometry; spectrophotometry; atomic force microscopy;
   composite films
ID INHOMOGENEOUS OPTICAL COATINGS; STABILIZED ZIRCONIA; REFRACTIVE-INDEX;
   MICROSTRUCTURAL PROPERTIES; INTRINSIC STRESS; DIELECTRIC FILMS; SOL-GEL;
   ULTRAVIOLET; EVAPORATION; MICROSCOPY
AB Tailoring of the refractive index of optical thin films has been a very fascinating as well as challenging topic for developing new generation optical coatings. In the present work a novel Gd2O3/SiO2 composite system has been experimented and probed for its superior optical properties through phase modulated spectroscopic ellipsometry, spectrophotometry and atomic force microscopy. The optical parameters of the composite films have been evaluated using Tauc-Lorentz (TL) formulations. In order to derive the growth dependent refractive index profiles, each sample film has been modeled as an appropriate multilayer structure where each sub-layer was treated with the above TL parameterizations. All codeposited films demonstrated superiority with respect to the band gap and morphological measurements. At lower silica mixing compositions such as in 10-20% level, the composite films depicted superior spectral refractive index profile, band gap as well as the morphology. This aspect highlighted the fact that microstructural densifications in composite films can override the chemical compositions while deciding the refractive index and optical properties in such thin films. (c) 2006 Elsevier B.V. All rights reserved.
C1 Bhabha Atom Res Ctr, Spect Div, Bombay 400085, Maharashtra, India.
RP Sahoo, NK (reprint author), Bhabha Atom Res Ctr, Spect Div, Bombay 400085, Maharashtra, India.
EM nksahoo@apsara.barc.ernet.in
CR Alvarez-Herrero A, 2004, THIN SOLID FILMS, V455, P356, DOI 10.1016/j.tsf.2004.01.023
   BATES B, 1966, APPL OPTICS, V5, P971, DOI 10.1364/AO.5.000971
   BERTRAM R, 1989, APPL OPTICS, V28, P2935, DOI 10.1364/AO.28.002935
   BRADFORD AP, 1969, APPL OPTICS, V8, P1183, DOI 10.1364/AO.8.001183
   CAMAGNI P, 1992, SOLID STATE COMMUN, V83, P943, DOI 10.1016/0038-1098(92)90916-W
   Chen H, 2005, EUR PHYS J B, V43, P503, DOI 10.1140/epjb/e2005-00083-9
   CHINDAUDOM P, 1994, APPL OPTICS, V33, P2664, DOI 10.1364/AO.33.002664
   Cho YJ, 2002, APPL PHYS LETT, V80, P1249, DOI 10.1063/1.1448384
   Dakhel AA, 2001, J OPT A-PURE APPL OP, V3, P452, DOI 10.1088/1464-4258/3/6/304
   DELARIVIERE GP, 1992, APPL OPTICS, V31, P6056, DOI 10.1364/AO.31.006056
   Diebold AC, 2001, MAT SCI SEMICON PROC, V4, P3, DOI 10.1016/S1369-8001(00)00153-0
   Eva E, 1996, APPL OPTICS, V35, P5613, DOI 10.1364/AO.35.005613
   FARABAUGH EN, 1983, J VAC SCI TECHNOL A, V1, P356, DOI 10.1116/1.572134
   FARABAUGH EN, 1987, J VAC SCI TECHNOL A, V5, P1671, DOI 10.1116/1.574544
   FELDMAN A, 1986, J VAC SCI TECHNOL A, V4, P2969, DOI 10.1116/1.573610
   GLUCK NS, 1991, J APPL PHYS, V69, P3037, DOI 10.1063/1.348591
   Howitt D. G., 1987, Journal of Materials Research, V2, P201, DOI 10.1557/JMR.1987.0201
   JACOBSSON R, 1966, APPL OPTICS, V5, P29, DOI 10.1364/AO.5.000029
   Jacobsson R., 1975, PHYS THIN FILMS, V8, P51
   Jellison GE, 2000, THIN SOLID FILMS, V377, P68, DOI 10.1016/S0040-6090(00)01384-5
   Jellison GE, 1996, APPL PHYS LETT, V69, P371, DOI 10.1063/1.118064
   JUN N, 2002, COMP PHYS COMMUN, V14, P234
   Koo WH, 2004, J VAC SCI TECHNOL A, V22, P2048, DOI 10.1116/1.1782638
   Kriventsov VV, 2001, NUCL INSTRUM METH A, V470, P347, DOI 10.1016/S0168-9002(01)01072-5
   Lee H, 2001, J APPL PHYS, V90, P813, DOI 10.1063/1.1378337
   NIKLASSON GA, 1981, APPL OPTICS, V20, P26, DOI 10.1364/AO.20.000026
   Osipov AV, 2005, THIN SOLID FILMS, V472, P31, DOI 10.1016/j.tsf.2004.06.102
   Portinha A, 2004, SURF COAT TECH, V188, P107, DOI 10.1016/j.surfcoat.2004.08.016
   Quesnel E, 2000, J VAC SCI TECHNOL A, V18, P2869, DOI 10.1116/1.1290374
   RAINER F, 1985, APPL OPTICS, V24, P496, DOI 10.1364/AO.24.000496
   Sahoo NK, 2003, THIN SOLID FILMS, V440, P155, DOI 10.1016/S0040-6090(03)00678-3
   Sahoo NK, 2002, APPL SURF SCI, V200, P219, DOI 10.1016/S0169-4332(02)00900-5
   SANKUR H, 1988, APPL OPTICS, V27, P1564, DOI 10.1364/AO.27.001564
   SANKUR H, 1989, J APPL PHYS, V66, P4747, DOI 10.1063/1.343784
   SANKUR H, 1989, J APPL PHYS, V66, P807, DOI 10.1063/1.343501
   SOUTHWELL WH, 1985, APPL OPTICS, V24, P457, DOI 10.1364/AO.24.000457
   Taylor MA, 2005, J EUR CERAM SOC, V25, P1591, DOI 10.1016/j.jeurceramsoc.2004.05.020
   TCHELIEBOU F, 1994, THIN SOLID FILMS, V249, P86, DOI 10.1016/0040-6090(94)90090-6
   Tikhonravov AV, 1997, APPL OPTICS, V36, P7188, DOI 10.1364/AO.36.007188
   Tikhonravov AV, 1998, APPL OPTICS, V37, P5902, DOI 10.1364/AO.37.005902
   Verly PG, 1998, APPL OPTICS, V37, P7327, DOI 10.1364/AO.37.007327
   von Blanckenhagen B, 2002, APPL OPTICS, V41, P3137, DOI 10.1364/AO.41.003137
   Yang JM, 2001, APPL OPTICS, V40, P3256, DOI 10.1364/AO.40.003256
   Yoon JG, 1998, J KOREAN PHYS SOC, V33, P699
NR 44
TC 5
Z9 5
U1 2
U2 12
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0169-4332
EI 1873-5584
J9 APPL SURF SCI
JI Appl. Surf. Sci.
PD DEC 15
PY 2006
VL 253
IS 4
BP 1787
EP 1795
DI 10.1016/j.apsusc.2006.03.013
PG 9
WC Chemistry, Physical; Materials Science, Coatings & Films; Physics,
   Applied; Physics, Condensed Matter
SC Chemistry; Materials Science; Physics
GA 122RM
UT WOS:000243244200017
DA 2018-12-27
ER

PT J
AU Leadon, SA
   Barbee, SL
   Dunn, AB
AF Leadon, Steven A.
   Barbee, Susan L.
   Dunn, Ann Bridget
TI RETRACTED: "The yeast RAD2, but not RAD1, gene is involved in the
   transcription-coupled repair of thymine glycols" (Retracted Article)
SO DNA REPAIR
LA English
DT Correction; Retracted Publication
ID COCKAYNE-SYNDROME PATIENTS; SEE; DAMAGE; XPG
CR Cooper PK, 1997, SCIENCE, V275, P990, DOI 10.1126/science.275.5302.990
   Cressman VL, 1999, MOL CELL BIOL, V19, P7061
   Gowen LC, 1998, SCIENCE, V281, P1009, DOI 10.1126/science.281.5379.1009
   Le Page F, 2000, CELL, V101, P159, DOI 10.1016/S0092-8674(00)80827-2
   Leadon SA, 1997, CANCER RES, V57, P3784
   LEADON SA, 1995, DNA REPAIR, V337, P169
   LEADON SA, 1997, MUTAT RES, V407, P177
   Nouspikel T, 1997, P NATL ACAD SCI USA, V94, P3116, DOI 10.1073/pnas.94.7.3116
NR 8
TC 0
Z9 0
U1 2
U2 7
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1568-7864
EI 1568-7856
J9 DNA REPAIR
JI DNA Repair
PD DEC 9
PY 2006
VL 5
IS 12
BP 1507
EP 1507
DI 10.1016/0921-8777
PG 1
WC Genetics & Heredity; Toxicology
SC Genetics & Heredity; Toxicology
GA 114KT
UT WOS:000242665800011
DA 2018-12-27
ER

PT J
AU Chandrasekaran, S
   Deffenbaugh, AE
   Ford, DA
   Bailly, E
   Mathias, N
   Skowyra, D
AF Chandrasekaran, Srikripa
   Deffenbaugh, Andrew E.
   Ford, David A.
   Bailly, Eric
   Mathias, Neal
   Skowyra, Dorota
TI RETRACTED: Destabilization of binding to cofactors and SCFMet30 is the
   rate-limiting regulatory step in degradation of polyubiquitinated Met4
   (Retracted article. See vol. 70, pg. 381, 2018)
SO MOLECULAR CELL
LA English
DT Article; Retracted Publication
ID TRANSCRIPTIONAL ACTIVATOR MET4; F-BOX PROTEINS;
   SACCHAROMYCES-CEREVISIAE; MULTIUBIQUITIN CHAIN; UBIQUITIN; YEAST;
   COMPLEX; METABOLISM; PROTEASOME; DOMAIN
AB The Met4 transcriptional activator of methionine biosynthesis is negatively regulated by the SCFMet30 ubiquitin ligase in response to accumulation of methionine. This mechanism requires polyubiquitination, but not proteolysis. We report that a previously unappreciated mechanism involving growth control regulates Met4. Unless methionine is present in the growth medium, polyubiquitinated Met4 is stabilized in late exponential cultures, correlating with transcriptional repression. Polyubiquitinated Met4 becomes destabilized in a proteasome-dependent manner upon reentry into exponential growth, correlating with transcriptional activation. Met4 stabilization is regulated at the level of SCFMet30 binding and requires transcriptional cofactors. These lock Met4 and SCFMet30 into a tight complex active in ubiquitination but incapable of binding the proteasome. Release of polyubiquitinated Met4 from SCFMet30 is sufficient for degradation, and specific sulfur amino acids can promote the degradation by destabilizing Met4 binding to cofactors and SCFMet30. Thus, destabilization of cofactors and SCFMet30 binding is the rate-limiting regulatory step in Met4 proteolysis.
C1 St Louis Univ, Sch Med, Edward A Doisy Dept Biochem & Mol Biol, St Louis, MO 63104 USA.
   Louisiana State Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, Shreveport, LA 71130 USA.
   CNRS, LISM, Marseille 20, France.
RP Skowyra, D (reprint author), St Louis Univ, Sch Med, Edward A Doisy Dept Biochem & Mol Biol, St Louis, MO 63104 USA.
EM skowyrad@slu.edu
OI Ford, David/0000-0002-0029-1560
FU NIGMS NIH HHS [GM65267]
CR Babbitt SE, 2005, CELL, V121, P553, DOI 10.1016/j.cell.2005.03.028
   Blaiseau PL, 1998, EMBO J, V17, P6327, DOI 10.1093/emboj/17.21.6327
   Blaiseau PL, 1997, MOL CELL BIOL, V17, P3640, DOI 10.1128/MCB.17.7.3640
   CAI MJ, 1990, CELL, V61, P437, DOI 10.1016/0092-8674(90)90525-J
   CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923
   Deffenbaugh AE, 2003, CELL, V114, P611, DOI 10.1016/S0092-8674(03)00641-X
   Dixon C, 2003, EUKARYOT CELL, V2, P123, DOI 10.1128/EC.2.1.123-133.2003
   Feldman RMR, 1997, CELL, V91, P221, DOI 10.1016/S0092-8674(00)80404-3
   Fleming JA, 2002, P NATL ACAD SCI USA, V99, P1461, DOI 10.1073/pnas.032516399
   Flick K, 2004, NAT CELL BIOL, V6, P634, DOI 10.1038/ncb1143
   Flick K, 2006, NAT CELL BIOL, V8, P509, DOI 10.1038/ncb1402
   Hansen J, 2000, MOL GEN GENET, V263, P535, DOI 10.1007/s004380051199
   Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425
   Kaiser P, 2000, CELL, V102, P303, DOI 10.1016/S0092-8674(00)00036-2
   Kuras L, 2002, MOL CELL, V10, P69, DOI 10.1016/S1097-2765(02)00561-0
   Kuras L, 1997, EMBO J, V16, P2441, DOI 10.1093/emboj/16.9.2441
   Kuras L, 1996, EMBO J, V15, P2519, DOI 10.1002/j.1460-2075.1996.tb00609.x
   KURAS L, 1995, MOL CELL BIOL, V15, P208, DOI 10.1128/MCB.15.1.208
   Leroy C, 2006, MOL CELL BIOL, V26, P3149, DOI 10.1128/MCB.26.8.3149-3163.2006
   Lipford JR, 2005, NATURE, V438, P113, DOI 10.1038/nature04098
   Menant A, 2006, J BIOL CHEM, V281, P11744, DOI 10.1074/jbc.M600037200
   Patton EE, 2000, EMBO J, V19, P1613, DOI 10.1093/emboj/19.7.1613
   Patton EE, 1998, GENE DEV, V12, P692, DOI 10.1101/gad.12.5.692
   Petroski MD, 2005, NAT REV MOL CELL BIO, V6, P9, DOI 10.1038/nrm1547
   ROSE MD, 1990, METHODS YEAST GENETI
   Rouillon A, 2000, EMBO J, V19, P282, DOI 10.1093/emboj/19.2.282
   Salghetti SE, 2001, SCIENCE, V293, P1651, DOI 10.1126/science.1062079
   Sekinger EA, 1999, EMBO J, V18, P7041, DOI 10.1093/emboj/18.24.7041
   Shearer AG, 2005, EMBO J, V24, P149, DOI 10.1038/sj.emboj.7600498
   Skowyra D, 1997, CELL, V91, P209, DOI 10.1016/S0092-8674(00)80403-1
   Skowyra D, 1999, SCIENCE, V284, P662, DOI 10.1126/science.284.5414.662
   Smothers DB, 2000, MOL CELL BIOL, V20, P7845, DOI 10.1128/MCB.20.21.7845-7852.2000
   Thomas D, 1997, MICROBIOL MOL BIOL R, V61, P503
   THOMPSON AH, 1995, CAN J PSYCHIAT, V40, P15, DOI 10.1177/070674379504000106
   Thrower JS, 2000, EMBO J, V19, P94, DOI 10.1093/emboj/19.1.94
   Verma R, 2004, CELL, V118, P99, DOI 10.1016/j.cell.2004.06.014
   Verma R, 2000, MOL BIOL CELL, V11, P3425, DOI 10.1091/mbc.11.10.3425
   WATSON TG, 1976, J GEN MICROBIOL, V96, P263, DOI 10.1099/00221287-96-2-263
NR 38
TC 25
Z9 25
U1 1
U2 2
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 1097-2765
EI 1097-4164
J9 MOL CELL
JI Mol. Cell
PD DEC 8
PY 2006
VL 24
IS 5
BP 689
EP 699
DI 10.1016/j.molcel.2006.10.028
PG 11
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 116OK
UT WOS:000242812000006
PM 17157252
OA Bronze
DA 2018-12-27
ER

PT J
AU Sui, Y
   Xiao, YA
   Fang, XN
   Zeng, XR
   Li, MH
AF Sui, Yan
   Xiao, Yi-An
   Fang, Xiao-Niu
   Zeng, Xi-Rui
   Li, Meng-Hua
TI RETRACTED: A new dinuclear Cu-II-Lu-III complex with a salen-type Schiff
   base ligand (Retracted article. See vol. 66, pg. e21, 2010)
SO ACTA CRYSTALLOGRAPHICA SECTION E-STRUCTURE REPORTS ONLINE
LA English
DT Article; Retracted Publication
ID MAGNETIC-PROPERTIES; GD
AB A heteronuclear Cu-II-Lu-III complex (systematic name: {6,6'-diethoxy-2,2'-[ethane-1,2-diylbis(nitrilomethylidyne)]diphenolato} trinitratolutetium(III) copper(II)), [CuLu(C20H22N2O4)(NO3)(3)], with the hexadentate Schiff base compartmental ligand N,N'-ethylenebis(3-ethoxy-salicylaldiimine) (H2L), has been synthesized and structurally characterized. The Cu and Lu atoms are doubly bridged by two phenolate O atoms afforded by the Schiff base ligand. No classical intermolecular hydrogen bonds are found. Some weak O (.) (.) (.) Cu and C - H (.) (.) (.) O interactions generate a two-dimensional zigzag sheet.
C1 JingGangShan Univ, Coll Life Sci, Jian 343009, Jiangxi, Peoples R China.
   JingGangShan Univ, Coll CHem & Chem Engn, JiangXi Province Key Lab Coordinat Chem, Jian 343009, Jiangxi, Peoples R China.
RP Xiao, YA (reprint author), JingGangShan Univ, Coll Life Sci, Jian 343009, Jiangxi, Peoples R China.
EM ysui@163.com
CR Baggio R, 2000, J CHEM SOC DALTON, P2061, DOI 10.1039/a909544f
   Brewer C, 2001, INORG CHIM ACTA, V313, P65, DOI 10.1016/S0020-1693(00)00354-6
   *BRUK, 2004, APEX2 VERS 1 22 SADA
   Caravan P, 1999, CHEM REV, V99, P2293, DOI 10.1021/cr980440x
   Edder C, 2000, INORG CHEM, V39, P5059, DOI 10.1021/ic000687o
   FLACK HD, 1983, ACTA CRYSTALLOGR A, V39, P876, DOI 10.1107/S0108767383001762
   Mohanta S, 2002, INORG CHEM COMMUN, V5, P585, DOI 10.1016/S1387-7003(02)00482-3
   Wong WK, 2002, NEW J CHEM, V26, P275, DOI 10.1039/b104175b
NR 8
TC 2
Z9 2
U1 5
U2 12
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1600-5368
J9 ACTA CRYSTALLOGR E
JI Acta Crystallogr. Sect. E.-Struct Rep. Online
PD DEC
PY 2006
VL 62
BP M3205
EP M3207
DI 10.1107/S160053680604565X
PN 12
PG 3
WC Crystallography
SC Crystallography
GA 111EQ
UT WOS:000242434600034
DA 2018-12-27
ER

PT J
AU Zhong, H
   Zeng, XR
   Liu, YQ
   Luo, QY
AF Zhong, H.
   Zeng, X. -R.
   Liu, Y. -Q.
   Luo, Q. -Y.
TI RETRACTED: Tris(quinolin-8-olato-kappa N-2,O)cobalt(III) glyoxal
   hemisolvate monohydrate (Retracted article. See vol. 66, pg. E11, 2010)
SO ACTA CRYSTALLOGRAPHICA SECTION E-STRUCTURE REPORTS ONLINE
LA English
DT Article; Retracted Publication
AB In the molecule of the title compound, [Co(C9H6NO)(3)]center dot-0.5C(2)H(2)O(2)center dot H2O, the Co atom has an octahedral coordination formed by three O and three N atoms from three quinolin-8-olate ligands. In the crystal structure, molecules are linked into a three-dimensional framework by O-H center dot center dot center dot O hydrogen bonds. The supramolecular structure is also consolidated by pi-pi stacking interactions. The glyoxal molecule lies on an inversion centre.
C1 Jinggangshan Univ, Provincial Key Lab Coordinat Chem, Coll Chem & Chem Engn, Jian 343009, Peoples R China.
RP Zhong, H (reprint author), Jinggangshan Univ, Provincial Key Lab Coordinat Chem, Coll Chem & Chem Engn, Jian 343009, Peoples R China.
EM huazhong06@126.com
CR ALLEN FH, 1987, J CHEM SOC PERK T 2, pS1, DOI 10.1039/p298700000s1
   BARTON JK, 1986, SCIENCE, V233, P727, DOI 10.1126/science.3016894
   DEISENHOFER J, 1989, EMBO J, V8, P2149, DOI 10.1002/j.1460-2075.1989.tb08338.x
   Li H, 2005, ACTA CRYSTALLOGR C, V61, pM19, DOI 10.1107/S0108270104029580
   Liu BX, 2004, ACTA CRYSTALLOGR C, V60, pM183, DOI 10.1107/S0108270104005529
   NAING K, 1995, INORG CHEM, V34, P350, DOI 10.1021/ic00105a054
   Pan TT, 2004, ACTA CRYSTALLOGR E, V60, pM56, DOI 10.1107/S1600536803028149
   Pope M. T., 1983, HETEROPOLY ISOPOLY O
   Pope M. T., 2001, POLYOXOMETALATE CHEM
   Sheldrick G. M., 1997, SHELXS97 SHELXL97
   Sheldrick G.M, 1996, SADABS
   *SIEM AN XRAY INST, 1996, SMART SAINT SHELXTL
   Wall M, 1999, J AM CHEM SOC, V121, P4710, DOI 10.1021/ja981227l
   Wu ZY, 2003, ACTA CRYSTALLOGR E, V59, pM809, DOI 10.1107/S1600536803018762
NR 14
TC 0
Z9 0
U1 4
U2 9
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1600-5368
J9 ACTA CRYSTALLOGR E
JI Acta Crystallogr. Sect. E.-Struct Rep. Online
PD DEC
PY 2006
VL 62
BP M3557
EP M3559
DI 10.1107/S1600536806050240
PN 12
PG 3
WC Crystallography
SC Crystallography
GA 111EQ
UT WOS:000242434600174
DA 2018-12-27
ER

PT J
AU Zhong, H
   Zeng, XR
   Luo, QY
AF Zhong, H.
   Zeng, X. -R.
   Luo, Q. -Y.
TI RETRACTED: cis-Dichlorobis(1,10-phenanthroline)cobalt(II) (Retracted
   article. See vol. 66, pg. E11, 2010)
SO ACTA CRYSTALLOGRAPHICA SECTION E-STRUCTURE REPORTS ONLINE
LA English
DT Article; Retracted Publication
AB In the molecule of the title compound, cis-[CoCl(2)(C(12)H(8)N(2))(2)], the Co(II) atom has a distorted octahedral coordination formed by four N atoms from two 1,10-phenanthroline ligands and two Cl atoms. In the crystal structure, molecules are linked into a three-dimensional framework by C-H center dot center dot center dot Cl hydrogen bonds. The supramolecular network is also consolidated by pi-pi stacking interactions.
C1 Jinggangshan Univ, Provincial Key Lab Coordinat Chem, Coll Chem & Chem Engn, Jian 343009, Peoples R China.
RP Zhong, H (reprint author), Jinggangshan Univ, Provincial Key Lab Coordinat Chem, Coll Chem & Chem Engn, Jian 343009, Peoples R China.
EM huazhong06@126.com
CR ALLEN FH, 1987, J CHEM SOC PERK T 2, pS1, DOI 10.1039/p298700000s1
   BARTON JK, 1986, SCIENCE, V233, P727, DOI 10.1126/science.3016894
   DEISENHOFER J, 1989, EMBO J, V8, P2149, DOI 10.1002/j.1460-2075.1989.tb08338.x
   Li H, 2005, ACTA CRYSTALLOGR C, V61, pM19, DOI 10.1107/S0108270104029580
   NAING K, 1995, INORG CHEM, V34, P350, DOI 10.1021/ic00105a054
   Pan TT, 2004, ACTA CRYSTALLOGR E, V60, pM56, DOI 10.1107/S1600536803028149
   Sheldrick G. M., 1997, SHELXS97 SHELXL97
   Sheldrick G.M, 1996, SADABS
   SIEMENS, 1996, SMART SAINT SHELXTL
   Wall M, 1999, J AM CHEM SOC, V121, P4710, DOI 10.1021/ja981227l
   Wu ZY, 2003, ACTA CRYSTALLOGR E, V59, pM809, DOI 10.1107/S1600536803018762
NR 11
TC 6
Z9 6
U1 4
U2 10
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1600-5368
J9 ACTA CRYSTALLOGR E
JI Acta Crystallogr. Sect. E.-Struct Rep. Online
PD DEC
PY 2006
VL 62
BP M3330
EP M3332
DI 10.1107/S1600536806047295
PN 12
PG 3
WC Crystallography
SC Crystallography
GA 111EQ
UT WOS:000242434600084
DA 2018-12-27
ER

PT J
AU Taljsten, B
AF Taljsten, B.
TI RETRACTED: The importance of bonding - A historic overview and future
   possibilities (Retracted article. See vol. 12, pg. 721, 2009)
SO ADVANCES IN STRUCTURAL ENGINEERING
LA English
DT Article; Proceedings Paper; Retracted Publication
CT International Symposium on Bond Behaviour of FRP in Structures
CY DEC 07-09, 2005
CL Hong Kong, PEOPLES R CHINA
SP Int Inst FRP Construct, WG Bond FRP & Concrete, Hong Kong Polytech Univ, Dept Civil & Struct Engn
DE adhesives; structural bonding; joints; construction industry; organic
ID STRENGTH; BEAMS
AB An adhesive is a substance that has the capability to hold materials together. The manner by which adhesives are able to serve this function is due to a surface attachment that is resistant to separation. A bond occurs when the adhesive molecules adsorb onto a solid surface and chemically react with it. Adhesives have a very large importance for most industries, both for structural and for non-structural use. In this paper, an overview of the use of adhesives in different industries is presented - with focus on the building industry and on structural use. Not surprisingly, the use of structural bonding has increased considerably during the last decade. The main reasons for this are probably a combination of lower cost, more need of lightweight structures, development of more durable adhesives and improved structural adhesive perf(1)ormance. Additionally, adhesives often provide better load transfer than welded structures.
   In this paper, an overview of the use of adhesive in the service of man is presented. The overview is brief, but nonetheless gives an idea of the possibilities of adhering materials by bonding. The paper briefly discusses the use of adhesives in the aerospace, automotive and marine industries, but focuses on the construction industry. Finally some ideas about "sticking things together" tomorrow are presented.
C1 Tech Univ Denmark, Dept Civil Engn, DK-2800 Lyngby, Denmark.
RP Taljsten, B (reprint author), Tech Univ Denmark, Dept Civil Engn, DK-2800 Lyngby, Denmark.
EM bt@byg.dtu.dk
CR BARYOSEF O, 1989, NATL GEOGR RES, V5, P176
   BREWIS D, 2005, ADHESIVE BONDING SCI, P75
   CADEI JMC, 2004, STRENGTHENING METALL, P174
   Cantrill J., 2004, Proceedings of the Institution of Mechanical Engineers, Part M (Journal of Engineering for the Maritime Environment), V218, P267
   Chen JF, 2001, J STRUCT ENG-ASCE, V127, P784, DOI 10.1061/(ASCE)0733-9445(2001)127:7(784)
   Clarke JL, 1996, EUROCOMP DESIGN CODE
   COMYN J, 2005, ADHESIVE BONDING SCI, P23
   Critchlow GW, 1996, INT J ADHES ADHES, V16, P255, DOI 10.1016/S0143-7496(96)00014-0
   Dilger K., 2005, ADHESIVE BONDING SCI, P357
   FAY PA, 2005, ADHESIVE BONDING SCI, P3
   GAUL RW, 1959, CIVIL ENG NEW YORK, V29, P50
   *GERM BOND BRIDG, 1979, CONSTR IND INT, V5, P31
   GUNES O, 2005, COBRAE C P APR 3
   Hart-Smith L. J., 2005, ADHESIVE BONDING SCI, P489
   JOHANSSON T, 2004, THESIS LULEA U TECHN
   KECSMAR J, 2003, THESIS U SOUTHAMPTON
   Luke S., 2002, STRUCT ENG INT, V12, P76
   Mays G. C., 1992, ADHESIVES CIVIL ENG
   MULLER JN, 1964, ANN I TECH TRAV PU S, V204
   Newton Isaac, 1717, OPTICKS TREATISE REF
   Ninan L, 2003, BIOMATERIALS, V24, P4091, DOI 10.1016/S0142-9612(03)00257-6
   Roberts T.M., 1989, STRUCT ENG, V67, P229
   Shaw JDN, 1990, CONSTR BUILD MATER, V4, P92
   *SICOMP, 2004, SICOMP WORKSH DIM KO
   Sun WX, 2005, BIOPHYS J, V89, pL14, DOI 10.1529/biophysj.105.065268
   Taljsten B, 1997, J MATER CIVIL ENG, V9, P206
   Taljsten B., 2004, FRP STRENGTHENING EX
   TALJSTEN B, 1994, THESIS LULEA U TECHN
   Teng JG, 2003, CONSTR BUILD MATER, V17, P447, DOI 10.1016/S0950-0618(03)0043-6
   Tremper B., 1960, J ACI, V57, P173
   VILNAY O, 1988, INT J CEMENT COMPOS, V10, P73, DOI DOI 10.1016/0262-5075(88)90033-4
   WAKEMAN CM, 1962, ASTM B, V2, P93
   Walker A. A., 1998, ARCHAEOLOGY ONL 0521
NR 33
TC 6
Z9 6
U1 3
U2 10
PU MULTI-SCIENCE PUBL CO LTD
PI BRENTWOOD
PA 5 WATES WAY, BRENTWOOD CM15 9TB, ESSEX, ENGLAND
SN 1369-4332
J9 ADV STRUCT ENG
JI Adv. Struct. Eng.
PD DEC
PY 2006
VL 9
IS 6
BP 721
EP 736
DI 10.1260/136943306779369509
PG 16
WC Construction & Building Technology; Engineering, Civil
SC Construction & Building Technology; Engineering
GA 116YL
UT WOS:000242839600002
DA 2018-12-27
ER

PT J
AU Emsen, IM
AF Emsen, Ilteris M.
TI RETRACTED: The use of metatarsal bone grafts in the treatment of saddle
   nose deformities (Retracted Article. See vol 33, pg 677, 2009)
SO AESTHETIC PLASTIC SURGERY
LA English
DT Article; Retracted Publication
DE dorsal; graft; Kirschner; L-strut; metatar-sal; septal-conchal
   cartilage; solid
ID NASAL RECONSTRUCTION; RHINOPLASTY
AB The results from segmental fourth metatarsal bone reconstruction of significant nasal dorsal defects are described. Solid bone graft reconstructions frequently lead to an unnatural hardness of the nasal tip. Rib cartilage reconstructions are pliable and soft, but pose a problem because they easily undergo warpage. The operation is performed using the open approach. An outer fourth metatarsal bone graft used for the bone component extends at least two-thirds of the dorsum length. It is secured in place with a compression screw and a Kirschner wire. The cartilage component comprises an abbreviated L-strut constructed of septal cartilage. It is slotted into the metatarsal bone in a tongue-in-groove manner and sutured to it through a drill hole in the bone. The dorsal profile is completed in this manner.
C1 Numune State Hosp, Dept Plast & Reconstruct Surg, Erzurum, Turkey.
RP Emsen, IM (reprint author), Ataturk Univ Lojmanlari, 4 Blok,30, TR-25240 Erzurum, Turkey.
EM ilterisemsen@hotmail.com
CR CHAIT LA, 1980, BRIT J PLAST SURG, V33, P179, DOI 10.1016/0007-1226(80)90008-9
   DANIEL RK, 1994, PLAST RECONSTR SURG, V94, P597, DOI 10.1097/00006534-199410000-00005
   FRODEL JL, 1995, ARCH OTOLARYNGOL, V121, P307
   Gibson T, 1958, BRIT J PLAST SURG, V10, P257
   Gunter JP, 1997, PLAST RECONSTR SURG, V100, P161, DOI 10.1097/00006534-199707000-00026
   MILLARD DR, 1974, PLAST RECONSTR SURG, V53, P133, DOI 10.1097/00006534-197402000-00003
   POSNICK JC, 1990, PLAST RECONSTR SURG, V86, P894, DOI 10.1097/00006534-199011000-00010
   Sheen JH, 1998, PLAST RECONSTR SURG, V102, P2490, DOI 10.1097/00006534-199812000-00036
   Sheen JH, 1987, AESTHETIC RHINOPLAST
   STUZIN JM, 1988, CLIN PLAST SURG, V15, P83
NR 10
TC 3
Z9 3
U1 3
U2 8
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0364-216X
EI 1432-5241
J9 AESTHET PLAST SURG
JI Aesthet. Plast. Surg.
PD DEC
PY 2006
VL 30
IS 6
BP 705
EP 707
DI 10.1007/s00266-006-0062-3
PG 3
WC Surgery
SC Surgery
GA 113ML
UT WOS:000242601900018
PM 17077952
DA 2018-12-27
ER

PT J
AU Bradshaw, EL
   Li, XA
   Guerin, T
   Everson, WV
   Wilson, ME
   Bruce-Keller, AJ
   Greenberg, RN
   Guo, L
   Ross, SA
   Smart, EJ
AF Bradshaw, Emily L.
   Li, Xiang-An
   Guerin, Theresa
   Everson, William V.
   Wilson, Melinda E.
   Bruce-Keller, Annadora J.
   Greenberg, Richard N.
   Guo, Ling
   Ross, Stuart A.
   Smart, Eric J.
TI RETRACTED: Nucleoside reverse transcriptase inhibitors prevent HIV
   protease inhibitor-induced atherosclerosis by ubiquitination and
   degradation of protein kinase C (Retracted article. See vol. 304, pg.
   C811, 2013)
SO AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY
LA English
DT Article; Retracted Publication
DE CD36; macrophage; proteasome; low-density lipoprotein receptor
ID ERYTHROID PROGENITOR CELLS; ANTIRETROVIRAL THERAPY; SIGNALING PATHWAY;
   ALPHA-TOCOPHEROL; PPAR-GAMMA; VITAMIN-E; TOXICITY; DYSLIPIDEMIA;
   ACCUMULATION; MACROPHAGES
AB HIV protease inhibitors are important pharmacological agents used in the treatment of HIV-infected patients. One of the major disadvantages of HIV protease inhibitors is that they increase several cardiovascular risk factors, including the expression of CD36 in macrophages. The expression of CD36 in macrophages promotes the accumulation of cholesterol, the development of foam cells, and ultimately atherosclerosis. Recent studies have suggested that alpha-tocopherol can prevent HIV protease inhibitor-induced increases in macrophage CD36 levels. Because of the potential clinical utility of using alpha-tocopherol to limit some of the side effects of HIV protease inhibitors, we tested the ability of alpha-tocopherol to prevent ritonavir, a common HIV protease inhibitor, from inducing atherosclerosis in the LDL receptor (LDLR) null mouse model. Surprisingly, alpha-tocopherol did not prevent ritonavir-induced atherosclerosis. However, cotreatment with the nucleoside reverse transcriptase inhibitors (NRTIs), didanosine or D4T, did prevent ritonavir-induced atherosclerosis. Using macrophages isolated from LDLR null mice, we demonstrated that the NRTIs prevented the upregulation of CD36 and cholesterol accumulation in macrophages. Treatment of LDLR null mice with NRTIs promoted the ubiquitination and downregulation of protein kinase C alpha (PKC). Previous studies demonstrated that HIV protease inhibitor activation of PKC was necessary for the upregulation of CD36. Importantly, the in vivo inhibition of PKC with chelerythrine prevented ritonavir-induced upregulation of CD36, accumulation of cholesterol, and the formation of atherosclerotic lesions. These novel mechanistic studies suggest that NRTIs may provide protection from one of the negative side effects associated with HIV protease inhibitors, namely the increase in CD36 levels and subsequent cholesterol accumulation and atherogenesis.
C1 Univ Kentucky, Dept Pediat, Lexington, KY 40536 USA.
   Univ Kentucky, Dept Physiol, Lexington, KY 40536 USA.
   Univ Kentucky, Dept Med, Lexington, KY 40536 USA.
   Univ Kentucky, Dept Anat & Neurobiol, Lexington, KY 40536 USA.
   Lexington Vet Affairs Med Ctr, Lexington, KY USA.
RP Smart, EJ (reprint author), Univ Kentucky, Dept Pediat, 423 Sanders Brown,800 Limestone St, Lexington, KY 40536 USA.
EM ejsmart@email.uky.edu
RI Bruce-Keller, Annadora/N-1954-2017
FU NIDDK NIH HHS [DK-63025]; NHLBI NIH HHS [HL-073693, HL-68509]; NCRR NIH
   HHS [RR-O15592]
CR Andre P, 1998, P NATL ACAD SCI USA, V95, P13120, DOI 10.1073/pnas.95.22.13120
   Caron M, 2001, DIABETES, V50, P1378, DOI 10.2337/diabetes.50.6.1378
   Chmura SJ, 2000, CLIN CANCER RES, V6, P737
   Daugherty A, 2005, METHODS, V36, P129, DOI 10.1016/j.ymeth.2004.11.008
   Dressman J, 2003, J CLIN INVEST, V111, P389, DOI 10.1172/JCI200316261
   Feng JW, 2000, J LIPID RES, V41, P688
   Fisher SD, 2006, ATHEROSCLEROSIS, V185, P1, DOI 10.1016/j.atherosclerosis.2005.09.025
   GOGU SR, 1991, EXP HEMATOL, V19, P649
   GOGU SR, 1995, BIOCHEM PHARMACOL, V50, P413, DOI 10.1016/0006-2952(95)00134-L
   Hruz PW, 2001, AM J PHYSIOL-ENDOC M, V280, pE549
   Hui DY, 2003, PROG LIPID RES, V42, P81, DOI 10.1016/S0163-7827(02)00046-2
   Koster JC, 2003, DIABETES, V52, P1695, DOI 10.2337/diabetes.52.7.1695
   LAEMMLI UK, 1985, NATURE, V227, P680
   Lee H, 2003, BIOCHEMISTRY-US, V42, P14711, DOI 10.1021/bi035596s
   Lemoine M, 2006, AIDS, V20, P387, DOI 10.1097/01.aids.0000206503.01536.11
   Liang JS, 2001, NAT MED, V7, P1327, DOI 10.1038/nm1201-1327
   MARTIN DL, 2006, ATHEROSCLEROSIS, V185, P361
   Munteanu A, 2004, IUBMB LIFE, V56, P629, DOI 10.1080/15216540400020387
   Munteanu A, 2005, FREE RADICAL BIO MED, V38, P1047, DOI 10.1016/j.freeradbiomed.2004.12.030
   NICHOLSON AC, 2002, TRENDS CARDIOVAS MED, V14, P8
   Nolan David, 2004, J HIV Ther, V9, P34
   Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301
   Piccinini M, 2002, AIDS, V16, P693, DOI 10.1097/00002030-200203290-00004
   Riddle TM, 2001, J BIOL CHEM, V276, P37514, DOI 10.1074/jbc.M104557200
   Schmidtke G, 1999, J BIOL CHEM, V274, P35734, DOI 10.1074/jbc.274.50.35734
   Stein JH, 2001, CIRCULATION, V104, P257
   Tapper ML, 2005, AIDS PATIENT CARE ST, V19, P224, DOI 10.1089/apc.2005.19.224
   Violi F, 2004, ANN NY ACAD SCI, V1031, P292, DOI 10.1196/annals.1331.029
   Whitman SC, 2000, J BIOL CHEM, V275, P35807, DOI 10.1074/jbc.M001797200
NR 29
TC 12
Z9 12
U1 3
U2 12
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0363-6143
J9 AM J PHYSIOL-CELL PH
JI Am. J. Physiol.-Cell Physiol.
PD DEC
PY 2006
VL 291
IS 6
BP C1271
EP C1278
DI 10.1152/ajpcell.00211.2006
PG 8
WC Cell Biology; Physiology
SC Cell Biology; Physiology
GA 104WT
UT WOS:000241992000020
PM 16822947
DA 2018-12-27
ER

PT J
AU Guo, XH
   Huang, QB
   Chen, B
   Wang, SY
   Li, Q
   Zhu, YJ
   Hou, FF
   Fu, N
   Brunk, UT
   Zhao, M
AF Guo, Xiao-Hua
   Huang, Qiao-Bing
   Chen, Bo
   Wang, Shu-Yun
   Li, Qiang
   Zhu, Yan-Jun
   Hou, Fan-Fan
   Fu, Ning
   Brunk, Ulf T.
   Zhao, Ming
TI RETRACTED: Advanced glycation end products induce actin rearrangement
   and subsequent hyperpermeability of endothelial cells (Retracted
   Article. See vol 117, pg 549, 2009)
SO APMIS
LA English
DT Article; Retracted Publication
DE advanced glycation end products (AGEs); endothelial cells; actin;
   cytoskeleton; MAPK
ID MYOSIN LIGHT-CHAIN; ACTIVATED PROTEIN-KINASE; CULTURED HUMAN; KAPPA-B;
   RECEPTOR; PHOSPHORYLATION; PERMEABILITY; ATHEROSCLEROSIS;
   AMINOGUANIDINE; GLYCOSYLATION
AB This study aimed to determine the effects of advanced glycation end products (AGEs) on endothelial cytoskeleton morphology and permeability, and to detect the underlying signaling mechanisms involved in these responses. Cultured endothelial cells (ECs) were exposed to AGE-modified human serum albumin (AGE-HSA), and EC cytoskeletal changes were evaluated by observing fluorescence of F-actin following ligation with labeled antibodies. Endothelial permeability was detected by measuring the flux of TRITC-albumin across the EC monolayers. To explore the signaling pathways behind AGE-induced EC alteration, ECs were treated with either soluble anti-AGE receptor (RAGE) IgG, or the MAPK inhibitors PD98059 and SB203580 before AGE-HSA administration. To further elucidate possible involvement of the ERK and p38 pathways in AGE-induced EC changes, adenovirus-carried recombinant constitutive dominant-negative forms of upstream ERK and p38 kinases, namely MEK1(A) and MKK6b(A), were pre-infected into ECs 24 h prior to AGE-HSA exposure. AGE-HSA induced actin cytoskeleton rearrangement, as well as EC hyperpermeability, in a dose and time-dependent manner. The effects were attenuated in cells pretreated with anti-RAGE IgG, PD98059 or SB203580, respectively. EC pre-infection with MEK1(A) and MKK6b(A) also alleviated the effect of AGEs. Furthermore, adenovirus-mediated administration of activated forms of either MEK1 or MKK6b alone induced rearrangement of F-actin and hyperpermeability. The results indicate that ERK and p38 MAPK play important roles in the mediation of AGE-induced EC barrier dysfunction associated with morphological changes of the F-actin.
C1 So Med Univ, Dept Pathophysiol, Guangzhou, Peoples R China.
   So Med Univ, Key Lab Shock & Microcirculat Res, Guangzhou, Peoples R China.
   So Med Univ, Nanfang Hosp, Dept Nephrol, Guangzhou, Peoples R China.
   Linkoping Univ, Fac Hlth Sci, Div Pharmacol, S-58183 Linkoping, Sweden.
   Lund Univ, Dept Cell & Mol Biol, Div Med Inflammat Res, S-22100 Lund, Sweden.
RP Huang, QB (reprint author), So Med Univ, Dept Pathophysiol, Guangzhou, Peoples R China.
EM bing@fimmu.com
CR Borbiev T, 2004, AM J PHYSIOL-LUNG C, V287, pL911, DOI 10.1152/ajplung.00372.2003
   BROWNLEE M, 1995, ANNU REV MED, V46, P223, DOI 10.1146/annurev.med.46.1.223
   Dudek SM, 2001, J APPL PHYSIOL, V91, P1487
   EMERT L, 1995, AM J PHYSIOL, V268, pL753
   Forbes JM, 2004, DIABETES, V53, P1813, DOI 10.2337/diabetes.53.7.1813
   GOECKELER ZM, 1995, J CELL BIOL, V130, P613, DOI 10.1083/jcb.130.3.613
   Guo Zhijian, 2002, Zhonghua Yi Xue Za Zhi, V82, P1328
   Hou FF, 2001, KIDNEY INT, V59, P990, DOI 10.1046/j.1523-1755.2001.059003990.x
   Hou FF, 1998, J AM SOC NEPHROL, V9, P277
   Huttunen HJ, 1999, J BIOL CHEM, V274, P19919, DOI 10.1074/jbc.274.28.19919
   Ishihara K, 2003, FEBS LETT, V550, P107, DOI 10.1016/S0014-5793(03)00846-9
   Kayyali US, 2002, J BIOL CHEM, V277, P42596, DOI 10.1074/jbc.M205863200
   Klingenberg D, 2004, AM J PHYSIOL-CELL PH, V286, pC807, DOI 10.1152/ajpcell.00002.2003
   Lander HM, 1997, J BIOL CHEM, V272, P17810, DOI 10.1074/jbc.272.28.17810
   Lee JC, 1999, PHARMACOL THERAPEUT, V82, P389, DOI 10.1016/S0163-7258(99)00008-X
   Leto G, 2001, DIABETES METAB RES, V17, P448, DOI 10.1002/dmrr.227
   Li YM, 1996, P NATL ACAD SCI USA, V93, P3902, DOI 10.1073/pnas.93.9.3902
   MADARA JL, 1987, AM J PHYSIOL, V253, pC854
   NIGGLI V, 1987, J MEMBRANE BIOL, V100, P97, DOI 10.1007/BF02209144
   Otero K, 2001, BIOCHEM J, V359, P567, DOI 10.1042/0264-6021:3590567
   PEPPA J, 2003, CLIN DIABETES, V21, P186
   SCHMIDT AM, 1994, P NATL ACAD SCI USA, V91, P8807, DOI 10.1073/pnas.91.19.8807
   SCHMIDT AM, 1995, J CLIN INVEST, V96, P1395, DOI 10.1172/JCI118175
   Schmidt AM, 2000, BBA-MOL CELL RES, V1498, P99, DOI 10.1016/S0167-4889(00)00087-2
   SHELDON R, 1993, AM J PHYSIOL, V265, pL606
   Stitt AW, 1997, MOL MED, V3, P617, DOI 10.1007/BF03401819
   Tanaka N, 2000, J BIOL CHEM, V275, P25781, DOI 10.1074/jbc.M001235200
   Thornalley PJ, 1998, CELL MOL BIOL, V44, P1013
   THURSTON G, 1995, AM J PHYSIOL, V269, pH1528
   Tinsley JH, 2000, AM J PHYSIOL-CELL PH, V279, pC1285
   Tinsley JH, 1999, J BIOL CHEM, V274, P24930, DOI 10.1074/jbc.274.35.24930
   VLASSARA H, 1994, LAB INVEST, V70, P138
   VOLBERG T, 1986, J CELL BIOL, V102, P1832, DOI 10.1083/jcb.102.5.1832
   Wautier JL, 1996, J CLIN INVEST, V97, P238, DOI 10.1172/JCI118397
   Wautier MP, 2001, AM J PHYSIOL-ENDOC M, V280, pE685
   Widmann C, 1999, PHYSIOL REV, V79, P143
   WYSOLMERSKI RB, 1990, P NATL ACAD SCI USA, V87, P16, DOI 10.1073/pnas.87.1.16
   Yuan Y, 1997, AM J PHYSIOL-HEART C, V272, pH1437
   Zhu Ping, 2004, Di Yi Jun Yi Da Xue Xue Bao, V24, P129
   Zill H, 2001, BIOCHEM BIOPH RES CO, V288, P1108, DOI 10.1006/bbrc.2001.5901
NR 40
TC 16
Z9 22
U1 4
U2 17
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0903-4641
EI 1600-0463
J9 APMIS
JI APMIS
PD DEC
PY 2006
VL 114
IS 12
BP 874
EP 883
DI 10.1111/j.1600-0463.2006.apm_372.x
PG 10
WC Immunology; Microbiology; Pathology
SC Immunology; Microbiology; Pathology
GA 117WA
UT WOS:000242902800007
PM 17207088
DA 2018-12-27
ER

PT J
AU Gordijn, EH
   Stapel, DA
AF Gordijn, Ernestine H.
   Stapel, Diederik A.
TI RETRACTED: Behavioural effects of automatic interpersonal versus
   intergroup social comparison (Retracted article. See vol. 51, pg. 498,
   2012)
SO BRITISH JOURNAL OF SOCIAL PSYCHOLOGY
LA English
DT Article; Retracted Publication
ID STEREOTYPE ACTIVATION; IN-GROUP; CONTRAST; ASSIMILATION; PERCEPTION;
   IMPLICIT
AB Does information about other people automatically affect one's own behaviour as a function of the salience of interpersonal or intergroup contexts? Study I revealed that exposure to an intelligent comparison target led to worse performance than exposure to an unintelligent target when an interpersonal context was salient (contrast) whereas the opposite effect was found when an intergroup context was salient. Study 2 showed better performance after exposure to an intelligent in-group target and worse performance when the in-group target was unintelligent (assimilation), whereas opposite effects were found when the target was an out-group member or when no intergroup context was salient. Finally, Study 3 showed better performance after exposure to a group of intelligent targets and worse performance after exposure to a group of unintelligent targets suggesting assimilation; opposite effects were found when the group consisted of out-group targets.
C1 Univ Groningen, Dept Social & Org Psychol, NL-9712 TS Groningen, Netherlands.
   Tilburg Univ, Tilburg Inst Behav Econ Res, NL-5000 LE Tilburg, Netherlands.
RP Gordijn, EH (reprint author), Univ Groningen, Dept Social & Org Psychol, Grote Kruisstr 2-1, NL-9712 TS Groningen, Netherlands.
EM e.gordijn@rug.nl
CR Bargh JA, 1996, J PERS SOC PSYCHOL, V71, P230, DOI 10.1037/0022-3514.71.2.230
   Blanton H, 2001, COGNITIVE SOCIAL PSYCHOLOGY, P75
   BREWER MB, 1994, J PERS SOC PSYCHOL, V66, P268, DOI 10.1037/0022-3514.66.2.268
   CERVONE D, 1986, J PERS SOC PSYCHOL, V50, P492, DOI 10.1037/0022-3514.50.3.492
   Dijksterhuis A, 1998, J PERS SOC PSYCHOL, V75, P862, DOI 10.1037//0022-3514.75.4.862
   Dijksterhuis A, 1998, J PERS SOC PSYCHOL, V74, P865, DOI 10.1037/0022-3514.74.4.865
   Dijksterhuis A, 2001, J EXP SOC PSYCHOL, V37, P286, DOI 10.1006/jesp.2000.1449
   Festinger L, 1954, HUM RELAT, V7, P117, DOI 10.1177/001872675400700202
   GILBERT DT, 1995, J PERS SOC PSYCHOL, V69, P227, DOI 10.1037/0022-3514.69.2.227
   Haddock G, 2002, SOC COGNITION, V20, P461, DOI 10.1521/soco.20.6.461.22976
   Haslam SA, 1999, PERS SOC PSYCHOL B, V25, P809, DOI 10.1177/0146167299025007004
   Levy B, 1996, J PERS SOC PSYCHOL, V71, P1092, DOI 10.1037/0022-3514.71.6.1092
   Mussweiler T, 2002, J PERS SOC PSYCHOL, V82, P19, DOI 10.1037//0022-3514.82.1.19
   Mussweiler T, 2000, J PERS SOC PSYCHOL, V78, P1038, DOI 10.1037//0022-3514.78.6.1038
   ORONATO RS, 2004, EUROPEAN J SOCIAL PS, V34, P257
   Pickett CL, 2002, J PERS SOC PSYCHOL, V82, P543, DOI 10.1037//0022-3514.82.4.543
   Schmitt MT, 2000, PERS SOC PSYCHOL B, V26, P1598, DOI 10.1177/01461672002612013
   Schubert TW, 2003, J EXP SOC PSYCHOL, V39, P577, DOI 10.1016/S0022-1031(03)00034-9
   SETA JJ, 1982, J PERS SOC PSYCHOL, V42, P281, DOI 10.1037/0022-3514.42.2.281
   SIMON B, 1994, J PERS SOC PSYCHOL, V66, P699, DOI 10.1037//0022-3514.66.4.699
   Spears R, 2004, PERS SOC PSYCHOL B, V30, P605, DOI 10.1177/0146167203262087
   Stapel DA, 2004, J PERS SOC PSYCHOL, V87, P468, DOI 10.1037/0022-3514.87.4.468
   Stapel DA, 2001, J PERS SOC PSYCHOL, V80, P766, DOI 10.1037//0022-3514.80.5.766
   Suls J., 2000, HDB SOCIAL COMP
   Wheeler SC, 2001, PSYCHOL BULL, V127, P797, DOI 10.1037//0033-2909.127.6.797
NR 25
TC 6
Z9 6
U1 2
U2 15
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0144-6665
EI 2044-8309
J9 BRIT J SOC PSYCHOL
JI Br. J. Soc. Psychol.
PD DEC
PY 2006
VL 45
BP 717
EP 729
DI 10.1348/014466605X79589
PN 4
PG 13
WC Psychology, Social
SC Psychology
GA 125GP
UT WOS:000243430700004
PM 17393877
DA 2018-12-27
ER

PT J
AU Alyaqoub, FS
   Tao, L
   Kramer, PM
   Steele, VE
   Lubet, RA
   Gunning, WT
   Pereira, MA
AF Alyaqoub, Fadel S.
   Tao, Lianhui
   Kramer, Paula M.
   Steele, Vernon E.
   Lubet, Ronald A.
   Gunning, William T.
   Pereira, Michael A.
TI RETRACTED: Prevention of mouse lung tumors and modulation of DNA
   methylation by combined treatment with budesonide and R115777
   (Zarnestra(MT)) (Retracted Article. See vol 28, pg 2426, 2007)
SO CARCINOGENESIS
LA English
DT Article; Retracted Publication
ID FARNESYLTRANSFERASE INHIBITORS; A/J MICE; PULMONARY CARCINOGENESIS;
   AEROSOLIZED BUDESONIDE; CANCER; CHEMOPREVENTION; HYPOMETHYLATION;
   PROGRESSION; EXPRESSION; RECEPTOR
AB Budesonide (an anti-inflammatory glucocorticoid), R115777 (a farnesyl transferase inhibitor, Zarnestra, Tipifarnib) or combinations of them were evaluated for prevention of lung tumors and for modulation of DNA methylation in tumors. Lung tumors were induced by vinyl carbamate in female Strain A mice. One week later, mice received 60 or 100 mg/kg R115777 by oral gavage and 5 days/week, 0.8 or 1.6 mg/kg of budesonide in their diet, or their combined treatment until killed at 20, 28 and 36 weeks after administering the vinyl carbamate. Other mice were administered the drugs for 2 weeks before killing at 20 weeks. At Week 20, the rank order for prevention of lung tumors was the combined treatment > budesonide > R115777. At later killings, R115777 was no longer effective, whereas budesonide and the combinations continued to prevent tumors, albeit at a reduced efficacy. DNA hypomethylation in lung tumors was prevented by treatment with R115777, budesonide and the combinations. When administered starting at Week 18 to tumor-bearing mice, the drugs reversed DNA hypomethylation in the tumors. In summary, combined treatment with budesonide and R115777 produced the following results: (i) it was more efficacious in preventing lung tumors than the individual drugs; and (ii) it prevented and reversed DNA hypomethylation in lung tumors. These results support the combined use of budesonide and R115777 in prevention of lung tumors and suggest that reversal of DNA hypomethylation in lung tumors would be useful as a surrogate endpoint biomarker for prevention.
C1 Ohio State Univ, Coll Med & Publ Hlth, Dept Internal Med, Columbus, OH 43210 USA.
   Med Univ Ohio, Toledo, OH 43614 USA.
   NCI, Bethesda, MD 20892 USA.
RP Alyaqoub, FS (reprint author), Ohio State Univ, Coll Med & Publ Hlth, Dept Internal Med, 300 W 10th Ave, Columbus, OH 43210 USA.
EM Pereira.25@osu.edu
FU PHS HHS [25126]; NCI NIH HHS [R01-CA096129, N01-CN-15125]
CR Adjei AA, 2003, J CLIN ONCOL, V21, P1760, DOI 10.1200/JCO.2003.09.075
   Banov CH, 2004, J ASTHMA, V41, P5, DOI 10.1081/JAS-120026092
   Counts J L, 1995, Prog Clin Biol Res, V391, P81
   Cox AD, 2001, DRUGS, V61, P723, DOI 10.2165/00003495-200161060-00002
   Cox AD, 2002, CURR OPIN PHARMACOL, V2, P388, DOI 10.1016/S1471-4892(02)00181-9
   Cox AD, 2002, CANCER BIOL THER, V1, P599, DOI 10.4161/cbt.306
   Ehrlich M, 2002, ONCOGENE, V21, P5400, DOI 10.1038/sj.onc.1205651
   Esteller M, 2002, J PATHOL, V196, P1, DOI 10.1002/path.1024
   Estensen RD, 2004, CARCINOGENESIS, V25, P197, DOI 10.1093/carcin/bgg196
   Gaudet F, 2003, SCIENCE, V300, P489, DOI 10.1126/science.1083558
   GOELZ SE, 1985, SCIENCE, V228, P187, DOI 10.1126/science.2579435
   Gunning WT, 2003, CLIN CANCER RES, V9, P1927
   Gunning WT, 2002, CANCER RES, V62, P4199
   HANSON LA, 1991, EXP LUNG RES, V17, P371, DOI 10.3109/01902149109064425
   Head J, 2004, BREAST CANCER RES, V6, P262, DOI 10.1186/bcr947
   Lam S, 2004, CLIN CANCER RES, V10, P6502, DOI 10.1158/1078-0432.CCR-04-0686
   LI J, 1995, MOL CARCINOGEN, V13, P135, DOI 10.1002/mc.2940130303
   MASSEY TE, 1995, CARCINOGENESIS, V16, P1065, DOI 10.1093/carcin/16.5.1065
   Mesa RA, 2006, EXPERT REV ANTICANC, V6, P313, DOI 10.1586/14737140.6.3.313
   Pereira MA, 2004, CARCINOGENESIS, V25, P1917, DOI 10.1093/carcin/bgh209
   Pereira MA, 2004, TOXICOL SCI, V77, P243, DOI 10.1093/toxsci/kfh031
   Pereira MA, 2005, EXP LUNG RES, V31, P145, DOI 10.1080/01902140490495534
   Pereira MA, 2002, CARCINOGENESIS, V23, P1185, DOI 10.1093/carcin/23.7.1185
   Tao LH, 2004, MOL CARCINOGEN, V39, P79, DOI 10.1002/mc.2003
   Tao LH, 2002, MOL CARCINOGEN, V35, P93, DOI 10.1002/mc.10078
   Wang Y, 2003, CANCER RES, V63, P4389
   Wattenberg LW, 1997, CANCER RES, V57, P5489
   Wattenberg LW, 2000, CARCINOGENESIS, V21, P179, DOI 10.1093/carcin/21.2.179
NR 28
TC 5
Z9 5
U1 1
U2 6
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0143-3334
EI 1460-2180
J9 CARCINOGENESIS
JI Carcinogenesis
PD DEC
PY 2006
VL 27
IS 12
BP 2442
EP 2447
DI 10.1093/carcin/bgl088
PG 6
WC Oncology
SC Oncology
GA 111RJ
UT WOS:000242471600010
PM 16733249
OA Bronze
DA 2018-12-27
ER

PT J
AU Ding, SM
   Tao, LA
   Zhang, C
   Yan, JC
   Zhang, ZL
AF Ding, ShiMing
   Tao Liang
   Zhang, ChaoSheng
   Yan, JunCai
   Zhang, ZiLi
TI RETRACTED: Effects of organic ligands on fractionation of rare earth
   elements (REEs) in hydroponic plants: An application to the
   determination of binding capacities by humic acid for modeling
   (Retracted article. See vol. 80, pg. 1408, 2010)
SO CHEMOSPHERE
LA English
DT Article; Retracted Publication
DE Fractionation; humic acid; metal; model; rare earth elements (REEs)
ID STABILITY-CONSTANTS; ION-BINDING; AQUEOUS GEOCHEMISTRY; COLLOIDAL
   PARTICLES; TRACE-ELEMENTS; RIVER WATERS; METAL-IONS; SUBSTANCES;
   SPECIATION; COMPLEXES
AB Previous studies have revealed the fractionation processes of rare earth elements (REEs) in hydroponic plants, with a heavy REE (HREE, the elements from Gd to Lu) enrichment in leaves. In this study, effects on the HREE enrichment in soybean leaves with additions of carboxylic acids (acetate, malate, citrate, NTA, EDTA and DTPA) and two soil humic acids (HAs) were investigated. REE speciation in carboxylic acid and HA solutions was simulated using Visual MINTEQ and Model V, respectively. The results showed that the effects caused by carboxylic acids were strongly dependent on the differences between their binding strengths for light REEs (LREEs, the elements from La to Eu) and those for HREEs. A good correlation existed between these effects and the changes of free REE ions in solutions. This relationship was also observed for the HA treatments, provided that the intrinsic equilibrium constants of REEs for cation-proton exchange with HA (i.e., pK(MHA)) in Model V were estimated using a free-energy relationship with the stability constants for REE complexation with lactic acid. It is suggested that this set of pK(MHA) values is more suitable for use in Model V for the simulation of REE complexation with HA. (c) 2006 Elsevier Ltd. All rights reserved.
C1 Chinese Acad Sci, Inst Geog Sci & Nat Resources Res, Beijing 100101, Peoples R China.
   Chinese Acad Sci, Nanjing Inst Geog & Limnol, Nanjing 210008, Peoples R China.
   Natl Univ Ireland Univ Coll Galway, Dept Geog, Galway, Ireland.
   Anhui Agr Univ, Dept Soil & Agrichem, Hefei 230036, Peoples R China.
RP Tao, LA (reprint author), Chinese Acad Sci, Inst Geog Sci & Nat Resources Res, Beijing 100101, Peoples R China.
EM Liangt@igsnrr.ac.cn
CR CACHERIS WP, 1990, MAGN RESON IMAGING, V8, P467, DOI 10.1016/0730-725X(90)90055-7
   Dia A, 2000, GEOCHIM COSMOCHIM AC, V64, P4131, DOI 10.1016/S0016-7037(00)00494-4
   DIERCKX A, 1994, RADIOCHIM ACTA, V66-7, P149
   Ding SM, 2006, ENVIRON SCI TECHNOL, V40, P2686, DOI 10.1021/es052091b
   Ding SM, 2005, BIOL TRACE ELEM RES, V107, P73, DOI 10.1385/BTER:107:1:073
   Ding SM, 2005, J EXP BOT, V56, P2765, DOI 10.1093/jxb/eri270
   ELDERFIELD H, 1990, GEOCHIM COSMOCHIM AC, V54, P971, DOI 10.1016/0016-7037(90)90432-K
   GOLDSTEIN SJ, 1988, EARTH PLANET SC LETT, V89, P35, DOI 10.1016/0012-821X(88)90031-3
   Gu XY, 2001, CHINESE J ANAL CHEM, V29, P569
   Gu ZM, 2000, CHINESE J ANAL CHEM, V28, P314
   GUSTAFSSON JP, 2003, VISUAL MINTEQ VMINTE
   Henderson P., 1984, RARE EARTH ELEMENT G, p1~32
   Hewitt E. J., 1966, SAND WATER CULTURE M
   Hur J, 2003, ENVIRON SCI TECHNOL, V37, P880, DOI 10.1021/es0260824
   Ingri J, 2000, CHEM GEOL, V166, P23, DOI 10.1016/S0009-2541(99)00178-3
   Johannesson KH, 2004, CHEM GEOL, V209, P271, DOI 10.1016/j.chemgeo.2004.06.012
   Klungness GD, 2000, POLYHEDRON, V19, P99, DOI 10.1016/S0277-5387(99)00332-0
   Lead JR, 1998, ANAL CHIM ACTA, V369, P171, DOI 10.1016/S0003-2670(98)00230-X
   Marschner H., 1995, MINERAL NUTR HIGHER
   MARTELL AE, 2004, NIST STANDARD REFERE, V46
   Milne CJ, 2003, ENVIRON SCI TECHNOL, V37, P958, DOI 10.1021/es0258879
   Parker DR, 2001, ENVIRON TOXICOL CHEM, V20, P899, DOI 10.1897/1551-5028(2001)020<0899:RTFIAM>2.0.CO;2
   Plaschke M, 2004, J ELECTRON SPECTROSC, V135, P53, DOI 10.1016/j.elspec.2003.12.007
   Shan XQ, 2002, CHEMOSPHERE, V47, P701, DOI 10.1016/S0045-6535(02)00032-2
   Sholkovitz ER, 1995, AQUAT GEOCHEM, V1, P1, DOI 10.1007/BF01025229
   Smith R.M., 2001, NIST STANDARD REFERE, V46
   Sonke JE, 2006, GEOCHIM COSMOCHIM AC, V70, P1495, DOI 10.1016/j.gca.2005.11.017
   STANLEY JK, 1990, GEOCHIM COSMOCHIM AC, V54, P1587, DOI 10.1016/0016-7037(90)90393-Y
   Takahashi Y, 1997, SCI TOTAL ENVIRON, V198, P61, DOI 10.1016/S0048-9697(97)05442-9
   Tang JW, 2003, GEOCHIM COSMOCHIM AC, V67, P2321, DOI 10.1016/S0016-7037(02)01413-8
   TANIZAKI Y, 1992, ENVIRON SCI TECHNOL, V26, P1433, DOI 10.1021/es00031a023
   TIPPING E, 1994, COMPUT GEOSCI, V20, P973, DOI 10.1016/0098-3004(94)90038-8
   TIPPING E, 1993, RADIOCHIM ACTA, V62, P141
   TIPPING E, 1992, GEOCHIM COSMOCHIM AC, V56, P3627, DOI 10.1016/0016-7037(92)90158-F
   Tipping E, 1998, AQUAT GEOCHEM, V4, P3, DOI 10.1023/A:1009627214459
   TURNER DR, 1981, GEOCHIM COSMOCHIM AC, V45, P855, DOI 10.1016/0016-7037(81)90115-0
   Viers J, 1997, CHEM GEOL, V140, P181, DOI 10.1016/S0009-2541(97)00048-X
   Wang XP, 2004, CHEMOSPHERE, V55, P811, DOI 10.1016/j.chemosphere.2003.12.003
   Weltje L, 2004, ENVIRON SCI TECHNOL, V38, P6597, DOI 10.1021/es049916m
   Wen B, 2006, CHEMOSPHERE, V63, P1179, DOI 10.1016/j.chemosphere.2005.09.002
   WOOD SA, 1993, ENG GEOL, V34, P229, DOI 10.1016/0013-7952(93)90092-Q
   WOOD SA, 1990, CHEM GEOL, V82, P159, DOI 10.1016/0009-2541(90)90080-Q
   Yamamoto Y, 2005, CHEM LETT, V34, P880, DOI 10.1246/cl.2005.880
NR 43
TC 7
Z9 7
U1 4
U2 39
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0045-6535
EI 1879-1298
J9 CHEMOSPHERE
JI Chemosphere
PD DEC
PY 2006
VL 65
IS 11
BP 1942
EP 1948
DI 10.1016/j.chemosphere.2006.07.031
PG 7
WC Environmental Sciences
SC Environmental Sciences & Ecology
GA 119NQ
UT WOS:000243019400005
PM 16930675
DA 2018-12-27
ER

PT J
AU Chang, HS
   Anway, MD
   Rekow, SS
   Skinner, MK
AF Chang, Hung-Shu
   Anway, Matthew D.
   Rekow, Stephen S.
   Skinner, Michael K.
TI RETRACTED: Transgenerational epigenetic imprinting of the male germline
   by endocrine disruptor exposure during gonadal sex determination
   (Retracted article. See vol. 150, pg. 2976, 2009)
SO ENDOCRINOLOGY
LA English
DT Article; Retracted Publication
ID CELL-ADHESION MOLECULE; CA(V)2.3 ALPHA-1E SUBUNIT; GATED CA2+ CHANNELS;
   IN-UTERO EXPOSURE; GENE-EXPRESSION; DNA METHYLATION; DEVELOPMENTAL
   ORIGINS; GAMMA-SECRETASE; HUMAN-DISEASE; PROTEIN
AB Embryonic exposure to the endocrine disruptor vinclozolin at the time of gonadal sex determination was previously found to promote transgenerational disease states. The actions of vinclozolin appear to be due to epigenetic alterations in the male germline that are transmitted to subsequent generations. Analysis of the transgenerational epigenetic effects on the male germline (i.e. sperm) identified 25 candidate DNA sequences with altered methylation patterns in the vinclozolin generation sperm. These sequences were identified and mapped to specific genes and noncoding DNA regions. Bisulfite sequencing was used to confirm the altered methylation pattern of 15 of the candidate DNA sequences. Alterations in the epigenetic pattern (i.e. methylation) of these genes/DNA sequences were found in the F2 and F3 generation germline. Therefore, the reprogramming of the male germline involves the induction of new imprinted-like genes/DNA sequences that acquire an apparent permanent DNA methylation pattern that is passed at least through the paternal allele. The expression pattern of several of the genes during embryonic development were found to be altered in the vinclozolin F-1 and F2 generation testis. A number of the imprinted-like genes/DNA sequences identified are associated with epigenetic linked diseases. In summary, an endocrine disruptor exposure during embryonic gonadal sex determination was found to promote an alteration in the epigenetic ( i.e. induction of imprinted-like genes/DNA sequences) programming of the male germline, and this is associated with the development of transgenerational disease states.
C1 Washington State Univ, Sch Mol Biosci, Ctr Reprod Biol, Pullman, WA 99164 USA.
RP Skinner, MK (reprint author), Washington State Univ, Sch Mol Biosci, Ctr Reprod Biol, Pullman, WA 99164 USA.
EM skinner@mail.wsu.edu
RI Anway, Matthew/B-1480-2008
CR Akingbemi BT, 2001, ANN MED, V33, P391, DOI 10.3109/07853890108995952
   Allegrucci C, 2005, REPRODUCTION, V129, P137, DOI 10.1530/rep.1.00360
   Anway MD, 2006, ENDOCRINOLOGY, V147, P5515, DOI 10.1210/en.2006-0640
   Anway MD, 2005, SCIENCE, V308, P1466, DOI 10.1126/science.1108190
   Atanassova N, 2005, REPRODUCTION, V129, P589, DOI 10.1530/rep.1.00546
   Barber R, 2002, P NATL ACAD SCI USA, V99, P6877, DOI 10.1073/pnas.102015399
   BARTOLOMEI MS, 1991, NATURE, V351, P153, DOI 10.1038/351153a0
   Bertram L, 1998, NEUROGENETICS, V1, P277, DOI 10.1007/s100480050041
   Chao W, 2005, AM J PHYSIOL-HEART C, V289, pH2073, DOI 10.1152/ajpheart.01216.2005
   Cheng RYS, 2004, MOL CARCINOGEN, V40, P1, DOI 10.1002/mc.20022
   Clayton-Smith J, 2003, J MED GENET, V40, P87, DOI 10.1136/jmg.40.2.87
   Colbert NKW, 2005, ENVIRON HEALTH PERSP, V113, P700, DOI 10.1289/ehp.7509
   Confaloni A, 2003, NEUROSCI LETT, V353, P61, DOI 10.1016/j.neulet.2003.09.007
   d'Ancona FCH, 2005, HUM REPROD UPDATE, V11, P309, DOI 10.1093/humupd/dmi004
   De Strooper B, 2005, CELL, V122, P318, DOI 10.1016/j.cell.2005.07.021
   Deak KL, 2005, HUM GENET, V117, P133, DOI 10.1007/s00439-005-1299-7
   Dong H, 2004, BIOCHEMISTRY-US, V43, P15922, DOI 10.1021/bi0482194
   Dubourg C, 2004, HUM MUTAT, V24, P43, DOI 10.1002/humu.20056
   Eilers H, 2004, EUR J NEUROSCI, V20, P2283, DOI 10.1111/j.1460-9568.2004.03703.x
   Euling SY, 2001, SCI TOTAL ENVIRON, V274, P103, DOI 10.1016/S0048-9697(01)00736-7
   Fernebro J, 2006, INT J CANCER, V118, P1165, DOI 10.1002/ijc.21475
   Fiorentino F, 2005, Hum Genet, V116, P539
   Fraga MF, 2005, P NATL ACAD SCI USA, V102, P10604, DOI 10.1073/pnas.0500398102
   Gillman MW, 2005, NEW ENGL J MED, V353, P1848, DOI 10.1056/NEJMe058187
   Gluckman PD, 2004, PEDIATR RES, V56, P311, DOI 10.1203/01.PDR.0000135998.08025.FB
   Gong G, 2004, HUM MOL GENET, V13, pR91, DOI 10.1093/hmg/ddh074
   GOYAL HO, 1992, ANAT RECORD, V233, P53, DOI 10.1002/ar.1092330108
   Hakansson J, 2005, TUMOR BIOL, V26, P103, DOI 10.1159/000085817
   Hao XP, 2006, LEUKEMIA RES, V30, P397, DOI 10.1016/j.leukres.2005.08.021
   Heindel JJ, 2005, BIRTH DEFECTS RES A, V73, P131, DOI 10.1002/bdra.20119
   Hellwig J, 2000, REGUL TOXICOL PHARM, V32, P42, DOI 10.1006/rtph.2000.1400
   Hisano M, 2003, NUCLEIC ACIDS RES, V31, P4797, DOI 10.1093/nar/gkg670
   Hof D, 2005, AUTOIMMUN REV, V4, P380, DOI 10.1016/j.autrev.2005.02.003
   Hoffman RW, 2004, ARTHRITIS RHEUM, V50, P2891, DOI 10.1002/art.20428
   Hoyer PB, 2001, BIOCHEM PHARMACOL, V62, P1557, DOI 10.1016/S0006-2952(01)00814-0
   Hughes IA, 2001, ENDOCRINOLOGY, V142, P3281, DOI 10.1210/en.142.8.3281
   Jiang YH, 2004, ANNU REV GENOM HUM G, V5, P479, DOI 10.1146/annurev.genom.5.061903.180014
   Kanai Y, 2005, J BIOCHEM, V138, P13, DOI 10.1093/jb/mvi098
   Kaneda M, 2004, NATURE, V429, P900, DOI 10.1038/nature02633
   Kanemura Yonehiro, 2005, Congenital Anomalies, V45, P67, DOI 10.1111/j.1741-4520.2005.00067.x
   Kawamura S, 2004, INTERNAL MED, V43, P218, DOI 10.2169/internalmedicine.43.218
   Kim HJ, 2005, TOXICOL SCI, V88, P52, DOI 10.1093/toxsci/kfi287
   Kimberly WT, 2003, J NEUROSCI RES, V74, P353, DOI 10.1002/jnr.10736
   Kuroda M, 2005, FEBS LETT, V579, P167, DOI 10.1016/j.febslet.2004.11.070
   Laflamme C, 2003, CANCER RES, V63, P449
   Langley-Evans SC, 2006, P NUTR SOC, V65, P97, DOI 10.1079/PNS2005478
   Lazaro L, 2004, AM J MED GENET A, V129A, P21, DOI 10.1002/ajmg.a.30110
   Li E, 2002, NAT REV GENET, V3, P662, DOI 10.1038/nrg887
   Li JY, 2004, GENOMICS, V84, P952, DOI 10.1016/j.ygeno.2004.08.012
   Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427
   Li T, 2003, J NEUROSCI, V23, P3272
   Liu SJ, 2005, CANCER RES, V65, P1277, DOI 10.1158/0008-5472.CAN-04-4532
   Look A Thomas, 2005, Hematology Am Soc Hematol Educ Program, P156
   Lu ZJ, 2004, CELL PHYSIOL BIOCHEM, V14, P11, DOI 10.1159/000076922
   Lucifero D, 2004, HUM REPROD UPDATE, V10, P3, DOI 10.1093/humupd/dmh002
   Luedi PP, 2005, GENOME RES, V15, P875, DOI 10.1101/gr.3303505
   MAJDIC G, 1995, J ENDOCRINOL, V147, P285, DOI 10.1677/joe.0.1470285
   McLean DJ, 2002, MOL ENDOCRINOL, V16, P2780, DOI 10.1210/me.2002-0059
   Melnikov Anatoliy A, 2005, Nucleic Acids Res, V33, pe93, DOI 10.1093/nar/gni092
   Monk M, 2001, MOL CELL ENDOCRINOL, V183, pS35, DOI 10.1016/S0303-7207(01)00575-5
   Morgan HD, 2005, HUM MOL GENET, V14, pR47, DOI 10.1093/hmg/ddi114
   Morison IM, 2005, TRENDS GENET, V21, P457, DOI 10.1016/j.tig.2005.06.008
   Nanni L, 2000, AM J MED GENET, V90, P315, DOI 10.1002/(SICI)1096-8628(20000214)90:4<315::AID-AJMG10>3.0.CO;2-Y
   Nekrep N, 2001, MOL CELL BIOL, V21, P5566, DOI 10.1128/MCB.21.16.5566-5576.2001
   Nicolopoulou-Stamati P, 2001, HUM REPROD UPDATE, V7, P323, DOI 10.1093/humupd/7.3.323
   Nishino K, 2004, J BIOL CHEM, V279, P22306, DOI 10.1074/jbc.M309513200
   Pembrey ME, 2017, EUR J HUM GENET, V25, pS95, DOI [10.1038/sj.ejhg.5201538, 10.1038/sj.ejhg.5204538]
   Pereverzev A, 2002, MOL ENDOCRINOL, V16, P884, DOI 10.1210/me.16.4.884
   Pfeifer K, 2000, AM J HUM GENET, V67, P777, DOI 10.1086/303101
   Plappert CF, 2005, NEUROREPORT, V16, P1009, DOI 10.1097/00001756-200506210-00025
   Pohlers M, 2005, CURR BIOL, V15, P1051, DOI 10.1016/j.cub.2005.04.060
   Putz G, 2006, ONCOGENE, V25, P929, DOI 10.1038/sj.onc.1209136
   Rassoulzadegan M, 2006, NATURE, V441, P469, DOI 10.1038/nature04674
   Robertson KD, 2005, NAT REV GENET, V6, P597, DOI 10.1038/nrg1655
   Sajjad Y, 2004, HUM REPROD, V19, P1659, DOI 10.1093/humrep/deh295
   Sakata Y, 2002, FEBS LETT, V516, P229, DOI 10.1016/S0014-5793(02)02529-2
   Sarfarazi Mansoor, 2003, Ophthalmol Clin North Am, V16, P529
   Scarano MI, 2005, J CELL PHYSIOL, V204, P21, DOI 10.1002/jcp.20280
   Schumacher A, 2006, NUCLEIC ACIDS RES, V34, P528, DOI 10.1093/nar/gkj461
   Shima JE, 2004, BIOL REPROD, V71, P319, DOI 10.1095/biolreprod.103.026880
   Shu TZ, 2003, J NEUROSCI, V23, P203
   Stoll C, 2003, ANN GENET-PARIS, V46, P459, DOI 10.1016/S0003-3995(03)00031-5
   Takeuchi T, 2004, ENDOCR J, V51, P165, DOI 10.1507/endocrj.51.165
   Todaro L, 2004, NEUROBIOL DIS, V15, P387, DOI 10.1016/j.nbd.2003.11.014
   Turner KJ, 2003, TOXICOL SCI, V74, P114, DOI 10.1093/toxsci/kfg096
   Turner KJ, 2002, TOXICOL SCI, V68, P174, DOI 10.1093/toxsci/68.1.174
   Uzumcu M, 2004, REPROD TOXICOL, V18, P765, DOI 10.1016/j.reprotox.2004.05.008
   Valkova N, 2005, MOL CELL PROTEOMICS, V4, P1009, DOI 10.1074/mcp.M500091-MCP200
   Vissing J, 2005, ARCH NEUROL-CHICAGO, V62, P1440, DOI 10.1001/archneur.62.9.1440
   Wang JD, 2005, ONCOGENE, V24, P5637, DOI 10.1038/sj.onc.1208720
   Weksberg R, 2005, AM J MED GENET C, V137C, P12, DOI 10.1002/ajmg.c.30058
   Wolf CJ, 2000, TOXICOL SCI, V55, P152, DOI 10.1093/toxsci/55.1.152
   Wu YP, 2005, MOL GENET METAB, V84, P9, DOI 10.1016/ymgme.2004.08.017
   Xie WS, 2002, J BIOL CHEM, V277, P17765, DOI 10.1074/jbc.M200954200
   Yamazaki Y, 2003, P NATL ACAD SCI USA, V100, P12207, DOI 10.1073/pnas.2035119100
   Zambrano E, 2005, J PHYSIOL-LONDON, V566, P225, DOI 10.1113/jphysiol.2005.086462
   Zhang YW, 2005, J BIOL CHEM, V280, P17020, DOI 10.1074/jbc.M409467200
NR 97
TC 105
Z9 112
U1 6
U2 32
PU ENDOCRINE SOC
PI WASHINGTON
PA 2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA
SN 0013-7227
EI 1945-7170
J9 ENDOCRINOLOGY
JI Endocrinology
PD DEC
PY 2006
VL 147
IS 12
BP 5524
EP 5541
DI 10.1210/en.2006-0987
PG 18
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 105QK
UT WOS:000242047200005
PM 16973722
OA Bronze
DA 2018-12-27
ER

PT J
AU Yang, R
   Yang, X
   Zhang, Z
   Zhang, Y
   Wang, S
   Cai, Z
   Jia, Y
   Ma, Y
   Zheng, C
   Lu, Y
   Roden, R
   Chen, Y
AF Yang, R.
   Yang, X.
   Zhang, Z.
   Zhang, Y.
   Wang, S.
   Cai, Z.
   Jia, Y.
   Ma, Y.
   Zheng, C.
   Lu, Y.
   Roden, R.
   Chen, Y.
TI RETRACTED: Single-walled carbon nanotubes-mediated in vivo and in vitro
   delivery of siRNA into antigen-presenting cells (Retracted Article. See
   vol 14, 920, 2007)
SO GENE THERAPY
LA English
DT Article; Retracted Publication
DE single-walled carbon nanotubes; siRNA; dendritic cell;
   antigen-presenting cell
ID DENDRITIC CELLS; IMMUNE-RESPONSES; DNA; RNA; FUNCTIONALIZATION;
   COMPLEXES; EFFICIENT; VECTORS; CANCER; SOCS1
AB Antigen-presenting cells such as dendritic cells (DCs) play a critical role in inducing and regulating immune responses. One effective strategy for DC-based immunotherapy is to regulate maturation and function of DC. In this study, we apply single-walled carbon nanotubes (SWNTs) to carry small interfering RNA (siRNA) to reach, enter and genetically modify DCs in vivo. We prepared positively charged SWNTs (SWNTs+) using 1,6-diaminohexane which was demonstrated by transmission electron microscopy equipped with energy-dispersive X-ray spectroscopy and atomic force microscope. The functionalized SWNTs+ could absorb siRNA to form complexes of siRNA with SWNTs. These siRNA: SWNT+ complexes were preferentially taken up by splenic CD11c+ DCs, CD11b+ cells and also Gr-1+CD11b+ cells comprising DCs, macrophages and other myeloid cells to silence the targeting gene. Suppressor of cytokine signaling 1 (SOCS1) restricts the ability of DCs to break self-tolerance and induce antitumor immunity. Infusion of SWNTs+ carrying SOCS1 siRNA reduced SOCS1 expression and retarded the growth of established B16 tumor in mice, indicating the possibility of in vivo immunotherapeutics using SWNTs-based siRNA transfer system.
C1 Nankai Univ, Coll Med, Dept Immunol, Minist Educ,Key Lab Bioact Mat, Tianjin 300071, Peoples R China.
   Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA.
   Johns Hopkins Univ, Coll Chem, Inst Polymer Chem, Baltimore, MD 21205 USA.
   Johns Hopkins Univ, Coll Chem, Key Lab Funct Polymer Mat, Baltimore, MD 21205 USA.
   Tianjin Chest Hosp, China Clin Lab, Tianjin, Peoples R China.
   China Civil Aviat Univ, Dept Math, Tianjin, Peoples R China.
RP Yang, R (reprint author), Nankai Univ, Coll Med, Dept Immunol, Minist Educ,Key Lab Bioact Mat, Weijin Rd 94, Tianjin 300071, Peoples R China.
EM ryang@nankai.edu.cn; yschen99@nankai.edu.cn
RI Chen, Yongsheng/D-3256-2011
OI Chen, Yongsheng/0000-0003-1448-8177
CR Agrawal S, 2004, NAT BIOTECHNOL, V22, P1533, DOI 10.1038/nbt1042
   Akbari O, 2005, CURR ALLERGY ASTHM R, V5, P56, DOI 10.1007/s11882-005-0055-3
   An WY, 2005, J CLIN ONCOL, V23, P8535, DOI 10.1200/JCO.2004.00.6817
   Chen J, 1998, SCIENCE, V282, P95, DOI 10.1126/science.282.5386.95
   Far S, 2004, EUR J ORG CHEM, P1781, DOI 10.1002/ejoc.200300311
   Gabrilovich DI, 2001, J IMMUNOL, V166, P5398, DOI 10.4049/jimmunol.166.9.5398
   Han G, 2001, J PEPT RES, V58, P338, DOI 10.1034/j.1399-3011.2001.00935.x
   Hazani M, 2003, NANO LETT, V3, P153, DOI 10.1021/nl025874t
   Hill JA, 2003, J IMMUNOL, V171, P691, DOI 10.4049/jimmunol.171.2.691
   Huang WJ, 2002, NANO LETT, V2, P311, DOI [10.1021/nl010095i, 10.1021/n1010095i]
   Kam NWS, 2005, J AM CHEM SOC, V127, P12492, DOI 10.1021/ja053962k
   Kobayashi T, 2005, TRENDS IMMUNOL, V26, P177, DOI 10.1016/j.it.2005.02.004
   Kubo M, 2003, NAT IMMUNOL, V4, P1169, DOI 10.1038/ni1012
   Lv X, 2005, CARBON, V43, P2020, DOI 10.1016/j.carbon.2005.02.042
   Manoharan M, 2004, CURR OPIN CHEM BIOL, V8, P570, DOI 10.1016/j.cbpa.2004.10.007
   Nguyen CV, 2002, NANO LETT, V2, P1079, DOI 10.1021/nl025689f
   Pantarotto D, 2004, CHEM COMMUN, P16, DOI 10.1039/b311254c
   Paroo Z, 2004, TRENDS BIOTECHNOL, V22, P390, DOI 10.1016/j.tibtech.2004.06.004
   Peng SW, 2005, HUM GENE THER, V16, P584, DOI 10.1089/hum.2005.16.584
   Pompeo F, 2002, NANO LETT, V2, P369, DOI 10.1021/nl015680y
   Sano M, 2001, LANGMUIR, V17, P5125, DOI 10.1021/la010126p
   Serafini P, 2006, SEMIN CANCER BIOL, V16, P53, DOI 10.1016/j.semcancer.2005.07.005
   Shen L, 2004, NAT BIOTECHNOL, V22, P1546, DOI 10.1038/nbt1035
   Shortman K, 2002, NAT REV IMMUNOL, V2, P151, DOI 10.1038/nri746
   Singh R, 2005, J AM CHEM SOC, V127, P4388, DOI 10.1021/ja0441561
   SIOUD M, 2005, EXPERT OPIN DRUG DEL, V4, P639
   Sontheimer EJ, 2005, NAT REV MOL CELL BIO, V6, P127, DOI 10.1038/nrm1568
   Thomas CE, 2003, NAT REV GENET, V4, P346, DOI 10.1038/nrg1066
   Williams KA, 2002, NATURE, V420, P761, DOI 10.1038/420761a
   Yang RC, 2004, J VIROL, V78, P11152, DOI 10.1128/JVI.78.20.11152-11160.2004
   Yang RC, 2004, J IMMUNOL, V173, P2624, DOI 10.4049/jimmunol.173.4.2624
NR 31
TC 74
Z9 82
U1 4
U2 22
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0969-7128
EI 1476-5462
J9 GENE THER
JI Gene Ther.
PD DEC
PY 2006
VL 13
IS 24
BP 1714
EP 1723
DI 10.1038/sj.gt.3302808
PG 10
WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Genetics & Heredity; Medicine, Research & Experimental
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Genetics & Heredity; Research & Experimental Medicine
GA 115DZ
UT WOS:000242716300005
PM 16838032
OA Bronze
DA 2018-12-27
ER

PT J
AU Lamotte, M
   Annemans, L
   Kawalec, P
   Zoellner, Y
AF Lamotte, Mark
   Annemans, Lieven
   Kawalec, Pawel
   Zoellner, York
TI RETRACTED: A multi-country health-economic evaluation of highly
   concentrated n-3 polyunsaturated fatty acids in the secondary prevention
   after myocardial infarction (Retracted article. See vol. 39, pg. 221,
   2014)
SO HERZ
LA English
DT Article; Retracted Publication
DE cost-effectiveness; myocardial infarction; sudden death; n-3 PUFA
ID COST-EFFECTIVENESS ANALYSIS; ACUTE CORONARY SYNDROMES; HEART-DISEASE;
   SUDDEN-DEATH; TRIAL; (GISSI)-PREVENZIONE; PRAVASTATIN; POPULATION;
   CARDIOLOGY; MORTALITY
AB Patients who survive an acute myocardial infarction (MI) are at increased risk of subsequent major cardiovascular events and cardiac (often sudden) death. The use of highly concentrated and purified omega-3 polyunsaturated fatty acids (n-3 PUFAs), in addition to standard secondary prevention after MI, results in a significant reduction in the risk of sudden death. This study assessed the cost-effectiveness of adding n-3 PUFAs to the current secondary prevention treatment after acute MI in 5 countries: Australia, Belgium, Canada, Germany, Poland.
   Based on the clinical outcomes of GISSI-Prevenzione (MI, stroke, revascularisation rate and mortality), a decision-model was built in DataPROTM. The implications of adding n-3 PUFAs to standard treatment in patients with a recent history of MI were analysed from the health care payer's perspective. The time horizon was 3.5 years (identical to GISSI-Prevenzione). Event costs were based on literature data. Life expectancy data for survivors of cardiac disease were taken from the Saskatchewan database and then country-adjusted. Results are expressed as extra cost (E) per life-year gained (LYG). Annual discounting of 5% was applied to health effects and costs.
   Treatment with highly concentrated n-3 PUFAs yielded between 0.260 (Poland) and 0.284 (Australia) LYG, at an additional cost of EURO 807 (Canada) to EURO 1,451 (Belgium). The incremental cost-effectiveness ratio (ICER) varied between EURO 2,867 (Canada) and EURO 5,154 (Belgium) per LYG. Sensitivity analyses on effectiveness, cost of complications and discounting proved the robustness of the results. A 2nd order Monte Carlo simulation based on the 95% CIs obtained from GISSI showed that highly concentrated n-3 PUFAs are cost-effective in more than 99% of patients (assuming societal willingness to pay threshold of EURO 20,000/LYG). Including health care costs incurred during the remaining life-years considerably increased total costs, but had no impact on the ICER-based treatment recommendation.
   Adding highly concentrated n-3 PUFAs to standard treatment in the secondary prevention after MI appears to be cost-effective in the 5 countries studied.
C1 IMS, HEDM, B-1000 Brussels, Belgium.
   Univ Ghent VIB, B-9052 Ghent, Belgium.
   HTA Ctr, Krakow, Poland.
   Jagiellonian Univ, Coll Med, Inst Publ Hlth, Krakow, Poland.
   Solvay Pharmaceut GMBH, Global Hlth Econ, Hannover, Germany.
RP Lamotte, M (reprint author), IMS, HEDM, Rue Crayer 6, B-1000 Brussels, Belgium.
CR Abhyankar B, 2002, HOSP MED, V63, P610, DOI 10.12968/hosp.2002.63.10.1933
   Annemans L, 2003, J MED ECON, V6, P55
   Braunwald E, 1998, LANCET, V352, P1771, DOI 10.1016/S0140-6736(98)03212-7
   Brown RE, 2002, EUR HEART J, V23, P50, DOI 10.1053/euhj.2001.2711
   Capewell S, 2000, EUR HEART J, V21, P1833, DOI 10.1053/euhj.2000.2318
   Caro J, 1997, BRIT MED J, V315, P1577, DOI 10.1136/bmj.315.7122.1577
   Caro JJ, 2000, ACTA CARDIOL, V55, P239, DOI 10.2143/AC.55.4.2005746
   Coy P, 2000, INT J RADIAT ONCOL, V48, P1025, DOI 10.1016/S0360-3016(00)00713-6
   de Lorgeril M, 2000, CURR OPIN CARDIOL, V15, P364, DOI 10.1097/00001573-200009000-00009
   Franzosi MG, 2001, PHARMACOECONOMICS, V19, P411, DOI 10.2165/00019053-200119040-00008
   *GISSI PREV INV, 1999, LANCET, V354, P447
   Grover SA, 2001, DIABETES CARE, V24, P45, DOI 10.2337/diacare.24.1.45
   Haffner SM, 1998, NEW ENGL J MED, V339, P229, DOI 10.1056/NEJM199807233390404
   HALDEMANN R, 2001, SCHWEIZ RUNDSCH MED, V90, P539
   Hasdai D, 2002, EUR HEART J, V23, P1190, DOI 10.1053/euhj.2002.3193
   Huikuri HV, 2001, NEW ENGL J MED, V345, P1473, DOI 10.1056/NEJMra000650
   Johannesson M, 1997, MED DECIS MAKING, V17, P382, DOI 10.1177/0272989X9701700403
   Kotseva K, 2001, EUR HEART J, V22, P554, DOI 10.1053/euhj.2001.2610
   Lamotte M, 2003, VALUE HEALTH, V6, P658, DOI 10.1016/S1098-3015(10)61684-1
   Lampe FC, 2000, EUR HEART J, V21, P1052, DOI 10.1053/euhj.1999.1866
   Marchioli R, 2002, CIRCULATION, V105, P1897, DOI 10.1161/01.CIR.0000014682.14181.F2
   Marchioli R, 2001, EUR HEART J SUPPL, V3, pD85, DOI 10.1016/S1520-765X(01)90126-9
   Mauskopf JA, 2000, PHARMACOECONOMICS, V17, P611, DOI 10.2165/00019053-200017060-00007
   Muls E, 1998, ATHEROSCLEROSIS, V137, pS111, DOI 10.1016/S0021-9150(97)00321-3
   Myerburg RJ, 2001, CARDIOVASC RES, V50, P177, DOI 10.1016/S0008-6363(01)00253-X
   OPOLSKI G, 2002, URBAN PARTNER, P8
   PAJ A, 1996, PRZEGL LEK, V53, P767
   Pharoah PDP, 1996, BMJ-BRIT MED J, V312, P1443, DOI 10.1136/bmj.312.7044.1443
   Priori SG, 2001, EUR HEART J, V22, P1374, DOI 10.1053/euhj.2001.2824
   Tsevat J, 2001, AM HEART J, V141, P727, DOI 10.1067/mhj.2001.114805
   WITCZAK W, 1999, MED SCI MONITOR, V5, P1163
NR 31
TC 3
Z9 4
U1 1
U2 16
PU URBAN & VOGEL
PI MUNICH
PA NEUMARKTER STRASSE 43, D-81673 MUNICH, GERMANY
SN 0340-9937
EI 1615-6692
J9 HERZ
JI Herz
PD DEC
PY 2006
VL 31
SU 3
BP 74
EP 82
PG 9
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 129NG
UT WOS:000243735600009
PM 17575809
DA 2018-12-27
ER

PT J
AU Suttner, S
   Schollhorn, T
   Boldt, J
   Mayer, J
   Rohm, KD
   Lang, K
   Piper, SN
AF Suttner, Stefan
   Schoellhorn, Thilo
   Boldt, Joachim
   Mayer, Jochen
   Roehm, Kerstin D.
   Lang, Katrin
   Piper, Swen N.
TI RETRACTED: Noninvasive assessment of cardiac output using thoracic
   electrical bioimpedance in hemodynamically stable and unstable patients
   after cardiac surgery: a comparison with pulmonary artery thermodilution
   (Retracted article. See vol. 37, pg. 1232, 2011)
SO INTENSIVE CARE MEDICINE
LA English
DT Article; Retracted Publication
DE hemodynamic monitoring; cardiac output; thoracic electrical
   bioimpedance; pulmonary artery catheter; thermodilution; cardiac surgery
ID IMPEDANCE CARDIOGRAPHY; STROKE VOLUME; DEVICE
AB Objective: To compare noninvasive cardiac output (CO) measurement obtained with a new thoracic electrical bioimpedance (TEB) device, using a proprietary modification of the impedance equation, with invasive measurement obtained via pulmonary artery thermodilution. Design: Prospective, observational study. Setting: Surgical intensive care unit (ICU) of a university-affiliated community hospital. Patients and participants: Seventy-four adult patients undergoing elective cardiac surgery with routine pulmonary artery catheter placement. Interventions: None. Measurements and results: Simultaneous paired CO and cardiac index (CI) measurements by TEB and thermodilution were obtained in mechanically ventilated patients upon admission to the ICU. For analysis of CI data the patients were subdivided into a hemodynamically stable group and a hemodynamically unstable group. The groups were analyzed using linear regression and tests of bias and precision. We found a significant correlation between thermodilution and TEB (r=0.83; n < 0.001), accompanied by a bias of -0.01 l/min/m(2) and a precision of +/- 0.57 l/min/m(2) for all CI data pairs. Correlation, bias, and precision were not influenced by stratification of the data. The correlation coefficient, bias, and precision for CI were 0.86 (n < 0.001), 0.03 l/min/m(2), and +/- 0.47 l/min/m(2) in hemodynamically stable patients and 0.79 (n < 0.001), 0.06 l/min/m(2), and +/- 0.68 l/min/m(2) in hemodynamically unstable patients. Conclusions: Our results demonstrate a close correlation and clinically acceptable agreement and precision between CO measurements obtained with impedance cardiography using a new algorithm to calculate CO from variations in TEB, and those obtained with the clinical standard of care, pulmonary artery thermodilution, in hemodynamically stable and unstable patients after cardiac surgery.
C1 Klinikum Stadt Ludwigshafen, Dept Anesthesiol & Intens Care Med, D-67063 Ludwigshafen, Germany.
RP Suttner, S (reprint author), Klinikum Stadt Ludwigshafen, Dept Anesthesiol & Intens Care Med, Bremser Str 79, D-67063 Ludwigshafen, Germany.
EM suttner@gmx.de
CR APPEL PL, 1986, CRIT CARE MED, V14, P933, DOI 10.1097/00003246-198611000-00004
   BERNSTEIN DP, 1986, CRIT CARE MED, V14, P904, DOI 10.1097/00003246-198610000-00017
   BLAND JM, 1986, LANCET, V1, P307
   CAPEK JM, 1988, IEEE T BIO-MED ENG, V35, P653, DOI 10.1109/10.7266
   CROSS SJ, 1993, EUR HEART J, V14, P809, DOI 10.1093/eurheartj/14.6.809
   DOERING L, 1995, CRIT CARE MED, V23, P1667, DOI 10.1097/00003246-199510000-00010
   KUBICEK WG, 1966, AEROSPACE MED, V37, P1208
   Linton R, 1997, CRIT CARE MED, V25, P1796, DOI 10.1097/00003246-199711000-00015
   MORRIS AH, 1984, CRIT CARE MED, V12, P164, DOI 10.1097/00003246-198403000-00003
   Moshkovitz Y, 2004, CURR OPIN CARDIOL, V19, P229, DOI 10.1097/00001573-200405000-00008
   Osypka M J, 1999, AACN Clin Issues, V10, P385, DOI 10.1097/00044067-199908000-00008
   Pianosi PT, 1997, CHEST, V111, P333, DOI 10.1378/chest.111.2.333
   Pinsky MR, 2001, CRIT CARE MED, V29, P2021, DOI 10.1097/00003246-200110000-00028
   SAGEMAN WS, 1993, CRIT CARE MED, V21, P1139, DOI 10.1097/00003246-199308000-00011
   Schmidt C, 2005, BRIT J ANAESTH, V95, P603, DOI 10.1093/bja/aei224
   SHOEMAKER WC, 1994, CRIT CARE MED, V22, P1907
   Van de Water JM, 2003, CHEST, V123, P2028, DOI 10.1378/chest.123.6.2028
   YOUNG JD, 1993, BRIT J ANAESTH, V70, P58, DOI 10.1093/bja/70.1.58
NR 18
TC 50
Z9 52
U1 4
U2 16
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0342-4642
EI 1432-1238
J9 INTENS CARE MED
JI Intensive Care Med.
PD DEC
PY 2006
VL 32
IS 12
BP 2053
EP 2058
DI 10.1007/s00134-006-0409-x
PG 6
WC Critical Care Medicine
SC General & Internal Medicine
GA 110EU
UT WOS:000242361900023
PM 17039348
DA 2018-12-27
ER

PT J
AU Garg, D
   Saxena, SC
   Bhardwaj, LM
AF Garg, Deepak
   Saxena, Suresh C.
   Bhardwaj, Lalit M.
TI RETRACTED: A new middle path approach for alignments in BLAST (Retracted
   article, see vol 15, pg 417, 2007)
SO JOURNAL OF BIOLOGICAL SYSTEMS
LA English
DT Article; Retracted Publication
DE gapped alignment; BLAST; middle path; DNA sequences; HSPs
ID SEQUENCE; ACID
AB This paper deals with a new middle path approach developed for reducing alignment calculations in BLAST algorithm. This is a new step which is introduced in BLAST algorithm in between the ungapped and gapped alignments. This step of middle path approach between the ungapped and gapped alignments reduces the number of sequences going for gapped alignment. This results in the improvement in speed for alignment up to 30%.
C1 Thapar Inst Engn & Technol, Dept Comp Sci & Engn, Patiala, Punjab, India.
   Indian Inst Technol, Roorkee, Uttar Pradesh, India.
   Cent Sci Instruments Org, Chandigarh, India.
RP Garg, D (reprint author), Thapar Inst Engn & Technol, Dept Comp Sci & Engn, Patiala, Punjab, India.
EM dgarg@tiet.ac.in
OI Garg, Deepak/0000-0002-7243-3599
CR Altschul SF, 1998, PROTEINS, V32, P88, DOI 10.1002/(SICI)1097-0134(19980701)32:1<88::AID-PROT10>3.0.CO;2-J
   ALTSCHUL SF, 1994, NAT GENET, V6, P119, DOI 10.1038/ng0294-119
   Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389
   ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2
   Brenner SE, 1998, P NATL ACAD SCI USA, V95, P6073, DOI 10.1073/pnas.95.11.6073
   Dayhoff M.O., 1978, ATLAS PROTEIN SEQ S3, V5, P345
   GARG D, 2005, USING DROP PERCENTAG, P99
   GARG D, 2004, P BIOT APPR SUST DEV, P45
   GUSFIELD D, 1997, ALGORITHMS STRINGS T, P297
   HENIKOFF S, 1992, P NATL ACAD SCI USA, V89, P10915, DOI 10.1073/pnas.89.22.10915
   KORF I, 2003, BLAST, P55
   MA B, 2002, J BIOINF COMPUT BIOL, V2, P417
   Park J, 1998, J MOL BIOL, V284, P1201, DOI 10.1006/jmbi.1998.2221
   PEARSON WR, 1992, METHOD ENZYMOL, V210, P575
   PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444
   WILBUR WJ, 1983, P NATL ACAD SCI-BIOL, V80, P726, DOI 10.1073/pnas.80.3.726
   ZHANG Z, 1997, P ANN C RES COMPUT M, V4, P339
NR 17
TC 1
Z9 1
U1 3
U2 11
PU WORLD SCIENTIFIC PUBL CO PTE LTD
PI SINGAPORE
PA 5 TOH TUCK LINK, SINGAPORE 596224, SINGAPORE
SN 0218-3390
EI 1793-6470
J9 J BIOL SYST
JI J. Biol. Syst.
PD DEC
PY 2006
VL 14
IS 4
BP 567
EP 581
DI 10.1142/S0218339006001982
PG 15
WC Biology; Mathematical & Computational Biology
SC Life Sciences & Biomedicine - Other Topics; Mathematical & Computational
   Biology
GA 126FW
UT WOS:000243498800004
DA 2018-12-27
ER

PT J
AU Cai, G
   Nie, XM
   Guo, PE
   Guan, Z
   Zhang, J
   Shen, Q
AF Cai, Gang
   Nie, Xiaomeng
   Guo, Pin'e
   Guan, Zheng
   Zhang, Jun
   Shen, Qian
TI RETRACTED: A new inducible adenoviral expression system that responds to
   inflammatory stimuli in vivo (Retracted article. See vol 9, pg 424,
   2007)
SO JOURNAL OF GENE MEDICINE
LA English
DT Article; Retracted Publication
DE inducible promoter; gene therapy; adenoviral vector; autoimmune diseases
ID COLLAGEN-INDUCED ARTHRITIS; MEDIATED TRANSFER; CPG METHYLATION; GENE;
   INTERLEUKIN-1; INHIBITION; ASTROCYTES; TRANSGENE; IL-1-BETA; PROMOTER
AB Background Gene transfer using inducible promoters, which control expression of transgenic proteins in response to physiological conditions, may have significant advantages. In this study, we tried to achieve an inducible adenoviral expression system for physiologically responsive gene therapy of autoimmune or inflammatory diseases.
   Methods A luciferase reporter vector with a hybrid promoter containing the human IL-1 beta enhancer region (-3690 to -2720) and the human ClITA promoter IV (-399 to +2) was constructed. A replication-deficient adenovirus was engineered with luciferase controlled by the 1L1 beta/CIITApIV promoter (Ad-IL1 beta/CIITApIV-Luc). The reporter vector or adenovirus was transfected to C57131/6 myeloid dendritic cells (DCs), RAW264.7, and Hep G2 to study the in vitro characteristics of this hybrid promoter. An inflammation model was prepared by injecting lipopolysaccharide (LPS) into Balb/c mice intraperitoneally (i.p.), and infected with Ad-IL1 beta/CIITApIV-Luc or Ad-CMW-Luc to study the in vivo characteristics of the IL1 beta/CIITApIV promoter.
   Results The IL1 beta/CIITApIV hybrid promoter has pronounced promoter activity, broad-range responsiveness to cytokines or LPS, and can be rechallenged after first induction. In the inflammation model, IL1 beta/CIITApIV could drive hepatic luciferase expression increasedly rapidly after LPS challenge and in a LPS dose-dependent manner.
   Conclusions Using the IL1 beta/CIITApIV hybrid promoter in gene transfer vectors may make it possible to produce transgenic proteins in vivo in direct relationship with the intensity and duration of an individual's status. By providing endogenously controlled production of transgenic proteins, this approach might limit the severity of autoimmune or inflammatory response without interfering with the beneficial components of host defense and immunity. Copyright (c) 2006 John Wiley & Sons, Ltd.
C1 Mil Med Univ 2, Changhai Hosp, Dept Lab Diagnosis, Shanghai 200433, Peoples R China.
   Mil Med Univ 2, Changhai Hosp, Dept Resp Dis, Shanghai 200433, Peoples R China.
RP Shen, Q (reprint author), Mil Med Univ 2, Changhai Hosp, Dept Lab Diagnosis, 174 Changhai Rd, Shanghai 200433, Peoples R China.
EM shenqiansmmu@yahoo.com.cn
CR Abe M, 1997, J RHEUMATOL, V24, P420
   Bakker AC, 2002, ARTHRITIS RHEUM, V46, P1661, DOI 10.1002/art.10481
   Brigham K L, 1995, New Horiz, V3, P321
   Butler M, 2006, EUR J IMMUNOL, V36, P864, DOI 10.1002/eji.200535497
   Cai G, 2005, J MOL CELL CARDIOL, V38, P593, DOI 10.1016/j.yjmcc.2005.01.009
   Cheeran MCJ, 2000, J IMMUNOL, V164, P926, DOI 10.4049/jimmunol.164.2.926
   Coulthard MG, 1996, INFECT IMMUN, V64, P1510
   Curradi M, 2002, MOL CELL BIOL, V22, P3157, DOI 10.1128/MCB.22.9.3157-3173.2002
   Fang IM, 2005, J OCUL PHARMACOL TH, V21, P420, DOI 10.1089/jop.2005.21.420
   GARDEN GA, 2005, BRAIN RES BRAIN RES, V50, P14
   Hartung HP, 2005, J NEUROL, V252, P44, DOI 10.1007/s00415-005-2017-z
   He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509
   HERZ J, 1993, P NATL ACAD SCI USA, V90, P2812, DOI 10.1073/pnas.90.7.2812
   HUARD J, 1995, GENE THER, V2, P107
   Imhof MO, 2002, J BIOTECHNOL, V97, P275, DOI 10.1016/S0168-1656(02)00104-9
   Lahiri T, 2002, AM J PHYSIOL-LUNG C, V283, pL1239, DOI 10.1152/ajplung.00231.2001
   Miagkov AV, 2002, J CLIN INVEST, V109, P1223, DOI 10.1172/JCI200214536
   Nikcevich KM, 1999, J NEUROIMMUNOL, V99, P195, DOI 10.1016/S0165-5728(99)00117-4
   Perry MG, 2006, RHEUMATOLOGY, V45, P229, DOI 10.1093/rheumatology/kei196
   Prosch S, 1996, BIOL CHEM H-S, V377, P195, DOI 10.1515/bchm3.1996.377.3.195
   Razin A, 1998, EMBO J, V17, P4905, DOI 10.1093/emboj/17.17.4905
   Smith R, 2003, GENE THER, V10, P1248, DOI 10.1038/sj.gt.3301980
   Tellez N, 2005, GENE THER, V12, P120, DOI 10.1038/sj.gt.3302351
   VANDELOO AAJ, 1995, AM J PATHOL, V146, P239
   Varley AW, 1997, NAT BIOTECHNOL, V15, P1002, DOI 10.1038/nbt1097-1002
NR 25
TC 3
Z9 4
U1 4
U2 12
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1099-498X
EI 1521-2254
J9 J GENE MED
JI J. Gene. Med.
PD DEC
PY 2006
VL 8
IS 12
BP 1369
EP 1378
DI 10.1002/jgm.983
PG 10
WC Biotechnology & Applied Microbiology; Genetics & Heredity; Medicine,
   Research & Experimental
SC Biotechnology & Applied Microbiology; Genetics & Heredity; Research &
   Experimental Medicine
GA 118ZF
UT WOS:000242981300001
PM 17133340
DA 2018-12-27
ER

PT J
AU Pathak, SK
   Basu, S
   Bhattacharyya, A
   Pathak, S
   Banerjee, A
   Basu, J
   Kundu, M
AF Pathak, Sushil Kumar
   Basu, Sanchita
   Bhattacharyya, Asima
   Pathak, Shresh
   Banerjee, Anirban
   Basu, Joyoti
   Kundu, Manikuntala
TI RETRACTED: TLR4-dependent NF-kappa B activation and mitogen- and
   stress-activated protein kinase 1-triggered phosphorylation events are
   central to Helicobacter pylori peptidyl prolyl cis-, trans-isomerase
   (HP0175)-mediated induction of IL-6 release from macrophages (Retracted
   article. See vol. 195, pg. 1902, 2015)
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article; Retracted Publication
ID TUMOR-NECROSIS-FACTOR; GASTRIC EPITHELIAL-CELLS; TOLL-LIKE RECEPTOR-4;
   INNATE IMMUNITY; SIGNAL-TRANSDUCTION; ADAPTER PROTEIN; FACTOR-ALPHA;
   TAK1 MAPKKK; EXPRESSION; INTERLEUKIN-6
AB Helicobacter pylori infection is associated with the local production of chemokines and cytokines, of which IL-6 is overexpressed at the margin of gastric ulcer in H. pylori-positive gastritis. Cells of the monocytic lineage are the major sources of IL-6, and mononuclear cell infiltration in the lamina propria is characteristic of H. pylori-induced chronic infection. Our study shows for the first time that a secreted peptidyl prolyl cis-, trans-isomerase, HP0175 elicits IL-6 gene expression and IL-6 release from macrophages. An isogenic strain inactivated in the HSP0175 gene (knockout) was attenuated in its IL-6-inducing ability, which was restored after complementation with the HP017.5 gene. The specificity of the HP0175-induced effect was confirmed by the fact that rHP0175 purified from HEK293 cells could also induce IL-6 release, ruling out the possibility that the observed effect was due to bacterial contaminants. HP0175 was capable of interacting directly with the extracellular domain of TLR4. HP0175-induced IL-6 gene expression was critically dependent on TLR4-dependent NF-kappa B and MAPK activation. TLR4/PI3K-dependent ERK1/2 and p38 MAPK signaling converged upon activation of mitogen- and stress-activated protein kinase 1 (MSK1). The central role of MSK1 was borne out by the fact that silencing of MSK1 expression abrogated HP0175-mediated NF-kappa B-dependent IL-6 gene transcription. MSK1 regulated the recruitment of p65 and phopbo-Ser(10)-histone H3 to the IL-6 promoter. HP0175 therefore regulated IL-6 gene transcription through chromatin modification at the IL-6 promoter.
C1 Bose Inst, Dept Chem, Kolkata 700009, W Bengal, India.
RP Kundu, M (reprint author), Bose Inst, Dept Chem, 93-1 APC Rd, Kolkata 700009, W Bengal, India.
EM manikuntala@vsnl.net
RI PATHAK, SHRESH/I-6938-2012
OI Banerjee, Anirban/0000-0001-7678-1868; Bhattacharyya,
   Asima/0000-0001-7292-6644; PATHAK, SHRESH/0000-0001-5275-1816
CR Aderem A, 2000, NATURE, V406, P782, DOI 10.1038/35021228
   AKIRA S, 1993, ADV IMMUNOL, V54, P1, DOI 10.1016/S0065-2776(08)60532-5
   Akira S, 2003, J BIOL CHEM, V278, P38105, DOI 10.1074/jbc.R300028200
   AKIRA S, 1992, IMMUNOL REV, V127, P25, DOI 10.1111/j.1600-065X.1992.tb01407.x
   ALESSI DR, 1995, METHOD ENZYMOL, V255, P279
   Atanassov C, 2002, J CLIN MICROBIOL, V40, P547, DOI 10.1128/JCM.40.2.547-552.2002
   Basak C, 2005, J IMMUNOL, V174, P5672, DOI 10.4049/jimmunol.174.9.5672
   Benard V, 1999, J BIOL CHEM, V274, P13198, DOI 10.1074/jbc.274.19.13198
   Bhattacharyya A, 2002, BIOCHEM J, V368, P121, DOI 10.1042/BJ20020555
   Bradley JR, 2001, ONCOGENE, V20, P6482, DOI 10.1038/sj.onc.1204788
   Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0
   Cao ZD, 1996, SCIENCE, V271, P1128, DOI 10.1126/science.271.5252.1128
   CRABTREE JE, 1991, GUT, V32, P1473, DOI 10.1136/gut.32.12.1473
   Deak M, 1998, EMBO J, V17, P4426, DOI 10.1093/emboj/17.15.4426
   FURUKAWA K, 1989, GASTROENTEROLOGY, V33, P625
   Gobert AP, 2004, J BIOL CHEM, V279, P245, DOI 10.1074/jbc.M307858200
   Harris PR, 2000, J INFECT DIS, V181, P783, DOI 10.1086/315257
   Hermans PWM, 2006, J BIOL CHEM, V281, P968, DOI 10.1074/jbc.M510014200
   Heuermann D, 1998, MOL GEN GENET, V257, P519, DOI 10.1007/s004380050677
   Hyakushima N, 2004, J IMMUNOL, V173, P6949, DOI 10.4049/jimmunol.173.11.6949
   Ishihara S, 2004, J IMMUNOL, V173, P1406, DOI 10.4049/jimmunol.173.2.1406
   Janknecht R, 2003, ONCOGENE, V22, P746, DOI 10.1038/sj.onc.1206185
   Kim N, 2002, J BACTERIOL, V184, P6155, DOI 10.1128/JB.184.22.6155-6162.2002
   Kohler R, 2003, INFECT IMMUN, V71, P4389, DOI 10.1128/IAI.71.8.4389-4397.2003
   Mandell L, 2004, INFECT IMMUN, V72, P6446, DOI [10.1128/IAI.72.11.6446-6454.2004, 10.1128/IAI.72.11.6446.6454.2004]
   McAtee CP, 1998, J CHROMATOGR B, V714, P325, DOI 10.1016/S0378-4347(98)00215-1
   Medzhitov R, 2001, NAT REV IMMUNOL, V1, P135, DOI 10.1038/35100529
   Medzhitov R, 1998, MOL CELL, V2, P253, DOI 10.1016/S1097-2765(00)80136-7
   Muzio M, 1997, SCIENCE, V278, P1612, DOI 10.1126/science.278.5343.1612
   NOACH LA, 1994, SCAND J GASTROENTERO, V29, P425, DOI 10.3109/00365529409096833
   Saccani S, 2002, NAT IMMUNOL, V3, P69, DOI 10.1038/ni748
   Shaw PE, 2002, EMBO REP, V3, P521, DOI 10.1093/embo-reports/kvf118
   Shibuya H, 1996, SCIENCE, V272, P1179, DOI 10.1126/science.272.5265.1179
   Smith MF, 2003, J BIOL CHEM, V278, P32552, DOI 10.1074/jbc.M305536200
   Su B, 2003, INFECT IMMUN, V71, P3496, DOI 10.1128/IAI.3496-3502.2003
   Suerbaum S, 2002, NEW ENGL J MED, V347, P1175, DOI 10.1056/NEJMra020542
   Swantek JL, 2000, J IMMUNOL, V164, P4301, DOI 10.4049/jimmunol.164.8.4301
   Takaesu G, 2000, MOL CELL, V5, P649, DOI 10.1016/S1097-2765(00)80244-0
   Tanahashi T, 2000, INFECT IMMUN, V68, P664, DOI 10.1128/IAI.68.2.664-671.2000
   Taylor SJ, 2001, METHOD ENZYMOL, V333, P333
   Thomson S, 1999, EMBO J, V18, P4779, DOI 10.1093/emboj/18.17.4779
   TILG H, 1994, BLOOD, V83, P113
   Vanden Berghe W, 1998, J BIOL CHEM, V273, P3285, DOI 10.1074/jbc.273.6.3285
   VERMEULEN I, 2003, EMBO J, V22, P1313
   Wesche H, 1997, IMMUNITY, V7, P837, DOI 10.1016/S1074-7613(00)80402-1
   Yamaoka Y, 2001, HELICOBACTER, V6, P116, DOI 10.1046/j.1523-5378.2001.00017.x
   Zhang GL, 2001, J CLIN INVEST, V107, P13, DOI 10.1172/JCI11837
   Zhong HH, 2002, MOL CELL, V9, P625, DOI 10.1016/S1097-2765(02)00477-X
NR 48
TC 74
Z9 76
U1 3
U2 12
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
EI 1550-6606
J9 J IMMUNOL
JI J. Immunol.
PD DEC 1
PY 2006
VL 177
IS 11
BP 7950
EP 7958
DI 10.4049/jimmunol.177.11.7950
PG 9
WC Immunology
SC Immunology
GA 108TJ
UT WOS:000242261800054
PM 17114467
OA Bronze
DA 2018-12-27
ER

PT J
AU Han, CS
AF Han, Chang-Suk
TI RETRACTED: Precipitation behavior of B2-ordered aluminide (Retracted
   article. See vol. 21, pg. 607, 2015)
SO METALS AND MATERIALS INTERNATIONAL
LA English
DT Article; Retracted Publication
DE age-hardening; precipitates; mechanical properties
ID MECHANICAL-PROPERTIES; INTERMETALLIC ALLOYS; SLIP SYSTEMS; NI SYSTEM;
   PHASE; DIFFUSION
AB Fine dispersion of disordered phases is obtained in Ni-Al-Cr and Fe-Al-Co ternary systems. A transmission electron microscope investigation has been performed on the precipitation of alpha-Cr in B2-ordered beta-NiAl with different stoichiometry and alpha-Fe in B2-FeAl(Co) compound. Precipitation behavior and hardening were investigated by measuring the hardness variation. The hardness of NiAl and FeAl increases appreciably with the fine precipitation of alpha-Cr and alpha-Fe, and over-age softening occurs after prolonged aging. In the case of B2-NiAl(Cr), perfect lattice coherency is maintained at the interfaces between the alpha-Cr particles and the matrix during the initial stage of aging. After prolonged aging, a loss of coherency occurs by the attraction of matrix dislocations to the particle/matrix interface, followed by climbing around the particles. On the other hand, in the case of B2-FeAl(Co), the disordered alpha-Fe phase is present as a precipitate in the B2-FeAl(Co) matrix and has a cubic-cubic orientation with the matrix. At the early aging periods, prismatic dislocation loops formed in the B2-FeAl(Co) matrix. B2-FeAl(Co) matrix is typically hardened by the precipitation of alpha-Fe.
C1 Hoseo Univ 165, Dept Def Sci & Technol, Chungnam 336795, South Korea.
RP Han, CS (reprint author), Hoseo Univ 165, Dept Def Sci & Technol, Chungnam 336795, South Korea.
EM hancs@office.hoseo.ac.kr
CR Ackermann H., 1987, CALPHAD M 14 IRS, P15
   BOWMAN RR, 1992, METALL TRANS A, V23, P1493, DOI 10.1007/BF02647332
   Bradley AJ, 1937, PROC R SOC LON SER-A, V159, P0056, DOI 10.1098/rspa.1937.0056
   CHANG YA, 1982, PROG SOLID STATE CH, V14, P221, DOI 10.1016/0079-6786(82)90004-8
   CLINE HE, 1971, ACTA METALL MATER, V19, P405, DOI 10.1016/0001-6160(71)90163-5
   COTTON JD, 1993, INTERMETALLICS, V1, P117, DOI 10.1016/0966-9795(93)90029-U
   DAROLIA R, 1991, JOM-J MIN MET MAT S, V43, P44, DOI 10.1007/BF03220163
   Darolia R., 2004, MET MATER INT, V10, P679
   FIELD RD, 1991, ACTA METALL MATER, V39, P2961, DOI 10.1016/0956-7151(91)90028-Y
   FIELD RD, 1989, MAT RES SOC S INT P, V133, P225
   HANCOCK GF, 1971, PHYS STATUS SOLIDI A, V4, P143, DOI 10.1002/pssa.2210040115
   Khan T., 1990, HIGH TEMPERATURE ALU, P219
   KORNILOV II, 1958, ZH NEORG KHIM+, V3, P699
   KOZAKAI T, 1991, INTERMETALLIC COMPOU, P257
   Mendiratta M. G., 1982, INT P 3 C RAP SOL PR, P112
   Mendiratta M. G., 1987, METALL T, V18, P989
   MENDIRATTA MG, 1987, HIGH TEMPERATURE ORD, V2, P393
   MERCHANT SM, 1984, MATER SCI ENG, V66, P47, DOI 10.1016/0025-5416(84)90140-X
   MIRACLE DB, 1993, ACTA METALL MATER, V41, P649, DOI 10.1016/0956-7151(93)90001-9
   MIYAZAKI T, 1987, ACTA METALL MATER, V35, P317, DOI 10.1016/0001-6160(87)90240-9
   Morgan E. R., 1955, METAL PROGR, V68, P126
   NAKA S, 1992, NATO ASI SERIES E, P645
   NATHAL MV, 1992, NATO ASI SERIES E, P541
   NOEBE RD, 1993, INT MATER REV, V38, P193, DOI 10.1179/imr.1993.38.4.193
   NOEBE RD, 1992, J MATER RES, V7, P605, DOI 10.1557/JMR.1992.0605
   ROGL P, 1991, TERNARY ALLOYS, V4, P400
   SHANKAR S, 1978, METALL TRANS A, V9, P1467, DOI 10.1007/BF02661819
   Song SH, 2004, MET MATER-INT, V10, P307, DOI 10.1007/BF03185978
   Sykes C., 1934, J IRON STEEL I, V130, P389
   TAYLOR A, 1972, J APPL CRYSTALLOGR, V5, P201, DOI 10.1107/S0021889872009203
   WALTER JL, 1969, T METALL SOC AIME, V245, P2073
   YAMAGUCHI M, 1990, PROG MATER SCI, V34, P1, DOI 10.1016/0079-6425(90)90002-Q
NR 32
TC 4
Z9 4
U1 4
U2 15
PU KOREAN INST METALS MATERIALS
PI SEOUL
PA KIM BLDG 6TH FLOOR, SEOCHO-DAERO 56 GIL 38, SEOCHO-GU, SEOUL 137-881,
   SOUTH KOREA
SN 1598-9623
EI 2005-4149
J9 MET MATER INT
JI Met. Mater.-Int.
PD DEC
PY 2006
VL 12
IS 6
BP 467
EP 475
DI 10.1007/BF03027746
PG 9
WC Materials Science, Multidisciplinary; Metallurgy & Metallurgical
   Engineering
SC Materials Science; Metallurgy & Metallurgical Engineering
GA 121DD
UT WOS:000243137400003
DA 2018-12-27
ER

PT J
AU Gu, PL
   Le Menuet, D
   Chung, ACK
   Cooney, AJ
AF Gu, Peili
   Le Menuet, Damien
   Chung, Arthur C. -K.
   Cooney, Austin J.
TI RETRACTED: Differential recruitment of methylated CpG binding domains by
   the orphan receptor GCNF initiates the repression and silencing of Oct4
   expression (Retracted article. See vol. 29, pg. 1987, 2009)
SO MOLECULAR AND CELLULAR BIOLOGY
LA English
DT Article; Retracted Publication
ID EMBRYONIC STEM-CELLS; TESTIS-ASSOCIATED RECEPTOR; TRANSCRIPTION FACTOR
   OCT4; DNA METHYLATION; NUCLEAR FACTOR; RESPONSE ELEMENT; OCT-3/4 GENE;
   PROTEINS; PLURIPOTENCY; COMPLEX
AB The pluripotent factor Oct4 is a key transcription factor that maintains embryonic stem (ES) cell self-renewal and is down-regulated upon the differentiation of ES cells and silenced in somatic cells. A combination of cis elements, transcription factors, and epigenetic modifications, such as DNA methylation, are involved in the regulation of Oct4 gene expression. Here we show that the orphan nuclear receptor GCNF initiates Oct4 repression and DNA methylation by the differential recruitment of MBD (methylated CpG binding domain) factors to the promoter. Compared with wild-type ES cells and gastrulating embryos, Oct4 repression is lost and its proximal promoter is significantly hypomethylated in RA-differentiated GCNF(-/-) ES cells. The Oct4 gene is reexpressed in some somatic cells of GCNF(-/-) embryos, showing that it has not been properly silenced coincident with reduced DNA methylation of its promoter. Efforts to characterize mediators of GCNF's repressive function and DNA methylation of the Oct4 promoter identified methyl-DNA binding proteins, MBD3 and MBD2, as GCNF-interacting factors. In P19 and ES cells, upon differentiation, endogenous GCNF binds to the Oct4 proximal promoter and differentially recruits MBD3 and MBD2. In differentiated GCNF(-/-) ES cells, recruitment of MBD3 and MBD2 to the Oct4 promoter is lost, and repression of Oct4 expression and DNA methylation fails to occur. RNA interference-mediated knockdown of MBD3 and/or MBD2 expression results in reduced Oct4 repression in differentiated P19 and ES cells. Repression of Oct4 expression and recruitment of MBD3 are maintained in de novo DNA methylation-deficient ES cells (Dnmt3A/3B-null cells), while MBD2 recruitment is lost. Thus, recruitment of MBD3 and MBD2 by GCNF links two events, gene-specific repression and DNA methylation, which occur differentially at the Oct4 promoter. GCNF initiates the repression and epigenetic modification of Oct4 gene during ES cell differentiation.
C1 Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA.
RP Cooney, AJ (reprint author), Baylor Coll Med, Dept Mol & Cellular Biol, 1 Baylor Plaza, Houston, TX 77030 USA.
EM acooney@bcm.edu
FU NICHD NIH HHS [T32 HD007165, HD07165]; PHS HHS [07352401]
CR Barnea E, 2000, J BIOL CHEM, V275, P6608, DOI 10.1074/jbc.275.9.6608
   BENSHUSHAN E, 1993, MOL CELL BIOL, V13, P891, DOI 10.1128/MCB.13.2.891
   Bird A, 1999, SCIENCE, V286, P2287, DOI 10.1126/science.286.5448.2287
   Boeke J, 2000, J BIOL CHEM, V275, P34963, DOI 10.1074/jbc.M005929200
   Boiani M, 2005, NAT REV MOL CELL BIO, V6, P872, DOI 10.1038/nrm1744
   Boyer LA, 2005, CELL, V122, P947, DOI 10.1016/j.cell.2005.08.020
   Chambers I, 2004, CLONING STEM CELLS, V6, P386, DOI 10.1089/clo.2004.6.386
   Chung ACK, 2001, MOL CELL BIOL, V21, P663, DOI 10.1128/MCB.21.2.663-677.2001
   Cooney AJ, 2001, TRENDS ENDOCRIN MET, V12, P247, DOI 10.1016/S1043-2760(01)00424-6
   Deb-Rinker P, 2005, J BIOL CHEM, V280, P6257, DOI 10.1074/jbc.C400479200
   DI CL, 2002, SCIENCE, V295, P1079
   Elliott K, 1999, ONCOGENE, V18, P3564, DOI 10.1038/sj.onc.1202670
   Feldman N, 2006, NAT CELL BIOL, V8, P188, DOI 10.1038/ncb1353
   Fuhrmann G, 2001, DEV CELL, V1, P377, DOI 10.1016/S1534-5807(01)00038-7
   Gidekel S, 2002, J BIOL CHEM, V277, P34521, DOI [10.1074/jbc.M203338200, 10.1047/jbc.M203338200]
   Gu PL, 2005, MOL CELL BIOL, V25, P8507, DOI 10.1128/MCB.25.19.8507-8519.2005
   Gu PL, 2005, J BIOL CHEM, V280, P31818, DOI 10.1074/jbc.M501924200
   Gu PL, 2005, MOL CELL BIOL, V25, P3492, DOI 10.1128/MCB.25.9.3492-3505.2005
   Hendrich B, 1998, MOL CELL BIOL, V18, P6538, DOI 10.1128/MCB.18.11.6538
   Hendrich B, 2001, GENE DEV, V15, P710, DOI 10.1101/gad.194101
   Hendrich B, 2000, CURR TOP MICROBIOL, V249, P55
   Jackson M, 2004, MOL CELL BIOL, V24, P8862, DOI 10.1128/MCB.24.20.8862-8871.2004
   Jorgensen HF, 2002, MENT RETARD DEV D R, V8, P87, DOI 10.1002/mrdd.10021
   Kaji K, 2006, NAT CELL BIOL, V8, P285, DOI 10.1038/ncb1372
   Kehler J, 2004, EMBO REP, V5, P1078, DOI 10.1038/sj.embor.7400279
   Lan ZJ, 2002, J BIOL CHEM, V277, P50660, DOI 10.1074/jbc.M209586200
   Le Guezennec X, 2006, MOL CELL BIOL, V26, P843, DOI 10.1128/MCB.26.3.843-851.2006
   Lei W, 1997, J MOL ENDOCRINOL, V18, P167, DOI 10.1677/jme.0.0180167
   Nichols J, 1998, CELL, V95, P379, DOI 10.1016/S0092-8674(00)81769-9
   Niwa H, 2000, NAT GENET, V24, P372, DOI 10.1038/74199
   Okumura-Nakanishi S, 2005, J BIOL CHEM, V280, P5307, DOI 10.1074/jbc.m410015200
   Pan GJ, 2002, CELL RES, V12, P321, DOI 10.1038/sj.cr.7290134
   Pesce M, 2000, MOL REPROD DEV, V55, P452, DOI 10.1002/(SICI)1098-2795(200004)55:4<452::AID-MRD14>3.3.CO;2-J
   Saito M, 2002, J BIOL CHEM, V277, P35434, DOI 10.1074/jbc.M203455200
   SCHOLER HR, 1989, EMBO J, V8, P2543, DOI 10.1002/j.1460-2075.1989.tb08392.x
   SCHOORLEMMER J, 1994, MOL CELL BIOL, V14, P1122, DOI 10.1128/MCB.14.2.1122
   Schwarz DS, 2003, CELL, V115, P199, DOI 10.1016/S0092-8674(03)00759-1
   Simmen MW, 1999, SCIENCE, V283, P1164, DOI 10.1126/science.283.5405.1164
   Simonsson S, 2004, NAT CELL BIOL, V6, P984, DOI 10.1038/ncb1176
   Tatematsu K, 2000, GENES CELLS, V5, P677, DOI 10.1046/j.1365-2443.2000.00359.x
   Tsuji-Takayama K, 2004, BIOCHEM BIOPH RES CO, V323, P86, DOI 10.1016/j.bbrc.2004.08.052
   Villa R, 2006, P NATL ACAD SCI USA, V103, P1400, DOI 10.1073/pnas.0509343103
   Wade PA, 1999, NAT GENET, V23, P62
   Yamazaki Y, 2006, MOL REPROD DEV, V73, P180, DOI 10.1002/mrd.20411
   Yan ZH, 1997, J BIOL CHEM, V272, P10565
   Zhang Y, 1999, GENE DEV, V13, P1924, DOI 10.1101/gad.13.15.1924
NR 46
TC 40
Z9 42
U1 3
U2 10
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0270-7306
EI 1098-5549
J9 MOL CELL BIOL
JI Mol. Cell. Biol.
PD DEC
PY 2006
VL 26
IS 24
BP 9471
EP 9483
DI 10.1128/MCB.00898-06
PG 13
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 117FV
UT WOS:000242859200028
PM 17030610
OA Green Published, Bronze
DA 2018-12-27
ER

PT J
AU Barnett, RL
AF Barnett, Richard-Laurent
TI RETRACTED: The subhuman word - Essay on Racinian hermeneutics (Retracted
   article. See vol. 42, pg. 359, 2015)
SO NEOHELICON
LA French
DT Article; Retracted Publication
C1 Frederick A Treuhaft Fdn, B-1348 Louvain, Belgium.
RP Barnett, RL (reprint author), Frederick A Treuhaft Fdn, Pl Univ, B-1348 Louvain, Belgium.
EM DrRLBarnett@msn.com
CR ABEL Lionel, 1961, METATHEATER NEW DRAM
   ADELANTE Maria, 1999, ESSAYS FRENCH LIT, V31, P209
   ALIN JM, 1988, CYCLE GENRE TRAGIQUE
   ALLEN Frederick J., 1995, CONTINUITY CESSATION
   AMIENS Marguerite, 1991, REV ROMANE, V52, P88
   APOSTOLIDES JM, 1985, PRICE SAFRIFIE
   ARTAUD A., 1964, THEATRE SON DOUBLE
   BAETENS Jan, 1995, ETHIQUE CONTRAINTE
   BANVILLE Edward, 1994, STUDIES MODERN LANGU, V44, P102
   BARNETT Richard- Laurent, 2004, LITTERATURES TOULOUS, V62, P29
   BARNETT Richard-Laurent, 2001, REV HIST THEATRE
   BARNETT Richard-Laurent, 1991, DEGRES, V68, P129
   BARNETT Richard-Laurent, 1999, DALHOUSIE FRENCH STU, V49
   BARNETT Richard-Laurent, 1999, TEXTE, V27, P102
   BARNETT Richard-Laurent, 1979, STUDI LETTERATURA FR, V154, P157
   BARNETT Richard-Laurent, 2003, TRAVAUX LITERATURE, V42, P88
   BARNETT Richard-Laurent, 1997, DEGRES REV SYNTHESE, V91, P17
   BARNETT Richard-Laurent, 1986, BIBLIO, V17, P1
   BARNETT Richard-Laurent, 2000, RIV LETTERATURE MODE, V61, P37
   BARNETT Richard-Laurent, 1990, REV HIST THEATRE, V71, P279
   BARNETT Richard-Laurent, 2001, REV LETRAS
   BARNETT Richard-Laurent, 1999, TRAVAUX LIT, V34, P111
   BARNETT RL, 1991, ESPRIT CREATEUR, V31, P14
   BARNETT RL, 1980, ORBIS LIT, V35, P115, DOI 10.1111/j.1600-0730.1980.tb00767.x
   BARNETT RL, 1977, LETT ROMANES, V31, P144, DOI 10.1484/J.LLR.4.00343
   Barnett RL, 1998, ESPRIT CREATEUR, V38, P3
   BARNETT RL, 1998, ESPRIT CREATEUR, V38
   BARNETT RL, 1998, ESPRIT CREATEUR, V22, P168
   BARNETT RL, 1991, RELECTURES RACINIENN
   Barthes R., 1970, S Z
   Barthes R., 1963, SUR RACINE
   Beckett Samuel, 1953, INNOMMABLE
   BENVENISTE Emile, 1947, DEUCALION, V17, P55
   BERG EL, 1982, ROMANIC REV, V73, P421
   BERSANI J, 1970, LITTERATURE FRANCE D
   BRODY J, 1977, FR FORUM, V2, P110
   Caillois R., 1958, JEUX HOMMES
   CIORAN E, 1989, ELAN VERS PIRE
   DALLENBACH Lucien, 1977, RECIT SPECULAIRE
   DE MAN P., 1979, ALLEGORIES READING
   De Man Paul, 1986, RESISTANCE THEORY
   DEALCARON JR, 1999, TRUTH CANT BE TRUSTE
   DECLERQ G, 1986, DIX-SEPTIEME SIECLE, V150, P43
   DERRIDA Jacques, 1967, ECRITURE DIFFERENCE, P87
   Doubrovsky Serge, 1980, PARCOURS CRITIQUE
   Genette Gerard, 1979, INTRO ARCHITEXTE
   GOLDMANN L, 1959, DIEU CACHE
   GUTWIRTH Marcel, 1986, RELECTURES RACINIENN, V17, P69
   HEYNDELSBIRMAN I, 1977, REV LANGUES VIVANTES, V43, P160
   HJEMSLEV L., 1966, LANGAGE, P98
   HUTCHEON L, 1977, POETIQUE, P90
   KRISTEVA Julia, 1966, TEL QUEL, V76, P118
   KUHN R, 1979, ROMANIC REV, V70, P336
   LEWIS P, 1984, SEMIOTICA, V51, P71, DOI 10.1515/semi.1984.51.1-3.71
   LYOTARD Jean-Francois, 1971, DISCOURS FIGURE
   Marin L, 1978, RECIT EST PIEGE
   MARIN L, 1986, RELECTURES RACINIENN, P99
   Marin Louis, 1975, CRITIQUE DISCOURS
   Muratore M. J., 1993, DALHOUSIE FRENCH STU, V24, p[57, 61]
   PARISH R, 1980, FR STUD, V34, P385, DOI 10.1093/fs/34.4.385
   PHILLIPS H, 1989, MOD LANG REV, V84, P37, DOI 10.2307/3731948
   PHILLIPS H, 1980, THEATRE ITS CRITICS
   PILHAN Y., 1964, CAHIERS RACINIENS, V16, P41
   Ponge F, 1942, PARTI PRIS CHOSES
   POULET G, 1986, RELECTURES RACINIENN, V17, P127
   Racine Jean, 1950, OEUVRES COMPLETES
   REISS RJ, 1985, DISCOURSE MODERNISM
   RICHARD Jean-Pierre, 1964, ONZE ETUDES POESIE M
   RIFFATERRE M, 1979, PROD TEXTE
   RIGGS Larry W., 1999, DALHOUSIE FRENCH STU, V49, P38
   SCHERER J, 1982, RACINE ET CEREMONIE
   SOARE Antoine, 1999, DALHOUSIE FRENCH STU, V49, P145
   SOURIAU Etienne, 1961, REV ESTHET, V46, P138
   UBERSFELD A, 1993, LIRE THEATRE
   VELEQQUINONES H, 1998, MONSTROUS DISPLAYS R
   VINAVER Eugene, 1984, ENTRETIENS RACINE
   VOGEL S, 1979, LITTERATURE, P57
NR 77
TC 2
Z9 2
U1 0
U2 3
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0324-4652
EI 1588-2810
J9 NEOHELICON
JI Neohelicon
PD DEC
PY 2006
VL 33
IS 2
BP 165
EP 178
DI 10.1007/s11059-006-0032-4
PG 14
WC Literature
SC Literature
GA 107TK
UT WOS:000242193700011
DA 2018-12-27
ER

PT J
AU Hbaieb, R
   Chaari, F
   Fakhfakh, T
   Haddar, M
AF Hbaieb, R.
   Chaari, F.
   Fakhfakh, T.
   Haddar, M.
TI RETRACTED: Dynamic stability of a planetary gear train under the
   influence of variable meshing stiffnesses (Retracted article. See vol.
   224, pg. 1123, 2010)
SO PROCEEDINGS OF THE INSTITUTION OF MECHANICAL ENGINEERS PART D-JOURNAL OF
   AUTOMOBILE ENGINEERING
LA English
DT Article; Retracted Publication
DE stability; perturbation technique; natural frequencies; vibration modes;
   parameter design
ID VIBRATION; SYSTEMS; MODEL
AB The main source of vibration and noise in planetary gear train systems is the parametric instability caused by variable meshing stiffnesses. The operating conditions leading to parametric instability are investigated for planetary gear trains with three and four planets. Perturbation technique is used to study the primary, secondary, and combination instabilities. The effects of mesh stiffness parameters, including stiffness variation amplitudes, contact ratios, and mesh phasing, on these instabilities are identified. A rectangular waveform is used to describe the mesh stiffness variation. The boundaries separating stable and unstable conditions are obtained as simple expressions in terms of mesh parameters. These expressions allow the suppression of particular instabilities by adjusting the contact ratios and mesh phasing.
C1 Natl Sch Engineers Sfax, Mech Syst Dynam Res Unit, Sfax, Tunisia.
RP Hbaieb, R (reprint author), Natl Sch Engineers Sfax BP, Mech Syst Dynam Res Unit, W-3038, Sfax, Tunisia.
EM riadh_hbaieb@yahoo.fr
CR Amabili M, 1997, MECH SYST SIGNAL PR, V11, P375, DOI 10.1006/mssp.1996.0072
   Andersson A, 2003, J SOUND VIB, V260, P195, DOI 10.1016/S0022-460X(02)00920-3
   BENTON M, 1978, J MECH DES-T ASME, V100, P26, DOI 10.1115/1.3453888
   BENTON M, 1980, J MECH DES-T ASME, V102, P379, DOI 10.1115/1.3254754
   BOLLINGER JG, 1967, J IND MATH, V17, P39
   BONORI G, 2004, ASME P INT MECH ENG
   HBAIEB R, 2006, P AFM 2006 ASS FRANC
   IBRAHIM RA, 1978, SHOCK VIBRATION DIGE, V10, P15
   Lin J, 1999, J VIB ACOUST, V121, P316, DOI 10.1115/1.2893982
   Lin J, 2000, J SOUND VIB, V233, P921, DOI 10.1006/jsvi.1999.2581
   Lin J, 2002, J VIB ACOUST, V124, P68, DOI 10.1115/1.1424889
   LYAPUNOV AM, 1892, COMM SOC MATH KHARKO
   NATRAJ C, 1997, P AM SOC MECH ENG DE
   Nayfeh AH, 1979, NONLINEAR OSCILLATIO
   Parker RG, 2000, J SOUND VIB, V236, P561, DOI 10.1006/jsvi.1999.2859
   SEAGER DL, 1975, J MECH ENG SCI, V17, P293, DOI 10.1243/JMES_JOUR_1975_017_042_02
   TORDION GV, 1977, J ENG IND-T ASME, V99, P785, DOI 10.1115/1.3439314
   VELEX P, 1988, THESIS I NAT SCI APP
NR 18
TC 4
Z9 9
U1 3
U2 18
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 0954-4070
EI 2041-2991
J9 P I MECH ENG D-J AUT
JI Proc. Inst. Mech. Eng. Part D-J. Automob. Eng.
PD DEC
PY 2006
VL 220
IS D12
BP 1711
EP 1725
DI 10.1243/09544070JAUTO248
PG 15
WC Engineering, Mechanical; Transportation Science & Technology
SC Engineering; Transportation
GA 124BE
UT WOS:000243341100004
DA 2018-12-27
ER

PT J
AU Pirozynski, M
AF Pirozynski, Michaet
TI RETRACTED: 100 years of lung cancer (Retracted article. See vol 103, pg
   1244, 2009)
SO RESPIRATORY MEDICINE
LA English
DT Review; Retracted Publication
DE lung cancer; therapy; diagnosis; screening; staging
ID FINE-NEEDLE-ASPIRATION; RANDOMIZED PHASE-III; THORACIC
   RADIATION-THERAPY; SMALL-CELL-CARCINOMA; BRONCHOGENIC-CARCINOMA;
   BRONCHIAL-CARCINOMA; ADJUVANT CHEMOTHERAPY; EXTRATHORACIC METASTASES;
   PALLIATIVE RADIOTHERAPY; SEGMENTAL RESECTION
AB Lung cancer is the most common cause of cancer death in the world. It continues to have an enormous impact on health systems of all countries. The number of new cases is increasing in a rate of about 3% annually. Despite the advances in the detection and treatment of lung cancer, the overall 5-year survival still remains grim. Cigarette smoking remains the major risk factor on the incidence of cancer, with 90% of all lung cancers occurring in smokers. The frequency of different types of lung cancer is changing. Adenocarcinoma has become the most frequent histologic type (similar to 50%) white squamous, previously the most common, accounts for approximately one third of lung cancers, and small. cell cancer for 15%. Prognosis is influenced by the stage of the disease at diagnosis and by the treatment. Screening trials that have begun in the early 1950s based on chest X-ray and sputum cytology did not produce improvement in overall mortality. Refinements in the staging classification of lung cancer and advances in stage identification were introduced in the 1990s. Post surgical mortality has declined since the 1950s but the 5-year survival rates have improved only minimally. A gradual improvement is seen in Locally advanced inoperable non-small cell lung cancer, mainly due to addition of advanced chemotherapy and radical radiotherapy. Chemotherapy offers small improvement for patients with NSCLC. The management of small cell lung cancer, which appeared so promising in the 1970s has hit a plateau with vary little advance in the last years. The biological active agents currently in phase III traits offer some hope in the advance of therapy of Lung cancer. The most important and cost-effective management for lung cancer is smoking cessation, but for those with this disease novel methods of treatment are urgently needed. (c) 2006 Elsevier Ltd. Alt rights reserved.
C1 Postgrad Med Sch, Dept Anesthesiol & Crit Care Med, PL-00416 Warsaw, Poland.
RP Pirozynski, M (reprint author), Postgrad Med Sch, Dept Anesthesiol & Crit Care Med, Czerniakowska 231, PL-00416 Warsaw, Poland.
EM piromich@nbp.pl
CR Alam N, 2006, CRIT REV ONCOL HEMAT, V58, P146, DOI 10.1016/j.critrevonc.2005.10.002
   [Anonymous], 1992, Br J Cancer, V65, P934
   [Anonymous], 2006, PRESCRIRE INT, V15, P86
   Arriagada R, 1991, J NATL CANCER I, V83, P417
   Bach PB, 2003, CHEST, V123, p72S, DOI 10.1378/chest.123.1_suppl.72S
   Ball D, 1999, RADIOTHER ONCOL, V52, P129, DOI 10.1016/S0167-8140(99)00093-6
   Barlesi F, 2004, RESP MED, V98, P357, DOI 10.1016/j.rmed.2003.11.003
   Beasley MB, 2005, SEMIN ROENTGENOL, V40, P90, DOI 10.1053/j.ro.2005.01.001
   Belvedere O, 2006, ONCOLOGIST, V11, P39, DOI 10.1634/theoncologist.11-1-39
   BENTLEY FJ, 1937, BR J TUBERCULOSIS, V31, P47
   Bilaceroglu S, 1998, RESPIRATION, V65, P441, DOI 10.1159/000029312
   Blackhall F, 2005, EXPERT OPIN PHARMACO, V6, P1157, DOI 10.1517/14656566.6.7.1157
   BLEEHEN N M, 1991, British Journal of Cancer, V63, P265
   Bray F, 2004, EUR J CANCER, V40, P96, DOI 10.1016/j.ejca.2003.08.005
   BREYER RH, 1981, J THORAC CARDIOV SUR, V81, P187
   Brock CS, 2002, EUR RESPIR J, V19, P557, DOI 10.1183/09031936.02.00293002
   Burdett S, 1998, LANCET, V352, P257
   Cardenal F, 1999, J CLIN ONCOL, V17, P12, DOI 10.1200/JCO.1999.17.1.12
   CARLENS E, 1959, DIS CHEST, V36, P343, DOI 10.1378/chest.36.4.343
   Chella A, 2000, LUNG CANCER, V27, P169, DOI 10.1016/S0169-5002(99)00102-6
   Chua YJ, 2004, CANCER TREAT REV, V30, P521, DOI 10.1016/j.ctrv.2004.06.003
   COY P, 1980, CANCER, V45, P698, DOI 10.1002/1097-0142(19800215)45:4<698::AID-CNCR2820450414>3.0.CO;2-8
   Depierre A, 2002, J CLIN ONCOL, V20, P247, DOI 10.1200/JCO.20.1.247
   Detterbeck FC, 2003, CHEST, V123, p167S, DOI 10.1378/chest.123.1_suppl.167S
   DOLL R, 1950, BRIT MED J, V2, P739, DOI 10.1136/bmj.2.4682.739
   Ece F, 2005, RESP MED, V99, P1258, DOI 10.1016/j.rmed.2005.02.038
   Erasmus JJ, 2005, SEMIN ROENTGENOL, V40, P126, DOI 10.1053/j.ro.2005.01.004
   Erasmus JJ, 1998, RADIOGRAPHICS, V18, P5, DOI 10.1148/radiographics.18.1.9460106
   Erasmus JJ, 1999, J THORAC IMAG, V14, P247, DOI 10.1097/00005382-199910000-00004
   Etzel CJ, 2006, LUNG CANCER-J IASLC, V52, P129, DOI 10.1016/j.lungcan.2005.11.018
   FERRIGNO D, 1995, RESP MED, V89, P587, DOI 10.1016/0954-6111(95)90225-2
   Fielding P, 1999, CLIN CANCER RES, V5, P4048
   Fong KM, 2005, RESP MED, V99, P1071, DOI 10.1016/j.rmed.2005.05.002
   FONTANA RS, 1986, J OCCUP ENVIRON MED, V28, P746, DOI 10.1097/00043764-198608000-00038
   Fried DB, 2004, J CLIN ONCOL, V22, P4837, DOI 10.1200/JCO.2004.01.178
   Fukuoka M, 2003, J CLIN ONCOL, V21, P2237, DOI 10.1200/JCO.2003.10.038
   GIACCONE G, 2006, UPDATE CANC THERAPEU, V1, P235
   Ginsberg Robert J., 1995, Annals of Thoracic Surgery, V60, P615, DOI 10.1016/0003-4975(95)00537-U
   Gould MK, 2001, JAMA-J AM MED ASSOC, V285, P914, DOI 10.1001/jama.285.7.914
   GRAHAM EA, 1984, JAMA-J AM MED ASSOC, V251, P257, DOI 10.1001/jama.251.2.257
   Gridelli C, 2003, JNCI-J NATL CANCER I, V95, P362, DOI 10.1093/jnci/95.5.362
   Guyatt GH, 2001, ANN THORAC SURG, V71, P425
   Hanna N, 2006, J CLIN ONCOL, V24, P2038, DOI 10.1200/JCO.2005.04.8595
   Hayman JA, 2001, J CLIN ONCOL, V19, P127, DOI 10.1200/JCO.2001.19.1.127
   Henschke CI, 1999, LANCET, V354, P99, DOI 10.1016/S0140-6736(99)06093-6
   HILLERS TK, 1994, THORAX, V49, P14, DOI 10.1136/thx.49.1.14
   HUNG J, 1991, LASER SURG MED, V11, P99, DOI 10.1002/lsm.1900110203
   Ikeda N, 2006, LUNG CANCER, V52, P21, DOI 10.1016/j.lungcan.2005.11.009
   Iyodal A, 2006, THORAC CARDIOV SURG, V54, P117, DOI 10.1055/s-2005-865924
   Jemal A, 2004, CANCER, V101, P3, DOI 10.1002/cncr.20288
   JENSIK RJ, 1973, J THORAC CARDIOV SUR, V66, P563
   Jeremic B, 1997, J CLIN ONCOL, V15, P893, DOI 10.1200/JCO.1997.15.3.893
   JOHNSON DH, 1990, ANN INTERN MED, V113, P33, DOI 10.7326/0003-4819-113-1-33
   Jumper C, 2004, RESP MED, V98, P173, DOI 10.1016/j.rmed.2003.08.014
   Kerr KM, 2001, J CLIN PATHOL, V54, P257, DOI 10.1136/jcp.54.4.257
   Kramer H, 2005, RESP MED, V99, P179, DOI 10.1016/j.rmed.2004.06.011
   Kris MG, 2003, JAMA-J AM MED ASSOC, V290, P2149, DOI 10.1001/jama.290.16.2149
   Lam S, 1998, CHEST, V113, P696, DOI 10.1378/chest.113.3.696
   Le Chevalier T, 2004, NEW ENGL J MED, V350, P351
   LEROUX BT, 1972, THORAX, V27, P70, DOI 10.1136/thx.27.1.70
   Lorigan P, 2005, JNCI-J NATL CANCER I, V97, P666, DOI 10.1093/jnci/dji114
   Macbeth F R, 1996, Clin Oncol (R Coll Radiol), V8, P167, DOI 10.1016/S0936-6555(96)80041-0
   Manfredi R, 1996, MAGN RESON MATER PHY, V4, P257, DOI 10.1007/BF01772015
   Manser RL, 2005, RESP MED, V99, P501, DOI 10.1016/j.rmed.2004.08.017
   Marcus PM, 2000, J NATL CANCER I, V92, P1308, DOI 10.1093/jnci/92.16.1308
   MARTINI N, 1993, CA-CANCER J CLIN, V43, P201, DOI 10.3322/canjclin.43.4.201
   MCLOUD TC, 1992, RADIOLOGY, V182, P319, DOI 10.1148/radiology.182.2.1732943
   Molina JR, 2006, AM J CLIN ONCOL-CANC, V29, P246, DOI 10.1097/01.coc.0000217566.11742.b5
   Mori K, 2006, CANCER CHEMOTH PHARM, V58, P86, DOI 10.1007/s00280-005-0114-4
   MORITTU L, 1989, BRIT J CANCER, V59, P801, DOI 10.1038/bjc.1989.167
   MORRISON R, 1963, LANCET, V1, P683
   Mountain CF, 1997, CHEST, V111, P1710, DOI 10.1378/chest.111.6.1710
   MOUNTAIN CF, 1974, AM J ROENTGENOL, V120, P130, DOI 10.2214/ajr.120.1.130
   MUHM JR, 1983, RADIOLOGY, V148, P609, DOI 10.1148/radiology.148.3.6308709
   MURRAY N, 1993, J CLIN ONCOL, V11, P336, DOI 10.1200/JCO.1993.11.2.336
   Nowak D, 2006, RESP MED, V100, P157, DOI 10.1016/j.rmed.2005.04.002
   OCHSNER A, 1973, PREV MED, V2, P611, DOI 10.1016/0091-7435(73)90059-5
   ONUIGBO W I B, 1971, British Journal of Diseases of the Chest, V65, P119, DOI 10.1016/0007-0971(71)90014-3
   OSTERLIND K, 1986, CANCER RES, V46, P4189
   Parker S, 2005, HIST TODAY, V55, P2
   PARKIN DM, 1993, INT J CANCER, V54, P594, DOI 10.1002/ijc.2910540413
   PASS HI, 1992, ANN THORAC SURG, V53, P992, DOI 10.1016/0003-4975(92)90373-C
   PEREZ CA, 1986, INT J RADIAT ONCOL, V12, P539, DOI 10.1016/0360-3016(86)90061-1
   Perry MC, 1998, J CLIN ONCOL, V16, P2466, DOI 10.1200/JCO.1998.16.7.2466
   PIGNON JP, 1992, NEW ENGL J MED, V327, P1618, DOI 10.1056/NEJM199212033272302
   PIROZYNSKI M, 1992, CHEST, V102, P372, DOI 10.1378/chest.102.2.372
   PIROZYNSKI M, 1999, EUR RESPIR REV, V9, P135
   RAWSON NSB, 1990, BRIT J CANCER, V61, P597, DOI 10.1038/bjc.1990.133
   Reck M, 2005, RESP MED, V99, P298, DOI 10.1016/j.rmed.2004.08.009
   REDMOND DE, 1970, NEW ENGL J MED, V282, P18, DOI 10.1056/NEJM197001012820105
   Remer EM, 2000, AM J ROENTGENOL, V174, P1033, DOI 10.2214/ajr.174.4.1741033
   ROSELL R, 1994, NEW ENGL J MED, V330, P153, DOI 10.1056/NEJM199401203300301
   Rossi A, 2006, CRIT REV ONCOL HEMAT, V59, P139, DOI 10.1016/j.critrevonc.2006.02.006
   ROTH JA, 1994, J NATL CANCER I, V86, P9
   Scagliotti GV, 2003, JNCI-J NATL CANCER I, V95, P1453, DOI 10.1093/jnci/djg059
   SCHAAKEKONING C, 1992, NEW ENGL J MED, V326, P524, DOI 10.1056/NEJM199202203260805
   SCHENK DA, 1993, AM REV RESPIR DIS, V147, P1251, DOI 10.1164/ajrccm/147.5.1251
   Schiller JH, 2002, NEW ENGL J MED, V346, P92, DOI 10.1056/NEJMoa011954
   SHEPHERD FA, 1983, J THORAC CARDIOV SUR, V86, P498
   SHIELDS TW, 1972, CANCER, V30, P1388, DOI 10.1002/1097-0142(197211)30:5<1388::AID-CNCR2820300537>3.0.CO;2-6
   Shimizu K, 2006, LUNG CANCER-J IASLC, V51, P173, DOI 10.1016/j.lungcan.2005.10.019
   SHURE D, 1983, CHEST, V83, P865, DOI 10.1378/chest.83.6.865
   SIDER L, 1988, AM J ROENTGENOL, V151, P893, DOI 10.2214/ajr.151.5.893
   SILVESTRI GA, 1995, AM J RESP CRIT CARE, V152, P225, DOI 10.1164/ajrccm.152.1.7599828
   Silvestri GA, 2003, CHEST, V123, p147S, DOI 10.1378/chest.123.1_suppl.147S
   Silvestri GA, 1996, ANN THORAC SURG, V61, P1441, DOI 10.1016/0003-4975(95)00052-6
   Sone S, 2000, BRIT J RADIOL, V73, P137, DOI 10.1259/bjr.73.866.10884725
   SOUHAMI RL, 1985, CANCER RES, V45, P2878
   SPEISER BL, 1993, INT J RADIAT ONCOL, V25, P579, DOI 10.1016/0360-3016(93)90002-D
   Spiro SG, 2004, THORAX, V59, P828, DOI 10.1136/thx.2003.020164
   Spiro SG, 2002, AM J RESP CRIT CARE, V166, P1166, DOI 10.1064/rccm.200202-070S0
   Strauss GM, 2002, J CLIN ONCOL, V20, P1973, DOI 10.1200/JCO.2002.08.074
   Tanaka K, 1999, ANN THORAC SURG, V68, P1039, DOI 10.1016/S0003-4975(99)00694-3
   Tibaldi C, 2006, BRIT J CANCER, V94, P1263, DOI 10.1038/sj.bjc.6603074
   TOCKMAN MS, 1988, J CLIN ONCOL, V6, P1685, DOI 10.1200/JCO.1988.6.11.1685
   Toloza EM, 2003, CHEST, V123, p157S, DOI 10.1378/chest.123.1_suppl.157S
   Tyczynski JE, 2004, INT J CANCER, V109, P598, DOI 10.1002/ijc.20019
   UERBACH O, 1957, NEW ENGL J MED, V256, P97
   van der Linden YM, 2001, RESP MED, V95, P235, DOI 10.1053/rmed.2000.1022
   Venmans BJW, 2000, CHEST, V117, P1572, DOI 10.1378/chest.117.6.1572
   Waller D, 2004, EUR J CARDIO-THORAC, V26, P173, DOI 10.1016/j.ejcts.2004.03.041
   WARDE P, 1992, J CLIN ONCOL, V10, P890, DOI 10.1200/JCO.1992.10.6.890
   Witschi H, 2001, TOXICOL SCI, V64, P4, DOI 10.1093/toxsci/64.1.4
   Work E, 1997, J CLIN ONCOL, V15, P3030, DOI 10.1200/JCO.1997.15.9.3030
   WYNDER EL, 1985, JAMA-J AM MED ASSOC, V253, P2986, DOI 10.1001/jama.253.20.2986
   1995, BMJ, V311, P899, DOI DOI 10.1136/BMJ.311.7010.899
NR 126
TC 86
Z9 103
U1 3
U2 23
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD DEC
PY 2006
VL 100
IS 12
BP 2073
EP 2084
DI 10.1016/j.rmed.2006.09.002
PG 12
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA 124NO
UT WOS:000243374700001
PM 17056245
OA Bronze
DA 2018-12-27
ER

PT J
AU Bastemir, M
   Emral, R
   Erdogan, G
   Gullu, S
AF Bastemir, Mehmet
   Emral, Rifat
   Erdogan, Gurbuz
   Gullu, Sevim
TI RETRACTED: High prevalence of thyroid dysfunction and autoimmune
   thyroiditis in adolescents after elimination of iodine deficiency in the
   Eastern Black Sea Region of Turkey (Retracted Article. See vol 17, pg
   189, 2007)
SO THYROID
LA English
DT Article; Retracted Publication
ID ENDEMIC GOITER; INDUCED THYROTOXICOSIS; NONTOXIC GOITER;
   HYPERTHYROIDISM; INCREASE; AUTOANTIBODIES; AREAS; THYROGLOBULIN;
   PATHOGENESIS; PROPHYLAXIS
AB In the present study we evaluated the effects of iodine intake on the prevalence of thyroid dysfunction, autoimmunity, and goiter in two regions with different iodine status after two years of iodization in Turkey. In total 1733 adolescent subjects were enrolled into the study (993 from an iodine-sufficient area-the Eastern Black Sea Region (group 1) and 740 from an iodine-deficient area-Middle Anatolia (group 2). We measured free thyroxine (FT4), thyrotropin (TSH), antithyroid peroxidase antibodies (Anti-TPO), antithyroglobulin antibodies (Anti-Tg), and urinary iodine (UI), and examined the thyroid gland by ultrasound. Median urinary iodine excretion was found to be significantly different in group 1 and group 2 (139 mu g/l vs 61 mu g/l, p < 0.001). Hyperthyroidism was more frequent in group 1 (3.6% vs 0.7%; p < 0.001), but the hypothyroidism rate was similar between groups (1.8% vs 1.4%; p > 0.05). The percentage of anti-Tg positive subjects was found to be 17.6% in group 1 and 6.4% in group 2; that of anti-TPO positive subjects was 4.3% in group 1 and 1.5% in group 2. The prevalence of antithyroid antibody (anti-Tg and/or anti-TPO) positivity was significantly higher in group 1 than in group 2 (18.52% vs 6.62%; p < 0.001). Thyroid volumes of the hyperthyroid subjects in both groups were significantly higher than hypo- and euthyroid subjects. In conclusion, iodine supplementation in Turkey has resulted in the elimination of iodine deficiency in the Eastern Black Sea Region, and this has been accompanied by an increase in the prevalence of autoimmune thyroiditis and thyroid dysfunction.
C1 Ankara Univ, Sch Med, Dept Endocrinol & Metab Dis, Ankara, Turkey.
RP Bastemir, M (reprint author), Pamukkale Univ, Sch Med, Dept Endocrinol & Metab, Kinikli Kampusu, TR-20070 Denizli, Turkey.
EM bastemir@yahoo.com
CR Aghini-Lombardi F, 1999, J CLIN ENDOCR METAB, V84, P561, DOI 10.1210/jc.84.2.561
   BERGHOUT A, 1990, AM J MED, V89, P602, DOI 10.1016/0002-9343(90)90178-G
   BOUKIS MA, 1983, J CLIN ENDOCR METAB, V57, P859, DOI 10.1210/jcem-57-4-859
   Bourdoux PP, 1996, LANCET, V347, P552, DOI 10.1016/S0140-6736(96)91188-5
   BOYAGES SC, 1989, CLIN ENDOCRINOL, V31, P453, DOI 10.1111/j.1365-2265.1989.tb01269.x
   BRUNN J, 1981, DTSCH MED J, V287, P1206
   Cakir Mehtap, 2005, J Natl Med Assoc, V97, P1547
   Carella C, 2001, J CLIN ENDOCR METAB, V86, P1925, DOI 10.1210/jc.86.5.1925
   CONNOLLY RJ, 1970, LANCET, V1, P500
   Corvilain B, 1998, THYROID, V8, P107, DOI 10.1089/thy.1998.8.107
   COSTA A, 1984, CLIN EXP IMMUNOL, V56, P143
   COSTA A, 1986, CLIN IMMUNOL IMMUNOP, V41, P265, DOI 10.1016/0090-1229(86)90110-8
   Dayan CM, 1996, NEW ENGL J MED, V335, P99, DOI 10.1056/NEJM199607113350206
   Doufas AG, 1999, EUR J ENDOCRINOL, V140, P505, DOI 10.1530/eje.0.1400505
   DUPREZ L, 1994, NAT GENET, V7, P396, DOI 10.1038/ng0794-396
   Emral R, 2003, EUR J ENDOCRINOL, V148, P497, DOI 10.1530/eje.0.1480497
   Erdogan G, 2002, J ENDOCRINOL INVEST, V25, P224, DOI 10.1007/BF03343994
   Erdogan G, 2000, EUR J EPIDEMIOL, V16, P1131, DOI 10.1023/A:1010959928862
   GARDAS A, 1991, AUTOIMMUNITY, V9, P331, DOI 10.3109/08916939108997135
   HARACH HR, 1985, ACTA ENDOCRINOL-COP, V108, P55, DOI 10.1530/acta.0.1080055
   Henzen C, 1999, SCHWEIZ MED WSCHR, V129, P658
   HINTZE G, 1989, EUR J CLIN INVEST, V19, P527, DOI 10.1111/j.1365-2362.1989.tb00270.x
   Kasagi K, 1997, J ENDOCRINOL INVEST, V20, P183, DOI 10.1007/BF03346900
   Knudsen N, 2000, EUR J ENDOCRINOL, V143, P485, DOI 10.1530/eje.0.1430485
   Koutras DA, 1996, ANN ENDOCRINOL-PARIS, V57, P463
   Krohn K, 2000, J PATHOL, V192, P37
   Krohn K, 2005, ENDOCR REV, V26, P504, DOI 10.1210/er.2004-0005
   Kusic Z, 1999, J ENDOCRINOL INVEST, V22, P747, DOI 10.1007/BF03343639
   Lind P, 1998, THYROID, V8, P1179, DOI 10.1089/thy.1998.8.1179
   Lind P, 2002, THYROID, V12, P903, DOI 10.1089/105072502761016539
   LINDBERG O, 1989, J ENDOCRINOL INVEST, V12, P789, DOI 10.1007/BF03350061
   Loviselli A, 2001, THYROID, V11, P849, DOI 10.1089/105072501316973109
   Mariotti S, 1998, EXP GERONTOL, V33, P535, DOI 10.1016/S0531-5565(98)00030-8
   Markou K, 2001, THYROID, V11, P501, DOI 10.1089/105072501300176462
   Marqusee E, 1998, ENDOCRIN METAB CLIN, V27, P37, DOI 10.1016/S0889-8529(05)70296-6
   Mostbeck A, 1998, EUR J NUCL MED, V25, P367, DOI 10.1007/s002590050234
   OECHSLIN E, 1985, SCHWEIZ MED WSCHR, V115, P1182
   Pacini F, 1998, LANCET, V352, P763, DOI 10.1016/S0140-6736(97)11397-6
   Papanastasiou L, 2000, THYROID, V10, P493, DOI 10.1089/thy.2000.10.493
   Rasooly L, 1996, CLIN IMMUNOL IMMUNOP, V81, P287, DOI 10.1006/clin.1996.0191
   RATH T, 1988, BURNS, V14, P320, DOI 10.1016/0305-4179(88)90074-5
   Rose NR, 1999, ENVIRON HEALTH PERSP, V107, P749, DOI 10.2307/3434337
   Rose NR, 1997, CRIT REV IMMUNOL, V17, P511
   Roti E, 2001, THYROID, V11, P493, DOI 10.1089/105072501300176453
   Ruwhof C, 2001, THYROID, V11, P427, DOI 10.1089/105072501300176381
   Schuppert F, 2000, J CLIN ENDOCR METAB, V85, P858, DOI 10.1210/jc.85.2.858
   Stanbury JB, 1998, THYROID, V8, P83, DOI 10.1089/thy.1998.8.83
   SUNDICK RS, 1992, AUTOIMMUNITY, V13, P61, DOI 10.3109/08916939209014636
   Szybinski Z, 1993, Endokrynol Pol, V44, P235
   TAKALO RM, 1991, ACTA ENDOCRINOL-COP, V124, P238, DOI 10.1530/acta.0.1240238
   Takamatsu J, 1998, THYROID, V8, P1101, DOI 10.1089/thy.1998.8.1101
   TODD CH, 1995, LANCET, V346, P1563, DOI 10.1016/S0140-6736(95)92095-1
   VIDOR GI, 1973, J CLIN ENDOCR METAB, V37, P901, DOI 10.1210/jcem-37-6-901
   *WHO ICCIDD, 1997, B WORLD HEALTH ORGAN, V75, P95
   *WHO UNICEF ICCIDD, 2001, ASS IOD DEF DIS MON
   World Health Organization, 1994, IND ASS IDD THEIR CO, P6
   Yang F, 2002, EUR J ENDOCRINOL, V146, P613, DOI 10.1530/eje.0.1460613
NR 57
TC 17
Z9 17
U1 3
U2 11
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1050-7256
EI 1557-9077
J9 THYROID
JI Thyroid
PD DEC
PY 2006
VL 16
IS 12
BP 1265
EP 1271
DI 10.1089/thy.2006.16.1265
PG 7
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 123RD
UT WOS:000243312200010
PM 17199437
DA 2018-12-27
ER

PT J
AU Sahoo, NK
   Thakur, S
   Tokas, RB
AF Sahoo, N. K.
   Thakur, S.
   Tokas, R. B.
TI RETRACTED: Superior refractive index tailoring properties in composite
   ZrO2/SiO2 thin film systems achieved through reactive electron beam
   codeposition process (Retracted article. See vol. 420, pg. 993, 2017)
SO APPLIED SURFACE SCIENCE
LA English
DT Article; Retracted Publication
DE optical coatings; optical thin films; codeposition; electron beam
   evaporation; ellipsometry; atomic force microscopy; composite films;
   correlation functions
ID OPTICAL-PROPERTIES; SPECTROSCOPIC ELLIPSOMETRY; COMPOUND SEMICONDUCTORS;
   DIELECTRIC-CONSTANT; OXIDE FILMS; MICROSTRUCTURE; ABSORPTION;
   MICROSCOPY; MORPHOLOGY; EVOLUTION
AB Composite optical thin-film materials have received a significant amount of interest in order to relieve the material constraints on refractive indices as well as reducing the number of layers required in optical coating design. Amongst others binary zirconia-silica composite thin films have attracted considerable attentions due to their several favorable opto-mechanical properties. In the present studies such a composite system under certain compositional mixings displayed both refractive index and band gap supremacy over pure zirconia films violating the most popular Moss rule. This unexpected evolution has several practical applications one of which can be directly employed in extending the range of tunability of the refractive index. Besides, the probing of such a novel evolution through the analysis of ellipsometric refractive index modeling and morphological correlation functions has revealed several novel as well as superior microstructural properties in the composite thin film systems. All these characterization and analysis techniques distinctly indicate a strong interrelation between the microstructural ordering and superior optical properties of the present zirconia-silica codeposited composites. (c) 2006 Elsevier B.V. All rights reserved.
C1 Bhabha Atom Res Ctr, Div Spect, Bombay 400085, Maharashtra, India.
RP Sahoo, NK (reprint author), Bhabha Atom Res Ctr, Div Spect, Bombay 400085, Maharashtra, India.
EM nksahoo@apsara.barc.ernet.in
CR Armelao L, 2005, J MATER CHEM, V15, P1838, DOI 10.1039/b500521c
   Boukortt A, 2003, MATER CHEM PHYS, V82, P911, DOI 10.1016/j.matchemphys.2003.08.004
   Chen YH, 2004, MEAS SCI TECHNOL, V15, P2005, DOI 10.1088/0957-0233/15/10/010
   Cho YJ, 2002, APPL PHYS LETT, V80, P1249, DOI 10.1063/1.1448384
   FARABAUGH EN, 1983, J VAC SCI TECHNOL A, V1, P356, DOI 10.1116/1.572134
   FELDMAN A, 1989, APPL OPTICS, V28, P5229, DOI 10.1364/AO.28.005229
   FELDMAN A, 1986, J VAC SCI TECHNOL A, V4, P2969, DOI 10.1116/1.573610
   FESQUET J, 1986, J OPT SOC AM A, V3, P369, DOI 10.1364/JOSAA.3.000369
   FINKENRATH H, 1988, INFRARED PHYS, V28, P363, DOI 10.1016/0020-0891(88)90061-9
   Gaffar MA, 2003, CRYST RES TECHNOL, V38, P798, DOI 10.1002/crat.200310098
   GU PF, 1993, APPL OPTICS, V32, P1528, DOI 10.1364/AO.32.001528
   GUNNING WJ, 1989, APPL OPTICS, V28, P2945, DOI 10.1364/AO.28.002945
   Jacobsson R., 1975, PHYS THIN FILMS, V8, P51
   KANO H, 1980, ELECTRON LETT, V16, P146, DOI 10.1049/el:19800107
   Koo WH, 2004, J VAC SCI TECHNOL A, V22, P2048, DOI 10.1116/1.1782638
   Lee H, 2001, J APPL PHYS, V90, P813, DOI 10.1063/1.1378337
   Liu ZJ, 2002, J APPL PHYS, V92, P3559, DOI 10.1063/1.1504497
   Mannelquist A, 1998, APPL PHYS A-MATER, V66, pS891, DOI 10.1007/s003390051262
   Mohamed SH, 2004, PHYS STATUS SOLIDI A, V201, P90, DOI 10.1002/pssa.200306707
   Norris DJ, 2001, ADV MATER, V13, P371, DOI 10.1002/1521-4095(200103)13:6<371::AID-ADMA371>3.0.CO;2-K
   Osipov AV, 2005, THIN SOLID FILMS, V472, P31, DOI 10.1016/j.tsf.2004.06.102
   OUELLETTE MF, 1991, J VAC SCI TECHNOL A, V9, P1188, DOI 10.1116/1.577600
   POND BJ, 1989, APPL OPTICS, V28, P2800, DOI 10.1364/AO.28.002800
   RAVINDRA NM, 1979, INFRARED PHYS, V19, P605, DOI 10.1016/0020-0891(79)90082-4
   Reicher D, 1997, APPL OPTICS, V36, P1626, DOI 10.1364/AO.36.001626
   Salem MA, 2003, CHINESE J PHYS, V41, P288
   SANKUR H, 1989, J APPL PHYS, V66, P807, DOI 10.1063/1.343501
   SANKUR HO, 1991, APPL OPTICS, V30, P495, DOI 10.1364/AO.30.000495
   SEELEY JS, 1981, APPL OPTICS, V20, P31, DOI 10.1364/AO.20.000031
   Trofimov VI, 2003, THIN SOLID FILMS, V428, P56, DOI 10.1016/S0040-6090(02)01270-1
   Utsugi Y, 1999, PHYS STATUS SOLIDI B, V212, pR9, DOI 10.1002/(SICI)1521-3951(199903)212:1<R9::AID-PSSB99999>3.0.CO;2-Z
   Vodopyanov KL, 1999, J OPT SOC AM B, V16, P1579, DOI 10.1364/JOSAB.16.001579
   von Blanckenhagen B, 2002, APPL OPTICS, V41, P3137, DOI 10.1364/AO.41.003137
   WEMPLE SH, 1971, PHYS REV B, V3, P1338, DOI 10.1103/PhysRevB.3.1338
   WEMPLE SH, 1969, PHYS REV LETT, V23, P1156, DOI 10.1103/PhysRevLett.23.1156
   WEMPLE SH, 1973, PHYS REV B, V7, P3767, DOI 10.1103/PhysRevB.7.3767
   YANG HN, 1993, J APPL PHYS, V74, P101, DOI 10.1063/1.354139
   Zhang CH, 2004, J APPL PHYS, V95, P1460, DOI 10.1063/1.1638611
NR 38
TC 14
Z9 16
U1 2
U2 9
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0169-4332
EI 1873-5584
J9 APPL SURF SCI
JI Appl. Surf. Sci.
PD NOV 15
PY 2006
VL 253
IS 2
BP 618
EP 626
DI 10.1016/j.apsusc.2005.12.148
PG 9
WC Chemistry, Physical; Materials Science, Coatings & Films; Physics,
   Applied; Physics, Condensed Matter
SC Chemistry; Materials Science; Physics
GA 114DV
UT WOS:000242647800036
DA 2018-12-27
ER

PT J
AU Ding, YH
   Zhang, XM
   Liu, XX
   Guo, R
AF Ding, Yuanhua
   Zhang, Xumin
   Liu, Xiaoxia
   Guo, Rong
TI RETRACTED: Studies on interactions of thionine with gold nanoparticles
   (Retracted article. See vol 317, pg. 768, 2008)
SO COLLOIDS AND SURFACES A-PHYSICOCHEMICAL AND ENGINEERING ASPECTS
LA English
DT Article; Retracted Publication
DE gold nanoparticles; thionine; interaction; adsorption characteristics
ID ELECTRON-TRANSFER; SIZE; ADSORPTION; CATALYSIS; SURFACES; BINDING;
   ARRAYS; SILVER; DYES; DNA
AB The interactions of thionine with gold nanoparticles have been studied by using UV-vis absorption spectroscopy, fluorescence spectroscopy, transmission electron microscopy, and Fourier transform infrared spectroscopy. With addition of small amounts of gold nanoparticles, the absorption peak intensity of monomers of thionine decreases significantly, whereas that of H-type dimers of thionine increases. With further addition of gold nanoparticles, both the absorption peak intensities of the monomers and dimers of thionine increase, and the increasing magnitude of the peak intensity of the dimers is larger than that of monomers. The addition of gold nanoparticles makes the equilibrium between the monomer and H-type dimer forms of thionine move toward the dimer forms. Due to the binding between thionine and gold nanoparticles, the fluorescence quenching of thionine by gold nanoparticles is enhanced with increasing amounts of gold nanoparticles, and the quenching is both static and dynamic. TEM images show that the addition of thionine results in the formation of gold clusters, and further support the spectral results. Infrared spectroscopic studies show that the nitrogen atoms of both the NH2 moieties of thionine strongly bind to the gold nanoparticle surfaces through the electrostatic interaction of thionine with gold nanoparticles. For 3-6 nm particles, the number of adsorbed thionine molecules per gold particle is about 1.21 x 10(3). Thionine molecules can not only bind to a particle to form a compact monolayer via both the NH2 moieties of thionine, but also bind to two particles via their two NH2 moieties, respectively. (c) 2006 Elsevier B.V. All rights reserved.
C1 Yangzhou Univ, Sch Chem & Chem Engn, Yangzhou 225002, Peoples R China.
   Nanjing Univ, Sch Chem & Chem Engn, Nanjing 210093, Peoples R China.
RP Guo, R (reprint author), Yangzhou Univ, Sch Chem & Chem Engn, Yangzhou 225002, Peoples R China.
EM yhding@yzu.edu.cn; guorong@yzu.edu.cn
CR Awan MA, 1997, COLLOID SURFACE A, V122, P97, DOI 10.1016/S0927-7757(96)03825-3
   Barazzouk S, 2005, J PHYS CHEM B, V109, P716, DOI 10.1021/jp046474s
   BUNTON CA, 1979, J PHYS CHEM-US, V83, P680, DOI 10.1021/j100469a008
   Chandrasekharan N, 2000, J PHYS CHEM B, V104, P11103, DOI 10.1021/jp002171w
   Daniel MC, 2004, CHEM REV, V104, P293, DOI 10.1021/cr030698+
   Das S, 1999, J PHYS CHEM B, V103, P209, DOI 10.1021/jp983816j
   Dean J. A., 1985, LANGES HDB CHEM
   Dohno C, 2003, J AM CHEM SOC, V125, P9586, DOI 10.1021/ja036397z
   Franzen S, 2002, J PHYS CHEM A, V106, P6533, DOI 10.1021/jp025536g
   GEORGE K, 2003, ACCOUNTS CHEM RES, V36, P888
   GEORGE TK, 2000, J AM CHEM SOC, V122, P2655
   GEORGE TK, 2002, LANGMUIR, V18, P3722
   Ghosh SK, 2004, CHEM PHYS LETT, V395, P366, DOI 10.1016/j.cplett.2004.08.016
   Hu J, 2001, J AM CHEM SOC, V123, P1464, DOI 10.1021/ja003180l
   Ipe BI, 2002, J PHYS CHEM B, V106, P18, DOI 10.1021/jp0134695
   Kometani N, 2001, LANGMUIR, V17, P578, DOI 10.1021/la0013190
   Lakowicz J. R., 1983, PRINCIPLES FLUORESCE
   Lee CR, 2004, J COLLOID INTERF SCI, V271, P41, DOI 10.1016/j.jcis.2003.10.020
   LEE PC, 1982, J PHYS CHEM-US, V86, P3391, DOI 10.1021/j100214a025
   Makarova OV, 1999, J PHYS CHEM B, V103, P9080, DOI 10.1021/jp9900786
   Obare SO, 2002, LANGMUIR, V18, P10407, DOI 10.1021/la0260335
   PATRICK B, 1992, J PHYS CHEM-US, V96, P1423, DOI 10.1021/j100182a072
   Raj CR, 2003, J ELECTROANAL CHEM, V543, P127, DOI 10.1016/S0022-0728(02)01481-X
   Reid GD, 2002, J AM CHEM SOC, V124, P5518, DOI 10.1021/ja0172363
   Shenhar R, 2003, ACCOUNTS CHEM RES, V36, P549, DOI 10.1021/ar020083j
   Shipway AN, 2000, CHEMPHYSCHEM, V1, P18, DOI 10.1002/1439-7641(20000804)1:1<18::AID-CPHC18>3.0.CO;2-L
   Simoncic P, 2004, J PHYS CHEM B, V108, P17352, DOI 10.1021/jp047288p
   Subramanian V, 2004, J AM CHEM SOC, V126, P4943, DOI 10.1021/ja0315199
   Sudeep PK, 2002, NANO LETT, V2, P29, DOI 10.1021/nl010073w
   Thomas KG, 2003, ACCOUNTS CHEM RES, V36, P888, DOI 10.1021/ar030030h
   Thomas KG, 2002, LANGMUIR, V18, P3722, DOI 10.1021/la015669d
   Thomas KG, 2000, J AM CHEM SOC, V122, P2655, DOI 10.1021/ja9941835
   Tom RT, 2004, LANGMUIR, V20, P1909, DOI 10.1021/la0358567
   Xu W, 2004, J PHYS CHEM B, V108, P5588, DOI 10.1021/jp037994a
   Zhang J, 2005, J PHYS CHEM B, V109, P8701, DOI 10.1021/jp046016j
NR 35
TC 7
Z9 7
U1 6
U2 29
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0927-7757
EI 1873-4359
J9 COLLOID SURFACE A
JI Colloid Surf. A-Physicochem. Eng. Asp.
PD NOV 15
PY 2006
VL 290
IS 1-3
BP 82
EP 88
DI 10.1016/j.colsurfa.2006.05.003
PG 7
WC Chemistry, Physical
SC Chemistry
GA 111BJ
UT WOS:000242425500012
DA 2018-12-27
ER

PT J
AU Ajees, AA
   Gunasekaran, K
   Volanakis, JE
   Narayana, SVL
   Kotwal, GJ
   Murthy, HMK
AF Ajees, A. Abdul
   Gunasekaran, K.
   Volanakis, John E.
   Narayana, Sthanam. V. L.
   Kotwal, Girish J.
   Krishna Murthy, H. M.
TI RETRACTED: The structure of complement C3b provides insights into
   complement activation and regulation (Retracted article. See vol.
   532,2016)
SO NATURE
LA English
DT Article; Retracted Publication
ID FACTOR-H; CRYSTAL-STRUCTURE; CONTROL PROTEIN; 3RD COMPONENT; X-RAY;
   BINDING-SITE; RECEPTOR 2; FACTOR-B; CR-1; IDENTIFICATION
AB The human complement system is an important component of innate immunity. Complement-derived products mediate functions contributing to pathogen killing and elimination(1). However, inappropriate activation of the system contributes to the pathogenesis of immunological and inflammatory diseases(1). Complement component 3 (C3) occupies a central position because of the manifold biological activities of its activation fragments, including the major fragment, C3b, which anchors the assembly of convertases effecting C3 and C5 activation. C3 is converted to C3b by proteolysis of its anaphylatoxin domain(2), by either of two C3 convertases. This activates a stable thioester bond, leading to the covalent attachment of C3b to cell-surface or protein-surface hydroxyl groups through transesterification(3). The cleavage and activation of C3 exposes binding sites for factors B, H and I, properdin, decay accelerating factor (DAF, CD55), membrane cofactor protein (MCP, CD46), complement receptor 1 (CR1, CD35) and viral molecules such as vaccinia virus complement-control protein(4). C3b associates with these molecules in different configurations and forms complexes mediating the activation, amplification and regulation of the complement response(1,4). Structures of C3 and C3c, a fragment derived from the proteolysis of C3b, have revealed a domain configuration, including six macroglobulin domains (MG1 - MG6; nomenclature follows ref. 5) arranged in a ring, termed the beta-ring(5). However, because neither C3 nor C3c is active in complement activation and regulation, questions about function can be answered only through direct observations on C3b. Here we present a structure of C3b that reveals a marked loss of secondary structure in the CUB ( for 'complement C1r/C1s, Uegf, Bmp1') domain, which together with the resulting translocation of the thioester domain provides a molecular basis for conformational changes accompanying the conversion of C3 to C3b. The total conformational changes make many proposed ligand-binding sites more accessible and create a cavity that shields target peptide bonds from access by factor I. A covalently bound N-acetyl-L-threonine residue demonstrates the geometry of C3b attachment to surface hydroxyl groups.
C1 Univ Alabama Birmingham, Ctr Biophys Sci & Engn, Birmingham, AL 35294 USA.
   Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA.
   Univ Cape Town, HSC, Div Med Virol, Inst Infect Dis & Mol Med, ZA-7925 Cape Town, South Africa.
RP Murthy, HMK (reprint author), Univ Alabama Birmingham, Ctr Biophys Sci & Engn, 1530 3rd Ave S, Birmingham, AL 35294 USA.
EM murthy@cbse.uab.edu
CR Aslam M, 2001, J MOL BIOL, V309, P1117, DOI 10.1006/jmbi.2001.4720
   BECHERER JD, 1992, BIOCHEMISTRY-US, V31, P1787, DOI 10.1021/bi00121a029
   Bernet J, 2004, J VIROL, V78, P9446, DOI 10.1128/JVI.78.17.9446-9457.2004
   Bork P, 1996, Q REV BIOPHYS, V29, P119, DOI 10.1017/S0033583500005783
   CCP4, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI DOI 10.1107/S0907444994003112
   Clemenza L, 2000, J IMMUNOL, V165, P3839, DOI 10.4049/jimmunol.165.7.3839
   DAOUDAKI ME, 1988, J IMMUNOL, V140, P1577
   Feinberg H, 2003, EMBO J, V22, P2348, DOI 10.1093/emboj/cdg236
   Ganesh VK, 2004, P NATL ACAD SCI USA, V101, P8924, DOI 10.1073/pnas.0400744101
   GETTINS PGW, 1995, BIOCHEMISTRY-US, V34, P12233, DOI 10.1021/bi00038a018
   HIGGINS JMG, 1995, J IMMUNOL, V155, P5777
   Janssen BJC, 2005, NATURE, V437, P505, DOI 10.1038/nature04005
   KOISTINEN V, 1989, COMPLEMENT INFLAMMAT, V6, P270, DOI 10.1159/000463102
   Kotwal GJ, 2000, IMMUNOL TODAY, V21, P242, DOI 10.1016/S0167-5699(00)01606-6
   LAMBRIS JD, 1988, IMMUNOL TODAY, V9, P387, DOI 10.1016/0167-5699(88)91240-6
   LAMBRIS JD, 1988, J BIOL CHEM, V263, P12147
   Law SKA, 1997, PROTEIN SCI, V6, P263
   Murthy KHM, 2001, CELL, V104, P301, DOI 10.1016/S0092-8674(01)00214-8
   Nagar B, 1998, SCIENCE, V280, P1277, DOI 10.1126/science.280.5367.1277
   OKEEFE MC, 1988, J BIOL CHEM, V263, P12690
   Oran AE, 1999, J BIOL CHEM, V274, P5120, DOI 10.1074/jbc.274.8.5120
   Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X
   Puliti R, 2000, ACTA CRYSTALLOGR C, V56, P496
   Smith BO, 2002, CELL, V108, P769, DOI 10.1016/S0092-8674(02)00672-4
   Smith SA, 2003, BBA-PROTEINS PROTEOM, V1650, P30, DOI 10.1016/S1570-9639(03)00189-4
   Tsiftsoglou SA, 2005, BIOCHEMISTRY-US, V44, P6239, DOI 10.1021/bi0476080t
   VOLANAKIS JE, 1998, HUMAN COMPLEMENT SYS
   Winters MS, 2005, J IMMUNOL, V174, P3469, DOI 10.4049/jimmunol.174.6.3469
   Xu YY, 2001, IMMUNOL REV, V180, P123, DOI 10.1034/j.1600-065X.2001.1800111.x
   Zanotti G, 2000, BBA-PROTEIN STRUCT M, V1478, P232, DOI 10.1016/S0167-4838(00)00040-6
NR 30
TC 45
Z9 46
U1 2
U2 15
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0028-0836
EI 1476-4687
J9 NATURE
JI Nature
PD NOV 9
PY 2006
VL 444
IS 7116
BP 221
EP 225
DI 10.1038/nature05258
PG 5
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 103DZ
UT WOS:000241867200044
DA 2018-12-27
ER

PT J
AU Riahi, S
   Ganjali, MR
   Moghaddam, AB
   Norouzi, P
   Niasari, M
AF Riahi, Siavash
   Ganjali, Mohamad Reza
   Moghaddam, Abdolmajid Bayandori
   Norouzi, Parviz
   Niasari, Marjan
TI RETRACTED: Determination of the electrode potentials for substituted
   1,2-dihydroxybenzenes in aqueous solution: Theory and experiment
   (Retracted article. See vol. 964, pg. 331, 2011)
SO JOURNAL OF MOLECULAR STRUCTURE-THEOCHEM
LA English
DT Article; Retracted Publication
DE electrode potentials; solvation model; ab initio calculations;
   1,2-dihydroxybenzenes; density functional theory; HOMO and LUMO
ID REDOX POTENTIALS; CONTINUUM; OXIDATION; MODEL; ELECTROCHEMISTRY;
   BENZOQUINONES; REDUCTION; ENERGIES; QUINONES; CAVITY
AB Electrode potential of 1,2-dihydroxybenzene derivatives, an important biological molecules, in aqueous solution is computed theoretically using density functional theory (DFT) at the level of B3LYP and by employing the 6-3 1 G(d,p) basis set. It was also obtained experimentally with the aim of an electrochemical technique (cyclic voltammetry). Frequency calculations have been carried out and thermal corrections and entropies have been taken into account, in the calculations. The polarizable continuum model is used to describe the solvent. The theoretical and experimental values for the standard electrode potential of the studied 1,2-dihydroxybenzenes are in excellent agreement with each other and there is only a 0.009 V discrepancy between experimental and theoretical results. The agreement mutually verifies the accuracy of the experimental method and the validity of the applied mathematical model. Analysis of correlation between the experimental electrode potentials and the calculated molecular descriptors has also been performed and notable relations have been found between the electrode potentials and the eigenvalues of the specific molecular orbitals. (c) 2006 Elsevier B.V. All rights reserved.
C1 Univ Yasuj, Dept Chem, Yasuj, Iran.
   Univ Tehran, Fac Chem, Ctr Excellence Electrochem, Tehran, Iran.
RP Riahi, S (reprint author), Univ Yasuj, Dept Chem, POB 75914-353, Yasuj, Iran.
EM riahisv@yahoo.com
RI Riahi, Siavash/E-6826-2010; Ganjali, Mohammad Reza/C-7640-2009; norouzi,
   parviz/B-4647-2009
OI Ganjali, Mohammad Reza/0000-0002-2968-0981
CR Baranski A. S., 1996, P ELECTROCHEM SOC, V9, P41
   Barone V, 1998, J PHYS CHEM A, V102, P1995, DOI 10.1021/jp9716997
   BARONE V, 1988, J COMPUT CHEM, P404
   CANCES MT, 1997, J CHEM PHYS, V107, P3032, DOI DOI 10.1063/1.474659
   Chichirau A, 2005, FREE RADICAL BIO MED, V38, P344, DOI 10.1016/j.freeradbiomed.2004.10.035
   Colic M, 2000, J MOL MED-JMM, V78, P333, DOI 10.1007/s001090000121
   COMPTON RG, 1989, J ELECTROANAL CHEM, V258, P79, DOI 10.1016/0022-0728(89)85163-0
   Cossi M, 2000, J PHYS CHEM A, V104, P10614, DOI 10.1021/jp000997s
   Cossi M, 1996, CHEM PHYS LETT, V255, P327, DOI 10.1016/0009-2614(96)00349-1
   DRIEBERGEN RJ, 1990, ANAL CHIM ACTA, V234, P285, DOI 10.1016/S0003-2670(00)83570-9
   Foresman J.B., 1998, EXPLORING CHEM ELECT
   JalaliHeravi M, 1997, J ELECTROANAL CHEM, V425, P139, DOI 10.1016/S0022-0728(96)04943-1
   JALALIHERAVI M, 1995, J ELECTROANAL CHEM, V385, P1, DOI 10.1016/0022-0728(95)03779-G
   LISTER SG, 1992, INT J QUANTUM CHEM, V41, P293, DOI 10.1002/qua.560410206
   MIERTUS S, 1981, CHEM PHYS, V55, P117, DOI 10.1016/0301-0104(81)85090-2
   MIERTUS S, 1982, CHEM PHYS, V65, P239, DOI 10.1016/0301-0104(82)85072-6
   REYNOLDS CA, 1990, J AM CHEM SOC, V112, P7545, DOI 10.1021/ja00177a015
   REYNOLDS CA, 1988, J CHEM SOC CHEM COMM, P1434, DOI 10.1039/c39880001434
   SAEVA FD, 1980, J AM CHEM SOC, V102, P299, DOI 10.1021/ja00521a047
   SASAKI K, 1990, J ELECTROCHEM SOC, V137, P2437, DOI 10.1149/1.2086957
   SMITH BJ, 1991, J PHYS CHEM-US, V95, P10549, DOI 10.1021/j100179a009
   Winget P, 2004, THEOR CHEM ACC, V112, P217, DOI 10.1007/s00214-004-0577-0
   Winget P, 2000, PHYS CHEM CHEM PHYS, V2, P1231, DOI 10.1039/a909076b
NR 23
TC 33
Z9 33
U1 3
U2 23
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0166-1280
J9 J MOL STRUC-THEOCHEM
JI Theochem-J. Mol. Struct.
PD NOV 6
PY 2006
VL 774
IS 1-3
BP 107
EP 111
DI 10.1016/j.theochem.2006.06.035
PG 5
WC Chemistry, Physical
SC Chemistry
GA 107YJ
UT WOS:000242206600018
DA 2018-12-27
ER

PT J
AU Zhong, H
   Zeng, XR
   Liu, YQ
   Luo, QY
AF Zhong, Hua
   Zeng, Xi-Rui
   Liu, Yin-Qiu
   Luo, Qiu-Yan
TI RETRACTED: Aquachlorobis(1,10-phenanthroline) cobalt(II) chloride
   thiourea solvate (Retracted article. See vol. 66, pg. E11, 2010)
SO ACTA CRYSTALLOGRAPHICA SECTION E-STRUCTURE REPORTS ONLINE
LA English
DT Article; Retracted Publication
AB The Co(II) ion in the title compound, [CoCl(phen)(2)(H(2)O)]-Cl center dot C(NH(2))(2)S [phen = 1,10-phenanthroline, (C(12)H(8)N(2))], has a distorted octahedral coordination formed by one Cl atom, one water molecule, and four N atoms of two phen ligands. Ions and molecules are linked into a three-dimensional framework by N-H center dot center dot center dot S, N-H center dot center dot center dot Cl and O-H center dot center dot center dot Cl hydrogen bonds. The supramolecular network structure is consolidated by pi-pi stacking interactions and hydrogen bonds.
C1 JingGangShan Univ, State Key Lab Coordinat Chem, Coll Chem & Chem Engn, Jian 343009, Jiangxi, Peoples R China.
RP Zhong, H (reprint author), JingGangShan Univ, State Key Lab Coordinat Chem, Coll Chem & Chem Engn, Jian 343009, Jiangxi, Peoples R China.
EM huazhong06@126.com
CR Bottcher A, 1995, J INORG BIOCHEM, V59, P221
   *BRUK AXS INC, 2004, APEX2 VERS 1 22 SADA
   Hazell A, 1997, ACTA CRYSTALLOGR C, V53, P723, DOI 10.1107/S0108270197004150
   HUSSEINI R H, 1981, Microbios Letters, V16, P85
   MCAULIFFE CA, 1992, ACTA CRYSTALLOGR C, V48, P1841, DOI 10.1107/S0108270192002105
   Russell V., 2001, CRYSTENGCOMM, V3, P96
   Sheldrick G. M., 1997, SHELXL97 SHELXS97
   Zhang XM, 2000, CHEM COMMUN, P1817, DOI 10.1039/b005880g
   Zhu HL, 2004, J CHEM CRYSTALLOGR, V34, P199, DOI 10.1023/B:JOCC.0000021565.54253.24
NR 9
TC 1
Z9 1
U1 4
U2 13
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1600-5368
J9 ACTA CRYSTALLOGR E
JI Acta Crystallogr. Sect. E.-Struct Rep. Online
PD NOV
PY 2006
VL 62
BP M2925
EP M2927
DI 10.1107/S1600536806041122
PN 11
PG 3
WC Crystallography
SC Crystallography
GA 100TK
UT WOS:000241691500064
DA 2018-12-27
ER

PT J
AU Lu, JL
   Zhang, DS
   Li, L
   Liu, BP
AF Lu, Ji-Lin
   Zhang, Da-Shun
   Li, Lin
   Liu, Bei-Ping
TI RETRACTED:
   1,4-dihydro-3,6-dipyrazin-2-yl-1,2,4,5-tetrazine-benzene-1,3-dicarboxyli
   c acid (1/1) (Retracted article. See vol 64, pg E21, 2007)
SO ACTA CRYSTALLOGRAPHICA SECTION E-STRUCTURE REPORTS ONLINE
LA English
DT Article; Retracted Publication
AB In the title compound, C10H8N8 center dot C8H6O4, both acid and base molecules (A: B) have twofold crystallographic symmetry. One-dimensional zigzag chains of rings form as (A center dot center dot center dot B center dot center dot center dot)(n) through O-H center dot center dot center dot N and C-H center dot center dot center dot O=C interactions; further association of B (with A) along the a axis via bifurcated N-H center dot center dot center dot N and pi-pi stacking interactions gives a three-dimensional self-penetrating structure.
C1 Hunan Univ Arts & Sci, Dept Chem, Hunan 41500, Peoples R China.
RP Lu, JL (reprint author), Hunan Univ Arts & Sci, Dept Chem, Hunan 41500, Peoples R China.
EM lu_j_l@163.com
CR Batten SR, 2001, CRYSTENGCOMM, DOI 10.1039/b102400k
   BERNSTEIN J, 1995, ANGEW CHEM INT EDIT, V34, P1555, DOI 10.1002/anie.199515551
   Bradford FE, 2004, POLYHEDRON, V23, P2141, DOI 10.1016/j.poly.2004.06.018
   *BRUK AXS INC, 1998, SMART NT SAINT NT SH
   Sarkar B, 2003, Z ANORG ALLG CHEM, V629, P1353, DOI 10.1002/zaac.200300076
   Sheldrick G. M., 1997, SHELXS97 SHELXL97
   Sheldrick G.M, 1996, SADABS
   Spek AL, 2003, J APPL CRYSTALLOGR, V36, P7, DOI 10.1107/S0021889802022112
NR 8
TC 0
Z9 0
U1 4
U2 11
PU BLACKWELL PUBLISHING
PI OXFORD
PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND
SN 1600-5368
J9 ACTA CRYSTALLOGR E
JI Acta Crystallogr. Sect. E.-Struct Rep. Online
PD NOV
PY 2006
VL 62
BP O4855
EP O4857
DI 10.1107/s1600536806039894
PN 11
PG 3
WC Crystallography
SC Crystallography
GA 100TK
UT WOS:000241691500192
DA 2018-12-27
ER

PT J
AU Ben-Gal, Y
   Moshkovitz, Y
   Nesher, N
   Uretzky, G
   Braunstein, R
   Hendler, A
   Zivi, E
   Herz, I
   Mohr, R
AF Ben-Gal, Yanai
   Moshkovitz, Yaron
   Nesher, Nachum
   Uretzky, Gideon
   Braunstein, Rony
   Hendler, Alberto
   Zivi, Einat
   Herz, Itzhak
   Mohr, Rephael
TI RETRACTED: Drug-eluting stents versus coronary artery bypass grafting in
   patients with diabetes mellitus (Retracted Article. See vol 84, pg 712,
   2007)
SO ANNALS OF THORACIC SURGERY
LA English
DT Article; Retracted Publication
ID INTERNAL-MAMMARY-ARTERY; RESTENOSIS; DISEASE; REVASCULARIZATION;
   ANGIOPLASTY; SURGERY; TRIALS; IMPLANTATION; METAANALYSIS; PREDICTORS
AB Background. Reduction of restenosis and reinterventions was recently reported with percutaneous interventions ( PCI) with drug-eluting stents ( Cypher). This study compares results of Cypher ( Cordis, Miami Lakes, FL) stenting and surgical revascularization in diabetic patients.
   Methods. From January 2002 to January 2005, 518 consecutive diabetic patients underwent myocardial revascularization; 176 by PCI incorporating Cyphers and 342 treated surgically. Single-vessel patients in the surgical group were treated with the left internal thoracic artery ( ITA) and most multivessel patients were treated with two ITAs. After matching for age, sex, right system revascularization, and extent of coronary disease, two groups ( 86 patients each) were used to compare the two revascularization modalities.
   Results. Both groups were similar; however, left main, poor ejection fraction, total occlusion, and bifurcation lesions were more prevalent in the surgical group, and in-stent restenosis in the PCI group. The mean number of coronary vessels treated was higher in the surgical group ( 2.05 vs 1.6, p < 0.001). Mean follow-up was 18 months. Overall mortality ( early and late) was 2.3% and 3.5% in the Cypher and surgical groups, respectively ( p = 0.65). Angina returned in 39.5% of the Cypher group and 15.1% of the surgical group, p < 0.001. There were 25 reinterventions in the Cypher group compared with five in the surgical group ( p = 0.010). The Cox proportional hazard model revealed assignment to the Cypher group to be the only independent predictor of reangina ( odds ratio [ OR] 3.26, 95% confidence interval [ CI] 1.63 to 6.53) and reintervention ( OR 4.17, 95% CI 1.92 to 20.83).
   Conlusions. Despite improved results of PCI with Cyphers, midterm clinical outcome of diabetic patients treated surgically is better.
C1 Tel Aviv Univ, Dept Cardiothorac Surg, Tel Aviv Sourasky Med, IL-64239 Tel Aviv, Israel.
   Tel Aviv Univ, Dept Cardiol, Tel Aviv Sourasky Med, IL-64239 Tel Aviv, Israel.
   Tel Aviv Univ, Sackler Fac Med, IL-64239 Tel Aviv, Israel.
   Assuta Med Ctr, Dept Cardiol, Tel Aviv, Israel.
   Assuta Med Ctr, Dept Cardiac Surg, Tel Aviv, Israel.
   Hadassah Hebrew Univ Hosp, Ctr Qual Safety & Data, Jerusalem, Israel.
RP Mohr, R (reprint author), Tel Aviv Univ, Dept Cardiothorac Surg, Tel Aviv Sourasky Med, 6 Weizman St, IL-64239 Tel Aviv, Israel.
EM marion@tasmc.health.gov.il
CR Abizaid A, 2001, CIRCULATION, V104, P533, DOI 10.1161/hc3101.093700
   Alderman EL, 2000, J AM COLL CARDIOL, V35, P1122
   *BARI INV, 1996, NEW ENGL J MED, V335, P217
   BARNER HB, 1982, ANN THORAC SURG, V34, P408, DOI 10.1016/S0003-4975(10)61402-6
   Buxton BF, 1998, CIRCULATION, V98, pII1
   Cutlip DE, 2002, J AM COLL CARDIOL, V40, P2082, DOI 10.1016/S0735-1097(02)02597-4
   Dauerman HL, 1998, CIRCULATION, V98, P22
   Elezi S, 1998, J AM COLL CARDIOL, V32, P1866, DOI 10.1016/S0735-1097(98)00467-7
   Gurevitch J, 1997, ANN THORAC SURG, V63, P382
   Hermiller JB, 2005, J AM COLL CARDIOL, V45, P1172, DOI 10.1016/j.jacc.2004.10.075
   Herz I, 2005, ANN THORAC SURG, V79, P88, DOI 10.1016/j.athoracsur.2004.06.068
   Kasaoka S, 1998, J AM COLL CARDIOL, V32, P1630, DOI 10.1016/S0735-1097(98)00404-5
   KIMURA T, 1993, J AM COLL CARDIOL, V21, P1557, DOI 10.1016/0735-1097(93)90368-B
   King SB, 2000, J AM COLL CARDIOL, V35, P1116, DOI 10.1016/S0735-1097(00)00546-5
   Kobayashi Y, 1999, J AM COLL CARDIOL, V34, P651, DOI 10.1016/S0735-1097(99)00303-4
   Kurbaan AS, 2001, AM J CARDIOL, V87, P947, DOI 10.1016/S0002-9149(01)01426-6
   LOOP FD, 1986, NEW ENGL J MED, V314, P1, DOI 10.1056/NEJM198601023140101
   Lytle BW, 1999, J THORAC CARDIOV SUR, V117, P855, DOI 10.1016/S0022-5223(99)70365-X
   McFadden EP, 2004, LANCET, V364, P1519, DOI 10.1016/S0140-6736(04)17275-9
   Mercado N, 2001, J AM COLL CARDIOL, V38, P645, DOI 10.1016/S0735-1097(01)01431-0
   Moussa I, 2004, CIRCULATION, V109, P2273, DOI 10.1161/01.CIR.0000129767.45513.71
   O'Neill WW, 2002, LANCET, V360, P961, DOI 10.1016/S0140-6736(02)11118-4
   Radford MJ, 2005, CIRCULATION, V112, P1888, DOI 10.1161/CIRCULATIONAHA.105.170073
   Schofer J, 2000, J AM COLL CARDIOL, V35, P1554, DOI 10.1016/S0735-1097(00)00574-X
   Serruys PW, 1999, J AM COLL CARDIOL, V34, P1067, DOI 10.1016/S0735-1097(99)00308-3
   SIM I, 1995, AM J CARDIOL, V76, P1025, DOI 10.1016/S0002-9149(99)80289-6
   Stone GW, 2004, NEW ENGL J MED, V350, P221, DOI 10.1056/NEJMoa032441
   Vander Salm TJ, 2002, J AM COLL CARDIOL, V39, P565
   VIMANI R, 2004, CORONARY ARTERY DIS, V15, P313
   Weintraub WS, 1998, J AM COLL CARDIOL, V31, P10, DOI 10.1016/S0735-1097(97)00441-5
NR 30
TC 20
Z9 23
U1 3
U2 12
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0003-4975
EI 1552-6259
J9 ANN THORAC SURG
JI Ann. Thorac. Surg.
PD NOV
PY 2006
VL 82
IS 5
BP 1692
EP 1697
DI 10.1016/j.athoracsur.2006.05.080
PG 6
WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery
SC Cardiovascular System & Cardiology; Respiratory System; Surgery
GA 098CC
UT WOS:000241497600017
PM 17062230
DA 2018-12-27
ER

PT J
AU Malik, G
   Gorbounov, N
   Das, S
   Gurusamy, N
   Otani, H
   Maulik, N
   Goswami, S
   Das, DK
AF Malik, Gautam
   Gorbounov, Nikolai
   Das, Samarjit
   Gurusamy, Narasimman
   Otani, Hajime
   Maulik, Nilanjana
   Goswami, Shyamal
   Das, Dipak K.
TI RETRACTED: Ischemic preconditioning triggers nuclear translocation of
   thioredoxin and its interaction with Ref-1 potentiating a survival
   signal through the PI-3-kinase-Akt pathway (Retracted article. See vol.
   16, pg. 746, 2012)
SO ANTIOXIDANTS & REDOX SIGNALING
LA English
DT Article; Retracted Publication
ID NF-KAPPA-B; CARDIOMYOCYTE APOPTOSIS; REPERFUSION INJURY; DIRECT
   ASSOCIATION; HEART; PROTEIN; STRESS; CELLS; AP-1; TRANSACTIVATION
AB Thioredoxin (Trx-1), a key mediator of cellular redox homeostasis and cell survival, is implicated in redox signaling in the ischemic myocardium. To investigate further its mechanism of action, Trx expression in rat heart was suppressed by direct injection of small hairpin RNA against Trx-1 (shRNA-Trx-1). Forty-eight hours after treatment, hearts were excised for isolated working-heart preparation. A group of hearts was preconditioned (PC) by subjecting them to four cyclic episodes of 5-min ischemia, each followed by 10 min of reperfusion. All the hearts, PC or non-PC, were subjected to 30-min ischemia followed by 2 h of reperfusion. As expected, the PC hearts exhibited improved ventricular function, reduced infarct size, and cardiomyocyte apoptosis. Also in PC hearts, an increase was noted in Trx-1 and other cardioprotective and redox-regulated proteins like Ref-1, phospho-Akt, and NF-kappa B DNA-binding activity. PC also caused nuclear translocation of Trx-1 and Ref-1 followed by their association. However, in hearts treated with shRNA-Trx1, the cardioprotective effects of PC were abolished along with a concomitant decrease in nuclear localized Trx-1 and Ref-1, along with a decrease in phospho-Akt and NF-kappa B. These results demonstrate that PC triggers translocation of Trx-1 into the nucleus, where it becomes associated with Ref-1 and performs redox signaling through the activation of NF-kappa B and an increase in prosurvival signal inducer phospho-Akt.
C1 Univ Connecticut, Sch Med, Cardiovasc Res Ctr, Farmington, CT 06030 USA.
   Walter Reed Army Inst Res, Washington, DC 20307 USA.
RP Das, DK (reprint author), Univ Connecticut, Sch Med, Cardiovasc Res Ctr, Farmington, CT 06030 USA.
EM ddas@neuron.uchc.edu
FU NHLBI NIH HHS [HL56803, HL69910, HL 34360, HL33889, HL22559]
CR Aota M, 1996, J CARDIOVASC PHARM, V27, P727, DOI 10.1097/00005344-199605000-00016
   Bloomfield KL, 2003, GENE, V319, P107, DOI 10.1016/S0378-1119(03)00799-6
   Das DK, 2004, ANTIOXID REDOX SIGN, V6, P405, DOI 10.1089/152308604322899477
   Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905
   Djavaheri-Mergny M, 2004, FEBS LETT, V578, P111, DOI 10.1016/j.febslet.2004.10.082
   ENGELMAN DT, 1995, CARDIOVASC RES, V29, P133, DOI 10.1016/0008-6363(96)88558-0
   Freemerman AJ, 1999, CANCER RES, V59, P4090
   Fujio Y, 2000, CIRCULATION, V101, P660, DOI 10.1161/01.CIR.101.6.660
   HAYASHI T, 1993, J BIOL CHEM, V268, P11380
   Hirota K, 1997, P NATL ACAD SCI USA, V94, P3633, DOI 10.1073/pnas.94.8.3633
   HOLMGREN A, 1995, METHOD ENZYMOL, V252, P199
   Isowa N, 2000, J CELL PHYSIOL, V182, P33, DOI 10.1002/(SICI)1097-4652(200001)182:1<33::AID-JCP4>3.0.CO;2-5
   KAGHAD M, 1994, GENE, V140, P273, DOI 10.1016/0378-1119(94)90557-6
   KAIMUL AM, 2005, FREE RADIC BIOL MED, V39, P1545
   Makino Y, 1999, J BIOL CHEM, V274, P3182, DOI 10.1074/jbc.274.5.3182
   Masutani H, 1996, IMMUNOL LETT, V54, P67, DOI 10.1016/S0165-2478(96)02651-X
   Maulik N, 1998, FEBS LETT, V429, P365, DOI 10.1016/S0014-5793(98)00632-2
   Maulik N, 1999, FEBS LETT, V443, P331, DOI 10.1016/S0014-5793(98)01719-0
   Miyamoto M, 2003, CIRC J, V67, P116, DOI 10.1253/circj.67.116
   Mustacich D, 2000, BIOCHEM J, V346, P1, DOI 10.1042/0264-6021:3460001
   Nakamura H, 1998, FREE RADICAL BIO MED, V24, P1176, DOI 10.1016/S0891-5849(97)00429-2
   Nimata M, 2003, MOL CELL BIOCHEM, V248, P193, DOI 10.1023/A:1024156923322
   Ray PS, 2001, FASEB J, V15, P393, DOI 10.1096/fj.00-0199com
   Sato M, 2000, AM J PHYSIOL-HEART C, V279, pH901
   SCHENK H, 1994, P NATL ACAD SCI USA, V91, P1672, DOI 10.1073/pnas.91.5.1672
   Seemann S, 2005, ONCOGENE, V24, P3853, DOI 10.1038/sj.onc.1208549
   Shibuki H, 1998, INVEST OPHTH VIS SCI, V39, P1470
   Taniguchi Y, 1996, NUCLEIC ACIDS RES, V24, P2746, DOI 10.1093/nar/24.14.2746
   Tong HY, 2000, CIRC RES, V87, P309, DOI 10.1161/01.RES.87.4.309
   TUROCZI T, 2004, J MOL CELL CARDIOL, V109, P3042
   UCHIYAMA T, 2003, CIRCULATION, V35, P695
NR 31
TC 34
Z9 37
U1 7
U2 18
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1523-0864
EI 1557-7716
J9 ANTIOXID REDOX SIGN
JI Antioxid. Redox Signal.
PD NOV-DEC
PY 2006
VL 8
IS 11-12
BP 2101
EP 2109
DI 10.1089/ars.2006.8.2101
PG 9
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism
GA 100BD
UT WOS:000241641200014
PM 17034353
DA 2018-12-27
ER

PT J
AU Sato, Y
   Honda, Y
   Iwamoto, J
AF Sato, Yoshihiro
   Honda, Yoshiaki
   Iwamoto, Jun
TI RETRACTED: Etidronate for fracture prevention in amyotrophic lateral
   sclerosis: A randomized controlled trial (Retracted article. See vol.
   106, pg. 214, 2018)
SO BONE
LA English
DT Article; Retracted Publication
ID VITAMIN-D DEFICIENCY; PRIMARY HYPERPARATHYROIDISM; IMMOBILIZATION
   HYPERCALCEMIA; POSTMENOPAUSAL OSTEOPOROSIS; PARKINSONS-DISEASE;
   HYPOVITAMINOSIS D; HIP-FRACTURES; ELDERLY-WOMEN; BONE MASS; CALCIUM
AB Incidence of fractures is high in patients with amyotrophic lateral sclerosis (ALS) as compared to age-matched healthy controls. Our previous cross-sectional study showed that immobilization-induced hypercalcemia (i.e., increased bone resorption) and 25-hydroxyvitamin D (25-OHD) deficiency contribute to reduced bone mineral density (BMD). This study aims to address the possibility that treatment with etidronate may reduce the bone resorption and lower the incidence of fractures in patients with ALS. ALS patients were randomly assigned to daily treatment with 400 mg of etidronate (n = 41) or a placebo (n = 41) and followed for 2 years. At baseline, both groups had low BMD with high levels of serum ionized calcium and pyridinoline cross-linked carboxy-terminal telopeptide of type I collagen (ICTP). In the etidronate group, serum calcium and ICTP levels decreased significantly during the study period, while the levels in the placebo group were increased. Over 2 years, serum 25-OHD reduced to the potentially osteomalacic level (less than 5 mg/mL) in both groups. BMD decreased by 3.6% in the etidronate group and decreased by 12.1% in the placebo group (P < 0.0001). Fractures occurred in 7 patients in the placebo group and one patient in the risedronate group. The relative risk in the risedronate group as compared with the placebo group was 0.14 (95% confidence interval, 0.02 to 1.11). The number of fractures per 1000 patient-years was 14 and 92 for the etidronate and placebo groups, respectively. Treatment with etidronate prevents further loss of BMD in patients with ALS and leads to the prevention of fractures. (C) 2006 Elsevier Inc. All rights reserved.
C1 Mitate Hosp, Dept Neurol, Tagawa 8260041, Japan.
   Keio Univ, Sch Med, Dept Sport Med, Tokyo 1608582, Japan.
RP Sato, Y (reprint author), Mitate Hosp, Dept Neurol, 3237 Yugeta, Tagawa 8260041, Japan.
EM y-sato@ktarn.or.jp
CR APPEL V, 1987, ANN NEUROL, V22, P328, DOI 10.1002/ana.410220308
   BENSIMON G, 1994, NEW ENGL J MED, V330, P585, DOI 10.1056/NEJM199403033300901
   Cameron A, 2002, CURR OPIN CLIN NUTR, V5, P631, DOI [10.1097/00075197-200211000-00005, 10.1097/01.mco.0000038805.16540.09]
   CARNEVALE V, 1992, J NEUROL, V239, P57, DOI 10.1007/BF00839215
   CHAPUY MC, 1992, NEW ENGL J MED, V327, P1637, DOI 10.1056/NEJM199212033272305
   DEMIAUX B, 1992, J CLIN ENDOCR METAB, V74, P1146, DOI 10.1210/jc.74.5.1146
   FLEISCH H, 1981, METAB BONE DIS RELAT, V3, P279, DOI 10.1016/0221-8747(81)90044-8
   Francis RM, 1996, OSTEOPOROSIS INT, V6, P284, DOI 10.1007/BF01623386
   Gelanis Deborah F., 2001, Curr Treat Options Neurol, V3, P133, DOI 10.1007/s11940-001-0048-z
   GRESHAM LS, 1987, NEUROLOGY, V37, P717, DOI 10.1212/WNL.37.4.717
   GRISSO JA, 1991, NEW ENGL J MED, V324, P1326, DOI 10.1056/NEJM199105093241905
   Guirguis-Blake J, 2003, J FAM PRACTICE, V52, P431
   HARRIS ST, 1993, AM J MED, V95, P557, DOI 10.1016/0002-9343(93)90350-X
   Hayashi H, 2003, NEUROLOGY, V61, P135, DOI 10.1212/01.WNL.0000069925.02052.1F
   HEIKINHEIMO RJ, 1992, CALCIFIED TISSUE INT, V51, P105, DOI 10.1007/BF00298497
   HYMAN LR, 1972, AM J DIS CHILD, V124, P723, DOI 10.1001/archpedi.1972.02110170101017
   Jackson CE, 1998, NEUROLOGY, V50, P1795, DOI 10.1212/WNL.50.6.1795
   KOMAR L, 1993, J AM GERIATR SOC, V41, P1057, DOI 10.1111/j.1532-5415.1993.tb06452.x
   KURTZKE JF, 1980, NEUROLOGY, V30, P453, DOI 10.1212/WNL.30.5.453
   Lark RK, 2001, AM J CLIN NUTR, V73, P602
   Lechtzin N, 2002, AMYOTROPH LATERAL SC, V3, P5, DOI 10.1080/146608202317576480
   Massagli TL, 1999, ARCH PHYS MED REHAB, V80, P998, DOI 10.1016/S0003-9993(99)90050-3
   MATSUMOTO C, 1994, CALCIFIED TISSUE INT, V55, P324, DOI 10.1007/BF00299308
   Miller RG, 2005, JCR-J CLIN RHEUMATOL, V11, P2, DOI 10.1097/01.rhu.0000152141.47663.e4
   Nakamura K, 2002, NUTRITION, V18, P415, DOI 10.1016/S0899-9007(02)00751-7
   PATTEN BM, 1982, HUMAN MOTOR NEURON D, P181
   Peterlik M, 2005, EUR J CLIN INVEST, V35, P290, DOI 10.1111/j.1365-2362.2005.01487.x
   Ramnemark A, 1998, OSTEOPOROSIS INT, V8, P92, DOI 10.1007/s001980050053
   Rodriguez GE, 2003, REV NEUROLOGIA, V36, P104
   Sambrook PN, 2003, J BONE MINER RES, V18, P919, DOI 10.1359/jbmr.2003.18.5.919
   Sato Y, 2002, BONE, V31, P114, DOI 10.1016/S8756-3282(02)00783-4
   Sato Y, 2001, STROKE, V32, P1673, DOI 10.1161/01.STR.32.7.1673
   Sato Y, 2000, J BONE MINER RES, V15, P2487, DOI 10.1359/jbmr.2000.15.12.2487
   Sato Y, 1999, J NEUROL NEUROSUR PS, V66, P64, DOI 10.1136/jnnp.66.1.64
   Sato Y, 1997, EUR NEUROL, V37, P225, DOI 10.1159/000117447
   Siris E, 1996, J CLIN ENDOCR METAB, V81, P961, DOI 10.1210/jc.81.3.961
   SOBUE I, 1976, CALCIUM STUDIES AMYO, P83
   STORM T, 1990, NEW ENGL J MED, V322, P1265, DOI 10.1056/NEJM199005033221803
   THOMAS P, 1994, NEUROLOGY, V44, P178, DOI 10.1212/WNL.44.1.178
   *WORLD FED NEUR SU, 1994, J NEUROL SCI S, V124, P98
   YANAGIHARA R, 1984, ANN NEUROL, V15, P42, DOI 10.1002/ana.410150108
NR 41
TC 15
Z9 15
U1 2
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 8756-3282
EI 1873-2763
J9 BONE
JI Bone
PD NOV
PY 2006
VL 39
IS 5
BP 1080
EP 1086
DI 10.1016/j.bone.2006.04.025
PG 7
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 099HP
UT WOS:000241584500016
PM 16777503
DA 2018-12-27
ER

PT J
AU El-Rayes, BF
   Ali, S
   Ali, IF
   Philip, PA
   Abbruzzese, J
   Sarkar, FH
AF El-Rayes, Basil F.
   Ali, Shadan
   Ali, Ifrah F.
   Philip, Philip A.
   Abbruzzese, James
   Sarkar, Fazlul H.
TI RETRACTED: Potentiation of the effect of erlotinib by genistein in
   pancreatic cancer: The role of Akt and nuclear factor-kappa B (Retracted
   article. See vol. 78, pg. 5472, 2018)
SO CANCER RESEARCH
LA English
DT Article; Retracted Publication
ID GROWTH-FACTOR RECEPTOR; SOY ISOFLAVONE GENISTEIN; SIGNALING PATHWAY;
   PROSTATE-CANCER; HEALTHY-MEN; APOPTOSIS; CELLS; INHIBITION; GEMCITABINE;
   BCL-2
AB The epidermal growth factor receptor (EGFR) is a target of new therapies in most nonhematologic cancers. EGFR blockade alone may not be sufficient for the control of growth and invasion of human pancreas cancer because of the independent activation of Akt and nuclear factor-kappa B (NF-kappa B). The expression of EGFR, Akt, and NF-kappa B was determined in six human pancreatic cancer cell lines. Selected cells for specific expression,were treated with erlotinib, genistein, gemcitabine, or the combination. Growth inhibition was evaluated using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay, and apoptosis was assayed by ELISA. EGFR, phosphorylated EGFR, phosphorylated Akt, and survivin expressions were determined by immunoblotting. Electrophoretic mobility shift assay was used to evaluate the DNA binding activity of TNF-kappa B. Genistein significantly increased (P < 0.05) erlotinib-induced growth inhibition and apoptosis in BxPC-3, CAPAN-2, and AsPC-1 cells. In the BxPC-3 cell line, significant down-regulation of EGFR, phosphorylated Akt, NF-kappa B activation, and survivn was observed in the cells treated with the combination compared with the erlotinib-treated cells. In the HPAC and MIAPaCa cell line, no potentiation of the effects of erlotinib by genistein on cell growth or inhibition of the EGFR/Akt/NF-kappa B was observed. Genistein potentiated growth inhibition and apoptosis of the gemcitabine and erlotinib combination in COLO-357 cell line. Genistein potentiates the growth inhibition and apoptosis induced by erlotinib and gemcitabine in certain pancreatic cancer cells. Akt and NF-kappa B inhibition represents one of the mechanisms for the potentiation of erlotinib- and gemcitabine-induced cell death by genistein.
C1 Wayne State Univ, Sch Med, Dept Pathol,Hudson Webber Canc Res Inst 740, Karmanos Canc Inst, Detroit, MI 48201 USA.
   Wayne State Univ, Dept Pathol, Div Hematol Oncol, Karmanos Canc Inst, Detroit, MI 48201 USA.
   Univ Texas, MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, Houston, TX 77030 USA.
RP Sarkar, FH (reprint author), Wayne State Univ, Sch Med, Dept Pathol,Hudson Webber Canc Res Inst 740, Karmanos Canc Inst, Detroit, MI 48201 USA.
EM fsarkar@med.wayne.edu
FU NCI NIH HHS [1R01CA101870-03, SP20CA101936-04]
CR Ahn KS, 2005, ANN NY ACAD SCI, V1056, P218, DOI 10.1196/annals.1352.026
   Arlt A, 2001, ONCOGENE, V20, P859, DOI 10.1038/sj.onc.1204168
   Asano T, 2004, ONCOGENE, V23, P8571, DOI 10.1038/sj.onc.1207902
   Banerjee S, 2005, CANCER RES, V65, P9064, DOI 10.1158/0008-5472.CAN-05-1330
   Baselga J, 2005, J CLIN ONCOL, V23, P5323, DOI 10.1200/JCO.2005.08.326
   Bharti AC, 2002, BIOCHEM PHARMACOL, V64, P883, DOI 10.1016/S0006-2952(02)01154-1
   Buchsbaum DJ, 2002, INT J RADIAT ONCOL, V54, P1180, DOI 10.1016/S0360-3016(02)03788-4
   Busby MG, 2002, AM J CLIN NUTR, V75, P126
   Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174
   Catz SD, 2001, ONCOGENE, V20, P7342, DOI 10.1038/sj.onc.1204926
   Chen XF, 2003, CANCER RES, V63, P1059
   Cheng JQ, 1996, P NATL ACAD SCI USA, V93, P3636, DOI 10.1073/pnas.93.8.3636
   Chinni SR, 2002, CLIN CANCER RES, V8, P1228
   Chun PY, 2006, CANCER RES, V66, P981, DOI 10.1158/0008-5472.CAN-05-2665
   Davis JN, 2001, FREE RADICAL BIO MED, V30, P1293, DOI 10.1016/S0891-5849(01)00535-4
   El-Rayes BF, 2003, CANCER INVEST, V21, P73, DOI 10.1081/CNV-120016406
   Fahy BN, 2005, CANCER CHEMOTH PHARM, V56, P46, DOI 10.1007/s00280-004-0944-5
   Fahy BN, 2003, BRIT J CANCER, V89, P391, DOI 10.1038/sj.bjc.6601037
   Hsu AL, 2000, J BIOL CHEM, V275, P11397, DOI 10.1074/jbc.275.15.11397
   Jemal A, 2006, CA-CANCER J CLIN, V56, P106, DOI 10.3322/canjclin.56.2.106
   Jimeno A, 2005, CANCER RES, V65, P3003, DOI 10.1158/0008-5472.CAN-04-3586
   LEMOINE NR, 1992, J PATHOL, V166, P7, DOI 10.1002/path.1711660103
   Li YW, 2005, CANCER RES, V65, P6934, DOI 10.1158/0008-5472.CAN-04-4604
   Li YW, 2004, PANCREAS, V28, pE90, DOI 10.1097/00006676-200405000-00020
   Liptay S, 2003, INT J CANCER, V105, P735, DOI 10.1002/ijc.11081
   MOORE M, 2005, P ASCO 2005
   Ng SSW, 2000, CANCER RES, V60, P5451
   Perugini RA, 2000, J SURG RES, V90, P39, DOI 10.1006/jsre.2000.5833
   Ross JA, 2002, ANNU REV NUTR, V22, P19, DOI 10.1146/annurev.nutr.22.111401.144957
   Sarkar FH, 2002, CANCER METAST REV, V21, P265, DOI 10.1023/A:1021210910821
   Shah SA, 2001, J CELL BIOCHEM, V82, P110, DOI 10.1002/jcb.1150
   Sohur US, 1999, GENE EXPRESSION, V8, P219
   Solorzano CC, 2001, CLIN CANCER RES, V7, P2563
   Sordella R, 2004, SCIENCE, V305, P1163, DOI 10.1126/science.1101637
   Wang Q, 2005, EXP MOL PATHOL, V79, P100, DOI 10.1016/j.yexmp.2005.05.002
   Yamanaka Y, 1992, Nihon Ika Daigaku Zasshi, V59, P51
   Yamasaki T, 2001, NDT&E INT, V34, P207, DOI 10.1016/S0963-8695(00)00060-8
   Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073
NR 38
TC 96
Z9 100
U1 0
U2 9
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD NOV 1
PY 2006
VL 66
IS 21
BP 10553
EP 10559
DI 10.1158/0008-5472.CAN-06-2333
PG 7
WC Oncology
SC Oncology
GA 101ZY
UT WOS:000241781600045
PM 17079479
OA Bronze
DA 2018-12-27
ER

PT J
AU Blocki, FA
   Radhakrishnan, S
   Van Keulen, VP
   Heckman, KL
   Ciric, B
   Howe, CL
   Rodriguez, M
   Kwon, E
   Pease, LR
AF Blocki, Frank A.
   Radhakrishnan, Suresh
   Van Keulen, Virginia P.
   Heckman, Karin L.
   Ciric, Bogoljub
   Howe, Charles L.
   Rodriguez, Moses
   Kwon, Eugene
   Pease, Larry R.
TI RETRACTED: Induction of a gene expression program in dendritic cells
   with a cross-linking IgM antibody to the co-stimulatory molecule B7-DC
   (Retracted Article. See vol 24, pg 2135, 2010)
SO FASEB JOURNAL
LA English
DT Article; Retracted Publication
DE cellular activation; gene regulation; immune regulation; immune
   modulation; immunotherapy
ID SERINE-PROTEASE INHIBITOR-6; NF-KAPPA-B; VOL. 184; IN-VIVO; C-JUN;
   ANTIGEN; FOS; REMYELINATION; TOLERANCE; IMMUNE
AB While bivalent antibodies can block ligand-receptor interactions, IgM pentamers efficiently cross-link cell surface targets and evoke physiological responses. We have described one such interaction between an IgM antibody (Ab) and the B7-DC costimulatory molecule expressed by dendritic cells that induces strong antitumor immunity and modulates pathogenic responses associated with allergic asthma. Progressive changes in gene expression in dendritic cells activated by an IgM B7-DC cross-linking Ab resulted in the increased expression in 350 genes and decreased expression of more than 200 genes over the course of 24 h following Ab treatment. In particular, up-regulation of the caspase inhibitor FLIP and the chemokine receptor CCR7, and the down-regulation of the CXCR4 receptor provide a mechanistic basis of Ab-induced survival and enhanced migration into draining lymph nodes. Increased expression of both cell surface and secreted molecules known to be mediators of the immunomodulatory properties of dendritic cells was detected at both the levels of RNA and protein expression. This analysis documents the ability of IgM Ab to activate a gene expression cascade leading to important biological changes in cellular function and provides mechanistic insight into the potent immunomodulatory properties attributed to this Ab.
C1 Mayo Clin & Mayo Fdn, Coll Med, Dept Immunol, Rochester, MN 55905 USA.
   Mayo Clin & Mayo Fdn, Coll Med, Dept Neurol, Rochester, MN 55905 USA.
   Mayo Clin & Mayo Fdn, Coll Med, Dept Urol, Rochester, MN 55905 USA.
RP Pease, LR (reprint author), Mayo Clin & Mayo Fdn, Coll Med, Dept Immunol, 200 1st St SW, Rochester, MN 55905 USA.
EM pease.larry@mayo.edu
RI Howe, Charles/B-4945-2009
OI Howe, Charles/0000-0002-3889-8739; Rodriguez, Moses/0000-0001-6328-6497
FU NIAMS NIH HHS [T32 AR007610]; NCI NIH HHS [R01 CA105138, R01 CA104996,
   R01 CA096859]
CR Akbari O, 2001, NAT IMMUNOL, V2, P725, DOI 10.1038/90667
   Banchereau J, 2001, CANCER RES, V61, P6451
   BIEBER AJ, 2001, TRENDS NEUROSCI, V24, P39
   Chang CCJ, 2000, J IMMUNOL, V165, P3584, DOI 10.4049/jimmunol.165.7.3584
   Dhodapkar MV, 1999, J CLIN INVEST, V104, P173, DOI 10.1172/JCI6909
   Dhodapkar MV, 2001, J EXP MED, V193, P233, DOI 10.1084/jem.193.2.233
   HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X
   Howe CL, 2004, NEUROBIOL DIS, V15, P120, DOI 10.1016/j.nbd.2003.09.002
   INABA K, 1992, J EXP MED, V176, P1693, DOI 10.1084/jem.176.6.1693
   Jonuleit H, 2000, J EXP MED, V192, P1213, DOI 10.1084/jem.192.9.1213
   Kaisho T, 2003, CURR MOL MED, V3, P373, DOI 10.2174/1566524033479726
   KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483
   Kim TW, 2004, CANCER RES, V64, P400, DOI 10.1158/0008-5472.CAN-03-1475
   KOVARY K, 1992, MOL CELL BIOL, V12, P5015, DOI 10.1128/MCB.12.11.5015
   KOVARY K, 1991, MOL CELL BIOL, V11, P4466, DOI 10.1128/MCB.11.9.4466
   Maldonado-Lopez R, 1999, J EXP MED, V189, P587, DOI 10.1084/jem.189.3.587
   Mann J, 2002, J BIOL CHEM, V277, P17125, DOI 10.1074/jbc.M109250200
   Medema JP, 2001, J EXP MED, V194, P657, DOI 10.1084/jem.194.5.657
   Nguyen LT, 2002, J EXP MED, V196, P1393, DOI 10.1084/jem.20021466
   Pulendran B, 1999, P NATL ACAD SCI USA, V96, P1036, DOI 10.1073/pnas.96.3.1036
   Radhakrishnan S, 2005, J ALLERGY CLIN IMMUN, V116, P668, DOI 10.1016/j.jaci.2005.04.038
   Radhakrishnan S, 2005, P NATL ACAD SCI USA, V102, P11438, DOI 10.1073/pnas.0501420102
   Radhakrishnan S, 2004, J IMMUNOL, V173, P1360, DOI 10.4049/jimmunol.173.2.1360
   Radhakrishnan S, 2004, CANCER RES, V64, P4965, DOI 10.1158/0008-5472.CAN-03-3025
   Radhakrishnan S, 2003, J IMMUNOL, V170, P1830, DOI 10.4049/jimmunol.170.4.1830
   RAUSCHER FJ, 1988, GENE DEV, V2, P1687, DOI 10.1101/gad.2.12b.1687
   RODRIGUEZ M, 1990, ANN NEUROL, V27, P12, DOI 10.1002/ana.410270104
   Roncarolo MG, 2001, IMMUNOL REV, V182, P68, DOI 10.1034/j.1600-065X.2001.1820105.x
   RONCAROLO MG, 2001, J EXP MED, V193, P5
   Soldan MMP, 2003, MOL CELL NEUROSCI, V22, P14, DOI 10.1016/S1044-7431(02)00018-0
   Steinman RM, 2000, J EXP MED, V191, P411, DOI 10.1084/jem.191.3.411
   Steinman RM, 2001, INT J CANCER, V94, P459, DOI 10.1002/ijc.1503
   Steinman RM, 2002, P NATL ACAD SCI USA, V99, P351, DOI 10.1073/pnas.231606698
   Tanaka H, 2000, J EXP MED, V192, P405, DOI 10.1084/jem.192.3.405
   Thomson S, 1999, SEMIN CELL DEV BIOL, V10, P205, DOI 10.1006/scdb.1999.0302
   Turley SJ, 2002, CURR OPIN IMMUNOL, V14, P765, DOI 10.1016/S0952-7915(02)00399-0
   Van Keulen VP, 2006, CLIN EXP IMMUNOL, V143, P314, DOI 10.1111/j.1365-2249.2005.02992.x
   Yao J, 1997, J BIOL CHEM, V272, P17795, DOI 10.1074/jbc.272.28.17795
   Zhu C, 2001, J BIOL CHEM, V276, P18519, DOI 10.1074/jbc.M100440200
NR 39
TC 16
Z9 16
U1 4
U2 10
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
EI 1530-6860
J9 FASEB J
JI Faseb J.
PD NOV
PY 2006
VL 20
IS 13
BP 2408
EP +
DI 10.1096/fj.06-6171fje
PG 10
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
   Topics; Cell Biology
GA 100XD
UT WOS:000241702600036
PM 17023390
DA 2018-12-27
ER

PT J
AU Zhang, YX
   Wang, ZW
   Ahmed, F
   Banerjee, S
   Li, YW
   Sarkar, FH
AF Zhang, Yuxiang
   Wang, Zhiwei
   Ahmed, Fakhara
   Banerjee, Sanjeev
   Li, Yiwei
   Sarkar, Fazlul H.
TI RETRACTED: Down-regulation of Jagged-1 induces cell growth inhibition
   and S phase arrest in prostate cancer cells (Retracted article. See
   vol.139,pg.2145,2016)
SO INTERNATIONAL JOURNAL OF CANCER
LA English
DT Article; Retracted Publication
DE Jagged-1; prostate cancer; cell growth; S phase
ID NOTCH; EXPRESSION; LIGANDS; TRANSFORMATION; SURVIVAL; RECEPTOR
AB Notch is an ancient cell signaling system that regulates cell fate specification, stem cell maintenance and initiation of differentiation in many tissues. It has been reported that Jagged-1, a Notch ligand, is significantly over expressed in metastatic prostate cancer compared to localized prostate cancer or benign prostatic tissues. Therefore, deregulation of Jagged-1 protein levels may play a role in prostate cancer cell growth and progression. Hence, the aim of our current study was to investigate the mechanistic role of Jagged-1 in prostate cancer cell growth and cell cycle progression. Our results show, for the first time, that down-regulation of Jagged-1 induces cell growth inhibition and S phase cell cycle arrest in prostate cancer cells, with reduced CDK2 kinase activity and increased p27 expression. These results suggest that Jagged-1 could be a potential therapeutic target for the treatment of prostate cancer. (c) 2006 Wiley-Liss, Inc.
C1 Capital Univ Med Sci, Dept Biochem & Mol Biol, Beijing, Peoples R China.
   Wayne State Univ, Karmanos Canc Inst, Dept Pathol, Detroit, MI USA.
RP Sarkar, FH (reprint author), 740 HWCRC,110 E Warren Ave, Detroit, MI 48201 USA.
EM fsarkar@med.wayne.edu
RI Wang, Zhiwei/A-6809-2011
FU NCI NIH HHS [5R01CA0803695]
CR Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770
   Ascano JM, 2003, J BIOL CHEM, V278, P8771, DOI 10.1074/jbc.M211427200
   Chen CD, 2004, NAT MED, V10, P33, DOI 10.1038/nm972
   Dalrymple S, 2005, CANCER RES, V65, P9269, DOI 10.1158/0008-5472.CAN.04.3989
   Fischer PM, 2004, CELL CYCLE, V3, P742
   Gladden AB, 2003, CANCER CELL, V4, P160, DOI 10.1016/S1535-6108(03)00217-4
   GRAVDAL K, 2003, CLIN CANCER RES, V9, P1474
   Gray GE, 1999, AM J PATHOL, V154, P785, DOI 10.1016/S0002-9440(10)65325-4
   Guo YP, 1997, CLIN CANCER RES, V3, P2269
   Landis SH, 1999, CA-CANCER J CLIN, V49, P8, DOI 10.3322/canjclin.49.1.8
   LaVoie MJ, 2003, J BIOL CHEM, V278, P34427, DOI 10.1074/jbc.M302659200
   Machida YJ, 2005, CELL, V123, P13, DOI 10.1016/j.cell.2005.09.019
   Macri E, 1998, CANCER METAST REV, V17, P337, DOI 10.1023/A:1006133620914
   Martin DB, 2004, CANCER RES, V64, P347, DOI 10.1158/0008-5472.CAN-03-2062
   Miele L, 1999, J CELL PHYSIOL, V181, P393, DOI 10.1002/(SICI)1097-4652(199912)181:3<393::AID-JCP3>3.0.CO;2-6
   Nicolas M, 2003, NAT GENET, V33, P416, DOI 10.1038/ng1099
   Purow BW, 2005, CANCER RES, V65, P2353, DOI 10.1158/0008-5472.CAN-04-1890
   Reedijk M, 2005, CANCER RES, V65, P8530, DOI 10.1158/0008-5472.CAN-05-1069
   Ronchini C, 2001, MOL CELL BIOL, V21, P5925, DOI 10.1128/MCB.21.17.5925-5934.2001
   Santagata S, 2004, CANCER RES, V64, P6854, DOI 10.1158/0008-5472.CAN-04-2500
   Shou JY, 2001, CANCER RES, V61, P7291
   Sriuranpong V, 2001, CANCER RES, V61, P3200
   Velasco AM, 2004, ENDOCRINOLOGY, V145, P3913, DOI 10.1210/en.2004-0311
   Weng AP, 2004, CURR OPIN GENET DEV, V14, P48, DOI 10.1016/j.gde.2003.11.004
   Weng AP, 2003, MOL CELL BIOL, V23, P655, DOI 10.1128/MCB.23.2.655-664.2003
   Yong EL, 2000, ANN MED, V32, P15, DOI 10.3109/07853890008995905
NR 26
TC 68
Z9 75
U1 3
U2 4
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0020-7136
EI 1097-0215
J9 INT J CANCER
JI Int. J. Cancer
PD NOV 1
PY 2006
VL 119
IS 9
BP 2071
EP 2077
DI 10.1002/ijc.22077
PG 7
WC Oncology
SC Oncology
GA 086LE
UT WOS:000240674000010
PM 16823852
OA Bronze
DA 2018-12-27
ER

PT J
AU Arranz, N
   Haza, AI
   Garcia, A
   Moller, L
   Rafter, J
   Morales, P
AF Arranz, Nuria
   Haza, Ana I.
   Garcia, Almudena
   Moller, Lennart
   Rafter, Joseph
   Morales, Paloma
TI RETRACTED: Protective effects of isothiocyanates towards
   N-nitrosamine-induced DNA damage in the single-cell gel electrophoresis
   (SCGE)/HepG2 assay (Retracted Article. See vol 27, pg 200, 2007)
SO JOURNAL OF APPLIED TOXICOLOGY
LA English
DT Article; Retracted Publication
DE isothiocyanates compounds; N-nitrosamines; comet assay
ID LUNG-CANCER RISK; PHENETHYL ISOTHIOCYANATE; ALLYL-ISOTHIOCYANATE; COLON
   CARCINOGENESIS; BRUSSELS-SPROUTS; RAT-LIVER; AMES TEST; G2 ASSAY;
   ACTIVATION; EXTRACTS
AB The aim of this study was to investigate the protective effect of isothiocyanates towards N-nitrosamine-induced DNA damage in the single-cell gel electrophoresis (SCGE)/HepG2 assay. None of the isothiocyanates (ITCs) concentrations tested in the presence or absence of formamidopyrimidine-DNA glycosylase (Fpg), caused DNA damage per se. Combined treatments of HepG2 cells with phenethyl isothiocyanate (PEITC), allyl isothiocyanate (AITC) or indol-3-carbinol (I3C) and N-nitrosopyrrolidine (NPYR) or N-nitrosodimethylamine (NDMA) reduced the genotoxic effects of the N-nitrosamines in a dose-dependent manner. The protective effect of the three ITCs tested was higher towards NPYR-induced oxidative DNA damage than against NDMA. The greatest protective effect towards NPYR-induced oxidative DNA damage was shown by I3C (1 mu M, 79%) and by PEITC (1 mu M, 67%) and I3C (1 mu M, 61%) towards NDMA (in the presence of Fpg enzyme). However, in the absence of Fpg enzyme, AITC (1 mu M, 72%) exerted the most drastic reduction towards NPYR-induced oxidative DNA damage, and PEITC (1 mu M, 55%) towards NDMA. The results indicate that ITCs protect human-derived cells against the DNA damaging effect of NPYR and NDMA, two carcinogenic compounds which occur in the environment. Copyright (c) 2006 John Wiley & Sons, Ltd.
C1 Univ Complutense Madrid, Fac Vet, Dept Nutr Bromatol & Tecnol, E-28040 Madrid, Spain.
   Huddinge Univ Hosp, Karolinska Inst, Dept Biosci & Nutr, S-14186 Huddinge, Sweden.
RP Morales, P (reprint author), Univ Complutense Madrid, Fac Vet, Dept Nutr Bromatol & Tecnol, E-28040 Madrid, Spain.
EM pmorales@vet.ucm.es
OI Morales, Paloma/0000-0002-3606-9507; HAZA DUASO, ANA
   ISABEL/0000-0002-6656-1113
CR ARRANZ N, 2006, UNPUB FOOD CHEM TOXI
   BARTSCH H, 1977, ARCH TOXICOL, V39, P51, DOI 10.1007/BF00343275
   CALMELS S, 1988, J GEN MICROBIOL, V134, P221
   EVANS MD, 1995, BIOCHEM SOC T, V23, pS434, DOI 10.1042/bst023434s
   HECHT SS, 1995, J CELL BIOCHEM, P195
   Hwang ES, 2003, FOOD CHEM TOXICOL, V41, P1817, DOI 10.1016/S0278-6915(03)00235-7
   IKEDA K, 1990, J SOC COSMET CHEM, V41, P283
   Ikken Y, 1999, J AGR FOOD CHEM, V47, P3257, DOI 10.1021/jf990166n
   Ikken Y, 1998, J AGR FOOD CHEM, V46, P5194, DOI 10.1021/jf980657s
   Jeong WS, 2004, PHARM RES-DORDR, V21, P661, DOI 10.1023/B:PHAM.0000022413.43212.cf
   Kassie F, 2003, CHEM-BIOL INTERACT, V142, P285, DOI 10.1016/S0009-2797(02)00123-0
   Kassie F, 2000, CHEM-BIOL INTERACT, V127, P163, DOI 10.1016/S0009-2797(00)00178-2
   Knasmuller S, 1996, MUTAT RES-FUND MOL M, V350, P93, DOI 10.1016/0027-5107(95)00095-X
   KNASMULLER S, 1992, CARCINOGENESIS, V13, P1643, DOI 10.1093/carcin/13.9.1643
   Laky B, 2002, FOOD CHEM TOXICOL, V40, P1077, DOI 10.1016/S0278-6915(02)00031-5
   Leoni O, 1997, BIOORGAN MED CHEM, V5, P1799, DOI 10.1016/S0968-0896(97)00112-0
   Lijinsky W, 1999, MUTAT RES-GEN TOX EN, V443, P129, DOI 10.1016/S1383-5742(99)00015-0
   LINDL T, 1994, METHODEN ANWENDUNGEN
   LIU HJ, 2000, PHARMACOGENETICS, V12, P175
   London SJ, 2000, LANCET, V356, P724, DOI 10.1016/S0140-6736(00)02631-3
   Magee P N, 1967, Adv Cancer Res, V10, P163, DOI 10.1016/S0065-230X(08)60079-2
   MAGEE PN, 1989, CANCER SURV, V8, P207
   Martinez A, 1998, J AGR FOOD CHEM, V46, P585, DOI 10.1021/jf970636i
   Martinez A, 2000, ARCH LEBENSMITTELHYG, V51, P150
   MIRVISH SS, 1995, CANCER LETT, V93, P17, DOI 10.1016/0304-3835(95)03786-V
   Mori Y, 2003, MUTAGENESIS, V18, P87, DOI 10.1093/mutage/18.1.87
   Murdock DJL, 2004, BIOCHEM PHARMACOL, V68, P523, DOI 10.1016/j.bcp.2004.04.008
   Murillo G, 2005, J STEROID BIOCHEM, V97, P129, DOI 10.1016/j.jsbmb.2005.06.008
   OLIVE PL, 1990, RADIAT RES, V122, P86, DOI 10.2307/3577587
   OLIVE PL, 1992, EXP CELL RES, V198, P259, DOI 10.1016/0014-4827(92)90378-L
   Plate AYA, 2006, CARCINOGENESIS, V27, P287, DOI 10.1093/carcin/bgi210
   Preussmann R, 1984, CHEM CARCINOGENS, V182, P643
   Reed GA, 2005, CANCER EPIDEM BIOMAR, V14, P1953, DOI 10.1158/1055-9965.EPI-05-0121
   Sawamura M, 2005, J AGR FOOD CHEM, V53, P4281, DOI 10.1021/jf047816u
   Smith TK, 2004, CARCINOGENESIS, V25, P1409, DOI 10.1093/carcin/bgh149
   Spitz MR, 2000, CANCER EPIDEM BIOMAR, V9, P1017
   STOHS SJ, 1995, OXIDATIVE STRESS ANT, P117
   SUZUKI K, 1984, N NITROSO COMPOUNDS, P275
   Uhl M, 2003, ARCH TOXICOL, V77, P477, DOI 10.1007/s00204-003-0469-4
   Uhl M, 2000, MUTAT RES-GEN TOX EN, V468, P213, DOI 10.1016/S1383-5718(00)00051-6
   UHL M, 2003, TERATOG CARCINOG S1, V23, P273
   Vermeer ITM, 2004, TOXICOL LETT, V154, P175, DOI 10.1016/j.toxlet.2004.07.013
   Wong HL, 2003, CARCINOGENESIS, V24, P291, DOI 10.1093/carcin/24.2.291
   Wu SJ, 2005, EUR J PHARMACOL, V518, P96, DOI 10.1016/j.ejphar.2005.06.021
   ZHANG YS, 1994, CANCER RES, V54, pS1976
   Zhang YS, 2003, MOL CANCER THER, V2, P1045
NR 46
TC 5
Z9 6
U1 3
U2 8
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0260-437X
EI 1099-1263
J9 J APPL TOXICOL
JI J. Appl. Toxicol.
PD NOV-DEC
PY 2006
VL 26
IS 6
BP 493
EP 499
DI 10.1002/jat.1168
PG 7
WC Toxicology
SC Toxicology
GA 112MK
UT WOS:000242529900004
PM 17080405
DA 2018-12-27
ER

PT J
AU Fujii, Y
   Shiga, Y
AF Fujii, Yoshitaka
   Shiga, Yuka
TI RETRACTED: Influence of aging on lidocaine requirements for pain on
   injection of propofol (Retracted article. See vol. 25, pg. 354, 2013)
SO JOURNAL OF CLINICAL ANESTHESIA
LA English
DT Article; Retracted Publication
DE complications; pain; propofol; lidocaine
ID PRETREATMENT; PREVENTION
AB Study Objective: To evaluate the influence of aging on lidocaine requirements for propofol-induced pain on injection.
   Design: Prospective, randomized, double-blind, placebo-controlled study.
   Setting: The study was undertaken at a University hospital.
   Patients: 160 ASA physical status I and II adult patients scheduled for elective surgery with general anesthesia.
   Interventions: Patients received placebo (saline) or lidocaine intravenously at three different doses (10, 20, or 40 mg), with venous occlusion for two minutes, followed by injection of propofol 0.5 mg/kg into a dorsal hand vein.
   Measurement and Main Results: Pain during injection of propofol was evaluated. For young patients, the frequency of propofol-induced pain was 70% in patients receiving lidocaine 10 mg (P = not significant); 50% in those receiving lidocaine 20 mg (P = not significant); and 30% in those receiving lidocaine 40 mg (P < 0.05), compared with placebo (80%). For elderly patients, 15 patients (75%) complained of pain in the placebo group, compared with 13 (65%) in the lidocaine 10 mg group (P = not significant); 5 (25%) in the lidocaine 20 mg group (P < 0.05); and 4 (20%) in the lidocaine 40 mg group (P < 0.05).
   Conclusions: A lidocaine dose of 40 mg for young patients and 20 mg for old patients, with venous occlusion for two minutes, is sufficient to reduce pain on injection of propofol. (C) 2006 Elsevier Inc. All rights reserved.
C1 Univ Tsukuba, Inst Clin Med, Dept Anesthesiol, Tsukuba, Ibaraki 3058525, Japan.
RP Fujii, Y (reprint author), Toho Univ, Sch Med, Dept Anesthesiol 1, Tokyo 1438541, Japan.
EM yfujii@med.toho-u.ac.jp
CR Agarwal A, 2004, ANESTH ANALG, V98, P683, DOI 10.1213/01.ANE.0000103266.73568.18
   Ambesh SP, 1999, ANESTH ANALG, V89, P197, DOI 10.1097/00000539-199907000-00035
   CODERRE TJ, 1993, PAIN, V52, P259, DOI 10.1016/0304-3959(93)90161-H
   FLETCHER JE, 1994, BRIT J ANAESTH, V72, P342, DOI 10.1093/bja/72.3.342
   GIL KM, 1992, CLIN J PAIN, V8, P215, DOI 10.1097/00002508-199209000-00005
   HYNYNEN M, 1985, ACTA ANAESTH SCAND, V29, P651, DOI 10.1111/j.1399-6576.1985.tb02274.x
   JOHNSON RA, 1990, ANAESTHESIA, V45, P439, DOI 10.1111/j.1365-2044.1990.tb14328.x
   KING SY, 1992, ANESTH ANALG, V74, P246, DOI 10.1213/00000539-199202000-00013
   Lai YY, 1993, ACTA ANESTHESIOL SIN, V31, P31
   Liaw WJ, 1999, ACTA ANAESTH SCAND, V43, P24, DOI 10.1034/j.1399-6576.1999.430106.x
   Liljeroth E, 2001, ACTA ANAESTH SCAND, V45, P839, DOI 10.1034/j.1399-6576.2001.045007839.x
   Macario A, 1999, ANESTH ANALG, V88, P1085, DOI 10.1097/00000539-199905000-00023
   MCCRIRRICK A, 1990, ANAESTHESIA, V45, P443, DOI 10.1111/j.1365-2044.1990.tb14329.x
   MCCULLOCH MJ, 1985, ANAESTHESIA, V40, P1117, DOI 10.1111/j.1365-2044.1985.tb10615.x
   Minto CF, 1997, ANESTHESIOLOGY, V86, P10, DOI 10.1097/00000542-199701000-00004
   Picard P, 2000, ANESTH ANALG, V90, P963
   SCOTT RP, 1998, ANAESTHESIA, V43, P492
   SMITH I, 1994, ANESTHESIOLOGY, V81, P1005
   STOKES DN, 1989, BRIT J ANAESTH, V62, P202, DOI 10.1093/bja/62.2.202
   Tan CH, 1998, ANAESTHESIA, V53, P302, DOI 10.1046/j.1365-2044.1998.00287.x
   Tan CH, 1998, ANAESTHESIA, V53, P468, DOI 10.1046/j.1365-2044.1998.00405.x
NR 21
TC 5
Z9 9
U1 3
U2 8
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0952-8180
EI 1873-4529
J9 J CLIN ANESTH
JI J. Clin. Anesth.
PD NOV
PY 2006
VL 18
IS 7
BP 526
EP 529
DI 10.1016/j.jclinane.2006.03.008
PG 4
WC Anesthesiology
SC Anesthesiology
GA 114SM
UT WOS:000242685900010
PM 17126782
DA 2018-12-27
ER

PT J
AU Pal, S
   Lee, KH
   Kim, JU
   Han, SH
   Song, JM
AF Pal, Sukdeb
   Lee, Kyeong-Hee
   Kim, Jong-Uk
   Han, Seung-Hee
   Song, Joon Myong
TI RETRACTED: Adsorption of cyanuric acid on activated carbon from aqueous
   solution: Effect of carbon surface modification and thermodynamic
   characteristics (Retracted Article. See vol 314, pg 347, 2007)
SO JOURNAL OF COLLOID AND INTERFACE SCIENCE
LA English
DT Article; Retracted Publication
DE activated carbon; surface modification; cyanuric acid; operational
   parameters; adsorption isotherm; thermodynamic characteristics
ID POROUS GRAPHITIC CARBON; SWIMMING POOL WATERS; ATRAZINE; REMOVAL;
   AMMONIA; ENHANCEMENT; DEGRADATION; MELAMINE; FIBERS; SAMPLE
AB The performance of a conventional and two surface-modified activated carbon samples was investigated for the sorption of cyanuric acid from aqueous solution by varying the process parameters such as initial concentration, pH, temperature, dose of adsorbents, and agitation time. The modified carbon samples obtained by acid and ammonia treatment of the conventional sample had a higher BET surface area (989 and 1010 m(2) g(-1), respectively) and higher specific mesopore surface area (27.36 and 33.21 m(2) g(-1), respectively) compared to the untreated material (820 and 18.25 m(2) g(-1)). The solute removal was found to be favored at lower solute concentration, increased agitation time, increased adsorbent dose, and lower temperature. The modified adsorbents outperformed the conventional activated carbon for sorption of cyanuric acid especially at higher pH (> 7.5) and with increasing temperature. The Freundlich model appears to fit the isotherm data better than the Langmuir model. The thermodynamic parameters (Delta G(ads)degrees, Delta H degrees, and Delta S degrees) were evaluated showing that the sorption process was thermodynamically favorable, spontaneous, and exothermic. The findings can be used for predictive modeling for analysis and design adsorption systems for removal of cyanuric acid and other polar atrazine degradation products from environmental a lueous samples. (c) 2006 Elsevier Inc. All rights reserved.
C1 Seoul Natl Univ, Pharmaceut Sci Res Inst, Seoul 151742, South Korea.
   Seoul Natl Univ, Coll Pharm, Seoul 151742, South Korea.
   Korea Electrotechnol Res Inst, Appl Imaging Res Grp, Ansan 426901, South Korea.
RP Song, JM (reprint author), Seoul Natl Univ, Pharmaceut Sci Res Inst, Seoul 151742, South Korea.
EM jmsong@snu.ac.kr
RI Pal, Sukdeb/E-2082-2013
OI Pal, Sukdeb/0000-0001-7668-5745
CR Bhabendra KP, 1999, CARBON, V37, P1323
   Bodalbhai LH, 1998, J AGR FOOD CHEM, V46, P161, DOI 10.1021/jf970397z
   BOEHM HP, 1966, ADV CATAL, V16, P179, DOI DOI 10.1016/S0360-0564(08)60354-5
   Cantu R, 2001, ANAL CHEM, V73, P3358, DOI 10.1021/ac001412t
   Cantu R, 2000, ANAL CHEM, V72, P5820, DOI 10.1021/ac0005868
   Chen JP, 2003, CARBON, V41, P1979, DOI 10.1016/S0008-6223(03)00197-0
   Chingombe P, 2006, J COLLOID INTERF SCI, V297, P434, DOI 10.1016/j.jcis.2005.10.054
   Cooper C, 1999, WATER RES, V33, P3689, DOI 10.1016/S0043-1354(99)00095-0
   dos Santos LBO, 2005, TALANTA, V68, P165, DOI 10.1016/j.talanta.2005.05.025
   DOWNES CJ, 1984, WATER RES, V18, P277, DOI 10.1016/0043-1354(84)90100-3
   ECONOMY J, 1992, CHEMTECH, V22, P597
   Freundlich H, 1906, Z PHYS CHEM-STOCH VE, V57, P385
   GUENU S, 1994, J CHROMATOGR A, V665, P243, DOI 10.1016/0021-9673(94)85054-2
   Ho YS, 2003, WATER RES, V37, P2323, DOI 10.1016/S0043-1354(03)00002-2
   HUANG CP, 1984, WATER RES, V18, P37, DOI 10.1016/0043-1354(84)90045-9
   JESSEE JA, 1981, J CHROMATOGR, V207, P454, DOI 10.1016/S0021-9673(00)88754-3
   KLOTZ IM, 1947, J AM CHEM SOC, V69, P801, DOI 10.1021/ja01196a017
   Langmuir I, 1918, J AM CHEM SOC, V40, P1361, DOI 10.1021/ja02242a004
   LIA K, 2001, CARBON, V39, P1803
   Mangun CL, 2001, CARBON, V39, P1809, DOI 10.1016/S0008-6223(00)00319-5
   Mangun CL, 2001, CHEM MATER, V13, P2356, DOI 10.1021/cm000880g
   MCBAY G, 1987, J CHEM TECHNOL BIOT, V37, P81
   Menendez JA, 1996, LANGMUIR, V12, P4404, DOI 10.1021/la9602022
   Mohamed FS, 2006, CHEM ENG J, V116, P47, DOI 10.1016/j.cej.2005.10.015
   MORALES R, 1968, ANAL CHEM, V40, P1148, DOI 10.1021/ac60263a037
   Mostafa MR, 1997, ADSORPT SCI TECHNOL, V15, P551, DOI 10.1177/026361749701500801
   Nakano Y., 2002, J JPN SOC WATER ENV, V25, P619
   PELIZZETTI E, 1990, ENVIRON SCI TECHNOL, V24, P1559, DOI 10.1021/es00080a016
   PICHON V, 1995, J CHROMATOGR A, V711, P257, DOI 10.1016/0021-9673(95)00527-T
   RUPE CO, 1989, Patent No. 8906355
   Sarkar M, 2006, WASTE MANAGE, V26, P559, DOI 10.1016/j.wasman.2005.12.016
   STOHR B, 1991, CARBON, V29, P707, DOI 10.1016/0008-6223(91)90006-5
   STRUYS J, 1987, ANAL CHIM ACTA, V199, P173, DOI 10.1016/S0003-2670(00)82810-X
   Swiatkowski A, 2002, COLLOID SURFACE A, V208, P313, DOI 10.1016/S0927-7757(02)00158-9
   Toles CA, 1999, CARBON, V37, P1207, DOI 10.1016/S0008-6223(98)00315-7
   TOMLINSON JB, 1993, CARBON, V31, P13, DOI 10.1016/0008-6223(93)90150-9
   XIEA F, 2000, CARBON, V38, P691
NR 37
TC 15
Z9 18
U1 3
U2 28
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0021-9797
EI 1095-7103
J9 J COLLOID INTERF SCI
JI J. Colloid Interface Sci.
PD NOV 1
PY 2006
VL 303
IS 1
BP 39
EP 48
DI 10.1016/j.jcis.2006.07.027
PG 10
WC Chemistry, Physical
SC Chemistry
GA 092EJ
UT WOS:000241079500006
PM 16899252
DA 2018-12-27
ER

PT J
AU Hard, BM
   Lozano, SC
   Tversky, B
AF Hard, Bridgette Martin
   Lozano, Sandra C.
   Tversky, Barbara
TI RETRACTED: Hierarchical encoding of behavior: Translating perception
   into action (Retracted article. See vol. 137, pg. 672, 2008)
SO JOURNAL OF EXPERIMENTAL PSYCHOLOGY-GENERAL
LA English
DT Article; Proceedings Paper; Retracted Publication
CT 26th Annual Conference of the Cognitive-Science-Society
CY AUG 04-07, 2004
CL Chicago, IL
SP Cognit Sci Soc
DE hierarchical encoding; observational learning; goal hierarchies;
   intentional inference; perspective taking
ID ONGOING BEHAVIOR; IMITATION; CHILDREN; EVENTS; RECALL; PREDICTABILITY;
   ORGANIZATION; INFORMATION; ATTRIBUTION; INTENTIONS
AB People encode goal-directed behaviors, such as assembling an object, by segmenting them into discrete actions, organized as goal-subgoal hierarchies. Does hierarchical encoding contribute to observational learning? Participants in 3 experiments segmented an object assembly task into coarse and fine units of action and later performed it themselves. Hierarchical encoding, measured by segmentation patterns, correlated with more accurate and more hierarchically structured performance of the later assembly task. Furthermore, hierarchical encoding increased when participants (a) segmented coarse units first, (b) explicitly looked for hierarchical structure, and (c) described actions while segmenting them. Improving hierarchical encoding always led to improvements in learning, as well as a surprising shift toward encoding and executing actions from the actor's spatial perspective instead of the participants' own. Hierarchical encoding facilitates observational learning by organizing perceived actions into a representation that can serve as an action plan.
C1 Univ Oregon, Dept Psychol, Eugene, OR 97403 USA.
   Stanford Univ, Stanford, CA 94305 USA.
RP Hard, BM (reprint author), Univ Oregon, Dept Psychol, 1227, Eugene, OR 97403 USA.
EM hard@psych.stanford.edu
CR BAIRD JA, 2006, UNPUB PARSING BEHAV
   Baldwin DA, 2001, CHILD DEV, V72, P708, DOI 10.1111/1467-8624.00310
   BARON RM, 1986, J PERS SOC PSYCHOL, V51, P1173, DOI 10.1037/0022-3514.51.6.1173
   Bauer PJ, 1998, BEHAV BRAIN SCI, V21, P684, DOI 10.1017/S0140525X98221741
   BAUER PJ, 1989, DEV PSYCHOL, V25, P197, DOI 10.1037//0012-1649.25.2.197
   Bekkering H, 2000, Q J EXP PSYCHOL-A, V53, P153, DOI 10.1080/027249800390718
   BOWER GH, 1979, COGNITIVE PSYCHOL, V11, P177, DOI 10.1016/0010-0285(79)90009-4
   Byrne R. W., 2002, IMITATIVE MIND DEV E, P122
   CARROLL WR, 1990, J MOTOR BEHAV, V22, P85
   COHEN J, 1993, BEHAV RES METH INSTR, V25, P257, DOI 10.3758/BF03204507
   DAWKINS R, 1976, GROWING POINTS ETHOL, P7
   DICKMAN HR, 1963, STREAM BEHAV, P23
   Gergely G, 2002, NATURE, V415, P755
   GERNSBACHER MA, 1985, COGNITIVE PSYCHOL, V17, P324, DOI 10.1016/0010-0285(85)90012-X
   Gleissner B, 2000, DEVELOPMENTAL SCI, V3, P405, DOI 10.1111/1467-7687.00135
   HABERLANDT K, 1989, MEM COGNITION, V17, P186, DOI 10.3758/BF03197068
   HARD BM, IN PRESS MEMORY COGN
   Heiser Julie, 2004, P ADV VIS INT, P311, DOI 10.1145/989863.989917
   HYDE TS, 1973, J VERB LEARN VERB BE, V12, P471, DOI 10.1016/S0022-5371(73)80027-1
   JUDD CM, 1981, EVALUATION REV, V5, P602, DOI 10.1177/0193841X8100500502
   KEPHART NC, 1971, SLOW LEARNER CLASSRO
   Lashley K., 1951, CEREBRAL MECH BEHAV, P112
   LOZANO SC, IN PRESS J EXPT PSYC
   LOZANO SC, IN PRESS COGNITION
   MARKUS H, 1985, J PERS SOC PSYCHOL, V49, P1494, DOI 10.1037/0022-3514.49.6.1494
   MARTIN BA, 2006, THESIS STANFORD U
   MELTZOFF AN, 1995, DEV PSYCHOL, V31, P838, DOI 10.1037//0012-1649.31.5.838
   Midford PE, 1998, BEHAV BRAIN SCI, V21, P698, DOI 10.1017/S0140525X98381741
   MILLER GA, 1956, PSYCHOL REV, V63, P81, DOI 10.1037/0033-295X.101.2.343
   Newell A., 1972, HUMAN PROBLEM SOLVIN
   NEWTSON D, 1976, J EXP SOC PSYCHOL, V12, P436, DOI 10.1016/0022-1031(76)90076-7
   NEWTSON D, 1973, J PERS SOC PSYCHOL, V28, P28, DOI 10.1037/h0035584
   SCHANK RC, 1977, SCRIPTS PLANTS GOALS
   SCHOFIELD WN, 1976, Q J EXP PSYCHOL, V28, P571, DOI 10.1080/14640747608400584
   Sobel M. E., 1982, SOCIOL METHODOL, P290, DOI [rg/10.2307/270723, DOI 10.2307/270723]
   TRAVIS LL, 1997, DEV SPANS EVENT COMP, P111
   TULVING E, 1962, PSYCHOL REV, V69, P344, DOI 10.1037/h0043150
   VALLACHER RR, 1987, PSYCHOL REV, V94, P3, DOI 10.1037/0033-295X.94.1.3
   van Dijk T, 1983, STRATEGIES DISCOURSE
   WAPNER S, 1968, CHILD DEV, V39, P887, DOI 10.1111/j.1467-8624.1968.tb04469.x
   WHITEN A, 2002, IMITATIVE MIND DEV E, P98
   WILDER DA, 1978, PERS SOC PSYCHOL B, V4, P604, DOI 10.1177/014616727800400422
   WILDER DA, 1978, PERS SOC PSYCHOL B, V4, P281, DOI 10.1177/014616727800400222
   Wohlschlager A, 2003, PHILOS T R SOC B, V358, P501, DOI 10.1098/rstb.2002.1257
   Zacks JM, 2004, COGNITIVE SCI, V28, P979, DOI 10.1016/j.cogsci.2004.06.003
   Zacks JM, 2001, PSYCHOL BULL, V127, P3, DOI 10.1037//0033-2909.127.1.3
   Zacks JM, 2001, J EXP PSYCHOL GEN, V130, P29, DOI 10.1037//0096-3445.130.1.29
   Zacks JM, 2001, NAT NEUROSCI, V4, P651, DOI 10.1038/88486
NR 48
TC 21
Z9 21
U1 2
U2 10
PU AMER PSYCHOLOGICAL ASSOC
PI WASHINGTON
PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA
SN 0096-3445
EI 1939-2222
J9 J EXP PSYCHOL GEN
JI J. Exp. Psychol.-Gen.
PD NOV
PY 2006
VL 135
IS 4
BP 588
EP 608
DI 10.1037/0096-3445.135.4.588
PG 21
WC Psychology, Experimental
SC Psychology
GA 102LK
UT WOS:000241812300007
PM 17087575
DA 2018-12-27
ER

PT J
AU Huo, TM
   Peng, CF
   Chu, XG
   Xu, CL
AF Huo, Tieming
   Peng, Chifang
   Chu, Xiaogang
   Xu, Chuanlai
TI RETRACTED: Rapid determination of time-resolved fluoroimmunoassay for
   medroxyprogesterone acetate residues in pork tissues and comparison with
   liquid chromatography and tandem mass spectrometry (Retracted Article.
   See vol 17, pg 817, 2007)
SO JOURNAL OF FLUORESCENCE
LA English
DT Article; Retracted Publication
DE medroxyprogesterone acetate; residues; screening; immunoassay;
   time-resolved fluorometry
AB A competitive time-resolved fluoroimmunoassay (TR-FIA) was developed for the determination of medroxyprogesterone acetate (MPA) residues in pork tissues. The limits of detection (LOD) was determined to be 0.06 ng g(-1) and the limits of quantification (LOQ) was less than 0.8 ng g(-1). The intra-assay variations were below 10% and the interassay variations ranged between 9.7 and 12.7%. The mean recoveries established at six concentration levels varied from 87.3 to 108.3%. The results obtained by the TR-FIA and ELISA showed a good correlation. The established TR-FIA was validated for the determination of incurred pork tissues and confirmed by high-performance liquid chromatography and tandem mass spectrometry (LC-MS-MS). This proposed technique could be applied to routine residue analysis.
C1 YanCheng Friend Biotechnol Corp, YanCheng 22100, Jiang Su Prov, Peoples R China.
   So Yangtze Univ, Sch Food Sci & Technol, WuXi 214036, Jiang Su Prov, Peoples R China.
RP Huo, TM (reprint author), YanCheng Friend Biotechnol Corp, YanCheng 22100, Jiang Su Prov, Peoples R China.
EM tmh3@163.com
CR BERNARD FE, 1971, PRINCIPLES METHODS, V70, P85
   *CCRVDF, 14 SESS CCRVDF
   CHIFANG P, 2006, J FOOD SCI, V71, P44
   Choi MH, 2000, STEROIDS, V65, P54, DOI 10.1016/S0039-128X(99)00082-3
   DAESELEIRE E, 1991, J CHROMATOGR-BIOMED, V562, P673, DOI 10.1016/0378-4347(91)80617-L
   Draisci R, 1998, ANALYST, V123, P2605, DOI 10.1039/a805224g
   Dykman LA, 1997, BIOCHEMISTRY-MOSCOW+, V62, P350
   ELLIOTT CT, 1994, ANALYST, V119, P2565, DOI 10.1039/an9941902565
   LEWIS LK, 1992, J STEROID BIOCHEM, V42, P179, DOI 10.1016/0960-0760(92)90026-F
   Philippe A., 1999, J CHROMATOGR B, V736, P209
   Rambaud L, 2005, ANAL CHIM ACTA, V532, P165, DOI 10.1016/j.aca.2004.10.083
   SOINI E, 1987, CRC CR REV ANAL CHEM, V18, P105, DOI 10.1080/10408348708085565
   Stolker AAM, 2002, ANALYST, V127, P748, DOI 10.1039/b201268p
   TAKALO H, 1994, BIOCONJUGATE CHEM, V5, P278, DOI 10.1021/bc00027a015
   Tuomola M, 2002, ANALYST, V127, P83, DOI 10.1039/b108671p
   ZHUANG WJ, 2003, METHODS ANAL VET DRU, V6, P127
NR 16
TC 1
Z9 2
U1 3
U2 17
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1053-0509
J9 J FLUORESC
JI J. Fluoresc.
PD NOV
PY 2006
VL 16
IS 6
BP 743
EP 747
DI 10.1007/s10895-006-0132-6
PG 5
WC Biochemical Research Methods; Chemistry, Analytical; Chemistry, Physical
SC Biochemistry & Molecular Biology; Chemistry
GA 109CP
UT WOS:000242285800003
DA 2018-12-27
ER

PT J
AU Chen, QY
   Sen, G
   Snapper, CM
AF Chen, Quanyi
   Sen, Goutam
   Snapper, Clifford M.
TI RETRACTED: Endogenous IL-1R1 signaling is critical for cognate CD4(+) T
   cell help for induction of in vivo type 1 and type 2 antipolysaccharide
   and antiprotein Ig isotype responses to intact Streptococcus pneumoniae,
   but not to a soluble pneumococcal conjugate vaccine (Retracted article.
   See vol. 186, pg. 1289, 2011)
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article; Retracted Publication
ID RECEPTOR-DEFICIENT MICE; DEPENDENT ANTIBODY-PRODUCTION; IMPAIRED
   HOST-DEFENSE; TUMOR-NECROSIS-FACTOR; DENDRITIC CELLS; IFN-GAMMA;
   CHEMOKINE RECEPTOR; IMMUNE-RESPONSES; GLYCOCONJUGATE VACCINE;
   LYMPHOCYTES-T
AB MyD88(-/-) mice exhibit defective innate, diminished CD4(+) T cell-dependent (TD) type 1, but enhanced type 2, Immoral immunity in response to intact Streptococcus pneumoniae (Pn). Because type I IL-1R (IL-1R1) signaling is MyD88 dependent, a role for endogenous IL-1 was determined. IL-1R1(-/-), in contrast to MyD88(-/-), mice exhibited relatively intact innate splenic cytokine expression in response to Pn. Nevertheless, IL-1R1(-/-), like MyD88(-/-), mice were more sensitive to killing with live Pn relative to wild-type controls. Although IL-1R1(-/-) mice elicited a normal T cell-independent IgM antipolysaccharide (PS) response to heat-killed Pn, the induction of PS- and protein-specific cognate, but not noncognate, TD type I and type 2 IgG isotypes were markedly reduced. Additionally, CD4(+) T cells from Pn-primed IL-1R1(-/-) mice failed to elicit IFN-gamma, IL-5, or IL-13 secretion upon restimulation with Pn in vitro, whereas MyD88(-/-) mice secreted normal levels of IFN-gamma and enhanced levels of IL-5 and IL-13. In contrast, IgG responses to a soluble, pneumococcal protein-PS conjugate, with or without adjuvant, showed little dependence on IL-1R1 and normal CD4(+) T cell priming. These data are the first to demonstrate a nonredundant role for endogenous IL-1 in TD induction of humoral immune responses to an intact pathogen, although not a pathogen-derived soluble conjugate, suggesting that antigenic context is a key determinant for IL-1 dependence. These data further suggest that IL-1 may be critical for preserving CD4(+) Th2 function in the presence, but not absence, of MyD88-dependent signaling via TLRs.
C1 Uniformed Serv Univ Hlth Sci, Dept Pathol, Bethesda, MD 20814 USA.
RP Snapper, CM (reprint author), Uniformed Serv Univ Hlth Sci, Dept Pathol, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA.
EM csnapper@usuhs.mil
FU NIAID NIH HHS [1R01 AI 49192]
CR Adachi O, 1998, IMMUNITY, V9, P143, DOI 10.1016/S1074-7613(00)80596-8
   Akiba H, 2000, J EXP MED, V191, P375, DOI 10.1084/jem.191.2.375
   Albiger B, 2005, CELL MICROBIOL, V7, P1603, DOI 10.1111/j.1462-5822.00578.x
   Ansel KM, 1999, J EXP MED, V190, P1123, DOI 10.1084/jem.190.8.1123
   Balazs M, 2002, IMMUNITY, V17, P341, DOI 10.1016/S1074-7613(02)00389-8
   Brocker T, 1999, EUR J IMMUNOL, V29, P1610, DOI 10.1002/(SICI)1521-4141(199905)29:05<1610::AID-IMMU1610>3.0.CO;2-8
   Burns K, 1998, J BIOL CHEM, V273, P12203, DOI 10.1074/jbc.273.20.12203
   Chu RS, 2000, INFECT IMMUN, V68, P1450, DOI 10.1128/IAI.68.3.1450-1456.2000
   Colino J, 2002, J EXP MED, V195, P1, DOI 10.1084/jem.20011432
   De Smedt T, 2002, J IMMUNOL, V168, P661, DOI 10.4049/jimmunol.168.2.661
   Debus A, 2003, INFECT IMMUN, V71, P7215, DOI 10.1128/IAI.71.12.7215-7218.2003
   Dinarello CA, 1996, BLOOD, V87, P2095
   DINARELLO CA, 1984, REV INFECT DIS, V6, P51, DOI 10.1016/S1359-6101(97)00023-3
   Flynn S, 1998, J EXP MED, V188, P297, DOI 10.1084/jem.188.2.297
   Forster R, 1996, CELL, V87, P1037, DOI 10.1016/S0092-8674(00)81798-5
   Glaccum MB, 1997, J IMMUNOL, V159, P3364
   Gramaglia I, 1998, J IMMUNOL, V161, P6510
   GREENBAUM LA, 1988, J IMMUNOL, V140, P1555
   Guttormsen HK, 1998, INFECT IMMUN, V66, P2026
   Guttormsen HK, 1999, INFECT IMMUN, V67, P6375
   Hemmi H, 2000, NATURE, V408, P740
   HOWARD M, 1983, J EXP MED, V157, P1529, DOI 10.1084/jem.157.5.1529
   Hultner L, 2000, J IMMUNOL, V164, P5556, DOI 10.4049/jimmunol.164.11.5556
   HUNTER CA, 1995, J IMMUNOL, V155, P4347
   Juffermans NP, 2000, J INFECT DIS, V182, P902, DOI 10.1086/315771
   KASAHARA K, 1993, PATHOBIOLOGY, V61, P57, DOI 10.1159/000163762
   Khan AQ, 2005, INFECT IMMUN, V73, P298, DOI 10.1128/IAI.73.1.298-307.2005
   Khan AQ, 2004, J IMMUNOL, V172, P532, DOI 10.4049/jimmunol.172.1.532
   Khan AQ, 2002, INFECT IMMUN, V70, P749, DOI 10.1128/IAI.70.2.749-761.2002
   Koedel U, 2004, BRAIN, V127, P1437, DOI 10.1093/brain/awh171
   KOIDE SL, 1987, J EXP MED, V165, P515, DOI 10.1084/jem.165.2.515
   KURTJONES EA, 1987, J EXP MED, V166, P1774, DOI 10.1084/jem.166.6.1774
   Labow M, 1997, J IMMUNOL, V159, P2452
   LARSSON EL, 1980, NATURE, V283, P664, DOI 10.1038/283664a0
   Latz E, 2004, J IMMUNOL, V172, P2431, DOI 10.4049/jimmunol.172.4.2431
   LICHTMAN AH, 1988, P NATL ACAD SCI USA, V85, P9699, DOI 10.1073/pnas.85.24.9699
   Lin KW, 2002, J BIOMED SCI, V9, P26, DOI 10.1007/BF02256575
   Malley R, 2003, P NATL ACAD SCI USA, V100, P1966, DOI 10.1073/pnas.0435928100
   Martin-Fontecha A, 2003, J EXP MED, V198, P615, DOI 10.1084/jem.20030448
   Murphy KM, 2002, NAT REV IMMUNOL, V2, P933, DOI 10.1038/nri954
   Muzio M, 1997, SCIENCE, V278, P1612, DOI 10.1126/science.278.5343.1612
   Nakae S, 2003, INT IMMUNOL, V15, P483, DOI 10.1093/intimm/dxg054
   Nakae S, 2001, J IMMUNOL, V167, P90, DOI 10.4049/jimmunol.167.1.90
   Nakae S, 2001, IMMUNOLOGY, V104, P402, DOI 10.1046/j.1365-2567.2001.01337.x
   Nakata S, 2003, INT CONGR SER, V1257, P95, DOI 10.1016/S0531(03)01167-1
   REED SG, 1989, J IMMUNOL, V142, P3129
   Rijneveld AW, 2003, EUR CYTOKINE NETW, V14, P242
   Rijneveld AW, 2001, J IMMUNOL, V167, P5240, DOI 10.4049/jimmunol.167.9.5240
   Rodenburg RJT, 1998, J LEUKOCYTE BIOL, V63, P606
   Satoskar AR, 1998, EUR J IMMUNOL, V28, P2066, DOI 10.1002/(SICI)1521-4141(199807)28:07<2066::AID-IMMU2066>3.0.CO;2-X
   SCHMITT E, 1991, J IMMUNOL, V147, P3848
   Schnare M, 2001, NAT IMMUNOL, V2, P947, DOI 10.1038/ni712
   Schwandner R, 1999, J BIOL CHEM, V274, P17406, DOI 10.1074/jbc.274.25.17406
   Secord EA, 1996, CELL IMMUNOL, V174, P173, DOI 10.1006/cimm.1996.0307
   Sen G, 2006, INFECT IMMUN, V74, P2177, DOI 10.1128/IAI.74.4.2177-2186.2006
   Sen G, 2004, CELL IMMUNOL, V232, P64, DOI 10.1016/j.cellimm.2005.01.010
   Shibuya K, 1998, J IMMUNOL, V160, P1708
   SIMS JE, 1993, P NATL ACAD SCI USA, V90, P6155, DOI 10.1073/pnas.90.13.6155
   SKEEN MJ, 1995, J IMMUNOL, V154, P5832
   STARUCH MJ, 1983, J IMMUNOL, V130, P2191
   Su SB, 2005, J IMMUNOL, V175, P6303, DOI 10.4049/jimmunol.175.10.6303
   Tominaga K, 2000, INT IMMUNOL, V12, P151, DOI 10.1093/intimm/12.2.151
   Wesche H, 1997, IMMUNITY, V7, P837, DOI 10.1016/S1074-7613(00)80402-1
   WILDE DB, 1983, J IMMUNOL, V131, P2178
   Wu ZQ, 2002, J IMMUNOL, V168, P5551, DOI 10.4049/jimmunol.168.11.5551
   Wu ZQ, 2000, J IMMUNOL, V165, P6840, DOI 10.4049/jimmunol.165.12.6840
   Wu ZQ, 1999, J IMMUNOL, V163, P659
   Zwijnenburg PJG, 2003, J IMMUNOL, V170, P4724, DOI 10.4049/jimmunol.170.9.4724
NR 68
TC 14
Z9 14
U1 2
U2 9
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
EI 1550-6606
J9 J IMMUNOL
JI J. Immunol.
PD NOV 1
PY 2006
VL 177
IS 9
BP 6044
EP 6051
DI 10.4049/jimmunol.177.9.6044
PG 8
WC Immunology
SC Immunology
GA 097VN
UT WOS:000241477400034
PM 17056530
OA Bronze
DA 2018-12-27
ER

PT J
AU Tomita, M
   Kikuchi, A
   Akiyama, T
   Tanaka, Y
   Mori, N
AF Tomita, Mariko
   Kikuchi, Akira
   Akiyama, Tetsu
   Tanaka, Yuetsu
   Mori, Naoki
TI RETRACTED: Human T-cell leukemia virus type 1 tax dysregulates
   beta-catenin signaling (Retracted Article. See vol 85, pg 1417, 2011)
SO JOURNAL OF VIROLOGY
LA English
DT Article; Retracted Publication
ID ADENOMATOUS POLYPOSIS-COLI; GENE-EXPRESSION; I TAX; ACTIVATION;
   LYMPHOCYTES; PATHWAY; ANTIGEN; PROTEIN; CANCER; LINES
AB Dysregulation of beta-catenin signaling has been implicated in the malignant transformation of cells. However, the role of beta-catenin in the human T-cell leukemia virus type 1 (HTLV-1) -induced transformation of T cells is unknown. Here we found that beta-catenin protein was overexpressed in the nucleus and that beta-catenin-dependent transcription was significantly enhanced in Tax-positive HTLV-1-infected T-cell lines compared to that in Tax-negative HTLV-1-infected T-cell lines. Transfection with beta-catenin-specific small interfering RNA inhibited the growth of the Tax-positive HTLV-1-infected T-cell line HUT-102. Transient transfection of Tax appeared to enhance beta-catenin-dependent transcription by stabilizing the beta-catenin protein via activation of the cyclic AMP (cAMP) response element-binding protein. HTLV-1-infected T-cell lines overexpressing beta-catenin also showed increased Akt activity via Tax activation of the cAMP response element-binding protein, resulting in the phosphorylation and inactivation of glycogen synthase kinase 3 beta, which phosphorylates beta-catenin for ubiquitination. The phosphatirlylinositol 3-kinase inhibitor LY294002 reduced beta-catenin expression in Tax-positive T-cell lines, and inactivation of glycogen synthase kinase 3 beta by lithium chloride restored beta-catenin expression in Tax-negative T-cell lines. Finally, we showed that dominant-negative Akt inhibited Tax-induced beta-catenin-dependent transcription. These results indicate that Tax activates beta-catenin through the Akt signaling pathway. Our findings suggest that activation of beta-catenin by Tax may be important in the transformation of T cells by HTLV-1 infection.
C1 Univ Ryukyus, Grad Sch Med, Div Mol Virol & Oncol, Nishihara, Okinawa 9030215, Japan.
   Univ Ryukyus, Fac Med, Div Immunol, Nishihara, Okinawa 9030215, Japan.
   Hiroshima Univ, Grad Sch Biomed Sci, Dept Biochem, Hiroshima, Japan.
   Univ Tokyo, Inst Mol & Cellular Biosci, Lab Mol & Genet Informat, Tokyo, Japan.
RP Mori, N (reprint author), Univ Ryukyus, Grad Sch Med, Div Mol Virol & Oncol, 207 Uehara, Nishihara, Okinawa 9030215, Japan.
EM n-mori@med.u-ryukyu.ac.jp
CR Akagi T, 1997, ONCOGENE, V14, P2071, DOI 10.1038/sj.onc.1201045
   Besnard-Guerin C, 2004, J BIOL CHEM, V279, P788, DOI 10.1074/jbc.M308068200
   Cha MY, 2004, HEPATOLOGY, V39, P1683, DOI 10.1002/hep.20245
   Chung EJ, 2002, BLOOD, V100, P982, DOI 10.1182/blood.V100.3.982
   Enam S, 2002, CANCER RES, V62, P7093
   Fujimuro M, 2003, J VIROL, V77, P8019, DOI 10.1128/JVI.77.14.8019-8030.2003
   Fujimuro M, 2003, NAT MED, V9, P300, DOI 10.1038/nm829
   Gan DD, 2004, ONCOGENE, V23, P483, DOI 10.1038/sj.onc.1207018
   Giles RH, 2003, BBA-REV CANCER, V1653, P1, DOI 10.1016/S0304-419X(03)00005-2
   Grassmann R, 2005, ONCOGENE, V24, P5976, DOI 10.1038/sj.onc.1208978
   GRASSMANN R, 1992, J VIROL, V66, P4570
   GRASSMANN R, 1989, P NATL ACAD SCI USA, V86, P3351, DOI 10.1073/pnas.86.9.3351
   Harrod R, 1998, MOL CELL BIOL, V18, P5052, DOI 10.1128/MCB.18.9.5052
   HINUMA Y, 1981, P NATL ACAD SCI-BIOL, V78, P6476, DOI 10.1073/pnas.78.10.6476
   Jeang KT, 1997, J VIROL, V71, P6277
   Jeong SJ, 2005, ONCOGENE, V24, P6719, DOI 10.1038/sj.onc.1208825
   Kishida M, 2001, J BIOL CHEM, V276, P33147, DOI 10.1074/jbc.M103555200
   Kishida S, 1998, J BIOL CHEM, V273, P10823, DOI 10.1074/jbc.273.18.10823
   Klein PS, 1996, P NATL ACAD SCI USA, V93, P8455, DOI 10.1073/pnas.93.16.8455
   KOEFFLER HP, 1984, BLOOD, V64, P482
   Liu Y, 2001, ONCOGENE, V20, P2514, DOI 10.1038/sj.onc.1204364
   Lu DS, 2004, P NATL ACAD SCI USA, V101, P3118, DOI 10.1073/pnas.0308648100
   MAEDA M, 1985, J EXP MED, V162, P2169, DOI 10.1084/jem.162.6.2169
   Matsumoto K, 1997, J VIROL, V71, P4445
   Misra UK, 2005, J BIOL CHEM, V280, P38276, DOI 10.1074/jbc.M507332200
   MIYOSHI I, 1980, GANN, V71, P155
   MIYOSHI I, 1981, NATURE, V294, P770, DOI 10.1038/294770a0
   Morrison JA, 2003, J VIROL, V77, P12276, DOI 10.1128/JVI.77.22.12276-12284.2003
   NERENBERG M, 1987, SCIENCE, V237, P1324, DOI 10.1126/science.2888190
   OHTANI K, 1987, EMBO J, V6, P389, DOI 10.1002/j.1460-2075.1987.tb04767.x
   Peifer M, 2000, SCIENCE, V287, P1606, DOI 10.1126/science.287.5458.1606
   Peloponese JM, 2006, J BIOL CHEM, V281, P8927, DOI 10.1074/jbc.M510598200
   POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415
   Polakis P, 2000, GENE DEV, V14, P1837
   Rosin O, 1998, J BIOL CHEM, V273, P6698, DOI 10.1074/jbc.273.12.6698
   Sharma M, 2002, J BIOL CHEM, V277, P30935, DOI 10.1074/jbc.M201919200
   Shih IM, 2000, CANCER RES, V60, P1671
   Street A, 2005, J VIROL, V79, P5006, DOI 10.1128/JVI.79.8.5006-5016.2005
   SUGAMURA K, 1984, INT J CANCER, V34, P221, DOI 10.1002/ijc.2910340213
   TANAKA Y, 1990, JPN J CANCER RES, V81, P225, DOI 10.1111/j.1349-7006.1990.tb02554.x
   Yamamoto-Mitani N, 2001, Sch Inq Nurs Pract, V15, P113
   Yang Y, 2005, LEUKEMIA RES, V29, P47, DOI 10.1016/j.leukres.2004.05.004
   YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031
NR 43
TC 26
Z9 28
U1 3
U2 11
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
EI 1098-5514
J9 J VIROL
JI J. Virol.
PD NOV
PY 2006
VL 80
IS 21
BP 10497
EP 10505
DI 10.1128/JVI.00739-06
PG 9
WC Virology
SC Virology
GA 099OZ
UT WOS:000241606100020
PM 16920823
OA Bronze, Green Published
DA 2018-12-27
ER

PT J
AU Wang, L
   Huang, JS
   Saha, P
   Kulkarni, RN
   Hu, M
   Kim, YD
   Park, KG
   Chan, L
   Rajan, AS
   Lee, I
   Moore, DD
AF Wang, Li
   Huang, Jiansheng
   Saha, Pradip
   Kulkarni, Rohit N.
   Hu, Min
   Kim, YongDeuk
   Park, KeunGyu
   Chan, Lawrence
   Rajan, Arun S.
   Lee, Inkyu
   Moore, David D.
TI RETRACTED: Orphan receptor small heterodimer partner is an important
   mediator of glucose homeostasis (Retracted Article. See vol 22, pg 2203,
   2008)
SO MOLECULAR ENDOCRINOLOGY
LA English
DT Article; Retracted Publication
ID NUCLEAR HORMONE-RECEPTOR; INSULIN-RESISTANCE; PPAR-GAMMA; METABOLIC
   ADAPTATIONS; LIPID-METABOLISM; BIRTH-WEIGHT; DNA-BINDING; NULL MICE;
   SHP; LIVER
AB The orphan receptor small heterodimer partner (SHP; NROB2) is a transcriptional repressor that inhibits nuclear receptor signaling in diverse metabolic pathways. Here, we report that SHP-/- mice exhibited hypoinsulinemia with age, which was associated with increased peripheral insulin sensitivity and increased response of isolated islets to glucose stimulation, yet maintain normal levels of blood glucose. Deficiency in SHP function resulted in up-regulation of glucose transporter 4 mRNA and glucose uptake in muscles, and overexpression of SHP in C2C12 cells inhibited both basal and peroxisomal proliferator-activated receptor gamma (wPPAR gamma) coactivator-1 alpha-stimulated glucose transporter 4 expression and glucose uptake. SHP-/- hepatocytes showed markedly decreased basal glucose production in cultures, and SHP-/- livers had increased glycogen stores and were more sensitive to insulin inhibition of glucose output, which were concomitant with decreased expression for PPAR gamma 1, fatty acid translocase, glucose-6-phosphatase, and phosphoenol/pyruvate carboxykinase, and increased mRNAs for glucokinase and pyruvate kinase. In white fat, SHP deficiency resulted in up-regulation of genes involved in insulin sensitizing, including PPAR gamma 2 and adiponectin. We show that, at the transcriptional level, SHP directly represses adiponectin promoter activity by PPAR gamma/liver receptor homolog-1. The results suggest that the increases in insulin sensitivity through multiple signaling pathways in muscle, liver, and fat, with an increase in islet secretory function, represent the complex mechanism whereby SHP deficiency leads to improvement in insulin sensitivity, secretion, and diabetes.
C1 Univ Kansas, Med Ctr, Dept Med, Kansas City, KS 66160 USA.
   Univ Kansas, Med Ctr, Dept Pharmacol, Kansas City, KS 66160 USA.
   Baylor Coll Med, Dept Mol & Cell Biol, Houston, TX 77030 USA.
   Baylor Coll Med, Dept Med, Houston, TX 77030 USA.
   Harvard Univ, Sch Med, Joslin Diabet Ctr, Boston, MA 02115 USA.
   Keimyung Univ, Sch Med, Dept Internal Med, Taegu 700712, South Korea.
RP Wang, L (reprint author), Univ Kansas, Med Ctr, Dept Med, 3901 Rainbow Blvd, Kansas City, KS 66160 USA.
EM lwang2@kumc.edu
FU NCRR NIH HHS [P20 RR016475]; NHLBI NIH HHS [R01 HL51586]; NIDDK NIH HHS
   [DK68037, R01 DK53366, P01 DK57743, R01 DK67536]
CR Bavner A, 2005, TRENDS ENDOCRIN MET, V16, P478, DOI 10.1016/j.tem.2005.10.005
   Boulias K, 2005, EMBO J, V24, P2624, DOI 10.1038/sj.emboj.7600728
   Chae JH, 2004, MOL CELLS, V18, P271
   Datta S, 2006, J BIOL CHEM, V281, P807, DOI 10.1074/jbc.M511050200
   Deng T, 2006, ENDOCRINOLOGY, V147, P875, DOI 10.1210/en.2005-0623
   Duan CJ, 2004, MOL CELL BIOL, V24, P7435, DOI 10.1128/MCB.24.17.7435-7443.2004
   Fajas L, 2001, J MOL ENDOCRINOL, V27, P1, DOI 10.1677/jme.0.0270001
   Goetzman ES, 2005, MOL GENET METAB, V84, P39, DOI 10.1016/j.ymgme.2004.09.010
   He WM, 2003, P NATL ACAD SCI USA, V100, P15712, DOI 10.1073/pnas.2536828100
   Herzig S, 2003, NATURE, V426, P190, DOI 10.1038/nature02110
   Hung CCC, 2003, DIABETES, V52, P1288, DOI 10.2337/diabetes.52.5.1288
   Iwaki M, 2003, DIABETES, V52, P1655, DOI 10.2337/diabetes.52.7.1655
   Johansson L, 2000, MOL CELL BIOL, V20, P1124, DOI 10.1128/MCB.20.4.1124-1133.2000
   Kadowaki T, 2000, J CLIN INVEST, V106, P459, DOI 10.1172/JCI10830
   Kim JY, 2004, MOL ENDOCRINOL, V18, P776, DOI 10.1210/me.2003-0311
   Kim JY, 2004, MOL ENDOCRINOL, V18, P2880, DOI 10.1210/me.2004-0211
   Kulkarni RN, 1999, CELL, V96, P329, DOI 10.1016/S0092-8674(00)80546-2
   Lantz KA, 2004, J CLIN INVEST, V114, P512, DOI 10.1172/JCI200421149
   Lee YK, 2000, MOL CELL BIOL, V20, P187, DOI 10.1128/MCB.20.1.187-195.2000
   Lee YK, 2002, J BIOL CHEM, V277, P2463, DOI 10.1074/jbc.M105161200
   Mead JR, 1999, FEBS LETT, V462, P1, DOI 10.1016/S0014-5793(99)01495-7
   Memon RA, 2000, ENDOCRINOLOGY, V141, P4021, DOI 10.1210/en.141.11.4021
   Michael MD, 2000, MOL CELL, V6, P87, DOI 10.1016/S1097-2765(00)00010-1
   Mitchell SMS, 2003, DIABETES, V52, P1276, DOI 10.2337/diabetes.52.5.1276
   Munoz A, 2005, ENDOCRINOLOGY, V146, P5514, DOI 10.1210/en2005-0637
   Nishigori H, 2001, P NATL ACAD SCI USA, V98, P575, DOI 10.1073/pnas.98.2.575
   Niswender KD, 2004, TRENDS ENDOCRIN MET, V15, P362, DOI 10.1016/j.tem.2004.07.009
   Riserus U, 2005, DIABETES, V54, P1379, DOI 10.2337/diabetes.54.5.1379
   Saha PK, 2004, J BIOL CHEM, V279, P35150, DOI 10.1074/jbc.M405499200
   Samson SL, 2006, TRENDS ENDOCRIN MET, V17, P92, DOI 10.1016/j.tem.2006.02.002
   Sanyal S, 2002, J BIOL CHEM, V277, P1739, DOI 10.1074/jbc.M106140200
   Savage David B., 2005, Expert Reviews in Molecular Medicine, V7, P1, DOI 10.1017/S1462399405008793
   Seol W, 1996, SCIENCE, V272, P1336, DOI 10.1126/science.272.5266.1336
   Seol W, 1997, MOL CELL BIOL, V17, P7126, DOI 10.1128/MCB.17.12.7126
   Seufert J, 2004, DIABETES, V53, pS152, DOI 10.2337/diabetes.53.2007.S152
   Stiles B, 2004, P NATL ACAD SCI USA, V101, P2082, DOI 10.1073/pnas.0308617100
   Suh YH, 2004, J ENDOCRINOL, V183, P133, DOI 10.1677/joe.1.05675
   Tsao TS, 2001, FASEB J, V15, P958, DOI 10.1096/fj.00-0381
   Wang L, 2003, J BIOL CHEM, V278, P44475, DOI 10.1074/jbc.M305258200
   Wang L, 2002, DEV CELL, V2, P721, DOI 10.1016/S1534-5807(02)00187-9
   Wang L, 2005, CELL METAB, V2, P227, DOI 10.1016/j.cmet.2005.08.010
   Watanabe M, 2004, J CLIN INVEST, V113, P1408, DOI 10.1172/JCI200421025
   Wolfrum C, 2004, NATURE, V432, P1027, DOI 10.1038/nature03047
   Yamashita K, 2004, LAB CHIP, V4, P1, DOI 10.1039/b311571b
   Yamauchi T, 2003, NATURE, V423, P762, DOI 10.1038/nature01705
   ZAVARONI I, 1987, J CLIN ENDOCR METAB, V65, P494, DOI 10.1210/jcem-65-3-494
NR 46
TC 36
Z9 36
U1 3
U2 14
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0888-8809
EI 1944-9917
J9 MOL ENDOCRINOL
JI Mol. Endocrinol.
PD NOV
PY 2006
VL 20
IS 11
BP 2671
EP 2681
DI 10.1210/me.2006-0224
PG 11
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 098WH
UT WOS:000241553100006
PM 16803864
OA Bronze
DA 2018-12-27
ER

PT J
AU Gu, XM
   Cheng, L
   Chueng, WL
   Yao, XS
   Liu, HW
   Qi, GQ
   Li, M
AF Gu, Xuemei
   Cheng, Lei
   Chueng, Winghong L.
   Yao, Xinsheng
   Liu, Hongwei
   Qi, Guoqing
   Li, Ming
TI RETRACTED: Neovascularization of ischemic myocardium by newly isolated
   tannins prevents cardiomyocyte apoptosis and improves cardiac function
   (Retracted article. See vol. 15, pg. 359, 2009)
SO MOLECULAR MEDICINE
LA English
DT Article; Retracted Publication
ID FIBROBLAST-GROWTH-FACTOR; ANGIOGENESIS; ACTIVATION; INFARCTION;
   SURVIVAL; CELLS; HEART; DIFFERENTIATION; THERAPY; PATHWAY
AB During remodeling progress post myocardial infarction, the contribution of neoanglogenesis to the infarct-bed capillary is insufficient to support the greater demands of the hypertrophied but viable myocardium resulting in further ischemic injury to the viable cardiomyocytes at risk. Here we reported the bio-assay-guided identification and isolation of angiogenic tannins (anglo-T) from Geum joponicum that induced rapid revascularization of infarcted myocardium and promoted survival potential of the viable cardiomyocytes at risk after myocardial infarction. Our results demonstrated that angio-T displayed potent dual effects on up-regulating expression of angiogenic factors, which would contribute to the early revoscularization and protection of the cardiomyocytes against further ischemic injury, and inducing antiapoptotic protein expression, which inhibited apoptotic death of cardiomyocytes in the infarcted hearts and limited infarct size, Echocardiographic studies demonstrated that angio-T-induced therapeutic effects on acute infarcted myocardium were accompanied by significant functional improvement by 2 days after infarction. This improvement was sustained for 14 days. These therapeutic properties of anglo-T to induce early reconstitution of a blood supply network, prevent apoptotic death of cardiomyocytes at risk, and improve heart function post infarction appear entirely novel and may provide a new dimension for therapeutic angiogenesis medicine for the treatment of ischemic heart diseases.
C1 Chinese Univ Hong Kong, Prince Wales Hosp, Dept Med, Hong Kong, Hong Kong, Peoples R China.
   Chinese Univ Hong Kong, Prince Wales Hosp, Dept Therapeut, Hong Kong, Hong Kong, Peoples R China.
   Tradit Chinese Med & Nat Prod Res Ctr, Shenzhen, Peoples R China.
RP Gu, XM (reprint author), Prince Wales Hosp, Dept Med & Therapeut, 9th Floor,Clin Sci Bldg, Shatin, Hong Kong, Peoples R China.
EM li-ming@cuhk.edu.hk
CR Arras M, 1998, J CLIN INVEST, V101, P40, DOI 10.1172/JCI119877
   Arras M, 1998, NAT BIOTECHNOL, V16, P159, DOI 10.1038/nbt0298-159
   BANAI S, 1991, CIRC RES, V69, P76, DOI 10.1161/01.RES.69.1.76
   Benekli M, 2003, BLOOD, V101, P2940, DOI 10.1182/blood-2002-04-1204
   Cheng L, 2006, INT J BIOCHEM CELL B, V38, P1123, DOI 10.1016/j.biocel.2005.12.004
   Cheng W, 1996, EXP CELL RES, V226, P316, DOI 10.1006/excr.1996.0232
   Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905
   Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5
   Davani S, 2003, CIRCULATION, V108, P253, DOI 10.1161/01.cir.0000089186.09692.fa
   Dong H, 1998, J NAT PROD, V61, P1356, DOI 10.1021/np9801458
   Folkman J, 1995, NEW ENGL J MED, V333, P1757, DOI 10.1056/NEJM199512283332608
   Harada M, 2005, NAT MED, V11, P305, DOI 10.1038/nm1199
   Kawasuji M, 2000, ANN THORAC SURG, V69, P1155, DOI 10.1016/S0003-4975(99)01557-X
   Kocher AA, 2001, NAT MED, V7, P430, DOI 10.1038/86498
   Liu YH, 1997, AM J PHYSIOL-HEART C, V272, pH722
   Liu Y, 2006, EUR J CARDIO-THORAC, V30, P103, DOI 10.1016/j.ejcts.2006.03.043
   PERRY LM, 1980, MED PLANTS E SE ASIA, P343
   PU LQ, 1993, CIRCULATION, V88, P208, DOI 10.1161/01.CIR.88.1.208
   Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0
   SCHLAUDRAFF K, 1993, EUR J CARDIO-THORAC, V7, P637, DOI 10.1016/1010-7940(93)90258-D
   Seo KH, 2004, CANCER RES, V64, P6482, DOI 10.1158/0008-5472.CAN-03-2774
   Smithgall TE, 2000, ONCOGENE, V19, P2612, DOI 10.1038/sj.onc.1203477
   STOLTZ R, MOL CELL BIOCH, V246, P57
   UNGER EF, 1993, AM J PHYSIOL, V264, pH1567
   Yang F, 2002, EXP PHYSIOL, V87, P547, DOI 10.1113/eph8702385
   Zhang WG, 2003, BIOCHEM BIOPH RES CO, V301, P147, DOI 10.1016/S0006-291X(02)02981-9
NR 26
TC 9
Z9 10
U1 4
U2 14
PU FEINSTEIN INST MED RES
PI MANHASSET
PA 350 COMMUNITY DR, MANHASSET, NY 11030 USA
SN 1076-1551
EI 1528-3658
J9 MOL MED
JI Mol. Med.
PD NOV-DEC
PY 2006
VL 12
IS 11-12
BP 275
EP 283
DI 10.2119/2006-00039.Gu
PG 9
WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research &
   Experimental
SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental
   Medicine
GA 151QD
UT WOS:000245304600002
PM 17380192
OA DOAJ Gold
DA 2018-12-27
ER

PT J
AU Potti, A
   Dressman, HK
   Bild, A
   Riedel, RF
   Chan, G
   Sayer, R
   Cragun, J
   Cottrill, H
   Kelley, MJ
   Petersen, R
   Harpole, D
   Marks, J
   Berchuck, A
   Ginsburg, GS
   Febbo, P
   Lancaster, J
   Nevins, JR
AF Potti, Anil
   Dressman, Holly K.
   Bild, Andrea
   Riedel, Richard F.
   Chan, Gina
   Sayer, Robyn
   Cragun, Janiel
   Cottrill, Hope
   Kelley, Michael J.
   Petersen, Rebecca
   Harpole, David
   Marks, Jeffrey
   Berchuck, Andrew
   Ginsburg, Geoffrey S.
   Febbo, Phillip
   Lancaster, Johnathan
   Nevins, Joseph R.
TI RETRACTED: Genomic signatures to guide the use of chemotherapeutics
   (Retracted article. See vol. 17, pg. 135, 2011)
SO NATURE MEDICINE
LA English
DT Article; Retracted Publication
ID ACUTE LYMPHOBLASTIC-LEUKEMIA; METASTATIC BREAST-CANCER; PACLITAXEL
   SENSITIVITY; THERAPEUTIC RESPONSE; EXPRESSION PATTERNS; SINGLE-AGENT;
   LUNG-CANCER; PREDICTION; RESISTANCE; MARKER
AB Using in vitro drug sensitivity data coupled with Affymetrix microarray data, we developed gene expression signatures that predict sensitivity to individual chemotherapeutic drugs. Each signature was validated with response data from an independent set of cell line studies. We further show that many of these signatures can accurately predict clinical response in individuals treated with these drugs. Notably, signatures developed to predict response to individual agents, when combined, could also predict response to multidrug regimens. Finally, we integrated the chemotherapy response signatures with signatures of oncogenic pathway deregulation to identify new therapeutic strategies that make use of all available drugs. The development of gene expression profiles that can predict response to commonly used cytotoxic agents provides opportunities to better use these drugs, including using them in combination with existing targeted therapies.
C1 Duke Univ, Duke Inst Gen Sci & Policy, Durham, NC 27710 USA.
   Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA.
   Duke Univ, Med Ctr, Dept Mol Genet & Microbiol, Durham, NC 27710 USA.
   Univ S Florida, Div Gynecol Surg Oncol, H Lee Moffitt Canc Ctr, Tampa, FL 33612 USA.
   Univ S Florida, Res Inst, Tampa, FL 33612 USA.
   Duke Univ, Med Ctr, Dept Surg, Durham, NC 27710 USA.
   Duke Univ, Med Ctr, Dept Obstet & Gynecol, Durham, NC 27710 USA.
RP Nevins, JR (reprint author), Duke Univ, Duke Inst Gen Sci & Policy, Box 3383, Durham, NC 27710 USA.
EM nevin001@mc.duke.edu
OI Kelley, Michael/0000-0001-9523-6080
FU NCI NIH HHS [U54 CA112952-02, R01CA106520]
CR Bild AH, 2006, NATURE, V439, P353, DOI 10.1038/nature04296
   Blagosklonny MV, 2005, CELL CYCLE, V4, P1693, DOI 10.4161/cc.4.12.2259
   Breathnach OS, 2001, J CLIN ONCOL, V19, P1734, DOI 10.1200/JCO.2001.19.6.1734
   Broxterman HJ, 2005, DRUG RESIST UPDATE, V8, P183, DOI 10.1016/j.drup.2005.07.002
   Chang JC, 2003, LANCET, V362, P362, DOI 10.1016/S0140-6736(03)14023-8
   DEVITA VT, 2005, CANC PRINCIPLES PRAC
   Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863
   Emi M, 2005, BREAST CANCER RES, V7, pR940, DOI 10.1186/bcr1323
   Gyorffy B, 2006, INT J CANCER, V118, P1699, DOI 10.1002/ijc.21570
   Herbst RS, 2006, J CLIN ONCOL, V24, P190, DOI 10.1200/JCO.2005.04.8678
   Holleman A, 2004, NEW ENGL J MED, V351, P533, DOI 10.1056/NEJMoa033513
   IHAKA R, 1996, J COMPUTATIONAL GRAP, V5, P299, DOI DOI 10.2307/1390807
   Langer R, 2005, CLIN CANCER RES, V11, P7462, DOI 10.1158/1078-0432.CCR-05-0042
   Lugthart S, 2005, CANCER CELL, V7, P375, DOI 10.1016/j.ccr.2005.03.002
   MILLER AB, 1981, CANCER, V47, P207, DOI 10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6
   Minna JD, 2004, SCIENCE, V304, P1458, DOI 10.1126/science.1099578
   Modi S, 2005, CANCER INVEST, V23, P483, DOI 10.1080/07357900500201301
   Pittman J, 2004, BIOSTATISTICS, V5, P587, DOI 10.1093/biostatistics/kxh011
   Rouzier R, 2005, CLIN CANCER RES, V11, P5678, DOI 10.1158/1078-0432.CCR-04-2421
   Rouzier R, 2005, P NATL ACAD SCI USA, V102, P8315, DOI 10.1073/pnas.0408974102
   Sargent DJ, 2005, J CLIN ONCOL, V23, P2020, DOI 10.1200/JCO.2005.01.112
   Staunton JE, 2001, P NATL ACAD SCI USA, V98, P10787, DOI 10.1073/pnas.191368598
   Takahashi T, 2005, MOL CANCER THER, V4, P1039, DOI 10.1158/1535-7163.MCT-04-0282
   Vogel CL, 2002, J CLIN ONCOL, V20, P719, DOI 10.1200/JCO.20.3.719
   West M, 2001, P NATL ACAD SCI USA, V98, P11462, DOI 10.1073/pnas.201162998
NR 25
TC 417
Z9 432
U1 5
U2 42
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1078-8956
EI 1546-170X
J9 NAT MED
JI Nat. Med.
PD NOV
PY 2006
VL 12
IS 11
BP 1294
EP 1300
DI 10.1038/nm1491
PG 7
WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research &
   Experimental
SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental
   Medicine
GA 102WU
UT WOS:000241844900027
PM 17057710
DA 2018-12-27
ER

PT J
AU Tost, J
   Jammes, H
   Dupont, JM
   Buffat, C
   Robert, B
   Mignot, TM
   Mondon, F
   Carbonne, B
   Simeoni, U
   Grange, G
   Kerjean, A
   Ferre, F
   Gut, IG
   Vaiman, D
AF Tost, Jorg
   Jammes, Helene
   Dupont, Jean-Michel
   Buffat, Christophe
   Robert, Brigitte
   Mignot, Therese-Marie
   Mondon, Francoise
   Carbonne, Bruno
   Simeoni, Umberto
   Grange, Gilles
   Kerjean, Antoine
   Ferre, Francoise
   Gut, Ivo Glynne
   Vaiman, Daniel
TI RETRACTED: Non-random, individual-specific methylation profiles are
   present at the sixth CTCF binding site in the human H19/IGF2 imprinting
   control region (Retracted article see vol 35, pg 701, 2007)
SO NUCLEIC ACIDS RESEARCH
LA English
DT Article; Retracted Publication
ID GROWTH-FACTOR-II; BECKWITH-WIEDEMANN-SYNDROME; REPRESSIVE HISTONE
   METHYLATION; COLORECTAL-CANCER; DNA METHYLATION; H19 GENE; EPIGENETIC
   HETEROGENEITY; CHROMOSOME 11P15; WILMS-TUMOR; IGF2
AB Expression of imprinted genes is classically associated with differential methylation of specific CpG-rich DNA regions (DMRs). The H19/IGF2 locus is considered a paradigm for epigenetic regulation. In mice, as in humans, the essential H19 DMR-target of the CTCF insulator-is located between the two genes. Here, we performed a pyrosequencing-based quantitative analysis of its CpG methylation in normal human tissues. The quantitative analysis of the methylation level in the H19 DMR revealed three unexpected discrete, individual-specific methylation states. This epigenetic polymorphism was confined to the sixth CTCF binding site while a unique median-methylated profile was found at the third CTCF binding site as well as in the H19 promoter. Monoallelic expression of H19 and IGF2 was maintained independently of the methylation status at the sixth CTCF binding site and the IGF2 DMR2 displayed a median-methylated profile in all individuals and tissues analyzed. Interestingly, the methylation profile was genetically transmitted. Transgenerational inheritance of the H19 methylation profile was compatible with a simple model involving one gene with three alleles. The existence of three individual-specific epigenotypes in the H19 DMR in a non-pathological situation means it is important to reconsider the diagnostic value and functional importance of the sixth CTCF binding site.
C1 Ctr Natl Genotypage, Lab Epigenet, F-91057 Evry, France.
   Hop Cochin, CNRS, UMR 8104, F-75014 Paris, France.
   Hop Cochin, INSERM, GEPP, U567, F-75014 Paris, France.
   Univ Paris 05, F-75014 Paris, France.
   Hop Cochin, APHP, Fac Med, Lab Histol Embryol Cytogenet, F-75014 Paris, France.
   Univ Mediterrannee, Fac Med, F-13385 Marseille, France.
   Hop Conception, AP HM, Serv Neonatol, F-13385 Marseille, France.
   Hop St Antoine, Serv Gynecol Obstet, F-75013 Paris, France.
   Hop Cochin, APHP, Serv Gynecol Obstet, F-75014 Paris, France.
RP Tost, J (reprint author), Ctr Natl Genotypage, Lab Epigenet, 2 Rue Gaston Cremieux,CP5721, F-91057 Evry, France.
EM tost@cng.fr
OI DUPONT, Jean-Michel/0000-0002-9680-3662; Tost, Jorg/0000-0002-2683-0817
CR Bell AC, 2000, NATURE, V405, P482
   Constancia M, 2002, NATURE, V417, P945, DOI 10.1038/nature00819
   Cui HM, 2001, CANCER RES, V61, P4947
   Cui HM, 2002, CANCER RES, V62, P6442
   Dupont JM, 2004, ANAL BIOCHEM, V333, P119, DOI 10.1016/j.ab.2004.05.007
   Esteves LID, 2006, INT J MOL MED, V17, P397
   Fedoriw AM, 2004, SCIENCE, V303, P238, DOI 10.1126/science.1090934
   FEIL R, 1994, DEVELOPMENT, V120, P2933
   Ferguson-Smith AC, 2001, SCIENCE, V293, P1086, DOI 10.1126/science.1064020
   Fowden AL, 2006, J PHYSIOL-LONDON, V572, P5, DOI 10.1113/jphysiol.2005.104141
   Frevel MAE, 1999, TRENDS GENET, V15, P216, DOI 10.1016/S0168-9525(99)01752-7
   Gabory A, 2006, CYTOGENET GENOME RES, V113, P188, DOI 10.1159/000090831
   Gicquel C, 2005, NAT GENET, V37, P1003, DOI 10.1038/ng1629
   Hark AT, 2000, NATURE, V405, P486
   Hitchins M, 2005, GASTROENTEROLOGY, V129, P1392, DOI 10.1053/j.gastro.2005.09.003
   Holmes R, 2006, CYTOGENET GENOME RES, V113, P122, DOI 10.1159/000090823
   JINNO Y, 1995, NAT GENET, V10, P318, DOI 10.1038/ng0795-318
   Kim SJ, 2003, GYNECOL ONCOL, V88, P411, DOI 10.1016/S0090-8258(02)00143-9
   Kurukuti S, 2006, P NATL ACAD SCI USA, V103, P10684, DOI 10.1073/pnas.0600326103
   Lewis A, 2006, CYTOGENET GENOME RES, V113, P81, DOI 10.1159/000090818
   Lewis A, 2004, NAT GENET, V36, P1291, DOI 10.1038/ng1468
   Lewis A, 2004, CURR BIOL, V14, pR284, DOI 10.1016/j.cub.2004.03.026
   Lopes S, 2003, HUM MOL GENET, V12, P295, DOI 10.1093/hmg/ddg022
   Morgan HD, 1999, NAT GENET, V23, P314, DOI 10.1038/15490
   Nakagawa H, 2001, P NATL ACAD SCI USA, V98, P591, DOI 10.1073/pnas.011528698
   Prawitt D, 2005, P NATL ACAD SCI USA, V102, P4085, DOI 10.1073/pnas.0500037102
   Rakyan VK, 2003, P NATL ACAD SCI USA, V100, P2538, DOI 10.1073/pnas.0436776100
   REIK W, 1995, HUM MOL GENET, V4, P2379, DOI 10.1093/hmg/4.12.2379
   Reik W, 2001, NAT REV GENET, V2, P21, DOI 10.1038/35047554
   Richards EJ, 2006, NAT REV GENET, V7, P395, DOI 10.1038/nrg1834
   Sakatani T, 2001, BIOCHEM BIOPH RES CO, V283, P1124, DOI 10.1006/bbrc.2001.4916
   Sandovici I, 2003, HUM MOL GENET, V12, P1569, DOI 10.1093/hmg/ddg167
   Sparago A, 2004, NAT GENET, V36, P958, DOI 10.1038/ng1410
   Su AI, 2004, P NATL ACAD SCI USA, V101, P6062, DOI 10.1073/pnas.0400782101
   Suter CM, 2004, NAT GENET, V36, P497, DOI 10.1038/ng1342
   Takai D, 2001, HUM MOL GENET, V10, P2619, DOI 10.1093/hmg/10.23.2619
   Thorvaldsen JL, 1998, GENE DEV, V12, P3693, DOI 10.1101/gad.12.23.3693
   Tost J, 2006, BIOTECHNIQUES, V40, P721, DOI 10.2144/000112190
   Tost J, 2003, BIOTECHNIQUES, V35, P152, DOI 10.2144/03351md02
   Tost J, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng050
   Ulaner GA, 2003, ENDOCRINOLOGY, V144, P4420, DOI 10.1210/en.2003-0681
   Umlauf D, 2004, NAT GENET, V36, P1296, DOI 10.1038/ng1467
NR 42
TC 9
Z9 10
U1 3
U2 10
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0305-1048
EI 1362-4962
J9 NUCLEIC ACIDS RES
JI Nucleic Acids Res.
PD NOV
PY 2006
VL 34
IS 19
BP 5438
EP 5448
DI 10.1093/nar/gkl657
PG 11
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 104JR
UT WOS:000241955200019
PM 17012269
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Rao, JS
   Ertley, RN
   Lee, HJ
   Rapoport, SI
   Bazinet, RP
AF Rao, J. S.
   Ertley, R. N.
   Lee, H-J
   Rapoport, S. I.
   Bazinet, R. P.
TI RETRACTED: Chronic fluoxetine upregulates activity, protein and mRNA
   levels of cytosolic phospholipase A(2) in rat frontal cortex (Retracted
   article. See vol. 17, pg. 563, 2017)
SO PHARMACOGENOMICS JOURNAL
LA English
DT Article; Retracted Publication
DE fluoxetine; brain; cPLA(2); AUF-1; arachidonic acid; depression
ID SEROTONIN REUPTAKE INHIBITORS; ARACHIDONIC-ACID RELEASE;
   CENTRAL-NERVOUS-SYSTEM; GROUP-SPECIFIC ASSAYS; BRAIN PHOSPHOLIPIDS;
   GENE-EXPRESSION; DOCOSAHEXAENOIC ACID; 5-HT1A AUTORECEPTORS; PREFRONTAL
   CORTEX; BIPOLAR DISORDER
AB Chronic lithium and carbamazepine, which are effective against mania in bipolar disorder, decrease the activity of cytosolic phospholipase A(2) (cPLA(2)) and the turnover rate of arachidonic acid in phospholipids in rat brain. Assuming that stages of bipolar disorder are related to brain arachidonic acid metabolism, we hypothesized that drugs effective in depression would increase cPLA2 activity. To test this hypothesis, adult male CDF-344 rats were administered fluoxetine (10 mg/kg intraperitoneally (i.p.) or saline (control) (i.p.) chronically for 21 days. Frontal cortex cPLA2 protein, phosphorylated cPLA2, activity and mRNA levels were increased after chronic fluoxetine. Transcription factors (activator protein-1, activator protein-2, glucocorticoid response element, polyoma enhancer element-3 and nuclear factor-kappa B) that are known to regulate cPLA2 gene expression were not significantly changed by chronic fluoxetine, but nuclear AU-rich element/poly(U)-binding/degradation factor-1 RNA-stabilizing protein was increased significantly. The results suggest that chronic fluoxetine increases brain cPLA2 gene expression post-transcriptionally by increasing cPLA2 mRNA stabilization. Chronic fluoxetine's effect on cPLA2 expression was opposite to the effect reported with chronic lithium or carbamazepine administration, and may be part of fluoxetine's mode of action.
C1 NIA, Brain Physiol & Metab Sect, NIH, Bethesda, MD 20892 USA.
RP Rao, JS (reprint author), NIA, Brain Physiol & Metab Sect, NIH, 9000 Rockville Pike,Bldg 9,1s-126, Bethesda, MD 20892 USA.
EM jrao@mail.nih.gov
RI Rao, Jagadeesh/C-1250-2009
FU Intramural NIH HHS
CR ABOUSAMRA AB, 1986, ENDOCRINOLOGY, V119, P972, DOI 10.1210/endo-119-3-972
   Akiba S, 1999, J BIOL CHEM, V274, P19906, DOI 10.1074/jbc.274.28.19906
   BASSELIN M, 2005, NEUROPSYCHOPHAR 1109
   Bazinet RP, 2006, BIOL PSYCHIAT, V59, P401, DOI 10.1016/j.biopsych.2005.07.024
   Bazinet RP, 2006, PSYCHOPHARMACOLOGY, V184, P122, DOI 10.1007/s00213-005-0272-4
   Bazinet RP, 2005, PSYCHOPHARMACOLOGY, V182, P180, DOI 10.1007/s00213-005-0059-7
   BENFIELD P, 1986, DRUGS, V32, P481, DOI 10.2165/00003495-198632060-00002
   Borsch-Haubold AG, 1998, J BIOL CHEM, V273, P4449, DOI 10.1074/jbc.273.8.4449
   CACCIA S, 1990, PSYCHOPHARMACOLOGY, V100, P509, DOI 10.1007/BF02244004
   CAMBRONERO JC, 1992, J NEUROIMMUNOL, V39, P57, DOI 10.1016/0165-5728(92)90174-J
   Chang MCJ, 1996, NEUROSCI LETT, V220, P171, DOI 10.1016/S0304-3940(96)13264-X
   Chang MCJ, 1999, NEUROCHEM RES, V24, P399, DOI 10.1023/A:1020989701330
   Chang MCJ, 2001, J NEUROCHEM, V77, P796, DOI 10.1046/j.1471-4159.2001.00311.x
   Cotter D, 2002, CEREB CORTEX, V12, P386, DOI 10.1093/cercor/12.4.386
   Coulon L, 2003, FREE RADICAL BIO MED, V35, P616, DOI 10.1016/S0891-5849(03)00386-1
   Damjanoska KJ, 2003, J PHARMACOL EXP THER, V306, P563, DOI 10.1124/jpet.103.050534
   Dawson LA, 2000, BRIT J PHARMACOL, V130, P797, DOI 10.1038/sj.bjp.0703378
   De Foubert G, 2004, NEUROSCIENCE, V128, P597, DOI 10.1016/j.neuroscience.2004.06.054
   Dean JLE, 2004, CELL SIGNAL, V16, P1113, DOI 10.1016/j.cellsig.2004.04.006
   Drevets WC, 1999, ANN NY ACAD SCI, V877, P614, DOI 10.1111/j.1749-6632.1999.tb09292.x
   Drevets WC, 1998, MOL PSYCHIATR, V3, P220, DOI 10.1038/sj.mp.4000370
   Dulawa SC, 2004, NEUROPSYCHOPHARMACOL, V29, P1321, DOI 10.1038/sj.npp.1300433
   Durand M, 1999, NEUROPHARMACOLOGY, V38, P893, DOI 10.1016/S0028-3908(99)00009-X
   El Yacoubi M, 2003, P NATL ACAD SCI USA, V100, P6227, DOI 10.1073/pnas.1034823100
   FEDER R, 1990, J CLIN PSYCHIAT, V51, P524
   FELDER CC, 1990, P NATL ACAD SCI USA, V87, P2187, DOI 10.1073/pnas.87.6.2187
   Funk CD, 2001, SCIENCE, V294, P1871, DOI 10.1126/science.294.5548.1871
   Garcia MC, 1997, BRAIN RES, V768, P43, DOI 10.1016/S0006-8993(97)00583-0
   Gardier AM, 1996, FUND CLIN PHARMACOL, V10, P16, DOI 10.1111/j.1472-8206.1996.tb00145.x
   Ghaemi SN, 2003, BIPOLAR DISORD, V5, P421, DOI 10.1046/j.1399-5618.2003.00074.x
   Ghelardoni S, 2004, BIOL PSYCHIAT, V56, P248, DOI 10.1016/j.biophysc.2004.05.012
   Giovacchini G, 2004, J NUCL MED, V45, P1471
   Giovacchini G, 2002, J CEREBR BLOOD F MET, V22, P1453, DOI 10.1097/01.WCB.0000033209.60867.7A
   Goodwin GM, 2003, J PSYCHOPHARMACOL, V17, P149, DOI 10.1177/0269881103017002003
   Hayakawa T, 2001, J PHARMACOL EXP THER, V296, P1074
   Hefner Y, 2000, J BIOL CHEM, V275, P37542, DOI 10.1074/jbc.M003395200
   Hjorth S, 1996, BEHAV BRAIN RES, V73, P281
   Hussain T, 1997, CLIN EXP HYPERTENS, V19, P131, DOI 10.3109/10641969709080810
   Kam PCA, 2000, ANAESTHESIA, V55, P442, DOI 10.1046/j.1365-2044.2000.01271.x
   KOIDE H, 1992, P NATL ACAD SCI USA, V89, P1149, DOI 10.1073/pnas.89.4.1149
   Kucia K, 2003, POL J PHARMACOL, V55, P5
   Laakso A, 1996, NEUROPSYCHOPHARMACOL, V15, P143, DOI 10.1016/0893-133X(95)00176-E
   LePoul E, 1997, SYNAPSE, V27, P303, DOI 10.1002/(SICI)1098-2396(199712)27:4<303::AID-SYN4>3.0.CO;2-G
   LESLIE JB, 1985, J NEUROSURG, V63, P659, DOI 10.3171/jns.1985.63.5.0659
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lucas KK, 2005, PROSTAG OTH LIPID M, V77, P235, DOI 10.1016/j.prostaglandins.2005.02.004
   Massou JM, 1997, PSYCHOPHARMACOLOGY, V133, P99, DOI 10.1007/s002130050377
   Mercier G, 2004, J MOL NEUROSCI, V24, P207, DOI 10.1385/JMN:24:2:207
   MORII H, 1994, BIOCHEM BIOPH RES CO, V205, P6, DOI 10.1006/bbrc.1994.2621
   Murakami M, 1999, J BIOL CHEM, V274, P3103, DOI 10.1074/jbc.274.5.3103
   Murakami M, 2002, J BIOCHEM, V131, P285, DOI 10.1093/oxfordjournals.jbchem.a003101
   Murakami M, 1998, J BIOL CHEM, V273, P14411, DOI 10.1074/jbc.273.23.14411
   NEMENOFF RA, 1993, J BIOL CHEM, V268, P1960
   Nierenberg AA, 2001, J CLIN PSYCHIAT, V62, P22
   O'Banion MK, 1999, CRIT REV NEUROBIOL, V13, P45, DOI 10.1615/CritRevNeurobiol.v13.i1.30
   Ong WY, 1999, J BRAIN RES, V39, P391
   Pfennig A, 2005, BIOL PSYCHIAT, V57, P336, DOI 10.1016/j.biosych.2004.11.017
   Qu Y, 2005, PSYCHOPHARMACOLOGY, V180, P12, DOI 10.1007/s00213-005-2231-5
   Qu Y, 2003, NEUROPSYCHOPHARMACOL, V28, P1219, DOI 10.1038/sj.npp.1300177
   QU Y, 2006, EUR J PHARM     0302
   Rajkowska G, 2003, NEUROSCIENTIST, V9, P273, DOI 10.1177/1073858403252773
   Rao JS, 2005, NEUROPSYCHOPHARMACOL, V30, P2006, DOI 10.1038/sj.npp.1300740
   RAO JS, 2005, NEUR S 44 ACNP ANN M
   Rintala J, 1999, NEUROREPORT, V10, P3887, DOI 10.1097/00001756-199912160-00030
   Stout BD, 2002, J PHARMACOL EXP THER, V302, P957, DOI 10.1124/jpet.302.3.957
   TAY A, 1994, BIOCHEM J, V304, P417, DOI 10.1042/bj3040417
   TILAKARATNE N, 1995, EUR J PHARM-MOLEC PH, V290, P263, DOI 10.1016/0922-4106(95)90003-9
   Tohen M, 2003, ARCH GEN PSYCHIAT, V60, P1079, DOI 10.1001/archpsyc.60.11.1079
   Uranova NA, 2004, SCHIZOPHR RES, V67, P269, DOI 10.1016/S0920-9964(03)00181-6
   Weerasinghe GR, 2004, BRAIN RES BULL, V63, P485, DOI 10.1016/j.brainresbull.2004.04.005
   Weichel O, 1999, N-S ARCH PHARMACOL, V360, P609, DOI 10.1007/s002109900131
   Wong DT, 2005, NAT REV DRUG DISCOV, V4, P764, DOI 10.1038/nrd1821
   Yang HC, 1999, ANAL BIOCHEM, V269, P278, DOI 10.1006/abio.1999.4053
NR 73
TC 32
Z9 32
U1 3
U2 6
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1470-269X
EI 1473-1150
J9 PHARMACOGENOMICS J
JI Pharmacogenomics J.
PD NOV
PY 2006
VL 6
IS 6
BP 413
EP 420
DI 10.1038/sj.tpj.6500391
PG 8
WC Genetics & Heredity; Pharmacology & Pharmacy
SC Genetics & Heredity; Pharmacology & Pharmacy
GA 110TL
UT WOS:000242403500008
PM 16636684
OA Bronze
DA 2018-12-27
ER

PT J
AU Hsu, HH
   Chung, KM
   Chen, TC
   Chang, BY
AF Hsu, Hsin-Hsien
   Chung, Kuei-Min
   Chen, Tsung-Ching
   Chang, Ban-Yang
TI RETRACTED: Role of the sigma factor in transcription initiation in the
   absence of core RNA polymerase (Retracted Article. See vol 128, pg 211,
   2007)
SO CELL
LA English
DT Article; Retracted Publication
ID ESCHERICHIA-COLI SIGMA(70); AROMATIC-AMINO-ACIDS; PROMOTER OPEN COMPLEX;
   BACILLUS-SUBTILIS; REGION 3; ABORTIVE TRANSCRIPTION; ANGSTROM
   RESOLUTION; CRYSTAL-STRUCTURE; R PROMOTER; START SITE
AB Sigma factors (sigma s) are bacterial transcription factors that bind core RNA polymerase (RNAP) and direct transcription initiation at cognate promoter sites. However, most of their functions have been investigated in the context of RNAP. This has made the exact function of a, and the importance of core RNAP in modulating a function, ambiguous. Here we identify a Bacillus subtilis mutant sigma(A) that is independently capable of specific binding and melting of the promoter DNA. Interestingly, specific and independent promoter binding of a is sufficient for the temperature- and Mg2+-independent melting of promoter DNA around the transcription start site, in contrast to the temperature- and Mg2+-dependent melting by RNAP around the promoter -10 element. Thus core RNAP is able to negatively modulate the sigma-initiated melting of the transcription start site and, by sensing the changes in temperature and Mg2+ concentration, to regulate the efficiency of promoter -10 melting.
C1 Natl Chung Hsing Univ, Inst Biochem, Taichung 40227, Taiwan.
RP Chang, BY (reprint author), Natl Chung Hsing Univ, Inst Biochem, Taichung 40227, Taiwan.
EM bychang@mail.nchu.edu.tw
CR Borukhov S, 2002, RES MICROBIOL, V153, P557, DOI 10.1016/S0923-2508(02)01368-2
   Brodolin K, 2005, J MOL BIOL, V350, P930, DOI 10.1016/j.jmb.2005.05.048
   BURGESS RR, 1969, NATURE, V221, P43, DOI 10.1038/221043a0
   Camarero JA, 2002, P NATL ACAD SCI USA, V99, P8536, DOI 10.1073/pnas.132033899
   CHANG BY, 1990, J BACTERIOL, V172, P3257, DOI 10.1128/jb.172.6.3257-3263.1990
   CRAIG ML, 1995, BIOCHEMISTRY-US, V34, P15624, DOI 10.1021/bi00048a004
   DANIELS D, 1990, P NATL ACAD SCI USA, V87, P8075, DOI 10.1073/pnas.87.20.8075
   DOMBROSKI AJ, 1993, GENE DEV, V7, P2446, DOI 10.1101/gad.7.12a.2446
   DOMBROSKI AJ, 1992, CELL, V70, P501, DOI 10.1016/0092-8674(92)90174-B
   GARDELLA T, 1989, J MOL BIOL, V206, P579, DOI 10.1016/0022-2836(89)90567-6
   HERNANDEZ VJ, 1995, J MOL BIOL, V252, P536
   Hernandez VJ, 1996, J BIOL CHEM, V271, P18775, DOI 10.1074/jbc.271.31.18775
   Hsu HH, 2004, J BACTERIOL, V186, P2366, DOI 10.1128/JB.186.8.2366-2375.2004
   JENSEN DE, 1976, J BIOL CHEM, V251, P7198
   JUANG YL, 1995, BIOCHEMISTRY-US, V34, P8465, DOI 10.1021/bi00026a030
   JUANG YL, 1994, J MOL BIOL, V235, P1470, DOI 10.1006/jmbi.1994.1102
   KAHN D, 1991, MOL MICROBIOL, V5, P987, DOI 10.1111/j.1365-2958.1991.tb00774.x
   KEENER J, 1993, P NATL ACAD SCI USA, V90, P1751, DOI 10.1073/pnas.90.5.1751
   KIRKEGAARD K, 1983, P NATL ACAD SCI-BIOL, V80, P2544, DOI 10.1073/pnas.80.9.2544
   Kuznedelov K, 2002, SCIENCE, V295, P855, DOI 10.1126/science.1066303
   Landini P, 1999, J BACTERIOL, V181, P1524
   Liao CT, 1999, MOL MICROBIOL, V33, P377, DOI 10.1046/j.1365-2958.1999.01480.x
   Marr MT, 1997, SCIENCE, V276, P1258, DOI 10.1126/science.276.5316.1258
   Mekler V, 2002, CELL, V108, P599, DOI 10.1016/S0092-8674(02)00667-0
   Murakami KS, 2002, SCIENCE, V296, P1285, DOI 10.1126/science.1069595
   Panaghie G, 2000, J MOL BIOL, V299, P1217, DOI 10.1006/jmbi.2000.3808
   RECORD MT, 1976, J MOL BIOL, V107, P145, DOI 10.1016/S0022-2836(76)80023-X
   Rhodius VA, 2000, J MOL BIOL, V299, P295, DOI 10.1006/jmbi.2000.3736
   Ring BZ, 1996, CELL, V86, P485, DOI 10.1016/S0092-8674(00)80121-X
   ROE JH, 1985, J MOL BIOL, V184, P441, DOI 10.1016/0022-2836(85)90293-1
   RONG JC, 1994, J BACTERIOL, V176, P5218
   Sen R, 1998, J BIOL CHEM, V273, P9872, DOI 10.1074/jbc.273.16.9872
   SIEBENLIST U, 1979, NATURE, V279, P651, DOI 10.1038/279651a0
   SIEGELE DA, 1989, J MOL BIOL, V206, P591, DOI 10.1016/0022-2836(89)90568-8
   SPOLAR RS, 1994, SCIENCE, V263, P777, DOI 10.1126/science.8303294
   STRANEY DC, 1985, CELL, V43, P449, DOI 10.1016/0092-8674(85)90175-8
   SUH WC, 1993, SCIENCE, V259, P358, DOI 10.1126/science.8420002
   Tomsic M, 2001, J BIOL CHEM, V276, P31891, DOI 10.1074/jbc.M105027200
   Vassylyev DG, 2002, NATURE, V417, P712, DOI 10.1038/nature752
   Young BA, 2004, SCIENCE, V303, P1382, DOI 10.1126/science.1092462
   Young BA, 2001, CELL, V105, P935, DOI 10.1016/S0092-8674(01)00398-1
   Zhang GY, 1999, CELL, V98, P811, DOI 10.1016/S0092-8674(00)81515-9
   ZUBER P, 1989, J MOL BIOL, V206, P605, DOI 10.1016/0022-2836(89)90569-X
NR 43
TC 4
Z9 4
U1 3
U2 12
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 0092-8674
EI 1097-4172
J9 CELL
JI Cell
PD OCT 20
PY 2006
VL 127
IS 2
BP 317
EP 327
DI 10.1016/j.cell.2006.08.042
PG 11
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 102QH
UT WOS:000241827100019
PM 17055433
OA Bronze
DA 2018-12-27
ER

PT J
AU Zheng, LJ
   Kotschenreuther, M
AF Zheng, L. -J.
   Kotschenreuther, M.
TI RETRACTED: Resonance of static-error-field amplification in tokamak
   plasmas (Retracted Article. See vol 99, art. no. 165001, 2007)
SO PHYSICAL REVIEW LETTERS
LA English
DT Article; Retracted Publication
ID RESISTIVE WALL MODES; ROTATIONAL STABILIZATION; DIII-D; STABILITY
AB With explicit torque expression derived, it is found that the resonance of the static-error-field amplification (i.e., the maximum of the static-error-field-induced torque) in tokamak plasmas lies at the no-wall stability limit, instead of at the resistive wall mode stability limit as given by the existing theories. This brings theoretical predictions into qualitative conformity with experiments.
C1 Univ Texas, Inst Fus Studies, Austin, TX 78712 USA.
RP Zheng, LJ (reprint author), Univ Texas, Inst Fus Studies, Austin, TX 78712 USA.
CR BETTI R, 1995, PHYS REV LETT, V74, P2949, DOI 10.1103/PhysRevLett.74.2949
   BONDESON A, 1994, PHYS REV LETT, V72, P2709, DOI 10.1103/PhysRevLett.72.2709
   Boozer AH, 2003, PHYS PLASMAS, V10, P1458, DOI 10.1063/1.1568751
   Boozer AH, 2001, PHYS REV LETT, V86, P5059, DOI 10.1103/PhysRevLett.86.5059
   Chance MS, 1997, PHYS PLASMAS, V4, P2161, DOI 10.1063/1.872380
   FREIDBERG J. P., 1987, IDEAL MAGNETOHYDRODY
   Garofalo AM, 2003, PHYS PLASMAS, V10, P4776, DOI 10.1063/1.1625942
   Garofalo AM, 2002, PHYS PLASMAS, V9, P1997, DOI 10.1063/1.1446036
   Garofalo AM, 1999, PHYS REV LETT, V82, P3811, DOI 10.1103/PhysRevLett.82.3811
   Gimblett CG, 2004, PHYS PLASMAS, V11, P1019, DOI 10.1063/1.1639155
   Gimblett CG, 2005, PHYS PLASMAS, V12, DOI 10.1063/1.1995669
   Sabbagh SA, 2002, PHYS PLASMAS, V9, P2085, DOI 10.1063/1.1468230
   STRAIT EJ, 1995, PHYS REV LETT, V74, P2483, DOI 10.1103/PhysRevLett.74.2483
   Zheng LJ, 2005, PHYS REV LETT, V95, DOI 10.1103/PhysRevLett.95.255003
   Zheng LJ, 2006, J COMPUT PHYS, V211, P748, DOI 10.1016/j.jcp.2005.06.009
NR 15
TC 3
Z9 3
U1 5
U2 16
PU AMER PHYSICAL SOC
PI COLLEGE PK
PA ONE PHYSICS ELLIPSE, COLLEGE PK, MD 20740-3844 USA
SN 0031-9007
EI 1079-7114
J9 PHYS REV LETT
JI Phys. Rev. Lett.
PD OCT 20
PY 2006
VL 97
IS 16
AR 165001
DI 10.1103/PhysRevLett.97.165001
PG 4
WC Physics, Multidisciplinary
SC Physics
GA 096VR
UT WOS:000241405400030
PM 17155403
DA 2018-12-27
ER

PT J
AU Huo, TM
   Wang, LY
   Liu, LQ
   Chu, XG
   Xu, CL
AF Huo, Tieming
   Wang, Liyin
   Liu, Liqiang
   Chu, Xiaogang
   Xu, Chuanlai
TI RETRACTED: Rapid time-resolved fluoroimmunoassay for diethylstilbestrol
   residues in chicken liver (Retracted Article. See vol 378, 2008)
SO ANALYTICAL BIOCHEMISTRY
LA English
DT Article; Retracted Publication
DE diethylstilbestrol; residues; time-resolved fluoroimmunoassay
ID LIQUID-CHROMATOGRAPHIC DETERMINATION; MASS-SPECTROMETRY; HEXOESTROL
   IMPLANTATION; METABOLIC-ACTIVATION; HEXESTROL RESIDUES; SCREENING
   METHOD; POULTRY EGGS; DIENESTROL; ESTROGEN; STEROIDS
AB A competitive time-resolved fluoroimmunoassay (TR-FIA) was developed for the determination of diethylstilbestrol (DES) residues in chicken liver. Prior to analysis, the residues were extracted from chicken liver with acetonitrile. The assay could be used in a quantitative or qualitative mode. The limit of detection (LOD) was determined to be 0.05 ng g(-1), and the limit of quantification (LOQ) was less than 0.18 ng g(-1). The intraassay variations were less than 10%, and the interassay variations were from 9.8 to 12.7%. The mean recoveries established at six concentration levels varied from 84.3 to 109.6%, and the coefficients of variation were from 8.3 to 12.4%. The results obtained by the TR-FIA and enzyme-linked immunosorbent assay (ELISA) showed a good correlation. The established TR-FIA was validated for the determination of incurred chicken liver and was confirmed by liquid chromatography and tandem mass spectrometry (LC-MS/MS). This proposed technique could be applied to routine residue analysis. (c) 2006 Elsevier Inc. All rights reserved.
C1 YanCheng Friend Biotechnol Engn Corp, Yan Cheng 224000, Jiang Su Prov, Peoples R China.
   So Yangtze Univ, Sch Food Sci & Technol, Wu Xi 214036, Jiang Su Prov, Peoples R China.
RP Xu, CL (reprint author), YanCheng Friend Biotechnol Engn Corp, Yan Cheng 224000, Jiang Su Prov, Peoples R China.
EM xcl@sytu.edu.cn
CR AITKEN JN, 1956, BRIT J NUTR, V10, P220, DOI 10.1079/BJN19560033
   BAGNATI R, 1990, J CHROMATOGR-BIOMED, V527, P267, DOI 10.1016/S0378-4347(00)82111-8
   Berg C, 1999, SCI TOTAL ENVIRON, V233, P57, DOI 10.1016/S0048-9697(99)00179-5
   CHUANLAI X, 2006, IN PRESS BIOMED CHRO, DOI DOI 10.1002/BMC.638
   Dickson LC, 2003, J AOAC INT, V86, P631
   DINUSSON WE, 1950, J ANIM SCI, V9, P321
   Dykman LA, 1997, BIOCHEMISTRY-MOSCOW+, V62, P350
   ELLIOTT CT, 1994, ANALYST, V119, P2565, DOI 10.1039/an9941902565
   GILL JC, 1956, BRIT J NUTR, V10, P226, DOI 10.1079/BJN19560034
   Hagren V, 2005, ANAL CHIM ACTA, V529, P21, DOI 10.1016/j.aca.2004.07.028
   Hagren V, 2004, J AGR FOOD CHEM, V52, P2429, DOI 10.1021/jf030758c
   Hewitt SA, 2002, ANAL CHIM ACTA, V473, P99, DOI 10.1016/S0003-2670(02)00750-X
   Jan ST, 1998, CHEM RES TOXICOL, V11, P412, DOI 10.1021/tx970141n
   LI JJ, 1983, CANCER RES, V43, P5200
   LI JJ, 1984, ARCH TOXICOL, V55, P110, DOI 10.1007/BF00346048
   LIEHR JG, 1985, CHEM-BIOL INTERACT, V55, P157, DOI 10.1016/S0009-2797(85)80125-3
   Piersma AH, 2002, TOXICOLOGY, V174, P173, DOI 10.1016/S0300-483X(02)00059-8
   Rambaud L, 2005, ANAL CHIM ACTA, V532, P165, DOI 10.1016/j.aca.2004.10.083
   Sawaya WN, 1998, FOOD CHEM, V63, P563, DOI 10.1016/S0308-8146(98)00056-9
   SOINI E, 1987, CRC CR REV ANAL CHEM, V18, P105, DOI 10.1080/10408348708085565
   TAKALO H, 1994, BIOCONJUGATE CHEM, V5, P278, DOI 10.1021/bc00027a015
   TALAT S, 1999, J FOOD CONTROL, V10, P169
   TOBIOKA H, 1978, J ASSOC OFF ANA CHEM, V61, P1054
   TOBIOKA H, 1981, J ASSOC OFF ANA CHEM, V64, P709
   Tuomola M, 2002, ANALYST, V127, P83, DOI 10.1039/b108671p
   Yu NH, 2005, J PHARMACEUT BIOMED, V37, P1031, DOI 10.1016/j.jpba.2004.08.041
   14 SESS COD COMM RES
NR 27
TC 10
Z9 13
U1 4
U2 22
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0003-2697
EI 1096-0309
J9 ANAL BIOCHEM
JI Anal. Biochem.
PD OCT 15
PY 2006
VL 357
IS 2
BP 272
EP 276
DI 10.1016/j.ab.2006.07.026
PG 5
WC Biochemical Research Methods; Biochemistry & Molecular Biology;
   Chemistry, Analytical
SC Biochemistry & Molecular Biology; Chemistry
GA 092DS
UT WOS:000241077800016
PM 16945319
DA 2018-12-27
ER

PT J
AU Bhuiyan, MMR
   Li, YW
   Banerjee, S
   Ahmed, F
   Wang, ZW
   Ali, S
   Sarkar, FH
AF Bhuiyan, Mohammad M. R.
   Li, Yiwei
   Banerjee, Sanjeev
   Ahmed, Fakhara
   Wang, Zhiwei
   Ali, Shadan
   Sarkar, Fazlul H.
TI RETRACTED: Down-regulation of androgen receptor by 3,3'-diindolylmethane
   contributes to inhibition of cell proliferation and induction of
   apoptosis in both hormone-sensitive LNCaP and insensitive C4-2B prostate
   cancer cells (Retracted article. See vol. 78, pg. 5473, 2018)
SO CANCER RESEARCH
LA English
DT Article; Retracted Publication
ID NF-KAPPA-B; TRANSCRIPTION FACTOR; CYCLE ARREST; ACTIVATION; GENE;
   3,3'-DIINDOLYLMETHANE; EXPRESSION; AKT; INDOLE-3-CARBINOL; RESISTANCE
AB Despite the initial efficacy of androgen deprivation therapy, most patients with advanced prostate cancer eventually progress to hormone-refractory prostate cancer, for which there is no curative therapy. Previous studies from our laboratory and others have shown the antiproliferative and proapoptotic effects of 3,3'-diindolylmethane (DIM) in prostate cancer cells. However, the molecular mechanism of action of DIM has not been investigated in androgen receptor (AR)-positive hormone-responsive and -nonresponsive prostate cancer cells. Therefore, we investigated the effects of B-DIM, a formulated DIM with greater bioavailability, on AR, Akt, and nuclear factor kappa B (NF-kappa B) signaling in hormone-sensitive LNCaP (AR+) and hormone-insensitive C4-2B (AR+) prostate cancer cells. We found that B-DIM significantly inhibited cell proliferation and induced apoptosis in both cell lines. By Akt gene transfection, reverse transcription-PCR, Western blot analysis, and electrophoretic mobility shift assay, we found a potential crosstalk between Akt, NF-kappa B, and AR. Importantly, B-DIM significantly inhibited Akt activation, NF-kappa B DNA binding activity, AR phosphorylation, and the expressions of AR and prostate-specific antigen, suggesting that B-DIM could interrupt the crosstalk. Confocal studies revealed that B-DIM inhibited AB nuclear translocation, leading to the down-regulation of AR target genes. Moreover, B-DIM significantly inhibited C4-2B cell growth in a severe combined immunodeficiency-human model of experimental prostate cancer bone metastasis. These results suggest that B-DIM-induced cell proliferation inhibition and apoptosis induction are partly mediated through the downregulation of AR, Akt, and NF-kappa B signaling. These observations provide a rationale for devising novel therapeutic approaches for the treatment of hormone-sensitive, but more importantly, hormone-refractory prostate cancer by using B-DIM alone or in combination with other therapeutics.
C1 Wayne State Univ, Sch Med, Dept Pathol, Barbara Ann Karmanos Canc Inst, Detroit, MI 48201 USA.
   Wayne State Univ, Sch Med, Dept Internal Med, Barbara Ann Karmanos Canc Inst, Detroit, MI 48201 USA.
RP Sarkar, FH (reprint author), Wayne State Univ, Sch Med, Dept Pathol, Barbara Ann Karmanos Canc Inst, 740 Hudson Webber Canc Res Ctr,110 E Warren, Detroit, MI 48201 USA.
EM fsarkar@med.wayne.edu
RI Wang, Zhiwei/A-6809-2011
FU NCI NIH HHS [5R01CA108535]
CR Anderton MJ, 2004, DRUG METAB DISPOS, V32, P632, DOI 10.1124/dmd.32.6.632
   Bracarda S, 2005, CRIT REV ONCOL HEMAT, V56, P379, DOI 10.1016/j.critrevonc.2005.03.010
   Chatterjee B, 2003, MOL CELL BIOCHEM, V253, P89, DOI 10.1023/A:1026057402945
   Chaturvedi MM, 2000, METHOD ENZYMOL, V319, P585
   Chen CD, 2004, NAT MED, V10, P33, DOI 10.1038/nm972
   Chen CD, 2002, MOL CELL BIOL, V22, P2862, DOI 10.1128/MCB.22.8.2862-2870.2002
   Chinni SR, 2001, ONCOGENE, V20, P2927, DOI 10.1038/sj.onc.1204365
   Denmeade SR, 2002, NAT REV CANCER, V2, P389, DOI 10.1038/nrc801
   Edwards J, 2005, BJU INT, V95, P1320, DOI 10.1111/j.1464-410X.2005.05526.x
   Fenton MA, 1997, CLIN CANCER RES, V3, P1383
   Firestone GL, 2003, J NUTR, V133, p2448S, DOI 10.1093/jn/133.7.2448S
   Heinlein CA, 2004, ENDOCR REV, V25, P276, DOI 10.1210/er.2002-0032
   Hong CB, 2002, CARCINOGENESIS, V23, P1297, DOI 10.1093/carcin/23.8.1297
   Jemal A, 2006, CA-CANCER J CLIN, V56, P106, DOI 10.3322/canjclin.56.2.106
   Kikuchi E, 2003, CANCER RES, V63, P107
   Koivisto P, 1997, CANCER RES, V57, P314
   Le HT, 2003, J BIOL CHEM, V278, P21136, DOI 10.1074/jbc.M300588200
   Lee SO, 2005, PROSTATE, V64, P160, DOI 10.1002/pros.20218
   Li YW, 2006, CANCER RES, V66, P4816, DOI 10.1158/0008-5472.CAN-05-3752
   Lieberman Ronald, 2004, Am J Ther, V11, P501
   Majumder PK, 2005, ONCOGENE, V24, P7465, DOI 10.1038/sj.onc.1209096
   Murillo H, 2001, ENDOCRINOLOGY, V142, P4795, DOI 10.1210/en.142.11.4795
   Nachshon-Kedmi M, 2003, FOOD CHEM TOXICOL, V41, P745, DOI 10.1016/S0278-6915(03)00004-8
   Nemeth JA, 1999, CANCER RES, V59, P1987
   Ozes ON, 1999, NATURE, V401, P82
   Palvimo JJ, 1996, J BIOL CHEM, V271, P24151, DOI 10.1074/jbc.271.39.24151
   Pfeil K, 2004, PROSTATE, V58, P259, DOI 10.1002/pros.10332
   Rahman KW, 2004, NUTR CANCER, V48, P84, DOI 10.1207/s15327914nc4801_12
   Ripple MO, 1999, JNCI-J NATL CANCER I, V91, P1227, DOI 10.1093/jnci/91.14.1227
   Ryan CJ, 2005, J CLIN ONCOL, V23, P8242, DOI 10.1200/JCO.2005.03.3092
   Sarkar FH, 2004, J NUTR, V134, p3493S, DOI 10.1093/jn/134.12.3493S
   Sharma M, 2002, J BIOL CHEM, V277, P30935, DOI 10.1074/jbc.M201919200
   Suh JH, 2002, PROSTATE, V52, P183, DOI 10.1002/pros.10082
   Sweeney C, 2004, CLIN CANCER RES, V10, P5501, DOI 10.1158/1078-0432.CCR-0571-03
   TAPLIN ME, 1995, NEW ENGL J MED, V332, P1393, DOI 10.1056/NEJM199505253322101
   VISAKORPI T, 1995, NAT GENET, V9, P401, DOI 10.1038/ng0495-401
   Wang L, 2004, J BIOL CHEM, V279, P32444, DOI 10.1074/jbc.M313963200
   Wang LG, 2001, CANCER RES, V61, P7544
   Wen Y, 2000, CANCER RES, V60, P6841
   Yang L, 2005, J BIOL CHEM, V280, P33558, DOI 10.1074/jbc.M504461200
   Zerbini LF, 2003, CANCER RES, V63, P2206
   Zhang LY, 2004, ENDOCRINOLOGY, V145, P781, DOI 10.1210/en.2003-0987
NR 42
TC 89
Z9 92
U1 1
U2 1
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD OCT 15
PY 2006
VL 66
IS 20
BP 10064
EP 10072
DI 10.1158/0008-5472.CAN-06-2011
PG 9
WC Oncology
SC Oncology
GA 096QU
UT WOS:000241392700035
PM 17047070
OA Bronze
DA 2018-12-27
ER

PT J
AU Kan, CW
   Yuen, CWM
AF Kan, Chi-wai
   Yuen, Chun-wah Marcus
TI RETRACTED: Dyeing behaviour of low temperature plasma treated wool
   (Retracted article. See vol. 14, 2017)
SO PLASMA PROCESSES AND POLYMERS
LA English
DT Article; Retracted Publication
DE acid dyeing; chrome dyeing; low temperature discharges; reactive dyeing;
   wool
AB In this paper the effects of low temperature plasma (LTP) treatments on the dyeing properties of the wool fibres were studied. The wool fibres were treated with oxygen plasma and three types of dyes commonly used for wool dyeing namely (i) acid dye, (ii) chrome dye and (iii) reactive dye, were used in the dying process. For acid dyeing the dyeing rate of the LTP-treated wool fibre was greatly increased but the final dyeing exhaustion equilibrium did not show any significant change. For the chrome dyeing the dyeing rate of the LTP treated wool fibre was also increased but the final dyeing exhaustion equilibrium was only increased to a small extent. In addition the rate of afterchroming process was similar to the chrome dying process. For the reactive dyeing the dyeing rate of the LTP treated wool fibre was greatly increased and the final dyeing exhaustion equilibrium was also increased significantly. Wit such results one could conclude that the LTP treatments improve the dyeing behavior of wool fibres in different dyeing systems.
C1 Hong Kong Polytech Univ, Inst Text & Clothing, Kowloon, Hong Kong, Peoples R China.
RP Kan, CW (reprint author), Hong Kong Polytech Univ, Inst Text & Clothing, Kowloon, Hong Kong, Peoples R China.
EM tccwk@inet.polyu.edu.hk
OI Kan, Chi-wai/0000-0002-7668-2410
CR ASPLAND JR, 1991, TEXT CHEM COLOR, V23, P13
   Binias D, 2004, FIBRES TEXT EAST EUR, V12, P58
   BIRD CL, 1971, THEORY PRACTICE WOOL
   Chan CM, 1996, SURF SCI REP, V24, P3
   FELLENBERG R, 2000, P 10 INT WOOL TEXT R
   FORSTER F, 2000, P 10 INT WOOL TEXT R
   HOCKER H, 1994, MELLIAND TEXTIBER, V75, pE131
   HOCKER H, 2000, P 10 INT WOOL TEXT R
   JANSEN B, 2000, P 10 INT WOOL TEXT R
   Kan CW, 2004, FIBER POLYM, V5, P52, DOI 10.1007/BF02875495
   Kan CW, 2004, AUTEX RES J, V4, P37
   KAN CW, 2003, AUTEX RES J, V3, P194
   LEEDER JD, 1985, P INT S FIB SCI TECH, V2, P203
   Lewis DM, 1992, WOOL DYEING
   MACLAREN JM, 1981, WOOL SCI CHEM REACTI
   PAVLATH AE, 1971, P 4 INT WOOL TEXT RE, V2, P1317
   RADU CD, 2000, P 10 INT WOOL TEXT R
   THEIRICH D, 2000, P 10 INT WOOL TEXT R
   THOMAS H, 1995, P 9 INT WOOL TEXT RE, V4, P351
   THOMAS H, 2000, P 10 INT WOOL TEXT R
   YAN HJ, 1989, P 4 ANN INT C PLASM, P181
NR 21
TC 17
Z9 18
U1 7
U2 12
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 1612-8850
EI 1612-8869
J9 PLASMA PROCESS POLYM
JI Plasma Process. Polym.
PD OCT 11
PY 2006
VL 3
IS 8
BP 627
EP 635
DI 10.1002/ppap.200600086
PG 9
WC Physics, Applied; Physics, Fluids & Plasmas; Physics, Condensed Matter;
   Polymer Science
SC Physics; Polymer Science
GA 100CO
UT WOS:000241645000006
DA 2018-12-27
ER

PT J
AU Atkin, JD
   Farg, MA
   Turner, BJ
   Tomas, D
   Lysaght, JA
   Nunan, J
   Rembach, A
   Nagley, P
   Beart, PM
   Cheema, SS
   Horne, MK
AF Atkin, Julie D.
   Farg, Manal A.
   Turner, Bradley J.
   Tomas, Doris
   Lysaght, Judith A.
   Nunan, Janelle
   Rembach, Alan
   Nagley, Phillip
   Beart, Philip M.
   Cheema, Surindar S.
   Horne, Malcolm K.
TI RETRACTED: Induction of the unfolded protein response in familial
   amyotrophic lateral sclerosis and association of protein-disulfide
   isomerase with superoxide dismutase 1 (Retracted article. See vol. 292,
   pg. 12007, 2017)
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article; Retracted Publication
ID ENDOPLASMIC-RETICULUM STRESS; CU,ZN SUPEROXIDE-DISMUTASE; WILD-TYPE
   SOD1; CU,ZN-SUPEROXIDE DISMUTASE; MOUSE MODEL; GOLGI-APPARATUS;
   TRANSGENIC MICE; UP-REGULATION; PARKINSONS-DISEASE; MOTOR-NEURONS
AB Mutations in Cu/Zn superoxide dismutase (SOD1) are linked to motor neuron death in familial amyotrophic lateral sclerosis (ALS) by an unclear mechanism, although misfolded SOD1 aggregates are commonly associated with disease. Proteomic analysis of the transgenic SOD1(G93A) ALS rat model revealed significant up-regulation of endoplasmic reticulum (ER)-resident protein-disulfide isomerase (PDI) family members in lumbar spinal cords. Expression of SOD1 mutants (mSOD1) led to an up-regulation of PDI in motor neuron-like NSC-34 cells but not other cell lines. Inhibition of PDI using bacitracin increased aggregate production, even in wild type SOD1 transfectants that do not readily form inclusions, suggesting PDI may protect SOD1 from aggregation. Moreover, PDI co-localized with intracellular aggregates of mSOD1 and bound to both wild type and mSOD1. SOD1 was also found in the microsomal fraction of cells despite being a predominantly cytosolic enzyme, confirming ER-Golgi-dependent secretion. In SOD1G93A mice, a significant up-regulation of unfolded protein response entities was also observed during disease, including caspase-12, -9, and -3 cleavage. Our findings therefore implicate unfolded protein response and ER stress-induced apoptosis in the pathophysiology of familial ALS. The possibility that PDI may be a therapeutic target to prevent SOD1 aggregation is also raised by this study.
C1 Univ Melbourne, Howard Florey Inst, Brain Injury & Repair Grp, Parkville, Vic 3010, Australia.
   Monash Univ, Dept Biochem & Mol Biol, Clayton, Vic 3800, Australia.
RP Atkin, JD (reprint author), Univ Melbourne, Howard Florey Inst, Brain Injury & Repair Grp, Parkville, Vic 3010, Australia.
EM j.atkin@hfi.unimelb.edu.au
OI Turner, Bradley/0000-0001-6580-7655
CR Arnesano F, 2004, J BIOL CHEM, V279, P47998, DOI 10.1074/jbc.M406021200
   Bendotti C, 2004, TRENDS MOL MED, V10, P393, DOI 10.1016/j.molmed.2004.06.009
   Bruening W, 1999, J NEUROCHEM, V72, P693, DOI 10.1046/j.1471-4159.1999.0720693.x
   Bruijn LI, 1998, SCIENCE, V281, P1851, DOI 10.1126/science.281.5384.1851
   CHANG LY, 1988, J CELL BIOL, V107, P2169, DOI 10.1083/jcb.107.6.2169
   Conn KJ, 2004, BRAIN RES, V1022, P164, DOI 10.1016/j.brainres.2004.07.026
   Cozzolino M, 2006, NEUROBIOL DIS, V21, P69, DOI 10.1016/j.nbd.2005.06.010
   DALCANTO MC, 1995, BRAIN RES, V676, P25, DOI 10.1016/0006-8993(95)00063-V
   Deng HX, 2006, P NATL ACAD SCI USA, V103, P7142, DOI 10.1073/pnas.0602046103
   Dinter A, 1998, HISTOCHEM CELL BIOL, V109, P571, DOI 10.1007/s004180050256
   Doucette PA, 2004, J BIOL CHEM, V279, P54558, DOI 10.1074/jbc.M409744200
   Dringen R, 2000, EUR J BIOCHEM, V267, P4912, DOI 10.1046/j.1432-1327.2000.01597.x
   Elliott JG, 1997, J BIOL CHEM, V272, P13849, DOI 10.1074/jbc.272.21.13849
   Engelhardt JI, 1997, J NEUROPATH EXP NEUR, V56, P21, DOI 10.1097/00005072-199701000-00003
   FORMAN HJ, 1973, J BIOL CHEM, V248, P2645
   Frickel EM, 2004, J BIOL CHEM, V279, P18277, DOI 10.1074/jbc.M314089200
   Fujita Y, 2000, J NEUROL SCI, V174, P137, DOI 10.1016/S0022-510X(00)00265-3
   Furukawa Y, 2005, J BIOL CHEM, V280, P17266, DOI 10.1074/jbc.M500482200
   Furukawa Y, 2004, EMBO J, V23, P2872, DOI 10.1038/sj.emboj.7600276
   Furukawa Y, 2006, P NATL ACAD SCI USA, V103, P7148, DOI 10.1073/pnas.0602048103
   GURNEY ME, 1994, SCIENCE, V264, P1772, DOI 10.1126/science.8209258
   Hetz C, 2005, J NEUROSCI, V25, P2793, DOI 10.1523/JNEUROSCI.4090-04.2005
   Hetz C, 2003, EMBO J, V22, P5435, DOI 10.1093/emboj/cdg537
   Higuchi T, 2004, BIOCHEM BIOPH RES CO, V318, P46, DOI 10.1016/j.bbrc.2004.04.002
   Howland DS, 2002, P NATL ACAD SCI USA, V99, P1604, DOI 10.1073/pnas.032539299
   Inarrea P, 2005, BIOCHEM J, V387, P203, DOI 10.1042/BJ20041683
   Jessop CE, 2004, J BIOL CHEM, V279, P55341, DOI 10.1074/jbc.M411409200
   Johnston JA, 2000, P NATL ACAD SCI USA, V97, P12571, DOI 10.1073/pnas.220417997
   Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211
   Kaufman RJ, 2002, J CLIN INVEST, V110, P1389, DOI 10.1172/JC1200216886
   Kim HT, 2000, ANTIOXID REDOX SIGN, V2, P485, DOI 10.1089/15230860050192260
   Lindenau J, 2000, GLIA, V29, P25, DOI 10.1002/(SICI)1098-1136(20000101)29:1<25::AID-GLIA3>3.0.CO;2-G
   Ma YJ, 2002, J MOL BIOL, V318, P1351, DOI 10.1016/S0022-2836(02)00234-6
   MANDEL R, 1993, P NATL ACAD SCI USA, V90, P4112, DOI 10.1073/pnas.90.9.4112
   MAZZARELLA RA, 1994, ARCH BIOCHEM BIOPHYS, V308, P454, DOI 10.1006/abbi.1994.1064
   MIZUNAGA T, 1990, J BIOCHEM-TOKYO, V108, P846, DOI 10.1093/oxfordjournals.jbchem.a123291
   Mondola P, 2003, MOL BRAIN RES, V110, P45, DOI 10.1016/S0169-328X(02)00583-1
   Mondola P, 1996, INT J BIOCHEM CELL B, V28, P677, DOI 10.1016/1357-2725(96)00004-0
   Mourelatos Z, 1996, P NATL ACAD SCI USA, V93, P5472, DOI 10.1073/pnas.93.11.5472
   MOURELATOS Z, 1990, P NATL ACAD SCI USA, V87, P4393, DOI 10.1073/pnas.87.11.4393
   Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513
   Novoa I, 2003, EMBO J, V22, P1180, DOI 10.1093/emboj/cdg112
   Ogawa Y, 1997, BIOCHEM BIOPH RES CO, V241, P251, DOI 10.1006/bbrc.1997.7804
   Okado-Matsumoto A, 2001, J BIOL CHEM, V276, P38388, DOI 10.1074/jbc.M105395200
   Oyadomari S, 2004, CELL DEATH DIFFER, V11, P381, DOI 10.1038/sj.cdd.4401373
   Parton MJ, 2002, HUM MUTAT, V20, DOI 10.1002/humu.9081
   Rakhit R, 2004, J BIOL CHEM, V279, P15499, DOI 10.1074/jbc.M313295200
   ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0
   ROTH RA, 1981, J BIOL CHEM, V256, P4633
   Rutkowski DT, 2004, TRENDS CELL BIOL, V14, P20, DOI 10.1016/j.tcb.2003.11.001
   Ryu EJ, 2002, J NEUROSCI, V22, P10690
   SAITO T, 1989, HISTOL HISTOPATHOL, V4, P1
   Sathasivam S, 2005, NEUROPATH APPL NEURO, V31, P467, DOI 10.1111/j.1365-2990.2005.00658.x
   Schafer FQ, 2001, FREE RADICAL BIO MED, V30, P1191, DOI 10.1016/S0891-5849(01)00480-4
   Shinder GA, 2001, J BIOL CHEM, V276, P12791, DOI 10.1074/jbc.M010759200
   Strey CW, 2004, AM J PATHOL, V165, P1701, DOI 10.1016/S0002-9440(10)63426-8
   Takeuchi H, 2002, J BIOL CHEM, V277, P50966, DOI 10.1074/jbc.M209356200
   Tanaka S, 2000, J BIOL CHEM, V275, P10388, DOI 10.1074/jbc.275.14.10388
   Tiwari A, 2005, J BIOL CHEM, V280, P29771, DOI 10.1074/jbc.M504039200
   Tiwari A, 2003, J BIOL CHEM, V278, P5984, DOI 10.1074/jbc.M210419200
   Tobisawa S, 2003, BIOCHEM BIOPH RES CO, V303, P496, DOI 10.1016/S0006-291X(03)00353-X
   Turano C, 2002, J CELL PHYSIOL, V193, P154, DOI 10.1002/jcp.10172
   Turner BJ, 2005, J NEUROSCI, V25, P108, DOI 10.1523/JNEUROSCI.4253-04.2005
   Turner BJ, 2006, CURR MOL MED, V6, P79, DOI 10.2174/156652406775574550
   Urushitani M, 2006, NAT NEUROSCI, V9, P108, DOI 10.1038/nn1603
   Vlug AS, 2005, EUR J NEUROSCI, V22, P1881, DOI 10.1111/j.1460-9568.2005.04389.x
   Wate R, 2005, ACTA NEUROPATHOL, V110, P557, DOI 10.1007/s00401-005-1080-y
   Wootz H, 2004, BIOCHEM BIOPH RES CO, V322, P281, DOI 10.1016/j.bbrc.2004.07.118
   Yoo BC, 2002, NEUROSCI LETT, V334, P196, DOI 10.1016/S0304-3940(02)01071-6
NR 69
TC 210
Z9 214
U1 3
U2 19
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD OCT 6
PY 2006
VL 281
IS 40
BP 30152
EP 30165
DI 10.1074/jbc.M603393200
PG 14
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 089QT
UT WOS:000240896300076
PM 16847061
OA Green Published, Bronze
DA 2018-12-27
ER

PT J
AU Ben-Hamu, G
   Eliezer, A
   Gutman, EM
AF Ben-Hamu, G.
   Eliezer, A.
   Gutman, E. M.
TI RETRACTED: Electrochemical behavior of magnesium alloys strained in
   buffer solutions (Retracted article. See vol. 52, pg. 6395, 2007)
SO ELECTROCHIMICA ACTA
LA English
DT Article; Retracted Publication
DE magnesium alloys; die cast and extruded; mechano-chemical effect;
   electrochemical tests
ID MECHANOELECTROCHEMICAL BEHAVIOR; CORROSION-FATIGUE; STRESS; AZ91D
AB The mechano-chemical effect in a group of five die cast and extruded magnesium alloys has been investigated. Corrosion rates were determined as a function of both the processing conditions, used to produce the alloys, and the applied tensile strain by means of potentiodynamic polarisation measurements and immersion tests. These were conducted at 25 degrees C in several borate buffer solutions containing NaCl, Mg(OH)(2) or NaOH. In order to understand the reason for the advantages of AM50 Alloy under stress corrosion, TEM analysis were performed. This analysis revealed the location of dislocation pile-ups at a further stage in the stressed AM50 alloy which were found to be beneficial to it is resistance to stress-corrosion cracking.
   It is shown that the mechano-chemical effect is strongly dependent on the aluminium content in the alloy. (c) 2006 Elsevier Ltd. All rights reserved.
C1 Ben Gurion Univ Negev, Dept Mat Engn, IL-84105 Beer Sheva, Israel.
   Sami Shamoon Coll Engn, Corros Res Ctr, IL-84100 Beer Sheva, Israel.
RP Ben-Hamu, G (reprint author), Ben Gurion Univ Negev, Dept Mat Engn, POB 653, IL-84105 Beer Sheva, Israel.
EM guyben@bgumail.bgu.ac.il
CR Ben-Hamu G, 2006, MAT SCI ENG A-STRUCT, V420, P109, DOI 10.1016/j.msea.2006.01.060
   Eliezer A, 1998, MATER SCI FORUM, V289-2, P517, DOI 10.4028/www.scientific.net/MSF.289-292.517
   Eliezer A, 1998, CORROS REV, V16, P1
   Eliezer A., 2001, J LIGHT MET, V1, P179
   ELIEZER A, 2000, MAGNESIUM 2000, P356
   ELIEZER A, 2000, P INT C MAGN 2000 MA, P498
   Gutman EM, 2001, MAT SCI ENG A-STRUCT, V302, P63, DOI 10.1016/S0921-5093(00)01355-1
   Gutman EM, 2000, J MATER SYNTH PROCES, V8, P133, DOI 10.1023/A:1011399723559
   GUTMAN EM, 2000, LIGHT METAL AGE  DEC, P14
   GUTMAN EM, 1994, MECHANOCHEMISTRY SOL, P1
   Harwood J. J., 1956, STRESS CORROSION CRA, P1
   HILPERT M, 2000, P INT C MAGN 2000 MA, P304
   HOAR TP, 1964, J ELECTROCHEM SOC, V111, P348, DOI 10.1149/1.2426120
   MAKAR GL, 1990, J ELECTROCHEM SOC, V137, P414, DOI 10.1149/1.2086455
   Mayer HR, 1999, FATIGUE FRACT ENG M, V22, P591
   MIILLER C, 2000, P INT C MAGN 2000 MA, P457
   Romanov VV, 1961, STRESS CORROSION CRA
   SAGER GF, 1945, S STRESS CORR CRACK, P255
   Song GL, 1999, CORROS SCI, V41, P249
   Song GL, 1999, ADV ENG MATER, V1, P11, DOI 10.1002/(SICI)1527-2648(199909)1:1<11::AID-ADEM11>3.0.CO;2-N
   Song GL, 2005, ADV ENG MATER, V7, P563, DOI 10.1002/adem.200500013
   Song GL, 2004, MAT SCI ENG A-STRUCT, V366, P74, DOI 10.1016/j.msea.2003.08.060
   SONSINO CM, 2000, P INT C MAGN 2000 MA, P304
   SPEIDEL MO, 1967, P C FUNDAMENTAL ASPE, P561
   SPEIDEL MO, 1972, P INT C CORROSION FA, P324
   STEPHENS RI, 1995, J ENG MATER-T ASME, V117, P293, DOI 10.1115/1.2804542
   TIMONOVA MA, 1957, DOKL AKAD NAUK SSSR+, V117, P848
   Uhlig H.H., 1963, CORROSION CORROSION
   Unigovski Y, 2003, MAT SCI ENG A-STRUCT, V360, P132, DOI 10.1016/S0921-5093(03)00409-X
   Wang RM, 2003, MAT SCI ENG A-STRUCT, V344, P279, DOI 10.1016/S0921-5093(02)00413-6
   WITT M, 2000, MAGNESIUM 2000, P263
   Zhang S, 1998, CORROSION, V54, P428, DOI 10.5006/1.3284870
NR 32
TC 16
Z9 16
U1 4
U2 21
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0013-4686
EI 1873-3859
J9 ELECTROCHIM ACTA
JI Electrochim. Acta
PD OCT 5
PY 2006
VL 52
IS 1
BP 304
EP 313
DI 10.1016/j.electacta.2006.05.009
PG 10
WC Electrochemistry
SC Electrochemistry
GA 094QC
UT WOS:000241253100039
DA 2018-12-27
ER

PT J
AU Ramanathan, S
   Bandyopadhyay, S
   Hussey, LK
   Munoz, M
AF Ramanathan, S.
   Bandyopadhyay, S.
   Hussey, L. K.
   Munoz, M.
TI RETRACTED: Observation of numerous E-2 mode phonon replicas in the room
   temperature photoluminescence spectra of ZnO nanowires: Evidence of
   strong deformation potential electron-phonon coupling (Retracted
   article. See vol 94, art. no. 129902, 2009)
SO APPLIED PHYSICS LETTERS
LA English
DT Article; Retracted Publication
ID ASSEMBLED QUANTUM DOTS; EXCITATION SPECTROSCOPY; ZINC-OXIDE; ARRAYS;
   ALUMINUM; STATES
AB The authors report the observation of numerous (> 20) phonon replica peaks in the room temperature photoluminescence spectrum of ZnO nanowires embedded in 50 nm diameter pores of an anodic alumina film. The peaks are spaced in energy by similar to 54 meV, which is the energy of a nonpolar phonon with symmetry E-2 in ZnO. These peaks are possibly caused by resonant phonon-assisted decay of photoexcited electrons to an impurity band, followed by radiative recombination. These results suggest that even though ZnO is strongly polar, deformation potential coupling to a nonpolar phonon mode may be stronger than Frohlich coupling to polar phonon modes. (c) 2006 American Institute of Physics.
C1 Virginia Commonwealth Univ, Dept Elect & Comp Engn, Richmond, VA 23284 USA.
   Univ S Florida, Dept Phys, Tampa, FL 33620 USA.
RP Ramanathan, S (reprint author), Virginia Commonwealth Univ, Dept Elect & Comp Engn, Med Coll Virginia Campus, Richmond, VA 23284 USA.
EM sbandy@vcu.edu
CR Alim KA, 2005, APPL PHYS LETT, V86, DOI 10.1063/1.1861509
   Bandyopadhyay S, 1996, NANOTECHNOLOGY, V7, P360, DOI 10.1088/0957-4484/7/4/010
   BETHKE S, 1988, APPL PHYS LETT, V52, P138, DOI 10.1063/1.99030
   Du Y, 1999, APPL PHYS LETT, V74, P2951, DOI 10.1063/1.123976
   FAN Z, 2004, APPL PHYS LETT, V85, P2274
   FARFAD S, 1995, PHYS REV B, V52, P5752, DOI 10.1103/PhysRevB.52.5752
   Fonoberov VA, 2006, PHYS REV B, V73, DOI 10.1103/PhysRevB.73.165317
   GUTOWSKI J, 1988, PHYS REV B, V38, P9746, DOI 10.1103/PhysRevB.38.9746
   Hamby DW, 2003, J APPL PHYS, V93, P3214, DOI 10.1063/1.1545157
   Harada Y, 2005, J APPL PHYS, V98, DOI 10.1063/1.2128690
   Heitz R, 1997, PHYS REV B, V56, P10435, DOI 10.1103/PhysRevB.56.10435
   Jie JS, 2004, J PHYS CHEM B, V108, P11976, DOI 10.1021/jp048974r
   Johnson JC, 2004, NANO LETT, V4, P197, DOI 10.1021/nl034780w
   Lemaitre A, 2001, PHYS REV B, V63, DOI 10.1103/PhysRevB.63.161309
   Li Y, 2000, APPL PHYS LETT, V76, P2011, DOI 10.1063/1.126238
   Liu ZW, 2006, APPL PHYS LETT, V88, DOI 10.1063/1.2168675
   Makino T, 2005, J APPL PHYS, V98, DOI 10.1063/1.2127167
   Masuda H, 1996, JPN J APPL PHYS 2, V35, pL126, DOI 10.1143/JJAP.35.L126
   Ozgur U, 2005, J APPL PHYS, V98, DOI 10.1063/1.1992666
   RAMANTHAN S, IN PRESS J MAT SCI E
   Reynolds DC, 2000, J APPL PHYS, V88, P2152, DOI 10.1063/1.1305546
   Shan W, 2005, APPL PHYS LETT, V86, DOI 10.1063/1.1923757
   Toda Y, 1999, PHYS REV LETT, V82, P4114, DOI 10.1103/PhysRevLett.82.4114
   TOMZIG E, 1976, J LUMIN, V14, P403, DOI 10.1016/S0022-2313(76)91392-2
   Vasilevskiy MI, 2004, PHYS REV B, V70, DOI 10.1103/PhysRevB.70.035318
   Wang LJ, 2003, J APPL PHYS, V94, P973, DOI 10.1063/1.1586977
   Wang QT, 2005, MATER LETT, V59, P1378, DOI 10.1016/j.matlet.2004.12.046
   XIE J, 2005, APPL PHYS LETT, V86
   YAMAMOTO Y, 1981, NATURE, V289, P572, DOI 10.1038/289572a0
   Zhang YF, 2005, APPL PHYS LETT, V87, DOI 10.1063/1.2001754
NR 30
TC 11
Z9 11
U1 3
U2 18
PU AMER INST PHYSICS
PI MELVILLE
PA 1305 WALT WHITMAN RD, STE 300, MELVILLE, NY 11747-4501 USA
SN 0003-6951
EI 1077-3118
J9 APPL PHYS LETT
JI Appl. Phys. Lett.
PD OCT 2
PY 2006
VL 89
IS 14
AR 143121
DI 10.1063/1.2360255
PG 3
WC Physics, Applied
SC Physics
GA 091VR
UT WOS:000241056900111
DA 2018-12-27
ER

PT J
AU Liu, JT
   Fan, SD
AF Liu, Ju-Tao
   Fan, Sheng-Di
TI RETRACTED: Tetraaqua(1,10-phenanthroline-kappa(2) N,N ')nickel(II)
   naphthalene-1,5-disulfonate dihydrate (Retracted article. See vol. 66,
   pg e21, 2010)
SO ACTA CRYSTALLOGRAPHICA SECTION E-STRUCTURE REPORTS ONLINE
LA English
DT Article; Retracted Publication
AB The title compound, [Ni(C12H8N2)(H2O)(4)](C10H6S2O6)center dot 2H(2)O, is isostructural with a copper(II) analog, whose structure has been reported recently [Liu, Fan & Li (2006). Acta Cryst. E62, m2165-m2166]. The cation lies on a crystallographic twofold rotation axis and the anion lies on a centre of inversion. The Ni II atom is in a distorted octahedral geometry.
C1 Dalian Nationalities Univ, Sch Life Sci, Dalian 116600, Peoples R China.
RP Liu, JT (reprint author), Dalian Nationalities Univ, Sch Life Sci, Dalian 116600, Peoples R China.
EM jutaoliu@yahoo.com.cn
CR *BRUK AXS INC, 1998, SMART VERS 5 051 SAI
   Liu JT, 2006, ACTA CRYSTALLOGR E, V62, pM2165, DOI 10.1016/S1600536806030637
   Sheldrick G. M., 1997, SHELXL97 SHELXS97
NR 3
TC 4
Z9 4
U1 2
U2 7
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1600-5368
J9 ACTA CRYSTALLOGR E
JI Acta Crystallogr. Sect. E.-Struct Rep. Online
PD OCT
PY 2006
VL 62
BP M2507
EP M2508
DI 10.1107/S1600536806035410
PN 10
PG 2
WC Crystallography
SC Crystallography
GA 089XE
UT WOS:000240914400046
DA 2018-12-27
ER

PT J
AU Erin, EM
   Leaker, BR
   Nicholson, GC
   Tan, AJ
   Green, LM
   Neighbour, H
   Zacharasiewicz, AS
   Turner, J
   Barnathan, ES
   Kon, OM
   Barnes, PJ
   Hansel, TT
AF Erin, Edward M.
   Leaker, Brian R.
   Nicholson, Grant C.
   Tan, Andrew J.
   Green, Linda M.
   Neighbour, Helen
   Zacharasiewicz, Angela S.
   Turner, Jackie
   Barnathan, Elliot S.
   Kon, Onn Min
   Barnes, Peter J.
   Hansel, Trevor T.
TI RETRACTED: The effects of a monoclonal antibody directed against tumor
   necrosis factor-alpha in asthma (Retracted article. See vol. 183, pg.
   418, 2011)
SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
LA English
DT Article; Retracted Publication
DE asthma; monoclonal antibody; pharmacology; tumor necrosis factor-alpha
ID CORTICOSTEROID-DEPENDENT ASTHMA; OBSTRUCTIVE PULMONARY-DISEASE; NASAL
   NITRIC-OXIDE; TNF-ALPHA; AIRWAY HYPERRESPONSIVENESS;
   RHEUMATOID-ARTHRITIS; INFLIXIMAB TREATMENT; REFRACTORY ASTHMA;
   ALLERGIC-ASTHMA; INDUCED SPUTUM
AB Rationale: Neutralization of tumor necrosis factor-alpha (TNF-alpha) is an effective antiinflammatory therapy for several chronic inflammatory diseases.
   Methods and Objectives: We undertook a double-blind, placebo-controlled, parallel-group design study in 38 patients with moderate asthma treated with inhaled corticosteroids but symptomatic during a run-in phase. Infliximab (5 mg/kg) or placebo was administered by intravenous infusion at Weeks 0, 2, and 6. We assessed clinical response by monitoring lung function, symptoms, and inhaled beta(2)-agonist usage using hand-held electronic devices.
   Results: The primary endpoint, change in morning PEF at Days 50-56 compared with the last 7 d of the run-in, was not significantly different on treatment. However, infliximab was associated with a decrease in mean diurnal variation of PEF at Week 8 (p = 0.02; 95% confidence interval [CI], -8.1 to -0.72). Furthermore, there was a decrease in the number of patients with exacerbations of asthma (p = 0.01; 95% CI, 4.4 to 52.7) and an increased probability of freedom from exacerbation with time (p = 0.03) in patients on infliximab (n = 14) compared with placebo (n = 18). In addition, infliximab decreased levels of TNF-alpha (p = 0.01) and other cytokines in sputum supernatants. There were no serious adverse events related to the study agent.
   Conclusions: Treatment with infliximab was well tolerated and caused a decrease in the number of patients with exacerbations in symptomatic moderate asthma. The promising preliminary findings underscore the need to evaluate therapy directed against TNF-alpha in larger trials enrolling patients with more severe asthma.
C1 Natl Heart & Lung Inst, Clin Studies Unit, London, England.
   Univ London Imperial Coll Sci Technol & Med, Dept Thorac Med, London, England.
   Royal Free Hosp, Dept Nephrol, London NW3 2QG, England.
   St Marys Hosp, Dept Resp Med, London, England.
   Centocor Inc, Malvern, PA 19355 USA.
RP Hansel, TT (reprint author), Royal Brompton Hosp, NHLI Clin Studies Unit, Fulham Rd, London SW3 6HP, England.
EM t.hansel@imperial.ac.uk
OI Kon, Onn Min/0000-0003-2647-4688
FU Medical Research Council [G0400503B]
CR Abraham LJ, 1999, J LEUKOCYTE BIOL, V66, P562
   ALEXANDER AG, 1992, LANCET, V339, P324, DOI 10.1016/0140-6736(92)91646-P
   Babu KS, 2004, IMMUNOL ALLERGY CLIN, V24, P583, DOI 10.1016/j.iac.2004.06.010
   Barnes PJ, 2004, NAT REV DRUG DISCOV, V3, P831, DOI 10.1038/nrd1524
   Barnes PJ, 2003, CYTOKINE GROWTH F R, V14, P511, DOI 10.1016/S1359-6101(03)00058-3
   Berry MA, 2006, NEW ENGL J MED, V354, P697, DOI 10.1056/NEJMoa050580
   Braun J, 2002, LANCET, V359, P1187, DOI 10.1016/S0140-6736(02)08215-6
   Busse W, 2001, J ALLERGY CLIN IMMUN, V108, P184, DOI 10.1067/mai.2001.117880
   Casale TB, 1996, AM J RESP CELL MOL, V15, P35, DOI 10.1165/ajrcmb.15.1.8679220
   Conroy CA, 2001, POSTGRAD MED J, V77, P436, DOI 10.1136/pmj.77.909.436
   Cookson W, 2004, NEW ENGL J MED, V351, P1794, DOI 10.1056/NEJMe048232
   Corrigan Chris J, 2002, Am J Respir Med, V1, P47
   Corry DB, 2006, J ALLERGY CLIN IMMUN, V117, pS461, DOI 10.1016/j.jaci.2005.09.001
   Djukanovic R, 2002, EUR RESPIR J, V20, p1S, DOI 10.1183/09031936.02.00000102
   Dolan CM, 2004, ANN ALLERG ASTHMA IM, V92, P32, DOI 10.1016/S1081-1206(10)61707-3
   Erin EM, 2006, CLIN EXP ALLERGY, V36, P458, DOI 10.1111/j.1365-2222.2006.02474.x
   Erzurum SC, 2006, NEW ENGL J MED, V354, P754, DOI 10.1056/NEJMe058266
   Evans DJ, 1997, NEW ENGL J MED, V337, P1412, DOI 10.1056/NEJM199711133372002
   Feldmann M, 2001, ANNU REV IMMUNOL, V19, P163, DOI 10.1146/annurev.immunol.19.1.163
   Flood-Page P, 2003, J CLIN INVEST, V112, P1029, DOI 10.1172/JCI200317974
   Haraoui B, 2005, SEMIN ARTHRITIS RHEU, V34, P7, DOI 10.1016/j.semarthrit.2005.01.003
   Holgate S, 2005, J ALLERGY CLIN IMMUN, V115, P459, DOI 10.1016/j.jaci.2004.11.053
   Holgate ST, 2006, J ALLERGY CLIN IMMUN, V117, P496, DOI 10.1016/j.jaci.2006.01.039
   Holtzman MJ, 2003, AM J RESP CELL MOL, V29, P163, DOI 10.1165/rcmb.F276
   Howarth PH, 2005, THORAX, V60, P1012, DOI 10.1136/thx.2005.045260
   Ito K, 2006, J ALLERGY CLIN IMMUN, V117, P522, DOI 10.1016/j.jaci.2006.01.032
   Keatings VM, 1997, AM J RESP CRIT CARE, V155, P542, DOI 10.1164/ajrccm.155.2.9032192
   Keatings VM, 1996, AM J RESP CRIT CARE, V153, P530, DOI 10.1164/ajrccm.153.2.8564092
   Kharitonov S, 1997, EUR RESPIR J, V10, P1683, DOI 10.1183/09031936.97.10071683
   Kips JC, 2003, AM J RESP CRIT CARE, V167, P1655, DOI 10.1164/rccm.200206-525OC
   Kon OM, 1998, LANCET, V352, P1109, DOI 10.1016/S0140-6736(97)12261-9
   Leckie MJ, 2000, LANCET, V356, P2144, DOI 10.1016/S0140-6736(00)03496-6
   Leonardi CL, 2003, NEW ENGL J MED, V349, P2014, DOI 10.1056/NEJMoa030409
   Lock SH, 1996, AM J RESP CRIT CARE, V153, P509, DOI 10.1164/ajrccm.153.2.8564089
   Marin MG, 1997, CHEST, V112, P29, DOI 10.1378/chest.112.1.29
   Milgrom H, 1999, NEW ENGL J MED, V341, P1966, DOI 10.1056/NEJM199912233412603
   MOFFAT MF, 1997, AM J RESP CRIT CARE, pS110
   Moore WC, 2006, J ALLERGY CLIN IMMUN, V117, P487, DOI 10.1016/j.jaci.2006.01.033
   *NAT I HLTH NAT HE, 2006, GLOB IN ASTHM GINA
   Obase Y, 2001, ANN ALLERG ASTHMA IM, V86, P304, DOI 10.1016/S1081-1206(10)63303-0
   Pauwels RA, 1997, NEW ENGL J MED, V337, P1405, DOI 10.1056/NEJM199711133372001
   Reddel H, 1999, LANCET, V353, P758
   Saadeh CK, 2002, J ALLERGY CLIN IMMUN, V109, pS243, DOI 10.1016/S0091-6749(02)81876-0
   Schwartz HJ, 2006, ALLERGY ASTHMA PROC, V27, P53
   Slutsky AS, 1999, AM J RESP CRIT CARE, V160, P2104
   Steinke JW, 2006, J ALLERGY CLIN IMMUN, V117, pS441, DOI 10.1016/j.jaci.2005.07.001
   Thomas PS, 2001, IMMUNOL CELL BIOL, V79, P132, DOI 10.1046/j.1440-1711.2001.00980.x
   Thomas PS, 2002, THORAX, V57, P774, DOI 10.1136/thorax.57.9.774
   THOMAS PS, 1995, AM J RESP CRIT CARE, V152, P76, DOI 10.1164/ajrccm.152.1.7599866
   van der Vaart H, 2005, AM J RESP CRIT CARE, V172, P465, DOI 10.1164/rccm.200501-147OC
   Vilcek J, 2004, TRENDS PHARMACOL SCI, V25, P201, DOI 10.1016/j.tips.2004.02.011
   Wenzel S, 2006, J ALLERGY CLIN IMMUN, V117, P508, DOI 10.1016/j.jaci.2005.12.1316
NR 52
TC 196
Z9 209
U1 8
U2 22
PU AMER THORACIC SOC
PI NEW YORK
PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA
SN 1073-449X
EI 1535-4970
J9 AM J RESP CRIT CARE
JI Am. J. Respir. Crit. Care Med.
PD OCT 1
PY 2006
VL 174
IS 7
BP 753
EP 762
DI 10.1164/rccm.200601-072OC
PG 10
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA 089PD
UT WOS:000240891900006
PM 16840747
DA 2018-12-27
ER

PT J
AU Mantena, SK
   Sharma, SD
   Katiyar, SK
AF Mantena, Sudheer K.
   Sharma, Som D.
   Katiyar, Santosh K.
TI RETRACTED: Berberine inhibits growth, induces G(1) arrest and apoptosis
   in human epidermoid carcinoma A431 cells by regulating Cdki-Cdk-cyclin
   cascade, disruption of mitochondrial membrane potential and cleavage of
   caspase 3 and PARP (Retracted article. See vol. 39, pg. 739, 2018)
SO CARCINOGENESIS
LA English
DT Article; Retracted Publication
ID DEPENDENT KINASE INHIBITORS; CYTOCHROME-C; BCL-2 FAMILY; CANCER; DEATH;
   INDUCTION; PROTEIN; NEOPLASIA; HEALTH; DRUGS
AB Chemotherapeutic approach using non-toxic botanicals may be one of the strategies for the management of the skin cancers. Here we report that in vitro treatment of human epidermoid carcinoma A431 cells with berberine, a naturally occurring isoquinoline alkaloid, decreased cell viability (3-77%, P < 0.05-0.001) and induced cell death (3-51%, P < 0.01-0.001) in a dose (5-75 mu M)- and time (12-72 h)-dependent manner, which was associated with an increase in G(1) arrest. G(0)/G(1) phase of the cell cycle is known to be controlled by cyclin dependent kinases (Cdk), cyclin kinase inhibitors (Cdki) and cyclins. Our western blot analysis showed that berberine-induced G(1) cell cycle arrest was mediated through the increased expression of Cdki proteins (Cip1/p21 and Kip1/p27), a simultaneous decrease in Cdk2, Cdk4, Cdk6 and cyclins D1, D2 and E and enhanced binding of Cdki-Cdk. In additional studies, treatment of A431 cells with berberine (15-75 mu M) for 72 h resulted in a significant dose-dependent increase in apoptosis (31-60%, P < 0.05-0.001) than non-berberine-treated control (11.7%), which was associated with an increased expression of pro-apoptotic protein Bax, decreased expression of anti-apoptotic proteins Bcl-2 and Bcl-xl, disruption of mitochondrial membrane potential, and activation of caspases 9, 3 and poly (ADP-ribose) polymerase. Pretreatment of A431 cells with the pan-caspase inhibitor (z-VAD-fmk) significantly blocked the berberine-induced apoptosis in A431 cells confirmed that berberine-induced apoptosis is mediated through activation of caspase 3-dependent pathway. Together, this study for the first time identified berberine as a chemotherapeutic agent against human epidermoid carcinoma A431 cells in vitro, further in vivo studies are required to determine whether berberine could be an effective chemotherapeutic agent for the management of non-melanoma skin cancers.
C1 Univ Alabama Birmingham, Dept Dermatol, Birmingham, AL 35294 USA.
   Univ Alabama Birmingham, Skin Dis Res Ctr, Birmingham, AL 35294 USA.
   Birmingham VA Med Ctr, Birmingham, AL 35294 USA.
RP Katiyar, SK (reprint author), Univ Alabama Birmingham, Dept Dermatol, 1670,Univ Blvd,Volker Hall 557,POB 202, Birmingham, AL 35294 USA.
EM skatiyar@uab.edu
FU NIAMS NIH HHS [AR050948-01]
CR Adams JM, 2001, TRENDS BIOCHEM SCI, V26, P61, DOI 10.1016/S0968-0004(00)01740-0
   Chao DT, 1998, ANNU REV IMMUNOL, V16, P395, DOI 10.1146/annurev.immunol.16.1.395
   Craig WJ, 1997, J AM DIET ASSOC, V97, pS199, DOI 10.1016/S0002-8223(97)00765-7
   Craig WJ, 1999, AM J CLIN NUTR, V70, p491S, DOI 10.1093/ajcn/70.3.491s
   Crompton M, 2000, CURR OPIN CELL BIOL, V12, P414, DOI 10.1016/S0955-0674(00)00110-1
   Fischer P M, 2001, Curr Opin Drug Discov Devel, V4, P623
   Fukuda K, 1999, J ETHNOPHARMACOL, V66, P227, DOI 10.1016/S0378-8741(98)00162-7
   Fukuda K, 1999, PLANTA MED, V65, P381, DOI 10.1055/s-2006-960795
   GRANA X, 1995, ONCOGENE, V11, P211
   Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309
   Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899
   Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710
   HICKMAN JA, 1992, CANCER METAST REV, V11, P121, DOI 10.1007/BF00048059
   HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0
   Housman TS, 2003, J AM ACAD DERMATOL, V48, P425, DOI 10.1067/mjd.2003.186
   HUANG WM, 1989, ZHONGHUA XIN XUE GUA, V5, P300
   HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6
   Iizuka N, 2000, CANCER LETT, V148, P19, DOI 10.1016/S0304-3835(99)00264-5
   KASTAN MB, 1995, CANCER METAST REV, V14, P3, DOI 10.1007/BF00690207
   Kim SA, 1998, BIOCHEMISTRY-US, V37, P16316, DOI 10.1021/bi9810961
   Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132
   Lin JG, 1999, AM J CHINESE MED, V27, P265, DOI 10.1142/S0192415X99000306
   LIU LF, 1989, ANNU REV BIOCHEM, V58, P351, DOI 10.1146/annurev.bi.58.070189.002031
   Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9
   Molinari M, 2000, CELL PROLIFERAT, V33, P261, DOI 10.1046/j.1365-2184.2000.00191.x
   MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0
   NAYLOR MF, 1995, ARCH DERMATOL, V131, P170, DOI 10.1001/archderm.131.2.170
   NISHINO H, 1986, ONCOLOGY, V43, P131
   O'Shaughnessy JA, 2002, CLIN CANCER RES, V8, P314
   Ortenblad A, 2002, INT J MANAG REV, V4, P87, DOI 10.1111/1468-2370.00078
   Pavletich NP, 1999, J MOL BIOL, V287, P821, DOI 10.1006/jmbi.1999.2640
   Pilat MJP, 1998, CANCER METAST REV, V17, P373, DOI 10.1023/A:1006166511344
   Reed John C., 1995, Current Opinion in Oncology, V7, P541, DOI 10.1097/00001622-199511000-00012
   Roy AM, 2005, NEOPLASIA, V7, P24, DOI 10.1593/neo.04412
   SATHYAVATHI GV, 1987, SPEC REP SER INDIAN, V2, P230
   Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135
   TAKASE H, 1993, NIPPON YAKURIGAKU ZA, V2, P101, DOI DOI 10.1254/FPJ.102.101
   Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312
   TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8
   Wang LK, 1996, CHEM RES TOXICOL, V9, P75, DOI 10.1021/tx950080y
   Wesierska-Gadek J, 2003, POL J PHARMACOL, V55, P895
   Wolf BB, 1999, J BIOL CHEM, V274, P20049, DOI 10.1074/jbc.274.29.20049
NR 42
TC 145
Z9 155
U1 0
U2 12
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0143-3334
EI 1460-2180
J9 CARCINOGENESIS
JI Carcinogenesis
PD OCT
PY 2006
VL 27
IS 10
BP 2018
EP 2027
DI 10.1093/carcin/bgl043
PG 10
WC Oncology
SC Oncology
GA 090CF
UT WOS:000240927500010
PM 16621886
OA Bronze
DA 2018-12-27
ER

PT J
AU Pal, S
   Joardar, J
   Song, JM
AF Pal, Sukdeb
   Joardar, J.
   Song, Joon Myong
TI RETRACTED: Removal of E-coli from water using surface-modified activated
   carbon filter media and its performance over an extended use (Retracted
   Article. See vol 42, pg 3906, 2008)
SO ENVIRONMENTAL SCIENCE & TECHNOLOGY
LA English
DT Article; Retracted Publication
ID FIBER SUPPORTING SILVER; BACTERIA; DEPOSITION; TRANSPORT; VIRUSES
AB Modification of activated carbon (AC) by aluminum hydroxychloride (AHC), and diatomaceous earth by zinc hydroxide changed the zeta potentials of these filter media from negative to positive. The modification method is amenable to room temperature, and eliminates the essential requirement of strong base treatment for making metal hydroxide coated filter media. Solid-state MAS 27Al NMR spectra suggested the presence of Al13-mer in the AHC-treated AC. AHC-modified AC samples were further treated with silver halide, and two antibacterial compounds to prevent microbial growth on filter media. In situ precipitation of silver bromide on AC resulted in formation of nanosized AgBr crystals. Bacteria removal performances of the modified media were tested in columns. For the first time, we demonstrated that only 30 g of either AHC-treated AC (60 x 200 mesh) or nano AgBr supported AC could provide > 6 log E. coli removal over similar to 1000 L when the input water had a bacterial load of 10(7) CFU/mL. The filter media were robust enough to perform even when water was passed at superficial velocities 3-10 times the typical velocity (6 cm/min) of water treatment processes. Metal leaching from the modified media was found to be less than the USEPA specified Maximum Contaminant Level.
C1 Seoul Natl Univ, Res Inst Pharmaceut Sci, Seoul 151742, South Korea.
   Seoul Natl Univ, Coll Pharm, Seoul 151742, South Korea.
   Seoul Natl Univ, Sch Mat Sci & Engn, Seoul 151742, South Korea.
RP Song, JM (reprint author), Seoul Natl Univ, Res Inst Pharmaceut Sci, Seoul 151742, South Korea.
EM jmsong@snu.ac.kr
RI Pal, Sukdeb/E-2082-2013
OI Pal, Sukdeb/0000-0001-7668-5745
CR BOTTERO JY, 1987, J COLLOID INTERF SCI, V117, P47, DOI 10.1016/0021-9797(87)90166-4
   Camesano TA, 1998, ENVIRON SCI TECHNOL, V32, P1699, DOI 10.1021/es970996m
   CHAUDHURI M, 1986, WATER SCI TECHNOL, V18, P77
   DEKEIJSER TH, 1982, J APPL CRYSTALLOGR, V15, P308, DOI 10.1107/S0021889882012035
   Dickinson RB, 1997, J COLLOID INTERF SCI, V190, P142, DOI 10.1006/jcis.1997.4882
   Duan JM, 2003, ADV COLLOID INTERFAC, V100, P475, DOI 10.1016/S0001-8686(02)00067-2
   ELIMELECH M, 1990, LANGMUIR, V6, P1153, DOI 10.1021/la00096a023
   *EPA, 1992, 810K92001 US EPA
   FARRAH SR, 1991, APPL ENVIRON MICROB, V57, P2502
   GERBA CP, 1981, ENVIRON SCI TECHNOL, V15, P940, DOI 10.1021/es00090a600
   Hiradate S, 2003, J INORG BIOCHEM, V97, P26, DOI 10.1016/S0162-0134(03)00242-3
   Israelachvili J. N., 1992, INTERMOLECULAR SURFA
   Jucker BA, 1998, ENVIRON SCI TECHNOL, V32, P2909, DOI 10.1021/es980211s
   KINOSHITA T, 1993, WATER RES, V27, P1295, DOI 10.1016/0043-1354(93)90216-5
   Klaus T, 1999, P NATL ACAD SCI USA, V96, P13611, DOI 10.1073/pnas.96.24.13611
   Li CY, 1998, CARBON, V36, P61, DOI 10.1016/S0008-6223(97)00151-6
   MenachemElimelech M., 1995, PARTICLE DEPOSITION
   OYA A, 1993, CARBON, V31, P71, DOI 10.1016/0008-6223(93)90157-6
   PRASAD VS, 1989, WATER SCI TECHNOL, V21, P67
   Schafer A, 1998, ENVIRON SCI TECHNOL, V32, P3704, DOI 10.1021/es980191u
   Scott T., 2002, KONA, V20, P159
   SPADARO JA, 1974, ANTIMICROB AGENTS CH, V6, P637, DOI 10.1128/AAC.6.5.637
   Truesdail SE, 1998, J COLLOID INTERF SCI, V203, P369, DOI 10.1006/jcis.1998.5541
   Wang YL, 1998, CARBON, V36, P1567, DOI 10.1016/S0008-6223(98)00101-8
NR 24
TC 23
Z9 23
U1 5
U2 31
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0013-936X
EI 1520-5851
J9 ENVIRON SCI TECHNOL
JI Environ. Sci. Technol.
PD OCT 1
PY 2006
VL 40
IS 19
BP 6091
EP 6097
DI 10.1021/es060708z
PG 7
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA 088QK
UT WOS:000240826000047
PM 17051805
DA 2018-12-27
ER

PT J
AU Webster, R
   Heuvelink, GBM
AF Webster, R.
   Heuvelink, G. B. M.
TI RETRACTED: The Kalman filter for the pedologist's tool kit (Retracted
   article. See vol 57, pg 767, 2006)
SO EUROPEAN JOURNAL OF SOIL SCIENCE
LA English
DT Article; Retracted Publication
ID SOIL-WATER CONTENT; SEQUENTIAL DATA ASSIMILATION; TABLE FLUCTUATIONS;
   TIME-SERIES; MODEL
AB The Kalman filter is a tool designed primarily to estimate the values of the 'state' of a dynamic system in time. There are two main equations. These are the state equation, which describes the behaviour of the state over time, and the measurement equation, which describes at what times and in what manner the state is observed. For the discrete Kalman filter, discussed in this paper, the state equation is a stochastic difference equation that incorporates a random component for noise in the system and that may include external forcing. The measurement equation is defined such that it can handle indirect measurements, gaps in the sequence of measurements and measurement errors. The Kalman filter operates recursively to predict forwards one step at a time the state of the system from the previously predicted state and the next measurement. Its predictions are optimal in the sense that they have minimum variance among all unbiased predictors, and in this respect the filter behaves like kriging. The equations can also be applied in reverse order to estimate the state variable at all time points from a complete series of measurements, including past, present and future measurements. This process is known as smoothing.
   This paper describes the 'predictor-corrector' algorithm for the Kalman filter and smoother with all the equations in full, and it illustrates the method with examples on the dynamics of groundwater level in the soil. The height of the water table at any one time depends partly on the height at previous times and partly on the precipitation excess. Measurements of the height of water table and their errors are incorporated into the measurement equation to improve prediction. Results show how diminishing the measurement error increases the accuracy of the predictions, and estimates achieved with the Kalman smoother are even more accurate.
C1 Rothamsted Res, Harpenden AL5 2JQ, Herts, England.
   Univ Wageningen & Res Ctr, Soil Sci Ctr, NL-6700 AA Wageningen, Netherlands.
RP Webster, R (reprint author), Rothamsted Res, Harpenden AL5 2JQ, Herts, England.
EM richard.webster@bbsrc.ac.uk
CR ABOITIZ M, 1986, WATER RESOUR RES, V22, P180, DOI 10.1029/WR022i002p00180
   Berendrecht WL, 2004, J HYDROL, V292, P249, DOI 10.1016/j.jhydrol.2004.01.001
   Bertino L, 2003, INT STAT REV, V71, P223, DOI 10.1111/j.1751-5823.2003.tb00194.x
   Bierkens MFP, 1998, WATER RESOUR RES, V34, P2485, DOI 10.1029/98WR02298
   Box G., 1994, TIME SERIES ANAL FOR
   Cressie N., 1993, STAT SPATIAL DATA
   EVENSEN G, 1994, J GEOPHYS RES-OCEANS, V99, P10143, DOI 10.1029/94JC00572
   Gelb A., 1974, APPL OPTIMAL ESTIMAT
   Grewal M. S., 2001, KALMAN FILTERING THE
   Heemink AW, 2001, MON WEATHER REV, V129, P1718, DOI 10.1175/1520-0493(2001)129<1718:VREKF>2.0.CO;2
   Heuvelink GBM, 2001, GEODERMA, V100, P269, DOI 10.1016/S0016-7061(01)00025-8
   Hoeben R, 2000, WATER RESOUR RES, V36, P2805, DOI 10.1029/2000WR900100
   Huerta G, 2004, J ROY STAT SOC C-APP, V53, P231, DOI 10.1046/j.1467-9876.2003.05100.x
   KALMAN RE, T ASME D, V82, P35, DOI DOI 10.1115/1.3662552
   Knotters M, 1997, J HYDROL, V197, P25, DOI 10.1016/S0022-1694(96)03278-7
   Kroes JG, 2000, HYDROL PROCESS, V14, P1993, DOI 10.1002/1099-1085(20000815/30)14:11/12<1993::AID-HYP50>3.0.CO;2-#
   Kyriakidis PC, 1999, MATH GEOL, V31, P651, DOI 10.1023/A:1007528426688
   Maybeck P.S., 1979, STOCHASTIC MODELS ES, VI
   MORKOC F, 1985, SOIL SCI SOC AM J, V49, P798, DOI 10.2136/sssaj1985.03615995004900040002x
   Snepvangers JJJC, 2003, GEODERMA, V112, P253, DOI 10.1016/S0016-7061(02)00310-5
   WELCH G, 2005, KALMAN FILTER
   Wendroth O, 1999, SOIL TILL RES, V50, P85, DOI 10.1016/S0167-1987(98)00201-3
NR 22
TC 4
Z9 4
U1 4
U2 13
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1351-0754
EI 1365-2389
J9 EUR J SOIL SCI
JI Eur. J. Soil Sci.
PD OCT
PY 2006
VL 57
IS 5
BP 677
EP 692
DI 10.1111/j.1365-2389.2005.00759.x
PG 16
WC Soil Science
SC Agriculture
GA 081WV
UT WOS:000240349200008
DA 2018-12-27
ER

PT J
AU Iwamoto, J
   Takeda, T
   Sato, Y
   Shen, CL
   Yeh, JK
AF Iwamoto, Jun
   Takeda, Tsuyoshi
   Sato, Yoshihiro
   Shen, Chwan-Li
   Yeh, James K.
TI RETRACTED: Effect of pre- and post-surgery treatment with risedronate on
   trabecular bone loss in ovariectomized rats (Retracted article. See vol.
   67, pg. 393, 2018)
SO EXPERIMENTAL ANIMALS
LA English
DT Article; Retracted Publication
DE bone turnover; cancellous osteopenia; ovariectomy; pretreatment;
   risedronate
ID POSTMENOPAUSAL OSTEOPOROSIS; WOMEN; HISTOMORPHOMETRY; BISPHOSPHONATES;
   ALENDRONATE; PREVENTION; HORMONE; DENSITY
AB The purposes of the present study were to differentiate the effects of pre-surgery treatment with risedronate and post-surgery treatment with a reduced dosing frequency of risedronate on trabecular bone loss in ovariectomized rats and to determine whether postsurgery treatment with a reduced dosing frequency of risedronate would have a beneficial effect on trabecular bone loss after pre-surgery treatment with risedronate by means of bone histomorphometric analysis. The short-term experiment (6 weeks) was performed on fifty, 4-month-old, female Sprague-Dawley rats randomized into five groups (n=10 in each group). Forty rats were treated with vehicle or risedronate for 4 weeks before ovariectomy (OVX), and then treated with either vehicle or risedronate for 2 weeks following OVX (the Vehicle-OVX- Vehicle [OVX control], Vehicle-OVX-Risedronate [post-OVX treatment with risedronate], Risedronate-OVX-Vehicle [pre-OVX treatment with risedronate], and Risedronate-OVX-Risedronate [continuous treatment with risedronate] groups). The remaining 10 rats were treated with vehicle for 6 weeks, with a sham operation performed 4 weeks after the start of the experiment (the Vehicle-Sham-Vehicle [Sham control] group). During the 4 weeks prior to surgery, risedronate was administered five times a week subcutaneously at a dose of Z5 mu g/kg body weight, and during the 2 weeks after surgery, the dosing frequency was reduced to twice a week. The long-term experiment (10 weeks) had the same design as the short-term one, except that the post-OVX treatment was 6 weeks. In the short-term experiment, both pre- and post-OVX treatments with risedronate prevented trabecular bone loss of the proximal tibial metaphysis 2 weeks after OVX. In long-term experiment, however, pre- and post-OVX treatments with risedronate attenuated trabecular bone loss until 6 weeks after OVX, with pre-OVX treatment having a less pronounced effect than post-OVX treatment. In the short- and long-term experiments, preand post-OVX treatments had an additive effect on trabecular bone mass. The present study has shown the efficacy of pre-OVX treatment with risedronate or post-OVX treatment with a low dosing frequency of risedronate for preventing trabecular bone loss early after OVX. Post-OVX treatment with a low dosing frequency of risedronate was beneficial for attenuating trabecular bone loss late after OVX Treatment with risedronate before OVX had an additive effect on trabecular bone mass with the treatment after OVX, suggesting that treatment with a low dosing frequency of risedronate might be acceptable for reducing OVX-induced trabecular bone loss after treatment with risedronate prior to OVX.
C1 Keio Univ, Sch Med, Dept Sports Med, Shinjuku Ku, Tokyo 1608582, Japan.
   Mitate Hosp, Dept Neurol, Fukuoka, Japan.
   Texas Tech Univ, Ctr Hlth Sci, Dept Pathol, Lubbock, TX USA.
RP Iwamoto, J (reprint author), Keio Univ, Sch Med, Dept Sports Med, Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan.
CR Bone HG, 2004, NEW ENGL J MED, V350, P1189, DOI 10.1056/NEJMoa030897
   Chen QX, 2003, J CLIN ENDOCR METAB, V88, P4655, DOI 10.1210/jc.2003-030470
   Cranney A, 2002, ENDOCR REV, V23, P570, DOI 10.1210/er.2001-9002
   Erben RG, 1997, J HISTOCHEM CYTOCHEM, V45, P307, DOI 10.1177/002215549704500215
   Erben RG, 2002, J BONE MINER RES, V17, P1498, DOI 10.1359/jbmr.2002.17.8.1498
   Fleisch H, 1998, ENDOCR REV, V19, P80, DOI 10.1210/er.19.1.80
   GAMBACCIANI M, 1994, MATURITAS, V18, P191, DOI 10.1016/0378-5122(94)90125-2
   Khan AA, 2004, J CLIN DENSITOM, V7, P85, DOI 10.1385/JCD:7:1:85
   LEU CT, 2005, BONE
   LIN BY, 1994, BONE, V15, P489, DOI 10.1016/8756-3282(94)90272-0
   Mashiba T, 2000, J BONE MINER RES, V15, P613, DOI 10.1359/jbmr.2000.15.4.613
   Mellstrom DD, 2004, CALCIFIED TISSUE INT, V75, P462, DOI 10.1007/s00223-004-0286-7
   NANCOLLAS GH, 2005, BONE
   Otomo H, 2004, J BONE MINER METAB, V22, P404, DOI 10.1007/s00774-004-0502-6
   PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617
   Prakasam G, 1999, BONE, V24, P491, DOI 10.1016/S8756-3282(99)00018-6
   Ravn P, 1999, ANN INTERN MED, V131, P935, DOI 10.7326/0003-4819-131-12-199912210-00005
NR 17
TC 5
Z9 5
U1 0
U2 1
PU INT PRESS EDITING CENTRE INC
PI TOKYO
PA 1-2-3 SUGAMO, TOSHIMA-KU, TOKYO, 170 0002, JAPAN
SN 1341-1357
EI 1881-7122
J9 EXP ANIM TOKYO
JI Exp. Anim.
PD OCT
PY 2006
VL 55
IS 5
BP 457
EP 466
DI 10.1538/expanim.55.457
PG 10
WC Veterinary Sciences; Zoology
SC Veterinary Sciences; Zoology
GA 098MY
UT WOS:000241528100007
PM 17090962
OA Bronze
DA 2018-12-27
ER

PT J
AU Narayanan, NK
   Narayanan, BA
   Bosland, M
   Condon, MS
   Nargi, D
AF Narayanan, Narayanan K.
   Narayanan, Bhagavathi A.
   Bosland, Maarten
   Condon, Mark S.
   Nargi, Dominick
TI RETRACTED: Docosahexaenoic acid in combination with celecoxib modulates
   HSP70 and p53 proteins in prostate cancer cells (Retracted article. See
   vol. 138, pg. 2050, 2016)
SO INTERNATIONAL JOURNAL OF CANCER
LA English
DT Article; Retracted Publication
DE n-3 PUFA; docosahexaenoic acid; COX-2 inhibitor; proteomics; prostate
   cancer
ID NONSTEROIDAL ANTIINFLAMMATORY DRUGS; HEAT-SHOCK PROTEINS;
   POLYUNSATURATED FATTY-ACIDS; NITRIC-OXIDE SYNTHASE; COLON-CANCER;
   CYCLOOXYGENASE-2 INHIBITOR; INDUCED APOPTOSIS; DIFFERENTIAL EXPRESSION;
   GROWTH-INHIBITION; PIFITHRIN-ALPHA
AB The role of cyclooxygenase-2 (COX-2) and the mechanism by which it influences the development and behavior of prostate cancer is unclear. Selective COX-2 inhibitors may be effective against prostate cancer via COX-2-independent mechanisms. But administration of high doses of COX-2 inhibitors over longer period of time may not be devoid of side effects. There is increasing interest in using COX-2 inhibitors in combination with other chemopreventive agents to overcome the issue of toxicity. However, the molecular mechanisms underlying their combined actions are not well understood. Therefore, the present study was designed to determine the effects of low doses of docosahexaenoic acid (DHA) in combination with celecoxib on the molecular targets at the proteins level in rat prostate cancer cells. Two-dimensional gel electrophoresis, in combination with mass spectrometry analysis, was used for protein identification. Western blot analysis confirmed the proteins identified. Paraffin-embedded tissue sections from the rat prostate tumor were used to detect base level expression of heat shock protein 70 (HSP70) and p53. The rate of cancer cell growth was inhibited more effectively (p < 0.01) by DHA in combination with celecoxib at lower doses (2.5 mu M each). A total number of twelve proteins were differentially expressed by the combined action of DHA and celecoxib at low doses. It was interesting to note that these agents activated both HSP70 and p53 proteins. Activation of HSP70 by the combined actions of DHA and celecoxib in the presence of wild-type p53 reveals a unique COX-2 in dependent mode of action against prostate cancer. (c) 2006 Wiley-Liss, Inc.
C1 NYU, Sch Med, Dept Environm Med, Tuxedo Pk, NY 10987 USA.
   SUNY, Dutchess Community Coll, Poughkeepsie, NY USA.
RP Narayanan, NK (reprint author), NYU, Sch Med, Dept Environm Med, Tuxedo Pk, NY 10987 USA.
EM nnarayan@env.med.nyu.edu
FU NCI NIH HHS [CA-17613, CA106286]
CR Aronson AJ, 2001, UROLOGY, V58, P283, DOI 10.1016/S0090-4295(01)01116-5
   Asea A, 2002, J BIOL CHEM, V277, P15028, DOI 10.1074/jbc.M200497200
   Bartek J, 1992, Cas Lek Cesk, V131, P737
   Baryshev M, 2004, J MOL ENDOCRINOL, V32, P903, DOI 10.1677/jme.0.0320903
   BONAY M, 1994, AM J RESP CELL MOL, V10, P453, DOI 10.1165/ajrcmb.10.4.8136161
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
   Calviello G, 1999, LIPIDS, V34, P599, DOI 10.1007/s11745-999-0404-6
   Cappello F, 2005, BMC CANCER, V5, DOI 10.1186/1471-2407-5-139
   Chen YC, 1996, MOL CARCINOGEN, V17, P224, DOI 10.1002/(SICI)1098-2744(199612)17:4<224::AID-MC6>3.3.CO;2-I
   Chung BH, 2001, CARCINOGENESIS, V22, P1201, DOI 10.1093/carcin/22.8.1201
   Collett ED, 2001, AM J PHYSIOL-CELL PH, V280, pC1066
   Condon MS, 1999, MOL CARCINOGEN, V25, P179, DOI 10.1002/(SICI)1098-2744(199907)25:3<179::AID-MC4>3.3.CO;2-J
   Dandekar DS, 2005, INT J CANCER, V115, P484, DOI 10.1002/ijc.20878
   Dennis LK, 2002, UROLOGY, V60, P78, DOI 10.1016/S0090-4295(02)01637-0
   Dewailly E, 2003, CANCER EPIDEM BIOMAR, V12, P926
   Fosslien E, 1998, ANN CLIN LAB SCI, V28, P67
   Gambaro G, 2003, J INTERN MED, V253, P643, DOI 10.1046/j.1365-2796.2003.01146.x
   Grau MV, 2005, CANCER EPIDEM BIOMAR, V14, P2353, DOI 10.1158/1055-9965.EPI-05-0003
   GRESS TM, 1994, CANCER RES, V54, P547
   Gupta S, 2000, PROSTATE, V42, P73, DOI 10.1002/(SICI)1097-0045(20000101)42:1<73::AID-PROS9>3.0.CO;2-G
   Hwang Daniel H., 2002, Neoplasia (New York), V4, P91, DOI 10.1038/sj.neo.7900226
   Irani J, 1999, UROLOGY, V54, P467, DOI 10.1016/S0090-4295(99)00152-1
   Ishihara K, 2004, EUR J BIOCHEM, V271, P4552, DOI 10.1111/j.1432-1033.2004.04419.x
   Ito A, 2006, CANCER IMMUNOL IMMUN, V55, P320, DOI 10.1007/s00262-005-0049-y
   Jacoby RF, 2004, GASTROENTEROLOGY, V127, P838, DOI 10.1053/j.gastro.2004.06.003
   Jemal A, 2005, CA-CANCER J CLIN, V55, P10, DOI 10.3322/canjclin.55.1.10
   Kamishima T, 1997, PATHOL INT, V47, P166, DOI 10.1111/j.1440-1827.1997.tb03735.x
   Kaur J, 1997, INT J CANCER, V74, P609, DOI 10.1002/(SICI)1097-0215(19971219)74:6<609::AID-IJC9>3.0.CO;2-Y
   Kaur J, 1995, INT J CANCER, V63, P774, DOI 10.1002/ijc.2910630604
   Kiang JG, 1998, PHARMACOL THERAPEUT, V80, P183, DOI 10.1016/S0163-7258(98)00028-X
   Kirschenbaum A, 2000, UROLOGY, V56, P671, DOI 10.1016/S0090-4295(00)00674-9
   Komarova EA, 2003, J BIOL CHEM, V278, P15465, DOI 10.1074/jbc.C300011200
   Lazaris AC, 1997, BREAST CANCER RES TR, V43, P43, DOI 10.1023/A:1005706110275
   Li WX, 1996, RADIAT RES, V145, P324, DOI 10.2307/3578988
   Lipinski KS, 2006, CANCER IMMUNOL IMMUN, V55, P347, DOI 10.1007/s00262-005-0014-9
   Liu GM, 2003, J BIOL CHEM, V278, P2124, DOI 10.1074/jbc.M202443200
   Madaan S, 2000, BJU INT, V86, P736, DOI 10.1046/j.1464-410x.2000.00867.x
   Maehara Y, 2000, ONCOLOGY-BASEL, V58, P144, DOI 10.1159/000012091
   Miller R. G., 1981, SIMULTANEOUS STAT IN
   Murphy PJM, 2004, J BIOL CHEM, V279, P30195, DOI 10.1074/jbc.M403539200
   Narayanan BA, 2004, CLIN CANCER RES, V10, P7727, DOI 10.1158/1078-0432.CCR-04-0732
   Narayanan BA, 2003, CLIN CANCER RES, V9, P3503
   Narayanan BA, 2003, CANCER RES, V63, P972
   Narayanan NK, 2004, CANCER DETECT PREV, V28, P443, DOI 10.1016/j.cdp.2004.08.009
   Narayanan NK, 2005, INT J ONCOL, V26, P785
   Nelson WG, 2002, CANCER METAST REV, V21, P3, DOI 10.1023/A:1020110718701
   Norrish AE, 1999, BRIT J CANCER, V81, P1238, DOI 10.1038/sj.bjc.6690835
   Nylandsted J, 2004, PFLUG ARCH EUR J PHY, V449, P175, DOI 10.1007/s00424-004-1332-z
   OFARRELL PH, 1975, J BIOL CHEM, V250, P4007
   Patel MI, 2005, CLIN CANCER RES, V11, P1999, DOI 10.1158/1078-0432.CCR-04-1877
   Perazella MA, 2001, AM J MED, V111, P64, DOI 10.1016/S0002-9343(01)00757-4
   Rainsford KD, 2001, J PHYSIOL-PARIS, V95, P11, DOI 10.1016/S0928-4257(01)00004-3
   Reddy BS, 2005, CANCER RES, V65, P8022, DOI 10.1158/0008-5472.CAN-05-0212
   Reddy BS, 2000, CANCER RES, V60, P293
   ROSE DP, 1988, CARCINOGENESIS, V9, P603, DOI 10.1093/carcin/9.4.603
   Schloss I, 1997, S AFR MED J, V87, P152
   Shappell SB, 2001, NEOPLASIA, V3, P287, DOI 10.1038/sj.neo.7900166
   Shureiqi I, 2000, CANCER RES, V60, P6846
   Solomon SD, 2005, NEW ENGL J MED, V352, P1071, DOI 10.1056/NEJMoa050405
   Song XQ, 2002, J NATL CANCER I, V94, P585
   Subbaramaiah K, 2003, TRENDS PHARMACOL SCI, V24, P96, DOI 10.1016/S0165-6147(02)00043-3
   Tanimura Susumu, 2004, Nihon Rinsho, V62, P1291
   Tanji N, 2000, ANTICANCER RES, V20, P2313
   Terry PD, 2003, AM J CLIN NUTR, V77, P532
   Vabulas RM, 2002, J BIOL CHEM, V277, P15107, DOI 10.1074/jbc.M111204200
   Wagner M, 2005, BIOCHEM BIOPH RES CO, V332, P800, DOI 10.1016/j.bbrc.2005.05.025
   Wang MH, 2004, BRIT J CANCER, V90, P926, DOI 10.1038/sj.bjc.6601583
   Wang WZ, 2005, CLIN CANCER RES, V11, P3250, DOI 10.1158/1078-0432.CCR-04-2405
   Waskewich C, 2002, CANCER RES, V62, P2029
   WEITZMAN SA, 1990, BLOOD, V76, P655
   Yeo M, 2004, PROTEOMICS, V4, P3335, DOI 10.1002/pmic.200400951
   Zha S, 2001, CANCER RES, V61, P8617
   Zhang XP, 1999, J EXP MED, V190, P451, DOI 10.1084/jem.190.4.451
NR 73
TC 31
Z9 32
U1 3
U2 10
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0020-7136
EI 1097-0215
J9 INT J CANCER
JI Int. J. Cancer
PD OCT 1
PY 2006
VL 119
IS 7
BP 1586
EP 1598
DI 10.1002/ijc.22031
PG 13
WC Oncology
SC Oncology
GA 077QX
UT WOS:000240046000010
PM 16646082
DA 2018-12-27
ER

PT J
AU Kim, DH
   Cho, JH
AF Kim, Dong Hwa
   Cho, Jae Hoon
TI RETRACTED: A biologically inspired intelligent PID controller tuning for
   AVR systems (Retracted article. See vol. 9, pg. 814, 2011)
SO INTERNATIONAL JOURNAL OF CONTROL AUTOMATION AND SYSTEMS
LA English
DT Article; Retracted Publication
DE bacterial foraging optimization; genetic algorithm; hybrid system;
   optimal algorithm
ID PARTICLE SWARM OPTIMIZATION; EVOLUTIONARY ALGORITHMS; IDENTIFICATION
AB This paper proposes a hybrid approach involving Genetic Algorithm (GA) and Bacterial Foraging (BF) for tuning the PID controller of an AVR. Recently the social foraging behavior of E. coli bacteria has been used to solve optimization problems. We first illustrate the proposed method using four test functions and the performance of the algorithm is studied with an emphasis on mutation, crossover, variation of step sizes, chemotactic steps, and the life time of the bacteria. Further; the proposed algorithm is used for tuning the PID controller of an AVR. Simulation results are very encouraging and this approach provides us a novel hybrid model based on foraging behavior with a possible new connection between evolutionary forces in social foraging and distributed non-gradient optimization algorithm design for global optimization over noisy surfaces.
C1 Hanbat Natl Univ, Sch Elect Elect Control & Instrumentat Engn, Taejon 305716, South Korea.
   Chungbuk Natl Univ, Sch Elect & Comp Engn, Chungbuk 361763, South Korea.
RP Kim, DH (reprint author), Hanbat Natl Univ, Sch Elect Elect Control & Instrumentat Engn, San 16-1, Taejon 305716, South Korea.
EM kimdh@hanbat.ac.kr; jhcho@hanbat.ac.kr
CR Alcock J., 1998, ANIMAL BEHAV EVOLUTI
   Arabas J., 1994, Proceedings of the First IEEE Conference on Evolutionary Computation. IEEE World Congress on Computational Intelligence (Cat. No.94TH0650-2), P73, DOI 10.1109/ICEC.1994.350039
   Bell WJ, 1991, SEARCHING BEHAV BEHA
   Collins R. J., 1991, P 4 INT C GEN ALG, P249
   Dong Hwa Kim, 2004, WSEAS Transactions on Systems, V3, P2834
   Dotoli M, 2001, SMCIA/01: PROCEEDINGS OF THE 2001 IEEE MOUNTAIN WORKSHOP ON SOFT COMPUTING IN INDUSTRIAL APPLICATIONS, P65, DOI 10.1109/SMCIA.2001.936730
   Fleming PJ, 2002, CONTROL ENG PRACT, V10, P1223, DOI 10.1016/S0967-0661(02)00081-3
   Fonseca CM, 1998, IEEE T SYST MAN CY A, V28, P26, DOI 10.1109/3468.650319
   Gray GJ, 1998, CONTROL ENG PRACT, V6, P1341, DOI 10.1016/S0967-0661(98)00087-2
   Grunbaum D, 1998, EVOL ECOL, V12, P503, DOI 10.1023/A:1006574607845
   Juang CF, 2004, IEEE T SYST MAN CY B, V34, P997, DOI 10.1109/TSMCB.2003.818557
   KIM DH, 2004, LECT NOTES COMPUTER
   KIM DH, 2005, LECT NOTES COMPUTER
   Krah JO, 1999, IEEE T IND APPL, V35, P1039, DOI 10.1109/28.793364
   KRISTINSSON K, 1992, IEEE T SYST MAN CYB, V22, P1033, DOI 10.1109/21.179842
   LIN CL, 2000, P NAT SCI COUNC ROCA, V24, P15
   Maione B., 2001, P EUR CONTR C PORT P, P3570
   Michalewicz Z., 1999, GENETIC ALGORITHMS D
   Passino K. M., 2001, BIOMIMICRY BACTERIAL
   Passino KM, 2002, IEEE CONTR SYST MAG, V22, P52, DOI 10.1109/MCS.2002.1004010
   Stephens D. W, 1986, FORAGING THEORY
   TANESE R, 1989, PROCEEDINGS OF THE THIRD INTERNATIONAL CONFERENCE ON GENETIC ALGORITHMS, P434
   Tsutsui S, 2002, IEEE C EVOL COMPUTAT, P974, DOI 10.1109/CEC.2002.1007057
   Yoshida H, 2000, IEEE T POWER SYST, V15, P1232, DOI 10.1109/59.898095
NR 24
TC 30
Z9 33
U1 0
U2 9
PU INST CONTROL ROBOTICS & SYSTEMS, KOREAN INST ELECTRICAL ENGINEERS
PI BUCHEON
PA BUCHEON TECHNO PARK 401-1506, 193 YAKDAE-DONG WONMI-GU, BUCHEON,
   GYEONGGI-DO 420-734, SOUTH KOREA
SN 1598-6446
EI 2005-4092
J9 INT J CONTROL AUTOM
JI Int. J. Control Autom. Syst.
PD OCT
PY 2006
VL 4
IS 5
BP 624
EP 636
PG 13
WC Automation & Control Systems
SC Automation & Control Systems
GA 089KV
UT WOS:000240880400010
DA 2018-12-27
ER

PT J
AU Blanco, G
   Lemus, JA
   Grande, J
AF Blanco, Guillermo
   Lemus, Jesus A.
   Grande, Javier
TI RETRACTED: Faecal bacteria associated with different diets of wintering
   red kites: influence of livestock carcass dumps in microflora alteration
   and pathogen acquisition (Retracted article. See vol. 50, pg. 805, 2013)
SO JOURNAL OF APPLIED ECOLOGY
LA English
DT Article; Retracted Publication
DE carrion; intestinal microflora; Milvus milvus; muladares; Salmonella;
   scavenger diet
ID WILD BIRDS; SALMONELLOSIS; MORTALITY; ZOONOSES; DISEASES; RAPTORS;
   THREATS; HEALTH; MILVUS; SPAIN
AB 1. Despite the important role of refuse dumps for the conservation of threatened avian scavengers, there is no information about the direct effects on scavenger health from feeding on meat remains found at these places, including the potential for exposure to infections agents and harmful chemical residues.
   2. We assessed the composition, species richness and prevalence of faecal microflora of wintering red kites Milvus milvus in two areas of central Spain where kites fed primarily on carrion from stabled livestock reared in intensive conditions (Segovia) versus those that fed on wild rabbits Oryctolagus cuniculus (Madrid).
   3. Faecal bacterial flora composition, species richness and prevalence differed between areas. These differences were attributed to diet and the environmental conditions found at the sites where the kites obtained most of their food. The intestinal microflora of kites feeding on carrion from stabled livestock (mostly fattening pigs) differed from the flora considered to be normal for a healthy raptor.
   4. Salmonella sp. was found in a relatively high proportion of samples from Segovia (25%), 6% of those samples yielded in pure culture (serotypes enteritidis and gallinarum). If these serotypes cause disease in kites and other raptors, as they do for poultry and some other birds, there may be cause for concern regarding the health of an important sector of the red kite wintering population.
   5. Synthesis and applications. Conservation of wintering red kites in Spain should involve management to promote the recovery of populations of wild prey, especially wild rabbits, and measures to allow free-range livestock carcasses to be placed in the countryside for scavenger elimination without posing a risk from the spread and transfer of disease, especially bovine spongiform encephalopathy (BSE). Periodic inspections by management agencies should ensure that meat originating from stabled livestock and disposed of in refuse dumps does not pose major hazards for avian scavengers. The risk to scavengers from ingestion of residues of veterinary drugs, pathogen acquisition and gut flora alteration, arising from disposal and accumulation of infected carcasses and rotten meat in refuse dumps, must be carefully monitored and managed.
C1 UCLM, CSIC, JCCM, IREC, Ciudad Real 13005, Spain.
RP Blanco, G (reprint author), UCLM, CSIC, JCCM, IREC, C Ronda de Toledo S-N, Ciudad Real 13005, Spain.
EM gblanco@irec.uclm.es
RI Blanco, Guillermo/L-3170-2014
OI Blanco, Guillermo/0000-0001-5742-4929
CR ANGULO FJ, 2004, REV SCI TECH OIE, V23, P467
   BANGERT RL, 1988, AVIAN DIS, V32, P53, DOI 10.2307/1590948
   Battisti A, 1998, J WILDLIFE DIS, V34, P64, DOI 10.7589/0090-3558-34.1.64
   Bengis RH, 2004, REV SCI TECH OIE, V23, P497
   Blanco G, 1997, J RAPTOR RES, V31, P71
   Blanco G., 2004, SPATIAL ANAL RAPTOR, P133
   Blanco Juan Carlos, 1990, Ardeola, V37, P267
   BRITTINGHAM MC, 1988, J WILDLIFE DIS, V24, P299, DOI 10.7589/0090-3558-24.2.299
   Calvete C, 2004, VET REC, V155, P388, DOI 10.1136/vr.155.13.388
   Contreras A., 2001, IMPACTO AVIFAUNA IMP
   Daszak P, 2000, SCIENCE, V287, P443, DOI 10.1126/science.287.5452.443
   Donazar Jose A., 1997, P117
   Friend M, 2001, AUK, V118, P290, DOI 10.1642/0004-8038(2001)118[0290:DEIBCF]2.0.CO;2
   Friend M., 1999, FIELD MANUAL WILDLIF, P349
   Garcia JT, 1998, IBIS, V140, P302, DOI 10.1111/j.1474-919X.1998.tb04393.x
   Green RE, 2004, J APPL ECOL, V41, P793, DOI 10.1111/j.0021-8901.2004.00954.x
   Hatch Jeremy J., 1996, International Journal of Environmental Health Research, V6, P5, DOI 10.1080/09603129609356867
   HIRALDO F, 1991, BIRD STUDY, V38, P200, DOI 10.1080/00063659109477089
   Holt J. G., 1994, BERGEYS MANUAL SYSTE
   HOUSTON D C, 1975, Journal of Wildlife Diseases, V11, P306
   Hubalek Zdenek, 1994, Acta Scientiarum Naturalium Academiae Scientiarum Bohemicae Brno, V28, P1
   Lamberski N, 2003, J AVIAN MED SURG, V17, P131, DOI 10.1647/2002-025
   LANGAN GP, 2000, LAB MED AVIAN EXOTIC, P325
   Langelier K.M., 1993, P231
   LEMBKE LL, 1985, CAN J MICROBIOL, V31, P198, DOI 10.1139/m85-038
   MAGURRAN A.E., 1988, ECOLOGICAL DIVERSITY
   MARTINEZ F, 2004, QUERCUS, V227, P69
   Moreno S, 2004, BIOL CONSERV, V118, P183, DOI 10.1016/j.biocon.2003.07.020
   Needham J.R., 1981, P3
   Ortega A., 1991, Donana Acta Vertebrata, V18, P195
   Poiani A, 2000, AUK, V117, P1061, DOI 10.1642/0004-8038(2000)117[1061:STDAPC]2.0.CO;2
   Reche MP, 2003, J VET MED B, V50, P42, DOI 10.1046/j.1439-0450.2003.00623.x
   Refsum T, 2003, J WILDLIFE DIS, V39, P64, DOI 10.7589/0090-3558-39.1.64
   Rodrigues L, 2003, BRAZ J MICROBIOL, V34, P218
   Schneitz C, 2005, FOOD CONTROL, V16, P657, DOI 10.1016/j.foodcont.2004.06.002
   Serrano Larraz David, 1999, Journal of Raptor Research, V33, P338
   Shultz S., 2004, P ROY SOC LOND B BIO, V271, P5458, DOI DOI 10.1098/RSBL.2004.0223
   Sunyer Carlos, 1994, Ardeola, V41, P161
   Tella JL, 2001, NATURE, V410, P408, DOI 10.1038/35068717
   THIOLLAY JM, 2001, RAPTOR NEWS, V2, P29
   Thorns CJ, 2000, REV SCI TECH OIE, V19, P226, DOI 10.20506/rst.19.1.1219
   Tizard I, 2004, SEMIN AVIAN EXOT PET, V13, P50, DOI 10.1053/j.saep.2004.01.008
   VINUELA J, 1999, EL MILANO REAL ESPAN
   WINSOR DK, 1981, APPL ENVIRON MICROB, V42, P1123
   WRAY C, 2000, SALMONELLA DOMESTIC
NR 45
TC 35
Z9 38
U1 5
U2 29
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0021-8901
J9 J APPL ECOL
JI J. Appl. Ecol.
PD OCT
PY 2006
VL 43
IS 5
BP 990
EP 998
DI 10.1111/j.1365-2664.2006.01200.x
PG 9
WC Biodiversity Conservation; Ecology
SC Biodiversity & Conservation; Environmental Sciences & Ecology
GA 076WB
UT WOS:000239987700016
DA 2018-12-27
ER

PT J
AU Bezstarosti, K
   Das, S
   Lamers, JMJ
   Das, DK
AF Bezstarosti, Karel
   Das, Samarjit
   Lamers, Jos. M. J.
   Das, Dipak K.
TI RETRACTED: Differential proteomic profiling to study the mechanism of
   cardiac pharmacological preconditioning by resveratrol (Retracted
   article. See vol. 16, pg. 2548, 2012)
SO JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
LA English
DT Article; Retracted Publication
DE ischemia/reperfusion; heart; resveratrol; proteomics; alpha
   B-crystallin; hsp27; phosphatidylethanolamine binding protein
ID ELEMENT-BINDING PROTEIN; SIGNALING COMPLEXES; ADENOSINE-A(3) RECEPTOR;
   CARDIOMYOCYTE APOPTOSIS; MYOCARDIAL-ISCHEMIA; RAT HEARTS; ACTIVATION;
   REPERFUSION; SURVIVAL; HYPERTROPHY
AB Recent studies demonstrated that resveratrol, a grape-derived polyphenolic phytoalexin, provides pharmacological preconditioning of the heart through a NO-dependent mechanism. To further explore the molecular mechanisms involved in resveratrol-mediated cardioprotection, we monitored the effects of resveratrol treatment after ischemia-reperfusion on the protein profile by implementation of proteomic analysis. Two groups of rats were studied; one group of animals was fed resveratrol for 7 days, while the other group was given vehicle only. The rats were sacrificed for the isolated working heart preparation and for isolation of cytoplasmic fraction from left ventricle homogenates to carry out the proteomic as well as immunoblot at baseline and at the end of 30 min ischemia/2-h perfusion. The results demonstrate significant cardioprotection with resveratrol evidenced by improved ventricular recovery and reduced infarct size and cardiomyocyte apoptosis. The left ventricular cytoplasmic fractions were separated by two-dimensional electrophoresis (2-DE). Differentially regulated proteins were detected with quantitative computer analysis of the Coomassie blue stained 2-DE images and identified by MALDI-TOF (MS) and nanoLC-ESI-Q-TOF mass spectrometry (MS/MS). Five redox-regulated and preconditioning-related proteins were identified that were all upregulated by resveratrol: MAPKK, two different alpha B-crystallin species, HSP 27 and PE binding protein. Another HSP27 species and aldose reductase were downregulated and peroxiredoxin-2 remained constant. The results of the immunoblot analysis of phosphorylated MAPKK, -HSP27 and -alpha B-ctystallin and PE binding protein were consistent with the proteomic findings, but not with peroxiredoxin-2. The proteomic analysis showed also downregulation of some proteins in the mitochondrial respiratory chain and matrix and the myofilament regulating protein MLC kinase-2. The results of the present study demonstrate that proteomic profiling enables the identification of resveratrol induced preconditioning-associated proteins which reflects not only changes in their expression level but also isoforms, post-translational modifications and regulating binding or activating partner proteins.
C1 Univ Connecticut, Sch Med, Cardiovasc Res Ctr, Farmington, CT 06030 USA.
   Erasmus MC, Cardiovasc Res Sch COEUR, Dept Biochem, Rotterdam, Netherlands.
RP Das, DK (reprint author), Univ Connecticut, Sch Med, Cardiovasc Res Ctr, Farmington, CT 06030 USA.
EM DDAS@NEURON.UCHC.EDU
FU NHLBI NIH HHS [HL22559, HL 34360, HL33889]
CR Arrell DK, 2001, CIRC RES, V88, P763, DOI 10.1161/hh0801.090193
   Arrell DK, 2001, CIRC RES, V89, P480, DOI 10.1161/hh1801.097240
   Bradamante S, 2000, INT J TISSUE REACT, V22, P1
   Das DK, 2001, ANTIOXID REDOX SIGN, V3, P23, DOI 10.1089/152308601750100461
   Das DK, 2006, MOL INTERV, V6, P36, DOI 10.1124/mi.6.1.7
   Das S, 2005, VASC PHARMACOL, V42, P281, DOI 10.1016/j.vph.2005.02.013
   Das S, 2005, AM J PHYSIOL-HEART C, V288, pH328, DOI 10.1152/ajpheart.00453.2004
   Das S, 2005, J PHARMACOL EXP THER, V314, P762, DOI 10.1124/jpet.105.084285
   Das S, 2006, J PHARMACOL EXP THER, V317, P980, DOI 10.1124/jpet.105.095133
   Edmondson RD, 2002, MOL CELL PROTEOMICS, V1, P421, DOI 10.1074/mcp.M100036-MCP200
   ENGELMAN DT, 1995, CARDIOVASC RES, V29, P133, DOI 10.1016/0008-6363(96)88558-0
   Faber MJ, 2006, CELL BIOCHEM BIOPHYS, V44, P11, DOI 10.1385/CBB:44:1:011
   Faber MJ, 2005, PROTEOMICS, V5, P2519, DOI 10.1002/pmic.200401313
   Hattori R, 2002, AM J PHYSIOL-HEART C, V282, pH1988, DOI 10.1152/ajpheart.01012.2001
   Hung LM, 2000, CARDIOVASC RES, V47, P549, DOI 10.1016/S0008-6363(00)00102-4
   Hung LM, 2004, FREE RADICAL BIO MED, V36, P774, DOI 10.1016/j.freeradbiomed.2003.12.016
   IMAMURA G, 2000, AM J PHYSIOL-HEART C, V282, pH1996
   Kopp P, 1998, EUR J ENDOCRINOL, V138, P619, DOI 10.1530/eje.0.1380619
   Kutuk O, 2006, TOXICOL SCI, V90, P120, DOI 10.1093/toxsci/kfj055
   Larn L, 2006, INT J CARDIOL, V108, P12, DOI 10.1016/j.ijcard.2206.01.002
   Maulik N, 1996, FEBS LETT, V396, P233, DOI 10.1016/0014-5793(96)01109-X
   Maulik N, 2000, FEBS LETT, V485, P7, DOI 10.1016/S0014-5793(00)02174-8
   McGregor E, 2006, CIRC RES, V98, P309, DOI 10.1161/01.RES.0000201280.20709.26
   Pataki T, 2002, AM J CLIN NUTR, V75, P894
   Ping PP, 2003, CIRC RES, V93, P595, DOI 10.1161/01.RES.0000093221.98213.E0
   Ray PS, 2001, FASEB J, V15, P393, DOI 10.1096/fj.00-0199com
   Sato M, 2000, AM J PHYSIOL-HEART C, V279, pH901
   Uchiyama T, 2004, CIRCULATION, V109, P3042, DOI 10.1161/01.CIR.0000130647.29030.90
   Van Eyk JE, 2001, CURR OPIN MOL THER, V3, P546
   Vondriska TM, 2003, J MOL CELL CARDIOL, V35, P1027, DOI 10.1016/S0022-2828(03)00175-5
   Wang XJ, 2004, J BIOL CHEM, V279, P45855, DOI 10.1074/jbc.M405147200
   Yeung K, 1999, NATURE, V401, P173
NR 32
TC 15
Z9 18
U1 3
U2 16
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1582-4934
J9 J CELL MOL MED
JI J. Cell. Mol. Med.
PD OCT-DEC
PY 2006
VL 10
IS 4
BP 896
EP 907
DI 10.2755/jcmm010.004.12
PG 12
WC Cell Biology; Medicine, Research & Experimental
SC Cell Biology; Research & Experimental Medicine
GA 117MG
UT WOS:000242876700008
PM 17125593
DA 2018-12-27
ER

PT J
AU Kim, JD
   Lee, CG
AF Kim, Jeong-Dong
   Lee, Choul-Gyun
TI RETRACTED: Antialgal effect of a novel polysaccharolytic Sinorhizobium
   kostiense AFK-13 on Anabaena flos-aquae causing water bloom (Retracted
   Article. See vol 17, pg 1908, 2007)
SO JOURNAL OF MICROBIOLOGY AND BIOTECHNOLOGY
LA English
DT Article; Retracted Publication
DE algal lytic bacteria; Sinorhizobium kostiense; extracellular products;
   polysaccharolytic enzyme; Anabaena flos-aquae
ID BIOLOGICAL-CONTROL; ENZYME-ACTIVITY; CYANOBACTERIA; IDENTIFICATION;
   BACTERIA; PURIFICATION; GYMNODINIUM; DEGRADATION; BIOMASS
AB Isolation and identification of algal lytic bacteria were carried out. Nine strains of algal lytic bacteria were isolated by the double-layer method using Anabaena flos-aquae as a sole nutrient. The isolate, AFK-13, showing the highest algal lytic activity was identified as Sinorhizobium kostiense based on the 16S rDNA sequence. The algal lytic experiments of the culture supernatants of AFK-13 demonstrated that the bacterial cell growth reached a maximum at 36-h culture, but the supernatant of 72-h culture exhibited the highest activity. Components among the extracellular products in the crude enzyme of the supernatant from S. kostiense AFK-13 culture were responsible for degradation of cell walls of Anabaena flos-aquae. Algal lytic assay tests of the culture supernatants suggest that the main substances for algal lytic activity could be proteinaceous. The activity of glucosidase was observed highly by polysaccharolytic analysis using the crude enzyme from S. kostiense AFK-13, whereas activities of galactosidase, mannosidase, rhamnosidase, and arabinosidase were also detected in low levels. The molecular weights (MW) of alpha- and beta-glucosidases were estimated to be approximately 50-100 kDa by the ultrafiltration method.
C1 Inha Univ, Dept Biol Engn, Inst Ind Biotechnol, Inchon 402751, South Korea.
RP Lee, CG (reprint author), Inha Univ, Dept Biol Engn, Inst Ind Biotechnol, Inchon 402751, South Korea.
EM leecg@inha.ac.kr
OI Lee, Choul-Gyun/0000-0002-4684-7990
CR APHA, 1998, STAND METH EX WAT WA
   BEGUIN P, 1994, FEMS MICROBIOL REV, V13, P25, DOI 10.1016/0168-6445(94)90099-X
   BEGUIN P, 1990, ANNU REV MICROBIOL, V44, P219, DOI 10.1146/annurev.mi.44.100190.001251
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
   BURNHAM JC, 1976, J PHYCOL, V12, P306, DOI 10.1111/j.1529-8817.1976.tb02849.x
   BURNS EM, 1981, NEUROBIOL AGING, V2, P285, DOI 10.1016/0197-4580(81)90037-3
   CARMICHAEL WW, 1993, DOKL AKAD NAUK+, V330, P659
   CASTENHOLZ RW, 1988, METHOD ENZYMOL, V167, P68
   CHET I, 1967, CAN J MICROBIOL, V13, P137, DOI 10.1139/m67-019
   Choi HJ, 2005, BIOL CONTROL, V33, P335, DOI 10.1016/j.biocontrol.2005.03.007
   CHROST RJ, 1992, HYDROBIOLOGIA, V243, P61, DOI 10.1007/BF00007020
   CHROST RJ, 1986, ARCH HYDROBIOL, V106, P79
   Chrost RJ, 1991, MICROBIAL ENZYMES AQ
   Chung S, 2005, J MICROBIOL BIOTECHN, V15, P1011
   Colombo V, 2004, BRAZ J MICROBIOL, V35, P110, DOI 10.1590/S1517-83822004000100018
   Doucette GJ, 1999, J PHYCOL, V35, P1447, DOI 10.1046/j.1529-8817.1999.3561447.x
   EOM HYUNSUK, 2005, Journal of Microbiology and Biotechnology, V15, P1060
   Farkas E, 2000, CARBOHYD RES, V328, P293, DOI 10.1016/S0008-6215(00)00113-0
   Felsenstein J, 1993, PHYLIP PHYLOGENETIC
   Gallego MV, 2001, J FOOD SCI, V66, P204, DOI 10.1111/j.1365-2621.2001.tb11317.x
   Gonzalez JM, 1996, APPL ENVIRON MICROB, V62, P4433
   Harada K, 1996, TOXICON, V34, P701, DOI 10.1016/0041-0101(95)00163-8
   IMAI I, 1993, MAR BIOL, V116, P527, DOI 10.1007/BF00355470
   Kang YH, 2005, J APPL MICROBIOL, V98, P1030, DOI 10.1111/j.1365-2672.2005.02533.x
   KHAN ZUM, 1994, WORLD J MICROB BIOT, V10, P296, DOI 10.1007/BF00414867
   Kim Jeong-Dong, 2005, Journal of Microbiology and Biotechnology, V15, P337
   Kodani S, 2002, J APPL PHYCOL, V14, P109, DOI 10.1023/A:1019533414018
   KUKIMURA Y, 1995, BIOSCI BIOTECH BIOCH, V59, P589
   Lee BS, 2005, J MICROBIOL BIOTECHN, V15, P701
   Lovejoy C, 1998, APPL ENVIRON MICROB, V64, P2806
   LUONTERI E, 1995, J BIOTECHNOL, V38, P279, DOI 10.1016/0168-1656(94)00139-4
   MCGUIRE RM, 1984, RES TECHNOL, V27, P60
   MITSUTANI A, 1987, B JAP SOC MICROBIAL, V2, P21
   MUNSTER U, 1992, HYDROBIOLOGIA, V243, P47, DOI 10.1007/BF00007019
   Nigam P, 2000, BIORESOURCE TECHNOL, V72, P219, DOI 10.1016/S0960-8524(99)00123-6
   Park JY, 2005, J MICROBIOL BIOTECHN, V15, P749
   PARSONS TR, 1963, J MAR RES, V21, P155
   REYSSAC SJ, 1990, AQUACULTURE, V88, P1
   RIPPKA R, 1988, METHOD ENZYMOL, V167, P3
   Romani AM, 2000, MICROB ECOL, V40, P16, DOI 10.1007/s002480000041
   SAITOU N, 1987, MOL BIOL EVOL, V4, P406
   SAKATA T, 1991, NIPPON SUISAN GAKK, V57, P1147
   Sigee DC, 1999, HYDROBIOLOGIA, V395, P161, DOI 10.1023/A:1017097502124
   STACKEBRANDT E, 1993, HDB NEW BACTERIAL SY, P152
   Tsuchiya Y, 1997, JPN J TOX ENV HEALTH, V43, P190
   Wang XL, 2005, HARMFUL ALGAE, V4, P433, DOI 10.1016/j.hal.2004.06.001
   Yamamoto Y, 1998, J APPL PHYCOL, V10, P391, DOI 10.1023/A:1008077414808
   Yoon JH, 1997, INT J SYST BACTERIOL, V47, P111, DOI 10.1099/00207713-47-1-111
   Yoshikawa K, 2000, APPL ENVIRON MICROB, V66, P718, DOI 10.1128/AEM.66.2.718-722.2000
NR 49
TC 7
Z9 10
U1 1
U2 9
PU KOREAN SOC MICROBIOLOGY & BIOTECHNOLOGY
PI SEOUL
PA KOREA SCI TECHNOL CENTER #507,  635-4 YEOGSAM-DONG, KANGNAM-GU, SEOUL
   135-703, SOUTH KOREA
SN 1017-7825
EI 1738-8872
J9 J MICROBIOL BIOTECHN
JI J. Microbiol. Biotechnol.
PD OCT
PY 2006
VL 16
IS 10
BP 1613
EP 1621
PG 9
WC Biotechnology & Applied Microbiology; Microbiology
SC Biotechnology & Applied Microbiology; Microbiology
GA 100QB
UT WOS:000241682500018
DA 2018-12-27
ER

PT J
AU Tamura, S
   Fukamiya, N
   Okano, M
   Koike, K
AF Tamura, Sadaaki
   Fukamiya, Narihiko
   Okano, Masayoshi
   Koike, Kazuo
TI RETRACTED: A new quassinoid, ailantinol H from Ailanthus altissima
   (Retracted article. See vol 23, pg 1161, 2009)
SO NATURAL PRODUCT RESEARCH
LA English
DT Article; Retracted Publication
DE Ailanthus altissima; Simaroubaceae; quassinoid; isolation
ID PICRASMA-AILANTHOIDES; BRUCEA-JAVANICA
AB A new quassinoid, ailantinol H, was isolated from a methanol extract of the aerial parts of Ailanthus altissima collected in Taiwan. Its structure was established on the basis of I D and 2D NMR and HREIMS spectroscopic methods.
C1 Hiroshima Univ, Fac Integrated Arts & Sci, Higashihiroshima 7398521, Japan.
   Toho Univ, Sch Pharmaceut Sci, Chiba 2748510, Japan.
RP Fukamiya, N (reprint author), Hiroshima Univ, Fac Integrated Arts & Sci, 1-7-1 Kagamiyama, Higashihiroshima 7398521, Japan.
EM nfuka@hiroshima-u.ac.jp
CR DAIDO M, 1992, J NAT PROD, V55, P1643, DOI 10.1021/np50089a013
   FUKAMIYA N, 1992, J NAT PROD, V55, P468, DOI 10.1021/np50082a011
   IMAMURA K, 1993, J NAT PROD, V56, P2091, DOI 10.1021/np50102a010
   Kubota K, 1996, J NAT PROD, V59, P683, DOI 10.1021/np960427c
   Kubota K, 1996, B CHEM SOC JPN, V69, P3613, DOI 10.1246/bcsj.69.3613
   OKANO M, 1985, B CHEM SOC JPN, V58, P1793, DOI 10.1246/bcsj.58.1793
   Okano M, 2000, STUDIES NATURAL PROD, V23, P285
   OKANO M, 1990, STUDIES NATURAL PROD, V7, P369, DOI DOI 10.1016/S1572-5995
   Rahman S, 1999, B CHEM SOC JPN, V72, P751, DOI 10.1246/bcsj.72.751
   Tamura S, 2003, CHEM PHARM BULL, V51, P385, DOI 10.1248/cpb.51.385
NR 10
TC 4
Z9 5
U1 3
U2 12
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1478-6419
EI 1478-6427
J9 NAT PROD RES
JI Nat. Prod. Res.
PD OCT
PY 2006
VL 20
IS 12
BP 1105
EP 1109
DI 10.1080/14786410600825907
PG 5
WC Chemistry, Applied; Chemistry, Medicinal
SC Chemistry; Pharmacology & Pharmacy
GA 117UK
UT WOS:000242898600013
PM 17127664
DA 2018-12-27
ER

PT J
AU Agizzio, AP
   Da Cunha, M
   Carvalho, AO
   Oliveira, MA
   Ribeiro, SFF
   Gomes, VM
AF Agizzio, Ana Paula
   Da Cunha, Maura
   Carvalho, Andre O.
   Oliveira, Marco Antonio
   Ribeiro, Suzanna F. F.
   Gomes, Valdirene M.
TI RETRACTED: The antifungal properties of a 2S albumin-homologous protein
   from passion fruit seeds involve plasma membrane permeabilization and
   ultrastructural alterations in yeast cells (Retracted article. See vol
   172, pg 1060, 2007)
SO PLANT SCIENCE
LA English
DT Article; Retracted Publication
DE 2S albumins; antifungal protein; fungal cell wall; membrane
   permeabilization; Saccharomyces cerevisiae
ID LIPID TRANSFER PROTEIN; PLANT PR-5 PROTEIN; STORAGE PROTEINS; FUNGAL
   GROWTH; OSMOTIN; RESISTANCE; ACIDIFICATION; APOPTOSIS; PEPTIDES;
   CYSTEINE
AB Different types of antimicrobial proteins were purified from plant seeds, including chifinases, beta-1,3-glucanases, defensins, thionins, lipid transfer proteins and 2S albumins. It has become clear that these groups of proteins play an important role in the protection of plants from microbial infection. Recent results from our laboratory have shown that the defense-related proteins from passion fruit seeds, named Pf1 and Pf2 (which show sequence homology with 2S albumins), inhibit fungal growth and glucose-stimulated acidification of the medium by Saccharomyces cerevisiae cells. The aim of this study was to determine whether 2S albumins from passion fruit seeds induce plasma membrane permeabilization and cause morphological alterations in yeast cells. Initially, we used an assay based on the uptake of SYTOX Green, an organic compound that fluoresces upon interaction with nucleic acids and penetrates cells with compromised plasma membranes, to investigate membrane permeabilization in S. cerevisiae cells. When viewed with a confocal laser microscope, S. cervisiae cells showed strong SYTOX Green fluorescence in the cytosol, especially in the nuclei. 2S albumins also inhibited glucose-stimulated acidification of the medium by S. cerevisiae cells, which indicates a probable impairment of fungal metabolism. The microscopical analysis of the yeast cells treated with 2S albumins demonstrated several morphological alterations in cell shape, cell surface, cell wall and bud formation, as well as in the organization of intracellular organelles. (c) 2006 Elsevier Ireland Ltd. All rights reserved.
C1 Univ Estadual Norte Fluminense, Ctr Biociencias & Biotecnol, Lab Fisiol & Bioquim Microrganismos, BR-28013602 Campos Dos Goytacazes, RJ, Brazil.
   Univ Estadual Norte Fluminense, Ctr Biociencias & Biotecnol, Lab Biol Celular & Tecidual, BR-28013602 Campos Dos Goytacazes, RJ, Brazil.
   Univ Vale Paraiba, Inst Pesquisa & Desenvolvimento, Sao Jose Dos Campos, SP, Brazil.
RP Gomes, VM (reprint author), Univ Estadual Norte Fluminense, Ctr Biociencias & Biotecnol, Lab Fisiol & Bioquim Microrganismos, BR-28013602 Campos Dos Goytacazes, RJ, Brazil.
EM valmg@uenf.br
OI Gomes, Valdirene/0000-0003-4145-428X
CR Abad LR, 1996, PLANT SCI, V118, P11, DOI 10.1016/0168-9452(96)04420-2
   Agizzio AP, 2003, ARCH BIOCHEM BIOPHYS, V416, P188, DOI 10.1016/S0003-9861(03)00313-8
   Anzlovar S, 1998, MOL PLANT MICROBE IN, V11, P610, DOI 10.1094/MPMI.1998.11.7.610
   Broekaert WF, 1997, CRIT REV PLANT SCI, V16, P297, DOI 10.1080/713608148
   Crimi M, 2006, ARCH BIOCHEM BIOPHYS, V445, P65, DOI 10.1016/j.abb.2005.10.024
   Garcia-Olmedo F, 1998, BIOPOLYMERS, V47, P479, DOI 10.1002/(SICI)1097-0282(1998)47:6<479::AID-BIP6>3.0.CO;2-K
   Gomes VM, 1997, J AGR FOOD CHEM, V45, P4110, DOI 10.1021/jf960942g
   Gomes VM, 1998, BBA-GEN SUBJECTS, V1379, P207, DOI 10.1016/S0304-4165(97)00100-1
   Ibeas JI, 2001, PLANT J, V25, P271, DOI 10.1046/j.1365-313x.2001.00967.x
   Ibeas JI, 2000, PLANT J, V23, P375, DOI 10.1046/j.1365-313x.2000.00792.x
   KREBBERS E, 1988, PLANT PHYSIOL, V87, P859, DOI 10.1104/pp.87.4.859
   Narasimhan ML, 2005, MOL CELL, V17, P171, DOI 10.1016/j.molcel.2004.11.050
   Narasimhan ML, 2001, MOL CELL, V8, P921, DOI 10.1016/S1097-2765(01)00365-3
   Regente MC, 2005, LETT APPL MICROBIOL, V40, P183, DOI 10.1111/j.1472-765X.2004.01647.x
   SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2
   Shewry PR, 1997, ADV BOT RES, V26, P135, DOI 10.1016/S0065-2296(08)60120-2
   Sitaram N, 1999, BBA-BIOMEMBRANES, V1462, P29, DOI 10.1016/S0005-2736(99)00199-6
   Tarchevsky IA, 2001, APPL BIOCHEM MICRO+, V37, P441, DOI 10.1023/A:1010267704445
   Taylor CB, 1998, PLANT CELL, V10, P873
   TERRAS FRG, 1993, FEBS LETT, V316, P233, DOI 10.1016/0014-5793(93)81299-F
   TERRAS FRG, 1992, PLANT PHYSIOL, V100, P1055, DOI 10.1104/pp.100.2.1055
   Terras FRG, 1996, PLANT PHYSIOL BIOCH, V34, P599
   THERISSEN K, 1999, APPL ENVIRON MICROB, V62, P5451
   Thomma BPHJ, 2002, PLANTA, V216, P193, DOI 10.1007/s00425-002-0902-6
   Wang X, 2000, BIOCHEM BIOPH RES CO, V279, P669, DOI 10.1006/bbrc.2000.3997
   Wang X, 2001, BIOCHEM BIOPH RES CO, V282, P1224, DOI 10.1006/bbrc.2001.4716
   YOULE RJ, 1981, AM J BOT, V68, P44, DOI 10.2307/2442990
   Yun DJ, 1998, MOL CELL, V1, P807, DOI 10.1016/S1097-2765(00)80080-5
   Yun DJ, 1997, P NATL ACAD SCI USA, V94, P7082, DOI 10.1073/pnas.94.13.7082
NR 29
TC 2
Z9 2
U1 3
U2 11
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0168-9452
J9 PLANT SCI
JI Plant Sci.
PD OCT
PY 2006
VL 171
IS 4
BP 523
EP 530
DI 10.1016/j.plantsci.2006.06.008
PG 8
WC Biochemistry & Molecular Biology; Plant Sciences
SC Biochemistry & Molecular Biology; Plant Sciences
GA 079EO
UT WOS:000240158500011
PM 25193650
DA 2018-12-27
ER

PT J
AU Alberto, CO
   Trask, RB
   Quinlan, ME
   Hirasawa, M
AF Alberto, Christian O.
   Trask, Robert B.
   Quinlan, Michelle E.
   Hirasawa, Michiru
TI RETRACTED: Bidirectional dopaminergic modulation of excitatory synaptic
   transmission in orexin neurons (Retracted article. See vol. 32, pg.
   9116, 2012)
SO JOURNAL OF NEUROSCIENCE
LA English
DT Article; Retracted Publication
DE orexin neuron; dopamine; miniature EPSC; food intake; obesity; patch
   clamp
ID NUCLEUS-ACCUMBENS SHELL; VENTRAL TEGMENTAL AREA; MELANIN-CONCENTRATING
   HORMONE; LATERAL HYPOTHALAMUS; FEEDING-BEHAVIOR; PREFRONTAL CORTEX;
   FOOD-INTAKE; GLUTAMATE RECEPTORS; ZUCKER RATS; MEAL SIZE
AB Orexin neurons in the lateral hypothalamus (LH)/perifornical area (PFA) are known to promote food intake as well as provide excitatory influence on the dopaminergic reward pathway. Dopamine (DA), in turn, inhibits the reward pathway and food intake through its action in the LH/PFA. However, the cellular mechanism by which DA modulates orexin neurons remains largely unknown. Therefore, we examined the effect of DA on the excitatory neurotransmission to orexin neurons. Whole-cell patch-clamp recordings were performed using acute rat hypothalamic slices, and orexin neurons were identified by their electrophysiological and immunohistochemical characteristics. Pharmacologically isolated action potential-independent miniatures EPSCs (mEPSCs) were monitored. Bath application of DA induced a bidirectional effect on the excitatory synaptic transmission dose dependently. A low dose of DA (1 mu M) increased mEPSC frequency, which was blocked by the D-1-like receptor antagonist SCH 23390, and mimicked by the D-1-like receptor agonist SKF 81297. In contrast, higher doses of DA (10-100 mu M) decreased mEPSC frequency, which could be blocked with the D-2-like receptor antagonist, sulpiride. Quinpirole, the D-2-like receptor agonist, also reduced mEPSC frequency. None of these compounds affected the mEPSCs amplitude, suggesting the locus of action was presynaptic. Furthermore, DA (1 mu M) induced an increase in the action potential firing, whereas DA (100 mu M) hyperpolarized and ceased the firing of orexin neurons, indicating the effect of DA on excitatory synaptic transmission may influence the activity of the postsynaptic cell. In conclusion, our results suggest that D-1- and D-2- like receptors have opposing effects on the excitatory presynaptic terminals impinging onto orexin neurons.
C1 Mem Univ Newfoundland, Div Basic Med Sci, Fac Med, St John, NF A1B 3V6, Canada.
RP Hirasawa, M (reprint author), Mem Univ Newfoundland, Div Basic Med Sci, Fac Med, 300 Prince Philip Dr,St Johns Campus, St John, NF A1B 3V6, Canada.
EM michiru@mun.ca
CR Baldo BA, 2004, EUR J NEUROSCI, V19, P376, DOI 10.1046/j.1460-9568.2003.03093.x
   Borgland SL, 2006, NEURON, V49, P589, DOI 10.1016/j.neuron.2006.01.016
   Boutrel B, 2005, P NATL ACAD SCI USA, V102, P19168, DOI 10.1073/pnas.0507480102
   Burdakov D, 2004, EUR J NEUROSCI, V20, P3281, DOI 10.1111/j.1460-9568.2004.03815.x
   Centonze D, 2004, NEUROSCIENCE, V129, P157, DOI 10.1016/j.neuroscience.2004.07.043
   CHAVEZNORIEGA LE, 1994, J NEUROSCI, V14, P310
   Chen CF, 1997, J NEUROSCI, V17, P8687
   Clegg DJ, 2002, ENDOCRINOLOGY, V143, P2995, DOI 10.1210/en.143.8.2995
   Cota D, 2006, BRAIN RES REV, V51, P85, DOI 10.1016/j.brainresrev.2005.10.004
   Eggermann E, 2003, J NEUROSCI, V23, P1557
   Epstein LH, 2006, APPETITE, V46, P22, DOI 10.1016/j.appet.2005.04.006
   Fadel J, 2002, J NEUROSCI, V22, P6742
   Fadel J, 2002, NEUROSCIENCE, V111, P379, DOI 10.1016/S0306-4522(02)00017-9
   Ferguson AV, 2003, FRONT NEUROENDOCRIN, V24, P141, DOI 10.1016/S0091-3022(03)00028-1
   Fetissov SO, 2000, NEUROSCIENCE, V101, P657, DOI 10.1016/S0306-4522(00)00374-2
   Fetissov SO, 2002, AM J PHYSIOL-REG I, V283, pR905, DOI 10.1152/ajpregu.00092.2002
   Gao XB, 2003, J NEUROPHYSIOL, V90, P3978, DOI 10.1152/jn.00593.2003
   Georgescu D, 2003, J NEUROSCI, V23, P3106
   Hara J, 2001, NEURON, V30, P345, DOI 10.1016/S0896-6273(01)00293-8
   Harris GC, 2005, NATURE, V437, P556, DOI 10.1038/nature04071
   Hirasawa M, 2003, P NATL ACAD SCI USA, V100, P6139, DOI 10.1073/pnas.0936131100
   Jo YH, 2005, NEURON, V48, P1055, DOI 10.1016/j.neuron.2005.10.021
   Kelley AE, 2005, J COMP NEUROL, V493, P72, DOI 10.1002/cne.20769
   Kelley AE, 2002, J NEUROSCI, V22, P3306
   Korotkova TM, 2003, J NEUROSCI, V23, P7
   LEIBOWITZ SF, 1979, PSYCHOPHARMACOLOGY, V61, P273, DOI 10.1007/BF00432272
   LEIBOWITZ SF, 1986, BRAIN RES BULL, V17, P681, DOI 10.1016/0361-9230(86)90200-5
   LEIBOWITZ SF, 1978, EUR J PHARMACOL, V53, P69, DOI 10.1016/0014-2999(78)90269-8
   LEIBOWITZ SF, 1975, BRAIN RES, V98, P529, DOI 10.1016/0006-8993(75)90371-6
   LEIBOWITZ SF, 1980, BRAIN RES, V201, P315, DOI 10.1016/0006-8993(80)91038-0
   Li Y, 2005, J NEUROSCI, V25, P173, DOI 10.1523/JNEUROSCI.4015-04.2004
   Li Y, 2002, NEURON, V36, P1169, DOI 10.1016/S0896-6273(02)01132-7
   MALDONADOIRIZARRY CS, 1995, J NEUROSCI, V15, P6779
   MARGULES DL, 1962, SCIENCE, V135, P374, DOI 10.1126/science.135.3501.374
   MEGUID MM, 1995, BRAIN RES BULL, V36, P487, DOI 10.1016/0361-9230(95)92128-3
   Missale C, 1998, PHYSIOL REV, V78, P189
   Morutto SL, 1998, PSYCHOPHARMACOLOGY, V136, P105, DOI 10.1007/s002130050545
   Narita M, 2006, J NEUROSCI, V26, P398, DOI 10.1523/JNEUROSCI.2761-05.2006
   PARADA MA, 1995, PHARMACOL BIOCHEM BE, V52, P179, DOI 10.1016/0091-3057(95)00086-C
   PARADA MA, 1988, PHARMACOL BIOCHEM BE, V30, P917, DOI 10.1016/0091-3057(88)90120-7
   Rada P, 2003, BEHAV NEUROSCI, V117, P222, DOI 10.1037/0735-7044.117.2.222
   Sakurai T, 1998, CELL, V92, P573, DOI 10.1016/S0092-8674(00)80949-6
   Sato T, 2001, AM J PHYSIOL-REG I, V281, pR1907
   Scislowski PWD, 1999, INT J OBESITY, V23, P425, DOI 10.1038/sj.ijo.0800893
   Seamans JK, 2001, J NEUROSCI, V21, P3628, DOI 10.1523/JNEUROSCI.21-10-03628.2001
   SEEMAN P, 1993, CURR OPIN NEUROL NEU, V6, P602
   STANLEY BG, 1993, BRAIN RES, V630, P41
   Stratford TR, 1999, J NEUROSCI, V19, P11040
   Stratford TR, 1997, J NEUROSCI, V17, P4434
   Stratford TR, 1998, BEHAV BRAIN RES, V93, P43, DOI 10.1016/S0166-4328(97)00140-X
   Sun X, 2005, J NEUROSCI, V25, P7342, DOI 10.1523/JNEUROSCI.4603-04.2005
   Thorpe AJ, 2005, PSYCHOPHARMACOLOGY, V182, P75, DOI 10.1007/s00213-005-0040-5
   Trantham-Davidson H, 2004, J NEUROSCI, V24, P10652, DOI 10.1523/JNEUROSCI.3179-04.2004
   Tsujino N, 2005, J NEUROSCI, V25, P7459, DOI 10.1523/JNEUROSCI.1193-05.2005
   Vittoz NM, 2006, NEUROPSYCHOPHARMACOL, V31, P384, DOI 10.1038/sj.npp.1300807
   Volkow ND, 2005, NAT NEUROSCI, V8, P555, DOI 10.1038/nn1452
   Yamanaka A, 2006, J NEUROPHYSIOL, V96, P284, DOI 10.1152/jn.01361.2005
   Yang ZJ, 1997, PHARMACOL BIOCHEM BE, V58, P631, DOI 10.1016/S0091-3057(97)00022-1
   YANG ZJ, 1995, NEUROREPORT, V6, P1191, DOI 10.1097/00001756-199505300-00029
   Yoshida K, 2006, J COMP NEUROL, V494, P845, DOI 10.1002/cne.20859
   Zheng HY, 2003, AM J PHYSIOL-REG I, V284, pR1436, DOI 10.1152/ajpregu.00781.2002
   Zheng P, 1999, NEUROSCIENCE, V91, P527, DOI 10.1016/S0306-4522(98)00604-6
   Zou SW, 2005, J NEUROSCI, V25, P4385, DOI 10.1523/JNEUROSCI.5099-04.2005
NR 63
TC 46
Z9 47
U1 4
U2 9
PU SOC NEUROSCIENCE
PI WASHINGTON
PA 11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA
SN 0270-6474
J9 J NEUROSCI
JI J. Neurosci.
PD SEP 27
PY 2006
VL 26
IS 39
BP 10043
EP 10050
DI 10.1523/JNEUROSCI.1819-06.2006
PG 8
WC Neurosciences
SC Neurosciences & Neurology
GA 088QH
UT WOS:000240825700023
PM 17005867
DA 2018-12-27
ER

PT J
AU Gianni, T
   Forghieri, C
   Campadelli-Fiume, G
AF Gianni, Tatiana
   Forghieri, Cristina
   Campadelli-Fiume, Gabriella
TI RETRACTED: The herpesvirus glycoproteins B and H center dot L are
   sequentially recruited to the receptor-bound gD to effect membrane
   fusion at virus entry (Retracted Article. See vol 104, pg 3668, 2007)
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article; Retracted Publication
DE complex; herpes simplex virus
ID CELL-CELL FUSION; SIMPLEX-VIRUS; HUMAN CYTOMEGALOVIRUS;
   HERPES-SIMPLEX-VIRUS-1 GH; MONOCLONAL-ANTIBODIES; POLIOVIRUS RECEPTOR;
   INFECTED-CELLS; HEPTAD-REPEAT; ALPHA-HELIX; TYPE-1
AB Four glycoproteins (gD, gB, gH, and gL) are required for herpes simplex virus entry into the cell or for cell-cell fusion intransfected cells. gD serves as the receptor-binding glycoprotein and as the trigger of fusion; the other three execute fusion between the viral envelope and the plasma and endocytic membranes or the membranes of adjacent cells and are highly conserved among members of the herpesvirus family. Details of the interaction of gD with gB, gH, and gL were not known. Here, we report that the four glycoproteins assemble into a complex initiated by the interaction of gD with its cellular receptor. gB is recruited to the gD-receptor complex next, even in the absence of gH(.)gL. gH(.)gL is recruited next, but only to the receptor-gD-gB ensemble. A complex with the composition receptor-gD-gB-gH(.)gL is assembled transiently with a life span of 15-30 min in cells exposed to virus but can also be found in infected cells and in cells committed to form polykaryocytes after transfection of the glycoprotein quartet. The results indicate that the complex assembly is a critical step in the process of virus entry and fusion, and that no viral protein other than those that participate in the complex itself is required for complex assembly. These findings imply critical protein-protein interactions among the quartet as herpes simplex virions enter the cells and at cell-cell fusion, define a specific order of recruitment, and place gH(.)gL as the last link in the process of glycoprotein recruitment to the complex.
C1 Univ Bologna, Dept Expt Pathol, Sect Microbiol & Virol, Alma Mater Studiorum, I-40126 Bologna, Italy.
RP Campadelli-Fiume, G (reprint author), Univ Bologna, Dept Expt Pathol, Sect Microbiol & Virol, Alma Mater Studiorum, Via San Giacomo 12, I-40126 Bologna, Italy.
EM gabrielia.campadelli@unibo.it
CR Akkapaiboon P, 2004, J VIROL, V78, P7969, DOI 10.1128/JVI.78.15.7969-7983.2004
   Akula SM, 2002, CELL, V108, P407, DOI 10.1016/S0092-8674(02)00628-1
   Avitabile E, 2003, J VIROL, V77, P6836, DOI 10.1128/JVI.77.12.6836-6844.2003
   CAL WH, 1988, J VIROL, V62, P2596
   Campadelli-Fiume G, 2000, REV MED VIROL, V10, P305, DOI 10.1002/1099-1654(200009/10)10:5<305::AID-RMV286>3.0.CO;2-T
   CAMPADELLIFIUME G, 1990, J VIROL, V64, P6070
   CAMPADELLIFIUME G, 1988, J VIROL, V62, P159
   Cocchi F, 1998, J VIROL, V72, P9992
   Cocchi F, 2004, P NATL ACAD SCI USA, V101, P7445, DOI 10.1073/pnas.0401883101
   EJERCITO PM, 1968, J GEN VIROL, V2, P357, DOI 10.1099/0022-1317-2-3-357
   Feire AL, 2004, P NATL ACAD SCI USA, V101, P15470, DOI 10.1073/pnas.0406821101
   FORRESTER A, 1992, J VIROL, V66, P341
   Fusco D, 2005, P NATL ACAD SCI USA, V102, P9323, DOI 10.1073/pnas.0503907102
   Galdiero S, 2005, J BIOL CHEM, V280, P28632, DOI 10.1074/jbc.M505196200
   Galdiero S, 2006, J GEN VIROL, V87, P1085, DOI 10.1099/vir.0.81794-0
   Geraghty RJ, 2000, VIROLOGY, V268, P147, DOI 10.1006/viro.1999.0157
   Geraghty RJ, 1998, SCIENCE, V280, P1618, DOI 10.1126/science.280.5369.1618
   Gianni T, 2006, J VIROL, V80, P2216, DOI 10.1128/JVI.80.5.2216-2224.2006
   Gianni T, 2005, J VIROL, V79, P7042, DOI 10.1128/JVI.79.11.7042-7049.2005
   Gianni T, 2005, J VIROL, V79, P2931, DOI 10.1128/JVI.79.5.2931-2940.2005
   Gianni T, 2004, J VIROL, V78, P12268, DOI 10.1128/JVI.78.22.12268-12276.2004
   Gianni T, 2006, J VIROL, V80, P8190, DOI 10.1128/JVI.00504-06
   Handler CG, 1996, J VIROL, V70, P6076
   Heldwein EE, 2006, SCIENCE, V313, P217, DOI 10.1126/science.1126548
   HUANG AS, 1964, P SOC EXP BIOL MED, V116, P863
   HUTCHINSON L, 1992, J VIROL, V66, P2240
   ISOLA VJ, 1989, J VIROL, V63, P2325
   Kinzler ER, 2005, J VIROL, V79, P7827, DOI 10.1128/JVI.79.12.7827-7837.2005
   Krummenacher C, 2005, EMBO J, V24, P4144, DOI 10.1038/sj.emboj.7600875
   Krummenacher C, 2003, J VIROL, V77, P8985, DOI 10.1128/JVI.77.16.8985-8999.2003
   Krummenacher C, 2002, J VIROL, V76, P2424, DOI 10.1128/JVI.76.5.2424-2433.2002
   Krummenacher C, 2000, J VIROL, V74, P10863, DOI 10.1128/JVI.74.23.10863-10872.2000
   LI QX, 1995, J VIROL, V69, P3987
   LIGAS MW, 1988, J VIROL, V62, P1486
   Montgomery RI, 1996, CELL, V87, P427, DOI 10.1016/S0092-8674(00)81363-X
   Mori Y, 2004, J VIROL, V78, P4609, DOI 10.1128/JVI.78.9.4609-4616.2004
   Nicola AV, 2004, J VIROL, V78, P7508, DOI 10.1128/JVI.78.14.7508-7517.2004
   Novotny MJ, 1996, VIROLOGY, V221, P1, DOI 10.1006/viro.1996.0347
   Peng T, 1998, J VIROL, V72, P6092
   Perez-Romero P, 2005, J VIROL, V79, P4540, DOI 10.1128/JVI.79.7.4540-4544.2005
   Rodger G, 2001, J VIROL, V75, P710, DOI 10.1128/JVI.75.2.710-716.2001
   ROOP C, 1993, J VIROL, V67, P2285
   SHOWALTER SD, 1981, INFECT IMMUN, V34, P684
   SPEAR PG, 1992, ADV EXP MED BIOL, V313, P341
   Spear PG, 2003, J VIROL, V77, P10179, DOI 10.1128/JVI.77.19.10179-10185.2003
   Turner A, 1998, J VIROL, V72, P873
   Wang D, 2005, P NATL ACAD SCI USA, V102, P18153, DOI 10.1073/pnas.0509201102
   Whitbeck JC, 1997, J VIROL, V71, P6083
NR 48
TC 13
Z9 13
U1 2
U2 9
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD SEP 26
PY 2006
VL 103
IS 39
BP 14572
EP 14577
DI 10.1073/pnas.0606127103
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 090RG
UT WOS:000240968100057
PM 16973744
OA Green Published, Bronze
DA 2018-12-27
ER

PT J
AU Khalil, PN
   Erb, N
   Khalil, MN
   Escherich, G
   Janka-Schaub, GE
AF Khalil, Philipe N.
   Erb, Norbert
   Khalil, Maurice N.
   Escherich, Gabriele
   Janka-Schaub, Gritta E.
TI RETRACTED: Validation and application of a high-performance liquid
   chromatographic-based assay for determination of the inosine 5
   '-monophosphate dehydrogenase activity in erythrocytes (Retracted
   Article. See vol 864, pg 179, 2008)
SO JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL
   AND LIFE SCIENCES
LA English
DT Article; Retracted Publication
DE HPLC; enzyme; inosine-5 '-monophosphate dehydrogenase; thiopurine;
   leukaemia
ID ACUTE LYMPHOBLASTIC-LEUKEMIA; S-METHYLTRANSFERASE ACTIVITY; DELAYED
   CYTOTOXIC REACTION; IMP DEHYDROGENASE; THIOPURINE METHYLTRANSFERASE;
   GENETIC-POLYMORPHISM; CHILDHOOD; 6-MERCAPTOPURINE; MERCAPTOPURINE; CELLS
AB Thiopurine drug monitoring has become an important issue in treating children with acute lymphoblastic leukaemia (ALL). In this population, a genetic polymorphism causes wide differences in the activity of thiopurine S-methyletransferase (TPMT) - the rate-limiting enzyme of the thiopurine degradation metabolism - leading to the necessity of drug dose adjustments. It is not yet known if similar differences exist in the inosine 5'-monophosphate dehydrogenase (IMPDH; EC 1.1.1.205), the rate-limiting enzyme of the thiopurine synthesis. To test this, we established and validated a high-performance liquid chromatographic (HPLC)-based assay to determine the IMPDH enzyme activity in erythrocytes. The remarkable features of this assay are its simple erythrocyte separation/haemolysis and assay conditions and a distinct segregation of xanthosine 5'-monophosphate (XMP) from the clear supernatant after precipitation. The probes were processed without a time-consuming extraction and heating procedure and the assay demonstrated a good intra- and interday stability as well as a recovery rate of approximately 100%. The IMPDH enzyme activity was measured in erythrocytes of 75 children with diagnosis of ALL before starting antileukaemic therapy and their activity compared to those of 35 healthy adult controls. The measured enzyme activity was wide ranging in both groups. The individual enzyme activity differences observed in children with ALL might led to differences in the thionucleotide levels in those undergoing the standard thiopurine dose regimen. (c) 2006 Elsevier B.V. All rights reserved.
C1 Univ Hamburg, Med Ctr, Clin Paediat Haematol & Oncol, D-20251 Hamburg, Germany.
   Univ Munich, Downtown Med Ctr, Dept Surg, D-80336 Munich, Germany.
RP Khalil, MN (reprint author), Univ Hamburg, Med Ctr, Clin Paediat Haematol & Oncol, Martinistr 52, D-20251 Hamburg, Germany.
EM khalil@uke.uni-hamburg.de
CR Aarbakke J, 1997, TRENDS PHARMACOL SCI, V18, P3, DOI 10.1016/S0165-6147(96)01007-3
   Albrecht W, 2000, THER DRUG MONIT, V22, P283, DOI 10.1097/00007691-200006000-00009
   BECHER HL, 1979, KLIN WOCHENSCHR, V50, P1109
   ELION GB, 1989, SCIENCE, V244, P41, DOI 10.1126/science.2649979
   Erb N, 1998, CANCER CHEMOTH PHARM, V42, P266, DOI 10.1007/s002800050816
   Erb N, 2003, J CHROMATOGR B, V796, P87, DOI 10.1016/j.jchromb.2003.08.006
   GALE RP, 1991, LANCET, V338, P1315, DOI 10.1016/0140-6736(91)92604-Z
   Harms DO, 2003, BLOOD, V102, P2736, DOI 10.1182/blood-2002-08-2372
   Harms DO, 2000, LEUKEMIA, V14, P2234, DOI 10.1038/sj.leu.2401974
   Holleman A, 2004, NEW ENGL J MED, V351, P533, DOI 10.1056/NEJMoa033513
   JACKSON RC, 1975, NATURE, V256, P331, DOI 10.1038/256331a0
   Khalil MN, 2005, J CHROMATOGR B, V821, P105, DOI 10.1016/j.jchromb.2005.04.028
   Kroplin T, 1998, EUR J CLIN PHARMACOL, V54, P265, DOI 10.1007/s002280050457
   LANGMAN LJ, 1995, CLIN CHEM, V41, P295
   LENNARD L, 1992, EUR J CLIN PHARMACOL, V43, P329, DOI 10.1007/BF02220605
   LENNARD L, 1990, LANCET, V336, P225, DOI 10.1016/0140-6736(90)91745-V
   LENNARD L, 1989, CLIN PHARMACOL THER, V46, P149, DOI 10.1038/clpt.1989.119
   LENNARD L, 1989, J CLIN ONCOL, V7, P1816, DOI 10.1200/JCO.1989.7.12.1816
   LENNARD L, 1983, BRIT J CLIN PHARMACO, V16, P359, DOI 10.1111/j.1365-2125.1983.tb02178.x
   LOMMEN EJP, 1974, ACTA PAEDIATR SCAND, V63, P140, DOI 10.1111/j.1651-2227.1974.tb04362.x
   MARKOWITZ JF, 2003, REV GASTROENTEROL DI, V3, P23
   McLeod HL, 2000, LEUKEMIA, V14, P567, DOI 10.1038/sj.leu.2401723
   MONTERO C, 1995, CLIN CHIM ACTA, V238, P169, DOI 10.1016/0009-8981(95)06088-U
   NAGAI M, 1992, CANCER RES, V52, P258
   PEHLKE DM, 1972, J CLIN INVEST, V51, P1398, DOI 10.1172/JCI106935
   PRICE GM, 1987, LEUKEMIA RES, V11, P525, DOI 10.1016/0145-2126(87)90087-7
   TIDD DM, 1974, CANCER RES, V34, P738
   TIDD DM, 1974, CANCER RES, V34, P733
   WEINSHILBOUM RM, 1980, AM J HUM GENET, V32, P651
NR 29
TC 6
Z9 6
U1 4
U2 13
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1570-0232
EI 1873-376X
J9 J CHROMATOGR B
JI J. Chromatogr. B
PD SEP 14
PY 2006
VL 842
IS 1
BP 1
EP 7
DI 10.1016/j.jchromb.2006.04.040
PG 7
WC Biochemical Research Methods; Chemistry, Analytical
SC Biochemistry & Molecular Biology; Chemistry
GA 086ZV
UT WOS:000240712700001
PM 16725387
DA 2018-12-27
ER

PT J
AU Yamaguchi, I
   Gobara, Y
   Sato, M
AF Yamaguchi, Isao
   Gobara, Yoshiaki
   Sato, Moriyuki
TI RETRACTED: One-pot synthesis of N-substituted diaza[12] annulenes
   (Retracted Article. See vol 9, pg 5139, 2007)
SO ORGANIC LETTERS
LA English
DT Article; Retracted Publication
ID ELECTRON-SPIN-RESONANCE; RADICAL-ANION; DIANION; <12>ANNULENE; IONS; NMR
AB N-Substituted diaza[12]annulenes are obtained by one -pot reaction of N-(2,4-dinitrophenyl) pyridinium chloride with amines in moderate to high yields. The H-1 NMR spectrum reveals that diamagnetic ring current is generated in the diaza[12]annulene ring. The N-substituted diaza[12] annulenes are electrochemically active in solution.
C1 Shimane Univ, Fac Sci & Engn, Dept Mat Sci, Matsue, Shimane 6908504, Japan.
RP Yamaguchi, I (reprint author), Shimane Univ, Fac Sci & Engn, Dept Mat Sci, 1060 Nishikawatsu, Matsue, Shimane 6908504, Japan.
EM iyamaguchi@riko.shimane-u.ac.jp
CR ANASTASSIOU AG, 1973, TETRAHEDRON LETT, P3805
   ANASTASSIOU AG, 1974, J AM CHEM SOC, V96, P7823, DOI 10.1021/ja00832a042
   ANASTASSIOU AG, 1970, CHEM COMMUN, P1133
   BAUMANN H, 1980, HELV CHIM ACTA, V63, P618, DOI 10.1002/hlca.19800630309
   BECHER J, 1980, SYNTHESIS-STUTTGART, P589
   BINDRA AP, 1970, TETRAHEDRON, V26, P3749, DOI 10.1016/S0040-4020(01)92951-5
   Castro C, 2005, J ORG CHEM, V70, P3602, DOI 10.1021/jo047955a
   COX RH, 1973, J PHYS CHEM-US, V77, P200, DOI 10.1021/j100621a011
   Gard MN, 2004, ORG LETT, V6, P393, DOI 10.1021/ol0362921
   HOLMES AB, 1970, J AM CHEM SOC, V92, P5284, DOI 10.1021/ja00720a084
   KAVALEK J, 1974, COLLECT CZECH CHEM C, V39, P2056, DOI 10.1135/cccc19742056
   Kennedy RD, 2002, J CHEM SOC PERK T 1, P1601, DOI 10.1039/b109576p
   Mitchell RH, 2001, CHEM REV, V101, P1301, DOI 10.1021/cr990359+
   OTH JFM, 1971, J CHEM SOC B, P904, DOI 10.1039/j29710000904
   OTH JFM, 1970, TETRAHEDRON LETT, P67
   OTH JFM, 1970, TETRAHEDRON LETT, P61
   OTH JFM, 1972, J AM CHEM SOC, V94, P3498, DOI 10.1021/ja00765a042
   OTH JFM, 1973, J AM CHEM SOC, V95, P7337, DOI 10.1021/ja00803a022
   ROTTELE H, 1978, CHEM BER-RECL, V111, P84, DOI 10.1002/cber.19781110108
   SCHRODER G, 1974, ANGEW CHEM, V86, P237
   SCHRODER G, 1972, ANGEW CHEM, V84, P474
   SONDHEIMER F, 1972, ACCOUNTS CHEM RES, V5, P81, DOI 10.1021/ar50051a001
   STEVENSON GR, 1983, J ORG CHEM, V48, P2777, DOI 10.1021/jo00164a032
   STRAUSS HL, 1963, J AM CHEM SOC, V85, P2360, DOI 10.1021/ja00899a004
   Willstatter R, 1911, BER DTSCH CHEM GES, V44, P3423, DOI 10.1002/cber.191104403216
NR 25
TC 8
Z9 9
U1 3
U2 18
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1523-7060
EI 1523-7052
J9 ORG LETT
JI Org. Lett.
PD SEP 14
PY 2006
VL 8
IS 19
BP 4279
EP 4281
DI 10.1021/ol061585q
PG 3
WC Chemistry, Organic
SC Chemistry
GA 081TK
UT WOS:000240339700027
PM 16956206
DA 2018-12-27
ER

PT J
AU Prasad, BCN
   Kumar, V
   Gururaj, HB
   Parimalan, R
   Giridhar, P
   Ravishankar, GA
AF Prasad, B. C. Narasimha
   Kumar, Vinod
   Gururaj, H. B.
   Parimalan, R.
   Giridhar, P.
   Ravishankar, G. A.
TI RETRACTED: Characterization of capsaicin synthase and identification of
   its gene (csy1) for pungency factor capsaicin in pepper (Capsicum sp.)
   (Retracted Article. See vol 105, pg 20558, 2008)
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article; Retracted Publication
DE chili; gene cloning; localization
ID IMMOBILIZED CELL-CULTURES; DIRECT SOMATIC EMBRYOGENESIS;
   PLANT-REGENERATION; ANNUUM-L; FRUTESCENS MILL; IN-VITRO; ACID;
   BIOTRANSFORMATION; METABOLISM; FRUITS
AB Capsaicin is a unique alkaloid of the plant kingdom restricted to the genus Capsicum. Capsaicin is the pungency factor, a bioactive molecule of food and of medicinal importance. Capsaicin is useful as a counterirritant, antiarthritic, analgesic, antioxidant, and anticancer agent. Capsaicin biosynthesis involves condensation of vanillylamine and 8-methyl nonenoic acid, brought about by capsaicin synthase (CS). We found that CS activity correlated with genotype-specific capsaicin levels. We purified and characterized CS (approximate to 35 kDa). Immunolocalization studies confirmed that CS is specifically localized to the placental tissues of Capsicum fruits. Western blot analysis revealed concomitant enhancement of CS levels and capsaicin accumulation during fruit development. We determined the N-terminal amino acid sequence of purified CS, cloned the CS gene (csy1) and sequenced full-length cDNA (981 bp). The deduced amino acid sequence of CS from full-length cDNA was 38 kDa. Functionality of csyl through heterologous expression in recombinant Escherichia coli was also demonstrated. Here we report the gene responsible for capsaicin biosynthesis, which is unique to Capsicum spp. With this information on the CS gene, speculation on the gene for pungency is unequivocally resolved. our findings have implications in the regulation of capsaicin levels in Capsicum genotypes.
C1 Cent Food Technol Res Inst, Plant Cell Biotechnol Dept, Constituent Lab Council Sci & Ind Res, Mysore 570020, Karnataka, India.
RP Ravishankar, GA (reprint author), Cent Food Technol Res Inst, Plant Cell Biotechnol Dept, Constituent Lab Council Sci & Ind Res, Mysore 570020, Karnataka, India.
EM pcbt@cftri.res.in
RI Prasad, Bellur/A-5079-2013; RAVISHANKAR, Gokare A/C-7363-2009
CR Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389
   ANDREWS J, 1995, PEPPERS DOMESTICATED
   BENNETT DJ, 1968, J CHEM SOC C, P442, DOI 10.1039/j39680000442
   Binzel ML, 1996, PLANT CELL REP, V15, P536, DOI 10.1007/BF00232989
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
   CATERINA MJ, 1997, NATURE, V389, P316
   Chayapathy B, 2006, J AGR FOOD CHEM, V54, P1854, DOI 10.1021/jf052085z
   COLLINS MD, 1995, HORT SCI, V30, P2253
   DE AK, 2003, CAPSICUM
   Goodwin DC, 2003, ARCH BIOCHEM BIOPHYS, V417, P18, DOI 10.1016/S0003-9861(03)00321-7
   GUNAY AL, 1978, PLANT SCI LETT, V11, P365, DOI 10.1016/0304-4211(78)90024-X
   HARINI I, 1993, PLANT SCI, V89, P107, DOI 10.1016/0168-9452(93)90176-Z
   Hyde CL, 1996, IN VITRO CELL DEV-PL, V32, P72
   Ito K, 2004, CANCER RES, V64, P1071, DOI 10.1158/0008-5472.CAN-03-1670
   IWAI K, 1977, AGR BIOL CHEM TOKYO, V41, P1877, DOI 10.1080/00021369.1977.10862780
   IWAI K, 1978, AGR BIOL CHEM TOKYO, V42, P201, DOI 10.1080/00021369.1978.10862954
   Johnson TS, 1996, PLANT CELL TISS ORG, V44, P117
   JOHNSON TS, 1991, FOOD BIOTECHNOL, V5, P197, DOI 10.1080/08905439109549802
   Kang BC, 2001, THEOR APPL GENET, V102, P531, DOI 10.1007/s001220051678
   Kim M, 2001, MOL CELLS, V11, P213
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   Manoharan M, 1998, PLANT SCI, V131, P77, DOI 10.1016/S0168-9452(97)00231-8
   Mazzone SB, 1999, BRIT J PHARMACOL, V127, P473, DOI 10.1038/sj.bjp.0702522
   MCGUCKIN WF, 1958, CLIN CHEM, V4, P477
   Min JK, 2004, CANCER RES, V64, P644, DOI 10.1158/0008-5472.CAN-03-3250
   Morgenstern B, 2004, NUCLEIC ACIDS RES, V32, pW33, DOI 10.1093/nar/gkh373
   Prasad N.B.C., 2005, EVID BASE INTEGR MED, V2, P147, DOI DOI 10.2165/01197065-200502030-00006
   PRASAD NBC, 2003, Patent No. 20060073121A1
   PURSEGLORE JW, 1981, SPICES
   Rao SR, 2000, J BIOTECHNOL, V76, P137, DOI 10.1016/S0168-1656(99)00177-7
   Rao SR, 1999, PROCESS BIOCHEM, V35, P341, DOI 10.1016/S0032-9592(99)00077-1
   RAVISHANKAR GA, 1988, CURR SCI INDIA, V57, P381
   Rozen S, 2000, Methods Mol Biol, V132, P365
   Stewart C, 2005, PLANT J, V42, P675, DOI 10.1111/j.1365-313X.2005.02410.x
   Sudha G, 2002, CURR SCI INDIA, V83, P480
   SUKRASNO N, 1993, PHYTOCHEMISTRY, V32, P839, DOI 10.1016/0031-9422(93)85217-F
   Tewksbury JJ, 2001, NATURE, V412, P403, DOI 10.1038/35086653
   TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350
   Tsaftaris A, 1996, FIELD CROP RES, V45, P115, DOI 10.1016/0378-4290(95)00064-X
   TUKEY JW, 1953, T NEW YORK ACAD SCI, V16, P88, DOI 10.1111/j.2164-0947.1953.tb01326.x
   Walsh BM, 2001, INT J PLANT SCI, V162, P1409, DOI 10.1086/323273
   Zhu YX, 1996, PLANT CELL REP, V16, P71, DOI 10.1007/BF01275453
NR 42
TC 25
Z9 27
U1 1
U2 17
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD SEP 5
PY 2006
VL 103
IS 36
BP 13315
EP 13320
DI 10.1073/pnas.0605805103
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 084DR
UT WOS:000240512700013
PM 16938870
OA Green Published, Bronze
DA 2018-12-27
ER

PT J
AU Liu, JT
   Fan, SD
   Li, DQ
AF Liu, Ju-Tao
   Fan, Sheng-Di
   Li, De-Qian
TI RETRACTED: Tetraaqua(1,10-phenanthroline-kappa(2) N, N
   ')copper(II)naphthalene-1,5-disulfonate dihydrate (Retracted article.
   See vol. 66, pg e21, 2010)
SO ACTA CRYSTALLOGRAPHICA SECTION E-STRUCTURE REPORTS ONLINE
LA English
DT Article; Retracted Publication
AB In the title structure, [Cu(C12H8N2)(H2O)(4)](C10H6S2O6)center dot-2H(2)O, the cation lies on a crystallographic twofold rotation axis and the anion lies on a centre of inversion. The Cu-II atom is coordinated by two N atoms of a 1,10-phenanthroline ligand and four O atoms from four water ligands in a distorted octahedral geometry. The unique Cu-O distances are 2.054 (2) and 2.088 (2) angstrom and the Cu-N distance is 2.073 (2) angstrom. In the crystal structure, a three-dimensional supramolecular framework is constructed by extensive intermolecular O-H center dot center dot center dot O hydrogen bonds.
C1 Dalian Nationalities Univ, Sch Life Sci, Dalian 116600, Peoples R China.
   Acad Sinica, Changchun Inst Appl Chem, Changchun 130022, Peoples R China.
RP Liu, JT (reprint author), Dalian Nationalities Univ, Sch Life Sci, Dalian 116600, Peoples R China.
EM jutaoliu@yahoo.com.cn
CR BRUKER, 1998, SMART VERSION 5 051
   Cai JW, 2001, J CHEM SOC DALTON, P1137, DOI 10.1039/b009851p
   Cherni SN, 1999, ACTA CRYSTALLOGR C, V55, P1248, DOI 10.1107/S0108270199004874
   PIGUET C, 1989, INORG CHEM, V28, P2920, DOI 10.1021/ic00314a010
   Sheldrick G. M., 1997, SHELXL97 SHELXS97
   Zhang CG, 1999, ACTA CRYSTALLOGR C, V55, P1815, DOI 10.1107/S0108270199009294
NR 6
TC 6
Z9 7
U1 2
U2 9
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1600-5368
J9 ACTA CRYSTALLOGR E
JI Acta Crystallogr. Sect. E.-Struct Rep. Online
PD SEP
PY 2006
VL 62
BP M2165
EP M2166
DI 10.1016/S1600536806030637
PN 9
PG 2
WC Crystallography
SC Crystallography
GA 080DO
UT WOS:000240227400073
DA 2018-12-27
ER

PT J
AU Ghosh, A
   Bala, SK
AF Ghosh, Arnab
   Kumar Bala, Sanjib
TI RETRACTED: Anthropometric characteristics and nutritional status of
   Kondh: A tribal population of Kandhmal District, Orissa, India
   (Retracted article. See vol. 36, pg. 361, 2009)
SO ANNALS OF HUMAN BIOLOGY
LA English
DT Article; Retracted Publication
DE BMI; chronic energy deficiency (CED); malnutrition; kondh; India
ID CALCUTTA; MEN
AB A cross-sectional study, using body mass index (BMI), was undertaken to describe the anthropometric profile and nutritional status of the Desia Kondh, a tribal population of Orissa, India, which is characterized by rural poverty. A total of 326 (male = 154 and female = 172) adult (aged > 18 years) Kondh (Desia Kondh) from three villages were studied. Approximately 16% of males and 26% of females were severely thin (BMI < 16.0). Overall, the extent of undernutrition (BMI < 18.5) was found to be very high (> 75%), with prevalence of undernutrition in men and women of 74.5% and 76.6%, respectively. There was a significantly, p < 0.05, greater proportion of females in the lowest BMI groups. There was also a significant, p < 0.01, positive association between monthly income and BMI. In conclusion, this study demonstrated a high proportion of adult undernutrition and indicates a need for nutrition intervention programmes among the Kondh.
C1 Visva Bharati Univ, Palli Charcha Kendra, Santini Ketan, W Bengal, India.
RP Ghosh, A (reprint author), Visva Bharati Univ, Palli Charcha Kendra, Sriniketan 731236, W Bengal, India.
EM arnab_cu@rediffmail.com
CR BEHRA DK, 1996, TRIBAL CULTURE MODER
   Boal B. M., 1997, HUMAN SACRIFICE RELI
   BURR ML, 1984, BRIT J NUTR, V51, P165, DOI 10.1079/BJN19840020
   CAMERON N, 1984, MEASUREMENTS HUMAN G
   Das Dilip Kumar, 2005, Indian J Public Health, V49, P18
   Ghosh A, 2005, DIABETES-METAB RES, V21, P58, DOI 10.1002/dmrr.481
   Ghosh A, 2004, ANN HUM BIOL, V31, P364, DOI 10.1080/03014460410001670139
   JENA MK, 2006, FOREST TRIBE ORISSA, V2
   Khongsdier R, 2001, ANN HUM BIOL, V28, P374, DOI 10.1080/03014460010004610
   Lohman TG, 1988, ANTHR STANDARDIZATIO
   Paeratakul S, 1999, EUR J CLIN NUTR, V53, P865, DOI 10.1038/sj.ejcn.1600867
   Singh S, 2001, Australas Radiol, V45, P128, DOI 10.1046/j.1440-1673.2001.00892.x
   Ulijaszek S. J., 1994, ANTHROPOMETRY INDIVI, P30
   Yadav R J, 1999, Indian Pediatr, V36, P37
NR 14
TC 6
Z9 6
U1 4
U2 11
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0301-4460
EI 1464-5033
J9 ANN HUM BIOL
JI Ann. Hum. Biol.
PD SEP-DEC
PY 2006
VL 33
IS 5-6
BP 641
EP 647
DI 10.1080/03014460601011871
PG 7
WC Anthropology; Biology; Public, Environmental & Occupational Health
SC Anthropology; Life Sciences & Biomedicine - Other Topics; Public,
   Environmental & Occupational Health
GA 130GC
UT WOS:000243786800013
PM 17381062
DA 2018-12-27
ER

PT J
AU Radhakrishnan, R
AF Radhakrishnan, Ravi
TI RETRACTED: Mechanism of nucleotide incorporation in DNA polymerase beta
   (Retracted Article. See vol 350, pg 498, 2006)
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article; Retracted Publication
DE DNA polymerase fidelity; phosphoryl transfer; molecular dynamics; mixed
   quantum mechanics molecular mechanics simulations
ID ACTIVE-SITE; 2-METAL-ION MECHANISM; REPLICATION FIDELITY;
   MOLECULAR-DYNAMICS; CRYSTAL-STRUCTURES; TRANSITION-STATE;
   KINETIC-ANALYSIS; REPAIR ENZYME; CATALYSIS; SIMULATIONS
AB DNA polymerases play a central role in the mechanisms of DNA replication and repair. Here, we report mechanisms of the beta-polymerase catalyzed phosphoryl transfer reactions corresponding to correct and incorrect nucleotide incorporations in the DNA. Based on energy minimizations, molecular dynamics simulations, and free energy calculations of solvated ternary complexes of pol beta and by employing a mixed quantum mechanics molecular mechanics Hamiltonian, we have uncovered the identities of transient intermediates in the phosphoryl transfer pathways. Our study has revealed that an intriguing Grotthuss hopping mechanism of proton transfer involving water and three conserved aspartate residues in pol beta's active site mediates the phosphoryl transfer in the correct as well as misincorporation of nucleotides. The significance of this catalytic step in serving as a kinetic check point of polymerase fidelity may be unique to DNA polymerase beta, and is discussed in relation to other known mechanisms of DNA polymerases. (c) 2006 Elsevier Inc. All rights reserved.
C1 Univ Penn, Dept Bioengn, Philadelphia, PA 19104 USA.
RP Radhakrishnan, R (reprint author), Univ Penn, Dept Bioengn, 120 Hayden Hall, Philadelphia, PA 19104 USA.
EM rradhak@seas.upenn.edu
RI Radhakrishnan, Ravi/A-2964-2011
CR AGMON N, 1995, CHEM PHYS LETT, V244, P456, DOI 10.1016/0009-2614(95)00905-J
   Ahn J, 1997, BIOCHEMISTRY-US, V36, P1100, DOI 10.1021/bi961653o
   Ahn JW, 1998, BIOCHEM J, V331, P79, DOI 10.1042/bj3310079
   ARORA K, 2005, BIOCHEMISTRY
   Banerjee A, 2005, NATURE, V434, P612, DOI 10.1038/nature03458
   Benkovic SJ, 2006, SCIENCE, V312, P208, DOI 10.1126/science.1127654
   Bolhuis PG, 2002, ANNU REV PHYS CHEM, V53, P291, DOI 10.1146/annurev.physchem.53.082301.113146
   Bolhuis PG, 1998, FARADAY DISCUSS, V110, P421, DOI 10.1039/a801266k
   Bolhuis PG, 2003, P NATL ACAD SCI USA, V100, P12129, DOI 10.1073/pnas.1534924100
   Bose-Basu B, 2004, BIOCHEMISTRY-US, V43, P8911, DOI 10.1021/bi049641n
   Bustamante C, 2003, NATURE, V421, P423, DOI 10.1038/nature01405
   Cui Q, 2001, J AM CHEM SOC, V123, P2284, DOI 10.1021/ja002886c
   Dellago C, 2002, ADV CHEM PHYS, V123, P1, DOI 10.1002/0471231509.ch1
   Doublie S, 1998, NATURE, V391, P251
   Elber R, 1999, J PHYS CHEM B, V103, P899, DOI 10.1021/jp983774z
   Florian J, 2003, J AM CHEM SOC, V125, P8163, DOI 10.1021/ja028997o
   Florian J, 2005, P NATL ACAD SCI USA, V102, P6819, DOI 10.1073/pnas.0408173102
   Guo H, 2001, P NATL ACAD SCI USA, V98, P9032, DOI 10.1073/pnas.141230998
   Hu H, 2005, J CHEM PHYS, V123, DOI 10.1063/1.1990113
   Joyce CM, 2004, BIOCHEMISTRY-US, V43, P14317, DOI 10.1021/bi048422z
   Kiefer JR, 1998, NATURE, V391, P304
   Kim K, 1998, J AM CHEM SOC, V120, P6851, DOI 10.1021/ja9808393
   Kunkel TA, 2000, ANNU REV BIOCHEM, V69, P497, DOI 10.1146/annurev.biochem.69.1.497
   Lahiri SD, 2003, SCIENCE, V299, P2067, DOI 10.1126/science.1082710
   Li Y, 1998, EMBO J, V17, P7514, DOI 10.1093/emboj/17.24.7514
   Maier B, 2000, P NATL ACAD SCI USA, V97, P12002, DOI 10.1073/pnas.97.22.12002
   Mildvan AS, 1997, PROTEINS, V29, P401, DOI 10.1002/(SICI)1097-0134(199712)29:4<401::AID-PROT1>3.3.CO;2-#
   Olsson MHM, 2004, J AM CHEM SOC, V126, P15167, DOI 10.1021/ja047151c
   Radhakrishnan R, 2004, P NATL ACAD SCI USA, V101, P5970, DOI 10.1073/pnas.0308585101
   Radhakrishnan R, 2005, J AM CHEM SOC, V127, P13245, DOI 10.1021/ja052623o
   Rega N, 2004, J PHYS CHEM B, V108, P4210, DOI 10.1021/jp0370829
   Reuter N, 2000, J PHYS CHEM A, V104, P1720, DOI 10.1021/jp9924124
   Rittenhouse RC, 2003, PROTEINS, V53, P667, DOI 10.1002/prot.10451
   Sawaya MR, 1997, BIOCHEMISTRY-US, V36, P11205, DOI 10.1021/bi9703812
   Simonson T, 2002, ACCOUNTS CHEM RES, V35, P430, DOI 10.1021/ar010030m
   Stahley MR, 2005, SCIENCE, V309, P1587, DOI 10.1126/science.1114994
   STEITZ TA, 1994, SCIENCE, V266, P2022, DOI 10.1126/science.7528445
   STEITZ TA, 1993, P NATL ACAD SCI USA, V90, P6498, DOI 10.1073/pnas.90.14.6498
   Trylska J, 2004, BIOPOLYMERS, V74, P423, DOI 10.1002/bip.20093
   Webster CE, 2004, J AM CHEM SOC, V126, P6840, DOI 10.1021/ja049232e
   Werneburg BG, 1996, BIOCHEMISTRY-US, V35, P7041, DOI 10.1021/bi9527202
   Yang LJ, 2002, J MOL BIOL, V317, P651, DOI 10.1006/jmbi.2002.5450
   Young MA, 2001, CELL, V105, P115, DOI 10.1016/S0092-8674(01)00301-4
   Zhang YK, 2002, J AM CHEM SOC, V124, P10572, DOI 10.1021/ja020243m
NR 44
TC 5
Z9 5
U1 4
U2 12
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
EI 1090-2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD SEP 1
PY 2006
VL 347
IS 3
BP 626
EP 633
DI 10.1016/j.bbrc.2006.06.142
PG 8
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA 071GN
UT WOS:000239587200012
PM 16842743
DA 2018-12-27
ER

PT J
AU Eudoxie, GD
   Springer, RO
AF Eudoxie, G. D.
   Springer, R. O.
TI RETRACTED: Assessing and predicting compaction on agriculturally
   important soils in Trinidad (Retracted article. See vol. 101, pg. 281,
   2008)
SO BIOSYSTEMS ENGINEERING
LA English
DT Article; Retracted Publication
ID ENGINEERING PROPERTIES; CLAY SOILS; STRENGTH
AB Traditional production systems in the Caribbean rarely incorporate soil physical monitoring to assess potential degradation and reduction,in land productivity. This paper reports data for a comprehensive physical and engineering characterisation study performed on five agriculturally important soils to identify susceptibility to compactive degradation and provide simple techniques for predicting such effects. Most of the parameters defined correlated with clay content, which ranged from 23.3% to 73.8% and also clay mineralogy. Lower bulk and particle densities were associated with higher clay contents, whilst the Atterberg limits and aggregate stability indices showed higher values with increasing clay content. Mean maximum dry bulk density and penetration resistance values of 15 and 25 Proctor compaction blows decreased and increased respectively with increasing clay content. Values ranged from 1.29 to 1.67 Mg m(-3) for dry bulk density and 2.61-7.8 MPa for penetration resistance. Regression analysis indicated significant relationships between soil moisture content and both dry bulk density and penetration resistance, the latter being more strongly associated. Over all, these results indicated that the heavy clay soils were most prone to compactive damage from traffic and that penetration resistance better modelled these effects. Soil moisture content was shown to be a simple predictive indicator of the extent of compaction, and could be determined in-field with direct measuring devices (TDR) for immediate decision making. (c) 2006 IAgrE. All rights reserved Published by Elsevier Ltd
C1 Univ W Indies, Fac Sci & Agr, Dept Food Prod, St Augustine, Trinid & Tobago.
RP Eudoxie, GD (reprint author), Univ W Indies, Fac Sci & Agr, Dept Food Prod, St Augustine, Trinid & Tobago.
EM geudoxie@fsa.uwi.tt
CR AHMAD N, 1971, SOIL SCI, V112, P100, DOI 10.1097/00010694-197108000-00003
   Blake GR, 1986, METHODS SOIL ANAL, V1, P377, DOI DOI 10.2136/SSSAB00KSER5.1.2ED.C14
   Brady N. C, 2002, NATURE PROPERTIES SO
   Brown C., 1966, LAND CAPABILITY SURV, V3
   BROWN CB, 1970, LAND CAPABILITY SURV, V4
   BROWN CB, 1968, LAND CAPABILITY SURV, V5
   CANARACHE A, 1990, SOIL TILL RES, V16, P51, DOI 10.1016/0167-1987(90)90021-5
   CHANDLER AP, 1999, THESIS UWI TRINIDAD
   EKWUE EI, 1995, T ASAE, V38, P357
   EKWUE EI, 1994, J AGR ENG RES, V57, P129, DOI 10.1006/jaer.1994.1012
   Ekwue EI, 2002, APPL ENG AGRIC, V18, P37
   EUDOXIE GD, 2003, THESIS U W INDIES ST
   FOLLETSMITH RR, 1934, SUGAR CANE SOILS BRI
   GARDNER WH, 1986, METHODS SOIL ANAL 1, V2, P493
   Gee G.W., 1986, METHODS SOIL ANAL, V9, P383, DOI DOI 10.2136/SSSAB00KSER5.1.2ED.C15
   GEORGES JEW, 1970, THESIS MCGILL U MONT
   GERARD CJ, 1982, AGRON J, V74, P875, DOI 10.2134/agronj1982.00021962007400050025x
   Gouveia G, 2002, COMMUN SOIL SCI PLAN, V33, P1751, DOI 10.1081/CSS-120004820
   GREACEN EL, 1982, TROP AGR, V59, P123
   GUMBS FA, 1987, SOIL WATER CONSERVAT
   Hillel D, 1998, ENV SOIL PHYS
   Jumikis A.R., 1984, SOIL MECH
   Kay B. D., 1999, HDB SOIL SCI, P229
   Kemper W. D., 1986, Methods of soil analysis. Part 1. Physical and mineralogical methods, P425
   Lado M, 2004, SOIL SCI SOC AM J, V68, P1992, DOI 10.2136/sssaj2004.1992
   Lambe TW, 1951, SOIL TESTING ENG
   Motavalli PP, 2003, SOIL TILL RES, V74, P103, DOI 10.1016/S0167-1987(03)00150-8
   NELSON DW, 1996, METHODS SOIL ANAL, V3, P961, DOI DOI 10.2136/SSSABOOKSER5.3.C34
   Ohu J, 1989, SOIL TECHNOL, V2, P211, DOI DOI 10.1016/0933-3630(89)90007-X
   PAUL CL, 1982, TROP AGR, V59, P162
   PETERSEN LW, 1995, SOIL SCI, V159, P149, DOI 10.1097/00010694-199515930-00001
   RAMANA KV, 1991, STUDY EXPANSIVE CLAY
   SOANE BD, 1970, J P I AGR ENG, V25, P115
   Stone RJ, 1998, J AGR ENG RES, V70, P221, DOI 10.1006/jaer.1998.0266
   STONE RJ, 1993, T ASAE, V36, P1713
   Thomas G. W., 1996, Methods of soil analysis. Part 3 - chemical methods., P475
   TOPP GC, 1985, ADV IRRIGATION, V3
   van den Akker J.J.H., 2005, ENCY SOIL SCI, P285
NR 38
TC 2
Z9 2
U1 1
U2 8
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1537-5110
EI 1537-5129
J9 BIOSYST ENG
JI Biosyst. Eng.
PD SEP
PY 2006
VL 95
IS 1
BP 119
EP 126
DI 10.1016/j.biosystemseng.2006.04.012
PG 8
WC Agricultural Engineering; Agriculture, Multidisciplinary
SC Agriculture
GA 082DH
UT WOS:000240366400012
DA 2018-12-27
ER

PT J
AU Kannan, S
   Jaiswal, AK
AF Kannan, Sankaranarayanan
   Jaiswal, Anil K.
TI RETRACTED: Low and high dose UVB regulation of transcription factor
   NF-E2-Related factor 2 (Retracted article. See vol. 78, pg. 6346, 2018)
SO CANCER RESEARCH
LA English
DT Article; Retracted Publication
ID ANTIOXIDANT-RESPONSE ELEMENT; PROTEIN-KINASE-C; NAD(P)H-QUINONE
   OXIDOREDUCTASE1 GENE; MEDIATED EXPRESSION; NUCLEAR EXPORT; MENADIONE
   TOXICITY; OXIDATIVE STRESS; EPITHELIAL-CELLS; SKIN-CANCER; NQO1 GENE
AB Transcription factor NF-E2-related factor 2 (Nrf2) regulates antioxidant response element (ARE)-mediated expression and coordinated induction of chemoprotective proteins in response to chemical stress. In this report, we investigated Nrf2 response to low and high dose UVB irradiation. Low dose (7.5 J/M-2) UVB exposure of mouse hepatoma, mouse keratinocyte, and human skin fibroblast cells led to the nuclear accumulation of Nrf2 and up-regulation of ARE-mediated gene expression. On the contrary, and intriguingly, high dose (20 J/m(2)) UVB exposure of cells led to the nuclear exclusion of Nrf2 and down-regulation of chemoprotective gene expression with possible implications in UVB carcinogenesis. We investigated the mechanism by which high dose UVB induced the nuclear exclusion of Nrf2. Prior treatment with nuclear export inhibitor, leptomycin B, abrogated the UVB-induced nuclear exclusion of Nrf2, indicating that the decrease of Nrf2 in the nucleus was due to the nuclear export of Nrf2. High dose UVB increased the phosphorylation of Nrf2Y568 which stimulated the nuclear export of Nrf2. Mutation of Nrf2Y568 to phenylalanine and src kinase inhibitor PP2 abrogated/reduced the UVB-induced phosphorylation of Nrf2Y568 and nuclear exclusion of Nrf2. Transfection with src family member Fyn small interfering RNA resulted in the nuclear accumulation of Nrf2 and an increase in the expression and UVB induction of ARE-mediated gene expression. UVB exposure also induced the nuclear localization of Fyn. These results suggest that high dose UVB induced the activation/nuclear localization of Fyn which led to increased phosphorylation of Nrf2Y568 and enhanced nuclear export of Nrf2. This resulted in nuclear exclusion of Nrf2 and down-regulation of ARE-mediated chemoprotective gene expression.
C1 Baylor Coll Med, Dept Pharmacol, Houston, TX 77030 USA.
RP Jaiswal, AK (reprint author), Baylor Coll Med, Dept Pharmacol, 1 Baylor Pl, Houston, TX 77030 USA.
EM ajaiswal@bcm.tmc.edu
FU NIGMS NIH HHS [R01 GM47466]
CR Alam J, 2000, J BIOL CHEM, V275, P27694
   Bloom DA, 2003, J BIOL CHEM, V278, P44675, DOI 10.1074/jbc.M307633200
   BRASH DE, 2006, J INVEST DERMATOL, V1, P136
   Chan KM, 1996, P NATL ACAD SCI USA, V93, P13943, DOI 10.1073/pnas.93.24.13943
   Dhakshinamoorthy S, 2001, ONCOGENE, V20, P3906, DOI 10.1038/sj.onc.1204506
   Dhakshinamoorthy S, 2000, J BIOL CHEM, V275, P40134, DOI 10.1074/jbc.M003531200
   Ducret C, 1999, MOL CELL BIOL, V19, P7076
   Gao XQ, 2004, P NATL ACAD SCI USA, V101, P10446, DOI 10.1073/pnas.0403886101
   Haendeler J, 2003, MOL CELL BIOL, V23, P4598, DOI 10.1128/MCB.23.13.4598-4610.2003
   He ZH, 2005, J BIOL CHEM, V280, P15719, DOI 10.1074/jbc.M413493200
   Hirota A, 2005, J INVEST DERMATOL, V124, P825, DOI 10.1111/j.0022-202X.2005.23670.x
   Huang HC, 2000, P NATL ACAD SCI USA, V97, P12475, DOI 10.1073/pnas.220418997
   Huang HC, 2002, J BIOL CHEM, V277, P42769, DOI 10.1074/jbc.M206911200
   Iskander K, 2004, CANCER RES, V64, P5925, DOI 10.1158/0008-5472.CAN-04-0763
   Itoh K, 1999, GENE DEV, V13, P76, DOI 10.1101/gad.13.1.76
   Jain AK, 2005, J BIOL CHEM, V280, P29158, DOI 10.1074/jbc.M502083200
   Jaiswal AK, 2004, FREE RADICAL BIO MED, V36, P1199, DOI 10.1016/j.freeradbiomed.2004.02.074
   Kang KW, 2003, J NATL CANCER I, V95, P53, DOI 10.1093/jnci/95.1.53
   Karapetian RN, 2005, MOL CELL BIOL, V25, P1089, DOI 10.1128/MCB.25.3.1089-1099.2005
   Kong ANT, 2001, DRUG METAB REV, V33, P255, DOI 10.1081/DMR-120000652
   Kraemer KH, 1997, P NATL ACAD SCI USA, V94, P11, DOI 10.1073/pnas.94.1.11
   Larson RA, 1999, BLOOD, V94, P803
   Lee JM, 2001, J BIOL CHEM, V276, P20011, DOI 10.1074/jbc.M100734200
   Levonen AL, 2004, BIOCHEM J, V378, P373, DOI 10.1042/BJ20031049
   Long DJ, 2002, CANCER RES, V62, P3030
   Long DJ, 2002, J BIOL CHEM, V277, P46131, DOI 10.1074/jbc.M208675200
   Long DJ, 2001, JNCI-J NATL CANCER I, V93, P1166, DOI 10.1093/jnci/93.15.1166
   Long DJ, 2000, CHEM-BIOL INTERACT, V129, P99, DOI 10.1016/S0009-2797(00)00200-3
   Menzel HJ, 2004, BRIT J CANCER, V90, P1989, DOI 10.1038/sj.bjc.6601779
   Nguyen T, 2003, J BIOL CHEM, V278, P4536, DOI 10.1074/jbc.M207293200
   Numazawa S, 2003, AM J PHYSIOL-CELL PH, V285, pC334, DOI 10.1152/ajpcell.00043.2003
   Park SJ, 2003, MUTAT RES-GEN TOX EN, V536, P131, DOI 10.1016/S1383-5718(03)00041-X
   Parsons SJ, 2004, ONCOGENE, V23, P7906, DOI 10.1038/sj.onc.1208160
   Radjendirane V, 1998, J BIOL CHEM, V273, P7382, DOI 10.1074/jbc.273.13.7382
   Ramos J, 2004, CANCER EPIDEM BIOMAR, V13, P2006
   Ross D, 2000, CHEM-BIOL INTERACT, V129, P77, DOI 10.1016/S0009-2797(00)00199-X
   Rothman N, 1997, CANCER RES, V57, P2839
   Sankaranarayanan K, 2004, J BIOL CHEM, V279, P50810, DOI 10.1074/jbc.M404984200
   Sano S, 2005, CANCER RES, V65, P5720, DOI 10.1158/0008-5472.CAN-04-4359
   Sarbia M, 2003, INT J CANCER, V107, P381, DOI 10.1002/ijc.11430
   Sekhar KR, 2002, ONCOGENE, V21, P6829, DOI 10.1038/sj.onc.1205905
   Velichkova M, 2005, MOL CELL BIOL, V25, P4501, DOI 10.1128/MCB.25.11.4501-4513.2005
   Wakabayashi N, 2003, NAT GENET, V35, P238, DOI 10.1038/ng1248
   Yu R, 2000, J BIOL CHEM, V275, P39907, DOI 10.1074/jbc.M004037200
   Zipper LM, 2000, BIOCHEM BIOPH RES CO, V278, P484, DOI 10.1006/bbrc.2000.3830
   Zipper LM, 2003, TOXICOL SCI, V73, P124, DOI 10.1093/toxsci/kfg083
NR 46
TC 41
Z9 46
U1 0
U2 2
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD SEP 1
PY 2006
VL 66
IS 17
BP 8421
EP 8429
DI 10.1158/0008-5472.CAN-06-1181
PG 9
WC Oncology
SC Oncology
GA 081PL
UT WOS:000240329400017
PM 16951152
OA Bronze
DA 2018-12-27
ER

PT J
AU Pierantoni, GM
   Rinaldo, C
   Esposito, F
   Mottolese, M
   Soddu, S
   Fusco, A
AF Pierantoni, G. M.
   Rinaldo, C.
   Esposito, F.
   Mottolese, M.
   Soddu, S.
   Fusco, A.
TI RETRACTED: High Mobility Group A1 (HMGA1) proteins interact with p53 and
   inhibit its apoptotic activity (Retracted article. See vol. 21, pg. 503,
   2014)
SO CELL DEATH AND DIFFERENTIATION
LA English
DT Article; Retracted Publication
DE apoptosis; HMGA1; p53; antibody array; UV
ID CHROMOSOMAL-PROTEINS; HMGI(Y) PROTEINS; NUCLEAR PROTEINS; THYROID-CELLS;
   EXPRESSION; GENE; TRANSFORMATION; CARCINOMAS; CANCER; I(Y)
AB HMGA gene overexpression and rearrangements are frequent in several tumours, but their oncogenic function is still unclear. Here we report of a physical and functional interaction between High Mobility Group A1 (HMGA1) protein and p53 oncosuppressor. We found that HMGA1 binds p53 in vitro and in vivo, and both proteins are present in the same complexes bound to the Bax gene promoter. HMGA1 interferes with the p53-mediated transcription of p53 effectors Bax and p21(waf1) while cooperates with p53 in the transcriptional activation of the p53 inhibitor mdm2. This transcriptional modulation is associated with a reduced p53-dependent apoptosis in cells expressing exogenous HMGA1 and p53, or in cells expressing endogenously the proteins and in which p53 was activated by UV-irradiation. Furthermore, antisense inhibition of HMGA1b expression dramatically increases the UV-induced p53-mediated apoptosis. These data define a new physical and functional interaction between HMGA1 and p53 that modulates transcription of p53 target genes and inhibits apoptosis.
C1 Univ Naples Federico II, Dipartimento Biol & Patol Cellulare & Mol, Fac Med & Chirurg, I-80131 Naples, Italy.
   Inst Nazl Tumori Regina Elena, Dipartimento Oncol Sperimentale, I-00158 Rome, Italy.
   Inst Nazl Tumori Regina Elena, Serv Anat Patol, I-00144 Rome, Italy.
   European Sch Mol Med, NOGEC, CEINGE, I-80145 Naples, Italy.
RP Fusco, A (reprint author), Univ Naples Federico II, Dipartimento Biol & Patol Cellulare & Mol, Fac Med & Chirurg, Via S Pansini 5, I-80131 Naples, Italy.
EM afusco@napoli.com
RI Soddu, Silvia/K-2467-2018
OI Soddu, Silvia/0000-0001-8526-0044; Rinaldo, Cinzia/0000-0001-6124-762X
CR Abe N, 1999, CANCER RES, V59, P1169
   Abe N, 2002, PANCREAS, V25, P198, DOI 10.1097/01.MPA.0000018635.15184.82
   BACCHETTI S, 1993, INT J ONCOL, V3, P781
   Balde JW, 2003, EME TEC ADV PACK, V1, P1
   Bandiera A, 1998, CANCER RES, V58, P426
   BERLINGIERI MT, 1995, MOL CELL BIOL, V15, P1545
   Berlingieri MT, 2002, ONCOGENE, V21, P2971, DOI 10.1038/sj/onc/1205368
   Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497
   Bustin M, 1996, PROG NUCLEIC ACID RE, V54, P35, DOI 10.1016/S0079-6603(08)60360-8
   Chiappetta G, 1998, CANCER RES, V58, P4193
   Chiappetta G, 1996, ONCOGENE, V13, P2439
   Chiappetta G, 2001, INT J CANCER, V91, P147, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1033>3.3.CO;2-M
   CHIAPPETTA G, 1995, ONCOGENE, V10, P1307
   D'Orazi G, 2002, NAT CELL BIOL, V4, P11, DOI 10.1038/ncb714
   D'Orazi G, 2000, J GENE MED, V2, P11
   Fedele M, 1996, CANCER RES, V56, P1896
   Gao X, 1997, PROSTATE, V31, P264, DOI 10.1002/(SICI)1097-0045(19970601)31:4<264::AID-PROS8>3.0.CO;2-K
   GIANCOTTI V, 1985, CANCER RES, V45, P6051
   GIANCOTTI V, 1989, EXP CELL RES, V184, P538, DOI 10.1016/0014-4827(89)90352-2
   GIANCOTTI V, 1987, EMBO J, V6, P1981, DOI 10.1002/j.1460-2075.1987.tb02461.x
   Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C
   GROSSCHEDL R, 1994, TRENDS GENET, V10, P94, DOI 10.1016/0168-9525(94)90232-1
   HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q
   ITO T, 1992, CANCER RES, V52, P1369
   Jayaraman L, 1998, GENE DEV, V12, P462, DOI 10.1101/gad.12.4.462
   LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0
   Masciullo V, 2003, CARCINOGENESIS, V24, P1191, DOI 10.1093/carcin/bgg075
   Pierantoni GM, 2001, ONCOGENE, V20, P6132, DOI 10.1038/sj.onc.1204635
   REEVES R, 1990, J BIOL CHEM, V265, P8573
   Reeves R, 2000, ENVIRON HEALTH PERSP, V108, P803, DOI 10.2307/3454310
   Scala S, 2000, P NATL ACAD SCI USA, V97, P4256, DOI 10.1073/pnas.070029997
   Schmitt CA, 2002, CANCER CELL, V1, P289, DOI 10.1016/S1535-6108(02)00047-8
   Stros M, 2002, J BIOL CHEM, V277, P7157, DOI 10.1074/jbc.M110233200
   TAMIMI Y, 1993, CANCER RES, V53, P5512
   Thanos D, 1995, CELL, V83, P1091, DOI 10.1016/0092-8674(95)90136-1
   Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675
   Vousden KH, 2000, CELL, V103, P691, DOI 10.1016/S0092-8674(00)00171-9
   Zhao RB, 2000, GENE DEV, V14, P981
   ZHOU XJ, 1995, NATURE, V376, P771, DOI 10.1038/376771a0
NR 39
TC 53
Z9 54
U1 3
U2 11
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1350-9047
EI 1476-5403
J9 CELL DEATH DIFFER
JI Cell Death Differ.
PD SEP
PY 2006
VL 13
IS 9
BP 1554
EP 1563
DI 10.1038/sj.cdd.4401839
PG 10
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 075XL
UT WOS:000239920600014
PM 16341121
OA Bronze
DA 2018-12-27
ER

PT J
AU Huang, HH
   Lin, MC
   Lin, CC
   Lin, SC
   Hsu, CC
   Chen, FL
   Lee, SY
   Hung, CC
AF Huang, Her-Hsiung
   Lin, Mau-Chin
   Lin, Chien-Chan
   Lin, Sheng-Chieh
   Hsu, Chii-Chih
   Chen, Fang-Lung
   Lee, Shyh-Yuan
   Hung, Chun-Cheng
TI RETRACTED: Effects of welding pulse energy and fluoride ion on the
   cracking susceptibility and fatigue behavior of Nd : YAG laser-welded
   cast titanium joints (Retracted article. See vol. 32, pg. 195, 2013)
SO DENTAL MATERIALS JOURNAL
LA English
DT Article; Retracted Publication
DE welding pulse energy; fluoride; mechanical property
ID COMMERCIALLY PURE TITANIUM; MECHANICAL-PROPERTIES; CORROSION-RESISTANCE;
   TI-6AL-4V ALLOY; SOLDER JOINTS; ENVIRONMENTS
AB In this study, the cracking susceptibility and fatigue behavior of Nd:YAG laser-welded cast Ti joints (welding pulse energy: 11, 15, and 18 J) in fluoride-containing (0 and 0.5% NaF) artificial saliva were evaluated using constant elongation rate test (CERT) and fatigue test (FT), respectively. Both CERT and FT were also carried out in open air as controls. Results showed that increasing the welding energy increased the elongation and fatigue life, but decreased the tensile strength, of cast Ti joints in open-air environment. With a welding energy of 11 J, the fluoride ions in the artificial saliva increased the cracking susceptibility and decreased the fatigue life of Ti joints. When the welding energy exceeded 15 J, the presence of fluoride ions still increased the cracking susceptibility, but did not reduce the fatigue life of Ti joints. Rupture of Ti joints - if it occurred - occurred only at the welded metal (versus the non-welded part).
C1 Kaohsiung Med Univ, Grad Inst Dent Sci, Kaohsiung 807, Taiwan.
   Natl Yang Ming Univ, Fac Dent, Sch Dent, Taipei 112, Taiwan.
   Cent Taiwan Univ Sci & Technol, Dent Dent Lab Technol, Taichung 406, Taiwan.
   Chung Shan Med Univ, Inst Oral Mat Sci, Taichung 402, Taiwan.
   Shu Zen Coll Med & Management, Dept Dent Lab Technol, Kaohsiung 821, Taiwan.
RP Hung, CC (reprint author), Kaohsiung Med Univ, Grad Inst Dent Sci, Kaohsiung 807, Taiwan.
EM biomaterial@msn.com
RI Lee, Shyh-Yuan/F-8295-2012; Hung, Chun-Cheng/C-8661-2009
OI Lee, Shyh-Yuan/0000-0002-9880-2372; 
CR BARD AJ, 1976, ENCY ELECTROCHEMISTR, P305
   BERG E, 1995, J PROSTHET DENT, V74, P250, DOI 10.1016/S0022-3913(05)80131-3
   BLACKMAN R, 1991, J PROSTHET DENT, V65, P309, DOI 10.1016/0022-3913(91)90181-U
   BOERE G, 1995, J APPL BIOMATER, V6, P283, DOI 10.1002/jab.770060409
   Chai T, 1998, J PROSTHET DENT, V79, P477, DOI 10.1016/S0022-3913(98)70165-9
   Craig RG, 2002, RESTORATIVE DENT MAT, P479
   Huang HH, 2005, DENT MATER, V21, P749, DOI 10.1016/j.dental.2005.01.009
   Huang HH, 2005, J MATER SCI, V40, P789, DOI 10.1007/s10853-005-6325-6
   Huang HH, 2002, BIOMATERIALS, V23, P59, DOI 10.1016/S0142-9612(01)00079-5
   KONONEN MHO, 1995, DENT MATER, V11, P269, DOI 10.1016/0109-5641(95)80061-1
   Lothar P, 1992, INT J ORAL MAXILLOF, V7, P390
   Lucas L C, 1992, Adv Dent Res, V6, P32
   MARTIN G, 1995, WELDING RES S, V74, P77
   Nakagawa M, 2001, Dent Mater J, V20, P305
   Nakagawa M, 2002, DENT MATER J, V21, P83, DOI 10.4012/dmj.21.83
   Neo TK, 1996, INT J PROSTHODONT, V9, P379
   Oda Y, 1996, JPN J DENT MAT DEV, V15, P317
   Qi YL, 2000, MAT SCI ENG A-STRUCT, V280, P177, DOI 10.1016/S0921-5093(99)00662-0
   Schiff N, 2005, EUR J ORTHODONT, V27, P541, DOI 10.1093/ejo/cji050
   Watanabe I, 2003, AM J ORTHOD DENTOFAC, V123, P653, DOI 10.1016/S0889-5406(03)00197-5
   Wiskott HWA, 2001, J MATER SCI-MATER M, V12, P719, DOI 10.1023/A:1011224710916
   Wiskott HWA, 2001, INT J PROSTHODONT, V14, P40
   Wiskott HWA, 1997, J PROSTHET DENT, V77, P607, DOI 10.1016/S0022-3913(97)70103-3
   Yung WKC, 1997, J MATER PROCESS TECH, V63, P759, DOI 10.1016/S0924-0136(96)02719-7
   Zavanelli RA, 2000, J PROSTHET DENT, V84, P274, DOI 10.1067/mpr.2000.108758
   Zavanelli RA, 2004, J ORAL REHABIL, V31, P1029, DOI 10.1111/j.1365-2842.2004.01336.x
NR 26
TC 7
Z9 8
U1 3
U2 19
PU JAPANESE SOC DENTAL MATERIALS DEVICES
PI TOKYO
PA C/O KOKU HOKEN KYOKAI, 1-43-9 KOMAGOME TS BDG, KOMAGOME, TOSHIMA-KU,
   TOKYO, 170-0003, JAPAN
SN 0287-4547
J9 DENT MATER J
JI Dent. Mater. J.
PD SEP
PY 2006
VL 25
IS 3
BP 632
EP 640
DI 10.4012/dmj.25.632
PG 9
WC Dentistry, Oral Surgery & Medicine; Materials Science, Biomaterials
SC Dentistry, Oral Surgery & Medicine; Materials Science
GA 106RO
UT WOS:000242118600031
PM 17076339
OA Bronze
DA 2018-12-27
ER

PT J
AU Flores, MBS
   Fernandes, MFA
   Ropelle, ER
   Faria, MC
   Ueno, M
   Velloso, LA
   Saad, MJA
   Carvalheira, JBC
AF Flores, Marcelo B. S.
   Fernandes, Maria Fernanda A.
   Ropelle, Eduardo R.
   Faria, Marcel C.
   Ueno, Mirian
   Velloso, Licio A.
   Saad, Mario J. A.
   Carvalheira, Jose B. C.
TI RETRACTED: Exercise improves insulin and leptin sensitivity in
   hypothalamus of Wistar rats (Retracted article. See vol. 65, pg. 1127,
   2016)
SO DIABETES
LA English
DT Article; Retracted Publication
ID HUMAN SKELETAL-MUSCLE; PHOSPHATIDYLINOSITOL 3-KINASE; RECEPTOR
   SUBSTRATE-1; ENERGY-BALANCE; ADIPOSE-TISSUE; SIGNAL-TRANSDUCTION;
   INDUCED ANOREXIA; ARCUATE NUCLEUS; IN-VIVO; INTERLEUKIN-6
AB Prolonged exercise of medium to high intensity is known to promote a substantial effect on the energy balance of rats. In male rats, moderately to severely intense programs lead to a reduction in food intake. However, the exact causes for the appetite-suppressive effects of exercise are not known. Here, we show that intracerebroventricular insulin or leptin infusion reduced food intake in exercised rats to a greater extent than that observed in control animals. Exercise was associated with a markedly increased phosphorylation/activity of several proteins involved in leptin and insulin signal transduction in the hypothalamus. The regulatory role of interleukin (IL)-6 in mediating the increase in leptin and insulin sensitivity in hypothalamus was also investigated. Treatment with insulin or leptin markedly reduced food intake in exercised rats that were pre-treated with vehicle, although no increase in sensitivity to leptin- and insulin-induced anorexia after pretreatment with anti-IL-6 antibody was detected. The current study provides direct measurements of leptin and insulin signaling in the hypothalamus and documents increased sensitivity to these hormones in the hypothalamus of exercised rats in an IL-6-dependent manner. These findings provide support for the hypothesis that the appetite-suppressive actions of exercise may be mediated by the hypothalamus.
C1 Univ Estadual Campinas, Fac Med Sci, Dept Internal Med, FCM State, BR-13081970 Campinas, SP, Brazil.
RP Carvalheira, JBC (reprint author), Univ Estadual Campinas, Fac Med Sci, Dept Internal Med, FCM State, BR-13081970 Campinas, SP, Brazil.
EM carvalheirajbc@uol.com.br
RI Carvalheira, Jose/H-8405-2012; Ropelle, Eduardo/C-3977-2012
OI Ropelle, Eduardo/0000-0003-1655-9557
CR Baumann H, 1996, P NATL ACAD SCI USA, V93, P8374, DOI 10.1073/pnas.93.16.8374
   Bjorbaek C, 1999, J BIOL CHEM, V274, P30059, DOI 10.1074/jbc.274.42.30059
   Bjorbaek C, 1997, J BIOL CHEM, V272, P32686, DOI 10.1074/jbc.272.51.32686
   CAMPFIELD LA, 1995, SCIENCE, V269, P546, DOI 10.1126/science.7624778
   Carvalheira JBC, 2003, DIABETOLOGIA, V46, P1629, DOI 10.1007/s00125-003-1246-x
   Carvalheira JBC, 2001, FEBS LETT, V500, P119, DOI 10.1016/S0014-5793(01)02591-1
   Carvalheira JBC, 2003, BIOL CHEM, V384, P151, DOI 10.1515/BC.2003.016
   Chibalin AV, 2000, P NATL ACAD SCI USA, V97, P38, DOI 10.1073/pnas.97.1.38
   De Souza CT, 2005, ENDOCRINOLOGY, V146, P4192, DOI 10.1210/en.2004-1520
   Febbraio MA, 2002, FASEB J, V16, P1335, DOI 10.1096/fj.01-0876rev
   FOLLI F, 1992, J BIOL CHEM, V267, P22171
   Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665
   Ghilardi N, 1997, MOL ENDOCRINOL, V11, P393, DOI 10.1210/me.11.4.393
   Ghilardi N, 1996, P NATL ACAD SCI USA, V93, P6231, DOI 10.1073/pnas.93.13.6231
   HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777
   Hideshima T, 2001, ONCOGENE, V20, P5991, DOI 10.1038/sj.onc.1204833
   Keller C, 2003, J PHYSIOL-LONDON, V550, P927, DOI 10.1113/jphysiol.2003.044883
   Keller P, 2003, BIOCHEM BIOPH RES CO, V310, P550, DOI 10.1016/j.bbrc.2003.09.048
   Kellerer M, 1997, DIABETOLOGIA, V40, P1358, DOI 10.1007/s001250050832
   Kimura M, 2004, NEUROREPORT, V15, P713, DOI 10.1097/01.wnr.0000117648.18300.ce
   Kobayashi T, 1999, BIOCHEM J, V339, P319, DOI 10.1042/0264-6021:3390319
   KUHNE MR, 1993, J BIOL CHEM, V268, P11479
   Lavan BE, 1997, J BIOL CHEM, V272, P11439
   Li G, 2002, NEUROSCIENCE, V115, P879, DOI 10.1016/S0306-4522(02)00447-5
   Lyngso D, 2002, J PHYSIOL-LONDON, V543, P379, DOI 10.1113/jphysiol.2002.021022
   MAFFEI M, 1995, NAT MED, V1, P1155, DOI 10.1038/nm1195-1155
   Niswender KD, 2003, DIABETES, V52, P227, DOI 10.2337/diabetes.52.2.227
   Niswender KD, 2001, NATURE, V413, P794, DOI 10.1038/35101657
   Nybo L, 2002, J PHYSIOL-LONDON, V542, P991, DOI 10.1113/jphysiol.2002.022285
   Ohtani T, 2000, IMMUNITY, V12, P95, DOI 10.1016/S1074-7613(00)80162-4
   Ostrowski K, 1998, J PHYSIOL-LONDON, V508, P949, DOI 10.1111/j.1469-7793.1998.949bp.x
   Pedersen BK, 2000, PHYSIOL REV, V80, P1055
   Pedersen BK, 2001, J PHYSIOL-LONDON, V536, P329, DOI 10.1111/j.1469-7793.2001.0329c.xd
   Penkowa M, 2003, FASEB J, V17, DOI 10.1096/fj.03-0311fje
   Prada PO, 2005, ENDOCRINOLOGY, V146, P1576, DOI 10.1210/en.2004-0767
   RICHARD D, 1989, CAN J PHYSIOL PHARM, V67, P402, DOI 10.1139/y89-064
   RICHARD D, 1989, AM J PHYSIOL, V256, pR886
   RIVEST S, 1989, AM J PHYSIOL, V257, pR550
   ROTHWELL NJ, 1991, CAN J PHYSIOL PHARM, V69, P1465, DOI 10.1139/y91-219
   SAAD MJA, 1993, J CLIN INVEST, V92, P2065, DOI 10.1172/JCI116803
   Senn JJ, 2002, DIABETES, V51, P3391, DOI 10.2337/diabetes.51.12.3391
   SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x
   Sopasakis VR, 2004, DIABETOLOGIA, V47, P1879, DOI 10.1007/s00125-004-1544-y
   Steensberg A, 2003, J PHYSIOL-LONDON, V548, P631, DOI 10.1113/jphysiol.2002.032938
   Steensberg A, 2000, J PHYSIOL-LONDON, V529, P237, DOI 10.1111/j.1469-7793.2000.00237.x
   STOUTHARD JML, 1995, AM J PHYSIOL-ENDOC M, V268, pE813
   SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0
   Tsigos C, 1997, NEUROENDOCRINOLOGY, V66, P54, DOI 10.1159/000127219
   Vaisse C, 1996, NAT GENET, V14, P95, DOI 10.1038/ng0996-95
   Wallenius V, 2002, NAT MED, V8, P75, DOI 10.1038/nm0102-75
   Wing RR, 2001, ANNU REV NUTR, V21, P323, DOI 10.1146/annurev.nutr.21.1.323
   YAMAUCHI K, 1995, P NATL ACAD SCI USA, V92, P664, DOI 10.1073/pnas.92.3.664
   Yamauchi T, 1997, NATURE, V390, P91, DOI 10.1038/36369
NR 53
TC 98
Z9 101
U1 4
U2 16
PU AMER DIABETES ASSOC
PI ALEXANDRIA
PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA
SN 0012-1797
EI 1939-327X
J9 DIABETES
JI Diabetes
PD SEP
PY 2006
VL 55
IS 9
BP 2554
EP 2561
DI 10.2337/db05-1622
PG 8
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 083LC
UT WOS:000240456400018
PM 16936204
OA Bronze
DA 2018-12-27
ER

PT J
AU Marx, DM
   Stapel, DA
AF Marx, David M.
   Stapel, Diederik A.
TI RETRACTED: It's all in the timing: Measuring emotional reactions to
   stereotype threat before and after taking a test (Retracted article. See
   vol. 42, pg. 933, 2012)
SO EUROPEAN JOURNAL OF SOCIAL PSYCHOLOGY
LA English
DT Article; Retracted Publication
ID WOMENS MATH PERFORMANCE; AFRICAN-AMERICANS; ANXIETY; IDENTITY; AROUSAL
AB Stereotype threat is often described as resulting from increased anxiety over confirming a negative stereotype about one's group (Steele, 1997). However, variations in the type of emotional reactions targets experience as a function of stereotype threat has never been examined systematically before and after taking a test, thus it is unclear whether targets experience different emotions at different points in the testing session. The present study investigated this issue of emotional specificity. Results demonstrate that targets of a negative stereotype, but not non-targets, experienced heightened anxiety prior to taking a test under stereotype threat conditions and heightened frustration once the test was concluded. No effects were found in the non-stereotype threat conditions. These findings, therefore, highlight the specific affective states that targets and non-targets experience in threat and non-threat conditions, as well as how these affective states can be assessed using self-report measures. Copyright (c) 2006 John Wiley & Sons, Ltd.
C1 Univ Groningen, Dept Social & Org Psychol, NL-9712 TS Groningen, Netherlands.
RP Marx, DM (reprint author), Univ Groningen, Dept Social & Org Psychol, Grote Kruisstr 2-1, NL-9712 TS Groningen, Netherlands.
EM d.marx@ppsw.rug.nl; d.a.stapel@ppsw.rug.nl
CR ARASON IG, 1978, STRESS ANXIETY, V5
   Aronson J, 1999, J EXP SOC PSYCHOL, V35, P29, DOI 10.1006/jesp.1998.1371
   Ben-Zeev T, 2005, J EXP SOC PSYCHOL, V41, P174, DOI 10.1016/j.jesp.2003.11.007
   Blascovich J, 2001, PSYCHOL SCI, V12, P225, DOI 10.1111/1467-9280.00340
   Bosson JK, 2004, J EXP SOC PSYCHOL, V40, P247, DOI 10.1016/S0022-1031(03)00099-4
   Brown RP, 1999, J PERS SOC PSYCHOL, V76, P246, DOI 10.1037//0022-3514.76.2.246
   Croizet JC, 1998, PERS SOC PSYCHOL B, V24, P588, DOI 10.1177/0146167298246003
   Davies PG, 2002, PERS SOC PSYCHOL B, V28, P1615, DOI 10.1177/014616702237644
   FOLKMAN S, 1986, J ABNORM PSYCHOL, V95, P107, DOI 10.1037/0021-843X.95.2.107
   GEEN RG, 1991, ANNU REV PSYCHOL, V42, P377, DOI 10.1146/annurev.ps.42.020191.002113
   Gonzales PM, 2002, PERS SOC PSYCHOL B, V28, P659, DOI 10.1177/0146167202288010
   Keller J, 2003, PERS SOC PSYCHOL B, V29, P371, DOI 10.1177/0146167202250218
   Maass A., 2003, EUROPEAN REV SOCIAL, V14, P243, DOI DOI 10.1080/10463280340000072
   Major B, 1998, PERS SOC PSYCHOL B, V24, P34, DOI 10.1177/0146167298241003
   Marx DM, 2005, J PERS SOC PSYCHOL, V88, P432, DOI 10.1037/0022-3514.88.3.432
   MARX DM, IN PRESS BRIT J SOCI
   O'Brien LT, 2003, PERS SOC PSYCHOL B, V29, P782, DOI 10.1177/0146167203029006010
   Osborne JW, 2001, CONTEMP EDUC PSYCHOL, V26, P291, DOI 10.1006/ceps.2000.1052
   Oswald DL, 2000, CURR PSYCHOL, V19, P338, DOI 10.1007/s12144-000-1025-5
   SARASON IG, 1972, ANXIETY CURRENT TREN, V2
   SCHLENKER BR, 1982, PSYCHOL BULL, V92, P641, DOI 10.1037/0033-2909.92.3.641
   Schmader T, 2002, J EXP SOC PSYCHOL, V38, P194, DOI 10.1006/jesp.2001.1500
   Smith JL, 2004, EDUC PSYCHOL REV, V16, P177, DOI 10.1023/B:EDPR.0000034020.20317.89
   Smith JL, 2002, SEX ROLES, V47, P179, DOI 10.1023/A:1021051223441
   Spencer SJ, 1999, J EXP SOC PSYCHOL, V35, P4, DOI 10.1006/jesp.1998.1373
   Spielberger C. D, 1970, MANUAL STATE TRAIT A
   Stangor C, 1998, J PERS SOC PSYCHOL, V75, P1191, DOI 10.1037/0022-3514.75.5.1191
   Steele CM, 1997, AM PSYCHOL, V52, P613, DOI 10.1037//0003-066X.52.6.613
   STEELE CM, 1995, J PERS SOC PSYCHOL, V69, P797, DOI 10.1037/0022-3514.69.5.797
   Steele CM, 2002, ADV EXP SOC PSYCHOL, V34, P379, DOI 10.1016/S0065-2601(02)80009-0
   Stone J, 1999, J PERS SOC PSYCHOL, V77, P1213, DOI 10.1037//0022-3514.77.6.1213
NR 31
TC 21
Z9 24
U1 3
U2 14
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0046-2772
EI 1099-0992
J9 EUR J SOC PSYCHOL
JI Eur. J. Soc. Psychol.
PD SEP-OCT
PY 2006
VL 36
IS 5
BP 687
EP 698
DI 10.1002/ejsp.310
PG 12
WC Psychology, Social
SC Psychology
GA 091QS
UT WOS:000241044000005
DA 2018-12-27
ER

PT J
AU Kan, CW
AF Kan, C. W.
TI RETRACTED: Dyeing behavior of low temperature plasma treated wool
   (Retracted article. See vol. 14, art no e1770018, 2017)
SO FIBERS AND POLYMERS
LA English
DT Article; Retracted Publication
DE wool; low temperature plasma; acid dyeing; chrome dyeing; reactive
   dyeing
AB In this paper, the effects of low temperature plasma (LTP) treatment on the dyeing properties of the wool fiber were studied. The wool fibers were treated with oxygen plasma and three types of dye that commonly used for wool dyeing, namely: (i) acid dye, (ii) chrome dye and (iii) reactive dye, were used in the dyeing process. For acid dyeing, the dyeing rate of the UP-treated wool fiber was greatly increased but the final dyeing exhaustion equilibrium did not show any significant change. For chrome dyeing, the dyeing rate of the UP-treated wool fiber was also increased but the final dyeing exhaustion equilibrium was only increased to a small extent. In addition, the rate of afterchroming process was similar to the chrome dyeing process. For the reactive dyeing, the dyeing rate of the UP-treated wool fiber was greatly increased and also the final dyeing exhaustion equilibrium was increased significantly. As a result, it could conclude that the LTP treatment could improve the dyeing behavior of wool fiber in different dyeing systems.
C1 Hong Kong Polytech Univ, Inst Text & Clothing, Kowloon, Hong Kong, Peoples R China.
RP Kan, CW (reprint author), Hong Kong Polytech Univ, Inst Text & Clothing, Kowloon, Hong Kong, Peoples R China.
EM tccwk@inet.polyu.edu.hk
OI Kan, Chi-wai/0000-0002-7668-2410
CR ASPLAND JR, 1991, TEXT CHEM COLOR, V23, P13
   BIRD CL, 1971, THEORY PRACTICE WOOL
   Chan CM, 1996, SURF SCI REP, V24, P3
   HOCKER H, 1994, MELLIAND TEXTIBER, V75, pE131
   Kan CW, 2004, FIBER POLYM, V5, P52, DOI 10.1007/BF02875495
   LEEDER JD, 1985, P INT S FIB SCI TECH, V2, P203
   LEWIS DM, 1992, WOOL DYEING, P224
   LEWIS DM, 1992, WOOL DYEING, P5
   MACLANE S, 1998, GRAD TEXT M, V5, P1
   THOMAS H, 1995, P 9 INT WOOL TEXT RE, P351
   YAN HJ, 1989, P 4 ANN INT C PLASM, P181
NR 11
TC 18
Z9 18
U1 5
U2 10
PU KOREAN FIBER SOC
PI SEOUL
PA KOREA SCIENCE TECHNOLOGY CTR #501 635-4 YEOGSAM-DONG, KANGNAM-GU, SEOUL
   135-703, SOUTH KOREA
SN 1229-9197
EI 1875-0052
J9 FIBER POLYM
JI Fiber. Polym.
PD SEP
PY 2006
VL 7
IS 3
BP 262
EP 269
DI 10.1007/BF02875683
PG 8
WC Materials Science, Textiles; Polymer Science
SC Materials Science; Polymer Science
GA 092ZA
UT WOS:000241135300009
DA 2018-12-27
ER

PT J
AU Deif, AM
   ElMaraghy, W
AF Deif, Ahmed M.
   ElMaraghy, Waguih
TI RETRACTED: Effect of reconfiguration costs on planning for capacity
   scalability in reconfigurable manufacturing systems (Retracted article.
   See vol. 26, pg. 609, 2014)
SO INTERNATIONAL JOURNAL OF FLEXIBLE MANUFACTURING SYSTEMS
LA English
DT Article; Proceedings Paper; Retracted Publication
CT 3rd International Conference on Reconfigurable Manufacturing
CY MAY, 2005
CL Univ Michigan, Ann Arbor, MI
HO Univ Michigan
DE reconfigurable manufacturing system; regeneration point; capacity
   scalability
ID EXPANSION
AB In a globally competitive market for products, manufacturers are faced with an increasing need to improve their flexibility, reliability, and responsiveness to meet the demands of their customers. Reconfigurable manufacturing systems (RMS) have become an important manufacturing paradigm, because they broadly encompass the ability to react efficiently to this environment by providing the exact capacity and functionality needed when needed. This paper studies how such new systems can manage their capacity scalability planning in a cost effective manner. An approach for modeling capacity scalability planning is proposed. The development of the model is based on set theory and the regeneration point theorem which is mapped to the reconfigurable manufacturing paradigm as the capacity scalability points of that system. The cost function of the model incorporates both the physical capacity cost based on capacity size and costs associated with the reconfiguration process which referred to as the scalability penalty cost and scalability effort cost. A dynamic programming (DP) approach is manipulated for the development of optimal capacity scalability plans. The effect of the reconfiguration costs on the capacity scalability planning horizon and overall cost is investigated. The results showed the relation between deciding on the optimal capacity scalability planning horizon and the different reconfiguration costs. Results also highlighted the fact that decreasing costs of reconfiguration will lead to cost effective implementation of reconfigurable manufacturing systems.
C1 Univ Windsor, Intelligent Mfg Syst Ctr, Windsor, ON N9B 3P4, Canada.
RP Deif, AM (reprint author), Univ Windsor, Intelligent Mfg Syst Ctr, Windsor, ON N9B 3P4, Canada.
EM deif@uwindsor.ca; wem@uwindsor.ca
CR ANGELUS A, 1997, 1479R2 STANF U GRAD
   ASL R, 2002, P ASME INT MECH ENG
   ASL R, 2002, P JAP US S FLEX MAN
   BERTSEKAS DP, 1987, DYNAMIC PROGRAMMING
   ElMaraghy HA, 2005, INT J FLEX MANUF SYS, V17, P261, DOI 10.1007/s10696-006-9028-7
   Freidenfelds J., 1981, CAPACITY EXPANSION A
   Koren Y, 1999, CIRP ANNALS 1999: MANUFACTURING TECHNOLOGY, VOL 48 NO 2 1999, P527, DOI 10.1016/S0007-8506(07)63232-6
   LEACHMAN RC, 1992, IIE TRANS, V24, P62, DOI 10.1080/07408179208964234
   Liberopoulos G, 2002, INT J FLEX MANUF SYS, V14, P345, DOI 10.1023/A:1020915200984
   LUSS H, 1982, OPER RES, V30, P907, DOI 10.1287/opre.30.5.907
   MANNE AS, 1961, ECONOMETRICA, V29, P632, DOI 10.2307/1911809
   MANNE AS, 1967, INVESTMENTS CAPACITY
   ROCKLIN SM, 1984, OPER RES, V32, P133, DOI 10.1287/opre.32.1.133
   ROUNDY R, 2000, 1271 CORN U SCH OP R
   SON SY, 2001, INTEGRATED MANUFACTU, V12, P500, DOI DOI 10.1108/09576060110407815
   SON SY, 2000, THESIS U MICHIGAN
   SPICER JP, 2002, THESIS U MICHIGAN
   Youssef AMA, 2006, INT J ADV MANUF TECH, V30, P174, DOI 10.1007/s00170-005-0034-9
NR 18
TC 15
Z9 16
U1 2
U2 13
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0920-6299
J9 INT J FLEX MANUF SYS
JI Int. J. Flexible Manuf. Syst.
PD SEP
PY 2006
VL 18
IS 3
BP 225
EP 238
DI 10.1007/s10696-006-9006-0
PG 14
WC Engineering, Manufacturing; Operations Research & Management Science
SC Engineering; Operations Research & Management Science
GA 162RJ
UT WOS:000246106900005
DA 2018-12-27
ER

PT J
AU Vuijk, P
   van Lier, PAC
   Huizink, AC
   Verhulst, FC
   Crijnen, AAM
AF Vuijk, Patricia
   van Lier, Pol A. C.
   Huizink, Anja C.
   Verhulst, Frank C.
   Crijnen, Alfons A. M.
TI RETRACTED: Prenatal smoking predicts non-responsiveness to an
   intervention targeting attention-deficit/hyperactivity symptoms in
   elementary schoolchildren (Retracted article. See vol. 50, pg. 1561,
   2009)
SO JOURNAL OF CHILD PSYCHOLOGY AND PSYCHIATRY
LA English
DT Article; Retracted Publication
DE prenatal smoking; fetal programming; preventive interventions; ADHD
   symptoms; early-onset experimentation with smoking
ID DEFICIT HYPERACTIVITY DISORDER; CHILDHOOD CONDUCT PROBLEMS; MATERNAL
   SMOKING; ANTISOCIAL-BEHAVIOR; PREVENTIVE INTERVENTIONS; NICOTINE
   EXPOSURE; PREGNANCY; CHILDREN; IMPACT; ADHD
AB Background: Some evidence suggests that prenatal exposure to maternal smoking contributes to the etiology of Attention-Deficit/Hyperactivity Disorder (ADHD). The present study tested an intervention targeting disruptive behavior to establish whether exposure to maternal smoking during pregnancy predicts intervention failure in elementary schoolchildren. Methods: Five hundred and eight elementary schoolchildren were followed from ages 7 to 11. At ages 8 and 9, they were randomly assigned to a control condition, or to a two-year universal classroom-based intervention targeting disruptive behavior. Measures included maternal reports of smoking during pregnancy, teacher-rated symptoms of ADHD from ages 7 to 9 years, and children's self-report of experimentation with smoking at ages 10 and 11 years. Results: At age 7, prenatally exposed children had higher ADHD symptom scores. The intervention did not affect the course of their ADHD symptoms and the probability of early-onset experimentation with smoking. Among non-exposed children, the intervention positively affected the course of ADHD symptoms, and reduced the probability of early-onset experimentation with smoking. Conclusions: Prenatally exposed children are most prone to follow a path of high levels of ADHD symptoms and associated elevated risk for early-onset experimentation with smoking, which is unreceptive to a universal preventive intervention. In these children, the developmental course of ADHD symptoms seems to have been influenced by their prenatal exposure to maternal smoking. Future research should further explore whether prenatal smoking is a proxy measure that indexes another risk factor, or a causal factor for adverse developmental outcomes.
C1 Erasmus MC, Dept Child & Adolescent Psychiat, NL-3000 CB Rotterdam, Netherlands.
   Vrije Univ Amsterdam, Dept Dev Psychol, NL-1081 HV Amsterdam, Netherlands.
RP Vuijk, P (reprint author), Erasmus MC, Dept Child & Adolescent Psychiat, POB 2060, NL-3000 CB Rotterdam, Netherlands.
EM p.vuijk@erasmusmc.nl
CR Achenbach T. M., 1991, MANUAL TEACHERS REPO
   American Psychiatric Association, 1994, DIAGN STAT MAN MENT
   Barker DJP, 1998, CLIN SCI, V95, P115, DOI 10.1042/CS19980019
   Bongers IL, 2003, J ABNORM PSYCHOL, V112, P179, DOI 10.1037/0021-843X.112.2.179
   Brennan PA, 2002, AM J PSYCHIAT, V159, P48, DOI 10.1176/appi.ajp.159.1.48
   Burke JD, 2001, J CHILD PSYCHOL PSYC, V42, P493, DOI 10.1111/1469-7610.00743
   Button TMM, 2005, BRIT J PSYCHIAT, V187, P155, DOI 10.1192/bjp.187.2.155
   Cohen J, 1988, STAT POWER ANAL BEHA
   Cohen J., 1983, APPL MULTIPLE REGRES
   Cornelius M D, 2000, Nicotine Tob Res, V2, P45
   Crone MR, 2000, PATIENT EDUC COUNS, V39, P149, DOI 10.1016/S0738-3991(99)00016-6
   DiFranza JR, 2000, TOB CONTROL, V9, P313, DOI 10.1136/tc.9.3.313
   Dolan L. J., 1989, GOOD BEHAV GAME MANU
   Erasmus M., 2000, PROBLEM BEHAV SCH IN
   ERASMUS MC, 2002, SUBSTANCE USE PREGNA
   ERASMUS MC, 2000, SUBSTANCE USE QUESTI
   Ernst M, 2001, J AM ACAD CHILD PSY, V40, P630, DOI 10.1097/00004583-200106000-00007
   Goldberg D. P., 1988, USERS GUIDE GEN HLTH
   Goldberg DP, 1972, DETECTION PSYCHIAT I
   Ialongo N, 2001, J EMOT BEHAV DISORD, V9, P146, DOI 10.1177/106342660100900301
   Koeter M. W. J., 1991, GEN HLTH QUESTIONNAI
   Linnet KM, 2003, AM J PSYCHIAT, V160, P1028, DOI 10.1176/appi.ajp.160.6.1028
   Loeber R, 2000, Clin Child Fam Psychol Rev, V3, P37, DOI 10.1023/A:1009567419190
   Maughan B, 2004, ARCH GEN PSYCHIAT, V61, P836, DOI 10.1001/archpsyc.61.8.836
   Maughan B, 2001, J CHILD PSYCHOL PSYC, V42, P1021, DOI 10.1111/1469-7610.00800
   Milberger S, 1997, J AM ACAD CHILD PSY, V36, P37, DOI 10.1097/00004583-199701000-00015
   Monshouwer K., 2004, JEUGD RISKANT GEDRAG
   Muthen B, 2001, DECADE BEHAV, P291, DOI 10.1037/10409-010
   Muthen B, 2002, BIOSTATISTICS, V3, P459, DOI 10.1093/biostatistics/3.4.459
   Muthen LK, 1998, MPLUS STAT ANAL LATE
   Pauly JR, 2004, INT J DEV NEUROSCI, V22, P329, DOI 10.1016/j.ijdevneu.2004.05.009
   Rodriguez A, 2005, J CHILD PSYCHOL PSYC, V46, P246, DOI 10.1111/j.1469-7610.2004.00359.x
   Rutter M, 2002, CHILD ADOLESCENT PSY, P309
   Shelton KK, 1996, J CLIN CHILD PSYCHOL, V25, P317, DOI 10.1207/s15374424jccp2503_8
   Slotkin TA, 2005, NEUROPSYCHOPHARMACOL, V30, P129, DOI 10.1038/sj.npp.1300544
   *STAT NET, 1999, STAND BER 1999
   Storr CL, 2002, DRUG ALCOHOL DEPEN, V66, P51, DOI 10.1016/S0376-8716(01)00184-3
   Thapar A, 2003, AM J PSYCHIAT, V160, P1985, DOI 10.1176/appi.ajp.160.11.1985
   Thapar A, 1999, BRIT J PSYCHIAT, V174, P105, DOI 10.1192/bjp.174.2.105
   van der Sar A. M., 2001, DOCENTENHANDLEIDING
   van Lier PAC, 2005, J ABNORM CHILD PSYCH, V33, P521, DOI 10.1007/s10802-005-6735-7
   van Lier PAC, 2004, J CONSULT CLIN PSYCH, V72, P467, DOI 10.1037/0022-006X.72.3.467
   Verhulst F. C., 1997, HANDLEIDING TEACHERS
   Wakschlag LS, 2002, AM J PUBLIC HEALTH, V92, P966, DOI 10.2105/AJPH.92.6.966
   Wakschlag LS, 2002, DEV PSYCHOPATHOL, V14, P351
   Williams GM, 1998, PEDIATRICS, V102, DOI 10.1542/peds.102.1.e11
NR 46
TC 12
Z9 12
U1 3
U2 13
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0021-9630
EI 1469-7610
J9 J CHILD PSYCHOL PSYC
JI J. Child Psychol. Psychiatry
PD SEP
PY 2006
VL 47
IS 9
BP 891
EP 901
DI 10.1111/j.1469-7610.2006.01647.x
PG 11
WC Psychology, Developmental; Psychiatry; Psychology
SC Psychology; Psychiatry
GA 076EZ
UT WOS:000239941100004
PM 16930383
DA 2018-12-27
ER

PT J
AU Frumento, RJ
   Logginidou, HG
   Wahlander, S
   Wagener, G
   Playford, HR
   Sladen, RN
AF Frumento, Robert J.
   Logginidou, HeLene G.
   Wahlander, Staffan
   Wagener, Gebhard
   Playford, Hugh R.
   Sladen, Robert N.
TI RETRACTED: Dexmedetomidine infusion is associated with enhanced renal
   function after thoracic surgery (Retracted article. See vol. 18, pg.
   422, 2006)
SO JOURNAL OF CLINICAL ANESTHESIA
LA English
DT Article; Retracted Publication
DE analgesia; epidural; dexmedetomidine; fluid restriction; intraoperative;
   glomerular filtration; renal function; thoracic surgery; thoracotomy
ID CARDIAC-SURGERY; BYPASS-SURGERY; RISK-FACTORS; CLONIDINE; CREATININE;
   ANESTHESIA; SEDATION; AGONISTS; FAILURE; STRESS
AB Study Objective: To test the hypothesis that dexmedetomidine, a selective alpha-2 agonist, enhances urine flow rate and perioperative renal function, a post hoc analysis was conducted on a recently completed study of dexmedetomidine used as an adjunct to epidural analgesia after thoracotomy.
   Design: Post hoc analysis of a randomized, placebo-controlled, double-blind clinical trial.
   Setting: Tertiary-care university medical center.
   Patients: 28 patients undergoing elective thoracotomy.
   Interventions: Patients were prospectively randomized to receive a supplemental 24-hour intravenous infusion of either dexmedetomidine (0.4 mu g kg(-1) h(-1), n = 14) or saline placebo (equivalent infusion rate, n = 14).
   Measurements: Available renal parameters including urine output, calculated creatinine clearance (cCl(Cr)), daily serum creatinine level (S-Cr), and the fractional change in S-Cr level (Delta S-Cr%, [peak postoperative Sc, - baseline S-Cr] / baseline S-Cr) X 100) were recorded.
   Main Results: Values are expressed as means +/- SD. There were no significant differences in baseline values between the groups. The dexmedetomidine group had significantly greater cumulative urine output at postoperative hour 4 (473 +/- 35 vs 290 +/- 122 mL, P = 0.001) and 12 (1033 +/- 240 vs 822 +/- 234 mL, P = 0.02), although only 14% of the group received diuretic agents, compared with 43% in the control group. The dexmedetomidine group had significantly better preserved perioperative renal function compared with the control group, as assessed by Delta S-Cr% (0.04% decrease vs 21% increase, P = 0.0007) and cCl(Cr) (75.3 +/- 13.2 vs 62.5 +/- 15.5 mL/min, P = 0.02).
   Conclusion: Dexmedetomidine infusion administered as a supplement to epidural analgesia induced diuresis in postthoracotomy patients with normal preoperative renal function and undergoing fluid restriction. Although this finding may represent simple reversal of a tubular antidiuresis, the lower Delta S-Cr% and preservation of cCl(Cr) suggest a beneficial effect on glomerular filtration compared with controls. (c) 2006 Elsevier Inc. All rights reserved.
C1 Columbia Univ, Coll Phys & Surg, Dept Anesthesiol, New York, NY 10032 USA.
RP Sladen, RN (reprint author), Columbia Univ, Coll Phys & Surg, Dept Anesthesiol, New York, NY 10032 USA.
EM rs543@columbia.edu
CR Battafarano RJ, 2002, J THORAC CARDIOV SUR, V123, P280, DOI 10.1067/mtc.2002.119338
   Bhana N, 2000, DRUGS, V59, P263, DOI 10.2165/00003495-200059020-00012
   COCKCROFT DW, 1976, NEPHRON, V16, P31, DOI 10.1159/000180580
   CONGER JD, 1995, AM J KIDNEY DIS, V26, P565, DOI 10.1016/0272-6386(95)90590-1
   Conlon PJ, 1999, NEPHROL DIAL TRANSPL, V14, P1158, DOI 10.1093/ndt/14.5.1158
   Ebert TJ, 2000, ANESTHESIOLOGY, V93, P382, DOI 10.1097/00000542-200008000-00016
   FLACKE JW, 1987, ANESTHESIOLOGY, V67, P11, DOI 10.1097/00000542-198707000-00003
   GOLLEDGE J, 1994, ANN THORAC SURG, V58, P524, DOI 10.1016/0003-4975(94)92245-4
   HAYASHI Y, 1993, BRIT J ANAESTH, V71, P108, DOI 10.1093/bja/71.1.108
   HELBOHANSEN S, 1986, ACTA ANAESTH SCAND, V30, P235, DOI 10.1111/j.1399-6576.1986.tb02404.x
   Herr DL, 2003, J CARDIOTHOR VASC AN, V17, P576, DOI 10.1053/S1053-0770(03)00200-3
   JAAKOLA ML, 1991, PAIN, V46, P281, DOI 10.1016/0304-3959(91)90111-A
   Kulka PJ, 1996, CRIT CARE MED, V24, P947, DOI 10.1097/00003246-199606000-00012
   KULKA PJ, 1995, ANESTH ANALG, V80, P263, DOI 10.1097/00000539-199502000-00011
   NASCIMENTO PVN, 2003, NAESTHESIOLOGY, pA502
   Ryckwaert F, 2002, CRIT CARE MED, V30, P1495, DOI 10.1097/00003246-200207000-00016
   Talke P, 1997, ANESTH ANALG, V85, P1136, DOI 10.1097/00000539-199711000-00033
   Taoda M, 2001, NEUROCHEM INT, V38, P317, DOI 10.1016/S0197-0186(00)00096-6
   TINETTI ME, 1983, J AM GERIATR SOC, V31, P174, DOI 10.1111/j.1532-5415.1983.tb04859.x
   Venn RM, 1999, ANAESTHESIA, V54, P1136, DOI 10.1046/j.1365-2044.1999.01114.x
   Wahlander S, 2005, J CARDIOTHOR VASC AN, V19, P630, DOI 10.1053/j.jvca.2005.07.006
NR 21
TC 49
Z9 57
U1 2
U2 12
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0952-8180
EI 1873-4529
J9 J CLIN ANESTH
JI J. Clin. Anesth.
PD SEP
PY 2006
VL 18
IS 6
BP 422
EP 426
DI 10.1016/j.jclinane.2006.02.005
PG 5
WC Anesthesiology
SC Anesthesiology
GA 091JF
UT WOS:000241022600005
PM 16980158
DA 2018-12-27
ER

PT J
AU Fang, YT
   Zhou, J
AF Fang, Yun-tuan
   Zhou, Jun
TI RETRACTED: Focusing properties of a photonic crystal slab with multiple
   mechanisms in addition to negative refraction (Retracted Article. See
   vol 104, pg 283, 2007)
SO JOURNAL OF THE OPTICAL SOCIETY OF AMERICA A-OPTICS IMAGE SCIENCE AND
   VISION
LA English
DT Article; Retracted Publication
ID FLAT LENS
AB A brief review of imaging by a photonic crystal (PC) slab with negative refraction is given. The focusing properties of the PC with multiple mechanisms in addition to negative refraction are studied by the finite-difference time-domain method. In addition to the effect of negative refraction, there are multiple mechanisms that are all attributed to the PC focusing properties, including Bragg diffraction, excitation of the surface mode, and self-collimation. The resulting field pattern is the total result of these factors. Bragg diffraction occurs in the high-frequency domain and mainly influences the quality of focusing in the optical axis direction. The excitation of the surface mode improves the resolution of focusing. Self-collimation makes the focusing position deviate from Snell's law. (c) 2006 Optical Society of America.
C1 Zhenjiang Watercraft Coll, Dept Phys, Zhenjiang 212003, Peoples R China.
   Jiangsu Univ, Dept Opt Engn, Zhenjiang 212013, Peoples R China.
RP Fang, YT (reprint author), Zhenjiang Watercraft Coll, Dept Phys, Zhenjiang 212003, Peoples R China.
EM fang_yt1965@sina.com
CR BERENGER JP, 1994, J COMPUT PHYS, V114, P185, DOI 10.1006/jcph.1994.1159
   Chien HT, 2004, PHYS REV B, V70, DOI 10.1103/113101
   Cubukcu E, 2003, NATURE, V423, P604, DOI 10.1038/423604b
   FANG Y, IN PRESS OPT MAT
   Foteinopoulou S, 2003, PHYS REV B, V67, DOI 10.1103/PhysRevB.67.235107
   Guven K, 2004, PHYS REV B, V70, DOI 10.1103/PhysRevB.70.205125
   He SL, 2004, PHYS REV B, V70, DOI 10.1103/PhysRevB.70.115113
   Jiang W, 2005, PHYS REV B, V71, DOI 10.1103/PhysRevB.71.245115
   Li ZY, 2003, PHYS REV B, V68, DOI 10.1103/PhysRevB.68.245110
   Luo CY, 2003, PHYS REV B, V68, DOI 10.1103/PhysRevB.68.045115
   Moussa R, 2005, PHYS REV B, V71, DOI 10.1103/PhysRevB.71.085106
   Notomi M, 2000, PHYS REV B, V62, P10696, DOI 10.1103/PhysRevB.62.10696
   Parimi PV, 2003, NATURE, V426, P404, DOI 10.1038/426404a
   Ruan ZC, 2005, PHYS REV B, V71, DOI 10.1103/PhysRevB.71.045111
   VESELAGO VG, 1968, SOV PHYS USPEKHI, V10, P509, DOI 10.1070/PU1968v010n04ABEH003699
   Wang X, 2004, OPT EXPRESS, V12, P2919, DOI 10.1364/OPEX.12.002919
   Wang X, 2005, PHYS REV B, V71, DOI 10.1103/PhysRevB.71.233101
   YEE KS, 1966, IEEE T ANTENN PROPAG, VAP14, P302
   Zhang XD, 2005, PHYS REV B, V71, DOI 10.1103/PhysRevB.71.165116
   Zhang XD, 2004, PHYS REV B, V70, DOI 10.1103/PhysRevB.70.195110
NR 20
TC 4
Z9 4
U1 4
U2 5
PU OPTICAL SOC AMER
PI WASHINGTON
PA 2010 MASSACHUSETTS AVE NW, WASHINGTON, DC 20036 USA
SN 1084-7529
EI 1520-8532
J9 J OPT SOC AM A
JI J. Opt. Soc. Am. A-Opt. Image Sci. Vis.
PD SEP
PY 2006
VL 23
IS 9
BP 2283
EP 2289
DI 10.1364/JOSAA.23.002283
PG 7
WC Optics
SC Optics
GA 078AZ
UT WOS:000240074600023
PM 16912754
DA 2018-12-27
ER

PT J
AU Starkman, JS
   Wolter, C
   Gomelsky, A
   Scarpero, HM
   Dmochowski, RR
AF Starkman, Jonathan S.
   Wolter, Christopher
   Gomelsky, Alex
   Scarpero, Harriette M.
   Dmochowski, Roger R.
TI RETRACTED: Voiding dysfunction following removal of eroded synthetic mid
   urethral slings (Retracted Article. See vol 176, pg 2749, 2006)
SO JOURNAL OF UROLOGY
LA English
DT Article; Retracted Publication
DE urinary incontinence; vagina; urethra; bladder; prostheses and implants
ID FREE VAGINAL TAPE; STRESS URINARY-INCONTINENCE; POLYPROPYLENE MESH;
   PUBOVAGINAL SLINGS; COMPLICATIONS; MANAGEMENT; EROSION; DIAGNOSIS
AB Purpose: Voiding dysfunction following genitourinary erosion of synthetic mid urethral slings is not clearly reported. We investigated the incidence of voiding dysfunction in patients following sling excision due to vaginal, urethral or intravesical mesh erosion.
   Materials and Methods: Retrospective review identified 19 patients with genitourinary erosion of polypropylene mesh slings. Comprehensive urological evaluation was performed in all patients, and perioperative and postoperative data were analyzed. Voiding dysfunction was defined as refractory storage symptoms, emptying symptoms and pelvic pain. All subsequent medical and surgical interventions were recorded.
   Results: In 19 patients a total of 11 vaginal, 7 intravesical and 5 urethral erosions occurred. Mean patient age was 52 years (range 32 to 69) and average followup was 8.4 months (range 3 to 34). Average time from symptom onset to sling removal was 10.1 months (range 1.5 to 38). Of the 19 patients 14 (74%) presented with multiple symptoms. Symptoms varied, including refractory pain, recurrent infections and bladder storage/emptying dysfunction. Urodynamic studies were abnormal preoperatively and postoperatively in 9 of 13 (69%) and 4 of 6 patients (67%), respectively. Following surgery lower urinary tract symptoms resolved completely in only 4 of the 19 patients (21%). Stress incontinence recurred in 8 of the 19 patients (42%). Five patients underwent simultaneous pubovaginal sling, of whom none had recurrent stress urinary incontinence. Only 9 patients (47%) considered themselves dry with no pads following surgery. Four patients required further surgery for refractory voiding symptoms.
   Conclusions: Voiding dysfunction is not an uncommon finding after sling excision in the setting of genitourinary erosion. It may cause additional patient morbidity.
C1 Vanderbilt Univ, Med Ctr, Dept Urol Surg, Nashville, TN 37232 USA.
   Louisiana State Univ, Dept Urol, Shreveport, LA 71105 USA.
RP Dmochowski, RR (reprint author), Vanderbilt Univ, Med Ctr, Dept Urol Surg, A-1302 Med Ctr N, Nashville, TN 37232 USA.
EM roger.dmochowski@vanderbilt.edu
CR Amundsen CL, 2003, J UROLOGY, V170, P134, DOI 10.1097/01.ju.0000064442.45724.af
   Clemens JQ, 2000, UROLOGY, V56, P589, DOI 10.1016/S0090-4295(00)00740-8
   de Tayrac R, 2004, Gynecol Obstet Fertil, V32, P1031, DOI 10.1016/j.gyobfe.2004.10.019
   Delorme E, 2001, PROG UROL, V11, P1306
   Domingo S, 2005, J UROLOGY, V173, P1627, DOI 10.1097/01.ju.0000154941.24547.0f
   Huang KH, 2005, INT UROGYNECOL J, V16, P437, DOI 10.1007/s00192-004-1275-0
   Jorion JL, 2002, J UROLOGY, V168, P197, DOI 10.1016/S0022-5347(05)64867-7
   Karram MM, 2003, OBSTET GYNECOL, V101, P929, DOI 10.1016/S0029-7844(03)00122-4
   Kobashi KC, 2003, J UROLOGY, V169, P2242, DOI 10.1097/01.ju.0000060119.43064.f6
   Kuuva N, 2002, ACTA OBSTET GYN SCAN, V81, P72, DOI 10.1080/obs.81.1.72
   Leach GE, 1997, J UROLOGY, V158, P875, DOI 10.1016/S0022-5347(01)64346-5
   Levin I, 2004, NEUROUROL URODYNAM, V23, P7, DOI 10.1002/nau.10164
   McLennan MT, 2004, INT UROGYNECOL J, V15, P360, DOI 10.1007/s00192-004-1169-1
   Meschia M, 2001, INT UROGYNECOL J, V12, pS24, DOI 10.1007/s001920170008
   Pit MJ, 2002, J UROLOGY, V167, P647, DOI 10.1016/S0022-5347(01)69107-9
   Rardin CR, 2002, OBSTET GYNECOL, V100, P898, DOI 10.1016/S0029-7844(02)02279-2
   Slack M, 2006, INT UROGYNECOL J, V17, P106, DOI 10.1007/s00192-005-1320-7
   Sweat SD, 2002, J UROLOGY, V168, P144, DOI 10.1016/S0022-5347(05)64848-3
   Tsivian A, 2004, J UROLOGY, V171, P762, DOI 10.1097/01.ju.0000106083.51860.ca
   Ulmsten U, 1996, Int Urogynecol J Pelvic Floor Dysfunct, V7, P81, DOI 10.1007/BF01902378
NR 20
TC 20
Z9 21
U1 3
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0022-5347
EI 1527-3792
J9 J UROLOGY
JI J. Urol.
PD SEP
PY 2006
VL 176
IS 3
BP 1040
EP 1044
DI 10.1016/j.juro.2006.04.103
PG 5
WC Urology & Nephrology
SC Urology & Nephrology
GA 073KD
UT WOS:000239740800050
PM 16890687
DA 2018-12-27
ER

PT J
AU Bryant, JE
AF Bryant, Julie E.
TI RETRACTED: In-cell protein dynamics (Retracted Article. See vol 3, pg
   862, 2007)
SO MOLECULAR BIOSYSTEMS
LA English
DT Article; Retracted Publication
ID MAGNETIC-RESONANCE RELAXATION; MODEL-FREE APPROACH; NMR-SPECTROSCOPY;
   APOCYTOCHROME B(5); LIVING CELLS; BACKBONE DYNAMICS; ESCHERICHIA-COLI;
   STATE; MACROMOLECULES; IDENTIFICATION
AB The native intracellular environment of proteins is crowded with metabolites and macromolecules. However, most biophysical information concerning proteins is acquired in dilute solution. To determine whether there are differences in dynamics, nuclear magnetic resonance spectroscopy can be used to measure N-15 relaxation in uniformly N-15-enriched apocytochrome b(5) inside living Escherichia coli and in dilute solution. Such data can then be used to compare the fast backbone dynamics of the partially folded protein in cells to its dynamics in dilute solution by using Lipari-Szabo analysis. It appears that the intracellular environment does not alter the protein's structure, or significantly change its fast dynamics. Specifically, the cytosol does not change the amplitude of fast backbone motions, but does increase the average timescale of these motions, most likely due to the increase in viscosity of the cytosol.
C1 Univ N Carolina, Dept Chem, Chapel Hill, NC 27599 USA.
RP Bryant, JE (reprint author), Schering Plough Corp, Kenilworth, NJ 07033 USA.
EM bryant.je@gmail.com
CR Andrec M, 2000, J BIOMOL NMR, V18, P83, DOI 10.1023/A:1008302101116
   Bhattacharya S, 1999, BIOCHEMISTRY-US, V38, P2577, DOI 10.1021/bi982316d
   BICKNESE S, 1993, BIOPHYS J, V65, P1272, DOI 10.1016/S0006-3495(93)81179-2
   Bryant JE, 2005, BIOCHEMISTRY-US, V44, P9275, DOI 10.1021/bi050786j
   BRYANT JE, 2006, IN PRESS BIOCHEMISTR
   Burz DS, 2006, NAT METHODS, V3, P91, DOI 10.1038/NMETH851
   Constans AJ, 1998, PROTEIN SCI, V7, P1983, DOI 10.1002/pro.5560070914
   Dedmon MM, 2002, P NATL ACAD SCI USA, V99, P12681, DOI 10.1073/pnas.202331299
   Falzone CJ, 1996, BIOCHEMISTRY-US, V35, P6519, DOI 10.1021/bi960501q
   Hanson WM, 2003, J MOL BIOL, V333, P425, DOI 10.1016/j.jmb.2003.08.023
   Hatters DM, 2002, J BIOL CHEM, V277, P7824, DOI 10.1074/jbc.M110429200
   Hubbard JA, 2003, MOL MICROBIOL, V49, P1191, DOI 10.1046/j.1365-2958.2003.03628.x
   KAY LE, 1989, BIOCHEMISTRY-US, V28, P8972, DOI 10.1021/bi00449a003
   Lindorff-Larsen K, 2005, NATURE, V433, P128, DOI 10.1038/nature03199
   LIPARI G, 1982, J AM CHEM SOC, V104, P4559, DOI 10.1021/ja00381a010
   LIPARI G, 1982, J AM CHEM SOC, V104, P4546, DOI 10.1021/ja00381a009
   Luby-Phelps K, 2000, INT REV CYTOL, V192, P189
   McNulty BC, 2006, J MOL BIOL, V355, P893, DOI 10.1016/j.jmb.2005.11.033
   Minton AP, 2001, J BIOL CHEM, V276, P10577, DOI 10.1074/jbc.R100005200
   Palmer AG, 2001, ANNU REV BIOPH BIOM, V30, P129, DOI 10.1146/annurev.biophys.30.1.129
   PFEIL W, 1993, PROTEIN SCI, V2, P1497, DOI 10.1002/pro.5560020914
   Rivas G, 2001, P NATL ACAD SCI USA, V98, P3150, DOI 10.1073/pnas.051634398
   Sasahara K, 2003, J MOL BIOL, V326, P1227, DOI 10.1016/S0022-2836(02)01443-2
   Serber Z, 2005, METHOD ENZYMOL, V394, P17, DOI 10.1016/S0076-6879(05)94002-0
   Serber Z, 2004, J AM CHEM SOC, V126, P7119, DOI 10.1021/ja049977k
   Serber Z, 2001, J AM CHEM SOC, V123, P8895, DOI 10.1021/ja0112846
   Serber Z, 2001, BIOCHEMISTRY-US, V40, P14317, DOI 10.1021/bi011751w
   Serber Z, 2001, J AM CHEM SOC, V123, P2446, DOI 10.1021/ja0057528
   Shimba N, 2003, BIOCHEMISTRY-US, V42, P9227, DOI 10.1021/bi0344679
NR 29
TC 4
Z9 4
U1 3
U2 8
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 1742-206X
EI 1742-2051
J9 MOL BIOSYST
JI Mol. Biosyst.
PD SEP
PY 2006
VL 2
IS 9
BP 406
EP 410
DI 10.1039/b604684c
PG 5
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 080YL
UT WOS:000240284300006
PM 17153136
DA 2018-12-27
ER

PT J
AU Grueter, CE
   Abiria, SA
   Dzhura, I
   Wu, Y
   Ham, AJL
   Mohler, PJ
   Anderson, ME
   Colbran, RJ
AF Grueter, Chad E.
   Abiria, Sunday A.
   Dzhura, Igor
   Wu, Yuejin
   Ham, Amy-Joan L.
   Mohler, Peter J.
   Anderson, Mark E.
   Colbran, Roger J.
TI RETRACTED: L-type Ca2+ channel facilitation mediated by phosphorylation
   of the beta subunit by CaMKII (Retracted article. See vol. 58, pg. 388,
   2015)
SO MOLECULAR CELL
LA English
DT Article; Retracted Publication
ID PROTEIN-KINASE-II; D-ASPARTATE RECEPTOR; RABBIT VENTRICULAR MYOCYTES;
   CARDIAC RYANODINE RECEPTOR; CALCIUM-CHANNELS; CALMODULIN KINASE;
   DEPENDENT FACILITATION; HEART-FAILURE; NR2B SUBUNIT;
   SUBCELLULAR-LOCALIZATION
AB L-type Ca2+ channels (LTCCs) are major entry points for Ca2+ in many cells. Ca2+/calmodulin-dependent protein kinase II (CaMKII) is associated with cardiac LTCC complexes and increases channel open probability (P-O) to dynamically increase Ca2+ current (I-Ca) and augment cellular Ca2+ signaling by a process called facilitation. However, the critical molecular mechanisms for CaMKII localization to LTCCs and I-Ca facilitation in cardiomyocytes have not been defined. We show CaMKII binds to the LTCC beta(2a) subunit and preferentially phosphorylates Thr498 in beta(2a). Mutation of Thr498 to Ala (T498A) in beta(2a) prevents CaMKII-mediated increases in the P-O of recombinant LTCCs. Moreover, expression of beta(2a).(T498A) in adult cardiomyocytes ablates CaMKII-mediated I-Ca facilitation, demonstrating that phosphorylation of beta(2a) at Thr498 modulates native calcium channels. These findings reveal a molecular mechanism for targeting CaMKII to LTCCs and facilitating I-Ca that may modulate Ca2+ entry in diverse cell types coexpressing CaMKII and the beta(2a) subunit.
C1 Vanderbilt Univ, Med Ctr, Dept Mol Physiol & Biophys, Nashville, TN 37232 USA.
   Vanderbilt Univ, Med Ctr, Dept Internal Med, Nashville, TN 37232 USA.
   Vanderbilt Univ, Med Ctr, Dept Biochem, Nashville, TN 37232 USA.
   Vanderbilt Univ, Med Ctr, Dept Pathol, Nashville, TN 37232 USA.
   Vanderbilt Univ, Med Ctr, Dept Pharmacol, Nashville, TN 37232 USA.
   Vanderbilt Univ, Med Ctr, Dept Pharmacol, Nashville, TN 37232 USA.
   Vanderbilt Univ, Med Ctr, Ctr Mol Neurosci, Nashville, TN 37232 USA.
   Vanderbilt Univ, Med Ctr, Mass Spectrometry Res Ctr, Nashville, TN 37232 USA.
   Vanderbilt Univ, Med Ctr, Vanderbilt Kennedy Ctr Res Human Dev, Nashville, TN 37232 USA.
RP Anderson, ME (reprint author), Univ Iowa, Dept Internal Med, Iowa City, IA 52242 USA.
EM mark-e-anderson@uiowa.edu; roger.colbran@vanderbilt.edu
OI Colbran, Roger/0000-0001-7401-8244
FU NHLBI NIH HHS [HL46681, HL062494, HL70250, HL07411]; NIMH NIH HHS [R01
   MH063232, R01 MH063232-07, MH63232]
CR Ai X, 2005, CIRC RES, V97, P1314, DOI 10.1161/01.RES.0000194329.41863.89
   Alseikhan BA, 2002, P NATL ACAD SCI USA, V99, P17185, DOI 10.1073/pnas.262372999
   ANDERSON ME, 1994, CIRC RES, V75, P854, DOI 10.1161/01.RES.75.5.854
   Anderson ME, 1998, J PHARMACOL EXP THER, V287, P996
   Arikkath J, 2003, CURR OPIN NEUROBIOL, V13, P298, DOI 10.1016/S0959-4388(03)00066-7
   ARTALEJO CR, 1994, NATURE, V367, P72, DOI 10.1038/367072a0
   Bayer KU, 1999, MOL BRAIN RES, V70, P147, DOI 10.1016/S0169-328X(99)00131-X
   Bayer KU, 2001, NATURE, V411, P801, DOI 10.1038/35081080
   Bunemann M, 1999, J BIOL CHEM, V274, P33851, DOI 10.1074/jbc.274.48.33851
   Catterall WA, 2000, ANNU REV CELL DEV BI, V16, P521, DOI 10.1146/annurev.cellbio.16.1.521
   Chen XW, 2005, CIRC RES, V97, P1009, DOI 10.1161/01.RES.0000189270.72915.D1
   COLBRAN RJ, 1993, J BIOL CHEM, V268, P7163
   Colecraft HM, 2002, J PHYSIOL-LONDON, V541, P435, DOI 10.1113/jphysiol.2002.018515
   De Koninck P, 1998, SCIENCE, V279, P227, DOI 10.1126/science.279.5348.227
   Dolmetsch RE, 2001, SCIENCE, V294, P333, DOI 10.1126/science.1063395
   Dolphin AC, 2003, J BIOENERG BIOMEMBR, V35, P599, DOI 10.1023/B:JOBB.0000008026.37790.5a
   Dzhura I, 2003, J PHYSIOL-LONDON, V550, P731, DOI 10.1113/jphysiol.2003.043778
   Dzhura I, 2002, J PHYSIOL-LONDON, V545, P399, DOI 10.1113/jphysiol.2002.021881
   Dzhura I, 2000, NAT CELL BIOL, V2, P173
   Erxleben C, 2006, P NATL ACAD SCI USA, V103, P3932, DOI 10.1073/pnas.0511322103
   Eshete F, 2001, J NEUROSCI, V21, P6694
   Foell JD, 2004, PHYSIOL GENOMICS, V17, P183, DOI 10.1152/physiolgenomics.00207.2003
   Ganesan AN, 2006, CIRC RES, V98, pE11, DOI 10.1161/01.RES.0000202695.23001.e2
   Gao TY, 1997, NEURON, V19, P185, DOI 10.1016/S0896-6273(00)80358-X
   Gao TY, 1997, J BIOL CHEM, V272, P19401, DOI 10.1074/jbc.272.31.19401
   GROVER LM, 1990, NATURE, V347, P477, DOI 10.1038/347477a0
   Hansen BT, 2005, J PROTEOME RES, V4, P358, DOI 10.1021/pr0498234
   Hudmon A, 2005, J CELL BIOL, V171, P537, DOI 10.1083/jcb.200505155
   Hulme JT, 2003, P NATL ACAD SCI USA, V100, P13093, DOI 10.1073/pnas.2135335100
   Ji Y, 2006, AM J PHYSIOL-HEART C, V290, pH599, DOI 10.1152/ajpheart.00214.2005
   Ji Y, 2003, J BIOL CHEM, V278, P25063, DOI 10.1074/jbc.M302193200
   Lee A, 2000, J NEUROSCI, V20, P6830
   Maier LS, 2003, CIRC RES, V92, P904, DOI 10.1161/01.RES.0000069685.20258.F1
   Manza LL, 2005, PROTEOMICS, V5, P1742, DOI 10.1002/pmic.200401063
   MCNEILL RB, 1995, J BIOL CHEM, V270, P10043, DOI 10.1074/jbc.270.17.10043
   MIKAMI A, 1989, NATURE, V340, P230, DOI 10.1038/340230a0
   Mohler PJ, 2004, P NATL ACAD SCI USA, V101, P17533, DOI 10.1073/pnas.0403711101
   O-Uchi J, 2005, P NATL ACAD SCI USA, V102, P9400, DOI 10.1073/pnas.0503569102
   Omkumar RV, 1996, J BIOL CHEM, V271, P31670, DOI 10.1074/jbc.271.49.31670
   Robison AJ, 2005, J BIOL CHEM, V280, P39316, DOI 10.1074/jbc.M508189200
   Schroder F, 1998, CIRCULATION, V98, P969, DOI 10.1161/01.CIR.98.10.969
   Strack S, 2000, J BIOL CHEM, V275, P23798, DOI 10.1074/jbc.M001471200
   Strack S, 1998, J BIOL CHEM, V273, P20689, DOI 10.1074/jbc.273.33.20689
   TANABE T, 1990, NATURE, V344, P451, DOI 10.1038/344451a0
   Van Petegem F, 2004, NATURE, V429, P671, DOI 10.1038/nature02588
   WAKAMORI M, 1993, BIOCHEM BIOPH RES CO, V196, P1170, DOI 10.1006/bbrc.1993.2374
   Wehrens XHT, 2004, CIRC RES, V94, pE61, DOI 10.1161/01.RES.0000125626.33738.E2
   Wei S, 2000, CIRC RES, V86, P175, DOI 10.1161/01.RES.86.2.175
   Wu YJ, 2004, J PHYSIOL-LONDON, V554, P145, DOI 10.1113/jphysiol.2003.053314
   Wu YJ, 2001, P NATL ACAD SCI USA, V98, P2877, DOI 10.1073/pnas.051449198
   Wu YJ, 2001, J PHYSIOL-LONDON, V535, P679, DOI 10.1111/j.1469-7793.2001.t01-1-00679.x
   Wu YJ, 1999, AM J PHYSIOL-HEART C, V276, pH2168, DOI 10.1152/ajpheart.1999.276.6.H2168
   XIAO RP, 1994, P NATL ACAD SCI USA, V91, P9659, DOI 10.1073/pnas.91.20.9659
   Yasuda R, 2003, NAT NEUROSCI, V6, P948, DOI 10.1038/nn1112
   YUAN WL, 1994, AM J PHYSIOL, V267, pH982
   Zhang R, 2005, FASEB J, V19, P1153, DOI 10.1096/fj.04-3283fje
   Zhang R, 2005, NAT MED, V11, P409, DOI 10.1038/nm1215
   Zhang T, 2004, CARDIOVASC RES, V63, P476, DOI 10.1016/j.cardiores.2004.04.026
   Zhang T, 2003, CIRC RES, V92, P912, DOI 10.1161/01.RES.0000069686.31472.C5
   Zhang T, 2002, J BIOL CHEM, V277, P1261, DOI 10.1074/jbc.M108525200
   Zuhlke RD, 1999, NATURE, V399, P159
NR 61
TC 142
Z9 148
U1 4
U2 15
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 1097-2765
EI 1097-4164
J9 MOL CELL
JI Mol. Cell
PD SEP 1
PY 2006
VL 23
IS 5
BP 641
EP 650
DI 10.1016/j.molcel.2006.07.006
PG 10
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 086HC
UT WOS:000240663400003
PM 16949361
OA Bronze
DA 2018-12-27
ER

PT J
AU Hua, ZM
   Yang, XC
   Fromm, ME
AF Hua, Zhi-Ming
   Yang, Xianci
   Fromm, Michael E.
TI RETRACTED: Activation of the NaCl- and drought-induced RD29A and RD29B
   promoters by constitutively active Arabidopsis MAPKK or MAPK proteins
   (Retracted Article. See vol 29, pg 2253, 2006)
SO PLANT CELL AND ENVIRONMENT
LA English
DT Article; Retracted Publication
DE Arabidopsis thaliana; hypersensitive response
ID DISEASE RESISTANCE; SIGNALING PATHWAYS; ABSCISIC-ACID;
   SACCHAROMYCES-CEREVISIAE; KINASE PATHWAYS; CROSS-TALK; STRESS; PLANTS;
   ETHYLENE; CASCADE
AB Mitogen-activated protein (MAP) kinases mediate cellular responses to a wide variety of stimuli. Activation of a MAP kinase (MAPK) occurs after phosphorylation by an upstream MAP kinase kinase (MAPKK). The Arabidopsis thaliana genome encodes 10 MKKs, but few of these have been shown directly to activate any of the 20 Arabidopsis MAPKs (AtMPKs) and NaCl-, drought- or abscisic acid (ABA)-induced genes RD29A or RD29B. We have constructed the constitutively activated form for nine of the 10 AtMKK proteins, and tested their ability to activate the RD29A and RD29B promoters and also checked the ability of the nine activated AtMKK proteins to phosphorylate 11 of the AtMPK proteins in transient assays. The results show that three proteins, AtMKK1, AtMKK2 and AtMKK3, could activate the RD29A promoter, while these three and two additional AtMKK6/8 proteins could activate the RD29B promoter. Four other proteins, AtMKK7/AtMKK9 and AtMKK4/AtMKK5, can cause hypersensitive response (HR) in tobacco leaves using transient analysis. The activation of the RD29A promoter correlated with four uniquely activated AtMPK proteins. A novel method of activating AtMPK proteins by fusion to a cis-acting mutant of a human MAPK kinase MEK1 was used to confirm that specific members of the AtMPK gene family can activate the RD29A stress pathway.
C1 Univ Nebraska, Plant Sci Initiat, Lincoln, NE 68508 USA.
   Yangtze Univ, Sch Biol, Jingzhu 434025, Peoples R China.
RP Hua, ZM (reprint author), Univ Nebraska, Plant Sci Initiat, Lincoln, NE 68508 USA.
EM zhimingh@hotmail.com
CR Asai T, 2002, NATURE, V415, P977, DOI 10.1038/415977a
   Cardinale F, 2002, PLANT CELL, V14, P703, DOI 10.1105/tpc.010256
   Chang CR, 2003, TRENDS PLANT SCI, V8, P365, DOI 10.1016/S1360-1385(03)00156-0
   Cormack BP, 1996, GENE, V173, P33, DOI 10.1016/0378-1119(95)00685-0
   Cowan KJ, 2003, J EXP BIOL, V206, P1107, DOI 10.1242/jeb.00220
   de Nadal E, 2002, EMBO REP, V3, P735, DOI 10.1093/embo-reports/kvf158
   Droillard MJ, 2002, FEBS LETT, V527, P43, DOI 10.1016/S0014-5793(02)03162-9
   Ecker JR, 2004, PLANT CELL, V16, P3169, DOI 10.1105/tpc.104.161210
   Ekengren SK, 2003, PLANT J, V36, P905, DOI 10.1046/j.1365-313X.2003.01944.x
   Gagiano M, 2002, FEMS YEAST RES, V2, P433, DOI 10.1111/j.1567-1364.2002.tb00114.x
   Guo HW, 2004, CURR OPIN PLANT BIOL, V7, P40, DOI 10.1016/j.pbi.2003.11.011
   Gustin MC, 1998, MICROBIOL MOL BIOL R, V62, P1264
   Hoyos ME, 2000, PLANT PHYSIOL, V122, P1355, DOI 10.1104/pp.122.4.1355
   Ichimura K, 2002, TRENDS PLANT SCI, V7, P301
   Ichimura K, 2000, PLANT J, V24, P655, DOI 10.1046/j.1365-313x.2000.00913.x
   Jin HL, 2003, PLANT J, V33, P719, DOI 10.1046/j.1365-313X.2003.01664.x
   Jonak C, 2002, CURR OPIN PLANT BIOL, V5, P415, DOI 10.1016/S1369-5266(02)00285-6
   Kiegerl S, 2000, PLANT CELL, V12, P2247, DOI 10.1105/tpc.12.11.2247
   Kim CY, 2003, PLANT CELL, V15, P2707, DOI 10.1105/tpc.011411
   Knight H, 2001, TRENDS PLANT SCI, V6, P262, DOI 10.1016/S1360-1385(01)01946-X
   Kovtun Y, 2000, P NATL ACAD SCI USA, V97, P2940, DOI 10.1073/pnas.97.6.2940
   Lu C, 2002, P NATL ACAD SCI USA, V99, P15812, DOI 10.1073/pnas.242607499
   Matsuoka D, 2002, PLANT J, V29, P637, DOI 10.1046/j.0960-7412.2001.01246.x
   Menke FLH, 2004, PLANT CELL, V16, P897, DOI 10.1105/tpc.015552
   Mikolajczyk M, 2000, PLANT CELL, V12, P165, DOI 10.1105/tpc.12.1.165
   Nakagami H, 2005, TRENDS PLANT SCI, V10, P339, DOI 10.1016/j.tplants.2005.05.009
   Narusaka Y, 2003, PLANT J, V34, P137, DOI 10.1046/j.1365-313X.2003.01708.x
   O'Rourke SM, 2002, TRENDS GENET, V18, P405, DOI 10.1016/S0168-9525(02)02723-3
   Ouaked F, 2003, EMBO J, V22, P1282, DOI 10.1093/emboj/cdg131
   Petersen M, 2000, CELL, V103, P1111, DOI 10.1016/S0092-8674(00)00213-0
   Ren DT, 2002, J BIOL CHEM, V277, P559, DOI 10.1074/jbc.M109495200
   Rivas S, 2002, PLANT CELL, V14, P689, DOI [10.1105/tpc.010357, 10.​1105/​tpc.​010357]
   Robinson MJ, 1998, CURR BIOL, V8, P1141, DOI 10.1016/S0960-9822(07)00485-X
   Rohila JS, 2004, PLANT J, V38, P172, DOI 10.1111/j.1365-313X.2004.02031.x
   Shinozaki K, 1996, CURR OPIN BIOTECH, V7, P161, DOI 10.1016/S0958-1669(96)80007-3
   Soyano T, 2003, GENE DEV, V17, P1055, DOI 10.1101/gad.1071103
   Teige M, 2004, MOL CELL, V15, P141, DOI 10.1016/j.molcel.2004.06.023
   Uno Y, 2000, P NATL ACAD SCI USA, V97, P11632, DOI 10.1073/pnas.190309197
   Xiong LZ, 2003, PLANT CELL, V15, P745, DOI 10.1105/tpc.008714
   Xu BE, 2001, J BIOL CHEM, V276, P26509, DOI 10.1074/jbc.M102769200
   Zhang SQ, 2001, PLANT CELL, V13, P1877, DOI 10.1105/tpc.13.8.1877
   Zuo JR, 2000, PLANT J, V24, P265, DOI 10.1046/j.1365-313x.2000.00868.x
NR 42
TC 27
Z9 31
U1 4
U2 25
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0140-7791
EI 1365-3040
J9 PLANT CELL ENVIRON
JI Plant Cell Environ.
PD SEP
PY 2006
VL 29
IS 9
BP 1761
EP 1770
DI 10.1111/j.1365-3040.2006.01552.x
PG 10
WC Plant Sciences
SC Plant Sciences
GA 068JU
UT WOS:000239370700008
PM 16913865
OA Bronze
DA 2018-12-27
ER

PT J
AU Lee, SH
   Lee, DG
   Woo, HS
   Lee, KW
   Kim, DH
   Kwak, SS
   Kim, JS
   Kim, H
   Ahsan, N
   Choi, MS
   Yang, JK
   Lee, BH
AF Lee, Sang-Hoon
   Lee, Dong-Gi
   Woo, Hyun-Sook
   Lee, Ki-Won
   Kim, Do-Hyun
   Kwak, Sang-Soo
   Kim, Jin-Seog
   Kim, Hyegi
   Ahsan, Nagib
   Choi, Myung Suk
   Yang, Jae-Kyung
   Lee, Byung-Hyun
TI RETRACTED: Production of transgenic orchardgrass via
   Agrobacterium-mediated transformation of seed-derived callus tissues
   (Retracted article. See vol. 198, pg. 110, 2013)
SO PLANT SCIENCE
LA English
DT Article; Retracted Publication
DE Agrobacterium tumefaciens; forage grass; orchardgrass; transgenic plants
ID HIGH-EFFICIENCY TRANSFORMATION; HIGHLY REGENERATIVE TISSUES; BARLEY
   HORDEUM-VULGARE; T-DNA; GENETIC-TRANSFORMATION; TALL FESCUE;
   SEQUENCE-ANALYSIS; TUMEFACIENS; PLANTS; RICE
AB An Agrobacterium-mediated genetic transformation method for orchardgrass (Dactylis glomerata L.) has been developed from seed-derived callus. In order to optimize the conditions for orchardgrass transformation, several factors known to influence Agrobacterium-mediated DNA transfer were examined. Seed-derived embryogenic calli were co-cultivated with A. tumefaciens strains harboring the binary vector pIG 121 Hm. Transient GUS expression was greatly affected by the A. tumefaciens strain, the duration of co-cultivation, and the presence of acetosyringone during inoculation and co-cultivation. Among the three strains tested, EHA101 was most effective for transient GUS expression, followed by GV3101 and LBA4404. The inclusion of 200 mu M acetosyringone in both the inoculation and co-cultivation media increased transient GUS expression from 16.1 to 56.1% in targeted callus tissues. The transgenic nature of primary transformants was demonstrated by GUS activity. Integration of T-DNA into the genome of putative transgenic plants was confirmed by PCR and Southern blot analyses. One or two copies of the transgene were observed in all transgenic plants analyzed. The transgenic plants had a morphologically normal phenotype and the overall transformation efficiency was 4.8%. Thus, Agrobacterium-mediated genetic transformation can be used for the generation of transgenic orchardgrass containing genes of agronomic importance. (c) 2006 Elsevier Ireland Ltd. All rights reserved.
C1 Gyeongsang Natl Univ, Div Appl Life Sci, Jinju 660701, South Korea.
   Korea Res Inst Biosci & Biotechnol, Environm Biotechnol Res Ctr, Taejon 305806, South Korea.
   Korea Res Inst Chem Technol, Biol Funct Res Team, Taejon 305606, South Korea.
   Kyungpook Natl Univ, Dept Anim Sci & Biotechnol, Taegu 702701, South Korea.
   Gyeongsang Natl Univ, Div Environm Forest Sci, Jinju 660701, South Korea.
RP Lee, BH (reprint author), Gyeongsang Natl Univ, Div Appl Life Sci, Jinju 660701, South Korea.
EM hyun@gsnu.ac.kr
OI Lee, Dong-Gi/0000-0002-6767-9543
CR Akutsu M, 2004, PLANT CELL REP, V22, P561, DOI 10.1007/s00299-003-0729-z
   Bajaj S, 2006, PLANT CELL REP, V25, P651, DOI 10.1007/s00299-005-0099-9
   Bettany AJE, 2003, PLANT CELL REP, V21, P437, DOI 10.1007/s00299-002-0531-3
   Casler MD, 2000, CROP SCI, V40, P1019, DOI 10.2135/cropsci2000.4041019x
   Cervera M, 1998, PLANT CELL REP, V18, P271, DOI 10.1007/s002990050570
   Cheng M, 1997, PLANT PHYSIOL, V115, P971, DOI 10.1104/pp.115.3.971
   Cho MJ, 2001, PLANT CELL REP, V20, P318, DOI 10.1007/s002990100330
   Cho MJ, 2000, PLANT CELL REP, V19, P1084, DOI 10.1007/s002990000238
   Christie BR, 1995, FORAGES, VI, P325
   CHU CC, 1975, SCI SINICA, V18, P659
   Denchev PD, 1997, PLANT CELL REP, V16, P813, DOI 10.1007/s002990050326
   Dong SJ, 2005, PLANT SCI, V168, P1453, DOI 10.1016/j.plantsci.2005.01.008
   Fang YD, 2002, J PLANT PHYSIOL, V159, P1131, DOI 10.1078/0176-1617-00707
   GODWIN I, 1991, PLANT CELL REP, V9, P671, DOI 10.1007/BF00235354
   Guo GQ, 1998, CEREAL RES COMMUN, V26, P15
   Han N, 2005, PLANT CELL TISS ORG, V81, P131, DOI 10.1007/s11240-004-4042-5
   HIEI Y, 1994, PLANT J, V6, P271, DOI 10.1046/j.1365-313X.1994.6020271.x
   Hiei Y, 2000, BREED RES, V2, P205
   HORN ME, 1988, PLANT CELL REP, V7, P469, DOI 10.1007/BF00272733
   Ishida Y, 1996, NAT BIOTECHNOL, V14, P745, DOI 10.1038/nbt0696-745
   JEFFERSON RA, 1987, EMBO J, V6, P3901
   Jo JK, 2004, BIOTECHNOL LETT, V26, P1391, DOI 10.1023/B:BILE.0000045638.82348.7a
   Kohli A, 1998, P NATL ACAD SCI USA, V95, P7203, DOI 10.1073/pnas.95.12.7203
   Kondo T, 2000, PLANT CELL REP, V19, P989, DOI 10.1007/s002990000222
   Lee BH, 2000, GENE, V245, P283, DOI 10.1016/S0378-1119(00)00043-3
   Lee SH, 2004, ASIAN AUSTRAL J ANIM, V17, P1390, DOI 10.5713/ajas.2004.1390
   MILLER DA, 1984, FORAGE CROPS, P396
   MURASHIGE T, 1962, PHYSIOL PLANTARUM, V15, P473, DOI 10.1111/j.1399-3054.1962.tb08052.x
   MURRAY MG, 1980, NUCLEIC ACIDS RES, V8, P4321, DOI 10.1093/nar/8.19.4321
   OHTA S, 1990, PLANT CELL PHYSIOL, V31, P805
   SPANGENBERG G, 1998, BIOTECHNOLOGY FORAGE
   Toyama K, 2003, MOL CELLS, V16, P19
   Trifonova A, 2001, PLANT SCI, V161, P871, DOI 10.1016/S0168-9452(01)00479-4
   Tsukazaki H, 2002, PLANT CELL REP, V21, P257, DOI 10.1007/s00299-002-0506-4
   USAMI S, 1987, MOL GEN GENET, V209, P221, DOI 10.1007/BF00329646
   Wu H, 2003, PLANT CELL REP, V21, P659, DOI 10.1007/s00299-002-0564-7
   Wu HX, 1998, PLANT CELL TISS ORG, V54, P161, DOI 10.1023/A:1006106916542
   Zhao ZY, 2002, MOL BREEDING, V8, P323, DOI 10.1023/A:1015243600325
NR 38
TC 22
Z9 27
U1 4
U2 21
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0168-9452
J9 PLANT SCI
JI Plant Sci.
PD SEP
PY 2006
VL 171
IS 3
BP 408
EP 414
DI 10.1016/j.plantsci.2006.05.006
PG 7
WC Biochemistry & Molecular Biology; Plant Sciences
SC Biochemistry & Molecular Biology; Plant Sciences
GA 069VA
UT WOS:000239475500014
PM 22980211
DA 2018-12-27
ER

PT J
AU Chen, BY
AF Chen, Bo-Yong
TI RETRACTED: Infinite dimensionality of the middle L(2)-cohomology on
   non-compact Kahler hyperbolic manifolds (Retracted Article. See vol 44,
   pg 163, 2008)
SO PUBLICATIONS OF THE RESEARCH INSTITUTE FOR MATHEMATICAL SCIENCES
LA English
DT Article; Retracted Publication
ID PSEUDOCONVEX DOMAINS; COHOMOLOGY; CURVATURE; SPACE
AB We prove that the space of L(2) harmonic forms of middle degree is infinite dimensional on any non-compact Kahler hyperbolic manifold.
C1 Tongji Univ, Dept Math, Shanghai 200092, Peoples R China.
RP Chen, BY (reprint author), Tongji Univ, Dept Math, Shanghai 200092, Peoples R China.
EM chenbo-yong@lycos.com
CR Atiyah M. F., 1974, ASTERISQUE, V32-33, P43
   BERS L, 1973, ACTA MATH-DJURSHOLM, V130, P89, DOI 10.1007/BF02392263
   Cao J, 2001, MATH ANN, V319, P483, DOI 10.1007/PL00004444
   Chen BY, 2004, INT J MATH, V15, P1085, DOI 10.1142/S0129167X04002697
   DIEDERICH K, 1995, ANN MATH, V141, P181, DOI 10.2307/2118631
   DONNELLY H, 1994, MICH MATH J, V41, P433
   DONNELLY H, 1983, ANN MATH, V118, P593, DOI 10.2307/2006983
   Donnelly H, 1997, ILLINOIS J MATH, V41, P151
   FEFFERMAN C, 1974, INVENT MATH, V26, P1, DOI 10.1007/BF01406845
   GROMOV M, 1991, J DIFFER GEOM, V33, P263
   Hirzebruch F., 1958, S INT TOPOLOGIA ALGE, P129
   Jost J, 2000, COMMUN ANAL GEOM, V8, P1
   KLEMBECK PF, 1978, INDIANA U MATH J, V27, P275, DOI 10.1512/iumj.1978.27.27020
   McMullen CT, 2000, ANN MATH, V151, P327, DOI 10.2307/121120
   McNeal JD, 2002, MATH ANN, V323, P319, DOI 10.1007/s002080100305
   OHSAWA T, 1989, PUBL RES I MATH SCI, V25, P499, DOI 10.2977/prims/1195173354
   OHSAWA T, 1987, MATH Z, V195, P197, DOI 10.1007/BF01166457
   OHSAWA T, 1991, MATH Z, V206, P219, DOI 10.1007/BF02571337
NR 18
TC 2
Z9 3
U1 6
U2 13
PU KYOTO UNIV
PI KYOTO
PA RESEARCH INST MATHEMATICAL SCIENCES,, KYOTO, 606-8502, JAPAN
SN 0034-5318
J9 PUBL RES I MATH SCI
JI Publ. Res. Inst. Math. Sci.
PD SEP
PY 2006
VL 42
IS 3
BP 683
EP 689
DI 10.2977/prims/1166642154
PG 7
WC Mathematics
SC Mathematics
GA 103HL
UT WOS:000241876200002
OA Bronze
DA 2018-12-27
ER

PT J
AU Zhao, BW
   Zhu, LZ
AF Zhao, Baowei
   Zhu, Lizhong
TI RETRACTED: Solubilization of DNAPLs by mixed surfactant: Synergism and
   solubilization capacity (Retracted Article. See vol 161, pg 1576, 2009)
SO JOURNAL OF HAZARDOUS MATERIALS
LA English
DT Article; Retracted Publication
DE DNAPLs; mixed surfactant; solubilization; partitioning; synergism
ID ETHOXYLATED NONIONIC SURFACTANTS; MIXTURES; DODECANE; LIQUIDS
AB Efforts to remove the dense nonaqueous phase liquids (DNAPLs) in subsurface by mobilizing them face with risks of driving the contaminants deeper into aquifer zones. In this paper, a synergistical solubilization of DNAPLs by mixed nonionic and anionic surfactant, Triton X-100 (TX100) and sodium dodecylbenzene sulfonate (SDBS) in DNAPL/water systems was presented. Given 1:40 phase ratio of DNAPL:water (v/v), mixed TX100-SDBS exhibited significantly synergistical solubilization for the DNAPLs, trichloroethene (TCE), chlorobenzene (CB) and 1,2-dichlorobenzene (1,2-DCB), respectively, when the total surfactant concentration was up to 6000 mg/L, i.e. the condition when solubilization by the mixture was better than those attainable with individual components by themselves. The synergistical extents depended on the initial ratios of TX100 to SDBS, the initial surfactant concentrations and the properties of DNAPLs. Given the total surfactant concentration, synergistical extents increased with the fraction of SDBS in mixed surfactant. On the contrary, did with the total surfactant concentration. The solubilization capacity by 3: 1, 1:1 and 1:3 of mass ratio of TX100-SDBS were determined and compared with those by single ones. In the view of the mass solubilization ratio (SR), the mixed TX100-SDBS could solubilize more DNAPLs than single SDBS at given surfactant concentration. Reduction in partition of TX100 and synergistic solubilization were responsible for the significant solubilization extent of mixed system. The work presented here demonstrates that mixed nonionic-anionic surfactants would be preferred over the corresponding single surfactants for solubilization remediation of DNAPLs, which could decrease risks of driving the contaminants deeper into aquifers. (c) 2005 Elsevier B.V. All rights reserved.
C1 Lanzhou Jiaotong Univ, Sch Environm & Municipal Engn, Lanzhou 730070, Gansu, Peoples R China.
   Zhejiang Univ, Dept Environm Sci, Hangzhou 310028, Peoples R China.
RP Zhao, BW (reprint author), Lanzhou Jiaotong Univ, Sch Environm & Municipal Engn, Lanzhou 730070, Gansu, Peoples R China.
EM baoweizhao@mail.lzjtu.cn; zlz@zju.edu.cn
RI x, z/A-9144-2010
CR *AGWSE, 1992, GROUND WATER, V30, P781
   Boving TB, 2000, J CONTAM HYDROL, V42, P51, DOI 10.1016/S0169-7722(99)00077-7
   Butler EC, 1998, WATER RES, V32, P1345, DOI 10.1016/S0043-1354(97)00360-6
   Cowell MA, 2000, ENVIRON SCI TECHNOL, V34, P1583, DOI 10.1021/es9908826
   FOUNTAIN JC, 1991, J HAZARD MATER, V28, P295, DOI 10.1016/0304-3894(91)87081-C
   Harwell JH, 1999, COLLOID SURFACE A, V151, P255, DOI 10.1016/S0927-7757(98)00785-7
   HOLLAND PM, 1983, J PHYS CHEM-US, V87, P1984, DOI 10.1021/j100234a030
   Jawitz JW, 2003, ENVIRON SCI TECHNOL, V37, P1983, DOI 10.1021/es0256921
   KILE DE, 1989, ENVIRON SCI TECHNOL, V23, P832, DOI 10.1021/es00065a012
   PENNELL KD, 1993, ENVIRON SCI TECHNOL, V27, P2332, DOI 10.1021/es00048a005
   Pennell KD, 1997, ENVIRON SCI TECHNOL, V31, P1382, DOI 10.1021/es960604w
   POPE GA, 1996, ACS S SERIES, V594
   Prak DJL, 2002, WATER RES, V36, P3463, DOI 10.1016/S0043-1354(02)00070-2
   Rosen Milton J., 1989, SURFACTANTS INTERFAC
   ROSEN MJ, 1982, J COLLOID INTERF SCI, V86, P164, DOI 10.1016/0021-9797(82)90052-2
   Rubingh D. N., 1979, SOLUTION CHEM SURFAC, P337
   *USEPA, 1993, 9355413 USEPA
   WEST CC, 1992, ENVIRON SCI TECHNOL, V26, P2324, DOI 10.1021/es00036a002
   YAWS CL, 1999, CHEM PROPERTIES HDB
   Zhao BW, 2005, CHEMOSPHERE, V58, P33, DOI 10.1016/j.chemosphere.2004.08.067
   Zhong LR, 2003, J CONTAM HYDROL, V60, P55, DOI 10.1016/S0169-7722(02)00063-3
   Zhou MF, 2000, ENVIRON SCI TECHNOL, V34, P1985, DOI 10.1021/es9811546
   Zhu LZ, 2003, CHEMOSPHERE, V53, P459, DOI 10.1016/S0045-6535(03)00541-1
   Zimmerman JB, 1999, ENVIRON SCI TECHNOL, V33, P169, DOI 10.1021/es9802910
NR 24
TC 11
Z9 11
U1 3
U2 17
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0304-3894
EI 1873-3336
J9 J HAZARD MATER
JI J. Hazard. Mater.
PD AUG 25
PY 2006
VL 136
IS 3
BP 513
EP 519
DI 10.1016/j.jhazmat.2005.08.036
PG 7
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA 079WX
UT WOS:000240209700015
PM 16236435
DA 2018-12-27
ER

PT J
AU Bryant, JE
   Lecomte, JTJ
   Lee, AL
   Young, GB
   Pielak, GJ
AF Bryant, Julie E.
   Lecomte, Juliette T. J.
   Lee, Andrew L.
   Young, Gregory B.
   Pielak, Gary J.
TI RETRACTED: Cytosol has a small effect on protein backbone dynamics
   (Retracted Article. See vol 46, pg 8206, 2007)
SO BIOCHEMISTRY
LA English
DT Article; Retracted Publication
ID MAGNETIC-RESONANCE RELAXATION; CELL NMR-SPECTROSCOPY; MODEL-FREE
   APPROACH; ESCHERICHIA-COLI; APOCYTOCHROME B(5); LIVING CELLS;
   MACROMOLECULES; ANISOTROPY; DIFFUSION
AB Cells are crowded with macromolecules, yet most biophysical information about proteins is obtained in dilute solution. To determine the impact of this dichotomy, we used nuclear magnetic resonance spectroscopy to measure the backbone N-15 T-1 and T-2 relaxation times and the {H-1}-N-15 nuclear Overhauser enhancement (nOe) of uniformly N-15-enriched apocytochrome b(5) in living Escherichia coli and in dilute solution. These data allowed us to assess the backbone dynamics of this partially folded protein in cells and in dilute solution. The two data sets were analyzed by using the model-free approach. Transfer from dilute solution to the cytosol has a quantitative effect on T-1, T-2, and nOe values. Most of the effects are attributed to an increase in the overall correlation time, caused by the increased viscosity of the cytosol compared to that of the dilute solution. Our main conclusion is that the cytosol does not alter the pattern of backbone dynamics of apocytochrome b5. Increases in the time scale of both the picosecond and millisecond motions are observed, but the increases are less than similar to 30%.
C1 Univ N Carolina, Dept Chem, Div Med Chem & Nat Prod, Chapel Hill, NC 27599 USA.
   Univ N Carolina, Dept Biochem & Biophys, Div Med Chem & Nat Prod, Chapel Hill, NC 27599 USA.
   Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA.
   Penn State Univ, Dept Chem, University Pk, PA 16802 USA.
RP Pielak, GJ (reprint author), Univ N Carolina, Dept Chem, Div Med Chem & Nat Prod, Chapel Hill, NC 27599 USA.
EM gary_pielak@unc.edu
FU NIGMS NIH HHS [GM-54217]
CR Abragam A., 1961, PRINCIPLES NUCL MAGN
   Bhattacharya S, 1999, BIOCHEMISTRY-US, V38, P2577, DOI 10.1021/bi982316d
   Bryant JE, 2005, BIOCHEMISTRY-US, V44, P9275, DOI 10.1021/bi050786j
   Dedmon MM, 2002, P NATL ACAD SCI USA, V99, P12681, DOI 10.1073/pnas.202331299
   DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809
   DELANO WL, 2005, MACPYMOL PYMOL BASED
   DELLWO MJ, 1989, J AM CHEM SOC, V111, P4571, DOI 10.1021/ja00195a007
   Ernst RR, 1996, NMR AS A STRUCTURAL TOOL FOR MACROMOLECULES, P15
   Falzone CJ, 1996, BIOCHEMISTRY-US, V35, P6519, DOI 10.1021/bi960501q
   Falzone CJ, 2001, BIOCHEMISTRY-US, V40, P4879, DOI 10.1021/bi002681g
   FARROW NA, 1994, BIOCHEMISTRY-US, V33, P5984, DOI 10.1021/bi00185a040
   Jarymowycz VA, 2006, CHEM REV, V106, P1624, DOI 10.1021/cr040421p
   KAY LE, 1992, J MAGN RESON, V97, P359, DOI 10.1016/0022-2364(92)90320-7
   KAY LE, 1992, J AM CHEM SOC, V114, P10663, DOI 10.1021/ja00052a088
   Lee AL, 1999, J BIOMOL NMR, V13, P101, DOI 10.1023/A:1008304220445
   LIPARI G, 1982, J AM CHEM SOC, V104, P4559, DOI 10.1021/ja00381a010
   LIPARI G, 1982, J AM CHEM SOC, V104, P4546, DOI 10.1021/ja00381a009
   Luby-Phelps K, 2000, INT REV CYTOL, V192, P189
   McNulty BC, 2006, J MOL BIOL, V355, P893, DOI 10.1016/j.jmb.2005.11.033
   Mittermaier A, 2006, SCIENCE, V312, P224, DOI 10.1126/science.1124964
   Palmer AG, 2004, CHEM REV, V104, P3623, DOI 10.1021/cr030413t
   Palmer AG, 2001, ANNU REV BIOPH BIOM, V30, P129, DOI 10.1146/annurev.biophys.30.1.129
   PEDERSEN S, 1978, CELL, V14, P179, DOI 10.1016/0092-8674(78)90312-4
   Rivas G, 2001, P NATL ACAD SCI USA, V98, P3150, DOI 10.1073/pnas.051634398
   Sasahara K, 2003, J MOL BIOL, V326, P1227, DOI 10.1016/S0022-2836(02)01443-2
   Serber Z, 2005, METHOD ENZYMOL, V394, P17, DOI 10.1016/S0076-6879(05)94002-0
   Serber Z, 2001, J AM CHEM SOC, V123, P8895, DOI 10.1021/ja0112846
   Taylor J., 1982, INTRO ERROR ANAL
   Tjandra N, 1995, J AM CHEM SOC, V117, P12562, DOI 10.1021/ja00155a020
   Williams SP, 1997, BIOPHYS J, V72, P490, DOI 10.1016/S0006-3495(97)78690-9
   Zeeb M, 2003, J BIOMOL NMR, V27, P221, DOI 10.1023/A:1025449611201
NR 31
TC 13
Z9 14
U1 3
U2 14
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0006-2960
J9 BIOCHEMISTRY-US
JI Biochemistry
PD AUG 22
PY 2006
VL 45
IS 33
BP 10085
EP 10091
DI 10.1021/bi060547b
PG 7
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 073QP
UT WOS:000239758000014
PM 16906766
DA 2018-12-27
ER

PT J
AU Yao, J
   Sun, XH
   Wang, Y
   Wang, L
AF Yao, Jing
   Sun, Xinghuai
   Wang, Yang
   Wang, Ling
TI RETRACTED: Muller glia induce retinal progenitor cells to differentiate
   into retinal ganglion cells (Retracted article. See vol. 21, pg. 907,
   2010)
SO NEUROREPORT
LA English
DT Article; Retracted Publication
DE retinal progenitor cells; retinal ganglion cells; Muller glia; cell
   differentiation
ID NEURAL STEM-CELLS; CHICKEN RETINA; NEURONS; INJURY; RAT
AB Retinal progenitor cells could differentiate into various retinal cells that made cell-replacement therapy possible. Here, we investigated the role of cellular microenvironment on their regulation and differentiation and found that the percentage of proliferating cells and the percentage of retinal ganglion cells produced from them increased, when retinal progenitor cells were cocultured with Muller glia. Muller glia conditioned medium had the similar results. It is speculated that rather than traditional supportive roles, Muller glia may have an active regulatory role inducing retinal progenitor cells to proliferate and differentiate into ganglion cells by secreting some diffusible and membrane-associated factors. Identification of Muller glia-derived factors will be made to elucidate the molecular mechanisms of neurogenesis.
C1 Fudan Univ, Eye & ENT Hosp, Dept Ophthalmol, China Australia Link Lab, Shanghai 200031, Peoples R China.
   Fudan Univ, Shanghai Med Coll, Dept Anat & Embryo, Shanghai 200031, Peoples R China.
RP Sun, XH (reprint author), Fudan Univ, Eye & ENT Hosp, Dept Ophthalmol, China Australia Link Lab, Shanghai 200031, Peoples R China.
EM sun-doctor@163.com
CR Abmad I, 2001, INVEST OPHTH VIS SCI, V42, P2743
   Belliveau MJ, 2000, J NEUROSCI, V20, P2247
   Cao W, 1997, EXP EYE RES, V65, P241, DOI 10.1006/exer.1997.0328
   Cepko CL, 1999, CURR OPIN NEUROBIOL, V9, P37, DOI 10.1016/S0959-4388(99)80005-1
   Chacko DM, 2003, VISION RES, V43, P937, DOI 10.1016/S0042-6989(02)00688-0
   Chacko DM, 2000, BIOCHEM BIOPH RES CO, V268, P842, DOI 10.1006/bbrc.2000.2153
   Fischer AJ, 2001, NAT NEUROSCI, V4, P247, DOI 10.1038/85090
   Fischer AJ, 2002, J NEUROSCI, V22, P9387
   Marquardt T, 2002, TRENDS NEUROSCI, V25, P32, DOI 10.1016/S0166-2236(00)02028-2
   Nakayama T, 2003, NEUROSCI RES, V46, P241, DOI 10.1016/S0168-0102(03)00063-4
   Nishida A, 2000, INVEST OPHTH VIS SCI, V41, P4268
   Song HJ, 2002, NAT NEUROSCI, V5, P438, DOI 10.1038/nn844
   Song SH, 2002, NATURE, V417, P39, DOI 10.1038/417039a
NR 13
TC 2
Z9 3
U1 7
U2 13
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0959-4965
EI 1473-558X
J9 NEUROREPORT
JI Neuroreport
PD AUG 21
PY 2006
VL 17
IS 12
BP 1263
EP 1267
DI 10.1097/01.wnr.0000227991.23046.b7
PG 5
WC Neurosciences
SC Neurosciences & Neurology
GA 080VW
UT WOS:000240277600007
PM 16951566
DA 2018-12-27
ER

PT J
AU Potti, A
   Mukherjee, S
   Petersen, R
   Dressman, HK
   Bild, A
   Koontz, J
   Kratzke, R
   Watson, MA
   Kelley, M
   Ginsburg, GS
   West, M
   Harpole, DH
   Nevins, JR
AF Potti, Anil
   Mukherjee, Sayan
   Petersen, Rebecca
   Dressman, Holly K.
   Bild, Andrea
   Koontz, Jason
   Kratzke, Robert
   Watson, Mark A.
   Kelley, Michael
   Ginsburg, Geoffrey S.
   West, Mike
   Harpole, David H., Jr.
   Nevins, Joseph R.
TI RETRACTED: A genomic strategy to refine prognosis in early-stage
   non-small-cell lung cancer (Retracted Article. See vol 356, pg 201,
   2007)
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Article; Retracted Publication
ID GENE-EXPRESSION PROFILES; BREAST-CANCER; ADJUVANT CHEMOTHERAPY;
   ADENOCARCINOMA; SURVIVAL; PREDICTION; OUTCOMES; CLASSIFICATION;
   IDENTIFICATION; THERAPY
AB BACKGROUND:
   Clinical trials have indicated a benefit of adjuvant chemotherapy for patients with stage IB, II, or IIIA -- but not stage IA -- non-small-cell lung cancer (NSCLC). This classification scheme is probably an imprecise predictor of the prognosis of an individual patient. Indeed, approximately 25 percent of patients with stage IA disease have a recurrence after surgery, suggesting the need to identify patients in this subgroup for more effective therapy.
   METHODS:
   We identified gene-expression profiles that predicted the risk of recurrence in a cohort of 89 patients with early-stage NSCLC (the lung metagene model). We evaluated the predictor in two independent groups of 25 patients from the American College of Surgeons Oncology Group (ACOSOG) Z0030 study and 84 patients from the Cancer and Leukemia Group B (CALGB) 9761 study.
   RESULTS:
   The lung metagene model predicted recurrence for individual patients significantly better than did clinical prognostic factors and was consistent across all early stages of NSCLC. Applied to the cohorts from the ACOSOG Z0030 trial and the CALGB 9761 trial, the lung metagene model had an overall predictive accuracy of 72 percent and 79 percent, respectively. The predictor also identified a subgroup of patients with stage IA disease who were at high risk for recurrence and who might be best treated by adjuvant chemotherapy.
   CONCLUSIONS:
   The lung metagene model provides a potential mechanism to refine the estimation of a patient's risk of disease recurrence and, in principle, to alter decisions regarding the use of adjuvant chemotherapy in early-stage NSCLC.
C1 Duke Univ, Duke Inst Genome Sci & Policy, Durham, NC 27708 USA.
   Duke Univ, Inst Stat & Decis Sci, Durham, NC 27708 USA.
   Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA.
   Duke Univ, Med Ctr, Dept Surg, Durham, NC 27710 USA.
   Duke Univ, Med Ctr, Dept Mol Genet & Microbiol, Durham, NC 27710 USA.
   Univ Minnesota, Dept Med, Minneapolis, MN 55455 USA.
   Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO USA.
RP Nevins, JR (reprint author), Duke Univ, Duke Inst Genome Sci & Policy, 101 Sci Dr,Box 3382, Durham, NC 27708 USA.
EM nevin001@mc.duke.edu
OI Kelley, Michael/0000-0001-9523-6080
CR Beer DG, 2002, NAT MED, V8, P816, DOI 10.1038/nm733
   Berrar D, 2005, J COMPUT BIOL, V12, P534, DOI 10.1089/cmb.2005.12.534
   Bhattacharjee A, 2001, P NATL ACAD SCI USA, V98, P13790, DOI 10.1073/pnas.191502998
   Breiman L, 2001, STAT SCI, V16, P199, DOI 10.1214/ss/1009213726
   Brundage MD, 2002, CHEST, V122, P1037, DOI 10.1378/chest.122.3.1037
   Chen GA, 2003, P NATL ACAD SCI USA, V100, P13537, DOI 10.1073/pnas.2233850100
   D'Amico TA, 1999, J THORAC CARDIOV SUR, V117, P736, DOI 10.1016/S0022-5223(99)70294-1
   Denison DGT, 1998, BIOMETRIKA, V85, P363
   DOUILLARD JY, 2005, J CLIN ONCOL, V23, P7013
   Garber ME, 2001, P NATL ACAD SCI USA, V98, P13784, DOI 10.1073/pnas.241500798
   Hoffman PC, 2000, LANCET, V355, P1280
   Huang E, 2003, LANCET, V361, P1590, DOI 10.1016/S0140-6736(03)13308-9
   Ju Z, 2005, MOL GENET GENOMICS, V274, P141, DOI 10.1007/s00438-005-0014-7
   Kato H, 2004, NEW ENGL J MED, V350, P1713, DOI 10.1056/NEJMoa032792
   Kikuchi T, 2003, ONCOGENE, V22, P2192, DOI 10.1038/sj.onc.1206288
   Le Chevalier T, 2004, NEW ENGL J MED, V350, P351
   Meyerson M, 2005, J CLIN ONCOL, V23, P3219, DOI 10.1200/JCO.2005.15.511
   Mountain CF, 1997, CHEST, V111, P1710, DOI 10.1378/chest.111.6.1710
   MOUNTAIN CF, 1987, SURG CLIN N AM, V67, P925
   NESBITT JC, 1995, ANN THORAC SURG, V60, P466, DOI 10.1016/0003-4975(95)00169-L
   Nevins JR, 2003, HUM MOL GENET, V12, pR153, DOI 10.1093/hmg/ddg287
   Pittman J, 2004, BIOSTATISTICS, V5, P587, DOI 10.1093/biostatistics/kxh011
   Pittman J, 2004, P NATL ACAD SCI USA, V101, P8431, DOI 10.1073/pnas.0401736101
   Schneider PM, 2000, BRIT J CANCER, V83, P473, DOI 10.1054/bjoc.2000.1287
   Spira A, 2004, NEW ENGL J MED, V350, P379, DOI 10.1056/NEJMra035536
   Strauss GM, 2004, J CLIN ONCOL, V22, p621S
   Tonon G, 2005, P NATL ACAD SCI USA, V102, P9625, DOI 10.1073/pnas.0504126102
   West M, 2001, P NATL ACAD SCI USA, V98, P11462, DOI 10.1073/pnas.201162998
   Wigle DA, 2002, CANCER RES, V62, P3005
   Winton T, 2005, NEW ENGL J MED, V352, P2589, DOI 10.1056/NEJMoa043623
   Yanaihara N, 2006, CANCER CELL, V9, P189, DOI 10.1016/j.ccr.2006.01.025
NR 31
TC 441
Z9 459
U1 4
U2 42
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
EI 1533-4406
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD AUG 10
PY 2006
VL 355
IS 6
BP 570
EP 580
DI 10.1056/NEJMoa060467
PG 11
WC Medicine, General & Internal
SC General & Internal Medicine
GA 071QM
UT WOS:000239616700007
PM 16899777
DA 2018-12-27
ER

PT J
AU Majumder, S
   Ghoshal, K
   Datta, J
   Smith, DS
   Bai, SM
   Jacob, ST
AF Majumder, Sarmila
   Ghoshal, Kalpana
   Datta, Jharna
   Smith, David Spencer
   Bai, Shoumei
   Jacob, Samson T.
TI RETRACTED: Role of DNA methyltransferases in regulation of human
   ribosomal RNA gene transcription (Retracted article. See vol. 293, pg.
   3591, 2018)
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article; Retracted Publication
ID HUMAN CANCER-CELLS; EPIGENETIC REGULATION; HISTONE MODIFICATIONS;
   SILENCE GENES; POLYMERASE-I; PWWP DOMAIN; METHYLATION; CHROMATIN;
   DNMT3B; COMPLEX
AB We have previously demonstrated that the expression of human ribosomal RNA genes (rDNA) in normal and cancer cells is differentially regulated by methylation of the promoter CpG islands. Furthermore, we showed that the methyl CpG-binding protein MBD2 plays a selective role in the methylation-mediated block in rDNA expression. Here, we analyzed the role of three functional mammalian DNA methyltransferases (DNMTs) in regulating the rDNA promoters activity. Immunofluorescence analysis and biochemical fractionation showed that all three DNMTs (DNMT1, DNMT3A, and DNMT3B) are associated with the inactive rDNA in the nucleolus. Although DNMTs associate with both methylated and unmethylated rDNA promoters, DNMT1 preferentially associates with the methylated genes. The rDNA primary transcript level was significantly elevated in DNMT1(-/-) or DNMT3B(-/-) human colon carcinoma (HCT116) cells. Southern blot analysis demonstrated a moderate level of rDNA promoter hypomethylation in DNMT1(-/-) cells and a dramatic loss of rDNA promoter methylation in double knockout cells. Transient overexpression of DNMT1 or DNMT3B suppressed the luciferase expression from both methylated and unmethylated pHrD-IRES-Luc, a reporter plasmid where the rDNA promoter drives luciferase expression. DNMT1-mediated suppression of the unmethylated promoter involves de novo methylation of the promoter, whereas histone deacetylase 2 cooperates with DNMT1 to inhibit the methylated rDNA promoter. Unlike DNMT1, both the wild type and catalytically inactive DNMT3B mutant can suppress rDNA promoter irrespective of its methylation status. DNMT3B-mediated suppression of the rDNA promoter also involves histone deacetylation. Treatment of HCT116 cells with Decitabine (a DNMT inhibitor) or trichostatin A (a histone deacetylase inhibitor) up-regulated endogenous rDNA expression. These inhibitors synergistically activated methylated pHrD-IRES-Luc, whereas they exhibited additive effects on the unmethylated promoter. These results demonstrate localization of DNMTs with the inactive rDNA in the nucleolus, the specific role of DNMT1 and DNMT3B in rDNA expression and the differential regulation of rDNA expression from the methylated and unmethylated rDNA promoters.
C1 Ohio State Univ, Coll Med, Dept Mol & Cellular Biochem, Columbus, OH 43210 USA.
RP Majumder, S (reprint author), Ohio State Univ, Coll Med, Dept Mol & Cellular Biochem, Columbus, OH 43210 USA.
EM majumder.2@osu.edu
FU NCI NIH HHS [R01 CA086978-03, R01 CA086978, R01 CA086978-04, R01
   CA086978-06A1, R01 CA086978-05, R01 CA086978-01A2, CA86978, R01
   CA086978-02]; NIEHS NIH HHS [R01 ES010874, R01 ES010874-01, R01
   ES010874-02, R01 ES010874-04, R01 ES010874-03, ES10874, R01 ES010874-05]
CR Bachman KE, 2001, J BIOL CHEM, V276, P32282, DOI 10.1074/jbc.M104661200
   Bai SM, 2005, MOL CELL BIOL, V25, P751, DOI 10.1128/MCB.25.2.751-766.2005
   Baylin Stephen B, 2004, Novartis Found Symp, V259, P226
   BESTOR TH, 1992, EMBO J, V11, P2611, DOI 10.1002/j.1460-2075.1992.tb05326.x
   Bestor TH, 2000, HUM MOL GENET, V9, P2395, DOI 10.1093/hmg/9.16.2395
   BESTOR TH, 1994, CURR OPIN CELL BIOL, V6, P380, DOI 10.1016/0955-0674(94)90030-2
   Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9
   BUSCH H, 1963, EXP CELL RES, P150
   Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047
   Chen TP, 2004, CURR TOP DEV BIOL, V60, P55
   Chen TP, 2004, MOL CELL BIOL, V24, P9048, DOI 10.1128/MCB.24.20.9048-9058.2004
   Christman JK, 2002, ONCOGENE, V21, P5483, DOI 10.1038/sj.onc.1205699
   Chuang LSH, 1996, J MOL BIOL, V257, P935, DOI 10.1006/jmbi.1996.0213
   Chuang LSH, 1997, SCIENCE, V277, P1996, DOI 10.1126/science.277.5334.1996
   CONCONI A, 1989, CELL, V57, P753, DOI 10.1016/0092-8674(89)90790-3
   CROSS SH, 1995, CURR OPIN GENET DEV, V5, P309, DOI 10.1016/0959-437X(95)80044-1
   Datta J, 2005, CANCER RES, V65, P10891, DOI 10.1158/0008-5472.CAN-05-1455
   Datta J, 2003, J CELL BIOCHEM, V88, P855, DOI 10.1002/jcb.10457
   El-Osta A, 2000, GENE EXPRESSION, V9, P63
   Fuks F, 2001, EMBO J, V20, P2536, DOI 10.1093/emboj/20.10.2536
   Fuks F, 2005, CURR OPIN GENET DEV, V15, P490, DOI 10.1016/j.gde.2005.08.002
   Geiman TM, 2002, J CELL BIOCHEM, V87, P117, DOI 10.1002/jcb.10286
   Geiman TM, 2004, NUCLEIC ACIDS RES, V32, P2716, DOI 10.1093/nar/gkh589
   Geiman TM, 2004, BIOCHEM BIOPH RES CO, V318, P544, DOI 10.1016/j.bbrc.2004.04.058
   Ghoshal K, 2005, MOL CELL BIOL, V25, P4727, DOI 10.1128/MCB.25.11.4727-4741.2005
   Ghoshal K, 2002, MOL CELL BIOL, V22, P8302, DOI 10.1128/MCB.22.23.8302-8319.2002
   Ghoshal K, 2004, J BIOL CHEM, V279, P6783, DOI 10.1074/jbc.M309393200
   Goll MG, 2005, ANNU REV BIOCHEM, V74, P481, DOI 10.1146/annurev.biochem.74.010904.153721
   Grummt I, 2003, NAT REV MOL CELL BIO, V4, P641, DOI 10.1038/nrm1171
   Hermann A, 2004, CELL MOL LIFE SCI, V61, P2571, DOI 10.1007/s00018-004-4201-1
   Hirschler-Laszkiewicz I, 2001, NUCLEIC ACIDS RES, V29, P4114, DOI 10.1093/nar/29.20.4114
   Issa Jean-Pierre, 2003, Current Opinion in Oncology, V15, P446, DOI 10.1097/00001622-200311000-00007
   Jaenisch R, 2003, NAT GENET, V33, P245, DOI 10.1038/ng1089
   Jair KW, 2006, CANCER RES, V66, P682, DOI 10.1158/0008-5472.CAN-05-1980
   Jeltsch A, 2002, CHEMBIOCHEM, V3, P275, DOI 10.1002/1439-7633(20020402)3:4<274::AID-CBIC274>3.0.CO;2-S
   Lawrence RJ, 2004, MOL CELL, V13, P599, DOI 10.1016/S1097-2765(04)00064-4
   Leary DJ, 2001, FEBS LETT, V509, P145, DOI 10.1016/S0014-5793(01)03143-X
   LEONHARDT H, 1992, CELL, V71, P865, DOI 10.1016/0092-8674(92)90561-P
   LONG EO, 1980, ANNU REV BIOCHEM, V49, P727, DOI 10.1146/annurev.bi.49.070180.003455
   Majumder S, 2002, J BIOL CHEM, V277, P16048, DOI 10.1074/jbc.M111662200
   McStay B, 2002, GENE EXPRESSION, V10, P263, DOI 10.3727/000000002783992415
   Morgan HD, 2005, HUM MOL GENET, V14, pR47, DOI 10.1093/hmg/ddi114
   Mutskov VJ, 1996, J BIOL CHEM, V271, P11852, DOI 10.1074/jbc.271.20.11852
   Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6
   Qiu C, 2002, NAT STRUCT BIOL, V9, P217, DOI 10.1038/nsb759
   Rhee I, 2002, NATURE, V416, P552, DOI 10.1038/416552a
   Rice JC, 2001, CURR OPIN CELL BIOL, V13, P263, DOI 10.1016/S0955-0674(00)00208-8
   Robertson KD, 2000, NAT GENET, V25, P338
   Robertson KD, 2002, ONCOGENE, V21, P5361, DOI 10.1038/sj.onc.1205609
   Rountree MR, 2000, NAT GENET, V25, P269, DOI 10.1038/77023
   Santoro R, 2002, NAT GENET, V32, P393, DOI 10.1038/ng1010
   Santoro R, 2005, MOL CELL BIOL, V25, P2539, DOI 10.1128/MCB.25.7.2539-2546.2005
   Santoro R, 2001, MOL CELL, V8, P719, DOI 10.1016/S1097-2765(01)00317-3
   Weinmann AS, 2001, MOL CELL BIOL, V21, P6820, DOI 10.1128/MCB.21.20.6820-6832.2001
NR 54
TC 35
Z9 35
U1 0
U2 6
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD AUG 4
PY 2006
VL 281
IS 31
BP 22062
EP 22072
DI 10.1074/jbc.M601155200
PG 11
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 068PO
UT WOS:000239387100053
PM 16735507
OA Green Accepted, Green Published, Bronze
DA 2018-12-27
ER

PT J
AU McNaught, KS
   Olanow, CW
AF McNaught, Kevin St. P.
   Olanow, C. Warren
TI RETRACTED: Proteasome inhibitor-induced model of Parkinson's disease
   (Retracted Article. See vol 65, pg 485, 2009)
SO ANNALS OF NEUROLOGY
LA English
DT Article; Retracted Publication
ID ALPHA-SYNUCLEIN; LEWY BODIES; CELL-DEATH; NEURONS; RATS; DEGENERATION;
   IMPAIRMENT; MECHANISMS; INCLUSIONS; CULTURES
AB We recently reported that systemic administration of a proteasome inhibitor induced a progressive levodopa-responsive, bradykinetic syndrome in rats with imaging, pathological, and biochemical features that strikingly resemble what is found in PD. This model has the potential to be a useful tool for studying the mechanism of cell death in Parkinson's disease and for testing putative neuroprotective agents. Since publication of these findings, several laboratories have sought to reproduce the model; some have been successful in replicating our findings, but others have not. The reason for this variability is not known, but resolution is critically important given the potential utility of this model. We have begun to examine various factors that alone or in combination might explain these differences, and we present in this article preliminary results from these studies.
C1 Mt Sinai Sch Med, Dept Neurol, New York, NY 10029 USA.
RP McNaught, KS (reprint author), Mt Sinai Sch Med, Dept Neurol, Annenberg 14-73,1 Gustave L Levy Pl, New York, NY 10029 USA.
EM kevin.mcnaught@mssm.edu
FU NINDS NIH HHS [1 R01 NS045999-01]
CR Beal F, 2006, ANN NEUROL, V60, P158, DOI 10.1002/ana.20939
   Bove J, 2006, ANN NEUROL, V60, P260, DOI 10.1002/ana.20937
   Camacho-Arroyo I, 2002, NEUROENDOCRINOLOGY, V76, P267, DOI 10.1159/000066623
   Fornai F, 2003, J NEUROSCI, V23, P8955
   Hattori N, 2004, LANCET, V364, P722, DOI 10.1016/S0140-6736(04)16901-8
   Kisselev AF, 2001, CHEM BIOL, V8, P739, DOI 10.1016/S1074-5521(01)00056-4
   Kordower JH, 2006, ANN NEUROL, V60, P264, DOI 10.1002/ana.20935
   Manning-Bog AB, 2006, ANN NEUROL, V60, P256, DOI 10.1002/ana.20938
   McNaught KS, 2002, NEUROREPORT, V13, P1437, DOI 10.1097/00001756-200208070-00018
   McNaught KS, 2002, J NEUROCHEM, V81, P301, DOI 10.1046/j.1471-4159.2002.00821.x
   McNaught KS, 2003, EXP NEUROL, V179, P38, DOI 10.1006/exnr.2002.8050
   McNaught KSP, 2004, ANN NEUROL, V56, P149, DOI 10.1002/ana.20186
   McNaught KSP, 2002, EUR J NEUROSCI, V16, P2136, DOI 10.1046/j.1460-9568.2002.02301.x
   McNaught KSP, 2006, NEUROBIOL AGING, V27, P530, DOI 10.1016/j.neurobiolaging.2005.08.012
   McNaught KSP, 2001, NEUROSCI LETT, V297, P191, DOI 10.1016/S0304-3940(00)01701-8
   Miwa H, 2005, NEUROSCI LETT, V380, P93, DOI 10.1016/j.neulet.2005.01.024
   Moore DJ, 2005, ANNU REV NEUROSCI, V28, P57, DOI 10.1146/annurev.neuro.28.061604.135718
   NAIR V, 2005, MOV DISORD S10, V20, pLB12
   Petrucelli L, 2002, NEURON, V36, P1007, DOI 10.1016/S0896-6273(02)01125-X
   Rideout HJ, 2005, J NEUROCHEM, V93, P1304, DOI 10.1111/j.1471-4159.2005.03124.x
   Schapira AHV, 2006, ANN NEUROL, V60, P253, DOI 10.1002/ana.20934
   THOMAS A, 2006, MOV DISORD S, V21, pP80
   Tofaris GK, 2003, J BIOL CHEM, V278, P44405, DOI 10.1074/jbc.M308041200
   Zeng BY, 2006, ANN NEUROL, V60, P248, DOI 10.1002/ana.20932
NR 24
TC 64
Z9 67
U1 3
U2 11
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0364-5134
EI 1531-8249
J9 ANN NEUROL
JI Ann. Neurol.
PD AUG
PY 2006
VL 60
IS 2
BP 243
EP 247
DI 10.1002/ana.20936
PG 5
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 070PX
UT WOS:000239536600013
PM 16862580
DA 2018-12-27
ER

PT J
AU Wang, ZW
   Sengupta, R
   Banerjee, S
   Li, YW
   Zhang, YX
   Wahidur, KM
   Aboukameel, A
   Mohammad, R
   Majumdar, APN
   Abbruzzese, JL
   Sarkar, FH
AF Wang, Zhiwei
   Sengupta, Radha
   Banerjee, Sanjeev
   Li, Yiwei
   Zhang, Yuxiang
   Wahidur, K. M.
   Aboukameel, Amro
   Mohammad, Ramzi
   Majumdar, Adhip P. N.
   Abbruzzese, James L.
   Sarkar, Fazlul H.
TI RETRACTED: Epidermal growth factor receptor-related protein inhibits
   cell growth and invasion in pancreatic cancer (Retracted article. See
   vol. 78, pg. 5474, 2018)
SO CANCER RESEARCH
LA English
DT Article; Retracted Publication
ID NF-KAPPA-B; GENE-EXPRESSION; DOWN-REGULATION; IN-VITRO; APOPTOSIS;
   ACTIVATION; METASTASIS; PATHWAYS; COLON; MATRIX-METALLOPROTEINASE-9
AB The epidermal growth factor receptor (EGFR) signaling network plays critical roles in human cancers, including pancreatic cancer, suggesting that the discovery of specific agents targeting EGFR would be extremely valuable for pancreatic cancer therapy. EGFR-related protein (ERRP), a recently identified pan-erbB inhibitor, has been shown to inhibit growth and induce apoptosis of pancreatic cancer cells in vitro and tumor growth in a xenograft model. However, the precise molecular mechanism(s) by which ERRP exerts its antitumor activity remains unclear. The current investigation was undertaken to delineate the tumor growth inhibitory mechanism(s) of ERRP in pancreatic cancer cells. Using multiple molecular assays, such as 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay, apoptosis, gene transfection, real-time reverse transcription-PCR, Western blotting, invasion, and electrophoretic mobility shift assay for measuring DNA-binding activity of nuclear factor-kappa B (NF-kappa B), we found that ERRP caused marked inhibition of pancreatic cancer cell growth. This was accompanied by increased apoptosis and concomitant attenuation of Notch-1 and NF-kappa B and down-regulation of NF-kappa B downstream genes, such as matrix metalloproteinase-9 and vascular endothelial growth factor, resulting in the inhibition of pancreatic cancer cell invasion through the Matrigel. We also found that down-regulation of Notch-1 by small interfering RNA before ERRP treatment resulted in enhanced cell growth inhibition and apoptosis. Our data suggest that the ERRP-mediated inactivation of EGFR, Notch-1, NF-kappa B, and its downstream target genes contributed to the inhibition of cell growth and invasion. We conclude that ERRP could be an effective agent for inhibiting tumor growth and invasion for the treatment of pancreatic cancer.
C1 Wayne State Univ, Karmanos Canc Inst, Dept Pathol, Div Hematol & Oncol, Detroit, MI 48201 USA.
   Wayne State Univ, Karmanos Canc Inst, Dept Internal Med, Div Hematol & Oncol, Detroit, MI 48201 USA.
   Vet Affairs Med Ctr, Dept Internal Med, Detroit, MI USA.
   Capital Univ Med Sci, Dept Biochem & Mol Biol, Beijing, Peoples R China.
   Univ Texas, MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, Houston, TX 77030 USA.
RP Sarkar, FH (reprint author), Wayne State Univ, Karmanos Canc Inst, Dept Pathol, Div Hematol & Oncol, 740 HWCRC,110 E Warren Ave, Detroit, MI 48201 USA.
EM fskukar@med.wayne.edu
RI Wang, Zhiwei/A-6809-2011
FU NCI NIH HHS [P20 CA 101936-02, 1R01 CA 101870-02]
CR Ali S, 2005, MOL CANCER THER, V4, P1943, DOI 10.1158/1535-7163.MCT-05-0065
   Biliran H, 2005, CLIN CANCER RES, V11, P6075, DOI 10.1158/1078-0432.CCR-04-2419
   BOONSTRA J, 1995, CELL BIOL INT, V19, P413, DOI 10.1006/cbir.1995.1086
   Curran S, 2000, EUR J CANCER, V36, P1621, DOI 10.1016/S0959-8049(00)00156-8
   Dong M, 1998, ANTICANCER RES, V18, P4613
   Dong Z, 2005, AM J PATHOL, V166, P1173, DOI 10.1016/S0002-9440(10)62337-1
   Feng J, 2002, PANCREAS, V25, P342, DOI 10.1097/00006676-200211000-00004
   Fukushima N, 2004, ONCOGENE, V23, P9042, DOI 10.1038/sj.onc.1208117
   Garcea G, 2005, EUR J CANCER, V41, P2213, DOI 10.1016/j.ejca.2005.04.044
   Jang MS, 2004, J CELL PHYSIOL, V199, P418, DOI 10.1002/jcp.10467
   Jemal A, 2005, CA-CANCER J CLIN, V55, P10, DOI 10.3322/canjclin.55.1.10
   Lee LT, 2002, ANTICANCER RES, V22, P1615
   Levi E, 2004, ANTICANCER RES, V24, P2885
   Marciniak DJ, 2004, MOL CANCER THER, V3, P1615
   Marciniak DJ, 2003, GASTROENTEROLOGY, V124, P1337, DOI 10.1016/S0016-5085(03)00264-6
   Matsuda K, 2002, CANCER RES, V62, P5611
   Mimeault M, 2005, PANCREAS, V31, P301, DOI 10.1097/01.mpa.0000175893.04660.1b
   Miyamoto Y, 2003, CANCER CELL, V3, P565, DOI 10.1016/S1535-6108(03)00140-5
   Mohammad RM, 1998, PANCREAS, V16, P19, DOI 10.1097/00006676-199801000-00004
   Murphy LO, 2001, BRIT J CANCER, V84, P926, DOI 10.1054/bjoc.2001.1698
   Nagakawa Y, 2002, PANCREAS, V24, P169, DOI 10.1097/00006676-200203000-00008
   Nickoloff BJ, 2002, CELL DEATH DIFFER, V9, P842, DOI 10.1038/sj.cdd.4401036
   Niu JG, 2004, J BIOL CHEM, V279, P16452, DOI 10.1074/jbc.M309789200
   Rishi AK, 2006, ANTICANCER RES, V26, P1029
   Takada Y, 2005, J BIOL CHEM, V280, P17203, DOI 10.1074/jbc.M500077200
   Takada Y, 2004, ONCOGENE, V23, P9247, DOI 10.1038/sj.onc.1208169
   Terris B, 2002, AM J PATHOL, V160, P1745, DOI 10.1016/S0002-9440(10)61121-2
   Uegaki K, 1997, ANTICANCER RES, V17, P3841
   Wang Y, 2004, P NATL ACAD SCI USA, V101, P9458, DOI 10.1073/pnas.0308126101
   Wang ZW, 2006, CANCER RES, V66, P2778, DOI 10.1158/0008-5472.CAN-05-4281
   Wang ZW, 2006, MOL CANCER THER, V5, P483, DOI 10.1158/1535-7163.MCT-05-0299
   Wang ZW, 2006, INT J CANCER, V118, P1930, DOI 10.1002/ijc.21589
   Weijzen S, 2002, NAT MED, V8, P979, DOI 10.1038/nm754
   Xu H, 2005, MOL CANCER THER, V4, P435
   YAMANAKA Y, 1993, ANTICANCER RES, V13, P565
   Yu YJ, 2001, AM J PHYSIOL-CELL PH, V280, pC1083
   Zhang H, 2006, PANCREAS, V32, P101, DOI 10.1097/01.mpa.0000191644.94301.be
   Zhang YX, 2006, CANCER RES, V66, P1025, DOI 10.1158/0008-5472.CAN-05-2968
   Zhang YX, 2005, CANCER RES, V65, P3877, DOI 10.1158/0008-5472.CAN-04-3654
NR 39
TC 43
Z9 51
U1 1
U2 3
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD AUG 1
PY 2006
VL 66
IS 15
BP 7653
EP 7660
DI 10.1158/0008-5472.CAN-06-1019
PG 8
WC Oncology
SC Oncology
GA 069XU
UT WOS:000239483500037
PM 16885366
OA Bronze
DA 2018-12-27
ER

PT J
AU Fang, GC
   Wu, YS
   Chang, CN
   Ho, TT
AF Fang, Guor-Cheng
   Wu, Yuh-Shen
   Chang, Cheng-Nan
   Ho, Tse-Tsung
TI RETRACTED: A study of polycyclic aromatic hydrocarbons concentrations
   and source identifications by methods of diagnostic ratio and principal
   component analysis at Taichung chemical Harbor near Taiwan Strait
   (Retracted article. See vol 72, pg. 1620, 2008)
SO CHEMOSPHERE
LA English
DT Article; Retracted Publication
DE fine particulate (PM2.5); coarse particulate (PM2.5-10); PAHs; Harbor;
   GC/MS; PCA; Taiwan Strait
ID URBAN ATMOSPHERE; HONG-KONG; SUSPENDED PARTICULATE; CARBONYL-COMPOUNDS;
   ORGANIC-COMPOUNDS; PAH EMISSION; N-ALKANES; AIR; CITY; INDOOR
AB Fine (PM2.5) and Coarse (PM2.5-10) particulates concentrations of ambient air particle-bound polycyclic aromatic hydrocarbons (PAHs) were measured simultaneously from February 004 to January 2005 at the Taichung Harbor (TH) sampling site near Taiwan of central Taiwan. Particle-bound polycyclic aromatic hydrocarbons (PAHs) were collected on quartz filters, the collected sample used soxhlet analytical method extracted with a dichloromethane (DCM)/n-hexane mixture (50150, v/v) for 24 h, and then the extracts were subjected to gas chromatography-mass spectrometric (GC-MS) analysis. The results indicated that vehicle emissions, coal combustion, incomplete combustion and pyrolysis of fuel and oil burning were the main source of PAHs near Taiwan Strait of central Taiwan. Diagnostic ratio and principal component analysis (PCA) were also used to characterize and identify PAHs emission source in this study. (c) 2005 Elsevier Ltd. All rights reserved.
C1 Hungkuang Univ, Air Tox & Environm Anal Lab, Taichung 433, Taiwan.
   Tunghai Univ, Dept Environm Sci, Taichung 407, Taiwan.
RP Fang, GC (reprint author), Hungkuang Univ, Air Tox & Environm Anal Lab, Taichung 433, Taiwan.
EM gcfang@sunrise.hk.edu.tw
CR Bae SY, 2002, ATMOS ENVIRON, V36, P5491, DOI 10.1016/S1352-2310(02)00666-0
   Bi XH, 2003, ATMOS ENVIRON, V37, P289, DOI 10.1016/S1352-2310(02)00832-4
   Caricchia AM, 1999, ATMOS ENVIRON, V33, P3731, DOI 10.1016/S1352-2310(99)00199-5
   Chetwittayachan T, 2002, ATMOS ENVIRON, V36, P2027, DOI 10.1016/S1352-2310(02)00099-7
   Dickhut RM, 2000, ENVIRON SCI TECHNOL, V34, P4635, DOI 10.1021/es000971e
   Fang GC, 2002, ATMOS ENVIRON, V36, P1921, DOI 10.1016/S1352-2310(02)00187-5
   Fang GC, 2003, SCI TOTAL ENVIRON, V308, P157, DOI 10.1016/S0048-9697(02)00648-4
   FANG GC, IN PRESS SCI TOTAL E
   Garban B, 2002, ATMOS ENVIRON, V36, P5395, DOI 10.1016/S1352-2310(02)00414-4
   Guo H, 2003, ATMOS ENVIRON, V37, P5307, DOI 10.1016/j.atmosenv.2003.09.011
   Ho KF, 2002, ATMOS ENVIRON, V36, P57, DOI 10.1016/S1352-2310(01)00475-7
   HUYNH CK, 1991, SCI TOTAL ENVIRON, V102, P241, DOI 10.1016/0048-9697(91)90318-9
   Hwang HM, 2003, ATMOS ENVIRON, V37, P2259, DOI 10.1016/S1352-2310(03)00090-6
   Kavouras IG, 2001, ENVIRON SCI TECHNOL, V35, P2288, DOI 10.1021/es001540z
   Kulkarni P, 2000, ATMOS ENVIRON, V34, P2785, DOI 10.1016/S1352-2310(99)00312-X
   Lee SC, 2001, ATMOS ENVIRON, V35, P5949, DOI 10.1016/S1352-2310(01)00374-0
   LI C, 2005, BUILD ENVIRON, V40, P327
   Li CS, 2000, ATMOS ENVIRON, V34, P611, DOI 10.1016/S1352-2310(99)00171-5
   Lin TC, 2002, J HAZARD MATER, V95, P1, DOI 10.1016/S0304-3894(02)00146-2
   Lodovici M, 2003, CHEMOSPHERE, V50, P377, DOI 10.1016/S0045-6535(02)00404-6
   Menichini E, 1999, ATMOS ENVIRON, V33, P3739, DOI 10.1016/S1352-2310(99)00114-4
   Nielsen T, 1996, SCI TOTAL ENVIRON, V189, P41, DOI 10.1016/0048-9697(96)05189-3
   Nielsen T, 1996, ATMOS ENVIRON, V30, P3481, DOI 10.1016/1352-2310(96)00096-9
   Odabasi M, 1999, SCI TOTAL ENVIRON, V227, P57, DOI 10.1016/S0048-9697(99)00004-2
   Ohura T, 2004, ATMOS ENVIRON, V38, P2045, DOI 10.1016/j.atmosenv.2004.01.038
   Omar NYMJ, 2002, ATMOS ENVIRON, V36, P247, DOI 10.1016/S1352-2310(01)00425-3
   Park SS, 2002, ATMOS ENVIRON, V36, P2917, DOI 10.1016/S1352-2310(02)00206-6
   ROGGE WF, 1993, ENVIRON SCI TECHNOL, V27, P636, DOI 10.1021/es00041a007
   SERGEY VK, 2005, ENVIRON POLLUT, V133, P383
   Sheu HL, 1997, ENVIRON POLLUT, V96, P369, DOI 10.1016/S0269-7491(97)00044-4
   Tsai PJ, 2002, J HAZARD MATER, V91, P25, DOI 10.1016/S0304-3894(01)00384-3
   *US EPA, 1999, TO13A142
   Vasconcellos PC, 2003, ATMOS ENVIRON, V37, P3009, DOI 10.1016/S1352-2310(03)00181-X
   VENKATARAMAN C, 1994, ENVIRON SCI TECHNOL, V28, P555, DOI 10.1021/es00053a005
   WHO, 1987, AIR QUAL GUID EUR, P105
   Yang HH, 1998, J HAZARD MATER, V60, P159, DOI 10.1016/S0304-3894(98)00089-2
   Yang HH, 2002, CHEMOSPHERE, V48, P1061, DOI 10.1016/S0045-6535(02)00175-3
   Yassaa N, 2001, ATMOS ENVIRON, V35, P1843, DOI 10.1016/S1352-2310(00)00514-8
   Zheng M, 2000, ATMOS ENVIRON, V34, P2691, DOI 10.1016/S1352-2310(99)00521-X
NR 39
TC 40
Z9 40
U1 5
U2 33
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0045-6535
EI 1879-1298
J9 CHEMOSPHERE
JI Chemosphere
PD AUG
PY 2006
VL 64
IS 7
BP 1233
EP 1242
DI 10.1016/j.chemosphere.2005.11.031
PG 10
WC Environmental Sciences
SC Environmental Sciences & Ecology
GA 079EA
UT WOS:000240157100023
PM 16406483
DA 2018-12-27
ER

PT J
AU Fujii, Y
   Nakayama, M
AF Fujii, Yoshitaka
   Nakayama, Masahiro
TI RETRACTED: Influence of age on flurbiprofen axetil requirements for
   preventing pain on injection of propofol in Japanese adult surgical
   patients: A prospective, randomized, double-blind, vehicle-controlled,
   parallel-group, dose-ranging study (Retracted article. See vol. 40, pg.
   1048, 2018)
SO CLINICAL THERAPEUTICS
LA English
DT Article; Retracted Publication
DE complications; pain; propofol; flurbiprofen axetil; age
ID POSTOPERATIVE PAIN; VENOUS OCCLUSION; REDUCES PAIN; PRETREATMENT;
   LIDOCAINE; FORMULATION; ANALGESIA
AB Background: Pain on injection is a recognized adverse event (AE) of propofol administration for the induction of general anesthesia. Preceded by venous occlusion, flurbiprofen axetil, a prodrug of the NSAID flurbiprofen, has been associated with a reduction in pain induced by propofol injection. A review of the literature determined that no published data were available on the influence of age on the requirements for flurbiprofen axetil dose.
   Objective: This study was undertaken to examine the influence of age on flurbiprofen axetil requirements for the treatment of propofol-Induced pain on injection in Japanese adult surgical patients.
   Methods: This prospective, randomized, double-blind, vehicle-controlled, parallel-group, dose-ranging study was conducted at the Department of Anesthesiology, Institute of Clinical Medicine, University of Tsukuba, Tsukuba, Japan. Young (age 20-40 years) and older (age 60-80 years) Japanese patients scheduled for various types of surgery (eg, cholecystectomy) were eligible. Patients were randomized to receive flurbiprofen axetil at I of 2 doses (25 or 50 mg, regardless of body weight) or inactive vehicle (saline), preceded by manual venous occlusion with a rubber tourniquet for 2 minutes and followed by the infusion of the first 25% of calculated propofol dose (0.5 mg/kg at room temperature, 23 degrees C) into the largest dorsal vein of the hand through a 20-G IV cannula (without local anesthesia), followed by the release of the occlusion and delivery of propofol 2 mg/kg. An investigator blinded to treatment questioned each patient about pain intensity during propofol injection which was assessed using a verbal rating scale: 0 = none; 1 = mild; 2 = moderate; and 3 severe. The overall prevalence of pain was calculated in each group. AEs at the injection site (pain, edema, wheal, inflammation) were assessed by the study investigator for 24 hours after surgery using spontaneous reporting and patient interview.
   Results: A total of 150 patients, 75 young adults (3 8 men, 3 7 women; mean [SDI age, 31 [5] years; mean [SDI height, 163 [7] cm; mean [SD] body weight, 58 [9] kg) and 75 older adults (38 men, 37 women; mean [SDI age, 70 [6] years; mean [SD] height, 154 [8] cm; mean [SD] body weight, 53 [101 kg), were enrolled. Each treatment group comprised 25 patients. No differences in demographic characteristics were observed among the 3 study groups. In young patients, the overall prevalence of propofol-induced pain was significantly lower in patients who received flurbiprofen axetil 5 0 mg (12 [48%]) compared with that in patients who received flurbiprofen axetil 25 mg (20 [80%]) or vehicle (22 [88%]) (P < 0.05 and P < 0.01, respectively). The median pain intensity score was significantly lower in patients who received flurbiprofen axetil 50 mg (0) compared with that in patients who received flurbiprofen axetil 25 mg (1) or vehicle (2) (P < 0.05 and P < 0.01, respectively). In older patients, the overall prevalences of pain on propofol injection were 9 (36%) in the flurbiprofen axetil 50-mg group and 11 (44%) in the flurbiprofen axetil 25-mg group compared with 21 (84%) in the vehicle group (both, P < 0.01). The median pain score was significantly lower in patients who received flurbiprofen 50 mg (0) or 25 mg (0) than in those who received vehicle (1) (both, P < 0.01). All treatments were well tolerated.
   Conclusions: In this small clinical trial in Japanese surgical patients undergoing general anesthesia, flurbiprofen axetil requirements for the reduction of pain during injection of propofol were found to be 50 mg in young adults (age 20-40 years) and 25 or 50 mg in older adults (age 60-80 years), regardless of weight, preceded by venous occlusion for 2 minutes.
C1 Toho Univ, Sch Med, Dept Anesthesiol 1, Tokyo 1438541, Japan.
   Univ Tsukuba, Inst Clin Med, Dept Anesthesiol, Tsukuba, Ibaraki 305, Japan.
RP Fujii, Y (reprint author), Toho Univ, Sch Med, Dept Anesthesiol 1, 6-11-1,OhmoriNishi, Tokyo 1438541, Japan.
EM yfujii@med.toho-u.ac.jp
CR Agarwal A, 2004, ANESTH ANALG, V98, P683, DOI 10.1213/01.ANE.0000103266.73568.18
   Ambesh SP, 1999, ANESTH ANALG, V89, P197, DOI 10.1097/00000539-199907000-00035
   Barbi E, 2003, PAEDIATR ANAESTH, V13, P764, DOI 10.1046/j.1460-9592.2003.01150.x
   *EUR AG EV MED PRO, 2002, INT C HARM WHO GUID
   FERREIRA SH, 1980, BRIT J CLIN PHARMACO, V10, pS237, DOI 10.1111/j.1365-2125.1980.tb01806.x
   FLEISHER LA, 1996, CLIN ANESTH, P443
   FLETCHER JE, 1994, BRIT J ANAESTH, V72, P342, DOI 10.1093/bja/72.3.342
   Fujii Y, 2005, CLIN THER, V27, P588, DOI 10.1016/j.clinithera.2005.05.003
   Fujii Y, 2004, ANAESTH INTENS CARE, V32, P653
   GIL KM, 1992, CLIN J PAIN, V8, P215, DOI 10.1097/00002508-199209000-00005
   HYNYNEN M, 1985, ACTA ANAESTH SCAND, V29, P651, DOI 10.1111/j.1399-6576.1985.tb02274.x
   INSEL PA, 1996, GOODMAN GILMANS PHAR, P617
   Karasawa F, 2000, J Anesth, V14, P135, DOI 10.1007/s005400070020
   KING SY, 1992, ANESTH ANALG, V74, P246, DOI 10.1213/00000539-199202000-00013
   Larsen B, 2001, ANAESTHESIST, V50, P842, DOI 10.1007/s00101-001-0234-0
   Lee P, 2004, ANAESTH INTENS CARE, V32, P482
   Macario A, 1999, ANESTH ANALG, V88, P1085, DOI 10.1097/00000539-199905000-00023
   MCCRIRRICK A, 1990, ANAESTHESIA, V45, P443, DOI 10.1111/j.1365-2044.1990.tb14329.x
   MCCULLOCH MJ, 1985, ANAESTHESIA, V40, P1117, DOI 10.1111/j.1365-2044.1985.tb10615.x
   Memis D, 2002, ANESTH ANALG, V95, P606, DOI 10.1213/01.ANE.0000023204.79877.7A
   Minto CF, 1997, ANESTHESIOLOGY, V86, P10, DOI 10.1097/00000542-199701000-00004
   Nakayama M, 2001, CAN J ANAESTH, V48, P234, DOI 10.1007/BF03019751
   OHara JF, 1997, ANESTH ANALG, V84, P865, DOI 10.1097/00000539-199704000-00030
   Roszkowski MT, 1997, PAIN, V73, P339, DOI 10.1016/S0304-3959(97)00120-6
   SCOTT RPF, 1988, ANAESTHESIA, V43, P492, DOI 10.1111/j.1365-2044.1988.tb06641.x
   SMITH I, 1994, ANESTHESIOLOGY, V81, P1005
   STOKES DN, 1989, BRIT J ANAESTH, V62, P202, DOI 10.1093/bja/62.2.202
   Yokota S, 1997, ANESTH ANALG, V85, P672, DOI 10.1097/00000539-199709000-00034
   Yull DN, 2000, ANAESTHESIA, V55, P284, DOI 10.1046/j.1365-2044.2000.01320.x
NR 29
TC 6
Z9 9
U1 2
U2 7
PU ELSEVIER
PI BRIDGEWATER
PA 685 ROUTE 202-206, BRIDGEWATER, NJ 08807 USA
SN 0149-2918
EI 1879-114X
J9 CLIN THER
JI Clin. Ther.
PD AUG
PY 2006
VL 28
IS 8
BP 1116
EP 1122
DI 10.1016/j.clinthera.2006.08.015
PG 7
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 084GP
UT WOS:000240521000004
PM 16982288
DA 2018-12-27
ER

PT J
AU Das, S
   Otani, H
   Maulik, N
   Das, DK
AF Das, Samarjit
   Otani, Hajime
   Maulik, Nilanjana
   Das, Dipak K.
TI RETRACTED: Redox regulation of angiotensin II preconditioning of the
   myocardium requires MAP kinase signaling (Retracted article. See vol.
   53, pg. 742, 2012)
SO JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY
LA English
DT Article; Retracted Publication
DE heart; ROS; MAPK; Erk (1/2); JNK; p38MAPK; Akt; Bcl-2; preconditioning
ID SMOOTH-MUSCLE-CELLS; ACTIVATED PROTEIN-KINASE; ISOLATED RABBIT HEARTS;
   ISOLATED RAT-HEART; ADENOSINE-A(3) RECEPTOR; GENE BCL-2; APOPTOSIS;
   SYSTEM; ERK1/2; ISCHEMIA/REPERFUSION
AB A recent study documented reactive oxygen species (ROS), generated through NADPH oxidase by angiotensin II (Ang II) with the activation of NADPH oxidase subunits, p22phox and gp91phox, to be responsible for the preconditioning effect of Ang II. The present study was designed to determine if similar to ischemic preconditioning (PC), mitogen-activated protein (MAP) kinases are also involved in Ang II PC of the heart. Isolated working rat hearts were perfused for 15 min with KHB (Krebs-Henseleit bicarbonate) buffer containing Ang II in the absence or presence of an Erk (1/2) inhibitor, PD 098059, a p38MAPK inhibitor, SB 202190, a JNK inhibitor, SP 600125 or a ROS scavenger, N-acetyl cysteine (NAC). All hearts were subsequently subjected to 30 min global ischemia followed by 2 h reperfiision with KHB buffer only. Cardioprotection was examined by determining infarct size, cardiomyocyte apoptosis and ventricular recovery. Redox and MAP kinase regulation were studied by determining the survival signaling mediated by Akt and Bcl-2. In consistent with previous results, Ang II preconditioned the heart as evidenced by improved postischemic ventricular recovery and reduced infaret size and decreases cardiomyocyte apoptosis. Ang II phosphorylated both Akt, Bcl-2 and Bad, which was blocked by NAC, PD 098059 or SP 600125, but not by SB 202190. NAC, PD 098059 and SP600125, but not SB202190, also abolished the cardioprotective effect of Ang II preconditioning. The results indicate that Ang II preconditioning is potentiated through MAP kinases that are regulated by redox signaling. (c) 2006 Elsevier Inc. All rights reserved.
C1 Univ Connecticut, Sch Med, Cardiovasc Res Ctr, Farmington, CT 06030 USA.
   Kansai Med Univ, Dept Cardiothorac Surg, Moriguchi, Osaka 570, Japan.
RP Das, DK (reprint author), Univ Connecticut, Sch Med, Cardiovasc Res Ctr, Farmington, CT 06030 USA.
EM DDAS@NEURON.UCHC.EDU
FU NHLBI NIH HHS [HL 34360, HL 56803, HL 22559, HL 33889]
CR Booz GW, 2002, J MOL CELL CARDIOL, V34, P1443, DOI 10.1006/jmcc.2002.2076
   DAS DK, 2000, J CELL MOL MED, V214, P31
   Das S, 2006, CELL BIOCHEM BIOPHYS, V44, P103, DOI 10.1385/CBB:44:1:103
   Das S, 2005, FREE RADICAL RES, V39, P449, DOI 10.1080/10715760500053685
   Das S, 2005, AM J PHYSIOL-HEART C, V288, pH328, DOI 10.1152/ajpheart.00453.2004
   Das S, 2005, J PHARMACOL EXP THER, V314, P762, DOI 10.1124/jpet.105.084285
   DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5
   Diaz RJ, 1997, J MOL CELL CARDIOL, V29, P129, DOI 10.1006/jmcc.1996.0258
   EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0
   ENGELMAN DT, 1995, CARDIOVASC RES, V29, P133, DOI 10.1016/0008-6363(96)88558-0
   Ferreira AJ, 2001, HYPERTENSION, V38, P665, DOI 10.1161/01.HYP.38.3.665
   Gauthier R, 2001, J CELL BIOCHEM, V82, P339, DOI 10.1002/jcb.1172
   Gorin Y, 2004, BIOCHEM J, V381, P231, DOI 10.1042/BJ20031614
   GRIENDLING KK, 1994, CIRC RES, V74, P1141, DOI 10.1161/01.RES.74.6.1141
   Hattori R, 2001, ANTIOXID REDOX SIGN, V3, P403, DOI 10.1089/15230860152409059
   HOKENBERY DM, 1993, CELL, V75, P241
   Izawa Y, 2005, EXP CELL RES, V308, P291, DOI 10.1016/j.yexcr.2005.04.028
   Jung Young D., 2001, Angiogenesis, V4, P155, DOI 10.1023/A:1012291524723
   Kyaw M, 2001, HYPERTENS RES, V24, P251, DOI 10.1291/hypres.24.251
   Li JM, 2004, CIRCULATION, V109, P1307, DOI 10.1161/01.CIR.0000118463.23388.B9
   LIU YG, 1995, J MOL CELL CARDIOL, V27, P883, DOI 10.1016/0022-2828(95)90038-1
   Maulik N, 1999, CIRCULATION, V100, P369
   MAULIK N, 1998, AM J PHYSIOL, V275, P1857
   MAULIK N, 1998, SURG FORUM, V49, P209
   Miki T, 1996, J AM COLL CARDIOL, V28, P1616, DOI 10.1016/S0735-1097(96)00371-3
   Nakano A, 1997, CORONARY ARTERY DIS, V8, P343, DOI 10.1097/00019501-199706000-00003
   O'Gorman DM, 2000, LEUKEMIA, V14, P602, DOI 10.1038/sj.leu.2401726
   PAGANO PJ, 1995, AM J PHYSIOL-HEART C, V268, pH2274
   Pinzar E, 2005, FEBS LETT, V579, P5100, DOI 10.1016/j.febslet.2005.08.019
   Sharma A, 2000, EUR J PHARMACOL, V406, P85, DOI 10.1016/S0014-2999(00)00582-3
   Sharma A, 2000, MOL CELL BIOCHEM, V214, P31, DOI 10.1023/A:1007167519596
   UshioFukai M, 1996, J BIOL CHEM, V271, P23317, DOI 10.1074/jbc.271.38.23317
   VEGH A, 1994, BRIT J PHARMACOL, V113, P1167, DOI 10.1111/j.1476-5381.1994.tb17120.x
   Xiao XH, 2003, PFLUG ARCH EUR J PHY, V445, P643, DOI 10.1007/s00424-002-0990-y
   Xie ZL, 2004, J CELL PHYSIOL, V198, P399, DOI 10.1002/jcp.10419
   Xie ZL, 2001, J CELL PHYSIOL, V188, P132, DOI 10.1002/jcp.1104
NR 36
TC 33
Z9 39
U1 2
U2 10
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0022-2828
EI 1095-8584
J9 J MOL CELL CARDIOL
JI J. Mol. Cell. Cardiol.
PD AUG
PY 2006
VL 41
IS 2
BP 248
EP 255
DI 10.1016/j.yjmcc.2006.03.009
PG 8
WC Cardiac & Cardiovascular Systems; Cell Biology
SC Cardiovascular System & Cardiology; Cell Biology
GA 074WK
UT WOS:000239842300008
PM 16697003
DA 2018-12-27
ER

PT J
AU Marx, DM
   Stapel, DA
AF Marx, David M.
   Stapel, Diederik A.
TI RETRACTED: Distinguishing stereotype threat from priming effects: On the
   role of the social self and threat-based concerns (Retracted article.
   See vol. 104, pg. 196, 2013)
SO JOURNAL OF PERSONALITY AND SOCIAL PSYCHOLOGY
LA English
DT Article; Retracted Publication
DE stereotype threat; priming; threat-based concerns; social identity;
   performance
ID MATH PERFORMANCE; IDENTITY; BEHAVIOR; ACTIVATION; WOMEN; PERCEPTION;
   PSYCHOLOGY; CATEGORY; IMPACT; OTHERS
AB It has been argued that priming negative stereotypic traits is sufficient to cause stereotype threat. The present research challenges this assumption by highlighting the role of the social self and targets' concerns about confirming a negative group-based stereotype. Specifically, in 3 experiments the authors demonstrate that stereotype threat adversely affects the test performance and threat-based concerns of targets (but not nontargets) because only targets' social self is linked to the negative group stereotype. Trait priming, however, harms the test performance of both targets and nontargets but has no effect on their threat-based concerns because trait priming does not require such a link between the social self and the group stereotype. Moreover, the authors show that merely increasing the accessibility of the social self in nonthreatening situations leads to the underperformance of targets but has no meaningful effect on nontargets' test performance.
C1 Univ Groningen, Dept Social & Org Psychol, Groningen, Netherlands.
RP Marx, DM (reprint author), San Diego State Univ, Dept Psychol, 5500 Campanile Dr, San Diego, CA 92182 USA.
EM dmarx@sciences.sdsu.edu; d.a.stapel@rug.nl
CR Ambady N, 2004, J EXP SOC PSYCHOL, V40, P401, DOI 10.1016/j.jesp.2003.08.003
   Aronson J, 1999, J EXP SOC PSYCHOL, V35, P29, DOI 10.1006/jesp.1998.1371
   Bar-On R., 1997, EMOTIONAL INTELLIGEN
   Bargh JA, 1996, J PERS SOC PSYCHOL, V71, P230, DOI 10.1037/0022-3514.71.2.230
   Blanton H, 2002, J EXP SOC PSYCHOL, V38, P253, DOI 10.1006/jesp.2001.1510
   Brewer MB, 1996, J PERS SOC PSYCHOL, V71, P83, DOI 10.1037/0022-3514.71.1.83
   Croizet JC, 1998, PERS SOC PSYCHOL B, V24, P588, DOI 10.1177/0146167298246003
   Dijksterhuis A, 1998, J PERS SOC PSYCHOL, V74, P865, DOI 10.1037/0022-3514.74.4.865
   Dijksterhuis A, 2001, ADV EXP SOC PSYCHOL, V33, P1, DOI 10.1016/S0065-2601(01)80003-4
   DIJKSTERHUIS A, 2004, UNPUB RELATIONS STER
   Gladwell M., 2005, BLINK POWER THINKING
   Gonzales PM, 2002, PERS SOC PSYCHOL B, V28, P659, DOI 10.1177/0146167202288010
   Inzlicht M, 2000, PSYCHOL SCI, V11, P365, DOI 10.1111/1467-9280.00272
   Kawakami K, 2002, PERS SOC PSYCHOL B, V28, P3, DOI 10.1177/0146167202281001
   Levy B, 1996, J PERS SOC PSYCHOL, V71, P1092, DOI 10.1037/0022-3514.71.6.1092
   Leyens JP, 2000, PERS SOC PSYCHOL B, V26, P1189, DOI 10.1177/0146167200262002
   Major B, 2005, ANNU REV PSYCHOL, V56, P393, DOI 10.1146/annurev.psych.56.091103.070137
   Marx D. M., 2002, PERSONALITY SOCIAL P, V28, P1185, DOI DOI 10.1177/01461672022812004
   Marx DM, 2005, J PERS SOC PSYCHOL, V88, P432, DOI 10.1037/0022-3514.88.3.432
   Marx DM, 1999, J SOC ISSUES, V55, P491, DOI 10.1111/0022-4537.00129
   MARX DM, J EXPT SOCIAL PSYCHO
   Onorato RS, 2004, EUR J SOC PSYCHOL, V34, P257, DOI 10.1002/ejsp.195
   Oswald DL, 2000, CURR PSYCHOL, V19, P338, DOI 10.1007/s12144-000-1025-5
   Pronin E, 2004, J EXP SOC PSYCHOL, V40, P152, DOI 10.1016/S0022-1031(03)00088-X
   Schutte NS, 1998, PERS INDIV DIFFER, V25, P167, DOI 10.1016/S0191-8869(98)00001-4
   Shih M, 1999, PSYCHOL SCI, V10, P80, DOI 10.1111/1467-9280.00111
   Shih M, 2002, J PERS SOC PSYCHOL, V83, P638, DOI 10.1037//0022-3514.83.3.638
   Spears R, 2004, PERS SOC PSYCHOL B, V30, P605, DOI 10.1177/0146167203262087
   Spencer SJ, 1999, J EXP SOC PSYCHOL, V35, P4, DOI 10.1006/jesp.1998.1373
   SRULL TK, 1979, J PERS SOC PSYCHOL, V37, P1660, DOI 10.1037//0022-3514.37.10.1660
   Stapel DA, 2001, J PERS SOC PSYCHOL, V80, P766, DOI 10.1037//0022-3514.80.5.766
   Steele CM, 1997, AM PSYCHOL, V52, P613, DOI 10.1037//0003-066X.52.6.613
   STEELE CM, 1995, J PERS SOC PSYCHOL, V69, P797, DOI 10.1037/0022-3514.69.5.797
   Steele CM, 2002, ADV EXP SOC PSYCHOL, V34, P379, DOI 10.1016/S0065-2601(02)80009-0
   Stone J, 1999, J PERS SOC PSYCHOL, V77, P1213, DOI 10.1037//0022-3514.77.6.1213
   Turner J. C., 1987, REDISCOVERING SOCIAL
   Walton GM, 2003, J EXP SOC PSYCHOL, V39, P456, DOI 10.1016/S0022-1031(03)00019-2
   Wheeler SC, 2001, J EXP SOC PSYCHOL, V37, P173, DOI 10.1006/jesp.2000.1448
   Wheeler SC, 2001, PSYCHOL BULL, V127, P797, DOI 10.1037//0033-2909.127.6.797
NR 39
TC 34
Z9 34
U1 3
U2 28
PU AMER PSYCHOLOGICAL ASSOC
PI WASHINGTON
PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA
SN 0022-3514
J9 J PERS SOC PSYCHOL
JI J. Pers. Soc. Psychol.
PD AUG
PY 2006
VL 91
IS 2
BP 243
EP 254
DI 10.1037/0022-3514.91.2.243
PG 12
WC Psychology, Social
SC Psychology
GA 071ZJ
UT WOS:000239642100004
PM 16881762
DA 2018-12-27
ER

PT J
AU Crawford, RM
   Treharne, KJ
   Arnaud-Dabernat, S
   Daniel, JY
   Foretz, M
   Viollet, B
   Mehta, A
AF Crawford, Russell M.
   Treharne, Kate J.
   Arnaud-Dabernat, Sandrine
   Daniel, Jean-Yves
   Foretz, Marc
   Viollet, Benoit
   Mehta, Anil
TI RETRACTED: Understanding the molecular basis of the interaction between
   NDPK-A and AMPK alpha 1 (Retracted Article. See vol 28, pg 5827, 2008)
SO MOLECULAR AND CELLULAR BIOLOGY
LA English
DT Article; Retracted Publication
ID ACTIVATED PROTEIN-KINASE; NUCLEOSIDE-DIPHOSPHATE KINASE;
   SKELETAL-MUSCLE; IN-VITRO; CELLS; PHOSPHORYLATION; INHIBITION;
   EXPRESSION; KNOCKOUT; ISOFORM
AB Nucleoside diphosphate kinase (NDPK) (nm23/awd) belongs to a multifunctional family of highly conserved proteins (similar to 16 to 20 kDa) including two well-characterized isoforms (NDPK-A and -B). NDPK catalyzes the conversion of nucleoside diphosphates to nucleoside triphosphates, regulates a diverse array of cellular events, and can act as a protein histidine kinase. AMP-activated protein kinase (AMPK) is a heterotrimeric protein complex that responds to the cellular energy status by switching off ATP-consuming pathways and switching on ATP-generating pathways when ATP is limiting. AMPK was first discovered as an activity that inhibited preparations of acetyl coenzyme A carboxylase 1 (ACC1), a regulator of cellular fatty acid synthesis. We recently reported that NDPK-A (but not NDPK-B) selectively regulates the alpha 1 isoform of AMPK independently of the AMP concentration such that the manipulation of NDPK-A nucleotide trans-phosphorylation activity to generate ATP enhanced the activity of AMPK. This regulation occurred irrespective of the surrounding ATP concentration, suggesting that "substrate channeling" was occurring with the shielding of NDPK-generated ATP from the surrounding medium. We speculated that AMPK alpha 1 phosphorylated NDPK-A during their interaction, and here, we identify two residues on NDPK-A targeted by AMPK alpha 1 in vivo. We find that NDPK-A 5122 and 5144 are phosphorylated by AMPK alpha 1 and that the phosphorylation status of 5122, but not 5144, determines whether substrate channeling can occur. We report the cellular effects of the S122 mutation on ACC1 phosphorylation and demonstrate that the presence of E124 (absent in NDPK-B) is necessary and sufficient to permit both AMPK alpha 1 binding and substrate channeling.
C1 Univ Dundee, Dept Maternal & Child Hlth Sci, Ninewells Hosp, Dundee DD1 9SY, Scotland.
   Univ Victor Segalen Bordeaux 2, Lab Biol Differenciat & Dev, EA 3674, F-33076 Bordeaux, France.
   Univ Paris 05, INSERM, CNRS, U567,Inst Cochin,Dpt GDPM, F-75014 Paris, France.
RP Mehta, A (reprint author), Univ Dundee, Dept Maternal & Child Hlth Sci, Dundee DD1 9SY, Scotland.
EM a.mehta@dundee.ac.uk
RI FORETZ, Marc/O-7334-2017
OI FORETZ, Marc/0000-0001-7017-9032
FU Wellcome Trust [075237/Z/04/Z]
CR Arnaud-Dabernat S, 2003, J BIOENERG BIOMEMBR, V35, P19, DOI 10.1023/A:1023561821551
   Biondi RM, 1996, FEBS LETT, V399, P183, DOI 10.1016/S0014-5793(96)01299-9
   Bosnar MH, 2004, EXP CELL RES, V298, P275, DOI 10.1016/j.yexcr.2004.04.018
   CALIGO MA, 1995, INT J CANCER, V60, P837, DOI 10.1002/ijc.2910600619
   Crawford RM, 2005, BIOCHEM J, V392, P201, DOI 10.1042/BJ20050269
   Crawford RM, 2001, FASEB J, V15, P102, DOI 10.1096/fj.01-0446fje
   DALE S, 1995, FEBS LETT, V361, P191, DOI 10.1016/0014-5793(95)00172-6
   ENGEL M, 1995, EUR J BIOCHEM, V234, P200, DOI 10.1111/j.1432-1033.1995.200_c.x
   Fukuda M, 1996, INT J CANCER, V65, P531, DOI 10.1002/(SICI)1097-0215(19960208)65:4<531::AID-IJC23>3.0.CO;2-B
   Hardie DG, 2001, BIOESSAYS, V23, P1112, DOI 10.1002/bies.10009
   Hardie DG, 1997, EUR J BIOCHEM, V246, P259, DOI 10.1111/j.1432-1033.1997.00259.x
   Hayashi T, 1998, DIABETES, V47, P1369, DOI 10.2337/diabetes.47.8.1369
   HEIDBUCHEL H, 1992, CIRC RES, V71, P808, DOI 10.1161/01.RES.71.4.808
   Ishijima Y, 1999, FEBS LETT, V445, P155, DOI 10.1016/S0014-5793(99)00116-7
   Jorgensen SB, 2004, J BIOL CHEM, V279, P1070, DOI 10.1074/jbc.M306205200
   Kahn BB, 2005, CELL METAB, V1, P15, DOI 10.1016/j.cmet.2004.12.003
   Konig J, 2002, BBA-BIOMEMBRANES, V1565, P17, DOI 10.1016/S0005-2736(02)00502-3
   MACDONALD NJ, 1993, J BIOL CHEM, V268, P25780
   Merrill GF, 1997, AM J PHYSIOL-ENDOC M, V273, pE1107
   Muimo R, 2000, J BIOL CHEM, V275, P36632, DOI 10.1074/jbc.M000829200
   Nielsen JN, 2003, J APPL PHYSIOL, V94, P631, DOI 10.1152/japplphysiol.00642.2002
   Postel EH, 1998, INT J BIOCHEM CELL B, V30, P1291, DOI 10.1016/S1357-2725(98)00087-9
   Ranki HJ, 2002, MECH AGEING DEV, V123, P695, DOI 10.1016/S0047-6374(01)00415-8
   Roymans D, 2002, CLIN EXP METASTAS, V19, P465, DOI 10.1023/A:1020396722860
   Salt I, 1998, BIOCHEM J, V334, P177, DOI 10.1042/bj3340177
   Schreiber R, 1999, P NATL ACAD SCI USA, V96, P5310, DOI 10.1073/pnas.96.9.5310
   Stapleton D, 1996, J BIOL CHEM, V271, P611, DOI 10.1074/jbc.271.2.611
   SULLIVAN JE, 1994, BIOCHEM BIOPH RES CO, V200, P1551, DOI 10.1006/bbrc.1994.1627
   Viollet B, 2003, BIOCHEM SOC T, V31, P216, DOI 10.1042/bst0310216
   Viollet B, 2003, J CLIN INVEST, V111, P91, DOI 10.1172/JCI200316567
   Woods A, 1996, FEBS LETT, V397, P347, DOI 10.1016/S0014-5793(96)01209-4
NR 31
TC 13
Z9 13
U1 3
U2 9
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0270-7306
EI 1098-5549
J9 MOL CELL BIOL
JI Mol. Cell. Biol.
PD AUG
PY 2006
VL 26
IS 15
BP 5921
EP 5931
DI 10.1128/MCB.00315-06
PG 11
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 067FG
UT WOS:000239286600032
PM 16847342
OA Bronze, Green Published
DA 2018-12-27
ER

PT J
AU Moon, H
   Jung, JC
AF Moon, Hyungin
   Jung, Jae-Chul
TI RETRACTED: Effect of meso-dihydroguaiaretic acid from Machilus
   thunbergii Sieb et Zucc on NIMP-1 expression in heat shock-induced
   cultured primary human fibroblasts (Retracted article. See vol 21, pg
   599, 2007)
SO PHYTOTHERAPY RESEARCH
LA English
DT Article; Retracted Publication
DE Machilus thunbergii; meso-dihydroguaiaretic acid; matrix
   metalloproteinase-1; heat shock-induced; human fibroblasts
ID MATRIX METALLOPROTEINASES; COLLAGENASE; RADIATION; LIGNANS; CELLS
AB Ethanol and aqueous extracts of Machilus thunbergii Sieb et Zucc (Lauraceae) used traditionally for the treatment of a variety of diseases were screened in vitro for MMP-1 inhibitory actions. Meso-dihydroguaiaretic acid (MDGA) from the stem bark of M. thunbergii showed a significant inhibition of matrix metalloproteinase (NIMP)-1 in primary human fibroblasts by heat shock-induced. This study investigated the effect of MDGA isolated from M. thunbergii on heat shock-induced premature skin aging. MDGA reduced the expression of MMP-1 at the protein level in a dose-dependent manner in heat shock-induced cultured primary human fibroblasts. Taken together, these results show that MDGA can prevent the harmful effects of heat (and/or IR) that lead to skin aging. Copyright (c) 2006 John Wiley & Sons, Ltd.
C1 Univ Mississippi, Sch Pharm, Natl Ctr Nat Prod Res, University, MS 38677 USA.
   Univ Mississippi, Sch Pharm, Dept Med Chem, University, MS 38677 USA.
RP Moon, H (reprint author), Univ Mississippi, Sch Pharm, Natl Ctr Nat Prod Res, University, MS 38677 USA.
EM himoon@olemiss.edu
CR AIBA CJ, 1973, PHYTOCHEMISTRY, V12, P1163, DOI 10.1016/0031-9422(73)85034-4
   Brenneisen P, 1998, BRIT J DERMATOL, V139, P537
   Chen Z, 2005, J INVEST DERMATOL, V124, P70, DOI 10.1111/j.0022-202X.2004.23550.x
   Fisher GJ, 1996, NATURE, V379, P335, DOI 10.1038/379335a0
   HITRAYA EG, 1995, BIOCHEM J, V308, P743, DOI 10.1042/bj3080743
   KARIKOME H, 1991, PHYTOCHEMISTRY, V30, P315, DOI 10.1016/0031-9422(91)84145-I
   Kim NY, 2003, PHYTOTHER RES, V17, P372, DOI 10.1002/ptr.1160
   LEE TB, 1982, ILLUSTRATED FLORA KO, P614
   Moon HI, 2005, BIOL PHARM BULL, V28, P2176, DOI 10.1248/bpb.28.2176
   MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4
   NII H, 1981, Nippon Nogeikagaku Kaishi, V55, P37
   Park BY, 2004, BIOL PHARM BULL, V27, P1305, DOI 10.1248/bpb.27.1305
   Park CH, 2004, J INVEST DERMATOL, V123, P1012, DOI 10.1111/j.0022-202X.2004.23487.x
   Schieke SM, 2003, PHOTODERMATOL PHOTO, V19, P228, DOI 10.1034/j.1600-0781.2003.00054.x
   Sternlicht MD, 2001, ANNU REV CELL DEV BI, V17, P463, DOI 10.1146/annurev.cellbio.17.1.463
   TOMITA M, 1964, Yakugaku Zasshi, V84, P362
   VANCE BA, 1989, J CELL BIOL, V108, P2037, DOI 10.1083/jcb.108.6.2037
   Visse R, 2003, CIRC RES, V92, P827, DOI 10.1161/01.RES.0000070112.80711.3D
   Yu YU, 2000, J PHARM PHARMACOL, V52, P1163, DOI 10.1211/0022357001774949
NR 19
TC 8
Z9 10
U1 4
U2 12
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0951-418X
EI 1099-1573
J9 PHYTOTHER RES
JI Phytother. Res.
PD AUG
PY 2006
VL 20
IS 8
BP 714
EP 716
DI 10.1002/ptr.1941
PG 3
WC Chemistry, Medicinal; Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 075BT
UT WOS:000239857900019
PM 16775809
DA 2018-12-27
ER

PT J
AU Ravanshad, M
   Mahboudi, F
   Sabahi, F
   Bayanolhagh, S
AF Ravanshad, Mehrdad
   Mahboudi, Fereidoun
   Sabahi, Farzaneh
   Bayanolhagh, Saeed
TI RETRACTED: Indeterminate human immunodeficiency virus western blot
   results in Iranian patients with discordant screening assay results
   (Retracted article. See vol. 30, pg. 858, 2009)
SO SAUDI MEDICAL JOURNAL
LA English
DT Article; Retracted Publication
ID ANTIBODIES; HIV-1
AB Objective: The Western blot (WB) assay is the most widely accepted confirmatory assay for the detection and confirmation of antibodies to human immunodeficiency virus type 1 (HIV-1) and 2 (HIV-2). However, indeterminate WB reactivity to HIV-1 and HIV-2 proteins may occur in individuals who do not appear to be infected with HIV.
   Methods: In this study, we describe the results of indeterminate WB reactivity in Iranian patients with discordant screening assays. The samples were obtained from the Iranian Blood Transfusion Center, Tehran, Iran and evaluated in the Biotechnology Process Development Center, Pasteur Institute of Iran, Tehran, Iran between 2003 and 2004. A total of 4707 were tested for the presence of HIV-1 antibodies.
   Results: Six hundred and four (12.8%) patients tested for HIV were positive for HIV-1 antibody. Nine (1.49%) have discordant results among screening assays and indeterminate WB results as interpreted by Centers for Disease Control and Prevention (CDC) criteria. Most (66.7%) of these indeterminate WB results were due to p24 reactivity. However, 2 (22.2%) display reactivity to both gp41 and gp120 proteins [Positive by World Health Organization (WHO) criteria]. Of 9 WB assays initially indeterminate by the CDC criteria and with follow-up samples, 8 (88.8%) became negative when retested subsequently while one (11.1%) remained indeterminate for more than a year and were thus considered negative. In addition, all the indeterminate samples were negative when assessed by polymerase chain reaction assay.
   Conclusion: In general, there was an 88.8% concordance between the CDC and WHO criteria for an indeterminate WB result. The CDC 11 criteria best met the specified objectives for diagnosis in our setting.
C1 Pasture Inst, Biotechnol Res Ctr, Tehran, Iran.
   Tarbiat Modares Univ, Fac Med Sci, Dept Virol, Tehran, Iran.
RP Mahboudi, F (reprint author), Pasture Inst, Biotechnol Res Ctr, Tehran, Iran.
EM mahboudi@institute.pasteur.ac.ir
RI Mahboudi, Fereidoun/L-5057-2017
OI Mahboudi, Fereidoun/0000-0002-3380-5257
CR ALLAIN JP, 1987, NEW ENGL J MED, V317, P1114, DOI 10.1056/NEJM198710293171804
   *ASS STAT TERR PUB, 1988, 3 CONS C HIV TEST U, P9
   Casseb J, 2002, BRAZ J MED BIOL RES, V35, P369, DOI 10.1590/S0100-879X2002000300013
   Centers for Disease Control (CDC), 1989, MMWR Suppl, V38, P1
   CONSTANTINE NT, 1992, RETROVIRAL TESTING E
   Downing RG, 1998, J ACQ IMMUN DEF SYND, V18, P384, DOI 10.1097/00042560-199808010-00011
   Kleinman S, 1998, JAMA-J AM MED ASSOC, V280, P1080, DOI 10.1001/jama.280.12.1080
   Mylonakis E, 2000, ARCH INTERN MED, V160, P2386, DOI 10.1001/archinte.160.15.2386
   Powderly WG, 2003, CLIN INFECT DIS, V37, P813, DOI 10.1086/378279
   Preiser W, 2000, J MED VIROL, V60, P43
   Rizzardini G, 1996, AIDS, V10, P1535, DOI 10.1097/00002030-199611000-00012
   SARRAMIFOROOSHA.R, 2006, IN PRESS J CLIN VIRO
   Watt G, 2000, CLIN INFECT DIS, V30, P819, DOI 10.1086/313777
   *WHO, 1990, WKLY EPIDEMIOL REC, V37, P281
   1998, J AM MED ASS, V260, P674
NR 15
TC 2
Z9 2
U1 1
U2 8
PU SAUDI MED J
PI RIYADH
PA ARMED FORCES HOSPITAL, PO BOX 7897,, RIYADH 11159, SAUDI ARABIA
SN 0379-5284
J9 SAUDI MED J
JI Saudi Med. J.
PD AUG
PY 2006
VL 27
IS 8
BP 1130
EP 1133
PG 4
WC Medicine, General & Internal
SC General & Internal Medicine
GA 085WG
UT WOS:000240634500005
PM 16883439
OA DOAJ Gold
DA 2018-12-27
ER

PT J
AU Seki, T
   Akita, M
   Kamimura, Y
   Muramatsu, S
   Araki, H
   Sugino, A
AF Seki, Takashi
   Akita, Masaki
   Kamimura, Yoichiro
   Muramatsu, Sachiko
   Araki, Hiroyuki
   Sugino, Akio
TI RETRACTED: GINS is a DNA polymerase epsilon accessory factor during
   chromosomal DNA replication in budding yeast (Retracted Article. See vol
   283, pg 11860, 2008)
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article; Retracted Publication
ID SACCHAROMYCES-CEREVISIAE; SCHIZOSACCHAROMYCES-POMBE; STRANDED-DNA; 4TH
   SUBUNIT; S-PHASE; DELTA; FORK; PROTEINS; IDENTIFICATION; PROGRESSION
AB GINS is a protein complex found in eukaryotic cells that is composed of Sld5p, Psf1p, Psf2p, and Psf3p. GINS polypeptides are highly conserved in eukaryotes, and the GINS complex is required for chromosomal DNA replication in yeasts and Xenopus egg. This study reports purification and biochemical characterization of GINS from Saccharomyces cerevisiae. The results presented here demonstrate that GINS forms a 1: 1 complex with DNA polymerase is an element of (Pol epsilon) holoenzyme and greatly stimulates its catalytic activity in vitro. In the presence of GINS, Pol epsilon is more processive and dissociates more readily from replicated DNA, while under identical conditions, proliferating cell nuclear antigen slightly stimulates Pol epsilon in vitro. These results strongly suggest that GINS is a Pol epsilon accessory protein during chromosomal DNA replication in budding yeast. Based on these results, we propose a model for molecular dynamics at eukaryotic chromosomal replication fork.
C1 Osaka Univ, Grad Sch Frontier Biosci, Labs Biomol Networks, Suita, Osaka 5650871, Japan.
   Nagoya Univ, Grad Sch Sci, Div Biol Sci, Nagoya, Aichi 4648602, Japan.
   Natl Inst Genet, Div Microbiol Genet, Mishima, Shizuoka 4118540, Japan.
RP Sugino, A (reprint author), Osaka Univ, Grad Sch Frontier Biosci, Labs Biomol Networks, 1-3 Yamada Oka, Suita, Osaka 5650871, Japan.
EM asugino@fbs.osaka-u.ac.jp
CR Aparicio OM, 1997, CELL, V91, P59, DOI 10.1016/S0092-8674(01)80009-X
   ARAKI H, 1991, NUCLEIC ACIDS RES, V19, P4867, DOI 10.1093/nar/19.18.4867
   ARAKI H, 1995, P NATL ACAD SCI USA, V92, P11791, DOI 10.1073/pnas.92.25.11791
   ARAKI H, 1992, EMBO J, V11, P733, DOI 10.1002/j.1460-2075.1992.tb05106.x
   Asturias FJ, 2006, NAT STRUCT MOL BIOL, V13, P35, DOI 10.1038/nsmb1040
   Bell SP, 2002, ANNU REV BIOCHEM, V71, P333, DOI 10.1146/annurev.biochem.71.110601.135425
   BUDD ME, 1993, MOL CELL BIOL, V13, P496, DOI 10.1128/MCB.13.1.496
   Dua R, 1999, J BIOL CHEM, V274, P22283, DOI 10.1074/jbc.274.32.22283
   Gambus A, 2006, NAT CELL BIOL, V8, P358, DOI 10.1038/ncb1382
   Garg P, 2005, CRIT REV BIOCHEM MOL, V40, P115, DOI 10.1080/10409230590935433
   Gerik KJ, 1998, J BIOL CHEM, V273, P19747, DOI 10.1074/jbc.273.31.19747
   Gomes XV, 2000, J BIOL CHEM, V275, P14541, DOI 10.1074/jbc.275.19.14541
   HAMATAKE RK, 1990, J BIOL CHEM, V265, P4072
   Hashimoto K, 1998, NUCLEIC ACIDS RES, V26, P477, DOI 10.1093/nar/26.2.477
   Hashimoto K, 2003, BIOCHEMISTRY-US, V42, P14207, DOI 10.1021/bi0348359
   Hiraga SI, 2005, GENES CELLS, V10, P297, DOI 10.1111/j.1365-2443.2005.00843.x
   Johnson A, 2005, ANNU REV BIOCHEM, V74, P283, DOI 10.1146/annurev.biochem.73.011303.073859
   Kamimura Y, 1998, MOL CELL BIOL, V18, P6102, DOI 10.1128/MCB.18.10.6102
   Kamimura Y, 2001, EMBO J, V20, P2097, DOI 10.1093/emboj/20.8.2097
   Kanemaki M, 2003, NATURE, V423, P720, DOI 10.1038/nature01692
   Kanemaki M, 2006, EMBO J, V25, P1753, DOI 10.1038/sj.emboj.7601063
   Karthikeyan R, 2000, J MOL BIOL, V299, P405, DOI 10.1006/jmbi.2000.3744
   Kawasaki Y, 2000, GENES CELLS, V5, P975, DOI 10.1046/j.1365-2443.2000.00387.x
   Kesti T, 1999, MOL CELL, V3, P679, DOI 10.1016/S1097-2765(00)80361-5
   Kim SS, 1996, CELL, V84, P643, DOI 10.1016/S0092-8674(00)81039-9
   Kubota Y, 2003, GENE DEV, V17, P1141, DOI 10.1101/gad.1070003
   LEE SH, 1991, J BIOL CHEM, V266, P22707
   Liu L, 2000, J BIOL CHEM, V275, P18739, DOI 10.1074/jbc.M001217200
   Maki S, 1998, J BIOL CHEM, V273, P21332, DOI 10.1074/jbc.273.33.21332
   Masumoto H, 2000, MOL CELL BIOL, V20, P2809, DOI 10.1128/MCB.20.8.2809-2817.2000
   Masumoto H, 2002, NATURE, V415, P651, DOI 10.1038/nature713
   MORRISON A, 1994, MOL GEN GENET, V242, P289, DOI 10.1007/BF00280418
   MORRISON A, 1990, CELL, V62, P1143, DOI 10.1016/0092-8674(90)90391-Q
   Ohya T, 2000, NUCLEIC ACIDS RES, V28, P3846, DOI 10.1093/nar/28.20.3846
   Ohya T, 2002, J BIOL CHEM, V277, P28099, DOI 10.1074/jbc.M111573200
   Pacek M, 2006, MOL CELL, V21, P581, DOI 10.1016/j.molcel.2006.01.030
   Podust VN, 2002, J BIOL CHEM, V277, P3894, DOI 10.1074/jbc.M109684200
   Shcherbakova PV, 1996, GENETICS, V142, P717
   STERN DF, 1991, MOL CELL BIOL, V11, P987, DOI 10.1128/MCB.11.2.987
   SUGINO A, 1995, TRENDS BIOCHEM SCI, V20, P319, DOI 10.1016/S0968-0004(00)89059-3
   Sugino A, 1998, GENES CELLS, V3, P99, DOI 10.1046/j.1365-2443.1998.00169.x
   Takayama Y, 2003, GENE DEV, V17, P1153, DOI 10.1101/gad.1065903
   Tran HT, 1997, MOL CELL BIOL, V17, P2859, DOI 10.1128/MCB.17.5.2859
   Tsubota T, 2003, GENES CELLS, V8, P873, DOI 10.1046/j.1365-2443.2003.00683.x
   Zuo SJ, 1997, P NATL ACAD SCI USA, V94, P11244, DOI 10.1073/pnas.94.21.11244
NR 45
TC 11
Z9 14
U1 2
U2 9
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD JUL 28
PY 2006
VL 281
IS 30
BP 21422
EP 21432
DI 10.1074/jbc.M603482200
PG 11
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 065VF
UT WOS:000239187300078
PM 16714283
OA Bronze
DA 2018-12-27
ER

PT J
AU Alvarez, VA
   Ridenour, DA
   Sabatini, BL
AF Alvarez, Veronica A.
   Ridenour, Dennis A.
   Sabatini, Bernardo L.
TI RETRACTED: Retraction of synapses and dendritic spines induced by
   off-target effects of RNA interference (Retracted Article. See vol 26,
   issue 43, Oct 25 2006)
SO JOURNAL OF NEUROSCIENCE
LA English
DT Correction; Retracted Publication
DE RNA interference; short hairpin RNA; interferon response; synaptic
   transmission; dendritic spine; off-target effects
ID DOUBLE-STRANDED-RNA; DEPENDENT STIMULATION; MAMMALIAN-CELLS; SYNTHETIC
   SIRNA; GENE-EXPRESSION; MORPHOGENESIS; PATHWAYS; KINASE; POTENT
AB RNA interference (RNAi), which allows selective gene silencing, has been proposed for functional genomic analysis and for the treatment of human disease. However, induction of RNAi in mammalian cells by expression of double-stranded RNA can activate innate antiviral response pathways that perturb off-target gene expression. The activation and functional consequences of these effects in neurons are unknown. We find that expression of subsets of short hairpin RNAs (shRNAs) in rat hippocampal pyramidal neurons can have off-target effects that reduce the complexity of dendritic arbors and trigger the loss of dendritic spines. Morphological changes are accompanied by electrophysiological perturbations in passive membrane properties and a decrease in the number and strength of excitatory and inhibitory synapses. These perturbations depend on the shRNA sequence and are independent of the identity of the targeted protein. Our results indicate that off-target effects of RNAi severely perturb neuronal structure and function and may lead to the functional withdrawal of affected cells from the brain circuitry.
C1 Harvard Univ, Sch Med, Dept Neurobiol, Boston, MA 02115 USA.
RP Sabatini, BL (reprint author), Harvard Univ, Sch Med, Dept Neurobiol, 220 Longwood Ave, Boston, MA 02115 USA.
EM bsabatini@hms.harvard.edu
RI Alvarez, Veronica/E-9745-2015
OI Alvarez, Veronica/0000-0003-2611-8675
FU NINDS NIH HHS [R01 NS046579, 5T32 NS07484]
CR Asano A, 2003, GENE, V306, P105, DOI 10.1016/S0378-1119(03)00428-1
   Banker G., 1998, CULTURING NERVE CELL
   Bertram MJ, 1999, MOL CELL BIOL, V19, P1479
   Birmingham A, 2006, NAT METHODS, V3, P199, DOI 10.1038/NMETH854
   Bridge AJ, 2003, NAT GENET, V34, P263, DOI 10.1038/ng1173
   Chih B, 2005, SCIENCE, V307, P1324, DOI 10.1126/science.1107470
   De Veer MJ, 2005, IMMUNOL CELL BIOL, V83, P224, DOI 10.1111/j.1440-1711.2005.01337.x
   Dunah AW, 2005, NAT NEUROSCI, V8, P458, DOI 10.1038/nn1416
   Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107
   Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888
   Hannon GJ, 2002, NATURE, V418, P244, DOI 10.1038/418244a
   Hering H, 2003, J NEUROSCI, V23, P11759
   Judge AD, 2005, NAT BIOTECHNOL, V23, P457, DOI 10.1038/nbt1081
   Judge AD, 2006, MOL THER, V13, P494, DOI 10.1016/j.ymthe.2005.11.002
   LO DC, 1994, NEURON, V13, P1263, DOI 10.1016/0896-6273(94)90412-X
   Persengiev SP, 2004, RNA, V10, P12, DOI 10.1261/rna5160904
   Samuel CE, 2001, CLIN MICROBIOL REV, V14, P778, DOI 10.1128/CMR.14.4.778-809.2001
   Schratt GM, 2006, NATURE, V439, P283, DOI 10.1038/nature04367
   Shi Y, 2003, TRENDS GENET, V19, P9, DOI 10.1016/S0168-9525(02)00005-7
   Sledz CA, 2004, BIOCHEM SOC T, V32, P952, DOI 10.1042/BST0320952
   Sledz CA, 2003, NAT CELL BIOL, V5, P834, DOI 10.1038/ncb1038
   STOPPINI L, 1991, J NEUROSCI METH, V37, P173, DOI 10.1016/0165-0270(91)90128-M
   Sui GC, 2002, P NATL ACAD SCI USA, V99, P5515, DOI 10.1073/pnas.082117599
   Takizawa T, 2002, EUR J BIOCHEM, V269, P6126, DOI 10.1046/j.1432-1033.2002.03325.x
   Tavazoie SF, 2005, NAT NEUROSCI, V8, P1727, DOI 10.1038/nn1566
   Vo N, 2005, P NATL ACAD SCI USA, V102, P16426, DOI 10.1073/pnas.0508448102
   Williams BRG, 1999, ONCOGENE, V18, P6112, DOI 10.1038/sj.onc.1203127
   Yang XJ, 2004, NUCLEIC ACIDS RES, V32, P959, DOI 10.1093/nar/gkh252
NR 28
TC 80
Z9 82
U1 6
U2 33
PU SOC NEUROSCIENCE
PI WASHINGTON
PA 11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA
SN 0270-6474
J9 J NEUROSCI
JI J. Neurosci.
PD JUL 26
PY 2006
VL 26
IS 30
BP 7820
EP 7825
DI 10.1523/JNEUROSCI.1957-06.2006
PG 6
WC Neurosciences
SC Neurosciences & Neurology
GA 068GP
UT WOS:000239361200006
PM 16870727
OA Bronze
DA 2018-12-27
ER

PT J
AU Su, SB
   Adikesavan, AK
   Jaiswal, AK
AF Su, Shibing
   Adikesavan, Anbu Karani
   Jaiswal, Anil K.
TI RETRACTED: Si RNA inhibition of GRP58 associated with decrease in
   mitomycin C-induced DNA cross-linking and cytotoxicity (Retracted
   article. See vol. 294, pg. 178, 2018)
SO CHEMICO-BIOLOGICAL INTERACTIONS
LA English
DT Article; Retracted Publication
DE GRP58; mitomycin C; DNA cross-linking; cytotoxicity
ID DISULFIDE-ISOMERASE ISOFORM; UNIQUE CYTOSOLIC ACTIVITY; DT-DIAPHORASE;
   BIOREDUCTIVE ACTIVATION; REDUCTIVE ACTIVATION; CELLS; IDENTIFICATION;
   EXPRESSION; CLONING; ERP57
AB The anti-cancer drug mitomycin C is metabolically activated to bind and cross-link DNA. The cross-linking contributes significantly to the cytotoxicity. The complex chemical structure of mitomycin C allows its metabolism by several known (cytosolic NAD(P)H:quinone oxidoreductase and microsomal NADPH:cytochrome P450 reductase) and unknown enzymes. The identification of new enzymes/proteins that metabolize mitomycin C and like drugs is an area of significant research interest since these studies have direct implications in drug development and clinical usage. In the present studies, we have investigated a role of cytosolic glucose regulatory protein GRP58 in mitomycin C-induced DNA cross-linking and cytotoxicity. The control and GRP58 siRNA were transfected in human colon carcinoma HCT116 cells in culture. The transfection of GRP58 siRNA but not control siRNA significantly inhibited GRP58 in human colon carcinoma HCT116 cells. The inhibition of GRP58 led to decrease in mitomycin C-induced DNA cross-linking and cytotoxicity. These results establish a role of GRP58 in mitomycin C-induced DNA cross-linking and cytotoxicity. Site-directed mutagenesis of cysteines to serines in thioredoxin domains of GRP58 and cross-linking assays revealed that both N- and C-terminal thioredoxin domains are required for GRP58-mediated mitomycin C-induced DNA cross-linking. These results suggest that GRP58 might be an important target enzyme for further studies on mitomycin C and similar drug therapy. (c) 2006 Elsevier Ireland Ltd. All rights reserved.
C1 Baylor Coll Med, Dept Pharmacol, Houston, TX 77030 USA.
   Shanghai Univ Tradit Chinese Med, Res Ctr Tradit Chinese Med Complex Syst, Shanghai 201203, Peoples R China.
RP Jaiswal, AK (reprint author), Baylor Coll Med, Dept Pharmacol, 1 Baylor Plaza, Houston, TX 77030 USA.
EM ajaiswal@bcm.tmc.edu
RI KARANI ADIKESAVAN, ANBU/B-2385-2008
OI KARANI ADIKESAVAN, ANBU/0000-0002-1389-2111
FU NCI NIH HHS [R01 CA81057]
CR Antoniou AN, 2002, EMBO J, V21, P2655, DOI 10.1093/emboj/21.11.2655
   Belcourt MF, 1996, P NATL ACAD SCI USA, V93, P456, DOI 10.1073/pnas.93.1.456
   BOURDI M, 1995, ARCH BIOCHEM BIOPHYS, V323, P397, DOI 10.1006/abbi.1995.0060
   Briquet-Laugier V, 1998, MAMM GENOME, V9, P176, DOI 10.1007/s003359900717
   Celli CM, 2003, CANCER RES, V63, P6016
   Coppari S, 2002, J CELL BIOCHEM, V85, P325, DOI 10.1002/jcb.10137
   DENIZOT F, 1986, J IMMUNOL METHODS, V89, P271, DOI 10.1016/0022-1759(86)90368-6
   Ferraro A, 1999, J CELL BIOCHEM, V72, P528, DOI 10.1002/(SICI)1097-4644(19990315)72:4<528::AID-JCB8>3.0.CO;2-V
   HIRANO N, 1995, EUR J BIOCHEM, V234, P336, DOI 10.1111/j.1432-1033.1995.336_c.x
   Jain AK, 2005, J BIOL CHEM, V280, P29158, DOI 10.1074/jbc.M502083200
   Joseph P, 1996, INT J CANCER, V65, P263
   JOSEPH P, 1994, P NATL ACAD SCI USA, V91, P8413, DOI 10.1073/pnas.91.18.8413
   Joseph P, 2000, BRIT J CANCER, V82, P1305
   Kumar GS, 1997, BIOCHEMISTRY-US, V36, P14128, DOI 10.1021/bi971394i
   Ndubuisi MI, 1999, J BIOL CHEM, V274, P25499, DOI 10.1074/jbc.274.36.25499
   PAN SS, 1984, J BIOL CHEM, V259, P959
   PRITSOS CA, 1994, ONCOL RES, V6, P477
   ROSS D, 1993, CANCER METAST REV, V12, P83, DOI 10.1007/BF00689803
   SIEGEL D, 1992, BIOCHEMISTRY-US, V31, P7879, DOI 10.1021/bi00149a019
   SIEGEL D, 1990, CANCER RES, V50, P7293
   Tomida A, 1999, ANTI-CANCER DRUG DES, V14, P169
   VERWEIJ J, 1990, ANNUAL, V11, P63
   Wang X, 1999, BRIT J CANCER, V80, P1223, DOI 10.1038/sj.bjc.6690489
   WORKMAN P, 1994, ONCOL RES, V6, P461
NR 24
TC 7
Z9 8
U1 3
U2 7
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0009-2797
EI 1872-7786
J9 CHEM-BIOL INTERACT
JI Chem.-Biol. Interact.
PD JUL 25
PY 2006
VL 162
IS 1
BP 81
EP 87
DI 10.1016/j.cbi.2006.05.009
PG 7
WC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Toxicology
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Toxicology
GA 076HV
UT WOS:000239948500009
PM 16806134
DA 2018-12-27
ER

PT J
AU Boeda, F
   Mosset, P
   Crevisy, C
AF Boeda, Fabien
   Mosset, Paul
   Crevisy, Christophe
TI RETRACTED: First rhodium/phosphoramidite complex-catalyzed
   enantioselective isomerization of allylic alcohols into aldehydes
   (Retracted article. See vol. 52, pg. 5894, 2011)
SO TETRAHEDRON LETTERS
LA English
DT Article; Retracted Publication
ID MONODENTATE PHOSPHORAMIDITE LIGANDS; ASYMMETRIC ISOMERIZATION;
   CARBONYL-COMPOUNDS; HYDROGENATION; ALLYLAMINES
AB Primary allylic alcohols are converted into chiral aldehydes in the presence of a catalytic amount (7 mol %) of a monodentate phosphoramidite rhodium catalyst. The aldehydes are isolated in high yields (84-89%) and moderate to good ee's (38-70%). A preliminary mechanistic study showed that the reaction proceeds through a 1,3-H migration pathway. (c) 2006 Elsevier Ltd. All rights reserved.
C1 Ecole Natl Super Chim Rennes, CNRS, UMR 6226, F-35700 Rennes, France.
RP Crevisy, C (reprint author), Ecole Natl Super Chim Rennes, CNRS, UMR 6226, Ave Gen Leclerc, F-35700 Rennes, France.
EM crevisy@ensc-rennes.fr
OI Mosset, Paul/0000-0003-0199-7415
CR Alcutagawa S, 1992, CHIRALITY IND
   Bernsmann H, 2005, J ORG CHEM, V70, P943, DOI 10.1021/jo048374o
   BOTTEGHI C, 1976, GAZZ CHIM ITAL, V106, P1131
   Chapuis C, 2001, HELV CHIM ACTA, V84, P230, DOI 10.1002/1522-2675(20010131)84:1<230::AID-HLCA230>3.0.CO;2-V
   Duursma A, 2003, J AM CHEM SOC, V125, P3700, DOI 10.1021/ja029817d
   Graening T, 2005, J AM CHEM SOC, V127, P17192, DOI 10.1021/ja0566275
   Hu AG, 2002, ANGEW CHEM INT EDIT, V41, P2348, DOI 10.1002/1521-3773(20020703)41:13<2348::AID-ANIE2348>3.0.CO;2-K
   Ito M, 2005, J AM CHEM SOC, V127, P6172, DOI 10.1021/ja050770g
   Jensen JF, 2002, J AM CHEM SOC, V124, P4558, DOI 10.1021/ja025617q
   Liu Y, 2005, J AM CHEM SOC, V127, P10488, DOI 10.1021/ja052749l
   Ma MFP, 1999, TETRAHEDRON-ASYMMETR, V10, P3259, DOI 10.1016/S0957-4166(99)00323-7
   OTSUKA S, 1991, SYNTHESIS-STUTTGART, P665
   Reetz MT, 2005, ANGEW CHEM INT EDIT, V44, P412, DOI 10.1002/anie.200461624
   Rimkus A, 2003, ORG LETT, V5, P79, DOI 10.1021/ol027252k
   SHAKHIDAYATOV K, 1970, RUSS CHEM REV, V39, P859
   Tanaka K, 2000, J AM CHEM SOC, V122, P9870, DOI 10.1021/ja002471r
   Tanaka K, 2001, J ORG CHEM, V66, P8177, DOI 10.1021/jo010792v
   TANI K, 1985, PURE APPL CHEM, V57, P1845, DOI 10.1351/pac198557121845
   TANI K, 1984, J AM CHEM SOC, V106, P5208, DOI 10.1021/ja00330a029
   TROST BM, 1995, ANGEW CHEM INT EDIT, V34, P259, DOI 10.1002/anie.199502591
   Uma R, 2003, CHEM REV, V103, P27, DOI 10.1021/cr0103165
   van den Berg M, 2003, ADV SYNTH CATAL, V345, P308, DOI 10.1002/adsc.200390026
   van den Berg M, 2000, J AM CHEM SOC, V122, P11539, DOI 10.1021/ja002507f
   van der Drift RC, 2002, J ORGANOMET CHEM, V650, P1, DOI 10.1016/S0022-328X(02)01150-6
NR 24
TC 16
Z9 16
U1 2
U2 13
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0040-4039
J9 TETRAHEDRON LETT
JI Tetrahedron Lett.
PD JUL 17
PY 2006
VL 47
IS 29
BP 5021
EP 5024
DI 10.1016/j.tetlet.2006.05.108
PG 4
WC Chemistry, Organic
SC Chemistry
GA 058XJ
UT WOS:000238697600007
DA 2018-12-27
ER

PT J
AU Wang, JS
   Shinkura, R
   Muramatsu, M
   Nagaoka, H
   Kinoshita, K
   Honjo, T
AF Wang, Jishu
   Shinkura, Reiko
   Muramatsu, Masamichi
   Nagaoka, Hitoshi
   Kinoshita, Kazuo
   Honjo, Tasuku
TI RETRACTED: Identification of a specific domain required for dimerization
   of activation-induced cytidine deaminase (Retracted Article. See vol
   283, pg 660, 2008)
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article; Retracted Publication
ID CLASS-SWITCH RECOMBINATION; RNA EDITING ENZYME; SINGLE-STRANDED-DNA;
   SOMATIC HYPERMUTATION; ESCHERICHIA-COLI; GENE CONVERSION; ANTIBODY
   DIVERSIFICATION; AID GENE; FIBROBLASTS; MECHANISM
AB Activation-induced cytidine deaminase (AID) is essential to all three genetic alterations required for generation of antigen-specific immunoglobulin: class switch recombination, somatic hypermutation, and gene conversion. Here we demonstrate that AID molecules form a homodimer autonomously in the absence of RNA, DNA, other cofactors, or post-translational modifications. Studies on serial deletion mutants revealed the minimum region between Thr(27) and His(56) responsible for dimerization. Analyses of point mutations within this region revealed that the residues between Gly(47) and Gly(54) are most important for the dimer formation. Functional analyses of these mutations indicate that all mutations impairing the dimer formation are inefficient for class switching, suggesting that dimer formation is required for class switching activity. Dimer formation and its requirement for the function of AID are features that AID shares with APOBEC-1, an RNAediting enzyme of apolipoprotein B100 mRNA.
C1 Kyoto Univ, Grad Sch Med, Dept Immunol & Genom Med, Sakyo Ku, Kyoto 6068501, Japan.
RP Honjo, T (reprint author), Kyoto Univ, Grad Sch Med, Dept Immunol & Genom Med, Sakyo Ku, Kyoto 6068501, Japan.
EM honjo@mfour.med.kyoto-u.ac.jp
RI Honjo, Tasuku/N-4470-2016
CR Almog R, 2004, BIOCHEMISTRY-US, V43, P13715, DOI 10.1021/bi048928h
   Arakawa H, 2002, SCIENCE, V295, P1301, DOI 10.1126/science.1067308
   Barreto V, 2003, MOL CELL, V12, P501, DOI 10.1016/S1097-2765(03)00309-5
   Barreto VM, 2005, TRENDS IMMUNOL, V26, P90, DOI 10.1016/j.it.2004.12.004
   Bransteitter R, 2003, P NATL ACAD SCI USA, V100, P4102, DOI 10.1073/pns.0730835100
   Carlow DC, 1999, BIOCHEMISTRY-US, V38, P12258, DOI 10.1021/bi990819t
   Chaudhuri J, 2003, NATURE, V422, P726, DOI 10.1038/nature01574
   Chung SJ, 2005, J MED CHEM, V48, P658, DOI 10.1021/jm0496279
   Conticello SG, 2005, MOL BIOL EVOL, V22, P367, DOI 10.1093/molbev/msi026
   DANCE GS, 2001, NUCLEIC ACIDS RES, V29, P1172
   Dickerson SK, 2003, J EXP MED, V197, P1291, DOI 10.1084/jem.20030481
   Durandy A, 2003, EUR J IMMUNOL, V33, P2069, DOI 10.1002/eji.200324133
   Harris RS, 2002, CURR BIOL, V12, P435, DOI 10.1016/S0960-9822(02)00717-0
   Honjo T, 2005, NAT IMMUNOL, V6, P655, DOI 10.1038/ni1218
   Honjo T, 2004, IMMUNITY, V20, P659, DOI 10.1016/j.immuni.2004.05.011
   Imai K, 2005, CLIN IMMUNOL, V115, P277, DOI 10.1016/j.clim.2005.02.003
   Ito S, 2004, P NATL ACAD SCI USA, V101, P1975, DOI 10.1073/pnas.0307335101
   Joung JK, 2000, P NATL ACAD SCI USA, V97, P7382, DOI 10.1073/pnas.110149297
   Martin A, 2002, NATURE, V415, P802
   McBride KM, 2004, J EXP MED, V199, P1235, DOI 10.1084/jem.20040373
   Muramatsu M, 2000, CELL, V102, P553, DOI 10.1016/S0092-8674(00)00078-7
   Muto T, 2000, GENOMICS, V68, P85, DOI 10.1006/geno.2000.6268
   Muto T, 2006, P NATL ACAD SCI USA, V103, P2752, DOI 10.1073/pnas.0510970103
   Nambu Y, 2003, SCIENCE, V302, P2137, DOI 10.1126/science.1092481
   NAVARATNAM N, 1993, J BIOL CHEM, V268, P20709
   Navaratnam N, 1998, J MOL BIOL, V275, P695, DOI 10.1006/jmbi.1997.1506
   NAVARATNAM N, 1995, CELL, V81, P187, DOI 10.1016/0092-8674(95)90328-3
   Okazaki IM, 2002, NATURE, V416, P340, DOI 10.1038/nature727
   Petersen-Mahrt SK, 2002, NATURE, V418, P99, DOI 10.1038/nature00862
   Revy P, 2000, CELL, V102, P565, DOI 10.1016/S0092-8674(00)00079-9
   Shinkura R, 2004, NAT IMMUNOL, V5, P707, DOI 10.1038/ni1086
   Ta VT, 2003, NAT IMMUNOL, V4, P843, DOI 10.1038/ni964
   Teng BB, 1999, J LIPID RES, V40, P623
   TENG BB, 1993, SCIENCE, V260, P1816, DOI 10.1126/science.8511591
   Xie KF, 2004, P NATL ACAD SCI USA, V101, P8114, DOI 10.1073/pnas.0400493101
   Yoshikawa K, 2002, SCIENCE, V296, P2033, DOI 10.1126/science.1071556
NR 36
TC 16
Z9 16
U1 2
U2 8
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
J9 J BIOL CHEM
JI J. Biol. Chem.
PD JUL 14
PY 2006
VL 281
IS 28
BP 19115
EP 19123
DI 10.1074/jbc.M601645200
PG 9
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 061BU
UT WOS:000238847000026
PM 16687409
OA Bronze
DA 2018-12-27
ER

PT J
AU Gupta, A
   Gartner, JJ
   Sethupathy, P
   Hatzigeorgiou, AG
   Fraser, NW
AF Gupta, A.
   Gartner, J. J.
   Sethupathy, P.
   Hatzigeorgiou, A. G.
   Fraser, N. W.
TI RETRACTED: Anti-apoptotic function of a microRNA encoded by the HSV-1
   latency-associated transcript (Retracted Article. See vol 451, pg 600,
   2008)
SO NATURE
LA English
DT Article; Retracted Publication
ID SIMPLEX-VIRUS TYPE-1; REACTIVATION PHENOTYPE
AB MicroRNAs (miRNAs) are a class of small RNA molecules that regulate the stability or the translational efficiency of target messenger RNAs (mRNAs)(1,2). The latency-associated transcript (LAT) of herpes simplex virus-1 (HSV-1) is the only viral gene expressed during latent infection in neurons(3). LAT inhibits apoptosis and maintains latency by promoting the survival of infected neurons(4). No protein product has been attributed to the LAT gene and the mechanism by which LAT protects cells from apoptosis is not yet known. Here we show that a miRNA encoded by the HSV-1 LAT gene confers resistance to apoptosis. Neuroblastoma cells transfected with a fragment of the LAT gene show reduced susceptibility to cell death. The anti-apoptotic function of LAT has been mapped to a region within the first exon(5,6). We have identified and characterized a microRNA (miR-LAT) generated from the exon 1 region of the HSV-1 LAT gene. The LAT miRNA was found to accumulate in cells transiently transfected with the LAT gene fragment or infected with a wild-type strain of HSV-1. A mutant virus in which a 372-nucleotide fragment encompassing the mature miRNA was deleted neither protected the infected cells from apoptosis nor generated an miRNA. miR-LAT exerts its antiapoptotic effect by downregulation of transforming growth factor (TGF)-beta 1 and SMAD3 expression, both of which are functionally linked in the TGF-beta pathway. Our results suggest that the miRNA encoded by the HSV-1 LAT gene regulates the induction of apoptosis in infected cells by modulation of TGF-beta signalling and thus contributes to the persistence of HSV in a latent form in sensory neurons.
C1 Univ Penn, Sch Med, Dept Microbiol, Philadelphia, PA 19104 USA.
   Univ Penn, Sch Med, Dept Genet, Philadelphia, PA 19104 USA.
   Univ Penn, Sch Med, Penn Ctr Bioinformat, Philadelphia, PA 19104 USA.
RP Fraser, NW (reprint author), Univ Penn, Sch Med, Dept Microbiol, Philadelphia, PA 19104 USA.
EM nwfraser@mail.med.upenn.edu
CR Ahmed M, 2002, J VIROL, V76, P717, DOI 10.1128/JVI.76.2.717-729.2002
   Ambros V, 2001, CELL, V107, P823, DOI 10.1016/S0092-8674(01)00616-X
   Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5
   Bennasser Y, 2005, IMMUNITY, V22, P607, DOI 10.1016/j.immune.2005.03.010
   Chendrimada TP, 2005, NATURE, V436, P740, DOI 10.1038/nature03868
   Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117
   Feng XH, 2005, ANNU REV CELL DEV BI, V21, P659, DOI 10.1146/annurev.cellbio.21.022404.142018
   Inman M, 2001, J VIROL, V75, P3636, DOI 10.1128/JVI.75.8.3636-3646.2001
   Jin L, 2005, J VIROL, V79, P12286, DOI 10.1128/JVI.79.19.12286-12295.2005
   Jin L, 2003, J VIROL, V77, P6556, DOI 10.1128/JVI.77.11.6556-6561.2003
   John B, 2004, PLOS BIOL, V2, P1862, DOI 10.1371/journal.pbio.0020363
   Jones C, 2003, CLIN MICROBIOL REV, V16, P79, DOI 10.1128/CMR.16.1.79-95.2003
   LAFERRIERE A, 1994, COMPUT APPL BIOSCI, V10, P211
   Lau NC, 2001, SCIENCE, V294, P858, DOI 10.1126/science.1065062
   Perng GC, 2000, SCIENCE, V287, P1500, DOI 10.1126/science.287.5457.1500
   PFEFFER S, 2003, CURRENT PROTOCOLS MO
   Schuetz S, 2006, VIROLOGY, V344, P151, DOI 10.1016/j.virol.2005.09.034
   Schuster N, 2002, CELL TISSUE RES, V307, P1, DOI 10.1007/s00441-001-0479-6
   Sullivan CS, 2005, MOL CELL, V20, P3, DOI 10.1016/j.molcel.2005.09.012
   Tomari Y, 2005, GENE DEV, V19, P517, DOI 10.1101/gad.1284105
   Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1
   Zuker M, 2003, NUCLEIC ACIDS RES, V31, P3406, DOI 10.1093/nar/gkg595
NR 22
TC 194
Z9 233
U1 4
U2 32
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0028-0836
EI 1476-4687
J9 NATURE
JI Nature
PD JUL 6
PY 2006
VL 442
IS 7098
BP 82
EP 85
DI 10.1038/nature04836
PG 4
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 059HS
UT WOS:000238724500041
PM 16738545
DA 2018-12-27
ER

PT J
AU Wang, Q
   Fang, XN
AF Wang, Qing
   Fang, Xiao-Niu
TI RETRACTED: Bis(2-formylphenolato-kappa O-2,O ') manganese(II) (Retracted
   article. See vol. 66, pg e21, 2010)
SO ACTA CRYSTALLOGRAPHICA SECTION E-STRUCTURE REPORTS ONLINE
LA English
DT Article; Retracted Publication
ID SCHIFF-BASE COMPLEXES; MAGNETIC-PROPERTIES
AB The title compound, [Mn(C7H5O2)(2)], is a mononuclear manganese(II) complex. The Mn-II atom, lying on an inversion centre, is four-coordinated by four O atoms from two salicylaldehyde ligands, forming a square-planar geometry.
C1 Fuyang Normal Coll, Off Org, Fuyang Anhui 236041, Peoples R China.
   JingGangShan Univ, Coll Chem & Chem Engn, JiangXi Province Key Lab Coordinat Chem, Jian 343009, Jiangxi, Peoples R China.
RP Wang, Q (reprint author), Fuyang Normal Coll, Off Org, Fuyang Anhui 236041, Peoples R China.
EM wangqing_fy@126.com
CR *BRUK AXS INC, 1998, SMART VERS 5 628 SAI
   Ciringh Y, 1997, INORG CHEM, V36, P4968, DOI 10.1021/ic970747z
   Gao J, 2005, ACTA CRYSTALLOGR E, V61, pM1692, DOI 10.1107/S1600536805024293
   MABAD B, 1986, INORG CHEM, V25, P1420, DOI 10.1021/ic00229a025
   Miyasaka H, 1996, J AM CHEM SOC, V118, P981, DOI 10.1021/ja952706c
   NAKASUKA N, 1985, ACTA CRYSTALLOGR C, V41, P1176, DOI 10.1107/S0108270185007041
   Okabe N, 1998, ACTA CRYSTALLOGR C, V54, P288, DOI 10.1107/S0108270197016326
   Sheldrick G. M., 1997, SHELXS97 SHELXL97
   Sheldrick G.M, 1996, SADABS
   SHELDRICK GM, 1997, SHELXTL VERS 5 10
   Zhang YL, 2006, ACTA CRYSTALLOGR E, V62, pM900, DOI 10.1107/S1600536806009809
NR 11
TC 2
Z9 2
U1 4
U2 16
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1600-5368
J9 ACTA CRYSTALLOGR E
JI Acta Crystallogr. Sect. E.-Struct Rep. Online
PD JUL
PY 2006
VL 62
BP M1492
EP M1493
DI 10.1107/S1600536806021039
PN 7
PG 2
WC Crystallography
SC Crystallography
GA 059KO
UT WOS:000238731900024
DA 2018-12-27
ER

PT J
AU Wansink, B
   Bascoul, G
   Chen, GT
AF Wansink, Brian
   Bascoul, Ganael
   Chen, Gary T.
TI RETRACTED: The sweet tooth hypothesis: How fruit consumption relates to
   snack consumption (Retracted article. See vol. 131, pg. 170, 2018)
SO APPETITE
LA English
DT Article; Retracted Publication
DE fruit and vegetables; five-a-day; sweet snacks; salty snacks; taste
   profiles
ID VEGETABLE CONSUMPTION; PSYCHOSOCIAL FACTORS; PREFERENCE; CONSUMERS;
   HEALTH
AB Building on prior work related to taste preferences of fruit lovers, we investigate the "sweet tooth" hypothesis. First, using CSFII survey data, we show that fruit consumption is more highly related to sweet snack consumption than it is to salty snack consumption. Second, a follow-up study with a different population supports the relationship by showing that sweet snack consumption is more related to fruit consumption than it is to vegetable consumption. Knowing that people who frequently eat sweet snacks may be predisposed to increasing their fruit consumption will enable better targeting and tailoring of educational efforts, such as those used in the 5-a-Day for Better Health campaign. (c) 2006 Elsevier Ltd. All rights reserved.
C1 Cornell Univ, Ithaca, NY 14853 USA.
   HEC, Cergy, France.
   Univ Penn, Philadelphia, PA 19104 USA.
RP Wansink, B (reprint author), Cornell Univ, 110 Warren Hall, Ithaca, NY 14853 USA.
EM Wansink@Cornell.edu
RI Wansink, Brian/G-1219-2011; Wansink, Brian/G-4284-2010
CR Baranowski T, 2003, OBES RES, V11, p23S, DOI 10.1038/oby.2003.222
   Bradburn N. M., 2004, ASKING QUESTIONS DEF
   BRUG J, 1995, APPETITE, V25, P285, DOI 10.1006/appe.1995.0062
   LAFORGE RG, 1994, J BEHAV MED, V17, P361, DOI 10.1007/BF01858008
   Neuhouser ML, 2000, J AM DIET ASSOC, V100, P576, DOI 10.1016/S0002-8223(00)00176-0
   RAUDENBUSH B, 1995, APPETITE, V25, P1, DOI 10.1006/appe.1995.0037
   Satia JA, 2002, NUTRITION, V18, P247, DOI 10.1016/S0899-9007(01)00758-4
   Serdula MK, 1996, EPIDEMIOLOGY, V7, P161, DOI 10.1097/00001648-199603000-00010
   Sudman Seymour, 2002, CONSUMER PANELS
   Thompson RL, 1999, J EPIDEMIOL COMMUN H, V53, P294, DOI 10.1136/jech.53.5.294
   *USDA, 1998, CONT SURV FOOD INT I
   Wansink B, 2000, J ADVERTISING RES, V40, P61, DOI 10.2501/JAR-40-4-61-72
   Wansink B, 2004, J AM DIET ASSOC, V104, P1648, DOI 10.1016/j.jada.2004.09.017
   Wansink B, 2004, J SENS STUD, V19, P327, DOI 10.1111/j.1745-459X.2004.tb00151.x
   Wansink B, 2003, APPETITE, V41, P323, DOI 10.1016/S0195-6663(03)00120-X
   Wansink B., 2002, Pakistan Journal of Nutrition, V1, P276
   Wansink B., 2005, MARKETING NUTR SOY F
NR 17
TC 17
Z9 18
U1 0
U2 4
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0195-6663
EI 1095-8304
J9 APPETITE
JI Appetite
PD JUL
PY 2006
VL 47
IS 1
BP 107
EP 110
DI 10.1016/j.appet.2005.07.011
PG 4
WC Behavioral Sciences; Nutrition & Dietetics
SC Behavioral Sciences; Nutrition & Dietetics
GA 073MO
UT WOS:000239747400014
PM 16574275
DA 2018-12-27
ER

PT J
AU Esarte, J
   Blanco, JM
   Mendia, F
   Pena, F
AF Esarte, J
   Blanco, JM
   Mendia, F
   Pena, F
TI RETRACTED: Improving cooling devices for the hot face of Peltier pellets
   based on phase change fluids (Retracted Article. See vol 27, pg 273,
   2007)
SO APPLIED THERMAL ENGINEERING
LA English
DT Review; Retracted Publication
DE thermoelectricity; computational fluid dynamics; coefficient of
   performance; heat sinks; thermosyphon
AB The thermoelectricity has not suffered any important progress for the last twenty years, owed mainly to the low efficiency of the heat sinks, because the Peltier pellet provides a high calorific power across a small surface. In this paper a deep study of the fin cooling for Peltier pellets, has been carried out, by means of both an experimental model and also through computational fluid dynamics. A phase change device called thermosyphon has also been designed and optimized, which allows to uniform the heat flow, decreasing in this way the pellet thermal resistance. The work focuses on its hot face and leaves for another study the cold face optimization. (C) 2005 Elsevier Ltd. All rights reserved.
C1 Univ Pais Vasco EHU, Dept Maquinas & Motores Termicos, Bilbao 48013, Spain.
   Poligono Ind Noain, Ctr Tecnol Navarra, Navarra 31009, Spain.
   Iberdrola Generac, Vizcaya 48009, Spain.
RP Blanco, JM (reprint author), Univ Pais Vasco EHU, Dept Maquinas & Motores Termicos, Alameda Urquijo S-N, Bilbao 48013, Spain.
EM nmpblilj@bi.ehu.es
RI Blanco, Jesus Maria/K-9988-2014
CR APARICIO JLP, 1998, P 4 EUR WORKSH THERM
   ARENAS A, 2002, P 7 EUR WORKSH THERM
   Astrain D, 2003, APPL THERM ENG, V23, P2183, DOI 10.1016/S1359-4311(03)00202-3
   Bailey M, 2004, ENERG CONVERS MANAGE, V45, P495, DOI 10.1016/S0196-8904(03)00161-4
   Bass J., 1995, P AIP C, P295
   Bass J, 2000, P 19 INT C THERM, P317
   Chein RY, 2005, INT J REFRIG, V28, P828, DOI 10.1016/j.ijrefrig.2005.02.001
   Esarte J, 2003, APPL THERM ENG, V23, P1619, DOI 10.1016/S1359-4311(03)00111-X
   Esarte J, 2001, J POWER SOURCES, V93, P72, DOI 10.1016/S0378-7753(00)00566-8
   Gordon JM, 2002, INT J REFRIG, V25, P1025, DOI 10.1016/S0140-7007(02)00026-9
   Haidar J. G., 2001, Proceedings ICT2001. 20 International Conference on Thermoelectrics (Cat. No.01TH8589), P413, DOI 10.1109/ICT.2001.979919
   Hara T, 1998, APPL THERM ENG, V18, P1159, DOI 10.1016/S1359-4311(98)00046-5
   HEENAN P, 1992, P 11 INT C THERM EN, P181
   Ikoma K, 1999, J JPN I MET, V63, P1475, DOI 10.2320/jinstmet1952.63.11_1475
   Maneewan S, 2004, RENEW ENERG, V29, P743, DOI 10.1016/j.renene.2003.10.005
   Nuwayhid RY, 2003, ENERG CONVERS MANAGE, V44, P647, DOI 10.1016/S0196-8904(02)00090-0
   PALACIOS R, 2001, P 6 EUR WORKSH THERM
   Shinohara K., 1999, J JAPAN SOC POWDER P, V46, P524
   STOCKHOLM JG, 1997, P 16 INT C THERM DRE
   VIAN JG, 2001, J THERMOELECTR, P55
   VIAN JG, 1999, J THERMOELECTR, V3, P52
   VIAN JG, 2001, J THERMOELECTRICITY, P38
NR 22
TC 3
Z9 5
U1 2
U2 10
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 1359-4311
J9 APPL THERM ENG
JI Appl. Therm. Eng.
PD JUL
PY 2006
VL 26
IS 10
BP 967
EP 973
DI 10.1016/j.applthermaleng.2005.10.026
PG 7
WC Thermodynamics; Energy & Fuels; Engineering, Mechanical; Mechanics
SC Thermodynamics; Energy & Fuels; Engineering; Mechanics
GA 027QK
UT WOS:000236430000001
DA 2018-12-27
ER

PT J
AU Iwamoto, J
   Seki, A
   Takeda, T
   Sato, Y
   Yamada, H
   Yeh, JK
AF Iwamoto, Jun
   Seki, Azusa
   Takeda, Tsuyoshi
   Sato, Yoshihiro
   Yamada, Harumoto
   Yeh, James K.
TI RETRACTED: Therapeutic effect of risedronate on cancellous and cortical
   bone in ovariectomized osteopenic rats: A comparison with the effects of
   alfacalcidol (Retracted article. See vol. 67, pg. 393, 2018)
SO EXPERIMENTAL ANIMALS
LA English
DT Article; Retracted Publication
DE alfacalcidol; osteopenia; ovariectomy; rat; risedronate
ID POSTMENOPAUSAL OSTEOPOROSIS; CONTROLLED-TRIAL; VITAMIN-K-2; STRENGTH;
   WOMEN; HISTOMORPHOMETRY; FRACTURES; DENSITY
AB The purpose of the present study was to compare the therapeutic effects of risedronate (RIS) and alfacalcidol (ALF) on cancellous and cortical bone in ovariectomized osteopenic rats. Forty-two female Sprague-Dawley rats, 7 months of age, were randomized by the stratified weight method into six groups: the sham-operated control (Sham) group, and five ovariectomized groups: treated with vehicle, RIS (0.1, 1.0, or 2.5 mg/kg, p.o., daily), and ALF (0.5 mu g/kg, p.o., daily). Treatment was started 6 weeks after surgery and continued for 6 weeks. Evaluation at 12 weeks after surgery revealed that ovariectomy (OVX) decreased the cancellous bone volume/total tissue volume (BV/TV) of the proximal tibial metaphysis as a result of an increase of the bone formation rate/bone surface (BFR/BS), BFR/BV, and eroded surface (ES/BS), while having no effect on the cortical area (Ct At) of the tibial diaphysis. OVX also decreased the maximum load of the femoral distal metaphysis, while having no effect on any mechanical property parameters of the femoral diaphysis. RIS (at all the doses) increased the BV/TV relative to the value in the OVX-Vehicle group, but the value was not restored to that observed in the Sham group. The effects of RIS (1.0 mg/kg and 2.5 mg/kg) were similar, and greater than those of RIS (0.1 mg/kg). ALF also increased the BV/TV relative to the OVX-Vehicle group, but the value was not restored to that observed in the Sham group, similar to the results of RIS (1.0 mg/kg and 2.5 mg/kg) treatment. The alterations of the structural parameters induced by RIS (at the doses) were attributable to suppression of the increase of ES/BS, BFR/BS, and BFR/BV. The alterations of the structural parameters induced by ALF were attributable to suppression of the increase of ES/BS and attenuation of the increase of BFR/BV, while the BFR/BS was maintained. ALF also increased the Ct Ar to beyond the value observed in the Sham group. RIS (at all the doses) had no effect on the mechanical properties of the femoral distal metaphysis, whereas ALF prevented the loss of the maximum load of the femoral distal metaphysis. Thus, the results of the present study show differential effects of RIS and ALF on cancellous and cortical bone in ovariectomized osteopenic rats.
C1 Keio Univ, Sch Med, Dept Sports Med, Shinjuku Ku, Tokyo 1608582, Japan.
   Hamri Co Ltd, Tokyo, Japan.
   Mitate Hosp, Dept Neurol, Fukuoka, Japan.
   Fujita Hlth Univ, Dept Orthopaed Surg, Aichi, Japan.
RP Iwamoto, J (reprint author), Keio Univ, Sch Med, Dept Sports Med, Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan.
CR BROMMAGE R, 1985, ENDOCR REV, V6, P491, DOI 10.1210/edrv-6-4-491
   CHAPPARD D, 1991, J BONE MINER RES, V6, P673
   Cranney A, 2002, ENDOCR REV, V23, P570, DOI 10.1210/er.2001-9002
   Eastell R., 1997, Vitamin D., P695
   Erben RG, 1997, J HISTOCHEM CYTOCHEM, V45, P307, DOI 10.1177/002215549704500215
   Erben RG, 2002, J BONE MINER RES, V17, P1498, DOI 10.1359/jbmr.2002.17.8.1498
   Fogelman I, 2000, J CLIN ENDOCR METAB, V85, P1895, DOI 10.1210/jc.85.5.1895
   Harris ST, 1999, JAMA-J AM MED ASSOC, V282, P1344, DOI 10.1001/jama.282.14.1344
   ITO M, 2002, J JPN SOC BONE MORPH, V12, P51
   Iwamoto J, 2005, CALCIFIED TISSUE INT, V77, P119, DOI 10.1007/s00223-004-0277-8
   Iwamoto J, 2003, J BONE MINER RES, V18, P776, DOI 10.1359/jbmr.2003.18.4.776
   McClung MR, 2001, NEW ENGL J MED, V344, P333, DOI 10.1056/NEJM200102013440503
   Mosekilde L, 2000, BONE, V27, P639, DOI 10.1016/S8756-3282(00)00375-6
   ORIMO H, 1994, CALCIFIED TISSUE INT, V54, P370, DOI 10.1007/BF00305521
   Otomo H, 2004, J BONE MINER METAB, V22, P404, DOI 10.1007/s00774-004-0502-6
   PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617
   REICHEL H, 1989, NEW ENGL J MED, V320, P980, DOI 10.1056/NEJM198904133201506
   Rogers MJ, 1999, BONE, V24, p73S, DOI 10.1016/S8756-3282(99)00070-8
   Seeman E, 2003, NEW ENGL J MED, V349, P320, DOI 10.1056/NEJMp038101
   Shiraishi A, 2000, J BONE MINER RES, V15, P770, DOI 10.1359/jbmr.2000.15.4.770
NR 20
TC 5
Z9 6
U1 0
U2 1
PU INT PRESS EDITING CENTRE INC
PI TOKYO
PA 1-2-3 SUGAMO, TOSHIMA-KU, TOKYO, 170 0002, JAPAN
SN 1341-1357
EI 1881-7122
J9 EXP ANIM TOKYO
JI Exp. Anim.
PD JUL
PY 2006
VL 55
IS 4
BP 333
EP 342
DI 10.1538/expanim.55.333
PG 10
WC Veterinary Sciences; Zoology
SC Veterinary Sciences; Zoology
GA 065ZV
UT WOS:000239199900001
PM 16880680
OA Bronze
DA 2018-12-27
ER

PT J
AU Iwamoto, J
   Seki, A
   Takeda, T
   Sato, Y
   Yamada, H
   Yeh, JK
AF Iwamoto, Jun
   Seki, Azusa
   Takeda, Tsuyoshi
   Sato, Yoshihiro
   Yamada, Harumoto
   Yeh, James K.
TI RETRACTED: Comparative effects of alendronate and alfacalcidol on
   cancellous and cortical bone mass and bone mechanical properties in
   ovariectomized rats (Retracted article. See vol. 67, pg. 393, 2018)
SO EXPERIMENTAL ANIMALS
LA English
DT Article; Retracted Publication
DE alendronate; alfacalcidol; osteopenia; ovariectomy; rat
ID VERTEBRAL FRACTURES; MINERAL DENSITY; POSTMENOPAUSAL WOMEN; GROWING
   RATS; OSTEOPOROSIS; HISTOMORPHOMETRY; RESORPTION; STRENGTH; RISK;
   PAMIDRONATE
AB The purpose of the present study was to compare the effects of alendronate and alfacalcidol on cancellous and cortical bone mass and bone mechanical properties in ovariectomized rats. Twenty-six female Sprague-Dawley rats, 7 months of age, were randomized by the stratified weight method into four groups: the sham-operated control (Sham) group and the three ovariectomy (OVX) groups, namely, OVX + vehicle, OVX + alendronate (2.5 mg/kg, p.o., daily), and OVX + alfacalcidal (0.5,mu g/kg, p.o., daily). At the end of the 8-week experimental period, bone histomorphometric analyses of cancellous bone at the proximal tibial metaphysis and cortical bone at the tibial diaphysis were performed, and the mechanical properties of the femoral distal metaphysis and femoral diaphysis were evaluated. OVX decreased cancellous bone volume per total tissue volume, (BV/TV), and the maximum load of the femoral distal metaphysis, as a result of increases in serum osteocalcin (OC) levels, and also the number of osteoclasts (N.Oc), osteoclast surface (OcS) and bone formation rate (BFR) per bone surface (BS), and BFR/BV, without any, effect on cortical area (Ct At), or maximum load of the femoral diaphysis. Alendronate prevented this decrease in cancellous BV/TV by suppressing increases in N.Oc/BS; OcS/BS, BFR/BS, and BFR/BV, without any apparent effect on Ct Ar or maximum load of the femoral distal metaphysis and femoral diaphysis. On the other hand, alfacalcidol increased cancellous BV/TV, Ct Ar, and the maximum load of the femoral distal metaphysis and femoral diaphysis, by mildly decreasing trabecular BFR/BV, maintaining trabecular mineral apposition rate and osteoblast surface per BS, increasing periosteal and endocortical BFR/BS, and preventing an increase in endocortical eroded surface per BS. The present study clearly showed the differential skeletal effects of alendronate and alfacalcidol in ovariectomized rats. Alendronate prevented OVX-induced cancellous bone loss by suppressing bone turnover, while alfacalcidol improved cancellous and cortical bone mass and bone strength by suppressing bone resorption and maintaining or even increasing bone formation.
C1 Keio Univ, Sch Med, Dept Sports Med, Shinjuku Ku, Tokyo 1608582, Japan.
   Hamri Co Ltd, Tokyo, Japan.
   Mitate Hosp, Dept Neurol, Fukuoka, Japan.
   Fujita Hlth Univ, Dept Orthopaed Surg, Aichi, Japan.
RP Iwamoto, J (reprint author), Keio Univ, Sch Med, Dept Sports Med, Shinjuku Ku, Tokyo 1608582, Japan.
CR Azuma Y, 1998, J PHARMACOL EXP THER, V286, P128
   Black DM, 1996, LANCET, V348, P1535, DOI 10.1016/S0140-6736(96)07088-2
   Bone HG, 2004, NEW ENGL J MED, V350, P1189, DOI 10.1056/NEJMoa030897
   BROMMAGE R, 1985, ENDOCR REV, V6, P491, DOI 10.1210/edrv-6-4-491
   Cummings SR, 1998, JAMA-J AM MED ASSOC, V280, P2077, DOI 10.1001/jama.280.24.2077
   da Paz LHBC, 2001, BRAZ J MED BIOL RES, V34, P1015, DOI 10.1590/S0100-879X2001000800007
   Erben RG, 1997, J HISTOCHEM CYTOCHEM, V45, P307, DOI 10.1177/002215549704500215
   FUJITA T, 1990, METABOLISM, V39, P39, DOI 10.1016/0026-0495(90)90271-D
   Giavaresi G, 2001, BIOMED PHARMACOTHER, V55, P397, DOI 10.1016/S0753-3322(01)00069-5
   Ito M, 2002, BONE, V31, P351, DOI 10.1016/S8756-3282(02)00830-X
   Iwamoto J, 2005, J BONE MINER METAB, V23, P456, DOI 10.1007/s00774-005-0628-1
   Iwamoto J, 2004, CLIN RHEUMATOL, V23, P383, DOI 10.1007/s10067-004-0881-z
   Kodama Y, 1997, J BONE MINER RES, V12, P1058, DOI 10.1359/jbmr.1997.12.7.1058
   Kushida K, 2004, J BONE MINER METAB, V22, P462, DOI 10.1007/s00774-004-0508-0
   Mosekilde L, 2000, BONE, V27, P639, DOI 10.1016/S8756-3282(00)00375-6
   ORIMO H, 1994, CALCIFIED TISSUE INT, V54, P370, DOI 10.1007/BF00305521
   PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617
   REICHEL H, 1989, NEW ENGL J MED, V320, P980, DOI 10.1056/NEJM198904133201506
   Sato M, 1996, J PHARMACOL EXP THER, V279, P298
   SEEDOR JG, 1991, J BONE MINER RES, V6, P339
   Shiraishi A, 2000, J BONE MINER RES, V15, P770, DOI 10.1359/jbmr.2000.15.4.770
   Shiraishi A, 2002, CALCIFIED TISSUE INT, V71, P69, DOI 10.1007/s00223-001-2090-y
   Shiraki M, 1999, OSTEOPOROSIS INT, V10, P183, DOI 10.1007/s001980050214
NR 23
TC 16
Z9 19
U1 1
U2 2
PU INT PRESS EDITING CENTRE INC
PI TOKYO
PA 1-2-3 SUGAMO, TOSHIMA-KU, TOKYO, 170 0002, JAPAN
SN 1341-1357
EI 1881-7122
J9 EXP ANIM TOKYO
JI Exp. Anim.
PD JUL
PY 2006
VL 55
IS 4
BP 357
EP 367
DI 10.1538/expanim.55.357
PG 11
WC Veterinary Sciences; Zoology
SC Veterinary Sciences; Zoology
GA 065ZV
UT WOS:000239199900004
PM 16880683
OA Bronze
DA 2018-12-27
ER

PT J
AU Dianez, F
   Santos, M
   de Cara, M
   Tello, JC
AF Dianez, F.
   Santos, M.
   de Cara, M.
   Tello, J. C.
TI RETRACTED: Presence of siderophores on grape marc aerated compost tea
   (Retracted article. See vol. 28, pg. 382, 2011)
SO GEOMICROBIOLOGY JOURNAL
LA English
DT Article; Proceedings Paper; Retracted Publication
CT 1st International Conference on Environmental Industrial and Applied
   Microbiology
CY MAR 15-18, 2005
CL Badajoz, SPAIN
DE aerated compost tea; grape marc compost; suppressiveness; siderophores;
   plant pathogens
AB It is important to know about the mechanisms that suppress plant diseases when compost from vegetable residues and/or their liquid extracts (compost tea) are used in order to improve the efficiency of this suppressing effect on pathogens. In this study we assessed the presence of siderophores in various grape marc aerated compost tea (ACT) and there suppressing effect on 8 phytopathogens and the mycopathogen. Three concentrations (5, 10 and 15%) filtered, microfiltered and sterilized ACT were added to Petri dishes with a PDA medium, and 1 mM of ferric chloride (FeCl3). After adding this mixture, a 0.5 cm disc was placed at the center of each dish containing the vegetative and reproductive body of each of the fungi to be tested. All the dishes were incubated at 25 degrees C for 7 days, except R. solani y P. aphanidermatum, which developed after 4 days. The addition of 1 mM of FeCl3 deactivated the siderophores present in the ACT, suppressing their inhibition of fungal development. The results obtained with the microfiltered ACT revealed that the microorganisms present in grape marc compost excreted siderophores into the medium that were responsible for inhibiting the growth of the 9 fungi tested. This activity was annulled by the addition of ferric chloride. The same results were achieved with the ACT obtained from filtering. This inhibition was not 100% after adding FeCl3, due to the fact that the microorganisms present in this tea exhibited other biocontrol mechanisms.
C1 Univ Almeria, Escuela Politecn Super, Dept Prod Vegetal, Almeria 04120, Spain.
RP Santos, M (reprint author), Univ Almeria, Escuela Politecn Super, Dept Prod Vegetal, Carretera Sacramento S-N, Almeria 04120, Spain.
EM msantos@ual.es
OI Dianez Martinez, Fernando/0000-0002-1890-6594
CR BECKER JO, 1984, PHYTOPATHOLOGY, V74, P806
   Brinton WF, 1996, BIOCYCLE, V37, P68
   Brinton WF, 1995, BIODYNAMICS, V197, P12
   DIVER S, 2001, NOTES COMPOST TEAS 2
   HADAR Y, 1991, SOIL BIOL BIOCHEM, V23, P303, DOI 10.1016/0038-0717(91)90068-U
   Hidalgo L, 2002, TRATADO VITICULTURA
   HUBER DM, 1982, SUPPRESSIVE SOILS PL, P1
   KLOEPPER JW, 1980, CURR MICROBIOL, V4, P317, DOI 10.1007/BF02602840
   LOCKWOOD JL, 1988, ANNU REV PHYTOPATHOL, V26, P93, DOI 10.1146/annurev.py.26.090188.000521
   Ma LiPing, 2001, Chinese Journal of Applied and Environmental Biology, V7, P84
   NEILANDS JB, 1981, ANNU REV BIOCHEM, V50, P715, DOI 10.1146/annurev.bi.50.070181.003435
   TRANKNER A, 1992, NATO ADV SCI I A-LIF, V230, P35
   WELLER DM, 1986, PHYTOPATHOLOGY, P75
   YORK A, 1996, C EC AGR PAC GROV CA
   Zhang W, 1998, PHYTOPATHOLOGY, V88, P450, DOI 10.1094/PHYTO.1998.88.5.450
NR 15
TC 4
Z9 4
U1 5
U2 19
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0149-0451
EI 1521-0529
J9 GEOMICROBIOL J
JI Geomicrobiol. J.
PD JUL-AUG
PY 2006
VL 23
IS 5
BP 323
EP 331
DI 10.1080/01490450600762498
PG 9
WC Environmental Sciences; Geosciences, Multidisciplinary
SC Environmental Sciences & Ecology; Geology
GA 071TX
UT WOS:000239626800012
DA 2018-12-27
ER

PT J
AU Zhi, L
   Leung, BP
   Melendez, AJ
AF Zhi, Liang
   Leung, Bernard P.
   Melendez, Alirio J.
TI RETRACTED: Sphingosine kinase 1 regulates pro-inflammatory responses
   triggered by TNF alpha in primary human monocytes (Retracted article.
   See vol. 227, pg. 2974, 2012)
SO JOURNAL OF CELLULAR PHYSIOLOGY
LA English
DT Article; Retracted Publication
ID TUMOR-NECROSIS-FACTOR; FC-GAMMA-RI; RHEUMATOID-ARTHRITIS;
   SIGNAL-TRANSDUCTION; IMMUNE-RESPONSE; CA2+ SIGNALS; RECEPTOR; MICE;
   CELLS; SPHINGOSINE-1-PHOSPHATE
AB Monocytes play an important role in inflammation, angiogenesis, and atherosclerosis. During these processes monocytes release pre-formed proinflammatory mediators from granules, and synthesize de novo cytokines and chemokines important in the amplification of the inflammatory response. One of the most prominent triggers of inflammatory responses is the cytokine TNF alpha. However, the intracellular signaling cascades triggered by TNF alpha are not fully understood. In this study we investigated the roles of SPHK on the TNF alpha-triggered responses on human primary monocytes. We show that TNFa rapidly triggers S1P generation and activation of SPHK. Moreover, our data shows that SPHK1 is the isoform activated by TNFa, and plays an essential role on the TNF alpha-triggered intracellular Ca2+ signals, degranulation, cytokine production, and activation of NF kappa B, thus suggesting a pivotal role for SPHK1 on the proinflammatory responses triggered by TNF alpha.
C1 Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Physiol, Singapore 117597, Singapore.
RP Melendez, AJ (reprint author), Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Physiol, MD9 01-05, Singapore 117597, Singapore.
EM phsmraj@nus.edu.sg
RI Zhi, Liang/C-7765-2009
FU Medical Research Council [G0700794]
CR Alemany R, 1999, J BIOL CHEM, V274, P3994, DOI 10.1074/jbc.274.7.3994
   Baeten D, 2003, ANN RHEUM DIS, V62, P829, DOI 10.1136/ard.62.9.829
   BEUTLER B, 1989, ANNU REV IMMUNOL, V7, P625, DOI 10.1146/annurev.iy.07.040189.003205
   BORNFELDT KE, 1995, J CELL BIOL, V130, P193, DOI 10.1083/jcb.130.1.193
   Choi OH, 1996, NATURE, V380, P634
   DeVries ME, 1999, SEMIN IMMUNOL, V11, P95, DOI 10.1006/smim.1999.0165
   Feldmann M, 2002, NAT REV IMMUNOL, V2, P364, DOI 10.1038/nri802
   Feldmann M, 1995, ANN NY ACAD SCI, V766, P272, DOI 10.1111/j.1749-6632.1995.tb26675.x
   FLYNN JL, 1995, IMMUNITY, V2, P561, DOI 10.1016/1074-7613(95)90001-2
   Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225
   HANNUN YA, 1994, J BIOL CHEM, V269, P3125
   HELLER RA, 1994, J CELL BIOL, V126, P5, DOI 10.1083/jcb.126.1.5
   Hillion P, 1999, J OPT A-PURE APPL OP, V1, P459, DOI 10.1088/1464-4258/1/4/307
   Ibrahim FBM, 2004, J BIOL CHEM, V279, P44802, DOI 10.1074/jbc.M403977200
   Kassiotis G, 2001, J EXP MED, V193, P427, DOI 10.1084/jem.193.4.427
   KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3
   Liu H, 2000, J BIOL CHEM, V275, P19513, DOI 10.1074/jbc.M002759200
   Matsumoto K, 1999, CLIN EXP IMMUNOL, V117, P361, DOI 10.1046/j.1365-2249.1999.00975.x
   Melendez A, 1998, CURR BIOL, V8, P210, DOI 10.1016/S0960-9822(98)70085-5
   Melendez A, 1998, J BIOL CHEM, V273, P9393, DOI 10.1074/jbc.273.16.9393
   Melendez AJ, 2000, GENE, V251, P19, DOI 10.1016/S0378-1119(00)00205-5
   Melendez AJ, 2004, J IMMUNOL, V173, P1596, DOI 10.4049/jimmunol.173.3.1596
   Melendez AJ, 2002, J BIOL CHEM, V277, P17255, DOI 10.1074/jbc.M110944200
   Melendez AJ, 2001, BLOOD, V98, P3421, DOI 10.1182/blood.V98.12.3421
   Mohan AK, 2003, CURR OPIN RHEUMATOL, V15, P179, DOI 10.1097/00002281-200305000-00002
   Naismith JH, 1998, TRENDS BIOCHEM SCI, V23, P74, DOI 10.1016/S0968-0004(97)01164-X
   OLIVERA A, 1993, NATURE, V365, P557, DOI 10.1038/365557a0
   Papadakis KA, 2000, GASTROENTEROLOGY, V119, P1148, DOI 10.1053/gast.2000.18160
   Pettus BJ, 2004, CURR MOL MED, V4, P405, DOI 10.2174/1566524043360573
   PFEFFER K, 1993, CELL, V73, P457, DOI 10.1016/0092-8674(93)90134-C
   Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085
   ROTHE J, 1993, NATURE, V364, P798, DOI 10.1038/364798a0
   Shaffer AL, 2001, IMMUNITY, V15, P375, DOI 10.1016/S1074-7613(01)00194-7
   Spiegel S, 2003, BIOCHEM SOC T, V31, P1216
   SPIEGEL S, 1995, J MEMBRANE BIOL, V146, P225
   TAY HK, 2005, CLIN EXP PHARM PHYSL, V32, P153
   ZUHERINGDORF DM, 1997, FEBS LETT, V410, P34
NR 37
TC 59
Z9 60
U1 3
U2 14
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0021-9541
EI 1097-4652
J9 J CELL PHYSIOL
JI J. Cell. Physiol.
PD JUL
PY 2006
VL 208
IS 1
BP 109
EP 115
DI 10.1002/jcp.20646
PG 7
WC Cell Biology; Physiology
SC Cell Biology; Physiology
GA 050RX
UT WOS:000238106700010
PM 16575915
DA 2018-12-27
ER

PT J
AU Sreenivasan, Y
   Raghavendra, PB
   Manna, SK
AF Sreenivasan, Yashin
   Raghavendra, Pongali B.
   Manna, Sunil K.
TI RETRACTED: Oleandrin-mediated expression of fas potentiates apoptosis in
   tumor cells (Retracted article. See vol. 33, pg. 1031, 2013)
SO JOURNAL OF CLINICAL IMMUNOLOGY
LA English
DT Article; Retracted Publication
DE NF-kappa B; oleandrin; Fas; apoptosis; FADD
ID NF-KAPPA-B; ACTIVATOR PROTEIN-1; CARDIAC-GLYCOSIDES; NECROSIS-FACTOR;
   CONSTITUTIVE ACTIVATION; SUPPRESSES ACTIVATION; BREAST-CANCER;
   INHIBITION; GROWTH; PATHWAY
AB Chemotherapeutic agent is characterized by its concentration in tumor cells with minimum side effects. Oleandrin, a polyphenolic cardiac glycoside is known to induce apoptosis in tumor cells. However, no report is available on its efficacy in primary cells. In this report we are providing the evidence that oleandrin induces apoptosis, not necrosis in tumor cells but not in primary cells like peripheral blood mononuclear cells (PBMC) and neutrophils. Oleandrin inhibited NF-kappa B activation in tumor cells but not in primary cells. It induced cell death in NF-kappa B-overexpressed tumor cells. Oleandrin induced Fas expression thereby inducing apoptosis in tumor cells but not in primary cells. Dominant negative FADD inhibited oleandrin-induced cell death in tumor cells. Overall, these results suggest that oleandrin mediates apoptosis in tumor cells by inducing Fas but not in primary cells indicating its potential anti-cancer property with no or slight side effect.
C1 Ctr DNA Fingerprinting & Diagnost, Immunol Lab, Hyderabad 500076, Andhra Pradesh, India.
RP Manna, SK (reprint author), Ctr DNA Fingerprinting & Diagnost, Immunol Lab, ECIL Rd, Hyderabad 500076, Andhra Pradesh, India.
EM manna@cdfd.org.in
CR Baeuerle PA, 1997, ADV IMMUNOL, V65, P111, DOI 10.1016/S0065-2776(08)60742-7
   Baichwal VR, 1997, CURR BIOL, V7, pR94, DOI 10.1016/S0960-9822(06)00046-7
   Bours V, 2000, BIOCHEM PHARMACOL, V60, P1085, DOI 10.1016/S0006-2952(00)00391-9
   Chung JY, 1999, CANCER RES, V59, P4610
   Dhawan P, 2002, J BIOL CHEM, V277, P7920, DOI 10.1074/jbc.M112210200
   Dong G, 1999, CANCER RES, V59, P3495
   Epinat JC, 1999, ONCOGENE, V18, P6896, DOI 10.1038/sj.onc.1203218
   Giri DK, 1998, J BIOL CHEM, V273, P14008, DOI 10.1074/jbc.273.22.14008
   Goel A, 2005, EXP HEMATOL, V33, P784, DOI 10.1016/j.exphem.2005.04.005
   GUPTA RS, 1986, J CELL PHYSIOL, V127, P197, DOI 10.1002/jcp.1041270202
   GUPTA RS, 1987, BIOCHEM PHARMACOL, V36, P3829, DOI 10.1016/0006-2952(87)90445-X
   GUPTA RS, 1985, J BIOL CHEM, V260, P6843
   Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3
   Kochetkova M, 1997, J CLIN INVEST, V99, P3000, DOI 10.1172/JCI119495
   Kumar A, 1999, METHOD ENZYMOL, V300, P339
   Li NX, 1999, FASEB J, V13, P1137
   Lu QP, 2005, WORLD J GASTROENTERO, V11, P534, DOI 10.3748/wjg.v11.i4.534
   Manna P, 2005, INT J CANCER, V113, P549, DOI 10.1002/ijc.20590
   Manna SK, 1998, J BIOL CHEM, V273, P13245, DOI 10.1074/jbc.273.21.13245
   Manna SK, 2005, J BIOL CHEM, V280, P7010, DOI 10.1074/jbc.M410994200
   Manna SK, 1999, J IMMUNOL, V162, P1510
   Manna SK, 1997, J IMMUNOL, V159, P5042
   Manna SK, 1999, J IMMUNOL, V163, P6800
   Manna SK, 2006, J CELL PHYSIOL, V207, P195, DOI 10.1002/jcp.20555
   Manna SK, 1999, ONCOGENE, V18, P4371, DOI 10.1038/sj.onc.1202811
   Manna SK, 2000, CANCER RES, V60, P3838
   Manna SX, 2006, EUR J IMMUNOL, V36, P754, DOI 10.1002/eji.200535209
   McConkey DJ, 2000, CANCER RES, V60, P3807
   Meinhold-Heerlein I, 2001, AM J PATHOL, V158, P1335, DOI 10.1016/S0002-9440(10)64084-9
   Nakshatri H, 1997, MOL CELL BIOL, V17, P3629, DOI 10.1128/MCB.17.7.3629
   Pathak S, 2000, ANTI-CANCER DRUG, V11, P455, DOI 10.1097/00001813-200007000-00006
   Raoul C, 2000, CURR OPIN NEUROBIOL, V10, P111, DOI 10.1016/S0959-4388(99)00055-0
   Sarkar A, 2004, J BIOL CHEM, V279, P33768, DOI 10.1074/jbc.M403424200
   SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X
   Smith JA, 2001, BIOCHEM PHARMACOL, V62, P469, DOI 10.1016/S0006-2952(01)00690-6
   Sreenivasan Y, 2003, BIOCHEM PHARMACOL, V66, P2223, DOI 10.1016/j.bcp.2003.07.010
   Toillon RA, 2002, EXP CELL RES, V275, P31, DOI 10.1006/excr.2002.5490
   VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787
   Waddick KG, 1999, BIOCHEM PHARMACOL, V57, P9, DOI 10.1016/S0006-2952(98)00224-X
   Wang CY, 1999, MOL CELL BIOL, V19, P5923
   Wang CY, 1999, NAT MED, V5, P412
   Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784
NR 42
TC 38
Z9 42
U1 3
U2 9
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0271-9142
J9 J CLIN IMMUNOL
JI J. Clin. Immunol.
PD JUL
PY 2006
VL 26
IS 4
BP 308
EP 322
DI 10.1007/s10875-006-9028-0
PG 15
WC Immunology
SC Immunology
GA 063MG
UT WOS:000239021800002
PM 16779680
DA 2018-12-27
ER

PT J
AU Zanin-Zhorov, A
   Cahalon, L
   Tal, G
   Margalit, R
   Lider, O
   Cohen, IR
AF Zanin-Zhorov, Alexandra
   Cahalon, Liora
   Tal, Guy
   Margalit, Raanan
   Lider, Ofer
   Cohen, Irun R.
TI RETRACTED: Heat shock protein 60 enhances CD4(+)CD25(+) regulatory T
   cell function via innate TLR2 signaling (Retracted article. See vol.
   128, pg. 2651, 2018)
SO JOURNAL OF CLINICAL INVESTIGATION
LA English
DT Article; Retracted Publication
ID HEAT-SHOCK PROTEINS; IMMUNOLOGICAL-TOLERANCE; TRANSCRIPTION FACTOR;
   SUPPRESSOR FUNCTION; IL-10 PRODUCTION; INFLAMMATION; ACTIVATION; BETA;
   LIPOPOLYSACCHARIDE; DISCRIMINATION
AB CD4(+)CD25(+) Tregs regulate immunity, but little is known about their own regulation. We now report that the human 60-kDa heat shock protein (HSP60) acts as a costimulator of human Tregs, both CD4(+)CD25(int) and CD4(+)CD25(hi). Treatment of Tregs with HSP60, or its peptide p277, before anti-CD3 activation significantly enhanced the ability of relatively low concentrations of the Tregs to downregulate CD4(+)CD25(-) or CD8(+) target T cells, detected as inhibition of target T cell proliferation and IFN-gamma and TNF-alpha secretion. The enhancing effects of HSP60 costimulation on Tregs involved innate signaling via TLR2, led to activation of PKC, PI3K, and p38, and were further enhanced by inhibition of ERK. HSP60-treated Tregs suppressed target T cells both by cell-to-cell contact and by secretion of TGF-beta and IL-10. In addition, the expression of ERK, NF-kappa B, and T-bet by downregulated target T cells was inhibited. Thus, HSP60, a self-molecule, can downregulate adaptive immune responses by upregulating Tregs innately through TLR2 signaling.
C1 Weizmann Inst Sci, Dept Immunol, IL-76100 Rehovot, Israel.
RP Cohen, IR (reprint author), Weizmann Inst Sci, Dept Immunol, Herzl St, IL-76100 Rehovot, Israel.
EM irun.cohen@weizmann.ac.il
RI Cohen, Irun/B-3542-2009
CR Altan-Bonnet G, 2005, PLOS BIOL, V3, P1925, DOI 10.1371/journal.pbio.0030356
   Annunziato F, 2002, J EXP MED, V196, P379, DOI 10.1084/jem.20020110
   Asseman C, 1999, J EXP MED, V190, P995, DOI 10.1084/jem.190.7.995
   Baecher-Allan C, 2001, J IMMUNOL, V167, P1245, DOI 10.4049/jimmunol.167.3.1245
   Birebent B, 2004, EUR J IMMUNOL, V34, P3485, DOI 10.1002/eji.200324632
   Caramalho I, 2003, J EXP MED, V197, P403, DOI 10.1084/jem.20021633
   Cohen IR, 2004, J CLIN INVEST, V114, P1227, DOI 10.1172/JCI200422396
   Cohen IR, 2000, SEMIN IMMUNOL, V12, P215, DOI 10.1006/smim.2000.0234
   Cohen IR, 2000, SEMIN IMMUNOL, V12, P257
   Elias D, 1997, DIABETES, V46, P758, DOI 10.2337/diabetes.46.5.758
   Fontenot JD, 2003, NAT IMMUNOL, V4, P330, DOI 10.1038/ni904
   Gao BC, 2003, J BIOL CHEM, V278, P22523, DOI 10.1074/jbc.M303161200
   Herbelin A, 1998, J IMMUNOL, V161, P2620
   Hori S, 2003, SCIENCE, V299, P1057, DOI 10.1126/science.1079490
   Jonuleit H, 2002, J EXP MED, V196, P255, DOI 10.1084/jem.20020394
   Jonuleit H, 2001, J EXP MED, V193, P1285, DOI 10.1084/jem.193.11.1285
   Koprak S, 1999, CELL IMMUNOL, V192, P87, DOI 10.1006/cimm.1998.1448
   Kumanogoh A, 2001, J IMMUNOL, V166, P353, DOI 10.4049/jimmunol.166.1.353
   Lindley S, 2005, DIABETES, V54, P92, DOI 10.2337/diabetes.54.1.92
   McHugh RS, 2002, IMMUNITY, V16, P311, DOI 10.1016/S1074-7613(02)00280-7
   MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4
   Ohkusu-Tsukada K, 2004, MOL CELL BIOL, V24, P6957, DOI 10.1128/MCB.24.16.6957-6966.2004
   Okamoto N, 2003, BIOCHEM BIOPH RES CO, V310, P691, DOI 10.1016/j.bbrc.2003.09.065
   Piccirillo CA, 2001, J IMMUNOL, V167, P1137, DOI 10.4049/jimmunol.167.3.1137
   Quintana FJ, 2005, J IMMUNOL, V175, P2777, DOI 10.4049/jimmunol.175.5.2777
   Raz I, 2001, LANCET, V358, P1749, DOI 10.1016/S0140-6736(01)06801-5
   Sakaguchi S, 2005, NAT IMMUNOL, V6, P345, DOI 10.1038/ni1178
   Sakaguchi S, 2001, IMMUNOL REV, V182, P18, DOI 10.1034/j.1600-065X.2001.1820102.x
   Shevach EM, 2002, NAT REV IMMUNOL, V2, P389, DOI 10.1038/nri821
   Shevach EM, 2001, IMMUNOL REV, V182, P58, DOI 10.1034/j.1600-065X.2001.1820104.x
   Sutmuller RPM, 2006, J CLIN INVEST, V116, P485, DOI 10.1172/JCI25439
   Szabo SJ, 2000, CELL, V100, P655, DOI 10.1016/S0092-8674(00)80702-3
   Takahashi T, 2000, J EXP MED, V192, P303, DOI 10.1084/jem.192.2.303
   Tang QZ, 2004, EUR J IMMUNOL, V34, P2996, DOI 10.1002/eji.200425143
   Thornton AM, 2004, EUR J IMMUNOL, V34, P366, DOI 10.1002/eji.200324455
   van Eden W, 2005, NAT REV IMMUNOL, V5, P318, DOI 10.1038/nri1593
   Viglietta V, 2004, J EXP MED, V199, P971, DOI 10.1084/jem.20031579
   Yang RB, 1998, NATURE, V395, P284
   Zanin-Zhorov A, 2005, J IMMUNOL, V175, P276, DOI 10.4049/jimmunol.175.1.276
   Zanin-Zhorov A, 2005, J IMMUNOL, V174, P3227, DOI 10.4049/jimmunol.174.6.3227
   Zanin-Zhorov A, 2003, FASEB J, V17, P1567, DOI 10.1096/fj.02-1139fje
   Zrihan-Licht S, 2000, ONCOGENE, V19, P1318, DOI 10.1038/sj.onc.1203422
NR 42
TC 242
Z9 262
U1 0
U2 9
PU AMER SOC CLINICAL INVESTIGATION INC
PI ANN ARBOR
PA 2015 MANCHESTER RD, ANN ARBOR, MI 48104 USA
SN 0021-9738
EI 1558-8238
J9 J CLIN INVEST
JI J. Clin. Invest.
PD JUL
PY 2006
VL 116
IS 7
BP 2022
EP 2032
DI 10.1172/JCI28423
PG 11
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA 062DN
UT WOS:000238924900035
PM 16767222
OA Green Published, Bronze
DA 2018-12-27
ER

PT J
AU Lozano, SC
   Tversky, B
AF Lozano, Sandra C.
   Tversky, Barbara
TI RETRACTED: Communicative gestures facilitate problem solving for both
   communicators and recipients (Retracted article. See vol. 92, pg. 359,
   2017)
SO JOURNAL OF MEMORY AND LANGUAGE
LA English
DT Article; Retracted Publication
DE gesture; action learning; language; communication; embodied cognition
ID HAND ILLUSTRATORS; SPEECH PRODUCTION; SPEAKING; REPRESENTATIONS;
   ADDRESSEES; LANGUAGE; THINKING
AB Gestures are a common, integral part of communication. Here, we investigate the roles of gesture and speech in explanations, both for communicators and recipients. Communicators explained how to assemble a simple object, using either speech with gestures or gestures alone. Gestures used for explaining included pointing and exhibiting to indicate parts, action models to demonstrate assembly, and gestures used to convey narrative structure. Communicators using gestures alone learned assembly better, making fewer assembly errors than those communicating via speech with gestures. Recipients understood and learned better from gesture-only instructions than from speech-only instructions. Gestures demonstrating action were particularly crucial, suggesting that superiority of gestures to speech may reside, at least in part, in compatibility between gesture and action. (c) 2005 Elsevier Inc. All rights reserved.
C1 Stanford Univ, Dept Psychol, Stanford, CA 94305 USA.
RP Lozano, SC (reprint author), Stanford Univ, Dept Psychol, Jordan Hall,Bldg 420, Stanford, CA 94305 USA.
EM scl@psych.stanford.edu
RI Galantucci, Bruno/E-5770-2010; X, Simon/F-4678-2011
CR Alibali MW, 2001, J MEM LANG, V44, P169, DOI 10.1006/jmla.2000.2752
   Alibali MW, 1999, PSYCHOL SCI, V10, P327, DOI 10.1111/1467-9280.00163
   Alibali MW, 1999, COGNITIVE DEV, V14, P37, DOI 10.1016/S0885-2014(99)80017-3
   Alibali MW, 2000, LANG COGNITIVE PROC, V15, P593, DOI 10.1080/016909600750040571
   ANDERSON RC, 1975, COGNITIVE PSYCHOL, V7, P167, DOI 10.1016/0010-0285(75)90008-0
   Barsalou LW, 1999, BEHAV BRAIN SCI, V22, P577
   Clark H. H., 1996, USING LANGUAGE
   Clark HH, 2004, J MEM LANG, V50, P62, DOI 10.1016/j.jml.2003.08.004
   COHEN AA, 1977, J COMMUN, V27, P54, DOI 10.1111/j.1460-2466.1977.tb01856.x
   COHEN AA, 1973, J PERS SOC PSYCHOL, V28, P276, DOI 10.1037/h0035792
   COHEN J, 1993, BEHAV RES METH INSTR, V25, P257, DOI 10.3758/BF03204507
   DITTMANN AT, 1969, J PERS SOC PSYCHOL, V23, P283
   EMMOREY K, 2000, SPAT COGN COMPUT, V2, P157, DOI DOI 10.1023/A:1013118114571
   ENGLE RA, 1998, SPATIAL LANGUAGE COG
   Frick-Horbury D, 1998, AM J PSYCHOL, V111, P43, DOI 10.2307/1423536
   Glenberg AM, 2002, PSYCHON B REV, V9, P558, DOI 10.3758/BF03196313
   Glenberg AM, 1997, BEHAV BRAIN SCI, V20, P1
   Goldin-Meadow S., 2003, HEARING GESTURE OUR
   GOLDINMEADOW S, 1993, PSYCHOL REV, V100, P279, DOI 10.1037/0033-295X.100.2.279
   GRAHAM JA, 1975, INT J PSYCHOL, V10, P57, DOI 10.1080/00207597508247319
   GRAHAM JA, 1975, EUR J SOC PSYCHOL, V5, P189, DOI 10.1002/ejsp.2420050204
   Haviland J. B., 2000, LANGUAGE GESTURE, P13, DOI [DOI 10.1017/CBO9780511620850.003, 10.1017/CBO9780511620850.003]
   HEISER J, 2002, P 24 ANN M COGN SCI
   HEISER J, 2003, P 25 ANN M COGN SCI
   Heiser Julie, 2004, P ADV VIS INT, P311, DOI 10.1145/989863.989917
   HEWES GW, 1973, CURR ANTHROPOL, V14, P5, DOI 10.1086/201401
   Kendon A, 2004, GESTURE VISIBLE ACTI
   Kita S, 2003, J MEM LANG, V48, P16, DOI 10.1016/S0749-596X(02)00505-3
   Krauss R. M, 1999, GESTURE SPEECH SIGN, P93, DOI DOI 10.1093/ACPROF:OSO/9780198524519.003.0006
   Krauss RM, 1998, CURR DIR PSYCHOL SCI, V7, P54, DOI 10.1111/1467-8721.ep13175642
   KRAUSS RM, 1996, ADV EXPT SOCIAL PSYC, V28
   Levinson Stephen C., 1983, PRAGMATICS
   McNeill D, 2000, COGN LINGUIST, V11, P43
   McNeill D., 1992, HAND MIND WHAT GESTU
   Ozyurek A, 2002, J MEM LANG, V46, P688, DOI 10.1006/jmla.2001.2826
   QUINTILIAN, 1920, I ORATORY
   Rauscher FH, 1996, PSYCHOL SCI, V7, P226, DOI 10.1111/j.1467-9280.1996.tb00364.x
   RISEBOROUGH MG, 1981, J NONVERBAL BEHAV, V5, P172, DOI 10.1007/BF00986134
   Rogers W. T., 1978, HUMAN COMMUNICATION, V5, P54, DOI DOI 10.1111/J.1468-2958.1978.TB00622.X
   ROGERS WT, 1979, J COMMUN DISORD, V12, P273, DOI 10.1016/0021-9924(79)90048-0
   SCHOOLER JW, 1990, COGNITIVE PSYCHOL, V22, P36, DOI 10.1016/0010-0285(90)90003-M
   Tucker M, 1998, J EXP PSYCHOL HUMAN, V24, P830, DOI 10.1037/0096-1523.24.3.830
   TVERSKY B, 2004, HUMAN BEHAV DESIGN I, P79
   Tversky B., 2001, SPATIAL SCHEMAS ABST, P79
   VANDENBERG SG, 1978, PERCEPT MOTOR SKILL, V47, P599, DOI 10.2466/pms.1978.47.2.599
NR 45
TC 29
Z9 30
U1 2
U2 10
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0749-596X
EI 1096-0821
J9 J MEM LANG
JI J. Mem. Lang.
PD JUL
PY 2006
VL 55
IS 1
BP 47
EP 63
DI 10.1016/j.jml.2005.09.002
PG 17
WC Linguistics; Psychology; Psychology, Experimental
SC Linguistics; Psychology
GA 055NM
UT WOS:000238457400004
DA 2018-12-27
ER

PT J
AU Arnold, L
   Campbell, A
   Dubree, M
   Fuchs, MA
   Davis, N
   Hertzler, B
   Talarek, D
   Wessman, J
AF Arnold, Lauren
   Campbell, Ann
   Dubree, Marilyn
   Fuchs, Mary Ann
   Davis, Nancy
   Hertzler, Barbara
   Talarek, Diane
   Wessman, Joan
TI RETRACTED: priorities and challenges of health system chief nursing
   executives: Insights for nursing educators (Retracted Article. See vol
   23, pg 186, 2007)
SO JOURNAL OF PROFESSIONAL NURSING
LA English
DT Article; Retracted Publication
AB The health system chief nursing executive (CNE) is responsible for providing high-quality, service-oriented nursing care; delivering such care with disciplined cost management; leading and developing a group of nursing executives and managers at the facility level to establish nursing professional development programs and to build and maintain an effective supply of nurses; and advocating nurses and patients. This article provides insight into the strategies and priorities of large health system CNEs in balancing their obligations to their health systems, to patients and their families, and to the nurses they lead. It is hoped that these insights will provide perspectives that will support the ability of nursing educators to meet their own obligations to their schools of nursing, the faculty and students they represent, and to the profession. These insights will also set a context for further dialogue between two very important groups of nursing leaders-nursing executives and nursing educators.
C1 Alliance Healthcare Consulting, Huntingdon Valley, PA 19006 USA.
   Virtua Hlth, Marlton, NJ USA.
   Vanderbilt Univ, Med Ctr, Patient Care Serv, Nashville, TN USA.
   Duke Univ Hlth Syst, Durham, NC USA.
   Alton Ochsner Med Fdn & Ochsner Clin, New Orleans, LA 70121 USA.
   Trinity Hlth, Novi, MI USA.
   Christiana Care Hlth Syst, Wilmington, DE USA.
   Moses Cone Hlth Syst, Greensboro, NC USA.
RP Arnold, L (reprint author), Alliance Healthcare Consulting, 1470 Creek Rd, Huntingdon Valley, PA 19006 USA.
EM laurenarnold1@yahoo.com
CR *ADV COMM FED RUL, 2004, EP CIV RUL ADV COMM, P2
   *AM ASS COLL NURS, 2005, ACC PROGR FAST TRACK
   Arnold Lauren, 2006, Nurs Adm Q, V30, P11
   Barger SE, 2004, J PROF NURS, V20, P97, DOI 10.1016/j.profnurs.2004.02.005
   *CTR MED MED SERV, 2005, NAT HLTH EXP PROJ 20
   *CTR MED MED SERV, 2003, NAT HLTH EXP PROJ 20
   Curtin Leah L, 2005, Nurs Adm Q, V29, P288
   Goode Colleen J, 2005, Nurs Adm Q, V29, P202
   McClure Margaret L, 2005, Nurs Adm Q, V29, P198
NR 9
TC 8
Z9 8
U1 3
U2 11
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 8755-7223
EI 1532-8481
J9 J PROF NURS
JI J. Prof. Nurs.
PD JUL-AUG
PY 2006
VL 22
IS 4
BP 213
EP 220
DI 10.1016/j.profnurs.2006.06.002
PG 8
WC Nursing
SC Nursing
GA 073JZ
UT WOS:000239740400002
PM 16873043
DA 2018-12-27
ER

PT J
AU Kim, J
   Kim, MH
AF Kim, Jeongbae
   Kim, Moo Hwan
TI RETRACTED: A photochromic dye activation method for measuring the
   thickness of liquid films (Retracted article. See vol. 44, pg. 791,
   2011)
SO MEASUREMENT
LA English
DT Article; Retracted Publication
DE liquid film thickness; photochromic dye activation
ID DYNAMIC CONTACT-ANGLE; 2-PHASE FLOW; FLUORESCENCE; CAPACITANCE;
   VELOCITY; PROBE
AB To measure the thickness of liquid films from 10 to 60 mu m thick, we used photochromic dye activation of the non-intrusive methods. Photochromic dye activation method is being used as one of the method to measure the liquid velocity distribution in the flow field. The method utilizes the change of the dye from a colorless form to a colored form when irradiated with a specific wavelength. Based on the characteristics of photochromic dye, when a thicker liquid film is irradiated with the beam of a fixed intensity, the color will be darker because the number of dye molecules increases at a fixed dye mass fraction.
   For the activation method, we used silicone oil with a viscosity of 10 centi-Stokes and commercial SO (spironaphthoxazine) and SO-ANTH (spiroanthraoxazine) dyes from Sigma-Aldrich Inc. To make liquid films with exact and known thicknesses, we used two glass wafers. A film formed between the two wafers within a few seconds after placing a drop of the liquid of known volume on one wafer and covering it with the second. The film thickness could be estimated from the diameter of the wafer and the dropped liquid volume. To quantitatively evaluate the color intensity of dyes, we captured the images using digital camera then analyzed the images using the Paint shop pro.
   The gray scale color intensity using the captured images of the activated dye with thickness from 10 to 60 mu m showed the repeatability below +/- 1.0% when measured with a silicone oil solution containing 0.1% SO and SO-ANTH dyes. And the color intensity with our liquid film thickness ranges linearly changed. So, this photochromic dye activation method can be used to measure the thickness of thin liquid films. (C) 2006 Elsevier Ltd. All rights reserved.
C1 Pohang Univ Sci & Technol, Dept Mech Engn, Pohang 790784, South Korea.
RP Kim, J (reprint author), Pohang Univ Sci & Technol, Dept Mech Engn, San 31, Pohang 790784, South Korea.
EM jebikim@postech.ac.kr; mhkim@postech.ac.kr
CR DRISCOLL DI, 1992, J FLUID ENG-T ASME, V114, P107, DOI 10.1115/1.2909984
   Evseev A. R., 1998, Heat Transfer Research, V29, P535
   Fogwell TW, 1987, EXP HEAT TRANSFER, V1, P141
   Fukano T, 1998, NUCL ENG DES, V184, P363, DOI 10.1016/S0029-5493(98)00209-X
   Hurlburt ET, 1996, EXP FLUIDS, V21, P357, DOI 10.1007/BF00189056
   JAYANTI S, 1990, INT J MULTIPHAS FLOW, V16, P1097, DOI 10.1016/0301-9322(90)90108-U
   Johnson MFG, 1997, REV SCI INSTRUM, V68, P4097, DOI 10.1063/1.1148352
   Kamei T, 1998, NUCL ENG DES, V184, P349, DOI 10.1016/S0029-5493(98)00208-8
   KANG HC, 1992, INT J MULTIPHAS FLOW, V18, P423, DOI 10.1016/0301-9322(92)90026-D
   Kawaji M, 1998, NUCL ENG DES, V184, P379, DOI 10.1016/S0029-5493(98)00210-6
   Kawaji M, 1997, NUCL ENG DES, V175, P37, DOI 10.1016/S0029-5493(97)00160-X
   Kim S. H., 1993, J KOREAN CHEM SOC, V37, P523
   KLAUSNER JF, 1992, REV SCI INSTRUM, V63, P3147, DOI 10.1063/1.1142568
   Lee Y. S., 1994, J KOREAN CHEM SOC, V38, P864
   Lorencez C, 1997, INT J MULTIPHAS FLOW, V23, P205, DOI 10.1016/S0301-9322(96)00073-0
   Makarytchev SV, 2001, CHEM ENG SCI, V56, P77, DOI 10.1016/S0009-2509(00)00428-0
   MCADAM DW, 1975, APPL OPTICS, V14, P1764
   Mouza AA, 2000, EXP FLUIDS, V28, P355, DOI 10.1007/s003480050394
   SALAZAR RP, 1975, REV SCI INSTRUM, V46, P1539, DOI 10.1063/1.1134099
   Shedd TA, 1998, REV SCI INSTRUM, V69, P4205, DOI 10.1063/1.1149232
   SMART AE, 1974, WEAR, V29, P41, DOI 10.1016/0043-1648(74)90132-X
   Thorncroft GE, 1997, J FLUID ENG-T ASME, V119, P164, DOI 10.1115/1.2819103
   Zhang JT, 2000, REV SCI INSTRUM, V71, P1883, DOI 10.1063/1.1150557
NR 23
TC 2
Z9 2
U1 4
U2 20
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0263-2241
EI 1873-412X
J9 MEASUREMENT
JI Measurement
PD JUL
PY 2006
VL 39
IS 6
BP 497
EP 504
DI 10.1016/j.measurement.2005.12.013
PG 8
WC Engineering, Multidisciplinary; Instruments & Instrumentation
SC Engineering; Instruments & Instrumentation
GA 057OH
UT WOS:000238604600003
DA 2018-12-27
ER

PT J
AU Mandal, PK
   Pettegrew, JW
   McKeag, DW
   Mandal, R
AF Mandal, Pravat K.
   Pettegrew, Jay W.
   McKeag, Dennish W.
   Mandal, Ratna
TI RETRACTED: Alzheimer's disease: Halothane induces A beta peptide to
   oligomeric form - Solution NMR studies (Retracted Article. See vol 33,
   pg 220, 2008)
SO NEUROCHEMICAL RESEARCH
LA English
DT Article; Retracted Publication
DE Alzheimer's disease; anesthesia; halothane; A beta peptide;
   oligomerization
ID POSTOPERATIVE COGNITIVE DYSFUNCTION; VOLATILE GENERAL-ANESTHETICS;
   4-ALPHA-HELIX BUNDLE PROTEIN; MEMBRANE MIMIC ENVIRONMENT; HUMAN
   SERUM-ALBUMIN; INHALED ANESTHETICS; MOLECULAR-DYNAMICS; A-BETA(1-40)
   PEPTIDE; AMYLOID FORMATION; BINDING-SITES
AB Alzheimer's disease (AD) is a significant contributor to cognitive decline and is responsible for about half of the cases of dementia in later life. Although exact etiology of AD is not known, however, many risk factors for AD are identified. Anesthesia for elderly patients is considered as a risk factor in AD as they frequently experience deterioration in cognitive function with long exposure to anesthetics during surgery. Inhaled anesthetic agents remain the mainstay for patients undergoing major surgical operations. This study using multidimensional NMR spectroscopy provides the first direct evidence in vitro that inhaled anesthetic, halothane specifically interacts with A beta 40 and A beta 42 peptide. Halothane induces structural alternation of A beta peptide from soluble monomeric alpha-helical form to oligomeric beta-sheet conformation, which may hasten the onset of AD. A beta 42 is more prone to oligomerization compared to A beta 40 in the presence of halothane. The molecular mechanism of halothane induced structural alternation of A beta peptide is discussed.
C1 Univ Pittsburgh, Sch Med, Western Psychiat Inst & Clin, Dept Psychiat, Pittsburgh, PA 15213 USA.
RP Mandal, PK (reprint author), Univ Pittsburgh, Sch Med, Western Psychiat Inst & Clin, Dept Psychiat, 3811 O'Hara St, Pittsburgh, PA 15213 USA.
EM mandalp@upmc.edu
CR ARISPE N, 1993, P NATL ACAD SCI USA, V90, P567, DOI 10.1073/pnas.90.2.567
   Balasubramanian SV, 2002, CHEM PHYS LIPIDS, V114, P35, DOI 10.1016/S0009-3084(01)00199-2
   BEDFORD PD, 1955, LANCET, V2, P259
   Bhattacharya AA, 2000, J BIOL CHEM, V275, P38731, DOI 10.1074/jbc.M005460200
   BOHNEN N, 1994, INT J NEUROSCI, V77, P181, DOI 10.3109/00207459408986029
   BOHNEN NILJ, 1994, J AM GERIATR SOC, V42, P198, DOI 10.1111/j.1532-5415.1994.tb04952.x
   BRACCO L, 1994, ARCH NEUROL-CHICAGO, V51, P1213, DOI 10.1001/archneur.1994.00540240057016
   Brennan LK, 2000, BIOCHEM BIOPH RES CO, V271, P770, DOI 10.1006/bbrc.2000.2688
   BRUCE DL, 1976, BRIT J ANAESTH, V48, P871, DOI 10.1093/bja/48.9.871
   Campagna JA, 2003, NEW ENGL J MED, V348, P2110, DOI 10.1056/NEJMra021261
   Charoonruk G, 2005, AM J EPIDEMIOL, V161, pS91
   Cohendy R, 2005, CURR OPIN CLIN NUTR, V8, P17, DOI 10.1097/00075197-200501000-00004
   Coles M, 1998, BIOCHEMISTRY-US, V37, P11064, DOI 10.1021/bi972979f
   DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809
   Eckenhoff RG, 2004, ANESTHESIOLOGY, V101, P703, DOI 10.1097/00000542-200409000-00019
   Eckenhoff RG, 1996, J BIOL CHEM, V271, P15521, DOI 10.1074/jbc.271.26.15521
   Eckenhoff RG, 1997, PHARMACOL REV, V49, P343
   Eckenhoff RG, 2000, J BIOL CHEM, V275, P30439, DOI 10.1074/jbc.M005052200
   Edland SD, 2002, ALZ DIS ASSOC DIS, V16, P1, DOI 10.1097/00002093-200201000-00001
   EGER EI, 1965, ANESTHESIOLOGY, V26, P756, DOI 10.1097/00000542-196511000-00010
   Fleminger S, 2003, J NEUROL NEUROSUR PS, V74, P857, DOI 10.1136/jnnp.74.7.857
   FRANKS NP, 1994, NATURE, V367, P607, DOI 10.1038/367607a0
   Friedland RP, 2001, P NATL ACAD SCI USA, V98, P3440, DOI 10.1073/pnas.061002998
   GARRETT DS, 1991, J MAGN RESON, V95, P214, DOI 10.1016/0022-2364(91)90341-P
   Gasparini M, 2002, NEUROL SCI, V23, P11, DOI 10.1007/s100720200017
   GODDARD TD, 1994, SPARKY 3
   Grasshoff C, 2004, ANESTHESIOLOGY, V101, P1167, DOI 10.1097/00000542-200411000-00017
   Hanning CD, 2005, BRIT J ANAESTH, V95, P82, DOI 10.1093/bja/aei062
   HARRIS RA, 1995, FASEB J, V9, P1454
   JARRETT JT, 1993, BIOCHEMISTRY-US, V32, P4693, DOI 10.1021/bi00069a001
   JOHANSSON JS, 1995, ANESTHESIOLOGY, V83, P1385, DOI 10.1097/00000542-199512000-00050
   Johansson JS, 2005, FEBS J, V272, P573, DOI 10.1111/j.1742-4658.2004.04500.x
   Johansson JS, 1999, ANESTHESIOLOGY, V90, P235, DOI 10.1097/00000542-199901000-00030
   JONES MJT, 1988, ACTA CHIR SCAND    S, V550, P169
   Kayed R, 2003, SCIENCE, V300, P486, DOI 10.1126/science.1079469
   Koubi L, 2000, BIOPHYS J, V78, P800, DOI 10.1016/S0006-3495(00)76637-9
   LI CY, 1994, P NATL ACAD SCI USA, V91, P8200, DOI 10.1073/pnas.91.17.8200
   Mandal PK, 2004, NEUROCHEM RES, V29, P2267, DOI 10.1007/s11064-004-7035-1
   Mandal PK, 2004, CONCEPT MAGN RESON A, V20A, P1, DOI 10.1002/cmr.a.10095
   Mandal PK, 2002, MONATSH CHEM, V133, P205, DOI 10.1007/s706-002-8252-5
   Mandal PK, 2004, NEUROCHEM RES, V29, P447, DOI 10.1023/B:NERE.0000013750.80925.25
   MANDAL PK, IN PRESS BIOPHYS J
   Manderson GA, 2002, BIOCHEMISTRY-US, V41, P4080, DOI 10.1021/bi0160718
   Marcinowski KJ, 1998, J AM CHEM SOC, V120, P11082, DOI 10.1021/ja9738687
   MCKEONOMALLEY C, 2001, FUNCTIONAL NEUROLOGY, P333
   Moller JT, 1998, LANCET, V351, P857, DOI 10.1016/S0140-6736(97)07382-0
   MULLER WE, 1995, BRAIN RES, V674, P133, DOI 10.1016/0006-8993(94)01463-R
   MURAVCHICK S, 1995, ANESTHESIOLOGY, V82, P305, DOI 10.1097/00000542-199501000-00039
   Pidikiti R, 2005, BIOCHEMISTRY-US, V44, P12128, DOI 10.1021/bi050896q
   Pidikiti R, 2005, BIOMACROMOLECULES, V6, P1516, DOI 10.1021/bm049226a
   Pohorille A, 1996, CHEM PHYS, V204, P337, DOI 10.1016/0301-0104(95)00292-8
   Pohorille A, 1998, TOXICOL LETT, V101, P421
   Prough DS, 2005, J AM COLL SURGEONS, V200, P784, DOI 10.1016/j.collsurg.2004.12.010
   Rasmussen LS, 2003, ACTA ANAESTH SCAND, V47, P260, DOI 10.1034/j.1399-6576.2003.00057.x
   Ravona-Springer R, 2003, CNS SPECTRUMS, V8, P824, DOI 10.1017/S109285290001926X
   Solt K, 2006, BIOCHEMISTRY-US, V45, P1435, DOI 10.1021/bi052206o
   Sonner JM, 2003, ANESTH ANALG, V97, P718, DOI 10.1213/01.ANE.0000081063.76651.33
   Stewart R, 1999, DIABETIC MED, V16, P93, DOI 10.1046/j.1464-5491.1999.00027.x
   TALAFOUS J, 1994, BIOCHEMISTRY-US, V33, P7788, DOI 10.1021/bi00191a006
   Teplow DB, 1998, AMYLOID, V5, P121, DOI 10.3109/13506129808995290
   Tu KC, 1998, BIOPHYS J, V75, P2123, DOI 10.1016/S0006-3495(98)77655-6
   Weigl LG, 2001, MOL PHARMACOL, V60, P282
   WENKER OC, 1999, INTERNET J ANESTHESI, P3
   Wymore T, 1999, BIOPHYS J, V76, P1199, DOI 10.1016/S0006-3495(99)77284-X
   Xi J, 2004, J BIOL CHEM, V279, P19628, DOI 10.1074/jbc.M313864200
   Yamakura T, 2001, ANNU REV PHARMACOL, V41, P23, DOI 10.1146/annurev.pharmtox.41.1.23
   YOKONO S, 1989, BIOCHIM BIOPHYS ACTA, V982, P300, DOI 10.1016/0005-2736(89)90068-0
   Zeng H, 2001, BIOL PSYCHIAT, V49, P248, DOI 10.1016/S0006-3223(00)01111-2
NR 68
TC 23
Z9 23
U1 4
U2 10
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0364-3190
EI 1573-6903
J9 NEUROCHEM RES
JI Neurochem. Res.
PD JUL
PY 2006
VL 31
IS 7
BP 883
EP 890
DI 10.1007/s11064-006-9092-0
PG 8
WC Biochemistry & Molecular Biology; Neurosciences
SC Biochemistry & Molecular Biology; Neurosciences & Neurology
GA 068HB
UT WOS:000239362700005
PM 16807784
DA 2018-12-27
ER

PT J
AU Qiu, XY
AF Qiu, Xiao-Yang
TI RETRACTED: Bis(2-formyl-phenolato)cobalt(II) (Retracted article. See
   vol. 66, pg e21, 2010)
SO ACTA CRYSTALLOGRAPHICA SECTION E-STRUCTURE REPORTS ONLINE
LA English
DT Article; Retracted Publication
ID COMPLEXES; BINDING; COBALT
AB In the title compound, [Co(C(7)H(5)O(2))(2)], the Co atom is connected to four O atoms from two 2-formyl-phenolate ligands in a square-planar coordination. The mol-ecule possesses a crystallographically imposed centre of symmetry.
C1 Fuyang Normal Coll, Dept Chem, Fuyang 236041, Anhui, Peoples R China.
RP Qiu, XY (reprint author), Fuyang Normal Coll, Dept Chem, Fuyang 236041, Anhui, Peoples R China.
EM xiaoyang_qiu@126.com
CR Bruker, 1998, SMART VERS 5 628 SAI
   DeAngelis S, 1996, INORG CHEM, V35, P5995, DOI 10.1021/ic951661d
   Henson NJ, 1999, INORG CHEM, V38, P1618, DOI 10.1021/ic9813056
   Ruiz-Molina D, 2000, INORG CHEM, V39, P617, DOI 10.1021/ic990714e
   RybakAkimova EV, 1997, INORG CHEM, V36, P2746, DOI 10.1021/ic961371c
   Sheldrick G.M, 1996, SADABS
   Sheldrick G. M., 1997, SHELXL97 SHELXS97
NR 7
TC 2
Z9 2
U1 4
U2 12
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1600-5368
J9 ACTA CRYSTALLOGR E
JI Acta Crystallogr. Sect. E.-Struct Rep. Online
PD JUN
PY 2006
VL 62
BP M1190
EP M1191
DI 10.1107/S1600536806015704
PN 6
PG 2
WC Crystallography
SC Crystallography
GA 049EL
UT WOS:000237998600010
DA 2018-12-27
ER

PT J
AU Wang, ZW
   Zhang, YX
   Banerjee, S
   Li, YW
   Sarkar, FH
AF Wang, Zhiwei
   Zhang, Yuxiang
   Banerjee, Sanjeev
   Li, Yiwei
   Sarkar, Fazlul H.
TI RETRACTED: Notch-1 down-regulation by curcumin is associated with the
   inhibition of cell growth and the induction of apoptosis in pancreatic
   cancer cells (Retracted article. See vol. 122, pg. 3247, 2016)
SO CANCER
LA English
DT Article; Retracted Publication
DE apoptosis; Notch-1 signaling pathway; curcumin; nuclear factor kappa
   beta
ID FACTOR-KAPPA-B; SIGNALING PATHWAY; DIETARY CURCUMIN; GENE-EXPRESSION;
   DIFFERENTIATION; ACTIVATION; TARGET; PROLIFERATION; GENISTEIN; SURVIVAL
AB BACKGROUND. Notch signaling plays a critical role in maintaining the balance between cell proliferation, differentiation, and apoptosis, and thereby may contribute to the development of pancreatic cancer. Therefore, the down-regulation of Notch signaling may be a novel approach for pancreatic cancer therapy. It has been reported that curcumin down-regulates many genes that are known to promote survival and also up-regulates genes that are known promoters of apoptosis in pancreatic cancer cells in vitro. It also has been reported that there is cross-talk between Notch-1 and another major cell growth and apoptotic regulatory pathway, the nuclear factor kappa B (NF-kappa B) pathway, which is down-regulated by both curcumin and reduction of Notch-1 levels. However, to the authors' knowledge to date, no studies have determined whether the down-regulation of Notch-1 signaling, resulting in the inactivation of NF-kappa B activity, contributes to curcum-ininduced cell growth inhibition and apoptosis in pancreatic cancer cells.
   METHODS. The authors used multiple molecular approaches, such as the 3-(4,5dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, an apoptosis assay, gene transfection, real-time reverse transcriptase-polymerase chain reaction analysis, Western blot analysis, and an electrophoretic mobility shift assay to measure the DNA binding activity of NF-kappa B.
   RESULTS. Curcumin inhibited cell growth and induced apoptosis in pancreatic cancer cells. Notch-1, Hes-1, and Bcl-X-L expression levels concomitantly were down-regulated by curcumin treatment. These results correlated with the inactivation of NF-kappa B activity and increased apoptosis induced by curcumin. The downregulation of Notch-1 by small-interfering RNA prior to curcumin treatment resulted in enhanced cell growth inhibition and apoptosis.
   CONCLUSIONS. The current results provide the first demonstration to the authors' knowledge that the Notch-1 signaling pathway is associated mechanistically with NF-kappa B activity during curcumin-induced cell growth inhibition and apoptosis of pancreatic cells. These results suggest that the down-regulation of Notch signaling by curcumin may be a novel strategy for the treatment of patients with pancreatic cancer.
C1 Wayne State Univ, Sch Med, Karmanos Canc Inst, Dept Pathol, Detroit, MI 48201 USA.
   Capital Univ Med Sci, Dept Biochem & Mol Biol, Beijing, Peoples R China.
RP Sarkar, FH (reprint author), Wayne State Univ, Sch Med, Karmanos Canc Inst, Dept Pathol, 9374 Scott Hall,540 E Canfield, Detroit, MI 48201 USA.
EM sarkarf@karmanos.org
RI Wang, Zhiwei/A-6809-2011
FU NCI NIH HHS [5R01CA101870-02, 1P20-CA010193-01]
CR Aster JC, 2000, MOL CELL BIOL, V20, P7505, DOI 10.1128/MCB.20.20.7505-7515.2000
   Bigas A, 1998, MOL CELL BIOL, V18, P2324, DOI 10.1128/MCB.18.4.2324
   Biliran H, 2005, CLIN CANCER RES, V11, P6075, DOI 10.1158/1078-0432.CCR-04-2419
   Bresnick EH, 2000, J CELL BIOCHEM, P46
   Chen LF, 2001, SCIENCE, V293, P1653, DOI 10.1126/science.1062374
   Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905
   Dorai T, 2000, PROSTATE CANCER P D, V3, P84, DOI 10.1038/sj.pcan.4500399
   Fukushima N, 2004, ONCOGENE, V23, P9042, DOI 10.1038/sj.onc.1208117
   Huang MT, 1998, CARCINOGENESIS, V19, P1697, DOI 10.1093/carcin/19.9.1697
   Jang MS, 2004, J CELL PHYSIOL, V199, P418, DOI 10.1002/jcp.10467
   Jemal A, 2005, CA-CANCER J CLIN, V55, P10, DOI 10.3322/canjclin.55.1.10
   Joutel A, 1998, SEMIN CELL DEV BIOL, V9, P619, DOI 10.1006/scdb.1998.0261
   Jundt F, 2002, BLOOD, V99, P3398, DOI 10.1182/blood.V99.9.3398
   Kawamori T, 1999, CANCER RES, V59, P597
   Li L, 2004, CANCER-AM CANCER SOC, V101, P2351, DOI 10.1002/cncr.20605
   Miele L, 1999, J CELL PHYSIOL, V181, P393, DOI 10.1002/(SICI)1097-4652(199912)181:3<393::AID-JCP3>3.0.CO;2-6
   Miyamoto Y, 2003, CANCER CELL, V3, P565, DOI 10.1016/S1535-6108(03)00140-5
   Mumm JS, 2000, DEV BIOL, V228, P151, DOI 10.1006/dbio.2000.9960
   Nair P, 2003, J VIROL, V77, P7106, DOI 10.1128/JVI.77.12.7106-7112.2003
   Nickoloff BJ, 2003, ONCOGENE, V22, P6598, DOI 10.1038/sj.onc.1206758
   Nickoloff BJ, 2002, CELL DEATH DIFFER, V9, P842, DOI 10.1038/sj.cdd.4401036
   Ohishi K, 2003, SEMIN CELL DEV BIOL, V14, P143, DOI 10.1016/S1084-9521(02)00183-0
   Osborne B, 1999, IMMUNITY, V11, P653, DOI 10.1016/S1074-7613(00)80140-5
   Oswald F, 1998, MOL CELL BIOL, V18, P2077, DOI 10.1128/MCB.18.4.2077
   Plummer SM, 1999, ONCOGENE, V18, P6013, DOI 10.1038/sj.onc.1202980
   RADHAKRISHNA PG, 2004, CANC LETT, V208, P163, DOI DOI 10.1016/J.CANLET.2004.01.008
   RAO CV, 1995, CANCER RES, V55, P259
   Sade H, 2004, J BIOL CHEM, V279, P2937, DOI 10.1074/jbc.M309924200
   Terris B, 2002, AM J PATHOL, V160, P1745, DOI 10.1016/S0002-9440(10)61121-2
   Verma SP, 1997, BIOCHEM BIOPH RES CO, V233, P692, DOI 10.1006/bbrc.1997.6527
   Wang WX, 1999, CLIN CANCER RES, V5, P119
   Wang Y, 2004, P NATL ACAD SCI USA, V101, P9458, DOI 10.1073/pnas.0308126101
   Wang ZW, 2006, INT J CANCER, V118, P1930, DOI 10.1002/ijc.21589
   Weijzen S, 2002, NAT MED, V8, P979, DOI 10.1038/nm754
   Yanagawa S, 2000, J VIROL, V74, P9786, DOI 10.1128/JVI.74.20.9786-9791.2000
NR 35
TC 196
Z9 203
U1 4
U2 16
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0008-543X
EI 1097-0142
J9 CANCER-AM CANCER SOC
JI Cancer
PD JUN 1
PY 2006
VL 106
IS 11
BP 2503
EP 2513
DI 10.1002/cncr.21904
PG 11
WC Oncology
SC Oncology
GA 045TE
UT WOS:000237764600026
PM 16628653
DA 2018-12-27
ER

PT J
AU Essner, R
AF Essner, Richard
TI RETRACTED: Experimental frontiers for clinical applications: Novel
   approaches to understanding mechanisms of lymph Node metastases in
   melanoma (Retracted Article. See vol 27, pg 539, 2008)
SO CANCER AND METASTASIS REVIEWS
LA English
DT Article; Proceedings Paper; Retracted Publication
CT 1st International Symposium on Cancer Metastasis and the Lymphovascular
   System
CY APR 28-30, 2005
CL San Francisco, CA
ID COLONY-STIMULATING FACTOR; EARLY-STAGE MELANOMA; ANTIGEN-PRESENTING
   CELLS; CHEMOKINE RECEPTOR CCR7; MYELOID DENDRITIC CELLS; BREAST-CANCER;
   T-CELL; SENTINEL-LYMPHADENECTOMY; MALIGNANT-MELANOMA; TUMOR-CELLS
AB Sentinel lymph nodes are the first nodes to receive lymph from primary tumors and are the preferential site of initial metastases. Sentinel nodes show morphology changes that suggests immune modulation with reduced antigen-presenting dendritic cells, activated T lymphocytes, high endothelial venules and transvenular migration of T lymphocytes. Tumor cells generate down-regulatory molecules. We postulate that tumor-induced immune dysfunction facilitates establishment of nodal metastases. Nodal immune modulation can be reversed by granulocyte macrophage colony-stimulating factor (GMCSF), a finding with implications for future therapy to prevent or reverse these nodal metastases.
C1 John Wayne Canc Inst, Dept Mol Therapeut, Santa Monica, CA 90404 USA.
RP Essner, R (reprint author), John Wayne Canc Inst, Dept Mol Therapeut, Santa Monica, CA 90404 USA.
EM Essner@jwci.org
FU PHS HHS [LA 12382, LA 29605]
CR Banchereau J, 2000, ANNU REV IMMUNOL, V18, P767, DOI 10.1146/annurev.immunol.18.1.767
   Botella-Estrada R, 2005, MELANOMA RES, V15, P99, DOI 10.1097/00008390-200504000-00003
   Clary BM, 2001, ANN SURG, V233, P250, DOI 10.1097/00000658-200102000-00015
   COCHRAN AJ, 1989, ANTICANCER RES, V9, P859
   Cochran AJ, 2004, PATHOLOGY, V36, P478, DOI 10.1080/00313020412331282726
   Cochran AJ, 2000, CANCER, V89, P236, DOI 10.1002/1097-0142(20000715)89:2<236::AID-CNCR5>3.3.CO;2-S
   COCHRAN AJ, 1988, AM J SURG PATHOL, V12, P612, DOI 10.1097/00000478-198808000-00002
   COCHRAN AJ, 1985, FED PROC, V44, P965
   Cochran AJ, 2001, MODERN PATHOL, V14, P604, DOI 10.1038/modpathol.3880358
   COCHRAN AJ, 1987, J NATL CANCER I, V78, P399
   Cochran Alistair J, 2003, Int J Clin Oncol, V8, P139
   Dieu MC, 1998, J EXP MED, V188, P373, DOI 10.1084/jem.188.2.373
   Dranoff G, 2002, IMMUNOL REV, V188, P147, DOI 10.1034/j.1600-065X.2002.18813.x
   DRANOFF G, 1993, P NATL ACAD SCI USA, V90, P3539, DOI 10.1073/pnas.90.8.3539
   Essner R, 2002, ONCOLOGY-NY, V16, P27
   Essner R, 2001, Ann Surg Oncol, V8, p31S
   Farzad Z, 1997, MELANOMA RES, V7, pS59
   FARZAD Z, 1990, CANCER RES, V50, P3585
   FISHER B, 1971, CANCER, V27, P1001, DOI 10.1002/1097-0142(197105)27:5<1001::AID-CNCR2820270502>3.0.CO;2-U
   Forster R, 1999, CELL, V99, P23, DOI 10.1016/S0092-8674(00)80059-8
   Frumento G, 2002, J EXP MED, V196, P459, DOI 10.1084/jem.20020121
   Gadd MA, 1999, ARCH SURG-CHICAGO, V134, P381, DOI 10.1001/archsurg.134.4.381
   Geissmann F, 2002, J EXP MED, V196, P417, DOI 10.1084/jem.20020018
   Gershenwald JE, 1998, J CLIN ONCOL, V16, P2253, DOI 10.1200/JCO.1998.16.6.2253
   Gimeno MJ, 2003, HISTOL HISTOPATHOL, V18, P695, DOI 10.14670/HH-18.695
   Gunn MD, 1999, J EXP MED, V189, P451, DOI 10.1084/jem.189.3.451
   Gunn MD, 1998, P NATL ACAD SCI USA, V95, P258, DOI 10.1073/pnas.95.1.258
   GUPTA R, IN PRESS MELANOCYTES
   GUPTA RK, 1984, J NATL CANCER I, V72, P75, DOI 10.1093/jnci/72.1.75
   Haigh PI, 2001, CANCER, V92, P535, DOI 10.1002/1097-0142(20010801)92:3<535::AID-CNCR1352>3.0.CO;2-3
   Hendrix MJC, 2003, ANN NY ACAD SCI, V995, P151, DOI 10.1111/j.1749-6632.2003.tb03218.x
   Hirakawa S, 2005, J EXP MED, V201, P1089, DOI 10.1084/jem.20041896
   HOON DSB, 1987, CANCER RES, V47, P1740
   HOON DSB, 1989, IMMUNOL LETT, V20, P269, DOI 10.1016/0165-2478(89)90034-5
   HOON DSB, 1988, CELL IMMUNOL, V111, P410, DOI 10.1016/0008-8749(88)90104-9
   HOON DSB, 1987, CANCER RES, V47, P1529
   HUANG RR, 2005, MODERN PATHOL, V18, P379
   HUANG RR, 2004, MOD PATHOL S1, V27, P382
   HUANG RR, 2000, BREAST J, V6, P225
   Inaba K, 1997, J EXP MED, V186, P665, DOI 10.1084/jem.186.5.665
   Ishigami S, 2003, J GASTROINTEST SURG, V7, P735, DOI 10.1016/S1091-255X(03)00076-3
   ITAKURA E, 2004, MOD PATHOL S1, V17, P385
   Jansen L, 2000, BRIT J SURG, V87, P484, DOI 10.1046/j.1365-2168.2000.01362.x
   Kass E, 2001, CANCER RES, V61, P206
   KOKOSCHKA EM, 1983, J INVEST DERMATOL, V80, P368
   Laguens G, 2002, IMMUNOL LETT, V84, P159, DOI 10.1016/S0165-2478(02)00172-4
   Lana AMA, 2001, MELANOMA RES, V11, P401, DOI 10.1097/00008390-200108000-00011
   Lee JH, 2005, CLIN CANCER RES, V11, P107
   Lee JH, 2004, J CLIN ONCOL, V22, P3677, DOI 10.1200/JCO.2004.01.012
   Leong SPL, 2002, ANN SURG ONCOL, V9, P82, DOI 10.1245/aso.2002.9.1.82
   Leong SPL, 1999, J IMMUNOTHER, V22, P166, DOI 10.1097/00002371-199903000-00008
   Littlepage LE, 2005, CANCER CELL, V7, P499, DOI 10.1016/j.ccr.2005.05.019
   Molenkamp BG, 2005, AM J PATHOL, V167, P1301, DOI 10.1016/S0002-9440(10)61217-5
   Moretta A, 2002, NAT REV IMMUNOL, V2, P957, DOI 10.1038/nri956
   MORTON BA, 1986, CANCER RES, V46, P2121
   MORTON DL, 1974, ANN SURG, V180, P635, DOI 10.1097/00000658-197410000-00029
   Morton DL, 2005, ANN SURG, V242, P302, DOI 10.1097/01.sla.0000181092.50141.fa
   Morton DL, 2004, BRIT J DERMATOL, V151, P308, DOI 10.1111/j.1365-2133.2004.06133.x
   Morton DL, 2005, J CLIN ONCOL, V23, p710S
   MORTON DL, 1992, ARCH SURG-CHICAGO, V127, P392
   Morton DL, 2003, ANN SURG, V238, P538, DOI 10.1097/01.sla.0000086543.45557.cb
   Movassagh M, 2004, CANCER RES, V64, P2192, DOI 10.1158/0008-5472.CAN-03-2969
   Munn DH, 2002, SCIENCE, V297, P1867, DOI 10.1126/science.1073514
   Munn DH, 1998, SCIENCE, V281, P1191, DOI 10.1126/science.281.5380.1191
   Murphy PM, 2000, PHARMACOL REV, V52, P145
   Nakamura M, 2002, CLIN CANCER RES, V8, P2742
   Nakano H, 1997, EUR J IMMUNOL, V27, P215, DOI 10.1002/eji.1830270132
   Palucka KA, 1998, J IMMUNOL, V160, P4587
   Peguet-Navarro J, 2003, J IMMUNOL, V170, P3488, DOI 10.4049/jimmunol.170.7.3488
   Pinedo HM, 2003, EUR J CANCER, V39, P1061, DOI 10.1016/S0959-8049(03)00131-X
   Poindexter NJ, 2004, BREAST CANCER RES, V6, pR408, DOI 10.1186/bcr808
   REISS CK, 1983, J SURG ONCOL, V22, P249, DOI 10.1002/jso.2930220408
   Ridolfi L, 2002, HEPATO-GASTROENTEROL, V49, P335
   ROSENBERG SA, 1976, MED CLIN N AM, V60, P419, DOI 10.1016/S0025-7125(16)31889-2
   Ross R, 1998, J IMMUNOL, V160, P3776
   Sakakura K, 2005, ORAL ONCOL, V41, P89, DOI 10.1016/j.oraloncology.2004.07.004
   Schule JM, 2004, J TRANSL MED, V2, P45, DOI DOI 10.1186/1479-5876-2-45
   Seo N, 2001, IMMUNOLOGY, V103, P449, DOI 10.1046/j.1365-2567.2001.01279.x
   Si Z, 1996, MELANOMA RES, V6, P247, DOI 10.1097/00008390-199606000-00008
   Steinbrink K, 1999, BLOOD, V93, P1634
   Steinbrink K, 2002, BLOOD, V99, P2468, DOI 10.1182/blood.V99.7.2468
   STRATEN PT, 2005, CANC IMMUNOL IMMUNOT
   Sun XL, 2002, VACCINE, V20, P1466, DOI 10.1016/S0264-410X(01)00476-5
   Takayama T, 2001, TRANSPLANTATION, V71, P1334, DOI 10.1097/00007890-200105150-00027
   Takeuchi H, 2004, CLIN CANCER RES, V10, P2351, DOI 10.1158/1078-0432.CCR-03-0195
   TSAKRAKLIDES E, 1975, J NATL CANCER I, V54, P549
   Vaquerano JE, 1999, ARCH DERMATOL, V135, P1276, DOI 10.1001/archderm.135.10.1276
   VAQUERO J, 1992, NEUROREPORT, V3, P981, DOI 10.1097/00001756-199211000-00008
   Vermi W, 2003, J PATHOL, V200, P255, DOI 10.1002/path.1344
   VOGELZANG NJ, 1994, HUM GENE THER, V5, P1357, DOI 10.1089/hum.1994.5.11-1357
   Vuylsteke RJCLM, 2004, CANCER RES, V64, P8456, DOI 10.1158/0008-5472.CAN-03-3251
   Wang Shui, 2004, Zhonghua Zhongliu Zazhi, V26, P220
   WEN DR, 1989, CANCER IMMUNOL IMMUN, V30, P277, DOI 10.1007/BF01744894
   Widner B, 2000, IMMUNOL TODAY, V21, P250, DOI 10.1016/S0167-5699(00)01616-9
   Willimann K, 1998, EUR J IMMUNOL, V28, P2025, DOI 10.1002/(SICI)1521-4141(199806)28:06<2025::AID-IMMU2025>3.0.CO;2-C
   WONG JH, 1991, ANN SURG, V214, P637, DOI 10.1097/00000658-199111000-00015
   Yanagihara S, 1998, J IMMUNOL, V161, P3096
   Yoshida R, 1998, J BIOL CHEM, V273, P7118, DOI 10.1074/jbc.273.12.7118
   Yue FY, 1997, INT J CANCER, V71, P630, DOI 10.1002/(SICI)1097-0215(19970516)71:4<630::AID-IJC20>3.3.CO;2-H
   Zlotnik A, 2000, IMMUNITY, V12, P121, DOI 10.1016/S1074-7613(00)80165-X
   Zogakis TG, 2005, ARCH SURG-CHICAGO, V140, P865, DOI 10.1001/archsurg.140.9.865
NR 101
TC 13
Z9 14
U1 3
U2 8
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0167-7659
EI 1573-7233
J9 CANCER METAST REV
JI Cancer Metastasis Rev.
PD JUN
PY 2006
VL 25
IS 2
BP 257
EP 267
DI 10.1007/s10555-006-8506-4
PG 11
WC Oncology
SC Oncology
GA 052YA
UT WOS:000238268800009
PM 16770538
DA 2018-12-27
ER

PT J
AU Tanriverdi, H
   Evrengul, H
   Kaftan, A
   Kara, CO
   Kuru, O
   Tanriverdi, S
   Ozkurt, S
   Semiz, E
AF Tanriverdi, Halil
   Evrengul, Harun
   Kaftan, Asuman
   Kara, Cuneyt Orhan
   Kuru, Ornur
   Tanriverdi, Seyhan
   Ozkurt, Sibel
   Semiz, Ender
TI RETRACTED: Effect of obstructive sleep apnea on aortic elastic
   parameters - Relationship to left ventricular mass and function
   (Retracted article. See vol. 74, pg. 2026, 2010)
SO CIRCULATION JOURNAL
LA English
DT Article; Retracted Publication
DE aortic elastic properties; left ventricular function; obstructive sleep
   apnea; stiffness
ID POSITIVE AIRWAY PRESSURE; CORONARY-ARTERY-DISEASE; ASCENDING AORTA;
   DISTENSIBILITY ABNORMALITIES; BLOOD-PRESSURE; HEART-FAILURE;
   HYPERTROPHY; CARDIOMYOPATHY; HYPERTENSION; PERFORMANCE
AB Background Obstructive sleep apnea (OSA) syndrome has a critical association with cardiovascular mortality and morbidity. Aortic elastic parameters are important markers for left ventricular (LV) function and are deteriorated in cardiovascular disease.
   Methods and Results Aortic elastic parameters and LV functions and mass were investigated in 40 patients with OSA (apnea-hypopnea index (AHI) >= 5) (mean age 51.3 +/- 9 years, 32 males) and 24 controls (AHI < 5) (mean age 51.9 +/- 5.2 years, 19 males). All subjects underwent polysomnographic examination and recordings were obtained during sleep. They also underwent a complete echocardiographic examination and systolic and diastolic aortic measurements were noted from M-mode traces of the aortic root. There were no significant differences in the demographic data of the patients with OSA and the controls. Subjects with OSA demonstrated higher values of aortic stiffness (7.1 +/- 1.88 vs 6.42 +/- 1.56, p = 0.0001), but lower distensibility (9.47 +/- 1.33 vs 11.8 +/- 3.36, p=0.0001) than the controls. LV ejection fraction was significantly lower in patients with OSA when compared with the control group (61.3 +/- 5.2% vs 65.9 +/- 8.4%, p=0.0001). LV diastolic parameters were also compared and were worse in the subjects with OSA than in the control subjects (mitral E/A: 0.91 +/- 0.42 vs 1.35 +/- 0.66, p = 0.001; Em/Am: 0.86 +/- 0.54 vs 1.23 +/- 0.59, p=0.021). Respiratory disturbance index had a positive correlation with aortic stiffness (r=0.63, p=0.0001 and negative correlation with distensibility (r=-0.41, p=0.001).
   Conclusion Aortic elastic parameters are deteriorated in OSA, which has an extremely high association with cardiovascular disease. Increased aortic stiffness might be responsible for the LV systolic and diastolic deterioration in OSA syndrome.
C1 Pamukkale Univ, Tip Fak Kalp Merkezi, Sch Med, Dept Cardiol, Kinikli Denizli, Turkey.
   Pamukkale Univ, Sch Med, Dept Otorhinolaryngol, Kinikli Denizli, Turkey.
   Pamukkale Univ, Sch Med, Dept Radiol, Kinikli Denizli, Turkey.
   Pamukkale Univ, Sch Med, Dept Chest Dis, Kinikli Denizli, Turkey.
RP Tanriverdi, H (reprint author), Pamukkale Univ, Tip Fak Kalp Merkezi, Sch Med, Dept Cardiol, Kinikli Denizli, Turkey.
EM drhaliltanriverdi@yahoo.com.tr
CR Alchanatis M, 2000, RESPIRATION, V67, P367, DOI 10.1159/000029532
   Banno K, 2004, CIRC J, V68, P338, DOI 10.1253/circj.68.338
   Chen CH, 1998, J AM COLL CARDIOL, V32, P1221, DOI 10.1016/S0735-1097(98)00374-X
   DAVIES RJO, 1994, CLIN SCI, V86, P417, DOI 10.1042/cs0860417
   DEAN RT, 1993, SLEEP, V16, pS15, DOI 10.1093/sleep/16.suppl_8.S15
   DEVEREUX RB, 1977, CIRCULATION, V55, P613, DOI 10.1161/01.CIR.55.4.613
   DOUGLAS PS, 1987, J AM COLL CARDIOL, V9, P945, DOI 10.1016/S0735-1097(87)80253-X
   Fletcher EC, 1997, RESPIRATION, V64, P22
   Fung JWH, 2002, CHEST, V121, P422, DOI 10.1378/chest.121.2.422
   GREENFIELD JC, 1962, CIRC RES, V10, P778, DOI 10.1161/01.RES.10.5.778
   HANLY P, 1992, CHEST, V102, P100, DOI 10.1378/chest.102.1.100
   HEDNER J, 1990, J HYPERTENS, V8, P941, DOI 10.1097/00004872-199010000-00009
   Jelic S, 2002, SLEEP, V25, P850
   Kato M, 2000, CIRCULATION, V102, P2607
   KELLY RP, 1992, CIRC RES, V71, P490, DOI 10.1161/01.RES.71.3.490
   KOSKENVUO M, 1987, BRIT MED J, V294, P16, DOI 10.1136/bmj.294.6563.16
   KRIEGER J, 1991, CHEST, V100, P917, DOI 10.1378/chest.100.4.917
   Meguro K, 2005, CIRC J, V69, P695, DOI 10.1253/circj.69.695
   Mitchell GF, 2001, HYPERTENSION, V38, P1433, DOI 10.1161/hy1201.098298
   Nichols WW, 1998, MCDONALDS BLOOD FLOW
   Niroumand M, 2001, AM J RESP CRIT CARE, V163, P1632, DOI 10.1164/ajrccm.163.7.2007014
   NODA A, 1995, CHEST, V107, P1538, DOI 10.1378/chest.107.6.1538
   Ohike Y, 2005, CIRC J, V69, P221, DOI 10.1253/circj.69.221
   Peppard PE, 2000, NEW ENGL J MED, V342, P1378, DOI 10.1056/NEJM200005113421901
   Rechtschaffen A, 1968, MANUAL STANDARDIZED, P204
   Schafer H, 1999, CARDIOLOGY, V92, P79, DOI 10.1159/000006952
   Schiller N B, 1989, J Am Soc Echocardiogr, V2, P358
   SHEN WF, 1992, AM HEART J, V124, P1524, DOI 10.1016/0002-8703(92)90067-6
   STEFANADIS C, 1990, EUR HEART J, V11, P990, DOI 10.1093/oxfordjournals.eurheartj.a059639
   STEFANADIS C, 1987, AM J CARDIOL, V59, P1300, DOI 10.1016/0002-9149(87)90908-8
   STRATOS C, 1992, AM J MED, V93, P505, DOI 10.1016/0002-9343(92)90577-X
   TILKIAN AG, 1977, AM J MED, V63, P348, DOI 10.1016/0002-9343(77)90272-8
   URSCHEL CW, 1968, AM J PHYSIOL, V214, P298
   VIROLAINEN J, 1993, AM J CARDIOL, V71, P878, DOI 10.1016/0002-9149(93)90845-4
   WATANABE H, 1993, J AM COLL CARDIOL, V21, P1497, DOI 10.1016/0735-1097(93)90330-4
   WEBER KT, 1991, CIRCULATION, V83, P1849, DOI 10.1161/01.CIR.83.6.1849
   WILCKEN DEL, 1964, CIRC RES, V14, P283, DOI 10.1161/01.RES.14.4.283
NR 37
TC 25
Z9 28
U1 3
U2 15
PU JAPANESE CIRCULATION SOC
PI TOYKO
PA 18TH FLOOR IMPERIAL HOTEL TOWER, 1-1-1 UCHISAIWAI-CHO CHIYODA-KU, TOYKO,
   100-0011, JAPAN
SN 1346-9843
EI 1347-4820
J9 CIRC J
JI Circ. J.
PD JUN
PY 2006
VL 70
IS 6
BP 737
EP 743
DI 10.1253/circj.70.737
PG 7
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 047WK
UT WOS:000237909200016
PM 16723796
OA Bronze
DA 2018-12-27
ER

PT J
AU Bagheri, M
   Abdi-Rad, I
   Omrani, D
   Khalkhali, HR
AF Bagheri, M.
   Abdi-Rad, I.
   Omrani, D.
   Khalkhali, H. R.
TI RETRACTED: Cytokine typing: SNP allele frequencies in the Iranian
   population (Retracted Article. See vol 34, pg 223, 2007)
SO INTERNATIONAL JOURNAL OF IMMUNOGENETICS
LA English
DT Article; Retracted Publication
ID NECROSIS-FACTOR-ALPHA; INTERFERON-GAMMA; POLYMORPHISMS; INTERLEUKIN-10;
   ASSOCIATION; GENES; RISK
AB Single nucleotide polymorphisms within the promoter or other regulatory sequences of cytokine genes were evaluated and compared between an Iranian population and populations of different ethnic/geographical background. In 40 healthy Iranian subjects, cytokine typing was performed by polymerase chain reaction-sequence-specific primers assay. Allele frequencies were calculated and compared with those of other populations.
C1 Uromieh Med Sci Univ, Fac Med, Dept Genet, Uromieh, Iran.
RP Bagheri, M (reprint author), Uromieh Med Sci Univ, Fac Med, Dept Genet, Uromieh, Iran.
EM m_bagheri@umsu.ac.ir
OI Abdi Rad, Isa/0000-0002-3931-669X
CR BAGHERI M, 2005, IRANIAN J IMMUNOLOGY, V2, P43
   Cox ED, 2001, TRANSPLANTATION, V72, P720, DOI 10.1097/00007890-200108270-00027
   Hoffmann SC, 2001, TRANSPLANTATION, V72, P1444, DOI 10.1097/00007890-200110270-00019
   HUMPHRIES SE, 1994, TRENDS CARDIOVAS MED, V4, P8, DOI 10.1016/1050-1738(94)90020-5
   KING RA, 1992, GENETIC BASIS COMMON
   Marshall SE, 2001, TRANSPLANTATION, V71, P469, DOI 10.1097/00007890-200102150-00022
   MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215
   Nieters A, 2001, HUM GENET, V108, P241, DOI 10.1007/s004390100464
   Perrey C, 1998, TRANSPL IMMUNOL, V6, P193, DOI 10.1016/S0966-3274(98)80045-2
   Rebbeck TR, 2004, NAT REV GENET, V5, P589, DOI 10.1038/nrg1403
   Reynard MP, 2000, EUR J IMMUNOGENET, V27, P241, DOI 10.1046/j.1365-2370.2000.00227.x
   SING CF, 1989, INT J EPIDEMIOL, V18, pS183
   UBOLDI MC, 2003, EUROPEAN J IMMUNOGEN, V30, P5
NR 13
TC 4
Z9 4
U1 3
U2 10
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1744-3121
J9 INT J IMMUNOGENET
JI Int. J. Immunogenet.
PD JUN
PY 2006
VL 33
IS 3
BP 193
EP 195
DI 10.1111/j.1744-313X.2006.00595.x
PG 3
WC Genetics & Heredity; Immunology
SC Genetics & Heredity; Immunology
GA 049XU
UT WOS:000238051900009
PM 16712650
DA 2018-12-27
ER

PT J
AU Bhargava, S
AF Bhargava, Santosh
TI RETRACTED: Genetically modified cyanobacterium Nostoc muscorum
   overproducing proline in response to salinity and osmotic stresses
   (Retracted Article. See vol 33, pg 307, 2008)
SO JOURNAL OF BIOSCIENCES
LA English
DT Article; Retracted Publication
DE diazotrophy; L-azetidine-2-carboxylate; mutation; proline accumulation;
   proline oxidase; salinity/osmotic stress
ID BETAINE TRANSPORT-SYSTEM; SALMONELLA-TYPHIMURIUM; WATER-STRESS;
   KLEBSIELLA-PNEUMONIAE; ESCHERICHIA-COLI; GLYCINE BETAINE; WILD-TYPE;
   ACCUMULATION; OSMOREGULATION; ADAPTATION
AB In the parent Nostoc muscorum an active proline oxidase enzyme is required to assimilate exogenous proline as a fixed nitrogen source. Cyanobacterial mutants, resistant to growth inhibitory action of proline analogue L-azetidine2-carboxylate (Ac-R), were deficient in proline oxidase activity, and were over-accumulators of proline. Proline over-accumulation, resulting either from mutational acquisition of the Ac-R phenotype, or from salinity- induced uptake of exogenous proline, confirmed enhanced salinity/osmotic tolerance in the mutant strain. The nitrogenase activity and photosynthetic O-2 evolution of the parent were sensitive to both salinity as well as osmotic stresses than of Ac-R mutant strain. In addition, the mutation to Ac-resistant phenotype showed no alteration in salinity inducible potassium transport system in the cyanobacterium.
C1 Swami Vivekanand Govt Coll, Dept Bot, Raisen 464551, India.
RP Bhargava, S (reprint author), Swami Vivekanand Govt Coll, Dept Bot, Raisen 464551, India.
EM santoshbhargava@hotmail.com
CR Alahari A, 2004, J BIOSCIENCES, V29, P153, DOI 10.1007/BF02703413
   BARTELS D, 1994, PLANT CELL ENVIRON, V17, P659, DOI 10.1111/j.1365-3040.1994.tb00157.x
   Bhargava S, 2003, CURR MICROBIOL, V47, P5, DOI 10.1007/s00284-002-3921-4
   BHASKARAN S, 1985, PLANT PHYSIOL, V79, P266, DOI 10.1104/pp.79.1.266
   BLUMWALD E, 1982, ARCH MICROBIOL, V132, P168, DOI 10.1007/BF00508725
   Borowitzka L. J., 1981, The physiology and biochemistry of drought resistance in plants., P97
   BROWN LM, 1980, J PHYCOL, V16, P265
   CAIRNEY J, 1985, J BACTERIOL, V164, P1218
   CAIRNEY J, 1985, J BACTERIOL, V164, P1224
   CHRISTIAN JHB, 1950, AUST J BIOL SCI, V8, P75
   CSONKA LN, 1991, ANNU REV MICROBIOL, V45, P569, DOI 10.1146/annurev.mi.45.100191.003033
   CSONKA LN, 1989, MICROBIOL REV, V53, P121
   CSONKA LN, 1981, MOL GEN GENET, V182, P82, DOI 10.1007/BF00422771
   DENDINGER S, 1970, J BACTERIOL, V103, P144
   DIX PJ, 1981, Z PFLANZENPHYSIOL, V102, P243, DOI 10.1016/S0044-328X(81)80226-7
   ERDMANN N, 1992, J GEN MICROBIOL, V138, P363, DOI 10.1099/00221287-138-2-363
   GERLOFF GC, 1950, AM J BOT, V37, P216, DOI 10.2307/2437904
   GIAEVER HM, 1988, J BACTERIOL, V170, P2841, DOI 10.1128/jb.170.6.2841-2849.1988
   Gour RK, 1997, J PHOTOCH PHOTOBIO B, V40, P61, DOI 10.1016/S1011-1344(97)00024-9
   HANDA S, 1986, PLANT PHYSIOL, V80, P938, DOI 10.1104/pp.80.4.938
   JAKOWEC MW, 1988, APPL ENVIRON MICROB, V50, P441
   JENNINGS DH, 1990, NEW PHYTOL, V116, P277, DOI 10.1111/j.1469-8137.1990.tb04715.x
   KAPUYA JA, 1985, ACTA BOT NEERL, V34, P293, DOI 10.1111/j.1438-8677.1985.tb01921.x
   LERUDULIER D, 1982, BIOCHIM BIOPHYS ACTA, V719, P273, DOI 10.1016/0304-4165(82)90099-X
   LERUDULIER D, 1983, APPL ENVIRON MICROB, V46, P152
   LOWRY OH, 1951, J BIOL CHEM, V193, P265
   LUCHT JM, 1994, FEMS MICROBIOL REV, V14, P3, DOI 10.1016/0168-6445(94)90008-6
   MACKAY MA, 1984, J GEN MICROBIOL, V130, P2177
   MacKinney G, 1941, J BIOL CHEM, V140, P315
   MAHAN MJ, 1983, J BACTERIOL, V156, P1249
   Roosens NH, 1999, PLANT PHYSIOL, V121, P1281, DOI 10.1104/pp.121.4.1281
   SCHOBERT B, 1978, BIOCHIM BIOPHYS ACTA, V541, P270, DOI 10.1016/0304-4165(78)90400-2
   SINGH AK, 1989, FEMS MICROBIOL LETT, V60, P187, DOI 10.1016/0378-1097(89)90506-5
   Singh AK, 1996, PLANT CELL ENVIRON, V19, P490, DOI 10.1111/j.1365-3040.1996.tb00342.x
   SPENCE DW, 1986, BIOCHEM BIOPH RES CO, V139, P940, DOI 10.1016/S0006-291X(86)80268-6
   SUTHERLAND L, 1986, J BACTERIOL, V168, P805, DOI 10.1128/jb.168.2.805-814.1986
   VOETBERG G, 1984, PLANT PHYSIOL, V76, P567, DOI 10.1104/pp.76.3.567
   WALDERHAUG MO, 1987, ION TRANSPORT PROKAR, P85
   WARR SRC, 1988, PLANT CELL ENVIRON, V11, P137, DOI 10.1111/1365-3040.ep11604910
   YANCEY PH, 1982, SCIENCE, V217, P1214, DOI 10.1126/science.7112124
NR 40
TC 2
Z9 3
U1 2
U2 8
PU INDIAN ACAD SCIENCES
PI BANGALORE
PA C V RAMAN AVENUE, SADASHIVANAGAR, P B #8005, BANGALORE 560 080, INDIA
SN 0250-5991
EI 0973-7138
J9 J BIOSCIENCES
JI J. Biosci.
PD JUN
PY 2006
VL 31
IS 2
BP 265
EP 272
DI 10.1007/BF02703919
PG 8
WC Biology
SC Life Sciences & Biomedicine - Other Topics
GA 051CH
UT WOS:000238137600013
PM 16809859
DA 2018-12-27
ER

PT J
AU Motlekar, NA
   Fasano, A
   Wachtel, MS
   Youan, BBC
AF Motlekar, Nusrat A.
   Fasano, Alessio
   Wachtel, Mitchell S.
   Youan, Bi-Botti C.
TI RETRACTED: Zonula occludens toxin synthetic peptide derivative AT1002
   enhances in vitro and in vivo intestinal absorption of low molecular
   weight heparin (Retracted Article. See vol 16, pg 723, 2008)
SO JOURNAL OF DRUG TARGETING
LA English
DT Article; Retracted Publication
DE AT1002; low molecular weight heparin; enhancer; oral delivery; zonula
   occludens toxin
ID TIGHT JUNCTIONS; ORAL ABSORPTION; DELTA-G; PERMEABILITY; CACO-2;
   RECEPTOR; CELLS; MACROMOLECULES; PERMEATION; MONOLAYERS
AB Zonula occludens toxin (Zot) is an enterotoxin obtained from the bacterium vibrio cholerae that has been shown to reversibly and safely open the tight junctions and enhance paracellular transport. AT1002 is a novel synthetic hexapeptide derived from Zot. The hypothesis to be tested in this study is that AT1002 enhances the oral absorption of ardeparin, a low molecular weight heparin (LMWH). To test this hypothesis, drug transport through Caco-2 cell monolayers was monitored in the presence and absence of AT1002. Regional permeability studies using rat intestine were performed. Cell viability in the presence of various concentrations of enhancer was determined. The absorption of ardeparin after oral administration in rats was measured by anti-factor Xa assay. Furthermore, the eventual mucosal and epithelial damage was histologically evaluated. Higher ardeparin permeability (similar to 2-fold) compared to control was observed in the presence of 0.025% of AT1002. Regional permeability studies revealed that the permeability of ardeparin across the duodenal membrane was improved by the AT1002. Cell viability studies showed no significant cytotoxicity below 0.0028% of AT1002. In the presence of 100 mu g/kg of AT1002, ardeparin oral bioavailability was significantly increased ( F-relative/s.c similar to 20.5%). Furthermore, AT1002 at a dose of 100 mu g/kg did not induce any observable morphological damage on gastrointestinal (GI) tissues in vivo . These in vivo and in vitro results suggest that the co-administration of LMWH with AT1002 may be a useful delivery strategy to increase its permeability and hence oral absorption.
C1 Texas Tech Univ, Hlth Sci Ctr, Sch Pharm, Dept Pharmaceut Sci, Amarillo, TX 79106 USA.
   Univ Maryland, Div Pediat Gastroenterol & Nutr, Dept Pediat, Sch Med, Baltimore, MD 21201 USA.
   Texas Tech Univ, Hlth Sci Ctr, Div Anat Pathol, Dept Pathol, Lubbock, TX 79409 USA.
   Texas Tech Univ, Hlth Sci Ctr, Div Res, Dept Pathol, Lubbock, TX 79409 USA.
RP Youan, BBC (reprint author), Texas Tech Univ, Hlth Sci Ctr, Sch Pharm, Dept Pharmaceut Sci, 1300 Coulter Dr, Amarillo, TX 79106 USA.
EM bibotti.youan@ttuhsc.edu
FU NIGMS NIH HHS [R15 GM069397, GM 069397-01A2]
CR ANDERSON JM, 1995, AM J PHYSL 1, V69, pG467
   ASADA H, 1995, J PHARM SCI-US, V84, P682, DOI 10.1002/jps.2600840604
   Aungst BJ, 2000, J PHARM SCI, V89, P429, DOI 10.1002/(SICI)1520-6017(200004)89:4<429::AID-JPS1>3.0.CO;2-J
   Bernkop-Schnurch A, 1999, PHARMACEUT RES, V16, P876, DOI 10.1023/A:1018830204170
   BIANCHINI P, 1995, HAEMOSTASIS, V25, P288
   Clarke H, 2000, ADV DRUG DELIVER REV, V41, P283, DOI 10.1016/S0169-409X(00)00047-8
   Cox DS, 2002, PHARMACEUT RES, V19, P1680, DOI 10.1023/A:1020709513562
   Cox DS, 2001, EUR J PHARM BIOPHARM, V52, P145, DOI 10.1016/S0939-6411(01)00172-2
   Di Pierro M, 2001, J BIOL CHEM, V276, P19160, DOI 10.1074/jbc.M009674200
   Dodane V, 1999, INT J PHARM, V182, P21, DOI 10.1016/S0378-5173(99)00030-7
   Duizer E, 1998, J PHARMACOL EXP THER, V287, P395
   Fasano A, 2000, LANCET, V355, P1518, DOI 10.1016/S0140-6736(00)02169-3
   Fasano A, 1997, GASTROENTEROLOGY, V112, P839, DOI 10.1053/gast.1997.v112.pm9041245
   Fasano A, 1997, J CLIN INVEST, V99, P1158, DOI 10.1172/JCI119271
   FASANO A, 1995, J CLIN INVEST, V96, P710, DOI 10.1172/JCI118114
   FASANO A, 1991, P NATL ACAD SCI USA, V88, P5242, DOI 10.1073/pnas.88.12.5242
   Hirsh J, 1998, CHEST, V114, p489S, DOI 10.1378/chest.114.5_Supplement.489S
   Karyekar CS, 2003, J PHARM SCI-US, V92, P414, DOI 10.1002/jps.10310
   LEE VHL, 1991, CRIT REV THER DRUG, V8, P91
   Leone-Bay A, 1998, J CONTROL RELEASE, V50, P41, DOI 10.1016/S0168-3659(97)00101-6
   Salama NN, 2004, J PHARM SCI-US, V93, P1310, DOI 10.1002/jps.20052
   Salama NN, 2003, INT J PHARM, V251, P113, DOI 10.1016/S0378-5173(02)00589-6
   Sethia S, 2004, J PHARM SCI-US, V93, P2985, DOI 10.1002/jps.20199
   SWENSON ES, 1994, PHARMACEUT RES, V11, P1132, DOI 10.1023/A:1018984731584
   TEIEN AN, 1976, THROMB RES, V8, P413, DOI 10.1016/0049-3848(76)90034-7
   Thakar M, 2005, GASTROENTEROLOGY, V128, pA541
   Thanou M, 2001, PHARMACEUT RES, V18, P1638, DOI 10.1023/A:1013055120007
   Uzzau S, 2001, FEMS MICROBIOL LETT, V194, P1, DOI 10.1016/S0378-1097(00)00478-X
NR 28
TC 15
Z9 16
U1 4
U2 13
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1061-186X
EI 1029-2330
J9 J DRUG TARGET
JI J. Drug Target.
PD JUN
PY 2006
VL 14
IS 5
BP 321
EP 329
DI 10.1080/10611860600613316
PG 9
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 069NC
UT WOS:000239453400008
PM 16882552
OA Green Accepted
DA 2018-12-27
ER

PT J
AU Fisher, B
   Tas, K
AF Fisher, B
   Tas, K
TI RETRACTED: On the composition of the distributions x(+)(lambda) and
   x(+)(mu) (Retracted article. See vol. 330, pg. 1494 2007)
SO JOURNAL OF MATHEMATICAL ANALYSIS AND APPLICATIONS
LA English
DT Article; Retracted Publication
DE distribution; delta-function; composition of distributions; neutrix;
   neutrix limit
AB Let F be a distribution and let f be a locally summable function. The distribution F(f) is defined as the neutrix limit of the sequence {F-n(f)}, where F-n(x) = F(x) * delta(n)(x) and {delta(n)(x)) is a certain sequence of infinitely differentiable functions converging to the Dirac delta-function delta(x). The distributions (x(+)(mu) )(+)(lambda) are evaluated for lambda < 0, mu > 0 and lambda, lambda mu not equal -1, -2.... (c) 2005 Elsevier Inc. All rights reserved.
C1 Univ Leicester, Dept Math, Leicester LE1 7RH, Leics, England.
   Cankaya Univ, Fac Arts & Sci, Dept Math & Comp Sci, Ankara, Turkey.
RP Fisher, B (reprint author), Univ Leicester, Dept Math, Leicester LE1 7RH, Leics, England.
EM fbr@le.ac.uk; kenan@cankaya.edu.tr
RI Tas, Kenan/D-8441-2011
OI Tas, Kenan/0000-0001-8173-453X
CR Fisher B, 2005, INTEGR TRANSF SPEC F, V16, P13, DOI 10.1080/10652460412331270661
   Fisher B., 1985, ROSTOCK MATH K, V28, P75
   FISHER B, 2003, THAI J MATH, V1, P39
   Fisher B., 1985, U NOVOM SADU ZB RA M, V15, P119
   FISHER B, 2002, NOVI SAD J MATH, V32, P87
   GELFAND IM, 1964, GENERALIZED FUNCTION, V1
   van der Corput J. G, 1959, J ANAL MATH, V7, P291
NR 7
TC 3
Z9 3
U1 3
U2 10
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0022-247X
J9 J MATH ANAL APPL
JI J. Math. Anal. Appl.
PD JUN 1
PY 2006
VL 318
IS 1
BP 102
EP 111
DI 10.1016/j.jmaa.2005.05.022
PG 10
WC Mathematics, Applied; Mathematics
SC Mathematics
GA 027LS
UT WOS:000236417700010
OA Bronze
DA 2018-12-27
ER

PT J
AU Kocak, I
   Ustun, C
AF Kocak, Idris
   Ustun, Cazip
TI RETRACTED: Effects of metformin on insulin resistance, androgen
   concentration, ovulation and pregnancy rates in women with polycystic
   ovary syndrome following laparoscopic ovarian drilling (Retracted
   Article. See vol 36, pg 218, 2010)
SO JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH
LA English
DT Article; Retracted Publication
DE metformin; polycystic ovary syndrome; pregnancy; surgically induced
ID CLOMIPHENE CITRATE; OBESE WOMEN; WEIGHT-LOSS; HYPERANDROGENISM;
   SENSITIVITY; PREVALENCE; RISK
AB To evaluate the effects of metformin on insulin resistance, androgen concentration, ovulation rates and pregnancy rates in infertile women with polycystic ovary syndrome (PCOS).
   Forty-two infertile women with PCOS were selected in this randomized clinical study. Basal steroid and gonadotropin levels were measured, and oral glucose tolerance test (OGTT) was performed. The patients were randomly divided into group 1 (n = 21) and group 2 (n = 21). Group 1 patients were treated with laparoscopic ovarian drilling (LOD). Group 2 patients underwent laparoscopic ovarian drilling (LOD) and received 1700 mg per day of metformin for 6 months. LOD was performed in women with PCOS using a unipolar electrode. Serum progesterone (P) level > 5 ng/mL was considered as a confirmation of ovulation. Ovulation and pregnancy rates were determined after six cycles.
   Serum androgens and insulin response to OGTT decreased significantly after metformin therapy. Mean serum P levels and endometrial thickness were significantly higher in cycles treated with metformin plus LOD (34.6 +/- 25.4 ng/mL, 8.4 +/- 1.1 mm) than in those treated with LOD alone (26.2 +/- 24.7 ng/mL, 7.9 +/- 2.8 mm) (P < 0.05). The ovulation (56 of 65 cycles, 86.1% vs 29 of 65 cycles, 44.6%) and pregnancy rates (nine of 21 women, 47.6% vs four of 21 women, 19.1%) were significantly higher in group 2 than in group I.
   Metformin improves insulin resistance, reduces androgen levels and significantly increases the ovulation and pregnancy rates in infertile women, following LOD.
C1 Ondokuz Mayis Univ, Dept Obstet & Gynecol, Fac Med, Samsun, Turkey.
RP Kocak, I (reprint author), 100 Yil Bul Adalet Mah Caykara,Apt 242, Samsun, Turkey.
EM idriskocak@hotmail.com
CR ANDERSEN P, 1995, METABOLISM, V44, P611, DOI 10.1016/0026-0495(95)90118-3
   CRAVE JC, 2005, J CLIN ENDOCR METAB, V80, P2057
   De Leo V, 2000, J CLIN ENDOCR METAB, V85, P1598, DOI 10.1210/jc.85.4.1598
   Deedwania PC, 1998, AM J MED, V105, p77S
   Diamanti-Kandarakis E, 1998, EUR J ENDOCRINOL, V138, P269, DOI 10.1530/eje.0.1380269
   Dunaif A, 1997, ENDOCR REV, V18, P774, DOI 10.1210/er.18.6.774
   FARQUHAR C, 2001, COCHRANE LIB
   Felemban A, 2000, FERTIL STERIL, V73, P266, DOI 10.1016/S0015-0282(99)00534-8
   FRANKS S, 1985, CLIN OBSTET GYNAECOL, V12, P605
   FRANKS S, 1995, NEW ENGL J MED, V333, P853, DOI 10.1056/NEJM199509283331307
   FUTTERWEIT W, 1994, OBESITY NEW DIRECTIO, P96
   GARCIA J, 1977, FERTIL STERIL, V28, P707
   GJONNAESS H, 1984, FERTIL STERIL, V41, P20
   HOLTE J, 1995, J CLIN ENDOCR METAB, V80, P2586, DOI 10.1210/jc.80.9.2586
   KIDDY DS, 1992, CLIN ENDOCRINOL, V36, P105, DOI 10.1111/j.1365-2265.1992.tb02909.x
   KISTNER RW, 1969, FERTIL STERIL, V20, P35
   Knochenhauer ES, 1998, J CLIN ENDOCR METAB, V83, P3078, DOI 10.1210/jc.83.9.3078
   Kocak M, 2002, FERTIL STERIL, V77, P101, DOI 10.1016/S0015-0282(01)02941-7
   Kolodziejczyk B, 2000, FERTIL STERIL, V73, P1149, DOI 10.1016/S0015-0282(00)00501-X
   KOVACS G, 1991, BRIT J OBSTET GYNAEC, V98, P30, DOI 10.1111/j.1471-0528.1991.tb10307.x
   Legro RS, 1999, J CLIN ENDOCR METAB, V84, P165, DOI 10.1210/jc.84.1.165
   LOBO RA, 1982, OBSTET GYNECOL, V60, P497
   Nestler JE, 1998, NEW ENGL J MED, V338, P1876, DOI 10.1056/NEJM199806253382603
   Nestler JE, 1997, ANDROGEN EXCESS DISORDERS IN WOMEN, P473
   PASQUALI R, 1989, J CLIN ENDOCR METAB, V68, P173, DOI 10.1210/jcem-68-1-173
   Saleh AM, 2004, ACTA OBSTET GYN SCAN, V83, P614, DOI 10.1111/j.0001-6349.2004.00481.x
   Talbott E, 1998, J CLIN EPIDEMIOL, V51, P415, DOI 10.1016/S0895-4356(98)00010-9
   Tan SL, 1996, OBSTET GYNECOL, V88, P221, DOI 10.1016/0029-7844(96)00190-1
   Vandermolen DT, 2001, FERTIL STERIL, V75, P310, DOI 10.1016/S0015-0282(00)01675-7
   YU NEH, 2001, HUM REPROD, V16, P1625
NR 30
TC 19
Z9 20
U1 3
U2 9
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1341-8076
EI 1447-0756
J9 J OBSTET GYNAECOL RE
JI J. Obstet. Gynaecol. Res.
PD JUN
PY 2006
VL 32
IS 3
BP 292
EP 298
DI 10.1111/j.1447-0756.2006.00401.x
PG 7
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA 044TG
UT WOS:000237694700005
PM 16764619
DA 2018-12-27
ER

PT J
AU Munir, K
AF Munir, Khalid
TI RETRACTED: Characterization of Chinook head salmon embryo phenotypes of
   infectious salmon anemia virus by real-time RT-PCR (Retracted Article.
   See vol 7, pg 307, 2006)
SO JOURNAL OF VETERINARY SCIENCE
LA English
DT Article; Retracted Publication
DE CHSE-214 cell line; infectious salmon anemia virus isolates; SYBR Green
   real-time RT-PCR
ID ATLANTIC SALMON; CHSE-214 CELLS; ONCORHYNCHUS-MYKISS; HEMAGGLUTININ
   GENE; TISSUE-SECTIONS; RAINBOW-TROUT; ISA VIRUS; SALAR L.; FISH;
   SUSCEPTIBILITY
AB We have previously described the development of a one-tube SYBR Green real-time RT-PCR assay for the detection and quantitation of infectious salmon anemia virus (ISAV) in various biological samples. The twofold aim of the present study was to verify that the optimized SYBR Green real-time RT-PCR conditions could detect ISAV isolates of different geographic origins, and to analyze the growth patterns of the selected ISAV isolates in the Chinook head salmon embryo (CHSE)-214 cells by pes. this assay to better characterize their CHSE-phenotypes. A total of 24 ISAV isolates were used in this study. The results indicated that the SYBR Green real-time RT-PCR could detect ISAV of different geographic origins or laboratory sources. The capacity of ISAV isolates to cause cytopathic effects (CPE) in the CHSE-214 cell line, viral titration of the infected CHSE-cell harvests, and analysis of viral RNA levels in CHSE-214 cells at post-infection day zero, 7 and 14 by SYBR Green real-time RT-PCR confirmed the existence of three CHSE-phenotypes of ISAV: replicating cytopathic, replicating non-cytopathic, and non-replicating non-cytopathic. The identification of these three CHSE- phenotypes of ISAV has important implications from diagnostic and biological points of view.
C1 Univ Prince Edward Isl, Atlantic Vet Coll, Dept Pathol & Microbiol, Charlottetown, PE C1A 4P3, Canada.
RP Munir, K (reprint author), Univ Prince Edward Isl, Atlantic Vet Coll, Dept Pathol & Microbiol, 550 Univ Ave, Charlottetown, PE C1A 4P3, Canada.
EM kmunir@upei.ca
CR ASPEHAUG VT, 2005, THESIS U BERGEN NORW
   Bouchard D, 1999, DIS AQUAT ORGAN, V35, P131, DOI 10.3354/dao035131
   Clouthier SC, 2002, J GEN VIROL, V83, P421, DOI 10.1099/0022-1317-83-2-421
   DANNEVIG BH, 1995, VET RES, V26, P438
   DEREGT D, 1995, CAN VET J, V36, P371
   Devold M, 2001, DIS AQUAT ORGAN, V47, P119, DOI 10.3354/dao047119
   Devold M, 2000, DIS AQUAT ORGAN, V40, P9, DOI 10.3354/dao040009
   FALK K, 1995, VET RES, V26, P499
   Falk K, 1998, DIS AQUAT ORGAN, V34, P77, DOI 10.3354/dao034077
   Falk K, 1997, J VIROL, V71, P9016
   Grant R, 2003, BULL EUR ASSN FISH P, V23, P80
   Gregory A, 2002, DIS AQUAT ORGAN, V50, P105, DOI 10.3354/dao050105
   Hellebo A, 2004, J VIROL, V78, P3055, DOI 10.1128/JVI.78.6.3055-3062.2004
   Hodneland K, 2006, J VIROL METHODS, V131, P184, DOI 10.1016/j.jviromet.2005.08.012
   Joseph T, 2003, J GEN VIROL, V84, P1701, DOI 10.1099/vir.0.19087-0
   Kibenge F. S. B., 2004, Bulletin of the Aquaculture Association of Canada, V104, P71
   Kibenge Frederick S. B., 2004, Animal Health Research Reviews, V5, P65, DOI 10.1079/AHRR200461
   Kibenge FSB, 2001, J GEN VIROL, V82, P2869, DOI 10.1099/0022-1317-82-12-2869
   Kibenge FSB, 2001, DIS AQUAT ORGAN, V45, P9, DOI 10.3354/dao045009
   Kibenge FSB, 2000, J GEN VIROL, V81, P143, DOI 10.1099/0022-1317-81-1-143
   Kibenge MJT, 2005, VIROL J, V2, DOI 10.1186/1743-422X-2-75
   Kristiansen M, 2002, J GEN VIROL, V83, P2693, DOI 10.1099/0022-1317-83-11-2693
   Krossoy B, 2001, J GEN VIROL, V82, P1757, DOI 10.1099/0022-1317-82-7-1757
   Lovdal T, 2002, DIS AQUAT ORGAN, V49, P123, DOI 10.3354/dao049123
   Mackay IM, 2002, NUCLEIC ACIDS RES, V30, P1292, DOI 10.1093/nar/30.6.1292
   Mikalsen AB, 2001, DIS AQUAT ORGAN, V47, P175, DOI 10.3354/dao047175
   Mjaaland S, 1997, J VIROL, V71, P7681
   Mjaaland S, 2005, ARCH VIROL, V150, P2195, DOI 10.1007/s00705-005-0588-8
   Moneke EE, 2003, J VET DIAGN INVEST, V15, P407, DOI 10.1177/104063870301500502
   Munir K, 2004, J VIROL METHODS, V117, P37, DOI 10.1016/j.jviroment.203.11.020
   Niesters HGM, 2002, J CLIN VIROL, V25, pS3
   Niesters HGM, 2001, METHODS, V25, P419, DOI 10.1006/meth.2001.1264
   Nylund A, 1997, J FISH DIS, V20, P275, DOI 10.1046/j.1365-2761.1997.00300.x
   Nylund A, 2003, DIS AQUAT ORGAN, V56, P11, DOI 10.3354/dao056011
   Nylund A., 1995, Bulletin of the European Association of Fish Pathologists, V15, P152
   Opitz HM, 2000, BULL EUR ASSN FISH P, V20, P12
   Plarre H, 2005, DIS AQUAT ORGAN, V66, P71, DOI 10.3354/dao066071
   Raynard RS, 2001, DIS AQUAT ORGAN, V46, P93, DOI 10.3354/dao046093
   REED L. J., 1938, AMER JOUR HYG, V27, P493
   Ridpath JF, 2003, BIOLOGICALS, V31, P127, DOI 10.1016/S1045-1056(03)00028-9
   Rimstad E, 1999, DIS AQUAT ORGAN, V36, P107, DOI 10.3354/dao036107
   Rimstad E, 2002, APMIS, V110, P273, DOI 10.1034/j.1600-0463.2002.100401.x
   Rodger H.D., 1998, Bulletin of the European Association of Fish Pathologists, V18, P115
   Rolland JB, 2005, J VET DIAGN INVEST, V17, P151, DOI 10.1177/104063870501700209
   Rolland JB, 2003, J FISH DIS, V26, P511, DOI 10.1046/j.1365-2761.2003.00473.x
   Snow M, 2001, AQUACULTURE, V196, P47, DOI 10.1016/S0044-8486(00)00588-3
   Wergeland HI, 2001, DIS AQUAT ORGAN, V44, P183, DOI 10.3354/dao044183
   Wittwer CT, 2001, METHODS, V25, P430, DOI 10.1006/meth.2001.1265
NR 48
TC 2
Z9 2
U1 2
U2 9
PU KOREAN SOC VETERINARY SCIENCE
PI SEOUL
PA SEOUL NATL UNIV,  COLLEGE VETERINARY MEDICINE,, SEOUL, 151-742, SOUTH
   KOREA
SN 1229-845X
EI 1976-555X
J9 J VET SCI
JI J. Vet. Sci.
PD JUN
PY 2006
VL 7
IS 2
BP 167
EP 176
DI 10.4142/jvs.2006.7.2.167
PG 10
WC Veterinary Sciences
SC Veterinary Sciences
GA 054HY
UT WOS:000238368600013
PM 16645343
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Mi, QS
   Deng, ZB
   Joshi, SK
   Wang, ZZ
   Zhou, L
   Eckenrode, S
   Joshi, R
   Ly, D
   Yi, B
   Delovitch, TL
   She, JX
AF Mi, Qing-Sheng
   Deng, Zhong-Bin
   Joshi, Sunil K.
   Wang, Zai-Zhao
   Zhou, Li
   Eckenrode, Sarah
   Joshi, Ratanmani
   Ly, Dalam
   Yi, Bing
   Delovitch, Terry L.
   She, Jin-Xiong
TI RETRACTED: The autoimmune regulator (Aire) controls iNKT cell
   development and maturation (Retracted Article. See vol 12, pg 1100,
   2006)
SO NATURE MEDICINE
LA English
DT Article; Retracted Publication
ID DEFICIENT MICE; NKT CELLS; T-CELLS; TYPE-1; EXPRESSION; TOLERANCE;
   LINEAGE; PROTEIN; THYMUS; MOUSE
AB The mechanism underlying the autoimmune polyglandular syndrome type-1 ( APS1) has been attributed to defective T-cell negative selection resulting from reduced expression and presentation of autoantigens in thymic medullary epithelial cells ( MECs). It has also been postulated that Aire is involved in development of regulatory T cells, although supporting evidence is lacking. Here we show that expression of Aire in MECs is required for development of iNKT cells, suggesting a role for iNKT cells in APS1.
C1 Med Coll Georgia, Ctr Biotechnol & Genom Med, Augusta, GA 30912 USA.
   Med Coll Georgia, Dept Pathol, Augusta, GA 30912 USA.
   Med Coll Georgia, Dept Med, Dermatol Sect, Augusta, GA 30912 USA.
   Univ Western Ontario, Dept Microbiol & Immunol, London, ON N6A 5K8, Canada.
   Univ Western Ontario, Robarts Res Inst, Lab Autoimmune Diabet, London, ON N6A 5K8, Canada.
RP Mi, QS (reprint author), Med Coll Georgia, Ctr Biotechnol & Genom Med, 1120 15th St, Augusta, GA 30912 USA.
EM qmi@mail.mcg.edu; jshe@mail.mcg.edu
OI Ly, Dalam/0000-0002-1177-0225
CR Anderson MS, 2005, IMMUNITY, V23, P227, DOI 10.1016/j.immuni.2005.07.005
   Anderson MS, 2002, SCIENCE, V298, P1395, DOI 10.1126/science.1075958
   Chin RK, 2003, NAT IMMUNOL, V4, P1121, DOI 10.1038/ni982
   Heino M, 2000, EUR J IMMUNOL, V30, P1884, DOI 10.1002/1521-4141(200007)30:7<1884::AID-IMMU1884>3.0.CO;2-P
   Kuroda N, 2005, J IMMUNOL, V174, P1862, DOI 10.4049/jimmunol.174.4.1862
   Liston A, 2003, NAT IMMUNOL, V4, P350, DOI 10.1038/ni906
   Mathis D, 2004, IMMUNITY, V20, P509, DOI 10.1016/S1074-7613(04)00111-6
   Matsuda JL, 2005, CURR OPIN IMMUNOL, V17, P122, DOI 10.1016/j.coi.2005.01.002
   Mi QS, 2004, DIABETES, V53, P1303, DOI 10.2337/diabetes.53.5.1303
   Ramsey C, 2002, HUM MOL GENET, V11, P397, DOI 10.1093/hmg/11.4.397
   Ruan QG, 2004, CLIN LAB MED, V24, P305, DOI 10.1016/j.cll.2004.01.008
   Sivakumar V, 2003, J EXP MED, V197, P1613, DOI 10.1084/jem.2002234
   Wagner MJD, 2005, J IMMUNOL, V174, P6764, DOI 10.4049/jimmunol.174.11.6764
   Wei DG, 2005, J EXP MED, V202, P239, DOI 10.1084/jem.20050413
   Zhou DP, 2004, SCIENCE, V306, P1786, DOI 10.1126/science/1103440
NR 15
TC 5
Z9 6
U1 4
U2 9
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1078-8956
J9 NAT MED
JI Nat. Med.
PD JUN
PY 2006
VL 12
IS 6
BP 624
EP 626
DI 10.1038/nm1424
PG 3
WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research &
   Experimental
SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental
   Medicine
GA 051GI
UT WOS:000238149200022
PM 16732280
DA 2018-12-27
ER

PT J
AU Bagheri, M
   Abdi-Rad, I
   Omrani, D
   Khalkhali, HR
AF Bagheri, M.
   Abdi-Rad, I.
   Omrani, D.
   Khalkhali, H. R.
TI RETRACTED: Heterogeneity of cytokine single-nucleotide polymorphisms
   among the Iranian and in the other East-South Asian populations
   (Retracted Article. See vol 16, pg 439, 2006)
SO TRANSFUSION MEDICINE
LA English
DT Article; Retracted Publication
DE cytokine gene polymorphism; Iran; SNP
ID NECROSIS-FACTOR-ALPHA; GENE POLYMORPHISMS; PROMOTER POLYMORPHISMS;
   RENAL-TRANSPLANTATION; ASSOCIATION; JAPANESE; INTERLEUKIN-10;
   FREQUENCIES; REJECTION; TAIWAN
AB Cytokine gene polymorphisms may affect their transcription, influence their level of production and may be implicated in inducing susceptibility or resistance to diseases. In 40 Iranian healthy subjects, cytokine single-nucleotide polymorphisms ( SNPs) were used to determine allelic and genotypic frequencies for the following cytokine genes: IL-1a (T/C - 889), IL-1 beta (C/T - 511, T/C 3962), IL-12 (C/A - 1188), IFN-gamma (A/T UTR 5644), TGF-beta (C/T codon 10, G/ C codon 25), TNF-a (G/A - 308, G/ A - 238), IL-2 (T/G - 330, G/T 166), IL-4 (T/G - 1089, T/C - 590, T/C - 33), IL-6 (G/C - 174, G/A nt565), IL-10 (G/A - 1082, C/T - 819, C/A - 592), IL-1R (C/T pst11970), IL-1RA (T/C mspa111100) and IL-4RA (G/A 1902). All typing were performed with polymerase chain reaction with sequence specific primers assay. Significant heterogeneity of cytokine SNPs among the Iranian and the other East-South Asian populations was observed. Heterogeneity of cytokine SNPs may explain the role of natural selection in susceptibilities of populations to different disorders.
C1 Uremia Med Sci Univ, Dept Genet, Fac Med, Uremia, Iran.
RP Bagheri, M (reprint author), Uremia Med Sci Univ, Dept Genet, Fac Med, Uremia, Iran.
EM mortaza_bagheri_sa@yahoo.com
RI Abdi Rad, Isa/R-2167-2016
OI Abdi Rad, Isa/0000-0002-3931-669X
CR Amirzargar AA, 2005, INT J IMMUNOGENET, V32, P167, DOI 10.1111/j.1744-313X.2005.00502.x
   Amirzargar AA, 2004, IRAN J IMMUNOL, V1, P125
   BAGHERI M, 2005, IRANIAN J IMMUNOLOGY, V2, P43
   BELLWOOD P, 1991, SCI AM, V265, P88, DOI 10.1038/scientificamerican0791-88
   Bidwell J, 2001, GENES IMMUN, V2, P61, DOI 10.1038/sj.gene.6363733
   Costeas PA, 2003, EUR J IMMUNOGENET, V30, P341, DOI 10.1046/j.1365-2370.2003.00413.x
   Cox ED, 2001, TRANSPLANTATION, V72, P720, DOI 10.1097/00007890-200108270-00027
   de Capei MU, 2003, EUR J IMMUNOGENET, V30, P5
   Dickinson AM, 2002, ARCH IMMUNOL THER EX, V50, P371
   Higuchi T, 1998, TISSUE ANTIGENS, V51, P605, DOI 10.1111/j.1399-0039.1998.tb03002.x
   Hoffmann SC, 2002, AM J TRANSPLANT, V2, P560, DOI 10.1034/j.1600-6143.2002.20611.x
   Hoffmann SC, 2001, TRANSPLANTATION, V72, P1444, DOI 10.1097/00007890-200110270-00019
   Kato S, 2001, J GASTROENTEROL, V36, P696, DOI 10.1007/s005350170033
   Kawaguchi Y, 2003, ARTHRITIS RHEUM, V48, P186, DOI 10.1002/art.10736
   Lin M, 2000, TISSUE ANTIGENS, V55, P1, DOI 10.1034/j.1399-0039.2000.550101.x
   Lin M, 2001, TISSUE ANTIGENS, V57, P192, DOI 10.1034/j.1399-0039.2001.057003192.x
   Loughrey BV, 1998, CYTOKINE, V10, P984, DOI 10.1006/cyto.1998.0388
   LOUIE L, 2002, HLA 2002 IMMUNOBIOLO, V2
   Marshall SE, 2001, TRANSPLANTATION, V71, P469, DOI 10.1097/00007890-200102150-00022
   Meenagh A, 2002, HUM IMMUNOL, V63, P1055, DOI 10.1016/S0198-8859(02)00440-8
   MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215
   Mok CC, 1998, ARTHRITIS RHEUM, V41, P1090, DOI 10.1002/1529-0131(199806)41:6<1090::AID-ART16>3.0.CO;2-6
   NEI M, 1983, J MOL EVOL, V19, P153, DOI 10.1007/BF02300753
   Noguchi E, 1998, CLIN EXP ALLERGY, V28, P449
   Ozaki K, 2002, J BIOL CHEM, V277, P29355, DOI 10.1074/jbc.R200003200
   Park KS, 1997, JPN J HUM GENET, V42, P241, DOI 10.1007/BF02766929
   Perrot LJ, 2001, ADV HEALTH SCI EDUC, V6, P193, DOI 10.1023/A:1012606722230
   Reynard MP, 2000, EUR J IMMUNOGENET, V27, P241, DOI 10.1046/j.1365-2370.2000.00227.x
   ROOK GAW, 1992, IMMUNOL TODAY, V13, P160, DOI 10.1016/0167-5699(92)90119-R
   ROSENWASSER LJ, 1995, CLIN EXP ALLERGY, V25, P74, DOI 10.1111/j.1365-2222.1995.tb00428.x
   Sankaran D, 1999, KIDNEY INT, V56, P281, DOI 10.1046/j.1523-1755.1999.00536.x
   Trejaut JA, 2004, TISSUE ANTIGENS, V64, P492, DOI 10.1111/j.1399.2004.00287.x
   TSANG CH, 1971, PREHISTORY TAIWAN BR
   Yea SS, 2001, J CLIN PATHOL, V54, P703, DOI 10.1136/jcp.54.9.703
NR 34
TC 13
Z9 13
U1 3
U2 7
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0958-7578
EI 1365-3148
J9 TRANSFUSION MED
JI Transfus. Med.
PD JUN
PY 2006
VL 16
IS 3
BP 192
EP 199
DI 10.1111/j.1365-3148.2006.00666.x
PG 8
WC Hematology
SC Hematology
GA 049EQ
UT WOS:000237999100006
PM 16764598
DA 2018-12-27
ER

PT J
AU Kiruluta, AJM
AF Kiruluta, Andrew J. M.
TI RETRACTED: Multidimensional spatial-spectral holographic interpretation
   of NMR photography (Retracted article. See vol. 135, 189901, 2011)
SO JOURNAL OF CHEMICAL PHYSICS
LA English
DT Article; Retracted Publication
ID OPTICAL COHERENT TRANSIENTS; STORAGE; ECHO
AB A spectral holographic interpretation arises naturally in nuclear magnetic resonance (NMR) photography from either the intrinsic chemical shift anisotropy of the spin system or the field inhomogeneity due to the applied spatial encoding gradients. We can thus think of NMR photography as arising from a "diffraction" off a spatial-spectral holographic grating. The spatial holographic component arises from a high dielectric constant (> 50) of the NMR medium at high field strength (> 4 T) when the excitation wavelength is commensurate with the size of the NMR sample; otherwise, it is a volume spectral holographic grating. In this paper, the NMR localized spectroscopy (imaging) equation is derived from the principles of spatial-spectral holography. Holographic properties of storage and programmable time delay and time reversal are shown to follow naturally from this viewpoint and are experimentally demonstrated in an inhomogeneously broadened NMR sample. These ideas are shown to be extendable to complex signal processing functions such as recognition, correlations, and triple products.
C1 Harvard Univ, Dept Phys, Jefferson Phys Labs, Cambridge, MA 02138 USA.
RP Kiruluta, AJM (reprint author), Harvard Univ, Dept Phys, Jefferson Phys Labs, Cambridge, MA 02138 USA.
EM kiruluta@physics.harvard.edu
CR Dey KK, 2004, J MAGN RESON, V171, P359, DOI 10.1016/j.jmr.2004.09.002
   FERNBACH S, 1955, J APPL PHYS, V26, P170, DOI 10.1063/1.1721955
   HAHN EL, 1990, PHILOS R SOC LONDO A, V1632, P401
   HINSHAW WS, 1983, P IEEE, V71, P338, DOI 10.1109/PROC.1983.12592
   Khitrin AK, 2002, CHEM PHYS LETT, V360, P161, DOI 10.1016/S0009-2614(02)00822-9
   Khitrin AK, 2002, J CHEM PHYS, V117, P6903, DOI 10.1063/1.1513310
   KIRULUTA A, 2003, APPL OPTICS, V42, P212
   KORPEL A, 1981, P IEEE, V69, P1539, DOI 10.1109/PROC.1981.12200
   Kriehn G, 2000, APPL OPTICS, V39, P212, DOI 10.1364/AO.39.000212
   KURNIT NA, 1964, PHYS REV LETT, V13, P567, DOI 10.1103/PhysRevLett.13.567
   Levitt M. H, 2001, SPIN DYNAMICS BASICS
   LIANG ZP, 2000, PRINCIPLES MAGNETIC
   Mansfield P., 1982, NMR IMAGING BIOMEDIC
   MITSUNAGA M, 1985, PHYS REV A, V32, P1605, DOI 10.1103/PhysRevA.32.1605
   MOSSBERG TW, 1982, OPT LETT, V7, P77, DOI 10.1364/OL.7.000077
   MOSSBERG TW, 1986, J OPT SOC AM B, V3, P476
   REBANE A, 1983, OPT COMMUN, V47, P173, DOI 10.1016/0030-4018(83)90110-4
   Renn A, 2002, J PHYS CHEM A, V106, P3045, DOI 10.1021/jp0138025
   SCHENZLE A, 1976, PHYS REV A, V14, P1756, DOI 10.1103/PhysRevA.14.1756
   Wehrli FW, 1995, PROG NUCL MAG RES SP, V28, P87, DOI 10.1016/0079-6565(95)01021-1
NR 20
TC 4
Z9 4
U1 3
U2 12
PU AMER INST PHYSICS
PI MELVILLE
PA CIRCULATION & FULFILLMENT DIV, 2 HUNTINGTON QUADRANGLE, STE 1 N O 1,
   MELVILLE, NY 11747-4501 USA
SN 0021-9606
J9 J CHEM PHYS
JI J. Chem. Phys.
PD MAY 21
PY 2006
VL 124
IS 19
AR 194108
DI 10.1063/1.2191045
PG 10
WC Chemistry, Physical; Physics, Atomic, Molecular & Chemical
SC Chemistry; Physics
GA 044OY
UT WOS:000237683200009
PM 16729804
DA 2018-12-27
ER

PT J
AU Liu, ZH
   Feldman, LC
   Tolk, NH
   Zhang, ZY
   Cohen, PI
AF Liu, ZH
   Feldman, LC
   Tolk, NH
   Zhang, ZY
   Cohen, PI
TI RETRACTED: Desorption of H from Si(111) by resonant excitation of the
   Si-H vibrational stretch mode (Retracted article. See vol. 333, pg.
   1824, 2011)
SO SCIENCE
LA English
DT Article; Retracted Publication
ID SCANNING-TUNNELING-MICROSCOPY; LASER-INDUCED DESORPTION; SILICON
   SURFACES; VICINAL SI(111); X 7; HYDROGEN; MECHANISMS; KINETICS; ENERGY;
   STATE
AB Past efforts to achieve selective bond scission by vibrational excitation have been thwarted by energy thermalization. Here we report resonant photodesorption of hydrogen from a Si(111) surface using tunable infrared radiation. The wavelength dependence of the desorption yield peaks at 0.26 electron volt: the energy of the Si-H vibrational stretch mode. The desorption yield is quadratic in the infrared intensity. A strong H/D isotope effect rules out thermal desorption mechanisms, and electronic effects are not applicable in this low-energy regime. A molecular mechanism accounting for the desorption event remains elusive.
C1 Univ Minnesota, Dept Elect & Comp Engn, Minneapolis, MN 55455 USA.
   Vanderbilt Univ, Dept Phys & Astron, Nashville, TN 37235 USA.
   Oak Ridge Natl Lab, Div Mat Sci & Technol, Oak Ridge, TN 37831 USA.
   Univ Tennessee, Dept Phys & Astron, Knoxville, TN 37996 USA.
RP Cohen, PI (reprint author), Univ Minnesota, Dept Elect & Comp Engn, Minneapolis, MN 55455 USA.
EM picohen@umn.edu
CR AVOURIS P, 1989, ANNU REV PHYS CHEM, V40, P173
   Buehler EJ, 2000, SCIENCE, V290, P506, DOI 10.1126/science.290.5491.506
   Chuang T. J., 1983, Surface Science Reports, V3, P1, DOI 10.1016/0167-5729(83)90005-5
   CHUANG TJ, 1981, J CHEM PHYS, V74, P1453, DOI 10.1063/1.441132
   Corcelli SA, 2002, J PHYS CHEM A, V106, P10849, DOI 10.1021/jp0205012
   Durr M, 2002, SCIENCE, V296, P1838, DOI 10.1126/science.1070859
   GORTEL ZW, 1983, PHYS REV B, V28, P2119, DOI 10.1103/PhysRevB.28.2119
   GUPTA P, 1988, PHYS REV B, V37, P8234, DOI 10.1103/PhysRevB.37.8234
   HEIDBERG J, 1982, PHYS REV LETT, V49, P666, DOI 10.1103/PhysRevLett.49.666
   Herring C, 1997, PHYS REV B, V55, P13314, DOI 10.1103/PhysRevB.55.13314
   Hudson LT, 2000, PHYS REV B, V62, P10535, DOI 10.1103/PhysRevB.62.10535
   JAKOB P, 1991, J CHEM PHYS, V95, P2897, DOI 10.1063/1.460892
   KOEHLER BG, 1991, SURF SCI, V248, P158, DOI 10.1016/0039-6028(91)90069-5
   Lyding JW, 1998, APPL SURF SCI, V130, P221, DOI 10.1016/S0169-4332(98)00054-3
   RAGHAVACHARI K, 1993, CHEM PHYS LETT, V206, P156, DOI 10.1016/0009-2614(93)85533-T
   REIDER GA, 1991, PHYS REV LETT, V66, P1994, DOI 10.1103/PhysRevLett.66.1994
   REIDER GA, 1991, J CHEM PHYS, V94, P4080, DOI 10.1063/1.460660
   SHEN TC, 1995, SCIENCE, V268, P1590, DOI 10.1126/science.268.5217.1590
   Vondrak T, 1999, PHYS REV LETT, V82, P1967, DOI 10.1103/PhysRevLett.82.1967
   Williams PA, 1997, PHYS REV LETT, V79, P3459, DOI 10.1103/PhysRevLett.79.3459
   Wu B, 2004, APPL PHYS LETT, V84, P2175, DOI 10.1063/1.1687452
   ZHU XY, 1994, ANNU REV PHYS CHEM, V45, P113, DOI 10.1146/annurev.pc.45.100194.000553
   ZIMMERMANN FM, 1995, SURF SCI REP, V22, P127, DOI 10.1016/0167-5729(96)80001-X
NR 23
TC 65
Z9 65
U1 2
U2 9
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 0036-8075
EI 1095-9203
J9 SCIENCE
JI Science
PD MAY 19
PY 2006
VL 312
IS 5776
BP 1024
EP 1026
DI 10.1126/science.1124529
PG 3
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 043UX
UT WOS:000237628800037
PM 16709778
DA 2018-12-27
ER

PT J
AU Meeran, SM
   Mantena, SK
   Elmets, CA
   Katiyar, SK
AF Meeran, Syed M.
   Mantena, Sudheer K.
   Elmets, Craig A.
   Katiyar, Santosh K.
TI RETRACTED: (-)-Epigallocatechin-3-gallate prevents photocarcinogenesis
   in mice through interieukin-12-dependent DNA repair (Retracted article.
   See vol. 78, pg. 6709, 2018)
SO CANCER RESEARCH
LA English
DT Article; Retracted Publication
ID SKIN-CANCER; GREEN TEA; INDUCED IMMUNOSUPPRESSION; CONTACT
   HYPERSENSITIVITY; ULTRAVIOLET-RADIATION; PYRIMIDINE DIMERS;
   INTERLEUKIN-12; SUPPRESSION; LIPOSOMES; SUNBURN
AB We have shown previously that topical application of epigallocatechin-3-gallate (EGCG), the major polyphenol of green tea, prevents photocarcinogenesis in mice. EGCG prevents UVB-induced immunosuppression by inducing interleukin-12 (IL-12). As immunosuppression is a risk factor for photocarcinogenesis, we investigated the possibility that EGCG also prevents UVB-induced photocarcinogenesis through an IL-12-dependent DNA repair mechanism. To investigate this possibility, we determined the effects of EGCG on photocarcinogenesis in IL-12 knockout (KO) mice using the formation of cyclobutane pyrimidine dimers (CPD) as an indicator of the extent of UVB-induced DNA damage. Topical application of EGCG (1 mg/cm(2) skin) prevented photocarcinogenesis in wild-type (C3H/HeN) mice in terms of tumor incidence and tumor multiplicity but did not prevent photocarcinogenesis in IL-12 KO mice. UVB-induced DNA damage, as determined by the formation of CPDs and the number of sunburn cells, was resolved more rapidly in the skin of wild-type mice treated with EGCG than untreated control mice. In contrast, the extent of UVB-induced DNA damage and the numbers of sunburn cells were not significantly different in the EGCG-treated IL-12 KO mice and untreated control mice. In addition, treatment of XPA-proficient human fibroblast cells with EGCG promoted repair of UVB-induced CPDs in a dose-dependent manner but not in an XPA-deficient cells, indicating that the nucleotide excision repair mechanism is involved in EGCG-mediated DNA repair. Taken together, these results indicate for the first time that EGCG can prevent photocarcinogenesis through an EGCG-induced IL-12-dependent DNA repair mechanism.
C1 Univ Alabama Birmingham, Dept Dermatol, Birmingham, AL 35294 USA.
   Birmingham VA Med Ctr, Birmingham, AL USA.
RP Katiyar, SK (reprint author), Univ Alabama Birmingham, Dept Dermatol, 1670 Univ Blvd,Volker Hall 557,POB 202, Birmingham, AL 35294 USA.
EM skatiyar@uab.edu
FU NIAMS NIH HHS [AR050948-01]; NCRR NIH HHS [C06 RR15490]; NCCIH NIH HHS
   [1 R01 AT002536]
CR APPLEGATE LA, 1989, J EXP MED, V170, P1117, DOI 10.1084/jem.170.4.1117
   BRUNDA MJ, 1993, J EXP MED, V178, P1223, DOI 10.1084/jem.178.4.1223
   CHAPMAN RS, 1995, PHOTOCHEM PHOTOBIOL, V61, P223
   Colombo MP, 1996, CANCER RES, V56, P2531
   DEVRIES A, 1995, NATURE, V377, P169, DOI 10.1038/377169a0
   Duckett CS, 1998, MOL CELL BIOL, V18, P608, DOI 10.1128/MCB.18.1.608
   Fisher GJ, 1996, NATURE, V379, P335, DOI 10.1038/379335a0
   Katiyar SK, 1999, CARCINOGENESIS, V20, P2117, DOI 10.1093/carcin/20.11.2117
   Katiyar SK, 1996, INT J ONCOL, V8, P221
   KATIYAR SK, 1995, PHOTOCHEM PHOTOBIOL, V62, P855
   Katiyar SK, 2000, PHOTOCHEM PHOTOBIOL, V72, P788, DOI 10.1562/0031-8655(2000)072<0788:KOULIC>2.0.CO;2
   KRIPKE ML, 1992, P NATL ACAD SCI USA, V89, P7516, DOI 10.1073/pnas.89.16.7516
   Kulms D, 1999, P NATL ACAD SCI USA, V96, P7974, DOI 10.1073/pnas.96.14.7974
   LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293
   Mantena SK, 2005, J NUTR, V135, P2871
   Markel P, 1997, NAT GENET, V17, P280, DOI 10.1038/ng1197-280
   MEERAN SM, 2006, IN PRESS MOL CANC TH
   MEERAN SM, 2006, IN PRESS CLIN CANC R
   Meunier L, 1998, REV MED INTERNE, V19, P247, DOI 10.1016/S0248-8663(97)89326-5
   Mittal A, 2003, NEOPLASIA, V5, P555, DOI 10.1016/S1476-5586(03)80039-8
   MULLER G, 1995, J IMMUNOL, V155, P4661
   Murphy G, 2001, EXP DERMATOL, V10, P155, DOI 10.1034/j.1600-0625.2001.010003155.x
   NASTALA CL, 1994, J IMMUNOL, V153, P1697
   Schwarz A, 2005, J EXP MED, V201, P173, DOI 10.1084/jem.20041212
   Schwarz A, 2002, NAT CELL BIOL, V4, P26, DOI 10.1038/ncb717
   Schwarz A, 1996, J INVEST DERMATOL, V106, P1187, DOI 10.1111/1523-1747.ep12347944
   SIMON MM, 1995, J CLIN INVEST, V95, P926, DOI 10.1172/JCI117800
   TRINCHIERI G, 1994, BLOOD, V84, P4008
   WANG ZY, 1992, CANCER RES, V52, P1162
   Wigginton JM, 1996, JNCI-J NATL CANCER I, V88, P38, DOI 10.1093/jnci/88.1.38
   WOLF P, 1995, J INVEST DERMATOL, V104, P287, DOI 10.1111/1523-1747.ep12612828
   Yang CS, 2002, ANNU REV PHARMACOL, V42, P25, DOI 10.1146/annurev.pharmtox.42.082101.154309
   YAROSH D, 1994, J INVEST DERMATOL, V103, P461, DOI 10.1111/1523-1747.ep12395551
   YAROSH D, 1992, CANCER RES, V52, P4227
   Yarosh D, 2001, LANCET, V357, P926, DOI 10.1016/S0140-6736(00)04214-8
   YOSHIKAWA T, 1990, J INVEST DERMATOL, V95, P530, DOI 10.1111/1523-1747.ep12504877
   YOUNG AR, 1987, PHOTODERMATOLOGY, V4, P127
   ZIEGLER A, 1994, NATURE, V372, P773, DOI 10.1038/372773a0
NR 38
TC 72
Z9 78
U1 0
U2 6
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD MAY 15
PY 2006
VL 66
IS 10
BP 5512
EP 5520
DI 10.1158/0008-5472.CAN-06-0218
PG 9
WC Oncology
SC Oncology
GA 044NS
UT WOS:000237679900066
PM 16707481
OA Bronze
DA 2018-12-27
ER

PT J
AU Bai, SM
   Ghoshal, K
   Jacob, ST
AF Bai, SM
   Ghoshal, K
   Jacob, ST
TI RETRACTED: Identification of T-cadherin as a novel target of DNA
   methyltransferase 3B and its role in the suppression of nerve growth
   factor-mediated neurite outgrowth in PC12 cells (Retracted article. See
   vol. 293, pg. 3592, 2018)
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article; Retracted Publication
ID HISTONE DEACETYLASE ACTIVITY; H-CADHERIN; BINDING PROTEIN;
   GENE-EXPRESSION; SMOOTH-MUSCLE; PWWP DOMAIN; TRANSCRIPTIONAL REPRESSOR;
   PROMOTER METHYLATION; BREAST-CANCER; CDH13 GENE
AB Previously we showed that DNA methyltransferase 3b (Dnmt3b) is required for nerve growth factor (NGF)- induced differentiation of PC12 cells to neuronal phenotype. The present study identified T-cadherin (T-Cad) as one of the targets of Dnmt3b by chromatin immunoprecipitation (ChIP) assay. Combined bisulfite restriction analysis and bisulfite sequencing showed that T- Cad promoter was sparsely methylated in PC12 cells. ChIP-CHOP analysis demonstrated that Dnmt3b is associated with T-Cad promoter irrespective of its methylation status. The mRNA and protein levels of T-Cad were markedly elevated in cells depleted of Dnmt3b by antisense or small interfering RNA. Suppression of T- Cad promoter activity by Dnmt3b was independent of its catalytic activity, which was consistent with the insignificant change in T-Cad promoter methylation status in Dnmt3b-depleted cells. In contrast, deletion of its N-terminal ATRX and PWWP domain abolished its repressor function. Association of histone deacetylase 2 (Hdac2) with T-Cad promoter and restoration of the promoter activity from Dnmt3b-mediated suppression upon treatment with Hdac inhibitor indicated involvement of histone deacetylation in this process. NGF-induced neurite outgrowth was inhibited in a dose dependent manner upon ectopic expression of T-Cad in PC12 cells. Immunofluorescence studies showed that T-Cad was redistributed upon NGF treatment, as evident from its concentration in axon growth cones as opposed to its localization at cell-cell contact region in undifferentiated cells. These results demonstrate a novel role of T-Cad in the NGF-mediated differentiation of PC12 cells to neuronal phenotype.
C1 Ohio State Univ, Coll Med, Dept Mol & Cellular Biochem, Columbus, OH 43210 USA.
RP Jacob, ST (reprint author), Ohio State Univ, Coll Med, Dept Mol & Cellular Biochem, 333 Hamilton Hall,1645 Neil Ave, Columbus, OH 43210 USA.
EM jacob.42@osu.edu
FU NCI NIH HHS [R01 CA086978-05, R01 CA086978-06A1, CA 86978, R01 CA086978,
   R01 CA086978-03, R01 CA086978-02, R01 CA086978-01A2, R01 CA086978-04];
   NIEHS NIH HHS [R01 ES010874-05, R01 ES010874-02, R01 ES010874-03, ES
   10874, R01 ES010874, R01 ES010874-04, R01 ES010874-01]
CR Aapola U, 2002, NUCLEIC ACIDS RES, V30, P3602, DOI 10.1093/nar/gkf474
   Angst BD, 2001, J CELL SCI, V114, P629
   Bachman KE, 2001, J BIOL CHEM, V276, P32282, DOI 10.1074/jbc.M104661200
   Bai SM, 2005, MOL CELL BIOL, V25, P751, DOI 10.1128/MCB.25.2.751-766.2005
   Baylin SB, 2001, HUM MOL GENET, V10, P687, DOI 10.1093/hmg/10.7.687
   Baylin SB, 1998, ADV CANCER RES, V72, P141
   Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047
   CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2
   Datta J, 2005, CANCER RES, V65, P10891, DOI 10.1158/0008-5472.CAN-05-1455
   Deplus R, 2002, NUCLEIC ACIDS RES, V30, P3831, DOI 10.1093/nar/gkf509
   Esteller M, 2005, J PATHOL, V205, P172, DOI 10.1002/path.1707
   FREDETTE BJ, 1994, J NEUROSCI, V14, P7331
   Fredette BJ, 1996, DEVELOPMENT, V122, P3163
   Fuks F, 2001, EMBO J, V20, P2536, DOI 10.1093/emboj/20.10.2536
   Fuks F, 2000, NAT GENET, V24, P88
   Fuks F, 2003, J BIOL CHEM, V278, P4035, DOI 10.1074/jbc.M210256200
   Ge YZ, 2004, J BIOL CHEM, V279, P25447, DOI 10.1074/jbc.M312296200
   Geiman TM, 2002, J CELL BIOCHEM, V87, P117, DOI 10.1002/jcb.10286
   Ghoshal K, 2002, MOL CELL BIOL, V22, P8302, DOI 10.1128/MCB.22.23.8302-8319.2002
   Ghoshal K, 2004, J BIOL CHEM, V279, P6783, DOI 10.1074/jbc.M309393200
   Ghoshal K, 2002, METHOD ENZYMOL, V353, P476
   Gibbons RJ, 2000, NAT GENET, V24, P368
   Goll MG, 2005, ANNU REV BIOCHEM, V74, P481, DOI 10.1146/annurev.biochem.74.010904.153721
   Herman JG, 2000, CURR TOP MICROBIOL, V249, P35
   Hermann A, 2004, CELL MOL LIFE SCI, V61, P2571, DOI 10.1007/s00018-004-4201-1
   Hibi K, 2004, BRIT J CANCER, V90, P1030, DOI 10.1038/sj.bjc.6601647
   Hibi K, 2004, BRIT J CANCER, V91, P1139, DOI 10.1038/sj.bjc.6602095
   Hug C, 2004, P NATL ACAD SCI USA, V101, P10308, DOI 10.1073/pnas.0403382101
   Ivanov D, 2004, CARDIOVASC RES, V64, P132, DOI 10.1016/j.cardiores.2004.06.010
   Kuzmenko YS, 1998, FEBS LETT, V434, P183, DOI 10.1016/S0014-5793(98)00977-6
   Lee SW, 1996, NAT MED, V2, P776, DOI 10.1038/nm0796-776
   LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F
   Majumder S, 2002, J BIOL CHEM, V277, P16048, DOI 10.1074/jbc.M111662200
   Marin-Vicente C, 2005, MOL BIOL CELL, V16, P2848, DOI 10.1091/mbc.E05-01-0067
   Motiwala T, 2003, ONCOGENE, V22, P6319, DOI 10.1038/sj.onc.1206750
   Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6
   Ooms LM, 2006, MOL BIOL CELL, V17, P607, DOI 10.1091/mbc.E05-05-0469
   Philippova MP, 1998, FEBS LETT, V429, P207, DOI 10.1016/S0014-5793(98)00598-5
   Qiu C, 2002, NAT STRUCT BIOL, V9, P217, DOI 10.1038/nsb759
   RANSCHT B, 1991, DEVELOPMENT, V111, P15
   Reddy CVG, 2004, BBA-BIOMEMBRANES, V1667, P15, DOI 10.1016/j.bbamem.2004.08.011
   Robertson KD, 2000, CARCINOGENESIS, V21, P461, DOI 10.1093/carcin/21.3.461
   Rountree MR, 2000, NAT GENET, V25, P269, DOI 10.1038/77023
   Sato M, 1998, HUM GENET, V103, P96, DOI 10.1007/s004390050790
   Shimazu K, 2005, J CELL PHYSIOL, V203, P501, DOI 10.1002/jcp.20309
   Shirohzu H, 2002, AM J MED GENET, V112, P31, DOI 10.1002/ajmg.10658
   Stec I, 2000, FEBS LETT, V473, P1, DOI 10.1016/S0014-5793(00)01449-6
   Takeuchi T, 2000, HISTOPATHOLOGY, V37, P193, DOI 10.1046/j.1365-2559.2000.00985-5.x
   Takeuchi T, 1999, HISTOPATHOLOGY, V35, P87
   Takeuchi T, 2000, J NEUROCHEM, V74, P1489, DOI 10.1046/j.1471-4159.2000.0741489.x
   Takeuchi T, 2002, MOL CARCINOGEN, V35, P173, DOI 10.1002/mc.10088
   Takeuchi T, 2002, LAB INVEST, V82, P1023, DOI 10.1097/01.LAB.0000025391.35798.F1
   Takeuchi T, 2001, HISTOL HISTOPATHOL, V16, P1287, DOI 10.14670/HH-16.1287
   Tkachuk VA, 1998, FEBS LETT, V421, P208, DOI 10.1016/S0014-5793(97)01562-7
   Weinstein LS, 2001, BIOL PSYCHIAT, V50, P927, DOI 10.1016/S0006-3223(01)01295-1
   Widschwendter A, 2004, INT J CANCER, V109, P163, DOI 10.1002/ijc.11706
NR 56
TC 30
Z9 31
U1 0
U2 3
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD MAY 12
PY 2006
VL 281
IS 19
BP 13604
EP 13611
DI 10.1074/jbc.M513278200
PG 8
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 039VV
UT WOS:000237336600070
PM 16537533
OA Green Accepted, Bronze, Green Published
DA 2018-12-27
ER

PT J
AU Doglio, LE
   Kanwar, R
   Jackson, GR
   Perez, M
   Avila, J
   Dingwal, C
   Dotti, CG
   Fortini, ME
   Feiguin, F
AF Doglio, Laura E.
   Kanwar, Ritu
   Jackson, George R.
   Perez, Mar
   Avila, Jesus
   Dingwal, Colin
   Dotti, Carlos G.
   Fortini, Mark E.
   Feiguin, Fabian
TI RETRACTED: gamma-cleavage-independent functions of presenilin,
   nicastrin, and aph-1 regulate cell-junction organization and prevent tau
   toxicity in vivo (Retracted article. See vol. 53, pg. 463, 2007)
SO NEURON
LA English
DT Article; Retracted Publication
ID FAMILIAL ALZHEIMERS-DISEASE; GLYCOGEN-SYNTHASE KINASE-3; TRANSGENIC
   MICE; NEUROFIBRILLARY TANGLES; AMYLOID HYPOTHESIS; WILD-TYPE; A-BETA;
   DROSOPHILA; NEURODEGENERATION; MUTATIONS
AB Genetic analysis of familial Alzheimer's disease has revealed that mutations in the gamma-secretase enzyme presenilin promote toxic A beta secretion; however, presenilin mutations might also influence tau hyperphosphorylation and neurodegeneration through gamma-secretase-independent mechanisms. To address this possibility and determine whether other components of the gamma-secretase complex possess similar regulatory functions, we analyzed the roles of presenilin, nicastrin, and aph-1 in a Drosophila model for tau-induced neurodegeneration. Here, we show that presenilin and nicastrin prevent tau toxicity by modulating the PI3K/Akt/GSK3 beta phosphorylation pathway, whereas aph-1 regulates aPKC/PAR-1 activities. Moreover, we found that these transmembrane proteins differentially regulate the intracellular localization of GSK3 beta and aPKC at cell junctions. Inhibition of gamma-secretase activity neither interfered with these kinase pathways nor induced aberrant tau phosphorylation. These results establish new in vivo molecular functions for the three components of the gamma-secretase complex and reveal a different mechanism that might contribute to neuronal degeneration in Alzheimer's disease.
C1 NCI, Canc Res Ctr, Frederick, MD 21702 USA.
   Univ Turin, Cavalieri Ottolenghi Sci Inst, I-10043 Turin, Italy.
   Flanders Interuniv Inst Biotechnol VIB, B-3000 Louvain, Belgium.
   Catholic Univ Louvain, Dept Human Genet, B-3000 Louvain, Belgium.
   Univ Calif Los Angeles, Dept Neurol, Neurogenet Program, David Geffen Sch Med, Los Angeles, CA 90095 USA.
   Univ Autonoma Madrid, Ctr Biol Mol Severo Ochoa, Madrid 28049, Spain.
   GlaxoSmithKline, Neurol & GI CEDD, Harlow CM19 5AW, Essex, England.
RP Fortini, ME (reprint author), NCI, Canc Res Ctr, Frederick, MD 21702 USA.
EM carlos.dotti@med.kuleuven.be; fortini@ncifcrf.gov;
   fabian.feiguin@unito.it
RI Dotti, Carlos/I-5533-2015
OI Dotti, Carlos/0000-0003-4052-1719
FU NINDS NIH HHS [NS046489]; NIA NIH HHS [AG016570]; Intramural NIH HHS
CR Baki L, 2004, EMBO J, V23, P2586, DOI 10.1038/sj.emboj.7600251
   Baumeister R, 1997, Genes Funct, V1, P149
   Bilen J, 2005, ANNU REV GENET, V39, P153, DOI 10.1146/annurev.genet.39.110304.095804
   Chung HM, 2001, NAT CELL BIOL, V3, P1129, DOI 10.1038/ncb1201-1129
   Davis JA, 1998, NEURON, V20, P603, DOI 10.1016/S0896-6273(00)80998-8
   De Strooper B, 2003, NEURON, V38, P9, DOI 10.1016/S0896-6273(03)00205-8
   Dermaut B, 2004, ANN NEUROL, V55, P617, DOI 10.1002/ana.20083
   Feng RB, 2004, P NATL ACAD SCI USA, V101, P8162, DOI 10.1073/pnas.0402733101
   Gotz J, 2001, SCIENCE, V293, P1491, DOI 10.1126/science.1062097
   Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994
   Hashimoto Y, 2004, J NEUROSCI RES, V75, P417, DOI 10.1002/jnr.10861
   Hernandez F, 2003, NEUROBIOL AGING, V24, P1087, DOI 10.1016/j.neurobiolaging.2003.04.002
   Hu Y, 2003, J CELL BIOL, V161, P685, DOI 10.1083/jcb.200304014
   Hu Y, 2002, DEV CELL, V2, P69, DOI 10.1016/S1534-5807(01)00105-8
   Hurov JB, 2004, CURR BIOL, V14, P736, DOI 10.1016/j.cub.2004.04.007
   Jackson GR, 2002, NEURON, V34, P509, DOI 10.1016/S0896-6273(02)00706-7
   Jackson GR, 1998, NEURON, V21, P633, DOI 10.1016/S0896-6273(00)80573-5
   Koo EH, 2004, NAT MED, V10, pS26, DOI 10.1038/nm1065
   Lee VMY, 2001, ANNU REV NEUROSCI, V24, P1121, DOI 10.1146/annurev.neuro.24.1.1121
   Levitan D, 1996, P NATL ACAD SCI USA, V93, P14940, DOI 10.1073/pnas.93.25.14940
   Lewis J, 2001, SCIENCE, V293, P1487, DOI 10.1126/science.1058189
   Lopez-Schier H, 2002, DEV CELL, V2, P79, DOI 10.1016/S1534-5807(01)00109-5
   LOVESTONE S, 1994, CURR BIOL, V4, P1077, DOI 10.1016/S0960-9822(00)00246-3
   Lucas JJ, 2001, EMBO J, V20, P27, DOI 10.1093/emboj/20.1.27
   LUO LQ, 1990, J NEUROSCI, V10, P3849
   Marjaux E, 2004, NEURON, V42, P189, DOI 10.1016/S0896-6273(04)00218-1
   Matsubayashi H, 2004, MOL CELL BIOL, V24, P2012, DOI 10.1128/MCB.24.5.2012-2024.2004
   Menendez M, 2004, J ALZHEIMERS DIS, V6, P475
   Micchelli CA, 2002, FASEB J, V16, P79, DOI 10.1096/fj.02-0394fje
   Newsome TP, 2000, DEVELOPMENT, V127, P851
   Nishimura I, 2004, CELL, V116, P671, DOI 10.1016/S0092-8674(04)00170-9
   Nusse R, 1997, CELL, V89, P321, DOI 10.1016/S0092-8674(00)80210-X
   Oddo S, 2003, NEURON, V39, P409, DOI 10.1016/S0896-6273(03)00434-3
   Oddo S, 2004, NEURON, V43, P321, DOI 10.1016/j.neuron.2004.07.003
   Pigino G, 2001, J NEUROSCI, V21, P834
   Price DL, 1998, ANNU REV GENET, V32, P461, DOI 10.1146/annurev.genet.32.1.461
   Price DL, 1998, ANNU REV NEUROSCI, V21, P479, DOI 10.1146/annurev.neuro.21.1.479
   Qian S, 1998, NEURON, V20, P611, DOI 10.1016/S0896-6273(00)80999-X
   Rapoport M, 2002, P NATL ACAD SCI USA, V99, P6364, DOI 10.1073/pnas.092136199
   Saura CA, 2004, NEURON, V42, P23, DOI 10.1016/S0896-6273(04)00182-5
   Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864
   SEUBERT P, 1995, J BIOL CHEM, V270, P18917, DOI 10.1074/jbc.270.32.18917
   SIEGFRIED E, 1992, CELL, V71, P1167, DOI 10.1016/S0092-8674(05)80065-0
   St George-Hyslop PH, 2005, CR BIOL, V328, P119, DOI 10.1016/j.crvi.2004.10.013
   Struhl G, 2000, MOL CELL, V6, P625, DOI 10.1016/S1097-2765(00)00061-7
   Tanzi RE, 2001, NEURON, V32, P181, DOI 10.1016/S0896-6273(01)00476-7
   Tanzi RE, 2005, CELL, V120, P545, DOI 10.1016/j.cell.2005.02.008
   Tysoe C, 1998, AM J HUM GENET, V62, P70, DOI 10.1086/301672
   Wittmann CW, 2001, SCIENCE, V293, P711, DOI 10.1126/science.1062382
   Ye YH, 1999, J CELL BIOL, V146, P1351, DOI 10.1083/jcb.146.6.1351
   Ye YH, 1999, NATURE, V398, P525, DOI 10.1038/19096
   ZIPURSKY SL, 1984, CELL, V36, P15, DOI 10.1016/0092-8674(84)90069-2
   Zoghbi HY, 2002, TRENDS GENET, V18, P463, DOI 10.1016/S0168-9525(02)02729-4
NR 53
TC 20
Z9 20
U1 3
U2 10
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 0896-6273
EI 1097-4199
J9 NEURON
JI Neuron
PD MAY 4
PY 2006
VL 50
IS 3
BP 359
EP 375
DI 10.1016/j.neuron.2006.03.038
PG 17
WC Neurosciences
SC Neurosciences & Neurology
GA 045FA
UT WOS:000237726800007
PM 16675392
OA Bronze
DA 2018-12-27
ER

PT J
AU Ahimastos, AA
   Lawler, A
   Reid, CM
   Blombery, PA
   Kingwell, BA
AF Ahimastos, AA
   Lawler, A
   Reid, CM
   Blombery, PA
   Kingwell, BA
TI RETRACTED: Brief communication: Ramipril markedly improves walking
   ability in patients with peripheral arterial disease - A randomized
   trial (Retracted article)
SO ANNALS OF INTERNAL MEDICINE
LA English
DT Article; Retracted Publication
ID CONVERTING ENZYME-INHIBITION; INTERMITTENT CLAUDICATION; BLOOD-FLOW;
   HYPERTENSION; MULTICENTER; CAPTOPRIL; THERAPY
AB Background: Peripheral arterial disease (PAD) affects up to 12% of adults older than 50 years of age. Conventional therapies have only modest effects in improving symptoms.
   Objective: To examine the effects of angiotensin-converting enzyme inhibition on walking ability in patients with PAD.
   Design: Randomized, double-blind, placebo-controlled trial initiated in March 2003 and completed in January 2005.
   Setting: The Alfred Hospital, Melbourne, Australia.
   Participants: 40 older adults with symptomatic PAD and no history of diabetes or hypertension. Intervention: 10 mg of ramipril (n = 20) or placebo (n = 20) once daily for 24 weeks. All patients completed the trial.
   Measurements: Pain-free and maximum walking time were recorded during a standard treadmill test, and the standard Walking Impairment Questionnaire was administered.
   Results: After adjustment for the baseline pain-free walking time, mean pain-free walking time after ramipril treatment was 227 seconds (95% Cl, 175 seconds to 278 seconds; P < 0.001) longer than that after placebo treatment. Similarly, maximum walking time improved by 451 seconds in the ramipril group (CI, 367 seconds to 536 seconds; P < 0.001) but did not change in the placebo group. Ramipril improved the Walking Impairment Questionnaire median distance score from 5% (range, 1% to 39%) to 21% (range, 12% to 58%; P < 0.001), speed score from 3% (range, 3% to 39%) to 18% (range, 8% to 50%; P < 0.001), and stair-climbing score from 17% (range, 4% to 80%) to 67% (range, 38% to 88%; P < 0.001). No adverse events were reported.
   Limitations: The sample size is modest and the strict inclusion criteria limit the applicability of the results to patients with claudication and infrainguinall disease and those without diabetes.
   Conclusion: Ramipril improved pain-free and maximum walking time in some adults with symptomatic PAD.
C1 Alfred Hosp, Baker Heart Res Inst, Melbourne, Vic 8008, Australia.
   Monash Univ, Melbourne, Vic 3004, Australia.
RP Kingwell, BA (reprint author), Baker Heart Res Inst, Alfred & Baker Med Unit, POB 6492,St Kilda Rd Cent, Melbourne, Vic 8008, Australia.
EM b.kingwell@alfred.org.au
OI Reid, Christopher/0000-0001-9173-3944
CR Beebe HG, 1999, ARCH INTERN MED, V159, P2041, DOI 10.1001/archinte.159.17.2041
   BERNARDI D, 1988, ANGIOLOGY, V39, P942, DOI 10.1177/000331978803901103
   BREWSTER DC, 2000, DIREST RECONSTRUCTIO
   Dawson DL, 2000, AM J MED, V109, P523, DOI 10.1016/S0002-9343(00)00569-6
   Fabre JE, 1999, CIRCULATION, V99, P3043, DOI 10.1161/01.CIR.99.23.3043
   GARDNER AW, 1995, JAMA-J AM MED ASSOC, V274, P975, DOI 10.1001/jama.274.12.975
   HIATT WR, 1995, CIRCULATION, V92, P614, DOI 10.1161/01.CIR.92.3.614
   Higashi Y, 2000, J AM COLL CARDIOL, V35, P284, DOI 10.1016/S0735-1097(99)00561-6
   Mancini GBJ, 1996, CIRCULATION, V94, P258, DOI 10.1161/01.CIR.94.3.258
   Nehler MR, 1999, ANN VASC SURG, V13, P109, DOI 10.1007/s100169900228
   Newman AB, 2000, J AM GERIATR SOC, V48, P1157
   O'Keefe JH, 2001, J AM COLL CARDIOL, V37, P1, DOI 10.1016/S0735-1097(00)01044-5
   Regensteiner JG, 1990, J VASC MED BIOL, V2, P142
   ROBERTS DH, 1992, ANGIOLOGY, V43, P748, DOI 10.1177/000331979204300905
   Silvestre JS, 2001, CIRC RES, V89, P678, DOI 10.1161/hh2001.097691
   SONECHA TN, 1990, INT ANGIOL, V9, P22
   SUMNER DS, 1969, SURGERY, V65, P763
   VANDEVEN LLM, 1994, VASA-J VASCULAR DIS, V23, P357
   Yusuf S, 2000, NEW ENGL J MED, V342, P145
NR 19
TC 64
Z9 67
U1 4
U2 12
PU AMER COLL PHYSICIANS
PI PHILADELPHIA
PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA
SN 0003-4819
EI 1539-3704
J9 ANN INTERN MED
JI Ann. Intern. Med.
PD MAY 2
PY 2006
VL 144
IS 9
BP 660
EP 664
DI 10.7326/0003-4819-144-9-200605020-00009
PG 5
WC Medicine, General & Internal
SC General & Internal Medicine
GA 039GJ
UT WOS:000237293700005
PM 16670135
OA Bronze
DA 2018-12-27
ER

PT J
AU Li, YG
   Chen, HJ
AF Li, YG
   Chen, HJ
TI RETRACTED: Bis(2-formylphenolato-kappa O-2,O ')nickel(II) (Retracted
   article. See vol. 66, pg. E21, 2010)
SO ACTA CRYSTALLOGRAPHICA SECTION E-STRUCTURE REPORTS ONLINE
LA English
DT Article; Retracted Publication
ID CRYSTAL-STRUCTURE
AB The title compound, [Ni(C7H5O2)(2)], exhibits a mononuclear structure in which the central Ni-II atom is located on an inversion centre and is coordinated by four O atoms from two salicylaldehyde ligands in a distorted square-planar geometry. The complex was obtained by the reaction of salicylaldehyde and nickel(II) nitrate hexahydrate in ethanol, using 3-amino-1,2-propanediol as a growth-directing reagent.
C1 Jinan Univ, Dept Mat Sci & Engn, Guangzhou 510632, Peoples R China.
RP Chen, HJ (reprint author), Jinan Univ, Dept Mat Sci & Engn, Guangzhou 510632, Peoples R China.
EM thjchen@jnu.edu.cn
CR BRUKER, 1998, SHELXTL PLUS VERS 5
   Gupta T., 1999, POLYHEDRON, V18, P197
   KOPFMANN G, 1968, ACTA CRYSTALL A-CRYS, VA 24, P348, DOI 10.1107/S0567739468000690
   Sheldrick G. M., 1997, SHELXS97 SHELXL97
   SIEMENS, 1990, XSCANS USERS MANUAL
   STEWART JM, 1961, ACTA CRYSTALLOGR, V14, P888, DOI 10.1107/S0365110X61002540
   Wu SZ, 2003, J MOL CATAL A-CHEM, V198, P29, DOI 10.1016/S1381-1169(02)00697-0
NR 7
TC 7
Z9 7
U1 5
U2 10
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1600-5368
J9 ACTA CRYSTALLOGR E
JI Acta Crystallogr. Sect. E.-Struct Rep. Online
PD MAY
PY 2006
VL 62
BP M1038
EP M1039
DI 10.1107/S1600536806012391
PN 5
PG 2
WC Crystallography
SC Crystallography
GA 038QE
UT WOS:000237237000046
DA 2018-12-27
ER

PT J
AU Li, YW
   Kucuk, O
   Hussain, M
   Abrams, J
   Cher, ML
   Sarkar, FH
AF Li, Yiwei
   Kucuk, Omer
   Hussain, Maha
   Abrams, Judith
   Cher, Michael L.
   Sarkar, Fazlul H.
TI RETRACTED: Antitumor and antimetastatic activities of docetaxel are
   enhanced by genistein through regulation of osteoprotegerin/receptor
   activator of nuclear factor-kappa B (RANK)/RANK ligand/MMP-9 signaling
   in prostate cancer (Retracted article. See vol. 78, pg. 5475, 2018)
SO CANCER RESEARCH
LA English
DT Article; Retracted Publication
ID OSTEOCLAST DIFFERENTIATION; GENE-EXPRESSION; BONE METASTASIS;
   DOWN-REGULATION; IN-VITRO; CELLS; APOPTOSIS; INHIBITION; ANGIOGENESIS;
   MICROARRAY
AB Bone metastasis is very common in advanced prostate cancer. Docetaxel has been shown to improve survival in patients with metastatic prostate cancer. However, treatment with docetaxel is associated with a certain degree of toxicity. Genistein, derived from soybeans, has been found to inhibit cancer cell growth without toxicity. We have recently reported that genistein could potentiated the antitumor activity of chemotherapeutic agents both in vitro and in vivo. However, the molecular mechanism of this novel effect of genistein has not been fully elucidated. In this study, we found that genistein significantly potentiated the antitumor, anti-invasive, and antimetastatic activities of docetaxel both in culture and in severe combined immunodeficient (SCID)-human model of experimental prostate cancer bone metastasis. We further conducted microarray analysis, real-time reverse transcription-PCR, Western blot analysis, small interfering RNA and cDNA transfection, matrix metalloproteinase-9 (MMP-9) activity assay, and invasion assay. We found that the expression of osteoprotegerin (OPG) was induced by genistein and inhibited by docetaxel, whereas genistein significantly down-regulated the expression and secretion of receptor activator of nuclear factor-kappa B (RANK) ligand (RANKL) and inhibited osteoclast formation. Moreover, genistein down-regulated the expression and activity of MMP-9, which was induced by docetaxel treatment, and inhibited invasion of PC-3 cells. These results suggest that the observed potentiation of antitumor activity of docetaxel by genistein in the SCID-human model of experimental bone metastasis could be mediated by regulation of OPG/RANK/RANKL/MMP-9 signaling, resulting in the inhibition of osteoclastic bone resorption and prostate cancer bone metastasis. From these results, we conclude that genistein could be a promising nontoxic agent to improve the treatment outcome of metastatic prostate cancer with docetaxel.
C1 Wayne State Univ, Sch Med, Dept Pathol, Barbara Ann Karmanos Canc Inst, Detroit, MI 48201 USA.
   Wayne State Univ, Sch Med, Dept Urol, Barbara Ann Karmanos Canc Inst, Detroit, MI 48201 USA.
   Wayne State Univ, Sch Med, Dept Internal Med, Barbara Ann Karmanos Canc Inst, Detroit, MI 48201 USA.
   Univ Michigan, Dept Internal Med, Div Hematol Oncol, Ann Arbor, MI 48109 USA.
RP Sarkar, FH (reprint author), Wayne State Univ, Sch Med, Dept Pathol, Barbara Ann Karmanos Canc Inst, 740 Hudson Webber Canc Res Ctr,110 E Warren, Detroit, MI 48201 USA.
EM fsarkar@med.wayne.edu
FU NCI NIH HHS [5R01CA083695, 5R01CA101870]; NIDDK NIH HHS [5R01DK067687]
CR ADLERCREUTZ CHT, 1995, J NUTR, V125, pS757, DOI 10.1093/jn/125.3_Suppl.757S
   Banerjee S, 2005, CANCER RES, V65, P9064, DOI 10.1158/0008-5472.CAN-05-1330
   BARNES S, 1995, J NUTR, V125, pS777, DOI 10.1093/jn/125.3_Suppl.777S
   Beer Tomasz M, 2003, Expert Rev Anticancer Ther, V3, P261, DOI 10.1586/14737140.3.3.261
   Bubendorf L, 2000, HUM PATHOL, V31, P578, DOI 10.1053/hp.2000.6698
   Crisafulli A, 2004, J CLIN ENDOCR METAB, V89, P188, DOI 10.1210/jc.2003-030891
   Curran S, 2000, EUR J CANCER, V36, P1621, DOI 10.1016/S0959-8049(00)00156-8
   Davis JN, 1999, NUTR CANCER, V35, P167, DOI 10.1207/S15327914NC352_11
   Davis JN, 1998, NUTR CANCER, V32, P123, DOI 10.1080/01635589809514730
   Dong Z, 2005, AM J PATHOL, V166, P1173, DOI 10.1016/S0002-9440(10)62337-1
   Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863
   Goltzman D, 2001, J CLIN INVEST, V107, P1219, DOI 10.1172/JCI13073
   Hofbauer LC, 2004, JAMA-J AM MED ASSOC, V292, P490, DOI 10.1001/jama.292.4.490
   Hong WK, 2002, ONCOLOGY-NY, V16, P9
   Hsu HL, 1999, P NATL ACAD SCI USA, V96, P3540, DOI 10.1073/pnas.96.7.3540
   John Anitha, 2001, Pathology and Oncology Research, V7, P14
   Kantoff P, 2005, ONCOLOGY-NY, V19, P631
   Khatri P, 2002, GENOMICS, V79, P266, DOI 10.1006/geno.2002.6698
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092-8674(00)81569-X
   Li YW, 2005, CANCER RES, V65, P6934, DOI 10.1158/0008-5472.CAN-04-4604
   Li YW, 1999, ONCOGENE, V18, P3166, DOI 10.1038/sj.onc.1202650
   Li YW, 2004, NEOPLASIA, V6, P354, DOI 10.1593/neo.03478
   Li YW, 2004, NEOPLASIA, V6, P158, DOI 10.1593/neo.03391
   Li YW, 2002, J NUTR, V132, P3623
   Li YW, 2002, CLIN CANCER RES, V8, P2369
   Li YW, 2002, CANCER LETT, V186, P157, DOI 10.1016/S0304-3835(02)00349-X
   Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867
   Nemeth JA, 1999, CANCER RES, V59, P1987
   Palacios VG, 2005, J BIOL CHEM, V280, P13720, DOI 10.1074/jbc.M410995200
   Rubin MA, 2000, CLIN CANCER RES, V6, P1038
   Santibanez JF, 1997, ANTICANCER RES, V17, P1199
   Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092-8674(00)80209-3
   Tannock IF, 2004, NEW ENGL J MED, V351, P1502, DOI 10.1056/NEJMoa040720
   Theoleyre S, 2004, CYTOKINE GROWTH F R, V15, P457, DOI 10.1016/j.cytogfr.2004.06.004
   Voronov I, 2005, BIOCHEM PHARMACOL, V70, P300, DOI 10.1016/j.bcp.2005.04.028
   Wittrant Y, 2004, BBA-REV CANCER, V1704, P49, DOI 10.1016/j.bbcan.2004.05.002
   Wittrant Y, 2003, BIOCHEM BIOPH RES CO, V310, P774, DOI 10.1016/j.bbrc.2003.09.084
   Yonou H, 2003, CANCER RES, V63, P2096
   Zhou JR, 1999, J NUTR, V129, P1628
NR 39
TC 85
Z9 90
U1 1
U2 6
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD MAY 1
PY 2006
VL 66
IS 9
BP 4816
EP 4825
DI 10.1158/0008-5472.CAN-05-3752
PG 10
WC Oncology
SC Oncology
GA 041ZS
UT WOS:000237496900036
PM 16651437
OA Bronze
DA 2018-12-27
ER

PT J
AU Nabhan, AFI
AF Nabhan, AFI
TI RETRACTED: A randomized clinical trial of the effects of isosorbide
   mononitrate on bone formation and resorption in post-menopausal women: a
   pilot study (Retracted Article. See vol 21, pg 2466, 2006)
SO HUMAN REPRODUCTION
LA English
DT Article; Retracted Publication
DE bone turnover; isosorbide mononitrate; nitric oxide; post-menopausal
   osteoporosis; randomized trial
ID ESTROGEN REPLACEMENT THERAPY; NITRIC-OXIDE SYNTHASE; NONVERTEBRAL
   FRACTURES; STRONTIUM RANELATE; INDUCED OSTEOPENIA; OSTEOPOROSIS;
   NITROGLYCERIN; RELEASE; DENSITY; MARKERS
AB BACKGROUND: Nitric oxide (NO) stimulates bone formation and inhibits bone resorption in vitro. NO donors (nitrates) are inexpensive and widely available, but their value for post-menopausal osteoporosis has never been evaluated in a randomized trial. The objective of this study was to compare the effects of 5 and 20 mg of isosorbide mononitrate (ISMO) on markers of bone turnover in post-menopausal women. METHODS: A prospective randomized trial was carried out in the Department of Obstetrics & Gynecology, Ain Shams University, Egypt. The study included 50 healthy post-menopausal women with a hip bone mineral density T score between 0 and -2.5. Participants were randomly assigned to 5 or 20 mg/day of ISMO for 12 weeks. Urine N-telopeptide (NTx), a marker of bone resorption, and serum bone-specific alkaline phosphatase (BSALP), a marker of bone formation, were measured. Markers were measured immediately before randomization and after 12 weeks of treatment. The percent change in NTx and BSALP for each of the treatment groups (5 mg ISMO and 20 mg ISMO) was calculated. The main outcome measures were serum NTx and BSALP in the 5 and 20 mg ISMO groups after 12 weeks of treatment. RESULTS: Women adhering to 20 mg of ISMO had a 42.03% (95% confidence interval (CI), 20.1-73.7) reduction in NTx and a 29.05% (95% CI, 10.8-48.4) increase in BSALP, and women adhering to 5 mg of ISMO had a 31.12% (95% CI, 8.3-68.2) reduction in NTx and a 28.4% (95% CI, 4.6-52.1) increase in BSALP. CONCLUSION: ISMO, as a NO donor, may be useful for the prevention of post-menopausal osteoporosis.
C1 Ain Shams Univ, Dept Obstet & Gynecol, Cairo 11351, Egypt.
RP Nabhan, AFI (reprint author), Ain Shams Univ, Dept Obstet & Gynecol, 16 Ali Fahmi Kamel St, Cairo 11351, Egypt.
EM ashraf.nabhan@gmail.com
CR Chow J W, 2000, Exerc Sport Sci Rev, V28, P185
   Cicinelli E, 1999, AM J OBSTET GYNECOL, V180, P334, DOI 10.1016/S0002-9378(99)70209-7
   Clowes JA, 2000, BEST PRACT RES CL EN, V14, P213, DOI 10.1053/beem.2000.0070
   Csont T, 2005, PHARMACOL THERAPEUT, V105, P57, DOI 10.1016/j.pharmthera.2004.10.001
   Garnero P., 2004, Journal of Musculoskeletal & Neuronal Interactions, V4, P50
   Greenblatt D, 2005, PHARMACOTHERAPY, V25, P574, DOI 10.1592/phco.25.4.574.61031
   Hannon Rosemary A, 2003, J Br Menopause Soc, V9, P10, DOI 10.1258/136218003100322080
   HAO YJ, 2005, CLIN ORTHOP RELAT R, V435, P226
   Hochberg MC, 2002, J CLIN ENDOCR METAB, V87, P1586, DOI 10.1210/jc.87.4.1586
   Hukkanen M, 2003, BONE, V32, P142, DOI 10.1016/S8756-3282(02)00955-9
   Jung JY, 2003, J CELL BIOCHEM, V89, P613, DOI 10.1002/jcb.10527
   Kalinowski L, 2001, J ENDOCRINOL, V170, P433, DOI 10.1677/joe.0.1700433
   Looker AC, 2000, OSTEOPOROSIS INT, V11, P467, DOI 10.1007/s001980070088
   Marquis P., 2001, Annales de Cardiologie et d'Angeiologie, V50, P340, DOI 10.1016/S0003-3928(01)00034-8
   Meunier PJ, 2002, J CLIN ENDOCR METAB, V87, P2060, DOI 10.1210/jc.87.5.2060
   *OST INT, 2002, OST NTX UR PROD DESC, P1
   Piccinini F, 2000, GYNECOL ENDOCRINOL, V14, P142, DOI 10.3109/09513590009167673
   *QUID CORP, 2002, METR BAP EIA KIT, P1
   Reginster JY, 2005, J CLIN ENDOCR METAB, V90, P2816, DOI 10.1210/jc.2004-1774
   Selby Peter, 2004, Curr Osteoporos Rep, V2, P101, DOI 10.1007/s11914-004-0018-y
   Simoncini T, 2000, J CLIN ENDOCR METAB, V85, P2966, DOI 10.1210/jc.85.8.2966
   Thatcher GRJ, 2004, FREE RADICAL BIO MED, V37, P1122, DOI 10.1016/j.freeradbiomed.2004.06.013
   Wimalawansa SJ, 2000, CALCIFIED TISSUE INT, V66, P56, DOI 10.1007/s002230050011
   Wimalawansa SJ, 2000, J BONE MINER RES, V15, P2240, DOI 10.1359/jbmr.2000.15.11.2240
NR 24
TC 6
Z9 6
U1 2
U2 7
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0268-1161
EI 1460-2350
J9 HUM REPROD
JI Hum. Reprod.
PD MAY
PY 2006
VL 21
IS 5
BP 1320
EP 1324
DI 10.1093/humrep/dei487
PG 5
WC Obstetrics & Gynecology; Reproductive Biology
SC Obstetrics & Gynecology; Reproductive Biology
GA 033AP
UT WOS:000236818600036
PM 16410328
OA Bronze
DA 2018-12-27
ER

PT J
AU Samarth, RM
   Panwar, M
   Kumar, M
   Kumar, A
AF Samarth, Ravindra M.
   Panwar, Meenakshi
   Kumar, Madhu
   Kumar, Ashok
TI RETRACTED: Radioprotective influence of Mentha piperita (Linn) against
   gamma irradiation in mice: Antioxidant and radical scavenging activity
   (Retracted Article. See vol 83, pg 897, 2007)
SO INTERNATIONAL JOURNAL OF RADIATION BIOLOGY
LA English
DT Article; Retracted Publication
DE Mentha piperita; Swiss albino mice; radical scavenging activity;
   radioprotection; antioxidant enzymes
ID GLUTATHIONE; FLAVONOIDS; CELLS
AB Purpose: To evaluate the radiomodulatory influence of a leaf extract of Mentha piperita (Linn) on hepatic antioxidant status and lipid peroxidation in Swiss albino mice.
   Materials and methods: Animals were given either double distilled water or leaf extract of M. piperita orally (1 g/kg bwt/day) once a day for three consecutive days. Thirty min after the last treatment mice were exposed to 8 Gy of gamma radiation. Mice were autopsied at 30 min post-irradiation. Biochemical parameters were studied to assess the radioprotective effect of leaf extract of M. piperita.
   Results: Animals pretreated with leaf extract of M. piperita and exposed to 8.0 Gy gamma radiation showed a significant increase in the activities of reduced glutathione content (p < 0.001), glutathione peroxidase (p < 0.005), glutathione reductase (p < 0.001), glutathione S-transferase (p < 0.005), superoxide dismutase (p < 0.005), and catalase (p < 0.005). Irradiated group pretreated with leaf extract of M. piperita showed significant decrease in malondialdehyde (MDA) formation in liver. The leaf extract of M. piperita showed strong radical scavenging activity in both the 1, 1 diphenyl-2-picryl hydrazyl radical (DPPH center dot) and 2, 2 azinobis (3-ethylbenzothiazoline-6-sulfonic acid) radical cation (ABTS(center dot+)) assays.
   Conclusions: The results of the present investigation suggest the antioxidant and free radical scavenging activities of leaf extract of M. piperita are the likely mechanism of radiation protection.
C1 Univ Rajasthan, Dept Zool, Radiat & Canc Biol Lab, Jaipur 302004, Rajasthan, India.
RP Samarth, RM (reprint author), Univ Rajasthan, Dept Zool, Radiat & Canc Biol Lab, Jaipur 302004, Rajasthan, India.
EM rmsamarth@yahoo.co.in
CR Aebi H., 1984, METHODS ENZYMOLOGY, V105
   BIAGLOW JE, 1987, ANTICARCINOGENESIS R
   BUMP EA, 1990, PHARMACOL THERAPEUT, V47, P117, DOI 10.1016/0163-7258(90)90048-7
   CARLBERG I, 1985, METHODS ENZYMOLOGY, V113
   Cuendet M, 1997, HELV CHIM ACTA, V80, P1144, DOI 10.1002/hlca.19970800411
   DeLeve LD, 1996, HEPATOLOGY, V23, P589
   Devi PU, 2000, RADIAT RES, V154, P455, DOI 10.1667/0033-7587(2000)154[0455:RPBTOF]2.0.CO;2
   Dorman HJD, 2003, J AGR FOOD CHEM, V51, P4563, DOI 10.1021/jf034108k
   Gracy RW, 1999, MUTAT RES-FUND MOL M, V428, P17, DOI 10.1016/S1383-5742(99)00027-7
   HABIG WH, 1974, J BIOL CHEM, V249, P7130
   HBALL EJ, 1978, RADIOBIOLOGY RADIOLO
   HERTOG MGL, 1995, ARCH INTERN MED, V155, P381, DOI 10.1001/archinte.155.4.381
   LOWRY OH, 1951, J BIOL CHEM, V193, P265
   MARKLUND S, 1974, EUR J BIOCHEM, V47, P469
   Mimica-Dukic N, 2003, PLANTA MED, V69, P413, DOI 10.1055/s-2003-39704
   MORON MS, 1979, BIOCHIM BIOPHYS ACTA, V582, P67, DOI 10.1016/0304-4165(79)90289-7
   Nair CKK, 2001, J RADIAT RES, V42, P21, DOI 10.1269/jrr.42.21
   Niki E., 1997, FOOD FACTORS CANC PR, P55
   OHKAWA H, 1979, ANAL BIOCHEM, V95, P351, DOI 10.1016/0003-2697(79)90738-3
   PAGLIA DE, 1967, J LAB CLIN MED, V70, P158
   RALEIGH JA, 1987, PROSTAGLANDIN LIPID
   Rastogi R. P., 1991, COMPENDIUM INDIAN ME, VIII
   Re R, 1999, FREE RADICAL BIO MED, V26, P1231, DOI 10.1016/S0891-5849(98)00315-3
   Romero-Jimenez M, 2005, MUTAT RES-GEN TOX EN, V585, P147, DOI 10.1016/j.mrgentox.2005.05.004
   Samarth R. M., 2002, Indian Journal of Experimental Biology, V40, P1245
   Samarth R. M., 2003, Indian Journal of Experimental Biology, V41, P229
   Samarth RM, 2003, J RADIAT RES, V44, P101, DOI 10.1269/jrr.44.101
   Samman MA, 1998, CARCINOGENESIS, V19, P1795, DOI 10.1093/carcin/19.10.1795
   Shimoi K, 1996, MUTAT RES-FUND MOL M, V350, P153, DOI 10.1016/0027-5107(95)00116-6
   VOKOVICGACIC B, 1993, BASIC LIFE SCI, V61, P269
   WEISS JF, 2000, RAD MOL BIOL, V899, P44
   WEISS JF, 1988, CELLULAR ANTIOXIDANT, V2, P163
   Yu TW, 2004, ENVIRON MOL MUTAGEN, V44, P387, DOI 10.1002/em.20063
NR 33
TC 11
Z9 13
U1 3
U2 10
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0955-3002
EI 1362-3095
J9 INT J RADIAT BIOL
JI Int. J. Radiat. Biol.
PD MAY
PY 2006
VL 82
IS 5
BP 331
EP 337
DI 10.1080/09553000600771523
PG 7
WC Biology; Nuclear Science & Technology; Radiology, Nuclear Medicine &
   Medical Imaging
SC Life Sciences & Biomedicine - Other Topics; Nuclear Science &
   Technology; Radiology, Nuclear Medicine & Medical Imaging
GA 065FV
UT WOS:000239146000003
PM 16782650
DA 2018-12-27
ER

PT J
AU Kenett, RS
AF Kenett, RS
TI RETRACTED: On the planning and design of sample surveys (Retracted
   article. See vol. 38, pg. 2681, 2011)
SO JOURNAL OF APPLIED STATISTICS
LA English
DT Article; Retracted Publication
DE questionnaire design; cognitive science; individual surveys; household
   surveys; establishment surveys; control charts analysis of survey data
ID INFORMATIVE FUNCTIONS; RATING-SCALES; QUESTION; LOGIC
AB Surveys rely on structured questions used to map out reality, using sample observations from a population frame, into data that can be statistically analyzed. This paper focuses on the planning and design of surveys, making a distinction between individual surveys, household surveys and establishment surveys. Knowledge from cognitive science is used to provide guidelines on questionnaire design. Non-standard, but simple, statistical methods are described for analyzing survey results. The paper is based on experience gained by conducting over 150 customer satisfaction surveys in Europe, America and the Far East.
C1 Univ Toronto, Turin, Italy.
   KPA Ltd, Raanana, Israel.
RP Kenett, RS (reprint author), Univ Toronto, Turin, Italy.
EM ron@kpa.co.il
OI Kenett, Ron/0000-0003-2315-0477
CR ANDERSON R, 1980, COGNITIVE PSYCHOL IT
   BLESS H, 1993, EUR J SOC PSYCHOL, V23, P149, DOI 10.1002/ejsp.2420230204
   Clark HH, 1992, QUESTIONS QUESTIONS, P15
   CLARK HH, 1977, PSYCHOL LANGUAGE
   FORSYTH B, 1999, P ANN M AM STAT ASS
   FUCHS C, 1980, J AM STAT ASSOC, V75, P395, DOI 10.2307/2287465
   Grice H. P., 1975, SYNTAX SEMANTICS, V3, P41, DOI DOI 10.1017/S0022226700005296
   KAPLAN O, 2003, P 3 ANN C EUR NETW B
   KENETT R, 1997, P 8 ANN C ISR HUM RE
   KENETT R, 1998, SURVEYS SOME GOOD SO
   KENETT R, 2002, DEINDE 2002 TOR IT
   KENETT R, 2003, P 3 ANN C EUR NETW B
   KENETT R, 2003, RES SPEAK MARKET RES
   Kenett R. S., 1998, MODERN IND STAT DESI
   KENETT RS, 1991, J QUAL TECHNOL, V23, P27
   Presser Stanley, 1981, QUESTIONS ANSWERS AT
   SCHWARZ N, 1991, PUBLIC OPIN QUART, V55, P570, DOI 10.1086/269282
   SCHWARZ N, 1988, SOC COGNITION, V6, P107, DOI 10.1521/soco.1988.6.2.107
   SCHWARZ N, 1991, PUBLIC OPIN QUART, V55, P3, DOI 10.1086/269239
   Schwarz N, 1998, INT J PUBLIC OPIN R, V10, P177
   Schwarz N., 1992, Z KLINISCHE PSYCHOL, V22, P197
   Strack F., 1987, SOCIAL INFORMATION P, P123
   Tourangeau R, 1984, COGNITIVE ASPECTS SU, P73
   Winkielman P, 1998, J PERS SOC PSYCHOL, V75, P719, DOI 10.1037/0022-3514.75.3.719
NR 24
TC 6
Z9 6
U1 3
U2 11
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0266-4763
EI 1360-0532
J9 J APPL STAT
JI J. Appl. Stat.
PD MAY
PY 2006
VL 33
IS 4
BP 405
EP 415
DI 10.1080/02664760500448974
PG 11
WC Statistics & Probability
SC Mathematics
GA 038LK
UT WOS:000237221300004
DA 2018-12-27
ER

PT J
AU Shang, E
   Weiss, C
   Post, S
   Kaehler, G
AF Shang, Edward
   Weiss, Christel
   Post, Stefan
   Kaehler, Georg
TI RETRACTED: The influence of early supplementation of parenteral
   nutrition on quality of life and body composition in patients with
   advanced cancer (Retracted article. See vol. 36, pg. 485, 2012)
SO JOURNAL OF PARENTERAL AND ENTERAL NUTRITION
LA English
DT Article; Retracted Publication
ID WEIGHT-LOSS; EUROPEAN-ORGANIZATION; PROTEIN-METABOLISM;
   PANCREATIC-CANCER; CACHEXIA; QUESTIONNAIRE; CHEMOTHERAPY; THERAPY;
   SUPPORT; RECOMMENDATIONS
AB Background: According to current evidence, most organizations, including the American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.), do not recommend the routine use of artificial nutrition for patients with cancer. Despite the recommendation for parenteral nutrition (PN), data for early PN supplementation (PNS) in patients with an advanced malignancy are extremely limited, especially in terms of the affects on nutrition outcomes, body composition, and quality of life (QOL), as well as effects on oncologic outcomes. The aim of the study was to evaluate the effect of PNS on body composition and the quality of life in patients with advanced malignancies. Methods: One hundred fifty-two consecutive patients with advanced cancer were prospectively randomized to either use of oral enteral nutrition supplement (PN-) or use of oral enteral nutrition supplement plus supplemental PN (PN+). Body weight, body mass index (BMI), and caloric intake were assessed, and hemoglobin (g/dL) and serum albumin (g/L) were measured. Body composition was assessed by body impedance analysis (BIA), and QOL was evaluated by European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30 questionnaire every 6 weeks. Results: No significant differences were evident at baseline between the 2 groups for age, gender, medical diagnosis, weight, BMI, or QOL. A statistically significant difference in mean BMI was observed by week 48 for the PN + group (PN + = 21.9, PN - 20.5, p =.0 149), by week 6 in mean body cell mass (PN+ 55%, PN- = 50,1%, P <.001), mean albumin (PN+ = 40.2 g/L, PN- = 36.2 g/L, p =.015), mean QOL (PN+ = 55.7, PN- = 50.9, p =.035). The cumulative survival rate was significantly greater in the PN+ group (p <.0001). Conclusions: According to the positive effect of supplemental PN on survival, body composition, and QOL, additional controlled studies must be conducted to confirm these findings.
C1 Univ Hosp Manheim, Dept Surg, D-68135 Mannheim, Germany.
   Univ Hosp Manheim, Dept Biostat, D-68135 Mannheim, Germany.
RP Shang, E (reprint author), Univ Hosp Manheim, Dept Surg, Theodor Kutzer Ufer 1-3, D-68135 Mannheim, Germany.
EM edward.shang@urz.uni-heidelberg.de
CR AARONSON NK, 1993, J NATL CANCER I, V85, P365, DOI 10.1093/jnci/85.5.365
   Agteresch HJ, 2002, J CLIN ONCOL, V20, P371, DOI 10.1200/JCO.20.2.371
   *ASPEN BOARD DIR C, 2002, JPEN J PARENTER ENTE, V26, P144
   *ASPEN BOARD DIR C, 2002, JPEN J PARENTER ENTE, V26, pA15
   Bachmann P, 2001, B CANCER, V88, P985
   Barber MD, 1999, SURG ONCOL, V8, P133, DOI 10.1016/S0960-7404(99)00045-6
   BODY JJ, 1987, EUR J CANCER CLIN ON, V23, P127, DOI 10.1016/0277-5379(87)90005-8
   Bozzetti F, 2003, CLIN NUTR, V22, P109, DOI 10.1054/clnu.2002.0629
   Bozzetti F, 2000, TUMORI, V86, P470
   BRENNAN MF, 1981, NEW ENGL J MED, V305, P375, DOI 10.1056/NEJM198108133050705
   Charuhas PM, 1997, JPEN-PARENTER ENTER, V21, P157, DOI 10.1177/0148607197021003157
   COPELAND EM, 1986, JPEN J PARENTER ENTE, V39, P105
   COSTA G, 1979, NEW ENGL J MED, V300, P1471, DOI 10.1056/NEJM197906283002606
   DEWYS WD, 1980, AM J MED, V69, P491, DOI 10.1016/S0149-2918(05)80001-3
   FAN ST, 1994, NEW ENGL J MED, V331, P1547, DOI 10.1056/NEJM199412083312303
   FISCHER JE, 1984, SURGERY, V96, P578
   Giacosa A, 1996, NUTRITION, V12, pS20
   GOUTTEBEL MC, 1987, JPEN-PARENTER ENTER, V11, P475, DOI 10.1177/0148607187011005475
   GROSVENOR M, 1989, CANCER, V63, P330, DOI 10.1002/1097-0142(19890115)63:2<330::AID-CNCR2820630221>3.0.CO;2-U
   HAGMULLER E, 1995, CANCER RES, V55, P1160
   HEBER D, 1985, CANCER, V55, P225, DOI 10.1002/1097-0142(19850101)55:1+<225::AID-CNCR2820551304>3.0.CO;2-7
   HJERMSTAD MJ, 1995, J CLIN ONCOL, V13, P1249, DOI 10.1200/JCO.1995.13.5.1249
   HOLLAND JCB, 1977, CANCER RES, V37, P2425
   HOLROYDE CP, 1984, CANCER RES, V44, P5910
   Jatoi A, 2002, J CLIN ONCOL, V20, P567, DOI 10.1200/JCO.20.2.567
   JEEVANANDAM M, 1984, LANCET, V1, P1423
   Jehn U, 2002, DEUT MED WOCHENSCHR, V127, P2682, DOI 10.1055/s-2002-36120
   Kaasa S, 1995, EUR J CANCER, V31A, P2260, DOI 10.1016/0959-8049(95)00296-0
   KERN KA, 1988, JPEN-PARENTER ENTER, V12, P286, DOI 10.1177/0148607188012003286
   Khan ZH, 2003, ALIMENT PHARM THERAP, V17, P677, DOI 10.1046/j.0269-2813.2003.01457.x
   KORETZ RL, 1984, J CLIN ONCOL, V2, P534, DOI 10.1200/JCO.1984.2.5.534
   Lindholm E, 2004, CLIN CANCER RES, V10, P6855, DOI 10.1158/1078-0432.CCR-04-0373
   LUNDHOLM K, 1982, CANCER-AM CANCER SOC, V50, P1142, DOI 10.1002/1097-0142(19820915)50:6<1142::AID-CNCR2820500618>3.0.CO;2-I
   MCANENA OJ, 1986, SURG CLIN N AM, V66, P1213
   McMillan DC, 2000, CLIN NUTR, V19, P403, DOI 10.1054/clnu.2000.0136
   MCNAMARA MJ, 1992, JPEN-PARENTER ENTER, V16, pS50, DOI 10.1177/014860719201600603
   MULLER JM, 1986, INFUSIONSTHERAPIE, V13, P126
   Nelson K A, 1993, J Palliat Care, V9, P27
   NIEZGODA HE, 1993, QUAL LIFE RES, V2, P319, DOI 10.1007/BF00449426
   Nitenberg G, 2000, CRIT REV ONCOL HEMAT, V34, P137, DOI 10.1016/S1040-8428(00)00048-2
   PEREZ SC, 1999, NUTR HOSP S2, V14, pS43
   PISTERS PWT, 1993, CRIT REV CL LAB SCI, V30, P223, DOI 10.3109/10408369309084669
   RINGDAL GI, 1993, QUAL LIFE RES, V2, P129, DOI 10.1007/BF00435732
   Ripamonti C, 2001, SUPPORT CARE CANCER, V9, P223, DOI 10.1007/s005200000198
   Ross PJ, 2004, BRIT J CANCER, V90, P1905, DOI 10.1038/sj.bjc.6601781
   Sarhill N, 2003, SUPPORT CARE CANCER, V11, P652, DOI 10.1007/s00520-003-0486-0
   SHAMBERGER RC, 1984, SURGERY, V96, P1
   SOLASSOL C, 1978, BEITRAGE INFUSIONSTH, P178
   SOUBA WW, 1989, CA-CANCER J CLIN, V39, P105, DOI 10.3322/canjclin.39.2.105
   Tashiro T, 1996, NUTRITION, V12, P763, DOI 10.1016/S0899-9007(96)00214-6
   Wigmore SJ, 1997, BRIT J CANCER, V75, P106, DOI 10.1038/bjc.1997.17
   Wigmore SJ, 2000, NUTR CANCER, V36, P177, DOI 10.1207/S15327914NC3602_6
NR 52
TC 63
Z9 63
U1 4
U2 16
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0148-6071
EI 1941-2444
J9 JPEN-PARENTER ENTER
JI J. Parenter. Enter. Nutr.
PD MAY-JUN
PY 2006
VL 30
IS 3
BP 222
EP 230
DI 10.1177/0148607106030003222
PG 9
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA 195WW
UT WOS:000248444000007
PM 16639069
DA 2018-12-27
ER

PT J
AU Peng, T
   Kotla, S
   Bumgarner, RE
   Gustin, KE
AF Peng, Tao
   Kotla, Swathi
   Bumgarner, Roger E.
   Gustin, Kurt E.
TI RETRACTED: Human rhinovirus attenuates the type I interferon response by
   disrupting activation of interferon regulatory factor 3 (Retracted
   Article. See vol 81, pg 6161, 2007)
SO JOURNAL OF VIROLOGY
LA English
DT Article; Retracted Publication
ID NF-KAPPA-B; RESPIRATORY SYNCYTIAL VIRUS; DOUBLE-STRANDED-RNA; BRONCHIAL
   EPITHELIAL-CELLS; CREB-BINDING PROTEIN/P300; INNATE IMMUNE-RESPONSE;
   VIRAL-DIARRHEA-VIRUS; TRANSCRIPTIONAL ACTIVITY; ALPHA/BETA INTERFERON;
   NSS COUNTERACTS
AB The type I interferon (IFN) response requires the coordinated activation of the latent transcription factors NF-kappa B, interferon regulatory factor 3 (IRF-3), and ATF-2, which in turn activate transcription from the IFN-beta promoter. Synthesis and subsequent secretion of IFN-beta activate the Jak/STAT signaling pathway, resulting in the transcriptional induction of the full spectrum of antiviral gene products. We utilized high-density microarrays to examine the transcriptional response to rhinovirus type 14 (RV14) infection in HeLa cells, with particular emphasis on the type I interferon response and production of IFN-beta. We found that, although RV14 infection results in altered levels of a wide variety of host mRNAs, induction of IFN-beta mRNA or activation of the Jak/STAT pathway is not seen. Prior work has shown, and our results have confirmed. that NF-kappa B and ATF-2 are activated following infection. Since many viruses are known to target IRF-3 to inhibit the induction of IFN-beta mRNA, we analyzed the status of IRF-3 in infected cells. IRF-3 was translocated to the nucleus and phosphorylated in RV14-infected cells. Despite this apparent activation, very little homodimerization of IRF-3 was evident following infection. Similar results in A549 lung alveolar epithelial cells demonstrated the biological relevance of these findings to RV14 pathogenesis. In addition, prior infection of cells with RV14 prevented the induction of IFN-beta mRNA following treatment with double-stranded RNA, indicating that RV14 encodes an activity that specifically inhibits this innate host defense pathway. Collectively, these results indicate that RV14 infection inhibits the host type I interferon response by interfering with IRF-3 activation.
C1 Univ Idaho, Dept Microbiol Mol Biol & Biochem, Moscow, ID 83844 USA.
   Univ Washington, Dept Microbiol, Seattle, WA 98195 USA.
RP Gustin, KE (reprint author), Univ Idaho, Dept Microbiol Mol Biol & Biochem, Moscow, ID 83844 USA.
EM kgustin@uidaho.edu
RI Bumgarner, Roger/K-3531-2015
OI Bumgarner, Roger/0000-0002-8168-6985; Gustin, Kurt/0000-0002-1824-9002
FU NCRR NIH HHS [P20 RR015587, 1S10RR019423, P20 RR016454, P20 RR15587, S10
   RR019423]; NIAID NIH HHS [P01 AI052106, 5P01AI052106]
CR ABZUG MJ, 1990, PEDIATR INFECT DIS J, V9, P881, DOI 10.1097/00006454-199012000-00005
   Baigent SJ, 2002, J VIROL, V76, P8979, DOI 10.1128/JVI.76.18.8979-8988.2002
   Barro M, 2005, P NATL ACAD SCI USA, V102, P4114, DOI 10.1073/pnas.0408376102
   Basler CF, 2003, J VIROL, V77, P7945, DOI 10.1128/JVI.77.14.7945-7956.2003
   Bertino JS, 2002, AM J MED, V112, p42S
   BIRON AB, 2001, FIELDS VIROLOGY, P321
   Bossert B, 2003, J VIROL, V77, P8661, DOI 10.1128/JVI.77.16.8661-8668.2003
   Browne EP, 2001, J VIROL, V75, P12319, DOI 10.1128/JVI.75.24.12319-12330.2001
   Chen Y, 2006, AM J RESP CELL MOL, V34, P192, DOI 10.1165/rcmb.2004-0417OC
   COUCH RB, 2001, FIELDS VIROLOGY, V1, P777
   Dodd DA, 2002, THESIS STANFORD U ST
   Einarsson O, 1996, J CLIN INVEST, V97, P915, DOI 10.1172/JCI118514
   Foy E, 2003, SCIENCE, V300, P1145, DOI 10.1126/science.1082604
   Garofalo R, 1996, J IMMUNOL, V157, P2506
   Geiss GK, 2003, J VIROL, V77, P6367, DOI 10.1128/JVI.77.11.6367-6375.2003
   Ghosh S, 1999, CLIN INFECT DIS, V29, P528, DOI 10.1086/598627
   Gustin KE, 2002, J VIROL, V76, P8787, DOI 10.1128/JVI.76.17.8787-8796.2002
   Hall AC, 2005, J MIDWEST MOD LANG, V38, P1
   Iwamura T, 2001, GENES CELLS, V6, P375, DOI 10.1046/j.1365-2443.2001.00426.x
   Jamaluddin M, 2001, AM J PHYSIOL-LUNG C, V280, pL248
   JOHNSTON SL, 1995, BRIT MED J, V310, P1225, DOI 10.1136/bmj.310.6989.1225
   Kim J, 2000, J IMMUNOL, V165, P3384, DOI 10.4049/jimmunol.165.6.3384
   Kohl A, 2003, J VIROL, V77, P7999, DOI 10.1128/JVI.77.14.7999-8008.2003
   Kumar KS, 2000, WIND STRUCT, V3, P1
   Lin RT, 2004, J VIROL, V78, P1675, DOI 10.1128/JVI.78.4.1675-1684.2004
   Lin RT, 1998, MOL CELL BIOL, V18, P2986, DOI 10.1128/MCB.18.5.2986
   Loveys DA, 2000, VIROLOGY, V271, P390, DOI 10.1006/viro.2000.0290
   MCMILLAN JA, 1993, PEDIATR INFECT DIS J, V12, P321, DOI 10.1097/00006454-199304000-00011
   Monto AS, 2001, CLIN THER, V23, P1615, DOI 10.1016/S0149-2918(01)80133-8
   Mori M, 2004, J BIOL CHEM, V279, P9698, DOI 10.1074/jbc.M310616200
   Neznanov N, 2005, J BIOL CHEM, V280, P24153, DOI 10.1074/jbc.M502303200
   OLSON MOJ, 1981, EXP CELL RES, V135, P259, DOI 10.1016/0014-4827(81)90161-0
   Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239
   Papi A, 1999, J BIOL CHEM, V274, P30041, DOI 10.1074/jbc.274.42.30041
   Papi A, 1999, J BIOL CHEM, V274, P9707, DOI 10.1074/jbc.274.14.9707
   Peng T, 2002, MOL CELL BIOL, V22, P5575, DOI 10.1128/MCB.22.15.5575-5584.2002
   RAJ NBK, 1980, NUCLEIC ACIDS RES, V8, P3427, DOI 10.1093/nar/8.15.3427
   Richtsteiger R, 2003, CYTOKINE, V24, P190, DOI 10.1016/j.cyto.2003.09.001
   Ronco LV, 1998, GENE DEV, V12, P2061, DOI 10.1101/gad.12.13.2061
   Samuel CE, 2001, CLIN MICROBIOL REV, V14, P778, DOI 10.1128/CMR.14.4.778-809.2001
   Schroth MK, 1999, AM J RESP CELL MOL, V20, P1220, DOI 10.1165/ajrcmb.20.6.3261
   Schweizer M, 2001, J VIROL, V75, P4692, DOI 10.1128/JVI.75.10.4692-4698.2001
   Servant MJ, 2003, J BIOL CHEM, V278, P9441, DOI 10.1074/jbc.M209851200
   Servant MJ, 2001, J BIOL CHEM, V276, P355, DOI 10.1074/jbc.M007790200
   Spiegel M, 2005, J VIROL, V79, P2079, DOI 10.1128/JVI.79.4.2079-2086.2005
   STOKER D, 1973, P SOC EXP BIOL MED, V143, P23
   SUBAUSTE MC, 1995, J CLIN INVEST, V96, P549, DOI 10.1172/JCI118067
   Suhara W, 2002, J BIOL CHEM, V277, P22304, DOI 10.1074/jbc.M200192200
   Suzuki T, 2001, AM J PHYSIOL-LUNG C, V280, pL409
   Talon J, 2000, J VIROL, V74, P7989, DOI 10.1128/JVI.74.17.7989-7996.2000
   Terajima M, 1997, AM J PHYSIOL-LUNG C, V273, pL749, DOI 10.1152/ajplung.1997.273.4.L749
   Thomas D, 2004, J BIOL CHEM, V279, P31471, DOI 10.1074/jbc.M400938200
   Turner RB, 2001, ANTIVIR RES, V49, P1, DOI 10.1016/S0166-3542(00)00135-2
   Unterstab G, 2005, P NATL ACAD SCI USA, V102, P13640, DOI 10.1073/pnas.0502883102
   VANDAM H, 1995, EMBO J, V14, P1798, DOI 10.1002/j.1460-2075.1995.tb07168.x
   Wark PAB, 2005, J EXP MED, V201, P937, DOI 10.1084/jem.20041901
   Weaver BK, 1998, MOL CELL BIOL, V18, P1359, DOI 10.1128/MCB.18.3.1359
   Weber F, 2002, J VIROL, V76, P7949, DOI 10.1128/JVI.76.16.7949-7955.2002
   Yang HM, 2002, EUR J BIOCHEM, V269, P6142, DOI 10.1046/j.1432-1033.2002.03330.x
   Yoneyama M, 1998, EMBO J, V17, P1087, DOI 10.1093/emboj/17.4.1087
   Yoneyama M, 2002, J INTERF CYTOK RES, V22, P73, DOI 10.1089/107999002753452674
   Zhang YH, 2001, J VIROL, V75, P9044, DOI 10.1128/JVI.75.19.9044-9058.2001
   Zhu Z, 1996, J CLIN INVEST, V97, P421, DOI 10.1172/JCI118431
   Zhu Z, 1997, AM J PHYSIOL-LUNG C, V273, pL814, DOI 10.1152/ajplung.1997.273.4.L814
NR 64
TC 20
Z9 21
U1 2
U2 7
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
EI 1098-5514
J9 J VIROL
JI J. Virol.
PD MAY
PY 2006
VL 80
IS 10
BP 5021
EP 5031
DI 10.1128/JVI.80.10.5021-5031.2006
PG 11
WC Virology
SC Virology
GA 041LK
UT WOS:000237457500037
PM 16641293
OA Green Published, Bronze
DA 2018-12-27
ER

PT J
AU Kreipke, CW
   Morgan, NC
   Petrov, T
   Rafols, JA
AF Kreipke, Christian W.
   Morgan, Noah C.
   Petrov, Theodor
   Rafols, Jose A.
TI RETRACTED: Calponin and caldesmon cellular domains in reacting
   microvessels following traumatic brain injury(Retracted article. See
   vol. 110, pg. 64, 2017)
SO MICROVASCULAR RESEARCH
LA English
DT Article; Retracted Publication
DE microvascular tone; neurotrauma; contractile proteins
ID VASCULAR SMOOTH-MUSCLE; ENDOTHELIAL GROWTH-FACTOR; PORCINE
   CORONARY-ARTERY; NITRIC-OXIDE SYNTHASE; PROTEIN-KINASE-C; CONTRACTILE
   PROTEINS; MESSENGER-RNA; EXPRESSION; PHOSPHORYLATION; MYOSIN
AB Calponin (Cp) and caldesmon (Cd) are actin-binding proteins involved in the regulation of smooth muscle (SM) tone during blood vessel contraction. While in vitro studies have reported modifications of these proteins during vessel contractility, their role in vivo remains unclear. Traumatic brain injury (TBI) causes disruption of cerebral microvascular tone, leading to sustained contractility in reacting microvessels and cerebral hypoperfusion. This study aimed to determine the spatial and temporal expressions of Cp and Cd in rat cerebral cortical and hippocampal microvessels post-TBI. Reacting microvessels were analyzed in control, 4, 24, and 48 h post-injury. Single and double immunocytochemical techniques together with semiquantitative analyses revealed a Cp upregulation in SM at all time frames post-TBI; with the protein migrating from SM cytosol to the vicinity of the cell membrane. Similarly, Cd immunoreactivity significantly increased in both SM and endothelial cells (En). However, while Cp and Cd in SM remained elevated, their levels in En returned to normal at 48 h post-TBI. The results suggest that Cp and Cd levels increase while compartmentalizing to specific subcellular domains. These changes are temporally associated with modifications in the cytoskeleton and contractile apparatus of SM and En during blood vessel contractility. Furthermore, these changes may underlie the state of sustained contractility and hypoperfusion observed in reacting microvessels after TBI. (c) 2006 Elsevier Inc. All rights reserved.
C1 Wayne State Univ, Sch Med, Dept Anat & Cell Biol, Detroit, MI 48201 USA.
RP Rafols, JA (reprint author), Wayne State Univ, Sch Med, Dept Anat & Cell Biol, 540 E Cranfield, Detroit, MI 48201 USA.
EM jrafols@med.wayne.edu
FU NINDS NIH HHS [NS039860]
CR Abu-Judeh HH, 1999, NUCL MED COMMUN, V20, P505, DOI 10.1097/00006231-199906000-00003
   Ahn MJ, 2004, J NEUROTRAUM, V21, P1431, DOI 10.1089/neu.2004.21.1431
   ARBUSTINI E, 1993, AM J CARDIOL, V71, P1382, DOI 10.1016/0002-9149(93)90597-6
   Armstead WM, 2004, J NEUROTRAUM, V21, P1204, DOI 10.1089/0897715041953849
   Bandopadhyay R, 2001, J NEUROCYTOL, V30, P35, DOI 10.1023/A:1011965307612
   BARANY K, 1992, BIOCHEM BIOPH RES CO, V187, P847, DOI 10.1016/0006-291X(92)91274-T
   BIRUKOV KG, 1991, CELL TISSUE RES, V266, P579, DOI 10.1007/BF00318599
   Borovikov YS, 1999, INT REV CYTOL, V189, P267, DOI 10.1016/S0074-7696(08)61389-3
   CHALOVICH JM, 1990, ANN NY ACAD SCI, V599, P85
   Fee DB, 2004, BRAIN RES, V1012, P52, DOI 10.1016/j.brainres.2004.03.028
   Folkerts MM, 1998, J NEUROTRAUM, V15, P349, DOI 10.1089/neu.1998.15.349
   Foster DB, 2004, J BIOL CHEM, V279, P53387, DOI 10.1074/jbc.M410109200
   FURST DO, 1986, EMBO J, V5, P251, DOI 10.1002/j.1460-2075.1986.tb04206.x
   Gimona M, 1996, BIOCH SMOOTH MUSCLE, P91
   Graceffa P, 1996, J BIOL CHEM, V271, P30336, DOI 10.1074/jbc.271.48.30336
   KAMM KE, 1985, AM J PHYSIOL, V249, pC238
   KATSUYAMA H, 1992, J BIOL CHEM, V267, P14555
   Lee YH, 2000, J BIOL CHEM, V275, P3213, DOI 10.1074/jbc.275.5.3213
   LEHMAN W, 1987, BIOCHIM BIOPHYS ACTA, V914, P35, DOI 10.1016/0167-4838(87)90158-0
   LIN Y, 1993, J BIOCHEM-TOKYO, V113, P643, DOI 10.1093/oxfordjournals.jbchem.a124096
   Mabuchi K, 1996, J MUSCLE RES CELL M, V17, P243, DOI 10.1007/BF00124246
   MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291
   MARSTON SB, 1991, BIOCHEM J, V279, P1
   McBeth BD, 2005, ACAD EMERG MED, V12, P483, DOI 10.1197/j.aem.2004.11.028
   MINO T, 1995, BIOCHEM BIOPH RES CO, V208, P397, DOI 10.1006/bbrc.1995.1351
   Mirzapoiazova T, 2005, J CELL PHYSIOL, V203, P520, DOI 10.1002/jcp.20244
   Nag S, 2002, J NEUROPATH EXP NEUR, V61, P778, DOI 10.1093/jnen/61.9.778
   NORTH AJ, 1994, J CELL SCI, V107, P437
   Petrov T, 2002, NEUROSCIENCE, V115, P275, DOI 10.1016/S0306-4522(02)00345-7
   Petrov T, 2001, NEUROL RES, V23, P139, DOI 10.1179/016164101101198479
   Petrov T, 2000, ACTA NEUROPATHOL, V100, P196, DOI 10.1007/s004019900167
   Rafols D, 2004, NEUROSCI LETT, V362, P154, DOI 10.1016/j.neulet.2004.03.021
   Sakihara C, 1996, BIOCHEM BIOPH RES CO, V222, P195, DOI 10.1006/bbrc.1996.0721
   Skold MK, 2005, J NEUROTRAUM, V22, P353, DOI 10.1089/neu.2005.22.353
   Small JV, 1998, ACTA PHYSIOL SCAND, V164, P341
   SOBUE K, 1991, J BIOL CHEM, V266, P12115
   Steiner J, 2004, NITRIC OXIDE-BIOL CH, V10, P162, DOI 10.1016/j.niox.2004.03.005
   Suzuki R, 2003, ACTA NEUROCHIR SUPPL, V86, P277
   Szmydynger-Chodobska J, 2004, J NEUROTRAUM, V21, P1090, DOI 10.1089/0897715041651033
   Walsh MP, 1996, BIOCHEM CELL BIOL, V74, P485, DOI 10.1139/o96-053
   Worth NF, 2001, CELL MOTIL CYTOSKEL, V49, P130, DOI 10.1002/cm.1027
   Yang JX, 2004, ACTA BIOCH BIOPH SIN, V36, P529, DOI 10.1093/abbs/36.8.529
   Yuasa U, 1999, J MOL CELL CARDIOL, V31, P1281, DOI 10.1006/jmcc.1999.0960
NR 43
TC 17
Z9 18
U1 3
U2 6
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0026-2862
EI 1095-9319
J9 MICROVASC RES
JI Microvasc. Res.
PD MAY
PY 2006
VL 71
IS 3
BP 197
EP 204
DI 10.1016/j.mvr.2006.02.002
PG 8
WC Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA 056FP
UT WOS:000238507300006
PM 16635497
DA 2018-12-27
ER

PT J
AU Sain, N
   Krishnan, B
   Ormerod, MG
   De Rienzo, A
   Liu, WM
   Kaye, SB
   Workman, P
   Jackman, AL
AF Sain, Nivedita
   Krishnan, Bhavani
   Ormerod, Michael G.
   De Rienzo, Assunta
   Liu, Wai M.
   Kaye, Stanley B.
   Workman, Paul
   Jackman, Ann L.
TI RETRACTED: Potentiation of paclitaxel activity by the HSP90 inhibitor
   17-allylamino-17-demethoxygeldanamycin in human ovarian carcinoma cell
   lines with high levels of activated AKT (Retracted article. See vol. 17,
   pg. 2075, 2018)
SO MOLECULAR CANCER THERAPEUTICS
LA English
DT Article; Retracted Publication
ID CHEMOTHERAPY-INDUCED APOPTOSIS; BREAST-CANCER CELLS; IN-VITRO; MOLECULAR
   CHAPERONE; SIGNAL-TRANSDUCTION; PHASE-I; EXPRESSION; PATHWAY; KINASE;
   GROWTH
AB Activation of the phosphatidylinositol-3-kinase (PI3K)/AKT survival pathway is a mechanism of cytotoxic drug resistance in ovarian cancer, and inhibitors of this pathway can sensitize to cytotoxic drugs. The HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin (17-AAG) depletes some proteins involved in PI3K/AKT signaling, e.g., ERBB2, epidermal growth factor receptor (EGFR), and phosphorylated AKT (p-AKT). 17-AAG and paclitaxel were combined (at a fixed 1:1 ratio of their IC50) in four ovarian cancer cell lines that differ in expression of p-AKT, EGFR, and ERBB2. The EGFR-overexpressing A431 and KB epidermoid cell lines were also included. Combination indices (CO were calculated using the median-effect equation and interpreted in the context of 17-AAG-mediated inhibition of PI3K signaling. Synergy was observed in IGROV-1- and ERbB2-overexpressing SKOV-3 ovarian cancer cells that express a high level of constitutively activated p-AKT [Cl at fraction unaffected (fu)(0.5) = 0.50 and 0.53, respectively]. Slight synergy was observed in A431 cells (moderate p-AKT/overexpressed EGFR; CI at fu(0.5) = 0.76) and antagonism in CH1 (moderate p-AKT), HX62 cells (low p-AKT), and KB cells (low p-AKT/overexpressed EGFR; CI at fu(50) = 3.0, 3.5, and 2.0, respectively). The observed effects correlated with changes in the rate of apoptosis induction. 17-AAG induced a decrease in HSP90 client proteins (e.g., C-RAF, ERBB2, and p-AKT) or in downstream markers of their activity (e.g., phosphorylated extracellular signal-regulated kinase or p-AKT) in SKOV-3, IGROV-1, and CH1 cells at IC50 concentrations. A non-growth-inhibitory concentration (6 nmol/L) reduced the phosphorylation of AKT (but not extracellular signal-regulated kinase) and sensitized SKOV-3 cells to paclitaxel. In conclusion, 17-AAG may sensitize a subset of ovarian cancer to paclitaxel, particularly those tumors in which resistance is driven by ERBB2 and/or p-AKT.
C1 Inst Canc Res, Haddow Labs, Med Sect, Sutton SM2 5NG, Surrey, England.
   Inst Canc Res, Haddow Labs, Canc Res UK Ctr Canc Therapeut, Sutton SM2 5NG, Surrey, England.
RP Jackman, AL (reprint author), Inst Canc Res, Haddow Labs, Med Sect, 15 Cotswold Rd, Sutton SM2 5NG, Surrey, England.
EM ann.jackman@icr.ac.uk
RI Liu, Wai/B-7877-2008
OI Liu, Wai/0000-0001-7099-7510
CR Agarwal R, 2003, NAT REV CANCER, V3, P502, DOI 10.1038/nrc1123
   Altomare DA, 2004, ONCOGENE, V23, P5853, DOI 10.1038/sj.onc.1207721
   Arboleda MJ, 2003, CANCER RES, V63, P196
   Banerji U, 2005, J CLIN ONCOL, V23, P4152, DOI 10.1200/JCO.2005.00.612
   Basso AD, 2002, ONCOGENE, V21, P1159, DOI 10.1038/sj.onc.1205184
   Blagosklonny MV, 2001, LEUKEMIA, V15, P1537, DOI 10.1038/sj.leu.2402257
   Cheung KMJ, 2005, BIOORG MED CHEM LETT, V15, P3338, DOI 10.1016/j.bmcl.2005.05.046
   CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4
   Clarke PA, 2000, ONCOGENE, V19, P4125, DOI 10.1038/sj.onc.1203753
   Cruet-Hennequart S, 2003, ONCOGENE, V22, P1688, DOI 10.1038/sj.onc.1206347
   Druker BJ, 2002, TRENDS MOL MED, V8, pS14, DOI 10.1016/S1471-4914(02)02305-5
   Dymock BW, 2004, EXPERT OPIN THER PAT, V14, P837, DOI 10.1517/13543776.14.6.837
   Grem JL, 2005, J CLIN ONCOL, V23, P1885, DOI 10.1200/JCO.2005.12.085
   Guo WC, 2005, CANCER RES, V65, P10006, DOI 10.1158/0005-5472.CAN-05-2029
   Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/j.cell.2011.02.013
   HILLS CA, 1989, BRIT J CANCER, V59, P527, DOI 10.1038/bjc.1989.108
   Holford J, 1998, BRIT J CANCER, V77, P366, DOI 10.1038/bjc.1998.59
   Hostein I, 2001, CANCER RES, V61, P4003
   Hu LM, 2002, CANCER RES, V62, P1087
   Hu LM, 2000, CLIN CANCER RES, V6, P880
   Hynes NE, 2005, NAT REV CANCER, V5, P341, DOI 10.1038/nrc1609
   JACKMAN AL, 2004, DRUG DISCOV TODAY, V1, P445
   Kelland LR, 1999, J NATL CANCER I, V91, P1940, DOI 10.1093/jnci/91.22.1940
   Maloney A, 2002, EXPERT OPIN BIOL TH, V2, P3, DOI 10.1517/14712598.2.1.3
   Mills GB, 2001, SEMIN ONCOL, V28, P125, DOI 10.1053/sonc.2001.28554
   Moroni M, 2005, LANCET ONCOL, V6, P279, DOI 10.1016/S1470-2045(05)70102-9
   Munster PN, 2002, CANCER RES, V62, P3132
   Munster PN, 2001, CLIN CANCER RES, V7, P2228
   NECKERS L, 2002, EXPERT OPIN EMERG DR, V10, P137
   Nguyen DM, 1999, J THORAC CARDIOV SUR, V118, P908, DOI 10.1016/S0022-5223(99)70061-9
   Page C, 2000, ANTICANCER RES, V20, P407
   Sausville EA, 2003, CURR CANCER DRUG TAR, V3, P377, DOI 10.2174/1568009033481831
   Sellers WR, 2005, J NATL CANCER I, V97, P326, DOI 10.1093/jnci/dji079
   Shayesteh L, 1999, NAT GENET, V21, P99, DOI 10.1038/5042
   Solit DB, 2003, CANCER RES, V63, P2139
   Solit DB, 2003, SEMIN ONCOL, V30, P709, DOI 10.1053/S0093-7754(03)00346-4
   Thompson JE, 2004, J CLIN ONCOL, V22, P4217, DOI 10.1200/jco.2004.01.103
   TWENTYMAN PR, 1987, BRIT J CANCER, V56, P279, DOI 10.1038/bjc.1987.190
   Vasilevskaya IA, 2004, MOL PHARMACOL, V65, P235, DOI 10.1124/mol.65.1.235
   Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/mrc839
   Walton MI, 1998, BRIT J CANCER, V78, P19
   Whitesell L, 2003, CURR CANCER DRUG TAR, V3, P349, DOI 10.2174/1568009033481787
   Workman P, 2004, CANCER LETT, V206, P149, DOI 10.1016/j.canlet.2003.08.032
   Workman P, 2002, TRENDS MOL MED, V8, pS1, DOI 10.1016/S1471-4914(02)02319-5
   Xu FJ, 1999, CLIN CANCER RES, V5, P3653
   Yuan ZQ, 2000, ONCOGENE, V19, P2324, DOI 10.1038/sj.onc.1203598
   Zuco V, 2004, CELL DEATH DIFFER, V11, P280, DOI 10.1038/sj.cdd.4401304
NR 47
TC 74
Z9 81
U1 1
U2 8
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1535-7163
EI 1538-8514
J9 MOL CANCER THER
JI Mol. Cancer Ther.
PD MAY
PY 2006
VL 5
IS 5
BP 1197
EP 1208
DI 10.1158/1535-7163.MCT-05-0445
PG 12
WC Oncology
SC Oncology
GA 050FV
UT WOS:000238073800013
PM 16731752
OA Bronze
DA 2018-12-27
ER

PT J
AU Glaros, S
   Atanaskova, N
   Zhao, CQ
   Skafar, DF
   Reddy, KB
AF Glaros, S
   Atanaskova, N
   Zhao, CQ
   Skafar, DF
   Reddy, KB
TI RETRACTED: Activation function-1 domain of estrogen receptor regulates
   the agonistic and antagonistic actions of tamoxifen (Retracted Article.
   See vol 22, pg 772, 2008)
SO MOLECULAR ENDOCRINOLOGY
LA English
DT Article; Retracted Publication
ID BREAST-CANCER CELLS; SOUTHWEST-ONCOLOGY-GROUP; PROTEIN-KINASE;
   TRANSCRIPTIONAL ACTIVATION; PROSTATE-CANCER; IN-VIVO; ANTIESTROGEN
   RESISTANCE; NUCLEAR RECEPTORS; HER-2 EXPRESSION; GROWTH-FACTORS
AB The antiestrogen tamoxifen has been widely used for decades as selective estrogen receptor (ER) modulator for ER alpha- positive breast tumors. Tamoxifen significantly reduces tumor recurrence by binding to the activation function-2 (AF-2) domain of the ER. Acquired resistance to tamoxifen in breast cancer patients is a serious therapeutic problem. Antiestrogen-resistant breast cancer often shows increased expression of the epidermal growth factor receptor (EGFR) family members, EGFR and ErbB2. In this report we now show that overexpression of EGFR or activated AKT-2 in MCF-7 cells leads to phosphorylation of Ser167 in the AF-1 domain of ER alpha, enhanced ER-amplified in breast cancer 1 (ER:AIB1) interaction in the presence of tamoxifen, and resistance to tamoxifen. In contrast, transfection of activated MAPK kinase, an immediate upstream activator of MAPK (ERK 1 and 2) into MCF-7 cells leads to phosphorylation of Ser118 in the AF-1 domain of ER alpha, inhibition of ER-amplified in breast cancer 1 (ER:AIB1) interaction in the presence of Tam, and maintenance of sensitivity to tamoxifen. Inhibition of AKT by short inhibitory RNA blocked Ser167 phosphorylation in ER and restored tamoxifen sensitivity. However, maximum sensitivity to tamoxifen was observed when both AKT and MAPK were inhibited. Taken together, these data demonstrate that different phosphorylation sites in the AF-1 domain of ER alpha regulate the agonistic and antagonistic actions of tamoxifen in human breast cancer cells.
C1 Wayne State Univ, Dept Pathol, Detroit, MI 48201 USA.
   Wayne State Univ, Dept Physiol, Detroit, MI 48201 USA.
   Barbara Ann Karmanos Canc Inst, Sch Med, Detroit, MI 48201 USA.
RP Reddy, KB (reprint author), Wayne State Univ, Dept Pathol, 540 E Canfield Ave, Detroit, MI 48201 USA.
EM kreddy@med.wayne.edu
FU NCI NIH HHS [R01-CA 83964-01]
CR Adeyinka A, 2002, CLIN CANCER RES, V8, P1747
   Ali S, 2002, NAT REV CANCER, V2, P101, DOI 10.1038/nrc721
   Arpino G, 2004, CLIN CANCER RES, V10, P5670, DOI 10.1158/1078-0432.CCR-04-0110
   Atanaskova N, 2002, ONCOGENE, V21, P4000, DOI 10.1038/sj.onc.120556
   BENZ CC, 1992, BREAST CANCER RES TR, V24, P85, DOI 10.1007/BF01961241
   Campbell RA, 2001, J BIOL CHEM, V276, P9817, DOI 10.1074/jbc.M010840200
   Castano E, 1997, BIOCHEM J, V326, P149, DOI 10.1042/bj3260149
   Chisamore MJ, 2001, CLIN CANCER RES, V7, P3156
   Clarke R, 2001, PHARMACOL REV, V53, P25
   DANIELIAN PS, 1992, EMBO J, V11, P1025, DOI 10.1002/j.1460-2075.1992.tb05141.x
   De Laurentiis M, 2005, CLIN CANCER RES, V11, P4741, DOI 10.1158/1078-0432.CCR-04-2569
   de Mora JF, 2000, MOL CELL BIOL, V20, P5041, DOI 10.1128/MCB.20.14.5041-5047.2000
   Djakiew D, 2000, PROSTATE, V42, P150, DOI 10.1002/(SICI)1097-0045(20000201)42:2<150::AID-PROS10>3.0.CO;2-H
   Elledge RM, 1998, CLIN CANCER RES, V4, P7
   EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939
   Faridi J, 2003, CLIN CANCER RES, V9, P2933
   Fujita T, 2003, J BIOL CHEM, V278, P26704, DOI 10.1074/jbc.M301031200
   Gee JM, 2005, ENDOCR-RELAT CANCER, V12, pS99, DOI 10.1677/erc.1.01005
   Gee JMW, 2003, ENDOCRINOLOGY, V144, P5105, DOI 10.1210/en.2003-0705
   GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4
   Guvakova MA, 1997, EXP CELL RES, V231, P149, DOI 10.1006/excr.1996.3457
   Henttu PMA, 1997, MOL CELL BIOL, V17, P1832, DOI 10.1128/MCB.17.4.1832
   Jones HE, 2004, ENDOCR-RELAT CANCER, V11, P793, DOI 10.1677/erc.1.00799
   KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491
   Kirkegaard T, 2005, J PATHOL, V207, P139, DOI 10.1002/path.1829
   Kobayashi Y, 2000, J BIOL CHEM, V275, P15645, DOI 10.1074/jbc.M000042200
   Kruger JS, 2003, MOL CANCER RES, V1, P801
   Kuiper GGJM, 1996, P NATL ACAD SCI USA, V93, P5925, DOI 10.1073/pnas.93.12.5925
   KUMAR V, 1987, CELL, V51, P941, DOI 10.1016/0092-8674(87)90581-2
   Kurokawa H, 2000, CANCER RES, V60, P5887
   LAHOOTI H, 1994, MOL ENDOCRINOL, V8, P182, DOI 10.1210/me.8.2.182
   LEGOFF P, 1994, J BIOL CHEM, V269, P4458
   LIU YL, 1995, BREAST CANCER RES TR, V34, P97, DOI 10.1007/BF00665783
   Lopez GN, 2001, J BIOL CHEM, V276, P22177, DOI 10.1074/jbc.M010718200
   Lopez GN, 1999, MOL ENDOCRINOL, V13, P897, DOI 10.1210/me.13.6.897
   Lupu R, 1996, BREAST CANCER RES TR, V38, P57, DOI 10.1007/BF01803784
   MacGregor JI, 1998, PHARMACOL REV, V50, P151
   MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857
   McClelland RA, 2001, ENDOCRINOLOGY, V142, P2776, DOI 10.1210/en.142.7.2776
   METZGER D, 1995, J BIOL CHEM, V270, P9535, DOI 10.1074/jbc.270.16.9535
   Michalides R, 2004, CANCER CELL, V5, P597, DOI 10.1016/j.ccr.2004.05.016
   Murphy L, 2004, CLIN CANCER RES, V10, P1354, DOI 10.1158/1078-0432.CCR-03-0112
   Murphy LC, 2000, CANCER RES, V60, P6266
   Nabha SM, 2005, ONCOGENE, V24, P3166, DOI 10.1038/sj.onc.1208502
   Nakatani K, 1999, J BIOL CHEM, V274, P21528, DOI 10.1074/jbc.274.31.21528
   Norris JD, 1996, MOL ENDOCRINOL, V10, P1605, DOI 10.1210/mend.10.12.8961270
   OSBORNE CK, 1991, J NATL CANCER I, V83, P1477, DOI 10.1093/jnci/83.20.1477
   Pasqualini JR, 1996, J CLIN ENDOCR METAB, V81, P1460, DOI 10.1210/jc.81.4.1460
   Perez-Tenorio G, 2002, BRIT J CANCER, V86, P540, DOI 10.1038/sj/bjc/6600126
   PIETRAS RJ, 1995, ONCOGENE, V10, P2435
   Reddy KB, 1999, INT J CANCER, V82, P268, DOI 10.1002/(SICI)1097-0215(19990719)82:2<268::AID-IJC18>3.3.CO;2-W
   RIBEIRO RCJ, 1995, ANNU REV MED, V46, P443, DOI 10.1146/annurev.med.46.1.443
   Rogatsky I, 1999, J BIOL CHEM, V274, P22296, DOI 10.1074/jbc.274.32.22296
   Salomon D S, 1988, Cancer Treat Res, V40, P363
   Shang YF, 2002, SCIENCE, V295, P2465, DOI 10.1126/science.1068537
   Shou J, 2004, J NATL CANCER I, V96, P926, DOI 10.1093/jnci/djh166
   Stal O, 2003, BREAST CANCER RES, V5, pR37, DOI 10.1186/bcr569
   Stephen RL, 2001, J BIOL CHEM, V276, P40080, DOI 10.1074/jbc.M105892200
   Sun DX, 2001, AAPS PHARMSCI, V3
   Sun M, 2001, CANCER RES, V61, P5985
   Sun M, 2001, AM J PATHOL, V159, P431, DOI 10.1016/S0002-9440(10)61714-2
   Yarden Y, 2001, EUR J CANCER, V37, pS3
   Zinda MJ, 2001, CLIN CANCER RES, V7, P2475
NR 63
TC 27
Z9 31
U1 3
U2 9
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0888-8809
EI 1944-9917
J9 MOL ENDOCRINOL
JI Mol. Endocrinol.
PD MAY
PY 2006
VL 20
IS 5
BP 996
EP 1008
DI 10.1210/me.2005-0285
PG 13
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 038MB
UT WOS:000237223900004
PM 16455819
OA Bronze
DA 2018-12-27
ER

PT J
AU Datta, BK
AF Datta, B. K.
TI RETRACTED: Approximate solution for the Thomas-Fermi equation (Retracted
   article. See vol. 124, pg. 258, 2009)
SO NUOVO CIMENTO DELLA SOCIETA ITALIANA DI FISICA B-BASIC TOPICS IN PHYSICS
LA English
DT Article; Retracted Publication
AB An approximate analytical solution is derived for the Thomas-Fermi (TF) equation using the delta-perturbation technique. The Pade approximate method is used to accelerate the convergence of the power series. The initial slope of the TF potential is calculated in a third-order application of the theory. The comparison with the exact result shows the accuracy of the present solution.
C1 Chakdaha Coll, Dept Math, Chakdaha 741222, Dist Nadia, India.
RP Datta, BK (reprint author), Chakdaha Coll, Dept Math, Chakdaha 741222, Dist Nadia, India.
CR Abamowitz M., 1972, HDB MATH FUNCTIONS
   BAKER G, 1981, PADE APPROX
   Datta BK, 1996, NUOVO CIM B, V111, P1385, DOI 10.1007/BF02742511
   DATTA BK, 2003, IND J PURE APPL MATH, V34
   Epele LN, 1999, PHYS REV A, V60, P280, DOI 10.1103/PhysRevA.60.280
   Esposito S, 2002, AM J PHYS, V70, P852, DOI 10.1119/1.1484144
   Esposito S, 2002, INT J THEOR PHYS, V41, P2417, DOI 10.1023/A:1021398203046
   KOBAYASHI S, 1955, J PHYS SOC JPN, V10, P759, DOI 10.1143/JPSJ.10.759
NR 8
TC 0
Z9 0
U1 3
U2 10
PU SOC ITALIANA FISICA
PI BOLOGNA
PA VIA SARAGOZZA, 12, I-40123 BOLOGNA, ITALY
SN 2037-4895
EI 1594-9982
J9 NUOVO CIM B
JI Nouvo Cimento Soc. Ital. Fis. B-Basic Top. Phys.
PD MAY
PY 2006
VL 121
IS 5
BP 501
EP 504
DI 10.1393/ncb/i2006-10046-5
PG 4
WC Physics, Multidisciplinary
SC Physics
GA 106MB
UT WOS:000242103500004
DA 2018-12-27
ER

PT J
AU Sahoo, NK
   Thakur, S
   Tokas, RB
AF Sahoo, NK
   Thakur, S
   Tokas, RB
TI RETRACTED: Fractals and superstructures in gadolinia thin film
   morphology: Influence of process variables on their characteristic
   parameters (Retracted article. See vol. 665, pg. 194, 2018)
SO THIN SOLID FILMS
LA English
DT Article; Retracted Publication
DE reactive electron beam evaporation; surface microroughness; morphology;
   power spectral density; optical coating; fractals; superstructures
ID ROUGHNESS SPECTRUM; LIGHT-SCATTERING; SURFACE; ULTRAVIOLET; COATINGS;
   ELLIPSOMETRY; OPTICS; COPPER; SILVER
AB Characteristic topographic parameters like fractals and superstructures contribute substantially to the thin film morphology, which directly or indirectly influences the physical, optical and mechanical properties. Fractal geometry and scaling concepts can concisely as well as more effectively describe the complex rough surface morphology. In the present study, such microstructural analysis has been carried out for gadolinia thin films, a most promising candidate to develop multilayer optical coatings in the deep ultraviolet spectral region. Extended power spectral density (PSD) spectra for these films acquired through atomic force measurements have been modeled and analyzed using several thin film morphological functions appropriately modified to suit the present requirements. Analysis results of the PSD functions have distinctly indicated the presence of Brownian fractals and uniformly distributed superstructures in the most experimental films deposited through reactive electron beam deposition technique. Process variables such as the rate of deposition and the oxygen partial pressure have affected the microstructural and related morphological evolutions very differently. The rate parameter strongly influenced the intrinsic microroughness, whereas the oxygen pressure influenced the grain sizes of the gadolinia films. One can advantageously use such information in tailoring a desired surface morphology in thin films by choosing appropriate combinations of process variables. (c) 2005 Elsevier B.V. All rights reserved.
C1 Bhabha Atom Res Ctr, Div Spect, Bombay 400085, Maharashtra, India.
RP Sahoo, NK (reprint author), Bhabha Atom Res Ctr, Div Spect, Bombay 400085, Maharashtra, India.
EM nksahoo@apsara.barc.ernet.in
CR ASPNES DE, 1979, PHYS REV B, V20, P3292, DOI 10.1103/PhysRevB.20.3292
   Bruggeman DAG, 1935, ANN PHYS-BERLIN, V24, P636
   CHURCH EL, 1988, APPL OPTICS, V27, P1518, DOI 10.1364/AO.27.001518
   DUMPICH G, 1995, THIN SOLID FILMS, V260, P239, DOI 10.1016/0040-6090(94)06468-7
   Duparre A., 1995, HDB OPTICAL PROPERTI, V1, P273
   ELSON JM, 1995, APPL OPTICS, V34, P201, DOI 10.1364/AO.34.000201
   ELSON JM, 1983, APPL OPTICS, V22, P3207, DOI 10.1364/AO.22.003207
   ELSON JM, 1980, APPL OPTICS, V19, P669, DOI 10.1364/AO.19.000669
   ELSON JM, 1979, J OPT SOC AM, V69, P31, DOI 10.1364/JOSA.69.000031
   Ferre-Borrull J, 2001, APPL OPTICS, V40, P2190, DOI 10.1364/AO.40.002190
   Hou SM, 1998, THIN SOLID FILMS, V315, P322, DOI 10.1016/S0040-6090(97)00713-X
   Huang ZF, 2003, PHYS REV B, V67, DOI 10.1103/PhysRevB.67.075416
   Jakobs S, 1998, APPL OPTICS, V37, P1180, DOI 10.1364/AO.37.001180
   Kwasny W, 2004, J MATER PROCESS TECH, V157, P188, DOI 10.1016/j.jmatprotec.2004.09.028
   Li JM, 2000, APPL SURF SCI, V161, P187, DOI 10.1016/S0169-4332(00)00297-X
   Mannelquist A, 1998, APPL PHYS A-MATER, V66, pS891, DOI 10.1007/s003390051262
   PALASANTZAS G, 1993, PHYS REV B, V48, P14472, DOI 10.1103/PhysRevB.48.14472
   RASIGNI G, 1983, PHYS REV B, V27, P819, DOI 10.1103/PhysRevB.27.819
   Ruppe C, 1996, THIN SOLID FILMS, V288, P8, DOI 10.1016/S0040-6090(96)08807-4
   Sahoo NK, 2003, THIN SOLID FILMS, V440, P155, DOI 10.1016/S0040-6090(03)00678-3
   Sahoo NK, 2002, APPL SURF SCI, V200, P219, DOI 10.1016/S0169-4332(02)00900-5
   Shilkrot LE, 2000, APPL PHYS LETT, V77, P304, DOI 10.1063/1.126958
   Sridhar N, 1997, J APPL PHYS, V82, P4852, DOI 10.1063/1.366347
   Wang Y, 2004, THIN SOLID FILMS, V468, P310, DOI 10.1016/j.tsf.2004.05.132
   WU F, 2001, NONLINEAR SCI NUMER, V6, P61
   YEHODA JE, 1985, APPL SURF SC, V22-3, P590, DOI 10.1016/0378-5963(85)90190-4
   Yu JG, 2002, PHYS REV E, V65, DOI 10.1103/PhysRevE.65.060601
   Yu JG, 2002, PHYS REV E, V66, DOI 10.1103/PhysRevE.66.021603
   Zerkout S, 2003, THIN SOLID FILMS, V441, P135, DOI 10.1016/S0040-6090(03)00850-2
NR 29
TC 36
Z9 36
U1 1
U2 10
PU ELSEVIER SCIENCE SA
PI LAUSANNE
PA PO BOX 564, 1001 LAUSANNE, SWITZERLAND
SN 0040-6090
J9 THIN SOLID FILMS
JI Thin Solid Films
PD MAY 1
PY 2006
VL 503
IS 1-2
BP 85
EP 95
DI 10.1016/j.tsf.2005.11.107
PG 11
WC Materials Science, Multidisciplinary; Materials Science, Coatings &
   Films; Physics, Applied; Physics, Condensed Matter
SC Materials Science; Physics
GA 027UG
UT WOS:000236440500014
DA 2018-12-27
ER

PT J
AU Sastry, SK
   Rajfur, Z
   Liu, BP
   Cote, JF
   Tremblay, ML
   Burridge, K
AF Sastry, SK
   Rajfur, Z
   Liu, BP
   Cote, JF
   Tremblay, ML
   Burridge, K
TI RETRACTED: PTP-PEST couples membrane protrusion and tail retraction via
   VAV2 and p190RhoGAP (Retracted Article. See vol 281, pg 38967, 2006)
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article; Retracted Publication
ID NUCLEOTIDE EXCHANGE FACTOR; PROTEIN-TYROSINE PHOSPHATASES; GROWTH-FACTOR
   RECEPTORS; CELL-MIGRATION; RHO-GTPASES; RAC ACTIVATION; C-SRC; SIGNALING
   PATHWAYS; COMPLEX-FORMATION; ADHESION
AB Cell motility is regulated by a balance between forward protrusion and tail retraction. These phenomena are controlled by a spatial asymmetry in signals at the front and the back of the cell. We show here that the protein-tyrosine phosphatase, PTP-PEST, is required for the coupling of protrusion and retraction during cell migration. PTP-PEST null fibroblasts, which are blocked in migration, exhibit exaggerated protrusions at the leading edge and long, unretracted tails in the rear. This altered morphology is accompanied by changes in the activity of Rho GTPases, Rac1 and RhoA, which mediate protrusion and retraction, respectively. PTP-PEST null cells exhibit enhanced Rac1 activity and decreased RhoA activity. We further show that PTP-PEST directly targets the upstream regulators of Rac1 and RhoA, VAV2 and p190RhoGAP. Moreover, we demonstrate that the activities of VAV2 and p190RhoGAP are regulated by PTP-PEST. Finally, we present evidence indicating the VAV2 can be regulated by integrin-mediated adhesion. These data suggest that PTP-PEST couples protrusion and retraction by acting on VAV2 and p190RhoGAP to reciprocally modulate the activity of Rac1 and RhoA.
C1 Univ Texas, Med Branch, Sealy Ctr Canc Cell Biol, Galveston, TX 77555 USA.
   Yale Univ, Sch Med, Dept Neurol, New Haven, CT 06510 USA.
   Clin Res Inst Montreal, Montreal, PQ H2W 1R7, Canada.
   McGill Univ, Dept Biochem, Montreal, PQ H2W 1R7, Canada.
   Univ N Carolina, Dept Cell & Dev Biol, Chapel Hill, NC 27599 USA.
   Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA.
RP Sastry, SK (reprint author), Univ Texas, Med Branch, Sealy Ctr Canc Cell Biol, 301 Univ Blvd, Galveston, TX 77555 USA.
EM sasastry@utmb.edu
RI Rajfur, Zenon/H-2506-2013; Sastry, Sarita/A-1291-2013
OI Rajfur, Zenon/0000-0003-1265-6480
FU Canadian Institutes of Health Research [77591-1]; NIGMS NIH HHS [R01
   GM029860, GM29860]; NHLBI NIH HHS [HL45100, P01 HL045100]
CR Abe K, 2000, J BIOL CHEM, V275, P10141, DOI 10.1074/jbc.275.14.10141
   Alblas J, 2001, MOL BIOL CELL, V12, P2137, DOI 10.1091/mbc.12.7.2137
   Angers-Loustau A, 1999, J CELL BIOL, V144, P1019, DOI 10.1083/jcb.144.5.1019
   Arthur WT, 2004, J CELL BIOL, V167, P111, DOI 10.1083/jcb.200404068
   Arthur WT, 2002, J BIOL CHEM, V277, P42964, DOI 10.1074/jbc.M207401200
   Arthur WT, 2001, MOL BIOL CELL, V12, P2711, DOI 10.1091/mbc.12.9.2711
   Arthur WT, 2000, CURR BIOL, V10, P719, DOI 10.1016/S0960-9822(00)00537-6
   Ballestrem C, 2001, J CELL BIOL, V155, P1319, DOI 10.1083/jcb.200107107
   Brahmbhatt AA, 2003, J BIOL CHEM, V278, P13016, DOI 10.1074/jbc.M211873200
   Brugnera E, 2002, NAT CELL BIOL, V4, P574, DOI 10.1038/ncb824
   Burridge K, 2004, CELL, V116, P167, DOI 10.1016/S0092-8674(04)00003-0
   Bustelo XR, 2000, MOL CELL BIOL, V20, P1461, DOI 10.1128/MCB.20.5.1461-1477.2000
   CHANG JH, 1995, J CELL BIOL, V130, P355, DOI 10.1083/jcb.130.2.355
   Cho SY, 2002, J CELL BIOL, V156, P725, DOI 10.1083/jcb.200111032
   Cote JF, 2005, NAT CELL BIOL, V7, P797, DOI 10.1038/ncb1280
   Cote JF, 1998, BIOCHEMISTRY-US, V37, P13128, DOI 10.1021/bi981259l
   Cox EA, 2001, MOL BIOL CELL, V12, P265, DOI 10.1091/mbc.12.2.265
   Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0
   Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148
   FEIG LA, 1999, NAT CELL BIOL, V1, P25
   Flint AJ, 1997, P NATL ACAD SCI USA, V94, P1680, DOI 10.1073/pnas.94.5.1680
   Gardiner EM, 2002, CURR BIOL, V12, P2029, DOI 10.1016/S0960-9822(02)01334-9
   Garton AJ, 1999, J BIOL CHEM, V274, P3811, DOI 10.1074/jbc.274.6.3811
   Garton AJ, 1996, MOL CELL BIOL, V16, P6408
   Glaven JA, 1999, J BIOL CHEM, V274, P2279, DOI 10.1074/jbc.274.4.2279
   Grimsley CM, 2004, J BIOL CHEM, V279, P6087, DOI 10.1074/jbc.M307087200
   HART M, 1995, METHOD ENZYMOL, V255, P129
   Hart MJ, 1996, J BIOL CHEM, V271, P25452, DOI 10.1074/jbc.271.41.25452
   Hu KQ, 1997, EMBO J, V16, P473, DOI 10.1093/emboj/16.3.473
   Jamieson JS, 2005, J CELL SCI, V118, P5835, DOI 10.1242/jcs.02693
   Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656
   Kiosses WB, 2001, NAT CELL BIOL, V3, P316, DOI 10.1038/35060120
   Kiyokawa E, 1998, J BIOL CHEM, V273, P24479, DOI 10.1074/jbc.273.38.24479
   Kiyokawa E, 1998, GENE DEV, V12, P3331, DOI 10.1101/gad.12.21.3331
   Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961
   Kraynov VS, 2000, SCIENCE, V290, P333, DOI 10.1126/science.290.5490.333
   Kulkarni SV, 2000, J CELL BIOL, V149, P457, DOI 10.1083/jcb.149.2.457
   Larsen M, 2003, NAT REV MOL CELL BIO, V4, P700, DOI 10.1038/nrm1199
   Liu BP, 2000, MOL CELL BIOL, V20, P7160, DOI 10.1128/MCB.20.19.7160-7169.2000
   Lopez-Lago M, 2000, MOL CELL BIOL, V20, P1678, DOI 10.1128/MCB.20.5.1678-1691.2000
   Lyons PD, 2001, J BIOL CHEM, V276, P24422, DOI 10.1074/jbc.M011080200
   Marignani PA, 2001, J CELL BIOL, V154, P177, DOI 10.1083/jcb.200103134
   Meller N, 2002, NAT CELL BIOL, V4, P639, DOI 10.1038/ncb835
   Moores SL, 2000, MOL CELL BIOL, V20, P6364, DOI 10.1128/MCB.20.17.6364-6373.2000
   Nakahara H, 1998, J BIOL CHEM, V273, P9, DOI 10.1074/jbc.273.1.9
   Nimnual AS, 2003, NAT CELL BIOL, V5, P236, DOI 10.1038/ncb938
   Nobes CD, 1999, J CELL BIOL, V144, P1235, DOI 10.1083/jcb.144.6.1235
   Noren NK, 2003, J BIOL CHEM, V278, P13615, DOI 10.1074/jbc.C200657200
   O'Connor KL, 2000, J CELL BIOL, V148, P253, DOI 10.1083/jcb.148.2.253
   Pandey A, 2000, P NATL ACAD SCI USA, V97, P179, DOI 10.1073/pnas.97.1.179
   Price LS, 1998, MOL BIOL CELL, V9, P1863, DOI 10.1091/mbc.9.7.1863
   Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578
   Reuther GW, 2001, J BIOL CHEM, V276, P27145, DOI 10.1074/jbc.M103565200
   Ridley AJ, 2001, J CELL SCI, V114, P2713
   Ridley AJ, 2003, SCIENCE, V302, P1704, DOI 10.1126/science.1092053
   Roof RW, 1998, MOL CELL BIOL, V18, P7052, DOI 10.1128/MCB.18.12.7052
   Rottner K, 1999, CURR BIOL, V9, P640, DOI 10.1016/S0960-9822(99)80286-3
   Sander EE, 1999, J CELL BIOL, V147, P1009, DOI 10.1083/jcb.147.5.1009
   Sastry SK, 2002, J CELL SCI, V115, P4305, DOI 10.1242/jcs.00105
   Schmidt A, 2002, GENE DEV, V16, P1587, DOI 10.1101/gad.1003302
   Somlyo AV, 2000, BIOCHEM BIOPH RES CO, V269, P652, DOI 10.1006/bbrc.2000.2343
   TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350
   Tsubouchi A, 2002, J CELL BIOL, V159, P673, DOI 10.1083/jcb.200202117
   Tsuji T, 2002, J CELL BIOL, V157, P819, DOI 10.1083/jcb.200112107
   Worthylake RA, 2001, J CELL BIOL, V154, P147, DOI 10.1083/jcb.200103048
   Worthylake RA, 2003, J BIOL CHEM, V278, P13578, DOI 10.1074/jbc.M211584200
NR 66
TC 47
Z9 50
U1 2
U2 10
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
J9 J BIOL CHEM
JI J. Biol. Chem.
PD APR 28
PY 2006
VL 281
IS 17
BP 11627
EP 11636
DI 10.1074/jbc.M600897200
PG 10
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 035GH
UT WOS:000236988100026
PM 16513648
OA Bronze, Green Accepted
DA 2018-12-27
ER

PT J
AU Spadaccini, R
   Perrin, H
   Bottomley, MJ
   Ansieau, S
   Sattler, M
AF Spadaccini, R
   Perrin, H
   Bottomley, MJ
   Ansieau, S
   Sattler, M
TI RETRACTED: Structure and functional analysis of the MYND domain
   (Retracted article. See vol 376, pg. 1523, 2008)
SO JOURNAL OF MOLECULAR BIOLOGY
LA English
DT Article; Retracted Publication
DE MYND; DEAF-1; BS69; zinc binding; transcriptional regulation
ID MACROMOLECULAR STRUCTURE DETERMINATION; PROTEIN-STRUCTURE; REGULATOR
   PROTEIN; NMR EXPERIMENTS; LIM DOMAIN; TRANSCRIPTION; COREPRESSOR;
   REPRESSION; MOTIF; REFINEMENT
AB The MYND domain (named after myeloid translocation protein 8, Nervy, and DEAF-1) is a conserved zinc binding domain. It is defined by seven conserved cysteine residues and a single histidine residue that are arranged in a C(4)-C(2)HC consensus. MYND domains exist in a large number of proteins that play important roles in development or are associated with cancers and have been shown to mediate protein-protein interactions, mainly in the context of transcriptional regulation.
   We have determined the three-dimensional structure of the MYND domain from human deformed epidermal autoregulatory factor-1 (DEAF-1). The structure reveals a novel zinc binding fold, in which the C(4)-C(2)HC motif forms two sequential zinc binding sites. The first and second zinc binding modules comprise a small beta hairpin and two short alpha helices, respectively. The sequential topology of the two zinc binding sites is distinct from the cross-brace PHD and RING finger folds but has some resemblance to LIM domains. The structure reveals that the MYND domain is a novel member of the treble-clef family of zinc binding domains.
   The MYND domains of BS69 and BOP bind ligands comprising a PXLXP peptide motif. On the basis of the solution structure of the DEAF-1 MYND domain we calculated a homology model of the MYND domain of the BS69 tumor suppressor. A mutational analysis of the BS69 MYND domain indicates that positively charged residues located on one face of its MYND domain are crucial for the molecular interactions of BS69. Different binding specificities of MYND domains may depend on distinct surface charge distributions. (c) 2006 Elsevier Ltd. All rights reserved.
C1 EMBL Heidelberg, D-69117 Heidelberg, Germany.
   Ecole Normale Super Lyon, INSERM, U412, Lab Virol Humaine, F-69364 Lyon, France.
   Ist Ric Biol Mol, I-00040 Pomezia, RM, Italy.
RP Sattler, M (reprint author), EMBL Heidelberg, Meyerhofstr 1, D-69117 Heidelberg, Germany.
EM sattler@embl.de
RI Sattler, Michael/A-2407-2012; Ansieau, Stephane/I-6195-2016
OI Sattler, Michael/0000-0002-1594-0527; 
CR Ansieau S, 2002, J BIOL CHEM, V277, P4906, DOI 10.1074/jbc.M110078200
   Bottomley MJ, 2005, J BIOL CHEM, V280, P11505, DOI 10.1074/jbc.M413959200
   Bottomley MJ, 2004, EMBO REP, V5, P464, DOI 10.1038/sj.embor.7400146
   Bottomley MJ, 2001, NAT STRUCT BIOL, V8, P626, DOI 10.1038/89675
   Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254
   Capili AD, 2001, EMBO J, V20, P165, DOI 10.1093/emboj/20.1.165
   Chevallier N, 2004, BLOOD, V103, P1454
   Clore GM, 1998, P NATL ACAD SCI USA, V95, P5891, DOI 10.1073/pnas.95.11.5891
   Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740
   Cornilescu G, 1998, J AM CHEM SOC, V120, P6836, DOI 10.1021/ja9812610
   DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809
   FARROW NA, 1994, BIOCHEMISTRY-US, V33, P5984, DOI 10.1021/bi00185a040
   Gottlieb PD, 2002, NAT GENET, V31, P25, DOI 10.1038/ng866
   Grishin NV, 2001, NUCLEIC ACIDS RES, V29, P1703, DOI 10.1093/nar/29.8.1703
   Gross CT, 1996, EMBO J, V15, P1961, DOI 10.1002/j.1460-2075.1996.tb00547.x
   Hahm KM, 2004, MOL CELL BIOL, V24, P2074, DOI 10.1128/MCB.24.5.2074-2082.2004
   HOLM L, 1995, TRENDS BIOCHEM SCI, V20, P478, DOI 10.1016/S0968-0004(00)89105-7
   Huggenvik JI, 1998, MOL ENDOCRINOL, V12, P1619, DOI 10.1210/me.12.10.1619
   Hughes-Davies L, 2003, CELL, V115, P523, DOI 10.1016/S0092-8674(03)00930-9
   Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127
   Johnson Bruce A, 2004, Methods Mol Biol, V278, P313
   Kadrmas JL, 2004, NAT REV MOL CELL BIO, V5, P920, DOI 10.1038/nrm1499
   Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4
   Krishna SS, 2003, NUCLEIC ACIDS RES, V31, P532, DOI 10.1093/nar/gkg161
   KUBONIWA H, 1994, J BIOMOL NMR, V4, P871, DOI 10.1007/BF00398416
   Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148
   Lee JO, 1998, NATURE, V391, P859, DOI 10.1038/36038
   Lemonde S, 2003, J NEUROSCI, V23, P8788
   Linge JP, 2003, PROTEINS, V50, P496, DOI 10.1002/prot.10299
   Linge JP, 2001, METHOD ENZYMOL, V339, P71, DOI 10.1016/S0076-6879(01)39310-2
   Lutterbach B, 1998, MOL CELL BIOL, V18, P3604, DOI 10.1128/MCB.18.6.3604
   Marti-Renom MA, 2000, ANNU REV BIOPH BIOM, V29, P291, DOI 10.1146/annurev.biophys.29.1.291
   Masselink H, 2000, ONCOGENE, V19, P1538, DOI 10.1038/sj.onc.1203421
   Michelson RJ, 1999, J BIOL CHEM, V274, P30510, DOI 10.1074/jbc.274.43.30510
   PELTON JG, 1993, PROTEIN SCI, V2, P543
   Rossetti S, 2004, GENOMICS, V84, P1, DOI 10.1016/j.ygeno.2004.02.011
   Ruckert M, 2000, J AM CHEM SOC, V122, P7793, DOI 10.1021/ja001068h
   Sattler M, 1999, PROG NUCL MAG RES SP, V34, P93, DOI 10.1016/S0079-6565(98)00025-9
   Sims RJ, 2002, J BIOL CHEM, V277, P26524, DOI 10.1074/jbc.M204121200
   Sugawara K, 2001, GENES CELLS, V6, P599, DOI 10.1046/j.1365-2443.2001.00444.x
   Sum EYM, 2002, J BIOL CHEM, V277, P7849, DOI 10.1074/jbc.M110603200
   Tjandra N, 1997, NAT STRUCT BIOL, V4, P732, DOI 10.1038/nsb0997-732
   Wang L, 1998, EUR T ELECTR POWER, V8, P21
NR 43
TC 29
Z9 33
U1 2
U2 15
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0022-2836
J9 J MOL BIOL
JI J. Mol. Biol.
PD APR 28
PY 2006
VL 358
IS 2
BP 498
EP 508
DI 10.1016/j.jmb.2006.01.087
PG 11
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 037LY
UT WOS:000237149600014
PM 16527309
DA 2018-12-27
ER

PT J
AU Brunini, A
AF Brunini, A
TI RETRACTED: Origin of the obliquities of the giant planets in mutual
   interactions in the early Solar System (Retracted Article. See vol 443,
   pg 1013, 2006)
SO NATURE
LA English
DT Article; Retracted Publication
ID URANUS GREAT COLLISION; ANGULAR-MOMENTUM; ORBIT; PLANETESIMALS;
   ACCRETION; COMPONENT; ROTATION
AB The origin of the spin-axis orientations (obliquities) of the giant planets is a fundamental issue because if the obliquities resulted from tangential collisions with primordial Earth-sized protoplanets, then they are related to the masses of the largest planetesimals out of which the planets form(1-7). A problem with this mechanism, however, is that the orbital planes of regular satellites would probably be uncorrelated with the obliquities, contrary to observations(6,7). Alternatively, they could have come from an external twist that affected the orientation of the Solar System plane(2); but in this model, the outer planets must have formed too rapidly, before the event that produced the twist(8). Moreover, the model cannot be quantitatively tested. Here I show that the present obliquities of the giant planets were probably achieved when Jupiter and Saturn crossed the 1:2 orbital resonance(9) during a specific migration process: different migration scenarios cannot account for the large observed obliquities. The existence of the regular satellites of the giant planets does not represent a problem in this model because, although they formed soon after the planetary formation, they can follow the slow evolution of the equatorial plane it produces.
C1 Natl Univ La Plata, Fac Ciencias Astron & Geofis, RA-1900 La Plata, Argentina.
   Consejo Nacl Invest Cient & Tecn, Inst Astrofis La Plata, RA-1900 La Plata, Argentina.
RP Brunini, A (reprint author), Natl Univ La Plata, Fac Ciencias Astron & Geofis, Paseo Bosque S-N, RA-1900 La Plata, Argentina.
EM abrunini@fcaglp.unlp.edu.ar
CR ARTYMOWICZ P, 1993, ASTROPHYS J, V419, P166, DOI 10.1086/173470
   BRUNINI A, 1995, PLANET SPACE SCI, V43, P1019, DOI 10.1016/0032-0633(95)00009-T
   COLOMBO G, 1971, ICARUS, V15, P186, DOI 10.1016/0019-1035(71)90073-X
   DONES L, 1993, ICARUS, V103, P67, DOI 10.1006/icar.1993.1059
   FERNANDEZ JA, 1984, ICARUS, V58, P109, DOI 10.1016/0019-1035(84)90101-5
   GOLDREICH P, 1965, ASTRON J, V70, P5, DOI 10.1086/109673
   Gomes R, 2005, NATURE, V435, P466, DOI 10.1038/nature03676
   KORYCANSKY DG, 1990, ICARUS, V84, P528, DOI 10.1016/0019-1035(90)90051-A
   LASKAR J, 1993, NATURE, V361, P608, DOI 10.1038/361608a0
   LISSAUER JJ, 1991, ICARUS, V94, P126, DOI 10.1016/0019-1035(91)90145-J
   Lissauer JJ, 1997, ICARUS, V127, P65, DOI 10.1006/icar.1997.5689
   LISSAUER JJ, 1991, ICARUS, V93, P288, DOI 10.1016/0019-1035(91)90213-D
   MALHOTRA R, 1993, NATURE, V365, P819, DOI 10.1038/365819a0
   MIKI S, 1982, PROG THEOR PHYS, V67, P1053, DOI 10.1143/PTP.67.1053
   Parisi MG, 1997, PLANET SPACE SCI, V45, P181, DOI 10.1016/S0032-0633(96)00076-1
   Petit JM, 1999, ICARUS, V141, P367, DOI 10.1006/icar.1999.6166
   PRESS WH, 1989, NUMERICAL RECIPES, P718
   SAFRONOV VS, 1969, EVOLUTION PROTOPLANE, P113
   Thommes EW, 2003, ICARUS, V161, P431, DOI 10.1016/S0019-1035(02)00043-X
   TREMAINE S, 1991, ICARUS, V89, P85, DOI 10.1016/0019-1035(91)90089-C
   Tsiganis K, 2005, NATURE, V435, P459, DOI 10.1038/nature03539
   Ward WR, 2004, ASTRON J, V128, P2501, DOI 10.1086/424533
   WARD WR, 1988, ICARUS, V73, P330, DOI 10.1016/0019-1035(88)90103-0
NR 23
TC 7
Z9 7
U1 3
U2 10
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0028-0836
J9 NATURE
JI Nature
PD APR 27
PY 2006
VL 440
IS 7088
BP 1163
EP 1165
DI 10.1038/nature04577
PG 3
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 036OG
UT WOS:000237080000038
PM 16641989
DA 2018-12-27
ER

PT J
AU Martin, MM
   Buckenberger, JA
   Knoell, DL
   Strauch, AR
   Elton, TS
AF Martin, MM
   Buckenberger, JA
   Knoell, DL
   Strauch, AR
   Elton, TS
TI RETRACTED: TGF-beta(1) regulation of human AT(1) receptor mRNA splice
   variants harboring exon 2 (Retracted article. See vol. 434, pg. 288,
   2016)
SO MOLECULAR AND CELLULAR ENDOCRINOLOGY
LA English
DT Article; Retracted Publication
DE angiotensin II receptors; translational regulation; alternative splicing
ID ANGIOTENSIN-II TYPE-1; OPEN READING FRAMES; 5' LEADER SEQUENCE;
   MESSENGER-RNA; AT(1) RECEPTOR; TRANSLATIONAL REGULATION; 1A RECEPTOR;
   GENOMIC ORGANIZATION; CYTOSOLIC PROTEINS; GENE-EXPRESSION
AB At least four alternatively spliced mRNAs can be synthesized from the human AT(1)R (hAT(1)R) gene that differ only in the inclusion or exclusion of exon 2 and/or 3. RT-PCR experiments demonstrate that splice variants harboring exon 2 accounts for at least 30% of all the hAT(1)R mRNA transcripts expressed in the human tissues investigated. Since exon 2 contains two upstream AUGs or open reading frames (uORFs), we hypothesized that these AUGs would inhibit the translation of the downstream hAT(1)R protein ORF harbored in exon 4. This study demonstrates that the inclusion of exon 2 in hAT(1)R mRNA transcripts dramatically reduces hAT(1)R protein levels (nine-fold) and significantly attenuates Ang 11 responsiveness (similar to four-fold). Interestingly, only when both AUGs were mutated in combination were the hAT(1)R density and Ang 11 signaling levels comparable with those values obtained using mRNA splice variants that did not include exon 2. This observation is consistent with a model where the majority of the ribosomes likely translate uORF#1 and are then unable to reinitiate at the downstream hAT(1)R ORF, in part due to the presence of AUG#2 and to the short intercistronic spacing. Importantly, TGF-beta(1) treatment (4 ng/ml for 4 h) of fibroblasts up-regulated hAT(1)R mRNA splice variants, which harbored exon 2, six-fold. Since AT, R activation is closely associated with cardiovascular disease, the inclusion of exon 2 by alternative splicing represents a novel mechanism to reduce the overall production of the hAT(1)R protein and possibly limit the potential pathological effects of AT, R activation. (c) 2006 Elsevier Ireland Ltd. All rights reserved.
C1 Ohio State Univ, Div Pharmacol, Coll Pharm, Columbus, OH 43210 USA.
   Ohio State Univ, Coll Med, Dept Physiol & Cell Biol, Columbus, OH 43210 USA.
   Ohio State Univ, Davis Heart & Lung Res Inst, Columbus, OH 43210 USA.
RP Elton, TS (reprint author), Ohio State Univ, Div Pharmacol, Coll Pharm, Columbus, OH 43210 USA.
EM terry.elton@osumc.edu
FU NHLBI NIH HHS [HL48848, HL70294]
CR Berry C, 2001, AM J PHYSIOL-HEART C, V281, pH2337
   BIRD IM, 1994, ENDOCRINOLOGY, V134, P2468, DOI 10.1210/en.134.6.2468
   BORDER WA, 1994, NEW ENGL J MED, V331, P1286
   CURNOW KM, 1995, MOL ENDOCRINOL, V9, P1250, DOI 10.1210/me.9.9.1250
   Elton TS, 2003, TRENDS ENDOCRIN MET, V14, P66, DOI 10.1016/S1043-2760(02)00038-3
   Gaba A, 2001, EMBO J, V20, P6453, DOI 10.1093/emboj/20.22.6453
   GRANT CM, 1995, NUCLEIC ACIDS RES, V23, P3980, DOI 10.1093/nar/23.19.3980
   Griendling KK, 1996, ANNU REV PHARMACOL, V36, P281, DOI 10.1146/annurev.pharmtox.36.1.281
   GUO DF, 1994, BIOCHEM BIOPH RES CO, V200, P313, DOI 10.1006/bbrc.1994.1450
   Hinnebusch AG, 1997, J BIOL CHEM, V272, P21661, DOI 10.1074/jbc.272.35.21661
   HINNEBUSCH AG, 2000, TRANSLATIONAL CONTRO, P184
   Iacono M, 2005, GENE, V349, P97, DOI 10.1016/j.gene.2004.11.041
   Ji H, 2004, J BIOL CHEM, V279, P45322, DOI 10.1074/jbc.M407261200
   KASPAR RL, 1990, J BIOL CHEM, V265, P3619
   Kozak M, 2002, GENE, V299, P1, DOI 10.1016/S0378-1119(02)01056-9
   Krishnamurthi K, 1999, ENDOCRINOLOGY, V140, P5435, DOI 10.1210/en.140.11.5435
   Krishnamurthi K, 1998, BIOCHEM BIOPH RES CO, V245, P865, DOI 10.1006/bbrc.1998.8538
   LEE S, 2005, AM J PHYSL
   Martin MM, 2003, MOL CELL ENDOCRINOL, V212, P51, DOI 10.1016/j.mce.2003.09.017
   Martin MM, 2001, MOL ENDOCRINOL, V15, P281, DOI 10.1210/me.15.2.281
   Meijer HA, 2002, BIOCHEM J, V367, P1, DOI 10.1042/BJ20011706
   Mok KYK, 2003, AM J PHYSIOL-RENAL, V285, pF1085, DOI 10.1152/ajprenal.00383.2002
   Mori Y, 1996, HYPERTENSION, V28, P810, DOI 10.1161/01.HYP.28.5.810
   Morris DR, 2000, MOL CELL BIOL, V20, P8635, DOI 10.1128/MCB.20.23.8635-8642.2000
   PEACH MJ, 1990, J CARDIOVASC PHARM, V16, pS25, DOI 10.1097/00005344-199016004-00007
   Pesole G, 2001, GENE, V276, P73, DOI 10.1016/S0378-1119(01)00674-6
   Renzoni EA, 2004, RESP RES, V5, DOI 10.1186/1465-9921-5-24
   Rosenkranz S, 2004, CARDIOVASC RES, V63, P423, DOI 10.1016/j.cardiores.2004.04.030
   Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207
   Strasburger JF, 2000, PROG PEDIATR CARDIOL, V11, P1, DOI 10.1016/S1058-9813(00)00031-X
   SU BG, 1994, BIOCHEM BIOPH RES CO, V204, P1039, DOI 10.1006/bbrc.1994.2567
   Su BG, 1996, ADV EXP MED BIOL, V396, P11
   Toyz RM, 2002, BRAZ J MED BIOL RES, V35, P1001, DOI 10.1590/S0100-879X2002000900001
   Vaughan DE, 2000, CIRCULATION, V101, P1496, DOI 10.1161/01.CIR.101.13.1496
   Warnecke C, 1999, J MOL MED-JMM, V77, P718, DOI 10.1007/s001099900049
   Yamashita R, 2003, CR BIOL, V326, P987, DOI 10.1016/j.crvi.2003.09.028
   Zhang YH, 2004, GENE, V341, P93, DOI 10.1016/j.gene.2004.07.017
   Zhao X, 2001, BBA-GENE STRUCT EXPR, V1522, P195, DOI 10.1016/S0167-4781(01)00341-4
NR 38
TC 8
Z9 8
U1 3
U2 5
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0303-7207
J9 MOL CELL ENDOCRINOL
JI Mol. Cell. Endocrinol.
PD APR 25
PY 2006
VL 249
IS 1-2
BP 21
EP 31
DI 10.1016/j.mce.2006.01.009
PG 11
WC Cell Biology; Endocrinology & Metabolism
SC Cell Biology; Endocrinology & Metabolism
GA 037QC
UT WOS:000237160800004
PM 16504375
DA 2018-12-27
ER

PT J
AU Wang, ZW
   Zhang, YX
   Banerjee, S
   Li, YW
   Sarkar, FH
AF Wang, ZW
   Zhang, YX
   Banerjee, S
   Li, YW
   Sarkar, FH
TI RETRACTED: Inhibition of nuclear factor kappa B activity by genistein is
   mediated via Notch-1 signaling pathway in pancreatic cancer cells
   (Retracted article. See vol.139,pg.2145,2016)
SO INTERNATIONAL JOURNAL OF CANCER
LA English
DT Article; Retracted Publication
DE Notch-1 signaling pathway; genistein; NF-kappa B
ID BREAST-CANCER; UP-REGULATION; APOPTOSIS; DIFFERENTIATION; INDUCTION;
   TARGET; DEATH; ACTIVATION; P21(WAF1); SURVIVAL
AB Pancreatic cancer remains the fourth most common cause of cancer related death in the United States. Therefore, novel strategies for the prevention and treatment are urgently needed. Genistein is a prominent isoflavonoid found in soy products and has been proposed to be responsible for lowering the rate of pancreatic cancer in Asians. However, the molecular mechanism(s) by which genistein elicits its effects on pancreatic cancer cells has not been fully elucidated. We have previously shown that genistein induces apoptosis and inhibits the activation of nuclear factor KB (NF-kappa B) pathway. Moreover, Notch signaling is known to play a critical role in maintaining the balance between cell proliferation, differentiation and apoptosis, and thereby may contribute to the development of pancreatic cancer. Hence, in our study, we investigated whether there is any cross talk between Notch and NF-kappa B during genisteminduced apoptosis in BxPC-3 pancreatic cancer cells. We used multiple cellular and molecular approaches such as MTT assay, apoptosis assay, gene transfection, Western blotting and EMSA for measuring DNA binding activity of NF-kappa B. We found that genistein inhibits cell growth and induces apoptotic processes in BxPC-3 pancreatic cancer cells. This was partly due to inhibition of Notch-1 activity. BxPC-3 cells transfected with Notch-1 cDNA showed induction of NF-kappa B activity, and this was inhibited by genistein treatment. From these results, we conclude that the inhibition of Notch-1 and NF-kappa B activity and their cross talk provides a novel mechanism by which genistein inhibits cell growth and induces apoptotic processes in pancreatic cancer cells. (c) 2005 Wiley-Liss, Inc.
C1 Wayne State Univ, Karmanos Canc Inst, Sch Med, Dept Pathol, Detroit, MI 48201 USA.
RP Sarkar, FH (reprint author), Wayne State Univ, Karmanos Canc Inst, Sch Med, Dept Pathol, 9374 Scott Hall,540 E Canfield, Detroit, MI 48201 USA.
EM fsarkar@med.wayne.edu
RI Wang, Zhiwei/A-6809-2011
FU NCI NIH HHS [1P20-CA010193-01, 5R01CA101870-02]
CR Aster JC, 2000, MOL CELL BIOL, V20, P7505, DOI 10.1128/MCB.20.20.7505-7515.2000
   Bigas A, 1998, MOL CELL BIOL, V18, P2324, DOI 10.1128/MCB.18.4.2324
   Bradlow HL, 2002, ANN NY ACAD SCI, V963, P247
   Bresnick EH, 2000, J CELL BIOCHEM, P46
   Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4
   Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318
   Chen LF, 2001, SCIENCE, V293, P1653, DOI 10.1126/science.1062374
   Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905
   Davis JN, 1998, NUTR CANCER, V32, P123, DOI 10.1080/01635589809514730
   FOTSIS T, 1995, J NUTR, V125, pS790, DOI 10.1093/jn/125.suppl_3.790S
   Gong LJ, 2003, ONCOGENE, V22, P4702, DOI 10.1038/sj.onc.1206583
   Goodman MT, 1997, AM J EPIDEMIOL, V146, P294
   GRILLI M, 1993, INT REV CYTOL, V143, P1
   Jang MS, 2004, J CELL PHYSIOL, V199, P418, DOI 10.1002/jcp.10467
   Jemal A, 2004, CA-CANCER J CLIN, V54, P8, DOI 10.3322/canjclin.54.1.8
   Li YW, 1999, ONCOGENE, V18, P3166, DOI 10.1038/sj.onc.1202650
   Li YW, 1999, INT J ONCOL, V15, P525
   Li YW, 2004, PANCREAS, V28, pE90, DOI 10.1097/00006676-200405000-00020
   Li YW, 2002, CLIN CANCER RES, V8, P2369
   Lian FR, 1998, NUTR CANCER, V31, P184, DOI 10.1080/01635589809514701
   Miele L, 1999, J CELL PHYSIOL, V181, P393, DOI 10.1002/(SICI)1097-4652(199912)181:3<393::AID-JCP3>3.0.CO;2-6
   Miyamoto Y, 2003, CANCER CELL, V3, P565, DOI 10.1016/S1535-6108(03)00140-5
   Mumm JS, 2000, DEV BIOL, V228, P151, DOI 10.1006/dbio.2000.9960
   Nair P, 2003, J VIROL, V77, P7106, DOI 10.1128/JVI.77.12.7106-7112.2003
   Nickoloff BJ, 2003, ONCOGENE, V22, P6598, DOI 10.1038/sj.onc.1206758
   Ohishi K, 2003, SEMIN CELL DEV BIOL, V14, P143, DOI 10.1016/S1084-9521(02)00183-0
   Osborne B, 1999, IMMUNITY, V11, P653, DOI 10.1016/S1074-7613(00)80140-5
   Oswald F, 1998, MOL CELL BIOL, V18, P2077, DOI 10.1128/MCB.18.4.2077
   Sade H, 2004, J BIOL CHEM, V279, P2937, DOI 10.1074/jbc.M309924200
   Wang Y, 2004, P NATL ACAD SCI USA, V101, P9458, DOI 10.1073/pnas.0308126101
   Weijzen S, 2002, NAT MED, V8, P979, DOI 10.1038/nm754
   Yanagawa S, 2000, J VIROL, V74, P9786, DOI 10.1128/JVI.74.20.9786-9791.2000
NR 32
TC 104
Z9 109
U1 3
U2 10
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0020-7136
EI 1097-0215
J9 INT J CANCER
JI Int. J. Cancer
PD APR 15
PY 2006
VL 118
IS 8
BP 1930
EP 1936
DI 10.1002/ijc.21589
PG 7
WC Oncology
SC Oncology
GA 027ES
UT WOS:000236397200011
PM 16284950
OA Bronze
DA 2018-12-27
ER

PT J
AU Ali, SM
AF Ali, SM
TI RETRACTED: Scaling law of shear viscosity in atomic liquid and liquid
   mixtures (Retracted Article. See vol 125, ARTN 019901, 2006)
SO JOURNAL OF CHEMICAL PHYSICS
LA English
DT Article; Retracted Publication
ID BINARY-FLUID MIXTURE; MODE-COUPLING THEORY; DIFFUSION-COEFFICIENT;
   CROSS-DIFFUSIVITY; SELF-DIFFUSION
AB A scaling law relating the shear viscosity of one and two component liquid mixtures to their excess thermodynamic entropies defined through pair correlation functions is derived by approximating the mode coupling theory expressions of frictions and then combining with the Stokes-Einstein relation. Molecular dynamics simulation has been performed to generate the data of shear viscosity for one and two component liquid mixtures to test the derived scaling law. The derived scaling laws yield numerical results of shear viscosity for one component and two component liquid mixtures, which are in excellent agreement with the molecular dynamics simulation results for a wide range of density and interaction potential. (c) 2006 American Institute of Physics.
C1 Bhabha Atom Res Ctr, Div Chem Engn, Bombay 400085, Maharashtra, India.
RP Ali, SM (reprint author), Bhabha Atom Res Ctr, Div Chem Engn, Bombay 400085, Maharashtra, India.
EM musharaf@magnum.barc.ernet.in
CR ALCHALABI HA, 1970, MOL PHYS, V19, P703, DOI 10.1080/00268977000101721
   Ali SM, 2002, CHEM PHYS, V276, P301, DOI 10.1016/S0301-0104(01)00577-8
   Ali SM, 2001, J CHEM PHYS, V114, P10419, DOI 10.1063/1.1371261
   ALI SM, 1977, PHYS REV A, V15, P2545
   Allen M. P., 1987, COMPUTER SIMULATION
   Bagchi B, 2001, ADV CHEM PHYS <D>, V116, P67, DOI 10.1002/9780470141762.ch2
   Balucani U, 1994, DYNAMICS LIQUID STAT
   Bird R B, 1960, TRANSPORT PHENOMENA
   Bretonnet JL, 2002, J CHEM PHYS, V117, P9370, DOI 10.1063/1.1516594
   Cussler E. L, 1998, DIFFUSION MASS TRANS
   Duh DM, 1996, J CHEM PHYS, V104, P6742, DOI 10.1063/1.471391
   Dzugutov M, 2002, PHYS REV E, V65, DOI 10.1103/PhysRevE.65.032501
   Dzugutov M, 1996, NATURE, V381, P137, DOI 10.1038/381137a0
   FRENKEL D, 1987, UNDERSTANDING MOL SI
   GESTZI T, 1983, J PHYS C SOLID STATE, V16, P5805
   GOTZE W, 1989, LIQUIDS FREEZING GLA
   Hansen J P, 1986, THEORY SIMPLE LIQUID
   Hoheisel C., 1993, THEORETICAL TREATMEN
   Hoyt JJ, 2000, PHYS REV LETT, V85, P594, DOI 10.1103/PhysRevLett.85.594
   JACUCCI G, 1975, PHYSICA A, V80, P607, DOI 10.1016/0378-4371(75)90121-1
   MA SK, 1976, MODERN THEORY CRITI
   RAVACHE HJ, 1971, J CHEM PHYS, V35, P2242
   Rosenfeld Y, 1999, J PHYS-CONDENS MAT, V11, P5415, DOI 10.1088/0953-8984/11/28/303
   Samanta A, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.245901
   SJOGREN L, 1979, J PHYS C SOLID STATE, V12, P4369, DOI 10.1088/0022-3719/12/21/005
   VESOVIC V, 1989, CHEM ENG SCI, V44, P2181, DOI 10.1016/0009-2509(89)85152-8
   WALLACE DC, 1987, J CHEM PHYS, V87, P2282, DOI 10.1063/1.453158
NR 27
TC 5
Z9 5
U1 4
U2 12
PU AMER INST PHYSICS
PI MELVILLE
PA 1305 WALT WHITMAN RD, STE 300, MELVILLE, NY 11747-4501 USA
SN 0021-9606
EI 1089-7690
J9 J CHEM PHYS
JI J. Chem. Phys.
PD APR 14
PY 2006
VL 124
IS 14
AR 144504
DI 10.1063/1.2186322
PG 8
WC Chemistry, Physical; Physics, Atomic, Molecular & Chemical
SC Chemistry; Physics
GA 032TD
UT WOS:000236796700041
PM 16626211
DA 2018-12-27
ER

PT J
AU Tomita, M
   Kawakami, H
   Uchihara, JN
   Okudaira, T
   Masuda, M
   Matsuda, T
   Tanaka, Y
   Ohshiro, K
   Mori, N
AF Tomita, Mariko
   Kawakami, Hirochika
   Uchihara, Jun-nosuke
   Okudaira, Taeko
   Masuda, Masato
   Matsuda, Takehiro
   Tanaka, Yuetsu
   Ohshiro, Kazuiku
   Mori, Naoki
TI RETRACTED: Inhibition of constitutively active Jak-Stat pathway
   suppresses cell growth of human T-cell leukemia virus type I-infected
   T-cell lines and primary adult T-cell leukemia cells (Retracted article.
   See vol. 8, artn no. 1, 2011)
SO RETROVIROLOGY
LA English
DT Article; Retracted Publication
ID NF-KAPPA-B; TYROSINE KINASE INHIBITOR; ONCOGENE PRODUCT TAX; HTLV-I;
   MONOCLONAL-ANTIBODIES; C-MYC; ACTIVATION; PROTEIN; EXPRESSION; APOPTOSIS
AB Background: Human T-cell leukemia virus type 1 (HTLV-1), the etiologic agent for adult T-cell leukemia (ATL), induces cytokine-independent proliferation of T-cells, associated with the acquisition of constitutive activation of Janus kinases (Jak) and signal transducers and activators of transcription (Stat) proteins. Our purposes in this study were to determine whether activation of Jak-Stat pathway is responsible for the proliferation and survival of ATL cells, and to explore mechanisms by which inhibition of Jak-Stat pathway kills ATL cells.
   Results: Constitutive activation of Stat3 and Stat5 was observed in HTLV-1-infected T-cell lines and primary ATL cells, but not in HTLV-1-negative T-cell lines. Using AG490, a Jak-specific inhibitor, we demonstrated that the activation of Stat3 and Stat5 was mediated by the constitutive phosphorylation of Jak proteins. AG490 inhibited the growth of HTLV-1-infected T-cell lines and primary ATL cells by inducing G(1)cell-cycle arrest mediated by altering the expression of cyclin D2, Cdk4, p53, p21, Pim-1 and c-Myc, and by apoptosis mediated by the reduced expression of c-IAP2, XIAP, survivin and Bcl-2. Importantly, AG490 did not inhibit the growth of normal peripheral blood mononuclear cells.
   Conclusion: Our results indicate that activation of Jak-Stat pathway is responsible for the proliferation and survival of ATL cells. Inhibition of this pathway may provide a new approach for the treatment of ATL.
C1 Univ Ryukyus, Grad Sch Med, Div Mol Virol & Oncol, Nishihara, Okinawa 9030215, Japan.
   Univ Ryukyus, Fac Med, Div Endocrinol & Metab, Nishihara, Okinawa 9030215, Japan.
   Univ Ryukyus, Fac Med, Div Child Hlth & Welf, Nishihara, Okinawa 9030215, Japan.
   Univ Ryukyus, Fac Med, Div Immunol, Nishihara, Okinawa 9030215, Japan.
   Naha Prefectural Hosp, Dept Internal Med, Okinawa 9028531, Japan.
RP Mori, N (reprint author), Univ Ryukyus, Grad Sch Med, Div Mol Virol & Oncol, 207 Uehara, Nishihara, Okinawa 9030215, Japan.
EM mtomita@med.u-ryukyu.ac.jp; k018701@eve.u-ryukyu.ac.jp;
   juchi@mte.biglobe.ne.jp; taetae@k2.dion.ne.jp;
   mmasuda@med.u-ryukyu.ac.jp; h037233@med.u-ryukyu.ac.jp;
   yuetsu@S4.dion.ne.jp; kazuoo@ryukyu.ne.jp; n-mori@med.u-ryukyu.ac.jp
CR Aoki Y, 2003, BLOOD, V101, P1535, DOI 10.1182/blood-2002-07-2130
   Borg KE, 1999, ENDOCRINOLOGY, V140, P5659, DOI 10.1210/en.140.12.5659
   Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527
   Coffer PJ, 2000, ONCOGENE, V19, P2511, DOI 10.1038/sj.onc.1203479
   Constantin G, 1999, J IMMUNOL, V162, P1144
   Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630
   De Vos J, 2000, BRIT J HAEMATOL, V109, P823, DOI 10.1046/j.1365-2141.2000.02127.x
   FRANCHINI G, 1995, BLOOD, V86, P3619
   Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0
   HINUMA Y, 1981, P NATL ACAD SCI-BIOL, V78, P6476, DOI 10.1073/pnas.78.10.6476
   Huang YP, 2001, ONCOGENE, V20, P1094, DOI 10.1038/sj.onc.1204198
   Ishiyama M, 1996, BIOL PHARM BULL, V19, P1518
   Iwanaga R, 2001, ONCOGENE, V20, P2055, DOI 10.1038/sj.onc.1204304
   Kawakami A, 1999, BLOOD, V94, P3847
   Kawakami H, 2005, INT J CANCER, V115, P967, DOI 10.1002/ijc.20954
   Kirken RA, 2000, J IMMUNOL, V165, P5097, DOI 10.4049/jimmunol.165.9.5097
   Kiuchi N, 1999, J EXP MED, V189, P63, DOI 10.1084/jem.189.1.63
   Koiwa T, 2002, J VIROL, V76, P9389, DOI 10.1128/JVI.76.18.9389-9397.2002
   Levitzki A, 2002, EUR J CANCER, V38, pS11, DOI 10.1016/S0959-8049(02)80598-6
   Lin TS, 2000, ONCOGENE, V19, P2496, DOI 10.1038/sj.onc.1203486
   MAEDA M, 1985, J EXP MED, V162, P2169, DOI 10.1084/jem.162.6.2169
   Matsuoka M, 2005, RETROVIROLOGY, V2, DOI 10.1186/1742-4690-2-27
   Meydan N, 1996, NATURE, V379, P645, DOI 10.1038/379645a0
   MIGONE TS, 1995, SCIENCE, V269, P79, DOI 10.1126/science.7604283
   MIYOSHI I, 1981, NATURE, V294, P770, DOI 10.1038/294770a0
   Mohapatra S, 2003, CANCER RES, V63, P8523
   Mori N, 1996, BLOOD, V87, P3410
   Mori N, 2002, BLOOD, V100, P1828, DOI 10.1182/blood-2002-01-0151
   Mori N, 2002, INT J CANCER, V99, P378, DOI 10.1002/ijc.10388
   Mori N, 1999, BLOOD, V93, P2360
   Mori N, 2000, BLOOD, V95, P3915
   Mulloy JC, 1998, J VIROL, V72, P4408
   NAGATA K, 1989, J VIROL, V63, P3220
   Nakamura N, 1999, ONCOGENE, V18, P2667, DOI 10.1038/sj.onc.1202608
   Nicot C, 2001, BLOOD, V98, P823, DOI 10.1182/blood.V98.3.823
   POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415
   Rainio EM, 2002, J IMMUNOL, V168, P1524, DOI 10.4049/jimmunol.168.4.1524
   SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201
   TAJIMA K, 1990, INT J CANCER, V45, P237, DOI 10.1002/ijc.2910450206
   Takemoto S, 1997, P NATL ACAD SCI USA, V94, P13897, DOI 10.1073/pnas.94.25.13897
   TANAKA Y, 1990, JPN J CANCER RES, V81, P225, DOI 10.1111/j.1349-7006.1990.tb02554.x
   TANAKA Y, 1986, INT J CANCER, V37, P35, DOI 10.1002/ijc.2910370107
   TANAKA Y, 1990, INT J CANCER, V46, P675, DOI 10.1002/ijc.2910460421
   Tomita M, 2006, INT J CANCER, V118, P765, DOI 10.1002/ijc.21389
   Tomita M, 2004, ONCOGENE, V23, P8272, DOI 10.1038/sj.onc.1208059
   Wang LH, 1999, J IMMUNOL, V162, P3897
   Yamada Y, 2001, BRIT J HAEMATOL, V113, P375, DOI 10.1046/j.1365-2141.2001.02737.x
   YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031
NR 48
TC 33
Z9 34
U1 3
U2 14
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1742-4690
J9 RETROVIROLOGY
JI Retrovirology
PD APR 9
PY 2006
VL 3
AR 22
DI 10.1186/1742-4690-3-22
PG 10
WC Virology
SC Virology
GA 067OP
UT WOS:000239312800001
PM 16603085
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Hricak, H
AF Hricak, H
TI RETRACTED: New horizons in genitourinary oncologic imaging (Retracted
   article. See vol. 40, pg. 2065, 2015)
SO ABDOMINAL IMAGING
LA English
DT Article; Proceedings Paper; Retracted Publication
CT 11th Annual Symposium of the European-Society-of-Urogenital-Radiology
CY SEP, 2004
CL Santiago de Compostela, SPAIN
SP European Soc Urogenital Radiol
DE genitourinary cancer; magnetic resonance imaging; magetic resonance
   spectroscopic imaging; molecular probes
ID RADICAL RETROPUBIC PROSTATECTOMY; EXTRACAPSULAR EXTENSION; SEXTANT
   BIOPSY; CANCER; LOCALIZATION; PREDICTION; ANTIGEN; HISTORY
AB In the management of prostate cancer, combined anatomic and metabolic imaging is already in clinical use. In daily clinical practice, fusion of magnetic resonance imaging and magnetic resonance spectroscopic imaging is improving the evaluation of cancer location, size, and extent and is simultaneously providing assessment of tumor aggressiveness. Pretreatment knowledge of these prognostic variables is essential if minimally invasive, patient-specific cancer therapy is to be achieved. This report discusses the changes that are occurring in oncologic imaging and in genitourinary oncologic imaging in particular. It presents an overview of the applications of magnetic resonance imaging and magnetic resonance spectroscopic imaging for prostate cancer that is intended to illustrate the evolution of state-of-the-art imaging in a clinical setting. It also provides a short review of molecular imaging probes from the field of ongoing prostate cancer research. It concludes with a broader discussion of the nature of molecular imaging and the benefits it offers for cancer research and clinical care, which include noninvasive, in vivo imaging of specific cellular and molecular processes, nearly simultaneous monitoring of multiple molecular events, real-time imaging of the trafficking and targeting of cells, optimal patient-specific adjustment of drug and gene therapy, and assessment of disease progression at a molecular pathologic level.
C1 Mem Sloan Kettering Canc Ctr, Dept Radiol, New York, NY 10021 USA.
RP Hricak, H (reprint author), Mem Sloan Kettering Canc Ctr, Dept Radiol, 1275 York Ave,Room C-278, New York, NY 10021 USA.
EM hricakh@mskcc.org
CR Bander NH, 2003, SEMIN ONCOL, V30, P667, DOI 10.1053/S0093-7754(03)00358-0
   Beyersdorff D, 2002, RADIOLOGY, V224, P701, DOI 10.1148/radiol.2243011553
   BRETHEAU D, 1995, EUR UROL, V27, P319
   Coakley FV, 2002, J UROLOGY, V168, P1032, DOI 10.1097/01.ju.0000025881.75827.a5
   Coakley FV, 2002, UROLOGY, V59, P884, DOI 10.1016/S0090-4295(02)01614-X
   Heath James R, 2003, Mol Imaging Biol, V5, P312, DOI 10.1016/j.mibio.2003.10.001
   Hricak H, 2004, CANCER, V100, P2655, DOI 10.1002/cncr.20319
   Rendon RA, 2000, J UROLOGY, V164, P1143, DOI 10.1016/S0022-5347(05)67129-7
   Ries LA, 1975, SEER CANC STAT REV
   Scheidler J, 1999, RADIOLOGY, V213, P473, DOI 10.1148/radiology.213.2.r99nv23473
   Steinberg DM, 1997, AM J SURG PATHOL, V21, P566, DOI 10.1097/00000478-199705000-00010
   Terris MK, 2002, UROL CLIN N AM, V29, P205, DOI 10.1016/S0094-0143(02)00005-8
   Wang L, 2004, RADIOLOGY, V232, P133, DOI 10.1148/radiol.2321031086
   Wefer AE, 2000, J UROLOGY, V164, P400, DOI 10.1016/S0022-5347(05)67370-3
   Yu KK, 1999, RADIOLOGY, V213, P481, DOI 10.1148/radiology.213.2.r99nv26481
   Zakian KL, 2005, RADIOLOGY, V234, P804, DOI 10.1148/radiol.2343040363
NR 16
TC 9
Z9 10
U1 3
U2 6
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0942-8925
EI 1432-0509
J9 ABDOM IMAGING
JI Abdom. Imaging
PD APR
PY 2006
VL 31
IS 2
BP 182
EP 187
DI 10.1007/s00261-005-0385-6
PG 6
WC Gastroenterology & Hepatology; Radiology, Nuclear Medicine & Medical
   Imaging
SC Gastroenterology & Hepatology; Radiology, Nuclear Medicine & Medical
   Imaging
GA 028MI
UT WOS:000236491200007
PM 16333696
DA 2018-12-27
ER

PT J
AU Oka, H
   Mochio, S
   Yoshioka, M
   Morita, M
   Onouchi, K
   Inoue, K
AF Oka, H
   Mochio, S
   Yoshioka, M
   Morita, M
   Onouchi, K
   Inoue, K
TI RETRACTED: Cardiovascular dysautonomia in Parkinson's disease and
   multiple system atrophy (Retracted Article. See vol 118, pg 208, 2008)
SO ACTA NEUROLOGICA SCANDINAVICA
LA English
DT Article; Retracted Publication
DE Parkinson's disease; multiple system atrophy; cardiovascular
   dysautonomia; cardiac iodine-123 meta-iodobenzylguanidine (I-123-MIBG)
   scintigraphy; Valsalva maneuver; baroreceptor reflex sensitivity
ID ORTHOSTATIC HYPOTENSION; VALSALVA MANEUVER; AUTONOMIC DYSFUNCTION;
   SYMPATHETIC DENERVATION; MYOCARDIAL SCINTIGRAPHY; BAROREFLEX
   SENSITIVITY; MIBG UPTAKE; DIFFERENTIATION; FAILURE
AB Obectives - To determine whether Parkinson's disease (PD) can be distinguished from multiple system atrophy (MSA) on the basis of the assessment of iodine-123 meta-iodobenzylguanidine (I-123-MIBG) radioactivity in heart and cardiovascular autonomic function.
   Patients and methods - Seventeen patients with MSA, 39 with PD, and 25 healthy volunteers underwent I-123-MIBG scintigraphy and hemodynamic autonomic function tests using Valsalva maneuver (VM). Baroreceptor reflex sensitivity (BRS) was measured using the slope of the relation between RR interval and blood pressure during the fourth phase.
   Results - I-123-MIBG radioactivity in heart of patients with PD was lower than that of control subjects and patients with MSA, but there was some overlap between PD and MSA. BRS in patients with PD who had a I-123-MIBG radioactivity similar to that in MSA was larger than that in patients with MSA, with no overlap in any patient.
   Conclusion - Assessment of BRS may be useful for differentiating between MSA and PD that had a I-123-MIBG radioactivity similar to MSA.
C1 Jikei Univ, Aoto Hosp, Sch Med, Dept Neurol,Katsushika Ku, Tokyo 1258506, Japan.
   Third Hosp, Tokyo, Japan.
   Jikei Univ, Sch Med, Main Hosp, Tokyo, Japan.
RP Oka, H (reprint author), Jikei Univ, Aoto Hosp, Sch Med, Dept Neurol,Katsushika Ku, 6-41-2 Aoto, Tokyo 1258506, Japan.
EM h.oka@jikei.ac.jp
CR Benarroch EE, 2003, NEUROLOGY, V60, P115, DOI 10.1212/01.WNL.0000042087.07133.87
   BENNETT T, 1978, DIABETES, V27, P1167, DOI 10.2337/diabetes.27.12.1167
   Braune S, 1999, NEUROLOGY, V53, P1020, DOI 10.1212/WNL.53.5.1020
   CALNE DB, 1992, ANN NEUROL, V32, pS125, DOI 10.1002/ana.410320721
   COHEN J, 1987, ANN NEUROL, V22, P692, DOI 10.1002/ana.410220604
   COLOSIMO C, 1995, ARCH NEUROL-CHICAGO, V52, P294, DOI 10.1001/archneur.1995.00540270090024
   DANIEL SE, 1999, AUTONOMIC FAILURE TX, P321
   Druschky A, 2000, J NEUROL SCI, V175, P3, DOI 10.1016/S0022-510X(00)00279-3
   ELISBERG EI, 1953, AM HEART J, V45, P227, DOI 10.1016/0002-8703(53)90183-5
   Gilman S, 1999, J NEUROL SCI, V163, P94, DOI 10.1016/S0022-510X(98)00304-9
   GILMAN S, 1998, PARKINSONS DIS MOVEM, P245
   Goldstein DS, 2002, NEUROLOGY, V58, P1247, DOI 10.1212/WNL.58.8.1247
   Goldstein DS, 2000, ANN INTERN MED, V133, P338, DOI 10.7326/0003-4819-133-5-200009050-00009
   Goldstein DS, 2003, LANCET NEUROL, V2, P669, DOI 10.1016/S1474-4422(03)00555-6
   Hillen ME, 1996, ARCH PHYS MED REHAB, V77, P710, DOI 10.1016/S0003-9993(96)90013-1
   Hopkins DA, 1996, PROG BRAIN RES, V107, P79
   HOSHINO PK, 1988, AM J CARDIOL, V61, P400, DOI 10.1016/0002-9149(88)90953-8
   Kautzner J, 1996, AM J CARDIOL, V78, P575, DOI 10.1016/S0002-9149(96)00370-0
   MAGALHAES M, 1995, ACTA NEUROL SCAND, V91, P98
   Mathias CJ, 1998, CLIN NEUROSCI, V5, P153
   MATTHEWS MR, 1999, AUTONOMIC FAILURE TX, P331
   MICIELI G, 1987, NEUROLOGY, V37, P386, DOI 10.1212/WNL.37.3.386
   Oka H, 2001, Rinsho Shinkeigaku, V41, P283
   Oka H, 2003, EUR NEUROL, V50, P230, DOI 10.1159/000073865
   Oka Hisayoshi, 2003, Rinsho Shinkeigaku, V43, P465
   Orimo S, 1999, J NEUROL NEUROSUR PS, V67, P189, DOI 10.1136/jnnp.67.2.189
   Orimo S, 2002, J NEUROL NEUROSUR PS, V73, P776, DOI 10.1136/jnnp.73.6.776
   Orimo S, 2001, NEUROLOGY, V57, P1140, DOI 10.1212/WNL.57.6.1140
   PALMERO HA, 1981, HYPERTENSION, V3, P134, DOI 10.1161/01.HYP.3.6_Pt_2.II-134
   PERANI D, 1995, ARCH NEUROL-CHICAGO, V52, P179, DOI 10.1001/archneur.1995.00540260085021
   QUINN N, 1989, J NEUROL NEUROSUR PS, P78
   RAJPUT AH, 1984, ANN NEUROL, V16, P278, DOI 10.1002/ana.410160303
   Reinhardt MJ, 2000, EUR J NUCL MED, V27, P595, DOI 10.1007/s002590050548
   Sandroni P, 1991, Clin Auton Res, V1, P147, DOI 10.1007/BF01826212
   SANDRONI P, 1991, J APPL PHYSIOL, V71, P1563
   Senard JM, 1997, J NEUROL NEUROSUR PS, V63, P584, DOI 10.1136/jnnp.63.5.584
   Senard JM, 2001, DRUG AGING, V18, P495, DOI 10.2165/00002512-200118070-00003
   Yoshita M, 1998, J NEUROL SCI, V155, P60, DOI 10.1016/S0022-510X(97)00278-5
NR 38
TC 18
Z9 18
U1 3
U2 9
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0001-6314
EI 1600-0404
J9 ACTA NEUROL SCAND
JI Acta Neurol. Scand.
PD APR
PY 2006
VL 113
IS 4
BP 221
EP 227
DI 10.1111/j.1600-0404.2005.00526.x
PG 7
WC Clinical Neurology
SC Neurosciences & Neurology
GA 019WG
UT WOS:000235867400002
PM 16542160
DA 2018-12-27
ER

PT J
AU Lee, SW
   Yang, JS
   Chouinard, Y
   Van, BN
AF Lee, SW
   Yang, JS
   Chouinard, Y
   Van, BN
TI RETRACTED: Effect of dietary soybeans extruded at different temperatures
   on dairy cow milk composition (Retracted Article. See vol 20, Jan 2007)
SO ASIAN-AUSTRALASIAN JOURNAL OF ANIMAL SCIENCES
LA English
DT Article; Retracted Publication
DE milk fatty acids; extruded soybeans; biohydrogenation
ID TREATED WHOLE SOYBEANS; FATTY-ACID-COMPOSITION; EARLY LACTATION;
   PROTEIN; RAW; RATIONS; RUMEN; YIELD; MEAL; OIL
AB Twenty-four multiparous Holstein cows, 4 of which were ruminanlly fistulated, were assigned to one of four diets containing full-fat soy beans, either raw or extruded at 120, 130, or 140 degrees C. Our hypothesis was that the extrusion of full-fat soybeans, as well as the extrusion temperature, would affect the bypass of fatty acids in the rumen and, thus would modify the ratty acid profile of milk fat. Total mixed diets containing 23.7% soybeans (percentage of DM) were fed for 8 wks. Milk yield was lower, and the proportion of milk CP was higher, for cows fed raw soybeans than for cows fed extruded soybeans. Compared with raw soybeans, extruded soybeans increased the concentration of Delta-11-trans-C-18:1 from 2.72 to 11.41% in milk fat but had no effect on yield of percentage of milk fat. Polyunsaturated fatty acids of raw soybeans disappeared more rapidly than did those of extruded soybeans from bags incubated in the rumen of fistulated cows. However, more Delta-11-trans-C-18:1 and C-18:0 appeared in bags containing extruded soybeans than in bags containing raw soybeans. Extrusion of full-fat soybeans influenced the metabolism of fatty acids in the rumen and the fatty acid profile of milk fat, but the temperature of extrusion had only minor effects on these parameters.
C1 Sungkyunkwan Univ, Fac Life Sci & Technol, Seoul, South Korea.
RP Van, BN (reprint author), Sungkyunkwan Univ, Fac Life Sci & Technol, Seoul, South Korea.
EM ngbinh2002@yahoo.com
CR AHRAR M, 1979, J DAIRY SCI, V62, P932, DOI 10.3168/jds.S0022-0302(79)83351-2
   *ASS OFF AN CHEM, 1984, OFF METH AN
   BANKS W, 1990, J DAIRY RES, V57, P179, DOI 10.1017/S0022029900026789
   BANKS W, 1980, J SCI FOOD AGR, V31, P368, DOI 10.1002/jsfa.2740310407
   BANKS W, 1983, P NUTR SOC, V42, P399, DOI 10.1079/PNS19830047
   BLOCK E, 1981, J DAIRY SCI, V64, P1813, DOI 10.3168/jds.S0022-0302(81)82770-1
   Christie W. W., 1981, LIPID METABOLISM RUM, P193
   CHRISTIE W. W., 1989, GAS CHROMATOGRAPHY L
   FALDET MA, 1991, J DAIRY SCI, V74, P3047, DOI 10.3168/jds.S0022-0302(91)78490-7
   GAYNOR PJ, 1994, J DAIRY SCI, V77, P157, DOI 10.3168/jds.S0022-0302(94)76938-1
   GROERING HK, 1970, AGR HDB, V379
   GUILLAUME B, 1991, J DAIRY SCI, V74, P1912, DOI 10.3168/jds.S0022-0302(91)78357-4
   LEONARD M, 1988, J DAIRY SCI, V71, P2709, DOI 10.3168/jds.S0022-0302(88)79864-1
   MIELKE CD, 1981, J DAIRY SCI, V64, P1579, DOI 10.3168/jds.S0022-0302(81)82728-2
   MOHAMED OE, 1988, J DAIRY SCI, V71, P2677, DOI 10.3168/jds.S0022-0302(88)79861-6
   MOJONIER T, 1992, INSTRUCTION MANUAL S
   *NAT RES COUNC, 1989, NUTR REQ DAIR CATTL
   PALMQUIST DL, 1980, J DAIRY SCI, V63, P391, DOI 10.3168/jds.S0022-0302(80)82945-6
   PALMQUIST DL, 1980, J DAIRY SCI, V63, P1, DOI 10.3168/jds.S0022-0302(80)82881-5
   REDDY PV, 1994, J DAIRY SCI, V77, P3410, DOI 10.3168/jds.S0022-0302(94)77283-0
   RUEGSEGGER GJ, 1985, J DAIRY SCI, V68, P3272, DOI 10.3168/jds.S0022-0302(85)81236-4
   SAS (Statistical Analysis System Institute Inc. USA), 1985, SAS US GUID STAT VER
   SCOTT TA, 1991, J DAIRY SCI, V74, P2555, DOI 10.3168/jds.S0022-0302(91)78433-6
   STEELE W, 1985, J DAIRY SCI, V68, P1409, DOI 10.3168/jds.S0022-0302(85)80977-2
   STERN MD, 1985, J DAIRY SCI, V68, P45, DOI 10.3168/jds.S0022-0302(85)80796-7
   TICE EM, 1993, J DAIRY SCI, V76, P224, DOI 10.3168/jds.S0022-0302(93)77341-5
   Ure AL, 2005, ASIAN AUSTRAL J ANIM, V18, P980, DOI 10.5713/ajas.2005.980
   VANDIJK HJ, 1983, J DAIRY SCI, V66, P2521, DOI 10.3168/jds.S0022-0302(83)82121-3
   VARLEY JA, 1966, ANALYST, V91, P119, DOI 10.1039/an9669100119
NR 29
TC 3
Z9 3
U1 2
U2 12
PU ASIAN-AUSTRALASIAN ASSOC ANIMAL PRODUCTION SOC
PI SEOUL
PA ROOM 708 SAMMO SPOREX, 1638-32, SEOWON-DONG, GWANAK-GU, SEOUL 151-730,
   SOUTH KOREA
SN 1011-2367
EI 1976-5517
J9 ASIAN AUSTRAL J ANIM
JI Asian Australas. J. Anim. Sci.
PD APR
PY 2006
VL 19
IS 4
BP 541
EP 548
PG 8
WC Agriculture, Dairy & Animal Science
SC Agriculture
GA 007IN
UT WOS:000234962400014
OA DOAJ Gold
DA 2018-12-27
ER

PT J
AU Mei, YQ
   Liu, H
   Long, C
   Cheng, BC
   Gao, SZ
   Hu, DY
AF Mei, Yunqing
   Liu, Hua
   Long, Cun
   Cheng, Bangchang
   Gao, Shangzhi
   Hu, Dayi
TI RETRACTED: Effect of four crystalloid cardioplegias on immature rabbit
   hearts during global ischaemia (Retracted article. See vol 31, pg. 40,
   2008)
SO ASIAN JOURNAL OF SURGERY
LA English
DT Article; Retracted Publication
DE crystalloid cardioplegia; immature myocardium; ischaemia; Langendorff
   mode
ID MYOCARDIAL PROTECTION; BRETSCHNEIDER; CALCIUM; ARREST
AB OBJECTIVE: Controversy surrounds the reported beneficial effects of crystalloid cardioplegic solutions in the immature myocardium. In the present study, we investigated the efficacy of four clinical cardioplegic solutions in the immature myocardium to determine if cardioplegic protection could be demonstrated and, if yes, the relative efficacy of the four solutions.
   METHODS: Isolated, working hearts (n = 6 per group) from neonatal rabbits (age, 7-14 days) were perfused aerobically (37 degrees C) for 15 minutes in the Langendorff mode and 30 minutes in the working mode before a 2-minute infusion of one of four cardioplegic solutions: the modified St. Thomas' Hospital no. 1 cardioplegic solution, Tyers solution, Bretschneider solution or Roe solution. Hearts were then rendered globally ischaemic for 120 minutes at 14 degrees C before reperfusion for 15 minutes in the Langendorff mode and 30 minutes in the working mode. The post-ischaemic recovery of cardiac function and leakage of myocardial enzymes (GOT, CK, CK-MB, LDH, LDH1) were compared with results in noncardioplegic control hearts.
   RESULTS: Good protection was observed with modified St. Thomas' Hospital and Tyers solutions: post-ischaemic recovery of cardiac output was increased from 80.43 +/- 3.62% in the noncardioplegic group to 85.19 +/- 3.12% and 70.66 +/- 3.48% in the St. Thomas' Hospital and Tyers groups (p < 0.05), respectively. In contrast, no obvious protection was observed with either the Bretschneider or Roe solutions: cardiac output recovered to 45.08 +/- 3.16% and 30.06 +/- 2.59%, respectively. Post-ischaemic CK leakage was 19.83 +/- 2.14 IU/mL and 21.17 +/- 2.32 IU/mL in the St. Thomas' Hospital and Tyers groups (p > 0.05). In the Bretschneider group, CK leakage increased to 30.00 +/- 3.16 IU/mL (p < 0.01 vs. noncardioplegic control hearts), and in the Roe group, CK leakage was 31.00 +/- 5.10 IU/mL (p < 0.05 vs. cardioplegic-free hearts). Post-ischaemic ATP was 1.98 +/- 0.54 mu mol/g.dry weight and 1.35 +/- 0.39 mu mol/g.dry weight in the St. Thomas' Hospital and Tyers groups (p < 0.01 vs. noncardioplegic control group), respectively. In the Bretschneider group, ATP decreased to 0.91 +/- 0.16 mu mol/g.dry weight (p < 0.05 vs. noncardioplegic control hearts), and in the Roe group to 0.88 +/- 0.10 mu mol/g.dry weight (p < 0.01 vs. cardioplegic-free hearts).
   CONCLUSION: In conclusion, cardioplegic protection can be achieved in the immature rabbit myocardium with both St. Thomas' Hospital and Tyers solutions, but acalcaemic solutions such as Bretschneider and Roe solutions increased damage. The reported lack of cardioplegic efficacy in the immature myocardium may, therefore, reflect the choice of cardioplegic solution rather than a greater vulnerability to injury in the neonatal heart.
C1 Tongji Univ, Affiliated Tongji Hosp, Dept Cardiovasc Thorac Surg, Shanghai 200065, Peoples R China.
RP Mei, YQ (reprint author), Tongji Univ, Affiliated Tongji Hosp, Dept Cardiovasc Thorac Surg, Shanghai 200065, Peoples R China.
EM meiyq2000@yahoo.com.cn
CR BAKER J E, 1986, Surgical Forum (Chicago), V37, P293
   BOVE EL, 1987, J THORAC CARDIOV SUR, V94, P115
   BULL C, 1984, J THORAC CARDIOV SUR, V88, P287
   CHRISTOFFERSEN GRJ, 1975, COMP BIOCHEM PHYS A, V52, P317, DOI 10.1016/S0300-9629(75)80094-6
   DELNIDO PJ, 1988, J THORAC CARDIOV SUR, V95, P223
   HEARSE DJ, 1981, PROTECTION ISCHEMIC, P209
   Kober IM, 1998, EUR SURG RES, V30, P243, DOI 10.1159/000008583
   MEI YQ, 2002, ANHUI MED ACTA, V37, P290
   MEI YQ, 2000, CHIN J EXP SURG, V17, P245
   MEI YQ, 2000, CHIN J ANESTH, V20, P493
   MEI YQ, 2000, CHIN J EXP SURG, V17, P497
   PODESSER B, 1994, EUR SURG RES, V26, P133, DOI 10.1159/000129328
   ROBINSON LA, 1984, ANN THORAC SURG, V38, P268, DOI 10.1016/S0003-4975(10)62250-3
   TOMLINSON C W, 1987, Canadian Journal of Cardiology, V3, P136
   WILSON GJ, 1990, THORAC CARDIOV SURG, V38, P10, DOI 10.1055/s-2007-1013983
   YAMAMOTO F, 1984, J THORAC CARDIOV SUR, V87, P908
NR 16
TC 4
Z9 6
U1 6
U2 11
PU ELSEVIER SINGAPORE PTE LTD
PI SINGAPORE
PA 3 KILLINEY ROAD 08-01, WINSLAND HOUSE 1, SINGAPORE, 239519, SINGAPORE
SN 1015-9584
EI 0219-3108
J9 ASIAN J SURG
JI Asian J. Surg.
PD APR
PY 2006
VL 29
IS 2
BP 79
EP 85
DI 10.1016/S1015-9584(09)60112-3
PG 7
WC Surgery
SC Surgery
GA 122JW
UT WOS:000243223500004
PM 16644507
OA Bronze
DA 2018-12-27
ER

PT J
AU Safarinejad, MR
   Hosseini, SY
AF Safarinejad, MR
   Hosseini, SY
TI RETRACTED: Safety and efficacy of tramadol in the treatment of
   idiopathic detrusor overactivity: a double-blind, placebo-controlled,
   randomized study (Retracted article. See vol. 77, pg. 216, 2014)
SO BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
LA English
DT Article; Retracted Publication
DE bladder; detrusor overactivity; tramadol; treatment; urinary
   incontinence
ID CENTRAL-NERVOUS-SYSTEM; URINARY-TRACT FUNCTION; INTRAVESICAL
   RESINIFERATOXIN; BLADDER; RAT; MECHANISMS; STANDARDIZATION;
   CONTRACTIONS; TERMINOLOGY; OXYBUTYNIN
AB Aim To evaluate the efficacy and safety of tramadol in patients with idiopathic detrusor overactivity (IDO).
   Methods A total of 76 patients 18 years or older with IDO were randomly assigned to receive 100 mg tramadol sustained release (group 1, n = 38) or placebo (group 2, n = 38) every 12 h for 12 weeks. Clinical evaluation was performed at baseline and every 2 weeks during treatment. All patients underwent urodynamics and ice water test at baseline and 12-week treatment. Main outcome measures were number of voids per 24 h, urine volume per void and episodes of urge incontinence per 24 h on a frequency volume chart and detailed recording of adverse effect.
   Results After 12 weeks of treatment mean number of voids per 24 h +/- SD decreased from 9.3 +/- 3.2 to 5.1 +/- 2.1 (P < 0.001 vs. placebo) [95% confidence interval (CI) -5.1--0.4]. At that time mean urine volume per void increased from 158 +/- 32 to 198 +/- 76 ml (P < 0.001 vs. placebo) (95% CI 8-22), while mean number of incontinence episodes per 24 h decreased from 3.2 +/- 3.3 to 1.6 +/- 2.8 (P < 0.001 vs. placebo) (95% CI -2-0.3). Tramadol induced significant improvements in urodynamic parameters. More adverse effects were associated with tramadol treatment than with placebo (P < 0.05). The main adverse event with tramadol was nausea.
   Conclusions In patients with non-neurogenic IDO tramadol provided beneficial clinical and urodynamic results. Further studies are required to draw final conclusions on the efficacy of this drug in IDO.
C1 Shaheed Beheshti Univ Med Sci, Urol Nephrol Res Ctr, Tehran, Iran.
RP Safarinejad, MR (reprint author), POB 19395-1849, Tehran, Iran.
EM safarinejad@unrc.ir
OI Safarinejad, Mohammad Reza/0000-0003-3055-5915; Hosseini,
   Yousef/0000-0001-5069-8548
CR Abrams P, 1998, BRIT J UROL, V81, P801
   Abrams P, 2002, NEUROUROL URODYNAM, V21, P167, DOI 10.1002/nau.10052
   Altunkaya H, 2003, BRIT J ANAESTH, V90, P320, DOI 10.1093/bja/aeg079
   Andersson KE, 2002, UROLOGY, V59, P18, DOI 10.1016/S0090-4295(01)01634-X
   CARLSSON KH, 1987, EUR J PHARMACOL, V139, P1, DOI 10.1016/0014-2999(87)90491-2
   Chai TC, 1998, J UROLOGY, V160, P34, DOI 10.1016/S0022-5347(01)63020-9
   DEGROAT WC, 1990, J AUTONOM NERV SYST, V30, pS71, DOI 10.1016/0165-1838(90)90105-R
   DRAY A, 1987, NEUROSCIENCE, V22, P281, DOI 10.1016/0306-4522(87)90218-1
   DUNN JS, 2004, J PELVIC MED SURG, V10, P43
   ERLACIN S, 1981, ARZNEIMITTEL FORTRAM, V31, P1932
   Fleiss JL, 1986, DESIGN ANAL CLIN EXP, P49
   FOWLER CJ, 1992, LANCET, V16, P339
   Griffiths D, 1997, NEUROUROL URODYNAM, V16, P1, DOI 10.1002/(SICI)1520-6777(1997)16:1<1::AID-NAU1>3.0.CO;2-I
   Grond S, 2004, CLIN PHARMACOKINET, V43, P879, DOI 10.2165/00003088-200443130-00004
   KELLEHER CJ, 1994, NEUROUROL URODYNAM, V13, P432
   KHACHATURIAN H, 1982, BRAIN RES BULL, V9, P441, DOI 10.1016/0361-9230(82)90154-X
   Kuo HC, 2003, J UROLOGY, V170, P835, DOI 10.1097/01.ju.0000081652.31524.27
   Lehmann KA, 1997, DRUGS, V53, P25, DOI 10.2165/00003495-199700532-00007
   Lintz W, 1999, INT J CLIN PHARM TH, V37, P175
   Marcou TA, 2005, ANESTH ANALG, V100, P469, DOI 10.1213/01.ANE.0000142121.24052.25
   MASUDA N, 1995, J UROLOGY, V154, P1914, DOI 10.1016/S0022-5347(01)66825-3
   Milsom I, 2001, BJU INT, V87, P760, DOI 10.1046/j.1464-410x.2001.02228.x
   Pandita RK, 2003, BRIT J PHARMACOL, V139, P741, DOI 10.1038/sj.bjp.0705297
   Pehrson R, 2003, EUR UROL, V44, P495, DOI 10.1016/S0302-2838(03)00353-1
   Pehrson R, 2003, J UROLOGY, V170, P272, DOI 10.1097/01.ju.0000062528.54550.65
   Sagata K, 2002, ANESTH ANALG, V94, P901, DOI 10.1097/00000539-200204000-00024
   Shiga Y, 2002, ANESTH ANALG, V95, P1269, DOI 10.1213/01.ANE.0000029102.24999.B0
   Silva C, 2002, J UROLOGY, V168, P575, DOI 10.1016/S0022-5347(05)64683-6
   Stewart WF, 2003, WORLD J UROL, V20, P327, DOI 10.1007/s00345-002-0301-4
   THUROFF JW, 1991, J UROLOGY, V145, P813
   Yalcin P, 2005, PHARMACOL BIOCHEM BE, V80, P69, DOI 10.1016/j.pbb.2004.10.020
   ZHOU Q, 1995, EUR J PHARMACOL, V273, P153, DOI 10.1016/0014-2999(94)00685-Z
NR 32
TC 32
Z9 34
U1 2
U2 8
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0306-5251
EI 1365-2125
J9 BRIT J CLIN PHARMACO
JI Br. J. Clin. Pharmacol.
PD APR
PY 2006
VL 61
IS 4
BP 456
EP 463
DI 10.1111/j.1365-2125.2006.02597.x
PG 8
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 021YR
UT WOS:000236022300013
PM 16542207
OA Green Published, Bronze
DA 2018-12-27
ER

PT J
AU Tomita, M
   Matsuda, T
   Kawakami, H
   Uchihara, J
   Okudaira, T
   Masuda, M
   Ohshiro, K
   Mori, N
AF Tomita, M
   Matsuda, T
   Kawakami, H
   Uchihara, J
   Okudaira, T
   Masuda, M
   Ohshiro, K
   Mori, N
TI RETRACTED: Curcumin targets Akt cell survival signaling pathway in
   HTLV-I-infected T-cell lines (Retracted article. See vol. 102, pg. 498,
   2011)
SO CANCER SCIENCE
LA English
DT Article; Retracted Publication
ID NF-KAPPA-B; PROTEIN-KINASE B; VIRUS TYPE-I; LUNG-CANCER CELLS;
   LEUKEMIA-CELLS; CONSTITUTIVE ACTIVATION; MOUSE EPIDERMIS; TUMOR
   PROMOTION; DOWN-REGULATION; INHIBITION
AB The Akt signaling pathway is important for survival and growth of cancer cells. In the present paper we show that the Akt signaling pathway is constitutively activated in human T-cell leukemia virus type I (HTLV-I)-infected T-cell lines and in primary adult T-cell leukemia (ATL) cells. Curcumin, a natural compound present in turmeric, has been studied vigorously as a potent chemopreventive agent for cancer therapy because of its inhibitory effect on proliferation and induction of apoptosis in several tumor cell lines. We investigated the effect of curcumin on Akt activity in HTLV-I-infected T-cell lines and primary ATL cells. Phosphorylated PDK1 is an activator of Akt by phosphorylating Akt. Curcumin reduced phosphorylation of PDK1 and inhibited constitutive activation of Akt. Curcumin activated glycogen synthase kinase (GSK)-3 beta, a downstream target of Akt kinase, by inhibiting phosphorylation of this protein. Curcumin reduced the expression of cell cycle regulators, cyclin D1 and c-Myc proteins, which are both degraded by activated GSK-3 beta. Our results suggest that activation of the Akt signaling pathway plays an important role in ATL cell survival, and that curcumin may have anti-ATL properties mediated, at least in part, by inhibiting Akt activity. We propose that Akt-targeting agents could be useful for the treatment of ATL. In this regard, curcumin is a potentially promising compound for the treatment of ATL.
C1 Univ Ryukyus, Grad Sch Med, Div Mol Virol & Oncol, Okinawa 9030215, Japan.
   Univ Ryukyus, Fac Med, Div Child Hlth & Welf, Okinawa 9030215, Japan.
   Univ Ryukyus, Fac Med, Div Endocrinol & Metab, Okinawa 9030215, Japan.
   Naha Prefectural Hosp, Dept Internal Med, Okinawa 9028531, Japan.
RP Mori, N (reprint author), Univ Ryukyus, Grad Sch Med, Div Mol Virol & Oncol, 207 Uehara, Okinawa 9030215, Japan.
EM n-mori@med.u-ryukyu.ac.jp
CR Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x
   AMMON HPT, 1991, PLANTA MED, V57, P1, DOI 10.1055/s-2006-960004
   Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515
   Balendran A, 1999, CURR BIOL, V9, P393, DOI 10.1016/S0960-9822(99)80186-9
   Bharti AC, 2003, J IMMUNOL, V171, P3863, DOI 10.4049/jimmunol.171.7.3863
   Brognard J, 2001, CANCER RES, V61, P3986
   Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655
   Chaudhury LR, 2003, J CELL BIOCHEM, V89, P1, DOI 10.1002/jcb.10495
   Chen YR, 1998, ONCOGENE, V17, P173, DOI 10.1038/sj.onc.1201941
   Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499
   GESSAIN A, 1985, LANCET, V2, P407
   Han SS, 2002, J BIOCHEM MOL BIOL, V35, P337
   Hill MM, 2002, PHARMACOL THERAPEUT, V93, P243, DOI 10.1016/S0163-7258(02)00193-6
   HINUMA Y, 1981, P NATL ACAD SCI-BIOL, V78, P6476, DOI 10.1073/pnas.78.10.6476
   Huang MT, 1997, CARCINOGENESIS, V18, P83, DOI 10.1093/carcin/18.1.83
   Huang MT, 1997, J CELL BIOCHEM, P26
   HUANG TS, 1991, P NATL ACAD SCI USA, V88, P5292, DOI 10.1073/pnas.88.12.5292
   Ishiyama M, 1996, BIOL PHARM BULL, V19, P1518
   Jeong SJ, 2005, ONCOGENE, V24, P6719, DOI 10.1038/sj.onc.1208825
   KOEFFLER HP, 1984, BLOOD, V64, P482
   Krystal GW, 2002, MOL CANCER THER, V1, P913
   Kumar AP, 2003, NEOPLASIA, V5, P255, DOI 10.1016/S1476-5586(03)80057-X
   LIU JY, 1993, CARCINOGENESIS, V14, P857, DOI 10.1093/carcin/14.5.857
   Liu Y, 2001, ONCOGENE, V20, P2514, DOI 10.1038/sj.onc.1204364
   LU YP, 1993, CARCINOGENESIS, V14, P293, DOI 10.1093/carcin/14.2.293
   Luo J, 2003, CANCER CELL, V4, P257, DOI 10.1016/S1535-6108(03)00248-4
   MIGONE TS, 1995, SCIENCE, V269, P79, DOI 10.1126/science.7604283
   MIYOSHI I, 1981, NATURE, V294, P770, DOI 10.1038/294770a0
   Mori N, 1999, BLOOD, V93, P2360
   Mori N, 2000, BLOOD, V95, P3915
   OSAME M, 1986, LANCET, V2, P104
   Plummer SM, 1999, ONCOGENE, V18, P6013, DOI 10.1038/sj.onc.1202980
   POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415
   POPOVIC M, 1983, SCIENCE, V219, P856, DOI 10.1126/science.6600519
   Sears R, 2000, GENE DEV, V14, P2501, DOI 10.1101/gad.836800
   Sharma RA, 2004, CLIN CANCER RES, V10, P6847, DOI 10.1158/1078-0432.CCR-04-0744
   SINGH S, 1995, J BIOL CHEM, V270, P24995, DOI 10.1074/jbc.270.42.24995
   Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710
   Toker A, 2000, J BIOL CHEM, V275, P8271, DOI 10.1074/jbc.275.12.8271
   Tomita M, 2006, LEUKEMIA RES, V30, P313, DOI 10.1016/j.leukres.2005.08.004
   Tomita M, 2006, INT J CANCER, V118, P765, DOI 10.1002/ijc.21389
   Tomita M, 2004, ONCOGENE, V23, P8272, DOI 10.1038/sj.onc.1208059
   van Weeren PC, 1998, J BIOL CHEM, V273, P13150, DOI 10.1074/jbc.273.21.13150
   VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241
   Woo JH, 2003, CARCINOGENESIS, V24, P1199, DOI 10.1093/carcin/bgg082
   Yamada Y, 2001, BRIT J HAEMATOL, V113, P375, DOI 10.1046/j.1365-2141.2001.02737.x
   YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031
NR 47
TC 20
Z9 20
U1 2
U2 9
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1349-7006
J9 CANCER SCI
JI Cancer Sci.
PD APR
PY 2006
VL 97
IS 4
BP 322
EP 327
DI 10.1111/j.1349-7006.2006.00175.x
PG 6
WC Oncology
SC Oncology
GA 026GG
UT WOS:000236326800012
PM 16630125
DA 2018-12-27
ER

PT J
AU Samarth, RM
   Panwar, M
   Kumar, A
AF Samarth, RM
   Panwar, M
   Kumar, A
TI RETRACTED: Modulatory effects of Mentha piperita on lung tumor
   incidence, genotoxicity, and oxidative stress in benzo [a]pyrene-treated
   Swiss albino mice (Retracted article, see vol 46, pg 503, 2007)
SO ENVIRONMENTAL AND MOLECULAR MUTAGENESIS
LA English
DT Article; Retracted Publication
DE benzo[a]pyrene; chemoprevention; lung adenomas; Mentha piperita;
   chromosomal aberrations; micronuclei; mouse bone marrow
ID ERYTHROCYTE MICRONUCLEUS ASSAY; GLUTATHIONE S-TRANSFERASES; IN-VIVO;
   MOUSE SKIN; DAMAGE; CARCINOGENESIS; ABERRATIONS; ANTICANCER; PREVENTION;
   INDUCTION
AB Mentha piperita or peppermint is currently used for alleviating nausea, flatulence, and vomiting. In the present investigation, we evaluated the chemopreventive, antigenotoxic, and antioxidative effects of an aqueous extract of Mentha piperita leaves. One-day-old Swiss albino mice were treated with a single subcutaneous injection of 0.5 mg benzo[a]pyrene (BP) and then given either water or a Mentha extract (ME; 1 g/kg body weight) by gavage starting at 3 weeks of age (weaning). The mice were killed at 9 weeks of age and tested for lung tumor incidence (chemoprevention); bone marrow micronucleus and chromosome aberration frequency (antigenotoxicity); and levels of liver and lung sulfhydral groups, superoxide dismutase (SOD) and catalase (CAT) activity, and lipid peroxidation (LPO) (antioxidative properties). The ME treatment resulted in a significant reduction in the number of lung adenomas from an incidence of 67.92% in animals given only BP to 26.31%, an inhibition of 61.26%. Tumor multiplicity was 1.22 in the BP-alone group and 1.15 in the BP + ME group. In addition, compared with the animals in the BP-alone group, ME reduced the frequency of chromosomal aberrations and micronuclei in bone marrow cells and decreased the levels of LPO and increased reduced glutathione content, and SOD and CAT activities in liver as well as lung. The results of this study indicate that ME is chemopreventive and antigenotoxic when given subsequent to an initiating dose of BP in newborn Swiss albino mice. The chemopreventive action and antigenotoxic effects observed in the present study may be due to the antioxidative properties of ME.
C1 Univ Rajasthan, Dept Zool, Radiat & Canc Biol Lab, Jaipur 302004, Rajasthan, India.
RP Samarth, RM (reprint author), Univ Rajasthan, Dept Zool, Radiat & Canc Biol Lab, Jaipur 302004, Rajasthan, India.
EM rmsamarth@yahoo.co.in
CR AEBI H, 1984, METHOD ENZYMOL, V105, P121
   Al-Sereiti M. R., 1999, Indian Journal of Experimental Biology, V37, P124
   AMMON HPT, 1991, PLANTA MED, V57, P1, DOI 10.1055/s-2006-960004
   AQIL F, 2001, J MED ARO PLANT SCI, V22, P177
   BENDER MA, 1988, MUTAT RES, V196, P103, DOI 10.1016/0165-1110(88)90017-6
   Chasseaud L F, 1979, Adv Cancer Res, V29, P175, DOI 10.1016/S0065-230X(08)60848-9
   Das U., 2002, MED SCI MONITOR, V8, P79
   FURSTENBERGER G, 1989, CARCINOGENESIS, V10, P749, DOI 10.1093/carcin/10.4.749
   HAESEN S, 1993, CARCINOGENESIS, V14, P2319, DOI 10.1093/carcin/14.11.2319
   HAYASHI M, 1994, MUTAT RES, V312, P293, DOI 10.1016/0165-1161(94)90039-6
   Hayashi M, 2000, ENVIRON MOL MUTAGEN, V35, P234, DOI 10.1002/(SICI)1098-2280(2000)35:3<234::AID-EM10>3.0.CO;2-L
   KAINA B, 1989, TERATOGEN CARCIN MUT, V9, P331, DOI 10.1002/tcm.1770090602
   KELLOFF GJ, 1994, CANCER EPIDEM BIOMAR, V3, P85
   Ketterer B, 1998, FREE RADICAL RES, V28, P647, DOI 10.3109/10715769809065820
   Krishnaswamy K, 1998, INDIAN J MED RES, V108, P167
   Kumar A, 2004, BIOFACTORS, V22, P87, DOI 10.1002/biof.5520220117
   Lirio LG, 1998, PHARM BIOL, V36, P357, DOI 10.1076/phbi.36.5.357.4656
   Locigno R, 2001, INT J ONCOL, V19, P221
   LOWRY OH, 1951, J BIOL CHEM, V193, P265
   Lu SC, 1999, FASEB J, V13, P1169
   MARKLUND S, 1974, EUR J BIOCHEM, V47, P469
   Mayer C, 2000, CANCER LETT, V152, P169, DOI 10.1016/S0304-3835(00)00332-3
   MORON MS, 1979, BIOCHIM BIOPHYS ACTA, V582, P67, DOI 10.1016/0304-4165(79)90289-7
   MORSE EC, 1996, CARCINOGENESIS, V14, P1737
   OHKAWA H, 1979, ANAL BIOCHEM, V95, P351, DOI 10.1016/0003-2697(79)90738-3
   Ohyama W, 2002, MUTAT RES-GEN TOX EN, V518, P39, DOI 10.1016/S1383-5718(02)00061-X
   Pezzuto JM, 1997, BIOCHEM PHARMACOL, V53, P121, DOI 10.1016/S0006-2952(96)00654-5
   RASTOGI RP, 1991, COMPENDIUM INDIAN ME, V3, P420
   Samarth R. M., 2002, Indian Journal of Experimental Biology, V40, P1245
   Samarth R. M., 2003, Indian Journal of Experimental Biology, V41, P229
   Samarth RM, 2003, J RADIAT RES, V44, P101, DOI 10.1269/jrr.44.101
   Samarth RM, 2004, PHYTOTHER RES, V18, P546, DOI 10.1002/ptr.1483
   Samman MA, 1998, CARCINOGENESIS, V19, P1795, DOI 10.1093/carcin/19.10.1795
   SAVAGE J R K, 1976, Journal of Medical Genetics, V13, P103
   SCHMID W, 1975, MUTAT RES, V31, P9, DOI 10.1016/0165-1161(75)90058-8
   Seo KW, 2000, XENOBIOTICA, V30, P535, DOI 10.1080/004982500237532
   SIPES G, 1993, TOXICOLOGY BASIC SCI, P88
   STEINEL HH, 1993, MUTAT RES, V285, P19, DOI 10.1016/0027-5107(93)90047-J
   TANAKA T, 1994, ONCOL REP, V1, P1139
   Villasenor IM, 2002, MUTAT RES-GEN TOX EN, V515, P141, DOI 10.1016/S1383-5718(02)00006-2
   VOKOVICGACIC B, 1993, BASIC LIFE SCI, V61, P269
   Yu TW, 2004, ENVIRON MOL MUTAGEN, V44, P387, DOI 10.1002/em.20063
   YUN TK, 1995, ANTICANCER RES, V15, P839
   1962, WEALTH INDIA, V6, P337
NR 44
TC 8
Z9 8
U1 3
U2 13
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0893-6692
EI 1098-2280
J9 ENVIRON MOL MUTAGEN
JI Environ. Mol. Mutagen.
PD APR
PY 2006
VL 47
IS 3
BP 192
EP 198
DI 10.1002/em.20185
PG 7
WC Environmental Sciences; Genetics & Heredity; Toxicology
SC Environmental Sciences & Ecology; Genetics & Heredity; Toxicology
GA 027XE
UT WOS:000236448600007
PM 16355390
DA 2018-12-27
ER

PT J
AU Takabayshi, K
   Corr, M
   Hayashi, T
   Redecke, V
   Beck, L
   Guiney, D
   Sheppard, D
   Raz, E
AF Takabayshi, K
   Corr, M
   Hayashi, T
   Redecke, V
   Beck, L
   Guiney, D
   Sheppard, D
   Raz, E
TI RETRACTED: Induction of a homeostatic circuit in lung tissue by
   microbial compounds (Retracted Article. See vol 28, pg 724, 2008)
SO IMMUNITY
LA English
DT Article; Retracted Publication
ID TOLL-LIKE RECEPTORS; MONOCYTE-DERIVED MACROPHAGES; TGF-BETA ACTIVATION;
   ALVEOLAR MACROPHAGES; EPITHELIAL-CELLS; ACTIN; INFLAMMATION; EXPRESSION;
   CYTOPATHOLOGY; MECHANISMS
AB TGF beta presented and activated by integrin alpha v beta 6 expressed on alveolar epithelial cells (AEC) continuously inhibits the functionality of alveolar macrophages (AM). Despite this inhibition, AM retain their ability to respond to inhaled microorganisms. Herein we describe a homeostatic circuit through which the effects of microbial products on macrophages transiently circumvent this inhibition by repressing alpha v beta 6 expression on AEC. Subsequent production of matrix metalloproteinases by activated AM activates latent TGF beta, reinduces alpha v beta 6 expression, and thereby reinstates tonic inhibition of AM function. Our results reveal how AM can be activated while minimizing their potential to inflict collateral damage to the adjacent lung tissue and indicate that tissue-specific microenvironmental factors shape organ-specific defense strategies against microbial invasion.
C1 Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA.
   Univ Calif San Francisco, Lung Biol Ctr, San Francisco, CA 94158 USA.
RP Raz, E (reprint author), Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA.
EM eraz@ucsd.edu
FU NIAID NIH HHS [AI57709, AI56453, AI40682]; NHLBI NIH HHS [HL79449,
   HL66600, HL64353, HL56365, HL53949]
CR Annes JP, 2003, J CELL SCI, V116, P217, DOI 10.1242/jcs.00229
   Bingisser RM, 2001, SWISS MED WKLY, V131, P171
   Browne SH, 2002, INFECT IMMUN, V70, P7126, DOI 10.1128/IAI.70.12.7126-7135.2002
   CHEN CY, 1995, J BACTERIOL, V177, P5303, DOI 10.1128/jb.177.18.5303-5309.1995
   Cho HJ, 2002, J IMMUNOL, V168, P4907, DOI 10.4049/jimmunol.168.10.4907
   DeFife KM, 1999, FASEB J, V13, P823
   Deng JC, 2004, J IMMUNOL, V173, P5148, DOI 10.4049/jimmunol.173.8.5148
   Dobrovolskaia MA, 2003, J IMMUNOL, V170, P508, DOI 10.4049/jimmunol.170.1.508
   Fitzpatrick DR, 1999, TRENDS MICROBIOL, V7, P232, DOI 10.1016/S0966-842X(99)01498-5
   Giannone G, 2004, CELL, V116, P431, DOI 10.1016/S0092-8674(04)00058-3
   Hayashi F, 2003, BLOOD, V102, P2660, DOI 10.1182/blood-2003-04-1078
   Huang XZ, 1998, AM J RESP CELL MOL, V19, P636, DOI 10.1165/ajrcmb.19.4.3293
   Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6
   Kinbara K, 2003, NAT REV MOL CELL BIO, V4, P767, DOI 10.1038/nrm1229
   Krutzik SR, 2004, SEMIN IMMUNOL, V16, P35, DOI 10.1016/j.smim.2003.10.005
   Kutsuna H, 2004, AM J PHYSIOL-CELL PH, V286, pC55, DOI 10.1152/ajpcell.00131.2003
   Libby SJ, 2000, CELL MICROBIOL, V2, P49, DOI 10.1046/j.1462-5822.2000.00030.x
   Lipscomb Mary F., 1993, Regional Immunology, V5, P151
   Martinez-Torres FJ, 2004, NEUROSCI LETT, V368, P274, DOI 10.1016/j.neulet.2004.06.064
   MCCOY R, 1995, J EXP MED, V182, P207, DOI 10.1084/jem.182.1.207
   Morris DG, 2003, NATURE, V422, P169, DOI 10.1038/nature01413
   Mott JD, 2004, CURR OPIN CELL BIOL, V16, P558, DOI 10.1016/j.ceb.2004.07.010
   Munger JS, 1999, CELL, V96, P319, DOI 10.1016/S0092-8674(00)80545-0
   O'Reilly PJ, 2003, AM J RESP CELL MOL, V28, P443, DOI 10.1165/rcmb.2002-0153OC
   Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X
   Takeda K, 2003, ANNU REV IMMUNOL, V21, P335, DOI 10.1146/annurev.immunol.21.120601.141126
   THEPEN T, 1994, ANN NY ACAD SCI, V725, P200, DOI 10.1111/j.1749-6632.1994.tb39802.x
   van der Flier A, 2001, CELL TISSUE RES, V305, P285, DOI 10.1007/s004410100417
   Yu Q, 2000, GENE DEV, V14, P163
   ZAMBRUNO G, 1995, J CELL BIOL, V129, P853, DOI 10.1083/jcb.129.3.853
NR 30
TC 66
Z9 69
U1 3
U2 11
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 1074-7613
J9 IMMUNITY
JI Immunity
PD APR
PY 2006
VL 24
IS 4
BP 475
EP 487
DI 10.1016/j.immuni.2006.02.008
PG 13
WC Immunology
SC Immunology
GA 037NF
UT WOS:000237153000016
PM 16618605
OA Bronze
DA 2018-12-27
ER

PT J
AU Bartoc, C
   Frumento, RJ
   Jalbout, M
   Bennett-Guerrero, E
   Du, E
   Nishanian, E
AF Bartoc, C
   Frumento, RJ
   Jalbout, M
   Bennett-Guerrero, E
   Du, E
   Nishanian, E
TI RETRACTED: A randomized, double-blind, placebo-controlled study
   assessing the antiinflammatory effects of ketamine in cardiac surgical
   patient (Retracted article. See vol. 28, pg. 1435, 2014)
SO JOURNAL OF CARDIOTHORACIC AND VASCULAR ANESTHESIA
LA English
DT Article; Retracted Publication
DE ketamine; cardiopulmonary bypass; inflammation
ID KAPPA-B ACTIVATION; C-REACTIVE PROTEIN; NECROSIS-FACTOR-ALPHA;
   CARDIOPULMONARY BYPASS; PROINFLAMMATORY CYTOKINE;
   CARDIOVASCULAR-DISEASES; INTERLEUKIN-6 RESPONSE; CALCIUM ELEVATION;
   INFLAMMATION; MORBIDITY
AB Objective: To determine whether ketamine administration affects markers of inflammation in cardiac surgery with cardiopulmonary bypass (CPB) and to investigate differences between 2 low-dose ketamine regimens.
   Design: Prospective, randomized, placebo-controlled trial.
   Setting: Single-center university hospital.
   Participants: Patients undergoing cardiac surgery with CPB.
   Intervention: Patients (n = 50) were randomized to 1 of 3 groups: ketamine, 0.25 mg/kg (n = 15); ketamine, 0.5 mg/kg (n = 18);or placebo (n = 17) in a double-blind manner at the time of induction of general anesthesia.
   Measurements and Main Results: Serum C-reactive protein (CRP) and interleukin (IL)-6, IL-8, and IL-10 were measured at baseline, on intensive care unit (ICU) arrival, and on the first postoperative day (POD 1). Both ketamine doses decreased the serum IL-6 response at ICU arrival and POD 1 compared with placebo (p < 0.05). CRP was lower in the 0.5-mg/kg group than placebo on POD 1 (p = 0.003). IL-10 was lower in the ketamine groups (p = 0.01) at POD 1 compared with placebo; IL-8 levels were not affected by ketamine. Mean arterial pressure and systemic vascular resistance were higher at the end of surgery, arrival in the ICU, and POD 1 in the ketamine groups (p < 0.05).
   Conclusion: Low-dose ketamine (0.5 mg/kg) attenuates increases in CRP, IL-6, and IL-10 while decreasing vasodilatation after CPB. (c) 2006 Elsevier Inc. All rights reserved.
C1 Columbia Univ Coll Phys & Surg, Dept Anesthesiol, New York, NY 10032 USA.
   Columbia Univ Coll Phys & Surg, Dept Biostat, New York, NY 10032 USA.
   Duke Univ, Med Ctr, Dept Anesthesiol, Durham, NC 27710 USA.
RP Nishanian, E (reprint author), Columbia Univ Coll Phys & Surg, Dept Anesthesiol, PH5-505,630 W 168th St, New York, NY 10032 USA.
CR *AHA, AM HEART ASS OP HEAR
   [Anonymous], 1998, CARDIAC ANESTHESIA, P297
   Aouifi A, 1999, BRIT J ANAESTH, V83, P602
   Arranz J, 2003, TRANSPLANT P, V35, P1884, DOI 10.1016/S0041-1345(03)00603-1
   Bennett-Guerrero E, 1999, ANESTH ANALG, V89, P514, DOI 10.1097/00000539-199908000-00050
   Bisoendial RJ, 2005, CIRC RES, V96, P714, DOI 10.1161/01.RES.0000163015.37711.AB
   BONE RC, 1992, CHEST, V101, P1644, DOI 10.1378/chest.101.6.1644
   Cao De-quan, 2001, Hunan Yike Daxue Xuebao, V26, P350
   Foey A, 2002, ARTHRITIS RES, V4, P64, DOI 10.1186/ar385
   GORIS RJA, 1985, ARCH SURG-CHICAGO, V120, P1109
   Hill GE, 1998, J CARDIOTHOR VASC AN, V12, P21
   Hsuan SL, 1999, MICROB PATHOGENESIS, V26, P263, DOI 10.1006/mpat.1998.0271
   Kanda T, 2004, JPN HEART J, V45, P183, DOI 10.1536/jhj.45.183
   Kawasaki C, 2001, CAN J ANAESTH, V48, P819, DOI 10.1007/BF03016701
   Lee FY, 1996, SCAND J GASTROENTERO, V31, P500, DOI 10.3109/00365529609006772
   Lewis E, 2001, ANESTH ANALG, V92, P927
   Li JJ, 2004, MED HYPOTHESES, V62, P499, DOI 10.1016/j.mehy.2003.12.014
   MANGANO DT, 1990, ANESTHESIOLOGY, V72, P153, DOI 10.1097/00000542-199001000-00025
   MERIN RG, 1975, SURG CLIN N AM, V55, P759
   Rady MY, 1998, CRIT CARE MED, V26, P225, DOI 10.1097/00003246-199802000-00016
   Rallidis LS, 2002, CLIN CARDIOL, V25, P505, DOI 10.1002/clc.4960251106
   Roytblat L, 1998, ANESTH ANALG, V87, P266, DOI 10.1097/00000539-199808000-00006
   Roytblat L, 1996, PAIN CLINIC, V9, P327
   Shaked G, 2004, RESUSCITATION, V62, P237, DOI 10.1016/j.resuscitation.2004.02.013
   SLOGOFF S, 1974, ANESTH ANALG, V53, P354
   *STS, 1990, AD CARD DAT 1990 199
   Sun J, 2004, INFLAMM RES, V53, P304, DOI 10.1007/s00011-004-1262-4
   Sun J, 2004, ACTA ANAESTH SCAND, V48, P317, DOI 10.1111/j.0001-5172.2004.0312.x
   Sun J, 2004, WORLD J GASTROENTERO, V10, P1028
   Taniguchi T, 2003, ANESTH ANALG, V97, P1769, DOI 10.1213/01.ANE.0000085634.72426.ED
   Volk T, 2003, CYTOKINE, V24, P237, DOI 10.1016/S1043-4666(03)00090-5
   Yan ZY, 1999, INFECT IMMUN, V67, P6611
NR 32
TC 48
Z9 53
U1 4
U2 13
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 1053-0770
EI 1532-8422
J9 J CARDIOTHOR VASC AN
JI J. Cardiothorac. Vasc. Anesth.
PD APR
PY 2006
VL 20
IS 2
BP 217
EP 222
DI 10.1053/j.jvca.2005.12.005
PG 6
WC Anesthesiology; Cardiac & Cardiovascular Systems; Respiratory System;
   Peripheral Vascular Disease
SC Anesthesiology; Cardiovascular System & Cardiology; Respiratory System
GA 036LG
UT WOS:000237072000014
PM 16616662
DA 2018-12-27
ER

PT J
AU Han, C
   Michalopoulos, GK
   Wu, T
AF Han, C
   Michalopoulos, GK
   Wu, T
TI RETRACTED: Prostaglandin E-2 receptor EP1 transactivates EGFR/MET
   receptor tyrosine kinases and enhances invasiveness in human
   hepatocellular carcinoma cells(Retracted article. See vol. 230, pg.
   1401, 2015)
SO JOURNAL OF CELLULAR PHYSIOLOGY
LA English
DT Article; Retracted Publication
ID GROWTH-FACTOR RECEPTOR; ACID-DEFINED DIET; HUMAN HEPATOMA-CELLS;
   CHOLINE-DEFICIENT; POSSIBLE INVOLVEMENT; CYCLOOXYGENASE-2 INHIBITORS;
   ACETYLSALICYLIC-ACID; PROSTANOID RECEPTORS; CANCER-CELLS; LIVER
AB Recent evidence indicates that cyclooxygenase-2 (COX-2) and epidermal growth factor receptor (EGFR) are involved in hepatocarcinogenesis. This study was designed to evaluate the possible interaction between the COX-2 and EGFR signaling pathways in human hepatocellular carcinoma (HCC) cells. Immunohistochemical analysis using serial sections of human HCC tissues revealed positive correlation between COX-2 and EGFR in HCC cells (P < 0.01). Overexpression of COX-2 in cultured HCC cells (Hep3B) or treatment with PGE(2) or the selective EP1 receptor agonist, ONO-DI-004, increased EGFR phosphorylation and tumor cell invasion. The PGE(2)-induced EGFR phosphorylation and cell invasiveness were blocked by the EP1 receptor siRNA or antagonist ONO-8711 and by two EGFR tyrosine kinase inhibitors, AG1478 and PD153035. The EP1-induced EGFR transactivation and cell invasion involves c-Src, in light of the presence of native binding complex of EP1/Src/EGFR and the inhibition of PGE(2)-induced EGFR phosphorylation and cell invasion by the Src siRNA and the Src inhibitor, PP2. Further, overexpression of COX-2 or treatment with PGE2 also induced phosphorylation of c-Mel, another receptor tyrosine kinase critical for HCC cell invasion. Moreover, activation of EGFR by EGF increased COX-2 promoter activity and protein expression in Hep3B and Huh-7 cells, whereas blocking PGE2 synthesis or EP1 attenuated EGFR phosphorylation induced by EGF, Suggesting that the COX-2/PGE(2)/EP1 pathway also Modulate the activation of EGFR by its cognate ligand. These findings disclose a cross-talk between the COX-2/PGE(2)/EP1 and EGFR/c-Met signaling pathways that coordinately regulate human HCC cell invasion.
C1 Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA 15213 USA.
RP Wu, T (reprint author), Univ Pittsburgh, Sch Med, Dept Pathol, MUH E-740,200 Lothrop St, Pittsburgh, PA 15213 USA.
EM wut@upmc.edu
FU NCI NIH HHS [R01 CA102325, R01 CA106280]
CR Abiru S, 2002, HEPATOLOGY, V35, P1117, DOI 10.1053/jhep.2002.32676
   Anthony TL, 2001, INVEST OPHTH VIS SCI, V42, P3182
   Bae SH, 2001, CLIN CANCER RES, V7, P1410
   BAYER BM, 1979, BIOCHEM PHARMACOL, V28, P441, DOI 10.1016/0006-2952(79)90112-6
   Belley A, 1999, GASTROENTEROLOGY, V117, P1352, DOI 10.1016/S0016-5085(99)70285-4
   Breyer RM, 2001, ANNU REV PHARMACOL, V41, P661, DOI 10.1146/annurev.pharmtox.41.1.661
   Buchanan FG, 2003, J BIOL CHEM, V278, P35451, DOI 10.1074/jbc.M302474200
   DENDA A, 1994, CARCINOGENESIS, V15, P1279, DOI 10.1093/carcin/15.6.1279
   Denda A, 1998, MUTAT RES-FUND MOL M, V402, P279, DOI 10.1016/S0027-5107(97)00307-2
   DENDA A, 1989, CARCINOGENESIS, V10, P1929, DOI 10.1093/carcin/10.10.1929
   Dohadwala M, 2002, J BIOL CHEM, V277, P50828, DOI 10.1074/jbc.M210707200
   Endoh T, 1996, CARCINOGENESIS, V17, P467, DOI 10.1093/carcin/17.3.467
   Fischer OM, 2003, BIOCHEM SOC T, V31, P1203
   Gschwind A, 2001, ONCOGENE, V20, P1594, DOI 10.1038/sj.onc.1204192
   GUPTA C, 1989, CANCER LETT, V46, P129, DOI 10.1016/0304-3835(89)90020-7
   Han C, 2004, J BIOL CHEM, V279, P44344, DOI 10.1074/jbc.M404852200
   Han C, 2005, J BIOL CHEM, V280, P24053, DOI 10.1074/jbc.M500562200
   Han C, 2002, AM J PHYSIOL-GASTR L, V282, pG586, DOI 10.1152/ajpgi.00305.2001
   Jo MJ, 2000, J BIOL CHEM, V275, P8806, DOI 10.1074/jbc.275.12.8806
   Kern MA, 2004, CARCINOGENESIS, V25, P1193, DOI 10.1093/carcin/bgh110
   Kern MA, 2002, HEPATOLOGY, V36, P885, DOI 10.1053/jhep.2002.36125
   Koga H, 1999, HEPATOLOGY, V29, P688, DOI 10.1002/hep.510290355
   Kondo M, 1999, CLIN CANCER RES, V5, P4005
   Leng J, 2003, HEPATOLOGY, V38, P756, DOI 10.1053/jhep.2003.50380
   Liu D, 2002, CANCER CELL, V1, P445, DOI 10.1016/S1535-6108(02)00072-7
   Miyaki M, 2000, INT J CANCER, V85, P518, DOI 10.1002/(SICI)1097-0215(20000215)85:4<518::AID-IJC12>3.0.CO;2-7
   Mukai M, 2000, FEBS LETT, V484, P69, DOI 10.1016/S0014-5793(00)02129-3
   Narumiya S, 2001, J CLIN INVEST, V108, P25, DOI 10.1172/JCI13455
   Otsuka M, 2004, HEPATOLOGY, V40, P243, DOI 10.1002/hep.20260
   Pai R, 2002, NAT MED, V8, P289, DOI 10.1038/nm0302-289
   Rahman MA, 2001, CLIN CANCER RES, V7, P1325
   Shiota G, 1999, HEPATO-GASTROENTEROL, V46, P407
   Stock JL, 2001, J CLIN INVEST, V107, P325, DOI 10.1172/JCI6749
   Su JL, 2004, CANCER RES, V64, P554, DOI 10.1158/0008-5472.CAN-03-1301
   Takafuji V, 2000, PROSTAG LEUKOTR ESS, V63, P223, DOI 10.1054/plef.2000.0144
   TANAKA T, 1993, CANCER LETT, V68, P111, DOI 10.1016/0304-3835(93)90136-W
   Wetzker R, 2003, NAT REV MOL CELL BIO, V4, P651, DOI 10.1038/nrm1173
   Wu T, 2004, MOL CANCER THER, V3, P299
NR 38
TC 103
Z9 117
U1 5
U2 13
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0021-9541
EI 1097-4652
J9 J CELL PHYSIOL
JI J. Cell. Physiol.
PD APR
PY 2006
VL 207
IS 1
BP 261
EP 270
DI 10.1002/jcp.20560
PG 10
WC Cell Biology; Physiology
SC Cell Biology; Physiology
GA 021LE
UT WOS:000235983900028
PM 16331686
DA 2018-12-27
ER

PT J
AU Akyol, A
   Ulusoy, H
   Ozen, I
AF Akyol, A
   Ulusoy, H
   Ozen, I
TI RETRACTED: Handwashing: a simple, economical and effective method for
   preventing nosocomial infections in intensive care units (Retracted
   Article. See vol 64, pg 99, 2006)
SO JOURNAL OF HOSPITAL INFECTION
LA English
DT Review; Retracted Publication
DE handwashing; critical care; hand hygiene; cultural; behaviour
ID HAND HYGIENE; PATIENT-CARE; ARTIFICIAL FINGERNAILS; BACTERIAL TRANSFER;
   WORKERS; GLOVES; CONTAMINATION; SOAP; TRANSMISSION; HOSPITALS
AB As most nosocomial infections are thought to be transmitted by the hands of healthcare workers, handwashing is considered to be the single most important intervention to prevent nosocomial infections. However, studies have shown that handwashing practices are poor, especially among medical personnel. This review gives an overview of handwashing in health care and in the community, including some aspects that have attracted little attention, such as hand drying and cultural issues determining hand hygiene behaviour. Hand hygiene is the most effective measure for interrupting the transmission of micro-organisms which cause infection, both in the community and in the healthcare setting. Using hand hygiene as a sole measure to reduce infection is unlikely to be successful when other factors in infection control, such as environmental hygiene, crowding, staffing levels and education, are inadequate. Hand hygiene must be part of an integrated approach to infection control. Compliance with hand hygiene recommendations is poor worldwide. White the techniques involved in hand hygiene are simple, the complex interdependence of factors that determine hand hygiene behaviour makes the study of hand hygiene complex. It is now recognized that improving compliance with hand hygiene recommendations depends on altering human behaviour. Input from behavioural. and social sciences is essential when designing studies to investigate compliance. Interventions to increase compliance with hand hygiene practices must be appropriate for different cultural and social needs.
C1 Karadeniz Tech Univ, Fac Med, Dept Anaesthesiol & Crit Care, TR-61080 Trabzon, Turkey.
RP Akyol, A (reprint author), Karadeniz Tech Univ, Fac Med, Dept Anaesthesiol & Crit Care, TR-61080 Trabzon, Turkey.
EM ahmetmelike@yahoo.com
CR AKHTAR G, 2002, NURS TIMES, V98, P40
   ARROWSMITH VA, 2001, COCHRANE DB SYST REV, V4
   Barza M, 2004, CLIN INFECT DIS, V38, P857, DOI 10.1086/382535
   BLOOMFIELD SF, 2003, INT J ENVIRON HEAL R, V1, P57
   CASEWELL M, 1977, BRIT MED J, V2, P1315, DOI 10.1136/bmj.2.6098.1315
   *CDCP, 1988, MMWR-MORBID MORTAL W, V37, P377
   COPPAGE CM, 1961, HANDWASHING PATIENT
   Dancer SJ, 2004, J HOSP INFECT, V56, P10, DOI 10.1016/j.jhin.2003.09.017
   De Costa CM, 2002, MED J AUSTRALIA, V177, P668
   EHRENKRANZ NJ, 1991, INFECT CONT HOSP EP, V12, P654
   FEACHEM RG, 1984, B WORLD HEALTH ORGAN, V62, P467
   GARNER JS, 1986, INFECT CONT HOSP EP, V7, P231
   Girou E, 2002, BRIT MED J, V325, P362, DOI 10.1136/bmj.325.7360.362
   Gould D, 1995, Nurs Times, V91, P42
   Gould D, 1994, Nurs Times, V90, P33
   Gould D, 2000, J CLIN NURS, V9, P95, DOI 10.1046/j.1365-2702.2000.00334.x
   Halabi M, 2001, J HOSP INFECT, V49, P117, DOI 10.1053/jhin.2001.1060
   Harbarth S, 1999, INFECT CONT HOSP EP, V20, P598, DOI 10.1086/501677
   Harrison WA, 2003, AM J INFECT CONTROL, V31, P387, DOI 10.1067/mic.2003.81
   Hartley JC, 1999, BRIT MED J, V318, P328, DOI 10.1136/bmj.318.7179.328a
   HARTSTEIN AI, 1995, INFECT CONT HOSP EP, V16, P405
   Hateley PM, 1999, BRIT MED J, V319, P519
   Hedderwick SA, 2000, INFECT CONT HOSP EP, V21, P505, DOI 10.1086/501794
   HEINZE JE, 1988, EPIDEMIOL INFECT, V101, P135, DOI 10.1017/S0950268800029290
   HUNT LW, 1995, J OCCUP ENVIRON MED, V37, P1204, DOI 10.1097/00043764-199510000-00011
   Jeanes A, 2001, J HOSP INFECT, V49, P139, DOI 10.1053/jhin.2001.1062
   Centers for Disease Control and Prevention (CDC), 2002, MMWR Morb Mortal Wkly Rep, V51, P1
   KAPLAN LM, 1986, INFECT CONT HOSP EP, V7, P408, DOI 10.1017/S019594170006464X
   Knights B, 1993, HAND DRYING ASSESSME
   KORNIEWICZ DM, 1993, AM IND HYG ASSOC J, V54, P22, DOI 10.1202/0002-8894(1993)054<0022:LOLAVE>2.0.CO;2
   KORNIEWICZ DM, 1994, AM J INFECT CONTROL, V22, P12, DOI 10.1016/0196-6553(94)90085-X
   Larson E, 1999, CLIN INFECT DIS, V29, P1287, DOI 10.1086/313468
   LARSON EL, 1992, AM J INFECT CONTROL, V20, P65, DOI 10.1016/S0196-6553(05)80003-3
   Larson EL, 2003, AM J INFECT CONTROL, V31, P72, DOI 10.1067/mic.2003.33
   Larson EL, 1998, AM J INFECT CONTROL, V26, P513, DOI 10.1016/S0196-6553(98)70025-2
   Lin CM, 2003, J FOOD PROTECT, V66, P2296, DOI 10.4315/0362-028X-66.12.2296
   Matricardi PM, 2000, BRIT MED J, V320, P412, DOI 10.1136/bmj.320.7232.412
   McCormick RD, 2000, AM J INFECT CONTROL, V28, P302, DOI 10.1067/mic.2000.107425
   MCGINLEY KJ, 1988, J CLIN MICROBIOL, V26, P950
   McNeil SA, 2001, CLIN INFECT DIS, V32, P367, DOI 10.1086/318488
   Mody L, 2003, INFECT CONT HOSP EP, V24, P157
   Montville R, 2002, INT J FOOD MICROBIOL, V73, P305, DOI 10.1016/S0168-1605(01)00666-3
   MOOLENAAR RL, 2000, INFECT CONT HOSP EP, V21, P77
   Naikoba S, 2001, J HOSP INFECT, V47, P173, DOI 10.1053/jhin.2000.0882
   NOBLE WC, 1974, MIROBIOLOGY HUMAN SK
   O'Boyle CA, 2001, AM J INFECT CONTROL, V29, P352, DOI 10.1067/mic.2001.118405
   Omotade OO, 1995, J DIARRHOEAL DIS RES, V13, P224
   Parry MF, 2001, CLIN INFECT DIS, V32, P352, DOI 10.1086/318487
   PASSARO DJ, 1997, J INFECT DIS
   Patrick DR, 1997, EPIDEMIOL INFECT, V119, P319, DOI 10.1017/S0950268897008261
   PATTERSON JE, 1991, AM J MED, V91, P479, DOI 10.1016/0002-9343(91)90183-X
   Pittet D, 1999, ARCH INTERN MED, V159, P821, DOI 10.1001/archinte.159.8.821
   Pittet D, 2001, EMERG INFECT DIS, V7, P234, DOI 10.3201/eid0702.010217
   REINGOLD AL, 1988, JAMA-J AM MED ASSOC, V259, P2558, DOI 10.1001/jama.259.17.2558
   Salisbury DM, 1997, AM J INFECT CONTROL, V25, P24
   Sartor C, 2000, INFECT CONT HOSP EP, V21, P196, DOI 10.1086/501743
   Sattar SA, 2002, J VIROL METHODS, V103, P171, DOI 10.1016/S0166-0934(02)00025-3
   Sattar SA, 2002, AM J INFECT CONTROL, V30, P355, DOI 10.1067/mic.2002.124532
   Silvestri L, 2005, J HOSP INFECT, V59, P172, DOI 10.1016/j.jhin.2004.11.005
   STRAUSBAUGH LJ, 1994, J CLIN MICROBIOL, V32, P2299
   Taylor JH, 2000, J APPL MICROBIOL, V89, P910, DOI 10.1046/j.1365-2672.2000.01122.x
   TEARE EL, 2001, BMJ-BRIT MED J, V323, P412
   Tenorio AR, 2001, CLIN INFECT DIS, V32, P826, DOI 10.1086/319214
   Thompson BL, 1997, INFECT CONT HOSP EP, V18, P97
   Trampuz A, 2004, MAYO CLIN PROC, V79, P109, DOI 10.4065/79.1.109
   Trick WE, 2003, CLIN INFECT DIS, V36, P1383, DOI 10.1086/374852
   Wendt C, 2001, J HOSP INFECT, V48, pS23, DOI 10.1016/S0195-6701(01)90008-8
   Widmer AF, 2000, CLIN INFECT DIS, V31, P136, DOI 10.1086/313888
   Winnefeld M, 2000, BRIT J DERMATOL, V143, P546
   Wynd C A, 1994, AORN J, V60, P799, DOI 10.1016/S0001-2092(07)63328-6
   ZIMAKOFF J, 1993, J HOSP INFECT, V24, P63, DOI 10.1016/0195-6701(93)90090-M
NR 71
TC 19
Z9 20
U1 3
U2 14
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0195-6701
EI 1532-2939
J9 J HOSP INFECT
JI J. Hosp. Infect.
PD APR
PY 2006
VL 62
IS 4
BP 395
EP 405
DI 10.1016/j.jhin.2005.10.007
PG 11
WC Public, Environmental & Occupational Health; Infectious Diseases
SC Public, Environmental & Occupational Health; Infectious Diseases
GA 029II
UT WOS:000236555400001
PM 16478645
DA 2018-12-27
ER

PT J
AU Siristatidis, C
   Nissotakis, C
   Chrelias, C
   Iacovidou, H
   Salamalekis, E
AF Siristatidis, C
   Nissotakis, C
   Chrelias, C
   Iacovidou, H
   Salamalekis, E
TI RETRACTED: Immunological factors and their role in the genesis and
   development of endometriosis (Retracted article. See vol. 35, pg. 390,
   2009)
SO JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH
LA English
DT Article; Retracted Publication
DE cytokines; endometriosis; growth and adhesion factors
ID ENDOTHELIAL GROWTH-FACTOR; TUMOR-NECROSIS-FACTOR; MACROPHAGE-CONDITIONED
   MEDIA; STROMAL CELL-PROLIFERATION; TOTAL ANTIOXIDANT STATUS;
   PERITONEAL-FLUID; IN-VITRO; INTERLEUKIN-6 LEVELS; AUTOIMMUNE-DISEASE;
   INFERTILE PATIENTS
AB The article presents an overview of immunological factors and their role in the genesis and development of endometriosis, with emphasis on inflammatory cytokines and growth and adhesion factors. Although retrograde menstruation is a common phenomenon among women of reproductive age, not all women with retrograde menstruation suffer the disease. Development of endometriosis seems to be a complex process, facilitated by several factors, including quantity and quality of endometrial cells in peritoneal fluid (PF), increased inflammatory activity in PF, increased endometrial-peritoneal adhesion and angiogenesis, reduced immune surveillance and clearance of endometrial cells, and increased production of autoantibodies against endometrial cells. Potential biomarkers like cytokines and autoantibodies, upregulated during development of endometriosis, seem useful in the development of a non-surgical diagnostic tool. In this review work, the immune role in endometriosis is examined through the role of immunological factors in the genesis and development of the disease. Furthermore, it could be concluded that, although endometriosis can be treated using hormonal suppression, there is a need today for non-hormonal drugs, probably to modulate immune function, in order to confront the disease and alleviate pain or infertility without inhibition of ovulation.
C1 Univ Athens, Sch Med, Attikon Hosp, Dept Obstet & Gynecol 3, Athens, Greece.
RP Siristatidis, C (reprint author), Didimotichou 17, Athens 13676, Greece.
EM harrysiri@hotmail.com
CR Aeby TC, 1996, AM J OBSTET GYNECOL, V174, P1779, DOI 10.1016/S0002-9378(96)70210-7
   Arici A, 2003, HUM REPROD, V18, P429, DOI 10.1093/humrep/deg083
   Arici A, 2002, ANN NY ACAD SCI, V955, P101, DOI 10.1111/j.1749-6632.2002.tb02770.x
   Arici A, 1998, J CLIN ENDOCR METAB, V83, P1201, DOI 10.1210/jc.83.4.1201
   BALASCH J, 1985, INT J FERTIL, V30, P4
   Barnhart K, 2002, FERTIL STERIL, V77, P1148, DOI 10.1016/S0015-0282(02)03112-6
   Bedaiwy MA, 2002, HUM REPROD, V17, P426, DOI 10.1093/humrep/17.2.426
   BUYALOS RP, 1992, FERTIL STERIL, V58, P302
   CARPENTER G, 1993, PEPTIDE GROWTH FACTO, P89
   Chishima F, 2000, J Obstet Gynaecol Res, V26, P141
   D'Hooghe TM, 2003, SEMIN REPROD MED, V21, P243
   EISERMANN J, 1988, FERTIL STERIL, V50, P573
   FAKIH H, 1987, FERTIL STERIL, V47, P213
   Farquhar CM, 2000, BMJ-BRIT MED J, V320, P1449, DOI 10.1136/bmj.320.7247.1449
   Gaetje R, 1997, AM J PATHOL, V150, P461
   GIUDICE LC, 1994, J CLIN ENDOCR METAB, V79, P1284, DOI 10.1210/jc.79.5.1284
   GLEICHER N, 1987, OBSTET GYNECOL, V70, P115
   Gottschalk C, 2000, ADV EXP MED BIOL, V477, P483
   Harada T, 2001, FERTIL STERIL, V76, P1, DOI 10.1016/S0015-0282(01)01816-7
   Harada T, 1997, AM J OBSTET GYNECOL, V176, P593, DOI 10.1016/S0002-9378(97)70553-2
   Ho HN, 1997, HUM REPROD, V12, P2810, DOI 10.1093/humrep/12.12.2810
   Hornung D, 1998, FERTIL STERIL, V69, P909, DOI 10.1016/S0015-0282(98)00044-2
   HORUK R, 1994, IMMUNOL TODAY, V15, P169, DOI 10.1016/0167-5699(94)90314-X
   HUANG JC, 1994, J CLIN ENDOCR METAB, V79, P1097, DOI 10.1210/jc.79.4.1097
   HUNT JS, 1992, BIOL REPROD, V47, P141, DOI 10.1095/biolreprod47.1.141
   Iwabe T, 2000, J CLIN ENDOCR METAB, V85, P824, DOI 10.1210/jc.85.2.824
   Kamada Y, 2000, HUM REPROD, V15, P2512, DOI 10.1093/humrep/15.12.2512
   Kats R, 2002, FERTIL STERIL, V78, P69, DOI 10.1016/S0015-0282(02)03189-8
   KEENAN JA, 1995, AM J REPROD IMMUNOL, V34, P381, DOI 10.1111/j.1600-0897.1995.tb00968.x
   KEENAN JA, 1994, AM J REPROD IMMUNOL, V32, P180, DOI 10.1111/j.1600-0897.1994.tb01111.x
   Kitawaki J, 2000, J CLIN ENDOCR METAB, V85, P1946, DOI 10.1210/jc.85.5.1946
   Koninckx PR, 1996, FERTIL STERIL, V65, P280, DOI 10.1016/S0015-0282(16)58086-8
   KOYAMA N, 1993, INT J GYNECOL OBSTET, V43, P45, DOI 10.1016/0020-7292(93)90273-Y
   LAIRD SM, 1993, HUM REPROD, V8, P793, DOI 10.1093/oxfordjournals.humrep.a138144
   Lebovic DI, 1999, CURR OPIN OBSTET GYN, V11, P255, DOI 10.1097/00001703-199906000-00004
   Lima-Couy I, 2004, MOL HUM REPROD, V10, P777, DOI 10.1093/molehr/gah115
   McLaren J, 1996, J CLIN INVEST, V98, P482, DOI 10.1172/JCI118815
   MELEGA C, 1991, ANN NY ACAD SCI, V622, P256, DOI 10.1111/j.1749-6632.1991.tb37869.x
   Nothnick WB, 2001, FERTIL STERIL, V76, P223, DOI 10.1016/S0015-0282(01)01878-7
   OLIVE DL, 1991, AM J OBSTET GYNECOL, V164, P953
   Ortiz BD, 1996, MOL CELL BIOL, V16, P202
   Ota H, 2001, FERTIL STERIL, V75, P785, DOI 10.1016/S0015-0282(01)01670-3
   Polak G, 2001, EUR J OBSTET GYN R B, V94, P261, DOI 10.1016/S0301-2115(00)00352-3
   Rana N, 1996, FERTIL STERIL, V65, P925, DOI 10.1016/S0015-0282(16)58262-4
   RIER SE, 1994, FERTIL STERIL, V61, P294
   Sampson JA, 1927, AM J OBSTET GYNECOL, V14, P422, DOI 10.1016/S0002-9378(15)30003-X
   Shifren JL, 1996, J CLIN ENDOCR METAB, V81, P3112, DOI 10.1210/jcem.81.8.8768883
   SIMON C, 1994, ENDOCRINOLOGY, V134, P521, DOI 10.1210/en.134.2.521
   STRATHY JH, 1982, FERTIL STERIL, V38, P667
   SYROP CH, 1987, OBSTET GYNECOL, V69, P416
   Tseng JF, 1996, J CLIN ENDOCR METAB, V81, P1118, DOI 10.1210/jc.81.3.1118
   Tsudo T, 2000, FERTIL STERIL, V73, P205, DOI 10.1016/S0015-0282(99)00496-3
   Wieser F, 2002, J SOC GYNECOL INVEST, V9, P313, DOI 10.1016/S1071-5576(02)00174-0
   Wu MH, 2002, MOL HUM REPROD, V8, P456, DOI 10.1093/molehr/8.5.456
   Yeaman GR, 2002, ANN NY ACAD SCI, V955, P174, DOI 10.1111/j.1749-6632.2002.tb02778.x
   ZELLER JM, 1987, AM J REPROD IMMUNOL, V13, P78
   Zeyneloglu HB, 1998, AM J REPROD IMMUNOL, V39, P152
NR 57
TC 76
Z9 86
U1 3
U2 12
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1341-8076
EI 1447-0756
J9 J OBSTET GYNAECOL RE
JI J. Obstet. Gynaecol. Res.
PD APR
PY 2006
VL 32
IS 2
BP 162
EP 170
DI 10.1111/j.1447-0756.2006.00373.x
PG 9
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA 021MD
UT WOS:000235986400007
PM 16594919
DA 2018-12-27
ER

PT J
AU Tsakraklides, V
   Papaioannou, D
   Agamanolis, DP
AF Tsakraklides, V
   Papaioannou, D
   Agamanolis, DP
TI RETRACTED: Survey of diagnostic accuracy in the College of American
   Pathologists' Performance Improving Program (1993-2003) (Retracted
   Article)
SO PATHOLOGY INTERNATIONAL
LA English
DT Article; Retracted Publication
DE diagnostic accuracy; interobserver variations; surgical pathology
ID 23 EUROPEAN PATHOLOGISTS; SURGICAL PATHOLOGY; 2ND OPINIONS; ANATOMIC
   PATHOLOGY; OBSERVER VARIATION; BREAST; LESIONS; DISEASE
AB The diagnostic accuracy of participants in the College of American Pathologists' Performance Improving Program (PIP) was surveyed for 364 cases ranging from 1993 to 2003. For each case, participating pathologists were provided with a single hematoxylin and eosin (HE)-stained histological slide, a brief clinical history and a master list of 4-13 diagnoses from which they were asked to select the appropriate diagnosis. A committee of PIP experts subsequently provided the correct diagnosis. The mean number of annual participants was 3045. The proportion of participants who agreed with the experts' diagnosis in each case (diagnostic accuracy) varied from 2.2% to 99.7% (mean 77.6%). The highest mean diagnostic accuracy was found in cases of benign tumors (82.7%), the lowest, in borderline tumors (74.4%), and intermediate rates in cases of malignant tumors (77.6%), non-neoplastic lesions (78.2%) and infections (80.4%). The overall rate of diagnostic accuracy increased from 76.9% in 1993 to 82.9% in 2003 (P < 0.001). Despite this improving trend, these results demonstrate a persistently wide range of discrepancy among a cohort of pathologists in evaluating HE sections; and highlight the need for alternative diagnostic techniques in order for pathology to remain the gold standard of diagnosis in medicine.
C1 Hygeia Hosp, Dept Pathol, Athens, Greece.
   Childrens Hosp Med Ctr Akron, Akron, OH 44308 USA.
RP Tsakraklides, V (reprint author), 15 Logothetidi St, Athens 11524, Greece.
EM vastsakr@otenet.gr
CR ABT AB, 1995, ARCH PATHOL LAB MED, V119, P514
   Arbiser ZK, 2001, AM J CLIN PATHOL, V116, P473
   *COLL AM PATH, 2005, PERF IMPR PROGR SURG
   Cook IS, 2001, EUR J SURG ONCOL, V27, P589, DOI 10.1053/ejso.2001.1150
   Elston CW, 2000, EUR J CANCER, V36, P1769, DOI 10.1016/S0959-8049(00)00181-7
   Gephardt GN, 1996, ARCH PATHOL LAB MED, V120, P804
   Glaser SL, 2001, CANCER-AM CANCER SOC, V92, P218, DOI 10.1002/1097-0142(20010715)92:2<218::AID-CNCR1312>3.0.CO;2-6
   HARRIS M, 1991, BRIT J CANCER, V64, P315, DOI 10.1038/bjc.1991.298
   Hirokawa M, 2002, AM J SURG PATHOL, V26, P1508, DOI 10.1097/00000478-200211000-00014
   Kronz JD, 1999, CANCER, V86, P2426, DOI 10.1002/(SICI)1097-0142(19991201)86:11<2426::AID-CNCR34>3.3.CO;2-V
   Ormsby AH, 2002, GUT, V51, P671, DOI 10.1136/gut.51.5.671
   Prayson RA, 2000, J NEUROL SCI, V175, P33, DOI 10.1016/S0022-510X(00)00274-4
   PRESCOTT RJ, 1995, J CLIN PATHOL, V48, P245, DOI 10.1136/jcp.48.3.245
   Rorke LB, 1997, CANCER, V79, P665, DOI 10.1002/(SICI)1097-0142(19970215)79:4<665::AID-CNCR1>3.0.CO;2-D
   ROSAI J, 1991, AM J SURG PATHOL, V15, P209, DOI 10.1097/00000478-199103000-00001
   ROSAI J, 2004, ROSAI ACKERMANS SURG, P1
   SAFRIN RE, 1993, AM J SURG PATHOL, V17, P1190, DOI 10.1097/00000478-199311000-00014
   Sirota RL, 2000, ARCH PATHOL LAB MED, V124, P1674
   Sloane JP, 1998, HUM PATHOL, V29, P1056
   Sloane JP, 1999, VIRCHOWS ARCH, V434, P3
   Staradub VL, 2002, ANN SURG ONCOL, V9, P982, DOI 10.1245/ASO.2002.03.056
   Tomaszewski JE, 2000, AM J CLIN PATHOL, V114, P329, DOI 10.1093/ajcp/114.3.329
   Verkooijen HM, 2003, EUR J CANCER, V39, P2187, DOI 10.1016/S0959-8049(03)00540-9
   Wells WA, 1998, J NATL CANCER I, V90, P142, DOI 10.1093/jnci/90.2.142
   Zardawi IM, 1998, J CLIN PATHOL, V51, P695, DOI 10.1136/jcp.51.9.695
NR 25
TC 0
Z9 0
U1 3
U2 10
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1320-5463
EI 1440-1827
J9 PATHOL INT
JI Pathol. Int.
PD APR
PY 2006
VL 56
IS 4
BP 206
EP 210
DI 10.1111/j.1440-1827.2006.01947.x
PG 5
WC Pathology
SC Pathology
GA 024UL
UT WOS:000236221600006
DA 2018-12-27
ER

PT J
AU Abdelmoula, N
   Chaabane, H
   Khemakhem, H
   Von der Muhll, R
   Simon, A
AF Abdelmoula, N
   Chaabane, H
   Khemakhem, H
   Von der Muhll, R
   Simon, A
TI RETRACTED: Relaxor or classical ferroelectric behavior in A site
   substituted perovskite type Ba1-x(SM0.5Na0.5)(x),TiO3 (Retracted
   article. See vol 204, pg 4305, 2007)
SO PHYSICA STATUS SOLIDI A-APPLICATIONS AND MATERIALS SCIENCE
LA English
DT Article; Retracted Publication
ID DIELECTRIC-PROPERTIES; PHASE-TRANSITIONS; CERAMICS; SYSTEM; TITANATES;
   POLARIZATION; DISORDER
AB New ferroelectric ceramics of ABO(3) perovskite type were synthesized in the Ba1-x(Sm0.5Na0.5)(x)TiO3 system by solid state reaction technique. The effect of the replacement of barium by samariurn and sodium in the A cationic site on structural and physical properties was investigated. These compounds crystallize with tetragonal or cubic symmetry. The material is classical ferroclectric for 0 <= x <= 0.1 and 0.5 <= x <= 0.6, and present a relaxor behavior for 0.2 <= x <= 0.4. The dielectric behavior depends upon the cationic disorder in the A site and the cell size. Small rate substitution allows a ferroelectric-paraelectric transition. For higher rate of substitution the possible random position of the Sm-Na cations brings to a relaxor sate and when the substitution rate x becomes higher than 0.5, the material comes back to a ferroelectric state due to the reduced cell size. Some of these new compositions are of interest for applications due to their physical properties and environmentally friendly character. (c) 2006 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
C1 Fac Sci Sfax, Lab Mat Ferroelect, Sfax, Tunisia.
   CNRS, Inst Chim Mat Condensee Bordeaux, F-33608 Pessac, France.
RP Abdelmoula, N (reprint author), Fac Sci Sfax, Lab Mat Ferroelect, BP 802, Sfax, Tunisia.
EM Najmeddine.Abdelmoula@fss.rnu.tn
CR Aydi A, 2004, SOLID STATE SCI, V6, P333, DOI 10.1016/j.solidstatesciences.2003.12.006
   Aydi A, 2005, SOLID STATE SCI, V7, P249, DOI 10.1016/j.solidstatesciences.2004.10.009
   BEDNORZ JG, 1984, PHYS REV LETT, V52, P2289, DOI 10.1103/PhysRevLett.52.2289
   BURNS G, 1990, FERROELECTRICS, V104, P25, DOI 10.1080/00150199008223809
   Cross LE, 1994, FERROELECTRICS, V151, P305, DOI 10.1080/00150199408244755
   CROSS LE, 1987, FERROELECTRICS, V76, P241, DOI 10.1080/00150198708016945
   ISUPOV VA, 1989, FERROELECTRICS, V90, P113, DOI 10.1080/00150198908211278
   Jha P, 2004, SOLID STATE SCI, V6, P663, DOI 10.1016/j.solidstatesciences.2004.03.028
   KCHIKECH M, 1994, J PHYS-CONDENS MAT, V6, P10159, DOI 10.1088/0953-8984/6/46/031
   Khemakhem H, 2000, J PHYS-CONDENS MAT, V12, P5951, DOI 10.1088/0953-8984/12/27/313
   Komine S, 2002, J PHYS-CONDENS MAT, V14, P2043, DOI 10.1088/0953-8984/14/8/330
   Li GB, 2004, J SOLID STATE CHEM, V177, P1695, DOI 10.1016/j.jssc.2003.12.025
   Lorenz M, 2003, SOLID STATE ELECTRON, V47, P2199, DOI 10.1016/S0038-1101(03)00197-7
   Outzourhit A, 2002, J ALLOY COMPD, V340, P214, DOI 10.1016/S0925-8388(01)01986-7
   Prosandeev SA, 2001, J PHYS-CONDENS MAT, V13, P5957, DOI 10.1088/0953-8984/13/26/311
   Ravez J, 1997, PHYS STATUS SOLIDI A, V159, P517, DOI 10.1002/1521-396X(199702)159:2<517::AID-PSSA517>3.0.CO;2-O
   Ravez J, 1999, J MATER CHEM, V9, P1609, DOI 10.1039/a902335f
   Ravez J., 1998, J KOREAN PHYS SOC, V32, P955
   RODRIGUEZCARVAJ.J, 1998, PROGRAM FULLPROF VER
   SCIAU P, 2000, SOLID STATE COMMUN, V113, P77
   SETTER N, 1980, J MATER SCI, V15, P2478, DOI 10.1007/BF00550750
   SETTER N, 1980, J APPL PHYS, V51, P4356, DOI 10.1063/1.328296
   SHANNON RD, 1976, ACTA CRYSTALLOGR A, V32, P751, DOI 10.1107/S0567739476001551
   SIMON A, 2000, FERROELECTRICS, V240, P335
   Smolenskii G. A., 1970, J PHYS SOC JAPAN   S, V28, P26
   Sun PH, 1997, FERROELECTRICS, V200, P93
   Tang XG, 2004, SOLID STATE COMMUN, V131, P163, DOI 10.1016/j.ssc.2004.05.016
   Vieland D, 1990, J APPL PHYS, V68, P2916
   VIELHAND D, 1984, J APPL PHYS, V68, P2916
   Xu Q, 2005, MATER CHEM PHYS, V90, P111, DOI 10.1016/j.matchemphys.2004.10.018
   YAO X, 1983, J APPL PHYS, V54, P3399
NR 31
TC 10
Z9 10
U1 3
U2 11
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA PO BOX 10 11 61, D-69451 WEINHEIM, GERMANY
SN 0031-8965
J9 PHYS STATUS SOLIDI A
JI Phys. Status Solidi A-Appl. Mat.
PD APR
PY 2006
VL 203
IS 5
BP 987
EP 996
DI 10.1002/pssa.200521465
PG 10
WC Materials Science, Multidisciplinary; Physics, Applied; Physics,
   Condensed Matter
SC Materials Science; Physics
GA 038BG
UT WOS:000237192000026
DA 2018-12-27
ER

PT J
AU Gonzalez, S
   Klatt, P
   Delgado, S
   Conde, E
   Lopez-Rios, F
   Sanchez-Cespedes, M
   Mendez, J
   Antequera, F
   Serrano, M
AF Gonzalez, S
   Klatt, P
   Delgado, S
   Conde, E
   Lopez-Rios, F
   Sanchez-Cespedes, M
   Mendez, J
   Antequera, F
   Serrano, M
TI RETRACTED: Oncogenic activity of Cdc6 through repression of the INK4/ARF
   locus (Retracted article. See vol. 547, pg. 246, 2017)
SO NATURE
LA English
DT Article; Retracted Publication
ID ORIGIN RECOGNITION COMPLEX; DNA-REPLICATION; HUMAN-CELLS; INITIATION
   SITES; TUMOR; PROTEINS; IDENTIFICATION; TRANSCRIPTION; METHYLATION;
   P16(INK4A)
AB The INK4/ARF locus encodes three tumour suppressors (p15(INK4b), ARF and p16(INK4a)) and is among the most frequently inactivated loci in human cancer(1,2). However, little is known about the mechanisms that govern the expression of this locus. Here we have identified a putative DNA replication origin at the INK4/ARF locus that assembles a multiprotein complex containing Cdc6, Orc2 and MCMs, and that coincides with a conserved noncoding DNA element ( regulatory domain RDINK4/ARF). Targeted and localized RNA-interference-induced heterochromatinization of RDINK4/ARF results in transcriptional repression of the locus, revealing that RDINK4/ARF is a relevant transcriptional regulatory element. Cdc6 is overexpressed in human cancers, where it might have roles in addition to DNA replication(3-5). We have found that high levels of Cdc6 result in RDINK4/ARF-dependent transcriptional repression, recruitment of histone deacetylases and heterochromatinization of the INK4/ARF locus, and a concomitant decrease in the expression of the three tumour suppressors encoded by this locus. This mechanism is reminiscent of the silencing of the mating-type HM loci in yeast by replication factors(6). Consistent with its ability to repress the INK4/ARF locus, Cdc6 has cellular immortalization activity and neoplastic transformation capacity in cooperation with oncogenic Ras. Furthermore, human lung carcinomas with high levels of Cdc6 are associated with low levels of p16(INK4a). We conclude that aberrant expression of Cdc6 is oncogenic by directly repressing the INK4/ARF locus through the RDINK4/ARF element.
C1 Spanish Natl Canc Res Ctr CNIO, Tumor Suppress Grp, E-28029 Madrid, Spain.
   Spanish Natl Canc Res Ctr CNIO, Lung Canc Grp, E-28029 Madrid, Spain.
   Spanish Natl Canc Res Ctr CNIO, DNA Replicat Grp, E-28029 Madrid, Spain.
   Univ Salamanca, CSIC, Inst Microbiol Bioquim, E-37007 Salamanca, Spain.
   Hosp Univ 12 Octubre, Dept Anat Patol, E-28041 Madrid, Spain.
RP Serrano, M (reprint author), Spanish Natl Canc Res Ctr CNIO, Tumor Suppress Grp, E-28029 Madrid, Spain.
EM mserrano@cnio.es
RI Mendez, Juan/K-8001-2014; Antequera, Francisco/B-1115-2017; Serrano,
   Manuel/H-2634-2015; Gonzalez, Susana/I-3154-2015; Sanchez-Cespedes,
   Montse/H-8485-2012
OI Mendez, Juan/0000-0002-3235-2559; Antequera,
   Francisco/0000-0003-2623-4131; Serrano, Manuel/0000-0001-7177-9312;
   Gonzalez, Susana/0000-0002-7443-6195; Sanchez-Cespedes,
   Montse/0000-0002-6045-5627
CR Abdurashidova G, 2003, EMBO J, V22, P4294, DOI 10.1093/emboj/cdg404
   Antequera F, 2004, EMBO J, V23, P4365, DOI 10.1038/sj.emboj.7600450
   Araujo FD, 1999, J BIOL CHEM, V274, P9335, DOI 10.1074/jbc.274.14.9335
   Arcellana-Panlilio MY, 2000, GENE CHROMOSOME CANC, V29, P63, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1006>3.0.CO;2-L
   Cvetic C, 2005, SEMIN CELL DEV BIOL, V16, P343, DOI 10.1016/j.semcdb.2005.02.009
   Delgado S, 1998, EMBO J, V17, P2426, DOI 10.1093/emboj/17.8.2426
   Ekholm-Reed S, 2004, J CELL BIOL, V165, P789, DOI 10.1083/jcb.200404092
   Fox CA, 2005, J BIOL CHEM, V280, P8629, DOI 10.1074/jbc.R400033200
   Frolova NS, 2002, MOL BIOL CELL, V13, P1298, DOI 10.1091/mbc.01-08-0382
   Gonzalez MA, 2005, NAT REV CANCER, V5, P135, DOI 10.1038/nrc1548
   Gonzalez S, 2003, MOL CELL BIOL, V23, P8161, DOI 10.1128/MCB.23.22.8161-8171.2003
   Karakaidos P, 2004, AM J PATHOL, V165, P1351, DOI 10.1016/S0002-9440(10)63393-7
   Katan-Khaykovich Y, 2005, EMBO J, V24, P2138, DOI 10.1038/sj.emboj.7600692
   Kawasaki H, 2004, NATURE, V431, P211, DOI 10.1038/nature02889
   Ladenburger EM, 2002, MOL CELL BIOL, V22, P1036, DOI 10.1128/MCB.22.4.1036-1048.2002
   Lowe SW, 2003, CURR OPIN GENET DEV, V13, P77, DOI 10.1016/S0959-437X(02)00013-8
   Mendez J, 2000, MOL CELL BIOL, V20, P8602, DOI 10.1128/MCB.20.22.8602-8612.2000
   Morris KV, 2004, SCIENCE, V305, P1289, DOI 10.1126/science.1101372
   Murphy N, 2005, J CLIN PATHOL, V58, P525, DOI 10.1136/jcp.2004.018895
   Mutskov V, 2004, EMBO J, V23, P138, DOI 10.1038/sj.emboj.7600013
   Pennacchio LA, 2001, NAT REV GENET, V2, P100, DOI 10.1038/35052548
   Semple JW, 2004, BIOTECHNOL ADV, V22, P621, DOI 10.1016/j.biotechadv.2004.06.001
   Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9
   Sherr CJ, 2001, NAT REV MOL CELL BIO, V2, P731, DOI 10.1038/35096061
   Stucki M, 2001, PROG NUCLEIC ACID RE, V65, P261
   Tao L, 2000, J CELL BIOCHEM, V78, P442, DOI 10.1002/1097-4644(20000901)78:3<442::AID-JCB9>3.0.CO;2-1
   Wei WY, 2001, MOL CELL BIOL, V21, P6748, DOI 10.1128/MCB.21.20.6748-6757.2001
   Wistuba II, 2001, SEMIN ONCOL, V28, P3, DOI 10.1053/sonc.2001.25738
NR 28
TC 141
Z9 146
U1 6
U2 21
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0028-0836
EI 1476-4687
J9 NATURE
JI Nature
PD MAR 30
PY 2006
VL 440
IS 7084
BP 702
EP 706
DI 10.1038/nature04585
PG 5
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 026OY
UT WOS:000236350400051
PM 16572177
DA 2018-12-27
ER

PT J
AU Mehrotra, R
   Gupta, A
   Singh, M
   Ibrahim, R
AF Mehrotra, Ravi
   Gupta, Anurag
   Singh, Mamta
   Ibrahim, Rahela
TI RETRACTED: Application of cytology and molecular biology in diagnosing
   premalignant or malignant oral lesions (Retracted article. See vol. 11,
   57, 2012)
SO MOLECULAR CANCER
LA English
DT Review; Retracted Publication
ID SQUAMOUS-CELL CARCINOMA; QUANTITATIVE EXFOLIATIVE CYTOLOGY; BRUSH
   BIOPSY; MICROSATELLITE ALTERATIONS; PROMOTER HYPERMETHYLATION;
   CONVENTIONAL SMEARS; SUSPICIOUS LESIONS; CERVICAL CYTOLOGY; CANCER; HEAD
AB Early detection of a premalignant or cancerous oral lesion promises to improve the survival and the morbidity of patients suffering from these conditions. Cytological study of oral cells is a non-aggressive technique that is well accepted by the patient, and is therefore an attractive option for the early diagnosis of oral cancer, including epithelial atypia and squamous cell carcinoma. However its usage has been limited so far due to poor sensitivity and specificity in diagnosing oral malignancies. Lately it has re-emerged due to improved methods and it's application in oral precancer and cancer as a diagnostic and predictive method as well as for monitoring patients. Newer diagnostic techniques such as "brush biopsy" and molecular studies have been developed. Recent advances in cytological techniques and novel aspects of applications of scraped or exfoliative cytology for detecting these lesions and predicting their progression or recurrence are reviewed here.
C1 Moti Lal Nehru Med Coll, Dept Pathol, Allahabad, Uttar Pradesh, India.
RP Mehrotra, R (reprint author), Moti Lal Nehru Med Coll, Dept Pathol, Allahabad, Uttar Pradesh, India.
EM rm8509@rediffmail.com; ganuragdr@rediffmail.com; mms85@rediffmail.com;
   rahela_biotech@sify.com
RI Mehrotra, Ravi/E-3285-2010
OI Mehrotra, Ravi/0000-0001-9453-1408
CR Ahmed HGE, 2003, ANTICANCER RES, V23, P1943
   BANOCZY J, 1976, INT DENT J, V26, P398
   Bishop JW, 1998, ACTA CYTOL, V42, P189, DOI 10.1159/000331545
   BOYLE JO, 1994, AM J SURG, V168, P429, DOI 10.1016/S0002-9610(05)80092-3
   Califano J, 1996, CANCER RES, V56, P2488
   Casiglia Jeffrey, 2001, General Dentistry, V49, P72
   Cheng B, 2004, ORAL SURG ORAL MED O, V97, P465, DOI 10.1016/j.tripleo.2003.12.020
   COWPE JG, 1988, J ROY SOC MED, V81, P509
   COWPE JG, 1991, ANAL QUANT CYTOL, V13, P11
   COWPE JG, 1993, CYTOPATHOLOGY, V4, P27, DOI 10.1111/j.1365-2303.1993.tb00070.x
   COWPE JG, 1985, J ROY SOC MED, V78, P995, DOI 10.1177/014107688507801204
   El-Naggar AK, 2001, J MOL DIAGN, V3, P164, DOI 10.1016/S1525-1578(10)60668-X
   ELNAGGAR AK, 1995, CANCER RES, V55, P2656
   Epstein Joel B, 2002, J Can Dent Assoc, V68, P617
   Frist S, 2003, ORAL SURG ORAL MED O, V96, P654, DOI 10.1016/j.tripleo.2003.11.002
   Garcia del Moral R, 1993, LAB ANATOMIA PATOLOG, P245
   Grohs HK, 1994, AUTOMATED CERVICAL C, P176
   HAYAMA HF, 2005, ORAL MED PATHOLOGY, V23, P1927
   Howell LP, 1998, ACTA CYTOL, V42, P171, DOI 10.1159/000331542
   Huang MF, 1999, ORAL ONCOL, V35, P296, DOI 10.1016/S1368-8375(98)00119-5
   JONES AC, 1994, ORAL SURG ORAL MED O, V77, P101, DOI 10.1016/S0030-4220(06)80117-9
   Kaugars G E, 1998, J Cancer Educ, V13, P85
   Lane E B, 1990, Semin Cancer Biol, V1, P165
   LIAM PH, 2000, ORAL ONCOL, V36, P272
   Lopez M, 2003, EUR J CANCER, V39, P2306, DOI 10.1016/S0959-8049(03)00550-1
   LOPEZ M, 2004, IN PRESS CLIN ONCOL
   MAO L, 1994, P NATL ACAD SCI USA, V91, P9871, DOI 10.1073/pnas.91.21.9871
   Mao L, 1996, NAT MED, V2, P682, DOI 10.1038/nm0696-682
   Maraki D, 2004, J ORAL PATHOL MED, V33, P398, DOI 10.1111/j.1600-0714.2004.0235.x
   MASHBERG A, 1988, AM J SURG, V156, P273, DOI 10.1016/S0002-9610(88)80290-3
   McGoogan E, 1996, ACTA CYTOL, V40, P107
   Mehrotra Madhu R, 2004, INDIAN J PATHOL MICR, V47, P497
   Mehrotra R, 2003, Indian J Med Sci, V57, P400
   MEHROTRA R, 2004, TOBACCO COUNTERS HLT, V3, P216
   NICHOLS ML, 1991, ARCH OTOLARYNGOL, V117, P1350
   Nunes DN, 2000, ORAL ONCOL, V36, P525, DOI 10.1016/S1368-8375(00)00045-2
   OGDEN GR, 1991, CANCER, V68, P1611, DOI 10.1002/1097-0142(19911001)68:7<1611::AID-CNCR2820680724>3.0.CO;2-L
   Ogden GR, 1997, J ORAL PATHOL MED, V26, P201, DOI 10.1111/j.1600-0714.1997.tb01224.x
   OGDEN GR, 1993, J ORAL PATHOL MED, V22, P82, DOI 10.1111/j.1600-0714.1993.tb00049.x
   OGDEN GR, 1993, J CLIN PATHOL, V46, P352, DOI 10.1136/jcp.46.4.352
   OGDEN GR, 1994, ORAL ONCOL, V30B, P405, DOI 10.1016/0964-1955(94)90020-5
   OGDEN GR, 1992, ACTA CYTOL, V36, P706
   Orellana-Bustos Alejandra Isabel, 2004, Med Oral, V9, P197
   Partridge M, 2000, CANCER RES, V60, P3893
   PATEL K, 2004, HAW 82 IADR C, P1240
   Potter TJ, 2003, J ORAL MAXIL SURG, V61, P674, DOI 10.1053/joms.2003.50136
   Ramaesh T, 1998, J ORAL PATHOL MED, V27, P83
   Remmerbach TW, 2003, ANAL CELL PATHOL, V25, P159, DOI 10.1155/2003/305151
   Remmerbach TW, 2003, ANAL CELL PATHOL, V25, P139, DOI 10.1155/2003/647685
   Remmerbach TW, 2001, ANAL CELL PATHOL, V22, P211, DOI 10.1155/2001/807358
   Rick GM, 2003, ORAL SURG ORAL MED O, V96, P252, DOI 10.1016/S1079-2104(03)00362-7
   Rosas SLB, 2001, CANCER RES, V61, P939
   Rosin MP, 2000, CLIN CANCER RES, V6, P357
   Scheifele C, 2002, Mund Kiefer Gesichtschir, V6, P410, DOI 10.1007/s10006-002-0425-0
   Sciubba JJ, 1999, J AM DENT ASSOC, V130, P1445, DOI 10.14219/jada.archive.1999.0055
   Sharma Prashant, 2005, Med Oral Patol Oral Cir Bucal, V10 Suppl 1, pE15
   Sidransky D, 1995, J Natl Cancer Inst Monogr, P27
   SILVERMAN S, 1990, J AM DENT ASSOC, V120, P495, DOI 10.14219/jada.archive.1990.0082
   Spafford MF, 2001, CLIN CANCER RES, V7, P607
   Sprenger E, 1996, ACTA CYTOL, V40, P81
   Sudbo J, 2001, NEW ENGL J MED, V344, P1270, DOI 10.1056/NEJM200104263441702
   Svirsky J A, 2001, Compend Contin Educ Dent, V22, P99
   UMUDUM H, 2005, CANCER
   Vassilakos P, 1996, ACTA CYTOL, V40, P496
   Walling DM, 2003, ORAL ONCOL, V39, P436, DOI 10.1016/S1368-8375(03)00002-2
   Wesley R, 1997, BRIT J CANCER, V75, P436, DOI 10.1038/bjc.1997.72
   Williams HK, 2000, J CLIN PATHOL-MOL PA, V53, P165, DOI 10.1136/mp.53.4.165
NR 67
TC 80
Z9 83
U1 4
U2 14
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1476-4598
J9 MOL CANCER
JI Mol. Cancer
PD MAR 23
PY 2006
VL 5
AR 11
DI 10.1186/1476-4598-5-11
PG 9
WC Biochemistry & Molecular Biology; Oncology
SC Biochemistry & Molecular Biology; Oncology
GA 076OS
UT WOS:000239968200001
PM 16556320
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Mohammad, RM
   Banerjee, S
   Li, YW
   Aboukameel, A
   Kucuk, O
   Sarkar, FH
AF Mohammad, RM
   Banerjee, S
   Li, YW
   Aboukameel, A
   Kucuk, O
   Sarkar, FH
TI RETRACTED: Cisplatin-induced antitumor activity is potentiated by the
   soy isoflavone genistein in BxPC-3 pancreatic tumor xenografts
   (Retracted article. See vol. 122, pg. 3247, 2016)
SO CANCER
LA English
DT Article; Retracted Publication
DE BxPC-3 pancreatic carcinoma cell line; xenografts; cisplatin; genistein
ID NF-KAPPA-B; PROSTATE-CANCER CELLS; CARCINOMA-CELLS; PHASE-II; APOPTOSIS;
   GEMCITABINE; ACTIVATION; DOCETAXEL; CARCINOGENESIS; CHEMOTHERAPY
AB BACKGROUND. The activation of nuclear factor kappa B (NF-kappa B) contributes to drug resistance in pancreatic carcinoma. The authors previously showed that the soy isoflavone genistein down-regulates the activation of NF-kappa B in many carcinoma cell lines in vitro. In the current study, they focused their investigation on testing whether the inactivation of NF-kappa B by genistein could enhance cisplatin-induced cell growth inhibition and apoptosis in BxPC-3 cells in vitro and antitumor activity of cisplatin in vivo.
   METHODS. BxPC-3 cells were preexposed to 25 mu M genistein for 24 hours and then exposed to cisplatin (0.5 mu M) for an additional 72 hours. A cell growth inhibition assay, an apoptosis assay, and an NF-kappa B electrophoretic mobility shift assay were conducted. For the in vivo study, a xenograft model of BxPC-3 cells in severe combined immunodeficient mice was used. Genistein was given at a dose of 800 mu g/kg orally for 5 days, cisplatin was given at a dose of 9 mg/kg as an intraperitoneal bolus, and another group of mice received both cisplatin and genistein (given on Day 1 concurrently followed by genistein for 4 days).
   RESULTS. The combination of 25 mu M genistein with 0.5 mu M cisplatin resulted in significantly greater growth inhibition (P < 0.01) and more apoptosis in BxPC-3 cells compared with either agent alone. Preexposure of BYPC-3 cells to genistein abrogated cisplatin-induced activation of NF-kappa B, which appeared to be consistent with the authors' hypothesis. The authors also demonstrated for the first time that the in vivo effect of genistein enhanced the antitumor activity of cisplatin. The tumor weight for the control, genistein, cisplatin, and combined genistein and cisplatin mice was 940 mg, 762 mg, 261 mg, and 108 mg, respectively. Most important, for the first time, the authors observed that the DNA-binding activity of NF-kappa B was inactivated in genistein-treated animal tumors, whereas cisplatin significantly induced NF-kappa B DNA binding activity, and this was completely abrogated in genistein-pretreated tumors that were exposed to cisplatin, consistent with the in vitro data.
   CONCLUSIONS. overall, the current results were consistent with the authors' hypothesis and suggested that pretreatment of pancreatic carcinoma cells with genistein down-regulates NF-kappa B activity and contributes toward enhancing the apoptosis-inducing effect of cisplatin, leading to greater antitumor activity in vivo.
C1 Wayne State Univ, Dept Pathol, Karmanos Canc Inst, Sch Med,Hudson Webber Canc Res Ctr 715, Detroit, MI 48201 USA.
   Wayne State Univ, Div Hematol & Oncol, Dept Internal Med, Sch Med,Karmanos Canc Inst, Detroit, MI 48201 USA.
RP Sarkar, FH (reprint author), Wayne State Univ, Dept Pathol, Karmanos Canc Inst, Sch Med,Hudson Webber Canc Res Ctr 715, 110 E Warren, Detroit, MI 48201 USA.
EM fsarkar@med.wayne.edu
FU NCI NIH HHS [1R01 CA 101870-02, 5R01 CA 083695-04, 1P20 CA 010193-02]
CR ADLERCREUTZ H, 1994, CANCER DETECT PREV, V18, P259
   AKIYAMA T, 1987, J BIOL CHEM, V262, P5592
   Arlt A, 2001, ONCOGENE, V20, P859, DOI 10.1038/sj.onc.1204168
   Banerjee S, 2002, CANCER RES, V62, P4945
   Buchler P, 2003, PANCREAS, V26, P264, DOI 10.1097/00006676-200304000-00010
   Cascinu S, 1999, ANN ONCOL, V10, P1377, DOI 10.1023/A:1008394111533
   Chawla-Sarkar M, 2003, J BIOL CHEM, V278, P39461, DOI 10.1074/jbc.M306111200
   Chuang SE, 2002, BIOCHEM PHARMACOL, V63, P1709, DOI 10.1016/S0006-2952(02)00931-0
   Davis JN, 1999, NUTR CANCER, V35, P167, DOI 10.1207/S15327914NC352_11
   El-Rayes BF, 2003, J CLIN ONCOL, V21, P2920, DOI 10.1200/JCO.2003.03.022
   Evans TRJ, 1996, BRIT J CANCER, V73, P1260, DOI 10.1038/bjc.1996.241
   Ganjoo KN, 2002, ONCOLOGY-BASEL, V62, P299, DOI 10.1159/000065060
   Gukovsky I, 1998, AM J PHYSIOL-GASTR L, V275, pG1402, DOI 10.1152/ajpgi.1998.275.6.G1402
   Hillman GG, 2001, CLIN CANCER RES, V7, P382
   Jacobs AD, 2002, CANCER, V95, P923, DOI 10.1002/cncr.10756
   Jemal A, 2003, CA-CANCER J CLIN, V53, P5, DOI 10.3322/canjclin.53.1.5
   Lenzi R, 2002, CANCER INVEST, V20, P464, DOI 10.1081/CNV-120002146
   Li YW, 2004, PANCREAS, V28, pE90, DOI 10.1097/00006676-200405000-00020
   Li YW, 2002, J NUTR, V132, P3623
   Lian FR, 1999, NUTR CANCER, V33, P125, DOI 10.1207/S15327914NC330202
   Mohammad RM, 2003, MOL CANCER THER, V2, P1361
   Mohammad RM, 1999, PANCREAS, V19, P353, DOI 10.1097/00006676-199911000-00006
   Mohammad RM, 2001, ANTI-CANCER DRUG, V12, P735, DOI 10.1097/00001813-200110000-00005
   Sarkar FH, 2004, FRONT BIOSCI-LANDMRK, V9, P2714, DOI 10.2741/1430
   SUN Y, 1990, FREE RADICAL BIO MED, V8, P583, DOI 10.1016/0891-5849(90)90156-D
   Wang CY, 1999, NAT MED, V5, P412
NR 26
TC 53
Z9 62
U1 3
U2 9
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0008-543X
EI 1097-0142
J9 CANCER-AM CANCER SOC
JI Cancer
PD MAR 15
PY 2006
VL 106
IS 6
BP 1260
EP 1268
DI 10.1002/cncr.21731
PG 9
WC Oncology
SC Oncology
GA 021XP
UT WOS:000236019500008
PM 16475211
DA 2018-12-27
ER

PT J
AU Yao, ZQ
   Shata, MT
   Tricoche, N
   Shan, MM
   Brotman, B
   Pfahler, W
   Hahn, YS
   Prince, AM
AF Yao, ZQ
   Shata, MT
   Tricoche, N
   Shan, MM
   Brotman, B
   Pfahler, W
   Hahn, YS
   Prince, AM
TI RETRACTED: grC1qR expression in chimpanzees with resolved and chronic
   infection: Potential role of HCV core/gC1qR-mediated T cell suppression
   in the outcome of HCV infection (Retracted Article. See vol 368, pg 432,
   2007)
SO VIROLOGY
LA English
DT Article; Retracted Publication
DE HCV; core protein; gC1qR; T cells; immunosuppression; viral persistence
ID HEPATITIS-C VIRUS; CORE PROTEIN; IMMUNE-RESPONSE; PROTECTIVE IMMUNITY;
   REGULATORY PATHWAY; CD4(+); RECEPTOR; PROLIFERATION; ASSOCIATION;
   RECURRENCE
AB Chimpanzee is a unique animal model for HCV infection, in which about 50% of infections resolve spontaneously. It has been reported that the magnitude of T cell responses to HCV core in recovered chimpanzees is greater than that in chronically infected ones. However, the mechanism(s) by which the chimpanzees with resolved infection overcome core-mediated immunosuppression remains unknown. In this study, we examined the effect of HCV core on T cell responsiveness in chimpanzees with resolved and chronic HCV infection. We found that core protein strongly inhibited T cell activation and proliferation in chimpanzees with chronic infection, while this inhibition was limited in chimpanzees with resolved infection. Notably, the level of gC1qR, as well as the binding of core protein, on the surface of T cells was lower in recovered chimpanzees when compared to chimpanzees with chronic HCV infection. Intriguingly, the observed differences in gC1qR expression levels and susceptibility to core-induced suppression amongst HCV-chronically infected and recovered chimpanzees were observed prior to HCV challenge, suggesting a possible genetic determination of the outcome of infection. These findings suggest that gC1qR expression on the surface of T cells is crucial for HCV core-mediated T cell suppression and viral clearance, and that represents a novel mechanism by which a virus usurps host machinery for persistence. (C) 2005 Elsevier Inc. All rights reserved.
C1 Univ Virginia, Beirne Carter Ctr Immunol Res, Dept Pathol & Microbiol, Charlottesville, VA 22908 USA.
   Univ Cincinnati, Med Ctr, Dept Internal Med, Div Digest Dis,Viral Immunol Lab, Cincinnati, OH 45267 USA.
   New York Blood Ctr, Lindsley F Kimball Res Inst, Virol Lab, New York, NY 10021 USA.
RP Hahn, YS (reprint author), Univ Virginia, Beirne Carter Ctr Immunol Res, Dept Pathol & Microbiol, Charlottesville, VA 22908 USA.
EM ysh5e@virginia.edu
FU NIDDK NIH HHS [R01-DK066754]; PHS HHS [R01-AZ057591]; NIAID NIH HHS
   [R01-AI47349]
CR Alter MJ, 1997, HEPATOLOGY, V26, pS62, DOI 10.1002/hep.510260711
   Blanton RE, 2002, J INFECT DIS, V185, P1644, DOI 10.1086/340574
   Braun L, 2000, EMBO J, V19, P1458, DOI 10.1093/emboj/19.7.1458
   Bruni R, 1996, P NATL ACAD SCI USA, V93, P10423, DOI 10.1073/pnas.93.19.10423
   Chang KM, 1997, J CLIN INVEST, V100, P2376, DOI 10.1172/JCI119778
   CHEN A, 1994, J IMMUNOL, V153, P1430
   Cooper S, 1999, IMMUNITY, V10, P439, DOI 10.1016/S1074-7613(00)80044-8
   Di Bisceglie AM, 1998, LANCET, V351, P351, DOI 10.1016/S0140-6736(97)07361-3
   Eisen-Vandervelde AL, 2004, CLIN IMMUNOL, V111, P16, DOI 10.1016/j.clim.2003.12.003
   FARCI P, 1992, SCIENCE, V258, P135, DOI 10.1126/science.1279801
   Gerlach JT, 1999, GASTROENTEROLOGY, V117, P933, DOI 10.1016/S0016-5085(99)70353-7
   GHEBREHIWET B, 1990, CLIN IMMUNOL IMMUNOP, V54, P148, DOI 10.1016/0090-1229(90)90014-H
   Ghebrehiwet B, 2001, IMMUNOL REV, V180, P65, DOI 10.1034/j.1600-065X.2001.1800106.x
   Gruner NH, 2000, J INFECT DIS, V181, P1528, DOI 10.1086/315450
   Kittlesen DJ, 2000, J CLIN INVEST, V106, P1239, DOI 10.1172/JCI10323
   Large MK, 1999, J IMMUNOL, V162, P931
   Lechmann M, 1999, J HEPATOL, V31, P971, DOI 10.1016/S0168-8278(99)80307-9
   Lechner F, 2000, J EXP MED, V191, P1499, DOI 10.1084/jem.191.9.1499
   Lee JH, 2000, J MED VIROL, V60, P264, DOI 10.1002/(SICI)1096-9071(200003)60:3<264::AID-JMV3>3.0.CO;2-J
   LIAW YF, 1995, HEPATOLOGY, V22, P1101, DOI 10.1002/hep.1840220413
   Liu ZX, 2002, J VIROL, V76, P990, DOI 10.1128/JVI.76.3.990-997.2002
   LUO Y, 1994, REV J VIROL, V68, P3850
   Maillard P, 2001, J VIROL, V75, P8240, DOI 10.1128/JVI.75.17.8240-8250.2001
   Masalova OV, 1998, J MED VIROL, V55, P1, DOI 10.1002/(SICI)1096-9071(199805)55:1<1::AID-JMV1>3.0.CO;2-7
   Matthews DA, 1998, J GEN VIROL, V79, P1677, DOI 10.1099/0022-1317-79-7-1677
   Missale G, 1996, J CLIN INVEST, V98, P706, DOI 10.1172/JCI118842
   Mohamed A, 1998, HEPATO-GASTROENTEROL, V45, P1492
   Nguyen T, 2000, INFECT IMMUN, V68, P2061, DOI 10.1128/IAI.68.4.2061-2068.2000
   Pellicano R, 2000, J HEPATOL, V33, P648, DOI 10.1034/j.1600-0641.2000.033004648.x
   Ray RB, 2001, FEMS MICROBIOL LETT, V202, P149, DOI 10.1016/S0378-1097(01)00286-5
   Rehermann B, 1996, J CLIN INVEST, V98, P1432, DOI 10.1172/JCI118931
   Rosen HR, 1999, GASTROENTEROLOGY, V117, P926, DOI 10.1016/S0016-5085(99)70352-5
   Sarobe P, 2002, J VIROL, V76, P5062, DOI 10.1128/JVI.76.10.5062-5070.2002
   Shata MT, 2002, J VIRAL HEPATITIS, V9, P400, DOI 10.1046/j.1365-2893.2002.00373.x
   Sugimoto K, 2005, J VIROL, V79, P6976, DOI 10.1128/JVI.79.11.6976-6983.2005
   Sugimoto K, 2003, HEPATOLOGY, V38, P1437, DOI 10.1016/j.hep.2003.09.026
   Takaki A, 2000, NAT MED, V6, P578
   Thimme R, 2001, J EXP MED, V194, P1395, DOI 10.1084/jem.194.10.1395
   Tsai SL, 1997, J GASTROEN HEPATOL, V12, pS227, DOI 10.1111/j.1440-1746.1997.tb00505.x
   Wang YL, 1997, VIROLOGY, V236, P18, DOI 10.1006/viro.1997.8739
   Wedemeyer H, 2002, J IMMUNOL, V169, P3447, DOI 10.4049/jimmunol.169.6.3447
   Widell A, 2002, TRANSFUSION MED, V12, P107, DOI 10.1046/j.1365-3148.2002.00359.x
   Yao ZQ, 2005, J VIROL, V79, P15417, DOI 10.1128/JVI.79.24.15417-15429.2005
   Yao ZQ, 2004, J VIROL, V78, P6409, DOI 10.1128/78.12.6409-6419.2004
   Yao ZQ, 2003, VIROLOGY, V314, P271, DOI 10.1016/S0042-6822(03)00419-7
   Yao ZQ, 2001, VIRAL IMMUNOL, V14, P277, DOI 10.1089/08828240152716547
   Yao ZQ, 2001, J IMMUNOL, V167, P5264, DOI 10.4049/jimmunol.167.9.5264
NR 47
TC 12
Z9 14
U1 5
U2 11
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0042-6822
J9 VIROLOGY
JI Virology
PD MAR 15
PY 2006
VL 346
IS 2
BP 324
EP 337
DI 10.1016/j.virol.2005.11.020
PG 14
WC Virology
SC Virology
GA 024JR
UT WOS:000236191800008
PM 16368125
OA Bronze
DA 2018-12-27
ER

PT J
AU Coldren, BA
   Warriner, H
   van Zanten, R
   Zasadzinski, JA
AF Coldren, BA
   Warriner, H
   van Zanten, R
   Zasadzinski, JA
TI RETRACTED: Lamellar gels and spontaneous vesicles in catanionic
   surfactant mixtures (Retracted Article. See vol 22, pg 10296, 2006)
SO LANGMUIR
LA English
DT Article; Retracted Publication
ID FREEZE-FRACTURE REPLICATION; SYNCHROTRON X-RAY; FLUID MEMBRANES;
   PHASE-BEHAVIOR; THERMAL UNDULATIONS; ELECTRON-MICROSCOPY;
   LIQUID-CRYSTAL; SCATTERING; SIZE; FLUCTUATIONS
AB Caille analysis of the small-angle X-ray line shape of the lamellar phase of 7:3 wt/wt cetyltrimethylammonium tosylate (CTAT)/sodium dodecylbenzene sulfonate (SDBS) bilayers shows that the bending elastic constant is kappa = (0.62 +/- 0.09)k(B)T. From this and previous results, the Gaussian curvature constant is kappa = (-0.9 +/- 0.2)k(B)T. For 13:7 wt/wt CTAT/SDBS bilayers, the measured bending elasticity decreases with increasing water dilution, in good agreement with predictions based on renormalization theory, giving kappa(o) = 0.28k(B)T. These results show that surfactant mixing is sufficient to make K approximate to k(B)T, which promotes strong, Helfrich-type repulsion between bilayers that can dominate the van der Waals attraction. These are necessary conditions for spontaneous vesicles to be equilibrium structures. The measurements of the bending elasticity are confirmed by the transition of the lamellar phase of CTAT/SDBS from a turbid, viscoelastic gel to a translucent fluid as the water fraction is decreased below 40 wt %. Freeze-fracture electron microscopy shows that the gel is characterized by spherulite defects made possible by spontaneous bilayer curvature and low bending elasticity. This lamellar gel phase is common to a number of catanionic surfactant mixtures, suggesting that low bending elasticity and spontaneous curvature are typical of these mixtures that form spontaneous vesicles.
C1 Univ Calif Santa Barbara, Dept Chem Engn, Santa Barbara, CA 93106 USA.
   ExxonMobil Res & Engn Co, Corp Strateg Res, Annandale, NJ 08801 USA.
RP Zasadzinski, JA (reprint author), Univ Calif Santa Barbara, Dept Chem Engn, Santa Barbara, CA 93106 USA.
EM gorilla@engineering.ucsb.edu
CR Almgren M, 2004, LANGMUIR, V20, P6611, DOI 10.1021/la049211y
   ALSNIELSEN J, 1980, PHYS REV B, V22, P312, DOI 10.1103/PhysRevB.22.312
   Brocca P, 2004, LANGMUIR, V20, P2141, DOI 10.1021/la035374v
   CAILLE A, 1972, CR ACAD SCI B PHYS, V274, P891
   CHIRUVOLU S, 1994, ACS SYM SER, V578, P86
   CHIRUVOLU S, 1995, LANGMUIR, V11, P4256, DOI 10.1021/la00011a016
   Coldren B, 2003, LANGMUIR, V19, P5632, DOI 10.1021/la034311+
   COLDREN B, 2002, THESIS U CALIFORNIA
   DIAT O, 1993, J PHYS II, V3, P9
   Dubois M, 2004, P NATL ACAD SCI USA, V101, P15082, DOI 10.1073/pnas.0400837101
   DUBOIS M, 1991, LANGMUIR, V7, P1352, DOI 10.1021/la00055a011
   Dubois M, 2001, NATURE, V411, P672, DOI 10.1038/35079541
   DUBOIS M, 1998, C R ACAD SCI 2, V9, P567
   FRANK FC, 1958, DISCUSS FARADAY SOC, P19, DOI 10.1039/df9582500019
   Gradzielski M, 2003, J PHYS-CONDENS MAT, V15, pR655, DOI 10.1088/0953-8984/15/19/202
   HELFRICH W, 1985, J PHYS-PARIS, V46, P1263, DOI 10.1051/jphys:019850046070126300
   HELFRICH W, 1973, Z NATURFORSCH C, VC 28, P693
   HELFRICH W, 1978, Z NATURFORSCH A, V33, P305
   HILBERT D, 1983, GEOMETRY IMAGINATION
   Hoffmann H, 1995, FARADAY DISCUSS, V101, P319, DOI 10.1039/fd9950100319
   IHN KJ, 1992, SCIENCE, V258, P275, DOI 10.1126/science.258.5080.275
   Israelachvili J. N., 1992, INTERMOLECULAR SURFA
   Jung HT, 2002, P NATL ACAD SCI USA, V99, P15318, DOI 10.1073/pnas.242374499
   Jung HT, 2001, P NATL ACAD SCI USA, V98, P1353, DOI 10.1073/pnas.041420998
   KALER EW, 1992, J PHYS CHEM-US, V96, P6698, DOI 10.1021/j100195a033
   KALER EW, 1989, SCIENCE, V245, P1371, DOI 10.1126/science.2781283
   KALER EW, 2005, MIXED SURFACTANT SYS, P298
   Kelly KP, 1997, BRIT J ANAESTH, V78, P1
   PELITI L, 1985, PHYS REV LETT, V54, P1690, DOI 10.1103/PhysRevLett.54.1690
   Pinnow HA, 2000, EUR PHYS J E, V3, P149, DOI 10.1007/s101890070028
   ROUX D, 1988, J PHYS-PARIS, V49, P307, DOI 10.1051/jphys:01988004902030700
   Rovira-Bru M, 2002, BIOPHYS J, V83, P2419, DOI 10.1016/S0006-3495(02)75255-7
   SAFINYA CR, 1986, PHYS REV LETT, V57, P2718, DOI 10.1103/PhysRevLett.57.2718
   SAFINYA CR, 1989, PHYS REV LETT, V62, P1134, DOI 10.1103/PhysRevLett.62.1134
   SAFRAN SA, 1991, PHYS REV A, V43, P1071, DOI 10.1103/PhysRevA.43.1071
   SAFRAN SA, 1990, SCIENCE, V248, P354, DOI 10.1126/science.248.4953.354
   Safran SA, 2002, SURF SCI, V500, P127, DOI 10.1016/S0039-6028(01)01535-7
   SIMONS BD, 1992, J PHYS II, V2, P1439
   Warriner HE, 1996, SCIENCE, V271, P969, DOI 10.1126/science.271.5251.969
   Warriner HE, 1998, BIOPHYS J, V75, P272, DOI 10.1016/S0006-3495(98)77514-9
   Xia Y, 2002, LANGMUIR, V18, P3822, DOI 10.1021/la0156762
   ZASADZINSKI JAN, 1990, J PHYS-PARIS, V51, P747, DOI 10.1051/jphys:01990005108074700
   ZASADZINSKI JAN, 1989, J ELECTRON MICR TECH, V13, P309, DOI 10.1002/jemt.1060130406
NR 43
TC 23
Z9 23
U1 5
U2 17
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0743-7463
J9 LANGMUIR
JI Langmuir
PD MAR 14
PY 2006
VL 22
IS 6
BP 2465
EP 2473
DI 10.1021/la052447x
PG 9
WC Chemistry, Multidisciplinary; Chemistry, Physical; Materials Science,
   Multidisciplinary
SC Chemistry; Materials Science
GA 021TX
UT WOS:000236009900016
PM 16519442
DA 2018-12-27
ER

PT J
AU Zou, ZH
   Buck, LB
AF Zou, ZH
   Buck, LB
TI RETRACTED: Combinatorial effects of odorant mixes in olfactory cortex
   (Retracted article. See vol. 329, pg. 1598, 2010)
SO SCIENCE
LA English
DT Article; Retracted Publication
ID RECEPTOR GENE-EXPRESSION; IMMEDIATE-EARLY GENE; PIRIFORM CORTEX; SENSORY
   MAP; BULB; MIXTURES; MOUSE; NEURONS; DISCRIMINATION; ORGANIZATION
C1 Fred Hutchinson Canc Res Ctr, Howard Hughes Med Inst, Seattle, WA 98109 USA.
   Fred Hutchinson Canc Res Ctr, Div Basic Sci, Seattle, WA 98109 USA.
RP Buck, LB (reprint author), Fred Hutchinson Canc Res Ctr, Howard Hughes Med Inst, 1100 Fairview Ave N, Seattle, WA 98109 USA.
EM lbuck@fhcrc.org
FU NIDCD NIH HHS [R03 DC008700-01, R21 DC008628-01]
CR BUCK L, 1991, CELL, V65, P175, DOI 10.1016/0092-8674(91)90418-X
   CHESS A, 1994, CELL, V78, P823, DOI 10.1016/S0092-8674(94)90562-2
   Duchamp-Viret P, 2003, EUR J NEUROSCI, V18, P2690, DOI 10.1046/j.1460-9568.2003.03001.x
   Giraudet P, 2002, J NEUROPHYSIOL, V88, P829, DOI 10.1152/jn.00436.2001
   Godfrey PA, 2004, P NATL ACAD SCI USA, V101, P2156, DOI 10.1073/pnas.0308051100
   Guzowski JF, 1999, NAT NEUROSCI, V2, P1120, DOI 10.1038/16046
   Haberly LB, 2001, CHEM SENSES, V26, P551, DOI 10.1093/chemse/26.5.551
   Illig KR, 2003, J COMP NEUROL, V457, P361, DOI 10.1002/cne.10557
   Kajiya K, 2001, J NEUROSCI, V21, P6018
   Kandel E. R., 2000, PRINCIPLES NEURAL SC
   KANG JS, 1995, J NEUROPHYSIOL, V74, P1435
   LAING DG, 1989, PHYSIOL BEHAV, V46, P809, DOI 10.1016/0031-9384(89)90041-3
   Lin DY, 2005, NATURE, V434, P470, DOI 10.1038/nature03414
   LINK W, 1995, P NATL ACAD SCI USA, V92, P5734, DOI 10.1073/pnas.92.12.5734
   LYFORD GL, 1995, NEURON, V14, P433, DOI 10.1016/0896-6273(95)90299-6
   Malnic B, 1999, CELL, V96, P713, DOI 10.1016/S0092-8674(00)80581-4
   MARGOT C, COMMUNICATION
   Mombaerts P, 2004, NAT REV NEUROSCI, V5, P263, DOI 10.1038/nrn1365
   Mombaerts P, 1996, CELL, V87, P675, DOI 10.1016/S0092-8674(00)81387-2
   Neville KR, 2004, SYNAPTIC ORG BRAIN, V5, P415, DOI DOI 10.1093/ACPR0F:0S0/9780195159561.003.0010
   RESSLER KJ, 1994, CELL, V79, P1245, DOI 10.1016/0092-8674(94)90015-9
   RESSLER KJ, 1993, CELL, V73, P597, DOI 10.1016/0092-8674(93)90145-G
   Shepherd GM, 2004, SYNAPTIC ORG BRAIN, P165, DOI DOI 10.1093/ACPR0F:0S0/9780195159561.003.0005
   Tabor R, 2004, J NEUROSCI, V24, P6611, DOI 10.1523/JNEUROSCI.1834-04.2004
   Tagawa Y, 2005, NAT NEUROSCI, V8, P380, DOI 10.1038/nn1410
   VASSAR R, 1994, CELL, V79, P981, DOI 10.1016/0092-8674(94)90029-9
   VASSAR R, 1993, CELL, V74, P309, DOI 10.1016/0092-8674(93)90422-M
   Wilson DA, 2003, J NEUROPHYSIOL, V90, P65, DOI 10.1152/jn.00133.2003
   Wilson DA, 2001, CHEM SENSES, V26, P577, DOI 10.1093/chemse/26.5.577
   Young JM, 2002, HUM MOL GENET, V11, P1153, DOI 10.1093/hmg/11.10.1153
   Zhang XM, 2002, NAT NEUROSCI, V5, P124, DOI 10.1038/nn800
   Zou ZH, 2005, P NATL ACAD SCI USA, V102, P7724, DOI 10.1073/pnas.0503027102
   Zou ZH, 2001, NATURE, V414, P173, DOI 10.1038/35102506
NR 33
TC 111
Z9 113
U1 11
U2 34
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 0036-8075
EI 1095-9203
J9 SCIENCE
JI Science
PD MAR 10
PY 2006
VL 311
IS 5766
BP 1477
EP 1481
DI 10.1126/science.1124755
PG 5
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 022BJ
UT WOS:000236029400054
PM 16527983
DA 2018-12-27
ER

PT J
AU Adcock, IM
   Chung, KF
   Caramori, G
   Ito, K
AF Adcock, IM
   Chung, KF
   Caramori, G
   Ito, K
TI RETRACTED: Kinase inhibitors and airway inflammation (Retracted article.
   See vol. 683, pg. 340, 2012)
SO EUROPEAN JOURNAL OF PHARMACOLOGY
LA English
DT Review; Retracted Publication
DE asthma; COPD; inhibitor MAP kinase; IKK; gene expression
ID ACTIVATED PROTEIN-KINASE; P38 MAP KINASE; NF-KAPPA-B; OBSTRUCTIVE
   PULMONARY-DISEASE; GROWTH-FACTOR RECEPTOR; DEPENDENT GENE-EXPRESSION;
   SMALL-MOLECULE INHIBITORS; THERAPEUTIC TARGET; TERMINAL KINASE; TYROSINE
   KINASE
AB Kinases are believed to play a crucial role in the expression and activation of inflammatory mediators in the airway, in T-cell function and airway remodelling. Important kinases such as Inhibitor of kappa B kinase (IKK)2, initogen activated protein (MAP) kinases and phsopho-inositol (PI) 3 kinase regulate inflammation either through activation of pro-inflammatory transcription factors such as activating protein-1 (AP-1) and nuclear factor kappa B (NF-kappa B), which are activated in airway disease, or through regulation of mRNA half-life. Selective kinase inhibitors have been developed which reduce inflammation and some characteristics of disease in animal models. Targeting specific kinases that are overexpressed or over active in disease should allow for selective treatment of respiratory diseases. Interest in this area has intensified due to the success of the specific Abelson murine leukaemia viral oncogene (Abl) kinase inhibitor imatinib mesylate (Gleevec) in the treatment of chronic myelogenous leukaemia. Encouraging data from animal models and primary cells and early Phase I and II Studies in other diseases suggest that inhibitors of p38 MAP kinase and IKK2 may prove to be useful novel therapies in the treatment of severe asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis and other inflammatory airway diseases. (c) 2006 Elsevier B.V. All rights reserved.
C1 Natl Heart & Lung Inst, Cell & Mol Biol Grp, Airways Dis Sect, Imperial Coll London, London SW3 6LY, England.
RP Adcock, IM (reprint author), Natl Heart & Lung Inst, Cell & Mol Biol Grp, Airways Dis Sect, Imperial Coll London, Dovehouse St, London SW3 6LY, England.
EM ian.adcock@imperial.ac.uk
OI Chung, Kian Fan/0000-0001-7101-1426; Adcock, Ian/0000-0003-2101-8843
FU Wellcome Trust; Medical Research Council [G0400503B]
CR Adachi T, 1999, J IMMUNOL, V163, P939
   Adams JL, 1998, BIOORG MED CHEM LETT, V8, P3111, DOI 10.1016/S0960-894X(98)00549-6
   Adams JL, 2001, PROGR MED CHEM, V38, P1, DOI 10.1016/S0079-6468(08)70091-2
   Adcock IM, 2003, J ENDOCRINOL, V178, P347, DOI 10.1677/joe.0.1780347
   Aiello LP, 2002, SURV OPHTHALMOL, V47, pS263, DOI 10.1016/S0039-6257(02)00391-0
   Amoui M, 1997, EUR J IMMUNOL, V27, P321, DOI 10.1002/eji.1830270146
   Bain J, 2003, BIOCHEM J, V371, P199, DOI 10.1042/BJ20021535
   Barnes PJ, 2000, NEW ENGL J MED, V343, P269, DOI 10.1056/NEJM200007273430407
   Barnes PJ, 2003, ANNU REV MED, V54, P113, DOI 10.1146/annurev.med.54.101601.152209
   Barnes PJ, 1996, EUR RESPIR J, V9, P636, DOI 10.1183/09031936.96.09040636
   Barnes PJ, 1998, PHARMACOL REV, V50, P515
   Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506
   Barnett SF, 2005, CURR TOP MED CHEM, V5, P109, DOI 10.2174/1568026053507714
   Baumruker T, 2005, IMMUNOL LETT, V96, P175, DOI 10.1016/j.implet.2004.09.001
   Beckett PA, 2003, THORAX, V58, P163, DOI 10.1136/thorax.58.2.163
   Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298
   Berlin AA, 2005, AM J RESP CRIT CARE, V171, P35, DOI 10.1164/rccm.200403-385OC
   BIANCHI M, 1995, MOL MED, V1, P254, DOI 10.1007/BF03401550
   Blease K., 2003, Inflammation Research, V52, P153
   Boschetto P, 2003, EUR RESPIR J, V21, P450, DOI 10.1183/09031936.03.00048703
   Bozyczko-Coyne Donna, 2002, Current Drug Targets - CNS and Neurological Disorders, V1, P31, DOI 10.2174/1568007023339472
   Branger J, 2002, J IMMUNOL, V168, P4070, DOI 10.4049/jimmunol.168.8.4070
   BUCHAT AF, 2002, BIOORG MED CHEM LETT, V12, P1687
   Burke JR, 2003, J BIOL CHEM, V278, P1450, DOI 10.1074/jbc.M209677200
   Busse WW, 2001, NEW ENGL J MED, V344, P350, DOI 10.1056/NEJM200102013440507
   Caramori G, 2003, PULM PHARMACOL THER, V16, P247, DOI 10.1016/S1094-5539(03)00070-1
   Cetkovic-Cvrlje M, 2003, CLIN IMMUNOL, V106, P213, DOI 10.1016/S1521-6616(02)00049-9
   CHAZIN VR, 1992, ONCOGENE, V7, P1859
   Cohen P, 2002, NAT REV DRUG DISCOV, V1, P309, DOI 10.1038/nrd773
   Condliffe A M, 2000, Respir Res, V1, P24, DOI 10.1186/rr8
   Corry DB, 2002, NAT REV DRUG DISCOV, V1, P55, DOI 10.1038/nrd702
   Cortes J, 2003, BLOOD, V101, P4714, DOI 10.1182/blood-2003-01-0081
   Costello PS, 1996, ONCOGENE, V13, P2595
   Craxton A, 1998, J IMMUNOL, V161, P3225
   Dancey JE, 2003, LANCET, V362, P62, DOI 10.1016/S0140-6736(03)13810-X
   DEMOLY P, 1995, RESP MED, V89, P329, DOI 10.1016/0954-6111(95)90003-9
   Dempsey EC, 2000, AM J PHYSIOL-LUNG C, V279, pL429
   Di Stefano A, 2002, EUR RESPIR J, V20, P556, DOI 10.1183/09031936.02.00272002
   Dong C, 1998, SCIENCE, V282, P2092, DOI 10.1126/science.282.5396.2092
   Druker BJ, 2001, NEW ENGL J MED, V344, P1038, DOI 10.1056/NEJM200104053441402
   Duan W, 2005, AM J RESP CRIT CARE, V171, P571, DOI 10.1164/rccm.200408
   Escott KJ, 2000, BRIT J PHARMACOL, V131, P173, DOI 10.1038/sj.bjp.0703605
   Evans DJ, 1999, AM J PHYSIOL-LUNG C, V277, pL233, DOI 10.1152/ajplung.1999.277.2.L233
   Eynott PR, 2003, BRIT J PHARMACOL, V140, P1373, DOI 10.1038/sj.bjp.0705569
   Fijen JW, 2002, CRIT CARE MED, V30, P841, DOI 10.1097/00003246-200204000-00021
   Finan PM, 2004, BIOCHEM SOC T, V32, P378, DOI 10.1042/BST0320378
   Fitzgerald CE, 2003, NAT STRUCT BIOL, V10, P764, DOI 10.1038/nsb949
   Fowell DJ, 1999, IMMUNITY, V11, P399, DOI 10.1016/S1074-7613(00)80115-6
   Frelin C, 2003, ONCOGENE, V22, P8187, DOI 10.1038/sj.onc.1206963
   Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1
   Goekjian PG, 2001, EXPERT OPIN INV DRUG, V10, P2117
   Goleva E, 2002, J IMMUNOL, V169, P5934, DOI 10.4049/jimmunol.169.10.5934
   Grimshaw C. E., 2001, Inflammation Research, V50, pS149
   Haddad J J, 2001, Curr Opin Investig Drugs, V2, P1070
   Hamilton LM, 2005, EUR RESPIR J, V25, P978, DOI 10.1183/09031936.05.00098604
   Han ZN, 2001, J CLIN INVEST, V108, P73, DOI 10.1172/JCI200112466
   Hart LA, 1998, AM J RESP CRIT CARE, V158, P1585, DOI 10.1164/ajrccm.158.5.9706116
   Heim MH, 1999, J RECEPT SIGNAL TR R, V19, P75, DOI 10.3109/10799899909036638
   HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135
   Hideshima T, 2002, J BIOL CHEM, V277, P16639, DOI 10.1074/jbc.M200360200
   Hogg JC, 2004, NEW ENGL J MED, V350, P2645, DOI 10.1056/NEJMoa032158
   Hommes D, 2002, GASTROENTEROLOGY, V122, P7, DOI 10.1053/gast.2002.30770
   Huang TJ, 2001, BRIT J PHARMACOL, V134, P1029, DOI 10.1038/sj.bjp.0704344
   INUSEN E, 2002, J ALLERGY CLIN IMMUN, V109, P649
   Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682
   Kankaanranta H, 1999, J PHARMACOL EXP THER, V290, P621
   Kapahi P, 2000, J BIOL CHEM, V275, P36062, DOI 10.1074/jbc.M007204200
   Karin M, 1998, ANN NY ACAD SCI, V851, P139, DOI 10.1111/j.1749-6632.1998.tb08987.x
   Kishore N, 2003, J BIOL CHEM, V278, P32861, DOI 10.1074/jbc.M211439200
   Koehler DR, 2004, AM J RESP CELL MOL, V31, P377, DOI 10.1165/rcmb.2004-0124TR
   Kotlyarov A, 1999, NAT CELL BIOL, V1, P94
   Kujime K, 2000, J IMMUNOL, V164, P3222, DOI 10.4049/jimmunol.164.6.3222
   Kuma Y, 2005, J BIOL CHEM, V280, P19472, DOI 10.1074/jbc.M414221200
   Kumar S, 2003, NAT REV DRUG DISCOV, V2, P717, DOI 10.1038/nrd1177
   Kyriakis JM, 2001, PHYSIOL REV, V81, P807
   Lange P, 1998, NEW ENGL J MED, V339, P1194, DOI 10.1056/NEJM199810223391703
   Leckie MJ, 2000, LANCET, V356, P2144, DOI 10.1016/S0140-6736(00)03496-6
   Lee JC, 2000, IMMUNOPHARMACOLOGY, V47, P185, DOI 10.1016/S0162-3109(00)00206-X
   Lee M, 2001, ESSAYS BIOCHEM, V37, P71, DOI 10.1042/bse0370071
   Leung DYM, 2003, J ALLERGY CLIN IMMUN, V111, P3, DOI 10.1067/mai.2003.97
   Li LB, 2004, J ALLERGY CLIN IMMUN, V114, P1059, DOI 10.1016/j.jaci.2004.08.005
   Li ZW, 2003, J IMMUNOL, V170, P4630, DOI 10.4049/jimmunol.170.9.4630
   Lopez AD, 1998, NAT MED, V4, P1241, DOI 10.1038/3218
   Luedde T, 2005, J CLIN INVEST, V115, P849, DOI 10.1172/JCI200523493
   Lynch OT, 2000, BLOOD, V95, P3541
   Malaviya R, 1999, J BIOL CHEM, V274, P27028, DOI 10.1074/jbc.274.38.27028
   Manning AM, 2003, NAT REV DRUG DISCOV, V2, P554, DOI 10.1037/nrd.1132
   Manning G, 2002, SCIENCE, V298, P1912, DOI 10.1126/science.1075762
   Martin JH, 1996, MOL BRAIN RES, V35, P47, DOI 10.1016/0169-328X(95)00181-Q
   McInnes C, 2005, CURR PHARM DESIGN, V11, P1845, DOI 10.2174/1381612053764850
   Mejias A, 2005, CURR OPIN INFECT DIS, V18, P199, DOI 10.1097/01.qco.0000168378.07110.72
   Meltzer EO, 2005, J ALLERGY CLIN IMMUN, V115, P791, DOI 10.1016/j.jaci.2005.01.040
   Nagar B, 2002, CANCER RES, V62, P4236
   Nath P, 2005, EUR J PHARMACOL, V506, P273, DOI 10.1016/j.ejphar.2004.11.040
   Nikas Spyros N, 2004, Curr Opin Investig Drugs, V5, P1205
   Noble MEM, 2004, SCIENCE, V303, P1800, DOI 10.1126/science.1095920
   Oltmanns U, 2003, BRIT J PHARMACOL, V139, P1228, DOI 10.1038/sj.bjp.0705345
   Orlowski RZ, 2002, TRENDS MOL MED, V8, P385, DOI 10.1016/S1471-4914(02)02375-4
   Page K, 2003, J IMMUNOL, V170, P5681, DOI 10.4049/jimmunol.170.11.5681
   Pargellis C, 2002, NAT STRUCT BIOL, V9, P268, DOI 10.1038/nsb770
   Pernis AB, 2002, J CLIN INVEST, V109, P1279, DOI 10.1172/JCI200215786
   Podolin PL, 2005, J PHARMACOL EXP THER, V312, P373, DOI 10.1124/jpet.104.074484
   Puddicombe SM, 2000, FASEB J, V14, P1362, DOI 10.1096/fj.14.10.1362
   Recchi I, 2003, EUR J CANCER, V39, P1927, DOI 10.1016/S0959-8049(03)00394-0
   Regan J, 2002, J MED CHEM, V45, P2994, DOI 10.1021/jm020057r
   RUSSELL SM, 1994, SCIENCE, V266, P1042, DOI 10.1126/science.7973658
   Saetta M, 2001, AM J RESP CRIT CARE, V163, P1304, DOI 10.1164/ajrccm.163.6.2009116
   Saklatvala J, 2004, CURR OPIN PHARMACOL, V4, P372, DOI 10.1016/j.coph.2004.03.009
   Schafer PH, 1999, J IMMUNOL, V162, P7110
   Schwiebert LM, 1996, AM J RESP CRIT CARE, V154, pS16, DOI 10.1164/ajrccm/154.2_Pt_2.S16
   Sousa AR, 1999, J ALLERGY CLIN IMMUN, V104, P565, DOI 10.1016/S0091-6749(99)70325-8
   Stelmach JE, 2003, BIOORG MED CHEM LETT, V13, P277, DOI 10.1016/S0960-894X(02)00752-7
   Stenton GR, 2002, J IMMUNOL, V169, P1028, DOI 10.4049/jimmunol.169.2.1028
   Takeyama K, 1999, P NATL ACAD SCI USA, V96, P3081, DOI 10.1073/pnas.96.6.3081
   Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513
   Traxler P, 2003, EXPERT OPIN THER TAR, V7, P215, DOI 10.1517/14728222.7.2.215
   Trifilieff A, 2005, BRIT J PHARMACOL, V144, P1002, DOI 10.1038/sj.bjp.0706132
   Tsitoura DC, 2004, J CLIN INVEST, V113, P619, DOI 10.1172/JCI200418975
   Underwood DC, 2000, AM J PHYSIOL-LUNG C, V279, pL895
   Vachier I, 1997, AM J RESP CRIT CARE, V155, P1211, DOI 10.1164/ajrccm.155.4.9105056
   Waetzig GH, 2003, GASTROENTEROLOGY, V125, P633, DOI 10.1016/S0016-5085(03)00979-X
   Wagner PD, 2003, AM J MED, V114, P413, DOI 10.1016/S0002-9343(03)00075-5
   Wakeling AE, 2002, CURR OPIN PHARMACOL, V2, P382, DOI 10.1016/S1471-4892(02)00183-2
   Wong WSF, 2004, BBA-PROTEINS PROTEOM, V1697, P53, DOI 10.1016/j.bbapap.2003.11.013
   Yamamoto N, 2003, J PHARMACOL EXP THER, V306, P1174, DOI 10.1124/jpet.103.052316
   Yousefi S, 1996, J EXP MED, V183, P1407, DOI 10.1084/jem.183.4.1407
   Ziegelbauer K, 2005, BRIT J PHARMACOL, V145, P178, DOI 10.1038/sj.bjp.0706176
NR 127
TC 116
Z9 120
U1 3
U2 14
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0014-2999
EI 1879-0712
J9 EUR J PHARMACOL
JI Eur. J. Pharmacol.
PD MAR 8
PY 2006
VL 533
IS 1-3
BP 118
EP 132
DI 10.1016/j.ejphar.2005.12.054
PG 15
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 025KS
UT WOS:000236265400013
PM 16469308
DA 2018-12-27
ER

PT J
AU Moon, HI
   Kim, EJ
   Lee, J
   Lee, HK
   Chung, JH
AF Moon, HI
   Kim, EJ
   Lee, J
   Lee, HK
   Chung, JH
TI RETRACTED: The effect of sativan from Viola verecunda A. GRAY on the
   expressions of matrix metalloproteinase-1 cause by ultraviolet
   irradiated cultured primary human skin fibroblasts (Retracted Article.
   See vol 117, pg 182, 2008)
SO JOURNAL OF ETHNOPHARMACOLOGY
LA English
DT Article; Retracted Publication
DE Viola; matrix metalloproteinase-1 inhibitor; Viola hondoensis W. BECKER
   et H. BOISS; Viola ibukiana MAKINO; Viola lactiflora NAKAI; Viola
   verecunda A. GRAY
ID TISSUE INHIBITORS; HONDOENSIS; INDUCTION
AB Matrix metalloproteinases (MMPs) are a family of enzymes whose main function is degradation of the extracellular matrix. Matrix metalloproteinase-1 (MMP-1) degrades type I procollagen constituting the major structural component of the basement membrane and extra cellular membrane. The enzymatic activity is found to be elevated in photoaging. With the aim of finding novel MMP-1 inhibitors from natural products, 15 extracts of the Viola taxa, which are used as prescriptions for skin eruption treatment in traditional medicine, were screened for their inhibitory activities towards MMP-1. Among the 15 tested materials, the methanol extracts of Viola hondoensis W. BECKER et H. BOISS, Viola ibukiana MAKINO, Viola lactiflora NAKAI and Viola verecunda A. GRAY were potential inhibitory to MMP-1, and other Viola taxa showed a weak inhibitory effect at a concentration of 100 mu g/ml. We investigated the effect of MMP-1 inhibitory of the solvent fractions of the same plants (Viola hondoensis, Viola ibukiana and Viola verecunda). Therefore, a strong inhibition was found in the ethylacetate fractions of Viola verecunda with inhibitory activity (> 90%) at a concentration of 10 mu g/ml. Here we investigated the effect of sativan isolated from the ethylacetate fractions of Viola verecunda on the expression of MMPs in UV-irradiated human skin fibroblasts in vitro. Sativan markedly reduced UV-induced MMP-1 expression at the protein levels in a dose-dependent manner. Our report is the first description for the ability of sativan to regulate UV-induced MMP-1 expression. (c) 2005 Elsevier Ireland Ltd. All rights reserved.
C1 Seoul Natl Univ, Dept Dermatol, Coll Med, Seoul 110744, South Korea.
   Seoul Natl Univ, Inst Dermatol Sci, Seoul 110744, South Korea.
   Korea Res Inst Biosci & Biotechnol, Taejon 305333, South Korea.
RP Moon, HI (reprint author), Seoul Natl Univ, Dept Dermatol, Coll Med, Seoul 110744, South Korea.
EM himun@snu.ac.kr; jhchung@snu.ac.kr
OI Lee, Joongku/0000-0001-6250-3138
CR Bawadi HA, 2004, J AGR FOOD CHEM, V52, P4730, DOI 10.1021/jf034576u
   BONDE MR, 1973, PHYTOCHEMISTRY, V12, P2957, DOI 10.1016/0031-9422(73)80514-X
   Brenneisen P, 2002, ANN NY ACAD SCI, V973, P31, DOI 10.1111/j.1749-6632.2002.tb04602.x
   Carnat AP, 1998, J NAT PROD, V61, P272, DOI 10.1021/np9701485
   Chung JH, 2003, J AM ACAD DERMATOL, V49, P690, DOI 10.1067/S0190-9622(03)02127-3
   Fisher GJ, 1996, NATURE, V379, P335, DOI 10.1038/379335a0
   Kim JH, 2004, ARCH PHARM RES, V27, P177, DOI 10.1007/BF02980103
   Kim MR, 2004, CHEM PHARM BULL, V52, P1466, DOI 10.1248/cpb.52.1466
   Lee Y. N, 1996, FLORA KOREA
   Lin N, 2001, ARTHRITIS RHEUM-US, V44, P2193, DOI 10.1002/1529-0131(200109)44:9<2193::AID-ART373>3.0.CO;2-5
   Lindholm P, 2002, MOL CANCER THER, V1, P365
   Moon HI, 2005, BIOL PHARM BULL, V28, P1123, DOI 10.1248/bpb.28.1123
   Moon HI, 2005, BIOL PHARM BULL, V28, P925, DOI 10.1248/bpb.28.925
   Moon HI, 2005, J ETHNOPHARMACOL, V98, P185, DOI 10.1016/j.jep.2005.01.027
   Moon HI, 2005, FOOD SCI BIOTECHNOL, V14, P143
   MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4
   Pierce RA, 1996, J CLIN INVEST, V97, P1890, DOI 10.1172/JCI118620
   Rittie L, 2002, AGEING RES REV, V1, P705, DOI 10.1016/S1568-1637(02)00024-7
   Schuele S, 2004, MOVEMENT DISORD, V19, P43, DOI 10.1002/mds.10647
   Sternlicht MD, 2001, ANNU REV CELL DEV BI, V17, P463, DOI 10.1146/annurev.cellbio.17.1.463
   Stetler-Stevenson WG, 2001, SEMIN CANCER BIOL, V11, P143, DOI 10.1006/scbi.2000.0365
   SUBARNAS A, 1991, PHYTOCHEMISTRY, V30, P2777, DOI 10.1016/0031-9422(91)85143-N
   Visse R, 2003, CIRC RES, V92, P827, DOI 10.1161/01.RES.0000070112.80711.3D
NR 23
TC 6
Z9 7
U1 3
U2 14
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0378-8741
J9 J ETHNOPHARMACOL
JI J. Ethnopharmacol.
PD MAR 8
PY 2006
VL 104
IS 1-2
BP 12
EP 17
DI 10.1016/j.jep.2005.08.060
PG 6
WC Plant Sciences; Chemistry, Medicinal; Integrative & Complementary
   Medicine; Pharmacology & Pharmacy
SC Plant Sciences; Pharmacology & Pharmacy; Integrative & Complementary
   Medicine
GA 022WA
UT WOS:000236085600003
PM 16207520
DA 2018-12-27
ER

PT J
AU Ding, KJ
   Zhan, FR
   Cai, DQ
   Yu, ZL
AF Ding, KJ
   Zhan, FR
   Cai, DQ
   Yu, ZL
TI RETRACTED: Velocity of polymer translocation through a pore (Retracted
   article. See vol 387, pg 624, 2009)
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article; Retracted Publication
DE polymer; translocation time; mean velocity; polymer extended model;
   partition function
ID MONTE-CARLO SIMULATIONS; PHASE-TRANSITIONS; POLYNUCLEOTIDE MOLECULES;
   KRAMERS PROBLEM; MEMBRANE; NANOPORE; DYNAMICS; ADSORPTION; KINETICS;
   HOLE
AB We theoretically Study the translocation time and the mean velocity of a long polymer threading a long nanopore oil an external electric field. Theoretical method, which explicitly takes into account the nucleation theory, is presented based on the built polymer expanded model. We overcame the previous theory's defect which did not consider the real length of the pore. The present model implies that the length scale of a pore plays a very important role in the process of polymer translocation. Our calculation results are in agreement with those of previous experiments. (c) 2006 Elsevier Inc. All rights reserved.
C1 Chinese Acad Sci, Key Lab Ion Beam Bioengn, Hefei 230031, Peoples R China.
RP Yu, ZL (reprint author), Chinese Acad Sci, Key Lab Ion Beam Bioengn, Hefei 230031, Peoples R China.
EM ionbeam@163.com
CR Akeson M, 1999, BIOPHYS J, V77, P3227, DOI 10.1016/S0006-3495(99)77153-5
   Aksimentiev A, 2004, BIOPHYS J, V87, P2086, DOI 10.1529/biophysj.104.042960
   ALBERTS B., 1994, MOL BIOL CELL
   Ambjornsson T, 2002, J CHEM PHYS, V117, P4063, DOI 10.1063/1.1486208
   Chen CM, 2005, PHYSICA A, V350, P95, DOI 10.1016/j.physa.2004.11.026
   Chern SS, 2001, J CHEM PHYS, V115, P7772, DOI 10.1063/1.1392367
   Di Marzio EA, 1999, PROG POLYM SCI, V24, P329, DOI 10.1016/S0079-6700(99)00008-8
   Di Marzio EA, 2003, J CHEM PHYS, V119, P6378, DOI 10.1063/1.1603725
   DiMarzio EA, 1997, J CHEM PHYS, V107, P5510, DOI 10.1063/1.474256
   DING KJ, UNPUB CHIN PHYS
   EISENRIEGLER R, 1993, POLYM NEAR SURFACES
   Han J, 1999, PHYS REV LETT, V83, P1688, DOI 10.1103/PhysRevLett.83.1688
   Henrickson SE, 2000, PHYS REV LETT, V85, P3057, DOI 10.1103/PhysRevLett.85.3057
   Howorka S, 2001, P NATL ACAD SCI USA, V98, P12996, DOI 10.1073/pnas.231434698
   ITHACA N, 1986, THEORY POLYM DYNAMIC
   Kasianowicz JJ, 1996, P NATL ACAD SCI USA, V93, P13770, DOI 10.1073/pnas.93.24.13770
   Li YL, 2002, ACTA PHYS SIN-CH ED, V51, P2589
   LIFSHITZ EM, 1989, PHYS KINETICS
   Lodish H, 1995, MOL CELL BIOL
   Lubensky DK, 1999, BIOPHYS J, V77, P1824, DOI 10.1016/S0006-3495(99)77027-X
   Matsuyama A, 2005, J PHYS-CONDENS MAT, V17, pS2847, DOI 10.1088/0953-8984/17/31/010
   Matsuyama A, 2004, J CHEM PHYS, V121, P8098, DOI 10.1063/1.1800933
   Matsuyama A, 2004, J CHEM PHYS, V121, P604, DOI 10.1063/1.1758939
   Meller A, 2000, P NATL ACAD SCI USA, V97, P1079, DOI 10.1073/pnas.97.3.1079
   Meller A, 2001, PHYS REV LETT, V86, P3435, DOI 10.1103/PhysRevLett.86.3435
   Movileanu L, 2001, P NATL ACAD SCI USA, V98, P10137, DOI 10.1073/pnas.181089798
   Muthukumar M, 1999, J CHEM PHYS, V111, P10371, DOI 10.1063/1.480386
   Muthukumar M, 2003, J CHEM PHYS, V118, P5174, DOI 10.1063/1.1553753
   Muthukumar M, 2001, PHYS REV LETT, V86, P3188, DOI 10.1103/PhysRevLett.86.3188
   Park PJ, 1998, J CHEM PHYS, V108, P3013, DOI 10.1063/1.475688
   Park PJ, 1998, PHYS REV E, V57, P730, DOI 10.1103/PhysRevE.57.730
   Park PJ, 1998, INT J BIFURCAT CHAOS, V8, P927, DOI 10.1142/S0218127498000735
   Park PP, 1999, J CHEM PHYS, V111, P5259, DOI 10.1063/1.479779
   PESKIN CS, 1993, BIOPHYS J, V65, P316, DOI 10.1016/S0006-3495(93)81035-X
   Sebastian KL, 2000, PHYS REV E, V62, P927, DOI 10.1103/PhysRevE.62.927
   SIMON SM, 1992, P NATL ACAD SCI USA, V89, P3770, DOI 10.1073/pnas.89.9.3770
   Sung W, 1996, PHYS REV LETT, V77, P783, DOI 10.1103/PhysRevLett.77.783
   Tian P, 2003, J CHEM PHYS, V119, P11475, DOI 10.1063/1.1621614
   Xie YJ, 2004, ACTA PHYS SIN-CH ED, V53, P2796
   Zhang XR, 2003, ACTA PHYS SIN-CH ED, V52, P163
NR 40
TC 5
Z9 5
U1 3
U2 12
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
EI 1090-2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD MAR 3
PY 2006
VL 341
IS 1
BP 139
EP 142
DI 10.1016/j.bbrc.2005.12.154
PG 4
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA 012BO
UT WOS:000235313400022
DA 2018-12-27
ER

PT J
AU Zhou, LB
   Zou, H
   Gao, YQ
AF Zhou, LB
   Zou, H
   Gao, YQ
TI RETRACTED: Middle-high latitude N2O distributions related to the arctic
   vortex breakup (Retracted article. See vol 23, pg 542, 2006)
SO ADVANCES IN ATMOSPHERIC SCIENCES
LA English
DT Article; Retracted Publication
DE N2O distribution; chemical transport model; vortex breakup time
ID STRATOSPHERIC POLAR VORTICES; POTENTIAL VORTICITY; TRACE CONSTITUENTS;
   MODEL; TRANSPORT; CIRCULATION; AIR; CO2
AB The relationship of N2O distributions with the Arctic vortex breakup is first analyzed with a probability distribution function (PDF) analysis. The N2O concentration shows different distributions between the early and late vortex breakup years. In the early breakup years, the N2O concentration shows low values and large dispersions after the vortex breakup, which is related to the inhomogeneity in the vertical advection in the middle and high latitude lower stratosphere. The horizontal diffusion coefficient (K,,) shows a larger value accordingly. In the late breakup years, the N2O concentration shows high values and more uniform distributions than in the early years after the vortex breakup, with a smaller vertical advection and K,, after the vortex breakup. It is found that the N2O distributions are largely affected by the Arctic vortex breakup time but the dynamically defined vortex breakup time is not the only factor.
C1 Chinese Acad Sci, State Key Lab Atmospher Boundary Layer Phys & Atm, Inst Atmospher Phys, Beijing 100029, Peoples R China.
   Chinese Acad Sci, Nansen Zhu Int Res Ctr, Inst Atmospher Phys, Beijing 100029, Peoples R China.
RP Zhou, LB (reprint author), Chinese Acad Sci, State Key Lab Atmospher Boundary Layer Phys & Atm, Inst Atmospher Phys, Beijing 100029, Peoples R China.
EM zhoulibo@mail.iap.ac.cn
RI AAS, AAS/C-2949-2014; Wang, ZF/D-7202-2012
OI Wang, ZF/0000-0002-7062-6012
CR AKIYOSHI H, 1992, J GEOPHYS RES-ATMOS, V97, P20837, DOI 10.1029/92JD02040
   Akiyoshi H, 2002, J METEOROL SOC JPN, V80, P1308
   Akiyoshi H, 2002, J METEOROL SOC JPN, V80, P451, DOI 10.2151/jmsj.80.451
   Akiyoshi H, 2000, J METEOROL SOC JPN, V78, P563, DOI 10.2151/jmsj1965.78.5_563
   Brasseur G. P., 1986, AERONOMY MIDDLE ATMO
   Fleming EL, 1999, J GEOPHYS RES-ATMOS, V104, P23911, DOI 10.1029/1999JD900332
   Fleming EL, 2001, J GEOPHYS RES-ATMOS, V106, P14245, DOI 10.1029/2000JD900732
   HARTMANN DL, 1978, J ATMOS SCI, V35, P1125, DOI 10.1175/1520-0469(1978)035<1125:ANCTEO>2.0.CO;2
   Herman RL, 1998, GEOPHYS RES LETT, V25, P2781, DOI 10.1029/98GL02109
   HESS PG, 1991, J ATMOS SCI, V48, P1625, DOI 10.1175/1520-0469(1991)048<1625:MPFTFS>2.0.CO;2
   HOLTON JR, 1986, J ATMOS SCI, V43, P1238, DOI 10.1175/1520-0469(1986)043<1238:MDOSTC>2.0.CO;2
   MAHLMAN JD, 1986, J GEOPHYS RES-ATMOS, V91, P2687, DOI 10.1029/JD091iD02p02687
   Nakamura N, 1997, J GEOPHYS RES-ATMOS, V102, P25721, DOI 10.1029/97JD02153
   Nash ER, 1996, J GEOPHYS RES-ATMOS, V101, P9471, DOI 10.1029/96JD00066
   NEWMAN PA, 1988, J GEOPHYS RES-ATMOS, V93, P5221, DOI 10.1029/JD093iD05p05221
   Orsolini YJ, 2001, GEOPHYS RES LETT, V28, P3855, DOI 10.1029/2001GL013103
   Sparling LC, 2000, REV GEOPHYS, V38, P417, DOI 10.1029/1999RG000070
   Strunk M, 2000, GEOPHYS RES LETT, V27, P341, DOI 10.1029/1999GL011044
   Waugh DW, 2002, J METEOROL SOC JPN, V80, P997, DOI 10.2151/jmsj.80.997
   Waugh DW, 1997, J GEOPHYS RES-ATMOS, V102, P13119, DOI 10.1029/96JD03715
   Waugh DW, 1999, J GEOPHYS RES-ATMOS, V104, P27191, DOI 10.1029/1999JD900795
   *WMO, 2003, 47 GLOB OZ RES MON P
   YANG H, 1990, J ATMOS SCI, V47, P215, DOI 10.1175/1520-0469(1990)047<0215:NTOZAC>2.0.CO;2
   YANG HJ, 1995, J ATMOS SCI, V52, P1513, DOI 10.1175/1520-0469(1995)052<1513:TDTOTE>2.0.CO;2
   Zhou ST, 2000, GEOPHYS RES LETT, V27, P1123, DOI 10.1029/1999GL011018
NR 25
TC 1
Z9 1
U1 5
U2 12
PU SCIENCE PRESS
PI BEIJING
PA 16 DONGHUANGCHENGGEN NORTH ST, BEIJING 100717, PEOPLES R CHINA
SN 0256-1530
J9 ADV ATMOS SCI
JI Adv. Atmos. Sci.
PD MAR
PY 2006
VL 23
IS 2
BP 215
EP 223
DI 10.1007/s00376-006-0215-y
PG 9
WC Meteorology & Atmospheric Sciences
SC Meteorology & Atmospheric Sciences
GA 023JX
UT WOS:000236124100006
DA 2018-12-27
ER

PT J
AU Zhao, F
   Wang, ZY
   Yang, JJ
   Sun, J
   Wang, QP
   Xu, JG
AF Zhao, F
   Wang, ZY
   Yang, JJ
   Sun, J
   Wang, QP
   Xu, JG
TI RETRACTED: Low-dosage adrenaline induces transient marked decrease of
   blood pressure during functional endoscopic sinus surgery (Retracted
   article. See vol 20, p 673, 2006)
SO AMERICAN JOURNAL OF RHINOLOGY
LA English
DT Article; Retracted Publication
ID HYPOTENSION
AB Background: Low-dosage adrenaline contained in local anesthetics is commonly used for hemostasis during functional endoscopic sinus surgery (FESS), but often causes significant hemodynamic side effects that might be neglected. A randomized, controlled, prospective clinical trial was designed to find out these effects after local infiltration of different concentrations and/or different dosages of adrenaline during FESS tinder general anesthesia.
   Methods: One hundred eight adult patients were randomized into one of four groups to receive 2 mL of 2% lidocaine and adrenaline 1:200,000 (group I), 4 mL of 1% lidocaine and adrenaline 1:400,000 (group II), 4 mL of 1% lidocaine and adrenaline 1:200,000 (group III), or 4 mL of 1% lidocaine (group IV) for local infiltration, respectively, Heart rate, systolic blood pressure (BP), diastolic BP, and mean arterial pressure were monitored continuously in radial artery.
   Results: Significant hemodynamic changes, particularly decrease of BP (p < 0.001) with slightly increased heart rate (p < 0.001) similar to 1.5 minutes after local infiltration, were observed in group I, group II, and group III compared with the baseline, but not in group IV. However, no significant hemodynamic changes were observed between group I, group II, and group III at the same time points (p > 0.05).
   Conclusions: Local infiltration of low-dosage adrenaline causes temporary significant hemodynamic changes, particularly marked decrease of BP during FESS, and there were no significant hemodynamic changes between adrenaline 1:200,000 and 1:400,000.
C1 Nanjing Univ, Jinling Hosp, Sch Med, Dept Anesthesiol, Nanjing 210002, Peoples R China.
   Nanjing Univ, Jinling Hosp, Sch Med, Dept Otolaryngol, Nanjing 210002, Peoples R China.
   Nanjing Med Univ, Affiliated Hosp 1, Dept Anesthesiol, Nanjing, Peoples R China.
RP Xu, JG (reprint author), Nanjing Univ, Jinling Hosp, Sch Med, Dept Anesthesiol, 305 E Zhongshan Rd, Nanjing 210002, Peoples R China.
EM zhaofeng.nju@163.com
CR Anderhuber W, 1999, LARYNGOSCOPE, V109, P204, DOI 10.1097/00005537-199902000-00006
   Enlund M, 2001, ACTA ANAESTH SCAND, V45, P294, DOI 10.1034/j.1399-6576.2001.045003294.x
   JOHN G, 1995, CLIN OTOLARYNGOL, V20, P213, DOI 10.1111/j.1365-2273.1995.tb01850.x
   Middlehurst R J, 1999, Anesth Prog, V46, P118
   Moss J, 2000, ANESTHESIA, P523
   PHILLIPS S, 1993, BRIT J ANAESTH, V70, P687, DOI 10.1093/bja/70.6.687
   Sia S, 2003, ANESTH ANALG, V97, P583, DOI 10.1213/01.ANE.0000070232.06352.48
   Sorensen WT, 2003, AURIS NASUS LARYNX, V30, P159, DOI 10.1016/S0385-8146(03)00047-6
   STAMMBERGER H, 1990, EUR ARCH OTO-RHINO-L, V247, P63
NR 9
TC 8
Z9 8
U1 4
U2 15
PU OCEAN SIDE PUBLICATIONS INC
PI PROVIDENCE
PA 95 PITMAN ST, PROVIDENCE, RI 02906 USA
SN 1050-6586
J9 AM J RHINOL
JI Am. J. Rhinol.
PD MAR-APR
PY 2006
VL 20
IS 2
BP 182
EP 185
DI 10.1177/194589240602000213
PG 4
WC Otorhinolaryngology
SC Otorhinolaryngology
GA 035LY
UT WOS:000237003900013
PM 16686385
DA 2018-12-27
ER

PT J
AU Triem, JG
   Rohm, KD
   Boldt, J
   Piper, SN
AF Triem, JG
   Rohm, KD
   Boldt, J
   Piper, SN
TI RETRACTED: Comparison of a propofol-based anesthesia regimen using
   optimated-target-controlled-infusion (OTCI) and manually-controlled
   infusion (MCI) technique (Retracted article. See vol. 46, pg. 491, 2011)
SO ANASTHESIOLOGIE INTENSIVMEDIZIN NOTFALLMEDIZIN SCHMERZTHERAPIE
LA German
DT Article; Retracted Publication
DE target controlled infusion; TCI; optimated target controlled infusion;
   manual controlled infusion; propofol; effect target; plasma target;
   costs
ID BISPECTRAL INDEX; TCI
AB Background: Propofol anesthesia based on target-controlled-in fusion (TCI) has been shown to be superior to a manually-controlled-infusion (MCI) technique. A new optimated-target-controlled-infusion (OTCI) technique enables an individual plasma-targeted adjustment by including the concentration in the effect-compartment. This study compared practicability and costs of the new system with a conventional MCI-based propofol anesthesia regimen. Methods: In a prospective study, 50 patients scheduled for elective surgery of nose or nasal sinuses were randomly enrolled to receive BIS-controlled anaesthesia (level: 40-55) using either OTCI (n = 25) or MCI (n = 25). Hemodynamics, extubation times and time of awaking, rate and quality of propofol adjustment, total drug requirements, costs, postanaesthetic care unit (PACU) stay, Aldrete and pain scores, and adverse effects (postoperative nausea and vomiting (PONV), shivering) were recorded. Results: Demographics, hemodynamics, and perioperative data including extubation times were comparable for both study groups. Propofol consumption was similar within the first 60min for both groups, therafter, significantly less propofol in the OTCI group (5,03 mg/kg/h) than the MCI group (5,79 mg/kg/h) was used. Costs for propofol was significantly reduced with OTCI (0.2 vs. 0.23 Cent/anaesthesia minute/kg), the administration of other anaesthetics (fentanyl, remifentanil, cis-atracurium) did not differ between the groups. The number of infusion adjustments to BIS values were not significantly different. Conclusion: The new OTCI-system is a safe and easily controllable technique. The obvious advantage of this infusion system appears to be a reduction in propofol consumption and direct drug costs for anaesthesia lasting longer than 60 min.
C1 Klinikum Stadt Ludwigshafen, Klin Anasthesiol & Operat Intensivmed, D-67063 Ludwigshafen, Germany.
RP Triem, JG (reprint author), Klinikum Stadt Ludwigshafen, Klin Anasthesiol & Operat Intensivmed, Bremserstr 79, D-67063 Ludwigshafen, Germany.
EM triemj@klilu.de
CR ALDRETE JA, 1970, ANESTH ANAL CURR RES, V49, P924
   Bonhomme V, 2000, ANESTH ANALG, V91, P1398, DOI 10.1097/00000539-200012000-00018
   Breslin DS, 2004, ANAESTHESIA, V59, P1059, DOI 10.1111/j.1365-2044.2004.03870.x
   BRUHN J, 2005, ANAESTHESIST
   CAMPBELL MJ, 1995, BRIT MED J, V311, P1145, DOI 10.1136/bmj.311.7013.1145
   CHAUDHRI S, 1992, ANAESTHESIA, V47, P551, DOI 10.1111/j.1365-2044.1992.tb02321.x
   Ekman A, 2004, ACTA ANAESTH SCAND, V48, P20, DOI 10.1111/j.1399-6576.2004.00260.x
   FECHNER J, 2001, ANASTHESIOLOGIE, P619
   Frolich MA, 2005, BRIT J ANAESTH, V94, P434, DOI 10.1093/bja/aei081
   Gale T, 2001, ANAESTH INTENS CARE, V29, P579
   Heidegger T, 2004, ANAESTHESIST, V53, P95, DOI 10.1007/s00101-003-0628-2
   Hunt-Smith J, 1999, ANAESTH INTENS CARE, V27, P260
   Irwin MG, 2002, ANAESTHESIA, V57, P242, DOI 10.1046/j.0003-2409.2001.02446.x
   Lehmann A, 2002, ANESTH ANALG, V95, P639, DOI 10.1213/01.ANE.0000024203.86693.2E
   Lehmann A, 2001, J CARDIOTHOR VASC AN, V15, P445, DOI 10.1053/jcan.2001.24979
   MARSH B, 1991, BRIT J ANAESTH, V67, P41, DOI 10.1093/bja/67.1.41
   Morley A, 2000, ANAESTHESIA, V55, P953, DOI 10.1046/j.1365-2044.2000.01527.x
   Passot S, 2002, ANESTH ANALG, V94, P1212, DOI 10.1097/00000539-200205000-00030
   RAATZ U, 1966, BIOMETR Z, V8, P42, DOI 10.1002/bimj.19660080107
   RENZ D, 2002, MEC KONZEPT OPTIMIER
   RENZ D, 2000, OPTIMIERTES DOSIERUN
   Schraag S, 2000, ANASTH INTENSIV NOTF, V35, P12, DOI 10.1055/s-2000-10845
   Struys M, 1998, ANAESTHESIA, V53, P4, DOI 10.1046/j.1365-2044.1998.00279.x
   VERNON JM, 1995, ANESTH ANALG, V80, P780, DOI 10.1097/00000539-199504000-00023
   Weninger B, 2004, ANASTH INTENSIV NOTF, V39, P212, DOI 10.1055/s-2004-814363
   Wilhelm W, 2003, ANAESTHESIST, V52, P473, DOI 10.1007/s00101-003-0540-9
NR 26
TC 7
Z9 9
U1 3
U2 17
PU GEORG THIEME VERLAG KG
PI STUTTGART
PA RUDIGERSTR 14, D-70469 STUTTGART, GERMANY
SN 0939-2661
EI 1439-1074
J9 ANASTH INTENSIV NOTF
JI Anasthesiol. Intensivmed. NotfMed. Schmerzther.
PD MAR
PY 2006
VL 41
IS 3
BP 150
EP 155
DI 10.1055/s-2005-921199
PG 6
WC Anesthesiology; Critical Care Medicine
SC Anesthesiology; General & Internal Medicine
GA 037RA
UT WOS:000237163400004
PM 16557440
DA 2018-12-27
ER

PT J
AU Guo, HT
   Gao, CJ
   Mi, ZY
   Wai, PY
   Kuo, PC
AF Guo, HT
   Gao, CJ
   Mi, ZY
   Wai, PY
   Kuo, PC
TI RETRACTED: Phosphorylation of Ser(158) regulates inflammatory
   redox-dependent hepatocyte nuclear factor-4 alpha transcriptional
   activity (Retracted article. See vol. 461, pg. 347, 2014)
SO BIOCHEMICAL JOURNAL
LA English
DT Article; Retracted Publication
DE hepatocyte nuclear factor-4 alpha; inducible nitric oxide synthase
   (iNOS); inflammatory redox; oxidative stress; phosphorylation; p38
   mitogen-activated protein kinase (MAPK)
ID NITRIC-OXIDE SYNTHASE; ISCHEMIA-REPERFUSION INJURY; SIGNAL-TRANSDUCTION;
   DNA-BINDING; SERINE/THREONINE PHOSPHORYLATION; GENE; LIVER; ENDOTOXEMIA;
   EXPRESSION; INOS
AB In IL-1 beta (interleukin 1 beta)-stimulated rat hepatocytes exposed to superoxide, we have previously identified an IRX (inflammatory redox)-sensitive DR1 [direct repeat of RG(G/T)TCA with one base spacing] cis-acting activator element (nt -1327 to -1315) in the iNOS (inducible nitric oxide synthase) promoter: AGGTCAGGGGACA. The corresponding transcription factor was identified to be HNF4 alpha (hepatocyte nuclear factor-4 alpha). HNF4 alpha DNA binding activity and transactivation potential are tightly regulated by its state of phosphorylation. However, the functional consequences of IRX-mediated post-translational phosphorylation of HNF4 alpha have not been well characterized. In the setting of IL-1 beta + H2O2, HNF4 alpha functional activity is associated with a unique serine/threonine phosphorylation pattern. This indicates that an IRX-sensitive serine/threonine kinase pathway targets HNF4 alpha to augment hepatocyte iNOS transcription. In the present study, following identification of phosphorylated residues in HNF4 alpha, serial mutations were performed to render the target residues phosphorylation-resistant. Electrophoretic mobility-shift assays and transient transfection studies utilizing the iNOS promoter showed that the S158A mutation ablates IRX-mediated HNF4 alpha DNA binding and transactivation. Gain-of-function mutation with the S158D phosphomimetic HNF4a vector supports a critical role for Ser(158) phosphorylation. In vitro phosphorylation and kinase inhibitor studies implicate p38 kinase activity. Our results indicate that p38 kinase-mediated Ser(158) phosphorylation is essential for augmentation of the DNA binding and transactivation potential of HNF4 alpha in the presence of IL-1 beta + H2O2. This pathway results in enhanced iNOS expression in hepatocytes exposed to pro-inflammatory cytokines and oxidative stress.
C1 Duke Univ, Med Ctr, Dept Surg, Durham, NC 27710 USA.
RP Kuo, PC (reprint author), Duke Univ, Med Ctr, Dept Surg, 110 Bell Bldg,Box 3522, Durham, NC 27710 USA.
EM kuo00004@mc.duke.edu
FU NIGMS NIH HHS [T32 GM069331, GM665113, GM069331]; NIAID NIH HHS [R29
   AI044629, AI44629, R01 AI044629]
CR Aggelidou E, 2004, J BIOL CHEM, V279, P30680, DOI 10.1074/jbc.M401120200
   Allen RG, 2000, FREE RADICAL BIO MED, V28, P463, DOI 10.1016/S0891-5849(99)00242-7
   Berk BC, 1999, THROMB HAEMOSTASIS, V82, P810
   Bohlinger I, 1995, HEPATOLOGY, V22, P1829, DOI 10.1002/hep.1840220632
   BURKE P, 1997, SHOCK S, V7, P17
   CHEN WS, 1994, GENE DEV, V8, P2466, DOI 10.1101/gad.8.20.2466
   Chittum HS, 1998, BIOCHEMISTRY-US, V37, P10866, DOI 10.1021/bi981042r
   CHODOSH LA, 1995, CURRENT PROTOCOLS MO
   ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2
   Gabbita SP, 2000, ARCH BIOCHEM BIOPHYS, V376, P1, DOI 10.1006/abbi.1999.1685
   Green VJ, 1998, J BIOL CHEM, V273, P29950, DOI 10.1074/jbc.273.45.29950
   Guo HT, 2003, AM J PHYSIOL-CELL PH, V284, pC1090, DOI 10.1152/ajpcell.00394.2002
   Guo HT, 2002, J BIOL CHEM, V277, P5054, DOI 10.1074/jbc.M109017200
   HARBRECHT BG, 1992, J LEUKOCYTE BIOL, V52, P390
   HARBRECHT BG, 1992, CRIT CARE MED, V20, P1568, DOI 10.1097/00003246-199211000-00015
   Hayhurst GP, 2001, MOL CELL BIOL, V21, P1393, DOI 10.1128/MCB.21.4.1393-1403.2001
   Hong YH, 2003, J BIOL CHEM, V278, P27495, DOI 10.1074/jbc.M304112200
   Iordanidou P, 2005, J BIOL CHEM, V280, P21810, DOI 10.1074/jbc.M501221200
   Jahan A, 2005, AM J PHYSIOL-GASTR L, V288, pG685, DOI 10.1152/ajpgi.00207.2004
   Jiang GQ, 1997, ARCH BIOCHEM BIOPHYS, V340, P1, DOI 10.1006/abbi.1997.9914
   Kobayashi H, 1995, J SURG RES, V59, P772, DOI 10.1006/jsre.1995.1238
   KTISTAKI E, 1995, P NATL ACAD SCI USA, V92, P9876, DOI 10.1073/pnas.92.21.9876
   KUO PC, 1995, GASTROENTEROLOGY, V109, P206, DOI 10.1016/0016-5085(95)90286-4
   Kuo PC, 2000, GASTROENTEROLOGY, V118, P608, DOI 10.1016/S0016-5085(00)70268-X
   Lee VG, 2001, SHOCK, V16, P355, DOI 10.1097/00024382-200116050-00006
   Li XM, 2002, BIOCHEM J, V368, P203, DOI 10.1042/BJ20020233
   MACMICKING JD, 1995, CELL, V81, P641, DOI 10.1016/0092-8674(95)90085-3
   Marroquin CE, 2005, SURGERY, V138, P93, DOI 10.1016/j.surg.2005.03.014
   Mi ZY, 2004, J BIOL CHEM, V279, P46659, DOI 10.1074/jbc.M407952200
   NISHIDA J, 1994, AM J PHYSIOL-GASTR L, V267, pG1135
   Owuor ED, 2002, BIOCHEM PHARMACOL, V64, P765, DOI 10.1016/S0006-2952(02)01137-1
   Sladek R, 2000, ADV PHARMACOL, V47, P23
   Viollet B, 1997, MOL CELL BIOL, V17, P4208, DOI 10.1128/MCB.17.8.4208
   WANG GS, 1995, BIOCHEM PHARMACOL, V49, P1277, DOI 10.1016/0006-2952(95)00061-4
   Wisely GB, 2002, STRUCTURE, V10, P1225, DOI 10.1016/S0969-2126(02)00829-8
   Zarubin T, 2005, CELL RES, V15, P11, DOI 10.1038/sj.cr.7290257
NR 36
TC 26
Z9 26
U1 3
U2 11
PU PORTLAND PRESS LTD
PI LONDON
PA CHARLES DARWIN HOUSE, 12 ROGER STREET, LONDON WC1N 2JU, ENGLAND
SN 0264-6021
EI 1470-8728
J9 BIOCHEM J
JI Biochem. J.
PD MAR 1
PY 2006
VL 394
BP 379
EP 387
DI 10.1042/BJ20051730
PN 2
PG 9
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 017WJ
UT WOS:000235723700002
PM 16351573
OA Green Published
DA 2018-12-27
ER

PT J
AU Nakajima, A
   Ueda, K
   Takaoka, M
   Kurata, H
   Takayama, J
   Ohkita, M
   Matsumura, Y
AF Nakajima, A
   Ueda, K
   Takaoka, M
   Kurata, H
   Takayama, J
   Ohkita, M
   Matsumura, Y
TI RETRACTED: Effects of pre- and post-ischemic treatments with FK409, a
   nitric oxide donor, on ischemia/reperfusion-induced renal injury and
   endothelin-1 production in rats (Retracted article. See vol. 37, pg.
   1080, 2014)
SO BIOLOGICAL & PHARMACEUTICAL BULLETIN
LA English
DT Article; Retracted Publication
DE acute renal failure; ischemia; reperfusion; endothelin-1; nitric oxide
ID PEROXYNITRITE; HYPERTENSION; ISCHEMIA; RECEPTOR; FAILURE
AB We have demonstrated that ischemic acute renal failure (ARF) is attenuated by pre-ischemic treatment with a spontaneous nitric oxide (NO) donor, (+/-)-(E)-4-ethyl-2-[(E)-hydroxyimino]-5-nitro-3-hexenamide (FK409). In the present study, we evaluated the effect of post-ischemic treatment with FK409 on ARF, compared with the pre-ischemic treatment effect. Ischemic ARF was induced by occlusion of the left renal artery and vein for 45 min followed by reperfusion, 2 weeks after contralateral nephrectomy. At 24 h after reperfusion, renal function in untreated ARF rats markedly decreased. In addition, increases in renal contents of endothelin-1 (ET-1), a deleterious mediator in the pathogenesis of ischemic ARF, were evident in untreated ARF rats at 24 h after reperfusion. Pre-ischemic treatment with FK409 (1 or 3 mg/kg, i.v.) at 5 min before ischemia attenuated ischemia/reperfusion-induced renal dysfunction and increased ET-1 contents after reperfusion. In contrast, post-ischemic treatment with FK409 (3 or 10 mg/kg, i.v.) at 6 h after reperfusion aggravated the renal injury, but did not affect the increased ET-1 content after reperfusion. These results suggest that pre-ischemic treatment with FK409 exerts renoprotective effects on ischemic ARF, probably through the suppression of renal ET-1 overproduction, whereas post-ischemic treatment with the NO donor worsens the ischemia/reperfusion-induced renal injury, through mechanisms unrelated to the ET-1 production after reperfusion.
C1 Osaka Univ Pharmaceut Sci, Dept Pharmacol, Takatsuki, Osaka 5691094, Japan.
RP Matsumura, Y (reprint author), Osaka Univ Pharmaceut Sci, Dept Pharmacol, 4-20-1 Nasahara, Takatsuki, Osaka 5691094, Japan.
EM matumrh@gly.oups.ac.jp
CR Beckman JS, 1996, CHEM RES TOXICOL, V9, P836, DOI 10.1021/tx9501445
   BOULANGER C, 1990, J CLIN INVEST, V85, P587, DOI 10.1172/JCI114477
   CHINTALA MS, 1993, N-S ARCH PHARMACOL, V348, P305
   FIRTH JD, 1992, J CLIN INVEST, V90, P1023, DOI 10.1172/JCI115915
   FUJITA K, 1995, BRIT J PHARMACOL, V114, P925, DOI 10.1111/j.1476-5381.1995.tb13292.x
   Kato M, 1996, BIOORG MED CHEM LETT, V6, P33, DOI 10.1016/0960-894X(95)00547-7
   Kuro T, 2000, JPN J PHARMACOL, V82, P307, DOI 10.1254/jjp.82.307
   Matsumura H, 1998, J PHARMACOL EXP THER, V287, P1084
   Mitsutomi N, 1999, EUR J PHARMACOL, V364, P65, DOI 10.1016/S0014-2999(98)00806-1
   Radi R, 2001, FREE RADICAL BIO MED, V30, P463, DOI 10.1016/S0891-5849(00)00373-7
   SCHIFFRIN EL, 1995, HYPERTENSION, V25, P1135, DOI 10.1161/01.HYP.25.6.1135
   Takaoka M., 2003, RECENT RES DEV LIFE, V1, P203
   Wilhelm SM, 1999, KIDNEY INT, V55, P1011, DOI 10.1046/j.1523-1755.1999.0550031011.x
   YU L, 1994, P NATL ACAD SCI USA, V91, P1691, DOI 10.1073/pnas.91.5.1691
NR 14
TC 10
Z9 14
U1 3
U2 12
PU PHARMACEUTICAL SOC JAPAN
PI TOKYO
PA 2-12-15 SHIBUYA, SHIBUYA-KU, TOKYO, 150-0002, JAPAN
SN 0918-6158
J9 BIOL PHARM BULL
JI Biol. Pharm. Bull.
PD MAR
PY 2006
VL 29
IS 3
BP 577
EP 579
DI 10.1248/bpb.29.577
PG 3
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 024WH
UT WOS:000236226600038
PM 16508172
OA Bronze
DA 2018-12-27
ER

PT J
AU Wang, ZW
   Banerjee, S
   Li, YW
   Rahman, KMW
   Zhang, YX
   Sarkar, FH
AF Wang, ZW
   Banerjee, S
   Li, YW
   Rahman, KMW
   Zhang, YX
   Sarkar, FH
TI RETRACTED: Down-regulation of Notch-1 inhibits invasion by inactivation
   of nuclear Factor-kappa B, vascular endothelial growth factor, and
   matrix metalloproteinase-9 in pancreatic cancer cells. (Retracted
   article. See vol. 78, pg. 5476, 2018)
SO CANCER RESEARCH
LA English
DT Article; Retracted Publication
ID METASTATIC GENE-EXPRESSION; ALPHA KINASE ACTIVATION; CARCINOMA;
   APOPTOSIS; DIFFERENTIATION; PROLIFERATION; SUPPRESSION; PATHWAYS;
   LEUKEMIA; TARGET
AB Notch signaling plays a critical role in the pathogenesis and progression of human malignancies but the precise role and mechanism of Notch-1 for tumor invasion remains unclear. In our earlier report, we showed that down-regulation of Notch-1 reduced nuclear factor-kappa B (NF-kappa B) DNA-binding activity and matrix metalloproteinase-9 (MMP-9) expression. Because NF-kappa B, VEGF, and MMPs are critically involved in the processes of tumor cell invasion and metastasis, we investigated the role and mechanism(s) by which Notch-1 down-regulation (using molecular approaches) may lead to the down-regulation of NF-kappa B, vascular endothelial growth factor (VEGF), and MMP-9, thereby inhibiting invasion of pancreatic cancer cells through Matrigel. We found that the down-regulation of Notch-1 by small interfering RNA decreased cell invasion, whereas Notch-1 overexpression by cDNA transfection led to increased tumor cell invasion. Consistent with these results, we found that the down-regulation of Notch-1 reduced NF-kappa B DNA-binding activity and VEGF expression. Down-regulation of Notch-1 also decreased not only MMP-9 mRNA and its protein expression but also inactivated the pro-MMP-9 protein to its active form. Taken together, we conclude that the down-regulation of Notch-1 could be an effective approach for the down-regulation and inactivation of NF-kappa B and its target genes, such as MMP-9 and VEGF expression, resulting in the inhibition of invasion and metastasis.
C1 Wayne State Univ, Sch Med, Dept Pathol, Karmanos Canc Inst, Detroit, MI 48201 USA.
   Capital Univ Med Sci, Dept Biochem & Mol Biol, Beijing, Peoples R China.
RP Sarkar, FH (reprint author), Wayne State Univ, Sch Med, Dept Pathol, Karmanos Canc Inst, 9374 Scott Hall,540 E Canfield, Detroit, MI 48201 USA.
EM fsarkar@med.wayne.edu
RI Wang, Zhiwei/A-6809-2011
FU NCI NIH HHS [5R01CA101870-02, 1P20-CA10193-01]
CR Aster JC, 2000, MOL CELL BIOL, V20, P7505, DOI 10.1128/MCB.20.20.7505-7515.2000
   Bresnick EH, 2000, J CELL BIOCHEM, P46
   Chen LF, 2001, SCIENCE, V293, P1653, DOI 10.1126/science.1062374
   Curran S, 2000, EUR J CANCER, V36, P1621, DOI 10.1016/S0959-8049(00)00156-8
   Dong Z, 2005, AM J PATHOL, V166, P1173, DOI 10.1016/S0002-9440(10)62337-1
   El-Rayes BF, 2004, MOL CANCER THER, V3, P1421
   Fujioka S, 2003, ONCOGENE, V22, P1365, DOI 10.1038/sj.onc.1206323
   Greenwald I, 1998, GENE DEV, V12, P1751, DOI 10.1101/gad.12.12.1751
   Jang MS, 2004, J CELL PHYSIOL, V199, P418, DOI 10.1002/jcp.10467
   John Anitha, 2001, Pathology and Oncology Research, V7, P14
   Joo Young Eun, 2002, Korean Journal of Internal Medicine, V17, P153
   Lee MA, 2005, BMC CANCER, V5, DOI 10.1186/1471-2407-5-127
   Leethanakul C, 2000, ONCOGENE, V19, P3220, DOI 10.1038/sj.onc.1203703
   Merati K, 2001, AM J CLIN ONCOL-CANC, V24, P447, DOI 10.1097/00000421-200110000-00007
   Miele L, 1999, J CELL PHYSIOL, V181, P393, DOI 10.1002/(SICI)1097-4652(199912)181:3<393::AID-JCP3>3.0.CO;2-6
   Nagakawa Y, 2002, PANCREAS, V24, P169, DOI 10.1097/00006676-200203000-00008
   Nickoloff BJ, 2002, CELL DEATH DIFFER, V9, P842, DOI 10.1038/sj.cdd.4401036
   Ohishi K, 2003, SEMIN CELL DEV BIOL, V14, P143, DOI 10.1016/S1084-9521(02)00183-0
   Okami J, 2003, CLIN EXP METASTAS, V20, P577, DOI 10.1023/A:1027319903359
   Osborne B, 1999, IMMUNITY, V11, P653, DOI 10.1016/S1074-7613(00)80140-5
   Rae FK, 2000, INT J CANCER, V88, P726, DOI 10.1002/1097-0215(20001201)88:5<726::AID-IJC7>3.0.CO;2-H
   Sclabas GM, 2005, CANCER-AM CANCER SOC, V103, P2485, DOI 10.1002/cncr.21075
   Shin HM, 2006, EMBO J, V25, P129, DOI 10.1038/sj.emboj.7600902
   Takada Y, 2005, ONCOGENE, V24, P6957, DOI 10.1038/sj.onc.1208845
   Takada Y, 2005, J BIOL CHEM, V280, P17203, DOI 10.1074/jbc.M500077200
   Takada Y, 2004, ONCOGENE, V23, P9247, DOI 10.1038/sj.onc.1208169
   Tohda S, 2001, LEUKEMIA LYMPHOMA, V42, P467, DOI 10.3109/10428190109064603
   Wang Y, 2004, P NATL ACAD SCI USA, V101, P9458, DOI 10.1073/pnas.0308126101
   WANG Z, 2006, IN PRESS INT J CANC
   Weijzen S, 2002, NAT MED, V8, P979, DOI 10.1038/nm754
   Wey JS, 2005, CANCER, V104, P427, DOI 10.1002/cncr.21145
   Xiong HQ, 2004, INT J CANCER, V108, P181, DOI 10.1002/ijc.11562
   Yanagawa S, 2000, J VIROL, V74, P9786, DOI 10.1128/JVI.74.20.9786-9791.2000
   Zeng HY, 2003, BIOCHEM BIOPH RES CO, V302, P46, DOI 10.1016/S0006-291X(03)00107-4
NR 34
TC 258
Z9 286
U1 0
U2 25
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD MAR 1
PY 2006
VL 66
IS 5
BP 2778
EP 2784
DI 10.1158/0008-5472.CAN-05-4281
PG 7
WC Oncology
SC Oncology
GA 019HO
UT WOS:000235826400038
PM 16510599
OA Bronze
DA 2018-12-27
ER

PT J
AU Ejrnaes, M
   Von Herrath, MG
   Christen, U
AF Ejrnaes, Mette
   Von Herrath, Matthias G.
   Christen, Urs
TI RETRACTED: Cure of chronic viral infection and virus-induced type 1
   diabetes by neutralizing antibodies (Retracted article. See 2747402,
   2016)
SO CLINICAL & DEVELOPMENTAL IMMUNOLOGY
LA English
DT Article; Retracted Publication
DE autoimmune disease; chronic infection; CXCR3; dendritic cells; LCMV;
   molecular mimicry
ID LYMPHOCYTIC CHORIOMENINGITIS VIRUS; CENTRAL-NERVOUS-SYSTEM;
   GAMMA-INDUCIBLE PROTEIN; CHRONIC HEPATITIS-C; AMINO-ACID CHANGE; INDUCED
   DEMYELINATING DISEASE; ISLET-SPECIFIC EXPRESSION; T-HELPER-CELLS;
   DENDRITIC CELLS; IN-VIVO
AB The use of neutralizing antibodies is one of the most successful methods to interfere with receptor-ligand interactions in vivo. In particular blockade of soluble inflammatory mediators or their corresponding cellular receptors was proven an effective way to regulate inflammation and/or prevent its negative consequences. However, one problem that comes along with an effective neutralization of inflammatory mediators is the general systemic immunomodulatory effect. It is, therefore, important to design a treatment regimen in a way to strike at the right place and at the right time in order to achieve maximal effects with minimal duration of immunosuppression or hyperactivation. In this review, we reflect on two examples of how short time administration of such neutralizing antibodies can block two distinct inflammatory consequences of viral infection. First, we review recent findings that blockade of IL-10/IL-10R interaction can resolve chronic viral infection and second, we reflect on how neutralization of the chemokine CXCL10 can abrogate virus-induced type 1 diabetes.
C1 La Jolla Inst Allergy & Immunol, Dept Dev Immunol, San Diego, CA 92121 USA.
   Goethe Univ Frankfurt, D-6000 Frankfurt, Germany.
RP Ejrnaes, M (reprint author), La Jolla Inst Allergy & Immunol, Dept Dev Immunol, 10355 Sci Ctr Dr, San Diego, CA 92121 USA.
EM mejrnaes@liai.org; christen@med.uni-frankfurt.de
RI Christen, Urs/A-7338-2009
CR Accapezzato D, 2004, J CLIN INVEST, V113, P963, DOI 10.1172/JCI200420415
   AKRIDGE RE, 1994, J IMMUNOL, V153, P5782
   AMEGLIO E, 1994, J BIOL REG HOMEOS AG, V8, P48
   Asensio VC, 1997, J VIROL, V71, P7832
   AUTRAN B, 1995, J IMMUNOL, V154, P1408
   BORROW P, 1995, J VIROL, V69, P1059
   Borrow Persephone, 1997, P593
   BUELENS C, 1995, EUR J IMMUNOL, V25, P2668, DOI 10.1002/eji.1830250940
   Cantor H, 2000, ADV IMMUNOL, V75, P209, DOI 10.1016/S0065-2776(00)75005-X
   Cao W, 1998, SCIENCE, V282, P2079, DOI 10.1126/science.282.5396.2079
   Charles PC, 1999, J NEUROVIROL, V5, P55, DOI 10.3109/13550289909029746
   Christen U, 2004, IMMUNOL RES, V30, P309, DOI 10.1385/IR:30:3:309
   Christen U, 2004, CURR OPIN IMMUNOL, V16, P759, DOI 10.1016/j.coi.2004.09.002
   Christen U, 2004, J CLIN INVEST, V114, P1290, DOI 10.1172/JCI200422557
   Christen U, 2004, AUTOIMMUNITY, V37, P273, DOI 10.1080/08916930410001713124
   Christen U, 2004, MOL IMMUNOL, V40, P1113, DOI 10.1016/j.molimm.20033.11.014
   Christen U, 2004, J CLIN INVEST, V113, P74, DOI 10.1172/JCI200417005
   Christen U, 2003, J IMMUNOL, V171, P6838, DOI 10.4049/jimmunol.171.12.6838
   Christen U, 2002, ANN NY ACAD SCI, V958, P166
   Christen U, 2005, J IMMUNOL, V174, P7481, DOI 10.4049/jimmunol.174.12.7481
   Christen U, 2001, J IMMUNOL, V166, P7023, DOI 10.4049/jimmunol.166.12.7023
   Coon B, 1999, J CLIN INVEST, V104, P189, DOI 10.1172/JCI7209
   DING L, 1993, J IMMUNOL, V151, P1224
   Dockter J, 1996, J VIROL, V70, P1799
   Ejrnaes M, 2005, J IMMUNOL, V174, P2746, DOI 10.4049/jimmunol.174.5.2746
   EJRNAES M, UNPUB RESOLUTION CHR
   Evans CF, 1996, J EXP MED, V184, P2371, DOI 10.1084/jem.184.6.2371
   Fife BT, 2001, J IMMUNOL, V166, P7617, DOI 10.4049/jimmunol.166.12.7617
   FIORENTINO DF, 1991, J IMMUNOL, V147, P3815
   Frigerio S, 2002, NAT MED, V8, P1414, DOI 10.1038/nm792
   GATTASS CR, 1994, J EXP MED, V179, P1373, DOI 10.1084/jem.179.4.1373
   Granelli-Piperno A, 2004, P NATL ACAD SCI USA, V101, P7669, DOI 10.1073/pnas.0402431101
   Hoffman LM, 1999, J NEUROVIROL, V5, P635, DOI 10.3109/13550289909021292
   Homann D, 2001, NAT MED, V7, P913, DOI 10.1038/90950
   Homann D, 1999, J IMMUNOL, V163, P1833
   JAMIESON BD, 1987, J VIROL, V61, P3930
   Ji JX, 2005, INT IMMUNOL, V17, P729, DOI 10.1093/intimm/dxh252
   Kaech SM, 2002, CELL, V111, P837, DOI 10.1016/S0092-8674(02)01139-X
   Kamar N, 2005, J MED VIROL, V76, P61, DOI 10.1002/jmv.20323
   KASAMA T, 1994, J IMMUNOL, V152, P3559
   Khan IA, 2000, IMMUNITY, V12, P483, DOI 10.1016/S1074-7613(00)80200-9
   Kolb SA, 1999, J NEUROIMMUNOL, V93, P172, DOI 10.1016/S0165-5728(98)00223-9
   Lane TE, 1998, J IMMUNOL, V160, P970
   LAU LL, 1994, NATURE, V369, P648, DOI 10.1038/369648a0
   Lin MY, 1998, J EXP MED, V188, P1993, DOI 10.1084/jem.188.11.1993
   Liu MT, 2000, J IMMUNOL, V165, P2327, DOI 10.4049/jimmunol.165.5.2327
   Liu YJ, 2001, CELL, V106, P259, DOI 10.1016/S0092-8674(01)00456-1
   LO D, 1993, EUR J IMMUNOL, V23, P1693, DOI 10.1002/eji.1830230744
   LO D, 1992, EUR J IMMUNOL, V22, P1013, DOI 10.1002/eji.1830220421
   Loetscher M, 1996, J EXP MED, V184, P963, DOI 10.1084/jem.184.3.963
   Luster AD, 1998, P ASSOC AM PHYSICIAN, V110, P183
   LUSTER AD, 1985, NATURE, V315, P672, DOI 10.1038/315672a0
   LUSTER AD, 1987, J EXP MED, V166, P1084, DOI 10.1084/jem.166.4.1084
   Maldonado-Lopez R, 1999, J EXP MED, V189, P587, DOI 10.1084/jem.189.3.587
   Maldonado-Lopez R, 2001, J IMMUNOL, V167, P4345, DOI 10.4049/jimmunol.167.8.4345
   MARKER O, 1973, J EXP MED, V137, P1511, DOI 10.1084/jem.137.6.1511
   MATLOUBIAN M, 1990, J EXP MED, V172, P1043, DOI 10.1084/jem.172.4.1043
   McGavern DB, 2002, NAT IMMUNOL, V3, P918, DOI 10.1038/ni843
   Miller SD, 2001, ADV VIRUS RES, V56, P199, DOI 10.1016/S0065-3527(01)56008-X
   Mocellin S, 2001, J IMMUNOTHER, V24, P392, DOI 10.1097/00002371-200109000-00002
   Moore KW, 2001, ANNU REV IMMUNOL, V19, P683, DOI 10.1146/annurev.immunol.19.1.683
   Morimoto J, 2004, J IMMUNOL, V173, P7017, DOI 10.4049/jimmunol.173.11.7017
   MOSKOPHIDIS D, 1987, EUR J IMMUNOL, V17, P937, DOI 10.1002/eji.1830170707
   MOSKOPHIDIS D, 1993, NATURE, V362, P758, DOI 10.1038/362758a0
   MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.iy.07.040189.001045
   Murali-Krishna K, 1999, SCIENCE, V286, P1377, DOI 10.1126/science.286.5443.1377
   Murali-Krishna K, 1998, IMMUNITY, V8, P177, DOI 10.1016/S1074-7613(00)80470-7
   OHASHI PS, 1991, CELL, V65, P305, DOI 10.1016/0092-8674(91)90164-T
   OLDSTONE MBA, 1990, J EXP MED, V171, P2077, DOI 10.1084/jem.171.6.2077
   OLDSTONE MBA, 1989, CURR TOP MICROBIOL, V145, P127
   OLDSTONE MBA, 1986, NATURE, V321, P239, DOI 10.1038/321239a0
   OLDSTONE MBA, 1991, CELL, V65, P319, DOI 10.1016/0092-8674(91)90165-U
   OLDSTONE MBA, 1988, SCIENCE, V239, P500, DOI 10.1126/science.3277269
   Olsen JK, 2001, J CLIN INVEST, V108, P311
   Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301
   Pestka S, 2004, ANNU REV IMMUNOL, V22, P929, DOI 10.1146/annurev.immunol.22.012703.104622
   Re F, 2004, J IMMUNOL, V173, P7548, DOI 10.4049/jimmunol.173.12.7548
   Rhode A, 2005, J IMMUNOL, V175, P3516, DOI 10.4049/jimmunol.175.6.3516
   Rigopoulou EI, 2005, CLIN IMMUNOL, V117, P57, DOI 10.1016/j.clim.2005.06.003
   Sallusto F, 1998, IMMUNOL TODAY, V19, P568, DOI 10.1016/S0167-5699(98)01346-2
   SALVATO M, 1991, J VIROL, V65, P1863
   Seewaldt S, 2000, DIABETES, V49, P1801, DOI 10.2337/diabetes.49.11.1801
   Sevilla N, 2004, J CLIN INVEST, V113, P737, DOI 10.1172/JCI20243
   Smelt SC, 2001, J VIROL, V75, P448, DOI 10.1128/JVI.75.1.448-457.2001
   Sozzani S, 1998, J EXP MED, V187, P439, DOI 10.1084/jem.187.3.439
   Takayama T, 2001, J IMMUNOL, V166, P7136, DOI 10.4049/jimmunol.166.12.7136
   TAN JQ, 1993, J IMMUNOL, V151, P4545
   Torriani FJ, 2004, NEW ENGL J MED, V351, P438, DOI 10.1056/NEJMoa040842
   Vicari AP, 2004, IMMUNOL REV, V202, P223, DOI 10.1111/j.0105-2896.2004.00216.x
   Vicari AP, 2002, J EXP MED, V196, P541, DOI 10.1084/jem.20020732
   VONHERRATH MG, 1994, IMMUNITY, V1, P231, DOI 10.1016/1074-7613(94)90101-5
   WILLEMS F, 1994, EUR J IMMUNOL, V24, P1007, DOI 10.1002/eji.1830240435
   Wolk K, 2002, J IMMUNOL, V168, P5397, DOI 10.4049/jimmunol.168.11.5397
   ZINKERNA.RM, 1974, NATURE, V248, P701, DOI 10.1038/248701a0
   ZINKERNAGEL RM, 1976, J IMMUNOL, V117, P1495
NR 95
TC 3
Z9 4
U1 3
U2 5
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1740-2522
EI 1740-2530
J9 CLIN DEV IMMUNOL
JI Clin. Dev. Immunol.
PD MAR
PY 2006
VL 13
IS 1
BP 67
EP 77
DI 10.1080/17402520600579028
PG 11
WC Immunology
SC Immunology
GA 051WG
UT WOS:000238191800007
PM 16603445
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Xia, YF
   Huang, S
   Li, X
   Yang, N
   Huang, J
   Xue, C
   Zhang, M
   Leung, JCK
   Lam, MF
   Li, J
AF Xia, YF
   Huang, S
   Li, X
   Yang, N
   Huang, J
   Xue, C
   Zhang, M
   Leung, JCK
   Lam, MF
   Li, J
TI RETRACTED: A family-based association study of megsin A23167G
   polymorphism with susceptibility and progression of IgA nephropathy in a
   Chinese population (Retracted article. See vol 66 pg 314 2006)
SO CLINICAL NEPHROLOGY
LA English
DT Article; Retracted Publication
DE genetic polymorphism; haplotype relative risk; IgA nephropathy; megsin;
   transmission disequilibrium test
ID MESANGIUM-PREDOMINANT GENE; PLASMINOGEN-ACTIVATOR INHIBITOR-1; LINKAGE
   DISEQUILIBRIUM; RENAL-FAILURE; STRATIFICATION; DISEASE; RISK;
   GLOMERULONEPHRITIS; TRANSMISSION; UTEROGLOBIN
AB Aims: To investigate the association of megsin A23167G polymorphism with susceptibility and progression of IgA nephropathy ill Chinese population. Methods: 435 IgA nephropathy patients and their family members were recruited for a family-based association study. Genotypes of megsin A23167G were determined by direct sequencing. The results were analyzed by transmission disequilibrium test (TDT) and haplotype relative risk (HRR). Clinical data and histological scores of renal lesions were compared between patients with different genotypes. According to disease stability, IgA nephropathy patients were divided into progressive group and stable group. The distribution of genotype frequencies were compared between the 2 groups. Results: TDT revealed that megsin 23167G alleles were transmitted more frequently from heterozygous parents to patients than expected (classical TDT: chi(2) = 5.435, p = 0.020, extended TDT: chi(2) = 5.017, p = 0.025). HRR analyses showed significant differences between transmitted and nontransmitted allele frequencies (chi(2) = 7.006, p = 0.008, HRR = 1.762). The scores of glomerular index and glomerular sclerosis index were higher in GG genotype patients than those ill other genotypes (F = 4.570, p = 0.033, F = 4.324, p = 0.038, respectively). The distribution frequency of GG genotype ill the progressive group was higher than that of the stable group (chi(2) = 4.370, p = 0.037). No statistical difference was found in tubulo-interstitial index, vascular index and clinical characteristics between the 2 groups. Conclusion: The polymorphism of megsin A23167G is associated With Susceptibility and progression of IgA nephropathy in Chinese Population. GG genotype is associated with severe histological lesions and progression of the disease.
C1 Sun Yat Sen Univ, Affiliated Hosp 1, Dept Nephrol, Guangzhou 510080, Peoples R China.
   Sun Yat Sen Univ, Dept Med Genet, Guangzhou 510080, Peoples R China.
   Sun Yat Sen Univ, Zhongshan Med Coll, Dept Med Stat, Guangzhou 510080, Peoples R China.
   Univ Hong Kong, Queen Mary Hosp, Dept Med, Hong Kong, Hong Kong, Peoples R China.
RP Li, J (reprint author), Sun Yat Sen Univ, Affiliated Hosp 1, Dept Nephrol, 74 Zhongshan Rd 2, Guangzhou 510080, Peoples R China.
EM bq0531@126.com
CR Clayton D, 1999, AM J HUM GENET, V65, P1170, DOI 10.1086/302577
   D'Amico G, 2004, SEMIN NEPHROL, V24, P179, DOI 10.1016/j.semnephrol.2004.01.001
   DAMICO G, 1987, Q J MED, V64, P709
   Donadio JV, 2002, NEW ENGL J MED, V347, P738, DOI 10.1056/NEJMra020109
   FALK CT, 1987, ANN HUM GENET, V51, P227, DOI 10.1111/j.1469-1809.1987.tb00875.x
   Fofi C, 2001, J NEPHROL, V14, P280
   Fogo AB, 2000, AM J KIDNEY DIS, V35, P179, DOI 10.1016/S0272-6386(00)70324-6
   Freedman ML, 2004, NAT GENET, V36, P388, DOI 10.1038/ng1333
   Gharavi AG, 2000, NAT GENET, V26, P354
   Habib R, 1994, RENAL PATHOLOGY CLIN, P472
   Hsu SIH, 2000, KIDNEY INT, V57, P1818, DOI 10.1046/j.1523-1755.2000.00032.x
   IMAI H, 1985, KIDNEY INT, V27, P756, DOI 10.1038/ki.1985.76
   Inagi R, 2002, J AM SOC NEPHROL, V13, P2715, DOI 10.1097/01.ASN.0000033507.32175.FA
   Kittles RA, 2002, HUM GENET, V110, P553, DOI 10.1007/s00439-002-0731-5
   LEVY M, 1988, AM J KIDNEY DIS, V12, P340, DOI 10.1016/S0272-6386(88)80021-0
   Li YJ, 2004, J AM SOC NEPHROL, V15, P1739, DOI 10.1097/01.ASN.0000130858.00688.46
   Maisonneuve P, 2000, AM J KIDNEY DIS, V35, P157, DOI 10.1016/S0272-6386(00)70316-7
   Miyata T, 1998, J CLIN INVEST, V102, P828, DOI 10.1172/JCI2450
   Miyata T, 2002, J CLIN INVEST, V109, P585, DOI 10.1172/JCI200214336
   Nakamura S, 2000, KIDNEY INT, V58, P251, DOI 10.1046/j.1523-1755.2000.00160.x
   Nangaku M, 2001, KIDNEY INT, V60, P641, DOI 10.1046/j.1523-1755.2001.060002641.x
   Ohhashi A, 1993, Nihon Hoigaku Zasshi, V47, P108
   Rauta V, 2002, CLIN NEPHROL, V58, P85
   Spielman RS, 1996, AM J HUM GENET, V59, P983
   SPIELMAN RS, 1993, AM J HUM GENET, V52, P506
   Suzuki D, 1999, J AM SOC NEPHROL, V10, P2606
   TERWILLIGER JD, 1992, HUM HERED, V42, P337, DOI 10.1159/000154096
   Thomas DC, 2002, CANCER EPIDEM BIOMAR, V11, P505
   Vleming LJ, 1998, CLIN NEPHROL, V49, P337
   YOSHIKAWA N, 1992, NEPHRON, V60, P60, DOI 10.1159/000186706
   Zhang ZJ, 1997, SCIENCE, V276, P1408, DOI 10.1126/science.276.5317.1408
   Zhang ZJ, 2000, ANN NY ACAD SCI, V923, P210
NR 32
TC 12
Z9 15
U1 7
U2 17
PU DUSTRI-VERLAG DR KARL FEISTLE
PI DEISENHOFEN-MUENCHEN
PA BAHNHOFSTRASSE 9 POSTFACH 49, D-82032 DEISENHOFEN-MUENCHEN, GERMANY
SN 0301-0430
J9 CLIN NEPHROL
JI Clin. Nephrol.
PD MAR
PY 2006
VL 65
IS 3
BP 153
EP 159
PG 7
WC Urology & Nephrology
SC Urology & Nephrology
GA 025AF
UT WOS:000236237000001
PM 16550745
DA 2018-12-27
ER

PT J
AU Tomita, M
   Kawakami, H
   Uchihara, JN
   Okudaira, T
   Masuda, M
   Takasu, N
   Matsuda, T
   Ohta, T
   Tanaka, Y
   Ohshiro, K
   Mori, N
AF Tomita, M
   Kawakami, H
   Uchihara, JN
   Okudaira, T
   Masuda, M
   Takasu, N
   Matsuda, T
   Ohta, T
   Tanaka, Y
   Ohshiro, K
   Mori, N
TI RETRACTED: Curcumin (diferuloylmethane) inhibits constitutive active
   NF-kappa B, leading to suppression of cell growth of human T-cell
   leukemia virus type I-infected T-cell lines and primary adult T-cell
   leukemia cells (Retracted article. See vol. 129, pg. 2762, 2011)
SO INTERNATIONAL JOURNAL OF CANCER
LA English
DT Article; Retracted Publication
DE ATL; HTLV-1; curcumin; NF-kappa B; apoptosis
ID MULTIPLE-MYELOMA CELLS; TAX PROTEIN; GENE-EXPRESSION; KINASE-ACTIVITY;
   ACTIVATION; APOPTOSIS; LYMPHOMA; ALPHA; SURVIVIN; CANCER
AB Adult T-cell leukemia (ATL) is a fatal malignancy of T lymphocytes caused by infection with human T-cell leukemia virus type I (HTLV-I) and remains incurable. Curcumin (diferuloylmethane), the major pigment of the spice turmeric, can be potentially effective by promoting cell apoptosis. Here we examined whether curcumin is effective in the treatment of ATL. Curcumin prevented cell growth of HTLV-I-infected T-cell lines and primary ATL cells but not of normal peripheral blood mononuclear cells. Curcumin induced cell cycle arrest by reducing the expression of cyclin D1, Cdk1 and Cdc25C and apoptosis by reducing the expression of XIAP and survivin. Most of these genes are known to be regulated by NF-kappa B, which plays a critical role in oncogenesis by HTLV-I. Curcumin suppressed constitutive active NF-kappa B of HTLV-I-infected T-cell lines and primary ATL cells by inhibiting phosphorylation of I kappa B alpha. Curcumin also inhibited Tax-induced NF-kappa B transcriptional activity. However, curcumin-induced suppression of cell growth did not correlate with Tax expression level. Curcumin inhibited the growth of HTLV-I-infected T-cell tumors implanted subcutaneously in SCID mice. Our results indicate that curcumin has tumor-suppressive activity against ATL. (c) 2005 Wiley-Liss, hic.
C1 Univ Ryukyus, Grad Sch Med, Div Mol Virol & Oncol, Nishihara, Okinawa 9030215, Japan.
   Univ Ryukyus, Fac Med, Div Endocrinol & Metab, Nishihara, Okinawa 9030215, Japan.
   Univ Ryukyus, Fac Med, Div Child Hlth & Welf, Nishihara, Okinawa 9030215, Japan.
   Univ Ryukyus, Fac Med, Div Immunol, Nishihara, Okinawa 9030215, Japan.
   Naha Prefectural Hosp, Dept Internal Med, Naha, Japan.
RP Mori, N (reprint author), Univ Ryukyus, Grad Sch Med, Div Mol Virol & Oncol, 207 Uehara, Nishihara, Okinawa 9030215, Japan.
EM n-mori@med.u-ryukyu.ac.jp
CR Aggarwal BB, 2003, ANTICANCER RES, V23, P363
   Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917
   ARIMA N, 1992, J EXP MED, V176, P1265, DOI 10.1084/jem.176.5.1265
   Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649
   Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782
   Bharti AC, 2003, J IMMUNOL, V171, P3863, DOI 10.4049/jimmunol.171.7.3863
   Bharti AC, 2003, BLOOD, V101, P1053, DOI 10.1182/blood-2002-05-1320
   Chaudhury LR, 2003, J CELL BIOCHEM, V89, P1, DOI 10.1002/jcb.10495
   Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8
   Cheng AL, 2001, ANTICANCER RES, V21, P2895
   Chu ZL, 1998, J BIOL CHEM, V273, P15891, DOI 10.1074/jbc.273.26.15891
   GILL PS, 1995, NEW ENGL J MED, V332, P1744, DOI 10.1056/NEJM199506293322603
   GROSSMAN WJ, 1995, P NATL ACAD SCI USA, V92, P1057, DOI 10.1073/pnas.92.4.1057
   Han SS, 2002, J BIOCHEM MOL BIOL, V35, P337
   HINUMA Y, 1981, P NATL ACAD SCI-BIOL, V78, P6476, DOI 10.1073/pnas.78.10.6476
   Hironaka N, 2004, NEOPLASIA, V6, P266, DOI 10.1593/neo.03388
   Ishiyama M, 1996, BIOL PHARM BULL, V19, P1518
   Kawakami A, 1999, BLOOD, V94, P3847
   Kawakami H, 2005, INT J CANCER, V115, P967, DOI 10.1002/ijc.20954
   Matsumoto K, 1997, J VIROL, V71, P4445
   Mitsiades N, 2002, BLOOD, V99, P4079, DOI 10.1182/blood.V99.11.4079
   MIYOSHI I, 1980, GANN, V71, P155
   MIYOSHI I, 1981, NATURE, V294, P770, DOI 10.1038/294770a0
   Mohapatra S, 2003, CANCER RES, V63, P8523
   Mori N, 1996, BLOOD, V87, P3410
   Mori N, 2002, BLOOD, V100, P1828, DOI 10.1182/blood-2002-01-0151
   Mori N, 2002, INT J CANCER, V99, P378, DOI 10.1002/ijc.10388
   Mori N, 2001, BIOCHEM BIOPH RES CO, V282, P1110, DOI 10.1006/bbrc.2001.4708
   Mori N, 1999, BLOOD, V93, P2360
   Mori N, 2000, BLOOD, V95, P3915
   Nasr R, 2003, BLOOD, V101, P4576, DOI 10.1182/blood-2002-09-2986
   Nawata H, 2001, LEUKEMIA RES, V25, P323, DOI 10.1016/S0145-2126(00)00126-0
   NERENBERG M, 1987, SCIENCE, V237, P1324, DOI 10.1126/science.2888190
   OHTANI K, 1987, EMBO J, V6, P389, DOI 10.1002/j.1460-2075.1987.tb04767.x
   POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415
   POZZATTI R, 1990, MOL CELL BIOL, V10, P413, DOI 10.1128/MCB.10.1.413
   Salvesen GS, 2002, NAT REV MOL CELL BIO, V3, P401, DOI 10.1038/nrm830
   Satou Y, 2004, LEUKEMIA, V18, P1357, DOI 10.1038/sj.leu.2403400
   Sharma RA, 2001, CLIN CANCER RES, V7, P1894
   Stehlik C, 1998, J EXP MED, V188, P211, DOI 10.1084/jem.188.1.211
   Sun SC, 1999, ONCOGENE, V18, P6948, DOI 10.1038/sj.onc.1203220
   TAJIMA K, 1990, INT J CANCER, V45, P237, DOI 10.1002/ijc.2910450206
   Tamm I, 2000, CLIN CANCER RES, V6, P1796
   TANAKA A, 1990, P NATL ACAD SCI USA, V87, P1071, DOI 10.1073/pnas.87.3.1071
   TANAKA Y, 1990, JPN J CANCER RES, V81, P225, DOI 10.1111/j.1349-7006.1990.tb02554.x
   Tomita M, 2004, ONCOGENE, V23, P8272, DOI 10.1038/sj.onc.1208059
   Yamada Y, 2001, BRIT J HAEMATOL, V113, P375, DOI 10.1046/j.1365-2141.2001.02737.x
   Yin MJ, 1998, CELL, V93, P875, DOI 10.1016/S0092-8674(00)81447-6
   YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031
NR 49
TC 69
Z9 73
U1 3
U2 14
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0020-7136
EI 1097-0215
J9 INT J CANCER
JI Int. J. Cancer
PD MAR 1
PY 2006
VL 118
IS 3
BP 765
EP 772
DI 10.1002/ijc.21389
PG 8
WC Oncology
SC Oncology
GA 000EO
UT WOS:000234443900033
PM 16106398
OA Bronze
DA 2018-12-27
ER

PT J
AU Uchihara, JN
   Matsuda, T
   Okudaira, T
   Ishikawa, C
   Masuda, M
   Horie, R
   Watanabe, T
   Ohta, T
   Takasu, N
   Mori, N
AF Uchihara, JN
   Matsuda, T
   Okudaira, T
   Ishikawa, C
   Masuda, M
   Horie, R
   Watanabe, T
   Ohta, T
   Takasu, N
   Mori, N
TI RETRACTED: Transactivation of the ICAM-1 gene by CD30 in Hodgkin's
   lymphoma (Retracted article. See vol. 129, pg. 2762, 2011)
SO INTERNATIONAL JOURNAL OF CANCER
LA English
DT Article; Retracted Publication
DE ICAM-1; CD30; NF-kappa B; Hodgkin's lymphoma; TRAF
ID NF-KAPPA-B; INTERCELLULAR-ADHESION MOLECULE-1; REED-STERNBERG CELLS;
   LEUKEMIA-VIRUS TYPE-1; KINASE-ALPHA; RECEPTOR SUPERFAMILY;
   MONOCLONAL-ANTIBODY; ANTIGEN-1 LFA-1; SOLUBLE FORM; DISEASE
AB The ICAM-1/LFA-1 complex mediates cell-cell interaction. ICAM-1 is overexpressed in Hodgkin/Reed-Sternberg (H/RS) cells, and serum levels of its soluble form are higher in Hodgkin's lymphoma (HL) patients than in controls. There are no data, however, regarding the regulation of expression of ICAM-1 in H/RS cells. CD30 was identified in H/RS cells of HL and has attracted much interest as a molecular marker of HL. To analyze ICAM-1 expression in H/RS cells, we examined the expression of ICAM-1, LFA-1, CD30 and CD30L in HL-derived cell lines. All cell lines expressed ICAM-1 and CD30, but not LFA-1 or CD30L. CD30 induced ICAM-1 expression. Analysis of the ICAM-1 promoter showed the importance of NF-kappa B binding site for CD30-induced ICAM-1 gene expression. Coexpression of I kappa B, IKK, NIK and TRAF dominant-negative constructs with CD30 inhibited CD30-induced activation of ICAM-1 promoter, suggesting that CD30 induces ICAM-1 via NF-kappa B signalling. The ICAM-1 promoter was activated by the C-terminal region of CD30, which activated NF-kappa B signalling. A decoy CD30 lacking the cytoplasmic region inhibited ICAM-1 promoter activity in HL cell lines. Thus, in H/RS cells, ligand-independent activation of CD30 signalling activates NF-kappa B and this leads to constitutive ICAM-1 expression, suggesting a link between 2 well known phenotypic characteristics of HL, CD30 and ICAM-1 overexpression. (c) 2005 Wiley-Liss, Inc.
C1 Univ Ryukyus, Grad Sch Med, Div Mol Virol & Oncol, Nishihara, Okinawa 9030215, Japan.
   Univ Ryukyus, Fac Med, Div Endocrinol & Metab, Nishihara, Okinawa 9030215, Japan.
   Univ Ryukyus, Fac Med, Div Child Hlth & Welf, Nishihara, Okinawa 90301, Japan.
   Kitasato Univ, Sch Med, Dept Internal Med 4, Sagamihara, Kanagawa 228, Japan.
   Univ Tokyo, Grad Sch Frontier Sci, Tumor Cell Biol Lab, Tokyo, Japan.
RP Mori, N (reprint author), Univ Ryukyus, Grad Sch Med, Div Mol Virol & Oncol, 207 Uehara, Nishihara, Okinawa 9030215, Japan.
EM n-mori@med.u-ryukyu.ac.jp
CR Aizawa S, 1997, J BIOL CHEM, V272, P2042
   Ansai T, 2002, CLIN SCI, V103, p327S, DOI 10.1042/CS103S327S
   Baker SJ, 1998, ONCOGENE, V17, P3261
   BANKS RE, 1993, BRIT J CANCER, V68, P122, DOI 10.1038/bjc.1993.298
   Bargou RC, 1996, BLOOD, V87, P4340
   BOWEN MA, 1993, J IMMUNOL, V151, P5896
   Bowen MA, 1996, J IMMUNOL, V156, P442
   BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809
   Cabannes E, 1999, ONCOGENE, V18, P3063, DOI 10.1038/sj.onc.1202893
   CARLOS TM, 1994, BLOOD, V84, P2068
   CHRISTIANSEN I, 1995, LEUKEMIA LYMPHOMA, V19, P243, DOI 10.3109/10428199509107894
   Coussens LM, 2001, J EXP MED, V193, pF23, DOI 10.1084/jem.193.6.F23
   DORREEN MS, 1984, BRIT J CANCER, V49, P465, DOI 10.1038/bjc.1984.74
   DOUGHERTY GJ, 1987, EUR J IMMUNOL, V17, P943, DOI 10.1002/eji.1830170708
   Emmerich F, 1999, BLOOD, V94, P3129
   FALINI B, 1995, BLOOD, V85, P1
   Gattei V, 1997, BLOOD, V89, P2048
   Gedrich RW, 1996, J BIOL CHEM, V271, P12852, DOI 10.1074/jbc.271.22.12852
   Geleziunas R, 1998, MOL CELL BIOL, V18, P5157, DOI 10.1128/MCB.18.9.5157
   Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225
   Gruss HJ, 1996, AM J PATHOL, V149, P469
   GRUSS HJ, 1994, BLOOD, V83, P2045
   Gruss HJ, 1997, IMMUNOL TODAY, V18, P156, DOI 10.1016/S0167-5699(97)84661-0
   GRUSS HJ, 1995, BLOOD, V85, P3378
   Hinz M, 2002, J EXP MED, V196, P605, DOI 10.1084/jem.20020062
   Horie R, 1998, INT IMMUNOL, V10, P203, DOI 10.1093/intimm/10.2.203
   Horie R, 2003, INT J HEMATOL, V77, P37, DOI 10.1007/BF02982601
   Horie R, 2002, ONCOGENE, V21, P2493, DOI 10.1038/sj/onc/1205337
   HOU JZ, 1994, P NATL ACAD SCI USA, V91, P11641, DOI 10.1073/pnas.91.24.11641
   Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621
   Krappmann D, 1999, ONCOGENE, V18, P943, DOI 10.1038/sj.onc.1202351
   LECA G, 1994, CELL IMMUNOL, V156, P230, DOI 10.1006/cimm.1994.1167
   LEDEBUR HC, 1995, J BIOL CHEM, V270, P933, DOI 10.1074/jbc.270.2.933
   Lee FS, 1998, P NATL ACAD SCI USA, V95, P9319, DOI 10.1073/pnas.95.16.9319
   Lee SY, 1996, P NATL ACAD SCI USA, V93, P9699, DOI 10.1073/pnas.93.18.9699
   MARLIN SD, 1987, CELL, V51, P813, DOI 10.1016/0092-8674(87)90104-8
   Masuda M, 1998, INT J HEMATOL, V67, P257
   MCDONALD PP, 1995, EUR J IMMUNOL, V25, P2870, DOI 10.1002/eji.1830251024
   McKinsey TA, 1996, MOL CELL BIOL, V16, P2083
   Molin D, 2001, BRIT J HAEMATOL, V114, P616, DOI 10.1046/j.1365-2141.2001.02977.x
   Mori N, 1999, BLOOD, V93, P2360
   Nadali G, 1998, BLOOD, V91, P3011
   Nam SY, 2002, CELL IMMUNOL, V219, P38, DOI 10.1016/S0008-8749(02)00583-X
   Pinto A, 1996, BLOOD, V88, P3299
   PIZZOLO G, 1993, BRIT J HAEMATOL, V84, P161, DOI 10.1111/j.1365-2141.1993.tb03040.x
   RUCO LP, 1992, AM J PATHOL, V140, P1337
   SCHWAB U, 1982, NATURE, V299, P65, DOI 10.1038/299065a0
   SIMMONS D, 1988, NATURE, V331, P624, DOI 10.1038/331624a0
   SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0
   STEIN H, 1985, BLOOD, V66, P848
   VORABERGER G, 1991, J IMMUNOL, V147, P2777
   WANG P, 1990, CELL IMMUNOL, V131, P366, DOI 10.1016/0008-8749(90)90261-O
   Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866
   Younes A, 1996, BRIT J HAEMATOL, V93, P569, DOI 10.1046/j.1365-2141.1996.d01-1686.x
   Zandi E, 1999, MOL CELL BIOL, V19, P4547
NR 55
TC 3
Z9 3
U1 3
U2 10
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0020-7136
EI 1097-0215
J9 INT J CANCER
JI Int. J. Cancer
PD MAR 1
PY 2006
VL 118
IS 5
BP 1098
EP 1107
DI 10.1002/ijc.21427
PG 10
WC Oncology
SC Oncology
GA 008QP
UT WOS:000235056100004
PM 16152613
OA Bronze
DA 2018-12-27
ER

PT J
AU Dubytska, L
   Godfrey, HP
   Cabello, FC
AF Dubytska, L
   Godfrey, HP
   Cabello, FC
TI RETRACTED: Borrelia burgdorferi ftsZ plays a role in cell division
   (Retracted Article. See vol 188, pg 3430, 2006)
SO JOURNAL OF BACTERIOLOGY
LA English
DT Article; Retracted Publication
ID REGULATED GENE-EXPRESSION; LYME-DISEASE SPIROCHETE; ESCHERICHIA-COLI;
   ANTISENSE RNA; STAPHYLOCOCCUS-AUREUS; BACILLUS-SUBTILIS;
   STREPTOMYCES-COELICOLOR; EUKARYOTIC CELLS; SURFACE-PROTEIN; MUTATIONS
AB ftsZ is essential for cell division in many microorganisms. In Escherichia coli and Bacillus subtilis, FtsZ plays a role in ring formation at the leading edge of the cell division septum. An ftsZ homologue is present in the Borrelia burgdorferi genome (ftsZ(Bbu)). Its gene product (FtsZ(Bbu)) is strongly homologous to other bacterial FtsZ proteins, but its function has not been established. Because loss-of-function mutants of ftsZ(Bbu) might be lethal, the tetR/tetO system was adapted for regulated control of this gene in B. burgdorferi. Sixty-two nucleotides of an ftsZ(Bbu) antisense DNA sequence under the control of a tetracycline-responsive modified hybrid borrelial promoter were cloned into pKFSS1. This construct was electroporated into a B. burgdorferi host strain carrying a chromosomally located tetR under the control of the B. burgdorferi flaB promoter. After induction by anhydrotetracycline, expression of antisense ftsZ RNA resulted in generation of filamentous B. burgdorferi that were unable to divide and grew more slowly than uninduced cells. To determine whether FtsZ(Bbu) could interfere with the function of E. coli FtsZ, ftsZ(Bbu) was amplified from chromosomal DNA and placed under the control of the tetracycline-regulated hybrid promoter. After introduction of the construct into E. coli and induction with anhydrotetracycline, overexpression of ftsZ(Bbu) generated a filamentous phenotype. This suggested interference of ftsZ(Bbu) with E. coli FtsZ function and confirmed the role of ftsZ(Bbu) in cell division. This is the first report of the generation of a B. burgdorferi conditional lethal mutant equivalent by tetracycline-controlled expression of antisense RNA.
C1 New York Med Coll, Dept Microbiol & Immunol, Valhalla, NY 10595 USA.
   New York Med Coll, Dept Pathol, Valhalla, NY 10595 USA.
RP Cabello, FC (reprint author), New York Med Coll, Dept Microbiol & Immunol, Valhalla, NY 10595 USA.
EM cabello@nymc.edu
OI Godfrey, Henry/0000-0002-7195-6363
FU NIAID NIH HHS [R01 AI08856]
CR AKINS DR, 1995, MOL MICROBIOL, V18, P507, DOI 10.1111/j.1365-2958.1995.mmi_18030507.x
   Alverson J, 2003, MOL MICROBIOL, V48, P1665, DOI 10.1046/j.1365-2958.2003.03537.x
   Baron U, 2000, METHOD ENZYMOL, V327, P401, DOI 10.1016/S0076-6879(00)27292-3
   BEALL B, 1991, GENE DEV, V5, P447, DOI 10.1101/gad.5.3.447
   Berens Christian, 2004, Genet Eng (N Y), V26, P255
   BI E, 1991, NATURE, V354, P161, DOI 10.1038/354161a0
   Blevins JS, 2004, INFECT IMMUN, V72, P4864, DOI 10.1128/IAI.72.8.4864-4867.2004
   Bramhill D, 1997, ANNU REV CELL DEV BI, V13, P395, DOI 10.1146/annurev.cellbio.13.1.395
   Bugrysheva JV, 2005, INFECT IMMUN, V73, P4972, DOI 10.1128/IAI.73.8.4972-4981.2005
   BURGDORFER W, 1988, ANN NY ACAD SCI, V539, P172, DOI 10.1111/j.1749-6632.1988.tb31851.x
   Cabello FC, 2001, TRENDS MICROBIOL, V9, P245, DOI 10.1016/S0966-842X(01)02046-7
   DAI K, 1991, J BACTERIOL, V173, P3500, DOI 10.1128/jb.173.11.3500-3506.1991
   DAI K, 1994, J BACTERIOL, V176, P130
   Dewar SJ, 2000, FEMS MICROBIOL LETT, V187, P1
   EBRT S, 2005, NUCLEIC ACIDS RES, V33, pE21
   ERICKSON HP, 1995, CELL, V80, P367, DOI 10.1016/0092-8674(95)90486-7
   Frank KL, 2003, J BACTERIOL, V185, P6723, DOI 10.1128/JB.185.22.6723-6727.2003
   Fraser CM, 1997, NATURE, V390, P580, DOI 10.1038/37551
   GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547
   Gossen M, 2002, ANNU REV GENET, V36, P153, DOI 10.1146/annurev.genet.36.041002.120114
   GOSSEN M, 1993, NUCLEIC ACIDS RES, V21, P4411, DOI 10.1093/nar/21.18.4411
   Grantcharova N, 2003, MOL MICROBIOL, V47, P645, DOI 10.1046/j.1365-2958.2003.03334.x
   Herring CD, 2004, J BACTERIOL, V186, P2673, DOI 10.1128/JB.186.9.2673-2681.2004
   HORIUCHI T, 1981, MOL GEN GENET, V181, P24, DOI 10.1007/BF00339000
   Izard J, 2001, J BACTERIOL, V183, P1078, DOI 10.1128/JB.183.3.1078-1084.2001
   Ji YD, 1999, J BACTERIOL, V181, P6585
   Ji YD, 2002, METHOD ENZYMOL, V358, P123
   Kameni APT, 2002, J BACTERIOL, V184, P452, DOI 10.1128/JB.184.2.452-458.2002
   Kamionka A, 2005, APPL ENVIRON MICROB, V71, P728, DOI 10.1128/AEM.71.2.728-733.2005
   Knee R, 1997, NEUROCHEM INT, V31, P379, DOI 10.1016/S0197-0186(96)00108-8
   Kukekova AV, 1999, BIOCHEM BIOPH RES CO, V262, P44, DOI 10.1006/bbrc.1999.1135
   Lee LK, 2003, CURR OPIN BIOTECH, V14, P505, DOI 10.1016/S0958-1669(03)00115-0
   Lutz R, 1997, NUCLEIC ACIDS RES, V25, P1203, DOI 10.1093/nar/25.6.1203
   Ma XL, 1999, J BACTERIOL, V181, P7531
   MARGOLIN W, 1991, J BACTERIOL, V173, P5822, DOI 10.1128/jb.173.18.5822-5830.1991
   Mirochnitchenko O, 2000, METHOD ENZYMOL, V313, P467
   Momynaliev KT, 2002, BIOCHEM BIOPH RES CO, V293, P155, DOI 10.1016/S0006-291X(02)00184-5
   MUKHERJEE A, 1993, P NATL ACAD SCI USA, V90, P1053, DOI 10.1073/pnas.90.3.1053
   Nagahashi S, 1998, J BACTERIOL, V180, P5020
   Nogales E, 1998, NAT STRUCT BIOL, V5, P451, DOI 10.1038/nsb0698-451
   Ohashi Y, 1999, J BACTERIOL, V181, P1348
   OLD IG, 1992, FEMS MICROBIOL LETT, V99, P245, DOI 10.1111/j.1574-6968.1992.tb05575.x
   Ostberg Y, 2004, J BACTERIOL, V186, P8472, DOI 10.1128/JB.186.24.8472-8477.2004
   Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45
   Qian F, 2002, INFECT IMMUN, V70, P2029, DOI 10.1128/IAI.70.4.2029-2038.2002
   Rosa PA, 2005, NAT REV MICROBIOL, V3, P129, DOI 10.1038/nrmicro1068
   Sambrook J, 2001, MOL CLONING LAB MANU
   Schwedock J, 1997, MOL MICROBIOL, V25, P847, DOI 10.1111/j.1365-2958.1997.mmi507.x
   Shevchuk NA, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh014
   Shin JJ, 2004, INFECT IMMUN, V72, P2280, DOI 10.1128/IAI.72.4.2280-2287.2004
   Stieger M, 1999, GENE, V226, P243, DOI 10.1016/S0378-1119(98)00561-7
   Sun Q, 2004, J BACTERIOL, V186, P3951, DOI 10.1128/JB.186.12.3951-3959.2004
   TRIEUCUOT P, 1991, GENE, V106, P21, DOI 10.1016/0378-1119(91)90561-O
   Urlinger S, 2000, P NATL ACAD SCI USA, V97, P7963, DOI 10.1073/pnas.130192197
   Wang Y, 2001, MOL MICROBIOL, V40, P347, DOI 10.1046/j.1365-2958.2001.02395.x
   WARD JE, 1985, CELL, V42, P941, DOI 10.1016/0092-8674(85)90290-9
   Weiss DS, 2004, MOL MICROBIOL, V54, P588, DOI 10.1111/j.1365-2958.2004.04283.x
   Zhang L, 2000, GENE, V255, P297, DOI 10.1016/S0378-1119(00)00325-5
   Zhao Y, 2004, DNA CELL BIOL, V23, P127, DOI 10.1089/104454904322759948
NR 59
TC 10
Z9 11
U1 3
U2 12
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0021-9193
EI 1098-5530
J9 J BACTERIOL
JI J. Bacteriol.
PD MAR
PY 2006
VL 188
IS 5
BP 1969
EP 1978
DI 10.1128/JB.188.5.1969-1978.2006
PG 10
WC Microbiology
SC Microbiology
GA 019EU
UT WOS:000235819200032
PM 16484209
OA Bronze, Green Published
DA 2018-12-27
ER

PT J
AU Nakajima, A
   Ueda, K
   Takaoka, M
   Yoshimi, Y
   Matsumura, Y
AF Nakajima, A
   Ueda, K
   Takaoka, M
   Yoshimi, Y
   Matsumura, Y
TI RETRACTED: Opposite effects of pre- and postischemic treatments with
   nitric oxide donor on ischemia/reperfusion-induced renal injury
   (Retracted article. See vol. 349, pg. 345, 2014)
SO JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
LA English
DT Article; Retracted Publication
ID ISCHEMIA-REPERFUSION INJURY; SPONTANEOUS NO RELEASER; L-ARGININE;
   PEROXYNITRITE FORMATION; TYROSINE NITRATION; RELAXING FACTOR; FAILURE;
   RATS; FK409; INHIBITION
AB We have demonstrated previously that preischemic treatment with FK409 [(+/-)-( E)-4-ethyl-2-[(E)-hydroxyimino]-5-nitro-3-hexenamide], a spontaneous nitric oxide ( NO) donor, markedly improves ischemia/reperfusion-induced renal injury. However, there is conflicting information (renoprotective or cytotoxic) as to the contribution of NO to ischemic acute renal failure (ARF). In the present study, we investigated the effect of postischemic treatment with FK409 ( 1, 3, and 10 mg/kg i.v.) at 6 h after reperfusion on ischemic ARF, in comparison with the preischemic treatment effect. Ischemic ARF was induced by clamping of the left renal artery and vein for 45 min, followed by reperfusion, 2 weeks after contralateral nephrectomy. Renal function in ARF rats markedly decreased at 24 h after reperfusion. Histopathological examination of the kidney of ARF rats revealed severe renal damage. In contrast to the renoprotective effect by preischemic treatment, postischemic treatment with FK409 aggravated the ischemia/reperfusion-induced renal dysfunction and histological damage. Immunohistochemical analysis of renal sections obtained from ARF rats revealed positive staining for nitrotyrosine, a biomarker of peroxynitrite formation, in injured tubular cells, and more intense staining was observed in renal tissues from the animals that received postischemic treatment with FK409. On the other hand, the formation of nitrotyrosine, neutrophil infiltration into renal tissues, and renal superoxide production, all of which were enhanced in ARF rats, were efficiently attenuated by the preischemic treatment with FK409. These results demonstrate that, although preischemic treatment with an NO donor is renoprotective, postischemic treatment with the same agent aggravates the ischemia/reperfusion-induced renal injury, probably through peroxynitrite overproduction.
C1 Osaka Univ Pharmaceut Sci, Dept Pharmacol, Takatsuki, Osaka 5691094, Japan.
RP Matsumura, Y (reprint author), Osaka Univ Pharmaceut Sci, Dept Pharmacol, 4-20-1 Nasahara, Takatsuki, Osaka 5691094, Japan.
EM matumrh@gly.oups.ac.jp
CR ASHAB I, 1995, KIDNEY INT, V47, P1515, DOI 10.1038/ki.1995.214
   Beckman JS, 1996, CHEM RES TOXICOL, V9, P836, DOI 10.1021/tx9501445
   Caramelo C, 1996, CIRC RES, V79, P1031, DOI 10.1161/01.RES.79.5.1031
   Chatterjee PK, 2003, KIDNEY INT, V63, P853, DOI 10.1046/j.1523-1755.2003.00802.x
   Chatterjee PK, 2002, KIDNEY INT, V61, P862, DOI 10.1046/j.1523-1755.2002.00234.x
   Chiao H, 1997, J CLIN INVEST, V99, P1165, DOI 10.1172/JCI119272
   CHINTALA MS, 1993, N-S ARCH PHARMACOL, V348, P305
   CLANCY RM, 1992, J CLIN INVEST, V90, P1116, DOI 10.1172/JCI115929
   CONGER JD, 1988, J CLIN INVEST, V82, P532, DOI 10.1172/JCI113628
   CONGER JD, 1991, KIDNEY INT, V39, P1087, DOI 10.1038/ki.1991.138
   CROW JP, 1996, BIOL REACT INTERMED, V5, P147
   Edelstein CL, 1997, KIDNEY INT, V51, P1341, DOI 10.1038/ki.1997.183
   Fujii T, 2003, EUR J PHARMACOL, V481, P241, DOI 10.1016/j.ejphar.2003.09.036
   Goligorsky MS, 1999, SEMIN NEPHROL, V19, P263
   Kelly KJ, 2000, SEMIN NEPHROL, V20, P4
   KITA Y, 1994, BRIT J PHARMACOL, V113, P385, DOI 10.1111/j.1476-5381.1994.tb17000.x
   KITA Y, 1994, BRIT J PHARMACOL, V113, P1137, DOI 10.1111/j.1476-5381.1994.tb17115.x
   KITA Y, 1994, EUR J PHARMACOL, V257, P123, DOI 10.1016/0014-2999(94)90703-X
   KNOWLES RG, 1994, BIOCHEM J, V298, P249, DOI 10.1042/bj2980249
   Kone BC, 1997, AM J PHYSIOL-RENAL, V272, pF561
   Kooy NW, 1997, CRIT CARE MED, V25, P812, DOI 10.1097/00003246-199705000-00017
   KUBES P, 1991, P NATL ACAD SCI USA, V88, P4651, DOI 10.1073/pnas.88.11.4651
   Kurata H, 2004, J CARDIOVASC PHARM, V44, pS455, DOI 10.1097/01.fjc.0000166314.38258.a8
   Lieberthal W, 1996, AM J PHYSIOL-RENAL, V271, pF477
   Linas S, 1997, AM J PHYSIOL-RENAL, V272, pF48
   LINAS SL, 1988, AM J PHYSIOL, V255, pF728
   LINAS SL, 1992, KIDNEY INT, V42, P610, DOI 10.1038/ki.1992.325
   Ling H, 1999, AM J PHYSIOL-RENAL, V277, pF383, DOI 10.1152/ajprenal.1999.277.3.F383
   Liu PT, 1997, AM J PHYSIOL-HEART C, V272, pH2327
   MAJID DSA, 2007, AM J HYPERTENS, V14, pS74
   Matsumura H, 1998, J PHARMACOL EXP THER, V287, P1084
   Matsumura Y, 2000, JPN J PHARMACOL, V84, P16, DOI 10.1254/jjp.84.16
   MOLONEY WC, 1960, J HISTOCHEM CYTOCHEM, V8, P200, DOI 10.1177/8.3.200
   PRYOR WA, 1995, AM J PHYSIOL-LUNG C, V268, pL699
   RABB H, 1994, AM J PHYSIOL-RENAL, V267, pF1052
   Radi R, 2001, FREE RADICAL BIO MED, V30, P463, DOI 10.1016/S0891-5849(00)00373-7
   Schneider R, 2003, KIDNEY INT, V64, P216, DOI 10.1046/j.1523-1755.2003.00063.x
   SCHRAMM L, 1994, RENAL FAILURE, V16, P555, DOI 10.3109/08860229409044885
   Schwartz D, 1997, J CLIN INVEST, V100, P439, DOI 10.1172/JCI119551
   Skatchkov MP, 1999, BIOCHEM BIOPH RES CO, V254, P319, DOI 10.1006/bbrc.1998.9942
   SOLEZ K, 1974, KIDNEY INT, V6, P24, DOI 10.1038/ki.1974.74
   Thadhani R, 1996, NEW ENGL J MED, V334, P1448, DOI 10.1056/NEJM199605303342207
   Walker LM, 2000, J PHARMACOL EXP THER, V295, P417
   Wilhelm SM, 1999, KIDNEY INT, V55, P1011, DOI 10.1046/j.1523-1755.1999.0550031011.x
   YAMADA H, 1991, BRIT J PHARMACOL, V103, P1713, DOI 10.1111/j.1476-5381.1991.tb09852.x
   Yamasowa H, 2005, J PHARMACOL EXP THER, V312, P153, DOI 10.1124/jpet.104.074427
   Zhang CJ, 2000, BIOCHEM PHARMACOL, V59, P203, DOI 10.1016/S0006-2952(99)00324-X
NR 47
TC 26
Z9 26
U1 3
U2 10
PU AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3995 USA
SN 0022-3565
EI 1521-0103
J9 J PHARMACOL EXP THER
JI J. Pharmacol. Exp. Ther.
PD MAR
PY 2006
VL 316
IS 3
BP 1038
EP 1046
DI 10.1124/jpet.105.092049
PG 9
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 014JM
UT WOS:000235476000009
PM 16306274
OA Bronze
DA 2018-12-27
ER

PT J
AU Zhao, FY
   Wang, ZL
   Zhang, Q
   Zhao, YX
   Zhang, H
AF Zhao, FY
   Wang, ZL
   Zhang, Q
   Zhao, YX
   Zhang, H
TI RETRACTED: Analysis of the physiological mechanism of salt-tolerant
   transgenic rice carrying a vacuolar Na+/H+ antiporter gene from Suaeda
   salsa (Retracted article. See vol. 122, pg. 351, 2009)
SO JOURNAL OF PLANT RESEARCH
LA English
DT Article; Retracted Publication
DE Na+/H+ antiporter; salt tolerance; SsNHX1; Suaeda salsa; transgenic rice
ID H+-ATPASE ACTIVITY; OSMOTIC-STRESS; PLANTS; ARABIDOPSIS; TRANSPORTERS;
   EXPRESSION; OVEREXPRESSION; ENERGIZATION; ACCUMULATION; FAMILIES
AB Salt stress is one of the most serious factors limiting the productivity of agricultural crops. Increasing evidence has demonstrated that vacuolar Na+/H+ antiporters play a crucial role in plant salt tolerance. In the present study, we expressed the Suaeda salsa Vacuolar Na+/H+ antiporter SsNHX1 in transgenic rice to investigate whether this can increase the salt tolerance of rice, and to study how overexpression of this gene affected other salt-tolerant mechanisms. It was found that transgenic rice plants showed markedly enhanced tolerance to salt stress and to water deprivation compared with non-transgenic controls upon salt stress imposition under outdoor conditions. Measurements of ion levels indicated that K+, Ca2+ and Mg2+ contents were all higher in transgenic plants than in non-transformed controls. Furthermore, shoot V-ATPase hydrolytic activity was dramatically increased in transgenics compared to that of non-transformed controls under salt stress conditions. Physiological analysis also showed that the photosynthetic activity of the transformed plants was higher whereas the same plants had reduced reactive oxygen species generation. In addition, the soluble sugar content increased in the transgenics compared with that in non-transgenics. These results imply that up-regulation of a vacuolar Na+/H+ antiporter gene in transgenic rice might cause pleiotropic up-regulation of other salt-resistance-related mechanisms to improve salt tolerance.
C1 Shandong Normal Univ, Life Sci Coll, Key Lab Plant Stress, Jinan 250014, Shandong Prov, Peoples R China.
   Shandong Sci & Engn Univ, Life Sci Coll, Zibo 255049, Shandong Prov, Peoples R China.
RP Zhang, H (reprint author), Shandong Normal Univ, Life Sci Coll, Key Lab Plant Stress, Wenhua E Rd 88, Jinan 250014, Shandong Prov, Peoples R China.
EM Zhangh@sdnu.ecu.cn
CR Apse MP, 1999, SCIENCE, V285, P1256, DOI 10.1126/science.285.5431.1256
   BARKLA BJ, 1995, PLANT PHYSIOL, V109, P549, DOI 10.1104/pp.109.2.549
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
   Fairbairn N J, 1953, CHEMISTRY INDUSTRY, V4, P86
   Fukuda A, 2004, PLANT CELL PHYSIOL, V45, P146, DOI 10.1093/pcp/pch014
   Gao XH, 2003, PLANT PHYSIOL, V133, P1873, DOI 10.1104/pp.103.026062
   Gaxiola RA, 2002, PLANT PHYSIOL, V129, P967, DOI 10.1104/pp.020009
   GREENWAY H, 1980, ANNU REV PLANT PHYS, V31, P149, DOI 10.1146/annurev.pp.31.060180.001053
   Han N, 2005, J PLANT PHYSIOL, V162, P267, DOI 10.1016/j.jplph.2004.07.016
   HEATH RL, 1968, ARCH BIOCHEM BIOPHYS, V125, P189, DOI 10.1016/0003-9861(68)90654-1
   Hong ZL, 2000, PLANT PHYSIOL, V122, P1129, DOI 10.1104/pp.122.4.1129
   Horie T, 2004, PLANT PHYSIOL, V136, P2457, DOI 10.1104/pp.104.046664
   Hu YC, 2000, AUST J PLANT PHYSIOL, V27, P363, DOI 10.1071/PP99147
   Jang IC, 1999, MOL BREEDING, V5, P453, DOI 10.1023/A:1009665314850
   Liu Qiao-Quan, 1998, Acta Phytophysiologica Sinica, V24, P259
   Ma XL, 2004, BIOL PLANTARUM, V48, P219, DOI 10.1023/B:BIOP.0000033448.96998.44
   Maathuis FJM, 1999, ANN BOT-LONDON, V84, P123, DOI 10.1006/anbo.1999.0912
   Maathuis FJM, 2003, PLANT J, V35, P675, DOI 10.1046/j.1365-313X.2003.01839.x
   Maser P, 2001, PLANT PHYSIOL, V126, P1646, DOI 10.1104/pp.126.4.1646
   Mittova V, 2004, J EXP BOT, V55, P1105, DOI 10.1093/jxb/erh113
   MURASHIGE T, 1962, PHYSIOL PLANTARUM, V15, P473, DOI 10.1111/j.1399-3054.1962.tb08052.x
   NIU XM, 1995, PLANT PHYSIOL, V109, P735, DOI 10.1104/pp.109.3.735
   Ohta M, 2002, FEBS LETT, V532, P279, DOI 10.1016/S0014-5793(02)03679-7
   Parks GE, 2002, J EXP BOT, V53, P1055, DOI 10.1093/jexbot/53.371.1055
   Qiu NW, 2003, NEW PHYTOL, V159, P479, DOI 10.1046/j.1469-8137.2003.00825.x
   Qiu QS, 2004, J BIOL CHEM, V279, P207, DOI 10.1074/jbc.M307982200
   Shaul O, 2002, BIOMETALS, V15, P309
   Sze H, 1999, PLANT CELL, V11, P677, DOI 10.1105/tpc.11.4.677
   Talarczyk A, 2002, PLANT PHYSIOL, V129, P1032, DOI 10.1104/pp.010960
   Tester M, 2003, ANN BOT-LONDON, V91, P503, DOI 10.1093/aob/mcg058
   Wang BS, 2001, J EXP BOT, V52, P2355, DOI 10.1093/jexbot/52.365.2355
   Xue ZY, 2004, PLANT SCI, V167, P849, DOI 10.1016/j.plantsci.2004.05.034
   Yan F, 2002, PLANT PHYSIOL, V129, P50, DOI 10.1104/pp.010869
   Zhang HX, 2001, NAT BIOTECHNOL, V19, P765, DOI 10.1038/90824
   Zhang HX, 2001, P NATL ACAD SCI USA, V98, P12832, DOI 10.1073/pnas.231476498
NR 35
TC 28
Z9 46
U1 4
U2 18
PU SPRINGER JAPAN KK
PI TOKYO
PA CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065,
   JAPAN
SN 0918-9440
EI 1618-0860
J9 J PLANT RES
JI J. Plant Res.
PD MAR
PY 2006
VL 119
IS 2
BP 95
EP 104
DI 10.1007/s10265-005-0250-2
PG 10
WC Plant Sciences
SC Plant Sciences
GA 026MM
UT WOS:000236343000003
PM 16565882
DA 2018-12-27
ER

PT J
AU Hui, EKW
   Barman, S
   Tang, DHP
   France, B
   Nayak, DP
AF Hui, EKW
   Barman, S
   Tang, DHP
   France, B
   Nayak, DP
TI RETRACTED: YRKL sequence of influenza virus M1 functions as the L domain
   motif and interacts with VPS28 and Cdc42 (Retracted article. See vol 80
   pg 10289 2006)
SO JOURNAL OF VIROLOGY
LA English
DT Article; Retracted Publication
ID INFECTIOUS-ANEMIA VIRUS; LATE ASSEMBLY DOMAIN; ROUS-SARCOMA-VIRUS;
   MATRIX PROTEIN M1; LATE-BUDDING DOMAINS; A VIRUS; PARTICLE RELEASE; CELL
   POLARITY; CRYSTAL-STRUCTURE; TERMINAL DOMAIN
AB Earlier studies have shown that the C-terminal half of helix 6 (116) of the influenza A virus matrix protein (M1) containing the YRKL sequence is involved in virus budding (E. K.-W. Hui, S. Barman, T. Y. Yang, and D. P. Nayak, J. Virol. 77:7078-7092, 2003). In this report, we show that the YRKL sequence is the L domain motif of influenza virus. Like other L domains, YRKL can be inserted at different locations on the mutant M1 protein and can restore virus budding in a position-independent manner. Although YRKL is a part of the nuclear localization signal (NLS), the function of YRKL was independent of the NLS activity and the NLS function of M1 was not required for influenza virus replication. Some mutations in YRKL and the adjacent region caused a reduction in the virus titer by blocking virus release, and some affected virus morphology, producing elongated particles. Coimmunoprecipitation and Western blotting analyses showed that VPS28, a component of the ESCRT-I complex, and Cdc42, a member of the Rho family GTP-binding proteins, interacted with the M1 protein via the YRKL motif. In addition, depletion of VPS28 and Cdc42 by small interfering RNA resulted in reduction of influenza virus production. Moreover, overexpression of dominant-negative Cdc42 inhibited influenza virus replication, whereas a constitutively active Cdc42 mutant enhanced virus production in infected cells. These results indicated that VPS28, a component of ESCRT-I, and Cdc42, a small G protein, are associated with the M1 protein and involved in the influenza virus life cycle.
C1 Univ Calif Los Angeles, David Geffen Sch Med, Inst Mol Biol,Dept Microbiol Immunol & Mol Genet, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA.
RP Nayak, DP (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Inst Mol Biol,Dept Microbiol Immunol & Mol Genet, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA.
EM dnayak@ucla.edu
FU NIAID NIH HHS [R01 AI041681, R01 AI41681, R01 AI016348, R01 AI16348]
CR Accola MA, 2000, J VIROL, V74, P5395, DOI 10.1128/JVI.74.12.5395-5402.2000
   Akarsu H, 2003, EMBO J, V22, P4646, DOI 10.1093/emboj/cdg449
   Amara A, 2003, J CELL BIOL, V162, P371, DOI 10.1083/jcb.200307062
   Arzt S, 2001, VIROLOGY, V279, P439, DOI 10.1006/viro.2000.0727
   Aspenstrom P, 1999, EXP CELL RES, V246, P20, DOI 10.1006/excr.1998.4300
   Avalos RT, 1997, J VIROL, V71, P2947
   Babst M, 2000, TRAFFIC, V1, P248, DOI 10.1034/j.1600-0854.2000.010307.x
   Barman S, 2004, J VIROL, V78, P5258, DOI 10.1128/JVI.78.10.5258-5239.2004
   Barman S, 2003, VIROLOGY, V305, P138, DOI 10.1006/viro.2002.1731
   Baudin F, 2001, VIROLOGY, V281, P102, DOI 10.1006/viro.2000.0804
   Bishop N, 2001, J BIOL CHEM, V276, P11735, DOI 10.1074/jbc.M009863200
   Blot V, 2004, J CELL SCI, V117, P2357, DOI 10.1242/jcs.01095
   Bouamr F, 2003, J VIROL, V77, P11882, DOI 10.1128/JVI.77.22.11882-11895.2003
   Bourmakina SV, 2005, J VIROL, V79, P7926, DOI 10.1128/JVI.79.12.7926-7932.2005
   Burleigh LM, 2005, J VIROL, V79, P1262, DOI 10.1128/JVI.79.2.12162-1270.2005
   Clague MJ, 2003, TRENDS CELL BIOL, V13, P603, DOI 10.1016/j.tcb.2003.10.002
   Craven RC, 1999, J VIROL, V73, P3359
   Demirov DG, 2004, VIRUS RES, V106, P87, DOI 10.1016/j.virusres.2004.08.007
   Demirov DG, 2002, J VIROL, V76, P105, DOI 10.1128/JVI.76.1.105-117.2002
   Erickson JW, 2001, CURR OPIN CELL BIOL, V13, P153, DOI 10.1016/S0955-0674(00)00192-7
   Etienne-Manneville S, 2001, CELL, V106, P489, DOI 10.1016/S0092-8674(01)00471-8
   Freed EO, 2004, TRENDS MICROBIOL, V12, P170, DOI 10.1016/j.tim.2004.02.001
   Freed EO, 2003, TRENDS MICROBIOL, V11, P56, DOI 10.1016/S0966-842X(02)00013-6
   Freed EO, 2002, J VIROL, V76, P4679, DOI 10.1128/JVI.76.10.4679-4687.2002
   Garrett L C, 2000, J Public Health Manag Pract, V6, P1
   Gomez-Puertas P, 2000, J VIROL, V74, P11538, DOI 10.1128/JVI.74.24.11538-11547.2000
   GOTTLINGER HG, 1991, P NATL ACAD SCI USA, V88, P3195, DOI 10.1073/pnas.88.8.3195
   Gottwein E, 2003, J VIROL, V77, P9474, DOI 10.1128/JVI.77.17.9474-9485.2003
   Harris A, 1999, J GEN VIROL, V80, P863, DOI 10.1099/0022-1317-80-4-863
   Harris A, 2001, VIROLOGY, V289, P34, DOI 10.1006/viro.2001.1119
   Heidecker G, 2004, J VIROL, V78, P6636, DOI 10.1128/JVI.78.12.6636-6648.2004
   HUANG MJ, 1995, J VIROL, V69, P6810
   Huang XY, 2001, VIROLOGY, V287, P405, DOI 10.1006/viro.2001.1067
   Hui EKW, 2004, J GEN VIROL, V85, P1877, DOI 10.1099/vir.0.79906-0
   Hui EKW, 2003, J VIROL, V77, P7078, DOI 10.1128/JVI.77.12.7078-7092.2003
   HUI EKW, 1992, EXP HEMATOL, V20, P454
   Hui EKW, 2003, J GEN VIROL, V84, P3105, DOI 10.1099/vir.0.19389-0
   Hui EKW, 2002, J GEN VIROL, V83, P3055, DOI 10.1099/0022-1317-83-12-3055
   Hui EKW, 2001, VIROLOGY, V290, P329, DOI 10.1006/viro.2001.1181
   Irie T, 2005, VIROLOGY, V336, P291, DOI 10.1016/j.virol.2005.03.027
   Irie T, 2004, J VIROL, V78, P2657, DOI 10.1128/JVI.78.6.2657-2665.2004
   Jasenosky LD, 2004, VIRUS RES, V106, P181, DOI 10.1016/j.virusres.2004.08.014
   Jayakar HR, 2004, VIRUS RES, V106, P117, DOI 10.1016/j.virusres.2004.08.009
   JOHNSON DI, 1990, J CELL BIOL, V111, P143, DOI 10.1083/jcb.111.1.143
   Johnson DI, 1999, MICROBIOL MOL BIOL R, V63, P54
   Katzmann DJ, 2001, CELL, V106, P145, DOI 10.1016/S0092-8674(01)00434-2
   KOZMA R, 1995, MOL CELL BIOL, V15, P1942
   Lamb R. A., 2001, Fundamental virology, P725
   Latham T, 2001, J VIROL, V75, P6154, DOI 10.1128/JVI.75.13.6154-6165.2001
   Li F, 2002, J VIROL, V76, P1569, DOI 10.1128/JVI.76.4.1569-1577.2002
   Licata JM, 2003, J VIROL, V77, P1812, DOI 10.1128/JVI.77.3.1812-1819.2003
   Liu T, 2002, J VIROL, V76, P13055, DOI 10.1128/JVI.76.24.13055-13061.2002
   Martin-Serrano J, 2004, J VIROL, V78, P5554, DOI 10.1128/JVI.78.11.5554-5563.2004
   Martin-Serrano J, 2003, J VIROL, V77, P12373, DOI 10.1128/JVI.77.22.12373-12377.2003
   Martin-Serrano J, 2003, P NATL ACAD SCI USA, V100, P12414, DOI 10.1073/pnas.2133846100
   Martin-Serrano J, 2001, NAT MED, V7, P1313, DOI 10.1038/nm1201-1313
   Miletic AV, 2003, CURR OPIN IMMUNOL, V15, P261, DOI 10.1016/S0952-7915(03)00054-2
   Nayak DP, 2004, VIRUS RES, V106, P147, DOI 10.1016/j.virusres.2004.08.012
   Ott DE, 2005, J VIROL, V79, P9038, DOI 10.1128/JVI.79.14.9038-9045.2005
   Ott DE, 2002, J VIROL, V76, P3038, DOI 10.1128/JVI.76.6.3038-3044.2002
   PARENT LJ, 1995, J VIROL, V69, P5455
   Patnaik A, 2002, J VIROL, V76, P2789, DOI 10.1128/JVI.76.6.2789-2795.2002
   Patnaik A, 2002, J VIROL, V76, P2641, DOI 10.1128/JVI.76.6.2641-2647.2002
   Patton GS, 2005, J VIROL, V79, P6392, DOI 10.1128/JVI.79.10.6392-6399.2005
   Perez DR, 1998, VIROLOGY, V249, P52, DOI 10.1006/viro.1998.9318
   Pornillos O, 2002, TRENDS CELL BIOL, V12, P569, DOI 10.1016/S0962-8924(02)02402-9
   Puffer BA, 1998, J VIROL, V72, P10218
   Puffer BA, 1997, J VIROL, V71, P6541
   Roberts PC, 1998, P NATL ACAD SCI USA, V95, P5746, DOI 10.1073/pnas.95.10.5746
   Roberts PC, 1998, VIROLOGY, V240, P127, DOI 10.1006/viro.1997.8916
   RODRIGUEZBOULAN E, 1978, P NATL ACAD SCI USA, V75, P5071, DOI 10.1073/pnas.75.10.5071
   Ruigrok RWH, 2000, VIROLOGY, V267, P289, DOI 10.1006/viro.1999.0134
   Schmitt AP, 2005, ADV VIRUS RES, V64, P383, DOI 10.1016/S0065-3527(05)64012-2
   Schmitt AP, 2005, J VIROL, V79, P2988, DOI 10.1128/JVI.79.5.2988-2997.2005
   Seo MR, 2004, J BIOL CHEM, V279, P17366, DOI 10.1074/jbc.M312442200
   Sha BD, 1997, NAT STRUCT BIOL, V4, P239, DOI 10.1038/nsb0397-239
   Shehu-Xhilaga M, 2004, J VIROL, V78, P724, DOI 10.1128/JVI.78.2.724-732.2004
   Shishkov AV, 1999, P NATL ACAD SCI USA, V96, P7827, DOI 10.1073/pnas.96.14.7827
   Spidel JL, 2004, J VIROL, V78, P10606, DOI 10.1128/JVI.78.19.10606-10616.2004
   Stange A, 2005, J VIROL, V79, P5466, DOI 10.1128/JVI.79.9.5466-5476.2005
   Strack B, 2003, CELL, V114, P689, DOI 10.1016/S0092-8674(03)00653-6
   Strecker T, 2003, J VIROL, V77, P10700, DOI 10.1128/JVI.77.19.10700-10705.2003
   Tanzi GO, 2003, J VIROL, V77, P8440, DOI 10.1128/JVI.77.15.8440-8447.2003
   Timmins J, 2004, FEMS MICROBIOL LETT, V233, P179, DOI 10.1016/j.femsle.2004.03.002
   von Schwedler UK, 2003, CELL, V114, P701, DOI 10.1016/S0092-8674(03)00714-1
   Wang HT, 2004, J VIROL, V78, P1503, DOI 10.1128/JVI.78.3.1503-1512.2004
   Watanabe K, 1996, J VIROL, V70, P241
   WILLS JW, 1994, J VIROL, V68, P6605
   Xiang Y, 1996, J VIROL, V70, P5695
   Yasuda J, 2003, J VIROL, V77, P9987, DOI 10.1128/JVI.77.18.9987-9992.2003
   Ye ZP, 1999, J VIROL, V73, P7467
   YE ZP, 1989, J VIROL, V63, P3586
   YE ZP, 1995, J VIROL, V69, P1964
   Yuan B, 2000, J VIROL, V74, P7250, DOI 10.1128/JVI.74.16.7250-7260.2000
NR 94
TC 22
Z9 23
U1 4
U2 10
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
EI 1098-5514
J9 J VIROL
JI J. Virol.
PD MAR
PY 2006
VL 80
IS 5
BP 2291
EP 2308
DI 10.1128/JVI.80.5.2291-2308.2006
PG 18
WC Virology
SC Virology
GA 013CY
UT WOS:000235388400022
PM 16474136
OA Green Published, Bronze
DA 2018-12-27
ER

PT J
AU Tomita, M
   Kawakami, H
   Uchihara, JN
   Okudaira, T
   Masuda, M
   Takasu, N
   Matsuda, T
   Ohta, T
   Tanaka, Y
   Mori, N
AF Tomita, M
   Kawakami, H
   Uchihara, JN
   Okudaira, T
   Masuda, M
   Takasu, N
   Matsuda, T
   Ohta, T
   Tanaka, Y
   Mori, N
TI RETRACTED: Curcumin suppresses constitutive activation of AP-1 by
   downregulation of JunD protein in HTLV-1-infected T-cell lines
   (Retracted article. See vol. 36, pg. 661, 2012)
SO LEUKEMIA RESEARCH
LA English
DT Article; Retracted Publication
DE curcumin; AP-1; ATL; HTLV-1; JunD; cell cycle; apoptosis
ID VIRUS TYPE-I; NF-KAPPA-B; HTLV-I; LEUKEMIA-LYMPHOMA; TUMOR PROMOTION;
   TAX GENE; TRANSCRIPTION; EXPRESSION; TYPE-1; FOS
AB Activation of the activator protein 1 (AP-1) plays a critical role in oncogenesis by human T-cell leukemia virus type 1 (HTLV-1), the etiologic agent of adult T-cell leukemia (ATL), and is required for maintenance of the malignant phenotype. Curcumin (diferuloylmethane), the major pigment of the spice turmeric, has anti-tumor activity; however, the effect of curcumin against ATL has not been elucidated. In this study, we examined the effects of curcumin on AP-1 activity in HTLV-1-infected T-cell lines. Curcumin suppressed the constitutive AP-1 DNA-binding and transcriptional activity in HTLV-1-infected T-cell line. Curcumin also inhibited HTLV-1 Tax-induced AP-1 transcriptional activity. JunD was detectable as a major component of the AP--DNA complex in HTLV-1-infected T-cell lines using the supershift assay. The expression of JunD was suppressed by curcumin treatment. Curcumin inhibited the growth of HTLV-1-infected T-cell lines by inducing cell cycle arrest followed by apoptosis. Our results suggest that suppression of the constitutively active AP-1 by curcumin is due to, at least in-part, reducing the expression of JunD by curcumin. Inhibition of AP-1 activity by curcumin may be one of the mechanisms responsible for the anti-ATL effect of curcumin. We propose that curcumin is a potentially promising compound for the treatment of ATL. (c) 2005 Elsevier Ltd. All rights reserved.
C1 Univ Ryukyus, Div Mol Virol & Oncol, Grad Sch Med, Nishihara, Okinawa 9030215, Japan.
   Univ Ryukyus, Fac Med, Div Endocrinol & Metab, Nishihara, Okinawa 9030215, Japan.
   Univ Ryukyus, Fac Med, Div Child Hlth & Welf, Nishihara, Okinawa 9030215, Japan.
   Univ Ryukyus, Fac Med, Div Immunol, Nishihara, Okinawa 9030215, Japan.
RP Mori, N (reprint author), Univ Ryukyus, Div Mol Virol & Oncol, Grad Sch Med, 207 Uehara, Nishihara, Okinawa 9030215, Japan.
EM n-mori@med.u-ryukyu.ac.jp
CR AMMON HPT, 1991, PLANTA MED, V57, P1, DOI 10.1055/s-2006-960004
   Chen YR, 1998, ONCOGENE, V17, P173, DOI 10.1038/sj.onc.1201941
   Chinenov Y, 2001, ONCOGENE, V20, P2438, DOI 10.1038/sj.onc.1204385
   CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4
   FUJII M, 1988, P NATL ACAD SCI USA, V85, P8526, DOI 10.1073/pnas.85.22.8526
   FUJII M, 1991, ONCOGENE, V6, P1023
   GRASSMANN R, 1989, P NATL ACAD SCI USA, V86, P3351, DOI 10.1073/pnas.86.9.3351
   GROSSMAN WJ, 1995, P NATL ACAD SCI USA, V92, P1057, DOI 10.1073/pnas.92.4.1057
   HINUMA Y, 1981, P NATL ACAD SCI-BIOL, V78, P6476, DOI 10.1073/pnas.78.10.6476
   Huang MT, 1997, CARCINOGENESIS, V18, P83, DOI 10.1093/carcin/18.1.83
   HUANG TS, 1991, P NATL ACAD SCI USA, V88, P5292, DOI 10.1073/pnas.88.12.5292
   Ishiyama M, 1996, BIOL PHARM BULL, V19, P1518
   Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3
   KOVARY K, 1991, MOL CELL BIOL, V11, P2451, DOI 10.1128/MCB.11.5.2451
   MAEDA M, 1985, J EXP MED, V162, P2169, DOI 10.1084/jem.162.6.2169
   Matsumoto K, 1997, J VIROL, V71, P4445
   MIGONE TS, 1995, SCIENCE, V269, P79, DOI 10.1126/science.7604283
   MIYOSHI I, 1980, GANN, V71, P155
   MIYOSHI I, 1981, NATURE, V294, P770, DOI 10.1038/294770a0
   Mori N, 1998, CANCER RES, V58, P3993
   Mori N, 1999, BLOOD, V93, P2360
   Mori N, 2000, BLOOD, V95, P3915
   NERENBERG M, 1987, SCIENCE, V237, P1324, DOI 10.1126/science.2888190
   OHTANI K, 1987, EMBO J, V6, P389, DOI 10.1002/j.1460-2075.1987.tb04767.x
   PFARR CM, 1994, CELL, V76, P747, DOI 10.1016/0092-8674(94)90513-4
   POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415
   Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131
   Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984
   SINGH S, 1995, J BIOL CHEM, V270, P24995, DOI 10.1074/jbc.270.42.24995
   TAJIMA K, 1990, INT J CANCER, V45, P237, DOI 10.1002/ijc.2910450206
   TANAKA A, 1990, P NATL ACAD SCI USA, V87, P1071, DOI 10.1073/pnas.87.3.1071
   TANAKA Y, 1990, JPN J CANCER RES, V81, P225, DOI 10.1111/j.1349-7006.1990.tb02554.x
   TSUCHIYA H, 1993, J VIROL, V67, P7001
   UCHIJIMA M, 1994, J BIOL CHEM, V269, P14946
   Uchiyama T, 1997, ANNU REV IMMUNOL, V15, P15, DOI 10.1146/annurev.immunol.15.1.15
   Weitzman JB, 2000, MOL CELL, V6, P1109, DOI 10.1016/S1097-2765(00)00109-X
   Xu X, 1996, ONCOGENE, V13, P135
   Yamada Y, 2001, BRIT J HAEMATOL, V113, P375, DOI 10.1046/j.1365-2141.2001.02737.x
   YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031
   Yoshida M, 2001, ANNU REV IMMUNOL, V19, P475, DOI 10.1146/annurev.immunol.19.1.475
NR 40
TC 38
Z9 42
U1 3
U2 13
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0145-2126
EI 1873-5835
J9 LEUKEMIA RES
JI Leuk. Res.
PD MAR
PY 2006
VL 30
IS 3
BP 313
EP 321
DI 10.1016/j.leukres.2005.08.004
PG 9
WC Oncology; Hematology
SC Oncology; Hematology
GA 008KP
UT WOS:000235039900011
PM 16157375
DA 2018-12-27
ER

PT J
AU Demagh, K
   Chabil, H
   Turkia, H
AF Demagh, K.
   Chabil, H.
   Turkia, H.
TI RETRACTED: Period of vibrations of framed structures (Retracted article.
   See vol. 45, pg. 637, 2012)
SO MATERIALS AND STRUCTURES
LA English
DT Article; Retracted Publication
AB Approximated explicit formulae for estimating the fundamental period of vibration of frames are deduced from the free vibrations of cantilever column in which both bending and shear deformations are taken into account. They include reinforced concrete, steel and K braced frames. The proposed expressions give good results. They are compared with those obtained by SAP2000 and those presently available in different building codes and provisions: RPA99 (Algeria), EC8 (Europe) and ATC (USA). The explicit expressions have practical interest in seismic resistant design of buildings. They are employed to both equivalent static and spectrum analysis.
C1 Univ Batna, Dept Civil Engn, Charge Cours, Batna, Algeria.
RP Demagh, K (reprint author), Univ Batna, Dept Civil Engn, Charge Cours, Batna, Algeria.
CR ADELI H, 1985, CIVIL ENG PRACT DES, V4, P93
   DEGENKOLD HJ, 1970, EARTHQUAKE FORCES TA
   DEMAGH K, 2003, P 9 AR C AB DHAB UAE, P665
   Dowrick D. K., 1977, EARTHQUAKE RESISTANT
   *ENV, 1998, EC8 ENV
   HOUSNER GW, 1982, EARTHQUAKE DESIGN CR
   Rosenblueth E., 1980, DESIGN EARTHQUAKE RE
   *RPA, 1999, REGL PAR ALG
   SCHULLER W, 1977, HIGH RISE BUILDING S
   THOMPSON WT, 1981, THEORY VIBRATION APP
   Timoshenko S, 1974, VIBRATION PROBLEMS E
   TURKIA H, 2003, THESIS U CONSTANTINE
   *UN BUILD, 1988, INT C BUILD OFF
   Wiegel R. L., 1970, EARTHQUAKE ENG
NR 14
TC 1
Z9 1
U1 2
U2 9
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 1359-5997
EI 1871-6873
J9 MATER STRUCT
JI Mater. Struct.
PD MAR
PY 2006
VL 39
IS 2
BP 259
EP 267
DI 10.1617/s11527-005-9008-5
PG 9
WC Construction & Building Technology; Engineering, Civil; Materials
   Science, Multidisciplinary
SC Construction & Building Technology; Engineering; Materials Science
GA 121IJ
UT WOS:000243151000013
DA 2018-12-27
ER

PT J
AU Wang, ZC
   Pan, LM
   Luo, JB
   Wang, H
   Shi, FX
AF Wang, ZC
   Pan, LM
   Luo, JB
   Wang, H
   Shi, FX
TI RETRACTED: Role of phosphodiesterase in cyclic AMP signaling in cultured
   rat granulosa cells (Retracted article. See vol 46, pg 461, 2006)
SO REPRODUCTION NUTRITION DEVELOPMENT
LA English
DT Article; Retracted Publication
DE phosphodiesterase; cyclic AMP; granulosa cell; nitric oxide; rat
ID CAMP-SPECIFIC PHOSPHODIESTERASES; DEPENDENT PROTEIN-KINASE;
   NITRIC-OXIDE; NUCLEOTIDE PHOSPHODIESTERASES; ADENOSINE-MONOPHOSPHATE; B
   ACTIVATION; FOLLICLE; PHOSPHORYLATION; EXPRESSION; FAMILY
AB Inactivation of the cyclic nucleotide signal in granulosa cells depends on a complex array of cyclic nucleotide phosphodiesterases ( PDE). In order to examine the role of PDE in cyclic AMP ( cAMP) signaling in granulosa cells, the present study examined the expression of PDE4D proteins and regulation of cAMP-PDE activities in cultured rat granulosa cells. The results of immunoblot analyses showed that two predominant PDE4D subtypes of approximately 80 and 70 kDa appeared when immature rat granulosa cells were treated with FSH. However, these two new subtypes presumed to be PDE4D proteins were not influenced by treatments of DETA/NO, cGMP and PKB inhibitor, LY294002. Immature rat granulosa cells treated with medium alone displayed low cAMP-PDE activity throughout 48 h of culture while those treated with FSH ( 2 ng center dot mL(-1)) showed a marked increase in cAMP-PDE activity between 6 and 12 h of culture, followed by a decline. The findings from the present study indicate that the increased cAMP-PDE activity by FSH is mainly related to the changes of PDE4D protein levels. However, the inhibitory effects of NO on cAMP accumulation in rat granulosa cells are not via the increased cAMP-PDE activity.
C1 Nanjing Agr Univ, Coll Anim Sci & Technol, Lab Anim Reprod, Nanjing 210095, Peoples R China.
RP Shi, FX (reprint author), Nanjing Agr Univ, Coll Anim Sci & Technol, Lab Anim Reprod, Nanjing 210095, Peoples R China.
EM fxshi@njau.edu.cn
CR Beard MB, 2000, J BIOL CHEM, V275, P10349, DOI 10.1074/jbc.275.14.10349
   BEAVO JA, 1995, PHYSIOL REV, V75, P725
   BOLGER GB, 1994, CELL SIGNAL, V6, P851, DOI 10.1016/0898-6568(94)90018-3
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
   BREDT DS, 1994, ANNU REV BIOCHEM, V63, P175, DOI 10.1146/annurev.bi.63.070194.001135
   Coffer PJ, 1998, BIOCHEM J, V335, P1
   Crossthwaite AJ, 2004, J NEUROCHEM, V88, P1127, DOI 10.1046/j.1471-4159.2004.02257.x
   Filippa N, 1999, MOL CELL BIOL, V19, P4989
   Gonzalez-Robayna IJ, 2000, MOL ENDOCRINOL, V14, P1283, DOI 10.1210/me.14.8.1283
   Hemmings BA, 1997, SCIENCE, V275, P628, DOI 10.1126/science.275.5300.628
   Hill Elaine V., 2005, V307, P225
   IGNARRO LJ, 1991, BIOCHEM PHARMACOL, V41, P485, DOI 10.1016/0006-2952(91)90618-F
   Ishimaru RS, 2001, J ENDOCRINOL, V168, P249, DOI 10.1677/joe.0.1680249
   Jin SLC, 1999, P NATL ACAD SCI USA, V96, P11998, DOI 10.1073/pnas.96.21.11998
   KOFINAS AD, 1990, J REPROD MED, V35, P1045
   LACASA D, 1992, BIOCHIM BIOPHYS ACTA, V1136, P99, DOI 10.1016/0167-4889(92)90090-X
   LAPOLT PS, 1995, ENDOCRINOLOGY, V136, P5533, DOI 10.1210/en.136.12.5533
   Liu GT, 2005, REPROD NUTR DEV, V45, P185, DOI 10.1051/rnd:2005010
   MacKenzie SJ, 2000, J BIOL CHEM, V275, P16609, DOI 10.1074/jbc.275.22.16609
   McKenna SD, 2005, ENDOCRINOLOGY, V146, P208, DOI 10.1210/en.2004-0562
   Mei FC, 2002, J BIOL CHEM, V277, P11497, DOI 10.1074/jbc.M110856200
   MICHAELI T, 1993, J BIOL CHEM, V268, P12925
   Park JY, 2003, MOL ENDOCRINOL, V17, P1117, DOI 10.1210/me.2002-0435
   Richards JS, 2002, MOL ENDOCRINOL, V16, P580, DOI 10.1210/me.16.3.580
   Richter W, 2002, J BIOL CHEM, V277, P40212, DOI 10.1074/jbc.M203585200
   ROB JZ, 2002, BIOL REPROD, V67, P454
   Shi FangXiong, 1996, Chinese Journal of Veterinary Science, V16, P333
   Shi FangXiong, 2000, Journal of Reproduction and Development, V46, P293, DOI 10.1262/jrd.46.293
   Shi FX, 2004, BIOL REPROD, V70, P1552, DOI 10.1095/biolreprod.103.025510
   Shi FX, 1999, BIOL REPROD, V60, P78, DOI 10.1095/biolreprod60.1.78
   Soderling SH, 2000, CURR OPIN CELL BIOL, V12, P174, DOI 10.1016/S0955-0674(99)00073-3
   Thomas RE, 2002, DEV BIOL, V244, P215, DOI 10.1006/dbio.2002.0609
   THOMPSON WJ, 1971, BIOCHEMISTRY-US, V10, P311
   Tsafriri A, 1996, DEV BIOL, V178, P393, DOI 10.1006/dbio.1996.0226
   Zachow RJ, 2002, BIOL REPROD, V67, P454, DOI 10.1095/biolreprod67.2.454
NR 35
TC 1
Z9 1
U1 3
U2 14
PU EDP SCIENCES S A
PI LES ULIS CEDEX A
PA 17, AVE DU HOGGAR, PA COURTABOEUF, BP 112, F-91944 LES ULIS CEDEX A,
   FRANCE
SN 0926-5287
J9 REPROD NUTR DEV
JI Reprod. Nutr. Dev.
PD MAR-APR
PY 2006
VL 46
IS 2
BP 179
EP 187
DI 10.1051/rnd:2006004
PG 9
WC Developmental Biology; Nutrition & Dietetics; Reproductive Biology;
   Zoology
SC Developmental Biology; Nutrition & Dietetics; Reproductive Biology;
   Zoology
GA 029ZA
UT WOS:000236601700006
PM 16597423
OA Bronze
DA 2018-12-27
ER

PT J
AU Boo, YC
AF Boo, YC
TI RETRACTED: Shear stress stimulates phosphorylation of protein kinase A
   substrate proteins including endothelial nitric oxide synthase in
   endothelial cells (Retracted Article. See vol 38, pg 453, 2006)
SO EXPERIMENTAL AND MOLECULAR MEDICINE
LA English
DT Article; Retracted Publication
DE cyclic AMP responsive element-binding protein; endothelial cells; nitric
   oxide synthase type III; protein kinase A
ID FLOW-DEPENDENT REGULATION; CATALYTIC SUBUNIT; SIGNAL-TRANSDUCTION;
   ELECTRON-TRANSFER; CAMP; ACTIVATION; AKT; MECHANISMS; IDENTIFICATION;
   ENOS
AB Fluid shear stress plays a critical role in vascular health and disease. While protein kinase A (PKA) has been implicated in shear-stimulated signaling events in endothelial cells, it remains unclear whether and how PKA is stimulated in response to shear stress. This issue was addressed in the present study by monitoring the phosphorylation of endogenous substrates of PKA. Shear stress stimulated the phosphorylation of cAMP responsive element binding protein (CREB) in a PKA-dependent manner. Western blot analysis using the antibody reactive against the consensus motif of PKA substrates detected two proteins, P135 and P50, whose phosphorylation was increased by shear stress. The phosphorylation of P135 was blocked by a PKA inhibitor, H89, but not by a phosphoinositide 3-kinase inhibitor, wortmannin. Expression of a constitutively active PKA subunit stimulated P135 phosphorylation, supporting the potential of P135 as a PKA substrate. P135 was identified as endothelial nitric oxide synthase (eNOS) by immunoprecipitation study. PKA appeared to mediate shear stress-stimulated eNOS activation. Shear stress stimulated intracellular translocation of PKA activity from 'soluble' to 'particulate' fractions without involving cellular cAMP increase. Taken together, this study suggests that shear stress stimulates PKA-dependent phosphorylation of target proteins including eNOS, probably by enhancing intracellular site-specific interactions between protein kinase and substrates.
C1 Kyungpook Natl Univ, Sch Med, Dept Mol Med, Taegu 700422, South Korea.
RP Boo, YC (reprint author), Kyungpook Natl Univ, Sch Med, Dept Mol Med, Taegu 700422, South Korea.
EM ycboo@knu.ac.kr
CR Berk BC, 2002, DRUG NEWS PERSPECT, V15, P133, DOI 10.1358/dnp.2002.15.3.704684
   Boo YC, 2003, FREE RADICAL BIO MED, V35, P729, DOI 10.1016/S0891-5849(03)00397-6
   Boo YC, 2003, AM J PHYSIOL-CELL PH, V285, pC499, DOI 10.1152/ajpcell.00122.2003
   Boo YC, 2002, AM J PHYSIOL-HEART C, V283, pH1819, DOI 10.1152/ajpheart.00214.2002
   Boo YC, 2002, J BIOL CHEM, V277, P3388, DOI 10.1074/jbc.M108789200
   Brandon EP, 1997, CURR OPIN NEUROBIOL, V7, P397, DOI 10.1016/S0959-4388(97)80069-4
   Butt E, 2000, J BIOL CHEM, V275, P5179, DOI 10.1074/jbc.275.7.5179
   Chen PF, 2000, J BIOL CHEM, V275, P13155, DOI 10.1074/jbc.275.17.13155
   Cheng XD, 1998, P NATL ACAD SCI USA, V95, P9849, DOI 10.1073/pnas.95.17.9849
   Cunningham KS, 2005, LAB INVEST, V85, P9, DOI 10.1038/labinvest.3700215
   Davies PF, 2002, ARTERIOSCL THROM VAS, V22, P1755, DOI 10.1161/01.ATV.00000034391.00347.71
   Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224
   Dulin NO, 2001, J BIOL CHEM, V276, P20827, DOI 10.1074/jbc.C100195200
   Dusserre N, 2004, ARTERIOSCL THROM VAS, V24, P1796, DOI 10.1161/01.ATV.0000141133.32496.41
   Fleming I, 2005, J CELL SCI, V118, P4103, DOI 10.1242/jcs.02541
   Fujio Y, 1999, J BIOL CHEM, V274, P16349, DOI 10.1074/jbc.274.23.16349
   Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218
   Fulton D, 2004, J BIOL CHEM, V279, P30349, DOI 10.1074/jbc.M402155200
   Gonzalez E, 2002, J BIOL CHEM, V277, P39554, DOI 10.1074/jbc.M207299200
   Govers R, 2002, BIOCHEM J, V361, P193, DOI 10.1042/0264-6021:3610193
   Heijnen HFG, 2004, J HISTOCHEM CYTOCHEM, V52, P1277, DOI 10.1369/jhc4A6307.2004
   Illi B, 2003, CIRC RES, V93, P155, DOI 10.1161/01.RES.0000080933.82105.29
   LIU JW, 1994, J BIOL CHEM, V269, P11691
   MALEK AM, 1993, P NATL ACAD SCI USA, V90, P5999, DOI 10.1073/pnas.90.13.5999
   Michell BJ, 2002, J BIOL CHEM, V277, P42344, DOI 10.1074/jbc.M205144200
   Min KJ, 2004, EXP MOL MED, V36, P461, DOI 10.1038/emm.2004.58
   Nagai Y, 2000, NAT BIOTECHNOL, V18, P313
   Nishida CR, 1999, J BIOL CHEM, V274, P14692, DOI 10.1074/jbc.274.21.14692
   Niu JX, 2001, CURR BIOL, V11, P1686, DOI 10.1016/S0960-9822(01)00530-9
   ORELLANA SA, 1992, P NATL ACAD SCI USA, V89, P4726, DOI 10.1073/pnas.89.10.4726
   Razani B, 1999, J BIOL CHEM, V274, P26353, DOI 10.1074/jbc.274.37.26353
   Resnick N, 2003, PROG BIOPHYS MOL BIO, V81, P177, DOI 10.1016/S0079-6107(02)00052-4
   Sastri M, 2005, P NATL ACAD SCI USA, V102, P349, DOI 10.1073/pnas.0408608102
   SESSA WC, 1993, CIRC RES, V72, P921, DOI 10.1161/01.RES.72.4.921
   Traub O, 1998, ARTERIOSCL THROM VAS, V18, P677, DOI 10.1161/01.ATV.18.5.677
   Wei L, 2003, CLIN HEMORHEOL MICRO, V28, P113
   Zhang XP, 2001, ARTERIOSCL THROM VAS, V21, P797, DOI 10.1161/01.ATV.21.5.797
NR 37
TC 22
Z9 24
U1 6
U2 20
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1226-3613
EI 2092-6413
J9 EXP MOL MED
JI Exp. Mol. Med.
PD FEB 28
PY 2006
VL 38
IS 1
BP 63
EP 71
DI 10.1038/emm.2006.53
PG 9
WC Biochemistry & Molecular Biology; Medicine, Research & Experimental
SC Biochemistry & Molecular Biology; Research & Experimental Medicine
GA 019ZI
UT WOS:000235877100008
PM 16520554
OA Other Gold
DA 2018-12-27
ER

PT J
AU Ding, YH
   Zhang, XM
   Liu, XX
   Guo, R
AF Ding, YH
   Zhang, XM
   Liu, XX
   Guo, R
TI RETRACTED: Adsorption characteristics of thionine on gold nanoparticles
   (Retracted Article. See vol 23, pg 11342, 2007)
SO LANGMUIR
LA English
DT Article; Retracted Publication
ID FERMI-LEVEL EQUILIBRATION; SURFACE-ENHANCED RAMAN; SILVER NANOPARTICLES;
   ELECTRON-TRANSFER; OPTICAL-PROPERTIES; AU NANOPARTICLES; DYE; CHARGE;
   PARTICLES; COLLOIDS
AB Adsorption characteristics of thionine on gold nanoparticles have been studied by using UV-vis absorption spectroscopy, fluorescence spectroscopy, transmission electron microscopy (TEM), cyclic voltammetry and Fourier transform infrared spectroscopy. With the increasing concentration of gold nanoparticles, the absorption peak intensity of H-type dimers of thionine increases continuously, whereas that of monomers of thionine first increases and then decreases. The addition of gold nanoparticles makes the equilibrium between the monomer and H-type dimer forms of thionine move toward the dimer forms. Furthermore, the adsorption behavior of thionine on gold nanoparticles is also influenced by temperature. TEM images show that the addition of thionine results in an obvious aggregation, and further support the absorption spectral results. The fluorescence intensity of adsorbed thionine is quenched by gold nanoparticles due to the electronic interaction between thionine molecules and gold nanoparticles. Cyclic voltammetric and infrared spectroscopic studies show that the nitrogen atoms of both of the NH2 moieties of thionine strongly bind to the gold nanoparticle surfaces through the electrostatic interaction of thionine with gold nanoparticles. For 15-20 nm particles, the number of adsorbed thionine molecules per gold nanoparticle is about 7.66 x 10(4). Thionine molecules can not only bind to a particle to form a compact monolayer via both of the NH2 moieties, but they can also bind to two particles via their two NH2 moieties, respectively.
C1 Nanjing Univ, Sch Chem & Chem Engn, Nanjing 210093, Peoples R China.
   Yangzhou Univ, Sch Chem & Chem Engn, Yangzhou 225002, Peoples R China.
RP Ding, YH (reprint author), Nanjing Univ, Sch Chem & Chem Engn, Nanjing 210093, Peoples R China.
EM yhding@yzu.edu.cn; guorong@yzu.edu.cn
CR Aray Y, 2003, J PHYS CHEM B, V107, P8946, DOI 10.1021/jp0302257
   Awan MA, 1997, COLLOID SURFACE A, V122, P97, DOI 10.1016/S0927-7757(96)03825-3
   Barazzouk S, 2005, J PHYS CHEM B, V109, P716, DOI 10.1021/jp046474s
   BAULDREAY JM, 1993, ELECTROCHIM ACTA, V38, P1619
   Behar-Levy H, 2002, CHEM MATER, V14, P1736, DOI 10.1021/cm011558o
   BUNTON CA, 1979, J PHYS CHEM-US, V83, P680, DOI 10.1021/j100469a008
   Chandrasekharan N, 2000, J PHYS CHEM B, V104, P11103, DOI 10.1021/jp002171w
   Clapp AR, 2005, J AM CHEM SOC, V127, P1242, DOI 10.1021/ja045676z
   Daniel MC, 2004, CHEM REV, V104, P293, DOI 10.1021/cr030698+
   Das S, 1999, J PHYS CHEM B, V103, P209, DOI 10.1021/jp983816j
   Dean J. A., 1985, LANGES HDB CHEM
   Dohno C, 2003, J AM CHEM SOC, V125, P9586, DOI 10.1021/ja036397z
   Eckenrode HM, 2005, J PHYS CHEM B, V109, P4646, DOI 10.1021/jp045610q
   Franzen S, 2002, J PHYS CHEM A, V106, P6533, DOI 10.1021/jp025536g
   Freeman RG, 1996, J PHYS CHEM-US, V100, P718, DOI 10.1021/jp951379s
   Gonzalez-Garcia CM, 2002, J COLLOID INTERF SCI, V248, P13, DOI 10.1006/jcis.2001.8173
   Henglein A, 1998, CHEM MATER, V10, P444, DOI 10.1021/cm970613j
   HENGLEIN A, 1993, J PHYS CHEM-US, V97, P5457, DOI 10.1021/j100123a004
   Hornyak GL, 1997, J PHYS CHEM B, V101, P1548, DOI 10.1021/jp962685o
   Hu J, 2001, J AM CHEM SOC, V123, P1464, DOI 10.1021/ja003180l
   Ipe BI, 2002, J PHYS CHEM B, V106, P18, DOI 10.1021/jp0134695
   Kometani N, 2001, LANGMUIR, V17, P578, DOI 10.1021/la0013190
   Kreibig U., 1995, OPTICAL PROPERTIES M
   Lee CR, 2004, J COLLOID INTERF SCI, V271, P41, DOI 10.1016/j.jcis.2003.10.020
   LEE PC, 1982, J PHYS CHEM-US, V86, P3391, DOI 10.1021/j100214a025
   Liz-Marzan LM, 1996, LANGMUIR, V12, P4329, DOI 10.1021/la9601871
   Martino A, 1997, CHEM MATER, V9, P423, DOI 10.1021/cm9604625
   MULVANEY P, 1993, J PHYS CHEM-US, V97, P7061, DOI 10.1021/j100129a022
   Nath N, 2001, J AM CHEM SOC, V123, P8197, DOI 10.1021/ja015585r
   PATRICK B, 1992, J PHYS CHEM-US, V96, P1423, DOI 10.1021/j100182a072
   Pretsch E, 2000, STRUCTURE DETERMINAT
   RADOVIC LR, 1999, SURFACES NANOPARTICL, V78
   Raj CR, 2003, J ELECTROANAL CHEM, V543, P127, DOI 10.1016/S0022-0728(02)01481-X
   Reid GD, 2002, J AM CHEM SOC, V124, P5518, DOI 10.1021/ja0172363
   Shenhar R, 2003, ACCOUNTS CHEM RES, V36, P549, DOI 10.1021/ar020083j
   Simoncic P, 2004, J PHYS CHEM B, V108, P17352, DOI 10.1021/jp047288p
   Subramanian V, 2003, J PHYS CHEM B, V107, P7479, DOI 10.1021/jp0275037
   Subramanian V, 2004, J AM CHEM SOC, V126, P4943, DOI 10.1021/ja0315199
   Sudeep PK, 2002, NANO LETT, V2, P29, DOI 10.1021/nl010073w
   THOMAS G, 2000, J AM CHEM SOC, V122, P2655
   Thomas KG, 2003, ACCOUNTS CHEM RES, V36, P888, DOI 10.1021/ar030030h
   Thomas KG, 2002, LANGMUIR, V18, P3722, DOI 10.1021/la015669d
   Tom RT, 2004, LANGMUIR, V20, P1909, DOI 10.1021/la0358567
   TURKEVICH J, 1951, DISCUSS FARADAY SOC, P55, DOI 10.1039/df9511100055
   Xu P, 1999, CHEM MATER, V11, P2626, DOI 10.1021/cm990382b
   Xu W, 2004, J PHYS CHEM B, V108, P5588, DOI 10.1021/jp037994a
   Zhang J, 2005, J PHYS CHEM B, V109, P8701, DOI 10.1021/jp046016j
NR 47
TC 47
Z9 49
U1 3
U2 33
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0743-7463
J9 LANGMUIR
JI Langmuir
PD FEB 28
PY 2006
VL 22
IS 5
BP 2292
EP 2298
DI 10.1021/la052897p
PG 7
WC Chemistry, Multidisciplinary; Chemistry, Physical; Materials Science,
   Multidisciplinary
SC Chemistry; Materials Science
GA 018DR
UT WOS:000235744500052
PM 16489820
DA 2018-12-27
ER

PT J
AU Kim, SW
   Yang, JS
AF Kim, SW
   Yang, JS
TI RETRACTED: Human papillomavirus type 16 E5 protein as a therapeutic
   target (Retracted article. See vol. 52, pg. 551, 2011)
SO YONSEI MEDICAL JOURNAL
LA English
DT Review; Retracted Publication
DE cervical cancer; papillomavirus; E5 protein; therapeutic vaccine
ID GROWTH-FACTOR RECEPTOR; HUMAN FORESKIN KERATINOCYTES; VIRUS-LIKE
   PARTICLES; CERVICAL-CANCER; TRANSFORMING ACTIVITY; REGULATORY PROTEINS;
   HUMAN-ANTIBODIES; TUMOR-GROWTH; IN-VITRO; E7
AB Cervical cancer is a progressive disease with an onset of one to two decades on average. During the productive replication stage, the Human papillomavirus (HPV) genome is maintained episomally in the infected cervical epithelium and early gene products, including E5, are expressed. Therefore, E5 has a potential to contribute to the HPV-associated carcinogenic process. In invasive malignancies, the HPV genomes are commonly integrated into the host genome, and E6 and E7 genes remain intact. However, the E5 is lost or, if present, under-expressed as compared with the E6 and E7 proteins. This suggests that E5 may play a critical role in the genesis of cervical cancer but less of a role in its persistence or progression. In the initiation of neoplasia and the premalignant stage, there are fewer malignant cells than in the invasive malignancies. Moreover, cells in the invasive malignant stage are found to have a very low level of MHC class I and 11, which could hamper the presentation of the antigen and lead to a decreased immune response. Since the E5 protein is likely to play a role during the early tumorigenesis stage, a therapeutic vaccine to target and eliminate the E5-expressing cells may be a good strategy to prevent premalignant lesions from progressing toward invasive cervical cancers. This paper provides an overview of HPV-induced cervical carcinogenesis and strategies for designing prophylactic and therapeutic vaccines to prevent and cure the cervical cancer. In particular, focus will be on the rationale of targeting the E5 protein to develop therapeutic vaccines.
C1 Sungkyunkwan Univ, Fac Life Sci & Technol, Dept Genet Engn, Suwon 440746, South Korea.
RP Yang, JS (reprint author), Sungkyunkwan Univ, Fac Life Sci & Technol, Dept Genet Engn, 300 Chunchun Dong, Suwon 440746, South Korea.
EM jsyang@skku.edu
CR Angeline M, 2003, VIROLOGY, V317, P13, DOI 10.1016/j.virol.2003.08.024
   Auvinen E, 2004, ARCH VIROL, V149, P1745, DOI 10.1007/s00705-004-0325-8
   Bian J, 1997, Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi, V11, P271
   BORZACCHIELLO G, 2005, ONCOGENE
   Chen YF, 2004, J VIROL, V78, P1333, DOI 10.1128/JVI.78.3.1333-1343.2004
   CHIANG CM, 1992, P NATL ACAD SCI USA, V89, P5799, DOI 10.1073/pnas.89.13.5799
   CHIANG CM, 1992, J VIROL, V66, P5224
   Chu NR, 2000, CLIN EXP IMMUNOL, V121, P216, DOI 10.1046/j.1365-2249.2000.01293.x
   Crusius K, 1997, ONCOGENE, V15, P1437, DOI 10.1038/sj.onc.1201312
   Da Silva DM, 2001, VIROLOGY, V290, P350, DOI 10.1006/viro.2001.1179
   Davy CE, 2005, J VIROL, V79, P3998, DOI 10.1128/JVI.79.7.3998-4011.2005
   DiMaio D, 2001, ONCOGENE, V20, P7866, DOI 10.1038/sj.onc.1204915
   Doorbar J, 2005, J CLIN VIROL, V32, pS7, DOI 10.1016/j.jcv.2004.12.006
   DOORBAR J, 1991, NATURE, V352, P824, DOI 10.1038/352824a0
   Gill DK, 1998, J GEN VIROL, V79, P1971, DOI 10.1099/0022-1317-79-8-1971
   Hasegawa M, 2002, PATHOL INT, V52, P442, DOI 10.1046/j.1440-1827.2002.01373.x
   HAWLEYNELSON P, 1989, EMBO J, V8, P3905, DOI 10.1002/j.1460-2075.1989.tb08570.x
   He Z, 2000, VIROLOGY, V270, P146, DOI 10.1006/viro.2000.0271
   HEINO P, 1993, INT J CANCER, V53, P377, DOI 10.1002/ijc.2910530306
   HERNADI Z, 2005, EUR J OBSTET GY 1021
   Huang FY, 2005, CANCER GENET CYTOGEN, V157, P42, DOI 10.1016/j.cancergencyto.2004.06.002
   Ishiji Takaoki, 2000, Journal of Dermatology (Tokyo), V27, P73
   Jansen KU, 2004, ANNU REV MED, V55, P319, DOI 10.1146/annurev.med.55.091902.103520
   JENISON SA, 1989, J VIROL, V63, P809
   Jin H, 2001, Zhonghua Yi Xue Za Zhi, V81, P171
   KESSIS TD, 1993, P NATL ACAD SCI USA, V90, P3988, DOI 10.1073/pnas.90.9.3988
   Kessis TD, 1996, ONCOGENE, V13, P427
   Kim TW, 2003, J CLIN INVEST, V112, P109, DOI 10.1172/JCI200317293
   Lacey CJN, 1999, J INFECT DIS, V179, P612, DOI 10.1086/314616
   Liu DW, 2000, J VIROL, V74, P9083, DOI 10.1128/JVI.74.19.9083-9089.2000
   Liu DW, 2000, J VIROL, V74, P2888, DOI 10.1128/JVI.74.6.2888-2894.2000
   Liu HL, 2005, ACTA BIOCH BIOPH SIN, V37, P153, DOI 10.1111/j.1745-7270.2005.00027.x
   Longworth MS, 2004, MICROBIOL MOL BIOL R, V68, P362, DOI 10.1128/MMBR.68.2.362-372.2004
   Mahdavi A, 2005, ONCOLOGIST, V10, P528, DOI 10.1634/theoncologist.10-7-528
   MARTIN P, 1989, CELL, V59, P21, DOI 10.1016/0092-8674(89)90866-0
   MCBRIDE AA, 1991, J BIOL CHEM, V266, P18411
   McMurray HR, 2001, INT J EXP PATHOL, V82, P15, DOI 10.1046/j.1365-2613.2001.00177.x
   Nardelli-Haefliger D, 1999, J VIROL, V73, P9609
   Nardelli-Haefliger D, 2005, VACCINE, V23, P3634, DOI 10.1016/j.vaccine.2005.02.019
   Nardelli-Haefliger D, 2003, J NATL CANCER I, V95, P1128, DOI 10.1093/jnci/djg018
   Oetke C, 2000, ARCH VIROL, V145, P2183, DOI 10.1007/s007050070048
   Pastrana DV, 2001, VIROLOGY, V279, P361, DOI 10.1006/viro.2000.0702
   PETTI L, 1991, EMBO J, V10, P845, DOI 10.1002/j.1460-2075.1991.tb08017.x
   PIM D, 1992, ONCOGENE, V7, P27
   Riezebos-Brilman A, 2005, GENE THER, V12, P1410, DOI 10.1038/sj.gt.3302536
   Rodriguez MI, 2000, ONCOGENE, V19, P3727, DOI 10.1038/sj.onc.1203718
   Santin AD, 1999, J VIROL, V73, P5402
   Schiller J T, 2001, J Natl Cancer Inst Monogr, P50
   SLEBOS RJC, 1995, VIROLOGY, V208, P111, DOI 10.1006/viro.1995.1134
   SLEBOS RJC, 1994, P NATL ACAD SCI USA, V91, P5320, DOI 10.1073/pnas.91.12.5320
   Steller MA, 1998, CLIN CANCER RES, V4, P2103
   Stoppler MC, 1996, VIROLOGY, V223, P251, DOI 10.1006/viro.1996.0475
   STRAIGHT SW, 1995, J VIROL, V69, P3185
   Struyk L, 2000, MOL CARCINOGEN, V28, P42, DOI 10.1002/(SICI)1098-2744(200005)28:1<42::AID-MC6>3.3.CO;2-#
   Tamada Y, 1993, Hokkaido Igaku Zasshi, V68, P849
   Tsai TC, 2003, ARCH VIROL, V148, P1445, DOI 10.1007/s00705-003-0111-z
   Tsao YP, 1996, J VIROL, V70, P7535
   Wang P, 2000, Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi, V14, P117
   Wang Q, 2004, J VIROL, V78, P821, DOI 10.1128/JVI.78.2.821-833.2004
   Williams SMG, 2005, CANCER RES, V65, P6534, DOI 10.1158/0008-5472.CAN-05-0083
   Yang DH, 2003, PROTEIN EXPRES PURIF, V30, P1, DOI 10.1016/S1046-5928(03)00049-4
   Yasumoto S, 1989, Gan To Kagaku Ryoho, V16, P549
   Zhang BY, 2005, ONCOGENE, V24, P2585, DOI 10.1038/sj.onc.1208453
NR 63
TC 15
Z9 16
U1 3
U2 13
PU YONSEI UNIV COLL MEDICINE
PI SEOUL
PA 50-1 YONSEI-RO, SEODAEMUN-GU, SEOUL 120-752, SOUTH KOREA
SN 0513-5796
EI 1976-2437
J9 YONSEI MED J
JI Yonsei Med. J.
PD FEB 28
PY 2006
VL 47
IS 1
BP 1
EP 14
DI 10.3349/ymj.2006.47.1.1
PG 14
WC Medicine, General & Internal
SC General & Internal Medicine
GA 021CP
UT WOS:000235960900001
PM 16502480
OA Green Published, Other Gold
DA 2018-12-27
ER

PT J
AU Coldren, BA
   Warriner, H
   van Zanten, R
   Zasadzinski, JA
   Sirota, EB
AF Coldren, BA
   Warriner, H
   van Zanten, R
   Zasadzinski, JA
   Sirota, EB
TI RETRACTED: Flexible bilayers with spontaneous curvature lead to
   larnellar gels and spontaneous vesicles (Retracted Article. See vol 103,
   pg 19213, 2006)
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article; Retracted Publication
DE bending constants; electron microscopy; phase behavior; x-ray scattering
ID FREEZE-FRACTURE REPLICATION; SYNCHROTRON X-RAY; FLUID MEMBRANES; THERMAL
   FLUCTUATIONS; SURFACTANT SOLUTIONS; BENDING ELASTICITY; POLYMER LIPIDS;
   LIQUID-CRYSTAL; PHASES; THERMODYNAMICS
AB Mixtures of cetyltrimethylammonium tosylate (CTAT) and sodium dodecylbenzene sulfonate (SDBS) in water form a fluid lamellar phase at <= 40 wt % water but surprisingly turn into viscous gels at higher water fractions. The gels are characterized by spherulite and other bilayer defects consistent with a low bending elasticity, kappa similar to k(B)T, and a nonzero spontaneous curvature. Caille analysis of the small-angle x-ray line shape confirms that for 7:3 wt:wt CTAT:SDBS bilayers at 50% water, kappa = 0.62 +/- 0.09 k(B)T and (kappa) over bar = -0.9 +/- 0.2 k(B)T. For 13:7 wt:wt CTAT:SDBS bilayers, the measured bending elasticity decreases with increasing water dilution in good agreement with predictions based on renormalization theory, giving kappa(o) = 0.28 k(B)T. These results show that surfactant mixing is sufficient to make kappa similar to k(B)T, which promotes strong, Helfrich-type repulsion between bilayers that can dominate the van der Waals attraction. These are necessary conditions for spontaneous vesicles formed at even higher water fractions to be equilibrium structures.
C1 Univ Calif Santa Barbara, Dept Chem Engn, Santa Barbara, CA 93106 USA.
   ExxonMobil Res & Engn Co, Corp Strateg Res, Annandale, NJ 08801 USA.
RP Zasadzinski, JA (reprint author), Univ Calif Santa Barbara, Dept Chem Engn, Santa Barbara, CA 93106 USA.
EM gorilla@engineering.ucsb.edu
RI Sirota, Eric/A-7633-2009
CR Almgren M, 2004, LANGMUIR, V20, P6611, DOI 10.1021/la049211y
   ALSNIELSEN J, 1980, PHYS REV B, V22, P312, DOI 10.1103/PhysRevB.22.312
   CAILLE A, 1972, CR ACAD SCI B PHYS, V274, P891
   Coldren B, 2003, LANGMUIR, V19, P5632, DOI 10.1021/la034311+
   COLDREN B, 2002, THESIS U CALIFORNIA
   DIAT O, 1993, J PHYS II, V3, P9
   Dubois M, 2001, NATURE, V411, P672, DOI 10.1038/35079541
   EVANS E, 1990, PHYS REV LETT, V64, P2094, DOI 10.1103/PhysRevLett.64.2094
   FRANK FC, 1958, DISCUSS FARADAY SOC, P19, DOI 10.1039/df9582500019
   Gradzielski M, 2003, J PHYS-CONDENS MAT, V15, pR655, DOI 10.1088/0953-8984/15/19/202
   HELFRICH W, 1985, J PHYS-PARIS, V46, P1263, DOI 10.1051/jphys:019850046070126300
   HELFRICH W, 1973, Z NATURFORSCH C, VC 28, P693
   HELFRICH W, 1978, Z NATURFORSCH A, V33, P305
   HERVE P, 1993, J PHYS II, V3, P1255, DOI 10.1051/jp2:1993196
   HILBERT D, 1983, GEOMETRY IMAGINATION
   Hoffmann H, 1995, FARADAY DISCUSS, V101, P319, DOI 10.1039/fd9950100319
   IHN KJ, 1992, SCIENCE, V258, P275, DOI 10.1126/science.258.5080.275
   Israelachvili J. N., 1992, INTERMOLECULAR SURFA
   Jung HT, 2002, P NATL ACAD SCI USA, V99, P15318, DOI 10.1073/pnas.242374499
   Jung HT, 2001, P NATL ACAD SCI USA, V98, P1353, DOI 10.1073/pnas.041420998
   KALER EW, 1989, SCIENCE, V245, P1371, DOI 10.1126/science.2781283
   KALER EW, 2005, MIXED SURFACTANT SYS, P298
   Keller SL, 1997, PHYS REV LETT, V78, P4781, DOI 10.1103/PhysRevLett.78.4781
   PELITI L, 1985, PHYS REV LETT, V54, P1690, DOI 10.1103/PhysRevLett.54.1690
   Pinnow HA, 2000, EUR PHYS J E, V3, P149, DOI 10.1007/s101890070028
   Rawicz W, 2000, BIOPHYS J, V79, P328, DOI 10.1016/S0006-3495(00)76295-3
   ROUX D, 1988, J PHYS-PARIS, V49, P307, DOI 10.1051/jphys:01988004902030700
   SAFINYA CR, 1986, PHYS REV LETT, V57, P2718, DOI 10.1103/PhysRevLett.57.2718
   SAFINYA CR, 1989, PHYS REV LETT, V62, P1134, DOI 10.1103/PhysRevLett.62.1134
   SAFRAN SA, 1991, PHYS REV A, V43, P1071, DOI 10.1103/PhysRevA.43.1071
   SAFRAN SA, 1990, SCIENCE, V248, P354, DOI 10.1126/science.248.4953.354
   Safran SA, 2002, SURF SCI, V500, P127, DOI 10.1016/S0039-6028(01)01535-7
   SCHNEIDER MB, 1984, J PHYS-PARIS, V45, P1457, DOI 10.1051/jphys:019840045090145700
   SIMONS BD, 1992, J PHYS II, V2, P1439
   SZLEIFER I, 1990, J CHEM PHYS, V92, P6800, DOI 10.1063/1.458267
   SZLEIFER I, 1990, J PHYS CHEM-US, V94, P5081, DOI 10.1021/j100375a060
   Warriner HE, 1996, SCIENCE, V271, P969, DOI 10.1126/science.271.5251.969
   Warriner HE, 1998, BIOPHYS J, V75, P272, DOI 10.1016/S0006-3495(98)77514-9
   Xia Y, 2002, LANGMUIR, V18, P3822, DOI 10.1021/la0156762
   ZASADZINSKI JAN, 1990, J PHYS-PARIS, V51, P747, DOI 10.1051/jphys:01990005108074700
   ZASADZINSKI JAN, 1989, J ELECTRON MICR TECH, V13, P309, DOI 10.1002/jemt.1060130406
NR 41
TC 8
Z9 8
U1 2
U2 18
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD FEB 21
PY 2006
VL 103
IS 8
BP 2524
EP 2529
DI 10.1073/pnas.0507024103
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 015MG
UT WOS:000235554900011
PM 16467142
OA Green Published, Bronze
DA 2018-12-27
ER

PT J
AU Deb, K
   Sivaguru, M
   Yong, HY
   Roberts, RM
AF Deb, K
   Sivaguru, M
   Yong, HY
   Roberts, RM
TI RETRACTED: Cdx2 gene expression and trophectoderm lineage specification
   in mouse embryos (Retracted article. See vol 317, pg 450, 2007)
SO SCIENCE
LA English
DT Article; Retracted Publication
ID 1ST CLEAVAGE; POSTIMPLANTATION DEVELOPMENT; EMERGING ASYMMETRY;
   BLASTOCYST AXIS; 4-CELL EMBRYO; CELL LINEAGE; BLASTOMERES; PLANE; EGGS;
   DIFFERENTIATION
AB Controversy exists as to whether individual. blastomeres from two-cell-stage mouse embryos have identical developmental properties and fate. We show that the transcription factor Cdx2 is expressed in the nuclei of cells derived from the late-dividing but not the first-dividing blastomere of two-cell embryos and, by lineage tracing and RNA interference knock-down experiments, that this tagging cell is the precursor of trophectoderm. Cdx2 mRNA is localized toward the vegetal pole of oocytes, reorients after fertilization, and becomes concentrated in the late-dividing, two-cell-stage blastomere. The asymmetrical distribution of Cdx2 gene products in the oocyte and embryo defines the lineage to trophectoderm.
C1 Univ Missouri, Dept Anim Sci, Columbia, MO 65211 USA.
   Univ Missouri, Dept Biol Sci, Columbia, MO 65211 USA.
   Univ Missouri, Dept Biochem, Columbia, MO 65211 USA.
RP Roberts, RM (reprint author), Univ Missouri, Dept Anim Sci, Columbia, MO 65211 USA.
EM robertrm@missouri.edu
FU NICHD NIH HHS [R01 HD42201, R01 HD21896]; NCRR NIH HHS [R01 RR13438]
CR Alarcon VB, 2003, BIOL REPROD, V69, P1208, DOI 10.1095/biolreprod.103.018283
   BRULET P, 1980, P NATL ACAD SCI-BIOL, V77, P4113, DOI 10.1073/pnas.77.7.4113
   DEB K, UNPUB
   FRASER S, 1990, NATURE, V344, P431, DOI 10.1038/344431a0
   Fujimori T, 2003, DEVELOPMENT, V130, P5113, DOI 10.1242/dev.00725
   Gardner Richard L, 2005, Birth Defects Res C Embryo Today, V75, P142, DOI 10.1002/bdrc.20038
   Gardner RL, 2001, DEVELOPMENT, V128, P839
   Gardner RL, 2003, PHILOS T ROY SOC B, V358, P1331, DOI 10.1098/rstb.2003.1322
   Gray D, 2004, CURR BIOL, V14, P397, DOI 10.1016/j.cub.2004.02.031
   Hiiragi T, 2004, NATURE, V430, P360, DOI 10.1038/nature02595
   JOHNSON WH, 1995, VET REC, V137, P15, DOI 10.1136/vr.137.1.15
   King ML, 2005, BIOL CELL, V97, P19
   McConnell J, 2005, MOL REPROD DEV, V71, P399, DOI 10.1002/mrd.20318
   Motosugi N, 2005, GENE DEV, V19, P1081, DOI 10.1101/gad.1304805
   NUSSLEINVOLHARD C, 1991, DEVELOPMENT, P1
   Piotrowska K, 2001, DEVELOPMENT, V128, P3739
   Piotrowska-Nitsche K, 2005, DEVELOPMENT, V132, P479, DOI 10.1242/dev.01602
   Plusa B, 2005, NATURE, V434, P391, DOI 10.1038/nature03388
   Rossant J, 2004, DEV CELL, V7, P155, DOI 10.1016/j.devcel.2004.07.012
   ROSSANT J, 1976, J EMBRYOL EXP MORPH, V36, P283
   Schatten G, 2004, NATURE, V430, P301, DOI 10.1038/430301a
   Strumpf D, 2005, DEVELOPMENT, V132, P2093, DOI 10.1242/dev.01801
   Takizawa PA, 1997, NATURE, V389, P90, DOI 10.1038/38015
   TARKOWSKI AK, 1961, NATURE, V190, P857, DOI 10.1038/190857a0
   Tarkowski AK, 2001, INT J DEV BIOL, V45, P811
   TARKOWSKI AK, 1959, NATURE, V184, P1286, DOI 10.1038/1841286a0
   Tolkunova E, 2006, STEM CELLS, V24, P139, DOI 10.1634/stemcells.2005-0240
   Vogel G, 2005, SCIENCE, V308, P782, DOI 10.1126/science.308.5723.782
   WILLADSEN SM, 1981, J EMBRYOL EXP MORPH, V65, P165
   Zernicka-Goetz MZ, 2005, NAT REV MOL CELL BIO, V6, P919, DOI 10.1038/nrm1782
   ZIOMEK CA, 1982, J EXP ZOOL, V221, P345, DOI 10.1002/jez.1402210310
NR 31
TC 67
Z9 69
U1 2
U2 17
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 0036-8075
EI 1095-9203
J9 SCIENCE
JI Science
PD FEB 17
PY 2006
VL 311
IS 5763
BP 992
EP 996
DI 10.1126/science.1120925
PG 5
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 014CS
UT WOS:000235456900043
PM 16484492
DA 2018-12-27
ER

PT J
AU Potti, A
   Bild, A
   Dressman, HK
   Lewis, DA
   Nevins, JR
   Ortel, TL
AF Potti, A
   Bild, A
   Dressman, HK
   Lewis, DA
   Nevins, JR
   Ortel, TL
TI RETRACTED: Gene-expression patterns predict phenotypes of
   immune-mediated thrombosis (Retracted article. See vol. 118, pg. 4497,
   2011)
SO BLOOD
LA English
DT Article; Retracted Publication
ID SYSTEMIC-LUPUS-ERYTHEMATOSUS; ANTIPHOSPHOLIPID ANTIBODIES;
   AUTOIMMUNE-DISEASE; BREAST-CANCER; ANTICOAGULANT; PROTHROMBIN;
   PHOSPHOLIPIDS; BETA-2-GLYCOPROTEIN-I; THROMBOEMBOLISM; COAGULATION
AB Antiphospholipid antibody syndrome (APS) is a complex autoimmune thrombotic disorder with defined clinical phenotypes. Although not all patients with elevated antiphospholipid antibody (aPLA) levels develop complications, the severity of these potential events mandates aggressive and extended lifelong antithrombotic therapy. One hundred twenty-nine patients (57 patients with APS and venous thromboembolism [VTE], 32 patients with VTE without aPLA, 32 patients with aPLA only, and 8 healthy patients) were enrolled. RNA from peripheral-blood collection was used for DNA microarray analysis. Patterns of gene expression that characterize APS as well as thrombosis in the presence of aPLA were identified by hierarchical clustering and binary regression methods. Gene-expression profiles identify and predict individuals with APS from patients with VTE without aPLA. Importantly, similar methods identified expression profiles that accurately predicted those patients with aPLA at high risk for thrombotic events. All profiles were validated in independent cohorts of patients. The ability to predict APS, but more importantly, those patients at risk for venous thrombosis, represents a paradigm for a genomic approach that can be applied to other populations of patients with venous thrombosis, providing for more effective clinical management of disease, while also reflecting the possible underlying biologic processes.
C1 Duke Univ, Med Ctr, Dept Med, Div Hematol, Durham, NC 27710 USA.
   Duke Univ, Duke Inst Genome Sci & Policy, Durham, NC 27710 USA.
   Duke Univ, Dept Mol Genet & Microbiol, Durham, NC 27710 USA.
   Duke Hemostasis & Thrombosis Ctr, Durham, NC USA.
RP Potti, A (reprint author), Duke Univ, Med Ctr, Dept Med, Div Hematol, Durham, NC 27710 USA.
EM anil.potti@duke.edu
FU NHLBI NIH HHS [R01HL072208, U54-HL077878]; NCBDD CDC HHS [U18 DD00014]
CR ALARCONSEGOVIA D, 1989, MEDICINE, V68, P353, DOI 10.1097/00005792-198911000-00003
   BEVERS EM, 1991, THROMB HAEMOSTASIS, V66, P629
   DRESSMAN HK, MICROARRAY GENE EXPR
   Field SL, 1999, BLOOD, V94, P3421
   GALLI M, 1990, LANCET, V335, P1544, DOI 10.1016/0140-6736(90)91374-J
   Galli M, 1999, BLOOD, V93, P2149
   Greaves M, 1999, LANCET, V353, P1348, DOI 10.1016/S0140-6736(98)10362-8
   HARRIS EN, 1983, LANCET, V2, P1211
   Heit JA, 2001, THROMB HAEMOSTASIS, V86, P452, DOI 10.1161/ATVBAHA.108.162545
   Horbach DA, 1996, THROMB HAEMOSTASIS, V76, P916
   Horita Tetsuya, 2004, Curr Rheumatol Rep, V6, P458, DOI 10.1007/s11926-004-0025-0
   Huang E, 2003, LANCET, V361, P1590, DOI 10.1016/S0140-6736(03)13308-9
   KHAMASHTA MA, 1994, CLIN REV ALLERG, V12, P287
   Lockshin MD, 2000, ARTHRITIS RHEUM, V43, P440, DOI 10.1002/1529-0131(200002)43:2<440::AID-ANR26>3.0.CO;2-N
   MACCHIA L, 1995, BBA-LIPID LIPID MET, V1257, P58, DOI 10.1016/0005-2760(95)00048-H
   MATSUDA J, 1994, AM J HEMATOL, V47, P56, DOI 10.1002/ajh.2830470112
   MATSUURA E, 1992, J IMMUNOL, V148, P3885
   MCNEIL HP, 1990, P NATL ACAD SCI USA, V87, P4120, DOI 10.1073/pnas.87.11.4120
   Olsen NJ, 2004, ARTHRITIS RES THER, V6, P120, DOI 10.1186/ar1190
   OOSTING JD, 1992, THROMB HAEMOSTASIS, V67, P499
   OOSTING JD, 1993, BLOOD, V81, P2618
   Perry SL, 2003, CLIN CHEST MED, V24, P153, DOI 10.1016/S0272-5231(02)00054-0
   Pittman J, 2004, P NATL ACAD SCI USA, V101, P8431, DOI 10.1073/pnas.0401736101
   POTTI A, PAXGENE RNA SYSTEM
   POTTI A, GENE EXPRESSION PATT
   POTTI A, DUKE MICROARRAY CORE
   Rand JH, 2003, ANNU REV MED, V54, P409, DOI 10.1146/annurev.med.54.101601.152412
   Robinson WH, 2002, CLIN IMMUNOL, V103, P7, DOI 10.1006/clim.2002.5185
   Roubey RAS, 1997, LANCET, V350, P1491, DOI 10.1016/S0140-6736(05)63936-0
   ROUBEY RAS, 1994, BLOOD, V84, P2854
   Su ZW, 2003, THROMB HAEMOSTASIS, V90, P218, DOI 10.1160/TH02-09-0052
   West M, 2001, P NATL ACAD SCI USA, V98, P11462, DOI 10.1073/pnas.201162998
   White RH, 1998, ANN INTERN MED, V128, P737, DOI 10.7326/0003-4819-128-9-199805010-00006
   Wilson WA, 1999, ARTHRITIS RHEUM, V42, P1309, DOI 10.1002/1529-0131(199907)42:7<1309::AID-ANR1>3.0.CO;2-F
NR 34
TC 34
Z9 37
U1 2
U2 11
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD FEB 15
PY 2006
VL 107
IS 4
BP 1391
EP 1396
DI 10.1182/blood-2005-07-2669
PG 6
WC Hematology
SC Hematology
GA 011VH
UT WOS:000235296100027
PM 16263789
OA Bronze, Green Published
DA 2018-12-27
ER

PT J
AU Donev, RM
   Cole, DS
   Sivasankar, B
   Hughes, TR
   Morgan, BP
AF Donev, RM
   Cole, DS
   Sivasankar, B
   Hughes, TR
   Morgan, BP
TI RETRACTED: p53 regulates cellular resistance to complement lysis through
   enhanced expression of CD59(Retracted article. See vol. 73, pg. 6838,
   2013)
SO CANCER RESEARCH
LA English
DT Article; Retracted Publication
ID TUMOR-SUPPRESSOR P53; LUNG-CANCER; IN-VIVO; PROTECTIN CD59;
   BINDING-SITES; BREAST-CANCER; UP-REGULATION; FACTOR-ALPHA; CELLS; GENE
AB It has been recently hypothesized that the CD59 gene has two putative p53-responsive elements that may be involved in defense of host cells from damage by the complement system in inflammation. Here we have examined the roles of these putative p53-binding sequences within the CD59 gene in regulation of CD59 expression. We have shown that both of these potential responsive elements bind p53 in vitro. Knocking down expression of p53 using small interfering RNA led to a 6-fold decrease in CD59 protein expression in HeLa cells. We have previously observed a decrease of CD59 in camptothecin-induced apoptotic IMR32 cells, whereas expression was increased in the surviving fraction compared with untreated cells. Here, we have shown that these changes are associated with altered expression levels and acetylation status of p53. We have also shown that acetylation status of p53 regulates CD59 expression on cells exposed to inflammatory cytokines to model inflammation. Our data suggest that p53 and in vivo positive/negative regulators of p53 could be used to modulate susceptibility of tumor cells to complement lysis in chemotherapy.
C1 Cardiff Univ, Dept Med Biochem & Immunol, Sch Med, Cardiff CF14 4XN, Wales.
RP Morgan, BP (reprint author), Cardiff Univ, Dept Med Biochem & Immunol, Sch Med, Cardiff CF14 4XN, Wales.
EM morganbp@cardiff.ac.uk
RI Donev, Rossen/C-5105-2009
FU Medical Research Council [G0700102]; Wellcome Trust [068590]
CR Barlev NA, 2001, MOL CELL, V8, P1243, DOI 10.1016/S1097-2765(01)00414-2
   Bjorge L, 1997, INT J CANCER, V70, P14, DOI 10.1002/(SICI)1097-0215(19970106)70:1<14::AID-IJC3>3.0.CO;2-9
   Brooks CL, 2003, CURR OPIN CELL BIOL, V15, P164, DOI 10.1016/S0955-0674(03)00003-6
   BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0
   CHEN XB, 1995, CANCER RES, V55, P4257
   COLE DS, 2004, IMMUNOLOGY, V113, P75
   DEFFIE A, 1993, MOL CELL BIOL, V13, P3415, DOI 10.1128/MCB.13.6.3415
   DESONG X, 1999, J BIOL CHEM, V274, P1677
   Donev R, 2003, J BIOL CHEM, V278, P5214, DOI 10.1074/jbc.M206621200
   ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45
   ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P
   FEGHALI CA, 1997, FRONT BIOSCI, V2, P12
   Filipits M, 2005, J CLIN ONCOL, V23, P1161, DOI 10.1200/JCO.2005.03.033
   Furuhata T, 1996, ONCOGENE, V13, P1965
   Gazouli M, 2002, ANTICANCER RES, V22, P4237
   Gorter A, 1999, IMMUNOL TODAY, V20, P576, DOI 10.1016/S0167-5699(99)01537-6
   GOTLIEB WH, 1994, AM J OBSTET GYNECOL, V170, P1121, DOI 10.1016/S0002-9378(94)70106-7
   Goto H, 2000, MED PEDIATR ONCOL, V35, P619
   Hiremath MM, 2004, MOL IMMUNOL, V41, P901, DOI 10.1016/j.molimm.2004.04.025
   HOFMAN P, 1994, BREAST CANCER RES TR, V32, P213, DOI 10.1007/BF00665772
   Holguin MH, 1996, J IMMUNOL, V157, P1659
   Jarvis GA, 1997, INT J CANCER, V71, P1049, DOI 10.1002/(SICI)1097-0215(19970611)71:6<1049::AID-IJC22>3.0.CO;2-7
   Jurianz K, 1999, MOL IMMUNOL, V36, P929, DOI 10.1016/S0161-5890(99)00115-7
   Kagawa K, 1997, BIOCHEM BIOPH RES CO, V241, P481, DOI 10.1006/bbrc.1997.7818
   KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2
   Kimura Y, 1997, GENOMICS, V41, P477, DOI 10.1006/geno.1997.4680
   Kwong MS, 2002, ONCOLOGY-NY, V16, P33
   Langley E, 2002, EMBO J, V21, P2383, DOI 10.1093/emboj/21.10.2383
   Li MY, 2002, J BIOL CHEM, V277, P50607, DOI 10.1074/jbc.C200578200
   Liversidge J, 1996, J IMMUNOL, V156, P3696
   Lucas SD, 1996, HUM PATHOL, V27, P1329, DOI 10.1016/S0046-8177(96)90346-9
   Luo JY, 2004, P NATL ACAD SCI USA, V101, P2259, DOI 10.1073/pnas.0308762101
   MA W, 1998, J IMMUNOL, V131, P611
   Magyarlaki T, 1996, TUMORI, V82, P473
   Maio M, 1998, INT J ONCOL, V13, P305
   Matsumoto M, 1997, NAT MED, V3, P1266, DOI 10.1038/nm1197-1266
   MIYASHITA T, 1995, CELL, V80, P293
   MORGAN BP, 1994, SPRINGER SEMIN IMMUN, V15, P369, DOI 10.1007/BF01837366
   Morris GF, 1996, P NATL ACAD SCI USA, V93, P895, DOI 10.1073/pnas.93.2.895
   Nalca A, 1998, J BIOL CHEM, V273, P30517, DOI 10.1074/jbc.273.46.30517
   NICULESCU F, 1992, AM J PATHOL, V140, P1039
   ORLANDO V, 1993, CELL, V75, P1187, DOI 10.1016/0092-8674(93)90328-N
   Petryshyn R, 1996, ARCH BIOCHEM BIOPHYS, V326, P290, DOI 10.1006/abbi.1996.0078
   Rushmere NK, 2004, INT J CANCER, V108, P930, DOI 10.1002/ijc.11606
   Sampaziotis F, 2002, MED HYPOTHESES, V58, P136, DOI 10.1054/mehy.2001.1476
   Sessa C, 2000, ANN ONCOL, V11, P207, DOI 10.1023/A:1008372404504
   SHIN TH, 1995, MOL CELL BIOL, V15, P4694
   SPANDIDOS DA, 1995, INT J ONCOL, V7, P1029
   Spiller OB, 2000, CLIN EXP IMMUNOL, V121, P234, DOI 10.1046/j.1365-2249.2000.01305.x
   Takami A, 1999, BRIT J HAEMATOL, V107, P791, DOI 10.1046/j.1365-2141.1999.01790.x
   Tone M, 1999, J BIOL CHEM, V274, P710, DOI 10.1074/jbc.274.2.710
   Ueda K, 1999, ONCOL RES, V11, P125
   van Beek J, 2005, J IMMUNOL, V174, P2353, DOI 10.4049/jimmunol.174.4.2353
   Varsano S, 1998, CLIN EXP IMMUNOL, V113, P173
   Walport MJ, 2001, NEW ENGL J MED, V344, P1058, DOI 10.1056/NEJM200104053441406
   WOLF D, 1985, P NATL ACAD SCI USA, V82, P790, DOI 10.1073/pnas.82.3.790
   YAMAKAWA M, 1994, CANCER, V73, P2808, DOI 10.1002/1097-0142(19940601)73:11<2808::AID-CNCR2820731125>3.0.CO;2-P
   ZAUBERMAN A, 1995, ONCOGENE, V10, P2361
   ZAUBERMAN A, 1995, NUCLEIC ACIDS RES, V23, P2584, DOI 10.1093/nar/23.14.2584
NR 59
TC 24
Z9 26
U1 2
U2 7
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD FEB 15
PY 2006
VL 66
IS 4
BP 2451
EP 2458
DI 10.1158/0008-5472.CAN-05-3191
PG 8
WC Oncology
SC Oncology
GA 013CM
UT WOS:000235387200072
PM 16489052
OA Bronze
DA 2018-12-27
ER

PT J
AU Takahashi, T
   Shigematsu, H
   Shivapurkar, N
   Reddy, J
   Zheng, YY
   Feng, ZD
   Suzuki, M
   Nomura, M
   Augustus, M
   Yin, J
   Meltzer, SJ
   Gazdar, AF
AF Takahashi, T
   Shigematsu, H
   Shivapurkar, N
   Reddy, J
   Zheng, YY
   Feng, ZD
   Suzuki, M
   Nomura, M
   Augustus, M
   Yin, J
   Meltzer, SJ
   Gazdar, AF
TI RETRACTED: Aberrant promoter methylation of multiple genes during
   multistep pathogenesis of colorectal cancers (Retracted article. See
   vol. 132, pg. 499, 2012)
SO INTERNATIONAL JOURNAL OF CANCER
LA English
DT Article; Retracted Publication
DE methylation; tumor suppressor gene; colorectal cancer; colorectal
   adenoma; nonmalignant colonic epithelium
ID CPG-ISLAND METHYLATION; TUMOR-SUPPRESSOR GENE; K-RAS MUTATIONS; DNA
   METHYLATION; COLON-CANCER; APC GENE; MICROSATELLITE INSTABILITY;
   EPIGENETIC INACTIVATION; CHECKPOINT GENE; LUNG CARCINOMAS
AB Aberrant methylation of 5' gene promoter regions associated with gene silencing is an epigenetic phenomenon responsible for silencing of tumor suppressor genes in many cancer types. The aims of our study were to study the role of methylation of a large panel of genes during multistage pathogenesis and to correlate our findings with patient age and other clinico-pathological features. We investigated the aberrant promoter methylation profile of 19 genes in 92 colorectal cancers (CRCs) and, corresponding nonmalignant epithelia (NME) (n = 57), and selected 15 genes for studying 26 colorectal adenomas (CAs). On the Basis of our results, the genes could be divided into 3 groups. Group 1 consisted of 13 genes whose methylation:was tumor-specific. For 8 of these genes, the methylation frequencies in CAs were similar to those of CRCs, but significantly different from the frequencies in NME. Group 2, consisting of 2 genes demonstrating little or no methylation, were present in any sample type. In Group 3, consisting of 4 genes, relatively frequent methylation was present in both CRCs and NME, and the differences between these specimen types were not significant. Methylation of Group 1 genes were tightly correlated with each other, and these genes demonstrated increased methylation frequencies in CRCs with increasing age. Methylation was not correlated with other clinico-pathological features. In general, methylation frequencies of CAs were intermediate between CRCs and NME. Our study constitutes the most comprehensive methylation profile of CRCs, demonstrates that methylation commences early during CRC pathogenesis and is an age-related phenomenon. (c) 2005 Wiley-Liss, Inc.
C1 Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, Dallas, TX 75390 USA.
   Univ Texas, SW Med Ctr, Dept Pathol, Dallas, TX USA.
   Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Seattle, WA 98104 USA.
   Avalon Pharmaceut, Germantown, MD USA.
   Univ Maryland, Div Gastroenterol, Dept Med, Baltimore, MD USA.
   Greenebaum Canc Ctr, Baltimore, MD USA.
   Gifu Univ, Sch Med, Dept Surg, Gifu, Japan.
RP Gazdar, AF (reprint author), Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, 6000 Harry Hines Blvd, Dallas, TX 75390 USA.
EM adi.gazdar@UTSouthwestern.edu
FU NCI NIH HHS [CA95323, 5U01CA8497102, CA85069, CA77057, CA01808,
   CA098450]
CR Ahuja N, 1998, CANCER RES, V58, P5489
   Bachman KE, 1999, CANCER RES, V59, P798
   Baylin SB, 2001, HUM MOL GENET, V10, P687, DOI 10.1093/hmg/10.7.687
   Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691
   Burri N, 2001, LAB INVEST, V81, P217, DOI 10.1038/labinvest.3780230
   Chadwick RB, 2000, P NATL ACAD SCI USA, V97, P2662, DOI 10.1073/pnas.040579497
   Chan AOO, 2002, AM J PATHOL, V160, P529, DOI 10.1016/S0002-9440(10)64872-9
   Chung DC, 2000, GASTROENTEROLOGY, V119, P854, DOI 10.1053/gast.2000.16507
   Corn PG, 2003, CARCINOGENESIS, V24, P47, DOI 10.1093/carcin/24.1.47
   Costello JF, 2000, NAT GENET, V24, P132, DOI 10.1038/72785
   Du Y, 2001, CANCER RES, V61, P8094
   Esteller M, 2000, CANCER RES, V60, P4366
   Esteller M, 2002, ONCOGENE, V21, P5427, DOI 10.1038/sj.onc.1205600
   Esteller M, 2001, CANCER RES, V61, P3225
   Esteller M, 2002, CANCER RES, V62, P5902
   FEARON ER, 1999, CURR BIOL, V9, P62
   Fujitake S, 2004, J GASTROENTEROL, V39, P120, DOI 10.1007/s00535-003-1262-0
   Guan RJ, 1999, GASTROENTEROLOGY, V116, P1063, DOI 10.1016/S0016-5085(99)70009-0
   Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/j.cell.2011.02.013
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Hesson L, 2003, ONCOGENE, V22, P947, DOI 10.1038/sj.onc.1206191
   Issa JP, 2000, ANN NY ACAD SCI, V910, P140
   JERNAL A, 2003, CA CANC J CLIN, V53, P5
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Kato N, 2003, AM J PATHOL, V163, P387, DOI 10.1016/S0002-9440(10)63668-1
   Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1
   Krop IE, 2001, P NATL ACAD SCI USA, V98, P9796, DOI 10.1073/pnas.171138398
   Ku JL, 2004, ONCOGENE, V23, P6736, DOI 10.1038/sj.onc.1207731
   Lee S, 2004, LAB INVEST, V84, P884, DOI 10.1038/labinvest.3700108
   Li QL, 2002, CELL, V109, P113, DOI 10.1016/S0092-8674(02)00690-6
   Markowitz SD, 2002, CANCER CELL, V1, P233, DOI 10.1016/S1535-6108(02)00053-3
   Maruyama R, 2001, CANCER RES, V61, P8659
   Miyamoto K, 2003, ONCOGENE, V22, P274, DOI 10.1038/sj.onc.1206146
   Miyoshi Yasuo, 1992, Human Molecular Genetics, V1, P229
   Mizuno K, 2002, ONCOGENE, V21, P2328, DOI 10.1038/sj/onc/1205402
   OKA T, 2002, CANCER RES, V62, P63904
   Park SJ, 2003, AM J PATHOL, V162, P815, DOI 10.1016/S0002-9440(10)63878-3
   Potter JD, 1999, JNCI-J NATL CANCER I, V91, P916, DOI 10.1093/jnci/91.11.916
   Rashid A, 2001, AM J PATHOL, V159, P1129, DOI 10.1016/S0002-9440(10)61789-0
   Sato F, 2002, CANCER RES, V62, P6820
   Sato M, 1998, HUM GENET, V103, P96, DOI 10.1007/s004390050790
   Takahashi T, 2004, CLIN CANCER RES, V10, P2928, DOI 10.1158/1078-0432.CCR-03-0716
   Toyooka S, 2002, CANCER RES, V62, P3382
   Toyota M, 2000, P NATL ACAD SCI USA, V97, P710, DOI 10.1073/pnas.97.2.710
   Toyota M, 2003, P NATL ACAD SCI USA, V100, P7818, DOI 10.1073/pnas.1337066100
   Toyota M, 1999, SEMIN CANCER BIOL, V9, P349, DOI 10.1006/scbi.1999.0135
   Toyota M, 1999, P NATL ACAD SCI USA, V96, P8681, DOI 10.1073/pnas.96.15.8681
   Tsuchiya T, 2000, ONCOGENE, V19, P3642, DOI 10.1038/sj.onc.1203704
   van Engeland M, 2003, CANCER RES, V63, P3133
   van Engeland M, 2002, ONCOGENE, V21, P3792, DOI 10.1038/sj/onc/1205466
   van Rijnsoever M, 2002, GUT, V51, P797, DOI 10.1136/gut.51.6.797
   VANNOESEL MM, 2002, CANCER RES, V62, P5157
   Virmani AK, 2000, J NATL CANCER I, V92, P1303, DOI 10.1093/jnci/92.16.1303
   Virmani AK, 2001, CLIN CANCER RES, V7, P1998
   Wagner KJ, 2002, ONCOGENE, V21, P7277, DOI 10.1038/sj.onc.1205922
   Ward RL, 2003, J CLIN ONCOL, V21, P3729, DOI 10.1200/JCO.2003.03.123
   Whitehall VLJ, 2002, CANCER RES, V62, P6011
   Widschwendter M, 2002, ONCOGENE, V21, P5462, DOI 10.1038/sj.onc.1205606
   Wiencke JK, 1999, CANCER EPIDEM BIOMAR, V8, P501
   Xiong ZG, 2001, CANCER EPIDEM BIOMAR, V10, P799
   Yamamoto H, 2002, GENE CHROMOSOME CANC, V33, P322, DOI 10.1002/gcc.10010
   Yoshikawa H, 2001, NAT GENET, V28, P29, DOI 10.1038/ng0501-29
   Young J, 2001, P NATL ACAD SCI USA, V98, P265, DOI 10.1073/pnas.011415298
   Yuan YF, 2001, CANCER RES, V61, P5558
   Zochbauer-Muller S, 2001, CANCER RES, V61, P249
NR 65
TC 30
Z9 31
U1 2
U2 12
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0020-7136
J9 INT J CANCER
JI Int. J. Cancer
PD FEB 15
PY 2006
VL 118
IS 4
BP 924
EP 931
DI 10.1002/ijc.21453
PG 8
WC Oncology
SC Oncology
GA 007BZ
UT WOS:000234944000016
PM 16108009
DA 2018-12-27
ER

PT J
AU Ajees, AA
   Anantharamaiah, GM
   Mishra, VK
   Hussain, MM
   Murthy, HMK
AF Ajees, AA
   Anantharamaiah, GM
   Mishra, VK
   Hussain, MM
   Murthy, HMK
TI RETRACTED: Crystal structure of human apolipoprotein A-I: Insights into
   its protective effect against cardiovascular diseases (Retracted
   article. See vol. 115, pg. E6966, 2018)
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article; Retracted Publication
DE helical structure; high-density lipoproteins; x-ray crystal structure;
   atherosclerosis; lipid-free structure
ID HIGH-DENSITY-LIPOPROTEINS; CASSETTE TRANSPORTER A1; CELLULAR CHOLESTEROL
   EFFLUX; LIPID-FREE; APOLIPOPHORIN-III; EXCHANGEABLE APOLIPOPROTEIN;
   MOLECULAR-STRUCTURE; BINDING; PROTEIN; CONFORMATION
AB Despite three decades of extensive studies on human apolipoprotein A-I (apoA-I), the major protein component in high-density lipoproteins, the molecular basis for its antiatherogenic function is elusive, in part because of lack of a structure of the full-length protein. We describe here the crystal structure of lipid-free apoA-I at 2.4 angstrom. The structure shows that apoA-1 is comprised of an N-terminal four-helix bundle and two C-terminal helices. The N-terminal domain plays a prominent role in maintaining its lipid-free conformation, indicating that mutants with truncations in this region form inadequate models for explaining functional properties of apoA-I. A model for transformation of the lipid-free conformation to the high-density lipoprotein-bound form follows from an analysis of solvent-accessible hydrophobic patches on the surface of the structure and their proximity to the hydrophobic core of the four-helix bundle. The crystal structure of human apoA-I displays a hitherto-unobserved array of positively and negatively charged areas on the surface. Positioning of the charged surface patches relative to hydrophobic regions near the C terminus of the protein offers insights into its interaction with cell-surface components of the reverse cholesterol transport pathway and antiatherogenic properties of this protein. This structure provides a much-needed structural template for exploration of molecular mechanisms by which human apoA-I ameliorates atherosclerosis and inflammatory diseases.
C1 Univ Alabama Birmingham, Ctr Biophys Sci & Engn, Birmingham, AL 35294 USA.
   Univ Alabama Birmingham, Atherosclerosis Res Unit, Birmingham, AL 35294 USA.
   Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA.
   Univ Alabama Birmingham, Dept Biochem, Birmingham, AL 35294 USA.
   Univ Alabama Birmingham, Dept Mol Genet, Birmingham, AL 35294 USA.
   Suny Downstate Med Ctr, Dept Anat, Albany, NY 12203 USA.
   Suny Downstate Med Ctr, Dept Cell Biol, Albany, NY 12203 USA.
   Suny Downstate Med Ctr, Dept Pediat, Albany, NY 12203 USA.
RP Murthy, HMK (reprint author), Univ Alabama Birmingham, Ctr Biophys Sci & Engn, 1530 3rd Ave S, Birmingham, AL 35294 USA.
EM murthy@cbse.uab.edu
OI Mishra, Vinod/0000-0002-4527-1512
FU NHLBI NIH HHS [P01 HL034343, R01 HL064272]; NIAID NIH HHS [R01 AI045623,
   R01 AI051615]; NIDDK NIH HHS [R29 DK046900, R01 DK046900, R56 DK046900]
CR ANANTHARAMAIAH GM, 1988, J LIPID RES, V29, P309
   ASSMANN G, 1974, P NATL ACAD SCI USA, V71, P1534, DOI 10.1073/pnas.71.4.1534
   Barter PJ, 2004, CIRC RES, V95, P764, DOI 10.1161/01.RES.0000146094.59640.13
   Blum O, 1998, P NATL ACAD SCI USA, V95, P6659, DOI 10.1073/pnas.95.12.6659
   Borhani DW, 1997, P NATL ACAD SCI USA, V94, P12291, DOI 10.1073/pnas.94.23.12291
   BREITER DR, 1991, BIOCHEMISTRY-US, V30, P603, DOI 10.1021/bi00217a002
   Brewer HB, 2004, ARTERIOSCL THROM VAS, V24, P387, DOI 10.1161/01.ATV.0000121505.88326.d2
   Brouillette CG, 2001, BBA-MOL CELL BIOL L, V1531, P4, DOI 10.1016/S1388-1981(01)00081-6
   Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254
   CALABRESI L, 1993, BIOCHEMISTRY-US, V32, P6477, DOI 10.1021/bi00076a023
   Carson M, 1997, METHOD ENZYMOL, V277, P493, DOI 10.1016/S0076-6879(97)77027-7
   *CCP4, 1993, ACTA CRYSTALLOGR D, V55, P760
   Denis M, 2004, J BIOL CHEM, V279, P7384, DOI 10.1074/jbc.M306963200
   Diaz-Acosta I, 2001, J PHYS CHEM A, V105, P238, DOI 10.1021/jp0028599
   Fielding PE, 2000, BIOCHEMISTRY-US, V39, P14113, DOI 10.1021/bi0004192
   GLOMSET JA, 1968, J LIPID RES, V9, P155
   Gu XJ, 2000, J BIOL CHEM, V275, P9120, DOI 10.1074/jbc.275.13.9120
   Gursky O, 1996, P NATL ACAD SCI USA, V93, P2991, DOI 10.1073/pnas.93.7.2991
   HENDRICKSON WA, 1981, NATURE, V290, P107, DOI 10.1038/290107a0
   Jonas A, 2000, BBA-MOL CELL BIOL L, V1529, P245, DOI 10.1016/S1388-1981(00)00153-0
   JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224
   Kumar MS, 2002, BIOCHEMISTRY-US, V41, P11681, DOI 10.1021/bi026069w
   Li L, 2004, J MOL BIOL, V343, P1293, DOI 10.1016/j.jmb.2004.09.017
   Marcel YL, 2003, CURR OPIN LIPIDOL, V14, P151, DOI 10.1097/00041433-200304000-00006
   Narayanaswami V, 2000, BBA-MOL CELL BIOL L, V1483, P15, DOI 10.1016/S1388-1981(99)00176-6
   Natarajan P, 2004, J BIOL CHEM, V279, P24044, DOI 10.1074/jbc.M400561200
   NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407
   Nissen SE, 2003, JAMA-J AM MED ASSOC, V290, P2292, DOI 10.1001/jama.290.17.2292
   Oda MN, 2003, NAT STRUCT BIOL, V10, P455, DOI 10.1038/nsb931
   Okon M, 2001, FEBS LETT, V487, P390, DOI 10.1016/S0014-5793(00)02375-9
   Oram JF, 2002, CURR OPIN LIPIDOL, V13, P373, DOI 10.1097/00041433-200208000-00004
   Palgunachari MN, 1996, ARTERIOSCL THROM VAS, V16, P328, DOI 10.1161/01.ATV.16.2.328
   Remaley AT, 2003, J LIPID RES, V44, P828, DOI 10.1194/jlr.M200495-JLR200
   Rogers DP, 1998, BIOCHEMISTRY-US, V37, P11714, DOI 10.1021/bi973112k
   Rothblat GH, 1999, J LIPID RES, V40, P781
   Saito H, 2004, PROG LIPID RES, V43, P350, DOI 10.1016/j.plipres.2004.05.002
   Saito H, 2004, J BIOL CHEM, V279, P20974, DOI 10.1074/jbc.M402043200
   Segrest JP, 2000, CURR OPIN LIPIDOL, V11, P105, DOI 10.1097/00041433-200004000-00002
   Shao BH, 2005, J BIOL CHEM, V280, P5983, DOI 10.1074/jbc.M4118484200
   Silva RAGD, 2005, BIOCHEMISTRY-US, V44, P2759, DOI 10.1021/bi047717+
   Sorci-Thomas MG, 2002, TRENDS CARDIOVAS MED, V12, P121, DOI 10.1016/S1050-1738(01)00163-3
   Terwilliger TC, 2003, METHOD ENZYMOL, V374, P22, DOI 10.1016/S0076-6879(03)74002-6
   Thuahnai ST, 2003, J LIPID RES, V44, P1132, DOI 10.1194/jlr.M200429-JLR200
   WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127
   Wang JJ, 2002, P NATL ACAD SCI USA, V99, P1188, DOI 10.1073/pnas.032565999
   WEERS PMM, 1994, BIOCHEMISTRY-US, V33, P3617, DOI 10.1021/bi00178a019
   WEISGRABER KH, 1994, ADV PROTEIN CHEM, V45, P249
   WIENTZEK M, 1994, J BIOL CHEM, V269, P4605
   WILSON C, 1991, SCIENCE, V252, P1817, DOI 10.1126/science.2063194
   Yancey PG, 2003, ARTERIOSCL THROM VAS, V23, P712, DOI 10.1161/01.ATV.0000057572.97137.DD
NR 50
TC 176
Z9 186
U1 0
U2 12
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD FEB 14
PY 2006
VL 103
IS 7
BP 2126
EP 2131
DI 10.1073/pnas.0506877103
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 013LU
UT WOS:000235411600024
PM 16452169
OA Green Published, Bronze
DA 2018-12-27
ER

PT J
AU Doughan, DI
   Raff, LM
   Rockley, MG
   Hagan, M
   Agrawal, PM
   Komanduri, R
AF Doughan, DI
   Raff, LM
   Rockley, MG
   Hagan, M
   Agrawal, PM
   Komanduri, R
TI RETRACTED: Theoretical investigation of the dissociation dynamics of
   vibrationally excited vinyl bromide on an ab initio potential-energy
   surface obtained using modified novelty sampling and feed-forward neural
   networks - art. no. 054321 (Retracted Article. See vol 125, ARTN 079901,
   2006)
SO JOURNAL OF CHEMICAL PHYSICS
LA English
DT Article; Retracted Publication
ID LEAST-SQUARES METHODS; GROUND-STATE; INTERPOLATION; PHOTODISSOCIATION;
   EXCHANGE; H-3(+)((1)A(1)'); ACETYLENE; H-3; NM
AB The reaction dynamics of vibrationally excited vinyl bromide have been investigated using classical trajectory methods on a neural network potential surface that is fitted to an ab initio database of 12 122 configuration energies obtained from electronic structure calculations conducted at the MP4(SDQ) level of theory using a 6-31G(d,p) basis set for the carbon and hydrogen atoms and Huzinaga's (4333/433/4) basis set augmented with split outer s and p orbitals (43321/4321/4) and a polarization f orbital with an exponent of 0.5 for the bromine atom. The sampling of the 12-dimensional configuration hyperspace of vinyl bromide prior to execution of the electronic structure calculations is accomplished by combining novelty-sampling methods, chemical intuition, and trajectory sampling on empirical and neural network surfaces. The final potential is obtained using a two-layer feed-forward neural network comprising 38 and 1 neurons, respectively, with hyperbolic tangent sigmoid and linear transfer functions in the hidden and output layers, respectively. The fitting is accomplished using the Levenberg-Marquardt algorithm with early stopping and Bayesian regularization methods to avoid overfitting. The interpolated potentials have a standard deviation from the ab initio results of 0.0578 eV, which is within the range generally regarded as "chemical accuracy" for the purposes of electronic structure calculations. It is shown that the potential surface may be easily and conveniently transferred from one research group to another. The files required for transfer of the vinyl bromide surface can be obtained from the Electronic Physics Auxiliary Publication Service. Total dissociation rate coefficients for vinyl bromide are obtained at five different excitation energies between 4.50 and 6.44 eV. Branching ratios into each of the six open reaction channels are computed at 24 vibrational energies in the range between 4.00 and 6.44 eV. The distribution of vibrational energies in HBr formed via three-center dissociation from vinyl bromide is determined and compared with previous theoretical and experimental results. It is concluded that the combination of ab initio electronic structure calculations, novelty sampling with chemical intuition and trajectories on empirical analytic surfaces, and feed-forward neural networks provides a viable framework in which to execute purely ab initio molecular-dynamics studies on complex systems with multiple open reaction channels. (c) 2006 American Institute of Physics.
C1 Oklahoma State Univ, Dept Chem, Stillwater, OK 74078 USA.
   Oklahoma State Univ, Dept Elect & Comp Engn, Stillwater, OK 74078 USA.
   Oklahoma State Univ, Dept Mech & Aerosp Engn, Stillwater, OK 74078 USA.
RP Raff, LM (reprint author), Oklahoma State Univ, Dept Chem, Stillwater, OK 74078 USA.
EM lionelraff@hotmail.com
CR ABRASH SA, 1995, J PHYS CHEM-US, V99, P2959, DOI 10.1021/j100010a005
   Bettens RPA, 1998, J CHEM PHYS, V109, P9728, DOI 10.1063/1.477643
   Bettens RPA, 1999, J CHEM PHYS, V111, P816, DOI 10.1063/1.479368
   Bettens RPA, 1998, J CHEM PHYS, V108, P2424, DOI 10.1063/1.475655
   Bettens RPA, 1999, J CHEM PHYS, V111, P6322, DOI 10.1063/1.479937
   BODO E, 2003, HIGH ACCURACY POTENT, P43
   CHEN D, 1999, UNPUB P 1999 INT JOI, V2, P1275
   Collins MA, 2003, J CHEM PHYS, V118, P6222, DOI 10.1063/1.1559480
   Collins MA, 1999, J CHEM PHYS, V111, P9924, DOI 10.1063/1.480344
   Collins MA, 1999, PHYS CHEM CHEM PHYS, V1, P939, DOI 10.1039/a808154i
   Collins MA, 2002, THEOR CHEM ACC, V108, P313, DOI 10.1007/s00214-002-0383-5
   CREPOS C, 2004, J CHEM PHYS, V120, P2392
   DEMUTH HB, 2000, USERS GUIDE NERUAL N
   *EPAPS, EJCPSA6124011603 EPA
   Farwig R, 1987, ALGORITHMS APPROXIMA
   FORESEE FD, 1997, UNPUB P 1997 INT C N
   Frisch M. J., 2001, GAUSSIAN 98 REVISION
   Guo Y, 2004, J CHEM PHYS, V121, P5091, DOI 10.1063/1.1777572
   Hagan M., 1996, NEURAL NETWORK DESIG
   HAGAN MT, 1994, IEEE T NEURAL NETWOR, V5, P989, DOI 10.1109/72.329697
   Haykin S., 1994, NEURAL NETWORKS COMP
   Herzberg G., 1950, SPECTRA DIATOMIC MOL
   Ho TS, 1996, J CHEM PHYS, V105, P10472, DOI 10.1063/1.472977
   ISCHTWAN J, 1994, J CHEM PHYS, V100, P8080, DOI 10.1063/1.466801
   Jolliffe I. T., 1986, PRINCIPAL COMPONENT
   JORDAN MJT, 1995, J CHEM PHYS, V102, P5647, DOI 10.1063/1.469296
   KARPLUS M, 1964, J CHEM PHYS, V40, P2033, DOI 10.1063/1.1725438
   KARPLUS M, 1965, J CHEM PHYS, V43, P3259, DOI 10.1063/1.1697301
   Kawano A, 2004, J CHEM PHYS, V120, P6414, DOI 10.1063/1.1667458
   Kuhn B, 1999, J CHEM PHYS, V111, P2565, DOI 10.1063/1.479534
   Lancaster P., 1986, CURVE SURFACE FITTIN
   LIU B, 1973, J CHEM PHYS, V58, P1925, DOI 10.1063/1.1679454
   LIU B, 1984, J CHEM PHYS, V80, P581, DOI 10.1063/1.446441
   Liu DK, 2001, J CHEM PHYS, V115, P1734, DOI 10.1063/1.1382812
   MACKAY DJC, 1992, NEURAL COMPUT, V4, P448, DOI 10.1162/neco.1992.4.3.448
   Maisuradze GG, 2003, J CHEM PHYS, V119, P10002, DOI 10.1063/1.1617271
   MORZANO GE, 2003, J CHEM PHYS, V119, P5510
   NGUYEN KA, 1998, J CHEM PHYS, V103, P9728
   NYMAN G, 1990, J CHEM PHYS, V93, P6767, DOI 10.1063/1.458945
   OKABE H, 1975, J CHEM PHYS, V62, P2782, DOI 10.1063/1.430813
   Pederson LA, 2000, J PHYS CHEM A, V104, P2301, DOI 10.1021/jp9924575
   PORTER RN, 1974, ANNU REV PHYS CHEM, V25, P317, DOI 10.1146/annurev.pc.25.100174.001533
   PORTER RN, 1976, MODERN THEORETICAL C, P1
   PUKRITTAYAKAMEE A, UNPUB
   Raff L.M., 1985, THEORY CHEM REACTION, VIII, P1
   Raff LM, 2005, J CHEM PHYS, V122, DOI 10.1063/1.1850458
   RAFF LM, 1988, J CHEM PHYS, V89, P5680, DOI 10.1063/1.455575
   Rahaman A, 2001, J PHYS CHEM A, V105, P2156, DOI 10.1021/jp001695t
   SARLE WS, 1995, UNPUB P 27 S INT PIT
   SEVERIN ES, 1978, CHEM PHYS LETT, V57, P117, DOI 10.1016/0009-2614(78)80363-7
   SIEGBAHN P, 1978, J CHEM PHYS, V68, P2457, DOI 10.1063/1.436018
   SUDHAKARAN MP, 1985, CHEM PHYS, V95, P165, DOI 10.1016/0301-0104(85)80069-0
   SVERDLOV LM, 1974, VIBRATIONAL SPECTRA, P414
   Thompson KC, 1997, J CHEM SOC FARADAY T, V93, P871, DOI 10.1039/a606038b
   Thompson KC, 1998, J CHEM PHYS, V108, P8302, DOI 10.1063/1.476259
   TURHLAR DG, 1979, ATOM MOL COLLISION T, P505
   WODTKE AM, 1989, ISRAEL J CHEM, V29, P383
   WODTKE AM, 1985, J PHYS CHEM-US, V89, P4744, DOI 10.1021/j100268a019
NR 58
TC 16
Z9 17
U1 3
U2 23
PU AMER INST PHYSICS
PI MELVILLE
PA CIRCULATION & FULFILLMENT DIV, 2 HUNTINGTON QUADRANGLE, STE 1 N O 1,
   MELVILLE, NY 11747-4501 USA
SN 0021-9606
J9 J CHEM PHYS
JI J. Chem. Phys.
PD FEB 7
PY 2006
VL 124
IS 5
AR 054321
DI 10.1063/1.2162170
PG 17
WC Chemistry, Physical; Physics, Atomic, Molecular & Chemical
SC Chemistry; Physics
GA 010FA
UT WOS:000235171100039
PM 16468883
DA 2018-12-27
ER

PT J
AU Moon, HI
   Chung, JH
AF Moon, HI
   Chung, JH
TI RETRACTED: The effect of 2 ',4 ',7-trihydroxyisoflavone on
   ultraviolet-induced matrix metalloproteinases-1 expression in human skin
   fibroblasts (Retracted Article. See vol 580, pg 2993, 2006)
SO FEBS LETTERS
LA English
DT Article; Retracted Publication
DE 2 ',4 ',7-trihydroxyisoflavone; ultraviolet radiation; matrix
   metalloproteinase-1; human skin fibroblast
ID IN-VIVO; PROTEIN-1 ACTIVATION; HYDROGEN-PEROXIDE; MECHANISMS;
   BIOCHEMISTRY; INCREASES; OXIDANT; KINASE; UV
AB UV-induced matrix metalloproteinases (MMPs) cause connective tissue damage and the skin to become wrinkled and aged. Here, we investigated the effect of 2',4',7-trihydroxyisoflavone (THF) on UV-induced MMP-1 expression in human skin fibroblasts (HSFs). We found that UV irradiation increases MMP-1 expression and that this is mediated by ERK and JNK activation, but not by p38 activation. Pretreatment of HSFs with 2',4',7-THF inhibited UV-induced MMP-1 expression in a dose-dependent manner, and also inhibited the UV-induced activations of ERK and JNK by inhibiting MEK1 and SEK1 activation, respectively. Moreover, inhibitions of ERK and JNK by 2',4',7-THF resulted in the decrease of c-Fos expression and c-Jun phosphorylation/expression induced by UV, respectively, which led to the inhibition of UV-induced AP-1 DNA binding activity. This inhibitory effect of 2',4,7-THF on MMP-1 was not mediated by an antioxidant effect. In conclusion, our results demonstrate that 2',4',7-THF can inhibit UV-induced MMP-1 expression by inhibiting the MEK1/ERK/c-Fos and SEK1/ JNK/c-Jun pathways. Therefore, 2,4',7-THF is a potential agent for the prevention and treatment of skin aging. (c) 2006 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.
C1 Univ Kentucky, Med Ctr, Dept Surg, Mol Neurosci & Vasc Biol Lab, Lexington, KY 40536 USA.
   Seoul Natl Univ, Coll Med, Dept Dermatol, Seoul 110744, South Korea.
   Seoul Natl Univ Hosp, Clin Res Inst, Seoul 110744, South Korea.
RP Moon, HI (reprint author), Univ Kentucky, Med Ctr, Dept Surg, Mol Neurosci & Vasc Biol Lab, Lexington, KY 40536 USA.
EM hmoon2@uky.edu
CR Brenneisen P, 1997, FREE RADICAL BIO MED, V22, P515, DOI 10.1016/S0891-5849(96)00404-2
   Chen WX, 1998, J BIOL CHEM, V273, P32176, DOI 10.1074/jbc.273.48.32176
   Chung JH, 2002, J INVEST DERMATOL, V119, P507, DOI 10.1046/j.1523-1747.2002.01844.x
   Fisher G J, 1998, J Investig Dermatol Symp Proc, V3, P61
   Fisher GJ, 2002, ARCH DERMATOL, V138, P1462, DOI 10.1001/archderm.138.11.1462
   Fisher GJ, 1996, NATURE, V379, P335, DOI 10.1038/379335a0
   Huang CS, 1997, J BIOL CHEM, V272, P4187, DOI 10.1074/jbc.272.7.4187
   Jenkins G, 2002, MECH AGEING DEV, V123, P801, DOI 10.1016/S0047-6374(01)00425-0
   Kang S, 2003, J INVEST DERMATOL, V120, P835, DOI 10.1046/j.1523-1747.2003.12122.x
   KIM K, 2000, J BIOL CHEM, V275, P20685
   Liu GM, 2003, J BIOL CHEM, V278, P2124, DOI 10.1074/jbc.M202443200
   MIGNATTI P, 1993, PHYSIOL REV, V73, P161
   Moon HI, 2005, BIOL PHARM BULL, V28, P925, DOI 10.1248/bpb.28.925
   RHODES LE, 1994, J INVEST DERMATOL, V103, P151, DOI 10.1111/1523-1747.ep12392604
   Rittie L, 2002, AGEING RES REV, V1, P705, DOI 10.1016/S1568-1637(02)00024-7
   Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0
   Seo JY, 2003, MECH AGEING DEV, V124, P903, DOI 10.1016/S0047-6374(03)00150-7
   UITTO J, 1986, DERMATOL CLIN, V4, P433, DOI 10.1016/S0733-8635(18)30806-4
   Wenk J, 1999, J BIOL CHEM, V274, P25869, DOI 10.1074/jbc.274.36.25869
   WHISLER RL, 1995, ARCH BIOCHEM BIOPHYS, V319, P23, DOI 10.1006/abbi.1995.1263
NR 20
TC 5
Z9 5
U1 3
U2 12
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1873-3468
J9 FEBS LETT
JI FEBS Lett.
PD FEB 6
PY 2006
VL 580
IS 3
BP 769
EP 774
DI 10.1016/j.febslet.2005.12.094
PG 6
WC Biochemistry & Molecular Biology; Biophysics; Cell Biology
SC Biochemistry & Molecular Biology; Biophysics; Cell Biology
GA 010UD
UT WOS:000235222500010
PM 16413539
OA Bronze
DA 2018-12-27
ER

PT J
AU Zheng, RL
   Wen, GZ
AF Zheng, RL
   Wen, GZ
TI RETRACTED: Linear Stark effect of CdS/HgS/CdS spherical nanometric
   system (Retracted Article)
SO ACTA PHYSICA SINICA
LA Chinese
DT Article; Retracted Publication
DE CdS/HgS/CdS spherical nanometer system; Stark effect; energy and wave
   function
ID ELECTRONIC-ENERGY
AB Electronic energy and wave function of three-layer spherical nanometric system in homogeneous electric field is solved, the influence of applied field and sample size to the shift of Stark energy level is discussed.
C1 Southwest Univ, Dept Phys, Chongqing 400715, Peoples R China.
RP Zheng, RL (reprint author), Southwest Univ, Dept Phys, Chongqing 400715, Peoples R China.
EM zhengruilun@etang.com
CR CHEN X, 1994, ACTA PHYS SINICA, V43, P1008
   Empedocles SA, 1997, SCIENCE, V278, P2114, DOI 10.1126/science.278.5346.2114
   Mews A, 1996, PHYS REV B, V53, P13242, DOI 10.1103/PhysRevB.53.R13242
   NOMURA S, 1990, SOLID STATE COMMUN, V74, P1153, DOI 10.1016/0038-1098(90)90729-U
   SCHOOSS D, 1994, PHYS REV B, V49, P17072, DOI 10.1103/PhysRevB.49.17072
   TANG LY, 2005, ACTA PHYS SINICA, V54, P2278
   TKACH M, 1997, PHYS STATUS SOLIDI, V203, P578
   Yakimov AI, 2000, PHYS REV B, V62, pR16283, DOI 10.1103/PhysRevB.62.R16283
   Zheng RL, 2005, ACTA PHYS SIN-CH ED, V54, P886
   Zheng RL, 2003, ACTA PHYS SIN-CH ED, V52, P2284
   2001, PRACTICAL CHEM HDB C, P140
NR 11
TC 5
Z9 8
U1 3
U2 8
PU CHINESE PHYSICAL SOC
PI BEIJING
PA P O BOX 603, BEIJING 100080, PEOPLES R CHINA
SN 1000-3290
J9 ACTA PHYS SIN-CH ED
JI Acta Phys. Sin.
PD FEB
PY 2006
VL 55
IS 2
BP 791
EP 796
PG 6
WC Physics, Multidisciplinary
SC Physics
GA 013QE
UT WOS:000235423300056
DA 2018-12-27
ER

PT J
AU Zhang, H
   Saeki, K
   Kimura, A
   Saeki, K
   Nakahara, M
   Doshi, M
   Kondo, Y
   Nakano, T
   Yuo, A
AF Zhang, H
   Saeki, K
   Kimura, A
   Saeki, K
   Nakahara, M
   Doshi, M
   Kondo, Y
   Nakano, T
   Yuo, A
TI RETRACTED: Efficient and repetitive production of hematopoietic and
   endothelial cells from feeder-free monolayer culture system of primate
   embryonic stem cells (Retracted Article. See vol 75, pg 487, 2006)
SO BIOLOGY OF REPRODUCTION
LA English
DT Article; Retracted Publication
DE developmental biology; embryo
ID IN-VITRO; COMMON PRECURSOR; DIFFERENTIATION; IDENTIFICATION;
   HEMANGIOBLAST; COMMITMENT; LINEAGES; MESODERM
AB We have established an innovative culture system for the efficient differentiation of hematopoietic and endothelial cells from primate embryonic stem (ES) cells without feeder cells, embryoid bodies, or cell-sorting processes. After several days' culture in murine stromal OP9-conditioned medium supplemented with a cytokine cocktail on collagen-coated dishes, ES cells differentiated into a very unique population of cells with a finger-like appearance. These finger-like cells were positive for mesodermal and/or hemangioblastic markers of kinase insert domain receptor (KDR) and T-cell acute lymphocytic leukemia 1 (TAL1), and produced large amounts of protein tyrosine phosphatase, receptor type, C-positive hematopoietic cells. These hematopoietic cells showed the morphology of immature hematopoietic cells, formed blast cell colonies with high efficiency, and were positive for CD34 antigen, KDR, TAL1, and GATA binding protein 1. suggesting that these blast cells are equivalent to the multipotent hematopoietic progenitor cells. Moreover, they produced functional macrophages in murine stromal MS-5-conditioned medium and primitive erythroblasts in the presence of erythropoietin. The finger-like cells, putative mesodermal progenitors and/or hemangioblasts, actively proliferated and repetitively produced hematopoietic cells as long as they were maintained on the original dish. By contrast, the majority of the finger-like cells differentiated into endothelial cells with specific markers and specific functions after transfer to fresh dishes, indicating that conditions established in the original dish supported the proliferation and hematopoietic differentiation of the finger-like cells. Our method provides a highly controllable culture protocol for repetitive production of hematopoietic and endothelial cells from feeder-free monolayer cultivation of primate ES cells.
C1 Int Med Ctr Japan, Res Inst, Dept Hematol, Shinjuku Ku, Tokyo 1628655, Japan.
   Tanabe Seiyaku Co Ltd, Adv Med Res Labs, Yodogawa Ku, Osaka 5328505, Japan.
   Osaka Univ, Microbial Dis Res Inst, Dept Mol Cell Biol, Suita, Osaka 5650871, Japan.
RP Yuo, A (reprint author), Int Med Ctr Japan, Res Inst, Dept Hematol, Shinjuku Ku, 1-21-1 Toyama, Tokyo 1628655, Japan.
EM yuoakira@ri.imcj.go.jp
CR Chadwick K, 2003, BLOOD, V102, P906, DOI 10.1182/blood-2003-03-0832
   Choi K, 1998, DEVELOPMENT, V125, P725
   Crispino JD, 2005, SEMIN CELL DEV BIOL, V16, P137, DOI 10.1016/j.semcdb.2004.11.002
   Delabesse E, 2005, MOL CELL BIOL, V25, P5215, DOI 10.1128/MCB.25.12.5215-5225.2005
   Eichmann A, 1997, P NATL ACAD SCI USA, V94, P5141, DOI 10.1073/pnas.94.10.5141
   Fehling HJ, 2003, DEVELOPMENT, V130, P4217, DOI 10.1242/dev.00589
   GILBERT S, 2000, DEV BIOL, P358
   Hacein-Bey-Abina S, 2003, NEW ENGL J MED, V348, P255, DOI 10.1056/NEJM200301163480314
   Huber TL, 2004, NATURE, V432, P625, DOI 10.1038/nature03122
   JARSTRAND C, 1994, CHEM-BIOL INTERACT, V91, P141, DOI 10.1016/0009-2797(94)90034-5
   Kaufman DS, 2004, BLOOD, V103, P1325, DOI 10.1182/blood-2003-03-0799
   Kennedy M, 1997, NATURE, V386, P488, DOI 10.1038/386488a0
   Kyba M, 2002, CELL, V109, P29, DOI 10.1016/S0092-8674(02)00680-3
   Li F, 2001, BLOOD, V98, P335, DOI 10.1182/blood.V98.2.335
   Mcginn S, 2004, NEPHROLOGY, V9, P229, DOI 10.1111/j.1440-1797.2004.00254.x
   McHale CM, 1999, BRIT J HAEMATOL, V104, P829, DOI 10.1046/j.1365-2141.1999.01269.x
   Nakano T, 1996, SCIENCE, V272, P722, DOI 10.1126/science.272.5262.722
   Nishikawa S, 1998, DEVELOPMENT, V125, P1747
   Nishikawa S, 1998, IMMUNITY, V8, P761, DOI 10.1016/S1074-7613(00)80581-6
   Pelosi E, 2002, BLOOD, V100, P3203, DOI 10.1182/blood-2002-05-1511
   Perlingeiro RCR, 2001, DEVELOPMENT, V128, P4597
   Robertson SM, 2000, DEVELOPMENT, V127, P2447
   Saeki K, 2003, J LEUKOCYTE BIOL, V74, P1108, DOI 10.1189/jlb.0503211
   Sato N, 2004, NAT MED, V10, P55, DOI 10.1038/nm979
   Suemori H, 2001, DEV DYNAM, V222, P273, DOI 10.1002/dvdy.1191
   Takagi Y, 2005, J CLIN INVEST, V115, P102, DOI 10.1172/JCI200521137
   Vodyanik MA, 2005, BLOOD, V105, P617, DOI 10.1182/blood-2004-04-1649
   Wang LS, 2004, IMMUNITY, V21, P31, DOI 10.1016/j.immuni.2004.06.006
   Yuo A, 2001, INT J HEMATOL, V73, P438, DOI 10.1007/BF02994005
NR 29
TC 6
Z9 7
U1 3
U2 13
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0006-3363
EI 1529-7268
J9 BIOL REPROD
JI Biol. Reprod.
PD FEB
PY 2006
VL 74
IS 2
BP 295
EP 306
DI 10.1095/biolreprod.105.043331
PG 12
WC Reproductive Biology
SC Reproductive Biology
GA 005IU
UT WOS:000234816600009
PM 16221992
OA Bronze
DA 2018-12-27
ER

PT J
AU Chakraborty, C
   Saha, G
   Sarkar, B
   Pal, S
   Chatterjee, TK
   Sadhu, AK
AF Chakraborty, C
   Saha, G
   Sarkar, B
   Pal, S
   Chatterjee, TK
   Sadhu, AK
TI RETRACTED: Caspase-3 induced apoptosis in transgenic zebrafish
   (Retracted Article. See vol 29, pg 843, 2007)
SO BIOTECHNOLOGY LETTERS
LA English
DT Article; Retracted Publication
DE apoptosis; caspase-3; transgenic model; zebrafish
ID TRANSITION; PROTEASE
AB Zebrafish is an attractive model organism for studying apoptosis development because of its genetic accessibility. Here we describe the induction of clonally derived apoptosis in transgenic zebrafish expressing mouse caspase-3 (CASP3) under control of the zebrafish beta-actin promoter (beta p). Visualization of apoptotic cells, expressing a chimeric transgene encoding CASP3 fused to green fluorescent protein (GFP) gene, revealed that apoptosis arose in the thymus, spread locally into gill arches and retro-orbital soft tissue, and then disseminated into abdominal organs like testis, kidney. This transgenic model provides a platform for over-expression of caspase-3 induced extensive apoptosis in embryos and adult.
C1 Inst Appl Med & Res, Biotechnol Dept, Ghaziabad, Uttar Pradesh, India.
   Zool Survey India, Marine Aquarium & Res Ctr, Digha 721428, W Bengal, India.
   Burdwan Raj Coll, Dept Ind Fish & Fishery, Burdwan 713104, W Bengal, India.
   Univ Jadavpur, Dept Biotechnol, Kolkata, W Bengal, India.
RP Chakraborty, C (reprint author), Inst Appl Med & Res, Biotechnol Dept, 9th Mile Stone, Ghaziabad, Uttar Pradesh, India.
EM drchiranjib@yahoo.com
CR DETRICH HW, 1999, ZEBRAFISH BIOL
   Dorstyn L, 1999, J BIOL CHEM, V274, P30778, DOI 10.1074/jbc.274.43.30778
   Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383
   Hu SM, 1998, J BIOL CHEM, V273, P29648, DOI 10.1074/jbc.273.45.29648
   Humke EW, 1998, J BIOL CHEM, V273, P15702, DOI 10.1074/jbc.273.25.15702
   KANE DA, 1993, DEVELOPMENT, V119, P447
   KIMMEL CB, 1995, DEV DYNAM, V203, P253, DOI 10.1002/aja.1002030302
   KIMMEL CB, 1989, TRENDS GENET, V5, P283, DOI 10.1016/0168-9525(89)90103-0
   Langenau DM, 2003, SCIENCE, V299, P887, DOI 10.1126/science.1080280
   MORALES R, 2001, ELECTRON J BIOTECHN, V4, P52
   Nakajima K, 2000, J BIOL CHEM, V275, P10484, DOI 10.1074/jbc.275.14.10484
   NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0
   Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2
   Rotonda J, 1996, NAT STRUCT BIOL, V3, P619, DOI 10.1038/nsb0796-619
   Uchida D, 2002, J EXP BIOL, V205, P711
   Yabu T, 2001, BIOCHEM J, V360, P39, DOI 10.1042/0264-6021:3600039
NR 16
TC 6
Z9 7
U1 3
U2 12
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0141-5492
EI 1573-6776
J9 BIOTECHNOL LETT
JI Biotechnol. Lett.
PD FEB
PY 2006
VL 28
IS 3
BP 189
EP 196
DI 10.1007/s10529-005-5334-5
PG 8
WC Biotechnology & Applied Microbiology
SC Biotechnology & Applied Microbiology
GA 013YU
UT WOS:000235446700009
PM 16489497
DA 2018-12-27
ER

PT J
AU Okudaira, T
   Yamamoto, K
   Kawakami, H
   Uchihara, JN
   Tomita, M
   Masuda, M
   Matsuda, T
   Sairenji, T
   Iha, H
   Jeang, KT
   Matsuyama, T
   Takasu, N
   Mori, N
AF Okudaira, T
   Yamamoto, K
   Kawakami, H
   Uchihara, JN
   Tomita, M
   Masuda, M
   Matsuda, T
   Sairenji, T
   Iha, H
   Jeang, KT
   Matsuyama, T
   Takasu, N
   Mori, N
TI RETRACTED: Transactivation of CCL20 gene by Epstein-Barr virus latent
   membrane protein 1 (Retracted article. See vol. 152, pg. 787, 2011)
SO BRITISH JOURNAL OF HAEMATOLOGY
LA English
DT Article; Retracted Publication
DE CCL20; Epstein-Barr virus; latent membrane protein 1; nuclear
   factor-kappa B; signal transduction
ID NF-KAPPA-B; LYMPHOCYTE GROWTH TRANSFORMATION; DENDRITIC CELLS;
   KINASE-ALPHA; TRANSCRIPTION FACTOR; HISTONE ACETYLATION; CHEMOKINE
   RECEPTOR; MOLECULAR-CLONING; IKK-ALPHA; ACTIVATION
AB CCL20 is expected to play a crucial role in the initiation of immune responses and tumour growth. However, expression of CCL20 in Epstein-Barr virus (EBV)-associated diseases has not been studied. We examined the contribution of EBV infection and EBV-encoded latent membrane protein (LMP)-1 to CCL20 expression. EBV infection and LMP-1 induced CCL20 mRNA expression in the EBV-negative Burkitt lymphoma (BL) cell lines and the embryonic kidney cell line. Histone deacetylase inhibitor-stimulated endogenous LMP-1 also induced CCL20 expression in an EBV-positive BL cell line. Analysis of the CCL20 promoter showed that it was activated by LMP-1 C-terminal activation region (CTAR)-1 and CTAR-2. Co-expression Of I kappa B alpha, I kappa B beta, I kappa B kinase (IKK)alpha, IKK beta, IKK gamma, nuclear factor (NF)-kappa B-inducing kinase and tumour necrosis factor receptor-associated factor 2 dominant-negative constructs with LMP-1 inhibited the activation of the CCL20 promoter by LMP-1, suggesting that LMP-1 induces CCL20 via NF-kappa B signalling. The requirement for the NF-kappa B-binding site in the CCL20 promoter in LMP-1 responsiveness was established. Our results indicate that activation of the NF-kappa B pathway by LMP-1 is required for the activation of CCL20 expression.
C1 Univ Ryukyus, Div Mol Virol & Oncol, Grad Sch Med, Nishihara, Okinawa 9030215, Japan.
   Univ Ryukyus, Div Endocrinol & Metab, Fac Med, Nishihara, Okinawa 9030215, Japan.
   Nagasaki Univ, Div Cytokine Signaling, Grad Sch Biomed Sci, Nagasaki 852, Japan.
   Univ Ryukyus, Div Child Hlth & Welf, Fac Med, Nishihara, Okinawa 9030215, Japan.
   Tottori Univ, Fac Med, Div Biosignaling, Dept Biomed Sci,Sch Life Sci, Yonago, Tottori 683, Japan.
   Oita Univ, Dept Infect Dis, Fac Med, Oita 87011, Japan.
   NIAID, Lab Mol Microbiol, Mol Virol Sect, NIH, Bethesda, MD 20892 USA.
RP Mori, N (reprint author), Univ Ryukyus, Div Mol Virol & Oncol, Grad Sch Med, 207 Uehara, Nishihara, Okinawa 9030215, Japan.
EM n-mori@med.u-ryukyu.ac.jp
RI Jeang, Kuan-Teh/A-2424-2008
OI Iha, Hidekatsu/0000-0002-0999-5636
CR Baba M, 1997, J BIOL CHEM, V272, P14893, DOI 10.1074/jbc.272.23.14893
   BRENNER CA, 1989, BIOTECHNIQUES, V7, P1096
   BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809
   Chang LK, 2000, NUCLEIC ACIDS RES, V28, P3918, DOI 10.1093/nar/28.20.3918
   Eliopoulos AG, 1999, J BIOL CHEM, V274, P16085, DOI 10.1074/jbc.274.23.16085
   Floettmann JE, 1997, ONCOGENE, V15, P1851, DOI 10.1038/sj.onc.1201359
   Fushimi T, 2000, J CLIN INVEST, V105, P1383, DOI 10.1172/JCI7548
   Geleziunas R, 1998, MOL CELL BIOL, V18, P5157, DOI 10.1128/MCB.18.9.5157
   Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225
   Gires O, 1997, EMBO J, V16, P6131, DOI 10.1093/emboj/16.20.6131
   Greaves DR, 1997, J EXP MED, V186, P837, DOI 10.1084/jem.186.6.837
   Harant H, 2001, FEBS LETT, V509, P439, DOI 10.1016/S0014-5793(01)03138-6
   HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L
   Hieshima K, 1997, J BIOL CHEM, V272, P5846, DOI 10.1074/jbc.272.9.5846
   Hromas R, 1997, BLOOD, V89, P3315
   HUEN DS, 1995, ONCOGENE, V10, P549
   Iha H, 2003, ONCOGENE, V22, P8912, DOI 10.1038/sj.onc.1207058
   Imaizumi Y, 2002, INT IMMUNOL, V14, P147, DOI 10.1093/intimm/14.2.147
   Izumi KM, 1997, P NATL ACAD SCI USA, V94, P12592, DOI 10.1073/pnas.94.23.12592
   Jenkins PJ, 2000, J VIROL, V74, P710, DOI 10.1128/JVI.74.2.710-720.2000
   Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621
   Kaye KM, 1996, P NATL ACAD SCI USA, V93, P11085, DOI 10.1073/pnas.93.20.11085
   KAYE KM, 1993, P NATL ACAD SCI USA, V90, P9150, DOI 10.1073/pnas.90.19.9150
   KIEFF E, 2001, FIELDS VIROLOGY, P2511
   Kieser A, 1997, EMBO J, V16, P6478, DOI 10.1093/emboj/16.21.6478
   Kleeff J, 1999, INT J CANCER, V81, P650, DOI 10.1002/(SICI)1097-0215(19990517)81:4<650::AID-IJC23>3.0.CO;2-#
   Kwon JH, 2003, J BIOL CHEM, V278, P875, DOI 10.1074/jbc.M208241200
   LAHERTY CD, 1992, J BIOL CHEM, V267, P24157
   Lee FS, 1998, P NATL ACAD SCI USA, V95, P9319, DOI 10.1073/pnas.95.16.9319
   LIEBOWITZ D, 1986, J VIROL, V58, P233
   McKinsey TA, 1996, MOL CELL BIOL, V16, P2083
   Mori N, 1999, BLOOD, V93, P2360
   MOSIALOS G, 1995, CELL, V80, P389, DOI 10.1016/0092-8674(95)90489-1
   Muzio M, 1997, SCIENCE, V278, P1612, DOI 10.1126/science.278.5343.1612
   Nakayama T, 2004, J VIROL, V78, P1665, DOI 10.1128/JVI.78.4.1665-1674.2004
   Nelson RT, 2001, GENOMICS, V73, P28, DOI 10.1006/geno.2001.6482
   Park JH, 2002, VIROLOGY, V303, P345, DOI 10.1006/viro.2002.1638
   Power CA, 1997, J EXP MED, V186, P825, DOI 10.1084/jem.186.6.825
   Roberts ML, 1998, VIROLOGY, V240, P93, DOI 10.1006/viro.1997.8901
   Rossi DL, 1997, J IMMUNOL, V158, P1033
   ROWE M, 1994, J VIROL, V68, P5602
   Sylla BS, 1998, P NATL ACAD SCI USA, V95, P10106, DOI 10.1073/pnas.95.17.10106
   WANG D, 1985, CELL, V43, P831, DOI 10.1016/0092-8674(85)90256-9
   WANG D, 1988, J VIROL, V62, P4173
   WANG F, 1990, J VIROL, V64, P2309
   Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866
   Xu ZG, 2001, BRIT J CANCER, V84, P920, DOI 10.1054/bjoc.2000.1687
   Yoshie O, 2001, ADV IMMUNOL, V78, P57, DOI 10.1016/S0065-2776(01)78002-9
   Zaballos A, 1996, BIOCHEM BIOPH RES CO, V227, P846, DOI 10.1006/bbrc.1996.1595
   Zandi E, 1999, MOL CELL BIOL, V19, P4547
NR 50
TC 11
Z9 11
U1 3
U2 10
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0007-1048
J9 BRIT J HAEMATOL
JI Br. J. Haematol.
PD FEB
PY 2006
VL 132
IS 3
BP 293
EP 302
DI 10.1111/j.1365-2141.2005.05877.x
PG 10
WC Hematology
SC Hematology
GA 007NO
UT WOS:000234976600005
PM 16409294
OA Bronze
DA 2018-12-27
ER

PT J
AU McGwin, G
   Vaphiades, MS
   Hall, TA
   Owsley, C
AF McGwin, G
   Vaphiades, MS
   Hall, TA
   Owsley, C
TI RETRACTED: Non-arteritic anterior ischaemic optic neuropathy and the
   treatment of erectile dysfunction (Retracted article. See vol. 95, pg.
   595, 2011)
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article; Retracted Publication
ID SILDENAFIL VIAGRA; OPHTHALMOLOGY
AB Aim: To determine the association between Viagra (sildenafil) and Cialis (tadalafil) and non-arteritic anterior ischaemic optic neuropathy (NAION).
   Methods: A retrospective matched case-control study was conducted. 38 cases of NAION in males were identified from an academic ophthalmology practice in Birmingham, Alabama, and matched (on age) to 38 controls without a history of NAION. Self reported information regarding past and current use of Viagra and/or Cialis was obtained via a telephone questionnaire from interviewers who were not blind to case status.
   Results: Overall, males with NAION were no more likely to report a history of Viagra or Cialis use compared to similarly aged controls (odd ratio (OR) 1.75, 95% confidence interval (CI) 0.48 to 6.30 and OR 1.82, 95% CI 0.21 to 15.39). However, for those with a history of myocardial infarction, a statistically significant association was observed (OR 10.7, 95% CI 1.3 to 95.8). A similar association was observed for those with a history of hypertension though it lacked statistical significance (OR 6.9, 95% CI 0.8 to 63.6).
   Conclusions: For men with a history of myocardial infarction or hypertension the use of Viagra or Cialis may increase the risk of NAION. Physicians prescribing these medications to patients with these conditions should warn them about the potential risk of NAION.
C1 Univ Alabama Birmingham, Sch Med, Dept Ophthalmol, Birmingham, AL 35294 USA.
   Univ Alabama Birmingham, Sch Publ Hlth, Dept Epidemiol & Int Hlth, Birmingham, AL 35294 USA.
RP McGwin, G (reprint author), Univ Alabama Birmingham, Sch Med, Dept Ophthalmol, 700 S 18th St,Suite 609, Birmingham, AL 35294 USA.
EM mcgwin@uab.edu
RI Owsley, Cynthia/B-7986-2014
CR Buono Lawrence M, 2002, Curr Opin Ophthalmol, V13, P357, DOI 10.1097/00055735-200212000-00003
   Cunningham AV, 2001, J NEURO-OPHTHALMOL, V21, P22, DOI 10.1097/00041327-200103000-00006
   Egan R, 2000, ARCH OPHTHALMOL-CHIC, V118, P291
   Escaravage GK, 2005, ARCH OPHTHALMOL-CHIC, V123, P399, DOI 10.1001/archopht.123.3.399
   *FDA, 2005, FDA UPD LAB VIAGR
   Hattenhauer MG, 1997, AM J OPHTHALMOL, V123, P103, DOI 10.1016/S0002-9394(14)70999-7
   HAYREH SS, 1981, ARCH NEUROL-CHICAGO, V38, P675, DOI 10.1001/archneur.1981.00510110035002
   HAYREH SS, 1995, EXP EYE RES, V61, P259, DOI 10.1016/S0014-4835(05)80121-6
   HAYREH SS, 1990, EYE, V4, P25
   HAYREH SS, 1975, ANTERIOR OSCHEMIC OP
   *IONDT, 1992, MAN OOP, V1, P1
   JOHNSON LN, 1994, J NEURO-OPHTHALMOL, V14, P38
   Laties AM, 2002, PROG RETIN EYE RES, V21, P485, DOI 10.1016/S1350-9462(02)00013-7
   Marmor MF, 1999, SURV OPHTHALMOL, V44, P153, DOI 10.1016/S0039-6257(99)00079-X
   Pomeranz HD, 2005, J NEURO-OPHTHALMOL, V25, P9, DOI 10.1097/00041327-200503000-00003
   Pomeranz HD, 2002, OPHTHALMOLOGY, V109, P584, DOI 10.1016/S0161-6420(01)00976-9
   Rucker JC, 2004, CURR OPIN NEUROL, V17, P27, DOI 10.1097/01.wco.0000113943.12823.a9
NR 17
TC 50
Z9 50
U1 3
U2 9
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD FEB
PY 2006
VL 90
IS 2
BP 154
EP 157
DI 10.1136/bjo.2005.083519
PG 4
WC Ophthalmology
SC Ophthalmology
GA 003ZH
UT WOS:000234721300010
PM 16424524
OA Green Published, Bronze
DA 2018-12-27
ER

PT J
AU Suvardhan, K
   Krishnaiah, L
   Kumar, KS
   Rekha, D
   Jayaraj, B
   Ramanaiah, S
   Chiranjeevi, P
AF Suvardhan, K
   Krishnaiah, L
   Kumar, KS
   Rekha, D
   Jayaraj, B
   Ramanaiah, S
   Chiranjeevi, P
TI RETRACTED: Studies of selenium in environmental samples and synthetic
   mixtures by spectrophotometry (Retracted article. See vol 71, pg 2199,
   2008)
SO CHEMOSPHERE
LA English
DT Article; Retracted Publication
DE selenium(IV); oxidation; p-nitroaniline;
   N-(1-naphthalene-1-yl)ethane-1,2-diamine dihydrochloride (NEDA);
   spectrophotometry; environmental samples
ID ACID
AB A rapid, highly sensitive and selective spectrophotometric method for the determination of traces of selenium(IV) is described. The method is based on oxidation of p-nitroaniline by selenium(IV) followed by coupling reaction with N-(1-naphthalene-1-yl)ethane-1,2-diamine dihydrochloride (NEDA) in neutral medium to give red colored derivative with lambda(max) 515 nm and is stable for more than 10 days at 35 degrees C. Beer's law is obeyed for selenium(IV) in the concentration range of 0.02-3.2 mu g ml(-1) at the wavelength of maximum absorption. The optimum reaction conditions and other analytical parameters were investigated to enhance the sensitivity of the present method. The detailed study of various interferences made the method more selective. The proposed method was successfully applied to the analysis of selenium in polluted water, natural water samples, plant material, soil samples, and synthetic mixtures. The results obtained were agreed with the reported methods at the 95% confidence level. The performance of proposed method was evaluated in terms of Student's t-test and Variance ratio f-test which indicates the significance of proposed method over reported method. (c) 2005 Elsevier Ltd. All rights reserved.
C1 Sri Venkateswara Univ, Dept Chem, Environm Monitoring Lab, Tirupati 517502, Andhra Pradesh, India.
   Sri Venkateswara Univ, Dept Math, Tirupati 517502, Andhra Pradesh, India.
   Sri Venkateswara Univ, Dept Geol, Tirupati 517502, Andhra Pradesh, India.
RP Chiranjeevi, P (reprint author), Sri Venkateswara Univ, Dept Chem, Environm Monitoring Lab, Tirupati 517502, Andhra Pradesh, India.
EM chiranjeevi_sai@yahoo.co.in
CR AGARWAL D, 1998, J INDIAN CHEM SOC, V73, P151
   HOLAK W, 1994, ANALYST, V119, P2179, DOI 10.1039/an9941902179
   Kumar MSH, 2002, FRESEN ENVIRON BULL, V11, P396
   MANISH R, 1994, TALANTA, V41, P1623, DOI 10.1016/0039-9140(94)E0084-5
   PATHARE MN, 1995, ANAL LETT, V28, P317, DOI 10.1080/00032719508000325
   Pyrzynska K, 1997, ANAL SCI, V13, P629, DOI 10.2116/analsci.13.629
   Revanasiddappa HD, 2001, ANAL SCI, V17, P1309, DOI 10.2116/analsci.17.1309
   SAFAVI A, 1995, ANAL LETT, V28, P1095, DOI 10.1080/00032719508002681
NR 8
TC 12
Z9 14
U1 3
U2 14
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0045-6535
EI 1879-1298
J9 CHEMOSPHERE
JI Chemosphere
PD FEB
PY 2006
VL 62
IS 6
BP 899
EP 904
DI 10.1016/j.chemosphere.2005.05.034
PG 6
WC Environmental Sciences
SC Environmental Sciences & Ecology
GA 016BF
UT WOS:000235594800004
PM 16040081
DA 2018-12-27
ER

PT J
AU Motlekar, NA
   Srivenugopal, KS
   Wachtel, MS
   Youan, BBC
AF Motlekar, Nusrat A.
   Srivenugopal, Kalkunte S.
   Wachtel, Mitchell S.
   Youan, Bi-Botti C.
TI RETRACTED: Evaluation of the oral bioavailability of low molecular
   weight heparin formulated with glycyrrhetinic acid as permeation
   enhancer (Retracted article. See vol. 69, pg. 535, 2008)
SO DRUG DEVELOPMENT RESEARCH
LA English
DT Article; Retracted Publication
DE glycyrrhetinic acid; LMWH; Caco-2 cells; absorption enhancer; oral
   delivery
ID IN-VIVO EVALUATION; INTESTINAL-ABSORPTION; VENOUS THROMBOSIS; RECTAL
   ABSORPTION; PERMEABILITY; RAT; GLYCYRRHIZIN; TOXICITY; INSULIN;
   DERIVATIVES
AB Low molecular weight heparin (LMWH) is the agent of choice for anticoagulant therapy and prophylaxis of thrombosis and coronary syndromes. However, its therapeutic use is limited due to poor oral bioavailability. The aim of this study was to investigate the oral delivery of LMWH, ardeparin formulated with 18-beta glycyrrhetinic acid (GA), as an alternative to currently used subcutaneous (sc) delivery. Drug transport through Caco-2 cell monolayers was monitored in the presence and absence of CA by scintillation counting and transepithelial electrical resistance. Regional permeability studies using rat intestine were performed using a modified Ussing chamber. Cell viability in the presence of various concentrations of enhancer was determined by MTT assay. The absorption of ardeparin after oral administration in rats was measured by an anti-factor Xa assay. Furthermore, the eventual mucosal epithelial damage was histologically evaluated. Higher ardeparin permeability (similar to 7-fold) compared to control was observed in the presence of 0.02% GA. Regional permeability studies indicated predominant absorption in the duodenal segment. Cell viability studies showed no significant cytotoxicity below 0.01% GA. Ardeparin oral bioavailability was significantly increased (Frelative/s.c. = 13.3%) without causing any damage to the intestinal tissues. CA enhanced the oral absorption of ardeparin both in vitro and in vivo. The oral formulation of ardeparin with CA could be absorbed in the intestine. These results suggest that CA may be used as an absorption enhancer for the oral delivery of LMWH.
C1 Texas Tech Univ, Hlth Sci Ctr, Sch Pharm, Dept Pharmaceut Sci, Amarillo, TX 79106 USA.
   Texas Tech Univ, Dept Pathol, Div Anat Pathol, Ctr Hlth Sci, Lubbock, TX 79409 USA.
   Texas Tech Univ, Hlth Sci Ctr, Div Res, Lubbock, TX 79409 USA.
RP Youan, BBC (reprint author), Texas Tech Univ, Hlth Sci Ctr, Sch Pharm, Dept Pharmaceut Sci, 1300 Coulter Dr, Amarillo, TX 79106 USA.
EM bibotti.youan@ttuhsc.edu
FU NIGMS NIH HHS [R15 GM069397, R15 GM069397-01A2]
CR ASADA H, 1995, J PHARM SCI-US, V84, P682, DOI 10.1002/jps.2600840604
   Aungst BJ, 2000, J PHARM SCI, V89, P429, DOI 10.1002/(SICI)1520-6017(200004)89:4<429::AID-JPS1>3.0.CO;2-J
   Bertini S, 2005, BIOMACROMOLECULES, V6, P168, DOI 10.1021/bm049693s
   BIANCHINI P, 1995, HAEMOSTASIS, V25, P288
   Breddin HK, 2001, NEW ENGL J MED, V344, P626, DOI 10.1056/NEJM200103013440902
   DALPOZZO A, 1989, THROMB RES, V56, P119, DOI 10.1016/0049-3848(89)90014-5
   ENGEL RH, 1969, J PHARM SCI, V58, P1372, DOI 10.1002/jps.2600581116
   Gallus A S, 1990, Baillieres Clin Haematol, V3, P651, DOI 10.1016/S0950-3536(05)80023-X
   GRAN E, 2001, AM J HEMATOL, V67, P10
   Imai T, 1999, PHARMACEUT RES, V16, P80, DOI 10.1023/A:1018822829302
   Jiao YY, 2002, DRUG DEV IND PHARM, V28, P1033, DOI 10.1081/DDC-120014740
   KAN KS, 1988, BIOCHEM J, V256, P1039, DOI 10.1042/bj2561039
   KASKEL FJ, 1987, AM J PHYSIOL, V252, pF188
   Knipp GT, 1997, J PHARM SCI, V86, P1105, DOI 10.1021/js9700309
   KUMAGAI A, 1967, ENDOCRINOL JAPON, V14, P39
   LINDGREN E, 1998, CONS ECOL, V2, P5
   MA TY, 1995, J CELL PHYSIOL, V164, P533, DOI 10.1002/jcp.1041640311
   MISHIMA M, 1995, BIOL PHARM BULL, V18, P566
   MISHIMA M, 1989, J PHARMACOBIO-DYNAM, V12, P31, DOI 10.1248/bpb1978.12.31
   Money SR, 2001, CARDIOVASC SURG, V9, P211, DOI 10.1016/S0967-2109(00)00144-7
   PLATE LI, 1999, Patent No. 6004583
   Ross Benjamin P., 2005, Current Drug Delivery, V2, P277, DOI 10.2174/1567201054367968
   Salartash K, 1999, J VASC SURG, V30, P526, DOI 10.1016/S0741-5214(99)70080-7
   Sethia S, 2004, J PHARM SCI-US, V93, P2985, DOI 10.1002/jps.20199
   Shah RB, 2004, AAPS J, V6
   SIJICHI S, 2005, CHEM LETT, V34, P356
   SWENSON ES, 1994, PHARMACEUT RES, V11, P1132, DOI 10.1023/A:1018984731584
   TANAKA M, 1992, CHEM PHARM BULL, V40, P1559
   TEIEN AN, 1976, THROMB RES, V8, P413, DOI 10.1016/0049-3848(76)90034-7
   Thanou M, 2001, PHARMACEUT RES, V18, P1638, DOI 10.1023/A:1013055120007
   TOMITA M, 1988, PHARMACEUT RES, V5, P341, DOI 10.1023/A:1015999309353
   Turner JR, 1999, AM J PHYSIOL-CELL PH, V277, pC554, DOI 10.1152/ajpcell.1999.277.3.C554
   Uchiyama T, 1999, J PHARM PHARMACOL, V51, P1241, DOI 10.1211/0022357991776976
   UENO M, 1982, CHEM PHARM BULL, V30, P2245
   WANG Z, 1994, BIOL PHARM BULL, V17, P1399
   Weltermann Ansgar, 2003, Wien Med Wochenschr, V153, P426, DOI 10.1007/s10354-003-0030-3
   YAMAGUCHI Y, 1991, AM J PHYSIOL, V261, pG312
   Yamamoto A, 1996, J PHARM PHARMACOL, V48, P1285, DOI 10.1111/j.2042-7158.1996.tb03937.x
NR 38
TC 21
Z9 24
U1 5
U2 20
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0272-4391
EI 1098-2299
J9 DRUG DEVELOP RES
JI Drug Dev. Res.
PD FEB
PY 2006
VL 67
IS 2
BP 166
EP 174
DI 10.1002/ddr.20087
PG 9
WC Chemistry, Medicinal; Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 055OH
UT WOS:000238459500005
PM 17710191
OA Green Accepted
DA 2018-12-27
ER

PT J
AU Kim, JA
   Choi, YS
   Hong, JI
   Kim, SH
   Jung, HH
   Kim, SM
AF Kim, JA
   Choi, YS
   Hong, JI
   Kim, SH
   Jung, HH
   Kim, SM
TI RETRACTED: Association of metabolic syndrome with white blood cell
   subtype and red blood cells (Retracted Article. See vol 53, pg 871,
   2006)
SO ENDOCRINE JOURNAL
LA English
DT Article; Retracted Publication
DE metabolic syndrome; red blood cell; white blood cell; neutrophil;
   lymphocyte
ID CARDIOVASCULAR RISK-FACTORS; INSULIN-RESISTANCE; CORONARY
   ATHEROSCLEROSIS; HEMATOLOGICAL PARAMETERS; ERYTHROCYTE AGGREGATION;
   LEUKOCYTE COUNTS; HEART-DISEASE; MEN; POPULATION; SMOKING
AB Inflammation and thrombogenesis have been suggested as possible causes for cardiovascular events in patients Suffering from metabolic syndrome (MS). The primary objective of this study was to determine the relationship between red blood cell (RBC) or white blood cell (WBC) subtypes and MS. The secondary objective was to reveal any gender differences inherent to this association. Body mass index (BMI), blood pressure, serum high-density lipoprotein cholesterol, triglycerides, and glucose were measured. The numbers of WBC subtypes and RBCs were determined in healthy adults. In male subjects, the numbers of total leukocytes, neutrophils, and lymphocytes was elevated in the MS patients (P < 0.05). In the male Subjects, the numbers of total leukocytes, neutrophils. and lymphocytes were elevated in accordance with the metabolic component count (P < 0.05). RBC, monocyte, eosinophil, and basophil counts did not differ in accordance with metabolic component counts (r = 0.406, r = 0.304, r = 0.366; P < 0.05). In the female subjects, we determined there to be no differences in the numbers of RBC and WBC subtypes in the MS patients, in accordance with metabolic component counts. The numbers of total leukocytes, neutrophils, and lymphocytes were elevated in the male MS subjects in this study, and these counts increased in accordance with the metabolic component counts. In the female subjects in this study, we determined there to be no association between RBC and WBC subtype counts with MS.
C1 Korea Univ, Coll Med, Guro Hosp, Dept Family Med, Seoul 152703, South Korea.
   Pusan Natl Univ, Coll Med, Dept Family Med, Pusan 609735, South Korea.
RP Choi, YS (reprint author), Korea Univ, Coll Med, Guro Hosp, Dept Family Med, 97 Gurodong Gil, Seoul 152703, South Korea.
OI Kim, Seon Mee/0000-0002-1957-2928
CR American Heart Association, 2004, HEART DIS STROK STAT
   Anand SS, 2003, CIRCULATION, V108, P420, DOI 10.1161/01.CIR.0000080884.27358.49
   AOKI I, 1994, STEM CELLS, V12, P329, DOI 10.1002/stem.5530120309
   Barbieri M, 2001, DIABETOLOGIA, V44, P1232, DOI 10.1007/s001250100634
   Baskurt OK, 2004, AM J PHYSIOL-HEART C, V286, pH222, DOI 10.1152/ajpheart.00532.2003
   BERSCH N, 1982, J CLIN ENDOCR METAB, V55, P1209, DOI 10.1210/jcem-55-6-1209
   Bishop JJ, 2001, AM J PHYSIOL-HEART C, V280, pH222
   Ble A, 2001, NUTR METAB CARDIOVAS, V11, P221
   Brun JF, 2004, CLIN HEMORHEOL MICRO, V30, P203
   CaulinGlaser T, 1996, J CLIN INVEST, V98, P36, DOI 10.1172/JCI118774
   CHOI TS, 2004, J KOREAN ACAD FAM ME, V25, P34
   Facchini FS, 1998, METABOLISM, V47, P831, DOI 10.1016/S0026-0495(98)90121-4
   Fernandez-Real JM, 1999, DIABETOLOGIA, V42, P1367, DOI 10.1007/s001250051451
   Freedman DS, 1996, ANN EPIDEMIOL, V6, P299, DOI 10.1016/S1047-2797(96)00024-5
   Girman CJ, 2004, AM J CARDIOL, V93, P136, DOI 10.1016/j.amjcard.2003.09.028
   Henrichot E, 2005, ARTERIOSCL THROM VAS, V25, P2594, DOI 10.1161/01.ATV.0000188508.40052.35
   Horne BD, 2005, J AM COLL CARDIOL, V45, P1638, DOI 10.1016/j.jacc.2005.02.054
   Isomaa B, 2001, DIABETES CARE, V24, P683, DOI 10.2337/diacare.24.4.683
   Kawaguchi H, 1996, AM HEART J, V132, P9, DOI 10.1016/S0002-8703(96)90384-1
   Kullo IJ, 2004, AM J CARDIOL, V94, P1554, DOI 10.1016/j.amjcard.2004.08.038
   Lindsay Robert S, 2004, Curr Diab Rep, V4, P63, DOI 10.1007/s11892-004-0013-9
   Lowe G, 2000, THROMB HAEMOSTASIS, V84, P553
   Marroquin OC, 2004, CIRCULATION, V109, P714, DOI 10.1161/01.CIR.0000115517.26897.A7
   Mendelsohn ME, 2005, SCIENCE, V308, P1583, DOI 10.1126/science.1112062
   MH S, 2004, HARRISONS PRINCIPLES, V16, P349
   Muntner P, 2004, ANN EPIDEMIOL, V14, P686, DOI 10.1016/j.annepidem.2004.01.002
   Nagasawa N, 2004, CIRC J, V68, P892, DOI 10.1253/circj.68.892
   *NAT STAT OFF, 2005, IMP DEATH CAUS KOR
   National Cholesterol Education Program (NCEP), 2002, CIRCULATION, V106, P3143, DOI DOI 10.2215/CJN.04131206
   PERRINE SP, 1986, BRIT J HAEMATOL, V64, P503, DOI 10.1111/j.1365-2141.1986.tb02206.x
   Pickup JC, 1998, DIABETOLOGIA, V41, P1241, DOI 10.1007/s001250051058
   PRENTICE RL, 1982, AM J EPIDEMIOL, V116, P496, DOI 10.1093/oxfordjournals.aje.a113434
   SHIMAKAWA T, 1993, J CLIN EPIDEMIOL, V46, P1257, DOI 10.1016/0895-4356(93)90090-N
   Smith MR, 2003, ATHEROSCLEROSIS, V169, P331, DOI 10.1016/S0021-9150(03)00200-4
   Sunyer J, 1996, AM J EPIDEMIOL, V144, P734
   Sweetnam PM, 1997, AM J EPIDEMIOL, V145, P416
   Tateishi N, 2002, J BIOMECH, V35, P1241, DOI 10.1016/S0021-9290(02)00068-4
   Tateishi N, 2001, AM J PHYSIOL-HEART C, V281, pH448
   Wang YY, 2004, J DIABETES COMPLICAT, V18, P322, DOI 10.1016/S1056-8727(04)00003-0
   World Health Organization, 2000, AS PAC PERSP RED OB, P1
NR 40
TC 29
Z9 31
U1 3
U2 19
PU JAPAN ENDOCRINE SOC
PI KYOTO
PA 75  YANAGINOBANBA NISHIIRU-MASUYA-CHO, SANJOU-DORI, NAKAGYOU-KU, KYOTO,
   604-8111, JAPAN
SN 0918-8959
EI 1348-4540
J9 ENDOCR J
JI Endocr. J.
PD FEB
PY 2006
VL 53
IS 1
BP 133
EP 139
DI 10.1507/endocrj.53.133
PG 7
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 029CO
UT WOS:000236535900018
PM 16543683
OA Bronze
DA 2018-12-27
ER

PT J
AU Taylor, AH
   McParland, PC
   Taylor, DJ
   Bell, SC
AF Taylor, AH
   McParland, PC
   Taylor, DJ
   Bell, SC
TI RETRACTED: The progesterone receptor in human term amniochorion and
   placenta is isoform C (Retracted Article. See vol 149, pg 3224, 2008)
SO ENDOCRINOLOGY
LA English
DT Article; Retracted Publication
ID BREAST-CANCER CELLS; HUMAN PARTURITION; FETAL MEMBRANES; UTERINE CERVIX;
   HUMAN LABOR; FORM-A; EXPRESSION; WITHDRAWAL; ESTROGEN; LOCALIZATION
AB The mechanism that initiates human parturition has been proposed to be functional progesterone withdrawal whereby the 116-kDa B isoform of the progesterone receptor (PR-B) switches in favor of the 94-kDa A isoform (PR-A) in reproductive tissues. Recently other PR isoforms, PR-S, PR-C, and PR-M generated from the same gene have been identified and partially characterized. Using immunohistochemical, Western blotting, and RT-PCR techniques, evidence is provided that the major PR isoform present in human term fetal membranes (amnion and chorion) and syncytiotrophoblast of the placenta is neither of the classical nuclear PR-B or PR-A isoforms but is the N terminally truncated 60-kDa PR-C isoform. Evidence is also provided that the PR-C isoform resides in the cytoplasm of the expressing cell types. Data are also presented to show that PR-B, PR-A, and PR-S isoforms are essentially absent from the amnion and chorion, whereas PR isoforms A, B, C, and S are all present in the decidua, with PR-A being the major isoform. The syncytiotrophoblast of the placenta contains the cytoplasmic PR-C isoform but not PR-A, PR-B, or PR-S. The major PR isoform in the amnion, chorion, and placenta is PR-C, suggesting that the cytoplasmic PR-C isoform has a specific role in extraembryonic tissues and may be involved in the regulation of human parturition.
C1 Univ Leicester, Dept Canc Studies & Mol Med, Preterm Birth Res Grp, Leicester LE2 7LX, Leics, England.
RP Taylor, AH (reprint author), Univ Leicester, Dept Canc Studies & Mol Med, Preterm Birth Res Grp, Reprod Sci Sect, POB 65, Leicester LE3 7LX, Leics, England.
EM aht3@le.ac.uk
OI Taylor, Anthony/0000-0002-5746-9091
CR Allport VC, 2001, MOL HUM REPROD, V7, P581, DOI 10.1093/molehr/7.6.581
   Brown AG, 2004, ANN NY ACAD SCI, V1034, P36, DOI 10.1196/annals.1335.004
   Casey ML, 1997, ANN NY ACAD SCI, V828, P273, DOI 10.1111/j.1749-6632.1997.tb48548.x
   Challis JRG, 1999, J PERINAT MED, V27, P26, DOI 10.1515/JPM.1999.003
   Conneely OM, 2000, STEROIDS, V65, P571, DOI 10.1016/S0039-128X(00)00115-X
   Gao JG, 2000, MOL ENDOCRINOL, V14, P1954, DOI 10.1210/me.14.12.1954
   Goldman S, 2005, MOL HUM REPROD, V11, P269, DOI 10.1093/molehr/gah161
   Graham JD, 1997, ENDOCR REV, V18, P502, DOI 10.1210/er.18.4.502
   Haluska GJ, 2002, J SOC GYNECOL INVEST, V9, P125, DOI 10.1016/S1071-5576(02)00144-2
   HILDPETITO S, 1992, ENDOCRINOLOGY, V130, P2343, DOI 10.1210/en.130.4.2343
   Hirata S, 2002, J STEROID BIOCHEM, V83, P25, DOI 10.1016/S0960-0760(02)00255-8
   Hirata S, 2002, J STEROID BIOCHEM, V80, P299, DOI 10.1016/S0960-0760(02)00020-1
   KASTNER P, 1990, EMBO J, V9, P1603, DOI 10.1002/j.1460-2075.1990.tb08280.x
   McCormick P D, 1981, Placenta Suppl, V3, P123
   McGowan EM, 1999, MOL ENDOCRINOL, V13, P1657, DOI 10.1210/me.13.10.1657
   Mesiano S, 2004, J SOC GYNECOL INVEST, V11, P193, DOI 10.1016/j.jsgi.2003.12.004
   Mesiano S, 2002, J CLIN ENDOCR METAB, V87, P2924, DOI 10.1210/jc.87.6.2924
   Mote PA, 2001, J CLIN PATHOL, V54, P624, DOI 10.1136/jcp.54.8.624
   Pieber D, 2001, EUR J PHARMACOL, V427, P7, DOI 10.1016/S0014-2999(01)01189-X
   Pieber D, 2001, MOL HUM REPROD, V7, P875, DOI 10.1093/molehr/7.9.875
   READ LD, 1988, MOL ENDOCRINOL, V2, P263, DOI 10.1210/mend-2-3-263
   Rodriguez HA, 2003, MOL HUM REPROD, V9, P807, DOI 10.1093/molehr/gag099
   Saner KJ, 2003, MOL CELL ENDOCRINOL, V200, P155, DOI 10.1016/S0303-7207(02)00380-5
   SAVOURET JF, 1990, INT J BIOCHEM, V22, P579, DOI 10.1016/0020-711X(90)90033-Y
   Stjernholm-Vladic Y, 2004, GYNECOL ENDOCRINOL, V18, P41, DOI 10.1080/09513590310001651777
   TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.biochem.63.1.451
   WEI LL, 1988, MOL ENDOCRINOL, V2, P62, DOI 10.1210/mend-2-1-62
   Wei LL, 1996, MOL ENDOCRINOL, V10, P1379, DOI 10.1210/me.10.11.1379
   WEI LL, 1990, MOL ENDOCRINOL, V4, P1833, DOI 10.1210/mend-4-12-1833
   Yeates C, 1998, J CLIN ENDOCR METAB, V83, P460, DOI 10.1210/jc.83.2.460
   Zhu Y, 2003, P NATL ACAD SCI USA, V100, P2231, DOI 10.1073/pnas.0336132100
NR 31
TC 22
Z9 22
U1 3
U2 10
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0013-7227
EI 1945-7170
J9 ENDOCRINOLOGY
JI Endocrinology
PD FEB
PY 2006
VL 147
IS 2
BP 687
EP 693
DI 10.1210/en.2005-0510
PG 7
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 005NN
UT WOS:000234831200008
PM 16254035
OA Bronze, Green Published
DA 2018-12-27
ER

PT J
AU Taylor, DD
   Akyol, S
   Gercel-Taylor, C
AF Taylor, DD
   Akyol, S
   Gercel-Taylor, C
TI RETRACTED: Pregnancy-associated exosomes and their modulation of T cell
   signaling (Retracted article. See vol. 194, pg. 6190, 2015)
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article; Retracted Publication
ID TUMOR-DERIVED EXOSOMES; FAS LIGAND; PRETERM BIRTH; PERIODONTAL-DISEASE;
   LYMPHOCYTE SUBPOPULATIONS; REJECTION ANTIGENS; MEMBRANE-VESICLES; IMMUNE
   PRIVILEGE; INDUCED DEATH; APOPTOSIS
AB Exosome release by viable cells is a feature of activated cell types, including tumors, fetal cells, and cells of the immune system. Exosomes critically regulate immune activation, by mediating activation-induced cell death. Fetal cells may mimic these events to selectively delete reactive lymphocytes. In this study the presence and composition of placenta-derived exosomes are demonstrated in the maternal circulation along with their consequences on T cell activation markers. For all pregnant patients, exosomes were isolated from sera obtained between 28 and 30 wk gestation. For pregnant women, subsequently delivering at term, circulating levels of placental exosomes were 1.8 times greater than those delivering preterm (p < 0.0001). Exosomes isolated from pregnancies subsequently delivering at term expressed significantly higher levels of biologically active components, including Fas ligand (FasL) and HLA-DR, than those from pregnancies delivering preterm. Standardizing for protein concentrations, exosomes from term-delivering pregnancies exhibited greater suppression of CD3-zeta and JAK3 than those delivering preterm. The suppression of CD3-zeta and JAK3 correlated with exosome expression levels of FasL (r(2) = 0.92 and r(2) = 0.938, respectively). Fractionation of exosomes from term-delivering pregnancies by continuously eluting electrophoresis indicated that intact 42kD FasL and an unidentified 24-kDa protein were associated with CD3-zeta suppression. Our results demonstrated that exosomes from pregnancies ultimately delivering at term are present at significantly greater concentrations than those from pregnancies delivering preterm; however, exosomes from term-delivering pregnancies also exhibit significantly greater suppression of CD3-zeta and JAK3.
C1 Univ Louisville, Sch Med, Div Gynecol Oncol, Dept Obstet Gynecol & Womens Hlth, Louisville, KY 40202 USA.
RP Taylor, DD (reprint author), Univ Louisville, Sch Med, Div Gynecol Oncol, Dept Obstet Gynecol & Womens Hlth, 511 S Floyd St,MDR 420, Louisville, KY 40202 USA.
EM ddtaylor@louisville.edu
FU NICHD NIH HHS [HD42674]
CR Abrahams VM, 2004, MOL HUM REPROD, V10, P55, DOI 10.1093/molehr/gah006
   Aluvihare VR, 2004, NAT IMMUNOL, V5, P266, DOI 10.1038/ni1037
   Andre F, 2002, VACCINE, V20, pA28, DOI 10.1016/S0264-410X(02)00384-5
   BLIDARU IF, 2002, REV MED CHIR SOC MED, V10, P343
   Boggess KA, 2005, CLIN PERINATOL, V32, P561, DOI 10.1016/j.clp.2005.05.002
   BROWN R, 1993, INT J CANCER, V55, P678, DOI 10.1002/ijc.2910550428
   Challis JRG, 2001, CLIN INVEST MED, V24, P60
   Chaput N, 2004, CANCER IMMUNOL IMMUN, V53, P234, DOI 10.1007/s00262-003-0472-x
   Darmochwal-Kolarz D, 1999, EUR J OBSTET GYN R B, V86, P165, DOI 10.1016/S0301-2115(99)00065-2
   Dolo V, 1999, CLIN EXP METASTAS, V17, P131, DOI 10.1023/A:1006500406240
   Frangsmyr L, 2005, MOL HUM REPROD, V11, P35, DOI 10.1093/molehr/gah129
   Gercel-Taylor C, 2002, J REPROD IMMUNOL, V56, P29, DOI 10.1016/S0165-0378(02)00025-6
   Green DR, 2003, IMMUNOL REV, V193, P70, DOI 10.1034/j.1600-065X.2003.00051.x
   Griffith TS, 1997, IMMUNOL TODAY, V18, P240, DOI 10.1016/S0167-5699(97)81663-5
   Haram K, 2003, ACTA OBSTET GYN SCAN, V82, P687, DOI 10.1034/j.1600-0412.2003.00218.x
   Heijnen HFG, 1999, BLOOD, V94, P3791
   Hill G B, 1998, Ann Periodontol, V3, P222, DOI 10.1902/annals.1998.3.1.222
   Hill JA, 2000, SEMIN REPROD MED, V18, P401, DOI 10.1055/s-2000-13730
   Hsu HC, 2005, IMMUNOL REV, V205, P130, DOI 10.1111/j.0105-2896.2005.00270.x
   Karlsson M, 2001, EUR J IMMUNOL, V31, P2892, DOI 10.1002/1521-4141(2001010)31:10<2892::AID-IMMU2892>3.0.CO;2-I
   Kersh EN, 1999, J EXP MED, V190, P1627, DOI 10.1084/jem.190.11.1627
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   Martinez-Lorenzo MJ, 1999, J IMMUNOL, V163, P1274
   Monleon I, 2001, J IMMUNOL, V167, P6736, DOI 10.4049/jimmunol.167.12.6736
   Moore S, 2004, BJOG-INT J OBSTET GY, V111, P125, DOI 10.1046/j.1471-0528.2003.00044.x
   Moore S, 2004, BRIT DENT J, V197, P251, DOI 10.1038/sj.bdj.4811620
   Morelli AE, 2004, BLOOD, V104, P3257, DOI 10.1182/blood-2004-03-0824
   Moreu G, 2005, J CLIN PERIODONTOL, V32, P622, DOI 10.1111/j.1600-051X.2005.00722.x
   Offenbacher S, 2001, Ann Periodontol, V6, P164, DOI 10.1902/annals.2001.6.1.164
   Pelkonen AS, 1999, ARCH DIS CHILD, V81, pF188, DOI 10.1136/fn.81.3.F188
   Rabinowich H, 1998, J CLIN INVEST, V101, P2579, DOI 10.1172/JCI1518
   Raposo G, 1996, J EXP MED, V183, P1161, DOI 10.1084/jem.183.3.1161
   Raposo G, 1997, MOL BIOL CELL, V8, P2631, DOI 10.1091/mbc.8.12.2631
   SANCHEZRAMON S, 2005, IMMUNOL LETT, V96, P196
   Schwartz RH, 2003, ANNU REV IMMUNOL, V21, P305, DOI 10.1146/annurev.immunol.21.120601.141110
   Sendag F, 2002, AUST NZ J OBSTET GYN, V42, P358
   Shores EW, 1997, J EXP MED, V185, P893, DOI 10.1084/jem.185.5.893
   Somerset DA, 2004, IMMUNOLOGY, V112, P38, DOI 10.1111/j.1365-2567.2004.01869.x
   Taylor DD, 2002, J REPROD IMMUNOL, V54, P15, DOI 10.1016/S0165-0378(01)00067-5
   Taylor DD, 2005, BRIT J CANCER, V92, P305, DOI 10.1038/sj.bjc.6602316
   Thery C, 1999, J CELL BIOL, V147, P599, DOI 10.1083/jcb.147.3.599
   Tucker J, 2004, BRIT MED J, V329, P675, DOI 10.1136/bmj.329.7467.675
   Vacchio MS, 2005, J IMMUNOL, V174, P4657, DOI 10.4049/jimmunol.174.8.4657
   Varner MW, 2005, BJOG-INT J OBSTET GY, V112, P28, DOI 10.1111/j.1471-0528.2005.00581.x
   Viswanathan K, 2005, P NATL ACAD SCI USA, V102, P5808, DOI 10.1073/pnas.0501650102
   WEGMANN TG, 1993, IMMUNOL TODAY, V14, P353, DOI 10.1016/0167-5699(93)90235-D
   Whiteside TL, 2002, SEMIN CANCER BIOL, V12, P43, DOI 10.1006/scbi.2001.0402
   Wolfers J, 2001, NAT MED, V7, P297, DOI 10.1038/85438
NR 48
TC 202
Z9 210
U1 7
U2 26
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
EI 1550-6606
J9 J IMMUNOL
JI J. Immunol.
PD FEB 1
PY 2006
VL 176
IS 3
BP 1534
EP 1542
DI 10.4049/jimmunol.176.3.1534
PG 9
WC Immunology
SC Immunology
GA 004QF
UT WOS:000234766600031
PM 16424182
OA Other Gold
DA 2018-12-27
ER

PT J
AU Matsuyama, W
   Watanabe, M
   Shirahama, Y
   Hirano, R
   Mitsuyama, H
   Higashimoto, I
   Osame, M
   Arimura, K
AF Matsuyama, W
   Watanabe, M
   Shirahama, Y
   Hirano, R
   Mitsuyama, H
   Higashimoto, I
   Osame, M
   Arimura, K
TI RETRACTED: Suppression of discoidin domain receptor 1 by RNA
   interference attenuates lung inflammation (Retracted Article. See vol
   181, pg 6671, 2008)
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article; Retracted Publication
ID MONOCYTE CHEMOATTRACTANT PROTEIN-1; IDIOPATHIC PULMONARY-FIBROSIS;
   TYROSINE KINASE; CHEMOKINE PRODUCTION; CXC CHEMOKINE; GROWTH-FACTOR;
   ISOFORM-B; TGF-BETA; EXPRESSION; COLLAGEN
AB Discoidin domain receptor 1 (DDR1) is a receptor tyrosine kinase whose ligand is collagen. Recently, we have reported the association of DDR1 in the cytokine production of human leukocytes in in vitro and in vivo expression in idiopathic pulmonary fibrosis. However, its role in in vivo inflammation has not been fully elucidated. Small interference RNA (siRNA) can induce specific suppression of in vitro and in vivo gene expression. In this study, using a bleomycin-induced pulmonary fibrosis mouse model, we administered siRNA against DDR1 transnasally and evaluated histological changes, cytokine expression, and signaling molecule activation in the lungs. Histologically, siRNA against DDR1 successfully reduced in vivo DDR1 expression and attenuated bleomycin-induced infiltration of inflammatory cells. Furthermore, it significantly reduced inflammatory cell counts and concentrations of cytokines such as MCP-1, MIP-1 alpha, and MIP-2 in bronchoalveolar lavage fluid. Subsequently, bleomycin-induced up-regulation of TGF-beta in bronchoalveolar lavage fluid was significantly inhibited, and collagen deposition in the lungs was reduced. Furthermore, siRNA against DDR1 significantly inhibited bleomycin-induced P38 MAPK activation in the lungs. Considered together, we propose that DDR1 contributes to the development of bleomycin-induced pulmonary inflammation and fibrosis.
C1 Kagoshima Univ Hosp, Resp & Stress Care Ctr, Div Resp Med, Kagoshima 8908520, Japan.
RP Matsuyama, W (reprint author), Kagoshima Univ Hosp, Resp & Stress Care Ctr, Div Resp Med, Sakuragaoka 8-35-1, Kagoshima 8908520, Japan.
EM vega@xa2.so-net.ne.jp
CR ANTONIADES HN, 1992, P NATL ACAD SCI USA, V89, P5371, DOI 10.1073/pnas.89.12.5371
   ASHCROFT T, 1988, J CLIN PATHOL, V41, P467, DOI 10.1136/jcp.41.4.467
   Bitko V, 2005, NAT MED, V11, P50, DOI 10.1038/nm1164
   Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999
   Coker RK, 1997, AM J PATHOL, V150, P981
   COOK DN, 1995, SCIENCE, V269, P1583, DOI 10.1126/science.7667639
   Curat CA, 2002, J AM SOC NEPHROL, V13, P2648, DOI 10.1097/01.ASN.0000032419.13208.0C
   de Fougerolles AR, 2000, J CLIN INVEST, V105, P721, DOI 10.1172/JCI7911
   Dejmek J, 2005, CLIN CANCER RES, V11, P520
   Ferri N, 2004, AM J PATHOL, V164, P1575, DOI 10.1016/S0002-9440(10)63716-9
   Heinzelmann-Schwarz VA, 2004, CLIN CANCER RES, V10, P4427, DOI 10.1158/1078-0432.CCR-04-0073
   Hou GP, 2001, J CLIN INVEST, V107, P727, DOI 10.1172/JCI10720
   Inoshima I, 2004, AM J PHYSIOL-LUNG C, V286, pL1038, DOI 10.1152/ajplung.00167.2003
   IYONAGA K, 1994, HUM PATHOL, V25, P455, DOI 10.1016/0046-8177(94)90117-1
   Kamohara H, 2001, FASEB J, V15, P2724, DOI 10.1096/fj.01-0359fje
   Keane MP, 1999, J IMMUNOL, V162, P5511
   KHALIL N, 1991, CIBA F SYMP, V157, P194
   Koyama S, 1997, AM J PHYSIOL-LUNG C, V272, pL830
   Lemjabbar H, 1999, AM J RESP CELL MOL, V20, P903, DOI 10.1165/ajrcmb.20.5.3260
   Marra F, 1997, FEBS LETT, V414, P221, DOI 10.1016/S0014-5793(97)01004-1
   Matsuoka H, 2002, AM J PHYSIOL-LUNG C, V283, pL103, DOI 10.1152/ajplung.00187.2001
   Matsuyama W, 2003, J IMMUNOL, V171, P3520, DOI 10.4049/jimmunol.171.7.3520
   Matsuyama W, 2005, J IMMUNOL, V174, P6490, DOI 10.4049/jimmunol.174.10.6490
   Matsuyama W, 2004, J IMMUNOL, V172, P2332, DOI 10.4049/jimmunol.172.4.2332
   Matsuyama W, 2003, FASEB J, V17, P1286, DOI 10.1096/fj.02-0320fje
   Matsuyama W, 2004, BLOOD, V104, P184, DOI 10.1182/blood-2003-12-4274
   Matsuyama W, 2000, AM J RESP CRIT CARE, V162, P1120, DOI 10.1164/ajrccm.162.3.9911010
   McColl SR, 1999, J IMMUNOL, V163, P2829
   McManus MT, 2002, NAT REV GENET, V3, P737, DOI 10.1038/nrg908
   Nick JA, 2000, J IMMUNOL, V164, P2151, DOI 10.4049/jimmunol.164.4.2151
   Ongusaha PP, 2003, EMBO J, V22, P1289, DOI 10.1093/emboj/cdg129
   Pittet JF, 2001, J CLIN INVEST, V107, P1537, DOI 10.1172/JCI11963
   RAGHOW R, 1985, J CLIN INVEST, V76, P1733, DOI 10.1172/JCI112163
   Rollins BJ, 1997, BLOOD, V90, P909
   Sakamoto O, 2001, EUR RESPIR J, V17, P969, DOI 10.1183/09031936.01.17509690
   Shrivastava A, 1997, MOL CELL, V1, P25, DOI 10.1016/S1097-2765(00)80004-0
   SIRES UI, 1993, J BIOL CHEM, V268, P2069
   Smith RE, 1998, J LEUKOCYTE BIOL, V64, P528
   STANDIFORD TJ, 1991, J BIOL CHEM, V266, P9912
   STANDIFORD TJ, 1990, J CLIN INVEST, V86, P1945, DOI 10.1172/JCI114928
   Suga M, 1999, EUR RESPIR J, V14, P376, DOI 10.1034/j.1399-3003.1999.14b23.x
   Vogel W, 1997, MOL CELL, V1, P13, DOI 10.1016/S1097-2765(00)80003-9
   Vogel W, 1999, FASEB J, V13, pS77
   ZHANG K, 1995, AM J PATHOL, V147, P352
NR 44
TC 32
Z9 33
U1 6
U2 12
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
EI 1550-6606
J9 J IMMUNOL
JI J. Immunol.
PD FEB 1
PY 2006
VL 176
IS 3
BP 1928
EP 1936
DI 10.4049/jimmunol.176.3.1928
PG 9
WC Immunology
SC Immunology
GA 004QF
UT WOS:000234766600073
PM 16424224
OA Bronze
DA 2018-12-27
ER

PT J
AU Deinsberger, R
   Regatschnig, R
   Kaiser, B
   Bankl, HC
AF Deinsberger, R
   Regatschnig, R
   Kaiser, B
   Bankl, HC
TI RETRACTED: Spinal leptomeningeal metastases from prostate cancer
   (Retracted Article. See vol 152, pg 929, 2010)
SO JOURNAL OF NEURO-ONCOLOGY
LA English
DT Article; Retracted Publication
DE intradural extramedullary metastases; prostate carcinoma; radiotherapy;
   surgery
ID CORD COMPRESSION; COMPARTMENT; NEOPLASMS; MR
AB Objective: Prostate cancer is a well known cause of spinal column metastases; however, an intradural location is extremely rare. It is considered to be a type of leptomeningeal spread. Cerebral seeding has usually occurred by the time of presentation. Due to a poor prognosis, surgery is rarely indicated, and controversially discussed.
   Patient and results: We review the known cases of spinal leptomeningeal prostate cancer spread, including our patient, who developed paraparesis over 6 weeks, 3 years after prostate cancer was diagnosed. Following surgical decompression and resection, the patient additionally received radiation therapy of the spinal meninges and antihormonal treatment. Six months after surgery, the patient is still ambulatory with a good quality of life.
   Conclusion: Spinal leptomeningeal metastases occur at a late stage of systemic disease, and the prognosis is generally poor. In literature, outcomes after surgery are reported as devastating, with mortality and morbidity rates of up to 20 and 60%. The aim of surgery is to relieve pain, preserve or even restore neurological function, and reveal histology if uncertain. This may be achieved by debulking the tumor without placing the patient at an unacceptably high risk. Surgery should be performed in selected cases of spinal leptomeningeal metastases, in patients who are still ambulatory with controlled systemic disease, and should be followed by adjuvant therapy.
C1 Landesklinikum St Polten, Dept Neurosurg, A-3100 St Polten, Austria.
   Landesklinikum St Polten, Dept Diagnost & Intervent Radiol, A-3100 St Polten, Austria.
   Landesklinikum St Polten, Dept Pathol, A-3100 St Polten, Austria.
RP Deinsberger, R (reprint author), Landesklinikum St Polten, Dept Neurosurg, Propst Fuhrerstr 4, A-3100 St Polten, Austria.
EM r.deinsberger@kh-st-poelten.at
CR BAROLATROMANA G, 1983, SURG NEUROL, V19, P137, DOI 10.1016/0090-3019(83)90411-1
   CERECEDA LE, 2003, CLIN PROSTATE C 0602, P34
   Chow TSF, 1996, J NEUROSURG, V85, P225, DOI 10.3171/jns.1996.85.2.0225
   Collie DA, 1999, CLIN RADIOL, V54, P765, DOI 10.1016/S0009-9260(99)91181-9
   Frey I, 1998, EUR RADIOL, V8, P1187, DOI 10.1007/s003300050532
   Hentschel SJ, 2004, J NEUROSURG, V100, P375, DOI 10.3171/spi.2004.100.4.0375
   KUBAN DA, 1986, UROLOGY, V28, P364, DOI 10.1016/0090-4295(86)90062-2
   Landis SH, 1999, CA-CANCER J CLIN, V49, P8, DOI 10.3322/canjclin.49.1.8
   LICTENBERG DLM, 1992, SCAND J UROL NEPHROL, V26, P25
   Mehrotra R, 2002, Indian J Cancer, V39, P157
   OSBORN JL, 1995, J NEURO-ONCOL, V23, P135, DOI 10.1007/BF01053418
   PERRIN RG, 1982, J NEUROSURG, V56, P835, DOI 10.3171/jns.1982.56.6.0835
   Quinn M, 2002, BJU INT, V90, P174, DOI 10.1046/j.1464-410X.2002.02823.x
   Schioler P, 2005, J MICROPALAEONTOL, V24, P1, DOI 10.1144/jm.24.1.1
   SCHUKNECHT B, 1992, EUR NEUROL, V32, P11, DOI 10.1159/000116780
   SHOSKES DA, 1989, J UROLOGY, V142, P337, DOI 10.1016/S0022-5347(17)38750-5
   WEST CGH, 1979, J NEUROSURG, V51, P251, DOI 10.3171/jns.1979.51.2.0251
NR 17
TC 7
Z9 7
U1 3
U2 9
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0167-594X
EI 1573-7373
J9 J NEURO-ONCOL
JI J. Neuro-Oncol.
PD FEB
PY 2006
VL 76
IS 3
BP 293
EP 297
DI 10.1007/s11060-005-7284-0
PG 5
WC Oncology; Clinical Neurology
SC Oncology; Neurosciences & Neurology
GA 026ZI
UT WOS:000236381800011
PM 16151594
DA 2018-12-27
ER

PT J
AU Li, QR
   Ma, J
   Tan, L
   Wang, C
   Li, N
   Li, YS
   Xu, GW
   Li, JS
AF Li, QR
   Ma, J
   Tan, L
   Wang, C
   Li, N
   Li, YS
   Xu, GW
   Li, JS
TI RETRACTED: Effect of docosahexaenoic acid on interleukin-2 receptor
   signaling pathway in lipid rafts (Retracted article. See vol 50 pg 140,
   2007)
SO SCIENCE IN CHINA SERIES C-LIFE SCIENCES
LA English
DT Article; Retracted Publication
DE polyunsaurated fatty acids; docosahexaenoic acid; IL-2 receptor
   signaling pathway; lipid raft
ID POLYUNSATURATED FATTY-ACIDS; PROTEIN-TYROSINE KINASES; PLASMA-MEMBRANE
   RAFTS; GPI-MICRODOMAINS; RECEPTOR; LOCALIZATION; ACTIVATION; CELLS;
   STATS
AB Recent studies have shown that polyunsaturated fatty acids (PUFA) regulated the functions of membrane receptors in T cells and suppressed T cell-mediated immune responses. But the molecular mechanisms of immune regulation are not yet elucidated. Lipid rafts are plasma membrane microdomains, in which many receptors localized. The purpose of this study was to investigate the effect of DHA on IL-2R signaling pathway in lipid rafts. We isolated lipid rafts by discontinuous sucrose density gradient ultracentrifugation, and found that DHA could change the composition of lipid rafts and alter the distribution of key molecules of IL-2R signaling pathway, which transferred from lipid rafts to detergent-soluble membrane fractions. These results revealed that DHA treatment increased the proportion of polyunsaturated fatty acids especially n-3 polyunsaturated fatty acids in lipid rafts and changed the lipid environment of membrane microdomains in T cells. Compared with controls, DHA changed the localization of IL-2R, STAT5a and STAT5b in lipid rafts and suppressed the expression of JAK1, JAK3 and tyrosine phosphotyrosine in soluble membrane fractions. Summarily, this study concluded the effects of DHA on IL-2R signaling pathway in lipid rafts and explained the regulation of PUFAs in T cell-mediated immune responses.
C1 Gen Hosp Nanjing Command, Inst Gen Surg, Nanjing 210002, Peoples R China.
   Chinese Acad Sci, Inst Chem Phys, Natl Chromatogr R&A Ctr, Dalian 116011, Peoples R China.
RP Li, JS (reprint author), Gen Hosp Nanjing Command, Inst Gen Surg, Nanjing 210002, Peoples R China.
EM liqiurong@yahoo.com
CR BROUARD C, 1990, BIOCHIM BIOPHYS ACTA, V1047, P19, DOI 10.1016/0005-2760(90)90255-V
   DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455
   Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630
   Dillon SR, 2000, J IMMUNOL, V164, P1322, DOI 10.4049/jimmunol.164.3.1322
   Goebel J, 2002, J LEUKOCYTE BIOL, V72, P199
   Gratton JP, 2000, J BIOL CHEM, V275, P22268, DOI 10.1074/jbc.M001644200
   Heinrich PC, 1998, BIOCHEM J, V334, P297, DOI 10.1042/bj3340297
   Holowka D, 2000, J CELL SCI, V113, P1009
   Horejsi V, 1999, IMMUNOL TODAY, V20, P356, DOI 10.1016/S0167-5699(99)01489-9
   Ilangumaran S, 1999, MOL BIOL CELL, V10, P891, DOI 10.1091/mbc.10.4.891
   Jolly CA, 1997, J NUTR, V127, P37
   Ju H, 2000, BIOCHEM J, V351, P257, DOI 10.1042/0264-6021:3510257
   Jump DB, 2002, J BIOL CHEM, V277, P8755, DOI 10.1074/jbc.R100062200
   Leonard WJ, 1998, ANNU REV IMMUNOL, V16, P293, DOI 10.1146/annurev.immunol.16.1.293
   Lin JX, 2000, ONCOGENE, V19, P2566, DOI 10.1038/sj.onc.1203523
   Marmor MD, 2001, BLOOD, V98, P1489, DOI 10.1182/blood.V98.5.1489
   Matko J, 2002, EUR J BIOCHEM, V269, P1199, DOI 10.1046/j.0014-2956.2002.02759.x
   MIYAZAKI T, 1994, SCIENCE, V266, P1045, DOI 10.1126/science.7973659
   Moffett S, 2000, J BIOL CHEM, V275, P2191, DOI 10.1074/jbc.275.3.2191
   Rossetti RG, 1997, J LEUKOCYTE BIOL, V62, P438
   Sehgal PB, 2003, ACTA BIOCHIM POL, V50, P583
   Sehgal PB, 2002, J BIOL CHEM, V277, P12067, DOI 10.1074/jbc.M200018200
   SHENOYSCARIA AM, 1992, J IMMUNOL, V149, P3535
   Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408
   STEFANOVA I, 1991, SCIENCE, V254, P1016, DOI 10.1126/science.1719635
   Stulnig TM, 1998, J CELL BIOL, V143, P637, DOI 10.1083/jcb.143.3.637
   Stulnig TM, 2001, J BIOL CHEM, V276, P37335, DOI 10.1074/jbc.M106193200
   VAMOSI G, 2004, J IMMUNOL, V173, P6151
   Webb Y, 2000, J BIOL CHEM, V275, P261, DOI 10.1074/jbc.275.1.261
   ZURIER RB, 1993, PROSTAG LEUKOTR ESS, V48, P57, DOI 10.1016/0952-3278(93)90010-T
NR 30
TC 4
Z9 8
U1 4
U2 12
PU SCIENCE PRESS
PI BEIJING
PA 16 DONGHUANGCHENGGEN NORTH ST, BEIJING 100717, PEOPLES R CHINA
SN 1006-9305
J9 SCI CHINA SER C
JI Sci. China Ser. C-Life Sci.
PD FEB
PY 2006
VL 49
IS 1
BP 63
EP 72
DI 10.1007/s11427-005-0014-1
PG 10
WC Biology
SC Life Sciences & Biomedicine - Other Topics
GA 023WE
UT WOS:000236156100008
PM 16544577
DA 2018-12-27
ER

PT J
AU Kurtovic, J
   Boyle, M
   Bihari, D
   Riordan, SM
AF Kurtovic, J
   Boyle, M
   Bihari, D
   Riordan, SM
TI RETRACTED: An Australian experience with the molecular adsorbents
   recirculating system (MARS) (Retracted article. See vol. 16, pg. 200,
   2012)
SO THERAPEUTIC APHERESIS AND DIALYSIS
LA English
DT Article; Retracted Publication
DE albumin; artificial liver support; liver failure; molecular adsorbents
   recirculating system; toxins
ID ALBUMIN DIALYSIS; RECYCLING SYSTEM; LIVER-FAILURE; BIOARTIFICIAL LIVER;
   MEMBRANE; SUPPORT; TRIAL; BLOOD
AB The molecular adsorbents recirculating system (MARS) is a form of artificial extracorporeal liver support which has the potential to remove substantial quantities of albumin-bound toxins postulated to contribute to the pathogenesis of liver cell damage, hemodynamic instability and multi-organ failure in patients with acute liver failure and acute-on-chronic liver failure (AoCLF). We assessed the efficacy of MARS therapy in a cohort of patients with severe liver damage unresponsive to intensive medical therapy. MARS therapy was instituted late in the clinical course of six patients with severely impaired liver function refractory to intensive medical therapy, including four with AoCLF precipitated by sepsis and two with liver dysfunction due to sepsis in the absence of pre-existing chronic liver disease. Outcome measures included markers of hemodynamic stability, renal function, serum bilirubin and bile acid levels, arterial ammonia levels, the arterial ketone body (acetoacetate/beta-hydroxybutyrate) ratio, hepatic encephalopathy grade and the plasma disappearance rate of indocyanine green. The rates of discharge from the intensive care unit and in-hospital mortality were determined. Our findings suggest that MARS treatment might be associated with some clinical efficacy even in patients with advanced multi-organ dysfunction occurring in the setting of severe liver damage and in whom treatment is instituted late in the clinical course. However, the overall survival rate (1/6; 17%) was poor. More data obtained from larger cohorts of patients enrolled in randomized controlled studies will be required in order to identify categories of liver failure patients who might benefit most from MARS treatment and to ascertain the most appropriate timing of intervention.
C1 Prince Wales Hosp, Gastrointestinal & Liver Unit, Randwick, NSW 2031, Australia.
   Prince Wales Hosp, Dept Intens Care, Randwick, NSW 2031, Australia.
RP Riordan, SM (reprint author), Prince Wales Hosp, Gastrointestinal & Liver Unit, Barker St, Randwick, NSW 2031, Australia.
EM sriordan@ozemail.com.au
CR Catalina MV, 2003, LIVER INT, V23, P39, DOI 10.1034/j.1478-3231.23.s.3.10.x
   Evenepoel P, 2003, BLOOD PURIFICAT, V21, P244, DOI 10.1159/000070697
   Heemann U, 2002, HEPATOLOGY, V36, P949, DOI 10.1053/jhep.2002.36130
   McIntyre CW, 2002, CLIN NEPHROL, V58, P376
   Mitzner SR, 2000, LIVER TRANSPLANT, V6, P277, DOI 10.1053/lv.2000.6355
   Riordan SM, 2000, J HEPATOL, V32, P63, DOI 10.1016/S0168-8278(00)80416-X
   Schmidt LE, 2003, LIVER TRANSPLANT, V9, P290, DOI 10.1053/jlts.2003.50051
   SCHNEIDER T, 2003, 5 INT S ALB DIAL LIV, P61
   Sorkine P, 2001, CRIT CARE MED, V29, P1332, DOI 10.1097/00003246-200107000-00006
   Stange J, 1996, INT J ARTIF ORGANS, V19, P677
   Stange J, 1999, ARTIF ORGANS, V23, P319
NR 11
TC 11
Z9 12
U1 3
U2 9
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1744-9979
EI 1744-9987
J9 THER APHER DIAL
JI Ther. Apher. Dial.
PD FEB
PY 2006
VL 10
IS 1
BP 2
EP 6
DI 10.1111/j.1744-9987.2006.00338.x
PG 5
WC Hematology; Urology & Nephrology
SC Hematology; Urology & Nephrology
GA 025OO
UT WOS:000236276100002
PM 16556129
DA 2018-12-27
ER

PT J
AU Yao, DC
   Taguchi, T
   Matsumura, T
   Pestell, R
   Edelstein, D
   Giardino, I
   Suske, G
   Ahmed, N
   Thornalley, PJ
   Sarthy, VP
   Hammes, HP
   Brownlee, M
AF Yao, DC
   Taguchi, T
   Matsumura, T
   Pestell, R
   Edelstein, D
   Giardino, I
   Suske, G
   Ahmed, N
   Thornalley, PJ
   Sarthy, VP
   Hammes, HP
   Brownlee, M
TI RETRACTED: Methylglyoxal modification of rnSin3A links glycolysis to
   angiopoietin-2 transcription (Retracted Article. See vol 128, pg 625,
   2007)
SO CELL
LA English
DT Article; Retracted Publication
ID 3 MAJOR PATHWAYS; GLYOXALASE-I; DIABETIC-RETINOPATHY; ADVANCED
   GLYCATION; O-GLYCOSYLATION; POSTTRANSLATIONAL MODIFICATION;
   HYPERGLYCEMIC DAMAGE; CANCER-CHEMOTHERAPY; ENDOTHELIAL-CELLS; SP1
AB Methylglyoxal is a highly reactive dicarbonyl degradation product formed from triose phosphates during glycolysis. Methylglyoxal forms stable adducts primarily with arginine residues of intracellular proteins. The biologic role of this covalent modification in regulating cell function is not known. Here, we report that in retinal Muller cells, increased glycolytic flux causes increased methylglyoxal modification of the corepressor mSin3A. Methylglyoxal modification of mSin3A results in increased recruitment of O-GlcNAc transferase to an mSin3A-Sp3 complex, with consequent increased modification of Sp3 by O-linked N-acetylglucosamine. This modification of Sp3 causes decreased binding of the repressor complex to a glucose-responsive GC box in the angiopoietin-2 promoter, resulting in increased Ang-2 expression. A similar mechanism involving methylglyoxal-modification of other coregulator proteins may play a role in the pathobiology of a variety of conditions associated with changes in methylglyoxal concentration, including cancer and diabetic vascular disease.
C1 Yeshiva Univ Albert Einstein Coll Med, JDRF Int Ctr Diabet Complicat Res, Bronx, NY 10461 USA.
   Georgetown Univ, Dept Oncol, Lombardi Canc Ctr, Washington, DC 20057 USA.
   Univ Marburg, Inst Mol Biol & Tumorforsch, D-35037 Marburg, Germany.
   Univ Essex, Dept Biol Sci, Colchester CO4 3SQ, Essex, England.
   Northwestern Univ, Feinberg Sch Med, Dept Ophthalmol, Chicago, IL 60093 USA.
   Univ Mannheim, Med Klin 5, D-68167 Mannheim, Germany.
RP Brownlee, M (reprint author), Yeshiva Univ Albert Einstein Coll Med, JDRF Int Ctr Diabet Complicat Res, 1300 Morris Pk Ave, Bronx, NY 10461 USA.
EM brownlee@aecom.yu.edu
OI Thornalley, Paul/0000-0001-7659-443X
FU NIDDK NIH HHS [DK 33861, DK 20541]; NIA NIH HHS [AG 021654]
CR Agalou S, 2003, BIOCHEM SOC T, V31, P1394
   Ahmed N, 2005, J BIOL CHEM, V280, P5724, DOI 10.1074/jbc.M410973200
   Ahmed N, 2003, BIOCHEM SOC T, V31, P1417
   Ahringer J, 2000, TRENDS GENET, V16, P351, DOI 10.1016/S0168-9525(00)02066-7
   Beisswenger PJ, 2003, BIOCHEM SOC T, V31, P1358
   Brownlee M, 2001, NATURE, V414, P813, DOI 10.1038/414813a
   Carmeliet P, 2003, NAT MED, V9, P653, DOI 10.1038/nm0603-653
   Chakraborty S, 2001, J CELL BIOCHEM, V82, P310, DOI 10.1002/jcb.1165
   Chaplen FWR, 1998, P NATL ACAD SCI USA, V95, P5533, DOI 10.1073/pnas.95.10.5533
   Creighton DJ, 2003, BIOCHEM SOC T, V31, P1378
   Crowley PB, 2005, PROTEINS, V59, P231, DOI 10.1002/prot.20417
   DONG DLY, 1994, J BIOL CHEM, V269, P19321
   Du XL, 2000, P NATL ACAD SCI USA, V97, P12222, DOI 10.1073/pnas.97.22.12222
   Du XL, 2001, J CLIN INVEST, V108, P1341, DOI 10.1172/JCI200111235
   Du XL, 2003, J CLIN INVEST, V112, P1049, DOI 10.1172/JCI200318127
   Fingerman IM, 2004, CELL, V117, P690, DOI 10.1016/j.cell.2004.05.021
   Gale NW, 2002, DEV CELL, V3, P411, DOI 10.1016/S1534-5807(02)00217-4
   Ghayor C, 2001, J BIOL CHEM, V276, P36881, DOI 10.1074/jbc.M105083200
   Hackett SF, 2002, J CELL PHYSIOL, V192, P182, DOI 10.1002/jcp.10128
   HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x
   Hammes HP, 2004, DIABETES, V53, P1104, DOI 10.2337/diabetes.53.4.1104
   Hammes HP, 2003, NAT MED, V9, P294, DOI 10.1038/nm834
   Hammes HP, 2002, DIABETES, V51, P3107, DOI 10.2337/diabetes.51.10.3107
   Hanahan D, 1997, SCIENCE, V277, P48, DOI 10.1126/science.277.5322.48
   Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7
   HORSCH M, 1991, EUR J BIOCHEM, V197, P815, DOI 10.1111/j.1432-1033.1991.tb15976.x
   Iozef R, 2003, FEBS LETT, V554, P284, DOI 10.1016/S0014-5793(03)01146-3
   Jain RK, 2003, NAT MED, V9, P685, DOI 10.1038/nm0603-685
   Kamemura K, 2003, PROG NUCLEIC ACID RE, V73, P107, DOI 10.1016/S0079-6603(03)01004-3
   Kang HT, 2003, J BIOL CHEM, V278, P51223, DOI 10.1074/jbc.M307332200
   Knoepfler PS, 1999, CELL, V99, P447, DOI 10.1016/S0092-8674(00)81531-7
   Kuzmichev A, 2002, MOL CELL BIOL, V22, P835, DOI 10.1128/MCB.22.3.835-848.2002
   Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9
   Li L, 2004, BIOCHEM CELL BIOL, V82, P460, DOI 10.1139/O04-045
   Lin JD, 2004, CELL, V119, P121, DOI 10.1016/j.cell.2004.09.013
   Lu F, 2003, J VIROL, V77, P11425, DOI 10.1128/JVI.77.21.11425-11435.2003
   Maeta K, 2004, MOL CELL BIOL, V24, P8753, DOI 10.1128/MCB.24.19.8753
   Maisonpierre PC, 1997, SCIENCE, V277, P55, DOI 10.1126/science.277.5322.55
   Metivier R, 2003, CELL, V115, P751, DOI 10.1016/S0092-8674(03)00934-6
   PHILLIPS SA, 1993, EUR J BIOCHEM, V212, P101, DOI 10.1111/j.1432-1033.1993.tb17638.x
   RICHARD JP, 1993, BIOCHEM SOC T, V21, P549, DOI 10.1042/bst0210549
   Roos MD, 1997, MOL CELL BIOL, V17, P6472, DOI 10.1128/MCB.17.11.6472
   Sakamoto H, 2001, CLIN CANCER RES, V7, P2513
   Sapetschnig A, 2004, J BIOL CHEM, V279, P42095, DOI 10.1074/jbc.M404989200
   Sarthy VP, 1998, INVEST OPHTH VIS SCI, V39, P212
   Shinohara M, 1998, J CLIN INVEST, V101, P1142, DOI 10.1172/JCI119885
   Skowyra D, 2001, J BIOL CHEM, V276, P8734, DOI 10.1074/jbc.M007664200
   Suske G, 1999, GENE, V238, P291, DOI 10.1016/S0378-1119(99)00357-1
   Thornalley PJ, 2003, BIOCHEM SOC T, V31, P1372
   Thornalley PJ, 2003, BIOCHEM SOC T, V31, P1343
   Van Herreweghe F, 2002, P NATL ACAD SCI USA, V99, P949, DOI 10.1073/pnas.012432399
   Venkatraman J, 2001, CHEM BIOL, V8, P611, DOI 10.1016/S1074-5521(01)00036-9
   Wells L, 2003, FEBS LETT, V546, P154, DOI 10.1016/S0014-5793(03)00641-0
   Yang XY, 2002, CELL, V110, P69, DOI 10.1016/S0092-8674(02)00810-3
   Yang XY, 2001, P NATL ACAD SCI USA, V98, P6611, DOI 10.1073/pnas.111099998
   Zachara NE, 2004, TRENDS CELL BIOL, V14, P218, DOI 10.1016/j.tcb.2004.03.005
   Zhanel George G, 2002, Expert Opin Pharmacother, V3, P277
   Zhang FX, 2003, CELL, V115, P715, DOI 10.1016/S0092-8674(03)00974-7
NR 58
TC 62
Z9 66
U1 3
U2 20
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 0092-8674
EI 1097-4172
J9 CELL
JI Cell
PD JAN 27
PY 2006
VL 124
IS 2
BP 275
EP 286
DI 10.1016/j.cell.2005.11.024
PG 12
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 008VJ
UT WOS:000235068500017
PM 16413606
OA Bronze
DA 2018-12-27
ER

PT J
AU Razem, FA
   El-Kereamy, A
   Abrams, SR
   Hill, RD
AF Razem, FA
   El-Kereamy, A
   Abrams, SR
   Hill, RD
TI RETRACTED: The RNA-binding protein FCA is an abscisic acid receptor
   (Retracted Article. See vol 456, pg 824, 2008)
SO NATURE
LA English
DT Article; Retracted Publication
ID ARABIDOPSIS FLOWERING TIME; SIGNAL-TRANSDUCTION; BIOLOGICAL-ACTIVITY;
   AUTONOMOUS PATHWAY; AUXIN RECEPTOR; VERNALIZATION; MODULATION; ENCODES;
   ANALOGS; TIR1
AB The phytohormone abscisic acid (ABA) regulates various physiological processes in plants. The molecular mechanisms by which this is achieved are not fully understood. Genetic approaches have characterized several downstream components of ABA signalling, but a receptor for ABA has remained elusive. Although studies indicate that several ABA response genes encode RNA-binding or RNA-processing proteins, none has been found to be functional in binding ABA. Here we show that FCA, an RNA-binding protein involved in flowering, binds ABA with high affinity in an interaction that is stereospecific and follows receptor kinetics. The interaction between FCA and ABA has molecular effects on downstream events in the autonomous floral pathway and, consequently, on the ability of the plant to undergo transition to flowering. We further show that ABA binding exerts a direct control on the FCA-mediated processing of precursor messenger RNA. Our results indicate that FCA is an ABA receptor involved in RNA metabolism and in controlling flowering time.
C1 Univ Manitoba, Dept Plant Sci, Winnipeg, MB R3T 2N2, Canada.
   Natl Res Council Canada, Inst Plant Biotechnol, Saskatoon, SK S7N 0W9, Canada.
RP Hill, RD (reprint author), Univ Manitoba, Dept Plant Sci, Winnipeg, MB R3T 2N2, Canada.
EM rob_hill@umanitoba.ca
CR Bastow R, 2004, NATURE, V427, P164, DOI 10.1038/nature02269
   Cheng YL, 2004, CURR OPIN PLANT BIOL, V7, P20, DOI 10.1016/j.pbi.2003.11.005
   De Smet I, 2003, PLANT J, V33, P543, DOI 10.1046/j.1365-313X.2003.01652.x
   Dharmasiri N, 2005, NATURE, V435, P441, DOI 10.1038/nature03543
   Finkelstein RR, 2002, PLANT CELL, V14, pS15, DOI 10.1105/tpc.010441
   Finkelstein RR, 2002, ARABIDOPSIS BOOK, V45, P1, DOI [10.1199/tab.0058, DOI 10.1199/TAB.0058]
   GUSTA LV, 1992, CAN J BOT, V70, P1550, DOI 10.1139/b92-195
   Hays DB, 1996, J PLANT GROWTH REGUL, V15, P5, DOI 10.1007/BF00213128
   Henderson IR, 2004, DEVELOPMENT, V131, P3829, DOI 10.1242/dev.01294
   HILL RD, 1995, PLANT PHYSIOL, V108, P573, DOI 10.1104/pp.108.2.573
   Himmelbach A, 2003, CURR OPIN PLANT BIOL, V6, P470, DOI 10.1016/S1369-5266(03)00090-6
   Hugouvieux V, 2001, CELL, V106, P477, DOI 10.1016/S0092-8674(01)00460-3
   JEFFERSON RA, 1987, EMBO J, V6, P3901
   Kepinski S, 2005, NATURE, V435, P446, DOI 10.1038/nature03542
   Kuhn JM, 2003, CURR OPIN PLANT BIOL, V6, P463, DOI 10.1016/S1369-5266(03)00084-0
   Leung J, 1998, ANNU REV PLANT PHYS, V49, P199, DOI 10.1146/annurev.arplant.49.1.199
   Li JX, 2002, NATURE, V418, P793, DOI 10.1038/nature00936
   Lu C, 2000, PLANT CELL, V12, P2351, DOI 10.1105/tpc.12.12.2351
   Macknight R, 1997, CELL, V89, P737, DOI 10.1016/S0092-8674(00)80256-1
   Macknight R, 2002, PLANT CELL, V14, P877, DOI 10.1105/tpc.010456
   Markarov AM, 2002, RUSS J PLANT PHYSL+, V49, P465, DOI 10.1023/A:1016399606792
   Michaels SD, 1999, PLANT CELL, V11, P949, DOI 10.1105/tpc.11.5.949
   Michaels SD, 2001, PLANT CELL, V13, P935, DOI 10.1105/tpc.13.4.935
   Nyangulu JM, 2005, J AM CHEM SOC, V127, P1662, DOI 10.1021/ja0429059
   Quesada V, 2003, EMBO J, V22, P3142, DOI 10.1093/emboj/cdg305
   Razem FA, 2004, J BIOL CHEM, V279, P9922, DOI 10.1074/jbc.M311064200
   Sheldon CC, 2000, P NATL ACAD SCI USA, V97, P3753, DOI 10.1073/pnas.060023597
   Simpson GG, 2004, CURR OPIN PLANT BIOL, V7, P570, DOI 10.1016/j.pbi.2004.07.002
   Simpson GG, 2003, CELL, V113, P777, DOI 10.1016/S0092-8674(03)00425-2
   Su WR, 2002, J PLANT PHYSIOL, V159, P557, DOI 10.1078/0176-1617-00732
   Sung S, 2005, ANNU REV PLANT BIOL, V56, P491, DOI 10.1146/annurev.arplant.56.032604.144307
   Sutton F, 2000, PLANT PHYSIOL, V124, P223, DOI 10.1104/pp.124.1.223
   Wijayanti L, 1997, J PLANT GROWTH REGUL, V16, P115, DOI 10.1007/PL00006977
   Xiong LM, 2001, DEV CELL, V1, P771, DOI 10.1016/S1534-5807(01)00087-9
NR 34
TC 226
Z9 268
U1 5
U2 58
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0028-0836
EI 1476-4687
J9 NATURE
JI Nature
PD JAN 19
PY 2006
VL 439
IS 7074
BP 290
EP 294
DI 10.1038/nature04373
PG 5
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 003LA
UT WOS:000234682100034
PM 16421562
DA 2018-12-27
ER

PT J
AU Pisconti, A
   Brunelli, S
   Di Padova, M
   De Palma, C
   Deponti, D
   Baesso, S
   Sartorelli, V
   Cossu, G
   Clementi, E
AF Pisconti, A
   Brunelli, S
   Di Padova, M
   De Palma, C
   Deponti, D
   Baesso, S
   Sartorelli, V
   Cossu, G
   Clementi, E
TI RETRACTED: Follistatin induction by nitric oxide through cyclic GMP: a
   tightly regulated signaling pathway that controls myoblast fusion
   (Retracted article. See vol. 200, pg. 359, 2013)
SO JOURNAL OF CELL BIOLOGY
LA English
DT Article; Retracted Publication
ID DEPENDENT PROTEIN-KINASE; MUSCLE SATELLITE CELLS; GROWTH-FACTOR-I;
   SKELETAL-MUSCLE; CARDIAC MYOCYTES; GUANYLYL CYCLASE; GENE-EXPRESSION;
   STEM-CELLS; SYNTHASE; CGMP
AB T he mechanism of skeletal myoblast fusion is not well understood. We show that endogenous nitric oxide (NO) generation is required for myoblast fusion both in embryonic myoblasts and in satellite cells. The effect of NO is concentration and time dependent, being evident only at the onset of differentiation, and direct on the fusion process itself. The action of NO is mediated through a tightly regulated activation of guanylate cyclase and generation of cyclic guanosine monophosphate (cGMP), so much so that deregulation of cGMP signaling leads to a fusion-induced hypertrophy of satellite-derived myotubes and embryonic muscles, and to the acquisition of fusion competence by myogenic precursors in the presomitic mesoderm. NO and cGMP induce expression of follistatin, and this secreted protein mediates their action in myogenesis. These results establish a hitherto unappreciated role of NO and cGMP in regulating myoblast fusion and elucidate their mechanism of action, providing a direct link with follistatin, which is a key player in myogenesis.
C1 Hosp San Raffaele, Stem Cell Res Inst, I-20132 Milan, Italy.
   Univ Milano Bicocca, Dept Expt Environm Med & Med Biotechnol, I-20052 Monza, Italy.
   NIAMSD, Muscle Gene Express Grp, Muscle Biol Lab, NIH, Bethesda, MD 20892 USA.
   Eugenio Medea Sci Inst, I-23842 Bosisio Parini, Italy.
   San Raffaele Biomed Sci Pk Roma, Inst Cell Biol & Tissue Engn, I-00128 Milan, Italy.
   Univ Milan, Dept Biol, I-20130 Milan, Italy.
   Dept Preclin Sci, I-20157 Milan, Italy.
RP Cossu, G (reprint author), Hosp San Raffaele, Stem Cell Res Inst, I-20132 Milan, Italy.
EM guilio.cossu@hsr.it; clementi.emilio@hsr.it
RI De Palma, Clara/A-9172-2010; Brunelli, Silvia/J-3248-2014
OI Brunelli, Silvia/0000-0003-1753-5346; DI PADOVA,
   Monica/0000-0003-3808-7159
FU Telethon [GGP05007]
CR Alderton WK, 2001, BIOCHEM J, V357, P593, DOI 10.1042/0264-6021:3570593
   Amthor H, 2002, DEV BIOL, V243, P115, DOI 10.1006/dbio.2001.0555
   Anderson JE, 2000, MOL BIOL CELL, V11, P1859, DOI 10.1091/mbc.11.5.1859
   Aramburu J, 1999, SCIENCE, V285, P2129, DOI 10.1126/science.285.5436.2129
   Balemans W, 2002, DEV BIOL, V250, P231, DOI 10.1006/dbio.2002.0779
   Balon TW, 1997, J APPL PHYSIOL, V82, P359
   Bellamy TC, 2000, P NATL ACAD SCI USA, V97, P2928, DOI 10.1073/pnas.97.6.2928
   Bilezikjian LM, 2001, ENDOCRINOLOGY, V142, P1065, DOI 10.1210/en.142.3.1065
   Blottner D, 1998, CELL TISSUE RES, V292, P293, DOI 10.1007/s004410051060
   Bosc LVG, 2004, J BIOL CHEM, V279, P10702, DOI 10.1074/jbc.M312920200
   Bredt DS, 1998, P NATL ACAD SCI USA, V95, P14592, DOI 10.1073/pnas.95.25.14592
   Brunelli S, 2004, CIRC RES, V94, P1571, DOI 10.1161/01.RES.0000132747.12860.10
   Brunelli S, 2003, GENESIS, V36, P12, DOI 10.1002/gene.10193
   Buckingham M, 2003, J ANAT, V202, P59, DOI 10.1046/j.1469-7580.2003.00139.x
   Bulotta S, 2001, J BIOL CHEM, V276, P6529, DOI 10.1074/jbc.M006535200
   Charge SBP, 2004, PHYSIOL REV, V84, P209, DOI 10.1152/physrev.00019.2003
   Chen AE, 2005, NATURE, V433, P317, DOI 10.1038/nature03126
   Chen EH, 2004, TRENDS CELL BIOL, V14, P452, DOI 10.1016/j.tcb.2004.07.008
   Clementi E, 1997, TRENDS PHARMACOL SCI, V18, P266
   Clementi E, 1998, P NATL ACAD SCI USA, V95, P7631, DOI 10.1073/pnas.95.13.7631
   CORNWELL TL, 1994, AM J PHYSIOL-CELL PH, V267, pC1405
   Corradi N, 1996, J BIOL CHEM, V271, P27116, DOI 10.1074/jbc.271.43.27116
   Cossu G, 2005, SEMIN CELL DEV BIOL, V16, P623, DOI 10.1016/j.semcdb.2005.07.003
   COSSU G, 1980, CELL DIFFER DEV, V9, P357, DOI 10.1016/0045-6039(80)90035-4
   Cossu G, 1996, DEVELOPMENT, V122, P429
   COSSU G, 1987, DEV BIOL, V123, P43, DOI 10.1016/0012-1606(87)90425-8
   CUSELLADEANGELIS MG, 1994, DEVELOPMENT, V120, P925
   El Dwairi Q, 1998, AM J RESP CELL MOL, V18, P844, DOI 10.1165/ajrcmb.18.6.3109
   Eu JP, 2003, P NATL ACAD SCI USA, V100, P15229, DOI 10.1073/pnas.2433468100
   Fiedler B, 2002, P NATL ACAD SCI USA, V99, P11363, DOI 10.1073/pnas.162100799
   Fish JE, 2005, J BIOL CHEM, V280, P24824, DOI 10.1074/jbc.M502115200
   Friebe A, 2003, CIRC RES, V93, P96, DOI 10.1161/01.RES.0000082524.34487.31
   Galliano MF, 2000, J BIOL CHEM, V275, P13933, DOI 10.1074/jbc.275.18.13933
   Gan YH, 2005, J BIOL CHEM, V280, P16467, DOI 10.1074/jbc.M412960200
   Glass DJ, 2003, NAT CELL BIOL, V5, P87, DOI 10.1038/ncb0203-87
   Gudi T, 1996, J BIOL CHEM, V271, P4597
   Guttridge DC, 2004, CURR OPIN CLIN NUTR, V7, P443, DOI 10.1097/01.mco.0000134364.61406.26
   Herzig S, 2001, NATURE, V413, P179, DOI 10.1038/35093131
   Horsley V, 2004, CELLS TISSUES ORGANS, V176, P67, DOI 10.1159/000075028
   Horsley V, 2003, CELL, V113, P483, DOI 10.1016/S0092-8674(03)00319-2
   Ibarra C, 2004, J BIOL CHEM, V279, P7554, DOI 10.1074/jbc.M311604200
   Iemura S, 1998, P NATL ACAD SCI USA, V95, P9337, DOI 10.1073/pnas.95.16.9337
   Iezzi S, 2004, DEV CELL, V6, P673, DOI 10.1016/S1534-5807(04)00107-8
   Kaliman P, 1999, J BIOL CHEM, V274, P17437, DOI 10.1074/jbc.274.25.17437
   KELLY R, 1995, J CELL BIOL, V129, P383, DOI 10.1083/jcb.129.2.383
   LEE KH, 1994, J BIOL CHEM, V269, P14371
   Lee SJ, 2001, P NATL ACAD SCI USA, V98, P9306, DOI 10.1073/pnas.151270098
   Moncada S, 2002, NAT REV MOL CELL BIO, V3, P214, DOI 10.1038/nrm762
   MONCADA S, 1991, PHARMACOL REV, V43, P109
   Musaro A, 1999, MOL CELL BIOL, V19, P3115
   Nisoli E, 2004, P NATL ACAD SCI USA, V101, P16507, DOI 10.1073/pnas.0405432101
   ONTELL M, 1984, AM J ANAT, V171, P133, DOI 10.1002/aja.1001710202
   Parker MH, 2003, NAT REV GENET, V4, P497, DOI 10.1038/nrg1109
   Pilz RB, 2003, CIRC RES, V93, P1034, DOI 10.1161/01.RES.0000103311.52853.48
   Relaix F, 2005, NATURE, V435, P948, DOI 10.1038/nature03594
   Rommel C, 2001, NAT CELL BIOL, V3, P1009, DOI 10.1038/ncb1101-1009
   Schwander M, 2003, DEV CELL, V4, P673, DOI 10.1016/S1534-5807(03)00118-7
   Smolenski A, 1998, N-S ARCH PHARMACOL, V358, P134, DOI 10.1007/PL00005234
   Stamler JS, 2001, PHYSIOL REV, V81, P209
   Stitt TN, 2004, MOL CELL, V14, P395, DOI 10.1016/S1097-2765(04)00211-4
   Tajbakhsh S, 2003, CURR OPIN GENET DEV, V13, P413, DOI 10.1016/S0959-437X(03)00090-X
   Tatsumi R, 2002, MOL BIOL CELL, V13, P2909, DOI 10.1091/mbc.E02-01-0062
   Thompson M, 1996, J APPL PHYSIOL, V81, P2415
   WAKELAM MJO, 1985, BIOCHEM J, V228, P1
   WANG T, 1995, NATURE, V374, P262, DOI 10.1038/374262a0
   Wolosker H, 1997, BIOCHEM J, V321, P545, DOI 10.1042/bj3210545
   Yi HQ, 2005, J BIOL CHEM, V280, P23475, DOI 10.1074/jbc.M413550200
NR 67
TC 86
Z9 90
U1 3
U2 15
PU ROCKEFELLER UNIV PRESS
PI NEW YORK
PA 950 THIRD AVE, 2ND FLR, NEW YORK, NY 10022 USA
SN 0021-9525
EI 1540-8140
J9 J CELL BIOL
JI J. Cell Biol.
PD JAN 16
PY 2006
VL 172
IS 2
BP 233
EP 244
DI 10.1083/jcb.200507083
PG 12
WC Cell Biology
SC Cell Biology
GA 003JR
UT WOS:000234678500009
PM 16401724
OA Green Published, Bronze
DA 2018-12-27
ER

PT J
AU Zhang, YX
   Banerjee, S
   Wang, ZW
   Xu, H
   Zhang, LY
   Mohammad, R
   Aboukameel, A
   Adsay, NV
   Che, MX
   Abbruzzese, J
   Majumdar, APN
   Sarkar, FH
AF Zhang, YX
   Banerjee, S
   Wang, ZW
   Xu, H
   Zhang, LY
   Mohammad, R
   Aboukameel, A
   Adsay, NV
   Che, MX
   Abbruzzese, J
   Majumdar, APN
   Sarkar, FH
TI RETRACTED: Antitumor activity of epidermal growth factor
   receptor-related protein is mediated by inactivation of ErbB receptors
   and nuclear factor-kappa B in pancreatic cancer (Retracted article. See
   vol. 78, pg. 5477, 2018)
SO CANCER RESEARCH
LA English
DT Article; Retracted Publication
ID BREAST-CANCER; EXPRESSION; CELLS; APOPTOSIS; PEPTIDE; EGFR
AB The erbB family of receptor tyrosine kinases plays critical roles in human cancers, including pancreatic cancer. Discovering a specific agent, which targets multiple members of the erbB family, would be important in pancreatic cancer therapy. Recently, we isolated a novel negative regulator of epidermal growth factor receptor (EGFR), termed EGFR-related protein (ERRP), whose expression attenuates EGFR activation. In the current study, we examined the effects of recombinant ERRP on the growth and ligand-induced activation of multiple members of erbB family in three pancreatic cancer cell lines that express varying levels of EGFR and other member(s) of its family, specifically HER-2. Additionally, we compared the growth inhibitory effect of ERRP with that of Erbitux or Herceptin. Our results showed that ERRP is most effective in inhibiting proliferation of BxPC-3, HPAC, and PANC-1 pancreatic cancer cells. ERRP also inhibited ligand-induced activation of EGFR, HER-2, and HER-3 (ErbB3). In contrast, Erbitux and Herceptin only partially or modestly inhibited activation of EGFR, HER-2, and HER-3. Most importantly, ERRP was found to inhibit pancreatic tumor growth in a severe combined immunodeficient mouse xenograft model. The antitumor activity of ERRP correlates well with tumor differentiation and down-regulation of nuclear factor-kappa B activity. In summary, our results suggest that ERRP is an effective pan-erbB inhibitor, which could be a potential therapeutic agent for pancreatic cancers expressing different levels and subclasses of erbB family of proteins.
C1 Wayne State Univ, Sch Med, Dept Pathol, Detroit, MI 48201 USA.
   Wayne State Univ, Sch Med, Dept Internal Med, Div Hematol & Oncol,Karmanos Canc Inst, Detroit, MI USA.
   Vet Affairs Med Ctr, Dept Internal Med, Detroit, MI USA.
   Capital Univ Med Sci, Dept Biochem & Mol Biol, Beijing, Peoples R China.
   Univ Texas, MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, Houston, TX USA.
RP Sarkar, FH (reprint author), 740 HWCRC,110 E Warren Ave, Detroit, MI 48201 USA.
EM fsarkar@med.wayne.edu
RI Adsay, Volkan/N-7130-2017; Wang, Zhiwei/A-6809-2011
FU NCI NIH HHS [1R01 CA 101870-02, P20 CA 101936-02]
CR Adsay NV, 2003, AM J SURG PATHOL, V27, P571, DOI 10.1097/00000478-200305000-00002
   BALSEGA J, 2000, J CLIN ONCOL, V18, P904
   BANERJEE S, 2005, CANCER RES, V65, P1
   Ciardiello Fortunato, 2005, Future Oncol, V1, P221, DOI 10.1517/14796694.1.2.221
   Cobleigh MA, 1999, J CLIN ONCOL, V17, P2639, DOI 10.1200/JCO.1999.17.9.2639
   Feng J, 2002, PANCREAS, V25, P342, DOI 10.1097/00006676-200211000-00004
   Friess H, 1995, CLIN CANCER RES, V1, P1413
   Friess H, 1996, J MOL MED-JMM, V74, P35, DOI 10.1007/BF00202070
   Graber HU, 1999, INT J CANCER, V84, P24, DOI 10.1002/(SICI)1097-0215(19990219)84:1<24::AID-IJC5>3.0.CO;2-2
   Hirsch FR, 2004, SEMIN ONCOL, V31, P75, DOI 10.1053/j.seminoncol.2003.12.018
   Hynes NE, 2005, NAT REV CANCER, V5, P341, DOI 10.1038/nrc1609
   Jemal A, 2005, CA-CANCER J CLIN, V55, P10, DOI 10.3322/canjclin.55.1.10
   Lee LT, 2002, ANTICANCER RES, V22, P1615
   Majumdar Adhip P N, 2005, Future Oncol, V1, P235, DOI 10.1517/14796694.1.2.235
   Marciniak DJ, 2004, MOL CANCER THER, V3, P1615
   Marciniak DJ, 2003, GASTROENTEROLOGY, V124, P1337, DOI 10.1016/S0016-5085(03)00264-6
   Mohammad RM, 1998, PANCREAS, V16, P19, DOI 10.1097/00006676-199801000-00004
   OKADA N, 1995, ONCOLOGY, V52, P392
   Romashkova JA, 1999, NATURE, V401, P86
   Thybusch-Bernhardt A, 2001, Int J Surg Investig, V2, P393
   Uegaki K, 1997, ANTICANCER RES, V17, P3841
   Viatour P, 2005, TRENDS BIOCHEM SCI, V30, P43, DOI 10.1016/j.tiba.2004.11.009
   Wells A, 1999, INT J BIOCHEM CELL B, V31, P637, DOI 10.1016/S1357-2725(99)00015-1
   Xu H, 2005, MOL CANCER THER, V4, P435
   Yu YJ, 2001, AM J PHYSIOL-CELL PH, V280, pC1083
   Zhang YX, 2005, CANCER RES, V65, P3877, DOI 10.1158/0008-5472.CAN-04-3654
NR 26
TC 42
Z9 46
U1 0
U2 1
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD JAN 15
PY 2006
VL 66
IS 2
BP 1025
EP 1032
DI 10.1158/0008-5472.CAN-05-2968
PG 8
WC Oncology
SC Oncology
GA 006RQ
UT WOS:000234915100056
PM 16424038
OA Bronze
DA 2018-12-27
ER

PT J
AU Suvardhan, K
   Kumar, KS
   Rekha, D
   Jayaraj, B
   Naidu, GK
   Chiranjeevi, P
AF Suvardhan, K
   Kumar, KS
   Rekha, D
   Jayaraj, B
   Naidu, GK
   Chiranjeevi, P
TI RETRACTED: Preconcentration and solid-phase extraction of beryllium,
   lead, nickel, and bismuth from various water samples using
   2-propylpiperidine-1-carbodithioate with flame atomic absorption
   spectrometry (FAAS) (Retracted Article. See vol 75, pg 1400, 2008)
SO TALANTA
LA English
DT Article; Retracted Publication
DE solid-phase extraction; sorbent; syringe (20ml);
   2-propylpiperidine-1-carbodithioate; flame atomic absorption
   spectrometry (FAAS) and water samples
ID COPPER; SEPARATION; MANGANESE; CHROMIUM; ZINC; DITHIOCARBAMATE; CADMIUM;
   COBALT; RESIN; IONS
AB A facile and novel method has been developed for the determination of beryllium, lead, nickel, and bismuth in various water samples. In the present investigation, the use of syringe was loaded with sorbent for the separation and enrichment of beryllium, lead, nickel, and bismuth prior to their analysis by flame atomic absorption spectrometry was described to substitute the batch and column techniques. The proposed method was compared with column technique with respect to easiness, fastness, simplicity, recovery and risk of contamination. The syringe was loaded with 1.0 g of sorbent in order to retain the analyte elements. Seven millilitres of sample solution (pH 5.0 +/- 0.2) was drawn into the syringe in 15 s and discharged over 15 s. Then, 3.0 M HCl eluent, was drawn into the syringe and ejected back to desorb the analyte elements. At the Optimum conditions, the percentage recoveries of Be, Ph, Ni, and Bi in the range of 94.28-99.02% with standard deviations (S.D.) of 0.11%. The elements could be concentrated by drawing and discharging several portions of sample successively but eluting only one time. The detailed study of various interferences made the confirmation of the method highly selective. The risk of contamination is less than that with the column technique. The method was successfully applied for the determination of Be, Pb, Ni, and Bi in spiked and natural water samples. The results obtained are in good agreement with the reported methods at the 95% confidence level. (c) 2005 Elsevier B.V. All rights reserved.
C1 Sri Venkateswara Univ, Dept Chem, Environm Monitoring Lab, Tirupati 517502, Andhra Pradesh, India.
   Sri Venkateswara Univ, Dept Math, Tirupati 517502, Andhra Pradesh, India.
   SV Govt Polytech, Dept Pharm, Tirupati 517501, Andhra Pradesh, India.
RP Chiranjeevi, P (reprint author), Sri Venkateswara Univ, Dept Chem, Environm Monitoring Lab, Tirupati 517502, Andhra Pradesh, India.
EM chiranjeevi_sai@yahoo.co.in
CR AKMAN S, 1992, J ANAL ATOM SPECTROM, V7, P187, DOI 10.1039/ja9920700187
   ALEXANDROVA A, 1993, ANALYST, V118, P1309, DOI 10.1039/an9931801309
   *APHA AWWA WEF, 1995, STAND METH EX WAT WA, P15
   Bakircioglu Y, 2000, SPECTROCHIM ACTA B, V55, P1129, DOI 10.1016/S0584-8547(00)00226-3
   BALAJI T, 1993, THESIS SV U, P80
   Cesur H, 2003, TURK J CHEM, V27, P307
   CRESSUR MS, 1978, SOLVENT EXTRACTION F
   DEAN JA, 1975, FLAME EMISSION ATOMI, V3
   FANG ZL, 1988, ANAL CHIM ACTA, V214, P41
   Giokas DL, 2001, J ANAL ATOM SPECTROM, V16, P521, DOI 10.1039/b010055m
   GREENFIELD S, 1990, ANALYST, V115, P531, DOI 10.1039/an9901500531
   KONAR B, 1994, FRESEN J ANAL CHEM, V348, P281, DOI 10.1007/BF00324034
   Oliveros MCC, 1998, J ANAL ATOM SPECTROM, V13, P547, DOI 10.1039/a801635f
   Ozcan M, 1996, FRESEN J ANAL CHEM, V355, P665
   Ozcan M, 2002, ANAL LETT, V35, P1075, DOI 10.1081/AL-120004556
   Paleologos EK, 2000, J ANAL ATOM SPECTROM, V15, P287, DOI 10.1039/a908974h
   RALPH IK, 1979, CHEM SILICA, P622
   RAMADEVI P, 1989, THESIS SV U, P119
   RAMESH A, 2001, THESIS SV U, P79
   Saracoglu S, 2003, ACTA CHIM SLOV, V50, P807
   Soylak M, 1997, INT J ENVIRON AN CH, V66, P51, DOI 10.1080/03067319708026273
   Soylak M, 1996, ANAL LETT, V29, P635
   TERADA K, 1977, B CHEM SOC JPN, V50, P1060, DOI 10.1246/bcsj.50.1060
   Tokalioglu S, 2000, ANAL SCI, V16, P1169, DOI 10.2116/analsci.16.1169
   Zhang QB, 2000, ANAL CHIM ACTA, V407, P147, DOI 10.1016/S0003-2670(99)00803-X
NR 25
TC 44
Z9 45
U1 4
U2 22
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0039-9140
EI 1873-3573
J9 TALANTA
JI Talanta
PD JAN 15
PY 2006
VL 68
IS 3
BP 735
EP 740
DI 10.1016/j.talanta.2005.05.020
PG 6
WC Chemistry, Analytical
SC Chemistry
GA 007GA
UT WOS:000234955400036
PM 18970383
DA 2018-12-27
ER

PT J
AU Fernandez, A
   Scott, R
   Berry, RS
AF Fernandez, A
   Scott, R
   Berry, RS
TI RETRACTED: Packing defects as selectivity switches for drug-based
   protein inhibitors (Retracted Article. See vol 128, pg 3102, 2006)
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article; Retracted Publication
DE dehydron; hydrogen bond
ID SMALL-MOLECULE; TYROSINE KINASE; HIV-1 PROTEASE; BINDING-SITES; DESIGN;
   RECOGNITION; PREDICTION; COMPLEXES; THROMBIN; 3-KINASE
AB The conservation of structure across homolog proteins often diffuses the impact of drug-based inhibition by promoting alternative protein-ligand associations that may lead to toxic side effects. However, sticky packing defects are typically not conserved across homologs, making them valuable a priori targets to enhance specificity. By introducing a homology to quantify packing differences among proteins, we enable a previously undescribed strategy for the design of highly selective drug inhibitors involving ligands that wrap nonconserved packing defects. The selectivity of these ligands is validated by performing affinity assays on a cancer-related pharmacokinome. Minor reengineering of a powerful inhibitor guided by wrapping differences across its target kinome can selectively direct its impact toward a specific kinase. Thus, nonconserved packing defects may be used as selectivity switches across homolog targets, using spatial displacements of packing defects across aligned protein structures.
C1 Rice Univ, Dept Bioengn, Houston, TX 77005 USA.
   Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA.
   Univ Chicago, Dept Comp Sci, Chicago, IL 60637 USA.
   Univ Chicago, Dept Math, Chicago, IL 60637 USA.
   Univ Chicago, Dept Chem, Chicago, IL 60637 USA.
   Univ Chicago, Inst Biophys Dynam, Chicago, IL 60637 USA.
RP Fernandez, A (reprint author), Rice Univ, Dept Bioengn, Houston, TX 77005 USA.
EM arifer@rice.edu; berry@uchicago.edu
RI Fernandez, Ariel/I-7925-2016
OI Fernandez, Ariel/0000-0002-5102-4294
FU NIGMS NIH HHS [R01 GM072614, 1R01GM072614-01A1]
CR Adesokan AA, 2004, J MED CHEM, V47, P821, DOI 10.1021/jm0301890
   Arkin MR, 2004, NAT REV DRUG DISCOV, V3, P301, DOI 10.1038/nrd1343
   Attoub S, 2002, CANCER RES, V62, P4879
   Ban YEA, 2004, P 8 ANN INT C RES CO, P205, DOI DOI 10.1145/974614.974642
   Broder C, 2000, CURR OPIN BIOTECH, V11, P581
   Deremble C, 2005, CURR OPIN STRUC BIOL, V15, P171, DOI 10.1016/j.sbi.2005.01.018
   Dunker AK, 2002, ADV PROTEIN CHEM, V62, P25
   Fabian MA, 2005, NAT BIOTECHNOL, V23, P329, DOI 10.1038/nbt1068
   Fauman Eric B, 2003, Methods Biochem Anal, V44, P477
   Fernandez A, 2004, NAT BIOTECHNOL, V22, P1081, DOI 10.1038/nbt0904-1081
   Fernandez A, 2004, P NATL ACAD SCI USA, V101, P2823, DOI 10.1073/pnas.0308295100
   Fernandez A, 2004, P NATL ACAD SCI USA, V101, P13460, DOI 10.1073/pnas.0405585101
   Fernandez A, 2004, P NATL ACAD SCI USA, V101, P11640, DOI 10.1073/pnas.0404641101
   Fernandez A, 2003, PHYS REV LETT, V91, DOI 10.1103/PhysRevLett.91.018102
   Fernandez A, 2003, BIOPHYS J, V85, P1914, DOI 10.1016/S0006-3495(03)74619-0
   Fernandez A, 2003, P NATL ACAD SCI USA, V100, P2391, DOI 10.1073/pnas.0335642100
   Fernandez A, 2002, BIOPHYS J, V83, P2475, DOI 10.1016/S0006-3495(02)75258-2
   Fernandez A, 2003, P NATL ACAD SCI USA, V100, P113, DOI 10.1073/pnas.0136888100
   HUBER R, 1979, NATURE, V280, P538, DOI 10.1038/280538a0
   Kann MG, 2005, BIOINFORMATICS, V21, P1451, DOI 10.1093/bioinformatics/bti233
   Katz BA, 2000, CHEM BIOL, V7, P299, DOI 10.1016/S1074-5521(00)00104-6
   Kortemme T, 2004, CURR OPIN CHEM BIOL, V8, P91, DOI 10.1016/j.cpba.2003.12.008
   Kortvelyesi T, 2003, J COMPUT AID MOL DES, V17, P173, DOI 10.1023/A:1025369923311
   Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042
   LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X
   Li J. J., 2004, CONT DRUG SYNTHESIS
   Liang J, 1998, PROTEIN SCI, V7, P1884, DOI 10.1002/pro.5560070905
   Lu L, 2002, PROTEINS, V49, P350, DOI 10.1002/prot.10222
   Manning G, 2002, SCIENCE, V298, P1912, DOI 10.1126/science.1075762
   Mol CD, 2004, J BIOL CHEM, V279, P31655, DOI 10.1074/jbc.M403319200
   Mount D. W., 2001, BIOINFORMATICS
   Munshi S, 1998, ACTA CRYSTALLOGR D, V54, P1053, DOI 10.1107/S0907444998003588
   NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407
   PERLMUTTER RM, 1988, J CELL BIOCHEM, V38, P117, DOI 10.1002/jcb.240380206
   Schindler T, 2000, SCIENCE, V289, P1938, DOI 10.1126/science.289.5486.1938
   Sen TZ, 2004, BMC BIOINFORMATICS, V5, DOI 10.1186/1471-2105-5-205
   Steinmetzer T, 2001, EXPERT OPIN INV DRUG, V10, P845, DOI 10.1517/13543784.10.5.845
   Stevens RC, 2004, NAT STRUCT MOL BIOL, V11, P293, DOI 10.1038/nsmb0404-293
   Timokhina I, 1998, EMBO J, V17, P6250, DOI 10.1093/emboj/17.21.6250
   Verkhivker GM, 2003, P NATL ACAD SCI USA, V100, P5148, DOI 10.1073/pnas.0531373100
   Wlodawer A, 1998, ANNU REV BIOPH BIOM, V27, P249, DOI 10.1146/annurev.biophys.27.1.249
   ZDANOV A, 1993, PROTEINS, V17, P252, DOI 10.1002/prot.340170304
   Zhao H, 2002, P NATL ACAD SCI USA, V99, P14795, DOI 10.1073/pnas.18557299
NR 43
TC 6
Z9 6
U1 2
U2 7
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD JAN 10
PY 2006
VL 103
IS 2
BP 323
EP 328
DI 10.1073/pnas.0509351102
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 002PR
UT WOS:000234624100014
PM 16387853
OA Green Published, Bronze
DA 2018-12-27
ER

PT J
AU Hunton, JE
   Libby, R
   Mazza, CL
AF Hunton, JE
   Libby, R
   Mazza, CL
TI RETRACTED: Financial reporting transparency and earnings management
   (Retracted article. See vol. 90, pg. 1711, 2015)
SO ACCOUNTING REVIEW
LA English
DT Article; Retracted Publication
DE financial reporting; transparency; earnings management; comprehensive
   income; SFAS No. 130
ID VALUATION JUDGMENTS; COMMERCIAL-BANKS; DISCLOSURE; TAXES
AB Prior research indicates that greater transparency in reporting formats facilitates the detection of earnings management. The current study hypothesizes and demonstrates that greater transparency in comprehensive income reporting also reduces the likelihood that managers will engage in earnings management in the area of increased transparency. In our experiment, 62 financial executives and chief executive officers decide which available-for-sale security to sell from a portfolio. We manipulate the transparency of comprehensive income reporting and the relationship of projected earnings to the consensus forecast in a 2 X 2 between subjects design. When projected earnings are below (above) the consensus forecast, participants sell securities that increase (decrease) earnings. However, the rarely used, more transparent format for reporting comprehensive income significantly reduces both income-increasing and income-decreasing earnings management. Participants in the less transparent setting indicate that earnings management attempts will not be obvious to readers, will improve stock prices, and have no effect on management's reputation for reporting integrity. Conversely, respondents in the more transparent condition suggest that earnings management will be obvious to readers, harmful to stock prices, and damaging to reporting reputation. Results of this study suggest that more transparent reporting requirements will reduce earnings management in the area of increased transparency or change the focus of earnings management to less visible methods.
C1 Bentley Coll, Waltham, MA 02154 USA.
   Cornell Univ, Ithaca, NY 14853 USA.
   Fordham Univ, Bronx, NY 10458 USA.
RP Hunton, JE (reprint author), Bentley Coll, Waltham, MA 02154 USA.
RI alrefaei, hessa/F-1443-2015
CR ARYA A, 2003, ACCOUNT HORIZ, V17, P111, DOI DOI 10.2308/ACCH.2003.17.S-1.111
   BEATTY A, 1995, J ACCOUNTING RES, V33, P231, DOI 10.2307/2491487
   Bhojraj S, 2005, ACCOUNT REV, V80, P1, DOI 10.2308/accr.2005.80.1.1
   BIDDLE GC, 2002, IS COMPREHENSIVE INC
   BLOOMFIELD R, 2005, INVESTING YOUR OWN E
   Bloomfield R. J., 2002, ACCOUNT HORIZ, V16, P233, DOI [10.2308/acch.2002.16.3.233, DOI 10.2308/ACCH.2002.16.3.233]
   Brown LD, 2001, J ACCOUNTING RES, V39, P221, DOI 10.1111/1475-679X.00010
   Burgstahler DC, 2003, CONTEMP ACCOUNT RES, V20, P253, DOI 10.1506/BXXP-RGTD-H0PM-9XAL
   Cloyd CB, 1996, J ACCOUNTING RES, V34, P23, DOI 10.2307/2491330
   COLLINS JH, 1995, J ACCOUNTING RES, V33, P263, DOI 10.2307/2491488
   CROSSMAN S, 1980, AM ECON REV, V70, P393
   Degeorge F, 1999, J BUS, V72, P1, DOI 10.1086/209601
   *FASB, 1997, STAT FIN ACC STAND 1
   *FASB, 2005, PROJ UPD FIN PERF RE
   *FASB, 1996, EXP DRAFT PROP STAT
   Fields TD, 2001, J ACCOUNT ECON, V31, P255, DOI 10.1016/S0165-4101(01)00028-3
   FINANCIAL ACCOUNTING STANDARDS BOARD (FASB), 1993, STAT FIN ACC STAND 1
   GRAHAM JR, IN PRESS J ACCOUNTIN
   Healy P. M., 1999, ACCOUNT HORIZ, V13, P365, DOI DOI 10.2308/ACCH.1999.13.4.365
   Hirshleifer D, 2003, J ACCOUNT ECON, V36, P337, DOI 10.1016/j.jacceco.2003.10.002
   Hirst DE, 2004, ACCOUNT REV, V79, P453, DOI 10.2308/accr.2004.79.2.453
   Hirst DE, 1998, J ACCOUNTING RES, V36, P47, DOI 10.2307/2491306
   Hirst DE, 2003, CONTEMP ACCOUNT RES, V20, P165, DOI 10.1506/9T1W-PGGN-L36L-WD21
   Hodge FD, 2004, ACCOUNT REV, V79, P687, DOI 10.2308/accr.2004.79.3.687
   Kennedy J, 1998, J ACCOUNTING RES, V36, P257, DOI 10.2307/2491477
   LEE YJ, 2005, CHERRY PICKING DISCL
   Levitt A., 1998, NYU CTR LAW BUS NEW
   LIBBY R, 2000, ACCOUNT REV, V75, P384
   LIBBY R, 2002, ACCOUNT ORG SOC, V27, P775
   Lobo G.J., 2001, ASIA-PAC J ACCOUNT E, V8, P1
   Lundholm R., 1999, ACCOUNT HORIZ, V12, P315
   Maines L. A., 1995, JUDGMENT DECISION MA
   Maines LA, 2000, ACCOUNT REV, V75, P179, DOI 10.2308/accr.2000.75.2.179
   MAZZA C, 2004, ASSESSMENT TRANSPARE
   McDaniel L. S., 1996, CONTEMP ACCOUNT RES, V13, P339
   MOLLENKAMP C, 2003, WALL STREET J   0415, pA6
   MOYER S, 1990, J ACCOUNT ECON, V12, P123
   Nelson M.W., 2003, ACCOUNTING HORIZON S, P17
   Nelson MW, 2002, ACCOUNT REV, V77, P175, DOI 10.2308/accr.2002.77.s-1.175
   SCHOLES MS, 1990, REV FINANC STUD, V3, P625, DOI 10.1093/rfs/3.4.625
   Shaw KW, 2003, J BUS RES, V56, P1043, DOI 10.1016/S0148-2963(01)00328-9
NR 41
TC 70
Z9 70
U1 4
U2 53
PU AMER ACCOUNTING ASSOC
PI SARASOTA
PA 5717 BESSIE DR, SARASOTA, FL 34233 USA
SN 0001-4826
EI 1558-7967
J9 ACCOUNT REV
JI Account. Rev.
PD JAN
PY 2006
VL 81
IS 1
BP 135
EP 157
DI 10.2308/accr.2006.81.1.135
PG 23
WC Business, Finance
SC Business & Economics
GA 010FY
UT WOS:000235173700006
DA 2018-12-27
ER

PT J
AU Libby, R
   Tan, HT
   Hunton, JE
AF Libby, R
   Tan, HT
   Hunton, JE
TI RETRACTED: Does the form of management's earnings guidance affect
   analysts' earnings forecasts? (Retracted article. See vol. 90, pg. 1713,
   2015)
SO ACCOUNTING REVIEW
LA English
DT Article; Retracted Publication
DE earnings guidance; preannouncements; management forecasts; forecast
   form; analyst forecasts
ID AMBIGUITY; ATTRIBUTION; DISCLOSURES; UNCERTAINTY; SURPRISES; OUTCOMES
AB This study examines how the form of management's earnings guidance (point, narrow range, wide range) affects analysts' earnings forecasts. Results from two experiments demonstrate that: (1) guidance form has no effect on analysts' forecasts made immediately after the guidance; and (2) after the actual earnings announcement, guidance form and the relationship of the earnings guidance to actual earnings (guidance error) interact in their effect on analysts' forecasts. After the actual earnings announcement, guidance error leads to higher (lower) analysts' forecasts for firms with downwardly (upwardly) biased guidance; this effect of guidance error is magnified by a narrow range and reduced by a wide range, compared to a point estimate. These results suggest that treating the mean of the range endpoints as equivalent to a point estimate and failing to consider effects after the release of actual earnings may paint an incomplete picture of how management guidance affects analysts and investors. It also offers useful information to managers who issue earnings guidance, and presents a challenge to the psychology literature regarding the effects of information precision on judgment and decision making.
C1 Cornell Univ, Ithaca, NY 14853 USA.
   Nanyang Technol Univ, Singapore 639798, Singapore.
   Bentley Coll, Waltham, MA 02154 USA.
   Univ Maastricht, Maastricht, Netherlands.
RP Libby, R (reprint author), Cornell Univ, Ithaca, NY 14853 USA.
CR BAGINSKI SP, 1993, ACCOUNT REV, V68, P913
   Bamber LS, 1998, J ACCOUNTING RES, V36, P167, DOI 10.2307/2491473
   Bartov E, 2002, J ACCOUNT ECON, V33, P173, DOI 10.1016/S0165-4101(02)00045-9
   Brown LD, 2001, J ACCOUNTING RES, V39, P221, DOI 10.1111/1475-679X.00010
   CHOI JH, 2002, REEXAMINATION BIAS
   COTTER JA, 2004, EXPECTATIONS MANAGEM
   CURLEY SP, 1986, ORGAN BEHAV HUM DEC, V38, P230, DOI 10.1016/0749-5978(86)90018-X
   Degeorge F, 1999, J BUS, V72, P1, DOI 10.1086/209601
   EINHORN HJ, 1985, PSYCHOL REV, V92, P433, DOI 10.1037//0033-295X.92.4.433
   Heider F., 1958, PSYCHOL INTERPERSONA
   Helson H., 1964, ADAPTATION LEVEL THE
   HIGHHOUSE S, 1994, J ECON PSYCHOL, V15, P621, DOI 10.1016/0167-4870(94)90014-0
   Hirst DE, 1999, J ACCOUNTING RES, V37, P101, DOI 10.2307/2491347
   Hirst DE, 1998, J ACCOUNTING RES, V36, P47, DOI 10.2307/2491306
   JONES EE, 1965, ADV EXP SOC PSYCHOL, V2, P219
   KAHNEMAN D, 1979, ECONOMETRICA, V47, P263, DOI 10.2307/1914185
   KASZNIK R, 1995, ACCOUNT REV, V70, P113
   KELLEY HH, 1973, AM PSYCHOL, V28, P107, DOI 10.1037/h0034225
   KIDA T, 1995, ACCOUNT ORG SOC, V20, P585, DOI 10.1016/0361-3682(95)00014-Z
   Kile C., 1998, J FINANCIAL STATEMEN, V3, P5
   King R., 1990, J ACCOUNTING LITERAT, V9, P113
   Kuhn K.M., 1999, RISK DECISION POLICY, V4, P31
   Kuhn KM, 1996, ORGAN BEHAV HUM DEC, V68, P301, DOI 10.1006/obhd.1996.0107
   Libby R, 1999, J ACCOUNTING RES, V37, P415, DOI 10.2307/2491415
   Maines LA, 2000, ACCOUNT REV, V75, P179, DOI 10.2308/accr.2000.75.2.179
   MILLER JS, 2004, UNINTENDED EFFECTS P
   OPDYKE JD, 2001, WALL STREET     0302, pC1
   POWNALL G, 1993, ACCOUNT REV, V68, P896
   Soffer LC, 2000, REV ACCOUNT STUD, V5, P5, DOI DOI 10.1023/A:1009643517840
   Tan HT, 2002, J ACCOUNT RES, V40, P223, DOI 10.1111/1475-679X.00045
   Tan HT, 1997, J BEHAV DECIS MAKING, V10, P315, DOI 10.1002/(SICI)1099-0771(199712)10:4<315::AID-BDM257>3.0.CO;2-L
   TAYLOR SE, 1975, J PERS SOC PSYCHOL, V32, P439, DOI 10.1037/h0077095
   Thaler RH, 1999, J BEHAV DECIS MAKING, V12, P183, DOI 10.1002/(SICI)1099-0771(199909)12:3<183::AID-BDM318>3.0.CO;2-F
   Thibaut J. W., 1959, SOCIAL PSYCHOL GROUP
   WALLSTEN T, 1986, J EXPT PSYCHOL G DEC, P348
NR 35
TC 31
Z9 32
U1 2
U2 25
PU AMER ACCOUNTING ASSOC
PI SARASOTA
PA 5717 BESSIE DR, SARASOTA, FL 34233 USA
SN 0001-4826
EI 1558-7967
J9 ACCOUNT REV
JI Account. Rev.
PD JAN
PY 2006
VL 81
IS 1
BP 207
EP 225
DI 10.2308/accr.2006.81.1.207
PG 19
WC Business, Finance
SC Business & Economics
GA 010FY
UT WOS:000235173700009
OA Bronze
DA 2018-12-27
ER

PT J
AU Rohm, KD
   Piper, SN
   Suttner, S
   Schuler, S
   Boldt, J
AF Rohm, KD
   Piper, SN
   Suttner, S
   Schuler, S
   Boldt, J
TI RETRACTED: Early recovery, cognitive function and costs of a desflurane
   inhalational vs. a total intravenous anaesthesia regimen in long-term
   surgery (Retracted article. See vol. 55, pg. 903, 2011)
SO ACTA ANAESTHESIOLOGICA SCANDINAVICA
LA English
DT Article; Proceedings Paper; Retracted Publication
CT 28th Congress of the European-Society-of-Neuroradiology
CY SEP 11-14, 2003
CL Istanbul, TURKEY
SP European Soc Neuroradiol
DE cognitive function; recovery; MMST; desflurane; propofol; remifentanil;
   costs
ID PROPOFOL ANESTHESIA; ELDERLY-PATIENTS; GENERAL-ANESTHESIA; ISOFLURANE;
   REMIFENTANIL; SEVOFLURANE; COMBINATION; PROFILE
AB Background: The purpose of the study was to compare time of recovery, return of cognitive function, post-anaesthetic care unit (PACU) stay and costs of a propofol/remifentanil (TIVA) with a desflurane/fentanyl-based anaesthesia (desflurane group) in surgical procedures lasting more than 150 min.
   Methods: Forty-nine patients undergoing elective abdominal prostatectomy were allocated randomly to receive bispectal index (BIS)-controlled desflurane/fentanyl (n = 24) or propofol/remifentanil (n = 25). Awakening, clinical recovery, direct drug acquisition and post-operative pain treatment were documented. Cognitive skills were tested using the Mini-Mental Status (MMST) test.
   Results: Extubation was significantly faster with desflurane (6.9 +/- 3.5 min) than with TIVA (11.2 +/- 4.0 min) as well as times for stating name and date of birth (desflurane: 6.1 +/- 3.9 and 6.6 +/- 4.0 min; TIVA: 12.4 +/- 11.5 min and 13.4 +/- 11.3 min). There were no significant differences in PACU discharge times or MMS scores between the groups. Significantly more patients suffered post-operative nausea and vomiting (PONV) in the desflurane (33% vs. 0%) than the TIVA group. Overall costs were significantly higher in the TIVA (58.8 +/- 11.6) than in the desflurane group (35.0 +/- 5.7).
   Conclusion: Patients undergoing prolonged surgical procedures showed a faster early recovery after desflurane/fentanyl than using TIVA, whereas stay in the PACU and recovery of cognitive function were similar in both groups. Costs of a TIVA regimen were significantly higher than using a desflurane-based anaesthesia technique.
C1 Klinikum Stadt Ludwigshafen, Dept Anesthesiol & Intens Care Med, D-67063 Ludwigshafen, Germany.
RP Boldt, J (reprint author), Klinikum Stadt Ludwigshafen, Dept Anesthesiol & Intens Care Med, Bremserstr 79, D-67063 Ludwigshafen, Germany.
EM BoldtJ@gmx.net
CR ALDRETE JA, 1995, J CLIN ANESTH, V7, P89, DOI 10.1016/0952-8180(94)00001-K
   Apfelbaum JL, 1996, ANESTH ANALG, V83, P721, DOI 10.1097/00000539-199610000-00010
   Bekker AY, 2000, ANESTH ANALG, V91, P117, DOI 10.1097/00000539-200007000-00022
   Boldt J, 1998, ANESTH ANALG, V86, P504, DOI 10.1097/00000539-199803000-00010
   Chen XG, 2001, ANESTH ANALG, V93, P1489, DOI 10.1097/00000539-200112000-00029
   DEXTER F, 1995, ANESTHESIOLOGY, V83, P77
   Dolk A, 2002, EUR J ANAESTH, V19, P88, DOI 10.1017/S0265021502000157
   FOLSTEIN M, 1985, J AM GERIATR SOC, V33, P228, DOI 10.1111/j.1532-5415.1985.tb07109.x
   Fredman B, 2002, ANESTH ANALG, V94, P560, DOI 10.1097/00000539-200203000-00015
   Glass PS, 1999, ANESTH ANALG, V89, P7
   Grundmann U, 2001, ACTA ANAESTH SCAND, V45, P320, DOI 10.1034/j.1399-6576.2001.045003320.x
   Gupta A, 2004, ANESTH ANALG, V98, P632, DOI 10.1213/01.ANE.0000103187.70627.57
   Hogue CW, 1996, ANESTH ANALG, V83, P279, DOI 10.1097/00000539-199608000-00014
   Johansen JW, 2000, ANESTHESIOLOGY, V93, P1336, DOI 10.1097/00000542-200011000-00029
   Juvin P, 1997, ANESTH ANALG, V85, P647, DOI 10.1097/00000539-199709000-00029
   Larsen B, 2000, ANESTH ANALG, V90, P168, DOI 10.1097/00000539-200001000-00035
   LEBENBOMMANSOUR MH, 1993, ANESTH ANALG, V76, P936
   Luginbuhl M, 2003, ACTA ANAESTH SCAND, V47, P165, DOI 10.1034/j.1399-6576.2003.00041.x
   PARIKH SS, 1995, ANESTH ANALG, V80, P1223, DOI 10.1097/00000539-199506000-00027
   Rasmussen LS, 2003, ACTA ANAESTH SCAND, V47, P260, DOI 10.1034/j.1399-6576.2003.00057.x
   Rasmussen LS, 2001, ACTA ANAESTH SCAND, V45, P275, DOI 10.1034/j.1399-6576.2001.045003275.x
   Suttner SW, 2001, BRIT J ANAESTH, V87, P699, DOI 10.1093/bja/87.5.699
   WATCHA M, 1997, ANESTHESIOLOGY, V86, P170
   WEISKOPF RB, 1993, ANESTHESIOLOGY, V79, P1413, DOI 10.1097/00000542-199312000-00033
NR 24
TC 24
Z9 29
U1 4
U2 24
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0001-5172
J9 ACTA ANAESTH SCAND
JI Acta Anaesthesiol. Scand.
PD JAN
PY 2006
VL 50
IS 1
BP 14
EP 18
DI 10.1111/j.1399-6576.2005.00905.x
PG 5
WC Anesthesiology
SC Anesthesiology
GA 007XT
UT WOS:000235005500002
PM 16451145
DA 2018-12-27
ER

PT J
AU Chen, Q
AF Chen, Q
TI RETRACTED: Bis(4-bromo-2-formylphenolato-kappa O-2,O ')zinc(II)
   (Retracted article. See vol. 66, pg e21, 2010)
SO ACTA CRYSTALLOGRAPHICA SECTION E-STRUCTURE REPORTS ONLINE
LA English
DT Article; Retracted Publication
AB The title compound, [Zn(C7H4BrO2)(2)], is a square planar zinc(II)-phenolate complex. The Zn II atom lies on an inversion center and is coordinated by four O atoms from two deprotonated 5-bromo-2-hydroxybenzaldehyde molecules acting as bidentate chelate ligands.
C1 Baoji Coll Arts & Sci, Dept Chem & Chem Engn, Baoji 721007, Peoples R China.
RP Chen, Q (reprint author), Baoji Coll Arts & Sci, Dept Chem & Chem Engn, Baoji 721007, Peoples R China.
EM chenqiang_bj@126.com
CR *BRUK AXS INC, 2000, SMART VERS 5 618 SAI
   CASELLA L, 1981, J AM CHEM SOC, V103, P6338, DOI 10.1021/ja00411a013
   Sun YX, 2005, ACTA CRYSTALLOGR E, V61, pM354, DOI 10.1107/S160053680500187X
   Xiong ZY, 2005, ACTA CRYSTALLOGR E, V61, pM863, DOI 10.1107/S1600536805010913
NR 4
TC 14
Z9 14
U1 3
U2 8
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1600-5368
J9 ACTA CRYSTALLOGR E
JI Acta Crystallogr. Sect. E.-Struct Rep. Online
PD JAN
PY 2006
VL 62
BP M56
EP M57
DI 10.1107/S1600536805040432
PN 1
PG 2
WC Crystallography
SC Crystallography
GA 000FS
UT WOS:000234446900030
DA 2018-12-27
ER

PT J
AU La Clair, JF
AF La Clair, JF
TI RETRACTED: Total syntheses of hexacyclinol, 5-epi-hexacycyclinol, and
   desoxohexacyclinol unveil an antimalarial prodrug motif (Retracted
   article. See vol. 51, pg. 2769, 2012)
SO ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
LA English
DT Article; Retracted Publication
DE antimalarial agents; medicinal chemistry; natural products; terpenoids;
   total synthesis
ID ABSOLUTE-CONFIGURATION; HYDROLYSIS; ACID
C1 Xenobe Res Inst, San Diego, CA 92164 USA.
RP La Clair, JF (reprint author), Xenobe Res Inst, POB 4073, San Diego, CA 92164 USA.
EM i@xenobe.org
CR ANKER G, 1987, CARBOHYD RES, V159, P159, DOI 10.1016/S0008-6215(00)90014-4
   COHEN T, 1980, J AM CHEM SOC, V102, P6900, DOI 10.1021/ja00542a064
   KRAUS GA, 1981, TETRAHEDRON LETT, V22, P1171, DOI 10.1016/S0040-4039(01)90266-7
   LACLAIR JJ, UNPUB
   Li CM, 2003, J AM CHEM SOC, V125, P5095, DOI 10.1021/ja021396c
   Nguyen VH, 1997, TETRAHEDRON LETT, V38, P1773, DOI 10.1016/S0040-4039(97)00166-4
   Nicolaou K. C., 2005, ANGEW CHEM, V117, P1402
   Nicolaou KC, 2005, ANGEW CHEM INT EDIT, V44, P1378, DOI 10.1002/anie.200462207
   Nowak DM, 1998, TETRAHEDRON, V54, P319, DOI 10.1016/S0040-4020(97)10286-1
   PEARSON DE, 1974, CHEM REV, V74, P45, DOI 10.1021/cr60287a004
   Peters W, 1999, ANN TROP MED PARASIT, V93, P325, DOI 10.1080/00034983.1999.11813429
   Schlegel B, 2002, J ANTIBIOT, V55, P814, DOI 10.7164/antibiotics.55.814
   Smith AB, 2002, ORG LETT, V4, P4539, DOI 10.1021/ol027095p
   STORK G, 1985, J AM CHEM SOC, V107, P500, DOI 10.1021/ja00288a038
   Szpilman AM, 2005, J ORG CHEM, V70, P3618, DOI 10.1021/jo050074z
   TAMAI T, 1993, TETRAHEDRON LETT, V34, P2641, DOI 10.1016/S0040-4039(00)77645-3
   Tanaka M, 1996, J ORG CHEM, V61, P6952, DOI 10.1021/jo9608230
   Williams D. R., 2005, ANGEW CHEM, V<bold>117</bold>, P6873
   Williams DR, 2005, ANGEW CHEM INT EDIT, V44, P6715, DOI 10.1002/anie.200502015
NR 19
TC 35
Z9 35
U1 3
U2 25
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 1433-7851
EI 1521-3773
J9 ANGEW CHEM INT EDIT
JI Angew. Chem.-Int. Edit.
PY 2006
VL 45
IS 17
BP 2769
EP 2773
DI 10.1002/anie.200504033
PG 5
WC Chemistry, Multidisciplinary
SC Chemistry
GA 037OB
UT WOS:000237155200023
PM 16470558
OA Bronze
DA 2018-12-27
ER

PT J
AU Flower, KR
   Pritchard, RG
   McGown, AT
AF Flower, Kevin R.
   Pritchard, Robin G.
   McGown, Alan T.
TI RETRACTED: [NEt4][AuCl2][AuCl3]: Solid-state evidence of essentially
   Y-shaped Jahn-Teller-distorted AuCl3 (Retracted Article. See vol 45, pg
   7489, 2006)
SO ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
LA English
DT Article; Retracted Publication
DE crystal engineering; gold; halogens; Jahn-Teller distortion; structure
   elucidation
ID CRYSTAL-STRUCTURE; MOLECULAR-STRUCTURE; REDUCTIVE ELIMINATION;
   ELECTRON-DIFFRACTION; GOLD TRIFLUORIDE; STABILITY; COMPLEXES; GOLD(III);
   HALIDES
C1 Univ Manchester, Sch Chem, Manchester M13 9PL, Lancs, England.
   Univ Salford, Drug Discovery Unit, Salford M5 4WT, Lancs, England.
RP Flower, KR (reprint author), Univ Manchester, Sch Chem, Sackville St, Manchester M13 9PL, Lancs, England.
EM k.r.flower@manchester.ac.uk
CR Blackmore I. J., 2005, ANGEW CHEM, V117, P6904
   BLACKMORE IJ, 2005, ANGEW CHEM, V117, P6746
   BONDI A, 1964, J PHYS CHEM-US, V68, P441, DOI 10.1021/j100785a001
   CLARK ES, 1958, ACTA CRYSTALLOGR, V11, P284, DOI 10.1107/S0365110X58000694
   EINSTEIN FW, 1967, J CHEM SOC A, P478, DOI 10.1039/j19670000478
   Hargittai M, 2001, J AM CHEM SOC, V123, P1449, DOI 10.1021/ja003038k
   Hargittai M, 2000, CHEM REV, V100, P2233, DOI 10.1021/cr970115u
   HELGESSON G, 1987, ACTA CHEM SCAND A, V41, P556, DOI 10.3891/acta.chem.scand.41a-0556
   Jones C. J., 2001, D F BLOCK CHEM
   KOMIYA S, 1977, J AM CHEM SOC, V99, P8440, DOI 10.1021/ja00468a010
   KOMIYA S, 1976, J AM CHEM SOC, V98, P7255, DOI 10.1021/ja00439a024
   LORCHER KP, 1975, Z NATURFORSCH B, V30, P662
   Pyykko P., 2004, ANGEW CHEM, V116, P4512
   Reffy B, 2000, J AM CHEM SOC, V122, P3127, DOI 10.1021/ja992638k
   SCHELDRICK GM, 1997, SHELXL97
   Schulz A, 2001, CHEM-EUR J, V7, P3657, DOI 10.1002/1521-3765(20010903)7:17<3657::AID-CHEM3657>3.0.CO;2-Q
   Schwerdtfeger P, 2002, HETEROATOM CHEM, V13, P578, DOI 10.1002/hc.10093
   SCHWERDTFEGER P, 1992, INORG CHEM, V31, P3411, DOI 10.1021/ic00042a016
   Sohnel T, 2001, CHEM-EUR J, V7, P3167, DOI 10.1002/1521-3765(20010716)7:14<3167::AID-CHEM3167>3.0.CO;2-G
   TATSUMI K, 1981, B CHEM SOC JPN, V54, P1857, DOI 10.1246/bcsj.54.1857
   TINDEMANS JC, 1974, MATER RES BULL, V9, P1667
   ZEMVA B, 1991, J AM CHEM SOC, V113, P4192, DOI 10.1021/ja00011a021
NR 22
TC 3
Z9 3
U1 3
U2 14
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 1433-7851
EI 1521-3773
J9 ANGEW CHEM INT EDIT
JI Angew. Chem.-Int. Edit.
PY 2006
VL 45
IS 39
BP 6535
EP 6537
DI 10.1002/anie.200602092
PG 3
WC Chemistry, Multidisciplinary
SC Chemistry
GA 095NH
UT WOS:000241314100026
PM 16917797
DA 2018-12-27
ER

PT J
AU Roberts, JT
   von der Maase, H
   Sengelov, L
   Conte, PF
   Dogliotti, L
   Oliver, T
   Moore, MJ
   Zimmermann, A
   Arning, M
AF Roberts, J. T.
   von der Maase, H.
   Sengelov, L.
   Conte, P. F.
   Dogliotti, L.
   Oliver, T.
   Moore, M. J.
   Zimmermann, A.
   Arning, M.
TI RETRACTED: Long-term survival results of a randomized trial comparing
   gemcitabine/cisplatin and methotrexate/vinblastine/doxorubicin/cisplatin
   in patients with locally advanced and metastatic bladder cancer
   (Retracted article. See vol. 22, pg. 2536, 2011)
SO ANNALS OF ONCOLOGY
LA English
DT Article; Proceedings Paper; Retracted Publication
CT Workshop on Gemcitabine - Ten Years of Clinical Experience
CY SEP 19-21, 2005
CL Monastier di Treviso, ITALY
DE gemcitabine; cisplatin; bladder cancer; survival
ID TRANSITIONAL-CELL-CARCINOMA; PHASE-II TRIAL; PROGNOSTIC-FACTORS;
   UROTHELIAL CANCER; PLUS CISPLATIN; CLINICAL-TRIAL; METHOTREXATE;
   VINBLASTINE; DOXORUBICIN; COMBINATION
AB Purpose: To compare long-term survival in patients with locally advanced and metastatic transitional cell carcinoma (TCC) of the urothelium treated with gemcitabine plus cisplatin (GC) or methotrexate/vinblastine/doxorubicin/cisplatin (MVAC).
   Patients and methods: Efficacy data from a large randomized phase III study of GC versus MVAC were updated. Time-to-event analyses were performed on the observed distributions of overall survival time and progression-free survival.
   Results: Four hundred and five patients were randomized, 203 to the GC arm and 202 to the MVAC arm. At the time of this analysis, 347 patients have died (GC 176, MVAC 171). Overall survival was similar in both arms (HR 1.09; 95% confidence interval [CI] 0.88-1.34, P = 0.66) with a median survival of 14.0 months (95% CI 12.3-15.5 months) in the GC, and 15.2 months (95% CI 13.2-17.3 months) in the MVAC arm. The median progression-free survival was 7.7 months with GC (95% CI 6.8-8.8) and 8.3 months with MVAC (95% CI 7.3-9.7) with a HR of 1.09 (95% CI 0.89-1.34). Significant prognostic factors favoring overall survival included performance status (> 70), TNM staging (M0 vs. M1), low/normal alkaline phosphatase expression, number of sites of disease < 3, and the absence of visceral metastasis. By adjusting for these prognostic factors, the HR was 0.99 for overall survival and 1.01 for progression-free survival.
   Conclusions: Long-term overall and progression-free survival following treatment with GC or MVAC are similar. These results strengthen the role of GC as a standard of care in patients with locally advanced and metastatic transitional-cell carcinoma (TCC).
C1 Newcastle Gen Hosp, No Ctr Canc Treatment, Newcastle Upon Tyne NE4 6BE, Tyne & Wear, England.
   Herlev Univ Hosp, Dept Oncol, DK-2730 Herlev, Denmark.
   Aarhus Univ Hosp, Dept Oncol, DK-8000 Aarhus, Denmark.
   Univ Turin, St Luigi Hosp, Orbassano, Italy.
RP Roberts, JT (reprint author), Newcastle Gen Hosp, No Ctr Canc Treatment, Westgate Rd, Newcastle Upon Tyne NE4 6BE, Tyne & Wear, England.
EM trevor.roberts@nuth.nhs.uk
RI Conte, PierFranco/F-7418-2014
OI Conte, PierFranco/0000-0002-5210-5344
CR Bajorin DF, 1999, J CLIN ONCOL, V17, P3173, DOI 10.1200/JCO.1999.17.10.3173
   Kaufman D, 2000, J CLIN ONCOL, V18, P1921, DOI 10.1200/JCO.2000.18.9.1921
   LOEHRER PJ, 1992, J CLIN ONCOL, V10, P1066, DOI 10.1200/JCO.1992.10.7.1066
   Moore MJ, 1999, J CLIN ONCOL, V17, P2876, DOI 10.1200/JCO.1999.17.9.2876
   POCOCK SJ, 1975, BIOMETRICS, V31, P103, DOI 10.2307/2529712
   Robinson Paul, 2004, Expert Rev Pharmacoecon Outcomes Res, V4, P27, DOI 10.1586/14737167.4.1.27
   Saxman SB, 1997, J CLIN ONCOL, V15, P2564, DOI 10.1200/JCO.1997.15.7.2564
   Sengelov L, 2001, EUR UROL, V39, P634, DOI 10.1159/000052520
   Stadler WM, 2002, UROL ONCOL, V7, P153, DOI 10.1016/S1078-1439(02)00182-5
   STERNBERG CN, 1989, CANCER, V64, P2448, DOI 10.1002/1097-0142(19891215)64:12<2448::AID-CNCR2820641209>3.0.CO;2-7
   STERNBERG CN, 1985, J UROLOGY, V133, P403, DOI 10.1016/S0022-5347(17)48996-8
   von der Maase H, 2000, J CLIN ONCOL, V18, P3068, DOI 10.1200/JCO.2000.18.17.3068
   von der Maase H, 1999, ANN ONCOL, V10, P1461, DOI 10.1023/A:1008331111654
   von der Maase Hans, 2003, Expert Rev Anticancer Ther, V3, P11, DOI 10.1586/14737140.3.1.11
NR 14
TC 55
Z9 55
U1 3
U2 14
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0923-7534
J9 ANN ONCOL
JI Ann. Oncol.
PY 2006
VL 17
SU 5
BP V118
EP V122
DI 10.1093/annonc/mdj965
PG 5
WC Oncology
SC Oncology
GA 190SF
UT WOS:000248078700026
PM 16807438
OA Bronze
DA 2018-12-27
ER

PT J
AU Vedavathi, M
   Girish, KS
   Kumar, MK
AF Vedavathi, M
   Girish, KS
   Kumar, MK
TI RETRACTED: A novel low molecular weight alanine aminotransferase from
   fasted rat liver (Retracted Article. See vol 75, pg 1303, 2010)
SO BIOCHEMISTRY-MOSCOW
LA English
DT Article; Retracted Publication
DE alanine aminotransferase; fasting; purification
ID AMINO-ACID-METABOLISM; CHLAMYDOMONAS-REINHARDTII; MITOCHONDRIAL
   PROTEINS; TRANSAMINASE-ACTIVITY; PARTIAL-PURIFICATION; ASPARTATE;
   IDENTIFICATION; ISOZYMES; GROWTH; LEAVES
AB Alanine is the most effective precursor for gluconeogenesis among amino acids, and the initial reaction is catalyzed by alanine aminotransferase (AlaAT). Although the enzyme activity increases during fasting, this effect has not been studied extensively The present study describes the purification and characterization of an isoform of AlaAT from rat liver under fasting. The molecular mass of the enzyme is 17.7 kD with an isoelectric point of 4.2; glutamine is the N-terminal residue. The enzyme showed narrow substrate specificity for L-alanine with K-m values for alanine of 0.51 mM and for 2-oxoglutarate of 0.12 mM. The enzyme is a glycoprotein. Spectroscopic and inhibition studies showed that pyridoxal phosphate (PLP) and free -SH groups are involved in the enzymatic catalysis. PLP activated the enzyme with a K-m of 0.057 mM.
C1 Univ Mysore, Dept Biochem, Mysore 570006, Karnataka, India.
RP Kumar, MK (reprint author), Univ Mysore, Dept Biochem, Mysore 570006, Karnataka, India.
EM karunamkk@rediffmail.com
CR ANDREWS P, 1964, BIOCHEM J, V91, P222, DOI 10.1042/bj0910222
   BEATON GH, 1957, ARCH BIOCHEM BIOPHYS, V70, P288, DOI 10.1016/0003-9861(57)90104-2
   BONE DH, 1960, J EXP BOT, V11, P104, DOI 10.1093/jxb/11.1.104
   BULOS B, 1963, AM CHEM SOC M NEW YO
   DAVIS BJ, 1964, ANN NY ACAD SCI, V121, P404, DOI 10.1111/j.1749-6632.1964.tb14213.x
   DEROSA G, 1979, BIOCHIM BIOPHYS ACTA, V567, P116, DOI 10.1016/0005-2744(79)90178-5
   FELIG P, 1975, ANNU REV BIOCHEM, V44, P933, DOI 10.1146/annurev.bi.44.070175.004441
   FUJIWARA S, 1994, ARCH BIOCHEM BIOPHYS, V310, P497, DOI 10.1006/abbi.1994.1198
   GATEHOUSE PW, 1967, J BIOL CHEM, V242, P2319
   GAZEUREYJAL M, 1976, PHYTOCHEMISTRY, V15, P1619, DOI 10.1016/S0031-9422(00)97439-9
   GIVAN CV, 1980, BIOCH PLANTS COMPREH
   HOPPER S, 1964, ARCH BIOCHEM BIOPHYS, V105, P501, DOI 10.1016/0003-9861(64)90042-6
   HOPPER S, 1962, J BIOL CHEM, V237, P3189
   IRELAND RJ, 1985, TRANSAMINASES
   KARL IE, 1976, J BIOL CHEM, V251, P844
   KATUNUMA N, 1962, J VITAMINOL, V8, P68, DOI 10.5925/jnsv1954.8.68
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   LAINGUELBENZU B, 1991, EUR J BIOCHEM, V202, P881, DOI 10.1111/j.1432-1033.1991.tb16447.x
   LAINGUELBENZU B, 1990, EUR J BIOCHEM, V188, P529, DOI 10.1111/j.1432-1033.1990.tb15432.x
   LEACH BS, 1980, BIOCHEMISTRY-US, V19, P5734, DOI 10.1021/bi00566a011
   LOWRY OH, 1951, J BIOL CHEM, V193, P265
   MACDONALD M, 1976, AM J PHYSIOL, V231, P619
   MURAMATSU K, 1962, J NUTR, V76, P143, DOI 10.1093/jn/76.2.143
   PARICH DL, 1979, METHODS ENZYMOLOGY E
   RECH J, 1974, BIOCHIM BIOPHYS ACTA, V350, P392, DOI 10.1016/0005-2744(74)90513-0
   REED RE, 1975, J BIOL CHEM, V250, P4456
   REITMAN S, 1957, AM J CLIN PATHOL, V28, P56
   REMSEY C, 1978, BIOCHEM J, V170, P321
   ROSEN F, 1959, J BIOL CHEM, V234, P476
   RUSCAK M, 1982, COMP BIOCHEM PHYS B, V71, P141, DOI 10.1016/0305-0491(82)90190-0
   RUSCAK M, 1982, J NEUROCHEM, V39, P210, DOI 10.1111/j.1471-4159.1982.tb04720.x
   SAIER MH, 1967, J BIOL CHEM, V242, P91
   SCHIMKE RT, 1962, J BIOL CHEM, V237, P459
   SCHNEIDER M, 1981, INSECT BIOCHEM, V11, P657, DOI 10.1016/0020-1790(81)90056-1
   SON DY, 1991, ARCH BIOCHEM BIOPHYS, V289, P262, DOI 10.1016/0003-9861(91)90470-4
   SPLITTSTOESSER WE, 1976, PLANT CELL PHYSIOL, V17, P83, DOI 10.1093/oxfordjournals.pcp.a075269
   SWICK RW, 1965, J BIOL CHEM, V240, P3341
   SWICK RW, 1965, J BIOL CHEM, V240, P3334
   UMEMURA I, 1994, BIOSCI BIOTECH BIOCH, V58, P283, DOI 10.1271/bbb.58.283
   VELICK SF, 1962, J BIOL CHEM, V237, P2109
   WALDORF MA, 1963, P SOC EXP BIOL MED, V112, P764
   Ward DE, 2000, J BACTERIOL, V182, P2559, DOI 10.1128/JB.182.9.2559-2566.2000
   WATFORD M, 1994, BBA-GEN SUBJECTS, V1200, P73, DOI 10.1016/0304-4165(94)90029-9
   YAGI T, 1981, ANAL BIOCHEM, V110, P146, DOI 10.1016/0003-2697(81)90126-3
   YAMAMOTO H, 1974, AM J PHYSIOL, V226, P1428
   ZUCHLEWSKI AC, 1957, ARCH BIOCHEM BIOPHYS, V66, P463, DOI 10.1016/S0003-9861(57)80023-X
NR 46
TC 5
Z9 5
U1 2
U2 14
PU MAIK NAUKA/INTERPERIODICA/SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013-1578 USA
SN 0006-2979
EI 0320-9725
J9 BIOCHEMISTRY-MOSCOW+
JI Biochem.-Moscow
PY 2006
VL 71
SU 1
BP S105
EP S112
DI 10.1134/S0006297906130189
PG 8
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 024QY
UT WOS:000236212300018
PM 16487061
DA 2018-12-27
ER

PT J
AU Archer, CW
   Buxton, P
   Hall, BK
   Francis-West, P
AF Archer, Charles W.
   Buxton, Paul
   Hall, Brian K.
   Francis-West, Philippa
TI RETRACTED: Mechanical regulation of secondary chondrogenesis (Retracted
   Article. See vol 46, pg 73, 2009)
SO BIORHEOLOGY
LA English
DT Article; Proceedings Paper; Retracted Publication
CT 4th International Symposium on Mechanobiology of Cartilage and
   Chondrocyte
CY MAY 20-22, 2006
CL Budapest, HUNGARY
DE Cbfa-1; Ihh; Sox9; hypertrophy; chondrocyte; membrane bone;
   proliferation; chick
ID CHONDROCYTE DIFFERENTIATION; INDIAN HEDGEHOG; II COLLAGEN;
   CELL-DIFFERENTIATION; TARGETED DISRUPTION; FRACTURE REPAIR;
   BONE-FORMATION; MEMBRANE BONE; CHICK LIMB; EXPRESSION
AB The development of the skull is characterised by its dependence upon epigenetic influences. One of the most important of these is secondary chondrogenesis, which occurs following ossification within certain membrane bone periostea, as a result of biomechanical articulation. We have studied the genesis, character and function of the secondary chondrocytes of the quadratojugal of the chick between embryonic days 11 and 14. Analysis of gene expression revealed that secondary chondrocytes formed coincident with Sox9 upregulation from a precursor population expressing Cbfa1/Runx2: a reversal of the normal sequence. Such secondary chondrocytes rapidly acquired a phenotype that is a compound of prehypertrophic and hypertrophic chondrocytes, exited from the cell cycle and upregulated Ihh. Pulse and pulse/chase experiments with BrdU confirmed the germinal region as the highly proliferative source of the secondary chondrocytes, which formed by division of chondrocyte-committed precursors. By blocking Hh signalling in explant cultures we show that the enhanced proliferation of the germinal region surrounding the secondary chondrocytes derives from this Ihh source. Additionally, in vitro studies on membrane bone periosteal cells (nongerminal region) demonstrated that these cells can also respond to Ihh, and do so both by enhanced proliferation and precocious osteogenesis. Despite the pro-osteogenic effects of Ihh on periosteal cell differentiation, mechanical articulation of the quadratojugal/quadrate joint in explant culture revealed a negative role for articulation in the regulation of osteocalcin by germinal region descendants. Thus, the mechanical stimulus that is the spur to secondary chondrocyte formation appears able to override the osteogenic influence of Ihh on the periosteum, but does not interfere with the cell cycle-promoting component of Hh signalling.
C1 Cardiff Univ, Connect Tissue Biol Labs, Sch Biosci, Cardiff, Wales.
   Guys Hosp, Dept Craniofacial Dev, Guys Kings & St Thomas Sch Dent, London SE1 9RT, England.
   Dalhousie Univ, Dept Biol, Halifax, NS B3 4J1, Canada.
RP Archer, CW (reprint author), Cardiff Univ, Connect Tissue Biol Labs, Sch Biosci, Museum Ave, Cardiff, Wales.
CR AUBIN JE, 1996, PRINCIPLES BONE BIOL, V1, P51
   Beier F, 2001, MOL BIOL CELL, V12, P3852, DOI 10.1091/mbc.12.12.3852
   Bell DM, 1997, NAT GENET, V16, P174, DOI 10.1038/ng0697-174
   Beresford WA, 1981, CHONDROID BONE SECON
   Bi WM, 1999, NAT GENET, V22, P85
   de Crombrugghe B, 2000, MATRIX BIOL, V19, P389, DOI 10.1016/S0945-053X(00)00094-9
   DEVLIN CJ, 1988, DEVELOPMENT, V103, P111
   Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3
   Ducy P, 2000, DEV DYNAM, V219, P461, DOI 10.1002/1097-0177(2000)9999:9999<::AID-DVDY1074>3.0.CO;2-C
   Enomoto H, 2000, J BIOL CHEM, V275, P8695, DOI 10.1074/jbc.275.12.8695
   Ericson J, 1996, CELL, V87, P661, DOI 10.1016/S0092-8674(00)81386-0
   Fang JM, 1997, ANAT EMBRYOL, V196, P349, DOI 10.1007/s004290050104
   Fang JM, 1996, DEV BIOL, V180, P701, DOI 10.1006/dbio.1996.0339
   Ferguson C, 1999, MECH DEVELOP, V87, P57, DOI 10.1016/S0925-4773(99)00142-2
   FRANCIS PH, 1994, DEVELOPMENT, V120, P209
   Francis-West PH, 1999, DEVELOPMENT, V126, P1305
   HALL B. K., 1967, LIFE SCI, V6, P663, DOI 10.1016/0024-3205(67)90104-X
   HALL BK, 1968, J EXP ZOOL, V168, P283, DOI 10.1002/jez.1401680302
   HALL BK, 1979, TERATOLOGY, V20, P81, DOI 10.1002/tera.1420200112
   Hartmann C, 2001, CELL, V104, P341, DOI 10.1016/S0092-8674(01)00222-7
   Herring Susan W., 1993, P153
   Hill TP, 2005, DEV CELL, V8, P727, DOI 10.1016/j.devcel.2005.02.013
   HOUSTON B, 1994, J MOL ENDOCRINOL, V13, P289, DOI 10.1677/jme.0.0130289
   KARAPLIS AC, 1994, GENE DEV, V8, P277, DOI 10.1101/gad.8.3.277
   Kent J, 1996, DEVELOPMENT, V122, P2813
   Kim IS, 1999, MECH DEVELOP, V80, P159, DOI 10.1016/S0925-4773(98)00210-X
   Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5
   KWAN APL, 1989, J CELL BIOL, V109, P1849, DOI 10.1083/jcb.109.4.1849
   Ladher RK, 2000, DEV BIOL, V218, P183, DOI 10.1006/dbio.1999.9586
   Lanske B, 1996, SCIENCE, V273, P663, DOI 10.1126/science.273.5275.663
   Lefebvre V, 1997, MOL CELL BIOL, V17, P2336, DOI 10.1128/MCB.17.4.2336
   Long FX, 2001, DEVELOPMENT, V128, P5099
   MURRAY P. D. F., 1963, AUSTRALIAN JOUR ZOOL, V11, P368, DOI 10.1071/ZO9630368
   Murray P. D. F., 1965, Australian Journal of Zoology, V13, P351, DOI 10.1071/ZO9650351
   Pearse RV, 2001, DEV BIOL, V239, P15, DOI 10.1006/dbio.2001.0430
   SCOTT JH, 1954, P ROY SOC MED, V47, P91
   Shibata S, 1997, J ANAT, V191, P561, DOI 10.1046/j.1469-7580.1997.19140561.x
   Takahashi I, 1998, J CELL SCI, V111, P2067
   Takeda S, 2001, GENE DEV, V15, P467, DOI 10.1101/gad.845101
   Vortkamp A, 1998, MECH DEVELOP, V71, P65, DOI 10.1016/S0925-4773(97)00203-7
   Vortkamp A, 1996, SCIENCE, V273, P613, DOI 10.1126/science.273.5275.613
   Wu QQ, 2001, J BIOL CHEM, V276, P35290, DOI 10.1074/jbc.M101055200
   Zhang PM, 1997, NATURE, V387, P151, DOI 10.1038/387151a0
NR 43
TC 15
Z9 15
U1 0
U2 8
PU IOS PRESS
PI AMSTERDAM
PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS
SN 0006-355X
J9 BIORHEOLOGY
JI Biorheology
PY 2006
VL 43
IS 3-4
SI SI
BP 355
EP 370
PG 16
WC Biophysics; Engineering, Biomedical; Hematology
SC Biophysics; Engineering; Hematology
GA 071YB
UT WOS:000239638700019
PM 16912408
DA 2018-12-27
ER

PT J
AU Lefebvre, L
   Marino, L
   Sol, D
   Lemieux-Lefebvre, S
   Arshad, S
AF Lefebvre, Louis
   Marino, Lori
   Sol, Daniel
   Lemieux-Lefebvre, Sebastien
   Arshad, Saima
TI RETRACTED: Large brains and lengthened life history periods in
   odontocetes (Retracted Article)
SO BRAIN BEHAVIOR AND EVOLUTION
LA English
DT Correction; Retracted Publication
DE cetaceans; brain size; life history; longevity; sexual maturity;
   gestation
ID WESTERN NORTH-ATLANTIC; PHOCOENA-PHOCOENA; HARBOR PORPOISES;
   STENELLA-LONGIROSTRIS; DELPHINAPTERUS-LEUCAS; REPRODUCTIVE PATTERNS;
   DOLPHINS DELPHINIDAE; SOTALIA-FLUVIATILIS; TURSIOPS-TRUNCATUS; SPINNER
   DOLPHIN
AB Previous work on primates and birds suggests that large brains require longer periods of juvenile growth, leading to reproductive constraints due to delayed maturation. However, longevity is often extended in large-brained species, possibly compensating for delayed maturation. We examined the relationship between brain size and life history periods in cetaceans, a large-brained mammalian order that has been largely ignored. We looked at males and females of twenty-five species of Odontocetes, using independent contrasts and multiple regressions to disentangle possible phylogenetic effects and inter-correlations among life history traits. We corrected all variables for body size allometry and separated life span into adult and juvenile periods. For females and both sexes combined, gestation, time to sexual maturity, time as an adult and life span were all positively associated with residual brain size in simple regressions; in multiple regressions, maximum life span and time as an adult were the best predictors of brain size. Males showed few significant trends. Our results suggest that brain size has co-evolved with extended life history periods in Odontocetes, as it has in primates and birds, and that a lengthened adult period could have been an important component of encephalization in cetaceans.
C1 McGill Univ, Dept Biol, Montreal, PQ H3A 1B1, Canada.
   Emory Univ, Neurosci & Behav Biol Program, Atlanta, GA 30322 USA.
   Autonomous Univ Barcelona, CREAF, Ctr Ecol Res & Appl Forestries, Barcelona, Spain.
RP Lefebvre, L (reprint author), McGill Univ, Dept Biol, 1205 Doctor Penfield Ave, Montreal, PQ H3A 1B1, Canada.
EM louis.lefebvre@mcgill.ca
RI Sol, Daniel/A-5238-2008
OI Sol, Daniel/0000-0001-6346-6949
CR Addink Marjan, 1997, Report of the International Whaling Commission, V47, P637
   ALLMAN J, 1993, P NATL ACAD SCI USA, V90, P118, DOI 10.1073/pnas.90.1.118
   Anderson S., 1967, RECENT MAMMALS WORLD
   ASPER E D, 1988, International Zoo Yearbook, V27, P295
   BALCOMB K, 1979, P 3 BIENN C BIOL MAR
   Barton Robert, 1999, P167, DOI 10.1017/CBO9780511542466.010
   BENNETT PM, 1985, J ZOOL, V207, P491
   BENNETT PM, 1985, J ZOOL, V207, P151
   BEST RC, 1974, CAN J ZOOL, V52, P429, DOI 10.1139/z74-052
   Best RC, 1984, REP INT WHAL COMM, V6, P361
   Bloch D., 1993, BIOL NO HEMISPHERE P, P163
   Boness DJ, 2002, MARINE MAMMAL BIOLOGY: AN EVOLUTIONARY APPROACH, P278
   BOROBIA M, 1989, MAR MAMMAL SCI, V5, P395, DOI 10.1111/j.1748-7692.1989.tb00353.x
   BRODIE PF, 1971, J FISH RES BOARD CAN, V28, P1309, DOI 10.1139/f71-198
   BRODIE PF, 1982, REP INT WHALING COMM, V32, P445
   BROWNELL RL, 1984, REPORT INT WHALING C, V6, P149
   Bryden M.M., 1986, P211
   Caldwell DK, 1972, WORLD BOTTLENOSED DO
   CALDWELL MC, 1966, LA COUNTY MUS CONTR, V108, P24
   Calzada N, 1996, J ZOOL, V240, P581, DOI 10.1111/j.1469-7998.1996.tb05308.x
   Calzada N, 1997, CAN J ZOOL, V75, P632, DOI 10.1139/z97-078
   Cassens I, 2000, P NATL ACAD SCI USA, V97, P11343, DOI 10.1073/pnas.97.21.11343
   Chivers SJ, 2002, ENCY MARINE MAMMALS, P221
   CHRISTENSEN I, 1982, REPORT INT WHALING C, V32, P633
   CLUTTONBROCK TH, 1980, J ZOOL, V190, P309
   COCKCROFT VG, 1990, FISH B-NOAA, V88, P289
   Collet A., 1984, Reports of the International Whaling Commission Special Issue, P355
   Connor Richard C., 1992, P415
   DASILVA VM, 1989, HDB MARINE MAMMALS, V4, P1
   DASILVA VMF, 1994, HDB MARINE MAMMALS, V5, P43
   Deaner RO, 2000, BRAIN BEHAV EVOLUT, V55, P44, DOI 10.1159/000006641
   Deaner Robert O., 2003, P233
   Eisenberg JF, 1981, MAMMALIAN RAD
   Ferrero RC, 1999, MAR MAMMAL SCI, V15, P273, DOI 10.1111/j.1748-7692.1999.tb00803.x
   Ferrero RC, 1996, CAN J ZOOL, V74, P1673, DOI 10.1139/z96-185
   GAO AL, 1992, CAN J ZOOL, V70, P1484
   Garamszegi LZ, 2005, P ROY SOC B-BIOL SCI, V272, P159, DOI 10.1098/rspb.2004.2940
   GARLAND T, 1993, SYST BIOL, V42, P265, DOI 10.2307/2992464
   GASKIN DE, 1977, CAN J ZOOL, V55, P18, DOI 10.1139/z77-002
   GASKIN DE, 1984, REP INT WHAL COMMN, V6, P135
   GERACI JR, 1979, MMC7713
   GERACI TR, 1978, MMC7512
   GUREVICH VS, 1978, UNPUB STRUCTURE KILL
   HAIN JHW, 1982, FISH B-NOAA, V80, P259
   Hamilton H, 2001, P ROY SOC B-BIOL SCI, V268, P549, DOI 10.1098/rspb.2000.1385
   Harrison R. J., 1969, P253
   HARRISON RJ, 1981, J ZOOL, V193, P563, DOI 10.1111/j.1469-7998.1981.tb01504.x
   HARRISON RJ, 1969, NATURE, V222, P1143, DOI 10.1038/2221143b0
   HARRISON RJ, 1972, FUNCTIONAL ANATOMY M, V1, P361
   HARVEY PH, 1990, SCIENCE, V249, P140, DOI 10.1126/science.2196673
   Harvey PH, 1991, COMP METHOD EVOLUTIO
   Hay K. A., 1989, HDB MARINE MAMMALS, V4, P145
   HAY KA, 1980, REP INT WHALE COMM S, P119
   HEIMLICHBORAN JR, 1988, CAN J ZOOL, V66, P565, DOI 10.1139/z88-084
   Heise Kathy, 1997, Report of the International Whaling Commission, V47, P817
   HEYNING JE, 1993, REFINING AGE ESTIMAT
   HOENIG JM, 1983, FISH B US, V82, P898, DOI DOI 10.1890/04-0594
   HOFMAN MA, 1993, J EVOLUTION BIOL, V6, P209, DOI 10.1046/j.1420-9101.1993.6020209.x
   HOHN AA, 2002, ENCY MARINE MAMMALS, P6
   HUI CA, 1979, FISH B-NOAA, V77, P295
   *INT WHAL COMM, 1988, REP INT WHALE COMM, V38, P24
   International Whaling Commission, 1987, REP INT WHAL COMMN, V37, P121
   International Whaling Commission, 1989, REP INT WHAL COMM, V39, P117
   Iwaniuk AN, 2003, CAN J ZOOL, V81, P1913, DOI 10.1139/Z03-190
   IWASAKI T, 1991, P INT N PAC FISH COM
   Joffe TH, 1997, J HUM EVOL, V32, P593, DOI 10.1006/jhev.1997.0140
   JOHNSTON TD, 1982, ADV STUD BEHAV, V12, P65, DOI 10.1016/S0065-3454(08)60046-7
   Jones L. L., 1987, 3156 INT N PAC FISH
   JONES LL, 1985, P 6 BIENN C BIOL MAR
   JONES LL, 1988, 3280 INT N PAC FISH
   Jurasz C.M., 1979, Scientific Reports of the Whales Research Institute Tokyo, V31, P69
   Kaplan HS, 2002, P NATL ACAD SCI USA, V99, P10221, DOI 10.1073/pnas.152502899
   Kasuya T., 1979, Scientific Reports of the Whales Research Institute Tokyo, V31, P45
   Kasuya T., 1976, Scientific Rep Whales Res Inst Tokyo, VNo. 28, P73
   Kasuya T., 1986, REPORT INVESTIGATION, P178
   Kasuya T, 1972, SCI REP WHALES RES, V24, P57
   KASUYA T, 1978, SCI REP WHALES RES, V30, P1
   KASUYA T, 1988, SCI REPORTS WHALES R, V39, P103
   Kasuya T, 1972, SCI REP WHALES RES, V24, P87
   Kasuya T., 1985, SCI REP WHALES RES, V36, P107
   KAWAI S, 1981, STUDIES LEVELS ORGAN, P85
   Kleinenberg SE, 1964, BELUGA DELPHINAPTERU
   KLINOWSKA M, 1991, DOLPHINS PORPOISES W
   LEATHERWOOD S, 1990, BOTTLE NOSE DOLPHIN
   Lefebvre L, 2006, BRAIN BEHAV EVOLUT, V68, P218, DOI 10.1159/000094359
   Lockyer C., 1981, FAO FISHERIES SERIES, V5, P489
   LOCKYER C, 1995, REP INT WHALE COMM, V16, P190
   Marino L, 2004, ANAT REC PART A, V281A, P1247, DOI 10.1002/ar.a.20128
   Marino L, 2002, BRAIN BEHAV EVOLUT, V59, P21, DOI 10.1159/000063731
   Marino L, 1997, MAR MAMMAL SCI, V13, P133, DOI 10.1111/j.1748-7692.1997.tb00616.x
   Marino L, 1998, BRAIN BEHAV EVOLUT, V51, P230, DOI 10.1159/000006540
   MARINO L, 2002, ENCY MARINE MAMMALS, P158
   MARTIN AR, 1993, BIOL NO HEMISPHERE P, P263
   MARTIN AR, 1992, GROSSE BUCH WALE DEL
   MARTINS EP, 2003, COMPARE VERSION 4 5
   MEAD J, 2001, 14 BIENN C BIOL MAR
   Mead J.G., 1990, P165
   MEAD JG, 1980, FISH B-NOAA, V78, P353
   Miyasaki N, 1994, HDB MARINE MAMMALS, V5, P1
   Miyazaki N., 1984, REP INT WHALING COMM, V6, P343
   MIYAZAKI N, 1980, REPORTS INT WHALING, P171
   OKADA Y, 1951, 1 PREF U MIE P FAC F, P4
   Olesiuk P.F., 1990, LIFE HIST POPULATION, P209
   Pereira Michael E., 2003, P149
   Perrin W.F., 1994, HDB MARINE MAMMALS, P99
   PERRIN WF, 1977, FISH B-NOAA, V75, P725
   PERRIN WF, 1980, REP INT WHALE COMM S, P31
   PERRIN WF, 1984, REP INT WHALING COMM, V6, P97
   Peters R.H., 1983, P1
   PINEDO MC, 1989, 3 IUCN SPEC SURV COM, P46
   PIRLOT P, 1975, GROWTH, V39, P507
   PROMISLOW DEL, 1993, J GERONTOL, V48, pB115, DOI 10.1093/geronj/48.4.B115
   Purves P.E., 1978, Investigations on Cetacea, V9, P67
   Ramos Renata Maria Arruda, 2000, Aquatic Mammals, V26, P65
   READ AJ, 1995, MAR MAMMAL SCI, V11, P423, DOI 10.1111/j.1748-7692.1995.tb00667.x
   READ AJ, 1990, CAN J FISH AQUAT SCI, V47, P561, DOI 10.1139/f90-064
   Read AJ, 1997, CAN J ZOOL, V75, P122, DOI 10.1139/z97-016
   Reader SM, 2002, P NATL ACAD SCI USA, V99, P4436, DOI 10.1073/pnas.062041299
   Rendell L, 2001, BEHAV BRAIN SCI, V24, P309, DOI 10.1017/S0140525X0100396X
   Ricklefs RE, 2004, WILSON BULL, V116, P119, DOI 10.1676/04-054
   Ridgway SH, 1972, MAMMALS SEA BIOL MED
   ROBECK TR, 1994, 25 ANN C INT ASS AQ
   RODRIGUEZ D, 2002, LAJAM, V1, P1
   Rosas FCW, 2003, FISH B-NOAA, V101, P377
   ROSS G J B, 1984, Annals of the Cape Provincial Museums Natural History, V15, P173
   ROSS GFB, 1979, THESIS U PORT ELIZAB
   SACHER GA, 1974, AM NAT, V108, P593, DOI 10.1086/282938
   SACHER GA, 1978, BIOSCIENCE, V28, P497, DOI 10.2307/1307295
   SACHER GA, 1959, CIBA F COLLOQ AGEING, V5, P115
   SACHER GA, 1980, REPORTS INT WHALING, P209
   Santos MCD, 2003, J MAR BIOL ASSOC UK, V83, P233
   SERGEANT DE, 1973, J FISH RES BOARD CAN, V30, P1009, DOI 10.1139/f73-165
   SERGEANT DE, 1973, J FISH RES BOARD CAN, V30, P1065, DOI 10.1139/f73-178
   SERGEANT DE, 1962, J FISH RES BRD CAN, V32, P1
   SERGEANT DE, 1980, CETOLOGY, V37, P1
   SMITH BH, 1989, EVOLUTION, V43, P683, DOI 10.1111/j.1558-5646.1989.tb04266.x
   Smolker R, 1997, ETHOLOGY, V103, P454, DOI 10.1111/j.1439-0310.1997.tb00160.x
   Sol D, 2005, P NATL ACAD SCI USA, V102, P5460, DOI 10.1073/pnas.0408145102
   SORENSEN TB, 1994, OPHELIA, V39, P159, DOI 10.1080/00785326.1994.10429541
   Starck J.M., 1993, Current Ornithology, V10, P275
   STUART LJ, 1980, REP INT WHALE COMM S, P133
   Van Schaik CP, 2003, ANIMAL SOCIAL COMPLEXITY, P5
   VANUTRECHT WL, 1978, BIJDR DIERKD, V48, P16
   Waddell VG, 2000, MOL PHYLOGENET EVOL, V15, P314, DOI 10.1006/mpev.1999.0751
   Walker W.A., 1986, P441
   Whitehead H, 1998, SCIENCE, V282, P1708, DOI 10.1126/science.282.5394.1708
   WURSIG B, 1980, FISH B-NOAA, V77, P871
   ZHOU K, 2002, ENCY MARINE MAMMALS, P58
   WHALES RES I, V37, P85
NR 149
TC 11
Z9 11
U1 4
U2 29
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0006-8977
EI 1421-9743
J9 BRAIN BEHAV EVOLUT
JI Brain Behav. Evol.
PY 2006
VL 68
IS 4
BP 218
EP 228
DI 10.1159/000094359
PG 12
WC Behavioral Sciences; Neurosciences; Zoology
SC Behavioral Sciences; Neurosciences & Neurology; Zoology
GA 104GE
UT WOS:000241944600002
PM 16809909
OA Bronze
DA 2018-12-27
ER

PT J
AU Freeman, H
   Shimomura, K
   Horner, E
   Cox, RD
   Ashcroft, FM
AF Freeman, H
   Shimomura, K
   Horner, E
   Cox, RD
   Ashcroft, FM
TI RETRACTED: Nicotinamide nucleotide transhydrogenase: A key role in
   insulin secretion (Retracted article. See vol. 19, pg. 344, 2014)
SO CELL METABOLISM
LA English
DT Article; Retracted Publication
ID PANCREATIC BETA-CELLS; SENSITIVE K+ CHANNELS; DIABETES-MELLITUS;
   UNCOUPLING PROTEINS; HYDROGEN-PEROXIDE; OXIDATIVE STRESS; MOUSE STRAINS;
   SUPEROXIDE; GLUCOSE; GENE
AB The C57BL/6J mouse displays glucose intolerance and reduced insulin secretion. QTL mapping identified Nicotinamide Nucleotide Transhydrogenase (Nnt), a nuclear-encoded mitochondrial protein thought to be involved in free radical detoxification, as a candidate gene. To investigate its functional role, we used siRNA to knockdown Nnt in insulin-secreting MIN6 cells. This produced a dramatic reduction in insulin secretion and the rise in [Ca2+](i) evoked by glucose, but not tolbutamide. We identified two ENU-induced point mutations in Nnt (N68K, G745D). Nnt mutant mice were glucose intolerant and secreted less insulin during a glucose tolerance test. Isolated islets showed impaired insulin secretion in response to glucose, but not to tolbutamide, and glucose failed to enhance ATP levels. Glucose utilization and production of reactive oxygen species were increased in Nnt 0 cells. We hypothesize that Nnt mutations/deletion uncouple p cell mitochondrial metabolism leading to less ATP production, enhanced K-ATP channel activity, and consequently impaired insulin secretion.
C1 MRC, Mammalian Genet Unit, Didcot OX11 0RD, Oxon, England.
   Univ Oxford, Physiol Lab, Oxford OX1 3PT, England.
RP Cox, RD (reprint author), MRC, Mammalian Genet Unit, Didcot OX11 0RD, Oxon, England.
EM r.cox@har.mrc.ac.uk; frances.ashcroft@physiol.ox.ac.uk
FU Medical Research Council [MC_UP_1502/1]; Medical Research Council
   [MC_U142684172, MC_U142684175, MC_U142661184]; Wellcome Trust
CR Arkblad EL, 2005, FREE RADICAL BIO MED, V38, P1518, DOI 10.1016/j.freeradbiomed.2005.02.012
   Arkblad EL, 2002, COMP BIOCHEM PHYS B, V133, P13, DOI 10.1016/S1096-4959(02)00107-0
   Arkblad EL, 2001, BBA-GENE STRUCT EXPR, V1520, P115, DOI 10.1016/S0167-4781(01)00257-3
   Ashcroft F, 2004, HUM MOL GENET, V13, pR21, DOI 10.1093/hmg/ddh066
   ASHCROFT FM, 1989, J PHYSIOL-LONDON, V416, P349, DOI 10.1113/jphysiol.1989.sp017765
   ASHCROFT FM, 1989, PROG BIOPHYS MOL BIO, V54, P87, DOI 10.1016/0079-6107(89)90013-8
   ASHCROFT SJ, 1972, BIOCHEM J, V126, P525, DOI 10.1042/bj1260525
   Bell GI, 2001, NATURE, V414, P788, DOI 10.1038/414788a
   Bindokas VP, 2003, J BIOL CHEM, V278, P9796, DOI 10.1074/jbc.M206913200
   Brand MD, 2004, FREE RADICAL BIO MED, V37, P755, DOI 10.1016/j.freeradbiomed.2004.05.034
   Chan CB, 2001, DIABETES, V50, P1302, DOI 10.2337/diabetes.50.6.1302
   Coghill EL, 2002, NAT GENET, V30, P255, DOI 10.1038/ng847
   Del Guerra S, 2005, DIABETES, V54, P727, DOI 10.2337/diabetes.54.3.727
   Echtay KS, 2002, NATURE, V415, P96, DOI 10.1038/415096a
   Fridlyand LE, 2004, DIABETES, V53, P1942, DOI 10.2337/diabetes.53.8.1942
   Friesen NTE, 2004, DIABETOLOGIA, V47, P676, DOI 10.1007/s00125-004-1367-x
   Gloyn AL, 2004, NEW ENGL J MED, V350, P1838, DOI 10.1056/NEJMoa032922
   Green K, 2004, DIABETES, V53, pS110, DOI 10.2337/diabetes.53.2007.S110
   HOEK JB, 1988, BIOCHEM J, V254, P1
   Kahn SE, 2003, DIABETOLOGIA, V46, P3, DOI 10.1007/s00125-002-1009-0
   KAKU K, 1988, DIABETES, V37, P707, DOI 10.2337/diabetes.37.6.707
   Kayo T, 2000, COMPARATIVE MED, V50, P296
   King H, 1998, DIABETES CARE, V21, P1414, DOI 10.2337/diacare.21.9.1414
   Kooptiwut S, 2002, ENDOCRINOLOGY, V143, P2085, DOI 10.1210/en.143.6.2085
   Koster JC, 2000, CELL, V100, P645, DOI 10.1016/S0092-8674(00)80701-1
   Krauss S, 2003, J CLIN INVEST, V112, P1831, DOI 10.1172/JCI200319774
   Krippeit-Drews P, 1999, J PHYSIOL-LONDON, V514, P471, DOI 10.1111/j.1469-7793.1999.471ae.x
   Kulkarni RN, 2003, DIABETES, V52, P1528, DOI 10.2337/diabetes.52.6.1528
   Maechler P, 1999, J BIOL CHEM, V274, P27905, DOI 10.1074/jbc.274.39.27905
   Maechler P, 2001, NATURE, V414, P807, DOI 10.1038/414807a
   Martens GA, 2005, J BIOL CHEM, V280, P20389, DOI 10.1074/jbc.M411869200
   Muller FL, 2004, J BIOL CHEM, V279, P49064, DOI 10.1074/jbc.M407715200
   Proks P, 2004, P NATL ACAD SCI USA, V101, P17539, DOI 10.1073/pnas.0404756101
   Quwailid MM, 2004, MAMM GENOME, V15, P585, DOI 10.1007/s00335-004-2379-z
   Raha S, 2000, TRENDS BIOCHEM SCI, V25, P502, DOI 10.1016/S0968-0004(00)01674-1
   Rossmeisl M, 2003, DIABETES, V52, P1958, DOI 10.2337/diabetes.52.8.1958
   Sakura H, 1995, FEBS LETT, V377, P338, DOI 10.1016/0014-5793(95)01369-5
   SAZANOV LA, 1994, FEBS LETT, V344, P109, DOI 10.1016/0014-5793(94)00370-X
   Silva JP, 2000, NAT GENET, V26, P336
   Stoehr JP, 2000, DIABETES, V49, P1946, DOI 10.2337/diabetes.49.11.1946
   Terauchi Y, 1995, J BIOL CHEM, V270, P30253, DOI 10.1074/jbc.270.51.30253
   TOYE AA, 2005, DIABETOLOGIA
   Tucker SJ, 1997, NATURE, V387, P179, DOI 10.1038/387179a0
   YAMAGUCHI M, 1991, J BIOL CHEM, V266, P5728
   Zhang HF, 2002, NANO LETT, V2, P105, DOI 10.1021/nl015656k
NR 45
TC 118
Z9 122
U1 4
U2 18
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 1550-4131
EI 1932-7420
J9 CELL METAB
JI Cell Metab.
PD JAN
PY 2006
VL 3
IS 1
BP 35
EP 45
DI 10.1016/j.cmet.2005.10.008
PG 11
WC Cell Biology; Endocrinology & Metabolism
SC Cell Biology; Endocrinology & Metabolism
GA 002CP
UT WOS:000234589300007
PM 16399503
OA Bronze
DA 2018-12-27
ER

PT J
AU Liu, XY
   Gu, JF
AF Liu, XY
   Gu, JF
TI RETRACTED: Targeting gene-virotherapy of cancer (Retracted Article. See
   vol 16, pg 740, 2006)
SO CELL RESEARCH
LA English
DT Review; Retracted Publication
DE targeting therapy; cancer therapy; gene-virotherapy
ID ANTITUMOR-ACTIVITY; CELLS; APOPTOSIS; POTENT; TRAIL
AB Our purpose is to completely elimination of xenograft tumor in animal tumor model in order to work out a protocal for the cure of patient. Gene therapy and viral therapy for cancer have got some therapeutic effects, but both have no great breakthrough. Therefore, we worked out a new strategy called Targeting Gene-Virotherapy of Cancer which is a combination of the advantage of gene therapy and virotherapy. This new strategy has stronger antitumor effect than either of them alone. A tumor specific replicative adenovirus vector ZD55 (EIB 55KD deleted Adv.) which is similar to ONYX-015 in targeting fuction but significant different in construction was produced and various single therapeutic gene was inserted into ZD55. Now such a conception as Targeting Gene-Virotherapy of Cancer was raised and systemically studied before, although there are some works on ONYX-015-tk, -cd or cd/-tk etc. separately. The antitumor effect of ZD55-Gene (for example IL-24 gene) is much better than ZD55 (virotherapy) alone and hundred fold high than that of Ad-IL-24 (gene therapy) alone. ZD55-IL-24 was in preclinal Studying in the ZD55-IL-24 therapy, completely elimination of tumor mass was occurred in some mice but not in all mice, that means one gene was not effictive enough to eliminate all the tumor mass in all mice. Therefore two genes with compensative or synergetic effect were inserted into ZD55 sepearately and used in combinction. This strategy was called Targeting Dual Gene-Virotherapy of Cancer (with PCT patent). Then much better results were obtained and all the xenograft tumor masses were completely eliminated in all mice, if two suitable genes were chosen. On the basis of the initiation of two gene results, it was thought about that using two tumors promoter to control the virus vector will be better for the targeting effect and the safty of the drugs. Then double tumor controlled virus vector harboring two genes for cancer therapy was worked out. Better results have been obtained and another patent has been applied. This antitumor strategy could be used to kill all the tumor cells completely in all mice with minimum damage to normal cells.
C1 Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol, Shanghai 200031, Peoples R China.
   Zhejiang Sci Tech Univ, Sch Life Sci, Xinyuan Inst Med & Biotechnol, Hangzhou 310018, Peoples R China.
RP Liu, XY (reprint author), Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol, 320 Yue Yang Rd, Shanghai 200031, Peoples R China.
EM xyliu@sibs.ac.cn
CR Griffith TS, 1998, J IMMUNOL, V161, P2833
   KIM D, 2001, NAT MED, V7, P781
   Liu XY, 2005, MOL THER, V11, P531, DOI 10.1016/j.ymthe.2004.12.003
   Pei ZF, 2004, HEPATOLOGY, V39, P1371, DOI 10.1002/hep.20203
   Pitt RM, 1996, J BIOL CHEM, V271, P12687, DOI 10.1074/jbc.271.22.12687
   Tang Yun-Xia, 2005, Ai Zheng, V24, P536
   YUAN XL, 2001, CHINESE J CANC BIOTH, V8, P1
   Zhang Q, 2004, CANCER RES, V64, P5390, DOI 10.1158/0008-5472.CAN-04-1229
   Zhao LL, 2005, HUM GENE THER, V16, P845, DOI 10.1089/hum.2005.16.845
   Zou WG, 2004, ONCOGENE, V23, P457, DOI 10.1038/sj.onc.1207033
NR 10
TC 27
Z9 33
U1 5
U2 7
PU INST BIOCHEMISTRY & CELL BIOLOGY
PI SHANGHAI
PA SIBS, CAS, 319 YUEYANG ROAD, SHANGHAI, 200031, PEOPLES R CHINA
SN 1001-0602
EI 1748-7838
J9 CELL RES
JI Cell Res.
PD JAN
PY 2006
VL 16
IS 1
BP 25
EP 30
DI 10.1038/sj.cr.7310005
PG 6
WC Cell Biology
SC Cell Biology
GA 034WK
UT WOS:000236961100005
PM 16467873
OA Bronze
DA 2018-12-27
ER

PT J
AU Brown, DL
   Meagher, PJ
   Knight, KR
   Keramidaris, E
   Romeo-Meeuw, R
   Penington, AJ
   Morrison, WA
AF Brown, David L.
   Meagher, Peter J.
   Knight, Kenneth R.
   Keramidaris, Effie
   Romeo-Meeuw, Rosalind
   Penington, Anthony J.
   Morrison, Wayne A.
TI RETRACTED: Survival and function of transplanted islet cells on an in
   vivo, vascularized tissue engineering platform in the rat: A pilot study
   (Retracted Article. See vol 16, pg 1071, 2008)
SO CELL TRANSPLANTATION
LA English
DT Article; Retracted Publication
DE islet transplantation; tissue engineering; in vivo vascularization
ID EMBRYONIC STEM-CELLS; BIOARTIFICIAL PANCREAS; EXTRACELLULAR-MATRIX;
   ARTERIOVENOUS SHUNT; PROGENITOR CELLS; GENERATION; EXPANSION; CULTURE;
   LOOP
AB As in vivo tissue engineering of complex tissues and organs progresses, there is a need for an independently vascularized, alterable, and recoverable model. Current models of islet cell transplantation (release into the portal venous system, placement under the renal capsule, and microencapsulation) lack these qualities. We have developed a model of angiogenesis and spontaneous tissue generation in the rat that lends itself as a potential platform for tissue engineering. In this experiment, we examined the effectiveness of such a model in addressing some of the shortcomings of endocrine pancreatic transplantation. An arteriovenous loop was created in the groins of five adult inbred Sprague-Dawley rats, and placed within polycarbonate chambers. Isolated pancreatic islet cell clusters were placed within the chambers, suspended in a matrix of Matrigel (R). The chambers were recovered at 3 weeks, and the newly generated tissue was processed for histologic and immunohistochemical analysis. By 3 weeks, spontaneous generation of angiogenesis and collagen matrix and deposition of a collagen matrix was observed. Surviving islet cells were identified by histology and their viability was confirmed via immunohistochemistry for insulin and glucagon. This study demonstrates the ability to maintain viability and functionality of transplanted islet cells on a tissue-engineered platform with an independent vascular supply. The model provides the ability to alter the graft environment via matrix substitution, cellular coculture, and administration of growth factors. The transplanted tissues are recoverable without animal sacrifice and are microsurgically transferable. This model may provide an in vivo culture platform for the study of islet transplantation.
C1 Univ Melbourne, St Vincents Hosp, Bernard OBrien Inst Microsurg, Melbourne, Vic, Australia.
   Univ Melbourne, St Vincents Hosp, Dept Surg, Melbourne, Vic, Australia.
   Univ Michigan, Div Plast Surg, Ann Arbor, MI 48109 USA.
   Univ London, St Georges Hosp, Sch Med, Dept Plast Surg, London, England.
RP Brown, DL (reprint author), 2130 Taubman Ctr, 1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA.
EM davbrown@umich.edu
OI Brown, David/0000-0002-5889-9886
CR Assady S, 2001, DIABETES, V50, P1691, DOI 10.2337/diabetes.50.8.1691
   Bonner-Weir Susan, 2003, Hormone Research (Basel), V60, P10, DOI 10.1159/000074493
   Cassell OCS, 2001, ANN NY ACAD SCI, V944, P429
   Constantididis I, 2002, ANN NY ACAD SCI, V961, P298, DOI 10.1111/j.1749-6632.2002.tb03106.x
   Cronin KJ, 2004, PLAST RECONSTR SURG, V113, P260, DOI 10.1097/01.PRS.0000095942.71618.9D
   FONTENEAU JF, 2003, BLOOD, V2, P2
   Gaber AO, 2001, TRANSPLANTATION, V72, P1730, DOI 10.1097/00007890-200112150-00005
   Gao R, 2003, DIABETES, V52, P2007, DOI 10.2337/diabetes.52.8.2007
   Gmyr V, 2001, CELL TRANSPLANT, V10, P109
   Hofer SOP, 2003, PLAST RECONSTR SURG, V111, P1186, DOI 10.1097/01.PRS.0000046034.02158.EB
   Krieger NR, 2003, TRANSPLANTATION, V75, P1271, DOI 10.1097/01.TP.0000061603.95572.BF
   Liu EH, 2000, TRENDS ENDOCRIN MET, V11, P379, DOI 10.1016/S1043-2760(00)00324-6
   Liu M, 1995, TRANSPL P, V27, P3208
   Maria-Engler SS, 2001, BRAZ J MED BIOL RES, V34, P691, DOI 10.1590/S0100-879X2001000600001
   Mian RA, 2001, TISSUE ENG, V7, P73, DOI 10.1089/107632700300003305
   Mian RW, 2000, TISSUE ENG, V6, P595, DOI 10.1089/10763270050199541
   Papas KK, 1999, BIOTECHNOL BIOENG, V66, P231, DOI 10.1002/(SICI)1097-0290(1999)66:4<231::AID-BIT4>3.3.CO;2-L
   Soria B, 2000, DIABETES, V49, P157, DOI 10.2337/diabetes.49.2.157
   Tanaka Y, 2000, BRIT J PLAST SURG, V53, P51, DOI 10.1054/bjps.1999.3186
   Zhang YQ, 2003, DIABETES-METAB RES, V19, P363, DOI 10.1002/dmrr.406
NR 20
TC 19
Z9 20
U1 3
U2 15
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0963-6897
EI 1555-3892
J9 CELL TRANSPLANT
JI Cell Transplant.
PY 2006
VL 15
IS 4
BP 319
EP 324
DI 10.3727/000000006783981909
PG 6
WC Cell & Tissue Engineering; Medicine, Research & Experimental;
   Transplantation
SC Cell Biology; Research & Experimental Medicine; Transplantation
GA 067TN
UT WOS:000239325600004
PM 28863745
DA 2018-12-27
ER

PT J
AU Vialle, R
   Court, C
   Harding, I
   Lepeintre, JF
   Khouri, N
   Tadie, M
AF Vialle, R
   Court, C
   Harding, I
   Lepeintre, JF
   Khouri, N
   Tadie, M
TI RETRACTED: Multiple lumbar plexus neurotizations of the ninth, tenth,
   and eleventh intercostal nerves (Retracted article. See vol. 21, pg.
   754, 2008)
SO CLINICAL ANATOMY
LA English
DT Article; Retracted Publication
DE lower intercostal nerves; lumbar roots neurotization; surgical
   harvesting; anatomical study
ID ANATOMICAL ANALYSIS; ABDOMINAL MUSCLES
AB The topographic anatomy of the lower intercostal nerves is less known than the upper ones except for the twelfth intercostal nerve. It is possible to use the lower intercostal nerves to carry out a neurotization of the lumbar roots. We studied the anatomy of the ninth, tenth, and eleventh intercostal nerves in order to specify the data of descriptive and topographic anatomy allowing to carry out their harvesting under good conditions. Ninth, tenth, and eleventh intercostal nerves of 50 cadavers were dissected. The proximal part of the nerve in the posterior intercostal space was exposed through a posterior approach. The lateral intercostal space was exposed through a lateral approach, under the latissimus dorsi, which made it possible to harvest the intercostals nerve. The proximal course of the nerve in posterior intercostals space was the same in all the cases. The nerve moves obliquely towards the outside to reach the lower border of the rib. The exit of posterior intercostal space is a fibrous strait that marks the entry of a channel between two muscular layers. We describe an aponevrotic channel in which the nerve and the vessels are, immediately at the lower border of the cranial rib. The mean total length of intercostal nerve harvested by our technique was 17.96 cm for the ninth intercostal nerve, 17.14 cm for the tenth intercostal nerve, and 15.94 cm for the eleventh intercostal nerve. The bifurcation of the intercostal nerve in a deep branch and the ramus cutaneus lateralis was found in the majority of the cases, from 9.5 to 21 cm of the emergence of the intercostal nerve in posterior intercostal space. This anatomical study of the ninth, tenth, and eleventh intercostal nerves in posterior intercostal space and lateral intercostal space appears to us to allow the realization of a reliable surgical harvesting.
C1 Assistance Publ Hop Paris, Ecole Chirurg, Paris, France.
   Kremlin Bicetre Hosp, Dept Expt Neurosurg, Le Kremlin Bicetre, France.
   Armand Trousseau Hosp, Dept Paediat Orthopaed, Paris, France.
   Kremlin Bicetre Hosp, Dept Orthopaed Surg, Le Kremlin Bicetre, France.
   Nuffield Orthopaed Ctr, Dept Orthopaed Surg, Oxford OX3 7LD, England.
RP Vialle, R (reprint author), 105 Ave Andre Morizet, F-92100 Boulogne Billancourt, France.
EM ravialle@noos.fr
CR ASAFAZADOURIAN H, 1999, ANN CHIR MAIN, V18, P243
   AUBERT J, 1981, J UROLOGIE, V87, P283
   Davies F, 1932, J ANAT, V66, P323
   HARDY PAJ, 1988, BRIT J ANAESTH, V61, P338, DOI 10.1093/bja/61.3.338
   HAUGE EN, 1991, ACTA PHYSIOL SCAND, V143, P19
   Lang EM, 2004, J NEUROSURG-SPINE, V1, P64, DOI 10.3171/spi.2004.1.1.0064
   Lim H H, 2001, Med J Malaysia, V56 Suppl C, P61
   ROUVIERE H, 1967, ANATOMIE HUMAINE DES, V2
   Sakamoto H, 1996, ACTA ANAT, V156, P143
   Sakamoto H, 1996, ACTA ANAT, V156, P132
   Schardl Christopher L., 1992, Natural Toxins, V1, P171
   TOK S, 1991, SPINE, V16, P463, DOI 10.1097/00007632-199104000-00014
   Walmsley T, 1916, J ANAT PHYSIOL, V50, P165
   WILLIAMS P, 1989, GRAYS ANATOMY, P37
   Yan L, 2000, Zhonghua Zheng Xing Wai Ke Za Zhi, V16, P81
   Zhao SR, 1997, J RECONSTR MICROSURG, V13, P39, DOI 10.1055/s-2008-1063939
NR 16
TC 8
Z9 10
U1 4
U2 11
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0897-3806
EI 1098-2353
J9 CLIN ANAT
JI Clin. Anat.
PD JAN
PY 2006
VL 19
IS 1
BP 51
EP 58
DI 10.1002/ca.20148
PG 8
WC Anatomy & Morphology
SC Anatomy & Morphology
GA 000QB
UT WOS:000234476000011
PM 16187321
DA 2018-12-27
ER

PT J
AU House, MG
   Schulick, RD
AF House, MG
   Schulick, RD
TI RETRACTED: Endocrine tumors of the pancreas (Retracted Article. See vol
   18, pg 414, 2006)
SO CURRENT OPINION IN ONCOLOGY
LA English
DT Review; Retracted Publication
DE islet cell tumors; MEN-1; pancreas; therapy
ID NEUROENDOCRINE LIVER METASTASES; NEOPLASIA TYPE-1 GENE; MEN1 GENE;
   SPORADIC GASTRINOMAS; SOMATIC MUTATIONS; SUPPRESSOR GENE; EXPRESSION;
   TRANSPLANTATION; INSULINOMAS; RESECTION
AB Purpose of review Neoplasms of the endocrine pancreas, commonly referenced as pancreatic islet cell tumors, are rare, often well differentiated endocrine neoplasms, whose biology remains poorly characterized. This article reviews the current clinical management of pancreatic islet cell tumors and describes the molecular events that have been studied to guide future therapies of these peculiar neoplasms.
   Recent findings While some islet cell tumors arise in association with the MEN-1 syndrome, the majority of these neoplasms are sporadic lesions whose underlying genetic and molecular events remain largely unknown. Recent work has identified changes in gene expression occurring in metastatic and non-metastatic islet cell tumors, which appear to correlate with the occurrence of lymph node and liver metastases. Epigenetic alterations of select tumor suppressor genes may influence patient survival, and the presence of gene promoter methylation may be used as a prognostic marker system. In addition, multiple molecular alterations, including changes in expression of cellular proteins with migratory, cell cycle or angiogenic functions, have been demonstrated to influence islet cell tumor growth, invasion and metastatic spread.
   Summary Understanding the molecular events underlying the biology of pancreatic islet cell tumors will aid the development of accurate prognostic markers and will guide improved therapeutic modalities in the future.
C1 Johns Hopkins Univ Hosp, Dept Surg, Baltimore, MD 21287 USA.
RP Schulick, RD (reprint author), Johns Hopkins Med Inst, Canc Res Bldg I-442,1650 Orleans St, Baltimore, MD 21231 USA.
EM rschulick@jhmi.edu
CR Agarwal SK, 2004, ANN NY ACAD SCI, V1014, P189, DOI 10.1196/annals.1294.020
   Ahlman H, 2000, DIGESTION, V62, P59, DOI 10.1159/000051857
   Anthuber M, 1996, WORLD J SURG, V20, P73, DOI 10.1007/s002689900013
   Arnold R, 2000, DIGESTION, V62, P84, DOI 10.1159/000051861
   Bartsch DK, 2000, DIGESTION, V62, P171, DOI 10.1159/000007810
   Chamberlain RS, 2000, J AM COLL SURGEONS, V190, P432, DOI 10.1016/S1072-7515(00)00222-2
   Chandrasekharappa SC, 1997, SCIENCE, V276, P404, DOI 10.1126/science.276.5311.404
   Chen H, 1998, J AM COLL SURGEONS, V187, P88, DOI 10.1016/S1072-7515(98)00099-4
   Cupisti K, 2000, EUR J CLIN INVEST, V30, P325
   Dousset B, 1996, WORLD J SURG, V20, P908, DOI 10.1007/s002689900138
   Eriksson BK, 1998, CANCER, V83, P2293, DOI 10.1002/(SICI)1097-0142(19981201)83:11<2293::AID-CNCR8>3.0.CO;2-E
   Esni F, 2004, MECH DEVELOP, V121, P15, DOI 10.1016/j.mod.2003.08.010
   Florman S, 2004, J GASTROINTEST SURG, V8, P208, DOI 10.1016/j.gassur.2003.11.010
   Goebel SU, 2000, J CLIN ENDOCR METAB, V85, P116, DOI 10.1210/jc.85.1.116
   Grazi GL, 2000, HEPATO-GASTROENTEROL, V47, P481
   Gumbs AA, 2002, J SURG ONCOL, V81, P45, DOI 10.1002/jso.10142
   Guru SC, 1998, P NATL ACAD SCI USA, V95, P1630, DOI 10.1073/pnas.95.4.1630
   Hansel DE, 2004, CLIN CANCER RES, V10, P6152, DOI 10.1158/1078-0432.CCR-04-0285
   Hansel DE, 2004, AM J SURG PATHOL, V28, P347, DOI 10.1097/00000478-200403000-00007
   Hansel DE, 2003, MODERN PATHOL, V16, P652, DOI 10.1097/01.MP.0000077416.68489.50
   Hansel Donna E, 2003, Int J Gastrointest Cancer, V33, P141, DOI 10.1385/IJGC:33:2-3:141
   House MG, 2003, SURGERY, V134, P902, DOI 10.1016/S0039-6060(03)00412-4
   House MG, 2003, ANN SURG, V238, P423, DOI 10.1097/01.sla.0000086659.49569.9e
   HOUSE MG, IN PRESS J GASTROINT
   Iino S, 2004, CLIN CANCER RES, V10, P6179, DOI 10.1158/1078-0432.CCR-03-0750
   Karkkainen MJ, 2000, ONCOGENE, V19, P5598, DOI 10.1038/sj.onc.1203855
   Lang H, 1997, ANN SURG, V225, P347, DOI 10.1097/00000658-199704000-00002
   Lemmens I, 1997, HUM MOL GENET, V6, P1177, DOI 10.1093/hmg/6.7.1177
   Maitra A, 2003, CLIN CANCER RES, V9, P5988
   Marx SJ, 1999, RECENT PROG HORM RES, V54, P397
   MCENTEE GP, 1990, SURGERY, V108, P1091
   Moore PS, 2001, GENE CHROMOSOME CANC, V32, P177, DOI 10.1002/gcc.1180
   Muscarella P, 1998, CANCER RES, V58, P237
   Nehar D, 2004, CLIN ENDOCRINOL, V60, P644, DOI 10.1111/j.1365-2265.2004.02030.x
   Norton JA, 2003, SURGERY, V134, P1057, DOI 10.1016/S0039-6060(03)00496-3
   PAVELIC K, 1995, J PATHOL, V177, P395, DOI 10.1002/path.1711770410
   QUE FG, 1995, AM J SURG, V169, P36, DOI 10.1016/S0002-9610(99)80107-X
   Rahman A, 2003, AM J CLIN PATHOL, V120, P685, DOI 10.1309/LPJBRGQX95KRY3G3
   Rigaud G, 2001, CANCER RES, V61, P285
   Shan L, 1998, LAB INVEST, V78, P471
   SOLCIA E, 1990, EUR J CLIN INVEST, V20, pS72
   SOLCIA E, 2001, HIST TYPING ENDOCRIN
   Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001
   Sutcliffe R, 2004, AM J SURG, V187, P39, DOI 10.1016/j.amjsurg.2003.04.007
   Sutliff VE, 1997, J CLIN ONCOL, V15, P2420, DOI 10.1200/JCO.1997.15.6.2420
   UBELUBENSKY IA, 1996, CANCER RES, V56, P5272
   Wang EH, 1998, CANCER RES, V58, P4417
   Wick M R, 2001, Am J Clin Pathol, V115 Suppl, pS28
   Yaguchi H, 2004, MOL CELL BIOL, V24, P6569, DOI 10.1128/mcb.24.15.6569-6580.2004
   Yu F, 1999, J CLIN ONCOL, V17, P615, DOI 10.1200/JCO.1999.17.2.615
   Zhuang ZP, 1997, CANCER RES, V57, P4682
NR 51
TC 24
Z9 29
U1 1
U2 8
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1040-8746
EI 1531-703X
J9 CURR OPIN ONCOL
JI Curr. Opin. Oncol.
PD JAN
PY 2006
VL 18
IS 1
BP 23
EP 29
DI 10.1097/01.cco.0000198974.59239.3c
PG 7
WC Oncology
SC Oncology
GA 001AD
UT WOS:000234503400004
PM 16357560
DA 2018-12-27
ER

PT J
AU Loiseau, PM
   Bories, C
AF Loiseau, Philippe M.
   Bories, Christian
TI RETRACTED: Mechanisms of drug action and drug resistance in Leishmania
   as basis for therapeutic target identification and design of
   antileishmanial modulators (Retracted Article. See vol 7, pg 455, 2007)
SO CURRENT TOPICS IN MEDICINAL CHEMISTRY
LA English
DT Review; Retracted Publication
DE antileishmanial chemotherapy; mechanism of action; chemical strategies
ID PROTOZOAN PARASITE LEISHMANIA; INDIAN VISCERAL LEISHMANIASIS; PROGRAMMED
   CELL-DEATH; PROPRIETARY SODIUM STIBOGLUCONATE; MEGLUMINE ANTIMONIATE
   GLUCANTIME; INCREASED TRYPANOTHIONE LEVELS; GLYCOPROTEIN-LIKE
   TRANSPORTER; AXENICALLY GROWN AMASTIGOTES; STAGE-SPECIFIC ACTIVITY;
   HEAVY-METAL RESISTANCE
AB The control of Leishmania infections relies primarily on chemotherapy. The arsenal of drugs available against Leishmania infections is limited and includes pentavalent antimonials, pentamidine, amphotericin B, miltefosine, paromomycin, allopurinol, and few other drugs at various stages of their development process. Knowledge about action and resistance mechanisms involved may allow the development of new drugs that minimise or circumvent drug resistance or may identify new targets for drug development. The aim of this review is to propose some chemical topics to design new modulators from the mechanisms of action of drugs and resistance mechanisms to drugs used in the clinic against Leishmania infections. Thus, different classes of ABC transporters extrude antimonials in Leishmania resulting in drug-resistant phenotypes. Compounds interfering with thiol and polyamine metabolism could be designed to inhibit the antimonial detoxication and therefore, such compounds could be used in combination with antimonials. New diamidines could be synthesized in regard to their ability to inhibit topoisomerase II. The challenge for amphotericin B is to be absorbed by oral route requiring labile physico-chemical modifications. New sesquiterpens and flavonoids have to be developed as reversant of antimonial resistance. Although some studies have focused on developing inhibitors against these resistant phenotypes, new efficient modulators that are able to inhibit drug efflux are needed.
C1 Univ Paris S 11, Antiparasit Chemotherapy Grp, UMR 8076, CNRS,Fac Pharm, F-92290 Chatenay Malabry, France.
RP Loiseau, PM (reprint author), Univ Paris S 11, Antiparasit Chemotherapy Grp, UMR 8076, CNRS,Fac Pharm, F-92290 Chatenay Malabry, France.
EM philippe.loiseau@cep.u-psud.fr
RI Torero, Rebeca/C-1703-2012
CR Alrajhi AA, 2002, NEW ENGL J MED, V346, P891, DOI 10.1056/NEJMoa011882
   Amaral L, 2001, TROP MED INT HEALTH, V6, P1016, DOI 10.1046/j.1365-3156.2001.00804.x
   Arana FE, 1998, BIOCHEM PHARMACOL, V56, P1201, DOI 10.1016/S0006-2952(98)00129-4
   Azas N, 2001, PARASITE, V8, P335, DOI 10.1051/parasite/2001084335
   Bahamdan KA, 1997, INT J DERMATOL, V36, P59, DOI 10.1046/j.1365-4362.1997.00021.x
   Basselin M, 2000, MOL BIOCHEM PARASIT, V109, P37, DOI 10.1016/S0166-6851(00)00234-6
   Basselin M, 2002, ANTIMICROB AGENTS CH, V46, P3731, DOI [10.1128/AAC.46.12.3731-3738.2002, 10.1128/AAC.46.12.3731-3788.2002]
   Basselin M, 1997, PARASITOL RES, V83, P413, DOI 10.1007/s004360050274
   Basselin M, 1996, BIOCHEM J, V315, P631, DOI 10.1042/bj3150631
   Berman J, 2003, CURR OPIN INFECT DIS, V16, P397, DOI 10.1097/01.qco.0000092810.64370.65
   Borst P, 2002, ANNU REV BIOCHEM, V71, P537, DOI 10.1146/annurev.biochem.71.102301.093055
   Brochu C, 2004, CELL STRESS CHAPERON, V9, P294, DOI 10.1379/CSC-15R1.1
   Brochu C, 2003, ANTIMICROB AGENTS CH, V47, P3073, DOI 10.1128/AAC.47.10.3073-3079.2003
   Callahan HL, 1997, ANTIMICROB AGENTS CH, V41, P818, DOI 10.1128/AAC.41.4.818
   CALLAHAN HL, 1991, J BIOL CHEM, V266, P18427
   Carrio J, 2000, EXP PARASITOL, V95, P209, DOI 10.1006/expr.2000.4537
   Carter KC, 2003, ANTIMICROB AGENTS CH, V47, P1529, DOI 10.1128/AAC.47.5.1529-1535.2003
   Carter KC, 2001, ANTIMICROB AGENTS CH, V45, P3555, DOI 10.1128/AAC.45.12.3555-3559.2001
   *CDC, 2004, MMWR-MORBID MORTAL W, V53, P264
   Chen ZS, 1997, BIOCHEM BIOPH RES CO, V236, P586, DOI 10.1006/bbrc.1997.7015
   Chiquero MJ, 1998, BIOCHEM PHARMACOL, V55, P131, DOI 10.1016/S0006-2952(97)00385-7
   Coelho AC, 2003, MOL BIOCHEM PARASIT, V130, P83, DOI 10.1016/S0166-6851(03)00162-2
   COLE SPC, 1994, CANCER RES, V54, P5902
   Cotrim PC, 1999, J BIOL CHEM, V274, P37723, DOI 10.1074/jbc.274.53.37723
   Croft SL, 2003, TRENDS PARASITOL, V19, P502, DOI 10.1016/j.pt.2003.09.008
   CROFT SL, 1981, COMP BIOCHEM PHYS C, V68, P95, DOI 10.1016/0306-4492(81)90043-5
   CROFT SL, 1987, BIOCHEM PHARMACOL, V36, P2633, DOI 10.1016/0006-2952(87)90543-0
   Davis AJ, 2004, TRENDS PARASITOL, V20, P73, DOI 10.1016/j.pt.2003.11.006
   Debrabant A, 2003, INT J PARASITOL, V33, P257, DOI 10.1016/S0020-7519(03)00008-0
   Denerolle P, 1999, J VET INTERN MED, V13, P413, DOI 10.1892/0891-6640(1999)013<0413:CAAATV>2.3.CO;2
   Denton H, 2004, BIOCHEM J, V381, P405, DOI 10.1042/BJ20040283
   Desjeux P, 2001, MED MICROBIOL IMMUN, V190, P77, DOI 10.1007/s004300100085
   DESJEUX P, 2002, TDRNEWS, V69, P12
   Dey S, 1996, P NATL ACAD SCI USA, V93, P2192, DOI 10.1073/pnas.93.5.2192
   DEY S, 1994, MOL BIOCHEM PARASIT, V67, P49, DOI 10.1016/0166-6851(94)90095-7
   Dietze R, 2001, AM J TROP MED HYG, V65, P685, DOI 10.4269/ajtmh.2001.65.685
   Dodge MA, 2004, MOL MICROBIOL, V51, P1563, DOI 10.1111/j.1365-2958.2003.03927.x
   Enserink M, 2000, SCIENCE, V290, P1881, DOI 10.1126/science.290.5498.1881
   Ephros M, 1997, ANTIMICROB AGENTS CH, V41, P1064, DOI 10.1128/AAC.41.5.1064
   Ephros M, 1999, ANTIMICROB AGENTS CH, V43, P278, DOI 10.1128/AAC.43.2.278
   Essodaigui M, 1999, MOL BIOCHEM PARASIT, V100, P73, DOI 10.1016/S0166-6851(99)00036-5
   FAIRLAMB AH, 1992, ANNU REV MICROBIOL, V46, P695, DOI 10.1146/annurev.mi.46.100192.003403
   FarautGambarelli F, 1997, ANTIMICROB AGENTS CH, V41, P827, DOI 10.1128/AAC.41.4.827
   Ferreira CD, 2003, BIOMETALS, V16, P441
   FerreiraPinto KC, 1996, CAN J MICROBIOL, V42, P944, DOI 10.1139/m96-121
   FONG D, 1994, AM J TROP MED HYG, V51, P758, DOI 10.4269/ajtmh.1994.51.758
   FORD JM, 1989, MOL PHARMACOL, V35, P105
   Freire M, 1997, BRAZ J INFECT DIS, V1, P230
   GOAD LJ, 1984, MOL BIOCHEM PARASIT, V10, P161, DOI 10.1016/0166-6851(84)90004-5
   Gourbal B, 2004, J BIOL CHEM, V279, P31010, DOI 10.1074/jbc.M403959200
   GRAMICCIA M, 1992, ANN TROP MED PARASIT, V86, P613, DOI 10.1080/00034983.1992.11812717
   GROGL M, 1989, EXP PARASITOL, V69, P78, DOI 10.1016/0014-4894(89)90173-2
   Grondin K, 1997, EMBO J, V16, P3057, DOI 10.1093/emboj/16.11.3057
   Guerin PJ, 2002, LANCET INFECT DIS, V2, P494, DOI 10.1016/S1473-3099(02)00347-X
   Guimond C, 2003, NUCLEIC ACIDS RES, V31, P5886, DOI 10.1093/nar/gkg806
   Haimeur A, 1999, MOL MICROBIOL, V34, P726, DOI 10.1046/j.1365-2958.1999.01634.x
   Haimeur A, 2000, MOL BIOCHEM PARASIT, V108, P131, DOI 10.1016/S0166-6851(00)00187-0
   Haimeur A, 2004, CURR DRUG METAB, V5, P21, DOI 10.2174/1389200043489199
   Haimeur A, 1998, ANTIMICROB AGENTS CH, V42, P1689, DOI 10.1128/AAC.42.7.1689
   HERWALDT BL, 1992, AM J TROP MED HYG, V46, P296, DOI 10.4269/ajtmh.1992.46.296
   HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435
   IDOWU OR, 1995, DRUG METAB DISPOS, V23, P18
   IDOWU OR, 1995, DRUG METAB DISPOS, V23, P1
   Jha TK, 1999, NEW ENGL J MED, V341, P1795, DOI 10.1056/NEJM199912093412403
   Kamau SW, 2001, ANTIMICROB AGENTS CH, V45, P3654, DOI 10.1128/AAC.45.12.3654-3656.2001
   Kandpal M, 1997, LIFE SCI, V60, P1793, DOI 10.1016/S0024-3205(97)00139-2
   KINNAMON KE, 1978, AM J TROP MED HYG, V27, P751, DOI 10.4269/ajtmh.1978.27.751
   Klokouzas A, 2003, INT J ANTIMICROB AG, V22, P301, DOI 10.1016/S0924-8579(03)00210-3
   Koss T, 2002, J AM ACAD DERMATOL, V46, P945, DOI 10.1067/mjd.2001.120627
   Koutinas AF, 2001, VET PARASITOL, V98, P247, DOI 10.1016/S0304-4017(01)00399-5
   Kruh GD, 2003, ONCOGENE, V22, P7537, DOI 10.1038/sj.onc.1206953
   LANGRETH SG, 1983, J PROTOZOOL, V30, P555, DOI 10.1111/j.1550-7408.1983.tb01421.x
   Leandro C, 2003, INT J ANTIMICROB AG, V22, P352, DOI 10.1016/S0924-8579(03)00211-5
   Lee N, 2002, CELL DEATH DIFFER, V9, P53, DOI 10.1038/sj.cdd.4400952
   Legare D, 1997, EXP PARASITOL, V87, P275, DOI 10.1006/expr.1997.4222
   Legare D, 2001, J BIOL CHEM, V276, P26301, DOI 10.1074/jbc.M102351200
   Lira R, 1999, J INFECT DIS, V180, P564, DOI 10.1086/314896
   Lorente SO, 2004, ANTIMICROB AGENTS CH, V48, P2937, DOI 10.1128/AAC.48.8.2937-2950.2004
   Luque-Ortega JR, 2003, BIOCHEM J, V375, P221, DOI 10.1042/BJ20030544
   Lux H, 2000, MOL BIOCHEM PARASIT, V111, P1, DOI 10.1016/S0166-6851(00)00278-4
   Maarouf M, 1998, PARASITE, V5, P167, DOI 10.1051/parasite/1998052167
   Maarouf M, 1997, PARASITOL RES, V83, P198, DOI 10.1007/s004360050232
   MAAROUF M, 1995, PARASITOL RES, V81, P421, DOI 10.1007/BF00931504
   Magaraci F, 2003, J MED CHEM, V46, P4714, DOI 10.1021/jm021114j
   Mbongo N, 1998, ANTIMICROB AGENTS CH, V42, P352
   Mbui J, 2003, East Afr Med J, V80, P440
   McHugh CP, 2003, AM J TROP MED HYG, V69, P470, DOI 10.4269/ajtmh.2003.69.470
   Mehta A, 2004, J BIOL CHEM, V279, P11798, DOI 10.1074/jbc.M309341200
   Misslitz A, 2000, MOL BIOCHEM PARASIT, V107, P251, DOI 10.1016/S0166-6851(00)00195-X
   Moore E, 2001, B WORLD HEALTH ORGAN, V79, P388
   Mukhopadhyay R, 1996, P NATL ACAD SCI USA, V93, P10383, DOI 10.1073/pnas.93.19.10383
   Murray HW, 2001, ANTIMICROB AGENTS CH, V45, P2185, DOI 10.1128/AAC.45.8.2185-2197.2001
   Nacher M, 2001, ANN TROP MED PARASIT, V95, P331, DOI 10.1080/00034980120064355
   NELSON DJ, 1979, J BIOL CHEM, V254, P1544
   OLLIARO PL, 1993, PARASITOL TODAY, V9, P323, DOI 10.1016/0169-4758(93)90231-4
   Ordway D, 2003, ANTIMICROB AGENTS CH, V47, P917, DOI 10.1128/AAC.47.3.917-922.2003
   Ordway D, 2002, INT J ANTIMICROB AG, V20, P34, DOI 10.1016/S0924-8579(02)00110-3
   Ouellette M, 2004, DRUG RESIST UPDATE, V7, P257, DOI 10.1016/j.drup.2004.07.002
   OUELLETTE M, 1991, RES MICROBIOL, V142, P737, DOI 10.1016/0923-2508(91)90089-S
   PAPADOPOULOU B, 1994, J BIOL CHEM, V269, P11980
   Paris C, 2004, ANTIMICROB AGENTS CH, V48, P852, DOI 10.1128/AAC.48.3.852-859.2004
   Pathak MK, 2001, J IMMUNOL, V167, P3391, DOI 10.4049/jimmunol.167.6.3391
   PEARCE HL, 1990, ADV ENZYME REGUL, V30, P357
   Perez-Victoria FJ, 2003, J BIOL CHEM, V278, P49965, DOI 10.1074/jbc.M308352200
   Perez-Victoria FJ, 2003, ANTIMICROB AGENTS CH, V47, P2397, DOI 10.1128/AAC.47.8.2397-2403.2003
   Perez-Victoria JM, 2001, ANTIMICROB AGENTS CH, V45, P439, DOI 10.1128/AAC.45.2.439-446.2001
   Perez-Victoria JM, 2001, ANTIMICROB AGENTS CH, V45, P2468, DOI 10.1128/AAC.45.9.2468-2474.2001
   Pourshafie M, 2004, ANTIMICROB AGENTS CH, V48, P2409, DOI 10.1128/AAC.48.7.2409-2414.2004
   Rakotomanga M, 2005, ANTIMICROB AGENTS CH, V49, P2677, DOI 10.1128/AAC.49.7.2677-2686.2005
   RAMOS H, 1994, ANTIMICROB AGENTS CH, V38, P1079, DOI 10.1128/AAC.38.5.1079
   Ritmeijer K, 2001, T ROY SOC TROP MED H, V95, P668, DOI 10.1016/S0035-9203(01)90110-5
   Roberts CW, 2003, MOL BIOCHEM PARASIT, V126, P129, DOI 10.1016/S0166-6851(02)00280-3
   ROBERTS WL, 1993, ANTIMICROB AGENTS CH, V37, P1842, DOI 10.1128/AAC.37.9.1842
   ROBERTS WL, 1993, ANAL BIOCHEM, V211, P1, DOI 10.1006/abio.1993.1223
   Rodero L, 2002, J CLIN MICROBIOL, V40, P2266, DOI 10.1128/JCM.40.6.2266-2269.2002
   Rosen BP, 2002, FEBS LETT, V529, P86, DOI 10.1016/S0014-5793(02)03186-1
   Rosypal AC, 2003, J EUKARYOT MICROBIOL, V50, P691, DOI 10.1111/j.1550-7408.2003.tb00690.x
   Roy G, 2000, MOL BIOCHEM PARASIT, V110, P195, DOI 10.1016/S0166-6851(00)00270-X
   Salmanpour R, 2001, J DERMATOL TREAT, V12, P159, DOI 10.1080/09546630152607899
   Sangraula H, 2003, J Assoc Physicians India, V51, P686
   Seifert K, 2003, INT J ANTIMICROB AG, V22, P380, DOI 10.1016/S0924-8579(03)00125-0
   Sereno D, 1998, ANTIMICROB AGENTS CH, V42, P3097, DOI 10.1128/AAC.42.12.3097
   Sereno D, 1997, ANTIMICROB AGENTS CH, V41, P972, DOI 10.1128/AAC.41.5.972
   Sereno D, 2001, ANTIMICROB AGENTS CH, V45, P1168, DOI 10.1128/AAC.45.4.1168-1173.2001
   Sereno D, 2001, ANTIMICROB AGENTS CH, V45, P2064, DOI 10.1128/AAC.45.7.2064-2069.2001
   Shaked-Mishan P, 2001, J BIOL CHEM, V276, P3971, DOI 10.1074/jbc.M005423200
   SHERWOOD JA, 1994, CLIN INFECT DIS, V19, P1034, DOI 10.1093/clinids/19.6.1034
   Singh AK, 2001, EXP PARASITOL, V99, P141, DOI 10.1006/expr.2001.4663
   Singh N, 2003, J INFECT DIS, V188, P600, DOI 10.1086/377133
   Stein Wilfred D, 2002, Curr Opin Investig Drugs, V3, P812
   Sudhandiran G, 2003, J BIOL CHEM, V278, P25120, DOI 10.1074/jbc.M301975200
   Sundar S, 2004, CLIN INFECT DIS, V38, P377, DOI 10.1086/380971
   Sundar S, 2002, CURR OPIN INFECT DIS, V15, P593, DOI 10.1097/01.qco.0000044778.05458.f9
   Sundar S, 2002, NEW ENGL J MED, V347, P1739, DOI 10.1056/NEJMoa021556
   Sundar S, 2001, TROP MED INT HEALTH, V6, P849, DOI 10.1046/j.1365-3156.2001.00778.x
   Sundar S, 1996, LANCET, V348, P614, DOI 10.1016/S0140-6736(05)64828-3
   Sundar S, 2001, AM J TROP MED HYG, V65, P193, DOI 10.4269/ajtmh.2001.65.193
   Sundar S, 2000, T ROY SOC TROP MED H, V94, P200, DOI 10.1016/S0035-9203(00)90277-3
   Sundar S, 2000, CLIN INFECT DIS, V31, P1104, DOI 10.1086/318121
   Tamas MJ, 2001, CURR GENET, V40, P2, DOI 10.1007/s002940100234
   Thakur CP, 2000, T ROY SOC TROP MED H, V94, P429, DOI 10.1016/S0035-9203(00)90130-5
   Thakur CP, 1997, ANN TROP MED PARASIT, V91, P611, DOI 10.1080/00034983.1997.11813179
   THEOHARIDES AD, 1985, BIOCHEM PHARMACOL, V34, P181, DOI 10.1016/0006-2952(85)90122-4
   Tommasini R, 1996, P NATL ACAD SCI USA, V93, P6743, DOI 10.1073/pnas.93.13.6743
   Urbina JA, 1997, PARASITOLOGY, V114, pS91
   Velez I, 1997, ANN INTERN MED, V126, P232, DOI 10.7326/0003-4819-126-3-199702010-00010
   VERCESI AE, 1992, BIOCHEM J, V284, P463, DOI 10.1042/bj2840463
   Vercesi AE, 2000, FEBS LETT, V473, P203, DOI 10.1016/S0014-5793(00)01531-3
   Verma NK, 2004, ANTIMICROB AGENTS CH, V48, P3010, DOI 10.1128/AAC.48.8.3010-3015.2004
   Vernhet L, 1999, FEBS LETT, V443, P321, DOI 10.1016/S0014-5793(98)01716-5
   WERBOVETZ KA, 1992, ANTIMICROB AGENTS CH, V36, P495, DOI 10.1128/AAC.36.2.495
   Wyllie S, 2004, J BIOL CHEM, V279, P39925, DOI 10.1074/jbc.M405635200
   ZAMAN GJR, 1995, P NATL ACAD SCI USA, V92, P7690, DOI 10.1073/pnas.92.17.7690
   Zangger H, 2002, CELL DEATH DIFFER, V9, P1126, DOI 10.1038/sj.cdd.4401071
   Zhou Y, 2004, J BIOL CHEM, V279, P37445, DOI 10.1074/jbc.M404383200
   ZILBERSTEIN D, 2002, LEISHMANIA, P193
NR 156
TC 26
Z9 26
U1 4
U2 25
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1568-0266
EI 1873-5294
J9 CURR TOP MED CHEM
JI Curr. Top. Med. Chem.
PY 2006
VL 6
IS 5
BP 539
EP 550
DI 10.2174/156802606776743165
PG 12
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA 049SM
UT WOS:000238037000008
PM 16719806
DA 2018-12-27
ER

PT J
AU Grallath, S
   Schwarz, JP
   Bottcher, UMK
   Bracher, A
   Hartl, FU
   Siegers, K
AF Grallath, S
   Schwarz, JP
   Bottcher, UMK
   Bracher, A
   Hartl, FU
   Siegers, K
TI RETRACTED: L25 functions as a conserved ribosomal docking site shared by
   nascent chain-associated complex and signal-recognition particle
   (Retracted Article. See vol 8, pg 1086, 2007)
SO EMBO REPORTS
LA English
DT Article; Retracted Publication
DE molecular chaperone; L25; NAC; ribosomes; SRP
ID POLYPEPTIDE-ASSOCIATED COMPLEX; NEWLY SYNTHESIZED PROTEINS; TRIGGER
   FACTOR; ESCHERICHIA-COLI; ENDOPLASMIC-RETICULUM; CRYSTAL-STRUCTURE;
   YEAST; BINDING; NAC; CHAPERONES
AB The nascent chain-associated complex (NAC) is a dimeric protein complex of archaea and eukarya that interacts with ribosomes and translating polypeptide chains. We show that, in yeast, NAC and the signal-recognition particle (SRP)share the universally conserved ribosomal protein L25 as a docking site, which is in close proximity to the ribosomal exit tunnel. The amino-terminal segment of beta-NAC was found to be required for L25 binding. Purified NAC can prevent protein aggregation in vitro and thus shows certain properties of a molecular chaperone. Interestingly, the alpha-subunit of NAC interacts with the 54 kDa subunit of SRP. Consistent with a regulatory role of NAC in protein translocation into the endoplasmic reticulum (ER), we find that deletion of NAC results in an induction of the ER stress-response pathway. These results identify L25 as a conserved interaction platform for specific cytosolic factors that guide nascent polypeptides to their proper cellular destination.
C1 Max Planck Inst Biochem, Dept Cellular Biochem, D-82152 Martinsried, Germany.
RP Siegers, K (reprint author), Max Planck Inst Biochem, Dept Cellular Biochem, Klopferspitz 18, D-82152 Martinsried, Germany.
EM siegers@biochem.mpg.de
CR Ban N, 2000, SCIENCE, V289, P905, DOI 10.1126/science.289.5481.905
   Beatrix B, 2000, J BIOL CHEM, V275, P37838, DOI 10.1074/jbc.M006368200
   Bloss TA, 2003, NATURE, V424, P1066, DOI 10.1038/nature01920
   Bukau B, 2000, CELL, V101, P119, DOI 10.1016/S0092-8674(00)80806-5
   Buskiewicz I, 2004, P NATL ACAD SCI USA, V101, P7902, DOI 10.1073/pnas.0402231101
   Cox JS, 1997, MOL BIOL CELL, V8, P1805
   Deuerling E, 1999, NATURE, V400, P693
   Eisner G, 2003, J CELL BIOL, V163, P35, DOI 10.1083/jcb.200306069
   Ferbitz L, 2004, NATURE, V431, P590, DOI 10.1038/nature02899
   Gautschi M, 2001, P NATL ACAD SCI USA, V98, P3762, DOI 10.1073/pnas.071057198
   Gautschi M, 2002, P NATL ACAD SCI USA, V99, P4209, DOI 10.1073/pnas.062048599
   George R, 1998, P NATL ACAD SCI USA, V95, P2296, DOI 10.1073/pnas.95.5.2296
   Gu SQ, 2003, RNA, V9, P566, DOI 10.1261/rna.2196403
   Hartl FU, 2002, SCIENCE, V295, P1852, DOI 10.1126/science.1068408
   Hesterkamp T, 1996, P NATL ACAD SCI USA, V93, P4437, DOI 10.1073/pnas.93.9.4437
   Keenan RJ, 2001, ANNU REV BIOCHEM, V70, P755, DOI 10.1146/annurev.biochem.70.1.755
   Knop M, 1997, EMBO J, V16, P6985, DOI 10.1093/emboj/16.23.6985
   Kramer G, 2002, NATURE, V419, P171, DOI 10.1038/nature01047
   LAURING B, 1995, P NATL ACAD SCI USA, V92, P5411, DOI 10.1073/pnas.92.12.5411
   Lee HC, 2002, J BIOL CHEM, V277, P43527, DOI 10.1074/jbc.M205950200
   Ludlam AV, 2004, P NATL ACAD SCI USA, V101, P13436, DOI 10.1073/pnas.0405868101
   Ma YJ, 2001, CELL, V107, P827, DOI 10.1016/S0092-8674(01)00623-7
   NELSON RJ, 1992, CELL, V71, P97, DOI 10.1016/0092-8674(92)90269-I
   PARTHUN MR, 1992, MOL CELL BIOL, V12, P5683, DOI 10.1128/MCB.12.12.5683
   Pool MR, 2002, SCIENCE, V297, P1345, DOI 10.1126/science.1072366
   Reimann B, 1999, YEAST, V15, P397, DOI 10.1002/(SICI)1097-0061(19990330)15:5<397::AID-YEA384>3.3.CO;2-L
   Siegers K, 2003, EMBO J, V22, P5230, DOI 10.1093/emboj/cdg483
   SIKORSKI RS, 1989, GENETICS, V122, P19
   Spreter T, 2005, J BIOL CHEM, V280, P15849, DOI 10.1074/jbc.M500160200
   Teter SA, 1999, CELL, V97, P755, DOI 10.1016/S0092-8674(00)80787-4
   VALENT QA, 1995, EMBO J, V14, P5494, DOI 10.1002/j.1460-2075.1995.tb00236.x
   WANG S, 1995, J CELL BIOL, V130, P519, DOI 10.1083/jcb.130.3.519
   Weber F, 2000, METH MOL B, V140, P111
   WIEDMANN B, 1994, NATURE, V370, P434, DOI 10.1038/370434a0
NR 34
TC 22
Z9 23
U1 5
U2 16
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1469-221X
EI 1469-3178
J9 EMBO REP
JI EMBO Rep.
PD JAN
PY 2006
VL 7
IS 1
BP 78
EP 84
DI 10.1038/sj.embor.7400551
PG 7
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 023QV
UT WOS:000236142200018
PM 16239928
OA Green Published, Bronze
DA 2018-12-27
ER

PT J
AU Knight, KR
   Uda, Y
   Findlay, MW
   Brown, DL
   Cronin, KJ
   Jamieson, E
   Tai, T
   Keramidaris, E
   Penington, AJ
   Rophael, J
   Harrison, LC
   Morrison, WA
AF Knight, KR
   Uda, Y
   Findlay, MW
   Brown, DL
   Cronin, KJ
   Jamieson, E
   Tai, T
   Keramidaris, E
   Penington, AJ
   Rophael, J
   Harrison, LC
   Morrison, WA
TI RETRACTED: Vascularized tissue-engineered chambers promote survival and
   function of transplanted islets and improve glycemic control (Retracted
   Article. See vol 22, pg 3747, 2008)
SO FASEB JOURNAL
LA English
DT Article; Retracted Publication
DE streptozotocin; diabetes; islet transplantation; vascularized chambers;
   renal capsule
ID TYPE-1 DIABETES-MELLITUS; EXTRACELLULAR-MATRIX; GRAFT-SURVIVAL; MOUSE;
   ALGINATE; GROWTH; MODEL; MICROENCAPSULATION; GENERATION; MEMBRANE
AB We have developed a chamber model of islet engraftment that optimizes islet survival by rapidly restoring islet-extracellular matrix relationships and vascularization. Our aim was to assess the ability of syngeneic adult islets seeded into blood vessel-containing chambers to correct streptozotocin-induced diabetes in mice. Approximately 350 syngeneic islets suspended in Matrigel (R) extracellular matrix were inserted into chambers based on either the splenic or groin (epigastric) vascular beds, or, in the standard approach, injected under the renal capsule. Blood glucose was monitored weekly for 7 weeks, and an intraperitoneal glucose tolerance test performed at 6 weeks in the presence of the islet grafts. Relative to untreated diabetic animals, glycemic control significantly improved in all islet transplant groups, strongly correlating with islet counts in the graft (P < 0.01), and with best results in the splenic chamber group. Glycemic control deteriorated after chambers were surgically removed at week 8. Immunohistochemistry revealed islets with abundant insulin content in grafts from all groups, but with significantly more islets in splenic chamber grafts than the other treatment groups (P < 0.05). It is concluded that hyperglycemia in experimental type 1 diabetes can be effectively treated by islets seeded into a vascularized chamber functioning as a "pancreatic organoid".
C1 Univ Melbourne, Dept Surg, Fitzroy, Vic 3065, Australia.
   Univ Michigan, Div Plast Surg, Ann Arbor, MI 48109 USA.
   Mater Misericordiae Univ Hosp, Dept Plast & Reconstruct Surg, Dublin 7, Ireland.
   St Vincents Inst, Fitzroy, Vic, Australia.
   Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, Autoimmun & Transplantat Div, Melbourne, Vic, Australia.
RP Knight, KR (reprint author), OBrien Inst Microsurg, 42 Fitzroy St, Fitzroy, Vic 3065, Australia.
EM Kenneth.Knight@svhm.org.au
OI Brown, David/0000-0002-5889-9886
CR Bhargava R, 2004, DIABETES, V53, P1311, DOI 10.2337/diabetes.53.5.1311
   Bottino R, 2004, DIABETES, V53, P2559, DOI 10.2337/diabetes.53.10.2559
   BROWN DL, 2005, IN PRESS CELL T 0928
   Cassell OCS, 2001, ANN NY ACAD SCI, V944, P429
   Cronin KJ, 2004, PLAST RECONSTR SURG, V113, P260, DOI 10.1097/01.PRS.0000095942.71618.9D
   CUTHBERTSON RA, 1986, AUST J EXP BIOL MED, V64, P175, DOI 10.1038/icb.1986.19
   DeVos P, 1997, DIABETOLOGIA, V40, P262
   Dickson BC, 2003, TRANSPLANTATION, V75, P599, DOI 10.1097/01.TP.0000048226.28357.0D
   Duvivier-Kali VF, 2001, DIABETES, V50, P1698, DOI 10.2337/diabetes.50.8.1698
   FOLKMAN J, 1973, J EXP MED, V138, P745, DOI 10.1084/jem.138.4.745
   Gray DWR, 2001, WORLD J SURG, V25, P497, DOI 10.1007/s002680020343
   HILLER WFA, 1991, DIABETES, V40, P134, DOI 10.2337/diabetes.40.1.134
   Hirshberg B, 2002, J CLIN ENDOCR METAB, V87, P5424, DOI 10.1210/jc.2002-020684
   Hofer SOP, 2005, BRIT J PLAST SURG, V58, P1104, DOI 10.1016/j.bjps.2005.04.033
   Jiang FX, 1999, DIABETES, V48, P722, DOI 10.2337/diabetes.48.4.722
   Juang JH, 2000, TRANSPLANT P, V32, P1076, DOI 10.1016/S0041-1345(00)01131-3
   Kawaguchi N, 1998, P NATL ACAD SCI USA, V95, P1062, DOI 10.1073/pnas.95.3.1062
   Kin T, 2003, AM J TRANSPLANT, V3, P281, DOI 10.1034/j.1600-6143.2003.00049.x
   Li XY, 2004, J BIOL CHEM, V279, P765, DOI 10.1074/jbc.M307907200
   Matarazzo M, 2002, CELL TRANSPLANT, V11, P103
   MELLGREN A, 1986, DIABETOLOGIA, V29, P670, DOI 10.1007/BF00869269
   Messina A, 2005, FASEB J, V19, P1570, DOI 10.1096/fj.04-3241fje
   Mian RW, 2000, TISSUE ENG, V6, P595, DOI 10.1089/10763270050199541
   Nagata N, 2001, CELL TRANSPLANT, V10, P447
   Niklason LE, 2001, JAMA-J AM MED ASSOC, V285, P573, DOI 10.1001/jama.285.5.573
   Rother KI, 2004, J CLIN INVEST, V114, P877, DOI 10.1172/JC1200423235
   Ryan EA, 2002, DIABETES, V51, P2148, DOI 10.2337/diabetes.51.7.2148
   Shapiro AMJ, 2000, NEW ENGL J MED, V343, P230, DOI 10.1056/NEJM200007273430401
   Tanaka Y, 2000, BRIT J PLAST SURG, V53, P51, DOI 10.1054/bjps.1999.3186
   Thomas HE, 1999, J IMMUNOL, V163, P1562
NR 30
TC 25
Z9 25
U1 4
U2 12
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
EI 1530-6860
J9 FASEB J
JI Faseb J.
PD JAN
PY 2006
VL 20
IS 1
BP 565
EP +
DI 10.1096/fj.05-4879fje
PG 19
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
   Topics; Cell Biology
GA 021PU
UT WOS:000235996000005
PM 16436466
DA 2018-12-27
ER

PT J
AU Rao, AS
   Kremenevskaja, N
   von Wasielewski, R
   Jakubcakova, V
   Kant, S
   Resch, J
   Brabant, G
AF Rao, AS
   Kremenevskaja, N
   von Wasielewski, R
   Jakubcakova, V
   Kant, S
   Resch, J
   Brabant, G
TI RETRACTED: Wnt/beta-catenin signaling mediates antineoplastic effects of
   imatinib mesylate (gleevec) in anaplastic thyroid cancer (Retracted
   Article. See vol 91, pg 2118, 2006)
SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
LA English
DT Article; Retracted Publication
ID TYROSINE KINASE INHIBITOR; CHRONIC MYELOID-LEUKEMIA; CARCINOMA
   CELL-LINES; SRC FAMILY KINASES; BETA-CATENIN; GROWTH-FACTOR; IN-VITRO;
   BCR-ABL; C-ABL; BLAST-CRISIS
AB Context: Dysregulation of Wnt signaling is a key step in neoplastic thyrocyte proliferation. However, it is unclear whether the selective tyrosine kinase (TK) inhibitor, imatinib mesylate, is linked to the Wnt/beta-catenin cascade and is able to modulate the pathway.
   Objective: Conflicting data are reported on the therapeutic effects of imatinib in anaplastic thyroid carcinomas (ATCs), but the molecular mechanism of action is unclear. Here, we further delineated the antitumor effects and the potential efficacy of imatinib in dedifferentiated thyroid carcinomas.
   Results: Tissue microarray of histologically proven ATCs (n=12) demonstrated that six of 12 tumors expressed at least one of the imatinib-sensitive TKs. Similarily, imatinib-sensitive TKs were detected in seven of 10 thyroid cancer cell lines derived from metastatic papillary, follicular, and ATCs. Coimmunoprecipitation in ARO cells demonstrated a direct link between c-abl and beta-catenin. Imatinib (10 mu M for 48 h) drastically reduced beta-catenin expression and redistributed it from the nucleus to the cell membrane. It stabilized adherens junctions by increasing beta-catenin/E-cadherin binding and reduced the invasive potential of thyroid cancer. Furthermore, imatinib (10 mu M for 48 h) attenuated T cell factor/lymphoid enhancer factor activity, reduced cyclin D1 levels and dose-dependently suppressed thyrocyte proliferation by half without affecting apoptosis.
   Conclusion: Our data provide a molecular mechanism for the antitumor activity of imatinib that may help to develop it as a therapeutic option in a subset of ATC patients.
C1 Hannover Med Sch, Dept Gastroenterol Hepatol & Endocrinol, D-30625 Hannover, Germany.
   Hannover Med Sch, Dept Pathol, D-30625 Hannover, Germany.
   Hannover Med Sch, Inst Biochem, D-30625 Hannover, Germany.
   Max Planck Inst Expt Endocrinol, D-30625 Hannover, Germany.
RP Brabant, G (reprint author), Hannover Med Sch, Dept Gastroenterol Hepatol & Endocrinol, Carl Neuberg Str 1, D-30625 Hannover, Germany.
EM brabant.georg@mh-hannover.de
CR Ain KB, 1998, THYROID, V8, P715, DOI 10.1089/thy.1998.8.715
   Buchdunger E, 1996, CANCER RES, V56, P100
   Buchdunger E, 2000, J PHARMACOL EXP THER, V295, P139
   Calautti E, 1998, J CELL BIOL, V141, P1449, DOI 10.1083/jcb.141.6.1449
   Cowan-Jacob SW, 2004, MINI-REV MED CHEM, V4, P285, DOI 10.2174/1389557043487321
   Doggrell SA, 2005, EXPERT OPIN INV DRUG, V14, P89, DOI 10.1517/13543784.14.1.89
   Druker BJ, 2001, NEW ENGL J MED, V344, P1038, DOI 10.1056/NEJM200104053441402
   Dziba JM, 2004, J CLIN ENDOCR METAB, V89, P2127, DOI 10.1210/jc.2003-031734
   Fagman H, 2003, ONCOGENE, V22, P6013, DOI 10.1038/sj.onc.1206731
   Garcia-Rostan G, 2001, AM J PATHOL, V158, P987, DOI 10.1016/S0002-9440(10)64045-X
   Haigh PI, 2001, CANCER-AM CANCER SOC, V91, P2335, DOI 10.1002/1097-0142(20010615)91:12<2335::AID-CNCR1266>3.3.CO;2-T
   Heldin N E, 1991, Thyroidology, V3, P127
   HELDIN NE, 1988, P NATL ACAD SCI USA, V85, P9302, DOI 10.1073/pnas.85.23.9302
   Helmbrecht K, 2001, ENDOCRINOLOGY, V142, P5261, DOI 10.1210/en.142.12.5261
   Herynk MH, 2003, CLIN EXP METASTAS, V20, P291, DOI 10.1023/A:1024024218529
   Huang SH, 1999, THYROID, V9, P1095, DOI 10.1089/thy.1999.9.1095
   Hundahl SA, 1998, CANCER-AM CANCER SOC, V83, P2638, DOI 10.1002/(SICI)1097-0142(19981215)83:12<2638::AID-CNCR31>3.0.CO;2-1
   Irby RB, 2002, CANCER RES, V62, P2669
   Ishigaki K, 2002, J CLIN ENDOCR METAB, V87, P3433, DOI 10.1210/jc.87.7.3433
   Jamieson CHM, 2004, NEW ENGL J MED, V351, P657, DOI 10.1056/NEJMoa040258
   Joensuu H, 2001, NEW ENGL J MED, V344, P1052, DOI 10.1056/NEJM200104053441404
   Karim RZ, 2004, PATHOLOGY, V36, P120, DOI 10.1080/00313020410001671957
   KINCH MS, 1995, J CELL BIOL, V130, P461, DOI 10.1083/jcb.130.2.461
   Kremenevskaja N, 2005, ONCOGENE, V24, P2144, DOI 10.1038/sj.onc.1208370
   Krystal GW, 2000, CLIN CANCER RES, V6, P3319
   Mauro MJ, 2001, ONCOLOGIST, V6, P233, DOI 10.1634/theoncologist.6-3-233
   Mitsiades CS, 2003, J CLIN ENDOCR METAB, V88, P5043, DOI 10.1210/jc.2003-030968
   Muller-Tidow C, 2005, CANCER RES, V65, P1778, DOI 10.1158/0008-5472.CAN-04-3388
   Nagar B, 2002, CANCER RES, V62, P4236
   Naito A, 2001, J SURG ONCOL, V76, P176, DOI 10.1002/jso.1031
   Nakashima M, 2004, J PATHOL, V202, P446, DOI 10.1002/path.1534
   Pietras K, 2002, CANCER RES, V62, P5476
   Plattner R, 1999, GENE DEV, V13, P2400, DOI 10.1101/gad.13.18.2400
   Podtcheko A, 2003, J CLIN ENDOCR METAB, V88, P5044, DOI 10.1210/jc.2003-031269
   Podtcheko A, 2003, J CLIN ENDOCR METAB, V88, P1889, DOI 10.1210/jc.2002-021230
   Saldanha G, 2004, BRIT J DERMATOL, V151, P157, DOI 10.1111/j.1365-2133.2004.06048.x
   Schindler T, 2000, SCIENCE, V289, P1938, DOI 10.1126/science.289.5486.1938
   Shah NP, 2004, SCIENCE, V305, P399, DOI 10.1126/science.1099480
   Shigematsu H, 2005, CANCER RES, V65, P1642, DOI 10.1158/0008-5472.CAN-04-4235
   Shigematsu H, 2005, J NATL CANCER I, V97, P339, DOI 10.1093/jnci/dji055
   Stephenson J, 2000, JAMA-J AM MED ASSOC, V283, P317, DOI 10.1001/jama.283.3.317
   Thiesing JT, 2000, BLOOD, V96, P3195
   Van Etten RA, 1999, TRENDS CELL BIOL, V9, P179, DOI 10.1016/S0962-8924(99)01549-4
   van Oosterom AT, 2001, LANCET, V358, P1421, DOI 10.1016/S0140-6736(01)06535-7
   Veness MJ, 2004, ANZ J SURG, V74, P559, DOI 10.1111/j.1445-2197.2004.03062.x
   vonWasielewski R, 1997, CANCER RES, V57, P2501
   Wiseman SM, 2003, HEAD NECK-J SCI SPEC, V25, P662, DOI 10.1002/hed.10277
   Yu CR, 2002, CANCER RES, V62, P188
   Zhai Y, 2002, AM J PATHOL, V160, P1229, DOI 10.1016/S0002-9440(10)62550-3
   Zhou L, 2003, CANCER LETT, V193, P161, DOI 10.1016/S0304-3835(03)00013-2
NR 50
TC 27
Z9 30
U1 3
U2 11
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0021-972X
EI 1945-7197
J9 J CLIN ENDOCR METAB
JI J. Clin. Endocrinol. Metab.
PD JAN
PY 2006
VL 91
IS 1
BP 159
EP 168
DI 10.1210/jc.2005-1381
PG 10
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 000VN
UT WOS:000234490600028
PM 16263821
OA Other Gold
DA 2018-12-27
ER

PT J
AU Joshi, VY
   Sawant, MR
AF Joshi, Vishal Y.
   Sawant, Manohar R.
TI RETRACTED: Study on dissolution rate enhancement of poorly water soluble
   drug: Contributions of solubility enhancement and relatively low micelle
   diffusivity (Retracted article. See vol. 30, pg. 737, 2009)
SO JOURNAL OF DISPERSION SCIENCE AND TECHNOLOGY
LA English
DT Article; Retracted Publication
DE dissolution; mix surfactants; model; aceclofenac; solubility; sodium
   lauryl sulfate; alkyl polyglucoside
ID ABSORPTION; MECHANISMS; FOOD
AB The objective of this study was to assess the contribution of surfactant-mediated solubility and micellar diffusivity on the ability of surfactants to enhance drug dissolution. The effect of surfactants system of alkyl polyglucosides (C10APG, C12APG, and C12/14APG) and Sodium Lauryl Sulphate SLS) were taken in different mole ratio and aceclofenac a nonsteroidal antiinflammatory agent was used as a model drug as it has limited water solubility. Solid Dispersions (SD) of drug with single and mixed surfactants were prepared using solution method with ethanol as the solvent. In physicochemical evolution, critical micelle concentration (CMC) of single as well as mixed surfactant was calculate using the Du-Nouy tensiometer method and such CMC of surfactants were taken as surfactant concentration for study. The following model was derived to predict the degree to which surfactants enhance aceclofenac dissolution
   [GRAPHICS]
   where F is the degree of surfactant-mediated dissolution enhancement, f(m) is the fraction of the drug in micelle, and f(f) is the fraction of free drug and D-D and DD-M are the diffusivities of free drug and drug-loaded micelles, respectively. D-D and DD-M was estimated using Wilke-change equation obtained at room temperature. The mixed surfactant system enhances drug solubilization by many folds in comparison of single surfactants.
C1 Univ Bombay, Dept Chem, Inst Chem Technol, Bombay 400019, Maharashtra, India.
RP Sawant, MR (reprint author), Univ Bombay, Dept Chem, Inst Chem Technol, Bombay 400019, Maharashtra, India.
EM mrsawant2@rediffmail.com
OI Joshi, Vishal/0000-0002-7941-3080
CR ABE M, 1992, SURFACTANT SCI SERIE, V46
   Balakrishnan A, 2004, J PHARM SCI-US, V93, P2064, DOI 10.1002/jps.20118
   BUSCH P, 1993, TENSIDE SURFACT DET, V30, P11675
   Charman WN, 1997, J PHARM SCI-US, V86, P269, DOI 10.1021/js960085v
   CLINT JH, 1975, J CHEM SOC FARAD T 1, V71, P1327, DOI 10.1039/f19757101327
   GIBALDI M, 1970, J PHARM SCI-US, V59, P579, DOI 10.1002/jps.2600590502
   JAIN Z, 2004, DISP SCI TECHNOL, V25, P27
   Joshi VY, 2006, INDIAN J CHEM B, V45, P461
   Kenyon CJ, 1998, PHARMACEUT RES, V15, P417, DOI 10.1023/A:1011972230829
   LEVICH VG, 1963, PHYSICOCHEMICAL HYDR
   LUNER PE, 2001, J PHARM SCI, V90, P428
   McCarthy Leonard G, 2003, AAPS PharmSciTech, V4, pE22
   NAYLOR LJ, 1993, PHARMACEUT RES, V10, P865, DOI 10.1023/A:1018961227717
   POELMA FGJ, 1991, J PHARM PHARMACOL, V43, P317, DOI 10.1111/j.2042-7158.1991.tb06697.x
   Reid R. C, 1977, PROPERTIES GAS LIQUI
   Rubingh D. N., 1979, SOLUTION CHEM SURFAC, P337
   Ruddy SB, 1999, INT J PHARM, V182, P173, DOI 10.1016/S0378-5173(99)00056-3
   SCAMEHORN JF, 1986, ACS SYM SER, V311, P324
   Shiloach A, 1998, LANGMUIR, V14, P1618, DOI 10.1021/la971151r
   Tang LJ, 2001, PHARM DEV TECHNOL, V6, P531, DOI 10.1081/PDT-120000291
NR 20
TC 7
Z9 8
U1 4
U2 14
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0193-2691
EI 1532-2351
J9 J DISPER SCI TECHNOL
JI J. Dispersion Sci. Technol.
PY 2006
VL 27
IS 8
BP 1141
EP 1150
DI 10.1080/01932690600859374
PG 10
WC Chemistry, Physical
SC Chemistry
GA 081XZ
UT WOS:000240352200013
DA 2018-12-27
ER

PT J
AU Stapel, DA
   Koomen, W
AF Stapel, DA
   Koomen, W
TI RETRACTED: The flexible unconscious: Investigating the judgmental impact
   of varieties of unaware perception (Retracted article. See vol. 49, pg.
   782, 2013)
SO JOURNAL OF EXPERIMENTAL SOCIAL PSYCHOLOGY
LA English
DT Article; Retracted Publication
DE automaticity; goal; assimilation; contrast; priming; flexibility;
   contingency
ID COGNITION; IMPLICIT; STEREOTYPES; THINKING
AB Two studies were conducted to investigate the notion that stimulus exposure time, target category, and mindset orientation can influence the impact of subliminally presented emotion faces on judgments of neutral targets. Specifically, Study I showed that when the stimulus and target were from different categories, assimilative judgments occurred at both short and long (but still Subliminal) stimulus exposure times. Yet, when the stimulus and target were from the same category, assimilation occurred at short exposure times, and contrast occurred at long exposure times. Findings from Study 2 show that this effect is moderated by one's goal during processing. That is, when motivated to see a specific type of stimulus, contrast occurred regardless of stimulus exposure time; however, when one is not poised to see specific stimuli, assimilation occurred at short exposure times and contrast occurred at long exposure times. These findings support the notion that unconscious perception is flexible and goal contingent. (c) 2005 Elsevier Inc. All rights reserved.
C1 Univ Groningen, Dept Social & Org Psychol, Groningen, Netherlands.
   Univ Amsterdam, Dept Social Psychol, Amsterdam, Netherlands.
RP Stapel, DA (reprint author), Univ Groningen, Dept Social & Org Psychol, Groningen, Netherlands.
EM d.a.stapel@rug.nl
CR BARGH JA, 1997, ADV SOC COG, V10, P1
   BARSALOU LW, 1983, MEM COGNITION, V11, P211, DOI 10.3758/BF03196968
   BIERNAT M, 1991, J PERS SOC PSYCHOL, V60, P485, DOI 10.1037/0022-3514.60.4.485
   Dijksterhuis A, 2001, ADV EXP SOC PSYCHOL, V33, P1, DOI 10.1016/S0065-2601(01)80003-4
   EDWARDS K, 1990, J PERS SOC PSYCHOL, V59, P202, DOI 10.1037/0022-3514.59.2.202
   Fazio RH, 2001, COGNITION EMOTION, V15, P115, DOI 10.1080/02699930125908
   GREENWALD AG, 1995, PSYCHOL REV, V102, P4, DOI 10.1037//0033-295X.102.1.4
   Helson H., 1964, ADAPTATION LEVEL THE
   LAZARUS RS, 1982, AM PSYCHOL, V37, P1019, DOI 10.1037/0003-066X.37.9.1019
   Markman KD, 2003, PERS SOC PSYCHOL REV, V7, P244, DOI 10.1207/S15327957PSPR0703_04
   MURPHY ST, 1995, J PERS SOC PSYCHOL, V69, P589, DOI 10.1037/0022-3514.69.4.589
   MURPHY ST, 1993, J PERS SOC PSYCHOL, V64, P723, DOI 10.1037/0022-3514.64.5.723
   Mussweiler T, 2003, PSYCHOL REV, V110, P472, DOI 10.1037/0033-295X.110.3.472
   MUSSWEILER T, 2000, J PERS SOC PSYCHOL, V79, P344
   NIEDENTHAL PM, 1990, J EXP SOC PSYCHOL, V26, P505, DOI 10.1016/0022-1031(90)90053-O
   PARDUCCI A, 1990, PSYCHOL EXPLORATIONS, P94
   SCHWARZ N, 1992, CONSTRUCTION OF SOCIAL JUDGMENTS, P217
   Stapel DA, 2004, J PERS SOC PSYCHOL, V87, P468, DOI 10.1037/0022-3514.87.4.468
   Stapel DA, 2002, J PERS SOC PSYCHOL, V83, P60, DOI 10.1037//0022-3514.83.1.60
   Stapel DA, 2001, COGNITIVE SOCIAL PSYCHOLOGY, P229
   STAPEL DA, 2003, SOCIAL JUDGMENTS IMP, P227
   Winkielman P, 1997, COGNITION EMOTION, V11, P433, DOI 10.1080/026999397379872
   ZAJONC RB, 1980, AM PSYCHOL, V35, P151, DOI 10.1037/0003-066X.35.2.151
NR 23
TC 15
Z9 21
U1 2
U2 30
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0022-1031
EI 1096-0465
J9 J EXP SOC PSYCHOL
JI J. Exp. Soc. Psychol.
PD JAN
PY 2006
VL 42
IS 1
BP 112
EP 119
DI 10.1016/j.jesp.2005.02.002
PG 8
WC Psychology, Social
SC Psychology
GA 013JV
UT WOS:000235406500011
DA 2018-12-27
ER

PT J
AU Kim, TH
AF Kim, TH
TI RETRACTED: Temperature dependence of the tunneling magnetoresistance and
   ferromagnetism in Ni65Cu35 magnetic tunnel junctions (Retracted article.
   See vol. 56, pg. 171, 2010)
SO JOURNAL OF THE KOREAN PHYSICAL SOCIETY
LA English
DT Article; Retracted Publication
DE magnetic tunnel junctions; spin-polarized tunneling; temperature
   dependence of spin polarization; temperature dependent
   magnetoresistance; NiCu alloy film
ID SPIN-POLARIZATION; ALLOYS; SCATTERING; TRANSPORT; MEMORY; FILMS
AB The temperature dependence of the tunneling magnetoresistance and magnetization have been measured for spin-valve magnetic tunnel junctions in which the pinned magnetic electrodes is a Ni65Cu35 alloy with a Curie temperature of roughly 250 K. By extracting the spin polarization of the NiCu electrode using the Julliere formula, it is shown that the tunneling spin-polarization as a function of temperature can be related to the temperature-dependent magnetization. The observed quasi-linear relation between the magnetization and the tunneling spin polarization is consistent with the theoretical picture of predominantly s-electron tunneling with the spin-polarization arising via hybridization with the exchange split 3d band.
C1 Ewha Womans Univ, Dept Phys, Seoul 120750, South Korea.
RP Kim, TH (reprint author), Ewha Womans Univ, Dept Phys, Seoul 120750, South Korea.
EM taehee@ewha.ac.kr
CR Ambrose T, 1996, PHYS REV LETT, V76, P1743, DOI 10.1103/PhysRevLett.76.1743
   Choy TS, 1999, J APPL PHYS, V86, P562, DOI 10.1063/1.370766
   Davis AH, 2002, J APPL PHYS, V91, P7023, DOI 10.1063/1.1447213
   Davis AH, 2001, J APPL PHYS, V89, P7567, DOI 10.1063/1.1357126
   De Teresa JM, 1999, PHYS REV LETT, V82, P4288, DOI 10.1103/PhysRevLett.82.4288
   HERTZ JA, 1973, PHYS REV B, V8, P3252, DOI 10.1103/PhysRevB.8.3252
   Jansen R, 2000, PHYS REV B, V61, P9047, DOI 10.1103/PhysRevB.61.9047
   JULLIERE M, 1975, PHYS LETT A, V54, P225, DOI 10.1016/0375-9601(75)90174-7
   Kim TH, 2002, PHYS REV B, V66, DOI 10.1003/PhysRevB.66.104436
   KIM TH, IN PRESS
   LeClair P, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.107201
   MESERVEY R, 1976, PHYS REV LETT, V37, P858, DOI 10.1103/PhysRevLett.37.858
   MESERVEY R, 1994, PHYS REP, V238, P173, DOI 10.1016/0370-1573(94)90105-8
   Monsma DJ, 2000, APPL PHYS LETT, V77, P720, DOI 10.1063/1.127097
   Moodera JS, 1999, J MAGN MAGN MATER, V200, P248, DOI 10.1016/S0304-8853(99)00515-6
   Moodera JS, 1998, PHYS REV LETT, V80, P2941, DOI 10.1103/PhysRevLett.80.2941
   MOODERA JS, 1995, PHYS REV LETT, V74, P3273, DOI 10.1103/PhysRevLett.74.3273
   Nadgorny B, 2000, PHYS REV B, V61, pR3788, DOI 10.1103/PhysRevB.61.R3788
   PARASKEVOPOULOS D, 1977, PHYS REV B, V16, P4907, DOI 10.1103/PhysRevB.16.4907
   Parkin SSP, 1999, J APPL PHYS, V85, P5828, DOI 10.1063/1.369932
   STEARNS MB, 1977, J MAGN MAGN MATER, V5, P167
   Yi JH, 2002, J KOREAN PHYS SOC, V41, P855
NR 22
TC 9
Z9 9
U1 2
U2 12
PU KOREAN PHYSICAL SOC
PI SEOUL
PA 635-4, YUKSAM-DONG, KANGNAM-KU, SEOUL 135-703, SOUTH KOREA
SN 0374-4884
EI 1976-8524
J9 J KOREAN PHYS SOC
JI J. Korean Phys. Soc.
PD JAN
PY 2006
VL 48
IS 1
BP L1
EP L4
PG 4
WC Physics, Multidisciplinary
SC Physics
GA 003CV
UT WOS:000234660100001
DA 2018-12-27
ER

PT J
AU Blom, H
   Yeh, R
   Wojnarowski, R
   Ling, M
AF Blom, H
   Yeh, R
   Wojnarowski, R
   Ling, M
TI RETRACTED: Detection of degradation of ABS materials via DSC (Retracted
   article. See vol. 67, pg. 92, 2016)
SO JOURNAL OF THERMAL ANALYSIS AND CALORIMETRY
LA English
DT Article; Proceedings Paper; Retracted Publication
CT 32nd Annual Meeting of the North-American-Thermal-Analysis-Society
CY OCT 04-06, 2004
CL Williamsburg, VA
SP N Amer Thermal Anal Soc
DE ABS; acrylonitrile-butadiene-styrene; differential scanning calorimetry;
   hot-runner injection molding; polymer degradation; thermal oxidation
AB ABS is a well-known and widely-used rigid engineering polymer. The mechanical properties of ABS are critical to its proper functioning in a given application, such as a medical device. It is therefore important to retain those properties during processing, fabrication, and use. To that end, thermal analysis and mechanical testing were employed to understand the origin of observed mechanical property losses. Oxidation onset temperature (OOT) testing and differential scanning calorimetry (DSC) analysis indicated a slightly lower onset temperature and a higher glass transition temperature, respectively, for parts which demonstrated a reduction in mechanical properties. It is also demonstrated that degradation of the butadiene-phase of the ABS is responsible for the mechanical property reduction, and that this degradation only proceeds at an appreciable rate at elevated temperatures in the presence of oxygen.
C1 Baxter Healthcare Corp, Round Lake, IL 60060 USA.
RP Blom, H (reprint author), Baxter Healthcare Corp, Route 120 & Wilson Rd, Round Lake, IL 60060 USA.
EM henk_blom@baxter.com
CR ADENIYI JB, 1984, EUR POLYM J, V20, P291, DOI 10.1016/0014-3057(84)90050-8
   BORROFF EM, 1978, PLASTICS TELECOM, V2
   GHAEMY M, 1981, POLYM DEGRAD STABIL, V3, P233, DOI 10.1016/0141-3910(81)90037-9
   SHAPI MM, 1991, THERMOCHIM ACTA, V175, P25, DOI 10.1016/0040-6031(91)80242-B
NR 4
TC 14
Z9 16
U1 2
U2 12
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 1388-6150
EI 1572-8943
J9 J THERM ANAL CALORIM
JI J. Therm. Anal. Calorim.
PY 2006
VL 83
IS 1
BP 113
EP 115
DI 10.1007/s10973-005-6977-0
PG 3
WC Thermodynamics; Chemistry, Analytical; Chemistry, Physical
SC Thermodynamics; Chemistry
GA 014BA
UT WOS:000235452500022
DA 2018-12-27
ER

PT J
AU Dent, CL
   Spaeth, JP
   Jones, BV
   Schwartz, SM
   Glauser, TA
   Hallinan, B
   Pearl, JM
   Khoury, PR
   Kurth, CD
AF Dent, CL
   Spaeth, JP
   Jones, BV
   Schwartz, SM
   Glauser, TA
   Hallinan, B
   Pearl, JM
   Khoury, PR
   Kurth, CD
TI RETRACTED: Brain magnetic resonance imaging abnormalities after the
   Norwood procedure using regional cerebral perfusion (Retracted article.
   See vol 131, pg 1226, 2006)
SO JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY
LA English
DT Article; Retracted Publication
ID HYPOTHERMIC CIRCULATORY ARREST; LEFT-HEART SYNDROME; FLOW
   CARDIOPULMONARY BYPASS; NEAR-INFRARED SPECTROSCOPY; BLOOD-FLOW;
   OXYGEN-SATURATION; NEUROLOGIC STATUS; FONTAN OPERATION; CHILDREN;
   SURGERY
AB Objectives: Neurologic deficits are common after the Norwood procedure for hypoplastic left heart syndrome. Because of the association of deep hypothermic circulatory arrest with adverse neurologic outcome, regional low-flow cerebral perfusion has been used to limit the period of intraoperative brain ischemia. To evaluate the impact of this technique on brain ischemia, we performed serial brain magnetic resonance imaging in a cohort of infants before and after the Norwood operation using regional cerebral perfusion.
   Methods: Twenty-two term neonates with hypoplastic left heart syndrome were studied with brain magnetic resonance imaging before and at a median of 9.5 days after the Norwood operation. Results were compared with preoperative, intraoperative, and postoperative risk factors to identify predictors of neurologic injury.
   Results: Preoperative magnetic resonance imaging (n = 22) demonstrated ischemic lesions in 23% of patients. Postoperative magnetic resonance imaging (n = 15) demonstrated new or worsened ischemic lesions in 73% of patients, with periventricular leukomalacia and focal ischemic lesions occurring most commonly. Prolonged low postoperative cerebral oximetry (< 45% for > 180 minutes) was associated with the development of new or worsened ischemia on postoperative magnetic resonance imaging (P = .029).
   Conclusions: Ischemic lesions occur commonly in neonates with hypoplastic left heart syndrome before surgery. Despite the adoption of regional cerebral perfusion, postoperative cerebral ischemic lesions are frequent, occurring in the majority of infants after the Norwood operation. Long-term follow-up is necessary to assess the functional impact of these lesions.
C1 Childrens Hosp, Med Ctr, Dept Pediat, Div Cardiol, Cincinnati, OH 45229 USA.
   Childrens Hosp, Med Ctr, Dept Pediat, Div Neurol, Cincinnati, OH 45229 USA.
   Childrens Hosp, Med Ctr, Dept Pediat, Div Epidemiol Biostat, Cincinnati, OH 45229 USA.
   Childrens Hosp, Med Ctr, Dept Surg, Div Cardiothorac Surg, Cincinnati, OH 45229 USA.
   Childrens Hosp, Med Ctr, Dept Radiol, Cincinnati, OH 45229 USA.
   Childrens Hosp, Med Ctr, Dept Anesthesiol, Cincinnati, OH 45229 USA.
   Univ Cincinnati, Coll Med, Cincinnati, OH USA.
RP Dent, CL (reprint author), Childrens Hosp, Med Ctr, Dept Pediat, Div Cardiol, 3333 Burnet Ave,MLC 2003, Cincinnati, OH 45229 USA.
EM catherine.dent@cchmc.org
OI Schwartz, Steven/0000-0002-8563-5130
CR Austin EH, 1997, J THORAC CARDIOV SUR, V114, P707, DOI 10.1016/S0022-5223(97)70074-6
   AUSTIN EH, 1997, J THORAC CARDIOVASC, V114, P715, DOI DOI 10.1016/S0022-5223(97)70074-6
   Bellinger DC, 2003, J THORAC CARDIOV SUR, V126, P1385, DOI 10.1016/S0022-5223(03)00711-6
   BELLINGER DC, 1995, NEW ENGL J MED, V332, P549, DOI 10.1056/NEJM199503023320901
   Donofrio MT, 2003, PEDIATR CARDIOL, V24, P436, DOI 10.1007/s00246-002-0404-0
   Forbess JM, 2001, CIRCULATION, V104, pI127
   GLAUSER TA, 1990, PEDIATRICS, V85, P991
   Goldberg CS, 2000, J PEDIATR-US, V137, P646, DOI 10.1067/mpd.2000.108952
   Hickey PR, 1998, ANN THORAC SURG, V65, pS65, DOI 10.1016/S0003-4975(98)00334-8
   Hoffman GM, 2004, ANESTHESIOLOGY, V101, pA1448
   JONAS RA, 1993, J THORAC CARDIOV SUR, V106, P362
   Kaltman JR, 2005, ULTRASOUND OBST GYN, V25, P32, DOI 10.1002/uog.1785
   Kern JH, 1998, PEDIATRICS, V102, P1148, DOI 10.1542/peds.102.5.1148
   Kurth CD, 2002, J CEREBR BLOOD F MET, V22, P335, DOI 10.1097/00004647-200203000-00011
   Kurth CD, 2001, ANN THORAC SURG, V72, P187, DOI 10.1016/S0003-4975(01)02632-7
   Licht DJ, 2004, J THORAC CARDIOV SUR, V128, P841, DOI 10.1016/j.jtcvs.2004.07.022
   Mahle WT, 2000, PEDIATRICS, V105, P1082, DOI 10.1542/peds.105.5.1082
   Mahle WT, 2002, CIRCULATION, V106, pI109, DOI 10.1161/01.cir.0000032908.33237.b1
   MORRIS CD, 1990, PEDIATRICS, V85, P977
   Myung RJ, 2004, J THORAC CARDIOV SUR, V127, P1051, DOI 10.1016/j.jtcvs.2003.11.008
   NEWBURGER JW, 1993, NEW ENGL J MED, V329, P1057, DOI 10.1056/NEJM199310073291501
   Olsen P, 1998, PEDIATRICS, V102, P329, DOI 10.1542/peds.102.2.329
   Pigula FA, 2000, J THORAC CARDIOV SUR, V119, P331, DOI 10.1016/S0022-5223(00)70189-9
   ROGERS BT, 1995, J PEDIATR-US, V126, P496, DOI 10.1016/S0022-3476(95)70478-7
   Sakamoto T, 2001, J THORAC CARDIOV SUR, V122, P339, DOI 10.1067/mtc.2001.115242
   Shore S, 2001, AM J CARDIOL, V88, P591, DOI 10.1016/S0002-9149(01)01751-9
   SKRANES JS, 1993, NEUROPEDIATRICS, V24, P256, DOI 10.1055/s-2008-1071553
   WERNOVSKY G, 1995, CIRCULATION, V92, P2226, DOI 10.1161/01.CIR.92.8.2226
   Wernovsky G, 2000, CIRCULATION, V102, P883
   Wypij D, 2003, J THORAC CARDIOV SUR, V126, P1397, DOI 10.1016/S0022-5223(03)00940-1
NR 30
TC 115
Z9 120
U1 3
U2 13
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0022-5223
EI 1097-685X
J9 J THORAC CARDIOV SUR
JI J. Thorac. Cardiovasc. Surg.
PD JAN
PY 2006
VL 131
IS 1
BP 190
EP 197
DI 10.1016/j.jtcvs.2005.10.003
PG 8
WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery
SC Cardiovascular System & Cardiology; Respiratory System; Surgery
GA 003CY
UT WOS:000234660400029
PM 16399311
OA Bronze
DA 2018-12-27
ER

PT J
AU Samarth, RM
   Panwar, M
   Kumar, M
   Kumar, A
AF Samarth, RM
   Panwar, M
   Kumar, M
   Kumar, A
TI RETRACTED: Protective effects of Mentha piperita Linn on
   benzo[a]pyrene-induced lung carcinogenicity and mutagenicity in Swiss
   albino mice (Retracted Article. See vol 22, pg 303, 2007)
SO MUTAGENESIS
LA English
DT Article; Retracted Publication
ID ERYTHROCYTE MICRONUCLEUS ASSAY; IN-VIVO; MOUSE SKIN; TUMOR PROMOTION;
   GLUTATHIONE; DAMAGE; ABERRATIONS; PREVENTION; INDUCTION
AB The chemopreventive and antimutagenic effects of an aqueous extract of Mentha piperita leaves were evaluated by using 9 week medium term model of benzo[a]pyrene (BP)-induced lung tumors. Lung tumors were induced by a single subcutaneous injection in the scapular region with BP in newborn Swiss albino mice (< 24 h old). The oral administration of Mentha extract (ME) showed a significant reduction in the number of lung tumors from an incidence of 67.92% in animals given only BP to 26.31%. The inhibition rate was 61.26% in ME treated group with respect to reference group (BP-alone). However, tumor multiplicity was reduced from 0.83 in the BP-alone group to 0.31 in the BP + ME group. Also, ME treatment reduced the frequency of BP-induced chromosomal aberrations and micronuclei in bone marrow cells and decreased the levels of lipoperoxides and increased sulfhydryl groups in liver as well as lung. In cell-free assays, ME showed strong scavenging activity for both the DPPH(.) and ABTS(.+) radicals. ME had an IC(50) value of 272 mu g/ml in the DPPH(.) assay. The chemopreventive action and antimutagenic effects observed in the present study is attributed to the antioxidative and radical scavenging properties of ME.
C1 Univ Rajasthan, Dept Zool, Radiat & Canc Biol Lab, Jaipur 302004, Rajasthan, India.
RP Samarth, RM (reprint author), Univ Rajasthan, Dept Zool, Radiat & Canc Biol Lab, Jaipur 302004, Rajasthan, India.
EM rmsamarth@yahoo.co.in
CR Al-Sereiti M. R., 1999, Indian Journal of Experimental Biology, V37, P124
   AMMON HPT, 1991, PLANTA MED, V57, P1, DOI 10.1055/s-2006-960004
   [Anonymous], 1973, IARC MON EV CARC RIS, V3
   AQIL F, 2001, J MED ARO PLANT SCI, V22, P177
   BENDER MA, 1988, MUTAT RES, V196, P103, DOI 10.1016/0165-1110(88)90017-6
   *CSIR, 1962, WEALTH INDIA RAW MAT, V6, P337
   Cuendet M, 1997, HELV CHIM ACTA, V80, P1144, DOI 10.1002/hlca.19970800411
   Das U., 2002, MED SCI MONITOR, V8, P79
   Dorman HJD, 2003, J AGR FOOD CHEM, V51, P4563, DOI 10.1021/jf034108k
   FURSTENBERGER G, 1989, CARCINOGENESIS, V10, P749, DOI 10.1093/carcin/10.4.749
   HAESEN S, 1993, CARCINOGENESIS, V14, P2319, DOI 10.1093/carcin/14.11.2319
   HAYASHI M, 1994, MUTAT RES, V312, P293, DOI 10.1016/0165-1161(94)90039-6
   Hayashi M, 2000, ENVIRON MOL MUTAGEN, V35, P234, DOI 10.1002/(SICI)1098-2280(2000)35:3<234::AID-EM10>3.0.CO;2-L
   *IARC, 1983, IARC MON EV CARC RIS, V32
   KAINA B, 1989, TERATOGEN CARCIN MUT, V9, P331, DOI 10.1002/tcm.1770090602
   KELLOFF GJ, 1994, CANCER EPIDEM BIOMAR, V3, P85
   Ketterer B, 1998, FREE RADICAL RES, V28, P647, DOI 10.3109/10715769809065820
   Krishnaswamy K, 1998, INDIAN J MED RES, V108, P167
   Lirio LG, 1998, PHARM BIOL, V36, P357, DOI 10.1076/phbi.36.5.357.4656
   Locigno R, 2001, INT J ONCOL, V19, P221
   Lu SC, 1999, FASEB J, V13, P1169
   Mayer C, 2000, CANCER LETT, V152, P169, DOI 10.1016/S0304-3835(00)00332-3
   Mimica-Dukic N, 2003, PLANTA MED, V69, P413, DOI 10.1055/s-2003-39704
   MORON MS, 1979, BIOCHIM BIOPHYS ACTA, V582, P67, DOI 10.1016/0304-4165(79)90289-7
   MORSE EC, 1996, CARCINOGENESIS, V14, P1737
   Ohkhawa H, 1979, ANAL BIOCHEM, V95, P351
   Ohyama W, 2002, MUTAT RES-GEN TOX EN, V518, P39, DOI 10.1016/S1383-5718(02)00061-X
   Pezzuto JM, 1997, BIOCHEM PHARMACOL, V53, P121, DOI 10.1016/S0006-2952(96)00654-5
   RASTOGI RP, 1991, COMPENDIUM INDIAN ME, V3, P420
   Re R, 1999, FREE RADICAL BIO MED, V26, P1231, DOI 10.1016/S0891-5849(98)00315-3
   Romero-Jimenez M, 2005, MUTAT RES-GEN TOX EN, V585, P147, DOI 10.1016/j.mrgentox.2005.05.004
   Samarth R. M., 2002, Indian Journal of Experimental Biology, V40, P1245
   Samarth R. M., 2003, Indian Journal of Experimental Biology, V41, P229
   Samarth RM, 2003, J RADIAT RES, V44, P101, DOI 10.1269/jrr.44.101
   Samman MA, 1998, CARCINOGENESIS, V19, P1795, DOI 10.1093/carcin/19.10.1795
   Savage J. R. K., 1975, J MED GENET, V12, P103
   SCHMID W, 1975, MUTAT RES, V31, P9, DOI 10.1016/0165-1161(75)90058-8
   STEINEL HH, 1993, MUTAT RES, V285, P19, DOI 10.1016/0027-5107(93)90047-J
   TANAKA T, 1994, ONCOL REP, V1, P1139
   Villasenor IM, 2002, MUTAT RES-GEN TOX EN, V515, P141, DOI 10.1016/S1383-5718(02)00006-2
   VOKOVICGACIC B, 1993, BASIC LIFE SCI, V61, P269
   YANG SK, 1977, SCIENCE, V196, P1199, DOI 10.1126/science.870975
   Yu TW, 2004, ENVIRON MOL MUTAGEN, V44, P387, DOI 10.1002/em.20063
   YUN TK, 1995, ANTICANCER RES, V15, P839
NR 44
TC 33
Z9 37
U1 3
U2 13
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0267-8357
J9 MUTAGENESIS
JI Mutagenesis
PD JAN
PY 2006
VL 21
IS 1
BP 61
EP 66
DI 10.1093/mutage/gei075
PG 6
WC Genetics & Heredity; Toxicology
SC Genetics & Heredity; Toxicology
GA 013TE
UT WOS:000235431600011
PM 16399846
OA Bronze
DA 2018-12-27
ER

PT J
AU Chen, X
   Zhan, ZJ
   Yue, JM
AF Chen, X
   Zhan, ZJ
   Yue, JM
TI RETRACTED: Sesquiterpenoids from Vernonia cinerea (Retracted article.
   See vol 23, pg 1160, 2009)
SO NATURAL PRODUCT RESEARCH
LA English
DT Article; Retracted Publication
DE Vernonia cinerea; Asteraceae; sesquiterpenoids; vernocinolide A
ID LACTONES; GERMACRANOLIDE
AB A new sesquiterpenoid, namely vernocinolide A (1), as well as ten known ones (2-11), was isolated from the ethyl acetate soluble fraction of the Vernonia cinerea. The structure of vernocinolide A (1) was elucidated by spectroscopic methods. Among the known sesquiterpenoids, nine of them were isolated from this plant for the first time.
C1 Chinese Acad Sci, Shanghai Inst Biol Sci, State Key Lab Drug Res, Inst Mat Med, Shanghai 201203, Peoples R China.
RP Yue, JM (reprint author), Chinese Acad Sci, Shanghai Inst Biol Sci, State Key Lab Drug Res, Inst Mat Med, 555 Chong Zhi Rd,Zhangjiang Hi Tech Pk, Shanghai 201203, Peoples R China.
EM jmyue@mail.shcnc.ac.cn
CR BOHLMANN F, 1978, PHYTOCHEMISTRY, V17, P475, DOI 10.1016/S0031-9422(00)89342-5
   Borkosky S, 1997, PHYTOCHEMISTRY, V44, P465, DOI 10.1016/S0031-9422(96)00481-5
   JAKUPOVIC J, 1986, Phytochemistry (Oxford), V25, P145
   JAKUPOVIC J, 1986, PHYTOCHEMISTRY, V25, P1359, DOI 10.1016/S0031-9422(00)81290-X
   Kuo YH, 2003, CHEM PHARM BULL, V51, P425, DOI 10.1248/cpb.51.425
   1975, ENCY CHINESE TRADITI, P472
NR 6
TC 9
Z9 9
U1 3
U2 15
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1478-6419
EI 1478-6427
J9 NAT PROD RES
JI Nat. Prod. Res.
PD JAN
PY 2006
VL 20
IS 1
BP 31
EP 35
DI 10.1080/14786410500078276
PG 5
WC Chemistry, Applied; Chemistry, Medicinal
SC Chemistry; Pharmacology & Pharmacy
GA 006UM
UT WOS:000234922900006
PM 16286305
DA 2018-12-27
ER

PT J
AU Kang, HM
   Kim, JR
   Jeomg, TS
   Choi, SG
   Ryu, YH
   Oh, GT
   Baek, NI
   Kwon, BM
AF Kang, HM
   Kim, JR
   Jeomg, TS
   Choi, SG
   Ryu, YH
   Oh, GT
   Baek, NI
   Kwon, BM
TI RETRACTED: Cyclic diarylheptanoids inhibit cell mediated low-density
   lipoprotein oxidation (Retracted article. See vol. 23, pg. 201, 2009)
SO NATURAL PRODUCT RESEARCH
LA English
DT Article; Retracted Publication
DE diarylheptanoids; low-density lipoprotein oxidation; Alnus japonica
ID ATHEROSCLEROSIS; ANTIOXIDANTS
AB Two cyclic diarylheptanoids, garugamblin-3 (1) and acerogenin L (2), isolated from the MeOH extract of the fruits of Alnus japonica Steud., inhibited human low-density lipoprotein (LDL) oxidation in the thiobarbituric acid-reactive substance assay with IC50 values of 2.9 and 1.7 mu M, respectively, and they also inhibited cell-mediated LDL oxidation more than 5 times more strongly than that of a well-known antioxidant, probucol, at a concentration of 10 mu M. 1 had no effect on the anti-atherogenesis in low-density lipoprotein receptor-deficient mice.
C1 Korea Res Inst Biosci & Biotechnol, Taejon 305600, South Korea.
   Kyung Hee Univ, Grad Sch Biotechnol, Kyonggi Do 449701, South Korea.
RP Kwon, BM (reprint author), Korea Res Inst Biosci & Biotechnol, 52 Uendong, Taejon 305600, South Korea.
EM kwonbm@kribb.re.kr
CR Buege J A, 1978, Methods Enzymol, V52, P302
   Diaz MN, 1997, NEW ENGL J MED, V337, P408, DOI 10.1056/NEJM199708073370607
   Glass CK, 2001, CELL, V104, P503, DOI 10.1016/S0092-8674(01)00238-0
   Gonzalez GI, 1999, J ORG CHEM, V64, P914, DOI 10.1021/jo981844s
   HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182
   ISHIBASHI S, 1994, J CLIN INVEST, V93, P1885, DOI 10.1172/JCI117179
   Kang HM, 2004, NAT PROD RES, V18, P295, DOI 10.1080/14786410310001620691
   Kang SS, 1998, J NAT PROD, V61, P299, DOI 10.1021/np970449e
   Keseru GM, 1995, STUDIES NATURAL PROD, V17, P357
   Morikawa T, 2003, J NAT PROD, V66, P86, DOI 10.1021/np020351m
   Stocker R, 1999, CURR OPIN LIPIDOL, V10, P589, DOI 10.1097/00041433-199912000-00014
NR 11
TC 3
Z9 3
U1 3
U2 13
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1478-6419
EI 1478-6427
J9 NAT PROD RES
JI Nat. Prod. Res.
PD JAN
PY 2006
VL 20
IS 1
BP 37
EP 41
DI 10.1080/14786410500081494
PG 5
WC Chemistry, Applied; Chemistry, Medicinal
SC Chemistry; Pharmacology & Pharmacy
GA 006UM
UT WOS:000234922900007
PM 16286306
DA 2018-12-27
ER

PT J
AU Davies, KJA
   Shringarpure, R
AF Davies, KJA
   Shringarpure, R
TI RETRACTED: Preferential degradation of oxidized proteins by the 20S
   proteasome may be inhibited in aging and in inflammatory neuromuscular
   diseases (Retracted Article. See vol 67, pg 2087, 2006)
SO NEUROLOGY
LA English
DT Article; Retracted Publication
ID TYROSINE OXIDATION-PRODUCTS; HUMAN BJ FIBROBLASTS; RED-BLOOD-CELLS;
   GLUTAMINE-SYNTHETASE; MAMMALIAN-CELLS; OXYGEN RADICALS; SELECTIVE
   DEGRADATION; DEPENDENT PROTEOLYSIS; METHIONINE RESIDUES; CELLULAR
   SENESCENCE
AB Free radicals produced by chronic inflammation cause cumulative damage to cellular macromolecules and appear to contribute to senescence/aging, age-related disorders, and neuromuscular degenerative diseases such as inclusion-body myositis. Proteins are major targets for oxidative damage (in addition to DNA and lipids) and the accumulation of oxidized proteins has been reported in many aging and disease models. In young and healthy individuals, moderately oxidized soluble cell proteins are selectively and rapidly degraded by the 20S proteasome. The mechanism of selective proteolysis appears to depend upon oxidation-induced protein unfolding, with increasing surface hydrophobicity as (previously shielded) hydrophobic residues are exposed from the interior. The 20S proteasome can preferentially bind to and degrade such mildly oxidized, hydrophobic proteins without a need for ubiquitin targeting or ATP activation. Severely oxidized, aggregated, and crosslinked proteins, however, are poor substrates for degradation and actually inhibit the proteasome. During aging, and in many age-related diseases/disorders, the proteasome is progressively inhibited by binding to increasing levels of oxidized and cross-linked protein aggregates. Cellular aging and inflammatory neuromuscular degenerative diseases probably include both an increase in the generation of reactive oxygen species as well as a decline in proteasome activity, resulting in the progressive accumulation of oxidatively damaged protein aggregates that eventually contribute to cellular dysfunction and senescence.
C1 Univ So Calif, Ethel Percy Andrus Gerontol Ctr, Los Angeles, CA 90089 USA.
   Univ So Calif, Div Mol & Computat Biol, Los Angeles, CA 90089 USA.
RP Davies, KJA (reprint author), Univ So Calif, Ethel Percy Andrus Gerontol Ctr, 3715 McClintock Ave,GER 306, Los Angeles, CA 90089 USA.
EM Kelvin@usc.edu
FU NIEHS NIH HHS [ES03598]
CR Aksenova MV, 1998, MECH AGEING DEV, V100, P157, DOI 10.1016/S0047-6374(97)00133-4
   Berlett BS, 1997, J BIOL CHEM, V272, P20313, DOI 10.1074/jbc.272.33.20313
   BOHLEY P, 1992, EXPERIENTIA, V48, P151, DOI 10.1007/BF01923508
   Braeckman BP, 2001, MECH AGEING DEV, V122, P673, DOI 10.1016/S0047-6374(01)00222-6
   Brooks P, 2000, BIOCHEM J, V346, P155, DOI 10.1042/0264-6021:3460155
   Cadenas E, 2000, FREE RADICAL BIO MED, V29, P222, DOI 10.1016/S0891-5849(00)00317-8
   CARNEY JM, 1991, P NATL ACAD SCI USA, V88, P3633, DOI 10.1073/pnas.88.9.3633
   CERVERA J, 1988, FASEB J, V2, P2591
   Chao CC, 1997, P NATL ACAD SCI USA, V94, P2969, DOI 10.1073/pnas.94.7.2969
   COUX O, 1996, ANNU REV BIOCHEM, V29, P10289
   DAVIES KJA, 1987, J BIOL CHEM, V262, P9895
   DAVIES KJA, 1987, J BIOL CHEM, V262, P9908
   Davies KJA, 2001, BIOCHIMIE, V83, P301, DOI 10.1016/S0300-9084(01)01250-0
   DAVIES KJA, 1987, J BIOL CHEM, V262, P9914
   DAVIES KJA, 1987, J BIOL CHEM, P262
   DAZHONG Y, 1996, FREE RADIC BIOL MED, V21, P871
   Dean RT, 1997, BIOCHEM J, V324, P1
   Friguet B, 1997, FEBS LETT, V405, P21, DOI 10.1016/S0014-5793(97)00148-8
   GIULIVI C, 1994, ARCH BIOCHEM BIOPHYS, V311, P329, DOI 10.1006/abbi.1994.1245
   Giulivi C, 2001, J BIOL CHEM, V276, P24129, DOI 10.1074/jbc.M010697200
   GIULIVI C, 1993, J BIOL CHEM, V268, P8752
   GRANT AJ, 1993, FREE RADICAL RES COM, V18, P259, DOI 10.3109/10715769309147493
   GRUNE T, 1995, J BIOL CHEM, V270, P2344, DOI 10.1074/jbc.270.5.2344
   Grune T, 1996, J BIOL CHEM, V271, P15504, DOI 10.1074/jbc.271.26.15504
   Grune T, 1997, FASEB J, V11, P526
   GRUNE T, 2001, J GERONTOL A-BIOL, V56, pB1
   HARMAN D, 1956, J GERONTOL, V11, P298, DOI 10.1093/geronj/11.3.298
   HEINECKE JW, 1993, J BIOL CHEM, V268, P4069
   JahngenHodge J, 1997, J BIOL CHEM, V272, P28218, DOI 10.1074/jbc.272.45.28218
   LABOISSIERE MCA, 1995, J BIOL CHEM, V270, P28006
   LEEUWENBURGH C, 1998, AM J PHYSIOL, V274, P453
   Levine RL, 1996, P NATL ACAD SCI USA, V93, P15036, DOI 10.1073/pnas.93.26.15036
   LEVINE RL, 1990, METHOD ENZYMOL, V186, P464
   Levine RL, 1999, MECH AGEING DEV, V107, P323, DOI 10.1016/S0047-6374(98)00152-3
   MELLGREN RL, 1987, FASEB J, V1, P110
   PACIFICI RE, 1993, J BIOL CHEM, V268, P15405
   PACIFICI RE, 1989, FREE RADICAL BIO MED, V7, P521, DOI 10.1016/0891-5849(89)90028-2
   PETERS JM, 1994, J BIOL CHEM, V269, P7709
   Petropoulos I, 2000, J GERONTOL A-BIOL, V55, pB220, DOI 10.1093/gerona/55.5.B220
   Reinheckel T, 1998, BIOCHEM J, V335, P637, DOI 10.1042/bj3350637
   Reinheckel T, 2000, ARCH BIOCHEM BIOPHYS, V377, P65, DOI 10.1006/abbi.2000.1717
   RIVETT AJ, 1985, J BIOL CHEM, V260, P2600
   RIVETT AJ, 1985, J BIOL CHEM, V260, P300
   ROSEMAN JE, 1987, J BIOL CHEM, V262, P2101
   SALO DC, 1990, J BIOL CHEM, V265, P11919
   Shang F, 1997, J BIOL CHEM, V272, P23086, DOI 10.1074/jbc.272.37.23086
   Shringarpure R, 2001, CELL MOL LIFE SCI, V58, P1442, DOI 10.1007/PL00000787
   Shringarpure R, 2003, J BIOL CHEM, V278, P311, DOI 10.1074/jbc.M206279200
   Shringarpure R, 2000, CELL MOL LIFE SCI, V57, P1802, DOI 10.1007/PL00000660
   Sitte N, 2000, FASEB J, V14, P1490, DOI 10.1096/fj.14.11.1490
   Sitte N, 2000, FASEB J, V14, P2503, DOI 10.1096/fj.00-0210com
   Sitte N, 2000, FASEB J, V14, P2495, DOI 10.1096/fj.00-0209com
   SMITH CD, 1991, P NATL ACAD SCI USA, V88, P10540, DOI 10.1073/pnas.88.23.10540
   SOHAL RS, 1994, FREE RADICAL BIO MED, V16, P621, DOI 10.1016/0891-5849(94)90062-0
   STADTMAN ER, 1992, SCIENCE, V257, P1220, DOI 10.1126/science.1355616
   Sun JT, 1999, MOL CELL BIOL, V19, P216
   Tanahashi N, 2000, J BIOL CHEM, V275, P14336, DOI 10.1074/jbc.275.19.14336
   TAYLOR A, 1987, FREE RADICAL BIO MED, V3, P371, DOI 10.1016/0891-5849(87)90015-3
   Vittorini S, 1999, J GERONTOL A-BIOL, V54, pB318, DOI 10.1093/gerona/54.8.B318
   WILK S, 1980, J NEUROCHEM, V35, P1172, DOI 10.1111/j.1471-4159.1980.tb07873.x
   Wood WB, 1998, CELL, V95, P147, DOI 10.1016/S0092-8674(00)81744-4
NR 61
TC 44
Z9 47
U1 3
U2 13
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0028-3878
J9 NEUROLOGY
JI Neurology
PD JAN
PY 2006
VL 66
SU 1
BP S93
EP S96
DI 10.1212/01.wnl.0000192308.43151.63
PG 4
WC Clinical Neurology
SC Neurosciences & Neurology
GA 005RX
UT WOS:000234842600016
PM 16432154
DA 2018-12-27
ER

PT J
AU Papageorgiou, C
   Pitsavos, C
   Panagiotakos, DB
   Kontoangelos, K
   Chrysohoou, C
   Papadimitriou, GN
   Rabavilas, AD
AF Papageorgiou, C
   Pitsavos, C
   Panagiotakos, DB
   Kontoangelos, K
   Chrysohoou, C
   Papadimitriou, GN
   Rabavilas, AD
TI RETRACTED: Association between hostility and plasma total homocysteine
   concentrations in a general population sample (Retracted Article. See
   vol 53, pg 32, 2006)
SO NEUROPSYCHOBIOLOGY
LA English
DT Article; Retracted Publication
DE cardiovascular disease; hostility; homocysteine
ID ISCHEMIC-HEART-DISEASE; RISK-FACTOR; CARDIOVASCULAR REACTIVITY; CYNICAL
   HOSTILITY; BLOOD-PRESSURE; HEALTH; DEFENSIVENESS; QUESTIONNAIRE;
   DIMENSIONS; MORTALITY
AB Objective: The present study focuses on testing the association of hostility with plasma homocysteine levels in a general population sample. Method: Four hundred and ten healthy adults ( 200 men and 210 women), participating in a health survey in Greece, had blood samples taken for homocysteine concentrations and also completed a multidimensional hostility questionnaire, assessing direction of hostility ('extra- and intropunitive') as well as total hostility and its ingredients, i.e. urge to act out hostility, criticism of others, delusional hostility, self-criticism and delusional guilt. Multivariate relationship was tested between hostility components and homocysteine, after statistically controlling for potential confounders such as age, gender, educational status, smoking and body mass index. Results: Total hostility, delusional guilt as well as extrapunitive direction of hostility were positively related to homocysteine levels. Self-criticism was negatively related to homocysteine. Conclusion: The study provides further evidence that particular dimensions of hostility are associated with increased plasma homocysteine levels, thus deserving a place within the spectrum of the coronary heart disease risk factors. Copyright (C) 2006 S. Karger AG, Basel.
C1 Eginit Hosp, Dept Psychiat, Psychophysiol Lab, Psychiat Clin, Athens 11528, Greece.
   Univ Athens, Sch Med, Cardiol Clin 1, GR-11527 Athens, Greece.
   Harokopio Univ, Dept Nutr & Dietet, Athens, Greece.
   Univ Mental Hlth Res Inst, Athens, Greece.
RP Papageorgiou, C (reprint author), Eginit Hosp, Dept Psychiat, Psychophysiol Lab, Psychiat Clin, 74 Vas Sophias Ave, Athens 11528, Greece.
EM panchris@otenet.gr
RI Panagiotakos, Demosthenes/C-9776-2013
OI Panagiotakos, Demosthenes/0000-0001-8583-153X
CR BAREFOOT JC, 1995, AM J EPIDEMIOL, V142, P477, DOI 10.1093/oxfordjournals.aje.a117663
   BERRIOS GE, 1992, BRIT J PSYCHIAT, V160, P781, DOI 10.1192/bjp.160.6.781
   BITTI PER, 1995, PSYCHOTHER PSYCHOSOM, V64, P162, DOI 10.1159/000289007
   BURNS JW, 1995, J BEHAV MED, V18, P279, DOI 10.1007/BF01857874
   Caine T.M., 1967, MANUAL HOSTILITY DIR
   CONTRADA RJ, 1992, J APPL SOC PSYCHOL, V22, P615, DOI 10.1111/j.1559-1816.1992.tb00993.x
   Cook WW, 1954, J APPL PSYCHOL, V38, P414, DOI 10.1037/h0060667
   Everson SA, 1997, ARTERIOSCL THROM VAS, V17, P1490, DOI 10.1161/01.ATV.17.8.1490
   Graham IM, 1997, JAMA-J AM MED ASSOC, V277, P1775, DOI 10.1001/jama.277.22.1775
   Hathaway SR, 1940, J PSYCHOL, V10, P249, DOI 10.1080/00223980.1940.9917000
   Helmers KF, 1997, ACAD MED, V72, P708, DOI 10.1097/00001888-199708000-00018
   HELMERS KF, 1999, HEALTH PSYCHOL, V14, P202
   JAMNER LD, 1991, PSYCHOSOM MED, V53, P393, DOI 10.1097/00006842-199107000-00005
   JORGENSEN RS, 1995, PSYCHOTHER PSYCHOSOM, V64, P156, DOI 10.1159/000289006
   Jorgensen RS, 2001, PSYCHOSOM MED, V63, P463, DOI 10.1097/00006842-200105000-00016
   Karlson B, 2000, NEUROTOXICOLOGY, V21, P783
   Katsouyanni K, 1997, INT J EPIDEMIOL, V26, pS118, DOI 10.1093/ije/26.suppl_1.S118
   Kivimaki M, 2003, SOC SCI MED, V56, P2139, DOI 10.1016/S0277-9536(02)00219-8
   KOSKENVUO M, 1988, PSYCHOSOM MED, V50, P330, DOI 10.1097/00006842-198807000-00002
   Lenfant C, 2003, HYPERTENSION, V41, P1178, DOI 10.1161/01.HYP.0000075790.33892.AE
   Miczek KA, 2002, PSYCHOPHARMACOLOGY, V163, P434, DOI 10.1007/s00213-002-1139-6
   Miller TQ, 1996, PSYCHOL BULL, V119, P322, DOI 10.1037/0033-2909.119.2.322
   NYGARD O, 1995, JAMA-J AM MED ASSOC, V274, P1526, DOI 10.1001/jama.274.19.1526
   Panagiotakos DB, 2004, EUR HEART J, V25, P492, DOI 10.1016/j.ehj.2004.01.018
   PITSAVOS C, IN PRESS ATHEROSCLER
   Ravaja N, 2001, PSYCHOTHER PSYCHOSOM, V70, P66, DOI 10.1159/000056229
   ROSE RJ, 1988, J PERS SOC PSYCHOL, V55, P302, DOI 10.1037//0022-3514.55.2.302
   Rozanski A, 1999, CIRCULATION, V99, P2192, DOI 10.1161/01.CIR.99.16.2192
   SIMS A, 2000, NEW OXFORD TXB PSYCH, P55
   Sloan RP, 2001, PSYCHOSOM MED, V63, P434, DOI 10.1097/00006842-200105000-00012
   Spielberger C. D, 1970, MANUAL STATE TRAIT A
   Stoney CM, 2000, LIFE SCI, V66, P2267, DOI 10.1016/S0024-3205(00)00556-7
   Tangney JP, 1996, BEHAV RES THER, V34, P741, DOI 10.1016/0005-7967(96)00034-4
   Welch GN, 1998, NEW ENGL J MED, V338, P1042, DOI 10.1056/NEJM199804093381507
   WEST P, 1991, SOC SCI MED, V32, P373, DOI 10.1016/0277-9536(91)90338-D
   Williamson JB, 2003, BRAIN COGNITION, V52, P167, DOI 10.1016/S0278-2626(03)00038-1
   ZUNG WWK, 1965, ARCH GEN PSYCHIAT, V12, P63
NR 37
TC 2
Z9 2
U1 3
U2 10
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0302-282X
EI 1423-0224
J9 NEUROPSYCHOBIOLOGY
JI Neuropsychobiology
PY 2006
VL 53
IS 1
BP 26
EP 32
DI 10.1159/000089918
PG 7
WC Neurosciences; Psychiatry; Psychology
SC Neurosciences & Neurology; Psychiatry; Psychology
GA 012NP
UT WOS:000235346200004
PM 16319506
DA 2018-12-27
ER

PT J
AU Takai, N
   Ueda, T
   Nishida, M
   Nasu, K
   Matsuda, K
   Kusumoto, M
   Narahara, H
AF Takai, Noriyuki
   Ueda, Tami
   Nishida, Masakazu
   Nasu, Kaei
   Matsuda, Kaho
   Kusumoto, Mamiko
   Narahara, Hisashi
TI RETRACTED: CBHA is a family of hybrid polar compounds that inhibit
   histone deacetylase, and induces growth inhibition, cell cycle arrest
   and apoptosis in human endometrial and ovarian cancer cells (Retracted
   article. See vol. 88, pg. 320, 2015)
SO ONCOLOGY
LA English
DT Article; Retracted Publication
DE acetylation; apoptosis; cell cycle; endometrial cancer; ovarian cancer
ID TRICHOSTATIN-A; TRANSCRIPTIONAL REPRESSION; DIFFERENTIATION; EXPRESSION;
   LEUKEMIA; POTENT; ACETYLATION; COMPLEX
AB Objectives: We investigated the effect of a novel synthesized histone deacetylase inhibitor (HDACI), CBHA, on three endometrial cancer cell lines, two ovarian cancer cell lines, and normal human endometrial epithelial cells. Methods: Endometrial and ovarian cancer cells were treated with various concentrations of CBHA, and its effect on cell growth, cell cycle, apoptosis, and related measurements was investigated. Results: The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay showed that all endometrial and ovarian cancer cell lines were sensitive to the growth-inhibitory effect of CBHA, although normal endometrial epithelial cells were viable after treatment with the same doses of CBHA that induced growth inhibition in endometrial and ovarian cancer cells. Cell cycle analysis indicated that their exposure to CBHA decreased the proportion of cells in the S-phase and increased the proportion in the G(0)/G(1) phases of the cell cycle. Induction of apoptosis was confirmed byannexin V staining of externalized phosphatidylserine and loss of the transmembrane potential of mitochondria. This induction occurred in concert with altered expression of genes related to cell growth, malignant phenotype, and apoptosis. Furthermore, CBHA treatment of these cell lines increased acetylation of H3 and H4 histone tails. Conclusions: These results raise the possibility that CBHA may prove particularly effective in the treatment of endometrial and ovarian cancers. Copyright (c) 2006 S. Karger AG, Basel.
C1 Oita Univ, Fac Med, Dept Obstet & Gynecol, Oita 8795593, Japan.
RP Takai, N (reprint author), Oita Univ, Fac Med, Dept Obstet & Gynecol, 1-1 Idaigaoka,Hasama Machi, Oita 8795593, Japan.
EM takai@med.oita-u.ac.jp
CR Chen Y, 2001, CANCER RES, V61, P6437
   De Ruijter AJM, 2003, BIOCHEM J, V370, P737, DOI 10.1042/BJ20021321
   Dhordain P, 1998, NUCLEIC ACIDS RES, V26, P4645, DOI 10.1093/nar/26.20.4645
   FREYTAG SO, 1988, MOL CELL BIOL, V8, P1614, DOI 10.1128/MCB.8.4.1614
   Gelmetti V, 1998, MOL CELL BIOL, V18, P7185, DOI 10.1128/MCB.18.12.7185
   GRAFF JR, 1995, CANCER RES, V55, P5195
   Johnson DG, 1999, ANNU REV PHARMACOL, V39, P295, DOI 10.1146/annurev.pharmtox.39.1.295
   Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9
   Marks PA, 2000, JNCI-J NATL CANCER I, V92, P1210, DOI 10.1093/jnci/92.15.1210
   NEWMARK HL, 1995, J CELL BIOCHEM, P247
   Richon VM, 2000, P NATL ACAD SCI USA, V97, P10014, DOI 10.1073/pnas.180316197
   Richon VM, 1996, P NATL ACAD SCI USA, V93, P5705, DOI 10.1073/pnas.93.12.5705
   Richon VM, 1998, P NATL ACAD SCI USA, V95, P3003, DOI 10.1073/pnas.95.6.3003
   Rimon G, 1997, J NEUROSCI RES, V48, P563, DOI 10.1002/(SICI)1097-4547(19970615)48:6<563::AID-JNR9>3.0.CO;2-8
   Sandberg EM, 2004, J BIOL CHEM, V279, P34547, DOI 10.1074/jbc.M405045200
   Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412
   Takai N, 2004, CANCER-AM CANCER SOC, V101, P2760, DOI 10.1002/cncr.20709
   Takai N, 2004, CLIN CANCER RES, V10, P1141, DOI 10.1158/1078-0432.CCR-03-0100
   TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419
   Verdin E, 2003, TRENDS GENET, V19, P286, DOI 10.1016/S0168-9525(03)00073-8
   Warrell RP, 1998, J NATL CANCER I, V90, P1621, DOI 10.1093/jnci/90.21.1621
   YOSHIDA M, 1990, J BIOL CHEM, V265, P17174
   YOSHIDA M, 1990, J ANTIBIOT, V43, P1101, DOI 10.7164/antibiotics.43.1101
   YOSHIDA M, 1995, BIOESSAYS, V17, P423, DOI 10.1002/bies.950170510
   Zhou Q, 2000, J BIOL CHEM, V275, P35256, DOI 10.1074/jbc.M003106200
NR 25
TC 15
Z9 15
U1 3
U2 7
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-2414
EI 1423-0232
J9 ONCOLOGY-BASEL
JI Oncology
PY 2006
VL 70
IS 2
BP 97
EP 105
DI 10.1159/000092585
PG 9
WC Oncology
SC Oncology
GA 048LR
UT WOS:000237949100003
PM 16601366
DA 2018-12-27
ER

PT J
AU Tamiolakis, D
   Papadopoulos, N
   Venizelos, J
   Lambropoulou, M
   Romanidis, C
   Petrakis, G
   Limberis, V
   Galazios, G
   Koutsougeras, G
   Simopoulos, C
AF Tamiolakis, Demetrio
   Papadopoulos, Nikolaos
   Venizelos, John
   Lambropoulou, Maria
   Romanidis, Constantinos
   Petrakis, Georgios
   Limberis, Vasilios
   Galazios, Georgios
   Koutsougeras, Gerasimos
   Simopoulos, Constantinos
TI RETRACTED: Intraoperative touch imprint cytological analysis of sentinel
   lymph nodes for the presence of metastases in breast cancer (Retracted
   article. see vol 30, pg 662, 2007)
SO ONKOLOGIE
LA English
DT Article; Retracted Publication
DE breast cancer; sentinel lymph node; imprint cytology
ID AXILLARY DISSECTION; BIOPSY; CARCINOMA; DIAGNOSIS
AB Background: Imprint cytology may provide a fast and accurate method for intraoperative screening of sentinel lymph nodes, so a decision can be made regarding whether to perform axillary clearance during primary surgery. If the findings are negative, in many cases axillary dissection can be omitted. Patients and Methods: 128 sentinel nodes from a cohort of 87 patients that had been identified using technetium-99m nanocolloid as a radioactive tracer and Patent blue dye were disected for rapid Diff-Quick stained touch preparations. Intraoperative evaluation of sentinel node status by imprint cytology was correlated with histopathological results of permanent sections. Tumor-negative nodes in routine paraffin sections were further investigated with the employment of an anti-cytokeratin antibody. Results: 36 of all sentinel nodes harbored metastases in the paraffin sections, of which 32 were identified by imprint cytology (sensitivity 88.8%). 3 sentinel nodes were positive by imprint cytology and negative by histopathology of the paraffin sections. Comparison of the results of the touch preparations with the final histopathology (hematoxylin-eosin and anticytokeratin antibody stains) demonstrated a sensitivity of 83.3% and a negative predictive value of 92.5%. The specificity and positive predictive value were 100% each. Conclusions: Touch imprint cytology is potentially useful for intraoperative evaluation of sentinel lymph nodes in breast cancer patients.
C1 Democritus Univ Thrace, Dept Hist Embryol, Alexandroupolis 68100, Greece.
   Ippocrat Gen Hosp, Dept Pathol, Thessaloniki, Greece.
   Democritus Univ Thrace, Dept Surg, Alexandroupolis 68100, Greece.
   Democritus Univ Thrace, Dept Obstet & Gynecol, Alexandroupolis 68100, Greece.
   Reg Hosp Alexandroupolis, Dept Obstet & Gynecol, Alexandroupolis, Greece.
   Democritus Univ Thrace, Dept Expt Surg, Alexandroupolis 68100, Greece.
RP Papadopoulos, N (reprint author), Democritus Univ Thrace, Dept Hist Embryol, Alexandroupolis 68100, Greece.
EM npapad@med.duth.gr
CR Creager AJ, 2004, ANN SURG, V239, P61, DOI 10.1097/01.sla.0000103072.34708.c3
   Cserni G, 2001, AM SURGEON, V67, P273
   DIXON JM, 2001, ANN SURG ONCOL, V8, P361
   GIULIANO AE, 1994, ANN SURG, V220, P391, DOI 10.1097/00000658-199409000-00015
   KU N, 1999, EUR J NUCL MED S, V26, P556
   Ku NNK, 1997, ACTA CYTOL, V41, P1606
   Kuhn T, 2000, ONKOLOGIE, V23, P121, DOI 10.1159/000027083
   McMasters KM, 2000, J CLIN ONCOL, V18, P2560, DOI 10.1200/JCO.2000.18.13.2560
   Mokbel K, 2002, CURR MED RES OPIN, V18, P26, DOI 10.1185/030079902125000066
   Mokbel K, 2001, CURR MED RES OPIN, V17, P93, DOI 10.1185/030079901317010720
   Motomura K, 2000, BRIT J SURG, V87, P597, DOI 10.1046/j.1365-2168.2000.01423.x
   NOGUCHI M, 2001, J SURG ONCOL, V77, P149
   Rahusen FD, 2000, SURGERY, V128, P6, DOI 10.1067/msy.2000.107229
   Roumen R M, 2000, Ned Tijdschr Geneeskd, V144, P1864
   Rubio IT, 1998, ANN SURG ONCOL, V5, P689, DOI 10.1007/BF02303478
   Rutgers EJT, 2000, ANN CHIR GYNAECOL FE, V89, P331
   Sauer T, 2003, ACTA CYTOL, V47, P768, DOI 10.1159/000326603
   SPITZ MR, 1992, RECOMMENDATIONS CANC, P11
   Turner RR, 1999, AM J CLIN PATHOL, V112, P627
   Turner RR, 1997, ANN SURG, V226, P271, DOI 10.1097/00000658-199709000-00006
   Veronesi U, 1997, LANCET, V349, P1864, DOI 10.1016/S0140-6736(97)01004-0
   Viale G, 1999, CANCER, V85, P2433, DOI 10.1002/(SICI)1097-0142(19990601)85:11<2433::AID-CNCR18>3.0.CO;2-3
NR 22
TC 4
Z9 4
U1 3
U2 8
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0378-584X
J9 ONKOLOGIE
JI Onkologie
PY 2006
VL 29
IS 8-9
BP 372
EP 375
DI 10.1159/000094409
PG 4
GA 104FX
UT WOS:000241943800004
PM 16974114
DA 2018-12-27
ER

PT J
AU Reuben, SS
   Ekman, EF
   Raghunathan, K
   Steinberg, RB
   Blinder, JL
   Adesioye, J
AF Reuben, SS
   Ekman, EF
   Raghunathan, K
   Steinberg, RB
   Blinder, JL
   Adesioye, J
TI RETRACTED: The effect of cyclooxygenase-2 inhibition on acute and
   chronic donor-site pain after spinal-fusion surgery (Retracted article.
   See vol. 34, pg. 184, 2009)
SO REGIONAL ANESTHESIA AND PAIN MEDICINE
LA English
DT Article; Proceedings Paper; Retracted Publication
CT 79th Clinical and Scientific Congress of the
   International-Anesthesia-Research-Society
CY MAR 11-15, 2005
CL Honolulu, HI
SP Int Anesthesia Res Soc
DE cyclooxygenase-2; celecoxib; donor-site pain; spinal-fusion surgery;
   chronic pain; postoperative pain; preemptive analgesia
ID PERIPHERAL-NERVE INJURY; POSTOPERATIVE PAIN; PROSTAGLANDIN SYNTHESIS;
   PREEMPTIVE ANALGESIA; NEUROPATHIC PAIN; UP-REGULATION; CORD;
   MAINTENANCE; ALLODYNIA; HYPERSENSITIVITY
AB Background and Objectives: The development of chronic pain after spinal-fusion surgery represents a significant source of morbidity. One of the predictive factors for the development of chronic postsurgical pain is inadequate acute postoperative pain management. Further, the up-regulation of cyclooxygenase-2 (COX-2) after surgery may result in neuroplastic changes that may contribute to a progression from acute to chronic pain. The goal of this prospective, randomized, double-blind study was to examine the effect of perioperative COX-2 inhibition on acute and chronic donor-site pain in patients undergoing spinal-fusion surgery.
   Methods: Eighty patients scheduled to undergo instrumented posterior spinal fusion were randomized to either receive celecoxib 400 mg 1 hour before surgery, and then 200 mg every 12 hours after surgery for the first 5 days or receive matching placebo at similar time intervals. Patients were administered morphine via patient-controlled analgesia pump for the first 24 hours, and then acetaminophen and oxycodone tablets. Patients were asked to quantify their average pain on postoperative days 1 to 5. At 1 year after surgery, patients were questioned about the presence and subjective characteristics of any residual donor-site pain.
   Results: Patients administered celecoxib reported lower pain scores and less opioid use during the first 5 postoperative days. Chronic donor-site pain was significantly higher (P < .01) in the placebo group (12 of 40, or 30%) compared with the celecoxib group (4 of 40, or 10%) at 1 year after surgery.
   Conclusions: The administration of celecoxib for the first 5 days after spinal-fusion surgery resulted in improved analgesia and a reduction in chronic donor-site pain at I year after surgery.
C1 Baystate Med Ctr, Dept Anesthesiol & Pain Med, Springfield, MA 01199 USA.
   Tufts Univ, Sch Med, Springfield, MA 01199 USA.
   Parkridge Surg Ctr, Columbia, SC USA.
   Baystate Med Ctr, Dept Anesthesiol, Springfield, MA USA.
RP Reuben, SS (reprint author), Baystate Med Ctr, Dept Anesthesiol & Pain Med, 759 Chestnut St, Springfield, MA 01199 USA.
EM scott.reuben@bhs.org
CR Apfelbaum JL, 2003, ANESTH ANALG, V97, P534, DOI 10.1213/01.ANE.0000068822.10113.9E
   Atkinson JH, 1997, PAIN FORUM, V6, P137
   Bartfai T, 2001, NATURE, V410, P425, DOI 10.1038/35068663
   Beiche F, 1996, FEBS LETT, V390, P165, DOI 10.1016/0014-5793(96)00604-7
   Brennan TJ, 2005, ANESTHESIOLOGY, V103, P681, DOI 10.1097/00000542-200510000-00004
   BUVENANDRAN A, 2004, ANESTHESIOLOGY, V101, pA593
   CODERRE TJ, 1993, PAIN, V52, P259, DOI 10.1016/0304-3959(93)90161-H
   Cousins MJ, 2000, REGION ANESTH PAIN M, V25, P6, DOI 10.1016/S1098-7339(00)80005-X
   Dembo G, 2005, ANESTHESIOLOGY, V102, P409, DOI 10.1097/00000542-200502000-00026
   Dworkin RH, 1997, PAIN FORUM, V6, P148
   FERNYHOUGH JC, 1992, SPINE, V17, P1474, DOI 10.1097/00007632-199212000-00006
   GOLDSTEIN LA, 1974, ATLAS ORTHOPAEDIC SU, P450
   Gottschalk A, 2004, ANESTHESIOLOGY, V101, P1063, DOI 10.1097/00000542-200411000-00004
   Gottschalk A, 2001, AM FAM PHYSICIAN, V63, P1979
   GOULET JA, 1997, CLIN ORTHOP RELAT R, V339, P76, DOI DOI 10.1097/00003086-199706000-00011
   Hefferan MP, 2003, ANESTHESIOLOGY, V99, P1180, DOI 10.1097/00000542-200311000-00027
   Hefferan MP, 2003, PAIN, V101, P139, DOI 10.1016/S0304-3959(02)00322-6
   Kroin JS, 2004, ANESTHESIOLOGY, V100, P364, DOI 10.1097/00000542-200402000-00027
   KURZ LT, 1989, SPINE, V14, P1324, DOI 10.1097/00007632-198912000-00009
   Ma WY, 2002, EUR J NEUROSCI, V15, P1037, DOI 10.1046/j.1460-9568.2002.01940.x
   Ma WY, 2002, BRAIN RES, V937, P94, DOI 10.1016/S0006-8993(02)02593-3
   Macrae WA, 2001, BRIT J ANAESTH, V87, P88, DOI 10.1093/bja/87.1.88
   MCCORMACK K, 1994, PAIN, V59, P9, DOI 10.1016/0304-3959(94)90045-0
   Pellino T, 1998, Orthop Nurs, V17, P48
   Perkins FM, 2000, ANESTHESIOLOGY, V93, P1123, DOI 10.1097/00000542-200010000-00038
   PHILIPS HC, 1987, BEHAV RES THER, V25, P273, DOI 10.1016/0005-7967(87)90005-2
   Reuben SS, 2005, J BONE JOINT SURG AM, V87A, P536, DOI 10.2106/JBJS.D.02283
   Reuben SS, 2001, ANESTHESIOLOGY, V95, P390, DOI 10.1097/00000542-200108000-00021
   REUBEN SS, 2005, ANESTHESIOLOGY, V103, pA1476
   Samad TA, 2002, TRENDS MOL MED, V8, P390, DOI 10.1016/S1471-4914(02)02383-3
   Samad TA, 2001, NATURE, V410, P471, DOI 10.1038/35068566
   SUMMERS BN, 1989, J BONE JOINT SURG BR, V71, P677
   Takeda K, 2005, ANESTHESIOLOGY, V103, P837, DOI 10.1097/00000542-200510000-00023
   Tegeder I, 2001, J NEUROCHEM, V79, P777, DOI 10.1046/j.1471-4159.2001.00613.x
   Vanegas HN, 2001, PROG NEUROBIOL, V64, P327, DOI 10.1016/S0301-0082(00)00063-0
   Vasquez E, 2001, J NEUROSCI, V21, P9001, DOI 10.1523/JNEUROSCI.21-22-09001.2001
   Vlaeyen JWS, 2000, PAIN, V85, P317, DOI 10.1016/S0304-3959(99)00242-0
   Woolf CJ, 2000, SCIENCE, V288, P1765, DOI 10.1126/science.288.5472.1765
   WOOLF CJ, 1993, ANESTH ANALG, V77, P362, DOI 10.1213/00000539-199377020-00026
   YAKSH TL, 1993, AGENT ACTION SUPPL, V41, P89
   YAMAGATA K, 1993, NEURON, V11, P371, DOI 10.1016/0896-6273(93)90192-T
   Zhao Z, 2000, NEUROSCIENCE, V97, P743, DOI 10.1016/S0306-4522(00)00052-X
   Zhu XY, 2005, ANESTH ANALG, V100, P1390, DOI 10.1213/01.ANE.0000148127.53832.8E
   Zhu XY, 2003, ANESTHESIOLOGY, V99, P1175, DOI 10.1097/00000542-200311000-00026
   Zhu XY, 2003, PAIN, V104, P15, DOI 10.1016/S0304-3959(02)00465-7
NR 45
TC 27
Z9 56
U1 3
U2 10
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1098-7339
EI 1532-8651
J9 REGION ANESTH PAIN M
JI Region. Anesth. Pain Med.
PD JAN-FEB
PY 2006
VL 31
IS 1
BP 6
EP 13
DI 10.1016/j.rapm.2005.10.014
PG 8
WC Anesthesiology
SC Anesthesiology
GA 005IL
UT WOS:000234815700003
PM 16418018
DA 2018-12-27
ER

PT J
AU Solowiej, E
   Solowiej, J
   Godlewski, M
   Motyl, T
   Perkowska-Ptasinska, A
   Jaskiewicz, K
   Kasprzycka-Guttman, T
   Rowinski, W
AF Solowiej, E
   Solowiej, J
   Godlewski, M
   Motyl, T
   Perkowska-Ptasinska, A
   Jaskiewicz, K
   Kasprzycka-Guttman, T
   Rowinski, W
TI RETRACTED: Application of sulforaphane: Histopathological study of
   intraportal transplanted pancreatic islets into livers of diabetic rats
   (Retracted Article. See vol 41, pg 2006, 2009)
SO TRANSPLANTATION PROCEEDINGS
LA English
DT Article; Proceedings Paper; Retracted Publication
CT 7th International Congress of the Polish-Transplantation-Society
CY MAY 12-14, 2005
CL Wisla, POLAND
SP Polish Transplantation Soc
AB Background. Islet cell transplantation is a promising method to restore insulin independence to patients with type 1 diabetes mellitus. A main problem in clinical islet transplantation is the fact that only a small percentage of allogeneic islet-transplanted type 1 diabetic patients can completely omit insulin injections after transplantation. One reason for the impaired survival of islet grafts is aberration of the function of islets due to toxic agents, including oxygen radicals and nitric oxide, which arise during warm or cold ischemic time. Therefore, in clinical islet transplantation, islets have been preserved with a mixture of antioxidants to reduce free radical-mediated damage of transplanted beta cells. Our aim was to examine hepatic tissue after metabolic normalization following intraportal islet transplantation after application of sulforaphane.
   Materials and Methods. Islets were isolated from pancreata of WAG rats. Sulforaphane (24 mg/kg) was administered 24 hours before isolated islets were transplanted into the liver through the portal vein (1200 +/- 100 per rat). At 9 months after transplantation the animals were killed and liver tissue removed for morphological examination.
   Results. This report indicated that the intrahepatic portal vein site was indeed an excellent locus for implantation of free pancreatic islets. The islet grafts developed rich vascularization derived from both venous and arterial sources. The islet cells maintained their structural and functional integrity after implantation.
   Conclusion. Our results showed that sulforaphane improved islet function in vivo, indicating that combination of a free radical scavenger and an antioxidant (sulforaphane) may be used to increase the effectiveness of islet transplantation.
C1 Specialist Hosp, Dept Gen & Transplant Surg, Ostroleka, Poland.
   Specialist Hosp, Inst Transplantat, Dept Transplant Med, Ostroleka, Poland.
   Specialist Hosp, Inst Transplantat, Dept Nephrol, Ostroleka, Poland.
   Specialist Hosp, Dept Laryngol, Ostroleka, Poland.
   SGGW, Confocal Lab, Warsaw, Poland.
   Gdansk Med Univ, Dept Pathol, Gdansk, Poland.
   Warsaw Univ, Dept Chem, Warsaw, Poland.
RP Solowiej, E (reprint author), Warsaw Med Univ, Dept Gen & Transplant surg, Ul Nowogrodzka 59, PL-02006 Warsaw, Poland.
EM ewa-solowiej@wp.pl
RI Godlewski, Michal/D-6767-2012
CR Kaneto H, 1999, DIABETES, V48, P2398, DOI 10.2337/diabetes.48.12.2398
   Solowiej Ewa, 2004, Ann Transplant, V9, P68
   Solowiej Ewa, 2003, Acta Pol Pharm, V60, P97
NR 3
TC 6
Z9 8
U1 3
U2 12
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0041-1345
J9 TRANSPL P
JI Transplant. Proc.
PD JAN-FEB
PY 2006
VL 38
IS 1
BP 282
EP 283
DI 10.1016/j.transproceed.2005.11.074
PG 2
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 021AH
UT WOS:000235954200077
PM 16504726
DA 2018-12-27
ER

PT J
AU Flyvbjerg, B
   Holm, MKS
   Buhl, SL
AF Flyvbjerg, B
   Holm, MKS
   Buhl, SL
TI RETRACTED: Inaccuracy in traffic forecasts (Retracted article. See vol.
   32, pg. 265, 2012)
SO TRANSPORT REVIEWS
LA English
DT Article; Retracted Publication
ID TRANSPORT INFRASTRUCTURE PROJECTS; LIE
AB This paper presents results from the first statistically significant study of traffic forecasts in transportation infrastructure projects. The sample used is the largest of its kind, covering 210 projects in 14 nations worth US$58 billion. The study shows with very high statistical significance that forecasters generally do a poor job of estimating the demand for transportation infrastructure projects. The result is substantial downside financial and economic risk. Forecasts have not become more accurate over the 30-year period studied. If techniques and skills for arriving at accurate demand forecasts have improved over time, as often claimed by forecasters, this does not show in the data. For nine out of ten rail projects, passenger forecasts are overestimated; average overestimation is 106%. For 72% of rail projects, forecasts are overestimated by more than two-thirds. For 50% of road projects, the difference between actual and forecasted traffic is more than +/- 20%; for 25% of road projects, the difference is larger than +/- 40%. Forecasts for roads are more accurate and more balanced than for rail, with no significant difference between the frequency of inflated versus deflated forecasts. But for both rail and road projects, the risk is substantial that demand forecasts are incorrect by a large margin. The causes of inaccuracy in forecasts are different for rail and road projects, with political causes playing a larger role for rail than for road. The cure is more accountability and reference class forecasting. Highly inaccurate traffic forecasts combined with large standard deviations translate into large financial and economic risks. But such risks are typically ignored or downplayed by planners and decision-makers, to the detriment of social and economic welfare. The paper presents the data and approach with which planners may begin valid and reliable risk assessment.
C1 Univ Aalborg, Dept Dev & Planning, DK-9220 Aalborg, Denmark.
RP Flyvbjerg, B (reprint author), Univ Aalborg, Dept Dev & Planning, Fibigerstr 11, DK-9220 Aalborg, Denmark.
EM flyvbjerg@plan.aau.dk
CR American Planning Association, 1991, AICP COD ETH PROF CO
   ASCHER W, 1979, FORESCASTING APPRAIS
   BOOKS JA, 1979, HIGHWAY PLANNING DES, P2551
   *DEP TRANSP, 1993, COMP FOR OBS TRAFF T
   Flyvbjerg B, 2004, TRANSPORT REV, V24, P3, DOI 10.1080/0144164032000080494
   Flyvbjerg B, 2003, TRANSPORT REV, V23, P71, DOI 10.1080/0144164022000016667
   Flyvbjerg B, 2002, J AM PLANN ASSOC, V68, P279, DOI 10.1080/01944360208976273
   Flyvbjerg B., 1996, EXPLORATIONS PLANNIN, P383
   Flyvbjerg B., 1998, RATIONALITY POWER DE
   FLYVBJERG B, 2003, MEGAPORJECTS RISK AN
   Fouracre P. R, 1990, 278 TRANSP ROAD RES
   FULLERTON B, 1985, STUDIES MANAGEMENT E, P177
   Garett M., 1996, TRANSPORTATION PLANN
   Gilovich Thomas, 2002, HEURISTICS BIASES PS
   GORDON P, 1984, TRANSPORT RES A-POL, V18, P135, DOI 10.1016/0191-2607(84)90006-2
   Hall P., 1980, GREAT PLANNING DISAS
   KAHNEMAN D, 1994, J INST THEOR ECON, V150, P18
   Kahneman D, 1979, ECONOMETRICA, V47, P313, DOI DOI 10.2307/1914185
   KAIN JF, 1990, J AM PLANN ASSOC, V56, P184, DOI 10.1080/01944369008975758
   Leavitt Dan, 1993, 567 U CAL I URB REG
   LOVALLO D, 2003, HARVARD BUSINESS JUL, P56
   MACKINDER IH, 1981, 699 TRANSP ROAD RES
   Maldonado J., 1990, THESIS MIT CAMBRIDGE
   Mierzejewski E. A., 1995, NEW STRATEGIC URBAN
   *NAT AUD OFF, 1988, DEP TRANSP SCOTT DEV
   *NAT AUD OFF, 1985, DEP TRANSP OFF EXP M
   National Audit Office NAO, 1992, DEP TRANSP CONTR ROA
   Pickrell Don, 1990, URBAN RAIL TRANSIT P
   Richmond J. E. D., 1998, NEW RAIL TRANSIT INV
   Royal Town Planning Institute, 2001, COD PROF COND
   SKAMRIS MK, 1994, 151 AALB U DEP DEV P
   THOMPSON LS, 1993, TR NEWS
   *TRAF FIN SUND BAE, 2002, UDR OK A S OR DANSK
   *VEJDIREKTORATE, 1995, NOT ANL
   WACHS M, 1989, J AM PLANN ASSOC, V55, P476
   Wachs M., 1990, BUSINESS PROFESSIONA, V9, P141, DOI [10.5840/bpej199091/215, DOI 10.5840/BPEJ199091/215]
   Wachs M., 1986, URBAN RESOURCES, V4, P23
   Walmsley D. A, 1992, 352 TRANSP RES LAB
   WEBBER MM, 1976, MONOGRAPH I TRANSPOR, V26
   World Bank, 1986, URB TRANSP WORLD BAN
   World Bank, 1994, WORLD DEV REP 1994 I
   WTSON V, 2003, PLANNING THEOR PRACT, V4, P395
   Yiftachel O., 1998, J PLAN LIT, V12, P395, DOI DOI 10.1177/088541229801200401
NR 43
TC 91
Z9 93
U1 5
U2 19
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 0144-1647
J9 TRANSPORT REV
JI Transp. Rev.
PD JAN
PY 2006
VL 26
IS 1
BP 1
EP 24
DI 10.1080/01441640500124779
PG 24
WC Transportation
SC Transportation
GA 993YA
UT WOS:000233993400001
DA 2018-12-27
ER

PT J
AU Brown, WM
   Cronk, L
   Grochow, K
   Jacobson, A
   Liu, CK
   Popovic, Z
   Trivers, R
AF Brown, WM
   Cronk, L
   Grochow, K
   Jacobson, A
   Liu, CK
   Popovic, Z
   Trivers, R
TI RETRACTED: Dance reveals symmetry especially in young men (Retracted
   article. See vol. 504, pg. 470, 2013)
SO NATURE
LA English
DT Article; Retracted Publication
ID FLUCTUATING ASYMMETRY; DEVELOPMENTAL INSTABILITY; PERFORMANCE;
   ATTRACTIVENESS; STABILITY; PARASITES; FITNESS; SUCCESS
AB Dance is believed to be important in the courtship of a variety of species, including humans, but nothing is known about what dance reveals about the underlying phenotypic - or genotypic quality of the dancer(1-6). One measure of quality in evolutionary studies is the degree of bodily symmetry ( fluctuating asymmetry, FA), because it measures developmental stability(7,8). Does dance quality reveal FA to the observer and is the effect stronger for male dancers than female? To answer these questions, we chose a population that has been measured twice for FA since 1996 (ref. 9) in a society ( Jamaican) in which dancing is important in the lives of both sexes. Motion-capture cameras created controlled stimuli ( in the form of videos) that isolated dance movements from all other aspects of visual appearance ( including FA), and the same population evaluated these videos for dancing ability. Here we report that there are strong positive associations between symmetry and dancing ability, and these associations were stronger in men than in women. In addition, women rate dances by symmetrical men relatively more positively than do men, and more-symmetrical men value symmetry in women dancers more than do less-symmetrical men. In summary, dance in Jamaica seems to show evidence of sexual selection and to reveal important information about the dancer.
C1 Rutgers State Univ, Dept Anthropol, Ctr Human Evolutionary Studies, New Brunswick, NJ 08901 USA.
   Univ Washington, Dept Comp Sci & Engn, Seattle, WA 98195 USA.
RP Brown, WM (reprint author), Rutgers State Univ, Dept Anthropol, Ctr Human Evolutionary Studies, 131 George St, New Brunswick, NJ 08901 USA.
EM wmbrown@rci.rutgers.edu
RI Brown, William/B-5665-2008
OI Brown, William/0000-0001-6875-4296
CR Bronseth T, 1997, CAN J ZOOL, V75, P589, DOI 10.1139/z97-073
   Darwin C., 1871, DESCENT MAN SELECTIO
   GANGESTAD SW, 1994, ETHOL SOCIOBIOL, V15, P73, DOI 10.1016/0162-3095(94)90018-3
   Garland T, 2005, EVOLUTION, V59, P1851
   Grammer K, 2003, EVOLUTIONARY AESTHETICS, P295
   GUMMER DL, 1995, CAN J ZOOL, V73, P990, DOI 10.1139/z95-116
   HAMILTON WD, 1982, SCIENCE, V218, P384, DOI 10.1126/science.7123238
   Hanna Judith Lynne, 1988, DANCE SEX GENDER SIG
   Hughes SM, 2002, EVOL HUM BEHAV, V23, P173, DOI 10.1016/S1090-5138(01)00099-X
   Josefsson T, 1996, COMPUT METH PROG BIO, V49, P119, DOI 10.1016/0169-2607(96)01715-4
   Kellner JR, 2003, AM NAT, V161, P931, DOI 10.1086/375177
   Little AC, 2001, P ROY SOC B-BIOL SCI, V268, P39, DOI 10.1098/rspb.2000.1327
   MANNING JT, 1994, NATURE, V370, P185, DOI 10.1038/370185a0
   Manning JT, 1998, INT J SPORTS MED, V19, P205, DOI 10.1055/s-2007-971905
   Martin J, 2001, PHYSIOL BIOCHEM ZOOL, V74, P619, DOI 10.1086/322925
   Moller A. P., 1997, DEV STABILITY EVOLUT
   Moller AP, 1999, APPL ANIM BEHAV SCI, V62, P57, DOI 10.1016/S0168-1591(98)00213-5
   MOODIE GEE, 1977, CAN J ZOOL, V55, P398, DOI 10.1139/z77-054
   Nagata N, 2004, LECT NOTES COMPUT SC, V3333, P39
   Palmer AR, 1999, AM NAT, V154, P220, DOI 10.1086/303223
   PALMER AR, 1986, ANNU REV ECOL SYST, V17, P391, DOI 10.1146/annurev.es.17.110186.002135
   Polak M., 2003, DEV INSTABILITY CAUS
   Rintamaki PT, 1997, ANIM BEHAV, V54, P265, DOI 10.1006/anbe.1996.0434
   Singer F, 2000, BEHAVIOUR, V137, P93, DOI 10.1163/156853900501890
   Swaddle JP, 1997, BEHAV ECOL, V8, P601, DOI 10.1093/beheco/8.6.601
   Thornhill R, 1999, EVOL HUM BEHAV, V20, P175, DOI 10.1016/S1090-5138(99)00005-7
   Trivers R, 1999, HUM BIOL, V71, P417
   Trivers R. L., 1972, SEXUAL SELECTION DES, P136, DOI DOI 10.1111/J.1420-9101.2008.01540.X
   VANVALEN L, 1962, EVOLUTION, V16, P125
   Waddington C, 1957, STRATEGY GENES
NR 30
TC 100
Z9 102
U1 4
U2 70
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0028-0836
EI 1476-4687
J9 NATURE
JI Nature
PD DEC 22
PY 2005
VL 438
IS 7071
BP 1148
EP 1150
DI 10.1038/nature04344
PG 3
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 995OF
UT WOS:000234111500049
PM 16372008
DA 2018-12-27
ER

PT J
AU Budagian, V
   Bulanova, E
   Orinska, Z
   Thon, L
   Mamat, U
   Bellosta, P
   Basilico, C
   Adam, D
   Paus, R
   Bulfone-Paus, S
AF Budagian, V
   Bulanova, E
   Orinska, Z
   Thon, L
   Mamat, U
   Bellosta, P
   Basilico, C
   Adam, D
   Paus, R
   Bulfone-Paus, S
TI RETRACTED: A promiscuous liaison between IL-15 receptor and Axl receptor
   tyrosine kinase in cell death control (Retracted Article. See vol 30, pg
   627, 2011)
SO EMBO JOURNAL
LA English
DT Article; Retracted Publication
DE fibroblast; Gas6; TNF alpha; transactivation
ID GROWTH-FACTOR RECEPTOR; EXPRESSION ANALYSIS; TYRO-3 FAMILY; ALPHA-CHAIN;
   LIPID RAFTS; TNF-ALPHA; IN-VIVO; B-CELLS; HUMAN-T; GENE 6
AB Discrimination between cytokine receptor and receptor tyrosine kinase (RTK) signaling pathways is a central paradigm in signal transduction research. Here, we report a 'promiscuous liaison' between both receptors that enables interleukin (IL)-15 to transactivate the signaling pathway of a tyrosine kinase. IL-15 protects murine L929 fibroblasts from tumor necrosis factor alpha (TNF alpha)-induced cell death, but fails to rescue them upon targeted depletion of the RTK, Axl; however, Axl-overexpressing fibroblasts are TNF alpha-resistant. IL-15R alpha and Axl colocalize on the cell membrane and co-immunoprecipitate even in the absence of IL-15, whereby the extracellular part of Axl proved to be essential for Axl/IL-15R alpha interaction. Most strikingly, IL-15 treatment mimics stimulation by the Axl ligand, Gas6, resulting in a rapid tyrosine phosphorylation of both Axl and IL-15R alpha, and activation of the phosphatidylinositol 3-kinase/Akt pathway. This is also seen in mouse embryonic fibroblasts from wild-type but not Axl-/- or IL-15R alpha-/- mice. Thus, IL-15-induced protection from TNF alpha-mediated cell death involves a hitherto unknown IL-15 receptor complex, consisting of IL-15R alpha and Axl RTK, and requires their reciprocal activation initiated by ligand-induced IL-15R alpha.
C1 Res Ctr Borstel, Dept Immunol & Cell Biol, D-23845 Borstel, Germany.
   Univ Kiel, Inst Immunol, Kiel, Germany.
   Dept Med Sci, Novara, Italy.
   NYU, Sch Med, Dept Microbiol, New York, NY 10016 USA.
   Univ Lubeck, Dept Dermatol, Lubeck, Germany.
RP Bulfone-Paus, S (reprint author), Res Ctr Borstel, Dept Immunol & Cell Biol, Parkallee 22, D-23845 Borstel, Germany.
EM sbulfone@fz-borstel.de
OI Bellosta, Paola/0000-0003-1913-5661
CR Allen MP, 1999, MOL ENDOCRINOL, V13, P191, DOI 10.1210/me.13.2.191
   Bellosta P, 1997, ONCOGENE, V15, P2387, DOI 10.1038/sj.onc.1201419
   BELLOSTA P, 1995, MOL CELL BIOL, V15, P614
   Bennasroune A, 2004, CRIT REV ONCOL HEMAT, V50, P23, DOI 10.1016/j.critrevonc.2003.08.004
   Brandt K, 2003, BLOOD, V102, P4090, DOI 10.1182/blood-2003-03-0669
   Budagian V, 2005, MOL CELL BIOL, V25, P9324, DOI 10.1128/MCB.25.21.9324-9339.2005
   Bulanova E, 2001, J IMMUNOL, V167, P6292, DOI 10.4049/jimmunol.167.11.6292
   Bulfone-Paus S, 1999, FASEB J, V13, P1575
   BulfonePaus S, 1997, CYTOKINE, V9, P507, DOI 10.1006/cyto.1996.0194
   BulfonePaus S, 1997, NAT MED, V3, P1124, DOI 10.1038/nm1097-1124
   Burchert A, 1998, ONCOGENE, V16, P3177, DOI 10.1038/sj.onc.1201865
   Chen WS, 1999, INT J CANCER, V83, P579, DOI 10.1002/(SICI)1097-0215(19991126)83:5<579::AID-IJC1>3.0.CO;2-R
   Costa M, 1996, J CELL PHYSIOL, V168, P737, DOI 10.1002/(SICI)1097-4652(199609)168:3<737::AID-JCP27>3.0.CO;2-U
   Demarchi F, 2001, J BIOL CHEM, V276, P31738, DOI 10.1074/jbc.M104457200
   FAUST M, 1992, ONCOGENE, V7, P1287
   Fehniger TA, 2001, BLOOD, V97, P14, DOI 10.1182/blood.V97.1.14
   Gallicchio M, 2005, BLOOD, V105, P1970, DOI 10.1182/blood-2004-04-1469
   GIRI JG, 1995, EMBO J, V14, P3654, DOI 10.1002/j.1460-2075.1995.tb00035.x
   Goruppi S, 1997, MOL CELL BIOL, V17, P4442, DOI 10.1128/MCB.17.8.4442
   Goruppi S, 2001, MOL CELL BIOL, V21, P902, DOI 10.1128/MCB.21.3.902-915.2001
   GRAHAM DK, 1994, CELL GROWTH DIFFER, V5, P647
   Gschwind A, 2001, ONCOGENE, V20, P1594, DOI 10.1038/sj.onc.1204192
   Healy AM, 2001, AM J PHYSIOL-LUNG C, V280, pL1273
   Hirota K, 2001, J BIOL CHEM, V276, P25953, DOI 10.1074/jbc.M011021200
   Humphreys DT, 1999, CYTOKINE, V11, P773, DOI 10.1006/cyto.1998.0492
   Jensen JM, 1999, J CLIN INVEST, V104, P1761, DOI 10.1172/JCI5307
   Kumaki S, 1996, EUR J IMMUNOL, V26, P1235, DOI 10.1002/eji.1830260608
   LAI C, 1994, ONCOGENE, V9, P2567
   Lee WP, 2002, ONCOGENE, V21, P329, DOI 10.1038/sj.onc.1205066
   Lin CF, 2005, J BIOL CHEM, V280, P23758, DOI 10.1074/jbc.M412292200
   Lodolce JP, 1998, IMMUNITY, V9, P669, DOI 10.1016/S1074-7613(00)80664-0
   Los M, 2002, MOL BIOL CELL, V13, P978, DOI 10.1091/mbc.01-05-0272
   Lu QX, 1999, NATURE, V398, P723, DOI 10.1038/19554
   Lu QX, 2001, SCIENCE, V293, P306, DOI 10.1126/science.1061663
   MANFIOLETTI G, 1993, MOL CELL BIOL, V13, P4976, DOI 10.1128/MCB.13.8.4976
   MARK MR, 1994, J BIOL CHEM, V269, P10720
   Marmor MD, 2001, BLOOD, V98, P1489, DOI 10.1182/blood.V98.5.1489
   Melaragno MG, 2004, J MOL CELL CARDIOL, V37, P881, DOI 10.1016/j.yjmcc.2004.06.018
   Mera A, 1999, J BIOL CHEM, V274, P15766, DOI 10.1074/jbc.274.22.15766
   Nagata K, 1996, J BIOL CHEM, V271, P30022, DOI 10.1074/jbc.271.47.30022
   OBRYAN JP, 1991, MOL CELL BIOL, V11, P5016, DOI 10.1128/MCB.11.10.5016
   Prenzel N, 2000, BREAST CANCER RES, V2, P184, DOI 10.1186/bcr52
   QUI Y, 1998, NATURE, V393, P83
   Strelow A, 2000, J EXP MED, V192, P601, DOI 10.1084/jem.192.5.601
   THON L, 2005, IN PRESS FASEB J
   Vamosi G, 2004, P NATL ACAD SCI USA, V101, P11082, DOI 10.1073/pnas.0403916101
   Waldmann TA, 1999, ANNU REV IMMUNOL, V17, P19, DOI 10.1146/annurev.immunol.17.1.19
   Yanagita M, 1999, J AM SOC NEPHROL, V10, P2503
NR 48
TC 50
Z9 56
U1 4
U2 11
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0261-4189
EI 1460-2075
J9 EMBO J
JI Embo J.
PD DEC 21
PY 2005
VL 24
IS 24
BP 4260
EP 4270
DI 10.1038/sj.emboj.7600874
PG 11
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 005EJ
UT WOS:000234805100005
PM 16308569
OA Bronze, Green Published
DA 2018-12-27
ER

PT J
AU Asiedu, CK
   Goodwin, KJ
   Balgansuren, G
   Jenkins, SM
   Le Bas-Bernardet, S
   Jargal, U
   Neville, DM
   Thomas, JM
AF Asiedu, CK
   Goodwin, KJ
   Balgansuren, G
   Jenkins, SM
   Le Bas-Bernardet, S
   Jargal, U
   Neville, DM
   Thomas, JM
TI RETRACTED: Elevated T regulatory cells in tolerance in long-term stable
   transplant tolerance in rhesus macaques induced by anti-CD3 immunotoxin
   and deoxyspergualin (Retracted article see vol 177, pg 2023, 2006)
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article; Retracted Publication
ID POLYMERASE-CHAIN-REACTION; IMMUNOLOGICAL SELF-TOLERANCE;
   PERIPHERAL-BLOOD; CUTTING EDGE; ORGAN-TRANSPLANTATION;
   NONHUMAN-PRIMATES; INDUCTION; SUPPRESSION; ACTIVATION; REJECTION
AB Regulatory T cells (Tregs) are implicated in immune tolerance and are variably dependent on IL-10 for in vivo function. Brief peritransplant treatment of multiple nonhuman primates (NHP) with anti-CD3 immunotoxin and deoxyspergualin has induced stable (5-10 years) rejection-free tolerance to MHC-mismatched allografts, which associated with sustained elevations in serum IL-10. In this study, we demonstrate that resting and activated PBMC from long-term tolerant NHP recipients are biased to secrete high levels of IL-10, compared with normal NHP PBMC. Although IL-10-producing CD4(+) Tregs (type I regulatory cells (TR1)/IL-10 Tregs) were undetectable (< 0.5%) in normal rhesus monkeys, 7.5 +/- 1.7% of circulating CD4(+) T cells of tolerant rhesus recipients expressed IL-10. In addition to this > 15-fold increase in Tr1/IL-10 Tregs, the tolerant monkeys exhibited a nearly 3-fold increase in CD4(+)CD25(+) Tregs, 8.1 +/- 3.0% of CD4(+) T cells vs 2.8 +/- 1.4% in normal cohorts (p < 0.02). The frequency of CD4(+)CD25(+)IL-10(+) cells was elevated 5-fold in tolerant vs normal NHP (1.8 +/- 0.9% vs 0.4 +/- 0.2%). Rhesus CD4(+)CD25(+) Tregs exhibited a memory phenotype, and expressed high levels of Foxp3 and CTLA-4 compared with CD4(+)CD25(-) T cells. Also, NRP CD4(+)CD25(+) Tregs proliferated poorly after activation and suppressed proliferation of CD4(+)CD25(-) effector T cells, exhibiting regulatory properties similar to rodent and human CD4(+)CD25(+) Tregs. Of note, depletion of CD4(+)CD25(+) Tregs restored indirect pathway antidonor responses in tolerant NHP. Our study demonstrates an expanded presence of Treg populations in tolerant NHP recipients, suggesting that these adaptations may be involved in maintenance of stable tolerance.
C1 Univ Alabama, Dept Surg, Div Transplant Immunobiol, Birmingham, AL 35294 USA.
   NIH, Mol Biol Lab, Bethesda, MD 20892 USA.
RP Thomas, JM (reprint author), Univ Alabama, Dept Surg, Div Transplant Immunobiol, Birmingham, AL 35294 USA.
FU NIDDK NIH HHS [2 U19 DK057958]; NIAID NIH HHS [U19 AI056542-02]
CR Annacker O, 2001, J IMMUNOL, V166, P3008, DOI 10.4049/jimmunol.166.5.3008
   Asiedu C, 2002, TRANSPLANTATION, V74, P629, DOI 10.1097/01.TP.0000027408.35500.0F
   Asiedu CK, 2003, CELL IMMUNOL, V223, P103, DOI 10.1016/S0008-8749(03)00157-6
   Bashuda H, 2005, J CLIN INVEST, V115, P1896, DOI 10.1172/JCI23743
   Battaglia M, 2004, TRANSPLANTATION, V77, pS16, DOI 10.1097/01.TP.0000106468.96542.26
   Brunkow ME, 2001, NAT GENET, V27, P68, DOI 10.1038/83784
   Chatila TA, 2000, J CLIN INVEST, V106, pR75, DOI 10.1172/JCI11679
   Contreras JL, 1998, TRANSPLANTATION, V65, P1159, DOI 10.1097/00007890-199805150-00003
   Dieckmann D, 2001, J EXP MED, V193, P1303, DOI 10.1084/jem.193.11.1303
   Fontenot JD, 2003, NAT IMMUNOL, V4, P330, DOI 10.1038/ni904
   Game DS, 2003, J AM SOC NEPHROL, V14, P1652, DOI 10.1097/01.ASN.0000067411.03024.A9
   Graca L, 2003, IMMUNOL RES, V28, P181, DOI 10.1385/IR:28:3:181
   Hara M, 2001, J IMMUNOL, V166, P3789, DOI 10.4049/jimmunol.166.6.3789
   Herman AE, 2004, J EXP MED, V199, P1479, DOI 10.1084/jem.20040179
   Hofmann-Lehmann R, 2002, AIDS RES HUM RETROV, V18, P627, DOI 10.1089/088922202760019329
   Hori S, 2003, SCIENCE, V299, P1057, DOI 10.1126/science.1079490
   Huehn J, 2004, J EXP MED, V199, P303, DOI 10.1084/jem.20031562
   Hutchings A, 2003, TRANSPL IMMUNOL, V11, P335, DOI 10.1016/S0966-3274(03)00054-6
   Jiang SP, 2003, AM J TRANSPLANT, V3, P516, DOI 10.1034/j.1600-6143.2003.00124.x
   Jonuleit H, 2001, J EXP MED, V193, P1285, DOI 10.1084/jem.193.11.1285
   Kanmaz T, 2004, TRANSPLANTATION, V77, P914, DOI 10.1097/01.TP.0000116392.72152.75
   Khattri R, 2003, NAT IMMUNOL, V4, P337, DOI 10.1038/ni909
   Kukreja A, 2002, J CLIN INVEST, V109, P131, DOI 10.1172/JCI200213605
   Li Y, 2004, AM J TRANSPLANT, V4, P2118, DOI 10.1111/j.1600-6143.2004.00611.x
   Lobashevsky A, 1999, TISSUE ANTIGENS, V54, P254, DOI 10.1034/j.1399-0039.1999.540306.x
   LOBASHEVSKY A, 2005, HLA 2004 IMMUNOBIOLO
   Lobashevsky AL, 2000, HUM IMMUNOL, V61, P1013, DOI 10.1016/S0198-8859(00)00177-4
   Meloni F, 2004, TRANSPLANTATION, V77, P762, DOI 10.1097/01.TP.0000116565.82752.6B
   Ng WF, 2001, BLOOD, V98, P2736, DOI 10.1182/blood.V98.9.2736
   Oluwole SF, 2003, TRANSPL IMMUNOL, V11, P287, DOI 10.1016/S0966-3274(03)00046-7
   Piccirillo CA, 2004, SEMIN IMMUNOL, V16, P81, DOI 10.1016/j.smim.2003.12.003
   Piccirillo CA, 2001, J IMMUNOL, V167, P1137, DOI 10.4049/jimmunol.167.3.1137
   Pitcher CJ, 2002, J IMMUNOL, V168, P29, DOI 10.4049/jimmunol.168.1.29
   Read S, 2000, J EXP MED, V192, P295, DOI 10.1084/jem.192.2.295
   Roncarolo MG, 2001, IMMUNOL REV, V182, P68, DOI 10.1034/j.1600-065X.2001.1820105.x
   Sakaguchi S, 2000, CELL, V101, P455, DOI 10.1016/S0092-8674(00)80856-9
   Sakaguchi S, 2004, ANNU REV IMMUNOL, V22, P531, DOI 10.1146/annurev.immunol.21.120601.141122
   Salama AD, 2003, J AM SOC NEPHROL, V14, P1643, DOI 10.1097/01.ASN.0000057540.98231.C1
   Shevach EM, 2001, IMMUNOL REV, V182, P58, DOI 10.1034/j.1600-065X.2001.1820104.x
   SHEVACH EM, 2001, J EXP MED, V193, P41
   Suciu-Foca N, 2003, TRANSPL IMMUNOL, V11, P235, DOI 10.1016/S0966-3274(03)00052-2
   Taams LS, 2002, EUR J IMMUNOL, V32, P1621, DOI 10.1002/1521-4141(200206)32:6<1621::AID-IMMU1621>3.0.CO;2-Q
   Thomas JM, 1999, TRANSPLANTATION, V68, P1660, DOI 10.1097/00007890-199912150-00009
   Thomas JM, 2001, DIABETES, V50, P1227, DOI 10.2337/diabetes.50.6.1227
   Thomas JM, 2000, TRANSPLANTATION, V69, P2497, DOI 10.1097/00007890-200006270-00007
   Thompson C, 2004, CURR OPIN PHARMACOL, V4, P408, DOI 10.1016/j.coph.2004.05.001
   Thornton AM, 1998, J EXP MED, V188, P287, DOI 10.1084/jem.188.2.287
   Torrealba JR, 2004, J IMMUNOL, V172, P5753, DOI 10.4049/jimmunol.172.9.5753
   Torrealba JR, 2003, TRANSPLANTATION, V76, P524, DOI 10.1097/01.TP.0000075788.72614.D4
   Vieira PL, 2004, J IMMUNOL, V172, P5986, DOI 10.4049/jimmunol.172.10.5986
   Viglietta V, 2004, J EXP MED, V199, P971, DOI 10.1084/jem.20031579
   Waldmann H, 2004, SEMIN IMMUNOL, V16, P119, DOI 10.1016/j.smim.2003.12.007
   Watkins D I, 1994, Curr Top Microbiol Immunol, V188, P145
   Wise MP, 1998, J IMMUNOL, V161, P5813
   Womer KL, 2001, PHILOS T ROY SOC B, V356, P639, DOI 10.1098/rstb.2001.0843
   Wood KJ, 2003, NAT REV IMMUNOL, V3, P199, DOI 10.1038/nri1027
   Wood KJ, 2004, TRANSPLANTATION, V77, pS6, DOI 10.1097/01.TP.0000106477.70852.29
   Wood KJ, 2001, PHILOS T R SOC B, V356, P665, DOI 10.1098/rstb.2001.0840
   Yamada A, 2001, J IMMUNOL, V167, P5522, DOI 10.4049/jimmunol.167.10.5522
NR 59
TC 24
Z9 28
U1 3
U2 10
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD DEC 15
PY 2005
VL 175
IS 12
BP 8060
EP 8068
DI 10.4049/jimmunol.175.12.8060
PG 9
WC Immunology
SC Immunology
GA 994KJ
UT WOS:000234030400034
PM 16339543
OA Bronze
DA 2018-12-27
ER

PT J
AU Matsuyama, W
   Mitsuyama, H
   Watanabe, M
   Shirahama, Y
   Higashimoto, I
   Osame, M
   Arimura, K
AF Matsuyama, W
   Mitsuyama, H
   Watanabe, M
   Shirahama, Y
   Higashimoto, I
   Osame, M
   Arimura, K
TI RETRACTED: Involvement of discoidin domain receptor 1 in the
   deterioration of pulmonary sarcoidosis (Retracted article. See vol 39,
   pg. 380, 2008)
SO AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY
LA English
DT Article; Retracted Publication
DE chemokines; lung; NF-kappa B; monocyte chemoattractant; protein-1;
   matrix metalloproteinase-9
ID DISCOIDIN DOMAIN RECEPTOR-1; NF-KAPPA-B; MONOCYTE CHEMOATTRACTANT
   PROTEIN-1; BRONCHOALVEOLAR LAVAGE FLUID; INTERSTITIAL LUNG-DISEASES;
   ENDOTHELIAL GROWTH-FACTOR; MATRIX METALLOPROTEINASES; TYROSINE KINASE;
   ALVEOLAR MACROPHAGES; CHEMOKINE PRODUCTION
AB The prognosis of sarcoidosis with pulmonary infiltrates differs in each case, and several cytokines are reported to contribute to its deterioration. However, the detailed mechanism has not been fully elucidated. Discoidin domain receptor 1 (DDR1) is a receptor tyrosine kinase activated by Collagen and associated with cytolkine production from inflammatory cells. We previously reported the functional expression of DDR1 on CD14-positive bronchoalveolar lavage fluid (BALF) cells in vivo. In this study, we hypothesized that DDR1 might be associated with the deterioration of pulmonary sarcoidosis (PS), and investigated 33 patients with sarcoidosis with pulmonary infiltrates, prospectively. We found that patients with deteriorated PS showed significantly higher DDR1 expression in CD14-positive BALF cells predominant with DDR1b isoforms. Activation of DDR1 induced monocyte chemoattractant protein-1 (MCP-1) and matrix metalloproteinase-9 (MMP-9) production in a p38 mitogen-activated protein kinase-dependent manner from CD14-positive BALF cells of patients with deteriorated sarcoidosis. DDR1 activation also induced NF-kappa B nuclear translocation in CD14-positive BALF cells of patients with deteriorated PS. The inhibitor of NF-kappa B inhibited the production of MCP-1 and MMP-9. We propose that DDR1 is associated with the deterioration of pulmonary sarcoidosis.
C1 Kagoshima Univ Hosp, Div Resp Med, Resp & Stress Care Ctr, Kagoshima 8908520, Japan.
RP Matsuyama, W (reprint author), Kagoshima Univ Hosp, Div Resp Med, Resp & Stress Care Ctr, Sakuragaoka 8-35-1, Kagoshima 8908520, Japan.
EM vega@xa2.so-net.ne.jp
CR Aljada A, 1999, J CLIN ENDOCR METAB, V84, P3386, DOI 10.1210/jc.84.9.3386
   Alves F, 2001, FASEB J, V15, P1321
   Ammon C, 2000, IMMUNOLOGY, V100, P364, DOI 10.1046/j.1365-2567.2000.00056.x
   Buisson AC, 1996, J CELL PHYSIOL, V166, P413, DOI 10.1002/(SICI)1097-4652(199602)166:2<413::AID-JCP20>3.0.CO;2-A
   CAR BD, 1994, AM J RESP CRIT CARE, V149, P655, DOI 10.1164/ajrccm.149.3.8118632
   CHARO IF, 1994, P NATL ACAD SCI USA, V91, P2752, DOI 10.1073/pnas.91.7.2752
   Conron M, 2001, AM J RESP CELL MOL, V25, P141, DOI 10.1165/ajrcmb.25.2.4327
   Costabel U, 1999, EUR RESPIR J, V14, P735, DOI 10.1034/j.1399-3003.1999.14d02.x
   Culver DA, 2004, AM J RESP CELL MOL, V30, P1
   Fireman E, 2002, CLIN EXP IMMUNOL, V130, P331, DOI 10.1046/j.1365-2249.2002.t01-1-02001.x
   Fukuda Y, 1998, LAB INVEST, V78, P687
   Grunewald J, 2004, AM J RESP CRIT CARE, V169, P696, DOI 10.1164/rccm.200303-459OC
   Henry MT, 2002, EUR RESPIR J, V20, P1220, DOI 10.1183/09031936.02.00022302
   Hou GP, 2001, J CLIN INVEST, V107, P727, DOI 10.1172/JCI10720
   Hunninghake GW, 1999, AM J RESP CRIT CARE, V160, P736
   IYONAGA K, 1994, HUM PATHOL, V25, P455, DOI 10.1016/0046-8177(94)90117-1
   Iyonaga K, 1998, SARCOIDOSIS VASC DIF, V15, P165
   Kamohara H, 2001, FASEB J, V15, P2724, DOI 10.1096/fj.01-0359fje
   KUNA P, 1992, J EXP MED, V175, P489, DOI 10.1084/jem.175.2.489
   Lemjabbar H, 1999, AM J RESP CELL MOL, V20, P903, DOI 10.1165/ajrcmb.20.5.3260
   Ma W, 2004, J IMMUNOL, V172, P318, DOI 10.4049/jimmunol.172.1.318
   Marra F, 1997, FEBS LETT, V414, P221, DOI 10.1016/S0014-5793(97)01004-1
   Matsuyama W, 2003, J IMMUNOL, V171, P3520, DOI 10.4049/jimmunol.171.7.3520
   Matsuyama W, 2005, J IMMUNOL, V174, P6490, DOI 10.4049/jimmunol.174.10.6490
   Matsuyama W, 2004, J IMMUNOL, V172, P2332, DOI 10.4049/jimmunol.172.4.2332
   Matsuyama W, 2003, FASEB J, V17, P1286, DOI 10.1096/fj.02-0320fje
   Matsuyama W, 2001, J NEUROL SCI, V186, P75, DOI 10.1016/S0022-510X(01)00515-9
   Matsuyama W, 2004, BLOOD, V104, P184, DOI 10.1182/blood-2003-12-4274
   Matsuyama W, 2000, AM J RESP CRIT CARE, V162, P1120, DOI 10.1164/ajrccm.162.3.9911010
   MURPHY G, 1992, AM J RESP CELL MOL, V7, P120, DOI 10.1165/ajrcmb/7.2.120
   Nagase H, 1997, BIOL CHEM, V378, P151
   Newman LS, 1997, NEW ENGL J MED, V336, P1224, DOI 10.1056/NEJM199704243361706
   Oonakahara K, 2004, AM J RESP CELL MOL, V30, P671, DOI 10.1165/rcmb.2003-0340OC
   Petrek M, 2002, EUR RESPIR J, V20, P1206, DOI 10.1183/09031936.02.00289902
   RAGHU G, 1985, AM REV RESPIR DIS, V131, P281
   Ravichandran KS, 2001, ONCOGENE, V20, P6322, DOI 10.1038/sj.onc.1204776
   ROLLINS BJ, 1992, AM J RESP CELL MOL, V7, P126, DOI 10.1165/ajrcmb/7.2.126
   Sakamoto O, 2001, EUR RESPIR J, V17, P969, DOI 10.1183/09031936.01.17509690
   Sharma SK, 2003, AM J RESP CELL MOL, V29, P225, DOI 10.1165/rcmb.2002-0007OC
   Shrivastava A, 1997, MOL CELL, V1, P25, DOI 10.1016/S1097-2765(00)80004-0
   Sugiyama Y, 1997, INTERNAL MED, V36, P856, DOI 10.2169/internalmedicine.36.856
   Suri RM, 1998, J IMMUNOL METHODS, V214, P149, DOI 10.1016/S0022-1759(98)00048-9
   TSUCHIYA S, 1982, CANCER RES, V42, P1530
   Valentonyte R, 2005, NAT GENET, V37, P357, DOI 10.1038/ng1519
   Vogel W, 1997, MOL CELL, V1, P13, DOI 10.1016/S1097-2765(00)80003-9
   VOGEL W, 1999, FASEB J, V13, P77
NR 46
TC 14
Z9 14
U1 3
U2 7
PU AMER THORACIC SOC
PI NEW YORK
PA 61 BROADWAY, FL 4, NEW YORK, NY 10006 USA
SN 1044-1549
J9 AM J RESP CELL MOL
JI Am. J. Respir. Cell Mol. Biol.
PD DEC
PY 2005
VL 33
IS 6
BP 565
EP 573
DI 10.1165/rcmb.2005-0236OC
PG 9
WC Biochemistry & Molecular Biology; Cell Biology; Respiratory System
SC Biochemistry & Molecular Biology; Cell Biology; Respiratory System
GA 990FG
UT WOS:000233728000006
PM 16166739
DA 2018-12-27
ER

PT J
AU Tamiolakis, D
   Papadopoulos, N
   Venizelos, J
   Lambropoulou, M
   Tsikouras, P
   Koutsougeras, G
   Bolioti, S
   Tsiapali, M
   Menegaki, M
   Kouskoukis, C
AF Tamiolakis, D
   Papadopoulos, N
   Venizelos, J
   Lambropoulou, M
   Tsikouras, P
   Koutsougeras, G
   Bolioti, S
   Tsiapali, M
   Menegaki, M
   Kouskoukis, C
TI RETRACTED: NCL-CD30 staining of epithelial cells in the basal
   germinative layer of the epidermis and epithelial buds during foetal
   skin development (Retracted Article. See vol 10, pg 273, 2010)
SO CLINICAL AND EXPERIMENTAL MEDICINE
LA English
DT Article; Retracted Publication
DE NCL-CD30 antigen; human foetal skin; gestation; immunohistochemistry;
   Northern blotting
ID GROWTH-FACTOR-RECEPTOR; HODGKINS-DISEASE; CD30 ANTIGEN; EMBRYONAL
   CARCINOMA; LYMPHOID-CELLS; KI-1 ANTIGEN; EXPRESSION; MOLECULE; TUMORS;
   DIAGNOSIS
AB The fact that the CD30 molecule can mediate signals for cell proliferation or apoptosis prompted us to perform a systematic investigation of CD30 antigen expression in embryonal tissues during proliferation and differentiation stages. We first targeted the foetal human intestinal cryptae cells with positive results. The epidermis is a dynamic epithelium that is constantly renewed throughout life. The basal layer, attached to the basement membrane, contains the dividing cells of the skin and as cells move up from this layer they undergo differentiation, ending in the formation of a terminally differentiated anucleate cell called squame. It is intriguing to find out if cells in the basal layer can express the CD30 antigen. We investigated the immunohistochemical expression of CD30 antigen in 15 paraffin-embedded tissue samples representing epidermis and epidermal buds from foetuses after spontaneous abortion in the 8th, 10th and 12th weeks of gestation, respectively, using the monoclonal antibody NCL-CD30. A Northern blotting analysis was additionally performed. The results showed that: (1) the epithelial cells of the epidermis in the developing skin express the CD30 antigen; (2) CD30 expression in these epithelial cells is higher in cases of hormonal administration than in normal gestation; (3) a similar positive reaction involved the epidermal buds associated with the development of the skin appendages. Northern blots of tissue sections using a CD30 cDNA probe detected mRNAs of the same molecular mass and variety similarly to those in the positive control cell line HUT 102.
C1 Democritus Univ Thrace, Dept Histol Embryol, Alexandroupolis 68100, Greece.
   GenHosp Chania, Dept Cytol, Iraklion, Greece.
   Democritus Univ Thrace, Dept Obstet & Gynecol, Thessaloniki, Greece.
   Gen Hosp Alexandroupolis, Dept Obstet & Gynecol, Alexandroupolis, Greece.
   Democritus Univ Thrace, Dept Dermatol, Alexandroupolis, Greece.
RP Papadopoulos, N (reprint author), Democritus Univ Thrace, Dept Histol Embryol, Alexandroupolis 68100, Greece.
EM npapad@med.duth.gr
CR ANDREESEN R, 1989, AM J PATHOL, V134, P187
   DEPERALTAVENTURINA MN, 1994, AM J CLIN PATHOL, V102, P402, DOI 10.1093/ajcp/102.4.402
   Durkop H, 2000, J PATHOL, V190, P613
   DURKOP H, 1992, CELL, V68, P421, DOI 10.1016/0092-8674(92)90180-K
   Ekstrom ES, 2001, PLACENTA, V22, P372, DOI 10.1053/plac.2000.0619
   ELLIS TM, 1993, J IMMUNOL, V151, P2380
   FALINI B, 1995, BLOOD, V85, P1
   FERREIRO JA, 1994, HUM PATHOL, V25, P522, DOI 10.1016/0046-8177(94)90125-2
   FUCHS E, 1994, CURR OPIN GENET DEV, V4, P725, DOI 10.1016/0959-437X(94)90140-X
   Garcia-Prats MD, 1998, HISTOPATHOLOGY, V32, P462
   Hittmair A, 1996, HUM PATHOL, V27, P1166, DOI 10.1016/S0046-8177(96)90310-X
   Horie R, 1999, AM J PATHOL, V155, P2029, DOI 10.1016/S0002-9440(10)65522-8
   HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661
   ITO K, 1994, AM J PATHOL, V145, P276
   LATZA U, 1995, AM J PATHOL, V146, P463
   MECHTERSHEIMER G, 1990, CANCER, V66, P1732, DOI 10.1002/1097-0142(19901015)66:8<1732::AID-CNCR2820660815>3.0.CO;2-5
   NADALI G, 1995, J CLIN ONCOL, V13, P1355, DOI 10.1200/JCO.1995.13.6.1355
   PALLESEN G, 1990, HISTOPATHOLOGY, V16, P409, DOI 10.1111/j.1365-2559.1990.tb01151.x
   PALLESEN G, 1988, AM J PATHOL, V133, P446
   Papadopoulos N., 2001, Clinical and Experimental Obstetrics and Gynecology, V28, P225
   Polski JM, 1999, MODERN PATHOL, V12, P903
   RUDOLPH P, 1993, HISTOPATHOLOGY, V23, P173, DOI 10.1111/j.1365-2559.1993.tb00476.x
   SCHWAB U, 1982, NATURE, V299, P65, DOI 10.1038/299065a0
   SCHWARTING R, 1989, BLOOD, V74, P1678
   SOHAIL D, 1991, HISTOPATHOLOGY, V18, P191, DOI 10.1111/j.1365-2559.1991.tb01471.x
   STEIN H, 1985, BLOOD, V66, P848
   Suster S, 1998, HUM PATHOL, V29, P737, DOI 10.1016/S0046-8177(98)90284-2
   Tamiolakis D, 2005, THEOR BIOL MED MODEL, V2, DOI 10.1186/1742-4682-2-1
   Trovato M, 2001, THYROID, V11, P621, DOI 10.1089/105072501750362682
NR 29
TC 4
Z9 4
U1 3
U2 7
PU SPRINGER-VERLAG ITALIA SRL
PI MILAN
PA VIA DECEMBRIO, 28, MILAN, 20137, ITALY
SN 1591-8890
EI 1591-9528
J9 CLIN EXP MED
JI Clin. Exper. Med.
PD DEC
PY 2005
VL 5
IS 4
BP 184
EP 189
DI 10.1007/s10238-005-0084-1
PG 6
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA 994TK
UT WOS:000234053900006
PM 16362798
DA 2018-12-27
ER

PT J
AU Desa, K
   Sustic, A
   Zupan, Z
   Krstulovic, B
   Golubovic, V
AF Desa, K
   Sustic, A
   Zupan, Z
   Krstulovic, B
   Golubovic, V
TI RETRACTED: Evaluation of single intensive care unit performance by
   simplified acute physiology score II system (Retracted Article. See vol
   49, pg 421, 2008)
SO CROATIAN MEDICAL JOURNAL
LA English
DT Article; Retracted Publication
ID OUTCOME PREDICTION MODELS; SAPS-II; MULTICENTER; MORTALITY; DATABASE;
   COHORT
AB Aim To evaluate effectiveness and quality of care in a single intensive care unit(ICU) by the Simplified Acute Physiology Score II (SAPS II).
   Methods A prospective study included 395 patients from the ICU at Rijeka University Hospital, Croatia. The sum of the SAPS II points was used for calculating predicted mortality for each patient. The observed death rate was compared with predicted mortality calculated by SAPS II system. The ability of the SAPS II prognostic system to predict probability of hospital mortality was assessed with discrimination (receiver operating characteristic [ROC] curve) and calibration (Hosmer-Lemeshow test) measures.
   Results The SAPS II score on the first ICU day was low (median, 20; range, 3-83). SAPS II system showed a good ability to separate the patients predicted to live from those predicted to die, as shown by an area under the ROC curve of 0.827. The calibration curve demonstrated under-prediction of the actual death rate (Hosmer-Lemeshow goodness-of-fit test, C=22.961; df=8; P=0.003). The observed mortality was higher than predicted (observed-to-predicted ratio was 1.6).
   Conclusions SAPS II system is a useful too[ for the assessment of ICU performance. This system demonstrated a good ability of discrimination, but an under-prediction of the actual mortality rate in our ICU.
C1 Univ Hosp Rijeka, Dept Anesthesiol & Intens Care, Rijeka 51000, Croatia.
RP Desa, K (reprint author), Univ Hosp Rijeka, Dept Anesthesiol & Intens Care, Tome Striz 3, Rijeka 51000, Croatia.
EM kristi@medri.hr
RI Zupan, Zeljko/S-2786-2018
OI Zupan, Zeljko/0000-0003-4576-7961
CR Apolone G, 1996, INTENS CARE MED, V22, P1368, DOI 10.1007/BF01709553
   Bastos PG, 1996, INTENS CARE MED, V22, P664, DOI 10.1007/BF01709743
   Bertolini G, 1998, MED CARE, V36, P1371, DOI 10.1097/00005650-199809000-00009
   CIVETTA JM, 1990, ANN SURG, V212, P266, DOI 10.1097/00000658-199009000-00005
   Civetta Joseph M., 1997, P3
   Glance LG, 2000, CHEST, V117, P1112, DOI 10.1378/chest.117.4.1112
   Gunning K, 1999, BRIT MED J, V319, P241, DOI 10.1136/bmj.319.7204.241
   Krishnagopalan S, 2002, CRIT CARE MED, V30, P2588, DOI 10.1097/01.CCM.0000034455.71412.8C
   LEGALL JR, 1993, JAMA-J AM MED ASSOC, V270, P2957, DOI 10.1001/jama.270.24.2957
   Livingston BM, 2000, CRIT CARE MED, V28, P1820, DOI 10.1097/00003246-200006000-00023
   Metnitz PGH, 1999, INTENS CARE MED, V25, P192, DOI 10.1007/s001340050815
   Moreno R, 1998, INTENS CARE MED, V24, P40, DOI 10.1007/s001340050513
   Moreno R, 1997, INTENS CARE MED, V23, P177, DOI 10.1007/s001340050313
   Moreno R, 1998, CRIT CARE MED, V26, P50, DOI 10.1097/00003246-199801000-00016
   Nouira S, 1998, CRIT CARE MED, V26, P852, DOI 10.1097/00003246-199805000-00016
   RAPOPORT J, 1995, CRIT CARE MED, V23, P1336, DOI 10.1097/00003246-199508000-00006
   Tan I. K. S., 1998, Annals Academy of Medicine Singapore, V27, P318
   Teres D, 1999, INTENS CARE MED, V25, P140, DOI 10.1007/s001340050806
   Vosylius S, 2004, EUR J ANAESTH, V21, P619, DOI 10.1017/S0265021504008063
   Zimmerman JE, 2000, CRIT CARE MED, V28, P258, DOI 10.1097/00003246-200001000-00048
NR 20
TC 4
Z9 5
U1 1
U2 6
PU MEDICINSKA NAKLADA
PI ZAGREB
PA VLASKA 69, HR-10000 ZAGREB, CROATIA
SN 0353-9504
EI 1332-8166
J9 CROAT MED J
JI Croat. Med. J.
PD DEC
PY 2005
VL 46
IS 6
BP 964
EP 969
PG 6
WC Medicine, General & Internal
SC General & Internal Medicine
GA 997RQ
UT WOS:000234265400014
PM 16342351
OA DOAJ Gold
DA 2018-12-27
ER

PT J
AU Ogawa, S
   Oishi, H
   Mezaki, Y
   Kouzu-Fujita, M
   Matsuyama, R
   Nakagomi, M
   Mori, E
   Murayama, E
   Nagasawa, H
   Kitagawa, H
   Yanagisawa, J
   Yano, T
   Kato, S
AF Ogawa, S
   Oishi, H
   Mezaki, Y
   Kouzu-Fujita, M
   Matsuyama, R
   Nakagomi, M
   Mori, E
   Murayama, E
   Nagasawa, H
   Kitagawa, H
   Yanagisawa, J
   Yano, T
   Kato, S
TI RETRACTED: Repressive domain of unliganded human estrogen receptor alpha
   associates with Hsc70 (Retracted article. See vol. 18, pg. 1145, 2013)
SO GENES TO CELLS
LA English
DT Article; Retracted Publication
ID NUCLEAR RECEPTOR; TRANSCRIPTIONAL ACTIVATION; HISTONE ACETYLTRANSFERASE;
   COACTIVATOR COMPLEX; IDENTIFICATION; SUPERFAMILY; COREPRESSOR;
   PROTEASOME; ANTAGONISM; INTERACTS
AB Estrogen receptor (ER) is a hormone-inducible transcription factor as a member of the nuclear receptor gene superfamily. Unliganded ER is transcriptionally silent and capable of DNA binding; however, it is unable to suppress the basal activity of the target gene promoters, unlike non-steroid hormone receptors that associate with corepressors in the absence of their cognate ligands. To study the molecular basis of how unliganded human ER alpha is maintained silent in gene regulation upon the target gene promoters, we biochemically searched interactants for hER alpha, and identified heat shock protein 70 (Hsc70). Hsc70 appeared to associate with the N-terminal hormone binding E domain, that also turned out a transcriptionally repressive domain. Competitive association of Hsc70 with a best known coactivator p300 was observed. Thus, these findings suggest that Hsc70 associates with unliganded hER alpha, and thereby deters hER alpha from recruiting transcriptional coregulators, presumably as a component of chaperone complexes.
C1 Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo 1130032, Japan.
   Univ Tokyo, Grad Sch Agr & Life Sci, Dept Appl Biol Chem, Bunkyo Ku, Tokyo 1130032, Japan.
   Univ Tokyo, Dept Obstet & Gynecol, Bunkyo Ku, Tokyo 1138655, Japan.
   Japan Sci & Technol Agcy, ERATO, Kawaguchi, Saitama 3320012, Japan.
RP Kato, S (reprint author), Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 1130032, Japan.
EM uskato@mail.ecc.u-tokyo.ac.jp
CR Alberti S, 2002, J BIOL CHEM, V277, P45920, DOI 10.1074/jbc.M204196200
   Ballinger CA, 1999, MOL CELL BIOL, V19, P4535
   Belandia B, 2003, CELL, V114, P277, DOI 10.1016/S0092-8674(03)00599-3
   Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4
   Ciana P, 2003, NAT MED, V9, P82, DOI 10.1038/nm809
   Couse JF, 1999, ENDOCR REV, V20, P358, DOI 10.1210/er.20.3.358
   Endoh H, 1999, MOL CELL BIOL, V19, P5363
   Fondell JD, 1996, P NATL ACAD SCI USA, V93, P8329, DOI 10.1073/pnas.93.16.8329
   Freedman LP, 1999, CELL, V97, P5, DOI 10.1016/S0092-8674(00)80708-4
   Glass CK, 2000, GENE DEV, V14, P121
   Ito S, 2004, GENES CELLS, V9, P983, DOI 10.1111/j.1365-2443.2004.00777.x
   Jepsen K, 2000, CELL, V102, P753, DOI 10.1016/S0092-8674(00)00064-7
   Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6
   Kitagawa H, 2003, CELL, V113, P905, DOI 10.1016/S0092-8674(03)00436-7
   Kobayashi Y, 2000, J BIOL CHEM, V275, P15645, DOI 10.1074/jbc.M000042200
   KUMAR V, 1987, CELL, V51, P941, DOI 10.1016/0092-8674(87)90581-2
   KUROKAWA R, 1995, NATURE, V377, P451, DOI 10.1038/377451a0
   MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X
   McKenna NJ, 2002, CELL, V108, P465, DOI 10.1016/S0092-8674(02)00641-4
   Metivier R, 2003, CELL, V115, P751, DOI 10.1016/S0092-8674(03)00934-6
   Naar AM, 1999, NATURE, V398, P828
   Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4
   ONATE SA, 1995, SCIENCE, V270, P1354
   PICARD D, 1990, NATURE, V348, P166, DOI 10.1038/348166a0
   Rachez C, 1999, NATURE, V398, P824
   Shiau AK, 2002, NAT STRUCT BIOL, V9, P359, DOI 10.1038/nsb787
   Spencer TE, 1997, NATURE, V389, P194
   Takeyama KI, 1999, MOL CELL BIOL, V19, P1049
   Tateishi Y, 2004, EMBO J, V23, P4813, DOI 10.1038/sj.emboj.7600472
   TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7
   Watanabe M, 2001, EMBO J, V20, P1341, DOI 10.1093/emboj/20.6.1341
   Wu YL, 2005, MOL CELL, V18, P413, DOI 10.1016/j.molcel.2005.04.014
   Yamamoto Y, 2001, J BIOL CHEM, V276, P42684, DOI 10.1074/jbc.M107844200
   Yanagisawa J, 2002, MOL CELL, V9, P553, DOI 10.1016/S1097-2765(02)00478-1
   Yanagisawa J, 1999, SCIENCE, V283, P1317, DOI 10.1126/science.283.5406.1317
   YLIKOMI T, 1992, EMBO J, V11, P3681, DOI 10.1002/j.1460-2075.1992.tb05453.x
   Yuan CX, 1998, P NATL ACAD SCI USA, V95, P7939, DOI 10.1073/pnas.95.14.7939
NR 37
TC 14
Z9 14
U1 2
U2 15
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1356-9597
EI 1365-2443
J9 GENES CELLS
JI Genes Cells
PD DEC
PY 2005
VL 10
IS 12
BP 1095
EP 1102
DI 10.1111/j.1365-2443.2005.00904.x
PG 8
WC Cell Biology; Genetics & Heredity
SC Cell Biology; Genetics & Heredity
GA 988UK
UT WOS:000233626300001
PM 16324147
OA Bronze
DA 2018-12-27
ER

PT J
AU Roosta, SH
AF Roosta, SH
TI RETRACTED: A new model for distributed database systems (Retracted
   Article. See vol 83, pg 371, 2006)
SO INTERNATIONAL JOURNAL OF COMPUTER MATHEMATICS
LA English
DT Article; Retracted Publication
DE distributed databases; non-linear and integer programming; table; query
   processing
ID OPTIMIZATION; QUERIES
AB A model is developed for allocating tables in a distributed database system. The model considers memory cost, transmission cost, table size and request rates, as well as updating rates of tables. the maximum allowable expected access times to tables at each computer and the memory capacity of each computer. The objective function is concerned with overall operating cost optimality. In this regard, the model is formulated as a non-linear integer zero-one programming problem, which can be converted into a linear zero-one programming model.
C1 Univ S Carolina, Dept Math & Comp Sci, Spartanburg, SC 29303 USA.
RP Roosta, SH (reprint author), Univ S Carolina, Dept Math & Comp Sci, Spartanburg, SC 29303 USA.
EM sroosta@uscs.edu
CR Benetis R, 2002, IDEAS 2002: INTERNATIONAL DATABASE ENGINEERING AND APPLICATIONS SYMPOSIUM, PROCEEDINGS, P44, DOI 10.1109/IDEAS.2002.1029655
   BERCHTOLD S, 2001, P INT C DAT THEOR IC, P435
   Bohm C, 2000, ACM T DATABASE SYST, V25, P129, DOI 10.1145/357775.357776
   CALVERT JE, 1989, LINEAR PROGRAMMING
   Ceri S., 1984, DISTRIBUTED DATABASE
   Chaudhuri S, 1999, ACM T DATABASE SYST, V24, P177, DOI 10.1145/320248.320249
   Fegaras L, 2000, ACM T DATABASE SYST, V25, P457, DOI 10.1145/377674.377676
   Kossmann D, 2000, ACM T DATABASE SYST, V25, P43, DOI 10.1145/352958.352982
   SAATY TL, 1961, ELEMENTS QUEUING THE, P153
   Wolfson O, 1997, ACM T DATABASE SYST, V22, P255, DOI 10.1145/249978.249982
   Zhang AD, 2001, IEEE T KNOWL DATA EN, V13, P439, DOI 10.1109/69.929901
NR 11
TC 0
Z9 0
U1 2
U2 5
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0020-7160
EI 1029-0265
J9 INT J COMPUT MATH
JI Int. J. Comput. Math.
PD DEC
PY 2005
VL 82
IS 12
BP 1447
EP 1454
DI 10.1080/00204160512331331084
PG 8
WC Mathematics, Applied
SC Mathematics
GA 000WP
UT WOS:000234493400002
DA 2018-12-27
ER

PT J
AU Perry, LG
   Thelen, GC
   Ridenour, WM
   Weir, TL
   Callaway, RM
   Paschke, MW
   Vivanco, JM
AF Perry, LG
   Thelen, GC
   Ridenour, WM
   Weir, TL
   Callaway, RM
   Paschke, MW
   Vivanco, JM
TI RETRACTED: Dual role for an allelochemical: (+/-)-catechin from
   Centaurea maculosa root exudates regulates conspecific seedling
   establishment (Retracted article. See vol. 104, pg. 1210, 2016)
SO JOURNAL OF ECOLOGY
LA English
DT Article; Retracted Publication
DE allelopathy; autoinhibition; autotoxicity; chemical interference;
   intraspecific competition; invasive species; population density;
   seedling recruitment; spotted knapweed
ID SPOTTED KNAPWEED; EXOTIC INVASION; DESERT SHRUBS; FOREST SOIL; PLANT;
   COMMUNICATION; GERMINATION; ALLELOPATHY; NITRIFICATION; AUTOTOXICITY
AB 1 Plant allelopathic compounds may have other roles than interspecific interference. We investigated whether (+/-)-catechin, a phytotoxin exuded from the roots of the exotic invader Centaurea maculosa (spotted knapweed), is also one of the factors that regulates C. maculosa recruitment.
   2 Adding activated carbon, which adsorbs organic compounds, to soil around C. maculosa adults in the field increased seedling density by 78% 25 days after sowing, and by 34% 32 days after sowing, suggesting that soil-borne compounds inhibited or delayed recruitment.
   3 Analysis of field soils near mature C. maculosa revealed that they can contain exceptionally high (+/-)-catechin concentrations (mean = 1.55 mg g(-1) dry soil, with 60% of samples containing >= 1.0 mg (+/-)-catechin g(-1)).
   4 In laboratory experiments, treatment with >= 1.0 mg (+/-)-catechin mL(-1) reduced seedling root elongation by > 50%, indicating that field concentrations are sufficient to inhibit C. maculosa recruitment. Provided that 10% methanol was used to maintain (+/-)-catechin in solution for > 1 day, treatment with >= 1.0 mg mL(-1) also reduced C. maculosa germination by > 70%.
   5 (+/-)-Catechin maintained in solution with methanol did not significantly reduce C. maculosa seed survival, suggesting that inhibition of germination was due, at least in part, to delayed germination rather than to seed mortality.
   6 Depending on the solubility of (+/-)-catechin in soil and on the duration of its effects on recruitment, C. maculosa may avoid intraspecific competition or regulate the timing of seedling establishment by reducing seedling growth or postponing germination in response to its own phytotoxin.
   7 Chemical regulation of C. maculosa recruitment, as demonstrated here, suggests a dual role of (+/-)-catechin as an allelochemical and an autoinhibitor. The potential for a single plant root exudate to influence both inter- and intraspecific interactions emphasizes the complex effects that plant secondary metabolites may have on plant population and community structure.
C1 Colorado State Univ, Dept Hort & Landscape Architecture, Ft Collins, CO 80523 USA.
   Colorado State Univ, Ctr Rhizosphere Biol, Ft Collins, CO 80523 USA.
   Colorado State Univ, Dept Rangeland & Watershed Stewardship, Ft Collins, CO 80523 USA.
   Univ Montana, Div Biol Sci, Missoula, MT 59812 USA.
RP Vivanco, JM (reprint author), Colorado State Univ, Dept Hort & Landscape Architecture, Ft Collins, CO 80523 USA.
EM j.vivanco@colostate.edu
RI Paschke, Mark/E-3799-2013
OI Paschke, Mark/0000-0002-6345-5905; Perry, Laura/0000-0003-2796-868X
CR Bais HP, 2002, PLANT PHYSIOL, V128, P1173, DOI 10.1104/pp.011019
   Bais HP, 2003, SCIENCE, V301, P1377, DOI 10.1126/science.1083245
   BALDWIN IT, 2003, SCI STKE, pPE42
   BOGGS KW, 1987, WEED SCI, V35, P194
   Callaway RM, 2000, SCIENCE, V290, P521, DOI 10.1126/science.290.5491.521
   CALLAWAY RM, 2004, FRONTIERS ECOLOGY EN, V2, P433
   Czarnota MA, 2001, WEED TECHNOL, V15, P813, DOI 10.1614/0890-037X(2001)015[0813:MOALOP]2.0.CO;2
   DAVIS ES, 1993, WEED SCI, V41, P57
   Dyer AR, 2004, PLANT ECOL, V172, P211, DOI 10.1023/B:VEGE.0000026339.61069.33
   Falik O, 2003, J ECOL, V91, P525, DOI 10.1046/j.1365-2745.2003.00795.x
   GRABE DF, 1970, CONTRIBUTION, V29
   Hierro JL, 2005, J ECOL, V93, P5, DOI 10.1111/j.1365-2745.2004.00953.x
   Holzapfel C, 2003, OECOLOGIA, V134, P72, DOI 10.1007/s00442-002-1062-x
   Iqbal Z, 2003, WEED SCI, V51, P657, DOI 10.1614/0043-1745(2003)051[0657:AAOBIA]2.0.CO;2
   Jacobs JS, 1998, J RANGE MANAGE, V51, P665, DOI 10.2307/4003610
   Kraus TEC, 2004, SOIL BIOL BIOCHEM, V36, P309, DOI 10.1016/j.soilbio.2003.10.006
   MAHALL BE, 1991, P NATL ACAD SCI USA, V88, P874, DOI 10.1073/pnas.88.3.874
   MAHALL BE, 1992, ECOLOGY, V73, P2145, DOI 10.2307/1941462
   Mahall BE, 1996, AM J BOT, V83, P93, DOI 10.2307/2445959
   MCCORMICK J, 1968, VIA1 U PENNS GRAD SC, P22
   MCNAUGHTON SJ, 1968, ECOLOGY, V49, P367, DOI 10.2307/1934475
   MULLERSCHARER H, 1993, PESTIC SCI, V37, P343, DOI 10.1002/ps.2780370407
   MURASHIGE T, 1962, PHYSIOL PLANTARUM, V15, P476
   NILSSON MC, 1993, CAN J BOT, V71, P620, DOI 10.1139/b93-071
   Paavolainen L, 1998, PLANT SOIL, V205, P147, DOI 10.1023/A:1004335419358
   PICMAN J, 1984, BIOCHEM SYST ECOL, V12, P287, DOI 10.1016/0305-1978(84)90051-6
   POWELL RD, 1990, J ECOL, V78, P374, DOI 10.2307/2261118
   Preston CA, 1999, ECOLOGY, V80, P481, DOI 10.1890/0012-9658(1999)080[0481:PANSRG]2.0.CO;2
   RICE EL, 1973, AM J BOT, V60, P691, DOI 10.2307/2441448
   Ridenour WM, 2001, OECOLOGIA, V126, P444, DOI 10.1007/s004420000533
   Schenck J, 1999, ADV ECOL, V28, P145
   SCHIRMAN R, 1981, J RANGE MANAGE, V34, P45, DOI 10.2307/3898452
   Siemens DH, 2002, ECOLOGY, V83, P505, DOI 10.2307/2680031
   Singh HP, 1999, CRIT REV PLANT SCI, V18, P757, DOI 10.1016/S0735-2689(99)00399-8
   Sokal RR, 1995, BIOMETRY
   Story JM, 2001, WEED TECHNOL, V15, P750, DOI 10.1614/0890-037X(2001)015[0750:RAGAOS]2.0.CO;2
   *USDA NRCS USFS US, 1995, SOIL SURV MISS COUNT
   Veluri R, 2004, J AGR FOOD CHEM, V52, P1077, DOI 10.1021/jf040453d
   Vivanco JM, 2004, ECOL LETT, V7, P285, DOI 10.1111/j.1461-0248.2004.00576.x
   Wardle DA, 1998, BIOL REV, V73, P305, DOI 10.1017/S0006323198005192
   WARNER RR, 1985, AM NAT, V125, P769, DOI 10.1086/284379
   WATSON AK, 1974, CAN J PLANT SCI, V54, P687, DOI 10.4141/cjps74-118
   WEBB LJ, 1967, J APPL ECOL, V4, P13, DOI 10.2307/2401406
   Weir TL, 2004, J CHEM ECOL, V30, P2575, DOI 10.1007/s10886-004-0204-5
   Weir TL, 2004, CURR OPIN PLANT BIOL, V7, P472, DOI 10.1016/j.pbi.2004.05.007
   WEIR TL, 2003, J CHEM ECOL, V29, P2379
   WHITTAKER RH, 1971, SCIENCE, V171, P757, DOI 10.1126/science.171.3973.757
NR 47
TC 91
Z9 95
U1 4
U2 61
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0022-0477
EI 1365-2745
J9 J ECOL
JI J. Ecol.
PD DEC
PY 2005
VL 93
IS 6
BP 1126
EP 1135
DI 10.1111/j.1365-2745.2005.01044.x
PG 10
WC Plant Sciences; Ecology
SC Plant Sciences; Environmental Sciences & Ecology
GA 984FI
UT WOS:000233287500009
OA Bronze
DA 2018-12-27
ER

PT J
AU Yao, ZQ
   Waggoner, SN
   Cruise, MW
   Hall, C
   Xie, XF
   Oldach, DW
   Hahn, YS
AF Yao, ZQ
   Waggoner, SN
   Cruise, MW
   Hall, C
   Xie, XF
   Oldach, DW
   Hahn, YS
TI RETRACTED: SOCS1 and SOCS3 are targeted by hepatitis C virus core/gC1qR
   ligation to inhibit T-cell function (Retracted Article. See vol 80, pg
   8287, 2006)
SO JOURNAL OF VIROLOGY
LA English
DT Article; Retracted Publication
ID CYTOKINE SIGNALING SOCS; CORE PROTEIN; LISTERIA-MONOCYTOGENES;
   REGULATORY PATHWAY; SUPPRESSOR; INFECTION; RECEPTOR; ACTIVATION;
   RESPONSES; LIVER
AB T cells play an important role in the control of hepatitis C virus (HCV) infection. We have previously demonstrated that the HCV core inhibits T-cell responses through interaction with gC1qR. We show here that core proteins from chronic and resolved HCV patients differ in sequence, gC1qR-binding ability, and T-cell inhibition. Specifically, chronic core isolates bind to gC1qR more efficiently and inhibit T-cell proliferation as well as gamma interferon (IFN-gamma) production more profoundly than resolved core isolates. This inhibition is mediated by the disruption of STAT phosphorylation through the induction of SOCS molecules. Silencing either SOCS1 or SOCS3 by small interfering RNA dramatically augments the production of IFN-gamma in T cells, thereby abrogating the inhibitory effect of core. Additionally, the ability of core proteins from patients with chronic infections to induce SOCS proteins and suppress STAT activation greatly exceeds that of core proteins from patients with resolved infections. These results suggest that the HCV core/gC1qR-induced T-cell dysfunction involves the induction of SOCS, a powerful inhibitor of cytokine signaling, which represents a novel mechanism by which a virus usurps the host machinery for persistence.
C1 Univ Virginia, Dept Microbiol & Pathol, Beirne Carter Ctr Immunol Res, Charlottesville, VA 22908 USA.
   Univ Maryland, Inst Human Virol, Baltimore, MD 21201 USA.
RP Hahn, YS (reprint author), Univ Virginia, Dept Microbiol & Pathol, Beirne Carter Ctr Immunol Res, Charlottesville, VA 22908 USA.
EM ysh5e@virginia.edu
FU NIAID NIH HHS [T32 AI007046]; NIDDK NIH HHS [R01 DK066754, R01 DK063222,
   DK063222, DK066754]; PHS HHS [U19 AZ 066328]
CR Accapezzato D, 2004, EUR J IMMUNOL, V34, P438, DOI 10.1002/eji.200324540
   Alexander WS, 2002, NAT REV IMMUNOL, V2, P410, DOI 10.1038/nri818
   Bertholet S, 2003, INFECT IMMUN, V71, P2095, DOI 10.1128/IAI.71.4.2095-2101.2003
   Blanton RE, 2002, J INFECT DIS, V185, P1644, DOI 10.1086/340574
   Bode JG, 2003, FASEB J, V17, P488, DOI 10.1096/fj.02-0664fje
   Braun L, 2000, EMBO J, V19, P1458, DOI 10.1093/emboj/19.7.1458
   Bruni R, 1996, P NATL ACAD SCI USA, V93, P10423, DOI 10.1073/pnas.93.19.10423
   CHEN YDI, 1994, ENDOCRINOL METAB, V1, P153
   Egan PJ, 2003, J CLIN INVEST, V111, P915, DOI 10.1172/JCI200316156
   Gardner JP, 2003, P NATL ACAD SCI USA, V100, P4498, DOI 10.1073/pnas.0831128100
   GHEBREHIWET B, 1990, CLIN IMMUNOL IMMUNOP, V54, P148, DOI 10.1016/0090-1229(90)90014-H
   Ghebrehiwet B, 2001, IMMUNOL REV, V180, P65, DOI 10.1034/j.1600-065X.2001.1800106.x
   Gruener NH, 2001, J VIROL, V75, P5550, DOI 10.1128/JVI.75.12.5550-5558.2001
   Hahn CS, 2000, VIROLOGY, V276, P127, DOI 10.1006/viro.2000.0541
   Hughes MG, 2004, LIVER TRANSPLANT, V10, P208, DOI 10.1002/lt.20060
   Imanaka K, 2005, J VIRAL HEPATITIS, V12, P130, DOI 10.1111/j.1365-2893.2005.00575.x
   Kittlesen DJ, 2000, J CLIN INVEST, V106, P1239, DOI 10.1172/JCI10323
   Large MK, 1999, J IMMUNOL, V162, P931
   Lechmann M, 1999, J HEPATOL, V31, P971, DOI 10.1016/S0168-8278(99)80307-9
   Lechner F, 2000, J EXP MED, V191, P1499, DOI 10.1084/jem.191.9.1499
   LIAW YF, 1995, HEPATOLOGY, V22, P1101, DOI 10.1002/hep.1840220413
   Liu ZX, 2002, J VIROL, V76, P990, DOI 10.1128/JVI.76.3.990-997.2002
   LUO Y, 1994, REV J VIROL, V68, P3850
   Maillard P, 2001, J VIROL, V75, P8240, DOI 10.1128/JVI.75.17.8240-8250.2001
   Masalova OV, 1998, J MED VIROL, V55, P1, DOI 10.1002/(SICI)1096-9071(199805)55:1<1::AID-JMV1>3.0.CO;2-7
   Matthews DA, 1998, J GEN VIROL, V79, P1677, DOI 10.1099/0022-1317-79-7-1677
   Nguyen T, 2000, INFECT IMMUN, V68, P2061, DOI 10.1128/IAI.68.4.2061-2068.2000
   Ray RB, 2001, FEMS MICROBIOL LETT, V202, P149, DOI 10.1016/S0378-1097(01)00286-5
   Saito T, 2004, HEPATOL RES, V30, P57, DOI 10.1016/j.herpes.2004.07.007
   Song MM, 1998, J BIOL CHEM, V273, P35056, DOI 10.1074/jbc.273.52.35056
   Stoiber D, 1999, J IMMUNOL, V163, P2640
   Stoiber D, 2001, J IMMUNOL, V166, P466, DOI 10.4049/jimmunol.166.1.466
   Thimme R, 2001, J EXP MED, V194, P1395, DOI 10.1084/jem.194.10.1395
   Wang YL, 1997, VIROLOGY, V236, P18, DOI 10.1006/viro.1997.8739
   Wedemeyer H, 2002, J IMMUNOL, V169, P3447, DOI 10.4049/jimmunol.169.6.3447
   Yao ZQ, 2004, J VIROL, V78, P6409, DOI 10.1128/78.12.6409-6419.2004
   Yao ZQ, 2003, VIROLOGY, V314, P271, DOI 10.1016/S0042-6822(03)00419-7
   Yao ZQ, 2001, VIRAL IMMUNOL, V14, P277, DOI 10.1089/08828240152716547
   Yao ZQ, 2001, J IMMUNOL, V167, P5264, DOI 10.4049/jimmunol.167.9.5264
   Yokota S, 2004, J VIROL, V78, P6282, DOI 10.1128/JVI.78.12.6282-6286.2004
NR 40
TC 25
Z9 27
U1 3
U2 16
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
J9 J VIROL
JI J. Virol.
PD DEC
PY 2005
VL 79
IS 24
BP 15417
EP 15429
DI 10.1128/JVI.79.24.15417-15429.2005
PG 13
WC Virology
SC Virology
GA 997VK
UT WOS:000234276700043
PM 16306613
OA Bronze, Green Published
DA 2018-12-27
ER

PT J
AU Wu, JS
   Weierstall, U
   Spence, JCH
AF Wu, JS
   Weierstall, U
   Spence, JCH
TI RETRACTED: Diffractive electron imaging of nanoparticles on a substrate
   (Retracted Article. See vol 5, pg 837, 2006)
SO NATURE MATERIALS
LA English
DT Article; Retracted Publication
ID CHARGE-FLIPPING ALGORITHM; INITIO STRUCTURE SOLUTION; PHASE RETRIEVAL;
   RESOLUTION LIMIT; MICROSCOPY; CRYSTALLOGRAPHY; OXYGEN
AB The observation of the detailed atomic arrangement within nanostructures has previously required the use of an electron microscope for imaging. The development of diffractive (lensless) imaging in X-ray science and electron microscopy using ab initio phase retrieval provides a promising tool for nanostructural characterization. We show that it is possible experimentally to reconstruct the atomic-resolution complex image (exit-face wavefunction) of a small particle lying on a thin carbon substrate from its electron microdiffraction pattern alone. We use a modified iterative charge-flipping algorithm and an estimate of the complex substrate image is subtracted at each iteration. The diffraction pattern is recorded using a parallel beam with a diameter of similar to 50 nm, illuminating a gold nanoparticle of similar to 13.6 nm diameter. Prior knowledge of the boundary of the object is not required. The method has the advantage that the reconstructed exit-face wavefunction is free of the aberrations of the objective lens normally used in the microscope, whereas resolution is limited only by thermal vibration and noise.
C1 Arizona State Univ, Dept Phys & Astron, Tempe, AZ 85287 USA.
RP Wu, JS (reprint author), Arizona State Univ, Dept Phys & Astron, Tempe, AZ 85287 USA.
EM jinsong.wu@asu.edu
RI Weierstall, Uwe/B-3568-2011
CR BUERGER MJ, 1976, Z KRISTALLOGR, V143, P79
   CHAPMAN HN, IN PRESS J OPT SOC A
   COENE W, 1992, PHYS REV LETT, V69, P3743, DOI 10.1103/PhysRevLett.69.3743
   FIENUP JR, 1982, APPL OPTICS, V21, P2758, DOI 10.1364/AO.21.002758
   GERCHBERG RW, 1972, OPTIK, V35, P237
   Glaeser RM, 1999, J STRUCT BIOL, V128, P3, DOI 10.1006/jsbi.1999.4172
   Haider M, 1998, NATURE, V392, P768, DOI 10.1038/33823
   Jia CL, 2003, SCIENCE, V299, P870, DOI 10.1126/science.1079121
   Marchesini S, 2003, PHYS REV B, V68, DOI 10.1103/PhysRevB.68.140101
   McMahon PJ, 2003, PHYS REV LETT, V91, DOI 10.1103/PhysRevLett.91.145502
   Miao JW, 1999, NATURE, V400, P342, DOI 10.1038/22498
   ORCHOWSKI A, 1995, PHYS REV LETT, V74, P399, DOI 10.1103/PhysRevLett.74.399
   Oszlanyi G, 2004, ACTA CRYSTALLOGR A, V60, P134, DOI 10.1107/S0108767303027569
   Oszlanyi G, 2005, ACTA CRYSTALLOGR A, V61, P147, DOI 10.1107/S0108767304027746
   SCHERZER O, 1949, J APPL PHYS, V20, P20, DOI 10.1063/1.1698233
   SELDIN JH, 1990, J OPT SOC AM A, V7, P412, DOI 10.1364/JOSAA.7.000412
   Shapiro D, 2005, P NATL ACAD SCI USA, V102, P15343, DOI 10.1073/pnas.0503305102
   Spence JCH, 2004, ULTRAMICROSCOPY, V101, P149, DOI 10.1016/j.ultramic.2004.05.005
   Spence JCH, 2003, SCIENCE, V299, P839
   SPENCE JCH, 2003, HIGH RESOLUTION ELEC, P51161
   Wu JS, 2005, ACTA CRYSTALLOGR A, V61, P194, DOI [10.1107/S0108767304033525, 10.1107/S010876704033525]
   Wu JS, 2004, OPT LETT, V29, P2737, DOI 10.1364/OL.29.002737
   Wu JS, 2004, ACTA CRYSTALLOGR A, V60, P326, DOI 10.1107/S0108767304012231
   Zuo JM, 2003, SCIENCE, V300, P1419, DOI 10.1126/science.1083887
NR 24
TC 21
Z9 21
U1 8
U2 10
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1476-1122
EI 1476-4660
J9 NAT MATER
JI Nat. Mater.
PD DEC
PY 2005
VL 4
IS 12
BP 912
EP 916
DI 10.1038/nmat1531
PG 5
WC Chemistry, Physical; Materials Science, Multidisciplinary; Physics,
   Applied; Physics, Condensed Matter
SC Chemistry; Materials Science; Physics
GA 988QR
UT WOS:000233616200013
PM 16299507
DA 2018-12-27
ER

PT J
AU Diab, HM
   Abo-Elmgd, M
AF Diab, HM
   Abo-Elmgd, M
TI RETRACTED: Reproducibility study of (TLD-100) dosimeters using an
   automated and manual TLD reader for radiotherapy applications (Retracted
   article. See vol. 267, pg. 3492, 2009)
SO NUCLEAR INSTRUMENTS & METHODS IN PHYSICS RESEARCH SECTION B-BEAM
   INTERACTIONS WITH MATERIALS AND ATOMS
LA English
DT Article; Retracted Publication
DE reproducibility; TLD-100; TLD reader; radiotherapy applications
AB The precision of the response of Harshow thermoluminescent dosimeters (TLD-100) is investigated for two Harshow TLD readers. The mean reproducibility for chips pre-readout annealed at 100 degrees C for 15 min, evaluated with the manual planchet reader 4500, is 0.61% (1 standard deviation) using pre-readout method. When chips are evaluated with the automated hot-gas reader 4500, reproducibility values are undoubtedly worse, mean reproducibility for numerically stabilized dosimeters being equal to 2.12%(1 standard deviation) using pre-readout method also. The pre-readout method was used for elimination of lower temperature peaks in order to obtain more stability. These results indicate that the automated hot-gas 4500 reader, or, at least, the instrument used for the present measurements, is not adequate for chips evaluation, if precise and accurate dosimetry is required. The difference in precision for manual planchet reader is apparently due to geometry inconsistencies in the orientation of the planchet to imperfect chips faces during readout, requiring careful and manual reproducible arrangement of the selected chips faces in contact with the manual reader planchet. In order to elucidate this point, the planchet support face of all chips dosimeters was identified with a small point made by pencil, reducing in this way geometrical variations. (c) 2005 Elsevier B.V. All rights reserved.
C1 Natl Inst Stand, Radiat Dosimetry Lab, Giza, Egypt.
RP Diab, HM (reprint author), Natl Inst Stand, Radiat Dosimetry Lab, Tersa St,POB 136, Giza, Egypt.
EM diab20032003@yahoo.com
CR Fill U, 1996, RADIAT PROT DOSIM, V66, P249, DOI 10.1093/oxfordjournals.rpd.a031728
   NAHRSTEDT U, 1995, 995 GSF
   RANDALL JT, 1945, PROC R SOC LON SER-A, V184, P366
   REGULLA D, 1994, STRAHLENSCHUTZ PHYSI, P266
   Sprunck M, 1996, RADIAT PROT DOSIM, V66, P269, DOI 10.1093/oxfordjournals.rpd.a031732
NR 5
TC 1
Z9 1
U1 3
U2 8
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-583X
J9 NUCL INSTRUM METH B
JI Nucl. Instrum. Methods Phys. Res. Sect. B-Beam Interact. Mater. Atoms
PD DEC
PY 2005
VL 240
IS 4
BP 908
EP 912
DI 10.1016/j.nimb.2005.06.201
PG 5
WC Instruments & Instrumentation; Nuclear Science & Technology; Physics,
   Atomic, Molecular & Chemical; Physics, Nuclear
SC Instruments & Instrumentation; Nuclear Science & Technology; Physics
GA 989ZM
UT WOS:000233712900016
DA 2018-12-27
ER

PT J
AU Zheng, YM
   Zhao, QB
   Yu, HQ
AF Zheng, YM
   Zhao, QB
   Yu, HQ
TI RETRACTED: Adsorption of a cationic dye onto aerobic granules (Retracted
   Article. See vol 41, pg 2357, 2006)
SO PROCESS BIOCHEMISTRY
LA English
DT Article; Retracted Publication
DE adsorption; aerobic granules; dye; Langmuir model; rhodamine B;
   thermodynamics
ID SEQUENCING BATCH REACTOR; ACTIVATED-SLUDGE; RHODAMINE-B;
   AQUEOUS-SOLUTIONS; EQUILIBRIUM; BIOSORPTION; SYSTEM; CARBON
AB Batch experiments were conducted to study the adsorption characteristics of a cationic dye, Rhodamine B, onto aerobic granules. Effects of pH, suspended solids (SS), ionic strength and solution temperature on dye adsorption by aerobic granules were evaluated, and the thermodynamic analysis was also performed. Results show that pH was an important factor governing the adsorption and that the optimal pH for adsorption was around 7.0. At an initial dye concentration of 100 mu mol/l, a greater adsorption density could be achieved at SS level less than 1 g/l. However, at SS concentrations greater than 1 g/l, the dye adsorption density remained almost unchanged. An increase in an ionic strength and solution temperature decreased the dye adsorption density. Isotherm model analysis indicated that the dye adsorption by the aerobic granules could be described by Langmuir equation very well. With Langmuir isotherms, the change of adsorption free energy was calculated and the specific area of the aerobic granules was estimated. The maximal absorption quantity of the aerobic granules was three times greater than that of flocs, but it required more time for granules to reach adsorption equilibrium than the floes. The negative Delta G(degrees) values indicate the spontaneous nature of adsorption process, while the negative value of Delta H degrees implies the exothermic nature of the adsorption process. (c) 2005 Elsevier Ltd. All rights reserved.
C1 Univ Sci & Technol China, Sch Chem, Hefei 230026, Peoples R China.
RP Yu, HQ (reprint author), Univ Sci & Technol China, Sch Chem, Hefei 230026, Peoples R China.
EM hqyu@ustc.edu.cn
RI Yu, Han-Qing/F-7925-2010
CR Aksu Z, 2005, PROCESS BIOCHEM, V40, P1347, DOI 10.1016/j.procbio.2004.06.007
   Aksu Z, 2000, PROCESS BIOCHEM, V36, P431, DOI 10.1016/S0032-9592(00)00233-8
   Annadurai G, 2003, ADV ENVIRON RES, V7, P739, DOI 10.1016/S1093-0191(02)00044-8
   Annadurai G, 2002, J HAZARD MATER, V92, P263, DOI 10.1016/S0304-3894(02)00017-1
   Basibuyuk M, 2003, PROCESS BIOCHEM, V38, P1311, DOI 10.1016/S0032-9592(02)00327-8
   Beun JJ, 1999, WATER RES, V33, P2283, DOI 10.1016/S0043-1354(98)00463-1
   Guo YP, 2005, DYES PIGMENTS, V66, P123, DOI 10.1016/j.dyepig.2004.09.014
   Jaycock M. J, 1981, CHEM INTERFACES
   Kapdan IK, 2002, PROCESS BIOCHEM, V37, P973, DOI 10.1016/S0032-9592(01)00309-0
   Langmuir I, 1918, J AM CHEM SOC, V40, P1361, DOI 10.1021/ja02242a004
   Lin C, 1999, J ELECTROCHEM SOC, V146, P3639, DOI 10.1149/1.1392526
   Liu Y, 2003, J BIOTECHNOL, V102, P233, DOI 10.1016/S0168-1656(03)00030-0
   Ma Y, 1998, J PHOTOCH PHOTOBIO A, V116, P167, DOI 10.1016/S1010-6030(98)00295-0
   Malik PK, 2004, SEP PURIF TECHNOL, V36, P167, DOI 10.1016/S1383-5866(03)00212-0
   Malik PK, 2003, SEP PURIF TECHNOL, V31, P241, DOI 10.1016/S1383-5866(02)00200-9
   Morgenroth E, 1997, WATER RES, V31, P3191, DOI 10.1016/S0043-1354(97)00216-9
   Ozer A, 2004, PROCESS BIOCHEM, V39, P2183, DOI 10.1016/j.procbio.2003.11.008
   Sorensen BL, 1996, WATER RES, V30, P115, DOI 10.1016/0043-1354(95)00131-4
   Tay JH, 2002, ENVIRON TECHNOL, V23, P931, DOI 10.1080/09593332308618363
   Wang JM, 1998, J COLLOID INTERF SCI, V208, P518, DOI 10.1006/jcis.1998.5875
   Weng CH, 2001, WATER SCI TECHNOL, V44, P279
   Wong YC, 2004, PROCESS BIOCHEM, V39, P693, DOI 10.1016/S0032-9592(03)00152-3
   Zhao XK, 2003, CHEMOSPHERE, V52, P917, DOI 10.1016/S0045-6535(03)00258-3
   Zheng YM, 2005, PROCESS BIOCHEM, V40, P645, DOI 10.1016/j.procbio.2004.01.056
NR 24
TC 7
Z9 12
U1 2
U2 17
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1359-5113
J9 PROCESS BIOCHEM
JI Process Biochem.
PD DEC
PY 2005
VL 40
IS 12
BP 3777
EP 3782
DI 10.1016/j.procbio.2005.07.017
PG 6
WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Engineering, Chemical
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Engineering
GA 981DS
UT WOS:000233068200018
DA 2018-12-27
ER

PT J
AU Van Le, TS
   Miller, R
   Barder, T
   Babjuk, M
   Potter, DM
   Getzenberg, RH
AF Van Le, TS
   Miller, R
   Barder, T
   Babjuk, M
   Potter, DM
   Getzenberg, RH
TI RETRACTED: Highly specific urine-based marker of bladder cancer
   (Retracted article. See vol. 83, pg. 1448, 2014)
SO UROLOGY
LA English
DT Article; Retracted Publication
ID TRANSITIONAL-CELL CARCINOMA; NUCLEAR-MATRIX PROTEIN; BARD BTA TEST;
   BLCA-4; MANAGEMENT; CYTOLOGY; TRACT
AB Objectives. Bladder cancer represents a major health problem throughout the world, but advances in tumor biomarker development are revolutionizing how physicians diagnose the disease. We previously used an indirect immunoassay to demonstrate that the bladder cancer specific biomarker, BLCA-4, is present in urine samples from patients with bladder cancer, but not in samples from healthy individuals. In this study, a sandwich immunoassay was used to measure BLCA-4 in urine samples from patient populations with various urologic conditions and healthy individuals.
   Methods. Urine was collected from healthy individuals and from patients with bladder cancer, benign urologic conditions, or prostate cancer. BLCA-4 levels were evaluated by a sandwich immunoassay using two antibodies directed against distinct epitopes on BLCA-4.
   Results. Using a prospectively determined cutoff of an absorbance unit (OD) of 0.04, 67 of the 75 samples from patients with bladder cancer were positive for BLCA-4, resulting in an assay sensitivity of 89%. Also, 62 of the 65 samples from individuals without bladder cancer were negative for BLCA-4, resulting in an assay specificity of 95%.
   Conclusions. The high sensitivity and specificity of the sandwich BLCA-4 immunoassay may allow for earlier detection and treatment of disease, thus greatly improving patient care.
C1 Univ Pittsburgh, Inst Canc, Pittsburgh, PA USA.
   Univ Pittsburgh, Dept Urol, Pittsburgh, PA USA.
   Eprogen Inc, Darien, IL USA.
   Charles Univ Prague, Prague, Czech Republic.
   Univ Pittsburgh, Dept Biostat, Pittsburgh, PA 15261 USA.
RP Getzenberg, RH (reprint author), Johns Hopkins Med, Brady Urol Inst, Marburh 121,600 N Wolfe St, Baltimore, MD 21287 USA.
EM rgetzen1@jhmi.edu
FU NCI NIH HHS [CA82522]
CR Altieri DC, 2003, ONCOGENE, V22, P8581, DOI 10.1038/sj.onc.1207113
   *AM CANC SOC, 2005, CANC FACTS FIG 2005
   BISHOP ML, 2000, CLIN CHEM PRINCIPLES
   BURCH JD, 1989, INT J CANCER, V44, P622, DOI 10.1002/ijc.2910440411
   Carpinito GA, 1996, J UROLOGY, V156, P1280, DOI 10.1016/S0022-5347(01)65569-1
   Getzenberg RH, 2003, LAB MED, V34, P613, DOI 10.1309/MRF2YWMVUAVF88EC
   Getzenberg RH, 1996, CANCER RES, V56, P1690
   Hughes JH, 1999, DIAGN CYTOPATHOL, V20, P285, DOI 10.1002/(SICI)1097-0339(199905)20:5<285::AID-DC7>3.0.CO;2-T
   Ianari A, 1997, UROLOGY, V49, P786, DOI 10.1016/S0090-4295(97)00081-2
   Konety BR, 2000, CLIN CANCER RES, V6, P2618
   Konety BR, 2000, J UROLOGY, V164, P634, DOI 10.1016/S0022-5347(05)67269-2
   Mavrothalassitis G, 2000, ONCOGENE, V19, P6524, DOI 10.1038/sj.onc.1204045
   MILLER BA, 1996, NIH PUBLICATION
   MORRISON AS, 1984, UROL CLIN N AM, V11, P557
   Oge O, 2002, J UROLOGY, V167, P1318, DOI 10.1016/S0022-5347(05)65290-1
   Rahat MA, 1999, CANCER, V85, P919
   RIFE CC, 1979, UROL CLIN N AM, V6, P599
   SCHWALB DM, 1993, J UROLOGY, V150, P1751, DOI 10.1016/S0022-5347(17)35886-X
   Utting M, 2002, CLIN CANCER RES, V8, P35
   Van Le TS, 2004, CLIN CANCER RES, V10, P1384, DOI 10.1158/1078-0432.CCR-0455-03
   WHELAN P, 1993, BRIT J UROL, V72, P893, DOI 10.1111/j.1464-410X.1993.tb16292.x
   Wiener HG, 1998, J UROLOGY, V159, P1876, DOI 10.1016/S0022-5347(01)63184-7
   Zimmerman RL, 1998, UROLOGY, V51, P956, DOI 10.1016/S0090-4295(98)00115-0
NR 23
TC 55
Z9 55
U1 4
U2 10
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0090-4295
EI 1527-9995
J9 UROLOGY
JI Urology
PD DEC
PY 2005
VL 66
IS 6
BP 1256
EP 1260
DI 10.1016/j.urolog.2005.07.010
PG 5
WC Urology & Nephrology
SC Urology & Nephrology
GA 995UR
UT WOS:000234130200025
PM 16360453
DA 2018-12-27
ER

PT J
AU Li, XB
   Jiang, YQ
   Wang, ZC
   Liu, GT
   Hutz, RJ
   Liu, WB
   Xie, Z
   Shi, FX
AF Li, Xuebin
   Jiang, Yongqing
   Wang, Zhengchao
   Liu, Gentao
   Hutz, Reinhold J.
   Liu, Wenbin
   Xie, Zhuang
   Shi, Fangxiong
TI RETRACTED: Regulation of FoxO1 transcription factor by nitric oxide and
   cyclic GMP in cultured rat granulosa cells (Retracted article. See vol
   24, pg 281, 2007)
SO ZOOLOGICAL SCIENCE
LA English
DT Article; Retracted Publication
DE granulosa cell; FoxO1; forkhead; rat; nitric oxide; cGMP
ID PROMOTES NUCLEAR EXCLUSION; FOLLICULAR DEVELOPMENT; ESTROGEN PRODUCTION;
   HORMONAL-REGULATION; ADENYLYL-CYCLASE; EXPRESSION; OVARY; FKHR;
   DIFFERENTIATION; AKT
AB FoxO1 is a transcription factor implicated in a multitude of physiological processes including cell cycle progression, apoptosis and insulin signaling. Recent findings indicate that FoxO1 is a key regulator during the proliferation and maturation of granulosa cells. Over the past several years, it has become evident that nitric oxide (NO) and cGMP modulate ovarian function. There has been no information, however, about whether NO-cGMP affects FoxO1 expression or about the relationship between NO-cGMP and FoxO1. In the present study, we used immunoblot analysis to determine whether NO and cGMP affect FoxO1 expression in cultured granulosa cells. Our results clearly showed that FSH suppressed FoxO1 expression in a time-dependent manner, and that NO-cGMP stimulated FoxO1 expression in cultured granulosa cells. In addition, this stimulatory effects of NO and cGMP can be blocked by FSH in cultured granulosa cells. These findings demonstrate that NO and cGMP influence FoxO1 expression possibly through antagonizing the action of FSH in cultured granulosa cells. Results of both immunoblot analysis and immunohistochemistry also show that estradiol implantation do not affect the expression of FoxO1 in rat granulosa cells as gonadotrophins do, indicating that mechanism of estradiol on granulosa cells is different from gonaclotrophins. Together, our experiments suggest that expression of FoxO1 in rat granulosa cells can be regulated by gonadotrophins and the NO/cGMP signaling pathway.
C1 Nanjing Agr Univ, Coll Anim Sci & Technol, Lab Anim Reprod, Nanjing 210095, Peoples R China.
   Zhejiang Acad Agr Sci, Inst Anim Sci & Vet Med, Hangzhou 310021, Peoples R China.
   Cedars Sinai Med Ctr, Maxine Dunitz Neurosurg Inst, Los Angeles, CA 90048 USA.
   Univ Calif Los Angeles, David Geffen Sch Med, Cedars Sinai Med Ctr, Div Hematol Oncol, Los Angeles, CA 90048 USA.
   Univ Wisconsin, Dept Biol Sci, Milwaukee, WI 53201 USA.
RP Shi, FX (reprint author), Nanjing Agr Univ, Coll Anim Sci & Technol, Lab Anim Reprod, Nanjing 210095, Peoples R China.
EM fxshi@njau.edu.cn
CR Asboth G, 2001, REPRODUCTION, V121, P217
   Biggs WH, 2001, MAMM GENOME, V12, P416, DOI 10.1007/s003350020002
   Biggs WH, 1999, P NATL ACAD SCI USA, V96, P7421, DOI 10.1073/pnas.96.13.7421
   BREDT DS, 1994, ANNU REV BIOCHEM, V63, P175, DOI 10.1146/annurev.bi.63.070194.001135
   Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4
   Cunningham MA, 2004, MOL ENDOCRINOL, V18, P1756, DOI 10.1210/me.2004-0071
   Cunningham MA, 2003, ENDOCRINOLOGY, V144, P5585, DOI 10.1210/en.2003-0678
   Dixit VD, 2001, ANIM REPROD SCI, V65, P1, DOI 10.1016/S0378-4320(00)00224-4
   DUHE RJ, 1994, J BIOL CHEM, V269, P7290
   Durham SK, 1999, ENDOCRINOLOGY, V140, P3140, DOI 10.1210/en.140.7.3140
   Faletti AG, 2003, REPRODUCTION, V125, P469, DOI 10.1530/rep.0.1250469
   Furukawa-Hibi Y, 2002, J BIOL CHEM, V277, P26729, DOI 10.1074/jbc.C200256200
   GALILI N, 1993, NAT GENET, V5, P230, DOI 10.1038/ng1193-230
   Gonzalez-Robayna IJ, 2000, MOL ENDOCRINOL, V14, P1283, DOI 10.1210/me.14.8.1283
   HSUEH AJW, 1984, ENDOCR REV, V5, P76, DOI 10.1210/edrv-5-1-76
   IGNARRO LJ, 1991, BIOCHEM PHARMACOL, V41, P485, DOI 10.1016/0006-2952(91)90618-F
   Ishimaru RS, 2001, J ENDOCRINOL, V168, P249, DOI 10.1677/joe.0.1680249
   JablonkaShariff A, 1997, ENDOCRINOLOGY, V138, P460, DOI 10.1210/en.138.1.460
   Kaestner KH, 2000, GENE DEV, V14, P142
   Kagabu S, 1999, MOL HUM REPROD, V5, P396, DOI 10.1093/molehr/5.5.396
   Kops GJPL, 2002, MOL CELL BIOL, V22, P2025, DOI 10.1128/MCB.22.7.2025-2036.2002
   LAPOLT PS, 1995, ENDOCRINOLOGY, V136, P5533, DOI 10.1210/en.136.12.5533
   Li XB, 2005, PROG BIOCHEM BIOPHYS, V32, P600
   Masuda M, 1997, MOL HUM REPROD, V3, P285, DOI 10.1093/molehr/3.4.285
   McVey M, 1999, J BIOL CHEM, V274, P18887, DOI 10.1074/jbc.274.27.18887
   Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115
   MONCADA S, 1991, PHARMACOL REV, V43, P109
   Nakae J, 2003, DEV CELL, V4, P119, DOI 10.1016/S1534-5807(02)00401-X
   Nakai J, 2002, NAT GENET, V32, P245, DOI 10.1038/ng890
   Nemoto S, 2002, SCIENCE, V295, P2450, DOI 10.1126/science.1069004
   Park Y, 2005, J BIOL CHEM, V280, P9135, DOI 10.1074/jbc.M4094826200
   Rao VSN, 1995, J REPROD FERTIL, V105, P303
   RICHARDS JS, 1995, RECENT PROG HORM RES, V50, P223
   Richards JS, 2002, MOL ENDOCRINOL, V16, P580, DOI 10.1210/me.16.3.580
   Shi F, 2003, J ENDOCRINOL, V179, P195, DOI 10.1677/joe.0.1790195
   Shi FX, 2004, BIOL REPROD, V70, P1552, DOI 10.1095/biolreprod.103.025510
   Shi FX, 1999, BIOL REPROD, V60, P78, DOI 10.1095/biolreprod60.1.78
   Shi FX, 2000, ZOOL SCI, V17, P1311, DOI 10.2108/zsj.17.1311
   Suhara T, 2002, MOL CELL BIOL, V22, P680, DOI 10.1128/MCB.22.2.680-691.2002
   TAMANINI C, 2003, J ANIM SCI, V81, pE1
   Tang ED, 1999, J BIOL CHEM, V274, P16741, DOI 10.1074/jbc.274.24.16741
   Tang TTL, 2002, J BIOL CHEM, V277, P14255, DOI 10.1074/jbc.M110901200
   Tran H, 2002, SCIENCE, V296, P530, DOI 10.1126/science.1068712
   van der Heide LP, 2004, BIOCHEM J, V380, P297, DOI 10.1042/BJ20040167
   VANVOORHIS BJ, 1994, ENDOCRINOLOGY, V135, P1799, DOI 10.1210/en.135.5.1799
NR 45
TC 7
Z9 11
U1 4
U2 15
PU ZOOLOGICAL SOC JAPAN
PI TOKYO
PA HONGO MT BUILDING 4F, HONGO 7-2-2, BUNKYO-KU, TOKYO, 113-0033, JAPAN
SN 0289-0003
J9 ZOOL SCI
JI Zool. Sci.
PD DEC
PY 2005
VL 22
IS 12
BP 1339
EP 1346
DI 10.2108/zsj.22.1339
PG 8
WC Zoology
SC Zoology
GA 044DR
UT WOS:000237653100004
PM 16462106
DA 2018-12-27
ER

PT J
AU Hosseinkhani, H
   Tabata, Y
AF Hosseinkhani, H
   Tabata, Y
TI RETRACTED: Ultrasound enhances in vivo tumor expression of plasmid DNA
   by PEG-introduced cationized dextran (Retracted article. See vol. 232,
   pg. 269, 2016)
SO JOURNAL OF CONTROLLED RELEASE
LA English
DT Article; Retracted Publication
DE ultrasound irradiation; tumor targeting; enhanced gene expression;
   cationization; PEG introduction
ID LOW-FREQUENCY ULTRASOUND; CANCER MONOCLONAL-ANTIBODY; IN-VITRO
   TRANSFECTION; GENE-TRANSFER; THERAPEUTIC ULTRASOUND; ANTITUMOR-ACTIVITY;
   SKELETAL-MUSCLE; MEDIATED TRANSFECTION; FOCUSED ULTRASOUND; CIRCULATION
   TIME
AB This study is an investigation to experimentally confirm whether or not ultrasound (US) irradiation is effective in enhancing the in vivo gene expression of plasmid DNA in tumor. Dextran was cationized by introducing spermine to the hydroxyl groups to allow to polyionically complex with a plasmid DNA. The cationized dextran prepared was additionally modified with poly(ethylene glycol) (PEG) molecules which have an active ester and methoxy groups at each terminal, to obtain cationized dextran with different percentages of PEG introduced. Various cationized dextrans with or without PEG introduction were mixed with a plasmid DNA of LacZ to form cationized dextran-plasmid DNA complexes. Electrophoretical examination revealed that the plasmid DNA was complexed both with the cationized dextran and PEG-introduced cationized dextran, irrespective of the PEG introduction percentage, although the higher N/P ratio was needed for plasmid DNA complexation with the latter. By complexation with the cationized dextran, the zeta potential of plasmid DNA was changed to be positive. The charge of PEG-introduced cationized dextran-plasmid DNA complexes became close to 0 mV as their percentage of PEG introduced increased, although the molecular size was about 250 nm, irrespective of the PEG introduction. When cationized dextran-plasmid DNA complexes with or without PEG introduction were intravenously injected to mice carrying a subcutaneous Meth-AR-1 fibrosarcoma mass and the subsequent US irradiation to the tumor mass percutaneously, the PEG-introduced cationized dextran-plasmid DNA complex plus US irradiation enhanced the tumor level of gene expression to a significantly high extent compared with the cationized dextran-plasmid DNA complex and free plasmid DNA with or without US irradiation. The enhanced level depended on the time period and timing of US irradiation. Fluorescent microscopic studies revealed that the localization of plasmid DNA and the gene expression were observed in the tumor tissue injected with the PEG-introduced cationized dextran-plasmid DNA complex plus the subsequent US irradiation. We conclude that complexation with the PEG-introduced cationized dextran combined with US irradiation is a promising way to target the plasmid DNA to the tumor for gene expression. (c) 2005 Elsevier B.V. All rights reserved.
C1 Kyoto Univ, Inst Frontier Med Sci, Dept Biomat Field Tissue Engn, Sakyo Ku, Kyoto 6068507, Japan.
RP Tabata, Y (reprint author), Kyoto Univ, Inst Frontier Med Sci, Dept Biomat Field Tissue Engn, Sakyo Ku, 53 Kawaracho, Kyoto 6068507, Japan.
EM yasuhiko@frontier.kyoto-u.ac.jp
CR Allison DG, 1996, J BASIC MICROB, V36, P3
   Anwer K, 2000, GENE THER, V7, P1833, DOI 10.1038/sj.gt.3301302
   Aoyama T, 2002, J CONTROL RELEASE, V80, P345, DOI 10.1016/S0168-3659(02)00029-9
   Azzam T, 2004, J CONTROL RELEASE, V96, P309, DOI 10.1016/j.jconrel.2004.01.022
   Azzam T, 2002, J MED CHEM, V45, P1817, DOI 10.1021/jm0105528
   Bao SP, 1997, ULTRASOUND MED BIOL, V23, P953, DOI 10.1016/S0301-5629(97)00025-2
   BINDERMAN I, 1984, CALCIFIED TISSUE INT, V36, pS82, DOI 10.1007/BF02406139
   BUCKLEY MJ, 1988, BONE MINER, V4, P225
   Coll JL, 1998, HUM GENE THER, V9, P2063, DOI 10.1089/hum.1998.9.14-2063
   CRUM LA, 1992, J ACOUST SOC AM, V91, P1113, DOI 10.1121/1.402638
   DUARTE LR, 1983, ARCH ORTHOP TRAUM SU, V101, P153, DOI 10.1007/BF00436764
   Egilmez NK, 1996, BIOCHEM BIOPH RES CO, V221, P169, DOI 10.1006/bbrc.1996.0564
   FECHHEIMER M, 1987, P NATL ACAD SCI USA, V84, P8463, DOI 10.1073/pnas.84.23.8463
   Frediani B, 2002, CLIN RHEUMATOL, V21, P294, DOI 10.1007/s100670200077
   HASHIDA M, 1981, GANN, V72, P226
   HASLER JF, 1992, J DAIRY SCI, V75, P2857, DOI 10.3168/jds.S0022-0302(92)78049-7
   HERMANSON GT, 1992, IMMOBILIZED AFFINITY, P51
   HOGAN RD, 1982, MICROVASC RES, V23, P370, DOI 10.1016/S0026-2862(82)80009-5
   HONG Z, 1992, AGR BIOTECH, P311
   Hosseinkhani H, 2002, J DRUG TARGET, V10, P193, DOI 10.1080/10611860290022624
   Hosseinkhani H, 2004, GENE THER, V11, P194, DOI 10.1038/sj.gt.3302159
   Huber PE, 1999, ULTRASOUND MED BIOL, V25, P1451, DOI 10.1016/S0301-5629(99)00099-X
   Huber PE, 2000, GENE THER, V7, P1516, DOI 10.1038/sj.gt.3301242
   Hwu P, 1997, J INTERN MED, V242, P109, DOI 10.1111/joim.1997.242.s740.109
   JOERSBO M, 1992, PHYSIOL PLANTARUM, V85, P230, DOI 10.1034/j.1399-3054.1992.850215.x
   JONES DB, 1991, BIOMATERIALS, V12, P101, DOI 10.1016/0142-9612(91)90186-E
   KABANOV AV, 1998, SELF ASSEMBLING COMP
   Kim HJ, 1996, HUM GENE THER, V7, P1339, DOI 10.1089/hum.1996.7.11-1339
   Kircheis R, 2001, GENE THER, V8, P28, DOI 10.1038/sj.gt.3301351
   Lauer U, 1997, GENE THER, V4, P710, DOI 10.1038/sj.gt.3300462
   Ledley FD, 1996, PHARM RES-DORDR, V13, P1595, DOI 10.1023/A:1016420102549
   Mahato RI, 1997, PHARMACEUT RES, V14, P853, DOI 10.1023/A:1012187414126
   MATSUMOTO S, 1986, CANCER RES, V46, P4463
   Miller DL, 2002, ULTRASOUND MED BIOL, V28, P1343, DOI 10.1016/S0301-5629(02)00572-0
   Miller Douglas L., 2002, Somatic Cell and Molecular Genetics, V27, P115, DOI 10.1023/A:1022983907223
   Mitragotri S, 2000, PHARMACEUT RES, V17, P1354, DOI 10.1023/A:1007522114438
   Mitragotri S, 2000, PHARMACEUT RES, V17, P466, DOI 10.1023/A:1007537222591
   Mitragotri S, 2001, PHARMACEUT RES, V18, P1151, DOI 10.1023/A:1010979010907
   MITRAGOTRI S, 1995, SCIENCE, V269, P850, DOI 10.1126/science.7638603
   Mitragotri S, 2001, J CONTROL RELEASE, V71, P23, DOI 10.1016/S0168-3659(00)00344-8
   MORI A, 1991, FEBS LETT, V284, P263, DOI 10.1016/0014-5793(91)80699-4
   Newman CM, 2001, ECHOCARDIOGR-J CARD, V18, P339, DOI 10.1046/j.1540-8175.2001.00339.x
   NISHIKAWA M, 1992, J PHARM PHARMACOL, V44, P396, DOI 10.1111/j.2042-7158.1992.tb03632.x
   NOGUCHI A, 1991, JPN J CANCER RES, V82, P219, DOI 10.1111/j.1349-7006.1991.tb01832.x
   NOGUCHI A, 1992, BIOCONJUGATE CHEM, V3, P132, DOI 10.1021/bc00014a007
   Reher P, 1997, ULTRASOUND MED BIOL, V23, P1251, DOI 10.1016/S0301-5629(97)00031-8
   Sato N, 2001, CLIN CANCER RES, V7, P3606
   Schaaf A, 2003, ANTICANCER RES, V23, P4871
   Schaffer DV, 2000, BIOTECHNOL BIOENG, V67, P598, DOI 10.1002/(SICI)1097-0290(20000305)67:5<598::AID-BIT10>3.0.CO;2-G
   Schratzberger P, 2002, MOL THER, V6, P576, DOI 10.1006/mthe.2002.0715
   Schreier H, 1994, Pharm Acta Helv, V68, P145, DOI 10.1016/0031-6865(94)90037-X
   SENIOR J, 1991, BIOCHIM BIOPHYS ACTA, V1062, P77, DOI 10.1016/0005-2736(91)90337-8
   SNYDER SL, 1975, ANAL BIOCHEM, V64, P284, DOI 10.1016/0003-2697(75)90431-5
   SOMJEN D, 1980, BIOCHIM BIOPHYS ACTA, V627, P91, DOI 10.1016/0304-4165(80)90126-9
   Tabata Y, 1997, DRUG DELIV, V4, P213, DOI 10.3109/10717549709051895
   TAKAKURA Y, 1987, PHARMACEUT RES, V4, P293, DOI 10.1023/A:1016489002393
   Taniyama Y, 2002, CIRCULATION, V105, P1233, DOI 10.1161/hc1002.105228
   Taniyama Y, 2002, GENE THER, V9, P372, DOI 10.1038/sj/gt/3301678
   Terahara T, 2002, INT J PHARM, V235, P35, DOI 10.1016/S0378-5173(01)00981-4
   Tezel A, 2002, J PHARM SCI-US, V91, P444, DOI 10.1002/jps.10024
   Tezel A, 2002, J PHARM SCI, V91, P91, DOI 10.1002/jps.10000
   Tezel A, 2001, PHARMACEUT RES, V18, P1694, DOI 10.1023/A:1013366328457
   TORCHILIN VP, 1994, BBA-BIOMEMBRANES, V1195, P181, DOI 10.1016/0005-2736(94)90025-6
   Unger EC, 1997, INVEST RADIOL, V32, P723, DOI 10.1097/00004424-199712000-00001
   Vannan M, 2002, J AM SOC ECHOCARDIOG, V15, P214, DOI 10.1067/mje.2002.119913
   Virtanen HS, 2002, INT UROGYNECOL J PEL, V13, P218, DOI 10.1007/s001920200048
   Wasan EK, 1996, J PHARM SCI-US, V85, P427, DOI 10.1021/js9504752
   WEBSTER DF, 1980, ULTRASONICS, V18, P33, DOI 10.1016/0041-624X(80)90050-5
   WOODLE MC, 1994, BIOCONJUGATE CHEM, V5, P493, DOI 10.1021/bc00030a001
   Wyber JA, 1997, PHARMACEUT RES, V14, P750, DOI 10.1023/A:1012198321879
   Yang JP, 1996, GENE THER, V3, P542
   YOUNG SR, 1990, ULTRASOUND MED BIOL, V16, P809, DOI 10.1016/0301-5629(90)90045-E
   Zarnitsyn VG, 2004, ULTRASOUND MED BIOL, V30, P527, DOI 10.1016/j.ultrasmedbio.2004.01.008
   ZHANG LJ, 1991, BIO-TECHNOL, V9, P996, DOI 10.1038/nbt1091-996
NR 74
TC 42
Z9 43
U1 4
U2 16
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-3659
EI 1873-4995
J9 J CONTROL RELEASE
JI J. Control. Release
PD NOV 28
PY 2005
VL 108
IS 2-3
BP 540
EP 556
DI 10.1016/j.jconrel.2005.08.027
PG 17
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
SC Chemistry; Pharmacology & Pharmacy
GA 992IW
UT WOS:000233878600030
PM 16219383
DA 2018-12-27
ER

PT J
AU Kohno, H
   Bathe, KJ
AF Kohno, H
   Bathe, KJ
TI RETRACTED: A flow-condition-based interpolation finite element procedure
   for triangular grids (Retracted Article. See vol 51, pg 701, 2006)
SO INTERNATIONAL JOURNAL FOR NUMERICAL METHODS IN FLUIDS
LA English
DT Article; Retracted Publication
DE incompressible flows; high Reynolds number flows; stability; accuracy;
   flow-condition-based interpolation
ID FLUID-FLOWS; VISCOUS-FLOW; STEADY; CAVITY
AB A flow-condition-based interpolation finite element scheme is presented for use of triangular grids in the solution of the incompressible Navier-Stokes equations. The method provides spatially isotropic discretizations for low and high Reynolds number flows. Various example solutions are given to illustrate the capabilities of the procedure. Copyright (c) 2005 John Wiley & Sons, Ltd.
C1 MIT, Dept Mech Engn, Cambridge, MA 02139 USA.
RP Kohno, H (reprint author), MIT, Dept Mech Engn, 77 Massachusetts Ave, Cambridge, MA 02139 USA.
EM kjb@mit.edu; kohno@tana.mech.keio.ac.jp
CR Bathe K. J., 1996, FINITE ELEMENT PROCE
   Bathe KJ, 2004, INT J NUMER METH ENG, V60, P213, DOI 10.1002/nme.959
   Bathe KJ, 2002, COMPUT STRUCT, V80, P1267, DOI 10.1016/S0045-7949(02)00077-9
   Bathe KJ, 2002, MATH MOD METH APPL S, V12, P525, DOI 10.1142/S0218202502001775
   BATHE KJ, 2003, P 2 MIT C COMP FLUID
   BATHE KJ, 2005, P 3 MIT C COMP FLUID
   Drikakis D., 2005, HIGH RESOLUTION METH
   GHIA U, 1982, J COMPUT PHYS, V48, P387, DOI 10.1016/0021-9991(82)90058-4
   Gresho P., 2000, INCOMPRESSIBLE FLOW
   Hendriana D, 2000, INT J NUMER METH ENG, V47, P317, DOI 10.1002/(SICI)1097-0207(20000110/30)47:1/3<317::AID-NME773>3.0.CO;2-N
   JYOTSNA R, 1995, J COMPUT PHYS, V122, P107, DOI 10.1006/jcph.1995.1200
   Kohno H, 2005, INT J NUMER METH ENG, V63, P197, DOI 10.1002/nme.1276
   RIBBENS CJ, 1994, J COMPUT PHYS, V112, P173, DOI 10.1006/jcph.1994.1090
NR 13
TC 12
Z9 14
U1 3
U2 12
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0271-2091
EI 1097-0363
J9 INT J NUMER METH FL
JI Int. J. Numer. Methods Fluids
PD NOV 20
PY 2005
VL 49
IS 8
BP 849
EP 875
DI 10.1002/fld.1027
PG 27
WC Computer Science, Interdisciplinary Applications; Mathematics,
   Interdisciplinary Applications; Mechanics; Physics, Fluids & Plasmas
SC Computer Science; Mathematics; Mechanics; Physics
GA 976QH
UT WOS:000232747800003
DA 2018-12-27
ER

PT J
AU Fujiki, R
   Kim, MS
   Sasaki, Y
   Yoshimura, K
   Kitagawa, H
   Kato, S
AF Fujiki, R
   Kim, MS
   Sasaki, Y
   Yoshimura, K
   Kitagawa, H
   Kato, S
TI RETRACTED: Ligand-induced transrepression by VDR through association of
   WSTF with acetylated histones (retracted article)
SO EMBO JOURNAL
LA English
DT Article; Retracted Publication
DE acetylated histone; transrepression; VDIR; VDR; WSTF
ID NUCLEAR RECEPTOR; RECOMBINANT HISTONES; REMODELING FACTOR; CHROMATIN;
   COMPLEX; TRANSCRIPTION; BROMODOMAIN; PROMOTER; TRANSACTIVATION;
   COACTIVATOR
AB We have previously shown that the novel ATP-dependent chromatin-remodeling complex WINAC is required for the ligand-bound vitamin D receptor (VDR)-mediated transrepression of the 25(OH)D-3 1 alpha-hydroxylase (1 alpha(OH)ase) gene. However, the molecular basis for VDR promoter association, which does not involve its binding to specific DNA sequences, remains unclear. To address this issue, we investigated the function of WSTF in terms of the association between WINAC and chromatin for ligand-induced transrepression by VDR. Results of in vitro experiments using chromatin templates showed that the association of unliganded VDR with the promoter required physical interactions between WSTF and both VDR and acetylated histones prior to VDR association with chromatin. The acetylated histone-interacting region of WSTF was mapped to the bromodomain, and a WSTF mutant lacking the bromodomain served as a dominant-negative mutant in terms of ligand-induced transrepression of the 1 alpha(OH)ase gene. Thus, our findings indicate that WINAC associates with chromatin through a physical interaction between the WSTF bromodomain and acetylated his tones, which appears to be indispensable for VDR/promoter association for ligand-induced transrepression of 1 alpha(OH)ase gene expression.
C1 Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo 1130032, Japan.
   ERATO, Japan Sci & Technol, Kawaguchi, Saitama, Japan.
RP Kato, S (reprint author), Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 1130032, Japan.
EM uskato@mail.ecc.u-tokyo.ac.jp
CR Agalioti T, 2000, CELL, V103, P667, DOI 10.1016/S0092-8674(00)00169-0
   Brenza HL, 1998, P NATL ACAD SCI USA, V95, P1387, DOI 10.1073/pnas.95.4.1387
   Cote J, 1998, P NATL ACAD SCI USA, V95, P4947, DOI 10.1073/pnas.95.9.4947
   Dey A, 2003, P NATL ACAD SCI USA, V100, P8758, DOI 10.1073/pnas.1433065100
   Dhalluin C, 1999, NATURE, V399, P491
   Dilworth FJ, 2000, MOL CELL, V6, P1049, DOI 10.1016/S1097-2765(00)00103-9
   Dyer PN, 2004, METHOD ENZYMOL, V375, P23
   Emerson BM, 2002, CELL, V109, P267, DOI 10.1016/S0092-8674(02)00740-7
   Fyodorov DV, 2001, CELL, V106, P523, DOI 10.1016/S0092-8674(01)00478-0
   Glass CK, 2000, GENE DEV, V14, P121
   Gu W, 1999, MOL CELL, V3, P97, DOI 10.1016/S1097-2765(00)80178-1
   Hassan AH, 2002, CELL, V111, P369, DOI 10.1016/S0092-8674(02)01005-X
   Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0
   Ito M, 2000, MOL CELL, V5, P683, DOI 10.1016/S1097-2765(00)80247-6
   Ito T, 1997, CELL, V90, P145, DOI 10.1016/S0092-8674(00)80321-9
   Jacobson RH, 2000, SCIENCE, V288, P1422, DOI 10.1126/science.288.5470.1422
   Jones MH, 2000, GENOMICS, V63, P40, DOI 10.1006/geno.1999.6071
   Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6
   Kato S, 2004, J STEROID BIOCHEM, V89-90, P173, DOI 10.1016/j.jsbmb.2004.03.100
   Kitagawa H, 2003, CELL, V113, P905, DOI 10.1016/S0092-8674(03)00436-7
   Lau OD, 2000, MOL CELL, V5, P589, DOI 10.1016/S1097-2765(00)80452-9
   Lemon B, 2001, NATURE, V414, P924, DOI 10.1038/414924a
   Luger K, 1999, METHOD ENZYMOL, V304, P3
   MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X
   McKenna NJ, 2002, CELL, V108, P465, DOI 10.1016/S0092-8674(02)00641-4
   Murayama A, 2004, EMBO J, V23, P1598, DOI 10.1038/sj.emboj.7600157
   Murayama A, 1998, BIOCHEM BIOPH RES CO, V249, P11, DOI 10.1006/bbrc.1998.9098
   Nakagawa T, 2001, J BIOL CHEM, V276, P27384, DOI 10.1074/jbc.M101331200
   Narlikar GJ, 2002, CELL, V108, P475, DOI 10.1016/S0092-8674(02)00654-2
   ONATE SA, 1995, SCIENCE, V270, P1354
   Rachez C, 1998, GENE DEV, V12, P1787, DOI 10.1101/gad.12.12.1787
   Schiltz RL, 1999, J BIOL CHEM, V274, P1189, DOI 10.1074/jbc.274.3.1189
   Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412
   Takeyama K, 1997, SCIENCE, V277, P1827, DOI 10.1126/science.277.5333.1827
   Winston F, 1999, NAT STRUCT BIOL, V6, P601, DOI 10.1038/10640
   Yanagisawa J, 2002, MOL CELL, V9, P553, DOI 10.1016/S1097-2765(02)00478-1
   Yoshizawa T, 1997, NAT GENET, V16, P391, DOI 10.1038/ng0897-391
NR 37
TC 85
Z9 93
U1 3
U2 13
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0261-4189
EI 1460-2075
J9 EMBO J
JI Embo J.
PD NOV 16
PY 2005
VL 24
IS 22
BP 3881
EP 3894
DI 10.1038/sj.emboj.7600853
PG 14
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 990LM
UT WOS:000233744500006
PM 16252006
OA Green Published, Bronze
DA 2018-12-27
ER

PT J
AU Crawford, RM
   Treharne, KJ
   Best, OG
   Muimo, R
   Riemen, CE
   Mehta, A
AF Crawford, RM
   Treharne, KJ
   Best, OG
   Muimo, R
   Riemen, CE
   Mehta, A
TI RETRACTED: A novel physical and functional association between
   nucleoside diphosphate kinase A and AMP-activated protein kinase alpha 1
   in liver and lung (Retracted Article. See vol 417, pg 813, 2009)
SO BIOCHEMICAL JOURNAL
LA English
DT Article; Retracted Publication
DE acetyl-CoA carboxylase; AMP-activated protein kinase (AMPK); catalytic
   subunit; fatty acid synthesis; nucleoside diphosphate kinase (NDPK);
   nucleotide; SAMS peptide
ID SUBSTRATE-SPECIFICITY; PHOSPHORYLATION; CASCADE; LOCALIZATION;
   EXPRESSION; EXERCISE; ISOFORMS; MUSCLE; CELL
AB Nucleoside diphosphate kinase (NDPK, NM23/awd) belongs to a multifunctional family of highly conserved proteins (similar to 1620 kDa) containing two well-characterized isoforms (NM23-H1 and -H2; also known as NDPK A and 13). NDPK catalyses the conversion of nucleoside diphosphates into nucleoside triphosphates, regulates a diverse array of cellular events and can act as a protein histidine kinase. AMPK (AMP-activated protein kinase) is a heterotrimeric protein complex that responds to cellular energy status by switching off ATP-consuming pathways and switching on ATP-generating pathways when ATP is limiting. AMPK was first discovered as an activity that inhibited preparations of ACC1 (acetyl-CoA carboxylase), a regulator of cellular fatty acid synthesis. We report that NM23-H1/NDPK A and AMPK alpha 1 are associated in cytosol from two different tissue sources: rat liver and a human lung cell line (Calu-3). Co-immunoprecipitation and binding assay data from both cell types show that the H1/A (but not H2/B) isoform of NDPK is associated with AMPK complexes containing the alpha 1 (but not alpha 2) catalytic subunit. Manipulation of NM23-H1/NDPK A nucleotide transphosphorylation activity to generate ATP (but not GTP) enhances the activity of AMPK towards its specific peptide substrate in vitro and also regulates the phosphorylation of ACC1, an in vivo target for AMPK. Thus novel NM23-H1/NDPK A-dependent regulation of AMPK alpha 1-mediated phosphorylation is present in mammalian cells.
C1 Univ Dundee, Dept Maternal & Child Hlth Sci, Ninewells Hosp, Dundee DD1 9SY, Scotland.
   Sheffield Childrens Hosp, Acad Unit Child Hlth, Sheffield S10 2TH, S Yorkshire, England.
RP Mehta, A (reprint author), Univ Dundee, Dept Maternal & Child Hlth Sci, Ninewells Hosp, Dundee DD1 9SY, Scotland.
EM a.mehta@dundee.ac.uk
RI Best, Oliver/E-9060-2010
OI Best, Oliver/0000-0003-2685-3880
FU Wellcome Trust
CR Adams J, 2004, PROTEIN SCI, V13, P155, DOI 10.1110/ps.03340004
   Barnes K, 2002, J CELL SCI, V115, P2433
   Bosnar MH, 2004, EXP CELL RES, V298, P275, DOI 10.1016/j.yexcr.2004.04.018
   Cheung PCF, 2000, BIOCHEM J, V346, P659, DOI 10.1042/0264-6021:3460659
   Crawford RM, 2001, FASEB J, V15, P102, DOI 10.1096/fj.01-0446fje
   DAVIES SP, 1989, EUR J BIOCHEM, V186, P123, DOI 10.1111/j.1432-1033.1989.tb15185.x
   ENGEL M, 1995, EUR J BIOCHEM, V234, P200, DOI 10.1111/j.1432-1033.1995.200_c.x
   Hardie DG, 2001, BIOESSAYS, V23, P1112, DOI 10.1002/bies.10009
   Hardie DG, 2002, BIOCHEM SOC T, V30, P1064, DOI 10.1042/BST0301064
   Hardie DG, 1997, EUR J BIOCHEM, V246, P259, DOI 10.1111/j.1432-1033.1997.00259.x
   Hardie DG, 2003, ENDOCRINOLOGY, V144, P5179, DOI 10.1210/en.2003-0982
   HARLOW E, 1998, ANTIBODIES LAB MANUA
   Hawley SA, 2002, DIABETES, V51, P2420, DOI 10.2337/diabetes.51.8.2420
   HAWLEY SA, 1995, J BIOL CHEM, V270, P27186, DOI 10.1074/jbc.270.45.27186
   Hawley Simon A, 2003, J Biol, V2, P28, DOI 10.1186/1475-4924-2-28
   HEIDBUCHEL H, 1992, CIRC RES, V71, P808, DOI 10.1161/01.RES.71.4.808
   Holmes B, 2004, MED SCI SPORT EXER, V36, P1202, DOI 10.1249/01.MSS.0000132385.34889.FE
   Kowluru A, 2002, ARCH BIOCHEM BIOPHYS, V398, P160, DOI 10.1006/abbi.2001.2710
   Muimo R, 2000, J BIOL CHEM, V275, P36632, DOI 10.1074/jbc.M000829200
   Muimo R, 1998, AM J RESP CELL MOL, V18, P270, DOI 10.1165/ajrcmb.18.2.2850
   Nielsen JN, 2003, J APPL PHYSIOL, V94, P631, DOI 10.1152/japplphysiol.00642.2002
   Postel EH, 1998, INT J BIOCHEM CELL B, V30, P1291, DOI 10.1016/S1357-2725(98)00087-9
   Ranki HJ, 2002, MECH AGEING DEV, V123, P695, DOI 10.1016/S0047-6374(01)00415-8
   Roymans D, 2002, CLIN EXP METASTAS, V19, P465, DOI 10.1023/A:1020396722860
   Schaertl S, 1998, J BIOL CHEM, V273, P5662, DOI 10.1074/jbc.273.10.5662
   Stapleton D, 1996, J BIOL CHEM, V271, P611, DOI 10.1074/jbc.271.2.611
   SULLIVAN JE, 1994, BIOCHEM BIOPH RES CO, V200, P1551, DOI 10.1006/bbrc.1994.1627
   WAGNER PD, 1995, J BIOL CHEM, V270, P21758, DOI 10.1074/jbc.270.37.21758
   Winder WW, 1997, J APPL PHYSIOL, V82, P219
   Woods A, 1996, FEBS LETT, V397, P347, DOI 10.1016/S0014-5793(96)01209-4
NR 30
TC 21
Z9 23
U1 3
U2 10
PU PORTLAND PRESS LTD
PI LONDON
PA CHARLES DARWIN HOUSE, 12 ROGER STREET, LONDON WC1N 2JU, ENGLAND
SN 0264-6021
EI 1470-8728
J9 BIOCHEM J
JI Biochem. J.
PD NOV 15
PY 2005
VL 392
BP 201
EP 209
DI 10.1042/BJ20050269
PN 1
PG 9
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 987UM
UT WOS:000233542800022
PM 16026327
OA Green Published
DA 2018-12-27
ER

PT J
AU Liu, GY
   Zhang, XA
   Lin, HY
   Li, QL
   Wang, HM
   Ni, J
   Sang, QXA
   Zhu, C
AF Liu, GY
   Zhang, XA
   Lin, HY
   Li, QL
   Wang, HM
   Ni, J
   Sang, QXA
   Zhu, C
TI RETRACTED: Expression of matrix metalloproteinase-26 (MMP-26) mRNA in
   mouse uterus during the estrous cycle and early pregnancy (Retracted
   Article. See vol 79, pg 2500, 2006)
SO LIFE SCIENCES
LA English
DT Article; Retracted Publication
DE MMP-26; mouse; uterus; estrous cycle; implantation
ID TISSUE INHIBITORS; HUMAN ENDOMETRIUM; MENSTRUAL-CYCLE; RAT UTERUS;
   IMPLANTATION; MATRILYSIN; MATRIX-METALLOPROTEINASE-9; LEVONORGESTREL;
   IDENTIFICATION; PROGESTERONE
AB Matrix metalloproteinases (MMPs) and their tissue inhibitors play important roles in the remodeling of extracellular matrix (ECM). MMP-26, also called endometase or matrilysin-2, is a novel member of the MMP family. The present study was to investigate the temporal and spatial expression of MMP-26 mRNA in mouse uterus during the estrous cycle and early pregnancy by using in situ hybridization and semi-quantitative RT-PCR. In this study, MMP-26 mRNA was found to be localized to the luminal and glandular epithelium at proestrus and estrus, and the expression level was decreased significantly from metestrus to dioestrus. During pre-implantation period, MMP-26 mRNA was predominantly expressed in luminal and glandular epithelium at much higher level; whereas it switched to stroma during peri-implantation period, and also appeared in the blastocysts and the implantation sites. The results suggested that MMP-26 might play a role in the cycling changes of mouse uterus during the estrous cycle and embryo implantation. (c) 2005 Elsevier Inc. All rights reserved.
C1 Chinese Acad Sci, Inst Zool, State Key Lab Reprod Biol, Beijing 100080, Peoples R China.
   Harbin Med Univ, Dept Physiol, Lab Reprod Endocrinol, Harbin 150086, Peoples R China.
   Florida State Univ, Dept Chem, Tallahassee, FL 32306 USA.
   Florida State Univ, Inst Mol Biophys, Tallahassee, FL 32306 USA.
RP Zhu, C (reprint author), Chinese Acad Sci, Inst Zool, State Key Lab Reprod Biol, 25 Bei Si Huan Xi Lu, Beijing 100080, Peoples R China.
EM zhuc@ioz.ac.cn
CR BEHRENDTSEN O, 1992, DEVELOPMENT, V114, P447
   Chegini N, 2003, FERTIL STERIL, V80, P564, DOI 10.1016/S0015-0282(03)00797-0
   DAS SK, 1994, DEVELOPMENT, V120, P1071
   de Coignac AB, 2000, EUR J BIOCHEM, V267, P3323
   Fata JE, 2001, BIOL REPROD, V65, P680, DOI 10.1095/biolreprod65.3.680
   Goffin F, 2003, BIOL REPROD, V69, P976, DOI 10.1095/biolreprod.103.015933
   Hickey M, 2001, FERTIL STERIL, V75, P288, DOI 10.1016/S0015-0282(00)01690-3
   Hurst PR, 1999, REPROD FERT DEVELOP, V11, P395, DOI 10.1071/RD99021
   Isaka K, 2003, CANCER, V97, P79, DOI 10.1002/cncr.11030
   Li QL, 2002, MOL HUM REPROD, V8, P934, DOI 10.1093/molehr/8.10.934
   Lim H, 1999, GENE DEV, V13, P1561, DOI 10.1101/gad.13.12.1561
   Liu DL, 2003, BIOL REPROD, V69, P508, DOI 10.1095/biolreprod.102.011767
   Liu G, 2004, PLACENTA, V25, P530, DOI 10.1016/j.placenta.2003.11.006
   Marchenko GN, 2001, BIOCHEM J, V356, P705, DOI 10.1042/0264-6021:3560705
   Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491
   Osteen KG, 1997, ANN NY ACAD SCI, V828, P137, DOI 10.1111/j.1749-6632.1997.tb48532.x
   Paria BC, 2000, SEMIN CELL DEV BIOL, V11, P67, DOI 10.1006/scdb.2000.0153
   Park HI, 2000, J BIOL CHEM, V275, P20540, DOI 10.1074/jbc.M002349200
   Park HI, 2002, J BIOL CHEM, V277, P35168, DOI 10.1074/jbc.M205071200
   Pilka R, 2004, MOL HUM REPROD, V10, P641, DOI 10.1093/molehr/gah092
   Pilka R, 2004, GYNECOL ONCOL, V94, P661, DOI 10.1016/j.ygyno.2004.05.024
   Pilka R, 2003, MOL HUM REPROD, V9, P271, DOI 10.1093/molehr/gag039
   Qin XJ, 1997, BIOL REPROD, V56, P812, DOI 10.1095/biolreprod56.4.812
   RudolphOwen LA, 1997, ENDOCRINOLOGY, V138, P4902, DOI 10.1210/en.138.11.4902
   Skinner JL, 1999, HUM REPROD, V14, P793, DOI 10.1093/humrep/14.3.793
   Tabibzadeh S, 2002, FRONT BIOSCI-LANDMRK, V7, pD1475, DOI 10.2741/tabibza1
   Uria JA, 2000, CANCER RES, V60, P4745
   Wang HM, 2001, BIOL REPROD, V65, P31, DOI 10.1095/biolreprod65.1.31
   Whiteside EJ, 2001, BIOL REPROD, V64, P1331, DOI 10.1095/biolreprod64.5.1331
   Wilson CL, 1996, INT J BIOCHEM CELL B, V28, P123, DOI 10.1016/1357-2725(95)00121-2
   Woessner JF, 1996, BIOCHEM CELL BIOL, V74, P777, DOI 10.1139/o96-084
   Zhang X, 2004, PLACENTA, V25, P243, DOI 10.1016/j.placenta.2003.08.014
NR 32
TC 6
Z9 8
U1 5
U2 16
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0024-3205
EI 1879-0631
J9 LIFE SCI
JI Life Sci.
PD NOV 12
PY 2005
VL 77
IS 26
BP 3355
EP 3365
DI 10.1016/j.lfs.2005.05.045
PG 11
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA 977SI
UT WOS:000232823100009
PM 15987643
DA 2018-12-27
ER

PT J
AU Roman-Gomez, J
   Jimenez-Velasco, A
   Agirre, X
   Cervantes, F
   Sanchez, J
   Garate, L
   Barrios, M
   Castillejo, JA
   Navarro, G
   Colomer, D
   Prosper, F
   Heiniger, A
   Torres, A
AF Roman-Gomez, J
   Jimenez-Velasco, A
   Agirre, X
   Cervantes, F
   Sanchez, J
   Garate, L
   Barrios, M
   Castillejo, JA
   Navarro, G
   Colomer, D
   Prosper, F
   Heiniger, A
   Torres, A
TI RETRACTED: Promoter hypomethylation of the LINE-1 retrotransposable
   elements activates sense/antisense transcription and marks the
   progression of chronic myeloid leukemia (Retracted article. See vol. 32,
   pg. 804, 2013)
SO ONCOGENE
LA English
DT Article; Retracted Publication
DE CML; hypomethylation; retrotransposons; LINE-1; blast crisis
ID HUMAN L1 RETROTRANSPOSON; CHRONIC MYELOGENOUS LEUKEMIA; DNA
   HYPOMETHYLATION; C-MET; THERAPEUTIC INHIBITION; COLORECTAL-CANCER; HUMAN
   GENOME; CELL-LINES; IN-VITRO; METHYLATION
AB Aberrant genome-wide hypomethylation is thought to be related to tumorigenesis by promoting genomic instability. Since DNA methylation is considered an important mechanism for the silencing of retroelements, hypomethylation in human tumors may lead to their reactivation. However, the role of DNA hypomethylation in chronic myeloid leukemia (CML) remains to be elucidated. In this study, the methylation status of the LINE-1 (L1) retrotransposon promoter was analysed in CML samples from the chronic-phase (CP, n = 140) and the blast crisis (BC, n = 47). L1 hypomethylation was significantly more frequent in BC (74.5%) than in CP (38%) (P < 0.0001). Furthermore, L1 hypomethylation led to activation of both ORF1 sense transcription (P < 0.0001) and c-MET gene antisense transcription (P < 0.0001), and was significantly associated with high levels of BCR-ABL (P = 0.02) and DNMT3b4 (P = 0.001) transcripts. Interestingly, in CP-CML, extensive L1 hypomethylation was associated with poorer prognosis in terms of cytogenetic response to interferon (P = 0.004) or imatinib (P = 0.034) and progression-free survival (P = 0.005). The above results strongly suggest that activation of both sense and antisense transcriptions by aberrant promoter hypomethylation of the L1 elements plays a role in the progression and clinical behavior of the CML.
C1 Reina Sofia Hosp, Dept Hematol, Cordoba 14004, Spain.
   Carlos Haya Hosp, Dept Hematol, Malaga, Spain.
   Univ Navarra, Sch Med, Clin Univ, Hematol Dept,Cellular Therapy Area,Fdn Appl Med R, E-31080 Pamplona, Spain.
   Hosp Clin Barcelona, Dept Hematol, IDIBAPS, Barcelona, Spain.
RP Roman-Gomez, J (reprint author), Reina Sofia Hosp, Dept Hematol, Avda Menendez Pidal S-N, Cordoba 14004, Spain.
EM peperosa@teleline.es
RI Prosper, Felipe/H-6859-2017
OI Prosper, Felipe/0000-0001-6115-8790; COLOMER, DOLORS/0000-0001-7486-8484
CR Birchmeier C, 2003, NAT REV MOL CELL BIO, V4, P915, DOI 10.1038/nrm1261
   BRATTHAUER GL, 1992, ONCOGENE, V7, P507
   Brouha B, 2003, P NATL ACAD SCI USA, V100, P5280, DOI 10.1073/pnas.0831042100
   Buchdunger E, 2000, J PHARMACOL EXP THER, V295, P139
   Calabretta B, 2004, BLOOD, V103, P4010, DOI 10.1182/blood-2003-12-4111
   Chen RZ, 1998, NATURE, V395, P89
   Christensen JG, 2003, CANCER RES, V63, P7345
   Comoglio PM, 2001, NAT CELL BIOL, V3, P161
   DANTE R, 1992, ANTICANCER RES, V12, P559
   Deininger PL, 2002, GENOME RES, V12, P1455, DOI 10.1101/gr.282402
   Deutsch E, 2001, BLOOD, V97, P2084, DOI 10.1182/blood.V97.7.2084
   Deutsch E, 2003, BLOOD, V101, P4583, DOI 10.1182/blood-2002-10-3011
   Eden A, 2003, SCIENCE, V300, P455, DOI 10.1126/science.1083557
   Emig M, 1999, LEUKEMIA, V13, P1825, DOI 10.1038/sj.leu.2401566
   Feng QH, 1996, CELL, V87, P905, DOI 10.1016/S0092-8674(00)81997-2
   Florl AR, 1999, BRIT J CANCER, V80, P1312, DOI 10.1038/sj.bjc.6690524
   Gaudet F, 2003, SCIENCE, V300, P489, DOI 10.1126/science.1083558
   Hasford J, 1998, J NATL CANCER I, V90, P850, DOI 10.1093/jnci/90.11.850
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   HIGUMANN P, 2002, GENOMICS, V79, P628
   Huntly BJP, 2003, BLOOD, V102, P1160, DOI 10.1182/blood-2003-01-0123
   KANTARJIAN HM, 1999, AM J MED, V88, P1
   Kazazian HH, 1998, NAT GENET, V19, P19, DOI 10.1038/ng0598-19
   Lengauer C, 1997, P NATL ACAD SCI USA, V94, P2545, DOI 10.1073/pnas.94.6.2545
   Lin CH, 2001, CANCER RES, V61, P4238
   Liu J, 1997, GENE CHROMOSOME CANC, V18, P232, DOI 10.1002/(SICI)1098-2264(199703)18:3<232::AID-GCC10>3.0.CO;2-K
   Ma PC, 2003, CANCER METAST REV, V22, P309, DOI 10.1023/A:1023768811842
   Maulik G, 2002, CYTOKINE GROWTH F R, V13, P41, DOI 10.1016/S1359-6101(01)00029-6
   Menendez L, 2004, MOL CANCER, V3, DOI 10.1186/1476-4598-3-12
   MIKI Y, 1992, CANCER RES, V52, P643
   Mizuno S, 2001, BLOOD, V97, P1172, DOI 10.1182/blood.V97.5.1172
   MORSE B, 1988, NATURE, V333, P87, DOI 10.1038/333087a0
   NAGARAJAN L, 1990, BLOOD, V75, P82
   Ovchinnikov I, 2002, P NATL ACAD SCI USA, V99, P10522, DOI 10.1073/pnas.152346799
   POMYKALA HM, 1994, MOL CELL BIOL, V14, P7604, DOI 10.1128/MCB.14.11.7604
   Prak ETL, 2000, NAT REV GENET, V1, P134
   Rizwana R, 1999, J CELL SCI, V112, P4513
   Saito Y, 2002, P NATL ACAD SCI USA, V99, P10060, DOI 10.1073/pnas.152121799
   Santourlidis S, 1999, PROSTATE, V39, P166
   Schulz WA, 2002, GENE CHROMOSOME CANC, V35, P58, DOI 10.1002/gcc.10092
   Shet AS, 2002, LEUKEMIA, V16, P1402, DOI 10.1038/sj.leu.2402577
   Slupianek A, 2001, MOL CELL, V8, P795, DOI 10.1016/S1097-2765(01)00357-4
   SOKAL JE, 1984, BLOOD, V63, P789
   Speek M, 2001, MOL CELL BIOL, V21, P1973, DOI 10.1128/MCB.21.6.1973-1985.2001
   Suter CM, 2004, INT J COLORECTAL DIS, V19, P95, DOI 10.1007/s00384-003-0539-3
   Takai D, 2000, JPN J CLIN ONCOL, V30, P306, DOI 10.1093/jjco/hyd079
   Wong N, 2001, AM J PATHOL, V159, P465, DOI 10.1016/S0002-9440(10)61718-X
   Woodcock DM, 1997, J BIOL CHEM, V272, P7810, DOI 10.1074/jbc.272.12.7810
   Xu GL, 1999, NATURE, V402, P187
   Yoder JA, 1997, TRENDS GENET, V13, P335, DOI 10.1016/S0168-9525(97)01181-5
   Yu F, 2001, NUCLEIC ACIDS RES, V29, P4493, DOI 10.1093/nar/29.21.4493
NR 51
TC 156
Z9 167
U1 5
U2 16
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-9232
J9 ONCOGENE
JI Oncogene
PD NOV 3
PY 2005
VL 24
IS 48
BP 7213
EP 7223
DI 10.1038/sj.onc.1208866
PG 11
WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
GA 980BY
UT WOS:000232990100010
PM 16170379
OA Bronze, Green Published
DA 2018-12-27
ER

PT J
AU Sarzi-Puttini, P
   Atzeni, F
   Capsoni, F
   Lubrano, E
   Doria, A
AF Sarzi-Puttini, P
   Atzeni, F
   Capsoni, F
   Lubrano, E
   Doria, A
TI RETRACTED: Drug-induced lupus erythematosus (Retracted Article. See vol
   41, pg 241, 2008)
SO AUTOIMMUNITY
LA English
DT Review; Retracted Publication
DE drug-induced lupus; autoantibodies; autoimmunity; anti-histone
   antibodies
ID HORMONE REPLACEMENT THERAPY; PROCAINAMIDE-INDUCED LUPUS; INDUCED
   ANTINUCLEAR ANTIBODIES; MINOCYCLINE-INDUCED LUPUS; RHEUMATOID-ARTHRITIS;
   IN-VIVO; ANTIHISTONE ANTIBODIES; POSITIVE SELECTION; DISEASE-ACTIVITY;
   POSSIBLE TRIGGER
AB Drug-induced lupus is a syndrome which share symptoms and laboratory characteristics with idiopathic systemic lupus erythematosus (SLE). The terms drug-induced lupus (DIL) and drug-induced lupus erythematosus (DILE) are preferred, but other ones are also used-drug-related lupus, lupus-like syndrome and lupus erythematosus medicamentosus. The first case of DILE was reported in 1945 and associated with sulfadiazine. In 1953, it was reported that DILE was related to the use of hydralazine. More than 80 drugs have been associated with DILE. The average age of patients with DILE is nearly twice that of patients with idiopathic SLE. Approximately half the patients with drug-induced SLE are women, compared with 90% of patients with idiopathic SLE. Similarly to idiopathic lupus, DILE can be divided into systemic, sub-acute cutaneous and chronic cutaneous lupus. The syndrome is characterised by arthralgia, myalgia, pleurisy, rash and fever in association with antinuclear antibodies in the serum. The clinical and laboratory manifestations of drug-induced SLE are similar to those of idiopathic SLE, but central nervous system and renal involvement are rare in DILE. Recognition of DILE is important because it usually reverts within a few weeks after stopping the drug. This review discusses the general issues in DILE, such as pathogenic mechanisms, clinical forms and diagnostic criteria, and provides more detailed information for some of the most recent implicated drugs: minocycline, statins, anti-TNF-alpha agents.
C1 L Sacco Univ Hosp, Dept Rheumatol, Rheumatol Unit, I-20157 Milan, Italy.
   Univ Milan, IRCCS, Osped Maggiore Policlin, Dept Internal Med, Milan, Italy.
   Maugeri Fdn IRCCS, Res Inst Rehabil Med, Rheumatol & Rehabil Res Unit, Telese Terme, Italy.
   Univ Padua, Chair Rheumatol, Padua, Italy.
RP Sarzi-Puttini, P (reprint author), L Sacco Univ Hosp, Dept Rheumatol, Rheumatol Unit, Via GB Grassi 74, I-20157 Milan, Italy.
EM sarzi@tiscali.it; atzenifabiola@hotmail.com; francocapsoni@unimi.it;
   elubrano@fsm.it; adoria@unipd.it
OI LUBRANO DI SCORPANIELLO, Ennio/0000-0001-6189-5328; Sarzi-Puttini,
   Piercarlo/0000-0002-8673-5133
CR AHMAD S, 1991, ARCH INTERN MED, V151, P1667, DOI 10.1001/archinte.151.8.1667
   ALARCONSEGOVIA D, 1973, CLIN EXP IMMUNOL, V15, P543
   ALLOWAY JA, 1995, SEMIN ARTHRITIS RHEU, V24, P315, DOI 10.1016/S0049-0172(95)80003-4
   ANSELL BM, 1993, LUPUS, V2, P193, DOI 10.1177/096120339300200312
   ARDEN NK, 1994, LUPUS, V3, P11, DOI 10.1177/096120339400300104
   Askanase AD, 2002, BEST PRACT RES CL RH, V16, P265, DOI 10.1053/berh.2001.0225
   Atzeni F, 2003, Reumatismo, V55, P147
   BANNWARTH B, 1992, ARCH INTERN MED, V152, P1093, DOI 10.1001/archinte.1992.00400170157032
   BATCHELOR JR, 1980, LANCET, V1, P1107
   BENCHETRIT A, 1994, ARTHRITIS RHEUM, V37, P1614, DOI 10.1002/art.1780371109
   BERTIN P, 1993, CLIN EXP RHEUMATOL, V11, P695
   BLECK TP, 1994, EPILEPSIA, V35, P162
   Bleumink GS, 2001, RHEUMATOLOGY, V40, P1317, DOI 10.1093/rheumatology/40.11.1317
   Bonsmann G, 2001, J AM ACAD DERMATOL, V44, P925, DOI 10.1067/mjd.2001.114565
   BRAY VJ, 1994, J RHEUMATOL, V21, P2157
   Brooke R, 1998, BRIT J DERMATOL, V139, P1132
   BURLINGAME RW, 1991, J CLIN INVEST, V88, P680, DOI 10.1172/JCI115353
   Buyon JP, 2005, ANN INTERN MED, V142, P953, DOI 10.7326/0003-4819-142-12_Part_1-200506210-00004
   Callen JP, 2001, ARCH DERMATOL, V137, P1196
   Callen JP, 2001, J AM ACAD DERMATOL, V45, P315, DOI 10.1067/mjd.2001.116583
   CAMERON HA, 1984, BRIT MED J, V289, P410, DOI 10.1136/bmj.289.6442.410
   CANOSO RT, 1988, AM J HEMATOL, V27, P272, DOI 10.1002/ajh.2830270408
   Carter JD, 2001, SOUTHERN MED J, V94, P1122, DOI 10.1097/00007611-200111000-00017
   COHEN MG, 1989, ARTHRITIS RHEUM, V32, P1319, DOI 10.1002/anr.1780321020
   DARKEN M, 1988, J AM ACAD DERMATOL, V18, P38, DOI 10.1016/S0190-9622(88)70005-5
   Datta SK, 2000, NAT MED, V6, P259, DOI 10.1038/73101
   Day R, 2002, LANCET, V359, P540, DOI 10.1016/S0140-6736(02)07718-8
   di Fazano C S, 2001, Expert Opin Pharmacother, V2, P1623
   DUBOIS EL, 1969, MEDICINE, V48, P217
   Dunphy J, 2000, BRIT J DERMATOL, V142, P461, DOI 10.1046/j.1365-2133.2000.03357.x
   DVORY VE, 1989, CLIN NEUROPHARMACOL, V12, P115
   Elkayam O, 1998, AM J MED, V105, P484, DOI 10.1016/S0002-9343(98)00325-8
   Elkayam O, 1996, ANN RHEUM DIS, V55, P769, DOI 10.1136/ard.55.10.769
   FEDERMANN M, 1994, ANN RHEUM DIS, V53, P403, DOI 10.1136/ard.53.6.403
   Feldmann M, 2001, ANNU REV IMMUNOL, V19, P163, DOI 10.1146/annurev.immunol.19.1.163
   FRITZLER MJ, 1994, LUPUS, V3, P455, DOI 10.1177/096120339400300605
   GIOUD M, 1982, ARTHRITIS RHEUM, V25, P407, DOI 10.1002/art.1780250408
   GONZALO JA, 1992, INT ARCH ALLERGY IMM, V97, P251, DOI 10.1159/000236130
   GOODRICH AL, 1993, J AM ACAD DERMATOL, V28, P1001, DOI 10.1016/S0190-9622(08)80652-4
   Gough A, 1996, BRIT MED J, V312, P169
   GRANINGER WB, 1991, J RHEUMATOL, V18, P1621
   Grant ECG, 2001, LANCET, V358, P586, DOI 10.1016/S0140-6736(01)05731-2
   Greenstein BD, 2001, J WOMEN HEALTH GEN-B, V10, P233, DOI 10.1089/152460901300139989
   Grimaldi CM, 2001, J IMMUNOL, V167, P1886, DOI 10.4049/jimmunol.167.4.1886
   Gunnarsson I, 1997, BRIT J RHEUMATOL, V36, P1089
   Hanson J, 1998, LANCET, V352, P1070, DOI 10.1016/S0140-6736(05)60116-X
   HESS E, 1988, NEW ENGL J MED, V318, P1460, DOI 10.1056/NEJM198806023182209
   Holmes S, 1998, BRIT J DERMATOL, V139, P1133
   HORIO T, 1978, ARCH DERMATOL, V114, P1498, DOI 10.1001/archderm.114.10.1498
   HOSFTRA A, 1994, DRUG METAB REV, V26, P135
   JIANG XX, 1994, SCIENCE, V266, P810, DOI 10.1126/science.7973636
   KAUFFMAN CL, 2001, MED J, V2, P11
   KAWACHI Y, 1995, CLIN EXP DERMATOL, V20, P345, DOI 10.1111/j.1365-2230.1995.tb01340.x
   KHATTAK FH, 1993, BR J RHEUMATOL, V22, P104
   Kreidstein S, 1997, J RHEUMATOL, V24, P2149
   Kretz-Rommel A, 2000, NAT MED, V6, P298
   Kretz-Rommel A, 1999, J IMMUNOL, V162, P813
   KretzRommel A, 1997, J CLIN INVEST, V99, P1888, DOI 10.1172/JCI119356
   LADD AT, 1962, NEW ENGL J MED, V267, P1357, DOI 10.1056/NEJM196212272672608
   Lawson TM, 2001, RHEUMATOLOGY, V40, P329, DOI 10.1093/rheumatology/40.3.329
   LEE S L, 1975, Seminars in Arthritis and Rheumatism, V5, P83
   Li E, 2002, NAT REV GENET, V3, P662, DOI 10.1038/nrg887
   Lu QJ, 2002, ARTHRITIS RHEUM, V46, P1282, DOI 10.1002/art.10234
   MALLESON P, 1989, ARTHRITIS RHEUM, V32, P919
   MANSILLATINOCO R, 1982, BRIT MED J, V284, P936, DOI 10.1136/bmj.284.6320.936
   MASSAROTTI EM, 1992, AM J MED, V92, P693, DOI 10.1016/0002-9343(92)90789-E
   MCNEIL HP, 1991, ADV IMMUNOL, V49, P193
   Meier CR, 1998, J RHEUMATOL, V25, P1515
   MIELKE H, 1993, RHEUMATOLOGY, V22, P229
   Mohan AK, 2002, LANCET, V360, P646, DOI 10.1016/S0140-6736(02)09800-8
   MOLDEN DP, 1986, ARTHRITIS RHEUM, V29, P39, DOI 10.1002/art.1780290106
   Muramatsu M, 1995, Nihon Naika Gakkai Zasshi, V84, P1736
   Murphy M, 1998, BRIT J DERMATOL, V138, P708
   NASSBERGER L, 1994, SCAND J RHEUMATOL, V23, P206
   Nousari HC, 1998, LANCET, V352, P1825, DOI 10.1016/S0140-6736(05)79887-1
   PERRY HM, 1970, J LAB CLIN MED, V76, P114
   PETERSON LL, 1984, J AM ACAD DERMATOL, V10, P379, DOI 10.1016/S0190-9622(84)80011-0
   Phillips R, 1999, Dermatol Online J, V5, P9
   PORTANOVA JP, 1987, J IMMUNOL, V138, P446
   Raanani P, 2002, ACTA HAEMATOL-BASEL, V107, P133, DOI 10.1159/000057631
   Rider V, 2001, INT IMMUNOPHARMACOL, V1, P1009, DOI 10.1016/S1567-5769(01)00046-7
   ROTHFIELD NF, 1978, ANN INTERN MED, V88, P650, DOI 10.7326/0003-4819-88-5-650
   RUBIN RL, 1987, J RHEUMATOL, V14, P118
   RUBIN RL, 1995, J IMMUNOL, V154, P2483
   RUBIN RL, 1985, CLIN IMMUNOL IMMUNOP, V36, P49, DOI 10.1016/0090-1229(85)90038-8
   Sakurai Y, 1995, Nihon Naika Gakkai Zasshi, V84, P2069
   Sarzi-Puttini P, 2000, LUPUS, V9, P555, DOI 10.1177/096120330000900715
   Sarzi-Puttini P, 2003, DIGEST LIVER DIS, V35, P814, DOI 10.1016/S1590-8658(03)00448-1
   Sato-Matsumura Kazuko C., 1994, Journal of Dermatology (Tokyo), V21, P501
   Schaffer J, 2001, J AM ACAD DERMATOL, V44, P198, DOI 10.1067/mjd.2001.112218
   SCHWARTZ D, 1990, LANCET, V336, P187, DOI 10.1016/0140-6736(90)91717-O
   Shakoor N, 2002, LANCET, V359, P579, DOI 10.1016/S0140-6736(02)07714-0
   Sheikhzadeh A, 2002, ARCH INTERN MED, V162, P834, DOI 10.1001/archinte.162.7.834
   SHERMAN JD, 1967, ARCH INTERN MED, V120, P321, DOI 10.1001/archinte.120.3.321
   Siddiqui Mumtaz A, 2002, Am J Ther, V9, P163, DOI 10.1097/00045391-200203000-00012
   SPEIRS C, 1989, LANCET, V1, P922
   Spiera RF, 2002, ARCH INTERN MED, V162, P2240, DOI 10.1001/archinte.162.19.2240
   Sridhar MK, 1998, LANCET, V352, P114, DOI 10.1016/S0140-6736(98)85019-8
   Sturkenboom MCJM, 1999, ARCH INTERN MED, V159, P493, DOI 10.1001/archinte.159.5.493
   TORFFVIT O, 1994, HUM EXP TOXICOL, V13, P563, DOI 10.1177/096032719401300810
   TSANKOV NK, 1990, INT J DERMATOL, V29, P571, DOI 10.1111/j.1365-4362.1990.tb03471.x
   Uetrecht JP, 1997, TOXICOLOGY, V119, P37, DOI 10.1016/S0300-483X(96)03594-9
   URETRECH JP, 1988, CHEM RES TOXICOL, V1, P134
   Verma SP, 2000, CHEST, V117, P597, DOI 10.1378/chest.117.2.597
   Via CS, 2001, J IMMUNOL, V167, P6821, DOI 10.4049/jimmunol.167.12.6821
   Vidaver Regina, 2002, Trends in Immunology, V23, P229, DOI 10.1016/S1471-4906(02)02204-4
   VONSCHMIEDEBERG S, 1995, SCIENCE, V268, P585, DOI 10.1126/science.7725110
   WALSHE JM, 1981, J RHEUMATOL, V8, P155
   Weinstein A, 1980, Prog Clin Immunol, V4, P1
   Yang LY, 1999, RHEUMATOLOGY, V38, P372, DOI 10.1093/rheumatology/38.4.372
   Yoshimasu T, 2001, EUR J DERMATOL, V11, P54
   Yung R, 1997, ARTHRITIS RHEUM, V40, P1436, DOI 10.1002/art.1780400811
   Yung R, 1996, J CLIN INVEST, V97, P2866, DOI 10.1172/JCI118743
   YUNG RL, 1995, J IMMUNOL, V154, P3025
   YUNG RL, 1994, RHEUM DIS CLIN N AM, V20, P61
   ZAMBER RW, 1992, J RHEUMATOL, V19, P977
NR 116
TC 88
Z9 93
U1 4
U2 16
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0891-6934
EI 1607-842X
J9 AUTOIMMUNITY
JI Autoimmunity
PD NOV
PY 2005
VL 38
IS 7
BP 507
EP 518
DI 10.1080/08916930500285857
PG 12
WC Immunology
SC Immunology
GA 990XN
UT WOS:000233776800006
PM 16373256
DA 2018-12-27
ER

PT J
AU Prabhakaran, K
   Sheridan, BS
   Kinchington, PR
   Khanna, KM
   Decman, V
   Lathrop, K
   Hendricks, RL
AF Prabhakaran, K
   Sheridan, BS
   Kinchington, PR
   Khanna, KM
   Decman, V
   Lathrop, K
   Hendricks, RL
TI RETRACTED: Sensory neurons regulate the effector functions of CD8(+) T
   cells in controlling HSV-1 latency ex vivo (Retracted Article. See vol
   24, pg 657, 2006)
SO IMMUNITY
LA English
DT Article; Retracted Publication
ID HERPES-SIMPLEX-VIRUS; CHRONIC VIRAL-INFECTION; IMMUNE CONTROL;
   EXPRESSION; REACTIVATION; GANGLIA; GRANZYME; MICE; GAMMAHERPESVIRUS;
   IMMUNODOMINANCE
AB We provide evidence that sensory neurons regulate the effector functions and phenotype of CD8(+) T cells during active immunosurveillance of HSV-1 latency. Low-level viral gene expression in latently infected sensory ganglia gives rise to a unique, functionally active CD8(+) T cell population. Surprisingly, distinct neuronal subsets require different CD8 effector mechanisms to maintain viral latency, with some requiring IFN-gamma and others requiring lytic granules (LG). This nonredundant efficacy of CD8(+) T cell effector mechanisms in maintaining viral latency is explained as follows: (1) a subset of neurons that expresses IFN-gamma receptors (IFN-gamma R+) and Qa1 responds to IFN-gamma, but Qa1 engagement of CD94/NKG2a blocks LG exocytosis by CD8(+) T cells; (2) another neuronal subset is responsive to LG because it lacks Gal and is refractory to IFN-gamma because it also lacks IFN-gamma R. In the latter subset, LG appear to provide a nonlethal block of viral reactivation.
C1 Univ Pittsburgh, Sch Med, Grad Program Immunol, Pittsburgh, PA 15213 USA.
   Univ Pittsburgh, Sch Med, Dept Ophthalmol, Pittsburgh, PA 15213 USA.
   Univ Pittsburgh, Sch Med, Dept Mol Genet & Biochem, Pittsburgh, PA 15213 USA.
   Univ Pittsburgh, Sch Med, Dept Immunol, Pittsburgh, PA 15213 USA.
RP Hendricks, RL (reprint author), Univ Pittsburgh, Sch Med, Grad Program Immunol, 203 Lothrop St, Pittsburgh, PA 15213 USA.
EM hendricksrr@upmc.edu
FU NEI NIH HHS [P30EY08098, EY05945, EY015291]; NINDS NIH HHS [F30
   NS50905-01]
CR Betts MR, 2004, J IMMUNOL, V172, P6407, DOI 10.4049/jimmunol.172.10.6407
   BONNEAU RH, 1993, VIROLOGY, V195, P62, DOI 10.1006/viro.1993.1346
   Browne KA, 1999, MOL CELL BIOL, V19, P8604
   Chen SH, 2002, J VIROL, V76, P4764, DOI 10.1128/JVI.76.10.4764-4772.2002
   Decman V, 2005, J VIROL, V79, P10339, DOI 10.1128/JVI.79.16.10339-10347.2005
   Edwards KM, 1999, IMMUNOL CELL BIOL, V77, P76, DOI 10.1046/j.1440-1711.1999.00799.x
   Feldman LT, 2002, P NATL ACAD SCI USA, V99, P978, DOI 10.1073/pnas.022301899
   Kaech SM, 2003, NAT IMMUNOL, V4, P1191, DOI 10.1038/ni1009
   Khanna KM, 2004, CURR OPIN IMMUNOL, V16, P463, DOI 10.1016/j.coi.2004.05.003
   Khanna KM, 2003, IMMUNITY, V18, P593, DOI 10.1016/S1074-7613(03)00112-2
   Kramer J, 1995, Eur Spine J, V4, P69, DOI 10.1007/BF00278914
   Kubota A, 1999, J IMMUNOL, V163, P6488
   Lang KS, 2005, EUR J IMMUNOL, V35, P738, DOI 10.1002/eji.200425828
   Liu HsuanLiang, 2001, Recent Research Developments in Protein Engineering, V1, P75
   Liu T, 2000, J EXP MED, V191, P1459, DOI 10.1084/jem.191.9.1459
   Loh J, 2004, J VIROL, V78, P12519, DOI 10.1128/JVI.78.22.12519.12528.2004
   Miller JD, 2002, J IMMUNOL, V169, P693, DOI 10.4049/jimmunol.169.2.693
   Mullbacher A, 1996, P NATL ACAD SCI USA, V93, P5783, DOI 10.1073/pnas.93.12.5783
   Pereira RA, 2000, J VIROL, V74, P1029, DOI 10.1128/JVI.74.2.1029-1032.2000
   Perng GC, 2000, SCIENCE, V287, P1500, DOI 10.1126/science.287.5457.1500
   Sawtell NA, 2004, J VIROL, V78, P7784, DOI 10.1128/JVI.78.14.7784-7794.2004
   Slifka MK, 1999, NATURE, V401, P76, DOI 10.1038/43454
   Theil D, 2003, AM J PATHOL, V163, P2179, DOI 10.1016/S0002-9440(10)63575-4
   Tibbetts SA, 2002, J VIROL, V76, P7125, DOI 10.1128/JVI.76.14.7125-7132.2002
   van der Most RG, 2003, VIROLOGY, V315, P93, DOI 10.1016/S0042-6822(03)00594-4
   Wherry EJ, 2003, NAT IMMUNOL, V4, P225, DOI 10.1038/ni889
   Wherry EJ, 2004, P NATL ACAD SCI USA, V101, P16004, DOI 10.1073/pnas.0407192101
   Wherry EJ, 2003, J VIROL, V77, P4911, DOI 10.1128/JVI.77.8.4911-4927.2003
   Wojtasiak M, 2004, INT IMMUNOL, V16, P1333, DOI 10.1093/intimm/dxh136
   Wolint P, 2004, J EXP MED, V199, P925, DOI 10.1084/jem.20031799
   Zhang D, 2003, BLOOD, V101, P226, DOI 10.1182/blood-2002-03-0791
NR 31
TC 16
Z9 17
U1 3
U2 8
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 1074-7613
J9 IMMUNITY
JI Immunity
PD NOV
PY 2005
VL 23
IS 5
BP 515
EP 525
DI 10.1016/j.immuni.2005.09.017
PG 11
WC Immunology
SC Immunology
GA 989GK
UT WOS:000233660700008
PM 16286019
OA Bronze
DA 2018-12-27
ER

PT J
AU Wang, RX
   Li, XR
   Jang, WP
   Liu, ZH
   Yang, XJ
   Xiao, CH
   Shao, LZ
   Zhu, JQ
AF Wang, RX
   Li, XR
   Jang, WP
   Liu, ZH
   Yang, XJ
   Xiao, CH
   Shao, LZ
   Zhu, JQ
TI RETRACTED: Blood B-type natriuretic peptide changes in different periods
   and different cardiac pacing modes (Retracted article. See vol 50, pg
   405, 2009)
SO INTERNATIONAL HEART JOURNAL
LA English
DT Article; Retracted Publication
DE B-type natriuretic peptide; pacing mode; congestive heart failure;
   physiologic pacing; nonphysiologic pacing
ID SICK SINUS SYNDROME; HEART-FAILURE; RESYNCHRONIZATION THERAPY; PACEMAKER
   IMPLANTATION; DIAGNOSIS; ECHOCARDIOGRAPHY; MANAGEMENT; ATRIAL; MARKER
AB To observe blood B-type natriuretic peptide (BNP) level changes and the clinical implications in different periods and different cardiac pacing modes, the BNP levels of 105 patients with permanent cardiac pacing were assayed before pacemaker implantation and 1 day, 1 week, 1 month, 3 months, 6 months, and 9 months postoperatively. BNP level changes were compared in different periods and doting different pacing modes. DDD(R) pacing mode was performed in 32 patients for 9 months and then changed to AAI(R) and VVI(R) pacing modes for 2 months, respectively.
   BNP levels were assayed during three different pacing modes. BNP levels did not change at any time with any pacing mode in patients with New York Heart Association (NYHA) heart functional class I to II before pacemaker implantation, however, BNP levels did change significantly with physiologic pacing mode and nonphysiologic pacing mode in patients with NYHA heart functional class III to IV before pacemaker implantation. BNP levels during physiologic pacing mode decreased significantly while it increased during, nonphysiologic pacing mode. BNP levels were the lowest in AAI(R) pacing and the highest in VVI(R) pacing among the three pacing modes. The BNP level in DDD(R) pacing was between that for AAI(R) pacing and VVI(R) pacing.
   The results indicate that physiologic pacing, should first be chosen in patients with bradycardia and congestive heart failure (CHF), and that AAI(R) was the best pacing mode if atrioventricular conduction] function was normal.
C1 Nanjing Med Univ, Peoples Hosp Wuxi City 1, Dept Cardiol, Wuxi 214002, Peoples R China.
   Nanjing Med Univ, Affiliated Hosp 1, Wuxi 214002, Peoples R China.
   Soochow Univ, Affiliated Hosp 1, Dept Cardiol, Suzhou, Peoples R China.
RP Wang, RX (reprint author), Nanjing Med Univ, Peoples Hosp Wuxi City 1, Dept Cardiol, 111 Ranmin Zhonglu, Wuxi 214002, Peoples R China.
CR Abraham WT, 2002, NEW ENGL J MED, V346, P1845, DOI 10.1056/NEJMoa013168
   Bax JJ, 2003, AM J CARDIOL, V92, P1238, DOI 10.1016/j.amjcard.2003.06.016
   Bhatia V, 2003, J Postgrad Med, V49, P182
   Boriani G, 2004, INT J CARDIOL, V94, P151, DOI 10.1016/j.ijcard.2003.05.016
   Hoijer CJ, 2002, EUR HEART J, V23, P490, DOI 10.1053/euhj.2001.2817
   Horie H, 1999, PACE, V22, P282, DOI 10.1111/j.1540-8159.1999.tb00440.x
   Horie H, 2000, JPN CIRC J, V64, P965, DOI 10.1253/jcj.64.965
   Logeart D, 2002, J AM COLL CARDIOL, V40, P1794, DOI 10.1016/S0735-1097(02)02482-8
   Mair J, 2001, CLIN CHEM LAB MED, V39, P571, DOI 10.1515/CCLM.2001.093
   Maisel A, 2001, Cardiovasc Toxicol, V1, P159, DOI 10.1385/CT:1:2:159
   Maisel Alan, 2001, Cardiology Clinics, V19, P557, DOI 10.1016/S0733-8651(05)70243-5
   Mani H, 2004, PACE, V27, P1212, DOI 10.1111/j.1540-8159.2004.00611.x
   McNairy M, 2002, AM HEART J, V143, P406, DOI 10.1067/mhj.2002.120148
   Molhoek SG, 2004, HEART, V90, P97, DOI 10.1136/heart.90.1.97
   Penicka M, 2004, CIRCULATION, V109, P978, DOI 10.1161/01.CIR.0000116765.43251.D7
   Sinha AM, 2003, AM J CARDIOL, V91, P755, DOI 10.1016/S0002-9149(02)03425-2
   STRUTHERS AD, 1995, QJM-MON J ASSOC PHYS, V88, P303
   SUDOH T, 1988, NATURE, V332, P78, DOI 10.1038/332078a0
   van der Sloot JAP, 2003, NETH J MED, V61, P19
   Villacorta Humberto, 2002, Arq. Bras. Cardiol., V79, P569, DOI 10.1590/S0066-782X2002001500002
   WANG RX, 2004, CLIN J CARDIAC PACIN, V18, P392
   Wu XY, 2001, JPN HEART J, V42, P471, DOI 10.1536/jhj.42.471
NR 22
TC 2
Z9 4
U1 3
U2 8
PU INT HEART JOURNAL ASSOC
PI TOKYO
PA UNIV TOKYO, GRADUATE SCHOOL MEDICINE, DEPT CARDIOVASCULAR MEDICINE,
   HONGO 7-3-1, BUNKYO-KU, TOKYO, 113-8655, JAPAN
SN 1349-2365
EI 1349-3299
J9 INT HEART J
JI Int. Heart J.
PD NOV
PY 2005
VL 46
IS 6
BP 1015
EP 1022
DI 10.1536/ihj.46.1015
PG 8
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 010NK
UT WOS:000235201200008
PM 16394597
OA Bronze
DA 2018-12-27
ER

PT J
AU Nikoobakht, M
   Nasseh, H
   Pourkasmaee, M
AF Nikoobakht, M
   Nasseh, H
   Pourkasmaee, M
TI RETRACTED: The relationship between lipid profile and erectile
   dysfunction (Retracted Article. See vol 26, pg 4607, 2007)
SO INTERNATIONAL JOURNAL OF IMPOTENCE RESEARCH
LA English
DT Article; Retracted Publication
DE erectile dysfunction; lipids; cholesterol; LDL
ID ENDOTHELIUM-DEPENDENT RELAXATION; LOW-DENSITY LIPOPROTEINS;
   SMOOTH-MUSCLE; RISK-FACTORS; CHOLESTEROL; MEN; HYPERCHOLESTEROLEMIA;
   IMPOTENCE
AB The objective of this study is to investigate the relation between serum lipids (cholesterol, LDL, HDL, triglyceride (TG)) and erectile dysfunction (ED). The experimental methods involved comparison of 100 patients with organic ED (mean age of 43.59 +/- 10.51 y), with 100 healthy individuals (mean age of 43.72 +/- 9.76 y) regarding their lipid profile from January 2000 to June 2003 (cholesterol, TG, HDL, LDL). The results showed that there was a significant difference between mean plasma cholesterol and LDL levels in the individuals suffering from ED and the control group (P=0.04 and 0.02, respectively). The TG and HDL mean plasma level differences were not significant (P=0.583 and 0.299, respectively). Odds ratios for high plasma cholesterol level (>240 mg/dl) and high plasma LDL level (>160 mg/dl) were 1.74 and 1.97. The R-2 was 0.04 for both cholesterol and LDL. Applying linear regression, the coefficient for cholesterol and LDL reduced the International Index of Erectile Function questionnaire scores by -0.036 and -0.035. In conclusion, this study, the correlation of cholesterol and LDL levels with ED strongly supports the role of hyperlipidemia treatment in both the prevention and management of ED.
C1 Univ Tehran Med Sci, Sina Hosp, Urol Res Ctr, Dept Urol, Tehran 1995345432, Iran.
RP Nikoobakht, M (reprint author), Univ Tehran Med Sci, Sina Hosp, Urol Res Ctr, Dept Urol, Hassanabad Sq, Tehran 1995345432, Iran.
EM Nikoobakht_M@hotmail.com
OI Pourkasmaee, maziar/0000-0003-3873-3528
CR Atahan O., 1998, International Urology and Nephrology, V30, P185, DOI 10.1007/BF02550575
   AZADZOI KM, 1991, J UROLOGY, V146, P238, DOI 10.1016/S0022-5347(17)37759-5
   Broderick GA, 1996, UROL CLIN N AM, V23, P111, DOI 10.1016/S0094-0143(05)70297-4
   FELDMAN HA, 1994, J UROLOGY, V151, P54, DOI 10.1016/S0022-5347(17)34871-1
   Johannes CB, 2000, J UROLOGY, V163, P460, DOI 10.1016/S0022-5347(05)67900-1
   JUENEMANN KP, 1990, INT J IMPOT RES S2, V2, P33
   KIM JH, 1994, J UROLOGY, V151, P198, DOI 10.1016/S0022-5347(17)34916-9
   Kim SC, 2000, ASIAN J ANDROL, V2, P161
   KUGIYAMA K, 1990, NATURE, V344, P160, DOI 10.1038/344160a0
   LEUNG WH, 1993, LANCET, V341, P1496, DOI 10.1016/0140-6736(93)90634-S
   Lewis R, 2000, ERECTILE DYSFUNCTION, P21
   MANNING M, 1996, INT J IMPOT RES, V8, P67
   Mellinger BC, 1992, AM UROL ASS UPDATE S, V11, P146
   Pinnock CB, 1999, MED J AUSTRALIA, V171, P353
   ROSENFELD ME, 1991, CIRCULATION, V83, P2137, DOI 10.1161/01.CIR.83.6.2137
   Saltzman EA, 2004, J UROLOGY, V172, P255, DOI 10.1097/01.ju.0000132368.10458.66
   Sanchez-Cruz JJ, 2003, EUR UROL, V44, P245, DOI 10.1016/S0302-2838(03)00215-X
   Sullivan ME, 2001, BJU INT, V87, P838, DOI 10.1046/j.1464-410x.2001.02211.x
   TANNER FC, 1991, CIRCULATION, V83, P2012, DOI 10.1161/01.CIR.83.6.2012
   VIRAG R, 1985, LANCET, V1, P181
   Walczak Monika K, 2002, J Gend Specif Med, V5, P19
   WEI M, 1994, AM J EPIDEMIOL, V140, P930, DOI 10.1093/oxfordjournals.aje.a117181
NR 22
TC 32
Z9 35
U1 3
U2 8
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0955-9930
EI 1476-5489
J9 INT J IMPOT RES
JI Int. J. Impot. Res.
PD NOV-DEC
PY 2005
VL 17
IS 6
BP 523
EP 526
DI 10.1038/sj.ijir.3901350
PG 4
WC Urology & Nephrology
SC Urology & Nephrology
GA 979TH
UT WOS:000232967200008
PM 15988546
OA Bronze
DA 2018-12-27
ER

PT J
AU Pogrel, MA
AF Pogrel, MA
TI RETRACTED: Treatment of keratocysts: The case for decompression and
   marsupialization (Retracted Article. See vol 65, pg 362, 2007)
SO JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY
LA English
DT Editorial Material; Retracted Publication
ID TERM-FOLLOW-UP; LIQUID-NITROGEN CRYOTHERAPY; LARGE ODONTOGENIC
   KERATOCYSTS; MANAGEMENT; ENUCLEATION; RECURRENCE; LESIONS; GROWTH; CYSTS
C1 Univ Calif San Francisco, Dept Oral & Maxillofacial Surg, San Francisco, CA 94143 USA.
RP Pogrel, MA (reprint author), Univ Calif San Francisco, Dept Oral & Maxillofacial Surg, 521 Parnassus Ave,C-522,Box 0440, San Francisco, CA 94143 USA.
EM map@itsa.ucsf.edu
CR August M, 2000, J ORAL MAXIL SURG, V58, P935, DOI 10.1053/joms.2000.8731
   AUGUST M, 2000, J ORAL MAXILLOFAC SU, V58, P940
   BRAMLEY P, 1974, INT J ORAL MAXILLOF, V3, P337, DOI 10.1016/S0300-9785(74)80074-8
   BRANNON RB, 1976, ORAL SURG ORAL MED O, V42, P54, DOI 10.1016/0030-4220(76)90031-1
   BRONDUM N, 1991, ORAL SURG ORAL MED O, V72, P265, DOI 10.1016/0030-4220(91)90211-T
   Cranin A N, 1994, N Y State Dent J, V60, P41
   DOWSETT E, 1932, P ROY SOC MED, V25, P4756
   EYRE J, 1985, BRIT J ORAL MAX SURG, V23, P195, DOI 10.1016/0266-4356(85)90090-7
   HARRIS M, 1978, ANN ROY COLL SURG, V60, P85
   HOPPER FE, 1982, BRIT DENT J, V153, P306, DOI 10.1038/sj.bdj.4804925
   IRVINE GH, 1985, BRIT J ORAL MAX SURG, V23, P204, DOI 10.1016/0266-4356(85)90091-9
   JENSEN J, 1988, J CRANIO MAXILL SURG, V16, P362, DOI 10.1016/S1010-5182(88)80080-5
   Marker P, 1996, ORAL SURG ORAL MED O, V82, P122, DOI 10.1016/S1079-2104(96)80214-9
   Nakamura N, 2002, ORAL SURG ORAL MED O, V94, P543, DOI 10.1067/moe.2002.128022
   Ninomiya T, 2002, J ORAL PATHOL MED, V31, P526, DOI 10.1034/j.1600-0714.2002.00029.x
   Partsch C, 1892, DTSCH MSCHR ZAHNHEIL, V10, P271
   Partsch C, 1910, DTSCH MSCHR ZAHNHEIL, V28, P252
   Pogrel M A, 1995, J Calif Dent Assoc, V23, P54
   Pogrel M Anthony, 2003, Oral Maxillofac Surg Clin North Am, V15, P415, DOI 10.1016/S1042-3699(03)00038-4
   POGREL MA, 1993, J ORAL MAXIL SURG, V51, P269
   Pogrel MA, 2004, J ORAL MAXIL SURG, V62, P651, DOI 10.1016/j.joms.2003.08.029
   Pogrel MA, 2002, INT J ORAL MAX SURG, V31, P296, DOI 10.1054/ijom.2001.0210
   RUD J, 1969, J ORAL SURG, V27, P323
   SALMASSY DA, 1995, J ORAL MAXIL SURG, V53, P784, DOI 10.1016/0278-2391(95)90333-X
   Schmidt BL, 2001, J ORAL MAXIL SURG, V59, P720, DOI 10.1053/joms.2001.24278
   SCHMIDT BL, 1999, J ORAL MAXILLOFAC SU, V57, P46
   Schmidt Brian L, 2003, Oral Maxillofac Surg Clin North Am, V15, P393, DOI 10.1016/S1042-3699(03)00041-4
   Seward M H, 1969, Br J Oral Surg, V6, P149
   Stoelinga PJW, 2001, INT J ORAL MAX SURG, V30, P14, DOI 10.1054/ijom.2000.0027
   TOLLER P A, 1970, British Dental Journal, V129, P275, DOI 10.1038/sj.bdj.4802570
   TUCKER WM, 1972, J ORAL SURG, V30, P669
   VEDTOFTE P, 1979, INT J ORAL MAXILLOF, V8, P412, DOI 10.1016/S0300-9785(79)80079-4
   VOORSMIT RACA, 1981, J MAXILLOFAC SURG, V9, P228, DOI 10.1016/S0301-0503(81)80049-5
NR 33
TC 58
Z9 65
U1 3
U2 13
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0278-2391
EI 1531-5053
J9 J ORAL MAXIL SURG
JI J. Oral Maxillofac. Surg.
PD NOV
PY 2005
VL 63
IS 11
BP 1667
EP 1673
DI 10.1016/j.joms.2005.08.008
PG 7
WC Dentistry, Oral Surgery & Medicine
SC Dentistry, Oral Surgery & Medicine
GA 981NX
UT WOS:000233096400015
PM 16243185
DA 2018-12-27
ER

PT J
AU Budagian, V
   Bulanova, E
   Orinska, Z
   Duitman, E
   Brandt, K
   Ludwig, A
   Hartmann, D
   Lemke, G
   Saftig, P
   Bulfone-Paus, S
AF Budagian, V
   Bulanova, E
   Orinska, Z
   Duitman, E
   Brandt, K
   Ludwig, A
   Hartmann, D
   Lemke, G
   Saftig, P
   Bulfone-Paus, S
TI RETRACTED: Soluble Axl is generated by ADAM10-dependent cleavage and
   associates with Gas6 in mouse serum (Retracted article. See vol. 31, pg.
   1330, 2011)
SO MOLECULAR AND CELLULAR BIOLOGY
LA English
DT Article; Retracted Publication
ID RECEPTOR TYROSINE KINASE; NECROSIS-FACTOR-ALPHA; MESANGIAL
   CELL-PROLIFERATION; ARREST-SPECIFIC GENE-6; CONVERTING-ENZYME;
   TNF-ALPHA; METALLOPROTEASE-DISINTEGRINS; EXTRACELLULAR DOMAIN; SURVIVAL
   ACTIVITIES; EXPRESSION ANALYSIS
AB Axl receptor tyrosine kinase exists as a transmembrane protein and as a soluble molecule. We show that constitutive and phorbol 12-myristate 13-acetate-induced generation of soluble Axl (sAxl) involves the activity of disintegrin-like metalloproteinase 10 (ADAM10). Spontaneous and inducible Axl cleavage was inhibited by the broad-spectrum metalloproteinase inhibitor GM6001 and by hydroxamate GW280264X, which is capable of blocking ADAM10 and ADAM17. Furthermore, murine fibroblasts deficient in ADAM10 expression exhibited a significant reduction in constitutive and inducible Axl shedding, whereas reconstitution of ADAM10 restored sAxl production, suggesting that ADAM10-mediated proteolysis constitutes a major mechanism for sAxl generation in mice. Partially overlapping 14-amino-acid stretch deletions in the membrane-proximal region of Axl dramatically affected sAxl generation, indicating that these regions are involved in regulating the access of the protease to the cleavage site. Importantly, relatively high circulating levels of sAxl are present in mouse sera in a heterocomplex with Axl ligand Gas6. Conversely, two other family members, Tyro3 and Mer, were not detected in mouse sera and conditioned medium. sAxl is constitutively released by murine primary cells such as dendritic and transformed cell lines. Upon immobilization, sAxl promoted cell migration and induced the phosphorylation of Axl and phosphatidylinositol 3-kinase. Thus, ADAM10-mediated generation of sAxl might play an important role in diverse biological processes.
C1 Res Ctr Borstel, Dept Immunol & Cell Biol, D-23845 Borstel, Germany.
   Univ Kiel, Inst Biochem, D-24118 Kiel, Germany.
   Catholic Univ Louvain, Dept Human Genet, B-3000 Louvain, Belgium.
   Flanders Interuniv Inst Biotechnol, B-3000 Louvain, Belgium.
   Salk Inst Biol Studies, Mol Neurobiol Lab, San Diego, CA 92186 USA.
RP Budagian, V (reprint author), Res Ctr Borstel, Dept Immunol & Cell Biol, Parkallee 22, D-23845 Borstel, Germany.
EM vbudagian@fz-borstel.de
RI Saftig, Paul/A-7966-2010
CR Abel S, 2004, J IMMUNOL, V172, P6362, DOI 10.4049/jimmunol.172.10.6362
   Allen MP, 1999, MOL ENDOCRINOL, V13, P191, DOI 10.1210/me.13.2.191
   Althoff K, 2000, EUR J BIOCHEM, V267, P2624, DOI 10.1046/j.1432-1327.2000.01278.x
   Angelillo-Scherrer A, 2005, J CLIN INVEST, V115, P237, DOI 10.1172/JCI200522079
   Angelillo-Scherrer A, 2001, NAT MED, V7, P215, DOI 10.1038/84667
   ARRIBAS J, 1995, J CELL BIOL, V128, P433, DOI 10.1083/jcb.128.3.433
   Avanzi GC, 1998, BLOOD, V91, P2334
   BARGMANN CI, 1988, EMBO J, V7, P2043, DOI 10.1002/j.1460-2075.1988.tb03044.x
   Bellosta P, 1997, ONCOGENE, V15, P2387, DOI 10.1038/sj.onc.1201419
   BELLOSTA P, 1995, MOL CELL BIOL, V15, P614
   Biscardi JS, 1996, J BIOL CHEM, V271, P29049, DOI 10.1074/jbc.271.46.29049
   Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0
   Blobel CP, 2005, NAT REV MOL CELL BIO, V6, P32, DOI 10.1038/nrm1548
   Blobel CP, 1997, CELL, V90, P589, DOI 10.1016/S0092-8674(00)80519-X
   Brandt K, 2003, BLOOD, V102, P4090, DOI 10.1182/blood-2003-03-0669
   Brunelleschi S, 2002, CURR PHARM DESIGN, V8, P1959, DOI 10.2174/1381612023393530
   Budagian V, 2004, J BIOL CHEM, V279, P40368, DOI 10.1074/jbc.M404125200
   Budagian V, 2002, SCAND J IMMUNOL, V55, P484, DOI 10.1046/j.1365-3083.2002.01081.x
   Bulanova E, 2001, J IMMUNOL, V167, P6292, DOI 10.4049/jimmunol.167.11.6292
   Bulfone-Paus S, 1999, FASEB J, V13, P1575
   CHILTON PM, 1993, J IMMUNOL, V151, P5907
   Christianson TA, 1998, CANCER RES, V58, P5123
   Costa M, 1996, J CELL PHYSIOL, V168, P737, DOI 10.1002/(SICI)1097-4652(199609)168:3<737::AID-JCP27>3.0.CO;2-U
   Demarchi F, 2001, J BIOL CHEM, V276, P31738, DOI 10.1074/jbc.M104457200
   Dri P, 2000, J IMMUNOL, V165, P2165, DOI 10.4049/jimmunol.165.4.2165
   FAUST M, 1992, ONCOGENE, V7, P1287
   Fernandez-Botran R, 2000, EXPERT OPIN INV DRUG, V9, P497, DOI 10.1517/13543784.9.3.497
   Fortini ME, 2002, NAT REV MOL CELL BIO, V3, P673, DOI 10.1038/nrm910
   Fridell YWC, 1998, J BIOL CHEM, V273, P7123, DOI 10.1074/jbc.273.12.7123
   Fridell YWC, 1996, MOL CELL BIOL, V16, P135
   Goruppi S, 1997, MOL CELL BIOL, V17, P4442, DOI 10.1128/MCB.17.8.4442
   Goruppi S, 1996, ONCOGENE, V12, P471
   Goruppi S, 2001, MOL CELL BIOL, V21, P902, DOI 10.1128/MCB.21.3.902-915.2001
   GRAHAM DK, 1994, CELL GROWTH DIFFER, V5, P647
   Guttridge KL, 2002, J BIOL CHEM, V277, P24057, DOI 10.1074/jbc.M112086200
   Hartmann D, 2002, HUM MOL GENET, V11, P2615, DOI 10.1093/hmg/11.21.2615
   Heaney ML, 1996, BLOOD, V87, P847
   Hundhausen C, 2003, BLOOD, V102, P1186, DOI 10.1182/blood-2002-12-3775
   HWANG CD, 1993, J IMMUNOL, V151, P5631
   Jones SA, 2002, BBA-MOL CELL RES, V1592, P251, DOI 10.1016/S0167-4889(02)00319-1
   Lu QX, 1999, NATURE, V398, P723, DOI 10.1038/19554
   Lu QX, 2001, SCIENCE, V293, P306, DOI 10.1126/science.1061663
   MANFIOLETTI G, 1993, MOL CELL BIOL, V13, P4976, DOI 10.1128/MCB.13.8.4976
   MARK MR, 1994, J BIOL CHEM, V269, P10720
   McCloskey P, 1997, J BIOL CHEM, V272, P23285, DOI 10.1074/jbc.272.37.23285
   Melaragno MG, 1999, TRENDS CARDIOVAS MED, V9, P250, DOI 10.1016/S1050-1738(00)00027-X
   Nagai K, 2003, J BIOL CHEM, V278, P18229, DOI 10.1074/jbc.M213266200
   Nagata K, 1996, J BIOL CHEM, V271, P30022, DOI 10.1074/jbc.271.47.30022
   Nakano T, 1997, J BIOL CHEM, V272, P29411, DOI 10.1074/jbc.272.47.29411
   O'Donnell K, 1999, AM J PATHOL, V154, P1171, DOI 10.1016/S0002-9440(10)65369-2
   OBRYAN JP, 1995, J BIOL CHEM, V270, P551, DOI 10.1074/jbc.270.2.551
   PARADIES NE, 1993, J NEUROSCI RES, V36, P33, DOI 10.1002/jnr.490360105
   Peschon JJ, 1998, SCIENCE, V282, P1281, DOI 10.1126/science.282.5392.1281
   Reiss K, 2005, EMBO J, V24, P742, DOI 10.1038/sj.emboj.7600548
   Sahin U, 2004, J CELL BIOL, V164, P769, DOI 10.1083/jcb.200307137
   SATO TA, 1993, J IMMUNOL, V150, P2717
   Schlondorff J, 1999, J CELL SCI, V112, P3603
   SCHUERMANN M, 1990, NUCLEIC ACIDS RES, V18, P4945, DOI 10.1093/nar/18.16.4945
   Scott RS, 2001, NATURE, V411, P207, DOI 10.1038/35075603
   Six E, 2003, P NATL ACAD SCI USA, V100, P7638, DOI 10.1073/pnas.1230693100
   Slack BE, 2001, BIOCHEM J, V357, P787, DOI 10.1042/0264-6021:3570787
   Stenhoff J, 2004, BIOCHEM BIOPH RES CO, V319, P871, DOI 10.1016/j.bbrc.2004.05.070
   Sunnarborg SW, 2002, J BIOL CHEM, V277, P12838, DOI 10.1074/jbc.M112050200
   VARNUM BC, 1995, NATURE, V373, P623, DOI 10.1038/373623a0
   WANG LH, 1987, P NATL ACAD SCI USA, V84, P5725, DOI 10.1073/pnas.84.16.5725
   Wang XD, 2002, J BIOL CHEM, V277, P50510, DOI 10.1074/jbc.M208738200
   WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121
   Yanagita M, 2001, AM J PATHOL, V158, P1423, DOI 10.1016/S0002-9440(10)64093-X
   Yanagita M, 2001, J BIOL CHEM, V276, P42364, DOI 10.1074/jbc.M107488200
   Yanagita M, 1999, J AM SOC NEPHROL, V10, P2503
NR 70
TC 56
Z9 57
U1 5
U2 14
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0270-7306
EI 1098-5549
J9 MOL CELL BIOL
JI Mol. Cell. Biol.
PD NOV
PY 2005
VL 25
IS 21
BP 9324
EP 9339
DI 10.1128/MCB.25.21.9324-9339.2005
PG 16
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 976SW
UT WOS:000232754600015
PM 16227584
OA Green Published, Bronze
DA 2018-12-27
ER

PT J
AU Rao, JS
   Rapoport, SI
   Bosetti, F
AF Rao, JS
   Rapoport, SI
   Bosetti, F
TI RETRACTED: Decrease in the AP-2 DNA-binding activity and in the protein
   expression of AP-2 alpha and AP-2 beta in frontal cortex of rats treated
   with lithium for 6 weeks (Retracted article. See vol. 42, pg. 456, 2018)
SO NEUROPSYCHOPHARMACOLOGY
LA English
DT Article; Retracted Publication
DE brain; lithium; transcription factors; PKC; AP-2; AP-1
ID SIGNAL-TRANSDUCTION PATHWAYS; CYTOSOLIC PHOSPHOLIPASE A(2); BIPOLAR
   AFFECTIVE-DISORDER; TRANSCRIPTION FACTOR AP-2; KINASE-C ACTIVITY;
   GENE-EXPRESSION; ARACHIDONIC-ACID; CEREBRAL-CORTEX; CYCLIC-AMP;
   NEUROTROPHIC FACTOR
AB Lithium chloride (LiCl), when fed to rats for 6 weeks, has been reported to decrease brain mRNA, protein, and activity levels of arachidonic acid (AA)-selective cytosolic phospholipase A(2) (cPLA(2)), without affecting secretory sPLA(2) or Ca2+-independent iPLA(2) We investigated whether transcription factors known to regulate cPLA(2) gene expression are modulated by chronic lithium treatment. Male Fischer-344 rats were fed a LiCl-containing diet for 6 weeks to produce a therapeutically relevant brain lithium concentration. Control animals were fed a LiCl-free diet. Using a gelshift assay, we found that LiCl significantly decreased activating protein 2 (AP-2)-binding activity, and protein levels of the AP-2 alpha and AP-2 beta but not of the AP-2 gamma subunits in the frontal cortex. Activating protein 1 (AP- 1)binding activity was increased, whereas glucocorticoid response element, polyoma enhancer activator 3, and nuclear factor kappa B DNA-binding activities were not changed significantly, Since both cPLA(2) and AP-2 can be activated by protein kinase C (PKC), we examined the frontal cortex protein levels of PKC alpha and PKC epsilon, as well as AA-dependent PKC activity. The protein levels of PKC alpha and PKC e were decreased significantly, as was AA-dependent PKC activity, in the lithium-treated compared to control rats, Our results suggest that the reported decrease in brain gene expression of cPLA(2) by chronic lithium may be mediated by reduced AP-2 transcriptional activity, and that decreased expression of PKC a and PKC e. contributes to lowering the AP-2 activity.
C1 NIA, Brain Physiol & Metab Sect, NIH, Bethesda, MD 20892 USA.
RP Rao, JS (reprint author), NIA, Brain Physiol & Metab Sect, NIH, 9000 Rockville Pike,Bldg 9,IS 128, Bethesda, MD 20892 USA.
EM jrao@mail.nih.gov
RI Rao, Jagadeesh/C-1250-2009
CR Abe M, 2000, NEUROREPORT, V11, P3261, DOI 10.1097/00001756-200009280-00042
   Angelucci F, 2003, INT J NEUROPSYCHOPH, V6, P225, DOI 10.1017/S1461145703003468
   Asghari V, 1998, MOL BRAIN RES, V58, P95, DOI 10.1016/S0169-328X(98)00107-7
   Bosetti F, 2002, BRAIN RES BULL, V57, P205, DOI 10.1016/S0361-9230(01)00744-4
   Bosetti F, 2002, MOL PSYCHIATR, V7, P845, DOI 10.1038/sj.mp.4001111
   Brunello N, 2004, J AFFECT DISORDERS, V79, pS15, DOI 10.1016/j.jad.2004.01.002
   Chang MCJ, 1996, NEUROSCI LETT, V220, P171, DOI 10.1016/S0304-3940(96)13264-X
   Chang MCJ, 1998, NEUROCHEM RES, V23, P887, DOI 10.1023/A:1022415113421
   Chen HM, 2003, J WORLD BUS, V38, P1, DOI 10.1016/S1090-9516(02)00105-0
   Damberg M, 2000, LIFE SCI, V68, P669, DOI 10.1016/S0024-3205(00)00969-3
   Damberg M, 2001, NEUROSCI LETT, V313, P102, DOI 10.1016/S0304-3940(01)02243-1
   De Sarno P, 2002, NEUROPHARMACOLOGY, V43, P1158, DOI 10.1016/S0028-3908(02)00215-0
   FRIEDMAN E, 1993, BIOL PSYCHIAT, V33, P520, DOI 10.1016/0006-3223(93)90006-Y
   Ghelardoni S, 2004, BIOL PSYCHIAT, V56, P248, DOI 10.1016/j.biophysc.2004.05.012
   Gilmor ML, 2003, J PHARMACOL EXP THER, V305, P434, DOI 10.1124/jpet.102.045419
   Hahn C G, 1999, Bipolar Disord, V1, P81, DOI 10.1034/j.1399-5618.1999.010204.x
   Hyman SE, 1996, AM J PSYCHIAT, V153, P151
   IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8
   Jensen JB, 1997, EUR NEUROPSYCHOPHARM, V7, P173
   JOPE RS, 1994, BIOCHEM PHARMACOL, V47, P429, DOI 10.1016/0006-2952(94)90172-4
   Klein PS, 1996, P NATL ACAD SCI USA, V93, P8455, DOI 10.1073/pnas.93.16.8455
   KOIDE H, 1992, P NATL ACAD SCI USA, V89, P1149, DOI 10.1073/pnas.89.4.1149
   Lahiri DK, 1998, MOL BRAIN RES, V58, P112, DOI 10.1016/S0169-328X(98)00115-6
   LENOX RH, 1992, BRAIN RES, V570, P333, DOI 10.1016/0006-8993(92)90598-4
   LI PP, 1993, BIOL PSYCHIAT, V34, P162, DOI 10.1016/0006-3223(93)90387-S
   LIN A, 1993, ADV SEC MESS PHOSPH, V28, P255
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lopez-Larson MP, 2002, BIOL PSYCHIAT, V52, P93, DOI 10.1016/S0006-3223(02)01350-1
   Lyoo IK, 2004, BIOL PSYCHIAT, V55, P648, DOI 10.1016/j.biopsych.2003.10.017
   Manji HK, 1996, NEUROPSYCHOPHARMACOL, V15, P370, DOI 10.1016/0893-133X(95)00243-7
   Manji HK, 1999, J CLIN PSYCHIAT, V60, P27
   MANJI HK, 1993, J NEUROCHEM, V61, P2303, DOI 10.1111/j.1471-4159.1993.tb07474.x
   MANJI HK, 1999, J CLIN PSYCHIAT S2, V60, P113
   Miki M, 2001, EUR J PHARMACOL, V428, P303, DOI 10.1016/S0014-2999(01)01343-7
   Mori S, 1998, NEUROPSYCHOPHARMACOL, V19, P233, DOI 10.1016/S0893-133X(98)00018-9
   MORII H, 1994, BIOCHEM BIOPH RES CO, V205, P6, DOI 10.1006/bbrc.1994.2621
   MORK A, 1995, J NEUROCHEM, V65, P134
   MORK A, 1993, PHARMACOL TOXICOL, V73, P1, DOI 10.1111/j.1600-0773.1993.tb01704.x
   Moser M, 1997, DEV DYNAM, V208, P115, DOI 10.1002/(SICI)1097-0177(199701)208:1<115::AID-AJA11>3.0.CO;2-5
   NEMENOFF RA, 1993, J BIOL CHEM, V268, P1960
   Ozaki N, 1997, J NEUROCHEM, V69, P2336
   Rajkowska G, 2002, BIPOLAR DISORD, V4, P105, DOI 10.1034/j.1399-5618.2002.01149.x
   Rapoport SI, 2002, ARCH GEN PSYCHIAT, V59, P592, DOI 10.1001/archpsyc.59.7.592
   Rintala J, 1999, NEUROREPORT, V10, P3887, DOI 10.1097/00001756-199912160-00030
   Saluja I, 1999, NEUROCHEM RES, V24, P669, DOI 10.1023/A:1021004525979
   Schibler U, 1998, NATURE, V393, P620, DOI 10.1038/31337
   Siuciak JA, 1997, PHARMACOL BIOCHEM BE, V56, P131, DOI 10.1016/S0091-3057(96)00169-4
   Soares JC, 2000, PSYCHIAT RES, V95, P109, DOI 10.1016/S0165-1781(00)00175-X
   Stambolic V, 1996, CURR BIOL, V6, P1664, DOI 10.1016/S0960-9822(02)70790-2
   Stella N, 1997, J NEUROSCI, V17, P2939
   Sun GY, 2004, J LIPID RES, V45, P205, DOI 10.1194/jlr.R300016-JLR200
   TEIXEIRA NA, 1982, ACTA PHARMACOL TOX, V51, P1
   Wang HY, 1996, BIOL PSYCHIAT, V40, P568, DOI 10.1016/0006-3223(95)00611-7
   Wang HY, 1999, NEUROPHARMACOLOGY, V38, P403, DOI 10.1016/S0028-3908(98)00197-X
   Wang HY, 2001, PSYCHOPHARMACOLOGY, V158, P80, DOI 10.1007/s002130100834
   Watson DG, 1996, J NEUROCHEM, V67, P767
   Weerasinghe GR, 2004, BRAIN RES BULL, V63, P485, DOI 10.1016/j.brainresbull.2004.04.005
   Weerasinghe GR, 2003, BRAIN RES BULL, V59, P303, DOI 10.1016/S0361-9230(02)00913-9
   Xu JF, 2002, J NEUROCHEM, V83, P259, DOI 10.1046/j.1471-4159.2002.01145.x
   Yuan PX, 1999, J NEUROCHEM, V73, P2299, DOI 10.1046/j.1471-4159.1999.0732299.x
NR 60
TC 37
Z9 37
U1 1
U2 2
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0893-133X
EI 1740-634X
J9 NEUROPSYCHOPHARMACOL
JI Neuropsychopharmacology
PD NOV
PY 2005
VL 30
IS 11
BP 2006
EP 2013
DI 10.1038/sj.npp.1300740
PG 8
WC Neurosciences; Pharmacology & Pharmacy; Psychiatry
SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry
GA 977EJ
UT WOS:000232784900005
PM 15827566
OA Bronze
DA 2018-12-27
ER

PT J
AU Okugawa, H
   Yamamoto, D
   Uemura, Y
   Sakaida, N
   Yamada, M
   Tanaka, K
   Kamiyama, Y
AF Okugawa, H
   Yamamoto, D
   Uemura, Y
   Sakaida, N
   Yamada, M
   Tanaka, K
   Kamiyama, Y
TI RETRACTED: Prognostic factors in breast cancer: The value of the
   Nottingham prognostic index for patients treated in a single institution
   (Retracted Article. See vol 39, pg 738, 2009)
SO SURGERY TODAY
LA English
DT Article; Retracted Publication
DE Prognostic Index; histopathological grade; breast cancer
ID TERM-FOLLOW-UP; TNM STAGING SYSTEM; RECURRENCE
AB Purpose. The Nottingham Prognostic Index (NPI) is used to predict survival in patients with breast cancer. This index is based on tumor size, lymph node stage, and histological grade and allows the stratification of patients into three different prognostic groups. Our aim was to verify the effect of some prognostic variables on survival and to establish the independent influence of each of these variables by a survival regression analysis. We applied the NPI to the same group of patients to assess its predictive power and reproducibility.
   Methods. We evaluated 311 women with breast cancer treated between January 1993 and December 1998.
   Results. In a multivariate analysis (Cox proportional hazard model), only size, lymph node involvement, and histological grade were independent prognostic factors. The survival curves obtained after applying the NPI were similar to those for the factors with independent prognostic significance derived from our multivariate analysis.
   Conclusion. The NPI allows us to accurately predict prognosis, and we advocate its standardized use.
C1 Kansai Med Univ, Dept Surg, Moriguchi, Osaka 5708507, Japan.
   Kansai Med Univ, Dept Clin Pathol, Moriguchi, Osaka 5708507, Japan.
RP Tanaka, K (reprint author), Kansai Med Univ, Dept Surg, Moriguchi, Osaka 5708507, Japan.
CR BAAK JPA, 1985, CANCER, V56, P374, DOI 10.1002/1097-0142(19850715)56:2<374::AID-CNCR2820560229>3.0.CO;2-9
   BALSLEV I, 1994, BREAST CANCER RES TR, V32, P281, DOI 10.1007/BF00666005
   Benson JR, 2003, LANCET ONCOL, V4, P56, DOI 10.1016/S1470-2045(03)00961-6
   BRYAN RM, 1986, BRIT J SURG, V73, P267, DOI 10.1002/bjs.1800730408
   CHEVALLIER B, 1990, BRIT J CANCER, V61, P436, DOI 10.1038/bjc.1990.96
   Collett K, 1998, BREAST CANCER RES TR, V48, P1, DOI 10.1023/A:1005945000264
   D'Eredita G, 2001, EUR J CANCER, V37, P591, DOI 10.1016/S0959-8049(00)00435-4
   DORR FA, 1993, CANCER, V71, P2163, DOI 10.1002/1097-0142(19930315)71:6+<2163::AID-CNCR2820711607>3.0.CO;2-W
   DUTOIT RS, 1990, BRIT J SURG, V77, P163, DOI 10.1002/bjs.1800770216
   ELSTON CW, 1991, HISTOPATHOLOGY, V19, P403, DOI 10.1111/j.1365-2559.1991.tb00229.x
   GALEA MH, 1992, BREAST CANCER RES TR, V22, P207, DOI 10.1007/BF01840834
   Goldhirsch A, 2003, J CLIN ONCOL, V21, P3357, DOI 10.1200/JCO.2003.04.576
   Hermanek P, 1999, CANCER, V86, P2189, DOI 10.1002/(SICI)1097-0142(19991201)86:11<2189::AID-CNCR1>3.0.CO;2-R
   PINDER SE, 1994, HISTOPATHOLOGY, V24, P41, DOI 10.1111/j.1365-2559.1994.tb01269.x
   ROSEN PP, 1981, ANN SURG, V193, P15, DOI 10.1097/00000658-198101000-00003
   ROSES DF, 1982, AM J CLIN PATHOL, V78, P817, DOI 10.1093/ajcp/78.6.817
   Sauerbrei W, 1997, BREAST CANCER RES TR, V42, P149, DOI 10.1023/A:1005733404976
   SEARS HF, 1982, CANCER, V50, P1820, DOI 10.1002/1097-0142(19821101)50:9<1820::AID-CNCR2820500928>3.0.CO;2-S
   Sundquist M, 1999, BREAST CANCER RES TR, V53, P1, DOI 10.1023/A:1006052115874
NR 19
TC 19
Z9 19
U1 3
U2 4
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0941-1291
EI 1436-2813
J9 SURG TODAY
JI Surg. Today
PD NOV
PY 2005
VL 35
IS 11
BP 907
EP 911
DI 10.1007/s00595-005-3056-x
PG 5
WC Surgery
SC Surgery
GA 978FW
UT WOS:000232860000002
PM 16249842
DA 2018-12-27
ER

PT J
AU Chen, L
   Woo, SLC
AF Chen, L
   Woo, SLC
TI RETRACTED: Complete and persistent phenotypic correction of
   phenylketonuria in mice by site-specific genome integration of murine
   phenylalanine hydroxylase cDNA (Retracted article. See vol. 107, pg.
   14514, 2010)
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article; Retracted Publication
DE gene therapy; genetic disease; genome targeting
ID BETA-ACTIN PROMOTER; PHI-C31 INTEGRASE; TRANSGENE EXPRESSION; MOUSE
   MODEL; HUMAN-CELLS; IN-VIVO; MAMMALIAN-CELLS; PHAGE INTEGRASE;
   GENE-TRANSFER; PLASMID DNA
AB We explored the potential of using a bacteriophage integrase system to achieve site-specific genome integration of murine phenylalanine hydroxylase cDNA in the livers of phenylketonuric (PKU) mice. The phiBT1 phage integrase is an enzyme that catalyses the efficient recombination between unique sequences in the phage and bacterial genomes, leading to the site-specific integration of the former into the latter in a unidirectional manner. Here we showed that this phage integrase functions efficiently in mouse cells, and several naturally occurring pseudo-attP sites located in the intergenic regions of the mouse genome have been identified and molecularly characterized. We further demonstrated that the addition of nuclear localization signal sequences to the C terminus of the phage integrase enhanced the efficiency for transgene integration into the mouse genome. Using this phage integration system, we delivered mouse phenylalanine hydroxylase cDNA to the livers of PKU mice by hydrodynamic injection of plasmid DNA and showed that the severity of the hyperphenylalaninemic phenotype in the treated mice decreased significantly. After three applications, serum phenylalanine levels in all treated PKU mice were reduced to the normal range and remained stable thereafter. Their fur color also changed from gray to black, indicating the reconstitution of melanin biosynthesis as a result of available tyrosine derived from reconstituted pherrylalanine hydroxylation in the liver. Thus, the phiBT1 bacteriophage integrase represents an effective site-specific genome integration system in mammalian cells and can be of great value in DNA-mediated gene therapy for a multitude of genetic disorders.
C1 Mt Sinai Sch Med, Dept Genet & Cell Med, New York, NY 10029 USA.
RP Woo, SLC (reprint author), Mt Sinai Sch Med, Dept Genet & Cell Med, 1 Gustave L Levy Pl,Box 1496, New York, NY 10029 USA.
EM savio.woo@mssm.edu
CR Andreas S, 2002, NUCLEIC ACIDS RES, V30, P2299, DOI 10.1093/nar/30.11.2299
   Belteki G, 2003, NAT BIOTECHNOL, V21, P321, DOI 10.1038/nbt787
   Chen ZY, 2003, MOL THER, V8, P495, DOI 10.1016/S1525-0016(03)00168-0
   Chen ZY, 2001, MOL THER, V3, P403, DOI 10.1006/mthe.2001.0278
   Dale Y, 2003, J CHROMATOGR B, V788, P1, DOI 10.1016/S1570-0232(02)01005-X
   FANG B, 1994, GENE THER, V1, P247
   Garg S, 2004, J IMMUNOL, V173, P550, DOI 10.4049/jimmunol.173.1.550
   GASPAR GB, 2004, LANCET, V364, P2181
   Glover DJ, 2005, NAT REV GENET, V6, P299, DOI 10.1038/nrg1577
   Gregory MA, 2003, J BACTERIOL, V185, P5320, DOI 10.1128/JB.185.17.5320-5323.2003
   Groth AC, 2000, P NATL ACAD SCI USA, V97, P5995, DOI 10.1073/pnas.090527097
   Held PK, 2005, MOL THER, V11, P399, DOI 10.1016/j.ymthe.2004.11.001
   HOLLIS RP, 2003, REPROD BIOL ENDOCINR
   Khan MS, 2005, TRENDS PLANT SCI, V10, P1, DOI 10.1016/j.tplants.2004.11.001
   Kosuga M, 2000, CELL TRANSPLANT, V9, P675, DOI 10.1177/096368970000900513
   Lecocq M, 2003, J GENE MED, V5, P142, DOI 10.1002/jgm.328
   LEDLEY FD, 1990, BIOCHEM J, V267, P399, DOI 10.1042/bj2670399
   Liu F, 1999, GENE THER, V6, P1258, DOI 10.1038/sj.gt.3300947
   Lutz KA, 2004, PLANT J, V37, P906, DOI 10.1111/j.1365-313X.2004.02015.x
   Oh HJ, 2004, PEDIATR RES, V56, P278, DOI 10.1203/01.PDR.0000132873.29067.0E
   Olivares EC, 2001, GENE, V278, P167, DOI 10.1016/S0378-1119(01)00711-9
   Olivares EC, 2002, NAT BIOTECHNOL, V20, P1124, DOI 10.1038/nbt753
   Ortiz-Urda S, 2003, HUM GENE THER, V14, P923, DOI 10.1089/104303403765701204
   Quenneville SP, 2004, MOL THER, V10, P679, DOI 10.1016/j.ymthe.2004.05.034
   Sarkissian CN, 2000, MOL GENET METAB, V69, P188, DOI 10.1006/mgme.2000.2974
   SHEDLOVSKY A, 1993, GENETICS, V134, P1205
   Smith MCM, 2002, MOL MICROBIOL, V44, P299, DOI 10.1046/j.1365-2958.2002.02891.x
   Stoll SM, 2002, J BACTERIOL, V184, P3657, DOI 10.1128/JB.184.13.3657-3663.2002
   Thorpe HM, 1998, P NATL ACAD SCI USA, V95, P5505, DOI 10.1073/pnas.95.10.5505
   Thyagarajan B, 2001, MOL CELL BIOL, V21, P3926, DOI 10.1128/MCB.21.12.3926-3934.2001
   Yang HY, 2002, J BACTERIOL, V184, P1859, DOI 10.1128/JB.184.7.1859-1864.2002
NR 31
TC 45
Z9 45
U1 3
U2 13
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD OCT 25
PY 2005
VL 102
IS 43
BP 15581
EP 15586
DI 10.1073/pnas.0503877102
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 979GC
UT WOS:000232929400057
PM 16230623
OA Bronze, Green Published
DA 2018-12-27
ER

PT J
AU Gooseff, MN
   Anderson, JK
   Wondzell, SM
   LaNier, J
   Haggerty, R
AF Gooseff, MN
   Anderson, JK
   Wondzell, SM
   LaNier, J
   Haggerty, R
TI RETRACTED: A modelling study of hyporheic exchange pattern and the
   sequence, size, and spacing of stream bedforms in mountain stream
   networks, Oregon, USA (Retracted article. See vol 20, pg 2441, 2006)
SO HYDROLOGICAL PROCESSES
LA English
DT Article; Retracted Publication
DE hyporheic zone; geomorphology; MODFLOW; groundwater flow modelling;
   spatial scaling
ID SURFACE WATER EXCHANGE; ZONE; RIVER; FLOW; MORPHOLOGY; TRANSPORT;
   ECOSYSTEM; DYNAMICS; CREEK; REACH
AB Studies of hyporheic exchange flows have identified physical features of channels that control exchange flow at the channel unit scale, namely slope breaks in the longitudinal profile of streams that generate subsurface head distributions. We recently completed a field study that suggested channel unit spacing in stream longitudinal profiles can be used to predict the spacing between zones of upwelling (flux of hyporheic water into the stream) and downwelling (flux of stream water into the hyporheic zone) in the beds of mountain streams. Here, we use two-dimensional groundwater flow and particle tracking models to simulate vertical and longitudinal hyporheic exchange along the longitudinal axis of stream flow in second-, third-, and fourth-order mountain stream reaches. Modelling allowed us to (1) represent visually the effect that the shape of the longitudinal profile has on the flow net beneath streambeds; (2) isolate channel unit sequence and spacing as individual factors controlling the depth that stream water penetrates the hyporheic zone and the length of upwelling and downwelling zones; (3) evaluate the degree to which the effects of regular patterns in bedform size and sequence are masked by irregularities in real streams. We simulated hyporheic exchange in two sets of idealized stream reaches and one set of observed stream reaches. Idealized profiles were constructed using regression equations relating channel form to basin area. The size and length of channel units (step size, pool length, etc.) increased with increasing stream order. Simulations of hyporheic exchange flows in these reaches suggested that upwelling lengths increased (from 2.7 m to 7.6 m), and downwelling lengths increased (from 2.9 m to 6(.)0 m) with increase in stream order from second to fourth order. Step spacing in the idealized reaches increased from 5.3 m to 13.7 m as stream size increased from second to fourth order. Simulated upwelling lengths increased from 4.3 m in second-order streams to 9.7 m in fourth-order streams with a POOL-RIFFLE-STEP channel unit sequence, and increased from 2.5 m to 6(.)1 m from second- to fourth-order streams with a POOL-STEP-RIFFLE channel unit sequence. Downwelling lengths also increased with stream order in these idealized channels. Our results suggest that channel unit spacing, size, and sequence are all important in determining hyporheic exchange patterns of upwelling and downwelling. Though irregularities in the size and spacing of bedforms caused flow nets to be much more complex in surveyed stream reaches than in idealized stream reaches, similar trends emerged relating the average geomorphic wavelength to the average hyporheic wavelength in both surveyed and idealized reaches. Copyright (c) 2005 John Wiley & Sons, Ltd.
C1 Colorado Sch Mines, Dept Geol & Geol Engn, Golden, CO 80401 USA.
   Oregon State Univ, Dept Forest Sci, Corvallis, OR 97331 USA.
   US Forest Serv, Pacific NW Res Stn, Olympia Forestry Sci Lab, Olympia, WA 98512 USA.
   Oregon State Univ, Dept Geosci, Corvallis, OR 97331 USA.
RP Gooseff, MN (reprint author), Colorado Sch Mines, Dept Geol & Geol Engn, Golden, CO 80401 USA.
EM mgooseff@mines.edu
RI Gooseff, Michael/N-6087-2015; Gooseff, Michael/B-9273-2008; Haggerty,
   Roy/A-5863-2009
OI Gooseff, Michael/0000-0003-4322-8315; 
CR ANDERSON JK, 2002, THESIS OREGON STATE
   Baxter CV, 2000, CAN J FISH AQUAT SCI, V57, P1470, DOI 10.1139/cjfas-57-7-1470
   Bencala KE, 2000, HYDROL PROCESS, V14, P2797, DOI 10.1002/1099-1085(20001030)14:15<2797::AID-HYP402>3.0.CO;2-6
   BENCALA KE, 1984, WATER RESOUR RES, V20, P1804, DOI 10.1029/WR020i012p01804
   Cardenas MB, 2003, WATER RESOUR RES, V39, DOI 10.1029/2002WR001383
   Chin A, 1999, GEOMORPHOLOGY, V27, P191, DOI 10.1016/S0169-555X(98)00083-X
   Chin A, 2002, AM J SCI, V302, P144, DOI 10.2475/ajs.302.2.144
   Duckson DW, 2001, GEOMORPHOLOGY, V38, P267, DOI 10.1016/S0169-555X(00)00098-2
   DUFF JH, 1990, CAN J FISH AQUAT SCI, V47, P1140, DOI 10.1139/f90-133
   FINDLAY S, 1995, LIMNOL OCEANOGR, V40, P159, DOI 10.4319/lo.1995.40.1.0159
   Geist DR, 2000, CAN J FISH AQUAT SCI, V57, P1647, DOI 10.1139/cjfas-57-8-1647
   Gooseff MN, 2003, ADV WATER RESOUR, V26, P925, DOI 10.1016/S0309-1708(03)00105-2
   Gooseff MN, 2002, WATER RESOUR RES, V38, DOI 10.1029/2001WR000834
   GRANT GE, 1990, GEOL SOC AM BULL, V102, P340, DOI 10.1130/0016-7606(1990)102<0340:PAOOSB>2.3.CO;2
   Hack J. T., 1957, US GEOL SURVEY PRO B, P45
   Haggerty R., 2002, GEOPHYS RES LETT, V29, P18
   Harbaugh AW, 1996, 96485 US GEOL SURV
   HARVEY JW, 1993, WATER RESOUR RES, V29, P89, DOI 10.1029/92WR01960
   JONES JB, 1995, J N AM BENTHOL SOC, V14, P249, DOI 10.2307/1467777
   Kasahara T, 2003, WATER RESOUR RES, V39, DOI 10.1029/2002WR001386
   MATOS JER, 2003, MODFLOW MOR 2003 UND, P217
   Montgomery DR, 1997, GEOL SOC AM BULL, V109, P596, DOI 10.1130/0016-7606(1997)109<0596:CRMIMD>2.3.CO;2
   Morrice JA, 1997, HYDROL PROCESS, V11, P253, DOI 10.1002/(SICI)1099-1085(19970315)11:3<253::AID-HYP439>3.0.CO;2-J
   Mulholland PJ, 1997, LIMNOL OCEANOGR, V42, P443, DOI 10.4319/lo.1997.42.3.0443
   Pepin DM, 2002, J N AM BENTHOL SOC, V21, P370, DOI 10.2307/1468476
   Pollock D. W., 1994, 94464 US GEOL SURV
   Storey RG, 2003, WATER RESOUR RES, V39, DOI 10.1029/2002WR001367
   TOWNSEND CR, 1989, J N AM BENTHOL SOC, V8, P36, DOI 10.2307/1467400
   VALETT HM, 1994, ECOLOGY, V75, P548, DOI 10.2307/1939557
   VANNOTE RL, 1980, CAN J FISH AQUAT SCI, V37, P130, DOI 10.1139/f80-017
   VAUX WG, 1968, US FISH WLD S FISH B, V66, P479
   VERVIER P, 1993, FRESHWATER BIOL, V29, P275, DOI 10.1111/j.1365-2427.1993.tb00763.x
   Woessner WW, 2000, GROUND WATER, V38, P423, DOI 10.1111/j.1745-6584.2000.tb00228.x
   Wondzell SM, 1996, J N AM BENTHOL SOC, V15, P3, DOI 10.2307/1467429
NR 34
TC 23
Z9 24
U1 4
U2 27
PU JOHN WILEY & SONS LTD
PI CHICHESTER
PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND
SN 0885-6087
J9 HYDROL PROCESS
JI Hydrol. Process.
PD OCT 15
PY 2005
VL 19
IS 15
BP 2915
EP 2929
DI 10.1002/hyp.5790
PG 15
WC Water Resources
SC Water Resources
GA 975PH
UT WOS:000232673900003
DA 2018-12-27
ER

PT J
AU Sudbo, J
   Lee, JJ
   Lippman, SM
   Mork, J
   Sagen, S
   Flatner, N
   Ristimaki, A
   Sudbo, A
   Mao, L
   Zhou, X
   Kildal, W
   Evensen, JF
   Reith, A
   Dannenberg, AJ
AF Sudbo, J
   Lee, JJ
   Lippman, SM
   Mork, J
   Sagen, S
   Flatner, N
   Ristimaki, A
   Sudbo, A
   Mao, L
   Zhou, X
   Kildal, W
   Evensen, JF
   Reith, A
   Dannenberg, AJ
TI RETRACTED: Non-steroidal anti-inflammatory drugs and the risk of oral
   cancer: a nested case-control study (Retracted Article. See vol 367, pg
   382, 2006)
SO LANCET
LA English
DT Article; Retracted Publication
ID SQUAMOUS-CELL CARCINOMA; GROWTH-FACTOR RECEPTOR; ASPIRIN USE;
   COLORECTAL-CANCER; NECK-CANCER; CYCLOOXYGENASE-2; PREVENTION; HEAD;
   SMOKING; LEUKOPLAKIA
AB Background Non-steroidal anti-inflammatory drugs (NSAIDs) seem to prevent several types of cancer, but could increase the risk of cardiovascular complications. We investigated whether use of NSAIDs was associated with a change in the incidence of oral cancer or overall or cardiovascular mortality.
   Methods We undertook a nested case-control study to analyse data from a population-based database (Cohort of Norway; CONOR), which consisted of prospectively obtained health data from all regions of Norway. People with oral cancer were identified from the 9241 individuals in CONOR who were at increased risk of oral cancer because of heavy smoking (>= 15 pack-years), and matched controls were selected from the remaining heavy smokers (who did not have cancer).
   Findings We identified and analysed 454 (5%) people with oral cancer (279 men, 175 women, mean [SD] age at diagnosis 63.3 [13.2] years) and 454 matched controls (n=908); 263 (29%) had used NSAIDs, 83 (9%) had used paracetamol (for a minimum of 6 months), and 562 (62%) had used neither drug. NSAID use (but not paracetamol use) was associated with a reduced risk of oral cancer (including in active smokers; hazard ratio 0.47, 95% CI 0.37-0.60, p<0.0001). Smoking cessation also lowered the risk of oral cancer (0.41, 0.32-0.52, p<0.0001). Additionally, long-term use of NSAIDs (but not paracetamol) was associated with an increased risk of cardiovascular-disease-related death (2.06, 1.34-3.18, p=0.001). NSAID use did not significantly reduce overall mortality (p=0.17).
   Interpretation Long-term use of NSAIDs is associated with a reduced incidence of oral cancer (including in active smokers), but also with an increased risk of death due to cardiovascular disease. These findings highlight the need for a careful risk-benefit analysis when the long-term use of NSAIDs is considered.
C1 Norwegian Radium Hosp, Dept Med Oncol & Radiotherapy, N-0310 Oslo, Norway.
   Univ Texas, MD Anderson Canc Ctr, Dept Biostat & Appl Math, Houston, TX 77030 USA.
   Univ Texas, MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX 77030 USA.
   Univ Texas, MD Anderson Canc Ctr, Dept Clin Canc Prevent, Houston, TX 77030 USA.
   Univ Oslo, Natl Hosp, Oslo, Norway.
   Canc Registry Norway, Oslo, Norway.
   Norwegian Radium Hosp, Res Fdn, Montebello, Norway.
   Norwegian Radium Hosp, Dept Pathol, Div Cytol, Montebello, Norway.
   Norwegian Radium Hosp, Dept Med Informat, Oslo, Norway.
   Univ Helsinki, Cent Hosp, Dept Pathol, FIN-00014 Helsinki, Finland.
   Univ Helsinki, Biomedicum Helsinki, Mol & Canc Biol Res Programme, FIN-00014 Helsinki, Finland.
   Norwegian Univ Sci & Technol, Dept Phys, N-7034 Trondheim, Norway.
   Norwegian Radium Hosp, Dept Med Oncol & Radiotherapy, Montebello, Norway.
   Cornell Univ, Weill Med Coll, Dept Med, New York, NY USA.
RP Sudbo, J (reprint author), Norwegian Radium Hosp, Dept Med Oncol & Radiotherapy, N-0310 Oslo, Norway.
EM jon.sudbo@rh.uio.no
RI Mao, Li/C-7570-2011
OI Mao, Li/0000-0001-7263-3358
FU NCI NIH HHS [P01CA106451, R01 CA082578]
CR Abbruzzese JL, 2004, CANCER CELL, V6, P321, DOI 10.1016/j.ccr.2004.09.021
   AMES BN, 1990, SCIENCE, V249, P970, DOI 10.1126/science.2136249
   Baron JA, 2003, PROG EXP TUMOR RES, V37, P1
   BLOT WJ, 1988, CANCER RES, V48, P3282
   Bosetti C, 2003, BRIT J CANCER, V88, P672, DOI 10.1038/sj.bjc.660820
   Bresalier RS, 2005, NEW ENGL J MED, V352, P1092, DOI 10.1056/NEJMoa050493
   BUSKENS CJ, 2003, SCAND J GASTROENTE S, V239, P87
   Chan G, 1999, CANCER RES, V59, P991
   COHEN SM, 1990, SCIENCE, V249, P1007, DOI 10.1126/science.2204108
   CORNWALL H, 1983, J ORAL MAXIL SURG, V41, P795, DOI 10.1016/S0278-2391(83)80046-9
   Dannenberg AJ, 2001, LANCET ONCOL, V2, P544, DOI 10.1016/S1470-2045(01)00488-0
   Dannenberg AJ, 2005, J CLIN ONCOL, V23, P254, DOI 10.1200/JCO.2005.09.112
   ELING TE, 1990, ANNU REV PHARMACOL, V30, P1, DOI 10.1146/annurev.pa.30.040190.000245
   Engeland A, 1996, CANCER CAUSE CONTROL, V7, P366, DOI 10.1007/BF00052943
   Farrow DC, 1998, CANCER EPIDEM BIOMAR, V7, P97
   Gray N, 2004, ACTA ONCOL, V43, P8, DOI 10.1080/02841860310017937
   Greenspan D, 2004, NEW ENGL J MED, V350, P1382, DOI 10.1056/NEJMp048028
   Gupta RA, 2001, NAT REV CANCER, V1, P11, DOI 10.1038/35094017
   Johnsen SP, 2005, ARCH INTERN MED, V165, P978, DOI 10.1001/archinte.165.9.978
   JUNG TTK, 1985, LARYNGOSCOPE, V95, P307
   KARMALI RA, 1984, CANCER LETT, V22, P333, DOI 10.1016/0304-3835(84)90171-X
   Keller S, 2000, Educ Health (Abingdon), V13, P387
   LUBIN JH, 1986, J CHRON DIS, V39, P379, DOI 10.1016/0021-9681(86)90124-4
   Mann JR, 2004, CANCER J, V10, P145, DOI 10.1097/00130404-200405000-00001
   Mao L, 2004, CANCER CELL, V5, P311, DOI 10.1016/S1535-6108(04)00090-X
   MARNETT LJ, 1978, BIOCHEM BIOPH RES CO, V82, P210, DOI 10.1016/0006-291X(78)90597-1
   Moraitis D, 2005, CANCER RES, V65, P664
   MORK J, 1995, APMIS, V103, P375, DOI 10.1111/j.1699-0463.1995.tb01121.x
   Pai R, 2002, NAT MED, V8, P289, DOI 10.1038/nm0302-289
   PARKIN DM, 2002, CANC INCIDENCE 5 CON, V8, P516
   PERKINS TM, 1982, ORAL SURG ORAL MED O, V53, P170, DOI 10.1016/0030-4220(82)90283-3
   Quinn MJ, 2003, ANN ONCOL, V14, P1148, DOI 10.1093/annonc/mdg307
   Sandler RS, 2003, NEW ENGL J MED, V348, P883, DOI 10.1056/NEJMoa021633
   Sokka T, 2004, RHEUM DIS CLIN N AM, V30, P851, DOI 10.1016/j.rdc.2004.07.002
   Solomon SD, 2005, NEW ENGL J MED, V352, P1071, DOI 10.1056/NEJMoa050405
   Sorensen HT, 2003, BRIT J CANCER, V88, P1687, DOI 10.1038/sj.bjc.6600945
   Subbaramaiah K, 2003, TRENDS PHARMACOL SCI, V24, P96, DOI 10.1016/S0165-6147(02)00043-3
   Sudbo J, 2005, J CLIN ONCOL, V23, P1927, DOI 10.1200/JCO.2005.03.172
   Sudbo J, 2004, NEW ENGL J MED, V350, P1405, DOI 10.1056/NEJMoa033374
   Sudbo J, 2003, ORAL ONCOL, V39, P497, DOI 10.1016/S1368-8375(03)00012-5
   Sudbo J, 2001, NEW ENGL J MED, V344, P1270, DOI 10.1056/NEJM200104263441702
   Terry MB, 2004, JAMA-J AM MED ASSOC, V291, P2433, DOI 10.1001/jama.291.20.2433
   THUN MJ, 1993, CANCER RES, V53, P1322
   Thun MJ, 2002, JNCI-J NATL CANCER I, V94, P252, DOI 10.1093/jnci/94.4.252
   Tingle LR, 2003, J SCHOOL HEALTH, V73, P64, DOI 10.1111/j.1746-1561.2003.tb03574.x
   Wiesner M, 2002, J EARLY ADOLESCENCE, V22, P5, DOI 10.1177/0272431602022001001
   World Health Organization, 1955, INT CLASS DIS
NR 47
TC 53
Z9 56
U1 4
U2 33
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0140-6736
J9 LANCET
JI Lancet
PD OCT 15
PY 2005
VL 366
IS 9494
BP 1359
EP 1366
DI 10.1016/S0140-6736(05)67488-0
PG 8
WC Medicine, General & Internal
SC General & Internal Medicine
GA 973ZW
UT WOS:000232562100027
PM 16226613
DA 2018-12-27
ER

PT J
AU Ushio-Fukai, M
   Zuo, L
   Ikeda, S
   Tojo, T
   Patrushev, NA
   Alexander, RW
AF Ushio-Fukai, M
   Zuo, L
   Ikeda, S
   Tojo, T
   Patrushev, NA
   Alexander, RW
TI RETRACTED: CAbl tyrosine kinase mediates reactive oxygen species and
   caveolin-dependent AT(1) receptor signaling in vascular smooth muscle -
   Role in vascular hypertrophy (Retracted article. See vol. 106, pg. 1784,
   2010)
SO CIRCULATION RESEARCH
LA English
DT Article; Retracted Publication
DE cAbl; caveolin-1; NAD( P)H oxidase; angiotensin II; vascular smooth
   muscle
ID GROWTH-FACTOR RECEPTOR; II TYPE-1 RECEPTOR; DIABETES-ASSOCIATED
   ATHEROSCLEROSIS; ANGIOTENSIN-II; C-ABL; IN-VIVO; OXIDATIVE STRESS;
   NAD(P)H OXIDASE; PROTEIN-KINASE; CELLS
AB Important output signals of the angiotensin subtype 1 receptor ( AT(1)R) in vascular smooth muscle cells ( VSMCs) are mediated by angiotensin II ( Ang II)- stimulated transactivation of the epidermal growth factor receptor ( EGF-R), which is critical for vascular hypertrophy. Ang II-induced EGF-R transactivation is mediated through cSrc, a proximal target of reactive oxygen species ( ROS) derived from NAD( P) H oxidase ( NOX) and is dependent on AT1R trafficking through caveolin1 ( Cav1)-enriched lipid rafts. Underlying molecular mechanisms are incompletely understood. The nonreceptor tyrosine kinase, proto-oncogene cAbl is a substrate of Src and is a major mediator for ROS-dependent tyrosine phosphorylation of Cav1. We thus hypothesized that cAbl is important for ROS-, cSrc-, and Cav1-dependent growth-related AT1R signal transduction. Here we show that Ang II induces tyrosine phosphorylation of cAbl in rat VSMCs and mouse aorta, and that Ang II promotes association of cAbl with AT1R, both of which are Src-dependent. Pretreatment of rat VSMCs with the NOX inhibitor diphenylene iodonium or the antioxidants N-acetylcysteine or ebselen significantly inhibited Ang II-induced cAbl phosphorylation. Cell fractionation shows that both EGF-Rs and cAbl are found basally in Cav1-enriched membrane fractions. Knockdown of cAbl protein using small interference RNA inhibits Ang II-stimulated: ( 1) trafficking of AT1R into, and EGF-R out of, Cav1-enriched lipid rafts; ( 2) EGF-R transactivation; ( 3) appearance of the transactivated EGF-R and phospho-Cav1 at focal adhesions; and ( 4) vascular hypertrophy. These studies provide a novel role of cAbl in the spatial and temporal organization of growth-related AT1R signaling in VSMCs and suggest that cAbl may be generally important in signaling of G-protein coupled receptors.
C1 Emory Univ, Sch Med, Div Cardiol, Dept Med, Atlanta, GA 30322 USA.
RP Ushio-Fukai, M (reprint author), Emory Univ, Sch Med, Div Cardiol, Dept Med, 1639 Pierce Dr,Rm 319, Atlanta, GA 30322 USA.
EM mfukai@emory.edu
FU NHLBI NIH HHS [P01 HL075209, P01 HL058000, HL60728]
CR Candido R, 2004, CIRCULATION, V109, P1536, DOI 10.1161/01.CIR.0000124061.78478.94
   Cao HM, 2002, J BIOL CHEM, V277, P8771, DOI 10.1074/jbc.C100661200
   Doan T, 2004, CELL SIGNAL, V16, P301, DOI 10.1016/j.cellsig.2003.08.001
   Eguchi S, 1999, EUR J PHARMACOL, V376, P203, DOI 10.1016/S0014-2999(99)00357-X
   Eguchi S, 2000, REGUL PEPTIDES, V91, P13, DOI 10.1016/S0167-0115(00)00126-9
   EVANS JPM, 1987, LEUKEMIA, V1, P524
   Furstoss O, 2002, EMBO J, V21, P514, DOI 10.1093/emboj/21.4.514
   Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028
   Glover RT, 2000, J BIOL CHEM, V275, P12725, DOI 10.1074/jbc.275.17.12725
   Griendling KK, 2000, CIRC RES, V86, P494, DOI 10.1161/01.RES.86.5.494
   Ikeda S, 2005, CIRC RES, V96, P467, DOI 10.1161/01.RES.0000158286.51045.16
   ISHIDA M, 1995, CIRC RES, V77, P1053, DOI 10.1161/01.RES.77.6.1053
   Ishizaka N, 1998, HYPERTENSION, V32, P459, DOI 10.1161/01.HYP.32.3.459
   Kelly DJ, 2004, HYPERTENSION, V44, P195, DOI 10.1161/01.HYP.0000132883.20764.12
   Kim YN, 2000, J BIOL CHEM, V275, P7481, DOI 10.1074/jbc.275.11.7481
   Koch A, 2000, FEBS LETT, V469, P72, DOI 10.1016/S0014-5793(00)01242-4
   Kumar S, 2001, J BIOL CHEM, V276, P17281, DOI 10.1074/jbc.M101414200
   Labrecque L, 2003, MOL BIOL CELL, V14, P334, DOI 10.1091/mbc.E02-07-0379
   Lassila M, 2004, ARTERIOSCL THROM VAS, V24, P935, DOI 10.1161/01.ATV.0000124105.39900.db
   Lee H, 2000, MOL ENDOCRINOL, V14, P1750, DOI 10.1210/me.14.11.1750
   Lewis JM, 1996, P NATL ACAD SCI USA, V93, P15174, DOI 10.1073/pnas.93.26.15174
   Marrero MB, 1998, AM J PHYSIOL-CELL PH, V275, pC1216
   MARRERO MB, 1995, J BIOL CHEM, V270, P15734, DOI 10.1074/jbc.270.26.15734
   Meng TC, 2002, MOL CELL, V9, P387, DOI 10.1016/S1097-2765(02)00445-8
   Plattner R, 1999, GENE DEV, V13, P2400, DOI 10.1101/gad.13.18.2400
   Plattner R, 2003, NAT CELL BIOL, V5, P309, DOI 10.1038/ncb949
   Sanguinetti AR, 2003, CELL SIGNAL, V15, P289, DOI 10.1016/S0898-6568(02)00090-6
   Sawyers CL, 1999, NEW ENGL J MED, V340, P1330, DOI 10.1056/NEJM199904293401706
   Seta K, 2003, J BIOL CHEM, V278, P9019, DOI 10.1074/jbc.M208017200
   SMART EJ, 1995, P NATL ACAD SCI USA, V92, P10104, DOI 10.1073/pnas.92.22.10104
   Sun XG, 2000, J BIOL CHEM, V275, P17237, DOI 10.1074/jbc.C000099200
   TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M
   Ushio-Fukai M, 2001, J BIOL CHEM, V276, P48269, DOI 10.1074/jbc.M105901200
   Ushio-Fukai M, 2001, ARTERIOSCL THROM VAS, V21, P489, DOI 10.1161/01.ATV.21.4.489
   Ushio-Fukai M, 1999, J BIOL CHEM, V274, P22699, DOI 10.1074/jbc.274.32.22699
   Ushio-Fukai M, 1998, J BIOL CHEM, V273, P15022, DOI 10.1074/jbc.273.24.15022
   Van Etten RA, 1999, TRENDS CELL BIOL, V9, P179, DOI 10.1016/S0962-8924(99)01549-4
   Woodring PJ, 2003, J CELL SCI, V116, P2613, DOI 10.1242/jcs.00622
   Yano H, 2000, J NEUROSCI RES, V59, P356, DOI 10.1002/(SICI)1097-4547(20000201)59:3<356::AID-JNR9>3.0.CO;2-G
   Yu HH, 2001, ONCOGENE, V20, P3995, DOI 10.1038/sj.onc.1204524
   Zuo L, 2005, ARTERIOSCL THROM VAS, V25, P1824, DOI 10.1161/01.ATV.0000175295.09607.18
   ZUO L, 2004, ARTERIOSCLER THROMB, V24, P1
NR 42
TC 66
Z9 68
U1 3
U2 16
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0009-7330
EI 1524-4571
J9 CIRC RES
JI Circ.Res.
PD OCT 14
PY 2005
VL 97
IS 8
BP 829
EP 836
DI 10.1161/01.RES.0000185322.46009.F5
PG 8
WC Cardiac & Cardiovascular Systems; Hematology; Peripheral Vascular
   Disease
SC Cardiovascular System & Cardiology; Hematology
GA 973WT
UT WOS:000232554000014
PM 16151024
DA 2018-12-27
ER

PT J
AU Panagiotakos, DB
   Kromhout, D
   Menotti, A
   Chrysohoou, C
   Dontas, A
   Pitsavos, C
   Adachi, H
   Blackburn, H
   Nedeljkovic, S
   Nissinen, A
AF Panagiotakos, DB
   Kromhout, D
   Menotti, A
   Chrysohoou, C
   Dontas, A
   Pitsavos, C
   Adachi, H
   Blackburn, H
   Nedeljkovic, S
   Nissinen, A
TI RETRACTED: The relation between pulse pressure and cardiovascular
   mortality in 12763 middle-aged men from various parts of the world - A
   25-year follow-up of the seven countries study (Retracted Article. See
   vol 166, pg 1787, 2006)
SO ARCHIVES OF INTERNAL MEDICINE
LA English
DT Article; Retracted Publication
ID CORONARY-HEART-DISEASE; HIGH BLOOD-PRESSURE; RISK-FACTORS; HYPERTENSION;
   POPULATION
AB Background: Hypertension is a dominant characteristic in the prediction of cardiovascular diseases (CVDs). We aimed to evaluate the association of blood pressure measurements with CVD mortality among different populations of the world.
   Methods: A total of 12 763 men, aged 40 to 59 years, from 7 countries (United States, Japan, Italy, Greece, former Yugoslavia, Finland, and the Netherlands) were surveyed from 1958 to 1964. Follow-up for vital status and causes of death was carried out over 25 years.
   Results: All baseline blood pressure measurements were the best predictors of CVD mortality, compared with age, physical activity, total serum cholesterol level, body mass index or height, and smoking. Moreover, pulse pressure and diastolic and systolic blood pressures were the best predictors for CVD death, followed by mean and mid blood pressures. The age-adjusted hazard ratio per 10-mm Hg increase in pulse pressure varied among cohorts from 1.19 in the United States (P = .04) to 1.29 in southern Europe (P = .01). Differences among cohorts were not significant. In the pooled cohorts, pulse pressure measurements were also a significant predictor for coronary heart disease (hazard ratio per 10-mm Hg increase, 1.15; P = .04) as well as stroke death (hazard ratio per 10-mm Hg increase, 1.32; P = .01).
   Conclusions: Pulse pressure followed by diastolic and systolic blood pressures were the best predictors for CVD mortality among other blood pressures, as well as age, physical activity, total serum cholesterol level, anthropometric indexes, and smoking habits. No significant differences were observed among the different populations studied.
C1 Harokopio Univ, Dept Dieter & Nutr, Athens, Greece.
   Nutr & Comsumer Safety Div, Natl Inst Publ Hlth & Environm, Bilthoven, Netherlands.
   Assoc Cardiac Res, Rome, Italy.
   Athens Home Aged, Ctr Studies Age Related Changes Man, Athens, Greece.
   Univ Athens, Sch Med, Athens, Greece.
   Kurume Univ, Sch Med, Dept Med 3, Kurume, Fukuoka, Japan.
   Univ Minnesota, Dept Epidemiol, Minneapolis, MN USA.
   Univ Belgrade, Inst Cardiovasc Dis, Clin Ctr Serbia, Belgrade, Serbia Monteneg.
   Natl Publ Hlth Inst, Div Epidemiol & Hlth Promot, Helsinki, Finland.
RP Panagiotakos, DB (reprint author), 46 Paleon Polemiston St, Glifadha 16674, Greece.
EM d.b.panagiotakos@usa.net
RI Kromhout, Daan/A-8566-2014; Panagiotakos, Demosthenes/C-9776-2013
OI Panagiotakos, Demosthenes/0000-0001-8583-153X
FU PHS HHS [HE 04697, HE 6090, HE 00278]
CR ANDERSON JT, 1956, CLIN CHEM, V2, P145
   BENETOS A, 1993, ARTERIOSCLER THROMB, V13, P90, DOI 10.1161/01.ATV.13.1.90
   Benetos A, 1997, HYPERTENSION, V30, P1410, DOI 10.1161/01.HYP.30.6.1410
   Benetos A, 1999, J HYPERTENS, V17, pS21
   BURT VL, 1995, HYPERTENSION, V25, P305, DOI 10.1161/01.HYP.25.3.305
   Chobanian AV, 2003, JAMA-J AM MED ASSOC, V289, P2560, DOI 10.1001/jama.289.19.2560
   CHRISTENSEN KL, 1991, HYPERTENSION, V18, P722, DOI 10.1161/01.HYP.18.6.722
   Domanski M, 2002, JAMA-J AM MED ASSOC, V287, P2677, DOI 10.1001/jama.287.20.2677
   Franklin SS, 1999, CIRCULATION, V100, P354, DOI 10.1161/01.CIR.100.4.354
   KAWASAKE T, 1987, CARDIOVASC RES, V6, P12
   KEYS A, 1970, CIRCULATION, V41, pI1
   Lewington S, 2002, LANCET, V360, P1903
   Lopez AD, 1998, NAT MED, V4, P1241, DOI 10.1038/3218
   Menotti A, 1996, STROKE, V27, P381, DOI 10.1161/01.STR.27.3.381
   Menotti A, 1996, J Cardiovasc Risk, V3, P69, DOI 10.1097/00043798-199602000-00010
   Menotti A, 2001, EUR J EPIDEMIOL, V17, P337, DOI 10.1023/A:1012757616119
   MENOTTI A, 1994, LESSONS SCI 7 COUNTR, P17
   OROURKE M, 1995, HYPERTENSION, V26, P2, DOI 10.1161/01.HYP.26.1.2
   PALMER A, 1995, J HUM HYPERTENS, V9, P695
   van den Hoogen PCW, 2000, NEW ENGL J MED, V342, P1, DOI 10.1056/NEJM200001063420101
   *WORK GROUP PRIM P, 1993, ARCH INTERN MED, V153, P86
NR 21
TC 43
Z9 44
U1 3
U2 8
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0003-9926
EI 1538-3679
J9 ARCH INTERN MED
JI Arch. Intern. Med.
PD OCT 10
PY 2005
VL 165
IS 18
BP 2142
EP 2147
DI 10.1001/archinte.165.18.2142
PG 6
WC Medicine, General & Internal
SC General & Internal Medicine
GA 974FN
UT WOS:000232576800013
PM 16217005
OA Bronze
DA 2018-12-27
ER

PT J
AU Moon, HI
   Lee, J
   Zee, OP
   Chung, JH
AF Moon, HI
   Lee, J
   Zee, OP
   Chung, JH
TI RETRACTED: The effect of flavonol glycoside on the expressions of matrix
   metalloproteinase-1 in ultraviolet-irradiated cultured human skin
   fibroblasts (Retracted Article. See vol 117, pg 180, 2008)
SO JOURNAL OF ETHNOPHARMACOLOGY
LA English
DT Article; Retracted Publication
DE Viola hondoensis; quercetin-3-O-beta-D-(6
   ''-feruloyl)-galactopyranoside; MMP-1; ultraviolet
ID INHIBITORS
AB Long-term and repeated exposure of ultraviolet (UV) light, a harmful environmental stress, on the skin often induces chronic skin diseases, such as skin cancer as well as photo-aging (premature skin aging), and the mechanisms of these skin damages are closely associated with up-regulation of matrix metalloproteinases (MMPs) activities. Here, we investigated the effect of quercetin-3-O-beta-D-(6 ''-feruloyl)galactopyranoside isolated from the stems of Viola hondoensis (Violaceae) on the expression of MMP's in UV-irradiated human skin fibroblasts in vitro. Quercetin-3-O-beta-D-(6 ''-feruloyl)-galactopyranoside markedly reduced UV-induced MMP-1 expression at the protein levels in a dose-dependent manner. Our report is the first description for the ability of quercetin-3-O-beta-D-(6 ''-feruloyl)-galactopyranoside to regulate UV-induced MMP-1 expression. (C) 2005 Elsevier Ireland Ltd. All rights reserved.
C1 Seoul Natl Univ, Coll Med, Dept Dermatol, Seoul 110744, South Korea.
   Seoul Natl Univ Hosp, Clin Res Inst, Lab Cutaneous Aging Res, Seoul 110744, South Korea.
   Korea Res Inst Biosci & Biotechnol, Taejon 305333, South Korea.
   Sungkyunkwan Univ, Coll Pharm, Suwon 440746, South Korea.
RP Moon, HI (reprint author), Seoul Natl Univ, Coll Med, Dept Dermatol, Seoul 110744, South Korea.
EM himun@snu.ac.kr; jhchung@snu.ac.kr
OI Lee, Joongku/0000-0001-6250-3138
CR Brenneisen P, 2002, ANN NY ACAD SCI, V973, P31, DOI 10.1111/j.1749-6632.2002.tb04602.x
   Carnat AP, 1998, J NAT PROD, V61, P272, DOI 10.1021/np9701485
   Chung JH, 2003, J AM ACAD DERMATOL, V49, P690, DOI 10.1067/S0190-9622(03)02127-3
   Fisher GJ, 1996, NATURE, V379, P335, DOI 10.1038/379335a0
   Kim MR, 2004, CHEM PHARM BULL, V52, P1466, DOI 10.1248/cpb.52.1466
   Kim Y, 2000, PLANTA MED, V66, P72
   Lee Y. N, 1996, FLORA KOREA
   Lindholm P, 2002, MOL CANCER THER, V1, P365
   Moon HI, 2004, ARCH PHARM RES, V27, P730, DOI 10.1007/BF02980140
   MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4
   Rittie L, 2002, AGEING RES REV, V1, P705, DOI 10.1016/S1568-1637(02)00024-7
   Schuele S, 2004, MOVEMENT DISORD, V19, P43, DOI 10.1002/mds.10647
   Seo JY, 2001, J INVEST DERMATOL, V116, P915, DOI 10.1046/j.1523-1747.2001.01358.x
   Sternlicht MD, 2001, ANNU REV CELL DEV BI, V17, P463, DOI 10.1146/annurev.cellbio.17.1.463
   Stetler-Stevenson WG, 2001, SEMIN CANCER BIOL, V11, P143, DOI 10.1006/scbi.2000.0365
   Visse R, 2003, CIRC RES, V92, P827, DOI 10.1161/01.RES.0000070112.80711.3D
NR 16
TC 12
Z9 12
U1 4
U2 11
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0378-8741
J9 J ETHNOPHARMACOL
JI J. Ethnopharmacol.
PD OCT 3
PY 2005
VL 101
IS 1-3
BP 176
EP 179
DI 10.1016/j.jep.2005.04.032
PG 4
WC Plant Sciences; Chemistry, Medicinal; Integrative & Complementary
   Medicine; Pharmacology & Pharmacy
SC Plant Sciences; Pharmacology & Pharmacy; Integrative & Complementary
   Medicine
GA 970LR
UT WOS:000232312200026
PM 16009522
DA 2018-12-27
ER

PT J
AU Gibiansky, E
   Struys, MMRF
   Gibiansky, L
   Vanluchene, ALG
   Vornov, J
   Mortier, EP
   Burak, E
   Van Bortel, L
AF Gibiansky, E
   Struys, MMRF
   Gibiansky, L
   Vanluchene, ALG
   Vornov, J
   Mortier, EP
   Burak, E
   Van Bortel, L
TI RETRACTED: AQUAVANO (R) injection, a water-soluble prodrug of propofol,
   as a bolus injection: A phase I dose-escalation comparison with DIPRIVAN
   (R) (Part 1) - Pharmacokinetics (Retracted article. See vol. 112, pg.
   1058, 2010)
SO ANESTHESIOLOGY
LA English
DT Article; Proceedings Paper; Retracted Publication
CT Euroanaesthesia 2004 Meeting
CY JUN 05-08, 2004
CL Lisbon, PORTUGAL
ID GPI 15715; PHARMACODYNAMICS; SEDATION; RATS; VOLUNTEERS; SAFETY
AB Background: AQUAVAN((R)) Injection (AQ) (GPI 15715; Guilford Pharmaceutical Inc., Baltimore, MD) is a water-soluble prodrug of propofol (Propofol(GPI)). This study aimed to explore the pharmacokinetics of AQ, Propofol(GPI), and formate (a metabolite of AQ) and to compare them with the pharmacokinetics of propofol. lipid emulsion (Propofol.).
   Methods: After ethics committee approval, 36 healthy volunteers were randomly allocated into six cohorts (male/female: 3/3) and given a single bolus of AQ (5, 10, 15, 20, 25, or 30 mg/kg). For comparison, an equipotent dose (as measured by the Bispectral Index) of Propofol(D), was given to the same subjects 1 week later. For both drugs, blood samples were collected (1-480 min) to analyse AQ, Propofol(GPI,) Propofol(D), and formate concentrations. Noncompartmental pharmacokinetic analyses were performed for all analytes. A population compartmental model was developed for AQ and Propofol(GPI) using NONMEM. The models were evaluated using simulations and bootstraps.
   Results: The noncompartmental pharmacokinetic comparison revealed different dispositions of Propofol(GPI), and Propofol(D) The maximum plasma concentration was lower for Propofol(GPI) than for Propofol(D) at equipotent doses, and apparent clearance and distribution volume were much higher for Propofol(GPI), than for Propofol(D). Formate concentrations were similar when injecting both drugs and were not higher than baseline. Compartmental modeling revealed that the pharmacolkinetic behavior of AQ and its liberated PropofoI(GPI), was best described by a nonlinear, six-compartment model, composed of two three-compartment models connected to each other by hydrolysis of AQ to Propofol(GPI.)
   Conclusions: Propofol(GPI) showed different noncompartmental pharmacokinetics from Propofol(D,) hereby revealing the influence of the formulation. The combined model for AQ and Propofol(GPI) was best modeled by a nonlinear, six-compartment model.
C1 Ghent Univ Hosp, Dept Anesthesia, B-9000 Ghent, Belgium.
RP Struys, MMRF (reprint author), Ghent Univ Hosp, Dept Anesthesia, Pintelaan 185, B-9000 Ghent, Belgium.
EM michel.struys@ugent.be
OI Vornov, James/0000-0003-1965-5456
CR Barr J, 2001, ANESTHESIOLOGY, V95, P324, DOI 10.1097/00000542-200108000-00011
   BarrientosVega R, 1997, CRIT CARE MED, V25, P33, DOI 10.1097/00003246-199701000-00009
   Beal S.L., 1992, NONMEM USERS GUIDES
   COCKSHOTT ID, 1985, POSTGRAD MED J, V61, P45
   Dutta S, 1997, ANESTHESIOLOGY, V87, P1394, DOI 10.1097/00000542-199712000-00019
   Dutta S, 1998, J PHARM PHARMACOL, V50, P37, DOI 10.1111/j.2042-7158.1998.tb03302.x
   Dutta S, 1998, ANESTHESIOLOGY, V89, P678, DOI 10.1097/00000542-199809000-00018
   Fechner J, 2003, ANESTHESIOLOGY, V99, P303, DOI 10.1097/00000542-200308000-00012
   FULTON B, 1995, DRUGS, V50, P636, DOI 10.2165/00003495-199550040-00006
   Hanzlik RP, 2005, DRUG METAB DISPOS, V33, P282, DOI 10.1124/dmd.104.001289
   KAY NH, 1985, POSTGRAD MED J, V61, P55
   Kazama T, 2003, ANESTHESIOLOGY, V98, P299, DOI 10.1097/00000542-200302000-00006
   Kazama T, 2000, ANESTHESIOLOGY, V92, P1017, DOI 10.1097/00000542-200004000-00019
   Picard P, 2000, ANESTH ANALG, V90, P963
   PLUMMER GF, 1987, J CHROMATOGR-BIOMED, V421, P171, DOI 10.1016/0378-4347(87)80394-8
   Schnider TW, 1998, ANESTHESIOLOGY, V88, P1170, DOI 10.1097/00000542-199805000-00006
   Schywalsky M, 2003, EUR J ANAESTH, V20, P182, DOI 10.1097/00003643-200303000-00002
   SMITH I, 1994, ANESTHESIOLOGY, V81, P1005
   Struys MMRF, 2005, ANESTHESIOLOGY, V103, P730, DOI 10.1097/00000542-200510000-00011
   YAMAOKA K, 1978, J PHARMACOKINET BIOP, V6, P547, DOI 10.1007/BF01062109
NR 20
TC 40
Z9 43
U1 1
U2 9
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0003-3022
EI 1528-1175
J9 ANESTHESIOLOGY
JI Anesthesiology
PD OCT
PY 2005
VL 103
IS 4
BP 718
EP 729
DI 10.1097/00000542-200510000-00010
PG 12
WC Anesthesiology
SC Anesthesiology
GA 970PO
UT WOS:000232322300009
PM 16192764
DA 2018-12-27
ER

PT J
AU Struys, MMRF
   Vanluchene, ALG
   Gibiansky, E
   Gibiansky, L
   Vornov, J
   Mortier, EP
   Van Bortel, L
AF Struys, MMRF
   Vanluchene, ALG
   Gibiansky, E
   Gibiansky, L
   Vornov, J
   Mortier, EP
   Van Bortel, L
TI RETRACTED: AQUAVAN (R) injection, a water-soluble prodrug of propofol as
   a bolus injection: A phase I dose-escalation comparison with DIPRIVAN
   (R) (Part 2) - Pharmacodynamics and safety (Retracted article. See vol.
   112, pg. 1058, 2010)
SO ANESTHESIOLOGY
LA English
DT Article; Proceedings Paper; Retracted Publication
CT Annual Meeting of the Association-of-Anesthesiologists
CY OCT 12-16, 2002
CL Orlando, FL
SP Assoc Anesthesiologists
ID BISPECTRAL INDEX; GPI 15715; PHARMACOKINETICS; FOSPHENYTOIN;
   PHARMACOLOGY; SEDATION; INFUSION; EEG
AB Background: AQUAVAN((R)) injection (AQ) (GPI 15715; Guilford Pharmaceuticals Inc., Baltimore, MD) is a water-soluble prodrug of propofol. The authors explored the pharmacodynamics and safety of AQ and compared it with propofol lipid emulsion (Propofol(D)).
   Methods. After institutional review board approval, 36 volunteers with American Society of Anesthesiologists physical status of I were randomly allocated into six cohorts (male/female: 3/3 per cohort) and given a single bolus of AQ (5, 10, 15, 20, 25, or 30 mg/kg). A Bispectral Index((R)) monitor (Aspect Medical Systems Inc., Newton, MA) measured the hypnotic effect. The lowest Bispectral index level (BISpeak) was recorded. One week later, Propofol, was given to the same subjects at 50 mg/min to reach a similar BISpeak. Heart rate, oxygen saturation measured by pulse oximetry, blood pressure, and side effects were monitored. incidence and duration of apnea and loss (LOCverbal) and return of response to verbal command were measured. A population compartmental pharmacokinetic-pharniacodynamic model was developed for AQ using NONMEM and evaluated using simulations, leverage, and boot strap analyses.
   Results: In the higher dosages (cohorts 4-6), all subjects achieved LOCverbal. Similar times until LOCverbal were seen for AQ and Propofol(D). A dose-related increase in duration of LOCverbal was longer for AQ than for PropofolD. AQ BISpeak occurred later than with Propofol(D). Pain on injection was only present with Propofol(D) (12 of 36). With AQ, transient paresthesias and pruritus were seen. Hemodynamic profiles were similar for both drugs, except for an initial tachycardia after AQ administration. Dose-dependent apnea was more pronounced with Propofol, than with AQ. The AQ combined pharmacokinetic-pharmacodynamic profile was best described by a nonlinear, six-compartment pharmacokinetic model and an effect site compartment. A dependency of the k(e0) value on the Propofol(GFI) plasma concentration was noted.
   Conclusion: Bolus administration of AQ achieves LOCverbal at a similar time as an equipotent amount of Propofol(D) but shows a longer time to BISpeak and prolonged pharmacodynamics. For both drugs, excellent drug safety was achieved, although there was a tendency of fewer and shorter duration of apneas for AQ.
C1 Ghent Univ Hosp, Dept Anesthesia, B-9000 Ghent, Belgium.
RP Struys, MMRF (reprint author), Ghent Univ Hosp, Dept Anesthesia, Pintelaan 185, B-9000 Ghent, Belgium.
EM michel.struys@ugent.be
OI Vornov, James/0000-0003-1965-5456
CR Banaszczyk MG, 2002, ANESTH ANALG, V95, P1285, DOI 10.1213/01.ANE.0000031120.74200.D4
   BarrientosVega R, 1997, CRIT CARE MED, V25, P33, DOI 10.1097/00003246-199701000-00009
   Beal S.L., 1992, NONMEM USERS GUIDES
   Boucher BA, 1996, PHARMACOTHERAPY, V16, P638
   Browne TR, 1996, NEUROLOGY, V46, P3
   Fechner J, 2004, ANESTHESIOLOGY, V101, P626, DOI 10.1097/00000542-200409000-00011
   Fechner J, 2003, ANESTHESIOLOGY, V99, P303, DOI 10.1097/00000542-200308000-00012
   FORREST FC, 1994, BRIT J ANAESTH, V72, P35, DOI 10.1093/bja/72.1.35
   FULTON B, 1995, DRUGS, V50, P636, DOI 10.2165/00003495-199550040-00006
   Gibiansky E, 2005, ANESTHESIOLOGY, V103, P718, DOI 10.1097/00000542-200510000-00010
   Kazama T, 1999, ANESTHESIOLOGY, V90, P1517, DOI 10.1097/00000542-199906000-00004
   Kazama T, 2000, ANESTHESIOLOGY, V92, P1017, DOI 10.1097/00000542-200004000-00019
   KLAASSEN C, 2001, PHARMACOL BASIS THER, P1886
   Schnider T.W., 1994, ANAESTH PHARM REV, V2, P204
   Schnider TW, 1999, ANESTHESIOLOGY, V90, P1502, DOI 10.1097/00000542-199906000-00003
   Stone JG, 1996, ANESTHESIOLOGY, V85, P497, DOI 10.1097/00000542-199609000-00008
   Struys MMRF, 2002, ANESTHESIOLOGY, V96, P803, DOI 10.1097/00000542-200204000-00006
   Struys MMRF, 2001, ANESTHESIOLOGY, V95, P6, DOI 10.1097/00000542-200107000-00007
   Vanluchene ALG, 2004, ANESTHESIOLOGY, V101, P34, DOI 10.1097/00000542-200407000-00008
   Zheng D, 1998, ANESTH ANALG, V86, P1109
NR 20
TC 35
Z9 38
U1 2
U2 10
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0003-3022
EI 1528-1175
J9 ANESTHESIOLOGY
JI Anesthesiology
PD OCT
PY 2005
VL 103
IS 4
BP 730
EP 743
DI 10.1097/00000542-200510000-00011
PG 14
WC Anesthesiology
SC Anesthesiology
GA 970PO
UT WOS:000232322300010
PM 16192765
DA 2018-12-27
ER

PT J
AU Walker-Bone, K
   Cooper, C
AF Walker-Bone, K
   Cooper, C
TI RETRACTED: Hard work never hurt anyone: or did it? A review of
   occupational associations with soft tissue musculoskeletal disorders of
   the neck and upper limb (Retracted article. See vol. 68, pg. 1170, 2009)
SO ANNALS OF THE RHEUMATIC DISEASES
LA English
DT Review; Retracted Publication
ID CARPAL-TUNNEL-SYNDROME; RISK-FACTORS; PSYCHOSOCIAL FACTORS; RHEUMATIC
   DISORDERS; SHOULDER PAIN; CRITERIA; SYMPTOMS; ONSET
AB Pain in the neck and upper limb is common and contributes considerably to absence from work due to sickness. Evidence suggest that prolonged abnormal posture and repetition contribute to such conditions. Psychosocial risk factors may also play a part in the aetiology of upper limb disorders.
C1 Univ Brighton, Brighton & Sussex Med Sch, Brighton BN1 9PH, E Sussex, England.
   Southampton Gen Hosp, MRC, Epidemiol Ctr, Southampton SO16 6YD, Hants, England.
RP Walker-Bone, K (reprint author), Univ Brighton, Brighton & Sussex Med Sch, Mayfield House, Brighton BN1 9PH, E Sussex, England.
EM k.walker-bone@bsms.ac.uk
OI Cooper, Cyrus/0000-0003-3510-0709
CR Abbas M A, 1998, Int J Occup Environ Health, V4, P160
   Andersen JH, 2003, OCCUP ENVIRON MED, V60, P649, DOI 10.1136/oem.60.9.649
   Ariens GA, 2000, SCAND J WORK ENV HEA, V26, P7, DOI 10.5271/sjweh.504
   Bernard BP, 1997, MUSCULOSKELETAL DISO
   Bongers PM, 2002, AM J IND MED, V41, P315, DOI 10.1002/ajim.10050
   Buchbinder R, 1996, J CLIN EPIDEMIOL, V49, P141, DOI 10.1016/0895-4356(95)00519-6
   Croft PR, 2001, PAIN, V93, P317, DOI 10.1016/S0304-3959(01)00334-7
   D'Arcy CA, 2000, JAMA-J AM MED ASSOC, V283, P3110, DOI 10.1001/jama.283.23.3110
   Franzblau A, 1999, JAMA-J AM MED ASSOC, V282, P186, DOI 10.1001/jama.282.2.186
   Frost P, 1999, OCCUP ENVIRON MED, V56, P494, DOI 10.1136/oem.56.7.494
   Gerr F, 1998, J HAND SURG-BRIT EUR, V23B, P151, DOI 10.1016/S0266-7681(98)80163-0
   Harkness EF, 2003, OCCUP ENVIRON MED, V60, P850, DOI 10.1136/oem.60.11.850
   Harrington JM, 1998, OCCUP ENVIRON MED, V55, P264, DOI 10.1136/oem.55.4.264
   Helliwell PS, 2003, OCCUP MED-OXFORD, V53, P313, DOI 10.1093/occmed/kqg034
   Helliwell PS, 1996, BRIT J RHEUMATOL, V35, P1195
   KAMWENDO K, 1991, SCAND J REHABIL MED, V23, P143
   KUORINKA I, 1995, WORK RELATED MUSCULO, P17
   KURPPA K, 1991, SCAND J WORK ENV HEA, V17, P32, DOI 10.5271/sjweh.1737
   LEINO P, 1993, PAIN, V53, P89, DOI 10.1016/0304-3959(93)90060-3
   LODENKAMPER H, 1948, KLIN WOCHENSCHR, V26, P55, DOI 10.1007/BF01740404
   MACFARLANE GJ, 2000, BRIT MED J, V321, P1
   MOORE JS, 1992, OCCUP MED, V7, P741
   Palmer K, 2000, ANN RHEUM DIS, V59, P5, DOI 10.1136/ard.59.1.5
   RAMAZZINI B, 1940, MORBIS ARTIFICUM
   Reading I, 2003, AM J EPIDEMIOL, V157, P524, DOI 10.1093/aje/kwf225
   Silverstein B, 2004, J ELECTROMYOGR KINES, V14, P135, DOI 10.1016/j.jelekin.2003.09.023
   Sluiter JK, 2001, SCAND J WORK ENV HEA, V27, P1
   STOCK SR, 1991, AM J IND MED, V19, P87, DOI 10.1002/ajim.4700190111
   THOMSEN JF, THESIS U COPENHAGEN
   Van Eerd D, 2003, J CLIN EPIDEMIOL, V56, P940, DOI 10.1016/S0895-4356(03)00157-4
   Walker-Bone K, 2002, ANN RHEUM DIS, V61, P1103, DOI 10.1136/ard.61.12.1103
   Walker-Bone KE, 2003, SEMIN ARTHRITIS RHEU, V33, P185, DOI 10.1016/S0049-0172(03)00128-8
   Walker-Bone KE, 2003, SEMIN ARTHRITIS RHEU, V33, P168, DOI 10.1016/S0049-0172(03)00129-X
   WALKERBONE K, 2004, RHEUMATOLOOGY OXFO S, V43, pS143
   WALKERBONE K, 2004, RHEUMATOLOGY OXFO S1, V43, pS196
   WALKERBONE KE, 2004, RHEUMATOLOGY S2, V43, pS199
   White PD, 2003, J RHEUMATOL, V30, P139
NR 37
TC 65
Z9 65
U1 3
U2 8
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0003-4967
EI 1468-2060
J9 ANN RHEUM DIS
JI Ann. Rheum. Dis.
PD OCT
PY 2005
VL 64
IS 10
BP 1391
EP 1396
DI 10.1136/ard.2003.020016
PG 6
WC Rheumatology
SC Rheumatology
GA 964JA
UT WOS:000231875800002
PM 16162900
OA Green Published, Bronze
DA 2018-12-27
ER

PT J
AU Abdallah, AMA
   Abdallah, MA
   Beltagy, AI
AF Abdallah, AMA
   Abdallah, MA
   Beltagy, AI
TI RETRACTED: Contents of heavy metals in marine seaweeds from the Egyptian
   coast of the Red Sea (Retracted article. See vol 22, pg 437, 2006)
SO CHEMISTRY AND ECOLOGY
LA English
DT Article; Retracted Publication
DE heavy metals; seaweeds; contamination; Red Sea; Egypt
ID TRACE-METALS; THERMAIKOS GULF; GREEN SEAWEEDS; TURKISH COAST;
   ULVA-LACTUCA; BLACK-SEA; ALGAE; POLLUTION; CONTAMINATION; MOLLUSKS
AB Seaweeds belonging to 14 different genera of Chlorophyta,Phaeophyta, and Rhodophyta were analysed to determine the levels of heavy metals in two areas of the Egyptian Red Sea coast. Among the trace metals analysed, Mn and Zn showed the highest mass concentrations in the surface sea waters of the two studied areas. However, algae obtained from the Suez area had higher concentrations of the investigated heavy metals than those collect in the Mars Alam area. Nevertheless, a high variability of the metal levels occurs among the studied algae and also between the investigated areas. Moreover, Zn was the most abundant metal in the seaweeds of the Suez area, while Ph was predominant in the Mars Alam area in red and brown algae. Liagora spp. had the highest average concentration factor of Zn in Suez (29 161 -fold), while the average concentration factor in Enteromorpha spp. at Mars Alam was 20 091-fold. The highest Metal Pollution Index (MPI) value was recorded in Liogoro spp. (22.0) at Suez. This represents a 4.6-fold higher value than that recorded in Liagora spp. at Mars Alam. Among green, brown, and red algae in Suez, the highest values of MPI were recorded in Cladophora spp. and Halimeda spp. (18.2 and 18.3), Padina spp. (16.2), and Liagora spp. (22.1), respectively; while at Mars Alam, the highest values of MPI were recorded in Cladophora spp. (6.6), Padina spp. (3.4) and Liagora spp. (4.8), respectively.
C1 Natl Inst Oceanog & Fisheries, Alexandria, Egypt.
RP Abdallah, AMA (reprint author), 479 El Horria St, Alexandria, Egypt.
EM abdallah@wwwsol.com
CR AGADI VV, 1978, BOT MAR, V21, P247, DOI 10.1515/botm.1978.21.4.247
   Brown MT, 1999, MAR ENVIRON RES, V47, P175, DOI 10.1016/S0141-1136(98)00113-5
   BRYAN GW, 1985, MARINE BIOL ASS UK O, V4
   BuoOlayan AH, 1996, B ENVIRON CONTAM TOX, V57, P816, DOI 10.1007/s001289900262
   Caliceti M, 2002, CHEMOSPHERE, V47, P443, DOI 10.1016/S0045-6535(01)00292-2
   Campanella L, 2001, ENVIRON POLLUT, V111, P117, DOI 10.1016/S0269-7491(99)00327-9
   da Costa ACA, 2003, MAR BIOTECHNOL, V5, P149, DOI 10.1007/s10126-002-0109-7
   Diapoulis A, 1992, FRESEN ENVIRON BULL, V1, P483
   ELSARRAF WM, 1995, B FAC SCI ALEXANDRIA, V135, P475
   FITYANOS K, 1999, B ENVIRON CONTAM TOX, V62, P630
   Giusti L, 2001, ENVIRON INT, V26, P275, DOI 10.1016/S0160-4120(00)00117-3
   GOLDBERG ED, 1978, ENVIRON CONSERV, V5, P101, DOI 10.1017/S0376892900005555
   HARITONIDIS S, 1995, ENVIRON POLLUT, V89, P319, DOI 10.1016/0269-7491(94)00070-T
   HIGGINS HW, 1987, AUST J MAR FRESH RES, V38, P307
   HO YB, 1990, B MAR SCI, V47, P79
   HOLMES MA, 1991, MAR ENVIRON RES, V31, P55, DOI 10.1016/0141-1136(91)90005-S
   JALEEL T, 1993, MAR POLLUT B, V26, P644
   Kaimoussi A, 2004, CR BIOL, V327, P361, DOI 10.1016/j.crvi.2004.01.007
   KHALIL AN, 1991, ENV PROT MUST 11 14, P45
   Kut D, 2000, WATER AIR SOIL POLL, V118, P27, DOI 10.1023/A:1005149500870
   LELAND HV, 1979, J WATER POLLUT CON F, V51, P1592
   MALEA P, 1995, HYDROBIOLOGIA, V310, P19, DOI 10.1007/BF00008180
   Malea P, 2000, J APPL PHYCOL, V12, P169, DOI 10.1023/A:1008136320459
   Muse JO, 1999, ENVIRON POLLUT, V104, P315, DOI 10.1016/S0269-7491(98)00096-7
   Paez-Osuna F, 2000, B ENVIRON CONTAM TOX, V64, P846
   Phaneuf D, 1999, ENVIRON RES, V80, pS175, DOI 10.1006/enrs.1998.3915
   PHILLIPS DJH, 1977, ENVIRON POLLUT, V13, P281, DOI 10.1016/0013-9327(77)90047-7
   Romero-Gonzalez ME, 2001, ENVIRON SCI TECHNOL, V35, P3025, DOI 10.1021/es991133r
   Schmitt D, 2001, WATER RES, V35, P779, DOI 10.1016/S0043-1354(00)00317-1
   SEELIGER U, 1979, J MAR BIOL ASSOC UK, V59, P227, DOI 10.1017/S0025315400046300
   SHIBER JG, 1980, HYDROBIOLOGIA, V69, P147, DOI 10.1007/BF00016544
   SIVALINGAM PM, 1978, BOT MAR, V21, P327, DOI 10.1515/botm.1978.21.5.327
   Topcuoglu S, 2003, CHEMOSPHERE, V52, P1683, DOI 10.1016/S0045-6535(03)00301-1
   Topcuoglu S, 2002, ENVIRON INT, V27, P521, DOI 10.1016/S0160-4120(01)00099-X
   Usero J, 1997, ENVIRON INT, V23, P291, DOI 10.1016/S0160-4120(97)00030-5
   Villares R, 2002, ENVIRON POLLUT, V119, P79, DOI 10.1016/S0269-7491(01)00322-0
   Villares R, 2001, HYDROBIOLOGIA, V462, P221, DOI 10.1023/A:1013154821531
   WAHBEH MI, 1985, MAR ENVIRON RES, V16, P95, DOI 10.1016/0141-1136(85)90011-X
NR 38
TC 12
Z9 12
U1 4
U2 22
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0275-7540
EI 1029-0370
J9 CHEM ECOL
JI Chem. Ecol.
PD OCT
PY 2005
VL 21
IS 5
BP 399
EP 411
DI 10.1080/02757540500290222
PG 13
WC Biochemistry & Molecular Biology; Ecology; Environmental Sciences
SC Biochemistry & Molecular Biology; Environmental Sciences & Ecology
GA 989HT
UT WOS:000233664200007
DA 2018-12-27
ER

PT J
AU Bekaert, M
   Richard, H
   Prum, B
   Rousset, JP
AF Bekaert, M
   Richard, H
   Prum, B
   Rousset, JP
TI RETRACTED: Identification of programmed translational-1 frameshifting
   sites in the genome of Saccharomyces cerevisiae (Retracted Article. See
   vol 16, pg 1074, 2006)
SO GENOME RESEARCH
LA English
DT Article; Retracted Publication
ID STOP CODON READTHROUGH; HIDDEN MARKOV-MODELS; GENE-EXPRESSION; CODING
   REGIONS; YEAST; DNA; RECOGNITION; ALIGNMENT; SIGNAL; SEQUENCE
AB Frameshifting is a recoding event that allows the expression of two polypeptides from the same mRNA molecule. Most recoding events described so far are used by viruses and transposons to express their replicase protein. The very few number of cellular proteins known to be expressed by a -1 ribosomal frameshifting has been identified by chance. The goal of the present work was to set Lip a systematic strategy, based oil complementary bioinformatics, molecular biology, and functional approaches, Without a priori knowledge of the mechanism involved. Two independent methods were devised. The first looks for genomic regions in which two ORFs, each carrying a protein pattern, are in a frameshifted arrangement. The second uses Hidden Markov Models and likelihood in a two-step approach. When this strategy was applied to the Saccharomyces cerevisiae genome, 189 candidate regions were found, of which 58 were further functionally investigated. Twenty-eight of them expressed a full-length mRNA covering the two ORFs, and II showed a -1 frameshift efficiency varying from 5% to 13% (50-fold higher than background), some of which corresponds to genes with known functions. From other ascomycetes, four frameshifted ORFs are found fully conserved. Strikingly, most of the candidates do not display a classical viral-like frameshift signal and would have escaped a search based oil current models of frameshifting. These results strongly suggest that -1 frameshifting might be more widely distributed than previously thought.
C1 Univ Paris 11, CNRS, UMR 8621, Inst Genet & Microbiol, F-91405 Orsay, France.
   Univ Evry, INRA, CNRS, Lab Stat & Genome, F-91000 Evry, France.
RP Rousset, JP (reprint author), Univ Paris 11, CNRS, UMR 8621, Inst Genet & Microbiol, F-91405 Orsay, France.
EM jean-pierre.rousset@igmors.u-psud.fr
RI Bekaert, Michael/A-8393-2008
CR ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2
   Baranov PV, 2003, NUCLEIC ACIDS RES, V31, P87, DOI 10.1093/nar/gkg024
   Baranov PV, 2002, EMBO REP, V3, P373, DOI 10.1093/embo-reports/kvf065
   Baranov PV, 2002, GENE, V286, P187, DOI 10.1016/S0378-1119(02)00423-7
   Bekaert M, 2005, MOL CELL, V17, P61, DOI 10.1016/j.molcel.2004.12.009
   Bekaert M, 2003, BIOINFORMATICS, V19, P327, DOI 10.1093/bioinformatics/btf868
   Bertani R, 2000, INORG CHEM COMMUN, V3, P16, DOI 10.1016/S1387-7003(99)00174-4
   Birney E, 1996, NUCLEIC ACIDS RES, V24, P2730, DOI 10.1093/nar/24.14.2730
   BORODOVSKY M, 1993, BIOSYSTEMS, V30, P161, DOI 10.1016/0303-2647(93)90068-N
   Brachat S, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-7-r45
   BRIERLEY I, 1989, CELL, V57, P537, DOI 10.1016/0092-8674(89)90124-4
   Burge C, 1997, J MOL BIOL, V268, P78, DOI 10.1006/jmbi.1997.0951
   Cliften P, 2003, SCIENCE, V301, P71, DOI 10.1126/science.1084337
   Delneri D, 1999, GENETICS, V153, P1591
   DENISE A, 2003, RECOMB 03
   Dujon B, 2004, NATURE, V430, P35, DOI 10.1038/nature02579
   Gelfand MS, 1996, P NATL ACAD SCI USA, V93, P9061, DOI 10.1073/pnas.93.17.9061
   GESTELAND RF, 1992, SCIENCE, V257, P1640, DOI 10.1126/science.1529352
   Gurvich OL, 2003, EMBO J, V22, P5941, DOI 10.1093/emboj/cdg561
   HAMADA H, 1984, MOL CELL BIOL, V4, P2610, DOI 10.1128/MCB.4.12.2610
   Hammell AB, 1999, GENOME RES, V9, P417
   Harrison P, 2002, J MOL BIOL, V316, P409, DOI 10.1006/jmbi.2001.5343
   ITO H, 1983, J BACTERIOL, V153, P163
   Ito T, 2001, P NATL ACAD SCI USA, V98, P4569, DOI 10.1073/pnas.061034498
   JACKS T, 1985, SCIENCE, V230, P1237, DOI 10.1126/science.2416054
   JACKS T, 1988, CELL, V55, P447, DOI 10.1016/0092-8674(88)90031-1
   Kellis M, 2003, NATURE, V423, P241, DOI 10.1038/nature01644
   Klobutcher LA, 2002, CELL, V111, P763, DOI 10.1016/S0092-8674(02)01138-8
   LIPHARDT J, 1999, MECH 1 RIBOSOMAL FRA
   Lode A, 2002, YEAST, V19, P909, DOI 10.1002/yea.883
   Maglott DR, 2000, NUCLEIC ACIDS RES, V28, P126, DOI 10.1093/nar/28.1.126
   Manktelow E, 2005, NUCLEIC ACIDS RES, V33, P1553, DOI 10.1093/nar/gki299
   Mironov AA, 1998, GENOMICS, V51, P332, DOI 10.1006/geno.1998.5251
   Mulder NJ, 2003, NUCLEIC ACIDS RES, V31, P315, DOI 10.1093/nar/gkg046
   Namy O, 2004, MOL CELL, V13, P157, DOI 10.1016/S1097-2765(04)00031-0
   Namy O, 2003, NUCLEIC ACIDS RES, V31, P2289, DOI 10.1093/nar/gkg330
   Namy O, 2002, GENETICS, V161, P585
   Nicolas P, 2002, NUCLEIC ACIDS RES, V30, P1418, DOI 10.1093/nar/30.6.1418
   Nielsen H, 1999, PROTEIN ENG, V12, P3, DOI 10.1093/protein/12.1.3
   PEARSON WR, 1990, METHOD ENZYMOL, V183, P63
   RABINER LR, 1989, P IEEE, V77, P257, DOI 10.1109/5.18626
   Sato M, 2003, BIOINFORMATICS, V19, P1371, DOI 10.1093/bioinformafics/btg183
   SCHMITT ME, 1990, NUCLEIC ACIDS RES, V18, P3091, DOI 10.1093/nar/18.10.3091
   Shigemoto K, 2001, NUCLEIC ACIDS RES, V29, P4079, DOI 10.1093/nar/29.19.4079
   SNYDER EE, 1995, J MOL BIOL, V248, P1, DOI 10.1006/jmbi.1995.0198
   Solovyev V, 1997, ISMB-97 - FIFTH INTERNATIONAL CONFERENCE ON INTELLIGENT SYSTEMS FOR MOLECULAR BIOLOGY, PROCEEDINGS, P294
   SOLOVYEV VV, 1994, NUCLEIC ACIDS RES, V22, P5156, DOI 10.1093/nar/22.24.5156
   Sonnhammer E L, 1998, Proc Int Conf Intell Syst Mol Biol, V6, P175
   STAHL G, 1995, NUCLEIC ACIDS RES, V23, P1557, DOI 10.1093/nar/23.9.1557
   Stajich JE, 2002, GENOME RES, V12, P1611, DOI 10.1101/gr.361602
   TSUCHIHASHI Z, 1990, P NATL ACAD SCI USA, V87, P2516, DOI 10.1073/pnas.87.7.2516
   Zdobnov EM, 2001, BIOINFORMATICS, V17, P847, DOI 10.1093/bioinformatics/17.9.847
NR 52
TC 3
Z9 5
U1 3
U2 12
PU COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT
PI COLD SPRING HARBOR
PA 1 BUNGTOWN RD, COLD SPRING HARBOR, NY 11724 USA
SN 1088-9051
EI 1549-5469
J9 GENOME RES
JI Genome Res.
PD OCT
PY 2005
VL 15
IS 10
BP 1411
EP 1420
DI 10.1101/gr.4258005
PG 10
WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Genetics & Heredity
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Genetics & Heredity
GA 972EL
UT WOS:000232436800012
PM 16204194
OA Green Published, Bronze
DA 2018-12-27
ER

PT J
AU Nakamura, A
   Yamamoto, K
   Ishihara, J
   Aoki, T
   Temmyo, J
AF Nakamura, A
   Yamamoto, K
   Ishihara, J
   Aoki, T
   Temmyo, J
TI RETRACTED: Characterization of MgxZn1-xO films grown by
   remote-plasma-enhanced metalorganic chemical vapor-deposition using
   bis-ethylcyclopentadienyl magnesium (Retracted article. See vol. 49,
   art. no. 129201, 2010)
SO JAPANESE JOURNAL OF APPLIED PHYSICS PART 1-REGULAR PAPERS BRIEF
   COMMUNICATIONS & REVIEW PAPERS
LA English
DT Article; Retracted Publication
DE remote-plasma-enhanced MOCVD; MgxZn1-xO; diethyl zinc (DEZn);
   bis-ethylcyclopentadienyl magnesium (EtCp2Mg); Stokes' shift
ID MOLECULAR-BEAM EPITAXY; BAND-GAP; ALLOY
AB MgxZn1-xO films were successfully grown on a-plane sapphire (11 (2) over bar0) substrates by remote-plasma-enhanced metalorganic chemical vapor-deposition (RPE-MOCVD) using diethyl zinc (DEZn) and bis-ethylcyclopentadienyl magnesium (EtCp2Mg). By increasing magnesium content in the films, the crystal structure was shifted through a mixed state from wurtzite to rock salt. The optical band-gap of the films at nearly 3.28 eV was shifted to 3.69 eV by alloying with magnesium depending on the alloy composition. Both optical absorption edges and emission peaks of MgxZn1-xO films shifted to higher energy when the magnesium content at room temperature was increased, showing alloy broadening. The Stokes' shift of wurtzite MgxZn1-xO alloy films was quantitatively evaluated. The results are relevant to exciton localization.
C1 Shizuoka Univ, Grad Sch Elect Sci & Technol, Hamamatsu, Shizuoka 4328011, Japan.
   Shizuoka Univ, Elect Res Inst, Hamamatsu, Shizuoka 4328011, Japan.
RP Nakamura, A (reprint author), Shizuoka Univ, Grad Sch Elect Sci & Technol, 3-5-1 Johoku, Hamamatsu, Shizuoka 4328011, Japan.
CR Choopun S, 2002, APPL PHYS LETT, V80, P1529, DOI 10.1063/1.1456266
   Matsumoto Y, 1999, JPN J APPL PHYS 2, V38, pL603, DOI 10.1143/JJAP.38.L603
   Muthukumar S, 2003, APPL PHYS LETT, V82, P742, DOI 10.1063/1.1541950
   Nakamura A, 2004, JPN J APPL PHYS 2, V43, pL1452, DOI 10.1143/JJAP.43.L1452
   Ohtomo A, 1998, APPL PHYS LETT, V72, P2466, DOI 10.1063/1.121384
   Park WI, 2001, APPL PHYS LETT, V79, P2022, DOI 10.1063/1.1405811
   Shigemori S, 2004, JPN J APPL PHYS 2, V43, pL1088, DOI 10.1143/JJAP.43.L1088
   Takagi T, 2003, JPN J APPL PHYS 2, V42, pL401, DOI 10.1143/JJAP.42.L401
   Tsukazaki A, 2005, NAT MATER, V4, P42, DOI 10.1038/nmat1284
NR 9
TC 15
Z9 15
U1 3
U2 9
PU JAPAN SOC APPLIED PHYSICS
PI TOKYO
PA KUDAN-KITA BUILDING 5TH FLOOR, 1-12-3 KUDAN-KITA, CHIYODA-KU, TOKYO,
   102-0073, JAPAN
SN 0021-4922
J9 JPN J APPL PHYS 1
JI Jpn. J. Appl. Phys. Part 1 - Regul. Pap. Brief Commun. Rev. Pap.
PD OCT
PY 2005
VL 44
IS 10
BP 7267
EP 7270
DI 10.1143/JJAP.44.7267
PG 4
WC Physics, Applied
SC Physics
GA 976NC
UT WOS:000232739300013
OA Bronze
DA 2018-12-27
ER

PT J
AU Roman-Gomez, J
   Jimenez-Velasco, A
   Agirre, X
   Prosper, F
   Heiniger, A
   Torres, A
AF Roman-Gomez, J
   Jimenez-Velasco, A
   Agirre, X
   Prosper, F
   Heiniger, A
   Torres, A
TI RETRACTED: Lack of CpG island methylator phenotype defines a clinical
   subtype of T-cell acute lymphoblastic leukemia associated with good
   prognosis (Retracted article. See vol. 31, pg. 979, 2013)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Article; Retracted Publication
ID ACUTE LYMPHOCYTIC-LEUKEMIA; PROMOTER HYPERMETHYLATION; DNA METHYLATION;
   PETHEMA ALL-89; EXPRESSION; CANCER; CHILDREN; TRIAL; CHEMOTHERAPY;
   CARCINOMA
AB Purpose To examine cancer genes undergoing epigenetic inactivation in a set of T-cell acute lymphoblastic leukemias (T-ALLs) to obtain the CpG island methylator phenotype (CIMP) in the disease and its possible correlation with clinical features and outcome of the patients.
   Patients and Methods Methylation-specific polymerase. chain reaction was used to analyze methylation of the ADAMTS-1, ADAMTS-5, APAF-1, ASPP-1, CDH1, CDH13, DAPK DIABLO, DKK-3, LATS-1, LATS-2, NES-1, p14, p15, p16, p57, p73, PARK-2, PTEN, sFRP1/2/4/5, SHP-1, SYK TMS-1, and WIF-1 genes in samples from 50 consecutive T-ALL patients (19 children and 31 adults).
   Results were compared with results obtained in 286 B-cell acute lymphoblastic leukemias (B-ALLs). Results A total of 88% of the T-ALL samples had at least one gene methylated. According to the number of methylated genes observed in each individual sample, 12 patients (24%) were included in the CIMP- group (zero to two methylated genes), and 38 patients (76%) were included in the CIMP+ group (> two methylated genes). Clinical features and remission rate did not differ significantly among both groups of patients. Estimated disease-free survival QFS) rate at 12 years and overall survival (OS) rate at 13 years were 100% and 91% for the CIMP- group and 20% and 17% for the CIMP+ group, respectively (P =.0006 and P =.003, respectively). Multivariate analysis demonstrated that methylation profile was an independent prognostic factor in predicting DFS (P =.05) and CIS (P =.02). A group of five genes (SYK-1, ASPP-1, sFRP-2, sFRP-5, and WIF-1) showed specificity for T-ALL compared with B-ALL.
   Conclusion Our results suggest that the methylation profile may be a potential new biomarker of risk prediction in T-ALL.
C1 Reina Sofia Hosp, Dept Hematol, E-14004 Cordoba, Spain.
   Carlos Haya Hosp, Dept Hematol, Malaga, Spain.
   Univ Navarra, Sch Med Clin Univ, Fdn Appl Med Res, Cellular Therapy Area,Hematol Dept, E-31080 Pamplona, Spain.
RP Roman-Gomez, J (reprint author), Reina Sofia Hosp, Dept Hematol, Avda Menendez Pidal S-N, E-14004 Cordoba, Spain.
EM peperosa@teleline.es
RI Prosper, Felipe/H-6859-2017
OI Prosper, Felipe/0000-0001-6115-8790
CR Ballerini P, 2002, BLOOD, V100, P991, DOI 10.1128/blood-2001-11-0093
   BENE MC, 1995, LEUKEMIA, V9, P1783
   Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102
   Cave H, 1998, NEW ENGL J MED, V339, P591, DOI 10.1056/NEJM199808273390904
   Chiaretti S, 2004, BLOOD, V103, P2771, DOI 10.1182/blood-2003-09-3243
   Chim CS, 2004, ANN HEMATOL, V83, P527, DOI 10.1007/s00277-004-0843-1
   Das PM, 2004, J CLIN ONCOL, V22, P4632, DOI 10.1200/JCO.2004.07.151
   Dunn JR, 2004, BRIT J CANCER, V91, P1149, DOI 10.1038/sj.bjc.6602107
   Ferrando AA, 2004, LANCET, V363, P535, DOI 10.1016/S0140-6736(04)15542-6
   Goldberg JM, 2003, J CLIN ONCOL, V21, P3616, DOI 10.1200/JCO.2003.10.116
   Goodman PA, 2003, ONCOGENE, V22, P2504, DOI 10.1038/sj.onc.1206313
   Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Lee AY, 2004, ONCOGENE, V23, P6672, DOI 10.1038/sj.onc.1207881
   Li YF, 2003, ONCOGENE, V22, P4398, DOI 10.1038/sj.onc.1206603
   Mazieres J, 2004, CANCER RES, V64, P4717, DOI 10.1158/0008-5472.CAN-04-1389
   Mizutani Y, 2005, J CLIN ONCOL, V23, P448, DOI 10.1200/JCO.2005.02.191
   Mori S, 2004, CANCER, V100, P1673, DOI 10.1002/cncr.20164
   Ortega JJ, 1998, INT J PEDIAT HEM ONC, V5, P163
   Ortega JJ, 2001, HAEMATOLOGICA, V86, P586
   Pieters R, 1998, LEUKEMIA, V12, P1344, DOI 10.1038/sj.leu.2401129
   Pui CH, 1998, NEW ENGL J MED, V339, P605, DOI 10.1056/NEJM199808273390907
   Pullen J, 1999, LEUKEMIA, V13, P1696, DOI 10.1038/sj.leu.2401555
   Ribera JM, 2002, HAEMATOLOGICA, V87, P154
   Ribera JM, 1998, HAEMATOLOGICA, V83, P222
   Roman-Gomez J, 2004, BLOOD, V104, P2492, DOI 10.1182/blood-2004-03-0954
   Roman-Gomez J, 2003, J CLIN ONCOL, V21, P1472, DOI 10.1200/JCO.2003.08.166
   TAKEUCHI S, 1995, CANCER RES, V55, P5377
   Uckun FM, 1998, BLOOD, V91, P735
NR 29
TC 100
Z9 110
U1 4
U2 15
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD OCT 1
PY 2005
VL 23
IS 28
BP 7043
EP 7049
DI 10.1200/JCO.2005.01.4944
PG 7
WC Oncology
SC Oncology
GA 969KC
UT WOS:000232232000030
PM 16192589
OA Green Published
DA 2018-12-27
ER

PT J
AU Kim, JA
   Choi, YS
   Lee, J
   Park, J
   Lee, MA
   Yeom, CH
   Jang, SK
   Yoon, DM
   Kim, JS
AF Kim, JA
   Choi, YS
   Lee, J
   Park, J
   Lee, MA
   Yeom, CH
   Jang, SK
   Yoon, DM
   Kim, JS
TI RETRACTED: Reliability and validity of the Korean cancer pain assessment
   tool (KCPAT) (Retracted Article. See vol 21, pg 1139, 2006)
SO JOURNAL OF KOREAN MEDICAL SCIENCE
LA English
DT Article; Retracted Publication
DE neoplasms; pain; pain measurement; reliability; validily;
   reproducibility of results; Korean
AB The Korean Cancer Pain Assessment Tool (KCPAT), which was developed in 2003, consists of questions concerning the location of pain, the nature of pain, the present pain intensity, the symptoms associated with the pain, and psychosocial/spiritual pain assessments. This study was carded out to evaluate the reliability and validity of the KCPAT. A stratified, proportional-quota, clustered, systematic sampling procedure was used. The study population (903 cancer patients) was 1% of the target population (90,252 cancer patients). A total of 314 (34.8%) questionnaires were collected. The results showed that the average pain score (5 point on Likert scale) according to the cancer type and the at-present average pain score (VAS, 0-10) were correlated (r = 0.56, p < 0.0001), and showed moderate agreement (kappa = 0.364). The mean satisfaction score was 3.8 (1-5). The average time to complete the questionnaire was 8.9 min. In conclusion, the KCPAT is a reliable and valid instrument for assessing cancer pain in Koreans.
C1 Korea Univ, Coll Med, Dept Prevent Med, Dept Family Med, Seoul 136701, South Korea.
   Bobath Mem Hosp, Dept Internal Med, Seoungnam, South Korea.
   Catholic Univ, Korea Coll Med, Dept Internal Med, Seoul, South Korea.
   Kwandong Univ, Coll Med, Dept Family Med, Seoul, South Korea.
   Dongmyun Hlth Ctr, Cheonan, South Korea.
   Yonsei Univ, Coll Med, Dept Anesthesiol & Pain Med, Seoul 120749, South Korea.
   Korea Univ, Dept Internal Med, Coll Med, Seoul 136701, South Korea.
RP Choi, YS (reprint author), Korea Univ, Coll Med, Dept Family Med, Guro Hosp, 97 Guro Dong Gil, Seoul 152703, South Korea.
EM younseon@korea.ac.kr
CR BIERI D, 1990, PAIN, V41, P139, DOI 10.1016/0304-3959(90)90018-9
   DAUT RL, 1983, PAIN, V17, P197, DOI 10.1016/0304-3959(83)90143-4
   FISHMAN B, 1987, CANCER-AM CANCER SOC, V60, P1151, DOI 10.1002/1097-0142(19870901)60:5<1151::AID-CNCR2820600538>3.0.CO;2-G
   GROSSMAN SA, 1991, J PAIN SYMPTOM MANAG, V6, P53, DOI 10.1016/0885-3924(91)90518-9
   KIM KH, 2002, KOREAN J HOSPICE PAL, V4, P137
   *KOR CENTR CANC RE, 2001, 2001 ANN REP KOR CEN
   *KOR SOC HOSP PALL, 2001, GUID CANC PAIN MAN, P1
   Lee SW, 2003, KOREAN J HOSPICE PAL, V6, P22
   MELZACK R, 1975, PAIN, V1, P277, DOI 10.1016/0304-3959(75)90044-5
   MERSKEY H, 1979, PAIN, V7, P271, DOI 10.1016/0304-3959(79)90084-8
   SAUNDERS CM, 1967, MANAGEMENT TERMINAL
   SCOTT J, 1976, PAIN, V2, P175, DOI 10.1016/0304-3959(76)90113-5
   SRIWATANAKUL K, 1983, CLIN PHARMACOL THER, V34, P234, DOI 10.1038/clpt.1983.159
   VONROENN JH, 1993, ANN INTERN MED, V119, P121, DOI 10.7326/0003-4819-119-2-199307150-00005
   YUN YH, 1999, KOREAN J HOSPICE PAL, V2, P70
NR 15
TC 8
Z9 8
U1 3
U2 12
PU KOREAN ACAD MEDICAL SCIENCES
PI SEOUL
PA 302 75 DONG DU ICHON, DONG YONGSAN KU, SEOUL 140 031, SOUTH KOREA
SN 1011-8934
EI 1598-6357
J9 J KOREAN MED SCI
JI J. Korean Med. Sci.
PD OCT
PY 2005
VL 20
IS 5
BP 877
EP 882
DI 10.3346/jkms.2005.20.5.877
PG 6
WC Medicine, General & Internal
SC General & Internal Medicine
GA 981NK
UT WOS:000233095100027
PM 16224166
OA Other Gold, Green Published
DA 2018-12-27
ER

PT J
AU Christov, R
   Trusheva, B
   Popova, M
   Bankova, V
   Bertrand, M
AF Christov, R
   Trusheva, B
   Popova, M
   Bankova, V
   Bertrand, M
TI RETRACTED: Chemical composition of propolis from Canada, its antiradical
   activity and plant origin (Retracted article. See vol 23, pg 1160, 2009)
SO NATURAL PRODUCT RESEARCH
LA English
DT Article; Retracted Publication
DE propolis; dihydrochalcones; Populus
ID ETHANOL EXTRACT; BUD EXUDATE; GC-MS
AB The chemical composition of propolis from two regions in Canada was studied: Boreal forest and the Pacific coastal forest that lie outside the area of distribution of Aigeiros poplars, the usual propolis source plants. In the sample from Victoria, p-hydroxyacetophenone, benzyl hydroxybenzoate and cinnamic acid were the major components, accompanied by significant amounts of dihydrochalcones, which allowed the identification of its plant source: Populus trichocarpa of section Tacamahaca. Three dihydrochalcones were new for propolis. The sample from Richmond was characterized by large amounts of p-coumaric and cinnamic acid, typical for poplars of section Leuce, subsection Trepidae, its plant source was identified as P. tremuloides. Both samples showed a good radical scavenging activity against DPPH. Obviously, the Northern type propolis is a promising potential source of biologically active substances and deserves further investigation.
C1 Bulgarian Acad Sci, Ctr Phytochem, Inst Organ Chem, BU-1113 Sofia, Bulgaria.
   Univ Montreal, Dept Chem, Reg Ctr Mass Spectrometry, Montreal, PQ H3C 3J7, Canada.
RP Bankova, V (reprint author), Bulgarian Acad Sci, Ctr Phytochem, Inst Organ Chem, BU-1113 Sofia, Bulgaria.
EM bankova@orgchm.bas.bg
RI Bankova, Vassya/A-8972-2010
CR BANKOVA V, 1992, APIDOLOGIE, V23, P79, DOI 10.1051/apido:19920109
   Bankova V., 1989, ANIMAL SCI, V2, P94
   Bankova VS, 2000, APIDOLOGIE, V31, P3, DOI 10.1051/apido:2000102
   Banskota AH, 2000, J ETHNOPHARMACOL, V72, P239, DOI 10.1016/S0378-8741(00)00252-X
   Banskota AH, 2001, PHYTOTHER RES, V15, P561, DOI 10.1002/ptr.1029
   BRAYSHAW T. C., 1965, CAN FIELD NATUR, V79, P91
   Burdock GA, 1998, FOOD CHEM TOXICOL, V36, P347, DOI 10.1016/S0278-6915(97)00145-2
   CARDER AC, 1970, J RANGE MANAGE, V23, P263, DOI 10.2307/3896218
   ENGLISH S, 1991, PHYTOCHEMISTRY, V30, P531, DOI 10.1016/0031-9422(91)83721-V
   GARCIAVIGUERA C, 1993, Z NATURFORSCH C, V48, P731
   GARCIAVIGUERA C, 1992, Z NATURFORSCH C, V47, P634
   GHISALBERTI EL, 1979, BEE WORLD, V60, P59, DOI 10.1080/0005772X.1979.11097738
   GREENAWAY W, 1989, J CHROMATOGR, V472, P393, DOI 10.1016/S0021-9673(00)94139-6
   GREENAWAY W, 1990, BEE WORLD, V71, P107, DOI 10.1080/0005772X.1990.11099047
   Hamasaka T, 2004, FOOD SCI TECHNOL RES, V10, P86, DOI 10.3136/fstr.10.86
   Lu LC, 2003, J FOOD DRUG ANAL, V11, P277
   Plumb GW, 1996, J FOOD LIPIDS, V3, P171, DOI 10.1111/j.1745-4522.1996.tb00065.x
   Popravko S. A., 1978, REMARKABLE HIVE PROD, P15
   SCHELLER S, 1990, INT J RADIAT BIOL, V57, P461, DOI 10.1080/09553009014552601
   Wollenweber E, 1997, Z NATURFORSCH C, V52, P530
NR 20
TC 24
Z9 25
U1 4
U2 21
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1478-6419
EI 1478-6427
J9 NAT PROD RES
JI Nat. Prod. Res.
PD OCT
PY 2005
VL 19
IS 7
BP 673
EP 678
DI 10.1080/14786410512331328159
PG 6
WC Chemistry, Applied; Chemistry, Medicinal
SC Chemistry; Pharmacology & Pharmacy
GA 962FN
UT WOS:000231716500006
PM 16076637
DA 2018-12-27
ER

PT J
AU Peng, JP
   Chang, HC
   Hwang, CF
   Hung, WC
AF Peng, JP
   Chang, HC
   Hwang, CF
   Hung, WC
TI RETRACTED: Overexpression of cyclooxygenase-2 in nasopharyngeal
   carcinoma and association with lymph node metastasis (Retracted Article.
   See vol 42, pg 653, 2006)
SO ORAL ONCOLOGY
LA English
DT Article; Retracted Publication
DE cyclooxygenase-2; nasopharyngeal carcinoma; metastasis; RT-PCT; western
   blot analysis; immunohistochemical staining
ID COLON-CANCER CELLS; HUMAN GASTRIC-CARCINOMA; INCREASED EXPRESSION;
   ADENOCARCINOMAS; ANGIOGENESIS; INHIBITION; CARCINOGENESIS; APOPTOSIS;
   GROWTH
AB Cyctooxygenase-2 (COX-2) has been shown to be involved in multiple steps of carcinogenesis. In this study, we examined COX-2 expression in nasopharyngeal carcinoma (NPC). COX-2 mRNA analyzed by reverse-transcription polymerase chain reaction (RT-PCR) was detected in 66% (16 of 24) of tumor tissues. Western blot analysis demonstrated that COX-2 protein level was increased in tumor tissues and was correlated with the expression level of mRNA. Immunohistochemical study showed that COX-2 was predominantly detected in cancer cells, and the staining pattern was cytoplasmic. Ten histologically normal nasopharyngeal tissues obtained from nasopharyngeal hyperplasia were also investigated. We found that COX-2 mRNA was detectable in three tissues and the COX-2 protein level was very low. The frequency of COX-2 overexpression was significantly higher in patients of the N1-N3 group than in patients of the NO group (P = 0.006). Taken together, these data suggest that COX-2 is overexpressed and is associated with increased lymphatic invasion in NPC. (c) 2005 Elsevier Ltd. All rights reserved.
C1 Natl Sun Yat Sen Univ, Inst Biomed Sci, Kaohsiung 804, Taiwan.
   Chang Gung Mem Hosp, Kaohsiung Med Ctr, Dept Otolaryngol, Kaohsiung 83305, Taiwan.
RP Hung, WC (reprint author), Natl Sun Yat Sen Univ, Inst Biomed Sci, 70 Lien Hai Rd, Kaohsiung 804, Taiwan.
EM hung1228@ms10.hinet.net
CR Chen PY, 2004, ACTA PHARMACOL SIN, V25, P943
   Chen SH, 2000, J VAC SCI TECHNOL B, V18, P10, DOI 10.1116/1.591141
   Cheng SH, 1998, INT J RADIAT ONCOL, V41, P755, DOI 10.1016/S0360-3016(98)00092-3
   Costa C, 2002, J CLIN PATHOL, V55, P429, DOI 10.1136/jcp.55.6.429
   Dubois RN, 1998, FASEB J, V12, P1063
   EBERHART CE, 1994, GASTROENTEROLOGY, V107, P1183, DOI 10.1016/0016-5085(94)90246-1
   GOETZL EJ, 1995, FASEB J, V9, P1051
   Hida T, 1998, CANCER RES, V58, P3761
   Joki T, 2000, CANCER RES, V60, P4926
   Lee C, 2000, AUSTRALAS J AGEING, V19, P33
   Liu CH, 2001, J BIOL CHEM, V276, P18563, DOI 10.1074/jbc.M010787200
   Molina MA, 1999, CANCER RES, V59, P4356
   Murata H, 1999, AM J GASTROENTEROL, V94, P451
   Mutoh M, 2002, CANCER RES, V62, P28
   PENG JP, 2002, HUM PATHOL, V33, P1324
   Reddy BS, 1996, CANCER RES, V56, P4566
   Ristimaki A, 1997, CANCER RES, V57, P1276
   Sheehan KM, 1999, JAMA-J AM MED ASSOC, V282, P1254, DOI 10.1001/jama.282.13.1254
   Sheng HM, 1998, CANCER RES, V58, P362
   Shirahama T, 2001, CANCER, V92, P188, DOI 10.1002/1097-0142(20010701)92:1<188::AID-CNCR1308>3.0.CO;2-W
   Souza RF, 2000, CANCER RES, V60, P5767
   Tsao SW, 2002, SEMIN CANCER BIOL, V12, P473, DOI 10.1016/S1044-579X(02)00090-1
   Tsujii M, 1997, P NATL ACAD SCI USA, V94, P3336, DOI 10.1073/pnas.94.7.3336
   Tsujii M, 1998, CELL, V93, P705, DOI 10.1016/S0092-8674(00)81433-6
   Uefuji K, 2000, CLIN CANCER RES, V6, P135
   Vokes EE, 1997, LANCET, V350, P1087, DOI 10.1016/S0140-6736(97)07269-3
   Wilson KT, 1998, CANCER RES, V58, P2929
NR 27
TC 17
Z9 25
U1 4
U2 15
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1368-8375
EI 1879-0593
J9 ORAL ONCOL
JI Oral Oncol.
PD OCT
PY 2005
VL 41
IS 9
BP 903
EP 908
DI 10.1016/j.oraloncology.2005.05.003
PG 6
WC Oncology; Dentistry, Oral Surgery & Medicine
SC Oncology; Dentistry, Oral Surgery & Medicine
GA 972OU
UT WOS:000232463900007
PM 16054423
DA 2018-12-27
ER

PT J
AU Park, Y
   Hahm, KS
AF Park, Y
   Hahm, KS
TI RETRACTED: Antimicrobial peptides (AMPs): Peptide structure and mode of
   action (Retracted Article. See vol 38, pg 766, 2005)
SO JOURNAL OF BIOCHEMISTRY AND MOLECULAR BIOLOGY
LA English
DT Review; Retracted Publication
DE antibiotic agents; antimicrobial peptides (AMPs); barrel-stave; carpet;
   toroidal-pore mechanisms
ID CRAB TACHYPLEUS-TRIDENTATUS; DODECYL-SULFATE MICELLES; STATE
   NMR-SPECTROSCOPY; GRAM-POSITIVE BACTERIA; LINEAR DERIVATIVES; CATIONIC
   PEPTIDES; MAGAININ PEPTIDES; ESCHERICHIA-COLI; PORE FORMATION; MEMBRANE
AB Antimicrobial peptides (AMPs) have been isolated and characterized from tissues and organisms representing virtually every kingdom and phylum. Their amino acid composition, amphipathicity, cationic charge, and size allow them to attach to and insert into membrane bilayers to form pores by 'barrel-stave', 'carpet' or 'toroidal-pore' mechanisms. Although these models are helpful for defining mechanisms of AMP activity, their relevance to resolving how peptides damage and kill microorganisms still needs to be clarified. Moreover, many AMPs employ sophisticated and dynamic mechanisms of action to carry out their likely roles in antimicrobial host defense. Recently, it has been speculated that transmembrane pore formation is not the only mechanism of microbial killing by AMPs. In fact, several observations suggest that translocated AMPs can alter cytoplasmic membrane septum formation, reduce cell-wall, nucleic acid, and protein synthesis, and inhibit enzymatic activity. In this review, we present the structures of several AMPs as well as models of how AMPs induce pore formation. AMPs have received special attention as a possible alternative way to combat antibiotic-resistant bacterial strains. It may be possible to design synthetic AMPs with enhanced activity for microbial cells, especially those with antibiotic resistance, as well as synergistic effects with conventional antibiotic agents that lack cytotoxic or hemolytic activity.
C1 Chosun Univ, Res Ctr Proteineous Mat, Kwangju 501759, South Korea.
RP Hahm, KS (reprint author), Chosun Univ, Res Ctr Proteineous Mat, 375 Seosuk Dong, Kwangju 501759, South Korea.
EM kshahm@mail.chosun.ac.kr
CR BAKER MA, 1993, CANCER RES, V53, P3052
   Bechinger B, 1999, BBA-BIOMEMBRANES, V1462, P157, DOI 10.1016/S0005-2736(99)00205-9
   BESSALLE R, 1990, FEBS LETT, V274, P151, DOI 10.1016/0014-5793(90)81351-N
   BOMAN HG, 1995, ANNU REV IMMUNOL, V13, P61, DOI 10.1146/annurev.iy.13.040195.000425
   Brogden KA, 1998, INFECT IMMUN, V66, P5948
   Brogden KA, 1997, ANTIMICROB AGENTS CH, V41, P1615, DOI 10.1128/AAC.41.7.1615
   Brotz H, 1998, ANTIMICROB AGENTS CH, V42, P154, DOI 10.1128/AAC.42.1.154
   Cantor RS, 2002, BIOPHYS J, V82, P2520, DOI 10.1016/S0006-3495(02)75595-1
   Dathe M, 2001, FEBS LETT, V501, P146, DOI 10.1016/S0014-5793(01)02648-5
   Falla TJ, 1996, J BIOL CHEM, V271, P19298, DOI 10.1074/jbc.271.32.19298
   Fehlbaum P, 1996, P NATL ACAD SCI USA, V93, P1221, DOI 10.1073/pnas.93.3.1221
   Friedrich CL, 2000, ANTIMICROB AGENTS CH, V44, P2086, DOI 10.1128/AAC.44.8.2086-2092.2000
   Friedrich CL, 2001, J BIOL CHEM, V276, P24015, DOI 10.1074/jbc.M009691200
   Futaki S, 2001, J BIOL CHEM, V276, P5836, DOI 10.1074/jbc.M007540200
   GALLO RL, 1994, P NATL ACAD SCI USA, V91, P11035, DOI 10.1073/pnas.91.23.11035
   Ganz T, 1998, CURR OPIN IMMUNOL, V10, P41, DOI 10.1016/S0952-7915(98)80029-0
   Gennaro R, 2000, BIOPOLYMERS, V55, P31, DOI 10.1002/1097-0282(2000)55:1<31::AID-BIP40>3.3.CO;2-0
   Gesell J, 1997, J BIOMOL NMR, V9, P127, DOI 10.1023/A:1018698002314
   Giacometti A, 1999, PEPTIDES, V20, P1265, DOI 10.1016/S0196-9781(99)00131-X
   GIBSON BW, 1991, J BIOL CHEM, V266, P23103
   Hancock REW, 1998, TRENDS BIOTECHNOL, V16, P82, DOI 10.1016/S0167-7799(97)01156-6
   Hirakura Y, 2002, BBA-BIOMEMBRANES, V1562, P32, DOI 10.1016/S0005-2736(02)00358-9
   JAKOB S, 2005, BIOCH MOL BIOL ED, V33, P177
   Johansson J, 1998, J BIOL CHEM, V273, P3718, DOI 10.1074/jbc.273.6.3718
   JURETIC D, 1989, FEBS LETT, V249, P219, DOI 10.1016/0014-5793(89)80627-1
   KAWANO K, 1990, J BIOL CHEM, V265, P15365
   Kobayashi S, 2004, BIOCHEMISTRY-US, V43, P15610, DOI 10.1021/bi048206q
   Kragol G, 2001, BIOCHEMISTRY-US, V40, P3016, DOI 10.1021/bi002656a
   Laederach A, 2002, BIOCHEMISTRY-US, V41, P12359, DOI 10.1021/bi026185z
   Lee DG, 2004, J PEPT SCI, V10, P298, DOI 10.1002/psc.504
   Lee MT, 2004, BIOCHEMISTRY-US, V43, P3590, DOI 10.1021/bi036153r
   LEHRER RI, 1993, ANNU REV IMMUNOL, V11, P105, DOI 10.1146/annurev.iy.11.040193.000541
   Mandard N, 1998, EUR J BIOCHEM, V256, P404, DOI 10.1046/j.1432-1327.1998.2560404.x
   Matsuzaki K, 1996, BIOCHEMISTRY-US, V35, P11361, DOI 10.1021/bi960016v
   Matsuzaki K, 1998, BBA-REV BIOMEMBRANES, V1376, P391, DOI 10.1016/S0304-4157(98)00014-8
   MATSUZAKI K, 1993, BIOCHEMISTRY-US, V32, P11704, DOI 10.1021/bi00094a029
   Matsuzaki K, 1997, BBA-BIOMEMBRANES, V1327, P119, DOI 10.1016/S0005-2736(97)00051-5
   Matsuzaki K, 1997, BIOCHEMISTRY-US, V36, P9799, DOI 10.1021/bi970588v
   MURAKAMI T, 1991, CHEMOTHERAPY, V37, P327, DOI 10.1159/000238875
   NAKAMURA T, 1988, J BIOL CHEM, V263, P16709
   Oren Z, 1998, BIOPOLYMERS, V47, P451
   Otvos L, 2000, J PEPT SCI, V6, P497
   Otvos L, 2002, CELL MOL LIFE SCI, V59, P1138, DOI 10.1007/s00018-002-8493-8
   Park CB, 2000, P NATL ACAD SCI USA, V97, P8245, DOI 10.1073/pnas.150518097
   Park Y, 2005, J AGR FOOD CHEM, V53, P6491, DOI 10.1021/jf0505123
   Patrzykat A, 2002, ANTIMICROB AGENTS CH, V46, P605, DOI 10.1128/AAC.46.3.605-614.2002
   POUNY Y, 1992, BIOCHEMISTRY-US, V31, P12416, DOI 10.1021/bi00164a017
   Rao AG, 1999, ARCH BIOCHEM BIOPHYS, V361, P127, DOI 10.1006/abbi.1998.0962
   Rozek A, 2000, BIOCHEMISTRY-US, V39, P15765, DOI 10.1021/bi000714m
   Schutte BC, 2002, ANNU REV PHYSIOL, V64, P709, DOI 10.1146/annurev.physiol.64.081501.134340
   SELSTED ME, 1992, J BIOL CHEM, V267, P4292
   Shai Y, 1999, BBA-BIOMEMBRANES, V1462, P55, DOI 10.1016/S0005-2736(99)00200-X
   Simmaco M, 1998, BIOPOLYMERS, V47, P435, DOI 10.1002/(SICI)1097-0282(1998)47:6<435::AID-BIP3>3.3.CO;2-#
   Spaar A, 2004, BIOPHYS J, V87, P396, DOI 10.1529/biophysj.104.040667
   Subbalakshmi C, 1998, FEMS MICROBIOL LETT, V160, P91, DOI 10.1111/j.1574-6968.1998.tb12896.x
   TAMAMURA H, 1993, CHEM PHARM BULL, V41, P978
   Tang YQ, 1999, SCIENCE, V286, P498, DOI 10.1126/science.286.5439.498
   Vizioli J, 2002, TRENDS PHARMACOL SCI, V23, P494, DOI 10.1016/S0165-6147(02)02105-3
   von Horsten HH, 2004, PEPTIDES, V25, P1223, DOI 10.1016/j.peptides.2004.05.016
   Wu MH, 1999, BIOCHEMISTRY-US, V38, P7235, DOI 10.1021/bi9826299
   Yamaguchi S, 2002, BIOCHEMISTRY-US, V41, P9852, DOI 10.1021/bi0257991
   Yamaguchi S, 2001, BIOPHYS J, V81, P2203, DOI 10.1016/S0006-3495(01)75868-7
   Yang L, 2001, BIOPHYS J, V81, P1475, DOI 10.1016/S0006-3495(01)75802-X
   YONEZAWA A, 1992, BIOCHEMISTRY-US, V31, P2998, DOI 10.1021/bi00126a022
   ZASLOFF M, 1987, P NATL ACAD SCI USA, V84, P5449, DOI 10.1073/pnas.84.15.5449
   Zasloff M, 2002, NATURE, V415, P389, DOI 10.1038/415389a
   ZASLOFF M, 1988, P NATL ACAD SCI USA, V85, P910, DOI 10.1073/pnas.85.3.910
   Zhang LJ, 2001, J BIOL CHEM, V276, P35714, DOI 10.1074/jbc.M104925200
   Zhang LJ, 1999, BIOCHEMISTRY-US, V38, P8102, DOI 10.1021/bi9904104
NR 69
TC 55
Z9 63
U1 1
U2 6
PU SPRINGER SINGAPORE PTE LTD
PI SINGAPORE
PA #04-01 CENCON I, 1 TANNERY RD, SINGAPORE 347719, SINGAPORE
SN 1225-8687
J9 J BIOCHEM MOL BIOL
JI J. Biochem. Mol. Biol.
PD SEP 30
PY 2005
VL 38
IS 5
BP 507
EP 516
PG 10
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 969CX
UT WOS:000232212100001
PM 16202228
DA 2018-12-27
ER

PT J
AU Liao, LB
   Zhou, HY
   Xiao, MM
AF Liao, LB
   Zhou, HY
   Xiao, MM
TI RETRACTED: Surface enhanced Raman scattering at single crystal TiO2
   (Retracted article. See vol. 358, pg. 184, 2009)
SO CHEMICAL PHYSICS
LA English
DT Article; Retracted Publication
DE single crystal; physicochemical interaction; enhancement mechanism;
   coordinate bond
ID NICKEL ELECTRODES; PYRIDINE; SPECTROSCOPY; ADSORPTION; TIO2(110);
   SPECTRA; MOLECULES; PLATINUM; STM
AB Surface enhanced Raman scattering of pyridine molecules was observed on crystalline rutile TiO2 (110) in an Ultra High Vacuum (UHV) chamber along with in situ scanning tunneling micrograph (STM) and Quartz Crystals Microbalance (QCM). It was interesting to note that a new Raman band at 247 cm(-1) appeared and we ascribed it to the Ti-N vibration between nitrogen of adpyridine molecule and titanium of TiO2. The site and azimuthal orientation of adpyridine molecules on TiO2 (110)-(1x1) surface were explicitly recorded by in situ STM. Besides the charge transfer mechanism, a mechanism was proposed to interpret the origin of the Raman intensity enhancement. (C) 2005 Elsevier B.V. All rights reserved.
C1 Guangzhou Inst Geochem, State Key Lab Organ Geochem, Guangzhou 510640, Guangdong, Peoples R China.
   Zhongshan Univ, Instrumental & Anal Res Ctr, Guangzhou, Guangdong, Peoples R China.
RP Liao, LB (reprint author), Guangzhou Inst Geochem, State Key Lab Organ Geochem, Guangzhou 510640, Guangdong, Peoples R China.
EM lbliao@gig.ac.cn
CR BAHNICK DA, 1968, J CHEM PHYS, V48, P1251, DOI 10.1063/1.1668790
   Bruckbauer A, 1998, J RAMAN SPECTROSC, V29, P665, DOI 10.1002/(SICI)1097-4555(199808)29:8<665::AID-JRS288>3.0.CO;2-6
   BRYANT SP, 1991, ELECTROCHIM ACTA, V11, P1879
   Cai WB, 1998, J CHEM SOC FARADAY T, V94, P3127, DOI 10.1039/a803240h
   Cheng YH, 2002, J APPL PHYS, V92, P1845, DOI 10.1063/1.1491588
   DALIBART M, 1982, INORG CHEM, V21, P1040, DOI 10.1021/ic00133a034
   Daujotis V, 1997, ELECTROCHIM ACTA, V42, P1345, DOI 10.1016/S0013-4686(96)00288-5
   FLEISCHMANN M, 1974, CHEM PHYS LETT, V26, P163, DOI 10.1016/0009-2614(74)85388-1
   FURTAK TE, 1985, SURF SCI, V158, P126, DOI 10.1016/0039-6028(85)90291-2
   Futamata M, 1997, SURF SCI, V386, P89, DOI 10.1016/S0039-6028(97)00333-6
   Henderson MA, 1996, SURF SCI, V355, P151, DOI 10.1016/0039-6028(95)01357-1
   Huang QJ, 1997, CHEM PHYS LETT, V271, P101, DOI 10.1016/S0009-2614(97)00419-3
   JEANMAIRE DL, 1975, J AM CHEM SOC, V97, P1699, DOI 10.1021/ja00840a013
   JONES DEH, 1971, CHEM SOC A, P3135
   Kim SH, 1998, LANGMUIR, V14, P4156, DOI 10.1021/la980218n
   LOO BH, 1981, J CHEM PHYS, V75, P5955, DOI 10.1063/1.442050
   MANRIZIO MM, 2001, CHEM PHYS LETT, V340, P437
   METIU H, 1984, ANNU REV PHYS CHEM, V35, P507, DOI 10.1146/annurev.pc.35.100184.002451
   Nie SM, 1997, SCIENCE, V275, P1102, DOI 10.1126/science.275.5303.1102
   Pang CL, 1998, PHYS REV B, V58, P1586, DOI 10.1103/PhysRevB.58.1586
   Quagliano LG, 2004, J AM CHEM SOC, V126, P7393, DOI 10.1021/ja031640f
   Raza H, 1998, SURF SCI, V402, P710, DOI 10.1016/S0039-6028(97)00987-4
   Ren B, 1996, J ELECTROANAL CHEM, V415, P175, DOI 10.1016/S0022-0728(96)01004-2
   ROHRER GS, 1993, SURF SCI, V292, P261, DOI 10.1016/0039-6028(93)90331-D
   Suzuki S, 1998, CATAL LETT, V50, P117, DOI 10.1023/A:1019087607068
   Tian ZQ, 1996, J ELECTROANAL CHEM, V401, P247, DOI 10.1016/0022-0728(95)04367-5
   VILLARREAL TL, 2004, SURF SCI, V372, P329
   YAMADA H, 1983, SURF SCI, V134, P71, DOI 10.1016/0039-6028(83)90312-6
   Zambelli T, 1996, SCIENCE, V273, P1688, DOI 10.1126/science.273.5282.1688
NR 29
TC 14
Z9 14
U1 6
U2 21
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0301-0104
EI 1873-4421
J9 CHEM PHYS
JI Chem. Phys.
PD SEP 19
PY 2005
VL 316
IS 1-3
BP 164
EP 170
DI 10.1016/j.chemphys.2005.05.012
PG 7
WC Chemistry, Physical; Physics, Atomic, Molecular & Chemical
SC Chemistry; Physics
GA 965JD
UT WOS:000231945700019
DA 2018-12-27
ER

PT J
AU Ciesla, J
   Jagielska, E
   Skopinski, T
   Dabrowska, M
   Maley, F
   Rode, W
AF Ciesla, J
   Jagielska, E
   Skopinski, T
   Dabrowska, M
   Maley, F
   Rode, W
TI RETRACTED: Binding and repression of translation of the cognate mRNA by
   Trichinella spiralis thymidylate synthase differ from the corresponding
   interactions of the human enzyme (Retracted Article. See vol 402, pg
   601, 2007)
SO BIOCHEMICAL JOURNAL
LA English
DT Article; Retracted Publication
DE mRNA binding; parasite; reticulocyte; thymidylate synthase (TS);
   translation repression; Trichinella spiralis
ID DIHYDROFOLATE-REDUCTASE PROTEIN; HIGH-LEVEL EXPRESSION;
   ESCHERICHIA-COLI; DEVELOPMENTAL PATTERN; MALARIA PARASITE; COFACTOR
   ANALOGS; AMINO-ACID; PHOSPHORYLATION; IDENTIFICATION; TARGET
AB Thymidylate synthase (TS) of Trichinella spiralis, a parasitic nematode causing trichinellosis, was found to bind its own mRNA and repress translation of the latter, similar to its human counterpart [Chu, Koeller, Casey, Drake, Chabner, Elwood, Zinn and Allegra (1991) Proc. Natl. Acad. Sci. U.S.A. 88, 8977-8981]. However, in striking contrast with human TS, the parasite enzyme's interaction with mRNA was not affected by any of the substrate (deoxyuridylate or N-5.10-methylenetetrahydrofolate) nor by the inhibitor (fluorodeoxyuridylate; used alone or in the presence of N-5.10-methylenetetrahydrofolate) similar to that shown for the bifunctional enzyme from Plasmodium falciparum [Zhang and Rathod (2002) Science 296, 545-547]. Moreover, repression of the translation of the parasite enzyme was enhanced by the same ligands that were shown by others (Chu et al., 199 1) to prevent human TS from impairing its translation. On comparing the capacity of TS to bind to its cognate mRNA, relative to its ability to inhibit its translation, the same enzyme preparation was active as translational repressor at a considerably lower protein/mRNA ratio, suggesting the two phenomena to be disconnected. Of interest is the fact that the presence of the enzyme protein N-terminal methionine proved to be critical for binding, but not for repression of its translation, indicating that mRNA binding requires a methionine or an adduct (i.e. methionine-histidine) at the N-terminus of TS, but that the translational repression effect does not. Notably, chicken liver dihydrofolate reductase, which is incapable of binding to T. spiralis TS mRNA, repressed the translation of TS.
C1 M Nencki Inst Expt Biol, Dept Cellular Biochem, PL-02093 Warsaw, Poland.
   New York State Dept Hlth, Wadsworth Ctr, Albany, NY 12201 USA.
RP Rode, W (reprint author), M Nencki Inst Expt Biol, Dept Cellular Biochem, 3 Pasteur St, PL-02093 Warsaw, Poland.
EM rode@nencki.gov.pl
RI Ciesla, Joanna/D-7918-2015
OI Ciesla, Joanna/0000-0002-0115-5595
CR CARRERAS CW, 1995, ANNU REV BIOCHEM, V64, P721, DOI 10.1146/annurev.bi.64.070195.003445
   Changchien LM, 2000, PROTEIN EXPRES PURIF, V19, P265, DOI 10.1006/prep.2000.1245
   Chu E, 1996, NUCLEIC ACIDS RES, V24, P3222, DOI 10.1093/nar/24.16.3222
   CHU E, 1995, MOL CELL BIOL, V15, P179, DOI 10.1128/MCB.15.1.179
   CHU E, 1994, J BIOL CHEM, V269, P20289
   CHU E, 1993, BIOCHEMISTRY-US, V32, P4756, DOI 10.1021/bi00069a009
   CHU E, 1993, P NATL ACAD SCI USA, V90, P517, DOI 10.1073/pnas.90.2.517
   CHU E, 1991, P NATL ACAD SCI USA, V88, P8977, DOI 10.1073/pnas.88.20.8977
   CIESLA J, 1995, BBA-PROTEIN STRUCT M, V1249, P127, DOI 10.1016/0167-4838(95)00032-P
   CIESLA J, 1995, BBA-GENE STRUCT EXPR, V1261, P233, DOI 10.1016/0167-4781(95)00008-5
   COHEN SS, 1958, P NATL ACAD SCI USA, V44, P1004, DOI 10.1073/pnas.44.10.1004
   Dabrowska M, 1996, BIOCHEM BIOPH RES CO, V228, P440, DOI 10.1006/bbrc.1996.1679
   Dabrowska M, 2004, PARASITOLOGY, V128, P209, DOI 10.1017/S0031182003004426
   DANENBERG PV, 1977, BIOCHIM BIOPHYS ACTA, V473, P73, DOI 10.1016/0304-419X(77)90001-4
   DESPOMMIER DD, 1993, J PARASITOL, V79, P472, DOI 10.2307/3283370
   Despommier DD, 1998, PARASITOL TODAY, V14, P318, DOI 10.1016/S0169-4758(98)01287-3
   ErcikanAbali EA, 1997, BIOCHEMISTRY-US, V36, P12317, DOI 10.1021/bi971026e
   FU XD, 1985, J BIOL CHEM, V260, P9941
   GOLOS B, 2002, CHEM BIOL PTERIDINES, P519
   Haegebarth A, 2004, J BIOL CHEM, V279, P54398, DOI 10.1074/jbc.M409579200
   HARDY LW, 1987, SCIENCE, V235, P448, DOI 10.1126/science.3099389
   HIREL PH, 1989, P NATL ACAD SCI USA, V86, P8247, DOI 10.1073/pnas.86.21.8247
   JASMER DP, 1995, PARASITOL TODAY, V11, P185, DOI 10.1016/0169-4758(95)80155-3
   Ju JF, 1999, P NATL ACAD SCI USA, V96, P3769, DOI 10.1073/pnas.96.7.3769
   Knirsch L, 2001, BIOCHEMISTRY-US, V40, P7890, DOI 10.1021/bi010197n
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   LEIBOLD EA, 1988, P NATL ACAD SCI USA, V85, P2171, DOI 10.1073/pnas.85.7.2171
   Lin XK, 2003, NUCLEIC ACIDS RES, V31, P4882, DOI 10.1093/nar/gkg678
   Liu J, 2002, BBA-MOL BASIS DIS, V1587, P174, DOI 10.1016/S0925-4439(02)00080-7
   Liu XW, 2000, BIOCHEMISTRY-US, V39, P11523, DOI 10.1021/bi000665d
   Nirmalan N, 2004, MOL BIOCHEM PARASIT, V136, P63, DOI 10.1016/j.molbiopara.2004.02.013
   PedersenLane J, 1997, PROTEIN EXPRES PURIF, V10, P256, DOI 10.1006/prep.1997.0750
   Rahman L, 2004, CANCER CELL, V5, P341, DOI 10.1016/S1535-6108(04)00080-7
   Rode W, 2000, PARASITOLOGY, V120, P593, DOI 10.1017/S0031182099005880
   Samsonoff WA, 1997, J BIOL CHEM, V272, P13281, DOI 10.1074/jbc.272.20.13281
   SHOICHET BK, 1993, SCIENCE, V259, P1445, DOI 10.1126/science.8451640
   Tai NW, 2004, FRONT BIOSCI-LANDMRK, V9, P2521, DOI 10.2741/1413
   VOELLER DM, 1995, NUCLEIC ACIDS RES, V23, P869, DOI 10.1093/nar/23.5.869
   Voeller DM, 2002, BIOCHEM BIOPH RES CO, V297, P24, DOI 10.1016/S0006-291X(02)02080-6
   Zhang K, 2002, SCIENCE, V296, P545, DOI 10.1126/science.1068274
NR 40
TC 5
Z9 5
U1 2
U2 11
PU PORTLAND PRESS LTD
PI LONDON
PA CHARLES DARWIN HOUSE, 12 ROGER STREET, LONDON WC1N 2JU, ENGLAND
SN 0264-6021
EI 1470-8728
J9 BIOCHEM J
JI Biochem. J.
PD SEP 15
PY 2005
VL 390
BP 681
EP 688
DI 10.1042/BJ20050548
PN 3
PG 8
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 970ZF
UT WOS:000232350200005
PM 15882146
OA Green Published
DA 2018-12-27
ER

PT J
AU Lin, CC
   Chen, SY
   Cheng, SY
AF Lin, CC
   Chen, SY
   Cheng, SY
TI RETRACTED: Nucleation and growth behavior of well-aligned ZnO nanorods
   on organic substrates in aqueous solutions (Retracted article. See vol.
   504, pg. 62, 2018)
SO JOURNAL OF CRYSTAL GROWTH
LA English
DT Article; Retracted Publication
DE nanostructures; hydrothermal crystal growth; zinc compounds
ID ROOM-TEMPERATURE; BUILDING-BLOCKS; NANOWIRES; PHOTOLUMINESCENCE;
   DEVICES; ARRAYS; ROUTE; WAFER; FILMS
AB A low-temperature synthetic route was used to prepare well-aligned arrays of oriented ZnO nanorods on organic substrates coated with polystyrene beads (PS) in an aqueous solution. The corresponding growth behavior and photoluminescence properties of ZnO nanorods were analyzed. It was found that the ZnO nanorods are initially nucleated from the ZnO monolayer under the concave regions of the PS layers and preferentially grown along [0 0 0 1] direction. High-resolution transmission electron microscopy (HRTEM) observation reveals that the ZnO nanorods tend to coalesce together with other adjacent nanorods to form a larger ZnO crystal in the later growth stage. The room-temperature photoluminescence spectra demonstrate that a stronger ultraviolet (UV) emission with a broad yellow emission around 575 nm was observed for the ZnO nanorods grown on the organic substrates and the relative intensity ratio of ultraviolet emission to yellow emission depends on the growth periods of time. This simple approach demonstrates great potential for optoelectronic devices because it can produce large-scale highly well-aligned ZnO nanorods on the flexible organic substrates at lower temperatures. (c) 2005 Elsevier B.V. All rights reserved.
C1 Natl Chiao Tung Univ, Dept Mat Sci & Engn, Hsinchu, Taiwan.
   Ind Technol Res Inst, Mat Res Labs, Chutung, Taiwan.
RP Chen, SY (reprint author), Natl Chiao Tung Univ, Dept Mat Sci & Engn, 1001 Ta Hsueh Rd, Hsinchu, Taiwan.
EM sychen@cc.nctu.edu.tw
CR Audebrand N, 1998, CHEM MATER, V10, P2450, DOI 10.1021/cm980132f
   Bagnall DM, 1997, APPL PHYS LETT, V70, P2230, DOI 10.1063/1.118824
   Chiou WT, 2003, DIAM RELAT MATER, V12, P1841, DOI 10.1016/S0925-9635(03)00274-7
   Choy JH, 2003, ADV MATER, V15, P1911, DOI 10.1002/adma.200305327
   Cui Y, 2001, SCIENCE, V291, P851, DOI 10.1126/science.291.5505.851
   Djurisic AB, 2004, ADV FUNCT MATER, V14, P856, DOI 10.1002/adfm.200305082
   Duan XF, 2001, NATURE, V409, P66, DOI 10.1038/35051047
   Greene LE, 2003, ANGEW CHEM INT EDIT, V42, P3031, DOI 10.1002/anie.200351461
   Guo L, 2001, MAT SCI ENG C-BIO S, V16, P123, DOI 10.1016/S0928-4931(01)00286-7
   Guo L, 2000, CHEM MATER, V12, P2268, DOI 10.1021/cm9907817
   Huang MH, 2001, SCIENCE, V292, P1897, DOI 10.1126/science.1060367
   Huang MH, 2001, ADV MATER, V13, P113, DOI 10.1002/1521-4095(200101)13:2<113::AID-ADMA113>3.0.CO;2-H
   Li D, 2004, APPL PHYS LETT, V85, P1601, DOI 10.1063/1.1786375
   Liou SC, 2005, J CRYST GROWTH, V274, P438, DOI 10.1016/j.jcrysgro.2004.10.025
   Lu CH, 2000, CERAM INT, V26, P351, DOI 10.1016/S0272-8842(99)00063-2
   Pacholski C, 2002, ANGEW CHEM INT EDIT, V41, P1188, DOI 10.1002/1521-3773(20020402)41:7<1188::AID-ANIE1188>3.0.CO;2-5
   Park WI, 2003, ADV MATER, V15, P526, DOI 10.1002/adma.200390122
   Studenikin SA, 1998, J APPL PHYS, V84, P2287, DOI 10.1063/1.368295
   TINA ZR, 2003, NAT MATER, V2, P821
   Vayssieres L, 2003, ADV MATER, V15, P464, DOI 10.1002/adma.200390108
   Vayssieres L, 2001, CHEM MATER, V13, P4395, DOI 10.1021/cm011160s
   Vayssieres L, 2001, J PHYS CHEM B, V105, P3350, DOI 10.1021/jp010026s
   Wu XL, 2001, APPL PHYS LETT, V78, P2285, DOI 10.1063/1.1361288
   Xia YN, 2003, ADV FUNCT MATER, V13, P907, DOI 10.1002/adfm.200300002
   ZAMIRESCU M, 2002, PHYS REV B, V65, DOI UNSP 161205
   Zhang J, 2002, NEW J CHEM, V26, P33, DOI 10.1039/b108172a
NR 26
TC 38
Z9 39
U1 0
U2 16
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0022-0248
EI 1873-5002
J9 J CRYST GROWTH
JI J. Cryst. Growth
PD SEP 15
PY 2005
VL 283
IS 1-2
BP 141
EP 146
DI 10.1016/j.jcrysgro.2005.05.065
PG 6
WC Crystallography; Materials Science, Multidisciplinary; Physics, Applied
SC Crystallography; Materials Science; Physics
GA 964HJ
UT WOS:000231869700018
DA 2018-12-27
ER

PT J
AU Bois, PRJ
   Izeradjene, K
   Houghton, PJ
   Cleveland, JL
   Houghton, JA
   Grosveld, GC
AF Bois, PRJ
   Izeradjene, K
   Houghton, PJ
   Cleveland, JL
   Houghton, JA
   Grosveld, GC
TI RETRACTED: FOXO1a acts as a selective tumor suppressor in alveolar
   rhabdomyosarcoma (Retracted Article. See vol 177, pg 563, 2007)
SO JOURNAL OF CELL BIOLOGY
LA English
DT Article; Retracted Publication
ID FORKHEAD TRANSCRIPTION FACTORS; CELL-CYCLE; PEDIATRIC RHABDOMYOSARCOMA;
   FUSION; PAX3; DIFFERENTIATION; MOUSE; GENE; PHOSPHORYLATION; INTERFERES
AB Rhabdomyosarcoma (RMS), the most common pediatric soft-tissue sarcoma, has two major histological subtypes: embryonal RMS (ERMS), which has a favorable prognosis, and alveolar RMS (ARMS), which has a poor outcome. Although both forms of RMS express muscle cell-specific markers, only ARMS cells express PAX3-FOXO1a or PAX7-FOXO1a chimeric proteins. In mice, Pax3 and Pax7 play key roles in muscle cell development and differentiation, and FoxO1a regulates myoblast differentiation and fusion; thus, the aberrant regulation of these proteins may contribute to the development of ARMS. In this paper, we report that FOXO1a is not expressed in primary ARMS tumors or ARMS-derived tumor cell lines and that restoration of FOXO1a expression in ARMS cells is sufficient to induce cell cycle arrest and apoptosis. Strikingly, the effects of FOXO1a are selective, as enforced expression of FOXO1a in ERMS-derived tumor cell lines had no effect. Furthermore, FOXO1a induced apoptosis in ARMS by directly activating the transcription of caspase-3. We conclude that FOXO1a is a potent and specific tumor suppressor in ARMS, suggesting that agents that restore or augment FOXO1a activity may be effective as ARMS therapeutics.
C1 St Jude Childrens Res Hosp, Dept Biochem, Memphis, TN 38105 USA.
   St Jude Childrens Res Hosp, Dept Genet & Tumor Cell Biol, Memphis, TN 38105 USA.
   St Jude Childrens Res Hosp, Dept Hematol Oncol, Memphis, TN 38105 USA.
   St Jude Childrens Res Hosp, Dept Mol Pharmacol, Memphis, TN 38105 USA.
RP Grosveld, GC (reprint author), St Jude Childrens Res Hosp, Dept Biochem, 332 N Lauderdale St, Memphis, TN 38105 USA.
EM gerard.grosveld@stjude.org
FU NCI NIH HHS [CA 96696, CA 21765, P30 CA021765, P01 CA023099, CA 71907,
   R01 CA087952, P01 CA071907, CA 87952, CA 23099, R01 CA096696]
CR Accili D, 2004, CELL, V117, P421, DOI 10.1016/S0092-8674(04)00452-0
   Anderson J, 2001, BRIT J CANCER, V85, P831, DOI 10.1054/bjoc.2001.2008
   Anderson MJ, 2001, P NATL ACAD SCI USA, V98, P1589, DOI 10.1073/pnas.98.4.1589
   AUSUBEL FM, 2001, CURRENT PROTOCOLS MO
   Barr FG, 2001, ONCOGENE, V20, P5736, DOI 10.1038/sj.onc.1204599
   BERGER J, 1988, GENE, V66, P1, DOI 10.1016/0378-1119(88)90219-3
   Birkenkamp KU, 2003, BIOCHEM SOC T, V31, P292, DOI 10.1042/bst0310292
   Bois PRJ, 2005, MOL CELL BIOL, V25, P7645, DOI 10.1128/MCB.25.17.7645-7656.2005
   Bois PRJ, 2003, EMBO J, V22, P1147, DOI 10.1093/emboj/cdg116
   Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4
   Burgering BMT, 2002, TRENDS BIOCHEM SCI, V27, P352, DOI 10.1016/S0968-0004(02)02113-8
   Coleman ML, 2002, CELL DEATH DIFFER, V9, P493, DOI 10.1038/sj.cdd.4400987
   Conway SJ, 1997, CARDIOVASC RES, V36, P163, DOI 10.1016/S0008-6363(97)00172-7
   Dias P, 2000, AM J PATHOL, V156, P399, DOI 10.1016/S0002-9440(10)64743-8
   Dijkers PF, 2000, MOL CELL BIOL, V20, P9138, DOI 10.1128/MCB.20.24.9138-9148.2000
   EPSTEIN JA, 1995, J BIOL CHEM, V270, P11719, DOI 10.1074/jbc.270.20.11719
   Fernando P, 2002, P NATL ACAD SCI USA, V99, P11025, DOI 10.1073/pnas.162172899
   FREDERICKS WJ, 1995, MOL CELL BIOL, V15, P1522
   Furuyama T, 2000, BIOCHEM J, V349, P629, DOI 10.1042/0264-6021:3490629
   Gallo R, 1999, MOL BIOL CELL, V10, P3137, DOI 10.1091/mbc.10.10.3137
   Hall A, 2000, PHILOS T R SOC B, V355, P965, DOI 10.1098/rstb.2000.0632
   Hayashi S, 2002, DEV BIOL, V244, P305, DOI 10.1006/dbio.2002.0597
   HOUGHTON PJ, 1995, CANCER CHEMOTH PHARM, V36, P393
   Keller C, 2004, GENE DEV, V18, P2608, DOI 10.1101/gad.1243904
   Kops GJPL, 2002, MOL CELL BIOL, V22, P2025, DOI 10.1128/MCB.22.7.2025-2036.2002
   Lagutina I, 2002, MOL CELL BIOL, V22, P7204, DOI 10.1128/MCB.22.20.7204-7216.2002
   Lam PYP, 1999, MOL CELL BIOL, V19, P594
   MAHFOUDI A, 1995, P NATL ACAD SCI USA, V92, P4206, DOI 10.1073/pnas.92.10.4206
   Matsuzaki H, 2003, P NATL ACAD SCI USA, V100, P11285, DOI 10.1073/pnas.1934283100
   Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115
   NISHIYAMA T, 2004, J BIOL CHEM, V279, P47331
   Qu G, 1997, J CELL BIOCHEM, V67, P514, DOI 10.1002/(SICI)1097-4644(19971215)67:4<514::AID-JCB9>3.3.CO;2-I
   RANDO TA, 1994, J CELL BIOL, V125, P1275, DOI 10.1083/jcb.125.6.1275
   Sabourin LA, 2000, CLIN GENET, V57, P16, DOI 10.1034/j.1399-0004.2000.570103.x
   Seale P, 2000, CELL, V102, P777, DOI 10.1016/S0092-8674(00)00066-0
   Taylor AC, 2000, MED PEDIATR ONCOL, V35, P96, DOI 10.1002/1096-911X(200008)35:2<96::AID-MPO2>3.0.CO;2-Z
   TRAN H, 2003, SCI STKE, pRE5, DOI DOI 10.1126/STKE.2003.172.RE5
   Wan XL, 2003, ONCOGENE, V22, P8205, DOI 10.1038/sj.onc.1206878
NR 38
TC 20
Z9 20
U1 2
U2 9
PU ROCKEFELLER UNIV PRESS
PI NEW YORK
PA 1114 FIRST AVE, 4TH FL, NEW YORK, NY 10021 USA
SN 0021-9525
J9 J CELL BIOL
JI J. Cell Biol.
PD SEP 12
PY 2005
VL 170
IS 6
BP 903
EP 912
DI 10.1083/jcb.200501040
PG 10
WC Cell Biology
SC Cell Biology
GA 963RI
UT WOS:000231821400008
PM 16157701
OA Green Published, Bronze
DA 2018-12-27
ER

PT J
AU Han, S
   Roman, J
AF Han, S
   Roman, J
TI RETRACTED: COX-2 inhibitors suppress integrin alpha 5 expression in
   human lung carcinoma cells through activation of Erk: Involvement of Sp1
   and AP-1 sites (Retracted article. See vol. 137, pg. 2041, 2015)
SO INTERNATIONAL JOURNAL OF CANCER
LA English
DT Article; Retracted Publication
DE alpha 5 integrin; COX-2 inhibitor; human lung carcinoma; cells; Sp1;
   AP-1; Erk
ID CORNEAL EPITHELIAL-CELLS; GENE-EXPRESSION; RECEPTOR-GAMMA; TRANSCRIPTION
   FACTORS; CYCLOOXYGENASE-2; CANCER; APOPTOSIS; PROMOTER; FIBRONECTIN;
   DIFFERENTIATION
AB Tumor cell expression of COX-2 has been implicated in the progression of murine and human lung cancer. Inhibition of COX-2 by nonsteroidal antiinflammatory drugs reduces the risk of cancer development in humans and suppresses tumor growth in animal models. However, the underlying mechanisms for this beneficial effect are not fully understood. Here we explore the potential link between the anticancer effects of COX-2 inhibitors and the expression of the integrin alpha 5 beta 1. Expression of this integrin in carcinoma cells is associated with invasiveness and malignant progression. This, together with our studies showing that fibronectin, the ligand of alpha 5 beta 1, stimulates the growth of human lung carcinoma cells, and that this effect is mediated through alpha 5 beta 1-dependent signals, has prompted us to examine the effects of COX-2 inhibitors on alpha 5 beta 1 expression in human non small cell lung carcinoma (NSCLC) cells. We found that the selective COX-2 inhibitors NS398 and Nimesulide decreased mRNA expression and protein production of the integrin alpha 5 subunit. This effect was associated with inhibition of NSCLC cell adhesion to fibronectin. The COX-2 inhibitors triggered the phosphorylation of extracellular signal-regulated kinase (Erk) in a time-dependent manner, and the inhibitor of Mek-1/Erk PD98095 prevented their inhibitory effects on integrin a5 expression. Transient transfection assays showed that the COX-2 inhibitors affected integrin a5 gene transcription by acting between -92 to -41 bp of the human integrin alpha 5 gene promoter. Gel mobility shift assays showed that the COX-2 inhibitors increased Sp1 DNA binding, but decreased that of AP-1. These effects were accompanied by an increase in Sp1 protein and a decrease in c-Jun protein expression, as well as inhibition of SAPK/JNK phosphorylation. The Sp1 inhibitor, Mithramycin A, also blocked the inhibitory effect of the COX-2 inhibitors on alpha 5 expression and promoter activity. Overall, these findings suggest that COX-2 inhibitors suppress alpha 5 beta 1 integrin expression in NSCLC through effects on integrin alpha 5 gene transcription mediated by Erk activation, increased Sp1, decreased AP-1 DNA binding and inactivation of SAPK/JNK signals. Our observations unveil a new mechanism of action against NSCLC for COX-2 inhibitors that relates to regulation of integrin alpha 5 gene expression and, consequently, recognition of extracellular matrices (i.e., fibronectin) by tumor cells. (c) 2005 Wiley-Liss, Inc.
C1 Emory Univ, Sch Med, Dept Med, Div Pulm Allergy & Crit Care Med, Atlanta, GA 30322 USA.
   Emory Univ, Sch Med, Atlanta Vet Affairs Med Ctr, Atlanta, GA 30322 USA.
RP Han, S (reprint author), Emory Univ, Sch Med, Dept Med, Div Pulm Allergy & Crit Care Med, Whitehead Biores Bldg,615 Michael St,Suite 205-M, Atlanta, GA 30322 USA.
EM shan2@emory.edu
CR Adachi M, 2000, CLIN CANCER RES, V6, P96
   Akiba S, 2003, BIOCHEM BIOPH RES CO, V310, P491, DOI 10.1016/j.bbrc.2003.09.042
   Altorki NK, 2003, J CLIN ONCOL, V21, P2645, DOI 10.1200/JCO.2003.07.127
   Arico S, 2002, J BIOL CHEM, V277, P27613, DOI 10.1074/jbc.M201119200
   Boles BK, 2000, AM J PHYSIOL-LUNG C, V278, pL703
   Bonello MR, 2004, J BIOL CHEM, V279, P2377, DOI 10.1074/jbc.M308254200
   Castelao JE, 2003, ANN THORAC SURG, V76, P1327, DOI 10.1016/S0003-4975(03)00334-5
   Chun KS, 2004, CARCINOGENESIS, V25, P713, DOI 10.1093/carcin/bgh076
   Corbi AL, 2000, FEBS LETT, V474, P201, DOI 10.1016/S0014-5793(00)01591-X
   DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475
   Dormond O, 2002, J BIOL CHEM, V277, P45838, DOI 10.1074/jbc.M209213200
   Dormond O, 2001, NAT MED, V7, P1041, DOI 10.1038/nm0901-1041
   Elder DJE, 2002, INT J CANCER, V99, P323, DOI 10.1002/ijc.10330
   Gingras ME, 2003, INVEST OPHTH VIS SCI, V44, P3742, DOI 10.1167/iovs.03-0191
   Han JY, 2003, LUNG CANCER-J IASLC, V41, P65, DOI 10.1016/S0169-5002(03)00146-6
   Han S, 2002, IMMUNOLOGY, V106, P53, DOI 10.1046/j.1365-2567.2002.01404.x
   Han SW, 2001, CANCER RES, V61, P3998
   Han SW, 2004, INT J CANCER, V111, P322, DOI 10.1002/ijc.20281
   Han SW, 2003, CLIN CANCER RES, V9, P4627
   Han SW, 1996, ENDOCRINOLOGY, V137, P1791, DOI 10.1210/en.137.5.1791
   Hida T, 2000, CLIN CANCER RES, V6, P2006
   HO MK, 1983, J BIOL CHEM, V258, P2766
   Jendrossek V, 2003, FASEB J, V17, P1547, DOI 10.1096/fj.02-0947fje
   Kim S, 2000, AM J PATHOL, V156, P1345, DOI 10.1016/S0002-9440(10)65005-5
   Kita D, 2001, CANCER RES, V61, P7985
   Larouche K, 2000, J BIOL CHEM, V275, P39182, DOI 10.1074/jbc.M002945200
   Lefevre G, 2003, ONCOGENE, V22, P8813, DOI 10.1038/sj.onc.1207099
   Liao Zhongxing, 2003, Clin Lung Cancer, V4, P356, DOI 10.3816/CLC.2003.n.015
   Liu GM, 2003, J BIOL CHEM, V278, P2124, DOI 10.1074/jbc.M202443200
   Madsen CS, 1997, J BIOL CHEM, V272, P29842, DOI 10.1074/jbc.272.47.29842
   Masferrer JL, 2000, CANCER RES, V60, P1306
   Okegawa T, 2002, J UROLOGY, V167, P1836, DOI 10.1016/S0022-5347(05)65245-7
   Proulx S, 2003, MOL VIS, V9, P473
   Rajeswari J, 2002, CELL BIOL INT, V26, P1043, DOI 10.1006/cbir.2002.0964
   RAY R, 1989, J CLIN INVEST, V83, P2003, DOI 10.1172/JCI114110
   Sanchez-Alcazar JA, 2003, LUNG CANCER-J IASLC, V40, P33, DOI 10.1016/S0169-5002(02)00530-5
   Schmidt CM, 2003, J GASTROINTEST SURG, V7, P1024, DOI 10.1016/j.gassur.2003.09.009
   Sekar N, 2004, AM J PHYSIOL-ENDOC M, V287, pE128, DOI 10.1152/ajpendo.00400.2003
   Tani N, 2003, BRIT J CANCER, V88, P327, DOI 10.1038/sj.bjc.6600710
   Vartiainen N, 2001, J NEUROCHEM, V76, P480, DOI 10.1046/j.1471-4159.2001.00065.x
   Waldner C, 2004, J CLIN PATHOL, V57, P553, DOI 10.1136/jcp.2003.013169
   Watt FM, 2002, EMBO J, V21, P3919, DOI 10.1093/emboj/cdf399
   Wong BCY, 2004, GASTROENTEROLOGY, V126, P136, DOI 10.1053/j.gastro.2003.10.063
   Xie RL, 2003, J BIOL CHEM, V278, P26589, DOI 10.1074/jbc.M301491200
NR 44
TC 28
Z9 30
U1 3
U2 9
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0020-7136
EI 1097-0215
J9 INT J CANCER
JI Int. J. Cancer
PD SEP 10
PY 2005
VL 116
IS 4
BP 536
EP 546
DI 10.1002/ijc.21125
PG 11
WC Oncology
SC Oncology
GA 951MV
UT WOS:000230935500007
PM 15825163
OA Bronze
DA 2018-12-27
ER

PT J
AU Huang, T
   Bohlenius, H
   Eriksson, S
   Parcy, F
   Nilsson, O
AF Huang, T
   Bohlenius, H
   Eriksson, S
   Parcy, F
   Nilsson, O
TI RETRACTED: The mRNA of the Arabidopsis gene FT moves from leaf to shoot
   apex and induces flowering (Retracted Article. See vol 316, pg 367,
   2007)
SO SCIENCE
LA English
DT Article; Retracted Publication
ID CONSTANS; PROTEIN; PLANTS; THALIANA; MOVEMENT; SIGNALS; PHLOEM
AB Day length controls flowering time in many plants. The day-length signal is perceived in the leaf, but how this signal is transduced to the shoot apex, where floral initiation occurs, is not known. In Arabidopsis, the day-length response depends on the induction of the FLOWERING LOCUS T (FT) gene. We show here that local induction of FT in a single Arabidopsis leaf is sufficient to trigger flowering. The FT messenger RNA is transported to the shoot apex, where downstream genes are activated. These data suggest that the FT mRNA is an important component of the elusive "florigen" signal that moves from leaf to shoot apex.
C1 Swedish Univ Agr Sci, Dept Forest Genet & Plant Physiol, Umea Plant Sci Ctr, S-90183 Umea, Sweden.
   Univ Grenoble 1, INRA, CEA,Lab Physiol Cellulaire Vegetale, CNRS,UMR 5168,DRDC PCV, F-38054 Grenoble, France.
RP Nilsson, O (reprint author), Swedish Univ Agr Sci, Dept Forest Genet & Plant Physiol, Umea Plant Sci Ctr, S-90183 Umea, Sweden.
EM Ove.Nilsson@genfys.slu.se
CR Abe M, 2005, SCIENCE, V309, P1052, DOI 10.1126/science.1115983
   An HL, 2004, DEVELOPMENT, V131, P3615, DOI 10.1242/dev.01231
   Ayre BG, 2004, PLANT PHYSIOL, V135, P2271, DOI 10.1104/pp.104.040592
   CHAILAKHYAN MKH, 1936, DOKL ACAD SCI URSS, V13, P77
   Colasanti J, 2000, TRENDS BIOCHEM SCI, V25, P236, DOI 10.1016/S0968-0004(00)01542-5
   Corbesier L, 2005, PLANT CELL ENVIRON, V28, P54, DOI 10.1111/j.1365-3040.2005.01283.x
   Ding B, 2003, CURR OPIN PLANT BIOL, V6, P596, DOI 10.1016/j.pbi.2003.09.010
   Hempel FD, 1997, DEVELOPMENT, V124, P3845
   JACK T, 1992, CELL, V68, P683, DOI 10.1016/0092-8674(92)90144-2
   Kim M, 2001, SCIENCE, V293, P287, DOI 10.1126/science.1059805
   KNOTT JAMES E., 1934, PROC AMER SOC HORT SCI, V31, P152
   KOORNNEEF M, 1991, MOL GEN GENET, V229, P57, DOI 10.1007/BF00264213
   MANDEL MA, 1992, NATURE, V360, P273
   SEVERIN K, 1990, PLANT MOL BIOL, V15, P827, DOI 10.1007/BF00039423
   Takada S, 2003, PLANT CELL, V15, P2856, DOI 10.1105/tpc.016345
   Valverde F, 2004, SCIENCE, V303, P1003, DOI 10.1126/science.1091761
   Wigge PA, 2005, SCIENCE, V309, P1056, DOI 10.1126/science.1114358
   Xoconostle-Cazares B, 1999, SCIENCE, V283, P94, DOI 10.1126/science.283.5398.94
   Yanovsky MJ, 2003, NAT REV MOL CELL BIO, V4, P265, DOI 10.1038/nrm1077
   Yoo BC, 2004, PLANT CELL, V16, P1979, DOI 10.1105/tpc.104.023614
   ZEEVAART JAD, 1976, ANNU REV PLANT PHYS, V27, P321, DOI 10.1146/annurev.pp.27.060176.001541
   ZEEVAART JAD, 1985, HDB FLOWERING, P239
NR 22
TC 163
Z9 205
U1 2
U2 60
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 0036-8075
J9 SCIENCE
JI Science
PD SEP 9
PY 2005
VL 309
IS 5741
BP 1694
EP 1696
DI 10.1126/science.1117768
PG 3
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 963WK
UT WOS:000231836700035
PM 16099949
DA 2018-12-27
ER

PT J
AU Dobashi, S
   Kira, M
   Tanaka, R
   Izawa, Y
   Deguchi, Y
   Kubota, T
   Wada, A
   Hara, M
AF Dobashi, S
   Kira, M
   Tanaka, R
   Izawa, Y
   Deguchi, Y
   Kubota, T
   Wada, A
   Hara, M
TI RETRACTED: Rapid analysis of polychlorinated biphenyls in the gas phase
   with resonance-enhanced two-photon ionization: Optimal injection of ions
   into the ion-trap storage/time-of-flight mass spectrometer (Retracted
   Article. See vol 22, pg 803, 2006)
SO ANALYTICAL SCIENCES
LA English
DT Article; Retracted Publication
ID ISOMER-SELECTIVE IONIZATION; LASER-DESORPTION-IONIZATION;
   CAPILLARY-ELECTROPHORESIS; AROMATIC-HYDROCARBONS; HEMOGLOBIN-VARIANTS;
   DEVICE; SIMULATION; MOLECULES; CHEMISTRY; DIOXINS
AB LI-IT-TOFMS (laser ionization/ion-trap storage/time-of-flight mass spectrometry) is expected to be a powerful tool for environmental monitoring. In the research reported here, real-time LI-IT-TOFMS measurements were carried out on gaseous 2 - 4 chlorinated PCBs in order to evaluate the applicability of an environmental monitoring method. With respect to ion-trap storage for PCBs, we found that the effect was due to the driving RF voltage on the ring electrode in the ion trap. For PCBs ions produced by laser irradiation, we observed that it was more efficient to reach the center of the ion trap by using a gated RF voltage rather than by using a continuous RF voltage. The ion trajectories in the ion trap were simulated by SIMION 7.0. We found that the voltage of the exit end cap electrode affected both the number of ions trapped and the orbit of ions inside the trap cell. Optimization of this parameter was per-formed using both simulated and experimental results. The achievable PCBs sensitivity for real-time (1 min) measurement using the LI-IT-TOFMS method was found to be in the pptV range (<0.01 mg/m(3)N) by means of a comparison with the conventional gas sampling/GS-MS method. A satisfactory proportional relationship was confirmed between the laser-based and conventional results.
C1 Mitsubishi Heavy Ind Co Ltd, Nagasaki R&D Ctr, Nagasaki 8510392, Japan.
   Mitsubishi Heavy Ind Co Ltd, Machinery Headquarters, Minato Ku, Tokyo 1088215, Japan.
   Mitsubishu Heavy Ind Ltd, Nagasaki Shipyard & Machinery Works, Nagasaki 8508610, Japan.
   Tokyo Inst Technol, Chem Resources Lab, Midori Ku, Yokohama, Kanagawa 1848584, Japan.
RP Dobashi, S (reprint author), Mitsubishi Heavy Ind Co Ltd, Nagasaki R&D Ctr, 5-717-1 Fukahorimachi, Nagasaki 8510392, Japan.
EM shinsaku_dobashi@mhi.co.jp
RI Hara, Michikazu/E-6418-2014
OI Hara, Michikazu/0000-0003-3450-5704
CR BOESL U, 1992, INT J MASS SPECTROM, V112, P121, DOI 10.1016/0168-1176(92)80001-H
   COOKS RG, 1990, ACCOUNTS CHEM RES, V23, P213, DOI 10.1021/ar00175a002
   Deguchi Y, 2003, ENVIRON SCI TECHNOL, V37, P4737, DOI 10.1021/es034257j
   Ding L, 1999, P SOC PHOTO-OPT INS, V3777, P144, DOI 10.1117/12.370125
   Dobashi S, 2004, ANAL SCI, V20, P13, DOI 10.2116/analsci.20.13
   DOBSON RLM, 1986, ANAL CHEM, V58, P2129, DOI 10.1021/ac00124a006
   DUNN TM, 1985, CHEM PHYS LETT, V121, P453, DOI 10.1016/0009-2614(85)87212-2
   EIDEN GC, 1994, INT J MASS SPECTROM, V136, P119, DOI 10.1016/0168-1176(94)04013-3
   FOUNTAIN ST, 1994, RAPID COMMUN MASS SP, V8, P407, DOI 10.1002/rcm.1290080514
   Gittins CM, 1997, ANAL CHEM, V69, P286, DOI 10.1021/ac960969z
   He L, 1997, RAPID COMMUN MASS SP, V11, P1440
   He L, 1997, RAPID COMMUN MASS SP, V11, P1467, DOI 10.1002/(SICI)1097-0231(19970830)11:13<1467::AID-RCM54>3.0.CO;2-X
   Huang PQ, 2000, J AM SOC MASS SPECTR, V11, P127, DOI 10.1016/S1044-0305(99)00128-2
   Li MX, 1997, ANAL CHEM, V69, P2451, DOI 10.1021/ac970076m
   Li MX, 1997, RAPID COMMUN MASS SP, V11, P99, DOI 10.1002/(SICI)1097-0231(19970115)11:1<99::AID-RCM813>3.3.CO;2-Y
   LUBMAN DM, 1982, J PHYS CHEM-US, V86, P1129, DOI 10.1021/j100396a017
   LUBMAN DM, 1988, MASS SPECTROM REV, V7, P559, DOI 10.1002/mas.1280070602
   LUBMAN DM, 1988, MASS SPECTROM REV, V7, P535, DOI 10.1002/mas.1280070504
   LUBMAN DM, 1990, LASERS MASS SPECTROM
   MA C, 1992, APPL SPECTROSC, V46, P1769, DOI 10.1366/0003702924123458
   MARCH RE, 1989, QUADRUPLE STORAGE MA
   MATHER RE, 1980, INT J MASS SPECTROM, V33, P201, DOI 10.1016/0020-7381(80)85001-7
   MILLER TA, 1984, SCIENCE, V223, P545, DOI 10.1126/science.223.4636.545
   OSER H, 1996, P INT C INC THERM TR, P387
   POMERANTZ I, 1978, ENVIRON HEALTH PERSP, V24, P133, DOI 10.2307/3428806
   QIAN MG, 1995, ANAL CHEM, V67, P2870, DOI 10.1021/ac00113a022
   Qian MG, 1996, RAPID COMMUN MASS SP, V10, P1911, DOI 10.1002/(SICI)1097-0231(199612)10:15<1911::AID-RCM791>3.0.CO;2-S
   Qin J, 1996, ANAL CHEM, V68, P1784, DOI 10.1021/ac9511612
   RAPPE C, 1979, ANN NY ACAD SCI, V320, P1
   REILLY JP, 1980, J CHEM PHYS, V73, P5468, DOI 10.1063/1.440092
   RHODES G, 1983, ANAL CHEM, V55, P280, DOI 10.1021/ac00253a023
   TANADA TN, 1994, COMBUST SCI TECHNOL, V101, P333, DOI 10.1080/00102209408951881
   TEMBREULL R, 1985, ANAL CHEM, V57, P1186, DOI 10.1021/ac00284a006
   VERTS A, 1993, LASERS IONIZATION MA
   Wall DB, 2001, RAPID COMMUN MASS SP, V15, P1649, DOI 10.1002/rcm.421
   WEICKHARDT C, 1994, RAPID COMMUN MASS SP, V8, P381, DOI 10.1002/rcm.1290080508
   ZIMMERMANN R, 1994, CHEMOSPHERE, V29, P1877, DOI 10.1016/0045-6535(94)90353-0
   Zimmermann R, 1997, RAPID COMMUN MASS SP, V11, P1095, DOI 10.1002/(SICI)1097-0231(19970630)11:10<1095::AID-RCM960>3.3.CO;2-H
NR 38
TC 4
Z9 4
U1 3
U2 18
PU JAPAN SOC ANALYTICAL CHEMISTRY
PI TOKYO
PA 26-2 NISHIGOTANDA 1 CHOME SHINAGAWA-KU, TOKYO, 141, JAPAN
SN 0910-6340
EI 1348-2246
J9 ANAL SCI
JI Anal. Sci.
PD SEP
PY 2005
VL 21
IS 9
BP 1111
EP 1115
DI 10.2116/analsci.21.1111
PG 5
WC Chemistry, Analytical
SC Chemistry
GA 978QX
UT WOS:000232889200015
PM 16363482
OA Bronze
DA 2018-12-27
ER

PT J
AU Zuo, L
   Ushio-Fukai, M
   Ikeda, S
   Hilenski, L
   Patrushev, N
   Alexander, RW
AF Zuo, L
   Ushio-Fukai, M
   Ikeda, S
   Hilenski, L
   Patrushev, N
   Alexander, RW
TI RETRACTED: Caveolin-1 is essential for activation of Rac1 and NAD(P)H
   oxidase after angiotensin II type 1 receptor stimulation in vascular
   smooth muscle cells - Role in redox signaling and vascular hypertrophy
   (Retracted article. See vol. 31, pg. E9, 2011)
SO ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
LA English
DT Article; Retracted Publication
DE angiotensin II; reactive oxygen species; caveolin; caveolae; vascular
   hypertrophy; vascular smooth muscle
ID GROWTH-FACTOR RECEPTOR; MULTIPLE FUNCTIONS; FOCAL ADHESIONS;
   PROTEIN-KINASE; MEMBRANE; TRANSACTIVATION; EXPRESSION; ATHEROSCLEROSIS;
   TRANSDUCTION; CYTOSKELETON
AB Objective - Angiotensin II (Ang II) is a potent mediator of vascular hypertrophy in vascular smooth muscle cells (VSMCs). These effects are mediated through the Ang II type 1 receptor (AT(1)R) and require its trafficking through caveolin-1 (Cav1) - enriched lipid rafts and reactive oxygen species (ROS) derived from Rac1-dependent NAD(P) H oxidase. The specific role(s) of Cav1 in AT1R signaling is incompletely understood.
   Methods and Results - Knockdown of Cav1 protein by small interfering RNA ( siRNA) inhibits Ang II - stimulated Rac1 activation and membrane translocation, H2O2 production, ROS-dependent epidermal growth factor receptor (EGF-R) transactivation, and subsequent phosphorylation of Akt without affecting ROS-independent extracellular signal-regulated kinase 1/2 phosphorylation. Ang II stimulates tyrosine phosphorylation of Sos-1, a Rac-guanine nucleotide exchange factor, which is inhibited by Cav1 siRNA, demonstrating involvement of Cav1 in Rac1 activation. Detergent-free fractionation showed that EGF-Rs are found basally in Cav1-enriched lipid raft membranes and associate with Cav1. Ang II stimulates AT(1)R movement into these microdomains contemporaneously with the egress of EGF-R. Both aspects of this bidirectional receptor trafficking are inhibited by Cav1 siRNA. Moreover, Cav1 siRNA inhibits Ang II - induced vascular hypertrophy.
   Conclusions - Cav1 plays an essential role in AT1R targeting into Cav1-enriched lipid rafts and Rac1 activation, which are required for proper organization of ROS-dependent Ang II signaling linked to VSMC hypertrophy.
C1 Emory Univ, Sch Med, Dept Med, Div Cardiol, Atlanta, GA 30322 USA.
RP Ushio-Fukai, M (reprint author), Emory Univ, Sch Med, Dept Med, Div Cardiol, 1639 Pierce Dr,Room 319, Atlanta, GA 30322 USA.
EM mfukai@emory.edu
FU NHLBI NIH HHS [HL60728, HL075209, HL058000]
CR Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199
   Burridge K, 2004, CELL, V116, P167, DOI 10.1016/S0092-8674(04)00003-0
   CHO KA, 2004, J BIOL CHEM
   Cohen AW, 2004, PHYSIOL REV, V84, P1341, DOI 10.1152/physre.00046.2003
   del Pozo MA, 2004, SCIENCE, V303, P839, DOI 10.1126/science.1092571
   Eguchi S, 2000, REGUL PEPTIDES, V91, P13, DOI 10.1016/S0167-0115(00)00126-9
   Frank GD, 2003, ANTIOXID REDOX SIGN, V5, P771, DOI 10.1089/152308603770380070
   Frank GD, 2001, BIOCHEM BIOPH RES CO, V280, P1116, DOI 10.1006/bbrc.2001.4251
   Frank PG, 2004, ARTERIOSCL THROM VAS, V24, P98, DOI 10.1161/01.ATV.0000101182.89118.E5
   GONZLEZ E, 2004, J BIOL CHEM
   Gratton JP, 2004, CIRC RES, V94, P1408, DOI 10.1161/01.RES.0000129178.56294.17
   Griendling KK, 2000, ARTERIOSCL THROM VAS, V20, P2175, DOI 10.1161/01.ATV.20.10.2175
   Griendling KK, 2000, CIRC RES, V86, P494, DOI 10.1161/01.RES.86.5.494
   Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509
   Hilenski LL, 2004, ARTERIOSCL THROM VAS, V24, P677, DOI 10.1161/01.ATV.0000112024.13727.2c
   Ishida T, 1999, J CLIN INVEST, V103, P789, DOI 10.1172/JCI4189
   Ishizaka N, 1998, HYPERTENSION, V32, P459, DOI 10.1161/01.HYP.32.3.459
   Jackson AL, 2003, NAT BIOTECHNOL, V21, P635, DOI 10.1038/nbt831
   LeClerc PC, 2002, ENDOCRINOLOGY, V143, P4702, DOI 10.1210/en.2002-220679
   Liu PS, 2002, J BIOL CHEM, V277, P41295, DOI 10.1074/jbc.R200020200
   Michaely PA, 1999, J BIOL CHEM, V274, P21430, DOI 10.1074/jbc.274.30.21430
   Oh P, 1998, J CELL BIOL, V141, P101, DOI 10.1083/jcb.141.1.101
   QUINN MT, 1993, J BIOL CHEM, V268, P20983
   Seshiah PN, 2002, CIRC RES, V91, P406, DOI 10.1161/01.RES.0000033523.08033.16
   SMART EJ, 1995, P NATL ACAD SCI USA, V92, P10104, DOI 10.1073/pnas.92.22.10104
   Smith RM, 1998, CELL SIGNAL, V10, P355, DOI 10.1016/S0898-6568(97)00170-8
   Stahlhut M, 2000, EXP CELL RES, V261, P111, DOI 10.1006/excr.2000.4960
   Touyz RM, 2005, ARTERIOSCL THROM VAS, V25, P512, DOI 10.1161/01.ATV.0000154141.66879.98
   Ushio-Fukai M, 2001, J BIOL CHEM, V276, P48269, DOI 10.1074/jbc.M105901200
   Ushio-Fukai M, 2001, ARTERIOSCL THROM VAS, V21, P489, DOI 10.1161/01.ATV.21.4.489
   Ushio-Fukai M, 1999, J BIOL CHEM, V274, P22699, DOI 10.1074/jbc.274.32.22699
   Ushio-Fukai M, 1998, J BIOL CHEM, V273, P15022, DOI 10.1074/jbc.273.24.15022
   Wassmann S, 2001, MOL PHARMACOL, V59, P646
   Weiss D, 2001, CIRCULATION, V103, P448
   ZUO L, 2004, ARTERIOSCLER THROMB, V24, P1
NR 35
TC 98
Z9 105
U1 3
U2 14
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1079-5642
EI 1524-4636
J9 ARTERIOSCL THROM VAS
JI Arterioscler. Thromb. Vasc. Biol.
PD SEP
PY 2005
VL 25
IS 9
BP 1824
EP 1830
DI 10.1161/01.ATV.0000175295.09607.18
PG 7
WC Hematology; Peripheral Vascular Disease
SC Hematology; Cardiovascular System & Cardiology
GA 959FI
UT WOS:000231502500011
PM 15976327
OA Bronze
DA 2018-12-27
ER

PT J
AU Iwaniec, T
   Ding, S
AF Iwaniec, T
   Ding, S
TI RETRACTED: Global estimates for the Jacobians of orientation preserving
   mappings (Retracted article. See vol. 56, pg. 2779, 2008)
SO COMPUTERS & MATHEMATICS WITH APPLICATIONS
LA English
DT Article; Retracted Publication
DE Jacobians; John domains; orientation-preserving mappings
ID HIGHER INTEGRABILITY; DOMAINS
AB In this paper, we establish some global weighted integral estimates for the Jacobians J(x, f) of an orientation-preserving mapping f = (f(1), f(2),...,f(N)) : Omega -> R-n of the Sobolev class W-1,W-n(Omega, R-n) in John domains and L phi(mu)-domains. (c) 2005 Elsevier Ltd. All rights reserved.
C1 Syracuse Univ, Dept Math, Syracuse, NY 13210 USA.
   Seattle Univ, Dept Math, Seattle, WA 98122 USA.
RP Iwaniec, T (reprint author), Syracuse Univ, Dept Math, Syracuse, NY 13210 USA.
EM sding@seattleu.edu
CR Bao GJ, 2001, J MATH ANAL APPL, V259, P241, DOI 10.1006/jmaa.2001.7446
   BREZIS H, 1993, J FUNCT ANAL, V115, P425, DOI 10.1006/jfan.1993.1098
   Ding S, 2003, J MATH ANAL APPL, V283, P85, DOI 10.1016/S0022-247X(03)00216-6
   GEHRING FW, 1973, ACTA MATH-DJURSHOLM, V130, P265, DOI 10.1007/BF02392268
   GRECO L, 1994, ANN I H POINCARE-AN, V11, P17, DOI 10.1016/S0294-1449(16)30194-9
   Heinonen J., 1993, NONLINEAR POTENTIAL
   Hogan J, 2000, ANN I H POINCARE-AN, V17, P193, DOI 10.1016/S0294-1449(00)00108-6
   Iwaniec T, 1999, P ROY SOC EDINB A, V129, P539, DOI 10.1017/S0308210500021508
   IWANIEC T, 1992, ARCH RATION MECH AN, V119, P129, DOI 10.1007/BF00375119
   IWANIEC T, 2001, REP U JYVASKYLA DEP, V83, P181
   MULLER S, 1990, J REINE ANGEW MATH, V412, P20
   Nolder CA, 1999, ILLINOIS J MATH, V43, P613
NR 12
TC 3
Z9 3
U1 2
U2 8
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0898-1221
EI 1873-7668
J9 COMPUT MATH APPL
JI Comput. Math. Appl.
PD SEP
PY 2005
VL 50
IS 5-6
BP 707
EP 718
DI 10.1016/j.camwa.2005.04.014
PG 12
WC Mathematics, Applied
SC Mathematics
GA 972MA
UT WOS:000232456700006
OA Bronze
DA 2018-12-27
ER

PT J
AU Sersar, SI
   Hamza, UA
   AbdelHameed, WA
   AbulMaaty, RA
   Gowaeli, NN
   Moussa, SA
   AlMorsi, SM
   Hafez, MM
AF Sersar, SI
   Hamza, UA
   AbdelHameed, WA
   AbulMaaty, RA
   Gowaeli, NN
   Moussa, SA
   AlMorsi, SM
   Hafez, MM
TI RETRACTED: Inhaled foreign bodies: management according to early or late
   presentation (Retracted article. See vol 35, pg 1119, 2009)
SO EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY
LA English
DT Article; Retracted Publication
DE foreign bodies; radiography; bronchoscopy
ID VIRTUAL BRONCHOSCOPY; TRACHEOBRONCHIAL TREE; BODY ASPIRATION; CHILDREN;
   EXPERIENCE; COMPLICATIONS; RADIOGRAPHY; DIAGNOSIS; REMOVAL; CT
AB Objective: This retrospective study aims to compare the early and late clinical and management aspects of tracheobronchial aspirated foreign body (AFB), to evaluate the factors associated with delayed diagnosis of foreign body aspiration (FBA) in children and to compare clinical, radiological and bronchoscopic findings in the patients with suspected FBA. A retrospective review of a 10-year experience (from 1995 to 2005). A 1512-bed Mansoura University Hospital and 184-bed Mansoura University Emergency Hospital.
   Methods: The medical records of 3300 patients who underwent bronchoscopy for suspected FBA were reviewed. The data were analysed in three groups: the patients with negative bronchoscopy for FBA (group I), early (group II) and delayed diagnosis (group III). Foreign body was removed using the rigid bronchoscope with or without using the extracting forceps (Egyptian novel technique [Sersar IS, Abdulla AK, Abuleta SA, Elsaeid AS, Abdulmageed NA. A novel technique to remove an inhaled foreign body without using a forceps. J Cardiovasc Dis 2004;2(4):157-8] described in the hand made illustration).
   Results: The majority of the patients with FBA were between 3 and 10 years of age. The penetration syndrome and decreased breath sounds were determined in a significantly higher number of the patients with FBA. The plain chest radiography revealed radio-opaque foreign bodies (FBs) in 23.56% of all. patients with FBA. Pneumonia and atetectasis were significantly more common in the groups with negative bronchoscopy and with delayed diagnosis (P < 0.01). The FBs were most frequently of vegetable origin, such as seeds and peanuts. A significant tissue reaction with inflammation and postbronchoscopic complications were more common in the delayed cases. The novel technique was used since then in 100 cases (4.62%) with a history of FBI (Pins and or small rounded materials). It was successful in 73 (73%) cases of non-impacted inhaled pins. Use of forceps was needed in 21 (21%) cases. Rebronchoscopy despite using both techniques was needed in six (6%) cases within 72 h. Failed extraction of the inhaled FB occurred in three cases (3%) for whom bronchotomy was needed.
   Conclusions: Bronchoscopy is indicated on appropriate history and on suspicion. To prevent delayed diagnosis, characteristic symptoms, signs and radiological findings of FBA should be checked in all suspected cases. As clinical and radiological findings of FBA in delayed cases may mimic other disorders, the clinician must be aware of the likelihood of FBA. (c) 2005 Published by Elsevier B.V.
C1 Mansoura Univ, ICU, Mansoura 35516, Egypt.
   Mansoura Univ, ENT, Mansoura 35516, Egypt.
RP Sersar, SI (reprint author), Mansoura Univ, ICU, Mansoura 35516, Egypt.
EM sameh001@yahoo.com
CR BLACK RE, 1994, J PEDIATR SURG, V29, P682, DOI 10.1016/0022-3468(94)90740-4
   Burke AJ, 2000, LARYNGOSCOPE, V110, P23, DOI 10.1097/00005537-200001000-00005
   Ferretti GR, 1996, J COMPUT ASSIST TOMO, V20, P777, DOI 10.1097/00004728-199609000-00018
   Fleiter T, 1997, AM J ROENTGENOL, V169, P1591, DOI 10.2214/ajr.169.6.9393172
   Haponik EF, 1999, CLIN CHEST MED, V20, P201, DOI 10.1016/S0272-5231(05)70135-0
   Higgins WE, 1998, RADIOGRAPHICS, V18, P761, DOI 10.1148/radiographics.18.3.9599397
   Johnson DG, 1998, CURR PROB SURG, V35, P275
   Konen E, 1998, AM J ROENTGENOL, V171, P1699, DOI 10.2214/ajr.171.6.9843316
   Lam WWM, 2000, AM J ROENTGENOL, V174, P1009, DOI 10.2214/ajr.174.4.1741009
   McAdams HP, 1998, AM J ROENTGENOL, V170, P1361, DOI 10.2214/ajr.170.5.9574616
   Metrangolo S, 1999, J PEDIATR SURG, V34, P1229, DOI 10.1016/S0022-3468(99)90157-4
   PASAOGLU I, 1991, THORAC CARDIOV SURG, V39, P95
   SERSAR IS, 2004, J CARDIOVASC DIS, V2, P157
   SVEDSTROM E, 1989, PEDIATR RADIOL, V19, P520, DOI 10.1007/BF02389562
   SWISCHUK LE, 1994, EMERGENCY IMAGING AC, P1
   VANE DW, 1988, ARCH SURG-CHICAGO, V123, P885
   Vining DJ, 1996, CHEST, V109, P549, DOI 10.1378/chest.109.2.549
   Zaytoun GM, 2000, OTOLARYNG HEAD NECK, V123, P311, DOI 10.1067/mhn.2000.105060
   Zerella JT, 1998, J PEDIATR SURG, V33, P1651, DOI 10.1016/S0022-3468(98)90601-7
NR 19
TC 34
Z9 36
U1 2
U2 7
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1010-7940
EI 1873-734X
J9 EUR J CARDIO-THORAC
JI Eur. J. Cardio-Thorac. Surg.
PD SEP
PY 2005
VL 28
IS 3
BP 369
EP 374
DI 10.1016/j.ejcts.2005.05.013
PG 6
WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery
SC Cardiovascular System & Cardiology; Respiratory System; Surgery
GA 967CO
UT WOS:000232069300001
OA Bronze
DA 2018-12-27
ER

PT J
AU Kishali, NF
   Imamoglu, O
   Kaldirimci, M
   Akyol, P
   Yildirim, K
AF Kishali, NF
   Imamoglu, O
   Kaldirimci, M
   Akyol, P
   Yildirim, K
TI RETRACTED: Comparison of lipid and lipoprotein values in men and women
   differing in training status (Retracted article. See vol. 123, pg. 596,
   2013)
SO INTERNATIONAL JOURNAL OF NEUROSCIENCE
LA English
DT Article; Retracted Publication
DE different training level subjects; lipid and lipoprotein
ID CHOLESTEROL; EXERCISE
AB The aim of this study was to compare plasma lipid and lipoprotein concentrations of male and female subjects in different training levels and to examine the risks of cardiovascular diseases. For this purpose, 20 male athletes from the National Turkish Wrestling Team (age 23.5 +/- 1.25 years) and 44 male and 51 female students (ages 21.7 +/- 1.72 and 20.20 +/- 1.68 years, respectively) from physical education and sports department and 40 sedentary females (ages 21.14 +/- 1.72 years) participated in this study. Trighceride (TG), total cholesterol (TC), HDL-C and LDL-C levels were determined by a Hitachi 717 Autoanalyser. Apo A-1, Apo B, and Lp(a) levels were determined by Behringer Nephelometer 100. Maximum Oxygen Consumption (VO2 max) values were determined by 12-min run test and the anaerobic power values were measured by Jump Meter Instrument. Energy consumption of basal metabolic rates were for males 1 kcal for an hour and 0.9 kcal for females. There were no significant differences in plasma TC, TG, and small lipoprotein a (Lp(a)) values between four groups (p >.05). No significant differences were found in HDL-C, LDL-C, apolipoprotein AI (Apo-Al), and apolipoprotein B100 (Apo-B) values between wrestlers and male students, and between female students and sedentary females (p >.05). HDL-C values of female students and sedentary females were significantly higher when compared with the same values of wrestlers and male students (41.52 and 40.93 mg/100 ml versus 51.92 and 50.10 mg/100 ml). However, LDL-C values were found to be lower in females than males (121.83 and 101.10 mg/100 ml as opposed to 97.7 and 98.4 mg/100 ml) but only significantly lower than in wrestlers (p <.05). Although the wrestlers' training levels were always higher than male students, the lipid and lipoprotein values were not different. These variables were not different between female groups either. But the lipid and lipoprotein profile of female subjects was found to be better than that of males. These results showed that medium and high level of exercises did not cause significant differences in lipid and lipoprotein levels, but the sex differences were very pronounced. Lipid and lipoprotein values of the four groups have indicated that the individuals in these groups would not be exposed to danger of cardiovascular diseases.
C1 Ataturk Univ, Phys Educ & Sports High Sch, Erzurum, Turkey.
   Ondokuz Mayis Univ, Yasar Dogu Phys Educ & Sports High Sch, Samsun, Turkey.
RP Kishali, NF (reprint author), Ataturk Univ, Phys Educ & Sports High Sch, Erzurum, Turkey.
EM necipfazil@yahoo.com
CR AELLEN R, 1993, INT J SPORTS MED, V14, P396, DOI 10.1055/s-2007-1021198
   BEDIR A, 1998, NEW J MED S, V15, P12
   Bos K, 1998, GESUNDHEITSSPORT HDB
   CILOGLU F, 1995, BAYAN SPORCULARIN LI
   Durstine JL, 2001, SPORTS MED, V31, P1033, DOI 10.2165/00007256-200131150-00002
   EDWARD T, 1992, HLTH FITNESS
   Eisenmann JC, 2002, SPORTS MED, V32, P297, DOI 10.2165/00007256-200232050-00002
   FLETCHER GF, 1992, CIRCULATION, V86, P340, DOI 10.1161/01.CIR.86.1.340
   FRANKEN HP, 1993, DTSCH SPORTMEDIZIN, V44, P524
   FRIEDMANN B, 1987, VERGLEICHENDE UNTERS
   FRITZ K, 1987, LIPID DISORD, V5, P23
   Heyden S., 1993, Deutsche Zeitschrift fuer Sportmedizin, V44, P504
   HIGUCHI M, 1989, CLIN PHYSIOL, V9, P121, DOI 10.1111/j.1475-097X.1989.tb00963.x
   LOKEY EA, 1989, INT J SPORTS MED, V10, P424, DOI 10.1055/s-2007-1024937
   ROSATO FD, 1990, FITNESS WELLNESS PHY
   STAMLER J, 1986, JAMA-J AM MED ASSOC, V256, P2823, DOI 10.1001/jama.256.20.2823
   TAMER K, 2000, SPORDA FIZIKSEL FIZY
   TRAN ZV, 1983, MED SCI SPORT EXER, V15, P393
   WERNER WK, 1990, FITNESS WELLNESS
   WILLIAM EP, 1991, FITNESS COLL LIFE
   Wood PD, 1996, AM J SPORT MED, V24, pS59, DOI 10.1177/036354659602406S17
   YALAZ O, 1996, SPOR HEKIMLIGI DERGI, V31
NR 22
TC 11
Z9 11
U1 3
U2 9
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0020-7454
EI 1563-5279
J9 INT J NEUROSCI
JI Int. J. Neurosci.
PD SEP
PY 2005
VL 115
IS 9
BP 1247
EP 1257
DI 10.1080/00207450590934435
PG 11
WC Neurosciences
SC Neurosciences & Neurology
GA 955YZ
UT WOS:000231267400001
PM 16048804
DA 2018-12-27
ER

PT J
AU Rose, EA
AF Rose, EA
TI RETRACTED: From a punitive to a bargaining model of sanctions: Lessons
   from Iraq (Retracted Article. See vol 50, pg 1, 2006)
SO INTERNATIONAL STUDIES QUARTERLY
LA English
DT Article; Retracted Publication
ID ECONOMIC SANCTIONS
AB This article explores the effectiveness of the longest, most comprehensive, and most severe multilateral sanctions imposed by the United Nations (UN) Security Council against Iraq in 1990. It provides a different perspective with regard to the significance of sanctions in general, and against Iraq in particular. In contrast to the traditional use of the "punitive model" of sanctions, which mandated full compliance without reciprocating, this study offers a "bargaining model" framework that focuses on the process of negotiation and concessions for partial compliance. It claims that a decade of multilateral punitive sanctions against Iraq has led to some Iraqi compliance and the partial fulfillment of many of the UN's cease-fire objectives. But the failure of the UN to use the bargaining model to reciprocate Iraq squandered opportunities for additional Iraqi cooperation, and generated dynamics of deepening distrust and animosity made a negotiated solution more difficult and war a reality.
C1 CUNY, York Coll, New York, NY 10021 USA.
RP Rose, EA (reprint author), CUNY, York Coll, New York, NY 10021 USA.
CR AHTISAARI M, 1991, 522366 UN SEC COUNC
   Albright Madeleine K., 1997, COMMUNICATION   0326
   AMINI GM, 1997, 12 U CAL LOS ANG CTR
   ANNAN K, 1997, REPORT SECRETARY GEN
   ANNAN K, 1998, CAUSES CONFLICT PROM
   Axelrod R., 1984, EVOLUTION COOPERATIO
   BALDWIN DA, 1971, WORLD POLIT, V24, P19, DOI 10.2307/2009705
   Baldwin David A., 1985, EC STATECRAFT
   *BRIT FOR OFF, 1998, PAP IR THREAT WORK U
   BURGESS J, 1990, WASHINGTON POST NATL, V7, P20
   Clawson P, 1993, ETHICS INT AFF, V7, P17
   CORDESMAN AH, 1998, IRAQ CRISIS BACKGROU
   CORTRIGHT D, 1999, J INT AFF, V52, P735
   Cortright David, 1997, PRICE PEACE INCENTIV
   Crawford Neta C, 1999, SANCTIONS WORK LESSO
   CROSSETTE B, 1997, NY TIMES        1218, P4
   CROSSETTE B, 1999, NY TIMES        0114, pA5
   Damrosch LF, 1993, ENFORCING RESTRAINT
   DAVIS J, 1995, EC SANCTIONS PANACEA
   DELEVIC M, 1998, INT J PEACE STUDIES, V3, P78
   DEYOUNG K, 1999, WASHINGTON POST 0715
   Dolley Steven, 1998, IRAQ BOMB NUCL THREA
   DOWTY A, 1994, WASH QUART, V17, P179, DOI 10.1080/01636609409443416
   Doxey Margaret P., 1996, INT SANCTIONS CONT P
   Elliott KA, 1998, INT SECURITY, V23, P50, DOI 10.2307/2539262
   ELLIOTT KA, 1993, B ATOM SCI, V49, P32, DOI 10.1080/00963402.1993.11456419
   Elliott KA, 1999, AM ECON REV, V89, P403, DOI 10.1257/aer.89.2.403
   Evans G., 1993, COOPERATING PEACE
   FALK R, 1992, C INT EC SANCT POSTC
   FORLAND TE, 1993, J PEACE RES, V30, P151, DOI 10.1177/0022343393030002003
   GALTUNG J, 1983, DILEMMAS EC COERCION
   GARFIELD R, 1999, OCCASIONAL PAPERS SE, V16
   George Alexander Lawrence, 1991, FORCEFUL PERSUASION
   GHALI BB, 1995, AGENDA PEACE POSIT S
   Gibbons E. D., 1999, SANCTIONS HAITI HUMA
   Gordon Joy, 1999, ETHICS INT AFF, V13, P123, DOI DOI 10.1111/J.1747-7093.1999.TB00330.X
   Haass RN, 1997, FOREIGN AFF, V76, P74, DOI 10.2307/20048277
   HOAGLAND J, 1993, WASHINGTON POST 1112, pA25
   HOAGLAND J, 1996, INT HERALD TRIB 0208
   Holbrooke R., 1998, END WAR
   HOSKINS E, 1997, POLITICAL GAIN CIVIL
   Hufbauer G. C, 1990, EC SANCTIONS RECONSI
   Kaempfer WH, 1999, INT STUD QUART, V43, P37, DOI 10.1111/0020-8833.00110
   KEGLEY CW, 2004, GLOBAL POLITICS TREN
   LICHT S, 1995, EC SANCTIONS PANACEA
   Lopez George A., 1999, ETHICS INT AFF, V13, P143
   Martin L. L., 1992, COERCIVE COOPERATION
   MARTIN LL, 1977, UN EC SANCTIONS IMPR
   NATHAN JA, 1997, US TODAY, V126, P37
   Nossal Kim R., 1999, GLOBALIZATION GLOBAL
   Pape RA, 1997, INT SECURITY, V22, P90, DOI 10.2307/2539368
   POUND ET, 1994, US NEWS WORLD REP, P58
   Schelling T., 1966, ARMS INFLUENCE
   *UN, 1990, SRES678 UN
   *UN, 1998, S33217 UN SEC COUNC
   *UN CTR EC SOC RIG, 1996, UN SANCT SUFF HUM RI
   *UN DEP PUBL INF, 1996, UN IR KUW CONFL 1990
   *UN FAO, 1998, EV FOOD NUTR SIT IR
   *UN INT STAND COMM, 1996, REP HUM MAND CONFL S
   *UNICEF, 1996, DIS SIT CHILDR IR
   VANBERGEIJK P, 1997, C EFF EFF UN SANCT T
   WALKER P, 1995, RED CRESENT, P17
   Weiss Thomas, 1997, POLITICAL GAIN CIVIL
   ZAIDI S, 1995, LANCET, V346, P1485, DOI 10.1016/S0140-6736(95)92499-X
   1998, HARPERS MAGAZINE FEB
   2002, HARPERS MAGAZINE NOV
   2001, HARPERS MAGAZINE MAR
NR 67
TC 5
Z9 5
U1 2
U2 19
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0020-8833
EI 1468-2478
J9 INT STUD QUART
JI Int. Stud. Q.
PD SEP
PY 2005
VL 49
IS 3
BP 459
EP 479
DI 10.1111/j.1468-2478.2005.00373.x
PG 21
WC International Relations; Political Science
SC International Relations; Government & Law
GA 951LB
UT WOS:000230930600005
DA 2018-12-27
ER

PT J
AU Yu, C
   Dasmahapatra, G
   Dent, P
   Grant, S
AF Yu, C
   Dasmahapatra, G
   Dent, P
   Grant, S
TI RETRACTED: Synergistic interactions between MEK1/2 and histone
   deacetylase inhibitors in BCR/ABL plus human leukemia cells (Retracted
   article. See vol. 30, pg. 1452, 2016)
SO LEUKEMIA
LA English
DT Article; Retracted Publication
DE leukemia; histone deacetylase inhibitors; MEK1/2 inhibitors; p21(CIP1)
ID SUBEROYLANILIDE HYDROXAMIC ACID; CHRONIC MYELOID-LEUKEMIA; CHRONIC
   MYELOGENOUS LEUKEMIA; BCR-ABL ONCOGENE; KINASE INHIBITOR; TYROSINE
   KINASE; SELECTIVE INHIBITOR; OXIDATIVE STRESS; INDUCE APOPTOSIS;
   IMATINIB STI571
AB Interactions between the histone deacetylase inhibitor SAHA and the pharmacologic MEK1/2 inhibitor PD184352 were examined in Bcr/Abl+ human leukemia cells. Coadministration of minimally toxic concentrations of SAHA ( or sodium butyrate) and PD184352 ( or U0126) resulted in a synergistic increase in mitochondrial damage, caspase activation, and apoptosis in K562 and LAMA 84 cells. Similar interactions were observed in CD34(+) cells from two patients with CML and in imatinib mesylate-resistant K562 cells but not in normal human CD34(+) bone marrow cells. These events were associated with a marked increase in ROS generation, inactivation of ERK and Akt, downregulation of p21(CIP1), Bcr/Abl, and cyclin D-1, and activation of JNK. Of these events, ROS generation, ERK inactivation, and cytochrome c/AIF release were largely caspase-independent, whereas the other phenomena displayed varying degrees of caspase-dependence. Using pharmacologic and genetic approaches, generation of ROS, p21(CIP1) downregulation, and inactivation of Akt and MEK were found to play significant functional roles in SAHA/PD184352-mediated lethality, whereas JNK activation and Raf-1 downregulation were determined to represent secondary events. These findings indicate that interruption of the MEK/ERK pathway substantially lowers the threshold for HDAC inhibitor-mediated oxidative injury, mitochondrial dysfunction, and apoptosis, suggesting that this approach warrants further examination in Bcr/Abl+-related malignancies.
C1 Virginia Commonwealth Univ, Med Coll Virginia, Div Hematol & Oncol, Massey Canc Ctr,Dept Med, Richmond, VA 23298 USA.
   Virginia Commonwealth Univ, Massey Canc Ctr, Dept Biochem, Richmond, VA USA.
   Virginia Commonwealth Univ, Massey Canc Ctr, Dept Pharmacol, Richmond, VA USA.
RP Grant, S (reprint author), Virginia Commonwealth Univ, Med Coll Virginia, Div Hematol & Oncol, Massey Canc Ctr,Dept Med, MCV Stn Box 230, Richmond, VA 23298 USA.
EM stgrant@hsc.vcu.edu
FU NCI NIH HHS [CA93738, CA88906, CA 100866, CA63753, CA72955]
CR Allen LF, 2003, SEMIN ONCOL, V30, P105, DOI 10.1053/S0093-7754(03)00445-7
   Almenara J, 2002, LEUKEMIA, V16, P1331, DOI 10.1038/sj.leu.2402535
   Bachelder RE, 2001, J BIOL CHEM, V276, P34702, DOI 10.1074/jbc.M102806200
   BEDI A, 1995, BLOOD, V86, P1148
   Butler LM, 2002, P NATL ACAD SCI USA, V99, P11700, DOI 10.1073/pnas.182372299
   CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4
   Dai Y, 2004, J BIOL CHEM, V279, P34227, DOI 10.1074/jbc.M402290200
   Dai Y, 2005, BLOOD, V105, P1706, DOI 10.1182/blood-2004-07-2767
   Dai Y, 2001, CANCER RES, V61, P5106
   Dai Y, 2003, CELL CYCLE, V2, P467, DOI 10.4161/cc.2.5.465
   Dasmahapatra GP, 2004, CLIN CANCER RES, V10, P5242, DOI 10.1158/1078-0432.CCR-03-0534
   Donato NJ, 2004, CANCER RES, V64, P672, DOI 10.1158/0008-5472.CAN-03-1484
   Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561
   Faderl S, 1999, NEW ENGL J MED, V341, P164, DOI 10.1056/NEJM199907153410306
   George P, 2005, BLOOD, V105, P1768, DOI 10.1182/blood-2004-09-3413
   Hochhaus A, 2002, LEUKEMIA, V16, P2190, DOI 10.1038/sj.leu.2402741
   Horita M, 2000, J EXP MED, V191, P977, DOI 10.1084/jem.191.6.977
   Insinga A, 2005, NAT MED, V11, P71, DOI 10.1038/nm1160
   Johnstone RW, 2002, NAT REV DRUG DISCOV, V1, P287, DOI 10.1038/nrd772
   Knight GWA, 2004, BRIT J BIOMED SCI, V61, P103, DOI 10.1080/09674845.2004.11732653
   Kondapaka SB, 2003, MOL CANCER THER, V2, P1093
   Liu Y, 1996, CANCER RES, V56, P31
   Maggio SC, 2004, CANCER RES, V64, P2590, DOI 10.1158/0008-5472.CAN-03-2631
   MINDEN A, 1997, BIOCHIM BIOPHYS ACTA, V1333, P85, DOI DOI 10.1016/S0304-419X(97)00018-8
   Nakatani Y, 2001, GENES CELLS, V6, P79, DOI 10.1046/j.1365-2443.2001.00411.x
   Neshat MS, 2000, MOL CELL BIOL, V20, P1179, DOI 10.1128/MCB.20.4.1179-1186.2000
   Philpott NJ, 1996, BLOOD, V87, P2244
   Rahmani M, 2003, CANCER RES, V63, P8420
   Richon VM, 1996, P NATL ACAD SCI USA, V93, P5705, DOI 10.1073/pnas.93.12.5705
   Rossig L, 2002, J BIOL CHEM, V277, P9684, DOI 10.1074/jbc.M106157200
   Ruefli AA, 2001, P NATL ACAD SCI USA, V98, P10833, DOI 10.1073/pnas.191208598
   Sebolt-Leopold JS, 2000, ONCOGENE, V19, P6594, DOI 10.1038/sj.onc.1204083
   Shah NP, 2002, CANCER CELL, V2, P117, DOI 10.1016/S1535-6108(02)00096-X
   Shah NP, 2004, SCIENCE, V305, P399, DOI 10.1126/science.1099480
   Shelton JG, 2004, CELL CYCLE, V3, P503
   Ungerstedt JS, 2005, P NATL ACAD SCI USA, V102, P673, DOI 10.1073/pnas.0408732102
   Van Etten RA, 2004, LEUKEMIA RES, V28, pS21, DOI 10.1016/j.leukres.2003.10.005
   von Bubnoff N, 2003, LEUKEMIA, V17, P829, DOI 10.1038/sj.leu.2402889
   Vrana JA, 1999, ONCOGENE, V18, P7016, DOI 10.1038/sj.onc.1203176
   Wang XT, 2000, J BIOL CHEM, V275, P14624, DOI 10.1074/jbc.275.19.14624
   Wang XT, 1998, BIOCHEM J, V333, P291, DOI 10.1042/bj3330291
   Widmann C, 1998, J BIOL CHEM, V273, P7141, DOI 10.1074/jbc.273.12.7141
   XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326
   Yu CR, 2003, CANCER BIOL THER, V2, P544, DOI 10.4161/cbt.2.5.454
   Yu XD, 2002, J NATL CANCER I, V94, P504
NR 45
TC 62
Z9 67
U1 3
U2 9
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0887-6924
EI 1476-5551
J9 LEUKEMIA
JI Leukemia
PD SEP
PY 2005
VL 19
IS 9
BP 1579
EP 1589
DI 10.1038/sj.leu.2403868
PG 11
WC Oncology; Hematology
SC Oncology; Hematology
GA 958IV
UT WOS:000231438800011
PM 16015388
OA Bronze
DA 2018-12-27
ER

PT J
AU Al-Smadi, M
   Ratrout, S
AF Al-Smadi, M
   Ratrout, S
TI RETRACTED: New multi-1,2,3-selenadiazole aromatic derivatives (Retracted
   Article. See vol 12, pg 1289, 2007)
SO MOLECULES
LA English
DT Article; Proceedings Paper; Retracted Publication
CT 2nd International Conference on Natural Products and Physiologically
   Active Substances (ICNPAS-2004)/3rd EuroAsian Heterocyclic Meeting on
   Heterocycles in Organic and Combinatorial Chemistry (EAHM-2004)
CY SEP 12-17, 2004
CL Novosibirsk, RUSSIA
SP Novosibirsk Inst Organ Chem, Moscow State Univ, Dept Chem, Ghent Univ
DE 1,2,3-selenadiazoles; semicarbazones; aromatic derivatives
ID SELENIUM HETEROCYCLES; 1,2,3-SELENADIAZOLES
AB The aromatic polyketones 3a-d are versatile compounds for the synthesis of the multi-1,2,3-selenadiazole aromatic derivatives 1a-d. The preparation starts with the reaction between the multi-bromomethylene benzene derivatives 2a-d and 4-hydroxy-acetophenone to give compounds 3a-d which are transformed through the reaction with semicarbazide hydrochloride or ethyl hydrazine carboxylate into the corresponding semicarbazones derivatives 4a-d or hydrazones 5a-d. The reaction with selenium dioxide leads to regiospecific ring closure of semicarbazones or hydrazones to give the multi-1,2,3-selenadiazole aromatic derivatives in high yield.
C1 Jordan Univ Sci & Technol, Dept Appl Chem Sci, Irbid 22110, Jordan.
RP Al-Smadi, M (reprint author), Jordan Univ Sci & Technol, Dept Appl Chem Sci, POB 3030, Irbid 22110, Jordan.
EM mariam10@just.edu.jo
CR Abramov MA, 2000, TETRAHEDRON, V56, P3933, DOI 10.1016/S0040-4020(00)00315-X
   AlSmadi M, 1997, J HETEROCYCLIC CHEM, V34, P605, DOI 10.1002/jhet.5570340243
   AlSmadi M, 1997, LIEBIGS ANN-RECL, P2357
   Arsenyan P., 2002, CHEM HETEROCYCL COMP, V38, P1437, DOI DOI 10.1023/A:1022667309258
   BURLING FT, 1992, J AM CHEM SOC, V114, P2313, DOI 10.1021/ja00033a004
   Detert H, 1997, LIEBIGS ANN-RECL, P1557
   DHOOGE B, 1997, J CHEM SOC CHEM COMM, P1753
   Jalilian A. R., 2003, Farmaco (Lausanne), V58, P63, DOI 10.1016/S0014-827X(02)00029-0
   LABBE G, 1994, J CHEM SOC PERK T 1, P2203, DOI 10.1039/p19940002203
   LALEZARI I, 1973, J ORG CHEM, V38, P338, DOI 10.1021/jo00942a029
   LALEZARI I, 1969, TETRAHEDRON LETT, P5105
   Lalezari I., 1971, J ORG CHEM, V36, P2836
   Lalezari I., 1987, J PHARM SCI, V67, P1336
   MALEKYAZDI F, 1977, SYNTHESIS-STUTTGART, P328
   Nishiyama Y, 1999, TETRAHEDRON LETT, V40, P6293, DOI 10.1016/S0040-4039(99)01286-1
   Petrov ML, 1999, TETRAHEDRON LETT, V40, P3903, DOI 10.1016/S0040-4039(99)00565-1
   Reddy DB, 1997, TETRAHEDRON, V53, P17351
   Reddy DB, 2001, SYNTHETIC COMMUN, V31, P3429
   Zhou YH, 2000, HELV CHIM ACTA, V83, P539, DOI 10.1002/(SICI)1522-2675(20000315)83:3<539::AID-HLCA539>3.0.CO;2-6
NR 19
TC 11
Z9 11
U1 3
U2 12
PU MDPI AG
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
SN 1420-3049
J9 MOLECULES
JI Molecules
PD SEP
PY 2005
VL 10
IS 9
BP 1126
EP 1134
DI 10.3390/10091126
PG 9
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
SC Biochemistry & Molecular Biology; Chemistry
GA 998DC
UT WOS:000234297600009
PM 18007378
OA DOAJ Gold
DA 2018-12-27
ER

PT J
AU Srikanth, S
   Nagaraja, AV
AF Srikanth, S
   Nagaraja, AV
TI RETRACTED: A prospective study of reversible dementias: Frequency,
   causes, clinical profile and results of treatment (Retracted Article.
   See vol 55, pg 5, 2007)
SO NEUROLOGY INDIA
LA English
DT Article; Retracted Publication
DE dementia; reversible causes; neuroinfections; normal pressure
   hydrocephalus; vitamin B12 deficiency
ID ALZHEIMERS-DISEASE; DIAGNOSTIC-CRITERIA; PREVALENCE; INDIA; POPULATION;
   COMMUNITY; KERALA
AB Background: Dementia due to potentially reversible etiologies is an important group of dementias to be identified not only because of the number of such Patients encountered but also due to the potential for substantial improvement with treatment. Aims: To prospectively investigate the frequency and causes of dementias with potentially reversible etiologies; to examine the clinical features of this subgroup with a view to identifying a signature profile and to determine if this potential reversibility translates into actual reversibility with appropriate treatment. Setting and design: A prospective longitudinal study of patients with dementia presenting to the outpatient services of a tertiary referral hospital. Methods: All Patients above 40 years referred for evaluation of cognitive complaints were serially enrolled and underwent clinical examination, various laboratory tests and neuroimaging. Patients were followed-up for one year. Statistical analysis: One way analysis of variance for continuous variables followed by post hoc comparisons using Scheffe's procedure. Results: A total of 129 patients met Diagnostic and Statistical Manual of Mental Disorders edition 4 (DSM IV) criteria for dementia and qualified for inclusion into the study. Twenty-four patients (18%), all with moderately severe cognitive [mean mini mental state examination (MMSE) score +/- SD = 17.9 +/- 4.8] and neuropsychiatric [mean neuropsychiatric inventory (NPI) score +/- SD = 30.7 +/- 8.7] dysfunction were diagnosed to have reversible causes - neuroinfections in 11 patients, normal pressure hydrocephalus in 8 patients and vitamin B12 deficiency in 5 patients. The majority of these patients had gait and urinary dysfunction reminiscent of subcortical dementias. These reversible causes were clinically suspected in only 58% of patients. In 20/24 patients in whom follow up was possible mean MMSE score had improved to 22.2 and mean NPI score had improved to 8.0, following 6 months of treatment. Conclusions: Reversible causes, especially neuroinfections and vitamin B12 deficiency accounted for 18% all dementias in this study. The majority of these conditions was not clinically suspected though resulting in moderate to severe cognitive and psychiatric dysfunction. Most of these patients had a subcortical pattern of dementia and showed substantial improvement with treatment.
C1 Singapore Gen Hosp, Dept Neurol, Dementia Programme, Singapore 169608, Singapore.
   Nagaraj Neuroclin, Shimoga, Karnataka, India.
RP Srikanth, S (reprint author), Singapore Gen Hosp, Dept Neurol, Dementia Programme, Outram Rd, Singapore 169608, Singapore.
EM drssrikanth@rediffmail.com
CR American Psychiatric Association, 1994, DIAGN STAT MAN MENT
   Chandra V, 1998, NEUROLOGY, V51, P1000, DOI 10.1212/WNL.51.4.1000
   Clarfield AM, 2003, ARCH INTERN MED, V163, P2219, DOI 10.1001/archinte.163.18.2219
   CLARFIELD AM, 1988, ANN INTERN MED, V109, P476, DOI 10.7326/0003-4819-109-6-476
   CUMMINGS JL, 1994, NEUROLOGY, V44, P2308, DOI 10.1212/WNL.44.12.2308
   DEKOSKY ST, 2004, NEUROLOGY CLIN PRACT, P1901
   ERKINJUNTTI T, 1987, ACTA NEUROL SCAND, V76, P359, DOI 10.1111/j.1600-0404.1987.tb03594.x
   EVANS DA, 1989, JAMA-J AM MED ASSOC, V262, P2551, DOI 10.1001/jama.262.18.2551
   FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6
   Freter S, 1998, CAN MED ASSOC J, V159, P657
   Hejl A, 2002, J NEUROL NEUROSUR PS, V73, P390, DOI 10.1136/jnnp.73.4.390
   Jha S, 2004, NEUROL INDIA, V52, P213
   LARSON EB, 1984, ANN INTERN MED, V100, P417, DOI 10.7326/0003-4819-100-3-417
   MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939
   MORRIS JC, 1993, NEUROLOGY, V43, P2412, DOI 10.1212/WNL.43.11.2412-a
   Neary D, 1998, NEUROLOGY, V51, P1546, DOI 10.1212/WNL.51.6.1546
   Piccini C, 1998, J NEUROL SCI, V153, P172, DOI 10.1016/S0022-510X(97)00289-X
   Rajkumar S, 1997, INT J GERIATR PSYCH, V12, P702, DOI 10.1002/(SICI)1099-1166(199707)12:7<702::AID-GPS489>3.0.CO;2-H
   ROMAN GC, 1993, NEUROLOGY, V43, P250, DOI 10.1212/WNL.43.2.250
   Shaji S, 2005, BRIT J PSYCHIAT, V186, P136, DOI 10.1192/bjp.186.2.136
   Shaji S, 1996, BRIT J PSYCHIAT, V168, P745, DOI 10.1192/bjp.168.6.745
   Takada LT, 2003, ARQ NEURO-PSIQUIAT, V61, P925, DOI 10.1590/S0004-282X2003000600007
   Vas CJ, 2001, INT PSYCHOGERIATR, V13, P439, DOI 10.1017/S1041610201007852
   Walstra GJM, 1997, J NEUROL, V244, P17
   WEYTINGH MD, 1995, J NEUROL, V242, P466, DOI 10.1007/BF00873551
   World Health Organization, 1992, INT STAT CLASS DIS R
NR 26
TC 13
Z9 14
U1 3
U2 13
PU MEDKNOW PUBLICATIONS & MEDIA PVT LTD
PI MUMBAI
PA B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075,
   INDIA
SN 0028-3886
EI 1998-4022
J9 NEUROL INDIA
JI Neurol. India
PD SEP
PY 2005
VL 53
IS 3
BP 291
EP 294
DI 10.4103/0028-3886.16926
PG 4
WC Neurosciences
SC Neurosciences & Neurology
GA 979TG
UT WOS:000232967100008
PM 16230795
OA Other Gold
DA 2018-12-27
ER

PT J
AU Mantena, SK
   Roy, AM
   Katiyar, SK
AF Mantena, SK
   Roy, AM
   Katiyar, SK
TI RETRACTED: Epigallocatechin-3-gallate inhibits photocarcinogenesis
   through inhibition of anglogenic factors and activation of CD8(+) T
   cells in tumors (Retracted article. See vol. 94, pg. 618, 2018)
SO PHOTOCHEMISTRY AND PHOTOBIOLOGY
LA English
DT Article; Retracted Publication
ID ENDOTHELIAL GROWTH-FACTOR; NONMELANOMA SKIN-CANCER; GREEN TEA
   POLYPHENOLS; MATRIX METALLOPROTEINASES; INDUCED IMMUNOSUPPRESSION;
   CONTACT HYPERSENSITIVITY; ULTRAVIOLET-RADIATION; HYDROPHILIC CREAM;
   MOUSE SKIN; (-)-EPIGALLOCATECHIN-3-GALLATE
AB There has been considerable interest in the use of botanical supplements to protect skin from the adverse effects of solar UV radiation, including photocarcinogenesis. We and others have shown that topical application of (-)-epigallocatechin-3-gallate (EGCG) from green tea prevents photocarcinogenesis in mice; however, the chemopreventive mechanism of EGCG in an in vivo tumor model is not clearly understood. In this study, UV-B-induced skin tumors with and without treatment of EGCG (approximate to 1 mg/cm(2)) and age-matched skin biopsies from SKH-1 hairless mice were used to identify potential molecular targets of skin cancer prevention by EGCG. These biopsies were analyzed for various biomarkers of angiogenesis and antitumor immune response using immunostaining, Western blotting and gelatinolytic zymography. We report that compared to non-EGCG-treated tumors, topical application of EGCG in UV-induced tumors resulted in inhibition of protein expression and activity of matrix metalloproteinase (MMP)-2 and MMP-9, which play crucial roles in tumor growth and metastasis. In contrast, tissue inhibitor of MMP-1 (TIMP-1), which inhibits MMP activity, was increased in tumors. With respect to the tumor vasculature, EGCG decreased the expression of CD31, a cell surface marker of vascular endothelial cells, and inhibited the expression of vascular endothelial growth factor in tumors, which are essential for angiogenesis. EGCG inhibited proliferating cell nuclear antigen in UV-B-induced tumors as well. Additionally, higher numbers of cytotoxic T lymphocytes (CD8(+) T cells) were detected in EGCG-treated tumors compared with non-EGCG-treated tumors. Together, these in vivo tumor data suggested that inhibition of photocarcinogenesis in mice by EGCG is associated with inhibition of angiogenic factors and induction of antitumor immune reactivity.
C1 Univ Alabama Birmingham, Dept Dermatol, Birmingham, AL 35294 USA.
   Univ Alabama Birmingham, Skin Dis Res Ctr, Birmingham, AL USA.
   Birmingham VA Med Ctr, Birmingham, AL USA.
RP Katiyar, SK (reprint author), Univ Alabama Birmingham, Dept Dermatol, 1670 Univ Blvd,Volker Hall 557,POB 202, Birmingham, AL 35294 USA.
EM skatiyar@uab.edu
FU NCI NIH HHS [CA105368]; NIAMS NIH HHS [AR050948-01]
CR ALON T, 1995, NAT MED, V1, P1024, DOI 10.1038/nm1095-1024
   Benjamin LE, 1999, J CLIN INVEST, V103, P159, DOI 10.1172/JCI5028
   Conti CJ, 2002, ONCOLOGIST, V7, P4, DOI 10.1634/theoncologist.7-suppl_3-4
   de Gruijl FR, 2002, METHODS, V28, P122, DOI 10.1016/S1046-2023(02)00200-1
   Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745
   Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4
   Garbisa S, 1999, NAT MED, V5, P1216, DOI 10.1038/15145
   Gerber HP, 1998, J BIOL CHEM, V273, P13313, DOI 10.1074/jbc.273.21.13313
   John Anitha, 2001, Pathology and Oncology Research, V7, P14
   Johnson TM, 1998, J AM ACAD DERMATOL, V38, P681, DOI 10.1016/S0190-9622(98)70196-3
   Katiyar Santosh K., 2003, Current Drug Targets - Immune Endocrine and Metabolic Disorders, V3, P234, DOI 10.2174/1568008033340171
   Katiyar SK, 1999, CARCINOGENESIS, V20, P2117, DOI 10.1093/carcin/20.11.2117
   KATIYAR SK, 1995, PHOTOCHEM PHOTOBIOL, V62, P855
   Meunier L, 1998, REV MED INTERNE, V19, P247, DOI 10.1016/S0248-8663(97)89326-5
   MILLER DL, 1994, J AM ACAD DERMATOL, V30, P774, DOI 10.1016/S0190-9622(08)81509-5
   Mittal A, 2003, NEOPLASIA, V5, P555, DOI 10.1016/S1476-5586(03)80039-8
   Nihal M, 2005, INT J CANCER, V114, P513, DOI 10.1002/ijc.20785
   O'Shaughnessy JA, 2002, CLIN CANCER RES, V8, P314
   RISAU W, 1995, FASEB J, V9, P926
   Roy AM, 2005, MOL CANCER THER, V4, P81
   SCHMITT DA, 1995, J IMMUNOL, V154, P5114
   URBACH F, 1991, DERMATOL CLIN, V9, P751
   Vayalil PK, 2004, PROSTATE, V59, P33, DOI 10.1002/pros.10352
   Vayalil PK, 2003, CARCINOGENESIS, V24, P927, DOI 10.1093/carcin/bgg025
   WANG ZY, 1992, CANCER RES, V52, P1162
   YOSHIKAWA T, 1990, J INVEST DERMATOL, V95, P530, DOI 10.1111/1523-1747.ep12504877
   Yu AE, 1997, DRUG AGING, V11, P229, DOI 10.2165/00002512-199711030-00006
NR 27
TC 44
Z9 46
U1 1
U2 7
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0031-8655
EI 1751-1097
J9 PHOTOCHEM PHOTOBIOL
JI Photochem. Photobiol.
PD SEP-OCT
PY 2005
VL 81
IS 5
BP 1174
EP 1179
DI 10.1562/2005-04-11-RA-487
PG 6
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA 975CS
UT WOS:000232639200021
PM 15938647
DA 2018-12-27
ER

PT J
AU Schulz-Stubner, S
   Henszel, A
   Hata, JS
AF Schulz-Stubner, S
   Henszel, A
   Hata, JS
TI RETRACTED: A new rule for femoral nerve blocks (Retracted Article. See
   vol 31, pg 385, 2006)
SO REGIONAL ANESTHESIA AND PAIN MEDICINE
LA English
DT Article; Proceedings Paper; Retracted Publication
CT 23rd Annual Congress of the European-Society-of-Regional-Anesthesia
   (ESRA)
CY SEP, 2004
CL Athens, GREECE
SP European Soc Reg Anesthesia
DE femoral nerve block; acupuncture; nerve localization
ID BRACHIAL-PLEXUS BLOCK; SCIATIC-NERVE; ANTERIOR APPROACH; LANDMARKS;
   ANESTHESIA
AB Background and objectives: Acupuncture points are described by use of a proportional system that is based on the width of the thumb at the level of the distal interphalangeal joint, defined as 1 CUN. Our study tested first the correlation between the CUN and weight and height in 500 Americans and second the hypothesis that the CUN system is superior to the conventional landmarks to localize the femoral nerve 1 or 2 cm lateral to the artery in a prospective, double-blinded, randomized study.
   Methods: Sixty-two patients were randomized to receive a femoral nerve block by a needle entry point either 1 CUN lateral, 1 cm lateral, or 2 cm lateral to the femoral artery at the level of the inguinal crease. The time from needle entry to injection of local anesthetic was measured by an investigator blind to the technique, who also counted the frequency of needle repositioning, graded the ease of the block and its success, and registered complications.
   Results: Good correlation occurred between weight and CUN (r = 0.79) and height and CUN (r = 0.83), which indicates that the CUN of a normal person (predefined as 175 cm tall and 70 kg weight) is 18.7 +/- 1 mm. In the CUN group, the femoral block was achieved significantly faster (P < .01) with fewer attempts (P < .003). The success rate was the same and complications did not differ significantly between the groups.
   Conclusion: A needle insertion point 1 CUN lateral to the midpoint of the palpated femoral artery at the level of the inguinal crease makes femoral nerve blocks faster and easier compared with conventional landmark 1 cm to 2 cm lateral to the artery.
C1 Univ Iowa Hosp & Clin, Dept Anesthesia, Iowa City, IA 52242 USA.
RP Schulz-Stubner, S (reprint author), Univ Iowa Hosp & Clin, Dept Anesthesia, 6JCP,200 Hawkins Dr, Iowa City, IA 52242 USA.
EM sebastian-schulz-stubner@uiowa.edu
CR Barbero C, 2004, ANESTH ANALG, V98, P1785, DOI 10.1213/01.ANE.0000117224.99190.A8
   BROWN D, 1992, ATLAS REGIONAL ANEST
   Cheney FW, 1999, ANESTHESIOLOGY, V90, P1062, DOI 10.1097/00000542-199904000-00020
   Chernyak GV, 2005, ANESTHESIOLOGY, V102, P1031, DOI 10.1097/00000542-200505000-00024
   Flaatten H, 1991, Tidsskr Nor Laegeforen, V111, P3190
   Franco CD, 2003, ANESTHESIOLOGY, V98, P723, DOI 10.1097/00000542-200303000-00022
   JANKOVIC D, 2000, REGIOANLBLOCKADEN KL
   Klaastad O, 1999, ANESTH ANALG, V88, P593, DOI 10.1097/00000539-199903000-00025
   Marhofer P, 1997, ANESTH ANALG, V85, P854, DOI 10.1097/00000539-199710000-00026
   Marhofer P, 1998, REGION ANESTH PAIN M, V23, P584, DOI 10.1016/S1098-7339(98)90086-4
   RAJ PP, 1973, ANESTH ANALG, V52, P897
   SCHULZSTUBNER S, 2003, REGIONALANASTHESIE A
   SIMS JK, 1977, ANESTH ANALG, V56, P554
   Van Elstraete AC, 2002, ANESTH ANALG, V95, P214, DOI 10.1097/00000539-200207000-00038
   Vloka JD, 1999, ANESTH ANALG, V89, P1467, DOI 10.1097/00000539-199912000-00028
   WINNIE AP, 1973, ANESTH ANALG, V52, P989
   WINNIE AP, 1992, REGION ANESTH, V17, P176
NR 17
TC 13
Z9 13
U1 3
U2 10
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1098-7339
EI 1532-8651
J9 REGION ANESTH PAIN M
JI Region. Anesth. Pain Med.
PD SEP-OCT
PY 2005
VL 30
IS 5
BP 473
EP 477
DI 10.1016/j.rapm.2005.05.009
PG 5
WC Anesthesiology
SC Anesthesiology
GA 964YA
UT WOS:000231915700009
PM 16135352
DA 2018-12-27
ER

PT J
AU Xie, JC
   Wang, XH
   Deng, JY
   Zhang, LX
AF Xie, JC
   Wang, XH
   Deng, JY
   Zhang, LX
TI RETRACTED: Pore size control of Pitch-based activated carbon fibers by
   pyrolytic deposition of propylene (Retracted article. See vol. 448, pg.
   681, 2018)
SO APPLIED SURFACE SCIENCE
LA English
DT Article; Retracted Publication
DE activated carbon fiber; propylene; chemical vapor deposition; physical
   adsorption; porosity
ID MOLECULAR-SIEVES; MICROPOROUS CARBONS; POROUS CARBONS; ADSORPTION;
   NITROGEN; COAL; ADSORBENTS; SEPARATION; SYSTEMS; GASES
AB In this paper, we attempted to narrow the pore size of Pitch-based activated carbon fiber (Pitch-ACF) by chemical vapor deposition (CVD) of propylene at 700 degrees C. The BET equation was used to estimate the specific surface areas. The micropore volumes were determined using DR equation, t-plot and alpha(S)-plot, and mesopore surface areas were determined by t-plot and alpha(s)-plot. The pore size distribution (PSD) of micropores and mesopore was investigated by micropore analysis method (MP method) and MK method, respectively. The relation between the graphite-like crystal interlayer distance and pore size was analyzed by X-ray diffraction (XRD). The results showed that the pore size of Pitch-ACF was gradually narrowed with increasing deposition time. The catalytic activation of Ni was attempted when Pitch-ACF was modified simultaneously by pyrolysis of propylene. The results obtained from the analysis of PSD of micropores, mesopores, and macropores in Ni-P-ACF by density function theory (DFT) showed that the pore structure and surface chemistry were greatly changed due to introducing nickel catalyst. (c) 2004 Elsevier B.V. All rights reserved.
C1 NW Inst Nucl Technol, Dept 7, Xian 710613, Peoples R China.
RP Xie, JC (reprint author), NW Inst Nucl Technol, Dept 7, POB 69-14, Xian 710613, Peoples R China.
EM xiejinchuan@hotmail.com
CR BAILEY A, 1966, NATURE, V211, P1082, DOI 10.1038/2111082a0
   BARRETT EP, 1951, J AM CHEM SOC, V73, P373, DOI 10.1021/ja01145a126
   BRADLEY PR, 1994, CARBON, V32, P845
   Brunauer S, 1938, J AM CHEM SOC, V60, P309, DOI 10.1021/ja01269a023
   DEBOER JH, 1966, J COLLOID INTERF SCI, V21, P405, DOI 10.1016/0095-8522(66)90006-7
   Diaz-Diez MA, 2004, APPL SURF SCI, V238, P309, DOI 10.1016/j.apsusc.2004.05.228
   DOLLIMORE D, 1970, J COLLOID INTERF SCI, V33, P508, DOI 10.1016/0021-9797(70)90002-0
   DUBININ MM, 1960, CHEM REV, V60, P235, DOI 10.1021/cr60204a006
   DUBININ MM, 1980, J COLLOID INTERF SCI, V75, P34, DOI 10.1016/0021-9797(80)90346-X
   EVERETT DH, 1976, J CHEM SOC FARAD T 1, V72, P619, DOI 10.1039/f19767200619
   Ganan J, 2004, APPL SURF SCI, V238, P347, DOI 10.1016/j.apsusc.2004.05.222
   Gregg S. G., 1982, ADSORPTION SURFACE A, P94
   Hayashi J, 1997, J MEMBRANE SCI, V124, P243, DOI 10.1016/S0376-7388(96)00250-5
   HORVATH G, 1983, J CHEM ENG JPN, V16, P470, DOI 10.1252/jcej.16.470
   HU ZH, 1995, CARBON, V33, P561, DOI 10.1016/0008-6223(94)00141-L
   JUNTGEN H, 1981, FUEL, V60, P817, DOI 10.1016/0016-2361(81)90144-7
   KAKEI K, 1990, J CHEM SOC FARADAY T, V86, P371, DOI 10.1039/ft9908600371
   LASTOSKIE C, 1993, J PHYS CHEM-US, V97, P4786, DOI 10.1021/j100120a035
   Mangun CL, 2001, CARBON, V39, P1809, DOI 10.1016/S0008-6223(00)00319-5
   MCENANEY B, 1987, CARBON, V25, P69, DOI 10.1016/0008-6223(87)90041-8
   MIKHAIL RS, 1968, J COLLOID INTERF SCI, V26, P45, DOI 10.1016/0021-9797(68)90270-1
   MOORE SV, 1977, CARBON, V15, P177, DOI 10.1016/0008-6223(77)90054-9
   Orfanoudaki T, 2003, FUEL, V82, P2045, DOI 10.1016/S0016-2361(03)00172-8
   ROBERTS BF, 1967, J COLLOID INTERF SCI, V23, P266, DOI 10.1016/0021-9797(67)90111-7
   SEATON NA, 1989, CARBON, V27, P853, DOI 10.1016/0008-6223(89)90035-3
   SING KSW, 1985, PURE APPL CHEM, V57, P603, DOI 10.1351/pac198557040603
   Stoeckli F, 2002, MICROPOR MESOPOR MAT, V51, P197, DOI 10.1016/S1387-1811(01)00482-6
   VERMA SK, 1993, CARBON, V31, P1203, DOI 10.1016/0008-6223(93)90073-J
   VERMA SK, 1992, CARBON, V30, P829, DOI 10.1016/0008-6223(92)90003-F
   VERMA SK, 1991, CARBON, V29, P793, DOI 10.1016/0008-6223(91)90018-E
   VERMA SK, 1993, CARBON, V31, P533, DOI 10.1016/0008-6223(93)90145-Z
   VYAS SN, 1990, J CHEM SOC FARADAY T, V86, P3455, DOI 10.1039/ft9908603455
   YAN J, 1982, ADSORPTION CONDENSAT, P158
   Yang CM, 2001, LANGMUIR, V17, P675, DOI 10.1021/la000307b
   Yang JB, 2002, CARBON, V40, P911, DOI 10.1016/S0008-6223(01)00222-6
NR 35
TC 18
Z9 18
U1 6
U2 35
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0169-4332
EI 1873-5584
J9 APPL SURF SCI
JI Appl. Surf. Sci.
PD AUG 31
PY 2005
VL 250
IS 1-4
BP 152
EP 160
DI 10.1016/j.apsusc.2004.12.044
PG 9
WC Chemistry, Physical; Materials Science, Coatings & Films; Physics,
   Applied; Physics, Condensed Matter
SC Chemistry; Materials Science; Physics
GA 961IR
UT WOS:000231656100021
DA 2018-12-27
ER

PT J
AU DeMichele, A
   Aplenc, R
   Botbyl, J
   Colligan, T
   Wray, L
   Klein-Cabral, M
   Foulkes, A
   Gimotty, P
   Glick, J
   Weber, B
   Stadtmauer, E
   Rebbeck, TR
AF DeMichele, A
   Aplenc, R
   Botbyl, J
   Colligan, T
   Wray, L
   Klein-Cabral, M
   Foulkes, A
   Gimotty, P
   Glick, J
   Weber, B
   Stadtmauer, E
   Rebbeck, TR
TI RETRACTED: Drug-metabolizing enzyme polymorphisms predict clinical
   outcome in a node-positive breast cancer cohort (Retracted Article. See
   vol 24, pg 3315, 2006)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Article; Proceedings Paper; Retracted Publication
CT 94th Annual Meeting of the American-Association-for-Cancer-Research
CY JUL 11-14, 2003
CL WASHINGTON, DC
SP Amer Assoc Canc Res
ID SURGICAL ADJUVANT BREAST; HIGH-DOSE CHEMOTHERAPY; HUMAN
   LIVER-MICROSOMES; IFOSFAMIDE ACTIVATION; CYCLOPHOSPHAMIDE; GLUTATHIONE;
   EXPRESSION; GENOTYPES; LEUKEMIA; GSTM1
AB Purpose Adjuvant chemotherapy cures only a subset of women with nonmetastatic breast cancer. Genotypes in drug-metabolizing enzymes, including functional polymorphisms in cytochrome P450 (CYP) and glutathione S-transferases (GST), may predict treatment-related outcomes.
   Patients and Methods We examined CYP3A4*1B, CYP3A5*3, and deletions in GST mu (GSTM1) and theta (GSTT1), as well as a priori-defined combinations of polymorphisms in these genes. Using a cohort of 90 node-positive breast cancer patients who received anthracycline-based adjuvant chemotherapy followed by high-dose multiagent chemotherapy with stem-cell rescue, we estimated the effect of genotype and other known prognostic factors on disease-free survival (DFS) and overall survival (OS).
   Results Patients who carried homozygous CYP3A4*1B and CYP3A5*3 variants and did not carry homozygous deletions in both GSTM` and GSTT` (denoted low-drug genotype group) had a 4.9-fold poorer DFS (P =.021) and a four-fold poorer DFS (P =.031) compared with individuals who did not carry any CYP3A4*1B or CYP3A5*3 variants but had deletions in both GSTT1 and GSTM1 (denoted high-drug genotype group). After adjustment for other significant prognostic factors, the low-drug genotype group retained a significantly poorer DFS (hazard ratio [HR] = 4.9; 95% Cl, 1.7 to 14.6; P =.004) and OS (HR = 4.8; 95% Cl, 1.8 to 12.9; =.002) compared with the high- and intermediate-drug combined genotype group. In the multivariate model, having low-drug genotype group status had a greater impact on clinical outcome than estrogen receptor status.
   Conclusion Combined genotypes at CYP3A4, CYP3A5, DSTM1, and GSTT1 influence the probability of treatment failure after high-dose adjuvant chemotherapy for node-positive breast cancer.
C1 Univ Penn, Sch Med, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA.
   Univ Penn, Sch Med, Div Hematol Oncol, Dept Med, Philadelphia, PA 19104 USA.
   Univ Penn, Sch Med, Abramson Canc Ctr, Philadelphia, PA 19104 USA.
   Univ Penn, Sch Med, Abramson Family Res Inst, Philadelphia, PA 19104 USA.
   Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA.
   Childrens Hosp, Div Hematol Immunol, Philadelphia, PA USA.
RP DeMichele, A (reprint author), MSCE, 14 Penn Tower,3400 Spruce St, Philadelphia, PA 19104 USA.
EM dma@mail.med.upenn.edu
FU NCI NIH HHS [K23-CA81009]
CR Aapro MS, 2001, ONCOLOGIST, V6, P36, DOI 10.1634/theoncologist.6-4-376
   Abe O, 1998, LANCET, V352, P930
   Ambrosone CB, 2001, CANCER RES, V61, P7130
   Amirimani B, 2003, ENVIRON MOL MUTAGEN, V42, P299, DOI 10.1002/em.10199
   ANTMAN KH, 2001, BIOCHIM BIOPHYS ACTA, V1471, P89
   Aplenc R, 2003, BRIT J HAEMATOL, V122, P240, DOI 10.1046/j.1365-2141.2003.04430.x
   BODDY AV, 1992, J NATL CANCER I, V84, P1744, DOI 10.1093/jnci/84.22.1744
   CHANG TKH, 1993, CANCER RES, V53, P5629
   Chang TKH, 1997, CANCER RES, V57, P1946
   COX DR, 1972, J R STAT SOC B, V34, P187
   Dally H, 2004, CANCER LETT, V207, P95, DOI 10.1016/j.canlet.2003.12.011
   Davies SM, 2000, CANCER EPIDEM BIOMAR, V9, P563
   DeMichele A, 2003, CANCER RES, V63, P8051
   DIRVEN HAAM, 1994, CANCER RES, V54, P6215
   Ekins S, 1998, J PHARMACOL EXP THER, V286, P1253
   Fisher B, 1999, J CLIN ONCOL, V17, P3374, DOI 10.1200/JCO.1999.17.11.3374
   Fisher B, 1997, J CLIN ONCOL, V15, P1858, DOI 10.1200/JCO.1997.15.5.1858
   FREI E, 1988, CANCER RES, V48, P6417
   Hanna IH, 2000, CANCER RES, V60, P3440
   Jacobson PA, 2002, CANCER CHEMOTH PHARM, V49, P461, DOI 10.1007/s00280-002-0453-3
   JUSKO WJ, 1971, J PHARM SCI, V60, P892, DOI 10.1002/jps.2600600618
   Kristensen VN, 1998, PHARMACOGENETICS, V8, P441, DOI 10.1097/00008571-199810000-00009
   Kuehl P, 2001, NAT GENET, V27, P383, DOI 10.1038/86882
   Lizard-Nacol S, 1999, Breast Cancer Res, V1, P81, DOI 10.1186/bcr17
   Ludeman SM, 1999, CURR PHARM DESIGN, V5, P627
   Moore HCF, 1999, ANN ONCOL, V10, P929, DOI 10.1023/A:1008393204854
   Ren S, 1997, CANCER RES, V57, P4229
   Roy P, 1999, DRUG METAB DISPOS, V27, P655
   SEIDEGARD J, 1988, P NATL ACAD SCI USA, V85, P7293, DOI 10.1073/pnas.85.19.7293
   SEIDEGARD J, 1988, KLIN WOCHENSCHR, V66, P125
   Tallman MS, 2003, NEW ENGL J MED, V349, P17, DOI 10.1056/NEJMoa030684
   TEICHER BA, 1988, CANCER RES, V48, P94
   Walker A H, 1998, Hum Mutat, V12, P289
   West WL, 1997, J CLIN PHARMACOL, V37, P635, DOI 10.1002/j.1552-4604.1997.tb04347.x
   WILCOXAN F, 1945, BIOMETRICS, V1, pR30
   WOOD WC, 1994, NEW ENGL J MED, V330, P1253, DOI 10.1056/NEJM199405053301801
   Zander AR, 2004, J CLIN ONCOL, V22, P2273, DOI 10.1200/JCO.2004.07.028
NR 37
TC 39
Z9 40
U1 3
U2 12
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD AUG 20
PY 2005
VL 23
IS 24
BP 5552
EP 5559
DI 10.1200/JCO.2005.06.208
PG 8
WC Oncology
SC Oncology
GA 957LQ
UT WOS:000231371700027
PM 16110016
DA 2018-12-27
ER

PT J
AU Ganesh, VK
   Muthuvel, SK
   Smith, SA
   Kotwal, GJ
   Murthy, KHM
AF Ganesh, VK
   Muthuvel, SK
   Smith, SA
   Kotwal, GJ
   Murthy, KHM
TI RETRACTED: Structural basis for antagonism by suramin of heparin binding
   to vaccinia complement protein (Retracted article. See vol. 57, pg.
   6043, 2018)
SO BIOCHEMISTRY
LA English
DT Article; Retracted Publication
ID FIBROBLAST-GROWTH-FACTOR; CRYSTAL-STRUCTURE; ENVELOPE PROTEIN; FACTOR
   FGF; PHASE-II; VIRUS; SULFATE; CANCER; LIGAND; CELLS
AB Suramin is a competitive inhibitor of heparin binding to many proteins, including viral envelope proteins, protein tyrosine phosphatases, and fibroblast growth factors (FGFs). It has been clinically evaluated as a potential therapeutic in treatment of cancers caused by unregulated angiogenesis, triggered by FGFs. Although it has shown clinical promise in treatment of several cancers, suramin has many undesirable side effects. There is currently no experimental structure that reveals the molecular interactions responsible for suramin inhibition of heparin binding, which could be of potential use in structure-assisted design of improved analogues of suramin. We report the structure of suramin, in complex with the heparin-binding site of vaccinia virus complement control protein (VCP), which interacts with heparin in a geometrically similar manner to many FGFs. The larger than anticipated flexibility of suramin manifested in this structure, and other details of VCP-suramin interactions, might provide useful structural information for interpreting interactions of suramin with many proteins.
C1 Univ Alabama Birmingham, Ctr Biophys Sci & Engn, Birmingham, AL 35294 USA.
   Univ Louisville, Sch Med, Dept Microbiol & Immunol, Louisville, KY 40202 USA.
   Univ Cape Town, Div Med Virol, ZA-7925 Cape Town, South Africa.
   Univ Cape Town, Inst Infect Dis & Mol Med, ZA-7925 Cape Town, South Africa.
RP Murthy, KHM (reprint author), Univ Alabama Birmingham, Ctr Biophys Sci & Engn, Birmingham, AL 35294 USA.
EM murthy@cbse.uab.edu
FU Wellcome Trust; NIAID NIH HHS [AI51615]
CR Aguilar JS, 1999, VIROLOGY, V258, P141, DOI 10.1006/viro.1999.9723
   BORK P, 1995, REV BIOPHYS, V29, P119
   Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254
   Carfi A, 2001, MOL CELL, V8, P169, DOI 10.1016/S1097-2765(01)00298-2
   Carson M, 1997, METHOD ENZYMOL, V277, P493, DOI 10.1016/S0076-6879(97)77027-7
   CCP4, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI DOI 10.1107/S0907444994003112
   Chen YP, 1997, NAT MED, V3, P866, DOI 10.1038/nm0897-866
   COOPER NR, 1991, IMMUNOL TODAY, V12, P327, DOI 10.1016/0167-5699(91)90010-Q
   Cowtan K, 1998, ACTA CRYSTALLOGR D, V54, P487, DOI 10.1107/S0907444997011980
   DiGabriele AD, 1998, NATURE, V393, P812
   Dos Santos HF, 1998, THEOR CHEM ACC, V99, P301, DOI 10.1007/s002140050340
   Dreicer R, 1999, INVEST NEW DRUG, V17, P183, DOI 10.1023/A:1006331518952
   Falcone A, 1998, TUMORI, V84, P666
   Fernandez-Tornero C, 2003, J BIOL CHEM, V278, P21774, DOI 10.1074/jbc.M212833200
   Ganesh VK, 2004, P NATL ACAD SCI USA, V101, P8924, DOI 10.1073/pnas.0400744101
   Garson JA, 1999, J MED VIROL, V57, P238
   Ibrahimi OA, 2005, MOL CELL BIOL, V25, P671, DOI 10.1128/MCB.25.2.671-684.2005
   JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224
   Kaur M, 2002, INVEST NEW DRUG, V20, P209, DOI 10.1023/A:1015666024386
   Kotwal G, 1998, 10TH INTERNATIONAL CONGRESS ON IMMUNOLOGY, VOLS 1 AND 2, P315
   Kotwal GJ, 2000, IMMUNOL TODAY, V21, P242, DOI 10.1016/S0167-5699(00)01606-6
   KOTWAL GJ, 1988, NATURE, V335, P176, DOI 10.1038/335176a0
   KOTWAL GJ, 1990, SCIENCE, V250, P827, DOI 10.1126/science.2237434
   Liekens S, 2001, BIOCHEM PHARMACOL, V61, P253, DOI 10.1016/S0006-2952(00)00529-3
   Lozano RM, 1998, J MOL BIOL, V281, P899, DOI 10.1006/jmbi.1998.1977
   Manetti F, 1998, BIOORGAN MED CHEM, V6, P947, DOI 10.1016/S0968-0896(98)00052-2
   Manetti F, 2000, CURR PHARM DESIGN, V6, P1897, DOI 10.2174/1381612003398528
   MIDDAUGH CR, 1992, BIOCHEMISTRY-US, V31, P9016, DOI 10.1021/bi00152a044
   Mirza MR, 1997, ACTA ONCOL, V36, P171, DOI 10.3109/02841869709109226
   Modis Y, 2003, P NATL ACAD SCI USA, V100, P6986, DOI 10.1073/pnas.0832193100
   Modis Y, 2004, NATURE, V427, P313, DOI 10.1038/nature02165
   MOHAN P, 1989, ANTIVIR CHEM CHEMOTH, V2, P215
   Murakami MT, 2004, BBA-PROTEINS PROTEOM, V1703, P83, DOI 10.1016/j.bbapap.2004.08.009
   Murthy KHM, 2001, CELL, V104, P301, DOI 10.1016/S0092-8674(01)00214-8
   NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407
   Nok AJ, 2003, PARASITOL RES, V90, P71, DOI 10.1007/s00436-002-0799-9
   Olsen SK, 2003, J BIOL CHEM, V278, P34226, DOI 10.1074/jbc.M303183200
   Ornitz DM, 2000, BIOESSAYS, V22, P108, DOI 10.1002/(SICI)1521-1878(200002)22:2<108::AID-BIES2>3.0.CO;2-M
   Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X
   Pangburn MK, 2000, J IMMUNOL, V164, P4742, DOI 10.4049/jimmunol.164.9.4742
   Pellegrini L, 2000, NATURE, V407, P1029, DOI 10.1038/35039551
   Pellegrini L, 2001, CURR OPIN STRUC BIOL, V11, P629, DOI 10.1016/S0959-440X(00)00258-X
   Polenova T, 1997, BIOCHEMISTRY-US, V36, P14202, DOI 10.1021/bi970297m
   Read RJ, 2001, ACTA CRYSTALLOGR D, V57, P1373, DOI 10.1107/S0907444901012471
   Schlessinger J, 2000, MOL CELL, V6, P743, DOI 10.1016/S1097-2765(00)00073-3
   Small EJ, 2000, J CLIN ONCOL, V18, P1440, DOI 10.1200/JCO.2000.18.7.1440
   Smith SA, 2000, J VIROL, V74, P5659, DOI 10.1128/JVI.74.12.5659-5666.2000
   Smith SA, 2003, BBA-PROTEINS PROTEOM, V1650, P30, DOI 10.1016/S1570-9639(03)00189-4
   STEIN CA, 1993, CANCER RES, V53, P2239
   WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127
   WILES AP, 1997, J MOL BIOL, P272
   Zhang YL, 1998, J BIOL CHEM, V273, P12281, DOI 10.1074/jbc.273.20.12281
NR 52
TC 20
Z9 20
U1 1
U2 3
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0006-2960
J9 BIOCHEMISTRY-US
JI Biochemistry
PD AUG 16
PY 2005
VL 44
IS 32
BP 10757
EP 10765
DI 10.1021/bi050401x
PG 9
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 956ZT
UT WOS:000231339600002
PM 16086578
DA 2018-12-27
ER

PT J
AU Myers-Irvin, JM
   Van Le, TS
   Getzenberg, RH
AF Myers-Irvin, JM
   Van Le, TS
   Getzenberg, RH
TI RETRACTED: Mechanistic analysis of the role of BLCA-4 in bladder cancer
   pathobiology (Retracted article. See vol. 74, pg. 974, 2014)
SO CANCER RESEARCH
LA English
DT Article; Retracted Publication
ID TRANSITIONAL-CELL CARCINOMA; THROMBOMODULIN; BIOLOGY; UTILITY; GROWTH;
   D-3
AB Analysis of alterations in nuclear structure associated with bladder cancer has revealed specific changes associated with the disease. This includes the identification of six bladder cancer-specific proteins and the successful development of urine-based immunoassays for the detection of two of these biomarkers, BLCA-1 and BLCA-4. The purpose of this study is to examine the functional aspects of BLCA-4 and its potential role in bladder cancer pathobiology. Sequence analysis of BLCA-4 reveals that it is a member of the ETS transcription factor family and that it seems to associate with transcription factors. To examine the effects of this protein, the gene encoding BLCA-4 was stably transfected into human urothelial cells. BLCA-4 expression was confirmed by both PCR and Western blot analysis. BLCA-4 overexpressing clones exhibit a 4.3-fold greater proliferation rate than vector only controls or untransfected cells. Microarray analysis comparing gene expression patterns between overexpressing clones and vector only controls revealed that numerous genes were up-regulated in cells that overexpress BLCA4. Up-regulated genes included interleukin-1 alpha (IL-1 alpha), IL-8, and thrombomodulin, and the protein expression of these genes was confirmed by immunoblots. This information has provided a potential model of BLCA-4 action. Overexpression of BLCA-4 seems to increase the growth rate in cells and also causes cells to express a more tumorigenic phenotype.
C1 Univ Pittsburgh, Dept Urol, Pittsburgh, PA 15261 USA.
   Univ Pittsburgh, Dept Pathol, Pittsburgh, PA 15261 USA.
   Univ Pittsburgh, Dept Pharmacol, Pittsburgh, PA 15261 USA.
   Univ Pittsburgh, Inst Canc, Pittsburgh, PA USA.
RP Getzenberg, RH (reprint author), Johns Hopkins Univ Hosp, Brady Urol Inst, Marburg 121,600 N Wolfe St, Baltimore, MD 21287 USA.
EM rgetzen1@jhmi.edu
FU NCI NIH HHS [R01 CA82522]
CR Al-Sukhun S, 2003, CRIT REV ONCOL HEMAT, V47, P181, DOI 10.1016/S1040-8428(03)00081-7
   *AM CANC SOC, 2005, CANC FACTS FIG
   Getzenberg RH, 1996, CANCER RES, V56, P1690
   Han SH, 2003, ONCOGENE, V22, P4035, DOI 10.1038/sj.onc.1206610
   Inoue K, 2000, CANCER RES, V60, P2290
   Iqbal S, 2000, BREAST, V9, P264, DOI 10.1054/brst.2000.0186
   Khan N, 2004, CANCER, V101, P379, DOI 10.1002/cncr.20377
   Konety BR, 2000, CLIN CANCER RES, V6, P2618
   Konety BR, 1999, J CELL BIOCHEM, P183
   Kwak C, 2004, J UROLOGY, V171, P149, DOI 10.1097/01.ju.0000099825.98542.a8
   Leman ES, 2003, J UROLOGY, V170, P235, DOI 10.1097/01.ju.0000060117.61770.35
   Mian BM, 2003, CLIN CANCER RES, V9, P3167
   Parker DC, 2003, AM J SURG PATHOL, V27, P1, DOI 10.1097/00000478-200301000-00001
   Seddighzadeh M, 2001, BRIT J CANCER, V84, P329, DOI 10.1054/bjoc.2000.1684
   Sheryka E, 2003, UROLOGY, V62, P162, DOI 10.1016/S0090-4295(03)00134-1
   Tackels-Horne D, 2001, CANCER-AM CANCER SOC, V92, P395, DOI 10.1002/1097-0142(20010715)92:2<395::AID-CNCR1335>3.0.CO;2-U
   Van Le TS, 2004, CLIN CANCER RES, V10, P1384, DOI 10.1158/1078-0432.CCR-0455-03
NR 17
TC 31
Z9 32
U1 2
U2 7
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD AUG 15
PY 2005
VL 65
IS 16
BP 7145
EP 7150
DI 10.1158/0008-5472.CAN-05-1142
PG 6
WC Oncology
SC Oncology
GA 954XK
UT WOS:000231188600018
PM 16103064
OA Bronze
DA 2018-12-27
ER

PT J
AU Mclaughlin, AC
   Sher, F
   Attfield, JP
AF Mclaughlin, AC
   Sher, F
   Attfield, JP
TI RETRACTED: Negative lattice expansion from the
   superconductivity-antiferromagnetism crossover in ruthenium copper
   oxides (Retracted Article. See vol 437, pg 1057, 2005)
SO NATURE
LA English
DT Article; Retracted Publication
ID VALENCE TRANSITION; RUSR2GDCU2O8; COEXISTENCE; GD
AB The mechanism of high-transition-temperature (high-T-c) superconductivity in doped copper oxides is an enduring problem. Antiferromagnetism is established as the competing order(1,2), but the relationship between the two states in the intervening 'pseudogap' regime has become a central puzzle(3). The role of the crystal lattice, which is important in conventional superconductors, also remains unclear. Here we report an anomalous increase of the distance between copper oxide planes on cooling, which results in negative thermal volume expansion, for layered ruthenium copper oxides(4,5) that have been doped to the boundary of antiferromagnetism and superconductivity. We propose that a crossover between these states is driven by spin ordering in the ruthenium oxide layers, revealing a novel mechanism for negative lattice expansion in solids. The differences in volume and lattice strain between the distinct superconducting and antiferromagnetic states can account for the phase segregation phenomena found extensively in low-doped copper oxides, and show that Cooper pair formation is coupled to the lattice. Unusually large variations of resistivity with magnetic field are found in these ruthenium copper oxides at low temperatures through coupling between the ordered Ru and Cu spins.
C1 Univ Edinburgh, Ctr Sci Extreme Condit, Edinburgh EH9 3JZ, Midlothian, Scotland.
   Univ Aberdeen, Dept Chem, Aberdeen AB24 3UE, Scotland.
   Univ Edinburgh, Sch Chem, Edinburgh EH9 3JZ, Midlothian, Scotland.
   Univ Cambridge, Dept Chem, Cambridge CB2 1EW, England.
   PIEAS, Dept Chem & Mat Engn, Nilore, Islamabad, Pakistan.
RP Attfield, JP (reprint author), Univ Edinburgh, Ctr Sci Extreme Condit, Kings Bldg,Mayfield Rd, Edinburgh EH9 3JZ, Midlothian, Scotland.
EM j.p.attfield@ed.ac.uk
RI sher, Falak/G-3412-2015
OI Mclaughlin, Abbie/0000-0001-9960-723X
CR Ahn KH, 2004, NATURE, V428, P401, DOI 10.1038/nature02364
   Ando Y, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.247003
   Arvanitidis J, 2003, NATURE, V425, P599, DOI 10.1038/nature01994
   Awana VPS, 2002, PHYSICA C, V378, P249, DOI 10.1016/S0921-4534(02)01422-3
   Bernhard C, 1999, PHYS REV B, V59, P14099, DOI 10.1103/PhysRevB.59.14099
   Chen XH, 2001, PHYS REV B, V63, DOI 10.1103/PhysRevB.63.064506
   Chmaissem O, 2000, PHYS REV B, V61, P6401, DOI 10.1103/PhysRevB.61.6401
   Cuk T, 2004, PHYS REV LETT, V93, DOI 10.1103/PhysRevLett.93.117003
   EMERY VJ, 1995, NATURE, V374, P434, DOI 10.1038/374434a0
   Felner I, 1997, PHYS REV B, V55, pR3374, DOI 10.1103/PhysRevB.55.R3374
   Hinkov V, 2004, NATURE, V430, P650, DOI 10.1038/nature02774
   Kang HJ, 2003, NATURE, V423, P522, DOI 10.1038/nature01641
   Kiyama T, 1996, PHYS REV B, V54, pR756, DOI 10.1103/PhysRevB.54.R756
   Kobayashi KL, 1998, NATURE, V395, P677, DOI 10.1038/27167
   Lavrov AN, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.227003
   Lynn JW, 2000, PHYS REV B, V61, P14964, DOI 10.1103/PhysRevB.61.R14964
   Matsukawa M, 2004, PHYS REV B, V70, DOI 10.1103/PhysRevB.70.132402
   McCrone JE, 2003, PHYS REV B, V68, DOI 10.1103/PhysRevB.68.064514
   Mclaughlin AC, 2003, PHYS REV B, V68, DOI 10.1103/PhysRevB.68.014503
   McLaughlin AC, 1999, PHYS REV B, V60, P7512, DOI 10.1103/PhysRevB.60.7512
   McLaughlin AC, 2000, INT J INORG MATER, V2, P95, DOI 10.1016/S1466-6049(99)00070-7
   Noce C, 2002, RUTHENATE RUTHENO CU
   Orenstein J, 2000, SCIENCE, V288, P468, DOI 10.1126/science.288.5465.468
   Rao C. N. R, 1998, COLOSSAL MAGNETORESI
   Salvador JR, 2003, NATURE, V425, P702, DOI 10.1038/nature02011
   Shi L, 2003, PHYSICA C, V399, P69, DOI 10.1016/S0921-4534(03)01295-4
   Sleight A, 2003, NATURE, V425, P674, DOI 10.1038/425674a
   Tokura Y., 2000, COLOSSAL MAGNETORESI
   van Schilfgaarde M, 1999, NATURE, V400, P46, DOI 10.1038/21848
   Yanase Y, 1999, J PHYS SOC JPN, V68, P2999, DOI 10.1143/JPSJ.68.2999
NR 30
TC 33
Z9 33
U1 8
U2 47
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0028-0836
EI 1476-4687
J9 NATURE
JI Nature
PD AUG 11
PY 2005
VL 436
IS 7052
BP 829
EP 832
DI 10.1038/nature03828
PG 4
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 953XG
UT WOS:000231116500041
PM 16094364
DA 2018-12-27
ER

PT J
AU Radhakrishnan, S
   Celis, E
   Pease, LR
AF Radhakrishnan, S
   Celis, E
   Pease, LR
TI RETRACTED: B7-DC cross-linking restores antigen uptake and augments
   antigen-presenting cell function by matured dendritic cells (Retracted
   article. See vol. 107, pg. 8498, 2010)
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article; Retracted Publication
DE PD-L2; IgM; synergy; cytotoxic T cells; costimulation
ID TOLL-LIKE RECEPTORS; ANTITUMOR-ACTIVITY; T-CELLS; CPG DNA; IMMUNITY;
   STIMULATION; MATURATION; RESPONSES; ANTIBODY; PD-L2
AB Dendritic cells (DCs) are classified in two states: immature DCs (iDCs), which perform sentinel functions, sampling for antigen and danger signals, and mature DCs (mDCs), which exhibit enhanced antigen-presenting functions but are no longer capable of acquiring antigen. We now describe DCs with a different activation phenotype: cells having the strong antigen-presenting functions of mDCs and the antigen-acquiring functions of iDCs. We have described an antibody that binds the costimulatory molecule B7-DC and activates DCs. The resulting phenotype is distinct from iDCs or mDCs matured by using Toll-like receptor (TLR) agonists. Ability to take up antigen increases, while expression of B71/2 costimulatory and MHC molecules remains unchanged. DCs matured with TLR agonists and then superactivated through B7-DC exhibit a previously unrecognized phenotype. These DCs recover the ability to take up antigen, which is normally lost after treatment with TLR-3 and TLR-9 agonists, yet retain the high expression of costimulatory and MHC molecules and strong antigen-presenting functions of mDCs. Immunization using TLR agonists and B7-DC XAb (crosslinking antibody) together as adjuvant resulted in substantially increased cytolytic T cell responses, particularly when minimal peptide antigens were used. By stimulating DCs with two distinct activation signals, a previously unrecognized phenotype exhibiting augmented antigen-presenting functions was obtained.
C1 Mayo Clin, Coll Med, Dept Immunol, Rochester, MN 55905 USA.
RP Pease, LR (reprint author), Mayo Clin, Coll Med, Dept Immunol, 200 1st St SW, Rochester, MN 55905 USA.
EM pease.larry@mayo.edu
FU NCI NIH HHS [R01CA104996, R01 CA096859, P50 CA091956, R01CA80782, R01
   CA103921, R01CA103921, P50CA91956, R01 CA104996, R01 CA080782,
   R01CA096859]
CR Ahonen CL, 2004, J EXP MED, V199, P775, DOI 10.1084/jem.20031591
   ALEXANDER J, 1994, IMMUNITY, V1, P751, DOI 10.1016/S1074-7613(94)80017-0
   Banchereau J, 2000, ANNU REV IMMUNOL, V18, P767, DOI 10.1146/annurev.immunol.18.1.767
   Bhardwaj N, 1995, ADV EXP MED BIOL, V378, P375
   Blander JM, 2004, SCIENCE, V304, P1014, DOI 10.1126/science.1096158
   Davila E, 2000, J IMMUNOL, V165, P539, DOI 10.4049/jimmunol.165.1.539
   Davis HL, 1998, J IMMUNOL, V160, P870
   Gao JJ, 2001, J IMMUNOL, V166, P6855, DOI 10.4049/jimmunol.166.11.6855
   Garrett WS, 2000, CELL, V102, P325, DOI 10.1016/S0092-8674(00)00038-6
   Guermonprez P, 2002, ANNU REV IMMUNOL, V20, P621, DOI 10.1146/annurev.immunol.20.100301.064828
   Heath WR, 2004, IMMUNOL REV, V199, P9, DOI 10.1111/j.0105-2896.2004.00142.x
   Hertz CJ, 2001, J IMMUNOL, V166, P2444, DOI 10.4049/jimmunol.166.4.2444
   HOGQUIST KA, 1994, CELL, V76, P17, DOI 10.1016/0092-8674(94)90169-4
   INABA K, 1992, J EXP MED, V176, P1693, DOI 10.1084/jem.176.6.1693
   Iwasaki A, 2004, NAT IMMUNOL, V5, P987, DOI 10.1038/ni1112
   Latchman Y, 2001, NAT IMMUNOL, V2, P261, DOI 10.1038/85330
   Mellman I, 2001, CELL, V106, P255, DOI 10.1016/S0092-8674(01)00449-4
   Mendez-Fernandez YV, 2003, EUR J IMMUNOL, V33, P2501, DOI 10.1002/eji.200324007
   Michelsen KS, 2001, J BIOL CHEM, V276, P25680, DOI 10.1074/jbc.M011615200
   MURPHY KM, 1990, SCIENCE, V250, P1720, DOI 10.1126/science.2125367
   Nguyen LT, 2002, J EXP MED, V196, P1393, DOI 10.1084/jem.20021466
   Radhakrishnan S, 2004, J IMMUNOL, V173, P1360, DOI 10.4049/jimmunol.173.2.1360
   Radhakrishnan S, 2004, CANCER RES, V64, P4965, DOI 10.1158/0008-5472.CAN-03-3025
   Radhakrishnan S, 2003, J IMMUNOL, V170, P1830, DOI 10.4049/jimmunol.170.4.1830
   Shin T, 2003, J EXP MED, V198, P31, DOI 10.1084/jem.200030242
   Takeda K, 2004, SEMIN IMMUNOL, V16, P3, DOI 10.1016/j.smim.2003.10.003
   Takeda K, 2003, ANNU REV IMMUNOL, V21, P335, DOI 10.1146/annurev.immunol.21.120601.141126
   Tseng SY, 2001, J EXP MED, V193, P839, DOI 10.1084/jem.193.7.839
   Vremec D, 1997, J IMMUNOL, V159, P565
   Wang SD, 2003, J EXP MED, V197, P1083, DOI 10.1084/jem.20021752
   Watts TH, 2005, ANNU REV IMMUNOL, V23, P23, DOI 10.1146/annurev.immunol.23.021704.115839
   West MA, 2004, SCIENCE, V305, P1153, DOI 10.1126/science.1099153
   West MA, 2000, CURR BIOL, V10, P839, DOI 10.1016/S0960-9822(00)00595-9
   Whitmore MM, 2004, CANCER RES, V64, P5850, DOI 10.1158/0008-5472.CAN-04-0063
   Yanagawa Y, 2003, BLOOD, V101, P4923, DOI 10.1182/blood-2002-11-3474
NR 35
TC 36
Z9 41
U1 3
U2 11
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD AUG 9
PY 2005
VL 102
IS 32
BP 11438
EP 11443
DI 10.1073/pnas.0501420102
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 955UP
UT WOS:000231253400056
PM 16061819
OA Bronze, Green Published
DA 2018-12-27
ER

PT J
AU Sato, Y
   Kanoko, T
   Satoh, K
   Iwamoto, J
AF Sato, Y
   Kanoko, T
   Satoh, K
   Iwamoto, J
TI RETRACTED: The prevention of hip fracture with risedronate and
   ergocalciferol plus calcium supplementation in elderly women with
   Alzheimer disease: A randomized controlled trial (Retracted Article. See
   vol. 176, pg. 1256, 2016)
SO ARCHIVES OF INTERNAL MEDICINE
LA English
DT Article; Retracted Publication
ID VITAMIN-D; PSYCHIATRIC-ILLNESS; ETIDRONATE THERAPY; RISK-FACTORS; BONE
   MASS; DEMENTIA; OSTEOPOROSIS; POPULATION; SERVICES; DENSITY
AB Background: A high incidence of fractures, particularly of the hip, represents an important problem in patients with Alzheimer disease (AD), who are prone to falls and have osteoporosis. We previously found that deficiency of 25-hydroxyvitamin D and compensatory hyperparathyroidism cause reduced bone mineral density in female patients with AD. We address the possibility that treatment with risedronate sodium and ergocalciferol plus calcium supplementation may reduce the incidence of nonvertebral fractures in elderly women with AD.
   Methods: A total of 500 elderly women with AD were randomly assigned to daily treatment with 2.5 mg of risedronate sodium or a placebo, combined with 1000 IU of ergocalciferol and 1200 mg of elementary calcium, and followed up for 18 months.
   Results: At baseline, patients of both groups showed 25-hydroxyvitamin D deficiency with compensatory hyperparathyroidism. During the study period, bone mineral density in the risedronate group increased by 4.1% and decreased by 0.9% in the control group. Vertebral fractures occurred in 29 patients (24 hip fractures) in the control group and 8 patients (5 hip fractures) in the risedronate group. The relative risk in the risedronate group compared with the control group was 0.28 (95% confidence interval, 0.13-0.59).
   Conclusions: Elderly patients with AD hypovitaminosis D are at increased risk for hip fracture. Treatment with risedronate and ergocalciferol may be safe and effective in reducing the risk of a fracture in elderly patients with AD.
C1 Mitate Hosp, Dept Neurol, Tagawa 8260041, Japan.
   Hirosaki Univ, Sch Med, Dept Rehabil Med, Hirosaki, Aomori 036, Japan.
   Hirosaki Univ, Sch Med, Dept Vasc Biol, Hirosaki, Aomori 036, Japan.
   Keio Univ, Sch Med, Dept Sports Med, Tokyo, Japan.
RP Sato, Y (reprint author), Mitate Hosp, Dept Neurol, 3237 Yugeta, Tagawa 8260041, Japan.
EM y-sato@ktarn.or.jp
CR Bischoff-Ferrari HA, 2004, JAMA-J AM MED ASSOC, V291, P1999, DOI 10.1001/jama.291.16.1999
   BUCHNER DM, 1987, JAMA-J AM MED ASSOC, V257, P1492, DOI 10.1001/jama.257.11.1492
   BURNS A, 1989, PSYCHOL MED, V19, P383, DOI 10.1017/S0033291700012423
   CRANNEY A, 2003, COCHRANE DB SYST REV, V4
   FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6
   Fukunaga M, 2002, OSTEOPOROSIS INT, V13, P971, DOI 10.1007/s001980200135
   Holmes J, 2000, PSYCHOL MED, V30, P921, DOI 10.1017/S0033291799002548
   Johansson C, 1996, AGING CLIN EXP RES, V8, P189, DOI 10.1007/BF03339676
   KIPEN E, 1995, J AM GERIATR SOC, V43, P1088, DOI 10.1111/j.1532-5415.1995.tb07005.x
   KOMAR L, 1993, J AM GERIATR SOC, V41, P1057, DOI 10.1111/j.1532-5415.1993.tb06452.x
   MAHONEY F I, 1965, Md State Med J, V14, P61
   Matsueda M, 2000, Am J Orthop (Belle Mead NJ), V29, P691
   MATSUMOTO C, 1994, CALCIFIED TISSUE INT, V55, P324, DOI 10.1007/BF00299308
   McClung MR, 2001, NEW ENGL J MED, V344, P333, DOI 10.1056/NEJM200102013440503
   MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939
   MELTON LJ, 1994, J AM GERIATR SOC, V42, P614, DOI 10.1111/j.1532-5415.1994.tb06859.x
   Morrison RS, 2000, JAMA-J AM MED ASSOC, V284, P2448, DOI 10.1001/jama.284.19.2448-JLT1115-4-1
   Nightingale S, 2001, LANCET, V357, P1264, DOI 10.1016/S0140-6736(00)04421-4
   Nurmi I, 2003, ARCH ORTHOP TRAUM SU, V123, P551, DOI 10.1007/s00402-003-0583-z
   Ramnemark A, 1998, OSTEOPOROSIS INT, V8, P92, DOI 10.1007/s001980050053
   Reginster JY, 2000, OSTEOPOROSIS INT, V11, P83, DOI 10.1007/s001980050010
   Sato Y, 2000, J BONE MINER RES, V15, P2487, DOI 10.1359/jbmr.2000.15.12.2487
   Sato Y, 2004, J NEUROL SCI, V223, P107, DOI 10.1016/j.jns.2004.03.033
   Sato Y, 2004, AM J PHYS MED REHAB, V83, P298, DOI 10.1097/01.PHM.0000122877.28631.23
   Sato Y, 1998, BONE, V23, P555, DOI 10.1016/S8756-3282(98)00134-3
   Sato Y, 2001, J NEUROL SCI, V182, P89, DOI 10.1016/S0022-510X(00)00458-5
   van Beek ER, 2003, BONE, V33, P805, DOI 10.1016/j.bone.2003.07.007
   van Staa TP, 2002, BONE, V31, P508, DOI 10.1016/S8756-3282(02)00848-7
NR 28
TC 43
Z9 45
U1 3
U2 8
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0003-9926
EI 1538-3679
J9 ARCH INTERN MED
JI Arch. Intern. Med.
PD AUG 8
PY 2005
VL 165
IS 15
BP 1737
EP 1742
DI 10.1001/archinte.165.15.1737
PG 6
WC Medicine, General & Internal
SC General & Internal Medicine
GA 952VW
UT WOS:000231034800010
PM 16087821
OA Bronze
DA 2018-12-27
ER

PT J
AU Sato, Y
   Iwamoto, J
   Kanoko, T
   Satoh, K
AF Sato, Y
   Iwamoto, J
   Kanoko, T
   Satoh, K
TI RETRACTED: Risedronate sodium therapy for prevention of hip fracture in
   men 65 years or older after stroke (Retracted Article. See vol. 176, pg.
   1256, 2016)
SO ARCHIVES OF INTERNAL MEDICINE
LA English
DT Article; Retracted Publication
ID VITAMIN-D DEFICIENCY; ELDERLY-WOMEN; POSTMENOPAUSAL OSTEOPOROSIS;
   HEMIPLEGIC STROKE; HYPOVITAMINOSIS D; BONE MASS; RISK; IMMOBILIZATION;
   OSTEOPENIA; CALCIUM
AB Background: There is a high incidence of hip fractures in patients after hemiplegic stroke. Bone mineral density is decreased on the hemiplegic side in patients after stroke, correlating with the immobilization-induced bone resorption, the degree of paralysis, and hypovitaminosis D. The purpose of this study is to evaluate the effectiveness of risedronate sodium, an inhibitor of bone resorption, on osteoporosis and the risk of hip fractures in men 65 years or older after stroke.
   Methods: We conducted an 18-month randomized double-blind trial. Of 280 male patients 65 years or older who were poststroke, 140 received a daily dose of 2.5 mg risedronate sodium and the other 140 received placebo. incidence of hip fractures in the 2 groups was compared.
   Results: Ten patients sustained hip fractures in the placebo group, and 2 hip fractures occurred in the risedronate group. The relative risk of a hip fracture was 0.19 (95% confidence interval, 0.04-0.89). The number of patients needing the treatment was 16 (95% confidence interval, 9-32). Bone mineral density increased by 2.5% in the risedronate group and decreased by 3.5% in the placebo group (P < .001). Urinary deoxypyridinoline, a bone resorption marker, decreased by 58.7% in the risedronate group and by 37.2% in the placebo group.
   Conclusion: Treatment with risedronate increases bone mineral density and reduces hip fractures in elderly men who are poststroke.
C1 Mitate Hosp, Dept Neurol, Tagawa 8260041, Japan.
   Keio Univ, Sch Med, Dept Sport Med, Tokyo, Japan.
   Hirosaki Univ, Sch Med, Dept Rehabil Med, Hirosaki, Aomori 036, Japan.
   Hirosaki Univ, Sch Med, Dept Vasc Biol, Hirosaki, Aomori 036, Japan.
RP Sato, Y (reprint author), Mitate Hosp, Dept Neurol, 237 Yugeta, Tagawa 8260041, Japan.
EM y-sato@ktarn.or.jp
CR CHAPUY MC, 1992, NEW ENGL J MED, V327, P1637, DOI 10.1056/NEJM199212033272305
   CHIU KY, 1992, INJURY, V23, P297, DOI 10.1016/0020-1383(92)90171-N
   Dennis MS, 2002, STROKE, V33, P728, DOI 10.1161/hs0302.103621
   DERISQUEBOURG T, 1994, CALCIFIED TISSUE INT, V54, P461, DOI 10.1007/BF00334323
   GRISSO JA, 1991, NEW ENGL J MED, V324, P1326, DOI 10.1056/NEJM199105093241905
   Hagino H, 1999, BONE, V24, P265, DOI 10.1016/S8756-3282(98)00175-6
   Harris ST, 1999, JAMA-J AM MED ASSOC, V282, P1344, DOI 10.1001/jama.282.14.1344
   Ishihara C, 2000, SPINAL CORD, V38, P211, DOI 10.1038/sj.sc.3100989
   Kanis J, 2001, STROKE, V32, P702, DOI 10.1161/01.STR.32.3.702
   KOMAR L, 1993, J AM GERIATR SOC, V41, P1057, DOI 10.1111/j.1532-5415.1993.tb06452.x
   MAHONEY F I, 1965, Md State Med J, V14, P61
   MATSUMOTO C, 1994, CALCIFIED TISSUE INT, V55, P324, DOI 10.1007/BF00299308
   McClung MR, 2001, NEW ENGL J MED, V344, P333, DOI 10.1056/NEJM200102013440503
   MULLEY G, 1979, POSTGRAD MED J, V55, P264, DOI 10.1136/pgmj.55.642.264
   Nyberg L, 1996, STROKE, V27, P1821, DOI 10.1161/01.STR.27.10.1821
   Ramnemark A, 1998, OSTEOPOROSIS INT, V8, P92, DOI 10.1007/s001980050053
   Reginster JY, 2000, OSTEOPOROSIS INT, V11, P83, DOI 10.1007/s001980050010
   ROBINS SP, 1991, EUR J CLIN INVEST, V21, P310, DOI 10.1111/j.1365-2362.1991.tb01375.x
   Sato Y, 1998, J NEUROL SCI, V156, P205, DOI 10.1016/S0022-510X(98)00041-0
   Sato Y, 2001, STROKE, V32, P1673, DOI 10.1161/01.STR.32.7.1673
   Sato Y, 2000, J BONE MINER RES, V15, P2487, DOI 10.1359/jbmr.2000.15.12.2487
   Sato Y, 1999, J NEUROL NEUROSUR PS, V66, P64, DOI 10.1136/jnnp.66.1.64
   Sato Y, 2005, NEUROLOGY, V64, P811, DOI 10.1212/01.WNL.0000152871.65027.76
   Sato Y, 1998, BONE, V23, P291, DOI 10.1016/S8756-3282(98)00108-2
   Sato Y, 2000, J NEUROL SCI, V175, P135, DOI 10.1016/S0022-510X(00)00298-7
   Sato Y, 1999, AM J PHYS MED REHAB, V78, P457, DOI 10.1097/00002060-199909000-00008
   Sato Y, 1998, STROKE, V29, P1373, DOI 10.1161/01.STR.29.7.1373
   Sato Y, 1999, BONE, V24, P271, DOI 10.1016/S8756-3282(98)00185-9
   Sato Y, 1996, STROKE, V27, P2183, DOI 10.1161/01.STR.27.12.2183
   Scandinavian Stroke Study Group, 1985, STROKE, V16, P885
   SHAHAR E, 1995, STROKE, V26, P1
   Shiraki M, 2003, OSTEOPOROSIS INT, V14, P225, DOI 10.1007/s00198-002-1369-9
   van Beek ER, 2003, BONE, V33, P805, DOI 10.1016/j.bone.2003.07.007
NR 33
TC 106
Z9 111
U1 4
U2 6
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0003-9926
EI 1538-3679
J9 ARCH INTERN MED
JI Arch. Intern. Med.
PD AUG 8
PY 2005
VL 165
IS 15
BP 1743
EP 1748
DI 10.1001/archinte.165.15.1743
PG 6
WC Medicine, General & Internal
SC General & Internal Medicine
GA 952VW
UT WOS:000231034800011
PM 16087822
OA Bronze
DA 2018-12-27
ER

PT J
AU Choi, HJ
   Choi, JS
AF Choi, HJ
   Choi, JS
TI RETRACTED: Effects of morin pretreatment on the pharmacokinetics of
   diltiazem and its major metabolite, desacetyldiltiazem in rats
   (Retracted Article. See vol 29, pg 935, 2006)
SO ARCHIVES OF PHARMACAL RESEARCH
LA English
DT Article; Retracted Publication
DE diltiazem; desacetyldiltiazem; pharmacokinetics; morin; CYP3A4; rat
ID ENHANCED PACLITAXEL BIOAVAILABILITY; IN-VITRO;
   PHARMACOLOGICAL-PROPERTIES; MULTIDRUG-RESISTANCE; PLANT FLAVONOIDS;
   HUMAN LIVER; GLYCOPROTEIN; QUERCETIN; TRANSPORT; RABBITS
AB The purpose of this study was to investigate the effect of morin, a flavonoid, on the pharmacokinetics of diltiazem and one of its metabolites, desacetyldiltiazem in rats. Pharmacokinetic parameters of diltiazem and desacetyldiltiazem were determined after oral administration of diltiazem (15 mg/kg) in rats pretreated with morin (1.5, 7.5, and 15 mg/kg). Compared with the control group (given diltiazem alone), pretreatment of morin significantly increased the absorption rate constant (K-a) and peak concentration (C-max) of diltiazem (p < 0.05, p < 0.01). Area under the plasma concentration-time curve (AUC) of diltiazem in rats pretreated with morin were significantly higher than that in the control group (p < 0.05, p < 0.01), hence the absolute bioavailability (AB%) of diltiazem was significantly higher than that of the control group (p < 0.05, p < 0.01). Relative bioavailability (RB%) of diltiazem in rats pretreated with morin was increased by 1.36- to 2.03-fold. The terminal half-life (t(1/2)) and time to reach the peak concentration (T-max) of diltiazem were not altered significantly with morin pretreatment. AUC of desacetyldiltiazem was increased significantly (p < 0.05) in rats pretreated with morin at doses of 7.5 and 15 mg/kg, but metabolite-parent ratio (MR) of desacetyldiltiazem was decreased significantly (p < 0.05), implying that pretreatment of morin could be effective to inhibit the CYP 3A4-mediated metabolism of diltiazem. There were no apparent changes of T-max and t(1/2) of desacetyldiltiazem with morin pretreatment. Collectively, the pretreatment of morin significantly altered pharmacokinetics of diltiazem, which can be attributed to increased intestinal absorption as well as reduced first-pass metabolism. Based on these results, dose modification should be taken into consideration when diltiazem is used concomitantly with morin or morin-containing dietary supplements in clinical setting.
C1 Chosun Univ, Coll Pharm, Kwangju 501759, South Korea.
RP Choi, JS (reprint author), Chosun Univ, Coll Pharm, 375 Seosuk Dong, Kwangju 501759, South Korea.
EM jsachoi@chosun.ac.kr
CR BHATTACHARYA RK, 1988, CANCER LETT, V39, P85, DOI 10.1016/0304-3835(88)90043-2
   BUCKLEY MMT, 1990, DRUGS, V39, P757, DOI 10.2165/00003495-199039050-00009
   CHAFFMAN M, 1985, DRUGS, V29, P387, DOI 10.2165/00003495-198529050-00001
   Choi JS, 2005, INT J PHARM, V297, P1, DOI 10.1016/j.ijpharm.2004.12.004
   Choi JS, 2005, INT J PHARM, V292, P149, DOI 10.1016/j.ijpharm.2004.11.031
   Choi JS, 2004, J PHARM PHARMACOL, V56, P1537, DOI 10.1211/0022357044814
   Choi JS, 2004, AM J HEALTH-SYST PH, V61, P2406
   Choi JS, 2004, EUR J PHARM BIOPHARM, V57, P313, DOI 10.1016/j.ejpb.2003.11.002
   Dixon RA, 1999, TRENDS PLANT SCI, V4, P394, DOI 10.1016/S1360-1385(99)01471-5
   Dupuy J, 2003, VET PARASITOL, V112, P337, DOI 10.1016/S0304-4017(03)00008-6
   Fang SH, 2003, LIFE SCI, V74, P743, DOI 10.1016/j.lfs.2003.07.017
   Fraile LJ, 1996, PHARMACEUT RES, V13, P1875, DOI 10.1023/A:1016049628453
   FRANCIS AR, 1989, CARCINOGENESIS, V10, P1953, DOI 10.1093/carcin/10.10.1953
   GOEBEL KJ, 1985, J CHROMATOGR, V345, P355, DOI 10.1016/0378-4347(85)80172-9
   GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125
   HAN HK, 2005, UNPUB INT J PHARM
   HANASAKI Y, 1994, FREE RADICAL BIO MED, V16, P845, DOI 10.1016/0891-5849(94)90202-X
   Hodek P, 2002, CHEM-BIOL INTERACT, V139, P1, DOI 10.1016/S0009-2797(01)00285-X
   HOMSY W, 1995, PHARMACEUT RES, V12, P609, DOI 10.1023/A:1016226601988
   HOMSY W, 1995, PHARMACEUT RES, V12, P1722, DOI 10.1023/A:1016217822770
   Kim HK, 1999, BIOCHEM PHARMACOL, V58, P759, DOI 10.1016/S0006-2952(99)00160-4
   KIM HS, 2005, KOR J CLIN PHARM, V15, P55
   Kim Hyuong Joong, 2005, Yakhak Hoeji, V49, P230
   Kok LDS, 2000, LIFE SCI, V67, P91, DOI 10.1016/S0024-3205(00)00605-6
   KOLARS JC, 1992, GASTROENTEROLOGY, V102, P1186
   Lefebvre M, 1996, PHARMACEUT RES, V13, P124, DOI 10.1023/A:1016097805003
   Molden E, 2000, EUR J CLIN PHARMACOL, V56, P575, DOI 10.1007/s002280000182
   Molden E, 2000, DRUG METAB DISPOS, V28, P107
   NA JH, 2005, J KOR PHARM SCI, V35, P101
   Nguyen H, 2003, J PHARM SCI-US, V92, P250, DOI 10.1002/jps10283
   PICHARD L, 1990, DRUG METAB DISPOS, V18, P711
   POOL PE, 1996, CARDIOVASCULAR DRUG, P931
   RAMANATHAN L, 1994, BIOL TRACE ELEM RES, V40, P59, DOI 10.1007/BF02916821
   Raso GM, 2001, LIFE SCI, V68, P921, DOI 10.1016/S0024-3205(00)00999-1
   ROCCI ML, 1983, COMPUT PROG BIOMED, V16, P203, DOI 10.1016/0010-468X(83)90082-X
   SAEKI T, 1993, FEBS LETT, V324, P99, DOI 10.1016/0014-5793(93)81540-G
   Vaclavikova R, 2003, N-S ARCH PHARMACOL, V368, P200, DOI 10.1007/s00210-003-0781-9
   Wacher VJ, 2001, ADV DRUG DELIVER REV, V46, P89, DOI 10.1016/S0169-409X(00)00126-5
   WATKINS PB, 1987, J CLIN INVEST, V80, P1029, DOI 10.1172/JCI113156
   WEIR MR, 1995, J CLIN PHARMACOL, V35, P220, DOI 10.1002/j.1552-4604.1995.tb04051.x
   Yeung PKF, 1998, J PHARM PHARMACOL, V50, P1247, DOI 10.1111/j.2042-7158.1998.tb03341.x
   YUSA K, 1989, CANCER RES, V49, P5002
   Zhang SH, 2003, J PHARMACOL EXP THER, V304, P1258, DOI 10.1124/jpet.102.044412
NR 43
TC 5
Z9 5
U1 3
U2 10
PU PHARMACEUTICAL SOC KOREA
PI SEOUL
PA 1489-3 SUHCHO-DONG, SUHCHO-KU, SEOUL 137-071, SOUTH KOREA
SN 0253-6269
EI 1976-3786
J9 ARCH PHARM RES
JI Arch. Pharm. Res.
PD AUG
PY 2005
VL 28
IS 8
BP 970
EP 976
DI 10.1007/BF02973885
PG 7
WC Chemistry, Medicinal; Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 960FI
UT WOS:000231575200016
PM 16178425
DA 2018-12-27
ER

PT J
AU Rini, BI
   Sosman, JA
   Motzer, RJ
AF Rini, BI
   Sosman, JA
   Motzer, RJ
TI RETRACTED: Therapy targeted at vascular endothelial growth factor in
   metastatic renal cell carcinoma: biology, clinical results and future
   development (Retracted article. See vol. 109, pg. E43, 2012)
SO BJU INTERNATIONAL
LA English
DT Article; Retracted Publication
DE RCC; VEGF; VHL; bevacizumab; SU11248; BAY 43-9006
ID TUMOR-SUPPRESSOR PROTEIN; INTERFERON-ALPHA; ANTITUMOR-ACTIVITY; KINASE
   INHIBITOR; RANDOMIZED-TRIAL; FACTOR ANTIBODY; IN-VIVO; ANGIOGENESIS;
   CANCER; GENE
C1 Cleveland Clin Fdn, Taussig Canc Ctr, Cleveland, OH 44195 USA.
   Vanderbilt Ingram Canc Ctr, Nashville, TN USA.
   Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
RP Rini, BI (reprint author), 9500 Euclid Ave,Desk R35, Cleveland, OH 44195 USA.
EM rinib2@ccf.org
OI Motzer, Robert/0000-0001-6925-2327
CR Benjamin LE, 1999, J CLIN INVEST, V103, P159, DOI 10.1172/JCI5028
   Bukowski R M, 2001, Semin Urol Oncol, V19, P148
   Cockman ME, 2000, J BIOL CHEM, V275, P25733, DOI 10.1074/jbc.M002740200
   de Paulsen N, 2001, P NATL ACAD SCI USA, V98, P1387, DOI 10.1073/pnas.031587498
   Dvorak HF, 2002, J CLIN ONCOL, V20, P4368, DOI 10.1200/JCO.2002.10.088
   DVORAK HF, 1979, J IMMUNOL, V122, P166
   DVORAK HF, 1995, AM J PATHOL, V146, P1029
   Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4
   Flanigan RC, 2001, NEW ENGL J MED, V345, P1655, DOI 10.1056/NEJMoa003013
   Friberg G, 2004, J CLIN ONCOL, V22, p140S
   Gabrilovich DI, 1996, NAT MED, V2, P1096, DOI 10.1038/nm1096-1096
   Gabrilovich DI, 1999, CLIN CANCER RES, V5, P2963
   Gnarra JR, 1996, P NATL ACAD SCI USA, V93, P10589, DOI 10.1073/pnas.93.20.10589
   Gunaratnam L, 2003, J BIOL CHEM, V278, P44966, DOI 10.1074/jbc.M305502200
   Hurwitz HI, 2005, J CLIN ONCOL, V23, P3502, DOI 10.1200/JCO.2005.10.017
   Iliopoulos O, 1996, P NATL ACAD SCI USA, V93, P10595, DOI 10.1073/pnas.93.20.10595
   KIBEL A, 1995, SCIENCE, V269, P1444, DOI 10.1126/science.7660130
   Knebelmann B, 1998, CANCER RES, V58, P226
   KOUREMBANAS S, 1990, J CLIN INVEST, V86, P670, DOI 10.1172/JCI114759
   LATIF F, 1993, SCIENCE, V260, P1317, DOI 10.1126/science.8493574
   Lyons JF, 2001, ENDOCR-RELAT CANCER, V8, P219, DOI 10.1677/erc.0.0080219
   Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459
   Mendel DB, 2003, CLIN CANCER RES, V9, P327
   Mickisch GHJ, 2001, LANCET, V358, P966, DOI 10.1016/S0140-6736(01)06103-7
   Motzer RJ, 2003, INVEST NEW DRUG, V21, P99, DOI 10.1023/A:1022928612511
   Motzer RJ, 2002, J CLIN ONCOL, V20, P289, DOI 10.1200/JCO.20.1.289
   MOTZER RJ, 2004, J CLIN ONCOL, V23, pA4500
   Presta LG, 1997, CANCER RES, V57, P4593
   Rini BI, 2004, CLIN CANCER RES, V10, P2584, DOI 10.1158/1078-0432.CCR-03-0605
   Rini BI, 2005, J CLIN ONCOL, V23, P1028, DOI 10.1200/JCO.2005.01.186
   Viloria-Petit A, 2001, CANCER RES, V61, P5090
   Watanabe Y, 1997, ONCOGENE, V14, P2025, DOI 10.1038/sj.onc.1201033
   Wilhelm SM, 2004, CANCER RES, V64, P7099, DOI 10.1158/0008-5472.CAN-04-1443
   Yang JC, 2003, NEW ENGL J MED, V349, P427, DOI 10.1056/NEJMoa021491
NR 34
TC 39
Z9 43
U1 3
U2 11
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1464-4096
EI 1464-410X
J9 BJU INT
JI BJU Int.
PD AUG
PY 2005
VL 96
IS 3
BP 286
EP 290
DI 10.1111/j.1464-410X.2005.05616.x
PG 5
WC Urology & Nephrology
SC Urology & Nephrology
GA 948OQ
UT WOS:000230726000012
PM 16042715
OA Bronze
DA 2018-12-27
ER

PT J
AU Abdelkefi, A
   Torjman, L
   Ben Romdhane, N
   Ladeb, S
   El Omri, H
   Ben Othman, T
   Elloumi, M
   Bellaj, H
   Lakhal, A
   Jeddi, R
   Aissaoui, L
   Saad, A
   Hsairi, M
   Boukef, K
   Dellagi, K
   Ben Abdeladhim, A
AF Abdelkefi, A
   Torjman, L
   Ben Romdhane, N
   Ladeb, S
   El Omri, H
   Ben Othman, T
   Elloumi, M
   Bellaj, H
   Lakhal, A
   Jeddi, R
   Aissaoui, L
   Saad, A
   Hsairi, M
   Boukef, K
   Dellagi, K
   Ben Abdeladhim, A
CA Tunisian Multiple Myeloma Study Gr
TI RETRACTED: First-line thalidomide-dexamethasone therapy in preparation
   for autologous stem cell transplantation in young patients (< 61 years)
   with symptomatic multiple myeloma (Retracted Article. See vol 43, pg
   893, 2009)
SO BONE MARROW TRANSPLANTATION
LA English
DT Article; Retracted Publication
DE multiple myeloma; thalidomide; dexamethasone; stem cell transplantation;
   engraftment
ID BONE-MARROW ANGIOGENESIS; COMBINATION; CHEMOTHERAPY; MANAGEMENT;
   COLLECTION; PHASE-2; SINGLE; TRIAL
AB Thalidomide - dexamethasone therapy was given in patients (<61 years) with previously untreated symptomatic multiple myeloma. The aim of this study was to assess the efficacy and toxicity of this combination as first-line therapy, and to determine its effect on stem cell collection and engraftment. During first-line therapy, thalidomide and dexamethasone were administered for 75 days ( 200 mg/day) and 3 months, respectively. The monthly dose of dexamethasone was 20 mg/m(2)/day for 4 days, with cycles repeated on days 9 to 12 and 17 to 20 on the first and the third month of therapy. After first-line therapy, a collection of peripheral blood stem cells (PBSC) was performed. Between May 2003 and September 2004, 60 patients were included. On an intent-to-treat basis, the overall response (>= partial response) rate was 74%, including 24% of patients who obtained a complete remission. Grade 3 - 4 toxicities consisted of infections (12%), deep-vein thrombosis (3%), constipation (5%), and neuropathy ( 5%). A total of 58 patients (96%) proceeded to PBSC mobilisation and yielded a median number of 8 x 10(6) CD34+ cells/kg. First-line thalidomide - dexamethasone therapy is effective and relatively well tolerated in young patients with symptomatic multiple myeloma. This combination does not affect PBSC mobilisation.
C1 Ctr Natl Greffe Moelle Osseuse Tunis, Tunis, Tunisia.
   Hop La Rabta, Tunis, Tunisia.
   Hop Farhat Hached, Sousse, Tunisia.
   Hop Hedi Chaker, Sfax, Tunisia.
   Hop Aziza Othmana, Tunis, Tunisia.
   Hop Farhat Hached, Lab Cytogenet, Sousse, Tunisia.
   Inst Natl Sante Publ, Tunis, Tunisia.
   Ctr Natl Transfus Sanguine, Tunis, Tunisia.
   Inst Pasteur Tunis, Tunis, Tunisia.
RP Abdelkefi, A (reprint author), Ctr Natl Greffe Moelle Osseuse Tunis, Rue Jebel Lakhdar,1006 Bab Saadoun, Tunis, Tunisia.
EM aabdelkefi@yahoo.fr
CR ABDELKEFI A, 2005, HAEMA, V8, P118
   ALEXANIAN R, 1990, AM J HEMATOL, V33, P86, DOI 10.1002/ajh.2830330203
   Anagnostopoulos A, 2003, BRIT J HAEMATOL, V121, P768, DOI 10.1046/j.1365-2141.2003.04345.x
   Attal M, 2003, NEW ENGL J MED, V349, P2495, DOI 10.1056/NEJMoa032290
   Attal M, 1996, NEW ENGL J MED, V335, P91, DOI 10.1056/NEJM199607113350204
   Barlogie B, 2001, BLOOD, V98, P492, DOI 10.1182/blood.V98.2.492
   Blade Joan, 1998, British Journal of Haematology, V102, P1115, DOI 10.1046/j.1365-2141.1998.00930.x
   Cavo M, 2004, HAEMATOLOGICA, V89, P826
   Cavo M, 2002, HAEMATOLOGICA, V87, P934
   Child JA, 2003, NEW ENGL J MED, V348, P1875, DOI 10.1056/NEJMoa022340
   DAMATO RJ, 1994, P NATL ACAD SCI USA, V91, P4082, DOI 10.1073/pnas.91.9.4082
   Dimopoulos MA, 2001, ANN ONCOL, V12, P991, DOI 10.1023/A:1011132808904
   Gertz MA, 1997, BONE MARROW TRANSPL, V20, P375, DOI 10.1038/sj.bmt.1700897
   Ghobrial IM, 2003, BONE MARROW TRANSPL, V32, P587, DOI 10.1038/sj.bmt.1704173
   Goldschmidt H, 1997, BRIT J HAEMATOL, V98, P736, DOI 10.1046/j.1365-2141.1997.2783095.x
   Juliusson G, 2000, BRIT J HAEMATOL, V109, P89, DOI 10.1046/j.1365-2141.2000.01983.x
   Kumar S, 2004, LEUKEMIA, V18, P624, DOI 10.1038/sj.leu.2403285
   Kyle RA, 2004, NEW ENGL J MED, V351, P1860, DOI 10.1056/NEJMra041875
   Mileshkin L, 2003, BLOOD, V102, P69, DOI 10.1182/blood-2002-09-2846
   Prince HM, 1996, BRIT J HAEMATOL, V93, P142, DOI 10.1046/j.1365-2141.1996.448987.x
   Rajkumar SV, 2002, J CLIN ONCOL, V20, P4319, DOI 10.1200/JCO.2002.02.116
   Rajkumar SV, 1999, LEUKEMIA, V13, P469, DOI 10.1038/sj.leu.2401336
   Rajkumar SV, 2001, SEMIN ONCOL, V28, P560, DOI 10.1053/sonc.2001.28603
   Singhal S, 1999, NEW ENGL J MED, V341, P1565, DOI 10.1056/NEJM199911183412102
   Smith A, 2001, BRIT J HAEMATOL, V115, P522
   Stirling D, 2001, SEMIN ONCOL, V28, P602, DOI 10.1016/S0093-7754(01)90032-6
   VACCA A, 1994, BRIT J HAEMATOL, V87, P503, DOI 10.1111/j.1365-2141.1994.tb08304.x
   Weber D, 2003, J CLIN ONCOL, V21, P16, DOI 10.1200/JCO.2003.03.139
   YACOUBAGHA I, 2002, HEMATOL J, V3, P185
   Zangari M, 2002, BLOOD COAGUL FIBRIN, V13, P187, DOI 10.1097/00001721-200204000-00003
NR 30
TC 32
Z9 33
U1 2
U2 7
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0268-3369
J9 BONE MARROW TRANSPL
JI Bone Marrow Transplant.
PD AUG
PY 2005
VL 36
IS 3
BP 193
EP 198
DI 10.1038/sj.bmt.1705050
PG 6
WC Biophysics; Oncology; Hematology; Immunology; Transplantation
SC Biophysics; Oncology; Hematology; Immunology; Transplantation
GA 946QO
UT WOS:000230587400002
PM 15968290
OA Bronze
DA 2018-12-27
ER

PT J
AU Kramerova, I
   Kudryashova, E
   Venkatraman, G
   Spencer, MJ
AF Kramerova, I
   Kudryashova, E
   Venkatraman, G
   Spencer, MJ
TI RETRACTED: Calpain 3 participates in sarcomere remodeling by acting
   upstream of the ubiquitin-proteasome pathway (Retracted Article. See vol
   16, pg 1006, 2007)
SO HUMAN MOLECULAR GENETICS
LA English
DT Article; Retracted Publication
ID MUSCLE-SPECIFIC CALPAIN; RAT SOLEUS MUSCLE; SKELETAL-MUSCLE;
   MUSCULAR-DYSTROPHY; CALPASTATIN TRANSGENE; IN-VIVO; ATROPHY; EXPRESSION;
   PROTEINS; P94
AB Mutations in the non-lysosomal cysteine protease calpain 3 cause limb-girdle muscular dystrophy type 2A (LGMD2A). Our previous studies of the calpain 3 knockout mouse (C3KO) suggested a role for calpain 3 in sarcomere formation and remodeling. Calpain 3 may mediate remodeling by cleavage and release of myofibrillar proteins, targeting them for ubiquitination and proteasomal degradation. Loss of proper protein turnover may be the basis for this muscle disease. To test this hypothesis in vivo, we used an experimental model of hindlimb unloading and reloading that has been shown to induce sarcomere remodeling. We showed that the rate of atrophy and especially the rate of growth are decreased in C3KO muscles under conditions promoting sarcomere remodeling. In wild-type mice, an elevated level of ubiquitinated proteins was observed during muscle reloading, which is presumably necessary to remove atrophy-specific and damaged proteins. This increase in ubiquitination correlated with an increase in calpain 3 expression. C3KO muscles did not show any increase in ubiquitination at the reloading stage, suggesting that calpain 3 is necessary for ubiquitination and that it acts upstream of the ubiquitination machinery. We found upregulation of heat shock proteins in C3KO muscles following challenge with a physiological condition that requires highly increased protein degradation. Furthermore, old C3KO mice show evidence of insoluble protein aggregate formation in skeletal muscles. These studies suggest that accumulation of aged and damaged proteins can lead to cellular toxicity and a cell stress response in C3KO muscles, and that these characteristics are pathological features of LGMD2A.
C1 Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol & Pediat, Los Angeles, CA 90095 USA.
   Univ Calif Los Angeles, Duchenne Muscular Dystrophy Res Ctr, Los Angeles, CA 90095 USA.
RP Spencer, MJ (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol & Pediat, 635 Charles E Young Dr S, Los Angeles, CA 90095 USA.
EM mspencer@mednet.ucla.edu
OI Kudryashova, Elena/0000-0002-1646-1229
FU NIAMS NIH HHS [R01 AR048177-08, AR48177, R01 AR048177]
CR Alzghoul MB, 2004, FASEB J, V18, P221, DOI 10.1096/fj.03-0293fje
   Baldwin KM, 2002, AM J PHYS MED REHAB, V81, pS40, DOI 10.1097/01.PHM.0000029723.36419.0D
   BHATTACHARYYA J, 1991, CIRC SHOCK, V35, P117
   Duguez S, 2003, AM J PHYSIOL-ENDOC M, V285, pE206, DOI 10.1152/ajpendo.00331.2002
   Feasson L, 2002, J PHYSIOL-LONDON, V543, P297, DOI 10.1113/jphysiol.2002.018689
   Fischer DR, 2001, SHOCK, V15, P200, DOI 10.1097/00024382-200115030-00007
   Garcia-Mata R, 2002, TRAFFIC, V3, P388, DOI 10.1034/j.1600-0854.2002.30602.x
   Glass DJ, 2003, NAT CELL BIOL, V5, P87, DOI 10.1038/ncb0203-87
   Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001
   Goldberg AL, 2003, NATURE, V426, P895, DOI 10.1038/nature02263
   Goll DE, 2003, PHYSIOL REV, V83, P731, DOI 10.1152/physrev.00029.2002
   Gregorio CC, 1999, CURR OPIN CELL BIOL, V11, P18, DOI 10.1016/S0955-0674(99)80003-9
   Hainsey TA, 2003, NEUROMUSCULAR DISORD, V13, P294, DOI 10.1016/S0960-8966(02)00286-9
   Hasselgren PO, 2001, ANN SURG, V233, P9, DOI 10.1097/00000658-200101000-00003
   Hornberger TA, 2004, P NUTR SOC, V63, P331, DOI 10.1079/PNS2004357
   Jagoe RT, 2001, CURR OPIN CLIN NUTR, V4, P183, DOI 10.1097/00075197-200105000-00003
   Johnston JA, 1998, J CELL BIOL, V143, P1883, DOI 10.1083/jcb.143.7.1883
   Kato K, 2002, FASEB J, V16, P1432, DOI 10.1096/fj.02-0129fje.
   Kinbara K, 1997, ARCH BIOCHEM BIOPHYS, V342, P99, DOI 10.1006/abbi.1997.0108
   Kinbara K, 1998, BIOCHEM J, V335, P589, DOI 10.1042/bj3350589
   Kramerova I, 2004, HUM MOL GENET, V13, P1373, DOI 10.1093/hmg/ddh153
   KRIPPENDORF BB, 1993, MUSCLE NERVE, V16, P99, DOI 10.1002/mus.880160116
   Ordway GA, 2000, J APPL PHYSIOL, V88, P1134
   RICHARD I, 1995, CELL, V81, P27, DOI 10.1016/0092-8674(95)90368-2
   Richard I, 2000, J CELL BIOL, V151, P1583, DOI 10.1083/jcb.151.7.1583
   Solomon V, 1996, J BIOL CHEM, V271, P26690, DOI 10.1074/jbc.271.43.26690
   Sorimachi H, 1995, J BIOL CHEM, V270, P31158, DOI 10.1074/jbc.270.52.31158
   Spencer MJ, 2002, HUM MOL GENET, V11, P2645, DOI 10.1093/hmg/11.21.2645
   Stitt TN, 2004, MOL CELL, V14, P395, DOI 10.1016/S1097-2765(04)00211-4
   Straub V, 1997, J CELL BIOL, V139, P375, DOI 10.1083/jcb.139.2.375
   Taillandier D, 2004, P NUTR SOC, V63, P357, DOI [10.1079/PAR2004358, 10.1079/PNS2004358]
   Taillandier D, 2003, INT J BIOCHEM CELL B, V35, P665, DOI 10.1016/S1357-2725(03)00004-9
   Taillandier D, 1996, BIOCHEM J, V316, P65, DOI 10.1042/bj3160065
   THOMASON DB, 1990, J APPL PHYSIOL, V68, P1
   Tidball JG, 2002, J PHYSIOL-LONDON, V545, P819, DOI 10.1113/jphysiol.2002.024935
   Wei W, 2005, AM J PHYSIOL-REG I, V288, pR580, DOI 10.1152/ajpregu.00341.2004
NR 36
TC 83
Z9 92
U1 2
U2 8
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0964-6906
EI 1460-2083
J9 HUM MOL GENET
JI Hum. Mol. Genet.
PD AUG 1
PY 2005
VL 14
IS 15
BP 2125
EP 2134
DI 10.1093/hmg/ddi217
PG 10
WC Biochemistry & Molecular Biology; Genetics & Heredity
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 948OG
UT WOS:000230725000004
PM 15961411
OA Bronze
DA 2018-12-27
ER

PT J
AU Sato, Y
   Iwamoto, J
   Kanoko, T
   Satoh, K
AF Sato, Y
   Iwamoto, J
   Kanoko, T
   Satoh, K
TI RETRACTED: Amelioration of osteoporosis and hypovitaminosis D by
   sunlight exposure in hospitalized, elderly women with Alzheimer's
   disease: A randomized controlled trial (Retracted article. See vol. 30,
   pg. 2328, 2015)
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article; Retracted Publication
DE Alzheimer's disease; hip fracture; osteoporosis; sunlight exposure;
   vitamin D
ID VITAMIN-D; HIP FRACTURE; PSYCHIATRIC-ILLNESS; OLDER-ADULTS; BONE MASS;
   CALCIUM; 25-HYDROXYVITAMIN-D; POPULATION; DEMENTIA; DENSITY
AB Introduction: A high incidence of fractures, particularly of the hip, represents an important problem in patients with Alzheimer's disease (AD), who are prone to falls and have osteoporosis. We previously showed that 25-hydroxyvitamin D (25-OHD) deficiency caused by sunlight deprivation with compensatory hyperparathyroidism causes reduced BMD in elderly women with AD. This study was undertaken to address the possibility that sunlight exposure with calcium supplementation may maintain BMD and reduce the incidence of nonvertebral fractures in elderly women with AD.
   Materials and Methods: In a random and prospective study, AD patients were assigned to regular sunlight exposure (n = 132) or sunlight deprivation (n = 132) and followed for 1 year. BMD of the second metacarpal bone was measured using a computed X-ray densitometer (CXD). The CXD method measures BMD and cortical thickness at the middle of the second metacarpal bone on a radiogram of the hand and an aluminum step wedge as a standard (20 steps; 1 mm/step).
   Results and Conclusion: At baseline, average hospitalization period was 1.7 years in both groups, and activity of daily living (ADL) was decreased. Patients of both groups showed vitamin D deficiency caused by sunlight deprivation and decreased dietary intake of vitamin D with compensatory hyperparathyroidism. The exposed group patients were exposed to sunlight (3615 minutes/year). BMD increased by 2.7% in the sunlight-exposed group and decreased by 5.6% in the sunlight-deprived group (p < 0.0001). Serum 25-OHD level increased from 24.0 to 52.2 nM in the sunlight-exposed group. Eleven patients sustained fractures in the sunlight-deprived group, and three fractures occurred among the sunlight-exposed group (p = 0.0362; odds ratio = 3.7). Sunlight exposure can increase the BMD of vitamin D-deficient bone by increasing 25-OHD concentration and lead to the prevention of nonvertebral fractures.
C1 Mitate Hosp, Dept Neurol, Tagawa 8260041, Japan.
   Keio Univ, Sch Med, Dept Sport Med, Tokyo, Japan.
   Hirosaki Univ, Sch Med, Dept Rehabil Med, Hirosaki, Aomori 036, Japan.
   Hirosaki Univ, Sch Med, Dept Vasc Biol, Hirosaki, Aomori 036, Japan.
RP Sato, Y (reprint author), Mitate Hosp, Dept Neurol, 3237 Yugeta, Tagawa 8260041, Japan.
EM y-sato@ktarn.or.jp
CR BEADLE PC, 1977, BRIT J DERMATOL, V97, P585
   Bischoff-Ferrari HA, 2004, AM J MED, V116, P634, DOI 10.1016/j.amjmed.2003.12.029
   Bischoff-Ferrari HA, 2004, JAMA-J AM MED ASSOC, V291, P1999, DOI 10.1001/jama.291.16.1999
   BOUILLON R, 1984, CLIN CHEM, V30, P1731
   BUCHNER DM, 1987, JAMA-J AM MED ASSOC, V257, P1492, DOI 10.1001/jama.257.11.1492
   DawsonHughes B, 1997, NEW ENGL J MED, V337, P670, DOI 10.1056/NEJM199709043371003
   DERISQUEBOURG T, 1994, CALCIFIED TISSUE INT, V54, P461, DOI 10.1007/BF00334323
   FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6
   Heaney RP, 2003, J AM COLL NUTR, V22, P142, DOI 10.1080/07315724.2003.10719287
   Holmes J, 2000, PSYCHOL MED, V30, P921, DOI 10.1017/S0033291799002548
   Johansson C, 1996, AGING CLIN EXP RES, V8, P189, DOI 10.1007/BF03339676
   KIPEN E, 1995, J AM GERIATR SOC, V43, P1088, DOI 10.1111/j.1532-5415.1995.tb07005.x
   KOMAR L, 1993, J AM GERIATR SOC, V41, P1057, DOI 10.1111/j.1532-5415.1993.tb06452.x
   LESTER E, 1980, SCAND J CLIN LAB INV, V40, P145, DOI 10.3109/00365518009093017
   MACLAUGHLIN J, 1985, J CLIN INVEST, V76, P1536, DOI 10.1172/JCI112134
   MAHONEY F I, 1965, Md State Med J, V14, P61
   Matsueda M, 2000, Am J Orthop (Belle Mead NJ), V29, P691
   MATSUMOTO C, 1994, CALCIFIED TISSUE INT, V55, P324, DOI 10.1007/BF00299308
   MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939
   *MED RES COUNC UK, 1978, AUIDS EX PER NERV SY
   Meier C, 2004, J BONE MINER RES, V19, P1221, DOI 10.1359/JBMR.040511
   MELTON LJ, 1994, J AM GERIATR SOC, V42, P614, DOI 10.1111/j.1532-5415.1994.tb06859.x
   Morrison RS, 2000, JAMA-J AM MED ASSOC, V284, P2448, DOI 10.1001/jama.284.19.2448-JLT1115-4-1
   Nightingale S, 2001, LANCET, V357, P1264, DOI 10.1016/S0140-6736(00)04421-4
   Ramnemark A, 1998, OSTEOPOROSIS INT, V8, P92, DOI 10.1007/s001980050053
   ROBINS SP, 1991, EUR J CLIN INVEST, V21, P310, DOI 10.1111/j.1365-2362.1991.tb01375.x
   Sato Y, 2004, J NEUROL SCI, V223, P107, DOI 10.1016/j.jns.2004.03.033
   Sato Y, 2004, AM J PHYS MED REHAB, V83, P298, DOI 10.1097/01.PHM.0000122877.28631.23
   Sato Y, 1998, BONE, V23, P555, DOI 10.1016/S8756-3282(98)00134-3
   Sato Y, 2003, NEUROLOGY, V61, P338, DOI 10.1212/01.WNL.0000078892.24356.90
   Smith GE, 1998, NEUROLOGY, V50, P355, DOI 10.1212/WNL.50.2.355
   van Staa TP, 2002, BONE, V31, P508, DOI 10.1016/S8756-3282(02)00848-7
   Vieth R, 2003, J CLIN ENDOCR METAB, V88, P185, DOI 10.1210/jc.2002-021064
NR 33
TC 58
Z9 61
U1 2
U2 12
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0884-0431
EI 1523-4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD AUG
PY 2005
VL 20
IS 8
BP 1327
EP 1333
DI 10.1359/JBMR.050402
PG 7
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 948KE
UT WOS:000230713900003
PM 16007329
OA Bronze
DA 2018-12-27
ER

PT J
AU Malagon, I
   Onkenhout, W
   Klok, M
   Linthorst, L
   van der Poel, PFH
   Bovill, JG
   Hazekamp, MG
AF Malagon, I
   Onkenhout, W
   Klok, M
   Linthorst, L
   van der Poel, PFH
   Bovill, JG
   Hazekamp, MG
TI RETRACTED: Dexamethasone reduces gut permeability in pediatric cardiac
   surgery (Retracted Article. See vol 134, pg 771, 2007)
SO JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY
LA English
DT Article; Retracted Publication
ID SYSTEMIC INFLAMMATORY RESPONSE; CARDIOPULMONARY BYPASS; INTESTINAL
   PERMEABILITY; NECROTIZING ENTEROCOLITIS; SUGAR ABSORPTION; CHILDREN;
   INCREASES; THERAPY
AB Objectives: Little attention has been paid to the effect of the systemic inflammatory response syndrome on intestinal dysfunction in the postoperative period. Several proinflammatory cytokines have been reported to increase the permeability of intestinal mucosa in vitro. We investigated the effect of dexamethasone on gut permeability in pediatric patients undergoing cardiac surgery by using the dual sugar permeability test and absorption of 2 other saccharides.
   Methods: Thirty-four patients scheduled for cardiac surgery with cardiopulmonary bypass were prospectively randomized to either act as control subjects or to receive dexamethasone (I mg center dot kg(-1)) during induction of anesthesia. Intestinal permeability was measured with 3-O-methyl-D-glucose, D-Xylose, L-rhamnose, and lactulose administered orally after induction of anesthesia and 12 and 24 hours later.
   Results: Lactulose/rhamnose ratios were increased from the outset in both groups (mean 0.57 [95% confidence interval, 0.24-0.91] for the control group and 0.76 [95% confidence interval, 0.35-1.17] for patients receiving dexamethasone). Although the ratios decreased 12 hours (0.29 [95% confidence interval, 0.17-0.42]) and 24 hours later (0.17 [95% confidence interval, 0.08-0.15]) in the dexamethasone group, in the control group there was a rise at 12 hours (0.77 [95% confidence interval, 0-1.64]), with a slight reduction 24 hours later (0.46 [95% confidence interval, 0.06-0.85]).
   Conclusions: Infants and children undergoing cardiac surgery with cardiopulmonary bypass show a significant reduction in gut permeability when dexamethasone is used during induction of anesthesia. Dexamethasone does not affect the intestinal barrier at the functional level, as assessed on the basis of 3-O-methyl-D-glucose and D-xylose absorption.
C1 Leiden Univ, Med Ctr, Dept Anesthesia, NL-2300 RC Leiden, Netherlands.
   Leiden Univ, Med Ctr, Dept Pediat, NL-2300 RC Leiden, Netherlands.
   Leiden Univ, Med Ctr, Dept Pediat Cardiac Surg, NL-2300 RC Leiden, Netherlands.
RP Malagon, I (reprint author), Leiden Univ, Med Ctr, Dept Anesthesia, POB 9600, NL-2300 RC Leiden, Netherlands.
EM jmalagon@lumc.nl
CR BAUER CR, 1984, PEDIATRICS, V73, P682
   BEACH RC, 1982, ARCH DIS CHILD, V57, P141, DOI 10.1136/adc.57.2.141
   Brix-Christensen V, 2001, ACTA ANAESTH SCAND, V45, P671, DOI 10.1034/j.1399-6576.2001.045006671.x
   Bronicki RA, 2000, ANN THORAC SURG, V69, P1490, DOI 10.1016/S0003-4975(00)01082-1
   Butler J, 1996, ANN THORAC SURG, V62, P538, DOI 10.1016/0003-4975(96)00325-6
   Chaney MA, 2002, CHEST, V121, P921, DOI 10.1378/chest.121.3.921
   Chaney MA, 2001, J THORAC CARDIOV SUR, V121, P561, DOI 10.1067/mtc.2001.112343
   COLGAN SP, 1994, AM J PHYSIOL, V267, pC402
   *COMM FET NEWB, 2002, PEDIATRICS, V109, P330
   Fink MP, 1997, INTENS CARE MED, V23, P489, DOI 10.1007/s001340050363
   HEBRA A, 1993, J PEDIATR SURG, V28, P606, DOI 10.1016/0022-3468(93)90670-G
   HELLEMEESCH MM, 2000, AM J PHYSIOL-GASTR L, V278, pG83
   JANSEN G, 1986, CLIN CHIM ACTA, V157, P277, DOI 10.1016/0009-8981(86)90303-7
   Laffey JG, 2002, ANESTHESIOLOGY, V97, P215
   Lindberg L, 2003, BRIT J ANAESTH, V90, P728, DOI 10.1093/bja/aeg125
   Madsen KL, 1997, GASTROENTEROLOGY, V113, P151, DOI 10.1016/S0016-5085(97)70090-8
   Malagon I, 2005, BRIT J ANAESTH, V94, P181, DOI 10.1093/bja/aei014
   MENZIES IS, 1983, INTESTINAL ABSORPTIO, P527
   Miki K, 1996, CLIN CHEM, V42, P71
   OHRI SK, 1993, ANN THORAC SURG, V55, P1080, DOI 10.1016/0003-4975(93)90011-6
   Onkenhout W, 2002, MOL GENET METAB, V77, P80, DOI 10.1016/S1096-7192(02)00125-7
   Piena-Spoel M, 2001, J PEDIATR SURG, V36, P587, DOI 10.1053/jpsu.2001.22288
   Schroeder VA, 2003, CIRCULATION, V107, P2823, DOI 10.1161/01.CIR.0000070955.55636.25
   Schurr UP, 2001, ANN THORAC SURG, V72, P1316, DOI 10.1016/S0003-4975(01)03062-4
   Shore S, 2001, AM J CARDIOL, V88, P591, DOI 10.1016/S0002-9149(01)01751-9
   Sinclair DG, 1997, INTENS CARE MED, V23, P510, DOI 10.1007/s001340050366
   Taylor RM, 2002, SCAND J GASTROENTERO, V37, P807, DOI 10.1080/713786522
   Wang Q, 2001, AM J PHYSIOL-REG I, V281, pR1013
   Wenzl HH, 2003, DIGEST DIS SCI, V48, P1171, DOI 10.1023/A:1023789301547
NR 29
TC 10
Z9 11
U1 3
U2 9
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0022-5223
EI 1097-685X
J9 J THORAC CARDIOV SUR
JI J. Thorac. Cardiovasc. Surg.
PD AUG
PY 2005
VL 130
IS 2
BP 265
EP 271
DI 10.1016/j.jtcvs.2005.02.047
PG 7
WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery
SC Cardiovascular System & Cardiology; Respiratory System; Surgery
GA 953IL
UT WOS:000231069700006
PM 16077385
OA Bronze
DA 2018-12-27
ER

PT J
AU Jeong, SM
   Koo, WH
   Choi, SH
   Baik, HK
AF Jeong, SM
   Koo, WH
   Choi, SH
   Baik, HK
TI RETRACTED: Properties of organic light-emitting diodes by aluminum
   cathodes modification using Ar+ ion beam (Retracted Article. Se vol 8,
   pg iii, 2007)
SO ORGANIC ELECTRONICS
LA English
DT Article; Retracted Publication
DE OLED; ion beam-assisted deposition; passivation; lifetime
ID GAS BARRIER COATINGS; POLY(P-PHENYLENE VINYLENE); CURRENT TRANSPORT;
   DEVICES; DEGRADATION; ELECTROLUMINESCENCE; MICROSCOPY; FILMS;
   SPECTROSCOPY; PERMEATION
AB Organic light-emitting diodes (OLEDs) with aluminum cathodes prepared by the ion beam-assisted deposition (IBAD) have a longer lifetime than thermally evaporated one. The electroluminescent features were examined to compare the rate of degradation in the devices with thermally evaporated Al cathodes and ion beam-assisted Al cathodes. The dense and highly packed Al cathode effectively prevents the permeation of H2O and O-2 through pinhole defects, which results in retarding dark spot growth. Employing thin Al buffer layer diminished Ar+ ion-induced damages in phenyl-substituted poly-p-phenylene-vinylene (Ph-PPVs) and limited permeation against H2O and O-2. The interface between Al and Ph-PPV may be modified in IBAD case, even though buffered Al layer was deposited to 30 nm by thermal evaporation prior to Ar+ ion beam irradiation. It is believed that the buffered Al film cannot screen the Ar+ ions or Al atoms wholly due to the existence of pinholes or non-deposited regions among the columnar structures. (c) 2005 Elsevier B.V. All rights reserved.
C1 Yonsei Univ, Sch Mat Sci & Engn, Dept Met Engn, Seoul 120749, South Korea.
RP Baik, HK (reprint author), Yonsei Univ, Sch Mat Sci & Engn, Dept Met Engn, 134 Shinchon Dong, Seoul 120749, South Korea.
EM thinfilm@yonsei.ac.kr
CR ANTONIADIS H, 1994, APPL PHYS LETT, V65, P2030, DOI 10.1063/1.112784
   Aziz H, 1996, SYNTHETIC MET, V80, P7, DOI 10.1016/0379-6779(96)03660-0
   Aziz H, 1998, APPL PHYS LETT, V72, P756, DOI 10.1063/1.120867
   Blom PWM, 1996, APPL PHYS LETT, V68, P3308, DOI 10.1063/1.116583
   Burrows PE, 2000, J APPL PHYS, V87, P3080, DOI 10.1063/1.372303
   Burrows PE, 1996, J APPL PHYS, V79, P7991, DOI 10.1063/1.362350
   BURROWS PE, 1994, APPL PHYS LETT, V65, P2922, DOI 10.1063/1.112532
   BURROWS PE, 1994, APPL PHYS LETT, V64, P2285, DOI 10.1063/1.111645
   Cuomo J. J., 1989, HDB ION BEAM PROCESS
   Do LM, 1996, THIN SOLID FILMS, V273, P209, DOI 10.1016/0040-6090(95)06781-7
   DO LM, 1994, J APPL PHYS, V76, P5118, DOI 10.1063/1.357224
   Erlat AG, 1999, J PHYS CHEM B, V103, P6047, DOI 10.1021/jp990737e
   GarciaAyuso G, 1996, SURF COAT TECH, V80, P203, DOI 10.1016/0257-8972(95)02712-2
   Henry BM, 1999, THIN SOLID FILMS, V355, P500, DOI 10.1016/S0040-6090(99)00461-7
   HENRY BM, 1999, P SOC VAC COAT SOC 4, P403
   Hung LS, 2002, THIN SOLID FILMS, V410, P101, DOI 10.1016/S0040-6090(02)00270-5
   JAMIESON EHH, 1983, J MATER SCI, V18, P64, DOI 10.1007/BF00543811
   Kwak JS, 1997, APPL PHYS LETT, V71, P2451, DOI 10.1063/1.120086
   Lim SF, 2001, APPL PHYS LETT, V78, P2116, DOI 10.1063/1.1364658
   Meier M, 1997, J APPL PHYS, V82, P1961, DOI 10.1063/1.366003
   Roberts AP, 2002, J MEMBRANE SCI, V208, P75, DOI 10.1016/S0376-7388(02)00178-3
   SATO Y, 1994, MOL CRYST LIQ CRYS A, V252, P435
   Savvateev VN, 1997, APPL PHYS LETT, V71, P3344, DOI 10.1063/1.120332
   Smith D. L., 1997, THIN FILM DEPOSITION
   Sobrinho ASD, 2000, J VAC SCI TECHNOL A, V18, P149, DOI 10.1116/1.582156
   TANG CW, 1987, APPL PHYS LETT, V51, P913, DOI 10.1063/1.98799
   Tropsha YG, 1997, J PHYS CHEM B, V101, P2259, DOI 10.1021/jp9629856
NR 27
TC 1
Z9 1
U1 3
U2 10
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1566-1199
EI 1878-5530
J9 ORG ELECTRON
JI Org. Electron.
PD AUG
PY 2005
VL 6
IS 4
BP 149
EP 160
DI 10.1016/j.orgel.2005.03.010
PG 12
WC Materials Science, Multidisciplinary; Physics, Applied
SC Materials Science; Physics
GA 970ZJ
UT WOS:000232350600001
DA 2018-12-27
ER

PT J
AU Shi, H
   Eglitis, RI
   Borstel, G
AF Shi, H
   Eglitis, RI
   Borstel, G
TI RETRACTED: First-principles calculations of the CaF2 bulk and surface
   electronic structure (Retracted article. See vol 243 pg 555 2006)
SO PHYSICA STATUS SOLIDI B-BASIC SOLID STATE PHYSICS
LA English
DT Article; Retracted Publication
ID AB-INITIO; HARTREE-FOCK; PERIODIC-SYSTEMS; IONIC-CRYSTALS; OPTIMIZATION;
   ABSORPTION; ENERGIES; BATIO3; SRTIO3
AB We present and discuss the results of calculations of the CaF2 bulk and surface electronic structure. These are based on the ab initio Hartree-Fock (HF) method with electron correlation corrections and on Density Functional Theory (DFT) calculations with different exchange-correlation functionals, including hybrid exchange techniques. Both approaches use the localised Gaussian-type basis set. According to our calculations the ab initio HF method considerably overestimates (20.77 eV) the optical band gap, whereas the density functional calculations based on the Kohn-Sham equation with a number of exchange-correlation functionals, including local density approximation (LDA) (8.72 eV), generalized gradient approximations (GGA) by Perdew and Wang (PW) (8.51 eV), and Perdew, Burke, and Emzerhof (PBE) (8.45 eV) underestimate it. Our results show that the best agreement with experiment (12.1 eV) can be obtained using a hybrid HF-DFT exchange functional, in which Hartree-Fock exchange is mixed with DFT exchange functionals, using Beckes three parameter method, combined with the non-local correlation functionals by Perdew and Wang (B3PW) (10.96 eV). We also present calculations of CaF2(111), (110), and (100) surfaces. Our calculated surface energies using the hybrid B3PW method confirm that the CaF2(111) surface is the most stable one, in agreement with the experiment.
C1 Univ Osnabruck, Fachbereich Phys, D-49069 Osnabruck, Germany.
RP Eglitis, RI (reprint author), Univ Osnabruck, Fachbereich Phys, Barbarastr 7, D-49069 Osnabruck, Germany.
EM reglitis@uos.de
RI Dep Theor Physics, Computer Modeling/E-6336-2013; Eglitis,
   Roberts/A-6014-2012
CR BARTH J, 1990, PHYS REV B, V41, P3291, DOI 10.1103/PhysRevB.41.3291
   Camy P, 2004, OPT COMMUN, V236, P395, DOI 10.1016/j.optcom.2004.03.055
   CATTI M, 1991, J PHYS-CONDENS MAT, V3, P4151, DOI 10.1088/0953-8984/3/23/004
   CAUSA M, 1994, CHEM PHYS LETT, V220, P145, DOI 10.1016/0009-2614(94)00179-0
   CHIANG WY, 1995, PHYS REV B, V52, P1596
   Civalleri B, 2001, CHEM PHYS LETT, V348, P131, DOI 10.1016/S0009-2614(01)01081-8
   Eglitis RI, 2004, CERAM INT, V30, P1989, DOI 10.1016/j.ceramint.2003.12.176
   Foster AS, 2002, PHYS REV B, V66, DOI 10.1103/PhysRevB.66.235417
   GAN FQ, 1992, PHYS REV B, V45, P8248, DOI 10.1103/PhysRevB.45.8248
   GILMAN JJ, 1960, J APPL PHYS, V31, P2208, DOI 10.1063/1.1735524
   Heifets E, 2002, SURF SCI, V513, P211, DOI 10.1016/S0039-6028(02)01730-2
   Heifets E, 2001, PHYS REV B, V64, DOI 10.1103/PhysRevB.64.235417
   JOCKISCH A, 1993, J PHYS-CONDENS MAT, V5, P5401, DOI 10.1088/0953-8984/5/31/005
   Kumar GA, 2004, J APPL PHYS, V95, P3243, DOI 10.1063/1.1649807
   MERAWA M, 1998, CHEM PHYS LETT, V368, P7
   Muscat J, 2001, CHEM PHYS LETT, V342, P397, DOI 10.1016/S0009-2614(01)00616-9
   Padilla J, 1997, PHYS REV B, V56, P1625, DOI 10.1103/PhysRevB.56.1625
   Padilla J, 1998, SURF SCI, V418, P64, DOI 10.1016/S0039-6028(98)00670-0
   PISANI C, 1996, LECT NOTES CHEM, V67
   PUCHIN VE, 1993, J PHYS CONDENS MATT, V13, P5401
   Puchina AV, 1998, SOLID STATE COMMUN, V106, P285, DOI 10.1016/S0038-1098(98)00027-1
   RUBLOFF GW, 1972, PHYS REV B, V5, P662, DOI 10.1103/PhysRevB.5.662
   SAUNDERS VR, 2003, CRYSTAL 2003 USER MA
   SCHLEGEL HB, 1982, J COMPUT CHEM, V3, P214, DOI 10.1002/jcc.540030212
   Tsujibayashi T, 2002, APPL PHYS LETT, V80, P2883, DOI 10.1063/1.1471939
   Verstraete M, 2003, PHYS REV B, V68, DOI 10.1103/PhysRevB.68.195123
   Wyckoff R. W. G., 1963, CRYSTAL STRUCTURES, V1
NR 27
TC 17
Z9 18
U1 3
U2 22
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA PO BOX 10 11 61, D-69451 WEINHEIM, GERMANY
SN 0370-1972
J9 PHYS STATUS SOLIDI B
JI Phys. Status Solidi B-Basic Solid State Phys.
PD AUG
PY 2005
VL 242
IS 10
BP 2041
EP 2050
DI 10.1002/pssb.200540069
PG 10
WC Physics, Condensed Matter
SC Physics
GA 959GM
UT WOS:000231506200013
DA 2018-12-27
ER

PT J
AU Sun, QM
   Jiang, HC
   Xu, WM
   Liu, X
   Dai, CB
   Sun, MS
AF Sun, QM
   Jiang, HC
   Xu, WM
   Liu, X
   Dai, CB
   Sun, MS
TI RETRACTED: High-level expression and purification of recombinant
   huGM-CSF (9-127)/IL-6 (29-184) fusion protein in Escherichia coli.
   (Retracted Article. See vol 42, pg 486, 2007)
SO PROTEIN EXPRESSION AND PURIFICATION
LA English
DT Article; Retracted Publication
DE granulocyte-macrophage colony stimulating factor; interleukin-6; fusion
   protein; expression; purification
ID COLONY-STIMULATING FACTOR; HEMATOPOIETIC PROGENITOR CELLS; MODERATE-DOSE
   FLUOROURACIL; III BREAST-CANCER; HUMAN GM-CSF; HUMAN INTERLEUKIN-6;
   SOLID TUMORS; DOUBLE-BLIND; BONE-MARROW; STAGE-II
AB As HuGM-CSF and huIL-6 seem to have synergistic and complementary actions, researchers have proposed that fusion proteins incorporating these two cytokines could show increased biological activity, especially in terms of hematopoietic function. Here, we sought to obtain a functional GM-CSF/IL-6 fusion protein and to investigate its biological activities in vitro. A novel construct encoding a fusion protein of liuGM-CSF (9-127) and IL-6 (29-184) was generated in the pBV220 expression vector by step-by-step cloning. Amino acids 1-8 of huGM-CSF and amino acids 1-28 of huIL-6 were deleted by PCR. The mutant huGM-CSF (9-127) and huIL-6 (29-184) cDNAs were linked via a linker sequence encoding 15 amino acid residues (G-G-S-G-S)(3). Direct sequencing was used to confirm the validity of the desired construct, and the fusion protein was expressed in Escherichia coli host strain BL21 (DE3) in the form of inclusion bodies (IBs). The expression level was more than 25% of the total cell lysate, and a novel purification and refolding strategy was used to isolate the fusion protein product. Inclusion bodies were purified by Q Sepharose H.P. ion exchange in 8 mol/L urea, followed by in situ refolding by Sephacryl S-200. The renatured fusion proteins were obtained at a purity of > 95%, and the strategy of refolding on the gel filtration column was found to be efficient, with a relative refolding rate of 80%. This entire refolding and purification procedure could be performed within one day and may prove applicable to large-scale purification and refolding of recombinant proteins from 113s in E coli. This new method was used to obtain huGM-CSF (9-127)/IL-6 (29-184) fusion protein with high purity and biological activity. MTT assays in TF-1 and B9 cell lines showed that the specific biological activity of huGM-CSF was 1.14 +/- 0.10 x 10(8) U/mg, and that for huIL-6 was 1.89 +/- 0.11 x 10(7) U/mg. The fusion protein exhibited enhanced huGM-CSF, but similar huIL-6 biological activities compared with those of either GM-CSF or IL-6 alone. This suggests that our novel huGM-CSF (9-127)/IL-6 (29-184) fusion protein may hold future promise as a therapeutic agent. (c) 2005 Elsevier Inc. All rights reserved.
C1 Chinese Acad Med Sci, Inst Med Biol, Dept Mol Biol, Kunming 650118, Yunnan, Peoples R China.
   Peking Union Med Coll, Kunming 650118, Yunnan, Peoples R China.
RP Sun, MS (reprint author), Chinese Acad Med Sci, Inst Med Biol, Dept Mol Biol, Kunming 650118, Yunnan, Peoples R China.
EM maoshengsun2008@yahoo.com.cn
CR Baxevanis CN, 1997, EUR J CANCER, V33, P1202, DOI 10.1016/S0959-8049(97)00053-1
   Bracho F, 2001, CLIN CANCER RES, V7, P58
   BRAKENHOFF JPJ, 1989, J IMMUNOL, V143, P1175
   BRUNO E, 1992, EXP HEMATOL, V20, P494
   CARACCIOLO D, 1989, BLOOD, V73, P666
   CEBON J, 1990, J BIOL CHEM, V265, P4483
   Coscarella A, 1997, EUR J HAEMATOL, V59, P238
   CURTIS BM, 1991, P NATL ACAD SCI USA, V88, P5809, DOI 10.1073/pnas.88.13.5809
   FONTAINE V, 1994, EUR J IMMUNOL, V24, P1041, DOI 10.1002/eji.1830240505
   Galun E, 2000, FASEB J, V14, P1979, DOI 10.1096/fj.99-0913com
   GRANT S, 1993, CYTOKINE, V5, P490, DOI 10.1016/1043-4666(93)90040-C
   Hirano T, 1998, Int Rev Immunol, V16, P249
   HONDT VD, 1995, BLOOD, V85, P2347
   Imrie KR, 1997, LEUKEMIA LYMPHOMA, V25, P555, DOI 10.3109/10428199709039044
   Jones SE, 1996, J CLIN ONCOL, V14, P2976, DOI 10.1200/JCO.1996.14.11.2976
   Jones SE, 1999, J CLIN ONCOL, V17, P3025, DOI 10.1200/JCO.1999.17.10.3025
   Miller LL, 1999, BLOOD, V93, P3250
   Mumcuoglu M, 1999, J HEMATOTHER, V8, P247, DOI 10.1089/106161299320262
   NAND S, 1991, AM J HEMATOL, V37, P267, DOI 10.1002/ajh.2830370411
   NASH RA, 1995, BLOOD, V86, P1765
   NEMUNAITIS J, 1990, BLOOD, V76, P245
   Nishimura C, 1996, BIOCHEMISTRY-US, V35, P273, DOI 10.1021/bi951949e
   OShaughnessy JA, 1996, BLOOD, V87, P2205
   SCHIPPERUS MR, 1991, BRIT J HAEMATOL, V77, P515
   Takizawa T, 2001, CYTOKINE, V13, P272, DOI 10.1006/cyto.2000.0831
   VAN SJ, 1988, EUR J IMMUNOL, V18, P193
   VELDHUIS GJ, 1995, J CLIN ONCOL, V13, P2585, DOI 10.1200/JCO.1995.13.10.2585
   WALTER MR, 1992, J MOL BIOL, V224, P1075, DOI 10.1016/0022-2836(92)90470-5
   WERNER MH, 1994, FEBS LETT, V345, P125, DOI 10.1016/0014-5793(94)00401-3
   WONG GG, 1985, SCIENCE, V228, P810, DOI 10.1126/science.3923623
NR 30
TC 2
Z9 2
U1 3
U2 8
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1046-5928
EI 1096-0279
J9 PROTEIN EXPRES PURIF
JI Protein Expr. Purif.
PD AUG
PY 2005
VL 42
IS 2
BP 278
EP 285
DI 10.1016/j.pep.2005.04.007
PG 8
WC Biochemical Research Methods; Biochemistry & Molecular Biology;
   Biotechnology & Applied Microbiology
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology
GA 951EO
UT WOS:000230912100006
PM 15935697
DA 2018-12-27
ER

PT J
AU Wang, WD
   Chen, ZT
   Li, DZ
   Cao, ZH
   Sun, SL
   Pu, P
   Chen, XP
AF Wang, WD
   Chen, ZT
   Li, DZ
   Cao, ZH
   Sun, SL
   Pu, P
   Chen, XP
TI RETRACTED: Correlation between DNA repair capacity in lymphocytes and
   acute side effects to skin during radiotherapy in nasopharyngea cancer
   patients (Retracted Article. See vol 15, pg 3642, 2009)
SO CLINICAL CANCER RESEARCH
LA English
DT Article; Retracted Publication
ID IN-VITRO RADIOSENSITIVITY; NORMAL-TISSUE RADIOSENSITIVITY;
   PERIPHERAL-BLOOD LYMPHOCYTES; COMET ASSAY; CELLULAR RADIOSENSITIVITY;
   RADIATION-THERAPY; NECK-CANCER; FIBROBLASTS; DAMAGE; TUMORS
AB Purpose: Repair of radiation-induced DNA damage plays a critical role for both the susceptibility of patients to side effects after radiotherapy and their subsequent cancer risk. The study objective was to evaluate whether DNA repair data determined in vitro are correlated with the occurrence of acute side effects during radiotherapy.
   Experimental Design: Nasopharyngeal cancer patients receiving radiation therapy were recruited in a prospective epidemiologic study. As an indicator for clinical radiosensitivity, adverse reactions of the skin were recorded. Cryopreserved lymphocytes from 100 study participants were gamma-irradiated with 5 Gy in vitro and analyzed using the alkaline comet assay. Reproducibility of the assay was determined by repeated analysis (n = 22) of cells from a healthy donor. A coefficient of variation of 0.24 was calculated.
   Results: The various parameters determined to characterize the individual DNA repair capacity showed large differences between patients. Twenty-one patients were identified with considerably enhanced DNA damage induction, and 19 patients exhibited severely reduced DNA repair capacity after 15 and 30 minutes. Eight patients were considered as clinically radiosensitive, indicated by moist desquamation of the skin after a total radiation dose of 70 Gy.
   Conclusions: Using the alkaline comet assay as described here, nasopharyngeal cancer patients were identified showing abnormal cellular radiation effects, but this repair deficiency corresponded only at a very limited extent to the acute radiation sensitivity of the skin.
C1 Xinquao Hosp, Dept Oncol, Chongqing 400037, Peoples R China.
   Third Mil Med Univ, Dept Med Stat, Chongqing, Peoples R China.
   Chongqing Med Univ, Affiliated Hosp 1, Dept Radiat Oncol, Chongqing, Peoples R China.
RP Chen, XP (reprint author), Xinquao Hosp, Dept Oncol, Xinqiao St, Chongqing 400037, Peoples R China.
EM wwdlr@yahoo.com
CR Alsbeih G, 2000, INT J RADIAT ONCOL, V46, P143, DOI 10.1016/S0360-3016(99)00409-5
   Borgmann K, 2002, RADIOTHER ONCOL, V64, P141, DOI 10.1016/S0167-8140(02)00167-6
   Brammer I, 2001, INT J RADIAT BIOL, V77, P929, DOI 10.1080/095530001100664222
   Brock WA, 2000, RADIOTHER ONCOL, V55, P93, DOI 10.1016/S0167-8140(00)00175-4
   Burnet NG, 1998, INT J CANCER, V79, P606, DOI 10.1002/(SICI)1097-0215(19981218)79:6<606::AID-IJC9>3.0.CO;2-Y
   *CANC THER EV PROG, 1998, COMM TOX CRIT
   Cao J, 2002, MUTAT RES-FUND MOL M, V504, P85, DOI 10.1016/S0027-5107(02)00082-9
   Djuzenova CS, 1999, LAB INVEST, V79, P699
   Harney J, 2004, RADIOTHER ONCOL, V70, P319, DOI 10.1016/j.radonc.2004.01.015
   Johansen J, 1996, RADIOTHER ONCOL, V40, P101, DOI 10.1016/0167-8140(96)01777-X
   Jones Irene M., 2002, Proceedings of the American Association for Cancer Research Annual Meeting, V43, P493
   Leprat F, 1998, INT J RADIAT ONCOL, V40, P1019, DOI 10.1016/S0360-3016(97)00914-0
   Mayer C, 2002, DNA REPAIR, V1, P237, DOI 10.1016/S1568-7864(01)00019-2
   Mazur L, 2000, MUTAT RES-GEN TOX EN, V468, P27, DOI 10.1016/S1383-5718(00)00037-1
   MORI T, 1994, RADIAT RES, V140, P85, DOI 10.2307/3578572
   Muller WU, 2001, RADIAT ENVIRON BIOPH, V40, P83, DOI 10.1007/s004110000087
   Oppitz U, 1999, STRAHLENTHER ONKOL, V175, P341, DOI 10.1007/s000660050021
   Palazzi M, 2004, TUMORI, V90, P60
   Peacock J, 2000, RADIOTHER ONCOL, V55, P173, DOI 10.1016/S0167-8140(00)00173-0
   Powell SN, 1998, BRIT J RADIOL, V71, P1178, DOI 10.1259/bjr.71.851.10434913
   Rosen EM, 1999, CANCER INVEST, V17, P56
   Rudat V, 1999, RADIOTHER ONCOL, V53, P233, DOI 10.1016/S0167-8140(99)00149-8
   Schmezer P, 2001, MUTAGENESIS, V16, P25, DOI 10.1093/mutage/16.1.25
   Scott D, 2000, STRAHLENTHER ONKOL, V176, P229, DOI 10.1007/s000660050005
   SINGH NP, 1988, EXP CELL RES, V175, P184, DOI 10.1016/0014-4827(88)90265-0
   SPERIT G, 1999, METHOD MOL BIOL, V113, P203
   Tucker SL, 1996, RADIOTHER ONCOL, V38, P103, DOI 10.1016/0167-8140(95)01669-4
   Turesson I, 1996, INT J RADIAT ONCOL, V36, P1065, DOI 10.1016/S0360-3016(96)00426-9
   Twardella D, 2002, RADIOTHER ONCOL, V62, P249, DOI 10.1016/S0167-8140(01)00491-1
   von Sonntag C, 1999, NATO ADV SCI I A-LIF, V302, P407
   Ward JF, 1999, NATO ADV SCI I A-LIF, V302, P431
   WARDMAN P, 1992, INT J RADIAT ONCOL, V22, P751, DOI 10.1016/0360-3016(92)90517-L
   West CML, 2001, INT J RADIAT ONCOL, V51, P10, DOI 10.1016/S0360-3016(01)01575-9
NR 33
TC 10
Z9 10
U1 4
U2 11
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
EI 1557-3265
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD JUL 15
PY 2005
VL 11
IS 14
BP 5140
EP 5145
DI 10.1158/1078-0432.CCR-04-2548
PG 6
WC Oncology
SC Oncology
GA 945VG
UT WOS:000230529800012
PM 16033828
OA Bronze
DA 2018-12-27
ER

PT J
AU Zhu, JH
   Verslues, PE
   Zheng, XW
   Lee, B
   Zhan, XQ
   Manabe, Y
   Sokolchik, I
   Zhu, YM
   Dong, CH
   Zhu, JK
   Hasegawa, PM
   Bressan, RA
AF Zhu, JH
   Verslues, PE
   Zheng, XW
   Lee, B
   Zhan, XQ
   Manabe, Y
   Sokolchik, I
   Zhu, YM
   Dong, CH
   Zhu, JK
   Hasegawa, PM
   Bressan, RA
TI RETRACTED: HOS10 encodes an R2R3-type MYB transcription factor essential
   for cold acclimation in plants (Retracted article. See vol. 107, pg.
   13972, 2010)
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article; Retracted Publication
DE Arabidopsis; freezing; abscisic acid; NCED3
ID STRESS SIGNAL-TRANSDUCTION; ABSCISIC-ACID; GENE-EXPRESSION; FREEZING
   TOLERANCE; LOW-TEMPERATURE; ARABIDOPSIS-THALIANA; SALT STRESS; DROUGHT;
   PATHWAYS; PROTEIN
AB We report the identification and characterization of an Arabidopsis mutant, hos10-1 (for high expression of osmotically responsive genes), in which the expression of RD29A and other stress-responsive genes is activated to higher levels or more rapidly activated than in wild-type by low temperature, exogenous abscisic acid (ABA), or salt stress (NaCl). The hos10-1 plants are extremely sensitive to freezing temperatures, completely unable to acclimate to the cold, and are hypersensitive to NaCl. Induction of NCED3 (the gene that encodes the rate-limiting enzyme in ABA biosynthesis) by polyethylene glycol-mediated dehydration and ABA accumulation are reduced by this mutation. Detached shoots from the mutant plants display an increased transpiration rate compared with wild-type plants. The hos10-1 plants exhibit several developmental alterations, such as reduced size, early flowering, and reduced fertility. The HOS10 gene encodes a putative R2R3-type MYB transcription factor that is localized to the nucleus. Together, these results indicate that HOS10 is an important coordinating factor for responses to abiotic stress and for growth and development.
C1 Purdue Univ, Dept Hort, W Lafayette, IN 47907 USA.
   Univ Calif Riverside, Dept Bot & Plant Sci, Riverside, CA 92521 USA.
   Univ Calif Riverside, Inst Integrat Genome Biol, Riverside, CA 92521 USA.
   Univ Arizona, Dept Plant Sci, Tucson, AZ 85721 USA.
RP Bressan, RA (reprint author), Purdue Univ, Dept Hort, W Lafayette, IN 47907 USA.
EM bressan@hort.purdue.edu
OI Lee, Byeong-ha/0000-0001-7633-3264
CR Alonso JM, 2003, SCIENCE, V301, P653, DOI 10.1126/science.1086391
   Bertrand A, 1997, TREE PHYSIOL, V17, P31
   BRAY EA, 1985, PLANT PHYSIOL, V79, P746, DOI 10.1104/pp.79.3.746
   Chinnusamy V, 2003, GENE DEV, V17, P1043, DOI 10.1101/gad.1077503
   Fowler S, 2002, PLANT CELL, V14, P1675, DOI 10.1105/tpc.003483
   Gilmour SJ, 2000, PLANT PHYSIOL, V124, P1854, DOI 10.1104/pp.124.4.1854
   Gilmour SJ, 1998, PLANT J, V16, P433, DOI 10.1046/j.1365-313x.1998.00310.x
   GUY CL, 1990, ANNU REV PLANT PHYS, V41, P187, DOI 10.1146/annurev.pp.41.060190.001155
   Haake V, 2002, PLANT PHYSIOL, V130, P639, DOI 10.1104/pp.006478
   HEINO P, 1990, THEOR APPL GENET, V79, P801, DOI 10.1007/BF00224248
   Ishitani M, 1997, PLANT CELL, V9, P1935, DOI 10.1105/tpc.9.11.1935
   Jaglo-Ottosen KR, 1998, SCIENCE, V280, P104, DOI 10.1126/science.280.5360.104
   Kang JY, 2002, PLANT CELL, V14, P343, DOI 10.1105/tpc.010362
   Krebs JA, 2002, PLANT PHYSIOL, V130, P2129
   LALK I, 1985, PHYSIOL PLANTARUM, V63, P287, DOI 10.1111/j.1399-3054.1985.tb04267.x
   Lee BH, 2002, PLANT CELL, V14, P1235, DOI 10.1105/tpc.010433
   Lee HJ, 2001, GENE DEV, V15, P912, DOI 10.1101/gad.866801
   Liu Q, 1998, PLANT CELL, V10, P1391, DOI 10.2307/3870648
   MAZUR P, 1969, ANN REV PLANT PHYSIO, V20, P419, DOI 10.1146/annurev.pp.20.060169.002223
   Ruggiero B, 2004, PLANT PHYSIOL, V136, P3134, DOI 10.1104/pp.104.046169
   Shinozaki K, 2003, CURR OPIN PLANT BIOL, V6, P410, DOI 10.1016/S1369-5266(03)00092-X
   Stracke R, 2001, CURR OPIN PLANT BIOL, V4, P447, DOI 10.1016/S1369-5266(00)00199-0
   TAN BC, 2003, PLANT J, V35, P45
   Thomashow MF, 1999, ANNU REV PLANT PHYS, V50, P571, DOI 10.1146/annurev.arplant.50.1.571
   Uno Y, 2000, P NATL ACAD SCI USA, V97, P11632, DOI 10.1073/pnas.190309197
   Verslues PE, 2004, PLANT PHYSIOL, V136, P2831, DOI 10.1104/pp.104.045856
   Vogel JT, 2005, PLANT J, V41, P195, DOI 10.1111/j.1365-313X.2004.02288.x
   WEISER CJ, 1970, SCIENCE, V169, P1269, DOI 10.1126/science.169.3952.1269
   Xin ZG, 1998, P NATL ACAD SCI USA, V95, P7799, DOI 10.1073/pnas.95.13.7799
   XIONG L, 2002, PLANT CELL S, V14, P165
   Xiong LM, 2003, PLANT PHYSIOL, V133, P29, DOI 10.1104/pp.103.025395
   Xiong LM, 2001, PLANT CELL, V13, P2063, DOI 10.1105/tpc.13.9.2063
   YAMAGUCHISHINOZAKI K, 1994, PLANT CELL, V6, P251, DOI 10.1105/tpc.6.2.251
   Zhu JH, 2002, PLANT CELL, V14, P3009, DOI 10.1105/tpc.006981
   Zhu JH, 2004, P NATL ACAD SCI USA, V101, P9873, DOI 10.1073/pnas.0403166101
   Zhu JK, 2002, ANNU REV PLANT BIOL, V53, P247, DOI 10.1146/annurev.arplant.53.091401.143329
NR 36
TC 120
Z9 150
U1 7
U2 38
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD JUL 12
PY 2005
VL 102
IS 28
BP 9966
EP 9971
DI 10.1073/pnas.0503960102
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 946AU
UT WOS:000230545100042
PM 15994234
OA Green Published, Bronze
DA 2018-12-27
ER

PT J
AU Bryant, JE
   Lecomte, JTJ
   Lee, AL
   Young, GB
   Pielak, GJ
AF Bryant, JE
   Lecomte, JTJ
   Lee, AL
   Young, GB
   Pielak, GJ
TI RETRACTED: Protein dynamics in living cells (Retracted article. See vol
   46, pg 8206, 2007)
SO BIOCHEMISTRY
LA English
DT Article; Retracted Publication
ID MAGNETIC-RESONANCE RELAXATION; MODEL-FREE APPROACH; BACKBONE DYNAMICS;
   NMR-SPECTROSCOPY; APOCYTOCHROME B(5); ESCHERICHIA-COLI; N-15 NMR;
   IN-VIVO; STATE; MACROMOLECULES
AB A protein's structure is most often used to explain its function, but function also depends on dynamics. To date, protein dynamics have been studied only in vitro under dilute solution conditions where solute concentrations are typically less than 10 g/L, yet proteins function in a crowded environment where the solute concentration can exceed 400 g/L. Does the intracellular environment affect protein dynamics? The answer will help in assessing the biological significance of the NMR-derived dynamics data collected to date. We investigated fast protein dynamics inside living Escherichia coli by using in-cell NMR. The backbone dynamics of apocytochrome b(5) were quantified using {H-1}-N-15 nuclear Overhauser effect (nOe) measurements, which characterize motions on the pico- to nanosecond time scale. The overall trend of backbone dynamics remains the same in cells. Some of the nOe values differ, but most of the differences track the increased intracellular viscosity rather than a change in dynamics. Therefore, it appears that dilute solution steady-state {H-1}-N-15 nOe measurements provide biologically relevant information about pico- to nanosecond backbone motion in proteins.
C1 Univ N Carolina, Dept Chem & Biochem & Biophys, Div Med Chem & Nat Prod, Chapel Hill, NC 27599 USA.
   Univ N Carolina, Lineberger Canc Res Ctr, Chapel Hill, NC 27599 USA.
   Penn State Univ, Dept Chem, University Pk, PA 16802 USA.
RP Pielak, GJ (reprint author), Univ N Carolina, Dept Chem & Biochem & Biophys, Div Med Chem & Nat Prod, Chapel Hill, NC 27599 USA.
EM gary_pielak@unc.edu
FU NIGMS NIH HHS [GM-54217]
CR Bhattacharya S, 1999, BIOCHEMISTRY-US, V38, P2577, DOI 10.1021/bi982316d
   BICKNESE S, 1993, BIOPHYS J, V65, P1272, DOI 10.1016/S0006-3495(93)81179-2
   BODENHAUSEN G, 1980, CHEM PHYS LETT, V69, P185, DOI 10.1016/0009-2614(80)80041-8
   Davis-Searles PR, 2001, ANNU REV BIOPH BIOM, V30, P271, DOI 10.1146/annurev.biophys.30.1.271
   Dedmon MM, 2002, P NATL ACAD SCI USA, V99, P12681, DOI 10.1073/pnas.202331299
   DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809
   Erbel PJA, 2004, J BIOMOL NMR, V29, P199, DOI 10.1023/B:JNMR.0000019252.65073.24
   Falzone CJ, 1996, BIOCHEMISTRY-US, V35, P6519, DOI 10.1021/bi960501q
   Falzone CJ, 2001, BIOCHEMISTRY-US, V40, P4879, DOI 10.1021/bi002681g
   FARROW NA, 1994, BIOCHEMISTRY-US, V33, P5984, DOI 10.1021/bi00185a040
   Fetrow JS, 1999, BIOCHEMISTRY-US, V38, P4480, DOI 10.1021/bi9827417
   Hatters DM, 2002, J BIOL CHEM, V277, P7824, DOI 10.1074/jbc.M110429200
   Hubbard JA, 2003, MOL MICROBIOL, V49, P1191, DOI 10.1046/j.1365-2958.2003.03628.x
   Ishima R, 2000, NAT STRUCT BIOL, V7, P740, DOI 10.1038/78963
   KAY LE, 1989, BIOCHEMISTRY-US, V28, P8972, DOI 10.1021/bi00449a003
   KAY LE, 1992, J AM CHEM SOC, V114, P10663, DOI 10.1021/ja00052a088
   Lee AL, 1999, J BIOMOL NMR, V13, P101, DOI 10.1023/A:1008304220445
   Lindorff-Larsen K, 2005, NATURE, V433, P128, DOI 10.1038/nature03199
   LIPARI G, 1982, J AM CHEM SOC, V104, P4559, DOI 10.1021/ja00381a010
   LIPARI G, 1982, J AM CHEM SOC, V104, P4546, DOI 10.1021/ja00381a009
   Luby-Phelps K, 2000, INT REV CYTOL, V192, P189
   Nobeli I, 2003, J MOL BIOL, V334, P697, DOI 10.1016/j.jmb.2003.10.008
   Rivas G, 2001, P NATL ACAD SCI USA, V98, P3150, DOI 10.1073/pnas.051634398
   Sasahara K, 2003, J MOL BIOL, V326, P1227, DOI 10.1016/S0022-2836(02)01443-2
   Serber Z, 2004, J AM CHEM SOC, V126, P7119, DOI 10.1021/ja049977k
   Serber Z, 2001, BIOCHEMISTRY-US, V40, P14317, DOI 10.1021/bi011751w
   Serber Z, 2001, J AM CHEM SOC, V123, P2446, DOI 10.1021/ja0057528
   Shimba N, 2003, BIOCHEMISTRY-US, V42, P9227, DOI 10.1021/bi0344679
NR 28
TC 37
Z9 39
U1 3
U2 15
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0006-2960
J9 BIOCHEMISTRY-US
JI Biochemistry
PD JUL 5
PY 2005
VL 44
IS 26
BP 9275
EP 9279
DI 10.1021/bi050786j
PG 5
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 940XG
UT WOS:000230178600001
PM 15981993
DA 2018-12-27
ER

PT J
AU Penkowa, M
   Keller, P
   Keller, C
   Hidalgo, J
   Giralt, M
   Pedersen, BK
AF Penkowa, M
   Keller, P
   Keller, C
   Hidalgo, J
   Giralt, M
   Pedersen, BK
TI RETRACTED: Exercise-induced metallothionein expression in human skeletal
   muscle fibres (Retracted article. See vol. 96, pg. 816, 2011)
SO EXPERIMENTAL PHYSIOLOGY
LA English
DT Article; Retracted Publication
ID CENTRAL-NERVOUS-SYSTEM; II-DEFICIENT MICE; EXPERIMENTAL AUTOIMMUNE
   ENCEPHALOMYELITIS; ASTROCYTE-TARGETED EXPRESSION; TERT-BUTYL
   HYDROPEROXIDE; ELECTRON-SPIN-RESONANCE; OXIDATIVE STRESS; TRANSGENIC
   MICE; GENE-EXPRESSION; FREE-RADICALS
AB Exercise induces free oxygen radicals that cause oxidative stress, and metallothioneins (MTs) are increased in states of oxidative stress and possess anti-apoptotic effects. We therefore studied expression of the antioxidant factors metallothionein I and II (MT-I + II) in muscle biopsies obtained in response to 3 h of bicycle exercise performed by healthy men and in resting controls. Both MT-I + II proteins and MT-II mRNA expression increased significantly in both type I and II muscle fibres after exercise. Moreover, 24 h after exercise the levels of MT-II mRNA and MT-I + II proteins were still highly increased and the MT-II mRNA expression reached a 15-fold increase. As expected, immunohistochemical detection of malondialdehyde (MDA) and nitrotyrosine (NITT) showed that formation of free radicals and oxidative stress were clearly increased in exercising muscle peaking shortly after the end of exercise in both type I and II muscle fibres. This is the first report demonstrating that MT-I + II are significantly induced in human skeletal muscle fibres following exercise. As MT-I + II are antioxidant factors that protect various tissues during pathological conditions, the MT-I + II increases post exercise may represent a mechanism whereby contracting muscle fibres are protected against cellular stress and injury.
C1 Univ Copenhagen, Panum Inst, Dept Med Anat, DK-2200 Copenhagen, Denmark.
   Rigshosp, Dept Infect Dis, DK-2100 Copenhagen, Denmark.
   Rigshosp, Copenhagen Muscle Res Ctr, DK-2100 Copenhagen, Denmark.
   Autonomous Univ Barcelona, Fac Sci, Inst Neurosci, E-08193 Barcelona, Spain.
   Autonomous Univ Barcelona, Fac Sci, Dept Cellular Biol Physiol & Immunol, Anim Physiol Unit, E-08193 Barcelona, Spain.
RP Penkowa, M (reprint author), Univ Copenhagen, Panum Inst, Dept Med Anat, Blegdamsvej 3, DK-2200 Copenhagen, Denmark.
EM m.penkowa@mai.ku.dk
RI Giralt, Mercedes/K-1626-2014
OI Giralt, Mercedes/0000-0002-1806-1528; Hidalgo, Juan/0000-0003-0921-1122
CR ABEL J, 1989, TOXICOL LETT, V47, P191, DOI 10.1016/0378-4274(89)90075-1
   Andrade FH, 1998, J PHYSIOL-LONDON, V509, P565, DOI 10.1111/j.1469-7793.1998.565bn.x
   Aschner M, 1998, NEUROTOXICOLOGY, V19, P653
   Aschner M, 1996, FASEB J, V10, P1129
   Aschner M, 1997, TOXICOL APPL PHARM, V142, P229, DOI 10.1006/taap.1996.8054
   Beattie JH, 1998, P NATL ACAD SCI USA, V95, P358, DOI 10.1073/pnas.95.1.358
   BOVERIS A, 1972, BIOCHEM J, V128, P617, DOI 10.1042/bj1280617
   BROOKE MH, 1970, J HISTOCHEM CYTOCHEM, V18, P670, DOI 10.1177/18.9.670
   Cai L, 2000, J BIOL CHEM, V275, P38957, DOI 10.1074/jbc.C000593200
   Carrasco J, 1998, MOL BRAIN RES, V57, P221, DOI 10.1016/S0169-328X(98)00087-4
   Carrasco J, 2000, EUR J NEUROSCI, V12, P2311, DOI 10.1046/j.1460-9568.2000.00128.x
   Chaumont SB, 2001, MED SCI SPORT EXER, V33, P724
   Chen HN, 2001, DIABETES, V50, P2040, DOI 10.2337/diabetes.50.9.2040
   Cooper CE, 2002, BIOCHEM SOC T, V30, P280, DOI 10.1042/bst0300280
   DAVIES KJA, 1982, BIOCHEM BIOPH RES CO, V107, P1198, DOI 10.1016/S0006-291X(82)80124-1
   Febbraio MA, 2002, J PHYSIOL-LONDON, V538, P911, DOI 10.1013/jphysiol.2001.013145
   Febbraio MA, 2000, J APPL PHYSIOL, V89, P1055
   Fu K, 1998, PANCREAS, V17, P238, DOI 10.1097/00006676-199810000-00003
   Ghoshal K, 2001, PROG NUCLEIC ACID RE, V66, P357
   Ghoshal K, 1999, BIOCHEM BIOPH RES CO, V264, P735, DOI 10.1006/bbrc.1999.1563
   Giralt M, 2002, NEUROBIOL DIS, V9, P319, DOI 10.1006/nbdi.2002.0480
   Giralt M, 2002, EXP NEUROL, V173, P114, DOI 10.1006/exnr.2001.7772
   Haidara K, 1999, TOXICOL SCI, V49, P297, DOI 10.1093/toxsci/49.2.297
   Hernandez J, 1997, MOL BRAIN RES, V48, P125, DOI 10.1016/S0169-328X(97)00087-9
   Hernando R, 1997, EUR J BIOCHEM, V243, P460, DOI 10.1111/j.1432-1033.1997.0460a.x
   Hidalgo J, 2002, METHOD ENZYMOL, V348, P238, DOI 10.1016/S0076-6879(02)48642-9
   Hidalgo J, 2001, BRAIN RES BULL, V55, P133, DOI 10.1016/S0361-9230(01)00452-X
   JACKSON MJ, 1985, BIOCHIM BIOPHYS ACTA, V847, P185, DOI 10.1016/0167-4889(85)90019-9
   Jackson MJ, 1996, MED SPORT SCI, V41, P121
   JENKINS RR, 1984, INT J SPORTS MED, V5, P11, DOI 10.1055/s-2008-1025872
   JI LL, 1993, MED SCI SPORT EXER, V25, P225
   Jiang LJ, 1998, P NATL ACAD SCI USA, V95, P3483, DOI 10.1073/pnas.95.7.3483
   Keller C, 2001, FASEB J, V15, P2748, DOI 10.1096/fj.01-0507fje
   Kelly DA, 1996, J APPL PHYSIOL, V81, P2379
   Khassaf M, 2001, J APPL PHYSIOL, V90, P1031
   Kling PG, 2000, FREE RADICAL BIO MED, V28, P1628, DOI 10.1016/S0891-5849(00)00277-X
   Kumari MVR, 2000, CELL MOL BIOL, V46, P627
   LAZO JS, 1995, J BIOL CHEM, V270, P5506, DOI 10.1074/jbc.270.10.5506
   LAZO JS, 1995, ANNU REV PHARMACOL, V35, P635
   Lazo JS, 1998, CHEM-BIOL INTERACT, V112, P255, DOI 10.1016/S0009-2797(97)00165-8
   Liang QR, 2002, DIABETES, V51, P174, DOI 10.2337/diabetes.51.1.174
   McArdle A, 2003, FASEB J, V17, P355, DOI 10.1096/fj.03-0395fje
   Molinero A, 1998, NEUROCHEM INT, V33, P559, DOI 10.1016/S0197-0186(98)00065-5
   Molinero A, 2003, J NEUROPATH EXP NEUR, V62, P315, DOI 10.1093/jnen/62.3.315
   Moseley P L, 2000, Exerc Sport Sci Rev, V28, P128
   OH SH, 1978, AM J PHYSIOL, V234, pE282
   Ohly P, 2000, DIABETOLOGIA, V43, P1020, DOI 10.1007/s001250050009
   Patwell DM, 2004, FREE RADICAL BIO MED, V37, P1064, DOI 10.1016/j.freeradbiomed.2004.06.026
   Penkowa M, 2002, J COMP NEUROL, V444, P174, DOI 10.1002/cne.10149
   Penkowa M, 2003, FASEB J, V17, DOI 10.1096/fj.03-0311fje
   Penkowa M, 2003, GLIA, V42, P287, DOI 10.1002/glia.10208
   Penkowa M, 2000, J CEREBR BLOOD F MET, V20, P1174, DOI 10.1097/00004647-200008000-00003
   Penkowa M, 2001, J NEUROIMMUNOL, V119, P248, DOI 10.1016/S0165-5728(01)00357-5
   Penkowa M, 2000, GLIA, V32, P247, DOI 10.1002/1098-1136(200012)32:3<247::AID-GLIA50>3.0.CO;2-T
   PENKOWA M, 2003, BIOMED REV, V13, P1
   Pitt BR, 1997, AM J PHYSIOL-LUNG C, V273, pL856, DOI 10.1152/ajplung.1997.273.4.L856
   Rana Suresh V. S., 2000, Arhiv za Higijenu Rada i Toksikologiju, V51, P279
   ROBERTSON JD, 1991, CLIN SCI, V80, P611, DOI 10.1042/cs0800611
   RUDERMAN NB, 1992, DIABETES CARE, V15, P1787, DOI 10.2337/diacare.15.11.1787
   SALO DC, 1991, FREE RADICAL BIO MED, V11, P239, DOI 10.1016/0891-5849(91)90119-N
   SCHWARZ MA, 1994, J BIOL CHEM, V269, P15238
   SCHWARZ MA, 1995, P NATL ACAD SCI USA, V92, P4452, DOI 10.1073/pnas.92.10.4452
   Shinogi M, 1999, BIOL PHARM BULL, V22, P132
   Steensberg A, 2000, J PHYSIOL-LONDON, V529, P237, DOI 10.1111/j.1469-7793.2000.00237.x
   Suzuki Y, 2000, TOXICOLOGY, V145, P51, DOI 10.1016/S0300-483X(99)00220-6
   TAMAI KT, 1993, P NATL ACAD SCI USA, V90, P8013, DOI 10.1073/pnas.90.17.8013
   Theocharis SE, 2003, INT J BIOL MARKER, V18, P162
   THORNALLEY PJ, 1985, BIOCHIM BIOPHYS ACTA, V827, P36, DOI 10.1016/0167-4838(85)90098-6
   Trendelenburg G, 2002, J NEUROSCI, V22, P5879
   Viarengo A, 2000, CELL MOL BIOL, V46, P407
   Vina J, 2000, IUBMB LIFE, V50, P271, DOI 10.1080/15216540051080994
   Ye G, 2003, DIABETES, V52, P777, DOI 10.2337/diabetes.52.3.777
   Zheng H, 1996, TOXICOL LETT, V87, P139, DOI 10.1016/0378-4274(96)03770-8
NR 73
TC 25
Z9 28
U1 4
U2 11
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0958-0670
EI 1469-445X
J9 EXP PHYSIOL
JI Exp. Physiol.
PD JUL 1
PY 2005
VL 90
IS 4
BP 477
EP 486
DI 10.1113/expphysiol.2004.029371
PG 10
WC Physiology
SC Physiology
GA 939DH
UT WOS:000230052000008
PM 15640275
OA Bronze
DA 2018-12-27
ER

PT J
AU Takahashi, T
   Suzuki, M
   Shigematsu, H
   Shivapurkar, N
   Echebiri, C
   Nomura, M
   Stastny, V
   Augustus, M
   Wu, CW
   Wistuba, II
   Meltzer, SJ
   Gazdar, AF
AF Takahashi, T
   Suzuki, M
   Shigematsu, H
   Shivapurkar, N
   Echebiri, C
   Nomura, M
   Stastny, V
   Augustus, M
   Wu, CW
   Wistuba, II
   Meltzer, SJ
   Gazdar, AF
TI RETRACTED: Aberrant methylation of Reprimo in human malignancies
   (Retracted article. See vol. 132, pg. 498, 2013)
SO INTERNATIONAL JOURNAL OF CANCER
LA English
DT Article; Retracted Publication
DE Reprinzo; methylation; human cancer
ID CPG ISLAND HYPERMETHYLATION; PROMOTER METHYLATION; DNA METHYLATION;
   CHECKPOINT GENE; LUNG CANCERS; CELL-LINES; TUMOR; P53; EXPRESSION;
   BREAST
AB Reprimo is a new candidate mediator of p53-mediated cell cycle arrest at the G, phase. Loss of Reprimo gene expression accompanied by its promoter methylation was identified in pancreatic and lung cancers. Our aim was to examine the methylation status of Reprimo in a broad range of cancers. We examined Reprimo expression by RT-PCR and the DNA methylation status of the Reprimo promoter by MSP in 39 tumor cell lines. Loss or down-regulation of Reprimo expression was frequent (62%), and we confirmed that transcriptional repression of Reprimo was caused by hypermethylation (overall concordance 92%). Treatment of expression-negative cells with 5-aza-2'-deoxycytidine restored Reprimo expression. We then examined aberrant methylation of Reprimo in 645 tumors representing 16 tumor types. Promoter methylation of Reprimo was found in 79% of gastric cancers, 62% of gallbladder cancers, 57% of lymphomas, 56% of colorectal cancers, 40% of esophageal adenocarcinomas, 37% of breast cancers and 31% of leukemias. Methylation frequencies in ovarian cancers, bladder cancers, cervical cancers, brain tumors, malignant mesothelioma! and pediatric tumors were lower (0-20%). Reprimo methylation was rarely detected in nonmalignant tissues (0-11%) except for gastric epithelia. While colorectal Polyps were also frequently methylated (27%), chronic cholecystitis samples were infrequently methylated (4%). Furthermore, we failed to identify Reprimo mutation in colorectal and gastric cancer cell lines and 50 primary colorectal cancers. Aberrant methylation of Reprimo with loss 4 expression is a common event and may contribute to the pathogenesis of some types of human malignancy. (c) 2005 Wiley-Liss, Inc.
C1 Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, Dallas, TX 75390 USA.
   Gifu Univ, Sch Med, Dept Surg, Gifu, Japan.
   Univ Texas, SW Med Ctr, Dept Pathol, Dallas, TX USA.
   Avalon Pharmaceut, Germantown, MD USA.
   Vet Gen Hosp, Dept Surg, Taipei 11217, Taiwan.
   Univ Texas, MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA.
   Pontificia Univ Catolica Chile, Dept Anat Pathol, Santiago, Chile.
   Univ Maryland, Sch Med, Div Gastroenterol, Dept Med, Baltimore, MD USA.
   Greenebaum Canc Ctr, Baltimore, MD USA.
RP Gazdar, AF (reprint author), Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, 6000 Harry Hines Blvd, Dallas, TX 75390 USA.
EM Adi.Gazdar@UTSouthwestern.edu
FU NCI NIH HHS [CA95323, CA01808, CA85069, 5U01CA8497102, CA77057,
   CA098450]
CR Baylin SB, 2001, HUM MOL GENET, V10, P687, DOI 10.1093/hmg/10.7.687
   Corn PG, 2003, CARCINOGENESIS, V24, P47, DOI 10.1093/carcin/24.1.47
   Costello JF, 2000, NAT GENET, V24, P132, DOI 10.1038/72785
   Dasika GK, 1999, ONCOGENE, V18, P7883
   Gazdar AF, 1998, INT J CANCER, V78, P766, DOI 10.1002/(SICI)1097-0215(19981209)78:6<766::AID-IJC15>3.0.CO;2-L
   Harada K, 2002, ONCOGENE, V21, P4345, DOI 10.1038/sj.onc.1205446
   Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Kang GH, 2003, AM J PATHOL, V163, P1551, DOI 10.1016/S0002-9440(10)63511-0
   LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0
   Maruyama R, 2001, CANCER RES, V61, P8659
   Mizuno K, 2002, ONCOGENE, V21, P2328, DOI 10.1038/sj/onc/1205402
   NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0
   Ohki R, 2000, J BIOL CHEM, V275, P22627, DOI 10.1074/jbc.C000235200
   Olaru A, 2003, LAB INVEST, V83, P1867, DOI 10.1097/01.LAB.0000106723.75567.72
   Otsuka T, 1996, GENE CHROMOSOME CANC, V16, P113, DOI 10.1002/(SICI)1098-2264(199606)16:2<113::AID-GCC5>3.0.CO;2-2
   Piao Z, 2001, GENE CHROMOSOME CANC, V30, P113, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1069>3.3.CO;2-Y
   Sato N, 2003, CANCER RES, V63, P3735
   Suzuki H, 2000, CANCER RES, V60, P4353
   SUZUKI M, IN PRESS LUNG CANC
   Takahashi T, 2004, CLIN CANCER RES, V10, P2928, DOI 10.1158/1078-0432.CCR-03-0716
   Taylor WR, 2001, ONCOGENE, V20, P1803, DOI 10.1038/sj.onc.1204252
   Toyooka KO, 2001, CANCER RES, V61, P4556
   Toyooka S, 2002, CLIN CANCER RES, V8, P2292
   Toyooka S, 2001, CANCER RES, V61, P5727
   Toyota M, 2003, P NATL ACAD SCI USA, V100, P7818, DOI 10.1073/pnas.1337066100
   Waki T, 2002, AM J PATHOL, V161, P399, DOI 10.1016/S0002-9440(10)64195-8
   Wistuba II, 2004, NAT REV CANCER, V4, P695, DOI 10.1038/nrc1429
   Zhang ZQ, 2002, CANCER RES, V62, P3024
NR 30
TC 54
Z9 56
U1 3
U2 16
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0020-7136
J9 INT J CANCER
JI Int. J. Cancer
PD JUL 1
PY 2005
VL 115
IS 4
BP 503
EP 510
DI 10.1002/ijc.20910
PG 8
WC Oncology
SC Oncology
GA 925WA
UT WOS:000229082800001
PM 15700311
OA Bronze
DA 2018-12-27
ER

PT J
AU Roy, SD
   Philip, J
   Javle, P
AF Roy, SD
   Philip, J
   Javle, P
TI RETRACTED: Trends in prostate cancer incidence and survival in various
   socioeconomic classes: A population-based study (Retracted Article. See
   vol 13, pg 1364, 2006)
SO INTERNATIONAL JOURNAL OF UROLOGY
LA English
DT Article; Retracted Publication
DE cancer registry; prostate cancer; prostate-specific antigen test;
   socioeconomic deprivation; Townsend band
ID INTERPRETING TRENDS; SURVEILLANCE SERIES; DEPRIVATION INDEXES; RISING
   INCIDENCE; BREAST-CANCER; PART II; MORTALITY; PREVALENCE; CARCINOMA;
   ENGLAND
AB Objectives: Prostate cancer is currently the commonest cancer in men of all ages in UK, but robust demographic data of its distribution in various socioeconomic classes is lacking. We aimed to analyze its incidence, mortality and survival trends in West Midlands, England, from 1986 to 2000 in terms of socioeconomic deprivation.
   Methods: Data were collated from the regional cancer registry database and a well-validated demographic score, the Townsend band, was employed as an indicator of social deprivation, including four variables as proxy indicators of socioeconomic status. Individual cases were allocated to one of five deprivation categories using postcode at diagnosis. Regression trend analysis at 1 and 5 years was performed and a P-value derived from the t-test statistic.
   Results: In the mid-1980s, the incidence rate ratio in affluent:deprived classes was 0.9, with age-standardized rates of 35.23 and 39.53 per 100 000 people. This ratio increased to 1.5 by 2000 with age-standardized rates of 95.98 and 63.13, respectively (172% increase in affluent compared with 60% in deprived). The affluent groups had a 7 and 13% survival advantage at 1 and 5 years; the survival advantage at 1 year was statistically significant (P = 0.03).
   Conclusions: The preferential changes in incidence and survival in the affluent social classes are likely to be due to heightened awareness, resulting in increased prostate-specific antigen testing, which captures early and relatively slow-growing tumors with a better overall prognosis. If these bipolar trends are allowed to persist, then the gap between the affluent and deprived will continue to widen.
C1 Leighton Hosp, Dept Surg, Res Unit, Crewe CW1 4QJ, South Cheshire, England.
   Leighton Hosp, Dept Urol, Res Unit, Crewe CW1 4QJ, South Cheshire, England.
RP Roy, SD (reprint author), Leighton Hosp, Dept Surg, Res Unit, Crewe CW1 4QJ, South Cheshire, England.
EM subhodr@aol.com
CR ADLER NE, 1994, AM PSYCHOL, V49, P15, DOI 10.1037//0003-066X.49.1.15
   BAQUET CR, 1991, J NATL CANCER I, V83, P551, DOI 10.1093/jnci/83.8.551
   BARTLEY M, 1994, BRIT MED J, V309, P1479, DOI 10.1136/bmj.309.6967.1479
   Bennett CL, 1998, J CLIN ONCOL, V16, P3101, DOI 10.1200/JCO.1998.16.9.3101
   Brawley OW, 1997, CANCER-AM CANCER SOC, V80, P1857, DOI 10.1002/(SICI)1097-0142(19971101)80:9<1857::AID-CNCR26>3.0.CO;2-3
   Brewster DH, 2000, BJU INT, V85, P463, DOI 10.1046/j.1464-410x.2000.00487.x
   Bunker CH, 2002, CANCER EPIDEM BIOMAR, V11, P726
   *CANC RES UK, 2005, STAT PROST CANC
   Carstairs V, 1991, DEPRIVATION HLTH SCO
   Ciatto S, 2000, EUR J CANCER, V36, P1347, DOI 10.1016/S0959-8049(00)00119-2
   COLEMAN MP, 1999, 61 SMPS
   *DEP ENV, 1995, 1991 DEPR IND REV AP
   *DEP HLTH, 2000, NHS CANC PLAN PLAN I
   *DEP HLTH, 1998, REP IND INQ IN HLTH
   *DETR, 2000, 37 DEP ENV TRANSP RE
   *DETR, 2000, 31 DEP ENV TRANSP RE
   DREVER F, 1997, OFFICE NATL STAT HLT
   Etzioni R, 1999, J NATL CANCER I, V91, P1033, DOI 10.1093/jnci/91.12.1033
   Faggiano F, 1997, IARC Sci Publ, P65
   Feuer EJ, 1999, JNCI-J NATL CANCER I, V91, P1025, DOI 10.1093/jnci/91.12.1025
   Glover FE, 1998, J UROLOGY, V159, P1984, DOI 10.1016/S0022-5347(01)63220-8
   GOHAGAN JK, 1994, J UROLOGY, V152, P1905, DOI 10.1016/S0022-5347(17)32412-6
   GOREY KM, 1995, J COMMUN HEALTH, V20, P359, DOI 10.1007/BF02283060
   HAKKY SI, 1979, BRIT J UROL, V51, P393, DOI 10.1111/j.1464-410X.1979.tb02893.x
   HAKULINEN T, 1985, COMPUT PROG BIOMED, V19, P197, DOI 10.1016/0010-468X(85)90011-X
   Hankey BF, 1999, JNCI-J NATL CANCER I, V91, P1017, DOI 10.1093/jnci/91.12.1017
   Harvei S, 1997, PREV MED, V26, P623, DOI 10.1006/pmed.1997.0153
   *IARC, 1986, IARC MON EV CARC RIS, V38
   IARC - International Agency for Research on Cancer, 1988, IARC MON EV CARC RIS, V44
   Jensen O, 1991, IARC SCI PUBL, V95
   LAVECCHIA C, 1992, CANCER, V70, P2935, DOI 10.1002/1097-0142(19921215)70:12<2935::AID-CNCR2820701234>3.0.CO;2-3
   Liu LH, 2001, J NATL CANCER I, V93, P705, DOI 10.1093/jnci/93.9.705
   Mackenzie IF, 1998, J PUBLIC HEALTH MED, V20, P186, DOI 10.1093/oxfordjournals.pubmed.a024741
   Majeed A, 2000, BJU INT, V85, P1058, DOI 10.1046/j.1464-410x.2000.00661.x
   Marang-van de Mheen PJ, 1998, J EPIDEMIOL COMMUN H, V52, P214, DOI 10.1136/jech.52.4.214
   MCNEAL JE, 1998, LANCET, P60
   MORRIS R, 1991, J PUBLIC HEALTH MED, V13, P318
   Murphy M, 1999, BJU INT, V83, P786
   *OFF NAT STAT, 2002, CANC SURV ENGL 1993
   Pack Rebecca, 1993, Cancer Bulletin (Houston), V45, P384
   Parkin DM, 2001, EUR J CANCER, V37, pS4
   PHILLIMORE P, 1994, BRIT MED J, V308, P1125, DOI 10.1136/bmj.308.6937.1125
   PIENTA KJ, 1993, ANN INTERN MED, V118, P793, DOI 10.7326/0003-4819-118-10-199305150-00007
   Post PN, 1998, EUR J CANCER, V34, P705, DOI 10.1016/S0959-8049(97)10154-X
   POTOSKY AL, 1995, JAMA-J AM MED ASSOC, V273, P548, DOI 10.1001/jama.273.7.548
   Quinn M, 2002, BJU INT, V90, P174, DOI 10.1046/j.1464-410X.2002.02823.x
   SCHRIJVERS CTM, 1995, BRIT J CANCER, V72, P738, DOI 10.1038/bjc.1995.403
   Schroder FH, 2001, BJU INT, V88, P811, DOI 10.1046/j.1464-4096.2001.02449.x
   Schroder FH, 1996, INT J CANCER, V65, P145, DOI 10.1002/(SICI)1097-0215(19960117)65:2<145::AID-IJC4>3.0.CO;2-Z
   SELLEY S, 1997, HLTH TECHNOL ASSESS, V1
   SILVERBERG E, 1989, CA-CANCER J CLIN, V39, P3
   The Expert Advisory Group on Cancer to the Chief Medical Officers of England and Wales, 1995, POL FRAM COMM CANC S
   *U BIRM, 1997, P SEM HELD 24 NOV 19
NR 53
TC 11
Z9 12
U1 3
U2 11
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0919-8172
EI 1442-2042
J9 INT J UROL
JI Int. J. Urol.
PD JUL
PY 2005
VL 12
IS 7
BP 644
EP 653
DI 10.1111/j.1442-2042.2005.01111.x
PG 10
WC Urology & Nephrology
SC Urology & Nephrology
GA 946MK
UT WOS:000230576200006
PM 16045557
OA Bronze
DA 2018-12-27
ER

PT J
AU Crowther, LJ
   Yamagata, A
   Craig, L
   Tainer, JA
   Donnenberg, MS
AF Crowther, LJ
   Yamagata, A
   Craig, L
   Tainer, JA
   Donnenberg, MS
TI RETRACTED: The ATPase activity of BfpD is greatly enhanced by zinc and
   allosteric interactions with other Bfp proteins (Retracted Article. See
   vol 284, pg 21100, 2009)
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article; Retracted Publication
ID ENTEROPATHOGENIC ESCHERICHIA-COLI; CAG PATHOGENICITY ISLAND; HEXAMERIC
   TRAFFIC ATPASE; PSEUDOMONAS-AERUGINOSA; TWITCHING MOTILITY;
   VIBRIO-CHOLERAE; IV PILI; BACTERIAL CONJUGATION; CYTOPLASMIC MEMBRANE;
   SECRETION APPARATUS
AB Type IV pilus biogenesis, protein secretion, DNA transfer, and filamentous phage morphogenesis systems are thought to possess similar architectures and mechanisms. These multiprotein complexes include members of the PulE superfamily of putative NTPases that have extensive sequence similarity and probably similar functions as the energizers of macromolecular transport. We purified the PulE homologue BfpD of the enteropathogenic Escherichia coli bundle-forming pilus (BFP) biogenesis machine and characterized its ATPase activity, providing new insights into its mode of action. Numerous techniques revealed that BfpD forms hexamers in the presence of nucleotide. Hexameric BfpD displayed weak ATPase activity. We previously demonstrated that the N termini of membrane proteins BfpC and BfpE recruit BfpD to the cytoplasmic membrane. Here, we identified two BfpD-binding sites, BfpE(39-76) and BfpE(77-114), in the N terminus of BfpE using a yeast two-hybrid system. Isothermal titration calorimetry and protease sensitivity assays showed that hexameric BfpD-ATP gamma S binds to BfpE(77-114), whereas hexameric BfpD-ADP binds to BfpE(39-76). Interestingly, the N terminus of BfpC and BfpE(77-114) together increased the ATPase activity of hexameric BfpD over 1200-fold to a V-max of 75.3 mu mol of P-i min(-1) mg(-1), which exceeds by over 1200-fold the activity of other PulE family members. This augmented activity occurred only in the presence of Zn2+. We conclude that allosteric interactions between BfpD and BfpC and BfpE dramatically stimulate its ATPase activity. The differential nucleotide-dependent binding of hexameric BfpD to BfpE(39-76) and BfpE(77-114) suggests a model for the mechanism by which BfpD transduces mechanical energy to the biogenesis machine.
C1 Univ Maryland, Sch Med, Dept Med, Div Infect Dis, Baltimore, MD 21201 USA.
   Scripps Res Inst, Dept Biol Mol, La Jolla, CA 92037 USA.
   Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA.
RP Donnenberg, MS (reprint author), Univ Maryland, Sch Med, Dept Med, Div Infect Dis, HSF 2,20 Penn St, Baltimore, MD 21201 USA.
EM mdonnenb@umaryland.edu
OI Craig, Lisa/0000-0001-8515-9915
FU NIAID NIH HHS [R01 AI022160, R01 AI-37606, R01 AI037606, AI22160]
CR Anantha RP, 1998, INFECT IMMUN, V66, P122
   Anantha TP, 2000, J BACTERIOL, V182, P2498, DOI 10.1128/JB.182.9.2498-2506.2000
   Bhattacharjee MK, 2001, J BACTERIOL, V183, P5927, DOI 10.1128/JB.183.20.5927-5936.2001
   Bieber D, 1998, SCIENCE, V280, P2114, DOI 10.1126/science.280.5372.2114
   Blank TE, 2001, J BACTERIOL, V183, P4435, DOI 10.1128/JB.183.15.4435-4450.2001
   BRADLEY DE, 1980, CAN J MICROBIOL, V26, P146, DOI 10.1139/m80-022
   BRADLEY DE, 1972, BIOCHEM BIOPH RES CO, V47, P1080, DOI 10.1016/0006-291X(72)90944-8
   Camberg JL, 2005, J BACTERIOL, V187, P249, DOI 10.1128/JB.187.1.249-256.2005
   CHRISTIE PJ, 1989, P NATL ACAD SCI USA, V86, P9677, DOI 10.1073/pnas.86.24.9677
   Crowther LJ, 2004, MOL MICROBIOL, V52, P67, DOI 10.1046/j.1365-2958.2003.03963.x
   DONNENBERG MS, 1992, MOL MICROBIOL, V6, P3427, DOI 10.1111/j.1365-2958.1992.tb02210.x
   Dubnau D, 1999, ANNU REV MICROBIOL, V53, P217, DOI 10.1146/annurev.micro.53.1.217
   GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7
   Gomis-Ruth FX, 2001, NATURE, V409, P637, DOI 10.1038/35054586
   Hahn HP, 1997, GENE, V192, P99, DOI 10.1016/S0378-1119(97)00116-9
   HENRICHSEN J, 1983, ANNU REV MICROBIOL, V37, P81, DOI 10.1146/annurev.mi.37.100183.000501
   Herdendorf TJ, 2002, J BACTERIOL, V184, P6465, DOI 10.1128/JB.184.23.6465-6471.2002
   HERRINGTON DA, 1988, J EXP MED, V168, P1487, DOI 10.1084/jem.168.4.1487
   HOBBS M, 1993, MOL MICROBIOL, V10, P233, DOI 10.1111/j.1365-2958.1993.tb01949.x
   Hosfield DJ, 1999, CELL, V98, P397, DOI 10.1016/S0092-8674(00)81968-6
   Krause S, 2000, P NATL ACAD SCI USA, V97, P3067, DOI 10.1073/pnas.050578697
   Krause S, 2000, J BACTERIOL, V182, P2761, DOI 10.1128/JB.182.10.2761-2770.2000
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5
   Lenzen CU, 1998, CELL, V94, P525, DOI 10.1016/S0092-8674(00)81593-7
   Machon C, 2002, J BACTERIOL, V184, P1661, DOI 10.1128/JB.184.6.1661-1668.2002
   Merz AJ, 2000, NATURE, V407, P98, DOI 10.1038/35024105
   Merz AJ, 2000, ANNU REV CELL DEV BI, V16, P423, DOI 10.1146/annurev.cellbio.16.1.423
   Nataro JP, 1998, CLIN MICROBIOL REV, V11, P142
   O'Toole GA, 1998, MOL MICROBIOL, V30, P295, DOI 10.1046/j.1365-2958.1998.01062.x
   Outten CE, 2001, SCIENCE, V292, P2488, DOI 10.1126/science.1060331
   Peabody CR, 2003, MICROBIOL-SGM, V149, P3051, DOI 10.1099/mic.0.26364-0
   POSSOT O, 1994, MOL MICROBIOL, V12, P287, DOI 10.1111/j.1365-2958.1994.tb01017.x
   PUGSLEY AP, 1993, MICROBIOL REV, V57, P50
   Py B, 1999, J MOL BIOL, V289, P659, DOI 10.1006/jmbi.1999.2803
   Ramer SW, 1996, J BACTERIOL, V178, P6555, DOI 10.1128/jb.178.22.6555-6563.1996
   Ramer SW, 2002, J BACTERIOL, V184, P3457, DOI 10.1128/JB.184.13.3457-3465.2002
   Rivas S, 1997, J BIOL CHEM, V272, P25583, DOI 10.1074/jbc.272.41.25583
   Russel M, 1997, GENE, V192, P23, DOI 10.1016/S0378-1119(96)00801-3
   Sakai D, 2001, J BIOL CHEM, V276, P17968, DOI 10.1074/jbc.M010652200
   Sandkvist M, 1999, J BACTERIOL, V181, P3129
   SANDKVIST M, 1995, EMBO J, V14, P1664, DOI 10.1002/j.1460-2075.1995.tb07155.x
   SEIFERT HS, 1988, NATURE, V336, P392, DOI 10.1038/336392a0
   Sexton JA, 2004, J BACTERIOL, V186, P1658, DOI 10.1128/JB.186.6.1658-1666.2004
   SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5
   SOHEL I, 1993, MOL MICROBIOL, V7, P563, DOI 10.1111/j.1365-2958.1993.tb01147.x
   Sohel I, 1996, J BACTERIOL, V178, P2613, DOI 10.1128/jb.178.9.2613-2628.1996
   STINSON RA, 1973, BIOCHEM J, V131, P719, DOI 10.1042/bj1310719
   Stone KD, 1996, MOL MICROBIOL, V20, P325, DOI 10.1111/j.1365-2958.1996.tb02620.x
   STROM MS, 1993, ANNU REV MICROBIOL, V47, P565, DOI 10.1146/annurev.micro.47.1.565
   TURNER LR, 1993, J BACTERIOL, V175, P4962
   WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x
   Wall D, 1999, MOL MICROBIOL, V32, P1, DOI 10.1046/j.1365-2958.1999.01339.x
   WHITCHURCH CB, 1991, GENE, V101, P33, DOI 10.1016/0378-1119(91)90221-V
   WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3
   Yeo HJ, 2000, MOL CELL, V6, P1461, DOI 10.1016/S1097-2765(00)00142-8
   Yoshida T, 1999, J BACTERIOL, V181, P2038
   ZHANG HZ, 1994, J BACTERIOL, V176, P6885
   Zhang HZ, 1996, MOL MICROBIOL, V21, P787, DOI 10.1046/j.1365-2958.1996.431403.x
   Zhang XD, 2000, MOL CELL, V6, P1473, DOI 10.1016/S1097-2765(00)00143-X
NR 60
TC 31
Z9 33
U1 2
U2 8
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD JUL 1
PY 2005
VL 280
IS 26
BP 24839
EP 24848
DI 10.1074/jbc.M500253200
PG 10
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 939ZT
UT WOS:000230114000066
PM 15866879
OA Green Published, Bronze
DA 2018-12-27
ER

PT J
AU Cittadini, E
   Goadsby, PJ
AF Cittadini, E
   Goadsby, PJ
TI RETRACTED: Psychiatric side effects during methysergide treatment
   (Retracted article)
SO JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
LA English
DT Article; Retracted Publication
ID SCHIZOPHRENIA; AGONISTS
AB A patient is reported with psychological change characterised by impaired concentration and thought projection, followed by both severe anxiety and depression, starting after three weeks on high dose methysergide. The acute problem settled slowly after methysergide withdrawal and is likely to represent an unusual and serious side effect of that drug.
C1 Inst Neurol, London WC1N 3BG, England.
   UCL Natl Hosp Neurol & Neurosurg, London WC1, England.
RP Goadsby, PJ (reprint author), Inst Neurol, Queen Sq, London WC1N 3BG, England.
EM peterg@ion.ucl.ac.uk
RI Goadsby, Peter/B-2267-2009
CR Aghajanian GK, 2000, BRAIN RES REV, V31, P302, DOI 10.1016/S0165-0173(99)00046-6
   BERDE B, 1978, HDB EXPT PHARM, V49
   FISH B, 1969, DIS NERV SYST, V30, P534
   GLENNON RA, 1990, NEUROPSYCHOPHARMACOL, V3, P509
   HALE AR, 1962, AM J MED SCI, V243, P92, DOI 10.1097/00000441-196201000-00014
   Headache Classification Committee of the International Headache Society, 2004, CEPHALALGIA S1, V24, P1, DOI DOI 10.1111/J.1468-2982.2003.00824.X
   Heym J, 1987, Monogr Neural Sci, V13, P55
   MENDELS J, 1967, AM J PSYCHIAT, V124, P849, DOI 10.1176/ajp.124.6.849
   PERSYKO I, 1972, J NERV MENT DIS, V154, P299, DOI 10.1097/00005053-197204000-00010
   Rascol O, 2004, MOVEMENT DISORD, V19, P611, DOI 10.1002/mds.20202
   Roth Bryan L., 1995, P1215
   SANDERSBUSH E, 1995, GOODMAN GILMANS PHAR, P249
   Silberstein SD, 1998, CEPHALALGIA, V18, P421, DOI 10.1046/j.1468-2982.1998.1807421.x
   SKORZEWSKA A, 1989, NEUROPSYCHOBIOLOGY, V22, P125, DOI 10.1159/000118605
   WILCOX JA, 1987, J PSYCHOACTIVE DRUGS, V19, P387, DOI 10.1080/02791072.1987.10472428
NR 15
TC 5
Z9 5
U1 3
U2 13
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0022-3050
EI 1468-330X
J9 J NEUROL NEUROSUR PS
JI J. Neurol. Neurosurg. Psychiatry
PD JUL
PY 2005
VL 76
IS 7
BP 1037
EP 1038
DI 10.1136/jnnp.2004.048363
PG 2
WC Clinical Neurology; Psychiatry; Surgery
SC Neurosciences & Neurology; Psychiatry; Surgery
GA 940IL
UT WOS:000230137200035
PM 15965225
DA 2018-12-27
ER

PT J
AU Won, J
   Kim, M
   Yi, YW
   Kim, YH
   Jung, N
   Kim, TK
AF Won, J
   Kim, M
   Yi, YW
   Kim, YH
   Jung, N
   Kim, TK
TI RETRACTED: A magnetic nanoprobe technology for detecting molecular
   interactions in live cells (Retracted article. See vol. 324, pg. 463,
   2009)
SO SCIENCE
LA English
DT Article; Retracted Publication
ID TAT-FUSION PROTEINS; QUANTUM DOTS; IDENTIFICATION; MICROARRAYS;
   DELIVERY; RECEPTOR; INHIBITORS; TRACKING; CLONING; SYSTEM
AB Technologies to assess the molecular targets of biomolecules in living cells are lacking. We have developed a technology called magnetism-based interaction capture (MAGIC) that identifies molecular targets on the basis of induced movement of superparamagnetic nanoparticles inside living cells. Efficient intracellular uptake of superparamagnetic nanoparticles (coated with a small molecule of interest) was mediated by a transducible fusogenic peptide. These nanoprobes captured the small molecule's labeled target protein and were translocated in a direction specified by the magnetic field. Use of MAGIC in genome-wide expression screening identified multiple protein targets of a drug. MAGIC was also used to monitor signal-dependent modification and multiple interactions of proteins.
C1 Korea Adv Inst Sci & Technol, Dept Biol Sci, Taejon 305701, South Korea.
   CGK Co Ltd, Taejon 305701, South Korea.
RP Kim, TK (reprint author), Korea Adv Inst Sci & Technol, Dept Biol Sci, Taejon 305701, South Korea.
EM tkkim@kaist.ac.kr
CR Alexiou C, 2000, CANCER RES, V60, P6641
   Ashburn TT, 2004, NAT REV DRUG DISCOV, V3, P673, DOI 10.1038/nrd1468
   Baatz JE, 2001, BBA-MOL BASIS DIS, V1535, P100, DOI 10.1016/S0925-4439(00)00084-3
   Burdine L, 2004, CHEM BIOL, V11, P593, DOI 10.1016/j.chembiol.2004.05.001
   Caron NJ, 2004, BIOCHEM BIOPH RES CO, V319, P12, DOI 10.1016/j.bbrc.2004.04.180
   Clardy J, 2004, NATURE, V432, P829, DOI 10.1038/nature03194
   Derfus AM, 2004, ADV MATER, V16, P961, DOI 10.1002/adma.200306111
   Gonzalez-Gaitan Marcos, 2003, Cell, V115, P513, DOI 10.1016/S0092-8674(03)00932-2
   HARDING MW, 1989, NATURE, V341, P758, DOI 10.1038/341758a0
   JIN YJ, 1992, J BIOL CHEM, V267, P10942
   Joliot A, 2004, NAT CELL BIOL, V6, P189, DOI 10.1038/ncb0304-189
   Karin M, 2004, NAT REV DRUG DISCOV, V3, P17, DOI 10.1038/nrd1279
   Kuruvilla FG, 2002, NATURE, V416, P653, DOI 10.1038/416653a
   Lewin M, 2000, NAT BIOTECHNOL, V18, P410
   Licitra EJ, 1996, P NATL ACAD SCI USA, V93, P12817, DOI 10.1073/pnas.93.23.12817
   Liu JO, 2003, BIOCHEM BIOPH RES CO, V311, P1103, DOI 10.1016/j.bbrc.2003.10.020
   Lum PY, 2004, CELL, V116, P121, DOI 10.1016/S0092-8674(03)01035-3
   MacBeath G, 2000, SCIENCE, V289, P1760
   Mack A, 2000, J IMMUNOL METHODS, V241, P19, DOI 10.1016/S0022-1759(00)00195-2
   Marton MJ, 1998, NAT MED, V4, P1293, DOI 10.1038/3282
   Michalet X, 2005, SCIENCE, V307, P538, DOI 10.1126/science.1104274
   Oda Y, 2003, ANAL CHEM, V75, P2159, DOI 10.1021/ac026196y
   PEATTIE DA, 1992, P NATL ACAD SCI USA, V89, P10974, DOI 10.1073/pnas.89.22.10974
   Sche PP, 1999, CHEM BIOL, V6, P707, DOI 10.1016/S1074-5521(00)80018-6
   Stockwell BR, 2004, NATURE, V432, P846, DOI 10.1038/nature03196
   Strausberg RL, 2003, SCIENCE, V300, P294, DOI 10.1126/science.1083395
   Wadia JS, 2004, NAT MED, V10, P310, DOI 10.1038/nm996
NR 27
TC 124
Z9 130
U1 5
U2 11
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 0036-8075
EI 1095-9203
J9 SCIENCE
JI Science
PD JUL 1
PY 2005
VL 309
IS 5731
BP 121
EP 125
DI 10.1126/science.1112869
PG 5
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 941KD
UT WOS:000230212800072
PM 15994554
OA Bronze
DA 2018-12-27
ER

PT J
AU Schramke, V
   Sheedy, DM
   Denli, AM
   Bonila, C
   Ekwall, K
   Hannon, GJ
   Allshire, RC
AF Schramke, V
   Sheedy, DM
   Denli, AM
   Bonila, C
   Ekwall, K
   Hannon, GJ
   Allshire, RC
TI RETRACTED: RNA-interference-directed chromatin modification coupled to
   RNA polymerase II transcription (Retracted article. See vol. 437, pg.
   1057, 2005)
SO NATURE
LA English
DT Article; Retracted Publication
ID GENOME REARRANGEMENT; GENE-EXPRESSION; DNA METHYLATION; HUMAN-CELLS;
   HETEROCHROMATIN; YEAST; RITS; MAINTENANCE; TETRAHYMENA; COMPLEX
AB RNA interference (RNAi) acts on long double-stranded RNAs (dsRNAs) in a variety of eukaryotes to generate small interfering RNAs that target homologous messenger RNA, resulting in their destruction. This process is widely used to 'knock-down' the expression of genes of interest to explore phenotypes(1-3). In plants(3-5), fission yeast(6-8), ciliates(9,10), flies(11) and mammalian cells(12,13), short interfering RNAs (siRNAs) also induce DNA or chromatin modifications at the homologous genomic locus, which can result in transcriptional silencing or sequence elimination(14). siRNAs may direct DNA or chromatin modification by siRNA - DNA interactions at the homologous locus(4,5). Alternatively, they may act by interactions between siRNA and nascent transcript(15,16). Here we show that in fission yeast ( Schizosaccharomyces pombe), chromatin modifications are only directed by RNAi if the homologous DNA sequences are transcribed. Furthermore, transcription by exogenous T7 polymerase is not sufficient. Ago1, a component of the RNAi effector RISC/RITS complex, associates with target transcripts and RNA polymerase II. Truncation of the regulatory carboxy-terminal domain (CTD) of RNApol II disrupts transcriptional silencing, indicating that, like other RNA processing events(17-19), RNAi-directed chromatin modification is coupled to transcription.
C1 Univ Edinburgh, Inst Cell & Mol Biol, Wellcome Trust Ctr Cell Biol, Edinburgh EH9 3JR, Midlothian, Scotland.
   Cold Spring Harbor Lab, Watson Sch Biol Sci, Cold Spring Harbor, NY 11724 USA.
   Univ Coll Sodertorn, Karolinska Inst, Dept Biosci, Dept Nat Sci, S-14189 Huddinge, Sweden.
RP Allshire, RC (reprint author), Univ Edinburgh, Inst Cell & Mol Biol, Wellcome Trust Ctr Cell Biol, Kings Bldg, Edinburgh EH9 3JR, Midlothian, Scotland.
EM robin.allshire@ed.ac.uk
FU Wellcome Trust
CR Aranda A, 2001, MOL CELL, V7, P1003, DOI 10.1016/S1097-2765(01)00235-0
   Baulcombe D, 2004, NATURE, V431, P356, DOI 10.1038/nature02874
   Grewal SIS, 2003, SCIENCE, V301, P798, DOI 10.1126/science.1086887
   Hannon GJ, 2004, NATURE, V431, P371, DOI 10.1038/nature02870
   Herr AJ, 2005, SCIENCE, V308, P118, DOI 10.1126/science.1106910
   Jones L, 2001, CURR BIOL, V11, P747, DOI 10.1016/S0960-9822(01)00226-3
   Kawasaki H, 2004, NATURE, V431, P211, DOI 10.1038/nature02889
   Lippman Z, 2004, NATURE, V431, P364, DOI 10.1038/nature02875
   Martienssen RA, 2003, NAT GENET, V35, P213, DOI 10.1038/ng1252
   Matzke MA, 2005, NAT REV GENET, V6, P24, DOI 10.1038/nrg1500
   Mello CC, 2004, NATURE, V431, P338, DOI 10.1038/nature02872
   Mette MF, 2000, EMBO J, V19, P5194, DOI 10.1093/emboj/19.19.5194
   Mochizuki K, 2004, CURR OPIN GENET DEV, V14, P181, DOI 10.1016/j.gde.2004.01.004
   Mochizuki K, 2002, CELL, V110, P689, DOI 10.1016/S0092-8674(02)00909-1
   Morris KV, 2004, SCIENCE, V305, P1289, DOI 10.1126/science.1101372
   Motamedi MR, 2004, CELL, V119, P789, DOI 10.1016/j.cell.2004.11.034
   Noma K, 2004, NAT GENET, V36, P1174, DOI 10.1038/ng1452
   Onodera Y, 2005, CELL, V120, P613, DOI 10.1016/j.cell.2005.02.007
   Orphanides G, 2002, CELL, V108, P439, DOI 10.1016/S0092-8674(02)00655-4
   Pal-Bhadra M, 2004, SCIENCE, V303, P669, DOI 10.1126/science.1092653
   Partridge JF, 2000, GENE DEV, V14, P783
   Partridge JF, 2002, CURR BIOL, V12, P1652, DOI 10.1016/S0960-9822(02)01177-6
   Pidoux AL, 2003, J CELL BIOL, V161, P295, DOI 10.1083/jcb.200212110
   Proudfoot N, 2004, CURR OPIN CELL BIOL, V16, P272, DOI 10.1016/j.ceb.2004.03.007
   Reed R, 2003, CURR OPIN CELL BIOL, V15, P326, DOI 10.1016/S0955-0674(03)00048-6
   SCAFE C, 1990, MOL CELL BIOL, V10, P1010, DOI 10.1128/MCB.10.3.1010
   Schramke V, 2003, SCIENCE, V301, P1069, DOI 10.1126/science.1086870
   Sugiyama T, 2005, P NATL ACAD SCI USA, V102, P152, DOI 10.1073/pnas.0407641102
   Verdel A, 2004, SCIENCE, V303, P672, DOI 10.1126/science.1093686
   Volpe TA, 2002, SCIENCE, V297, P1833, DOI 10.1126/science.1074973
NR 30
TC 54
Z9 64
U1 43
U2 58
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0028-0836
EI 1476-4687
J9 NATURE
JI Nature
PD JUN 30
PY 2005
VL 435
IS 7046
BP 1275
EP 1279
DI 10.1038/nature03652
PG 5
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 940JJ
UT WOS:000230140500052
PM 15965464
DA 2018-12-27
ER

PT J
AU Jin, BH
   Kwon, HD
   Cho, YE
AF Jin, BH
   Kwon, HD
   Cho, YE
TI RETRACTED: Cortical margining capabilities of fins associated with
   ventral cervical spine instrumentation (Retracted Article. See vol 47,
   pg 291, 2006)
SO YONSEI MEDICAL JOURNAL
LA English
DT Article; Retracted Publication
DE biomechanics; cervical plate; fins
ID BIOMECHANICAL EVALUATION; VERTEBRAL BODY; COMPRESSIVE STRENGTH;
   TRABECULAR BONE; PLATE FIXATION; END-PLATE; ANTERIOR; FUSION;
   STABILIZATION; THICKNESS
AB Fins incorporated into the design of a dynamic cervical spine implant have been employed to enhance axial load-bearing ability, yet their true biomechanical advantages, if any, have not been defined. Therefore, the goal of this study was to assess the biomechanical and axial load-bearing contributions of the fin components of the DOC ventral cervical stabilization system. Eighteen fresh cadaveric thoracic vertebrae (T1-T3) were obtained. Three test conditions were devised and studied: Condition A (DOC implants with fins were placed against the superior endplate and bone screws were not inserted); Condition B (DOC implant without fins was placed and bone screws were inserted); and Condition C (DOC implant with fins were placed against the superior endplate and bone screws were inserted). Specimens were tested by applying a pure axial compressive load to the superior platform of the DOC construct, and load-displacement data were collected. Condition C specimens had the greatest stiffness (459 +/- 80 N/mm) and yield load (526 +/- 168 N). Condition A specimens were the least stiff (266 +/- 53 N/mm), and had the smallest yield loads (180 +/- 54 N). The yield load of condition A plus condition B was approximately equal to that of condition C, with condition A contributing about one-third and condition B contributing two-thirds of the overall load-bearing capacity. Although the screws alone contributed to a substantial portion of axial load-bearing ability, the addition of the fins further increased load-bearing capabilities.
C1 Yonsei Univ, Coll Med, Dept Neurosurg, Seoul, South Korea.
RP Jin, BH (reprint author), Yonsei Univ, Coll Med, Yongdong Severance Hosp, Dept Neurosurg, 146-92 Dogok Dong, Seoul 135720, South Korea.
EM bhjin61@yumc.yonsei.ac.kr
CR BENZEL EC, 2001, AM ASS NEUROLOGICAL, V155, P431
   BRINCKMANN P, 1983, SPINE, V8, P851, DOI 10.1097/00007632-198311000-00007
   Brodke DS, 2001, SPINE, V26, P1324, DOI 10.1097/00007632-200106150-00010
   BROWN JA, 1988, SPINE, V13, P236, DOI 10.1097/00007632-198803000-00003
   BURR DB, 1994, SPINAL DISORDERS AGI
   Clausen JD, 1996, J NEUROSURG, V84, P1039, DOI 10.3171/jns.1996.84.6.1039
   DiAngelo DJ, 2000, SPINE, V25, P783, DOI 10.1097/00007632-200004010-00005
   Edwards WT, 2001, SPINE, V26, P218
   Grubb MR, 1998, SPINE, V23, P886, DOI 10.1097/00007632-199804150-00009
   HORST M, 1981, SPINE, V6, P217, DOI 10.1097/00007632-198105000-00004
   Kanayama M, 1998, SPINE, V23, P767, DOI 10.1097/00007632-199804010-00004
   Koh YD, 2001, SPINE, V26, P15, DOI 10.1097/00007632-200101010-00005
   MAZESS RB, 1990, CALCIFIED TISSUE INT, V47, P191, DOI 10.1007/BF02555918
   MOSEKILDE L, 1985, BONE, V6, P291, DOI 10.1016/8756-3282(85)90317-5
   MOSEKILDE L, 1986, BONE, V7, P207, DOI 10.1016/8756-3282(86)90019-0
   NEWMAN M, 1993, SPINE, V18, P2380, DOI 10.1097/00007632-199312000-00002
   ROBINSON RA, 1962, J BONE JOINT SURG AM, V44, P1569, DOI 10.2106/00004623-196244080-00007
   ROCKOFF SD, 1969, CALC TISS RES, V3, P163, DOI 10.1007/BF02058659
   Silva MJ, 1997, SPINE, V22, P140, DOI 10.1097/00007632-199701150-00004
   SILVA MJ, 1994, BONE, V15, P409, DOI 10.1016/8756-3282(94)90817-6
   Spivak JM, 1999, SPINE, V24, P334, DOI 10.1097/00007632-199902150-00005
   Vaccaro AR, 1998, J SPINAL DISORD, V11, P410
   Wang JC, 1998, SPINE, V23, P2450, DOI 10.1097/00007632-199811150-00020
   Wang JL, 2000, SPINE, V25, P1649, DOI 10.1097/00007632-200007010-00008
   YOGANANDAN N, 1988, CLIN BIOMECH, V3, P11, DOI 10.1016/0268-0033(88)90119-2
NR 25
TC 1
Z9 1
U1 3
U2 5
PU YONSEI UNIV COLL MEDICINE
PI SEOUL
PA 50-1 YONSEI-RO, SEODAEMUN-GU, SEOUL 120-752, SOUTH KOREA
SN 0513-5796
EI 1976-2437
J9 YONSEI MED J
JI Yonsei Med. J.
PD JUN 30
PY 2005
VL 46
IS 3
BP 372
EP 378
DI 10.3349/ymj.2005.46.3.372
PG 7
WC Medicine, General & Internal
SC General & Internal Medicine
GA 944SH
UT WOS:000230448900009
PM 15988809
OA Green Published, Other Gold
DA 2018-12-27
ER

PT J
AU Gon, Y
   Wood, MR
   Kiosses, WB
   Jo, E
   Sanna, MG
   Chun, J
   Rosen, H
AF Gon, Y
   Wood, MR
   Kiosses, WB
   Jo, E
   Sanna, MG
   Chun, J
   Rosen, H
TI RETRACTED: S1P(3) receptor-induced reorganization of epithelial tight
   junctions compromises lung barrier integrity and is potentiated by TNF
   (Retracted Article. See vol 106, pg 12561, 2009)
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article; Retracted Publication
DE pulmonary integrity
ID NECROSIS-FACTOR-ALPHA; SPHINGOSINE 1-PHOSPHATE; PARACELLULAR
   PERMEABILITY; PULMONARY-EDEMA; RHO; SPHINGOSINE-1-PHOSPHATE; CERAMIDE;
   ADHESION; MURINE; CELLS
AB Pulmonary pathologies including adult respiratory distress syndrome are characterized by disruption of pulmonary integrity and edema compromising respiratory function. Sphingosine 1-phosphate (S1P) is a lipid mediator synthesized and/or stored in mast cells, platelets, and epithelial cells, with production up-regulated by the proinflammatory cytokines IL-1 and TNF. S1P administration via the airways but not via the vasculature induces lung leakage. Using receptor-null mice, we show that S1P, acting on S1P3 receptor expressed on both type I and type II alveolar epithelial cells but not vascular endothelium, induces pulmonary edema by acute tight junction opening. WT but not S1P(3)-null mice showed disruption of pulmonary epithelial tight junctions and the appearance of paracellular gaps between epithelial cells by electron microscopy within I h of airways exposure to S1P. We further show by fluorescence microscopy that S1P induced rapid loss of ZO-1 reactivity, an essential component of the cytoplasmic plaque associated with tight junctions, as well as of the tetraspannin Claudin-18, an integral membrane organizer of tight junctions. S1P shows synergistic activity with the proinflammatory cytokine TNF, showing both pulmonary edema and mortality at subthreshold S1P doses. Specifically, preexposure of mice to subthreshold doses of TNF, which alone induced no lung edema, exacerbated S1P-induced edema and impaired survival. S1P, acting through S1P3, regulates epithelial integrity and acts additively with TNF in compromising respiratory barrier function. Because S1P3-null mice are resistant to S1P-induced pulmonary leakage, either alone or in the presence of TNF, S1P3 antagonism may be useful in protecting epithelial integrity in pulmonary disease.
C1 Scripps Res Inst, Helen L Dorris Child & Adolescent Neuropsychiat D, Dept Immunol, La Jolla, CA 92037 USA.
   Scripps Res Inst, Helen L Dorris Child & Adolescent Neuropsychiat D, Core Microscopy Facil, La Jolla, CA 92037 USA.
   Scripps Res Inst, Helen L Dorris Child & Adolescent Neuropsychiat D, Dept Mol Biol, La Jolla, CA 92037 USA.
RP Rosen, H (reprint author), Scripps Res Inst, Helen L Dorris Child & Adolescent Neuropsychiat D, Dept Immunol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.
EM hrosen@scripps.edu
FU NIAID NIH HHS [AI055509, R01 AI055509]
CR Baluk P, 1999, BRIT J PHARMACOL, V126, P522, DOI 10.1038/sj.bjp.0702323
   Barnes PJ, 2004, NAT MED, V10, P130, DOI 10.1038/nm0204-130
   Benais-Pont G, 2003, J CELL BIOL, V160, P729, DOI 10.1083/jcb.200211047
   Borok Z, 1996, AM J PHYSIOL-LUNG C, V270, pL559
   BUHL AM, 1995, J BIOL CHEM, V270, P24631, DOI 10.1074/jbc.270.42.24631
   Clair T, 2003, CANCER RES, V63, P5446
   Drobnik W, 2003, J LIPID RES, V44, P754, DOI 10.1194/jlr.M200401-JLR200
   Ferro T, 2000, AM J PHYSIOL-LUNG C, V278, pL1107
   Forrest M, 2004, J PHARMACOL EXP THER, V309, P758, DOI 10.1124/jpet.103.062828
   Fujita H, 2000, BIOCHEM J, V346, P617, DOI 10.1042/0264-6021:3460617
   Garcia JGN, 2001, J CLIN INVEST, V108, P689, DOI 10.1172/JCI12450
   Goggel R, 2004, NAT MED, V10, P155, DOI 10.1038/nm977
   GOLDBLUM SE, 1993, AM J PHYSIOL, V264, pC894
   Gopalakrishnan S, 1998, AM J PHYSIOL-CELL PH, V275, pC798, DOI 10.1152/ajpcell.1998.275.3.C798
   GREEN TP, 1988, J LAB CLIN MED, V111, P173
   Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509
   Hasegawa H, 1999, J BIOL CHEM, V274, P20982, DOI 10.1074/jbc.274.30.20982
   Hirase T, 2001, J BIOL CHEM, V276, P10423, DOI 10.1074/jbc.M007136200
   Hla T, 2001, PROSTAG OTH LIPID M, V64, P135, DOI 10.1016/S0090-6980(01)00109-5
   HOCKING DC, 1990, CIRC RES, V67, P68, DOI 10.1161/01.RES.67.1.68
   Ishii I, 2001, J BIOL CHEM, V276, P33697, DOI 10.1074/jbc.M104441200
   Ishii I, 2004, ANNU REV BIOCHEM, V73, P321, DOI 10.1146/annurev.biochem.73.011303.073731
   JOHNSON J, 1989, J APPL PHYSIOL, V66, P1448
   Jolly PS, 2004, J EXP MED, V199, P959, DOI 10.1084/jem.20030680
   Jolly PS, 2002, MOL IMMUNOL, V38, P1239, DOI 10.1016/S0161-5890(02)00070-6
   Jou TS, 1998, J CELL BIOL, V142, P101, DOI 10.1083/jcb.142.1.101
   Kiuchi M, 2000, J MED CHEM, V43, P2946, DOI 10.1021/jm000173z
   Kiuchi M, 1998, BIOORG MED CHEM LETT, V8, P101, DOI 10.1016/S0960-894X(97)10188-3
   Liu F, 2001, AM J RESP CELL MOL, V24, P711, DOI 10.1165/ajrcmb.24.6.4323
   MA T, 2005, BIOCHEM BIOPH RES CO, V326, P521
   Mandala S, 2002, SCIENCE, V296, P346, DOI 10.1126/science.1070238
   Mandala SM, 1998, P NATL ACAD SCI USA, V95, P150, DOI 10.1073/pnas.95.1.150
   McVerry BJ, 2004, AM J RESP CRIT CARE, V170, P987, DOI 10.1164/rccm.200405-684oc
   McVerry BJ, 2005, CELL SIGNAL, V17, P131, DOI 10.1016/j.cellsig.2004.08.006
   McVerry BJ, 2004, J CELL BIOCHEM, V92, P1075, DOI 10.1002/jcb.20088
   Moxley MA, 2000, AM J PHYSIOL-LUNG C, V279, pL985
   NUSRAT A, 1995, P NATL ACAD SCI USA, V92, P10629, DOI 10.1073/pnas.92.23.10629
   Offermanns S, 1997, SCIENCE, V275, P533, DOI 10.1126/science.275.5299.533
   Petrache I, 2005, NAT MED, V11, P491, DOI 10.1038/nm1238
   Rosenfeldt HM, 2003, FASEB J, V17, P1789, DOI 10.1096/fj.02-0836com
   Rosenfeldt HM, 2001, FASEB J, V15, P2649, DOI 10.1096/fj.01-0523com
   Sanna MG, 2004, J BIOL CHEM, V279, P13839, DOI 10.1074/jbc.M311743200
   SERFILIPPI G, 1994, AM J PHYSIOL, V267, pL282
   Spiegel S, 2003, NAT REV MOL CELL BIO, V4, P397, DOI 10.1038/nrm1103
   STANDIFORD TJ, 1995, J IMMUNOL, V155, P1515
   STEVENSON BR, 1986, J CELL BIOL, V103, P755, DOI 10.1083/jcb.103.3.755
   Takaishi K, 1997, J CELL BIOL, V139, P1047, DOI 10.1083/jcb.139.4.1047
   TAYLOR AE, 1970, AM J PHYSIOL, V218, P1133
   Walsh SV, 2001, GASTROENTEROLOGY, V121, P566, DOI 10.1053/gast.2001.27060
   Weinacker AB, 2001, ANNU REV MED, V52, P221, DOI 10.1146/annurev.med.52.1.221
   Wojciak-Stothard B, 2001, J CELL SCI, V114, P1343
   Zhang GF, 1999, GENE, V227, P89, DOI 10.1016/S0378-1119(98)00589-7
NR 52
TC 94
Z9 98
U1 3
U2 9
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD JUN 28
PY 2005
VL 102
IS 26
BP 9270
EP 9275
DI 10.1073/pnas.0501997102
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 941CD
UT WOS:000230191400034
PM 15968000
OA Green Published, Bronze
DA 2018-12-27
ER

PT J
AU Hwang, WS
   Roh, SI
   Lee, BC
   Kang, SK
   Kwon, DK
   Kim, S
   Kim, SJ
   Park, SW
   Kwon, HS
   Lee, CK
   Lee, JB
   Kim, JM
   Ahn, C
   Paek, SH
   Chang, SS
   Koo, JJ
   Yoon, HS
   Hwang, JH
   Hwang, YY
   Park, YS
   Oh, SK
   Kim, HS
   Park, JH
   Moon, SY
   Schatten, G
AF Hwang, WS
   Roh, SI
   Lee, BC
   Kang, SK
   Kwon, DK
   Kim, S
   Kim, SJ
   Park, SW
   Kwon, HS
   Lee, CK
   Lee, JB
   Kim, JM
   Ahn, C
   Paek, SH
   Chang, SS
   Koo, JJ
   Yoon, HS
   Hwang, JH
   Hwang, YY
   Park, YS
   Oh, SK
   Kim, HS
   Park, JH
   Moon, SY
   Schatten, G
TI RETRACTED: Patient-specific embryonic stem cells derived from human SCNT
   blastocysts (Retracted Article. See vol 311, pg 335, 2006)
SO SCIENCE
LA English
DT Article; Retracted Publication
ID NUCLEAR TRANSFER; CENTROSOME; LINES; DERIVATION; DEFECTS; SCIENCE;
   PROTEIN; CLONING; FETAL; MICE
AB Patient-specific, immune-matched human embryonic stem cells (hESCs) are anticipated to be of great biomedical importance for studies of disease and development and to advance clinical deliberations regarding stem cell transplantation. Eleven hESC lines were established by somatic cell nuclear transfer (SCNT) of skin cells from patients with disease or injury into donated oocytes. These lines, nuclear transfer (NT)-hESCs, grown on human feeders from the same NT donor or from genetically unrelated individuals, were established at high rates, regardless of NT donor sex or age. NT-hESCs were pluripotent, chromosomally normal, and matched the NT patient's DNA. The major histocompatibility complex identity of each NT-hESC when compared to the patient's own showed immunological compatibility, which is important for eventual transplantation. With the generation of these NT-hESCs, evaluations of genetic and epigenetic stability can be made. Additional work remains to be done regarding the development of reliable directed differentiation and the elimination of remaining animal components. Before clinical use of these cells can occur, preclinical evidence is required to prove that transplantation of differentiated NT-hESCs can be safe, effective, and tolerated.
C1 Seoul Natl Univ, Coll Vet Med, Seoul 151742, South Korea.
   Seoul Natl Univ, Sch Agr Biotechnol, Seoul 151742, South Korea.
   MizMed Hosp, Med Res Ctr, Seoul 135280, South Korea.
   Seoul Natl Univ, Coll Med, Seoul 110744, South Korea.
   Hanna Womens Clin, Seoul 137872, South Korea.
   Hanyang Univ, Sch Med, Seoul 471701, South Korea.
   Univ Pittsburgh, Sch Med, Pittsburgh Dev Ctr, Magee Womens Res Inst,Dept Obstet Gynecol & Repro, Pittsburgh, PA 15213 USA.
   Univ Pittsburgh, Sch Med, Dept Cell Biol & Physiol, Pittsburgh, PA 15213 USA.
RP Hwang, WS (reprint author), Seoul Natl Univ, Coll Vet Med, Seoul 151742, South Korea.
EM hwangws@snu.ac.kr; gschatten@pdc.magee.edu
RI Schatten, Gerald/B-3253-2009; Ahn, Curie/J-5527-2012
OI Schatten, Gerald/0000-0001-5206-7782; 
CR Barberi T, 2003, NAT BIOTECHNOL, V21, P1200, DOI 10.1038/nbt870
   Brinkley BR, 2001, TRENDS CELL BIOL, V11, P18, DOI 10.1016/S0962-8924(00)01872-9
   Brivanlou AH, 2003, SCIENCE, V300, P913, DOI 10.1126/science.1082940
   Cowan CA, 2004, NEW ENGL J MED, V350, P1353, DOI 10.1056/NEJMsr040330
   Drukker M, 2004, TRENDS BIOTECHNOL, V22, P136, DOI 10.1016/j.tibtech.2004.01.003
   Gardner DK, 2004, FERTIL STERIL, V81, P551, DOI 10.1016/j.fertnstert.2003.07.023
   Hwang WS, 2004, SCIENCE, V303, P1669, DOI 10.1126/science.1094515
   Jaenisch R, 2004, NEW ENGL J MED, V351, P2787, DOI 10.1056/NEJMp048304
   Kim SJ, 2005, MOL CELLS, V19, P46
   Lai LX, 2002, SCIENCE, V295, P1089, DOI 10.1126/science.1068228
   Lanasa MC, 2000, SEMIN REPROD MED, V18, P97, DOI 10.1055/s-2000-13480
   Lee GS, 2005, THERIOGENOLOGY, V63, P973, DOI 10.1016/j.therigenology.2004.04.017
   Lindvall O, 2003, P NATL ACAD SCI USA, V100, P7430, DOI 10.1073/pnas.1332673100
   Martin MJ, 2005, NAT MED, V11, P228, DOI 10.1038/nm1181
   Navara CS, 1996, P NATL ACAD SCI USA, V93, P5384, DOI 10.1073/pnas.93.11.5384
   Nolen LD, 2005, DEV BIOL, V279, P525, DOI 10.1016/j.ydbio.2005.01.016
   Phelps CJ, 2003, SCIENCE, V299, P411, DOI 10.1126/science.1078942
   Quintyne NJ, 2005, SCIENCE, V307, P127, DOI 10.1126/science.1104905
   Rideout WM, 2002, CELL, V109, P17, DOI 10.1016/S0092-8674(02)00681-5
   Rothstein JD, 2004, NAT BIOTECHNOL, V22, P283, DOI 10.1038/nbt0304-283
   RUGGGUNN RJ, 2005, IN PRESS NAT GE 0501
   Schatten G, 2003, SCIENCE, V299, P344
   Semple JI, 2003, GENE, V314, P41, DOI 10.1016/S0378-1119(03)00735-2
   Senda S, 2004, BIOCHEM BIOPH RES CO, V321, P38, DOI 10.1016/j.bbrc.2004.06.096
   Simerly C, 2004, DEV BIOL, V276, P237, DOI 10.1016/j.ydbio.2004.10.006
   SIMERLY C, 1995, NAT MED, V1, P47, DOI 10.1038/nm0195-47
   St John JC, 2004, GENETICS, V167, P897, DOI 10.1534/genetics.103.025049
   Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145
   Wilmut I, 1997, NATURE, V385, P810, DOI 10.1038/385810a0
NR 29
TC 296
Z9 309
U1 6
U2 26
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 0036-8075
EI 1095-9203
J9 SCIENCE
JI Science
PD JUN 17
PY 2005
VL 308
IS 5729
BP 1777
EP 1783
DI 10.1126/science.1112286
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 937LY
UT WOS:000229926800052
PM 15905366
OA Bronze
DA 2018-12-27
ER

PT J
AU Schofer, JM
   Lee, J
AF Schofer, JM
   Lee, J
TI RETRACTED: Abdominal pregnancy (Retracted Article)
SO ANNALS OF EMERGENCY MEDICINE
LA English
DT Editorial Material; Retracted Publication
C1 USN, Ctr Med, Emergency Dept, San Diego, CA USA.
   Scripps Med Hosp, Emergency Dept, San Diego, CA USA.
RP Schofer, JM (reprint author), USN, Ctr Med, Emergency Dept, San Diego, CA USA.
NR 0
TC 0
Z9 1
U1 2
U2 16
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0196-0644
J9 ANN EMERG MED
JI Ann. Emerg. Med.
PD JUN
PY 2005
VL 45
IS 6
BP 676
EP +
DI 10.1016/j.annemergmed.2004.09.036
PG 2
WC Emergency Medicine
SC Emergency Medicine
GA 931AL
UT WOS:000229458100021
PM 15940106
DA 2018-12-27
ER

PT J
AU Fujii, Y
   Nakayama, M
AF Fujii, Y
   Nakayama, M
TI RETRACTED: Effects of dexamethasone in preventing postoperative emetic
   symptoms after total knee replacement surgery: A prospective,
   randomized, double-blind, vehicle-controlled trial in adult Japanese
   patients (Retracted article. See vol. 40, pg. 1048, 2018)
SO CLINICAL THERAPEUTICS
LA English
DT Article; Retracted Publication
DE complications; nausea; vomiting; antiemetics; dexamethasone; knee
ID HIGH-DOSE DEXAMETHASONE; NAUSEA; DROPERIDOL; METOCLOPRAMIDE; CHILDREN;
   EMESIS; SALINE
AB Background: Postoperative emetic symptoms (nausea, retching, and vomiting) are common following total Joint replacement, with an incidence as high as 83% when no prophylactic antiemetic is provided. However, most antiemetics currently used in Japan, such as antihistamines (eg, hydroxyzine), butyrophenones (eg, droperidol), and dopamine receptor antagonists (eg, metoclopramide), have been associated with adverse effects (AEs), such as excessive sedation, hypotension, dry mouth, dysphoria, hallucinations, and extrapyramidal symptoms.
   Objective: The aim of this study was to assess the efficacy and tolerability of 3 doses of intravenous dexamethasone monotherapy versus vehicle in preventing emetic symptoms after total knee replacement performed under combined general and epidural anesthesia.
   Methods: This prospective, randomized, double-blind, vehicle-controlled trial was conducted at the Department of Anesthesiology, University of Tsukuba Institute of Clinical Medicine, Tsukuba, Japan. Adult Japanese patients scheduled to undergo total knee replacement were eligible. Patients were randomly assigned to 1 of 4 treatment groups: dexamethasone 4, 8, or 16 mg, or vehicle (control). Patients received combination anesthesia with sevoflurane and nitrous oxide in pure oxygen (general) and lidocaine (epidural). Study drugs were administered intravenously after the completion of surgery. An investigator blinded to treatment assignment monitored patients for emetic symptoms for 24 hours after the patient awoke. Patients rated their satisfaction with the study drug using a linear, 11-point scale (0 = complete satisfaction to 10 = complete dissatisfaction). Tolerability was assessed by the study investigator using spontaneous reporting and patient interview.
   Results: A total of 8 0 patients were enrolled (5 8 women, 22 men; mean [SD] age, 59 [10] years; mean [SD] height, 154 [7] cm; mean [SD] body weight, 55 [7] kg; 20 patients per treatment group). The demographic, clinical, and surgical data were comparable between the 4 treatment groups. The rates of emesis-free patients were 35% (7 patients), 70% (14), and 75% (15) with dexamethasone 4, 8, and 16 mg, respectively, compared with 30% (6) with vehicle (P = NS, 0.013, and 0.005, respectively). Median (range) patient satisfaction scores were significantly higher in the groups receiving dexamethasone 8 and 16 mg (both, 0.0 [0-9]) compared with controls (6.0 [0-10]) (P = 0.013 and 0.008, respectively). This effect was not found with the 4-mg dose. No clinically serious AEs attributed to the study drug were observed in any of the 4 treatment groups.
   Conclusions: In this study of a small, select group of adult Japanese patients undergoing total knee replacement, the rates of emesis-free patients were higher with dexamethasone 8 and 16 mg compared with vehicle 24 hours after anesthesia induction. This effect was not found with the 4-mg dose. All treatments were well tolerated. Copyright (c) 2005 Excerpta Medica, Inc.
C1 Univ Tsukuba, Inst Clin Med, Dept Anesthesiol, Tsukuba, Ibaraki 3058576, Japan.
RP Fujii, Y (reprint author), Univ Tsukuba, Inst Clin Med, Dept Anesthesiol, Tsukuba, Ibaraki 3058576, Japan.
EM yfujii@md.tsukuba.ac.jp
CR AAPRO MS, 1984, J CLIN ONCOL, V2, P466, DOI 10.1200/JCO.1984.2.5.466
   FLEISHER LA, 1996, CLIN ANESTH, P443
   FREDRIKSON M, 1992, BRIT J CANCER, V65, P779, DOI 10.1038/bjc.1992.165
   GAN TJ, 1994, BRIT J ANAESTH, V72, P544, DOI 10.1093/bja/72.5.544
   GAN TJ, 1995, ANESTH ANALG, V80, P81, DOI 10.1097/00000539-199501000-00014
   Henzi I, 2000, ANESTH ANALG, V90, P186, DOI 10.1097/00000539-200001000-00038
   KAUSTE A, 1986, EUR J ANAESTH, V3, P1
   LERMAN J, 1995, CAN J ANAESTH, V42, P263, DOI 10.1007/BF03010699
   Liu K, 1998, BRIT J ANAESTH, V80, P85
   LIVREA P, 1985, J NEUROL, V231, P336, DOI 10.1007/BF00313712
   McCormick C., 2002, ASA NEWSL, V66, P19
   ROWBOTHAM DJ, 1992, BRIT J ANAESTH, V69, pS46, DOI 10.1093/bja/69.supplement_1.46S
   Schimmer BP, 1996, GOODMAN GILMANS PHAR, P1459
   Sekine I, 1997, BRIT J CANCER, V76, P90, DOI 10.1038/bjc.1997.341
   Splinter WM, 1996, ANESTH ANALG, V83, P913, DOI 10.1097/00000539-199611000-00004
   Wang JJ, 1999, BRIT J ANAESTH, V83, P772
   Wang JJ, 1999, ANESTH ANALG, V89, P200, DOI 10.1097/00000539-199907000-00036
   WATCHA MF, 1992, ANESTHESIOLOGY, V77, P162, DOI 10.1097/00000542-199207000-00023
   WHITE PF, 1993, ANESTHESIOLOGY, V78, P2, DOI 10.1097/00000542-199301000-00002
NR 19
TC 21
Z9 22
U1 1
U2 5
PU ELSEVIER
PI BRIDGEWATER
PA 685 ROUTE 202-206, BRIDGEWATER, NJ 08807 USA
SN 0149-2918
EI 1879-114X
J9 CLIN THER
JI Clin. Ther.
PD JUN
PY 2005
VL 27
IS 6
BP 740
EP 745
DI 10.1016/j.clinthera.2005.05.011
PG 6
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 945VS
UT WOS:000230531000007
PM 16117980
DA 2018-12-27
ER

PT J
AU Hattori, Y
   Akimoto, K
   Gross, SS
   Hattori, S
   Kasai, K
AF Hattori, Y
   Akimoto, K
   Gross, SS
   Hattori, S
   Kasai, K
TI RETRACTED: Angiotensin-II-induced oxidative stress elicits
   hypoadiponectinaemia in rats (Retracted article. See vol. 54, pg. 2475,
   2011)
SO DIABETOLOGIA
LA English
DT Article; Retracted Publication
DE adiponectin; angiotensin II; metabolic syndrome; oxidative stress;
   tempol; tetrahydrobiopterin
ID VASCULAR SMOOTH-MUSCLE; PLASMA-PROTEIN ADIPONECTIN; ADIPOSE-SPECIFIC
   PROTEIN; NADPH OXIDASE ACTIVITY; NF-KAPPA-B; ENDOTHELIAL DYSFUNCTION;
   NAD(P)H OXIDASE; CARDIOVASCULAR MORBIDITY; ESSENTIAL-HYPERTENSION;
   HORMONAL-REGULATION
AB Hypertension, endothelial dysfunction and insulin resistance are associated conditions that share oxidative stress and vascular inflammation as common features. Adiponectin is an abundant plasma adipokine that plays a physiological role in modulating lipid metabolism and exerts a potent anti-inflammatory activity. We hypothesised that adiponectin levels decrease in response to oxidative stress and that this may promote the development of hypertension, endothelial dysfunction and insulin resistance. Rats were infused with angiotensin II (AngII) or its vehicle, either alone or in combination with tempo1 (4-hydroxy-2,2,6,6-tetramethyl piperidinoxyl), a membrane-permeable metal-independent superoxide dismutase mimetic, or tetrahydrobiopterin (BH4), one of the most potent naturally occurring reducing agents and an essential cofactor for nitric oxide synthase activity. Heart rate, systolic blood pressure, body weight and serum levels of adiponectin were measured on day 7 of treatment, and then the animals were killed. Vessel tone and superoxide production were measured ex vivo in thoracic vascular rings. The expression of adiponectin mRNA in adipose tissue was assessed by Northern blotting, and in 3T3-L1 adipocytes exposed to H2O2 by real-time PCR. The expression of NAD(P)H oxidase subunit mRNAs in the rats was assessed by RT-PCR and real-time PCR. Hypertension and endothelial dysfunction were induced in rats by infusion of AngII and reversed by administration of tempol. Plasma concentrations of adiponectin and adipose tissue levels of adiponectin mRNA were decreased in AngII-infused rats, and this effect was prevented by cotreatment with tempol or BH4. The production of superoxide anions (O-2(-)) was significantly increased in the aortae of AngII-treated rats, and this increase was prevented by the administration of tempol or BH4. Levels of mRNAs that encode NAD(P)H oxidase components, including p22phox, gp91phox, p47phox and Rac1, were similarly increased in adipose tissue, aortae and hearts of AngII-infused rats. Cotreatment of rats with tempol or BH4 reversed AngII-induced increases in NAD(P)H oxidase subunit mRNAs. Fully differentiated 3T3-L1 adipocytes, also exhibited diminished adiponectin mRNA levels when exposed to low concentrations of H2O2. Our results demonstrate that AngII-induced oxidative stress and endothelial dysfunction are accompanied by a decrease in adiponectin gene expression. Since antioxidants were observed to prevent the actions of AngII, and H2O2 on its own suppressed adiponectin expression, we conclude that adiponectin gene expression is negatively modulated by oxidative stress. Plasma adiponectin levels may provide a useful indicator of oxidative stress in vivo, and suppressed levels may contribute to the proinflammatory and metabolic derangements associated with type 2 diabetes, coronary artery disease and the metabolic syndrome.
C1 Dokkyo Univ, Sch Med, Dept Endocrinol & Metab, Mibu, Tochigi 3210293, Japan.
   Dokkyo Univ, Sch Med, Mol & Cellular Biol Lab, Mibu, Tochigi, Japan.
   Cornell Univ, Weill Med Coll, Dept Pharmacol, New York, NY USA.
   Cornell Univ, Weill Med Coll, Program Biochem & Struct Biol, New York, NY USA.
RP Hattori, Y (reprint author), Dokkyo Univ, Sch Med, Dept Endocrinol & Metab, Mibu, Tochigi 3210293, Japan.
EM yhattori@dokkyomed.ac.jp
CR Agata J, 2004, CIRC J, V68, P1194, DOI 10.1253/circj.68.1194
   Al Suwaidi J, 2000, CIRCULATION, V101, P948, DOI 10.1161/01.CIR.101.9.948
   Arita Y, 2002, CIRCULATION, V105, P2893, DOI 10.1161/01.CIR.0000018622.84402.FF
   Arita Y, 1999, BIOCHEM BIOPH RES CO, V257, P79, DOI 10.1006/bbrc.1999.0255
   Dahlof B, 2002, LANCET, V359, P995, DOI 10.1016/S0140-6736(02)08089-3
   Fasshauer M, 2002, BIOCHEM BIOPH RES CO, V290, P1084, DOI 10.1006/bbrc.2001.6307
   Fukui T, 1997, CIRC RES, V80, P45, DOI 10.1161/01.RES.80.1.45
   Furuhashi M, 2003, HYPERTENSION, V42, P76, DOI 10.1161/01.HYP.0000078490.59735.6E
   Gorzelniak K, 2002, J HYPERTENS, V20, P965, DOI 10.1097/00004872-200205000-00032
   GRIENDLING KK, 1994, CIRC RES, V74, P1141, DOI 10.1161/01.RES.74.6.1141
   Griendling KK, 2000, CIRC RES, V86, P494, DOI 10.1161/01.RES.86.5.494
   Hansson L, 1999, LANCET, V353, P611, DOI 10.1016/S0140-6736(98)05012-0
   Hattori Y, 2003, DIABETOLOGIA, V46, P1543, DOI 10.1007/s00125-003-1224-3
   Hattori Y, 2004, CARDIOVASC RES, V63, P31, DOI 10.1016/j.cardiores.2004.03.014
   HATTORI Y, 1993, BIOCHEM BIOPH RES CO, V195, P435, DOI 10.1006/bbrc.1993.2062
   Higashi M, 2003, CIRC RES, V93, P767, DOI 10.1161/01.RES.0000096650.91688.28
   Hong HJ, 2001, HYPERTENSION, V38, P1044, DOI 10.1161/hy1101.095331
   Hotta K, 2000, ARTERIOSCL THROM VAS, V20, P1595, DOI 10.1161/01.ATV.20.6.1595
   Janke J, 2002, DIABETES, V51, P1699, DOI 10.2337/diabetes.51.6.1699
   Kashiwagi A, 1999, AM J PHYSIOL-ENDOC M, V277, pE976, DOI 10.1152/ajpendo.1999.277.6.E976
   Kubota N, 2002, J BIOL CHEM, V277, P25863, DOI 10.1074/jbc.C200251200
   Kumada M, 2003, ARTERIOSCL THROM VAS, V23, P85, DOI 10.1161/01.ATV.0000048856.22331.50
   Lassegue B, 2001, CIRC RES, V88, P888, DOI 10.1161/hh0901.090299
   Laursen JB, 1997, CIRCULATION, V95, P588, DOI 10.1161/01.CIR.95.3.588
   Matsuda M, 2002, J BIOL CHEM, V277, P37487, DOI 10.1074/jbc.M206083200
   Mukai Y, 2002, ARTERIOSCL THROM VAS, V22, P1445, DOI 10.1161/01.ATV.0000029121.63691.CE
   Ogihara T, 2002, HYPERTENSION, V40, P872, DOI 10.1161/01.HYP.0000040262.48405.A8
   Okamoto Y, 2002, CIRCULATION, V106, P2767, DOI 10.1161/01.CIR.0000042707.50032.19
   Ouchi N, 2000, CIRCULATION, V102, P1296, DOI 10.1161/01.CIR.102.11.1296
   Ouchi N, 2001, CIRCULATION, V103, P1057, DOI 10.1161/01.CIR.103.8.1057
   Ouchi N, 1999, CIRCULATION, V100, P2473, DOI 10.1161/01.CIR.100.25.2473
   Pagano PJ, 1997, P NATL ACAD SCI USA, V94, P14483, DOI 10.1073/pnas.94.26.14483
   Rajagopalan S, 1996, J CLIN INVEST, V97, P1916, DOI 10.1172/JCI118623
   Schachinger V, 2000, CIRCULATION, V101, P1899, DOI 10.1161/01.CIR.101.16.1899
   Schnackenberg CG, 1999, HYPERTENSION, V33, P424, DOI 10.1161/01.HYP.33.1.424
   Schnackenberg CG, 2001, KIDNEY INT, V59, P1859, DOI 10.1046/j.1523-1755.2001.0590051859.x
   Shimabukuro M, 2003, J CLIN ENDOCR METAB, V88, P3236, DOI 10.1219/jc.2002-021883
   Shimokawa H, 1999, J MOL CELL CARDIOL, V31, P23, DOI 10.1006/jmcc.1998.0841
   Tan KCB, 2004, J CLIN ENDOCR METAB, V89, P765, DOI 10.1210/jc.2003-031012
   Tirosh A, 1999, J BIOL CHEM, V274, P10595, DOI 10.1074/jbc.274.15.10595
   Vasquez-Vivar J, 1998, P NATL ACAD SCI USA, V95, P9220, DOI 10.1073/pnas.95.16.9220
   Wolf G, 2000, Curr Hypertens Rep, V2, P167, DOI 10.1007/s11906-000-0078-z
   Yusuf S, 2001, JAMA-J AM MED ASSOC, V286, P1882, DOI 10.1001/jama.286.15.1882
NR 43
TC 89
Z9 102
U1 3
U2 13
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0012-186X
EI 1432-0428
J9 DIABETOLOGIA
JI Diabetologia
PD JUN
PY 2005
VL 48
IS 6
BP 1066
EP 1074
DI 10.1007/s00125-005-1766-7
PG 9
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 936RU
UT WOS:000229873900006
PM 15864528
OA Bronze
DA 2018-12-27
ER

PT J
AU Rodriguez, VM
   Thiruchelvam, M
   Cory-Slechta, DA
AF Rodriguez, VM
   Thiruchelvam, M
   Cory-Slechta, DA
TI RETRACTED: Sustained exposure to the widely used herbicide atrazine:
   Altered function and loss of neurons in brain monoamine systems
   (Retracted article. See vol. 120, pg. A303, 2012)
SO ENVIRONMENTAL HEALTH PERSPECTIVES
LA English
DT Article; Retracted Publication
ID PHEOCHROMOCYTOMA PC12 CELLS; IN-VIVO MICRODIALYSIS; DOPAMINE RELEASE;
   PARKINSONS-DISEASE; THYROID-FUNCTION; PUBERTAL DEVELOPMENT; PESTICIDE
   EXPOSURE; PREFRONTAL CORTEX; COMBINED PARAQUAT; OVARIAN-FUNCTION
AB The widespread use of atrazine (ATR) and its persistence in the environment have resulted in documented human exposure. Alterations in hypothalamic catecholamines have been suggested as the mechanistic basis of the toxicity of ATR to hormonal systems in females and the reproductive tract in males. Because multiple catecholamine systems are present in the brain, however, ATR could have far broader effects than are currently understood. Catecholaminergic systems such as the two major long-length dopaminergic tracts of the central nervous system play key roles in mediating a wide array of critical behavioral functions. In this study we examined the hypothesis that ATR would adversely affect these brain dopaminergic systems. Male rats chronically exposed to 5 or 10 mg/kg ATR in the diet for 6 months exhibited persistent hyperactivity and altered behavioral responsivity to amphetamine. Moreover, when measured 2 weeks after the end of exposure, the levels of various monoamines and the numbers of tyrosine hydroxylase-positive (TH+) and -negative (TH-) cells measured using unbiased stereology were reduced in both doparninergic tracts. Acute exposures to 100 or 200 mg/kg ATR given intraperitoneally to evaluate potential mechanisms reduced both basal and potassium-evoked striatal dopamine release. Collectively, these studies demonstrate that ATR can produce neurotoxicity in doparninergic systems that are critical to the mediation of movement as well as cognition and executive function. Therefore, ATR may be an environmental risk factor contributing to dopaminergic system disorders, underscoring the need for further investigation of its mechanism(s) of action and corresponding assessment of its associated human health risks.
C1 Environm & Occupat Hlth Sci Inst, Piscataway, NJ 08854 USA.
   Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Environm & Occupat Med, Piscataway, NJ 08854 USA.
RP Cory-Slechta, DA (reprint author), Environm & Occupat Hlth Sci Inst, 170 Frelinghuysen Rd, Piscataway, NJ 08854 USA.
EM dcs@eohsi.rutgers.edu
OI Rodriguez, Veronica/0000-0002-3466-2892
FU NIEHS NIH HHS [ES10791]
CR Adgate JL, 2001, ENVIRON HEALTH PERSP, V109, P583, DOI 10.2307/3455032
   Badiani A, 1998, J NEUROSCI, V18, P10579
   Barlow BK, 2004, DEV NEUROSCI-BASEL, V26, P11, DOI 10.1159/000080707
   Betarbet R, 2000, NAT NEUROSCI, V3, P1301, DOI 10.1038/81834
   Birnbaum LS, 2003, ENVIRON HEALTH PERSP, V111, P389, DOI 10.1289/ehp.5686
   Breysse N, 2002, J NEUROSCI, V22, P5669
   Camarero J, 2002, J NEUROCHEM, V81, P961, DOI 10.1046/j.1471-4159.2002.00879.x
   CATENACCI G, 1993, TOXICOL LETT, V69, P217, DOI 10.1016/0378-4274(93)90107-9
   Clark L, 2004, BRAIN COGNITION, V55, P41, DOI 10.1016/s0278-2626(03)00284-7
   Clayton CA, 2003, J EXPO ANAL ENV EPID, V13, P100, DOI 10.1038/sj.jea.7500261
   Cooper J. R., 2003, BIOCH BASIS NEUROPHA
   Cooper RL, 1996, REPROD TOXICOL, V10, P257, DOI 10.1016/0890-6238(96)00054-8
   Cooper RL, 2000, TOXICOL SCI, V53, P297, DOI 10.1093/toxsci/53.2.297
   COOPER RL, 1998, TOXICOLOGIST, V42, P160
   Crossman AR, 2000, J ANAT, V196, P519, DOI 10.1046/j.1469-7580.2000.19640519.x
   Das PC, 2000, TOXICOL SCI, V56, P324, DOI 10.1093/toxsci/56.2.324
   Das PC, 2003, LIFE SCI, V73, P3123, DOI 10.1016/j.lfs.2003.05.002
   DENIAU JM, 1978, EXP BRAIN RES, V32, P409
   Dreher JC, 2002, J COGNITIVE NEUROSCI, V14, P853, DOI 10.1162/089892902760191081
   Du W, 1999, BRAIN RES, V836, P194, DOI 10.1016/S0006-8993(99)01567-X
   Eldridge JC, 1999, STEROIDS, V64, P672, DOI 10.1016/S0039-128X(99)00051-3
   Epstein J, 1999, ANN NY ACAD SCI, V877, P562, DOI 10.1111/j.1749-6632.1999.tb09289.x
   Friedmann AS, 2002, REPROD TOXICOL, V16, P275, DOI 10.1016/S0890-6238(02)00019-9
   FULLER RW, 1990, NEUROENDOCRINOLOGY, V52, P206, DOI 10.1159/000125586
   Fuller RW, 1996, BEHAV BRAIN RES, V73, P215
   Gammon DW, 2005, PEST MANAG SCI, V61, P331, DOI 10.1002/ps.1000
   GERFEN CR, 1985, P NATL ACAD SCI USA, V82, P8780, DOI 10.1073/pnas.82.24.8780
   Holson RR, 1998, BRAIN RES, V808, P182, DOI 10.1016/S0006-8993(98)00816-6
   *I LAB AN RES, 1996, GUID CAR US LAB AN
   Jorgensen H, 1998, BRAIN RES, V811, P10, DOI 10.1016/S0006-8993(98)00901-9
   Lamensdorf I, 1996, J NEUROCHEM, V67, P1532
   Laws SC, 2000, TOXICOL SCI, V58, P366, DOI 10.1093/toxsci/58.2.366
   Lioy PJ, 2000, J EXPO ANAL ENV EPID, V10, P327, DOI 10.1038/sj.jea.7500099
   MacLennan PA, 2003, J TOXICOL ENV HEAL A, V66, P501, DOI 10.1080/15287390390156254
   Mao L, 2001, NEUROSCIENCE, V106, P303, DOI 10.1016/S0306-4522(01)00284-6
   Mostofsky SH, 2002, BIOL PSYCHIAT, V52, P785, DOI 10.1016/S0006-3223(02)01412-9
   Paxinos G, 1986, BRAIN STEREOTAXIC CO
   Podda MV, 1997, PHARMACOL RES, V36, P199, DOI 10.1006/phrs.1997.0213
   Reeves R, 2003, NEUROTOXICOLOGY, V24, P839, DOI 10.1016/S0161-813X(03)00057-3
   Remy P, 2003, CURR OPIN NEUROL, V16, pS37, DOI 10.1097/00019052-200312002-00007
   ROBINSON TE, 1991, J NEUROSCI METH, V40, P211, DOI 10.1016/0165-0270(91)90070-G
   Rooney AA, 2003, TOXICOL SCI, V76, P366, DOI 10.1093/toxsci/kfg250
   Sathiakumar N, 1996, AM J IND MED, V29, P143, DOI 10.1002/(SICI)1097-0274(199602)29:2<143::AID-AJIM4>3.3.CO;2-D
   Sathiakumar N, 1997, CRIT REV TOXICOL, V27, P599, DOI 10.3109/10408449709084405
   SEROOGY KB, 1989, J COMP NEUROL, V279, P415, DOI 10.1002/cne.902790307
   Shafer TJ, 1999, TOXICOLOGY, V142, P57, DOI 10.1016/S0300-483X(99)00133-X
   Short P, 1999, TOXICOL IND HEALTH, V15, P240, DOI 10.1191/074823399678846736
   Stanford JA, 2000, INT J DEV NEUROSCI, V18, P411, DOI 10.1016/S0736-5748(00)00009-5
   Stoker TE, 2000, TOXICOL SCI, V58, P50, DOI 10.1093/toxsci/58.1.50
   Stoker TE, 2002, TOXICOL SCI, V67, P198, DOI 10.1093/toxsci/67.2.198
   Tam SY, 1997, BIOCHEM PHARMACOL, V53, P441
   Thiruchelvam M, 2000, BRAIN RES, V873, P225, DOI 10.1016/S0006-8993(00)02496-3
   Thiruchelvam M, 2000, J NEUROSCI, V20, P9207
   Thiruchelvam MJ, 2004, EUR J NEUROSCI, V19, P845, DOI 10.1111/j.1460-9568.2004.03139.x
   UGAZIO G, 1991, RES COMMUN CHEM PATH, V74, P349
   *US EPA, 2001, ATR TOX CHAPT RER EL
   VANDEKAR LD, 1980, NEUROENDOCRINOLOGY, V31, P309, DOI 10.1159/000123093
   Viggiano D, 2003, NEUROSCI BIOBEHAV R, V27, P683, DOI 10.1016/j.neubiorev.2003.08.011
   WESTERINK BHC, 1986, J NEUROCHEM, V46, P181, DOI 10.1111/j.1471-4159.1986.tb12942.x
NR 59
TC 56
Z9 57
U1 1
U2 16
PU US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE
PI RES TRIANGLE PK
PA NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233,
   RES TRIANGLE PK, NC 27709-2233 USA
SN 0091-6765
J9 ENVIRON HEALTH PERSP
JI Environ. Health Perspect.
PD JUN
PY 2005
VL 113
IS 6
BP 708
EP 715
DI 10.1289/ehp.7783
PG 8
WC Environmental Sciences; Public, Environmental & Occupational Health;
   Toxicology
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
   Health; Toxicology
GA 931BL
UT WOS:000229460700032
PM 15929893
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Zhang, R
   Dzhura, I
   Grueter, CE
   Thiel, W
   Colbran, RJ
   Anderson, ME
AF Zhang, R
   Dzhura, I
   Grueter, CE
   Thiel, W
   Colbran, RJ
   Anderson, ME
TI RETRACTED: A dynamic alpha-beta inter-subunit agonist signaling complex
   is a novel feedback mechanism for regulating L-type Ca2+ channel opening
   (Retracted article. See vol. 29, pg. 1125, 2015)
SO FASEB JOURNAL
LA English
DT Article; Retracted Publication
DE beta subunit; calcium channel; calmodulin
ID RABBIT VENTRICULAR MYOCYTES; CALCIUM-CHANNELS; CALMODULIN-BINDING;
   CA2+-DEPENDENT INACTIVATION; FACILITATION; KINASE; CONDUCTANCE;
   MODULATION; TERMINUS; DOMAINS
AB L-type Ca2+ channels are macromolecular protein complexes in neurons and myocytes that open in response to cell membrane depolarization to supply Ca2+ for regulating gene transcription and vesicle secretion and triggering cell contraction. L- type Ca2+ channels include a pore- forming a and an auxiliary beta subunit, and a subunit openings are regulated by cellular Ca2+ through a mechanism involving the Ca2+- sensing protein calmodulin ( CaM) and CaM binding motifs in the a subunit cytoplasmic C terminus. Here we show that these CaM binding motifs are " autoagonists" that increase a subunit openings by binding the beta subunit. The CaM binding domains are necessary and sufficient for the a subunit C terminus to bind the beta subunit in vitro, and excess CaM blocks this interaction. Addition of CaM binding domains to native cardiac L- type Ca2+ channels in excised cell membrane patches increases openings, and this agonist effect is prevented by excess CaM. Recombinant LTCC openings are also increased by exogenous CaM binding domains by a mechanism requiring the beta subunit, and excess CaM blocks this effect. Thus, the bifunctional ability of the alpha subunit CaM binding motifs to competitively associate with the beta subunit or CaM provides a novel paradigm for feedback control of cellular Ca2+ entry.
C1 Vanderbilt Univ, Med Ctr, Dept Med, Nashville, TN 37240 USA.
   Vanderbilt Univ, Med Ctr, Dept Physiol & Mol Biophys, Nashville, TN USA.
   Vanderbilt Univ, Med Ctr, Dept Pharmacol, Nashville, TN 37232 USA.
RP Zhang, R (reprint author), Vanderbilt Univ, Med Ctr, Dept Med, 383 Preston Res Bldg, Nashville, TN 37240 USA.
EM mark.anderson@vanderbilt.edu; roger.colbran@vanderbilt.edu
OI Colbran, Roger/0000-0001-7401-8244
CR BERS DM, 1994, METHOD CELL BIOL, V40, P3
   Bichet D, 2000, NEURON, V25, P177, DOI 10.1016/S0896-6273(00)80881-8
   CAMPBELL V, 1995, J PHYSIOL-LONDON, V485, P365, DOI 10.1113/jphysiol.1995.sp020735
   Catterall WA, 2000, ANNU REV CELL DEV BI, V16, P521, DOI 10.1146/annurev.cellbio.16.1.521
   Dzhura I, 2003, J PHYSIOL-LONDON, V550, P731, DOI 10.1113/jphysiol.2003.043778
   Dzhura I, 2000, NAT CELL BIOL, V2, P173
   Gamper N, 2003, J GEN PHYSIOL, V122, P17, DOI 10.1085/gp.200208783
   HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997
   Kepplinger KJF, 2000, FEBS LETT, V477, P161, DOI 10.1016/S0014-5793(00)01791-9
   Kobrinsky E, 2003, J BIOL CHEM, V278, P5021, DOI 10.1074/jbc.M211254200
   Lee A, 1999, NATURE, V399, P155
   Maltez JM, 2005, NAT STRUCT MOL BIOL, V12, P372, DOI 10.1038/nsmb909
   McGee AW, 2004, NEURON, V42, P89, DOI 10.1016/S0896-6273(04)00149-7
   Pate P, 2000, J BIOL CHEM, V275, P39786, DOI 10.1074/jbc.M007158200
   Peterson BZ, 1999, NEURON, V22, P549, DOI 10.1016/S0896-6273(00)80709-6
   Pitt GS, 2001, J BIOL CHEM, V276, P30794, DOI 10.1074/jbc.M104959200
   PRAGNELL M, 1994, NATURE, V368, P67, DOI 10.1038/368067a0
   Rojas M, 1998, NAT BIOTECHNOL, V16, P370, DOI 10.1038/nbt0498-370
   SARKAR G, 1990, BIOTECHNIQUES, V8, P404
   STRIESSNIG J, 1991, P NATL ACAD SCI USA, V88, P10769, DOI 10.1073/pnas.88.23.10769
   Takahashi SX, 2004, P NATL ACAD SCI USA, V101, P7193, DOI 10.1073/pnas.0306665101
   Tan HL, 2002, NATURE, V415, P442, DOI 10.1038/415442a
   VAN PF, 2004, NATURE, V429, P671
   VanDongen AMJ, 1996, BIOPHYS J, V70, P1303, DOI 10.1016/S0006-3495(96)79687-X
   Wu YJ, 2001, J PHYSIOL-LONDON, V535, P679, DOI 10.1111/j.1469-7793.2001.t01-1-00679.x
   Yasuda T, 2004, EUR J NEUROSCI, V20, P1, DOI 10.1111/j.1460-9568.2004.03434.x
   YUE DT, 1990, P NATL ACAD SCI USA, V87, P753, DOI 10.1073/pnas.87.2.753
   Zuhlke RD, 2000, J BIOL CHEM, V275, P21121, DOI 10.1074/jbc.M002986200
   Zuhlke RD, 1999, NATURE, V399, P159
NR 29
TC 23
Z9 23
U1 2
U2 7
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
EI 1530-6860
J9 FASEB J
JI Faseb J.
PD JUN
PY 2005
VL 19
IS 8
BP 1153
EP +
DI 10.1096/fj.04-3283fje
PG 16
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
   Topics; Cell Biology
GA 941IF
UT WOS:000230207800001
PM 15994413
DA 2018-12-27
ER

PT J
AU Kalkat, M
   Yildirim, S
   Uzmay, I
AF Kalkat, M
   Yildirim, S
   Uzmay, I
TI RETRACTED: Design of artificial neural networks for rotor dynamics
   analysis of rotating machine systems (Retracted article. See vol. 23,
   pg. 396, 2013)
SO MECHATRONICS
LA English
DT Article; Retracted Publication
DE neural network; shaft vibration; experimental setup
AB A Neural Network predictor investigation is presented for analyzing vibration parameters of the rotating system. The vibration parameters of the system such as amplitude, velocity and acceleration in vertical direction were measured at the bearing points. The system's vibration and noise were analyzed for different working conditions. The designed neural predictor has three layers which are input, hidden and output layers. In the hidden layer 10 neurons were used for this approximation. The results showed that the network would be used as analyzer of such systems in experimental applications. (c) 2005 Elsevier Ltd. All rights reserved.
C1 Erciyes Univ, Dept Mech Engn, TR-38039 Kayseri, Turkey.
   Nigde Univ, Dept Mech Engn, Nigde, Turkey.
RP Yildirim, S (reprint author), Erciyes Univ, Dept Mech Engn, TR-38039 Kayseri, Turkey.
EM sahiny@erciyes.edu.tr
CR CEMPEL C, 1991, MECH SYST SIGNAL PR, V5, P317, DOI 10.1016/0888-3270(91)90032-Z
   CHILDS DW, 1997, P ASME
   Cybenko G., 1989, Mathematics of Control, Signals, and Systems, V2, P303, DOI 10.1007/BF02551274
   FUNAHASHI K, 1989, NEURAL NETWORKS, V2, P183, DOI 10.1016/0893-6080(89)90003-8
   GHAURI MKK, 1996, P I MECH ENG VIBR RO, P383
   Halliwell NA, 1996, J SOUND VIB, V190, P399, DOI 10.1006/jsvi.1996.0071
   Haykin S., 1994, NEURAL NETWORKS COMP
   HE ZJ, 1990, MECH SYST SIGNAL PR, V4, P417
   LEE CW, 1994, MECH SYST SIGNAL PR, V8, P665, DOI 10.1006/mssp.1994.1047
   SEKHAR AS, 1995, J SOUND VIB, V185, P655, DOI 10.1006/jsvi.1995.0407
   SMALLEY AJ, 1996, P I MECH ENG 6 INT C, P517
   SU YT, 1992, J SOUND VIB, V155, P75, DOI 10.1016/0022-460X(92)90646-F
   TAYLOR JL, 1995, J SOUND VIBRATION, V29, P12
   Yildirim S, 2003, MECH MACH THEORY, V38, P27
NR 14
TC 8
Z9 13
U1 3
U2 25
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0957-4158
J9 MECHATRONICS
JI Mechatronics
PD JUN
PY 2005
VL 15
IS 5
BP 573
EP 588
DI 10.1016/j.mechantronics.2004.11.002
PG 16
WC Automation & Control Systems; Computer Science, Artificial Intelligence;
   Engineering, Electrical & Electronic; Engineering, Mechanical
SC Automation & Control Systems; Computer Science; Engineering
GA 927WM
UT WOS:000229231200004
DA 2018-12-27
ER

PT J
AU Dong, YH
   Zhang, XF
   Soo, HML
   Greenberg, EP
   Zhang, LH
AF Dong, YH
   Zhang, XF
   Soo, HML
   Greenberg, EP
   Zhang, LH
TI RETRACTED: The two-component response regulator PprB modulates
   quorum-sensing signal production and global gene expression in
   Pseudomonas aeruginosa (Retracted Article. See vol 69, pg 780, 2008)
SO MOLECULAR MICROBIOLOGY
LA English
DT Article; Retracted Publication
ID N-ACYLHOMOSERINE LACTONES; TO-CELL COMMUNICATION; HOMOSERINE LACTONE;
   AGROBACTERIUM-TUMEFACIENS; VIRULENCE DETERMINANTS; ERWINIA-CAROTOVORA;
   BIOFILM FORMATION; ACTIVE EFFLUX; AUTOINDUCER; SYSTEM
AB The response regulator PprB and its cognate sensor PprA were recently reported as a two-component regulatory system that controls membrane permeability and antibiotic sensitivity of Pseudomonas aeruginosa. We found that a Tn5 insertion mutation in pprB caused a drastic reduction in virulence factor production and cell motility. A transcriptome analysis revealed that 175 genes were regulated by PprB. Among the 113 PprB-activated genes, 85.5% are known to be activated by N-3-oxo-dodecanoyl-homoserine lactone (OdDHL) and N-butanoyl-homoserine lactone (BHL). In particular, the expression of lasI, rhlI and rhlR, which encode key components of the las and rhl quorum-sensing (QS) systems, were significantly decreased in the pprB mutant. These data suggest that PprB might regulate QS signal production. Measurement of OdDHL and BHL in cultures of the mutant sustained this hypothesis. By using various OdDHL- or BHL-responsive QS reporter systems, including lasB-lacZ, lasI-lacZ and rsaL-lacZ, we found that the mutation in pprB resulted in a large decrease in the sensitivity of P. aeruginosa to exogenous OdDHL. However, there was no difference in sensitivity to BHL. Further analysis showed that the OdDHL influx was significantly reduced in the pprB mutant. We conclude that PprB is a novel QS modulator that positively regulates N-acylhomoserine lactone production probably by affecting the OdDHL signal influx and thereby influences global expression of the QS-dependent genes.
C1 Inst Mol & Cell Biol, Singapore 138670, Singapore.
   Univ Washington, Sch Med, Dept Microbiol, Seattle, WA 98195 USA.
RP Zhang, LH (reprint author), Inst Mol & Cell Biol, 61 Biopolis Dr, Singapore 138670, Singapore.
EM lianhui@imcb.a-star.edu.sg
RI ASTAR, IMCB/E-2320-2012
OI Greenberg, Everett/0000-0001-9474-8041
CR Albus AM, 1997, J BACTERIOL, V179, P3928, DOI 10.1128/jb.179.12.3928-3935.1997
   Blumer C, 1999, P NATL ACAD SCI USA, V96, P14073, DOI 10.1073/pnas.96.24.14073
   BRYAN LE, 1988, J ANTIMICROB CHEMOTH, V22, P1
   BULLA LA, 1975, ANNU REV MICROBIOL, V29, P163, DOI 10.1146/annurev.mi.29.100175.001115
   CAETANOANNOLES G, 1993, PCR METH APPL, V28, P85
   Chugani SA, 2001, P NATL ACAD SCI USA, V98, P2752, DOI 10.1073/pnas.051624298
   Darby C, 1999, P NATL ACAD SCI USA, V96, P15202, DOI 10.1073/pnas.96.26.15202
   Davies DG, 1998, SCIENCE, V280, P295, DOI 10.1126/science.280.5361.295
   De Kievit T, 1999, J BACTERIOL, V181, P2175
   Diggle SP, 2003, MOL MICROBIOL, V50, P29, DOI 10.1046/j.1365-2958.2003.03672.x
   Diggle SP, 2002, J BACTERIOL, V184, P2576, DOI 10.1128/JB.184.10.2576-2586.2002
   Dong YH, 2000, P NATL ACAD SCI USA, V97, P3526, DOI 10.1073/pnas.060023897
   Dong YH, 2001, NATURE, V411, P813, DOI 10.1038/35081101
   DUNLAP PV, 1988, J BACTERIOL, V170, P4040, DOI 10.1128/jb.170.9.4040-4046.1988
   ESSAR DW, 1990, J BACTERIOL, V172, P884, DOI 10.1128/jb.172.2.884-900.1990
   Evans K, 1998, J BACTERIOL, V180, P5443
   Federle MJ, 2003, J CLIN INVEST, V112, P1291, DOI 10.1172/JCI200320195
   Fuqua C, 2002, NAT REV MOL CELL BIO, V3, P685, DOI 10.1038/nrm907
   Hentzer M, 2003, EMBO J, V22, P3803, DOI 10.1093/emboj/cdg366
   Heurlier K, 2003, J BACTERIOL, V185, P2227, DOI 10.1128/JB.185.7.2227-2235.2003
   Hoch JA, 2001, J BACTERIOL, V183, P4941, DOI 10.1128/JB.183.17.4941-4949.2001
   HOLLOWAY BW, 1979, MICROBIOL REV, V43, P73
   Juhas M, 2004, MICROBIOL-SGM, V150, P831, DOI 10.1099/mic.0.26906.0
   KAPLAN HB, 1985, J BACTERIOL, V163, P1210
   LATIFI A, 1995, MOL MICROBIOL, V17, P333, DOI 10.1111/j.1365-2958.1995.mmi_17020333.x
   LeClerc JE, 2000, SCIENCE, V289, P391
   LIN UY, 2003, MOL MICROBIOL, V47, P849
   LUKAT GS, 1992, P NATL ACAD SCI USA, V89, P718, DOI 10.1073/pnas.89.2.718
   Manefield M, 2001, FEMS MICROBIOL LETT, V205, P131, DOI 10.1016/S0378-1097(01)00460-8
   Maseda H, 2004, ANTIMICROB AGENTS CH, V48, P1320, DOI 10.1128/AAC.48.4.1320-1328.2004
   Mayville P, 1999, P NATL ACAD SCI USA, V96, P1218, DOI 10.1073/pnas.96.4.1218
   McClean KH, 1997, MICROBIOL-UK, V143, P3703, DOI 10.1099/00221287-143-12-3703
   MCCLEARY WR, 1994, J BIOL CHEM, V269, P31567
   McKnight SL, 2000, J BACTERIOL, V182, P2702, DOI 10.1128/JB.182.10.2702-2708.2000
   MOORE RA, 1986, ANTIMICROB AGENTS CH, V30, P923, DOI 10.1128/AAC.30.6.923
   NIKAIDO H, 1994, SCIENCE, V264, P382, DOI 10.1126/science.8153625
   O'Toole GA, 1998, MOL MICROBIOL, V28, P449, DOI 10.1046/j.1365-2958.1998.00797.x
   OHMAN DE, 1980, J BACTERIOL, V142, P836
   Parkins MD, 2001, MOL MICROBIOL, V40, P1215, DOI 10.1046/j.1365-2958.2001.02469.x
   PASSADOR L, 1993, SCIENCE, V260, P1127, DOI 10.1126/science.8493556
   Pearson JP, 1997, J BACTERIOL, V179, P5756, DOI 10.1128/jb.179.18.5756-5767.1997
   Pearson JP, 1999, J BACTERIOL, V181, P1203
   PEARSON JP, 1994, P NATL ACAD SCI USA, V91, P197, DOI 10.1073/pnas.91.1.197
   Pesci EC, 1999, P NATL ACAD SCI USA, V96, P11229, DOI 10.1073/pnas.96.20.11229
   Pessi G, 2001, J BACTERIOL, V183, P6676, DOI 10.1128/JB.183.22.6676-6683.2001
   RAHME L, 1995, SCIENCE, V269, P1899
   Reimmann C, 1997, MOL MICROBIOL, V24, P309, DOI 10.1046/j.1365-2958.1997.3291701.x
   Rodrigue A, 2000, TRENDS MICROBIOL, V8, P498, DOI 10.1016/S0966-842X(00)01833-3
   Rumbaugh KP, 2000, MICROBES INFECT, V2, P1721, DOI 10.1016/S1286-4579(00)01327-7
   Sambrook J., 1989, MOL CLONING LAB MANU
   Schuster M, 2003, J BACTERIOL, V185, P2066, DOI 10.1128/JB.185.7.2066-2079.2003
   Schuster M, 2004, MOL MICROBIOL, V51, P973, DOI 10.1046/j.1365-2958.2003.03886.x
   SEED PC, 1995, J BACTERIOL, V177, P654, DOI 10.1128/jb.177.3.654-659.1995
   SIMON R, 1983, BIO-TECHNOL, V1, P784, DOI 10.1038/nbt1183-784
   Tang X, 1999, FEMS MICROBIOL LETT, V179, P37, DOI 10.1016/S0378-1097(99)00388-2
   Wagner VE, 2003, J BACTERIOL, V185, P2080, DOI 10.1128/JB.185.7.2080-2095.2003
   Wang LH, 2004, J BIOL CHEM, V279, P13645, DOI 10.1074/jbc.M311194200
   Wang YP, 2003, ANTIMICROB AGENTS CH, V47, P95, DOI 10.1128/AAC.47.1.95-101.2003
   Welch M, 2000, EMBO J, V19, P631, DOI 10.1093/emboj/19.4.631
   Whiteley M, 2000, J BACTERIOL, V182, P4356, DOI 10.1128/JB.182.15.4356-4360.2000
   Williams P, 2000, PHILOS T R SOC B, V355, P667, DOI 10.1098/rstb.2000.0607
   WILLIAMS P, 2002, EXPER OPIN THER TAR, V6, P1
   Yamamoto K, 2005, J BIOL CHEM, V280, P1448, DOI 10.1074/jbc.M410104200
   Zhang LH, 2004, MOL MICROBIOL, V53, P1563, DOI 10.1111/j.1365-2958.2004.04234.x
   Zhang LH, 2003, TRENDS PLANT SCI, V8, P238, DOI 10.1016/S1360-1385(03)00063-3
   ZHANG LH, 1993, NATURE, V362, P446, DOI 10.1038/362446a0
   ZHANG LH, 1991, J BACTERIOL, V173, P1867, DOI 10.1128/jb.173.6.1867-1872.1991
NR 67
TC 36
Z9 40
U1 3
U2 18
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0950-382X
J9 MOL MICROBIOL
JI Mol. Microbiol.
PD JUN
PY 2005
VL 56
IS 5
BP 1287
EP 1301
DI 10.1111/j.1365-2958.2005.04612.x
PG 15
WC Biochemistry & Molecular Biology; Microbiology
SC Biochemistry & Molecular Biology; Microbiology
GA 924JO
UT WOS:000228975300015
PM 15882421
OA Bronze
DA 2018-12-27
ER

PT J
AU Mazur, YI
   Wang, ZM
   Tarasov, GG
   Salamo, GJ
   Tomm, JW
   Talalaev, V
   Kissel, H
AF Mazur, YI
   Wang, ZM
   Tarasov, GG
   Salamo, GJ
   Tomm, JW
   Talalaev, V
   Kissel, H
TI RETRACTED: Nonresonant tunneling carrier transfer in bilayer asymmetric
   InAs/GaAs quantum dots - (Retracted article. See vol 7, art. no. 039904,
   2006)
SO PHYSICAL REVIEW B
LA English
DT Article; Retracted Publication
ID OPTICAL-PROPERTIES; DENSITY; WELLS; GAAS; PHOTOLUMINESCENCE; DEPENDENCE;
   LAYER
AB Carrier transfer in InAs/GaAs asymmetric quantum dot pairs has been studied by means of continuous-wave and time-resolved photoluminescence in a bilayer InAs/GaAs quantum dots system. The dependence of the tunneling time on the thickness of the separation layer is determined and the tunneling time is found to span the range from 250 to 2500 ps. A microscopic model of carrier transfer, including nonresonant electron tunneling from a direct into a cross exciton state, with subsequent generation of two direct excitons in adjacent quantum dot layers, is proposed.
C1 Univ Arkansas, Dept Phys, Fayetteville, AR 72701 USA.
   Max Born Inst Nichtlineare Opt & Kurzzeitspekt, D-12489 Berlin, Germany.
   Ferdinand Braun Inst Hochstfrequenztech, D-12489 Berlin, Germany.
RP Mazur, YI (reprint author), Univ Arkansas, Dept Phys, Fayetteville, AR 72701 USA.
EM ymazur@uark.edu
RI Wang, Zhiming/B-6320-2009; Wang, Zhiming/Q-1031-2015; Tomm,
   Jens/D-2697-2011; Talalaev, Vadim/O-9470-2014
OI Tomm, Jens/0000-0002-9731-9397; Talalaev, Vadim/0000-0003-2559-889X;
   Kissel, Heiko/0000-0003-4171-5494
CR ALEXANDER MGW, 1989, APPL PHYS LETT, V55, P885, DOI 10.1063/1.101615
   Bayer M, 2001, SCIENCE, V291, P451, DOI 10.1126/science.291.5503.451
   BRIMBERG D, 1999, QUANTUM DOT HETEROST
   He J, 2003, J APPL PHYS, V93, P8898, DOI 10.1063/1.1570503
   Heitz R, 1999, J ELECTRON MATER, V28, P520, DOI 10.1007/s11664-999-0105-z
   Heitz R, 1998, PHYS REV B, V58, pR10151
   Horiguchi N, 1999, JPN J APPL PHYS 1, V38, P2559, DOI 10.1143/JJAP.38.2559
   Joyce PB, 2002, PHYS REV B, V66, DOI 10.1103/PhysRevB.66.075316
   Le Ru EC, 2003, PHYS REV B, V67, DOI 10.1103/PhysRevB.67.165303
   LEVI DH, 1992, PHYS REV B, V45, P4274, DOI 10.1103/PhysRevB.45.4274
   Lipinski MO, 2000, APPL PHYS LETT, V77, P1789, DOI 10.1063/1.1311314
   Liu HY, 2000, J APPL PHYS, V88, P5433, DOI 10.1063/1.1318371
   Malik S, 2001, PHYS REV B, V63, DOI 10.1103/PhysRevB.63.155313
   Mazur YI, 2002, APPL PHYS LETT, V81, P2469, DOI 10.1063/1.1510157
   Mazur YI, 2003, APPL PHYS LETT, V83, P1866, DOI 10.1063/1.1606109
   Mazur YI, 2003, APPL PHYS LETT, V83, P987, DOI 10.1063/1.1596712
   Mazur YI, 2001, APPL PHYS LETT, V78, P3214, DOI 10.1063/1.1371965
   Mukhametzhanov I, 1998, APPL PHYS LETT, V73, P1841, DOI 10.1063/1.122300
   SAUER R, 1988, PHYS REV LETT, V61, P609, DOI 10.1103/PhysRevLett.61.609
   Solomon GS, 1999, J ELECTRON MATER, V28, P392, DOI 10.1007/s11664-999-0087-x
   TACKEUCHI A, 1995, JPN J APPL PHYS 2, V34, pL1439
   Tackeuchi A, 2000, PHYS REV B, V62, P1568, DOI 10.1103/PhysRevB.62.1568
   Tomm JW, 2003, PHYS REV B, V67, DOI 10.1103/PhysRevB.67.045326
   WANG TH, 1992, PHYS REV B, V46, P16160, DOI 10.1103/PhysRevB.46.16160
NR 24
TC 14
Z9 14
U1 4
U2 11
PU AMER PHYSICAL SOC
PI COLLEGE PK
PA ONE PHYSICS ELLIPSE, COLLEGE PK, MD 20740-3844 USA
SN 2469-9950
EI 2469-9969
J9 PHYS REV B
JI Phys. Rev. B
PD JUN
PY 2005
VL 71
IS 23
AR 235313
DI 10.1103/PhysRevB.71.235313
PG 8
WC Materials Science, Multidisciplinary; Physics, Applied; Physics,
   Condensed Matter
SC Materials Science; Physics
GA 942IT
UT WOS:000230276800067
DA 2018-12-27
ER

PT J
AU Men'shikov, VV
   Ovchinnikov, SG
   Rudenko, VV
   Sudakov, AN
   Tugarinov, VI
   Vorotynov, AM
AF Men'shikov, VV
   Ovchinnikov, SG
   Rudenko, VV
   Sudakov, AN
   Tugarinov, VI
   Vorotynov, AM
TI RETRACTED: Magnetic anisotropy quantitative estimation for the
   rhombohedral antiferromagnetic crystals containing S-state ions - art.
   no. 224405 (Retracted Article. see vol 72, art. no. 189901, 2005)
SO PHYSICAL REVIEW B
LA English
DT Article; Retracted Publication
ID ELECTRON-PARAMAGNETIC-RES; EXCHANGE-COUPLED PAIRS; RESONANCE
   MEASUREMENTS; FIELD; GARNETS; FE3+
AB The method to investigate "single-ion" exchange anisotropy (as predicted by the pair model) is treated by exploration of several isostructural diamagnetic crystals containing magnetic impurities. The electron paramagnetic resonance (EPR) spectra were observed for ferric borate isostructural crystals MBO3: Fe3+ (M = Ga, In, Lu, Sc). The experimental dependences of the spin-Hamiltonian axial parameters of the second-order D-S and fourth-order (a-F)(cS) versus total pair spin S are presented. The contributions arising from the distortion of the parent crystal lattice MBO3 under magnetic dilution are estimated. The microscopic derived expressions for the "single-ion" contribution to the anisotropy are also presented. The present experimental data enable estimation of the "single- ion" exchange contribution for FeBO3, MnCO3, and alpha-Fe2O3 crystals at T= 0 K. The quantitative estimations for EPR are in satisfactory agreement among themselves and with the experimental data.
C1 LV Kirenskii Inst Phys, SB RAS, Krasnoyarsk 660036, Russia.
RP Men'shikov, VV (reprint author), LV Kirenskii Inst Phys, SB RAS, Krasnoyarsk 660036, Russia.
EM sasa@iph.krasn.ru
CR ABRAGAM A, 1972, ELECTRONNYI PARAMAGN, V1, P564
   BARAK J, 1978, J MAGN MAGN MATER, V9, P323, DOI 10.1016/0304-8853(78)90087-2
   BAYUKOV OA, 1992, FIZ TVERD TELA+, V34, P2665
   BAYUKOV OA, UNPUB
   BEMCINI A, 1990, ELECT PARAMAGNETIC R
   Callen HB, 1965, SOLID STATE COMMUN, V3, P5, DOI 10.1016/0038-1098(65)90158-4
   EMELYANOVA LS, 1984, FIZ TVERD TELA+, V26, P1844
   GARIFULLINA RL, 1973, FIZ TVERD TELA+, V15, P1909
   HARRIS EA, 1972, J PHYS PART C SOLID, V5, P338, DOI 10.1088/0022-3719/5/3/014
   HEMING M, 1982, SOLID STATE COMMUN, V44, P543, DOI 10.1016/0038-1098(82)90142-9
   KRUPICHKA S, 1976, FIZIKA FERRITOV RODS, V2, P39
   LUKIN SN, 1980, FIZ TVERD TELA+, V22, P51
   MCPHERSON GL, 1976, SOLID STATE COMMUN, V19, P53, DOI 10.1016/0038-1098(76)91727-0
   MISRA SK, 1985, J CHEM PHYS, V83, P1490, DOI 10.1063/1.449384
   MIYATA N, 1967, PHYS REV, V157, P448, DOI 10.1103/PhysRev.157.448
   MORRISON BR, 1973, PHYS STATUS SOLIDI B, V56, P183, DOI 10.1002/pssb.2220560117
   MOSKVIN AS, 1993, SOV PHYS JETP, V103, P2499
   NIKIFOROV AE, 1971, PHYS STATUS SOLIDI B, V45, P65, DOI 10.1002/pssb.2220450106
   OWEN J, 1961, J APPL PHYS, V32, pS213, DOI 10.1063/1.2000406
   PETRAKOVSKAYA EA, 1978, REZONANSNYE MAGNITNY, P155
   RIMAI L, 1966, PHYS REV, V143, P160, DOI 10.1103/PhysRev.143.160
   RODRIGUE GP, 1960, J APPL PHYS, V31, pS376, DOI 10.1063/1.1984756
   Rubinshtein B. E., 1969, Fizika Tverdogo Tela, V11, P1980
   RUDENKO VV, 1995, KRISTALLOGRAFIYA+, V40, P382
   RUDENKO VV, 1983, THESIS SGU SIMFEROPO
   RUDENKO VV, 1998, NEORGAN MAT, V34, P1483
   RUDENKO VV, 1999, IZVE VYZOV FIZ, V42, P82
   Rudowicz C, 2001, APPL SPECTROSC REV, V36, P11, DOI 10.1081/ASR-100103089
   STEVENS KWH, 1997, MAGNETIC IONS CRYSTA
   VELIKOV LV, 1974, ZH EKSP TEOR FIZ+, V66, P1847
   VOROTYNOV AI, 2000, FIZ TVERD TELA, V42, P1275
   WOLF WP, 1957, PHYS REV, V108, P1152, DOI 10.1103/PhysRev.108.1152
   YOSIDA K, 1968, J APPL PHYS, V39, P511, DOI 10.1063/1.2163506
NR 33
TC 1
Z9 1
U1 3
U2 10
PU AMER PHYSICAL SOC
PI COLLEGE PK
PA ONE PHYSICS ELLIPSE, COLLEGE PK, MD 20740-3844 USA
SN 2469-9950
EI 2469-9969
J9 PHYS REV B
JI Phys. Rev. B
PD JUN
PY 2005
VL 71
IS 22
AR 224405
DI 10.1103/PhysRevB.71.224405
PG 6
WC Materials Science, Multidisciplinary; Physics, Applied; Physics,
   Condensed Matter
SC Materials Science; Physics
GA 942IS
UT WOS:000230276700061
DA 2018-12-27
ER

PT J
AU Chen, YY
   Tzeng, HJ
   Wei, LI
   Shih, HC
AF Chen, YY
   Tzeng, HJ
   Wei, LI
   Shih, HC
TI RETRACTED: Mechanical properties and corrosion resistance of low-alloy
   steels in atmospheric conditions containing chloride (Retracted article.
   See vol. 661, pg. 254, 2016)
SO MATERIALS SCIENCE AND ENGINEERING A-STRUCTURAL MATERIALS PROPERTIES
   MICROSTRUCTURE AND PROCESSING
LA English
DT Article; Retracted Publication
DE atmospheric corrosion; weathering steel; accelerated test; weight loss;
   rust layer; corrosion potential
ID WEATHERING STEELS; CARBON-STEEL; RUST; IRON; TEMPERATURE; BEHAVIOR;
   COPPER
AB The corrosion resistance (weight loss) and mechanical properties (i.e., yield strength, ultimate tensile strength, and elongation) of four newly developed low-alloy steels (LAS) were compared with a weathering steel (Acr-Ten A) and a carbon steel (SS400) using a laboratory-accelerated test that involved cyclic wet/dry conditions in a chloride environment (5 wt.% NaCl). The new LAS were designated 1604A, 160413, 1605A, and 1605B. After 72 cycles of cyclic corrosion tests, the change in mechanical properties by corrosion was the least for SS400, Acr-Ten A was second, and effects of corrosion on the mechanical properties of the other four low-alloy steels were similar. The susceptibility of the steels to corrosion based on their weight loss was the most for SS400, and the least for 1605A and 1605B. In addition, it was found that the corrosion potentials of low-alloy steels are more active prior to accelerated corrosion tests than after the accelerated test, and the corrosion tendency of the six steels immersed in 3.5 wt.% NaCl solutions after 72 cycles of accelerated corrosion tests was the least for 1605A and 1605B because the corrosion potentials were higher than other steels. The rust characteristics observed by SEM and analyzed by FTIR and EPMA indicated that most of the rust layers on the test steels were composed of a loose outer rust layer and a dense inner rust layer. The outer rust layer of each steel was composed of alpha-FeOOH, gamma-FeOOH, magnetite (Fe3O4), H2O, and amorphous ferric oxyhydroxide (FeOx(OH)(3-2x), x = 0 to 1), while the inner rust layer was composed mainly of Fe3O4 with a little alpha-FeOOH. In addition, it was apparent that the copper and chromium alloying additions were enriched, respectively, at the rust-layer/substrate interface and in the rust layers. Finally, combining the results of the accelerated tests, the rust layer analysis, and the corrosion potential measurements showed that low-alloy steels, such as 1605A and 1605B, have better weathering steel properties than Acr-Ten A for use in the humid and salty weather. (c) 2005 Elsevier B.V. All rights reserved.
C1 Natl Tsing Hua Univ, Dept Mat Sci & Engn, Hsinchu 300, Taiwan.
   China Steel Corp, Kaohsiung 812, Taiwan.
RP Shih, HC (reprint author), Natl Tsing Hua Univ, Dept Mat Sci & Engn, 101 Sec ,2 Kuang Fu Rd, Hsinchu 300, Taiwan.
EM hcshih@mse.nthu.edu.tw
CR Asami K, 2003, CORROS SCI, V45, P2671, DOI 10.1016/S0010-938X(03)00070-2
   *ASTM B, 1997, 11797 ASTM B
   *ASTM E, 1998, 8M98 ASTM E
   *ASTM G, 1988, 188 ASTM G
   *ASTM G, 1992, 5076 ASTM G
   Chandler K.A., 1963, P 2 INT C MET CORR N, P325
   DAVALOS J, 1991, HYPERFINE INTERACT, V69, P871
   DEMEYBAUM BR, 1980, CORROSION, V36, P345, DOI 10.5006/0010-9312-36.7.345
   EVANS UR, 1969, CORROS SCI, V9, P813, DOI 10.1016/S0010-938X(69)80074-0
   FELIU S, 1993, CORROS SCI, V34, P403, DOI 10.1016/0010-938X(93)90112-T
   Hiller JE, 1966, WERKST KORROS, V17, P943
   HISAMATSU Y, 1971, BOSHU GISTO, V20, P207
   Hudson J.C., 1955, J IRON STEEL I, V180, P271
   IRVINE KJ, 1967, J IRON STEEL I, V205, P161
   KEISER JT, 1983, CORROS SCI, V23, P251, DOI 10.1016/0010-938X(83)90106-3
   KELLER P, 1967, WERKST KORROS, V18, P865
   KOCICH J, 1993, CORROS SCI, V35, P1
   LARRABEE CP, 1961, P 1 C MET CORR, P276
   LEGAULT RA, 1975, CORROSION, V31, P117, DOI 10.5006/0010-9312-31.4.117
   MISAWA T, 1971, CORROS SCI, V11, P35, DOI 10.1016/S0010-938X(71)80072-0
   MISAWA T, 1974, CORROS SCI, V14, P279, DOI 10.1016/S0010-938X(74)80037-5
   MISAWA T, 1974, CORROS SCI, V14, P131, DOI 10.1016/S0010-938X(74)80051-X
   OKADA H, 1970, CORROSION, V26, P429, DOI 10.5006/0010-9312-26.10.429
   POURBAIX M, 1989, CORROSION, V45, P71, DOI 10.5006/1.3577890
   Revie R. W., 1991, CORROSION CORROSION
   SCHMITTER H, 1980, J ELECTROCHEM SOC, V127, P15
   SHIH HC, 1994, MATER CHEM PHYS, V37, P230, DOI 10.1016/0254-0584(94)90158-9
   SHIRASAWA H, 1991, KOBELCO TECHNOL REV, V12, P44
   SOUTHWELL CR, 1970, MATER PROT PERFORM, V9, P14
   STRATMANN M, 1987, CORROS SCI, V27, P905, DOI 10.1016/0010-938X(87)90058-8
   SUZUKI I, 1980, J ELECTROCHEM SOC, V127, P345
   UNO T, 1971, B TPN I MET, V10, P208
   Wang JH, 1996, CORROSION, V52, P900, DOI 10.5006/1.3292083
   Wang JH, 1996, CORROSION, V52, P600, DOI 10.5006/1.3292150
   WILLIAMS E, 1965, CORROSION, V21, P9, DOI 10.5006/0010-9312-21.1.9
   YAMASHITA M, 1994, CORROS SCI, V36, P283, DOI 10.1016/0010-938X(94)90158-9
   Yamashita M., 2000, ZAIRYO TO KANKUO, V49, P82
   Zhang Q.C., 2002, MATER CHEM PHYS, V77, P603
NR 38
TC 38
Z9 42
U1 3
U2 35
PU ELSEVIER SCIENCE SA
PI LAUSANNE
PA PO BOX 564, 1001 LAUSANNE, SWITZERLAND
SN 0921-5093
EI 1873-4936
J9 MAT SCI ENG A-STRUCT
JI Mater. Sci. Eng. A-Struct. Mater. Prop. Microstruct. Process.
PD MAY 25
PY 2005
VL 398
IS 1-2
BP 47
EP 59
DI 10.1016/j.msea.2005.02.064
PG 13
WC Nanoscience & Nanotechnology; Materials Science, Multidisciplinary;
   Metallurgy & Metallurgical Engineering
SC Science & Technology - Other Topics; Materials Science; Metallurgy &
   Metallurgical Engineering
GA 938KH
UT WOS:000229998100006
DA 2018-12-27
ER

PT J
AU Zou, ZH
   Li, FS
   Buck, LB
AF Zou, ZH
   Li, FS
   Buck, LB
TI RETRACTED: Odor maps in the olfactory cortex (Retracted article. See
   vol. 107, pg. 17451, 2010)
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article; Retracted Publication
DE odorant receptor; smell
ID IMMEDIATE-EARLY GENES; C-FOS; PIRIFORM CORTEX; FUNCTIONAL-ORGANIZATION;
   ORBITOFRONTAL CORTEX; PYRIFORM CORTEX; NERVOUS-SYSTEM; SENSORY MAP;
   BULB; RECEPTOR
AB In the olfactory system, environmental chemicals are deconstructed into neural signals and then reconstructed to form odor perceptions. Much has been learned about odor coding in the olfactory epithelium and bulb, but little is known about how odors are subsequently encoded in the cortex to yield diverse perceptions. Here, we report that the representation of odors by fixed glomeruli in the olfactory bulb is transformed in the cortex into highly distributed and multiplexed odor maps. In the mouse olfactory cortex, individual odorants are represented by subsets of sparsely distributed neurons. Different odorants elicit distinct, but partially overlapping, patterns that are strikingly similar among individuals. With increases in odorant concentration, the representations expand spatially and include additional cortical neurons. Structurally related odorants have highly related representations, suggesting an underlying logic to the mapping of odor identities in the cortex.
C1 Fred Hutchinson Canc Res Ctr, Div Basic Sci, Seattle, WA 98109 USA.
   Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Seattle, WA 98109 USA.
   Fred Hutchinson Canc Res Ctr, Howard Hughes Med Inst, Seattle, WA 98109 USA.
RP Buck, LB (reprint author), Fred Hutchinson Canc Res Ctr, Div Basic Sci, A3-020,1100 Fairview Ave N,POB 19024, Seattle, WA 98109 USA.
EM lbuck@fhcrc.org
CR AMOORE JE, 1970, MOL BASIS ODOR
   Araneda RC, 2000, NAT NEUROSCI, V3, P1248
   BUCK L, 1991, CELL, V65, P175, DOI 10.1016/0092-8674(91)90418-X
   Buck LB, 2000, CELL, V100, P611, DOI 10.1016/S0092-8674(00)80698-4
   Cang JH, 2003, J NEUROSCI, V23, P4108
   Filipkowski RK, 2000, LEARN MEMORY, V7, P116, DOI 10.1101/lm.7.2.116
   Firestein S, 2001, NATURE, V413, P211, DOI 10.1038/35093026
   Fried HU, 2002, P NATL ACAD SCI USA, V99, P3222, DOI 10.1073/pnas.052658399
   Friedrich RW, 1997, NEURON, V18, P737, DOI 10.1016/S0896-6273(00)80314-1
   GETCHELL TV, 1978, J PHYSIOL-LONDON, V282, P521, DOI 10.1113/jphysiol.1978.sp012479
   Godfrey PA, 2004, P NATL ACAD SCI USA, V101, P2156, DOI 10.1073/pnas.0308051100
   GUTHRIE KM, 1995, CHEM SENSES, V20, P271, DOI 10.1093/chemse/20.2.271
   HABERLY LB, 1969, BRAIN RES, V12, P481, DOI 10.1016/0006-8993(69)90019-5
   Herrera DG, 1996, PROG NEUROBIOL, V50, P83, DOI 10.1016/S0301-0082(96)00021-4
   Horowitz LF, 1999, P NATL ACAD SCI USA, V96, P3194, DOI 10.1073/pnas.96.6.3194
   HUBEL D, 1988, EYE BRAIN VISION
   Illig KR, 2003, J COMP NEUROL, V457, P361, DOI 10.1002/cne.10557
   Johnson BA, 2000, J COMP NEUROL, V422, P496, DOI 10.1002/1096-9861(20000710)422:4<496::AID-CNE2>3.0.CO;2-4
   Johnson DE, 1998, APPL MULTIVARIATE ME
   Kajiya K, 2001, J NEUROSCI, V21, P6018
   Kandel E. R., 2000, PRINCIPLES NEURAL SC
   Litaudon P, 2003, EUR J NEUROSCI, V17, P2457, DOI 10.1046/j.1460-9568.2003.02654.x
   Ma MH, 2000, P NATL ACAD SCI USA, V97, P12869, DOI 10.1073/pnas.220301797
   Malnic B, 1999, CELL, V96, P713, DOI 10.1016/S0092-8674(00)80581-4
   MCCOLLUM J, 1991, J COGNITIVE NEUROSCI, V3, P293, DOI 10.1162/jocn.1991.3.3.293
   Melzer P, 1997, J COMP NEUROL, V380, P145, DOI 10.1002/(SICI)1096-9861(19970331)380:1<145::AID-CNE11>3.0.CO;2-Z
   Mombaerts P, 2004, NAT REV NEUROSCI, V5, P263, DOI 10.1038/nrn1365
   Mombaerts P, 1996, CELL, V87, P675, DOI 10.1016/S0092-8674(00)81387-2
   MONTERO VM, 1995, BRAIN RES, V690, P189, DOI 10.1016/0006-8993(95)00620-6
   MORGAN JI, 1991, ANNU REV NEUROSCI, V14, P421, DOI 10.1146/annurev.ne.14.030191.002225
   Mori K, 1999, SCIENCE, V286, P711, DOI 10.1126/science.286.5440.711
   NEMITZ JW, 1983, J NEUROPHYSIOL, V49, P188
   Neville KR, 2004, SYNAPTIC ORG BRAIN, V5, P415, DOI DOI 10.1093/ACPR0F:0S0/9780195159561.003.0010
   Price J.L., 1987, P179
   RESSLER KJ, 1994, CELL, V79, P1245, DOI 10.1016/0092-8674(94)90015-9
   RESSLER KJ, 1993, CELL, V73, P597, DOI 10.1016/0092-8674(93)90145-G
   Rubin BD, 1999, NEURON, V23, P499, DOI 10.1016/S0896-6273(00)80803-X
   SCHEICH H, 1995, BEHAV BRAIN RES, V66, P195, DOI 10.1016/0166-4328(94)00140-B
   SCHOENBAUM G, 1995, J NEUROPHYSIOL, V74, P733
   SCOTT JW, 1986, EXPERIENTIA, V42, P223, DOI 10.1007/BF01942502
   SCOTT JW, 1993, MICROSC RES TECHNIQ, V24, P142, DOI 10.1002/jemt.1070240206
   SHENG M, 1990, NEURON, V4, P477, DOI 10.1016/0896-6273(90)90106-P
   Shepherd GM, 2004, SYNAPTIC ORG BRAIN, P165, DOI DOI 10.1093/ACPR0F:0S0/9780195159561.003.0005
   Shipley MT, 1996, J NEUROBIOL, V30, P123
   TANABE T, 1975, J NEUROPHYSIOL, V38, P1284
   Uchida N, 2000, NAT NEUROSCI, V3, P1035, DOI 10.1038/79857
   VASSAR R, 1994, CELL, V79, P981, DOI 10.1016/0092-8674(94)90029-9
   VASSAR R, 1993, CELL, V74, P309, DOI 10.1016/0092-8674(93)90422-M
   Werntz D A, 1983, Hum Neurobiol, V2, P39
   WERNTZ DA, 1987, HUM NEUROBIOL, V6, P165
   West AE, 2001, P NATL ACAD SCI USA, V98, P11024, DOI 10.1073/pnas.191352298
   Wilson DA, 2000, J NEUROPHYSIOL, V83, P139
   Young JM, 2002, HUM MOL GENET, V11, P1153, DOI 10.1093/hmg/11.10.1153
   Zhang XM, 2002, NAT NEUROSCI, V5, P124, DOI 10.1038/nn800
   Zhao HQ, 1998, SCIENCE, V279, P237, DOI 10.1126/science.279.5348.237
   Zou ZH, 2001, NATURE, V414, P173, DOI 10.1038/35102506
NR 56
TC 74
Z9 75
U1 5
U2 22
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD MAY 24
PY 2005
VL 102
IS 21
BP 7724
EP 7729
DI 10.1073/pnas.0503027102
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 930LN
UT WOS:000229417500058
PM 15911779
OA Green Published, Bronze
DA 2018-12-27
ER

PT J
AU Babbitt, SE
   Kiss, A
   Deffenbaugh, AE
   Chang, YH
   Bailly, E
   Erdjument-Bromage, H
   Tempst, P
   Buranda, T
   Sklar, LA
   Baumler, J
   Gogol, E
   Skowyra, D
AF Babbitt, SE
   Kiss, A
   Deffenbaugh, AE
   Chang, YH
   Bailly, E
   Erdjument-Bromage, H
   Tempst, P
   Buranda, T
   Sklar, LA
   Baumler, J
   Gogol, E
   Skowyra, D
TI RETRACTED: ATP hydrolysis-dependent disassembly of the 26S proteasome is
   part of the catalytic cycle (Retracted article. See vol. 173, pg. 804,
   2018)
SO CELL
LA English
DT Article; Retracted Publication
ID REGULATORY PARTICLE; MULTIUBIQUITIN-CHAIN; 20S PROTEASOME; CORE
   PARTICLE; DEGRADATION SIGNAL; PROTEIN BREAKDOWN; ACTIVE-SITES;
   UBIQUITIN; COMPLEX; YEAST
AB ATP hydrolysis is required for degradation of poly-ubiquitinated proteins by the 26S proteasome but is thought to play no role in proteasomal stability during the catalytic cycle. In contrast to this view, we report that ATP hydrolysis triggers rapid dissociation of the 19S regulatory particles from immunopurified 26S complexes in a manner coincident with release of the bulk of proteasome-interacting proteins. Strikingly, this mechanism leads to quantitative disassembly of the 19S into subcomplexes and free Rpn10, the polyubiquitin binding subunit. Biochemical reconstitution with purified Sic1, a prototype substrate of the Cdc34/ SCF ubiquitin ligase, suggests that substrate degradation is essential for triggering the ATP hydrolysis-dependent dissociation and disassembly of the 19S and that this mechanism leads to release of degradation products. This is the first demonstration that a controlled dissociation of the 19S regulatory particles from the 26S proteasome is part of the mechanism of protein degradation.
C1 St Louis Univ, Sch Med, Edward A Doisy Dept Biochem & Mol Biol, St Louis, MO 63104 USA.
   CNRS, Lab Ingn Syst Macromol, Marseille 20, France.
   Mem Sloan Kettering Canc Ctr, Program Mol Biol, New York, NY 10021 USA.
   Univ New Mexico, Sch Med, Dept Pathol, Albuquerque, NM 87131 USA.
   Univ Missouri, Sch Biol Sci, Kansas City, MO 64110 USA.
RP Skowyra, D (reprint author), St Louis Univ, Sch Med, Edward A Doisy Dept Biochem & Mol Biol, St Louis, MO 63104 USA.
EM skowyrad@slu.edu
OI Tempst, Paul/0000-0002-6680-3987
FU NIGMS NIH HHS [GM 54703, GM 65267]; NIBIB NIH HHS [EB 00264]; NCI NIH
   HHS [P30 CA 08748]; NIAID NIH HHS [K25 AI 060036, K25 AI060036]
CR Adams GM, 1998, BIOCHEMISTRY-US, V37, P12927, DOI 10.1021/bi981482i
   ARMON T, 1990, J BIOL CHEM, V265, P20723
   Benaroudj N, 2003, MOL CELL, V11, P69, DOI 10.1016/S1097-2765(02)00775-X
   Braun BC, 1999, NAT CELL BIOL, V1, P221, DOI 10.1038/12043
   Buranda T, 1999, J PHYS CHEM B, V103, P3399, DOI 10.1021/jp983842h
   CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923
   Deffenbaugh AE, 2003, CELL, V114, P611, DOI 10.1016/S0092-8674(03)00641-X
   DEVERAUX Q, 1994, J BIOL CHEM, V269, P7059
   DRISCOLL J, 1990, J BIOL CHEM, V265, P4789
   EYTAN E, 1989, P NATL ACAD SCI USA, V86, P7751, DOI 10.1073/pnas.86.20.7751
   Ezhkova E, 2004, MOL CELL, V13, P435, DOI 10.1016/S1097-2765(04)00026-7
   Ferdous A, 2001, MOL CELL, V7, P981, DOI 10.1016/S1097-2765(01)00250-7
   Frank J, 1996, J STRUCT BIOL, V116, P190, DOI 10.1006/jsbi.1996.0030
   GANOTH D, 1988, J BIOL CHEM, V263, P12412
   Gavin AC, 2002, NATURE, V415, P141, DOI 10.1038/415141a
   Gillette TG, 2001, GENE DEV, V15, P1528, DOI 10.1101/gad.869601
   Glickman MH, 1998, CELL, V94, P615, DOI 10.1016/S0092-8674(00)81603-7
   Goldenberg SJ, 2004, CELL, V119, P517, DOI 10.1016/j.cell.2004.10.019
   Gonzalez F, 2002, SCIENCE, V296, P548, DOI 10.1126/science.1069490
   Groll M, 2000, NAT STRUCT BIOL, V7, P1062, DOI 10.1038/80992
   GROLL M, 1997, ANTURE, V386, P463
   Hendil KB, 2002, J MOL BIOL, V315, P627, DOI 10.1006/jmbi.2001.5285
   Hoffman L, 1997, MOL BIOL REP, V24, P13, DOI 10.1023/A:1006892220996
   Hutschenreiter S, 2004, EMBO J, V23, P2488, DOI 10.1038/sj.emboj.7600262
   Kaiser P, 1999, GENE DEV, V13, P1190, DOI 10.1101/gad.13.9.1190
   Kisselev AF, 2002, J BIOL CHEM, V277, P22260, DOI 10.1074/jbc.M112360200
   Kisselev AF, 2003, J BIOL CHEM, V278, P35869, DOI 10.1074/jbc.M303725200
   Kisselev AF, 1999, MOL CELL, V4, P395, DOI 10.1016/S1097-2765(00)80341-X
   Kohler A, 2001, MOL CELL, V7, P1143, DOI 10.1016/S1097-2765(01)00274-X
   Lam YA, 2002, NATURE, V416, P763, DOI 10.1038/416763a
   Lee C, 2001, MOL CELL, V7, P627, DOI 10.1016/S1097-2765(01)00209-X
   Leggett DS, 2002, MOL CELL, V10, P495, DOI 10.1016/S1097-2765(02)00638-X
   LOWE J, 1995, SCIENCE, V268, P533, DOI 10.1126/science.7725097
   Navon A, 2001, MOL CELL, V8, P1339, DOI 10.1016/S1097-2765(01)00407-5
   Osmulski PA, 2002, BIOCHEMISTRY-US, V41, P7047, DOI 10.1021/bi0159130
   Pickart CM, 2004, NAT REV MOL CELL BIO, V5, P177, DOI 10.1038/nrm1336
   Rubin DM, 1998, EMBO J, V17, P4909, DOI 10.1093/emboj/17.17.4909
   Schmidt M, 2005, NAT STRUCT MOL BIOL, V12, P294, DOI 10.1038/nsmb914
   SIGH SK, 1999, BIOCHEMISTRY-US, V38, P14906
   Skowyra D, 1997, CELL, V91, P209, DOI 10.1016/S0092-8674(00)80403-1
   Thrower JS, 2000, EMBO J, V19, P94, DOI 10.1093/emboj/19.1.94
   vanNocker S, 1996, MOL CELL BIOL, V16, P6020
   Verma R, 2002, SCIENCE, V298, P611, DOI 10.1126/science.1075898
   Verma R, 2004, CELL, V118, P99, DOI 10.1016/j.cell.2004.06.014
   Verma R, 2000, MOL BIOL CELL, V11, P3425, DOI 10.1091/mbc.11.10.3425
   Verma R, 2001, MOL CELL, V8, P439, DOI 10.1016/S1097-2765(01)00308-2
   Wang J, 2001, STRUCTURE, V9, P1107, DOI 10.1016/S0969-2126(01)00670-0
   Whitby FG, 2000, NATURE, V408, P115, DOI 10.1038/35040607
   Winkler GS, 2002, METHODS, V26, P260, DOI 10.1016/S1046-2023(02)00030-0
   Xie YM, 2000, P NATL ACAD SCI USA, V97, P2497, DOI 10.1073/pnas.060025497
   Xie YM, 2002, NAT CELL BIOL, V4, P1003, DOI 10.1038/ncb889
   Yao TT, 2002, NATURE, V419, P403, DOI 10.1038/nature01071
NR 52
TC 97
Z9 97
U1 0
U2 2
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 0092-8674
EI 1097-4172
J9 CELL
JI Cell
PD MAY 20
PY 2005
VL 121
IS 4
BP 553
EP 565
DI 10.1016/j.cell.2005.03.028
PG 13
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 929GX
UT WOS:000229331200012
PM 15907469
OA Bronze
DA 2018-12-27
ER

PT J
AU Chamberlain, MC
AF Chamberlain, MC
TI RETRACTED: Neoplastic meningitis (Retracted article. See vol. 28, pg
   4018, 2010)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Review; Retracted Publication
ID CEREBROSPINAL-FLUID CYTOLOGY; COMBINED-MODALITY THERAPY; INTRATHECALLY
   ADMINISTERED CHEMOTHERAPY; LACTATE-DEHYDROGENASE ACTIVITIES;
   NERVOUS-SYSTEM METASTASES; CELL LUNG-CANCER; LEPTOMENINGEAL METASTASES;
   MENINGEAL CARCINOMATOSIS; SOLID TUMORS; CSF FLOW
AB Neoplastic meningitis (NM) is a common problem in neuro-oncology occurring in approximately 5% of all patients with cancer, and is the third most common site of CNS metastases. NM is a disease affecting the entire neuraxis, and therefore clinical manifestations are pleomorphic affecting the spine, cranial nerves, and cerebral hemispheres. Because of craniospinal disease involvement, staging and treatment need to encompass all CSF compartments. Treatment of NM utilizes involved-field radiotherapy of bulky or symptomatic disease sites and intra-CSF drug therapy. The inclusion of concomitant systemic therapy may benefit patients with NM and may obviate the need for intra-CSF chemotherapy. At present, intra-CSF drug therapy is confined to three chemotherapeutic agents (ie, methotrexate, cytarabine, and thiotepa) administered by a variety of schedules either by intralumbar or intraventricular drug delivery. Although treatment of NM is palliative with an expected median patient survival of 2 to 6 months, it often affords stabilization and protection from further neurologic deterioration in patients with NM. 2005 by American Society of Clinical Oncology.
C1 Univ S Florida, H Lee Moffit Canc Ctr & Res Inst, Dept Interdisciplinary Oncol, Tampa, FL 33612 USA.
RP Chamberlain, MC (reprint author), Univ S Florida, H Lee Moffit Canc Ctr & Res Inst, Dept Neurooncol, 12902 Magnolia Dr,Suite 3136, Tampa, FL 33612 USA.
EM chambemc@moffitt.usf.edu
CR AMER MH, 1978, CANCER, V42, P660, DOI 10.1002/1097-0142(197808)42:2<660::AID-CNCR2820420237>3.0.CO;2-E
   Balm M, 1996, ARCH NEUROL-CHICAGO, V53, P626, DOI 10.1001/archneur.1996.00550070064013
   Berweiler U, 1998, J NEURO-ONCOL, V38, P141, DOI 10.1023/A:1005991027029
   BIESTERFELD S, 1993, ACTA NEUROPATHOL, V86, P428
   Blaney SM, 1998, J NEURO-ONCOL, V38, P219, DOI 10.1023/A:1005944622003
   BLEYER WA, 1973, NEW ENGL J MED, V289, P770, DOI 10.1056/NEJM197310112891503
   Bokstein F, 1998, CANCER, V82, P1756, DOI 10.1002/(SICI)1097-0142(19980501)82:9<1764::AID-CNCR24>3.0.CO;2-1
   Boogerd W, 2000, NEUROLOGY, V55, P117, DOI 10.1212/WNL.55.1.117
   BOOGERD W, 1988, J NEUROL NEUROSUR PS, V51, P142, DOI 10.1136/jnnp.51.1.142
   BOYLE R, 1980, POSTGRAD MED J, V56, P149, DOI 10.1136/pgmj.56.653.149
   Chamberlain Marc C., 2003, Neurology, V60, pA17
   Chamberlain MC, 1997, J NEUROSURG, V87, P694, DOI 10.3171/jns.1997.87.5.0694
   Chamberlain MC, 1997, ARCH NEUROL-CHICAGO, V54, P16, DOI 10.1001/archneur.1997.00550130008003
   Chamberlain MC, 2003, NEUROSURGERY, V52, P324, DOI 10.1227/01.NEU.0000043929.31608.62
   Chamberlain MC, 1997, J NEURO-ONCOL, V35, P55, DOI 10.1023/A:1005803918194
   Chamberlain MC, 1998, NEUROLOGY, V50, P1173, DOI 10.1212/WNL.50.4.1173
   Chamberlain MC, 1996, NEUROLOGY, V46, P1674, DOI 10.1212/WNL.46.6.1674
   Chamberlain MC, 1997, ARCH NEUROL-CHICAGO, V54, P1364, DOI 10.1001/archneur.1997.00550230037013
   CHAMBERLAIN MC, 1995, J NEURO-ONCOL, V23, P233, DOI 10.1007/BF01059954
   Chamberlain MC, 1998, ARCH NEUROL-CHICAGO, V55, P506, DOI 10.1001/archneur.55.4.506
   CHAMBERLAIN MC, 1990, NEUROLOGY, V40, P435, DOI 10.1212/WNL.40.3_Part_1.435
   CHAMBERLAIN MC, 1991, NEUROLOGY, V41, P1765, DOI 10.1212/WNL.41.11.1765
   Chamberlain MC, 1999, NEUROLOGY, V52, P216
   Chamberlain MC, 2001, NEURO-ONCOLOGY, V3, P42, DOI 10.1093/neuonc/3.1.42
   Chamberlain MC, 1998, J NEURO-ONCOL, V38, P135, DOI 10.1023/A:1005982826121
   CHENG TM, 1994, NEUROSURGERY, V34, P590, DOI 10.1227/00006123-199404000-00004
   CIBAS ES, 1987, AM J CLIN PATHOL, V88, P570, DOI 10.1093/ajcp/88.5.570
   Coakham HB, 1998, J NEURO-ONCOL, V38, P225, DOI 10.1023/A:1005996606073
   DeAngelis LM, 1998, J NEURO-ONCOL, V38, P245, DOI 10.1023/A:1005956925637
   FREILICH RJ, 1995, ANN NEUROL, V38, P51, DOI 10.1002/ana.410380111
   GARSON JA, 1985, J NEURO-ONCOL, V3, P165, DOI 10.1007/BF02228893
   GIANNONE L, 1986, J CLIN ONCOL, V4, P68, DOI 10.1200/JCO.1986.4.1.68
   GLANTZ MJ, 1995, CANCER, V75, P2919, DOI 10.1002/1097-0142(19950615)75:12<2919::AID-CNCR2820751220>3.0.CO;2-9
   Glantz MJ, 1998, J CLIN ONCOL, V16, P1561, DOI 10.1200/JCO.1998.16.4.1561
   Glantz MJ, 1999, J CLIN ONCOL, V17, P3110, DOI 10.1200/JCO.1999.17.10.3110
   Glantz MJ, 1998, CANCER, V82, P733, DOI 10.1002/(SICI)1097-0142(19980215)82:4<733::AID-CNCR17>3.0.CO;2-Z
   Glantz MJ, 1999, CLIN CANCER RES, V5, P3394
   GLASS JP, 1979, NEUROLOGY, V29, P1369, DOI 10.1212/WNL.29.10.1369
   GONZALEZVITALE JC, 1976, CANCER, V37, P2906, DOI 10.1002/1097-0142(197606)37:6<2906::AID-CNCR2820370648>3.0.CO;2-D
   Grisold W, 1998, J NEURO-ONCOL, V38, P103, DOI 10.1023/A:1005910203831
   Grossman SA, 1999, CANCER TREAT REV, V25, P103, DOI 10.1053/ctrv.1999.0119
   Herrlinger U, 1998, J NEURO-ONCOL, V38, P233, DOI 10.1023/A:1005948722912
   Hildebrand J, 1998, J NEURO-ONCOL, V38, P193, DOI 10.1023/A:1005976003347
   HITCHINS RN, 1987, J CLIN ONCOL, V5, P1655, DOI 10.1200/JCO.1987.5.10.1655
   HOVESTADT A, 1990, BRIT J CANCER, V62, P653, DOI 10.1038/bjc.1990.349
   Jaeckle KA, 2002, J NEURO-ONCOL, V57, P231, DOI 10.1023/A:1015752331041
   KAPLAN JG, 1990, J NEURO-ONCOL, V9, P225, DOI 10.1007/BF02341153
   Kerr JZ, 2001, CRIT REV ONCOL HEMAT, V37, P227, DOI 10.1016/S1040-8428(00)00115-3
   KLEE GG, 1986, MAYO CLIN PROC, V61, P9, DOI 10.1016/S0025-6196(12)61391-3
   Kolmel HW, 1998, J NEURO-ONCOL, V38, P121, DOI 10.1023/A:1005970406557
   LITTLE JR, 1974, ARCH NEUROL-CHICAGO, V30, P138, DOI 10.1001/archneur.1974.00490320026003
   Mason WP, 1998, NEUROLOGY, V50, P438, DOI 10.1212/WNL.50.2.438
   MITTL RL, 1994, AM J NEURORADIOL, V15, P633
   MURRAY JJ, 1983, AM J MED, V75, P289, DOI 10.1016/0002-9343(83)91207-X
   NUGENT JL, 1979, CANCER, V44, P1885, DOI 10.1002/1097-0142(197911)44:5<1885::AID-CNCR2820440550>3.0.CO;2-F
   OLSON ME, 1974, ARCH NEUROL-CHICAGO, V30, P122, DOI 10.1001/archneur.1974.00490320010002
   Rhodes CH, 1996, CANCER-AM CANCER SOC, V77, P543
   ROGERS LR, 1992, NEUROLOGY, V42, P1239, DOI 10.1212/WNL.42.6.1239
   ROSEN ST, 1982, MEDICINE, V61, P45, DOI 10.1097/00005792-198201000-00005
   Sampson JH, 1999, CLIN CANCER RES, V5, P1183
   Sandberg DI, 2000, NEUROSURGERY, V47, P49, DOI 10.1097/00006123-200007000-00011
   SAUSE WT, 1988, J NEURO-ONCOL, V6, P107, DOI 10.1007/BF02327385
   SCHUKNECHT B, 1992, EUR NEUROL, V32, P11, DOI 10.1159/000116780
   Schumacher M, 1998, J NEURO-ONCOL, V38, P111, DOI 10.1023/A:1005914321578
   SHAPIRO WR, 1977, CANCER TREAT REP, V61, P733
   SHAPIRO WR, 1975, NEW ENGL J MED, V293, P161, DOI 10.1056/NEJM197507242930402
   Siegal T, 1998, J NEURO-ONCOL, V38, P151, DOI 10.1023/A:1005999228846
   SIEGAL T, 1988, NEUROSURGERY, V22, P97, DOI 10.1227/00006123-198801000-00016
   SIEGAL T, 1994, NEUROLOGY, V44, P1463, DOI 10.1212/WNL.44.8.1463
   SORENSEN SC, 1984, MAYO CLIN PROC, V59, P91, DOI 10.1016/S0025-6196(12)60242-0
   Stockhammer G, 2000, NEUROLOGY, V54, P1670, DOI 10.1212/WNL.54.8.1670
   SZE G, 1989, AM J ROENTGENOL, V153, P1039, DOI 10.2214/ajr.153.5.1039
   THEODORE WH, 1981, ARCH NEUROL-CHICAGO, V38, P696, DOI 10.1001/archneur.1981.00510110056008
   TRUMP DL, 1982, ARCH INTERN MED, V142, P583
   TWIJNSTRA A, 1989, J NEURO-ONCOL, V7, P57, DOI 10.1007/BF00149379
   TWIJNSTRA A, 1987, J NEUROL NEUROSUR PS, V50, P313, DOI 10.1136/jnnp.50.3.313
   van Oostenbrugge RJ, 1999, NEUROLOGY, V53, P382, DOI 10.1212/WNL.53.2.382
   van Oostenbrugge RJ, 1998, J NEURO-ONCOL, V38, P127, DOI 10.1023/A:1005926624303
   van Oostenbrugge RJ, 1998, NEUROLOGY, V51, P906, DOI 10.1212/WNL.51.3.906
   VANZANTEN AP, 1986, CLIN CHIM ACTA, V161, P259, DOI 10.1016/0009-8981(86)90009-4
   Vrionis FD, 1998, J NEURO-ONCOL, V38, P241, DOI 10.1023/A:1005900807890
   WASSERSTROM WR, 1982, CANCER, V49, P759, DOI 10.1002/1097-0142(19820215)49:4<759::AID-CNCR2820490427>3.0.CO;2-7
   WASSERSTROM WR, 1981, ANN CLIN LAB SCI, V11, P239
   YAP HY, 1978, CANCER, V42, P283, DOI 10.1002/1097-0142(197807)42:1<283::AID-CNCR2820420142>3.0.CO;2-#
NR 84
TC 95
Z9 104
U1 3
U2 11
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2005
VL 23
IS 15
BP 3605
EP 3613
DI 10.1200/JCO.2005.01.131
PG 9
WC Oncology
SC Oncology
GA 929NI
UT WOS:000229352400042
PM 15908671
DA 2018-12-27
ER

PT J
AU Matsuyama, W
   Watanabe, M
   Shirahama, Y
   Oonakahara, KI
   Higashimoto, I
   Yoshimura, T
   Osame, M
   Arimura, K
AF Matsuyama, W
   Watanabe, M
   Shirahama, Y
   Oonakahara, KI
   Higashimoto, I
   Yoshimura, T
   Osame, M
   Arimura, K
TI RETRACTED: Activation of discoidin domain receptor 1 on CD14-positive
   pronchoalveolar lavage fluid cells induces chemokine production in
   idiopathic pulmonary fibrosis (Retracted Article. See vol 181, pg 6672,
   2008)
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article; Retracted Publication
ID INTERSTITIAL LUNG-DISEASES; MONOCYTE CHEMOATTRACTANT PROTEIN-1;
   ENDOTHELIAL GROWTH-FACTOR; TYROSINE KINASE; MATRIX METALLOPROTEINASES;
   ALVEOLAR MACROPHAGES; TISSUE INHIBITOR; DENDRITIC CELLS; GELATINASE B;
   WOUND REPAIR
AB Discoidin domain receptor. 1 (DDR1) is a receptor tyrosine kinase activated by collagen. We previously reported the functional expression of DDR1 on human monocyte-derived macrophages in vitro; however, information regarding its role in diseases is limited. Idiopathic pulmonary fibrosis (IPF) is a chronic lung disease, and the lesions contain an abundance of collagen. In this study, we examined DDR1 expression on bronchoalveolar lavage fluid (BALF) cells and investigated its functionality using samples obtained from 28 IPF patients, 13 chronic obstructive pulmonary disease patients, and 14 healthy volunteers. The DDR1 expression level in CD14-positive BALF cells was higher in IPF patients than in chronic obstructive pulmonary disease patients or healthy volunteers. The predominant isoform was DDR1b in the IPF group, while DDR1a was predominant in the other two groups. Using immunohistochemical analysis, we also detected DDR1 expression on infiltrating inflammatory cells in the IPF lesion. In IPF patients, DDR1 activation induced the production of MCP-1, IL-8, MIP-1 alpha, and matrix metalloproteinase-9 (MMP-9) from CD14-positive BALF cells in a p38 MAPK-dependent manner. In contrast, DDRI activation of CD14-positive BALF cells in the other groups did not induce the production of these chemokines or MMP-9. These chemokines and MMP-9 contribute to the development of IPF and, therefore, we suggest that DDRI might be associated with the pathogenesis of IPF in the tissue microenvironment.
C1 Kagoshima Univ Hosp, Resp & Stress Care Ctr, Div Resp Med, Kagoshima 8908520, Japan.
   NCI, Frederick Canc Res & Dev Ctr, Mol Immunoregulat Lab, Canc Res Ctr, Frederick, MD 21702 USA.
RP Matsuyama, W (reprint author), Kagoshima Univ Hosp, Resp & Stress Care Ctr, Div Resp Med, Sakuragaoka 8-35-1, Kagoshima 8908520, Japan.
EM vega@xa2.so-net.ne.jp
CR Agostini C, 1997, Curr Opin Pulm Med, V3, P348, DOI 10.1097/00063198-199709000-00006
   Alves F, 2001, FASEB J, V15, P1321
   American Thoracic Society European Respiratory Society. American Thoracic Society/ European Respiratory Society international multidisciplinary consensus classification of the idiopathic interstitial pneumonias, 2002, AM J RESP CRIT CARE, V165, P277, DOI DOI 10.1164/AJRCCM.165.2.ATS01
   Ammon C, 2000, IMMUNOLOGY, V100, P364, DOI 10.1046/j.1365-2567.2000.00056.x
   ANTONIADES HN, 1992, P NATL ACAD SCI USA, V89, P5371, DOI 10.1073/pnas.89.12.5371
   Atkinson JJ, 2003, AM J RESP CELL MOL, V28, P12, DOI 10.1165/rcmb.2002-0166TR
   Barbas-Filho JV, 2001, J CLIN PATHOL, V54, P132, DOI 10.1136/jcp.54.2.132
   BASSET F, 1986, AM J PATHOL, V122, P443
   Bjoraker JA, 1998, AM J RESP CRIT CARE, V157, P199, DOI 10.1164/ajrccm.157.1.9704130
   Buisson AC, 1996, J CELL PHYSIOL, V166, P413, DOI 10.1002/(SICI)1097-4652(199602)166:2<413::AID-JCP20>3.0.CO;2-A
   CARRE PC, 1991, J CLIN INVEST, V88, P1802, DOI 10.1172/JCI115501
   COOK DN, 1995, SCIENCE, V269, P1583, DOI 10.1126/science.7667639
   CORCORAN ML, 1995, J BIOL CHEM, V270, P13453, DOI 10.1074/jbc.270.22.13453
   CRYSTAL RG, 1981, AM J MED, V70, P542, DOI 10.1016/0002-9343(81)90577-5
   Fukuda Y, 1998, LAB INVEST, V78, P687
   Glynn PC, 2001, EUR RESPIR J, V18, P522, DOI 10.1183/09031936.01.00057901
   GOLDSTEIN RH, 1995, CHEST, V108, P848, DOI 10.1378/chest.108.3.848
   Gomez FP, 2002, CURR OPIN PULM MED, V8, P81, DOI 10.1097/00063198-200203000-00001
   Hayashi T, 1996, AM J PATHOL, V149, P1241
   Hou GP, 2002, CIRC RES, V90, P1147, DOI 10.1161/01.RES.0000022166.74073.F8
   Hou GP, 2001, J CLIN INVEST, V107, P727, DOI 10.1172/JCI10720
   HUNNINGHAKE GW, 1981, J CLIN INVEST, V68, P259, DOI 10.1172/JCI110242
   IYONAGA K, 1994, HUM PATHOL, V25, P455, DOI 10.1016/0046-8177(94)90117-1
   Kamohara H, 2001, FASEB J, V15, P2724, DOI 10.1096/fj.01-0359fje
   KAWANAMI O, 1982, LAB INVEST, V46, P39
   Khalil N, 2004, CAN MED ASSOC J, V171, P153, DOI 10.1503/cmaj.1030055
   Lemjabbar H, 1999, AM J RESP CELL MOL, V20, P903, DOI 10.1165/ajrcmb.20.5.3260
   LOHMANNMATTHES ML, 1994, EUR RESPIR J, V7, P1678
   Marra F, 1997, FEBS LETT, V414, P221, DOI 10.1016/S0014-5793(97)01004-1
   Matsuoka H, 2002, AM J PHYSIOL-LUNG C, V283, pL103, DOI 10.1152/ajplung.00187.2001
   Matsuyama W, 2003, J IMMUNOL, V171, P3520, DOI 10.4049/jimmunol.171.7.3520
   Matsuyama W, 2004, J IMMUNOL, V172, P2332, DOI 10.4049/jimmunol.172.4.2332
   Matsuyama W, 2003, FASEB J, V17, P1286, DOI 10.1096/fj.02-0320fje
   Matsuyama W, 2001, J NEUROL SCI, V186, P75, DOI 10.1016/S0022-510X(01)00515-9
   Matsuyama W, 2004, BLOOD, V104, P184, DOI 10.1182/blood-2003-12-4274
   Matsuyama W, 2000, AM J RESP CRIT CARE, V162, P1120, DOI 10.1164/ajrccm.162.3.9911010
   Mukaida N, 2003, AM J PHYSIOL-LUNG C, V284, pL566, DOI 10.1152/ajplung.00233.2002
   MURPHY G, 1992, AM J RESP CELL MOL, V7, P120, DOI 10.1165/ajrcmb/7.2.120
   Nagase H, 1997, BIOL CHEM, V378, P151
   Nick JA, 2000, J IMMUNOL, V164, P2151, DOI 10.4049/jimmunol.164.4.2151
   Oonakahara K, 2004, AM J RESP CELL MOL, V30, P671, DOI 10.1165/rcmb.2003-0340OC
   PFORTE A, 1993, EUR RESPIR J, V6, P951
   RAGHU G, 1985, AM REV RESPIR DIS, V131, P281
   Rollins BJ, 1997, BLOOD, V90, P909
   Sakamoto O, 2001, EUR RESPIR J, V17, P969, DOI 10.1183/09031936.01.17509690
   Shrivastava A, 1997, MOL CELL, V1, P25, DOI 10.1016/S1097-2765(00)80004-0
   STANDIFORD TJ, 1993, J IMMUNOL, V151, P2852
   Suga M, 2000, AM J RESP CRIT CARE, V162, P1949, DOI 10.1164/ajrccm.162.5.9906096
   Suga M, 1999, EUR RESPIR J, V14, P376, DOI 10.1034/j.1399-3003.1999.14b23.x
   Suri RM, 1998, J IMMUNOL METHODS, V214, P149, DOI 10.1016/S0022-1759(98)00048-9
   Taub DD, 1996, J IMMUNOL, V156, P2095
   Vogel W, 1997, MOL CELL, V1, P13, DOI 10.1016/S1097-2765(00)80003-9
   Vogel W, 1999, FASEB J, V13, pS77
   Yoshida K, 2002, J PATHOL, V198, P388, DOI 10.1002/path.1208
NR 54
TC 29
Z9 30
U1 3
U2 10
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
EI 1550-6606
J9 J IMMUNOL
JI J. Immunol.
PD MAY 15
PY 2005
VL 174
IS 10
BP 6490
EP 6498
DI 10.4049/jimmunol.174.10.6490
PG 9
WC Immunology
SC Immunology
GA 924DL
UT WOS:000228958900073
PM 15879152
OA Bronze
DA 2018-12-27
ER

PT J
AU Rangaswami, H
   Bulbule, A
   Kundu, GC
AF Rangaswami, H
   Bulbule, A
   Kundu, GC
TI RETRACTED: JNK1 differentially regulates osteopontin-induced nuclear
   factor-inducing kinase/MEKK1-dependent activating protein-1-mediated
   promatrix metalloproteinase-9 activation (Retracted Article. See vol
   282, pg 5968, 2007)
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article; Retracted Publication
ID BREAST-CANCER CELLS; B-MEDIATED SECRETION; KAPPA-B;
   PLASMINOGEN-ACTIVATOR; MATRIX-METALLOPROTEINASE; SIGNALING PATHWAYS;
   PROTEIN-KINASE; MELANOMA-CELLS; GELATINASE-B; UROKINASE
AB We have recently demonstrated that nuclear factor-inducing kinase (NIK) plays a crucial role in osteopontin (OPN)-induced mitogen-activated protein kinase/I kappa B alpha kinase-dependent nuclear factor kappa B (NF kappa B)-mediated promatrix metalloproteinase-9 activation (Rangaswami, H., Bulbule, A., and Kundu, G. C. ( 2004) J. Biol. Chem. 279, 38921-38935). However, the molecular mechanism(s) by which OPN regulates NIK/MEKK1-dependent activating protein-1 (AP-1)-mediated promatrix metalloproteinase-9 activation and whether JNK1 plays any role in regulating both these pathways that control the cell motility are not well defined. Here we report that OPN induces alpha v beta 3 integrin-mediated MEKK1 phosphorylation and MEKK1-dependent JNK1 phosphorylation and activation. Overexpression of NIK enhances OPN-induced c-Jun expression, whereas overexpressed NIK had no role in OPN-induced JNK1 phosphorylation and activation. Sustained activation of JNK1 by overexpression of wild type but not kinase negative MEKK1 resulted in suppression of ERK1/2 activation. But this did not affect the OPN-induced NIK-dependent ERK1/2 activation. OPN stimulated both NIK and MEKK1-dependent c-Jun expression, leading to AP-1 activation, whereas NIK-dependent AP-1 activation is independent of JNK1. OPN also enhanced JNK1-dependent/independent AP-1-mediated urokinase type plasminogen activator (uPA) secretion, uPA-dependent promatrix metalloproteinase-9 (MMP-9) activation, cell motility, and invasion. OPN stimulates tumor growth, and the levels of c-Jun, AP-1, urokinase type plasminogen activator, and MMP-9 were higher in OPN-induced tumor compared with control. To our knowledge this is first report that OPN induces NIK/MEKK1-mediated JNK1-dependent/independent AP-1-mediated pro-MMP-9 activation and regulates the negative crosstalk between NIK/ERK1/2 and MEKK1/JNK1 pathways that ultimately controls the cell motility, invasiveness, and tumor growth.
C1 Natl Ctr Cell Sci, Pune 411007, Maharashtra, India.
RP Kundu, GC (reprint author), Natl Ctr Cell Sci, NCCS Complex, Pune 411007, Maharashtra, India.
EM kundu@nccs.res.in
CR ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9
   Besser D, 1996, FIBRINOLYSIS, V10, P215, DOI 10.1016/S0268-9499(96)80018-X
   Blasi F, 1997, IMMUNOL TODAY, V18, P415, DOI 10.1016/S0167-5699(97)01121-3
   BROWN LF, 1994, AM J PATHOL, V145, P610
   BUTLER WT, 1989, CONNECT TISSUE RES, V23, P123, DOI 10.3109/03008208909002412
   COLLIER IE, 1988, J BIOL CHEM, V263, P6579
   CRAIG AM, 1990, INT J CANCER, V46, P133, DOI 10.1002/ijc.2910460124
   DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7
   Das R, 2004, J BIOL CHEM, V279, P11051, DOI 10.1074/jbc.M310256200
   Das R, 2003, J BIOL CHEM, V278, P28593, DOI 10.1074/jbc.M303445200
   DAVIES B, 1993, CANCER RES, V53, P5365
   DECESARE D, 1995, ONCOGENE, V11, P365
   DENHARDT DT, 1993, FASEB J, V7, P1475
   DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3
   Dubois B, 1999, J CLIN INVEST, V104, P1507, DOI 10.1172/JCI6886
   Folkman J, 1999, NAT BIOTECHNOL, V17, P749, DOI 10.1038/11676
   Gallo KA, 2002, NAT REV MOL CELL BIO, V3, P663, DOI 10.1038/nrm906
   Garrington TP, 1999, CURR OPIN CELL BIOL, V11, P211, DOI 10.1016/S0955-0674(99)80028-3
   Ghiso JAA, 1999, J CELL BIOL, V147, P89, DOI 10.1083/jcb.147.1.89
   HOUDE M, 1993, INT J CANCER, V53, P395, DOI 10.1002/ijc.2910530309
   Hrabec E, 2001, RESP MED, V95, P1, DOI 10.1053/rmed.2000.0923
   Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3
   Karin M, 1996, PHILOS T ROY SOC B, V351, P127, DOI 10.1098/rstb.1996.0008
   Kim J, 1998, CELL, V94, P353, DOI 10.1016/S0092-8674(00)81478-6
   LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802
   Liaw L, 1998, J CLIN INVEST, V101, P1468
   Mahabeleshwar GH, 2003, J BIOL CHEM, V278, P6209, DOI 10.1074/jbc.M208905200
   MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057
   Mukhina S, 2000, J BIOL CHEM, V275, P16450, DOI 10.1074/jbc.M909080199
   MURPHY G, 1994, ANN NY ACAD SCI, V732, P31, DOI 10.1111/j.1749-6632.1994.tb24722.x
   Natoli G, 1997, J BIOL CHEM, V272, P26079, DOI 10.1074/jbc.272.42.26079
   Panda D, 1997, P NATL ACAD SCI USA, V94, P9308, DOI 10.1073/pnas.94.17.9308
   Philip S, 2001, J BIOL CHEM, V276, P44926, DOI 10.1074/jbc.M103334200
   Philip S, 2003, J BIOL CHEM, V278, P14487, DOI 10.1074/jbc.M207309200
   PRINCE CW, 1989, CONNECT TISSUE RES, V21, P345, DOI 10.3109/03008208909049991
   Rangaswami H, 2004, J BIOL CHEM, V279, P38921, DOI 10.1074/jbc.M404674200
   Rittling SR, 1997, CELL GROWTH DIFFER, V8, P1061
   Sakamoto Y, 2000, INT J ONCOL, V17, P237
   Scorilas A, 2001, BRIT J CANCER, V84, P1488, DOI 10.1054/bjoc.2001.1810
   Sehgal G, 1998, AM J PATHOL, V152, P591
   SENGER DR, 1983, NATURE, V302, P714, DOI 10.1038/302714a0
   Shapiro SD, 1998, CURR OPIN CELL BIOL, V10, P602, DOI 10.1016/S0955-0674(98)80035-5
   She QB, 2002, CANCER RES, V62, P1343
   Shen KH, 2000, ANTICANCER RES, V20, P1307
   Shen YH, 2003, J BIOL CHEM, V278, P26715, DOI 10.1074/jbc.M303264200
   Tzivion G, 1998, NATURE, V394, P88
   Weber GF, 2001, BBA-REV CANCER, V1552, P61, DOI 10.1016/S0304-419X(01)00037-3
   Weber GF, 1996, SCIENCE, V271, P509, DOI 10.1126/science.271.5248.509
   YAN MH, 1994, NATURE, V372, P798
   Zeigler ME, 1999, J CELL PHYSIOL, V180, P271
NR 50
TC 45
Z9 46
U1 2
U2 10
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD MAY 13
PY 2005
VL 280
IS 19
BP 19381
EP 19392
DI 10.1074/jbc.M414204200
PG 12
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 923TN
UT WOS:000228932300096
PM 15757900
OA Bronze
DA 2018-12-27
ER

PT J
AU Chiu, YL
   Soros, VB
   Kreisberg, JF
   Stopak, K
   Yonemoto, W
   Greene, WC
AF Chiu, YL
   Soros, VB
   Kreisberg, JF
   Stopak, K
   Yonemoto, W
   Greene, WC
TI RETRACTED: Cellular APOBEC3G restricts HIV-1 infection in resting CD4(+)
   T cells (Retracted Article. See vol 466, pg 276, 2010)
SO NATURE
LA English
DT Article; Retracted Publication
ID VIRUS TYPE-1 INFECTION; RNA EDITING ENZYME; VIF PROTEIN; DNA;
   HYPERMUTATION; REPLICATION; ACTIVATION; DEGRADATION; LYMPHOCYTES; BLOCKS
AB In contrast to activated CD4(+) T cells, resting human CD4(+) T cells circulating in blood are highly resistant to infection with human immunodeficiency virus (HIV)(1-4). Whether the inability of HIV to infect these resting CD4(+) T cells is due to the lack of a key factor, or alternatively reflects the presence of an efficient mechanism for defence against HIV, is not clear. Here we show that the anti-retroviral deoxycytidine deaminase APOBEC3G(5) strongly protects unstimulated peripheral blood CD4(+) T cells against HIV-1 infection. In activated CD4(+) T cells, cytoplasmic APOBEC3G resides in an enzymatically inactive, high-molecular-mass (HMM) ribonucleoprotein complex that converts to an enzymatically active low-molecular-mass (LMM) form after treatment with RNase. In contrast, LMM APOBEC3G predominates in unstimulated CD4(+) T cells, where HIV-1 replication is blocked and reverse transcription is impaired(1-3). Mitogen activation induces the recruitment of LMM APOBEC3G into the HMM complex, and this correlates with a sharp increase in permissivity for HIV infection in these stimulated cells. Notably, when APOBEC3G-specific small interfering RNAs are introduced into unstimulated CD4(+) T cells, the early replication block encountered by HIV-1 is greatly relieved. Thus, LMM APOBEC3G functions as a potent post-entry restriction factor for HIV-1 in unstimulated CD4(+) T cells. Surprisingly, sequencing of the reverse transcripts slowly formed in unstimulated CD4(+) T cells reveals only low levels of dG --> dA hypermutation, raising the possibility that the APOBEC3G-restricting activity may not be strictly dependent on deoxycytidine deamination.
C1 Univ Calif San Francisco, Gladstone Inst Virol & Immunol, San Francisco, CA 94143 USA.
   Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA.
   Univ Calif San Francisco, Dept Microbiol, San Francisco, CA 94143 USA.
   Univ Calif San Francisco, Dept Immunol, San Francisco, CA 94143 USA.
RP Greene, WC (reprint author), Univ Calif San Francisco, Gladstone Inst Virol & Immunol, San Francisco, CA 94143 USA.
EM wgreene@gladstone.ucsf.edu
CR Anant S, 2001, CURR OPIN LIPIDOL, V12, P159, DOI 10.1097/00041433-200104000-00009
   Bishop KN, 2004, CURR BIOL, V14, P1392, DOI 10.1016/j.cub.2004.06.057
   Bransteitter R, 2003, P NATL ACAD SCI USA, V100, P4102, DOI 10.1073/pns.0730835100
   Camaur D, 1996, J VIROL, V70, P6106
   Eckstein DA, 2001, IMMUNITY, V15, P671, DOI 10.1016/S1074-7613(01)00217-5
   Ganesh L, 2003, NATURE, V426, P853, DOI 10.1038/nature02171
   Harris RS, 2003, CELL, V113, P803, DOI 10.1016/S0092-8674(03)00423-9
   Harris RS, 2002, MOL CELL, V10, P1247, DOI 10.1016/S1097-2765(02)00742-6
   Jarmuz A, 2002, GENOMICS, V79, P285, DOI 10.1006/geno.2002.6718
   Korin YD, 1998, J VIROL, V72, P3161
   Lecossier D, 2003, SCIENCE, V300, P1112, DOI 10.1126/science.1083338
   Liddament MT, 2004, CURR BIOL, V14, P1385, DOI 10.1016/j.cub.2004.06.050
   Mangeat B, 2003, NATURE, V424, P99, DOI 10.1038/nature01709
   Mariani R, 2003, CELL, V114, P21, DOI 10.1016/S0092-8674(03)00515-4
   Marin M, 2003, NAT MED, V9, P1398, DOI 10.1038/nm946
   Muramatsu M, 2000, CELL, V102, P553, DOI 10.1016/S0092-8674(00)00078-7
   Newman ENC, 2005, CURR BIOL, V15, P166, DOI 10.1016/j.cub.2004.12.068
   Pierson TC, 2002, J VIROL, V76, P8518, DOI 10.1128/JVI.76.17.8518-8531.2002
   Sheehy AM, 2003, NAT MED, V9, P1404, DOI 10.1038/nm945
   Sheehy AM, 2002, NATURE, V418, P646, DOI 10.1038/nature00969
   STEVENSON M, 1990, EMBO J, V9, P1551, DOI 10.1002/j.1460-2075.1990.tb08274.x
   Stopak K, 2003, MOL CELL, V12, P591, DOI 10.1016/S1097-2765(03)00353-8
   Stremlau M, 2004, NATURE, V427, P848, DOI 10.1038/nature02343
   Triques K, 2004, J VIROL, V78, P5523, DOI 10.1128/JVI.78.10.5523-5527.2004
   Turelli P, 2004, SCIENCE, V303, P1829, DOI 10.1126/science.1092066
   Wiegand HL, 2004, EMBO J, V23, P2451, DOI 10.1038/sj.emboj.7600246
   Yu XH, 2003, SCIENCE, V302, P1056, DOI 10.1126/science.1089591
   ZACK JA, 1990, CELL, V61, P213, DOI 10.1016/0092-8674(90)90802-L
   Zhang H, 2003, NATURE, V424, P94, DOI 10.1038/nature01707
   Zheng YH, 2004, J VIROL, V78, P6073, DOI 10.1128/JVI.78.11.6073-6076.2004
NR 30
TC 358
Z9 370
U1 4
U2 20
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0028-0836
J9 NATURE
JI Nature
PD MAY 5
PY 2005
VL 435
IS 7038
BP 108
EP 114
DI 10.1038/nature03493
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 922UL
UT WOS:000228864600048
PM 15829920
DA 2018-12-27
ER

PT J
AU Xiong, ZY
   Liu, LJ
AF Xiong, ZY
   Liu, LJ
TI RETRACTED: Bis(salicylaldehydo)zinc(II) (Retracted article. See vol. 66,
   pg e21, 2010)
SO ACTA CRYSTALLOGRAPHICA SECTION E-STRUCTURE REPORTS ONLINE
LA English
DT Article; Retracted Publication
AB The title compound, [Zn(C(7)H(5)O(2))(2)], is a mononuclear zinc(II) complex. The Zn II atom, lying on an inversion center, is coordinated by four O atoms from two salicylaldehyde ligands, forming a square planar geometry.
C1 Shaanxi Normal Univ, Coll Phys Educ, Xian 710062, Peoples R China.
RP Xiong, ZY (reprint author), Shaanxi Normal Univ, Coll Phys Educ, Xian 710062, Peoples R China.
EM xiongzhengying@163.com
CR ALLEN FH, 1987, J CHEM SOC PERK T 2, pS1, DOI 10.1039/p298700000s1
   *BRUK AXS INC, 1998, SMART VERS 5 628 SAI
   Sheldrick G.M, 1996, SADABS
   Sheldrick G. M, 1997, SHELXTL VERSION 5 1
   SHELDRICK GM, 1997, SHELXTL97 SHELXS97
NR 5
TC 9
Z9 9
U1 2
U2 13
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1600-5368
J9 ACTA CRYSTALLOGR E
JI Acta Crystallogr. Sect. E.-Struct Rep. Online
PD MAY
PY 2005
VL 61
BP M863
EP M864
DI 10.1107/S1600536805010913
PN 5
PG 2
WC Crystallography
SC Crystallography
GA 922JK
UT WOS:000228833300035
DA 2018-12-27
ER

PT J
AU Sahu, GR
   Mishra, R
   Nagpal, JK
   Das, BR
AF Sahu, GR
   Mishra, R
   Nagpal, JK
   Das, BR
TI RETRACTED: Alteration of p73 in acute myelogenous leukemia (Retracted
   Article. See vol 83, pg 691, 2008)
SO AMERICAN JOURNAL OF HEMATOLOGY
LA English
DT Article; Retracted Publication
DE p73; mutation; methylation; over-expression; AML
ID ACUTE MYELOID-LEUKEMIA; CPG ISLAND METHYLATION; TUMOR-SUPPRESSOR GENE;
   HUMAN CANCERS; CELL-LINES; DNA METHYLATION; P53 MUTATIONS; EXPRESSION;
   PROTEIN; HYPERMETHYLATION
AB The frequency of p73 mutation is low in hematologic malignancies as well as solid tumors. In the present study, we scanned for mutations in the exons 4, 5, 6, and 7 of p73, as well as methylation of the CpG island in the untranslated region of exon 1, in 100 de novo AML patients. Four patients showed mutation in exon 5 and one in exon 6, and none of the patients showed mutation in exons 4 and 7. None of the patients showed p73 gene methylation. The expression level of p73 mRNA was also examined in 40 AML samples using reverse transcriptase-polymerase chain reaction. Only six AML patients showed p73 mRNA expression, as analyzed by RT-PCR analysis. However, p73 over-expression in 30% of patients was demonstrated by immunocytochemistry and Western blot analysis. Further, mutation of p73 has been correlated with p73 mRNA and p73 protein status. The results show the presence of over-expressed p73 mRNA and protein in the samples with mutated p73 gene. Thus, it is presumed that mutation of p73 might lead to production of defective p73 protein and p73 mRNA, and this might have a role in the process of leukemo-genesis of AML. This report is the first demonstrating the presence of mutations in p73 gene in acute myelogenous leukemia. Am. J. Hematol. 79:1-7, 2005. (c) 2005 Wiley-Liss, lnc.
C1 SRL Ranbaxy Ltd, Clin Reference Labs, Bombay, Maharashtra, India.
   Inst Life Sci, Mol Oncol & Med Biotechnol Div, Bhubaneswar, Orissa, India.
RP Das, BR (reprint author), SRL Ranbaxy Ltd, Clin Reference Labs, 113,MIDC 15th St, Bombay, Maharashtra, India.
EM brdas@srlranbaxy.com
OI Mishra, Rajakishore/0000-0002-1735-2411
CR ARTHUR DC, 1983, BLOOD, V61, P994
   Bachman KE, 1999, CANCER RES, V59, P798
   BARTOLOMEI MS, 1993, GENE DEV, V7, P1663, DOI 10.1101/gad.7.9.1663
   Baylin SB, 1998, ADV CANCER RES, V72, P141
   BLIN N, 1976, NUCLEIC ACIDS RES, V3, P2303, DOI 10.1093/nar/3.9.2303
   BUESORAMOS CE, 1993, BLOOD, V82, P2617
   CHENG J, 1990, MOL CELL BIOL, V10, P5502, DOI 10.1128/MCB.10.10.5502
   COGHLAN DW, 1994, LEUKEMIA, V8, P1682
   Corn PG, 1999, CANCER RES, V59, P3352
   DAMICO D, 1992, ONCOGENE, V7, P339
   Di Como CJ, 1999, MOL CELL BIOL, V19, P1438
   DRACOPOLI NC, 1989, P NATL ACAD SCI USA, V86, P4614, DOI 10.1073/pnas.86.12.4614
   Esteller M, 1999, CANCER RES, V59, P793
   HAFFNER R, 1995, CURR OPIN GENET DEV, V5, P84, DOI 10.1016/S0959-437X(95)90058-6
   Hayashi K, 1991, PCR Methods Appl, V1, P34
   HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840
   Jost CA, 1997, NATURE, V389, P191
   Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1
   Kass SU, 1997, TRENDS GENET, V13, P444, DOI 10.1016/S0168-9525(97)01268-7
   Kawano S, 1999, BLOOD, V94, P1113
   Koduru PRK, 1997, BLOOD, V90, P4078
   KOEFFLER HP, 1986, P NATL ACAD SCI USA, V83, P4035, DOI 10.1073/pnas.83.11.4035
   Kovalev S, 1998, CELL GROWTH DIFFER, V9, P897
   LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0
   Litz CE, 1996, BLOOD, V88, P2241
   Mai M, 1998, GENOMICS, V51, P359, DOI 10.1006/geno.1998.5387
   MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716
   MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686
   MOWAT M, 1985, NATURE, V314, P633, DOI 10.1038/314633a0
   NAGAI H, 1995, CANCER RES, V55, P1752
   NEUBAUER A, 1994, BLOOD, V83, P1603
   Nomoto S, 1998, CANCER RES, V58, P1380
   Oren M, 1997, CELL, V90, P829, DOI 10.1016/S0092-8674(00)80347-5
   Peters UR, 1999, CANCER RES, V59, P4233
   RADICH JP, 1990, BLOOD, V76, P801
   Randhawa GS, 1998, BLOOD, V91, P3144
   RELK W, 1997, NATURE, V389, P669
   ROSS RA, 1995, CELL GROWTH DIFFER, V6, P449
   ROWLEY JD, 1990, SEMIN HEMATOL, V27, P122
   SAKAI E, 1992, ONCOGENE, V7, P927
   Schwab M, 1996, GENE CHROMOSOME CANC, V16, P211, DOI 10.1002/(SICI)1098-2264(199608)16:4<211::AID-GCC1>3.0.CO;2-0
   Stirewalt DL, 1999, LEUKEMIA, V13, P985, DOI 10.1038/sj.leu.2401418
   Sunahara M, 1998, INT J ONCOL, V13, P319
   Takahashi H, 1998, CANCER RES, V58, P2076
   Van Zee KJ, 1998, ONCOGENE, V16, P2723
   WATTEL E, 1994, BLOOD, V84, P3148
   Whang YE, 1998, P NATL ACAD SCI USA, V95, P5246, DOI 10.1073/pnas.95.9.5246
   WOLF D, 1984, MOL CELL BIOL, V4, P1402, DOI 10.1128/MCB.4.7.1402
   Wong IHN, 1998, BRIT J HAEMATOL, V103, P168
   Wu HK, 1997, BIOCHEM BIOPH RES CO, V231, P466, DOI 10.1006/bbrc.1997.6127
   Wutz A, 1997, NATURE, V389, P745, DOI 10.1038/39631
   ZHANG W, 1992, ONCOGENE, V7, P1645
   ZHANG W, 1994, LEUKEMIA LYMPHOMA, V14, P251, DOI 10.3109/10428199409049675
   ZION M, 1994, P NATL ACAD SCI USA, V91, P10722, DOI 10.1073/pnas.91.22.10722
NR 54
TC 6
Z9 7
U1 3
U2 9
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0361-8609
EI 1096-8652
J9 AM J HEMATOL
JI Am. J. Hematol.
PD MAY
PY 2005
VL 79
IS 1
BP 1
EP 7
DI 10.1002/ajh.20284
PG 7
WC Hematology
SC Hematology
GA 922MW
UT WOS:000228843000001
PM 15849769
OA Bronze
DA 2018-12-27
ER

PT J
AU Rohm, KD
   Riechmann, J
   Boldt, J
   Schuler, S
   Suttner, SW
   Piper, SN
AF Rohm, KD
   Riechmann, J
   Boldt, J
   Schuler, S
   Suttner, SW
   Piper, SN
TI RETRACTED: Physostigmine for the prevention of postanaesthetic shivering
   following general anaesthesia - a placebo-controlled comparison with
   nefopam (Retracted article. See vol. 66, pg. 646, 2011)
SO ANAESTHESIA
LA English
DT Article; Retracted Publication
ID NONLINEAR DECREASES; CLONIDINE; VASOCONSTRICTION; THRESHOLDS;
   TEMPERATURE; HYPOTHERMIA; MEPERIDINE; INDUCTION; RECOVERY; HUMANS
AB Physostigmine was studied for its efficacy in the prevention of postanaesthetic shivering compared to nefopam and placebo. We studied 89 patients undergoing abdominal and urological surgery. The study was randomised and double-blind, the patients received physostigmine 2 mg (n = 31), nefopam 10 mg (n = 30) or saline (n = 28). Haemodynamic parameters and temperature were measured at induction of anaesthesia (T0), and 5 min (T1), 15 min (T2), 30 min (T3) and 60 min (T4) after reaching the postanaesthetic care unit (PACU). Significantly less shivering occurred following administration of physostigmine and nefopam (9.7 and 3.3%) compared to placebo (53.6%). The degree of shivering was also significantly reduced following physostigmine and nefopam (p < 0.01). Extubation time, haemodynamic parameters and tympanic temperature were found to be similar in all groups. Aldrete score, duration of PACU stay and postoperative analgesic requirements did not differ between the groups. Only nefopam significantly (p < 0.01) reduced postoperative nausea and vomiting. Physostigmine is a safe alternative to nefopam, significantly reducing the incidence and severity of postanaesthetic shivering without affecting postanaesthetic recovery.
C1 Klinikum Stadt Ludwigshafen, Dept Anaesthesiol & Intens Care Med, D-6700 Ludwigshafen, Germany.
RP Rohm, KD (reprint author), Klinikum Stadt Ludwigshafen, Dept Anaesthesiol & Intens Care Med, D-6700 Ludwigshafen, Germany.
EM k.d.roehm@web.de
CR ALDRETE JA, 1970, ANESTH ANAL CURR RES, V49, P924
   Alfonsi P, 2001, DRUGS, V61, P2193, DOI 10.2165/00003495-200161150-00004
   Alfonsi P, 2002, ANESTHESIOLOGY, V96, pA257
   ANNADATA R, 1995, ANESTHESIOLOGY, V83, P1205, DOI 10.1097/00000542-199512000-00011
   Aschoff JC, 1996, NERVENARZT, V67, P311
   Buggy D, 1997, CAN J ANAESTH, V44, P263, DOI 10.1007/BF03015363
   BUGGY D, 1994, BRIT J ANAESTH, V72, P393, DOI 10.1093/bja/72.4.393
   CHEONG KF, 1995, ANAESTHESIA, V83, P1205
   CIOFOLO MJ, 1989, ANESTHESIOLOGY, V70, P737
   CROSSLEY AWA, 1995, BRIT MED J, V311, P764, DOI 10.1136/bmj.311.7008.764
   CROSSLEY AWA, 1992, ANAESTHESIA, V47, P193, DOI 10.1111/j.1365-2044.1992.tb02114.x
   De Witte J, 2002, ANESTHESIOLOGY, V96, P467, DOI 10.1097/00000542-200202000-00036
   DELAUNAY L, 1993, ANESTHESIOLOGY, V79, P470, DOI 10.1097/00000542-199309000-00009
   GORDON CJ, 1986, ANNU REV PHYSIOL, V48, P595, DOI 10.1146/annurev.ph.48.030186.003115
   Horn EP, 1998, ANESTHESIOLOGY, V88, P108, DOI 10.1097/00000542-199801000-00018
   Horn EP, 1999, ANESTHESIOLOGY, V91, P979, DOI 10.1097/00000542-199910000-00017
   Ikeda T, 1998, ANESTHESIOLOGY, V88, P866, DOI 10.1097/00000542-199804000-00004
   Kranke P, 2002, ANESTH ANALG, V94, P453, DOI 10.1097/00000539-200202000-00043
   KURZ A, 1995, J CLIN ANESTH, V7, P359, DOI 10.1016/0952-8180(95)00028-G
   Latasch L, 2003, ANASTH INTENSIV NOTF, V38, P528
   LIENHART A, 1992, ANN FR ANESTH, V11, P488, DOI 10.1016/S0750-7658(05)80753-1
   Lyons B, 1996, ANAESTHESIA, V51, P442, DOI 10.1111/j.1365-2044.1996.tb07788.x
   Meuret P, 2000, ANESTHESIOLOGY, V93, P708, DOI 10.1097/00000542-200009000-00020
   MILAM SB, 1987, INT J ORAL MAX SURG, V16, P190, DOI 10.1016/S0901-5027(87)80129-7
   Pappata S, 1996, J NEUROCHEM, V67, P876
   Piper SN, 2004, ANAESTHESIA, V59, P559, DOI 10.1111/j.1365-2044.2004.03734.x
   Piper SN, 1999, ANAESTHESIA, V54, P695, DOI 10.1046/j.1365-2044.1999.00849.x
   Piper SN, 2000, ANESTH ANALG, V90, P954, DOI 10.1213/00000539-200004000-00033
   Piper SN, 2002, ANESTH ANALG, V94, P106, DOI 10.1097/00000539-200201000-00020
   Powell RM, 2000, ANESTH ANALG, V90, P1423, DOI 10.1097/00000539-200006000-00032
   RISCH SC, 1986, PSYCHONEUROENDOCRINO, V11, P221, DOI 10.1016/0306-4530(86)90057-0
   Rupreht J, 1989, Anaesthesiol Reanim, V14, P235
   SESSLER DI, 1991, ANESTHESIOLOGY, V75, P594, DOI 10.1097/00000542-199110000-00009
   SESSLER DI, 1988, ANESTHESIOLOGY, V68, P843, DOI 10.1097/00000542-198806000-00003
   Wrench IJ, 1997, BRIT J ANAESTH, V79, P541, DOI 10.1093/bja/79.4.541
   Xiong JY, 1996, ANESTHESIOLOGY, V85, P240, DOI 10.1097/00000542-199608000-00003
NR 36
TC 13
Z9 15
U1 3
U2 12
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0003-2409
EI 1365-2044
J9 ANAESTHESIA
JI Anaesthesia
PD MAY
PY 2005
VL 60
IS 5
BP 433
EP 438
DI 10.1111/j.1365-2044.2005.04157.x
PG 6
WC Anesthesiology
SC Anesthesiology
GA 915IG
UT WOS:000228291300003
PM 15819761
OA Bronze
DA 2018-12-27
ER

PT J
AU Ismail, GAF
AF Ismail, GAF
TI RETRACTED: Numerical treatment of nonlinear mixed delay differential
   equations (Retracted article. See vol. 34, pg. 842, 2010)
SO APPLIED MATHEMATICAL MODELLING
LA English
DT Article; Retracted Publication
DE myelinated axons; membrane; nonlinear delay differential equations;
   convergence; stability; pure saltatory conduction
ID RUNGE-KUTTA METHODS; STABILITY
AB The mathematical modeling of many problems in biology (the model for myelinated axons) has been formulated as nonlinear delay differential equations. Some basic properties of the myelinated axons are discussed. The numerical scheme for solving this model is described. The convergence and stability of numerical treatments that are discussed analytically are tested. The dependence of both the solution and the internodal delay tau on the various physical parameters are investigated and its numerical results are presented and interpreted. (c) 2004 Elsevier Inc. All rights reserved.
C1 Ain Shams Univ, Univ Coll Women, Cairo, Egypt.
RP Ismail, GAF (reprint author), Ain Shams Univ, Univ Coll Women, 82 A Abdel Aziz Fahmy St, Cairo, Egypt.
EM gam_ismail@yahoo.com
CR Allgower E. L., 1990, SPRINGER SERIES COMP, V13
   ALLGOWER EL, 1981, NUMERICAL SOLUTION N
   Bell J, 1984, IMA J Math Appl Med Biol, V1, P149
   BELL J, 1981, MATH BIOSCI, V54, P181, DOI 10.1016/0025-5564(81)90085-7
   Bellen A, 2000, NUMER MATH, V84, P351, DOI 10.1007/s002119900106
   Bocharov GA, 2000, J COMPUT APPL MATH, V125, P183, DOI 10.1016/S0377-0427(00)00468-4
   DEUFLHARD P, 1979, NUMER MATH, V33, P115, DOI 10.1007/BF01399549
   Guglielmi N, 1999, NUMER MATH, V83, P371, DOI 10.1007/s002119900072
   Guglielmi N, 1997, NUMER MATH, V77, P467, DOI 10.1007/s002110050296
   HASTINGS SP, 1975, AM MATH MON, V82, P881, DOI 10.2307/2318490
   HONGJIONG T, 1996, SIAM J NUMER ANAL, V33, P883
   Jack J.J.B., 1975, ELECT CURRENT FLOW E
   LANDAHL H. D., 1949, BULL MATH BIOPHYS, V11, P19, DOI 10.1007/BF02477911
   MCNEAL DR, 1976, IEEE T BIO-MED ENG, V23, P329, DOI 10.1109/TBME.1976.324593
   MICHAEL CM, 1975, ION TRANSPORT BIOL M
   MORREL P, 1980, MYELIN SCI AM, V242, P88
   PAINTAL AS, 1972, J PHYSL, V184, P350
   STRAND FL, 1978, PHYSL REGULATORY SYS
   WACKER H, 1978, CONTINUATION METHOD
   WASSERSTROM E, 1973, SIAM REV, V15, P89, DOI 10.1137/1015003
   Zennaro M, 1997, NUMER MATH, V77, P549, DOI 10.1007/s002110050300
NR 21
TC 1
Z9 1
U1 3
U2 9
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0307-904X
EI 1872-8480
J9 APPL MATH MODEL
JI Appl. Math. Model.
PD MAY
PY 2005
VL 29
IS 5
BP 439
EP 460
DI 10.1016/j.apm.2004.09.014
PG 22
WC Engineering, Multidisciplinary; Mathematics, Interdisciplinary
   Applications; Mechanics
SC Engineering; Mathematics; Mechanics
GA 908UO
UT WOS:000227815900002
OA Bronze
DA 2018-12-27
ER

PT J
AU Jana, S
   Deb, JK
AF Jana, S
   Deb, JK
TI RETRACTED: Strategies for efficient production of heterologous proteins
   in Escherichia coli (Retracted article. See vol. 98, pg. 5787, 2014)
SO APPLIED MICROBIOLOGY AND BIOTECHNOLOGY
LA English
DT Review; Retracted Publication
ID HIGH-LEVEL EXPRESSION; MESSENGER-RNA DEGRADATION; TRANSLATION
   INITIATION; LACTOCOCCUS-LACTIS; FUSION PROTEIN; VITREOSCILLA HEMOGLOBIN;
   RECOMBINANT PROTEINS; SECONDARY STRUCTURE; ACETATE PRODUCTION;
   PICHIA-PASTORIS
AB In recent years, the number of recombinant proteins used for therapeutic applications has increased dramatically. Production of these proteins has a remarkable demand in the market. Escherichia coli offers a means for the rapid and economical production of recombinant proteins. These advantages, coupled with a wealth of biochemical and genetic knowledge, have enabled the production of such economically therapeutic proteins such as insulin and bovine growth hormone. These demands have driven the development of a variety of strategies for achieving high-level expression of protein, particularly involving several aspects such as expression vectors design, gene dosage, promoter strength (transcriptional regulation), mRNA stability, translation initiation and termination (translational regulation), host design considerations, codon usage, and fermentation factors available for manipulating the expression conditions, which are the major challenges is obtaining the high yield of protein at low cost.
C1 Indian Inst Technol, Dept Biochem Engn & Biotechnol, New Delhi 110016, India.
RP Deb, JK (reprint author), Indian Inst Technol, Dept Biochem Engn & Biotechnol, Hauz Khas, New Delhi 110016, India.
EM jkdeb@dbeb.iitd.ernet.in
CR ALLEN LH, 2002, J MICROBIOL METH, V49, P163
   ARISTIDOU AA, 1995, BIOTECHNOL PROGR, V11, P475, DOI 10.1021/bp00034a019
   ARISTIDOU AA, 1993, BIOTECHNOL LETT, V15, P331, DOI 10.1007/BF00128271
   Arsene F, 2000, INT J FOOD MICROBIOL, V55, P3, DOI 10.1016/S0168-1605(00)00206-3
   Baneyx F, 1999, CURR OPIN BIOTECH, V10, P411, DOI 10.1016/S0958-1669(99)00003-8
   BENTLEY WE, 1990, BIOTECHNOL BIOENG, V35, P668, DOI 10.1002/bit.260350704
   BILLMANJACOBE H, 1994, APPL ENVIRON MICROB, V60, P1641
   Bird PI, 2004, METHODS, V32, P169, DOI 10.1016/S1046-2023(03)00208-1
   BOWERS LM, 2004, IN PRESS GENE
   BRURBERG MB, 1994, APPL MICROBIOL BIOT, V42, P108, DOI 10.1007/BF00170232
   Chadd HE, 2001, CURR OPIN BIOTECH, V12, P188, DOI 10.1016/S0958-1669(00)00198-1
   CHEN GFT, 1994, GENE DEV, V8, P2641, DOI 10.1101/gad.8.21.2641
   CHEN HC, 1992, ENZYME MICROB TECH, V14, P321, DOI 10.1016/0141-0229(92)90159-L
   CHOU CH, 1994, BIOTECHNOL BIOENG, V44, P952, DOI 10.1002/bit.260440811
   CHOU CH, 1995, BIOTECHNOL BIOENG, V47, P186, DOI 10.1002/bit.260470210
   Chu L, 2001, CURR OPIN BIOTECH, V12, P180, DOI 10.1016/S0958-1669(00)00197-X
   Corisdeo S, 2004, PROTEIN EXPRES PURIF, V34, P270, DOI 10.1016/j.pep.2003.11.020
   Cruz-Vera LR, 2004, NUCLEIC ACIDS RES, V32, P4462, DOI 10.1093/nar/gkh784
   da Costa PN, 2003, FEMS MICROBIOL LETT, V218, P385, DOI 10.1016/S0378-1097(02)01186-2
   DAS A, 1990, METHOD ENZYMOL, V182, P93
   Doran PM, 2000, CURR OPIN BIOTECH, V11, P199, DOI 10.1016/S0958-1669(00)00086-0
   Duilio Angela, 2004, Methods Mol Biol, V267, P225
   Etchegaray JP, 1999, J BIOL CHEM, V274, P10079, DOI 10.1074/jbc.274.15.10079
   Farmer WR, 1997, APPL ENVIRON MICROB, V63, P3205
   Flores N, 1996, NAT BIOTECHNOL, V14, P620, DOI 10.1038/nbt0596-620
   Frey AD, 2000, APPL ENVIRON MICROB, V66, P98, DOI 10.1128/AEM.66.1.98-104.2000
   Gao WT, 2004, BIOTECHNOL PROGR, V20, P443, DOI 10.1021/bp0300467
   Goldstein M A, 1995, Biotechnol Annu Rev, V1, P105, DOI 10.1016/S1387-2656(08)70049-8
   Goodrick JC, 2001, BIOTECHNOL BIOENG, V74, P492, DOI 10.1002/bit.1140
   Gschaedler A, 1999, BIOTECHNOL BIOENG, V63, P712, DOI 10.1002/(SICI)1097-0290(19990620)63:6<712::AID-BIT9>3.0.CO;2-R
   Gupta P, 2001, BIOCHEM BIOPH RES CO, V285, P1025, DOI 10.1006/bbrc.2001.5282
   GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995
   Hagg P, 2004, J BIOTECHNOL, V111, P17, DOI 10.1016/j.jbiotec.2004.03.010
   HALL MN, 1982, NATURE, V295, P616, DOI 10.1038/295616a0
   HASAN N, 1995, GENE, V163, P35, DOI 10.1016/0378-1119(95)00409-Y
   Hewitt Lorraine, 2004, Methods Mol Biol, V278, P1
   Hienonen E, 2004, FEBS LETT, V571, P217, DOI 10.1016/j.febslet.2004.04.072
   IOST I, 1994, NATURE, V372, P193, DOI 10.1038/372193a0
   JANA S, 2004, IN PRESS PROTEIN EXP
   Jiang XP, 2001, J BIOSCI BIOENG, V91, P53
   JOLLIFFE LK, 1980, J BACTERIOL, V141, P1199
   Jones KL, 1998, BIOTECHNOL BIOENG, V59, P659, DOI 10.1002/(SICI)1097-0290(19980920)59:6<659::AID-BIT1>3.3.CO;2-1
   Jones KL, 2000, METAB ENG, V2, P328, DOI 10.1006/mben.2000.0161
   KANE JF, 1995, CURR OPIN BIOTECH, V6, P494, DOI 10.1016/0958-1669(95)80082-4
   Kim DM, 2001, BIOTECHNOL BIOENG, V74, P309, DOI 10.1002/bit.1121.abs
   Larrick JW, 2001, CURR OPIN BIOTECH, V12, P411, DOI 10.1016/S0958-1669(00)00236-6
   Leenhouts KJ, 1995, APPL MICROBIOL BIOT, V44, P75, DOI 10.1007/s002530050522
   Liang ST, 1999, J MOL BIOL, V292, P19, DOI 10.1006/jmbi.1999.3056
   Lim J, 2000, J MOL BIOL, V297, P553, DOI 10.1006/jmbi.2000.3585
   LINDSLEY D, 1993, P NATL ACAD SCI USA, V90, P5469, DOI 10.1073/pnas.90.12.5469
   Lopez PJ, 1999, MOL MICROBIOL, V33, P188, DOI 10.1046/j.1365-2958.1999.01465.x
   Love CA, 1996, GENE, V176, P49, DOI 10.1016/0378-1119(96)00208-9
   LULI GW, 1990, APPL ENVIRON MICROB, V56, P1004
   Ma J, 2002, J BACTERIOL, V184, P5733, DOI 10.1128/JB.184.20.5733-5745.2002
   Masse E, 2003, GENE DEV, V17, P2374, DOI 10.1101/gad.1127103
   Moll I, 2003, RNA, V9, P1308, DOI 10.1261/rna.5850703
   Morita M, 2001, BIOTECHNOL PROGR, V17, P573, DOI 10.1021/bp010018t
   Nakashima N, 2004, BIOTECHNOL BIOENG, V86, P136, DOI 10.1002/bit.20024
   Nierlich DP, 1996, PROG NUCLEIC ACID RE, V52, P153, DOI 10.1016/S0079-6603(08)60967-8
   Nilsson M, 1999, BIOTECHNOL PROGR, V15, P158, DOI 10.1021/bp9900155
   Nogueira T, 2001, J MOL BIOL, V310, P709, DOI 10.1006/jmbi.2001.4796
   Peixoto L, 2004, PARASITOLOGY, V128, P245, DOI 10.1017/S0031182003004517
   Piao YZ, 2004, J BIOSCI BIOENG, V97, P310, DOI 10.1263/jbb.97.310
   Qing GL, 2003, J MOL MICROB BIOTECH, V6, P133, DOI 10.1159/000077244
   Qiu J, 1998, APPL ENVIRON MICROB, V64, P4891
   Rao XC, 2004, PROTEIN EXPRES PURIF, V36, P11, DOI 10.1016/j.pep.2004.01.020
   RICHARDSON JP, 1993, CRIT REV BIOCHEM MOL, V28, P1, DOI 10.3109/10409239309082571
   RINGQUIST S, 1992, MOL MICROBIOL, V6, P1219, DOI 10.1111/j.1365-2958.1992.tb01561.x
   ROSS J, 1995, MICROBIOL REV, V59, P423
   SAIER MH, 1995, FEBS LETT, V362, P1, DOI 10.1016/0014-5793(95)00185-C
   Schmidt T, 1996, J BIOTECHNOL, V49, P219, DOI 10.1016/0168-1656(96)01519-2
   Sharp JM, 2001, BIOTECHNOL BIOENG, V73, P338, DOI 10.1002/bit.1067
   SHATZMAN AR, 1995, CURR OPIN BIOTECH, V6, P491, DOI 10.1016/0958-1669(95)80081-6
   Siegele DA, 1997, P NATL ACAD SCI USA, V94, P8168, DOI 10.1073/pnas.94.15.8168
   Simmons LC, 1996, NAT BIOTECHNOL, V14, P629, DOI 10.1038/nbt0596-629
   SIMONEN M, 1993, MICROBIOL REV, V57, P109
   SIPLEY J, 1993, P NATL ACAD SCI USA, V90, P2315, DOI 10.1073/pnas.90.6.2315
   Sprengart ML, 1997, MOL MICROBIOL, V24, P19, DOI 10.1046/j.1365-2958.1997.3161684.x
   Srivastava P, 2002, FEMS MICROBIOL LETT, V212, P209, DOI 10.1016/S0378-1097(02)00740-1
   STEIDLER L, 1995, APPL ENVIRON MICROB, V61, P1627
   Storz G, 2004, CURR OPIN MICROBIOL, V7, P140, DOI 10.1016/j.mib.2004.02.015
   Swartz JR, 2001, CURR OPIN BIOTECH, V12, P195, DOI 10.1016/S0958-1669(00)00199-3
   Toivonen JM, 2003, MITOCHONDRION, V3, P83, DOI 10.1016/S1567-7249(03)00077-1
   Toksoy E, 2002, APPL MICROBIOL BIOT, V59, P239, DOI 10.1007/s00253-002-1001-0
   Valesova R, 2004, ENZYME MICROB TECH, V35, P74, DOI 10.1016/j.enzmictec.2004.03.015
   Wang Y, 2001, BIOTECHNOL BIOENG, V73, P74, DOI 10.1002/1097-0290(20010405)73:1<74::AID-BIT1038>3.0.CO;2-V
   WELLS JM, 1993, MOL MICROBIOL, V8, P1155, DOI 10.1111/j.1365-2958.1993.tb01660.x
   Wild Jadwiga, 2004, Methods Mol Biol, V267, P155
   Wilms B, 2001, BIOTECHNOL BIOENG, V73, P95, DOI 10.1002/bit.1041
   Wu XQ, 2004, BIOCHEM BIOPH RES CO, V313, P89, DOI 10.1016/j.bbrc.2003.11.091
   YABUTA M, 1995, J BIOTECHNOL, V39, P67, DOI 10.1016/0168-1656(94)00144-2
   YEE L, 1992, BIO-TECHNOL, V10, P1550, DOI 10.1038/nbt1292-1550
   ZHANG SP, 1991, GENE, V105, P61, DOI 10.1016/0378-1119(91)90514-C
NR 93
TC 234
Z9 261
U1 6
U2 68
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0175-7598
EI 1432-0614
J9 APPL MICROBIOL BIOT
JI Appl. Microbiol. Biotechnol.
PD MAY
PY 2005
VL 67
IS 3
BP 289
EP 298
DI 10.1007/s00253-004-1814-0
PG 10
WC Biotechnology & Applied Microbiology
SC Biotechnology & Applied Microbiology
GA 920XH
UT WOS:000228728300001
PM 15635462
DA 2018-12-27
ER

PT J
AU Hew, TD
AF Hew, TD
TI RETRACTED: Women hydrate more than men during a marathon race -
   Hyponatremia in the Houston marathon: A report on 60 cases (Retracted
   Article. See vol 15, 286, 2005)
SO CLINICAL JOURNAL OF SPORT MEDICINE
LA English
DT Article; Retracted Publication
DE hyponatremia; marathon runner; hydration; electrolyte imbalance
ID WATER-INTOXICATION; ENDURANCE EXERCISE; RUNNERS; TRAINEE; DEATH; HEAT
AB Objective: To examine the relationship between gender and the development of hyponatremia in marathon runners.
   Design: A retrospective analysis of prerace and postrace data collected on 117 runners completing the Houston Marathon from 2000 to 2003.
   Setting: The Houston Marathon.
   Participants: A total of 117 marathon runners (63 male and 54 female) who consented to participate in hyponatremia research.
   Main Outcome Measures: Prerace and postrace body weight and serum sodium ([Na+]) concentrations were measured. Total fluid intake was self-reported immediately following the race.
   Results: Of the runners tested, 28% developed hyponatremia ([Na+] <= 135 mmol/L). Hyponatremic runners (n = 33) drank significantly more fluid (31.70 versus 18.90 cups; P < 0.001), lost the least weight (-0.14 versus -1.61 kg; P < 0.001), and dropped serum [Na+] levels further (-7.48 versus - 1.92; P < 0.001) compared with nonhyponatremic runners. Female runners (n = 54) were significantly lighter (62.46 versus 80.73 kg; P < 0.001), ran slower (303.02 versus 269.06 minutes; P < 0.001), lost the least weight (-0.62 versus -1.68 kg; P < 0.001), dropped serum [Na+] levels further (-4.44 versus -2.67; P < 0.01), and had lower postrace serum [Na+] values (136.87 versus 138.50; P < 0.01)compared with male runners while consuming the same total amount of fluid during the race (22.87 versus 22.30 cups,- P = 0.83, NS). There were significant inverse relationships between serum [Na+] change versus body weight change (r = -0.65; P < 0.001) and between postrace [Na+] versus body weight change (r = -0.60; P < 0.001), with significant sex differences noted only between nonhyponatremic female and male runners (-0.91 versus -0.2.05 kg; P < 0.001) and between hyponatremic and nonhyponatremic male runners (-0.11 versus -2.05 kg; P < 0.001).
   Conclusions: Female marathon runners drink more fluid than male runners in proportion to body size. A loss of 3 kg body weight corresponds to a 0 change in serum [Na+] from prerace to postrace, suggesting that a loss of 3 kg during a marathon represents euhydration and not dehydration. All cases of hyponatremia reported in this study are a result of overhydration based on this convention.
C1 UCT, MRC, Res Unit Exercise Sci & Sports Med, Sports Sci Inst S Africa,Dept Human Biol, ZA-7725 Newlands, South Africa.
RP Hew, TD (reprint author), UCT, MRC, Res Unit Exercise Sci & Sports Med, Sports Sci Inst S Africa,Dept Human Biol, POB 115, ZA-7725 Newlands, South Africa.
EM thew@sports.uct.ac.za
CR Abbott K. D., 2003, Medicine & Science in Sports & Exercise, V35, pS246, DOI 10.1097/00005768-200305001-01375
   ALMOND CS, 2003, ACAD EMERG MED, V10, P534
   ARMSTRONG LE, 1993, MED SCI SPORT EXER, V25, P543
   Ayus JC, 2000, ANN INTERN MED, V132, P711, DOI 10.7326/0003-4819-132-9-200005020-00005
   Backer HD, 1999, AM J EMERG MED, V17, P532, DOI 10.1016/S0735-6757(99)90191-2
   Davis C, 2000, Eat Behav, V1, P33, DOI 10.1016/S1471-0153(00)00007-6
   Davis DP, 2001, J EMERG MED, V21, P47, DOI 10.1016/S0736-4679(01)00320-1
   EICHNER ER, 2004, SPORTS MED DIG, V24, P54
   FLINN SD, 2004, PHYSICIAN SPORTSMED, V28, P61
   FORSLING ML, 1981, J ENDOCRINOL, V89, P263, DOI 10.1677/joe.0.0890263
   FRIZZELL RT, 1986, JAMA-J AM MED ASSOC, V255, P772, DOI 10.1001/jama.255.6.772
   Gardner JW, 2002, MIL MED, V167, P432
   Gardner JW, 2002, MIL MED, V167, P435
   Garigan TP, 1999, MIL MED, V164, P234
   Glace B. W., 2003, Medicine & Science in Sports & Exercise, V35, pS261, DOI 10.1097/00005768-200305001-01445
   Hew TD, 2003, CLIN J SPORT MED, V13, P192, DOI 10.1097/00042752-200305000-00015
   Hew TD, 2003, CLIN J SPORT MED, V13, P41, DOI 10.1097/00042752-200301000-00008
   Kavouras S. A., 2003, Medicine & Science in Sports & Exercise, V35, pS246, DOI 10.1097/00005768-200305001-01374
   Noakes TD, 2003, BRIT MED J, V327, P113, DOI 10.1136/bmj.327.7407.113
   Noakes TD, 2001, SAMJ S AFR MED J, V91, P843
   NOAKES TD, 1985, MED SCI SPORT EXER, V17, P370
   Noakes Tim, 2002, Curr Sports Med Rep, V1, P197, DOI 10.1007/s11932-002-0022-x
   O'Brien KK, 2001, MIL MED, V166, P405
   Pastene J, 1996, EUR J APPL PHYSIOL, V73, P49, DOI 10.1007/BF00262808
   Rogers G, 1997, MED SCI SPORT EXER, V29, P1477, DOI 10.1097/00005768-199711000-00014
   Speedy DB, 1999, MED SCI SPORT EXER, V31, P809, DOI 10.1097/00005768-199906000-00008
   Speedy DB, 2001, MED SCI SPORT EXER, V33, P1434, DOI 10.1097/00005768-200109000-00003
   Speedy DB, 1997, CLIN J SPORT MED, V7, P180, DOI 10.1097/00042752-199707000-00005
   Stuempfle KJ, 2003, CLIN J SPORT MED, V13, P171, DOI 10.1097/00042752-200305000-00008
   Stuempfle Kristin J, 2002, Alaska Med, V44, P51
NR 30
TC 34
Z9 34
U1 3
U2 16
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1050-642X
EI 1536-3724
J9 CLIN J SPORT MED
JI Clin. J. Sport Med.
PD MAY
PY 2005
VL 15
IS 3
BP 148
EP 153
DI 10.1097/01.jsm.0000157652.47572.56
PG 6
WC Orthopedics; Physiology; Sport Sciences
SC Orthopedics; Physiology; Sport Sciences
GA 943CH
UT WOS:000230329000006
PM 15867557
DA 2018-12-27
ER

PT J
AU Poehlman, ET
AF Poehlman, ET
TI RETRACTED: Retraction of publication (Retracted Article)
SO EUROPEAN JOURNAL OF CLINICAL INVESTIGATION
LA English
DT Correction; Retracted Publication
ID MENOPAUSE
C1 Univ Vermont, Burlington, VT 05405 USA.
CR Poehlman ET, 1997, EUR J CLIN INVEST, V27, P322, DOI 10.1046/j.1365-2362.1997.1160662.x
   POEHLMAN ET, 1995, ANN INTERN MED, V123, P673, DOI 10.7326/0003-4819-123-9-199511010-00005
   Sox HC, 2003, ANN INTERN MED, V139, P227, DOI 10.7326/0003-4819-139-3-200308050-00012
NR 3
TC 0
Z9 0
U1 2
U2 18
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0014-2972
EI 1365-2362
J9 EUR J CLIN INVEST
JI Eur. J. Clin. Invest.
PD MAY
PY 2005
VL 35
IS 5
BP 350
EP 350
DI 10.1111/j.1365-2362.2005.01498.x
PG 1
WC Medicine, General & Internal; Medicine, Research & Experimental
SC General & Internal Medicine; Research & Experimental Medicine
GA 921DO
UT WOS:000228744600009
PM 15860048
DA 2018-12-27
ER

PT J
AU Uchihara, JN
   Krensky, AM
   Matsuda, T
   Kawakami, H
   Okudaira, T
   Masuda, M
   Ohta, T
   Takasu, N
   Mori, N
AF Uchihara, JN
   Krensky, AM
   Matsuda, T
   Kawakami, H
   Okudaira, T
   Masuda, M
   Ohta, T
   Takasu, N
   Mori, N
TI RETRACTED: Transactivation of the CCL5/RANTES gene by Epstein-Barr virus
   latent membrane protein (Retracted article. See vol. 129, pg. 2762,
   2011)
SO INTERNATIONAL JOURNAL OF CANCER
LA English
DT Article; Retracted Publication
DE Epstein-Barr virus; LMP-1; CCL5; NF-kappa B; Burkitt's lymphoma
ID NF-KAPPA-B; LYMPHOCYTE GROWTH TRANSFORMATION; RANTES CHEMOKINE GENE;
   T-LYMPHOCYTES; KINASE-ALPHA; TRANSCRIPTIONAL REGULATION; HISTONE
   ACETYLATION; IKK-ALPHA; EXPRESSION; ACTIVATION
AB Chemokines and chemokine receptors mediate lymphocyte migration and tissue localization. To analyze CCL5 (RANTES) expression by EBV-infected cells, we examined the expression of CCL5 in BL cell lines. Among 4 BL cell lines, those infected with EBV selectively expressed the CCL5 gene and secreted CCL5. Four cell lines also expressed CCR5, a receptor for CCL5. EBV-encoded LMP-1, a pleiotropic protein that effects gene expression, cell transformation, growth and death, induces expression of CCL5 mRNA and secretion of CCL5 in the EBV-negative BL cell line BJAB and the embryonic kidney cell line 293T. HDACI-stimulated endogenous LMP-1 also induced CCL5 expression in an EBV-positive BL cell line. Analysis of the CCL5 promoter revealed that it is activated by both LMP-1 C-terminal activation domains, CTAR-1 and CTAR-2, which can activate NF-kappaB signaling. Coexpression Of IkappaBalpha, IkappaBbeta, IKKalpha, IKKbeta, NIK and TRAF2 dominant-negative constructs, with LMP-1 inhibited the activation of the CCL5 promoter by LMP-1, suggesting that LMP-1 induces CCL5 via NF-kappaB signaling. The NF-kappaB binding sites, R(A/B), located at positions -71 to -43 relative to the putative transcription start site in the CCL5 promoter, were essential for the activation of CCL5 gene expression by LMP-1. These results indicate that the activation of the NF-kappaB pathway by LMP-1 is required for the activation of CCL5 expression. (C) 2004 Wiley-Liss, Inc.
C1 Univ Ryukyus, Grad Sch Med, Div Mol Virol & Oncol, Nishihara, Okinawa 9030215, Japan.
   Univ Ryukyus, Fac Med, Div Endocrinol & Metab, Nishihara, Okinawa 90301, Japan.
   Stanford Univ, Sch Med, Dept Pediat, Stanford, CA 94305 USA.
   Univ Ryukyus, Fac Med, Div Child Hlth & Welfare, Nishihara, Okinawa 90301, Japan.
RP Mori, N (reprint author), Univ Ryukyus, Grad Sch Med, Div Mol Virol & Oncol, 207 Uehara, Nishihara, Okinawa 9030215, Japan.
EM n-mori@med.u-ryukyu.ac.jp
CR Baba M, 1996, INT J CANCER, V66, P124, DOI 10.1002/(SICI)1097-0215(19960328)66:1<124::AID-IJC21>3.0.CO;2-C
   Baggiolini M, 1998, NATURE, V392, P565, DOI 10.1038/33340
   Baggiolini M, 1997, ANNU REV IMMUNOL, V15, P675, DOI 10.1146/annurev.immunol.15.1.675
   Bradley LM, 1999, J IMMUNOL, V162, P2511
   BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809
   Chang LK, 2000, NUCLEIC ACIDS RES, V28, P3918, DOI 10.1093/nar/28.20.3918
   Eliopoulos AG, 1999, J BIOL CHEM, V274, P16085, DOI 10.1074/jbc.274.23.16085
   Floettmann JE, 1997, ONCOGENE, V15, P1851, DOI 10.1038/sj.onc.1201359
   Geleziunas R, 1998, MOL CELL BIOL, V18, P5157, DOI 10.1128/MCB.18.9.5157
   Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225
   Gires O, 1997, EMBO J, V16, P6131, DOI 10.1093/emboj/16.20.6131
   HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L
   HUEN DS, 1995, ONCOGENE, V10, P549
   Iijima W, 2003, AM J PATHOL, V163, P261, DOI 10.1016/S0002-9440(10)63649-8
   IMAI S, 1993, J MED VIROL, V40, P278, DOI 10.1002/jmv.1890400405
   Izumi KM, 1997, P NATL ACAD SCI USA, V94, P12592, DOI 10.1073/pnas.94.23.12592
   Jenkins PJ, 2000, J VIROL, V74, P710, DOI 10.1128/JVI.74.2.710-720.2000
   Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621
   Kaye KM, 1996, P NATL ACAD SCI USA, V93, P11085, DOI 10.1073/pnas.93.20.11085
   KAYE KM, 1993, P NATL ACAD SCI USA, V90, P9150, DOI 10.1073/pnas.90.19.9150
   Kieser A, 1997, EMBO J, V16, P6478, DOI 10.1093/emboj/16.21.6478
   LAHERTY CD, 1992, J BIOL CHEM, V267, P24157
   Lee FS, 1998, P NATL ACAD SCI USA, V95, P9319, DOI 10.1073/pnas.95.16.9319
   LIEBOWITZ D, 1986, J VIROL, V58, P233
   Lin RT, 1999, MOL CELL BIOL, V19, P959
   McKinsey TA, 1996, MOL CELL BIOL, V16, P2083
   Mori N, 1999, BLOOD, V93, P2360
   Moriuchi H, 1997, J IMMUNOL, V158, P3483
   MOSIALOS G, 1995, CELL, V80, P389, DOI 10.1016/0092-8674(95)90489-1
   Murono S, 2001, P NATL ACAD SCI USA, V98, P6905, DOI 10.1073/pnas.121016998
   Muzio M, 1997, SCIENCE, V278, P1612, DOI 10.1126/science.278.5343.1612
   Nakayama T, 2004, J VIROL, V78, P1665, DOI 10.1128/JVI.78.4.1665-1674.2004
   Nelson PJ, 1998, CURR OPIN IMMUNOL, V10, P265, DOI 10.1016/S0952-7915(98)80164-7
   NELSON PJ, 1993, J IMMUNOL, V151, P2601
   Nelson PJ, 1996, J IMMUNOL, V157, P1139
   Nikolcheva T, 2002, J CLIN INVEST, V110, P119, DOI 10.1172/JCI200215336
   OGARRA A, 1998, CURR BIOL, V8, P646
   Ortiz BD, 1996, MOL CELL BIOL, V16, P202
   Park JH, 2002, VIROLOGY, V303, P345, DOI 10.1006/viro.2002.1638
   ROWE M, 1994, J VIROL, V68, P5602
   SCHALL TJ, 1988, J IMMUNOL, V141, P1018
   Schluger NW, 1997, CURR OPIN IMMUNOL, V9, P504, DOI 10.1016/S0952-7915(97)80102-1
   Song A, 2000, IMMUNOL REV, V177, P236, DOI 10.1034/j.1600-065X.2000.17610.x
   Song A, 1999, IMMUNITY, V10, P93, DOI 10.1016/S1074-7613(00)80010-2
   Swanson BJ, 2002, IMMUNITY, V17, P605, DOI 10.1016/S1074-7613(02)00456-9
   Sylla BS, 1998, P NATL ACAD SCI USA, V95, P10106, DOI 10.1073/pnas.95.17.10106
   Tedla N, 1999, CYTOKINE, V11, P531, DOI 10.1006/cyto.1998.0439
   vonLuettichau I, 1996, CYTOKINE, V8, P89, DOI 10.1006/cyto.1996.0012
   Wakisaka N, 2003, ANTICANCER RES, V23, P2133
   Wakisaka N, 2002, CANCER RES, V62, P6337
   WANG D, 1988, J VIROL, V62, P4173
   WANG F, 1990, J VIROL, V64, P2309
   Wang JM, 1998, J IMMUNOL METHODS, V220, P1, DOI 10.1016/S0022-1759(98)00128-8
   Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866
   Xu ZG, 2001, BRIT J CANCER, V84, P920, DOI 10.1054/bjoc.2000.1687
   Yoshie O, 2001, ADV IMMUNOL, V78, P57, DOI 10.1016/S0065-2776(01)78002-9
   Yoshizaki T, 1998, P NATL ACAD SCI USA, V95, P3621, DOI 10.1073/pnas.95.7.3621
   Zandi E, 1999, MOL CELL BIOL, V19, P4547
NR 58
TC 22
Z9 22
U1 3
U2 8
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0020-7136
J9 INT J CANCER
JI Int. J. Cancer
PD MAY 1
PY 2005
VL 114
IS 5
BP 747
EP 755
DI 10.1002/ijc.20784
PG 9
WC Oncology
SC Oncology
GA 904YX
UT WOS:000227535600009
PM 15609310
OA Bronze
DA 2018-12-27
ER

PT J
AU de Ziegler, D
   Mattenberger, C
   Luyet, C
   Romoscanu, I
   Irion, NF
   Bianchi-Demicheli, F
AF de Ziegler, D
   Mattenberger, C
   Luyet, C
   Romoscanu, I
   Irion, NF
   Bianchi-Demicheli, F
TI RETRACTED: Clinical use of aromatase inhibitors (AI) in premenopausal
   women (Retracted Article. See vol 110, pg 295, 2008)
SO JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY
LA English
DT Article; Proceedings Paper; Retracted Publication
CT 7th International Aromatase Conference
CY SEP 06-08, 2004
CL Edinburgh, SCOTLAND
DE aromatase inhibitors; clomiphene citrate (CC); premenopausal women
ID ATTENUATING FACTOR GNSAF; IN-VITRO FERTILIZATION; CLOMIPHENE CITRATE;
   INTRAUTERINE INSEMINATION; UNEXPLAINED INFERTILITY; POSTMENOPAUSAL
   WOMEN; ENDOMETRIUM; INDUCTION; LETROZOLE; ESTRADIOL
AB Aromatase inhibitors (At) block the last enzymatic step of estrogen production, the aromatization of the A-cycle of aromatizable androgens and particularly, androstenedione (Delta 4) and testosterone (T). Molecules designed for interfering with aromatase activity have existed for many years. Yet the activity of products of the aminogluthetimide era was unspecific and these substances carried too many side effects for being used clinically. Newer third generation AIs, however, are highly specific and essentially devoid of side effects. These molecules have recently been approved for treating breast cancer in postmenopausal women either, in advanced forms or, as part of adjuvant therapy.
   In women whose ovaries are active, a temporary inhibition of E2 production will raise gonadotropins and in turn, stimulate follicular growth. In cancer patients, this property precludes the use of AIs in women whose ovaries are still active, unless gonadotropins are blocked. But in infertility patients, this property of AIs has been put to play for inducing ovulation. AIs have been used both in women who do not ovulate but whose hypothalamo-pituitary-gonadal (HPG) axis is active (oligo-anovulators of PCOD type) and those who ovulate regularly but in whom multiple ovulation is sought for treating unexplained infertility or as part of WE Like clomiphene citrate (CC), AIs are not usable in women whose gonadotropins are suppressed, as in the case of hypothalamic amenorrhea.
   The sum of data available on the use of AI for inducing ovulation remains however meager to this date and is mainly constituted of pilot and non-randomized trials. Yet mounting evidence tends to support AIs' advantages over CC for induction of ovulation. Hence, we think that the likelihood that these drugs will play a key role in induction of ovulation in the future is high. AIs appear particularly interesting for treating unexplained infertility because AI-FSH/hMG regimens are lighter than FSH-only regimens while retaining the high pregnancy rates of these latter treatments. (c) 2005 Elsevier Ltd. All rights reserved.
C1 Univ Hosp Geneva, Div Reprod Endocrinol & Infertil, Dept Obstet & Gynecol, Geneva, Switzerland.
   Nyon Med Ctr, Dept Obstet & Gynecol, Div Reprod Endocrinol & Infertil, Nyon, Switzerland.
RP de Ziegler, D (reprint author), Univ Hosp Geneva, Div Reprod Endocrinol & Infertil, Dept Obstet & Gynecol, Geneva, Switzerland.
EM ddeziegler@bluewin.ch
CR Aboulghar M, 2001, FERTIL STERIL, V75, P88, DOI 10.1016/S0015-0282(00)01641-1
   Casper RF, 2004, FERTIL STERIL, V81, P1159, DOI 10.1016/j.fertnstert.2004.01.007
   Costello MF, 2004, AUST NZ J OBSTET GYN, V44, P93, DOI 10.1111/j.1479-828X.2004.00192.x
   CUMMINGS AM, 1991, FUND APPL TOXICOL, V16, P506, DOI 10.1016/0272-0590(91)90091-H
   Dafopoulos K, 2004, HUM REPROD, V19, P1985, DOI 10.1093/humrep/deh383
   de Ziegler D, 2003, HUM REPROD, V18, P1598, DOI 10.1093/humrep/deg310
   DEZIEGLER D, 1991, FERTIL STERIL, V56, P851
   DEZIEGLER D, 1992, J CLIN ENDOCR METAB, V74, P322, DOI 10.1210/jc.74.2.322
   Dixon JM, 2003, J STEROID BIOCHEM, V86, P295, DOI 10.1016/S0960-0760(03)00370-4
   DODSON WC, 1987, FERTIL STERIL, V48, P441
   DZIADEK M, 1993, TERATOLOGY, V47, P263, DOI 10.1002/tera.1420470403
   Ferin M, 1999, J CLIN ENDOCR METAB, V84, P1768, DOI 10.1210/jc.84.6.1768
   Fisher SA, 2002, FERTIL STERIL, V78, P280, DOI 10.1016/S0015-0282(02)03241-7
   Fowler PA, 2003, REPRODUCTION, V126, P689, DOI 10.1530/reprod/126.6.689
   GONEN Y, 1990, FERTIL STERIL, V53, P282
   Homburg R, 2002, HUM REPROD UPDATE, V8, P449, DOI 10.1093/humupd/8.5.449
   Lonning PE, 2001, BREAST, V10, P198, DOI 10.1054/brst.2001.0293
   Martinez F, 2002, HUM REPROD, V17, P634, DOI 10.1093/humrep/17.3.634
   MASSAI MR, 1993, FERTIL STERIL, V59, P1179
   Mitwally MFM, 2003, HUM REPROD, V18, P1588, DOI 10.1093/humrep/deg311
   Mitwally MFM, 2001, FERTIL STERIL, V75, P305, DOI 10.1016/S0015-0282(00)01705-2
   SCHMIDT GE, 1986, AM J OBSTET GYNECOL, V154, P727, DOI 10.1016/0002-9378(86)90444-8
   Simpson D, 2004, DRUGS, V64, P1213, DOI 10.2165/00003495-200464110-00005
   Tiboni GM, 2004, FERTIL STERIL, V81, P1158, DOI 10.1016/j.fertnstert.2004.01.006
NR 24
TC 17
Z9 17
U1 2
U2 6
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-0760
J9 J STEROID BIOCHEM
JI J. Steroid Biochem. Mol. Biol.
PD MAY
PY 2005
VL 95
IS 1-5
BP 121
EP 127
DI 10.1016/j.jsbmb.2005.04.023
PG 7
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism
GA 958XE
UT WOS:000231480700018
PM 16002281
DA 2018-12-27
ER

PT J
AU Taechowisan, T
   Lu, CH
   Shen, YM
   Lumyong, S
AF Taechowisan, T
   Lu, CH
   Shen, YM
   Lumyong, S
TI RETRACTED: Secondary metabolites from endophytic Streptomyces
   aureofaciens CMUAc130 and their antifungal activity (Retracted Article.
   See vol 153, pg 915, 2007)
SO MICROBIOLOGY-SGM
LA English
DT Article; Retracted Publication
ID TRADITIONAL MEDICINE; PLANTS; SOIL; ANTAGONISM; FUSARIUM; AGENT; PEAT
AB Streptomyces aureofaciens CMUAc130 was isolated from the root tissue of Zingiber officinale Rosc. (Zingiberaceae). It was an antagonist of Colletotrichum musae and Fusarium oxysporum, the causative agents of anthracnose of banana and wilt of wheat, respectively. Evidence for the in vitro antibiosis of S. aureofaciens CMUAc130 was demonstrated by the zone of fungal-growth inhibition. Microscopic observations showed thickness and bulbous structures at the edges of the inhibited fungal hyphae. The culture filtrate and crude extract from this strain were all inhibitory to tested phytopathogenic fungi. The major active ingredients from the culture filtrate of S. aureofaciens CMUAc130 were purified by silica gel-column chromatography and identified to be (i) 5,7-dimethoxy-4-p-methoxylphenylcoumarin and (ii) 5,7-dimethoxy-4-phenylcoumarin by NMR and mass-spectral data, respectively. Bioassay studies showed that compounds (i) and (ii) had antifungal activities against tested fungi, and their MICs were found to be 120 and 150 mu g ml(-1), respectively. This is the first report of compounds (i) and (ii) from micro-organisms as active ingredients for the control of phytopathogenic fungi.
C1 Silpakorn Univ, Fac Sci, Dept Biol, Nakhon Pathom 73000, Thailand.
   Xiamen Univ, Sch Life Sci, Xiamen 361005, Peoples R China.
   Chinese Acad Sci, Kunming Inst Bot, Kunming 650204, Peoples R China.
RP Taechowisan, T (reprint author), Silpakorn Univ, Fac Sci, Dept Biol, Nakhon Pathom 73000, Thailand.
EM tewson84@hotmail.com
RI Lu, CH/G-4684-2010; Shen, YM/G-4681-2010
CR DELLEMONACHE G, 1983, PHYTOCHEMISTRY, V22, P1657
   ElShanshoury AER, 1996, CAN J BOT, V74, P1016, DOI 10.1139/b96-126
   ELSON MK, 1994, J CHEM ECOL, V20, P2835, DOI 10.1007/BF02098392
   KATZNELSON H, 1965, CAN J MICROBIOL, V11, P733, DOI 10.1139/m65-097
   MATA R, 1990, PHYTOCHEMISTRY, V29, P2037, DOI 10.1016/0031-9422(90)85067-P
   MATA R, 1988, J NAT PROD, V51, P851, DOI 10.1021/np50059a006
   MISHRA SK, 1987, J PLANT GROWTH REGUL, V6, P75, DOI 10.1007/BF02026457
   ROTHROCK CS, 1984, CAN J MICROBIOL, V30, P1440, DOI 10.1139/m84-230
   SHIRLING E. B., 1966, INT J SYST BACTERIOL, V16, P313
   Taechowisan T, 2003, ANN MICROBIOL, V53, P291
   Taechowisan T, 2003, WORLD J MICROB BIOT, V19, P381, DOI 10.1023/A:1023901107182
   TAHVONEN R, 1982, J AGR SCI FINLAND, V54, P357
   TAHVONEN R, 1982, J AGR SCI FINLAND, V54, P345
   TAHVONEN R, 1992, ACTA HORTIC, V342, P37
   Trejo-Estrada SR, 1998, WORLD J MICROB BIOT, V14, P865, DOI 10.1023/A:1008877224089
   Tuomi T, 2001, APPL BIOCHEM BIOTECH, V94, P135, DOI 10.1385/ABAB:94:2:135
   YUAN WM, 1995, APPL ENVIRON MICROB, V61, P3119
NR 17
TC 74
Z9 87
U1 3
U2 27
PU SOC GENERAL MICROBIOLOGY
PI READING
PA MARLBOROUGH HOUSE, BASINGSTOKE RD, SPENCERS WOODS, READING RG7 1AG,
   BERKS, ENGLAND
SN 1350-0872
J9 MICROBIOL-SGM
JI Microbiology-(UK)
PD MAY
PY 2005
VL 151
BP 1691
EP 1695
DI 10.1099/mic.0.27758-0
PN 5
PG 5
WC Microbiology
SC Microbiology
GA 928LC
UT WOS:000229272100035
PM 15870476
OA Bronze
DA 2018-12-27
ER

PT J
AU Thakur, S
   Sahoo, NK
   Senthilkumar, M
   Tokas, RB
AF Thakur, S
   Sahoo, NK
   Senthilkumar, M
   Tokas, RB
TI RETRACTED: Optical properties and morphological changes in gadolinia
   films deposited under ambient substrate temperature conditions(Retracted
   article. See vol. 64, pg. 583, 2017)
SO OPTICAL MATERIALS
LA English
DT Article; Retracted Publication
DE gadolinia films; deep UV optical coatings; optical properties; rare
   earth oxides; optical constants; phase modulated spectroscopic
   ellipsometry
ID THIN-FILMS; AMORPHOUS-SILICON; OXIDE; CONSTANTS; EVAPORATION
AB Depositing optical coatings at ambient substrate temperature has been stimulating interest as it has a range of potential applications. However, developing such optical coatings especially using refractory oxides is challenging since they yield stable thin films mostly at elevated substrate temperatures. Gadolinia films (Gd2O3), in the present experiment, however, observed to form stable films at ambient substrate temperatures when deposited through reactive electron beam deposition. In addition, the films exhibited interesting optical properties such as reasonably high refractive index and wide band gap, which are rarely obtainable with conventional oxide materials. During the deposition, rate and oxygen pressure have been systematically varied. The deposited films have subsequently been characterized for optical and band gap related properties using spectroscopic phase modulated ellipsometric and spectrophotometric measurements. Atomic force microscopy has also been employed to study the surface topography and morphological changes under various deposition conditions. Both oxygen pressure and rate of evaporation have observed to greatly influence both the optical constant and surface topography of the gadolinia films. (c) 2004 Elsevier B.V. All rights reserved.
C1 Bhabha Atom Res Ctr, Div Spect, Bombay 400085, Maharashtra, India.
RP Sahoo, NK (reprint author), Bhabha Atom Res Ctr, Div Spect, Bombay 400085, Maharashtra, India.
EM nksahoo@apsara.barc.ernet.in
CR BINNIG G, 1986, PHYS REV LETT, V56, P930, DOI 10.1103/PhysRevLett.56.930
   CHOW R, 1993, APPL OPTICS, V32, P5567, DOI 10.1364/AO.32.005567
   Dakhel AA, 2001, J OPT A-PURE APPL OP, V3, P452, DOI 10.1088/1464-4258/3/6/304
   DUPARRE A, 1995, LIGHT SCATTERING THI, V1
   Jellison GE, 1996, APPL PHYS LETT, V69, P371, DOI 10.1063/1.118064
   MARCINOW T, 1981, APPL OPTICS, V20, P1755, DOI 10.1364/AO.20.001755
   RITTER E, 1975, PHYS THIN FILMS, P1
   Sahoo NK, 2003, THIN SOLID FILMS, V440, P155, DOI 10.1016/S0040-6090(03)00678-3
   Sahoo NK, 2002, APPL SURF SCI, V200, P219, DOI 10.1016/S0169-4332(02)00900-5
   SAHOO NK, 2003, APPL SURF SCI, V214, P259
   SWANEPOEL R, 1983, J PHYS E SCI INSTRUM, V16, P1214, DOI 10.1088/0022-3735/16/12/023
   SWANEPOEL R, 1984, J PHYS E SCI INSTRUM, V17, P896, DOI 10.1088/0022-3735/17/10/023
   Wiktorczyk T, 2002, THIN SOLID FILMS, V405, P238, DOI 10.1016/S0040-6090(01)01760-6
NR 13
TC 11
Z9 12
U1 3
U2 10
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0925-3467
EI 1873-1252
J9 OPT MATER
JI Opt. Mater.
PD MAY
PY 2005
VL 27
IS 8
BP 1402
EP 1409
DI 10.1016/j.optmat.2004.10.003
PG 8
WC Materials Science, Multidisciplinary; Optics
SC Materials Science; Optics
GA 927MA
UT WOS:000229196800014
DA 2018-12-27
ER

PT J
AU Yilmaz, I
AF Yilmaz, I
TI RETRACTED: Domain wall solutions in the nonstatic and stationary Godel
   universes with a cosmological constant - art. no. 103503 (Retracted
   article. See vol. 77, pg. Nil_1735, 2008)
SO PHYSICAL REVIEW D
LA English
DT Article; Retracted Publication
ID COSMIC STRINGS; FIELD; STARS
AB In this article, we study rotating cosmological models with domain wall in the context of general relativity. For this purpose we consider domain walls with strange quark matter and normal matter in the nonstatic and stationary Godel universes with cosmological constant. We solve Einstein's field equations by using equation of state for strange quark matter and normal matter. Also, we discuss the features of obtained solutions.
C1 Canakkale Onsekiz Mart Univ, Dept Phys, Arts & Sci Fac, Astrophys Res Ctr, TR-17100 Canakkale, Turkey.
RP Yilmaz, I (reprint author), Canakkale Onsekiz Mart Univ, Dept Phys, Arts & Sci Fac, Astrophys Res Ctr, Terzioglu Campus, TR-17100 Canakkale, Turkey.
EM iyilmaz@comu.edu.tr
CR ALCOCK C, 1986, ASTROPHYS J, V310, P261, DOI 10.1086/164679
   Barrow JD, 2004, CLASSICAL QUANT GRAV, V21, P1773, DOI 10.1088/0264-9381/21/7/005
   Baysal H, 2001, INT J MOD PHYS D, V10, P935, DOI 10.1142/S0218271801001530
   BELAVIN AA, 1975, JETP LETT+, V22, P245
   BODMER AR, 1971, PHYS REV D, V4, P1601, DOI 10.1103/PhysRevD.4.1601
   Bonnor WB, 2003, INT J MOD PHYS D, V12, P1705, DOI 10.1142/S0218271803004122
   Campanelli L, 2003, INT J MOD PHYS D, V12, P1385, DOI 10.1142/S0218271803003773
   Cea P, 2000, J PHYS G NUCL PARTIC, V26, P411, DOI 10.1088/0954-3899/26/4/308
   COLLINS CB, 1980, GEN RELAT GRAVIT, V12, P805, DOI 10.1007/BF00763057
   Drukker N, 2004, PHYS REV D, V70, DOI 10.1103/PhysRevD.70.084031
   FARHI E, 1984, PHYS REV D, V30, P2379, DOI 10.1103/PhysRevD.30.2379
   GODEL K, 1949, REV MOD PHYS, V21, P447, DOI 10.1103/RevModPhys.21.447
   Gurses M, 2005, CLASSICAL QUANT GRAV, V22, P1527, DOI 10.1088/0264-9381/22/9/003
   HAENSEL P, 1986, ASTRON ASTROPHYS, V160, P121
   Iwazaki A, 1997, PHYS REV D, V56, P2435, DOI 10.1103/PhysRevD.56.2435
   KAJARI E, GRGC0404032
   Kolb EW, 1990, EARLY UNIVERSE
   OKUYAMA N, 2004, PHYS REV D, V70
   RAJARAMAN R, 1987, SOLUTIONS INSTANTOS
   REBOUCAS MJ, 1983, PHYS REV D, V28, P1251, DOI 10.1103/PhysRevD.28.1251
   SKYRME THR, 1961, P ROY SOC LOND A MAT, V262, P233, DOI DOI 10.1098/RSPA.1961.0115
   Sotani H, 2004, PHYS REV D, V69, DOI 10.1103/PhysRevD.69.084008
   VILENKIN A, 1982, PHYS REV LETT, V48, P1867, DOI 10.1103/PhysRevLett.48.1867
   VILENKIN A, 1985, PHYS REP, V121, P263, DOI 10.1016/0370-1573(85)90033-X
   VILENKIN A, 1994, COSMIC STRINGS TOPOL
   WITTEN E, 1984, PHYS REV D, V30, P272, DOI 10.1103/PhysRevD.30.272
   YAVUZ I, 1994, INT J THEOR PHYS, V33, P2285, DOI 10.1007/BF00675805
   YILMAZ I, 2005, IN PRESS INT J MOD P
   ZUREK WH, 1985, NATURE, V317, P505, DOI 10.1038/317505a0
NR 29
TC 13
Z9 13
U1 3
U2 9
PU AMER PHYSICAL SOC
PI COLLEGE PK
PA ONE PHYSICS ELLIPSE, COLLEGE PK, MD 20740-3844 USA
SN 2470-0010
EI 2470-0029
J9 PHYS REV D
JI Phys. Rev. D
PD MAY
PY 2005
VL 71
IS 10
AR 103503
DI 10.1103/PhysRevD.71.103503
PG 7
WC Astronomy & Astrophysics; Physics, Particles & Fields
SC Astronomy & Astrophysics; Physics
GA 930TQ
UT WOS:000229440400016
DA 2018-12-27
ER

PT J
AU Senzaki, H
   Chen, CH
   Ishido, H
   Masutani, S
   Matsunaga, T
   Taketazu, M
   Kobayashi, T
   Sasaki, N
   Kyo, S
   Yokote, Y
AF Senzaki, H
   Chen, CH
   Ishido, H
   Masutani, S
   Matsunaga, T
   Taketazu, M
   Kobayashi, T
   Sasaki, N
   Kyo, S
   Yokote, Y
TI RETRACTED: Arterial hemodynamics in patients after Kawasaki disease
   (Retracted article. See vol. 125, pg. E1020, 2012)
SO CIRCULATION
LA English
DT Article; Retracted Publication
DE arteries; coronary disease; Fourier analysis; hemodynamics; risk factors
ID VON-WILLEBRAND-FACTOR; ANGIOTENSIN-CONVERTING ENZYME; ASCENDING AORTIC
   PRESSURE; STAGE RENAL-DISEASE; SEE VOL. 125; INDEPENDENT PREDICTOR;
   HYPERTENSIVE PATIENTS; CARDIOVASCULAR RISK; ENDOTHELIAL INJURY; INPUT
   IMPEDANCE
AB Background - Histopathological findings in the acute stage of Kawasaki disease (KD) indicate widespread vascular inflammation that involves not only coronary arteries but also systemic arteries. This may cause changes in systemic arterial wall properties after KD, which could have adverse effects on arterial hemodynamics ( an important predictor of cardiovascular morbidity and mortality).
   Methods and Results - Systemic arterial hemodynamics were investigated by measuring aortic input impedance during cardiac catheterization in 42 KD patients who had developed coronary artery lesions (CALs) in the acute stage of KD. The KD patients were subdivided into 2 groups according to the angiographic findings ( group 1A, 26 patients with persistent CALs; group 1B, 16 patients with regressed CALs), and results were compared with those of 36 referents ( group 2). Compared with referents, characteristic impedance was significantly higher for KD patients (137.0 +/- 5.1, 125.7 +/- 8.2, and 97.9 +/- 4.1 dyne center dot s center dot cm(-5) center dot m(2) for group 1A, group 1B, and group 2, respectively), and total peripheral arterial compliance indexed to age-specific values was significantly lower for KD patients ( group 1A 72.9 +/- 4.2% of normal; group 1B 70.6 +/- 5.9% of normal; group 2 97.7 +/- 4.0% of normal; for both variables, P < 0.05 for each KD group versus group 2; P = NS between KD groups), which suggests that both central and peripheral arterial wall stiffness increase after KD regardless of persistence of CALs. Also, indices of arterial wave reflection ( reflection coefficient, reflection factor, and augmentation index) were all significantly higher in KD patients than in referents ( P < 0.05), with the result that the aortic pressure waveforms of the present KD patients resembled those generally observed in the elderly. In addition, levels of circulating markers of endothelial dysfunction ( ACE and von Willebrand factor) were associated with increased vascular stiffening in KD patients but not in referents.
   Conclusions - These results indicating abnormal arterial hemodynamics after KD highlight the importance of regular monitoring of the systemic arterial bed and potentially relevant cardiovascular events in long-term follow-up of KD.
C1 Saitama Med Sch Hosp, Saitama Heart Inst, Dept Pediat Cardiol & Pediat, Saitama, Japan.
   Natl Yang Ming Univ, Taipei Vet Gen Hosp, Cardiovasc Res Ctr, Taipei, Taiwan.
RP Senzaki, H (reprint author), Saitama Med Sch Hosp, Saitama Heart Inst, Dept Pediat Cardiol, 38 Morohongo, Moroyama, Saitama 3500495, Japan.
EM hsenzaki@saitama-med.ac.jp
OI Senzaki, Hideaki/0000-0002-8289-0953
CR AMANO S, 1979, JPN CIRC J, V43, P633, DOI 10.1253/jcj.43.633
   AMANO S, 1979, JPN CIRC J, V43, P741, DOI 10.1253/jcj.43.741
   Blacher J, 1999, CIRCULATION, V99, P2434, DOI 10.1161/01.CIR.99.18.2434
   Blacher J, 1998, HYPERTENSION, V32, P570, DOI 10.1161/01.HYP.32.3.570
   Blann AD, 1997, EUR J CLIN INVEST, V27, P916, DOI 10.1046/j.1365-2362.1997.2180766.x
   Boutouyrie P, 2002, HYPERTENSION, V39, P10, DOI 10.1161/hy0102.099031
   Burns J C, 2001, Adv Pediatr, V48, P157
   Burns JC, 1996, J AM COLL CARDIOL, V28, P253, DOI 10.1016/0735-1097(96)00099-X
   CALDWELL PRB, 1976, SCIENCE, V191, P1050, DOI 10.1126/science.175444
   Catto AJ, 1997, THROMB HAEMOSTASIS, V77, P1104
   Chen CH, 1996, HYPERTENSION, V27, P168, DOI 10.1161/01.HYP.27.2.168
   Cheung YF, 2004, J AM COLL CARDIOL, V43, P120, DOI 10.1016/j.jacc.2003.08.030
   Conway DSG, 2002, CIRCULATION, V106, P1962, DOI 10.1161/01.CIR.0000033220.97592.9A
   de Simone G, 1999, HYPERTENSION, V33, P800, DOI 10.1161/01.HYP.33.3.800
   Dhillon R, 1996, CIRCULATION, V94, P2103, DOI 10.1161/01.CIR.94.9.2103
   Foster BJ, 2000, ARCH DIS CHILD, V83, P253, DOI 10.1136/adc.83.3.253
   Franklin SS, 1999, CIRCULATION, V100, P354, DOI 10.1161/01.CIR.100.4.354
   FUJIWARA H, 1978, PEDIATRICS, V61, P100
   HIROSE S, 1978, EUR J PEDIATR, V129, P17, DOI 10.1007/BF00441370
   KASAHARA Y, 1981, CLIN CHEM, V27, P1922
   Kato H, 1996, CIRCULATION, V94, P1379, DOI 10.1161/01.CIR.94.6.1379
   KELLY R, 1989, CIRCULATION, V80, P1652, DOI 10.1161/01.CIR.80.6.1652
   Laurent S, 2003, STROKE, V34, P1203, DOI 10.1161/01.STR.0000065428.03209.64
   Laurent S, 2001, HYPERTENSION, V37, P1236, DOI 10.1161/01.HYP.37.5.1236
   LEAROYD BM, 1966, CIRC RES, V18, P278, DOI 10.1161/01.RES.18.3.278
   LING SC, 1973, CIRC RES, V33, P198, DOI 10.1161/01.RES.33.2.198
   LIU ZR, 1986, AM J PHYSIOL, V251, pH588
   LOMBARDI A, 1994, BRIT J RHEUMATOL, V33, P1197
   MACFARLANE DE, 1975, THROMB DIATH HAEMOST, V34, P306, DOI 10.1055/s-0038-1651343
   MASUDA H, 1986, ARCH PATHOL LAB MED, V110, P1136
   MATUCCICERINIC M, 1992, J LAB CLIN MED, V120, P428
   MURGO JP, 1981, CIRCULATION, V63, P122, DOI 10.1161/01.CIR.63.1.122
   MURGO JP, 1980, CIRCULATION, V62, P105, DOI 10.1161/01.CIR.62.1.105
   NAKASHIMA T, 1971, ANGIOLOGY, V22, P477, DOI 10.1177/000331977102200806
   Nichols W., 1987, VENTRICULAR VASCULAR, P79
   NICHOLS WW, 1990, MCDONALDS BLOOD FLOW, P283
   Noto N, 2001, PEDIATRICS, V107, P1095, DOI 10.1542/peds.107.5.1095
   Peng XQ, 2003, HYPERTENSION, V41, P378, DOI 10.1161/01.HYP.0000049624.99844.3D
   PERSCHAU RA, 1979, CIRCULATION, V59, P1312, DOI 10.1161/01.CIR.59.6.1312
   Rabbani LE, 2002, J AM COLL CARDIOL, V40, P1991, DOI 10.1016/S0735-1097(02)02565-2
   Senzaki H, 2003, PEDIATR RES, V53, P983, DOI 10.1203/01.PDR.0000061566.63383.F4
   Senzaki H, 2002, CIRCULATION, V105, P2885, DOI 10.1161/01.CIR.0000018621.96210.72
   Senzaki H, 2002, EUR J PEDIATR, V161, P547, DOI 10.1007/s00431-002-1025-6
   SENZAKI H, 1994, CIRCULATION, V89, P266, DOI 10.1161/01.CIR.89.1.266
   Senzaki H, 2001, CIRCULATION, V104, P860, DOI 10.1161/hc3301.095286
   TANAKA N, 1986, ACTA PATHOL JAPON, V36, P1513
   TATSUNO K, 1975, AM HEART J, V89, P171, DOI 10.1016/0002-8703(75)90042-3
   Taubert D, 2004, BRIT J PHARMACOL, V143, P159, DOI 10.1038/sj.bjp.0705907
   THOMPSON SG, 1995, NEW ENGL J MED, V332, P635, DOI 10.1056/NEJM199503093321003
NR 49
TC 40
Z9 42
U1 4
U2 14
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0009-7322
EI 1524-4539
J9 CIRCULATION
JI Circulation
PD APR 26
PY 2005
VL 111
IS 16
BP 2119
EP 2125
DI 10.1161/01.CIR.0000162483.51132.25
PG 7
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA 920BA
UT WOS:000228660800016
PM 15851619
OA Bronze
DA 2018-12-27
ER

PT J
AU Sezen, B
   Sames, D
AF Sezen, B
   Sames, D
TI RETRACTED: Selective and catalytic arylation of N-phenylpyrrolidine:
   sp(3) C-H bond functionalization in the absence of a directing group
   (Retracted Article. See vol 128, pg 3102, 2006)
SO JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
LA English
DT Article; Retracted Publication
ID COUPLING REACTION; SATURATED-HYDROCARBONS; TERTIARY-AMINES; NITROGEN
   ATOM; RUTHENIUM; ACTIVATION; COMPLEXES; HYDRIDE; ADJACENT; ETHYLENE
C1 Columbia Univ, Dept Chem, New York, NY 10027 USA.
RP Sames, D (reprint author), Columbia Univ, Dept Chem, 3000 Broadway, New York, NY 10027 USA.
EM sames@chem.columbia.edu
RI 丹丹, 李/D-2431-2010
CR BERGMAN RG, 1984, SCIENCE, V223, P902, DOI 10.1126/science.223.4639.902
   Chatani N, 2001, J AM CHEM SOC, V123, P10935, DOI 10.1021/ja011540e
   CHAUDRET B, 1985, ORGANOMETALLICS, V4, P1722, DOI 10.1021/om00129a005
   FALLER JW, 1995, ORGANOMETALLICS, V14, P1592, DOI 10.1021/om00004a012
   FELKIN H, 1984, TETRAHEDRON LETT, V25, P1279, DOI 10.1016/S0040-4039(01)80134-9
   Ferrando-Miguel G, 2002, NEW J CHEM, V26, P687, DOI 10.1039/b200168n
   FREDIANI P, 1993, J ORGANOMET CHEM, V454, pC17, DOI 10.1016/0022-328X(93)83258-W
   Guari Y, 1998, J AM CHEM SOC, V120, P4228, DOI 10.1021/ja971603m
   HOYANO JK, 1982, J AM CHEM SOC, V104, P3723, DOI 10.1021/ja00377a032
   JANOWICZ AH, 1982, J AM CHEM SOC, V104, P352, DOI 10.1021/ja00365a091
   Jessop PG, 1996, INORG CHIM ACTA, V250, P351, DOI 10.1016/S0020-1693(96)05251-6
   JONES WD, 1989, ACCOUNTS CHEM RES, V22, P91, DOI 10.1021/ar00159a002
   JONES WD, 1984, J AM CHEM SOC, V106, P1650, DOI 10.1021/ja00318a018
   Kakiuchi F, 2003, ADV SYNTH CATAL, V345, P1077, DOI 10.1002/adsc.200303094
   Li ZP, 2004, J AM CHEM SOC, V126, P11810, DOI 10.1021/ja0460763
   Murahashi SI, 2003, J AM CHEM SOC, V125, P15312, DOI 10.1021/ja0390303
   Ritleng V, 2002, CHEM REV, V102, P1731, DOI 10.1021/cr0104330
   Ritleng V, 2000, CHEM COMMUN, P129, DOI 10.1039/a908703f
   Sezen B, 2004, J AM CHEM SOC, V126, P13244, DOI 10.1021/ja045402b
   Sezen B, 2002, J AM CHEM SOC, V124, P13372, DOI 10.1021/ja027891q
   Yi CS, 2004, ORGANOMETALLICS, V23, P5392, DOI 10.1021/om0401206
NR 21
TC 21
Z9 21
U1 4
U2 31
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0002-7863
J9 J AM CHEM SOC
JI J. Am. Chem. Soc.
PD APR 20
PY 2005
VL 127
IS 15
BP 5284
EP 5285
DI 10.1021/050269o
PG 2
WC Chemistry, Multidisciplinary
SC Chemistry
GA 916TE
UT WOS:000228408300006
PM 15826142
DA 2018-12-27
ER

PT J
AU Rubio, D
   Garcia-Castro, J
   Martin, MC
   de la Fuente, R
   Cigudosa, JC
   Lloyd, AC
   Bernad, A
AF Rubio, D
   Garcia-Castro, J
   Martin, MC
   de la Fuente, R
   Cigudosa, JC
   Lloyd, AC
   Bernad, A
TI RETRACTED: Spontaneous human adult stem cell transformation (Retracted
   article. See vol. 70, pg. 6682, 2010)
SO CANCER RESEARCH
LA English
DT Article; Retracted Publication
ID CANCER; TELOMERASE; MECHANISMS; SENESCENCE
AB Human adult stem cells are being evaluated widely for various therapeutic approaches. Several recent clinical trials have reported their safety, showing them to be highly resistant to transformation. The clear similarities between stem cell and cancer stem cell genetic programs are nonetheless the basis of a recent proposal that some cancer stem cells could derive from human adult stem cells. Here we show that although they can be managed safely during the standard ex vivo expansion period (6-8 weeks), human mesenchymal stem cells can undergo spontaneous transformation following long-term in vitro culture (4-5 months). This is the first report of spontaneous transformation of human adult stem cells, supporting the hypothesis of cancer stem cell origin. Our findings indicate the importance of biosafety studies of mesenchymal stem cell biology to efficiently exploit their full clinical therapeutic potential.
C1 CSIC, Dept Immunol & Oncol, Ctr Nacl Biotechnol, E-28049 Madrid, Spain.
   Hosp Univ Nino Jesus, Dept Oncol, Madrid, Spain.
   Ctr Nacl Invest Oncol, Cytogenet Unit, Madrid, Spain.
   UCL, Mol Cell Biol Lab, London, England.
RP Garcia-Castro, J (reprint author), CSIC, Dept Immunol, Ctr Nacl Biotechnol, UAM Campus De Cantoblanco,Darwin 3, E-28049 Madrid, Spain.
EM igarciac.hnjs@salud.madrid.org
RI Garcia-Castro, Javier/H-5274-2011
OI Garcia-Castro, Javier/0000-0001-7604-1640
CR Bergers G, 2003, NAT REV CANCER, V3, P401, DOI 10.1038/nrc1093
   BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761
   Chin L, 1999, CELL, V97, P527, DOI 10.1016/S0092-8674(00)80762-X
   Czyz J, 2003, BIOL CHEM, V384, P1391, DOI 10.1515/BC.2003.155
   DePinho RA, 2000, NATURE, V408, P248, DOI 10.1038/35041694
   Helman LJ, 2003, NAT REV CANCER, V3, P685, DOI 10.1038/nrc1168
   Horwitz EM, 2002, P NATL ACAD SCI USA, V99, P8932, DOI 10.1073/pnas.132252399
   Lloyd AC, 2002, NAT CELL BIOL, V4, pE25, DOI 10.1038/ncb0202-e25
   Lustig AJ, 1999, P NATL ACAD SCI USA, V96, P3339, DOI 10.1073/pnas.96.7.3339
   Mangi AA, 2003, NAT MED, V9, P1195, DOI 10.1038/nm912
   Marx J, 2003, SCIENCE, V301, P1308, DOI 10.1126/science.301.5638.1308
   Milyavsky M, 2003, CANCER RES, V63, P7147
   Pardal R, 2003, NAT REV CANCER, V3, P895, DOI 10.1038/nrc1232
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Romanov SR, 2001, NATURE, V409, P633, DOI 10.1038/35054579
   Rosenthal N, 2003, NEW ENGL J MED, V349, P267, DOI 10.1056/NEJMra020849
   Secombe J, 2004, CELL, V117, P153, DOI 10.1016/S0092-8674(04)00336-8
   Sedivy JM, 1998, P NATL ACAD SCI USA, V95, P9078, DOI 10.1073/pnas.95.16.9078
   Serakinci N, 2004, ONCOGENE, V23, P5095, DOI 10.1038/sj.onc.1207651
   Zuk PA, 2001, TISSUE ENG, V7, P211, DOI 10.1089/107632701300062859
NR 20
TC 730
Z9 836
U1 8
U2 69
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2005
VL 65
IS 8
BP 3035
EP 3039
DI 10.1158/0008-5472.CAN-04-4194
PG 5
WC Oncology
SC Oncology
GA 916ZF
UT WOS:000228424800011
PM 15833829
OA Bronze
DA 2018-12-27
ER

PT J
AU Townsend, PA
   Cragg, MS
   Davidson, SM
   McCormick, J
   Barry, S
   Lawrence, KM
   Knight, RA
   Hubank, M
   Chen, PL
   Latchman, DS
   Stephanou, A
AF Townsend, PA
   Cragg, MS
   Davidson, SM
   McCormick, J
   Barry, S
   Lawrence, KM
   Knight, RA
   Hubank, M
   Chen, PL
   Latchman, DS
   Stephanou, A
TI RETRACTED: STAT-1 facilitates the ATM activated checkpoint pathway
   following DNA damage (Retracted article. See vol. 128, pg. 1064, 2015)
SO JOURNAL OF CELL SCIENCE
LA English
DT Article; Retracted Publication
DE ATM; cell cycle; Chk2; 53BP1; MDC1; STAT-1
ID S-PHASE CHECKPOINT; INDUCED APOPTOSIS; TRANSCRIPTIONAL CONTROL; CARDIAC
   MYOCYTES; MRE11 COMPLEX; 53BP1; CHK2; PHOSPHORYLATION; PROTEIN; CELLS
AB STAT-1 plays a role in mediating stress responses to various stimuli and has also been implied to be a tumour suppressor. Here, we report that STAT-1-deficient cells have defects both in intra-S-phase and G2-M checkpoints in response to DNA damage. Interestingly, STAT-1-deficient cells showed reduced Chk2 phosphorylation on threonine 68 (Chk2(-T68)) following DNA damage, suggesting that STAT-1 might function in the ATM-Chk2 pathway. Moreover, the defects in Chk2(-T68) phosphorylation in STAT-1-deficient cells also correlated with reduced degradation of Cdc25A compared with STAT-1-expressing cells after DNA damage. We also show that STAT-1 is required for ATM-dependent phosphorylation of NBS1 and p53 but not for BRCA1 or H2AX phosphorylation following DNA damage. Expression levels of BRCT mediator/adaptor proteins MDC1 and 53BP1, which are required for ATM-mediated pathways, are reduced in cells lacking STAT-1. Enforced expression of MDC1 into STAT-1-deficient cells restored ATM-mediated phosphorylation of downstream substrates. These results imply that STAT-1 plays a crucial role in the DNA-damage-response by regulating the expression of 53BP1 and MDC1, factors known to be important for mediating ATM-dependent checkpoint pathways.
C1 UCL, Med Mol Biol Unit, London WC1N 1EH, England.
   UCL, Inst Child Hlth, London WC1N 1EH, England.
   Univ Southampton, Southampton Gen Hosp, Canc Sci Div, Southampton SO16 6YD, Hants, England.
   Univ Texas, Hlth Sci Ctr, Dept Mol Med, San Antonio, TX 78245 USA.
   Univ Texas, Inst Biotechnol, Hlth Sci Ctr, San Antonio, TX 78245 USA.
RP Stephanou, A (reprint author), UCL, Med Mol Biol Unit, 30 Guilford St, London WC1N 1EH, England.
EM a.stephanou@ich.ucl.ac.uk
RI Hubank, Michael/C-1837-2008; Cragg, Mark/E-5965-2010; Davidson,
   Sean/F-5275-2010
OI Hubank, Michael/0000-0002-2901-0742; Davidson, Sean/0000-0001-5182-4980;
   Cragg, Mark/0000-0003-2077-089X
CR Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401
   Abraham RT, 2002, NAT CELL BIOL, V4, pE277, DOI 10.1038/ncb1202-e277
   Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368
   Bartek J, 2003, CANCER CELL, V3, P421, DOI 10.1016/S1535-6108(03)00110-7
   Bromberg J, 2000, ONCOGENE, V19, P2468, DOI 10.1038/sj.onc.1203476
   Buscemi G, 2001, MOL CELL BIOL, V21, P5214, DOI 10.1128/MCB.21.15.5214-5222.2001
   Carson CT, 2003, EMBO J, V22, P6610, DOI 10.1093/emboj/cdg630
   Celeste A, 2003, NAT CELL BIOL, V5, P675, DOI 10.1038/ncb1004
   Chehab NH, 2000, GENE DEV, V14, P278
   D'Amours D, 2002, NAT REV MOL CELL BIO, V3, P317, DOI 10.1038/nrm805
   DiTullio RA, 2002, NAT CELL BIOL, V4, P998, DOI 10.1038/ncb892
   Durbin JE, 1996, CELL, V84, P443, DOI 10.1016/S0092-8674(00)81289-1
   Falck J, 2002, NAT GENET, V30, P290, DOI 10.1038/ng845
   Falck J, 2001, NATURE, V410, P842, DOI 10.1038/35071124
   FERNANDEZCAPETILLO, 2002, NAT CELL BIOL, V4, P993
   Foray N, 2003, EMBO J, V22, P2860, DOI 10.1093/emboj/cdg274
   Goldberg M, 2003, NATURE, V421, P952, DOI 10.1038/nature01445
   HIRAI Y, 2000, P 3 INT C AGR MACH E, V2, P287
   Huang M, 2000, COLD SPRING HARB SYM, V65, P413, DOI 10.1101/sqb.2000.65.413
   Ihle JN, 2001, CURR OPIN CELL BIOL, V13, P211, DOI 10.1016/S0955-0674(00)00199-X
   Janjua S, 2002, CELL DEATH DIFFER, V9, P1140, DOI 10.1038/sj.cdd.4401082
   Kaplan DH, 1998, P NATL ACAD SCI USA, V95, P7556, DOI 10.1073/pnas.95.13.7556
   Kumar A, 1997, SCIENCE, V278, P1630, DOI 10.1126/science.278.5343.1630
   Lee JH, 2004, SCIENCE, V304, P93, DOI 10.1126/science.1091496
   Levy DE, 2002, NAT REV MOL CELL BIO, V3, P651, DOI 10.1038/nrm909
   Lim DS, 2000, NATURE, V404, P613
   Lou ZK, 2003, NATURE, V421, P957, DOI 10.1038/nature01447
   MCKENDRY R, 1991, P NATL ACAD SCI USA, V88, P11455, DOI 10.1073/pnas.88.24.11455
   Melchionna R, 2000, NAT CELL BIOL, V2, P762
   Mochan TA, 2003, CANCER RES, V63, P8586
   Paddison PJ, 2002, GENE DEV, V16, P948, DOI 10.1101/gad.981002
   Peng AM, 2003, J BIOL CHEM, V278, P8873, DOI 10.1074/jbc.C300001200
   Schultz LB, 2000, J CELL BIOL, V151, P1381, DOI 10.1083/jcb.151.7.1381
   Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011
   Stephanou A, 2003, INT J EXP PATHOL, V84, P239, DOI 10.1111/j.0959-9673.2003.00363.x
   Stephanou A, 2002, FASEB J, V16, P1841, DOI 10.1096/fj.02-0150fje
   Stephanou A, 2001, J BIOL CHEM, V276, P28340, DOI 10.1074/jbc.M101177200
   Stephanou A, 2000, J BIOL CHEM, V275, P10002, DOI 10.1074/jbc.275.14.10002
   Stevens C, 2003, NAT CELL BIOL, V5, P401, DOI 10.1038/ncb974
   Stewart GS, 2003, NATURE, V421, P961, DOI 10.1038/nature01446
   Takai H, 2002, EMBO J, V21, P5195, DOI 10.1093/emboj/cdf506
   Toh GWL, 2003, BIOCHEM SOC T, V31, P242, DOI 10.1042/bst0310242
   Townsend PA, 2004, J BIOL CHEM, V279, P5811, DOI 10.1074/jbc.M302637200
   Turkson J, 2000, ONCOGENE, V19, P6613, DOI 10.1038/sj.onc.1204086
   Uziel T, 2003, EMBO J, V22, P5612, DOI 10.1093/emboj/cdg541
   Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864
   Wang B, 2002, SCIENCE, V298, P1435, DOI 10.1126/science.1076182
   Wu XL, 2003, J BIOL CHEM, V278, P36163, DOI 10.1074/jbc.M303795200
   Xu XZ, 2003, FASEB J, V17, P1842, DOI 10.1096/fj.03-0310com
   Yang ST, 2002, NAT CELL BIOL, V4, P865, DOI 10.1038/ncb869
   Yazdi PT, 2002, GENE DEV, V16, P571, DOI 10.1101/gad.970702
NR 51
TC 54
Z9 59
U1 2
U2 14
PU COMPANY OF BIOLOGISTS LTD
PI CAMBRIDGE
PA BIDDER BUILDING CAMBRIDGE COMMERCIAL PARK COWLEY RD, CAMBRIDGE CB4 4DL,
   CAMBS, ENGLAND
SN 0021-9533
EI 1477-9137
J9 J CELL SCI
JI J. Cell Sci.
PD APR 15
PY 2005
VL 118
IS 8
BP 1629
EP 1639
DI 10.1242/jcs.01726
PG 11
WC Cell Biology
SC Cell Biology
GA 925YL
UT WOS:000229089500009
PM 15784679
OA Bronze
DA 2018-12-27
ER

PT J
AU Suvardhan, K
   Kumar, KS
   Babu, SH
   Jayaraj, B
   Chiranjeevi, P
AF Suvardhan, K
   Kumar, KS
   Babu, SH
   Jayaraj, B
   Chiranjeevi, P
TI RETRACTED: Simultaneous flow-through determination of nitrites, nitrates
   and their mixtures in environmental and biological samples using
   spectrophotometry (Retracted Article. See vol 75, pg 1148, 2008)
SO TALANTA
LA English
DT Article; Retracted Publication
DE 4,4 '-methylene-bis-m-nitroaniline; nitrite ion; nitrate ion;
   spectrophotometry; water; soil; human serum and urine samples
ID INJECTION-ANALYSIS; NITROGEN-DIOXIDE; WATER; OXIDE
AB Newly synthesised 4,4'-methylene-bis-m-nitroaniline has been used to detect nitrites, nitrates, their mixtures in environmental and biological samples. The method is based on the reaction of nitrite with 4,4'-methylene-bis-m-nitroaniline in HCl medium and the concentration of diazonium salt formed, monitored through simultaneous flow by spectrophotometrically. The absorbance of the resultant red colored diazonium salt was measured at 495 nm and stable for more than 12 h. The determination of nitrates can be carried out by using the same reaction prior to reduction in a flow-through reductor column containing zinc dust coated polyurethane foam. The reaction and flow conditions of the full experimental design were optimised. The molar absorptivity and Sandell's sensitivity were found to be 7.5 x 10(4) 1 mol(-1) cm(-1) and 0.00062 mu g ml(-1). Detection limits for nitrite and nitrate were 0.10 and 0.12 mu g ml(-1), respectively. The detailed study of various interference made the confirmation of high selectivity of the method. The method was successfully applied to the determination of nitrites and nitrates in water, soil and biological samples. The results obtained were agreed with the reported methods at the 95% confidence level. (c) 2004 Elsevier B.V. All rights reserved.
C1 Sri Venkateswara Univ, Dept Chem, Environm Monitoring Lab, Tirupati 517502, Andhra Pradesh, India.
   Sri Venkateswara Univ, Dept Math, Tirupati 517502, Andhra Pradesh, India.
RP Chiranjeevi, P (reprint author), Sri Venkateswara Univ, Dept Chem, Environm Monitoring Lab, Tirupati 517502, Andhra Pradesh, India.
EM chiranjeevi_sai@yahoo.co.in
CR ALHATIM AA, 1990, INT J ENVIRON AN CH, V38, P617, DOI 10.1080/03067319008026964
   Brabcova M, 2003, ANAL LETT, V36, P2303, DOI 10.1081/AL-120023720
   Dong CZ, 2002, CHINESE J ANAL CHEM, V30, P1407
   FURCHGOTT RF, 1980, NATURE, V288, P373, DOI 10.1038/288373a0
   Gardolinski PCFC, 2002, TALANTA, V58, P1015, DOI 10.1016/S0039-9140(02)00425-3
   GERZER R, 1988, THROMB RES, V52, P11, DOI 10.1016/0049-3848(88)90036-9
   Hoshino M, 1996, J PHYS CHEM-US, V100, P13569, DOI 10.1021/jp9606873
   Icardo MC, 2001, ANALYST, V126, P1423, DOI 10.1039/b100109o
   JACOBS MB, 1958, ANAL CHEM, V30, P426, DOI 10.1021/ac60135a032
   KAUR P, 1987, J INDIAN CHEM SOC, V64, P428
   Legnerova Z, 2002, WATER RES, V36, P2777, DOI 10.1016/S0043-1354(01)00513-9
   Li JS, 2003, TALANTA, V61, P797, DOI 10.1016/S0039-9140(03)00380-1
   LIJINSKY W, 1970, NATURE, V21, P225
   MALINSKI T, 1993, BIOCHEM BIOPH RES CO, V194, P960, DOI 10.1006/bbrc.1993.1914
   MONCADA S, 1991, PHARMACOL REV, V43, P109
   Monser L, 2002, TALANTA, V57, P511, DOI 10.1016/S0039-9140(02)00057-7
   Monteiro MIC, 2003, ANAL CHIM ACTA, V477, P125, DOI 10.1016/S0003-2670(02)01395-8
   Moorcroft MJ, 2001, TALANTA, V54, P785, DOI 10.1016/S0039-9140(01)00323-X
   Nagaraja P, 2001, INT J ENVIRON AN CH, V80, P39, DOI 10.1080/03067310108044384
   NAIR SS, 1991, INT J ENVIRON AN CH, V44, P153, DOI 10.1080/03067319108027546
   NEMCOVA I, 1996, FORMATION NEW ORGANI, P193
   PATEL MS, 2003, ACTA CIENC INDICA, V29, P75
   PATTAY FA, 1963, IND HYGIENE TOXICOLO, P917
   RAMAN V, 1989, J INDIAN CHEM SOC, V66, P840
   RATHORE HPS, 1991, ANAL CHIM ACTA, V242, P225, DOI 10.1016/0003-2670(91)87068-I
   Revanasiddappa HD, 2001, FRESEN ENVIRON BULL, V10, P781
   SALTZMAN BE, 1954, ANAL CHEM, V26, P1949, DOI 10.1021/ac60096a025
   SCHUMAN EM, 1991, SCIENCE, V254, P1503, DOI 10.1126/science.1720572
   TARAFDER PK, 1988, ANALYST, V113, P1073, DOI 10.1039/an9881301073
   VESELY J, 1978, ANAL ION SELECTIVE E, P166
NR 30
TC 10
Z9 12
U1 3
U2 17
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0039-9140
EI 1873-3573
J9 TALANTA
JI Talanta
PD APR 15
PY 2005
VL 66
IS 2
BP 505
EP 512
DI 10.1016/j.talanta.2004.11.025
PG 8
WC Chemistry, Analytical
SC Chemistry
GA 929WR
UT WOS:000229377800023
PM 18970014
DA 2018-12-27
ER

PT J
AU Babu, SH
   Suvardhan, K
   Kumar, KS
   Reddy, KM
   Rekha, D
   Chiranjeevi, R
AF Babu, SH
   Suvardhan, K
   Kumar, KS
   Reddy, KM
   Rekha, D
   Chiranjeevi, R
TI RETRACTED: The facile flow-injection spectrophotometric detection of
   gold(III) in water and pharmaceutical samples using
   3,5-dimethoxy-4-hydroxy-2-aminoacetophenone isonicotinoyl hydrazone
   (3,5-DMHAAINH) (Retracted Article. See vol 152, pg 892, 2008)
SO JOURNAL OF HAZARDOUS MATERIALS
LA English
DT Article; Retracted Publication
DE 3.5-Dimethoxy-4-hydroxy-2-aminoacetophenone isonicotinoyl hydrazone
   (3,5-DMHAAINH); dimethyl formamide (DMF); Au(III); flow-injection
   spectrophotometer (FIA); water and pharmaceutical samples
ID GOLD
AB A simple, sensitive and rapid flow-injection spectrophotometric method was developed for the determination of trace amounts of Au(III) in aqueous dimethylformamide (DMF). The method is based on formation of Au(III)-(3,5-DMHAAINH)(3) complex. The optimum conditions for the chromogenic reaction of Au(III) with 3,5-DMHAAINH is studied and the colored (reddish brown) complex is selectively monitored at lambda(max) 490 nm at pH 6.0. The reaction and flow conditions of the full experimental design were optimized. The detection limit (2 s) of 0.1 mu g l(-1) Au(III) was obtained at a sampling rate of 15 samples h(-1). Beer's law is obeyed over the range of 0.30-4.00 mu g ml(-1). The molar absorptivity and Sandell's sensitivity were 3.450 x 10(4) M and 0.0050 mu g ml(-1), respectively. Job's method of continuous variation and stability constants corresponding to these maxima was determined and found to be 9.3 x 10(15) (1:3, M:R) (M, metal; R, reagent). The detailed study of various interferences confirmed the high selectivity of the developed method. The method was successfully applied for the determination of trace amount of Au(III) in water and pharmaceutical samples. The results obtained were in agreement with the reported methods at the 95% confidence level. (c) 2004 Elsevier B.V. All rights reserved.
C1 SV Univ, Dept Chem, Environm Monitoring Lab, Tirupati 517502, Andhra Pradesh, India.
RP Chiranjeevi, R (reprint author), SV Univ, Dept Chem, Environm Monitoring Lab, Tirupati 517502, Andhra Pradesh, India.
EM chiranjeevi_sai@yahoo.co.in
CR Bagheri M, 2003, TALANTA, V60, P839, DOI 10.1016/S0039-9140(03)00136-X
   BAI J, 1989, TAIYUVAN GANGYAE DAX, V20, P73
   BALEERZAK M, 1992, CHEM ANALILYCZNA, V37, P683
   BUBA P, 1987, FRESEN J ANAL CHEM, V329, P1850
   ELSAYED AAY, 1994, B CHEM SOC JPN, V67, P3216, DOI 10.1246/bcsj.67.3216
   ELZAWAWY FM, 1995, ANALYST, V120, P549, DOI 10.1039/an9952000549
   *EPA 60014 79 02, 1983, EPA600147902
   KABIL MA, 1994, FRESEN J ANAL CHEM, V349, P775, DOI 10.1007/BF00325658
   LI ZB, 1994, MIKROCHIM ACTA, V116, P219, DOI 10.1007/BF01260368
   LI ZB, 1998, FENXI KEXUE XUEBAO, V14, P305
   LI ZB, 1998, FENXI SHIYANSHI, V17, P8
   LIANG M, 1996, SHZNXI DAXUE XUEBAO, V19, P297
   LIANG MX, 1996, ZIRAN KEXUEBAN, V19, P297
   LIU S, 1988, YOUKUANGYE, V7, P24
   MA G, 1988, YEJINFENXI, V8, P52
   MARCZENKO Z, 1976, SPECTROPHOTOMETRIC D, P283
   Mori I, 1997, ANAL LETT, V30, P953
   PURI BK, 1987, ANAL CHEM, V59, P1850, DOI 10.1021/ac00141a025
   SAH PPT, 1954, J AM PHARM ASSOC SCI, V43, P513, DOI 10.1002/jps.3030430902
   WANG W, 1988, XUAXUE FEXIE, V24, P171
   XUE G, 1989, GUIJINSHU, V10, P40
   YIN S, 1988, FENXI SHIYANSHI, V7, P64
   YU Y, 1996, YOUKUANGYE, V15, P112
NR 23
TC 13
Z9 13
U1 2
U2 13
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0304-3894
EI 1873-3336
J9 J HAZARD MATER
JI J. Hazard. Mater.
PD APR 11
PY 2005
VL 120
IS 1-3
BP 213
EP 218
DI 10.1016/j.jhazmat.2005.01.004
PG 6
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA 920EM
UT WOS:000228672200027
PM 15811683
DA 2018-12-27
ER

PT J
AU Moon, HI
   Lee, J
   Eun, HC
   Kim, KH
   Chung, JH
AF Moon, HI
   Lee, J
   Eun, HC
   Kim, KH
   Chung, JH
TI RETRACTED: The effect of tiarellic acid on the expressions of matrix
   metalloproteinase-1 and type 1 procollagen in ultraviolet irradiated
   cultured human skin fibroblasts (Retracted Article. See vol 117, pg 181,
   2008)
SO JOURNAL OF ETHNOPHARMACOLOGY
LA English
DT Article; Retracted Publication
DE tiarellic acid; MMP-1; type I-procollagen; ultraviolet irradiation
ID POLYPHYLLA; GROWTH
AB Long term and repeated exposure of ultraviolet (UV) light, a harmful environmental stress, on the skin often induces chronic skin diseases such as skin cancer as well as photoaging (premature skin aging), and the mechanisms of these skin damages are closely associated with up-regulation of matrix metalloproteinases (MMI's) activities. Here we investigated the effect of tiarellic acid on the expressions of MMP-1 and type 1 procollagen in ultraviolet irradiation of cultured human skin fibroblasts. Tiarellic acid reduced the expression of MMP-1 and induced the expression of type 1- procollagen at the protein levels in a dose-dependent manner by ultraviolet irradiation. Taken together, our results suggest that tiarellic acid plays an important role in the reduction of MMP-1 and induction of type 1 - procollagen by ultraviolet irradiation. (c) 2005 Elsevier Ireland Ltd. All rights reserved.
C1 Seoul Natl Univ, Coll Med, Dept Dermatol, Seoul 110744, South Korea.
   Seoul Natl Univ Hosp, Clin Res Inst, Seoul 110744, South Korea.
   Korea Res Inst Biosci & Biotechnol, Taejon 305333, South Korea.
RP Moon, HI (reprint author), Seoul Natl Univ, Coll Med, Dept Dermatol, Youngon Dong, Seoul 110744, South Korea.
EM himun@snu.ac.kr; jhchung@snu.ac.kr
RI Kim, Kyu Han/E-7814-2012
OI Lee, Joongku/0000-0001-6250-3138
CR BERNHARD EJ, 1994, P NATL ACAD SCI USA, V91, P4293, DOI 10.1073/pnas.91.10.4293
   Chambers AF, 1997, J NATL CANCER I, V89, P1260, DOI 10.1093/jnci/89.17.1260
   Fisher GJ, 1996, NATURE, V379, P335, DOI 10.1038/379335a0
   GILCHREST BA, 1989, J AM ACAD DERMATOL, V21, P610, DOI 10.1016/S0190-9622(89)70227-9
   LEE Y, 1996, FLORA KOREA, P287
   MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4
   Park SH, 1999, ARCH PHARM RES, V22, P428, DOI 10.1007/BF02979071
   Park SH, 2002, ARCH PHARM RES, V25, P57, DOI 10.1007/BF02975262
   Seo JY, 2001, J INVEST DERMATOL, V116, P915, DOI 10.1046/j.1523-1747.2001.01358.x
   Varani J, 2000, J INVEST DERMATOL, V114, P480, DOI 10.1046/j.1523-1747.2000.00902.x
NR 10
TC 8
Z9 8
U1 2
U2 9
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0378-8741
J9 J ETHNOPHARMACOL
JI J. Ethnopharmacol.
PD APR 8
PY 2005
VL 98
IS 1-2
BP 185
EP 189
DI 10.1016/j.jep.2005.01.027
PG 5
WC Plant Sciences; Chemistry, Medicinal; Integrative & Complementary
   Medicine; Pharmacology & Pharmacy
SC Plant Sciences; Pharmacology & Pharmacy; Integrative & Complementary
   Medicine
GA 912XR
UT WOS:000228113700024
PM 15763381
DA 2018-12-27
ER

PT J
AU Al-Assar, O
   Crouch, DH
AF Al-Assar, Osama
   Crouch, Dorothy H.
TI RETRACTED: Inactivation of MAP kinase signalling in Myc transformed
   cells and rescue by LiCl inhibition of GSK3 (Retracted Article, See vol
   4, art. no. 17, 2005)
SO MOLECULAR CANCER
LA English
DT Article; Retracted Publication
ID GLYCOGEN-SYNTHASE KINASE-3-BETA; C-MYC; V-MYC; INDUCED APOPTOSIS;
   ACTIVATE RAF-1; TARGET GENES; DNA-BINDING; PROTEIN; PHOSPHORYLATION;
   PROLIFERATION
AB c-Myc oncogene is an important regulator of cell cycle and apoptosis, and its dysregulated expression is associated with many malignancies. Myc is instrumental in directly or indirectly regulating the progression through the G1 phase and G1/S transition, and transformation by Myc results in perturbed cell cycle. Also contributory to the control of G1 is the Ras effector pathway Raf/MEK/ERK MAP kinase. Together with GSK3, ERK plays an important role in the critical hierarchical phosphorylation of S62/T58 controlling Myc protein levels. Therefore, our main aim was to examine the levels of MAPK in Myc transformed cells in light of the roles of ERK in cell cycle and control of Myc protein levels. We found that active forms of ERK were barely detectable in v-Myc (MC29) transformed cells. Furthermore, we could only detect reduced levels of activated ERK in c-Myc transformed cells compared to the non-transformed primary chick embryo fibroblast cells. The addition of LiCl inhibited GSK3 and successfully restored the levels of ERK in v-Myc and c-Myc transformed cells to those found in non-transformed cells. In addition, LiCl stabilised Myc protein in the non-transformed and c-Myc transformed cells but not in v-Myc transformed cells. These results can provide an important insight into the role of MAPK in the mechanism of Myc induced transformation and carcinogenesis.
C1 Univ Dundee, Ninewells Hosp & Med Sch, Biomed Res Ctr, Dundee DD1 9SY, Scotland.
   Univ Sheffield, Sch Med, Inst Canc Studies, Div Genom Med, Sheffield S10 2RX, S Yorkshire, England.
RP Al-Assar, O (reprint author), Univ Dundee, Ninewells Hosp & Med Sch, Biomed Res Ctr, Dundee DD1 9SY, Scotland.
EM o.al-assar@sheffield.ac.uk; dhcrouch@dundee.ac.uk
CR AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0
   Bijur GN, 2000, J BIOL CHEM, V275, P7583, DOI 10.1074/jbc.275.11.7583
   Black EJ, 2002, ONCOGENE, V21, P6540, DOI 10.1038/sj.onc.1205851
   BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410
   Bouchard C, 1998, TRENDS CELL BIOL, V8, P202, DOI 10.1016/S0962-8924(98)01251-3
   Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000
   Clark W, 2000, MOL CELL BIOL, V20, P2529, DOI 10.1128/MCB.20.7.2529-2542.2000
   Dang CV, 1999, MOL CELL BIOL, V19, P1
   Fincham VJ, 2000, EMBO J, V19, P2911, DOI 10.1093/emboj/19.12.2911
   Flinn EM, 1998, MOL CELL BIOL, V18, P5961, DOI 10.1128/MCB.18.10.5961
   Gavine PR, 1999, ONCOGENE, V18, P7552, DOI 10.1038/sj.onc.1203102
   Gopalbhai K, 1998, J CELL PHYSIOL, V174, P35, DOI 10.1002/(SICI)1097-4652(199801)174:1<35::AID-JCP5>3.0.CO;2-H
   Gregory MA, 2003, J BIOL CHEM, V278, P51606, DOI 10.1074/jbc.M310722200
   Hancock JF, 2003, NAT REV MOL CELL BIO, V4, P373, DOI 10.1038/nrm1105
   Hetman M, 2002, J BIOL CHEM, V277, P49577, DOI 10.1074/jbc.M111227200
   Hunter T, 1997, CELL, V88, P333, DOI 10.1016/S0092-8674(00)81872-3
   KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0
   Kim JW, 2003, J BIOL CHEM, V278, P13995, DOI 10.1074/jbc.M300253200
   Kimmelman AC, 2000, ONCOGENE, V19, P2014, DOI 10.1038/sj.onc.1203530
   LAROCCA SA, 1994, ONCOGENE, V9, P3499
   Lee CM, 1999, ONCOGENE, V18, P2997, DOI 10.1038/sj.onc.1202786
   Lee HY, 2003, J BIOL CHEM, V278, P23630, DOI 10.1074/jbc.M300997200
   Levens DL, 2003, GENE DEV, V17, P1071, DOI 10.1101/gad.1095203
   LUTTERBACH B, 1994, MOL CELL BIOL, V14, P5510, DOI 10.1128/MCB.14.8.5510
   Lutterbach B, 1999, J CELL BIOCHEM, V72, P483, DOI 10.1002/(SICI)1097-4644(19990315)72:4<483::AID-JCB4>3.0.CO;2-I
   MCCARTHY SA, 1995, GENE DEV, V9, P1953, DOI 10.1101/gad.9.16.1953
   Menssen A, 2002, P NATL ACAD SCI USA, V99, P6274, DOI 10.1073/pnas.082005599
   Morgan MA, 2001, BLOOD, V97, P1823, DOI 10.1182/blood.V97.6.1823
   Nesbit CE, 1999, ONCOGENE, V18, P3004, DOI 10.1038/sj.onc.1202746
   Petropoulos CJ, 1996, ONCOGENE, V12, P2611
   PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A
   Sears R, 2000, GENE DEV, V14, P2501, DOI 10.1101/gad.836800
   Self AJ, 2001, J CELL SCI, V114, P1357
   Treinies I, 1999, MOL CELL BIOL, V19, P321
   Voice JK, 1999, J BIOL CHEM, V274, P17164, DOI 10.1074/jbc.274.24.17164
   Watson JD, 2002, J BIOL CHEM, V277, P36921, DOI 10.1074/jbc.M201493200
   Yan J, 1998, J BIOL CHEM, V273, P24052, DOI 10.1074/jbc.273.37.24052
   Zheng B, 2003, BLOOD, V102, P1019, DOI 10.1182/blood-2002-11-3507
NR 38
TC 4
Z9 5
U1 3
U2 9
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1476-4598
J9 MOL CANCER
JI Mol. Cancer
PD APR 5
PY 2005
VL 4
AR 13
DI 10.1186/1476-4598-4-13
PG 8
WC Biochemistry & Molecular Biology; Oncology
SC Biochemistry & Molecular Biology; Oncology
GA 076NA
UT WOS:000239963800001
PM 15811177
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Kiepiela, P
   Smith, AN
   Rosenberg, E
AF Kiepiela, P
   Smith, AN
   Rosenberg, E
TI RETRACTED: Laboratory markers associated with progression of HIV
   infection (Retracted Article. See vol 21, pg 883, 2007)
SO BEST PRACTICE & RESEARCH CLINICAL OBSTETRICS & GYNAECOLOGY
LA English
DT Article; Retracted Publication
DE HIV; AIDS; CD4 cells; beta 2-microglobulin; neopterin; p24 antigen; HIV
   RNA
ID HUMAN-IMMUNODEFICIENCY-VIRUS; SYNCYTIUM-INDUCING PHENOTYPE;
   IMMUNE-DEFICIENCY-SYNDROME; POLYMERASE-CHAIN-REACTION; HOMOSEXUAL MEN;
   BETA-2-MICROGLOBULIN LEVEL; SERUM BETA-2-MICROGLOBULIN; PROGNOSTIC
   VALUE; AIDS; TYPE-1
AB Infection with HIV may develop to AIDS at different rates in different individuals, with a spectrum varying from rapid progression to long-term non-progression. The variable course of HIV-1 infection causes emotional trauma for the infected person and complicates the design and interpretation of therapeutic trials because of unrecognized differences in prognosis. Owing to the variable clinical expression of HIV infection, the use of non-clinical disease markers has become important to patient management. Thus, it is essential to have tests which can accurately assess the stage of infection in an individual, as well as predict its course and monitor its progression. These laboratory tests are valuable during the period of clinical latency and subsequently supplement various clinical parameters.
C1 Univ Kwazulu Natal, Nelson R Mandela Sch Med, HIV Pathogenesis Programme, DDMRI, ZA-4013 Congella, South Africa.
RP Kiepiela, P (reprint author), Univ Kwazulu Natal, Nelson R Mandela Sch Med, HIV Pathogenesis Programme, DDMRI, 719 Umbilo Rd, ZA-4013 Congella, South Africa.
EM kiepiela@ukzn.ac.za
CR Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955
   ALLAIN JP, 1987, NEW ENGL J MED, V317, P1114, DOI 10.1056/NEJM198710293171804
   Altfeld M, 2003, AIDS, V17, P2581, DOI 10.1097/01.aids.0000096870.36052.b6
   ANDERSON RE, 1990, ARCH INTERN MED, V150, P73, DOI 10.1001/archinte.150.1.73
   AUCOUTURIER P, 1986, CLIN EXP IMMUNOL, V63, P234
   BLATT SP, 1993, ANN INTERN MED, V119, P177, DOI 10.7326/0003-4819-119-3-199308010-00001
   BURCHAM J, 1991, AIDS, V5, P365, DOI 10.1097/00002030-199104000-00002
   Centers for Disease Control (CDC), 1989, MMWR Suppl, V38, P1
   CORUPOTIN C, 1990, 6 INT C AIDS SAN FRA
   Dar L, 1999, LAB TESTS MONITORING, P114
   DEWOLF F, 1987, BMJ-BRIT MED J, V295, P569, DOI 10.1136/bmj.295.6598.569
   Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0
   DWYER DE, 1997, MANAGING HIV, P59
   EYSTER ME, 1989, ANN INTERN MED, V110, P963, DOI 10.7326/0003-4819-110-12-963
   FAHEY JL, 1990, NEW ENGL J MED, V322, P166, DOI 10.1056/NEJM199001183220305
   Fauci AS, 1998, HASRRISONS PRINCIPLE, P1816
   Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872
   GIORGI JV, 2001, J ACQ IMMUN DEF SYND, V29, P346
   GOUDSMIT J, 1986, LANCET, V2, P177
   Hecht FM, 2002, AIDS, V16, P1119, DOI 10.1097/00002030-200205240-00005
   HOFMANN B, 1990, AIDS, V4, P207, DOI 10.1097/00002030-199003000-00005
   HOLODNIY M, 1991, J CLIN INVEST, V88, P1755, DOI 10.1172/JCI115494
   *IAS US, IAS US GUID US ANT A
   JACKSO JB, 1998, CLIN MICROB REV, V1, P124
   Kahn JO, 1998, NEW ENGL J MED, V339, P33, DOI 10.1056/NEJM199807023390107
   KASLOW RA, 1990, LANCET, V335, P927, DOI 10.1016/0140-6736(90)90995-H
   KATZENSTEIN DA, 1994, J INFECT DIS, V169, P416, DOI 10.1093/infdis/169.2.416
   KOOT M, 1993, ANN INTERN MED, V118, P681, DOI 10.7326/0003-4819-118-9-199305010-00004
   KOZAL MJ, 1994, J ACQ IMMUN DEF SYND, V7, P832
   LIFSON AR, 1992, LANCET, V339, P1436, DOI 10.1016/0140-6736(92)92030-J
   Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5
   Mellors JW, 1996, SCIENCE, V272, P1167, DOI 10.1126/science.272.5265.1167
   MELLORS JW, 1995, ANN INTERN MED, V122, P573, DOI 10.7326/0003-4819-122-8-199504150-00003
   MOSS AR, 1988, BRIT MED J, V296, P745, DOI 10.1136/bmj.296.6624.745
   MUNOZ A, 1989, AM J EPIDEMIOL, V130, P530, DOI 10.1093/oxfordjournals.aje.a115367
   Paxton WA, 1996, NAT MED, V2, P412, DOI 10.1038/nm0496-412
   PEDERSEN C, 1987, BRIT MED J, V295, P567, DOI 10.1136/bmj.295.6598.567
   PHAIR J, 1992, J ACQ IMMUN DEF SYND, V5, P490
   PHAIR J, 1990, NEW ENGL J MED, V322, P161, DOI 10.1056/NEJM199001183220304
   Quin JW, 1994, COULD IT BE HIV, P66
   REDFIELD RR, 1986, NEW ENGL J MED, V314, P131, DOI 10.1056/NEJM198601093140232
   RETEROVIRIDAE AB, 1999, TXB MICROBIOLOGY, P439
   Saag MS, 1996, NAT MED, V2, P625, DOI 10.1038/nm0696-625
   SETH P, 1996, P IND US CME DEC 28, P35
   SHAFER RW, 2004, GENOTYPIC TESTING HI
   SHEPPARD HW, 1993, AIDS, V7, P1159, DOI 10.1097/00002030-199309000-00002
   TERSMETTE M, 1993, AIDS, V7, P1123, DOI 10.1097/00002030-199308000-00016
   TSOUKAS CM, 1994, CLIN MICROBIOL REV, V7, P14
   Volberding PA, 1996, LANCET, V347, P71, DOI 10.1016/S0140-6736(96)90205-6
   WEBSTER A, 1989, LANCET, V2, P63
   1992, DGHS, V1, P1
NR 51
TC 7
Z9 8
U1 2
U2 9
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1521-6934
EI 1532-1932
J9 BEST PRACT RES CL OB
JI Best Pract. Res. Clin. Obstet. Gynaecol.
PD APR
PY 2005
VL 19
IS 2
BP 243
EP 254
DI 10.1016/j.bpobgyn.2004.11.002
PG 12
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA 915RI
UT WOS:000228321300007
PM 15778113
DA 2018-12-27
ER

PT J
AU Russo, P
   Catassi, A
   Malacarne, D
   Margaritora, S
   Cesario, A
   Festi, L
   Mule, A
   Ferri, L
   Granone, P
AF Russo, P
   Catassi, A
   Malacarne, D
   Margaritora, S
   Cesario, A
   Festi, L
   Mule, A
   Ferri, L
   Granone, P
TI RETRACTED: Tumor necrosis factor enhances SN38-mediated apoptosis in
   mesothelioma cells - The role of nuclear factor-kappa B pathway
   activation (Retracted Article. See vol 116, pg 2285, 2010)
SO CANCER
LA English
DT Article; Retracted Publication
DE malignant pleural mesothelioma; tumor necrosis factor; camptothecin;
   apoptosis; nuclear factor-kappa B; survival; BCL-XL; caspase 3; DNA
   damage; cell cycle
ID MALIGNANT PLEURAL MESOTHELIOMA; CANCER-THERAPY RESISTANCE; DNA STRAND
   BREAKAGE; FACTOR-ALPHA; INDUCIBLE CHEMORESISTANCE; MICHAELIS-MENTEN;
   KINETIC SYSTEMS; TOPOISOMERASE-I; INHIBITION; P53
AB BACKGROUND. Despite the best and most aggressive, often integrated, standard therapeutic approaches for mesothelioma, overall survival remains very poor. The actual failure points out clearly the need for the development of novel therapy. One of the promising paths of experimentation is artificial induction of apoptosis. A therapeutic strategy that relies on the down-regulation of BCL-XL inhibition nuclear factor kappa B (NF-kappa B) with a combination of SN38 and tumor necrosis factor (TNF) was studied in human mesothelioma cell lines (MSTO-221H, IST-MES1, IST-MES2, MPP89, H28, H513, H2052, and H290).
   METHODS AND RESULTS. Cell proliferation (clonogenic assay) was inhibited strongly by the combination of TNF and SN38. Examining the persistence of the NF-kappa B complexes using an electrophoretic mobility-shift assay, it appeared that they still were present at 24 hours in TNF-treated cells. In SN38-treated cells, NF-kappa B complexes persisted for 6 hours. In cells that were treated with combined SN38 and TNF, NF-kappa B complexes disappeared quickly and became undetectable at 6 hours. In flow cytometry analysis, only cells that were treated with combined SN38 and TNF demonstrated significant cellular accumulation in the sub-GO-G, phase, suggesting a specific induction of apoptosis. Morphologic examination (4,6-diamidino-2-phenylindole staining and electron microscopy) and internucleosomal DNA fragmentation (gel ladder) confirmed rigorously the induction of apoptosis.
   CONCLUSIONS. Because of NF-kappa B inhibition with the combination of SN38 and TNF, the expression of BCL-XL (both the protein [Western blot analysis] and the mRNA [reverse transcriptase-polymerase chain reaction analysis]) was down-regulated, cytochrome c was released into the cytoplasm, caspase 3 was activated (Western blot analysis), and, consequently, apoptosis was triggered. The authors hope that the results of the current study may contribute to the design and implementation of a novel therapeutic approach that improves patients' responses to treatment for mesothelioma. (c) 2005 American Cancer Society.
C1 Natl Canc Inst, Dept Integrated Med Oncol, Lab Translat Res B Lung Canc, I-16132 Genoa, Italy.
   Univ Cattolica Sacro Cuore, Dept Surg Sci, Div Gen Thorac Surg, I-00168 Rome, Italy.
   Univ Genoa, Dept Biol, DIBIO, Genoa, Italy.
   IRCCS San Raffaele, Pulm Rehabil, Rome, Italy.
   Insubria Univ, Div Thorac Surg, Varese, Italy.
   Univ Cattolica Sacro Cuore, Dept Pathol, I-00168 Rome, Italy.
RP Russo, P (reprint author), Natl Canc Inst, Dept Integrated Med Oncol, Lab Translat Res B Lung Canc, Largo Rosanna Bensi 10, I-16132 Genoa, Italy.
EM patrizia.russo@istge.it
RI CESARIO, Alfredo/O-4215-2015
OI CESARIO, Alfredo/0000-0003-4687-0709
CR Amundson SA, 2000, CANCER RES, V60, P6101
   Baldwin AS, 2001, J CLIN INVEST, V107, P241, DOI 10.1172/JCI11991
   BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0
   Carbone M, 2003, VIROLOGY, V315, P409, DOI 10.1016/S0042-6822(03)00547-6
   Carbone M, 2002, SEMIN ONCOL, V29, P2, DOI 10.1053/sonc.2002.30227
   Carson JP, 2004, CANCER RES, V64, P2096, DOI 10.1158/0008-5472.CAN-03-2029
   Cesario A, 2004, LANCET ONCOL, V5, P591, DOI 10.1016/S1470-2045(04)01590-6
   Chen CL, 2000, MOL CELL BIOL, V20, P2687, DOI 10.1128/MCB.20.8.2687-2695.2000
   CHENG JQ, 1994, CANCER RES, V54, P5547
   CHOU TC, 1981, EUR J BIOCHEM, V115, P207, DOI 10.1111/j.1432-1033.1981.tb06218.x
   CHOU TC, 1977, J BIOL CHEM, V252, P6438
   Cusack JC, 2001, CANCER RES, V61, P3535
   Cusack JC, 2000, CANCER RES, V60, P2323
   DelMastro L, 1995, ANTICANCER RES, V15, P2207
   Fennell DA, 2004, LANCET ONCOL, V5, P354, DOI 10.1016/S1470-2045(04)01492-5
   Garcia-Carbonero R, 2002, CLIN CANCER RES, V8, P641
   Hirao T, 2002, CARCINOGENESIS, V23, P1127, DOI 10.1093/carcin/23.7.1127
   Hirte HW, 1997, GYNECOL ONCOL, V64, P80, DOI 10.1006/gyno.1996.4529
   Huang TT, 2000, J BIOL CHEM, V275, P9501, DOI 10.1074/jbc.275.13.9501
   Korsmeyer SJ, 1999, CANCER RES, V59, p1693S
   Lloyd AC, 2000, NAT CELL BIOL, V2, pE48, DOI 10.1038/35004078
   Maksymiuk AW, 1998, AM J CLIN ONCOL-CANC, V21, P610, DOI 10.1097/00000421-199812000-00017
   Mayo MW, 2000, BBA-REV CANCER, V1470, pM55, DOI 10.1016/S0304-419X(00)00002-0
   Mor O, 1997, AM J RESP CELL MOL, V16, P9, DOI 10.1165/ajrcmb.16.1.8998073
   Nakano T, 1999, CANCER, V85, P2375, DOI 10.1002/(SICI)1097-0142(19990601)85:11<2375::AID-CNCR12>3.3.CO;2-5
   Narasimhan SR, 1998, AM J PHYSIOL-LUNG C, V275, pL165, DOI 10.1152/ajplung.1998.275.1.L165
   ORENGO G, 1992, JPN J CANCER RES, V83, P1132, DOI 10.1111/j.1349-7006.1992.tb02735.x
   Pommier Y, 2004, ONCOGENE, V23, P2934, DOI 10.1038/sj.onc.1207515
   Pourquier P, 2001, ADV CANCER RES, V80, P189, DOI 10.1016/S0065-230X(01)80016-6
   Schmitt CA, 1999, GENE DEV, V13, P2670, DOI 10.1101/gad.13.20.2670
   Shukla S, 2004, CLIN CANCER RES, V10, P3169, DOI 10.1158/1078-0432.CCR-03-0586
   Soini Y, 1999, CLIN CANCER RES, V5, P3508
   Stam TC, 2000, EUR J CLIN INVEST, V30, P336
   Tomek S, 2003, BRIT J CANCER, V88, P167, DOI 10.1038/sj.bjc.6600673
   Trombino S, 2004, CANCER RES, V64, P135, DOI 10.1158/0008-5472.CAN-03-1672
   UTSUGI T, 1990, CANCER RES, V50, P2636
   Valente P, 2003, EUR J CANCER, V39, P1468, DOI 10.1016/S0959-8049(03)00301-0
   Vikhanskaya F, 2002, INT J CANCER, V97, P732, DOI 10.1002/ijc.10114
   Wang CY, 1999, NAT MED, V5, P412
   Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680
   Yang CT, 2000, J NATL CANCER I, V92, P636, DOI 10.1093/jnci/92.8.636
   Yang CT, 2001, CANCER RES, V61, P5959
NR 42
TC 15
Z9 16
U1 3
U2 12
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0008-543X
EI 1097-0142
J9 CANCER-AM CANCER SOC
JI Cancer
PD APR 1
PY 2005
VL 103
IS 7
BP 1503
EP 1518
DI 10.1002/cncr.20924
PG 16
WC Oncology
SC Oncology
GA 908EO
UT WOS:000227770400025
PM 15700263
OA Bronze
DA 2018-12-27
ER

PT J
AU Gali-Muhtasib, HU
   Diab-Assaf, M
   Haddadin, MJ
AF Gali-Muhtasib, HU
   Diab-Assaf, M
   Haddadin, MJ
TI RETRACTED: Quinoxaline 1,4-dioxides induce G(2)/M cell cycle arrest and
   apoptosis in human colon cancer cells (Retracted article. See vol. 81,
   pg. 627, 2018)
SO CANCER CHEMOTHERAPY AND PHARMACOLOGY
LA English
DT Article; Retracted Publication
DE anticancer therapy; extracellular signal-regulated kinase;
   mitogen-activated protein kinases; transforming growth factor
ID GROWTH-FACTOR-BETA; ACTIVATED PROTEIN-KINASES; MEDIATED APOPTOSIS;
   CARCINOMA CELLS; IN-VIVO; DIFFERENTIATION; PATHWAY; ERK; DRUGS;
   INHIBITION
AB We have recently shown that quinoxaline 1,4-dioxide (QdNO) derivatives, namely 2-benzoyl-3phenyl-6,7-dichloroquinoxaline 1,4-dioxide (DCQ), 2-benzoyl-3-phenyl-quinoxaline 1,4-dioxide (BPQ) and 2-acetyl-3-methyl-quinoxaline 1,4-dioxide (AMQ), suppress the growth of T-84 human colon cancer cells. Here we show that the growth-suppressive effects of QdNOs are due to their ability to induce cell cycle arrest and/or apoptosis. While AMQ blocked more than 60% of cells at the G(2)/M phase without inducing apoptosis, DCQ caused a significant increase in apoptotic cells with no noticeable effects on the cycling of cells. Treatment with BPQ resulted in G2/M cell cycle arrest and induction of apoptosis. With regard to the effects of QdNOs on molecules that regulate apoptosis and the G(2) to M transition, both BPQ and AMQ inhibited the expression of cyclin B, while DCQ significantly decreased the levels of l3cl-2 and increased Bax expression. Next, we investigated whether transforming growth factor-betal (TGF-beta 1) and/or extracellular signal-regulated kinase (ERK) mediate the antiproliferative and apoptotic effects of QdNOs in colon cancer cells. Interestingly, the above QdNOs increased differentially total TGF beta 1 mRNA expression and decreased TGF alpha mRNA and ERK phosphorylation. None of these QdNOs induced changes in TGF beta-2 mRNA expression. The addition of a specific inhibitor of MEK greatly enhanced apoptosis in cells treated with DCQ, suggesting that the inhibition of ERK phosphorylation may explain, to an extent, the apoptogenic effects of this compound. Taken together, these findings provide insights into possible molecular mechanisms of growth inhibition by QdNOs that could aid in their evaluation for anticancer therapy.
C1 Amer Univ Beirut, Dept Biol, Beirut, Lebanon.
   Amer Univ Beirut, Dept Chem, Beirut, Lebanon.
RP Gali-Muhtasib, HU (reprint author), Amer Univ Beirut, Dept Biol, Beirut, Lebanon.
EM amro@aub.edu.lb
CR Akhurst RJ, 2002, J CLIN INVEST, V109, P1533, DOI 10.1172/JCI200215970
   ALEXANDROW MG, 1995, CANCER RES, V55, P1452
   Bennett AM, 1997, SCIENCE, V278, P1288, DOI 10.1126/science.278.5341.1288
   Biasi F, 2002, GUT, V50, P361, DOI 10.1136/gut.50.3.361
   Carnesecchi S, 2002, J PHARMACOL EXP THER, V303, P711, DOI 10.1124/jpet.102.039263
   Diab-Assef M, 2002, MOL CARCINOGEN, V33, P198, DOI 10.1002/mc.10036
   Frey RS, 1997, CANCER RES, V57, P628
   Gali-Muhtasib HU, 2001, ONCOL REP, V8, P679
   Gredinger E, 1998, J BIOL CHEM, V273, P10436, DOI 10.1074/jbc.273.17.10436
   Guda K, 2001, MOL CARCINOGEN, V31, P204, DOI 10.1002/mc.1055
   HADDADIN MJ, 1993, HETEROCYCLES, V35, P1503
   Hagimoto N, 2002, J IMMUNOL, V168, P6470, DOI 10.4049/jimmunol.168.12.6470
   HENNESSEY TD, 1972, VET REC, V90, P187, DOI 10.1136/vr.90.7.187
   Hoshino R, 1999, ONCOGENE, V18, P813, DOI 10.1038/sj.onc.1202367
   Kim BC, 2002, MOL CELL BIOL, V22, P1369, DOI 10.1128/MCB.22.5.1369-1378.2002
   Licato LL, 1997, GASTROENTEROLOGY, V113, P1589, DOI 10.1053/gast.1997.v113.pm9352861
   MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8
   MURTHY U, 1989, INT J CANCER, V44, P110, DOI 10.1002/ijc.2910440120
   Orlowski RZ, 2002, J BIOL CHEM, V277, P27864, DOI 10.1074/jbc.M201519200
   Plattner R, 1999, ONCOGENE, V18, P1807, DOI 10.1038/sj.onc.1202482
   Priyadarsini KI, 1996, J AM CHEM SOC, V118, P5648, DOI 10.1021/ja953761o
   Qiao D, 2001, CARCINOGENESIS, V22, P35, DOI 10.1093/carcin/22.1.35
   Reed JC, 1998, ONCOGENE, V17, P3225
   Rice PL, 2001, CANCER RES, V61, P1541
   Sebolt-Leopold JS, 1999, NAT MED, V5, P810, DOI 10.1038/10533
   Sebolt-Leopold JS, 2000, ONCOGENE, V19, P6594, DOI 10.1038/sj.onc.1204083
   Taupin D, 1999, GASTROENTEROLOGY, V116, P1072, DOI 10.1016/S0016-5085(99)70010-7
   Wang DG, 2002, ONCOGENE, V21, P2785, DOI 10.1038/sj/onc/1205375
   Wilson DJ, 1999, CELL IMMUNOL, V194, P67, DOI 10.1006/cimm.1999.1486
   XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326
   Yan ZF, 2001, J BIOL CHEM, V276, P1555, DOI 10.1074/jbc.M004553200
   Yang GH, 2000, TOXICOL APPL PHARM, V164, P149, DOI 10.1006/taap.1999.8888
   Yen A, 1998, CANCER RES, V58, P3163
NR 33
TC 25
Z9 26
U1 1
U2 2
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0344-5704
EI 1432-0843
J9 CANCER CHEMOTH PHARM
JI Cancer Chemother. Pharmacol.
PD APR
PY 2005
VL 55
IS 4
BP 369
EP 378
DI 10.1007/s00280-004-0907-x
PG 10
WC Oncology; Pharmacology & Pharmacy
SC Oncology; Pharmacology & Pharmacy
GA 906VB
UT WOS:000227671100009
PM 15538569
DA 2018-12-27
ER

PT J
AU Keller, P
   Penkowa, M
   Keller, C
   Steensberg, A
   Fischer, CP
   Giralt, M
   Hidalgo, J
   Pedersen, BK
AF Keller, P
   Penkowa, M
   Keller, C
   Steensberg, A
   Fischer, CP
   Giralt, M
   Hidalgo, J
   Pedersen, BK
TI RETRACTED: Interleukin-6 receptor expression in contracting human
   skeletal muscle: regulating role of IL-6 (Retracted article. See vol.
   28, pg. 1526, 2014)
SO FASEB JOURNAL
LA English
DT Article; Retracted Publication
DE gp130; exercise; rhIL-6 infusion; mouse; IL-6 KO
ID MESSENGER-RNA EXPRESSION; SIGNAL TRANSDUCER GP130;
   NECROSIS-FACTOR-ALPHA; IN-VIVO; TRANSCRIPTIONAL REGULATION; AUTOCRINE
   REGULATION; GENE-EXPRESSION; TRANSGENIC MICE; SOLUBLE IL-6; HALF-LIFE
AB Contracting muscle fibers produce and release IL-6, and plasma levels of this cytokine are markedly elevated in response to physical exercise. We recently showed autocrine regulation of IL-6 in human skeletal muscle in vivo and hypothesized that this may involve up-regulation of the IL-6 receptor. Therefore, we investigated IL-6 receptor regulation in response to exercise and IL-6 infusion in humans. Furthermore, using IL-6-deficient mice, we investigated the role of IL-6 in the IL-6 receptor response to exercise. Human skeletal muscle biopsies were obtained in relation to: 3 h of bicycle exercise and rest (n=6+5), or recombinant human IL-6 infusion (rhIL-6) or saline infusion (n=6+6). We further obtained skeletal muscle samples from IL-6 knockout (KO) mice and wild-type C57/BL-6 mice in response to a I-h bout of exercise. In exercising human skeletal muscle, IL-6 receptor mRNA increased sixfold with a peak at 6 h postexercise. Detection of the IL-6 receptor protein by immunohistochemistry revealed a pronounced staining following exercise that was primarily located at the cell membrane of the muscle fibers, whereas muscle gp130 expression and plasma levels of soluble IL-6 receptor were unaffected. Infusion of rhIL-6 to humans had no effect on the mRNA level of the IL-6 receptor, whereas there was an increase at the protein level. IL-6 receptor mRNA increased similarly in muscle of both IL-6 KO mice and wild-type mice in response to exercise. In conclusion, exercise increases IL-6 receptor production in human skeletal muscle. This effect is most prominent 6 h after the end of the exercise bout, suggesting a postexercise-sensitizing mechanism to IL-6 when plasma IL-6 is concomitantly low. Exercise-induced increases in IL-6 receptor mRNA most likely occurs via an IL-6 independent mechanism as shown in IL-6 KO mice and the human rhIL-6 infusion study, whereas IL-6 receptor protein levels are responsive to elevated plasma IL-6 levels.
C1 Univ Copenhagen Hosp, Dept Infect Dis, Ctr Inflammat & Metab, Copenhagen, Denmark.
   Univ Copenhagen Hosp, Copenhagen Muscle Res Ctr, Copenhagen, Denmark.
   Univ Copenhagen, Panum Inst, Dept Med Anat, DK-2200 Copenhagen, Denmark.
   Autonomous Univ Barcelona, Fac Sci, Anim Physiol Unit, E-08193 Barcelona, Spain.
RP Keller, P (reprint author), Univ Hosp, Rigshosp, Dept Infect Dis, Tagensvej 20, DK-2200 Copenhagen, Denmark.
EM pernillekeller@yahoo.com
RI Giralt, Mercedes/K-1626-2014
OI Giralt, Mercedes/0000-0002-1806-1528; Fischer,
   Christian/0000-0002-0657-9143; Hidalgo, Juan/0000-0003-0921-1122
CR BAUER J, 1989, J EXP MED, V170, P1537, DOI 10.1084/jem.170.5.1537
   Bruunsgaard H, 2004, EXP GERONTOL, V39, P255, DOI 10.1016/j.exger.2003.10.012
   CASTELL JV, 1988, EUR J BIOCHEM, V177, P357, DOI 10.1111/j.1432-1033.1988.tb14384.x
   Fasshauer M, 2003, HORM METAB RES, V35, P147, DOI 10.1055/s-2003-39075
   Febbraio MA, 2003, J PHYSIOL-LONDON, V549, P607, DOI 10.1113/jphysiol.2003.042374
   Franchimont N, 1997, J CLIN INVEST, V100, P1797, DOI 10.1172/JCI119707
   Fried SK, 1998, J CLIN ENDOCR METAB, V83, P847, DOI 10.1210/jc.83.3.847
   GEISTERFER M, 1995, CYTOKINE, V7, P503, DOI 10.1006/cyto.1995.0068
   GERHARTZ C, 1994, EUR J BIOCHEM, V223, P265, DOI 10.1111/j.1432-1033.1994.tb18991.x
   Hiscock N, 2004, FASEB J, V18, P992, DOI 10.1096/fj.03-1259fje
   KELLER C, 2001, FASEB J, V15, pU4
   Keller P, 2004, J APPL PHYSIOL, V97, P1309, DOI 10.1152/japplphysiol.00284.2004
   Keller P, 2003, BIOCHEM BIOPH RES CO, V310, P550, DOI 10.1016/j.bbrc.2003.09.048
   Klouche M, 1999, J IMMUNOL, V163, P4583
   Kubaszek A, 2003, DIABETES, V52, P558, DOI 10.2337/diabetes.52.2.558
   LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872
   Mohamed-Ali V, 1997, J CLIN ENDOCR METAB, V82, P4196, DOI 10.1210/jc.82.12.4196
   MULLBERG J, 1993, EUR J IMMUNOL, V23, P473
   MullerNewen G, 1996, EUR J BIOCHEM, V236, P837, DOI 10.1111/j.1432-1033.1996.00837.x
   Ostrowski K, 1998, J PHYSIOL-LONDON, V513, P889, DOI 10.1111/j.1469-7793.1998.889ba.x
   Path G, 2001, J CLIN ENDOCR METAB, V86, P2281, DOI 10.1210/jc.86.5.2281
   Penkowa M, 2003, FASEB J, V17, DOI 10.1096/fj.03-0311fje
   Peters M, 1996, J EXP MED, V183, P1399, DOI 10.1084/jem.183.4.1399
   Peters M, 1997, J EXP MED, V185, P755, DOI 10.1084/jem.185.4.755
   Pilegaard H, 2000, AM J PHYSIOL-ENDOC M, V279, pE806
   SAITO M, 1992, J IMMUNOL, V148, P4066
   STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873
   Steensberg A, 2000, J PHYSIOL-LONDON, V529, P237, DOI 10.1111/j.1469-7793.2000.00237.x
   TAGA T, 1989, CELL, V58, P573, DOI 10.1016/0092-8674(89)90438-8
   TAKIZAWA H, 1996, AM J PHYSIOL-LUNG C, V14, pL346
   Terry CF, 2000, J BIOL CHEM, V275, P18138, DOI 10.1074/jbc.M000379200
   Thabard W, 2001, CYTOKINE, V14, P352, DOI 10.1006/cyto.2001.0911
   van Hall G, 2003, J CLIN ENDOCR METAB, V88, P3005, DOI 10.1210/jc.2002-021687
   Van Wagoner NJ, 1999, J NEUROSCI, V19, P5236
   Vionnet N, 2000, AM J HUM GENET, V67, P1470, DOI 10.1086/316887
   Wallenius V, 2002, NAT MED, V8, P75, DOI 10.1038/nm0102-75
   Wolford JK, 2003, MOL GENET METAB, V80, P338, DOI 10.1016/j.ymgme.2003.07.003
   Zhang Y, 2000, AM J PHYSIOL-ENDOC M, V279, pE196
   ZOHLNHOFER D, 1992, FEBS LETT, V306, P219, DOI 10.1016/0014-5793(92)81004-6
NR 39
TC 57
Z9 60
U1 3
U2 10
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
EI 1530-6860
J9 FASEB J
JI Faseb J.
PD APR
PY 2005
VL 19
IS 6
BP 1181
EP +
DI 10.1096/fj.04-3278fje
PG 19
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
   Topics; Cell Biology
GA 922UP
UT WOS:000228865300013
PM 15837717
DA 2018-12-27
ER

PT J
AU Saeed, M
   Saleheen, D
   Siddiqui, S
   Khan, A
   Butt, ZA
   Frossard, PM
AF Saeed, M
   Saleheen, D
   Siddiqui, S
   Khan, A
   Butt, ZA
   Frossard, PM
TI RETRACTED: Association of angiotensin converting enzyme gene
   polymorphisms with left ventricular hypertrophy (Retracted article. See
   vol. 32, pg. 423, 2009)
SO HYPERTENSION RESEARCH
LA English
DT Article; Retracted Publication
DE angiotensin-coverting enzyme; genetics; left ventricular hypertrophy;
   polymorphisms
ID ESSENTIAL-HYPERTENSION; RENIN-ANGIOTENSIN; BLOOD-PRESSURE; DELETION
   POLYMORPHISM; MASS; POPULATION; JAPANESE; LINKAGE; SYSTEM;
   DISEQUILIBRIUM
AB The angiotensin converting enzyme gene (ACE) is of much interest as a candidate gene conferring an individual's genetic susceptibility to left ventricular hypertrophy (LVH). LVH has long been thought to be an end point of essential hypertension (EH), rather than a separate entity, though it is influenced by a unique set of hormonal, vascular and genetic factors. In this study, we attempted to determine whether two representative polymorphisms of the ACE gene, ACE I/D and 2350 G > A, known to be associated with EH and to have a highly significant influence on plasma ACE levels, could implicate ACE as a quantitative trait locus (QTL) for LVH. We carried out a retrospective, case-control study of the two ACE polymorphisms amongst 180 nationals (50 LVH patients and 130 controls) from the United Arab Emirates (Emirati)-an ethnic group characterized by an absence of alcohol intake and cigarette smoking-for putative correlations with LVH. Clinical diagnoses of LVH were based on echocardiographic and ECG criteria. ACE I/D and 2350 G > A genotypes were determined by polymerase chain reaction (PCR) and restriction digestion. Univariate and multivariate logistic regression analyses revealed an association between ACE polymorphisms and LVH. Haplotype analysis further supported this finding. The ACE I/D and ACE 2350 G > A polymorphisms were in strong linkage disequilibrium and were independently associated with LVH, suggesting that ACE is likely to be a QTL for LVH. In conclusion, This is the first association study of the ACE 2350 G > A polymorphism with LVH; the results showed that this polymorphism, along with ACE I/D, is associated with LVH.
C1 Aga Khan Univ, Dept Biol & Biomed Sci, Karachi 74800, Pakistan.
RP Frossard, PM (reprint author), Aga Khan Univ, Dept Biol & Biomed Sci, Stadium Rd,POB 3500, Karachi 74800, Pakistan.
EM philippe.frossard@aku.edu
CR CAMBIEN F, 1992, NATURE, V359, P641, DOI 10.1038/359641a0
   Dang AM, 1999, HYPERTENS RES-CLIN E, V22, P217, DOI 10.1291/hypres.22.217
   DRAYER JIM, 1983, ARCH INTERN MED, V143, P90, DOI 10.1001/archinte.143.1.90
   DZAU VJ, 1993, ARCH INTERN MED, V153, P937, DOI 10.1001/archinte.153.8.937
   GANAU A, 1990, CIRCULATION, V81, P25, DOI 10.1161/01.CIR.81.1.25
   Gesang L, 2002, HYPERTENS RES, V25, P481, DOI 10.1291/hypres.25.481
   HAVILAND MB, 1991, AM J HUM GENET, V49, P350
   Iwashima Y, 2002, HYPERTENS RES, V25, P49, DOI 10.1291/hypres.25.49
   Kuznetsova T, 2004, J HYPERTENS, V22, P287, DOI 10.1097/01.hjh.0000098237.37783.3b
   Lindpaintner K, 1996, NEW ENGL J MED, V334, P1023, DOI 10.1056/NEJM199604183341604
   Mahmood MS, 2003, J HUM HYPERTENS, V17, P719, DOI 10.1038/sj.jhh.1001600
   Mathew J, 2001, CIRCULATION, V104, P1615, DOI 10.1161/hc3901.096700
   Matsubara M, 2003, HYPERTENS RES, V26, P47
   Matsuzaki K, 1997, Hypertens Res, V20, P7, DOI 10.1291/hypres.20.7
   Miller JA, 2004, CURR OPIN NEPHROL HY, V13, P101, DOI 10.1097/01.mnh.0000109589.66112.91
   Obineche EN, 2001, HYPERTENS RES, V24, P635, DOI 10.1291/hypres.24.635
   Ono K, 2003, HYPERTENS RES, V26, P131, DOI 10.1291/hypres.26.131
   Sambrook J, 1989, MOL CLONING LAB MANU
   SAVAGE DD, 1990, AM J CARDIOL, V65, P371, DOI 10.1016/0002-9149(90)90304-J
   SCHUNKERT H, 1994, NEW ENGL J MED, V330, P1634, DOI 10.1056/NEJM199406093302302
   Shlyakhto EV, 2001, BLOOD PRESSURE, V10, P135, DOI 10.1080/080370501753182343
   SOKOLOW M, 1949, AM HEART J, V37, P161, DOI 10.1016/0002-8703(49)90562-1
   Tamaki S, 2002, HYPERTENS RES, V25, P843
   THOMPSON EA, 1988, AM J HUM GENET, V42, P113
   van Berlo JH, 2003, INT J BIOCHEM CELL B, V35, P932, DOI 10.1016/S1357-2725(02)00369-2
   Wu SL, 2000, HYPERTENS RES, V23, P261, DOI 10.1291/hypres.23.261
   Zhao JH, 2000, HUM HERED, V50, P133, DOI 10.1159/000022901
   Zhu XF, 2001, AM J HUM GENET, V68, P1139, DOI 10.1086/320104
NR 28
TC 24
Z9 28
U1 2
U2 7
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0916-9636
EI 1348-4214
J9 HYPERTENS RES
JI Hypertens. Res.
PD APR
PY 2005
VL 28
IS 4
BP 345
EP 349
DI 10.1291/hypres.28.345
PG 5
WC Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA 948AF
UT WOS:000230687700009
PM 16138565
OA Bronze
DA 2018-12-27
ER

PT J
AU Melillo, RM
   Castellone, MD
   Guarino, V
   De Falco, V
   Cirafici, AM
   Salvatore, G
   Caiazzo, F
   Basolo, F
   Giannini, R
   Kruhoffer, M
   Orntoft, T
   Fusco, A
   Santoro, M
AF Melillo, RM
   Castellone, MD
   Guarino, V
   De Falco, V
   Cirafici, AM
   Salvatore, G
   Caiazzo, F
   Basolo, F
   Giannini, R
   Kruhoffer, M
   Orntoft, T
   Fusco, A
   Santoro, M
TI RETRACTED: The RET/PTC-RAS-BRAF linear signaling cascade mediates the
   motile and mitogenic phenotype of thyroid cancer cells (Retracted
   article. See vol. 126, pg. 1603, 2016)
SO JOURNAL OF CLINICAL INVESTIGATION
LA English
DT Article; Retracted Publication
ID TYROSINE KINASE; PAPILLARY CARCINOMAS; ONCOGENE ACTIVATION; HIGH
   PREVALENCE; RET RECEPTOR; MUTATIONS; EXPRESSION; INFLAMMATION; TUMORS;
   GROWTH
AB In papillary thyroid carcinomas (PTCs), rearrangements of the PET receptor (RET/PTC) and activating mutations in the BRAF or RAS oncogenes are mutually exclusive. Here we show that the 3 proteins function along a linear oncogenic signaling cascade in which RET/PTC induces RAS-dependent BRAF activation and RAS- and BRAF-dependent ERK activation. Adoptive activation of the RET/PTC-RAS-BRAF axis induced cell proliferation and Matrigel invasion of thyroid follicular cells. Gene expression profiling revealed that the 3 oncogenes activate a common transcriptional program in thyroid cells that includes upregulation of the CXCL1 and CXCL10 chemokines, which in turn stimulate proliferation and invasion. Thus, motile and mitogenic properties are intrinsic to transformed thyroid cells and are governed by an epistatic oncogenic signaling cascade.
C1 Univ Naples Federico II, Dipartimento Biol & Pathol Cellulare & Mol, CNR G Salvatore, Inst Endocrinol Oncol Sperimentale, I-80131 Naples, Italy.
   Univ Pisa, Dipartimento Oncol, Pisa, Italy.
   Aarhus Univ Hosp, Dept Clin Biochem, Mol Diagnost Lab, Aarhus, Denmark.
RP Santoro, M (reprint author), Univ Naples Federico II, Dipartimento Biol & Pathol Cellulare & Mol, CNR G Salvatore, Inst Endocrinol Oncol Sperimentale, Via S Pansini 5, I-80131 Naples, Italy.
EM masantor@unina.it
RI DE FALCO, VALENTINA/C-2061-2015; Giannini, Riccardo/K-4223-2013
OI DE FALCO, VALENTINA/0000-0002-8972-7921; Giannini,
   Riccardo/0000-0001-9740-0219; CASTELLONE,
   MARIADOMENICA/0000-0003-0507-8037; MELILLO, Rosa
   Marina/0000-0002-9233-5275; Fusco, Alfredo/0000-0003-3332-5197
CR Balkwill F, 2001, LANCET, V357, P539, DOI 10.1016/S0140-6736(00)04046-0
   Bartolazzi A, 2001, LANCET, V357, P1644, DOI 10.1016/S0140-6736(00)04817-0
   Borrello MG, 1996, MOL CELL BIOL, V16, P2151
   Buckwalter TLF, 2002, ONCOGENE, V21, P8166, DOI 10.1038/sj.onc.1205938
   Califano D, 1998, CANCER RES, V58, P823
   Carlomagno F, 2002, CANCER RES, V62, P7284
   Castellone MD, 2004, ONCOGENE, V23, P2188, DOI 10.1038/sj.onc.1207322
   Castellone MD, 2003, ONCOGENE, V22, P246, DOI 10.1038/sj.onc.1206112
   Cohen J, 2003, J NATL CANCER I, V95, P625, DOI 10.1093/jnci/95.8.625
   Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322
   CURCIO F, 1994, P NATL ACAD SCI USA, V91, P9004, DOI 10.1073/pnas.91.19.9004
   Dahlman T, 2002, INT J CANCER, V98, P186, DOI 10.1002/ijc.10181
   Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766
   Dhawan P, 2002, J LEUKOCYTE BIOL, V72, P9
   Eblaghie MC, 2003, CURR BIOL, V13, P1009, DOI 10.1016/S0960-9822(03)00381-6
   El-Rifai W, 2002, CANCER RES, V62, P6823
   Elsalini OA, 2003, DEV BIOL, V263, P67, DOI 10.1016/S0012-1606(03)00436-6
   Encinas M, 2004, J BIOL CHEM, V279, P18262, DOI 10.1074/jbc.M400505200
   Fagin JA, 2004, J ENDOCRINOL, V183, P249, DOI 10.1677/joe.1.05895
   Fagin JA, 2002, ENDOCRINOLOGY, V143, P2025, DOI 10.1210/en.143.6.2025
   Fusco A, 2002, AM J PATHOL, V160, P2157, DOI 10.1016/S0002-9440(10)61164-9
   FUSCO A, 1987, MOL CELL BIOL, V7, P3365, DOI 10.1128/MCB.7.9.3365
   Gao P, 2003, J LEUKOCYTE BIOL, V73, P273, DOI 10.1189/jlb.0602269
   Hackel PO, 2001, BIOL CHEM, V382, P1649, DOI 10.1515/BC.2001.200
   Hingorani SR, 2003, CANCER RES, V63, P5198
   Huang Y, 2001, P NATL ACAD SCI USA, V98, P15044, DOI 10.1073/pnas.251547398
   Ichihara M, 2004, CANCER LETT, V204, P197, DOI 10.1016/S0304-3835(03)00456-7
   Kawamoto Y, 2004, J BIOL CHEM, V279, P14213, DOI 10.1074/jbc.M312600200
   Kimura ET, 2003, CANCER RES, V63, P1454
   Knauf JA, 2003, ONCOGENE, V22, P4406, DOI 10.1038/sj.onc.1206602
   Liotta LA, 2001, NATURE, V411, P375, DOI 10.1038/35077241
   Luster AD, 1998, NEW ENGL J MED, V338, P436, DOI 10.1056/NEJM199802123380706
   Lyons JF, 2001, ENDOCR-RELAT CANCER, V8, P219, DOI 10.1677/erc.0.0080219
   Malumbres M, 2003, NAT REV CANCER, V3, P459, DOI 10.1038/nrc1097
   Manie S, 2001, TRENDS GENET, V17, P580, DOI 10.1016/S0168-9525(01)02420-9
   Melillo RM, 2001, MOL CELL BIOL, V21, P4177, DOI 10.1128/MCB.21.13.4177-4187.2001
   Mellado M, 2001, ANNU REV IMMUNOL, V19, P397, DOI 10.1146/annurev.immunol.19.1.397
   Nikiforova MN, 2003, J CLIN ENDOCR METAB, V88, P5399, DOI 10.1210/jc.2003-030838
   Pandey A, 1996, J BIOL CHEM, V271, P10607, DOI 10.1074/jbc.271.18.10607
   Pierotti MA, 2001, CANCER LETT, V166, P1, DOI 10.1016/S0304-3835(01)00439-6
   Rosai J, 1992, ATLAS TUMOR PATHOLOG
   SANTORO M, 1992, J CLIN INVEST, V89, P1517, DOI 10.1172/JCI115743
   SANTORO M, 1993, CELL GROWTH DIFFER, V4, P77
   Santoro M, 1996, ONCOGENE, V12, P1821
   Scarpino S, 2000, AM J PATHOL, V156, P831, DOI 10.1016/S0002-9440(10)64951-6
   SCHLESSINGER J, 2003, SCI STKE, V191, pRE12
   Shirokawa JM, 2000, MOL ENDOCRINOL, V14, P1725, DOI 10.1210/me.14.11.1725
   Soares P, 2003, ONCOGENE, V22, P4578, DOI 10.1038/sj.onc.1206706
   White JR, 1998, J BIOL CHEM, V273, P10095, DOI 10.1074/jbc.273.17.10095
   Yuan BB, 2004, NUCLEIC ACIDS RES, V32, pW130, DOI 10.1093/nar/gkh366
   Zhu ZW, 2003, AM J CLIN PATHOL, V120, P71, DOI 10.1309/ND8D9LAJTRCTG6QD
NR 51
TC 257
Z9 258
U1 3
U2 17
PU AMER SOC CLINICAL INVESTIGATION INC
PI ANN ARBOR
PA 2015 MANCHESTER RD, ANN ARBOR, MI 48104 USA
SN 0021-9738
EI 1558-8238
J9 J CLIN INVEST
JI J. Clin. Invest.
PD APR
PY 2005
VL 115
IS 4
BP 1068
EP 1081
DI 10.1172/JCI200522758
PG 14
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA 913IU
UT WOS:000228145700039
PM 15761501
OA Green Published, Bronze
DA 2018-12-27
ER

PT J
AU Matsuda, T
   Almasan, A
   Tomita, M
   Tamaki, K
   Saito, M
   Tadano, M
   Yagita, H
   Ohta, T
   Mori, N
AF Matsuda, T
   Almasan, A
   Tomita, M
   Tamaki, K
   Saito, M
   Tadano, M
   Yagita, H
   Ohta, T
   Mori, N
TI RETRACTED: Dengue virus-induced apoptosis in hepatic cells is partly
   mediated by Apo2 ligand/tumour necrosis factor-related
   apoptosis-inducing ligand (Retracted article. See vol. 91, pg. 2658,
   2010)
SO JOURNAL OF GENERAL VIROLOGY
LA English
DT Article; Retracted Publication
ID NF-KAPPA-B; REOVIRUS-INDUCED APOPTOSIS; TRAIL-INDUCED APOPTOSIS;
   MONOCLONAL-ANTIBODY; NEUROBLASTOMA-CELLS; REQUIRES ACTIVATION; RECEPTOR
   EXPRESSION; HEMORRHAGIC-FEVER; PERIPHERAL-BLOOD; LIVER APOPTOSIS
AB Although hepatic injury is reported in cases with dengue haemorrhagic fever and dengue shock syndrome, its mechanism remains poorly understood. Several findings suggest that dengue virus (DEN) induces apoptosis of hepatocytes in vivo. In this work, DEN type 2 (DEN-2) strain NGC was shown to induce apoptosis in the hepatic cell line HepG2, and infection of HepG2 cells was found to induce Apo2 ligand (Apo2L, also known as tumour necrosis factor-related apoptosis-inducing ligand or TRAIL) expression. Furthermore, Apo2L/TRAIL induced apoptosis in HepG2 cells, which expressed the Apo2L/TRAIL receptor DR5/TRAIL-R2 on their surface. Analysis of the Apo2L/TRAIL promoter revealed that this gene was activated by DEN-2 infection, whose responsive element was overlapping NF-B-K- and Sp1-binding sites located at nt-75 to -65. The proteasome inhibitor N-acetyl-L-leucinyl-L-leucinyl-L-norleucinal (LLnL) inhibited Apo2L/TRAIL mRNA expression, and LLnL and anti-Apo2L/TRAIL antibody inhibited DEN-2-induced apoptosis. It was proposed that DEN infection promotes apoptosis partly through the induction of Apo2L/TRAIL expression.
C1 Univ Ryukyus, Div Mol Virol & Oncol, Grad Sch Med, Okinawa 9030215, Japan.
   Univ Ryukyus, Fac Med, Div Child Hlth & Welf, Okinawa 9030215, Japan.
   Cleveland Clin Fdn, Lerner Res Inst, Dept Canc Biol, Cleveland, OH 44195 USA.
   Juntendo Univ, Sch Med, Dept Immunol, Bunkyo Ku, Tokyo 1138421, Japan.
RP Mori, N (reprint author), Univ Ryukyus, Div Mol Virol & Oncol, Grad Sch Med, Uehara 207, Okinawa 9030215, Japan.
EM n-mori@med.u-ryukyu.ac.jp
RI Almasan, Alex/C-2715-2008
OI Almasan, Alex/0000-0002-8916-6650
FU NCI NIH HHS [R01 CA081504, R01 CA081504-06]
CR Almasan A, 2003, CYTOKINE GROWTH F R, V14, P337, DOI 10.1016/S1359-6101(03)00029-7
   An J, 1999, VIROLOGY, V263, P70, DOI 10.1006/viro.1999.9887
   Avirutnan P, 1998, J IMMUNOL, V161, P6338
   Baetu TM, 2001, J IMMUNOL, V167, P3164, DOI 10.4049/jimmunol.167.6.3164
   Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5
   BHAMARAP.N, 1967, ANN TROP MED PARASIT, V61, P500, DOI 10.1080/00034983.1967.11686519
   BOKISCH VA, 1973, NEW ENGL J MED, V289, P996, DOI 10.1056/NEJM197311082891902
   Bosch I, 2002, J VIROL, V76, P5588, DOI 10.1128/JVI.76.11.5588-5597.2002
   Chen Q, 2001, BLOOD, V98, P2183, DOI 10.1182/blood.V98.7.2183
   Chen XL, 1997, J GEN VIROL, V78, P3277, DOI 10.1099/0022-1317-78-12-3277
   Clarke P, 2000, J VIROL, V74, P8135, DOI 10.1128/JVI.74.17.8135-8139.2000
   Connolly JL, 2000, J VIROL, V74, P2981, DOI 10.1128/JVI.74.7.2981-2989.2000
   Couvelard A, 1999, HUM PATHOL, V30, P1106, DOI 10.1016/S0046-8177(99)90230-7
   DegliEsposti MA, 1997, J EXP MED, V186, P1165, DOI 10.1084/jem.186.7.1165
   Despres P, 1998, J VIROL, V72, P823
   Despres P, 1996, J VIROL, V70, P4090
   Faubion WA, 1999, HEPATOLOGY, V29, P1, DOI 10.1002/hep.510290101
   Feldmann G, 1997, J HEPATOL, V26, P1, DOI 10.1016/S0168-8278(97)80491-6
   Gong B, 2000, BIOCHEM BIOPH RES CO, V278, P747, DOI 10.1006/bbrc.2000.3872
   Grimm S, 1996, J CELL BIOL, V134, P13, DOI 10.1083/jcb.134.1.13
   Gubler DJ, 1998, CLIN MICROBIOL REV, V11, P480, DOI 10.1128/CMR.11.3.480
   HALL WC, 1991, AM J TROP MED HYG, V45, P408, DOI 10.4269/ajtmh.1991.45.408
   HALSTEAD SB, 1977, J EXP MED, V146, P218, DOI 10.1084/jem.146.1.218
   Hensley LE, 2002, IMMUNOL LETT, V80, P169, DOI 10.1016/S0165-2478(01)00327-3
   INNIS BL, 1995, EXOTIC VIRAL INFECT, P103
   ISHIMINE T, 1987, BIKEN J, V30, P39
   Jan JT, 2000, J VIROL, V74, P8680, DOI 10.1128/JVI.74.18.8680-8691.2000
   Jeremias I, 1998, BLOOD, V91, P4624
   Jo M, 2000, NAT MED, V6, P564
   KANGWANPONG D, 1995, CLIN DIAGN VIROL, V3, P165, DOI 10.1016/0928-0197(94)00032-P
   Katsikis PD, 1997, J EXP MED, V186, P1365, DOI 10.1084/jem.186.8.1365
   Kayagaki N, 1999, J IMMUNOL, V162, P2639
   KOGA Y, 1994, J VIROL, V68, P4322
   Kotelkin A, 2003, J VIROL, V77, P9156, DOI 10.1128/JVI.77.17.9156-9172.2003
   Lewis J, 1996, J VIROL, V70, P1828
   LIN KI, 1995, J CELL BIOL, V131, P1149, DOI 10.1083/jcb.131.5.1149
   Marianneau P, 1997, J VIROL, V71, P3244
   Mundt B, 2002, FASEB J, V16, P94, DOI 10.1096/fj.02-0537fje
   NIMMANNITYA S, 1987, Southeast Asian Journal of Tropical Medicine and Public Health, V18, P392
   Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815
   Pan GH, 1998, FEBS LETT, V424, P41, DOI 10.1016/S0014-5793(98)00135-5
   Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111
   Pitt RM, 1996, J BIOL CHEM, V271, P12687, DOI 10.1074/jbc.271.22.12687
   POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415
   ROSEN L, 1989, RES VIROLOGY, V140, P351, DOI 10.1016/S0923-2516(89)80115-3
   Rubio N, 2003, VIROLOGY, V311, P366, DOI 10.1016/S0042-6822(03)00157-0
   Satoh K, 2001, PANCREAS, V23, P251, DOI 10.1097/00006676-200110000-00005
   SCHNEIDER U, 1977, INT J CANCER, V19, P621, DOI 10.1002/ijc.2910190505
   Sedger LM, 1999, J IMMUNOL, V163, P920
   Seth A, 1997, AIDS, V11, P1059
   Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818
   Shigeno M, 2003, ONCOGENE, V22, P1653, DOI 10.1038/sj.onc.1206139
   TADANO M, 1989, J GEN VIROL, V70, P1409, DOI 10.1099/0022-1317-70-6-1409
   TAKAHASHI T, 1994, INT IMMUNOL, V6, P1567, DOI 10.1093/intimm/6.10.1567
   Vidalain PO, 2000, J VIROL, V74, P556, DOI 10.1128/JVI.74.1.556-559.2000
   Walczak H, 1997, EMBO J, V16, P5386, DOI 10.1093/emboj/16.17.5386
   Wang QD, 2000, BIOCHEM BIOPH RES CO, V276, P466, DOI 10.1006/bbrc.2000.3512
   Washburn B, 2003, J IMMUNOL, V170, P1814, DOI 10.4049/jimmunol.170.4.1814
   Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8
   Zhang CH, 1996, J IMMUNOL, V157, P3980
NR 60
TC 42
Z9 44
U1 3
U2 12
PU MICROBIOLOGY SOC
PI LONDON
PA CHARLES DARWIN HOUSE, 12 ROGER ST, LONDON WC1N 2JU, ERKS, ENGLAND
SN 0022-1317
EI 1465-2099
J9 J GEN VIROL
JI J. Gen. Virol.
PD APR
PY 2005
VL 86
BP 1055
EP 1065
DI 10.1099/vir.0.80531-0
PN 4
PG 11
WC Biotechnology & Applied Microbiology; Virology
SC Biotechnology & Applied Microbiology; Virology
GA 914OD
UT WOS:000228236300018
PM 15784899
OA Green Accepted, Bronze
DA 2018-12-27
ER

PT J
AU Bulanova, E
   Budagian, V
   Orinska, Z
   Hein, M
   Petersen, F
   Thon, L
   Adam, D
   Bulfone-Paus, S
AF Bulanova, E
   Budagian, V
   Orinska, Z
   Hein, M
   Petersen, F
   Thon, L
   Adam, D
   Bulfone-Paus, S
TI RETRACTED: Extracellular ATP induces cytokine expression and apoptosis
   through P2X(7) receptor in murine mast cells (Retracted article. See
   vol. 186, pg. 2683, 2011)
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article; Retracted Publication
ID ACTIVATED PROTEIN-KINASE; NF-KAPPA-B; PLASMA-MEMBRANE; NUCLEOTIDE
   RECEPTOR; P2Z PURINORECEPTOR; MICROGLIAL CELLS; DENDRITIC CELLS; PORE
   FORMATION; RELEASE; MACROPHAGES
AB Extracellular ATP and other nucleotides act through specific cell surface receptors and regulate a wide variety of cellular responses in many cell types and tissues. In this study, we demonstrate that murine mast cells express several P2Y and P2X receptor subtypes including P2X(7), and describe functional responses of these cells to extracellular ATP. Stimulation of bone marrow-derived mast cells (BMMC), as well as MC/9 and P815 mast cell lines with millimolar concentrations of ATP, resulted in Ca2+ influx across the cellular membrane and cell permeabilization. Moreover, brief exposures to ATP were sufficient to induce apoptosis in BMMCs, MC/9, and P815 cells which involved activation of caspase-3 and -8. However, in the time period between commitment to apoptosis and actual cell death, ATP triggered rapid but transient phosphorylation of multiple signaling molecules in BMMCs and MC/9 cells, including ERK, Jak2, and STAT6. In addition, ATP stimulation enhanced the expression of several proinflammatory cytokines, such as IL-4, IL-6, IL-13, and TNF-alpha. The effects of ATP were mimicked by submillimolar concentrations of 3-O-(4'-benzoyl)-benzoyl-benzoyl-ATP, and were inhibited by pretreatment of mast cells with a selective blocker of human and mouse P2X(7) receptor, I[N,O-bis(5-isoquinolinesulphonyl)-N-methyl-L-tyrosyl]-4-phenylpiperazine, as well as oxidized ATP. The nucleotide selectivity and pharmacological profile data support the role for P2X(7) receptor as the mediator of the ATP-induced responses. Given the importance of mast cells in diverse pathological conditions, the ability of extracellular ATP to induce the P2X(7)-mediated apoptosis in these cells may facilitate the development of new strategies to modulate mast cell activities.
C1 Res Ctr Borstel, Dept Immunol & Cell Biol, D-23845 Borstel, Germany.
   Univ Kiel, Inst Immunol, Kiel, Germany.
RP Bulanova, E (reprint author), Res Ctr Borstel, Dept Immunol & Cell Biol, Parkallee 22, D-23845 Borstel, Germany.
EM ebulanova@fz-borstel.de
CR Bankl HC, 2002, THROMB RES, V105, P359, DOI 10.1016/S0049-3848(02)00016-6
   Baricordi OR, 1999, J BIOL CHEM, V274, P33206, DOI 10.1074/jbc.274.47.33206
   Beigi R, 1999, AM J PHYSIOL, V276, P267
   Benoist C, 2002, NATURE, V420, P875, DOI 10.1038/nature01324
   Budagian V, 2003, J BIOL CHEM, V278, P1549, DOI 10.1074/jbc.M206383200
   Bulanova E, 2003, J IMMUNOL, V170, P5045, DOI 10.4049/jimmunol.170.10.5045
   CHAKRAVARTY N, 1980, ACTA PHARMACOL TOX, V47, P223
   COCKCROFT S, 1979, J PHYSIOL-LONDON, V296, P229, DOI 10.1113/jphysiol.1979.sp013002
   COUNTINHOSILVA R, 1999, AM J PHYSIOL, V276, pC1139
   Di Virgilio F, 2001, BLOOD, V97, P587, DOI 10.1182/blood.V97.3.587
   Donnelly-Roberts DL, 2004, J PHARMACOL EXP THER, V308, P1053, DOI 10.1124/jpet.103.059600
   EAMSHAW WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI DOI 10.1146/ANNUREV.BI0CHEM.68.1383
   Ferrari D, 1999, J BIOL CHEM, V274, P13205, DOI 10.1074/jbc.274.19.13205
   Ferrari D, 1996, J IMMUNOL, V156, P1531
   Ferrari D, 1997, J IMMUNOL, V159, P1451
   Ferrari D, 1997, J CELL BIOL, V139, P1635, DOI 10.1083/jcb.139.7.1635
   Ferrari D, 1999, FEBS LETT, V447, P71, DOI 10.1016/S0014-5793(99)00270-7
   FREDHOLM BB, 1994, PHARMACOL REV, V46, P143
   Galli SJ, 1999, CURR OPIN IMMUNOL, V11, P53, DOI 10.1016/S0952-7915(99)80010-7
   Gargett CE, 1997, BRIT J PHARMACOL, V120, P1483, DOI 10.1038/sj.bjp.0701081
   GREENBERG S, 1988, J BIOL CHEM, V263, P10337
   GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440
   Hillman KA, 2003, BIOCHEM PHARMACOL, V66, P415, DOI 10.1016/S0006-2952(03)00286-7
   Huff Thomas F., 1997, P1393
   Humphreys BD, 1998, MOL PHARMACOL, V54, P22
   Humphreys BD, 2000, J BIOL CHEM, V275, P26792
   McCloskey MA, 1999, J IMMUNOL, V163, P970
   Mehta VB, 2001, J BIOL CHEM, V276, P3820, DOI 10.1074/jbc.M006814200
   MURGIA M, 1993, J BIOL CHEM, V268, P8199
   Mutini C, 1999, J IMMUNOL, V163, P1958
   Naemsch LN, 2001, J BIOL CHEM, V276, P39107, DOI 10.1074/jbc.M105881200
   Nakamura H, 1989, Arerugi, V38, P1359
   Neary JT, 1998, NEUROSCI LETT, V242, P159, DOI 10.1016/S0304-3940(98)00067-6
   Nihei OK, 2000, BLOOD, V96, P996
   North RA, 2000, ANNU REV PHARMACOL, V40, P563, DOI 10.1146/annurev.pharmtox.40.1.563
   North RA, 2002, PHYSIOL REV, V82, P1013, DOI 10.1152/physrev.00015.2002
   OSIPCHUK Y, 1992, NATURE, V359, P241, DOI 10.1038/359241a0
   Perregaux DG, 2000, J IMMUNOL, V165, P4615, DOI 10.4049/jimmunol.165.8.4615
   Piliponsky AM, 2000, APOPTOSIS, V5, P435, DOI 10.1023/A:1009680500988
   Rassendren F, 1997, J BIOL CHEM, V272, P5482, DOI 10.1074/jbc.272.9.5482
   Robbie-Ryan M, 2002, CURR OPIN IMMUNOL, V14, P728, DOI 10.1016/S0952-7915(02)00394-1
   SAITO H, 1991, INT ARCH ALLER A IMM, V94, P68, DOI 10.1159/000235327
   SATO H, 1991, ARERUGI, V40, P680
   Schulman ES, 1999, AM J RESP CELL MOL, V20, P530, DOI 10.1165/ajrcmb.20.3.3387
   Seman M, 2003, IMMUNITY, V19, P571, DOI 10.1016/S1074-7613(03)00266-8
   Solle M, 2001, J BIOL CHEM, V276, P125, DOI 10.1074/jbc.M006781200
   STEINBERG TH, 1987, J BIOL CHEM, V262, P8884
   Stennicke HR, 1997, J BIOL CHEM, V272, P25719, DOI 10.1074/jbc.272.41.25719
   Sudo N, 1996, J IMMUNOL, V156, P3970
   Surprenant A, 1996, SCIENCE, V272, P735, DOI 10.1126/science.272.5262.735
   Swanson KD, 1998, J BIOL CHEM, V273, P19965, DOI 10.1074/jbc.273.32.19965
   TATHAM PER, 1990, J GEN PHYSIOL, V95, P459, DOI 10.1085/jgp.95.3.459
   Theoharides TC, 2004, J NEUROIMMUNOL, V146, P1, DOI 10.1016/j.jneuroim.2003.10.041
   Valent P, 2002, THROMB HAEMOSTASIS, V87, P786
   Vassort G, 2001, PHYSIOL REV, V81, P767
   Wedemeyer J, 2000, CURR OPIN IMMUNOL, V12, P624, DOI 10.1016/S0952-7915(00)00154-0
   Wen LT, 2003, MOL PHARMACOL, V63, P706, DOI 10.1124/mol.63.3.706
   WILEY JS, 1989, BLOOD, V73, P1316
   ZANOVELLO P, 1990, J IMMUNOL, V145, P1545
NR 59
TC 81
Z9 88
U1 7
U2 18
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD APR 1
PY 2005
VL 174
IS 7
BP 3880
EP 3890
DI 10.4049/jimmunol.174.7.3880
PG 11
WC Immunology
SC Immunology
GA 911KD
UT WOS:000228000100011
PM 15778342
OA Other Gold
DA 2018-12-27
ER

PT J
AU Shangguan, ZP
   Lei, TW
   Shao, MA
   Xue, QW
AF Shangguan, ZP
   Lei, TW
   Shao, MA
   Xue, QW
TI RETRACTED: Effects of phosphorus nutrient on the hydraulic conductivity
   of sorghum (Sorghum vulgare Pers.) seedling roots under water deficiency
   (Retracted Article. See vol 49, pg 127, 2007)
SO JOURNAL OF INTEGRATIVE PLANT BIOLOGY
LA English
DT Article; Retracted Publication
DE phosphorus nutrient; root hydraulic conductivity (Sorghum vulgare
   Pers.); sorghum; water deficiency
ID PLANT-ROOTS; AQUAPORINS; CHANNEL; STRESS; WHEAT; CONDUCTANCE; TRANSPORT
AB Hydroponic experiments were conducted in a growth chamber and changes in the hydraulic conductivity of sorghum (Sorghum vulgare Pers.) roots (Lp(r)) at the three-leaf stage were measured using the pressure chamber method. Water deficiency was imposed with polyethylene glycol (PEG) 6000 and the phosphorus (P) levels were controlled by complete Hoagland solution with and without P nutrient. The objective of this study was to investigate the effect of P nutrition on root Lp(r) under water deficiency. The results showed that the Lp(r) in P deficiency treatments decreased markedly, but the Lp(r) recovered to the same value as that of control when sufficient P was supplied for 4-24 h. Water deficiency decreased Lp(r) but the hydraulic conductivity of the roots with sufficient P supply was still higher than that of plants without P supply. When resuming water supply, the Lp(r) of the water-deficient plants under P supply recovered faster than that of plants without P supply, which indicates that plants with sufficient P nutrient are more drought tolerant and have a greater ability to recover after drought. The treatment of HgCl2 indicated that P nutrient could regulate the Lp(r) by affecting the activity and the expression levels of aquaporins.
C1 Chinese Acad Sci, State Key Lab Soil Eros & Dryland Agr Loess Plate, Inst Soil & Water Conserv, Yangling 712100, Peoples R China.
   NW Sci Tech Univ Agr Forestry, Yangling 712100, Peoples R China.
   China Agr Univ, Beijing 100083, Peoples R China.
   Montana State Univ, Agr Res Ctr, Kalispell, MT 59901 USA.
RP Shangguan, ZP (reprint author), Chinese Acad Sci, State Key Lab Soil Eros & Dryland Agr Loess Plate, Inst Soil & Water Conserv, Yangling 712100, Peoples R China.
EM shangguan@ms.iswc.ac.cn
OI Xue, Qingwu/0000-0002-6470-3245
CR BOYER JS, 1985, ANNU REV PLANT PHYS, V36, P473, DOI 10.1146/annurev.pp.36.060185.002353
   Carvajal M, 1996, PLANTA, V199, P372
   Clarkson DT, 2000, J EXP BOT, V51, P61, DOI 10.1093/jexbot/51.342.61
   DAVIES WJ, 1991, ANNU REV PLANT PHYS, V42, P55, DOI 10.1146/annurev.pp.42.060191.000415
   Hoarau J, 1996, PLANTA, V200, P405
   LIU WG, 2001, ACTA BOT BOREALI OCC, V21, P761
   Lo Gullo MA, 1998, NEW PHYTOL, V140, P25, DOI 10.1046/j.1469-8137.1998.00258.x
   MAGGIO A, 1995, PLANT PHYSIOL, V109, P331, DOI 10.1104/pp.109.1.331
   MANUELA MC, 2003, FUNCT PLANT BIOL, V30, P239
   Maurel C, 1997, ANNU REV PLANT PHYS, V48, P399, DOI 10.1146/annurev.arplant.48.1.399
   Niemietz CM, 1997, PLANT PHYSIOL, V115, P561, DOI 10.1104/pp.115.2.561
   NORTH GB, 1992, NEW PHYTOL, V120, P9, DOI 10.1111/j.1469-8137.1992.tb01053.x
   Shangguan ZP, 2002, INT J SUST DEV WORLD, V9, P341, DOI 10.1080/13504500209470129
   Shangguan ZP, 2000, ENVIRON EXP BOT, V44, P141, DOI 10.1016/S0098-8472(00)00064-2
   Siefritz F, 2002, PLANT CELL, V14, P869, DOI 10.1105/tpc.000901
   Steudle E, 2000, J EXP BOT, V51, P1531, DOI 10.1093/jexbot/51.350.1531
   Steudle E, 2000, PLANT SOIL, V226, P45, DOI 10.1023/A:1026439226716
   TANG QY, 1997, DATA ANAL PLATFORM
   Tazawa M, 2001, PLANT CELL PHYSIOL, V42, P28, DOI 10.1093/pcp/pce004
   Tyerman SD, 1999, J EXP BOT, V50, P1055, DOI 10.1093/jexbot/50.suppl_1.1055
   XIAN CW, 2000, PLANT PHYSIOL, V121, P939
   [张军锋 Zhang Junfeng], 2002, [植物生理学通讯, Plant Physiology Communications], V38, P88
   Zhang WH, 1999, PLANT PHYSIOL, V120, P849, DOI 10.1104/pp.120.3.849
   Zhao CX, 2004, ACTA BOT SIN, V46, P505
NR 24
TC 9
Z9 10
U1 6
U2 30
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1672-9072
EI 1744-7909
J9 J INTEGR PLANT BIOL
JI J. Integr. Plant Biol.
PD APR
PY 2005
VL 47
IS 4
BP 421
EP 427
DI 10.1111/j.1744-7909.2005.00069.x
PG 7
WC Biochemistry & Molecular Biology; Plant Sciences
SC Biochemistry & Molecular Biology; Plant Sciences
GA 913WE
UT WOS:000228185500004
DA 2018-12-27
ER

PT J
AU Lee, YK
   Shanafelt, TD
   Bone, ND
   Strege, AK
   Jelinek, DF
   Kay, NE
AF Lee, YK
   Shanafelt, TD
   Bone, ND
   Strege, AK
   Jelinek, DF
   Kay, NE
TI RETRACTED: VEGF receptors on chronic lymphocytic leukemia (CLL) B cells
   interact with STAT 1 and 3: implication for apoptosis resistance
   (Retracted Article. See vol 24, pg 908, 2010)
SO LEUKEMIA
LA English
DT Article; Retracted Publication
DE STAT 1 and 3; CLL; nucleus; VEGF
ID ENDOTHELIAL GROWTH-FACTOR; P38 MAP KINASE; TYROSINE KINASE;
   SIGNAL-TRANSDUCTION; SERINE PHOSPHORYLATION; TRANSCRIPTION FACTOR;
   IFN-GAMMA; ACTIVATION; GENE; VASCULOGENESIS
AB We have previously shown that chronic lymphocytic leukemia (CLL) B cells secrete vascular endothelial growth factor ( VEGF) in vitro, have constitutively active VEGF receptors R1 and R2, and respond to exogenous VEGF by specifically upregulating Mcl-1 and XIAP in association with decreased cell death. We found that epigallocatechin ( EGCG) decreases VEGF receptor phosphorylation and induces apoptosis in CLL B cells. The mechanism(s) by which VEGF receptor activation increases Mcl-1 and XIAP and promotes survival remains unknown. To further define the signaling pathway mediating VEGF induction of antiapoptotic proteins in CLL B-cells, we investigated downstream effects of VEGF - VEGF receptor binding on the STAT signaling pathway. We find that CLL B cells abundantly express cytoplasmic serine phosphorylated ( p)- STAT-1 and p-STAT-3, VEGF-R1/2 are physically associated with p-STAT-1 and p-STAT-3, and p-STAT-3 ( but not p-STAT-1) is found in the CLL nucleus. VEGF receptor ligation selectively induces activation and perinuclear translocation of STAT 3 through receptor-mediated endocytosis. The inhibition of VEGF receptor activation with either tyrosine kinase inhibitors or VEGF neutralizing antibodies inhibit VEGF receptor phosphorylation, decrease p-STAT-3 ( serine 727), Mcl-1, and induces cell death in CLL B cells. Thus, a VEGF - VEGF receptor pathway in CLL B cells can be linked to activation of STAT proteins that are able to enhance their apoptotic resistance.
C1 Mayo Clin & Mayo Fdn, Dept Internal Med, Div Hematol, Rochester, MN 55905 USA.
   Mayo Clin & Mayo Fdn, Dept Immunol, Rochester, MN 55905 USA.
RP Kay, NE (reprint author), Mayo Clin & Mayo Fdn, Dept Internal Med, Div Hematol, Stabile 628,200 1st St SW, Rochester, MN 55905 USA.
EM kay.neil@mayo.edu
FU NCI NIH HHS [R01 CA95241]
CR Bartoli M, 2000, J BIOL CHEM, V275, P33189, DOI 10.1074/jbc.C000318200
   Bild AH, 2002, EMBO J, V21, P3255, DOI 10.1093/emboj/cdf351
   Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527
   Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0
   Cheson BD, 1996, BLOOD, V87, P4990
   Cross MJ, 2003, TRENDS BIOCHEM SCI, V28, P488, DOI 10.1016/S0968-0004(03)00193-2
   DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455
   Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630
   DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256
   Dumont DJ, 1998, SCIENCE, V282, P946, DOI 10.1126/science.282.5390.946
   DUMONT DJ, 1994, GENE DEV, V8, P1897, DOI 10.1101/gad.8.16.1897
   Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0
   Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4
   FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0
   Frank DA, 1999, NAT MED, V5, P444, DOI 10.1038/7445
   Frank DA, 1997, J CLIN INVEST, V100, P3140, DOI 10.1172/JCI119869
   FU XY, 1993, CELL, V74, P1135, DOI 10.1016/0092-8674(93)90734-8
   Goh KC, 1999, EMBO J, V18, P5601, DOI 10.1093/emboj/18.20.5601
   Hanahan D, 1997, SCIENCE, V277, P48, DOI 10.1126/science.277.5322.48
   Higdon JV, 2003, CRIT REV FOOD SCI, V43, P89, DOI 10.1080/10408690390826464
   Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5
   Jelinek DF, 2003, MOL CANCER RES, V1, P346
   Kay NE, 2002, LEUKEMIA, V16, P911, DOI 10.1038/sj/leu/240467
   Keating MJ, 1999, SEMIN ONCOL, V26, P107
   Kipps T J, 1998, Curr Opin Hematol, V5, P244
   Kovarik P, 1999, P NATL ACAD SCI USA, V96, P13956, DOI 10.1073/pnas.96.24.13956
   Kovarik P, 1998, EMBO J, V17, P3660, DOI 10.1093/emboj/17.13.3660
   Landgren E, 1998, ONCOGENE, V16, P359, DOI 10.1038/sj.onc.1201545
   Lee YK, 2004, BLOOD, V104, P788, DOI 10.1182/blood-2003-08-2763
   Levy DE, 2002, NAT REV MOL CELL BIO, V3, P651, DOI 10.1038/nrm909
   Lin TS, 2000, ONCOGENE, V19, P2496, DOI 10.1038/sj.onc.1203486
   Liu HT, 2003, BLOOD, V102, P344, DOI 10.1182/blood-2002-11-3396
   Maisonpierre PC, 1997, SCIENCE, V277, P55, DOI 10.1126/science.277.5322.55
   Neufeld G, 1999, FASEB J, V13, P9
   Ortega N, 1999, FRONT BIOSCI, V4, P141
   Reed JC, 1998, SEMIN ONCOL, V25, P11
   Rousseau S, 1997, ONCOGENE, V15, P2169, DOI 10.1038/sj.onc.1201380
   Sano S, 1999, EMBO J, V18, P4657, DOI 10.1093/emboj/18.17.4657
   Santos SCR, 2004, BLOOD, V103, P3883, DOI 10.1182/BLOOD-2003-05-1634
   SATO TN, 1995, NATURE, V376, P70, DOI 10.1038/376070a0
   SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401
   SEETHARAM L, 1995, ONCOGENE, V10, P135
   Shalaby F, 1997, CELL, V89, P981, DOI 10.1016/S0092-8674(00)80283-4
   SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0
   Shen YH, 2004, MOL CELL BIOL, V24, P407, DOI 10.1128/MCB.24.1.407-419.2004
   Sohal J, 2003, BLOOD, V101, P3188, DOI 10.1182/blood-2002-06-1800
   Stoiber D, 1999, J IMMUNOL, V163, P2640
   Suri C, 1996, CELL, V87, P1171, DOI 10.1016/S0092-8674(00)81813-9
   Takeda K, 1999, IMMUNITY, V10, P39, DOI 10.1016/S1074-7613(00)80005-9
   TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2
   TERMAN BI, 1991, ONCOGENE, V6, P1677
   VAISMAN N, 1990, J BIOL CHEM, V265, P19461
   WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988
   Wang YZ, 2000, ONCOGENE, V19, P2075, DOI 10.1038/sj.onc.1203548
   WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9
   Yamamoto H, 1996, EXP CELL RES, V222, P125, DOI 10.1006/excr.1996.0016
NR 56
TC 87
Z9 93
U1 3
U2 12
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0887-6924
EI 1476-5551
J9 LEUKEMIA
JI Leukemia
PD APR
PY 2005
VL 19
IS 4
BP 513
EP 523
DI 10.1038/sj.leu.2403667
PG 11
WC Oncology; Hematology
SC Oncology; Hematology
GA 909LB
UT WOS:000227860300005
PM 15703780
OA Bronze
DA 2018-12-27
ER

PT J
AU Hattori, S
   Hattori, Y
   Kasai, K
AF Hattori, S
   Hattori, Y
   Kasai, K
TI RETRACTED: Hypoadiponectinemia is caused by chronic blockade of nitric
   oxide synthesis in rats (Retracted article. See vol. 60, pg. 1355, 2011)
SO METABOLISM-CLINICAL AND EXPERIMENTAL
LA English
DT Article; Retracted Publication
ID LONG-TERM BLOCKADE; PLASMA-PROTEIN ADIPONECTIN; VASCULAR
   ENDOTHELIAL-CELLS; ADIPOSE-SPECIFIC PROTEIN; TYPE-2 DIABETIC-PATIENTS;
   NF-KAPPA-B; INSULIN-RESISTANCE; SUPPRESSES; RECEPTOR; PATHOGENESIS
AB Adiponectin is an adipocyte-derived anti-atherogenic protein. Adiponectin levels are decreased in patients and animal models with obesity, diabetes, and coronary artery disease. However, the mechanism by which adiponectin levels are reduced remains unknown. Since hypoadiponectinemia is closely linked to endothelial dysfunction, we examined the regulation of adiponectin in a rat model of chronic blockade of nitric oxide (NO) synthesis by N-omega-nitro-L-arginine methyl ester (L-NAME). Decreased production of NO and increased production of O-2(-) were observed in aorta from L-NAME-treated rats. Plasma adiponectin levels and adiponectin mRNA levels of adipose tissue were markedly decreased in L-NAME-treated rats. Cotreatment of pioglitazone (PIO) or allopurinol (ALL) with L-NAME restored plasma adiponectin concentration and fat adiponectin mRNA levels to control levels. Thus, adiponectin levels were decreased in L-NAME-treated rats, however, they returned to normal following administration of PIO due to transcriptional activation of the adiponectin gene, as well as administration of ALL, likely due to elimination of oxidative stress. Oxidative stress appears to be an important cause of hypoadiponectinemia. (c) 2005 Elsevier Inc. All rights reserved.
C1 Dokkyo Univ, Sch Med, Dept Endocrinol & Metab, Mibu, Tochigi 3210293, Japan.
RP Hattori, Y (reprint author), Dokkyo Univ, Sch Med, Dept Endocrinol & Metab, Mibu, Tochigi 3210293, Japan.
EM yhattori@dokkyomed.ac.jp
CR Al Suwaidi J, 2000, CIRCULATION, V101, P948, DOI 10.1161/01.CIR.101.9.948
   Arita Y, 2002, CIRCULATION, V105, P2893, DOI 10.1161/01.CIR.0000018622.84402.FF
   Arita Y, 1999, BIOCHEM BIOPH RES CO, V257, P79, DOI 10.1006/bbrc.1999.0255
   Chen H, 2003, J BIOL CHEM, V278, P45021, DOI 10.1074/jbc.M307878200
   Erlich Y, 1998, AM J HYPERTENS, V11, P1129, DOI 10.1016/S0895-7061(98)00089-2
   Hanna IR, 2002, ANTIOXID REDOX SIGN, V4, P899, DOI 10.1089/152308602762197443
   Hattori Y, 2003, DIABETOLOGIA, V46, P1543, DOI 10.1007/s00125-003-1224-3
   Hattori Y, 2004, CARDIOVASC RES, V63, P31, DOI 10.1016/j.cardiores.2004.03.014
   Higashi M, 2003, CIRC RES, V93, P767, DOI 10.1161/01.RES.0000096650.91688.28
   Hotta K, 2000, ARTERIOSCL THROM VAS, V20, P1595, DOI 10.1161/01.ATV.20.6.1595
   Ishibashi M, 2002, HYPERTENSION, V40, P687, DOI 10.1161/01.HYP.0000023396.64769.C2
   Iwaki M, 2003, DIABETES, V52, P1655, DOI 10.2337/diabetes.52.7.1655
   Kubota N, 2002, J BIOL CHEM, V277, P25863, DOI 10.1074/jbc.C200251200
   Kumada M, 2003, ARTERIOSCL THROM VAS, V23, P85, DOI 10.1161/01.ATV.0000048856.22331.50
   Lin LY, 2004, FEBS LETT, V574, P106, DOI 10.1016/j.febslet.2004.08.012
   Maeda N, 2001, DIABETES, V50, P2094, DOI 10.2337/diabetes.50.9.2094
   Matsuda M, 2002, J BIOL CHEM, V277, P37487, DOI 10.1074/jbc.M206083200
   Motoshima H, 2004, BIOCHEM BIOPH RES CO, V315, P264, DOI 10.1016/j.bbrc.2004.01.049
   Ogihara T, 2002, HYPERTENSION, V40, P872, DOI 10.1161/01.HYP.0000040262.48405.A8
   Okamoto Y, 2002, CIRCULATION, V106, P2767, DOI 10.1161/01.CIR.0000042707.50032.19
   Ouchi N, 2000, CIRCULATION, V102, P1296, DOI 10.1161/01.CIR.102.11.1296
   Ouchi N, 2001, CIRCULATION, V103, P1057, DOI 10.1161/01.CIR.103.8.1057
   Ouchi N, 1999, CIRCULATION, V100, P2473, DOI 10.1161/01.CIR.100.25.2473
   Schachinger V, 2000, CIRCULATION, V101, P1899, DOI 10.1161/01.CIR.101.16.1899
   Shastri S, 2002, J HYPERTENS, V20, P1381, DOI 10.1097/00004872-200207000-00025
   Shimabukuro M, 2003, J CLIN ENDOCR METAB, V88, P3236, DOI 10.1219/jc.2002-021883
   Takemoto M, 1997, HYPERTENSION, V30, P1621, DOI 10.1161/01.HYP.30.6.1621
   Takemoto M, 1997, J CLIN INVEST, V99, P278, DOI 10.1172/JCI119156
   Tan KCB, 2004, J CLIN ENDOCR METAB, V89, P765, DOI 10.1210/jc.2003-031012
   Taniyama Y, 2003, HYPERTENSION, V42, P1075, DOI 10.1161/01.HYP.0000100443.09293.4F
   Usui M, 1999, HYPERTENSION, V34, P546, DOI 10.1161/01.HYP.34.4.546
   Usui M, 2000, CIRCULATION, V101, P305, DOI 10.1161/01.CIR.101.3.305
   Yang WS, 2002, DIABETES CARE, V25, P376, DOI 10.2337/diacare.25.2.376
NR 33
TC 30
Z9 33
U1 4
U2 10
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0026-0495
EI 1532-8600
J9 METABOLISM
JI Metab.-Clin. Exp.
PD APR
PY 2005
VL 54
IS 4
BP 482
EP 487
DI 10.1016/j.metabol.2004.10.017
PG 6
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 916AE
UT WOS:000228352600010
PM 15798955
DA 2018-12-27
ER

PT J
AU Abd El-Hady, D
   El-Maali, NA
   Gotti, R
   Andrisano, V
AF Abd El-Hady, D
   El-Maali, NA
   Gotti, R
   Andrisano, V
TI RETRACTED: Simultaneous micellar electrokinetic chromatography and
   liquid chromatography of adriblastina and tarabine PFS - Their
   application to some biological fluids (Retracted article. See vol. 78,
   pg. 1508, 2009)
SO TALANTA
LA English
DT Article; Retracted Publication
DE tarabine PFS; adriblastina; MEKC; LC; simultaneous determinations; urine
   samples
ID INDUCED FLUORESCENCE DETECTION; CHIRAL STATIONARY PHASES;
   CAPILLARY-ELECTROPHORESIS; CYTOSINE-ARABINOSIDE; URACIL ARABINOSIDE;
   DOXORUBICIN; HPLC; DAUNORUBICIN; METABOLITES; LEUKEMIA
AB The current work presents analytical procedures for simultaneous determination of tarabine PFS and adriblastina by micellar electrokinetic chromatography (MEKC) and liquid chromatography (LC). For MEKC analysis, separations and identifications were accomplished using uncoated fused-silica capillary with hydrodynamic injections in the presence of 50 mM borate/phophate pH 8.7 and 100 mM SDS. The migration times of tarabine PFS and adriblastina were found to be 2.70 and 6.40 min, respectively. Calibration curves were established for 10-300 ng/mL (r=0.998) tarabine PFS and for 8-120 mu g/mL (r=0.999) adriblastina. For LC analysis, separations were performed on teicoplanin stationary phase with reversed mobile phase containing methanol:buffer pH 4.05 (20:80%, v/v) at 285 nm. The retention times of tarabine PFS and adriblastina were 5.18 and 7.20 min, respectively. Calibration curves were established for 3-90 mu g/mL (r = 0.998) tarabine PFS and for 10-120 mu g/mL (r = 0.999) adriblastina. Both MEKC and LC methods were applied for the simultaneous determination of analytes in urine samples. (c) 2004 Elsevier B.V. All rights reserved.
C1 Assiut Univ, Fac Sci, Dept Chem, Assiut 71516, Egypt.
   Dipartimento Sci Farmaceut, I-40126 Bologna, Italy.
RP Abd El-Hady, D (reprint author), Assiut Univ, Fac Sci, Dept Chem, Assiut 71516, Egypt.
EM deiaabdelhady@yahoo.com
RI Abd elhady, Deia/H-5763-2012
CR Aboul-Enein HY, 2001, ARCH PHARM, V334, P258, DOI 10.1002/1521-4184(200107)334:7<258::AID-ARDP258>3.0.CO;2-G
   Anderson AB, 2002, J CHROMATOGR B, V769, P97, DOI 10.1016/S1570-0232(01)00633-X
   Armstrong DW, 2001, ANAL CHEM, V73, p557A, DOI 10.1021/ac012526n
   ASPEREN JV, 1998, J CHROMATOGR B, V712, P129
   Berthod A, 2000, ANAL CHEM, V72, P1767, DOI 10.1021/ac991004t
   BREITHAUPT H, 1981, J CHROMATOGR, V225, P99, DOI 10.1016/S0378-4347(00)80248-0
   BUCKLEY JD, 1989, MED PEDIATR ONCOL, V17, P382, DOI 10.1002/mpo.2950170507
   El-Maali NA, 2000, TALANTA, V51, P957, DOI 10.1016/S0039-9140(00)00280-0
   GALUSHKO SV, 1990, KHIM FARM ZH+, V24, P85
   GALUSHKO SV, 1987, ZH ANAL KHIM, V42, P1684
   Gavenda A, 2001, ELECTROPHORESIS, V22, P2782, DOI 10.1002/1522-2683(200108)22:13<2782::AID-ELPS2782>3.0.CO;2-I
   Gotti R, 2000, J CHROMATOGR A, V875, P411, DOI 10.1016/S0021-9673(99)01303-5
   HARDMAN JG, 1996, GOODMAN GILMANS PHAR
   Hempel G, 1998, ELECTROPHORESIS, V19, P2939, DOI 10.1002/elps.1150191624
   Houze P, 2001, J CHROMATOGR B, V754, P185, DOI 10.1016/S0378-4347(00)00605-8
   Karlsson C, 2000, J CHROMATOGR A, V897, P349, DOI 10.1016/S0021-9673(00)00805-0
   Krivankova L, 1996, ELECTROPHORESIS, V17, P1954, DOI 10.1002/elps.1150171225
   LUNTE SM, 1996, PHARM BIOMEDICAL APP
   Mazuel C, 2003, J PHARMACEUT BIOMED, V33, P1093, DOI 10.1016/S0731-7085(03)00434-5
   Mou CH, 1997, J CHROMATOGR B, V703, P217, DOI 10.1016/S0378-4347(97)00414-3
   Perez-Ruiz T, 2001, ELECTROPHORESIS, V22, P134, DOI 10.1002/1522-2683(200101)22:1<134::AID-ELPS134>3.3.CO;2-O
   PREISLER HD, 1977, CANCER TREAT REP, V61, P89
   PREISLER HD, 1979, BLOOD, V53, P455
   VANDERHEYDEN Y, 1996, ROBUSTNESS ANAL CHEM
   Zhao P, 1999, J PHARMACEUT BIOMED, V20, P543, DOI 10.1016/S0731-7085(99)00070-9
   Zhou QY, 2002, J PHARMACEUT BIOMED, V30, P1063, DOI 10.1016/S0731-7085(02)00442-9
NR 26
TC 1
Z9 1
U1 1
U2 9
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0039-9140
EI 1873-3573
J9 TALANTA
JI Talanta
PD MAR 31
PY 2005
VL 66
IS 1
BP 253
EP 260
DI 10.1016/j.talanta.2004.11.021
PG 8
WC Chemistry, Analytical
SC Chemistry
GA 920KA
UT WOS:000228686600038
DA 2018-12-27
ER

PT J
AU Godula, K
   Sezen, B
   Sames, D
AF Godula, K
   Sezen, B
   Sames, D
TI RETRACTED: Site-specific phenylation of pyridine catalyzed by
   phosphido-bridged ruthenium dimer complexes: A prototype for C-H
   arylation of electron-deficient heteroarenes (Retracted Article. See vol
   128, pg 3102, 2006)
SO JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
LA English
DT Article; Retracted Publication
ID CLUSTER COMPLEXES; CARBON; HETEROCYCLES; LIGANDS; BOND
C1 Columbia Univ, Dept Chem, New York, NY 10027 USA.
RP Sames, D (reprint author), Columbia Univ, Dept Chem, 3000 Broadway, New York, NY 10027 USA.
EM sames@chem.columbia.edu
CR ADAMS RD, 1995, ORGANOMETALLICS, V14, P4167, DOI 10.1021/om00009a019
   ADAMS RD, 1995, ORGANOMETALLICS, V14, P2238, DOI 10.1021/om00005a025
   AIME S, 1983, J ORGANOMET CHEM, V244, pC47, DOI 10.1016/S0022-328X(00)98625-X
   CABEZA JA, 1994, ORGANOMETALLICS, V13, P55, DOI 10.1021/om00013a015
   Cifuentes MP, 1996, J ORGANOMET CHEM, V513, P201, DOI 10.1016/0022-328X(95)05912-9
   CORRIGAN JF, 1992, J AM CHEM SOC, V114, P7557, DOI 10.1021/ja00045a034
   Deeming AJ, 1997, ORGANOMETALLICS, V16, P289, DOI 10.1021/om960878s
   EISENSTADT A, 1985, ORGANOMETALLICS, V4, P2033, DOI 10.1021/om00130a018
   Farina V., 1997, ORG REACTIONS, V50, P1
   Fukuyama T, 1998, J AM CHEM SOC, V120, P11522, DOI 10.1021/ja982794b
   JORDAN RF, 1989, J AM CHEM SOC, V111, P778, DOI 10.1021/ja00184a081
   Kotha S, 2002, TETRAHEDRON, V58, P9633, DOI 10.1016/S0040-4020(02)01188-2
   LUGAN N, 1985, J AM CHEM SOC, V107, P4484, DOI 10.1021/ja00301a018
   MOORE EJ, 1992, J AM CHEM SOC, V114, P5888, DOI 10.1021/ja00040a078
   Mukhopadhyay S, 2000, J CHEM SOC PERK T 2, P1809, DOI 10.1039/b004116p
   Murakami M, 2003, J AM CHEM SOC, V125, P4720, DOI 10.1021/ja029829z
   Nishibayashi Y, 2002, J AM CHEM SOC, V124, P11846, DOI 10.1021/ja027023t
   Wong WY, 2001, J CHEM SOC DALTON, P2981, DOI 10.1039/b104625j
NR 18
TC 57
Z9 58
U1 6
U2 31
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0002-7863
J9 J AM CHEM SOC
JI J. Am. Chem. Soc.
PD MAR 23
PY 2005
VL 127
IS 11
BP 3648
EP 3649
DI 10.1021/ja042510p
PG 2
WC Chemistry, Multidisciplinary
SC Chemistry
GA 907SQ
UT WOS:000227738700002
PM 15771470
DA 2018-12-27
ER

PT J
AU Moon, HI
   Seo, DW
   Kim, KH
   Cho, KH
   Eun, HC
   Chung, JH
AF Moon, HI
   Seo, DW
   Kim, KH
   Cho, KH
   Eun, HC
   Chung, JH
TI RETRACTED: Erythrodiol-3-acetate, pentacyclic triterpenoid from Styrax
   japonica, expressions of matrix metalloproteinase-1,2 in cultured human
   skin fibroblasts (Retracted Article. See vol 117, pg 179, 2008)
SO JOURNAL OF ETHNOPHARMACOLOGY
LA English
DT Article; Retracted Publication
DE Styrax japonica; erythrodiol-3-acetate; MMP-1; MMP-2
ID OFFICINALIS; BENZOFURANS; SAPOGENOL; SAPONIN; GROWTH
AB Although many studies have been performed to elucidate the molecular consequences of ultraviolet irradiation, little is known about the effect of natural products. Ultraviolet irradiation is widely considered to be an environmental stress. Here we investigated the effect of erythrodiol-3-acetate on the expressions of MMP-1,2 in cultured human skin fibroblasts. Erythrodiol-3-acetate was isolated from the stems of Styrax japonica (Styracaceae). Erythrodiol-3-acetate reduced the expression of MMP-1 but not MMP-2, at the mRNA and protein levels in a dose-dependent manner by ultraviolet irradiation. Taken together, our results suggest that erythrodiol-3-acetate an important role in the reduction of MMP-1 induction by ultraviolet irradiation. (c) 2005 Elsevier Ireland Ltd. All rights reserved.
C1 Seoul Natl Univ, Coll Med, Dept Dermatol, Seoul 110744, South Korea.
   Seoul Natl Univ Hosp, Clin Res Inst, Lab Cutaneous Aging Res, Seoul 110744, South Korea.
   NCI, NIH, Pathol Lab, Extracellular Matrix Pathol Sect, Bethesda, MD 20892 USA.
RP Moon, HI (reprint author), Seoul Natl Univ, Coll Med, Dept Dermatol, Seoul 110744, South Korea.
EM himun@snu.ac.kr; jhchung@snu.ac.kr
RI Kim, Kyu Han/E-7814-2012
CR Akgul YY, 2003, PHYTOCHEMISTRY, V63, P939, DOI 10.1016/S0031-9422(03)00357-1
   ANIL H, 1979, PHYTOCHEMISTRY, V18, P1760, DOI 10.1016/0031-9422(79)80211-3
   ANIL H, 1980, PHYTOCHEMISTRY, V19, P2784, DOI 10.1016/S0031-9422(00)83973-4
   BERNHARD EJ, 1994, P NATL ACAD SCI USA, V91, P4293, DOI 10.1073/pnas.91.10.4293
   Chambers AF, 1997, J NATL CANCER I, V89, P1260, DOI 10.1093/jnci/89.17.1260
   COSTA AF, 1968, FARMACOGNOSIA, V1, P737
   DAVIS PH, 1972, FLORA TURKEY E AEGEA, V4, P432
   Fisher GJ, 1996, NATURE, V379, P335, DOI 10.1038/379335a0
   GILCHREST BA, 1989, J AM ACAD DERMATOL, V21, P610, DOI 10.1016/S0190-9622(89)70227-9
   KITAGAWA I, 1983, CHEM PHARM BULL, V31, P664
   KITAGAWA I, 1975, CHEM PHARM BULL, V23, P1520
   MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4
   NOMURA M, 1981, PHYTOCHEMISTRY, V20, P1097, DOI 10.1016/0031-9422(81)83035-X
   Pauletti PM, 2000, PHYTOCHEMISTRY, V55, P597, DOI 10.1016/S0031-9422(00)00225-9
   Seo JY, 2001, J INVEST DERMATOL, V116, P915, DOI 10.1046/j.1523-1747.2001.01358.x
   TAKANASHI M, 1988, PHYTOCHEMISTRY, V27, P1224, DOI 10.1016/0031-9422(88)80314-5
   Varani J, 2000, J INVEST DERMATOL, V114, P480, DOI 10.1046/j.1523-1747.2000.00902.x
   VARDAR V, 1973, QUAL PLANT MATER VEG, V22, P145
NR 18
TC 5
Z9 6
U1 2
U2 14
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0378-8741
J9 J ETHNOPHARMACOL
JI J. Ethnopharmacol.
PD MAR 21
PY 2005
VL 97
IS 3
BP 567
EP 571
DI 10.1016/j.jep.2005.01.006
PG 5
WC Plant Sciences; Chemistry, Medicinal; Integrative & Complementary
   Medicine; Pharmacology & Pharmacy
SC Plant Sciences; Pharmacology & Pharmacy; Integrative & Complementary
   Medicine
GA 908XD
UT WOS:000227822600024
PM 15740897
DA 2018-12-27
ER

PT J
AU Sudbo, J
   Samuelsson, R
   Risberg, B
   Heistein, S
   Nyhus, C
   Samuelsson, M
   Puntervold, R
   Sigstad, E
   Davidson, B
   Reith, A
   Berner, A
AF Sudbo, J
   Samuelsson, R
   Risberg, B
   Heistein, S
   Nyhus, C
   Samuelsson, M
   Puntervold, R
   Sigstad, E
   Davidson, B
   Reith, A
   Berner, A
TI RETRACTED: Risk markers of oral cancer in clinically normal mucosa as an
   aid in smoking cessation counseling (Retracted Article. See vol 24, pg
   5621, 2006)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Article; Retracted Publication
ID SQUAMOUS-CELL CARCINOMA; DNA IMAGE CYTOMETRY; NECK-CANCER; CONSENSUS
   REPORT; BASAL CELLS; HEAD; LESIONS; LEUKOPLAKIA; PREVENTION; ANEUPLOIDY
AB Purpose Quitting smoking may prevent oral cancer. Behavioral intervention to quit smoking may be more efficient if persons are assigned an individual risk of cancer.
   Patients and Methods In this prospective study, we provided counseling and behavioral intervention toward smoking cessation, supplemented by genetic analyses in clinically normal oral mucosa of heavy smokers. Measurement of serum cotinine was used to assess changes in smoking habits.
   Results In cytologic scrapings from 275 heavy smokers with clinically normal mucosa, we found tetraploicly in four and aneuploidy in 19 persons (23 of 275; 8%). Twenty one (91%) of 23 persons with aneuploidy had quit or reduced their smoking habits at the 3-month follow-up, 20 (87%) of 23 persons had done so at 12 months, and 21 (91%) of 23 persons had done so at 24 months. Fifty-one (20%) of the 252 persons without genetic changes in their mucosa had quit or reduced their tobacco habits at the 3-month follow-up, 23 (9%) had done so at 12 months, and 17 (7%) had done so at 24 months (P < .001). After 24 months, normalization of DNA content to diploidy was observed in two of four persons with tetraploid (50%), and in 11 of 19 persons (58%) with aneuploid scrapings. One patient developed an oral carcinoma in the floor of the mouth: this patient had an aneuploid scraping obtained 43 months earlier and developed a leukoplakia 28 months before the carcinoma.
   Conclusion Risk markers of oral cancer are present in clinically normal mucosa of heavy smokers, and such findings enhance the adherence to smoking cessation on counseling. Cytogenetic aberrations may normalize after quitting smoking. (c) 2005 by American Society of Clinical Oncology.
C1 Norwegian Radium Hosp, Dept Med Oncol & Radiotherapy, Div Cytol, N-0310 Oslo, Norway.
   Norwegian Radium Hosp, Dept Pathol, N-0310 Oslo, Norway.
   Univ Oslo, Fac Dent, Oslo, Norway.
   Arvoll Tannhelse AS, Oslo, Norway.
RP Sudbo, J (reprint author), Norwegian Radium Hosp, Dept Med Oncol & Radiotherapy, Div Cytol, Ullernchausseen 70, N-0310 Oslo, Norway.
EM jon.sudbo@rh.ulo.no
FU NCI NIH HHS [P01 CA106451]
CR ABDELSALAM M, 1988, CANCER, V62, P1981, DOI 10.1002/1097-0142(19881101)62:9<1981::AID-CNCR2820620918>3.0.CO;2-O
   ABDELSALAM M, 1990, ORAL SURG ORAL MED O, V69, P345, DOI 10.1016/0030-4220(90)90297-6
   Ai H, 2001, LARYNGOSCOPE, V111, P1853, DOI 10.1097/00005537-200110000-00034
   Barrera JE, 2003, LARYNGOSCOPE, V113, P892, DOI 10.1097/00005537-200305000-00022
   BICKENBACH JR, 1986, CELL TISSUE KINET, V19, P325, DOI 10.1111/j.1365-2184.1986.tb00684.x
   BOCKING A, 1995, ANAL CELL PATHOL, V8, P67
   Browning Kristine K, 2003, Semin Oncol Nurs, V19, P268, DOI 10.1053/j.soncn.2003.08.004
   Das B. R., 2002, MED SCI MONITOR, V8, P258
   Day Terry A, 2003, Curr Treat Options Oncol, V4, P27, DOI 10.1007/s11864-003-0029-4
   Dempsey DA, 2001, DRUG SAFETY, V24, P277, DOI 10.2165/00002018-200124040-00005
   Edwards A, 2003, BMJ-BRIT MED J, V327, P703, DOI 10.1136/bmj.327.7417.703
   Gray N, 2004, ACTA ONCOL, V43, P8, DOI 10.1080/02841860310017937
   Greenspan D, 2004, NEW ENGL J MED, V350, P1382, DOI 10.1056/NEJMp048028
   Gritz ER, 1999, J CLIN ONCOL, V17, P352, DOI 10.1200/JCO.1999.17.1.352
   GRITZ ER, 1993, CANCER EPIDEM BIOMAR, V2, P261
   Gritz ER, 1999, HEAD NECK-J SCI SPEC, V21, P420, DOI 10.1002/(SICI)1097-0347(199908)21:5<420::AID-HED7>3.0.CO;2-U
   Hafstad A, 1997, HEALTH EDUC RES, V12, P227, DOI 10.1093/her/12.2.227
   Haroske G, 2001, ANAL CELL PATHOL, V23, P89, DOI 10.1155/2001/657642
   Haroske G, 1998, ANAL CELL PATHOL, V17, P189, DOI 10.1155/1998/390837
   Hogmo A, 1996, HEAD NECK-J SCI SPEC, V18, P433, DOI 10.1002/(SICI)1097-0347(199609/10)18:5<433::AID-HED6>3.0.CO;2-6
   HOLLIS JF, 1993, ANN INTERN MED, V118, P521, DOI 10.7326/0003-4819-118-7-199304010-00006
   Johnson N, 1997, FDI World, V6, P10
   Johnson N W, 2004, Eur J Dent Educ, V8 Suppl 4, P18
   Johnson NW, 2000, BRIT DENT J, V189, P200
   Keller S, 2000, Educ Health (Abingdon), V13, P387
   Mao L, 1996, CANCER RES, V56, P5600
   Mao L, 1996, NAT MED, V2, P682, DOI 10.1038/nm0696-682
   Mork J, 2001, NEW ENGL J MED, V344, P1125, DOI 10.1056/NEJM200104123441503
   PURKIS PE, 1990, J CELL SCI, V97, P39
   Reibel J, 2003, MED PRIN PRACT, V12, P22, DOI 10.1159/000069845
   Reichart P A, 2001, Clin Oral Investig, V5, P207, DOI 10.1007/s00784-001-0132-5
   Remmerbach TW, 2001, ANAL CELL PATHOL, V22, P211, DOI 10.1155/2001/807358
   RICE V, 2004, NURSING INTERVENTION
   Sankaranarayanan R, 1997, ORAL ONCOL, V33, P149, DOI 10.1016/S0964-1955(97)00013-4
   Sen S, 2000, CURR OPIN ONCOL, V12, P82, DOI 10.1097/00001622-200001000-00014
   Shain RN, 1999, NEW ENGL J MED, V340, P93, DOI 10.1056/NEJM199901143400203
   SUCHANEK HK, 2004, CANCER EPIDEM BIOMAR, V13, P477
   Sudbo J, 2004, NEW ENGL J MED, V350, P1405, DOI 10.1056/NEJMoa033374
   Sudbo J, 2002, J CLIN ONCOL, V20, P456, DOI 10.1200/JCO.20.2.456
   Sudbo J, 2001, ORAL ONCOL, V37, P558, DOI 10.1016/S1368-8375(00)00126-3
   Sudbo J, 2001, NEW ENGL J MED, V344, P1270, DOI 10.1056/NEJM200104263441702
   Tingle LR, 2003, J SCHOOL HEALTH, V73, P64, DOI 10.1111/j.1746-1561.2003.tb03574.x
   WALDRON CA, 1975, CANCER-AM CANCER SOC, V36, P1386, DOI 10.1002/1097-0142(197510)36:4<1386::AID-CNCR2820360430>3.0.CO;2-7
NR 43
TC 9
Z9 9
U1 3
U2 11
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAR 20
PY 2005
VL 23
IS 9
BP 1927
EP 1933
DI 10.1200/JCO.2005.03.172
PG 7
WC Oncology
SC Oncology
GA 911SK
UT WOS:000228024800019
PM 15774785
DA 2018-12-27
ER

PT J
AU Yun, H
   Lee, M
   Kim, SS
   Ha, J
AF Yun, H
   Lee, M
   Kim, SS
   Ha, J
TI RETRACTED: Glucose deprivation increases mRNA stability of vascular
   endothelial growth factor through activation of AMP-activated protein
   kinase in DU145 prostate carcinoma (Retracted article. See vol. 293, pg.
   18014, 2018)
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article; Retracted Publication
ID HYPOXIA-INDUCIBLE FACTOR-1; GENE-EXPRESSION; OXIDATIVE STRESS; O-2
   HOMEOSTASIS; LKB1; CELLS; STABILIZATION; IDENTIFICATION; TRANSCRIPTION;
   HYPOGLYCEMIA
AB The induction of proangiogenic cytokines such as vascular endothelial growth factor (VEGF) is a critical feature of tumor angiogenesis. In the present study, we examined the mechanisms of VEGF gene expression induced by glucose deprivation in cancer cells, a role of AMP-activated protein kinase (AMPK) in the process, and the signal transduction pathway. AMPK functions as an energy sensor to provide metabolic adaptation under ATP-depleting conditions such as hypoxia and nutritional deprivation. Here, we show that glucose deprivation leads to a significant increase in the mRNA level of VEGF, GLUT1, and PFKFB3 genes in several cancer cells via a hypoxia-inducible factor-1-independent mechanism, and we demonstrate an essential role of AMPK in these gene expressions. Our data suggest that VEGF mRNA induction by glucose deprivation is due to an increase in mRNA stability, and the AMPK activity is necessary and sufficient to confer the stability to VEGF mRNA. We further show that reactive oxygen species is involved in glucose deprivation-induced AMPK activity in DU145 human prostate carcinomas, and c-Jun aminoterminal kinase acts as an upstream component in AMPK activation cascades under these conditions. LKB1, which was recently identified as a direct upstream kinase of AMPK, was not detected in DU145 cells. In conclusion, our results demonstrate a novel and major role of AMPK in the post-transcriptional regulation of VEGF, further implying its potential role in tumor angiogenesis.
C1 Kyung Hee Univ, Coll Med, Dept Biochem & Mol Biol, Med Res Ctr Bioreact React Oxygen Species, Seoul 130701, South Korea.
RP Ha, J (reprint author), Kyung Hee Univ, Coll Med, Dept Biochem & Mol Biol, Med Res Ctr Bioreact React Oxygen Species, Hoegi Dong 1, Seoul 130701, South Korea.
EM hajh@khu.ac.kr
CR Altarejos JY, 2005, J BIOL CHEM, V280, P183, DOI 10.1074/jbc.M411810200
   Berra E, 2000, CANCER METAST REV, V19, P139, DOI 10.1023/A:1026506011458
   Boudeau J, 2003, FEBS LETT, V546, P159, DOI 10.1016/S0014-5793(03)00642-2
   Chen CY, 1998, SCIENCE, V280, P1945, DOI 10.1126/science.280.5371.1945
   Choi SL, 2001, BIOCHEM BIOPH RES CO, V287, P92, DOI 10.1006/bbrc.2001.5544
   Ferrara N, 2004, ENDOCR REV, V25, P581, DOI 10.1210/er.2003-0027
   Forsythe JA, 1996, MOL CELL BIOL, V16, P4604
   HA J, 1994, J BIOL CHEM, V269, P22162
   Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7
   Hardie DG, 1998, ANNU REV BIOCHEM, V67, P821, DOI 10.1146/annurev.biochem.67.1.821
   HAWLEY SA, 1995, J BIOL CHEM, V270, P27186, DOI 10.1074/jbc.270.45.27186
   Hawley SA, 1996, J BIOL CHEM, V271, P27879, DOI 10.1074/jbc.271.44.27879
   Hawley Simon A, 2003, J Biol, V2, P28, DOI 10.1186/1475-4924-2-28
   Iyer NV, 1998, GENE DEV, V12, P149, DOI 10.1101/gad.12.2.149
   Kemp BE, 2003, BIOCHEM SOC T, V31, P162
   Lee M, 2003, J BIOL CHEM, V278, P39653, DOI 10.1074/jbc.M306104200
   Lee YJ, 1998, J BIOL CHEM, V273, P5294, DOI 10.1074/jbc.273.9.5294
   Levy AP, 1998, TRENDS CARDIOVAS MED, V8, P246, DOI 10.1016/S1050-1738(98)00020-6
   LEVY AP, 1995, J BIOL CHEM, V270, P13333, DOI 10.1074/jbc.270.22.13333
   Levy AP, 1996, J BIOL CHEM, V271, P2746, DOI 10.1074/jbc.271.5.2746
   Levy NS, 1998, J BIOL CHEM, V273, P6417, DOI 10.1074/jbc.273.11.6417
   LIU YX, 1995, CIRC RES, V77, P638, DOI 10.1161/01.RES.77.3.638
   Lizcano JM, 2004, EMBO J, V23, P833, DOI 10.1038/sj.emboj.7600110
   Ming XF, 1998, EMBO J, V17, P6039, DOI 10.1093/emboj/17.20.6039
   Onesto C, 2004, J BIOL CHEM, V279, P34217, DOI 10.1074/jbc.M400219200
   Pages G, 2000, J BIOL CHEM, V275, P26484, DOI 10.1074/jbc.M002104200
   ROSS J, 1995, MICROBIOL REV, V59, P423
   Sakamoto K, 2004, AM J PHYSIOL-ENDOC M, V287, pE310, DOI 10.1152/ajpendo.00074.2004
   Semenza GL, 1999, ANNU REV CELL DEV BI, V15, P551, DOI 10.1146/annurev.cellbio.15.1.551
   Shaw RJ, 2004, P NATL ACAD SCI USA, V101, P3329, DOI 10.1073/pnas.0308061100
   Shih SC, 1999, J BIOL CHEM, V274, P1359, DOI 10.1074/jbc.274.3.1359
   SHWEIKI D, 1995, P NATL ACAD SCI USA, V92, P768, DOI 10.1073/pnas.92.3.768
   Singh P, 2004, MOL CELL BIOCHEM, V260, P153, DOI 10.1023/B:MCBI.0000026067.08356.13
   STEIN I, 1995, MOL CELL BIOL, V15, P5363
   Tiainen M, 1999, P NATL ACAD SCI USA, V96, P9248, DOI 10.1073/pnas.96.16.9248
   Torres M, 2003, FRONT BIOSCI, V8, pD369, DOI 10.2741/999
   Wenger RH, 2002, FASEB J, V16, DOI 10.1096/fj.01-0944rev
   Woods A, 2000, MOL CELL BIOL, V20, P6704, DOI 10.1128/MCB.20.18.6704-6711.2000
   Woods A, 2003, CURR BIOL, V13, P2004, DOI 10.1016/j.cub.2003.10.031
   Zhang L, 2002, BIOCHEM BIOPH RES CO, V292, P860, DOI 10.1006/bbrc.2002.6710
   Zhou GC, 2001, J CLIN INVEST, V108, P1167, DOI 10.1172/JCI13505
NR 41
TC 120
Z9 121
U1 1
U2 4
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD MAR 18
PY 2005
VL 280
IS 11
BP 9963
EP 9972
DI 10.1074/jbc.M412994200
PG 10
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 905HQ
UT WOS:000227559600028
PM 15640157
OA Bronze
DA 2018-12-27
ER

PT J
AU Suzuki, M
   Hao, C
   Takahashi, T
   Shigematsu, H
   Shivapurkar, N
   Sathyanarayana, UG
   Iizasa, T
   Fujisawa, T
   Hiroshima, K
   Gazdar, AF
AF Suzuki, M
   Hao, C
   Takahashi, T
   Shigematsu, H
   Shivapurkar, N
   Sathyanarayana, UG
   Iizasa, T
   Fujisawa, T
   Hiroshima, K
   Gazdar, AF
TI RETRACTED: Aberrant methylation of SPARC in human lung cancers
   (Retracted article. See vol. 108, pg. 744, 2013)
SO BRITISH JOURNAL OF CANCER
LA English
DT Article; Retracted Publication
DE methylation; SPARC; lung cancer; immunostaining
ID EPITHELIAL OVARIAN-CANCER; MESSENGER-RNA EXPRESSION; DIFFERENTIAL
   EXPRESSION; MATRICELLULAR PROTEIN; CELLS; GENE; OVEREXPRESSION;
   ANGIOGENESIS; PROGRESSION; CARCINOMA
AB SPARC (secreted protein acidic and rich in cysteine) is an extracellular Ca2+-binding matricellular glycoprotein associated with the regulation of cell adhesion and growth. We investigated loss of expression of SPARC gene and promoter methylation in lung cancers and correlated the data with clinicopathological features. We observed loss of SPARC expression in 12 of 20 (60%) lung cancer cell lines. Treatment of expression-negative cell lines with a demethylating agent restored expression in all cases. Methylation frequencies of SPARC gene were 55% in 20 lung cancer cell lines. Primary tumours had methylation at a rate of 69% (119 of 173), while nonmalignant lung tissues (n = 60) had very low rates (3%). In lung adenocarcinomas, SPARC methylation correlated with a negative prognosis (P = 0.0021; relative risk 4.65, 95% confidence interval 1.75-12.35, multivariate Cox's proportional-hazard model). Immunostaining revealed protein expression in bronchial epithelium (weak intensity) and in juxtatumoral stromal tissues (strong intensity) accompanied by frequent loss in cancer cells that correlated with the presence of methylation (P<0.001). Our findings are of biological interest and potentially of clinical importance in human lung cancers.
C1 Chiba Univ, Dept Basic Pathol, Grad Sch Med, Chiba 2608607, Japan.
   Chiba Univ, Dept Thorac Surg, Grad Sch Med, Chiba 2608607, Japan.
   Univ Texas, SW Med Ctr, Dept Pathol, Hamon Ctr Therapeut Oncol Res, Dallas, TX 75390 USA.
RP Suzuki, M (reprint author), Chiba Univ, Dept Thorac Surg, Grad Sch Med, Chuo Ku, 1-8-1 Inohana, Chiba 2608670, Japan.
EM smakoto@chiba-cc.jp
FU NCI NIH HHS [P50 CA070907, P50CA70907]
CR Brabender J, 2003, BRIT J CANCER, V89, P1508, DOI 10.1038/sj.bjc.6601324
   Bradshaw AD, 2001, J CLIN INVEST, V107, P1049, DOI 10.1172/JCI12939
   Brekken RA, 2003, J CLIN INVEST, V111, P487, DOI 10.1172/JCI16804
   Brekken Rolf A., 2001, Matrix Biology, V19, P816
   Briggs J, 2002, ONCOGENE, V21, P7077, DOI 10.1038/sj.onc.1205857
   Brown TJ, 1999, GYNECOL ONCOL, V75, P25, DOI 10.1006/gyno.1999.5552
   Chlenski A, 2002, CANCER RES, V62, P7357
   De S, 2003, J BIOL CHEM, V278, P39044, DOI 10.1074/jbc.M304494200
   Demopoulos K, 2002, J CELL MOL MED, V6, P215, DOI 10.1111/j.1582-4934.2002.tb00188.x
   Esteller M, 2001, CANCER RES, V61, P3225
   EVERITT EA, 1992, EXP CELL RES, V199, P134, DOI 10.1016/0014-4827(92)90471-J
   EVERITT EA, 1992, BIOCHEM CELL BIOL, V70, P1368, DOI 10.1139/o92-185
   Girard L, 2000, CANCER RES, V60, P4894
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   HERRMANN BG, 1987, METHOD ENZYMOL, V152, P180
   Jendraschak E, 1996, SEMIN CANCER BIOL, V7, P139, DOI 10.1006/scbi.1996.0019
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Koukourakis MI, 2003, CANCER RES, V63, P5376
   LANE TF, 1994, J CELL BIOL, V125, P929, DOI 10.1083/jcb.125.4.929
   LANE TF, 1994, FASEB J, V8, P163
   Le Bail B, 1999, J PATHOL, V189, P46
   Ledda MF, 1997, NAT MED, V3, P171, DOI 10.1038/nm0297-171
   Massi D, 1999, HUM PATHOL, V30, P339, DOI 10.1016/S0046-8177(99)90014-X
   Motamed K, 1997, KIDNEY INT, V51, P1383, DOI 10.1038/ki.1997.189
   Paley PJ, 2000, GYNECOL ONCOL, V78, P336, DOI 10.1006/gyno.2000.5894
   Phelps RM, 1996, J CELL BIOCHEM, P32
   PORTE H, 1995, INT J CANCER, V64, P70, DOI 10.1002/ijc.2910640114
   Rempel SA, 1999, CLIN CANCER RES, V5, P237
   Sage EH, 1997, NAT MED, V3, P144
   SAGE H, 1989, J CELL BIOL, V109, P341, DOI 10.1083/jcb.109.1.341
   Sato N, 2003, ONCOGENE, V22, P5021, DOI 10.1038/sj.onc.1206807
   Schneider S, 2004, CLIN CANCER RES, V10, P1588, DOI 10.1158/1078-0432.CCR-0565-3
   Schultz C, 2002, CANCER RES, V62, P6270
   Suzuki M, 2004, CANCER RES, V64, P3137, DOI 10.1158/0008-5472.CAN-03-3046
   Thomas R, 2000, CLIN CANCER RES, V6, P1140
   Toyooka S, 2002, CLIN CANCER RES, V8, P2292
   Wakefield LM, 2002, CURR OPIN GENET DEV, V12, P22, DOI 10.1016/S0959-437X(01)00259-3
   Yamanaka M, 2001, J UROLOGY, V166, P2495, DOI 10.1016/S0022-5347(05)65623-6
   Yamashita K, 2003, CANCER, V97, P2412, DOI 10.1002/cncr.11368
   Yan Q, 1999, J HISTOCHEM CYTOCHEM, V47, P1495, DOI 10.1177/002215549904701201
   Yiu GK, 2001, AM J PATHOL, V159, P609, DOI 10.1016/S0002-9440(10)61732-4
NR 41
TC 58
Z9 59
U1 3
U2 11
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0007-0920
J9 BRIT J CANCER
JI Br. J. Cancer
PD MAR 14
PY 2005
VL 92
IS 5
BP 942
EP 948
DI 10.1038/sj.bjc.6602376
PG 7
WC Oncology
SC Oncology
GA 908YY
UT WOS:000227827300025
PM 15756262
OA Green Published, Other Gold
DA 2018-12-27
ER

PT J
AU Sato, Y
   Iwamoto, J
   Kanoko, T
   Satoh, K
AF Sato, Y
   Iwamoto, J
   Kanoko, T
   Satoh, K
TI RETRACTED: Risedronate therapy for prevention of hip fracture after
   stroke in elderly women(Retracted article.See vol.87,pg.239,2016)
SO NEUROLOGY
LA English
DT Article; Retracted Publication
ID VITAMIN-D DEFICIENCY; HYPOVITAMINOSIS D; CALCIUM HOMEOSTASIS; HEMIPLEGIC
   PATIENTS; PARKINSONS-DISEASE; BONE MASS; OSTEOPENIA; IMMOBILIZATION;
   AMELIORATION; OSTEOPOROSIS
AB Background: There is a high incidence of hip fractures in patients with hemiplegic stroke. Bone mineral density (BMD) is decreased in the hemiplegic side in patients after stroke, correlating with the degree of paralysis and of hypovitaminosis D. Objective: To evaluate the efficacy of risedronate in reducing the severity of osteoporosis and in decreasing the risk of hip fractures in elderly women following an acute stroke. Methods: This was a 12-month, randomized, double blind, placebo-controlled trial. In a prospective study of stroke patients, 187 patients received a daily dose of 2.5 mg risedronate for 12 months, and the remaining 187 received placebo. Incidence of hip fracture was compared between the two groups at the endpoint of the study. Results: Seven patients sustained hip fractures on the hemiplegic side in the placebo group, and one hip fracture occurred in the risedronate group (p = 0.0360; OR = 7.0). BMD increased by 1.5% and decreased by 4.9% in the risedronate group and placebo group (p < 0.0001). Urinary deoxypyridinoline, a bone resorption marker, decreased by 53.4% in the risedronate group and increased by 35.8% in the placebo group. Conclusion: Treatment with risedronate increases bone mineral density in elderly women following an acute stroke and prevents hip fractures.
C1 Mitate Hosp, Dept Neurol, Tagawa 8260041, Japan.
   Keio Univ, Sch Med, Dept Sport Med, Tokyo, Japan.
   Hirosaki Univ, Sch Med, Dept Rehabil Med, Hirosaki, Aomori 036, Japan.
   Hirosaki Univ, Sch Med, Dept Vasc Biol, Hirosaki, Aomori 036, Japan.
RP Satoh, K (reprint author), Mitate Hosp, Dept Neurol, 3237 Yugeta, Tagawa 8260041, Japan.
EM y-sato@ktarn.or.jp
CR CHAPUY MC, 1992, NEW ENGL J MED, V327, P1637, DOI 10.1056/NEJM199212033272305
   CHIU KY, 1992, INJURY, V23, P297, DOI 10.1016/0020-1383(92)90171-N
   DERISQUEBOURG T, 1994, CALCIFIED TISSUE INT, V54, P461, DOI 10.1007/BF00334323
   Fukunaga M, 2002, OSTEOPOROSIS INT, V13, P971, DOI 10.1007/s001980200135
   HOLICK MF, 1990, J NUTR, V120, P1464, DOI 10.1093/jn/120.suppl_11.1464
   HOOPER G, 1979, INJURY, V10, P281, DOI 10.1016/0020-1383(79)90044-5
   KEENE GS, 1993, BRIT MED J, V307, P1248, DOI 10.1136/bmj.307.6914.1248
   KOMAR L, 1993, J AM GERIATR SOC, V41, P1057, DOI 10.1111/j.1532-5415.1993.tb06452.x
   MAHONEY F I, 1965, Md State Med J, V14, P61
   MATSUMOTO C, 1994, CALCIFIED TISSUE INT, V55, P324, DOI 10.1007/BF00299308
   McClung MR, 2001, NEW ENGL J MED, V344, P333, DOI 10.1056/NEJM200102013440503
   POPLINGHER AR, 1985, ACTA ORTHOP SCAND, V56, P226
   Ramnemark A, 1998, OSTEOPOROSIS INT, V8, P92, DOI 10.1007/s001980050053
   Reginster JY, 2000, OSTEOPOROSIS INT, V11, P83, DOI 10.1007/s001980050010
   ROBINS SP, 1991, EUR J CLIN INVEST, V21, P310, DOI 10.1111/j.1365-2362.1991.tb01375.x
   Sato Y, 1998, J NEUROL SCI, V156, P205, DOI 10.1016/S0022-510X(98)00041-0
   Sato Y, 2002, BONE, V31, P114, DOI 10.1016/S8756-3282(02)00783-4
   Sato Y, 2000, J BONE MINER RES, V15, P2487, DOI 10.1359/jbmr.2000.15.12.2487
   Sato Y, 1999, J NEUROL NEUROSUR PS, V66, P64, DOI 10.1136/jnnp.66.1.64
   Sato Y, 1998, BONE, V23, P291, DOI 10.1016/S8756-3282(98)00108-2
   Sato Y, 2000, J NEUROL SCI, V175, P135, DOI 10.1016/S0022-510X(00)00298-7
   Sato Y, 1996, EUR NEUROL, V36, P278, DOI 10.1159/000117272
   Sato Y, 1999, AM J PHYS MED REHAB, V78, P457, DOI 10.1097/00002060-199909000-00008
   Sato Y, 1997, STROKE, V28, P736, DOI 10.1161/01.STR.28.4.736
   Sato Y, 1998, STROKE, V29, P1373, DOI 10.1161/01.STR.29.7.1373
   Sato Y, 1996, STROKE, V27, P2183, DOI 10.1161/01.STR.27.12.2183
   Scandinavian Stroke Study Group, 1985, STROKE, V16, P885
   SHAHAR E, 1995, STROKE, V26, P1
   STEWART AF, 1982, NEW ENGL J MED, V306, P1136, DOI 10.1056/NEJM198205133061903
   Thomas MK, 1998, NEW ENGL J MED, V338, P777, DOI 10.1056/NEJM199803193381201
   van Beek ER, 2003, BONE, V33, P805, DOI 10.1016/j.bone.2003.07.007
NR 31
TC 63
Z9 65
U1 3
U2 7
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0028-3878
EI 1526-632X
J9 NEUROLOGY
JI Neurology
PD MAR 8
PY 2005
VL 64
IS 5
BP 811
EP 816
DI 10.1212/01.WNL.0000152871.65027.76
PG 6
WC Clinical Neurology
SC Neurosciences & Neurology
GA 904BL
UT WOS:000227470000009
PM 15753414
DA 2018-12-27
ER

PT J
AU Sathunuru, R
   Quirion, JC
AF Sathunuru, R
   Quirion, JC
TI RETRACTED: First stereoselective total synthesis of
   (-)-(2R,10S)-megapodiol (Retracted Article. See vol 17, pg 2953, 2006)
SO TETRAHEDRON-ASYMMETRY
LA English
DT Article; Retracted Publication
ID ASYMMETRIC EPOXIDATION
AB The first and efficient total synthesis of (-)-(2R,10S)-megapodiol 2 was accomplished stereoselectively, using a Sharpless asymmetric epoxidation of a trans allylic alcohol, intramolecular epoxide opening by phenolic hydroxyl, and cyclization as the key reaction steps. (C) 2005 Elsevier Ltd. All rights reserved.
C1 Univ Rouen, F-76821 Mont St Aignan, France.
   INSA, IRCOF, CNRS, Lab Heterochim Organ, F-76821 Mont St Aignan, France.
RP Sathunuru, R (reprint author), So Methodist Univ, Dept Chem, Fondern Sci Bldg,3215 Daniel Ave, Dallas, TX 75275 USA.
EM rsathunu@mail.smu.edu
CR BONNER WA, 1964, TETRAHEDRON, V20, P1419, DOI 10.1016/S0040-4020(01)99135-5
   COLONGE J, 1965, B SOC CHIM FR, P619
   Finn MG, 1985, ASYMMETRIC SYNTHESIS, P247
   GAO Y, 1987, J AM CHEM SOC, V109, P5765, DOI 10.1021/ja00253a032
   Goujon JY, 2002, J CHEM SOC PERK T 1, P496, DOI 10.1039/b110578g
   JARVIS BB, 1987, J ORG CHEM, V52, P45
   JARVIS BB, 1986, PHYTOCHEMISTRY, V25, P533, DOI 10.1016/S0031-9422(00)85519-3
   KATSUKI T, 1980, J AM CHEM SOC, V102, P5974, DOI 10.1021/ja00538a077
   MARQUARD I, Patent No. 183042
   PFENNINGER A, 1986, SYNTHESIS-STUTTGART, P89
   Ramadas S, 2000, TETRAHEDRON-ASYMMETR, V11, P3375, DOI 10.1016/S0957-4166(00)00302-5
   Rossiter B. E., 1985, ASYMMETRIC SYNTHESIS, V5, P193
NR 12
TC 3
Z9 3
U1 2
U2 10
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0957-4166
J9 TETRAHEDRON-ASYMMETR
JI Tetrahedron-Asymmetry
PD MAR 7
PY 2005
VL 16
IS 5
BP 917
EP 919
DI 10.1016/j.tetasy.2005.01.011
PG 3
WC Chemistry, Inorganic & Nuclear; Chemistry, Organic; Chemistry, Physical
SC Chemistry
GA 904OW
UT WOS:000227508600002
DA 2018-12-27
ER

PT J
AU Pins, JJ
   First, SM
   Keenan, JM
AF Pins, JJ
   First, SM
   Keenan, JM
TI RETRACTED: The effects of the dietary supplement pantethine on blood
   lipids and body composition in generally healthy dyslipidernic adults
   (Retracted article. See vol. 23, pg. 1616, 2009)
SO FASEB JOURNAL
LA English
DT Meeting Abstract; Retracted Publication
CT Experimental Biology 2005 Meeting/35th International Congress of
   Physiological Sciences
CY MAR 31-APR 06, 2005
CL San Diego, CA
SP Amer Assoc Anatomists, Amer Assoc Immunologists, Amer Physiol Soc, Amer Soc Biochem & Mol Biol, Amer Soc Investigat Pathol, Amer Soc Nutr Sci, Amer Soc Pharmacol & Expt Therapeut, Int Union Physiol Sci
C1 Univ Minnesota, Dept Family Med & Community Hlth, Minneapolis, MN 55455 USA.
NR 0
TC 1
Z9 1
U1 2
U2 6
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
EI 1530-6860
J9 FASEB J
JI Faseb J.
PD MAR 4
PY 2005
VL 19
IS 4
SU S
BP A417
EP A417
PN 1
PG 1
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
   Topics; Cell Biology
GA 905ZQ
UT WOS:000227610703003
DA 2018-12-27
ER

PT J
AU Sato, Y
   Honda, Y
   Iwamoto, J
   Kanoko, T
   Satoh, K
AF Sato, Y
   Honda, Y
   Iwamoto, J
   Kanoko, T
   Satoh, K
TI RETRACTED: Effect of folate and mecobalamin on hip fractures in patients
   with stroke - A randomized controlled trial (Retracted article. See vol.
   315, pg. 2405, 2016)
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Article; Retracted Publication
ID ISCHEMIC-STROKE; MYOCARDIAL-INFARCTION; PLASMA HOMOCYSTEINE; VERTEBRAL
   FRACTURES; HEMIPLEGIC PATIENTS; ELDERLY-PEOPLE; BONE-DENSITY;
   RISK-FACTORS; FOLIC-ACID; WOMEN
AB Context Stroke increases the risk of subsequent hip fracture by 2 to 4 times. Hyperhomocysteinemia is a risk factor for both ischemic stroke and osteoporotic fractures in elderly men and women. Treatment with folate and mecobalamin (vitamin B-12) may improve hyperhomocysteinemia. Objective To investigate whether treatment with folate and vitamin B12 reduces the incidence of hip fractures in patients with hemiplegia following stroke. Design, Setting, and Patients A double-blind, randomized controlled study of 628 consecutive patients aged 65 years or older with residual hemiplegia at least 1 year following first ischemic stroke, who were recruited from a single Japanese hospital from April 1, 2000, to May 31, 2001. Patients were assigned to daily oral treatment with 5 mg of folate and 1500 mug of mecobalamin, or double placebo; 559 completed the 2-year follow-up. Main Outcome Measure Incidence of hip fractures in the 2 patient groups during the 2-year follow-up. Results At baseline, patients in both groups had high levels of plasma homocysteine and low levels of serum cobalamin and serum folate. After 2 years, plasma homocysteine levels decreased by 38% in the treatment group and increased by 31 % in the placebo group (P<.001). The number of hip fractures per 1000 patient-years was 10 and 43 for the treatment and placebo groups, respectively (P<.001). The adjusted relative risk, absolute risk reduction, and the number needed to treat for hip fractures in the treatment vs placebo groups were 0.20 (95% confidence interval [CI], 0.080.50), 7.1 % (95% Cl, 3.6%-10.8%), and 14 (95% Cl, 9-28), respectively. No significant adverse effects were reported. Conclusion In this Japanese population with a high baseline fracture risk, combined treatment with folate and vitamin 131, is safe and effective in reducing the risk of a hip fracture in elderly patients following stroke.
C1 Mitate Hosp, Dept Neurol, Tagawa 8260041, Japan.
   Keio Univ, Sch Med, Dept Sports Med, Tokyo, Japan.
   Hirosaki Univ, Sch Med, Inst Brain Sci, Dept Rehabil Med, Hirosaki, Aomori 036, Japan.
   Hirosaki Univ, Sch Med, Inst Brain Sci, Dept Vasc Biol, Hirosaki, Aomori 036, Japan.
RP Sato, Y (reprint author), Mitate Hosp, Dept Neurol, 3237 Yugeta, Tagawa 8260041, Japan.
EM y-sato@ktarn.or.jp
CR ARAKI A, 1989, ATHEROSCLEROSIS, V79, P139, DOI 10.1016/0021-9150(89)90118-4
   ASPLUND K, 1985, STROKE, V16, P885
   Bainbridge KE, 2004, OSTEOPOROSIS INT, V15, P439, DOI 10.1007/s00198-003-1562-5
   Bots ML, 1999, ARCH INTERN MED, V159, P38, DOI 10.1001/archinte.159.1.38
   BRATTSTROM L, 1990, ATHEROSCLEROSIS, V81, P51, DOI 10.1016/0021-9150(90)90058-Q
   BRATTSTROM L, 1992, EUR J CLIN INVEST, V22, P214, DOI 10.1111/j.1365-2362.1992.tb01829.x
   BROWNER WS, 1991, LANCET, V338, P1470, DOI 10.1016/0140-6736(91)92782-W
   CHIU KY, 1992, INJURY, V23, P297, DOI 10.1016/0020-1383(92)90171-N
   Cummings SR, 1998, JAMA-J AM MED ASSOC, V280, P2077, DOI 10.1001/jama.280.24.2077
   DawsonHughes B, 1997, NEW ENGL J MED, V337, P670, DOI 10.1056/NEJM199709043371003
   Delmas PD, 2003, BONE, V33, P522, DOI 10.1016/S8756-3282(03)00241-2
   Eikelboom JW, 2000, STROKE, V31, P1069, DOI 10.1161/01.STR.31.5.1069
   El Kossi MMH, 2000, STROKE, V31, P1889, DOI 10.1161/01.STR.31.8.1889
   GRIECO AJ, 1977, AM J MED SCI, V273, P120, DOI 10.1097/00000441-197703000-00001
   Henderson LB, 2000, GENET MED, V2, P222, DOI 10.1097/00125817-200007000-00004
   HOOPER G, 1979, INJURY, V10, P281, DOI 10.1016/0020-1383(79)90044-5
   JACKSON SH, 1973, CLIN CHIM ACTA, V45, P215, DOI 10.1016/0009-8981(73)90429-4
   JOOSTEN E, 1993, AM J CLIN NUTR, V58, P468
   LINDGREN A, 1995, STROKE, V26, P795, DOI 10.1161/01.STR.26.5.795
   MAHONEY F I, 1965, Md State Med J, V14, P61
   Matsui T, 2001, STROKE, V32, P1116, DOI 10.1161/01.STR.32.5.1116
   MATSUMOTO C, 1994, CALCIFIED TISSUE INT, V55, P324, DOI 10.1007/BF00299308
   McKusick V. A., 1966, HERITABLE DISORDERS, P155
   McLean RR, 2004, NEW ENGL J MED, V350, P2042, DOI 10.1056/NEJMoa032739
   MORREELS CL, 1968, RADIOLOGY, V90, P1150, DOI 10.1148/90.6.1150
   MUDD SH, 1985, AM J HUM GENET, V37, P1
   MULLEY G, 1979, POSTGRAD MED J, V55, P264, DOI 10.1136/pgmj.55.642.264
   Nurmi I, 2003, ARCH ORTHOP TRAUM SU, V123, P551, DOI 10.1007/s00402-003-0583-z
   PERRY IJ, 1995, LANCET, V346, P1395, DOI 10.1016/S0140-6736(95)92407-8
   POPLINGHER AR, 1985, ACTA ORTHOP SCAND, V56, P226
   Ramnemark A, 1998, OSTEOPOROSIS INT, V8, P92, DOI 10.1007/s001980050053
   Sato Y, 2001, STROKE, V32, P1673, DOI 10.1161/01.STR.32.7.1673
   Sato Y, 2000, J BONE MINER RES, V15, P2487, DOI 10.1359/jbmr.2000.15.12.2487
   Sato Y, 2003, NEUROLOGY, V61, P338, DOI 10.1212/01.WNL.0000078892.24356.90
   Sato Y, 2002, J NEUROL SCI, V202, P65, DOI 10.1016/S0022-510X(02)00210-1
   Sato Y, 1996, EUR NEUROL, V36, P278, DOI 10.1159/000117272
   Toole JF, 2004, JAMA-J AM MED ASSOC, V291, P565, DOI 10.1001/jama.291.5.565
   UELAND PM, 1993, CLIN CHEM, V39, P1764
   UELAND PM, 1992, ATHEROSCLEROTIC CARD, P183
   van Meurs JBJ, 2004, NEW ENGL J MED, V350, P2033, DOI 10.1056/NEJMoa032546
   VERHOEF P, 1994, STROKE, V25, P1924, DOI 10.1161/01.STR.25.10.1924
NR 41
TC 195
Z9 205
U1 4
U2 17
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0098-7484
EI 1538-3598
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD MAR 2
PY 2005
VL 293
IS 9
BP 1082
EP 1088
DI 10.1001/jama.293.9.1082
PG 7
WC Medicine, General & Internal
SC General & Internal Medicine
GA 901LY
UT WOS:000227285200018
PM 15741530
OA Bronze
DA 2018-12-27
ER

PT J
AU Chen, H
   Mei, H
   Shen, PN
   Jiang, HQ
AF Chen, H
   Mei, H
   Shen, PN
   Jiang, HQ
TI RETRACTED: Heavy quarkonium mass spectra in a relativistic quark model
   (Retracted Article)
SO ACTA PHYSICA SINICA
LA Chinese
DT Article; Retracted Publication
DE heavy quarkonium; mass spectrum; relativistic correction; annihilation
   potential
ID CONFINEMENT; CHARMONIUM; MESONS
AB The mass spectra of heavy quarkonia are calculated with the relativistic quark model. The effective interaction between a quark and an antiquark of the same flavor is assumed to be the sum of the one-gluon exchange with the inclusion of annihilation terms and the mixture of scalar and vector linear confining potentials with the relativisic corrections. The effects of the annihilation and the relativistic correction terms on the hyperfine splittings of quarkonium states are discussed in detail,and a good fit to the observed experimental data is obtained on the mass spectra.
C1 SW China Normal Univ, Sch Phys, Chongqing 400715, Peoples R China.
   Chinese Acad Sci, Inst High Energy Phys, Beijing 100039, Peoples R China.
RP Chen, H (reprint author), SW China Normal Univ, Sch Phys, Chongqing 400715, Peoples R China.
CR Bali GS, 1999, PHYS LETT B, V460, P170, DOI 10.1016/S0370-2693(99)00757-1
   BARCHIELLI A, 1990, NUOVO CIMENTO A, V103, P59, DOI 10.1007/BF02902620
   Brambilla N, 1997, PHYS LETT B, V407, P167, DOI 10.1016/S0370-2693(97)00749-1
   BUCHMULLER W, 1982, PHYS LETT B, V112, P479, DOI 10.1016/0370-2693(82)90854-1
   CUPTA S, 1994, PHYS REV D, V49, P1551
   Ding YB, 1996, PHYS REV D, V54, P1136, DOI 10.1103/PhysRevD.54.1136
   Ebert D, 2003, PHYS REV D, V67, DOI 10.1103/PhysRevD.67.014027
   Ebert D, 2000, PHYS REV D, V62, DOI 10.1103/PhysRevD.62.034014
   EICHTEN E, 1980, PHYS REV D, V21, P203, DOI 10.1103/PhysRevD.21.203
   GODFREY S, 1985, PHYS REV D, V32, P189, DOI 10.1103/PhysRevD.32.189
   GROMES DE, 2000, EUR PHYS J C, V15, P651
   KEN PE, 1985, COMPUT PHYS COMMUN, V34, P287
   MCCLARY R, 1983, PHYS REV D, V28, P1692, DOI 10.1103/PhysRevD.28.1692
   OLSSON MG, 1987, PHYS REV D, V35, P1738, DOI 10.1103/PhysRevD.35.1738
   SCHNITZER HJ, 1975, PHYS REV LETT, V35, P1540, DOI 10.1103/PhysRevLett.35.1540
   SHEN PN, 1992, PHYS REV C, V45, P1894
   Szczepaniak AP, 1997, PHYS REV D, V55, P3987, DOI 10.1103/PhysRevD.55.3987
   Yang JJ, 1998, NUCL PHYS A, V640, P457, DOI 10.1016/S0375-9474(98)00448-5
NR 18
TC 1
Z9 2
U1 2
U2 5
PU CHINESE PHYSICAL SOC
PI BEIJING
PA P O BOX 603, BEIJING 100080, PEOPLES R CHINA
SN 1000-3290
J9 ACTA PHYS SIN-CH ED
JI Acta Phys. Sin.
PD MAR
PY 2005
VL 54
IS 3
BP 1136
EP 1141
PG 6
WC Physics, Multidisciplinary
SC Physics
GA 908KQ
UT WOS:000227786300024
DA 2018-12-27
ER

PT J
AU Fechner, J
   Ihmsen, H
   Schiessl, C
   Jeleazcov, C
   Vornov, JJ
   Schwilden, H
   Schuttler, J
AF Fechner, J
   Ihmsen, H
   Schiessl, C
   Jeleazcov, C
   Vornov, JJ
   Schwilden, H
   Schuttler, J
TI RETRACTED: Sedation with GPI 15715, a water-soluble prodrug of propofol,
   using target-controlled infusion in volunteers (Retracted article. See
   vol. 110, pg. 1238, 2010)
SO ANESTHESIA AND ANALGESIA
LA English
DT Article; Retracted Publication
ID COMPUTER-CONTROLLED INFUSION; MONITORED ANESTHESIA CARE; BISPECTRAL
   INDEX; PHARMACODYNAMICS; PERFORMANCE; PHARMACOKINETICS; COLONOSCOPY;
   FORMULATION; MIDAZOLAM; SAFETY
AB GPI 15715 is the first water-soluble propofol prodrug that has been studied in humans. Present propofol lipid formulations have well known undesirable properties, for example, pain on injection and increased triglyceride concentrations. We investigated whether GPI 15715 is suitable to achieve and maintain moderate sedation for 2 h. Six male and six female volunteers received a targetcontrolled infusion of GPI 15715, with an initial propofol target concentration of 1.8 mug/mL and the possibility to adjust the propofol target once after 1 h. Propofol concentrations, the bispectral index, and modified Observer's Assessment of Alertness/Sedation Scale (MOAA/S) scores were monitored. The median MOAA/S score was 4 during the first hour and was 3 during the second hour of infusion. The propofol target had to be changed to 2.4 mug/mL in seven volunteers and to 3.0 mug/mL in two volunteers. A propofol concentration of 1.9 mug/mL had the highest probability to result in an MOAA/S score of 3, which corresponds with moderate sedation. We observed no serious side effects. We conclude that GPI 15715 produces excellent sedation.
C1 Univ Erlangen Nurnberg, Dept Anesthesiol, D-91054 Erlangen, Germany.
   Guilford Pharmaceut Inc, Baltimore, MD USA.
RP Fechner, J (reprint author), Univ Erlangen Nurnberg, Dept Anesthesiol, Krankenhausstr 12, D-91054 Erlangen, Germany.
EM joerg.fechner@kfa.imed.uni-erlangen.de
OI Vornov, James/0000-0003-1965-5456
CR Bachmann-Mennenga B, 2003, ARZNEIMITTEL-FORSCH, V53, P621
   Banaszczyk MG, 2002, ANESTH ANALG, V95, P1285, DOI 10.1213/01.ANE.0000031120.74200.D4
   Bennett DJ, 2003, BIOORG MED CHEM LETT, V13, P1971, DOI 10.1016/S0960-894X(03)00346-9
   Casati A, 1999, CAN J ANAESTH, V46, P235, DOI 10.1007/BF03012602
   CHERNIK DA, 1990, J CLIN PSYCHOPHARM, V10, P244
   Doufas AG, 2003, ACTA ANAESTH SCAND, V47, P951, DOI 10.1034/j.1399-6576.2003.00184.x
   Egan TD, 2003, ANESTH ANALG, V97, P72, DOI 10.1213/01.ANE.0000066019.42467.7A
   Fechner J, 2003, ANESTHESIOLOGY, V99, P303, DOI 10.1097/00000542-200308000-00012
   Fechner J, 1998, ANAESTHESIST, V47, P663, DOI 10.1007/s001010050611
   Heuss LT, 2003, AM J GASTROENTEROL, V98, P1751, DOI 10.1016/S0002-9270(03)00447-7
   Kearse LA, 1998, ANESTHESIOLOGY, V88, P25, DOI 10.1097/00000542-199801000-00007
   Kimura T, 2001, Masui, V50, P1009
   Knibbe CAJ, 2002, CLIN PHARMACOL THER, V72, P670, DOI 10.1067/mcp.2002.129500
   Kulling D, 2003, ENDOSCOPY, V35, P679
   Leslie K, 2002, ANAESTHESIA, V57, P693, DOI 10.1046/j.1365-2044.2002.02572_2.x
   Liu J, 1997, ANESTH ANALG, V84, P185, DOI 10.1097/00000539-199701000-00033
   Luer MS, 1998, NEUROL RES, V20, P178
   NEWSON C, 1995, ANESTH ANALG, V81, P486, DOI 10.1097/00000539-199509000-00010
   PLUMMER GF, 1987, J CHROMATOGR-BIOMED, V421, P171, DOI 10.1016/0378-4347(87)80394-8
   SaRego MM, 1997, ANESTH ANALG, V85, P1020, DOI 10.1097/00000539-199711000-00012
   Shinozaki N, 2002, CAN J ANAESTH, V49, P927, DOI 10.1007/BF03016876
   Sklar GE, 1997, ANN PHARMACOTHER, V31, P1521
   Skoglosa J, 2003, ACTA PAEDIATR, V92, P704, DOI 10.1080/08035250310002362
   Somma J, 1998, ANESTHESIOLOGY, V89, P1430, DOI 10.1097/00000542-199812000-00021
   VARVEL JR, 1992, J PHARMACOKINET BIOP, V20, P63, DOI 10.1007/BF01143186
   Vasile B, 2003, INTENS CARE MED, V29, P1417, DOI 10.1007/s00134-003-1905-x
   VUYK J, 1995, ANESTH ANALG, V81, P1275, DOI 10.1097/00000539-199512000-00026
   WALMSLEY AJ, 1986, EUR J ANAESTH, V3, P19
NR 28
TC 29
Z9 32
U1 3
U2 14
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0003-2999
J9 ANESTH ANALG
JI Anesth. Analg.
PD MAR
PY 2005
VL 100
IS 3
BP 701
EP 706
DI 10.1213/01.ANE.0000144772.13372.F4
PG 6
WC Anesthesiology
SC Anesthesiology
GA 900NH
UT WOS:000227221100018
PM 15728055
DA 2018-12-27
ER

PT J
AU Mizuno, K
   Matsuyama, W
   Mitsuyama, H
   Watanabe, M
   Higashimoto, I
   Osame, M
   Arimura, K
AF Mizuno, K
   Matsuyama, W
   Mitsuyama, H
   Watanabe, M
   Higashimoto, I
   Osame, M
   Arimura, K
TI RETRACTED: Clinical investigation: increased serum stromal derived
   factor 1 alpha levels in pulmonary tuberculosis (Retracted article. See
   vol 154, pg. 433, 2008)
SO CLINICAL AND EXPERIMENTAL IMMUNOLOGY
LA English
DT Article; Retracted Publication
DE stromal derived factor 1 alpha; CXCR4; multinuclear giant cell; purified
   protein derivatives of tuberculin; macrophage
ID CHEMOKINE RECEPTOR CXCR4; IMMUNODEFICIENCY-VIRUS TYPE-1; ACTIVATED
   PROTEIN-KINASE; SKIN-TEST ANERGY; MYCOBACTERIUM-TUBERCULOSIS; LYMPHOCYTE
   CHEMOATTRACTANT; SIGNAL-TRANSDUCTION; PERIPHERAL-BLOOD; T-LYMPHOCYTES; I
   INFECTION
AB Pulmonary tuberculosis, a granulomatous disease, has few serological markers for its activity. Recently, an increased plasma level of stromal derived factor 1 alpha (SDF-1alpha), which can induce strong chemotaxis of cells through its receptor CXCR4, was detected in patients with tuberculosis. In this study we investigated serum SDF-1alpha levels and CXCR4 expression on peripheral blood mononuclear cells (PBMCs). Fifty-five active tuberculosis patients, 30 resolved tuberculosis patients, 27 acute bronchitis patients and 8 healthy volunteers were examined. Histological expression of SDF-1alpha in the tuberculosis lesion and CXCR4 expression of PBMCs were also analysed. Serum SDF-1alpha levels in active tuberculosis patients were significantly higher than other groups. The sensitivity and specificity for the diagnosis of active tuberculosis was 88.5% and 85.3% (cutoff value = 650 pg/ml), respectively. CXCR4 expression levels on PBMCs showed a significant negative correlation with serum SDF-1alpha levels. Inflammatory cells including multinuclear giant cells in the lesion expressed SDF-1alpha. Measurement of serum SDF-1alpha could be a useful screening marker for the identification of active pulmonary tuberuculosis. We propose that interaction of SDF-1alpha and CXCR4 might be involved in the pathogenesis of pulmonary tuberculosis.
C1 Kagoshima Univ, Fac Med, Dept Internal Med 3, Kagoshima 8908520, Japan.
RP Matsuyama, W (reprint author), Kagoshima Univ, Fac Med, Dept Internal Med 3, 8-35-1 Sakuragaoka, Kagoshima 8908520, Japan.
EM vega@xa2.so-net.ne.jp
CR Aiuti A, 1997, J EXP MED, V185, P111, DOI 10.1084/jem.185.1.111
   *AM THOR SOC, 1990, AM REV RESPIR DIS, V142, P725
   Amara A, 1997, J EXP MED, V186, P139, DOI 10.1084/jem.186.1.139
   Armengol MP, 2003, J IMMUNOL, V170, P6320, DOI 10.4049/jimmunol.170.12.6320
   Baggiolini M, 1997, ANNU REV IMMUNOL, V15, P675, DOI 10.1146/annurev.immunol.15.1.675
   Balabanian K, 2003, J IMMUNOL, V170, P3392, DOI 10.4049/jimmunol.170.6.3392
   Bleul CC, 1996, NATURE, V382, P829, DOI 10.1038/382829a0
   Bleul CC, 1996, J EXP MED, V184, P1101, DOI 10.1084/jem.184.3.1101
   CAIAFFA WT, 1995, ARCH INTERN MED, V155, P2111, DOI 10.1001/archinte.155.19.2111
   DApuzzo M, 1997, EUR J IMMUNOL, V27, P1788, DOI 10.1002/eji.1830270729
   Davis CB, 1997, J EXP MED, V186, P1793, DOI 10.1084/jem.186.10.1793
   Ferrero E, 2003, IMMUNOLOGY, V108, P365, DOI 10.1046/j.1365-2567.2003.01600.x
   Foulds J, 1998, INT J TUBERC LUNG D, V2, P778
   Ganju RK, 1998, J BIOL CHEM, V273, P23169, DOI 10.1074/jbc.273.36.23169
   GRAHAM NMH, 1992, JAMA-J AM MED ASSOC, V267, P369, DOI 10.1001/jama.267.3.369
   HUEBNER RE, 1994, CLIN INFECT DIS, V19, P26, DOI 10.1093/clinids/19.1.26
   Jourdan P, 1998, J IMMUNOL, V160, P4153
   Katsuta T, 2000, AM J GASTROENTEROL, V95, P3157
   KUNKEL SL, 1989, AM J RESP CELL MOL, V1, P439, DOI 10.1165/ajrcmb/1.6.439
   Kurashima K, 1997, AM J RESP CRIT CARE, V155, P1474, DOI 10.1164/ajrccm.155.4.9105097
   Lin YG, 1998, INFECT IMMUN, V66, P1121
   Matsuyama W, 2004, J IMMUNOL, V172, P2332, DOI 10.4049/jimmunol.172.4.2332
   Matsuyama W, 2003, FASEB J, V17, P1286, DOI 10.1096/fj.02-0320fje
   Matsuyama W, 2000, AM J RESP CRIT CARE, V162, P1120, DOI 10.1164/ajrccm.162.3.9911010
   Mittal GA, 2003, RHEUMATOLOGY, V42, P915, DOI 10.1093/rheumatology/keg234
   Mohle R, 1998, BLOOD, V91, P4523
   Moore JP, 1997, CURR OPIN IMMUNOL, V9, P551, DOI 10.1016/S0952-7915(97)80110-0
   NAGASAWA T, 1994, P NATL ACAD SCI USA, V91, P2305, DOI 10.1073/pnas.91.6.2305
   Nagasawa T, 1996, NATURE, V382, P635, DOI 10.1038/382635a0
   Oonakahara K, 2004, AM J RESP CELL MOL, V30, P671, DOI 10.1165/rcmb.2003-0340OC
   Phillips RJ, 2003, AM J RESP CRIT CARE, V167, P1676, DOI 10.1164/rccm.200301-071OC
   Popik W, 1998, J VIROL, V72, P6406
   Rollins BJ, 1997, BLOOD, V90, P909
   Rossi D, 2000, ANNU REV IMMUNOL, V18, P217, DOI 10.1146/annurev.immunol.18.1.217
   Sadek MI, 1998, AM J RESP CELL MOL, V19, P513, DOI 10.1165/ajrcmb.19.3.2815
   Saukkonen JJ, 2002, INFECT IMMUN, V70, P1684, DOI 10.1128/IAI.70.4.1684-1693.2002
   Shalekoff S, 2003, AIDS RES HUM RETROV, V19, P461, DOI 10.1089/088922203766774504
   Shalekoff S, 2001, J CLIN IMMUNOL, V21, P390, DOI 10.1023/A:1013121625962
   SHIROZU M, 1995, GENOMICS, V28, P495, DOI 10.1006/geno.1995.1180
   Soriano A, 2002, J INFECT DIS, V186, P922, DOI 10.1086/343741
   Sotsios Y, 1999, J IMMUNOL, V163, P5954
   Sozzani S, 1997, J IMMUNOL, V159, P1993
   Terada R, 2003, LAB INVEST, V83, P665, DOI 10.1097/01.LAB.0000067498.89585.06
   Verani Alessia, 2002, Current Molecular Medicine (Hilversum), V2, P691, DOI 10.2174/1566524023361862
   Wang JF, 1998, BLOOD, V92, P756
   Yamagami H, 2001, INFECT IMMUN, V69, P810, DOI 10.1128/IAI.69.2.810-815.2001
   Zlotnik A, 2000, IMMUNITY, V12, P121, DOI 10.1016/S1074-7613(00)80165-X
   Zou YR, 1998, NATURE, V393, P595, DOI 10.1038/31269
NR 48
TC 5
Z9 6
U1 3
U2 7
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0009-9104
EI 1365-2249
J9 CLIN EXP IMMUNOL
JI Clin. Exp. Immunol.
PD MAR
PY 2005
VL 139
IS 3
BP 490
EP 497
DI 10.1111/j.1365-2249.2005.02721.x
PG 8
WC Immunology
SC Immunology
GA 900PN
UT WOS:000227226900014
PM 15730395
OA Green Published
DA 2018-12-27
ER

PT J
AU Rohm, KD
   Suttner, SW
   Boldt, J
   Schollhorn, TAH
   Piper, SN
AF Rohm, KD
   Suttner, SW
   Boldt, J
   Schollhorn, TAH
   Piper, SN
TI RETRACTED: Insignificant effect of desflurane-fentanyl-thipental on
   hepatocellular integrity - a comparison with total intravenous
   anaesthesia using propofol-remifentanil (Retracted article. See vol. 28,
   pg. 468, 2011)
SO EUROPEAN JOURNAL OF ANAESTHESIOLOGY
LA English
DT Article; Retracted Publication
DE anaesthetics, desflurane, propofol; opioids, remifentanil; anaesthesia,
   intravenous, inhalational; glutathione transferase, alpha, hepatic;
   transaminases, alanine aminotransaminase, aspartate aminotransaminase
ID GLUTATHIONE-S-TRANSFERASE; INDOCYANINE GREEN CLEARANCE; PROLONGED
   ANESTHESIA; SEVOFLURANE ANESTHESIA; PLASMA-CONCENTRATIONS; INHALED
   ANESTHETICS; HEPATIC-FUNCTION; ISOFLURANE; HALOTHANE; HYPOTENSION
AB Background and objective: Inhalational anaesthetics have been associated with hepatotoxicity. Even desflurane, with its low solubility in blood and tissues, and its minimal hepatic biotransformation, is known to affect hepatic integrity. The effects of propofol on hepatic function are, however, a matter of controversy. Alpha-glutathione S-transferase (alpha-GST), a sensitive and specific biomarker for hepatic integrity, was measured to assess the influence of total intravenous anaesthesia (TIVA) with propofol vs. anaesthesia with desflurane.
   Methods: Forty-two patients scheduled for elective prostatectomy were randomly allocated to receive either desflurane, fentanyl and thiopental (desflurane group) or propofol and remifentanil (TIVA group). Depth of anaesthesia was guided by bispectral. index. Plasma concentrations of alpha-GST and aminotransferases were measured before induction of anaesthesia (T0), at the end of surgery (T1), as well as 2 h (T2) and 24 h (T3) postoperatively. Haemodynamic parameters and bispectral index values were documented.
   Results: alpha-GST increased significantly in the desflurane group from TO (3.0 +/- 2.2 mu g L-1) to T1 and T2 (5.5 +/- 4.3 and 5.6 +/- 3.7 mu g L-1, respectively), whereas no changes were seen in the TIVA group. alpha-GST values above the normal upper limit (>7.5 mu g L-1) were seen in 24% of the patients receiving desflurane. Aminotransferases remained unchanged in both groups throughout the study period.
   Conclusions: The use of propofol as part of a TIVA regimen seems to have no influence on hepatocellular function during and after surgery. In contrast, patients receiving desflurane showed a transient slight, but significant, increase of alpha-GST to above the normal upper limit after anaesthesia, although this was without further clinical relevance.
C1 Klinikum Ludwigshafen, Dept Anaesthesiol & Intens Care Med, D-67063 Ludwigshafen, Germany.
RP Rohm, KD (reprint author), Klinikum Ludwigshafen, Dept Anaesthesiol & Intens Care Med, Bremserstr 79, D-67063 Ludwigshafen, Germany.
EM k.d.roehm@t-online.de
CR ALDRIDGE LM, 1993, CLIN CHEM ENZYMOLOGY, V5, P195
   ALLAN LG, 1987, LANCET, V1, P771
   Armbruster K, 1997, ANESTH ANALG, V84, P271, DOI 10.1097/00000539-199702000-00007
   Bao YP, 1998, BRIT J ANAESTH, V81, P584, DOI 10.1093/bja/81.4.584
   Bauer C, 1995, Anasthesiol Intensivmed Notfallmed Schmerzther, V30, P226, DOI 10.1055/s-2007-996480
   BECKETT GJ, 1987, J CLIN BIOCHEM NUTR, V2, P1
   BECKETT GJ, 1993, ADV CLIN CHEM, V30, P281, DOI 10.1016/S0065-2423(08)60198-5
   BECKETT GJ, 1985, GUT, V26, P26, DOI 10.1136/gut.26.1.26
   Chen TL, 2000, BRIT J ANAESTH, V84, P771
   EGER EI, 1994, ANESTHESIOLOGY, V80, P906, DOI 10.1097/00000542-199404000-00024
   Fukushima M, 1999, Masui, V48, P1105
   HARTMAN JC, 1992, CAN J ANAESTH, V39, P877, DOI 10.1007/BF03008300
   HOWIE AF, 1992, CLIN CHEM, V38, P476
   HUSSEY AJ, 1988, BRIT J ANAESTH, V60, P130, DOI 10.1093/bja/60.2.130
   Johansen JW, 2000, ANESTHESIOLOGY, V93, P1336, DOI 10.1097/00000542-200011000-00029
   KENNA JG, 1995, ANESTH ANALG, V81, pS51, DOI 10.1097/00000539-199512001-00008
   KENNA JG, 1994, ANAESTH PHARM REV, V2, P29
   KOBLIN DD, 1992, ANESTH ANALG, V75, pS10
   MURRAY JM, 1992, BRIT J ANAESTH, V69, P643, DOI 10.1093/bja/69.6.643
   MURRAY JM, 1994, BRIT J ANAESTH, V72, P599, DOI 10.1093/bja/72.5.599
   MURRAY JM, 1992, BRIT J ANAESTH, V68, P168, DOI 10.1093/bja/68.2.168
   Piper SN, 2003, ANASTH INTENSIV NOTF, V38, P781
   Ray DC, 1996, BRIT J ANAESTH, V77, P404
   Ray DC, 2002, BRIT J ANAESTH, V88, P285, DOI 10.1093/bja/88.2.285
   RAY DC, 1991, BRIT J ANAESTH, V67, P84, DOI 10.1093/bja/67.1.84
   Schindler E, 1996, Anasthesiol Intensivmed Notfallmed Schmerzther, V31, P344, DOI 10.1055/s-2007-995933
   Schmidt CC, 1999, ANAESTHESIA, V54, P1207, DOI 10.1046/j.1365-2044.1999.01105.x
   Shimono H, 2003, ANESTH ANALG, V97, P442, DOI 10.1213/01.ANE.0000067407.25527.B7
   Suttner SW, 1999, ANESTH ANALG, V89, P1371, DOI 10.1097/00000539-199912000-00008
   Suttner SW, 2000, ANESTH ANALG, V91, P206, DOI 10.1097/00000539-200007000-00039
   TAIVAINEN T, 1994, BRIT J ANAESTH, V73, P590, DOI 10.1093/bja/73.5.590
   TIAINEN P, 1995, ACTA ANAESTH SCAND, V39, P840, DOI 10.1111/j.1399-6576.1995.tb04181.x
   TIANINEN P, 1998, BRIT J ANAESTH, V80, P87
NR 33
TC 11
Z9 11
U1 4
U2 15
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0265-0215
EI 1365-2346
J9 EUR J ANAESTH
JI Eur. J. Anaesth.
PD MAR
PY 2005
VL 22
IS 3
BP 209
EP 214
DI 10.1017/S0265021505000360
PG 6
WC Anesthesiology
SC Anesthesiology
GA 922VV
UT WOS:000228868900008
PM 15852994
DA 2018-12-27
ER

PT J
AU Reuben, SS
   Ekman, EF
AF Reuben, SS
   Ekman, EF
TI RETRACTED: The effect of cyclooxygenase-2 inhibition on analgesia and
   spinal fusion (Retracted Article. See vol 91A, pg 965, 2009)
SO JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME
LA English
DT Article; Retracted Publication
ID NONSTEROIDAL ANTIINFLAMMATORY DRUGS; POSTOPERATIVE PAIN; OTOLARYNGOLOGIC
   SURGERY; DIFFERENTIAL INHIBITION; ORTHOPEDIC-SURGERY; COX-2 INHIBITORS;
   PREVENTING PAIN; CELECOXIB; KETOROLAC; EFFICACY
AB Background: Cyclooxygenase (COX)-2-specific inhibitors demonstrate analgesic efficacy comparable with that of conventional nonsteroidal anti-inflammatory drugs but are associated with reduced gastrointestinal side effects and an absence of antiplatelet activity. Thus, they can be administered to patients undergoing spinal fusion surgery without an added risk of bleeding. However, concerns regarding a possible deleterious effect on bone-healing have limited their routine use. Celecoxib, a COX-2 inhibitor, recently was approved for the treatment of acute pain. The goals of the present study were to examine the analgesic efficacy of celecoxib and to determine the incidence of nonunion at one year following spinal fusion surgery.
   Methods: Eighty patients who were scheduled to undergo spinal fusion received either celecoxib or placebo one hour before the induction of anesthesia and every twelve hours after surgery for the first five postoperative days. Pain scores and morphine use were recorded one hour after arrival in the post-anesthesia care unit and at four, eight, twelve, sixteen, twenty, and twenty-four hours later. Intraoperative blood loss was recorded. The status of the fusion was determined radiographically at the time of the one-year follow-up.
   Results: There were no differences in demographic data or blood loss between the two groups. Pain scores were lower in the celecoxib group at one, four, eight, sixteen, and twenty hours postoperatively. There were no differences between the two groups with regard to the pain scores at twelve and twenty-four hours postoperatively. Morphine use was lower in the celecoxib group at all postoperative time-intervals. There was no difference between the celecoxib group and the placebo group with regard to the incidence of nonunion at the time of the one-year follow-up (7.5% [three of forty] compared with 10% [four of forty]).
   Conclusions: The perioperative administration of celecoxib resulted in a significant reduction in postoperative pain and opioid use following spinal fusion surgery. In addition, the short-term administration of this COX-2-specific nonsteroidal anti-inflammatory drug had no apparent effect on the rate of nonunion at the time of the one-year follow-up.
C1 Baystate Med Ctr, Springfield, MA 01199 USA.
   Tufts Univ, Sch Med, Springfield, MA 01199 USA.
   So Orthopaed Sports & Parkridge Surg Ctr, Columbia, SC 29204 USA.
RP Reuben, SS (reprint author), Baystate Med Ctr, 759 Chestnut St, Springfield, MA 01199 USA.
EM scott.reuben@bhs.org
CR *AC PAIN MAN GUID, 1992, OP MED PROC TRAUM CL
   Ashburn MA, 2004, ANESTHESIOLOGY, V100, P1573
   Barden J, 2003, COCHRANE DB SYST REV
   CONNELLY CS, 1991, ARCH INTERN MED, V151, P1963, DOI 10.1001/archinte.151.10.1963
   Cousins MJ, 2000, REGION ANESTH PAIN M, V25, P6, DOI 10.1016/S1098-7339(00)80005-X
   DAHL JB, 1991, BRIT J ANAESTH, V66, P703, DOI 10.1093/bja/66.6.703
   Deguchi M, 1998, J SPINAL DISORD, V11, P459
   Dumont AS, 2000, J PHARMACOL TOX MET, V43, P31, DOI 10.1016/S1056-8719(00)00077-0
   Gajraj NM, 2003, REGION ANESTH PAIN M, V28, P456, DOI 10.1016/S1098-7339(03)0-0440-1
   Gerstenfeld LC, 2003, J ORTHOPAED RES, V21, P670, DOI 10.1016/S0736-0266(03)00003-2
   Gerstenfeld Louis C, 2004, Expert Opin Drug Saf, V3, P131, DOI 10.1517/eods.3.2.131.27335
   Gilron I, 2003, ANESTHESIOLOGY, V99, P1198, DOI 10.1097/00000542-200311000-00029
   Gimbel JS, 2001, CLIN THER, V23, P228, DOI 10.1016/S0149-2918(01)80005-9
   Glassman SD, 1998, SPINE, V23, P834, DOI 10.1097/00007632-199804010-00020
   Hawkey CJ, 1999, LANCET, V353, P307, DOI 10.1016/S0140-6736(98)12154-2
   Issioui T, 2002, ANESTH ANALG, V94, P1188, DOI 10.1097/00000539-200205000-00025
   KAWAGUCHI H, 1995, CLIN ORTHOP RELAT R, P36
   Kehlet H, 2002, AM J SURG, V183, P630, DOI 10.1016/S0002-9610(02)00866-8
   KEHLET H, 1993, ANESTH ANALG, V77, P1048
   KINSELLA J, 1992, BRIT J ANAESTH, V69, P19, DOI 10.1093/bja/69.1.19
   Lee C, 2004, CLIN ORTHOP RELAT R, P71, DOI 10.1097/01.blo.0000118695.50144.33
   Leese PT, 2000, J CLIN PHARMACOL, V40, P124, DOI 10.1177/00912700022008766
   Long J, 2002, J BONE JOINT SURG AM, V84A, P1763, DOI 10.2106/00004623-200210000-00004
   Maxy RJ, 2001, REGION ANESTH PAIN M, V26, P156, DOI 10.1053/rapm.2001.18870
   MCCORMACK K, 1995, PAIN, V60, P353, DOI 10.1016/0304-3959(94)00224-3
   MCCORMACK K, 1994, PAIN, V59, P9, DOI 10.1016/0304-3959(94)90045-0
   MEADE EA, 1993, J BIOL CHEM, V268, P6610
   Perkins FM, 2000, ANESTHESIOLOGY, V93, P1123, DOI 10.1097/00000542-200010000-00038
   Recart A, 2003, ANESTH ANALG, V96, P1631, DOI 10.1213/01.ANE.0000062526.60681.7B
   Reuben SS, 2000, ANESTH ANALG, V91, P1221, DOI 10.1097/00000539-200011000-00032
   Reuben SS, 1997, REGION ANESTH, V22, P343, DOI 10.1016/S1098-7339(97)80009-0
   Reuben SS, 1998, ANESTH ANALG, V87, P98
   REUBEN SS, 2002, ANN SPRING M AM SOC
   Robinson C M, 1993, J Arthroplasty, V8, P607, DOI 10.1016/0883-5403(93)90007-Q
   Samad TA, 2002, TRENDS MOL MED, V8, P390, DOI 10.1016/S1471-4914(02)02383-3
   Schafer Andrew I., 1999, American Journal of Medicine, V106, p25S, DOI 10.1016/S0002-9343(99)00114-X
   SEIBERT K, 1994, RECEPTOR, V4, P17
   SEIBERT K, 1994, P NATL ACAD SCI USA, V91, P12013, DOI 10.1073/pnas.91.25.12013
   Simon AM, 2002, J BONE MINER RES, V17, P963, DOI 10.1359/jbmr.2002.17.6.963
   Sinatra R, 2002, J PAIN SYMPTOM MANAG, V24, pS18, DOI 10.1016/S0885-3924(02)00410-4
   SOUTER AJ, 1994, ANESTH ANALG, V79, P1178
   STEINMANN JC, 1992, CLIN ORTHOP RELAT R, P80
   Watcha MF, 2003, ANESTH ANALG, V96, P987, DOI 10.1213/01.ANE.0000053255.93270.31
   Wedel DJ, 2003, REGION ANESTH PAIN M, V28, P372, DOI 10.1016/S1098-7339(03)00400-0
NR 44
TC 73
Z9 82
U1 4
U2 16
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0021-9355
EI 1535-1386
J9 J BONE JOINT SURG AM
JI J. Bone Joint Surg.-Am. Vol.
PD MAR
PY 2005
VL 87A
IS 3
BP 536
EP 542
DI 10.2106/JBJS.D.02283
PG 7
WC Orthopedics; Surgery
SC Orthopedics; Surgery
GA 906CD
UT WOS:000227617200009
PM 15741619
DA 2018-12-27
ER

PT J
AU Akerstrom, T
   Steensberg, A
   Keller, P
   Keller, C
   Penkowa, M
   Pedersen, BK
AF Akerstrom, T
   Steensberg, A
   Keller, P
   Keller, C
   Penkowa, M
   Pedersen, BK
TI RETRACTED: Exercise induces interleukin-8 expression in human skeletal
   muscle (Retracted article. See vol. 589, pg. 3407, 2011)
SO JOURNAL OF PHYSIOLOGY-LONDON
LA English
DT Article; Retracted Publication
ID NECROSIS-FACTOR-ALPHA; GENE-EXPRESSION; ANGIOGENIC ACTIVITY; STRENUOUS
   EXERCISE; ENDOTHELIAL-CELLS; EPITHELIAL-CELLS; CXC CHEMOKINES; MARATHON
   RACE; WEIGHT-LOSS; TNF-ALPHA
AB Skeletal muscle has been recognized as an endocrine organ, and muscle cell cultures express several cytokines with potential hormonal effects. Interleukin-8 (IL-8), a chemokine, which induces angiogenesis, is expressed in working muscles; however, the cell source of origin has not been identified. We aimed to elucidate if IL-8 protein is: (1) expressed in contracting muscle fibres and (2) whether there is a release of IL-8 from exercising muscle. Seventeen healthy male volunteers were included in two independent protocols: 3 h of ergometer bicycle exercise at 60% of (V) over dot O-2,max (n = 6) or rest (n = 5), and 3 h of two-legged knee-extensor exercise at 60% of maximal workload (n = 6). Repetitive muscle biopsy samples were obtained from the vastus lateralis in all experiments. A marked increase in IL-8 mRNA was found in muscle biopsy samples obtained after exercise. A marked IL-8 protein expression was demonstrated within the cytoplasm of muscle fibres in biopsy samples obtained in the recovery phase following 3 h of bicycle exercise, and the peak occurred 3-6 h postexercise. A small transient net release of IL-8 from working muscle was found at 1.5 h of knee-extensor exercise. However, the small release of IL-8 from muscle did not result in an increase in the systemic plasma concentration of IL-8, suggesting that muscle-derived IL-8 may play a local role, e.g. in angiogenesis.
C1 Univ Copenhagen, Rigshosp, Fac Hlth, Dept Infect Dis,Ctr Inflammat & Metab, DK-2100 Copenhagen, Denmark.
   Univ Copenhagen, Rigshosp, Fac Hlth, Copenhagen Muscle Res Ctr, DK-2100 Copenhagen, Denmark.
   Univ Copenhagen, Panum Inst, Dept Med Anat, DK-2200 Copenhagen, Denmark.
RP Pedersen, BK (reprint author), Univ Copenhagen, Rigshosp, Fac Hlth, Dept Infect Dis,Ctr Inflammat & Metab, Blegdamsvej 9, DK-2100 Copenhagen, Denmark.
EM bkp@rh.dk
RI Akerstrom, Thorbjorn/D-9884-2015
OI Akerstrom, Thorbjorn/0000-0002-7330-1723
CR Addison CL, 2000, J IMMUNOL, V165, P5269, DOI 10.4049/jimmunol.165.9.5269
   Alvarez B, 2002, CANCER LETT, V175, P181, DOI 10.1016/S0304-3835(01)00717-0
   ANDERSEN P, 1985, J PHYSIOL-LONDON, V366, P233, DOI 10.1113/jphysiol.1985.sp015794
   BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97
   Baggiolini M, 2001, J INTERN MED, V250, P91, DOI 10.1046/j.1365-2796.2001.00867.x
   Bek EL, 2002, CLIN SCI, V103, p424S, DOI 10.1042/CS103S424S
   Belperio JA, 2000, J LEUKOCYTE BIOL, V68, P1
   Brenner IKM, 1999, EUR J APPL PHYSIOL O, V80, P452, DOI 10.1007/s004210050617
   BROOKE MH, 1970, J HISTOCHEM CYTOCHEM, V18, P670, DOI 10.1177/18.9.670
   Bruun JM, 2002, OBES RES, V10, P499, DOI 10.1038/oby.2002.68
   Bruun JM, 2003, EUR J ENDOCRINOL, V148, P535, DOI 10.1530/eje.0.1480535
   Chan MHS, 2004, AM J PHYSIOL-REG I, V287, pR322, DOI 10.1152/ajpregu.00030.2004
   Chang MMJ, 2001, AM J PHYSIOL-LUNG C, V280, pL107
   CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2
   De Rossi M, 2000, INT IMMUNOL, V12, P1329, DOI 10.1093/intimm/12.9.1329
   Feoktistov I, 1999, MOL PHARMACOL, V55, P726
   Heidemann J, 2003, J BIOL CHEM, V278, P8508, DOI 10.1074/jbc.M208231200
   Hellsten Y, 1998, CIRCULATION, V98, P6, DOI 10.1161/01.CIR.98.1.6
   Henson DA, 2000, MED SCI SPORT EXER, V32, P1384, DOI 10.1097/00005768-200008000-00005
   Hildebrandt AL, 2000, AM J PHYSIOL-ENDOC M, V278, pE1078
   Hoffmann E, 2002, J LEUKOCYTE BIOL, V72, P847
   Keane MP, 1997, J IMMUNOL, V159, P1437
   KJAER M, 1988, AM J PHYSIOL, V254, pR197
   KOCH AE, 1992, SCIENCE, V258, P1798, DOI 10.1126/science.1281554
   Malm C, 2000, J PHYSIOL-LONDON, V529, P243, DOI 10.1111/j.1469-7793.2000.00243.x
   Mucci P, 2000, MED SCI SPORT EXER, V32, P1094, DOI 10.1097/00005768-200006000-00009
   Nieman DC, 2003, J APPL PHYSIOL, V94, P1917, DOI 10.1152/japplphysiol.01130.2002
   Nieman DC, 2002, J APPL PHYSIOL, V92, P1970, DOI 10.1152/japplphysiol.00961.2001
   Nieman DC, 2001, J APPL PHYSIOL, V91, P109
   Norrby K, 1996, CELL PROLIFERAT, V29, P315, DOI 10.1111/j.1365-2184.1996.tb01583.x
   Ostrowski K, 2001, EUR J APPL PHYSIOL, V84, P244, DOI 10.1007/s004210170012
   Pedersen BK, 1998, CAN J PHYSIOL PHARM, V76, P505, DOI 10.1139/cjpp-76-5-505
   Pilegaard H, 2000, AM J PHYSIOL-ENDOC M, V279, pE806
   Qu ZQ, 1997, HISTOCHEM CELL BIOL, V107, P169, DOI 10.1007/s004180050101
   Radegran G, 1997, J APPL PHYSIOL, V83, P1383
   Saghizadeh M, 1996, J CLIN INVEST, V97, P1111, DOI 10.1172/JCI118504
   Sorichter S, 1997, J APPL PHYSIOL, V83, P1076
   Suzuki K, 2003, MED SCI SPORT EXER, V35, P348, DOI 10.1249/01.MSS.0000048861.57899.04
   VIRU A, 1992, INT J SPORTS MED, V13, P230, DOI 10.1055/s-2007-1021259
   Yu Y, 2001, INFLAMM RES, V50, P220, DOI 10.1007/s000110050747
   Zhao BT, 2003, AM J PHYSIOL-CELL PH, V284, pC1577, DOI 10.1152/ajpcell.00243.2002
NR 41
TC 97
Z9 99
U1 3
U2 25
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0022-3751
J9 J PHYSIOL-LONDON
JI J. Physiol.-London
PD MAR 1
PY 2005
VL 563
IS 2
BP 507
EP 516
DI 10.1113/jphysiol.2004.077610
PG 10
WC Neurosciences; Physiology
SC Neurosciences & Neurology; Physiology
GA 905NR
UT WOS:000227575900015
PM 15618276
OA Green Published
DA 2018-12-27
ER

PT J
AU Suzuki, M
   Shigematsu, H
   Takahashi, T
   Shivapurkar, N
   Sathyanarayana, UG
   Iizasa, T
   Fujisawa, T
   Gazdar, AF
AF Suzuki, M
   Shigematsu, H
   Takahashi, T
   Shivapurkar, N
   Sathyanarayana, UG
   Iizasa, T
   Fujisawa, T
   Gazdar, AF
TI RETRACTED: Aberrant methylation of Reprimo in lung cancer (Retracted
   article. See vol. 85, pg. 337, 2014)
SO LUNG CANCER
LA English
DT Article; Retracted Publication
DE Reprimo; methylation; p53; lung cancer; G2 cell cycle
ID DNA METHYLATION; GENE; HYPERMETHYLATION; CARCINOMA
AB Deregulation of cell cycle inhibition contributes to human carcinogenesis. Reprimo (for stop/repress) is a newly identified mediator of the p53-mediated cell cycle arrest at the G(2) phase. Loss of Reprimo expression due to promoter methylation was recently identified in pancreatic cancer. We examined Reprimo expression by reverse transcription PCR (RT-PCR) and aberrant methylation of Reprimo by methylation specific PCR (MSP) in lung cancer cell lines (n = 35) and primary tumors (n = 167). We also correlated the p53 gene status with Reprimo methylation in cell lines. Aberrant methylation of Reprimo was present in 32% (six of 19) of non-small cell lung cancer (NSCLC) cell lines, 6% (one of 16) of small cell lung cancer (SCLC) cell lines, and 31% (51 of 167) of primary tumors. Methylation was absent in normal lymphocytes and was rare in corresponding nonmalignant lung tissues (7%; four of 57). Overall concordance between loss of expression and aberrant methylation of Reprimo was 94% (33 of 35) in cell Lines. Reprimo expression was restored after treatment with the demethylating agent 5-aza-2'-deoxycytidine in all five-cell lines tested that Lacked Reprimo expression. There was no significant correlation between p53 gene status and Reprimo methylation in cell lines. These data indicate that Reprimo methylation is frequent in Lung cancers and occurs independently of p53 status. Methylation of Reprimo may play a role in the pathogenesis of lung cancers. (c) 2004 Published by Elsevier Ireland Ltd.
C1 Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, 6000 Harry Hines Blvd, Dallas, TX 75390 USA.
   Univ Texas, SW Med Ctr, Dept Pathol, Dallas, TX 75390 USA.
   Chiba Univ, Grad Sch Med, Dept Thorac Surg, Chiba 2608607, Japan.
RP Gazdar, AF (reprint author), Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, 6000 Harry Hines Blvd, Dallas, TX 75390 USA.
EM adi.gazdar@utsouthwestern.edu
FU NCI NIH HHS [5U01CA8497102, P50CA70907]
CR Dasika GK, 1999, ONCOGENE, V18, P7883
   Esteller M, 2001, CANCER RES, V61, P3225
   GREENBLATT MS, 1994, CANCER RES, V54, P4855
   Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/j.cell.2011.02.013
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   HERRMANN BG, 1987, METHOD ENZYMOL, V152, P180
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Ohki R, 2000, J BIOL CHEM, V275, P22627, DOI 10.1074/jbc.C000235200
   Otsuka T, 1996, GENE CHROMOSOME CANC, V16, P113, DOI 10.1002/(SICI)1098-2264(199606)16:2<113::AID-GCC5>3.0.CO;2-2
   Phelps RM, 1996, J CELL BIOCHEM, P32
   Sathyanarayana Ubaradka G., 2004, Cancer Genomics & Proteomics, V1, P1
   Sato N, 2003, CANCER RES, V63, P3735
   Smits VAJ, 2001, BBA-GENE STRUCT EXPR, V1519, P1, DOI 10.1016/S0167-4781(01)00204-4
   Suzuki H, 2000, CANCER RES, V60, P4353
   Suzuki M, 2004, CANCER RES, V64, P3137, DOI 10.1158/0008-5472.CAN-03-3046
   Toyooka S, 2001, MOL CANCER THER, V1, P61
   Toyooka S, 2002, CLIN CANCER RES, V8, P2292
   Zhang ZQ, 2002, CANCER RES, V62, P3024
   Zochbauer-Muller S, 2002, ONCOLOGIST, V7, P451, DOI 10.1634/theoncologist.7-5-451
NR 19
TC 26
Z9 27
U1 2
U2 7
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0169-5002
EI 1872-8332
J9 LUNG CANCER
JI Lung Cancer
PD MAR
PY 2005
VL 47
IS 3
BP 309
EP 314
DI 10.1016/j.lungcan.2004.08.006
PG 6
WC Oncology; Respiratory System
SC Oncology; Respiratory System
GA 905BI
UT WOS:000227542100003
PM 15713514
DA 2018-12-27
ER

PT J
AU Rini, BI
AF Rini, BI
TI RETRACTED: VEGF-targeted therapy in metastatic renal cell carcinoma
   (Retracted article. See vol. 16, pg. 1481, 2011)
SO ONCOLOGIST
LA English
DT Article; Retracted Publication
DE RCC; VEGF; VHL; bevacizumab; SU11248; BAY 43-9006
ID ENDOTHELIAL GROWTH-FACTOR; TUMOR-SUPPRESSOR GENE; RECEPTOR TYROSINE
   KINASES; INTERFERON-ALPHA; VHL GENE; FACTOR EXPRESSION;
   RANDOMIZED-TRIAL; PTK787/ZK 222584; FACTOR ANTIBODY; LINDAU DISEASE
AB Purpose. To review the biology of renal cell carcinoma (RCC) and the clinical results of vascular endothelial growth factor (VEGF) blockade in metastatic RCC.
   Methods. A review of relevant published literature regarding VEGF, von Hippel-Lindau (VHL) gene inactivation, and VEGF overexpression in RCC was performed. Further, a review of the mechanism, toxicity, and clinical development of VEGF-targeted therapy in metastatic RCC was undertaken.
   Results. VHL tumor suppressor gene inactivation is observed in the majority of clear cell RCC cases, leading to VEGF overexpression. Therapy with agents directed against the VEGF protein or the VEGF receptor have demonstrated initial clinical activity in metastatic RCC.
   Conclusions. Therapeutic targeting of VEGF in RCC has strong biologic rationale. Substantial clinical activity has been reported in initial clinical trials with VEGF-targeting agents. Further investigation is needed to optimally use these agents for maximal clinical benefit.
C1 Univ Calif San Francisco, Ctr Comprehens Canc, San Francisco, CA 94143 USA.
RP Rini, BI (reprint author), 1600 Divisadero,Room A717, San Francisco, CA 94115 USA.
EM brini@medicine.ucsf.edu
CR Benjamin LE, 1999, J CLIN INVEST, V103, P159, DOI 10.1172/JCI5028
   Brauch H, 2000, CANCER RES, V60, P1942
   Bukowski R M, 2001, Semin Urol Oncol, V19, P148
   Clifford SC, 1998, GENE CHROMOSOME CANC, V22, P200, DOI 10.1002/(SICI)1098-2264(199807)22:3<200::AID-GCC5>3.0.CO;2-#
   Cockman ME, 2000, J BIOL CHEM, V275, P25733, DOI 10.1074/jbc.M002740200
   CROSSEY PA, 1994, HUM GENET, V93, P53
   de Paulsen N, 2001, P NATL ACAD SCI USA, V98, P1387, DOI 10.1073/pnas.031587498
   Drevs J, 2000, CANCER RES, V60, P4819
   Dvorak HF, 2002, J CLIN ONCOL, V20, P4368, DOI 10.1200/JCO.2002.10.088
   DVORAK HF, 1979, J IMMUNOL, V122, P166
   DVORAK HF, 1995, AM J PATHOL, V146, P1029
   Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4
   Flanigan RC, 2001, NEW ENGL J MED, V345, P1655, DOI 10.1056/NEJMoa003013
   Gallou C, 1999, HUM MUTAT, V13, P464, DOI 10.1002/(SICI)1098-1004(1999)13:6<464::AID-HUMU6>3.0.CO;2-A
   GEORGE D, 2003, J CLIN ONCOL, V22, P385
   GNARRA JR, 1994, NAT GENET, V7, P85, DOI 10.1038/ng0594-85
   Gnarra JR, 1996, P NATL ACAD SCI USA, V93, P10589, DOI 10.1073/pnas.93.20.10589
   GREEN S, 1992, INVEST NEW DRUG, V10, P239, DOI 10.1007/BF00944177
   Gunaratnam L, 2003, J BIOL CHEM, V278, P44966, DOI 10.1074/jbc.M305502200
   Hainsworth JD, 2004, J CLIN ONCOL, V22, p382S
   Hemmerlein B, 2001, VIRCHOWS ARCH, V439, P645, DOI 10.1007/s004280100464
   HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700
   Igarashi H, 2002, CANCER-AM CANCER SOC, V95, P47, DOI 10.1002/cncr.10635
   Iliopoulos O, 1996, P NATL ACAD SCI USA, V93, P10595, DOI 10.1073/pnas.93.20.10595
   Kenck C, 1996, J PATHOL, V179, P157, DOI 10.1002/(SICI)1096-9896(199606)179:2<157::AID-PATH557>3.0.CO;2-S
   KIBEL A, 1995, SCIENCE, V269, P1444, DOI 10.1126/science.7660130
   Knebelmann B, 1998, CANCER RES, V58, P226
   KNUDSON AG, 1986, ANNU REV GENET, V20, P231
   Kondo K, 2002, GENE CHROMOSOME CANC, V34, P58, DOI 10.1002/gcc.10054
   KOUREMBANAS S, 1990, J CLIN INVEST, V86, P670, DOI 10.1172/JCI114759
   LATIF F, 1993, SCIENCE, V260, P1317, DOI 10.1126/science.8493574
   Lee JS, 2001, J SURG ONCOL, V77, P55, DOI 10.1002/jso.1066
   Lyons JF, 2001, ENDOCR-RELAT CANCER, V8, P219, DOI 10.1677/erc.0.0080219
   Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459
   Mendel DB, 2003, CLIN CANCER RES, V9, P327
   Mickisch GHJ, 2001, LANCET, V358, P966, DOI 10.1016/S0140-6736(01)06103-7
   Motzer RJ, 2004, J CLIN ONCOL, V22, p382S
   Motzer RJ, 2003, INVEST NEW DRUG, V21, P99, DOI 10.1023/A:1022928612511
   Motzer RJ, 2002, J CLIN ONCOL, V20, P289, DOI 10.1200/JCO.20.1.289
   Na X, 2003, J UROLOGY, V170, P588, DOI 10.1097/01.ju.0000074870.54671.98
   Nicol D, 1997, J UROLOGY, V157, P1482, DOI 10.1016/S0022-5347(01)65028-6
   Presta LG, 1997, CANCER RES, V57, P4593
   Ratain MJ, 2004, J CLIN ONCOL, V22, p382S
   Rini BI, 2004, CLIN CANCER RES, V10, P2584, DOI 10.1158/1078-0432.CCR-03-0605
   Schraml P, 2002, J PATHOL, V196, P186, DOI 10.1002/path.1034
   SHEN BQ, 2004, P AM ASSOC CANC RES, V45, pA3007
   SHUIN T, 1994, CANCER RES, V54, P2852
   TAKAHASHI A, 1994, CANCER RES, V54, P4233
   TISCHER E, 1991, J BIOL CHEM, V266, P11947
   Tomisawa M, 1999, EUR J CANCER, V35, P133, DOI 10.1016/S0959-8049(98)00278-0
   Viloria-Petit A, 2001, CANCER RES, V61, P5090
   Watanabe Y, 1997, ONCOGENE, V14, P2025, DOI 10.1038/sj.onc.1201033
   WILHELM S, 2003, P AM ASSOC CANC RES, V44, pA478
   Wood JM, 2000, CANCER RES, V60, P2178
   Yang JC, 2003, NEW ENGL J MED, V349, P427, DOI 10.1056/NEJMoa021491
NR 55
TC 48
Z9 48
U1 2
U2 8
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1083-7159
EI 1549-490X
J9 ONCOLOGIST
JI Oncologist
PD MAR
PY 2005
VL 10
IS 3
BP 191
EP 197
DI 10.1634/theoncologist.10-3-191
PG 7
WC Oncology
SC Oncology
GA 911UQ
UT WOS:000228031500004
PM 15793222
OA Bronze
DA 2018-12-27
ER

PT J
AU Mythili, DM
   Patra, S
   Pulimood, AB
   Gunasekaran, S
AF Mythili, DM
   Patra, S
   Pulimood, AB
   Gunasekaran, S
TI RETRACTED: Reversal of diabetes by xenotransplantation of monkey
   pancreatic islets in rats - An ultrastructural study (Retracted article.
   See vol 33, pg 318, 2006)
SO PANCREAS
LA English
DT Article; Retracted Publication
DE reversal of diabetes; xenotransplantation; ultrastructure; plasma
   glucose; pancreatic islets
ID XENOGRAFT SURVIVAL; TRANSPLANTATION; PROLONGATION; MOUSE; RECIPIENTS;
   MELLITUS; TISSUE
AB Objectives: Transplantation of pancreatic islets is considered a potential curative treatment of type 1 diabetes. Electron microscopy plays a major role in the evaluation of pancreatic islets. The aim of this study was to study the reversal of diabetes by xenotransplantation of monkey pancreatic islets into diabetic recipient by functional and structural findings.
   Methods: Islets of Langerhans were isolated from monkeys by collagenase digestion method. Two days after the induction of diabetes in rats with streptozotocin, diabetes was confirmed. Freshly isolated islets were transplanted under the renal capsule of the diabetic rats. The recipients received cyclosporin A ( 30 mg/kg) every day. Fasting plasma glucose was estimated on days 3, 7, and 14 after transplantation. The presence of glucose and ketone in urine was checked. After 14 days, the grafts were removed and processed for light and electron microscopic study.
   Results: After the induction of diabetes, the mean fasting plasma glucose was 347.20 mg/dL. On day 3 after transplantation, the mean fasting plasma glucose value was 100 mg/dL. The mean fasting plasma glucose was 94.6 mg/dL on day 7 and 94.8 mg/dL on day 14. Histology of the monkey islet grafts after 14 days showed the survival of pancreatic islets. Ultrastructure of the same grafts showed the presence of alpha, beta, and delta granules similar to those of native pancreatic islets with the other cellular organelles.
   Conclusion: The diabetic state of rats can be reversed by xenotransplantation of isolated monkey islets. Ultrastructural study confirms the normal synthesis and release of islet hormones. The released insulin from transplanted monkey islets had lowered the plasma glucose level of recipient rats.
C1 Christian Med Coll & Hosp, Dept Physiol, Vellore 632004, Tamil Nadu, India.
   Christian Med Coll & Hosp, Dept Williams Pathol, Vellore 632004, Tamil Nadu, India.
RP Gunasekaran, S (reprint author), Christian Med Coll & Hosp, Dept Physiol, Vellore 632002, Tamil Nadu, India.
EM gunasekaran@cmcvellore.ac.in
CR ALEJANDRO R, 1995, SCAND J GASTROENTERO, V30, P125, DOI 10.3109/00365529509107773
   ANH M, 1995, TRANSPL P, V27, P3302
   BONNEVIENIELSEN V, 1983, ENDOCRINOLOGY, V112, P1049, DOI 10.1210/endo-112-3-1049
   CHABOT J, 1987, TRANSPLANT P, V19, P1160
   GRAY DWR, 1989, TRANSPLANT INT, V2, P41
   GROTH CG, 1994, LANCET, V344, P1402, DOI 10.1016/S0140-6736(94)90570-3
   JAGAR C, 1994, ACTA DIABETOL, V31, P193
   JUN TW, 1990, TRANSPLANTATION, V49, P502
   LANZA RP, 1994, PANCREATIC ISLET TRA, V1
   LECHAGO J, 1997, BLOODWORTHS ENDOCRIN, P520
   LUKINIUS A, 1992, DEV BIOL, V153, P376, DOI 10.1016/0012-1606(92)90122-W
   MELLGREN A, 1986, DIABETOLOGIA, V29, P670, DOI 10.1007/BF00869269
   MUNGER BL, 1981, ISLETS LANGERHANS BI
   Mythili MD, 2002, PANCREAS, V24, P235, DOI 10.1097/00006676-200204000-00005
   NAKAJIMA Y, 1985, TRANSPLANTATION, V40, P73, DOI 10.1097/00007890-198507000-00015
   Rastellini C, 1995, TRANSPLANT P, V27, P3385
   Reinholt FP, 1998, XENOTRANSPLANTATION, V5, P222, DOI 10.1111/j.1399-3089.1998.tb00031.x
   ROBERTSON RP, 1991, DIABETES, V40, P1085, DOI 10.2337/diabetes.40.9.1085
   Shapiro AMJ, 2000, NEW ENGL J MED, V343, P230, DOI 10.1056/NEJM200007273430401
   SIMEONOVIC CJ, 1989, TRANSPLANT P, V21, P2728
   TAHIR M, 1992, ACTA ANAT, V145, P93
   TZE WJ, 1983, METABOLISM, V32, P279, DOI 10.1016/0026-0495(83)90193-2
   YASUNAMI Y, 1983, TRANSPLANTATION, V35, P281, DOI 10.1097/00007890-198304000-00003
NR 23
TC 2
Z9 2
U1 3
U2 8
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0885-3177
EI 1536-4828
J9 PANCREAS
JI Pancreas
PD MAR
PY 2005
VL 30
IS 2
BP 130
EP 137
DI 10.1097/01.mpa.0000148509.03047.79
PG 8
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 903DH
UT WOS:000227405200006
PM 15714135
DA 2018-12-27
ER

PT J
AU Moon, HI
   Kim, MR
   Cho, MK
   Park, S
   Chung, JH
AF Moon, HI
   Kim, MR
   Cho, MK
   Park, S
   Chung, JH
TI RETRACTED: Matrix metalloproteinase-1 expression inhibitory compound
   from the whole plants of Viola ibukiana makino (Retracted article. See
   vol 21, pg 600, 2007)
SO PHYTOTHERAPY RESEARCH
LA English
DT Article; Retracted Publication
DE Viola ibukiana Makino; Violaceae; triterpenoid saponins; matrix
   metalloproteinase-1 inhibitor
ID HUMAN SKIN; CYCLOTIDES; GROWTH
AB Bioassay-guided fractionation has led to the isolation of two triterpenoid saponins 3-O-[O-beta-D-glucopyranosyl-(1 -> 3)-O-beta-D-glueopyranosyl] oleanolic acid (1), and 3-O-[O-beta-D-glucopyranosyl-(1 -> 2)-O-beta-D-glucopyranosyl] oleanolic acid (2) from the whole plants of Viola ibukiana Makino. Compound 2 showed matrix metalloproteinase-1 expression inhibition activities in a dose-dependent manner. Copyright (c) 2005 John Wiley & Sons, Ltd.
C1 Seoul Natl Univ, Coll Med, Dept Dermatol, Seoul 110744, South Korea.
   Seoul Natl Univ Hosp, Clin Res Inst, Lab Cutaneous Aging Res, Seoul 110744, South Korea.
   Chosun Univ, Res Ctr Proteineous Mat, Kwangju 501759, South Korea.
   Soonchunhyang Univ, Coll Med, Dept Dermatol, Seoul 140743, South Korea.
RP Moon, HI (reprint author), Seoul Natl Univ, Coll Med, Dept Dermatol, Seoul 110744, South Korea.
EM himun@skku.edu
CR BERNHARD EJ, 1994, P NATL ACAD SCI USA, V91, P4293, DOI 10.1073/pnas.91.10.4293
   Carnat AP, 1998, J NAT PROD, V61, P272, DOI 10.1021/np9701485
   Chambers AF, 1997, J NATL CANCER I, V89, P1260, DOI 10.1093/jnci/89.17.1260
   Fisher GJ, 1996, NATURE, V379, P335, DOI 10.1038/379335a0
   Fisher GJ, 1997, NEW ENGL J MED, V337, P1419, DOI 10.1056/NEJM199711133372003
   GILCHREST BA, 1989, J AM ACAD DERMATOL, V21, P610, DOI 10.1016/S0190-9622(89)70227-9
   LEE YN, 1996, FLORA KOREA, P547
   Lindholm P, 2002, MOL CANCER THER, V1, P365
   MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4
   NAGAO T, 1991, CHEM PHARM BULL, V39, P599
   RiceEvans CA, 1996, FREE RADICAL BIO MED, V20, P933, DOI 10.1016/0891-5849(95)02227-9
   SALAH N, 1995, ARCH BIOCHEM BIOPHYS, V322, P339, DOI 10.1006/abbi.1995.1473
   Schuele S, 2004, MOVEMENT DISORD, V19, P43, DOI 10.1002/mds.10647
   Seo JY, 2001, J INVEST DERMATOL, V116, P915, DOI 10.1046/j.1523-1747.2001.01358.x
   SOTHEESWARAN S, 1989, PHYTOCHEMISTRY, V28, P1544, DOI 10.1016/S0031-9422(00)97788-4
   Svangard E, 2003, PHYTOCHEMISTRY, V64, P135, DOI 10.1016/S0031-9422(03)00218-8
   Tennstedt D, 1979, Derm Beruf Umwelt, V27, P165
   Varani J, 2000, J INVEST DERMATOL, V114, P480, DOI 10.1046/j.1523-1747.2000.00902.x
   Xie C, 2003, CHEM PHARM BULL, V51, P1204, DOI 10.1248/cpb.51.1204
NR 19
TC 4
Z9 4
U1 3
U2 13
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0951-418X
EI 1099-1573
J9 PHYTOTHER RES
JI Phytother. Res.
PD MAR
PY 2005
VL 19
IS 3
BP 239
EP 242
DI 10.1002/ptr.1682
PG 4
WC Chemistry, Medicinal; Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 933RX
UT WOS:000229651700013
PM 15934020
DA 2018-12-27
ER

PT J
AU Kwon, OJ
   Kwak, JY
   Kang, CM
AF Kwon, OJ
   Kwak, JY
   Kang, CM
TI RETRACTED: The impact of gender and age matching for long-term graft
   survival in living donor renal transplantation (Retracted Article. See
   vol 40, pg 328, 2008)
SO TRANSPLANTATION PROCEEDINGS
LA English
DT Article; Proceedings Paper; Retracted Publication
CT 20th International Congress of the Transplantation-Society
CY SEP 05-10, 2004
CL Vienna, AUSTRIA
SP Transplantat Soc
ID SIZE
AB In renal transplantation, donor age and allograft size are known to have an important influence on the outcome of the graft reflecting functional renal mass. Women tend to have smaller kidneys with 17% fewer nephrons than male kidneys. The number of glomeruli per kidney as well as the mean glomerular volume closely correlate with kidney weight and negatively correlate with subject age. We evaluated the impact of gender and age matching in living-donor renal transplantation on long-term graft survival.
   Materials and Methods. Four groups were discerned among 614 renal transplants, according to donor and recipient gender: Group 1 was male donor to male recipient; Group 2 was male donor to female recipient; Group 3 was female donor to male recipient; and Group 4 was female donor to female recipient. We analyzed long-term graft survival and risk factors between the four groups as well as according to age matching. Statistical significance was determined by the Kaplan-Meier method and log rank test (P < .05).
   Result. The graft survival rates at 1, 3, 5, and 10 years were 92.62%, 88.13%, 82.37%, and 76.07%, respectively. The risk factors affecting long-term graft survival were donor age, donor gender, acute rejection rate, and HLA-DR matching. Among the four groups, the graft survival rates of Group 3 (female donor to male recipient) were significantly different from the other groups (P = .0165). Also, the long-term graft survival rates according to age differences were significantly different between older donors than recipients and younger donors than recipients in each group (P = .0213).
   Conclusion. The importance of inadequate renal mass is magnified in high-risk recipients. Age matching could perhaps improve the results of transplantation, particularly when kidneys from older donors are used. Consideration of age and gender as criteria for the choice of donors and recipients may be considered in organ allocation.
C1 Hanyang Univ, Coll Med, Dept Surg, Seoul 133600, South Korea.
RP Kwon, OJ (reprint author), Hanyang Univ, Coll Med, Dept Surg, Seoungdong POB 93, Seoul 133600, South Korea.
EM ojkwon@hanyang.ac.kr
CR BRENNER BM, 1992, J AM SOC NEPHROL, V3, P162
   Busson M, 1997, CLIN TRANSPLANT, V11, P15
   CECKA JM, 1990, CLIN TRANSPLANT, V4, P82
   DONNELLY PK, 1990, NEW ENGL J MED, V322, P851
   Nicholson ML, 2000, BRIT J SURG, V87, P314, DOI 10.1046/j.1365-2168.2000.01390.x
   TERASAKI PI, 1994, TRANSPLANTATION, V57, P1450, DOI 10.1097/00007890-199405270-00008
NR 6
TC 25
Z9 27
U1 2
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0041-1345
EI 1873-2623
J9 TRANSPL P
JI Transplant. Proc.
PD MAR
PY 2005
VL 37
IS 2
BP 726
EP 728
DI 10.1016/j.transproceed.2004.12.137
PG 3
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 918SW
UT WOS:000228568900066
DA 2018-12-27
ER

PT J
AU Tchabanenko, K
   Adlington, RM
   Cowley, AR
   Baldwin, JE
AF Tchabanenko, K
   Adlington, RM
   Cowley, AR
   Baldwin, JE
TI RETRACTED: Biomimetic total synthesis of (+)-himbacine (Retracted
   article. See vol. 17, pg. 3190, 2015)
SO ORGANIC LETTERS
LA English
DT Article; Retracted Publication
ID DIELS-ALDER REACTION; CHEMICAL-CONSTITUENTS; POTENT ANTAGONIST;
   ORGANIC-SYNTHESIS; M-2 SUBTYPE; HIMBACINE; (+)-HIMBELINE; HIMGRAVINE;
   RECEPTOR; ROUTE
AB On treatment with trifluoroacetic acid butenolide 14 undergoes N-Boc deprotection and condensation followed by an iminium ion activated intramolecular Diels-Aider cycloaddition to give the (+)-himbacine precursor 11 on reductive work up. Compound 11 was converted into (+)-himbacine in four synthetic steps.
C1 Univ Oxford, Chem Res Lab, Oxford OX1 3TA, England.
RP Baldwin, JE (reprint author), Univ Oxford, Chem Res Lab, Mansfield Rd, Oxford OX1 3TA, England.
EM jack.baldwin@chem.ox.ac.uk
CR Baldwin JE, 1995, TETRAHEDRON LETT, V36, P9551, DOI 10.1016/0040-4039(95)02045-4
   BELLASSOUED M, 1993, J ORG CHEM, V58, P2517, DOI 10.1021/jo00061a027
   BLANCHETTE MA, 1984, TETRAHEDRON LETT, V25, P2183, DOI 10.1016/S0040-4039(01)80205-7
   BROWN RFC, 1956, AUST J CHEM, V9, P283
   Chackalamannil S, 1999, J ORG CHEM, V64, P1932, DOI 10.1021/jo981983+
   Chackalamannil S, 1996, J AM CHEM SOC, V118, P9812, DOI 10.1021/ja962542f
   COLLINS DJ, 1990, PLANTS MED
   DEBAECKE G, 1995, TETRAHEDRON LETT, V36, P7515, DOI 10.1016/0040-4039(95)01520-5
   Doller D, 1997, TETRAHEDRON-ASYMMETR, V8, P1275, DOI 10.1016/S0957-4166(97)00123-7
   GASSMAN PG, 1987, J AM CHEM SOC, V109, P2182, DOI 10.1021/ja00241a047
   HART DJ, 1995, J AM CHEM SOC, V117, P9369, DOI 10.1021/ja00141a036
   Hart DJ, 1997, J ORG CHEM, V62, P5023, DOI 10.1021/jo970612a
   Hofman S, 1998, SYNTHESIS-STUTTGART, P479, DOI 10.1055/s-1998-5928
   Hofman S, 2001, EUR J ORG CHEM, P2851, DOI 10.1002/1099-0690(200108)2001:15<2851::AID-EJOC2851>3.0.CO;2-U
   HUANG YZ, 1987, J ORG CHEM, V52, P3558, DOI 10.1021/jo00392a011
   KOZIKOWSKI AP, 1992, BIOORG MED CHEM LETT, V2, P797, DOI 10.1016/S0960-894X(00)80534-X
   MANDER LN, 1967, AUST J CHEM, V20, P1705, DOI 10.1071/CH9671705
   Occhiato EG, 2003, J ORG CHEM, V68, P9728, DOI 10.1021/jo034939p
   PINHEY JT, 1961, AUST J CHEM, V14, P106, DOI 10.1071/CH9610106
   RITCHIE E, 1973, ALKALOIDS, V13, P227
   Ritchie E., 1967, ALKALOIDS, V9, P529
   Takadoi M, 2002, TETRAHEDRON, V58, P9903, DOI 10.1016/S0040-4020(02)01358-3
   Takadoi M, 1999, TETRAHEDRON LETT, V40, P3399, DOI 10.1016/S0040-4039(99)00473-6
   Wong LSM, 2003, ORG LETT, V5, P3603, DOI 10.1021/ol0353058
NR 24
TC 33
Z9 33
U1 4
U2 25
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1523-7060
EI 1523-7052
J9 ORG LETT
JI Org. Lett.
PD FEB 17
PY 2005
VL 7
IS 4
BP 585
EP 588
DI 10.1021/ol047676+
PG 4
WC Chemistry, Organic
SC Chemistry
GA 896RB
UT WOS:000226950100016
PM 15704900
DA 2018-12-27
ER

PT J
AU Sun, YX
   Gao, GZ
AF Sun, YX
   Gao, GZ
TI RETRACTED: Bis(4-bromo-2-formylphenolato-kappa O-2,O ')copper(II)
   (Retracted article. See vol. 66, pg e21, 2010)
SO ACTA CRYSTALLOGRAPHICA SECTION E-STRUCTURE REPORTS ONLINE
LA English
DT Article; Retracted Publication
ID CIRCULAR DICHROISM; COMPLEXES
AB The title compound, [Cu(C7H4BrO2)(2)], is a centrosymmetric mononuclear copper(II) complex. The Cu-II atom is four-coordinated by four O atoms from two 5-bromosalicylaldehyde ligands, forming a slightly distorted square-planar coordination configuration.
C1 Qufu Normal Univ, Dept Chem, Qufu 273165, Peoples R China.
RP Sun, YX (reprint author), Qufu Normal Univ, Dept Chem, Qufu 273165, Peoples R China.
EM yuxisun@163.com
CR [Anonymous], 2002, SMART VERS 5 628
   [Anonymous], 2002, SAINT VERS 6 02
   BOSNICH B, 1968, J AM CHEM SOC, V90, P627, DOI 10.1021/ja01005a012
   *BRUK AXS INC, 2002, SHELXTL VERS 5 1
   COSTES JP, 1995, POLYHEDRON, V14, P2179, DOI 10.1016/0277-5387(95)00013-I
   DOWNING RS, 1969, J AM CHEM SOC, V91, P5977, DOI 10.1021/ja01050a009
   Ganeshpure PA, 1996, J MOL CATAL A-CHEM, V113, pL423, DOI 10.1016/S1381-1169(96)00373-1
   Sheldrick G.M, 1996, SADABS
   Sheldrick G. M., 1997, SHELXS97
   SHELDRICK GM, 1997, SHELXL97
   You ZL, 2004, ACTA CRYSTALLOGR E, V60, pM884, DOI 10.1107/S160053680401284X
NR 11
TC 10
Z9 10
U1 3
U2 13
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1600-5368
J9 ACTA CRYSTALLOGR E
JI Acta Crystallogr. Sect. E.-Struct Rep. Online
PD FEB
PY 2005
VL 61
BP M354
EP M355
DI 10.1107/S160053680500187X
PN 2
PG 2
WC Crystallography
SC Crystallography
GA 893AV
UT WOS:000226692400062
DA 2018-12-27
ER

PT J
AU Riccardi, D
   Maldonado-Perez, D
AF Riccardi, D
   Maldonado-Perez, D
TI RETRACTED: The calcium-sensing receptor as a nutrient sensor (Retracted
   Article. See vol 36, pg 1501, 2008)
SO BIOCHEMICAL SOCIETY TRANSACTIONS
LA English
DT Article; Proceedings Paper; Retracted Publication
CT Conference on Nutrient Sensing Through the Plasma Membrane of Eukaryotic
   Cells
CY SEP 25-29, 2004
CL Royal Agr Coll, Cirencester, ENGLAND
SP Flanders Interuniv Inst Biotechnol, Nestle UK Ltd
HO Royal Agr Coll
DE amino acids; calcium-sensing receptor; extracellular calcium;
   G-protein-coupled receptor; ionic strength; nutrient sensor; pH
ID EXTRACELLULAR CA2+-SENSING RECEPTOR; NEONATAL SEVERE
   HYPERPARATHYROIDISM; FAMILIAL HYPOCALCIURIC HYPERCALCEMIA;
   AUTOSOMAL-DOMINANT HYPOCALCEMIA; PARATHYROID-HORMONE; MUCOSAL GROWTH;
   VENUS FLYTRAP; RAT; CA2+; POLYAMINES
AB Critical to cell fate in many cell types is the ability to sense and respond to acute changes in free ionized extracellular calcium concentration ([Ca2+](0)). Such tight control is mediated by the activation of a protein known as the extracellular-calcium-sensing receptor (CaR). CaR belongs to the 'family C' of G-protein-coupled receptors and was the first G-protein-coupled receptor to be identified to have an inorganic cation, calcium, as its ligand. While calcium is the physiological agonist of the receptor, several other polyvalent cations and polycations can also modulate CaR function as do certain L-aromatic amino acids, polyamines, salinity and pH. This feature renders the CaR uniquely capable of generating cell- and tissue-specific responses, and of integrating inputs deriving from changes in the Ca-0(2+) concentration with signals deriving from the local metabolic environment. Here we address the role of the CaR in physiology and disease, the range of CaR modulators and the potential roles of the CaR as a metabolic sensor in a variety of physiological (and pathological) scenarios.
C1 Cardiff Univ, Cardiff Sch Biosci, Cardiff CF10 3US, S Glam, Wales.
RP Riccardi, D (reprint author), Cardiff Univ, Cardiff Sch Biosci, Museum Ave,POB 911, Cardiff CF10 3US, S Glam, Wales.
EM riccardid@cardiff.ac.uk
CR Bessis AS, 2002, P NATL ACAD SCI USA, V99, P11097, DOI 10.1073/pnas.162138699
   Bikle DD, 1996, J CLIN INVEST, V97, P1085, DOI 10.1172/JCI118501
   Breitwieser GE, 2004, CELL CALCIUM, V35, P209, DOI 10.1016/j.ceca.2003.10.013
   BROWN EM, 1991, J BONE MINER RES, V6, P1217
   BROWN EM, 1993, NATURE, V366, P575, DOI 10.1038/366575a0
   Brown EM, 2003, OSTEOPOROSIS INT, V14, pS25, DOI 10.1007/s00198-002-1343-6
   BROWN EM, 1991, PHYSIOL REV, V71, P371
   Brown EM, 2001, PHYSIOL REV, V81, P239
   Bruce JIE, 1999, J BIOL CHEM, V274, P20561, DOI 10.1074/jbc.274.29.20561
   Caroppo R, 2004, J CELL BIOL, V166, P111, DOI 10.1083/jcb.200310145
   Chang WH, 2004, CELL CALCIUM, V35, P183, DOI 10.1016/j.ceca.2003.10.012
   Chang YH, 1999, ENDOCRINOLOGY, V140, P5883, DOI 10.1210/en.140.12.5883
   Chattopadhyay N, 1998, AM J PHYSIOL-GASTR L, V274, pG122, DOI 10.1152/ajpgi.1998.274.1.G122
   Chattopadhyay N, 2003, CALCIUM SENSING RECE
   CHENG SX, 2002, AM J PHYSIOL, V83, pG240
   Conigrave AD, 2000, P NATL ACAD SCI USA, V97, P4814, DOI 10.1073/pnas.97.9.4814
   Conigrave AD, 2004, J BIOL CHEM, V279, P38151, DOI 10.1074/jbc.M406373200
   Dvorak MM, 2004, P NATL ACAD SCI USA, V101, P5140, DOI 10.1073/pnas.0306141101
   Dvorak MM, 2004, CELL CALCIUM, V35, P249, DOI 10.1016/j.ceca.2003.10.014
   FAGE D, 1992, J NEUROCHEM, V58, P2170, DOI 10.1111/j.1471-4159.1992.tb10960.x
   Felder CB, 1999, AAPS PHARMSCI, V1
   Geibel JP, 2001, J BIOL CHEM, V276, P39549, DOI 10.1074/jbc.M107315200
   Hebert SC, 2004, CELL CALCIUM, V35, P239, DOI 10.1016/j.ceca.2003.10.015
   HO C, 1995, NAT GENET, V11, P389, DOI 10.1038/ng1295-389
   Huttenlocher PR, 2000, EUR J PEDIATR, V159, pS102, DOI 10.1007/PL00014371
   Kallay E, 2000, CANCER DETECT PREV, V24, P127
   Kos CH, 2003, J CLIN INVEST, V111, P1021, DOI 10.1172/JCI200317416
   Kunishima N, 2000, NATURE, V407, P971, DOI 10.1038/35039564
   Loser C, 1999, GUT, V44, P12, DOI 10.1136/gut.44.1.12
   MCCORMACK SA, 1991, AM J PHYSIOL, V260, pG795
   Nearing J, 2002, P NATL ACAD SCI USA, V99, P9231, DOI 10.1073/pnas.152294399
   Nemeth EF, 2001, J PHARMACOL EXP THER, V299, P323
   Nemeth EF, 1998, P NATL ACAD SCI USA, V95, P4040, DOI 10.1073/pnas.95.7.4040
   Pallais JC, 2004, NEW ENGL J MED, V351, P362, DOI 10.1056/NEJMoa040008
   Pidasheva S, 2004, HUM MUTAT, V24, P107, DOI 10.1002/humu.20067
   POLLAK MR, 1994, NAT GENET, V8, P303, DOI 10.1038/ng1194-303
   POLLAK MR, 1993, CELL, V75, P1297, DOI 10.1016/0092-8674(93)90617-Y
   Quinn SJ, 1998, J BIOL CHEM, V273, P19579, DOI 10.1074/jbc.273.31.19579
   Quinn SJ, 2004, J BIOL CHEM, V279, P37241, DOI 10.1074/jbc.M404520200
   Quinn SJ, 1997, AM J PHYSIOL-CELL PH, V273, pC1315
   Reginster JY, 2003, DRUGS TODAY, V39, P89, DOI 10.1358/dot.2003.39.2.799416
   RICCARDI D, 1995, P NATL ACAD SCI USA, V92, P131, DOI 10.1073/pnas.92.1.131
   RICCARDI D, 2003, CALCIUM SENSING RECE, P69
   RUAT M, 1995, P NATL ACAD SCI USA, V92, P3161, DOI 10.1073/pnas.92.8.3161
   Stix B, 1998, NEUROSCI LETT, V243, P121, DOI 10.1016/S0304-3940(98)00106-2
   Thakker RV, 2004, CELL CALCIUM, V35, P275, DOI 10.1016/j.ceca.2003.10.010
   Tu QS, 2003, J CLIN INVEST, V111, P1029, DOI 10.1172/JCI200317054
   Ward DT, 2004, CELL CALCIUM, V35, P217, DOI 10.1016/j.ceca.2003.10.017
   Yano S, 2004, CELL CALCIUM, V35, P257, DOI 10.1016/j.ceca.2003.10.008
   Ye CP, 1997, J NEUROSCI RES, V47, P547, DOI 10.1002/(SICI)1097-4547(19970301)47:5<547::AID-JNR10>3.0.CO;2-V
   2004, CELL CALCIUM, V35, P179
NR 51
TC 15
Z9 15
U1 3
U2 10
PU PORTLAND PRESS LTD
PI LONDON
PA CHARLES DARWIN HOUSE, 12 ROGER STREET, LONDON WC1N 2JU, ENGLAND
SN 0300-5127
EI 1470-8752
J9 BIOCHEM SOC T
JI Biochem. Soc. Trans.
PD FEB
PY 2005
VL 33
BP 316
EP 320
DI 10.1042/BST0330316
PN 1
PG 5
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 901GA
UT WOS:000227269800089
PM 15667336
DA 2018-12-27
ER

PT J
AU Fujii, T
   Takaoka, M
   Tsuruoka, N
   Kiso, Y
   Tanaka, T
   Matsumura, Y
AF Fujii, T
   Takaoka, M
   Tsuruoka, N
   Kiso, Y
   Tanaka, T
   Matsumura, Y
TI RETRACTED: Dietary supplementation of L-carnosine prevents
   ischemia/reperfusion-induced renal injury in rats (Retracted article.
   See vol. 37, pg. 1080, 2014)
SO BIOLOGICAL & PHARMACEUTICAL BULLETIN
LA English
DT Article; Retracted Publication
DE L-carnosine; acute renal failure; ischemia; reperfusion
ID SYMPATHETIC-NERVOUS-SYSTEM; FAILURE; HOMOCARNOSINE; PATHOGENESIS;
   HYPERTENSION; ANSERINE; OXYGEN
AB The effects of dietary supplementation of L-carnosine (beta-alanyl-L-histidine) on ischemia/reperfusion-induced acute renal failure (ARF) in rats were examined. Ischemic ARF was induced by occlusion of the left renal artery and vein for 45 min followed by reperfusion, 2 weeks after contralateral nephrectomy. Renal functional parameters such as blood urea nitrogen, plasma creatinine, creatinine clearance, urine flow, urinary osmolality and fractional excretion of sodium were measured. Renal function in ARF rats markedly decreased at 1 d after reperfusion. Prior feeding of L-carnosine-containing diet (0.0001 w/w%) for 2 weeks attenuated the ischemia/reperfusion-induced renal dysfunction. Histopathological examination of the kidney of ARF rats revealed severe renal damages, such as tubular necrosis, proteinaceous casts in tubuli and medullary congestion, which were also significantly suppressed by the dietary supplementation Of L-carnosine. These findings strongly suggest that L(-)carnosine supplementation is useful as a prophylactic treatment in the development of the ischemic ARF.
C1 Osaka Univ Pharmaceut Sci, Dept Pharmacol, Takatsuki, Osaka 5691094, Japan.
   Suntory Ltd, Inst Hlth Care Sci, Osaka 6188503, Japan.
RP Matsumura, Y (reprint author), Osaka Univ Pharmaceut Sci, Dept Pharmacol, 4-20-1 Nasahara, Takatsuki, Osaka 5691094, Japan.
EM matumrh@gly.oups.ac.jp
RI Kiso, Yoshinobu/D-5424-2012
CR ARUOMA OI, 1989, BIOCHEM J, V264, P863, DOI 10.1042/bj2640863
   BAINES AD, 1983, CLIN BIOCHEM, V16, P134, DOI 10.1016/S0009-9120(83)93900-0
   Bharadwaj LA, 2002, PHARMACOL RES, V45, P175, DOI 10.1006/phrs.2001.0911
   DAHL TA, 1988, PHOTOCHEM PHOTOBIOL, V47, P357, DOI 10.1111/j.1751-1097.1988.tb02737.x
   Doi K, 2004, KIDNEY INT, V65, P1714, DOI 10.1111/j.1523-1755.2004.00567.x
   Edelstein CL, 1997, KIDNEY INT, V51, P1341, DOI 10.1038/ki.1997.183
   Fujii T, 2003, EUR J PHARMACOL, V481, P241, DOI 10.1016/j.ejphar.2003.09.036
   Fujii T, 2003, EUR J PHARMACOL, V474, P261, DOI 10.1016/S0014-2999(03)02079-X
   HARTMAN PE, 1990, PHOTOCHEM PHOTOBIOL, V51, P59, DOI 10.1111/j.1751-1097.1990.tb01684.x
   IAINA A, 1983, CLIN EXP DIAL A, V7, P115, DOI 10.3109/08860228309076043
   Kang JH, 2002, BBA-GEN SUBJECTS, V1570, P89, DOI 10.1016/S0304-4165(02)00158-7
   Lieberthal W, 1996, AM J PHYSIOL-RENAL, V271, pF477
   Nagai K, 2003, EXP BIOL MED, V228, P1138
   Niijima A, 2002, AUTON NEUROSCI-BASIC, V97, P99, DOI 10.1016/S1566-0702(02)00048-6
   Park JB, 2002, AM J HYPERTENS, V15, P78, DOI 10.1016/S0895-7061(01)02233-6
   SOLEZ K, 1974, KIDNEY INT, V6, P24, DOI 10.1038/ki.1974.74
   Stvolinsky SL, 2000, BIOCHEMISTRY-MOSCOW+, V65, P849
   Tabakman R, 2002, J NEUROSCI RES, V68, P463, DOI 10.1002/jnr.10228
   Yamano T, 2001, NEUROSCI LETT, V313, P78, DOI 10.1016/S0304-3940(01)02231-5
NR 19
TC 32
Z9 38
U1 2
U2 7
PU PHARMACEUTICAL SOC JAPAN
PI TOKYO
PA 2-12-15 SHIBUYA, SHIBUYA-KU, TOKYO, 150-0002, JAPAN
SN 0918-6158
J9 BIOL PHARM BULL
JI Biol. Pharm. Bull.
PD FEB
PY 2005
VL 28
IS 2
BP 361
EP 363
DI 10.1248/bpb.28.361
PG 3
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 897HT
UT WOS:000226995300033
PM 15684500
OA Bronze
DA 2018-12-27
ER

PT J
AU Xu, D
   Komai-Koma, M
   Liew, FY
AF Xu, D
   Komai-Koma, M
   Liew, FY
TI RETRACTED: Expression and function of Toll-like receptor on T cells
   (Retracted article. See vol. 281, pg. 170, 2013)
SO CELLULAR IMMUNOLOGY
LA English
DT Article; Proceedings Paper; Retracted Publication
CT EFIS Symposium on Chronic Inflammatory Autoimmune Diseases
CY SEP, 2004
CL Belgrade, SERBIA MONTENEG
SP European Federat Immunol Soc, Univ Belgrade, Fac Med, Servian Acad Sci & Arts
DE toll-like receptors; T cells; co-stimulation; T cell memory
ID MEMORY B-CELLS; DROSOPHILA TOLL; ACQUIRED-IMMUNITY; UP-REGULATION;
   ACTIVATION; LIPOPOLYSACCHARIDE; LYMPHOCYTES; FAMILY; NAIVE; GENE
AB Toll is the founder of a group of pattern recognition receptors, which play a critical role in the innate immunity in Drosophila. At least 13 distinct Toll-like receptors (TLRs), recognising pathogen-associated molecular pattern (PAMPs), have now been identified in humans. Most investigations on TLRs have focused on cells of the innate system. We report here that naive human T cells expressed high levels of cell surface TLR2 after activation by anti-T cell receptor (TCR) antibody and interferon-alpha. Activated cells produced elevated levels of cytokines in response to the TLR2 ligand, bacteria] lipopeptide (BLP). Furthermore, CD(4+)CD45RO(+) memory T cells from peripheral blood constitutively expressed TLR2 and produced IFN gamma in response to BLP. BLP also markedly enhanced the proliferation and IFN gamma production by CD45RO(+) T cells in the presence of IL-2 or IL-15. Thus, TLR2 serves as a costimulatory receptor for antigen-specific T cell development and participates in the maintenance of T cell memory. This suggests that pathogens, via their PAMPs, may contribute directly to the perpetuation and activation of long term T cell memory in both antigen dependent and independent manner. (c) 2005 Elsevier Inc. All rights reserved.
C1 Univ Glasgow, Div Immunol Infect & Inflammat, Glasgow G11 6NT, Lanark, Scotland.
RP Liew, FY (reprint author), Univ Glasgow, Div Immunol Infect & Inflammat, Glasgow G11 6NT, Lanark, Scotland.
EM f.y.liew@clinmed.gla.ac.uk
RI Xu, Damo/A-8212-2011
FU Wellcome Trust
CR Aderem A, 2000, NATURE, V406, P782, DOI 10.1038/35021228
   Akira S, 2001, NAT IMMUNOL, V2, P675, DOI 10.1038/90609
   Belvin MP, 1996, ANNU REV CELL DEV BI, V12, P393, DOI 10.1146/annurev.cellbio.12.1.393
   Bendigs S, 1999, EUR J IMMUNOL, V29, P1209, DOI 10.1002/(SICI)1521-4141(199904)29:04<1209::AID-IMMU1209>3.0.CO;2-J
   Bernasconi NL, 2002, SCIENCE, V298, P2199, DOI 10.1126/science.1076071
   Bernasconi NL, 2003, BLOOD, V101, P4500, DOI 10.1182/blood-2002-11-3569
   Brint EK, 2002, J BIOL CHEM, V277, P49205, DOI 10.1074/jbc.M209685200
   Caramalho I, 2003, J EXP MED, V197, P403, DOI 10.1084/jem.20021633
   Castro A, 1998, EUR J IMMUNOL, V28, P488, DOI 10.1002/(SICI)1521-4141(199802)28:02<488::AID-IMMU488>3.0.CO;2-R
   Chaudhary PM, 1998, BLOOD, V91, P4020
   Chuang TH, 2001, BBA-GENE STRUCT EXPR, V1518, P157, DOI 10.1016/S0167-4781(00)00289-X
   Geginat J, 2001, J EXP MED, V194, P1711, DOI 10.1084/jem.194.12.1711
   Lemaitre B, 1996, CELL, V86, P973, DOI 10.1016/S0092-8674(00)80172-5
   Marrack P, 2000, NAT IMMUNOL, V1, P107, DOI 10.1038/77778
   Matsuguchi T, 2000, BLOOD, V95, P1378
   Medzhitov R, 1997, NATURE, V388, P394, DOI 10.1038/41131
   Mokuno Y, 2000, J IMMUNOL, V165, P931, DOI 10.4049/jimmunol.165.2.931
   Muzio M, 2000, J IMMUNOL, V164, P5998, DOI 10.4049/jimmunol.164.11.5998
   Niedbala W, 2002, EUR J IMMUNOL, V32, P341, DOI 10.1002/1521-4141(200202)32:2<341::AID-IMMU341>3.0.CO;2-X
   Ohashi K, 2000, J IMMUNOL, V164, P558, DOI 10.4049/jimmunol.164.2.558
   Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085
   Rock FL, 1998, P NATL ACAD SCI USA, V95, P588, DOI 10.1073/pnas.95.2.588
   Schnare M, 2001, NAT IMMUNOL, V2, P947, DOI 10.1038/ni712
   Takeda K, 2003, ANNU REV IMMUNOL, V21, P335, DOI 10.1146/annurev.immunol.21.120601.141126
   Takeuchi O, 1999, GENE, V231, P59, DOI 10.1016/S0378-1119(99)00098-0
   Tough DF, 1997, J EXP MED, V185, P2089, DOI 10.1084/jem.185.12.2089
   UNUTMAZ D, 1994, J EXP MED, V180, P1159, DOI 10.1084/jem.180.3.1159
   Vilanova M, 1996, SCAND J IMMUNOL, V43, P155, DOI 10.1046/j.1365-3083.1996.d01-25.x
   Zanin-Zhorov A, 2003, FASEB J, V17, P1567, DOI 10.1096/fj.02-1139fje
   Zarember KA, 2002, J IMMUNOL, V168, P554, DOI 10.4049/jimmunol.168.2.554
   Zhang ZP, 1998, CHINESE PHYS LETT, V15, P591, DOI 10.1088/0256-307X/15/8/017
NR 31
TC 65
Z9 69
U1 3
U2 9
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0008-8749
J9 CELL IMMUNOL
JI Cell. Immunol.
PD FEB
PY 2005
VL 233
IS 2
SI SI
BP 85
EP 89
DI 10.1016/j.cellimm.2005.04.019
PG 5
WC Cell Biology; Immunology
SC Cell Biology; Immunology
GA 954YJ
UT WOS:000231191100003
PM 15950961
DA 2018-12-27
ER

PT J
AU Neyestani, TR
   Woodward, B
AF Neyestani, TR
   Woodward, B
TI RETRACTED: Blood concentrations of Th2-type immunoglobulins are
   selectively increased in weanling mice subjected to acute malnutrition
   (Retracted article. See vol 233, pg. 1189, 2008)
SO EXPERIMENTAL BIOLOGY AND MEDICINE
LA English
DT Article; Retracted Publication
DE energy deficiency; protein deficiency; immunoglobulin; blood; mice
ID SEVERE PROTEIN-DEFICIENCY; T-CELLS; ENERGY; MOUSE; INTERLEUKIN-4;
   RESTRICTION; MECHANISMS; NUTRITION; IMBALANCE; CHILDREN
AB Male and female C57BU6J mice, initially 19 days old, consumed a complete purified diet either ad libitum (age-matched control) or in restricted daily quantities (energy deficiency), or they consumed a purified isocaloric low-protein diet ad libitum (protein and energy deficit). In a 14-day experimental period, malnourished animals lost approximately 1.5% of their initial body weight daily. Zero-time controls, 19 days old, were also included in the study. Serum levels of Th2-type (IgG1 and IgE) and Th1-type (IgG2a and IgG3) immunoglobulins were quantified by enzyme-linked immunosorbent assay, and total IgG concentration was also assessed. Both malnourished groups exhibited high serum concentrations of IgG1 and IgE relative to the agematched control group, whereas levels of the Th1-type immunoglobulins were unaffected. Total IgG concentration in the malnourished groups reflected the usual finding in humans (i.e., no effect or elevated). The results are consistent with the proposition of Th2-polarized immune competence in acute weanling deficiencies of energy, protein, or both.
C1 Univ Guelph, Dept Human Biol & Nutr Sci, Guelph, ON N1G 2W1, Canada.
   Shahid Beheshti Univ Med Sci, Natl Inst Nutr Res & Food Technol, Lab Nutr Res, Tehran, Iran.
RP Woodward, B (reprint author), Univ Guelph, Dept Human Biol & Nutr Sci, Guelph, ON N1G 2W1, Canada.
EM wwoodwar@uoguelph.ca
OI Neyestani, Tirang R./0000-0002-0953-2594
CR CHANDRA RK, 1977, NUTRITION IMMUNITY I, P67
   Chapoval SP, 1999, J CLIN INVEST, V103, P1707, DOI 10.1172/JCI6175
   FILTEAU SM, 1982, J NUTR, V112, P1974
   FILTEAU SM, 1987, NUTR RES, V7, P101, DOI 10.1016/S0271-5317(87)80195-1
   Fraser DA, 1999, CLIN RHEUMATOL, V18, P394, DOI 10.1007/s100670050125
   Goldsby RA, 2000, KUBY IMMUNOLOGY, V4th, P303
   GROSS RL, 1980, PHYSIOL REV, V60, P188
   Ha CL, 2001, J NUTR, V131, P1812
   HAGEL I, 1995, T ROY SOC TROP MED H, V89, P562, DOI 10.1016/0035-9203(95)90109-4
   HILL ADK, 1995, ARCH SURG-CHICAGO, V130, P1273
   Hillyer LM, 2003, AM J PHYSIOL-REG I, V285, pR1514, DOI 10.1152/ajpregu.00378.2003
   Konyer JE, 2003, NUTR RES, V23, P921, DOI 10.1016/S0271-5317(03)00082-4
   MCMURRAY DN, 1981, AM J CLIN NUTR, V34, P2117
   MITTAL A, 1985, P SOC EXP BIOL MED, V178, P385
   Morlese JF, 1998, AM J PHYSIOL-ENDOC M, V275, pE112, DOI 10.1152/ajpendo.1998.275.1.E112
   NUSSLEIN HG, 1992, CLIN EXP IMMUNOL, V90, P286
   Peng SL, 1997, J CLIN INVEST, V99, P1936, DOI 10.1172/JCI119361
   Santana MA, 2003, J CELL PHYSIOL, V195, P392, DOI 10.1002/jcp.10258
   SAS, 1999, SAS STAT US GUID VER
   Shi HN, 1998, J NUTR, V128, P20
   Shipp K, 1998, CONTEMP TOP LAB ANIM, V37, P73
   SHIPP K, 1998, THESIS U GUELPH GUEL
   SNAPPER CM, 1993, IMMUNOL TODAY, V14, P15, DOI 10.1016/0167-5699(93)90318-F
   Sudo N, 2002, CLIN EXP ALLERGY, V32, P1112, DOI 10.1046/j.1365-2222.2002.01430.x
   Szabo SJ, 2003, ANNU REV IMMUNOL, V21, P713, DOI 10.1146/annurev.immunol.21.120601.140942
   Takahashi S, 1996, J CLIN INVEST, V97, P1597, DOI 10.1172/JCI118584
   TIZARD I, 2001, IMMUNOLOGICAL PROPER, P139
   WOODS JW, 1991, J NUTR, V121, P1425
   Woodward B, 2001, NESTLE NUTR WORKS SE, V45, P89
   WOODWARD B, 2004, NUTR IMMUNOLOGY 21 C, P23
   Zhang X, 2002, J NUTR, V132, P2748
NR 31
TC 17
Z9 17
U1 1
U2 7
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1535-3702
EI 1535-3699
J9 EXP BIOL MED
JI Exp. Biol. Med.
PD FEB
PY 2005
VL 230
IS 2
BP 128
EP 134
PG 7
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA 903MV
UT WOS:000227431000007
PM 15673561
DA 2018-12-27
ER

PT J
AU Barreiro, C
   Gonzalez-Lavado, E
   Brand, S
   Tauch, A
   Martin, JF
AF Barreiro, C
   Gonzalez-Lavado, E
   Brand, S
   Tauch, A
   Martin, JF
TI RETRACTED: Heat shock Proteome analysis of wild-type Corynebacterium
   glutamicum ATCC 13032 and a spontaneous mutant lacking GroEL1, a
   dispensable chaperone (Retracted article. See vol. 195, pg. 2707, 2013)
SO JOURNAL OF BACTERIOLOGY
LA English
DT Article; Retracted Publication
ID ACID-PRODUCING CORYNEBACTERIA; STREPTOMYCES-ALBUS-G; TRANSCRIPTIONAL
   ANALYSIS; GEL-ELECTROPHORESIS; ESCHERICHIA-COLI; GENE-EXPRESSION;
   PLASMID DNA; GENOME; SEQUENCE; PROTEINS
AB Proteome analysis of Corynebacterium glutanticum ATCC 13032 showed that levels of several proteins increased drastically in response to heat shock. These proteins were identified as DnaK, GroEL1, GroEL2, ClpB, GrpE, and PoxB, and their heat response was in agreement with previous transcriptomic results. A major heat-induced protein was absent in the proteome of strain 13032B of C. glutamicum, used for genome sequencing in Germany, compared with the wild-type ATCC 13032 strain. The missing protein was identified as GroEL1 by matrix-assisted laser desorption ionization-time of flight peptide mass fingerprinting, and the mutation was found to be due to an insertion sequence, IsCg1, that was integrated at position 327 downstream of the translation start codon of the groEL1 gene, resulting in a truncated transcript of this gene, as shown by Northern analysis. The GroEL1 chaperone is, therefore, dispensable in C. glutamicum. On the other hand, GroEL2 appears to be essential for growth. Based on these results, the role of the duplicate groEL1 and groEL2 genes is analyzed.
C1 INBIOTEC, Inst Biotechnol Leon, Leon 24006, Spain.
   Univ Leon, Fac CC Biol & Ambientales, Area Microbiol, E-24071 Leon, Spain.
   Univ Bielefeld, Inst Genomforsch, D-4800 Bielefeld, Germany.
RP Martin, JF (reprint author), INBIOTEC, Inst Biotechnol Leon, Parque Cientde Leon,Av Real 1, Leon 24006, Spain.
EM degjmm@unileon.es
CR Archibald JM, 2001, J STRUCT BIOL, V135, P157, DOI 10.1006/jsbi.2001.4353
   Barreiro C, 2004, J BACTERIOL, V186, P4813, DOI 10.1128/JB.186.14.4813-4817.2004
   Barrington K J, 2001, BMC Pediatr, V1, P1, DOI 10.1186/1471-2431-1-1
   Bathe B, 1996, MOL GEN GENET, V252, P255, DOI 10.1007/s004380050227
   BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513
   Burkovski A, 2002, APPL MICROBIOL BIOT, V58, P265, DOI 10.1007/s00253-001-0869-4
   Correia A, 1996, GENE, V170, P91, DOI 10.1016/0378-1119(95)00866-7
   CORREIA A, 1994, MICROBIOL-SGM, V140, P2841, DOI 10.1099/00221287-140-10-2841
   Delaunay S, 2002, J IND MICROBIOL BIOT, V28, P333, DOI 10.1038/sj/jim/7000251
   deLeon P, 1997, MICROBIOL-SGM, V143, P3563, DOI 10.1099/00221287-143-11-3563
   EIKMANNS BJ, 1993, ANTON LEEUW INT J G, V64, P145
   EIKMANNS BJ, 1994, MICROBIOL-SGM, V140, P1817, DOI 10.1099/13500872-140-8-1817
   Engels S, 2004, MOL MICROBIOL, V52, P285, DOI 10.1111/j.1365-2958.2003.03979.x
   FISCHER HM, 1993, EMBO J, V12, P2901, DOI 10.1002/j.1460-2075.1993.tb05952.x
   Grandvalet C, 1998, J BACTERIOL, V180, P5129
   HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8
   Hermann T, 1998, ELECTROPHORESIS, V19, P3217, DOI 10.1002/elps.1150191827
   Hermann T, 2001, ELECTROPHORESIS, V22, P1712, DOI 10.1002/1522-2683(200105)22:9<1712::AID-ELPS1712>3.0.CO;2-G
   Ikeda M, 2003, APPL MICROBIOL BIOT, V62, P99, DOI 10.1007/s00253-003-1328-1
   Kalinowski J, 2003, J BIOTECHNOL, V104, P5, DOI 10.1016/S0168-1656(03)00154-8
   Karlin S, 2000, P NATL ACAD SCI USA, V97, P11348, DOI 10.1073/pnas.97.21.11348
   Kinoshita S., 1957, J GEN APPL MICROBIOL, V3, P193, DOI DOI 10.2323/JGAM.3.193
   Kirchner O, 2003, J BIOTECHNOL, V104, P287, DOI 10.1016/S0168-1656(03)00148-2
   Malumbres M, 1996, FEMS MICROBIOL LETT, V143, P103, DOI 10.1016/0378-1097(96)00300-X
   MARTIN JF, 1987, BIO-TECHNOL, V5, P137, DOI 10.1038/nbt0287-137
   MARTIN JF, 1989, SYMP SOC GEN MICROBI, V44, P25
   MARTIN JF, 1999, MANUAL IND MICROBIOL, P379
   Mostertz J, 2004, MICROBIOL-SGM, V150, P497, DOI 10.1099/mic.0.26665-0
   Muffler A, 2002, J BIOTECHNOL, V98, P255, DOI 10.1016/S0168-1656(02)00136-0
   Ohnishi J, 2003, APPL MICROBIOL BIOT, V62, P69, DOI 10.1007/s00253-003-1254-2
   Perkins DN, 1999, ELECTROPHORESIS, V20, P3551, DOI 10.1002/(SICI)1522-2683(19991201)20:18<3551::AID-ELPS3551>3.0.CO;2-2
   Quast K, 1999, MOL GEN GENET, V262, P568, DOI 10.1007/s004380051119
   Rosen R, 2002, MASS SPECTROM REV, V21, P244, DOI 10.1002/mas.10031
   Sambrook J., 2001, MOL CLONING LAB MANU
   Schaffer S, 2001, ELECTROPHORESIS, V22, P4404, DOI 10.1002/1522-2683(200112)22:20<4404::AID-ELPS4404>3.0.CO;2-2
   SERVANT P, 1993, GENE, V134, P25, DOI 10.1016/0378-1119(93)90170-8
   SKERMAN VBD, 1980, INT J SYST BACTERIOL, V30, P225, DOI 10.1099/00207713-30-1-225
   van der Rest ME, 1999, APPL MICROBIOL BIOT, V52, P541, DOI 10.1007/s002530051557
   VERTES AA, 1994, MOL MICROBIOL, V11, P739, DOI 10.1111/j.1365-2958.1994.tb00351.x
   YOUNG DB, 1991, INFECT IMMUN, V59, P3086
   Yura T, 1999, CURR OPIN MICROBIOL, V2, P153, DOI 10.1016/S1369-5274(99)80027-7
NR 41
TC 39
Z9 43
U1 4
U2 12
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0021-9193
J9 J BACTERIOL
JI J. Bacteriol.
PD FEB
PY 2005
VL 187
IS 3
BP 884
EP 889
DI 10.1128/JB.187.3.884-889.2005
PG 6
WC Microbiology
SC Microbiology
GA 893FR
UT WOS:000226705200009
PM 15659666
OA Bronze, Green Published
DA 2018-12-27
ER

PT J
AU Takada, I
   Suzawa, M
   Kato, S
AF Takada, I
   Suzawa, M
   Kato, S
TI RETRACTED: Nuclear receptors as targets for drug development: Crosstalk
   between peroxisome proliferator-activated receptor gamma and cytokines
   in bone marrow-derived mesenchymal stem cells (Retracted article. See
   vol. 123, pg. 207, 2013)
SO JOURNAL OF PHARMACOLOGICAL SCIENCES
LA English
DT Review; Retracted Publication
DE nuclear receptor; adipogenesis; cytokine; mesenchymal stem cell;
   transcription
ID I-KAPPA-B; PPAR-GAMMA; SIGNAL-TRANSDUCTION; HORMONE-RECEPTORS;
   CO-REPRESSOR; TAK1 MAPKKK; KINASE; PROTEIN; LIGAND; BETA
AB (P)eroxisome proliferator-activated receptor gamma (PPARgamma) is a ligand-dependent nuclear receptor and regulates adipogenesis and fat metabolism. PPARgamma is activated by fatty acid derivatives and some synthetic compounds such as the thiazolidinediones. In addition, certain cytokines were known to affect the transactivation function of PPARgamma. However, the molecular mechanism of the functional interaction between PPARgamma and cytokine signaling remains unclear. We found that combined treatment of PPARgamma and cytokines (IL-1 or TNF-alpha) inhibited adipogenesis and induced osteoblastgenesis in bone marrow-derived mesenchymal stem cells. Furthermore, we showed that the ligand dependent transactivation function of PPARgamma was suppressed by IL-1 and TNF-alpha. This suppression was mediated through NF-kappaB activated by the TAK1/TAB1-NIK cascade, a downstream cascade triggered with IL-1 or TNF-alpha signaling. Thus, we have identified a molecular mechanism of functional cross-talk between PPARgamma and cytokine signaling that may provide a theoretical basis for development of novel therapeutical strategies and design of novel compounds for treatment of obesity, diabetes, and some other chronic diseases.
C1 Univ Tokyo, Inst Mol & Cellular Biosci, Tokyo 1130032, Japan.
RP Takada, I (reprint author), Univ Tokyo, Inst Mol & Cellular Biosci, Tokyo 1130032, Japan.
EM itakada@iam.u-tokyo.ac.jp
CR Ballas CB, 2002, J CELL BIOCHEM, P20, DOI 10.1002/jcb.10127
   Castillo G, 1999, EMBO J, V18, P3676, DOI 10.1093/emboj/18.13.3676
   Chen FE, 1998, NATURE, V391, P410
   CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0
   DREYER C, 1992, CELL, V68, P879, DOI 10.1016/0092-8674(92)90031-7
   FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0
   HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0
   ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0
   Jiang CY, 1998, NATURE, V391, P82
   KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491
   KONIG A, 1988, J BONE MINER RES, V3, P621
   LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953
   Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0
   Marx N, 2004, CIRC RES, V94, P1168, DOI 10.1161/01.RES.0000127122.22685.0A
   Ninomiya-Tsuji J, 1999, NATURE, V398, P252, DOI 10.1038/18465
   Nuttall ME, 2004, CURR OPIN PHARMACOL, V4, P290, DOI 10.1016/j.coph.2004.03.002
   OGAWA M, 1988, EMBO J, V7, P1337, DOI 10.1002/j.1460-2075.1988.tb02949.x
   ONATE SA, 1995, SCIENCE, V270, P1354
   Rachez C, 1998, GENE DEV, V12, P1787, DOI 10.1101/gad.12.12.1787
   Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X
   Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178
   RON D, 1992, J CLIN INVEST, V89, P223, DOI 10.1172/JCI115566
   Shibuya H, 1996, SCIENCE, V272, P1179, DOI 10.1126/science.272.5265.1179
   Steeve KT, 2004, CYTOKINE GROWTH F R, V15, P49, DOI 10.1016/j.cytog.fr.2003.10.005
   Suzawa M, 2003, NAT CELL BIOL, V5, P224, DOI 10.1038/ncb942
   Takaesu G, 2000, MOL CELL, V5, P649, DOI 10.1016/S1097-2765(00)80244-0
   TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224
   Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866
   Yanagisawa J, 1999, SCIENCE, V283, P1317, DOI 10.1126/science.283.5406.1317
NR 29
TC 21
Z9 23
U1 4
U2 14
PU JAPANESE PHARMACOLOGICAL SOC
PI KYOTO
PA EDITORIAL OFF, KANTOHYA BLDG GOKOMACHI-EBISUGAWA NAKAGYO-KU, KYOTO, 604,
   JAPAN
SN 1347-8613
EI 1347-8648
J9 J PHARMACOL SCI
JI J. Pharmacol. Sci.
PD FEB
PY 2005
VL 97
IS 2
BP 184
EP 189
DI 10.1254/jphs.FMJ04008X5
PG 6
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 902GS
UT WOS:000227343400006
PM 15725700
OA Bronze
DA 2018-12-27
ER

PT J
AU Matsuda, T
   Almasan, A
   Tomita, M
   Uchihara, J
   Masuda, M
   Ohshiro, K
   Takasu, N
   Yagita, H
   Ohta, T
   Mori, N
AF Matsuda, T
   Almasan, A
   Tomita, M
   Uchihara, J
   Masuda, M
   Ohshiro, K
   Takasu, N
   Yagita, H
   Ohta, T
   Mori, N
TI RETRACTED: Resistance to apo2 ligand (Apo2L)/tumor necrosis
   factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis and
   constitutive expression of Apo2L/TRAIL in human T-cell leukemia virus
   type 1-infected T-cell lines (Retracted Article. See vol 85, pg 1416,
   2011)
SO JOURNAL OF VIROLOGY
LA English
DT Article; Retracted Publication
ID NF-KAPPA-B; TRAIL-INDUCED APOPTOSIS; HIV-INFECTED INDIVIDUALS;
   FADD-DEPENDENT APOPTOSIS; HUMAN-MELANOMA CELLS; 2 DISTINCT PATHWAYS;
   PERIPHERAL-BLOOD; PROSTATE-CANCER; KINASE-ALPHA; TAX PROTEIN
AB Adult T-cell leukemia (ATL), a CD4(+)-T-cell malignancy caused by human T-cell leukemia virus type I (HTLV-1), is difficult to cure, and novel treatments are urgently needed. Apo2 ligand (Apo2L; also tumor necrosis factor-related apoptosis-inducing ligand [TRAIL]) has been implicated in antitumor therapy. We found that HTLV-1-infected T-cell lines and primary ATL cells were more resistant to Apo2L-induced apoptosis than uninfected cells. Interestingly, HTLV-1-infected T-cell lines and primary ATL cells constitutively expressed Apo2L mRNA. Inducible expression of the viral oncoprotein Tax in a T-cell line up-regulated Apo2L mRNA. Analysis of the Apo2L promoter revealed that this gene is activated by Tax via the activation of NF-kappaB. The sensitivity to Apo2L was not correlated with expression levels of Apo2L receptors, intracellular regulators of apoptosis (FLICE-inhibitory protein and active Akt). NF-kappaB plays a crucial role in the pathogenesis and survival of ATL cells. The resistance to Apo2L-induced apoptosis was reversed by N-acetyl-(L)-leucinyl-(L)-leucinyl-(L)-norleucinal (LLnL), an NF-kappaB inhibitor. LLnL significantly induced the Apo2L receptors DR4 and DR5. Our results suggest that the constitutive activation of NF-kappaB is essential for Apo2L gene induction and protection against Apo2L-induced apoptosis and that suppression of NF-kappaB may be a useful adjunct in clinical use of Apo2L against ATL.
C1 Univ Ryukyus, Grad Sch Med, Div Mol Virol & Oncol, Nishihara, Okinawa 9030215, Japan.
   Univ Ryukyus, Fac Med, Div Child Hlth & Welf, Nishihara, Okinawa 9030215, Japan.
   Univ Ryukyus, Fac Med, Div Endocrinol & Metab, Nishihara, Okinawa 9030215, Japan.
   Naha Prefectural Hosp, Dept Internal Med, Naha, Okinawa, Japan.
   Juntendo Univ, Sch Med, Dept Immunol, Tokyo 113, Japan.
   Cleveland Clin Fdn, Lerner Res Inst, Dept Canc Biol, Cleveland, OH 44195 USA.
RP Mori, N (reprint author), Univ Ryukyus, Grad Sch Med, Div Mol Virol & Oncol, 207 Uehara, Nishihara, Okinawa 9030215, Japan.
EM n-mori@med.u-ryukyu.ac.jp
RI Almasan, Alex/C-2715-2008
OI Almasan, Alex/0000-0002-8916-6650
CR AKAGI T, 1995, BLOOD, V86, P4243
   Almasan A, 2003, CYTOKINE GROWTH F R, V14, P337, DOI 10.1016/S1359-6101(03)00029-7
   Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926
   Baetu TM, 2001, J IMMUNOL, V167, P3164, DOI 10.4049/jimmunol.167.6.3164
   BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809
   Chaudhary PM, 1997, IMMUNITY, V7, P821, DOI 10.1016/S1074-7613(00)80400-8
   Chen XF, 2001, ONCOGENE, V20, P6073, DOI 10.1038/sj.onc.1204736
   Clarke P, 2000, J VIROL, V74, P8135, DOI 10.1128/JVI.74.17.8135-8139.2000
   Degli-Esposti MA, 1997, IMMUNITY, V7, P813, DOI 10.1016/S1074-7613(00)80399-4
   Gazitt Y, 1999, LEUKEMIA, V13, P1817, DOI 10.1038/sj.leu.2401501
   Geleziunas R, 1998, MOL CELL BIOL, V18, P5157, DOI 10.1128/MCB.18.9.5157
   Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225
   Gibson EM, 2002, CANCER RES, V62, P488
   Gliniak B, 1999, CANCER RES, V59, P6153
   Gong B, 2000, BIOCHEM BIOPH RES CO, V278, P747, DOI 10.1006/bbrc.2000.3872
   Griffith TS, 1998, J IMMUNOL, V161, P2833
   Griffith TS, 1998, CURR OPIN IMMUNOL, V10, P559, DOI 10.1016/S0952-7915(98)80224-0
   HINUMA Y, 1981, P NATL ACAD SCI-BIOL, V78, P6476, DOI 10.1073/pnas.78.10.6476
   HOLLSBERG P, 1994, J IMMUNOL, V153, P566
   Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657
   Jeremias I, 1998, BLOOD, V91, P4624
   KAGI D, 1994, SCIENCE, V265, P528, DOI 10.1126/science.7518614
   Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621
   Katsikis PD, 1996, INT IMMUNOL, V8, P1311, DOI 10.1093/intimm/8.8.1311
   Katsikis PD, 1997, J EXP MED, V186, P1365, DOI 10.1084/jem.186.8.1365
   Kayagaki N, 1999, J IMMUNOL, V162, P2639
   Kayagaki N, 1999, J IMMUNOL, V163, P1906
   Kim KH, 2000, CLIN CANCER RES, V6, P335
   KIM SJ, 1990, J EXP MED, V172, P121, DOI 10.1084/jem.172.1.121
   KOEFFLER HP, 1984, BLOOD, V64, P482
   KOJIMA H, 1994, IMMUNITY, V1, P357, DOI 10.1016/1074-7613(94)90066-3
   LANOTTE M, 1991, BLOOD, V77, P1080
   Lee FS, 1998, P NATL ACAD SCI USA, V95, P9319, DOI 10.1073/pnas.95.16.9319
   Leverkus M, 2000, CANCER RES, V60, P553
   Liu Y, 2001, ONCOGENE, V20, P2514, DOI 10.1038/sj.onc.1204364
   LOWIN B, 1994, NATURE, V370, P650, DOI 10.1038/370650a0
   Marsters SA, 1996, CURR BIOL, V6, P750, DOI 10.1016/S0960-9822(09)00456-4
   Matsumoto K, 1997, J VIROL, V71, P4445
   McKinsey TA, 1996, MOL CELL BIOL, V16, P2083
   MIYOSHI I, 1980, GANN, V71, P155
   MIYOSHI I, 1981, NATURE, V294, P770, DOI 10.1038/294770a0
   Mori N, 2002, BLOOD, V100, P1828, DOI 10.1182/blood-2002-01-0151
   Mori N, 1999, BLOOD, V93, P2360
   NAGATA K, 1989, J VIROL, V63, P3220
   NERENBERG M, 1987, SCIENCE, V237, P1324, DOI 10.1126/science.2888190
   Nesterov A, 2001, J BIOL CHEM, V276, P10767, DOI 10.1074/jbc.M005196200
   OHTANI K, 1989, NUCLEIC ACIDS RES, V17, P1589, DOI 10.1093/nar/17.4.1589
   Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815
   Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111
   Petak I, 2000, CLIN CANCER RES, V6, P4119
   Pierce JW, 1997, J BIOL CHEM, V272, P21096, DOI 10.1074/jbc.272.34.21096
   POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415
   POPOVIC M, 1983, SCIENCE, V219, P856, DOI 10.1126/science.6600519
   Satoh K, 2001, PANCREAS, V23, P251, DOI 10.1097/00006676-200110000-00005
   Schneider P, 1997, IMMUNITY, V7, P831, DOI 10.1016/S1074-7613(00)80401-X
   Sedger LM, 1999, J IMMUNOL, V163, P920
   Seth A, 1997, AIDS, V11, P1059
   Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818
   SMITH MR, 1990, GENE DEV, V4, P1875, DOI 10.1101/gad.4.11.1875
   Thakkar H, 2001, J BIOL CHEM, V276, P38361, DOI 10.1074/jbc.M103321200
   Thomas WD, 1998, J IMMUNOL, V161, P2195
   Vidalain PO, 2000, J VIROL, V74, P556, DOI 10.1128/JVI.74.1.556-559.2000
   Walczak H, 1997, EMBO J, V16, P5386, DOI 10.1093/emboj/16.17.5386
   Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8
   Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866
   YAMAMOTO N, 1982, SCIENCE, V217, P737, DOI 10.1126/science.6980467
   Yamamoto-Mitani N, 2001, Sch Inq Nurs Pract, V15, P113
   Yamaoka S, 1996, EMBO J, V15, P873, DOI 10.1002/j.1460-2075.1996.tb00422.x
   YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031
   Zandi E, 1999, MOL CELL BIOL, V19, P4547
   Zhang CH, 1996, J IMMUNOL, V157, P3980
   Zhang XD, 2000, J IMMUNOL, V164, P3961, DOI 10.4049/jimmunol.164.8.3961
   Zhang XD, 1999, CANCER RES, V59, P2747
NR 73
TC 18
Z9 23
U1 3
U2 10
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
EI 1098-5514
J9 J VIROL
JI J. Virol.
PD FEB
PY 2005
VL 79
IS 3
BP 1367
EP 1378
DI 10.1128/JVI.79.3.1367-1378.2005
PG 12
WC Virology
SC Virology
GA 892FB
UT WOS:000226634300004
PM 15650163
OA Bronze, Green Published
DA 2018-12-27
ER

PT J
AU Li, Y
   Qin, HQ
   Chen, QS
   Wang, JJ
AF Li, Y
   Qin, HQ
   Chen, QS
   Wang, JJ
TI RETRACTED: Neurochemical and behavioral effects of the intrahippocampal
   co-injection of beta-amyloid protein 1-40 and ibotenic acid in rats
   (Retracted article. See vol. 84, pg. 940, 2009)
SO LIFE SCIENCES
LA English
DT Article; Retracted Publication
DE beta-amyloid protein1-40; ibotenic acid; learning and memory; membrane
   fluidity; superoxide dismutase; malondialdehyde
ID ALZHEIMERS-DISEASE; MEMORY; BRAIN; TOXICITY; FLUIDITY; PEPTIDE
AB The present study was designed to investigate the effects of the intrahippocampal co-injection of beta-amyloid protein 1-40 (Abeta(t-40)) with ibotenic acid (Ibo) on learning and memory in normal and aging model rats, and to explore the mechanism underlying the effects of the co-injection. The normal and aging rats were bilaterally injected Abeta(1-40) (4 mug for each side) with Ibo (2 mug for each side) into the hippocampus. Two weeks after the intrahippocampal injection, the exploratory behavior and learning-memory ability of the rats were tested by using open field, Y-maze and passive avoidance task. And the changes of membrane fluidity in hippocampal mitochondria, the activity of superoxide dismutase (SOD) and the content of malondialdehyde (MDA) in hippocampus were also examined. The co-injection of Abeta(1-40) with Ibo induced tested rats a remarkable decrease in the explorative behaviors and a significant decline in learning-memory ability (P < 0.01). The neurochemical changes induced by the co-injection included a significant decrease in membrane fluidity of hippocampal mitochondria, (P < 0.01), a significant decrease in the activity of SOD (P < 0.01), as well as a remarkable increase in the content of MDA (P < 0.01). The results suggest that co-injection of Abeta(1-40) with Ibo may induce an increase of hippocampal damage by peroxidation and a serious deficit in the learning and memory of the rats. The results also suggest that the co-injection of Abeta(1-40) with Ibo may provide a useful animal model for the Alzheimer's disease (AD) research. (C) 2004 Elsevier Inc. All rights reserved.
C1 Nanjing Univ, Dept Biol Sci & Technol, Coll Life Sci, Nanjing 210093, Peoples R China.
   Nanjing Univ, State Key Lab Pharmaceut Biotechnol, Coll Life Sci, Nanjing 210093, Peoples R China.
   Nanjing Med Univ, Dept Physiol, Nanjing 210029, Peoples R China.
RP Li, Y (reprint author), Nanjing Univ, Dept Biol Sci & Technol, Coll Life Sci, Mailbox 426,22 Hankou Rd, Nanjing 210093, Peoples R China.
EM sdqfly@hotmail.com
CR CLEARY J, 1995, BRAIN RES, V682, P69, DOI 10.1016/0006-8993(95)00323-I
   Eckert GP, 2001, J NEURAL TRANSM, V108, P1051, DOI 10.1007/s007020170024
   GAMES D, 1992, NEUROBIOL AGING, V13, P569, DOI 10.1016/0197-4580(92)90057-5
   HYMAN BT, 1993, J NEUROPATH EXP NEUR, V52, P594, DOI 10.1097/00005072-199311000-00006
   KOWALL NW, 1991, P NATL ACAD SCI USA, V88, P7247, DOI 10.1073/pnas.88.16.7247
   Levin ED, 1999, COGNITIVE BRAIN RES, V7, P405, DOI 10.1016/S0926-6410(98)00044-5
   Liu P, 2001, BEHAV NEUROSCI, V115, P94, DOI 10.1037//0735-7044.115.1.94
   LOWRY OH, 1951, J BIOL CHEM, V193, P265
   Markesbery WR, 1997, FREE RADICAL BIO MED, V23, P134, DOI 10.1016/S0891-5849(96)00629-6
   MAY PC, 1992, NEUROBIOL AGING, V13, P605, DOI 10.1016/0197-4580(92)90064-5
   MCDONALD MP, 1994, BEHAV NEURAL BIOL, V62, P60, DOI 10.1016/S0163-1047(05)80059-7
   Mecocci P, 1996, NEUROSCI LETT, V207, P129, DOI 10.1016/0304-3940(96)12509-X
   Morimoto K, 1998, NEUROSCIENCE, V84, P479, DOI 10.1016/S0306-4522(97)00507-1
   OHKAWA H, 1979, ANAL BIOCHEM, V95, P351, DOI 10.1016/0003-2697(79)90738-3
   Omar R. A., 1999, J ALZHEIMERS DIS, V1, P139
   PAXINOS G, 1986, RAT BRAIN STEREOTAXI, P31
   PIKE CJ, 1991, EUR J PHARM-MOLEC PH, V207, P367, DOI 10.1016/0922-4106(91)90014-9
   SCIAMANNA MA, 1992, BIOCHIM BIOPHYS ACTA, V1134, P223, DOI 10.1016/0167-4889(92)90180-J
   SHINITZKY M, 1978, BIOCHIM BIOPHYS ACTA, V515, P367, DOI 10.1016/0304-4157(78)90010-2
   Waschuk SA, 2001, J BIOL CHEM, V276, P33561, DOI 10.1074/jbc.M103598200
   Zhang X., 1996, CHIN J GERONTOL, V16, P230
   Zhang X., 1990, CHINESE J PHARM TOXI, V4, P309
   Zhou G, 1986, PROGR BIOCH BIOPHYS, V13, P71
NR 23
TC 14
Z9 20
U1 4
U2 10
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0024-3205
EI 1879-0631
J9 LIFE SCI
JI Life Sci.
PD JAN 28
PY 2005
VL 76
IS 11
BP 1189
EP 1197
DI 10.1016/j.lfs.2004.05.039
PG 9
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA 893IJ
UT WOS:000226712200001
PM 15642590
DA 2018-12-27
ER

PT J
AU Fukuhara, A
   Matsuda, M
   Nishizawa, M
   Segawa, K
   Tanaka, M
   Kishimoto, K
   Matsuki, Y
   Murakami, M
   Ichisaka, T
   Murakami, H
   Watanabe, E
   Takagi, T
   Akiyoshi, M
   Ohtsubo, T
   Kihara, S
   Yamashita, S
   Makishima, M
   Funahashi, T
   Yamanaka, S
   Hiramatsu, R
   Matsuzawa, Y
   Shimomura, I
AF Fukuhara, A
   Matsuda, M
   Nishizawa, M
   Segawa, K
   Tanaka, M
   Kishimoto, K
   Matsuki, Y
   Murakami, M
   Ichisaka, T
   Murakami, H
   Watanabe, E
   Takagi, T
   Akiyoshi, M
   Ohtsubo, T
   Kihara, S
   Yamashita, S
   Makishima, M
   Funahashi, T
   Yamanaka, S
   Hiramatsu, R
   Matsuzawa, Y
   Shimomura, I
TI RETRACTED: Visfatin: A protein secreted by visceral fat that mimics the
   effects of insulin (Retracted article, see vol 318, pg 565, 2007)
SO SCIENCE
LA English
DT Article; Retracted Publication
ID COLONY-ENHANCING FACTOR; DIABETES-MELLITUS; OBESITY; EXPRESSION;
   RESISTANCE; ADIPOSE; CLONING; LEPTIN; ALPHA; MICE
AB Fat tissue produces a variety of secreted proteins (adipocytokines) with important roles in metabolism. We isolated a newly identified adipocytokine, visfatin, that is highly enriched in the visceral fat of both humans and mice and whose expression level in plasma increases during the development of obesity. Visfatin corresponds to a protein identified previously as pre-B cell colony-enhancing factor (PBEF), a 52-kilodalton cytokine expressed in lymphocytes. Visfatin exerted insulin-mimetic effects in cultured cells and lowered plasma glucose levels in mice. Mice heterozygous for a targeted mutation in the visfatin gene had modestly higher levels of plasma glucose relative to wild-type littermates. Surprisingly, visfatin binds to and activates the insulin receptor. Further study of visfatin's physiological role may lead to new insights into glucose homeostasis and/or new therapies for metabolic disorders such as diabetes.
C1 Osaka Univ, Grad Sch Med, Dept Med & Pathophysiol, Suita, Osaka 5650871, Japan.
   Osaka Univ, Grad Sch Frontier Biosci, Dept Organismal Biosyst, Suita, Osaka 5650871, Japan.
   Japan Soc Promot Sci, Chiyoda Ku, Tokyo 1028471, Japan.
   Sumitomo Pharmaceut Co Ltd, Genom Sci Labs, Takarazuka, Hyogo 6650051, Japan.
   Nara Inst Sci & Technol, Res & Educ Ctr Genet Informat, Lab Anim Mol Technol, JST,CREST, Nara 6300192, Japan.
   Osaka Univ, Grad Sch Med, Dept Internal Med & Mol Sci, Suita, Osaka 5650871, Japan.
   Sumitomo Hosp, Kita Ku, Osaka 5300005, Japan.
   Japan Sci & Technol Agcy, PRESTO, Kawaguchi, Saitama 3320012, Japan.
RP Shimomura, I (reprint author), Osaka Univ, Grad Sch Med, Dept Med & Pathophysiol, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.
EM ichi@imed2.med.osaka-u.ac.jp
OI Takagi, Toshiyuki/0000-0003-1283-4320; SEGAWA, Kouji/0000-0002-3633-4809
CR Friedman JM, 1998, NATURE, V395, P763, DOI 10.1038/27376
   FUJIOKA S, 1987, METABOLISM, V36, P54, DOI 10.1016/0026-0495(87)90063-1
   FUKUHARA A, UNPUB
   HOTAMISLIGIL GS, 1993, SCIENCE, V259, P87, DOI 10.1126/science.7678183
   Hu E, 1996, J BIOL CHEM, V271, P10697, DOI 10.1074/jbc.271.18.10697
   Jia SH, 2004, J CLIN INVEST, V113, P1318, DOI 10.1172/JCI200419930
   KADOWAKI T, 1990, J BIOL CHEM, V265, P19143
   KISSEBAH AH, 1989, DIABETES METAB REV, V5, P83, DOI 10.1002/dmr.5610050202
   LANDRETH KS, 1992, BLOOD, V80, P1207
   Maeda K, 1996, BIOCHEM BIOPH RES CO, V221, P286, DOI 10.1006/bbrc.1996.0587
   Maeda N, 2002, NAT MED, V8, P731, DOI 10.1038/nm724
   MATSUZAWA Y, 1993, ANN NY ACAD SCI, V676, P270
   Ognjanovic S, 2001, J MOL ENDOCRINOL, V26, P107, DOI 10.1677/jme.0.0260107
   SAMAL B, 1994, MOL CELL BIOL, V14, P1431, DOI 10.1128/MCB.14.2.1431
   SCHERER PE, 1995, J BIOL CHEM, V270, P26746, DOI 10.1074/jbc.270.45.26746
   Shimomura I, 1996, NAT MED, V2, P800, DOI 10.1038/nm0796-800
   Shimomura I, 1999, NATURE, V401, P73
   Steppan CM, 2001, NATURE, V409, P307, DOI 10.1038/35053000
NR 18
TC 1272
Z9 1555
U1 14
U2 215
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 0036-8075
J9 SCIENCE
JI Science
PD JAN 21
PY 2005
VL 307
IS 5708
BP 426
EP 430
DI 10.1126/science.1097243
PG 5
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 890DQ
UT WOS:000226492300048
PM 15604363
DA 2018-12-27
ER

PT J
AU Zhang, QP
   Xiong, J
   Jin, YX
   Wu, Q
   Ju, W
   Liu, C
   Wang, J
   Liu, Y
   Hu, CS
   Yang, MZ
   Gao, QP
   Li, Q
   Zhang, KJ
   Sun, ZM
   Liu, JY
   Tan, JQ
AF Zhang, QP
   Xiong, J
   Jin, YX
   Wu, Q
   Ju, W
   Liu, C
   Wang, J
   Liu, Y
   Hu, CS
   Yang, MZ
   Gao, QP
   Li, Q
   Zhang, KJ
   Sun, ZM
   Liu, JY
   Tan, JQ
TI RETRACTED: Selectively frequent expression of CXCR5 enhances resistance
   to apoptosis in CD8(+)CD34(+) T cells from patients with T-cell-lineage
   acute lymphocytic leukemia (Retracted article. See vol. 30, pg. 2798,
   2011)
SO ONCOGENE
LA English
DT Article; Retracted Publication
DE leukemia; T cells; chemokine receptor; apoptosis; chemotaxis
ID NECROSIS-FACTOR FAMILY; RECEPTOR 9/TECK INTERACTION; B-CELL; CHEMOKINE
   RECEPTOR; DENDRITIC CELLS; LYMPH-NODES; STRUCTURAL BASIS; PROTEIN
   FAMILY; ML-IAP; APRIL
AB We investigated CD4(+)CD34(+), CD8(+)CD34(+), CD4(+)CD34(-), and CD8(+)CD34(-) T cells from cord blood and from typical patients with T-cell-lineage acute lymphocytic leukemia and T-cell-lineage chronic lymphocytic leukemia in terms of expression and functions of CXCR5/CXCL13. We found that CXCR5 was selectively frequently expressed on T-cell-lineage acute (chronic) lymphocytic leukemia (T-ALL) CD8(+)CD34(+) T cells, but not on T-ALL CD4(+)CD34(+), CD4(+)CD34(-), and CD8(+)CD34(-) T cells. CXCR5 was rarely expressed on all types of CD34(+) and CD34(-) CB or T-CLL T cells. CXCL13/B cells attracting chemokine 1 induced significant resistance to TNF-alpha-mediated apoptosis in T-ALL CD8(+)CD34(-) T cells, instead of induction of chemotactic and adhesive responsiveness. A proliferation-inducing ligand expression in T-ALL CD8(+)CD34(+) T cells was upregulated by CXCL13/BCA-1 (B-cell attracting chemokine 1). The CXCR5/CXCL13 pair by means of activation of APRIL ( A proliferation-inducinglig and) induced resistance to apoptosis in T-ALL CD8(+)CD34(+) T cells in livin-dependent manner. In this process, cell - cell contact in culture was necessary. Based on our findings, we suggested that there were differential functions of CXCR5/CXCL13 in distinct types of cells. Normal lymphocytes, especially naive B and T cells, utilized CXCR5/CXCL13 for migration, homing, maturation, and cell homeostasis, as well as secondary lymphoid tissue organogenesis. Meanwhile, certain malignant cells took advantages of CXCR5/CXCL13 for infiltration, resistance to apoptosis, and inappropriate proliferation.
C1 Wuhan Univ, Sch Med, Med Res Ctr,Inst Allergy & Immune Related Dis, Dept Immunol,Lab Allergy & Clin Immunol, Wuhan 430071, Peoples R China.
   Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol, State Key Lab Mol Biol, Shanghai, Peoples R China.
   Anhui med Univ, Coll Basic Med Sci, Dept Immunol, Hefei 230032, Peoples R China.
   Anhui Med Univ, Affiliated Univ Hosp, Dept Hematol, Hefei 230031, Peoples R China.
   Wuhan Univ, Affiliated Univ Hosp 1, Dept Hematol, Wuhan 430071, Peoples R China.
   Wuhan Univ, Affiliated Univ Hosp 2, Dept Hematol, Wuhan 430071, Peoples R China.
   Prov Hosp Anhui, Dept Hematol, Hefei 230020, Peoples R China.
RP Tan, JQ (reprint author), Wuhan Univ, Sch Med, Med Res Ctr,Inst Allergy & Immune Related Dis, Dept Immunol,Lab Allergy & Clin Immunol, Dong Hu Rd 115, Wuhan 430071, Peoples R China.
EM jinquan_tan@hotmail.com
CR Algeciras-Schimnich A, 2002, AIDS, V16, P1467, DOI 10.1097/00002030-200207260-00003
   Ansel KM, 2000, NATURE, V406, P309
   BENNETT JM, 1981, BRIT J HAEMATOL, V47, P553, DOI 10.1111/j.1365-2141.1981.tb02684.x
   BENNETT JM, 1989, J CLIN PATHOL, V42, P567, DOI 10.1136/jcp.42.6.567
   Berndt C, 1998, P NATL ACAD SCI USA, V95, P12556, DOI 10.1073/pnas.95.21.12556
   Breitfeld D, 2000, J EXP MED, V192, P1545, DOI 10.1084/jem.192.11.1545
   Chai JJ, 2001, CELL, V104, P769, DOI 10.1016/S0092-8674(02)02034-2
   Cheson BD, 1996, BLOOD, V87, P4990
   Duckett CS, 1996, EMBO J, V15, P2685, DOI 10.1002/j.1460-2075.1996.tb00629.x
   Finke D, 2002, IMMUNITY, V17, P363, DOI 10.1016/S1074-7613(02)00395-3
   FORSTER R, 1994, BLOOD, V84, P830
   Forster R, 1996, CELL, V87, P1037, DOI 10.1016/S0092-8674(00)81798-5
   Gunn MD, 1998, NATURE, V391, P799
   Hahne M, 1998, J EXP MED, V188, P1185, DOI 10.1084/jem.188.6.1185
   Han ZC, 1997, BLOOD, V89, P2328
   Hargreaves DC, 2001, J EXP MED, V194, P45, DOI 10.1084/jem.194.1.45
   Jonuleit H, 2000, J EXP MED, V192, P1213, DOI 10.1084/jem.192.9.1213
   Kanbe K, 1999, VIROLOGY, V265, P264, DOI 10.1006/viro.1999.0036
   Kasof GM, 2001, J BIOL CHEM, V276, P3238, DOI 10.1074/jbc.M003670200
   Kelly K, 2000, CANCER RES, V60, P1021
   Kern C, 2004, BLOOD, V103, P679, DOI 10.1182/blood-2003-02-0540
   Kim CH, 2001, J EXP MED, V193, P1373, DOI 10.1084/jem.193.12.1373
   Kruse N, 1997, J IMMUNOL METHODS, V210, P195, DOI 10.1016/S0022-1759(97)00188-9
   Lin JH, 2000, BIOCHEM BIOPH RES CO, V279, P820, DOI 10.1006/bbrc.2000.4027
   Lopez-Fraga M, 2001, EMBO REP, V2, P945, DOI 10.1093/embo-reports/kve198
   Luther SA, 2000, IMMUNITY, V12, P471, DOI 10.1016/S1074-7613(00)80199-5
   Massari P, 2000, P NATL ACAD SCI USA, V97, P9070, DOI 10.1073/pnas.97.16.9070
   Mazzucchelli L, 1999, J CLIN INVEST, V104, pR49, DOI 10.1172/JCI7830
   Medema JP, 2003, CELL DEATH DIFFER, V10, P1121, DOI 10.1038/sj.cdd.4401291
   Miller LK, 1999, TRENDS CELL BIOL, V9, P323, DOI 10.1016/S0962-8924(99)01609-8
   Muller G, 2003, IMMUNOL REV, V195, P117, DOI 10.1034/j.1600-065X.2003.00073.x
   Ohl L, 2003, J EXP MED, V197, P1199, DOI 10.1084/jem.20030169
   Okada T, 2002, J EXP MED, V196, P65, DOI 10.1084/jem.20020201
   Pradet-Balade B, 2002, EMBO J, V21, P5711, DOI 10.1093/emboj/cdf565
   Reif K, 2002, NATURE, V416, P94, DOI 10.1038/416094a
   Rennert P, 2000, J EXP MED, V192, P1677, DOI 10.1084/jem.192.11.1677
   Riedl SJ, 2001, CELL, V104, P791, DOI 10.1016/S0092-8674(01)00274-4
   Roth W, 2001, CELL DEATH DIFFER, V8, P403, DOI 10.1038/sj.cdd.4400827
   Saeki H, 2000, EUR J IMMUNOL, V30, P2808, DOI 10.1002/1521-4141(200010)30:10<2808::AID-IMMU2808>3.0.CO;2-K
   Sanna MG, 2002, MOL CELL BIOL, V22, P1754, DOI 10.1128/MCB.22.6.1754-1766.2002
   Scheuerer B, 2000, BLOOD, V95, P1158
   Schmollinger JC, 2003, P NATL ACAD SCI USA, V100, P3398, DOI 10.1073/pnas.0530311100
   Sica A, 1997, J EXP MED, V185, P969, DOI 10.1084/jem.185.5.969
   Siegel RM, 2001, NAT IMMUNOL, V2, P577, DOI 10.1038/89715
   Smith JR, 2003, BLOOD, V101, P815, DOI 10.1182/blood-2002-05-1576
   Stein JV, 2002, J CLIN INVEST, V109, P1587, DOI 10.1172/JCI200215034
   Tan JQ, 2000, BLOOD, V96, P1230
   Tan JQ, 2003, J IMMUNOL, V171, P1722, DOI 10.4049/jimmunol.171.4.1722
   Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312
   Till KJ, 2002, BLOOD, V99, P2977, DOI 10.1182/blood.V99.8.2977
   Voigt I, 2000, EUR J IMMUNOL, V30, P560, DOI 10.1002/1521-4141(200002)30:2<560::AID-IMMU560>3.0.CO;2-T
   Vucic D, 2000, CURR BIOL, V10, P1359, DOI 10.1016/S0960-9822(00)00781-8
   Wu MT, 2002, J IMMUNOL, V168, P5096, DOI 10.4049/jimmunol.168.10.5096
   Youn BS, 2001, BLOOD, V98, P925, DOI 10.1182/blood.V98.4.925
   Youn BS, 2002, APOPTOSIS, V7, P271, DOI 10.1023/A:1015320321511
   Yu G, 2000, NAT IMMUNOL, V1, P252, DOI 10.1038/79802
   Yu P, 2002, J IMMUNOL, V168, P5117, DOI 10.4049/jimmunol.168.10.5117
   Zhang QP, 2003, CANCER RES, V63, P6469
NR 58
TC 2
Z9 8
U1 3
U2 10
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-9232
EI 1476-5594
J9 ONCOGENE
JI Oncogene
PD JAN 20
PY 2005
VL 24
IS 4
BP 573
EP 584
DI 10.1038/sj.onc.1208184
PG 12
WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
GA 889CF
UT WOS:000226420400005
OA Bronze
DA 2018-12-27
ER

PT J
AU Kim, SJ
   Cheon, SH
   Yoo, SJ
   Kwon, J
   Park, JH
   Kim, CG
   Rhee, K
   You, S
   Lee, JY
   Roh, SI
   Yoon, HS
AF Kim, SJ
   Cheon, SH
   Yoo, SJ
   Kwon, J
   Park, JH
   Kim, CG
   Rhee, K
   You, S
   Lee, JY
   Roh, SI
   Yoon, HS
TI RETRACTED: Contribution of the PI3K/Akt/PKB signal pathway to
   maintenance of self-renewal in human embryonic stem cells (Retracted
   Article. See vol 580, pg 1529, 2006)
SO FEBS LETTERS
LA English
DT Article; Retracted Publication
DE fibroblast growth factor signaling; differentiation and
   undifferentiation; extracellular matrix molecule
ID FIBROBLAST-GROWTH-FACTOR; BASEMENT-MEMBRANE; DIFFERENTIATION; MOUSE;
   STAT3; PLURIPOTENCY; EXPRESSION; MAINTAIN; MURINE; ACTIVATION
AB Although basic fibroblast growth factor (FGF2) Is generally included in the media for maintenance of human embryonic stem cells (hESCs), the action of FGF2 in these cells has not been well defined. Here, we determined the roles of FGF2 in maintaining hESC self-renewal. Withdrawal of FGF2 from the media led to acquisition of typical differentiated characteristics in hESCs. In the presence of FGF2, which is normally required for proliferation in an undifferentiated state, inhibition of phosphatidylinositol 3-kinase (PI3K)/Akt/PKB signal stimulated differentiation and attenuated the expression of extracellular matrix (ECM) molecules. We suggest that FGF2 maintains hESC self-renewal by supporting stable expression of ECM molecules through activation of the PI3K/Akt/PKB pathway. (C) 2004 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.
C1 MizMedi Hosp, Med Res Ctr, Div Stem Cell Biol, Seoul 157280, South Korea.
   Hanyang Univ, Coll Nat Sci, Dept Life Sci, Seoul, South Korea.
   Seoul Natl Univ, Sch Biol Sci, Seoul, South Korea.
   Korea Univ, Coll Life & Environm Sci, Div Biotechnol & Genet Engn, Seoul, South Korea.
RP Yoon, HS (reprint author), MizMedi Hosp, Med Res Ctr, Div Stem Cell Biol, 701-4 Naebalsandong, Seoul 157280, South Korea.
EM yoon@mizmedi.net
RI Lee, Joo-Yong/F-4545-2014
CR Amit M, 2000, DEV BIOL, V227, P271, DOI 10.1006/dibo.2000.9912
   Amit M, 2004, BIOL REPROD, V70, P837, DOI 10.1095/biolreprod.103.021147
   Anneren C, 2004, J BIOL CHEM, V279, P31590, DOI 10.1074/jbc.M403547200
   Brandenberger R, 2004, NAT BIOTECHNOL, V22, P707, DOI 10.1038/nbt971
   Chen Y, 2000, ONCOGENE, V19, P3750, DOI 10.1038/sj.onc.1203726
   Czyz J, 2001, DIFFERENTIATION, V68, P167, DOI 10.1046/j.1432-0436.2001.680404.x
   Daheron L, 2004, STEM CELLS, V22, P770, DOI 10.1634/stemcells.22-5-770
   Danen EHJ, 2001, J CELL PHYSIOL, V189, P1, DOI 10.1002/jcp.1137
   Dixelius J, 2004, J BIOL CHEM, V279, P23766, DOI 10.1074/jbc.M311675200
   Draper JS, 2003, ARCH MED RES, V34, P558, DOI 10.1016/j.arcmed.2003.08.006
   Humphrey RK, 2004, STEM CELLS, V22, P522, DOI 10.1634/stemcells.22-4-522
   Hwang WS, 2004, SCIENCE, V303, P1669, DOI 10.1126/science.1094515
   Li L, 2004, DEVELOPMENT, V131, P5277, DOI 10.1242/dev.01415
   Li XF, 2001, J CELL BIOL, V153, P811, DOI 10.1083/jcb.153.4.811
   Li XF, 2001, P NATL ACAD SCI USA, V98, P14416, DOI 10.1073/pnas.251547198
   Lim JWE, 2002, PROTEOMICS, V2, P1187, DOI 10.1002/1615-9861(200209)2:9<1187::AID-PROT1187>3.0.CO;2-T
   Matin MM, 2004, STEM CELLS, V22, P659, DOI 10.1634/stemcells.22-5-659
   Matsuda T, 1999, EMBO J, V18, P4261, DOI 10.1093/emboj/18.15.4261
   Murakami M, 2004, EUR J BIOCHEM, V271, P3330, DOI 10.1111/j.1432-1033.2004.04267.x
   Niwa H, 2000, NAT GENET, V24, P372, DOI 10.1038/74199
   PALING NR, IN PRESS J BIOL CHEM
   Park JH, 2003, BIOL REPROD, V69, P2007, DOI 10.1095/biolreprod.103.017467
   Prudhomme W, 2004, P NATL ACAD SCI USA, V101, P2900, DOI 10.1073/pnas.0308768101
   Rao M, 2004, DEV BIOL, V275, P269, DOI 10.1016/j.ydbio.2004.08.013
   Rathjen J, 2002, DEVELOPMENT, V129, P2649
   Reuveni H, 2002, BIOCHEMISTRY-US, V41, P10304, DOI 10.1021/bi0202530
   Sato N, 2004, NAT MED, V10, P55, DOI 10.1038/nm979
   Schuringa JJ, 2002, EXP CELL RES, V274, P119, DOI 10.1006/excr.2001.5454
   Smith AG, 2001, ANNU REV CELL DEV BI, V17, P435, DOI 10.1146/annurev.cellbio.17.1.435
   Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145
   XIHONG Z, 2002, CANCER RES, V62, P4369
   Xu CH, 2001, NAT BIOTECHNOL, V19, P971, DOI 10.1038/nbt1001-971
   Ying QL, 2003, CELL, V115, P281, DOI 10.1016/S0092-8674(03)00847-X
   Zhang PL, 2004, STEM CELLS, V22, P344, DOI 10.1634/stemcells.22-3-344
NR 34
TC 58
Z9 72
U1 3
U2 19
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0014-5793
J9 FEBS LETT
JI FEBS Lett.
PD JAN 17
PY 2005
VL 579
IS 2
BP 534
EP 540
DI 10.1016/j.febslet.2004.12.024
PG 7
WC Biochemistry & Molecular Biology; Biophysics; Cell Biology
SC Biochemistry & Molecular Biology; Biophysics; Cell Biology
GA 888WX
UT WOS:000226406000038
PM 15642372
DA 2018-12-27
ER

PT J
AU Badou, A
   Basavappa, S
   Desai, R
   Peng, YQ
   Matza, D
   Mehal, WZ
   Kaczmarek, LK
   Boulpaep, EL
   Flavell, RA
AF Badou, A
   Basavappa, S
   Desai, R
   Peng, YQ
   Matza, D
   Mehal, WZ
   Kaczmarek, LK
   Boulpaep, EL
   Flavell, RA
TI RETRACTED: Requirement of voltage-gated calcium channel beta(4) subunit
   for T lymphocyte functions (Retracted Article. See vol 310, pg 1903,
   2005)
SO SCIENCE
LA English
DT Article; Retracted Publication
ID CA2+ CHANNELS; TRANSCRIPTION FACTORS; MICE; CELL; ACTIVATION; INCREASES;
   SIGNAL
AB Calcium is known to play vital roles in diverse physiological processes, and it is known that voltage-gated calcium channels (Ca-v) mediate calcium influx in excitable cells. However, no consensus exists on the molecular identity of the calcium channels present in nonexcitable cells such as T lymphocytes. Here, we demonstrate that T lymphocytes express both regulatory beta(4) and pore-forming Ca(v)1 alpha(1) subunits of Ca-v channels. Ca-v beta(4)-mutant T lymphocytes fail to acquire normal functions and display impairment in the calcium response, activation of the transcription factor NFAT, and cytokine production. Although Ca(v)1 channels of lymphocytes retain their voltage dependency, T cell receptor stimulation dramatically increases channel opening, providing a new mechanism for calcium entry in lymphocytes.
C1 Yale Univ, Sch Med, Howard Hughes Med Inst, Immunobiol Sect, New Haven, CT 06510 USA.
   Yale Univ, Sch Med, Dept Cellular & Mol Physiol, New Haven, CT 06510 USA.
   Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06510 USA.
   Univ Rochester, Sch Med, Dept Med Pharmacol & Physiol, Digest Dis Unit, Rochester, NY 14627 USA.
RP Flavell, RA (reprint author), Yale Univ, Sch Med, Howard Hughes Med Inst, Immunobiol Sect, New Haven, CT 06510 USA.
EM richard.flavell@yale.edu
CR BADOU A, UNPUB
   Burgess DL, 1997, CELL, V88, P385, DOI 10.1016/S0092-8674(00)81877-2
   Cantrell D, 1996, ANNU REV IMMUNOL, V14, P259, DOI 10.1146/annurev.immunol.14.1.259
   Catterall WA, 2000, ANNU REV CELL DEV BI, V16, P521, DOI 10.1146/annurev.cellbio.16.1.521
   Chien AJ, 1998, J BIOL CHEM, V273, P23590, DOI 10.1074/jbc.273.36.23590
   Chin ER, 1998, GENE DEV, V12, P2499, DOI 10.1101/gad.12.16.2499
   Crabtree GR, 2002, CELL, V109, pS67, DOI 10.1016/S0092-8674(02)00699-2
   Dickie M.M., 1964, MOUSE NEWS LETT, V30, P31
   Dolmetsch RE, 1997, NATURE, V386, P855, DOI 10.1038/386855a0
   DUNG HC, 1976, AM J ANAT, V147, P255, DOI 10.1002/aja.1001470209
   Elliott AC, 2001, CELL CALCIUM, V30, P73, DOI 10.1054/ceca.2001.0215
   Freise D, 2000, J BIOL CHEM, V275, P14476, DOI 10.1074/jbc.275.19.14476
   Freise D, 1999, BIOL CHEM, V380, P897, DOI 10.1515/BC.1999.110
   Gao TY, 1999, J BIOL CHEM, V274, P2137, DOI 10.1074/jbc.274.4.2137
   Graef IA, 1999, NATURE, V401, P703, DOI 10.1038/44378
   Grafton G, 2001, IMMUNOLOGY, V104, P119, DOI 10.1046/j.0019-2805.2001.01321.x
   Koschak A, 2001, J BIOL CHEM, V276, P22100, DOI 10.1074/jbc.M101469200
   Lewis RS, 2001, ANNU REV IMMUNOL, V19, P497, DOI 10.1146/annurev.immunol.19.1.497
   Liu YW, 2001, J CELL BIOL, V155, P27, DOI 10.1083/jcb.200103020
   Mintz E, 1997, BBA-BIOENERGETICS, V1318, P52, DOI 10.1016/S0005-2728(96)00132-6
   MORRISON DG, 1984, DEV COMP IMMUNOL, V8, P435, DOI 10.1016/0145-305X(84)90050-8
   Peng SL, 2001, IMMUNITY, V14, P13, DOI 10.1016/S1074-7613(01)00085-1
   Pichler M, 1997, J BIOL CHEM, V272, P13877, DOI 10.1074/jbc.272.21.13877
   PRAGNELL M, 1994, NATURE, V368, P67, DOI 10.1038/368067a0
   Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707
   Schjott JM, 2003, J BIOL CHEM, V278, P33936, DOI 10.1074/jbc.M302059200
   SIDMAN RL, 1965, CATALOG NEUROLOGICAL
   Tanaka O, 1995, Brain Res Mol Brain Res, V30, P1
   Tareilus E, 1997, P NATL ACAD SCI USA, V94, P1703, DOI 10.1073/pnas.94.5.1703
   WAARD MD, 1994, NEURON, V13, P495
   Xu WF, 2001, J NEUROSCI, V21, P5944
   ZWEIFACH A, 1993, P NATL ACAD SCI USA, V90, P6295, DOI 10.1073/pnas.90.13.6295
NR 32
TC 18
Z9 19
U1 2
U2 11
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 0036-8075
EI 1095-9203
J9 SCIENCE
JI Science
PD JAN 7
PY 2005
VL 307
IS 5706
BP 117
EP 121
DI 10.1126/science.1100582
PG 5
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 886GG
UT WOS:000226214300051
PM 15637280
DA 2018-12-27
ER

PT J
AU Yuan, GD
   Ye, ZZ
   Qian, Q
   Zhu, UP
   Huang, JY
   Zhao, BH
AF Yuan, GD
   Ye, ZZ
   Qian, Q
   Zhu, UP
   Huang, JY
   Zhao, BH
TI RETRACTED: P-type Zno thin films fabricated by Al-N co-doping method at
   different substrate temperature (Retracted article. See vol 311, pg
   3812, 2009)
SO JOURNAL OF CRYSTAL GROWTH
LA English
DT Article; Retracted Publication
DE co-doping; p-type conduction; DC magnetron reactive sputtering; zinc
   compounds; semiconducting; II-VI materials
ID CODOPING METHOD; PHOTOLUMINESCENT PROPERTIES; ROOM-TEMPERATURE;
   ACCEPTORS
AB P-type conduction in ZnO thin films was realized by Al-N co-doping method. ZnO thin films were prepared in NH3-O-2 atmosphere with the substrate temperature in the range of 360-600degreesC with a 20degreesC space. The conduction type of Al-N co-doped ZnO thin films are dependant greatly on the growth temperature. With Al and N co-doping 1017 3 technique, we have observed a room temperature resistivity of 24.5 Omega cm and a hole concentration of 7.48 x 10(17) cm(-3) in ZnO thin films on sapphire substrate. Secondary ion mass spectroscopy (SIMS) tests proved that the presence of Al facilitated the incorporation of N into ZnO. A model showing nitrogen and aluminium incorparation suggests the difficultv of realizing p-type ZnO thin films of both high hole concentration and low resistivity by the Al-N co-doping method. X-ray diffraction (XRD) measurements showed that crystillinity of the Al-N co-doped ZnO thin films are also very dependant on the substrate temperature. (C) 2004 Elsevier B.V. All rights reserved.
C1 Zhejiang Univ, State Kye Lab Silicon Mat, Coll Mat Sci & Chem Engn, Hangzhou 310027, Peoples R China.
RP Ye, ZZ (reprint author), Zhejiang Univ, State Kye Lab Silicon Mat, Coll Mat Sci & Chem Engn, Hangzhou 310027, Peoples R China.
EM yezz@cmsce.zju.edu.cn
RI yuan, guodong/B-6314-2015
OI yuan, guodong/0000-0001-9627-0934
CR Alam MJ, 2001, J VAC SCI TECHNOL A, V19, P1642, DOI 10.1116/1.1340659
   Bagnall DM, 1997, APPL PHYS LETT, V70, P2230, DOI 10.1063/1.118824
   Guo XL, 2001, J CRYST GROWTH, V223, P135, DOI 10.1016/S0022-0248(00)00952-0
   Joseph M, 2001, PHYSICA B, V302, P140, DOI 10.1016/S0921-4526(01)00419-7
   Joseph M, 1999, JPN J APPL PHYS 2, V38, pL1205, DOI 10.1143/JJAP.38.L1205
   KAMATA A, 1993, APPL PHYS LETT, V63, P3353, DOI 10.1063/1.110142
   Komatsu M, 2002, APPL SURF SCI, V189, P349, DOI 10.1016/S0169-4332(01)01026-1
   Lee EC, 2001, PHYS REV B, V64, DOI 10.1103/PhysRevB.64.085120
   Minegishi K, 1997, JPN J APPL PHYS 2, V36, pL1453, DOI 10.1143/JJAP.36.L1453
   Nakahara K, 2001, APPL PHYS LETT, V79, P4139, DOI 10.1063/1.1424066
   Ogata K, 1996, J CRYST GROWTH, V159, P312, DOI 10.1016/0022-0248(95)00766-0
   QIU DJ, 2000, CHINESE J MAT RES, V14, P485
   Reynolds DC, 1996, SOLID STATE COMMUN, V99, P873, DOI 10.1016/0038-1098(96)00340-7
   Ryu YR, 2000, J CRYST GROWTH, V216, P330, DOI 10.1016/S0022-0248(00)00437-1
   Tang ZK, 1998, APPL PHYS LETT, V72, P3270, DOI 10.1063/1.121620
   TOMINAGA K, 1996, THIN SOLID FILMS, V84, P290
   Tsukazaki A, 2002, APPL PHYS LETT, V81, P235, DOI 10.1063/1.1491294
   Yamamoto T, 1999, JPN J APPL PHYS 2, V38, pL166, DOI 10.1143/JJAP.38.L166
   Ye ZZ, 2004, J CRYST GROWTH, V265, P127, DOI 10.1016/j.jcrysgro.2003.12.059
   Ye ZZ, 2003, J CRYST GROWTH, V256, P78, DOI 10.1016/S0022-0248(03)01314-9
   Ye ZZ, 2003, J CRYST GROWTH, V253, P258, DOI 10.1016/S0022-0248(03)01007-8
   Zou L, 2002, CHINESE PHYS LETT, V19, P1350, DOI 10.1088/0256-307X/19/9/341
NR 22
TC 12
Z9 16
U1 5
U2 23
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0022-0248
EI 1873-5002
J9 J CRYST GROWTH
JI J. Cryst. Growth
PD JAN 3
PY 2005
VL 273
IS 3-4
BP 451
EP 457
DI 10.1016/j.jcrysgro.2004.09.042
PG 7
WC Crystallography; Materials Science, Multidisciplinary; Physics, Applied
SC Crystallography; Materials Science; Physics
GA 886QJ
UT WOS:000226243100017
DA 2018-12-27
ER

EF